0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	toxicities	_	_	O
4	,	_	_	O
5	tumor	_	_	O
6	control	_	_	O
7	,	_	_	O
8	survival	_	_	O
9	,	_	_	O
10	and	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	of	_	_	O
15	nasopharyngeal	_	_	O
16	cancer	_	_	O
17	(	_	_	O
18	NPC	_	_	O
19	)	_	_	O
20	patients	_	_	O
21	treated	_	_	O
22	with	_	_	O
23	sequential	_	_	O
24	neoadjuvant	_	_	O
25	chemotherapy	_	_	O
26	followed	_	_	O
27	by	_	_	O
28	concurrent	_	_	O
29	cisplatin	_	_	O
30	-	_	_	O
31	radiotherapy	_	_	O
32	(	_	_	O
33	CRT	_	_	O
34	)	_	_	O
35	or	_	_	O
36	CRT	_	_	O
37	alone	_	_	O
38	.	_	_	O

39	Previously	_	_	O
40	untreated	_	_	O
41	stage	_	_	O
42	III	_	_	O
43	to	_	_	O
44	IVB	_	_	O
45	NPC	_	_	O
46	were	_	_	O
47	randomly	_	_	O
48	assigned	_	_	O
49	to	_	_	O
50	(	_	_	O
51	1	_	_	O
52	)	_	_	O
53	neoadjuvant	_	_	O
54	docetaxel	_	_	O
55	75	_	_	O
56	mg	_	_	O
57	/	_	_	O
58	m	_	_	O
59	(	_	_	O
60	2	_	_	O
61	)	_	_	O
62	and	_	_	O
63	cisplatin	_	_	O
64	75	_	_	O
65	mg	_	_	O
66	/	_	_	O
67	m	_	_	O
68	(	_	_	O
69	2	_	_	O
70	)	_	_	O
71	every	_	_	O
72	3	_	_	O
73	weeks	_	_	O
74	for	_	_	O
75	two	_	_	O
76	cycles	_	_	O
77	,	_	_	O
78	followed	_	_	O
79	by	_	_	O
80	cisplatin	_	_	O
81	40	_	_	O
82	mg	_	_	O
83	/	_	_	O
84	m	_	_	O
85	(	_	_	O
86	2	_	_	O
87	)	_	_	O
88	/	_	_	O
89	wk	_	_	O
90	concurrent	_	_	O
91	with	_	_	O
92	radiotherapy	_	_	O
93	,	_	_	O
94	or	_	_	O
95	(	_	_	O
96	2	_	_	O
97	)	_	_	O
98	CRT	_	_	O
99	alone	_	_	O
100	.	_	_	O

101	Planned	_	_	O
102	accrual	_	_	O
103	was	_	_	O
104	30	_	_	O
105	patients	_	_	O
106	per	_	_	O
107	arm	_	_	O
108	to	_	_	O
109	detect	_	_	O
110	20	_	_	O
111	%	_	_	O
112	difference	_	_	O
113	of	_	_	O
114	toxicities	_	_	O
115	based	_	_	O
116	on	_	_	O
117	95	_	_	O
118	%	_	_	O
119	CIs	_	_	O
120	.	_	_	O

121	From	_	_	O
122	November	_	_	O
123	2002	_	_	O
124	to	_	_	O
125	November	_	_	O
126	2004	_	_	O
127	,	_	_	O
128	65	_	_	O
129	eligible	_	_	O
130	patients	_	_	O
131	were	_	_	O
132	randomly	_	_	O
133	assigned	_	_	O
134	to	_	_	O
135	neoadjuvant	_	_	O
136	chemotherapy	_	_	O
137	followed	_	_	O
138	by	_	_	O
139	CRT	_	_	O
140	(	_	_	O
141	n	_	_	O
142	=	_	_	O
143	34	_	_	O
144	)	_	_	O
145	or	_	_	O
146	CRT	_	_	O
147	alone	_	_	O
148	(	_	_	O
149	n	_	_	O
150	=	_	_	O
151	31	_	_	O
152	)	_	_	O
153	.	_	_	O

154	There	_	_	B-Premise
155	was	_	_	I-Premise
156	a	_	_	I-Premise
157	high	_	_	I-Premise
158	rate	_	_	I-Premise
159	of	_	_	I-Premise
160	grade	_	_	I-Premise
161	3	_	_	I-Premise
162	/	_	_	I-Premise
163	4	_	_	I-Premise
164	neutropenia	_	_	I-Premise
165	(	_	_	I-Premise
166	97	_	_	I-Premise
167	%	_	_	I-Premise
168	)	_	_	I-Premise
169	but	_	_	I-Premise
170	not	_	_	I-Premise
171	neutropenic	_	_	I-Premise
172	fever	_	_	I-Premise
173	(	_	_	I-Premise
174	12	_	_	I-Premise
175	%	_	_	I-Premise
176	)	_	_	I-Premise
177	during	_	_	I-Premise
178	neoadjuvant	_	_	I-Premise
179	chemotherapy	_	_	I-Premise
180	.	_	_	I-Premise

181	No	_	_	B-Premise
182	significant	_	_	I-Premise
183	differences	_	_	I-Premise
184	in	_	_	I-Premise
185	rates	_	_	I-Premise
186	of	_	_	I-Premise
187	acute	_	_	I-Premise
188	toxicities	_	_	I-Premise
189	were	_	_	I-Premise
190	observed	_	_	I-Premise
191	between	_	_	I-Premise
192	the	_	_	I-Premise
193	two	_	_	I-Premise
194	arms	_	_	I-Premise
195	during	_	_	I-Premise
196	CRT	_	_	I-Premise
197	.	_	_	I-Premise

198	Dose	_	_	B-Premise
199	intensities	_	_	I-Premise
200	of	_	_	I-Premise
201	concurrent	_	_	I-Premise
202	cisplatin	_	_	I-Premise
203	,	_	_	I-Premise
204	late	_	_	I-Premise
205	RT	_	_	I-Premise
206	toxicities	_	_	I-Premise
207	and	_	_	I-Premise
208	quality	_	_	I-Premise
209	of	_	_	I-Premise
210	life	_	_	I-Premise
211	scores	_	_	I-Premise
212	were	_	_	I-Premise
213	comparable	_	_	I-Premise
214	in	_	_	I-Premise
215	both	_	_	I-Premise
216	arms	_	_	I-Premise
217	.	_	_	I-Premise

218	The	_	_	B-Premise
219	3	_	_	I-Premise
220	-	_	_	I-Premise
221	year	_	_	I-Premise
222	progression	_	_	I-Premise
223	-	_	_	I-Premise
224	free	_	_	I-Premise
225	survival	_	_	I-Premise
226	for	_	_	I-Premise
227	neoadjuvant	_	_	I-Premise
228	versus	_	_	I-Premise
229	control	_	_	I-Premise
230	arm	_	_	I-Premise
231	was	_	_	I-Premise
232	88	_	_	I-Premise
233	.	_	_	I-Premise

234	2	_	_	I-Premise
235	%	_	_	I-Premise
236	and	_	_	I-Premise
237	59	_	_	I-Premise
238	.	_	_	I-Premise

239	5	_	_	I-Premise
240	%	_	_	I-Premise
241	(	_	_	I-Premise
242	hazard	_	_	I-Premise
243	ratio	_	_	I-Premise
244	=	_	_	I-Premise
245	0	_	_	I-Premise
246	.	_	_	I-Premise

247	49	_	_	I-Premise
248	;	_	_	I-Premise
249	95	_	_	I-Premise
250	%	_	_	I-Premise
251	CI	_	_	I-Premise
252	,	_	_	I-Premise
253	0	_	_	I-Premise
254	.	_	_	I-Premise

255	20	_	_	I-Premise
256	to	_	_	I-Premise
257	1	_	_	I-Premise
258	.	_	_	I-Premise

259	19	_	_	I-Premise
260	;	_	_	I-Premise
261	P	_	_	I-Premise
262	=	_	_	I-Premise
263	.	_	_	I-Premise

264	12	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	The	_	_	B-Premise
268	3	_	_	I-Premise
269	-	_	_	I-Premise
270	year	_	_	I-Premise
271	overall	_	_	I-Premise
272	survival	_	_	I-Premise
273	for	_	_	I-Premise
274	neoadjuvant	_	_	I-Premise
275	versus	_	_	I-Premise
276	control	_	_	I-Premise
277	arm	_	_	I-Premise
278	was	_	_	I-Premise
279	94	_	_	I-Premise
280	.	_	_	I-Premise

281	1	_	_	I-Premise
282	%	_	_	I-Premise
283	and	_	_	I-Premise
284	67	_	_	I-Premise
285	.	_	_	I-Premise

286	7	_	_	I-Premise
287	%	_	_	I-Premise
288	(	_	_	I-Premise
289	hazard	_	_	I-Premise
290	ratio	_	_	I-Premise
291	=	_	_	I-Premise
292	0	_	_	I-Premise
293	.	_	_	I-Premise

294	24	_	_	I-Premise
295	;	_	_	I-Premise
296	95	_	_	I-Premise
297	%	_	_	I-Premise
298	CI	_	_	I-Premise
299	,	_	_	I-Premise
300	0	_	_	I-Premise
301	.	_	_	I-Premise

302	078	_	_	I-Premise
303	to	_	_	I-Premise
304	0	_	_	I-Premise
305	.	_	_	I-Premise

306	73	_	_	I-Premise
307	;	_	_	I-Premise
308	P	_	_	I-Premise
309	=	_	_	I-Premise
310	.	_	_	I-Premise

311	012	_	_	I-Premise
312	)	_	_	I-Premise
313	.	_	_	I-Premise

314	Neoadjuvant	_	_	B-Claim
315	docetaxel	_	_	I-Claim
316	-	_	_	I-Claim
317	cisplatin	_	_	I-Claim
318	followed	_	_	I-Claim
319	by	_	_	I-Claim
320	CRT	_	_	I-Claim
321	was	_	_	I-Claim
322	well	_	_	I-Claim
323	tolerated	_	_	I-Claim
324	with	_	_	I-Claim
325	a	_	_	I-Claim
326	manageable	_	_	I-Claim
327	toxicity	_	_	I-Claim
328	profile	_	_	I-Claim
329	that	_	_	I-Claim
330	allowed	_	_	I-Claim
331	subsequent	_	_	I-Claim
332	delivery	_	_	I-Claim
333	of	_	_	I-Claim
334	full	_	_	I-Claim
335	-	_	_	I-Claim
336	dose	_	_	I-Claim
337	CRT	_	_	I-Claim
338	.	_	_	I-Claim

339	Preliminary	_	_	B-Claim
340	results	_	_	I-Claim
341	suggested	_	_	I-Claim
342	a	_	_	I-Claim
343	positive	_	_	I-Claim
344	impact	_	_	I-Claim
345	on	_	_	I-Claim
346	survival	_	_	I-Claim
347	.	_	_	I-Claim

348	A	_	_	O
349	phase	_	_	O
350	III	_	_	O
351	study	_	_	O
352	to	_	_	O
353	definitively	_	_	O
354	test	_	_	O
355	this	_	_	O
356	neoadjuvant	_	_	O
357	-	_	_	O
358	concurrent	_	_	O
359	strategy	_	_	O
360	is	_	_	O
361	warranted	_	_	O
362	.	_	_	O


0	Relapse	_	_	B-Claim
1	after	_	_	I-Claim
2	completing	_	_	I-Claim
3	adjuvant	_	_	I-Claim
4	tamoxifen	_	_	I-Claim
5	therapy	_	_	I-Claim
6	is	_	_	I-Claim
7	a	_	_	I-Claim
8	persistent	_	_	I-Claim
9	threat	_	_	I-Claim
10	for	_	_	I-Claim
11	women	_	_	I-Claim
12	with	_	_	I-Claim
13	hormone	_	_	I-Claim
14	-	_	_	I-Claim
15	responsive	_	_	I-Claim
16	breast	_	_	I-Claim
17	cancer	_	_	I-Claim
18	.	_	_	I-Claim

19	Third	_	_	O
20	-	_	_	O
21	generation	_	_	O
22	aromatase	_	_	O
23	inhibitors	_	_	O
24	,	_	_	O
25	such	_	_	O
26	as	_	_	O
27	letrozole	_	_	O
28	,	_	_	O
29	provide	_	_	O
30	a	_	_	O
31	new	_	_	O
32	option	_	_	O
33	for	_	_	O
34	extended	_	_	O
35	adjuvant	_	_	O
36	hormonal	_	_	O
37	therapy	_	_	O
38	after	_	_	O
39	5	_	_	O
40	years	_	_	O
41	of	_	_	O
42	tamoxifen	_	_	O
43	.	_	_	O

44	MA	_	_	O
45	.	_	_	O

46	17	_	_	O
47	was	_	_	O
48	conducted	_	_	O
49	to	_	_	O
50	determine	_	_	O
51	whether	_	_	O
52	letrozole	_	_	O
53	improves	_	_	O
54	outcome	_	_	O
55	after	_	_	O
56	discontinuation	_	_	O
57	of	_	_	O
58	tamoxifen	_	_	O
59	.	_	_	O

60	Postmenopausal	_	_	O
61	women	_	_	O
62	with	_	_	O
63	hormone	_	_	O
64	receptor	_	_	O
65	-	_	_	O
66	positive	_	_	O
67	breast	_	_	O
68	cancer	_	_	O
69	(	_	_	O
70	N	_	_	O
71	=	_	_	O
72	5	_	_	O
73	,	_	_	O
74	187	_	_	O
75	)	_	_	O
76	were	_	_	O
77	randomized	_	_	O
78	to	_	_	O
79	letrozole	_	_	O
80	2	_	_	O
81	.	_	_	O

82	5	_	_	O
83	mg	_	_	O
84	or	_	_	O
85	placebo	_	_	O
86	once	_	_	O
87	daily	_	_	O
88	for	_	_	O
89	5	_	_	O
90	years	_	_	O
91	.	_	_	O

92	At	_	_	B-Premise
93	a	_	_	I-Premise
94	median	_	_	I-Premise
95	follow	_	_	I-Premise
96	-	_	_	I-Premise
97	up	_	_	I-Premise
98	of	_	_	I-Premise
99	30	_	_	I-Premise
100	months	_	_	I-Premise
101	,	_	_	I-Premise
102	letrozole	_	_	I-Premise
103	significantly	_	_	I-Premise
104	improved	_	_	I-Premise
105	disease	_	_	I-Premise
106	-	_	_	I-Premise
107	free	_	_	I-Premise
108	survival	_	_	I-Premise
109	(	_	_	I-Premise
110	DFS	_	_	I-Premise
111	;	_	_	I-Premise
112	P	_	_	I-Premise
113	<	_	_	I-Premise
114	0	_	_	I-Premise
115	.	_	_	I-Premise

116	001	_	_	I-Premise
117	)	_	_	I-Premise
118	,	_	_	I-Premise
119	the	_	_	I-Premise
120	primary	_	_	I-Premise
121	end	_	_	I-Premise
122	point	_	_	I-Premise
123	,	_	_	I-Premise
124	compared	_	_	I-Premise
125	with	_	_	I-Premise
126	placebo	_	_	I-Premise
127	(	_	_	I-Premise
128	hazard	_	_	I-Premise
129	ratio	_	_	I-Premise
130	[	_	_	I-Premise
131	HR	_	_	I-Premise
132	]	_	_	I-Premise
133	for	_	_	I-Premise
134	recurrence	_	_	I-Premise
135	or	_	_	I-Premise
136	contralateral	_	_	I-Premise
137	breast	_	_	I-Premise
138	cancer	_	_	I-Premise
139	0	_	_	I-Premise
140	.	_	_	I-Premise

141	58	_	_	I-Premise
142	;	_	_	I-Premise
143	95	_	_	I-Premise
144	%	_	_	I-Premise
145	confidence	_	_	I-Premise
146	interval	_	_	I-Premise
147	[	_	_	I-Premise
148	CI	_	_	I-Premise
149	]	_	_	I-Premise
150	0	_	_	I-Premise
151	.	_	_	I-Premise

152	45	_	_	I-Premise
153	,	_	_	I-Premise
154	0	_	_	I-Premise
155	.	_	_	I-Premise

156	76	_	_	I-Premise
157	]	_	_	I-Premise
158	P	_	_	I-Premise
159	<	_	_	I-Premise
160	0	_	_	I-Premise
161	.	_	_	I-Premise

162	001	_	_	I-Premise
163	)	_	_	I-Premise
164	.	_	_	I-Premise

165	Furthermore	_	_	B-Premise
166	,	_	_	I-Premise
167	letrozole	_	_	I-Premise
168	significantly	_	_	I-Premise
169	improved	_	_	I-Premise
170	distant	_	_	I-Premise
171	DFS	_	_	I-Premise
172	(	_	_	I-Premise
173	HR	_	_	I-Premise
174	=	_	_	I-Premise
175	0	_	_	I-Premise
176	.	_	_	I-Premise

177	60	_	_	I-Premise
178	;	_	_	I-Premise
179	95	_	_	I-Premise
180	%	_	_	I-Premise
181	CI	_	_	I-Premise
182	0	_	_	I-Premise
183	.	_	_	I-Premise

184	43	_	_	I-Premise
185	,	_	_	I-Premise
186	0	_	_	I-Premise
187	.	_	_	I-Premise

188	84	_	_	I-Premise
189	;	_	_	I-Premise
190	P	_	_	I-Premise
191	=	_	_	I-Premise
192	0	_	_	I-Premise
193	.	_	_	I-Premise

194	002	_	_	I-Premise
195	)	_	_	I-Premise
196	and	_	_	I-Premise
197	,	_	_	I-Premise
198	in	_	_	I-Premise
199	women	_	_	I-Premise
200	with	_	_	I-Premise
201	node	_	_	I-Premise
202	-	_	_	I-Premise
203	positive	_	_	I-Premise
204	tumors	_	_	I-Premise
205	,	_	_	I-Premise
206	overall	_	_	I-Premise
207	survival	_	_	I-Premise
208	(	_	_	I-Premise
209	HR	_	_	I-Premise
210	=	_	_	I-Premise
211	0	_	_	I-Premise
212	.	_	_	I-Premise

213	61	_	_	I-Premise
214	;	_	_	I-Premise
215	95	_	_	I-Premise
216	%	_	_	I-Premise
217	CI	_	_	I-Premise
218	0	_	_	I-Premise
219	.	_	_	I-Premise

220	38	_	_	I-Premise
221	,	_	_	I-Premise
222	0	_	_	I-Premise
223	.	_	_	I-Premise

224	98	_	_	I-Premise
225	;	_	_	I-Premise
226	P	_	_	I-Premise
227	=	_	_	I-Premise
228	0	_	_	I-Premise
229	.	_	_	I-Premise

230	04	_	_	I-Premise
231	)	_	_	I-Premise
232	.	_	_	I-Premise

233	Clinical	_	_	B-Premise
234	benefits	_	_	I-Premise
235	,	_	_	I-Premise
236	including	_	_	I-Premise
237	an	_	_	I-Premise
238	overall	_	_	I-Premise
239	survival	_	_	I-Premise
240	advantage	_	_	I-Premise
241	,	_	_	I-Premise
242	were	_	_	I-Premise
243	also	_	_	I-Premise
244	seen	_	_	I-Premise
245	in	_	_	I-Premise
246	women	_	_	I-Premise
247	who	_	_	I-Premise
248	crossed	_	_	I-Premise
249	over	_	_	I-Premise
250	from	_	_	I-Premise
251	placebo	_	_	I-Premise
252	to	_	_	I-Premise
253	letrozole	_	_	I-Premise
254	after	_	_	I-Premise
255	unblinding	_	_	I-Premise
256	,	_	_	I-Premise
257	indicating	_	_	I-Premise
258	that	_	_	I-Premise
259	tumors	_	_	I-Premise
260	remain	_	_	I-Premise
261	sensitive	_	_	I-Premise
262	to	_	_	I-Premise
263	hormone	_	_	I-Premise
264	therapy	_	_	I-Premise
265	despite	_	_	I-Premise
266	a	_	_	I-Premise
267	prolonged	_	_	I-Premise
268	period	_	_	I-Premise
269	since	_	_	I-Premise
270	discontinuation	_	_	I-Premise
271	of	_	_	I-Premise
272	tamoxifen	_	_	I-Premise
273	.	_	_	I-Premise

274	The	_	_	O
275	efficacy	_	_	O
276	and	_	_	O
277	safety	_	_	O
278	of	_	_	O
279	letrozole	_	_	O
280	therapy	_	_	O
281	beyond	_	_	O
282	5	_	_	O
283	years	_	_	O
284	is	_	_	O
285	being	_	_	O
286	assessed	_	_	O
287	in	_	_	O
288	a	_	_	O
289	re	_	_	O
290	-	_	_	O
291	randomization	_	_	O
292	study	_	_	O
293	,	_	_	O
294	following	_	_	O
295	the	_	_	O
296	emergence	_	_	O
297	of	_	_	O
298	new	_	_	O
299	data	_	_	O
300	suggesting	_	_	O
301	that	_	_	O
302	clinical	_	_	O
303	benefit	_	_	O
304	correlates	_	_	O
305	with	_	_	O
306	the	_	_	O
307	duration	_	_	O
308	of	_	_	O
309	letrozole	_	_	O
310	.	_	_	O

311	MA	_	_	B-Claim
312	.	_	_	I-Claim

313	17	_	_	I-Claim
314	showed	_	_	I-Claim
315	that	_	_	I-Claim
316	letrozole	_	_	I-Claim
317	is	_	_	I-Claim
318	extremely	_	_	I-Claim
319	well	_	_	I-Claim
320	-	_	_	I-Claim
321	tolerated	_	_	I-Claim
322	relative	_	_	I-Claim
323	to	_	_	I-Claim
324	placebo	_	_	I-Claim
325	.	_	_	I-Claim

326	Letrozole	_	_	B-Claim
327	should	_	_	I-Claim
328	be	_	_	I-Claim
329	considered	_	_	I-Claim
330	for	_	_	I-Claim
331	all	_	_	I-Claim
332	women	_	_	I-Claim
333	completing	_	_	I-Claim
334	tamoxifen	_	_	I-Claim
335	;	_	_	I-Claim
336	new	_	_	B-Claim
337	results	_	_	I-Claim
338	from	_	_	I-Claim
339	the	_	_	I-Claim
340	post	_	_	I-Claim
341	-	_	_	I-Claim
342	unblinding	_	_	I-Claim
343	analysis	_	_	I-Claim
344	suggest	_	_	I-Claim
345	that	_	_	I-Claim
346	letrozole	_	_	I-Claim
347	treatment	_	_	I-Claim
348	should	_	_	I-Claim
349	also	_	_	I-Claim
350	be	_	_	I-Claim
351	considered	_	_	I-Claim
352	for	_	_	I-Claim
353	all	_	_	I-Claim
354	disease	_	_	I-Claim
355	-	_	_	I-Claim
356	free	_	_	I-Claim
357	women	_	_	I-Claim
358	for	_	_	I-Claim
359	periods	_	_	I-Claim
360	up	_	_	I-Claim
361	to	_	_	I-Claim
362	5	_	_	I-Claim
363	years	_	_	I-Claim
364	following	_	_	I-Claim
365	completion	_	_	I-Claim
366	of	_	_	I-Claim
367	adjuvant	_	_	I-Claim
368	tamoxifen	_	_	I-Claim
369	.	_	_	I-Claim


0	Radiotherapy	_	_	B-Claim
1	is	_	_	I-Claim
2	an	_	_	I-Claim
3	effective	_	_	I-Claim
4	palliative	_	_	I-Claim
5	treatment	_	_	I-Claim
6	for	_	_	I-Claim
7	cancer	_	_	I-Claim
8	patients	_	_	I-Claim
9	with	_	_	I-Claim
10	painful	_	_	I-Claim
11	bone	_	_	I-Claim
12	metastases	_	_	I-Claim
13	.	_	_	I-Claim

14	Although	_	_	O
15	single	_	_	O
16	-	_	_	O
17	and	_	_	O
18	multiple	_	_	O
19	-	_	_	O
20	fraction	_	_	O
21	radiotherapy	_	_	O
22	are	_	_	O
23	thought	_	_	O
24	to	_	_	O
25	provide	_	_	O
26	equal	_	_	O
27	palliation	_	_	O
28	,	_	_	O
29	which	_	_	O
30	treatment	_	_	O
31	schedule	_	_	O
32	provides	_	_	O
33	better	_	_	O
34	value	_	_	O
35	for	_	_	O
36	the	_	_	O
37	money	_	_	O
38	is	_	_	O
39	unknown	_	_	O
40	.	_	_	O

41	We	_	_	O
42	compared	_	_	O
43	quality	_	_	O
44	-	_	_	O
45	adjusted	_	_	O
46	life	_	_	O
47	expectancy	_	_	O
48	(	_	_	O
49	the	_	_	O
50	overall	_	_	O
51	valuation	_	_	O
52	of	_	_	O
53	the	_	_	O
54	health	_	_	O
55	of	_	_	O
56	the	_	_	O
57	patients	_	_	O
58	)	_	_	O
59	and	_	_	O
60	societal	_	_	O
61	costs	_	_	O
62	for	_	_	O
63	patients	_	_	O
64	receiving	_	_	O
65	either	_	_	O
66	single	_	_	O
67	-	_	_	O
68	or	_	_	O
69	multiple	_	_	O
70	-	_	_	O
71	fraction	_	_	O
72	radiotherapy	_	_	O
73	.	_	_	O

74	A	_	_	O
75	societal	_	_	O
76	cost	_	_	O
77	-	_	_	O
78	utility	_	_	O
79	analysis	_	_	O
80	was	_	_	O
81	performed	_	_	O
82	on	_	_	O
83	a	_	_	O
84	Dutch	_	_	O
85	randomized	_	_	O
86	,	_	_	O
87	controlled	_	_	O
88	trial	_	_	O
89	of	_	_	O
90	1157	_	_	O
91	patients	_	_	O
92	with	_	_	O
93	painful	_	_	O
94	bone	_	_	O
95	metastases	_	_	O
96	that	_	_	O
97	compared	_	_	O
98	pain	_	_	O
99	responses	_	_	O
100	and	_	_	O
101	quality	_	_	O
102	of	_	_	O
103	life	_	_	O
104	from	_	_	O
105	a	_	_	O
106	single	_	_	O
107	-	_	_	O
108	fraction	_	_	O
109	treatment	_	_	O
110	schedule	_	_	O
111	of	_	_	O
112	8	_	_	O
113	Gy	_	_	O
114	with	_	_	O
115	a	_	_	O
116	treatment	_	_	O
117	schedule	_	_	O
118	of	_	_	O
119	six	_	_	O
120	fractions	_	_	O
121	of	_	_	O
122	4	_	_	O
123	Gy	_	_	O
124	each	_	_	O
125	.	_	_	O

126	The	_	_	O
127	societal	_	_	O
128	values	_	_	O
129	of	_	_	O
130	life	_	_	O
131	expectancies	_	_	O
132	were	_	_	O
133	assessed	_	_	O
134	with	_	_	O
135	the	_	_	O
136	EuroQol	_	_	O
137	classification	_	_	O
138	system	_	_	O
139	(	_	_	O
140	EQ	_	_	O
141	-	_	_	O
142	5D	_	_	O
143	)	_	_	O
144	questionnaire	_	_	O
145	.	_	_	O

146	A	_	_	O
147	subset	_	_	O
148	of	_	_	O
149	166	_	_	O
150	patients	_	_	O
151	also	_	_	O
152	answered	_	_	O
153	additional	_	_	O
154	questionnaires	_	_	O
155	to	_	_	O
156	estimate	_	_	O
157	nonradiotherapy	_	_	O
158	and	_	_	O
159	nonmedical	_	_	O
160	costs	_	_	O
161	.	_	_	O

162	Statistical	_	_	O
163	tests	_	_	O
164	were	_	_	O
165	two	_	_	O
166	-	_	_	O
167	sided	_	_	O
168	.	_	_	O

169	Comparing	_	_	B-Premise
170	the	_	_	I-Premise
171	single	_	_	I-Premise
172	-	_	_	I-Premise
173	and	_	_	I-Premise
174	multiple	_	_	I-Premise
175	-	_	_	I-Premise
176	fraction	_	_	I-Premise
177	radiotherapy	_	_	I-Premise
178	schedules	_	_	I-Premise
179	,	_	_	I-Premise
180	no	_	_	I-Premise
181	differences	_	_	I-Premise
182	were	_	_	I-Premise
183	found	_	_	I-Premise
184	in	_	_	I-Premise
185	life	_	_	I-Premise
186	expectancy	_	_	I-Premise
187	(	_	_	I-Premise
188	43	_	_	I-Premise
189	.	_	_	I-Premise

190	0	_	_	I-Premise
191	versus	_	_	I-Premise
192	40	_	_	I-Premise
193	.	_	_	I-Premise

194	4	_	_	I-Premise
195	weeks	_	_	I-Premise
196	,	_	_	I-Premise
197	P	_	_	I-Premise
198	=	_	_	I-Premise
199	.	_	_	I-Premise

200	20	_	_	I-Premise
201	)	_	_	I-Premise
202	or	_	_	I-Premise
203	quality	_	_	I-Premise
204	-	_	_	I-Premise
205	adjusted	_	_	I-Premise
206	life	_	_	I-Premise
207	expectancy	_	_	I-Premise
208	(	_	_	I-Premise
209	17	_	_	I-Premise
210	.	_	_	I-Premise

211	7	_	_	I-Premise
212	versus	_	_	I-Premise
213	16	_	_	I-Premise
214	.	_	_	I-Premise

215	0	_	_	I-Premise
216	weeks	_	_	I-Premise
217	,	_	_	I-Premise
218	P	_	_	I-Premise
219	=	_	_	I-Premise
220	.	_	_	I-Premise

221	21	_	_	I-Premise
222	)	_	_	I-Premise
223	.	_	_	I-Premise

224	The	_	_	B-Premise
225	estimated	_	_	I-Premise
226	cost	_	_	I-Premise
227	of	_	_	I-Premise
228	radiotherapy	_	_	I-Premise
229	,	_	_	I-Premise
230	including	_	_	I-Premise
231	retreatments	_	_	I-Premise
232	and	_	_	I-Premise
233	nonmedical	_	_	I-Premise
234	costs	_	_	I-Premise
235	,	_	_	I-Premise
236	was	_	_	I-Premise
237	statistically	_	_	I-Premise
238	significantly	_	_	I-Premise
239	lower	_	_	I-Premise
240	for	_	_	I-Premise
241	the	_	_	I-Premise
242	single	_	_	I-Premise
243	-	_	_	I-Premise
244	fraction	_	_	I-Premise
245	schedule	_	_	I-Premise
246	than	_	_	I-Premise
247	for	_	_	I-Premise
248	the	_	_	I-Premise
249	multiple	_	_	I-Premise
250	-	_	_	I-Premise
251	fraction	_	_	I-Premise
252	schedule	_	_	I-Premise
253	(	_	_	I-Premise
254	$	_	_	I-Premise
255	2438	_	_	I-Premise
256	versus	_	_	I-Premise
257	$	_	_	I-Premise
258	3311	_	_	I-Premise
259	,	_	_	I-Premise
260	difference	_	_	I-Premise
261	=	_	_	I-Premise
262	$	_	_	I-Premise
263	873	_	_	I-Premise
264	,	_	_	I-Premise
265	95	_	_	I-Premise
266	%	_	_	I-Premise
267	confidence	_	_	I-Premise
268	interval	_	_	I-Premise
269	[	_	_	I-Premise
270	CI	_	_	I-Premise
271	]	_	_	I-Premise
272	on	_	_	I-Premise
273	the	_	_	I-Premise
274	difference	_	_	I-Premise
275	=	_	_	I-Premise
276	$	_	_	I-Premise
277	449	_	_	I-Premise
278	to	_	_	I-Premise
279	$	_	_	I-Premise
280	1297	_	_	I-Premise
281	;	_	_	I-Premise
282	P	_	_	I-Premise
283	<	_	_	I-Premise
284	.	_	_	I-Premise

285	001	_	_	I-Premise
286	)	_	_	I-Premise
287	.	_	_	I-Premise

288	The	_	_	B-Premise
289	estimated	_	_	I-Premise
290	difference	_	_	I-Premise
291	in	_	_	I-Premise
292	total	_	_	I-Premise
293	societal	_	_	I-Premise
294	costs	_	_	I-Premise
295	was	_	_	I-Premise
296	larger	_	_	I-Premise
297	,	_	_	I-Premise
298	also	_	_	I-Premise
299	in	_	_	I-Premise
300	favor	_	_	I-Premise
301	of	_	_	I-Premise
302	the	_	_	I-Premise
303	single	_	_	I-Premise
304	-	_	_	I-Premise
305	fraction	_	_	I-Premise
306	schedule	_	_	I-Premise
307	,	_	_	I-Premise
308	but	_	_	B-Premise
309	it	_	_	I-Premise
310	was	_	_	I-Premise
311	not	_	_	I-Premise
312	statistically	_	_	I-Premise
313	significant	_	_	I-Premise
314	(	_	_	I-Premise
315	$	_	_	I-Premise
316	4700	_	_	I-Premise
317	versus	_	_	I-Premise
318	$	_	_	I-Premise
319	6453	_	_	I-Premise
320	,	_	_	I-Premise
321	difference	_	_	I-Premise
322	=	_	_	I-Premise
323	$	_	_	I-Premise
324	1753	_	_	I-Premise
325	,	_	_	I-Premise
326	95	_	_	I-Premise
327	%	_	_	I-Premise
328	CI	_	_	I-Premise
329	on	_	_	I-Premise
330	the	_	_	I-Premise
331	difference	_	_	I-Premise
332	=	_	_	I-Premise
333	-	_	_	I-Premise
334	$	_	_	I-Premise
335	99	_	_	I-Premise
336	to	_	_	I-Premise
337	$	_	_	I-Premise
338	3604	_	_	I-Premise
339	;	_	_	I-Premise
340	P	_	_	I-Premise
341	=	_	_	I-Premise
342	.	_	_	I-Premise

343	06	_	_	I-Premise
344	)	_	_	I-Premise
345	.	_	_	I-Premise

346	For	_	_	B-Premise
347	willingness	_	_	I-Premise
348	-	_	_	I-Premise
349	to	_	_	I-Premise
350	-	_	_	I-Premise
351	pay	_	_	I-Premise
352	between	_	_	I-Premise
353	$	_	_	I-Premise
354	5000	_	_	I-Premise
355	and	_	_	I-Premise
356	$	_	_	I-Premise
357	40	_	_	I-Premise
358	000	_	_	I-Premise
359	per	_	_	I-Premise
360	quality	_	_	I-Premise
361	-	_	_	I-Premise
362	adjusted	_	_	I-Premise
363	life	_	_	I-Premise
364	year	_	_	I-Premise
365	,	_	_	I-Premise
366	the	_	_	I-Premise
367	single	_	_	I-Premise
368	-	_	_	I-Premise
369	fraction	_	_	I-Premise
370	schedule	_	_	I-Premise
371	was	_	_	I-Premise
372	statistically	_	_	I-Premise
373	significantly	_	_	I-Premise
374	more	_	_	I-Premise
375	cost	_	_	I-Premise
376	-	_	_	I-Premise
377	effective	_	_	I-Premise
378	than	_	_	I-Premise
379	the	_	_	I-Premise
380	multiple	_	_	I-Premise
381	-	_	_	I-Premise
382	fraction	_	_	I-Premise
383	schedule	_	_	I-Premise
384	(	_	_	I-Premise
385	P	_	_	I-Premise
386	<	_	_	I-Premise
387	or	_	_	I-Premise
388	=	_	_	I-Premise
389	.	_	_	I-Premise

390	05	_	_	I-Premise
391	)	_	_	I-Premise
392	.	_	_	I-Premise

393	Compared	_	_	B-Claim
394	with	_	_	I-Claim
395	multiple	_	_	I-Claim
396	-	_	_	I-Claim
397	fraction	_	_	I-Claim
398	radiotherapy	_	_	I-Claim
399	,	_	_	I-Claim
400	single	_	_	I-Claim
401	-	_	_	I-Claim
402	fraction	_	_	I-Claim
403	radiotherapy	_	_	I-Claim
404	provides	_	_	I-Claim
405	equal	_	_	I-Claim
406	palliation	_	_	I-Claim
407	and	_	_	I-Claim
408	quality	_	_	I-Claim
409	of	_	_	I-Claim
410	life	_	_	I-Claim
411	and	_	_	I-Claim
412	has	_	_	I-Claim
413	lower	_	_	I-Claim
414	medical	_	_	I-Claim
415	and	_	_	I-Claim
416	societal	_	_	I-Claim
417	costs	_	_	I-Claim
418	,	_	_	I-Claim
419	at	_	_	I-Claim
420	least	_	_	I-Claim
421	in	_	_	I-Claim
422	The	_	_	I-Claim
423	Netherlands	_	_	I-Claim
424	.	_	_	I-Claim

425	Therefore	_	_	B-Claim
426	,	_	_	I-Claim
427	single	_	_	I-Claim
428	-	_	_	I-Claim
429	fraction	_	_	I-Claim
430	radiotherapy	_	_	I-Claim
431	should	_	_	I-Claim
432	be	_	_	I-Claim
433	considered	_	_	I-Claim
434	as	_	_	I-Claim
435	the	_	_	I-Claim
436	palliative	_	_	I-Claim
437	treatment	_	_	I-Claim
438	of	_	_	I-Claim
439	choice	_	_	I-Claim
440	for	_	_	I-Claim
441	cancer	_	_	I-Claim
442	patients	_	_	I-Claim
443	with	_	_	I-Claim
444	painful	_	_	I-Claim
445	bone	_	_	I-Claim
446	metastases	_	_	I-Claim
447	.	_	_	I-Claim


0	Vinorelbine	_	_	B-Claim
1	,	_	_	I-Claim
2	a	_	_	I-Claim
3	semisynthetic	_	_	I-Claim
4	vinca	_	_	I-Claim
5	alkaloid	_	_	I-Claim
6	,	_	_	I-Claim
7	represents	_	_	I-Claim
8	a	_	_	I-Claim
9	well	_	_	I-Claim
10	-	_	_	I-Claim
11	tolerated	_	_	I-Claim
12	treatment	_	_	I-Claim
13	for	_	_	I-Claim
14	elderly	_	_	I-Claim
15	patients	_	_	I-Claim
16	with	_	_	I-Claim
17	advanced	_	_	I-Claim
18	non	_	_	I-Claim
19	-	_	_	I-Claim
20	small	_	_	I-Claim
21	-	_	_	I-Claim
22	cell	_	_	I-Claim
23	lung	_	_	I-Claim
24	cancer	_	_	I-Claim
25	(	_	_	I-Claim
26	NSCLC	_	_	I-Claim
27	)	_	_	I-Claim
28	.	_	_	I-Claim

29	We	_	_	O
30	explored	_	_	O
31	the	_	_	O
32	quality	_	_	O
33	of	_	_	O
34	life	_	_	O
35	(	_	_	O
36	QoL	_	_	O
37	)	_	_	O
38	of	_	_	O
39	such	_	_	O
40	patients	_	_	O
41	in	_	_	O
42	a	_	_	O
43	multicenter	_	_	O
44	randomized	_	_	O
45	trial	_	_	O
46	that	_	_	O
47	compared	_	_	O
48	vinorelbine	_	_	O
49	treatment	_	_	O
50	with	_	_	O
51	supportive	_	_	O
52	care	_	_	O
53	alone	_	_	O
54	.	_	_	O

55	Eligible	_	_	O
56	patients	_	_	O
57	were	_	_	O
58	70	_	_	O
59	years	_	_	O
60	of	_	_	O
61	age	_	_	O
62	or	_	_	O
63	older	_	_	O
64	,	_	_	O
65	had	_	_	O
66	stage	_	_	O
67	IV	_	_	O
68	or	_	_	O
69	IIIB	_	_	O
70	NSCLC	_	_	O
71	that	_	_	O
72	was	_	_	O
73	ineligible	_	_	O
74	for	_	_	O
75	radiotherapy	_	_	O
76	,	_	_	O
77	and	_	_	O
78	had	_	_	O
79	a	_	_	O
80	performance	_	_	O
81	status	_	_	O
82	of	_	_	O
83	0	_	_	O
84	-	_	_	O
85	2	_	_	O
86	(	_	_	O
87	a	_	_	O
88	status	_	_	O
89	of	_	_	O
90	fully	_	_	O
91	active	_	_	O
92	to	_	_	O
93	a	_	_	O
94	status	_	_	O
95	of	_	_	O
96	capable	_	_	O
97	of	_	_	O
98	all	_	_	O
99	self	_	_	O
100	-	_	_	O
101	care	_	_	O
102	but	_	_	O
103	unable	_	_	O
104	to	_	_	O
105	work	_	_	O
106	)	_	_	O
107	.	_	_	O

108	Vinorelbine	_	_	O
109	was	_	_	O
110	given	_	_	O
111	intravenously	_	_	O
112	on	_	_	O
113	days	_	_	O
114	1	_	_	O
115	and	_	_	O
116	8	_	_	O
117	of	_	_	O
118	a	_	_	O
119	21	_	_	O
120	-	_	_	O
121	day	_	_	O
122	treatment	_	_	O
123	cycle	_	_	O
124	,	_	_	O
125	for	_	_	O
126	a	_	_	O
127	total	_	_	O
128	of	_	_	O
129	six	_	_	O
130	cycles	_	_	O
131	.	_	_	O

132	QoL	_	_	O
133	was	_	_	O
134	evaluated	_	_	O
135	with	_	_	O
136	European	_	_	O
137	Organization	_	_	O
138	for	_	_	O
139	Research	_	_	O
140	and	_	_	O
141	Treatment	_	_	O
142	of	_	_	O
143	Cancer	_	_	O
144	questionnaires	_	_	O
145	QLQ	_	_	O
146	-	_	_	O
147	C30	_	_	O
148	and	_	_	O
149	QLQ	_	_	O
150	-	_	_	O
151	LC13	_	_	O
152	,	_	_	O
153	and	_	_	O
154	the	_	_	O
155	QoL	_	_	O
156	data	_	_	O
157	were	_	_	O
158	analyzed	_	_	O
159	by	_	_	O
160	fitting	_	_	O
161	a	_	_	O
162	linear	_	_	O
163	mixed	_	_	O
164	model	_	_	O
165	for	_	_	O
166	each	_	_	O
167	QoL	_	_	O
168	scale	_	_	O
169	.	_	_	O

170	Survival	_	_	O
171	curves	_	_	O
172	were	_	_	O
173	plotted	_	_	O
174	and	_	_	O
175	were	_	_	O
176	compared	_	_	O
177	with	_	_	O
178	the	_	_	O
179	Mantel	_	_	O
180	-	_	_	O
181	Haenszel	_	_	O
182	test	_	_	O
183	.	_	_	O

184	Relative	_	_	O
185	hazards	_	_	O
186	of	_	_	O
187	death	_	_	O
188	and	_	_	O
189	95	_	_	O
190	%	_	_	O
191	confidence	_	_	O
192	intervals	_	_	O
193	(	_	_	O
194	CIs	_	_	O
195	)	_	_	O
196	were	_	_	O
197	estimated	_	_	O
198	by	_	_	O
199	the	_	_	O
200	Cox	_	_	O
201	model	_	_	O
202	.	_	_	O

203	Investigators	_	_	O
204	,	_	_	O
205	blinded	_	_	O
206	to	_	_	O
207	the	_	_	O
208	results	_	_	O
209	,	_	_	O
210	stopped	_	_	O
211	the	_	_	O
212	trial	_	_	O
213	early	_	_	O
214	because	_	_	O
215	of	_	_	O
216	a	_	_	O
217	low	_	_	O
218	enrollment	_	_	O
219	rate	_	_	O
220	.	_	_	O

221	(	_	_	O
222	From	_	_	O
223	April	_	_	O
224	1996	_	_	O
225	to	_	_	O
226	November	_	_	O
227	1997	_	_	O
228	,	_	_	O
229	191	_	_	O
230	of	_	_	O
231	the	_	_	O
232	350	_	_	O
233	targeted	_	_	O
234	patients	_	_	O
235	were	_	_	O
236	randomly	_	_	O
237	assigned	_	_	O
238	.	_	_	O

239	)	_	_	O
240	Data	_	_	O
241	from	_	_	O
242	161	_	_	O
243	patients	_	_	O
244	have	_	_	O
245	been	_	_	O
246	analyzed	_	_	O
247	.	_	_	O

248	Vinorelbine	_	_	B-Premise
249	-	_	_	I-Premise
250	treated	_	_	I-Premise
251	patients	_	_	I-Premise
252	scored	_	_	I-Premise
253	better	_	_	I-Premise
254	than	_	_	I-Premise
255	control	_	_	I-Premise
256	patients	_	_	I-Premise
257	on	_	_	I-Premise
258	QoL	_	_	I-Premise
259	functioning	_	_	I-Premise
260	scales	_	_	I-Premise
261	,	_	_	I-Premise
262	and	_	_	I-Premise
263	they	_	_	I-Premise
264	reported	_	_	I-Premise
265	fewer	_	_	I-Premise
266	lung	_	_	I-Premise
267	cancer	_	_	I-Premise
268	-	_	_	I-Premise
269	related	_	_	I-Premise
270	symptoms	_	_	I-Premise
271	but	_	_	I-Premise
272	reported	_	_	I-Premise
273	worse	_	_	I-Premise
274	toxicity	_	_	I-Premise
275	-	_	_	I-Premise
276	related	_	_	I-Premise
277	symptoms	_	_	I-Premise
278	.	_	_	I-Premise

279	There	_	_	B-Premise
280	was	_	_	I-Premise
281	a	_	_	I-Premise
282	statistically	_	_	I-Premise
283	significant	_	_	I-Premise
284	(	_	_	I-Premise
285	two	_	_	I-Premise
286	-	_	_	I-Premise
287	sided	_	_	I-Premise
288	P	_	_	I-Premise
289	=	_	_	I-Premise
290	.	_	_	I-Premise

291	03	_	_	I-Premise
292	)	_	_	I-Premise
293	survival	_	_	I-Premise
294	advantage	_	_	I-Premise
295	for	_	_	I-Premise
296	patients	_	_	I-Premise
297	receiving	_	_	I-Premise
298	vinorelbine	_	_	I-Premise
299	;	_	_	I-Premise
300	median	_	_	B-Premise
301	survival	_	_	I-Premise
302	increased	_	_	I-Premise
303	from	_	_	I-Premise
304	21	_	_	I-Premise
305	to	_	_	I-Premise
306	28	_	_	I-Premise
307	weeks	_	_	I-Premise
308	in	_	_	I-Premise
309	the	_	_	I-Premise
310	vinorelbine	_	_	I-Premise
311	-	_	_	I-Premise
312	treated	_	_	I-Premise
313	group	_	_	I-Premise
314	.	_	_	I-Premise

315	The	_	_	B-Premise
316	relative	_	_	I-Premise
317	hazard	_	_	I-Premise
318	of	_	_	I-Premise
319	death	_	_	I-Premise
320	for	_	_	I-Premise
321	vinorelbine	_	_	I-Premise
322	-	_	_	I-Premise
323	treated	_	_	I-Premise
324	patients	_	_	I-Premise
325	was	_	_	I-Premise
326	0	_	_	I-Premise
327	.	_	_	I-Premise

328	65	_	_	I-Premise
329	(	_	_	I-Premise
330	95	_	_	I-Premise
331	%	_	_	I-Premise
332	CI	_	_	I-Premise
333	=	_	_	I-Premise
334	0	_	_	I-Premise
335	.	_	_	I-Premise

336	45	_	_	I-Premise
337	-	_	_	I-Premise
338	0	_	_	I-Premise
339	.	_	_	I-Premise

340	93	_	_	I-Premise
341	)	_	_	I-Premise
342	.	_	_	I-Premise

343	Vinorelbine	_	_	B-Claim
344	improves	_	_	I-Claim
345	survival	_	_	I-Claim
346	of	_	_	I-Claim
347	elderly	_	_	I-Claim
348	patients	_	_	I-Claim
349	with	_	_	I-Claim
350	advanced	_	_	I-Claim
351	NSCLC	_	_	I-Claim
352	and	_	_	I-Claim
353	possibly	_	_	I-Claim
354	improves	_	_	I-Claim
355	overall	_	_	I-Claim
356	QoL	_	_	I-Claim
357	.	_	_	I-Claim


0	A	_	_	O
1	single	_	_	O
2	-	_	_	O
3	item	_	_	O
4	linear	_	_	O
5	analogue	_	_	O
6	self	_	_	O
7	-	_	_	O
8	assessment	_	_	O
9	scale	_	_	O
10	for	_	_	O
11	mood	_	_	O
12	was	_	_	O
13	compared	_	_	O
14	with	_	_	O
15	a	_	_	O
16	28	_	_	O
17	-	_	_	O
18	item	_	_	O
19	adjective	_	_	O
20	checklist	_	_	O
21	for	_	_	O
22	emotional	_	_	O
23	well	_	_	O
24	-	_	_	O
25	being	_	_	O
26	.	_	_	O

27	To	_	_	O
28	confirm	_	_	O
29	its	_	_	O
30	concurrent	_	_	O
31	validity	_	_	O
32	and	_	_	O
33	responsiveness	_	_	O
34	to	_	_	O
35	treatment	_	_	O
36	and	_	_	O
37	recurrence	_	_	O
38	in	_	_	O
39	patients	_	_	O
40	with	_	_	O
41	breast	_	_	O
42	cancer	_	_	O
43	,	_	_	O
44	emotional	_	_	O
45	well	_	_	O
46	-	_	_	O
47	being	_	_	O
48	was	_	_	O
49	assessed	_	_	O
50	every	_	_	O
51	3	_	_	O
52	months	_	_	O
53	for	_	_	O
54	2	_	_	O
55	years	_	_	O
56	and	_	_	O
57	at	_	_	O
58	1	_	_	O
59	and	_	_	O
60	6	_	_	O
61	months	_	_	O
62	after	_	_	O
63	recurrence	_	_	O
64	in	_	_	O
65	1	_	_	O
66	,	_	_	O
67	169	_	_	O
68	patients	_	_	O
69	who	_	_	O
70	were	_	_	O
71	premenopausal	_	_	O
72	and	_	_	O
73	960	_	_	O
74	patients	_	_	O
75	who	_	_	O
76	were	_	_	O
77	postmenopausal	_	_	O
78	.	_	_	O

79	These	_	_	O
80	patients	_	_	O
81	were	_	_	O
82	enrolled	_	_	O
83	in	_	_	O
84	two	_	_	O
85	International	_	_	O
86	Breast	_	_	O
87	Cancer	_	_	O
88	Study	_	_	O
89	Group	_	_	O
90	randomized	_	_	O
91	clinical	_	_	O
92	trials	_	_	O
93	in	_	_	O
94	operable	_	_	O
95	breast	_	_	O
96	cancer	_	_	O
97	conducted	_	_	O
98	from	_	_	O
99	1986	_	_	O
100	to	_	_	O
101	1993	_	_	O
102	.	_	_	O

103	To	_	_	O
104	assess	_	_	O
105	concurrent	_	_	O
106	validity	_	_	O
107	,	_	_	O
108	Pearson	_	_	O
109	'	_	_	O
110	s	_	_	O
111	correlation	_	_	O
112	between	_	_	O
113	the	_	_	O
114	linear	_	_	O
115	analogue	_	_	O
116	self	_	_	O
117	-	_	_	O
118	assessment	_	_	O
119	scale	_	_	O
120	and	_	_	O
121	the	_	_	O
122	adjective	_	_	O
123	checklist	_	_	O
124	were	_	_	O
125	calculated	_	_	O
126	for	_	_	O
127	each	_	_	O
128	time	_	_	O
129	-	_	_	O
130	point	_	_	O
131	within	_	_	O
132	each	_	_	O
133	treatment	_	_	O
134	group	_	_	O
135	and	_	_	O
136	for	_	_	O
137	the	_	_	O
138	two	_	_	O
139	assessments	_	_	O
140	after	_	_	O
141	recurrence	_	_	O
142	.	_	_	O

143	Responsiveness	_	_	O
144	to	_	_	O
145	treatment	_	_	O
146	and	_	_	O
147	recurrence	_	_	O
148	were	_	_	O
149	analyzed	_	_	O
150	using	_	_	O
151	paired	_	_	O
152	t	_	_	O
153	tests	_	_	O
154	and	_	_	O
155	the	_	_	O
156	squared	_	_	O
157	ratio	_	_	O
158	of	_	_	O
159	these	_	_	O
160	t	_	_	O
161	tests	_	_	O
162	,	_	_	O
163	an	_	_	O
164	estimate	_	_	O
165	of	_	_	O
166	relative	_	_	O
167	efficiency	_	_	O
168	.	_	_	O

169	Concurrent	_	_	O
170	validity	_	_	O
171	of	_	_	O
172	the	_	_	O
173	mood	_	_	O
174	linear	_	_	O
175	analogue	_	_	O
176	self	_	_	O
177	-	_	_	O
178	assessment	_	_	O
179	was	_	_	O
180	consistently	_	_	O
181	confirmed	_	_	O
182	across	_	_	O
183	four	_	_	O
184	language	_	_	O
185	groups	_	_	O
186	.	_	_	O

187	Both	_	_	B-Claim
188	measures	_	_	I-Claim
189	were	_	_	I-Claim
190	responsive	_	_	I-Claim
191	;	_	_	I-Claim
192	out	_	_	B-Premise
193	of	_	_	I-Premise
194	24	_	_	I-Premise
195	changes	_	_	I-Premise
196	over	_	_	I-Premise
197	time	_	_	I-Premise
198	,	_	_	I-Premise
199	19	_	_	I-Premise
200	were	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	expected	_	_	I-Premise
204	direction	_	_	I-Premise
205	for	_	_	I-Premise
206	the	_	_	I-Premise
207	linear	_	_	I-Premise
208	analogue	_	_	I-Premise
209	self	_	_	I-Premise
210	-	_	_	I-Premise
211	assessment	_	_	I-Premise
212	scale	_	_	I-Premise
213	(	_	_	I-Premise
214	p	_	_	I-Premise
215	<	_	_	I-Premise
216	or	_	_	I-Premise
217	=	_	_	I-Premise
218	0	_	_	I-Premise
219	.	_	_	I-Premise

220	05	_	_	I-Premise
221	for	_	_	I-Premise
222	9	_	_	I-Premise
223	of	_	_	I-Premise
224	19	_	_	I-Premise
225	)	_	_	I-Premise
226	and	_	_	I-Premise
227	17	_	_	I-Premise
228	for	_	_	I-Premise
229	the	_	_	I-Premise
230	adjective	_	_	I-Premise
231	checklist	_	_	I-Premise
232	(	_	_	I-Premise
233	p	_	_	I-Premise
234	<	_	_	I-Premise
235	or	_	_	I-Premise
236	=	_	_	I-Premise
237	0	_	_	I-Premise
238	.	_	_	I-Premise

239	05	_	_	I-Premise
240	for	_	_	I-Premise
241	10	_	_	I-Premise
242	of	_	_	I-Premise
243	17	_	_	I-Premise
244	)	_	_	I-Premise
245	.	_	_	I-Premise

246	The	_	_	B-Premise
247	linear	_	_	I-Premise
248	analogue	_	_	I-Premise
249	self	_	_	I-Premise
250	-	_	_	I-Premise
251	assessment	_	_	I-Premise
252	scale	_	_	I-Premise
253	was	_	_	I-Premise
254	less	_	_	I-Premise
255	but	_	_	I-Premise
256	significantly	_	_	I-Premise
257	efficient	_	_	I-Premise
258	for	_	_	I-Premise
259	detection	_	_	I-Premise
260	of	_	_	I-Premise
261	treatment	_	_	I-Premise
262	effects	_	_	I-Premise
263	,	_	_	I-Premise
264	with	_	_	I-Premise
265	relative	_	_	I-Premise
266	efficiency	_	_	I-Premise
267	estimates	_	_	I-Premise
268	ranging	_	_	I-Premise
269	from	_	_	I-Premise
270	0	_	_	I-Premise
271	.	_	_	I-Premise

272	16	_	_	I-Premise
273	to	_	_	I-Premise
274	2	_	_	I-Premise
275	.	_	_	I-Premise

276	45	_	_	I-Premise
277	and	_	_	I-Premise
278	a	_	_	I-Premise
279	median	_	_	I-Premise
280	of	_	_	I-Premise
281	0	_	_	I-Premise
282	.	_	_	I-Premise

283	66	_	_	I-Premise
284	among	_	_	I-Premise
285	the	_	_	I-Premise
286	comparisons	_	_	I-Premise
287	with	_	_	I-Premise
288	relatively	_	_	I-Premise
289	stable	_	_	I-Premise
290	estimates	_	_	I-Premise
291	(	_	_	I-Premise
292	/	_	_	I-Premise
293	t	_	_	I-Premise
294	/	_	_	I-Premise
295	>	_	_	I-Premise
296	or	_	_	I-Premise
297	=	_	_	I-Premise
298	1	_	_	I-Premise
299	.	_	_	I-Premise

300	0	_	_	I-Premise
301	)	_	_	I-Premise
302	and	_	_	I-Premise
303	more	_	_	I-Premise
304	efficient	_	_	I-Premise
305	for	_	_	I-Premise
306	recurrence	_	_	I-Premise
307	than	_	_	I-Premise
308	the	_	_	I-Premise
309	adjective	_	_	I-Premise
310	checklist	_	_	I-Premise
311	.	_	_	I-Premise

312	The	_	_	B-Claim
313	mood	_	_	I-Claim
314	linear	_	_	I-Claim
315	analogue	_	_	I-Claim
316	self	_	_	I-Claim
317	-	_	_	I-Claim
318	assessment	_	_	I-Claim
319	scale	_	_	I-Claim
320	is	_	_	I-Claim
321	a	_	_	I-Claim
322	valid	_	_	I-Claim
323	indicator	_	_	I-Claim
324	of	_	_	I-Claim
325	emotional	_	_	I-Claim
326	well	_	_	I-Claim
327	-	_	_	I-Claim
328	being	_	_	I-Claim
329	in	_	_	I-Claim
330	patients	_	_	I-Claim
331	with	_	_	I-Claim
332	breast	_	_	I-Claim
333	cancer	_	_	I-Claim
334	in	_	_	I-Claim
335	large	_	_	I-Claim
336	multicenter	_	_	I-Claim
337	,	_	_	I-Claim
338	multicultural	_	_	I-Claim
339	trials	_	_	I-Claim
340	in	_	_	I-Claim
341	which	_	_	I-Claim
342	comprehensive	_	_	I-Claim
343	scales	_	_	I-Claim
344	are	_	_	I-Claim
345	less	_	_	I-Claim
346	feasible	_	_	I-Claim
347	.	_	_	I-Claim

348	This	_	_	B-Claim
349	investigation	_	_	I-Claim
350	supports	_	_	I-Claim
351	the	_	_	I-Claim
352	clinical	_	_	I-Claim
353	relevance	_	_	I-Claim
354	of	_	_	I-Claim
355	linear	_	_	I-Claim
356	analogue	_	_	I-Claim
357	self	_	_	I-Claim
358	-	_	_	I-Claim
359	assessment	_	_	I-Claim
360	scales	_	_	I-Claim
361	as	_	_	I-Claim
362	indicators	_	_	I-Claim
363	of	_	_	I-Claim
364	components	_	_	I-Claim
365	of	_	_	I-Claim
366	quality	_	_	I-Claim
367	of	_	_	I-Claim
368	life	_	_	I-Claim
369	in	_	_	I-Claim
370	cancer	_	_	I-Claim
371	clinical	_	_	I-Claim
372	trials	_	_	I-Claim
373	.	_	_	I-Claim


0	We	_	_	O
1	sought	_	_	O
2	the	_	_	O
3	extent	_	_	O
4	to	_	_	O
5	which	_	_	O
6	arm	_	_	O
7	morbidity	_	_	O
8	could	_	_	O
9	be	_	_	O
10	reduced	_	_	O
11	by	_	_	O
12	using	_	_	O
13	sentinel	_	_	O
14	-	_	_	O
15	lymph	_	_	O
16	-	_	_	O
17	node	_	_	O
18	-	_	_	O
19	based	_	_	O
20	management	_	_	O
21	in	_	_	O
22	women	_	_	O
23	with	_	_	O
24	clinically	_	_	O
25	node	_	_	O
26	-	_	_	O
27	negative	_	_	O
28	early	_	_	O
29	breast	_	_	O
30	cancer	_	_	O
31	.	_	_	O

32	One	_	_	O
33	thousand	_	_	O
34	eighty	_	_	O
35	-	_	_	O
36	eight	_	_	O
37	women	_	_	O
38	were	_	_	O
39	randomly	_	_	O
40	allocated	_	_	O
41	to	_	_	O
42	sentinel	_	_	O
43	-	_	_	O
44	lymph	_	_	O
45	-	_	_	O
46	node	_	_	O
47	biopsy	_	_	O
48	followed	_	_	O
49	by	_	_	O
50	axillary	_	_	O
51	clearance	_	_	O
52	if	_	_	O
53	the	_	_	O
54	sentinel	_	_	O
55	node	_	_	O
56	was	_	_	O
57	positive	_	_	O
58	or	_	_	O
59	not	_	_	O
60	detected	_	_	O
61	(	_	_	O
62	SNBM	_	_	O
63	)	_	_	O
64	or	_	_	O
65	routine	_	_	O
66	axillary	_	_	O
67	clearance	_	_	O
68	(	_	_	O
69	RAC	_	_	O
70	,	_	_	O
71	sentinel	_	_	O
72	-	_	_	O
73	lymph	_	_	O
74	-	_	_	O
75	node	_	_	O
76	biopsy	_	_	O
77	followed	_	_	O
78	immediately	_	_	O
79	by	_	_	O
80	axillary	_	_	O
81	clearance	_	_	O
82	)	_	_	O
83	.	_	_	O

84	Sentinel	_	_	O
85	nodes	_	_	O
86	were	_	_	O
87	located	_	_	O
88	using	_	_	O
89	blue	_	_	O
90	dye	_	_	O
91	,	_	_	O
92	alone	_	_	O
93	or	_	_	O
94	with	_	_	O
95	technetium	_	_	O
96	-	_	_	O
97	labeled	_	_	O
98	antimony	_	_	O
99	sulfide	_	_	O
100	colloid	_	_	O
101	.	_	_	O

102	The	_	_	O
103	primary	_	_	O
104	endpoint	_	_	O
105	was	_	_	O
106	increase	_	_	O
107	in	_	_	O
108	arm	_	_	O
109	volume	_	_	O
110	from	_	_	O
111	baseline	_	_	O
112	to	_	_	O
113	the	_	_	O
114	average	_	_	O
115	of	_	_	O
116	measurements	_	_	O
117	at	_	_	O
118	6	_	_	O
119	and	_	_	O
120	12	_	_	O
121	months	_	_	O
122	.	_	_	O

123	Secondary	_	_	O
124	endpoints	_	_	O
125	were	_	_	O
126	the	_	_	O
127	proportions	_	_	O
128	of	_	_	O
129	women	_	_	O
130	with	_	_	O
131	at	_	_	O
132	least	_	_	O
133	15	_	_	O
134	%	_	_	O
135	increase	_	_	O
136	in	_	_	O
137	arm	_	_	O
138	volume	_	_	O
139	or	_	_	O
140	early	_	_	O
141	axillary	_	_	O
142	morbidity	_	_	O
143	,	_	_	O
144	and	_	_	O
145	average	_	_	O
146	scores	_	_	O
147	for	_	_	O
148	arm	_	_	O
149	symptoms	_	_	O
150	,	_	_	O
151	dysfunctions	_	_	O
152	,	_	_	O
153	and	_	_	O
154	disabilities	_	_	O
155	assessed	_	_	O
156	at	_	_	O
157	6	_	_	O
158	and	_	_	O
159	12	_	_	O
160	months	_	_	O
161	by	_	_	O
162	patients	_	_	O
163	with	_	_	O
164	the	_	_	O
165	SNAC	_	_	O
166	Study	_	_	O
167	-	_	_	O
168	Specific	_	_	O
169	Scales	_	_	O
170	and	_	_	O
171	other	_	_	O
172	quality	_	_	O
173	-	_	_	O
174	of	_	_	O
175	-	_	_	O
176	life	_	_	O
177	instruments	_	_	O
178	.	_	_	O

179	Sensitivity	_	_	O
180	,	_	_	O
181	false	_	_	O
182	-	_	_	O
183	negative	_	_	O
184	rates	_	_	O
185	,	_	_	O
186	and	_	_	O
187	negative	_	_	O
188	predictive	_	_	O
189	values	_	_	O
190	for	_	_	O
191	sentinel	_	_	O
192	-	_	_	O
193	lymph	_	_	O
194	-	_	_	O
195	node	_	_	O
196	biopsy	_	_	O
197	were	_	_	O
198	estimated	_	_	O
199	in	_	_	O
200	the	_	_	O
201	RAC	_	_	O
202	group	_	_	O
203	.	_	_	O

204	The	_	_	B-Premise
205	average	_	_	I-Premise
206	increase	_	_	I-Premise
207	in	_	_	I-Premise
208	arm	_	_	I-Premise
209	volume	_	_	I-Premise
210	was	_	_	I-Premise
211	2	_	_	I-Premise
212	.	_	_	I-Premise

213	8	_	_	I-Premise
214	%	_	_	I-Premise
215	in	_	_	I-Premise
216	the	_	_	I-Premise
217	SNBM	_	_	I-Premise
218	group	_	_	I-Premise
219	and	_	_	I-Premise
220	4	_	_	I-Premise
221	.	_	_	I-Premise

222	2	_	_	I-Premise
223	%	_	_	I-Premise
224	in	_	_	I-Premise
225	the	_	_	I-Premise
226	RAC	_	_	I-Premise
227	group	_	_	I-Premise
228	(	_	_	I-Premise
229	P	_	_	I-Premise
230	=	_	_	I-Premise
231	0	_	_	I-Premise
232	.	_	_	I-Premise

233	002	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	Patients	_	_	B-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	SNBM	_	_	I-Premise
240	group	_	_	I-Premise
241	gave	_	_	I-Premise
242	lower	_	_	I-Premise
243	ratings	_	_	I-Premise
244	for	_	_	I-Premise
245	arm	_	_	I-Premise
246	swelling	_	_	I-Premise
247	(	_	_	I-Premise
248	P	_	_	I-Premise
249	<	_	_	I-Premise
250	0	_	_	I-Premise
251	.	_	_	I-Premise

252	001	_	_	I-Premise
253	)	_	_	I-Premise
254	,	_	_	I-Premise
255	symptoms	_	_	I-Premise
256	(	_	_	I-Premise
257	P	_	_	I-Premise
258	<	_	_	I-Premise
259	0	_	_	I-Premise
260	.	_	_	I-Premise

261	001	_	_	I-Premise
262	)	_	_	I-Premise
263	,	_	_	I-Premise
264	and	_	_	I-Premise
265	dysfunctions	_	_	I-Premise
266	(	_	_	I-Premise
267	P	_	_	I-Premise
268	=	_	_	I-Premise
269	0	_	_	I-Premise
270	.	_	_	I-Premise

271	02	_	_	I-Premise
272	)	_	_	I-Premise
273	,	_	_	I-Premise
274	but	_	_	I-Premise
275	not	_	_	I-Premise
276	disabilities	_	_	I-Premise
277	(	_	_	I-Premise
278	P	_	_	I-Premise
279	=	_	_	I-Premise
280	0	_	_	I-Premise
281	.	_	_	I-Premise

282	5	_	_	I-Premise
283	)	_	_	I-Premise
284	.	_	_	I-Premise

285	Sentinel	_	_	B-Premise
286	nodes	_	_	I-Premise
287	were	_	_	I-Premise
288	found	_	_	I-Premise
289	in	_	_	I-Premise
290	95	_	_	I-Premise
291	%	_	_	I-Premise
292	of	_	_	I-Premise
293	the	_	_	I-Premise
294	SNBM	_	_	I-Premise
295	group	_	_	I-Premise
296	(	_	_	I-Premise
297	29	_	_	I-Premise
298	%	_	_	I-Premise
299	positive	_	_	I-Premise
300	)	_	_	I-Premise
301	and	_	_	I-Premise
302	93	_	_	I-Premise
303	%	_	_	I-Premise
304	of	_	_	I-Premise
305	the	_	_	I-Premise
306	RAC	_	_	I-Premise
307	group	_	_	I-Premise
308	(	_	_	I-Premise
309	25	_	_	I-Premise
310	%	_	_	I-Premise
311	positive	_	_	I-Premise
312	)	_	_	I-Premise
313	.	_	_	I-Premise

314	SNB	_	_	O
315	had	_	_	O
316	sensitivity	_	_	O
317	94	_	_	O
318	.	_	_	O

319	5	_	_	O
320	%	_	_	O
321	,	_	_	O
322	false	_	_	O
323	-	_	_	O
324	negative	_	_	O
325	rate	_	_	O
326	5	_	_	O
327	.	_	_	O

328	5	_	_	O
329	%	_	_	O
330	,	_	_	O
331	and	_	_	O
332	negative	_	_	O
333	predictive	_	_	O
334	value	_	_	O
335	98	_	_	O
336	%	_	_	O
337	.	_	_	O

338	SNBM	_	_	B-Claim
339	was	_	_	I-Claim
340	successfully	_	_	I-Claim
341	undertaken	_	_	I-Claim
342	in	_	_	I-Claim
343	a	_	_	I-Claim
344	wide	_	_	I-Claim
345	range	_	_	I-Claim
346	of	_	_	I-Claim
347	surgical	_	_	I-Claim
348	centers	_	_	I-Claim
349	and	_	_	I-Claim
350	caused	_	_	I-Claim
351	significantly	_	_	I-Claim
352	less	_	_	I-Claim
353	morbidity	_	_	I-Claim
354	than	_	_	I-Claim
355	RAC	_	_	I-Claim
356	.	_	_	I-Claim


0	Phase	_	_	O
1	III	_	_	O
2	EGF104900	_	_	O
3	data	_	_	O
4	demonstrated	_	_	O
5	that	_	_	O
6	lapatinib	_	_	O
7	plus	_	_	O
8	trastuzumab	_	_	O
9	significantly	_	_	O
10	improved	_	_	O
11	progression	_	_	O
12	-	_	_	O
13	free	_	_	O
14	survival	_	_	O
15	(	_	_	O
16	PFS	_	_	O
17	)	_	_	O
18	and	_	_	O
19	clinical	_	_	O
20	benefit	_	_	O
21	rate	_	_	O
22	versus	_	_	O
23	lapatinib	_	_	O
24	monotherapy	_	_	O
25	,	_	_	O
26	offering	_	_	O
27	a	_	_	O
28	chemotherapy	_	_	O
29	-	_	_	O
30	free	_	_	O
31	option	_	_	O
32	for	_	_	O
33	patients	_	_	O
34	with	_	_	O
35	heavily	_	_	O
36	pretreated	_	_	O
37	human	_	_	O
38	epidermal	_	_	O
39	growth	_	_	O
40	factor	_	_	O
41	receptor	_	_	O
42	2	_	_	O
43	(	_	_	O
44	HER2	_	_	O
45	)	_	_	O
46	-	_	_	O
47	positive	_	_	O
48	metastatic	_	_	O
49	breast	_	_	O
50	cancer	_	_	O
51	(	_	_	O
52	MBC	_	_	O
53	)	_	_	O
54	.	_	_	O

55	Final	_	_	O
56	planned	_	_	O
57	overall	_	_	O
58	survival	_	_	O
59	(	_	_	O
60	OS	_	_	O
61	)	_	_	O
62	analysis	_	_	O
63	from	_	_	O
64	EGF104900	_	_	O
65	is	_	_	O
66	reported	_	_	O
67	here	_	_	O
68	.	_	_	O

69	Patients	_	_	O
70	with	_	_	O
71	HER2	_	_	O
72	-	_	_	O
73	positive	_	_	O
74	MBC	_	_	O
75	whose	_	_	O
76	disease	_	_	O
77	progressed	_	_	O
78	during	_	_	O
79	prior	_	_	O
80	trastuzumab	_	_	O
81	-	_	_	O
82	based	_	_	O
83	therapies	_	_	O
84	were	_	_	O
85	randomly	_	_	O
86	assigned	_	_	O
87	to	_	_	O
88	receive	_	_	O
89	lapatinib	_	_	O
90	monotherapy	_	_	O
91	or	_	_	O
92	lapatinib	_	_	O
93	in	_	_	O
94	combination	_	_	O
95	with	_	_	O
96	trastuzumab	_	_	O
97	.	_	_	O

98	OS	_	_	O
99	and	_	_	O
100	updated	_	_	O
101	PFS	_	_	O
102	data	_	_	O
103	are	_	_	O
104	presented	_	_	O
105	using	_	_	O
106	Kaplan	_	_	O
107	-	_	_	O
108	Meier	_	_	O
109	curves	_	_	O
110	and	_	_	O
111	log	_	_	O
112	-	_	_	O
113	rank	_	_	O
114	tests	_	_	O
115	stratified	_	_	O
116	for	_	_	O
117	hormone	_	_	O
118	receptor	_	_	O
119	and	_	_	O
120	visceral	_	_	O
121	disease	_	_	O
122	status	_	_	O
123	.	_	_	O

124	Subgroup	_	_	O
125	analyses	_	_	O
126	were	_	_	O
127	conducted	_	_	O
128	to	_	_	O
129	identify	_	_	O
130	characteristics	_	_	O
131	of	_	_	O
132	patients	_	_	O
133	deriving	_	_	O
134	the	_	_	O
135	greatest	_	_	O
136	clinical	_	_	O
137	benefit	_	_	O
138	.	_	_	O

139	In	_	_	B-Premise
140	this	_	_	I-Premise
141	updated	_	_	I-Premise
142	final	_	_	I-Premise
143	analysis	_	_	I-Premise
144	of	_	_	I-Premise
145	all	_	_	I-Premise
146	patients	_	_	I-Premise
147	randomly	_	_	I-Premise
148	assigned	_	_	I-Premise
149	with	_	_	I-Premise
150	strata	_	_	I-Premise
151	(	_	_	I-Premise
152	n	_	_	I-Premise
153	=	_	_	I-Premise
154	291	_	_	I-Premise
155	)	_	_	I-Premise
156	,	_	_	I-Premise
157	lapatinib	_	_	I-Premise
158	plus	_	_	I-Premise
159	trastuzumab	_	_	I-Premise
160	continued	_	_	I-Premise
161	to	_	_	I-Premise
162	show	_	_	I-Premise
163	superiority	_	_	I-Premise
164	to	_	_	I-Premise
165	lapatinib	_	_	I-Premise
166	monotherapy	_	_	I-Premise
167	in	_	_	I-Premise
168	PFS	_	_	I-Premise
169	(	_	_	I-Premise
170	hazard	_	_	I-Premise
171	ratio	_	_	I-Premise
172	[	_	_	I-Premise
173	HR	_	_	I-Premise
174	]	_	_	I-Premise
175	,	_	_	I-Premise
176	0	_	_	I-Premise
177	.	_	_	I-Premise

178	74	_	_	I-Premise
179	;	_	_	I-Premise
180	95	_	_	I-Premise
181	%	_	_	I-Premise
182	CI	_	_	I-Premise
183	,	_	_	I-Premise
184	0	_	_	I-Premise
185	.	_	_	I-Premise

186	58	_	_	I-Premise
187	to	_	_	I-Premise
188	0	_	_	I-Premise
189	.	_	_	I-Premise

190	94	_	_	I-Premise
191	;	_	_	I-Premise
192	P	_	_	I-Premise
193	=	_	_	I-Premise
194	.	_	_	I-Premise

195	011	_	_	I-Premise
196	)	_	_	I-Premise
197	and	_	_	I-Premise
198	offered	_	_	I-Premise
199	significant	_	_	I-Premise
200	OS	_	_	I-Premise
201	benefit	_	_	I-Premise
202	(	_	_	I-Premise
203	HR	_	_	I-Premise
204	,	_	_	I-Premise
205	0	_	_	I-Premise
206	.	_	_	I-Premise

207	74	_	_	I-Premise
208	;	_	_	I-Premise
209	95	_	_	I-Premise
210	%	_	_	I-Premise
211	CI	_	_	I-Premise
212	,	_	_	I-Premise
213	0	_	_	I-Premise
214	.	_	_	I-Premise

215	57	_	_	I-Premise
216	to	_	_	I-Premise
217	0	_	_	I-Premise
218	.	_	_	I-Premise

219	97	_	_	I-Premise
220	;	_	_	I-Premise
221	P	_	_	I-Premise
222	=	_	_	I-Premise
223	.	_	_	I-Premise

224	026	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	Improvements	_	_	B-Premise
228	in	_	_	I-Premise
229	absolute	_	_	I-Premise
230	OS	_	_	I-Premise
231	rates	_	_	I-Premise
232	were	_	_	I-Premise
233	10	_	_	I-Premise
234	%	_	_	I-Premise
235	at	_	_	I-Premise
236	6	_	_	I-Premise
237	months	_	_	I-Premise
238	and	_	_	I-Premise
239	15	_	_	I-Premise
240	%	_	_	I-Premise
241	at	_	_	I-Premise
242	12	_	_	I-Premise
243	months	_	_	I-Premise
244	in	_	_	I-Premise
245	the	_	_	I-Premise
246	combination	_	_	I-Premise
247	arm	_	_	I-Premise
248	compared	_	_	I-Premise
249	with	_	_	I-Premise
250	the	_	_	I-Premise
251	monotherapy	_	_	I-Premise
252	arm	_	_	I-Premise
253	.	_	_	I-Premise

254	Multiple	_	_	B-Premise
255	baseline	_	_	I-Premise
256	factors	_	_	I-Premise
257	,	_	_	I-Premise
258	including	_	_	I-Premise
259	Eastern	_	_	I-Premise
260	Cooperative	_	_	I-Premise
261	Oncology	_	_	I-Premise
262	Group	_	_	I-Premise
263	performance	_	_	I-Premise
264	status	_	_	I-Premise
265	of	_	_	I-Premise
266	0	_	_	I-Premise
267	,	_	_	I-Premise
268	nonvisceral	_	_	I-Premise
269	disease	_	_	I-Premise
270	,	_	_	I-Premise
271	<	_	_	I-Premise
272	three	_	_	I-Premise
273	metastatic	_	_	I-Premise
274	sites	_	_	I-Premise
275	,	_	_	I-Premise
276	and	_	_	I-Premise
277	less	_	_	I-Premise
278	time	_	_	I-Premise
279	from	_	_	I-Premise
280	initial	_	_	I-Premise
281	diagnosis	_	_	I-Premise
282	until	_	_	I-Premise
283	random	_	_	I-Premise
284	assignment	_	_	I-Premise
285	,	_	_	I-Premise
286	were	_	_	I-Premise
287	associated	_	_	I-Premise
288	with	_	_	I-Premise
289	improved	_	_	I-Premise
290	OS	_	_	I-Premise
291	.	_	_	I-Premise

292	Incidence	_	_	B-Premise
293	of	_	_	I-Premise
294	adverse	_	_	I-Premise
295	events	_	_	I-Premise
296	was	_	_	I-Premise
297	consistent	_	_	I-Premise
298	with	_	_	I-Premise
299	previously	_	_	I-Premise
300	reported	_	_	I-Premise
301	rates	_	_	I-Premise
302	.	_	_	I-Premise

303	These	_	_	B-Claim
304	data	_	_	I-Claim
305	demonstrated	_	_	I-Claim
306	a	_	_	I-Claim
307	significant	_	_	I-Claim
308	4	_	_	I-Claim
309	.	_	_	I-Claim

310	5	_	_	I-Claim
311	-	_	_	I-Claim
312	month	_	_	I-Claim
313	median	_	_	I-Claim
314	OS	_	_	I-Claim
315	advantage	_	_	I-Claim
316	with	_	_	I-Claim
317	the	_	_	I-Claim
318	lapatinib	_	_	I-Claim
319	and	_	_	I-Claim
320	trastuzumab	_	_	I-Claim
321	combination	_	_	I-Claim
322	and	_	_	I-Claim
323	support	_	_	I-Claim
324	dual	_	_	I-Claim
325	HER2	_	_	I-Claim
326	blockade	_	_	I-Claim
327	in	_	_	I-Claim
328	patients	_	_	I-Claim
329	with	_	_	I-Claim
330	heavily	_	_	I-Claim
331	pretreated	_	_	I-Claim
332	HER2	_	_	I-Claim
333	-	_	_	I-Claim
334	positive	_	_	I-Claim
335	MBC	_	_	I-Claim
336	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	randomised	_	_	O
5	trial	_	_	O
6	was	_	_	O
7	to	_	_	O
8	evaluate	_	_	O
9	the	_	_	O
10	activity	_	_	O
11	and	_	_	O
12	toxicity	_	_	O
13	of	_	_	O
14	a	_	_	O
15	biweekly	_	_	O
16	regimen	_	_	O
17	including	_	_	O
18	6S	_	_	O
19	-	_	_	O
20	leucovorin	_	_	O
21	-	_	_	O
22	modulated	_	_	O
23	5	_	_	O
24	-	_	_	O
25	fluorouracil	_	_	O
26	(	_	_	O
27	LFA	_	_	O
28	-	_	_	O
29	5	_	_	O
30	-	_	_	O
31	FU	_	_	O
32	)	_	_	O
33	,	_	_	O
34	combined	_	_	O
35	with	_	_	O
36	either	_	_	O
37	irinotecan	_	_	O
38	(	_	_	O
39	CPT	_	_	O
40	-	_	_	O
41	11	_	_	O
42	+	_	_	O
43	LFA	_	_	O
44	5	_	_	O
45	-	_	_	O
46	FU	_	_	O
47	)	_	_	O
48	or	_	_	O
49	raltitrexed	_	_	O
50	(	_	_	O
51	Tomudex	_	_	O
52	)	_	_	O
53	(	_	_	O
54	TOM	_	_	O
55	+	_	_	O
56	LFA	_	_	O
57	-	_	_	O
58	5	_	_	O
59	-	_	_	O
60	FU	_	_	O
61	)	_	_	O
62	,	_	_	O
63	in	_	_	O
64	advanced	_	_	O
65	colorectal	_	_	O
66	cancer	_	_	O
67	patients	_	_	O
68	,	_	_	O
69	and	_	_	O
70	to	_	_	O
71	make	_	_	O
72	a	_	_	O
73	preliminary	_	_	O
74	comparison	_	_	O
75	of	_	_	O
76	both	_	_	O
77	these	_	_	O
78	experimental	_	_	O
79	regimens	_	_	O
80	with	_	_	O
81	a	_	_	O
82	biweekly	_	_	O
83	administration	_	_	O
84	of	_	_	O
85	LFA	_	_	O
86	-	_	_	O
87	5	_	_	O
88	-	_	_	O
89	FU	_	_	O
90	modulated	_	_	O
91	by	_	_	O
92	methotrexate	_	_	O
93	(	_	_	O
94	MTX	_	_	O
95	+	_	_	O
96	LFA	_	_	O
97	-	_	_	O
98	5	_	_	O
99	-	_	_	O
100	FU	_	_	O
101	)	_	_	O
102	.	_	_	O

103	One	_	_	O
104	hundred	_	_	O
105	fifty	_	_	O
106	-	_	_	O
107	nine	_	_	O
108	patients	_	_	O
109	with	_	_	O
110	advanced	_	_	O
111	colorectal	_	_	O
112	carcinoma	_	_	O
113	previously	_	_	O
114	untreated	_	_	O
115	for	_	_	O
116	the	_	_	O
117	metastatic	_	_	O
118	disease	_	_	O
119	(	_	_	O
120	34	_	_	O
121	of	_	_	O
122	them	_	_	O
123	previously	_	_	O
124	exposed	_	_	O
125	to	_	_	O
126	adjuvant	_	_	O
127	5	_	_	O
128	-	_	_	O
129	FU	_	_	O
130	)	_	_	O
131	were	_	_	O
132	randomly	_	_	O
133	allocated	_	_	O
134	to	_	_	O
135	receive	_	_	O
136	:	_	_	O
137	CPT	_	_	O
138	-	_	_	O
139	11	_	_	O
140	,	_	_	O
141	200	_	_	O
142	mg	_	_	O
143	/	_	_	O
144	m2	_	_	O
145	i	_	_	O
146	.	_	_	O

147	v	_	_	O
148	.	_	_	O

149	on	_	_	O
150	day	_	_	O
151	1	_	_	O
152	,	_	_	O
153	followed	_	_	O
154	on	_	_	O
155	day	_	_	O
156	2	_	_	O
157	by	_	_	O
158	LFA	_	_	O
159	,	_	_	O
160	250	_	_	O
161	mg	_	_	O
162	/	_	_	O
163	m2	_	_	O
164	i	_	_	O
165	.	_	_	O

166	v	_	_	O
167	.	_	_	O

168	infusion	_	_	O
169	and	_	_	O
170	5	_	_	O
171	-	_	_	O
172	FU	_	_	O
173	,	_	_	O
174	850	_	_	O
175	mg	_	_	O
176	/	_	_	O
177	m2	_	_	O
178	s	_	_	O
179	i	_	_	O
180	.	_	_	O

181	v	_	_	O
182	.	_	_	O

183	bolus	_	_	O
184	(	_	_	O
185	arm	_	_	O
186	A	_	_	O
187	)	_	_	O
188	;	_	_	O
189	TOM	_	_	O
190	,	_	_	O
191	3	_	_	O
192	mg	_	_	O
193	/	_	_	O
194	m2	_	_	O
195	i	_	_	O
196	.	_	_	O

197	v	_	_	O
198	.	_	_	O

199	on	_	_	O
200	day	_	_	O
201	1	_	_	O
202	,	_	_	O
203	followed	_	_	O
204	on	_	_	O
205	day	_	_	O
206	2	_	_	O
207	by	_	_	O
208	LFA	_	_	O
209	,	_	_	O
210	250	_	_	O
211	mg	_	_	O
212	/	_	_	O
213	m2	_	_	O
214	i	_	_	O
215	.	_	_	O

216	v	_	_	O
217	.	_	_	O

218	infusion	_	_	O
219	and	_	_	O
220	5	_	_	O
221	-	_	_	O
222	FU	_	_	O
223	,	_	_	O
224	1050	_	_	O
225	mg	_	_	O
226	/	_	_	O
227	m2	_	_	O
228	i	_	_	O
229	.	_	_	O

230	v	_	_	O
231	.	_	_	O

232	bolus	_	_	O
233	(	_	_	O
234	arm	_	_	O
235	B	_	_	O
236	)	_	_	O
237	;	_	_	O
238	or	_	_	O
239	MTX	_	_	O
240	,	_	_	O
241	750	_	_	O
242	mg	_	_	O
243	/	_	_	O
244	m2	_	_	O
245	i	_	_	O
246	.	_	_	O

247	v	_	_	O
248	.	_	_	O

249	on	_	_	O
250	day	_	_	O
251	1	_	_	O
252	,	_	_	O
253	followed	_	_	O
254	on	_	_	O
255	day	_	_	O
256	2	_	_	O
257	by	_	_	O
258	LFA	_	_	O
259	,	_	_	O
260	250	_	_	O
261	mg	_	_	O
262	/	_	_	O
263	m2	_	_	O
264	i	_	_	O
265	.	_	_	O

266	v	_	_	O
267	.	_	_	O

268	infusion	_	_	O
269	and	_	_	O
270	5	_	_	O
271	-	_	_	O
272	FU	_	_	O
273	,	_	_	O
274	800	_	_	O
275	mg	_	_	O
276	/	_	_	O
277	m2	_	_	O
278	i	_	_	O
279	.	_	_	O

280	v	_	_	O
281	.	_	_	O

282	bolus	_	_	O
283	(	_	_	O
284	arm	_	_	O
285	C	_	_	O
286	)	_	_	O
287	.	_	_	O

288	Courses	_	_	O
289	were	_	_	O
290	repeated	_	_	O
291	every	_	_	O
292	two	_	_	O
293	weeks	_	_	O
294	in	_	_	O
295	all	_	_	O
296	arms	_	_	O
297	of	_	_	O
298	the	_	_	O
299	trial	_	_	O
300	.	_	_	O

301	Response	_	_	O
302	rate	_	_	O
303	(	_	_	O
304	RR	_	_	O
305	)	_	_	O
306	was	_	_	O
307	evaluated	_	_	O
308	after	_	_	O
309	every	_	_	O
310	four	_	_	O
311	courses	_	_	O
312	.	_	_	O

313	The	_	_	O
314	sample	_	_	O
315	size	_	_	O
316	was	_	_	O
317	defined	_	_	O
318	to	_	_	O
319	have	_	_	O
320	an	_	_	O
321	80	_	_	O
322	%	_	_	O
323	power	_	_	O
324	to	_	_	O
325	detect	_	_	O
326	a	_	_	O
327	35	_	_	O
328	%	_	_	O
329	RR	_	_	O
330	for	_	_	O
331	each	_	_	O
332	experimental	_	_	O
333	treatment	_	_	O
334	,	_	_	O
335	and	_	_	O
336	to	_	_	O
337	show	_	_	O
338	a	_	_	O
339	difference	_	_	O
340	of	_	_	O
341	at	_	_	O
342	least	_	_	O
343	4	_	_	O
344	%	_	_	O
345	in	_	_	O
346	RR	_	_	O
347	with	_	_	O
348	the	_	_	O
349	standard	_	_	O
350	treatment	_	_	O
351	if	_	_	O
352	the	_	_	O
353	true	_	_	O
354	difference	_	_	O
355	is	_	_	O
356	15	_	_	O
357	%	_	_	O
358	or	_	_	O
359	more	_	_	O
360	.	_	_	O

361	The	_	_	O
362	RRs	_	_	O
363	were	_	_	O
364	:	_	_	O
365	34	_	_	O
366	%	_	_	O
367	(	_	_	O
368	95	_	_	O
369	%	_	_	O
370	confidence	_	_	O
371	interval	_	_	O
372	(	_	_	O
373	95	_	_	O
374	%	_	_	O
375	,	_	_	O
376	CI	_	_	O
377	)	_	_	O
378	:	_	_	O
379	21	_	_	O
380	%	_	_	O
381	-	_	_	O
382	48	_	_	O
383	%	_	_	O
384	)	_	_	O
385	in	_	_	O
386	arm	_	_	O
387	A	_	_	O
388	,	_	_	O
389	including	_	_	O
390	3	_	_	O
391	complete	_	_	O
392	responses	_	_	O
393	(	_	_	O
394	CRs	_	_	O
395	)	_	_	O
396	and	_	_	O
397	15	_	_	O
398	partial	_	_	O
399	responses	_	_	O
400	(	_	_	O
401	PRs	_	_	O
402	)	_	_	O
403	,	_	_	O
404	24	_	_	O
405	%	_	_	O
406	(	_	_	O
407	95	_	_	O
408	%	_	_	O
409	CI	_	_	O
410	:	_	_	O
411	14	_	_	O
412	%	_	_	O
413	-	_	_	O
414	38	_	_	O
415	%	_	_	O
416	)	_	_	O
417	in	_	_	O
418	arm	_	_	O
419	B	_	_	O
420	,	_	_	O
421	including	_	_	O
422	2	_	_	O
423	CRs	_	_	O
424	and	_	_	O
425	11	_	_	O
426	PRs	_	_	O
427	,	_	_	O
428	and	_	_	O
429	24	_	_	O
430	%	_	_	O
431	(	_	_	O
432	95	_	_	O
433	%	_	_	O
434	CI	_	_	O
435	:	_	_	O
436	14	_	_	O
437	%	_	_	O
438	-	_	_	O
439	38	_	_	O
440	%	_	_	O
441	)	_	_	O
442	,	_	_	O
443	with	_	_	O
444	2	_	_	O
445	CRs	_	_	O
446	and	_	_	O
447	11	_	_	O
448	PRs	_	_	O
449	,	_	_	O
450	in	_	_	O
451	arm	_	_	O
452	C	_	_	O
453	.	_	_	O

454	After	_	_	B-Premise
455	a	_	_	I-Premise
456	median	_	_	I-Premise
457	follow	_	_	I-Premise
458	-	_	_	I-Premise
459	up	_	_	I-Premise
460	time	_	_	I-Premise
461	of	_	_	I-Premise
462	62	_	_	I-Premise
463	(	_	_	I-Premise
464	range	_	_	I-Premise
465	18	_	_	I-Premise
466	-	_	_	I-Premise
467	108	_	_	I-Premise
468	)	_	_	I-Premise
469	weeks	_	_	I-Premise
470	,	_	_	I-Premise
471	the	_	_	I-Premise
472	median	_	_	I-Premise
473	time	_	_	I-Premise
474	to	_	_	I-Premise
475	progression	_	_	I-Premise
476	was	_	_	I-Premise
477	38	_	_	I-Premise
478	,	_	_	I-Premise
479	25	_	_	I-Premise
480	,	_	_	I-Premise
481	and	_	_	I-Premise
482	27	_	_	I-Premise
483	weeks	_	_	I-Premise
484	for	_	_	I-Premise
485	arm	_	_	I-Premise
486	A	_	_	I-Premise
487	,	_	_	I-Premise
488	B	_	_	I-Premise
489	,	_	_	I-Premise
490	and	_	_	I-Premise
491	C	_	_	I-Premise
492	,	_	_	I-Premise
493	respectively	_	_	I-Premise
494	.	_	_	I-Premise

495	With	_	_	B-Premise
496	94	_	_	I-Premise
497	patients	_	_	I-Premise
498	still	_	_	I-Premise
499	alive	_	_	I-Premise
500	,	_	_	I-Premise
501	the	_	_	I-Premise
502	one	_	_	I-Premise
503	-	_	_	I-Premise
504	year	_	_	I-Premise
505	probability	_	_	I-Premise
506	of	_	_	I-Premise
507	survival	_	_	I-Premise
508	was	_	_	I-Premise
509	61	_	_	I-Premise
510	%	_	_	I-Premise
511	,	_	_	I-Premise
512	54	_	_	I-Premise
513	%	_	_	I-Premise
514	,	_	_	I-Premise
515	and	_	_	I-Premise
516	59	_	_	I-Premise
517	%	_	_	I-Premise
518	,	_	_	I-Premise
519	respectively	_	_	I-Premise
520	.	_	_	I-Premise

521	WHO	_	_	B-Premise
522	grade	_	_	I-Premise
523	3	_	_	I-Premise
524	or	_	_	I-Premise
525	4	_	_	I-Premise
526	neutropenia	_	_	I-Premise
527	and	_	_	I-Premise
528	diarrhoea	_	_	I-Premise
529	affected	_	_	I-Premise
530	46	_	_	I-Premise
531	%	_	_	I-Premise
532	and	_	_	I-Premise
533	16	_	_	I-Premise
534	%	_	_	I-Premise
535	,	_	_	I-Premise
536	respectively	_	_	I-Premise
537	,	_	_	I-Premise
538	of	_	_	I-Premise
539	patients	_	_	I-Premise
540	treated	_	_	I-Premise
541	with	_	_	I-Premise
542	CPT	_	_	I-Premise
543	-	_	_	I-Premise
544	11	_	_	I-Premise
545	+	_	_	I-Premise
546	LFA	_	_	I-Premise
547	5	_	_	I-Premise
548	-	_	_	I-Premise
549	FU	_	_	I-Premise
550	.	_	_	I-Premise

551	Median	_	_	B-Premise
552	relative	_	_	I-Premise
553	dose	_	_	I-Premise
554	intensity	_	_	I-Premise
555	over	_	_	I-Premise
556	eight	_	_	I-Premise
557	cycles	_	_	I-Premise
558	(	_	_	I-Premise
559	DI8	_	_	I-Premise
560	)	_	_	I-Premise
561	was	_	_	I-Premise
562	78	_	_	I-Premise
563	%	_	_	I-Premise
564	for	_	_	I-Premise
565	CPT	_	_	I-Premise
566	-	_	_	I-Premise
567	11	_	_	I-Premise
568	and	_	_	I-Premise
569	82	_	_	I-Premise
570	%	_	_	I-Premise
571	for	_	_	I-Premise
572	5	_	_	I-Premise
573	-	_	_	I-Premise
574	FU	_	_	I-Premise
575	.	_	_	I-Premise

576	Severe	_	_	B-Premise
577	toxicities	_	_	I-Premise
578	of	_	_	I-Premise
579	TOM	_	_	I-Premise
580	+	_	_	I-Premise
581	LFA	_	_	I-Premise
582	-	_	_	I-Premise
583	5	_	_	I-Premise
584	-	_	_	I-Premise
585	FU	_	_	I-Premise
586	were	_	_	I-Premise
587	neutropenia	_	_	I-Premise
588	(	_	_	I-Premise
589	16	_	_	I-Premise
590	%	_	_	I-Premise
591	)	_	_	I-Premise
592	and	_	_	I-Premise
593	diarrhoea	_	_	I-Premise
594	(	_	_	I-Premise
595	16	_	_	I-Premise
596	%	_	_	I-Premise
597	)	_	_	I-Premise
598	,	_	_	I-Premise
599	but	_	_	I-Premise
600	median	_	_	I-Premise
601	relative	_	_	I-Premise
602	DI8	_	_	I-Premise
603	was	_	_	I-Premise
604	93	_	_	I-Premise
605	%	_	_	I-Premise
606	for	_	_	I-Premise
607	TOM	_	_	I-Premise
608	,	_	_	I-Premise
609	and	_	_	I-Premise
610	82	_	_	I-Premise
611	%	_	_	I-Premise
612	for	_	_	I-Premise
613	5	_	_	I-Premise
614	-	_	_	I-Premise
615	FU	_	_	I-Premise
616	.	_	_	I-Premise

617	CPT	_	_	B-Premise
618	-	_	_	I-Premise
619	11	_	_	I-Premise
620	+	_	_	I-Premise
621	LFA	_	_	I-Premise
622	-	_	_	I-Premise
623	5	_	_	I-Premise
624	-	_	_	I-Premise
625	FU	_	_	I-Premise
626	compares	_	_	I-Premise
627	favorably	_	_	I-Premise
628	in	_	_	I-Premise
629	term	_	_	I-Premise
630	of	_	_	I-Premise
631	activity	_	_	I-Premise
632	and	_	_	I-Premise
633	toxicity	_	_	I-Premise
634	with	_	_	I-Premise
635	other	_	_	I-Premise
636	combination	_	_	I-Premise
637	regimens	_	_	I-Premise
638	including	_	_	I-Premise
639	CPT	_	_	I-Premise
640	-	_	_	I-Premise
641	11	_	_	I-Premise
642	and	_	_	I-Premise
643	continuous	_	_	I-Premise
644	infusional	_	_	I-Premise
645	5	_	_	I-Premise
646	-	_	_	I-Premise
647	FU	_	_	I-Premise
648	.	_	_	I-Premise

649	The	_	_	B-Claim
650	hypothesis	_	_	I-Claim
651	of	_	_	I-Claim
652	a	_	_	I-Claim
653	RR	_	_	I-Claim
654	15	_	_	I-Claim
655	%	_	_	I-Claim
656	higher	_	_	I-Claim
657	than	_	_	I-Claim
658	the	_	_	I-Claim
659	MTX	_	_	I-Claim
660	+	_	_	I-Claim
661	LFA	_	_	I-Claim
662	-	_	_	I-Claim
663	5	_	_	I-Claim
664	-	_	_	I-Claim
665	FU	_	_	I-Claim
666	treatment	_	_	I-Claim
667	can	_	_	I-Claim
668	not	_	_	I-Claim
669	be	_	_	I-Claim
670	ruled	_	_	I-Claim
671	out	_	_	I-Claim
672	after	_	_	I-Claim
673	this	_	_	I-Claim
674	interim	_	_	I-Claim
675	analysis	_	_	I-Claim
676	.	_	_	I-Claim

677	The	_	_	B-Claim
678	TOM	_	_	I-Claim
679	+	_	_	I-Claim
680	LFA	_	_	I-Claim
681	5	_	_	I-Claim
682	-	_	_	I-Claim
683	FU	_	_	I-Claim
684	regimen	_	_	I-Claim
685	showed	_	_	I-Claim
686	a	_	_	I-Claim
687	RR	_	_	I-Claim
688	and	_	_	I-Claim
689	a	_	_	I-Claim
690	toxicity	_	_	I-Claim
691	profile	_	_	I-Claim
692	very	_	_	I-Claim
693	close	_	_	I-Claim
694	to	_	_	I-Claim
695	the	_	_	I-Claim
696	MTX	_	_	I-Claim
697	+	_	_	I-Claim
698	LFA	_	_	I-Claim
699	5	_	_	I-Claim
700	-	_	_	I-Claim
701	FU	_	_	I-Claim
702	combination	_	_	I-Claim
703	,	_	_	I-Claim
704	and	_	_	I-Claim
705	does	_	_	I-Claim
706	not	_	_	I-Claim
707	deserve	_	_	I-Claim
708	further	_	_	I-Claim
709	evaluation	_	_	I-Claim
710	in	_	_	I-Claim
711	advanced	_	_	I-Claim
712	colorectal	_	_	I-Claim
713	cancer	_	_	I-Claim
714	patients	_	_	I-Claim
715	.	_	_	I-Claim


0	Postoperative	_	_	B-Claim
1	outcomes	_	_	I-Claim
2	of	_	_	I-Claim
3	patients	_	_	I-Claim
4	undergoing	_	_	I-Claim
5	laparoscopic	_	_	I-Claim
6	-	_	_	I-Claim
7	assisted	_	_	I-Claim
8	colectomy	_	_	I-Claim
9	(	_	_	I-Claim
10	LAC	_	_	I-Claim
11	)	_	_	I-Claim
12	have	_	_	I-Claim
13	shown	_	_	I-Claim
14	modest	_	_	I-Claim
15	improvements	_	_	I-Claim
16	in	_	_	I-Claim
17	recovery	_	_	I-Claim
18	but	_	_	I-Claim
19	only	_	_	I-Claim
20	minimal	_	_	I-Claim
21	differences	_	_	I-Claim
22	in	_	_	I-Claim
23	quality	_	_	I-Claim
24	of	_	_	I-Claim
25	life	_	_	I-Claim
26	(	_	_	I-Claim
27	QOL	_	_	I-Claim
28	)	_	_	I-Claim
29	compared	_	_	I-Claim
30	with	_	_	I-Claim
31	open	_	_	I-Claim
32	colectomy	_	_	I-Claim
33	.	_	_	I-Claim

34	We	_	_	O
35	therefore	_	_	O
36	sought	_	_	O
37	to	_	_	O
38	assess	_	_	O
39	the	_	_	O
40	effect	_	_	O
41	of	_	_	O
42	LAC	_	_	O
43	on	_	_	O
44	QOL	_	_	O
45	in	_	_	O
46	the	_	_	O
47	short	_	_	O
48	and	_	_	O
49	long	_	_	O
50	term	_	_	O
51	,	_	_	O
52	using	_	_	O
53	individual	_	_	O
54	item	_	_	O
55	analysis	_	_	O
56	of	_	_	O
57	multi	_	_	O
58	-	_	_	O
59	item	_	_	O
60	QOL	_	_	O
61	assessments	_	_	O
62	.	_	_	O

63	QOL	_	_	O
64	variables	_	_	O
65	were	_	_	O
66	analyzed	_	_	O
67	in	_	_	O
68	449	_	_	O
69	randomized	_	_	O
70	patients	_	_	O
71	from	_	_	O
72	the	_	_	O
73	COST	_	_	O
74	trial	_	_	O
75	93	_	_	O
76	-	_	_	O
77	46	_	_	O
78	-	_	_	O
79	53	_	_	O
80	(	_	_	O
81	INT	_	_	O
82	0146	_	_	O
83	)	_	_	O
84	.	_	_	O

85	Both	_	_	O
86	cross	_	_	O
87	-	_	_	O
88	sectional	_	_	O
89	single	_	_	O
90	-	_	_	O
91	time	_	_	O
92	and	_	_	O
93	change	_	_	O
94	from	_	_	O
95	baseline	_	_	O
96	assessments	_	_	O
97	were	_	_	O
98	run	_	_	O
99	at	_	_	O
100	day	_	_	O
101	2	_	_	O
102	,	_	_	O
103	week	_	_	O
104	2	_	_	O
105	,	_	_	O
106	month	_	_	O
107	2	_	_	O
108	,	_	_	O
109	and	_	_	O
110	month	_	_	O
111	18	_	_	O
112	postoperatively	_	_	O
113	in	_	_	O
114	an	_	_	O
115	intention	_	_	O
116	-	_	_	O
117	to	_	_	O
118	-	_	_	O
119	treat	_	_	O
120	analysis	_	_	O
121	using	_	_	O
122	Wilcoxon	_	_	O
123	rank	_	_	O
124	-	_	_	O
125	sum	_	_	O
126	tests	_	_	O
127	.	_	_	O

128	Stepwise	_	_	O
129	regression	_	_	O
130	models	_	_	O
131	were	_	_	O
132	used	_	_	O
133	to	_	_	O
134	determine	_	_	O
135	predictors	_	_	O
136	of	_	_	O
137	QOL	_	_	O
138	.	_	_	O

139	Of	_	_	O
140	449	_	_	O
141	colon	_	_	O
142	cancer	_	_	O
143	patients	_	_	O
144	,	_	_	O
145	230	_	_	O
146	underwent	_	_	O
147	LAC	_	_	O
148	and	_	_	O
149	219	_	_	O
150	underwent	_	_	O
151	open	_	_	O
152	colectomy	_	_	O
153	.	_	_	O

154	Subdomain	_	_	B-Premise
155	analysis	_	_	I-Premise
156	revealed	_	_	I-Premise
157	a	_	_	I-Premise
158	clinically	_	_	I-Premise
159	moderate	_	_	I-Premise
160	improvement	_	_	I-Premise
161	from	_	_	I-Premise
162	baseline	_	_	I-Premise
163	for	_	_	I-Premise
164	LAC	_	_	I-Premise
165	in	_	_	I-Premise
166	total	_	_	I-Premise
167	QOL	_	_	I-Premise
168	index	_	_	I-Premise
169	at	_	_	I-Premise
170	18	_	_	I-Premise
171	months	_	_	I-Premise
172	(	_	_	I-Premise
173	P	_	_	I-Premise
174	=	_	_	I-Premise
175	0	_	_	I-Premise
176	.	_	_	I-Premise

177	02	_	_	I-Premise
178	)	_	_	I-Premise
179	as	_	_	I-Premise
180	well	_	_	I-Premise
181	as	_	_	I-Premise
182	other	_	_	I-Premise
183	small	_	_	I-Premise
184	symptomatic	_	_	I-Premise
185	improvements	_	_	I-Premise
186	.	_	_	I-Premise

187	Poor	_	_	O
188	preoperative	_	_	O
189	QOL	_	_	O
190	as	_	_	O
191	indicated	_	_	O
192	by	_	_	O
193	a	_	_	O
194	rating	_	_	O
195	scale	_	_	O
196	of	_	_	O
197	≤	_	_	O
198	50	_	_	O
199	was	_	_	O
200	an	_	_	O
201	independent	_	_	O
202	predictor	_	_	O
203	of	_	_	O
204	poor	_	_	O
205	QOL	_	_	O
206	at	_	_	O
207	2	_	_	O
208	months	_	_	O
209	postoperatively	_	_	O
210	.	_	_	O

211	QOL	_	_	O
212	variables	_	_	O
213	related	_	_	O
214	to	_	_	O
215	survival	_	_	O
216	were	_	_	O
217	baseline	_	_	O
218	support	_	_	O
219	(	_	_	O
220	P	_	_	O
221	=	_	_	O
222	0	_	_	O
223	.	_	_	O

224	001	_	_	O
225	)	_	_	O
226	and	_	_	O
227	baseline	_	_	O
228	outlook	_	_	O
229	(	_	_	O
230	P	_	_	O
231	=	_	_	O
232	0	_	_	O
233	.	_	_	O

234	01	_	_	O
235	)	_	_	O
236	.	_	_	O

237	Eighteen	_	_	B-Premise
238	months	_	_	I-Premise
239	after	_	_	I-Premise
240	surgery	_	_	I-Premise
241	,	_	_	I-Premise
242	any	_	_	I-Premise
243	differences	_	_	I-Premise
244	in	_	_	I-Premise
245	quality	_	_	I-Premise
246	of	_	_	I-Premise
247	life	_	_	I-Premise
248	between	_	_	I-Premise
249	patients	_	_	I-Premise
250	randomized	_	_	I-Premise
251	to	_	_	I-Premise
252	LAC	_	_	I-Premise
253	or	_	_	I-Premise
254	open	_	_	I-Premise
255	colectomy	_	_	I-Premise
256	favored	_	_	I-Premise
257	LAC	_	_	I-Premise
258	.	_	_	I-Premise

259	However	_	_	B-Premise
260	,	_	_	I-Premise
261	the	_	_	I-Premise
262	magnitude	_	_	I-Premise
263	of	_	_	I-Premise
264	the	_	_	I-Premise
265	benefits	_	_	I-Premise
266	was	_	_	I-Premise
267	small	_	_	I-Premise
268	.	_	_	I-Premise

269	Patients	_	_	B-Claim
270	with	_	_	I-Claim
271	poor	_	_	I-Claim
272	preoperative	_	_	I-Claim
273	QOL	_	_	I-Claim
274	appear	_	_	I-Claim
275	to	_	_	I-Claim
276	be	_	_	I-Claim
277	at	_	_	I-Claim
278	higher	_	_	I-Claim
279	risk	_	_	I-Claim
280	for	_	_	I-Claim
281	difficult	_	_	I-Claim
282	postoperative	_	_	I-Claim
283	courses	_	_	I-Claim
284	,	_	_	I-Claim
285	and	_	_	I-Claim
286	may	_	_	I-Claim
287	be	_	_	I-Claim
288	candidates	_	_	I-Claim
289	for	_	_	I-Claim
290	enhanced	_	_	I-Claim
291	ancillary	_	_	I-Claim
292	services	_	_	I-Claim
293	to	_	_	I-Claim
294	address	_	_	I-Claim
295	their	_	_	I-Claim
296	particular	_	_	I-Claim
297	needs	_	_	I-Claim
298	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	safety	_	_	O
4	,	_	_	O
5	tolerability	_	_	O
6	and	_	_	O
7	efficacy	_	_	O
8	of	_	_	O
9	abatacept	_	_	O
10	in	_	_	O
11	patients	_	_	O
12	with	_	_	O
13	rheumatoid	_	_	O
14	arthritis	_	_	O
15	(	_	_	O
16	RA	_	_	O
17	)	_	_	O
18	who	_	_	O
19	had	_	_	O
20	failed	_	_	O
21	anti	_	_	O
22	-	_	_	O
23	tumour	_	_	O
24	necrosis	_	_	O
25	factor	_	_	O
26	(	_	_	O
27	TNF	_	_	O
28	)	_	_	O
29	therapy	_	_	O
30	and	_	_	O
31	were	_	_	O
32	switched	_	_	O
33	to	_	_	O
34	abatacept	_	_	O
35	directly	_	_	O
36	or	_	_	O
37	after	_	_	O
38	completing	_	_	O
39	washout	_	_	O
40	.	_	_	O

41	In	_	_	O
42	this	_	_	O
43	international	_	_	O
44	,	_	_	O
45	6	_	_	O
46	-	_	_	O
47	month	_	_	O
48	,	_	_	O
49	open	_	_	O
50	-	_	_	O
51	label	_	_	O
52	trial	_	_	O
53	,	_	_	O
54	patients	_	_	O
55	had	_	_	O
56	active	_	_	O
57	RA	_	_	O
58	,	_	_	O
59	an	_	_	O
60	inadequate	_	_	O
61	response	_	_	O
62	to	_	_	O
63	anti	_	_	O
64	-	_	_	O
65	TNF	_	_	O
66	therapy	_	_	O
67	for	_	_	O
68	3	_	_	O
69	months	_	_	O
70	or	_	_	O
71	longer	_	_	O
72	and	_	_	O
73	a	_	_	O
74	disease	_	_	O
75	activity	_	_	O
76	score	_	_	O
77	in	_	_	O
78	28	_	_	O
79	joints	_	_	O
80	(	_	_	O
81	DAS28	_	_	O
82	(	_	_	O
83	C	_	_	O
84	-	_	_	O
85	reactive	_	_	O
86	protein	_	_	O
87	;	_	_	O
88	CRP	_	_	O
89	)	_	_	O
90	of	_	_	O
91	5	_	_	O
92	.	_	_	O

93	1	_	_	O
94	or	_	_	O
95	greater	_	_	O
96	.	_	_	O

97	"	_	_	O
98	Washout	_	_	O
99	"	_	_	O
100	patients	_	_	O
101	discontinued	_	_	O
102	anti	_	_	O
103	-	_	_	O
104	TNF	_	_	O
105	therapy	_	_	O
106	2	_	_	O
107	months	_	_	O
108	or	_	_	O
109	longer	_	_	O
110	pre	_	_	O
111	-	_	_	O
112	screening	_	_	O
113	;	_	_	O
114	"	_	_	O
115	direct	_	_	O
116	-	_	_	O
117	switch	_	_	O
118	"	_	_	O
119	patients	_	_	O
120	began	_	_	O
121	abatacept	_	_	O
122	(	_	_	O
123	approximately	_	_	O
124	10	_	_	O
125	mg	_	_	O
126	/	_	_	O
127	kg	_	_	O
128	)	_	_	O
129	at	_	_	O
130	their	_	_	O
131	next	_	_	O
132	scheduled	_	_	O
133	anti	_	_	O
134	-	_	_	O
135	TNF	_	_	O
136	therapy	_	_	O
137	dose	_	_	O
138	.	_	_	O

139	1046	_	_	O
140	patients	_	_	O
141	were	_	_	O
142	treated	_	_	O
143	(	_	_	O
144	449	_	_	O
145	washout	_	_	O
146	,	_	_	O
147	597	_	_	O
148	direct	_	_	O
149	-	_	_	O
150	switch	_	_	O
151	;	_	_	O
152	baseline	_	_	O
153	characteristics	_	_	O
154	were	_	_	O
155	similar	_	_	O
156	between	_	_	O
157	groups	_	_	O
158	)	_	_	O
159	.	_	_	O

160	At	_	_	B-Premise
161	6	_	_	I-Premise
162	months	_	_	I-Premise
163	,	_	_	I-Premise
164	adverse	_	_	I-Premise
165	events	_	_	I-Premise
166	(	_	_	I-Premise
167	AE	_	_	I-Premise
168	;	_	_	I-Premise
169	78	_	_	I-Premise
170	.	_	_	I-Premise

171	0	_	_	I-Premise
172	%	_	_	I-Premise
173	vs	_	_	I-Premise
174	79	_	_	I-Premise
175	.	_	_	I-Premise

176	2	_	_	I-Premise
177	%	_	_	I-Premise
178	)	_	_	I-Premise
179	,	_	_	I-Premise
180	serious	_	_	I-Premise
181	AE	_	_	I-Premise
182	(	_	_	I-Premise
183	11	_	_	I-Premise
184	.	_	_	I-Premise

185	1	_	_	I-Premise
186	%	_	_	I-Premise
187	vs	_	_	I-Premise
188	9	_	_	I-Premise
189	.	_	_	I-Premise

190	9	_	_	I-Premise
191	%	_	_	I-Premise
192	)	_	_	I-Premise
193	and	_	_	I-Premise
194	discontinuations	_	_	I-Premise
195	due	_	_	I-Premise
196	to	_	_	I-Premise
197	AE	_	_	I-Premise
198	(	_	_	I-Premise
199	3	_	_	I-Premise
200	.	_	_	I-Premise

201	8	_	_	I-Premise
202	%	_	_	I-Premise
203	vs	_	_	I-Premise
204	4	_	_	I-Premise
205	.	_	_	I-Premise

206	0	_	_	I-Premise
207	%	_	_	I-Premise
208	)	_	_	I-Premise
209	and	_	_	I-Premise
210	serious	_	_	I-Premise
211	AE	_	_	I-Premise
212	(	_	_	I-Premise
213	2	_	_	I-Premise
214	.	_	_	I-Premise

215	0	_	_	I-Premise
216	%	_	_	I-Premise
217	vs	_	_	I-Premise
218	1	_	_	I-Premise
219	.	_	_	I-Premise

220	3	_	_	I-Premise
221	%	_	_	I-Premise
222	)	_	_	I-Premise
223	were	_	_	I-Premise
224	comparable	_	_	I-Premise
225	in	_	_	I-Premise
226	washout	_	_	I-Premise
227	versus	_	_	I-Premise
228	direct	_	_	I-Premise
229	-	_	_	I-Premise
230	switch	_	_	I-Premise
231	patients	_	_	I-Premise
232	.	_	_	I-Premise

233	There	_	_	B-Premise
234	were	_	_	I-Premise
235	no	_	_	I-Premise
236	opportunistic	_	_	I-Premise
237	infections	_	_	I-Premise
238	.	_	_	I-Premise

239	At	_	_	B-Premise
240	6	_	_	I-Premise
241	months	_	_	I-Premise
242	,	_	_	I-Premise
243	in	_	_	I-Premise
244	washout	_	_	I-Premise
245	versus	_	_	I-Premise
246	direct	_	_	I-Premise
247	-	_	_	I-Premise
248	switch	_	_	I-Premise
249	patients	_	_	I-Premise
250	,	_	_	I-Premise
251	similar	_	_	I-Premise
252	clinically	_	_	I-Premise
253	meaningful	_	_	I-Premise
254	improvements	_	_	I-Premise
255	were	_	_	I-Premise
256	seen	_	_	I-Premise
257	in	_	_	I-Premise
258	DAS28	_	_	I-Premise
259	(	_	_	I-Premise
260	CRP	_	_	I-Premise
261	)	_	_	I-Premise
262	(	_	_	I-Premise
263	>	_	_	I-Premise
264	or	_	_	I-Premise
265	=	_	_	I-Premise
266	1	_	_	I-Premise
267	.	_	_	I-Premise

268	2	_	_	I-Premise
269	unit	_	_	I-Premise
270	improvement	_	_	I-Premise
271	,	_	_	I-Premise
272	59	_	_	I-Premise
273	.	_	_	I-Premise

274	5	_	_	I-Premise
275	%	_	_	I-Premise
276	vs	_	_	I-Premise
277	53	_	_	I-Premise
278	.	_	_	I-Premise

279	6	_	_	I-Premise
280	%	_	_	I-Premise
281	,	_	_	I-Premise
282	respectively	_	_	I-Premise
283	;	_	_	I-Premise
284	low	_	_	I-Premise
285	disease	_	_	I-Premise
286	activity	_	_	I-Premise
287	state	_	_	I-Premise
288	,	_	_	I-Premise
289	22	_	_	I-Premise
290	.	_	_	I-Premise

291	5	_	_	I-Premise
292	%	_	_	I-Premise
293	vs	_	_	I-Premise
294	22	_	_	I-Premise
295	.	_	_	I-Premise

296	3	_	_	I-Premise
297	%	_	_	I-Premise
298	;	_	_	I-Premise
299	DAS28	_	_	I-Premise
300	-	_	_	I-Premise
301	defined	_	_	I-Premise
302	remission	_	_	I-Premise
303	,	_	_	I-Premise
304	12	_	_	I-Premise
305	.	_	_	I-Premise

306	0	_	_	I-Premise
307	%	_	_	I-Premise
308	vs	_	_	I-Premise
309	13	_	_	I-Premise
310	.	_	_	I-Premise

311	7	_	_	I-Premise
312	%	_	_	I-Premise
313	)	_	_	I-Premise
314	,	_	_	I-Premise
315	physical	_	_	I-Premise
316	function	_	_	I-Premise
317	(	_	_	I-Premise
318	health	_	_	I-Premise
319	assessment	_	_	I-Premise
320	questionnaire	_	_	I-Premise
321	disability	_	_	I-Premise
322	index	_	_	I-Premise
323	>	_	_	I-Premise
324	or	_	_	I-Premise
325	=	_	_	I-Premise
326	0	_	_	I-Premise
327	.	_	_	I-Premise

328	22	_	_	I-Premise
329	improvement	_	_	I-Premise
330	;	_	_	I-Premise
331	46	_	_	I-Premise
332	.	_	_	I-Premise

333	3	_	_	I-Premise
334	%	_	_	I-Premise
335	vs	_	_	I-Premise
336	47	_	_	I-Premise
337	.	_	_	I-Premise

338	1	_	_	I-Premise
339	%	_	_	I-Premise
340	)	_	_	I-Premise
341	and	_	_	I-Premise
342	health	_	_	I-Premise
343	-	_	_	I-Premise
344	related	_	_	I-Premise
345	quality	_	_	I-Premise
346	of	_	_	I-Premise
347	life	_	_	I-Premise
348	(	_	_	I-Premise
349	mean	_	_	I-Premise
350	change	_	_	I-Premise
351	in	_	_	I-Premise
352	short	_	_	I-Premise
353	-	_	_	I-Premise
354	form	_	_	I-Premise
355	36	_	_	I-Premise
356	scores	_	_	I-Premise
357	:	_	_	I-Premise
358	physical	_	_	I-Premise
359	component	_	_	I-Premise
360	summary	_	_	I-Premise
361	,	_	_	I-Premise
362	5	_	_	I-Premise
363	.	_	_	I-Premise

364	5	_	_	I-Premise
365	vs	_	_	I-Premise
366	6	_	_	I-Premise
367	.	_	_	I-Premise

368	1	_	_	I-Premise
369	;	_	_	I-Premise
370	mental	_	_	I-Premise
371	component	_	_	I-Premise
372	summary	_	_	I-Premise
373	,	_	_	I-Premise
374	4	_	_	I-Premise
375	.	_	_	I-Premise

376	8	_	_	I-Premise
377	vs	_	_	I-Premise
378	5	_	_	I-Premise
379	.	_	_	I-Premise

380	4	_	_	I-Premise
381	)	_	_	I-Premise
382	.	_	_	I-Premise

383	Abatacept	_	_	B-Claim
384	demonstrated	_	_	I-Claim
385	acceptable	_	_	I-Claim
386	safety	_	_	I-Claim
387	and	_	_	I-Claim
388	tolerability	_	_	I-Claim
389	and	_	_	I-Claim
390	clinically	_	_	I-Claim
391	meaningful	_	_	I-Claim
392	efficacy	_	_	I-Claim
393	over	_	_	I-Claim
394	6	_	_	I-Claim
395	months	_	_	I-Claim
396	in	_	_	I-Claim
397	patients	_	_	I-Claim
398	with	_	_	I-Claim
399	inadequate	_	_	I-Claim
400	response	_	_	I-Claim
401	to	_	_	I-Claim
402	anti	_	_	I-Claim
403	-	_	_	I-Claim
404	TNF	_	_	I-Claim
405	therapy	_	_	I-Claim
406	.	_	_	I-Claim

407	Results	_	_	B-Claim
408	were	_	_	I-Claim
409	comparable	_	_	I-Claim
410	with	_	_	I-Claim
411	or	_	_	I-Claim
412	without	_	_	I-Claim
413	a	_	_	I-Claim
414	washout	_	_	I-Claim
415	,	_	_	I-Claim
416	supporting	_	_	I-Claim
417	direct	_	_	I-Claim
418	switching	_	_	I-Claim
419	from	_	_	I-Claim
420	anti	_	_	I-Claim
421	-	_	_	I-Claim
422	TNF	_	_	I-Claim
423	therapy	_	_	I-Claim
424	to	_	_	I-Claim
425	abatacept	_	_	I-Claim
426	as	_	_	I-Claim
427	an	_	_	I-Claim
428	option	_	_	I-Claim
429	in	_	_	I-Claim
430	clinical	_	_	I-Claim
431	practice	_	_	I-Claim
432	.	_	_	I-Claim


0	After	_	_	O
1	surgery	_	_	O
2	for	_	_	O
3	differentiated	_	_	O
4	thyroid	_	_	O
5	carcinoma	_	_	O
6	,	_	_	O
7	many	_	_	O
8	patients	_	_	O
9	are	_	_	O
10	treated	_	_	O
11	with	_	_	O
12	radioiodine	_	_	O
13	to	_	_	O
14	ablate	_	_	O
15	remnant	_	_	O
16	thyroid	_	_	O
17	tissue	_	_	O
18	.	_	_	O

19	This	_	_	B-Claim
20	procedure	_	_	I-Claim
21	has	_	_	I-Claim
22	been	_	_	I-Claim
23	performed	_	_	I-Claim
24	with	_	_	I-Claim
25	the	_	_	I-Claim
26	patient	_	_	I-Claim
27	in	_	_	I-Claim
28	the	_	_	I-Claim
29	hypothyroid	_	_	I-Claim
30	state	_	_	I-Claim
31	to	_	_	I-Claim
32	promote	_	_	I-Claim
33	endogenous	_	_	I-Claim
34	TSH	_	_	I-Claim
35	stimulation	_	_	I-Claim
36	and	_	_	I-Claim
37	is	_	_	I-Claim
38	often	_	_	I-Claim
39	associated	_	_	I-Claim
40	with	_	_	I-Claim
41	hypothyroid	_	_	I-Claim
42	symptoms	_	_	I-Claim
43	and	_	_	I-Claim
44	impaired	_	_	I-Claim
45	quality	_	_	I-Claim
46	of	_	_	I-Claim
47	life	_	_	I-Claim
48	.	_	_	I-Claim

49	This	_	_	O
50	international	_	_	O
51	,	_	_	O
52	randomized	_	_	O
53	,	_	_	O
54	controlled	_	_	O
55	,	_	_	O
56	multicenter	_	_	O
57	trial	_	_	O
58	aimed	_	_	O
59	to	_	_	O
60	compare	_	_	O
61	the	_	_	O
62	efficacy	_	_	O
63	and	_	_	O
64	safety	_	_	O
65	of	_	_	O
66	recombinant	_	_	O
67	human	_	_	O
68	TSH	_	_	O
69	(	_	_	O
70	rhTSH	_	_	O
71	)	_	_	O
72	to	_	_	O
73	prepare	_	_	O
74	euthyroid	_	_	O
75	patients	_	_	O
76	on	_	_	O
77	L	_	_	O
78	-	_	_	O
79	thyroxine	_	_	O
80	therapy	_	_	O
81	(	_	_	O
82	euthyroid	_	_	O
83	group	_	_	O
84	)	_	_	O
85	to	_	_	O
86	ablate	_	_	O
87	remnant	_	_	O
88	thyroid	_	_	O
89	tissue	_	_	O
90	with	_	_	O
91	3	_	_	O
92	.	_	_	O

93	7	_	_	O
94	GBq	_	_	O
95	(	_	_	O
96	100	_	_	O
97	mCi	_	_	O
98	)	_	_	O
99	131I	_	_	O
100	,	_	_	O
101	compared	_	_	O
102	with	_	_	O
103	that	_	_	O
104	with	_	_	O
105	conventional	_	_	O
106	remnant	_	_	O
107	ablation	_	_	O
108	performed	_	_	O
109	in	_	_	O
110	the	_	_	O
111	hypothyroid	_	_	O
112	state	_	_	O
113	(	_	_	O
114	hypothyroid	_	_	O
115	group	_	_	O
116	)	_	_	O
117	.	_	_	O

118	Quality	_	_	O
119	of	_	_	O
120	life	_	_	O
121	was	_	_	O
122	determined	_	_	O
123	at	_	_	O
124	the	_	_	O
125	time	_	_	O
126	of	_	_	O
127	randomization	_	_	O
128	and	_	_	O
129	ablation	_	_	O
130	.	_	_	O

131	After	_	_	O
132	the	_	_	O
133	administration	_	_	O
134	of	_	_	O
135	the	_	_	O
136	131	_	_	O
137	-	_	_	O
138	I	_	_	O
139	dose	_	_	O
140	,	_	_	O
141	the	_	_	O
142	rate	_	_	O
143	of	_	_	O
144	radiation	_	_	O
145	clearance	_	_	O
146	from	_	_	O
147	blood	_	_	O
148	,	_	_	O
149	thyroid	_	_	O
150	remnant	_	_	O
151	,	_	_	O
152	and	_	_	O
153	whole	_	_	O
154	body	_	_	O
155	was	_	_	O
156	measured	_	_	O
157	.	_	_	O

158	The	_	_	O
159	predefined	_	_	O
160	primary	_	_	O
161	criterion	_	_	O
162	for	_	_	O
163	successful	_	_	O
164	ablation	_	_	O
165	was	_	_	O
166	"	_	_	O
167	no	_	_	O
168	visible	_	_	O
169	uptake	_	_	O
170	in	_	_	O
171	the	_	_	O
172	thyroid	_	_	O
173	bed	_	_	O
174	,	_	_	O
175	or	_	_	O
176	if	_	_	O
177	visible	_	_	O
178	,	_	_	O
179	fractional	_	_	O
180	uptake	_	_	O
181	less	_	_	O
182	than	_	_	O
183	0	_	_	O
184	.	_	_	O

185	1	_	_	O
186	%	_	_	O
187	"	_	_	O
188	on	_	_	O
189	neck	_	_	O
190	scans	_	_	O
191	performed	_	_	O
192	8	_	_	O
193	months	_	_	O
194	after	_	_	O
195	therapy	_	_	O
196	and	_	_	O
197	was	_	_	O
198	satisfied	_	_	O
199	in	_	_	O
200	100	_	_	O
201	%	_	_	O
202	of	_	_	O
203	patients	_	_	O
204	in	_	_	O
205	both	_	_	O
206	groups	_	_	O
207	.	_	_	O

208	A	_	_	O
209	secondary	_	_	O
210	criterion	_	_	O
211	for	_	_	O
212	ablation	_	_	O
213	,	_	_	O
214	an	_	_	O
215	rhTSH	_	_	O
216	-	_	_	O
217	stimulated	_	_	O
218	serum	_	_	O
219	thyroglobulin	_	_	O
220	concentration	_	_	O
221	less	_	_	O
222	than	_	_	O
223	2	_	_	O
224	ng	_	_	O
225	/	_	_	O
226	ml	_	_	O
227	,	_	_	O
228	was	_	_	O
229	fulfilled	_	_	O
230	by	_	_	O
231	23	_	_	O
232	of	_	_	O
233	24	_	_	O
234	(	_	_	O
235	96	_	_	O
236	%	_	_	O
237	)	_	_	O
238	euthyroid	_	_	O
239	patients	_	_	O
240	and	_	_	O
241	18	_	_	O
242	of	_	_	O
243	21	_	_	O
244	(	_	_	O
245	86	_	_	O
246	%	_	_	O
247	)	_	_	O
248	hypothyroid	_	_	O
249	patients	_	_	O
250	(	_	_	O
251	P	_	_	O
252	=	_	_	O
253	0	_	_	O
254	.	_	_	O

255	2341	_	_	O
256	)	_	_	O
257	.	_	_	O

258	Quality	_	_	B-Premise
259	of	_	_	I-Premise
260	life	_	_	I-Premise
261	was	_	_	I-Premise
262	well	_	_	I-Premise
263	preserved	_	_	I-Premise
264	in	_	_	I-Premise
265	the	_	_	I-Premise
266	euthyroid	_	_	I-Premise
267	group	_	_	I-Premise
268	,	_	_	I-Premise
269	compared	_	_	I-Premise
270	with	_	_	I-Premise
271	the	_	_	I-Premise
272	hypothyroid	_	_	I-Premise
273	group	_	_	I-Premise
274	,	_	_	I-Premise
275	as	_	_	I-Premise
276	demonstrated	_	_	I-Premise
277	by	_	_	I-Premise
278	their	_	_	I-Premise
279	lower	_	_	I-Premise
280	pretreatment	_	_	I-Premise
281	scores	_	_	I-Premise
282	on	_	_	I-Premise
283	the	_	_	I-Premise
284	Billewicz	_	_	I-Premise
285	scale	_	_	I-Premise
286	for	_	_	I-Premise
287	hypothyroid	_	_	I-Premise
288	signs	_	_	I-Premise
289	and	_	_	I-Premise
290	symptoms	_	_	I-Premise
291	,	_	_	I-Premise
292	27	_	_	I-Premise
293	+	_	_	I-Premise
294	/	_	_	I-Premise
295	-	_	_	I-Premise
296	7	_	_	I-Premise
297	vs	_	_	I-Premise
298	.	_	_	I-Premise

299	18	_	_	I-Premise
300	+	_	_	I-Premise
301	/	_	_	I-Premise
302	-	_	_	I-Premise
303	4	_	_	I-Premise
304	(	_	_	I-Premise
305	P	_	_	I-Premise
306	<	_	_	I-Premise
307	0	_	_	I-Premise
308	.	_	_	I-Premise

309	0001	_	_	I-Premise
310	)	_	_	I-Premise
311	and	_	_	I-Premise
312	their	_	_	I-Premise
313	significantly	_	_	I-Premise
314	higher	_	_	I-Premise
315	Short	_	_	I-Premise
316	Form	_	_	I-Premise
317	-	_	_	I-Premise
318	36	_	_	I-Premise
319	Health	_	_	I-Premise
320	Assessment	_	_	I-Premise
321	Scale	_	_	I-Premise
322	scores	_	_	I-Premise
323	in	_	_	I-Premise
324	five	_	_	I-Premise
325	of	_	_	I-Premise
326	eight	_	_	I-Premise
327	categories	_	_	I-Premise
328	.	_	_	I-Premise

329	Euthyroid	_	_	B-Premise
330	patients	_	_	I-Premise
331	had	_	_	I-Premise
332	a	_	_	I-Premise
333	statistically	_	_	I-Premise
334	significant	_	_	I-Premise
335	one	_	_	I-Premise
336	third	_	_	I-Premise
337	lower	_	_	I-Premise
338	radiation	_	_	I-Premise
339	dose	_	_	I-Premise
340	to	_	_	I-Premise
341	the	_	_	I-Premise
342	blood	_	_	I-Premise
343	,	_	_	I-Premise
344	compared	_	_	I-Premise
345	with	_	_	I-Premise
346	patients	_	_	I-Premise
347	in	_	_	I-Premise
348	the	_	_	I-Premise
349	hypothyroid	_	_	I-Premise
350	group	_	_	I-Premise
351	.	_	_	I-Premise

352	This	_	_	B-Claim
353	study	_	_	I-Claim
354	demonstrates	_	_	I-Claim
355	comparable	_	_	I-Claim
356	remnant	_	_	I-Claim
357	ablation	_	_	I-Claim
358	rates	_	_	I-Claim
359	in	_	_	I-Claim
360	patients	_	_	I-Claim
361	prepared	_	_	I-Claim
362	for	_	_	I-Claim
363	131I	_	_	I-Claim
364	remnant	_	_	I-Claim
365	ablation	_	_	I-Claim
366	with	_	_	I-Claim
367	3	_	_	I-Claim
368	.	_	_	I-Claim

369	7	_	_	I-Claim
370	GBq	_	_	I-Claim
371	by	_	_	I-Claim
372	either	_	_	I-Claim
373	administering	_	_	I-Claim
374	rhTSH	_	_	I-Claim
375	or	_	_	I-Claim
376	withholding	_	_	I-Claim
377	thyroid	_	_	I-Claim
378	hormone	_	_	I-Claim
379	.	_	_	I-Claim

380	rhTSH	_	_	B-Claim
381	-	_	_	I-Claim
382	prepared	_	_	I-Claim
383	patients	_	_	I-Claim
384	maintained	_	_	I-Claim
385	a	_	_	I-Claim
386	higher	_	_	I-Claim
387	quality	_	_	I-Claim
388	of	_	_	I-Claim
389	life	_	_	I-Claim
390	and	_	_	I-Claim
391	received	_	_	I-Claim
392	less	_	_	I-Claim
393	radiation	_	_	I-Claim
394	exposure	_	_	I-Claim
395	to	_	_	I-Claim
396	the	_	_	I-Claim
397	blood	_	_	I-Claim
398	.	_	_	I-Claim


0	In	_	_	O
1	Lithuania	_	_	O
2	,	_	_	O
3	about	_	_	O
4	400	_	_	O
5	cases	_	_	O
6	of	_	_	O
7	pancreatic	_	_	O
8	cancer	_	_	O
9	are	_	_	O
10	diagnosed	_	_	O
11	each	_	_	O
12	year	_	_	O
13	,	_	_	O
14	and	_	_	O
15	more	_	_	O
16	than	_	_	O
17	50	_	_	O
18	%	_	_	O
19	of	_	_	O
20	patients	_	_	O
21	are	_	_	O
22	diagnosed	_	_	O
23	with	_	_	O
24	stage	_	_	O
25	IV	_	_	O
26	disease	_	_	O
27	.	_	_	O

28	Quality	_	_	B-Claim
29	of	_	_	I-Claim
30	life	_	_	I-Claim
31	is	_	_	I-Claim
32	an	_	_	I-Claim
33	important	_	_	I-Claim
34	issue	_	_	I-Claim
35	in	_	_	I-Claim
36	pancreatic	_	_	I-Claim
37	cancer	_	_	I-Claim
38	patients	_	_	I-Claim
39	.	_	_	I-Claim

40	A	_	_	O
41	prospective	_	_	O
42	randomized	_	_	O
43	clinical	_	_	O
44	study	_	_	O
45	on	_	_	O
46	the	_	_	O
47	treatment	_	_	O
48	of	_	_	O
49	patients	_	_	O
50	with	_	_	O
51	resectable	_	_	O
52	and	_	_	O
53	unresectable	_	_	O
54	pancreatic	_	_	O
55	cancer	_	_	O
56	was	_	_	O
57	conducted	_	_	O
58	at	_	_	O
59	the	_	_	O
60	Department	_	_	O
61	of	_	_	O
62	Oncology	_	_	O
63	of	_	_	O
64	Kaunas	_	_	O
65	University	_	_	O
66	of	_	_	O
67	Medicine	_	_	O
68	Hospital	_	_	O
69	,	_	_	O
70	and	_	_	O
71	in	_	_	O
72	this	_	_	O
73	study	_	_	O
74	,	_	_	O
75	quality	_	_	O
76	of	_	_	O
77	life	_	_	O
78	was	_	_	O
79	analyzed	_	_	O
80	.	_	_	O

81	The	_	_	O
82	aim	_	_	O
83	of	_	_	O
84	the	_	_	O
85	study	_	_	O
86	was	_	_	O
87	to	_	_	O
88	analyze	_	_	O
89	the	_	_	O
90	effect	_	_	O
91	of	_	_	O
92	combined	_	_	O
93	treatment	_	_	O
94	methods	_	_	O
95	on	_	_	O
96	quality	_	_	O
97	of	_	_	O
98	life	_	_	O
99	in	_	_	O
100	patients	_	_	O
101	diagnosed	_	_	O
102	with	_	_	O
103	pancreatic	_	_	O
104	cancer	_	_	O
105	.	_	_	O

106	During	_	_	O
107	2000	_	_	O
108	-	_	_	O
109	2005	_	_	O
110	,	_	_	O
111	two	_	_	O
112	concomitant	_	_	O
113	chemoradiation	_	_	O
114	treatment	_	_	O
115	methods	_	_	O
116	(	_	_	O
117	radiotherapy	_	_	O
118	with	_	_	O
119	5	_	_	O
120	-	_	_	O
121	fluorouracil	_	_	O
122	and	_	_	O
123	radiotherapy	_	_	O
124	with	_	_	O
125	gemcitabine	_	_	O
126	)	_	_	O
127	were	_	_	O
128	analyzed	_	_	O
129	in	_	_	O
130	the	_	_	O
131	study	_	_	O
132	.	_	_	O

133	A	_	_	O
134	total	_	_	O
135	of	_	_	O
136	60	_	_	O
137	patients	_	_	O
138	were	_	_	O
139	enrolled	_	_	O
140	:	_	_	O
141	41	_	_	O
142	patients	_	_	O
143	diagnosed	_	_	O
144	with	_	_	O
145	resectable	_	_	O
146	and	_	_	O
147	19	_	_	O
148	patients	_	_	O
149	diagnosed	_	_	O
150	with	_	_	O
151	unresectable	_	_	O
152	pancreatic	_	_	O
153	cancer	_	_	O
154	.	_	_	O

155	Quality	_	_	O
156	of	_	_	O
157	life	_	_	O
158	was	_	_	O
159	assessed	_	_	O
160	using	_	_	O
161	European	_	_	O
162	Organization	_	_	O
163	for	_	_	O
164	Research	_	_	O
165	and	_	_	O
166	Treatment	_	_	O
167	of	_	_	O
168	Cancer	_	_	O
169	Quality	_	_	O
170	of	_	_	O
171	Life	_	_	O
172	Core	_	_	O
173	30	_	_	O
174	(	_	_	O
175	EORTC	_	_	O
176	QLQ	_	_	O
177	-	_	_	O
178	C30	_	_	O
179	)	_	_	O
180	questionnaire	_	_	O
181	.	_	_	O

182	Three	_	_	O
183	main	_	_	O
184	quality	_	_	O
185	of	_	_	O
186	life	_	_	O
187	scales	_	_	O
188	(	_	_	O
189	general	_	_	O
190	health	_	_	O
191	status	_	_	O
192	,	_	_	O
193	functional	_	_	O
194	,	_	_	O
195	and	_	_	O
196	symptom	_	_	O
197	scales	_	_	O
198	)	_	_	O
199	were	_	_	O
200	assessed	_	_	O
201	and	_	_	O
202	compared	_	_	O
203	between	_	_	O
204	two	_	_	O
205	treatment	_	_	O
206	groups	_	_	O
207	.	_	_	O

208	The	_	_	B-Premise
209	analysis	_	_	I-Premise
210	of	_	_	I-Premise
211	quality	_	_	I-Premise
212	of	_	_	I-Premise
213	live	_	_	I-Premise
214	assessment	_	_	I-Premise
215	showed	_	_	I-Premise
216	a	_	_	I-Premise
217	statistically	_	_	I-Premise
218	significant	_	_	I-Premise
219	decrease	_	_	I-Premise
220	in	_	_	I-Premise
221	quality	_	_	I-Premise
222	of	_	_	I-Premise
223	life	_	_	I-Premise
224	after	_	_	I-Premise
225	treatment	_	_	I-Premise
226	in	_	_	I-Premise
227	patients	_	_	I-Premise
228	with	_	_	I-Premise
229	resectable	_	_	I-Premise
230	pancreatic	_	_	I-Premise
231	cancer	_	_	I-Premise
232	and	_	_	I-Premise
233	treated	_	_	I-Premise
234	with	_	_	I-Premise
235	radiotherapy	_	_	I-Premise
236	and	_	_	I-Premise
237	gemcitabine	_	_	I-Premise
238	.	_	_	I-Premise

239	Decreased	_	_	B-Premise
240	quality	_	_	I-Premise
241	of	_	_	I-Premise
242	life	_	_	I-Premise
243	later	_	_	I-Premise
244	after	_	_	I-Premise
245	treatment	_	_	I-Premise
246	was	_	_	I-Premise
247	also	_	_	I-Premise
248	observed	_	_	I-Premise
249	in	_	_	I-Premise
250	patients	_	_	I-Premise
251	diagnosed	_	_	I-Premise
252	with	_	_	I-Premise
253	unresectable	_	_	I-Premise
254	pancreatic	_	_	I-Premise
255	cancer	_	_	I-Premise
256	and	_	_	I-Premise
257	treated	_	_	I-Premise
258	with	_	_	I-Premise
259	the	_	_	I-Premise
260	same	_	_	I-Premise
261	regimen	_	_	I-Premise
262	.	_	_	I-Premise

263	Treatment	_	_	B-Claim
264	with	_	_	I-Claim
265	radiotherapy	_	_	I-Claim
266	and	_	_	I-Claim
267	5	_	_	I-Claim
268	-	_	_	I-Claim
269	fluorouracil	_	_	I-Claim
270	changed	_	_	I-Claim
271	only	_	_	I-Claim
272	some	_	_	I-Claim
273	aspects	_	_	I-Claim
274	of	_	_	I-Claim
275	quality	_	_	I-Claim
276	of	_	_	I-Claim
277	life	_	_	I-Claim
278	and	_	_	I-Claim
279	did	_	_	I-Claim
280	not	_	_	I-Claim
281	have	_	_	I-Claim
282	a	_	_	I-Claim
283	significant	_	_	I-Claim
284	impact	_	_	I-Claim
285	on	_	_	I-Claim
286	quality	_	_	I-Claim
287	of	_	_	I-Claim
288	life	_	_	I-Claim
289	.	_	_	I-Claim


0	Cancer	_	_	O
1	cells	_	_	O
2	rely	_	_	O
3	on	_	_	O
4	angiogenesis	_	_	O
5	for	_	_	O
6	growth	_	_	O
7	and	_	_	O
8	dissemination	_	_	O
9	,	_	_	O
10	and	_	_	O
11	small	_	_	O
12	cell	_	_	O
13	lung	_	_	O
14	cancer	_	_	O
15	(	_	_	O
16	SCLC	_	_	O
17	)	_	_	O
18	is	_	_	O
19	a	_	_	O
20	highly	_	_	O
21	angiogenic	_	_	O
22	tumor	_	_	O
23	.	_	_	O

24	We	_	_	O
25	evaluated	_	_	O
26	thalidomide	_	_	O
27	,	_	_	O
28	an	_	_	O
29	anti	_	_	O
30	-	_	_	O
31	angiogenic	_	_	O
32	agent	_	_	O
33	,	_	_	O
34	when	_	_	O
35	combined	_	_	O
36	with	_	_	O
37	chemotherapy	_	_	O
38	and	_	_	O
39	as	_	_	O
40	maintenance	_	_	O
41	treatment	_	_	O
42	.	_	_	O

43	A	_	_	O
44	total	_	_	O
45	of	_	_	O
46	724	_	_	O
47	patients	_	_	O
48	(	_	_	O
49	51	_	_	O
50	%	_	_	O
51	with	_	_	O
52	limited	_	_	O
53	and	_	_	O
54	49	_	_	O
55	%	_	_	O
56	with	_	_	O
57	extensive	_	_	O
58	disease	_	_	O
59	)	_	_	O
60	were	_	_	O
61	randomly	_	_	O
62	assigned	_	_	O
63	to	_	_	O
64	receive	_	_	O
65	placebo	_	_	O
66	or	_	_	O
67	thalidomide	_	_	O
68	capsules	_	_	O
69	,	_	_	O
70	100	_	_	O
71	-	_	_	O
72	200	_	_	O
73	mg	_	_	O
74	daily	_	_	O
75	for	_	_	O
76	up	_	_	O
77	to	_	_	O
78	2	_	_	O
79	years	_	_	O
80	.	_	_	O

81	All	_	_	O
82	patients	_	_	O
83	received	_	_	O
84	etoposide	_	_	O
85	and	_	_	O
86	carboplatin	_	_	O
87	every	_	_	O
88	3	_	_	O
89	weeks	_	_	O
90	for	_	_	O
91	up	_	_	O
92	to	_	_	O
93	six	_	_	O
94	cycles	_	_	O
95	.	_	_	O

96	Endpoints	_	_	O
97	were	_	_	O
98	overall	_	_	O
99	survival	_	_	O
100	,	_	_	O
101	progression	_	_	O
102	-	_	_	O
103	free	_	_	O
104	survival	_	_	O
105	,	_	_	O
106	tumor	_	_	O
107	response	_	_	O
108	rate	_	_	O
109	,	_	_	O
110	toxicity	_	_	O
111	,	_	_	O
112	and	_	_	O
113	quality	_	_	O
114	of	_	_	O
115	life	_	_	O
116	(	_	_	O
117	QoL	_	_	O
118	)	_	_	O
119	.	_	_	O

120	Hazard	_	_	O
121	ratios	_	_	O
122	(	_	_	O
123	HRs	_	_	O
124	)	_	_	O
125	for	_	_	O
126	comparing	_	_	O
127	thalidomide	_	_	O
128	against	_	_	O
129	placebo	_	_	O
130	were	_	_	O
131	estimated	_	_	O
132	using	_	_	O
133	Cox	_	_	O
134	regression	_	_	O
135	modeling	_	_	O
136	.	_	_	O

137	Statistical	_	_	O
138	tests	_	_	O
139	were	_	_	O
140	two	_	_	O
141	-	_	_	O
142	sided	_	_	O
143	.	_	_	O

144	The	_	_	B-Premise
145	median	_	_	I-Premise
146	overall	_	_	I-Premise
147	survival	_	_	I-Premise
148	was	_	_	I-Premise
149	10	_	_	I-Premise
150	.	_	_	I-Premise

151	5	_	_	I-Premise
152	months	_	_	I-Premise
153	(	_	_	I-Premise
154	placebo	_	_	I-Premise
155	)	_	_	I-Premise
156	and	_	_	I-Premise
157	10	_	_	I-Premise
158	.	_	_	I-Premise

159	1	_	_	I-Premise
160	months	_	_	I-Premise
161	(	_	_	I-Premise
162	thalidomide	_	_	I-Premise
163	)	_	_	I-Premise
164	(	_	_	I-Premise
165	HR	_	_	I-Premise
166	for	_	_	I-Premise
167	death	_	_	I-Premise
168	=	_	_	I-Premise
169	1	_	_	I-Premise
170	.	_	_	I-Premise

171	09	_	_	I-Premise
172	,	_	_	I-Premise
173	95	_	_	I-Premise
174	%	_	_	I-Premise
175	confidence	_	_	I-Premise
176	interval	_	_	I-Premise
177	[	_	_	I-Premise
178	CI	_	_	I-Premise
179	]	_	_	I-Premise
180	=	_	_	I-Premise
181	0	_	_	I-Premise
182	.	_	_	I-Premise

183	93	_	_	I-Premise
184	to	_	_	I-Premise
185	1	_	_	I-Premise
186	.	_	_	I-Premise

187	27	_	_	I-Premise
188	;	_	_	I-Premise
189	P	_	_	I-Premise
190	=	_	_	I-Premise
191	.	_	_	I-Premise

192	28	_	_	I-Premise
193	)	_	_	I-Premise
194	.	_	_	I-Premise

195	Among	_	_	B-Premise
196	patients	_	_	I-Premise
197	with	_	_	I-Premise
198	limited	_	_	I-Premise
199	-	_	_	I-Premise
200	stage	_	_	I-Premise
201	disease	_	_	I-Premise
202	,	_	_	I-Premise
203	there	_	_	I-Premise
204	was	_	_	I-Premise
205	no	_	_	I-Premise
206	evidence	_	_	I-Premise
207	of	_	_	I-Premise
208	a	_	_	I-Premise
209	survival	_	_	I-Premise
210	difference	_	_	I-Premise
211	(	_	_	I-Premise
212	HR	_	_	I-Premise
213	for	_	_	I-Premise
214	death	_	_	I-Premise
215	=	_	_	I-Premise
216	0	_	_	I-Premise
217	.	_	_	I-Premise

218	91	_	_	I-Premise
219	,	_	_	I-Premise
220	95	_	_	I-Premise
221	%	_	_	I-Premise
222	CI	_	_	I-Premise
223	=	_	_	I-Premise
224	0	_	_	I-Premise
225	.	_	_	I-Premise

226	73	_	_	I-Premise
227	to	_	_	I-Premise
228	1	_	_	I-Premise
229	.	_	_	I-Premise

230	15	_	_	I-Premise
231	)	_	_	I-Premise
232	,	_	_	I-Premise
233	but	_	_	B-Premise
234	among	_	_	I-Premise
235	patients	_	_	I-Premise
236	with	_	_	I-Premise
237	extensive	_	_	I-Premise
238	disease	_	_	I-Premise
239	,	_	_	I-Premise
240	survival	_	_	I-Premise
241	was	_	_	I-Premise
242	worse	_	_	I-Premise
243	in	_	_	I-Premise
244	the	_	_	I-Premise
245	thalidomide	_	_	I-Premise
246	group	_	_	I-Premise
247	(	_	_	I-Premise
248	HR	_	_	I-Premise
249	for	_	_	I-Premise
250	death	_	_	I-Premise
251	=	_	_	I-Premise
252	1	_	_	I-Premise
253	.	_	_	I-Premise

254	36	_	_	I-Premise
255	,	_	_	I-Premise
256	95	_	_	I-Premise
257	%	_	_	I-Premise
258	CI	_	_	I-Premise
259	=	_	_	I-Premise
260	1	_	_	I-Premise
261	.	_	_	I-Premise

262	10	_	_	I-Premise
263	to	_	_	I-Premise
264	1	_	_	I-Premise
265	.	_	_	I-Premise

266	68	_	_	I-Premise
267	)	_	_	I-Premise
268	.	_	_	I-Premise

269	Progression	_	_	B-Premise
270	-	_	_	I-Premise
271	free	_	_	I-Premise
272	survival	_	_	I-Premise
273	rates	_	_	I-Premise
274	were	_	_	I-Premise
275	also	_	_	I-Premise
276	similar	_	_	I-Premise
277	in	_	_	I-Premise
278	the	_	_	I-Premise
279	two	_	_	I-Premise
280	groups	_	_	I-Premise
281	(	_	_	I-Premise
282	HR	_	_	I-Premise
283	=	_	_	I-Premise
284	1	_	_	I-Premise
285	.	_	_	I-Premise

286	07	_	_	I-Premise
287	,	_	_	I-Premise
288	95	_	_	I-Premise
289	%	_	_	I-Premise
290	CI	_	_	I-Premise
291	=	_	_	I-Premise
292	0	_	_	I-Premise
293	.	_	_	I-Premise

294	92	_	_	I-Premise
295	to	_	_	I-Premise
296	1	_	_	I-Premise
297	.	_	_	I-Premise

298	24	_	_	I-Premise
299	)	_	_	I-Premise
300	.	_	_	I-Premise

301	Thalidomide	_	_	B-Premise
302	was	_	_	I-Premise
303	associated	_	_	I-Premise
304	with	_	_	I-Premise
305	an	_	_	I-Premise
306	increased	_	_	I-Premise
307	risk	_	_	I-Premise
308	of	_	_	I-Premise
309	having	_	_	I-Premise
310	a	_	_	I-Premise
311	thrombotic	_	_	I-Premise
312	event	_	_	I-Premise
313	,	_	_	I-Premise
314	mainly	_	_	I-Premise
315	pulmonary	_	_	I-Premise
316	embolus	_	_	I-Premise
317	and	_	_	I-Premise
318	deep	_	_	I-Premise
319	vein	_	_	I-Premise
320	thrombosis	_	_	I-Premise
321	(	_	_	I-Premise
322	19	_	_	I-Premise
323	%	_	_	I-Premise
324	thalidomide	_	_	I-Premise
325	vs	_	_	I-Premise
326	10	_	_	I-Premise
327	%	_	_	I-Premise
328	placebo	_	_	I-Premise
329	;	_	_	I-Premise
330	HR	_	_	I-Premise
331	=	_	_	I-Premise
332	2	_	_	I-Premise
333	.	_	_	I-Premise

334	13	_	_	I-Premise
335	,	_	_	I-Premise
336	95	_	_	I-Premise
337	%	_	_	I-Premise
338	CI	_	_	I-Premise
339	=	_	_	I-Premise
340	1	_	_	I-Premise
341	.	_	_	I-Premise

342	41	_	_	I-Premise
343	to	_	_	I-Premise
344	3	_	_	I-Premise
345	.	_	_	I-Premise

346	20	_	_	I-Premise
347	;	_	_	I-Premise
348	P	_	_	I-Premise
349	<	_	_	I-Premise
350	.	_	_	I-Premise

351	001	_	_	I-Premise
352	)	_	_	I-Premise
353	.	_	_	I-Premise

354	There	_	_	B-Premise
355	were	_	_	I-Premise
356	no	_	_	I-Premise
357	statistically	_	_	I-Premise
358	significant	_	_	I-Premise
359	differences	_	_	I-Premise
360	between	_	_	I-Premise
361	treatments	_	_	I-Premise
362	in	_	_	I-Premise
363	hematological	_	_	I-Premise
364	and	_	_	I-Premise
365	nonhematological	_	_	I-Premise
366	toxic	_	_	I-Premise
367	effects	_	_	I-Premise
368	,	_	_	I-Premise
369	except	_	_	B-Premise
370	more	_	_	I-Premise
371	patients	_	_	I-Premise
372	in	_	_	I-Premise
373	the	_	_	I-Premise
374	thalidomide	_	_	I-Premise
375	group	_	_	I-Premise
376	had	_	_	I-Premise
377	rash	_	_	I-Premise
378	,	_	_	I-Premise
379	constipation	_	_	I-Premise
380	,	_	_	I-Premise
381	or	_	_	I-Premise
382	neuropathy	_	_	I-Premise
383	.	_	_	I-Premise

384	Overall	_	_	O
385	,	_	_	O
386	QoL	_	_	B-Claim
387	scores	_	_	I-Claim
388	were	_	_	I-Claim
389	similar	_	_	I-Claim
390	in	_	_	I-Claim
391	the	_	_	I-Claim
392	two	_	_	I-Claim
393	treatment	_	_	I-Claim
394	groups	_	_	I-Claim
395	,	_	_	I-Claim
396	but	_	_	B-Claim
397	thalidomide	_	_	I-Claim
398	was	_	_	I-Claim
399	associated	_	_	I-Claim
400	with	_	_	I-Claim
401	less	_	_	I-Claim
402	insomnia	_	_	I-Claim
403	and	_	_	I-Claim
404	diarrhea	_	_	I-Claim
405	and	_	_	I-Claim
406	more	_	_	I-Claim
407	constipation	_	_	I-Claim
408	and	_	_	I-Claim
409	peripheral	_	_	I-Claim
410	neuropathy	_	_	I-Claim
411	.	_	_	I-Claim

412	In	_	_	O
413	this	_	_	O
414	large	_	_	O
415	randomized	_	_	O
416	trial	_	_	O
417	,	_	_	O
418	thalidomide	_	_	B-Claim
419	in	_	_	I-Claim
420	combination	_	_	I-Claim
421	with	_	_	I-Claim
422	chemotherapy	_	_	I-Claim
423	did	_	_	I-Claim
424	not	_	_	I-Claim
425	improve	_	_	I-Claim
426	survival	_	_	I-Claim
427	of	_	_	I-Claim
428	patients	_	_	I-Claim
429	with	_	_	I-Claim
430	SCLC	_	_	I-Claim
431	but	_	_	I-Claim
432	was	_	_	I-Claim
433	associated	_	_	I-Claim
434	with	_	_	I-Claim
435	an	_	_	I-Claim
436	increased	_	_	I-Claim
437	risk	_	_	I-Claim
438	of	_	_	I-Claim
439	thrombotic	_	_	I-Claim
440	events	_	_	I-Claim
441	.	_	_	I-Claim


0	Most	_	_	B-Claim
1	patients	_	_	I-Claim
2	with	_	_	I-Claim
3	advanced	_	_	I-Claim
4	ovarian	_	_	I-Claim
5	cancer	_	_	I-Claim
6	develop	_	_	I-Claim
7	recurrent	_	_	I-Claim
8	disease	_	_	I-Claim
9	.	_	_	I-Claim

10	For	_	_	B-Claim
11	those	_	_	I-Claim
12	patients	_	_	I-Claim
13	who	_	_	I-Claim
14	recur	_	_	I-Claim
15	at	_	_	I-Claim
16	least	_	_	I-Claim
17	6	_	_	I-Claim
18	months	_	_	I-Claim
19	after	_	_	I-Claim
20	initial	_	_	I-Claim
21	therapy	_	_	I-Claim
22	,	_	_	I-Claim
23	paclitaxel	_	_	I-Claim
24	platinum	_	_	I-Claim
25	has	_	_	I-Claim
26	shown	_	_	I-Claim
27	a	_	_	I-Claim
28	modest	_	_	I-Claim
29	survival	_	_	I-Claim
30	advantage	_	_	I-Claim
31	over	_	_	I-Claim
32	platinum	_	_	I-Claim
33	without	_	_	I-Claim
34	paclitaxel	_	_	I-Claim
35	;	_	_	I-Claim
36	however	_	_	B-Premise
37	,	_	_	I-Premise
38	many	_	_	I-Premise
39	patients	_	_	I-Premise
40	develop	_	_	I-Premise
41	clinically	_	_	I-Premise
42	relevant	_	_	I-Premise
43	neurotoxicity	_	_	I-Premise
44	,	_	_	I-Premise
45	frequently	_	_	I-Premise
46	resulting	_	_	I-Premise
47	in	_	_	I-Premise
48	treatment	_	_	I-Premise
49	discontinuation	_	_	I-Premise
50	.	_	_	O

51	Thus	_	_	O
52	,	_	_	O
53	an	_	_	O
54	alternative	_	_	O
55	regimen	_	_	O
56	without	_	_	O
57	significant	_	_	O
58	neurotoxicity	_	_	O
59	was	_	_	O
60	evaluated	_	_	O
61	by	_	_	O
62	comparing	_	_	O
63	gemcitabine	_	_	O
64	plus	_	_	O
65	carboplatin	_	_	O
66	with	_	_	O
67	single	_	_	O
68	-	_	_	O
69	agent	_	_	O
70	carboplatin	_	_	O
71	in	_	_	O
72	platinum	_	_	O
73	-	_	_	O
74	sensitive	_	_	O
75	recurrent	_	_	O
76	ovarian	_	_	O
77	cancer	_	_	O
78	patients	_	_	O
79	.	_	_	O

80	Patients	_	_	O
81	with	_	_	O
82	platinum	_	_	O
83	-	_	_	O
84	sensitive	_	_	O
85	recurrent	_	_	O
86	ovarian	_	_	O
87	cancer	_	_	O
88	were	_	_	O
89	randomly	_	_	O
90	assigned	_	_	O
91	to	_	_	O
92	receive	_	_	O
93	either	_	_	O
94	gemcitabine	_	_	O
95	plus	_	_	O
96	carboplatin	_	_	O
97	or	_	_	O
98	carboplatin	_	_	O
99	alone	_	_	O
100	,	_	_	O
101	every	_	_	O
102	21	_	_	O
103	days	_	_	O
104	.	_	_	O

105	The	_	_	O
106	primary	_	_	O
107	objective	_	_	O
108	was	_	_	O
109	to	_	_	O
110	compare	_	_	O
111	progression	_	_	O
112	-	_	_	O
113	free	_	_	O
114	survival	_	_	O
115	(	_	_	O
116	PFS	_	_	O
117	)	_	_	O
118	.	_	_	O

119	Three	_	_	O
120	hundred	_	_	O
121	fifty	_	_	O
122	-	_	_	O
123	six	_	_	O
124	patients	_	_	O
125	(	_	_	O
126	178	_	_	O
127	gemcitabine	_	_	O
128	plus	_	_	O
129	carboplatin	_	_	O
130	;	_	_	O
131	178	_	_	O
132	carboplatin	_	_	O
133	)	_	_	O
134	were	_	_	O
135	randomly	_	_	O
136	assigned	_	_	O
137	.	_	_	O

138	Patients	_	_	O
139	received	_	_	O
140	a	_	_	O
141	median	_	_	O
142	of	_	_	O
143	six	_	_	O
144	cycles	_	_	O
145	in	_	_	O
146	both	_	_	O
147	arms	_	_	O
148	.	_	_	O

149	With	_	_	B-Premise
150	a	_	_	I-Premise
151	median	_	_	I-Premise
152	follow	_	_	I-Premise
153	-	_	_	I-Premise
154	up	_	_	I-Premise
155	of	_	_	I-Premise
156	17	_	_	I-Premise
157	months	_	_	I-Premise
158	,	_	_	I-Premise
159	median	_	_	I-Premise
160	PFS	_	_	I-Premise
161	was	_	_	I-Premise
162	8	_	_	I-Premise
163	.	_	_	I-Premise

164	6	_	_	I-Premise
165	months	_	_	I-Premise
166	(	_	_	I-Premise
167	95	_	_	I-Premise
168	%	_	_	I-Premise
169	CI	_	_	I-Premise
170	,	_	_	I-Premise
171	7	_	_	I-Premise
172	.	_	_	I-Premise

173	9	_	_	I-Premise
174	to	_	_	I-Premise
175	9	_	_	I-Premise
176	.	_	_	I-Premise

177	7	_	_	I-Premise
178	months	_	_	I-Premise
179	)	_	_	I-Premise
180	for	_	_	I-Premise
181	gemcitabine	_	_	I-Premise
182	plus	_	_	I-Premise
183	carboplatin	_	_	I-Premise
184	and	_	_	I-Premise
185	5	_	_	I-Premise
186	.	_	_	I-Premise

187	8	_	_	I-Premise
188	months	_	_	I-Premise
189	(	_	_	I-Premise
190	95	_	_	I-Premise
191	%	_	_	I-Premise
192	CI	_	_	I-Premise
193	,	_	_	I-Premise
194	5	_	_	I-Premise
195	.	_	_	I-Premise

196	2	_	_	I-Premise
197	to	_	_	I-Premise
198	7	_	_	I-Premise
199	.	_	_	I-Premise

200	1	_	_	I-Premise
201	months	_	_	I-Premise
202	)	_	_	I-Premise
203	for	_	_	I-Premise
204	carboplatin	_	_	I-Premise
205	.	_	_	I-Premise

206	The	_	_	B-Premise
207	hazard	_	_	I-Premise
208	ration	_	_	I-Premise
209	(	_	_	I-Premise
210	HR	_	_	I-Premise
211	)	_	_	I-Premise
212	for	_	_	I-Premise
213	PFS	_	_	I-Premise
214	was	_	_	I-Premise
215	0	_	_	I-Premise
216	.	_	_	I-Premise

217	72	_	_	I-Premise
218	(	_	_	I-Premise
219	95	_	_	I-Premise
220	%	_	_	I-Premise
221	CI	_	_	I-Premise
222	,	_	_	I-Premise
223	0	_	_	I-Premise
224	.	_	_	I-Premise

225	58	_	_	I-Premise
226	to	_	_	I-Premise
227	0	_	_	I-Premise
228	.	_	_	I-Premise

229	90	_	_	I-Premise
230	;	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	.	_	_	I-Premise

234	0031	_	_	I-Premise
235	)	_	_	I-Premise
236	.	_	_	I-Premise

237	Response	_	_	B-Premise
238	rate	_	_	I-Premise
239	was	_	_	I-Premise
240	47	_	_	I-Premise
241	.	_	_	I-Premise

242	2	_	_	I-Premise
243	%	_	_	I-Premise
244	(	_	_	I-Premise
245	95	_	_	I-Premise
246	%	_	_	I-Premise
247	CI	_	_	I-Premise
248	,	_	_	I-Premise
249	39	_	_	I-Premise
250	.	_	_	I-Premise

251	9	_	_	I-Premise
252	%	_	_	I-Premise
253	to	_	_	I-Premise
254	54	_	_	I-Premise
255	.	_	_	I-Premise

256	5	_	_	I-Premise
257	%	_	_	I-Premise
258	)	_	_	I-Premise
259	for	_	_	I-Premise
260	gemcitabine	_	_	I-Premise
261	plus	_	_	I-Premise
262	carboplatin	_	_	I-Premise
263	and	_	_	I-Premise
264	30	_	_	I-Premise
265	.	_	_	I-Premise

266	9	_	_	I-Premise
267	%	_	_	I-Premise
268	(	_	_	I-Premise
269	95	_	_	I-Premise
270	%	_	_	I-Premise
271	CI	_	_	I-Premise
272	,	_	_	I-Premise
273	24	_	_	I-Premise
274	.	_	_	I-Premise

275	1	_	_	I-Premise
276	%	_	_	I-Premise
277	to	_	_	I-Premise
278	37	_	_	I-Premise
279	.	_	_	I-Premise

280	7	_	_	I-Premise
281	%	_	_	I-Premise
282	)	_	_	I-Premise
283	for	_	_	I-Premise
284	carboplatin	_	_	I-Premise
285	(	_	_	I-Premise
286	P	_	_	I-Premise
287	=	_	_	I-Premise
288	.	_	_	I-Premise

289	0016	_	_	I-Premise
290	)	_	_	I-Premise
291	.	_	_	I-Premise

292	The	_	_	B-Premise
293	HR	_	_	I-Premise
294	for	_	_	I-Premise
295	overall	_	_	I-Premise
296	survival	_	_	I-Premise
297	was	_	_	I-Premise
298	0	_	_	I-Premise
299	.	_	_	I-Premise

300	96	_	_	I-Premise
301	(	_	_	I-Premise
302	95	_	_	I-Premise
303	%	_	_	I-Premise
304	CI	_	_	I-Premise
305	,	_	_	I-Premise
306	0	_	_	I-Premise
307	.	_	_	I-Premise

308	75	_	_	I-Premise
309	to1	_	_	I-Premise
310	.	_	_	I-Premise

311	23	_	_	I-Premise
312	;	_	_	I-Premise
313	P	_	_	I-Premise
314	=	_	_	I-Premise
315	.	_	_	I-Premise

316	7349	_	_	I-Premise
317	)	_	_	I-Premise
318	.	_	_	I-Premise

319	While	_	_	B-Premise
320	myelosuppression	_	_	I-Premise
321	was	_	_	I-Premise
322	significantly	_	_	I-Premise
323	more	_	_	I-Premise
324	common	_	_	I-Premise
325	in	_	_	I-Premise
326	the	_	_	I-Premise
327	combination	_	_	I-Premise
328	,	_	_	I-Premise
329	sequelae	_	_	I-Premise
330	such	_	_	I-Premise
331	as	_	_	I-Premise
332	febrile	_	_	I-Premise
333	neutropenia	_	_	I-Premise
334	or	_	_	I-Premise
335	infections	_	_	I-Premise
336	were	_	_	I-Premise
337	uncommon	_	_	I-Premise
338	.	_	_	I-Premise

339	No	_	_	B-Premise
340	statistically	_	_	I-Premise
341	significant	_	_	I-Premise
342	differences	_	_	I-Premise
343	in	_	_	I-Premise
344	quality	_	_	I-Premise
345	of	_	_	I-Premise
346	life	_	_	I-Premise
347	scores	_	_	I-Premise
348	between	_	_	I-Premise
349	arms	_	_	I-Premise
350	were	_	_	I-Premise
351	noted	_	_	I-Premise
352	.	_	_	I-Premise

353	Gemcitabine	_	_	B-Claim
354	plus	_	_	I-Claim
355	carboplatin	_	_	I-Claim
356	significantly	_	_	I-Claim
357	improves	_	_	I-Claim
358	PFS	_	_	I-Claim
359	and	_	_	I-Claim
360	response	_	_	I-Claim
361	rate	_	_	I-Claim
362	without	_	_	I-Claim
363	worsening	_	_	I-Claim
364	quality	_	_	I-Claim
365	of	_	_	I-Claim
366	life	_	_	I-Claim
367	for	_	_	I-Claim
368	patients	_	_	I-Claim
369	with	_	_	I-Claim
370	platinum	_	_	I-Claim
371	-	_	_	I-Claim
372	sensitive	_	_	I-Claim
373	recurrent	_	_	I-Claim
374	ovarian	_	_	I-Claim
375	cancer	_	_	I-Claim
376	.	_	_	I-Claim


0	Depression	_	_	B-Claim
1	,	_	_	I-Claim
2	anxiety	_	_	I-Claim
3	,	_	_	I-Claim
4	fatigue	_	_	I-Claim
5	,	_	_	I-Claim
6	and	_	_	I-Claim
7	impaired	_	_	I-Claim
8	wellbeing	_	_	I-Claim
9	are	_	_	I-Claim
10	common	_	_	I-Claim
11	,	_	_	I-Claim
12	important	_	_	I-Claim
13	,	_	_	I-Claim
14	and	_	_	I-Claim
15	closely	_	_	I-Claim
16	related	_	_	I-Claim
17	in	_	_	I-Claim
18	advanced	_	_	I-Claim
19	cancer	_	_	I-Claim
20	.	_	_	I-Claim

21	We	_	_	O
22	aimed	_	_	O
23	to	_	_	O
24	identify	_	_	O
25	the	_	_	O
26	effects	_	_	O
27	of	_	_	O
28	an	_	_	O
29	established	_	_	O
30	antidepressant	_	_	O
31	on	_	_	O
32	these	_	_	O
33	symptoms	_	_	O
34	and	_	_	O
35	survival	_	_	O
36	in	_	_	O
37	patients	_	_	O
38	with	_	_	O
39	advanced	_	_	O
40	cancer	_	_	O
41	who	_	_	O
42	did	_	_	O
43	not	_	_	O
44	have	_	_	O
45	major	_	_	O
46	depression	_	_	O
47	as	_	_	O
48	assessed	_	_	O
49	by	_	_	O
50	clinicians	_	_	O
51	.	_	_	O

52	Between	_	_	O
53	July	_	_	O
54	,	_	_	O
55	2001	_	_	O
56	,	_	_	O
57	and	_	_	O
58	February	_	_	O
59	,	_	_	O
60	2006	_	_	O
61	,	_	_	O
62	189	_	_	O
63	patients	_	_	O
64	with	_	_	O
65	advanced	_	_	O
66	cancer	_	_	O
67	were	_	_	O
68	randomly	_	_	O
69	assigned	_	_	O
70	sertraline	_	_	O
71	50	_	_	O
72	mg	_	_	O
73	(	_	_	O
74	n	_	_	O
75	=	_	_	O
76	95	_	_	O
77	)	_	_	O
78	,	_	_	O
79	or	_	_	O
80	placebo	_	_	O
81	(	_	_	O
82	n	_	_	O
83	=	_	_	O
84	94	_	_	O
85	)	_	_	O
86	,	_	_	O
87	once	_	_	O
88	per	_	_	O
89	day	_	_	O
90	.	_	_	O

91	The	_	_	O
92	primary	_	_	O
93	outcome	_	_	O
94	was	_	_	O
95	depression	_	_	O
96	as	_	_	O
97	assessed	_	_	O
98	by	_	_	O
99	the	_	_	O
100	Centre	_	_	O
101	for	_	_	O
102	Epidemiologic	_	_	O
103	Studies	_	_	O
104	Depression	_	_	O
105	scale	_	_	O
106	(	_	_	O
107	CES	_	_	O
108	-	_	_	O
109	D	_	_	O
110	)	_	_	O
111	;	_	_	O
112	the	_	_	O
113	main	_	_	O
114	secondary	_	_	O
115	outcomes	_	_	O
116	were	_	_	O
117	:	_	_	O
118	anxiety	_	_	O
119	as	_	_	O
120	assessed	_	_	O
121	by	_	_	O
122	Hospital	_	_	O
123	Anxiety	_	_	O
124	and	_	_	O
125	Depression	_	_	O
126	Scales	_	_	O
127	(	_	_	O
128	HADS	_	_	O
129	-	_	_	O
130	A	_	_	O
131	)	_	_	O
132	;	_	_	O
133	overall	_	_	O
134	quality	_	_	O
135	of	_	_	O
136	life	_	_	O
137	and	_	_	O
138	fatigue	_	_	O
139	as	_	_	O
140	assessed	_	_	O
141	by	_	_	O
142	Functional	_	_	O
143	Assessment	_	_	O
144	of	_	_	O
145	Cancer	_	_	O
146	Therapy	_	_	O
147	General	_	_	O
148	and	_	_	O
149	Fatigue	_	_	O
150	scales	_	_	O
151	(	_	_	O
152	FACT	_	_	O
153	-	_	_	O
154	G	_	_	O
155	and	_	_	O
156	FACT	_	_	O
157	-	_	_	O
158	F	_	_	O
159	,	_	_	O
160	respectively	_	_	O
161	)	_	_	O
162	;	_	_	O
163	and	_	_	O
164	clinicians	_	_	O
165	'	_	_	O
166	ratings	_	_	O
167	of	_	_	O
168	quality	_	_	O
169	of	_	_	O
170	life	_	_	O
171	by	_	_	O
172	use	_	_	O
173	of	_	_	O
174	Spizter	_	_	O
175	'	_	_	O
176	s	_	_	O
177	Quality	_	_	O
178	of	_	_	O
179	Life	_	_	O
180	Index	_	_	O
181	(	_	_	O
182	SQLI	_	_	O
183	)	_	_	O
184	.	_	_	O

185	Multiple	_	_	O
186	measures	_	_	O
187	were	_	_	O
188	used	_	_	O
189	for	_	_	O
190	corroboration	_	_	O
191	of	_	_	O
192	the	_	_	O
193	most	_	_	O
194	important	_	_	O
195	outcomes	_	_	O
196	.	_	_	O

197	Primary	_	_	O
198	analyses	_	_	O
199	were	_	_	O
200	done	_	_	O
201	by	_	_	O
202	intention	_	_	O
203	to	_	_	O
204	treat	_	_	O
205	and	_	_	O
206	were	_	_	O
207	based	_	_	O
208	on	_	_	O
209	scale	_	_	O
210	scores	_	_	O
211	at	_	_	O
212	4	_	_	O
213	weeks	_	_	O
214	and	_	_	O
215	8	_	_	O
216	weeks	_	_	O
217	.	_	_	O

218	The	_	_	O
219	benefits	_	_	O
220	of	_	_	O
221	sertraline	_	_	O
222	compared	_	_	O
223	with	_	_	O
224	placebo	_	_	O
225	are	_	_	O
226	expressed	_	_	O
227	on	_	_	O
228	a	_	_	O
229	range	_	_	O
230	from	_	_	O
231	+	_	_	O
232	100	_	_	O
233	(	_	_	O
234	ie	_	_	O
235	,	_	_	O
236	maximum	_	_	O
237	benefit	_	_	O
238	)	_	_	O
239	to	_	_	O
240	-	_	_	O
241	100	_	_	O
242	(	_	_	O
243	ie	_	_	O
244	,	_	_	O
245	maximum	_	_	O
246	harm	_	_	O
247	)	_	_	O
248	;	_	_	O
249	a	_	_	O
250	difference	_	_	O
251	of	_	_	O
252	10	_	_	O
253	was	_	_	O
254	deemed	_	_	O
255	clinically	_	_	O
256	significant	_	_	O
257	.	_	_	O

258	This	_	_	O
259	clinical	_	_	O
260	trial	_	_	O
261	is	_	_	O
262	registered	_	_	O
263	at	_	_	O
264	Current	_	_	O
265	Controlled	_	_	O
266	Trials	_	_	O
267	website	_	_	O
268	http	_	_	O
269	:	_	_	O
270	/	_	_	O
271	/	_	_	O
272	www	_	_	O
273	.	_	_	O

274	controlled	_	_	O
275	-	_	_	O
276	trials	_	_	O
277	.	_	_	O

278	com	_	_	O
279	/	_	_	O
280	ISRCTN72466475	_	_	O
281	.	_	_	O

282	Sertraline	_	_	B-Premise
283	had	_	_	I-Premise
284	no	_	_	I-Premise
285	significant	_	_	I-Premise
286	effect	_	_	I-Premise
287	(	_	_	I-Premise
288	scale	_	_	I-Premise
289	,	_	_	I-Premise
290	benefit	_	_	I-Premise
291	over	_	_	I-Premise
292	placebo	_	_	I-Premise
293	[	_	_	I-Premise
294	95	_	_	I-Premise
295	%	_	_	I-Premise
296	CI	_	_	I-Premise
297	]	_	_	I-Premise
298	)	_	_	I-Premise
299	on	_	_	I-Premise
300	depression	_	_	I-Premise
301	(	_	_	I-Premise
302	CES	_	_	I-Premise
303	-	_	_	I-Premise
304	D	_	_	I-Premise
305	0	_	_	I-Premise
306	.	_	_	I-Premise

307	4	_	_	I-Premise
308	[	_	_	I-Premise
309	-	_	_	I-Premise
310	2	_	_	I-Premise
311	.	_	_	I-Premise

312	6	_	_	I-Premise
313	to	_	_	I-Premise
314	3	_	_	I-Premise
315	.	_	_	I-Premise

316	4	_	_	I-Premise
317	]	_	_	I-Premise
318	)	_	_	I-Premise
319	,	_	_	I-Premise
320	anxiety	_	_	I-Premise
321	(	_	_	I-Premise
322	HADS	_	_	I-Premise
323	-	_	_	I-Premise
324	A	_	_	I-Premise
325	2	_	_	I-Premise
326	.	_	_	I-Premise

327	0	_	_	I-Premise
328	[	_	_	I-Premise
329	-	_	_	I-Premise
330	1	_	_	I-Premise
331	.	_	_	I-Premise

332	5	_	_	I-Premise
333	to	_	_	I-Premise
334	5	_	_	I-Premise
335	.	_	_	I-Premise

336	5	_	_	I-Premise
337	]	_	_	I-Premise
338	)	_	_	I-Premise
339	,	_	_	I-Premise
340	fatigue	_	_	I-Premise
341	(	_	_	I-Premise
342	FACT	_	_	I-Premise
343	-	_	_	I-Premise
344	F	_	_	I-Premise
345	0	_	_	I-Premise
346	.	_	_	I-Premise

347	3	_	_	I-Premise
348	[	_	_	I-Premise
349	-	_	_	I-Premise
350	4	_	_	I-Premise
351	.	_	_	I-Premise

352	3	_	_	I-Premise
353	to	_	_	I-Premise
354	4	_	_	I-Premise
355	.	_	_	I-Premise

356	9	_	_	I-Premise
357	]	_	_	I-Premise
358	)	_	_	I-Premise
359	,	_	_	I-Premise
360	overall	_	_	I-Premise
361	quality	_	_	I-Premise
362	of	_	_	I-Premise
363	life	_	_	I-Premise
364	(	_	_	I-Premise
365	FACT	_	_	I-Premise
366	-	_	_	I-Premise
367	G	_	_	I-Premise
368	1	_	_	I-Premise
369	.	_	_	I-Premise

370	7	_	_	I-Premise
371	[	_	_	I-Premise
372	-	_	_	I-Premise
373	1	_	_	I-Premise
374	.	_	_	I-Premise

375	3	_	_	I-Premise
376	to	_	_	I-Premise
377	4	_	_	I-Premise
378	.	_	_	I-Premise

379	7	_	_	I-Premise
380	]	_	_	I-Premise
381	)	_	_	I-Premise
382	,	_	_	I-Premise
383	or	_	_	I-Premise
384	clinicians	_	_	I-Premise
385	'	_	_	I-Premise
386	ratings	_	_	I-Premise
387	(	_	_	I-Premise
388	SQLI	_	_	I-Premise
389	2	_	_	I-Premise
390	.	_	_	I-Premise

391	0	_	_	I-Premise
392	[	_	_	I-Premise
393	-	_	_	I-Premise
394	2	_	_	I-Premise
395	.	_	_	I-Premise

396	5	_	_	I-Premise
397	to	_	_	I-Premise
398	6	_	_	I-Premise
399	.	_	_	I-Premise

400	5	_	_	I-Premise
401	]	_	_	I-Premise
402	)	_	_	I-Premise
403	,	_	_	I-Premise
404	and	_	_	I-Premise
405	the	_	_	I-Premise
406	95	_	_	I-Premise
407	%	_	_	I-Premise
408	CI	_	_	I-Premise
409	ruled	_	_	I-Premise
410	out	_	_	I-Premise
411	a	_	_	I-Premise
412	clinically	_	_	I-Premise
413	significant	_	_	I-Premise
414	benefit	_	_	I-Premise
415	for	_	_	I-Premise
416	all	_	_	I-Premise
417	main	_	_	I-Premise
418	outcomes	_	_	I-Premise
419	.	_	_	I-Premise

420	Sertraline	_	_	B-Premise
421	was	_	_	I-Premise
422	discontinued	_	_	I-Premise
423	more	_	_	I-Premise
424	often	_	_	I-Premise
425	and	_	_	I-Premise
426	earlier	_	_	I-Premise
427	than	_	_	I-Premise
428	was	_	_	I-Premise
429	placebo	_	_	I-Premise
430	(	_	_	I-Premise
431	hazard	_	_	I-Premise
432	ratio	_	_	I-Premise
433	1	_	_	I-Premise
434	.	_	_	I-Premise

435	46	_	_	I-Premise
436	[	_	_	I-Premise
437	1	_	_	I-Premise
438	.	_	_	I-Premise

439	03	_	_	I-Premise
440	-	_	_	I-Premise
441	2	_	_	I-Premise
442	.	_	_	I-Premise

443	06	_	_	I-Premise
444	]	_	_	I-Premise
445	,	_	_	I-Premise
446	p	_	_	I-Premise
447	=	_	_	I-Premise
448	0	_	_	I-Premise
449	.	_	_	I-Premise

450	03	_	_	I-Premise
451	)	_	_	I-Premise
452	.	_	_	I-Premise

453	Recruitment	_	_	O
454	was	_	_	O
455	stopped	_	_	O
456	after	_	_	O
457	the	_	_	B-Premise
458	first	_	_	I-Premise
459	planned	_	_	I-Premise
460	interim	_	_	I-Premise
461	analysis	_	_	I-Premise
462	in	_	_	I-Premise
463	February	_	_	I-Premise
464	2006	_	_	I-Premise
465	(	_	_	I-Premise
466	n	_	_	I-Premise
467	=	_	_	I-Premise
468	150	_	_	I-Premise
469	)	_	_	I-Premise
470	showed	_	_	I-Premise
471	that	_	_	I-Premise
472	survival	_	_	I-Premise
473	was	_	_	I-Premise
474	longer	_	_	I-Premise
475	in	_	_	I-Premise
476	patients	_	_	I-Premise
477	assigned	_	_	I-Premise
478	placebo	_	_	I-Premise
479	than	_	_	I-Premise
480	in	_	_	I-Premise
481	patients	_	_	I-Premise
482	assigned	_	_	I-Premise
483	sertraline	_	_	I-Premise
484	(	_	_	I-Premise
485	unadjusted	_	_	I-Premise
486	hazard	_	_	I-Premise
487	ratio	_	_	I-Premise
488	1	_	_	I-Premise
489	.	_	_	I-Premise

490	60	_	_	I-Premise
491	[	_	_	I-Premise
492	95	_	_	I-Premise
493	%	_	_	I-Premise
494	CI	_	_	I-Premise
495	1	_	_	I-Premise
496	.	_	_	I-Premise

497	04	_	_	I-Premise
498	-	_	_	I-Premise
499	2	_	_	I-Premise
500	.	_	_	I-Premise

501	45	_	_	I-Premise
502	]	_	_	I-Premise
503	,	_	_	I-Premise
504	log	_	_	I-Premise
505	-	_	_	I-Premise
506	rank	_	_	I-Premise
507	p	_	_	I-Premise
508	=	_	_	I-Premise
509	0	_	_	I-Premise
510	.	_	_	I-Premise

511	04	_	_	I-Premise
512	;	_	_	I-Premise
513	adjusted	_	_	I-Premise
514	hazard	_	_	I-Premise
515	ratio	_	_	I-Premise
516	1	_	_	I-Premise
517	.	_	_	I-Premise

518	62	_	_	I-Premise
519	[	_	_	I-Premise
520	1	_	_	I-Premise
521	.	_	_	I-Premise

522	06	_	_	I-Premise
523	-	_	_	I-Premise
524	2	_	_	I-Premise
525	.	_	_	I-Premise

526	41	_	_	I-Premise
527	]	_	_	I-Premise
528	,	_	_	I-Premise
529	Cox	_	_	I-Premise
530	model	_	_	I-Premise
531	p	_	_	I-Premise
532	=	_	_	I-Premise
533	0	_	_	I-Premise
534	.	_	_	I-Premise

535	02	_	_	I-Premise
536	)	_	_	I-Premise
537	.	_	_	I-Premise

538	However	_	_	B-Premise
539	,	_	_	I-Premise
540	at	_	_	I-Premise
541	the	_	_	I-Premise
542	final	_	_	I-Premise
543	analysis	_	_	I-Premise
544	in	_	_	I-Premise
545	July	_	_	I-Premise
546	2006	_	_	I-Premise
547	of	_	_	I-Premise
548	all	_	_	I-Premise
549	patients	_	_	I-Premise
550	(	_	_	I-Premise
551	n	_	_	I-Premise
552	=	_	_	I-Premise
553	189	_	_	I-Premise
554	)	_	_	I-Premise
555	and	_	_	I-Premise
556	with	_	_	I-Premise
557	longer	_	_	I-Premise
558	follow	_	_	I-Premise
559	-	_	_	I-Premise
560	up	_	_	I-Premise
561	,	_	_	I-Premise
562	survival	_	_	I-Premise
563	did	_	_	I-Premise
564	not	_	_	I-Premise
565	differ	_	_	I-Premise
566	significantly	_	_	I-Premise
567	between	_	_	I-Premise
568	the	_	_	I-Premise
569	treatment	_	_	I-Premise
570	groups	_	_	I-Premise
571	(	_	_	I-Premise
572	unadjusted	_	_	I-Premise
573	hazard	_	_	I-Premise
574	ratio	_	_	I-Premise
575	1	_	_	I-Premise
576	.	_	_	I-Premise

577	35	_	_	I-Premise
578	[	_	_	I-Premise
579	0	_	_	I-Premise
580	.	_	_	I-Premise

581	95	_	_	I-Premise
582	-	_	_	I-Premise
583	1	_	_	I-Premise
584	.	_	_	I-Premise

585	91	_	_	I-Premise
586	]	_	_	I-Premise
587	,	_	_	I-Premise
588	log	_	_	I-Premise
589	-	_	_	I-Premise
590	rank	_	_	I-Premise
591	p	_	_	I-Premise
592	=	_	_	I-Premise
593	0	_	_	I-Premise
594	.	_	_	I-Premise

595	09	_	_	I-Premise
596	;	_	_	I-Premise
597	adjusted	_	_	I-Premise
598	hazard	_	_	I-Premise
599	ratio	_	_	I-Premise
600	1	_	_	I-Premise
601	.	_	_	I-Premise

602	27	_	_	I-Premise
603	[	_	_	I-Premise
604	0	_	_	I-Premise
605	.	_	_	I-Premise

606	87	_	_	I-Premise
607	-	_	_	I-Premise
608	1	_	_	I-Premise
609	.	_	_	I-Premise

610	84	_	_	I-Premise
611	]	_	_	I-Premise
612	,	_	_	I-Premise
613	Cox	_	_	I-Premise
614	model	_	_	I-Premise
615	p	_	_	I-Premise
616	=	_	_	I-Premise
617	0	_	_	I-Premise
618	.	_	_	I-Premise

619	20	_	_	I-Premise
620	)	_	_	I-Premise
621	.	_	_	I-Premise

622	The	_	_	O
623	trial	_	_	O
624	was	_	_	O
625	closed	_	_	O
626	because	_	_	O
627	it	_	_	O
628	had	_	_	O
629	ruled	_	_	O
630	out	_	_	O
631	a	_	_	O
632	significant	_	_	O
633	benefit	_	_	O
634	of	_	_	O
635	sertraline	_	_	O
636	.	_	_	O

637	Sertraline	_	_	B-Claim
638	did	_	_	I-Claim
639	not	_	_	I-Claim
640	improve	_	_	I-Claim
641	symptoms	_	_	I-Claim
642	,	_	_	I-Claim
643	wellbeing	_	_	I-Claim
644	,	_	_	I-Claim
645	or	_	_	I-Claim
646	survival	_	_	I-Claim
647	in	_	_	I-Claim
648	patients	_	_	I-Claim
649	with	_	_	I-Claim
650	advanced	_	_	I-Claim
651	cancer	_	_	I-Claim
652	who	_	_	I-Claim
653	do	_	_	I-Claim
654	not	_	_	I-Claim
655	have	_	_	I-Claim
656	major	_	_	I-Claim
657	depression	_	_	I-Claim
658	,	_	_	I-Claim
659	and	_	_	I-Claim
660	should	_	_	I-Claim
661	be	_	_	I-Claim
662	reserved	_	_	I-Claim
663	for	_	_	I-Claim
664	those	_	_	I-Claim
665	with	_	_	I-Claim
666	a	_	_	I-Claim
667	proven	_	_	I-Claim
668	indication	_	_	I-Claim
669	.	_	_	I-Claim


0	Patients	_	_	B-Claim
1	with	_	_	I-Claim
2	advanced	_	_	I-Claim
3	non	_	_	I-Claim
4	-	_	_	I-Claim
5	small	_	_	I-Claim
6	cell	_	_	I-Claim
7	lung	_	_	I-Claim
8	cancer	_	_	I-Claim
9	(	_	_	I-Claim
10	NSCLC	_	_	I-Claim
11	)	_	_	I-Claim
12	do	_	_	I-Claim
13	not	_	_	I-Claim
14	have	_	_	I-Claim
15	curative	_	_	I-Claim
16	treatment	_	_	I-Claim
17	options	_	_	I-Claim
18	;	_	_	I-Claim
19	therefore	_	_	O
20	,	_	_	O
21	treatments	_	_	O
22	should	_	_	O
23	prolong	_	_	O
24	survival	_	_	O
25	and	_	_	O
26	improve	_	_	O
27	quality	_	_	O
28	of	_	_	O
29	life	_	_	O
30	(	_	_	O
31	QoL	_	_	O
32	)	_	_	O
33	.	_	_	O

34	We	_	_	O
35	compared	_	_	O
36	the	_	_	O
37	effect	_	_	O
38	on	_	_	O
39	QoL	_	_	O
40	of	_	_	O
41	two	_	_	O
42	docetaxel	_	_	O
43	-	_	_	O
44	platinum	_	_	O
45	regimens	_	_	O
46	with	_	_	O
47	vinorelbine	_	_	O
48	-	_	_	O
49	cisplatin	_	_	O
50	.	_	_	O

51	QoL	_	_	O
52	was	_	_	O
53	assessed	_	_	O
54	by	_	_	O
55	the	_	_	O
56	Lung	_	_	O
57	Cancer	_	_	O
58	Symptom	_	_	O
59	Scale	_	_	O
60	(	_	_	O
61	LCSS	_	_	O
62	)	_	_	O
63	and	_	_	O
64	the	_	_	O
65	general	_	_	O
66	EuroQol	_	_	O
67	five	_	_	O
68	-	_	_	O
69	dimensional	_	_	O
70	questionnaire	_	_	O
71	(	_	_	O
72	EQ	_	_	O
73	-	_	_	O
74	5D	_	_	O
75	)	_	_	O
76	in	_	_	O
77	926	_	_	O
78	chemotherapy	_	_	O
79	-	_	_	O
80	naïve	_	_	O
81	patients	_	_	O
82	with	_	_	O
83	stages	_	_	O
84	IIIB	_	_	O
85	to	_	_	O
86	IV	_	_	O
87	NSCLC	_	_	O
88	.	_	_	O

89	Patients	_	_	O
90	were	_	_	O
91	randomly	_	_	O
92	assigned	_	_	O
93	to	_	_	O
94	receive	_	_	O
95	:	_	_	O
96	docetaxel	_	_	O
97	75	_	_	O
98	mg	_	_	O
99	/	_	_	O
100	m2	_	_	O
101	plus	_	_	O
102	cisplatin	_	_	O
103	75	_	_	O
104	mg	_	_	O
105	/	_	_	O
106	m2	_	_	O
107	,	_	_	O
108	every	_	_	O
109	3	_	_	O
110	weeks	_	_	O
111	(	_	_	O
112	DC	_	_	O
113	)	_	_	O
114	;	_	_	O
115	docetaxel	_	_	O
116	75	_	_	O
117	mg	_	_	O
118	/	_	_	O
119	m2	_	_	O
120	and	_	_	O
121	carboplatin	_	_	O
122	6	_	_	O
123	mg	_	_	O
124	/	_	_	O
125	ml	_	_	O
126	min	_	_	O
127	,	_	_	O
128	every	_	_	O
129	3	_	_	O
130	weeks	_	_	O
131	(	_	_	O
132	DCb	_	_	O
133	)	_	_	O
134	;	_	_	O
135	or	_	_	O
136	vinorelbine	_	_	O
137	25	_	_	O
138	mg	_	_	O
139	/	_	_	O
140	m2	_	_	O
141	/	_	_	O
142	week	_	_	O
143	plus	_	_	O
144	cisplatin	_	_	O
145	100	_	_	O
146	mg	_	_	O
147	/	_	_	O
148	m2	_	_	O
149	,	_	_	O
150	every	_	_	O
151	4	_	_	O
152	weeks	_	_	O
153	(	_	_	O
154	VC	_	_	O
155	)	_	_	O
156	.	_	_	O

157	Overall	_	_	B-Premise
158	,	_	_	I-Premise
159	patients	_	_	I-Premise
160	treated	_	_	I-Premise
161	with	_	_	I-Premise
162	either	_	_	I-Premise
163	docetaxel	_	_	I-Premise
164	-	_	_	I-Premise
165	containing	_	_	I-Premise
166	regimen	_	_	I-Premise
167	had	_	_	I-Premise
168	better	_	_	I-Premise
169	QoL	_	_	I-Premise
170	than	_	_	I-Premise
171	VC	_	_	I-Premise
172	-	_	_	I-Premise
173	treated	_	_	I-Premise
174	patients	_	_	I-Premise
175	(	_	_	I-Premise
176	LCSS	_	_	I-Premise
177	global	_	_	I-Premise
178	item	_	_	I-Premise
179	"	_	_	I-Premise
180	QoL	_	_	I-Premise
181	today	_	_	I-Premise
182	"	_	_	I-Premise
183	:	_	_	I-Premise
184	P	_	_	I-Premise
185	=	_	_	I-Premise
186	0	_	_	I-Premise
187	.	_	_	I-Premise

188	064	_	_	I-Premise
189	for	_	_	I-Premise
190	DC	_	_	I-Premise
191	and	_	_	I-Premise
192	P	_	_	I-Premise
193	=	_	_	I-Premise
194	0	_	_	I-Premise
195	.	_	_	I-Premise

196	016	_	_	I-Premise
197	for	_	_	I-Premise
198	DCb	_	_	I-Premise
199	versus	_	_	I-Premise
200	VC	_	_	I-Premise
201	;	_	_	I-Premise
202	EQ	_	_	I-Premise
203	-	_	_	I-Premise
204	5D	_	_	I-Premise
205	global	_	_	I-Premise
206	item	_	_	I-Premise
207	"	_	_	I-Premise
208	health	_	_	I-Premise
209	state	_	_	I-Premise
210	today	_	_	I-Premise
211	"	_	_	I-Premise
212	:	_	_	I-Premise
213	P	_	_	I-Premise
214	=	_	_	I-Premise
215	0	_	_	I-Premise
216	.	_	_	I-Premise

217	016	_	_	I-Premise
218	for	_	_	I-Premise
219	DC	_	_	I-Premise
220	and	_	_	I-Premise
221	P	_	_	I-Premise
222	<	_	_	I-Premise
223	0	_	_	I-Premise
224	.	_	_	I-Premise

225	001	_	_	I-Premise
226	for	_	_	I-Premise
227	DCb	_	_	I-Premise
228	versus	_	_	I-Premise
229	VC	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	DC	_	_	B-Premise
233	-	_	_	I-Premise
234	treated	_	_	I-Premise
235	patients	_	_	I-Premise
236	experienced	_	_	I-Premise
237	improved	_	_	I-Premise
238	pain	_	_	I-Premise
239	relief	_	_	I-Premise
240	compared	_	_	I-Premise
241	with	_	_	I-Premise
242	VC	_	_	I-Premise
243	(	_	_	I-Premise
244	P	_	_	I-Premise
245	=	_	_	I-Premise
246	0	_	_	I-Premise
247	.	_	_	I-Premise

248	033	_	_	I-Premise
249	)	_	_	I-Premise
250	,	_	_	I-Premise
251	whereas	_	_	O
252	pain	_	_	B-Premise
253	relief	_	_	I-Premise
254	with	_	_	I-Premise
255	DCb	_	_	I-Premise
256	and	_	_	I-Premise
257	VC	_	_	I-Premise
258	was	_	_	I-Premise
259	similar	_	_	I-Premise
260	.	_	_	I-Premise

261	Patients	_	_	B-Premise
262	treated	_	_	I-Premise
263	with	_	_	I-Premise
264	either	_	_	I-Premise
265	docetaxel	_	_	I-Premise
266	regimen	_	_	I-Premise
267	had	_	_	I-Premise
268	more	_	_	I-Premise
269	favorable	_	_	I-Premise
270	changes	_	_	I-Premise
271	in	_	_	I-Premise
272	performance	_	_	I-Premise
273	status	_	_	I-Premise
274	(	_	_	I-Premise
275	P	_	_	I-Premise
276	=	_	_	I-Premise
277	0	_	_	I-Premise
278	.	_	_	I-Premise

279	065	_	_	I-Premise
280	for	_	_	I-Premise
281	DC	_	_	I-Premise
282	and	_	_	I-Premise
283	P	_	_	I-Premise
284	<	_	_	I-Premise
285	0	_	_	I-Premise
286	.	_	_	I-Premise

287	001	_	_	I-Premise
288	for	_	_	I-Premise
289	DCb	_	_	I-Premise
290	versus	_	_	I-Premise
291	VC	_	_	I-Premise
292	)	_	_	I-Premise
293	and	_	_	I-Premise
294	mean	_	_	I-Premise
295	weight	_	_	I-Premise
296	loss	_	_	I-Premise
297	(	_	_	I-Premise
298	0	_	_	I-Premise
299	.	_	_	I-Premise

300	06	_	_	I-Premise
301	kg	_	_	I-Premise
302	,	_	_	I-Premise
303	gain	_	_	I-Premise
304	of	_	_	I-Premise
305	0	_	_	I-Premise
306	.	_	_	I-Premise

307	08	_	_	I-Premise
308	kg	_	_	I-Premise
309	,	_	_	I-Premise
310	and	_	_	I-Premise
311	2	_	_	I-Premise
312	.	_	_	I-Premise

313	27	_	_	I-Premise
314	kg	_	_	I-Premise
315	for	_	_	I-Premise
316	DC	_	_	I-Premise
317	,	_	_	I-Premise
318	DCb	_	_	I-Premise
319	,	_	_	I-Premise
320	and	_	_	I-Premise
321	VC	_	_	I-Premise
322	,	_	_	I-Premise
323	respectively	_	_	I-Premise
324	;	_	_	I-Premise
325	P	_	_	I-Premise
326	<	_	_	I-Premise
327	0	_	_	I-Premise
328	.	_	_	I-Premise

329	001	_	_	I-Premise
330	for	_	_	I-Premise
331	both	_	_	I-Premise
332	DC	_	_	I-Premise
333	versus	_	_	I-Premise
334	VC	_	_	I-Premise
335	and	_	_	I-Premise
336	DCb	_	_	I-Premise
337	versus	_	_	I-Premise
338	VC	_	_	I-Premise
339	)	_	_	I-Premise
340	.	_	_	I-Premise

341	The	_	_	B-Claim
342	TAX	_	_	I-Claim
343	326	_	_	I-Claim
344	study	_	_	I-Claim
345	shows	_	_	I-Claim
346	that	_	_	I-Claim
347	docetaxel	_	_	I-Claim
348	-	_	_	I-Claim
349	platinum	_	_	I-Claim
350	regimens	_	_	I-Claim
351	relieve	_	_	I-Claim
352	symptoms	_	_	I-Claim
353	and	_	_	I-Claim
354	improve	_	_	I-Claim
355	QoL	_	_	I-Claim
356	in	_	_	I-Claim
357	patients	_	_	I-Claim
358	with	_	_	I-Claim
359	advanced	_	_	I-Claim
360	NSCLC	_	_	I-Claim
361	.	_	_	I-Claim

362	DCb	_	_	B-Claim
363	and	_	_	I-Claim
364	DC	_	_	I-Claim
365	were	_	_	I-Claim
366	superior	_	_	I-Claim
367	to	_	_	I-Claim
368	VC	_	_	I-Claim
369	in	_	_	I-Claim
370	all	_	_	I-Claim
371	QoL	_	_	I-Claim
372	outcomes	_	_	I-Claim
373	assessed	_	_	I-Claim
374	except	_	_	I-Claim
375	for	_	_	I-Claim
376	the	_	_	I-Claim
377	difference	_	_	I-Claim
378	between	_	_	I-Claim
379	DC	_	_	I-Claim
380	and	_	_	I-Claim
381	VC	_	_	I-Claim
382	in	_	_	I-Claim
383	LCSS	_	_	I-Claim
384	"	_	_	I-Claim
385	QoL	_	_	I-Claim
386	today	_	_	I-Claim
387	"	_	_	I-Claim
388	,	_	_	I-Claim
389	which	_	_	I-Claim
390	was	_	_	I-Claim
391	not	_	_	I-Claim
392	significant	_	_	I-Claim
393	.	_	_	I-Claim


0	There	_	_	O
1	are	_	_	O
2	very	_	_	O
3	few	_	_	O
4	randomized	_	_	O
5	controlled	_	_	O
6	studies	_	_	O
7	on	_	_	O
8	exercise	_	_	O
9	in	_	_	O
10	cancer	_	_	O
11	patients	_	_	O
12	.	_	_	O

13	Consequently	_	_	O
14	,	_	_	O
15	there	_	_	O
16	are	_	_	O
17	no	_	_	O
18	guidelines	_	_	O
19	available	_	_	O
20	with	_	_	O
21	regard	_	_	O
22	to	_	_	O
23	the	_	_	O
24	exercises	_	_	O
25	that	_	_	O
26	can	_	_	O
27	be	_	_	O
28	recommended	_	_	O
29	and	_	_	O
30	difficulties	_	_	O
31	are	_	_	O
32	encountered	_	_	O
33	in	_	_	O
34	the	_	_	O
35	clinical	_	_	O
36	practice	_	_	O
37	as	_	_	O
38	to	_	_	O
39	which	_	_	O
40	exercise	_	_	O
41	is	_	_	O
42	more	_	_	O
43	suitable	_	_	O
44	to	_	_	O
45	the	_	_	O
46	patients	_	_	O
47	.	_	_	O

48	The	_	_	O
49	purpose	_	_	O
50	of	_	_	O
51	this	_	_	O
52	study	_	_	O
53	was	_	_	O
54	to	_	_	O
55	investigate	_	_	O
56	the	_	_	O
57	impact	_	_	O
58	of	_	_	O
59	pilates	_	_	O
60	exercises	_	_	O
61	on	_	_	O
62	physical	_	_	O
63	performance	_	_	O
64	,	_	_	O
65	flexibility	_	_	O
66	,	_	_	O
67	fatigue	_	_	O
68	,	_	_	O
69	depression	_	_	O
70	and	_	_	O
71	quality	_	_	O
72	of	_	_	O
73	life	_	_	O
74	in	_	_	O
75	women	_	_	O
76	who	_	_	O
77	had	_	_	O
78	been	_	_	O
79	treated	_	_	O
80	for	_	_	O
81	breast	_	_	O
82	cancer	_	_	O
83	.	_	_	O

84	Randomized	_	_	O
85	controlled	_	_	O
86	trial	_	_	O
87	.	_	_	O

88	Out	_	_	O
89	patient	_	_	O
90	group	_	_	O
91	,	_	_	O
92	Department	_	_	O
93	of	_	_	O
94	Physical	_	_	O
95	Medicine	_	_	O
96	and	_	_	O
97	Rehabilitation	_	_	O
98	and	_	_	O
99	Medical	_	_	O
100	Oncology	_	_	O
101	Department	_	_	O
102	,	_	_	O
103	University	_	_	O
104	Hospital	_	_	O
105	.	_	_	O

106	Fifty	_	_	O
107	-	_	_	O
108	two	_	_	O
109	patients	_	_	O
110	with	_	_	O
111	breast	_	_	O
112	cancer	_	_	O
113	were	_	_	O
114	divided	_	_	O
115	into	_	_	O
116	either	_	_	O
117	pilates	_	_	O
118	exercise	_	_	O
119	(	_	_	O
120	group	_	_	O
121	1	_	_	O
122	)	_	_	O
123	and	_	_	O
124	control	_	_	O
125	group	_	_	O
126	(	_	_	O
127	group	_	_	O
128	2	_	_	O
129	)	_	_	O
130	.	_	_	O

131	Patients	_	_	O
132	in	_	_	O
133	Group	_	_	O
134	1	_	_	O
135	performed	_	_	O
136	pilates	_	_	O
137	and	_	_	O
138	home	_	_	O
139	exercises	_	_	O
140	and	_	_	O
141	patients	_	_	O
142	in	_	_	O
143	group	_	_	O
144	2	_	_	O
145	performed	_	_	O
146	only	_	_	O
147	home	_	_	O
148	exercises	_	_	O
149	.	_	_	O

150	Pilates	_	_	O
151	exercise	_	_	O
152	sessions	_	_	O
153	were	_	_	O
154	performed	_	_	O
155	three	_	_	O
156	times	_	_	O
157	a	_	_	O
158	week	_	_	O
159	for	_	_	O
160	a	_	_	O
161	period	_	_	O
162	of	_	_	O
163	eight	_	_	O
164	weeks	_	_	O
165	in	_	_	O
166	the	_	_	O
167	rehabilitation	_	_	O
168	unit	_	_	O
169	.	_	_	O

170	Subjects	_	_	O
171	were	_	_	O
172	assessed	_	_	O
173	before	_	_	O
174	and	_	_	O
175	after	_	_	O
176	rehabilitation	_	_	O
177	program	_	_	O
178	,	_	_	O
179	with	_	_	O
180	respect	_	_	O
181	to	_	_	O
182	,	_	_	O
183	6	_	_	O
184	-	_	_	O
185	min	_	_	O
186	walk	_	_	O
187	test	_	_	O
188	(	_	_	O
189	6MWT	_	_	O
190	)	_	_	O
191	,	_	_	O
192	modified	_	_	O
193	sit	_	_	O
194	and	_	_	O
195	reach	_	_	O
196	test	_	_	O
197	,	_	_	O
198	Brief	_	_	O
199	Fatigue	_	_	O
200	Inventory	_	_	O
201	(	_	_	O
202	BFI	_	_	O
203	)	_	_	O
204	,	_	_	O
205	Beck	_	_	O
206	Depression	_	_	O
207	Index	_	_	O
208	(	_	_	O
209	BDI	_	_	O
210	)	_	_	O
211	and	_	_	O
212	the	_	_	O
213	European	_	_	O
214	Organisation	_	_	O
215	for	_	_	O
216	Research	_	_	O
217	and	_	_	O
218	Treatment	_	_	O
219	of	_	_	O
220	Cancer	_	_	O
221	Quality	_	_	O
222	of	_	_	O
223	Life	_	_	O
224	C30	_	_	O
225	(	_	_	O
226	EORTC	_	_	O
227	QLQ	_	_	O
228	-	_	_	O
229	C30	_	_	O
230	)	_	_	O
231	and	_	_	O
232	EORTC	_	_	O
233	QLQ	_	_	O
234	BR23	_	_	O
235	.	_	_	O

236	After	_	_	B-Premise
237	the	_	_	I-Premise
238	exercise	_	_	I-Premise
239	program	_	_	I-Premise
240	,	_	_	I-Premise
241	improvements	_	_	I-Premise
242	were	_	_	I-Premise
243	observed	_	_	I-Premise
244	in	_	_	I-Premise
245	Group	_	_	I-Premise
246	1	_	_	I-Premise
247	in	_	_	I-Premise
248	6	_	_	I-Premise
249	-	_	_	I-Premise
250	minute	_	_	I-Premise
251	walk	_	_	I-Premise
252	test	_	_	I-Premise
253	,	_	_	I-Premise
254	BDI	_	_	I-Premise
255	,	_	_	I-Premise
256	EORTC	_	_	I-Premise
257	QLQ	_	_	I-Premise
258	-	_	_	I-Premise
259	C30	_	_	I-Premise
260	functional	_	_	I-Premise
261	,	_	_	I-Premise
262	and	_	_	I-Premise
263	EORTC	_	_	I-Premise
264	QLQ	_	_	I-Premise
265	-	_	_	I-Premise
266	C30	_	_	I-Premise
267	BR23	_	_	I-Premise
268	functional	_	_	I-Premise
269	scores	_	_	I-Premise
270	(	_	_	I-Premise
271	P	_	_	I-Premise
272	<	_	_	I-Premise
273	0	_	_	I-Premise
274	.	_	_	I-Premise

275	05	_	_	I-Premise
276	)	_	_	I-Premise
277	.	_	_	I-Premise

278	In	_	_	O
279	contrast	_	_	O
280	,	_	_	O
281	no	_	_	B-Premise
282	significant	_	_	I-Premise
283	improvement	_	_	I-Premise
284	was	_	_	I-Premise
285	observed	_	_	I-Premise
286	in	_	_	I-Premise
287	Group	_	_	I-Premise
288	2	_	_	I-Premise
289	after	_	_	I-Premise
290	the	_	_	I-Premise
291	exercise	_	_	I-Premise
292	program	_	_	I-Premise
293	in	_	_	I-Premise
294	any	_	_	I-Premise
295	of	_	_	I-Premise
296	parameters	_	_	I-Premise
297	in	_	_	I-Premise
298	comparison	_	_	I-Premise
299	to	_	_	I-Premise
300	the	_	_	I-Premise
301	pre	_	_	I-Premise
302	-	_	_	I-Premise
303	exercise	_	_	I-Premise
304	period	_	_	I-Premise
305	(	_	_	I-Premise
306	P	_	_	I-Premise
307	>	_	_	I-Premise
308	0	_	_	I-Premise
309	.	_	_	I-Premise

310	05	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	When	_	_	B-Premise
314	the	_	_	I-Premise
315	two	_	_	I-Premise
316	exercise	_	_	I-Premise
317	groups	_	_	I-Premise
318	were	_	_	I-Premise
319	compared	_	_	I-Premise
320	,	_	_	I-Premise
321	there	_	_	I-Premise
322	were	_	_	I-Premise
323	significant	_	_	I-Premise
324	differences	_	_	I-Premise
325	in	_	_	I-Premise
326	6MWT	_	_	I-Premise
327	in	_	_	I-Premise
328	pilates	_	_	I-Premise
329	-	_	_	I-Premise
330	exercise	_	_	I-Premise
331	group	_	_	I-Premise
332	(	_	_	I-Premise
333	P	_	_	I-Premise
334	<	_	_	I-Premise
335	0	_	_	I-Premise
336	.	_	_	I-Premise

337	05	_	_	I-Premise
338	)	_	_	I-Premise
339	.	_	_	I-Premise

340	Pilates	_	_	B-Claim
341	exercises	_	_	I-Claim
342	are	_	_	I-Claim
343	effective	_	_	I-Claim
344	and	_	_	I-Claim
345	safe	_	_	I-Claim
346	in	_	_	I-Claim
347	female	_	_	I-Claim
348	breast	_	_	I-Claim
349	cancer	_	_	I-Claim
350	patients	_	_	I-Claim
351	.	_	_	I-Claim

352	There	_	_	B-Claim
353	is	_	_	I-Claim
354	a	_	_	I-Claim
355	need	_	_	I-Claim
356	for	_	_	I-Claim
357	further	_	_	I-Claim
358	studies	_	_	I-Claim
359	so	_	_	I-Claim
360	that	_	_	I-Claim
361	its	_	_	I-Claim
362	effect	_	_	I-Claim
363	can	_	_	I-Claim
364	be	_	_	I-Claim
365	confirmed	_	_	I-Claim
366	.	_	_	I-Claim

367	This	_	_	O
368	study	_	_	O
369	addressed	_	_	O
370	the	_	_	O
371	effects	_	_	O
372	of	_	_	O
373	pilates	_	_	O
374	exercise	_	_	O
375	,	_	_	O
376	as	_	_	O
377	a	_	_	O
378	new	_	_	O
379	approach	_	_	O
380	,	_	_	O
381	on	_	_	O
382	functional	_	_	O
383	capacity	_	_	O
384	,	_	_	O
385	fatigue	_	_	O
386	,	_	_	O
387	depression	_	_	O
388	and	_	_	O
389	quality	_	_	O
390	of	_	_	O
391	life	_	_	O
392	in	_	_	O
393	breast	_	_	O
394	cancer	_	_	O
395	patients	_	_	O
396	in	_	_	O
397	whom	_	_	O
398	there	_	_	O
399	are	_	_	O
400	doubts	_	_	O
401	regarding	_	_	O
402	the	_	_	O
403	efficacy	_	_	O
404	and	_	_	O
405	usefulness	_	_	O
406	of	_	_	O
407	the	_	_	O
408	exercise	_	_	O
409	.	_	_	O


0	The	_	_	O
1	impact	_	_	O
2	of	_	_	O
3	psychotherapeutic	_	_	O
4	support	_	_	O
5	on	_	_	O
6	survival	_	_	O
7	for	_	_	O
8	patients	_	_	O
9	with	_	_	O
10	gastrointestinal	_	_	O
11	cancer	_	_	O
12	undergoing	_	_	O
13	surgery	_	_	O
14	was	_	_	O
15	studied	_	_	O
16	.	_	_	O

17	A	_	_	O
18	randomized	_	_	O
19	controlled	_	_	O
20	trial	_	_	O
21	was	_	_	O
22	conducted	_	_	O
23	in	_	_	O
24	cooperation	_	_	O
25	with	_	_	O
26	the	_	_	O
27	Departments	_	_	O
28	of	_	_	O
29	General	_	_	O
30	Surgery	_	_	O
31	and	_	_	O
32	Medical	_	_	O
33	Psychology	_	_	O
34	,	_	_	O
35	University	_	_	O
36	Hospital	_	_	O
37	of	_	_	O
38	Hamburg	_	_	O
39	,	_	_	O
40	Germany	_	_	O
41	,	_	_	O
42	from	_	_	O
43	January	_	_	O
44	1991	_	_	O
45	to	_	_	O
46	January	_	_	O
47	1993	_	_	O
48	.	_	_	O

49	Consenting	_	_	O
50	patients	_	_	O
51	(	_	_	O
52	N	_	_	O
53	=	_	_	O
54	271	_	_	O
55	)	_	_	O
56	with	_	_	O
57	a	_	_	O
58	preliminary	_	_	O
59	diagnosis	_	_	O
60	of	_	_	O
61	cancer	_	_	O
62	of	_	_	O
63	the	_	_	O
64	esophagus	_	_	O
65	,	_	_	O
66	stomach	_	_	O
67	,	_	_	O
68	liver	_	_	O
69	/	_	_	O
70	gallbladder	_	_	O
71	,	_	_	O
72	pancreas	_	_	O
73	,	_	_	O
74	or	_	_	O
75	colon	_	_	O
76	/	_	_	O
77	rectum	_	_	O
78	were	_	_	O
79	stratified	_	_	O
80	by	_	_	O
81	sex	_	_	O
82	and	_	_	O
83	randomly	_	_	O
84	assigned	_	_	O
85	to	_	_	O
86	a	_	_	O
87	control	_	_	O
88	group	_	_	O
89	that	_	_	O
90	received	_	_	O
91	standard	_	_	O
92	care	_	_	O
93	as	_	_	O
94	provided	_	_	O
95	on	_	_	O
96	the	_	_	O
97	surgical	_	_	O
98	wards	_	_	O
99	,	_	_	O
100	or	_	_	O
101	to	_	_	O
102	an	_	_	O
103	experimental	_	_	O
104	group	_	_	O
105	that	_	_	O
106	received	_	_	O
107	formal	_	_	O
108	psychotherapeutic	_	_	O
109	support	_	_	O
110	in	_	_	O
111	addition	_	_	O
112	to	_	_	O
113	routine	_	_	O
114	care	_	_	O
115	during	_	_	O
116	the	_	_	O
117	hospital	_	_	O
118	stay	_	_	O
119	.	_	_	O

120	From	_	_	O
121	June	_	_	O
122	2003	_	_	O
123	to	_	_	O
124	December	_	_	O
125	2003	_	_	O
126	,	_	_	O
127	the	_	_	O
128	10	_	_	O
129	-	_	_	O
130	year	_	_	O
131	follow	_	_	O
132	-	_	_	O
133	up	_	_	O
134	was	_	_	O
135	conducted	_	_	O
136	.	_	_	O

137	Survival	_	_	O
138	status	_	_	O
139	for	_	_	O
140	all	_	_	O
141	patients	_	_	O
142	was	_	_	O
143	determined	_	_	O
144	from	_	_	O
145	our	_	_	O
146	own	_	_	O
147	records	_	_	O
148	and	_	_	O
149	from	_	_	O
150	three	_	_	O
151	external	_	_	O
152	sources	_	_	O
153	:	_	_	O
154	the	_	_	O
155	Hamburg	_	_	O
156	cancer	_	_	O
157	registry	_	_	O
158	,	_	_	O
159	family	_	_	O
160	doctors	_	_	O
161	,	_	_	O
162	and	_	_	O
163	the	_	_	O
164	general	_	_	O
165	citizen	_	_	O
166	registration	_	_	O
167	offices	_	_	O
168	.	_	_	O

169	Kaplan	_	_	B-Premise
170	-	_	_	I-Premise
171	Meier	_	_	I-Premise
172	survival	_	_	I-Premise
173	curves	_	_	I-Premise
174	demonstrated	_	_	I-Premise
175	better	_	_	I-Premise
176	survival	_	_	I-Premise
177	for	_	_	I-Premise
178	the	_	_	I-Premise
179	experimental	_	_	I-Premise
180	group	_	_	I-Premise
181	than	_	_	I-Premise
182	the	_	_	I-Premise
183	control	_	_	I-Premise
184	group	_	_	I-Premise
185	.	_	_	I-Premise

186	The	_	_	B-Premise
187	unadjusted	_	_	I-Premise
188	significance	_	_	I-Premise
189	level	_	_	I-Premise
190	for	_	_	I-Premise
191	group	_	_	I-Premise
192	differences	_	_	I-Premise
193	was	_	_	I-Premise
194	P	_	_	I-Premise
195	=	_	_	I-Premise
196	.	_	_	I-Premise

197	0006	_	_	I-Premise
198	for	_	_	I-Premise
199	survival	_	_	I-Premise
200	to	_	_	I-Premise
201	10	_	_	I-Premise
202	years	_	_	I-Premise
203	.	_	_	I-Premise

204	Cox	_	_	B-Premise
205	regression	_	_	I-Premise
206	models	_	_	I-Premise
207	that	_	_	I-Premise
208	took	_	_	I-Premise
209	TNM	_	_	I-Premise
210	staging	_	_	I-Premise
211	or	_	_	I-Premise
212	the	_	_	I-Premise
213	residual	_	_	I-Premise
214	tumor	_	_	I-Premise
215	classification	_	_	I-Premise
216	and	_	_	I-Premise
217	tumor	_	_	I-Premise
218	site	_	_	I-Premise
219	into	_	_	I-Premise
220	account	_	_	I-Premise
221	also	_	_	I-Premise
222	found	_	_	I-Premise
223	significant	_	_	I-Premise
224	differences	_	_	I-Premise
225	at	_	_	I-Premise
226	10	_	_	I-Premise
227	years	_	_	I-Premise
228	.	_	_	I-Premise

229	Secondary	_	_	B-Premise
230	analyses	_	_	I-Premise
231	found	_	_	I-Premise
232	that	_	_	I-Premise
233	differences	_	_	I-Premise
234	in	_	_	I-Premise
235	favor	_	_	I-Premise
236	of	_	_	I-Premise
237	the	_	_	I-Premise
238	experimental	_	_	I-Premise
239	group	_	_	I-Premise
240	occurred	_	_	I-Premise
241	in	_	_	I-Premise
242	patients	_	_	I-Premise
243	with	_	_	I-Premise
244	stomach	_	_	I-Premise
245	,	_	_	I-Premise
246	pancreatic	_	_	I-Premise
247	,	_	_	I-Premise
248	primary	_	_	I-Premise
249	liver	_	_	I-Premise
250	,	_	_	I-Premise
251	or	_	_	I-Premise
252	colorectal	_	_	I-Premise
253	cancer	_	_	I-Premise
254	.	_	_	I-Premise

255	The	_	_	B-Claim
256	results	_	_	I-Claim
257	of	_	_	I-Claim
258	this	_	_	I-Claim
259	study	_	_	I-Claim
260	indicate	_	_	I-Claim
261	that	_	_	I-Claim
262	patients	_	_	I-Claim
263	with	_	_	I-Claim
264	gastrointestinal	_	_	I-Claim
265	cancer	_	_	I-Claim
266	,	_	_	I-Claim
267	who	_	_	I-Claim
268	undergo	_	_	I-Claim
269	surgery	_	_	I-Claim
270	for	_	_	I-Claim
271	stomach	_	_	I-Claim
272	,	_	_	I-Claim
273	pancreatic	_	_	I-Claim
274	,	_	_	I-Claim
275	primary	_	_	I-Claim
276	liver	_	_	I-Claim
277	,	_	_	I-Claim
278	or	_	_	I-Claim
279	colorectal	_	_	I-Claim
280	cancer	_	_	I-Claim
281	,	_	_	I-Claim
282	benefit	_	_	I-Claim
283	from	_	_	I-Claim
284	a	_	_	I-Claim
285	formal	_	_	I-Claim
286	program	_	_	I-Claim
287	of	_	_	I-Claim
288	psychotherapeutic	_	_	I-Claim
289	support	_	_	I-Claim
290	during	_	_	I-Claim
291	the	_	_	I-Claim
292	inpatient	_	_	I-Claim
293	hospital	_	_	I-Claim
294	stay	_	_	I-Claim
295	in	_	_	I-Claim
296	terms	_	_	I-Claim
297	of	_	_	I-Claim
298	long	_	_	I-Claim
299	-	_	_	I-Claim
300	term	_	_	I-Claim
301	survival	_	_	I-Claim
302	.	_	_	I-Claim


0	Few	_	_	O
1	exercise	_	_	O
2	trials	_	_	O
3	in	_	_	O
4	cancer	_	_	O
5	patients	_	_	O
6	have	_	_	O
7	reported	_	_	O
8	longer	_	_	O
9	-	_	_	O
10	term	_	_	O
11	follow	_	_	O
12	-	_	_	O
13	up	_	_	O
14	.	_	_	O

15	Here	_	_	O
16	,	_	_	O
17	we	_	_	O
18	report	_	_	O
19	a	_	_	O
20	6	_	_	O
21	-	_	_	O
22	month	_	_	O
23	follow	_	_	O
24	-	_	_	O
25	up	_	_	O
26	of	_	_	O
27	exercise	_	_	O
28	behavior	_	_	O
29	and	_	_	O
30	patient	_	_	O
31	-	_	_	O
32	rated	_	_	O
33	outcomes	_	_	O
34	from	_	_	O
35	an	_	_	O
36	exercise	_	_	O
37	trial	_	_	O
38	in	_	_	O
39	breast	_	_	O
40	cancer	_	_	O
41	patients	_	_	O
42	.	_	_	O

43	Breast	_	_	O
44	cancer	_	_	O
45	patients	_	_	O
46	initiating	_	_	O
47	adjuvant	_	_	O
48	chemotherapy	_	_	O
49	(	_	_	O
50	n	_	_	O
51	=	_	_	O
52	242	_	_	O
53	)	_	_	O
54	were	_	_	O
55	randomly	_	_	O
56	assigned	_	_	O
57	to	_	_	O
58	usual	_	_	O
59	care	_	_	O
60	(	_	_	O
61	n	_	_	O
62	=	_	_	O
63	82	_	_	O
64	)	_	_	O
65	,	_	_	O
66	resistance	_	_	O
67	exercise	_	_	O
68	training	_	_	O
69	(	_	_	O
70	RET	_	_	O
71	;	_	_	O
72	n	_	_	O
73	=	_	_	O
74	82	_	_	O
75	)	_	_	O
76	,	_	_	O
77	or	_	_	O
78	aerobic	_	_	O
79	exercise	_	_	O
80	training	_	_	O
81	(	_	_	O
82	AET	_	_	O
83	;	_	_	O
84	n	_	_	O
85	=	_	_	O
86	78	_	_	O
87	)	_	_	O
88	for	_	_	O
89	the	_	_	O
90	duration	_	_	O
91	of	_	_	O
92	their	_	_	O
93	chemotherapy	_	_	O
94	.	_	_	O

95	At	_	_	O
96	6	_	_	O
97	-	_	_	O
98	month	_	_	O
99	follow	_	_	O
100	-	_	_	O
101	up	_	_	O
102	,	_	_	O
103	participants	_	_	O
104	were	_	_	O
105	mailed	_	_	O
106	a	_	_	O
107	questionnaire	_	_	O
108	that	_	_	O
109	assessed	_	_	O
110	quality	_	_	O
111	of	_	_	O
112	life	_	_	O
113	,	_	_	O
114	self	_	_	O
115	-	_	_	O
116	esteem	_	_	O
117	,	_	_	O
118	fatigue	_	_	O
119	,	_	_	O
120	anxiety	_	_	O
121	,	_	_	O
122	depression	_	_	O
123	,	_	_	O
124	and	_	_	O
125	exercise	_	_	O
126	behavior	_	_	O
127	.	_	_	O

128	Two	_	_	O
129	hundred	_	_	O
130	one	_	_	O
131	(	_	_	O
132	83	_	_	O
133	.	_	_	O

134	1	_	_	O
135	%	_	_	O
136	)	_	_	O
137	participants	_	_	O
138	provided	_	_	O
139	6	_	_	O
140	-	_	_	O
141	month	_	_	O
142	follow	_	_	O
143	-	_	_	O
144	up	_	_	O
145	data	_	_	O
146	.	_	_	O

147	Adjusted	_	_	B-Premise
148	linear	_	_	I-Premise
149	mixed	_	_	I-Premise
150	-	_	_	I-Premise
151	model	_	_	I-Premise
152	analyses	_	_	I-Premise
153	showed	_	_	I-Premise
154	that	_	_	I-Premise
155	,	_	_	I-Premise
156	at	_	_	I-Premise
157	6	_	_	I-Premise
158	-	_	_	I-Premise
159	month	_	_	I-Premise
160	follow	_	_	I-Premise
161	-	_	_	I-Premise
162	up	_	_	I-Premise
163	,	_	_	I-Premise
164	the	_	_	I-Premise
165	RET	_	_	I-Premise
166	group	_	_	I-Premise
167	reported	_	_	I-Premise
168	higher	_	_	I-Premise
169	self	_	_	I-Premise
170	-	_	_	I-Premise
171	esteem	_	_	I-Premise
172	[	_	_	I-Premise
173	adjusted	_	_	I-Premise
174	mean	_	_	I-Premise
175	difference	_	_	I-Premise
176	,	_	_	I-Premise
177	1	_	_	I-Premise
178	.	_	_	I-Premise

179	6	_	_	I-Premise
180	;	_	_	I-Premise
181	95	_	_	I-Premise
182	%	_	_	I-Premise
183	confidence	_	_	I-Premise
184	interval	_	_	I-Premise
185	(	_	_	I-Premise
186	95	_	_	I-Premise
187	%	_	_	I-Premise
188	CI	_	_	I-Premise
189	)	_	_	I-Premise
190	,	_	_	I-Premise
191	0	_	_	I-Premise
192	.	_	_	I-Premise

193	1	_	_	I-Premise
194	-	_	_	I-Premise
195	3	_	_	I-Premise
196	.	_	_	I-Premise

197	2	_	_	I-Premise
198	;	_	_	I-Premise
199	P	_	_	I-Premise
200	=	_	_	I-Premise
201	0	_	_	I-Premise
202	.	_	_	I-Premise

203	032	_	_	I-Premise
204	]	_	_	I-Premise
205	and	_	_	I-Premise
206	the	_	_	I-Premise
207	AET	_	_	I-Premise
208	group	_	_	I-Premise
209	reported	_	_	I-Premise
210	lower	_	_	I-Premise
211	anxiety	_	_	I-Premise
212	(	_	_	I-Premise
213	adjusted	_	_	I-Premise
214	mean	_	_	I-Premise
215	difference	_	_	I-Premise
216	,	_	_	I-Premise
217	-	_	_	I-Premise
218	4	_	_	I-Premise
219	.	_	_	I-Premise

220	7	_	_	I-Premise
221	;	_	_	I-Premise
222	95	_	_	I-Premise
223	%	_	_	I-Premise
224	CI	_	_	I-Premise
225	,	_	_	I-Premise
226	-	_	_	I-Premise
227	0	_	_	I-Premise
228	.	_	_	I-Premise

229	0	_	_	I-Premise
230	to	_	_	I-Premise
231	-	_	_	I-Premise
232	9	_	_	I-Premise
233	.	_	_	I-Premise

234	3	_	_	I-Premise
235	;	_	_	I-Premise
236	P	_	_	I-Premise
237	=	_	_	I-Premise
238	0	_	_	I-Premise
239	.	_	_	I-Premise

240	049	_	_	I-Premise
241	)	_	_	I-Premise
242	compared	_	_	I-Premise
243	with	_	_	I-Premise
244	the	_	_	I-Premise
245	usual	_	_	I-Premise
246	care	_	_	I-Premise
247	group	_	_	I-Premise
248	.	_	_	I-Premise

249	Moreover	_	_	O
250	,	_	_	O
251	compared	_	_	B-Premise
252	with	_	_	I-Premise
253	participants	_	_	I-Premise
254	reporting	_	_	I-Premise
255	no	_	_	I-Premise
256	regular	_	_	I-Premise
257	exercise	_	_	I-Premise
258	during	_	_	I-Premise
259	the	_	_	I-Premise
260	follow	_	_	I-Premise
261	-	_	_	I-Premise
262	up	_	_	I-Premise
263	period	_	_	I-Premise
264	,	_	_	I-Premise
265	those	_	_	I-Premise
266	reporting	_	_	I-Premise
267	regular	_	_	I-Premise
268	aerobic	_	_	I-Premise
269	and	_	_	I-Premise
270	resistance	_	_	I-Premise
271	exercise	_	_	I-Premise
272	also	_	_	I-Premise
273	reported	_	_	I-Premise
274	better	_	_	I-Premise
275	patient	_	_	I-Premise
276	-	_	_	I-Premise
277	rated	_	_	I-Premise
278	outcomes	_	_	I-Premise
279	,	_	_	I-Premise
280	including	_	_	I-Premise
281	quality	_	_	I-Premise
282	of	_	_	I-Premise
283	life	_	_	I-Premise
284	(	_	_	I-Premise
285	adjusted	_	_	I-Premise
286	mean	_	_	I-Premise
287	difference	_	_	I-Premise
288	,	_	_	I-Premise
289	9	_	_	I-Premise
290	.	_	_	I-Premise

291	5	_	_	I-Premise
292	;	_	_	I-Premise
293	95	_	_	I-Premise
294	%	_	_	I-Premise
295	CI	_	_	I-Premise
296	,	_	_	I-Premise
297	1	_	_	I-Premise
298	.	_	_	I-Premise

299	2	_	_	I-Premise
300	-	_	_	I-Premise
301	17	_	_	I-Premise
302	.	_	_	I-Premise

303	8	_	_	I-Premise
304	;	_	_	I-Premise
305	P	_	_	I-Premise
306	=	_	_	I-Premise
307	0	_	_	I-Premise
308	.	_	_	I-Premise

309	025	_	_	I-Premise
310	)	_	_	I-Premise
311	.	_	_	I-Premise

312	Improvements	_	_	B-Premise
313	in	_	_	I-Premise
314	self	_	_	I-Premise
315	-	_	_	I-Premise
316	esteem	_	_	I-Premise
317	observed	_	_	I-Premise
318	with	_	_	I-Premise
319	RET	_	_	I-Premise
320	during	_	_	I-Premise
321	breast	_	_	I-Premise
322	cancer	_	_	I-Premise
323	chemotherapy	_	_	I-Premise
324	were	_	_	I-Premise
325	maintained	_	_	I-Premise
326	at	_	_	I-Premise
327	6	_	_	I-Premise
328	-	_	_	I-Premise
329	month	_	_	I-Premise
330	follow	_	_	I-Premise
331	-	_	_	I-Premise
332	up	_	_	I-Premise
333	whereas	_	_	O
334	reductions	_	_	B-Premise
335	in	_	_	I-Premise
336	anxiety	_	_	I-Premise
337	not	_	_	I-Premise
338	observed	_	_	I-Premise
339	with	_	_	I-Premise
340	AET	_	_	I-Premise
341	during	_	_	I-Premise
342	breast	_	_	I-Premise
343	cancer	_	_	I-Premise
344	chemotherapy	_	_	I-Premise
345	emerged	_	_	I-Premise
346	at	_	_	I-Premise
347	6	_	_	I-Premise
348	-	_	_	I-Premise
349	month	_	_	I-Premise
350	follow	_	_	I-Premise
351	-	_	_	I-Premise
352	up	_	_	I-Premise
353	.	_	_	I-Premise

354	Moreover	_	_	O
355	,	_	_	O
356	adopting	_	_	B-Premise
357	a	_	_	I-Premise
358	combined	_	_	I-Premise
359	aerobic	_	_	I-Premise
360	and	_	_	I-Premise
361	resistance	_	_	I-Premise
362	exercise	_	_	I-Premise
363	program	_	_	I-Premise
364	after	_	_	I-Premise
365	breast	_	_	I-Premise
366	cancer	_	_	I-Premise
367	chemotherapy	_	_	I-Premise
368	was	_	_	I-Premise
369	associated	_	_	I-Premise
370	with	_	_	I-Premise
371	further	_	_	I-Premise
372	improvements	_	_	I-Premise
373	in	_	_	I-Premise
374	patient	_	_	I-Premise
375	-	_	_	I-Premise
376	rated	_	_	I-Premise
377	outcomes	_	_	I-Premise
378	.	_	_	I-Premise

379	Exercise	_	_	B-Claim
380	training	_	_	I-Claim
381	during	_	_	I-Claim
382	breast	_	_	I-Claim
383	cancer	_	_	I-Claim
384	chemotherapy	_	_	I-Claim
385	may	_	_	I-Claim
386	result	_	_	I-Claim
387	in	_	_	I-Claim
388	some	_	_	I-Claim
389	longer	_	_	I-Claim
390	-	_	_	I-Claim
391	term	_	_	I-Claim
392	and	_	_	I-Claim
393	late	_	_	I-Claim
394	effects	_	_	I-Claim
395	for	_	_	I-Claim
396	selected	_	_	I-Claim
397	patient	_	_	I-Claim
398	-	_	_	I-Claim
399	rated	_	_	I-Claim
400	outcomes	_	_	I-Claim
401	.	_	_	I-Claim


0	To	_	_	O
1	observe	_	_	O
2	the	_	_	O
3	clinical	_	_	O
4	efficacy	_	_	O
5	of	_	_	O
6	Shenqi	_	_	O
7	Fuzheng	_	_	O
8	Injection	_	_	O
9	(	_	_	O
10	SFI	_	_	O
11	)	_	_	O
12	combined	_	_	O
13	with	_	_	O
14	chemotherapy	_	_	O
15	in	_	_	O
16	treating	_	_	O
17	patients	_	_	O
18	with	_	_	O
19	advanced	_	_	O
20	breast	_	_	O
21	cancer	_	_	O
22	.	_	_	O

23	Sixty	_	_	O
24	patients	_	_	O
25	were	_	_	O
26	randomly	_	_	O
27	assigned	_	_	O
28	to	_	_	O
29	two	_	_	O
30	groups	_	_	O
31	by	_	_	O
32	digital	_	_	O
33	table	_	_	O
34	,	_	_	O
35	the	_	_	O
36	control	_	_	O
37	group	_	_	O
38	and	_	_	O
39	the	_	_	O
40	treatment	_	_	O
41	group	_	_	O
42	,	_	_	O
43	30	_	_	O
44	in	_	_	O
45	each	_	_	O
46	group	_	_	O
47	.	_	_	O

48	All	_	_	O
49	patients	_	_	O
50	were	_	_	O
51	treated	_	_	O
52	with	_	_	O
53	the	_	_	O
54	same	_	_	O
55	CTF	_	_	O
56	regimen	_	_	O
57	of	_	_	O
58	chemotherapy	_	_	O
59	for	_	_	O
60	21	_	_	O
61	days	_	_	O
62	as	_	_	O
63	one	_	_	O
64	therapeutic	_	_	O
65	cycle	_	_	O
66	,	_	_	O
67	while	_	_	O
68	those	_	_	O
69	in	_	_	O
70	the	_	_	O
71	treatment	_	_	O
72	group	_	_	O
73	were	_	_	O
74	given	_	_	O
75	SFI	_	_	O
76	additionally	_	_	O
77	in	_	_	O
78	the	_	_	O
79	meanwhite	_	_	O
80	.	_	_	O

81	The	_	_	O
82	therapeutic	_	_	O
83	efficacy	_	_	O
84	was	_	_	O
85	evaluated	_	_	O
86	after	_	_	O
87	2	_	_	O
88	cycles	_	_	O
89	of	_	_	O
90	treatment	_	_	O
91	by	_	_	O
92	observing	_	_	O
93	the	_	_	O
94	changes	_	_	O
95	of	_	_	O
96	short	_	_	O
97	-	_	_	O
98	term	_	_	O
99	efficacy	_	_	O
100	,	_	_	O
101	TCM	_	_	O
102	syndrome	_	_	O
103	,	_	_	O
104	quality	_	_	O
105	of	_	_	O
106	life	_	_	O
107	and	_	_	O
108	immune	_	_	O
109	function	_	_	O
110	,	_	_	O
111	as	_	_	O
112	well	_	_	O
113	as	_	_	O
114	the	_	_	O
115	adverse	_	_	O
116	reaction	_	_	O
117	.	_	_	O

118	The	_	_	B-Premise
119	total	_	_	I-Premise
120	short	_	_	I-Premise
121	-	_	_	I-Premise
122	term	_	_	I-Premise
123	remission	_	_	I-Premise
124	rate	_	_	I-Premise
125	,	_	_	I-Premise
126	the	_	_	I-Premise
127	improvement	_	_	I-Premise
128	rate	_	_	I-Premise
129	of	_	_	I-Premise
130	clinical	_	_	I-Premise
131	syndrome	_	_	I-Premise
132	and	_	_	I-Premise
133	quality	_	_	I-Premise
134	of	_	_	I-Premise
135	life	_	_	I-Premise
136	was	_	_	I-Premise
137	50	_	_	I-Premise
138	.	_	_	I-Premise

139	0	_	_	I-Premise
140	%	_	_	I-Premise
141	,	_	_	I-Premise
142	70	_	_	I-Premise
143	.	_	_	I-Premise

144	0	_	_	I-Premise
145	%	_	_	I-Premise
146	and	_	_	I-Premise
147	76	_	_	I-Premise
148	.	_	_	I-Premise

149	7	_	_	I-Premise
150	%	_	_	I-Premise
151	in	_	_	I-Premise
152	the	_	_	I-Premise
153	treatment	_	_	I-Premise
154	group	_	_	I-Premise
155	,	_	_	I-Premise
156	and	_	_	I-Premise
157	43	_	_	I-Premise
158	.	_	_	I-Premise

159	3	_	_	I-Premise
160	%	_	_	I-Premise
161	,	_	_	I-Premise
162	46	_	_	I-Premise
163	.	_	_	I-Premise

164	7	_	_	I-Premise
165	%	_	_	I-Premise
166	and	_	_	I-Premise
167	50	_	_	I-Premise
168	.	_	_	I-Premise

169	0	_	_	I-Premise
170	%	_	_	I-Premise
171	in	_	_	I-Premise
172	the	_	_	I-Premise
173	control	_	_	I-Premise
174	group	_	_	I-Premise
175	,	_	_	I-Premise
176	respectively	_	_	I-Premise
177	,	_	_	I-Premise
178	showing	_	_	I-Premise
179	significant	_	_	I-Premise
180	difference	_	_	I-Premise
181	between	_	_	I-Premise
182	the	_	_	I-Premise
183	two	_	_	I-Premise
184	groups	_	_	I-Premise
185	(	_	_	I-Premise
186	all	_	_	I-Premise
187	P	_	_	I-Premise
188	<	_	_	I-Premise
189	0	_	_	I-Premise
190	.	_	_	I-Premise

191	05	_	_	I-Premise
192	)	_	_	I-Premise
193	.	_	_	I-Premise

194	The	_	_	B-Premise
195	occurrence	_	_	I-Premise
196	of	_	_	I-Premise
197	adverse	_	_	I-Premise
198	reaction	_	_	I-Premise
199	in	_	_	I-Premise
200	the	_	_	I-Premise
201	treatment	_	_	I-Premise
202	group	_	_	I-Premise
203	was	_	_	I-Premise
204	lower	_	_	I-Premise
205	than	_	_	I-Premise
206	that	_	_	I-Premise
207	in	_	_	I-Premise
208	the	_	_	I-Premise
209	control	_	_	I-Premise
210	group	_	_	I-Premise
211	(	_	_	I-Premise
212	P	_	_	I-Premise
213	<	_	_	I-Premise
214	0	_	_	I-Premise
215	.	_	_	I-Premise

216	05	_	_	I-Premise
217	)	_	_	I-Premise
218	.	_	_	I-Premise

219	The	_	_	B-Premise
220	level	_	_	I-Premise
221	of	_	_	I-Premise
222	CD3	_	_	I-Premise
223	+	_	_	I-Premise
224	CD4	_	_	I-Premise
225	+	_	_	I-Premise
226	and	_	_	I-Premise
227	CD4	_	_	I-Premise
228	+	_	_	I-Premise
229	/	_	_	I-Premise
230	CD8	_	_	I-Premise
231	+	_	_	I-Premise
232	ratio	_	_	I-Premise
233	increased	_	_	I-Premise
234	(	_	_	I-Premise
235	P	_	_	I-Premise
236	<	_	_	I-Premise
237	0	_	_	I-Premise
238	.	_	_	I-Premise

239	05	_	_	I-Premise
240	)	_	_	I-Premise
241	and	_	_	I-Premise
242	CD8	_	_	I-Premise
243	+	_	_	I-Premise
244	decreased	_	_	I-Premise
245	in	_	_	I-Premise
246	the	_	_	I-Premise
247	treatment	_	_	I-Premise
248	group	_	_	I-Premise
249	(	_	_	I-Premise
250	P	_	_	I-Premise
251	<	_	_	I-Premise
252	0	_	_	I-Premise
253	.	_	_	I-Premise

254	01	_	_	I-Premise
255	)	_	_	I-Premise
256	,	_	_	I-Premise
257	while	_	_	I-Premise
258	they	_	_	I-Premise
259	showed	_	_	I-Premise
260	insignificant	_	_	I-Premise
261	change	_	_	I-Premise
262	in	_	_	I-Premise
263	the	_	_	I-Premise
264	control	_	_	I-Premise
265	group	_	_	I-Premise
266	.	_	_	I-Premise

267	For	_	_	B-Claim
268	treatment	_	_	I-Claim
269	of	_	_	I-Claim
270	advanced	_	_	I-Claim
271	breast	_	_	I-Claim
272	cancer	_	_	I-Claim
273	,	_	_	I-Claim
274	SFI	_	_	I-Claim
275	can	_	_	I-Claim
276	alleviate	_	_	I-Claim
277	the	_	_	I-Claim
278	bone	_	_	I-Claim
279	marrow	_	_	I-Claim
280	inhibition	_	_	I-Claim
281	caused	_	_	I-Claim
282	by	_	_	I-Claim
283	chemotherapy	_	_	I-Claim
284	,	_	_	I-Claim
285	improve	_	_	I-Claim
286	clinical	_	_	I-Claim
287	symptoms	_	_	I-Claim
288	and	_	_	I-Claim
289	quality	_	_	I-Claim
290	of	_	_	I-Claim
291	life	_	_	I-Claim
292	and	_	_	I-Claim
293	prolong	_	_	I-Claim
294	the	_	_	I-Claim
295	survival	_	_	I-Claim
296	period	_	_	I-Claim
297	by	_	_	I-Claim
298	regulating	_	_	I-Claim
299	cellular	_	_	I-Claim
300	immune	_	_	I-Claim
301	function	_	_	I-Claim
302	of	_	_	I-Claim
303	patients	_	_	I-Claim
304	,	_	_	I-Claim
305	so	_	_	I-Claim
306	as	_	_	I-Claim
307	to	_	_	I-Claim
308	enhance	_	_	I-Claim
309	the	_	_	I-Claim
310	therapeutic	_	_	I-Claim
311	effect	_	_	I-Claim
312	of	_	_	I-Claim
313	chemotherapy	_	_	I-Claim
314	.	_	_	I-Claim


0	Single	_	_	O
1	-	_	_	O
2	agent	_	_	O
3	therapy	_	_	O
4	with	_	_	O
5	bicalutamide	_	_	O
6	,	_	_	O
7	a	_	_	O
8	nonsteroidal	_	_	O
9	antiandrogen	_	_	O
10	,	_	_	O
11	was	_	_	O
12	compared	_	_	O
13	with	_	_	O
14	castration	_	_	O
15	,	_	_	O
16	either	_	_	O
17	surgical	_	_	O
18	or	_	_	O
19	medical	_	_	O
20	,	_	_	O
21	in	_	_	O
22	patients	_	_	O
23	with	_	_	O
24	untreated	_	_	O
25	Stage	_	_	O
26	D2	_	_	O
27	prostate	_	_	O
28	cancer	_	_	O
29	.	_	_	O

30	In	_	_	O
31	an	_	_	O
32	open	_	_	O
33	,	_	_	O
34	randomized	_	_	O
35	,	_	_	O
36	multicenter	_	_	O
37	trial	_	_	O
38	,	_	_	O
39	patients	_	_	O
40	were	_	_	O
41	randomized	_	_	O
42	to	_	_	O
43	treatment	_	_	O
44	with	_	_	O
45	50	_	_	O
46	mg	_	_	O
47	bicalutamide	_	_	O
48	(	_	_	O
49	n	_	_	O
50	=	_	_	O
51	243	_	_	O
52	)	_	_	O
53	once	_	_	O
54	daily	_	_	O
55	or	_	_	O
56	to	_	_	O
57	castration	_	_	O
58	(	_	_	O
59	n	_	_	O
60	=	_	_	O
61	243	_	_	O
62	)	_	_	O
63	,	_	_	O
64	either	_	_	O
65	orchiectomy	_	_	O
66	or	_	_	O
67	depot	_	_	O
68	injection	_	_	O
69	of	_	_	O
70	goserelin	_	_	O
71	acetate	_	_	O
72	every	_	_	O
73	28	_	_	O
74	days	_	_	O
75	.	_	_	O

76	Primary	_	_	O
77	efficacy	_	_	O
78	endpoints	_	_	O
79	were	_	_	O
80	times	_	_	O
81	to	_	_	O
82	treatment	_	_	O
83	failure	_	_	O
84	and	_	_	O
85	objective	_	_	O
86	disease	_	_	O
87	progression	_	_	O
88	and	_	_	O
89	survival	_	_	O
90	.	_	_	O

91	Assessments	_	_	O
92	included	_	_	O
93	review	_	_	O
94	of	_	_	O
95	measurable	_	_	O
96	metastases	_	_	O
97	,	_	_	O
98	prostate	_	_	O
99	dimensions	_	_	O
100	,	_	_	O
101	Eastern	_	_	O
102	Cooperative	_	_	O
103	Oncology	_	_	O
104	Group	_	_	O
105	performance	_	_	O
106	status	_	_	O
107	,	_	_	O
108	pain	_	_	O
109	,	_	_	O
110	analgesic	_	_	O
111	requirements	_	_	O
112	,	_	_	O
113	and	_	_	O
114	quality	_	_	O
115	of	_	_	O
116	life	_	_	O
117	responses	_	_	O
118	.	_	_	O

119	The	_	_	O
120	median	_	_	O
121	duration	_	_	O
122	of	_	_	O
123	therapy	_	_	O
124	was	_	_	O
125	39	_	_	O
126	weeks	_	_	O
127	for	_	_	O
128	bicalutamide	_	_	O
129	-	_	_	O
130	treated	_	_	O
131	patients	_	_	O
132	and	_	_	O
133	42	_	_	O
134	weeks	_	_	O
135	for	_	_	O
136	castrated	_	_	O
137	patients	_	_	O
138	;	_	_	O
139	treatment	_	_	O
140	failure	_	_	O
141	occurred	_	_	O
142	in	_	_	O
143	53	_	_	O
144	%	_	_	O
145	and	_	_	O
146	42	_	_	O
147	%	_	_	O
148	and	_	_	O
149	disease	_	_	O
150	progression	_	_	O
151	in	_	_	O
152	43	_	_	O
153	%	_	_	O
154	and	_	_	O
155	33	_	_	O
156	%	_	_	O
157	,	_	_	O
158	respectively	_	_	O
159	.	_	_	O

160	Treatment	_	_	B-Premise
161	effects	_	_	I-Premise
162	favored	_	_	I-Premise
163	castration	_	_	I-Premise
164	for	_	_	I-Premise
165	both	_	_	I-Premise
166	endpoints	_	_	I-Premise
167	(	_	_	I-Premise
168	P	_	_	I-Premise
169	<	_	_	I-Premise
170	or	_	_	I-Premise
171	=	_	_	I-Premise
172	0	_	_	I-Premise
173	.	_	_	I-Premise

174	002	_	_	I-Premise
175	)	_	_	I-Premise
176	,	_	_	I-Premise
177	with	_	_	I-Premise
178	hazard	_	_	I-Premise
179	ratios	_	_	I-Premise
180	(	_	_	I-Premise
181	bicalutamide	_	_	I-Premise
182	:	_	_	I-Premise
183	castration	_	_	I-Premise
184	)	_	_	I-Premise
185	of	_	_	I-Premise
186	1	_	_	I-Premise
187	.	_	_	I-Premise

188	54	_	_	I-Premise
189	(	_	_	I-Premise
190	95	_	_	I-Premise
191	%	_	_	I-Premise
192	confidence	_	_	I-Premise
193	interval	_	_	I-Premise
194	[	_	_	I-Premise
195	CI	_	_	I-Premise
196	]	_	_	I-Premise
197	,	_	_	I-Premise
198	1	_	_	I-Premise
199	.	_	_	I-Premise

200	18	_	_	I-Premise
201	to	_	_	I-Premise
202	2	_	_	I-Premise
203	.	_	_	I-Premise

204	00	_	_	I-Premise
205	)	_	_	I-Premise
206	for	_	_	I-Premise
207	time	_	_	I-Premise
208	to	_	_	I-Premise
209	treatment	_	_	I-Premise
210	failure	_	_	I-Premise
211	and	_	_	I-Premise
212	1	_	_	I-Premise
213	.	_	_	I-Premise

214	6	_	_	I-Premise
215	(	_	_	I-Premise
216	95	_	_	I-Premise
217	%	_	_	I-Premise
218	CI	_	_	I-Premise
219	,	_	_	I-Premise
220	1	_	_	I-Premise
221	.	_	_	I-Premise

222	19	_	_	I-Premise
223	to	_	_	I-Premise
224	2	_	_	I-Premise
225	.	_	_	I-Premise

226	15	_	_	I-Premise
227	)	_	_	I-Premise
228	for	_	_	I-Premise
229	time	_	_	I-Premise
230	to	_	_	I-Premise
231	disease	_	_	I-Premise
232	progression	_	_	I-Premise
233	.	_	_	I-Premise

234	From	_	_	B-Premise
235	the	_	_	I-Premise
236	1	_	_	I-Premise
237	-	_	_	I-Premise
238	year	_	_	I-Premise
239	survival	_	_	I-Premise
240	analysis	_	_	I-Premise
241	,	_	_	I-Premise
242	the	_	_	I-Premise
243	hazard	_	_	I-Premise
244	ratio	_	_	I-Premise
245	for	_	_	I-Premise
246	probability	_	_	I-Premise
247	of	_	_	I-Premise
248	death	_	_	I-Premise
249	was	_	_	I-Premise
250	1	_	_	I-Premise
251	.	_	_	I-Premise

252	29	_	_	I-Premise
253	(	_	_	I-Premise
254	95	_	_	I-Premise
255	%	_	_	I-Premise
256	CI	_	_	I-Premise
257	,	_	_	I-Premise
258	0	_	_	I-Premise
259	.	_	_	I-Premise

260	96	_	_	I-Premise
261	to	_	_	I-Premise
262	1	_	_	I-Premise
263	.	_	_	I-Premise

264	72	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	Thus	_	_	B-Premise
268	far	_	_	I-Premise
269	,	_	_	I-Premise
270	with	_	_	I-Premise
271	a	_	_	I-Premise
272	median	_	_	I-Premise
273	follow	_	_	I-Premise
274	-	_	_	I-Premise
275	up	_	_	I-Premise
276	of	_	_	I-Premise
277	86	_	_	I-Premise
278	weeks	_	_	I-Premise
279	,	_	_	I-Premise
280	median	_	_	I-Premise
281	survival	_	_	I-Premise
282	has	_	_	I-Premise
283	not	_	_	I-Premise
284	been	_	_	I-Premise
285	reached	_	_	I-Premise
286	in	_	_	I-Premise
287	either	_	_	I-Premise
288	group	_	_	I-Premise
289	.	_	_	I-Premise

290	Changes	_	_	B-Premise
291	from	_	_	I-Premise
292	baseline	_	_	I-Premise
293	in	_	_	I-Premise
294	several	_	_	I-Premise
295	quality	_	_	I-Premise
296	of	_	_	I-Premise
297	life	_	_	I-Premise
298	variables	_	_	I-Premise
299	were	_	_	I-Premise
300	significantly	_	_	I-Premise
301	different	_	_	I-Premise
302	(	_	_	I-Premise
303	P	_	_	I-Premise
304	<	_	_	I-Premise
305	or	_	_	I-Premise
306	=	_	_	I-Premise
307	0	_	_	I-Premise
308	.	_	_	I-Premise

309	01	_	_	I-Premise
310	)	_	_	I-Premise
311	between	_	_	I-Premise
312	treatment	_	_	I-Premise
313	groups	_	_	I-Premise
314	periodically	_	_	I-Premise
315	from	_	_	I-Premise
316	months	_	_	I-Premise
317	1	_	_	I-Premise
318	to	_	_	I-Premise
319	6	_	_	I-Premise
320	,	_	_	I-Premise
321	and	_	_	I-Premise
322	all	_	_	I-Premise
323	favored	_	_	I-Premise
324	bicalutamide	_	_	I-Premise
325	.	_	_	I-Premise

326	Overall	_	_	B-Premise
327	,	_	_	I-Premise
328	the	_	_	I-Premise
329	antiandrogen	_	_	I-Premise
330	was	_	_	I-Premise
331	well	_	_	I-Premise
332	tolerated	_	_	I-Premise
333	compared	_	_	I-Premise
334	with	_	_	I-Premise
335	castration	_	_	I-Premise
336	;	_	_	I-Premise
337	with	_	_	B-Premise
338	bicalutamide	_	_	I-Premise
339	,	_	_	I-Premise
340	hot	_	_	I-Premise
341	flushes	_	_	I-Premise
342	occurred	_	_	I-Premise
343	less	_	_	I-Premise
344	often	_	_	I-Premise
345	and	_	_	I-Premise
346	breast	_	_	I-Premise
347	tenderness	_	_	I-Premise
348	and	_	_	I-Premise
349	gynecomastia	_	_	I-Premise
350	more	_	_	I-Premise
351	often	_	_	I-Premise
352	.	_	_	I-Premise

353	Although	_	_	B-Premise
354	a	_	_	I-Premise
355	dosage	_	_	I-Premise
356	of	_	_	I-Premise
357	50	_	_	I-Premise
358	mg	_	_	I-Premise
359	of	_	_	I-Premise
360	bicalutamide	_	_	I-Premise
361	once	_	_	I-Premise
362	daily	_	_	I-Premise
363	was	_	_	I-Premise
364	not	_	_	I-Premise
365	as	_	_	I-Premise
366	effective	_	_	I-Premise
367	as	_	_	I-Premise
368	castration	_	_	I-Premise
369	,	_	_	I-Premise
370	the	_	_	B-Claim
371	favorable	_	_	I-Claim
372	quality	_	_	I-Claim
373	of	_	_	I-Claim
374	life	_	_	I-Claim
375	outcomes	_	_	I-Claim
376	and	_	_	I-Claim
377	the	_	_	I-Claim
378	low	_	_	I-Claim
379	incidence	_	_	I-Claim
380	of	_	_	I-Claim
381	nonhormonal	_	_	I-Claim
382	adverse	_	_	I-Claim
383	events	_	_	I-Claim
384	provide	_	_	I-Claim
385	reasons	_	_	I-Claim
386	to	_	_	I-Claim
387	evaluate	_	_	I-Claim
388	bicalutamide	_	_	I-Claim
389	,	_	_	I-Claim
390	as	_	_	I-Claim
391	a	_	_	I-Claim
392	single	_	_	I-Claim
393	therapeutic	_	_	I-Claim
394	agent	_	_	I-Claim
395	,	_	_	I-Claim
396	at	_	_	I-Claim
397	higher	_	_	I-Claim
398	doses	_	_	I-Claim
399	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	impact	_	_	O
4	of	_	_	O
5	letrozole	_	_	O
6	compared	_	_	O
7	with	_	_	O
8	placebo	_	_	O
9	after	_	_	O
10	adjuvant	_	_	O
11	tamoxifen	_	_	O
12	on	_	_	O
13	quality	_	_	O
14	of	_	_	O
15	life	_	_	O
16	(	_	_	O
17	QOL	_	_	O
18	)	_	_	O
19	in	_	_	O
20	the	_	_	O
21	MA	_	_	O
22	.	_	_	O

23	17	_	_	O
24	trial	_	_	O
25	.	_	_	O

26	Patients	_	_	O
27	completed	_	_	O
28	the	_	_	O
29	Short	_	_	O
30	Form	_	_	O
31	36	_	_	O
32	-	_	_	O
33	item	_	_	O
34	Health	_	_	O
35	Survey	_	_	O
36	(	_	_	O
37	SF	_	_	O
38	-	_	_	O
39	36	_	_	O
40	)	_	_	O
41	and	_	_	O
42	the	_	_	O
43	Menopause	_	_	O
44	Specific	_	_	O
45	Quality	_	_	O
46	of	_	_	O
47	Life	_	_	O
48	Questionnaire	_	_	O
49	(	_	_	O
50	MENQOL	_	_	O
51	)	_	_	O
52	at	_	_	O
53	baseline	_	_	O
54	,	_	_	O
55	6	_	_	O
56	months	_	_	O
57	,	_	_	O
58	and	_	_	O
59	annually	_	_	O
60	.	_	_	O

61	Mean	_	_	O
62	change	_	_	O
63	scores	_	_	O
64	from	_	_	O
65	baseline	_	_	O
66	were	_	_	O
67	compared	_	_	O
68	between	_	_	O
69	groups	_	_	O
70	for	_	_	O
71	summary	_	_	O
72	measures	_	_	O
73	and	_	_	O
74	domains	_	_	O
75	.	_	_	O

76	A	_	_	O
77	response	_	_	O
78	analysis	_	_	O
79	compared	_	_	O
80	the	_	_	O
81	proportion	_	_	O
82	of	_	_	O
83	patients	_	_	O
84	who	_	_	O
85	demonstrated	_	_	O
86	an	_	_	O
87	important	_	_	O
88	change	_	_	O
89	in	_	_	O
90	QOL	_	_	O
91	.	_	_	O

92	Of	_	_	O
93	5	_	_	O
94	,	_	_	O
95	187	_	_	O
96	randomly	_	_	O
97	assigned	_	_	O
98	women	_	_	O
99	in	_	_	O
100	the	_	_	O
101	trial	_	_	O
102	,	_	_	O
103	3	_	_	O
104	,	_	_	O
105	612	_	_	O
106	(	_	_	O
107	69	_	_	O
108	.	_	_	O

109	9	_	_	O
110	%	_	_	O
111	)	_	_	O
112	participated	_	_	O
113	in	_	_	O
114	the	_	_	O
115	QOL	_	_	O
116	substudy	_	_	O
117	:	_	_	O
118	1	_	_	O
119	,	_	_	O
120	799	_	_	O
121	were	_	_	O
122	allocated	_	_	O
123	to	_	_	O
124	placebo	_	_	O
125	and	_	_	O
126	1	_	_	O
127	,	_	_	O
128	813	_	_	O
129	were	_	_	O
130	allocated	_	_	O
131	to	_	_	O
132	letrozole	_	_	O
133	.	_	_	O

134	No	_	_	B-Premise
135	differences	_	_	I-Premise
136	were	_	_	I-Premise
137	seen	_	_	I-Premise
138	between	_	_	I-Premise
139	groups	_	_	I-Premise
140	in	_	_	I-Premise
141	mean	_	_	I-Premise
142	change	_	_	I-Premise
143	scores	_	_	I-Premise
144	from	_	_	I-Premise
145	baseline	_	_	I-Premise
146	for	_	_	I-Premise
147	the	_	_	I-Premise
148	SF	_	_	I-Premise
149	-	_	_	I-Premise
150	36	_	_	I-Premise
151	physical	_	_	I-Premise
152	and	_	_	I-Premise
153	mental	_	_	I-Premise
154	component	_	_	I-Premise
155	summary	_	_	I-Premise
156	scores	_	_	I-Premise
157	at	_	_	I-Premise
158	6	_	_	I-Premise
159	,	_	_	I-Premise
160	12	_	_	I-Premise
161	,	_	_	I-Premise
162	24	_	_	I-Premise
163	,	_	_	I-Premise
164	and	_	_	I-Premise
165	36	_	_	I-Premise
166	months	_	_	I-Premise
167	.	_	_	I-Premise

168	Small	_	_	B-Premise
169	(	_	_	I-Premise
170	<	_	_	I-Premise
171	0	_	_	I-Premise
172	.	_	_	I-Premise

173	2	_	_	I-Premise
174	standard	_	_	I-Premise
175	deviations	_	_	I-Premise
176	)	_	_	I-Premise
177	but	_	_	I-Premise
178	statistically	_	_	I-Premise
179	significant	_	_	I-Premise
180	differences	_	_	I-Premise
181	in	_	_	I-Premise
182	mean	_	_	I-Premise
183	change	_	_	I-Premise
184	scores	_	_	I-Premise
185	from	_	_	I-Premise
186	baseline	_	_	I-Premise
187	were	_	_	I-Premise
188	seen	_	_	I-Premise
189	for	_	_	I-Premise
190	the	_	_	I-Premise
191	SF	_	_	I-Premise
192	-	_	_	I-Premise
193	36	_	_	I-Premise
194	domains	_	_	I-Premise
195	of	_	_	I-Premise
196	physical	_	_	I-Premise
197	functioning	_	_	I-Premise
198	(	_	_	I-Premise
199	12	_	_	I-Premise
200	months	_	_	I-Premise
201	)	_	_	I-Premise
202	,	_	_	I-Premise
203	bodily	_	_	I-Premise
204	pain	_	_	I-Premise
205	(	_	_	I-Premise
206	6	_	_	I-Premise
207	months	_	_	I-Premise
208	)	_	_	I-Premise
209	and	_	_	I-Premise
210	vitality	_	_	I-Premise
211	(	_	_	I-Premise
212	6	_	_	I-Premise
213	and	_	_	I-Premise
214	12	_	_	I-Premise
215	months	_	_	I-Premise
216	)	_	_	I-Premise
217	,	_	_	I-Premise
218	and	_	_	I-Premise
219	the	_	_	I-Premise
220	MENQOL	_	_	I-Premise
221	vasomotor	_	_	I-Premise
222	(	_	_	I-Premise
223	6	_	_	I-Premise
224	,	_	_	I-Premise
225	12	_	_	I-Premise
226	,	_	_	I-Premise
227	and	_	_	I-Premise
228	24	_	_	I-Premise
229	months	_	_	I-Premise
230	)	_	_	I-Premise
231	and	_	_	I-Premise
232	sexual	_	_	I-Premise
233	domains	_	_	I-Premise
234	(	_	_	I-Premise
235	12	_	_	I-Premise
236	and	_	_	I-Premise
237	24	_	_	I-Premise
238	months	_	_	I-Premise
239	)	_	_	I-Premise
240	.	_	_	I-Premise

241	On	_	_	B-Premise
242	the	_	_	I-Premise
243	response	_	_	I-Premise
244	analysis	_	_	I-Premise
245	,	_	_	I-Premise
246	a	_	_	I-Premise
247	significant	_	_	I-Premise
248	difference	_	_	I-Premise
249	was	_	_	I-Premise
250	seen	_	_	I-Premise
251	between	_	_	I-Premise
252	groups	_	_	I-Premise
253	for	_	_	I-Premise
254	the	_	_	I-Premise
255	bodily	_	_	I-Premise
256	pain	_	_	I-Premise
257	domain	_	_	I-Premise
258	(	_	_	I-Premise
259	percentage	_	_	I-Premise
260	of	_	_	I-Premise
261	patients	_	_	I-Premise
262	reporting	_	_	I-Premise
263	a	_	_	I-Premise
264	worsening	_	_	I-Premise
265	of	_	_	I-Premise
266	QOL	_	_	I-Premise
267	,	_	_	I-Premise
268	47	_	_	I-Premise
269	%	_	_	I-Premise
270	placebo	_	_	I-Premise
271	v	_	_	I-Premise
272	51	_	_	I-Premise
273	%	_	_	I-Premise
274	letrozole	_	_	I-Premise
275	;	_	_	I-Premise
276	P	_	_	I-Premise
277	=	_	_	I-Premise
278	.	_	_	I-Premise

279	009	_	_	I-Premise
280	)	_	_	I-Premise
281	and	_	_	I-Premise
282	the	_	_	I-Premise
283	vasomotor	_	_	I-Premise
284	domain	_	_	I-Premise
285	(	_	_	I-Premise
286	22	_	_	I-Premise
287	%	_	_	I-Premise
288	placebo	_	_	I-Premise
289	v	_	_	I-Premise
290	29	_	_	I-Premise
291	%	_	_	I-Premise
292	letrozole	_	_	I-Premise
293	;	_	_	I-Premise
294	P	_	_	I-Premise
295	=	_	_	I-Premise
296	.	_	_	I-Premise

297	001	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	Letrozole	_	_	B-Claim
301	did	_	_	I-Claim
302	not	_	_	I-Claim
303	have	_	_	I-Claim
304	an	_	_	I-Claim
305	adverse	_	_	I-Claim
306	impact	_	_	I-Claim
307	on	_	_	I-Claim
308	overall	_	_	I-Claim
309	QOL	_	_	I-Claim
310	.	_	_	I-Claim

311	Small	_	_	B-Claim
312	effects	_	_	I-Claim
313	were	_	_	I-Claim
314	seen	_	_	I-Claim
315	in	_	_	I-Claim
316	some	_	_	I-Claim
317	domains	_	_	I-Claim
318	consistent	_	_	I-Claim
319	with	_	_	I-Claim
320	a	_	_	I-Claim
321	minority	_	_	I-Claim
322	of	_	_	I-Claim
323	patients	_	_	I-Claim
324	experiencing	_	_	I-Claim
325	changes	_	_	I-Claim
326	in	_	_	I-Claim
327	QOL	_	_	I-Claim
328	compatible	_	_	I-Claim
329	with	_	_	I-Claim
330	a	_	_	I-Claim
331	reduction	_	_	I-Claim
332	in	_	_	I-Claim
333	estrogen	_	_	I-Claim
334	synthesis	_	_	I-Claim
335	.	_	_	I-Claim


0	In	_	_	B-Claim
1	advanced	_	_	I-Claim
2	not	_	_	I-Claim
3	selected	_	_	I-Claim
4	NSCLC	_	_	I-Claim
5	chemotherapy	_	_	I-Claim
6	achieved	_	_	I-Claim
7	an	_	_	I-Claim
8	advantage	_	_	I-Claim
9	of	_	_	I-Claim
10	approximately	_	_	I-Claim
11	1	_	_	I-Claim
12	-	_	_	I-Claim
13	2	_	_	I-Claim
14	months	_	_	I-Claim
15	on	_	_	I-Claim
16	median	_	_	I-Claim
17	survival	_	_	I-Claim
18	versus	_	_	I-Claim
19	best	_	_	I-Claim
20	supportive	_	_	I-Claim
21	care	_	_	I-Claim
22	.	_	_	I-Claim

23	Chemotherapy	_	_	B-Claim
24	seems	_	_	I-Claim
25	to	_	_	I-Claim
26	improve	_	_	I-Claim
27	symptoms	_	_	I-Claim
28	control	_	_	I-Claim
29	,	_	_	I-Claim
30	even	_	_	O
31	if	_	_	O
32	randomised	_	_	O
33	studies	_	_	O
34	with	_	_	O
35	quality	_	_	O
36	of	_	_	O
37	life	_	_	O
38	as	_	_	O
39	first	_	_	O
40	endpoint	_	_	O
41	are	_	_	O
42	lacking	_	_	O
43	and	_	_	O
44	often	_	_	O
45	chemotherapy	_	_	O
46	toxicity	_	_	O
47	compromises	_	_	O
48	the	_	_	O
49	frail	_	_	O
50	cost	_	_	O
51	/	_	_	O
52	benefit	_	_	O
53	ratio	_	_	O
54	.	_	_	O

55	The	_	_	O
56	aim	_	_	O
57	of	_	_	O
58	the	_	_	O
59	present	_	_	O
60	study	_	_	O
61	is	_	_	O
62	to	_	_	O
63	evaluate	_	_	O
64	the	_	_	O
65	impact	_	_	O
66	on	_	_	O
67	QoL	_	_	O
68	,	_	_	O
69	substituting	_	_	O
70	cisplatin	_	_	O
71	,	_	_	O
72	a	_	_	O
73	pivot	_	_	O
74	drug	_	_	O
75	in	_	_	O
76	NSCLC	_	_	O
77	therapy	_	_	O
78	,	_	_	O
79	with	_	_	O
80	carboplatin	_	_	O
81	,	_	_	O
82	an	_	_	O
83	analogue	_	_	O
84	with	_	_	O
85	an	_	_	O
86	improved	_	_	O
87	toxicity	_	_	O
88	profile	_	_	O
89	.	_	_	O

90	The	_	_	O
91	combination	_	_	O
92	of	_	_	O
93	cisplatin	_	_	O
94	with	_	_	O
95	Mitomycin	_	_	O
96	and	_	_	O
97	Vinblastine	_	_	O
98	was	_	_	O
99	one	_	_	O
100	of	_	_	O
101	the	_	_	O
102	most	_	_	O
103	frequently	_	_	O
104	used	_	_	O
105	in	_	_	O
106	the	_	_	O
107	palliative	_	_	O
108	setting	_	_	O
109	at	_	_	O
110	the	_	_	O
111	time	_	_	O
112	of	_	_	O
113	design	_	_	O
114	of	_	_	O
115	our	_	_	O
116	study	_	_	O
117	.	_	_	O

118	Patients	_	_	O
119	were	_	_	O
120	randomized	_	_	O
121	to	_	_	O
122	receive	_	_	O
123	MVP	_	_	O
124	regimen	_	_	O
125	(	_	_	O
126	Mitomycin	_	_	O
127	-	_	_	O
128	C	_	_	O
129	8	_	_	O
130	mg	_	_	O
131	/	_	_	O
132	m2	_	_	O
133	d1	_	_	O
134	,	_	_	O
135	Vinblastine	_	_	O
136	4	_	_	O
137	mg	_	_	O
138	/	_	_	O
139	m2	_	_	O
140	d	_	_	O
141	1	_	_	O
142	-	_	_	O
143	8	_	_	O
144	,	_	_	O
145	Cisplatin	_	_	O
146	100	_	_	O
147	mg	_	_	O
148	/	_	_	O
149	m2	_	_	O
150	d1	_	_	O
151	)	_	_	O
152	or	_	_	O
153	MVC	_	_	O
154	regimen	_	_	O
155	(	_	_	O
156	Mitomycin	_	_	O
157	-	_	_	O
158	C	_	_	O
159	8	_	_	O
160	mg	_	_	O
161	/	_	_	O
162	m2	_	_	O
163	d1	_	_	O
164	,	_	_	O
165	Vinblastine	_	_	O
166	4	_	_	O
167	mg	_	_	O
168	/	_	_	O
169	m2	_	_	O
170	d	_	_	O
171	1	_	_	O
172	-	_	_	O
173	8	_	_	O
174	,	_	_	O
175	Carboplatin	_	_	O
176	300	_	_	O
177	mg	_	_	O
178	/	_	_	O
179	m2	_	_	O
180	d1	_	_	O
181	)	_	_	O
182	every	_	_	O
183	3	_	_	O
184	weeks	_	_	O
185	.	_	_	O

186	The	_	_	O
187	QoL	_	_	O
188	was	_	_	O
189	evaluated	_	_	O
190	by	_	_	O
191	the	_	_	O
192	Spitzer	_	_	O
193	QL	_	_	O
194	-	_	_	O
195	Index	_	_	O
196	and	_	_	O
197	by	_	_	O
198	the	_	_	O
199	EORTC	_	_	O
200	QLQ	_	_	O
201	-	_	_	O
202	C30	_	_	O
203	+	_	_	O
204	LC	_	_	O
205	13	_	_	O
206	questionnaires	_	_	O
207	before	_	_	O
208	chemotherapy	_	_	O
209	,	_	_	O
210	after	_	_	O
211	one	_	_	O
212	cycle	_	_	O
213	,	_	_	O
214	after	_	_	O
215	three	_	_	O
216	cycles	_	_	O
217	,	_	_	O
218	and	_	_	O
219	then	_	_	O
220	every	_	_	O
221	6	_	_	O
222	weeks	_	_	O
223	in	_	_	O
224	the	_	_	O
225	first	_	_	O
226	6	_	_	O
227	months	_	_	O
228	and	_	_	O
229	every	_	_	O
230	3	_	_	O
231	months	_	_	O
232	thenafter	_	_	O
233	.	_	_	O

234	From	_	_	O
235	September	_	_	O
236	1994	_	_	O
237	to	_	_	O
238	July	_	_	O
239	1997	_	_	O
240	,	_	_	O
241	153	_	_	O
242	consecutive	_	_	O
243	patients	_	_	O
244	were	_	_	O
245	randomized	_	_	O
246	to	_	_	O
247	MVP	_	_	O
248	(	_	_	O
249	75	_	_	O
250	patients	_	_	O
251	)	_	_	O
252	or	_	_	O
253	MVC	_	_	O
254	arm	_	_	O
255	(	_	_	O
256	78	_	_	O
257	patients	_	_	O
258	)	_	_	O
259	.	_	_	O

260	Despite	_	_	B-Premise
261	difficulties	_	_	I-Premise
262	in	_	_	I-Premise
263	carrying	_	_	I-Premise
264	out	_	_	I-Premise
265	and	_	_	I-Premise
266	analysing	_	_	I-Premise
267	QoL	_	_	I-Premise
268	items	_	_	I-Premise
269	in	_	_	I-Premise
270	such	_	_	I-Premise
271	patients	_	_	I-Premise
272	,	_	_	I-Premise
273	the	_	_	I-Premise
274	global	_	_	I-Premise
275	QoL	_	_	I-Premise
276	evaluated	_	_	I-Premise
277	by	_	_	I-Premise
278	the	_	_	I-Premise
279	Spitzer	_	_	I-Premise
280	'	_	_	I-Premise
281	s	_	_	I-Premise
282	questionnaire	_	_	I-Premise
283	suggested	_	_	I-Premise
284	an	_	_	I-Premise
285	advantage	_	_	I-Premise
286	for	_	_	I-Premise
287	MVC	_	_	I-Premise
288	regimen	_	_	I-Premise
289	(	_	_	I-Premise
290	P	_	_	I-Premise
291	=	_	_	I-Premise
292	0	_	_	I-Premise
293	.	_	_	I-Premise

294	05	_	_	I-Premise
295	)	_	_	I-Premise
296	and	_	_	I-Premise
297	a	_	_	I-Premise
298	significant	_	_	I-Premise
299	difference	_	_	I-Premise
300	was	_	_	I-Premise
301	observed	_	_	I-Premise
302	in	_	_	I-Premise
303	global	_	_	I-Premise
304	health	_	_	I-Premise
305	subdomain	_	_	I-Premise
306	(	_	_	I-Premise
307	P	_	_	I-Premise
308	=	_	_	I-Premise
309	0	_	_	I-Premise
310	.	_	_	I-Premise

311	04	_	_	I-Premise
312	)	_	_	I-Premise
313	.	_	_	I-Premise

314	The	_	_	B-Premise
315	disease	_	_	I-Premise
316	-	_	_	I-Premise
317	related	_	_	I-Premise
318	symptoms	_	_	I-Premise
319	improved	_	_	I-Premise
320	with	_	_	I-Premise
321	time	_	_	I-Premise
322	,	_	_	I-Premise
323	and	_	_	O
324	the	_	_	B-Premise
325	benefits	_	_	I-Premise
326	lasted	_	_	I-Premise
327	for	_	_	I-Premise
328	the	_	_	I-Premise
329	entire	_	_	I-Premise
330	treatment	_	_	I-Premise
331	period	_	_	I-Premise
332	.	_	_	I-Premise

333	When	_	_	B-Premise
334	evaluated	_	_	I-Premise
335	with	_	_	I-Premise
336	the	_	_	I-Premise
337	EORTC	_	_	I-Premise
338	questionnaire	_	_	I-Premise
339	there	_	_	I-Premise
340	was	_	_	I-Premise
341	significantly	_	_	I-Premise
342	less	_	_	I-Premise
343	nausea	_	_	I-Premise
344	and	_	_	I-Premise
345	vomiting	_	_	I-Premise
346	(	_	_	I-Premise
347	P	_	_	I-Premise
348	=	_	_	I-Premise
349	0	_	_	I-Premise
350	.	_	_	I-Premise

351	0001	_	_	I-Premise
352	)	_	_	I-Premise
353	,	_	_	I-Premise
354	appetite	_	_	I-Premise
355	loss	_	_	I-Premise
356	(	_	_	I-Premise
357	P	_	_	I-Premise
358	=	_	_	I-Premise
359	0	_	_	I-Premise
360	.	_	_	I-Premise

361	01	_	_	I-Premise
362	)	_	_	I-Premise
363	,	_	_	I-Premise
364	insomnia	_	_	I-Premise
365	(	_	_	I-Premise
366	P	_	_	I-Premise
367	=	_	_	I-Premise
368	0	_	_	I-Premise
369	.	_	_	I-Premise

370	03	_	_	I-Premise
371	)	_	_	I-Premise
372	,	_	_	I-Premise
373	constipation	_	_	I-Premise
374	(	_	_	I-Premise
375	P	_	_	I-Premise
376	=	_	_	I-Premise
377	0	_	_	I-Premise
378	.	_	_	I-Premise

379	01	_	_	I-Premise
380	)	_	_	I-Premise
381	and	_	_	I-Premise
382	peripheral	_	_	I-Premise
383	neuropathy	_	_	I-Premise
384	(	_	_	I-Premise
385	P	_	_	I-Premise
386	=	_	_	I-Premise
387	0	_	_	I-Premise
388	.	_	_	I-Premise

389	01	_	_	I-Premise
390	)	_	_	I-Premise
391	in	_	_	I-Premise
392	favour	_	_	I-Premise
393	of	_	_	I-Premise
394	MVC	_	_	I-Premise
395	,	_	_	I-Premise
396	and	_	_	I-Premise
397	a	_	_	I-Premise
398	trend	_	_	I-Premise
399	for	_	_	I-Premise
400	less	_	_	I-Premise
401	hair	_	_	I-Premise
402	loss	_	_	I-Premise
403	(	_	_	I-Premise
404	P	_	_	I-Premise
405	=	_	_	I-Premise
406	0	_	_	I-Premise
407	.	_	_	I-Premise

408	05	_	_	I-Premise
409	)	_	_	I-Premise
410	.	_	_	I-Premise

411	The	_	_	B-Premise
412	advantage	_	_	I-Premise
413	lasted	_	_	I-Premise
414	for	_	_	I-Premise
415	all	_	_	I-Premise
416	the	_	_	I-Premise
417	duration	_	_	I-Premise
418	of	_	_	I-Premise
419	chemotherapy	_	_	I-Premise
420	.	_	_	I-Premise

421	No	_	_	B-Premise
422	differences	_	_	I-Premise
423	were	_	_	I-Premise
424	observed	_	_	I-Premise
425	in	_	_	I-Premise
426	global	_	_	I-Premise
427	quality	_	_	I-Premise
428	of	_	_	I-Premise
429	life	_	_	I-Premise
430	subdomain	_	_	I-Premise
431	(	_	_	I-Premise
432	P	_	_	I-Premise
433	=	_	_	I-Premise
434	0	_	_	I-Premise
435	.	_	_	I-Premise

436	40	_	_	I-Premise
437	)	_	_	I-Premise
438	between	_	_	I-Premise
439	the	_	_	I-Premise
440	two	_	_	I-Premise
441	regimen	_	_	I-Premise
442	.	_	_	I-Premise

443	QoL	_	_	O
444	was	_	_	O
445	the	_	_	O
446	first	_	_	O
447	endpoint	_	_	O
448	and	_	_	O
449	the	_	_	O
450	statistical	_	_	O
451	power	_	_	O
452	was	_	_	O
453	inadequate	_	_	O
454	to	_	_	O
455	assess	_	_	O
456	other	_	_	O
457	parameters	_	_	O
458	.	_	_	O

459	However	_	_	O
460	,	_	_	O
461	we	_	_	B-Premise
462	reported	_	_	I-Premise
463	a	_	_	I-Premise
464	response	_	_	I-Premise
465	rate	_	_	I-Premise
466	of	_	_	I-Premise
467	43	_	_	I-Premise
468	.	_	_	I-Premise

469	1	_	_	I-Premise
470	and	_	_	I-Premise
471	38	_	_	I-Premise
472	.	_	_	I-Premise

473	6	_	_	I-Premise
474	%	_	_	I-Premise
475	,	_	_	I-Premise
476	respectively	_	_	I-Premise
477	,	_	_	I-Premise
478	in	_	_	I-Premise
479	MVP	_	_	I-Premise
480	and	_	_	I-Premise
481	MVC	_	_	I-Premise
482	arm	_	_	I-Premise
483	(	_	_	I-Premise
484	P	_	_	I-Premise
485	=	_	_	I-Premise
486	0	_	_	I-Premise
487	.	_	_	I-Premise

488	59	_	_	I-Premise
489	)	_	_	I-Premise
490	and	_	_	I-Premise
491	a	_	_	I-Premise
492	median	_	_	I-Premise
493	survival	_	_	I-Premise
494	of	_	_	I-Premise
495	10	_	_	I-Premise
496	.	_	_	I-Premise

497	2	_	_	I-Premise
498	and	_	_	I-Premise
499	7	_	_	I-Premise
500	.	_	_	I-Premise

501	2	_	_	I-Premise
502	months	_	_	I-Premise
503	,	_	_	I-Premise
504	respectively	_	_	I-Premise
505	,	_	_	I-Premise
506	for	_	_	I-Premise
507	cisplatin	_	_	I-Premise
508	and	_	_	I-Premise
509	carboplatin	_	_	I-Premise
510	arm	_	_	I-Premise
511	(	_	_	I-Premise
512	P	_	_	I-Premise
513	=	_	_	I-Premise
514	0	_	_	I-Premise
515	.	_	_	I-Premise

516	39	_	_	I-Premise
517	)	_	_	I-Premise
518	.	_	_	I-Premise

519	The	_	_	B-Premise
520	carboplatin	_	_	I-Premise
521	containing	_	_	I-Premise
522	regimen	_	_	I-Premise
523	(	_	_	I-Premise
524	MVC	_	_	I-Premise
525	)	_	_	I-Premise
526	has	_	_	I-Premise
527	a	_	_	I-Premise
528	significant	_	_	I-Premise
529	better	_	_	I-Premise
530	toxicity	_	_	I-Premise
531	profile	_	_	I-Premise
532	than	_	_	I-Premise
533	the	_	_	I-Premise
534	cisplatin	_	_	I-Premise
535	containing	_	_	I-Premise
536	(	_	_	I-Premise
537	MVP	_	_	I-Premise
538	)	_	_	I-Premise
539	regimen	_	_	I-Premise
540	as	_	_	I-Premise
541	proven	_	_	I-Premise
542	both	_	_	I-Premise
543	by	_	_	I-Premise
544	the	_	_	I-Premise
545	EORTC	_	_	I-Premise
546	questionnaires	_	_	I-Premise
547	and	_	_	I-Premise
548	by	_	_	I-Premise
549	the	_	_	I-Premise
550	WHO	_	_	I-Premise
551	toxicity	_	_	I-Premise
552	data	_	_	I-Premise
553	reported	_	_	I-Premise
554	by	_	_	I-Premise
555	physicians	_	_	I-Premise
556	.	_	_	I-Premise

557	No	_	_	B-Claim
558	significant	_	_	I-Claim
559	differences	_	_	I-Claim
560	in	_	_	I-Claim
561	terms	_	_	I-Claim
562	of	_	_	I-Claim
563	response	_	_	I-Claim
564	rate	_	_	I-Claim
565	,	_	_	I-Claim
566	time	_	_	I-Claim
567	to	_	_	I-Claim
568	progression	_	_	I-Claim
569	and	_	_	I-Claim
570	overall	_	_	I-Claim
571	survival	_	_	I-Claim
572	were	_	_	I-Claim
573	observed	_	_	I-Claim
574	between	_	_	I-Claim
575	the	_	_	I-Claim
576	two	_	_	I-Claim
577	regimen	_	_	I-Claim
578	.	_	_	I-Claim

579	The	_	_	B-Claim
580	two	_	_	I-Claim
581	chemotherapy	_	_	I-Claim
582	regimen	_	_	I-Claim
583	showed	_	_	I-Claim
584	a	_	_	I-Claim
585	similar	_	_	I-Claim
586	effectiveness	_	_	I-Claim
587	in	_	_	I-Claim
588	symptom	_	_	I-Claim
589	palliation	_	_	I-Claim
590	when	_	_	I-Claim
591	evaluated	_	_	I-Claim
592	with	_	_	I-Claim
593	C30	_	_	I-Claim
594	addendum	_	_	I-Claim
595	of	_	_	I-Claim
596	EORTC	_	_	I-Claim
597	QOL	_	_	I-Claim
598	questionnaire	_	_	I-Claim
599	.	_	_	I-Claim

600	With	_	_	B-Premise
601	the	_	_	I-Premise
602	Spitzer	_	_	I-Premise
603	'	_	_	I-Premise
604	s	_	_	I-Premise
605	questionnaires	_	_	I-Premise
606	a	_	_	I-Premise
607	trend	_	_	I-Premise
608	towards	_	_	I-Premise
609	an	_	_	I-Premise
610	improved	_	_	I-Premise
611	quality	_	_	I-Premise
612	of	_	_	I-Premise
613	life	_	_	I-Premise
614	index	_	_	I-Premise
615	was	_	_	I-Premise
616	observed	_	_	I-Premise
617	during	_	_	I-Premise
618	treatment	_	_	I-Premise
619	with	_	_	I-Premise
620	the	_	_	I-Premise
621	carboplatin	_	_	I-Premise
622	combination	_	_	I-Premise
623	in	_	_	I-Premise
624	comparison	_	_	I-Premise
625	to	_	_	I-Premise
626	the	_	_	I-Premise
627	cisplatin	_	_	I-Premise
628	combination	_	_	I-Premise
629	.	_	_	I-Premise

630	This	_	_	B-Premise
631	difference	_	_	I-Premise
632	,	_	_	I-Premise
633	however	_	_	I-Premise
634	,	_	_	I-Premise
635	was	_	_	I-Premise
636	not	_	_	I-Premise
637	observed	_	_	I-Premise
638	when	_	_	I-Premise
639	the	_	_	I-Premise
640	global	_	_	I-Premise
641	quality	_	_	I-Premise
642	of	_	_	I-Premise
643	life	_	_	I-Premise
644	was	_	_	I-Premise
645	evaluated	_	_	I-Premise
646	with	_	_	I-Premise
647	the	_	_	I-Premise
648	EORTC	_	_	I-Premise
649	patients	_	_	I-Premise
650	compiled	_	_	I-Premise
651	questionnaires	_	_	I-Premise
652	.	_	_	I-Premise

653	A	_	_	B-Claim
654	carboplatin	_	_	I-Claim
655	containing	_	_	I-Claim
656	regimen	_	_	I-Claim
657	with	_	_	I-Claim
658	better	_	_	I-Claim
659	toxicity	_	_	I-Claim
660	profile	_	_	I-Claim
661	and	_	_	I-Claim
662	a	_	_	I-Claim
663	similar	_	_	I-Claim
664	potentiality	_	_	I-Claim
665	for	_	_	I-Claim
666	symptoms	_	_	I-Claim
667	control	_	_	I-Claim
668	offers	_	_	I-Claim
669	an	_	_	I-Claim
670	option	_	_	I-Claim
671	in	_	_	I-Claim
672	comparison	_	_	I-Claim
673	to	_	_	I-Claim
674	similar	_	_	I-Claim
675	cisplatin	_	_	I-Claim
676	containing	_	_	I-Claim
677	combinations	_	_	I-Claim
678	in	_	_	I-Claim
679	the	_	_	I-Claim
680	palliative	_	_	I-Claim
681	treatment	_	_	I-Claim
682	of	_	_	I-Claim
683	advanced	_	_	I-Claim
684	NSCLC	_	_	I-Claim
685	.	_	_	I-Claim


0	For	_	_	B-Claim
1	patients	_	_	I-Claim
2	with	_	_	I-Claim
3	anthracycline	_	_	I-Claim
4	-	_	_	I-Claim
5	pretreated	_	_	I-Claim
6	metastatic	_	_	I-Claim
7	breast	_	_	I-Claim
8	carcinoma	_	_	I-Claim
9	,	_	_	I-Claim
10	capecitabine	_	_	I-Claim
11	plus	_	_	I-Claim
12	docetaxel	_	_	I-Claim
13	significantly	_	_	I-Claim
14	increased	_	_	I-Claim
15	overall	_	_	I-Claim
16	survival	_	_	I-Claim
17	compared	_	_	I-Claim
18	with	_	_	I-Claim
19	docetaxel	_	_	I-Claim
20	alone	_	_	I-Claim
21	.	_	_	I-Claim

22	The	_	_	O
23	current	_	_	O
24	study	_	_	O
25	evaluated	_	_	O
26	the	_	_	O
27	cost	_	_	O
28	-	_	_	O
29	effectiveness	_	_	O
30	of	_	_	O
31	the	_	_	O
32	capecitabine	_	_	O
33	/	_	_	O
34	docetaxel	_	_	O
35	combination	_	_	O
36	versus	_	_	O
37	docetaxel	_	_	O
38	monotherapy	_	_	O
39	,	_	_	O
40	comparing	_	_	O
41	the	_	_	O
42	gain	_	_	O
43	in	_	_	O
44	quality	_	_	O
45	-	_	_	O
46	adjusted	_	_	O
47	survival	_	_	O
48	with	_	_	O
49	associated	_	_	O
50	health	_	_	O
51	care	_	_	O
52	costs	_	_	O
53	.	_	_	O

54	Patients	_	_	O
55	were	_	_	O
56	randomized	_	_	O
57	to	_	_	O
58	receive	_	_	O
59	21	_	_	O
60	-	_	_	O
61	day	_	_	O
62	cycles	_	_	O
63	of	_	_	O
64	oral	_	_	O
65	capecitabine	_	_	O
66	1250	_	_	O
67	mg	_	_	O
68	/	_	_	O
69	m2	_	_	O
70	twice	_	_	O
71	daily	_	_	O
72	,	_	_	O
73	on	_	_	O
74	Days	_	_	O
75	1	_	_	O
76	-	_	_	O
77	14	_	_	O
78	,	_	_	O
79	plus	_	_	O
80	docetaxel	_	_	O
81	75	_	_	O
82	mg	_	_	O
83	/	_	_	O
84	m2	_	_	O
85	Day	_	_	O
86	1	_	_	O
87	(	_	_	O
88	n	_	_	O
89	=	_	_	O
90	255	_	_	O
91	)	_	_	O
92	,	_	_	O
93	or	_	_	O
94	docetaxel	_	_	O
95	100	_	_	O
96	mg	_	_	O
97	/	_	_	O
98	m2	_	_	O
99	on	_	_	O
100	Day	_	_	O
101	1	_	_	O
102	(	_	_	O
103	n	_	_	O
104	=	_	_	O
105	256	_	_	O
106	)	_	_	O
107	.	_	_	O

108	Health	_	_	O
109	and	_	_	O
110	cost	_	_	O
111	outcomes	_	_	O
112	in	_	_	O
113	the	_	_	O
114	two	_	_	O
115	arms	_	_	O
116	were	_	_	O
117	compared	_	_	O
118	,	_	_	O
119	and	_	_	O
120	cost	_	_	O
121	-	_	_	O
122	effectiveness	_	_	O
123	was	_	_	O
124	estimated	_	_	O
125	.	_	_	O

126	Data	_	_	O
127	on	_	_	O
128	survival	_	_	O
129	time	_	_	O
130	and	_	_	O
131	medical	_	_	O
132	care	_	_	O
133	resource	_	_	O
134	use	_	_	O
135	were	_	_	O
136	prospectively	_	_	O
137	collected	_	_	O
138	in	_	_	O
139	the	_	_	O
140	trial	_	_	O
141	.	_	_	O

142	Costs	_	_	O
143	associated	_	_	O
144	with	_	_	O
145	medical	_	_	O
146	care	_	_	O
147	resource	_	_	O
148	use	_	_	O
149	and	_	_	O
150	quality	_	_	O
151	-	_	_	O
152	of	_	_	O
153	-	_	_	O
154	life	_	_	O
155	adjustments	_	_	O
156	were	_	_	O
157	obtained	_	_	O
158	from	_	_	O
159	the	_	_	O
160	published	_	_	O
161	literature	_	_	O
162	.	_	_	O

163	The	_	_	O
164	incremental	_	_	O
165	cost	_	_	O
166	-	_	_	O
167	effectiveness	_	_	O
168	ratio	_	_	O
169	was	_	_	O
170	calculated	_	_	O
171	as	_	_	O
172	the	_	_	O
173	cost	_	_	O
174	per	_	_	O
175	quality	_	_	O
176	-	_	_	O
177	adjusted	_	_	O
178	life	_	_	O
179	year	_	_	O
180	(	_	_	O
181	QALY	_	_	O
182	)	_	_	O
183	gained	_	_	O
184	.	_	_	O

185	Capecitabine	_	_	B-Premise
186	/	_	_	I-Premise
187	docetaxel	_	_	I-Premise
188	increased	_	_	I-Premise
189	the	_	_	I-Premise
190	median	_	_	I-Premise
191	overall	_	_	I-Premise
192	survival	_	_	I-Premise
193	by	_	_	I-Premise
194	3	_	_	I-Premise
195	months	_	_	I-Premise
196	compared	_	_	I-Premise
197	with	_	_	I-Premise
198	docetaxel	_	_	I-Premise
199	alone	_	_	I-Premise
200	(	_	_	I-Premise
201	14	_	_	I-Premise
202	.	_	_	I-Premise

203	5	_	_	I-Premise
204	vs	_	_	I-Premise
205	.	_	_	I-Premise

206	11	_	_	I-Premise
207	.	_	_	I-Premise

208	5	_	_	I-Premise
209	months	_	_	I-Premise
210	)	_	_	I-Premise
211	.	_	_	I-Premise

212	The	_	_	B-Premise
213	mean	_	_	I-Premise
214	quality	_	_	I-Premise
215	-	_	_	I-Premise
216	adjusted	_	_	I-Premise
217	survival	_	_	I-Premise
218	was	_	_	I-Premise
219	increased	_	_	I-Premise
220	by	_	_	I-Premise
221	1	_	_	I-Premise
222	.	_	_	I-Premise

223	8	_	_	I-Premise
224	months	_	_	I-Premise
225	in	_	_	I-Premise
226	the	_	_	I-Premise
227	capecitabine	_	_	I-Premise
228	/	_	_	I-Premise
229	docetaxel	_	_	I-Premise
230	group	_	_	I-Premise
231	.	_	_	I-Premise

232	The	_	_	B-Premise
233	total	_	_	I-Premise
234	medical	_	_	I-Premise
235	-	_	_	I-Premise
236	resource	_	_	I-Premise
237	utilization	_	_	I-Premise
238	cost	_	_	I-Premise
239	per	_	_	I-Premise
240	patient	_	_	I-Premise
241	was	_	_	I-Premise
242	8	_	_	I-Premise
243	.	_	_	I-Premise

244	9	_	_	I-Premise
245	%	_	_	I-Premise
246	higher	_	_	I-Premise
247	with	_	_	I-Premise
248	the	_	_	I-Premise
249	combination	_	_	I-Premise
250	:	_	_	I-Premise
251	24	_	_	I-Premise
252	,	_	_	I-Premise
253	475	_	_	I-Premise
254	dollars	_	_	I-Premise
255	for	_	_	I-Premise
256	combination	_	_	I-Premise
257	therapy	_	_	I-Premise
258	versus	_	_	I-Premise
259	22	_	_	I-Premise
260	,	_	_	I-Premise
261	477	_	_	I-Premise
262	dollars	_	_	I-Premise
263	for	_	_	I-Premise
264	single	_	_	I-Premise
265	-	_	_	I-Premise
266	agent	_	_	I-Premise
267	docetaxel	_	_	I-Premise
268	.	_	_	I-Premise

269	The	_	_	B-Premise
270	mean	_	_	I-Premise
271	cost	_	_	I-Premise
272	per	_	_	I-Premise
273	QALY	_	_	I-Premise
274	gained	_	_	I-Premise
275	with	_	_	I-Premise
276	combination	_	_	I-Premise
277	therapy	_	_	I-Premise
278	was	_	_	I-Premise
279	13	_	_	I-Premise
280	,	_	_	I-Premise
281	558	_	_	I-Premise
282	dollars	_	_	I-Premise
283	(	_	_	I-Premise
284	standard	_	_	I-Premise
285	deviation	_	_	I-Premise
286	,	_	_	I-Premise
287	6742	_	_	I-Premise
288	dollars	_	_	I-Premise
289	)	_	_	I-Premise
290	.	_	_	I-Premise

291	Cost	_	_	B-Premise
292	savings	_	_	I-Premise
293	due	_	_	I-Premise
294	to	_	_	I-Premise
295	reduced	_	_	I-Premise
296	docetaxel	_	_	I-Premise
297	dose	_	_	I-Premise
298	and	_	_	I-Premise
299	hospital	_	_	I-Premise
300	use	_	_	I-Premise
301	were	_	_	I-Premise
302	the	_	_	I-Premise
303	major	_	_	I-Premise
304	cost	_	_	I-Premise
305	offsets	_	_	I-Premise
306	with	_	_	I-Premise
307	the	_	_	I-Premise
308	combination	_	_	I-Premise
309	.	_	_	I-Premise

310	Sensitivity	_	_	B-Premise
311	analyses	_	_	I-Premise
312	showed	_	_	I-Premise
313	that	_	_	I-Premise
314	varying	_	_	I-Premise
315	the	_	_	I-Premise
316	mean	_	_	I-Premise
317	hospital	_	_	I-Premise
318	cost	_	_	I-Premise
319	per	_	_	I-Premise
320	day	_	_	I-Premise
321	from	_	_	I-Premise
322	the	_	_	I-Premise
323	5th	_	_	I-Premise
324	to	_	_	I-Premise
325	the	_	_	I-Premise
326	95th	_	_	I-Premise
327	percentile	_	_	I-Premise
328	resulted	_	_	I-Premise
329	in	_	_	I-Premise
330	cost	_	_	I-Premise
331	-	_	_	I-Premise
332	utility	_	_	I-Premise
333	ratios	_	_	I-Premise
334	ranging	_	_	I-Premise
335	from	_	_	I-Premise
336	20	_	_	I-Premise
337	,	_	_	I-Premise
338	326	_	_	I-Premise
339	dollars	_	_	I-Premise
340	to	_	_	I-Premise
341	as	_	_	I-Premise
342	low	_	_	I-Premise
343	as	_	_	I-Premise
344	6360	_	_	I-Premise
345	dollars	_	_	I-Premise
346	.	_	_	I-Premise

347	Capecitabine	_	_	B-Claim
348	/	_	_	I-Claim
349	docetaxel	_	_	I-Claim
350	was	_	_	I-Claim
351	a	_	_	I-Claim
352	cost	_	_	I-Claim
353	-	_	_	I-Claim
354	effective	_	_	I-Claim
355	treatment	_	_	I-Claim
356	in	_	_	I-Claim
357	patients	_	_	I-Claim
358	with	_	_	I-Claim
359	anthracycline	_	_	I-Claim
360	-	_	_	I-Claim
361	pretreated	_	_	I-Claim
362	advanced	_	_	I-Claim
363	breast	_	_	I-Claim
364	carcinoma	_	_	I-Claim
365	,	_	_	I-Claim
366	and	_	_	I-Claim
367	had	_	_	I-Claim
368	an	_	_	I-Claim
369	incremental	_	_	I-Claim
370	cost	_	_	I-Claim
371	-	_	_	I-Claim
372	effectiveness	_	_	I-Claim
373	ratio	_	_	I-Claim
374	that	_	_	I-Claim
375	compares	_	_	I-Claim
376	very	_	_	I-Claim
377	favorably	_	_	I-Claim
378	with	_	_	I-Claim
379	that	_	_	I-Claim
380	of	_	_	I-Claim
381	many	_	_	I-Claim
382	other	_	_	I-Claim
383	oncology	_	_	I-Claim
384	therapies	_	_	I-Claim
385	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	blinded	_	_	O
5	,	_	_	O
6	randomized	_	_	O
7	clinical	_	_	O
8	trial	_	_	O
9	was	_	_	O
10	to	_	_	O
11	compare	_	_	O
12	two	_	_	O
13	topical	_	_	O
14	agents	_	_	O
15	(	_	_	O
16	Calendula	_	_	O
17	Weleda	_	_	O
18	cream	_	_	O
19	vs	_	_	O
20	.	_	_	O

21	Essex	_	_	O
22	cream	_	_	O
23	)	_	_	O
24	in	_	_	O
25	reducing	_	_	O
26	the	_	_	O
27	risk	_	_	O
28	of	_	_	O
29	severe	_	_	O
30	acute	_	_	O
31	radiation	_	_	O
32	skin	_	_	O
33	reactions	_	_	O
34	(	_	_	O
35	ARSR	_	_	O
36	)	_	_	O
37	in	_	_	O
38	relation	_	_	O
39	to	_	_	O
40	adjuvant	_	_	O
41	radiotherapy	_	_	O
42	(	_	_	O
43	RT	_	_	O
44	)	_	_	O
45	for	_	_	O
46	breast	_	_	O
47	cancer	_	_	O
48	.	_	_	O

49	The	_	_	O
50	primary	_	_	O
51	endpoint	_	_	O
52	was	_	_	O
53	the	_	_	O
54	difference	_	_	O
55	in	_	_	O
56	proportion	_	_	O
57	of	_	_	O
58	patients	_	_	O
59	with	_	_	O
60	ARSR	_	_	O
61	,	_	_	O
62	assessed	_	_	O
63	with	_	_	O
64	the	_	_	O
65	Radiation	_	_	O
66	Therapy	_	_	O
67	Oncology	_	_	O
68	Group	_	_	O
69	/	_	_	O
70	The	_	_	O
71	Organization	_	_	O
72	for	_	_	O
73	Research	_	_	O
74	and	_	_	O
75	Treatment	_	_	O
76	of	_	_	O
77	Cancer	_	_	O
78	Acute	_	_	O
79	Radiation	_	_	O
80	Morbidity	_	_	O
81	Scoring	_	_	O
82	Criteria	_	_	O
83	(	_	_	O
84	RTOG	_	_	O
85	/	_	_	O
86	EORTC	_	_	O
87	scale	_	_	O
88	)	_	_	O
89	at	_	_	O
90	follow	_	_	O
91	-	_	_	O
92	up	_	_	O
93	.	_	_	O

94	The	_	_	O
95	secondary	_	_	O
96	endpoints	_	_	O
97	included	_	_	O
98	patient	_	_	O
99	reported	_	_	O
100	outcome	_	_	O
101	measures	_	_	O
102	;	_	_	O
103	Quality	_	_	O
104	of	_	_	O
105	Life	_	_	O
106	Questionnaire	_	_	O
107	(	_	_	O
108	QLQ	_	_	O
109	-	_	_	O
110	C30	_	_	O
111	)	_	_	O
112	,	_	_	O
113	Sleep	_	_	O
114	disturbances	_	_	O
115	(	_	_	O
116	MOS	_	_	O
117	-	_	_	O
118	sleep	_	_	O
119	questionnaire	_	_	O
120	)	_	_	O
121	and	_	_	O
122	symptoms	_	_	O
123	from	_	_	O
124	the	_	_	O
125	irradiated	_	_	O
126	area	_	_	O
127	(	_	_	O
128	visual	_	_	O
129	analogue	_	_	O
130	scale	_	_	O
131	)	_	_	O
132	.	_	_	O

133	Patients	_	_	O
134	'	_	_	O
135	experiences	_	_	O
136	and	_	_	O
137	adherence	_	_	O
138	to	_	_	O
139	the	_	_	O
140	topical	_	_	O
141	agents	_	_	O
142	were	_	_	O
143	also	_	_	O
144	evaluated	_	_	O
145	.	_	_	O

146	A	_	_	O
147	total	_	_	O
148	of	_	_	O
149	420	_	_	O
150	patients	_	_	O
151	were	_	_	O
152	randomised	_	_	O
153	and	_	_	O
154	411	_	_	O
155	were	_	_	O
156	analysed	_	_	O
157	.	_	_	O

158	With	_	_	O
159	the	_	_	O
160	exception	_	_	O
161	of	_	_	O
162	previous	_	_	O
163	chemotherapy	_	_	O
164	,	_	_	O
165	the	_	_	O
166	treatment	_	_	O
167	groups	_	_	O
168	were	_	_	O
169	well	_	_	O
170	balanced	_	_	O
171	,	_	_	O
172	both	_	_	O
173	regarding	_	_	O
174	treatment	_	_	O
175	-	_	_	O
176	and	_	_	O
177	patient	_	_	O
178	-	_	_	O
179	related	_	_	O
180	factors	_	_	O
181	.	_	_	O

182	The	_	_	B-Premise
183	incidence	_	_	I-Premise
184	of	_	_	I-Premise
185	severe	_	_	I-Premise
186	ARSR	_	_	I-Premise
187	(	_	_	I-Premise
188	RTOG	_	_	I-Premise
189	/	_	_	I-Premise
190	EORTC	_	_	I-Premise
191	grade	_	_	I-Premise
192	≤	_	_	I-Premise
193	2	_	_	I-Premise
194	)	_	_	I-Premise
195	at	_	_	I-Premise
196	the	_	_	I-Premise
197	follow	_	_	I-Premise
198	-	_	_	I-Premise
199	up	_	_	I-Premise
200	visit	_	_	I-Premise
201	was	_	_	I-Premise
202	23	_	_	I-Premise
203	%	_	_	I-Premise
204	(	_	_	I-Premise
205	n	_	_	I-Premise
206	=	_	_	I-Premise
207	45	_	_	I-Premise
208	)	_	_	I-Premise
209	in	_	_	I-Premise
210	the	_	_	I-Premise
211	Calendula	_	_	I-Premise
212	group	_	_	I-Premise
213	and	_	_	I-Premise
214	19	_	_	I-Premise
215	%	_	_	I-Premise
216	(	_	_	I-Premise
217	n	_	_	I-Premise
218	=	_	_	I-Premise
219	38	_	_	I-Premise
220	)	_	_	I-Premise
221	in	_	_	I-Premise
222	the	_	_	I-Premise
223	Essex	_	_	I-Premise
224	group	_	_	I-Premise
225	.	_	_	I-Premise

226	We	_	_	B-Premise
227	found	_	_	I-Premise
228	no	_	_	I-Premise
229	difference	_	_	I-Premise
230	in	_	_	I-Premise
231	severe	_	_	I-Premise
232	ARSR	_	_	I-Premise
233	between	_	_	I-Premise
234	the	_	_	I-Premise
235	groups	_	_	I-Premise
236	at	_	_	I-Premise
237	any	_	_	I-Premise
238	point	_	_	I-Premise
239	of	_	_	I-Premise
240	assessment	_	_	I-Premise
241	.	_	_	I-Premise

242	The	_	_	B-Premise
243	patients	_	_	I-Premise
244	reported	_	_	I-Premise
245	low	_	_	I-Premise
246	levels	_	_	I-Premise
247	of	_	_	I-Premise
248	skin	_	_	I-Premise
249	related	_	_	I-Premise
250	symptoms	_	_	I-Premise
251	and	_	_	I-Premise
252	no	_	_	I-Premise
253	statistically	_	_	I-Premise
254	significant	_	_	I-Premise
255	differences	_	_	I-Premise
256	between	_	_	I-Premise
257	the	_	_	I-Premise
258	groups	_	_	I-Premise
259	were	_	_	I-Premise
260	found	_	_	I-Premise
261	.	_	_	I-Premise

262	No	_	_	B-Claim
263	differences	_	_	I-Claim
264	in	_	_	I-Claim
265	ARSR	_	_	I-Claim
266	between	_	_	I-Claim
267	patients	_	_	I-Claim
268	randomised	_	_	I-Claim
269	to	_	_	I-Claim
270	Calendula	_	_	I-Claim
271	or	_	_	I-Claim
272	Essex	_	_	I-Claim
273	cream	_	_	I-Claim
274	was	_	_	I-Claim
275	found	_	_	I-Claim
276	.	_	_	I-Claim

277	ARSR	_	_	B-Claim
278	seem	_	_	I-Claim
279	to	_	_	I-Claim
280	be	_	_	I-Claim
281	a	_	_	I-Claim
282	relatively	_	_	I-Claim
283	limited	_	_	I-Claim
284	problem	_	_	I-Claim
285	,	_	_	I-Claim
286	probably	_	_	I-Claim
287	more	_	_	I-Claim
288	influenced	_	_	I-Claim
289	by	_	_	I-Claim
290	treatment	_	_	I-Claim
291	related	_	_	I-Claim
292	factors	_	_	I-Claim
293	than	_	_	I-Claim
294	by	_	_	I-Claim
295	choice	_	_	I-Claim
296	of	_	_	I-Claim
297	skin	_	_	I-Claim
298	care	_	_	I-Claim
299	products	_	_	I-Claim
300	in	_	_	I-Claim
301	this	_	_	I-Claim
302	patient	_	_	I-Claim
303	group	_	_	I-Claim
304	.	_	_	I-Claim


0	This	_	_	O
1	randomised	_	_	O
2	non	_	_	O
3	-	_	_	O
4	inferiority	_	_	O
5	trial	_	_	O
6	was	_	_	O
7	designed	_	_	O
8	to	_	_	O
9	assess	_	_	O
10	whether	_	_	O
11	radiosurgery	_	_	O
12	plus	_	_	O
13	adjuvant	_	_	O
14	whole	_	_	O
15	brain	_	_	O
16	radiotherapy	_	_	O
17	(	_	_	O
18	RS	_	_	O
19	+	_	_	O
20	WBRT	_	_	O
21	)	_	_	O
22	is	_	_	O
23	as	_	_	O
24	effective	_	_	O
25	as	_	_	O
26	surgery	_	_	O
27	plus	_	_	O
28	whole	_	_	O
29	brain	_	_	O
30	radiotherapy	_	_	O
31	(	_	_	O
32	S	_	_	O
33	+	_	_	O
34	WBRT	_	_	O
35	)	_	_	O
36	for	_	_	O
37	cancer	_	_	O
38	patients	_	_	O
39	with	_	_	O
40	a	_	_	O
41	solitary	_	_	O
42	brain	_	_	O
43	metastasis	_	_	O
44	,	_	_	O
45	with	_	_	O
46	respect	_	_	O
47	to	_	_	O
48	overall	_	_	O
49	survival	_	_	O
50	and	_	_	O
51	quality	_	_	O
52	of	_	_	O
53	life	_	_	O
54	.	_	_	O

55	Major	_	_	O
56	inclusion	_	_	O
57	criteria	_	_	O
58	were	_	_	O
59	a	_	_	O
60	history	_	_	O
61	of	_	_	O
62	systemic	_	_	O
63	cancer	_	_	O
64	within	_	_	O
65	5	_	_	O
66	years	_	_	O
67	and	_	_	O
68	enhanced	_	_	O
69	magnetic	_	_	O
70	resonance	_	_	O
71	imaging	_	_	O
72	-	_	_	O
73	confirmed	_	_	O
74	solitary	_	_	O
75	brain	_	_	O
76	metastasis	_	_	O
77	suitable	_	_	O
78	for	_	_	O
79	both	_	_	O
80	radiosurgery	_	_	O
81	and	_	_	O
82	surgery	_	_	O
83	.	_	_	O

84	All	_	_	O
85	patients	_	_	O
86	were	_	_	O
87	to	_	_	O
88	receive	_	_	O
89	WBRT	_	_	O
90	(	_	_	O
91	30	_	_	O
92	Gy	_	_	O
93	in	_	_	O
94	10	_	_	O
95	fractions	_	_	O
96	)	_	_	O
97	.	_	_	O

98	Between	_	_	O
99	February	_	_	O
100	2003	_	_	O
101	and	_	_	O
102	April	_	_	O
103	2009	_	_	O
104	,	_	_	O
105	40	_	_	O
106	patients	_	_	O
107	were	_	_	O
108	considered	_	_	O
109	eligible	_	_	O
110	,	_	_	O
111	22	_	_	O
112	consented	_	_	O
113	to	_	_	O
114	randomisation	_	_	O
115	and	_	_	O
116	21	_	_	O
117	were	_	_	O
118	analysed	_	_	O
119	(	_	_	O
120	11	_	_	O
121	RS	_	_	O
122	+	_	_	O
123	WBRT	_	_	O
124	,	_	_	O
125	10	_	_	O
126	S	_	_	O
127	+	_	_	O
128	WBRT	_	_	O
129	)	_	_	O
130	.	_	_	O

131	The	_	_	O
132	trial	_	_	O
133	was	_	_	O
134	closed	_	_	O
135	early	_	_	O
136	due	_	_	O
137	to	_	_	O
138	slow	_	_	O
139	accrual	_	_	O
140	.	_	_	O

141	The	_	_	B-Premise
142	estimated	_	_	I-Premise
143	median	_	_	I-Premise
144	overall	_	_	I-Premise
145	survival	_	_	I-Premise
146	times	_	_	I-Premise
147	for	_	_	I-Premise
148	RS	_	_	I-Premise
149	+	_	_	I-Premise
150	WBRT	_	_	I-Premise
151	and	_	_	I-Premise
152	S	_	_	I-Premise
153	+	_	_	I-Premise
154	WBRT	_	_	I-Premise
155	patients	_	_	I-Premise
156	were	_	_	I-Premise
157	6	_	_	I-Premise
158	.	_	_	I-Premise

159	2	_	_	I-Premise
160	and	_	_	I-Premise
161	2	_	_	I-Premise
162	.	_	_	I-Premise

163	8	_	_	I-Premise
164	months	_	_	I-Premise
165	,	_	_	I-Premise
166	respectively	_	_	I-Premise
167	(	_	_	I-Premise
168	hazard	_	_	I-Premise
169	ratio	_	_	I-Premise
170	0	_	_	I-Premise
171	.	_	_	I-Premise

172	53	_	_	I-Premise
173	,	_	_	I-Premise
174	95	_	_	I-Premise
175	%	_	_	I-Premise
176	confidence	_	_	I-Premise
177	interval	_	_	I-Premise
178	0	_	_	I-Premise
179	.	_	_	I-Premise

180	20	_	_	I-Premise
181	-	_	_	I-Premise
182	1	_	_	I-Premise
183	.	_	_	I-Premise

184	43	_	_	I-Premise
185	,	_	_	I-Premise
186	P	_	_	I-Premise
187	=	_	_	I-Premise
188	0	_	_	I-Premise
189	.	_	_	I-Premise

190	20	_	_	I-Premise
191	)	_	_	I-Premise
192	.	_	_	I-Premise

193	Corresponding	_	_	B-Premise
194	median	_	_	I-Premise
195	failure	_	_	I-Premise
196	-	_	_	I-Premise
197	free	_	_	I-Premise
198	survival	_	_	I-Premise
199	times	_	_	I-Premise
200	were	_	_	I-Premise
201	3	_	_	I-Premise
202	.	_	_	I-Premise

203	1	_	_	I-Premise
204	and	_	_	I-Premise
205	1	_	_	I-Premise
206	.	_	_	I-Premise

207	7	_	_	I-Premise
208	months	_	_	I-Premise
209	(	_	_	I-Premise
210	P	_	_	I-Premise
211	=	_	_	I-Premise
212	0	_	_	I-Premise
213	.	_	_	I-Premise

214	20	_	_	I-Premise
215	)	_	_	I-Premise
216	.	_	_	I-Premise

217	For	_	_	B-Premise
218	19	_	_	I-Premise
219	'	_	_	I-Premise
220	per	_	_	I-Premise
221	protocol	_	_	I-Premise
222	'	_	_	I-Premise
223	patients	_	_	I-Premise
224	,	_	_	I-Premise
225	2	_	_	I-Premise
226	/	_	_	I-Premise
227	10	_	_	I-Premise
228	in	_	_	I-Premise
229	the	_	_	I-Premise
230	RS	_	_	I-Premise
231	+	_	_	I-Premise
232	WBRT	_	_	I-Premise
233	arm	_	_	I-Premise
234	had	_	_	I-Premise
235	distant	_	_	I-Premise
236	intracranial	_	_	I-Premise
237	failure	_	_	I-Premise
238	(	_	_	I-Premise
239	one	_	_	I-Premise
240	also	_	_	I-Premise
241	had	_	_	I-Premise
242	local	_	_	I-Premise
243	failure	_	_	I-Premise
244	)	_	_	I-Premise
245	and	_	_	I-Premise
246	3	_	_	I-Premise
247	/	_	_	I-Premise
248	9	_	_	I-Premise
249	S	_	_	I-Premise
250	+	_	_	I-Premise
251	WBRT	_	_	I-Premise
252	patients	_	_	I-Premise
253	had	_	_	I-Premise
254	distant	_	_	I-Premise
255	intracranial	_	_	I-Premise
256	failure	_	_	I-Premise
257	(	_	_	I-Premise
258	no	_	_	I-Premise
259	local	_	_	I-Premise
260	failures	_	_	I-Premise
261	)	_	_	I-Premise
262	.	_	_	I-Premise

263	There	_	_	B-Premise
264	were	_	_	I-Premise
265	no	_	_	I-Premise
266	grade	_	_	I-Premise
267	3	_	_	I-Premise
268	-	_	_	I-Premise
269	4	_	_	I-Premise
270	late	_	_	I-Premise
271	radiation	_	_	I-Premise
272	toxicities	_	_	I-Premise
273	.	_	_	I-Premise

274	Two	_	_	B-Claim
275	months	_	_	I-Claim
276	after	_	_	I-Claim
277	starting	_	_	I-Claim
278	treatment	_	_	I-Claim
279	there	_	_	I-Claim
280	were	_	_	I-Claim
281	no	_	_	I-Claim
282	significant	_	_	I-Claim
283	differences	_	_	I-Claim
284	in	_	_	I-Claim
285	quality	_	_	I-Claim
286	of	_	_	I-Claim
287	life	_	_	I-Claim
288	between	_	_	I-Claim
289	the	_	_	I-Claim
290	arms	_	_	I-Claim
291	.	_	_	I-Claim

292	This	_	_	B-Claim
293	randomised	_	_	I-Claim
294	trial	_	_	I-Claim
295	encountered	_	_	I-Claim
296	the	_	_	I-Claim
297	accrual	_	_	I-Claim
298	difficulties	_	_	I-Claim
299	and	_	_	I-Claim
300	consequent	_	_	I-Claim
301	low	_	_	I-Claim
302	statistical	_	_	I-Claim
303	power	_	_	I-Claim
304	commonly	_	_	I-Claim
305	associated	_	_	I-Claim
306	with	_	_	I-Claim
307	interdisciplinary	_	_	I-Claim
308	studies	_	_	I-Claim
309	drawing	_	_	I-Claim
310	from	_	_	I-Claim
311	a	_	_	I-Claim
312	small	_	_	I-Claim
313	eligible	_	_	I-Claim
314	population	_	_	I-Claim
315	,	_	_	I-Claim
316	but	_	_	O
317	can	_	_	O
318	contribute	_	_	O
319	to	_	_	O
320	future	_	_	O
321	overviews	_	_	O
322	on	_	_	O
323	the	_	_	O
324	management	_	_	O
325	of	_	_	O
326	solitary	_	_	O
327	brain	_	_	O
328	metastases	_	_	O
329	.	_	_	O


0	Hot	_	_	B-Claim
1	flashes	_	_	I-Claim
2	are	_	_	I-Claim
3	a	_	_	I-Claim
4	significant	_	_	I-Claim
5	problem	_	_	I-Claim
6	for	_	_	I-Claim
7	many	_	_	I-Claim
8	breast	_	_	I-Claim
9	cancer	_	_	I-Claim
10	survivors	_	_	I-Claim
11	.	_	_	I-Claim

12	Hot	_	_	B-Claim
13	flashes	_	_	I-Claim
14	can	_	_	I-Claim
15	cause	_	_	I-Claim
16	discomfort	_	_	I-Claim
17	,	_	_	I-Claim
18	disrupted	_	_	I-Claim
19	sleep	_	_	I-Claim
20	,	_	_	I-Claim
21	anxiety	_	_	I-Claim
22	,	_	_	I-Claim
23	and	_	_	I-Claim
24	decreased	_	_	I-Claim
25	quality	_	_	I-Claim
26	of	_	_	I-Claim
27	life	_	_	I-Claim
28	.	_	_	I-Claim

29	A	_	_	O
30	well	_	_	O
31	-	_	_	O
32	tolerated	_	_	O
33	and	_	_	O
34	effective	_	_	O
35	mind	_	_	O
36	-	_	_	O
37	body	_	_	O
38	treatment	_	_	O
39	for	_	_	O
40	hot	_	_	O
41	flashes	_	_	O
42	would	_	_	O
43	be	_	_	O
44	of	_	_	O
45	great	_	_	O
46	value	_	_	O
47	.	_	_	O

48	On	_	_	O
49	the	_	_	O
50	basis	_	_	O
51	of	_	_	O
52	previous	_	_	O
53	case	_	_	O
54	studies	_	_	O
55	,	_	_	O
56	this	_	_	O
57	study	_	_	O
58	was	_	_	O
59	developed	_	_	O
60	to	_	_	O
61	evaluate	_	_	O
62	the	_	_	O
63	effect	_	_	O
64	of	_	_	O
65	a	_	_	O
66	hypnosis	_	_	O
67	intervention	_	_	O
68	for	_	_	O
69	hot	_	_	O
70	flashes	_	_	O
71	.	_	_	O

72	Sixty	_	_	O
73	female	_	_	O
74	breast	_	_	O
75	cancer	_	_	O
76	survivors	_	_	O
77	with	_	_	O
78	hot	_	_	O
79	flashes	_	_	O
80	were	_	_	O
81	randomly	_	_	O
82	assigned	_	_	O
83	to	_	_	O
84	receive	_	_	O
85	hypnosis	_	_	O
86	intervention	_	_	O
87	(	_	_	O
88	five	_	_	O
89	weekly	_	_	O
90	sessions	_	_	O
91	)	_	_	O
92	or	_	_	O
93	no	_	_	O
94	treatment	_	_	O
95	.	_	_	O

96	Eligible	_	_	O
97	patients	_	_	O
98	had	_	_	O
99	to	_	_	O
100	have	_	_	O
101	a	_	_	O
102	history	_	_	O
103	of	_	_	O
104	primary	_	_	O
105	breast	_	_	O
106	cancer	_	_	O
107	without	_	_	O
108	evidence	_	_	O
109	of	_	_	O
110	detectable	_	_	O
111	disease	_	_	O
112	and	_	_	O
113	14	_	_	O
114	or	_	_	O
115	more	_	_	O
116	weekly	_	_	O
117	hot	_	_	O
118	flashes	_	_	O
119	for	_	_	O
120	at	_	_	O
121	least	_	_	O
122	1	_	_	O
123	month	_	_	O
124	.	_	_	O

125	The	_	_	O
126	major	_	_	O
127	outcome	_	_	O
128	measure	_	_	O
129	was	_	_	O
130	a	_	_	O
131	bivariate	_	_	O
132	construct	_	_	O
133	that	_	_	O
134	represented	_	_	O
135	hot	_	_	O
136	flash	_	_	O
137	frequency	_	_	O
138	and	_	_	O
139	hot	_	_	O
140	flash	_	_	O
141	score	_	_	O
142	,	_	_	O
143	which	_	_	O
144	was	_	_	O
145	analyzed	_	_	O
146	by	_	_	O
147	a	_	_	O
148	classic	_	_	O
149	sums	_	_	O
150	and	_	_	O
151	differences	_	_	O
152	comparison	_	_	O
153	.	_	_	O

154	Secondary	_	_	O
155	outcome	_	_	O
156	measures	_	_	O
157	were	_	_	O
158	self	_	_	O
159	-	_	_	O
160	reports	_	_	O
161	of	_	_	O
162	interference	_	_	O
163	of	_	_	O
164	hot	_	_	O
165	flashes	_	_	O
166	on	_	_	O
167	daily	_	_	O
168	activities	_	_	O
169	.	_	_	O

170	Fifty	_	_	O
171	-	_	_	O
172	one	_	_	O
173	randomly	_	_	O
174	assigned	_	_	O
175	women	_	_	O
176	completed	_	_	O
177	the	_	_	O
178	study	_	_	O
179	.	_	_	O

180	By	_	_	B-Premise
181	the	_	_	I-Premise
182	end	_	_	I-Premise
183	of	_	_	I-Premise
184	the	_	_	I-Premise
185	treatment	_	_	I-Premise
186	period	_	_	I-Premise
187	,	_	_	I-Premise
188	hot	_	_	I-Premise
189	flash	_	_	I-Premise
190	scores	_	_	I-Premise
191	(	_	_	I-Premise
192	frequency	_	_	I-Premise
193	x	_	_	I-Premise
194	average	_	_	I-Premise
195	severity	_	_	I-Premise
196	)	_	_	I-Premise
197	decreased	_	_	I-Premise
198	68	_	_	I-Premise
199	%	_	_	I-Premise
200	from	_	_	I-Premise
201	baseline	_	_	I-Premise
202	to	_	_	I-Premise
203	end	_	_	I-Premise
204	point	_	_	I-Premise
205	in	_	_	I-Premise
206	the	_	_	I-Premise
207	hypnosis	_	_	I-Premise
208	arm	_	_	I-Premise
209	(	_	_	I-Premise
210	P	_	_	I-Premise
211	<	_	_	I-Premise
212	.	_	_	I-Premise

213	001	_	_	I-Premise
214	)	_	_	I-Premise
215	.	_	_	I-Premise

216	Significant	_	_	B-Premise
217	improvements	_	_	I-Premise
218	in	_	_	I-Premise
219	self	_	_	I-Premise
220	-	_	_	I-Premise
221	reported	_	_	I-Premise
222	anxiety	_	_	I-Premise
223	,	_	_	I-Premise
224	depression	_	_	I-Premise
225	,	_	_	I-Premise
226	interference	_	_	I-Premise
227	of	_	_	I-Premise
228	hot	_	_	I-Premise
229	flashes	_	_	I-Premise
230	on	_	_	I-Premise
231	daily	_	_	I-Premise
232	activities	_	_	I-Premise
233	,	_	_	I-Premise
234	and	_	_	I-Premise
235	sleep	_	_	I-Premise
236	were	_	_	I-Premise
237	observed	_	_	I-Premise
238	for	_	_	I-Premise
239	patients	_	_	I-Premise
240	who	_	_	I-Premise
241	received	_	_	I-Premise
242	the	_	_	I-Premise
243	hypnosis	_	_	I-Premise
244	intervention	_	_	I-Premise
245	(	_	_	I-Premise
246	P	_	_	I-Premise
247	<	_	_	I-Premise
248	.	_	_	I-Premise

249	005	_	_	I-Premise
250	)	_	_	I-Premise
251	in	_	_	I-Premise
252	comparison	_	_	I-Premise
253	to	_	_	I-Premise
254	the	_	_	I-Premise
255	no	_	_	I-Premise
256	treatment	_	_	I-Premise
257	control	_	_	I-Premise
258	group	_	_	I-Premise
259	.	_	_	I-Premise

260	Hypnosis	_	_	B-Claim
261	appears	_	_	I-Claim
262	to	_	_	I-Claim
263	reduce	_	_	I-Claim
264	perceived	_	_	I-Claim
265	hot	_	_	I-Claim
266	flashes	_	_	I-Claim
267	in	_	_	I-Claim
268	breast	_	_	I-Claim
269	cancer	_	_	I-Claim
270	survivors	_	_	I-Claim
271	and	_	_	I-Claim
272	may	_	_	I-Claim
273	have	_	_	I-Claim
274	additional	_	_	I-Claim
275	benefits	_	_	I-Claim
276	such	_	_	I-Claim
277	as	_	_	I-Claim
278	reduced	_	_	I-Claim
279	anxiety	_	_	I-Claim
280	and	_	_	I-Claim
281	depression	_	_	I-Claim
282	,	_	_	I-Claim
283	and	_	_	I-Claim
284	improved	_	_	I-Claim
285	sleep	_	_	I-Claim
286	.	_	_	I-Claim


0	From	_	_	O
1	1984	_	_	O
2	to	_	_	O
3	1989	_	_	O
4	,	_	_	O
5	the	_	_	O
6	Swiss	_	_	O
7	Group	_	_	O
8	for	_	_	O
9	Clinical	_	_	O
10	Cancer	_	_	O
11	Research	_	_	O
12	(	_	_	O
13	SAKK	_	_	O
14	)	_	_	O
15	performed	_	_	O
16	a	_	_	O
17	randomized	_	_	O
18	phase	_	_	O
19	III	_	_	O
20	trial	_	_	O
21	comparing	_	_	O
22	early	_	_	O
23	versus	_	_	O
24	late	_	_	O
25	alternating	_	_	O
26	chemotherapy	_	_	O
27	in	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	small	_	_	O
31	-	_	_	O
32	cell	_	_	O
33	lung	_	_	O
34	cancer	_	_	O
35	.	_	_	O

36	406	_	_	O
37	eligible	_	_	O
38	patients	_	_	O
39	were	_	_	O
40	entered	_	_	O
41	into	_	_	O
42	the	_	_	O
43	trial	_	_	O
44	.	_	_	O

45	Regimen	_	_	O
46	A	_	_	O
47	consisted	_	_	O
48	of	_	_	O
49	PAV	_	_	O
50	(	_	_	O
51	cisPlatin	_	_	O
52	,	_	_	O
53	Adriamycin	_	_	O
54	,	_	_	O
55	VP	_	_	O
56	16	_	_	O
57	-	_	_	O
58	213	_	_	O
59	,	_	_	O
60	and	_	_	O
61	Regimen	_	_	O
62	B	_	_	O
63	of	_	_	O
64	CyMOC	_	_	O
65	(	_	_	O
66	Cyclophosphamide	_	_	O
67	,	_	_	O
68	Methotrexate	_	_	O
69	,	_	_	O
70	Oncovin	_	_	O
71	,	_	_	O
72	CCNU	_	_	O
73	)	_	_	O
74	.	_	_	O

75	Cycles	_	_	O
76	were	_	_	O
77	repeated	_	_	O
78	as	_	_	O
79	rapidly	_	_	O
80	as	_	_	O
81	possible	_	_	O
82	.	_	_	O

83	patients	_	_	O
84	were	_	_	O
85	randomized	_	_	O
86	to	_	_	O
87	receive	_	_	O
88	either	_	_	O
89	ABABAB	_	_	O
90	(	_	_	O
91	early	_	_	O
92	alternating	_	_	O
93	chemotherapy	_	_	O
94	)	_	_	O
95	or	_	_	O
96	AAABBB	_	_	O
97	(	_	_	O
98	late	_	_	O
99	alternating	_	_	O
100	chemotherapy	_	_	O
101	)	_	_	O
102	.	_	_	O

103	After	_	_	O
104	six	_	_	O
105	cycles	_	_	O
106	patients	_	_	O
107	with	_	_	O
108	limited	_	_	O
109	disease	_	_	O
110	in	_	_	O
111	complete	_	_	O
112	or	_	_	O
113	partial	_	_	O
114	remission	_	_	O
115	and	_	_	O
116	those	_	_	O
117	with	_	_	O
118	extensive	_	_	O
119	disease	_	_	O
120	in	_	_	O
121	complete	_	_	O
122	remission	_	_	O
123	received	_	_	O
124	irradiation	_	_	O
125	to	_	_	O
126	the	_	_	O
127	primary	_	_	O
128	(	_	_	O
129	45	_	_	O
130	Gy	_	_	O
131	)	_	_	O
132	and	_	_	O
133	the	_	_	O
134	CNS	_	_	O
135	(	_	_	O
136	36	_	_	O
137	Gy	_	_	O
138	)	_	_	O
139	.	_	_	O

140	The	_	_	B-Premise
141	overall	_	_	I-Premise
142	remission	_	_	I-Premise
143	rate	_	_	I-Premise
144	was	_	_	I-Premise
145	87	_	_	I-Premise
146	%	_	_	I-Premise
147	with	_	_	I-Premise
148	31	_	_	I-Premise
149	%	_	_	I-Premise
150	complete	_	_	I-Premise
151	remissions	_	_	I-Premise
152	.	_	_	I-Premise

153	The	_	_	B-Premise
154	median	_	_	I-Premise
155	survival	_	_	I-Premise
156	of	_	_	I-Premise
157	all	_	_	I-Premise
158	406	_	_	I-Premise
159	eligible	_	_	I-Premise
160	patients	_	_	I-Premise
161	was	_	_	I-Premise
162	346	_	_	I-Premise
163	days	_	_	I-Premise
164	with	_	_	I-Premise
165	15	_	_	I-Premise
166	%	_	_	I-Premise
167	of	_	_	I-Premise
168	the	_	_	I-Premise
169	patients	_	_	I-Premise
170	alive	_	_	I-Premise
171	at	_	_	I-Premise
172	two	_	_	I-Premise
173	years	_	_	I-Premise
174	.	_	_	I-Premise

175	The	_	_	B-Premise
176	overall	_	_	I-Premise
177	remission	_	_	I-Premise
178	rate	_	_	I-Premise
179	,	_	_	I-Premise
180	the	_	_	I-Premise
181	rate	_	_	I-Premise
182	of	_	_	I-Premise
183	complete	_	_	I-Premise
184	remission	_	_	I-Premise
185	,	_	_	I-Premise
186	the	_	_	I-Premise
187	median	_	_	I-Premise
188	survival	_	_	I-Premise
189	and	_	_	I-Premise
190	the	_	_	I-Premise
191	rate	_	_	I-Premise
192	of	_	_	I-Premise
193	long	_	_	I-Premise
194	-	_	_	I-Premise
195	term	_	_	I-Premise
196	survival	_	_	I-Premise
197	were	_	_	I-Premise
198	not	_	_	I-Premise
199	significantly	_	_	I-Premise
200	different	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	two	_	_	I-Premise
204	treatment	_	_	I-Premise
205	arms	_	_	I-Premise
206	.	_	_	I-Premise

207	In	_	_	B-Premise
208	limited	_	_	I-Premise
209	disease	_	_	I-Premise
210	the	_	_	I-Premise
211	estimated	_	_	I-Premise
212	percentages	_	_	I-Premise
213	of	_	_	I-Premise
214	survival	_	_	I-Premise
215	at	_	_	I-Premise
216	2	_	_	I-Premise
217	years	_	_	I-Premise
218	were	_	_	I-Premise
219	33	_	_	I-Premise
220	%	_	_	I-Premise
221	in	_	_	I-Premise
222	the	_	_	I-Premise
223	early	_	_	I-Premise
224	and	_	_	I-Premise
225	24	_	_	I-Premise
226	%	_	_	I-Premise
227	in	_	_	I-Premise
228	the	_	_	I-Premise
229	late	_	_	I-Premise
230	alternating	_	_	I-Premise
231	chemotherapy	_	_	I-Premise
232	arms	_	_	I-Premise
233	.	_	_	I-Premise

234	Patients	_	_	B-Premise
235	with	_	_	I-Premise
236	extensive	_	_	I-Premise
237	disease	_	_	I-Premise
238	survived	_	_	I-Premise
239	significantly	_	_	I-Premise
240	longer	_	_	I-Premise
241	with	_	_	I-Premise
242	late	_	_	I-Premise
243	alternating	_	_	I-Premise
244	chemotherapy	_	_	I-Premise
245	than	_	_	I-Premise
246	on	_	_	I-Premise
247	the	_	_	I-Premise
248	early	_	_	I-Premise
249	alternation	_	_	I-Premise
250	regimen	_	_	I-Premise
251	(	_	_	I-Premise
252	median	_	_	I-Premise
253	survival	_	_	I-Premise
254	336	_	_	I-Premise
255	days	_	_	I-Premise
256	versus	_	_	I-Premise
257	301	_	_	I-Premise
258	days	_	_	I-Premise
259	,	_	_	I-Premise
260	p	_	_	I-Premise
261	=	_	_	I-Premise
262	0	_	_	I-Premise
263	.	_	_	I-Premise

264	01	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	In	_	_	B-Premise
268	the	_	_	I-Premise
269	latter	_	_	I-Premise
270	patients	_	_	I-Premise
271	the	_	_	I-Premise
272	received	_	_	I-Premise
273	dose	_	_	I-Premise
274	intensities	_	_	I-Premise
275	(	_	_	I-Premise
276	RDI	_	_	I-Premise
277	)	_	_	I-Premise
278	of	_	_	I-Premise
279	cisplatin	_	_	I-Premise
280	,	_	_	I-Premise
281	adriamycin	_	_	I-Premise
282	and	_	_	I-Premise
283	etoposide	_	_	I-Premise
284	were	_	_	I-Premise
285	significantly	_	_	I-Premise
286	higher	_	_	I-Premise
287	in	_	_	I-Premise
288	the	_	_	I-Premise
289	late	_	_	I-Premise
290	-	_	_	I-Premise
291	alternation	_	_	I-Premise
292	arm	_	_	I-Premise
293	.	_	_	I-Premise

294	Patients	_	_	B-Premise
295	treated	_	_	I-Premise
296	with	_	_	I-Premise
297	early	_	_	I-Premise
298	alternating	_	_	I-Premise
299	chemotherapy	_	_	I-Premise
300	rated	_	_	I-Premise
301	their	_	_	I-Premise
302	tumor	_	_	I-Premise
303	symptoms	_	_	I-Premise
304	,	_	_	I-Premise
305	functional	_	_	I-Premise
306	states	_	_	I-Premise
307	,	_	_	I-Premise
308	fatigue	_	_	I-Premise
309	/	_	_	I-Premise
310	malaise	_	_	I-Premise
311	and	_	_	I-Premise
312	restriction	_	_	I-Premise
313	of	_	_	I-Premise
314	social	_	_	I-Premise
315	activity	_	_	I-Premise
316	significantly	_	_	I-Premise
317	better	_	_	I-Premise
318	,	_	_	I-Premise
319	reflecting	_	_	I-Premise
320	an	_	_	I-Premise
321	improved	_	_	I-Premise
322	subjective	_	_	I-Premise
323	adjustment	_	_	I-Premise
324	.	_	_	I-Premise

325	Alternating	_	_	B-Claim
326	chemotherapy	_	_	I-Claim
327	with	_	_	I-Claim
328	PAV	_	_	I-Claim
329	-	_	_	I-Claim
330	CyMOC	_	_	I-Claim
331	plus	_	_	I-Claim
332	consolidating	_	_	I-Claim
333	radiotherapy	_	_	I-Claim
334	is	_	_	I-Claim
335	a	_	_	I-Claim
336	feasible	_	_	I-Claim
337	and	_	_	I-Claim
338	effective	_	_	I-Claim
339	treatment	_	_	I-Claim
340	for	_	_	I-Claim
341	small	_	_	I-Claim
342	-	_	_	I-Claim
343	cell	_	_	I-Claim
344	lung	_	_	I-Claim
345	cancer	_	_	I-Claim
346	,	_	_	I-Claim
347	with	_	_	I-Claim
348	acceptable	_	_	I-Claim
349	toxicity	_	_	I-Claim
350	.	_	_	I-Claim

351	Whereas	_	_	O
352	patients	_	_	B-Claim
353	with	_	_	I-Claim
354	early	_	_	I-Claim
355	alternating	_	_	I-Claim
356	chemotherapy	_	_	I-Claim
357	achieve	_	_	I-Claim
358	a	_	_	I-Claim
359	better	_	_	I-Claim
360	subjective	_	_	I-Claim
361	adjustment	_	_	I-Claim
362	,	_	_	I-Claim
363	late	_	_	B-Claim
364	alternating	_	_	I-Claim
365	chemotherapy	_	_	I-Claim
366	allows	_	_	I-Claim
367	for	_	_	I-Claim
368	a	_	_	I-Claim
369	higher	_	_	I-Claim
370	RDI	_	_	I-Claim
371	of	_	_	I-Claim
372	cisplatin	_	_	I-Claim
373	,	_	_	I-Claim
374	adriamycin	_	_	I-Claim
375	and	_	_	I-Claim
376	etoposide	_	_	I-Claim
377	,	_	_	I-Claim
378	which	_	_	I-Claim
379	results	_	_	I-Claim
380	in	_	_	I-Claim
381	a	_	_	I-Claim
382	significantly	_	_	I-Claim
383	longer	_	_	I-Claim
384	median	_	_	I-Claim
385	survival	_	_	I-Claim
386	of	_	_	I-Claim
387	patients	_	_	I-Claim
388	with	_	_	I-Claim
389	extensive	_	_	I-Claim
390	disease	_	_	I-Claim
391	.	_	_	I-Claim


0	The	_	_	O
1	combination	_	_	O
2	of	_	_	O
3	cisplatin	_	_	O
4	and	_	_	O
5	etoposide	_	_	O
6	(	_	_	O
7	PE	_	_	O
8	)	_	_	O
9	has	_	_	O
10	been	_	_	O
11	a	_	_	O
12	standard	_	_	O
13	treatment	_	_	O
14	for	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	poor	_	_	O
18	-	_	_	O
19	prognosis	_	_	O
20	small	_	_	O
21	cell	_	_	O
22	lung	_	_	O
23	cancer	_	_	O
24	(	_	_	O
25	SCLC	_	_	O
26	)	_	_	O
27	.	_	_	O

28	This	_	_	O
29	non	_	_	O
30	-	_	_	O
31	inferiority	_	_	O
32	design	_	_	O
33	trial	_	_	O
34	aimed	_	_	O
35	to	_	_	O
36	determine	_	_	O
37	whether	_	_	O
38	the	_	_	O
39	combination	_	_	O
40	of	_	_	O
41	gemcitabine	_	_	O
42	and	_	_	O
43	carboplatin	_	_	O
44	(	_	_	O
45	GC	_	_	O
46	)	_	_	O
47	results	_	_	O
48	in	_	_	O
49	similar	_	_	O
50	survival	_	_	O
51	but	_	_	O
52	is	_	_	O
53	less	_	_	O
54	toxic	_	_	O
55	with	_	_	O
56	better	_	_	O
57	quality	_	_	O
58	of	_	_	O
59	life	_	_	O
60	.	_	_	O

61	Previously	_	_	O
62	untreated	_	_	O
63	patients	_	_	O
64	with	_	_	O
65	SCLC	_	_	O
66	with	_	_	O
67	extensive	_	_	O
68	disease	_	_	O
69	or	_	_	O
70	limited	_	_	O
71	stage	_	_	O
72	with	_	_	O
73	poor	_	_	O
74	prognostic	_	_	O
75	factors	_	_	O
76	were	_	_	O
77	randomly	_	_	O
78	assigned	_	_	O
79	to	_	_	O
80	six	_	_	O
81	3	_	_	O
82	-	_	_	O
83	weekly	_	_	O
84	cycles	_	_	O
85	of	_	_	O
86	GC	_	_	O
87	or	_	_	O
88	PE	_	_	O
89	.	_	_	O

90	241	_	_	O
91	patients	_	_	O
92	(	_	_	O
93	121	_	_	O
94	GC	_	_	O
95	,	_	_	O
96	120	_	_	O
97	PE	_	_	O
98	)	_	_	O
99	were	_	_	O
100	recruited	_	_	O
101	,	_	_	O
102	of	_	_	O
103	which	_	_	O
104	216	_	_	O
105	(	_	_	O
106	90	_	_	O
107	%	_	_	O
108	)	_	_	O
109	had	_	_	O
110	died	_	_	O
111	.	_	_	O

112	There	_	_	B-Premise
113	was	_	_	I-Premise
114	no	_	_	I-Premise
115	difference	_	_	I-Premise
116	in	_	_	I-Premise
117	overall	_	_	I-Premise
118	survival	_	_	I-Premise
119	(	_	_	I-Premise
120	HR	_	_	I-Premise
121	1	_	_	I-Premise
122	.	_	_	I-Premise

123	01	_	_	I-Premise
124	,	_	_	I-Premise
125	95	_	_	I-Premise
126	%	_	_	I-Premise
127	CI	_	_	I-Premise
128	0	_	_	I-Premise
129	.	_	_	I-Premise

130	77	_	_	I-Premise
131	to	_	_	I-Premise
132	1	_	_	I-Premise
133	.	_	_	I-Premise

134	32	_	_	I-Premise
135	)	_	_	I-Premise
136	.	_	_	I-Premise

137	Median	_	_	B-Premise
138	survival	_	_	I-Premise
139	with	_	_	I-Premise
140	GC	_	_	I-Premise
141	and	_	_	I-Premise
142	PE	_	_	I-Premise
143	was	_	_	I-Premise
144	8	_	_	I-Premise
145	.	_	_	I-Premise

146	0	_	_	I-Premise
147	and	_	_	I-Premise
148	8	_	_	I-Premise
149	.	_	_	I-Premise

150	1	_	_	I-Premise
151	months	_	_	I-Premise
152	,	_	_	I-Premise
153	respectively	_	_	I-Premise
154	.	_	_	I-Premise

155	Median	_	_	B-Premise
156	progression	_	_	I-Premise
157	-	_	_	I-Premise
158	free	_	_	I-Premise
159	survival	_	_	I-Premise
160	was	_	_	I-Premise
161	5	_	_	I-Premise
162	.	_	_	I-Premise

163	9	_	_	I-Premise
164	months	_	_	I-Premise
165	with	_	_	I-Premise
166	GC	_	_	I-Premise
167	and	_	_	I-Premise
168	6	_	_	I-Premise
169	.	_	_	I-Premise

170	3	_	_	I-Premise
171	months	_	_	I-Premise
172	with	_	_	I-Premise
173	PE	_	_	I-Premise
174	.	_	_	I-Premise

175	Grade	_	_	B-Premise
176	3	_	_	I-Premise
177	or	_	_	I-Premise
178	4	_	_	I-Premise
179	myelosuppressions	_	_	I-Premise
180	were	_	_	I-Premise
181	more	_	_	I-Premise
182	frequent	_	_	I-Premise
183	with	_	_	I-Premise
184	GC	_	_	I-Premise
185	(	_	_	I-Premise
186	anaemia	_	_	I-Premise
187	:	_	_	I-Premise
188	14	_	_	I-Premise
189	%	_	_	I-Premise
190	GC	_	_	I-Premise
191	vs	_	_	I-Premise
192	2	_	_	I-Premise
193	%	_	_	I-Premise
194	PE	_	_	I-Premise
195	;	_	_	I-Premise
196	leucopenia	_	_	I-Premise
197	:	_	_	I-Premise
198	32	_	_	I-Premise
199	%	_	_	I-Premise
200	GC	_	_	I-Premise
201	vs	_	_	I-Premise
202	13	_	_	I-Premise
203	%	_	_	I-Premise
204	PE	_	_	I-Premise
205	;	_	_	I-Premise
206	thrombocytopenia	_	_	I-Premise
207	:	_	_	I-Premise
208	22	_	_	I-Premise
209	%	_	_	I-Premise
210	GC	_	_	I-Premise
211	vs	_	_	I-Premise
212	4	_	_	I-Premise
213	%	_	_	I-Premise
214	PE	_	_	I-Premise
215	)	_	_	I-Premise
216	,	_	_	I-Premise
217	but	_	_	B-Premise
218	these	_	_	I-Premise
219	were	_	_	I-Premise
220	not	_	_	I-Premise
221	associated	_	_	I-Premise
222	with	_	_	I-Premise
223	increased	_	_	I-Premise
224	hospital	_	_	I-Premise
225	admissions	_	_	I-Premise
226	,	_	_	I-Premise
227	infections	_	_	I-Premise
228	or	_	_	I-Premise
229	fatalities	_	_	I-Premise
230	.	_	_	I-Premise

231	Grade	_	_	B-Premise
232	2	_	_	I-Premise
233	-	_	_	I-Premise
234	3	_	_	I-Premise
235	alopecia	_	_	I-Premise
236	(	_	_	I-Premise
237	68	_	_	I-Premise
238	%	_	_	I-Premise
239	PE	_	_	I-Premise
240	vs	_	_	I-Premise
241	17	_	_	I-Premise
242	%	_	_	I-Premise
243	GC	_	_	I-Premise
244	)	_	_	I-Premise
245	and	_	_	I-Premise
246	nausea	_	_	I-Premise
247	(	_	_	I-Premise
248	43	_	_	I-Premise
249	%	_	_	I-Premise
250	PE	_	_	I-Premise
251	vs	_	_	I-Premise
252	26	_	_	I-Premise
253	%	_	_	I-Premise
254	GC	_	_	I-Premise
255	)	_	_	I-Premise
256	were	_	_	I-Premise
257	more	_	_	I-Premise
258	frequent	_	_	I-Premise
259	with	_	_	I-Premise
260	PE	_	_	I-Premise
261	.	_	_	I-Premise

262	Patients	_	_	O
263	given	_	_	O
264	GC	_	_	O
265	received	_	_	O
266	more	_	_	O
267	chemotherapy	_	_	O
268	as	_	_	O
269	outpatients	_	_	O
270	(	_	_	O
271	89	_	_	O
272	%	_	_	O
273	GC	_	_	O
274	vs	_	_	O
275	66	_	_	O
276	%	_	_	O
277	PE	_	_	O
278	of	_	_	O
279	treatment	_	_	O
280	cycles	_	_	O
281	)	_	_	O
282	.	_	_	O

283	In	_	_	B-Premise
284	QoL	_	_	I-Premise
285	questionnaires	_	_	I-Premise
286	,	_	_	I-Premise
287	more	_	_	I-Premise
288	patients	_	_	I-Premise
289	receiving	_	_	I-Premise
290	PE	_	_	I-Premise
291	reported	_	_	I-Premise
292	being	_	_	I-Premise
293	upset	_	_	I-Premise
294	by	_	_	I-Premise
295	hair	_	_	I-Premise
296	loss	_	_	I-Premise
297	(	_	_	I-Premise
298	p	_	_	I-Premise
299	=	_	_	I-Premise
300	0	_	_	I-Premise
301	.	_	_	I-Premise

302	004	_	_	I-Premise
303	)	_	_	I-Premise
304	and	_	_	I-Premise
305	impaired	_	_	I-Premise
306	cognitive	_	_	I-Premise
307	functioning	_	_	I-Premise
308	(	_	_	I-Premise
309	p	_	_	I-Premise
310	=	_	_	I-Premise
311	0	_	_	I-Premise
312	.	_	_	I-Premise

313	04	_	_	I-Premise
314	)	_	_	I-Premise
315	.	_	_	I-Premise

316	GC	_	_	B-Claim
317	is	_	_	I-Claim
318	as	_	_	I-Claim
319	effective	_	_	I-Claim
320	as	_	_	I-Claim
321	PE	_	_	I-Claim
322	in	_	_	I-Claim
323	terms	_	_	I-Claim
324	of	_	_	I-Claim
325	overall	_	_	I-Claim
326	survival	_	_	I-Claim
327	and	_	_	I-Claim
328	progression	_	_	I-Claim
329	-	_	_	I-Claim
330	free	_	_	I-Claim
331	survival	_	_	I-Claim
332	and	_	_	I-Claim
333	has	_	_	I-Claim
334	a	_	_	I-Claim
335	toxicity	_	_	I-Claim
336	profile	_	_	I-Claim
337	more	_	_	I-Claim
338	acceptable	_	_	I-Claim
339	to	_	_	I-Claim
340	patients	_	_	I-Claim
341	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	protracted	_	_	O
3	venous	_	_	O
4	infusion	_	_	O
5	(	_	_	O
6	PVI	_	_	O
7	)	_	_	O
8	5	_	_	O
9	-	_	_	O
10	fluorouracil	_	_	O
11	(	_	_	O
12	5	_	_	O
13	-	_	_	O
14	FU	_	_	O
15	)	_	_	O
16	with	_	_	O
17	and	_	_	O
18	without	_	_	O
19	mitomycin	_	_	O
20	C	_	_	O
21	(	_	_	O
22	MMC	_	_	O
23	)	_	_	O
24	in	_	_	O
25	a	_	_	O
26	prospectively	_	_	O
27	randomised	_	_	O
28	study	_	_	O
29	and	_	_	O
30	analyse	_	_	O
31	for	_	_	O
32	tumour	_	_	O
33	response	_	_	O
34	,	_	_	O
35	survival	_	_	O
36	,	_	_	O
37	toxicity	_	_	O
38	and	_	_	O
39	quality	_	_	O
40	of	_	_	O
41	life	_	_	O
42	(	_	_	O
43	QL	_	_	O
44	)	_	_	O
45	.	_	_	O

46	Two	_	_	O
47	hundred	_	_	O
48	patients	_	_	O
49	with	_	_	O
50	advanced	_	_	O
51	colorectal	_	_	O
52	cancer	_	_	O
53	received	_	_	O
54	PVI	_	_	O
55	5	_	_	O
56	-	_	_	O
57	FU	_	_	O
58	300	_	_	O
59	mg	_	_	O
60	/	_	_	O
61	m2	_	_	O
62	/	_	_	O
63	day	_	_	O
64	for	_	_	O
65	a	_	_	O
66	maximum	_	_	O
67	of	_	_	O
68	24	_	_	O
69	weeks	_	_	O
70	and	_	_	O
71	were	_	_	O
72	randomised	_	_	O
73	to	_	_	O
74	PVI	_	_	O
75	5	_	_	O
76	-	_	_	O
77	FU	_	_	O
78	alone	_	_	O
79	or	_	_	O
80	PVI	_	_	O
81	5	_	_	O
82	-	_	_	O
83	FU	_	_	O
84	+	_	_	O
85	MMC	_	_	O
86	10	_	_	O
87	mg	_	_	O
88	/	_	_	O
89	m2	_	_	O
90	(	_	_	O
91	7	_	_	O
92	mg	_	_	O
93	/	_	_	O
94	m2	_	_	O
95	from	_	_	O
96	June	_	_	O
97	1995	_	_	O
98	)	_	_	O
99	6	_	_	O
100	weekly	_	_	O
101	for	_	_	O
102	4	_	_	O
103	courses	_	_	O
104	.	_	_	O

105	Overall	_	_	B-Premise
106	response	_	_	I-Premise
107	was	_	_	I-Premise
108	54	_	_	I-Premise
109	%	_	_	I-Premise
110	(	_	_	I-Premise
111	95	_	_	I-Premise
112	%	_	_	I-Premise
113	confidence	_	_	I-Premise
114	interval	_	_	I-Premise
115	[	_	_	I-Premise
116	CI	_	_	I-Premise
117	]	_	_	I-Premise
118	44	_	_	I-Premise
119	.	_	_	I-Premise

120	1	_	_	I-Premise
121	%	_	_	I-Premise
122	-	_	_	I-Premise
123	63	_	_	I-Premise
124	.	_	_	I-Premise

125	9	_	_	I-Premise
126	%	_	_	I-Premise
127	)	_	_	I-Premise
128	with	_	_	I-Premise
129	PVI	_	_	I-Premise
130	5	_	_	I-Premise
131	-	_	_	I-Premise
132	FU	_	_	I-Premise
133	+	_	_	I-Premise
134	MMC	_	_	I-Premise
135	compared	_	_	I-Premise
136	to	_	_	I-Premise
137	38	_	_	I-Premise
138	%	_	_	I-Premise
139	(	_	_	I-Premise
140	95	_	_	I-Premise
141	%	_	_	I-Premise
142	CI	_	_	I-Premise
143	:	_	_	I-Premise
144	28	_	_	I-Premise
145	.	_	_	I-Premise

146	3	_	_	I-Premise
147	%	_	_	I-Premise
148	-	_	_	I-Premise
149	47	_	_	I-Premise
150	.	_	_	I-Premise

151	7	_	_	I-Premise
152	%	_	_	I-Premise
153	)	_	_	I-Premise
154	for	_	_	I-Premise
155	PVI	_	_	I-Premise
156	5	_	_	I-Premise
157	-	_	_	I-Premise
158	FU	_	_	I-Premise
159	alone	_	_	I-Premise
160	(	_	_	I-Premise
161	P	_	_	I-Premise
162	=	_	_	I-Premise
163	0	_	_	I-Premise
164	.	_	_	I-Premise

165	024	_	_	I-Premise
166	)	_	_	I-Premise
167	.	_	_	I-Premise

168	The	_	_	B-Premise
169	median	_	_	I-Premise
170	failure	_	_	I-Premise
171	free	_	_	I-Premise
172	survival	_	_	I-Premise
173	was	_	_	I-Premise
174	7	_	_	I-Premise
175	.	_	_	I-Premise

176	9	_	_	I-Premise
177	months	_	_	I-Premise
178	in	_	_	I-Premise
179	PVI	_	_	I-Premise
180	5	_	_	I-Premise
181	-	_	_	I-Premise
182	FU	_	_	I-Premise
183	plus	_	_	I-Premise
184	MMC	_	_	I-Premise
185	and	_	_	I-Premise
186	5	_	_	I-Premise
187	.	_	_	I-Premise

188	4	_	_	I-Premise
189	months	_	_	I-Premise
190	with	_	_	I-Premise
191	PVI	_	_	I-Premise
192	5	_	_	I-Premise
193	-	_	_	I-Premise
194	FU	_	_	I-Premise
195	alone	_	_	I-Premise
196	(	_	_	I-Premise
197	P	_	_	I-Premise
198	=	_	_	I-Premise
199	0	_	_	I-Premise
200	.	_	_	I-Premise

201	033	_	_	I-Premise
202	)	_	_	I-Premise
203	and	_	_	I-Premise
204	at	_	_	I-Premise
205	one	_	_	I-Premise
206	year	_	_	I-Premise
207	31	_	_	I-Premise
208	.	_	_	I-Premise

209	9	_	_	I-Premise
210	%	_	_	I-Premise
211	for	_	_	I-Premise
212	the	_	_	I-Premise
213	combination	_	_	I-Premise
214	compared	_	_	I-Premise
215	to	_	_	I-Premise
216	17	_	_	I-Premise
217	.	_	_	I-Premise

218	7	_	_	I-Premise
219	%	_	_	I-Premise
220	for	_	_	I-Premise
221	PVI	_	_	I-Premise
222	5	_	_	I-Premise
223	-	_	_	I-Premise
224	FU	_	_	I-Premise
225	alone	_	_	I-Premise
226	.	_	_	I-Premise

227	Median	_	_	B-Premise
228	survival	_	_	I-Premise
229	was	_	_	I-Premise
230	14	_	_	I-Premise
231	months	_	_	I-Premise
232	with	_	_	I-Premise
233	MMC	_	_	I-Premise
234	and	_	_	I-Premise
235	15	_	_	I-Premise
236	months	_	_	I-Premise
237	in	_	_	I-Premise
238	5	_	_	I-Premise
239	-	_	_	I-Premise
240	FU	_	_	I-Premise
241	alone	_	_	I-Premise
242	;	_	_	I-Premise
243	one	_	_	I-Premise
244	-	_	_	I-Premise
245	year	_	_	I-Premise
246	survival	_	_	I-Premise
247	51	_	_	I-Premise
248	.	_	_	I-Premise

249	7	_	_	I-Premise
250	%	_	_	I-Premise
251	vs	_	_	I-Premise
252	.	_	_	I-Premise

253	57	_	_	I-Premise
254	.	_	_	I-Premise

255	2	_	_	I-Premise
256	%	_	_	I-Premise
257	.	_	_	I-Premise

258	PVI	_	_	B-Premise
259	5	_	_	I-Premise
260	-	_	_	I-Premise
261	FU	_	_	I-Premise
262	+	_	_	I-Premise
263	MMC	_	_	I-Premise
264	caused	_	_	I-Premise
265	more	_	_	I-Premise
266	overall	_	_	I-Premise
267	haematological	_	_	I-Premise
268	toxicity	_	_	I-Premise
269	but	_	_	I-Premise
270	CTC	_	_	I-Premise
271	grades	_	_	I-Premise
272	3	_	_	I-Premise
273	/	_	_	I-Premise
274	4	_	_	I-Premise
275	was	_	_	I-Premise
276	increased	_	_	I-Premise
277	only	_	_	I-Premise
278	for	_	_	I-Premise
279	thrombocytopaenia	_	_	I-Premise
280	.	_	_	I-Premise

281	Two	_	_	B-Premise
282	patients	_	_	I-Premise
283	treated	_	_	I-Premise
284	with	_	_	I-Premise
285	a	_	_	I-Premise
286	cumulative	_	_	I-Premise
287	dose	_	_	I-Premise
288	of	_	_	I-Premise
289	MMC	_	_	I-Premise
290	of	_	_	I-Premise
291	40	_	_	I-Premise
292	mg	_	_	I-Premise
293	/	_	_	I-Premise
294	m2	_	_	I-Premise
295	developed	_	_	I-Premise
296	haemolytic	_	_	I-Premise
297	uraemic	_	_	I-Premise
298	syndrome	_	_	I-Premise
299	warranting	_	_	I-Premise
300	the	_	_	I-Premise
301	reduction	_	_	I-Premise
302	in	_	_	I-Premise
303	cumulative	_	_	I-Premise
304	MMC	_	_	I-Premise
305	dose	_	_	I-Premise
306	to	_	_	I-Premise
307	28	_	_	I-Premise
308	mg	_	_	I-Premise
309	/	_	_	I-Premise
310	m2	_	_	I-Premise
311	.	_	_	I-Premise

312	The	_	_	B-Premise
313	global	_	_	I-Premise
314	QL	_	_	I-Premise
315	scores	_	_	I-Premise
316	were	_	_	I-Premise
317	better	_	_	I-Premise
318	for	_	_	I-Premise
319	PVI	_	_	I-Premise
320	5	_	_	I-Premise
321	-	_	_	I-Premise
322	FU	_	_	I-Premise
323	+	_	_	I-Premise
324	MMC	_	_	I-Premise
325	arm	_	_	I-Premise
326	at	_	_	I-Premise
327	24	_	_	I-Premise
328	weeks	_	_	I-Premise
329	,	_	_	I-Premise
330	but	_	_	B-Premise
331	the	_	_	I-Premise
332	remaining	_	_	I-Premise
333	QL	_	_	I-Premise
334	data	_	_	I-Premise
335	showed	_	_	I-Premise
336	no	_	_	I-Premise
337	differences	_	_	I-Premise
338	.	_	_	I-Premise

339	PVI	_	_	B-Claim
340	5	_	_	I-Claim
341	-	_	_	I-Claim
342	FU	_	_	I-Claim
343	+	_	_	I-Claim
344	MMC	_	_	I-Claim
345	results	_	_	I-Claim
346	in	_	_	I-Claim
347	failure	_	_	I-Claim
348	-	_	_	I-Claim
349	free	_	_	I-Claim
350	survival	_	_	I-Claim
351	and	_	_	I-Claim
352	response	_	_	I-Claim
353	advantage	_	_	I-Claim
354	,	_	_	I-Claim
355	tolerable	_	_	I-Claim
356	toxicity	_	_	I-Claim
357	and	_	_	I-Claim
358	better	_	_	I-Claim
359	QL	_	_	I-Claim
360	when	_	_	I-Claim
361	compared	_	_	I-Claim
362	to	_	_	I-Claim
363	PVI	_	_	I-Claim
364	5	_	_	I-Claim
365	-	_	_	I-Claim
366	FU	_	_	I-Claim
367	alone	_	_	I-Claim
368	but	_	_	I-Claim
369	no	_	_	I-Claim
370	overall	_	_	I-Claim
371	survival	_	_	I-Claim
372	advantage	_	_	I-Claim
373	.	_	_	I-Claim

374	There	_	_	B-Premise
375	is	_	_	I-Premise
376	no	_	_	I-Premise
377	irreversible	_	_	I-Premise
378	toxicity	_	_	I-Premise
379	with	_	_	I-Premise
380	MMC	_	_	I-Premise
381	at	_	_	I-Premise
382	a	_	_	I-Premise
383	cumulative	_	_	I-Premise
384	dose	_	_	I-Premise
385	of	_	_	I-Premise
386	28	_	_	I-Premise
387	mg	_	_	I-Premise
388	/	_	_	I-Premise
389	m2	_	_	I-Premise
390	.	_	_	I-Premise


0	To	_	_	O
1	analyze	_	_	O
2	the	_	_	O
3	predictive	_	_	O
4	value	_	_	O
5	of	_	_	O
6	PSA	_	_	O
7	for	_	_	O
8	progression	_	_	O
9	and	_	_	O
10	the	_	_	O
11	role	_	_	O
12	of	_	_	O
13	testosterone	_	_	O
14	for	_	_	O
15	quality	_	_	O
16	of	_	_	O
17	life	_	_	O
18	(	_	_	O
19	QOL	_	_	O
20	)	_	_	O
21	in	_	_	O
22	patients	_	_	O
23	with	_	_	O
24	androgen	_	_	O
25	deprivation	_	_	O
26	therapy	_	_	O
27	(	_	_	O
28	ADT	_	_	O
29	)	_	_	O
30	for	_	_	O
31	metastatic	_	_	O
32	prostate	_	_	O
33	cancer	_	_	O
34	.	_	_	O

35	PSA	_	_	O
36	and	_	_	O
37	testosterone	_	_	O
38	data	_	_	O
39	were	_	_	O
40	used	_	_	O
41	from	_	_	O
42	a	_	_	O
43	phase	_	_	O
44	III	_	_	O
45	trial	_	_	O
46	randomizing	_	_	O
47	patients	_	_	O
48	without	_	_	O
49	progression	_	_	O
50	and	_	_	O
51	PSA	_	_	O
52	<	_	_	O
53	4	_	_	O
54	ng	_	_	O
55	/	_	_	O
56	ml	_	_	O
57	(	_	_	O
58	n	_	_	O
59	=	_	_	O
60	193	_	_	O
61	)	_	_	O
62	,	_	_	O
63	after	_	_	O
64	6	_	_	O
65	months	_	_	O
66	induction	_	_	O
67	course	_	_	O
68	,	_	_	O
69	between	_	_	O
70	continuous	_	_	O
71	(	_	_	O
72	CAD	_	_	O
73	)	_	_	O
74	(	_	_	O
75	n	_	_	O
76	=	_	_	O
77	96	_	_	O
78	)	_	_	O
79	and	_	_	O
80	intermittent	_	_	O
81	(	_	_	O
82	IAD	_	_	O
83	)	_	_	O
84	(	_	_	O
85	n	_	_	O
86	=	_	_	O
87	97	_	_	O
88	)	_	_	O
89	ADT	_	_	O
90	.	_	_	O

91	The	_	_	O
92	2	_	_	O
93	-	_	_	O
94	year	_	_	O
95	risk	_	_	O
96	of	_	_	O
97	progression	_	_	O
98	was	_	_	O
99	calculated	_	_	O
100	for	_	_	O
101	baseline	_	_	O
102	PSA	_	_	O
103	,	_	_	O
104	'	_	_	O
105	fast	_	_	O
106	'	_	_	O
107	and	_	_	O
108	'	_	_	O
109	slow	_	_	O
110	'	_	_	O
111	PSA	_	_	O
112	decline	_	_	O
113	to	_	_	O
114	<	_	_	O
115	4	_	_	O
116	ng	_	_	O
117	/	_	_	O
118	ml	_	_	O
119	(	_	_	O
120	60	_	_	O
121	days	_	_	O
122	cut	_	_	O
123	-	_	_	O
124	off	_	_	O
125	)	_	_	O
126	,	_	_	O
127	PSA	_	_	O
128	nadir	_	_	O
129	,	_	_	O
130	performance	_	_	O
131	status	_	_	O
132	and	_	_	O
133	pain	_	_	O
134	.	_	_	O

135	Testosterone	_	_	O
136	kinetics	_	_	O
137	and	_	_	O
138	QOL	_	_	O
139	were	_	_	O
140	also	_	_	O
141	evaluated	_	_	O
142	.	_	_	O

143	Univariate	_	_	O
144	Kaplan	_	_	O
145	Meier	_	_	O
146	survival	_	_	O
147	analysis	_	_	O
148	and	_	_	O
149	log	_	_	O
150	rank	_	_	O
151	tests	_	_	O
152	were	_	_	O
153	used	_	_	O
154	to	_	_	O
155	compare	_	_	O
156	the	_	_	O
157	risk	_	_	O
158	of	_	_	O
159	progression	_	_	O
160	.	_	_	O

161	For	_	_	O
162	progression	_	_	O
163	analysis	_	_	O
164	,	_	_	O
165	173	_	_	O
166	patients	_	_	O
167	'	_	_	O
168	data	_	_	O
169	were	_	_	O
170	available	_	_	O
171	.	_	_	O

172	The	_	_	O
173	2	_	_	O
174	-	_	_	O
175	year	_	_	O
176	risk	_	_	O
177	of	_	_	O
178	progression	_	_	O
179	for	_	_	O
180	baseline	_	_	O
181	PSA	_	_	O
182	<	_	_	O
183	50	_	_	O
184	ng	_	_	O
185	/	_	_	O
186	ml	_	_	O
187	,	_	_	O
188	50	_	_	O
189	to	_	_	O
190	<	_	_	O
191	500	_	_	O
192	ng	_	_	O
193	/	_	_	O
194	ml	_	_	O
195	,	_	_	O
196	and	_	_	O
197	≥	_	_	O
198	500	_	_	O
199	ng	_	_	O
200	/	_	_	O
201	ml	_	_	O
202	was	_	_	O
203	25	_	_	O
204	%	_	_	O
205	,	_	_	O
206	55	_	_	O
207	%	_	_	O
208	,	_	_	O
209	and	_	_	O
210	76	_	_	O
211	%	_	_	O
212	(	_	_	O
213	P	_	_	O
214	=	_	_	O
215	0	_	_	O
216	.	_	_	O

217	03	_	_	O
218	)	_	_	O
219	in	_	_	O
220	CAD	_	_	O
221	,	_	_	O
222	and	_	_	O
223	38	_	_	O
224	%	_	_	O
225	,	_	_	O
226	64	_	_	O
227	%	_	_	O
228	,	_	_	O
229	and	_	_	O
230	85	_	_	O
231	%	_	_	O
232	(	_	_	O
233	P	_	_	O
234	=	_	_	O
235	0	_	_	O
236	.	_	_	O

237	006	_	_	O
238	)	_	_	O
239	in	_	_	O
240	IAD	_	_	O
241	,	_	_	O
242	respectively	_	_	O
243	.	_	_	O

244	The	_	_	B-Premise
245	2	_	_	I-Premise
246	-	_	_	I-Premise
247	year	_	_	I-Premise
248	risk	_	_	I-Premise
249	of	_	_	I-Premise
250	progression	_	_	I-Premise
251	for	_	_	I-Premise
252	PSA	_	_	I-Premise
253	nadir	_	_	I-Premise
254	≤	_	_	I-Premise
255	0	_	_	I-Premise
256	.	_	_	I-Premise

257	2	_	_	I-Premise
258	ng	_	_	I-Premise
259	/	_	_	I-Premise
260	ml	_	_	I-Premise
261	,	_	_	I-Premise
262	and	_	_	I-Premise
263	>	_	_	I-Premise
264	0	_	_	I-Premise
265	.	_	_	I-Premise

266	2	_	_	I-Premise
267	to	_	_	I-Premise
268	4	_	_	I-Premise
269	ng	_	_	I-Premise
270	/	_	_	I-Premise
271	ml	_	_	I-Premise
272	in	_	_	I-Premise
273	CAD	_	_	I-Premise
274	was	_	_	I-Premise
275	31	_	_	I-Premise
276	%	_	_	I-Premise
277	and	_	_	I-Premise
278	70	_	_	I-Premise
279	%	_	_	I-Premise
280	(	_	_	I-Premise
281	P	_	_	I-Premise
282	<	_	_	I-Premise
283	0	_	_	I-Premise
284	.	_	_	I-Premise

285	001	_	_	I-Premise
286	)	_	_	I-Premise
287	,	_	_	I-Premise
288	respectively	_	_	I-Premise
289	.	_	_	I-Premise

290	In	_	_	B-Premise
291	the	_	_	I-Premise
292	IAD	_	_	I-Premise
293	group	_	_	I-Premise
294	,	_	_	I-Premise
295	a	_	_	I-Premise
296	similar	_	_	I-Premise
297	trend	_	_	I-Premise
298	was	_	_	I-Premise
299	seen	_	_	I-Premise
300	.	_	_	I-Premise

301	Patients	_	_	B-Premise
302	with	_	_	I-Premise
303	PSA	_	_	I-Premise
304	nadir	_	_	I-Premise
305	≤	_	_	I-Premise
306	0	_	_	I-Premise
307	.	_	_	I-Premise

308	2	_	_	I-Premise
309	ng	_	_	I-Premise
310	/	_	_	I-Premise
311	ml	_	_	I-Premise
312	,	_	_	I-Premise
313	though	_	_	I-Premise
314	had	_	_	I-Premise
315	significantly	_	_	I-Premise
316	higher	_	_	I-Premise
317	2	_	_	I-Premise
318	-	_	_	I-Premise
319	year	_	_	I-Premise
320	risk	_	_	I-Premise
321	of	_	_	I-Premise
322	progression	_	_	I-Premise
323	compared	_	_	I-Premise
324	to	_	_	I-Premise
325	CAD	_	_	I-Premise
326	(	_	_	I-Premise
327	53	_	_	I-Premise
328	%	_	_	I-Premise
329	vs	_	_	I-Premise
330	.	_	_	I-Premise

331	31	_	_	I-Premise
332	%	_	_	I-Premise
333	(	_	_	I-Premise
334	P	_	_	I-Premise
335	=	_	_	I-Premise
336	0	_	_	I-Premise
337	.	_	_	I-Premise

338	03	_	_	I-Premise
339	)	_	_	I-Premise
340	,	_	_	I-Premise
341	respectively	_	_	I-Premise
342	.	_	_	I-Premise

343	PSA	_	_	O
344	decline	_	_	O
345	showed	_	_	O
346	no	_	_	O
347	predictive	_	_	O
348	value	_	_	O
349	.	_	_	O

350	Patients	_	_	B-Premise
351	without	_	_	I-Premise
352	pain	_	_	I-Premise
353	had	_	_	I-Premise
354	a	_	_	I-Premise
355	significantly	_	_	I-Premise
356	lower	_	_	I-Premise
357	2	_	_	I-Premise
358	-	_	_	I-Premise
359	year	_	_	I-Premise
360	risk	_	_	I-Premise
361	of	_	_	I-Premise
362	progression	_	_	I-Premise
363	in	_	_	I-Premise
364	both	_	_	I-Premise
365	groups	_	_	I-Premise
366	.	_	_	I-Premise

367	Without	_	_	B-Premise
368	ADT	_	_	I-Premise
369	testosterone	_	_	I-Premise
370	remained	_	_	I-Premise
371	at	_	_	I-Premise
372	castrate	_	_	I-Premise
373	level	_	_	I-Premise
374	for	_	_	I-Premise
375	4	_	_	I-Premise
376	months	_	_	I-Premise
377	.	_	_	I-Premise

378	After	_	_	O
379	the	_	_	O
380	first	_	_	O
381	and	_	_	O
382	second	_	_	O
383	IAD	_	_	O
384	cycle	_	_	O
385	92	_	_	O
386	%	_	_	O
387	and	_	_	O
388	46	_	_	O
389	%	_	_	O
390	,	_	_	O
391	respectively	_	_	O
392	,	_	_	O
393	had	_	_	O
394	a	_	_	O
395	normalized	_	_	O
396	testosterone	_	_	O
397	.	_	_	O

398	No	_	_	B-Premise
399	QOL	_	_	I-Premise
400	difference	_	_	I-Premise
401	was	_	_	I-Premise
402	found	_	_	I-Premise
403	,	_	_	I-Premise
404	although	_	_	I-Premise
405	more	_	_	I-Premise
406	side	_	_	I-Premise
407	effects	_	_	I-Premise
408	occurred	_	_	I-Premise
409	in	_	_	I-Premise
410	CAD	_	_	I-Premise
411	.	_	_	I-Premise

412	Metastatic	_	_	B-Claim
413	prostate	_	_	I-Claim
414	cancer	_	_	I-Claim
415	patients	_	_	I-Claim
416	with	_	_	I-Claim
417	high	_	_	I-Claim
418	baseline	_	_	I-Claim
419	PSA	_	_	I-Claim
420	,	_	_	I-Claim
421	pain	_	_	I-Claim
422	,	_	_	I-Claim
423	and	_	_	I-Claim
424	high	_	_	I-Claim
425	PSA	_	_	I-Claim
426	nadir	_	_	I-Claim
427	have	_	_	I-Claim
428	a	_	_	I-Claim
429	poor	_	_	I-Claim
430	prognosis	_	_	I-Claim
431	with	_	_	I-Claim
432	ADT	_	_	I-Claim
433	.	_	_	I-Claim

434	Patients	_	_	B-Claim
435	with	_	_	I-Claim
436	low	_	_	I-Claim
437	PSA	_	_	I-Claim
438	nadir	_	_	I-Claim
439	do	_	_	I-Claim
440	significantly	_	_	I-Claim
441	worse	_	_	I-Claim
442	with	_	_	I-Claim
443	IAD	_	_	I-Claim
444	compared	_	_	I-Claim
445	with	_	_	I-Claim
446	CAD	_	_	I-Claim
447	.	_	_	I-Claim

448	Low	_	_	O
449	testosterone	_	_	O
450	after	_	_	O
451	ADT	_	_	O
452	and	_	_	O
453	incomplete	_	_	O
454	testosterone	_	_	O
455	recovery	_	_	O
456	may	_	_	O
457	explain	_	_	O
458	similar	_	_	O
459	QOL	_	_	O
460	.	_	_	O

461	Therefore	_	_	O
462	,	_	_	O
463	IAD	_	_	B-Claim
464	is	_	_	I-Claim
465	not	_	_	I-Claim
466	a	_	_	I-Claim
467	good	_	_	I-Claim
468	treatment	_	_	I-Claim
469	option	_	_	I-Claim
470	for	_	_	I-Claim
471	many	_	_	I-Claim
472	metastatic	_	_	I-Claim
473	prostate	_	_	I-Claim
474	cancer	_	_	I-Claim
475	patients	_	_	I-Claim
476	.	_	_	I-Claim


0	N	_	_	O
1	,	_	_	O
2	N	_	_	O
3	-	_	_	O
4	diethyl	_	_	O
5	-	_	_	O
6	2	_	_	O
7	-	_	_	O
8	[	_	_	O
9	4	_	_	O
10	-	_	_	O
11	(	_	_	O
12	phenylmethyl	_	_	O
13	)	_	_	O
14	phenoxy	_	_	O
15	]	_	_	O
16	ethanamine	_	_	O
17	(	_	_	O
18	DPPE	_	_	O
19	;	_	_	O
20	tesmilifene	_	_	O
21	)	_	_	O
22	is	_	_	O
23	a	_	_	O
24	novel	_	_	O
25	agent	_	_	O
26	that	_	_	O
27	augments	_	_	O
28	chemotherapy	_	_	O
29	cytotoxicity	_	_	O
30	in	_	_	O
31	vitro	_	_	O
32	and	_	_	O
33	in	_	_	O
34	vivo	_	_	O
35	.	_	_	O

36	A	_	_	O
37	phase	_	_	O
38	II	_	_	O
39	trial	_	_	O
40	combining	_	_	O
41	DPPE	_	_	O
42	and	_	_	O
43	doxorubicin	_	_	O
44	(	_	_	O
45	DOX	_	_	O
46	)	_	_	O
47	in	_	_	O
48	metastatic	_	_	O
49	breast	_	_	O
50	carcinoma	_	_	O
51	showed	_	_	O
52	increased	_	_	O
53	response	_	_	O
54	over	_	_	O
55	that	_	_	O
56	expected	_	_	O
57	with	_	_	O
58	DOX	_	_	O
59	.	_	_	O

60	We	_	_	O
61	report	_	_	O
62	a	_	_	O
63	phase	_	_	O
64	III	_	_	O
65	trial	_	_	O
66	comparing	_	_	O
67	DOX	_	_	O
68	with	_	_	O
69	DPPE	_	_	O
70	plus	_	_	O
71	DOX	_	_	O
72	in	_	_	O
73	metastatic	_	_	O
74	or	_	_	O
75	recurrent	_	_	O
76	breast	_	_	O
77	cancer	_	_	O
78	.	_	_	O

79	Anthracycline	_	_	O
80	-	_	_	O
81	naive	_	_	O
82	women	_	_	O
83	with	_	_	O
84	measurable	_	_	O
85	metastatic	_	_	O
86	disease	_	_	O
87	were	_	_	O
88	randomly	_	_	O
89	assigned	_	_	O
90	to	_	_	O
91	receive	_	_	O
92	,	_	_	O
93	every	_	_	O
94	21	_	_	O
95	days	_	_	O
96	,	_	_	O
97	either	_	_	O
98	DOX	_	_	O
99	60	_	_	O
100	mg	_	_	O
101	/	_	_	O
102	m	_	_	O
103	(	_	_	O
104	2	_	_	O
105	)	_	_	O
106	intravenously	_	_	O
107	or	_	_	O
108	DOX	_	_	O
109	during	_	_	O
110	the	_	_	O
111	last	_	_	O
112	20	_	_	O
113	minutes	_	_	O
114	of	_	_	O
115	an	_	_	O
116	80	_	_	O
117	-	_	_	O
118	minute	_	_	O
119	infusion	_	_	O
120	of	_	_	O
121	DPPE	_	_	O
122	(	_	_	O
123	5	_	_	O
124	.	_	_	O

125	3	_	_	O
126	mg	_	_	O
127	/	_	_	O
128	kg	_	_	O
129	)	_	_	O
130	,	_	_	O
131	in	_	_	O
132	both	_	_	O
133	cases	_	_	O
134	to	_	_	O
135	cumulative	_	_	O
136	DOX	_	_	O
137	doses	_	_	O
138	of	_	_	O
139	450	_	_	O
140	mg	_	_	O
141	/	_	_	O
142	m	_	_	O
143	(	_	_	O
144	2	_	_	O
145	)	_	_	O
146	.	_	_	O

147	Patients	_	_	O
148	receiving	_	_	O
149	DPPE	_	_	O
150	were	_	_	O
151	aggressively	_	_	O
152	premedicated	_	_	O
153	to	_	_	O
154	ameliorate	_	_	O
155	toxicity	_	_	O
156	.	_	_	O

157	End	_	_	O
158	points	_	_	O
159	included	_	_	O
160	progression	_	_	O
161	-	_	_	O
162	free	_	_	O
163	survival	_	_	O
164	(	_	_	O
165	PFS	_	_	O
166	)	_	_	O
167	,	_	_	O
168	response	_	_	O
169	rate	_	_	O
170	(	_	_	O
171	RR	_	_	O
172	)	_	_	O
173	,	_	_	O
174	and	_	_	O
175	response	_	_	O
176	duration	_	_	O
177	(	_	_	O
178	RD	_	_	O
179	)	_	_	O
180	,	_	_	O
181	quality	_	_	O
182	of	_	_	O
183	life	_	_	O
184	(	_	_	O
185	QOL	_	_	O
186	)	_	_	O
187	,	_	_	O
188	toxicity	_	_	O
189	,	_	_	O
190	and	_	_	O
191	overall	_	_	O
192	survival	_	_	O
193	(	_	_	O
194	OS	_	_	O
195	)	_	_	O
196	.	_	_	O

197	A	_	_	O
198	planned	_	_	O
199	interim	_	_	O
200	analysis	_	_	O
201	failed	_	_	O
202	to	_	_	O
203	detect	_	_	O
204	an	_	_	O
205	RR	_	_	O
206	difference	_	_	O
207	more	_	_	O
208	than	_	_	O
209	5	_	_	O
210	%	_	_	O
211	.	_	_	O

212	The	_	_	O
213	study	_	_	O
214	was	_	_	O
215	closed	_	_	O
216	to	_	_	O
217	additional	_	_	O
218	accrual	_	_	O
219	and	_	_	O
220	all	_	_	O
221	DPPE	_	_	O
222	was	_	_	O
223	discontinued	_	_	O
224	.	_	_	O

225	The	_	_	O
226	final	_	_	O
227	analysis	_	_	O
228	was	_	_	O
229	conducted	_	_	O
230	as	_	_	O
231	planned	_	_	O
232	after	_	_	O
233	256	_	_	O
234	progression	_	_	O
235	events	_	_	O
236	(	_	_	O
237	median	_	_	O
238	follow	_	_	O
239	-	_	_	O
240	up	_	_	O
241	,	_	_	O
242	20	_	_	O
243	.	_	_	O

244	5	_	_	O
245	months	_	_	O
246	)	_	_	O
247	.	_	_	O

248	There	_	_	B-Premise
249	was	_	_	I-Premise
250	no	_	_	I-Premise
251	significant	_	_	I-Premise
252	difference	_	_	I-Premise
253	in	_	_	I-Premise
254	RR	_	_	I-Premise
255	,	_	_	I-Premise
256	RD	_	_	I-Premise
257	,	_	_	I-Premise
258	or	_	_	I-Premise
259	PFS	_	_	I-Premise
260	between	_	_	I-Premise
261	arms	_	_	I-Premise
262	.	_	_	I-Premise

263	DPPE	_	_	B-Premise
264	plus	_	_	I-Premise
265	DOX	_	_	I-Premise
266	was	_	_	I-Premise
267	statistically	_	_	I-Premise
268	superior	_	_	I-Premise
269	to	_	_	I-Premise
270	DOX	_	_	I-Premise
271	in	_	_	I-Premise
272	OS	_	_	I-Premise
273	(	_	_	I-Premise
274	hazard	_	_	I-Premise
275	ratio	_	_	I-Premise
276	,	_	_	I-Premise
277	0	_	_	I-Premise
278	.	_	_	I-Premise

279	66	_	_	I-Premise
280	;	_	_	I-Premise
281	95	_	_	I-Premise
282	%	_	_	I-Premise
283	CI	_	_	I-Premise
284	,	_	_	I-Premise
285	0	_	_	I-Premise
286	.	_	_	I-Premise

287	48	_	_	I-Premise
288	to	_	_	I-Premise
289	0	_	_	I-Premise
290	.	_	_	I-Premise

291	91	_	_	I-Premise
292	;	_	_	I-Premise
293	P	_	_	I-Premise
294	=	_	_	I-Premise
295	.	_	_	I-Premise

296	021	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	DPPE	_	_	B-Premise
300	plus	_	_	I-Premise
301	DOX	_	_	I-Premise
302	was	_	_	I-Premise
303	associated	_	_	I-Premise
304	with	_	_	I-Premise
305	more	_	_	I-Premise
306	gastrointestinal	_	_	I-Premise
307	and	_	_	I-Premise
308	CNS	_	_	I-Premise
309	toxicity	_	_	I-Premise
310	.	_	_	I-Premise

311	No	_	_	B-Premise
312	consistent	_	_	I-Premise
313	influence	_	_	I-Premise
314	on	_	_	I-Premise
315	QOL	_	_	I-Premise
316	was	_	_	I-Premise
317	detected	_	_	I-Premise
318	.	_	_	I-Premise

319	This	_	_	B-Claim
320	study	_	_	I-Claim
321	demonstrated	_	_	I-Claim
322	no	_	_	I-Claim
323	advantage	_	_	I-Claim
324	in	_	_	I-Claim
325	RR	_	_	I-Claim
326	,	_	_	I-Claim
327	RD	_	_	I-Claim
328	,	_	_	I-Claim
329	or	_	_	I-Claim
330	PFS	_	_	I-Claim
331	but	_	_	I-Claim
332	significantly	_	_	I-Claim
333	superior	_	_	I-Claim
334	OS	_	_	I-Claim
335	for	_	_	I-Claim
336	DPPE	_	_	I-Claim
337	plus	_	_	I-Claim
338	DOX	_	_	I-Claim
339	.	_	_	I-Claim

340	Additional	_	_	B-Claim
341	studies	_	_	I-Claim
342	of	_	_	I-Claim
343	DPPE	_	_	I-Claim
344	are	_	_	I-Claim
345	warranted	_	_	I-Claim
346	.	_	_	I-Claim


0	This	_	_	O
1	is	_	_	O
2	a	_	_	O
3	randomized	_	_	O
4	phase	_	_	O
5	II	_	_	O
6	study	_	_	O
7	designed	_	_	O
8	to	_	_	O
9	compare	_	_	O
10	the	_	_	O
11	toxicity	_	_	O
12	profile	_	_	O
13	of	_	_	O
14	a	_	_	O
15	non	_	_	O
16	-	_	_	O
17	platinum	_	_	O
18	-	_	_	O
19	based	_	_	O
20	with	_	_	O
21	a	_	_	O
22	platinum	_	_	O
23	-	_	_	O
24	based	_	_	O
25	regimen	_	_	O
26	in	_	_	O
27	the	_	_	O
28	treatment	_	_	O
29	of	_	_	O
30	advanced	_	_	O
31	non	_	_	O
32	-	_	_	O
33	small	_	_	O
34	cell	_	_	O
35	lung	_	_	O
36	cancer	_	_	O
37	.	_	_	O

38	Eighty	_	_	O
39	-	_	_	O
40	nine	_	_	O
41	chemotherapy	_	_	O
42	-	_	_	O
43	naïve	_	_	O
44	patients	_	_	O
45	were	_	_	O
46	randomized	_	_	O
47	either	_	_	O
48	to	_	_	O
49	gemcitabine	_	_	O
50	(	_	_	O
51	1	_	_	O
52	,	_	_	O
53	000	_	_	O
54	mg	_	_	O
55	/	_	_	O
56	m2	_	_	O
57	,	_	_	O
58	30	_	_	O
59	-	_	_	O
60	min	_	_	O
61	infusion	_	_	O
62	on	_	_	O
63	days	_	_	O
64	1	_	_	O
65	,	_	_	O
66	8	_	_	O
67	and	_	_	O
68	15	_	_	O
69	)	_	_	O
70	and	_	_	O
71	oral	_	_	O
72	etoposide	_	_	O
73	(	_	_	O
74	50	_	_	O
75	mg	_	_	O
76	,	_	_	O
77	days	_	_	O
78	1	_	_	O
79	-	_	_	O
80	14	_	_	O
81	;	_	_	O
82	GE	_	_	O
83	group	_	_	O
84	)	_	_	O
85	or	_	_	O
86	gemcitabine	_	_	O
87	at	_	_	O
88	the	_	_	O
89	same	_	_	O
90	schedule	_	_	O
91	and	_	_	O
92	cisplatin	_	_	O
93	(	_	_	O
94	75	_	_	O
95	mg	_	_	O
96	/	_	_	O
97	m2	_	_	O
98	on	_	_	O
99	day	_	_	O
100	15	_	_	O
101	;	_	_	O
102	GP	_	_	O
103	group	_	_	O
104	)	_	_	O
105	.	_	_	O

106	The	_	_	O
107	primary	_	_	O
108	endpoint	_	_	O
109	is	_	_	O
110	toxicity	_	_	O
111	,	_	_	O
112	and	_	_	O
113	secondary	_	_	O
114	endpoints	_	_	O
115	include	_	_	O
116	response	_	_	O
117	rate	_	_	O
118	,	_	_	O
119	survival	_	_	O
120	outcome	_	_	O
121	and	_	_	O
122	quality	_	_	O
123	of	_	_	O
124	life	_	_	O
125	(	_	_	O
126	QOL	_	_	O
127	)	_	_	O
128	.	_	_	O

129	The	_	_	B-Premise
130	incidence	_	_	I-Premise
131	of	_	_	I-Premise
132	WHO	_	_	I-Premise
133	grade	_	_	I-Premise
134	3	_	_	I-Premise
135	or	_	_	I-Premise
136	4	_	_	I-Premise
137	anemia	_	_	I-Premise
138	,	_	_	I-Premise
139	neutropenia	_	_	I-Premise
140	and	_	_	I-Premise
141	thrombocytopenia	_	_	I-Premise
142	was	_	_	I-Premise
143	29	_	_	I-Premise
144	,	_	_	I-Premise
145	44	_	_	I-Premise
146	and	_	_	I-Premise
147	22	_	_	I-Premise
148	%	_	_	I-Premise
149	(	_	_	I-Premise
150	GE	_	_	I-Premise
151	group	_	_	I-Premise
152	)	_	_	I-Premise
153	,	_	_	I-Premise
154	and	_	_	I-Premise
155	28	_	_	I-Premise
156	,	_	_	I-Premise
157	49	_	_	I-Premise
158	and	_	_	I-Premise
159	23	_	_	I-Premise
160	%	_	_	I-Premise
161	(	_	_	I-Premise
162	GP	_	_	I-Premise
163	group	_	_	I-Premise
164	)	_	_	I-Premise
165	,	_	_	I-Premise
166	respectively	_	_	I-Premise
167	(	_	_	I-Premise
168	p	_	_	I-Premise
169	=	_	_	I-Premise
170	0	_	_	I-Premise
171	.	_	_	I-Premise

172	75	_	_	I-Premise
173	,	_	_	I-Premise
174	0	_	_	I-Premise
175	.	_	_	I-Premise

176	95	_	_	I-Premise
177	and	_	_	I-Premise
178	0	_	_	I-Premise
179	.	_	_	I-Premise

180	87	_	_	I-Premise
181	,	_	_	I-Premise
182	respectively	_	_	I-Premise
183	)	_	_	I-Premise
184	.	_	_	I-Premise

185	The	_	_	B-Premise
186	rate	_	_	I-Premise
187	of	_	_	I-Premise
188	grade	_	_	I-Premise
189	2	_	_	I-Premise
190	or	_	_	I-Premise
191	above	_	_	I-Premise
192	nausea	_	_	I-Premise
193	was	_	_	I-Premise
194	numerically	_	_	I-Premise
195	higher	_	_	I-Premise
196	in	_	_	I-Premise
197	the	_	_	I-Premise
198	GP	_	_	I-Premise
199	arm	_	_	I-Premise
200	,	_	_	I-Premise
201	but	_	_	B-Premise
202	the	_	_	I-Premise
203	difference	_	_	I-Premise
204	was	_	_	I-Premise
205	not	_	_	I-Premise
206	statistically	_	_	I-Premise
207	significant	_	_	I-Premise
208	(	_	_	I-Premise
209	GE	_	_	I-Premise
210	15	_	_	I-Premise
211	.	_	_	I-Premise

212	5	_	_	I-Premise
213	%	_	_	I-Premise
214	,	_	_	I-Premise
215	GP	_	_	I-Premise
216	27	_	_	I-Premise
217	.	_	_	I-Premise

218	7	_	_	I-Premise
219	%	_	_	I-Premise
220	,	_	_	I-Premise
221	p	_	_	I-Premise
222	=	_	_	I-Premise
223	0	_	_	I-Premise
224	.	_	_	I-Premise

225	20	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	The	_	_	B-Premise
229	rate	_	_	I-Premise
230	of	_	_	I-Premise
231	vomiting	_	_	I-Premise
232	in	_	_	I-Premise
233	the	_	_	I-Premise
234	GE	_	_	I-Premise
235	and	_	_	I-Premise
236	GP	_	_	I-Premise
237	arms	_	_	I-Premise
238	was	_	_	I-Premise
239	20	_	_	I-Premise
240	.	_	_	I-Premise

241	0	_	_	I-Premise
242	and	_	_	I-Premise
243	20	_	_	I-Premise
244	.	_	_	I-Premise

245	5	_	_	I-Premise
246	%	_	_	I-Premise
247	,	_	_	I-Premise
248	respectively	_	_	I-Premise
249	(	_	_	I-Premise
250	p	_	_	I-Premise
251	=	_	_	I-Premise
252	0	_	_	I-Premise
253	.	_	_	I-Premise

254	96	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	However	_	_	B-Premise
258	,	_	_	I-Premise
259	subjective	_	_	I-Premise
260	changes	_	_	I-Premise
261	in	_	_	I-Premise
262	QOL	_	_	I-Premise
263	scores	_	_	I-Premise
264	on	_	_	I-Premise
265	nausea	_	_	I-Premise
266	and	_	_	I-Premise
267	vomiting	_	_	I-Premise
268	were	_	_	I-Premise
269	significantly	_	_	I-Premise
270	higher	_	_	I-Premise
271	in	_	_	I-Premise
272	the	_	_	I-Premise
273	GP	_	_	I-Premise
274	arm	_	_	I-Premise
275	(	_	_	I-Premise
276	p	_	_	I-Premise
277	=	_	_	I-Premise
278	0	_	_	I-Premise
279	.	_	_	I-Premise

280	001	_	_	I-Premise
281	)	_	_	I-Premise
282	.	_	_	I-Premise

283	Other	_	_	B-Premise
284	symptoms	_	_	I-Premise
285	including	_	_	I-Premise
286	sore	_	_	I-Premise
287	mouth	_	_	I-Premise
288	and	_	_	I-Premise
289	hair	_	_	I-Premise
290	loss	_	_	I-Premise
291	were	_	_	I-Premise
292	significantly	_	_	I-Premise
293	higher	_	_	I-Premise
294	in	_	_	I-Premise
295	the	_	_	I-Premise
296	GE	_	_	I-Premise
297	arm	_	_	I-Premise
298	(	_	_	I-Premise
299	p	_	_	I-Premise
300	=	_	_	I-Premise
301	0	_	_	I-Premise
302	.	_	_	I-Premise

303	003	_	_	I-Premise
304	and	_	_	I-Premise
305	0	_	_	I-Premise
306	.	_	_	I-Premise

307	007	_	_	I-Premise
308	,	_	_	I-Premise
309	respectively	_	_	I-Premise
310	)	_	_	I-Premise
311	.	_	_	I-Premise

312	There	_	_	B-Premise
313	were	_	_	I-Premise
314	also	_	_	I-Premise
315	significant	_	_	I-Premise
316	differences	_	_	I-Premise
317	observed	_	_	I-Premise
318	in	_	_	I-Premise
319	emotional	_	_	I-Premise
320	(	_	_	I-Premise
321	p	_	_	I-Premise
322	=	_	_	I-Premise
323	0	_	_	I-Premise
324	.	_	_	I-Premise

325	014	_	_	I-Premise
326	)	_	_	I-Premise
327	,	_	_	I-Premise
328	cognitive	_	_	I-Premise
329	(	_	_	I-Premise
330	p	_	_	I-Premise
331	=	_	_	I-Premise
332	0	_	_	I-Premise
333	.	_	_	I-Premise

334	028	_	_	I-Premise
335	)	_	_	I-Premise
336	and	_	_	I-Premise
337	social	_	_	I-Premise
338	functioning	_	_	I-Premise
339	(	_	_	I-Premise
340	p	_	_	I-Premise
341	=	_	_	I-Premise
342	0	_	_	I-Premise
343	.	_	_	I-Premise

344	034	_	_	I-Premise
345	)	_	_	I-Premise
346	in	_	_	I-Premise
347	favor	_	_	I-Premise
348	of	_	_	I-Premise
349	GP	_	_	I-Premise
350	.	_	_	I-Premise

351	The	_	_	B-Premise
352	differences	_	_	I-Premise
353	in	_	_	I-Premise
354	tumor	_	_	I-Premise
355	response	_	_	I-Premise
356	(	_	_	I-Premise
357	35	_	_	I-Premise
358	.	_	_	I-Premise

359	5	_	_	I-Premise
360	and	_	_	I-Premise
361	46	_	_	I-Premise
362	.	_	_	I-Premise

363	5	_	_	I-Premise
364	%	_	_	I-Premise
365	for	_	_	I-Premise
366	GE	_	_	I-Premise
367	and	_	_	I-Premise
368	GP	_	_	I-Premise
369	,	_	_	I-Premise
370	respectively	_	_	I-Premise
371	)	_	_	I-Premise
372	were	_	_	I-Premise
373	not	_	_	I-Premise
374	significantly	_	_	I-Premise
375	different	_	_	I-Premise
376	.	_	_	I-Premise

377	Median	_	_	B-Premise
378	time	_	_	I-Premise
379	to	_	_	I-Premise
380	disease	_	_	I-Premise
381	progression	_	_	I-Premise
382	(	_	_	I-Premise
383	33	_	_	I-Premise
384	.	_	_	I-Premise

385	8	_	_	I-Premise
386	and	_	_	I-Premise
387	40	_	_	I-Premise
388	.	_	_	I-Premise

389	7	_	_	I-Premise
390	weeks	_	_	I-Premise
391	,	_	_	I-Premise
392	respectively	_	_	I-Premise
393	)	_	_	I-Premise
394	and	_	_	I-Premise
395	overall	_	_	I-Premise
396	survival	_	_	I-Premise
397	(	_	_	I-Premise
398	41	_	_	I-Premise
399	.	_	_	I-Premise

400	4	_	_	I-Premise
401	and	_	_	I-Premise
402	57	_	_	I-Premise
403	.	_	_	I-Premise

404	3	_	_	I-Premise
405	weeks	_	_	I-Premise
406	,	_	_	I-Premise
407	respectively	_	_	I-Premise
408	)	_	_	I-Premise
409	were	_	_	I-Premise
410	of	_	_	I-Premise
411	borderline	_	_	I-Premise
412	significance	_	_	I-Premise
413	in	_	_	I-Premise
414	favor	_	_	I-Premise
415	of	_	_	I-Premise
416	the	_	_	I-Premise
417	GP	_	_	I-Premise
418	arm	_	_	I-Premise
419	(	_	_	I-Premise
420	p	_	_	I-Premise
421	=	_	_	I-Premise
422	0	_	_	I-Premise
423	.	_	_	I-Premise

424	055	_	_	I-Premise
425	)	_	_	I-Premise
426	.	_	_	I-Premise

427	This	_	_	B-Claim
428	toxicity	_	_	I-Claim
429	profile	_	_	I-Claim
430	of	_	_	I-Claim
431	GE	_	_	I-Claim
432	is	_	_	I-Claim
433	similar	_	_	I-Claim
434	to	_	_	I-Claim
435	GP	_	_	I-Claim
436	,	_	_	I-Claim
437	but	_	_	B-Claim
438	the	_	_	I-Claim
439	apparent	_	_	I-Claim
440	inferior	_	_	I-Claim
441	efficacy	_	_	I-Claim
442	may	_	_	I-Claim
443	discourage	_	_	I-Claim
444	further	_	_	I-Claim
445	investigation	_	_	I-Claim
446	.	_	_	O


0	Prior	_	_	O
1	studies	_	_	O
2	have	_	_	O
3	suggested	_	_	O
4	that	_	_	O
5	melatonin	_	_	O
6	,	_	_	O
7	a	_	_	O
8	frequently	_	_	O
9	used	_	_	O
10	integrative	_	_	O
11	medicine	_	_	O
12	,	_	_	O
13	can	_	_	O
14	attenuate	_	_	O
15	weight	_	_	O
16	loss	_	_	O
17	,	_	_	O
18	anorexia	_	_	O
19	,	_	_	O
20	and	_	_	O
21	fatigue	_	_	O
22	in	_	_	O
23	patients	_	_	O
24	with	_	_	O
25	cancer	_	_	O
26	.	_	_	O

27	These	_	_	O
28	studies	_	_	O
29	were	_	_	O
30	limited	_	_	O
31	by	_	_	O
32	a	_	_	O
33	lack	_	_	O
34	of	_	_	O
35	blinding	_	_	O
36	and	_	_	O
37	absence	_	_	O
38	of	_	_	O
39	placebo	_	_	O
40	controls	_	_	O
41	.	_	_	O

42	The	_	_	O
43	primary	_	_	O
44	purpose	_	_	O
45	of	_	_	O
46	this	_	_	O
47	study	_	_	O
48	was	_	_	O
49	to	_	_	O
50	compare	_	_	O
51	melatonin	_	_	O
52	with	_	_	O
53	placebo	_	_	O
54	for	_	_	O
55	appetite	_	_	O
56	improvement	_	_	O
57	in	_	_	O
58	patients	_	_	O
59	with	_	_	O
60	cancer	_	_	O
61	cachexia	_	_	O
62	.	_	_	O

63	We	_	_	O
64	performed	_	_	O
65	a	_	_	O
66	randomized	_	_	O
67	,	_	_	O
68	double	_	_	O
69	-	_	_	O
70	blind	_	_	O
71	,	_	_	O
72	28	_	_	O
73	-	_	_	O
74	day	_	_	O
75	trial	_	_	O
76	of	_	_	O
77	melatonin	_	_	O
78	20	_	_	O
79	mg	_	_	O
80	versus	_	_	O
81	placebo	_	_	O
82	in	_	_	O
83	patients	_	_	O
84	with	_	_	O
85	advanced	_	_	O
86	lung	_	_	O
87	or	_	_	O
88	GI	_	_	O
89	cancer	_	_	O
90	,	_	_	O
91	appetite	_	_	O
92	scores	_	_	O
93	≥	_	_	O
94	4	_	_	O
95	on	_	_	O
96	a	_	_	O
97	0	_	_	O
98	to	_	_	O
99	10	_	_	O
100	scale	_	_	O
101	(	_	_	O
102	10	_	_	O
103	=	_	_	O
104	worst	_	_	O
105	appetite	_	_	O
106	)	_	_	O
107	,	_	_	O
108	and	_	_	O
109	history	_	_	O
110	of	_	_	O
111	weight	_	_	O
112	loss	_	_	O
113	≥	_	_	O
114	5	_	_	O
115	%	_	_	O
116	.	_	_	O

117	Assessments	_	_	O
118	included	_	_	O
119	weight	_	_	O
120	,	_	_	O
121	symptoms	_	_	O
122	by	_	_	O
123	the	_	_	O
124	Edmonton	_	_	O
125	Symptom	_	_	O
126	Assessment	_	_	O
127	Scale	_	_	O
128	,	_	_	O
129	and	_	_	O
130	quality	_	_	O
131	of	_	_	O
132	life	_	_	O
133	by	_	_	O
134	the	_	_	O
135	Functional	_	_	O
136	Assessment	_	_	O
137	of	_	_	O
138	Anorexia	_	_	O
139	/	_	_	O
140	Cachexia	_	_	O
141	Therapy	_	_	O
142	(	_	_	O
143	FAACT	_	_	O
144	)	_	_	O
145	questionnaire	_	_	O
146	.	_	_	O

147	Differences	_	_	O
148	between	_	_	O
149	groups	_	_	O
150	from	_	_	O
151	baseline	_	_	O
152	to	_	_	O
153	day	_	_	O
154	28	_	_	O
155	were	_	_	O
156	analyzed	_	_	O
157	using	_	_	O
158	one	_	_	O
159	-	_	_	O
160	sided	_	_	O
161	,	_	_	O
162	two	_	_	O
163	-	_	_	O
164	sample	_	_	O
165	t	_	_	O
166	tests	_	_	O
167	or	_	_	O
168	Wilcoxon	_	_	O
169	two	_	_	O
170	-	_	_	O
171	sample	_	_	O
172	tests	_	_	O
173	.	_	_	O

174	Interim	_	_	O
175	analysis	_	_	O
176	halfway	_	_	O
177	through	_	_	O
178	the	_	_	O
179	trial	_	_	O
180	had	_	_	O
181	a	_	_	O
182	Lan	_	_	O
183	-	_	_	O
184	DeMets	_	_	O
185	monitoring	_	_	O
186	boundary	_	_	O
187	with	_	_	O
188	an	_	_	O
189	O	_	_	O
190	'	_	_	O
191	Brien	_	_	O
192	-	_	_	O
193	Fleming	_	_	O
194	stopping	_	_	O
195	rule	_	_	O
196	.	_	_	O

197	Decision	_	_	O
198	boundaries	_	_	O
199	were	_	_	O
200	to	_	_	O
201	accept	_	_	O
202	the	_	_	O
203	null	_	_	O
204	hypothesis	_	_	O
205	of	_	_	O
206	futility	_	_	O
207	if	_	_	O
208	the	_	_	O
209	test	_	_	O
210	statistic	_	_	O
211	z	_	_	O
212	<	_	_	O
213	0	_	_	O
214	.	_	_	O

215	39	_	_	O
216	(	_	_	O
217	P	_	_	O
218	≥	_	_	O
219	.	_	_	O

220	348	_	_	O
221	)	_	_	O
222	and	_	_	O
223	reject	_	_	O
224	the	_	_	O
225	null	_	_	O
226	hypothesis	_	_	O
227	if	_	_	O
228	z	_	_	O
229	>	_	_	O
230	2	_	_	O
231	.	_	_	O

232	54	_	_	O
233	(	_	_	O
234	P	_	_	O
235	≤	_	_	O
236	.	_	_	O

237	0056	_	_	O
238	)	_	_	O
239	.	_	_	O

240	After	_	_	O
241	interim	_	_	O
242	analysis	_	_	O
243	of	_	_	O
244	48	_	_	O
245	patients	_	_	O
246	,	_	_	O
247	the	_	_	O
248	study	_	_	O
249	was	_	_	O
250	closed	_	_	O
251	for	_	_	O
252	futility	_	_	O
253	.	_	_	O

254	There	_	_	B-Premise
255	were	_	_	I-Premise
256	no	_	_	I-Premise
257	significant	_	_	I-Premise
258	differences	_	_	I-Premise
259	between	_	_	I-Premise
260	groups	_	_	I-Premise
261	for	_	_	I-Premise
262	appetite	_	_	I-Premise
263	(	_	_	I-Premise
264	P	_	_	I-Premise
265	=	_	_	I-Premise
266	.	_	_	I-Premise

267	78	_	_	I-Premise
268	)	_	_	I-Premise
269	or	_	_	I-Premise
270	other	_	_	I-Premise
271	symptoms	_	_	I-Premise
272	,	_	_	I-Premise
273	weight	_	_	I-Premise
274	(	_	_	I-Premise
275	P	_	_	I-Premise
276	=	_	_	I-Premise
277	.	_	_	I-Premise

278	17	_	_	I-Premise
279	)	_	_	I-Premise
280	,	_	_	I-Premise
281	FAACT	_	_	I-Premise
282	score	_	_	I-Premise
283	(	_	_	I-Premise
284	P	_	_	I-Premise
285	=	_	_	I-Premise
286	.	_	_	I-Premise

287	95	_	_	I-Premise
288	)	_	_	I-Premise
289	,	_	_	I-Premise
290	toxicity	_	_	I-Premise
291	,	_	_	I-Premise
292	or	_	_	I-Premise
293	survival	_	_	I-Premise
294	from	_	_	I-Premise
295	baseline	_	_	I-Premise
296	to	_	_	I-Premise
297	day	_	_	I-Premise
298	28	_	_	I-Premise
299	.	_	_	I-Premise

300	In	_	_	B-Claim
301	cachectic	_	_	I-Claim
302	patients	_	_	I-Claim
303	with	_	_	I-Claim
304	advanced	_	_	I-Claim
305	cancer	_	_	I-Claim
306	,	_	_	I-Claim
307	oral	_	_	I-Claim
308	melatonin	_	_	I-Claim
309	20	_	_	I-Claim
310	mg	_	_	I-Claim
311	at	_	_	I-Claim
312	night	_	_	I-Claim
313	did	_	_	I-Claim
314	not	_	_	I-Claim
315	improve	_	_	I-Claim
316	appetite	_	_	I-Claim
317	,	_	_	I-Claim
318	weight	_	_	I-Claim
319	,	_	_	I-Claim
320	or	_	_	I-Claim
321	quality	_	_	I-Claim
322	of	_	_	I-Claim
323	life	_	_	I-Claim
324	compared	_	_	I-Claim
325	with	_	_	I-Claim
326	placebo	_	_	I-Claim
327	.	_	_	I-Claim


0	To	_	_	O
1	report	_	_	O
2	5	_	_	O
3	-	_	_	O
4	year	_	_	O
5	contrast	_	_	O
6	-	_	_	O
7	enhanced	_	_	O
8	magnetic	_	_	O
9	resonance	_	_	O
10	imaging	_	_	O
11	findings	_	_	O
12	of	_	_	O
13	the	_	_	O
14	REST	_	_	O
15	trial	_	_	O
16	recruits	_	_	O
17	who	_	_	O
18	underwent	_	_	O
19	either	_	_	O
20	uterine	_	_	O
21	artery	_	_	O
22	embolization	_	_	O
23	(	_	_	O
24	UAE	_	_	O
25	)	_	_	O
26	or	_	_	O
27	myomectomy	_	_	O
28	.	_	_	O

29	A	_	_	O
30	total	_	_	O
31	of	_	_	O
32	157	_	_	O
33	patients	_	_	O
34	were	_	_	O
35	randomized	_	_	O
36	to	_	_	O
37	UAE	_	_	O
38	or	_	_	O
39	surgery	_	_	O
40	(	_	_	O
41	hysterectomy	_	_	O
42	or	_	_	O
43	myomectomy	_	_	O
44	)	_	_	O
45	.	_	_	O

46	Ninety	_	_	O
47	-	_	_	O
48	nine	_	_	O
49	patients	_	_	O
50	who	_	_	O
51	had	_	_	O
52	UAE	_	_	O
53	and	_	_	O
54	eight	_	_	O
55	patients	_	_	O
56	who	_	_	O
57	had	_	_	O
58	myomectomy	_	_	O
59	were	_	_	O
60	analyzed	_	_	O
61	.	_	_	O

62	MRI	_	_	O
63	scans	_	_	O
64	at	_	_	O
65	baseline	_	_	O
66	,	_	_	O
67	6	_	_	O
68	months	_	_	O
69	,	_	_	O
70	and	_	_	O
71	5	_	_	O
72	years	_	_	O
73	were	_	_	O
74	independently	_	_	O
75	interpreted	_	_	O
76	by	_	_	O
77	two	_	_	O
78	radiologists	_	_	O
79	.	_	_	O

80	Dominant	_	_	O
81	fibroid	_	_	O
82	diameter	_	_	O
83	,	_	_	O
84	uterine	_	_	O
85	volume	_	_	O
86	,	_	_	O
87	total	_	_	O
88	fibroid	_	_	O
89	infarction	_	_	O
90	(	_	_	O
91	complete	_	_	O
92	100	_	_	O
93	%	_	_	O
94	,	_	_	O
95	almost	_	_	O
96	complete	_	_	O
97	90	_	_	O
98	-	_	_	O
99	99	_	_	O
100	%	_	_	O
101	,	_	_	O
102	partial	_	_	O
103	<	_	_	O
104	90	_	_	O
105	%	_	_	O
106	)	_	_	O
107	,	_	_	O
108	and	_	_	O
109	new	_	_	O
110	fibroid	_	_	O
111	formation	_	_	O
112	were	_	_	O
113	the	_	_	O
114	main	_	_	O
115	parameters	_	_	O
116	assessed	_	_	O
117	and	_	_	O
118	related	_	_	O
119	to	_	_	O
120	the	_	_	O
121	need	_	_	O
122	for	_	_	O
123	reintervention	_	_	O
124	.	_	_	O

125	In	_	_	B-Premise
126	the	_	_	I-Premise
127	UAE	_	_	I-Premise
128	group	_	_	I-Premise
129	,	_	_	I-Premise
130	mean	_	_	I-Premise
131	±	_	_	I-Premise
132	standard	_	_	I-Premise
133	deviation	_	_	I-Premise
134	uterine	_	_	I-Premise
135	volume	_	_	I-Premise
136	was	_	_	I-Premise
137	670	_	_	I-Premise
138	±	_	_	I-Premise
139	503	_	_	I-Premise
140	,	_	_	I-Premise
141	422	_	_	I-Premise
142	±	_	_	I-Premise
143	353	_	_	I-Premise
144	,	_	_	I-Premise
145	and	_	_	I-Premise
146	292	_	_	I-Premise
147	±	_	_	I-Premise
148	287	_	_	I-Premise
149	mL	_	_	I-Premise
150	at	_	_	I-Premise
151	baseline	_	_	I-Premise
152	,	_	_	I-Premise
153	6	_	_	I-Premise
154	months	_	_	I-Premise
155	,	_	_	I-Premise
156	and	_	_	I-Premise
157	5	_	_	I-Premise
158	years	_	_	I-Premise
159	,	_	_	I-Premise
160	respectively	_	_	I-Premise
161	.	_	_	I-Premise

162	Mean	_	_	B-Premise
163	dominant	_	_	I-Premise
164	fibroid	_	_	I-Premise
165	diameter	_	_	I-Premise
166	was	_	_	I-Premise
167	7	_	_	I-Premise
168	.	_	_	I-Premise

169	6	_	_	I-Premise
170	±	_	_	I-Premise
171	3	_	_	I-Premise
172	.	_	_	I-Premise

173	0	_	_	I-Premise
174	,	_	_	I-Premise
175	5	_	_	I-Premise
176	.	_	_	I-Premise

177	8	_	_	I-Premise
178	±	_	_	I-Premise
179	2	_	_	I-Premise
180	.	_	_	I-Premise

181	9	_	_	I-Premise
182	,	_	_	I-Premise
183	and	_	_	I-Premise
184	5	_	_	I-Premise
185	±	_	_	I-Premise
186	2	_	_	I-Premise
187	.	_	_	I-Premise

188	9	_	_	I-Premise
189	cm	_	_	I-Premise
190	at	_	_	I-Premise
191	baseline	_	_	I-Premise
192	,	_	_	I-Premise
193	6	_	_	I-Premise
194	months	_	_	I-Premise
195	,	_	_	I-Premise
196	and	_	_	I-Premise
197	5	_	_	I-Premise
198	years	_	_	I-Premise
199	.	_	_	I-Premise

200	Fibroid	_	_	B-Premise
201	infarction	_	_	I-Premise
202	at	_	_	I-Premise
203	6	_	_	I-Premise
204	months	_	_	I-Premise
205	was	_	_	I-Premise
206	complete	_	_	I-Premise
207	in	_	_	I-Premise
208	35	_	_	I-Premise
209	%	_	_	I-Premise
210	of	_	_	I-Premise
211	women	_	_	I-Premise
212	,	_	_	I-Premise
213	almost	_	_	I-Premise
214	complete	_	_	I-Premise
215	in	_	_	I-Premise
216	29	_	_	I-Premise
217	%	_	_	I-Premise
218	,	_	_	I-Premise
219	and	_	_	I-Premise
220	partial	_	_	I-Premise
221	in	_	_	I-Premise
222	36	_	_	I-Premise
223	%	_	_	I-Premise
224	.	_	_	I-Premise

225	Need	_	_	B-Premise
226	for	_	_	I-Premise
227	reintervention	_	_	I-Premise
228	was	_	_	I-Premise
229	19	_	_	I-Premise
230	,	_	_	I-Premise
231	10	_	_	I-Premise
232	,	_	_	I-Premise
233	and	_	_	I-Premise
234	33	_	_	I-Premise
235	%	_	_	I-Premise
236	in	_	_	I-Premise
237	these	_	_	I-Premise
238	groups	_	_	I-Premise
239	,	_	_	I-Premise
240	respectively	_	_	I-Premise
241	(	_	_	I-Premise
242	p	_	_	I-Premise
243	=	_	_	I-Premise
244	0	_	_	I-Premise
245	.	_	_	I-Premise

246	123	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	No	_	_	B-Premise
250	myomectomy	_	_	I-Premise
251	cases	_	_	I-Premise
252	had	_	_	I-Premise
253	further	_	_	I-Premise
254	intervention	_	_	I-Premise
255	.	_	_	I-Premise

256	At	_	_	B-Premise
257	5	_	_	I-Premise
258	years	_	_	I-Premise
259	,	_	_	I-Premise
260	the	_	_	I-Premise
261	prevalence	_	_	I-Premise
262	of	_	_	I-Premise
263	new	_	_	I-Premise
264	fibroid	_	_	I-Premise
265	was	_	_	I-Premise
266	60	_	_	I-Premise
267	%	_	_	I-Premise
268	in	_	_	I-Premise
269	the	_	_	I-Premise
270	myomectomy	_	_	I-Premise
271	group	_	_	I-Premise
272	and	_	_	I-Premise
273	7	_	_	I-Premise
274	%	_	_	I-Premise
275	in	_	_	I-Premise
276	the	_	_	I-Premise
277	UAE	_	_	I-Premise
278	group	_	_	I-Premise
279	(	_	_	I-Premise
280	p	_	_	I-Premise
281	=	_	_	I-Premise
282	0	_	_	I-Premise
283	.	_	_	I-Premise

284	008	_	_	I-Premise
285	)	_	_	I-Premise
286	.	_	_	I-Premise

287	There	_	_	B-Premise
288	is	_	_	I-Premise
289	a	_	_	I-Premise
290	further	_	_	I-Premise
291	significant	_	_	I-Premise
292	reduction	_	_	I-Premise
293	in	_	_	I-Premise
294	both	_	_	I-Premise
295	uterine	_	_	I-Premise
296	volume	_	_	I-Premise
297	and	_	_	I-Premise
298	dominant	_	_	I-Premise
299	fibroid	_	_	I-Premise
300	diameter	_	_	I-Premise
301	between	_	_	I-Premise
302	6	_	_	I-Premise
303	months	_	_	I-Premise
304	and	_	_	I-Premise
305	5	_	_	I-Premise
306	years	_	_	I-Premise
307	after	_	_	I-Premise
308	UAE	_	_	I-Premise
309	.	_	_	I-Premise

310	Complete	_	_	B-Claim
311	fibroid	_	_	I-Claim
312	infarction	_	_	I-Claim
313	does	_	_	I-Claim
314	not	_	_	I-Claim
315	translate	_	_	I-Claim
316	into	_	_	I-Claim
317	total	_	_	I-Claim
318	freedom	_	_	I-Claim
319	from	_	_	I-Claim
320	a	_	_	I-Claim
321	subsequent	_	_	I-Claim
322	reintervention	_	_	I-Claim
323	.	_	_	I-Claim

324	New	_	_	B-Claim
325	fibroid	_	_	I-Claim
326	formation	_	_	I-Claim
327	is	_	_	I-Claim
328	significantly	_	_	I-Claim
329	higher	_	_	I-Claim
330	after	_	_	I-Claim
331	myomectomy	_	_	I-Claim
332	.	_	_	I-Claim


0	To	_	_	O
1	observe	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	TCM	_	_	O
6	therapy	_	_	O
7	for	_	_	O
8	removing	_	_	O
9	toxic	_	_	O
10	substance	_	_	O
11	and	_	_	O
12	unblocking	_	_	O
13	meridians	_	_	O
14	on	_	_	O
15	post	_	_	O
16	-	_	_	O
17	radiation	_	_	O
18	quality	_	_	O
19	of	_	_	O
20	life	_	_	O
21	(	_	_	O
22	QOF	_	_	O
23	)	_	_	O
24	in	_	_	O
25	55	_	_	O
26	patients	_	_	O
27	with	_	_	O
28	lung	_	_	O
29	cancer	_	_	O
30	.	_	_	O

31	All	_	_	O
32	patients	_	_	O
33	were	_	_	O
34	randomly	_	_	O
35	assigned	_	_	O
36	to	_	_	O
37	two	_	_	O
38	groups	_	_	O
39	,	_	_	O
40	the	_	_	O
41	55	_	_	O
42	patients	_	_	O
43	in	_	_	O
44	the	_	_	O
45	treated	_	_	O
46	group	_	_	O
47	were	_	_	O
48	treated	_	_	O
49	with	_	_	O
50	radiotherapy	_	_	O
51	combined	_	_	O
52	with	_	_	O
53	the	_	_	O
54	TCM	_	_	O
55	therapy	_	_	O
56	,	_	_	O
57	and	_	_	O
58	the	_	_	O
59	53	_	_	O
60	in	_	_	O
61	the	_	_	O
62	control	_	_	O
63	group	_	_	O
64	were	_	_	O
65	given	_	_	O
66	radiotherapy	_	_	O
67	alone	_	_	O
68	.	_	_	O

69	The	_	_	O
70	clinical	_	_	O
71	efficacy	_	_	O
72	was	_	_	O
73	evaluated	_	_	O
74	by	_	_	O
75	indexes	_	_	O
76	including	_	_	O
77	KPS	_	_	O
78	scores	_	_	O
79	,	_	_	O
80	QLQ	_	_	O
81	-	_	_	O
82	C30	_	_	O
83	questionnaire	_	_	O
84	,	_	_	O
85	LC13	_	_	O
86	specific	_	_	O
87	scale	_	_	O
88	for	_	_	O
89	lung	_	_	O
90	cancer	_	_	O
91	,	_	_	O
92	evaluation	_	_	O
93	criteria	_	_	O
94	for	_	_	O
95	TCM	_	_	O
96	efficacy	_	_	O
97	,	_	_	O
98	the	_	_	O
99	6	_	_	O
100	-	_	_	O
101	min	_	_	O
102	walking	_	_	O
103	distance	_	_	O
104	,	_	_	O
105	and	_	_	O
106	body	_	_	O
107	weight	_	_	O
108	,	_	_	O
109	etc	_	_	O
110	.	_	_	O

111	The	_	_	B-Premise
112	KPS	_	_	I-Premise
113	score	_	_	I-Premise
114	in	_	_	I-Premise
115	the	_	_	I-Premise
116	treated	_	_	I-Premise
117	group	_	_	I-Premise
118	after	_	_	I-Premise
119	treatment	_	_	I-Premise
120	was	_	_	I-Premise
121	improved	_	_	I-Premise
122	in	_	_	I-Premise
123	13	_	_	I-Premise
124	patients	_	_	I-Premise
125	(	_	_	I-Premise
126	23	_	_	I-Premise
127	.	_	_	I-Premise

128	6	_	_	I-Premise
129	%	_	_	I-Premise
130	)	_	_	I-Premise
131	,	_	_	I-Premise
132	stabilized	_	_	I-Premise
133	in	_	_	I-Premise
134	27	_	_	I-Premise
135	(	_	_	I-Premise
136	49	_	_	I-Premise
137	.	_	_	I-Premise

138	6	_	_	I-Premise
139	%	_	_	I-Premise
140	)	_	_	I-Premise
141	and	_	_	I-Premise
142	declined	_	_	I-Premise
143	in	_	_	I-Premise
144	15	_	_	I-Premise
145	(	_	_	I-Premise
146	27	_	_	I-Premise
147	.	_	_	I-Premise

148	3	_	_	I-Premise
149	%	_	_	I-Premise
150	)	_	_	I-Premise
151	,	_	_	I-Premise
152	while	_	_	I-Premise
153	in	_	_	I-Premise
154	the	_	_	I-Premise
155	control	_	_	I-Premise
156	group	_	_	I-Premise
157	,	_	_	I-Premise
158	it	_	_	I-Premise
159	was	_	_	I-Premise
160	improved	_	_	I-Premise
161	in	_	_	I-Premise
162	7	_	_	I-Premise
163	(	_	_	I-Premise
164	13	_	_	I-Premise
165	.	_	_	I-Premise

166	2	_	_	I-Premise
167	%	_	_	I-Premise
168	)	_	_	I-Premise
169	,	_	_	I-Premise
170	stabilized	_	_	I-Premise
171	in	_	_	I-Premise
172	21	_	_	I-Premise
173	(	_	_	I-Premise
174	39	_	_	I-Premise
175	.	_	_	I-Premise

176	6	_	_	I-Premise
177	%	_	_	I-Premise
178	)	_	_	I-Premise
179	and	_	_	I-Premise
180	declined	_	_	I-Premise
181	in	_	_	I-Premise
182	25	_	_	I-Premise
183	(	_	_	I-Premise
184	47	_	_	I-Premise
185	.	_	_	I-Premise

186	2	_	_	I-Premise
187	%	_	_	I-Premise
188	)	_	_	I-Premise
189	,	_	_	I-Premise
190	the	_	_	I-Premise
191	difference	_	_	I-Premise
192	between	_	_	I-Premise
193	the	_	_	I-Premise
194	two	_	_	I-Premise
195	groups	_	_	I-Premise
196	was	_	_	I-Premise
197	significant	_	_	I-Premise
198	(	_	_	I-Premise
199	P	_	_	I-Premise
200	<	_	_	I-Premise
201	0	_	_	I-Premise
202	.	_	_	I-Premise

203	05	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	The	_	_	B-Premise
207	results	_	_	I-Premise
208	from	_	_	I-Premise
209	evaluation	_	_	I-Premise
210	with	_	_	I-Premise
211	QLQ	_	_	I-Premise
212	-	_	_	I-Premise
213	C30	_	_	I-Premise
214	questionnaire	_	_	I-Premise
215	and	_	_	I-Premise
216	LC30	_	_	I-Premise
217	scale	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	treated	_	_	I-Premise
221	group	_	_	I-Premise
222	was	_	_	I-Premise
223	also	_	_	I-Premise
224	superior	_	_	I-Premise
225	to	_	_	I-Premise
226	those	_	_	I-Premise
227	in	_	_	I-Premise
228	the	_	_	I-Premise
229	control	_	_	I-Premise
230	group	_	_	I-Premise
231	(	_	_	I-Premise
232	P	_	_	I-Premise
233	<	_	_	I-Premise
234	0	_	_	I-Premise
235	.	_	_	I-Premise

236	05	_	_	I-Premise
237	)	_	_	I-Premise
238	,	_	_	I-Premise
239	respectively	_	_	I-Premise
240	.	_	_	I-Premise

241	The	_	_	B-Premise
242	scores	_	_	I-Premise
243	of	_	_	I-Premise
244	TCM	_	_	I-Premise
245	efficacy	_	_	I-Premise
246	(	_	_	I-Premise
247	24	_	_	I-Premise
248	.	_	_	I-Premise

249	52	_	_	I-Premise
250	+	_	_	I-Premise
251	/	_	_	I-Premise
252	-	_	_	I-Premise
253	8	_	_	I-Premise
254	.	_	_	I-Premise

255	98	_	_	I-Premise
256	vs	_	_	I-Premise
257	29	_	_	I-Premise
258	.	_	_	I-Premise

259	76	_	_	I-Premise
260	+	_	_	I-Premise
261	/	_	_	I-Premise
262	-	_	_	I-Premise
263	7	_	_	I-Premise
264	.	_	_	I-Premise

265	09	_	_	I-Premise
266	,	_	_	I-Premise
267	P	_	_	I-Premise
268	<	_	_	I-Premise
269	0	_	_	I-Premise
270	.	_	_	I-Premise

271	05	_	_	I-Premise
272	)	_	_	I-Premise
273	and	_	_	I-Premise
274	the	_	_	I-Premise
275	6	_	_	I-Premise
276	-	_	_	I-Premise
277	min	_	_	I-Premise
278	walking	_	_	I-Premise
279	distance	_	_	I-Premise
280	(	_	_	I-Premise
281	233	_	_	I-Premise
282	.	_	_	I-Premise

283	4	_	_	I-Premise
284	+	_	_	I-Premise
285	/	_	_	I-Premise
286	-	_	_	I-Premise
287	29	_	_	I-Premise
288	.	_	_	I-Premise

289	2	_	_	I-Premise
290	m	_	_	I-Premise
291	vs	_	_	I-Premise
292	205	_	_	I-Premise
293	.	_	_	I-Premise

294	8	_	_	I-Premise
295	+	_	_	I-Premise
296	/	_	_	I-Premise
297	-	_	_	I-Premise
298	31	_	_	I-Premise
299	.	_	_	I-Premise

300	9	_	_	I-Premise
301	m	_	_	I-Premise
302	,	_	_	I-Premise
303	P	_	_	I-Premise
304	<	_	_	I-Premise
305	0	_	_	I-Premise
306	.	_	_	I-Premise

307	05	_	_	I-Premise
308	)	_	_	I-Premise
309	were	_	_	I-Premise
310	better	_	_	I-Premise
311	in	_	_	I-Premise
312	the	_	_	I-Premise
313	treated	_	_	I-Premise
314	group	_	_	I-Premise
315	.	_	_	I-Premise

316	After	_	_	B-Premise
317	treatment	_	_	I-Premise
318	in	_	_	I-Premise
319	the	_	_	I-Premise
320	treated	_	_	I-Premise
321	group	_	_	I-Premise
322	,	_	_	I-Premise
323	the	_	_	I-Premise
324	body	_	_	I-Premise
325	weight	_	_	I-Premise
326	was	_	_	I-Premise
327	increased	_	_	I-Premise
328	in	_	_	I-Premise
329	11	_	_	I-Premise
330	patients	_	_	I-Premise
331	(	_	_	I-Premise
332	20	_	_	I-Premise
333	.	_	_	I-Premise

334	0	_	_	I-Premise
335	%	_	_	I-Premise
336	)	_	_	I-Premise
337	,	_	_	I-Premise
338	stabilized	_	_	I-Premise
339	in	_	_	I-Premise
340	28	_	_	I-Premise
341	(	_	_	I-Premise
342	50	_	_	I-Premise
343	.	_	_	I-Premise

344	9	_	_	I-Premise
345	%	_	_	I-Premise
346	)	_	_	I-Premise
347	and	_	_	I-Premise
348	decreased	_	_	I-Premise
349	in	_	_	I-Premise
350	16	_	_	I-Premise
351	(	_	_	I-Premise
352	29	_	_	I-Premise
353	.	_	_	I-Premise

354	1	_	_	I-Premise
355	%	_	_	I-Premise
356	)	_	_	I-Premise
357	,	_	_	I-Premise
358	while	_	_	I-Premise
359	in	_	_	I-Premise
360	the	_	_	I-Premise
361	control	_	_	I-Premise
362	group	_	_	I-Premise
363	it	_	_	I-Premise
364	was	_	_	I-Premise
365	increased	_	_	I-Premise
366	in	_	_	I-Premise
367	5	_	_	I-Premise
368	(	_	_	I-Premise
369	9	_	_	I-Premise
370	.	_	_	I-Premise

371	4	_	_	I-Premise
372	%	_	_	I-Premise
373	)	_	_	I-Premise
374	,	_	_	I-Premise
375	stabilized	_	_	I-Premise
376	in	_	_	I-Premise
377	26	_	_	I-Premise
378	(	_	_	I-Premise
379	49	_	_	I-Premise
380	.	_	_	I-Premise

381	1	_	_	I-Premise
382	%	_	_	I-Premise
383	)	_	_	I-Premise
384	and	_	_	I-Premise
385	decreased	_	_	I-Premise
386	in	_	_	I-Premise
387	22	_	_	I-Premise
388	(	_	_	I-Premise
389	41	_	_	I-Premise
390	.	_	_	I-Premise

391	5	_	_	I-Premise
392	%	_	_	I-Premise
393	)	_	_	I-Premise
394	,	_	_	I-Premise
395	difference	_	_	I-Premise
396	between	_	_	I-Premise
397	the	_	_	I-Premise
398	two	_	_	I-Premise
399	groups	_	_	I-Premise
400	was	_	_	I-Premise
401	significant	_	_	I-Premise
402	,	_	_	I-Premise
403	too	_	_	I-Premise
404	(	_	_	I-Premise
405	P	_	_	I-Premise
406	<	_	_	I-Premise
407	0	_	_	I-Premise
408	.	_	_	I-Premise

409	05	_	_	I-Premise
410	)	_	_	I-Premise
411	.	_	_	I-Premise

412	TCM	_	_	B-Claim
413	therapy	_	_	I-Claim
414	for	_	_	I-Claim
415	removing	_	_	I-Claim
416	toxic	_	_	I-Claim
417	substance	_	_	I-Claim
418	and	_	_	I-Claim
419	unblocking	_	_	I-Claim
420	meridians	_	_	I-Claim
421	can	_	_	I-Claim
422	improve	_	_	I-Claim
423	the	_	_	I-Claim
424	post	_	_	I-Claim
425	-	_	_	I-Claim
426	radiation	_	_	I-Claim
427	QOL	_	_	I-Claim
428	of	_	_	I-Claim
429	patients	_	_	I-Claim
430	with	_	_	I-Claim
431	lung	_	_	I-Claim
432	cancer	_	_	I-Claim
433	to	_	_	I-Claim
434	some	_	_	I-Claim
435	extent	_	_	I-Claim
436	.	_	_	I-Claim


0	Systematic	_	_	B-Claim
1	assessment	_	_	I-Claim
2	is	_	_	I-Claim
3	vital	_	_	I-Claim
4	to	_	_	I-Claim
5	palliative	_	_	I-Claim
6	care	_	_	I-Claim
7	,	_	_	O
8	but	_	_	O
9	documentation	_	_	O
10	confirming	_	_	O
11	completion	_	_	O
12	of	_	_	O
13	systematic	_	_	O
14	assessment	_	_	O
15	in	_	_	O
16	hospice	_	_	O
17	settings	_	_	O
18	is	_	_	O
19	often	_	_	O
20	inadequate	_	_	O
21	or	_	_	O
22	absent	_	_	O
23	.	_	_	O

24	The	_	_	O
25	objective	_	_	O
26	of	_	_	O
27	the	_	_	O
28	study	_	_	O
29	was	_	_	O
30	to	_	_	O
31	determine	_	_	O
32	the	_	_	O
33	efficacy	_	_	O
34	of	_	_	O
35	systematic	_	_	O
36	feedback	_	_	O
37	from	_	_	O
38	standardized	_	_	O
39	assessment	_	_	O
40	tools	_	_	O
41	for	_	_	O
42	hospice	_	_	O
43	patient	_	_	O
44	-	_	_	O
45	caregiver	_	_	O
46	dyads	_	_	O
47	in	_	_	O
48	improving	_	_	O
49	hospice	_	_	O
50	outcomes	_	_	O
51	compared	_	_	O
52	with	_	_	O
53	the	_	_	O
54	usual	_	_	O
55	clinical	_	_	O
56	practice	_	_	O
57	.	_	_	O

58	The	_	_	O
59	sample	_	_	O
60	of	_	_	O
61	patients	_	_	O
62	(	_	_	O
63	n	_	_	O
64	=	_	_	O
65	709	_	_	O
66	)	_	_	O
67	newly	_	_	O
68	admitted	_	_	O
69	to	_	_	O
70	hospice	_	_	O
71	home	_	_	O
72	care	_	_	O
73	in	_	_	O
74	2	_	_	O
75	hospices	_	_	O
76	had	_	_	O
77	designated	_	_	O
78	family	_	_	O
79	caregivers	_	_	O
80	.	_	_	O

81	The	_	_	O
82	interdisciplinary	_	_	O
83	teams	_	_	O
84	(	_	_	O
85	IDTs	_	_	O
86	)	_	_	O
87	caring	_	_	O
88	for	_	_	O
89	these	_	_	O
90	dyads	_	_	O
91	were	_	_	O
92	randomly	_	_	O
93	assigned	_	_	O
94	to	_	_	O
95	either	_	_	O
96	experimental	_	_	O
97	(	_	_	O
98	n	_	_	O
99	=	_	_	O
100	338	_	_	O
101	)	_	_	O
102	or	_	_	O
103	control	_	_	O
104	(	_	_	O
105	n	_	_	O
106	=	_	_	O
107	371	_	_	O
108	)	_	_	O
109	conditions	_	_	O
110	.	_	_	O

111	Data	_	_	O
112	were	_	_	O
113	collected	_	_	O
114	from	_	_	O
115	both	_	_	O
116	groups	_	_	O
117	of	_	_	O
118	dyads	_	_	O
119	using	_	_	O
120	standardized	_	_	O
121	assessments	_	_	O
122	on	_	_	O
123	admission	_	_	O
124	and	_	_	O
125	1	_	_	O
126	week	_	_	O
127	after	_	_	O
128	each	_	_	O
129	of	_	_	O
130	the	_	_	O
131	first	_	_	O
132	2	_	_	O
133	IDT	_	_	O
134	meetings	_	_	O
135	in	_	_	O
136	which	_	_	O
137	these	_	_	O
138	dyads	_	_	O
139	were	_	_	O
140	discussed	_	_	O
141	.	_	_	O

142	The	_	_	O
143	experimental	_	_	O
144	intervention	_	_	O
145	consisted	_	_	O
146	of	_	_	O
147	reporting	_	_	O
148	data	_	_	O
149	from	_	_	O
150	the	_	_	O
151	standardized	_	_	O
152	assessments	_	_	O
153	to	_	_	O
154	the	_	_	O
155	IDTs	_	_	O
156	.	_	_	O

157	Results	_	_	B-Premise
158	showed	_	_	I-Premise
159	improved	_	_	I-Premise
160	patient	_	_	I-Premise
161	depression	_	_	I-Premise
162	(	_	_	I-Premise
163	P	_	_	I-Premise
164	<	_	_	I-Premise
165	.	_	_	I-Premise

166	001	_	_	I-Premise
167	)	_	_	I-Premise
168	as	_	_	I-Premise
169	a	_	_	I-Premise
170	result	_	_	I-Premise
171	of	_	_	I-Premise
172	the	_	_	I-Premise
173	intervention	_	_	I-Premise
174	and	_	_	I-Premise
175	improvement	_	_	I-Premise
176	in	_	_	I-Premise
177	both	_	_	I-Premise
178	groups	_	_	I-Premise
179	in	_	_	I-Premise
180	patients	_	_	I-Premise
181	'	_	_	I-Premise
182	quality	_	_	I-Premise
183	of	_	_	I-Premise
184	life	_	_	I-Premise
185	(	_	_	I-Premise
186	P	_	_	I-Premise
187	<	_	_	I-Premise
188	.	_	_	I-Premise

189	001	_	_	I-Premise
190	)	_	_	I-Premise
191	.	_	_	I-Premise

192	No	_	_	B-Premise
193	other	_	_	I-Premise
194	patient	_	_	I-Premise
195	outcomes	_	_	I-Premise
196	(	_	_	I-Premise
197	symptom	_	_	I-Premise
198	distress	_	_	I-Premise
199	,	_	_	I-Premise
200	spiritual	_	_	I-Premise
201	needs	_	_	I-Premise
202	)	_	_	I-Premise
203	or	_	_	I-Premise
204	caregiver	_	_	I-Premise
205	outcomes	_	_	I-Premise
206	(	_	_	I-Premise
207	depression	_	_	I-Premise
208	,	_	_	I-Premise
209	support	_	_	I-Premise
210	,	_	_	I-Premise
211	spiritual	_	_	I-Premise
212	needs	_	_	I-Premise
213	)	_	_	I-Premise
214	were	_	_	I-Premise
215	significantly	_	_	I-Premise
216	different	_	_	I-Premise
217	.	_	_	I-Premise

218	Assessment	_	_	O
219	of	_	_	O
220	depression	_	_	O
221	added	_	_	O
222	to	_	_	O
223	usual	_	_	O
224	care	_	_	O
225	probably	_	_	O
226	had	_	_	O
227	an	_	_	O
228	effect	_	_	O
229	because	_	_	O
230	it	_	_	O
231	is	_	_	O
232	not	_	_	O
233	normally	_	_	O
234	a	_	_	O
235	focus	_	_	O
236	of	_	_	O
237	hospice	_	_	O
238	staff	_	_	O
239	.	_	_	O

240	Hospice	_	_	B-Premise
241	care	_	_	I-Premise
242	was	_	_	I-Premise
243	so	_	_	I-Premise
244	good	_	_	I-Premise
245	during	_	_	I-Premise
246	the	_	_	I-Premise
247	study	_	_	I-Premise
248	that	_	_	I-Premise
249	overall	_	_	I-Premise
250	quality	_	_	I-Premise
251	of	_	_	I-Premise
252	life	_	_	I-Premise
253	improved	_	_	I-Premise
254	as	_	_	I-Premise
255	a	_	_	I-Premise
256	result	_	_	I-Premise
257	of	_	_	I-Premise
258	standard	_	_	I-Premise
259	care	_	_	I-Premise
260	and	_	_	I-Premise
261	left	_	_	I-Premise
262	little	_	_	I-Premise
263	room	_	_	I-Premise
264	for	_	_	I-Premise
265	improvement	_	_	I-Premise
266	in	_	_	I-Premise
267	other	_	_	I-Premise
268	variables	_	_	I-Premise
269	.	_	_	I-Premise

270	Systematic	_	_	B-Claim
271	assessment	_	_	I-Claim
272	of	_	_	I-Claim
273	depression	_	_	I-Claim
274	is	_	_	I-Claim
275	needed	_	_	I-Claim
276	in	_	_	I-Claim
277	hospice	_	_	I-Claim
278	patients	_	_	I-Claim
279	.	_	_	I-Claim

280	No	_	_	O
281	caregiver	_	_	O
282	variables	_	_	O
283	changed	_	_	O
284	,	_	_	O
285	which	_	_	O
286	may	_	_	O
287	indicate	_	_	O
288	a	_	_	O
289	need	_	_	O
290	for	_	_	O
291	a	_	_	O
292	focus	_	_	O
293	on	_	_	O
294	caregivers	_	_	O
295	.	_	_	O


0	Vinorelbine	_	_	B-Claim
1	prolongs	_	_	I-Claim
2	survival	_	_	I-Claim
3	and	_	_	I-Claim
4	improves	_	_	I-Claim
5	quality	_	_	I-Claim
6	of	_	_	I-Claim
7	life	_	_	I-Claim
8	in	_	_	I-Claim
9	elderly	_	_	I-Claim
10	patients	_	_	I-Claim
11	with	_	_	I-Claim
12	advanced	_	_	I-Claim
13	non	_	_	I-Claim
14	-	_	_	I-Claim
15	small	_	_	I-Claim
16	-	_	_	I-Claim
17	cell	_	_	I-Claim
18	lung	_	_	I-Claim
19	cancer	_	_	I-Claim
20	(	_	_	I-Claim
21	NSCLC	_	_	I-Claim
22	)	_	_	I-Claim
23	.	_	_	I-Claim

24	Some	_	_	B-Claim
25	studies	_	_	I-Claim
26	have	_	_	I-Claim
27	also	_	_	I-Claim
28	suggested	_	_	I-Claim
29	that	_	_	I-Claim
30	gemcitabine	_	_	I-Claim
31	is	_	_	I-Claim
32	well	_	_	I-Claim
33	tolerated	_	_	I-Claim
34	and	_	_	I-Claim
35	effective	_	_	I-Claim
36	in	_	_	I-Claim
37	such	_	_	I-Claim
38	patients	_	_	I-Claim
39	.	_	_	I-Claim

40	We	_	_	O
41	compared	_	_	O
42	the	_	_	O
43	effectiveness	_	_	O
44	and	_	_	O
45	toxicity	_	_	O
46	of	_	_	O
47	the	_	_	O
48	combination	_	_	O
49	of	_	_	O
50	vinorelbine	_	_	O
51	plus	_	_	O
52	gemcitabine	_	_	O
53	with	_	_	O
54	those	_	_	O
55	of	_	_	O
56	each	_	_	O
57	drug	_	_	O
58	given	_	_	O
59	alone	_	_	O
60	in	_	_	O
61	an	_	_	O
62	open	_	_	O
63	-	_	_	O
64	label	_	_	O
65	,	_	_	O
66	randomized	_	_	O
67	phase	_	_	O
68	III	_	_	O
69	trial	_	_	O
70	in	_	_	O
71	elderly	_	_	O
72	patients	_	_	O
73	with	_	_	O
74	advanced	_	_	O
75	NSCLC	_	_	O
76	.	_	_	O

77	Patients	_	_	O
78	aged	_	_	O
79	70	_	_	O
80	years	_	_	O
81	and	_	_	O
82	older	_	_	O
83	,	_	_	O
84	enrolled	_	_	O
85	between	_	_	O
86	December	_	_	O
87	1997	_	_	O
88	and	_	_	O
89	November	_	_	O
90	2000	_	_	O
91	,	_	_	O
92	were	_	_	O
93	randomly	_	_	O
94	assigned	_	_	O
95	to	_	_	O
96	receive	_	_	O
97	intravenous	_	_	O
98	vinorelbine	_	_	O
99	(	_	_	O
100	30	_	_	O
101	mg	_	_	O
102	/	_	_	O
103	m	_	_	O
104	(	_	_	O
105	2	_	_	O
106	)	_	_	O
107	of	_	_	O
108	body	_	_	O
109	surface	_	_	O
110	area	_	_	O
111	)	_	_	O
112	,	_	_	O
113	gemcitabine	_	_	O
114	(	_	_	O
115	1200	_	_	O
116	mg	_	_	O
117	/	_	_	O
118	m	_	_	O
119	(	_	_	O
120	2	_	_	O
121	)	_	_	O
122	)	_	_	O
123	,	_	_	O
124	or	_	_	O
125	vinorelbine	_	_	O
126	(	_	_	O
127	25	_	_	O
128	mg	_	_	O
129	/	_	_	O
130	m	_	_	O
131	(	_	_	O
132	2	_	_	O
133	)	_	_	O
134	)	_	_	O
135	plus	_	_	O
136	gemcitabine	_	_	O
137	(	_	_	O
138	1000	_	_	O
139	mg	_	_	O
140	/	_	_	O
141	m	_	_	O
142	(	_	_	O
143	2	_	_	O
144	)	_	_	O
145	)	_	_	O
146	.	_	_	O

147	All	_	_	O
148	treatments	_	_	O
149	were	_	_	O
150	delivered	_	_	O
151	on	_	_	O
152	days	_	_	O
153	1	_	_	O
154	and	_	_	O
155	8	_	_	O
156	every	_	_	O
157	3	_	_	O
158	weeks	_	_	O
159	for	_	_	O
160	a	_	_	O
161	maximum	_	_	O
162	of	_	_	O
163	six	_	_	O
164	cycles	_	_	O
165	.	_	_	O

166	The	_	_	O
167	primary	_	_	O
168	endpoint	_	_	O
169	was	_	_	O
170	survival	_	_	O
171	.	_	_	O

172	Survival	_	_	O
173	curves	_	_	O
174	were	_	_	O
175	drawn	_	_	O
176	using	_	_	O
177	the	_	_	O
178	Kaplan	_	_	O
179	-	_	_	O
180	Meier	_	_	O
181	method	_	_	O
182	and	_	_	O
183	analyzed	_	_	O
184	by	_	_	O
185	the	_	_	O
186	Mantel	_	_	O
187	-	_	_	O
188	Haenszel	_	_	O
189	test	_	_	O
190	.	_	_	O

191	Secondary	_	_	O
192	endpoints	_	_	O
193	were	_	_	O
194	quality	_	_	O
195	of	_	_	O
196	life	_	_	O
197	and	_	_	O
198	toxicity	_	_	O
199	.	_	_	O

200	Of	_	_	O
201	698	_	_	O
202	patients	_	_	O
203	available	_	_	O
204	for	_	_	O
205	intention	_	_	O
206	-	_	_	O
207	to	_	_	O
208	-	_	_	O
209	treat	_	_	O
210	analysis	_	_	O
211	,	_	_	O
212	233	_	_	O
213	were	_	_	O
214	assigned	_	_	O
215	to	_	_	O
216	receive	_	_	O
217	vinorelbine	_	_	O
218	,	_	_	O
219	233	_	_	O
220	to	_	_	O
221	gemcitabine	_	_	O
222	,	_	_	O
223	and	_	_	O
224	232	_	_	O
225	to	_	_	O
226	vinorelbine	_	_	O
227	plus	_	_	O
228	gemcitabine	_	_	O
229	.	_	_	O

230	Compared	_	_	B-Premise
231	with	_	_	I-Premise
232	each	_	_	I-Premise
233	single	_	_	I-Premise
234	drug	_	_	I-Premise
235	,	_	_	I-Premise
236	the	_	_	I-Premise
237	combination	_	_	I-Premise
238	treatment	_	_	I-Premise
239	did	_	_	I-Premise
240	not	_	_	I-Premise
241	improve	_	_	I-Premise
242	survival	_	_	I-Premise
243	.	_	_	I-Premise

244	The	_	_	B-Premise
245	hazard	_	_	I-Premise
246	ratio	_	_	I-Premise
247	of	_	_	I-Premise
248	death	_	_	I-Premise
249	for	_	_	I-Premise
250	patients	_	_	I-Premise
251	receiving	_	_	I-Premise
252	the	_	_	I-Premise
253	combination	_	_	I-Premise
254	treatment	_	_	I-Premise
255	was	_	_	I-Premise
256	1	_	_	I-Premise
257	.	_	_	I-Premise

258	17	_	_	I-Premise
259	(	_	_	I-Premise
260	95	_	_	I-Premise
261	%	_	_	I-Premise
262	confidence	_	_	I-Premise
263	interval	_	_	I-Premise
264	[	_	_	I-Premise
265	CI	_	_	I-Premise
266	]	_	_	I-Premise
267	=	_	_	I-Premise
268	0	_	_	I-Premise
269	.	_	_	I-Premise

270	95	_	_	I-Premise
271	to	_	_	I-Premise
272	1	_	_	I-Premise
273	.	_	_	I-Premise

274	44	_	_	I-Premise
275	)	_	_	I-Premise
276	that	_	_	I-Premise
277	of	_	_	I-Premise
278	patients	_	_	I-Premise
279	receiving	_	_	I-Premise
280	vinorelbine	_	_	I-Premise
281	and	_	_	I-Premise
282	1	_	_	I-Premise
283	.	_	_	I-Premise

284	06	_	_	I-Premise
285	(	_	_	I-Premise
286	95	_	_	I-Premise
287	%	_	_	I-Premise
288	CI	_	_	I-Premise
289	=	_	_	I-Premise
290	0	_	_	I-Premise
291	.	_	_	I-Premise

292	86	_	_	I-Premise
293	to	_	_	I-Premise
294	1	_	_	I-Premise
295	.	_	_	I-Premise

296	29	_	_	I-Premise
297	)	_	_	I-Premise
298	that	_	_	I-Premise
299	of	_	_	I-Premise
300	patients	_	_	I-Premise
301	receiving	_	_	I-Premise
302	gemcitabine	_	_	I-Premise
303	.	_	_	I-Premise

304	Although	_	_	B-Premise
305	quality	_	_	I-Premise
306	of	_	_	I-Premise
307	life	_	_	I-Premise
308	was	_	_	I-Premise
309	similar	_	_	I-Premise
310	across	_	_	I-Premise
311	the	_	_	I-Premise
312	three	_	_	I-Premise
313	treatment	_	_	I-Premise
314	arms	_	_	I-Premise
315	,	_	_	I-Premise
316	the	_	_	B-Premise
317	combination	_	_	I-Premise
318	treatment	_	_	I-Premise
319	was	_	_	I-Premise
320	more	_	_	I-Premise
321	toxic	_	_	I-Premise
322	than	_	_	I-Premise
323	the	_	_	I-Premise
324	two	_	_	I-Premise
325	drugs	_	_	I-Premise
326	given	_	_	I-Premise
327	singly	_	_	I-Premise
328	.	_	_	I-Premise

329	The	_	_	B-Claim
330	combination	_	_	I-Claim
331	of	_	_	I-Claim
332	vinorelbine	_	_	I-Claim
333	plus	_	_	I-Claim
334	gemcitabine	_	_	I-Claim
335	is	_	_	I-Claim
336	not	_	_	I-Claim
337	more	_	_	I-Claim
338	effective	_	_	I-Claim
339	than	_	_	I-Claim
340	single	_	_	I-Claim
341	-	_	_	I-Claim
342	agent	_	_	I-Claim
343	vinorelbine	_	_	I-Claim
344	or	_	_	I-Claim
345	gemcitabine	_	_	I-Claim
346	in	_	_	I-Claim
347	the	_	_	I-Claim
348	treatment	_	_	I-Claim
349	of	_	_	I-Claim
350	elderly	_	_	I-Claim
351	patients	_	_	I-Claim
352	with	_	_	I-Claim
353	advanced	_	_	I-Claim
354	NSCLC	_	_	I-Claim
355	.	_	_	I-Claim


0	In	_	_	B-Claim
1	phase	_	_	I-Claim
2	II	_	_	I-Claim
3	trials	_	_	I-Claim
4	,	_	_	I-Claim
5	paclitaxel	_	_	I-Claim
6	has	_	_	I-Claim
7	been	_	_	I-Claim
8	shown	_	_	I-Claim
9	to	_	_	I-Claim
10	have	_	_	I-Claim
11	antitumor	_	_	I-Claim
12	activity	_	_	I-Claim
13	in	_	_	I-Claim
14	patients	_	_	I-Claim
15	with	_	_	I-Claim
16	advanced	_	_	I-Claim
17	non	_	_	I-Claim
18	-	_	_	I-Claim
19	small	_	_	I-Claim
20	-	_	_	I-Claim
21	cell	_	_	I-Claim
22	lung	_	_	I-Claim
23	cancer	_	_	I-Claim
24	(	_	_	I-Claim
25	NSCLC	_	_	I-Claim
26	)	_	_	I-Claim
27	.	_	_	I-Claim

28	However	_	_	O
29	,	_	_	O
30	the	_	_	O
31	survival	_	_	O
32	and	_	_	O
33	quality	_	_	O
34	-	_	_	O
35	of	_	_	O
36	-	_	_	O
37	life	_	_	O
38	(	_	_	O
39	QOL	_	_	O
40	)	_	_	O
41	benefits	_	_	O
42	of	_	_	O
43	paclitaxel	_	_	O
44	used	_	_	O
45	as	_	_	O
46	a	_	_	O
47	single	_	_	O
48	agent	_	_	O
49	compared	_	_	O
50	with	_	_	O
51	supportive	_	_	O
52	care	_	_	O
53	alone	_	_	O
54	have	_	_	O
55	not	_	_	O
56	been	_	_	O
57	assessed	_	_	O
58	in	_	_	O
59	a	_	_	O
60	randomized	_	_	O
61	clinical	_	_	O
62	trial	_	_	O
63	.	_	_	O

64	A	_	_	O
65	total	_	_	O
66	of	_	_	O
67	157	_	_	O
68	patients	_	_	O
69	with	_	_	O
70	stage	_	_	O
71	IIIB	_	_	O
72	or	_	_	O
73	IV	_	_	O
74	NSCLC	_	_	O
75	who	_	_	O
76	had	_	_	O
77	received	_	_	O
78	no	_	_	O
79	prior	_	_	O
80	chemotherapy	_	_	O
81	were	_	_	O
82	randomly	_	_	O
83	assigned	_	_	O
84	to	_	_	O
85	receive	_	_	O
86	either	_	_	O
87	best	_	_	O
88	supportive	_	_	O
89	care	_	_	O
90	alone	_	_	O
91	(	_	_	O
92	78	_	_	O
93	patients	_	_	O
94	)	_	_	O
95	or	_	_	O
96	paclitaxel	_	_	O
97	plus	_	_	O
98	supportive	_	_	O
99	care	_	_	O
100	(	_	_	O
101	79	_	_	O
102	patients	_	_	O
103	)	_	_	O
104	.	_	_	O

105	Paclitaxel	_	_	O
106	was	_	_	O
107	administered	_	_	O
108	as	_	_	O
109	a	_	_	O
110	3	_	_	O
111	-	_	_	O
112	hour	_	_	O
113	intravenous	_	_	O
114	infusion	_	_	O
115	every	_	_	O
116	3	_	_	O
117	weeks	_	_	O
118	.	_	_	O

119	Supportive	_	_	O
120	care	_	_	O
121	included	_	_	O
122	palliative	_	_	O
123	radiotherapy	_	_	O
124	and	_	_	O
125	supportive	_	_	O
126	therapy	_	_	O
127	with	_	_	O
128	corticosteroids	_	_	O
129	,	_	_	O
130	antibiotics	_	_	O
131	,	_	_	O
132	analgesics	_	_	O
133	,	_	_	O
134	antiemetics	_	_	O
135	,	_	_	O
136	transfusions	_	_	O
137	,	_	_	O
138	and	_	_	O
139	other	_	_	O
140	symptomatic	_	_	O
141	therapy	_	_	O
142	as	_	_	O
143	required	_	_	O
144	.	_	_	O

145	The	_	_	O
146	primary	_	_	O
147	end	_	_	O
148	point	_	_	O
149	of	_	_	O
150	the	_	_	O
151	study	_	_	O
152	was	_	_	O
153	survival	_	_	O
154	.	_	_	O

155	Time	_	_	O
156	to	_	_	O
157	disease	_	_	O
158	progression	_	_	O
159	,	_	_	O
160	response	_	_	O
161	rate	_	_	O
162	,	_	_	O
163	adverse	_	_	O
164	events	_	_	O
165	,	_	_	O
166	and	_	_	O
167	QOL	_	_	O
168	were	_	_	O
169	secondary	_	_	O
170	end	_	_	O
171	points	_	_	O
172	.	_	_	O

173	Pretreatment	_	_	O
174	characteristics	_	_	O
175	were	_	_	O
176	evenly	_	_	O
177	distributed	_	_	O
178	between	_	_	O
179	the	_	_	O
180	two	_	_	O
181	arms	_	_	O
182	.	_	_	O

183	Survival	_	_	B-Premise
184	was	_	_	I-Premise
185	statistically	_	_	I-Premise
186	significantly	_	_	I-Premise
187	better	_	_	I-Premise
188	in	_	_	I-Premise
189	the	_	_	I-Premise
190	paclitaxel	_	_	I-Premise
191	plus	_	_	I-Premise
192	supportive	_	_	I-Premise
193	care	_	_	I-Premise
194	arm	_	_	I-Premise
195	than	_	_	I-Premise
196	in	_	_	I-Premise
197	the	_	_	I-Premise
198	supportive	_	_	I-Premise
199	care	_	_	I-Premise
200	alone	_	_	I-Premise
201	arm	_	_	I-Premise
202	(	_	_	I-Premise
203	two	_	_	I-Premise
204	-	_	_	I-Premise
205	sided	_	_	I-Premise
206	P	_	_	I-Premise
207	=	_	_	I-Premise
208	.	_	_	I-Premise

209	037	_	_	I-Premise
210	)	_	_	I-Premise
211	(	_	_	I-Premise
212	median	_	_	I-Premise
213	survival	_	_	I-Premise
214	=	_	_	I-Premise
215	6	_	_	I-Premise
216	.	_	_	I-Premise

217	8	_	_	I-Premise
218	months	_	_	I-Premise
219	versus	_	_	I-Premise
220	4	_	_	I-Premise
221	.	_	_	I-Premise

222	8	_	_	I-Premise
223	months	_	_	I-Premise
224	)	_	_	I-Premise
225	.	_	_	I-Premise

226	Cox	_	_	B-Premise
227	multivariate	_	_	I-Premise
228	analysis	_	_	I-Premise
229	showed	_	_	I-Premise
230	paclitaxel	_	_	I-Premise
231	plus	_	_	I-Premise
232	supportive	_	_	I-Premise
233	care	_	_	I-Premise
234	to	_	_	I-Premise
235	be	_	_	I-Premise
236	statistically	_	_	I-Premise
237	significantly	_	_	I-Premise
238	associated	_	_	I-Premise
239	with	_	_	I-Premise
240	improved	_	_	I-Premise
241	survival	_	_	I-Premise
242	(	_	_	I-Premise
243	two	_	_	I-Premise
244	-	_	_	I-Premise
245	sided	_	_	I-Premise
246	P	_	_	I-Premise
247	=	_	_	I-Premise
248	.	_	_	I-Premise

249	048	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	QOL	_	_	B-Premise
253	was	_	_	I-Premise
254	similar	_	_	I-Premise
255	for	_	_	I-Premise
256	both	_	_	I-Premise
257	treatment	_	_	I-Premise
258	arms	_	_	I-Premise
259	,	_	_	I-Premise
260	except	_	_	B-Premise
261	for	_	_	I-Premise
262	the	_	_	I-Premise
263	functional	_	_	I-Premise
264	activity	_	_	I-Premise
265	score	_	_	I-Premise
266	of	_	_	I-Premise
267	the	_	_	I-Premise
268	Rotterdam	_	_	I-Premise
269	Symptom	_	_	I-Premise
270	Checklist	_	_	I-Premise
271	,	_	_	I-Premise
272	where	_	_	I-Premise
273	QOL	_	_	I-Premise
274	data	_	_	I-Premise
275	statistically	_	_	I-Premise
276	significantly	_	_	I-Premise
277	favored	_	_	I-Premise
278	the	_	_	I-Premise
279	paclitaxel	_	_	I-Premise
280	plus	_	_	I-Premise
281	supportive	_	_	I-Premise
282	care	_	_	I-Premise
283	arm	_	_	I-Premise
284	(	_	_	I-Premise
285	two	_	_	I-Premise
286	-	_	_	I-Premise
287	sided	_	_	I-Premise
288	P	_	_	I-Premise
289	=	_	_	I-Premise
290	.	_	_	I-Premise

291	043	_	_	I-Premise
292	)	_	_	I-Premise
293	.	_	_	I-Premise

294	The	_	_	B-Claim
295	addition	_	_	I-Claim
296	of	_	_	I-Claim
297	paclitaxel	_	_	I-Claim
298	to	_	_	I-Claim
299	best	_	_	I-Claim
300	supportive	_	_	I-Claim
301	care	_	_	I-Claim
302	significantly	_	_	I-Claim
303	improved	_	_	I-Claim
304	survival	_	_	I-Claim
305	and	_	_	I-Claim
306	time	_	_	I-Claim
307	to	_	_	I-Claim
308	disease	_	_	I-Claim
309	progression	_	_	I-Claim
310	compared	_	_	I-Claim
311	with	_	_	I-Claim
312	best	_	_	I-Claim
313	supportive	_	_	I-Claim
314	care	_	_	I-Claim
315	in	_	_	I-Claim
316	patients	_	_	I-Claim
317	with	_	_	I-Claim
318	advanced	_	_	I-Claim
319	NSCLC	_	_	I-Claim
320	and	_	_	I-Claim
321	may	_	_	I-Claim
322	improve	_	_	I-Claim
323	some	_	_	I-Claim
324	aspects	_	_	I-Claim
325	of	_	_	I-Claim
326	QOL	_	_	I-Claim
327	.	_	_	I-Claim


0	Increased	_	_	O
1	attention	_	_	O
2	has	_	_	O
3	focused	_	_	O
4	on	_	_	O
5	exercise	_	_	O
6	as	_	_	O
7	a	_	_	O
8	quality	_	_	O
9	of	_	_	O
10	life	_	_	O
11	intervention	_	_	O
12	for	_	_	O
13	breast	_	_	O
14	cancer	_	_	O
15	survivors	_	_	O
16	during	_	_	O
17	and	_	_	O
18	after	_	_	O
19	adjuvant	_	_	O
20	therapy	_	_	O
21	.	_	_	O

22	Our	_	_	O
23	objective	_	_	O
24	was	_	_	O
25	to	_	_	O
26	examine	_	_	O
27	the	_	_	O
28	effects	_	_	O
29	of	_	_	O
30	an	_	_	O
31	oncologist	_	_	O
32	'	_	_	O
33	s	_	_	O
34	recommendation	_	_	O
35	to	_	_	O
36	exercise	_	_	O
37	on	_	_	O
38	self	_	_	O
39	-	_	_	O
40	reported	_	_	O
41	exercise	_	_	O
42	behavior	_	_	O
43	in	_	_	O
44	newly	_	_	O
45	diagnosed	_	_	O
46	breast	_	_	O
47	cancer	_	_	O
48	survivors	_	_	O
49	attending	_	_	O
50	their	_	_	O
51	first	_	_	O
52	adjuvant	_	_	O
53	therapy	_	_	O
54	consultation	_	_	O
55	.	_	_	O

56	Using	_	_	O
57	a	_	_	O
58	single	_	_	O
59	-	_	_	O
60	blinded	_	_	O
61	,	_	_	O
62	3	_	_	O
63	-	_	_	O
64	armed	_	_	O
65	,	_	_	O
66	randomized	_	_	O
67	controlled	_	_	O
68	trial	_	_	O
69	,	_	_	O
70	450	_	_	O
71	breast	_	_	O
72	cancer	_	_	O
73	survivors	_	_	O
74	were	_	_	O
75	randomly	_	_	O
76	assigned	_	_	O
77	to	_	_	O
78	receive	_	_	O
79	an	_	_	O
80	oncologist	_	_	O
81	exercise	_	_	O
82	recommendation	_	_	O
83	only	_	_	O
84	,	_	_	O
85	an	_	_	O
86	oncologist	_	_	O
87	exercise	_	_	O
88	recommendation	_	_	O
89	plus	_	_	O
90	referral	_	_	O
91	to	_	_	O
92	an	_	_	O
93	exercise	_	_	O
94	specialist	_	_	O
95	,	_	_	O
96	or	_	_	O
97	usual	_	_	O
98	care	_	_	O
99	.	_	_	O

100	The	_	_	O
101	primary	_	_	O
102	outcome	_	_	O
103	was	_	_	O
104	self	_	_	O
105	-	_	_	O
106	reported	_	_	O
107	total	_	_	O
108	exercise	_	_	O
109	(	_	_	O
110	in	_	_	O
111	metabolic	_	_	O
112	equivalent	_	_	O
113	[	_	_	O
114	MET	_	_	O
115	]	_	_	O
116	hours	_	_	O
117	per	_	_	O
118	week	_	_	O
119	)	_	_	O
120	at	_	_	O
121	5	_	_	O
122	weeks	_	_	O
123	postconsultation	_	_	O
124	.	_	_	O

125	The	_	_	O
126	follow	_	_	O
127	-	_	_	O
128	up	_	_	O
129	assessment	_	_	O
130	rate	_	_	O
131	was	_	_	O
132	73	_	_	O
133	%	_	_	O
134	(	_	_	O
135	329	_	_	O
136	of	_	_	O
137	450	_	_	O
138	)	_	_	O
139	.	_	_	O

140	Intention	_	_	B-Premise
141	-	_	_	I-Premise
142	to	_	_	I-Premise
143	-	_	_	I-Premise
144	treat	_	_	I-Premise
145	analysis	_	_	I-Premise
146	based	_	_	I-Premise
147	on	_	_	I-Premise
148	participants	_	_	I-Premise
149	with	_	_	I-Premise
150	follow	_	_	I-Premise
151	-	_	_	I-Premise
152	up	_	_	I-Premise
153	data	_	_	I-Premise
154	indicated	_	_	I-Premise
155	a	_	_	I-Premise
156	significant	_	_	I-Premise
157	difference	_	_	I-Premise
158	in	_	_	I-Premise
159	total	_	_	I-Premise
160	exercise	_	_	I-Premise
161	in	_	_	I-Premise
162	favor	_	_	I-Premise
163	of	_	_	I-Premise
164	the	_	_	I-Premise
165	recommendation	_	_	I-Premise
166	-	_	_	I-Premise
167	only	_	_	I-Premise
168	group	_	_	I-Premise
169	over	_	_	I-Premise
170	the	_	_	I-Premise
171	usual	_	_	I-Premise
172	care	_	_	I-Premise
173	group	_	_	I-Premise
174	(	_	_	I-Premise
175	mean	_	_	I-Premise
176	difference	_	_	I-Premise
177	,	_	_	I-Premise
178	3	_	_	I-Premise
179	.	_	_	I-Premise

180	4	_	_	I-Premise
181	MET	_	_	I-Premise
182	hr	_	_	I-Premise
183	per	_	_	I-Premise
184	week	_	_	I-Premise
185	;	_	_	I-Premise
186	95	_	_	I-Premise
187	%	_	_	I-Premise
188	confidence	_	_	I-Premise
189	interval	_	_	I-Premise
190	[	_	_	I-Premise
191	CI	_	_	I-Premise
192	]	_	_	I-Premise
193	,	_	_	I-Premise
194	0	_	_	I-Premise
195	.	_	_	I-Premise

196	7	_	_	I-Premise
197	-	_	_	I-Premise
198	6	_	_	I-Premise
199	.	_	_	I-Premise

200	1	_	_	I-Premise
201	MET	_	_	I-Premise
202	hr	_	_	I-Premise
203	per	_	_	I-Premise
204	week	_	_	I-Premise
205	;	_	_	I-Premise
206	p	_	_	I-Premise
207	=	_	_	I-Premise
208	.	_	_	I-Premise

209	011	_	_	I-Premise
210	)	_	_	I-Premise
211	.	_	_	I-Premise

212	There	_	_	B-Premise
213	was	_	_	I-Premise
214	no	_	_	I-Premise
215	significant	_	_	I-Premise
216	difference	_	_	I-Premise
217	between	_	_	I-Premise
218	the	_	_	I-Premise
219	recommendation	_	_	I-Premise
220	-	_	_	I-Premise
221	plus	_	_	I-Premise
222	-	_	_	I-Premise
223	referral	_	_	I-Premise
224	group	_	_	I-Premise
225	and	_	_	I-Premise
226	the	_	_	I-Premise
227	usual	_	_	I-Premise
228	care	_	_	I-Premise
229	group	_	_	I-Premise
230	(	_	_	I-Premise
231	mean	_	_	I-Premise
232	difference	_	_	I-Premise
233	,	_	_	I-Premise
234	1	_	_	I-Premise
235	.	_	_	I-Premise

236	5	_	_	I-Premise
237	MET	_	_	I-Premise
238	hr	_	_	I-Premise
239	per	_	_	I-Premise
240	week	_	_	I-Premise
241	;	_	_	I-Premise
242	95	_	_	I-Premise
243	%	_	_	I-Premise
244	CI	_	_	I-Premise
245	,	_	_	I-Premise
246	-	_	_	I-Premise
247	1	_	_	I-Premise
248	.	_	_	I-Premise

249	0	_	_	I-Premise
250	to	_	_	I-Premise
251	4	_	_	I-Premise
252	.	_	_	I-Premise

253	0	_	_	I-Premise
254	MET	_	_	I-Premise
255	hr	_	_	I-Premise
256	per	_	_	I-Premise
257	week	_	_	I-Premise
258	;	_	_	I-Premise
259	p	_	_	I-Premise
260	=	_	_	I-Premise
261	.	_	_	I-Premise

262	244	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	Ancillary	_	_	B-Premise
266	"	_	_	I-Premise
267	on	_	_	I-Premise
268	-	_	_	I-Premise
269	treatment	_	_	I-Premise
270	"	_	_	I-Premise
271	analyzes	_	_	I-Premise
272	showed	_	_	I-Premise
273	that	_	_	I-Premise
274	participants	_	_	I-Premise
275	who	_	_	I-Premise
276	recalled	_	_	I-Premise
277	an	_	_	I-Premise
278	exercise	_	_	I-Premise
279	recommendation	_	_	I-Premise
280	reported	_	_	I-Premise
281	significantly	_	_	I-Premise
282	more	_	_	I-Premise
283	total	_	_	I-Premise
284	exercise	_	_	I-Premise
285	than	_	_	I-Premise
286	participants	_	_	I-Premise
287	who	_	_	I-Premise
288	did	_	_	I-Premise
289	not	_	_	I-Premise
290	recall	_	_	I-Premise
291	an	_	_	I-Premise
292	exercise	_	_	I-Premise
293	recommendation	_	_	I-Premise
294	(	_	_	I-Premise
295	mean	_	_	I-Premise
296	difference	_	_	I-Premise
297	,	_	_	I-Premise
298	4	_	_	I-Premise
299	.	_	_	I-Premise

300	1	_	_	I-Premise
301	MET	_	_	I-Premise
302	hr	_	_	I-Premise
303	per	_	_	I-Premise
304	week	_	_	I-Premise
305	:	_	_	I-Premise
306	95	_	_	I-Premise
307	%	_	_	I-Premise
308	CI	_	_	I-Premise
309	,	_	_	I-Premise
310	1	_	_	I-Premise
311	.	_	_	I-Premise

312	9	_	_	I-Premise
313	-	_	_	I-Premise
314	6	_	_	I-Premise
315	.	_	_	I-Premise

316	4	_	_	I-Premise
317	MET	_	_	I-Premise
318	hr	_	_	I-Premise
319	per	_	_	I-Premise
320	week	_	_	I-Premise
321	;	_	_	I-Premise
322	p	_	_	I-Premise
323	<	_	_	I-Premise
324	.	_	_	I-Premise

325	001	_	_	I-Premise
326	)	_	_	I-Premise
327	.	_	_	I-Premise

328	Our	_	_	B-Claim
329	findings	_	_	I-Claim
330	suggest	_	_	I-Claim
331	that	_	_	I-Claim
332	an	_	_	I-Claim
333	oncologist	_	_	I-Claim
334	recommendation	_	_	I-Claim
335	may	_	_	I-Claim
336	increase	_	_	I-Claim
337	exercise	_	_	I-Claim
338	behavior	_	_	I-Claim
339	in	_	_	I-Claim
340	newly	_	_	I-Claim
341	diagnosed	_	_	I-Claim
342	breast	_	_	I-Claim
343	cancer	_	_	I-Claim
344	survivors	_	_	I-Claim
345	,	_	_	I-Claim
346	particularly	_	_	I-Claim
347	if	_	_	I-Claim
348	it	_	_	I-Claim
349	is	_	_	I-Claim
350	recalled	_	_	I-Claim
351	1	_	_	I-Claim
352	week	_	_	I-Claim
353	after	_	_	I-Claim
354	the	_	_	I-Claim
355	recommendation	_	_	I-Claim
356	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	quality	_	_	O
10	of	_	_	O
11	life	_	_	O
12	(	_	_	O
13	QOL	_	_	O
14	)	_	_	O
15	of	_	_	O
16	high	_	_	O
17	-	_	_	O
18	risk	_	_	O
19	breast	_	_	O
20	cancer	_	_	O
21	patients	_	_	O
22	included	_	_	O
23	in	_	_	O
24	a	_	_	O
25	randomized	_	_	O
26	clinical	_	_	O
27	trial	_	_	O
28	(	_	_	O
29	PEGASE	_	_	O
30	01	_	_	O
31	)	_	_	O
32	comparing	_	_	O
33	conventional	_	_	O
34	chemotherapy	_	_	O
35	versus	_	_	O
36	adding	_	_	O
37	an	_	_	O
38	additional	_	_	O
39	high	_	_	O
40	-	_	_	O
41	dose	_	_	O
42	chemotherapy	_	_	O
43	(	_	_	O
44	HDC	_	_	O
45	)	_	_	O
46	cycle	_	_	O
47	with	_	_	O
48	blood	_	_	O
49	stem	_	_	O
50	cell	_	_	O
51	support	_	_	O
52	.	_	_	O

53	A	_	_	O
54	total	_	_	O
55	of	_	_	O
56	314	_	_	O
57	patients	_	_	O
58	were	_	_	O
59	included	_	_	O
60	in	_	_	O
61	the	_	_	O
62	clinical	_	_	O
63	trial	_	_	O
64	.	_	_	O

65	QOL	_	_	O
66	evaluations	_	_	O
67	were	_	_	O
68	available	_	_	O
69	for	_	_	O
70	199	_	_	O
71	patients	_	_	O
72	.	_	_	O

73	QOL	_	_	O
74	was	_	_	O
75	assessed	_	_	O
76	over	_	_	O
77	a	_	_	O
78	1	_	_	O
79	-	_	_	O
80	year	_	_	O
81	follow	_	_	O
82	-	_	_	O
83	up	_	_	O
84	period	_	_	O
85	,	_	_	O
86	using	_	_	O
87	the	_	_	O
88	European	_	_	O
89	Organization	_	_	O
90	for	_	_	O
91	Research	_	_	O
92	and	_	_	O
93	Treatment	_	_	O
94	of	_	_	O
95	Cancer	_	_	O
96	Quality	_	_	O
97	of	_	_	O
98	Life	_	_	O
99	Questionnaire	_	_	O
100	C	_	_	O
101	-	_	_	O
102	30	_	_	O
103	.	_	_	O

104	The	_	_	O
105	results	_	_	O
106	were	_	_	O
107	analyzed	_	_	O
108	using	_	_	O
109	a	_	_	O
110	linear	_	_	O
111	mixed	_	_	O
112	-	_	_	O
113	effects	_	_	O
114	model	_	_	O
115	.	_	_	O

116	Toxicity	_	_	B-Premise
117	of	_	_	I-Premise
118	HDC	_	_	I-Premise
119	has	_	_	I-Premise
120	a	_	_	I-Premise
121	strong	_	_	I-Premise
122	negative	_	_	I-Premise
123	impact	_	_	I-Premise
124	on	_	_	I-Premise
125	patients	_	_	I-Premise
126	'	_	_	I-Premise
127	QOL	_	_	I-Premise
128	during	_	_	I-Premise
129	the	_	_	I-Premise
130	treatment	_	_	I-Premise
131	phase	_	_	I-Premise
132	.	_	_	I-Premise

133	This	_	_	B-Premise
134	negative	_	_	I-Premise
135	impact	_	_	I-Premise
136	tended	_	_	I-Premise
137	to	_	_	I-Premise
138	last	_	_	I-Premise
139	longer	_	_	I-Premise
140	in	_	_	I-Premise
141	the	_	_	I-Premise
142	HDC	_	_	I-Premise
143	group	_	_	I-Premise
144	,	_	_	I-Premise
145	as	_	_	I-Premise
146	for	_	_	I-Premise
147	most	_	_	I-Premise
148	of	_	_	I-Premise
149	the	_	_	I-Premise
150	QLQ	_	_	I-Premise
151	-	_	_	I-Premise
152	C30	_	_	I-Premise
153	scales	_	_	I-Premise
154	,	_	_	I-Premise
155	the	_	_	I-Premise
156	QOL	_	_	I-Premise
157	scores	_	_	I-Premise
158	of	_	_	I-Premise
159	HDC	_	_	I-Premise
160	patients	_	_	I-Premise
161	tend	_	_	I-Premise
162	to	_	_	I-Premise
163	improve	_	_	I-Premise
164	at	_	_	I-Premise
165	a	_	_	I-Premise
166	slower	_	_	I-Premise
167	rate	_	_	I-Premise
168	than	_	_	I-Premise
169	that	_	_	I-Premise
170	of	_	_	I-Premise
171	patients	_	_	I-Premise
172	receiving	_	_	I-Premise
173	standard	_	_	I-Premise
174	chemotherapy	_	_	I-Premise
175	.	_	_	I-Premise

176	In	_	_	O
177	particular	_	_	O
178	,	_	_	O
179	physical	_	_	B-Premise
180	functioning	_	_	I-Premise
181	remains	_	_	I-Premise
182	deteriorated	_	_	I-Premise
183	1	_	_	I-Premise
184	year	_	_	I-Premise
185	after	_	_	I-Premise
186	inclusion	_	_	I-Premise
187	for	_	_	I-Premise
188	HDC	_	_	I-Premise
189	patients	_	_	I-Premise
190	comparatively	_	_	I-Premise
191	to	_	_	I-Premise
192	conventional	_	_	I-Premise
193	chemotherapy	_	_	I-Premise
194	patients	_	_	I-Premise
195	(	_	_	I-Premise
196	85	_	_	I-Premise
197	.	_	_	I-Premise

198	99	_	_	I-Premise
199	vs	_	_	I-Premise
200	.	_	_	I-Premise

201	76	_	_	I-Premise
202	.	_	_	I-Premise

203	65	_	_	I-Premise
204	,	_	_	I-Premise
205	P	_	_	I-Premise
206	=	_	_	I-Premise
207	0	_	_	I-Premise
208	.	_	_	I-Premise

209	021	_	_	I-Premise
210	)	_	_	I-Premise
211	,	_	_	O
212	and	_	_	B-Premise
213	the	_	_	I-Premise
214	pain	_	_	I-Premise
215	score	_	_	I-Premise
216	was	_	_	I-Premise
217	still	_	_	I-Premise
218	higher	_	_	I-Premise
219	in	_	_	I-Premise
220	the	_	_	I-Premise
221	HDC	_	_	I-Premise
222	group	_	_	I-Premise
223	at	_	_	I-Premise
224	that	_	_	I-Premise
225	time	_	_	I-Premise
226	(	_	_	I-Premise
227	28	_	_	I-Premise
228	.	_	_	I-Premise

229	32	_	_	I-Premise
230	vs	_	_	I-Premise
231	.	_	_	I-Premise

232	15	_	_	I-Premise
233	.	_	_	I-Premise

234	97	_	_	I-Premise
235	,	_	_	I-Premise
236	P	_	_	I-Premise
237	=	_	_	I-Premise
238	0	_	_	I-Premise
239	.	_	_	I-Premise

240	004	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	HDC	_	_	B-Claim
244	has	_	_	I-Claim
245	a	_	_	I-Claim
246	negative	_	_	I-Claim
247	impact	_	_	I-Claim
248	on	_	_	I-Claim
249	QOL	_	_	I-Claim
250	even	_	_	I-Claim
251	after	_	_	I-Claim
252	treatment	_	_	I-Claim
253	phase	_	_	I-Claim
254	.	_	_	I-Claim

255	In	_	_	O
256	the	_	_	O
257	absence	_	_	O
258	of	_	_	O
259	an	_	_	O
260	overall	_	_	O
261	survival	_	_	O
262	benefit	_	_	O
263	of	_	_	O
264	using	_	_	O
265	HDC	_	_	O
266	for	_	_	O
267	high	_	_	O
268	-	_	_	O
269	risk	_	_	O
270	breast	_	_	O
271	cancer	_	_	O
272	patients	_	_	O
273	,	_	_	O
274	QOL	_	_	O
275	studies	_	_	O
276	with	_	_	O
277	a	_	_	O
278	longer	_	_	O
279	follow	_	_	O
280	-	_	_	O
281	up	_	_	O
282	play	_	_	O
283	an	_	_	O
284	important	_	_	O
285	role	_	_	O
286	in	_	_	O
287	informing	_	_	O
288	the	_	_	O
289	complex	_	_	O
290	trade	_	_	O
291	-	_	_	O
292	off	_	_	O
293	implied	_	_	O
294	by	_	_	O
295	HDC	_	_	O
296	between	_	_	O
297	higher	_	_	O
298	toxicity	_	_	O
299	,	_	_	O
300	reduced	_	_	O
301	risk	_	_	O
302	of	_	_	O
303	relapse	_	_	O
304	,	_	_	O
305	and	_	_	O
306	QOL	_	_	O
307	decrease	_	_	O
308	after	_	_	O
309	the	_	_	O
310	active	_	_	O
311	phase	_	_	O
312	of	_	_	O
313	treatment	_	_	O
314	.	_	_	O


0	Fatigue	_	_	O
1	is	_	_	O
2	a	_	_	O
3	frequent	_	_	O
4	problem	_	_	O
5	after	_	_	O
6	surgical	_	_	O
7	treatment	_	_	O
8	of	_	_	O
9	solid	_	_	O
10	tumours	_	_	O
11	.	_	_	O

12	Aerobic	_	_	B-Claim
13	exercise	_	_	I-Claim
14	and	_	_	I-Claim
15	psychosocial	_	_	I-Claim
16	interventions	_	_	I-Claim
17	have	_	_	I-Claim
18	been	_	_	I-Claim
19	shown	_	_	I-Claim
20	to	_	_	I-Claim
21	reduce	_	_	I-Claim
22	the	_	_	I-Claim
23	severity	_	_	I-Claim
24	of	_	_	I-Claim
25	this	_	_	I-Claim
26	symptom	_	_	I-Claim
27	in	_	_	I-Claim
28	cancer	_	_	I-Claim
29	patients	_	_	I-Claim
30	.	_	_	I-Claim

31	Therefore	_	_	O
32	,	_	_	O
33	we	_	_	O
34	compared	_	_	O
35	the	_	_	O
36	effect	_	_	O
37	of	_	_	O
38	the	_	_	O
39	two	_	_	O
40	therapies	_	_	O
41	on	_	_	O
42	fatigue	_	_	O
43	in	_	_	O
44	a	_	_	O
45	randomised	_	_	O
46	controlled	_	_	O
47	study	_	_	O
48	.	_	_	O

49	Seventy	_	_	O
50	-	_	_	O
51	two	_	_	O
52	patients	_	_	O
53	who	_	_	O
54	underwent	_	_	O
55	surgery	_	_	O
56	for	_	_	O
57	lung	_	_	O
58	(	_	_	O
59	n	_	_	O
60	=	_	_	O
61	27	_	_	O
62	)	_	_	O
63	or	_	_	O
64	gastrointestinal	_	_	O
65	tumours	_	_	O
66	(	_	_	O
67	n	_	_	O
68	=	_	_	O
69	42	_	_	O
70	)	_	_	O
71	were	_	_	O
72	assigned	_	_	O
73	to	_	_	O
74	an	_	_	O
75	aerobic	_	_	O
76	exercise	_	_	O
77	group	_	_	O
78	(	_	_	O
79	stationary	_	_	O
80	biking	_	_	O
81	30	_	_	O
82	min	_	_	O
83	five	_	_	O
84	times	_	_	O
85	weekly	_	_	O
86	)	_	_	O
87	or	_	_	O
88	a	_	_	O
89	progressive	_	_	O
90	relaxation	_	_	O
91	training	_	_	O
92	group	_	_	O
93	(	_	_	O
94	45	_	_	O
95	min	_	_	O
96	three	_	_	O
97	times	_	_	O
98	per	_	_	O
99	week	_	_	O
100	)	_	_	O
101	.	_	_	O

102	Both	_	_	O
103	interventions	_	_	O
104	were	_	_	O
105	carried	_	_	O
106	out	_	_	O
107	for	_	_	O
108	3	_	_	O
109	weeks	_	_	O
110	.	_	_	O

111	At	_	_	O
112	the	_	_	O
113	beginning	_	_	O
114	and	_	_	O
115	the	_	_	O
116	end	_	_	O
117	of	_	_	O
118	the	_	_	O
119	study	_	_	O
120	,	_	_	O
121	we	_	_	O
122	evaluated	_	_	O
123	physical	_	_	O
124	,	_	_	O
125	cognitive	_	_	O
126	and	_	_	O
127	emotional	_	_	O
128	status	_	_	O
129	and	_	_	O
130	somatic	_	_	O
131	complaints	_	_	O
132	with	_	_	O
133	the	_	_	O
134	European	_	_	O
135	Organization	_	_	O
136	for	_	_	O
137	Research	_	_	O
138	and	_	_	O
139	Treatment	_	_	O
140	of	_	_	O
141	Cancer	_	_	O
142	Quality	_	_	O
143	of	_	_	O
144	Life	_	_	O
145	Questionnaire	_	_	O
146	Core	_	_	O
147	Module	_	_	O
148	(	_	_	O
149	EORTC	_	_	O
150	-	_	_	O
151	QLQ	_	_	O
152	-	_	_	O
153	30	_	_	O
154	)	_	_	O
155	questionnaire	_	_	O
156	,	_	_	O
157	and	_	_	O
158	maximal	_	_	O
159	physical	_	_	O
160	performance	_	_	O
161	with	_	_	O
162	an	_	_	O
163	ergometric	_	_	O
164	stress	_	_	O
165	test	_	_	O
166	.	_	_	O

167	Physical	_	_	B-Premise
168	performance	_	_	I-Premise
169	of	_	_	I-Premise
170	the	_	_	I-Premise
171	training	_	_	I-Premise
172	group	_	_	I-Premise
173	improved	_	_	I-Premise
174	significantly	_	_	I-Premise
175	during	_	_	I-Premise
176	the	_	_	I-Premise
177	programme	_	_	I-Premise
178	(	_	_	I-Premise
179	9	_	_	I-Premise
180	.	_	_	I-Premise

181	4	_	_	I-Premise
182	+	_	_	I-Premise
183	/	_	_	I-Premise
184	-	_	_	I-Premise
185	20	_	_	I-Premise
186	watts	_	_	I-Premise
187	,	_	_	I-Premise
188	p	_	_	I-Premise
189	=	_	_	I-Premise
190	0	_	_	I-Premise
191	.	_	_	I-Premise

192	01	_	_	I-Premise
193	)	_	_	I-Premise
194	but	_	_	I-Premise
195	remained	_	_	I-Premise
196	unchanged	_	_	I-Premise
197	in	_	_	I-Premise
198	the	_	_	I-Premise
199	relaxation	_	_	I-Premise
200	group	_	_	I-Premise
201	(	_	_	I-Premise
202	1	_	_	I-Premise
203	.	_	_	I-Premise

204	5	_	_	I-Premise
205	+	_	_	I-Premise
206	/	_	_	I-Premise
207	-	_	_	I-Premise
208	14	_	_	I-Premise
209	.	_	_	I-Premise

210	8	_	_	I-Premise
211	watts	_	_	I-Premise
212	,	_	_	I-Premise
213	p	_	_	I-Premise
214	=	_	_	I-Premise
215	0	_	_	I-Premise
216	.	_	_	I-Premise

217	37	_	_	I-Premise
218	)	_	_	I-Premise
219	.	_	_	I-Premise

220	Fatigue	_	_	B-Premise
221	and	_	_	I-Premise
222	global	_	_	I-Premise
223	health	_	_	I-Premise
224	scores	_	_	I-Premise
225	improved	_	_	I-Premise
226	in	_	_	I-Premise
227	both	_	_	I-Premise
228	groups	_	_	I-Premise
229	during	_	_	I-Premise
230	the	_	_	I-Premise
231	intervention	_	_	I-Premise
232	(	_	_	I-Premise
233	fatigue	_	_	I-Premise
234	:	_	_	I-Premise
235	training	_	_	I-Premise
236	group	_	_	I-Premise
237	21	_	_	I-Premise
238	%	_	_	I-Premise
239	,	_	_	I-Premise
240	relaxation	_	_	I-Premise
241	group	_	_	I-Premise
242	19	_	_	I-Premise
243	%	_	_	I-Premise
244	;	_	_	I-Premise
245	global	_	_	I-Premise
246	health	_	_	I-Premise
247	of	_	_	I-Premise
248	both	_	_	I-Premise
249	groups	_	_	I-Premise
250	19	_	_	I-Premise
251	%	_	_	I-Premise
252	,	_	_	I-Premise
253	p	_	_	I-Premise
254	for	_	_	I-Premise
255	all	_	_	I-Premise
256	<	_	_	I-Premise
257	or	_	_	I-Premise
258	=	_	_	I-Premise
259	0	_	_	I-Premise
260	.	_	_	I-Premise

261	01	_	_	I-Premise
262	)	_	_	I-Premise
263	;	_	_	I-Premise
264	however	_	_	B-Premise
265	,	_	_	I-Premise
266	there	_	_	I-Premise
267	was	_	_	I-Premise
268	no	_	_	I-Premise
269	significant	_	_	I-Premise
270	difference	_	_	I-Premise
271	between	_	_	I-Premise
272	changes	_	_	I-Premise
273	in	_	_	I-Premise
274	the	_	_	I-Premise
275	scores	_	_	I-Premise
276	of	_	_	I-Premise
277	both	_	_	I-Premise
278	groups	_	_	I-Premise
279	(	_	_	I-Premise
280	p	_	_	I-Premise
281	=	_	_	I-Premise
282	0	_	_	I-Premise
283	.	_	_	I-Premise

284	67	_	_	I-Premise
285	)	_	_	I-Premise
286	.	_	_	I-Premise

287	We	_	_	B-Claim
288	conclude	_	_	I-Claim
289	that	_	_	I-Claim
290	a	_	_	I-Claim
291	structured	_	_	I-Claim
292	aerobic	_	_	I-Claim
293	training	_	_	I-Claim
294	programme	_	_	I-Claim
295	improves	_	_	I-Claim
296	the	_	_	I-Claim
297	physical	_	_	I-Claim
298	performance	_	_	I-Claim
299	of	_	_	I-Claim
300	patients	_	_	I-Claim
301	recovering	_	_	I-Claim
302	from	_	_	I-Claim
303	surgery	_	_	I-Claim
304	for	_	_	I-Claim
305	solid	_	_	I-Claim
306	tumours	_	_	I-Claim
307	.	_	_	I-Claim

308	However	_	_	B-Claim
309	,	_	_	I-Claim
310	exercise	_	_	I-Claim
311	is	_	_	I-Claim
312	not	_	_	I-Claim
313	better	_	_	I-Claim
314	than	_	_	I-Claim
315	progressive	_	_	I-Claim
316	relaxation	_	_	I-Claim
317	training	_	_	I-Claim
318	for	_	_	I-Claim
319	the	_	_	I-Claim
320	treatment	_	_	I-Claim
321	of	_	_	I-Claim
322	fatigue	_	_	I-Claim
323	in	_	_	I-Claim
324	this	_	_	I-Claim
325	setting	_	_	I-Claim
326	.	_	_	I-Claim


0	This	_	_	O
1	report	_	_	O
2	describes	_	_	O
3	the	_	_	O
4	quality	_	_	O
5	of	_	_	O
6	life	_	_	O
7	(	_	_	O
8	QOL	_	_	O
9	)	_	_	O
10	findings	_	_	O
11	of	_	_	O
12	a	_	_	O
13	randomized	_	_	O
14	placebo	_	_	O
15	controlled	_	_	O
16	study	_	_	O
17	of	_	_	O
18	erlotinib	_	_	O
19	,	_	_	O
20	an	_	_	O
21	epidermal	_	_	O
22	growth	_	_	O
23	factor	_	_	O
24	receptor	_	_	O
25	inhibitor	_	_	O
26	,	_	_	O
27	in	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	non	_	_	O
31	-	_	_	O
32	small	_	_	O
33	-	_	_	O
34	cell	_	_	O
35	lung	_	_	O
36	cancer	_	_	O
37	(	_	_	O
38	NSCLC	_	_	O
39	)	_	_	O
40	.	_	_	O

41	This	_	_	O
42	double	_	_	O
43	-	_	_	O
44	blind	_	_	O
45	phase	_	_	O
46	III	_	_	O
47	trial	_	_	O
48	randomly	_	_	O
49	assigned	_	_	O
50	731	_	_	O
51	patients	_	_	O
52	with	_	_	O
53	NSCLC	_	_	O
54	who	_	_	O
55	had	_	_	O
56	progressed	_	_	O
57	after	_	_	O
58	prior	_	_	O
59	chemotherapy	_	_	O
60	to	_	_	O
61	erlotinib	_	_	O
62	150	_	_	O
63	mg	_	_	O
64	daily	_	_	O
65	or	_	_	O
66	placebo	_	_	O
67	,	_	_	O
68	with	_	_	O
69	survival	_	_	O
70	as	_	_	O
71	the	_	_	O
72	primary	_	_	O
73	study	_	_	O
74	outcome	_	_	O
75	.	_	_	O

76	QOL	_	_	O
77	was	_	_	O
78	assessed	_	_	O
79	by	_	_	O
80	European	_	_	O
81	Organisation	_	_	O
82	for	_	_	O
83	Research	_	_	O
84	and	_	_	O
85	Treatment	_	_	O
86	of	_	_	O
87	Cancer	_	_	O
88	QLQ	_	_	O
89	-	_	_	O
90	C30	_	_	O
91	and	_	_	O
92	the	_	_	O
93	lung	_	_	O
94	cancer	_	_	O
95	module	_	_	O
96	QLQ	_	_	O
97	-	_	_	O
98	LC13	_	_	O
99	.	_	_	O

100	The	_	_	O
101	primary	_	_	O
102	end	_	_	O
103	points	_	_	O
104	for	_	_	O
105	QOL	_	_	O
106	analysis	_	_	O
107	were	_	_	O
108	time	_	_	O
109	to	_	_	O
110	deterioration	_	_	O
111	of	_	_	O
112	three	_	_	O
113	common	_	_	O
114	lung	_	_	O
115	cancer	_	_	O
116	symptoms	_	_	O
117	:	_	_	O
118	cough	_	_	O
119	,	_	_	O
120	dyspnea	_	_	O
121	,	_	_	O
122	and	_	_	O
123	pain	_	_	O
124	.	_	_	O

125	Survival	_	_	B-Premise
126	was	_	_	I-Premise
127	significantly	_	_	I-Premise
128	longer	_	_	I-Premise
129	(	_	_	I-Premise
130	hazard	_	_	I-Premise
131	ratio	_	_	I-Premise
132	,	_	_	I-Premise
133	0	_	_	I-Premise
134	.	_	_	I-Premise

135	70	_	_	I-Premise
136	;	_	_	I-Premise
137	P	_	_	I-Premise
138	<	_	_	I-Premise
139	.	_	_	I-Premise

140	0001	_	_	I-Premise
141	)	_	_	I-Premise
142	in	_	_	I-Premise
143	the	_	_	I-Premise
144	erlotinib	_	_	I-Premise
145	arm	_	_	I-Premise
146	.	_	_	I-Premise

147	Compliance	_	_	B-Premise
148	with	_	_	I-Premise
149	QOL	_	_	I-Premise
150	was	_	_	I-Premise
151	87	_	_	I-Premise
152	%	_	_	I-Premise
153	at	_	_	I-Premise
154	baseline	_	_	I-Premise
155	and	_	_	I-Premise
156	more	_	_	I-Premise
157	than	_	_	I-Premise
158	70	_	_	I-Premise
159	%	_	_	I-Premise
160	during	_	_	I-Premise
161	treatment	_	_	I-Premise
162	.	_	_	I-Premise

163	Patients	_	_	B-Premise
164	receiving	_	_	I-Premise
165	erlotinib	_	_	I-Premise
166	had	_	_	I-Premise
167	significantly	_	_	I-Premise
168	longer	_	_	I-Premise
169	median	_	_	I-Premise
170	time	_	_	I-Premise
171	to	_	_	I-Premise
172	deterioration	_	_	I-Premise
173	for	_	_	I-Premise
174	all	_	_	I-Premise
175	three	_	_	I-Premise
176	symptoms	_	_	I-Premise
177	(	_	_	I-Premise
178	4	_	_	I-Premise
179	.	_	_	I-Premise

180	9	_	_	I-Premise
181	v	_	_	I-Premise
182	3	_	_	I-Premise
183	.	_	_	I-Premise

184	7	_	_	I-Premise
185	months	_	_	I-Premise
186	for	_	_	I-Premise
187	cough	_	_	I-Premise
188	[	_	_	I-Premise
189	P	_	_	I-Premise
190	=	_	_	I-Premise
191	.	_	_	I-Premise

192	04	_	_	I-Premise
193	]	_	_	I-Premise
194	;	_	_	I-Premise
195	4	_	_	I-Premise
196	.	_	_	I-Premise

197	7	_	_	I-Premise
198	v	_	_	I-Premise
199	2	_	_	I-Premise
200	.	_	_	I-Premise

201	9	_	_	I-Premise
202	months	_	_	I-Premise
203	for	_	_	I-Premise
204	dyspnea	_	_	I-Premise
205	[	_	_	I-Premise
206	P	_	_	I-Premise
207	=	_	_	I-Premise
208	.	_	_	I-Premise

209	04	_	_	I-Premise
210	]	_	_	I-Premise
211	,	_	_	I-Premise
212	and	_	_	I-Premise
213	2	_	_	I-Premise
214	.	_	_	I-Premise

215	8	_	_	I-Premise
216	v	_	_	I-Premise
217	1	_	_	I-Premise
218	.	_	_	I-Premise

219	9	_	_	I-Premise
220	months	_	_	I-Premise
221	for	_	_	I-Premise
222	pain	_	_	I-Premise
223	[	_	_	I-Premise
224	P	_	_	I-Premise
225	=	_	_	I-Premise
226	.	_	_	I-Premise

227	03	_	_	I-Premise
228	]	_	_	I-Premise
229	)	_	_	I-Premise
230	.	_	_	I-Premise

231	QOL	_	_	B-Premise
232	response	_	_	I-Premise
233	analyses	_	_	I-Premise
234	showed	_	_	I-Premise
235	that	_	_	I-Premise
236	44	_	_	I-Premise
237	%	_	_	I-Premise
238	,	_	_	I-Premise
239	34	_	_	I-Premise
240	%	_	_	I-Premise
241	,	_	_	I-Premise
242	and	_	_	I-Premise
243	42	_	_	I-Premise
244	%	_	_	I-Premise
245	of	_	_	I-Premise
246	patients	_	_	I-Premise
247	receiving	_	_	I-Premise
248	erlotinib	_	_	I-Premise
249	had	_	_	I-Premise
250	improvement	_	_	I-Premise
251	in	_	_	I-Premise
252	these	_	_	I-Premise
253	three	_	_	I-Premise
254	symptoms	_	_	I-Premise
255	,	_	_	I-Premise
256	respectively	_	_	I-Premise
257	.	_	_	I-Premise

258	This	_	_	B-Premise
259	was	_	_	I-Premise
260	accompanied	_	_	I-Premise
261	by	_	_	I-Premise
262	a	_	_	I-Premise
263	significant	_	_	I-Premise
264	improvement	_	_	I-Premise
265	in	_	_	I-Premise
266	the	_	_	I-Premise
267	physical	_	_	I-Premise
268	function	_	_	I-Premise
269	(	_	_	I-Premise
270	31	_	_	I-Premise
271	%	_	_	I-Premise
272	erlotinib	_	_	I-Premise
273	v	_	_	I-Premise
274	19	_	_	I-Premise
275	%	_	_	I-Premise
276	placebo	_	_	I-Premise
277	,	_	_	I-Premise
278	P	_	_	I-Premise
279	=	_	_	I-Premise
280	.	_	_	I-Premise

281	01	_	_	I-Premise
282	)	_	_	I-Premise
283	,	_	_	I-Premise
284	and	_	_	I-Premise
285	global	_	_	I-Premise
286	QOL	_	_	I-Premise
287	(	_	_	I-Premise
288	35	_	_	I-Premise
289	%	_	_	I-Premise
290	v	_	_	I-Premise
291	26	_	_	I-Premise
292	%	_	_	I-Premise
293	,	_	_	I-Premise
294	P	_	_	I-Premise
295	<	_	_	I-Premise
296	.	_	_	I-Premise

297	0001	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	Patients	_	_	B-Premise
301	with	_	_	I-Premise
302	complete	_	_	I-Premise
303	or	_	_	I-Premise
304	partial	_	_	I-Premise
305	response	_	_	I-Premise
306	were	_	_	I-Premise
307	more	_	_	I-Premise
308	likely	_	_	I-Premise
309	to	_	_	I-Premise
310	have	_	_	I-Premise
311	improvement	_	_	I-Premise
312	in	_	_	I-Premise
313	the	_	_	I-Premise
314	QOL	_	_	I-Premise
315	response	_	_	I-Premise
316	than	_	_	I-Premise
317	patients	_	_	I-Premise
318	with	_	_	I-Premise
319	stable	_	_	I-Premise
320	or	_	_	I-Premise
321	progressive	_	_	I-Premise
322	disease	_	_	I-Premise
323	(	_	_	I-Premise
324	P	_	_	I-Premise
325	<	_	_	I-Premise
326	.	_	_	I-Premise

327	01	_	_	I-Premise
328	)	_	_	I-Premise
329	.	_	_	I-Premise

330	Erlotinib	_	_	B-Claim
331	not	_	_	I-Claim
332	only	_	_	I-Claim
333	improves	_	_	I-Claim
334	survival	_	_	I-Claim
335	in	_	_	I-Claim
336	previously	_	_	I-Claim
337	treated	_	_	I-Claim
338	patients	_	_	I-Claim
339	with	_	_	I-Claim
340	NSCLC	_	_	I-Claim
341	,	_	_	I-Claim
342	but	_	_	I-Claim
343	also	_	_	I-Claim
344	improves	_	_	I-Claim
345	tumor	_	_	I-Claim
346	-	_	_	I-Claim
347	related	_	_	I-Claim
348	symptoms	_	_	I-Claim
349	and	_	_	I-Claim
350	important	_	_	I-Claim
351	aspects	_	_	I-Claim
352	of	_	_	I-Claim
353	QOL	_	_	I-Claim
354	.	_	_	I-Claim


0	This	_	_	O
1	phase	_	_	O
2	III	_	_	O
3	trial	_	_	O
4	was	_	_	O
5	conducted	_	_	O
6	to	_	_	O
7	test	_	_	O
8	whether	_	_	O
9	the	_	_	O
10	novel	_	_	O
11	vascular	_	_	O
12	disrupting	_	_	O
13	agent	_	_	O
14	ASA404	_	_	O
15	(	_	_	O
16	vadimezan	_	_	O
17	)	_	_	O
18	,	_	_	O
19	when	_	_	O
20	combined	_	_	O
21	with	_	_	O
22	first	_	_	O
23	-	_	_	O
24	line	_	_	O
25	platinum	_	_	O
26	-	_	_	O
27	based	_	_	O
28	chemotherapy	_	_	O
29	,	_	_	O
30	improves	_	_	O
31	survival	_	_	O
32	in	_	_	O
33	patients	_	_	O
34	with	_	_	O
35	advanced	_	_	O
36	non	_	_	O
37	-	_	_	O
38	small	_	_	O
39	-	_	_	O
40	cell	_	_	O
41	lung	_	_	O
42	cancer	_	_	O
43	(	_	_	O
44	NSCLC	_	_	O
45	)	_	_	O
46	versus	_	_	O
47	chemotherapy	_	_	O
48	alone	_	_	O
49	.	_	_	O

50	Patients	_	_	O
51	with	_	_	O
52	advanced	_	_	O
53	stage	_	_	O
54	IIIB	_	_	O
55	or	_	_	O
56	IV	_	_	O
57	NSCLC	_	_	O
58	,	_	_	O
59	stratified	_	_	O
60	by	_	_	O
61	sex	_	_	O
62	and	_	_	O
63	tumor	_	_	O
64	histology	_	_	O
65	,	_	_	O
66	were	_	_	O
67	randomly	_	_	O
68	assigned	_	_	O
69	1	_	_	O
70	:	_	_	O
71	1	_	_	O
72	to	_	_	O
73	paclitaxel	_	_	O
74	(	_	_	O
75	200	_	_	O
76	mg	_	_	O
77	/	_	_	O
78	m	_	_	O
79	(	_	_	O
80	2	_	_	O
81	)	_	_	O
82	)	_	_	O
83	and	_	_	O
84	carboplatin	_	_	O
85	(	_	_	O
86	area	_	_	O
87	under	_	_	O
88	the	_	_	O
89	curve	_	_	O
90	,	_	_	O
91	6	_	_	O
92	.	_	_	O

93	0	_	_	O
94	)	_	_	O
95	with	_	_	O
96	or	_	_	O
97	without	_	_	O
98	ASA404	_	_	O
99	(	_	_	O
100	1	_	_	O
101	,	_	_	O
102	800	_	_	O
103	mg	_	_	O
104	m	_	_	O
105	(	_	_	O
106	2	_	_	O
107	)	_	_	O
108	)	_	_	O
109	,	_	_	O
110	given	_	_	O
111	intravenously	_	_	O
112	once	_	_	O
113	every	_	_	O
114	3	_	_	O
115	weeks	_	_	O
116	for	_	_	O
117	six	_	_	O
118	cycles	_	_	O
119	followed	_	_	O
120	by	_	_	O
121	maintenance	_	_	O
122	ASA404	_	_	O
123	or	_	_	O
124	placebo	_	_	O
125	.	_	_	O

126	Primary	_	_	O
127	end	_	_	O
128	point	_	_	O
129	was	_	_	O
130	overall	_	_	O
131	survival	_	_	O
132	(	_	_	O
133	OS	_	_	O
134	)	_	_	O
135	;	_	_	O
136	secondary	_	_	O
137	end	_	_	O
138	points	_	_	O
139	included	_	_	O
140	overall	_	_	O
141	response	_	_	O
142	rate	_	_	O
143	(	_	_	O
144	ORR	_	_	O
145	)	_	_	O
146	and	_	_	O
147	progression	_	_	O
148	-	_	_	O
149	free	_	_	O
150	survival	_	_	O
151	(	_	_	O
152	PFS	_	_	O
153	)	_	_	O
154	.	_	_	O

155	One	_	_	O
156	thousand	_	_	O
157	two	_	_	O
158	hundred	_	_	O
159	ninety	_	_	O
160	-	_	_	O
161	nine	_	_	O
162	patients	_	_	O
163	were	_	_	O
164	randomly	_	_	O
165	assigned	_	_	O
166	.	_	_	O

167	The	_	_	O
168	trial	_	_	O
169	was	_	_	O
170	stopped	_	_	O
171	for	_	_	O
172	futility	_	_	O
173	at	_	_	O
174	interim	_	_	O
175	analysis	_	_	O
176	.	_	_	O

177	At	_	_	O
178	final	_	_	O
179	analysis	_	_	O
180	,	_	_	O
181	there	_	_	B-Premise
182	was	_	_	I-Premise
183	no	_	_	I-Premise
184	difference	_	_	I-Premise
185	in	_	_	I-Premise
186	OS	_	_	I-Premise
187	seen	_	_	I-Premise
188	between	_	_	I-Premise
189	ASA404	_	_	I-Premise
190	(	_	_	I-Premise
191	n	_	_	I-Premise
192	=	_	_	I-Premise
193	649	_	_	I-Premise
194	)	_	_	I-Premise
195	and	_	_	I-Premise
196	placebo	_	_	I-Premise
197	(	_	_	I-Premise
198	n	_	_	I-Premise
199	=	_	_	I-Premise
200	650	_	_	I-Premise
201	)	_	_	I-Premise
202	arms	_	_	I-Premise
203	:	_	_	I-Premise
204	median	_	_	I-Premise
205	OS	_	_	I-Premise
206	was	_	_	I-Premise
207	13	_	_	I-Premise
208	.	_	_	I-Premise

209	4	_	_	I-Premise
210	and	_	_	I-Premise
211	12	_	_	I-Premise
212	.	_	_	I-Premise

213	7	_	_	I-Premise
214	months	_	_	I-Premise
215	respectively	_	_	I-Premise
216	(	_	_	I-Premise
217	hazard	_	_	I-Premise
218	ratio	_	_	I-Premise
219	[	_	_	I-Premise
220	HR	_	_	I-Premise
221	]	_	_	I-Premise
222	,	_	_	I-Premise
223	1	_	_	I-Premise
224	.	_	_	I-Premise

225	01	_	_	I-Premise
226	;	_	_	I-Premise
227	95	_	_	I-Premise
228	%	_	_	I-Premise
229	CI	_	_	I-Premise
230	,	_	_	I-Premise
231	0	_	_	I-Premise
232	.	_	_	I-Premise

233	85	_	_	I-Premise
234	to	_	_	I-Premise
235	1	_	_	I-Premise
236	.	_	_	I-Premise

237	19	_	_	I-Premise
238	;	_	_	I-Premise
239	P	_	_	I-Premise
240	=	_	_	I-Premise
241	.	_	_	I-Premise

242	535	_	_	I-Premise
243	)	_	_	I-Premise
244	.	_	_	I-Premise

245	Similarly	_	_	O
246	,	_	_	O
247	no	_	_	B-Premise
248	OS	_	_	I-Premise
249	difference	_	_	I-Premise
250	was	_	_	I-Premise
251	seen	_	_	I-Premise
252	in	_	_	I-Premise
253	the	_	_	I-Premise
254	histologic	_	_	I-Premise
255	(	_	_	I-Premise
256	squamous	_	_	I-Premise
257	or	_	_	I-Premise
258	nonsquamous	_	_	I-Premise
259	)	_	_	I-Premise
260	and	_	_	I-Premise
261	sex	_	_	I-Premise
262	(	_	_	I-Premise
263	male	_	_	I-Premise
264	or	_	_	I-Premise
265	female	_	_	I-Premise
266	)	_	_	I-Premise
267	strata	_	_	I-Premise
268	.	_	_	I-Premise

269	Median	_	_	B-Premise
270	PFS	_	_	I-Premise
271	was	_	_	I-Premise
272	5	_	_	I-Premise
273	.	_	_	I-Premise

274	5	_	_	I-Premise
275	months	_	_	I-Premise
276	in	_	_	I-Premise
277	both	_	_	I-Premise
278	arms	_	_	I-Premise
279	(	_	_	I-Premise
280	HR	_	_	I-Premise
281	,	_	_	I-Premise
282	1	_	_	I-Premise
283	.	_	_	I-Premise

284	04	_	_	I-Premise
285	;	_	_	I-Premise
286	P	_	_	I-Premise
287	=	_	_	I-Premise
288	.	_	_	I-Premise

289	727	_	_	I-Premise
290	)	_	_	I-Premise
291	,	_	_	I-Premise
292	while	_	_	I-Premise
293	ORR	_	_	I-Premise
294	was	_	_	I-Premise
295	25	_	_	I-Premise
296	%	_	_	I-Premise
297	in	_	_	I-Premise
298	both	_	_	I-Premise
299	arms	_	_	I-Premise
300	(	_	_	I-Premise
301	P	_	_	I-Premise
302	=	_	_	I-Premise
303	1	_	_	I-Premise
304	.	_	_	I-Premise

305	0	_	_	I-Premise
306	)	_	_	I-Premise
307	.	_	_	I-Premise

308	Overall	_	_	B-Premise
309	rate	_	_	I-Premise
310	of	_	_	I-Premise
311	adverse	_	_	I-Premise
312	events	_	_	I-Premise
313	(	_	_	I-Premise
314	AEs	_	_	I-Premise
315	)	_	_	I-Premise
316	was	_	_	I-Premise
317	comparable	_	_	I-Premise
318	between	_	_	I-Premise
319	the	_	_	I-Premise
320	ASA404	_	_	I-Premise
321	and	_	_	I-Premise
322	placebo	_	_	I-Premise
323	arms	_	_	I-Premise
324	.	_	_	I-Premise

325	Grade	_	_	B-Premise
326	4	_	_	I-Premise
327	neutropenia	_	_	I-Premise
328	(	_	_	I-Premise
329	27	_	_	I-Premise
330	%	_	_	I-Premise
331	v	_	_	I-Premise
332	19	_	_	I-Premise
333	%	_	_	I-Premise
334	)	_	_	I-Premise
335	and	_	_	I-Premise
336	infusion	_	_	I-Premise
337	site	_	_	I-Premise
338	pain	_	_	I-Premise
339	(	_	_	I-Premise
340	10	_	_	I-Premise
341	%	_	_	I-Premise
342	v	_	_	I-Premise
343	0	_	_	I-Premise
344	.	_	_	I-Premise

345	5	_	_	I-Premise
346	%	_	_	I-Premise
347	)	_	_	I-Premise
348	were	_	_	I-Premise
349	reported	_	_	I-Premise
350	more	_	_	I-Premise
351	frequently	_	_	I-Premise
352	in	_	_	I-Premise
353	the	_	_	I-Premise
354	ASA404	_	_	I-Premise
355	arm	_	_	I-Premise
356	.	_	_	I-Premise

357	The	_	_	B-Claim
358	addition	_	_	I-Claim
359	of	_	_	I-Claim
360	ASA404	_	_	I-Claim
361	to	_	_	I-Claim
362	carboplatin	_	_	I-Claim
363	and	_	_	I-Claim
364	paclitaxel	_	_	I-Claim
365	,	_	_	I-Claim
366	although	_	_	I-Claim
367	generally	_	_	I-Claim
368	well	_	_	I-Claim
369	tolerated	_	_	I-Claim
370	,	_	_	I-Claim
371	failed	_	_	I-Claim
372	to	_	_	I-Claim
373	improve	_	_	I-Claim
374	frontline	_	_	I-Claim
375	efficacy	_	_	I-Claim
376	in	_	_	I-Claim
377	advanced	_	_	I-Claim
378	NSCLC	_	_	I-Claim
379	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	aims	_	_	O
3	to	_	_	O
4	examine	_	_	O
5	the	_	_	O
6	effectiveness	_	_	O
7	of	_	_	O
8	a	_	_	O
9	self	_	_	O
10	-	_	_	O
11	management	_	_	O
12	multimodal	_	_	O
13	comprehensive	_	_	O
14	coping	_	_	O
15	strategy	_	_	O
16	program	_	_	O
17	(	_	_	O
18	CCSP	_	_	O
19	)	_	_	O
20	on	_	_	O
21	quality	_	_	O
22	of	_	_	O
23	life	_	_	O
24	(	_	_	O
25	QOL	_	_	O
26	)	_	_	O
27	among	_	_	O
28	breast	_	_	O
29	cancer	_	_	O
30	patients	_	_	O
31	1	_	_	O
32	year	_	_	O
33	after	_	_	O
34	treatment	_	_	O
35	.	_	_	O

36	Patients	_	_	O
37	(	_	_	O
38	n	_	_	O
39	=	_	_	O
40	110	_	_	O
41	)	_	_	O
42	with	_	_	O
43	stage	_	_	O
44	II	_	_	O
45	,	_	_	O
46	III	_	_	O
47	,	_	_	O
48	or	_	_	O
49	IV	_	_	O
50	breast	_	_	O
51	cancer	_	_	O
52	scheduled	_	_	O
53	to	_	_	O
54	receive	_	_	O
55	high	_	_	O
56	dose	_	_	O
57	chemotherapy	_	_	O
58	and	_	_	O
59	autologous	_	_	O
60	hematopoietic	_	_	O
61	stem	_	_	O
62	cell	_	_	O
63	transplantation	_	_	O
64	were	_	_	O
65	randomized	_	_	O
66	to	_	_	O
67	either	_	_	O
68	CCSP	_	_	O
69	treatment	_	_	O
70	or	_	_	O
71	control	_	_	O
72	group	_	_	O
73	.	_	_	O

74	The	_	_	O
75	CCSP	_	_	O
76	intervention	_	_	O
77	was	_	_	O
78	taught	_	_	O
79	2	_	_	O
80	week	_	_	O
81	before	_	_	O
82	hospital	_	_	O
83	admission	_	_	O
84	with	_	_	O
85	reinforcement	_	_	O
86	at	_	_	O
87	specified	_	_	O
88	times	_	_	O
89	during	_	_	O
90	treatment	_	_	O
91	and	_	_	O
92	3	_	_	O
93	months	_	_	O
94	after	_	_	O
95	discharge	_	_	O
96	.	_	_	O

97	The	_	_	O
98	CCSP	_	_	O
99	components	_	_	O
100	included	_	_	O
101	educational	_	_	O
102	information	_	_	O
103	,	_	_	O
104	cognitive	_	_	O
105	restructuring	_	_	O
106	,	_	_	O
107	coping	_	_	O
108	skills	_	_	O
109	enhancement	_	_	O
110	,	_	_	O
111	and	_	_	O
112	relaxation	_	_	O
113	with	_	_	O
114	guided	_	_	O
115	imagery	_	_	O
116	.	_	_	O

117	Instruments	_	_	O
118	administered	_	_	O
119	at	_	_	O
120	baseline	_	_	O
121	included	_	_	O
122	the	_	_	O
123	following	_	_	O
124	:	_	_	O
125	Quality	_	_	O
126	of	_	_	O
127	Life	_	_	O
128	Index	_	_	O
129	-	_	_	O
130	Cancer	_	_	O
131	Version	_	_	O
132	(	_	_	O
133	QOLI	_	_	O
134	-	_	_	O
135	CV	_	_	O
136	)	_	_	O
137	,	_	_	O
138	State	_	_	O
139	-	_	_	O
140	Trait	_	_	O
141	Anxiety	_	_	O
142	Inventory	_	_	O
143	,	_	_	O
144	Beck	_	_	O
145	Depression	_	_	O
146	Inventory	_	_	O
147	,	_	_	O
148	and	_	_	O
149	Coping	_	_	O
150	Strategies	_	_	O
151	Questionnaire	_	_	O
152	.	_	_	O

153	At	_	_	O
154	1	_	_	O
155	-	_	_	O
156	year	_	_	O
157	follow	_	_	O
158	-	_	_	O
159	up	_	_	O
160	,	_	_	O
161	patients	_	_	O
162	(	_	_	O
163	n	_	_	O
164	=	_	_	O
165	73	_	_	O
166	)	_	_	O
167	completed	_	_	O
168	and	_	_	O
169	returned	_	_	O
170	the	_	_	O
171	follow	_	_	O
172	-	_	_	O
173	up	_	_	O
174	QOLI	_	_	O
175	-	_	_	O
176	CV	_	_	O
177	.	_	_	O

178	Patients	_	_	O
179	were	_	_	O
180	mainly	_	_	O
181	≥	_	_	O
182	40	_	_	O
183	years	_	_	O
184	of	_	_	O
185	age	_	_	O
186	,	_	_	O
187	married	_	_	O
188	,	_	_	O
189	Caucasian	_	_	O
190	,	_	_	O
191	and	_	_	O
192	diagnosed	_	_	O
193	with	_	_	O
194	advanced	_	_	O
195	breast	_	_	O
196	cancer	_	_	O
197	.	_	_	O

198	A	_	_	B-Premise
199	model	_	_	I-Premise
200	measuring	_	_	I-Premise
201	effectiveness	_	_	I-Premise
202	of	_	_	I-Premise
203	CCSP	_	_	I-Premise
204	on	_	_	I-Premise
205	QOL	_	_	I-Premise
206	(	_	_	I-Premise
207	total	_	_	I-Premise
208	and	_	_	I-Premise
209	subscale	_	_	I-Premise
210	)	_	_	I-Premise
211	at	_	_	I-Premise
212	1	_	_	I-Premise
213	-	_	_	I-Premise
214	year	_	_	I-Premise
215	follow	_	_	I-Premise
216	-	_	_	I-Premise
217	up	_	_	I-Premise
218	showed	_	_	I-Premise
219	that	_	_	I-Premise
220	the	_	_	I-Premise
221	CCSP	_	_	I-Premise
222	group	_	_	I-Premise
223	(	_	_	I-Premise
224	n	_	_	I-Premise
225	=	_	_	I-Premise
226	38	_	_	I-Premise
227	)	_	_	I-Premise
228	had	_	_	I-Premise
229	significant	_	_	I-Premise
230	improvement	_	_	I-Premise
231	in	_	_	I-Premise
232	overall	_	_	I-Premise
233	QOL	_	_	I-Premise
234	(	_	_	I-Premise
235	p	_	_	I-Premise
236	<	_	_	I-Premise
237	0	_	_	I-Premise
238	.	_	_	I-Premise

239	01	_	_	I-Premise
240	)	_	_	I-Premise
241	,	_	_	I-Premise
242	health	_	_	I-Premise
243	and	_	_	I-Premise
244	functioning	_	_	I-Premise
245	(	_	_	I-Premise
246	p	_	_	I-Premise
247	<	_	_	I-Premise
248	0	_	_	I-Premise
249	.	_	_	I-Premise

250	05	_	_	I-Premise
251	)	_	_	I-Premise
252	,	_	_	I-Premise
253	and	_	_	I-Premise
254	socioeconomic	_	_	I-Premise
255	(	_	_	I-Premise
256	p	_	_	I-Premise
257	<	_	_	I-Premise
258	0	_	_	I-Premise
259	.	_	_	I-Premise

260	05	_	_	I-Premise
261	)	_	_	I-Premise
262	and	_	_	I-Premise
263	psychological	_	_	I-Premise
264	/	_	_	I-Premise
265	spiritual	_	_	I-Premise
266	well	_	_	I-Premise
267	-	_	_	I-Premise
268	being	_	_	I-Premise
269	(	_	_	I-Premise
270	p	_	_	I-Premise
271	<	_	_	I-Premise
272	0	_	_	I-Premise
273	.	_	_	I-Premise

274	01	_	_	I-Premise
275	)	_	_	I-Premise
276	compared	_	_	I-Premise
277	with	_	_	I-Premise
278	the	_	_	I-Premise
279	control	_	_	I-Premise
280	group	_	_	I-Premise
281	(	_	_	I-Premise
282	n	_	_	I-Premise
283	=	_	_	I-Premise
284	35	_	_	I-Premise
285	)	_	_	I-Premise
286	.	_	_	I-Premise

287	The	_	_	B-Premise
288	CCSP	_	_	I-Premise
289	patients	_	_	I-Premise
290	frequently	_	_	I-Premise
291	used	_	_	I-Premise
292	the	_	_	I-Premise
293	CCSP	_	_	I-Premise
294	to	_	_	I-Premise
295	manage	_	_	I-Premise
296	psychological	_	_	I-Premise
297	(	_	_	I-Premise
298	51	_	_	I-Premise
299	%	_	_	I-Premise
300	)	_	_	I-Premise
301	and	_	_	I-Premise
302	sleep	_	_	I-Premise
303	problems	_	_	I-Premise
304	(	_	_	I-Premise
305	60	_	_	I-Premise
306	%	_	_	I-Premise
307	)	_	_	I-Premise
308	.	_	_	I-Premise

309	The	_	_	B-Premise
310	CCSP	_	_	I-Premise
311	improved	_	_	I-Premise
312	QOL	_	_	I-Premise
313	for	_	_	I-Premise
314	patients	_	_	I-Premise
315	at	_	_	I-Premise
316	1	_	_	I-Premise
317	-	_	_	I-Premise
318	year	_	_	I-Premise
319	follow	_	_	I-Premise
320	-	_	_	I-Premise
321	up	_	_	I-Premise
322	.	_	_	I-Premise

323	Patients	_	_	B-Premise
324	overwhelmingly	_	_	I-Premise
325	reported	_	_	I-Premise
326	that	_	_	I-Premise
327	CCSP	_	_	I-Premise
328	was	_	_	I-Premise
329	beneficial	_	_	I-Premise
330	.	_	_	I-Premise

331	The	_	_	B-Claim
332	CCSP	_	_	I-Claim
333	as	_	_	I-Claim
334	an	_	_	I-Claim
335	effective	_	_	I-Claim
336	coping	_	_	I-Claim
337	intervention	_	_	I-Claim
338	has	_	_	I-Claim
339	potential	_	_	I-Claim
340	as	_	_	I-Claim
341	a	_	_	I-Claim
342	self	_	_	I-Claim
343	-	_	_	I-Claim
344	management	_	_	I-Claim
345	program	_	_	I-Claim
346	for	_	_	I-Claim
347	breast	_	_	I-Claim
348	cancer	_	_	I-Claim
349	survivors	_	_	I-Claim
350	.	_	_	I-Claim


0	Chemotherapy	_	_	B-Claim
1	is	_	_	I-Claim
2	moderately	_	_	I-Claim
3	efficient	_	_	I-Claim
4	as	_	_	I-Claim
5	a	_	_	I-Claim
6	treatment	_	_	I-Claim
7	for	_	_	I-Claim
8	pancreatic	_	_	I-Claim
9	adenocarcinoma	_	_	I-Claim
10	,	_	_	I-Claim
11	but	_	_	B-Claim
12	patient	_	_	I-Claim
13	survival	_	_	I-Claim
14	and	_	_	I-Claim
15	quality	_	_	I-Claim
16	of	_	_	I-Claim
17	life	_	_	I-Claim
18	has	_	_	I-Claim
19	improved	_	_	I-Claim
20	with	_	_	I-Claim
21	this	_	_	I-Claim
22	modality	_	_	I-Claim
23	in	_	_	I-Claim
24	some	_	_	I-Claim
25	trials	_	_	I-Claim
26	.	_	_	I-Claim

27	In	_	_	O
28	a	_	_	O
29	previous	_	_	O
30	phase	_	_	O
31	II	_	_	O
32	trial	_	_	O
33	,	_	_	O
34	5	_	_	O
35	-	_	_	O
36	fluorouracil	_	_	O
37	(	_	_	O
38	5	_	_	O
39	-	_	_	O
40	FU	_	_	O
41	)	_	_	O
42	plus	_	_	O
43	cisplatin	_	_	O
44	(	_	_	O
45	FUP	_	_	O
46	)	_	_	O
47	yielded	_	_	O
48	a	_	_	O
49	26	_	_	O
50	.	_	_	O

51	5	_	_	O
52	%	_	_	O
53	response	_	_	O
54	rate	_	_	O
55	and	_	_	O
56	a	_	_	O
57	29	_	_	O
58	%	_	_	O
59	survival	_	_	O
60	rate	_	_	O
61	at	_	_	O
62	1	_	_	O
63	year	_	_	O
64	.	_	_	O

65	The	_	_	O
66	present	_	_	O
67	study	_	_	O
68	aimed	_	_	O
69	to	_	_	O
70	compare	_	_	O
71	FUP	_	_	O
72	with	_	_	O
73	5	_	_	O
74	-	_	_	O
75	FU	_	_	O
76	alone	_	_	O
77	,	_	_	O
78	which	_	_	O
79	was	_	_	O
80	the	_	_	O
81	control	_	_	O
82	arm	_	_	O
83	in	_	_	O
84	former	_	_	O
85	Mayo	_	_	O
86	Clinic	_	_	O
87	trials	_	_	O
88	.	_	_	O

89	Patients	_	_	O
90	with	_	_	O
91	untreated	_	_	O
92	cytologically	_	_	O
93	or	_	_	O
94	histologically	_	_	O
95	proven	_	_	O
96	metastatic	_	_	O
97	or	_	_	O
98	locally	_	_	O
99	advanced	_	_	O
100	adenocarcinoma	_	_	O
101	of	_	_	O
102	the	_	_	O
103	pancreas	_	_	O
104	were	_	_	O
105	deemed	_	_	O
106	measurable	_	_	O
107	or	_	_	O
108	evaluable	_	_	O
109	.	_	_	O

110	Chemotherapy	_	_	O
111	regimens	_	_	O
112	consisted	_	_	O
113	of	_	_	O
114	a	_	_	O
115	control	_	_	O
116	FU	_	_	O
117	arm	_	_	O
118	(	_	_	O
119	5	_	_	O
120	-	_	_	O
121	FU	_	_	O
122	500	_	_	O
123	mg	_	_	O
124	/	_	_	O
125	m	_	_	O
126	(	_	_	O
127	2	_	_	O
128	)	_	_	O
129	/	_	_	O
130	day	_	_	O
131	for	_	_	O
132	5	_	_	O
133	days	_	_	O
134	)	_	_	O
135	and	_	_	O
136	the	_	_	O
137	investigational	_	_	O
138	FUP	_	_	O
139	arm	_	_	O
140	(	_	_	O
141	continuous	_	_	O
142	5	_	_	O
143	-	_	_	O
144	FU	_	_	O
145	1000	_	_	O
146	mg	_	_	O
147	/	_	_	O
148	m	_	_	O
149	(	_	_	O
150	2	_	_	O
151	)	_	_	O
152	/	_	_	O
153	day	_	_	O
154	for	_	_	O
155	5	_	_	O
156	days	_	_	O
157	plus	_	_	O
158	cisplatin	_	_	O
159	100	_	_	O
160	mg	_	_	O
161	/	_	_	O
162	m	_	_	O
163	(	_	_	O
164	2	_	_	O
165	)	_	_	O
166	on	_	_	O
167	day	_	_	O
168	1	_	_	O
169	or	_	_	O
170	day	_	_	O
171	2	_	_	O
172	)	_	_	O
173	.	_	_	O

174	In	_	_	O
175	both	_	_	O
176	arms	_	_	O
177	,	_	_	O
178	chemotherapy	_	_	O
179	was	_	_	O
180	repeated	_	_	O
181	at	_	_	O
182	day	_	_	O
183	29	_	_	O
184	.	_	_	O

185	Two	_	_	O
186	-	_	_	O
187	hundred	_	_	O
188	and	_	_	O
189	seven	_	_	O
190	patients	_	_	O
191	from	_	_	O
192	18	_	_	O
193	centres	_	_	O
194	were	_	_	O
195	randomised	_	_	O
196	:	_	_	O
197	103	_	_	O
198	in	_	_	O
199	the	_	_	O
200	FU	_	_	O
201	arm	_	_	O
202	and	_	_	O
203	104	_	_	O
204	in	_	_	O
205	FUP	_	_	O
206	arm	_	_	O
207	.	_	_	O

208	Treatment	_	_	O
209	arms	_	_	O
210	were	_	_	O
211	balanced	_	_	O
212	with	_	_	O
213	respect	_	_	O
214	to	_	_	O
215	performance	_	_	O
216	status	_	_	O
217	grade	_	_	O
218	0	_	_	O
219	-	_	_	O
220	1	_	_	O
221	(	_	_	O
222	83	_	_	O
223	%	_	_	O
224	versus	_	_	O
225	86	_	_	O
226	%	_	_	O
227	,	_	_	O
228	respectively	_	_	O
229	)	_	_	O
230	and	_	_	O
231	the	_	_	O
232	presence	_	_	O
233	of	_	_	O
234	metastases	_	_	O
235	(	_	_	O
236	92	_	_	O
237	%	_	_	O
238	versus	_	_	O
239	89	_	_	O
240	%	_	_	O
241	,	_	_	O
242	respectively	_	_	O
243	)	_	_	O
244	.	_	_	O

245	The	_	_	O
246	median	_	_	O
247	number	_	_	O
248	of	_	_	O
249	cycles	_	_	O
250	administered	_	_	O
251	was	_	_	O
252	two	_	_	O
253	in	_	_	O
254	both	_	_	O
255	arms	_	_	O
256	(	_	_	O
257	range	_	_	O
258	0	_	_	O
259	-	_	_	O
260	14	_	_	O
261	)	_	_	O
262	.	_	_	O

263	Five	_	_	O
264	patients	_	_	O
265	did	_	_	O
266	not	_	_	O
267	receive	_	_	O
268	any	_	_	O
269	chemotherapy	_	_	O
270	and	_	_	O
271	45	_	_	O
272	received	_	_	O
273	only	_	_	O
274	one	_	_	O
275	cycle	_	_	O
276	.	_	_	O

277	Toxicity	_	_	B-Premise
278	(	_	_	I-Premise
279	WHO	_	_	I-Premise
280	grade	_	_	I-Premise
281	3	_	_	I-Premise
282	-	_	_	I-Premise
283	4	_	_	I-Premise
284	)	_	_	I-Premise
285	was	_	_	I-Premise
286	lower	_	_	I-Premise
287	with	_	_	I-Premise
288	FU	_	_	I-Premise
289	than	_	_	I-Premise
290	with	_	_	I-Premise
291	FUP	_	_	I-Premise
292	(	_	_	I-Premise
293	20	_	_	I-Premise
294	%	_	_	I-Premise
295	versus	_	_	I-Premise
296	48	_	_	I-Premise
297	%	_	_	I-Premise
298	,	_	_	I-Premise
299	P	_	_	I-Premise
300	<	_	_	I-Premise
301	0	_	_	I-Premise
302	.	_	_	I-Premise

303	001	_	_	I-Premise
304	)	_	_	I-Premise
305	,	_	_	I-Premise
306	as	_	_	I-Premise
307	was	_	_	I-Premise
308	neutropenia	_	_	I-Premise
309	(	_	_	I-Premise
310	6	_	_	I-Premise
311	%	_	_	I-Premise
312	versus	_	_	I-Premise
313	23	_	_	I-Premise
314	%	_	_	I-Premise
315	)	_	_	I-Premise
316	,	_	_	I-Premise
317	vomiting	_	_	I-Premise
318	(	_	_	I-Premise
319	4	_	_	I-Premise
320	%	_	_	I-Premise
321	versus	_	_	I-Premise
322	17	_	_	I-Premise
323	%	_	_	I-Premise
324	)	_	_	I-Premise
325	and	_	_	I-Premise
326	toxicity	_	_	I-Premise
327	-	_	_	I-Premise
328	related	_	_	I-Premise
329	deaths	_	_	I-Premise
330	(	_	_	I-Premise
331	one	_	_	I-Premise
332	versus	_	_	I-Premise
333	four	_	_	I-Premise
334	early	_	_	I-Premise
335	in	_	_	I-Premise
336	the	_	_	I-Premise
337	trial	_	_	I-Premise
338	)	_	_	I-Premise
339	.	_	_	I-Premise

340	The	_	_	B-Premise
341	response	_	_	I-Premise
342	rate	_	_	I-Premise
343	was	_	_	I-Premise
344	low	_	_	I-Premise
345	in	_	_	I-Premise
346	both	_	_	I-Premise
347	arms	_	_	I-Premise
348	,	_	_	I-Premise
349	but	_	_	I-Premise
350	superior	_	_	I-Premise
351	in	_	_	I-Premise
352	the	_	_	I-Premise
353	FUP	_	_	I-Premise
354	arm	_	_	I-Premise
355	:	_	_	I-Premise
356	12	_	_	I-Premise
357	%	_	_	I-Premise
358	versus	_	_	I-Premise
359	0	_	_	I-Premise
360	%	_	_	I-Premise
361	(	_	_	I-Premise
362	intention	_	_	I-Premise
363	-	_	_	I-Premise
364	to	_	_	I-Premise
365	-	_	_	I-Premise
366	treat	_	_	I-Premise
367	analysis	_	_	I-Premise
368	,	_	_	I-Premise
369	P	_	_	I-Premise
370	<	_	_	I-Premise
371	0	_	_	I-Premise
372	.	_	_	I-Premise

373	01	_	_	I-Premise
374	)	_	_	I-Premise
375	.	_	_	I-Premise

376	The	_	_	B-Premise
377	survival	_	_	I-Premise
378	rates	_	_	I-Premise
379	at	_	_	I-Premise
380	6	_	_	I-Premise
381	months	_	_	I-Premise
382	were	_	_	I-Premise
383	28	_	_	I-Premise
384	%	_	_	I-Premise
385	and	_	_	I-Premise
386	38	_	_	I-Premise
387	%	_	_	I-Premise
388	for	_	_	I-Premise
389	the	_	_	I-Premise
390	FU	_	_	I-Premise
391	and	_	_	I-Premise
392	FUP	_	_	I-Premise
393	arms	_	_	I-Premise
394	,	_	_	I-Premise
395	respectively	_	_	I-Premise
396	,	_	_	I-Premise
397	and	_	_	I-Premise
398	1	_	_	I-Premise
399	-	_	_	I-Premise
400	year	_	_	I-Premise
401	survival	_	_	I-Premise
402	rates	_	_	I-Premise
403	were	_	_	I-Premise
404	9	_	_	I-Premise
405	%	_	_	I-Premise
406	and	_	_	I-Premise
407	17	_	_	I-Premise
408	%	_	_	I-Premise
409	(	_	_	I-Premise
410	log	_	_	I-Premise
411	-	_	_	I-Premise
412	rank	_	_	I-Premise
413	test	_	_	I-Premise
414	,	_	_	I-Premise
415	P	_	_	I-Premise
416	=	_	_	I-Premise
417	0	_	_	I-Premise
418	.	_	_	I-Premise

419	10	_	_	I-Premise
420	)	_	_	I-Premise
421	.	_	_	I-Premise

422	One	_	_	B-Premise
423	-	_	_	I-Premise
424	year	_	_	I-Premise
425	progression	_	_	I-Premise
426	-	_	_	I-Premise
427	free	_	_	I-Premise
428	survival	_	_	I-Premise
429	was	_	_	I-Premise
430	0	_	_	I-Premise
431	%	_	_	I-Premise
432	with	_	_	I-Premise
433	FU	_	_	I-Premise
434	versus	_	_	I-Premise
435	10	_	_	I-Premise
436	%	_	_	I-Premise
437	with	_	_	I-Premise
438	FUP	_	_	I-Premise
439	(	_	_	I-Premise
440	log	_	_	I-Premise
441	-	_	_	I-Premise
442	rank	_	_	I-Premise
443	test	_	_	I-Premise
444	,	_	_	I-Premise
445	P	_	_	I-Premise
446	=	_	_	I-Premise
447	0	_	_	I-Premise
448	.	_	_	I-Premise

449	0001	_	_	I-Premise
450	)	_	_	I-Premise
451	.	_	_	I-Premise

452	In	_	_	B-Claim
453	advanced	_	_	I-Claim
454	pancreatic	_	_	I-Claim
455	carcinomas	_	_	I-Claim
456	with	_	_	I-Claim
457	a	_	_	I-Claim
458	poor	_	_	I-Claim
459	prognosis	_	_	I-Claim
460	,	_	_	I-Claim
461	FUP	_	_	I-Claim
462	was	_	_	I-Claim
463	superior	_	_	I-Claim
464	to	_	_	I-Claim
465	FU	_	_	I-Claim
466	in	_	_	I-Claim
467	terms	_	_	I-Claim
468	of	_	_	I-Claim
469	response	_	_	I-Claim
470	and	_	_	I-Claim
471	progression	_	_	I-Claim
472	-	_	_	I-Claim
473	free	_	_	I-Claim
474	survival	_	_	I-Claim
475	,	_	_	I-Claim
476	but	_	_	I-Claim
477	not	_	_	I-Claim
478	in	_	_	I-Claim
479	terms	_	_	I-Claim
480	of	_	_	I-Claim
481	overall	_	_	I-Claim
482	survival	_	_	I-Claim
483	.	_	_	I-Claim

484	The	_	_	O
485	low	_	_	O
486	response	_	_	O
487	rate	_	_	O
488	is	_	_	O
489	partly	_	_	O
490	related	_	_	O
491	to	_	_	O
492	the	_	_	O
493	number	_	_	O
494	of	_	_	O
495	patients	_	_	O
496	who	_	_	O
497	received	_	_	O
498	only	_	_	O
499	one	_	_	O
500	cycle	_	_	O
501	of	_	_	O
502	chemotherapy	_	_	O
503	.	_	_	O

504	A	_	_	B-Claim
505	more	_	_	I-Claim
506	effective	_	_	I-Claim
507	,	_	_	I-Claim
508	better	_	_	I-Claim
509	tolerated	_	_	I-Claim
510	version	_	_	I-Claim
511	of	_	_	I-Claim
512	this	_	_	I-Claim
513	FUP	_	_	I-Claim
514	combination	_	_	I-Claim
515	is	_	_	I-Claim
516	needed	_	_	I-Claim
517	.	_	_	I-Claim


0	It	_	_	O
1	is	_	_	O
2	not	_	_	O
3	known	_	_	O
4	whether	_	_	O
5	low	_	_	O
6	-	_	_	O
7	dose	_	_	O
8	radioiodine	_	_	O
9	(	_	_	O
10	1	_	_	O
11	.	_	_	O

12	1	_	_	O
13	GBq	_	_	O
14	[	_	_	O
15	30	_	_	O
16	mCi	_	_	O
17	]	_	_	O
18	)	_	_	O
19	is	_	_	O
20	as	_	_	O
21	effective	_	_	O
22	as	_	_	O
23	high	_	_	O
24	-	_	_	O
25	dose	_	_	O
26	radioiodine	_	_	O
27	(	_	_	O
28	3	_	_	O
29	.	_	_	O

30	7	_	_	O
31	GBq	_	_	O
32	[	_	_	O
33	100	_	_	O
34	mCi	_	_	O
35	]	_	_	O
36	)	_	_	O
37	for	_	_	O
38	treating	_	_	O
39	patients	_	_	O
40	with	_	_	O
41	differentiated	_	_	O
42	thyroid	_	_	O
43	cancer	_	_	O
44	or	_	_	O
45	whether	_	_	O
46	the	_	_	O
47	effects	_	_	O
48	of	_	_	O
49	radioiodine	_	_	O
50	(	_	_	O
51	especially	_	_	O
52	at	_	_	O
53	a	_	_	O
54	low	_	_	O
55	dose	_	_	O
56	)	_	_	O
57	are	_	_	O
58	influenced	_	_	O
59	by	_	_	O
60	using	_	_	O
61	either	_	_	O
62	recombinant	_	_	O
63	human	_	_	O
64	thyrotropin	_	_	O
65	(	_	_	O
66	thyrotropin	_	_	O
67	alfa	_	_	O
68	)	_	_	O
69	or	_	_	O
70	thyroid	_	_	O
71	hormone	_	_	O
72	withdrawal	_	_	O
73	.	_	_	O

74	At	_	_	O
75	29	_	_	O
76	centers	_	_	O
77	in	_	_	O
78	the	_	_	O
79	United	_	_	O
80	Kingdom	_	_	O
81	,	_	_	O
82	we	_	_	O
83	conducted	_	_	O
84	a	_	_	O
85	randomized	_	_	O
86	noninferiority	_	_	O
87	trial	_	_	O
88	comparing	_	_	O
89	low	_	_	O
90	-	_	_	O
91	dose	_	_	O
92	and	_	_	O
93	high	_	_	O
94	-	_	_	O
95	dose	_	_	O
96	radioiodine	_	_	O
97	,	_	_	O
98	each	_	_	O
99	in	_	_	O
100	combination	_	_	O
101	with	_	_	O
102	either	_	_	O
103	thyrotropin	_	_	O
104	alfa	_	_	O
105	or	_	_	O
106	thyroid	_	_	O
107	hormone	_	_	O
108	withdrawal	_	_	O
109	before	_	_	O
110	ablation	_	_	O
111	.	_	_	O

112	Patients	_	_	O
113	(	_	_	O
114	age	_	_	O
115	range	_	_	O
116	,	_	_	O
117	16	_	_	O
118	to	_	_	O
119	80	_	_	O
120	years	_	_	O
121	)	_	_	O
122	had	_	_	O
123	tumor	_	_	O
124	stage	_	_	O
125	T1	_	_	O
126	to	_	_	O
127	T3	_	_	O
128	,	_	_	O
129	with	_	_	O
130	possible	_	_	O
131	spread	_	_	O
132	to	_	_	O
133	nearby	_	_	O
134	lymph	_	_	O
135	nodes	_	_	O
136	but	_	_	O
137	without	_	_	O
138	metastasis	_	_	O
139	.	_	_	O

140	End	_	_	O
141	points	_	_	O
142	were	_	_	O
143	the	_	_	O
144	rate	_	_	O
145	of	_	_	O
146	success	_	_	O
147	of	_	_	O
148	ablation	_	_	O
149	at	_	_	O
150	6	_	_	O
151	to	_	_	O
152	9	_	_	O
153	months	_	_	O
154	,	_	_	O
155	adverse	_	_	O
156	events	_	_	O
157	,	_	_	O
158	quality	_	_	O
159	of	_	_	O
160	life	_	_	O
161	,	_	_	O
162	and	_	_	O
163	length	_	_	O
164	of	_	_	O
165	hospital	_	_	O
166	stay	_	_	O
167	.	_	_	O

168	A	_	_	O
169	total	_	_	O
170	of	_	_	O
171	438	_	_	O
172	patients	_	_	O
173	underwent	_	_	O
174	randomization	_	_	O
175	;	_	_	O
176	data	_	_	O
177	could	_	_	O
178	be	_	_	O
179	analyzed	_	_	O
180	for	_	_	O
181	421	_	_	O
182	.	_	_	O

183	Ablation	_	_	B-Premise
184	success	_	_	I-Premise
185	rates	_	_	I-Premise
186	were	_	_	I-Premise
187	85	_	_	I-Premise
188	.	_	_	I-Premise

189	0	_	_	I-Premise
190	%	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	group	_	_	I-Premise
194	receiving	_	_	I-Premise
195	low	_	_	I-Premise
196	-	_	_	I-Premise
197	dose	_	_	I-Premise
198	radioiodine	_	_	I-Premise
199	versus	_	_	I-Premise
200	88	_	_	I-Premise
201	.	_	_	I-Premise

202	9	_	_	I-Premise
203	%	_	_	I-Premise
204	in	_	_	I-Premise
205	the	_	_	I-Premise
206	group	_	_	I-Premise
207	receiving	_	_	I-Premise
208	the	_	_	I-Premise
209	high	_	_	I-Premise
210	dose	_	_	I-Premise
211	and	_	_	I-Premise
212	87	_	_	I-Premise
213	.	_	_	I-Premise

214	1	_	_	I-Premise
215	%	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	thyrotropin	_	_	I-Premise
219	alfa	_	_	I-Premise
220	group	_	_	I-Premise
221	versus	_	_	I-Premise
222	86	_	_	I-Premise
223	.	_	_	I-Premise

224	7	_	_	I-Premise
225	%	_	_	I-Premise
226	in	_	_	I-Premise
227	the	_	_	I-Premise
228	group	_	_	I-Premise
229	undergoing	_	_	I-Premise
230	thyroid	_	_	I-Premise
231	hormone	_	_	I-Premise
232	withdrawal	_	_	I-Premise
233	.	_	_	I-Premise

234	All	_	_	B-Premise
235	95	_	_	I-Premise
236	%	_	_	I-Premise
237	confidence	_	_	I-Premise
238	intervals	_	_	I-Premise
239	for	_	_	I-Premise
240	the	_	_	I-Premise
241	differences	_	_	I-Premise
242	were	_	_	I-Premise
243	within	_	_	I-Premise
244	±	_	_	I-Premise
245	10	_	_	I-Premise
246	percentage	_	_	I-Premise
247	points	_	_	I-Premise
248	,	_	_	I-Premise
249	indicating	_	_	I-Premise
250	noninferiority	_	_	I-Premise
251	.	_	_	I-Premise

252	Similar	_	_	B-Premise
253	results	_	_	I-Premise
254	were	_	_	I-Premise
255	found	_	_	I-Premise
256	for	_	_	I-Premise
257	low	_	_	I-Premise
258	-	_	_	I-Premise
259	dose	_	_	I-Premise
260	radioiodine	_	_	I-Premise
261	plus	_	_	I-Premise
262	thyrotropin	_	_	I-Premise
263	alfa	_	_	I-Premise
264	(	_	_	I-Premise
265	84	_	_	I-Premise
266	.	_	_	I-Premise

267	3	_	_	I-Premise
268	%	_	_	I-Premise
269	)	_	_	I-Premise
270	versus	_	_	I-Premise
271	high	_	_	I-Premise
272	-	_	_	I-Premise
273	dose	_	_	I-Premise
274	radioiodine	_	_	I-Premise
275	plus	_	_	I-Premise
276	thyroid	_	_	I-Premise
277	hormone	_	_	I-Premise
278	withdrawal	_	_	I-Premise
279	(	_	_	I-Premise
280	87	_	_	I-Premise
281	.	_	_	I-Premise

282	6	_	_	I-Premise
283	%	_	_	I-Premise
284	)	_	_	I-Premise
285	or	_	_	I-Premise
286	high	_	_	I-Premise
287	-	_	_	I-Premise
288	dose	_	_	I-Premise
289	radioiodine	_	_	I-Premise
290	plus	_	_	I-Premise
291	thyrotropin	_	_	I-Premise
292	alfa	_	_	I-Premise
293	(	_	_	I-Premise
294	90	_	_	I-Premise
295	.	_	_	I-Premise

296	2	_	_	I-Premise
297	%	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	More	_	_	B-Premise
301	patients	_	_	I-Premise
302	in	_	_	I-Premise
303	the	_	_	I-Premise
304	high	_	_	I-Premise
305	-	_	_	I-Premise
306	dose	_	_	I-Premise
307	group	_	_	I-Premise
308	than	_	_	I-Premise
309	in	_	_	I-Premise
310	the	_	_	I-Premise
311	low	_	_	I-Premise
312	-	_	_	I-Premise
313	dose	_	_	I-Premise
314	group	_	_	I-Premise
315	were	_	_	I-Premise
316	hospitalized	_	_	I-Premise
317	for	_	_	I-Premise
318	at	_	_	I-Premise
319	least	_	_	I-Premise
320	3	_	_	I-Premise
321	days	_	_	I-Premise
322	(	_	_	I-Premise
323	36	_	_	I-Premise
324	.	_	_	I-Premise

325	3	_	_	I-Premise
326	%	_	_	I-Premise
327	vs	_	_	I-Premise
328	.	_	_	I-Premise

329	13	_	_	I-Premise
330	.	_	_	I-Premise

331	0	_	_	I-Premise
332	%	_	_	I-Premise
333	,	_	_	I-Premise
334	P	_	_	I-Premise
335	<	_	_	I-Premise
336	0	_	_	I-Premise
337	.	_	_	I-Premise

338	001	_	_	I-Premise
339	)	_	_	I-Premise
340	.	_	_	I-Premise

341	The	_	_	B-Premise
342	proportions	_	_	I-Premise
343	of	_	_	I-Premise
344	patients	_	_	I-Premise
345	with	_	_	I-Premise
346	adverse	_	_	I-Premise
347	events	_	_	I-Premise
348	were	_	_	I-Premise
349	21	_	_	I-Premise
350	%	_	_	I-Premise
351	in	_	_	I-Premise
352	the	_	_	I-Premise
353	low	_	_	I-Premise
354	-	_	_	I-Premise
355	dose	_	_	I-Premise
356	group	_	_	I-Premise
357	versus	_	_	I-Premise
358	33	_	_	I-Premise
359	%	_	_	I-Premise
360	in	_	_	I-Premise
361	the	_	_	I-Premise
362	high	_	_	I-Premise
363	-	_	_	I-Premise
364	dose	_	_	I-Premise
365	group	_	_	I-Premise
366	(	_	_	I-Premise
367	P	_	_	I-Premise
368	=	_	_	I-Premise
369	0	_	_	I-Premise
370	.	_	_	I-Premise

371	007	_	_	I-Premise
372	)	_	_	I-Premise
373	and	_	_	I-Premise
374	23	_	_	I-Premise
375	%	_	_	I-Premise
376	in	_	_	I-Premise
377	the	_	_	I-Premise
378	thyrotropin	_	_	I-Premise
379	alfa	_	_	I-Premise
380	group	_	_	I-Premise
381	versus	_	_	I-Premise
382	30	_	_	I-Premise
383	%	_	_	I-Premise
384	in	_	_	I-Premise
385	the	_	_	I-Premise
386	group	_	_	I-Premise
387	undergoing	_	_	I-Premise
388	thyroid	_	_	I-Premise
389	hormone	_	_	I-Premise
390	withdrawal	_	_	I-Premise
391	(	_	_	I-Premise
392	P	_	_	I-Premise
393	=	_	_	I-Premise
394	0	_	_	I-Premise
395	.	_	_	I-Premise

396	11	_	_	I-Premise
397	)	_	_	I-Premise
398	.	_	_	I-Premise

399	Low	_	_	B-Claim
400	-	_	_	I-Claim
401	dose	_	_	I-Claim
402	radioiodine	_	_	I-Claim
403	plus	_	_	I-Claim
404	thyrotropin	_	_	I-Claim
405	alfa	_	_	I-Claim
406	was	_	_	I-Claim
407	as	_	_	I-Claim
408	effective	_	_	I-Claim
409	as	_	_	I-Claim
410	high	_	_	I-Claim
411	-	_	_	I-Claim
412	dose	_	_	I-Claim
413	radioiodine	_	_	I-Claim
414	,	_	_	I-Claim
415	with	_	_	I-Claim
416	a	_	_	I-Claim
417	lower	_	_	I-Claim
418	rate	_	_	I-Claim
419	of	_	_	I-Claim
420	adverse	_	_	I-Claim
421	events	_	_	I-Claim
422	.	_	_	I-Claim


0	Improvements	_	_	O
1	can	_	_	O
2	be	_	_	O
3	made	_	_	O
4	in	_	_	O
5	the	_	_	O
6	quality	_	_	O
7	of	_	_	O
8	cancer	_	_	O
9	care	_	_	O
10	if	_	_	O
11	supportive	_	_	O
12	care	_	_	O
13	needs	_	_	O
14	are	_	_	O
15	addressed	_	_	O
16	;	_	_	O
17	however	_	_	O
18	,	_	_	O
19	there	_	_	O
20	are	_	_	O
21	few	_	_	O
22	trials	_	_	O
23	of	_	_	O
24	supportive	_	_	O
25	care	_	_	O
26	interventions	_	_	O
27	to	_	_	O
28	guide	_	_	O
29	policy	_	_	O
30	and	_	_	O
31	practice	_	_	O
32	.	_	_	O

33	This	_	_	O
34	study	_	_	O
35	aimed	_	_	O
36	to	_	_	O
37	determine	_	_	O
38	the	_	_	O
39	effectiveness	_	_	O
40	of	_	_	O
41	a	_	_	O
42	nurse	_	_	O
43	-	_	_	O
44	delivered	_	_	O
45	telephone	_	_	O
46	supportive	_	_	O
47	intervention	_	_	O
48	(	_	_	O
49	the	_	_	O
50	"	_	_	O
51	CONNECT	_	_	O
52	"	_	_	O
53	intervention	_	_	O
54	)	_	_	O
55	.	_	_	O

56	This	_	_	O
57	study	_	_	O
58	was	_	_	O
59	a	_	_	O
60	pilot	_	_	O
61	randomized	_	_	O
62	controlled	_	_	O
63	trial	_	_	O
64	.	_	_	O

65	Intervention	_	_	O
66	group	_	_	O
67	patients	_	_	O
68	received	_	_	O
69	5	_	_	O
70	calls	_	_	O
71	from	_	_	O
72	a	_	_	O
73	specialist	_	_	O
74	colorectal	_	_	O
75	nurse	_	_	O
76	in	_	_	O
77	the	_	_	O
78	6	_	_	O
79	months	_	_	O
80	after	_	_	O
81	hospital	_	_	O
82	discharge	_	_	O
83	.	_	_	O

84	Each	_	_	O
85	call	_	_	O
86	was	_	_	O
87	standardized	_	_	O
88	,	_	_	O
89	comprising	_	_	O
90	the	_	_	O
91	assessment	_	_	O
92	of	_	_	O
93	unmet	_	_	O
94	need	_	_	O
95	and	_	_	O
96	the	_	_	O
97	provision	_	_	O
98	of	_	_	O
99	information	_	_	O
100	and	_	_	O
101	emotional	_	_	O
102	support	_	_	O
103	.	_	_	O

104	CONNECT	_	_	O
105	was	_	_	O
106	in	_	_	O
107	addition	_	_	O
108	to	_	_	O
109	standard	_	_	O
110	clinical	_	_	O
111	follow	_	_	O
112	-	_	_	O
113	up	_	_	O
114	.	_	_	O

115	Patients	_	_	O
116	allocated	_	_	O
117	to	_	_	O
118	the	_	_	O
119	control	_	_	O
120	group	_	_	O
121	received	_	_	O
122	standard	_	_	O
123	follow	_	_	O
124	-	_	_	O
125	up	_	_	O
126	only	_	_	O
127	.	_	_	O

128	This	_	_	O
129	study	_	_	O
130	took	_	_	O
131	place	_	_	O
132	at	_	_	O
133	the	_	_	O
134	Royal	_	_	O
135	Prince	_	_	O
136	Alfred	_	_	O
137	Hospital	_	_	O
138	,	_	_	O
139	Sydney	_	_	O
140	,	_	_	O
141	Australia	_	_	O
142	.	_	_	O

143	Patients	_	_	O
144	(	_	_	O
145	n	_	_	O
146	=	_	_	O
147	75	_	_	O
148	)	_	_	O
149	were	_	_	O
150	included	_	_	O
151	who	_	_	O
152	had	_	_	O
153	been	_	_	O
154	surgically	_	_	O
155	treated	_	_	O
156	for	_	_	O
157	colorectal	_	_	O
158	cancer	_	_	O
159	(	_	_	O
160	any	_	_	O
161	stage	_	_	O
162	)	_	_	O
163	.	_	_	O

164	The	_	_	O
165	main	_	_	O
166	outcome	_	_	O
167	measures	_	_	O
168	were	_	_	O
169	the	_	_	O
170	unmet	_	_	O
171	supportive	_	_	O
172	care	_	_	O
173	needs	_	_	O
174	,	_	_	O
175	health	_	_	O
176	service	_	_	O
177	utilization	_	_	O
178	,	_	_	O
179	and	_	_	O
180	quality	_	_	O
181	of	_	_	O
182	life	_	_	O
183	at	_	_	O
184	1	_	_	O
185	,	_	_	O
186	3	_	_	O
187	,	_	_	O
188	and	_	_	O
189	6	_	_	O
190	months	_	_	O
191	postdischarge	_	_	O
192	.	_	_	O

193	Of	_	_	O
194	87	_	_	O
195	eligible	_	_	O
196	patients	_	_	O
197	,	_	_	O
198	75	_	_	O
199	consented	_	_	O
200	(	_	_	O
201	86	_	_	O
202	%	_	_	O
203	consent	_	_	O
204	rate	_	_	O
205	)	_	_	O
206	.	_	_	O

207	Thirty	_	_	O
208	-	_	_	O
209	nine	_	_	O
210	patients	_	_	O
211	were	_	_	O
212	randomly	_	_	O
213	assigned	_	_	O
214	to	_	_	O
215	CONNECT	_	_	O
216	and	_	_	O
217	36	_	_	O
218	to	_	_	O
219	usual	_	_	O
220	care	_	_	O
221	.	_	_	O

222	At	_	_	B-Premise
223	6	_	_	I-Premise
224	months	_	_	I-Premise
225	,	_	_	I-Premise
226	there	_	_	I-Premise
227	was	_	_	I-Premise
228	a	_	_	I-Premise
229	clinically	_	_	I-Premise
230	relevant	_	_	I-Premise
231	,	_	_	I-Premise
232	but	_	_	I-Premise
233	nonsignificant	_	_	I-Premise
234	reduction	_	_	I-Premise
235	in	_	_	I-Premise
236	presentations	_	_	I-Premise
237	to	_	_	I-Premise
238	emergency	_	_	I-Premise
239	departments	_	_	I-Premise
240	(	_	_	I-Premise
241	21	_	_	I-Premise
242	%	_	_	I-Premise
243	vs	_	_	I-Premise
244	33	_	_	I-Premise
245	%	_	_	I-Premise
246	;	_	_	I-Premise
247	χ1	_	_	I-Premise
248	=	_	_	I-Premise
249	1	_	_	I-Premise
250	.	_	_	I-Premise

251	41	_	_	I-Premise
252	,	_	_	I-Premise
253	P	_	_	I-Premise
254	=	_	_	I-Premise
255	.	_	_	I-Premise

256	23	_	_	I-Premise
257	)	_	_	I-Premise
258	and	_	_	I-Premise
259	readmission	_	_	I-Premise
260	to	_	_	I-Premise
261	the	_	_	I-Premise
262	hospital	_	_	I-Premise
263	(	_	_	I-Premise
264	37	_	_	I-Premise
265	%	_	_	I-Premise
266	vs	_	_	I-Premise
267	47	_	_	I-Premise
268	%	_	_	I-Premise
269	;	_	_	I-Premise
270	χ1	_	_	I-Premise
271	=	_	_	I-Premise
272	0	_	_	I-Premise
273	.	_	_	I-Premise

274	82	_	_	I-Premise
275	,	_	_	I-Premise
276	P	_	_	I-Premise
277	=	_	_	I-Premise
278	.	_	_	I-Premise

279	37	_	_	I-Premise
280	)	_	_	I-Premise
281	among	_	_	I-Premise
282	intervention	_	_	I-Premise
283	compared	_	_	I-Premise
284	with	_	_	I-Premise
285	control	_	_	I-Premise
286	group	_	_	I-Premise
287	participants	_	_	I-Premise
288	.	_	_	I-Premise

289	Nonsignificant	_	_	B-Premise
290	differences	_	_	I-Premise
291	between	_	_	I-Premise
292	groups	_	_	I-Premise
293	were	_	_	I-Premise
294	found	_	_	I-Premise
295	for	_	_	I-Premise
296	all	_	_	I-Premise
297	unmet	_	_	I-Premise
298	supportive	_	_	I-Premise
299	care	_	_	I-Premise
300	need	_	_	I-Premise
301	and	_	_	I-Premise
302	quality	_	_	I-Premise
303	-	_	_	I-Premise
304	of	_	_	I-Premise
305	-	_	_	I-Premise
306	life	_	_	I-Premise
307	scores	_	_	I-Premise
308	,	_	_	I-Premise
309	change	_	_	I-Premise
310	scores	_	_	I-Premise
311	,	_	_	I-Premise
312	and	_	_	I-Premise
313	trends	_	_	I-Premise
314	.	_	_	I-Premise

315	However	_	_	B-Premise
316	,	_	_	I-Premise
317	at	_	_	I-Premise
318	6	_	_	I-Premise
319	months	_	_	I-Premise
320	,	_	_	I-Premise
321	total	_	_	I-Premise
322	quality	_	_	I-Premise
323	-	_	_	I-Premise
324	of	_	_	I-Premise
325	-	_	_	I-Premise
326	life	_	_	I-Premise
327	scores	_	_	I-Premise
328	were	_	_	I-Premise
329	higher	_	_	I-Premise
330	for	_	_	I-Premise
331	intervention	_	_	I-Premise
332	group	_	_	I-Premise
333	patients	_	_	I-Premise
334	than	_	_	I-Premise
335	controls	_	_	I-Premise
336	(	_	_	I-Premise
337	106	_	_	I-Premise
338	.	_	_	I-Premise

339	0	_	_	I-Premise
340	vs	_	_	I-Premise
341	98	_	_	I-Premise
342	.	_	_	I-Premise

343	6	_	_	I-Premise
344	)	_	_	I-Premise
345	.	_	_	I-Premise

346	This	_	_	O
347	difference	_	_	O
348	(	_	_	O
349	7	_	_	O
350	.	_	_	O

351	4	_	_	O
352	)	_	_	O
353	was	_	_	O
354	clinically	_	_	O
355	relevant	_	_	O
356	.	_	_	O

357	Improvements	_	_	B-Claim
358	in	_	_	I-Claim
359	total	_	_	I-Claim
360	quality	_	_	I-Claim
361	-	_	_	I-Claim
362	of	_	_	I-Claim
363	-	_	_	I-Claim
364	life	_	_	I-Claim
365	change	_	_	I-Claim
366	scores	_	_	I-Claim
367	demonstrated	_	_	I-Claim
368	that	_	_	I-Claim
369	at	_	_	I-Claim
370	6	_	_	I-Claim
371	months	_	_	I-Claim
372	,	_	_	I-Claim
373	improvements	_	_	I-Claim
374	were	_	_	I-Claim
375	more	_	_	I-Claim
376	than	_	_	I-Claim
377	twice	_	_	I-Claim
378	as	_	_	I-Claim
379	large	_	_	I-Claim
380	and	_	_	I-Claim
381	clinically	_	_	I-Claim
382	significant	_	_	I-Claim
383	in	_	_	I-Claim
384	the	_	_	I-Claim
385	intervention	_	_	I-Claim
386	compared	_	_	I-Claim
387	with	_	_	I-Claim
388	the	_	_	I-Claim
389	control	_	_	I-Claim
390	group	_	_	I-Claim
391	.	_	_	I-Claim

392	CONNECT	_	_	B-Claim
393	has	_	_	I-Claim
394	shown	_	_	I-Claim
395	promising	_	_	I-Claim
396	indications	_	_	I-Claim
397	on	_	_	I-Claim
398	health	_	_	I-Claim
399	system	_	_	I-Claim
400	and	_	_	I-Claim
401	patient	_	_	I-Claim
402	outcomes	_	_	I-Claim
403	that	_	_	I-Claim
404	warrant	_	_	I-Claim
405	a	_	_	I-Claim
406	larger	_	_	I-Claim
407	study	_	_	I-Claim
408	to	_	_	I-Claim
409	further	_	_	I-Claim
410	investigate	_	_	I-Claim
411	the	_	_	I-Claim
412	potential	_	_	I-Claim
413	of	_	_	I-Claim
414	this	_	_	I-Claim
415	intervention	_	_	I-Claim
416	.	_	_	I-Claim


0	Few	_	_	O
1	intervention	_	_	O
2	studies	_	_	O
3	have	_	_	O
4	been	_	_	O
5	conducted	_	_	O
6	to	_	_	O
7	help	_	_	O
8	couples	_	_	O
9	manage	_	_	O
10	the	_	_	O
11	effects	_	_	O
12	of	_	_	O
13	prostate	_	_	O
14	cancer	_	_	O
15	and	_	_	O
16	maintain	_	_	O
17	their	_	_	O
18	quality	_	_	O
19	of	_	_	O
20	life	_	_	O
21	.	_	_	O

22	The	_	_	O
23	objective	_	_	O
24	of	_	_	O
25	this	_	_	O
26	study	_	_	O
27	was	_	_	O
28	to	_	_	O
29	determine	_	_	O
30	whether	_	_	O
31	a	_	_	O
32	family	_	_	O
33	-	_	_	O
34	based	_	_	O
35	intervention	_	_	O
36	could	_	_	O
37	improve	_	_	O
38	appraisal	_	_	O
39	variables	_	_	O
40	(	_	_	O
41	appraisal	_	_	O
42	of	_	_	O
43	illness	_	_	O
44	or	_	_	O
45	caregiving	_	_	O
46	,	_	_	O
47	uncertainty	_	_	O
48	,	_	_	O
49	hopelessness	_	_	O
50	)	_	_	O
51	,	_	_	O
52	coping	_	_	O
53	resources	_	_	O
54	(	_	_	O
55	coping	_	_	O
56	strategies	_	_	O
57	,	_	_	O
58	self	_	_	O
59	-	_	_	O
60	efficacy	_	_	O
61	,	_	_	O
62	communication	_	_	O
63	)	_	_	O
64	,	_	_	O
65	symptom	_	_	O
66	distress	_	_	O
67	,	_	_	O
68	and	_	_	O
69	quality	_	_	O
70	of	_	_	O
71	life	_	_	O
72	in	_	_	O
73	men	_	_	O
74	with	_	_	O
75	prostate	_	_	O
76	cancer	_	_	O
77	and	_	_	O
78	their	_	_	O
79	spouses	_	_	O
80	.	_	_	O

81	For	_	_	O
82	this	_	_	O
83	clinical	_	_	O
84	trial	_	_	O
85	,	_	_	O
86	263	_	_	O
87	patient	_	_	O
88	-	_	_	O
89	spouse	_	_	O
90	dyads	_	_	O
91	were	_	_	O
92	stratified	_	_	O
93	by	_	_	O
94	research	_	_	O
95	site	_	_	O
96	,	_	_	O
97	phase	_	_	O
98	of	_	_	O
99	illness	_	_	O
100	,	_	_	O
101	and	_	_	O
102	treatment	_	_	O
103	;	_	_	O
104	then	_	_	O
105	,	_	_	O
106	they	_	_	O
107	were	_	_	O
108	randomized	_	_	O
109	to	_	_	O
110	the	_	_	O
111	control	_	_	O
112	group	_	_	O
113	(	_	_	O
114	standard	_	_	O
115	care	_	_	O
116	)	_	_	O
117	or	_	_	O
118	the	_	_	O
119	experimental	_	_	O
120	group	_	_	O
121	(	_	_	O
122	standard	_	_	O
123	care	_	_	O
124	plus	_	_	O
125	a	_	_	O
126	5	_	_	O
127	-	_	_	O
128	session	_	_	O
129	family	_	_	O
130	intervention	_	_	O
131	)	_	_	O
132	.	_	_	O

133	The	_	_	O
134	intervention	_	_	O
135	targeted	_	_	O
136	couples	_	_	O
137	'	_	_	O
138	communication	_	_	O
139	,	_	_	O
140	hope	_	_	O
141	,	_	_	O
142	coping	_	_	O
143	,	_	_	O
144	uncertainty	_	_	O
145	,	_	_	O
146	and	_	_	O
147	symptom	_	_	O
148	management	_	_	O
149	.	_	_	O

150	The	_	_	O
151	final	_	_	O
152	sample	_	_	O
153	consisted	_	_	O
154	of	_	_	O
155	235	_	_	O
156	couples	_	_	O
157	:	_	_	O
158	123	_	_	O
159	couples	_	_	O
160	in	_	_	O
161	the	_	_	O
162	control	_	_	O
163	group	_	_	O
164	and	_	_	O
165	112	_	_	O
166	couples	_	_	O
167	in	_	_	O
168	the	_	_	O
169	experimental	_	_	O
170	group	_	_	O
171	.	_	_	O

172	Data	_	_	O
173	collection	_	_	O
174	occurred	_	_	O
175	at	_	_	O
176	baseline	_	_	O
177	before	_	_	O
178	randomization	_	_	O
179	and	_	_	O
180	at	_	_	O
181	4	_	_	O
182	months	_	_	O
183	,	_	_	O
184	8	_	_	O
185	months	_	_	O
186	,	_	_	O
187	and	_	_	O
188	12	_	_	O
189	months	_	_	O
190	.	_	_	O

191	At	_	_	B-Premise
192	4	_	_	I-Premise
193	-	_	_	I-Premise
194	month	_	_	I-Premise
195	follow	_	_	I-Premise
196	-	_	_	I-Premise
197	up	_	_	I-Premise
198	,	_	_	I-Premise
199	intervention	_	_	I-Premise
200	patients	_	_	I-Premise
201	reported	_	_	I-Premise
202	less	_	_	I-Premise
203	uncertainty	_	_	I-Premise
204	and	_	_	I-Premise
205	better	_	_	I-Premise
206	communication	_	_	I-Premise
207	with	_	_	I-Premise
208	spouses	_	_	I-Premise
209	than	_	_	I-Premise
210	control	_	_	I-Premise
211	patients	_	_	I-Premise
212	,	_	_	I-Premise
213	but	_	_	B-Premise
214	they	_	_	I-Premise
215	reported	_	_	I-Premise
216	no	_	_	I-Premise
217	other	_	_	I-Premise
218	effects	_	_	I-Premise
219	.	_	_	I-Premise

220	Intervention	_	_	B-Premise
221	spouses	_	_	I-Premise
222	reported	_	_	I-Premise
223	higher	_	_	I-Premise
224	quality	_	_	I-Premise
225	of	_	_	I-Premise
226	life	_	_	I-Premise
227	,	_	_	I-Premise
228	more	_	_	I-Premise
229	self	_	_	I-Premise
230	-	_	_	I-Premise
231	efficacy	_	_	I-Premise
232	,	_	_	I-Premise
233	better	_	_	I-Premise
234	communication	_	_	I-Premise
235	,	_	_	I-Premise
236	and	_	_	I-Premise
237	less	_	_	I-Premise
238	negative	_	_	I-Premise
239	appraisal	_	_	I-Premise
240	of	_	_	I-Premise
241	caregiving	_	_	I-Premise
242	,	_	_	I-Premise
243	uncertainty	_	_	I-Premise
244	,	_	_	I-Premise
245	hopelessness	_	_	I-Premise
246	,	_	_	I-Premise
247	and	_	_	I-Premise
248	symptom	_	_	I-Premise
249	distress	_	_	I-Premise
250	at	_	_	I-Premise
251	4	_	_	I-Premise
252	months	_	_	I-Premise
253	compared	_	_	I-Premise
254	with	_	_	I-Premise
255	controls	_	_	I-Premise
256	,	_	_	I-Premise
257	and	_	_	I-Premise
258	some	_	_	I-Premise
259	effects	_	_	I-Premise
260	were	_	_	I-Premise
261	sustained	_	_	I-Premise
262	to	_	_	I-Premise
263	8	_	_	I-Premise
264	months	_	_	I-Premise
265	and	_	_	I-Premise
266	12	_	_	I-Premise
267	months	_	_	I-Premise
268	.	_	_	I-Premise

269	Men	_	_	B-Premise
270	with	_	_	I-Premise
271	prostate	_	_	I-Premise
272	cancer	_	_	I-Premise
273	and	_	_	I-Premise
274	their	_	_	I-Premise
275	spouses	_	_	I-Premise
276	reported	_	_	I-Premise
277	positive	_	_	I-Premise
278	outcomes	_	_	I-Premise
279	from	_	_	I-Premise
280	a	_	_	I-Premise
281	family	_	_	I-Premise
282	intervention	_	_	I-Premise
283	that	_	_	I-Premise
284	offered	_	_	I-Premise
285	them	_	_	I-Premise
286	information	_	_	I-Premise
287	and	_	_	I-Premise
288	support	_	_	I-Premise
289	.	_	_	I-Premise

290	Programs	_	_	B-Claim
291	of	_	_	I-Claim
292	care	_	_	I-Claim
293	need	_	_	I-Claim
294	to	_	_	I-Claim
295	be	_	_	I-Claim
296	extended	_	_	I-Claim
297	to	_	_	I-Claim
298	spouses	_	_	I-Claim
299	who	_	_	I-Claim
300	likely	_	_	I-Claim
301	will	_	_	I-Claim
302	experience	_	_	I-Claim
303	multiple	_	_	I-Claim
304	benefits	_	_	I-Claim
305	from	_	_	I-Claim
306	intervention	_	_	I-Claim
307	.	_	_	I-Claim


0	With	_	_	O
1	the	_	_	O
2	adoption	_	_	O
3	of	_	_	O
4	enhanced	_	_	O
5	recovery	_	_	O
6	and	_	_	O
7	emerging	_	_	O
8	new	_	_	O
9	modalities	_	_	O
10	of	_	_	O
11	analgesia	_	_	O
12	after	_	_	O
13	laparoscopic	_	_	O
14	colorectal	_	_	O
15	resection	_	_	O
16	(	_	_	O
17	LCR	_	_	O
18	)	_	_	O
19	,	_	_	O
20	the	_	_	O
21	role	_	_	O
22	of	_	_	O
23	epidural	_	_	O
24	analgesia	_	_	O
25	has	_	_	O
26	been	_	_	O
27	questioned	_	_	O
28	.	_	_	O

29	This	_	_	O
30	pilot	_	_	O
31	trial	_	_	O
32	assessed	_	_	O
33	the	_	_	O
34	feasibility	_	_	O
35	of	_	_	O
36	a	_	_	O
37	randomized	_	_	O
38	controlled	_	_	O
39	trial	_	_	O
40	(	_	_	O
41	RCT	_	_	O
42	)	_	_	O
43	comparing	_	_	O
44	epidural	_	_	O
45	analgesia	_	_	O
46	and	_	_	O
47	use	_	_	O
48	of	_	_	O
49	a	_	_	O
50	local	_	_	O
51	anaesthetic	_	_	O
52	wound	_	_	O
53	infusion	_	_	O
54	catheter	_	_	O
55	(	_	_	O
56	WIC	_	_	O
57	)	_	_	O
58	following	_	_	O
59	LCR	_	_	O
60	.	_	_	O

61	Between	_	_	O
62	April	_	_	O
63	2010	_	_	O
64	and	_	_	O
65	May	_	_	O
66	2011	_	_	O
67	,	_	_	O
68	patients	_	_	O
69	undergoing	_	_	O
70	elective	_	_	O
71	LCR	_	_	O
72	in	_	_	O
73	two	_	_	O
74	centres	_	_	O
75	were	_	_	O
76	randomized	_	_	O
77	to	_	_	O
78	analgesia	_	_	O
79	via	_	_	O
80	epidural	_	_	O
81	or	_	_	O
82	WIC	_	_	O
83	.	_	_	O

84	Sham	_	_	O
85	procedures	_	_	O
86	were	_	_	O
87	used	_	_	O
88	to	_	_	O
89	blind	_	_	O
90	surgeons	_	_	O
91	,	_	_	O
92	patients	_	_	O
93	and	_	_	O
94	outcome	_	_	O
95	assessors	_	_	O
96	.	_	_	O

97	The	_	_	O
98	primary	_	_	O
99	outcome	_	_	O
100	was	_	_	O
101	the	_	_	O
102	feasibility	_	_	O
103	of	_	_	O
104	a	_	_	O
105	large	_	_	O
106	RCT	_	_	O
107	,	_	_	O
108	and	_	_	O
109	all	_	_	O
110	outcomes	_	_	O
111	for	_	_	O
112	a	_	_	O
113	definitive	_	_	O
114	trial	_	_	O
115	were	_	_	O
116	tested	_	_	O
117	.	_	_	O

118	The	_	_	O
119	success	_	_	O
120	of	_	_	O
121	blinding	_	_	O
122	was	_	_	O
123	assessed	_	_	O
124	using	_	_	O
125	a	_	_	O
126	mixed	_	_	O
127	-	_	_	O
128	methods	_	_	O
129	approach	_	_	O
130	.	_	_	O

131	Forty	_	_	O
132	-	_	_	O
133	five	_	_	O
134	patients	_	_	O
135	were	_	_	O
136	eligible	_	_	O
137	,	_	_	O
138	of	_	_	O
139	whom	_	_	O
140	34	_	_	O
141	were	_	_	O
142	randomized	_	_	O
143	(	_	_	O
144	mean	_	_	O
145	(	_	_	O
146	s	_	_	O
147	.	_	_	O

148	d	_	_	O
149	.	_	_	O

150	)	_	_	O
151	age	_	_	O
152	70	_	_	O
153	(	_	_	O
154	11	_	_	O
155	·	_	_	O
156	8	_	_	O
157	)	_	_	O
158	years	_	_	O
159	)	_	_	O
160	.	_	_	O

161	Patients	_	_	O
162	were	_	_	O
163	followed	_	_	O
164	up	_	_	O
165	per	_	_	O
166	-	_	_	O
167	protocol	_	_	O
168	;	_	_	O
169	there	_	_	O
170	were	_	_	O
171	no	_	_	O
172	deaths	_	_	O
173	,	_	_	O
174	and	_	_	O
175	five	_	_	O
176	patients	_	_	O
177	had	_	_	O
178	a	_	_	O
179	total	_	_	O
180	of	_	_	O
181	six	_	_	O
182	complications	_	_	O
183	.	_	_	O

184	Challenges	_	_	O
185	with	_	_	O
186	capturing	_	_	O
187	pain	_	_	O
188	data	_	_	O
189	were	_	_	O
190	identified	_	_	O
191	and	_	_	O
192	resolved	_	_	O
193	.	_	_	O

194	Mean	_	_	B-Premise
195	(	_	_	I-Premise
196	s	_	_	I-Premise
197	.	_	_	I-Premise

198	d	_	_	I-Premise
199	.	_	_	I-Premise

200	)	_	_	I-Premise
201	pain	_	_	I-Premise
202	scores	_	_	I-Premise
203	on	_	_	I-Premise
204	the	_	_	I-Premise
205	day	_	_	I-Premise
206	of	_	_	I-Premise
207	discharge	_	_	I-Premise
208	were	_	_	I-Premise
209	1	_	_	I-Premise
210	·	_	_	I-Premise
211	9	_	_	I-Premise
212	(	_	_	I-Premise
213	3	_	_	I-Premise
214	·	_	_	I-Premise
215	1	_	_	I-Premise
216	)	_	_	I-Premise
217	in	_	_	I-Premise
218	the	_	_	I-Premise
219	epidural	_	_	I-Premise
220	group	_	_	I-Premise
221	and	_	_	I-Premise
222	0	_	_	I-Premise
223	·	_	_	I-Premise
224	7	_	_	I-Premise
225	(	_	_	I-Premise
226	0	_	_	I-Premise
227	·	_	_	I-Premise
228	7	_	_	I-Premise
229	)	_	_	I-Premise
230	in	_	_	I-Premise
231	the	_	_	I-Premise
232	WIC	_	_	I-Premise
233	group	_	_	I-Premise
234	.	_	_	I-Premise

235	Median	_	_	B-Premise
236	length	_	_	I-Premise
237	of	_	_	I-Premise
238	stay	_	_	I-Premise
239	was	_	_	I-Premise
240	4	_	_	I-Premise
241	(	_	_	I-Premise
242	range	_	_	I-Premise
243	2	_	_	I-Premise
244	-	_	_	I-Premise
245	35	_	_	I-Premise
246	,	_	_	I-Premise
247	interquartile	_	_	I-Premise
248	range	_	_	I-Premise
249	3	_	_	I-Premise
250	-	_	_	I-Premise
251	5	_	_	I-Premise
252	)	_	_	I-Premise
253	days	_	_	I-Premise
254	.	_	_	I-Premise

255	Mean	_	_	B-Premise
256	use	_	_	I-Premise
257	of	_	_	I-Premise
258	additional	_	_	I-Premise
259	analgesia	_	_	I-Premise
260	(	_	_	I-Premise
261	intravenous	_	_	I-Premise
262	morphine	_	_	I-Premise
263	equivalents	_	_	I-Premise
264	)	_	_	I-Premise
265	was	_	_	I-Premise
266	12	_	_	I-Premise
267	mg	_	_	I-Premise
268	in	_	_	I-Premise
269	the	_	_	I-Premise
270	WIC	_	_	I-Premise
271	arm	_	_	I-Premise
272	and	_	_	I-Premise
273	9	_	_	I-Premise
274	mg	_	_	I-Premise
275	in	_	_	I-Premise
276	the	_	_	I-Premise
277	epidural	_	_	I-Premise
278	arm	_	_	I-Premise
279	.	_	_	I-Premise

280	Patient	_	_	O
281	blinding	_	_	O
282	was	_	_	O
283	successful	_	_	O
284	in	_	_	O
285	both	_	_	O
286	arms	_	_	O
287	.	_	_	O

288	Qualitative	_	_	B-Claim
289	interviews	_	_	I-Claim
290	suggested	_	_	I-Claim
291	that	_	_	I-Claim
292	patients	_	_	I-Claim
293	found	_	_	I-Claim
294	participation	_	_	I-Claim
295	in	_	_	I-Claim
296	the	_	_	I-Claim
297	trial	_	_	I-Claim
298	acceptable	_	_	I-Claim
299	and	_	_	I-Claim
300	that	_	_	I-Claim
301	they	_	_	I-Claim
302	would	_	_	I-Claim
303	consider	_	_	I-Claim
304	participating	_	_	I-Claim
305	in	_	_	I-Claim
306	a	_	_	I-Claim
307	future	_	_	I-Claim
308	trial	_	_	I-Claim
309	.	_	_	I-Claim

310	A	_	_	B-Claim
311	blinded	_	_	I-Claim
312	RCT	_	_	I-Claim
313	investigating	_	_	I-Claim
314	the	_	_	I-Claim
315	role	_	_	I-Claim
316	of	_	_	I-Claim
317	epidural	_	_	I-Claim
318	and	_	_	I-Claim
319	WIC	_	_	I-Claim
320	administration	_	_	I-Claim
321	for	_	_	I-Claim
322	postoperative	_	_	I-Claim
323	analgesia	_	_	I-Claim
324	following	_	_	I-Claim
325	LCR	_	_	I-Claim
326	is	_	_	I-Claim
327	feasible	_	_	I-Claim
328	.	_	_	I-Claim

329	Rigorous	_	_	B-Claim
330	standard	_	_	I-Claim
331	operating	_	_	I-Claim
332	procedures	_	_	I-Claim
333	for	_	_	I-Claim
334	data	_	_	I-Claim
335	collection	_	_	I-Claim
336	are	_	_	I-Claim
337	required	_	_	I-Claim
338	.	_	_	I-Claim


0	Epoetin	_	_	B-Claim
1	alfa	_	_	I-Claim
2	administered	_	_	I-Claim
3	at	_	_	I-Claim
4	40	_	_	I-Claim
5	,	_	_	I-Claim
6	000	_	_	I-Claim
7	U	_	_	I-Claim
8	once	_	_	I-Claim
9	weekly	_	_	I-Claim
10	(	_	_	I-Claim
11	qw	_	_	I-Claim
12	)	_	_	I-Claim
13	to	_	_	I-Claim
14	anemic	_	_	I-Claim
15	cancer	_	_	I-Claim
16	patients	_	_	I-Claim
17	receiving	_	_	I-Claim
18	chemotherapy	_	_	I-Claim
19	increases	_	_	I-Claim
20	hemoglobin	_	_	I-Claim
21	levels	_	_	I-Claim
22	,	_	_	I-Claim
23	improves	_	_	I-Claim
24	quality	_	_	I-Claim
25	of	_	_	I-Claim
26	life	_	_	I-Claim
27	(	_	_	I-Claim
28	QOL	_	_	I-Claim
29	)	_	_	I-Claim
30	,	_	_	I-Claim
31	and	_	_	I-Claim
32	reduces	_	_	I-Claim
33	transfusions	_	_	I-Claim
34	.	_	_	I-Claim

35	The	_	_	O
36	benefit	_	_	O
37	of	_	_	O
38	epoetin	_	_	O
39	alfa	_	_	O
40	in	_	_	O
41	maintaining	_	_	O
42	hemoglobin	_	_	O
43	levels	_	_	O
44	in	_	_	O
45	cancer	_	_	O
46	patients	_	_	O
47	with	_	_	O
48	hemoglobin	_	_	O
49	less	_	_	O
50	than	_	_	O
51	12	_	_	O
52	g	_	_	O
53	/	_	_	O
54	dL	_	_	O
55	has	_	_	O
56	not	_	_	O
57	been	_	_	O
58	evaluated	_	_	O
59	.	_	_	O

60	Breast	_	_	O
61	cancer	_	_	O
62	patients	_	_	O
63	(	_	_	O
64	N	_	_	O
65	=	_	_	O
66	354	_	_	O
67	)	_	_	O
68	receiving	_	_	O
69	chemotherapy	_	_	O
70	were	_	_	O
71	randomly	_	_	O
72	assigned	_	_	O
73	in	_	_	O
74	1	_	_	O
75	:	_	_	O
76	1	_	_	O
77	ratio	_	_	O
78	to	_	_	O
79	epoetin	_	_	O
80	alfa	_	_	O
81	(	_	_	O
82	40	_	_	O
83	,	_	_	O
84	000	_	_	O
85	U	_	_	O
86	qw	_	_	O
87	)	_	_	O
88	or	_	_	O
89	standard	_	_	O
90	of	_	_	O
91	care	_	_	O
92	(	_	_	O
93	SOC	_	_	O
94	)	_	_	O
95	.	_	_	O

96	QOL	_	_	O
97	was	_	_	O
98	assessed	_	_	O
99	at	_	_	O
100	baseline	_	_	O
101	and	_	_	O
102	week	_	_	O
103	12	_	_	O
104	.	_	_	O

105	Hemoglobin	_	_	O
106	responses	_	_	O
107	,	_	_	O
108	transfusion	_	_	O
109	requirements	_	_	O
110	,	_	_	O
111	and	_	_	O
112	prognostic	_	_	O
113	factors	_	_	O
114	for	_	_	O
115	responses	_	_	O
116	were	_	_	O
117	measured	_	_	O
118	.	_	_	O

119	At	_	_	B-Premise
120	week	_	_	I-Premise
121	12	_	_	I-Premise
122	,	_	_	I-Premise
123	Functional	_	_	I-Premise
124	Assessment	_	_	I-Premise
125	of	_	_	I-Premise
126	Cancer	_	_	I-Premise
127	Therapy	_	_	I-Premise
128	-	_	_	I-Premise
129	Anemia	_	_	I-Premise
130	(	_	_	I-Premise
131	FACT	_	_	I-Premise
132	-	_	_	I-Premise
133	An	_	_	I-Premise
134	;	_	_	I-Premise
135	mean	_	_	I-Premise
136	,	_	_	I-Premise
137	2	_	_	I-Premise
138	.	_	_	I-Premise

139	16	_	_	I-Premise
140	+	_	_	I-Premise
141	/	_	_	I-Premise
142	-	_	_	I-Premise
143	12	_	_	I-Premise
144	.	_	_	I-Premise

145	84	_	_	I-Premise
146	for	_	_	I-Premise
147	epoetin	_	_	I-Premise
148	alfa	_	_	I-Premise
149	v	_	_	I-Premise
150	-	_	_	I-Premise
151	4	_	_	I-Premise
152	.	_	_	I-Premise

153	43	_	_	I-Premise
154	+	_	_	I-Premise
155	/	_	_	I-Premise
156	-	_	_	I-Premise
157	13	_	_	I-Premise
158	.	_	_	I-Premise

159	42	_	_	I-Premise
160	for	_	_	I-Premise
161	SOC	_	_	I-Premise
162	)	_	_	I-Premise
163	and	_	_	I-Premise
164	FACT	_	_	I-Premise
165	-	_	_	I-Premise
166	An	_	_	I-Premise
167	fatigue	_	_	I-Premise
168	(	_	_	I-Premise
169	mean	_	_	I-Premise
170	,	_	_	I-Premise
171	1	_	_	I-Premise
172	.	_	_	I-Premise

173	85	_	_	I-Premise
174	+	_	_	I-Premise
175	/	_	_	I-Premise
176	-	_	_	I-Premise
177	10	_	_	I-Premise
178	.	_	_	I-Premise

179	52	_	_	I-Premise
180	for	_	_	I-Premise
181	epoetin	_	_	I-Premise
182	alfa	_	_	I-Premise
183	v	_	_	I-Premise
184	-	_	_	I-Premise
185	3	_	_	I-Premise
186	.	_	_	I-Premise

187	55	_	_	I-Premise
188	+	_	_	I-Premise
189	/	_	_	I-Premise
190	-	_	_	I-Premise
191	11	_	_	I-Premise
192	.	_	_	I-Premise

193	14	_	_	I-Premise
194	for	_	_	I-Premise
195	SOC	_	_	I-Premise
196	)	_	_	I-Premise
197	change	_	_	I-Premise
198	scores	_	_	I-Premise
199	were	_	_	I-Premise
200	significantly	_	_	I-Premise
201	higher	_	_	I-Premise
202	in	_	_	I-Premise
203	the	_	_	I-Premise
204	epoetin	_	_	I-Premise
205	alfa	_	_	I-Premise
206	group	_	_	I-Premise
207	(	_	_	I-Premise
208	P	_	_	I-Premise
209	<	_	_	I-Premise
210	.	_	_	I-Premise

211	0001	_	_	I-Premise
212	)	_	_	I-Premise
213	.	_	_	I-Premise

214	Hemoglobin	_	_	B-Premise
215	responses	_	_	I-Premise
216	defined	_	_	I-Premise
217	as	_	_	I-Premise
218	mean	_	_	I-Premise
219	hemoglobin	_	_	I-Premise
220	>	_	_	I-Premise
221	or	_	_	I-Premise
222	=	_	_	I-Premise
223	12	_	_	I-Premise
224	g	_	_	I-Premise
225	/	_	_	I-Premise
226	dL	_	_	I-Premise
227	or	_	_	I-Premise
228	a	_	_	I-Premise
229	>	_	_	I-Premise
230	or	_	_	I-Premise
231	=	_	_	I-Premise
232	2	_	_	I-Premise
233	g	_	_	I-Premise
234	/	_	_	I-Premise
235	dL	_	_	I-Premise
236	increase	_	_	I-Premise
237	compared	_	_	I-Premise
238	with	_	_	I-Premise
239	baseline	_	_	I-Premise
240	were	_	_	I-Premise
241	significantly	_	_	I-Premise
242	higher	_	_	I-Premise
243	in	_	_	I-Premise
244	the	_	_	I-Premise
245	epoetin	_	_	I-Premise
246	alfa	_	_	I-Premise
247	group	_	_	I-Premise
248	versus	_	_	I-Premise
249	SOC	_	_	I-Premise
250	:	_	_	I-Premise
251	52	_	_	I-Premise
252	.	_	_	I-Premise

253	0	_	_	I-Premise
254	%	_	_	I-Premise
255	v	_	_	I-Premise
256	5	_	_	I-Premise
257	.	_	_	I-Premise

258	1	_	_	I-Premise
259	%	_	_	I-Premise
260	and	_	_	I-Premise
261	65	_	_	I-Premise
262	.	_	_	I-Premise

263	7	_	_	I-Premise
264	%	_	_	I-Premise
265	v	_	_	I-Premise
266	6	_	_	I-Premise
267	.	_	_	I-Premise

268	3	_	_	I-Premise
269	%	_	_	I-Premise
270	,	_	_	I-Premise
271	respectively	_	_	I-Premise
272	(	_	_	I-Premise
273	P	_	_	I-Premise
274	<	_	_	I-Premise
275	.	_	_	I-Premise

276	0001	_	_	I-Premise
277	for	_	_	I-Premise
278	both	_	_	I-Premise
279	comparisons	_	_	I-Premise
280	)	_	_	I-Premise
281	.	_	_	I-Premise

282	Percentage	_	_	B-Premise
283	transfused	_	_	I-Premise
284	was	_	_	I-Premise
285	significantly	_	_	I-Premise
286	lower	_	_	I-Premise
287	in	_	_	I-Premise
288	the	_	_	I-Premise
289	epoetin	_	_	I-Premise
290	alfa	_	_	I-Premise
291	group	_	_	I-Premise
292	compared	_	_	I-Premise
293	with	_	_	I-Premise
294	SOC	_	_	I-Premise
295	(	_	_	I-Premise
296	8	_	_	I-Premise
297	.	_	_	I-Premise

298	6	_	_	I-Premise
299	%	_	_	I-Premise
300	v	_	_	I-Premise
301	22	_	_	I-Premise
302	.	_	_	I-Premise

303	9	_	_	I-Premise
304	%	_	_	I-Premise
305	)	_	_	I-Premise
306	.	_	_	I-Premise

307	More	_	_	B-Premise
308	than	_	_	I-Premise
309	90	_	_	I-Premise
310	%	_	_	I-Premise
311	of	_	_	I-Premise
312	patients	_	_	I-Premise
313	did	_	_	I-Premise
314	not	_	_	I-Premise
315	require	_	_	I-Premise
316	a	_	_	I-Premise
317	dose	_	_	I-Premise
318	increase	_	_	I-Premise
319	and	_	_	I-Premise
320	28	_	_	I-Premise
321	.	_	_	I-Premise

322	7	_	_	I-Premise
323	%	_	_	I-Premise
324	had	_	_	I-Premise
325	a	_	_	I-Premise
326	dose	_	_	I-Premise
327	reduction	_	_	I-Premise
328	.	_	_	I-Premise

329	Epoetin	_	_	B-Claim
330	alfa	_	_	I-Claim
331	administered	_	_	I-Claim
332	at	_	_	I-Claim
333	40	_	_	I-Claim
334	,	_	_	I-Claim
335	000	_	_	I-Claim
336	U	_	_	I-Claim
337	qw	_	_	I-Claim
338	is	_	_	I-Claim
339	effective	_	_	I-Claim
340	in	_	_	I-Claim
341	improving	_	_	I-Claim
342	QOL	_	_	I-Claim
343	,	_	_	I-Claim
344	maintaining	_	_	I-Claim
345	hemoglobin	_	_	I-Claim
346	level	_	_	I-Claim
347	,	_	_	I-Claim
348	and	_	_	I-Claim
349	reducing	_	_	I-Claim
350	transfusion	_	_	I-Claim
351	requirements	_	_	I-Claim
352	in	_	_	I-Claim
353	breast	_	_	I-Claim
354	cancer	_	_	I-Claim
355	patients	_	_	I-Claim
356	.	_	_	I-Claim

357	The	_	_	B-Claim
358	high	_	_	I-Claim
359	effectiveness	_	_	I-Claim
360	observed	_	_	I-Claim
361	could	_	_	I-Claim
362	be	_	_	I-Claim
363	attributed	_	_	I-Claim
364	in	_	_	I-Claim
365	part	_	_	I-Claim
366	to	_	_	I-Claim
367	early	_	_	I-Claim
368	treatment	_	_	I-Claim
369	with	_	_	I-Claim
370	epoetin	_	_	I-Claim
371	alfa	_	_	I-Claim
372	.	_	_	I-Claim


0	We	_	_	O
1	aimed	_	_	O
2	to	_	_	O
3	assess	_	_	O
4	the	_	_	O
5	effectiveness	_	_	O
6	of	_	_	O
7	acupuncture	_	_	O
8	for	_	_	O
9	cancer	_	_	O
10	-	_	_	O
11	related	_	_	O
12	fatigue	_	_	O
13	(	_	_	O
14	CRF	_	_	O
15	)	_	_	O
16	in	_	_	O
17	patients	_	_	O
18	with	_	_	O
19	breast	_	_	O
20	cancer	_	_	O
21	.	_	_	O

22	We	_	_	O
23	conducted	_	_	O
24	a	_	_	O
25	pragmatic	_	_	O
26	,	_	_	O
27	randomized	_	_	O
28	controlled	_	_	O
29	trial	_	_	O
30	comparing	_	_	O
31	acupuncture	_	_	O
32	with	_	_	O
33	enhanced	_	_	O
34	usual	_	_	O
35	care	_	_	O
36	.	_	_	O

37	Three	_	_	O
38	hundred	_	_	O
39	two	_	_	O
40	outpatients	_	_	O
41	with	_	_	O
42	breast	_	_	O
43	cancer	_	_	O
44	participated	_	_	O
45	.	_	_	O

46	We	_	_	O
47	randomly	_	_	O
48	assigned	_	_	O
49	75	_	_	O
50	patients	_	_	O
51	to	_	_	O
52	usual	_	_	O
53	care	_	_	O
54	and	_	_	O
55	227	_	_	O
56	patients	_	_	O
57	to	_	_	O
58	acupuncture	_	_	O
59	plus	_	_	O
60	usual	_	_	O
61	care	_	_	O
62	(	_	_	O
63	random	_	_	O
64	assignment	_	_	O
65	of	_	_	O
66	1	_	_	O
67	:	_	_	O
68	3	_	_	O
69	respectively	_	_	O
70	)	_	_	O
71	with	_	_	O
72	minimization	_	_	O
73	controlling	_	_	O
74	for	_	_	O
75	baseline	_	_	O
76	general	_	_	O
77	fatigue	_	_	O
78	and	_	_	O
79	maintenance	_	_	O
80	treatment	_	_	O
81	.	_	_	O

82	Treatment	_	_	O
83	was	_	_	O
84	delivered	_	_	O
85	by	_	_	O
86	acupuncturists	_	_	O
87	once	_	_	O
88	a	_	_	O
89	week	_	_	O
90	for	_	_	O
91	6	_	_	O
92	weeks	_	_	O
93	through	_	_	O
94	needling	_	_	O
95	three	_	_	O
96	pairs	_	_	O
97	of	_	_	O
98	acupoints	_	_	O
99	.	_	_	O

100	The	_	_	O
101	usual	_	_	O
102	care	_	_	O
103	group	_	_	O
104	received	_	_	O
105	a	_	_	O
106	booklet	_	_	O
107	with	_	_	O
108	information	_	_	O
109	about	_	_	O
110	fatigue	_	_	O
111	and	_	_	O
112	its	_	_	O
113	management	_	_	O
114	.	_	_	O

115	Primary	_	_	O
116	outcome	_	_	O
117	was	_	_	O
118	general	_	_	O
119	fatigue	_	_	O
120	at	_	_	O
121	6	_	_	O
122	weeks	_	_	O
123	,	_	_	O
124	measured	_	_	O
125	with	_	_	O
126	the	_	_	O
127	Multidimensional	_	_	O
128	Fatigue	_	_	O
129	Inventory	_	_	O
130	(	_	_	O
131	MFI	_	_	O
132	)	_	_	O
133	.	_	_	O

134	Other	_	_	O
135	measurements	_	_	O
136	included	_	_	O
137	the	_	_	O
138	Hospital	_	_	O
139	Anxiety	_	_	O
140	and	_	_	O
141	Depression	_	_	O
142	Scale	_	_	O
143	,	_	_	O
144	Functional	_	_	O
145	Assessment	_	_	O
146	of	_	_	O
147	Cancer	_	_	O
148	Therapy	_	_	O
149	-	_	_	O
150	General	_	_	O
151	quality	_	_	O
152	-	_	_	O
153	of	_	_	O
154	-	_	_	O
155	life	_	_	O
156	scale	_	_	O
157	,	_	_	O
158	and	_	_	O
159	expectation	_	_	O
160	of	_	_	O
161	acupuncture	_	_	O
162	effect	_	_	O
163	.	_	_	O

164	Analyses	_	_	O
165	were	_	_	O
166	by	_	_	O
167	intention	_	_	O
168	to	_	_	O
169	treat	_	_	O
170	.	_	_	O

171	Two	_	_	O
172	hundred	_	_	O
173	forty	_	_	O
174	-	_	_	O
175	six	_	_	O
176	of	_	_	O
177	302	_	_	O
178	patients	_	_	O
179	randomly	_	_	O
180	assigned	_	_	O
181	provided	_	_	O
182	complete	_	_	O
183	data	_	_	O
184	at	_	_	O
185	6	_	_	O
186	weeks	_	_	O
187	.	_	_	O

188	The	_	_	B-Premise
189	difference	_	_	I-Premise
190	in	_	_	I-Premise
191	the	_	_	I-Premise
192	mean	_	_	I-Premise
193	General	_	_	I-Premise
194	Fatigue	_	_	I-Premise
195	score	_	_	I-Premise
196	,	_	_	I-Premise
197	between	_	_	I-Premise
198	those	_	_	I-Premise
199	who	_	_	I-Premise
200	received	_	_	I-Premise
201	the	_	_	I-Premise
202	intervention	_	_	I-Premise
203	and	_	_	I-Premise
204	those	_	_	I-Premise
205	who	_	_	I-Premise
206	did	_	_	I-Premise
207	not	_	_	I-Premise
208	,	_	_	I-Premise
209	was	_	_	I-Premise
210	-	_	_	I-Premise
211	3	_	_	I-Premise
212	.	_	_	I-Premise

213	11	_	_	I-Premise
214	(	_	_	I-Premise
215	95	_	_	I-Premise
216	%	_	_	I-Premise
217	CI	_	_	I-Premise
218	,	_	_	I-Premise
219	-	_	_	I-Premise
220	3	_	_	I-Premise
221	.	_	_	I-Premise

222	97	_	_	I-Premise
223	to	_	_	I-Premise
224	-	_	_	I-Premise
225	2	_	_	I-Premise
226	.	_	_	I-Premise

227	25	_	_	I-Premise
228	;	_	_	I-Premise
229	P	_	_	I-Premise
230	<	_	_	I-Premise
231	.	_	_	I-Premise

232	001	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	The	_	_	B-Premise
236	intervention	_	_	I-Premise
237	also	_	_	I-Premise
238	improved	_	_	I-Premise
239	all	_	_	I-Premise
240	other	_	_	I-Premise
241	fatigue	_	_	I-Premise
242	aspects	_	_	I-Premise
243	measured	_	_	I-Premise
244	by	_	_	I-Premise
245	MFI	_	_	I-Premise
246	,	_	_	I-Premise
247	including	_	_	I-Premise
248	Physical	_	_	I-Premise
249	Fatigue	_	_	I-Premise
250	and	_	_	I-Premise
251	Mental	_	_	I-Premise
252	Fatigue	_	_	I-Premise
253	(	_	_	I-Premise
254	acupuncture	_	_	I-Premise
255	effect	_	_	I-Premise
256	,	_	_	I-Premise
257	-	_	_	I-Premise
258	2	_	_	I-Premise
259	.	_	_	I-Premise

260	36	_	_	I-Premise
261	and	_	_	I-Premise
262	-	_	_	I-Premise
263	1	_	_	I-Premise
264	.	_	_	I-Premise

265	94	_	_	I-Premise
266	,	_	_	I-Premise
267	respectively	_	_	I-Premise
268	;	_	_	I-Premise
269	both	_	_	I-Premise
270	at	_	_	I-Premise
271	P	_	_	I-Premise
272	<	_	_	I-Premise
273	.	_	_	I-Premise

274	001	_	_	I-Premise
275	)	_	_	I-Premise
276	,	_	_	I-Premise
277	anxiety	_	_	I-Premise
278	and	_	_	I-Premise
279	depression	_	_	I-Premise
280	(	_	_	I-Premise
281	acupuncture	_	_	I-Premise
282	effect	_	_	I-Premise
283	,	_	_	I-Premise
284	-	_	_	I-Premise
285	1	_	_	I-Premise
286	.	_	_	I-Premise

287	83	_	_	I-Premise
288	and	_	_	I-Premise
289	-	_	_	I-Premise
290	2	_	_	I-Premise
291	.	_	_	I-Premise

292	13	_	_	I-Premise
293	,	_	_	I-Premise
294	respectively	_	_	I-Premise
295	;	_	_	I-Premise
296	both	_	_	I-Premise
297	at	_	_	I-Premise
298	P	_	_	I-Premise
299	<	_	_	I-Premise
300	.	_	_	I-Premise

301	001	_	_	I-Premise
302	)	_	_	I-Premise
303	,	_	_	I-Premise
304	and	_	_	I-Premise
305	quality	_	_	I-Premise
306	of	_	_	I-Premise
307	life	_	_	I-Premise
308	(	_	_	I-Premise
309	Physical	_	_	I-Premise
310	Well	_	_	I-Premise
311	-	_	_	I-Premise
312	Being	_	_	I-Premise
313	effect	_	_	I-Premise
314	,	_	_	I-Premise
315	3	_	_	I-Premise
316	.	_	_	I-Premise

317	30	_	_	I-Premise
318	;	_	_	I-Premise
319	Functional	_	_	I-Premise
320	Well	_	_	I-Premise
321	-	_	_	I-Premise
322	Being	_	_	I-Premise
323	effect	_	_	I-Premise
324	,	_	_	I-Premise
325	3	_	_	I-Premise
326	.	_	_	I-Premise

327	57	_	_	I-Premise
328	;	_	_	I-Premise
329	both	_	_	I-Premise
330	at	_	_	I-Premise
331	P	_	_	I-Premise
332	<	_	_	I-Premise
333	.	_	_	I-Premise

334	001	_	_	I-Premise
335	;	_	_	I-Premise
336	Emotional	_	_	I-Premise
337	Well	_	_	I-Premise
338	-	_	_	I-Premise
339	Being	_	_	I-Premise
340	effect	_	_	I-Premise
341	,	_	_	I-Premise
342	1	_	_	I-Premise
343	.	_	_	I-Premise

344	93	_	_	I-Premise
345	;	_	_	I-Premise
346	P	_	_	I-Premise
347	=	_	_	I-Premise
348	.	_	_	I-Premise

349	001	_	_	I-Premise
350	;	_	_	I-Premise
351	and	_	_	I-Premise
352	Social	_	_	I-Premise
353	Functioning	_	_	I-Premise
354	Well	_	_	I-Premise
355	-	_	_	I-Premise
356	Being	_	_	I-Premise
357	effect	_	_	I-Premise
358	,	_	_	I-Premise
359	1	_	_	I-Premise
360	.	_	_	I-Premise

361	05	_	_	I-Premise
362	;	_	_	I-Premise
363	P	_	_	I-Premise
364	<	_	_	I-Premise
365	.	_	_	I-Premise

366	05	_	_	I-Premise
367	)	_	_	I-Premise
368	.	_	_	I-Premise

369	Acupuncture	_	_	B-Claim
370	is	_	_	I-Claim
371	an	_	_	I-Claim
372	effective	_	_	I-Claim
373	intervention	_	_	I-Claim
374	for	_	_	I-Claim
375	managing	_	_	I-Claim
376	the	_	_	I-Claim
377	symptom	_	_	I-Claim
378	of	_	_	I-Claim
379	CRF	_	_	I-Claim
380	and	_	_	I-Claim
381	improving	_	_	I-Claim
382	patients	_	_	I-Claim
383	'	_	_	I-Claim
384	quality	_	_	I-Claim
385	of	_	_	I-Claim
386	life	_	_	I-Claim
387	.	_	_	I-Claim


0	A	_	_	B-Claim
1	combination	_	_	I-Claim
2	of	_	_	I-Claim
3	mitoxantrone	_	_	I-Claim
4	plus	_	_	I-Claim
5	prednisone	_	_	I-Claim
6	is	_	_	I-Claim
7	preferable	_	_	I-Claim
8	to	_	_	I-Claim
9	prednisone	_	_	I-Claim
10	alone	_	_	I-Claim
11	for	_	_	I-Claim
12	reduction	_	_	I-Claim
13	of	_	_	I-Claim
14	pain	_	_	I-Claim
15	in	_	_	I-Claim
16	men	_	_	I-Claim
17	with	_	_	I-Claim
18	metastatic	_	_	I-Claim
19	,	_	_	I-Claim
20	hormone	_	_	I-Claim
21	-	_	_	I-Claim
22	resistant	_	_	I-Claim
23	,	_	_	I-Claim
24	prostate	_	_	I-Claim
25	cancer	_	_	I-Claim
26	.	_	_	I-Claim

27	The	_	_	O
28	purpose	_	_	O
29	of	_	_	O
30	this	_	_	O
31	study	_	_	O
32	was	_	_	O
33	to	_	_	O
34	assess	_	_	O
35	the	_	_	O
36	effects	_	_	O
37	of	_	_	O
38	these	_	_	O
39	treatments	_	_	O
40	on	_	_	O
41	health	_	_	O
42	-	_	_	O
43	related	_	_	O
44	quality	_	_	O
45	of	_	_	O
46	life	_	_	O
47	(	_	_	O
48	HQL	_	_	O
49	)	_	_	O
50	.	_	_	O

51	Men	_	_	O
52	with	_	_	O
53	metastatic	_	_	O
54	prostate	_	_	O
55	cancer	_	_	O
56	(	_	_	O
57	n	_	_	O
58	=	_	_	O
59	161	_	_	O
60	)	_	_	O
61	were	_	_	O
62	randomized	_	_	O
63	to	_	_	O
64	receive	_	_	O
65	either	_	_	O
66	daily	_	_	O
67	prednisone	_	_	O
68	alone	_	_	O
69	or	_	_	O
70	mitoxantrone	_	_	O
71	(	_	_	O
72	every	_	_	O
73	3	_	_	O
74	weeks	_	_	O
75	)	_	_	O
76	plus	_	_	O
77	prednisone	_	_	O
78	.	_	_	O

79	Those	_	_	O
80	who	_	_	O
81	received	_	_	O
82	prednisone	_	_	O
83	alone	_	_	O
84	could	_	_	O
85	have	_	_	O
86	mitoxantrone	_	_	O
87	added	_	_	O
88	after	_	_	O
89	6	_	_	O
90	weeks	_	_	O
91	if	_	_	O
92	there	_	_	O
93	was	_	_	O
94	no	_	_	O
95	improvement	_	_	O
96	in	_	_	O
97	pain	_	_	O
98	.	_	_	O

99	HQL	_	_	O
100	was	_	_	O
101	assessed	_	_	O
102	before	_	_	O
103	treatment	_	_	O
104	initiation	_	_	O
105	and	_	_	O
106	then	_	_	O
107	every	_	_	O
108	3	_	_	O
109	weeks	_	_	O
110	using	_	_	O
111	the	_	_	O
112	European	_	_	O
113	Organization	_	_	O
114	for	_	_	O
115	Research	_	_	O
116	and	_	_	O
117	Treatment	_	_	O
118	of	_	_	O
119	Cancer	_	_	O
120	Quality	_	_	O
121	-	_	_	O
122	of	_	_	O
123	-	_	_	O
124	Life	_	_	O
125	Questionnaire	_	_	O
126	C30	_	_	O
127	(	_	_	O
128	EORTC	_	_	O
129	QLQ	_	_	O
130	-	_	_	O
131	C30	_	_	O
132	)	_	_	O
133	and	_	_	O
134	the	_	_	O
135	Quality	_	_	O
136	of	_	_	O
137	Life	_	_	O
138	Module	_	_	O
139	-	_	_	O
140	Prostate	_	_	O
141	14	_	_	O
142	(	_	_	O
143	QOLM	_	_	O
144	-	_	_	O
145	P14	_	_	O
146	)	_	_	O
147	,	_	_	O
148	a	_	_	O
149	trial	_	_	O
150	-	_	_	O
151	specific	_	_	O
152	module	_	_	O
153	developed	_	_	O
154	for	_	_	O
155	this	_	_	O
156	study	_	_	O
157	.	_	_	O

158	An	_	_	O
159	intent	_	_	O
160	-	_	_	O
161	to	_	_	O
162	-	_	_	O
163	treat	_	_	O
164	analysis	_	_	O
165	was	_	_	O
166	used	_	_	O
167	to	_	_	O
168	determine	_	_	O
169	the	_	_	O
170	mean	_	_	O
171	duration	_	_	O
172	of	_	_	O
173	HQL	_	_	O
174	improvement	_	_	O
175	and	_	_	O
176	differences	_	_	O
177	in	_	_	O
178	improvement	_	_	O
179	duration	_	_	O
180	between	_	_	O
181	groups	_	_	O
182	of	_	_	O
183	patients	_	_	O
184	.	_	_	O

185	At	_	_	B-Premise
186	6	_	_	I-Premise
187	weeks	_	_	I-Premise
188	,	_	_	I-Premise
189	both	_	_	I-Premise
190	groups	_	_	I-Premise
191	showed	_	_	I-Premise
192	improvement	_	_	I-Premise
193	in	_	_	I-Premise
194	several	_	_	I-Premise
195	HQL	_	_	I-Premise
196	domains	_	_	I-Premise
197	,	_	_	I-Premise
198	and	_	_	O
199	only	_	_	B-Premise
200	physical	_	_	I-Premise
201	functioning	_	_	I-Premise
202	and	_	_	I-Premise
203	pain	_	_	I-Premise
204	were	_	_	I-Premise
205	better	_	_	I-Premise
206	in	_	_	I-Premise
207	the	_	_	I-Premise
208	mitoxantrone	_	_	I-Premise
209	-	_	_	I-Premise
210	plus	_	_	I-Premise
211	-	_	_	I-Premise
212	prednisone	_	_	I-Premise
213	group	_	_	I-Premise
214	than	_	_	I-Premise
215	in	_	_	I-Premise
216	the	_	_	I-Premise
217	prednisone	_	_	I-Premise
218	-	_	_	I-Premise
219	alone	_	_	I-Premise
220	group	_	_	I-Premise
221	.	_	_	I-Premise

222	After	_	_	B-Premise
223	6	_	_	I-Premise
224	weeks	_	_	I-Premise
225	,	_	_	I-Premise
226	patients	_	_	I-Premise
227	taking	_	_	I-Premise
228	prednisone	_	_	I-Premise
229	showed	_	_	I-Premise
230	no	_	_	I-Premise
231	improvement	_	_	I-Premise
232	in	_	_	I-Premise
233	HQL	_	_	I-Premise
234	scores	_	_	I-Premise
235	,	_	_	I-Premise
236	whereas	_	_	I-Premise
237	those	_	_	I-Premise
238	taking	_	_	I-Premise
239	mitoxantrone	_	_	I-Premise
240	plus	_	_	I-Premise
241	prednisone	_	_	I-Premise
242	showed	_	_	I-Premise
243	significant	_	_	I-Premise
244	improvements	_	_	I-Premise
245	in	_	_	I-Premise
246	global	_	_	I-Premise
247	quality	_	_	I-Premise
248	of	_	_	I-Premise
249	life	_	_	I-Premise
250	(	_	_	I-Premise
251	P	_	_	I-Premise
252	=	_	_	I-Premise
253	.	_	_	I-Premise

254	009	_	_	I-Premise
255	)	_	_	I-Premise
256	,	_	_	I-Premise
257	four	_	_	I-Premise
258	functioning	_	_	I-Premise
259	domains	_	_	I-Premise
260	,	_	_	I-Premise
261	and	_	_	I-Premise
262	nine	_	_	I-Premise
263	symptoms	_	_	I-Premise
264	(	_	_	I-Premise
265	.	_	_	I-Premise

266	001	_	_	I-Premise
267	<	_	_	I-Premise
268	P	_	_	I-Premise
269	<	_	_	I-Premise
270	.	_	_	I-Premise

271	01	_	_	I-Premise
272	)	_	_	I-Premise
273	,	_	_	I-Premise
274	and	_	_	O
275	the	_	_	B-Premise
276	improvement	_	_	I-Premise
277	(	_	_	I-Premise
278	>	_	_	I-Premise
279	10	_	_	I-Premise
280	units	_	_	I-Premise
281	on	_	_	I-Premise
282	a	_	_	I-Premise
283	scale	_	_	I-Premise
284	of	_	_	I-Premise
285	0	_	_	I-Premise
286	to100	_	_	I-Premise
287	)	_	_	I-Premise
288	lasted	_	_	I-Premise
289	longer	_	_	I-Premise
290	than	_	_	I-Premise
291	in	_	_	I-Premise
292	the	_	_	I-Premise
293	prednisone	_	_	I-Premise
294	-	_	_	I-Premise
295	alone	_	_	I-Premise
296	group	_	_	I-Premise
297	(	_	_	I-Premise
298	.	_	_	I-Premise

299	004	_	_	I-Premise
300	<	_	_	I-Premise
301	P	_	_	I-Premise
302	<	_	_	I-Premise
303	.	_	_	I-Premise

304	05	_	_	I-Premise
305	)	_	_	I-Premise
306	.	_	_	I-Premise

307	The	_	_	B-Premise
308	addition	_	_	I-Premise
309	of	_	_	I-Premise
310	mitoxantrone	_	_	I-Premise
311	to	_	_	I-Premise
312	prednisone	_	_	I-Premise
313	after	_	_	I-Premise
314	failure	_	_	I-Premise
315	of	_	_	I-Premise
316	prednisone	_	_	I-Premise
317	alone	_	_	I-Premise
318	was	_	_	I-Premise
319	associated	_	_	I-Premise
320	with	_	_	I-Premise
321	improvements	_	_	I-Premise
322	in	_	_	I-Premise
323	pain	_	_	I-Premise
324	,	_	_	I-Premise
325	pain	_	_	I-Premise
326	impact	_	_	I-Premise
327	,	_	_	I-Premise
328	pain	_	_	I-Premise
329	relief	_	_	I-Premise
330	,	_	_	I-Premise
331	insomnia	_	_	I-Premise
332	,	_	_	I-Premise
333	and	_	_	I-Premise
334	global	_	_	I-Premise
335	quality	_	_	I-Premise
336	of	_	_	I-Premise
337	life	_	_	I-Premise
338	(	_	_	I-Premise
339	.	_	_	I-Premise

340	001	_	_	I-Premise
341	<	_	_	I-Premise
342	P	_	_	I-Premise
343	<	_	_	I-Premise
344	.	_	_	I-Premise

345	003	_	_	I-Premise
346	)	_	_	I-Premise
347	.	_	_	I-Premise

348	Treatment	_	_	B-Claim
349	with	_	_	I-Claim
350	mitoxantrone	_	_	I-Claim
351	plus	_	_	I-Claim
352	prednisone	_	_	I-Claim
353	was	_	_	I-Claim
354	associated	_	_	I-Claim
355	with	_	_	I-Claim
356	greater	_	_	I-Claim
357	and	_	_	I-Claim
358	longer	_	_	I-Claim
359	-	_	_	I-Claim
360	lasting	_	_	I-Claim
361	improvement	_	_	I-Claim
362	in	_	_	I-Claim
363	several	_	_	I-Claim
364	HQL	_	_	I-Claim
365	domains	_	_	I-Claim
366	and	_	_	I-Claim
367	symptoms	_	_	I-Claim
368	than	_	_	I-Claim
369	treatment	_	_	I-Claim
370	with	_	_	I-Claim
371	prednisone	_	_	I-Claim
372	alone	_	_	I-Claim
373	.	_	_	I-Claim


0	To	_	_	O
1	examine	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	a	_	_	O
6	seated	_	_	O
7	exercise	_	_	O
8	program	_	_	O
9	on	_	_	O
10	fatigue	_	_	O
11	and	_	_	O
12	quality	_	_	O
13	of	_	_	O
14	life	_	_	O
15	(	_	_	O
16	QOL	_	_	O
17	)	_	_	O
18	in	_	_	O
19	women	_	_	O
20	with	_	_	O
21	metastatic	_	_	O
22	breast	_	_	O
23	cancer	_	_	O
24	.	_	_	O

25	Randomized	_	_	O
26	,	_	_	O
27	controlled	_	_	O
28	,	_	_	O
29	longitudinal	_	_	O
30	trial	_	_	O
31	.	_	_	O

32	Outpatient	_	_	O
33	clinic	_	_	O
34	of	_	_	O
35	a	_	_	O
36	comprehensive	_	_	O
37	cancer	_	_	O
38	center	_	_	O
39	.	_	_	O

40	Convenience	_	_	O
41	sample	_	_	O
42	of	_	_	O
43	38	_	_	O
44	women	_	_	O
45	who	_	_	O
46	were	_	_	O
47	beginning	_	_	O
48	outpatient	_	_	O
49	chemotherapy	_	_	O
50	.	_	_	O

51	Subjects	_	_	O
52	were	_	_	O
53	randomized	_	_	O
54	to	_	_	O
55	a	_	_	O
56	control	_	_	O
57	or	_	_	O
58	intervention	_	_	O
59	group	_	_	O
60	;	_	_	O
61	the	_	_	O
62	intervention	_	_	O
63	was	_	_	O
64	performance	_	_	O
65	of	_	_	O
66	a	_	_	O
67	seated	_	_	O
68	exercise	_	_	O
69	program	_	_	O
70	using	_	_	O
71	home	_	_	O
72	videotape	_	_	O
73	three	_	_	O
74	times	_	_	O
75	per	_	_	O
76	week	_	_	O
77	for	_	_	O
78	four	_	_	O
79	cycles	_	_	O
80	of	_	_	O
81	chemotherapy	_	_	O
82	.	_	_	O

83	All	_	_	O
84	subjects	_	_	O
85	completed	_	_	O
86	the	_	_	O
87	Functional	_	_	O
88	Assessment	_	_	O
89	of	_	_	O
90	Chronic	_	_	O
91	Illness	_	_	O
92	Therapy	_	_	O
93	Fatigue	_	_	O
94	Version	_	_	O
95	IV	_	_	O
96	(	_	_	O
97	FACIT	_	_	O
98	F	_	_	O
99	)	_	_	O
100	at	_	_	O
101	baseline	_	_	O
102	and	_	_	O
103	at	_	_	O
104	the	_	_	O
105	time	_	_	O
106	of	_	_	O
107	the	_	_	O
108	next	_	_	O
109	three	_	_	O
110	cycles	_	_	O
111	.	_	_	O

112	Subjects	_	_	O
113	were	_	_	O
114	asked	_	_	O
115	to	_	_	O
116	document	_	_	O
117	the	_	_	O
118	frequency	_	_	O
119	,	_	_	O
120	duration	_	_	O
121	,	_	_	O
122	and	_	_	O
123	intensity	_	_	O
124	of	_	_	O
125	all	_	_	O
126	exercise	_	_	O
127	participation	_	_	O
128	on	_	_	O
129	monthly	_	_	O
130	calendars	_	_	O
131	.	_	_	O

132	Exercise	_	_	O
133	,	_	_	O
134	fatigue	_	_	O
135	,	_	_	O
136	and	_	_	O
137	QOL	_	_	O
138	.	_	_	O

139	32	_	_	O
140	subjects	_	_	O
141	,	_	_	O
142	16	_	_	O
143	per	_	_	O
144	group	_	_	O
145	,	_	_	O
146	completed	_	_	O
147	the	_	_	O
148	study	_	_	O
149	follow	_	_	O
150	-	_	_	O
151	up	_	_	O
152	.	_	_	O

153	With	_	_	B-Premise
154	a	_	_	I-Premise
155	mixed	_	_	I-Premise
156	modeling	_	_	I-Premise
157	approach	_	_	I-Premise
158	,	_	_	I-Premise
159	total	_	_	I-Premise
160	FACIT	_	_	I-Premise
161	F	_	_	I-Premise
162	scores	_	_	I-Premise
163	for	_	_	I-Premise
164	the	_	_	I-Premise
165	entire	_	_	I-Premise
166	sample	_	_	I-Premise
167	declined	_	_	I-Premise
168	at	_	_	I-Premise
169	a	_	_	I-Premise
170	significant	_	_	I-Premise
171	rate	_	_	I-Premise
172	(	_	_	I-Premise
173	p	_	_	I-Premise
174	=	_	_	I-Premise
175	0	_	_	I-Premise
176	.	_	_	I-Premise

177	003	_	_	I-Premise
178	)	_	_	I-Premise
179	beginning	_	_	I-Premise
180	with	_	_	I-Premise
181	cycle	_	_	I-Premise
182	3	_	_	I-Premise
183	but	_	_	B-Premise
184	at	_	_	I-Premise
185	a	_	_	I-Premise
186	slower	_	_	I-Premise
187	rate	_	_	I-Premise
188	for	_	_	I-Premise
189	the	_	_	I-Premise
190	experimental	_	_	I-Premise
191	group	_	_	I-Premise
192	(	_	_	I-Premise
193	p	_	_	I-Premise
194	=	_	_	I-Premise
195	0	_	_	I-Premise
196	.	_	_	I-Premise

197	02	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	Fatigue	_	_	B-Premise
201	scores	_	_	I-Premise
202	indicated	_	_	I-Premise
203	less	_	_	I-Premise
204	increase	_	_	I-Premise
205	and	_	_	I-Premise
206	physical	_	_	I-Premise
207	well	_	_	I-Premise
208	-	_	_	I-Premise
209	being	_	_	I-Premise
210	subscale	_	_	I-Premise
211	scores	_	_	I-Premise
212	showed	_	_	I-Premise
213	less	_	_	I-Premise
214	decline	_	_	I-Premise
215	for	_	_	I-Premise
216	the	_	_	I-Premise
217	experimental	_	_	I-Premise
218	group	_	_	I-Premise
219	(	_	_	I-Premise
220	p	_	_	I-Premise
221	=	_	_	I-Premise
222	0	_	_	I-Premise
223	.	_	_	I-Premise

224	008	_	_	I-Premise
225	and	_	_	I-Premise
226	p	_	_	I-Premise
227	=	_	_	I-Premise
228	0	_	_	I-Premise
229	.	_	_	I-Premise

230	02	_	_	I-Premise
231	,	_	_	I-Premise
232	respectively	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	Women	_	_	B-Premise
236	with	_	_	I-Premise
237	advanced	_	_	I-Premise
238	breast	_	_	I-Premise
239	cancer	_	_	I-Premise
240	randomized	_	_	I-Premise
241	to	_	_	I-Premise
242	the	_	_	I-Premise
243	seated	_	_	I-Premise
244	exercise	_	_	I-Premise
245	intervention	_	_	I-Premise
246	had	_	_	I-Premise
247	a	_	_	I-Premise
248	slower	_	_	I-Premise
249	decline	_	_	I-Premise
250	in	_	_	I-Premise
251	total	_	_	I-Premise
252	and	_	_	I-Premise
253	physical	_	_	I-Premise
254	well	_	_	I-Premise
255	-	_	_	I-Premise
256	being	_	_	I-Premise
257	and	_	_	I-Premise
258	less	_	_	I-Premise
259	increase	_	_	I-Premise
260	in	_	_	I-Premise
261	fatigue	_	_	I-Premise
262	scores	_	_	I-Premise
263	starting	_	_	I-Premise
264	with	_	_	I-Premise
265	the	_	_	I-Premise
266	third	_	_	I-Premise
267	cycle	_	_	I-Premise
268	of	_	_	I-Premise
269	chemotherapy	_	_	I-Premise
270	.	_	_	I-Premise

271	Seated	_	_	B-Claim
272	exercise	_	_	I-Claim
273	may	_	_	I-Claim
274	be	_	_	I-Claim
275	a	_	_	I-Claim
276	feasible	_	_	I-Claim
277	exercise	_	_	I-Claim
278	program	_	_	I-Claim
279	for	_	_	I-Claim
280	women	_	_	I-Claim
281	with	_	_	I-Claim
282	advanced	_	_	I-Claim
283	cancer	_	_	I-Claim
284	for	_	_	I-Claim
285	controlling	_	_	I-Claim
286	fatigue	_	_	I-Claim
287	and	_	_	I-Claim
288	improving	_	_	I-Claim
289	physical	_	_	I-Claim
290	well	_	_	I-Claim
291	-	_	_	I-Claim
292	being	_	_	I-Claim
293	.	_	_	I-Claim


0	The	_	_	O
1	randomized	_	_	O
2	,	_	_	O
3	controlled	_	_	O
4	BOLERO	_	_	O
5	-	_	_	O
6	2	_	_	O
7	(	_	_	O
8	Breast	_	_	O
9	Cancer	_	_	O
10	Trials	_	_	O
11	of	_	_	O
12	Oral	_	_	O
13	Everolimus	_	_	O
14	)	_	_	O
15	trial	_	_	O
16	demonstrated	_	_	O
17	significantly	_	_	O
18	improved	_	_	O
19	progression	_	_	O
20	-	_	_	O
21	free	_	_	O
22	survival	_	_	O
23	with	_	_	O
24	the	_	_	O
25	use	_	_	O
26	of	_	_	O
27	everolimus	_	_	O
28	plus	_	_	O
29	exemestane	_	_	O
30	(	_	_	O
31	EVE	_	_	O
32	+	_	_	O
33	EXE	_	_	O
34	)	_	_	O
35	versus	_	_	O
36	placebo	_	_	O
37	plus	_	_	O
38	exemestane	_	_	O
39	(	_	_	O
40	PBO	_	_	O
41	+	_	_	O
42	EXE	_	_	O
43	)	_	_	O
44	in	_	_	O
45	patients	_	_	O
46	with	_	_	O
47	advanced	_	_	O
48	breast	_	_	O
49	cancer	_	_	O
50	who	_	_	O
51	developed	_	_	O
52	disease	_	_	O
53	progression	_	_	O
54	after	_	_	O
55	treatment	_	_	O
56	with	_	_	O
57	nonsteroidal	_	_	O
58	aromatase	_	_	O
59	inhibitors	_	_	O
60	.	_	_	O

61	This	_	_	O
62	analysis	_	_	O
63	investigated	_	_	O
64	the	_	_	O
65	treatment	_	_	O
66	effects	_	_	O
67	on	_	_	O
68	health	_	_	O
69	-	_	_	O
70	related	_	_	O
71	quality	_	_	O
72	of	_	_	O
73	life	_	_	O
74	(	_	_	O
75	HRQOL	_	_	O
76	)	_	_	O
77	.	_	_	O

78	Using	_	_	O
79	the	_	_	O
80	European	_	_	O
81	Organisation	_	_	O
82	for	_	_	O
83	Research	_	_	O
84	and	_	_	O
85	Treatment	_	_	O
86	of	_	_	O
87	Cancer	_	_	O
88	Quality	_	_	O
89	of	_	_	O
90	Life	_	_	O
91	Questionnaire	_	_	O
92	-	_	_	O
93	Core	_	_	O
94	30	_	_	O
95	(	_	_	O
96	EORTC	_	_	O
97	QLQ	_	_	O
98	-	_	_	O
99	C30	_	_	O
100	)	_	_	O
101	questionnaire	_	_	O
102	,	_	_	O
103	HRQOL	_	_	O
104	was	_	_	O
105	assessed	_	_	O
106	at	_	_	O
107	baseline	_	_	O
108	and	_	_	O
109	every	_	_	O
110	6	_	_	O
111	weeks	_	_	O
112	thereafter	_	_	O
113	until	_	_	O
114	disease	_	_	O
115	progression	_	_	O
116	and	_	_	O
117	/	_	_	O
118	or	_	_	O
119	treatment	_	_	O
120	discontinuation	_	_	O
121	.	_	_	O

122	The	_	_	O
123	30	_	_	O
124	items	_	_	O
125	in	_	_	O
126	15	_	_	O
127	subscales	_	_	O
128	of	_	_	O
129	the	_	_	O
130	QLQ	_	_	O
131	-	_	_	O
132	C30	_	_	O
133	include	_	_	O
134	global	_	_	O
135	health	_	_	O
136	status	_	_	O
137	wherein	_	_	O
138	higher	_	_	O
139	scores	_	_	O
140	(	_	_	O
141	range	_	_	O
142	,	_	_	O
143	0	_	_	O
144	-	_	_	O
145	100	_	_	O
146	)	_	_	O
147	indicate	_	_	O
148	better	_	_	O
149	HRQOL	_	_	O
150	.	_	_	O

151	This	_	_	O
152	analysis	_	_	O
153	included	_	_	O
154	a	_	_	O
155	protocol	_	_	O
156	-	_	_	O
157	specified	_	_	O
158	time	_	_	O
159	to	_	_	O
160	definitive	_	_	O
161	deterioration	_	_	O
162	(	_	_	O
163	TDD	_	_	O
164	)	_	_	O
165	analysis	_	_	O
166	at	_	_	O
167	a	_	_	O
168	5	_	_	O
169	%	_	_	O
170	decrease	_	_	O
171	in	_	_	O
172	HRQOL	_	_	O
173	versus	_	_	O
174	baseline	_	_	O
175	,	_	_	O
176	with	_	_	O
177	no	_	_	O
178	subsequent	_	_	O
179	increase	_	_	O
180	above	_	_	O
181	this	_	_	O
182	threshold	_	_	O
183	.	_	_	O

184	The	_	_	O
185	authors	_	_	O
186	report	_	_	O
187	additional	_	_	O
188	sensitivity	_	_	O
189	analyses	_	_	O
190	using	_	_	O
191	10	_	_	O
192	-	_	_	O
193	point	_	_	O
194	minimal	_	_	O
195	important	_	_	O
196	difference	_	_	O
197	decreases	_	_	O
198	in	_	_	O
199	the	_	_	O
200	global	_	_	O
201	health	_	_	O
202	status	_	_	O
203	score	_	_	O
204	versus	_	_	O
205	baseline	_	_	O
206	.	_	_	O

207	Treatment	_	_	O
208	arms	_	_	O
209	were	_	_	O
210	compared	_	_	O
211	using	_	_	O
212	the	_	_	O
213	stratified	_	_	O
214	log	_	_	O
215	-	_	_	O
216	rank	_	_	O
217	test	_	_	O
218	and	_	_	O
219	Cox	_	_	O
220	proportional	_	_	O
221	hazards	_	_	O
222	model	_	_	O
223	adjusted	_	_	O
224	for	_	_	O
225	trial	_	_	O
226	stratum	_	_	O
227	(	_	_	O
228	visceral	_	_	O
229	metastases	_	_	O
230	,	_	_	O
231	previous	_	_	O
232	hormone	_	_	O
233	sensitivity	_	_	O
234	)	_	_	O
235	,	_	_	O
236	age	_	_	O
237	,	_	_	O
238	sex	_	_	O
239	,	_	_	O
240	race	_	_	O
241	,	_	_	O
242	baseline	_	_	O
243	global	_	_	O
244	health	_	_	O
245	status	_	_	O
246	score	_	_	O
247	and	_	_	O
248	Eastern	_	_	O
249	Cooperative	_	_	O
250	Oncology	_	_	O
251	Group	_	_	O
252	performance	_	_	O
253	status	_	_	O
254	,	_	_	O
255	prognostic	_	_	O
256	risk	_	_	O
257	factors	_	_	O
258	,	_	_	O
259	and	_	_	O
260	treatment	_	_	O
261	history	_	_	O
262	.	_	_	O

263	Baseline	_	_	O
264	global	_	_	O
265	health	_	_	O
266	status	_	_	O
267	scores	_	_	O
268	were	_	_	O
269	found	_	_	O
270	to	_	_	O
271	be	_	_	O
272	similar	_	_	O
273	between	_	_	O
274	treatment	_	_	O
275	groups	_	_	O
276	(	_	_	O
277	64	_	_	O
278	.	_	_	O

279	7	_	_	O
280	vs	_	_	O
281	65	_	_	O
282	.	_	_	O

283	3	_	_	O
284	)	_	_	O
285	.	_	_	O

286	The	_	_	B-Premise
287	median	_	_	I-Premise
288	TDD	_	_	I-Premise
289	in	_	_	I-Premise
290	HRQOL	_	_	I-Premise
291	was	_	_	I-Premise
292	8	_	_	I-Premise
293	.	_	_	I-Premise

294	3	_	_	I-Premise
295	months	_	_	I-Premise
296	with	_	_	I-Premise
297	EVE	_	_	I-Premise
298	+	_	_	I-Premise
299	EXE	_	_	I-Premise
300	versus	_	_	I-Premise
301	5	_	_	I-Premise
302	.	_	_	I-Premise

303	8	_	_	I-Premise
304	months	_	_	I-Premise
305	with	_	_	I-Premise
306	PBO	_	_	I-Premise
307	+	_	_	I-Premise
308	EXE	_	_	I-Premise
309	(	_	_	I-Premise
310	hazard	_	_	I-Premise
311	ratio	_	_	I-Premise
312	,	_	_	I-Premise
313	0	_	_	I-Premise
314	.	_	_	I-Premise

315	74	_	_	I-Premise
316	;	_	_	I-Premise
317	P	_	_	I-Premise
318	=	_	_	I-Premise
319	.	_	_	I-Premise

320	0084	_	_	I-Premise
321	)	_	_	I-Premise
322	.	_	_	I-Premise

323	At	_	_	B-Premise
324	the	_	_	I-Premise
325	10	_	_	I-Premise
326	-	_	_	I-Premise
327	point	_	_	I-Premise
328	minimal	_	_	I-Premise
329	important	_	_	I-Premise
330	difference	_	_	I-Premise
331	,	_	_	I-Premise
332	the	_	_	I-Premise
333	median	_	_	I-Premise
334	TDD	_	_	I-Premise
335	with	_	_	I-Premise
336	EVE	_	_	I-Premise
337	+	_	_	I-Premise
338	EXE	_	_	I-Premise
339	was	_	_	I-Premise
340	11	_	_	I-Premise
341	.	_	_	I-Premise

342	7	_	_	I-Premise
343	months	_	_	I-Premise
344	versus	_	_	I-Premise
345	8	_	_	I-Premise
346	.	_	_	I-Premise

347	4	_	_	I-Premise
348	months	_	_	I-Premise
349	with	_	_	I-Premise
350	PBO	_	_	I-Premise
351	+	_	_	I-Premise
352	EXE	_	_	I-Premise
353	(	_	_	I-Premise
354	hazard	_	_	I-Premise
355	ratio	_	_	I-Premise
356	,	_	_	I-Premise
357	0	_	_	I-Premise
358	.	_	_	I-Premise

359	80	_	_	I-Premise
360	;	_	_	I-Premise
361	P	_	_	I-Premise
362	=	_	_	I-Premise
363	.	_	_	I-Premise

364	1017	_	_	I-Premise
365	)	_	_	I-Premise
366	.	_	_	I-Premise

367	In	_	_	B-Claim
368	patients	_	_	I-Claim
369	with	_	_	I-Claim
370	advanced	_	_	I-Claim
371	breast	_	_	I-Claim
372	cancer	_	_	I-Claim
373	who	_	_	I-Claim
374	develop	_	_	I-Claim
375	disease	_	_	I-Claim
376	progression	_	_	I-Claim
377	after	_	_	I-Claim
378	treatment	_	_	I-Claim
379	with	_	_	I-Claim
380	nonsteroidal	_	_	I-Claim
381	aromatase	_	_	I-Claim
382	inhibitors	_	_	I-Claim
383	,	_	_	I-Claim
384	EVE	_	_	I-Claim
385	+	_	_	I-Claim
386	EXE	_	_	I-Claim
387	was	_	_	I-Claim
388	associated	_	_	I-Claim
389	with	_	_	I-Claim
390	a	_	_	I-Claim
391	longer	_	_	I-Claim
392	TDD	_	_	I-Claim
393	in	_	_	I-Claim
394	global	_	_	I-Claim
395	HRQOL	_	_	I-Claim
396	versus	_	_	I-Claim
397	PBO	_	_	I-Claim
398	+	_	_	I-Claim
399	EXE	_	_	I-Claim
400	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	is	_	_	O
3	the	_	_	O
4	first	_	_	O
5	large	_	_	O
6	prospective	_	_	O
7	RCT	_	_	O
8	of	_	_	O
9	sentinel	_	_	O
10	node	_	_	O
11	biopsy	_	_	O
12	(	_	_	O
13	SNB	_	_	O
14	)	_	_	O
15	compared	_	_	O
16	with	_	_	O
17	standard	_	_	O
18	axillary	_	_	O
19	treatment	_	_	O
20	(	_	_	O
21	level	_	_	O
22	I	_	_	O
23	-	_	_	O
24	III	_	_	O
25	axillary	_	_	O
26	lymph	_	_	O
27	node	_	_	O
28	dissection	_	_	O
29	or	_	_	O
30	four	_	_	O
31	node	_	_	O
32	sampling	_	_	O
33	)	_	_	O
34	,	_	_	O
35	which	_	_	O
36	includes	_	_	O
37	comprehensive	_	_	O
38	and	_	_	O
39	repeated	_	_	O
40	quality	_	_	O
41	of	_	_	O
42	life	_	_	O
43	(	_	_	O
44	QOL	_	_	O
45	)	_	_	O
46	assessments	_	_	O
47	over	_	_	O
48	18	_	_	O
49	months	_	_	O
50	.	_	_	O

51	Patients	_	_	O
52	(	_	_	O
53	n	_	_	O
54	=	_	_	O
55	829	_	_	O
56	)	_	_	O
57	completed	_	_	O
58	the	_	_	O
59	Functional	_	_	O
60	Assessment	_	_	O
61	of	_	_	O
62	Cancer	_	_	O
63	Therapy	_	_	O
64	-	_	_	O
65	Breast	_	_	O
66	(	_	_	O
67	FACT	_	_	O
68	-	_	_	O
69	B	_	_	O
70	+	_	_	O
71	4	_	_	O
72	)	_	_	O
73	and	_	_	O
74	the	_	_	O
75	Spielberger	_	_	O
76	State	_	_	O
77	/	_	_	O
78	Trait	_	_	O
79	Anxiety	_	_	O
80	Inventory	_	_	O
81	(	_	_	O
82	STAI	_	_	O
83	)	_	_	O
84	at	_	_	O
85	baseline	_	_	O
86	(	_	_	O
87	pre	_	_	O
88	-	_	_	O
89	surgery	_	_	O
90	)	_	_	O
91	and	_	_	O
92	at	_	_	O
93	1	_	_	O
94	,	_	_	O
95	3	_	_	O
96	,	_	_	O
97	6	_	_	O
98	,	_	_	O
99	12	_	_	O
100	,	_	_	O
101	and	_	_	O
102	18	_	_	O
103	months	_	_	O
104	post	_	_	O
105	-	_	_	O
106	surgery	_	_	O
107	.	_	_	O

108	There	_	_	B-Claim
109	were	_	_	I-Claim
110	significant	_	_	I-Claim
111	differences	_	_	I-Claim
112	between	_	_	I-Claim
113	treatment	_	_	I-Claim
114	groups	_	_	I-Claim
115	favouring	_	_	I-Claim
116	the	_	_	I-Claim
117	SNB	_	_	I-Claim
118	group	_	_	I-Claim
119	throughout	_	_	I-Claim
120	the	_	_	I-Claim
121	18	_	_	I-Claim
122	months	_	_	I-Claim
123	assessment	_	_	I-Claim
124	.	_	_	I-Claim

125	Patients	_	_	B-Premise
126	in	_	_	I-Premise
127	the	_	_	I-Premise
128	standard	_	_	I-Premise
129	treatment	_	_	I-Premise
130	group	_	_	I-Premise
131	showed	_	_	I-Premise
132	a	_	_	I-Premise
133	greater	_	_	I-Premise
134	decline	_	_	I-Premise
135	in	_	_	I-Premise
136	Trial	_	_	I-Premise
137	Outcome	_	_	I-Premise
138	Index	_	_	I-Premise
139	(	_	_	I-Premise
140	TOI	_	_	I-Premise
141	)	_	_	I-Premise
142	scores	_	_	I-Premise
143	(	_	_	I-Premise
144	physical	_	_	I-Premise
145	well	_	_	I-Premise
146	-	_	_	I-Premise
147	being	_	_	I-Premise
148	,	_	_	I-Premise
149	functional	_	_	I-Premise
150	well	_	_	I-Premise
151	-	_	_	I-Premise
152	being	_	_	I-Premise
153	and	_	_	I-Premise
154	breast	_	_	I-Premise
155	cancer	_	_	I-Premise
156	concerns	_	_	I-Premise
157	subscales	_	_	I-Premise
158	in	_	_	I-Premise
159	FACT	_	_	I-Premise
160	-	_	_	I-Premise
161	B	_	_	I-Premise
162	+	_	_	I-Premise
163	4	_	_	I-Premise
164	)	_	_	I-Premise
165	and	_	_	I-Premise
166	recovered	_	_	I-Premise
167	more	_	_	I-Premise
168	slowly	_	_	I-Premise
169	than	_	_	I-Premise
170	patients	_	_	I-Premise
171	in	_	_	I-Premise
172	the	_	_	I-Premise
173	SNB	_	_	I-Premise
174	group	_	_	I-Premise
175	(	_	_	I-Premise
176	p	_	_	I-Premise
177	<	_	_	I-Premise
178	0	_	_	I-Premise
179	.	_	_	I-Premise

180	01	_	_	I-Premise
181	)	_	_	I-Premise
182	.	_	_	I-Premise

183	The	_	_	B-Premise
184	change	_	_	I-Premise
185	in	_	_	I-Premise
186	total	_	_	I-Premise
187	FACT	_	_	I-Premise
188	-	_	_	I-Premise
189	B	_	_	I-Premise
190	+	_	_	I-Premise
191	4	_	_	I-Premise
192	scores	_	_	I-Premise
193	(	_	_	I-Premise
194	measuring	_	_	I-Premise
195	global	_	_	I-Premise
196	QOL	_	_	I-Premise
197	)	_	_	I-Premise
198	closely	_	_	I-Premise
199	resembled	_	_	I-Premise
200	the	_	_	I-Premise
201	TOI	_	_	I-Premise
202	results	_	_	I-Premise
203	.	_	_	I-Premise

204	18	_	_	B-Premise
205	months	_	_	I-Premise
206	post	_	_	I-Premise
207	-	_	_	I-Premise
208	surgery	_	_	I-Premise
209	approximately	_	_	I-Premise
210	twice	_	_	I-Premise
211	as	_	_	I-Premise
212	many	_	_	I-Premise
213	patients	_	_	I-Premise
214	in	_	_	I-Premise
215	the	_	_	I-Premise
216	standard	_	_	I-Premise
217	group	_	_	I-Premise
218	compared	_	_	I-Premise
219	with	_	_	I-Premise
220	the	_	_	I-Premise
221	SNB	_	_	I-Premise
222	group	_	_	I-Premise
223	reported	_	_	I-Premise
224	substantial	_	_	I-Premise
225	arm	_	_	I-Premise
226	swelling	_	_	I-Premise
227	(	_	_	I-Premise
228	14	_	_	I-Premise
229	%	_	_	I-Premise
230	versus	_	_	I-Premise
231	7	_	_	I-Premise
232	%	_	_	I-Premise
233	)	_	_	I-Premise
234	(	_	_	I-Premise
235	p	_	_	I-Premise
236	=	_	_	I-Premise
237	0	_	_	I-Premise
238	.	_	_	I-Premise

239	002	_	_	I-Premise
240	)	_	_	I-Premise
241	or	_	_	I-Premise
242	numbness	_	_	I-Premise
243	(	_	_	I-Premise
244	19	_	_	I-Premise
245	%	_	_	I-Premise
246	versus	_	_	I-Premise
247	8	_	_	I-Premise
248	.	_	_	I-Premise

249	7	_	_	I-Premise
250	%	_	_	I-Premise
251	)	_	_	I-Premise
252	(	_	_	I-Premise
253	p	_	_	I-Premise
254	<	_	_	I-Premise
255	0	_	_	I-Premise
256	.	_	_	I-Premise

257	001	_	_	I-Premise
258	)	_	_	I-Premise
259	.	_	_	I-Premise

260	Despite	_	_	O
261	the	_	_	O
262	uncertainty	_	_	O
263	about	_	_	O
264	undergoing	_	_	O
265	a	_	_	O
266	relatively	_	_	O
267	new	_	_	O
268	procedure	_	_	O
269	and	_	_	O
270	the	_	_	O
271	possible	_	_	O
272	need	_	_	O
273	for	_	_	O
274	further	_	_	O
275	surgery	_	_	O
276	,	_	_	O
277	there	_	_	B-Premise
278	was	_	_	I-Premise
279	no	_	_	I-Premise
280	evidence	_	_	I-Premise
281	of	_	_	I-Premise
282	increased	_	_	I-Premise
283	anxiety	_	_	I-Premise
284	amongst	_	_	I-Premise
285	patients	_	_	I-Premise
286	randomised	_	_	I-Premise
287	to	_	_	I-Premise
288	SNB	_	_	I-Premise
289	(	_	_	I-Premise
290	p	_	_	I-Premise
291	>	_	_	I-Premise
292	0	_	_	I-Premise
293	.	_	_	I-Premise

294	05	_	_	I-Premise
295	)	_	_	I-Premise
296	.	_	_	I-Premise

297	For	_	_	B-Premise
298	6	_	_	I-Premise
299	months	_	_	I-Premise
300	post	_	_	I-Premise
301	-	_	_	I-Premise
302	surgery	_	_	I-Premise
303	younger	_	_	I-Premise
304	patients	_	_	I-Premise
305	reported	_	_	I-Premise
306	less	_	_	I-Premise
307	favourable	_	_	I-Premise
308	QOL	_	_	I-Premise
309	scores	_	_	I-Premise
310	(	_	_	I-Premise
311	p	_	_	I-Premise
312	<	_	_	I-Premise
313	0	_	_	I-Premise
314	.	_	_	I-Premise

315	001	_	_	I-Premise
316	)	_	_	I-Premise
317	and	_	_	I-Premise
318	greater	_	_	I-Premise
319	levels	_	_	I-Premise
320	of	_	_	I-Premise
321	anxiety	_	_	I-Premise
322	(	_	_	I-Premise
323	p	_	_	I-Premise
324	<	_	_	I-Premise
325	0	_	_	I-Premise
326	.	_	_	I-Premise

327	01	_	_	I-Premise
328	)	_	_	I-Premise
329	.	_	_	I-Premise

330	In	_	_	B-Claim
331	view	_	_	I-Claim
332	of	_	_	I-Claim
333	the	_	_	I-Claim
334	benefits	_	_	I-Claim
335	regarding	_	_	I-Claim
336	arm	_	_	I-Claim
337	functioning	_	_	I-Claim
338	and	_	_	I-Claim
339	quality	_	_	I-Claim
340	of	_	_	I-Claim
341	life	_	_	I-Claim
342	,	_	_	I-Claim
343	the	_	_	I-Claim
344	data	_	_	I-Claim
345	from	_	_	I-Claim
346	this	_	_	I-Claim
347	randomised	_	_	I-Claim
348	study	_	_	I-Claim
349	support	_	_	I-Claim
350	the	_	_	I-Claim
351	use	_	_	I-Claim
352	of	_	_	I-Claim
353	SNB	_	_	I-Claim
354	in	_	_	I-Claim
355	patients	_	_	I-Claim
356	with	_	_	I-Claim
357	clinically	_	_	I-Claim
358	node	_	_	I-Claim
359	negative	_	_	I-Claim
360	breast	_	_	I-Claim
361	cancer	_	_	I-Claim
362	.	_	_	I-Claim


0	Over	_	_	O
1	30	_	_	O
2	%	_	_	O
3	of	_	_	O
4	patients	_	_	O
5	with	_	_	O
6	non	_	_	O
7	-	_	_	O
8	small	_	_	O
9	cell	_	_	O
10	lung	_	_	O
11	cancer	_	_	O
12	(	_	_	O
13	NSCLC	_	_	O
14	)	_	_	O
15	develop	_	_	O
16	brain	_	_	O
17	metastases	_	_	O
18	.	_	_	O

19	If	_	_	O
20	inoperable	_	_	O
21	,	_	_	O
22	optimal	_	_	O
23	supportive	_	_	O
24	care	_	_	O
25	(	_	_	O
26	OSC	_	_	O
27	)	_	_	O
28	,	_	_	O
29	including	_	_	O
30	steroids	_	_	O
31	,	_	_	O
32	and	_	_	O
33	whole	_	_	O
34	brain	_	_	O
35	radiotherapy	_	_	O
36	(	_	_	O
37	WBRT	_	_	O
38	)	_	_	O
39	are	_	_	O
40	generally	_	_	O
41	considered	_	_	O
42	to	_	_	O
43	be	_	_	O
44	standard	_	_	O
45	care	_	_	O
46	,	_	_	O
47	although	_	_	O
48	there	_	_	O
49	is	_	_	O
50	no	_	_	O
51	randomised	_	_	O
52	evidence	_	_	O
53	demonstrating	_	_	O
54	that	_	_	O
55	the	_	_	O
56	addition	_	_	O
57	of	_	_	O
58	WBRT	_	_	O
59	to	_	_	O
60	OSC	_	_	O
61	improves	_	_	O
62	survival	_	_	O
63	or	_	_	O
64	quality	_	_	O
65	of	_	_	O
66	life	_	_	O
67	.	_	_	O

68	QUARTZ	_	_	O
69	is	_	_	O
70	a	_	_	O
71	randomised	_	_	O
72	,	_	_	O
73	non	_	_	O
74	-	_	_	O
75	inferiority	_	_	O
76	,	_	_	O
77	phase	_	_	O
78	III	_	_	O
79	trial	_	_	O
80	comparing	_	_	O
81	OSC	_	_	O
82	+	_	_	O
83	WBRT	_	_	O
84	versus	_	_	O
85	OSC	_	_	O
86	in	_	_	O
87	patients	_	_	O
88	with	_	_	O
89	inoperable	_	_	O
90	brain	_	_	O
91	metastases	_	_	O
92	from	_	_	O
93	NSCLC	_	_	O
94	.	_	_	O

95	The	_	_	O
96	primary	_	_	O
97	outcome	_	_	O
98	measure	_	_	O
99	is	_	_	O
100	quality	_	_	O
101	-	_	_	O
102	adjusted	_	_	O
103	life	_	_	O
104	years	_	_	O
105	(	_	_	O
106	QALYs	_	_	O
107	)	_	_	O
108	.	_	_	O

109	QUARTZ	_	_	O
110	was	_	_	O
111	threatened	_	_	O
112	with	_	_	O
113	both	_	_	O
114	loss	_	_	O
115	of	_	_	O
116	funding	_	_	O
117	and	_	_	O
118	early	_	_	O
119	closure	_	_	O
120	due	_	_	O
121	to	_	_	O
122	poor	_	_	O
123	accrual	_	_	O
124	.	_	_	O

125	A	_	_	O
126	lack	_	_	O
127	of	_	_	O
128	preliminary	_	_	O
129	randomised	_	_	O
130	data	_	_	O
131	supporting	_	_	O
132	the	_	_	O
133	trial	_	_	O
134	'	_	_	O
135	s	_	_	O
136	hypotheses	_	_	O
137	was	_	_	O
138	thought	_	_	O
139	to	_	_	O
140	underlie	_	_	O
141	the	_	_	O
142	poor	_	_	O
143	accrual	_	_	O
144	,	_	_	O
145	so	_	_	O
146	,	_	_	O
147	with	_	_	O
148	no	_	_	O
149	knowledge	_	_	O
150	of	_	_	O
151	the	_	_	O
152	data	_	_	O
153	,	_	_	O
154	the	_	_	O
155	independent	_	_	O
156	trial	_	_	O
157	steering	_	_	O
158	committee	_	_	O
159	agreed	_	_	O
160	to	_	_	O
161	the	_	_	O
162	unusual	_	_	O
163	step	_	_	O
164	of	_	_	O
165	releasing	_	_	O
166	interim	_	_	O
167	data	_	_	O
168	.	_	_	O

169	Between	_	_	O
170	March	_	_	O
171	2007	_	_	O
172	and	_	_	O
173	April	_	_	O
174	2010	_	_	O
175	,	_	_	O
176	151	_	_	O
177	(	_	_	O
178	of	_	_	O
179	the	_	_	O
180	planned	_	_	O
181	534	_	_	O
182	)	_	_	O
183	patients	_	_	O
184	were	_	_	O
185	randomised	_	_	O
186	(	_	_	O
187	75	_	_	O
188	OSC	_	_	O
189	+	_	_	O
190	WBRT	_	_	O
191	,	_	_	O
192	76	_	_	O
193	OSC	_	_	O
194	)	_	_	O
195	.	_	_	O

196	Participants	_	_	O
197	'	_	_	O
198	baseline	_	_	O
199	demographics	_	_	O
200	included	_	_	O
201	median	_	_	O
202	age	_	_	O
203	67	_	_	O
204	years	_	_	O
205	(	_	_	O
206	interquartile	_	_	O
207	range	_	_	O
208	62	_	_	O
209	-	_	_	O
210	73	_	_	O
211	)	_	_	O
212	,	_	_	O
213	60	_	_	O
214	%	_	_	O
215	male	_	_	O
216	,	_	_	O
217	50	_	_	O
218	%	_	_	O
219	with	_	_	O
220	a	_	_	O
221	Karnofsky	_	_	O
222	performance	_	_	O
223	status	_	_	O
224	<	_	_	O
225	70	_	_	O
226	;	_	_	O
227	steroid	_	_	O
228	usage	_	_	O
229	was	_	_	O
230	similar	_	_	O
231	in	_	_	O
232	the	_	_	O
233	two	_	_	O
234	groups	_	_	O
235	;	_	_	O
236	64	_	_	O
237	/	_	_	O
238	75	_	_	O
239	(	_	_	O
240	85	_	_	O
241	%	_	_	O
242	)	_	_	O
243	received	_	_	O
244	WBRT	_	_	O
245	(	_	_	O
246	20	_	_	O
247	Gy	_	_	O
248	in	_	_	O
249	five	_	_	O
250	fractions	_	_	O
251	)	_	_	O
252	.	_	_	O

253	Median	_	_	B-Premise
254	survival	_	_	I-Premise
255	was	_	_	I-Premise
256	:	_	_	I-Premise
257	OSC	_	_	I-Premise
258	+	_	_	I-Premise
259	WBRT	_	_	I-Premise
260	49	_	_	I-Premise
261	days	_	_	I-Premise
262	(	_	_	I-Premise
263	95	_	_	I-Premise
264	%	_	_	I-Premise
265	confidence	_	_	I-Premise
266	interval	_	_	I-Premise
267	39	_	_	I-Premise
268	-	_	_	I-Premise
269	61	_	_	I-Premise
270	)	_	_	I-Premise
271	,	_	_	I-Premise
272	OSC	_	_	I-Premise
273	51	_	_	I-Premise
274	days	_	_	I-Premise
275	(	_	_	I-Premise
276	95	_	_	I-Premise
277	%	_	_	I-Premise
278	confidence	_	_	I-Premise
279	interval	_	_	I-Premise
280	27	_	_	I-Premise
281	-	_	_	I-Premise
282	57	_	_	I-Premise
283	)	_	_	I-Premise
284	-	_	_	I-Premise
285	hazard	_	_	I-Premise
286	ratio	_	_	I-Premise
287	1	_	_	I-Premise
288	.	_	_	I-Premise

289	11	_	_	I-Premise
290	(	_	_	I-Premise
291	95	_	_	I-Premise
292	%	_	_	I-Premise
293	confidence	_	_	I-Premise
294	interval	_	_	I-Premise
295	0	_	_	I-Premise
296	.	_	_	I-Premise

297	80	_	_	I-Premise
298	-	_	_	I-Premise
299	1	_	_	I-Premise
300	.	_	_	I-Premise

301	53	_	_	I-Premise
302	)	_	_	I-Premise
303	in	_	_	I-Premise
304	favour	_	_	I-Premise
305	of	_	_	I-Premise
306	WBRT	_	_	I-Premise
307	.	_	_	I-Premise

308	Quality	_	_	B-Premise
309	of	_	_	I-Premise
310	life	_	_	I-Premise
311	assessed	_	_	I-Premise
312	using	_	_	I-Premise
313	EQ	_	_	I-Premise
314	-	_	_	I-Premise
315	5D	_	_	I-Premise
316	showed	_	_	I-Premise
317	no	_	_	I-Premise
318	evidence	_	_	I-Premise
319	of	_	_	I-Premise
320	a	_	_	I-Premise
321	difference	_	_	I-Premise
322	.	_	_	I-Premise

323	The	_	_	B-Premise
324	estimated	_	_	I-Premise
325	mean	_	_	I-Premise
326	QALYs	_	_	I-Premise
327	was	_	_	I-Premise
328	:	_	_	I-Premise
329	OSC	_	_	I-Premise
330	+	_	_	I-Premise
331	WBRT	_	_	I-Premise
332	31	_	_	I-Premise
333	days	_	_	I-Premise
334	and	_	_	I-Premise
335	OSC	_	_	I-Premise
336	30	_	_	I-Premise
337	days	_	_	I-Premise
338	,	_	_	I-Premise
339	difference	_	_	I-Premise
340	-	_	_	I-Premise
341	1	_	_	I-Premise
342	day	_	_	I-Premise
343	(	_	_	I-Premise
344	95	_	_	I-Premise
345	%	_	_	I-Premise
346	confidence	_	_	I-Premise
347	interval	_	_	I-Premise
348	-	_	_	I-Premise
349	12	_	_	I-Premise
350	.	_	_	I-Premise

351	0	_	_	I-Premise
352	to	_	_	I-Premise
353	+	_	_	I-Premise
354	13	_	_	I-Premise
355	.	_	_	I-Premise

356	2	_	_	I-Premise
357	days	_	_	I-Premise
358	)	_	_	I-Premise
359	.	_	_	I-Premise

360	These	_	_	B-Claim
361	interim	_	_	I-Claim
362	data	_	_	I-Claim
363	indicate	_	_	I-Claim
364	no	_	_	I-Claim
365	early	_	_	I-Claim
366	evidence	_	_	I-Claim
367	of	_	_	I-Claim
368	detriment	_	_	I-Claim
369	to	_	_	I-Claim
370	quality	_	_	I-Claim
371	of	_	_	I-Claim
372	life	_	_	I-Claim
373	,	_	_	I-Claim
374	overall	_	_	I-Claim
375	survival	_	_	I-Claim
376	or	_	_	I-Claim
377	QALYs	_	_	I-Claim
378	for	_	_	I-Claim
379	patients	_	_	I-Claim
380	allocated	_	_	I-Claim
381	to	_	_	I-Claim
382	OSC	_	_	I-Claim
383	alone	_	_	I-Claim
384	.	_	_	I-Claim

385	They	_	_	O
386	provide	_	_	O
387	key	_	_	O
388	information	_	_	O
389	for	_	_	O
390	discussing	_	_	O
391	the	_	_	O
392	trial	_	_	O
393	with	_	_	O
394	patients	_	_	O
395	and	_	_	O
396	strengthen	_	_	O
397	the	_	_	O
398	argument	_	_	O
399	for	_	_	O
400	continuing	_	_	O
401	QUARTZ	_	_	O
402	to	_	_	O
403	definitively	_	_	O
404	answer	_	_	O
405	this	_	_	O
406	important	_	_	O
407	clinical	_	_	O
408	question	_	_	O
409	.	_	_	O


0	A	_	_	O
1	phase	_	_	O
2	III	_	_	O
3	trial	_	_	O
4	(	_	_	O
5	Cancer	_	_	O
6	and	_	_	O
7	Leukemia	_	_	O
8	Group	_	_	O
9	B	_	_	O
10	CALGB	_	_	O
11	-	_	_	O
12	49907	_	_	O
13	)	_	_	O
14	was	_	_	O
15	conducted	_	_	O
16	to	_	_	O
17	test	_	_	O
18	whether	_	_	O
19	older	_	_	O
20	patients	_	_	O
21	with	_	_	O
22	early	_	_	O
23	-	_	_	O
24	stage	_	_	O
25	breast	_	_	O
26	cancer	_	_	O
27	would	_	_	O
28	have	_	_	O
29	equivalent	_	_	O
30	relapse	_	_	O
31	-	_	_	O
32	free	_	_	O
33	and	_	_	O
34	overall	_	_	O
35	survival	_	_	O
36	with	_	_	O
37	capecitabine	_	_	O
38	compared	_	_	O
39	with	_	_	O
40	standard	_	_	O
41	chemotherapy	_	_	O
42	.	_	_	O

43	The	_	_	O
44	quality	_	_	O
45	of	_	_	O
46	life	_	_	O
47	(	_	_	O
48	QoL	_	_	O
49	)	_	_	O
50	substudy	_	_	O
51	tested	_	_	O
52	whether	_	_	O
53	capecitabine	_	_	O
54	treatment	_	_	O
55	would	_	_	O
56	be	_	_	O
57	associated	_	_	O
58	with	_	_	O
59	a	_	_	O
60	better	_	_	O
61	QoL	_	_	O
62	than	_	_	O
63	standard	_	_	O
64	chemotherapy	_	_	O
65	.	_	_	O

66	QoL	_	_	O
67	was	_	_	O
68	assessed	_	_	O
69	in	_	_	O
70	350	_	_	O
71	patients	_	_	O
72	randomly	_	_	O
73	assigned	_	_	O
74	to	_	_	O
75	either	_	_	O
76	standard	_	_	O
77	chemotherapy	_	_	O
78	(	_	_	O
79	cyclophosphamide	_	_	O
80	,	_	_	O
81	methotrexate	_	_	O
82	,	_	_	O
83	and	_	_	O
84	fluorouracil	_	_	O
85	[	_	_	O
86	CMF	_	_	O
87	]	_	_	O
88	or	_	_	O
89	doxorubicin	_	_	O
90	and	_	_	O
91	cyclophosphamide	_	_	O
92	[	_	_	O
93	AC	_	_	O
94	]	_	_	O
95	;	_	_	O
96	n	_	_	O
97	=	_	_	O
98	182	_	_	O
99	)	_	_	O
100	or	_	_	O
101	capecitabine	_	_	O
102	(	_	_	O
103	n	_	_	O
104	=	_	_	O
105	168	_	_	O
106	)	_	_	O
107	.	_	_	O

108	Patients	_	_	O
109	were	_	_	O
110	interviewed	_	_	O
111	by	_	_	O
112	telephone	_	_	O
113	before	_	_	O
114	treatment	_	_	O
115	(	_	_	O
116	baseline	_	_	O
117	)	_	_	O
118	,	_	_	O
119	midtreatment	_	_	O
120	,	_	_	O
121	within	_	_	O
122	1	_	_	O
123	month	_	_	O
124	post	_	_	O
125	-	_	_	O
126	treatment	_	_	O
127	,	_	_	O
128	and	_	_	O
129	at	_	_	O
130	12	_	_	O
131	,	_	_	O
132	18	_	_	O
133	,	_	_	O
134	and	_	_	O
135	24	_	_	O
136	months	_	_	O
137	postbaseline	_	_	O
138	by	_	_	O
139	using	_	_	O
140	questionnaires	_	_	O
141	from	_	_	O
142	the	_	_	O
143	European	_	_	O
144	Organisation	_	_	O
145	for	_	_	O
146	Research	_	_	O
147	and	_	_	O
148	Treatment	_	_	O
149	of	_	_	O
150	Cancer	_	_	O
151	Quality	_	_	O
152	of	_	_	O
153	Life	_	_	O
154	Questionnaire	_	_	O
155	C30	_	_	O
156	(	_	_	O
157	EORTC	_	_	O
158	QLQ	_	_	O
159	-	_	_	O
160	C30	_	_	O
161	)	_	_	O
162	,	_	_	O
163	a	_	_	O
164	breast	_	_	O
165	systemic	_	_	O
166	adverse	_	_	O
167	effects	_	_	O
168	scale	_	_	O
169	(	_	_	O
170	EORTC	_	_	O
171	BR23	_	_	O
172	)	_	_	O
173	,	_	_	O
174	and	_	_	O
175	the	_	_	O
176	Hospital	_	_	O
177	Anxiety	_	_	O
178	and	_	_	O
179	Depression	_	_	O
180	Scale	_	_	O
181	(	_	_	O
182	HADS	_	_	O
183	)	_	_	O
184	.	_	_	O

185	Compared	_	_	B-Premise
186	with	_	_	I-Premise
187	patients	_	_	I-Premise
188	who	_	_	I-Premise
189	were	_	_	I-Premise
190	treated	_	_	I-Premise
191	with	_	_	I-Premise
192	standard	_	_	I-Premise
193	chemotherapy	_	_	I-Premise
194	,	_	_	I-Premise
195	patients	_	_	I-Premise
196	who	_	_	I-Premise
197	were	_	_	I-Premise
198	treated	_	_	I-Premise
199	with	_	_	I-Premise
200	capecitabine	_	_	I-Premise
201	had	_	_	I-Premise
202	significantly	_	_	I-Premise
203	better	_	_	I-Premise
204	QoL	_	_	I-Premise
205	,	_	_	I-Premise
206	role	_	_	I-Premise
207	function	_	_	I-Premise
208	,	_	_	I-Premise
209	and	_	_	I-Premise
210	social	_	_	I-Premise
211	function	_	_	I-Premise
212	,	_	_	I-Premise
213	fewer	_	_	I-Premise
214	systemic	_	_	I-Premise
215	adverse	_	_	I-Premise
216	effects	_	_	I-Premise
217	,	_	_	I-Premise
218	less	_	_	I-Premise
219	psychological	_	_	I-Premise
220	distress	_	_	I-Premise
221	,	_	_	I-Premise
222	and	_	_	I-Premise
223	less	_	_	I-Premise
224	fatigue	_	_	I-Premise
225	during	_	_	I-Premise
226	and	_	_	I-Premise
227	at	_	_	I-Premise
228	the	_	_	I-Premise
229	completion	_	_	I-Premise
230	of	_	_	I-Premise
231	treatment	_	_	I-Premise
232	(	_	_	I-Premise
233	P	_	_	I-Premise
234	≤	_	_	I-Premise
235	.	_	_	I-Premise

236	005	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	Capecitabine	_	_	B-Premise
240	treatment	_	_	I-Premise
241	was	_	_	I-Premise
242	associated	_	_	I-Premise
243	with	_	_	I-Premise
244	less	_	_	I-Premise
245	nausea	_	_	I-Premise
246	,	_	_	I-Premise
247	vomiting	_	_	I-Premise
248	,	_	_	I-Premise
249	and	_	_	I-Premise
250	constipation	_	_	I-Premise
251	and	_	_	I-Premise
252	with	_	_	I-Premise
253	better	_	_	I-Premise
254	appetite	_	_	I-Premise
255	than	_	_	I-Premise
256	standard	_	_	I-Premise
257	treatment	_	_	I-Premise
258	(	_	_	I-Premise
259	P	_	_	I-Premise
260	≤	_	_	I-Premise
261	.	_	_	I-Premise

262	004	_	_	I-Premise
263	)	_	_	I-Premise
264	,	_	_	I-Premise
265	but	_	_	I-Premise
266	worse	_	_	I-Premise
267	hand	_	_	I-Premise
268	-	_	_	I-Premise
269	foot	_	_	I-Premise
270	syndrome	_	_	I-Premise
271	and	_	_	I-Premise
272	diarrhea	_	_	I-Premise
273	(	_	_	I-Premise
274	P	_	_	I-Premise
275	<	_	_	I-Premise
276	.	_	_	I-Premise

277	005	_	_	I-Premise
278	)	_	_	I-Premise
279	.	_	_	I-Premise

280	These	_	_	O
281	differences	_	_	O
282	all	_	_	O
283	resolved	_	_	O
284	by	_	_	O
285	12	_	_	O
286	months	_	_	O
287	.	_	_	O

288	Standard	_	_	B-Claim
289	chemotherapy	_	_	I-Claim
290	was	_	_	I-Claim
291	superior	_	_	I-Claim
292	to	_	_	I-Claim
293	capecitabine	_	_	I-Claim
294	in	_	_	I-Claim
295	improving	_	_	I-Claim
296	relapse	_	_	I-Claim
297	-	_	_	I-Claim
298	free	_	_	I-Claim
299	and	_	_	I-Claim
300	overall	_	_	I-Claim
301	survival	_	_	I-Claim
302	for	_	_	I-Claim
303	older	_	_	I-Claim
304	women	_	_	I-Claim
305	with	_	_	I-Claim
306	early	_	_	I-Claim
307	-	_	_	I-Claim
308	stage	_	_	I-Claim
309	breast	_	_	I-Claim
310	cancer	_	_	I-Claim
311	.	_	_	I-Claim

312	Although	_	_	O
313	capecitabine	_	_	B-Claim
314	was	_	_	I-Claim
315	associated	_	_	I-Claim
316	with	_	_	I-Claim
317	better	_	_	I-Claim
318	QoL	_	_	I-Claim
319	during	_	_	I-Claim
320	treatment	_	_	I-Claim
321	,	_	_	O
322	QoL	_	_	B-Premise
323	was	_	_	I-Premise
324	similar	_	_	I-Premise
325	for	_	_	I-Premise
326	both	_	_	I-Premise
327	groups	_	_	I-Premise
328	at	_	_	I-Premise
329	1	_	_	I-Premise
330	year	_	_	I-Premise
331	.	_	_	I-Premise

332	The	_	_	O
333	brief	_	_	O
334	period	_	_	O
335	of	_	_	O
336	poorer	_	_	O
337	QoL	_	_	O
338	with	_	_	O
339	standard	_	_	O
340	treatment	_	_	O
341	is	_	_	O
342	a	_	_	O
343	modest	_	_	O
344	price	_	_	O
345	to	_	_	O
346	pay	_	_	O
347	for	_	_	O
348	a	_	_	O
349	chance	_	_	O
350	at	_	_	O
351	improved	_	_	O
352	survival	_	_	O
353	.	_	_	O


0	A	_	_	O
1	randomised	_	_	O
2	controlled	_	_	O
3	trial	_	_	O
4	of	_	_	O
5	radiotherapy	_	_	O
6	alone	_	_	O
7	versus	_	_	O
8	radiotherapy	_	_	O
9	with	_	_	O
10	concomitant	_	_	O
11	and	_	_	O
12	adjuvant	_	_	O
13	temozolomide	_	_	O
14	for	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	glioblastoma	_	_	O
18	showed	_	_	O
19	that	_	_	O
20	survival	_	_	O
21	was	_	_	O
22	higher	_	_	O
23	for	_	_	O
24	patients	_	_	O
25	assigned	_	_	O
26	combination	_	_	O
27	treatment	_	_	O
28	compared	_	_	O
29	with	_	_	O
30	those	_	_	O
31	assigned	_	_	O
32	standard	_	_	O
33	radiotherapy	_	_	O
34	alone	_	_	O
35	.	_	_	O

36	This	_	_	O
37	paper	_	_	O
38	reports	_	_	O
39	the	_	_	O
40	health	_	_	O
41	-	_	_	O
42	related	_	_	O
43	quality	_	_	O
44	of	_	_	O
45	life	_	_	O
46	(	_	_	O
47	HRQOL	_	_	O
48	)	_	_	O
49	of	_	_	O
50	the	_	_	O
51	patients	_	_	O
52	in	_	_	O
53	this	_	_	O
54	trial	_	_	O
55	.	_	_	O

56	573	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	newly	_	_	O
60	diagnosed	_	_	O
61	glioblastoma	_	_	O
62	were	_	_	O
63	randomly	_	_	O
64	allocated	_	_	O
65	either	_	_	O
66	radiotherapy	_	_	O
67	alone	_	_	O
68	or	_	_	O
69	radiotherapy	_	_	O
70	and	_	_	O
71	temozolomide	_	_	O
72	.	_	_	O

73	The	_	_	O
74	primary	_	_	O
75	endpoint	_	_	O
76	was	_	_	O
77	survival	_	_	O
78	,	_	_	O
79	and	_	_	O
80	HRQOL	_	_	O
81	was	_	_	O
82	a	_	_	O
83	secondary	_	_	O
84	endpoint	_	_	O
85	.	_	_	O

86	We	_	_	O
87	assessed	_	_	O
88	HRQOL	_	_	O
89	at	_	_	O
90	baseline	_	_	O
91	and	_	_	O
92	at	_	_	O
93	every	_	_	O
94	3	_	_	O
95	months	_	_	O
96	during	_	_	O
97	treatment	_	_	O
98	until	_	_	O
99	progression	_	_	O
100	using	_	_	O
101	the	_	_	O
102	European	_	_	O
103	Organisation	_	_	O
104	for	_	_	O
105	Research	_	_	O
106	and	_	_	O
107	Treatment	_	_	O
108	of	_	_	O
109	Cancer	_	_	O
110	(	_	_	O
111	EORTC	_	_	O
112	)	_	_	O
113	quality	_	_	O
114	of	_	_	O
115	life	_	_	O
116	questionnaire	_	_	O
117	core	_	_	O
118	-	_	_	O
119	30	_	_	O
120	(	_	_	O
121	QLQ	_	_	O
122	-	_	_	O
123	C30	_	_	O
124	)	_	_	O
125	and	_	_	O
126	the	_	_	O
127	EORTC	_	_	O
128	brain	_	_	O
129	cancer	_	_	O
130	module	_	_	O
131	(	_	_	O
132	EORTC	_	_	O
133	BN	_	_	O
134	-	_	_	O
135	20	_	_	O
136	)	_	_	O
137	.	_	_	O

138	We	_	_	O
139	calculated	_	_	O
140	changes	_	_	O
141	from	_	_	O
142	baseline	_	_	O
143	score	_	_	O
144	for	_	_	O
145	seven	_	_	O
146	predefined	_	_	O
147	HRQOL	_	_	O
148	measures	_	_	O
149	(	_	_	O
150	fatigue	_	_	O
151	,	_	_	O
152	overall	_	_	O
153	health	_	_	O
154	,	_	_	O
155	social	_	_	O
156	function	_	_	O
157	,	_	_	O
158	emotional	_	_	O
159	function	_	_	O
160	,	_	_	O
161	future	_	_	O
162	uncertainty	_	_	O
163	,	_	_	O
164	insomnia	_	_	O
165	,	_	_	O
166	and	_	_	O
167	communication	_	_	O
168	deficit	_	_	O
169	)	_	_	O
170	and	_	_	O
171	differences	_	_	O
172	between	_	_	O
173	groups	_	_	O
174	for	_	_	O
175	these	_	_	O
176	measures	_	_	O
177	at	_	_	O
178	every	_	_	O
179	time	_	_	O
180	point	_	_	O
181	.	_	_	O

182	The	_	_	O
183	significance	_	_	O
184	of	_	_	O
185	,	_	_	O
186	and	_	_	O
187	proportions	_	_	O
188	of	_	_	O
189	patients	_	_	O
190	with	_	_	O
191	,	_	_	O
192	improved	_	_	O
193	HRQOL	_	_	O
194	scores	_	_	O
195	-	_	_	O
196	-	_	_	O
197	defined	_	_	O
198	as	_	_	O
199	a	_	_	O
200	change	_	_	O
201	of	_	_	O
202	10	_	_	O
203	points	_	_	O
204	or	_	_	O
205	more	_	_	O
206	-	_	_	O
207	-	_	_	O
208	were	_	_	O
209	recorded	_	_	O
210	.	_	_	O

211	Baseline	_	_	O
212	questionnaires	_	_	O
213	were	_	_	O
214	available	_	_	O
215	for	_	_	O
216	490	_	_	O
217	(	_	_	O
218	86	_	_	O
219	%	_	_	O
220	)	_	_	O
221	patients	_	_	O
222	.	_	_	O

223	Baseline	_	_	O
224	HRQOL	_	_	O
225	scores	_	_	O
226	did	_	_	O
227	not	_	_	O
228	differ	_	_	O
229	between	_	_	O
230	groups	_	_	O
231	.	_	_	O

232	At	_	_	B-Premise
233	first	_	_	I-Premise
234	follow	_	_	I-Premise
235	-	_	_	I-Premise
236	up	_	_	I-Premise
237	,	_	_	I-Premise
238	groups	_	_	I-Premise
239	differed	_	_	I-Premise
240	only	_	_	I-Premise
241	in	_	_	I-Premise
242	social	_	_	I-Premise
243	functioning	_	_	I-Premise
244	,	_	_	I-Premise
245	favouring	_	_	I-Premise
246	the	_	_	I-Premise
247	radiotherapy	_	_	I-Premise
248	-	_	_	I-Premise
249	only	_	_	I-Premise
250	group	_	_	I-Premise
251	(	_	_	I-Premise
252	mean	_	_	I-Premise
253	score	_	_	I-Premise
254	79	_	_	I-Premise
255	.	_	_	I-Premise

256	0	_	_	I-Premise
257	[	_	_	I-Premise
258	SD	_	_	I-Premise
259	3	_	_	I-Premise
260	.	_	_	I-Premise

261	2	_	_	I-Premise
262	]	_	_	I-Premise
263	for	_	_	I-Premise
264	patients	_	_	I-Premise
265	assigned	_	_	I-Premise
266	radiotherapy	_	_	I-Premise
267	vs	_	_	I-Premise
268	67	_	_	I-Premise
269	.	_	_	I-Premise

270	4	_	_	I-Premise
271	[	_	_	I-Premise
272	2	_	_	I-Premise
273	.	_	_	I-Premise

274	7	_	_	I-Premise
275	]	_	_	I-Premise
276	for	_	_	I-Premise
277	those	_	_	I-Premise
278	assigned	_	_	I-Premise
279	radiotherapy	_	_	I-Premise
280	and	_	_	I-Premise
281	temozolomide	_	_	I-Premise
282	;	_	_	I-Premise
283	difference	_	_	I-Premise
284	between	_	_	I-Premise
285	groups	_	_	I-Premise
286	11	_	_	I-Premise
287	.	_	_	I-Premise

288	6	_	_	I-Premise
289	points	_	_	I-Premise
290	[	_	_	I-Premise
291	95	_	_	I-Premise
292	%	_	_	I-Premise
293	CI	_	_	I-Premise
294	3	_	_	I-Premise
295	.	_	_	I-Premise

296	5	_	_	I-Premise
297	-	_	_	I-Premise
298	19	_	_	I-Premise
299	.	_	_	I-Premise

300	7	_	_	I-Premise
301	]	_	_	I-Premise
302	,	_	_	I-Premise
303	p	_	_	I-Premise
304	=	_	_	I-Premise
305	0	_	_	I-Premise
306	.	_	_	I-Premise

307	0052	_	_	I-Premise
308	)	_	_	I-Premise
309	.	_	_	I-Premise

310	Over	_	_	B-Premise
311	subsequent	_	_	I-Premise
312	assessments	_	_	I-Premise
313	,	_	_	I-Premise
314	HRQOL	_	_	I-Premise
315	was	_	_	I-Premise
316	much	_	_	I-Premise
317	the	_	_	I-Premise
318	same	_	_	I-Premise
319	between	_	_	I-Premise
320	treatment	_	_	I-Premise
321	groups	_	_	I-Premise
322	.	_	_	I-Premise

323	Addition	_	_	B-Claim
324	of	_	_	I-Claim
325	temozolomide	_	_	I-Claim
326	during	_	_	I-Claim
327	and	_	_	I-Claim
328	after	_	_	I-Claim
329	radiotherapy	_	_	I-Claim
330	for	_	_	I-Claim
331	patients	_	_	I-Claim
332	with	_	_	I-Claim
333	newly	_	_	I-Claim
334	diagnosed	_	_	I-Claim
335	glioblastoma	_	_	I-Claim
336	significantly	_	_	I-Claim
337	improved	_	_	I-Claim
338	survival	_	_	I-Claim
339	without	_	_	I-Claim
340	a	_	_	I-Claim
341	negative	_	_	I-Claim
342	effect	_	_	I-Claim
343	on	_	_	I-Claim
344	HRQOL	_	_	I-Claim
345	.	_	_	I-Claim


0	Androgen	_	_	O
1	treatment	_	_	O
2	for	_	_	O
3	prostate	_	_	O
4	cancer	_	_	O
5	can	_	_	O
6	adversely	_	_	O
7	affect	_	_	O
8	functional	_	_	O
9	domains	_	_	O
10	of	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	.	_	_	O

15	We	_	_	O
16	aimed	_	_	O
17	to	_	_	O
18	assess	_	_	O
19	quality	_	_	O
20	of	_	_	O
21	life	_	_	O
22	in	_	_	O
23	men	_	_	O
24	with	_	_	O
25	locally	_	_	O
26	advanced	_	_	O
27	prostate	_	_	O
28	cancer	_	_	O
29	in	_	_	O
30	an	_	_	O
31	open	_	_	O
32	-	_	_	O
33	label	_	_	O
34	phase	_	_	O
35	III	_	_	O
36	randomised	_	_	O
37	comparison	_	_	O
38	between	_	_	O
39	lifelong	_	_	O
40	endocrine	_	_	O
41	treatment	_	_	O
42	with	_	_	O
43	and	_	_	O
44	without	_	_	O
45	radiotherapy	_	_	O
46	.	_	_	O

47	We	_	_	O
48	obtained	_	_	O
49	quality	_	_	O
50	-	_	_	O
51	of	_	_	O
52	-	_	_	O
53	life	_	_	O
54	information	_	_	O
55	from	_	_	O
56	872	_	_	O
57	(	_	_	O
58	99	_	_	O
59	%	_	_	O
60	)	_	_	O
61	of	_	_	O
62	875	_	_	O
63	eligible	_	_	O
64	men	_	_	O
65	with	_	_	O
66	locally	_	_	O
67	advanced	_	_	O
68	prostate	_	_	O
69	cancer	_	_	O
70	(	_	_	O
71	T3	_	_	O
72	;	_	_	O
73	78	_	_	O
74	%	_	_	O
75	)	_	_	O
76	who	_	_	O
77	were	_	_	O
78	randomly	_	_	O
79	assigned	_	_	O
80	,	_	_	O
81	between	_	_	O
82	1996	_	_	O
83	and	_	_	O
84	2002	_	_	O
85	,	_	_	O
86	to	_	_	O
87	3	_	_	O
88	months	_	_	O
89	of	_	_	O
90	total	_	_	O
91	androgen	_	_	O
92	blockade	_	_	O
93	followed	_	_	O
94	by	_	_	O
95	continuous	_	_	O
96	endocrine	_	_	O
97	treatment	_	_	O
98	(	_	_	O
99	439	_	_	O
100	patients	_	_	O
101	)	_	_	O
102	or	_	_	O
103	the	_	_	O
104	same	_	_	O
105	hormonal	_	_	O
106	treatment	_	_	O
107	with	_	_	O
108	radiotherapy	_	_	O
109	3	_	_	O
110	months	_	_	O
111	after	_	_	O
112	randomisation	_	_	O
113	(	_	_	O
114	436	_	_	O
115	patients	_	_	O
116	)	_	_	O
117	.	_	_	O

118	Prospective	_	_	O
119	outcomes	_	_	O
120	included	_	_	O
121	patient	_	_	O
122	-	_	_	O
123	reported	_	_	O
124	symptoms	_	_	O
125	and	_	_	O
126	quality	_	_	O
127	of	_	_	O
128	life	_	_	O
129	assessed	_	_	O
130	with	_	_	O
131	questionnaires	_	_	O
132	from	_	_	O
133	baseline	_	_	O
134	to	_	_	O
135	4	_	_	O
136	years	_	_	O
137	after	_	_	O
138	randomisation	_	_	O
139	.	_	_	O

140	Analysis	_	_	O
141	was	_	_	O
142	by	_	_	O
143	intention	_	_	O
144	to	_	_	O
145	treat	_	_	O
146	.	_	_	O

147	This	_	_	O
148	study	_	_	O
149	is	_	_	O
150	registered	_	_	O
151	as	_	_	O
152	an	_	_	O
153	international	_	_	O
154	standard	_	_	O
155	randomised	_	_	O
156	controlled	_	_	O
157	trial	_	_	O
158	,	_	_	O
159	number	_	_	O
160	ISRCTN01534787	_	_	O
161	.	_	_	O

162	438	_	_	O
163	of	_	_	O
164	439	_	_	O
165	men	_	_	O
166	assigned	_	_	O
167	endocrine	_	_	O
168	treatment	_	_	O
169	and	_	_	O
170	434	_	_	O
171	of	_	_	O
172	436	_	_	O
173	assigned	_	_	O
174	endocrine	_	_	O
175	plus	_	_	O
176	radiotherapy	_	_	O
177	completed	_	_	O
178	at	_	_	O
179	least	_	_	O
180	one	_	_	O
181	questionnaire	_	_	O
182	.	_	_	O

183	Missing	_	_	O
184	data	_	_	O
185	at	_	_	O
186	baseline	_	_	O
187	and	_	_	O
188	during	_	_	O
189	follow	_	_	O
190	-	_	_	O
191	up	_	_	O
192	was	_	_	O
193	equally	_	_	O
194	distributed	_	_	O
195	between	_	_	O
196	groups	_	_	O
197	.	_	_	O

198	At	_	_	B-Premise
199	4	_	_	I-Premise
200	years	_	_	I-Premise
201	,	_	_	I-Premise
202	64	_	_	I-Premise
203	(	_	_	I-Premise
204	18	_	_	I-Premise
205	%	_	_	I-Premise
206	)	_	_	I-Premise
207	of	_	_	I-Premise
208	353	_	_	I-Premise
209	patients	_	_	I-Premise
210	on	_	_	I-Premise
211	combined	_	_	I-Premise
212	therapy	_	_	I-Premise
213	and	_	_	I-Premise
214	39	_	_	I-Premise
215	(	_	_	I-Premise
216	12	_	_	I-Premise
217	%	_	_	I-Premise
218	)	_	_	I-Premise
219	of	_	_	I-Premise
220	337	_	_	I-Premise
221	on	_	_	I-Premise
222	endocrine	_	_	I-Premise
223	-	_	_	I-Premise
224	alone	_	_	I-Premise
225	therapy	_	_	I-Premise
226	had	_	_	I-Premise
227	moderate	_	_	I-Premise
228	to	_	_	I-Premise
229	severe	_	_	I-Premise
230	urinary	_	_	I-Premise
231	bother	_	_	I-Premise
232	(	_	_	I-Premise
233	p	_	_	I-Premise
234	=	_	_	I-Premise
235	0	_	_	I-Premise
236	.	_	_	I-Premise

237	005	_	_	I-Premise
238	)	_	_	I-Premise
239	,	_	_	I-Premise
240	and	_	_	I-Premise
241	16	_	_	I-Premise
242	(	_	_	I-Premise
243	4	_	_	I-Premise
244	%	_	_	I-Premise
245	)	_	_	I-Premise
246	of	_	_	I-Premise
247	355	_	_	I-Premise
248	on	_	_	I-Premise
249	combined	_	_	I-Premise
250	therapy	_	_	I-Premise
251	and	_	_	I-Premise
252	five	_	_	I-Premise
253	(	_	_	I-Premise
254	2	_	_	I-Premise
255	%	_	_	I-Premise
256	)	_	_	I-Premise
257	of	_	_	I-Premise
258	338	_	_	I-Premise
259	on	_	_	I-Premise
260	endocrine	_	_	I-Premise
261	treatment	_	_	I-Premise
262	alone	_	_	I-Premise
263	had	_	_	I-Premise
264	pain	_	_	I-Premise
265	while	_	_	I-Premise
266	urinating	_	_	I-Premise
267	(	_	_	I-Premise
268	p	_	_	I-Premise
269	=	_	_	I-Premise
270	0	_	_	I-Premise
271	.	_	_	I-Premise

272	024	_	_	I-Premise
273	)	_	_	I-Premise
274	.	_	_	I-Premise

275	37	_	_	B-Premise
276	(	_	_	I-Premise
277	11	_	_	I-Premise
278	%	_	_	I-Premise
279	)	_	_	I-Premise
280	of	_	_	I-Premise
281	350	_	_	I-Premise
282	in	_	_	I-Premise
283	the	_	_	I-Premise
284	combined	_	_	I-Premise
285	group	_	_	I-Premise
286	and	_	_	I-Premise
287	23	_	_	I-Premise
288	(	_	_	I-Premise
289	7	_	_	I-Premise
290	%	_	_	I-Premise
291	)	_	_	I-Premise
292	of	_	_	I-Premise
293	35	_	_	I-Premise
294	in	_	_	I-Premise
295	the	_	_	I-Premise
296	endocrine	_	_	I-Premise
297	-	_	_	I-Premise
298	only	_	_	I-Premise
299	group	_	_	I-Premise
300	had	_	_	I-Premise
301	overall	_	_	I-Premise
302	bother	_	_	I-Premise
303	from	_	_	I-Premise
304	all	_	_	I-Premise
305	bowel	_	_	I-Premise
306	symptoms	_	_	I-Premise
307	(	_	_	I-Premise
308	p	_	_	I-Premise
309	=	_	_	I-Premise
310	0	_	_	I-Premise
311	.	_	_	I-Premise

312	022	_	_	I-Premise
313	)	_	_	I-Premise
314	.	_	_	I-Premise

315	281	_	_	B-Premise
316	(	_	_	I-Premise
317	85	_	_	I-Premise
318	%	_	_	I-Premise
319	)	_	_	I-Premise
320	of	_	_	I-Premise
321	332	_	_	I-Premise
322	in	_	_	I-Premise
323	the	_	_	I-Premise
324	combined	_	_	I-Premise
325	-	_	_	I-Premise
326	treatment	_	_	I-Premise
327	group	_	_	I-Premise
328	and	_	_	I-Premise
329	227	_	_	I-Premise
330	(	_	_	I-Premise
331	72	_	_	I-Premise
332	%	_	_	I-Premise
333	)	_	_	I-Premise
334	of	_	_	I-Premise
335	313	_	_	I-Premise
336	in	_	_	I-Premise
337	the	_	_	I-Premise
338	endocrine	_	_	I-Premise
339	-	_	_	I-Premise
340	only	_	_	I-Premise
341	group	_	_	I-Premise
342	had	_	_	I-Premise
343	erectile	_	_	I-Premise
344	dysfunction	_	_	I-Premise
345	(	_	_	I-Premise
346	p	_	_	I-Premise
347	=	_	_	I-Premise
348	0	_	_	I-Premise
349	.	_	_	I-Premise

350	0002	_	_	I-Premise
351	)	_	_	I-Premise
352	.	_	_	I-Premise

353	Quality	_	_	B-Premise
354	of	_	_	I-Premise
355	life	_	_	I-Premise
356	at	_	_	I-Premise
357	4	_	_	I-Premise
358	years	_	_	I-Premise
359	was	_	_	I-Premise
360	similar	_	_	I-Premise
361	,	_	_	I-Premise
362	with	_	_	I-Premise
363	the	_	_	I-Premise
364	exception	_	_	I-Premise
365	of	_	_	I-Premise
366	decreased	_	_	I-Premise
367	social	_	_	I-Premise
368	function	_	_	I-Premise
369	in	_	_	I-Premise
370	patients	_	_	I-Premise
371	receiving	_	_	I-Premise
372	endocrine	_	_	I-Premise
373	treatment	_	_	I-Premise
374	plus	_	_	I-Premise
375	radiotherapy	_	_	I-Premise
376	.	_	_	I-Premise

377	Although	_	_	B-Claim
378	addition	_	_	I-Claim
379	of	_	_	I-Claim
380	radiotherapy	_	_	I-Claim
381	to	_	_	I-Claim
382	endocrine	_	_	I-Claim
383	treatment	_	_	I-Claim
384	significantly	_	_	I-Claim
385	increased	_	_	I-Claim
386	some	_	_	I-Claim
387	treatment	_	_	I-Claim
388	-	_	_	I-Claim
389	related	_	_	I-Claim
390	symptoms	_	_	I-Claim
391	,	_	_	I-Claim
392	none	_	_	I-Claim
393	were	_	_	I-Claim
394	serious	_	_	I-Claim
395	.	_	_	I-Claim

396	Given	_	_	O
397	the	_	_	O
398	substantial	_	_	O
399	survival	_	_	O
400	benefit	_	_	O
401	of	_	_	O
402	combined	_	_	O
403	treatment	_	_	O
404	,	_	_	O
405	the	_	_	B-Claim
406	increase	_	_	I-Claim
407	of	_	_	I-Claim
408	symptoms	_	_	I-Claim
409	seems	_	_	I-Claim
410	acceptable	_	_	I-Claim
411	and	_	_	I-Claim
412	has	_	_	I-Claim
413	little	_	_	I-Claim
414	extra	_	_	I-Claim
415	effect	_	_	I-Claim
416	on	_	_	I-Claim
417	quality	_	_	I-Claim
418	of	_	_	I-Claim
419	life	_	_	I-Claim
420	after	_	_	I-Claim
421	4	_	_	I-Claim
422	years	_	_	I-Claim
423	compared	_	_	I-Claim
424	with	_	_	I-Claim
425	endocrine	_	_	I-Claim
426	treatment	_	_	I-Claim
427	alone	_	_	I-Claim
428	.	_	_	I-Claim


0	Studies	_	_	O
1	have	_	_	O
2	shown	_	_	O
3	that	_	_	O
4	there	_	_	O
5	is	_	_	O
6	a	_	_	O
7	high	_	_	O
8	prevalence	_	_	O
9	of	_	_	O
10	depression	_	_	O
11	in	_	_	O
12	cancer	_	_	O
13	patients	_	_	O
14	.	_	_	O

15	Women	_	_	B-Claim
16	with	_	_	I-Claim
17	breast	_	_	I-Claim
18	cancer	_	_	I-Claim
19	may	_	_	I-Claim
20	have	_	_	I-Claim
21	an	_	_	I-Claim
22	even	_	_	I-Claim
23	higher	_	_	I-Claim
24	risk	_	_	I-Claim
25	of	_	_	I-Claim
26	depression	_	_	I-Claim
27	particularly	_	_	I-Claim
28	in	_	_	I-Claim
29	a	_	_	I-Claim
30	postmenopausal	_	_	I-Claim
31	or	_	_	I-Claim
32	estrogen	_	_	I-Claim
33	deficiency	_	_	I-Claim
34	state	_	_	I-Claim
35	.	_	_	I-Claim

36	A	_	_	O
37	small	_	_	O
38	number	_	_	O
39	of	_	_	O
40	randomized	_	_	O
41	controlled	_	_	O
42	trials	_	_	O
43	have	_	_	O
44	examined	_	_	O
45	the	_	_	O
46	efficacy	_	_	O
47	of	_	_	O
48	antidepressants	_	_	O
49	compared	_	_	O
50	to	_	_	O
51	that	_	_	O
52	of	_	_	O
53	a	_	_	O
54	placebo	_	_	O
55	in	_	_	O
56	cancer	_	_	O
57	patients	_	_	O
58	,	_	_	O
59	but	_	_	O
60	some	_	_	O
61	results	_	_	O
62	have	_	_	O
63	been	_	_	O
64	difficult	_	_	O
65	to	_	_	O
66	interpret	_	_	O
67	due	_	_	O
68	to	_	_	O
69	a	_	_	O
70	heterogeneous	_	_	O
71	patient	_	_	O
72	group	_	_	O
73	.	_	_	O

74	In	_	_	O
75	the	_	_	O
76	current	_	_	O
77	investigation	_	_	O
78	,	_	_	O
79	we	_	_	O
80	screened	_	_	O
81	newly	_	_	O
82	diagnosed	_	_	O
83	early	_	_	O
84	stage	_	_	O
85	breast	_	_	O
86	cancer	_	_	O
87	patients	_	_	O
88	for	_	_	O
89	depressive	_	_	O
90	symptoms	_	_	O
91	prior	_	_	O
92	to	_	_	O
93	the	_	_	O
94	initiation	_	_	O
95	of	_	_	O
96	adjuvant	_	_	O
97	therapy	_	_	O
98	and	_	_	O
99	investigated	_	_	O
100	whether	_	_	O
101	the	_	_	O
102	oral	_	_	O
103	antidepressant	_	_	O
104	fluoxetine	_	_	O
105	affected	_	_	O
106	depressive	_	_	O
107	symptoms	_	_	O
108	,	_	_	O
109	completion	_	_	O
110	of	_	_	O
111	adjuvant	_	_	O
112	treatment	_	_	O
113	,	_	_	O
114	and	_	_	O
115	quality	_	_	O
116	of	_	_	O
117	life	_	_	O
118	.	_	_	O

119	Patients	_	_	O
120	with	_	_	O
121	newly	_	_	O
122	diagnosed	_	_	O
123	early	_	_	O
124	stage	_	_	O
125	breast	_	_	O
126	cancer	_	_	O
127	were	_	_	O
128	screened	_	_	O
129	for	_	_	O
130	depressive	_	_	O
131	symptoms	_	_	O
132	prior	_	_	O
133	to	_	_	O
134	the	_	_	O
135	initiation	_	_	O
136	of	_	_	O
137	adjuvant	_	_	O
138	therapy	_	_	O
139	.	_	_	O

140	Patients	_	_	O
141	with	_	_	O
142	depressive	_	_	O
143	symptoms	_	_	O
144	were	_	_	O
145	randomized	_	_	O
146	to	_	_	O
147	a	_	_	O
148	daily	_	_	O
149	oral	_	_	O
150	fluoxetine	_	_	O
151	or	_	_	O
152	a	_	_	O
153	placebo	_	_	O
154	.	_	_	O

155	Patients	_	_	O
156	were	_	_	O
157	then	_	_	O
158	followed	_	_	O
159	for	_	_	O
160	6	_	_	O
161	months	_	_	O
162	and	_	_	O
163	evaluated	_	_	O
164	for	_	_	O
165	quality	_	_	O
166	of	_	_	O
167	life	_	_	O
168	,	_	_	O
169	completion	_	_	O
170	of	_	_	O
171	adjuvant	_	_	O
172	treatment	_	_	O
173	,	_	_	O
174	and	_	_	O
175	depressive	_	_	O
176	symptoms	_	_	O
177	.	_	_	O

178	A	_	_	O
179	high	_	_	O
180	percentage	_	_	O
181	of	_	_	O
182	patients	_	_	O
183	with	_	_	O
184	newly	_	_	O
185	diagnosed	_	_	O
186	early	_	_	O
187	stage	_	_	O
188	breast	_	_	O
189	cancer	_	_	O
190	were	_	_	O
191	found	_	_	O
192	to	_	_	O
193	have	_	_	O
194	depressive	_	_	O
195	symptoms	_	_	O
196	prior	_	_	O
197	to	_	_	O
198	the	_	_	O
199	initiation	_	_	O
200	of	_	_	O
201	adjuvant	_	_	O
202	therapy	_	_	O
203	.	_	_	O

204	The	_	_	B-Premise
205	use	_	_	I-Premise
206	of	_	_	I-Premise
207	fluoxetine	_	_	I-Premise
208	for	_	_	I-Premise
209	6	_	_	I-Premise
210	months	_	_	I-Premise
211	resulted	_	_	I-Premise
212	in	_	_	I-Premise
213	an	_	_	I-Premise
214	improvement	_	_	I-Premise
215	in	_	_	I-Premise
216	quality	_	_	I-Premise
217	of	_	_	I-Premise
218	life	_	_	I-Premise
219	,	_	_	I-Premise
220	a	_	_	I-Premise
221	higher	_	_	I-Premise
222	completion	_	_	I-Premise
223	of	_	_	I-Premise
224	adjuvant	_	_	I-Premise
225	treatment	_	_	I-Premise
226	(	_	_	I-Premise
227	chemotherapy	_	_	I-Premise
228	,	_	_	I-Premise
229	hormonal	_	_	I-Premise
230	therapy	_	_	I-Premise
231	,	_	_	I-Premise
232	chemotherapy	_	_	I-Premise
233	plus	_	_	I-Premise
234	hormonal	_	_	I-Premise
235	therapy	_	_	I-Premise
236	)	_	_	I-Premise
237	,	_	_	I-Premise
238	and	_	_	I-Premise
239	a	_	_	I-Premise
240	reduction	_	_	I-Premise
241	in	_	_	I-Premise
242	depressive	_	_	I-Premise
243	symptoms	_	_	I-Premise
244	compared	_	_	I-Premise
245	to	_	_	I-Premise
246	patients	_	_	I-Premise
247	who	_	_	I-Premise
248	received	_	_	I-Premise
249	placebo	_	_	I-Premise
250	.	_	_	I-Premise

251	An	_	_	B-Claim
252	antidepressant	_	_	I-Claim
253	should	_	_	I-Claim
254	be	_	_	I-Claim
255	considered	_	_	I-Claim
256	for	_	_	I-Claim
257	early	_	_	I-Claim
258	stage	_	_	I-Claim
259	breast	_	_	I-Claim
260	cancer	_	_	I-Claim
261	patients	_	_	I-Claim
262	with	_	_	I-Claim
263	depressive	_	_	I-Claim
264	symptoms	_	_	I-Claim
265	who	_	_	I-Claim
266	are	_	_	I-Claim
267	receiving	_	_	I-Claim
268	adjuvant	_	_	I-Claim
269	treatment	_	_	I-Claim
270	.	_	_	I-Claim


0	Gastrojejunostomy	_	_	O
1	(	_	_	O
2	GJJ	_	_	O
3	)	_	_	O
4	and	_	_	O
5	stent	_	_	O
6	placement	_	_	O
7	are	_	_	O
8	the	_	_	O
9	most	_	_	O
10	commonly	_	_	O
11	used	_	_	O
12	palliative	_	_	O
13	treatments	_	_	O
14	for	_	_	O
15	malignant	_	_	O
16	gastric	_	_	O
17	outlet	_	_	O
18	obstruction	_	_	O
19	(	_	_	O
20	GOO	_	_	O
21	)	_	_	O
22	.	_	_	O

23	In	_	_	O
24	a	_	_	O
25	recent	_	_	O
26	randomized	_	_	O
27	trial	_	_	O
28	,	_	_	O
29	stent	_	_	O
30	placement	_	_	O
31	was	_	_	O
32	preferred	_	_	O
33	in	_	_	O
34	patients	_	_	O
35	with	_	_	O
36	a	_	_	O
37	relatively	_	_	O
38	short	_	_	O
39	survival	_	_	O
40	and	_	_	O
41	GJJ	_	_	O
42	in	_	_	O
43	patients	_	_	O
44	with	_	_	O
45	a	_	_	O
46	longer	_	_	O
47	survival	_	_	O
48	.	_	_	O

49	As	_	_	O
50	health	_	_	O
51	economic	_	_	O
52	aspects	_	_	O
53	have	_	_	O
54	only	_	_	O
55	been	_	_	O
56	studied	_	_	O
57	in	_	_	O
58	general	_	_	O
59	terms	_	_	O
60	,	_	_	O
61	we	_	_	O
62	estimated	_	_	O
63	the	_	_	O
64	cost	_	_	O
65	of	_	_	O
66	GJJ	_	_	O
67	and	_	_	O
68	that	_	_	O
69	of	_	_	O
70	stent	_	_	O
71	placement	_	_	O
72	in	_	_	O
73	such	_	_	O
74	patients	_	_	O
75	.	_	_	O

76	In	_	_	O
77	the	_	_	O
78	SUSTENT	_	_	O
79	study	_	_	O
80	,	_	_	O
81	patients	_	_	O
82	were	_	_	O
83	randomized	_	_	O
84	to	_	_	O
85	GJJ	_	_	O
86	(	_	_	O
87	n	_	_	O
88	=	_	_	O
89	18	_	_	O
90	)	_	_	O
91	or	_	_	O
92	stent	_	_	O
93	placement	_	_	O
94	(	_	_	O
95	n	_	_	O
96	=	_	_	O
97	21	_	_	O
98	)	_	_	O
99	.	_	_	O

100	Pancreatic	_	_	O
101	cancer	_	_	O
102	was	_	_	O
103	the	_	_	O
104	most	_	_	O
105	common	_	_	O
106	cause	_	_	O
107	of	_	_	O
108	GOO	_	_	O
109	.	_	_	O

110	We	_	_	O
111	compared	_	_	O
112	initial	_	_	O
113	costs	_	_	O
114	and	_	_	O
115	costs	_	_	O
116	during	_	_	O
117	follow	_	_	O
118	-	_	_	O
119	up	_	_	O
120	.	_	_	O

121	For	_	_	O
122	cost	_	_	O
123	-	_	_	O
124	effectiveness	_	_	O
125	,	_	_	O
126	the	_	_	O
127	incremental	_	_	O
128	cost	_	_	O
129	-	_	_	O
130	effectiveness	_	_	O
131	ratio	_	_	O
132	was	_	_	O
133	calculated	_	_	O
134	.	_	_	O

135	Food	_	_	B-Premise
136	intake	_	_	I-Premise
137	improved	_	_	I-Premise
138	more	_	_	I-Premise
139	rapidly	_	_	I-Premise
140	after	_	_	I-Premise
141	stent	_	_	I-Premise
142	placement	_	_	I-Premise
143	than	_	_	I-Premise
144	after	_	_	I-Premise
145	GJJ	_	_	I-Premise
146	,	_	_	I-Premise
147	but	_	_	B-Premise
148	long	_	_	I-Premise
149	-	_	_	I-Premise
150	term	_	_	I-Premise
151	relief	_	_	I-Premise
152	of	_	_	I-Premise
153	obstructive	_	_	I-Premise
154	symptoms	_	_	I-Premise
155	was	_	_	I-Premise
156	better	_	_	I-Premise
157	after	_	_	I-Premise
158	GJJ	_	_	I-Premise
159	.	_	_	I-Premise

160	More	_	_	B-Premise
161	major	_	_	I-Premise
162	complications	_	_	I-Premise
163	(	_	_	I-Premise
164	P	_	_	I-Premise
165	=	_	_	I-Premise
166	0	_	_	I-Premise
167	.	_	_	I-Premise

168	02	_	_	I-Premise
169	)	_	_	I-Premise
170	occurred	_	_	I-Premise
171	and	_	_	I-Premise
172	more	_	_	I-Premise
173	reinterventions	_	_	I-Premise
174	were	_	_	I-Premise
175	performed	_	_	I-Premise
176	(	_	_	I-Premise
177	P	_	_	I-Premise
178	<	_	_	I-Premise
179	0	_	_	I-Premise
180	.	_	_	I-Premise

181	01	_	_	I-Premise
182	)	_	_	I-Premise
183	after	_	_	I-Premise
184	stent	_	_	I-Premise
185	placement	_	_	I-Premise
186	than	_	_	I-Premise
187	after	_	_	I-Premise
188	GJJ	_	_	I-Premise
189	.	_	_	I-Premise

190	Initial	_	_	B-Premise
191	costs	_	_	I-Premise
192	were	_	_	I-Premise
193	higher	_	_	I-Premise
194	for	_	_	I-Premise
195	GJJ	_	_	I-Premise
196	compared	_	_	I-Premise
197	to	_	_	I-Premise
198	stent	_	_	I-Premise
199	placement	_	_	I-Premise
200	(	_	_	I-Premise
201	euro8315	_	_	I-Premise
202	vs	_	_	I-Premise
203	.	_	_	I-Premise

204	euro4820	_	_	I-Premise
205	,	_	_	I-Premise
206	P	_	_	I-Premise
207	<	_	_	I-Premise
208	0	_	_	I-Premise
209	.	_	_	I-Premise

210	001	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	We	_	_	B-Premise
214	found	_	_	I-Premise
215	no	_	_	I-Premise
216	difference	_	_	I-Premise
217	in	_	_	I-Premise
218	follow	_	_	I-Premise
219	-	_	_	I-Premise
220	up	_	_	I-Premise
221	costs	_	_	I-Premise
222	.	_	_	I-Premise

223	Total	_	_	B-Premise
224	costs	_	_	I-Premise
225	per	_	_	I-Premise
226	patient	_	_	I-Premise
227	were	_	_	I-Premise
228	higher	_	_	I-Premise
229	for	_	_	I-Premise
230	GJJ	_	_	I-Premise
231	compared	_	_	I-Premise
232	to	_	_	I-Premise
233	stent	_	_	I-Premise
234	placement	_	_	I-Premise
235	(	_	_	I-Premise
236	euro12433	_	_	I-Premise
237	vs	_	_	I-Premise
238	.	_	_	I-Premise

239	euro8819	_	_	I-Premise
240	,	_	_	I-Premise
241	P	_	_	I-Premise
242	=	_	_	I-Premise
243	0	_	_	I-Premise
244	.	_	_	I-Premise

245	049	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	The	_	_	B-Premise
249	incremental	_	_	I-Premise
250	cost	_	_	I-Premise
251	-	_	_	I-Premise
252	effectiveness	_	_	I-Premise
253	ratio	_	_	I-Premise
254	of	_	_	I-Premise
255	GJJ	_	_	I-Premise
256	compared	_	_	I-Premise
257	to	_	_	I-Premise
258	stent	_	_	I-Premise
259	placement	_	_	I-Premise
260	was	_	_	I-Premise
261	euro164	_	_	I-Premise
262	per	_	_	I-Premise
263	extra	_	_	I-Premise
264	day	_	_	I-Premise
265	with	_	_	I-Premise
266	a	_	_	I-Premise
267	gastric	_	_	I-Premise
268	outlet	_	_	I-Premise
269	obstruction	_	_	I-Premise
270	scoring	_	_	I-Premise
271	system	_	_	I-Premise
272	(	_	_	I-Premise
273	GOOSS	_	_	I-Premise
274	)	_	_	I-Premise
275	>	_	_	I-Premise
276	or	_	_	I-Premise
277	=	_	_	I-Premise
278	2	_	_	I-Premise
279	adjusted	_	_	I-Premise
280	for	_	_	I-Premise
281	survival	_	_	I-Premise
282	.	_	_	I-Premise

283	Medical	_	_	B-Claim
284	effects	_	_	I-Claim
285	were	_	_	I-Claim
286	better	_	_	I-Claim
287	after	_	_	I-Claim
288	GJJ	_	_	I-Claim
289	,	_	_	O
290	although	_	_	B-Claim
291	GJJ	_	_	I-Claim
292	had	_	_	I-Claim
293	higher	_	_	I-Claim
294	total	_	_	I-Claim
295	costs	_	_	I-Claim
296	.	_	_	I-Claim

297	Since	_	_	B-Claim
298	the	_	_	I-Claim
299	cost	_	_	I-Claim
300	difference	_	_	I-Claim
301	between	_	_	I-Claim
302	the	_	_	I-Claim
303	two	_	_	I-Claim
304	treatments	_	_	I-Claim
305	was	_	_	I-Claim
306	only	_	_	I-Claim
307	small	_	_	I-Claim
308	,	_	_	I-Claim
309	cost	_	_	B-Claim
310	should	_	_	I-Claim
311	not	_	_	I-Claim
312	play	_	_	I-Claim
313	a	_	_	I-Claim
314	predominant	_	_	I-Claim
315	role	_	_	I-Claim
316	when	_	_	I-Claim
317	deciding	_	_	I-Claim
318	on	_	_	I-Claim
319	the	_	_	I-Claim
320	type	_	_	I-Claim
321	of	_	_	I-Claim
322	treatment	_	_	I-Claim
323	assigned	_	_	I-Claim
324	to	_	_	I-Claim
325	patients	_	_	I-Claim
326	with	_	_	I-Claim
327	malignant	_	_	I-Claim
328	GOO	_	_	I-Claim
329	.	_	_	I-Claim


0	This	_	_	O
1	randomized	_	_	O
2	,	_	_	O
3	multicenter	_	_	O
4	,	_	_	O
5	phase	_	_	O
6	III	_	_	O
7	study	_	_	O
8	compared	_	_	O
9	doxorubicin	_	_	O
10	and	_	_	O
11	docetaxel	_	_	O
12	(	_	_	O
13	AT	_	_	O
14	)	_	_	O
15	with	_	_	O
16	doxorubicin	_	_	O
17	and	_	_	O
18	cyclophosphamide	_	_	O
19	(	_	_	O
20	AC	_	_	O
21	)	_	_	O
22	as	_	_	O
23	first	_	_	O
24	-	_	_	O
25	line	_	_	O
26	chemotherapy	_	_	O
27	(	_	_	O
28	CT	_	_	O
29	)	_	_	O
30	in	_	_	O
31	metastatic	_	_	O
32	breast	_	_	O
33	cancer	_	_	O
34	(	_	_	O
35	MBC	_	_	O
36	)	_	_	O
37	.	_	_	O

38	Patients	_	_	O
39	(	_	_	O
40	n	_	_	O
41	=	_	_	O
42	429	_	_	O
43	)	_	_	O
44	were	_	_	O
45	randomly	_	_	O
46	assigned	_	_	O
47	to	_	_	O
48	receive	_	_	O
49	doxorubicin	_	_	O
50	50	_	_	O
51	mg	_	_	O
52	/	_	_	O
53	m	_	_	O
54	(	_	_	O
55	2	_	_	O
56	)	_	_	O
57	plus	_	_	O
58	docetaxel	_	_	O
59	75	_	_	O
60	mg	_	_	O
61	/	_	_	O
62	m	_	_	O
63	(	_	_	O
64	2	_	_	O
65	)	_	_	O
66	(	_	_	O
67	n	_	_	O
68	=	_	_	O
69	214	_	_	O
70	)	_	_	O
71	or	_	_	O
72	doxorubicin	_	_	O
73	60	_	_	O
74	mg	_	_	O
75	/	_	_	O
76	m	_	_	O
77	(	_	_	O
78	2	_	_	O
79	)	_	_	O
80	plus	_	_	O
81	cyclophosphamide	_	_	O
82	600	_	_	O
83	mg	_	_	O
84	/	_	_	O
85	m	_	_	O
86	(	_	_	O
87	2	_	_	O
88	)	_	_	O
89	(	_	_	O
90	n	_	_	O
91	=	_	_	O
92	215	_	_	O
93	)	_	_	O
94	on	_	_	O
95	day	_	_	O
96	1	_	_	O
97	,	_	_	O
98	every	_	_	O
99	3	_	_	O
100	weeks	_	_	O
101	for	_	_	O
102	up	_	_	O
103	to	_	_	O
104	eight	_	_	O
105	cycles	_	_	O
106	.	_	_	O

107	Time	_	_	B-Premise
108	to	_	_	I-Premise
109	progression	_	_	I-Premise
110	(	_	_	I-Premise
111	TTP	_	_	I-Premise
112	;	_	_	I-Premise
113	primary	_	_	I-Premise
114	end	_	_	I-Premise
115	point	_	_	I-Premise
116	)	_	_	I-Premise
117	and	_	_	I-Premise
118	time	_	_	I-Premise
119	to	_	_	I-Premise
120	treatment	_	_	I-Premise
121	failure	_	_	I-Premise
122	(	_	_	I-Premise
123	TTF	_	_	I-Premise
124	)	_	_	I-Premise
125	were	_	_	I-Premise
126	significantly	_	_	I-Premise
127	longer	_	_	I-Premise
128	with	_	_	I-Premise
129	AT	_	_	I-Premise
130	than	_	_	I-Premise
131	AC	_	_	I-Premise
132	(	_	_	I-Premise
133	median	_	_	I-Premise
134	TTP	_	_	I-Premise
135	,	_	_	I-Premise
136	37	_	_	I-Premise
137	.	_	_	I-Premise

138	3	_	_	I-Premise
139	v	_	_	I-Premise
140	31	_	_	I-Premise
141	.	_	_	I-Premise

142	9	_	_	I-Premise
143	weeks	_	_	I-Premise
144	;	_	_	I-Premise
145	log	_	_	I-Premise
146	-	_	_	I-Premise
147	rank	_	_	I-Premise
148	P	_	_	I-Premise
149	=	_	_	I-Premise
150	.	_	_	I-Premise

151	014	_	_	I-Premise
152	;	_	_	I-Premise
153	median	_	_	I-Premise
154	TTF	_	_	I-Premise
155	,	_	_	I-Premise
156	25	_	_	I-Premise
157	.	_	_	I-Premise

158	6	_	_	I-Premise
159	v	_	_	I-Premise
160	23	_	_	I-Premise
161	.	_	_	I-Premise

162	7	_	_	I-Premise
163	weeks	_	_	I-Premise
164	;	_	_	I-Premise
165	log	_	_	I-Premise
166	-	_	_	I-Premise
167	rank	_	_	I-Premise
168	P	_	_	I-Premise
169	=	_	_	I-Premise
170	.	_	_	I-Premise

171	048	_	_	I-Premise
172	)	_	_	I-Premise
173	.	_	_	I-Premise

174	The	_	_	B-Premise
175	overall	_	_	I-Premise
176	response	_	_	I-Premise
177	rate	_	_	I-Premise
178	(	_	_	I-Premise
179	ORR	_	_	I-Premise
180	)	_	_	I-Premise
181	was	_	_	I-Premise
182	significantly	_	_	I-Premise
183	greater	_	_	I-Premise
184	for	_	_	I-Premise
185	patients	_	_	I-Premise
186	taking	_	_	I-Premise
187	AT	_	_	I-Premise
188	(	_	_	I-Premise
189	59	_	_	I-Premise
190	%	_	_	I-Premise
191	,	_	_	I-Premise
192	with	_	_	I-Premise
193	10	_	_	I-Premise
194	%	_	_	I-Premise
195	complete	_	_	I-Premise
196	response	_	_	I-Premise
197	[	_	_	I-Premise
198	CR	_	_	I-Premise
199	]	_	_	I-Premise
200	,	_	_	I-Premise
201	49	_	_	I-Premise
202	%	_	_	I-Premise
203	partial	_	_	I-Premise
204	response	_	_	I-Premise
205	[	_	_	I-Premise
206	PR	_	_	I-Premise
207	]	_	_	I-Premise
208	)	_	_	I-Premise
209	than	_	_	I-Premise
210	for	_	_	I-Premise
211	those	_	_	I-Premise
212	taking	_	_	I-Premise
213	AC	_	_	I-Premise
214	(	_	_	I-Premise
215	47	_	_	I-Premise
216	%	_	_	I-Premise
217	,	_	_	I-Premise
218	with	_	_	I-Premise
219	7	_	_	I-Premise
220	%	_	_	I-Premise
221	CR	_	_	I-Premise
222	,	_	_	I-Premise
223	39	_	_	I-Premise
224	%	_	_	I-Premise
225	PR	_	_	I-Premise
226	)	_	_	I-Premise
227	(	_	_	I-Premise
228	P	_	_	I-Premise
229	=	_	_	I-Premise
230	.	_	_	I-Premise

231	009	_	_	I-Premise
232	)	_	_	I-Premise
233	.	_	_	I-Premise

234	The	_	_	B-Premise
235	ORR	_	_	I-Premise
236	was	_	_	I-Premise
237	also	_	_	I-Premise
238	higher	_	_	I-Premise
239	with	_	_	I-Premise
240	AT	_	_	I-Premise
241	in	_	_	I-Premise
242	patients	_	_	I-Premise
243	with	_	_	I-Premise
244	visceral	_	_	I-Premise
245	involvement	_	_	I-Premise
246	(	_	_	I-Premise
247	58	_	_	I-Premise
248	%	_	_	I-Premise
249	v	_	_	I-Premise
250	41	_	_	I-Premise
251	%	_	_	I-Premise
252	;	_	_	I-Premise
253	liver	_	_	I-Premise
254	,	_	_	I-Premise
255	62	_	_	I-Premise
256	%	_	_	I-Premise
257	v	_	_	I-Premise
258	42	_	_	I-Premise
259	%	_	_	I-Premise
260	;	_	_	I-Premise
261	lung	_	_	I-Premise
262	,	_	_	I-Premise
263	58	_	_	I-Premise
264	%	_	_	I-Premise
265	v	_	_	I-Premise
266	35	_	_	I-Premise
267	%	_	_	I-Premise
268	)	_	_	I-Premise
269	,	_	_	I-Premise
270	three	_	_	I-Premise
271	or	_	_	I-Premise
272	more	_	_	I-Premise
273	organs	_	_	I-Premise
274	involved	_	_	I-Premise
275	(	_	_	I-Premise
276	59	_	_	I-Premise
277	%	_	_	I-Premise
278	v	_	_	I-Premise
279	40	_	_	I-Premise
280	%	_	_	I-Premise
281	)	_	_	I-Premise
282	,	_	_	I-Premise
283	or	_	_	I-Premise
284	prior	_	_	I-Premise
285	adjuvant	_	_	I-Premise
286	CT	_	_	I-Premise
287	(	_	_	I-Premise
288	53	_	_	I-Premise
289	%	_	_	I-Premise
290	v	_	_	I-Premise
291	41	_	_	I-Premise
292	%	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	Overall	_	_	B-Premise
296	survival	_	_	I-Premise
297	(	_	_	I-Premise
298	OS	_	_	I-Premise
299	)	_	_	I-Premise
300	was	_	_	I-Premise
301	comparable	_	_	I-Premise
302	in	_	_	I-Premise
303	both	_	_	I-Premise
304	arms	_	_	I-Premise
305	.	_	_	I-Premise

306	Grade	_	_	B-Premise
307	3	_	_	I-Premise
308	/	_	_	I-Premise
309	4	_	_	I-Premise
310	neutropenia	_	_	I-Premise
311	was	_	_	I-Premise
312	frequent	_	_	I-Premise
313	in	_	_	I-Premise
314	both	_	_	I-Premise
315	groups	_	_	I-Premise
316	,	_	_	I-Premise
317	although	_	_	B-Premise
318	febrile	_	_	I-Premise
319	neutropenia	_	_	I-Premise
320	and	_	_	I-Premise
321	infections	_	_	I-Premise
322	were	_	_	I-Premise
323	more	_	_	I-Premise
324	frequent	_	_	I-Premise
325	for	_	_	I-Premise
326	patients	_	_	I-Premise
327	taking	_	_	I-Premise
328	AT	_	_	I-Premise
329	(	_	_	I-Premise
330	respectively	_	_	I-Premise
331	,	_	_	I-Premise
332	33	_	_	I-Premise
333	%	_	_	I-Premise
334	v	_	_	I-Premise
335	10	_	_	I-Premise
336	%	_	_	I-Premise
337	,	_	_	I-Premise
338	P	_	_	I-Premise
339	<	_	_	I-Premise
340	.	_	_	I-Premise

341	001	_	_	I-Premise
342	;	_	_	I-Premise
343	8	_	_	I-Premise
344	%	_	_	I-Premise
345	v	_	_	I-Premise
346	2	_	_	I-Premise
347	%	_	_	I-Premise
348	,	_	_	I-Premise
349	P	_	_	I-Premise
350	=	_	_	I-Premise
351	.	_	_	I-Premise

352	01	_	_	I-Premise
353	)	_	_	I-Premise
354	.	_	_	I-Premise

355	Severe	_	_	B-Premise
356	nonhematologic	_	_	I-Premise
357	toxicity	_	_	I-Premise
358	was	_	_	I-Premise
359	infrequent	_	_	I-Premise
360	in	_	_	I-Premise
361	both	_	_	I-Premise
362	groups	_	_	I-Premise
363	,	_	_	I-Premise
364	including	_	_	I-Premise
365	grade	_	_	I-Premise
366	3	_	_	I-Premise
367	/	_	_	I-Premise
368	4	_	_	I-Premise
369	cardiac	_	_	I-Premise
370	events	_	_	I-Premise
371	(	_	_	I-Premise
372	AT	_	_	I-Premise
373	,	_	_	I-Premise
374	3	_	_	I-Premise
375	%	_	_	I-Premise
376	;	_	_	I-Premise
377	AC	_	_	I-Premise
378	,	_	_	I-Premise
379	4	_	_	I-Premise
380	%	_	_	I-Premise
381	)	_	_	I-Premise
382	.	_	_	I-Premise

383	AT	_	_	B-Claim
384	significantly	_	_	I-Claim
385	improves	_	_	I-Claim
386	TTP	_	_	I-Claim
387	and	_	_	I-Claim
388	ORR	_	_	I-Claim
389	compared	_	_	I-Claim
390	with	_	_	I-Claim
391	AC	_	_	I-Claim
392	in	_	_	I-Claim
393	patients	_	_	I-Claim
394	with	_	_	I-Claim
395	MBC	_	_	I-Claim
396	,	_	_	I-Claim
397	but	_	_	B-Claim
398	there	_	_	I-Claim
399	is	_	_	I-Claim
400	no	_	_	I-Claim
401	difference	_	_	I-Claim
402	in	_	_	I-Claim
403	OS	_	_	I-Claim
404	.	_	_	I-Claim

405	AT	_	_	B-Claim
406	represents	_	_	I-Claim
407	a	_	_	I-Claim
408	valid	_	_	I-Claim
409	option	_	_	I-Claim
410	for	_	_	I-Claim
411	the	_	_	I-Claim
412	treatment	_	_	I-Claim
413	of	_	_	I-Claim
414	MBC	_	_	I-Claim
415	.	_	_	I-Claim


0	Hormonal	_	_	B-Claim
1	breast	_	_	I-Claim
2	cancer	_	_	I-Claim
3	treatment	_	_	I-Claim
4	increases	_	_	I-Claim
5	menopausal	_	_	I-Claim
6	symptoms	_	_	I-Claim
7	in	_	_	I-Claim
8	women	_	_	I-Claim
9	.	_	_	I-Claim

10	This	_	_	O
11	study	_	_	O
12	investigated	_	_	O
13	differences	_	_	O
14	between	_	_	O
15	the	_	_	O
16	symptoms	_	_	O
17	associated	_	_	O
18	with	_	_	O
19	either	_	_	O
20	adjuvant	_	_	O
21	tamoxifen	_	_	O
22	or	_	_	O
23	exemestane	_	_	O
24	.	_	_	O

25	Ten	_	_	O
26	common	_	_	O
27	symptoms	_	_	O
28	were	_	_	O
29	assessed	_	_	O
30	by	_	_	O
31	self	_	_	O
32	-	_	_	O
33	report	_	_	O
34	questionnaire	_	_	O
35	administered	_	_	O
36	to	_	_	O
37	1	_	_	O
38	,	_	_	O
39	614	_	_	O
40	consecutive	_	_	O
41	patients	_	_	O
42	at	_	_	O
43	baseline	_	_	O
44	and	_	_	O
45	every	_	_	O
46	3	_	_	O
47	months	_	_	O
48	during	_	_	O
49	the	_	_	O
50	first	_	_	O
51	year	_	_	O
52	of	_	_	O
53	a	_	_	O
54	double	_	_	O
55	-	_	_	O
56	blind	_	_	O
57	,	_	_	O
58	randomized	_	_	O
59	trial	_	_	O
60	of	_	_	O
61	postmenopausal	_	_	O
62	women	_	_	O
63	with	_	_	O
64	early	_	_	O
65	hormone	_	_	O
66	receptor	_	_	O
67	-	_	_	O
68	positive	_	_	O
69	breast	_	_	O
70	cancer	_	_	O
71	.	_	_	O

72	Symptoms	_	_	O
73	were	_	_	O
74	categorized	_	_	O
75	as	_	_	O
76	none	_	_	O
77	,	_	_	O
78	mild	_	_	O
79	,	_	_	O
80	moderate	_	_	O
81	,	_	_	O
82	or	_	_	O
83	severe	_	_	O
84	.	_	_	O

85	A	_	_	O
86	hot	_	_	O
87	flash	_	_	O
88	score	_	_	O
89	was	_	_	O
90	calculated	_	_	O
91	at	_	_	O
92	each	_	_	O
93	time	_	_	O
94	point	_	_	O
95	.	_	_	O

96	Symptoms	_	_	O
97	were	_	_	O
98	analyzed	_	_	O
99	by	_	_	O
100	repeated	_	_	O
101	-	_	_	O
102	measures	_	_	O
103	analysis	_	_	O
104	of	_	_	O
105	variance	_	_	O
106	.	_	_	O

107	Each	_	_	O
108	time	_	_	O
109	period	_	_	O
110	was	_	_	O
111	tested	_	_	O
112	repeatedly	_	_	O
113	against	_	_	O
114	the	_	_	O
115	baseline	_	_	O
116	;	_	_	O
117	an	_	_	O
118	overall	_	_	O
119	P	_	_	O
120	value	_	_	O
121	was	_	_	O
122	assigned	_	_	O
123	for	_	_	O
124	each	_	_	O
125	reported	_	_	O
126	symptom	_	_	O
127	.	_	_	O

128	Compliance	_	_	O
129	was	_	_	O
130	excellent	_	_	O
131	,	_	_	O
132	with	_	_	O
133	7	_	_	O
134	,	_	_	O
135	286	_	_	O
136	questionnaires	_	_	O
137	analyzed	_	_	O
138	.	_	_	O

139	Baseline	_	_	O
140	symptom	_	_	O
141	prevalence	_	_	O
142	ranged	_	_	O
143	from	_	_	O
144	2	_	_	O
145	%	_	_	O
146	(	_	_	O
147	vaginal	_	_	O
148	bleeding	_	_	O
149	)	_	_	O
150	to	_	_	O
151	60	_	_	O
152	%	_	_	O
153	to	_	_	O
154	70	_	_	O
155	%	_	_	O
156	(	_	_	O
157	bone	_	_	O
158	/	_	_	O
159	muscle	_	_	O
160	aches	_	_	O
161	and	_	_	O
162	low	_	_	O
163	energy	_	_	O
164	)	_	_	O
165	.	_	_	O

166	There	_	_	B-Premise
167	were	_	_	I-Premise
168	no	_	_	I-Premise
169	significant	_	_	I-Premise
170	differences	_	_	I-Premise
171	in	_	_	I-Premise
172	vaginal	_	_	I-Premise
173	bleeding	_	_	I-Premise
174	,	_	_	I-Premise
175	mood	_	_	I-Premise
176	alteration	_	_	I-Premise
177	,	_	_	I-Premise
178	or	_	_	I-Premise
179	low	_	_	I-Premise
180	energy	_	_	I-Premise
181	.	_	_	I-Premise

182	Patients	_	_	B-Premise
183	receiving	_	_	I-Premise
184	tamoxifen	_	_	I-Premise
185	had	_	_	I-Premise
186	significantly	_	_	I-Premise
187	more	_	_	I-Premise
188	vaginal	_	_	I-Premise
189	discharge	_	_	I-Premise
190	(	_	_	I-Premise
191	P	_	_	I-Premise
192	<	_	_	I-Premise
193	.	_	_	I-Premise

194	0001	_	_	I-Premise
195	)	_	_	I-Premise
196	.	_	_	I-Premise

197	Exemestane	_	_	B-Premise
198	patients	_	_	I-Premise
199	reported	_	_	I-Premise
200	more	_	_	I-Premise
201	bone	_	_	I-Premise
202	/	_	_	I-Premise
203	muscle	_	_	I-Premise
204	aches	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	<	_	_	I-Premise
208	.	_	_	I-Premise

209	0001	_	_	I-Premise
210	)	_	_	I-Premise
211	,	_	_	I-Premise
212	vaginal	_	_	I-Premise
213	dryness	_	_	I-Premise
214	(	_	_	I-Premise
215	P	_	_	I-Premise
216	=	_	_	I-Premise
217	.	_	_	I-Premise

218	0004	_	_	I-Premise
219	)	_	_	I-Premise
220	,	_	_	I-Premise
221	and	_	_	I-Premise
222	difficulty	_	_	I-Premise
223	sleeping	_	_	I-Premise
224	(	_	_	I-Premise
225	P	_	_	I-Premise
226	=	_	_	I-Premise
227	.	_	_	I-Premise

228	03	_	_	I-Premise
229	)	_	_	I-Premise
230	.	_	_	I-Premise

231	In	_	_	B-Premise
232	both	_	_	I-Premise
233	groups	_	_	I-Premise
234	,	_	_	I-Premise
235	the	_	_	I-Premise
236	hot	_	_	I-Premise
237	flash	_	_	I-Premise
238	score	_	_	I-Premise
239	peaked	_	_	I-Premise
240	at	_	_	I-Premise
241	3	_	_	I-Premise
242	months	_	_	I-Premise
243	and	_	_	I-Premise
244	decreased	_	_	I-Premise
245	thereafter	_	_	I-Premise
246	.	_	_	I-Premise

247	At	_	_	B-Premise
248	12	_	_	I-Premise
249	months	_	_	I-Premise
250	,	_	_	I-Premise
251	patients	_	_	I-Premise
252	receiving	_	_	I-Premise
253	tamoxifen	_	_	I-Premise
254	had	_	_	I-Premise
255	a	_	_	I-Premise
256	significantly	_	_	I-Premise
257	higher	_	_	I-Premise
258	mean	_	_	I-Premise
259	hot	_	_	I-Premise
260	flash	_	_	I-Premise
261	score	_	_	I-Premise
262	(	_	_	I-Premise
263	P	_	_	I-Premise
264	=	_	_	I-Premise
265	.	_	_	I-Premise

266	03	_	_	I-Premise
267	)	_	_	I-Premise
268	,	_	_	I-Premise
269	with	_	_	I-Premise
270	daily	_	_	I-Premise
271	hot	_	_	I-Premise
272	flashes	_	_	I-Premise
273	increasing	_	_	I-Premise
274	from	_	_	I-Premise
275	baseline	_	_	I-Premise
276	by	_	_	I-Premise
277	33	_	_	I-Premise
278	%	_	_	I-Premise
279	compared	_	_	I-Premise
280	with	_	_	I-Premise
281	a	_	_	I-Premise
282	7	_	_	I-Premise
283	%	_	_	I-Premise
284	increase	_	_	I-Premise
285	from	_	_	I-Premise
286	baseline	_	_	I-Premise
287	with	_	_	I-Premise
288	exemestane	_	_	I-Premise
289	.	_	_	I-Premise

290	At	_	_	B-Premise
291	12	_	_	I-Premise
292	months	_	_	I-Premise
293	,	_	_	I-Premise
294	exemestane	_	_	I-Premise
295	was	_	_	I-Premise
296	associated	_	_	I-Premise
297	with	_	_	I-Premise
298	fewer	_	_	I-Premise
299	hot	_	_	I-Premise
300	flashes	_	_	I-Premise
301	and	_	_	I-Premise
302	less	_	_	I-Premise
303	vaginal	_	_	I-Premise
304	discharge	_	_	I-Premise
305	than	_	_	I-Premise
306	tamoxifen	_	_	I-Premise
307	,	_	_	I-Premise
308	but	_	_	I-Premise
309	with	_	_	I-Premise
310	more	_	_	I-Premise
311	vaginal	_	_	I-Premise
312	dryness	_	_	I-Premise
313	,	_	_	I-Premise
314	bone	_	_	I-Premise
315	/	_	_	I-Premise
316	muscle	_	_	I-Premise
317	aches	_	_	I-Premise
318	,	_	_	I-Premise
319	and	_	_	I-Premise
320	difficulty	_	_	I-Premise
321	sleeping	_	_	I-Premise
322	.	_	_	I-Premise

323	Symptoms	_	_	B-Claim
324	were	_	_	I-Claim
325	common	_	_	I-Claim
326	in	_	_	I-Claim
327	both	_	_	I-Claim
328	groups	_	_	I-Claim
329	.	_	_	I-Claim


0	Recent	_	_	B-Claim
1	studies	_	_	I-Claim
2	have	_	_	I-Claim
3	shown	_	_	I-Claim
4	that	_	_	I-Claim
5	administering	_	_	I-Claim
6	the	_	_	I-Claim
7	aromatase	_	_	I-Claim
8	inhibitor	_	_	I-Claim
9	exemestane	_	_	I-Claim
10	after	_	_	I-Claim
11	2	_	_	I-Claim
12	-	_	_	I-Claim
13	3	_	_	I-Claim
14	years	_	_	I-Claim
15	of	_	_	I-Claim
16	tamoxifen	_	_	I-Claim
17	therapy	_	_	I-Claim
18	significantly	_	_	I-Claim
19	improves	_	_	I-Claim
20	disease	_	_	I-Claim
21	-	_	_	I-Claim
22	free	_	_	I-Claim
23	survival	_	_	I-Claim
24	in	_	_	I-Claim
25	postmenopausal	_	_	I-Claim
26	women	_	_	I-Claim
27	with	_	_	I-Claim
28	primary	_	_	I-Claim
29	breast	_	_	I-Claim
30	cancer	_	_	I-Claim
31	in	_	_	I-Claim
32	comparison	_	_	I-Claim
33	with	_	_	I-Claim
34	standard	_	_	I-Claim
35	5	_	_	I-Claim
36	-	_	_	I-Claim
37	year	_	_	I-Claim
38	tamoxifen	_	_	I-Claim
39	treatment	_	_	I-Claim
40	.	_	_	I-Claim

41	Although	_	_	O
42	many	_	_	O
43	of	_	_	O
44	the	_	_	O
45	adverse	_	_	O
46	effects	_	_	O
47	associated	_	_	O
48	with	_	_	O
49	exemestane	_	_	O
50	and	_	_	O
51	tamoxifen	_	_	O
52	have	_	_	O
53	been	_	_	O
54	analysed	_	_	O
55	,	_	_	O
56	there	_	_	O
57	are	_	_	O
58	no	_	_	O
59	comparative	_	_	O
60	data	_	_	O
61	concerning	_	_	O
62	body	_	_	O
63	weight	_	_	O
64	and	_	_	O
65	body	_	_	O
66	composition	_	_	O
67	.	_	_	O

68	The	_	_	O
69	aim	_	_	O
70	of	_	_	O
71	this	_	_	O
72	randomised	_	_	O
73	study	_	_	O
74	was	_	_	O
75	to	_	_	O
76	evaluate	_	_	O
77	the	_	_	O
78	longitudinal	_	_	O
79	changes	_	_	O
80	in	_	_	O
81	body	_	_	O
82	composition	_	_	O
83	and	_	_	O
84	lipid	_	_	O
85	profiles	_	_	O
86	in	_	_	O
87	postmenopausal	_	_	O
88	women	_	_	O
89	switched	_	_	O
90	from	_	_	O
91	tamoxifen	_	_	O
92	to	_	_	O
93	exemestane	_	_	O
94	.	_	_	O

95	In	_	_	O
96	total	_	_	O
97	,	_	_	O
98	60	_	_	O
99	overweight	_	_	O
100	or	_	_	O
101	obese	_	_	O
102	postmenopausal	_	_	O
103	patients	_	_	O
104	were	_	_	O
105	enrolled	_	_	O
106	.	_	_	O

107	Their	_	_	O
108	anthropometric	_	_	O
109	data	_	_	O
110	,	_	_	O
111	body	_	_	O
112	composition	_	_	O
113	,	_	_	O
114	including	_	_	O
115	fat	_	_	O
116	mass	_	_	O
117	(	_	_	O
118	FM	_	_	O
119	)	_	_	O
120	and	_	_	O
121	fat	_	_	O
122	-	_	_	O
123	free	_	_	O
124	mass	_	_	O
125	(	_	_	O
126	FFM	_	_	O
127	)	_	_	O
128	,	_	_	O
129	and	_	_	O
130	lipid	_	_	O
131	profiles	_	_	O
132	,	_	_	O
133	caloric	_	_	O
134	intake	_	_	O
135	and	_	_	O
136	physical	_	_	O
137	activity	_	_	O
138	were	_	_	O
139	assessed	_	_	O
140	1	_	_	O
141	week	_	_	O
142	before	_	_	O
143	randomisation	_	_	O
144	,	_	_	O
145	and	_	_	O
146	6	_	_	O
147	and	_	_	O
148	12	_	_	O
149	months	_	_	O
150	later	_	_	O
151	.	_	_	O

152	In	_	_	O
153	all	_	_	O
154	,	_	_	O
155	55	_	_	O
156	patients	_	_	O
157	(	_	_	O
158	27	_	_	O
159	on	_	_	O
160	tamoxifen	_	_	O
161	and	_	_	O
162	28	_	_	O
163	on	_	_	O
164	exemestane	_	_	O
165	)	_	_	O
166	completed	_	_	O
167	the	_	_	O
168	1	_	_	O
169	-	_	_	O
170	year	_	_	O
171	study	_	_	O
172	period	_	_	O
173	.	_	_	O

174	Fat	_	_	B-Premise
175	mass	_	_	I-Premise
176	had	_	_	I-Premise
177	significantly	_	_	I-Premise
178	decreased	_	_	I-Premise
179	by	_	_	I-Premise
180	month	_	_	I-Premise
181	12	_	_	I-Premise
182	in	_	_	I-Premise
183	the	_	_	I-Premise
184	exemestane	_	_	I-Premise
185	,	_	_	I-Premise
186	but	_	_	I-Premise
187	not	_	_	I-Premise
188	in	_	_	I-Premise
189	the	_	_	I-Premise
190	tamoxifen	_	_	I-Premise
191	group	_	_	I-Premise
192	;	_	_	I-Premise
193	the	_	_	B-Premise
194	between	_	_	I-Premise
195	-	_	_	I-Premise
196	group	_	_	I-Premise
197	difference	_	_	I-Premise
198	was	_	_	I-Premise
199	statistically	_	_	I-Premise
200	significant	_	_	I-Premise
201	(	_	_	I-Premise
202	P	_	_	I-Premise
203	<	_	_	I-Premise
204	0	_	_	I-Premise
205	.	_	_	I-Premise

206	01	_	_	I-Premise
207	)	_	_	I-Premise
208	.	_	_	I-Premise

209	The	_	_	B-Premise
210	FFM	_	_	I-Premise
211	/	_	_	I-Premise
212	FM	_	_	I-Premise
213	ratio	_	_	I-Premise
214	had	_	_	I-Premise
215	significantly	_	_	I-Premise
216	increased	_	_	I-Premise
217	in	_	_	I-Premise
218	the	_	_	I-Premise
219	exemestane	_	_	I-Premise
220	group	_	_	I-Premise
221	,	_	_	I-Premise
222	but	_	_	I-Premise
223	not	_	_	I-Premise
224	the	_	_	I-Premise
225	tamoxifen	_	_	I-Premise
226	group	_	_	I-Premise
227	;	_	_	I-Premise
228	the	_	_	B-Premise
229	between	_	_	I-Premise
230	-	_	_	I-Premise
231	group	_	_	I-Premise
232	difference	_	_	I-Premise
233	was	_	_	I-Premise
234	statistically	_	_	I-Premise
235	significant	_	_	I-Premise
236	(	_	_	I-Premise
237	P	_	_	I-Premise
238	<	_	_	I-Premise
239	0	_	_	I-Premise
240	.	_	_	I-Premise

241	05	_	_	I-Premise
242	)	_	_	I-Premise
243	.	_	_	I-Premise

244	Triglycerides	_	_	B-Premise
245	and	_	_	I-Premise
246	high	_	_	I-Premise
247	-	_	_	I-Premise
248	density	_	_	I-Premise
249	lipoprotein	_	_	I-Premise
250	cholesterol	_	_	I-Premise
251	significantly	_	_	I-Premise
252	decreased	_	_	I-Premise
253	(	_	_	I-Premise
254	P	_	_	I-Premise
255	<	_	_	I-Premise
256	0	_	_	I-Premise
257	.	_	_	I-Premise

258	01	_	_	I-Premise
259	;	_	_	I-Premise
260	P	_	_	I-Premise
261	<	_	_	I-Premise
262	0	_	_	I-Premise
263	.	_	_	I-Premise

264	05	_	_	I-Premise
265	)	_	_	I-Premise
266	,	_	_	I-Premise
267	and	_	_	O
268	low	_	_	B-Premise
269	-	_	_	I-Premise
270	density	_	_	I-Premise
271	lipoprotein	_	_	I-Premise
272	cholesterol	_	_	I-Premise
273	significantly	_	_	I-Premise
274	increased	_	_	I-Premise
275	(	_	_	I-Premise
276	P	_	_	I-Premise
277	<	_	_	I-Premise
278	0	_	_	I-Premise
279	.	_	_	I-Premise

280	01	_	_	I-Premise
281	)	_	_	I-Premise
282	in	_	_	I-Premise
283	the	_	_	I-Premise
284	exemestane	_	_	I-Premise
285	group	_	_	I-Premise
286	at	_	_	I-Premise
287	the	_	_	I-Premise
288	end	_	_	I-Premise
289	of	_	_	I-Premise
290	the	_	_	I-Premise
291	1	_	_	I-Premise
292	-	_	_	I-Premise
293	year	_	_	I-Premise
294	study	_	_	I-Premise
295	period	_	_	I-Premise
296	.	_	_	I-Premise

297	Our	_	_	B-Claim
298	findings	_	_	I-Claim
299	suggest	_	_	I-Claim
300	that	_	_	I-Claim
301	switching	_	_	I-Claim
302	patients	_	_	I-Claim
303	to	_	_	I-Claim
304	adjuvant	_	_	I-Claim
305	exemestane	_	_	I-Claim
306	treatment	_	_	I-Claim
307	after	_	_	I-Claim
308	at	_	_	I-Claim
309	least	_	_	I-Claim
310	2	_	_	I-Claim
311	years	_	_	I-Claim
312	of	_	_	I-Claim
313	tamoxifen	_	_	I-Claim
314	therapy	_	_	I-Claim
315	may	_	_	I-Claim
316	be	_	_	I-Claim
317	associated	_	_	I-Claim
318	with	_	_	I-Claim
319	an	_	_	I-Claim
320	advantage	_	_	I-Claim
321	over	_	_	I-Claim
322	continuing	_	_	I-Claim
323	adjuvant	_	_	I-Claim
324	tamoxifen	_	_	I-Claim
325	treatment	_	_	I-Claim
326	in	_	_	I-Claim
327	terms	_	_	I-Claim
328	of	_	_	I-Claim
329	body	_	_	I-Claim
330	composition	_	_	I-Claim
331	.	_	_	I-Claim


0	Imatinib	_	_	O
1	is	_	_	O
2	the	_	_	O
3	standard	_	_	O
4	treatment	_	_	O
5	of	_	_	O
6	advanced	_	_	O
7	GI	_	_	O
8	stromal	_	_	O
9	tumors	_	_	O
10	(	_	_	O
11	GISTs	_	_	O
12	)	_	_	O
13	.	_	_	O

14	It	_	_	B-Claim
15	is	_	_	I-Claim
16	not	_	_	I-Claim
17	known	_	_	I-Claim
18	whether	_	_	I-Claim
19	imatinib	_	_	I-Claim
20	may	_	_	I-Claim
21	be	_	_	I-Claim
22	stopped	_	_	I-Claim
23	in	_	_	I-Claim
24	patients	_	_	I-Claim
25	in	_	_	I-Claim
26	whom	_	_	I-Claim
27	disease	_	_	I-Claim
28	is	_	_	I-Claim
29	controlled	_	_	I-Claim
30	.	_	_	I-Claim

31	This	_	_	O
32	prospective	_	_	O
33	,	_	_	O
34	randomized	_	_	O
35	,	_	_	O
36	multicentric	_	_	O
37	phase	_	_	O
38	III	_	_	O
39	study	_	_	O
40	was	_	_	O
41	designed	_	_	O
42	to	_	_	O
43	compare	_	_	O
44	continuous	_	_	O
45	(	_	_	O
46	CONT	_	_	O
47	)	_	_	O
48	compared	_	_	O
49	with	_	_	O
50	interrupted	_	_	O
51	(	_	_	O
52	INT	_	_	O
53	)	_	_	O
54	imatinib	_	_	O
55	beyond	_	_	O
56	1	_	_	O
57	year	_	_	O
58	of	_	_	O
59	treatment	_	_	O
60	in	_	_	O
61	patients	_	_	O
62	with	_	_	O
63	advanced	_	_	O
64	GIST	_	_	O
65	.	_	_	O

66	The	_	_	O
67	primary	_	_	O
68	end	_	_	O
69	point	_	_	O
70	was	_	_	O
71	progression	_	_	O
72	-	_	_	O
73	free	_	_	O
74	survival	_	_	O
75	.	_	_	O

76	Secondary	_	_	O
77	end	_	_	O
78	points	_	_	O
79	included	_	_	O
80	overall	_	_	O
81	survival	_	_	O
82	,	_	_	O
83	response	_	_	O
84	rate	_	_	O
85	after	_	_	O
86	reinitiation	_	_	O
87	of	_	_	O
88	imatinib	_	_	O
89	,	_	_	O
90	and	_	_	O
91	quality	_	_	O
92	of	_	_	O
93	life	_	_	O
94	.	_	_	O

95	Early	_	_	O
96	stopping	_	_	O
97	rules	_	_	O
98	in	_	_	O
99	cases	_	_	O
100	of	_	_	O
101	rapid	_	_	O
102	progression	_	_	O
103	of	_	_	O
104	disease	_	_	O
105	were	_	_	O
106	defined	_	_	O
107	,	_	_	O
108	with	_	_	O
109	preplanned	_	_	O
110	interim	_	_	O
111	analyses	_	_	O
112	.	_	_	O

113	Between	_	_	O
114	May	_	_	O
115	2002	_	_	O
116	and	_	_	O
117	April	_	_	O
118	2004	_	_	O
119	,	_	_	O
120	182	_	_	O
121	patients	_	_	O
122	with	_	_	O
123	advanced	_	_	O
124	GIST	_	_	O
125	were	_	_	O
126	enrolled	_	_	O
127	.	_	_	O

128	Between	_	_	O
129	May	_	_	O
130	2003	_	_	O
131	and	_	_	O
132	April	_	_	O
133	2004	_	_	O
134	,	_	_	O
135	98	_	_	O
136	patients	_	_	O
137	in	_	_	O
138	response	_	_	O
139	or	_	_	O
140	stable	_	_	O
141	disease	_	_	O
142	under	_	_	O
143	imatinib	_	_	O
144	reached	_	_	O
145	more	_	_	O
146	than	_	_	O
147	1	_	_	O
148	year	_	_	O
149	of	_	_	O
150	follow	_	_	O
151	-	_	_	O
152	up	_	_	O
153	.	_	_	O

154	Forty	_	_	O
155	were	_	_	O
156	not	_	_	O
157	eligible	_	_	O
158	for	_	_	O
159	randomization	_	_	O
160	,	_	_	O
161	and	_	_	O
162	58	_	_	O
163	patients	_	_	O
164	were	_	_	O
165	randomly	_	_	O
166	assigned	_	_	O
167	,	_	_	O
168	32	_	_	O
169	and	_	_	O
170	26	_	_	O
171	patients	_	_	O
172	in	_	_	O
173	the	_	_	O
174	INT	_	_	O
175	and	_	_	O
176	CONT	_	_	O
177	arms	_	_	O
178	,	_	_	O
179	respectively	_	_	O
180	.	_	_	O

181	As	_	_	B-Premise
182	of	_	_	I-Premise
183	October	_	_	I-Premise
184	15	_	_	I-Premise
185	,	_	_	I-Premise
186	2005	_	_	I-Premise
187	,	_	_	I-Premise
188	eight	_	_	I-Premise
189	of	_	_	I-Premise
190	26	_	_	I-Premise
191	patients	_	_	I-Premise
192	in	_	_	I-Premise
193	the	_	_	I-Premise
194	CONT	_	_	I-Premise
195	group	_	_	I-Premise
196	and	_	_	I-Premise
197	26	_	_	I-Premise
198	of	_	_	I-Premise
199	32	_	_	I-Premise
200	patients	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	INT	_	_	I-Premise
204	group	_	_	I-Premise
205	had	_	_	I-Premise
206	documented	_	_	I-Premise
207	disease	_	_	I-Premise
208	progression	_	_	I-Premise
209	(	_	_	I-Premise
210	P	_	_	I-Premise
211	<	_	_	I-Premise
212	.	_	_	I-Premise

213	0001	_	_	I-Premise
214	)	_	_	I-Premise
215	.	_	_	I-Premise

216	Twenty	_	_	B-Premise
217	-	_	_	I-Premise
218	four	_	_	I-Premise
219	of	_	_	I-Premise
220	26	_	_	I-Premise
221	patients	_	_	I-Premise
222	with	_	_	I-Premise
223	documented	_	_	I-Premise
224	progression	_	_	I-Premise
225	in	_	_	I-Premise
226	the	_	_	I-Premise
227	INT	_	_	I-Premise
228	arm	_	_	I-Premise
229	responded	_	_	I-Premise
230	to	_	_	I-Premise
231	imatinib	_	_	I-Premise
232	reintroduction	_	_	I-Premise
233	.	_	_	I-Premise

234	No	_	_	B-Premise
235	differences	_	_	I-Premise
236	in	_	_	I-Premise
237	overall	_	_	I-Premise
238	survival	_	_	I-Premise
239	or	_	_	I-Premise
240	imatinib	_	_	I-Premise
241	resistance	_	_	I-Premise
242	were	_	_	I-Premise
243	observed	_	_	I-Premise
244	between	_	_	I-Premise
245	the	_	_	I-Premise
246	two	_	_	I-Premise
247	arms	_	_	I-Premise
248	.	_	_	I-Premise

249	Quality	_	_	B-Premise
250	of	_	_	I-Premise
251	life	_	_	I-Premise
252	evaluated	_	_	I-Premise
253	6	_	_	I-Premise
254	months	_	_	I-Premise
255	after	_	_	I-Premise
256	random	_	_	I-Premise
257	assignment	_	_	I-Premise
258	using	_	_	I-Premise
259	the	_	_	I-Premise
260	30	_	_	I-Premise
261	-	_	_	I-Premise
262	item	_	_	I-Premise
263	Quality	_	_	I-Premise
264	of	_	_	I-Premise
265	Life	_	_	I-Premise
266	Questionnaire	_	_	I-Premise
267	was	_	_	I-Premise
268	not	_	_	I-Premise
269	significantly	_	_	I-Premise
270	different	_	_	I-Premise
271	between	_	_	I-Premise
272	the	_	_	I-Premise
273	two	_	_	I-Premise
274	groups	_	_	I-Premise
275	of	_	_	I-Premise
276	randomly	_	_	I-Premise
277	assigned	_	_	I-Premise
278	patients	_	_	I-Premise
279	.	_	_	I-Premise

280	Imatinib	_	_	B-Claim
281	interruption	_	_	I-Claim
282	results	_	_	I-Claim
283	in	_	_	I-Claim
284	rapid	_	_	I-Claim
285	progression	_	_	I-Claim
286	in	_	_	I-Claim
287	most	_	_	I-Claim
288	patients	_	_	I-Claim
289	with	_	_	I-Claim
290	advanced	_	_	I-Claim
291	GIST	_	_	I-Claim
292	,	_	_	I-Claim
293	and	_	_	I-Claim
294	cannot	_	_	I-Claim
295	be	_	_	I-Claim
296	recommended	_	_	I-Claim
297	in	_	_	I-Claim
298	routine	_	_	I-Claim
299	practice	_	_	I-Claim
300	unless	_	_	I-Claim
301	patient	_	_	I-Claim
302	experience	_	_	I-Claim
303	significant	_	_	I-Claim
304	toxicity	_	_	I-Claim
305	.	_	_	I-Claim


0	Postoperative	_	_	B-Claim
1	adjuvant	_	_	I-Claim
2	chemoradiation	_	_	I-Claim
3	treatment	_	_	I-Claim
4	after	_	_	I-Claim
5	curative	_	_	I-Claim
6	resection	_	_	I-Claim
7	for	_	_	I-Claim
8	rectal	_	_	I-Claim
9	cancer	_	_	I-Claim
10	was	_	_	I-Claim
11	needed	_	_	I-Claim
12	to	_	_	I-Claim
13	reduce	_	_	I-Claim
14	recurrence	_	_	I-Claim
15	and	_	_	I-Claim
16	improve	_	_	I-Claim
17	a	_	_	I-Claim
18	survival	_	_	I-Claim
19	rate	_	_	I-Claim
20	.	_	_	I-Claim

21	Intravenous	_	_	B-Claim
22	5	_	_	I-Claim
23	-	_	_	I-Claim
24	fluorouracil	_	_	I-Claim
25	(	_	_	I-Claim
26	5	_	_	I-Claim
27	-	_	_	I-Claim
28	FU	_	_	I-Claim
29	)	_	_	I-Claim
30	and	_	_	I-Claim
31	leucovorin	_	_	I-Claim
32	has	_	_	I-Claim
33	been	_	_	I-Claim
34	a	_	_	I-Claim
35	mainstay	_	_	I-Claim
36	of	_	_	I-Claim
37	chemotherapy	_	_	I-Claim
38	,	_	_	I-Claim
39	but	_	_	O
40	oral	_	_	B-Claim
41	5	_	_	I-Claim
42	-	_	_	I-Claim
43	FU	_	_	I-Claim
44	derivatives	_	_	I-Claim
45	have	_	_	I-Claim
46	been	_	_	I-Claim
47	shown	_	_	I-Claim
48	a	_	_	I-Claim
49	comparable	_	_	I-Claim
50	antitumor	_	_	I-Claim
51	activity	_	_	I-Claim
52	.	_	_	I-Claim

53	Intravenous	_	_	O
54	5	_	_	O
55	-	_	_	O
56	FU	_	_	O
57	and	_	_	O
58	oral	_	_	O
59	doxifluridine	_	_	O
60	were	_	_	O
61	compared	_	_	O
62	with	_	_	O
63	respect	_	_	O
64	to	_	_	O
65	therapeutic	_	_	O
66	efficacy	_	_	O
67	,	_	_	O
68	drug	_	_	O
69	toxicity	_	_	O
70	,	_	_	O
71	and	_	_	O
72	quality	_	_	O
73	of	_	_	O
74	life	_	_	O
75	.	_	_	O

76	A	_	_	O
77	total	_	_	O
78	of	_	_	O
79	166	_	_	O
80	patients	_	_	O
81	were	_	_	O
82	randomized	_	_	O
83	to	_	_	O
84	receive	_	_	O
85	intravenous	_	_	O
86	5	_	_	O
87	-	_	_	O
88	FU	_	_	O
89	(	_	_	O
90	450	_	_	O
91	mg	_	_	O
92	/	_	_	O
93	m2	_	_	O
94	/	_	_	O
95	day	_	_	O
96	)	_	_	O
97	or	_	_	O
98	oral	_	_	O
99	doxifluridine	_	_	O
100	(	_	_	O
101	900	_	_	O
102	mg	_	_	O
103	/	_	_	O
104	m2	_	_	O
105	/	_	_	O
106	day	_	_	O
107	)	_	_	O
108	in	_	_	O
109	combination	_	_	O
110	with	_	_	O
111	leucovorin	_	_	O
112	(	_	_	O
113	20	_	_	O
114	mg	_	_	O
115	/	_	_	O
116	m2	_	_	O
117	/	_	_	O
118	day	_	_	O
119	)	_	_	O
120	for	_	_	O
121	depth	_	_	O
122	of	_	_	O
123	invasion	_	_	O
124	,	_	_	O
125	nodal	_	_	O
126	status	_	_	O
127	,	_	_	O
128	metastasis	_	_	O
129	(	_	_	O
130	TNM	_	_	O
131	)	_	_	O
132	stage	_	_	O
133	II	_	_	O
134	and	_	_	O
135	III	_	_	O
136	patients	_	_	O
137	between	_	_	O
138	October	_	_	O
139	1997	_	_	O
140	and	_	_	O
141	February	_	_	O
142	1999	_	_	O
143	.	_	_	O

144	Consecutive	_	_	O
145	daily	_	_	O
146	intravenous	_	_	O
147	infusion	_	_	O
148	for	_	_	O
149	5	_	_	O
150	days	_	_	O
151	per	_	_	O
152	every	_	_	O
153	month	_	_	O
154	for	_	_	O
155	a	_	_	O
156	total	_	_	O
157	of	_	_	O
158	12	_	_	O
159	cycles	_	_	O
160	(	_	_	O
161	IV	_	_	O
162	arm	_	_	O
163	,	_	_	O
164	n	_	_	O
165	=	_	_	O
166	74	_	_	O
167	)	_	_	O
168	and	_	_	O
169	oral	_	_	O
170	doxifluridine	_	_	O
171	daily	_	_	O
172	for	_	_	O
173	3	_	_	O
174	weeks	_	_	O
175	and	_	_	O
176	1	_	_	O
177	week	_	_	O
178	rest	_	_	O
179	for	_	_	O
180	a	_	_	O
181	total	_	_	O
182	of	_	_	O
183	12	_	_	O
184	cycles	_	_	O
185	(	_	_	O
186	oral	_	_	O
187	arm	_	_	O
188	,	_	_	O
189	n	_	_	O
190	=	_	_	O
191	92	_	_	O
192	)	_	_	O
193	.	_	_	O

194	Drug	_	_	O
195	toxicity	_	_	O
196	and	_	_	O
197	quality	_	_	O
198	of	_	_	O
199	life	_	_	O
200	were	_	_	O
201	observed	_	_	O
202	.	_	_	O

203	Quality	_	_	O
204	of	_	_	O
205	life	_	_	O
206	was	_	_	O
207	scored	_	_	O
208	according	_	_	O
209	to	_	_	O
210	22	_	_	O
211	daily	_	_	O
212	activity	_	_	O
213	items	_	_	O
214	(	_	_	O
215	good	_	_	O
216	,	_	_	O
217	>	_	_	O
218	or	_	_	O
219	=	_	_	O
220	71	_	_	O
221	;	_	_	O
222	fair	_	_	O
223	,	_	_	O
224	<	_	_	O
225	70	_	_	O
226	;	_	_	O
227	poor	_	_	O
228	,	_	_	O
229	<	_	_	O
230	52	_	_	O
231	)	_	_	O
232	.	_	_	O

233	There	_	_	O
234	was	_	_	O
235	no	_	_	O
236	difference	_	_	O
237	of	_	_	O
238	sex	_	_	O
239	between	_	_	O
240	two	_	_	O
241	groups	_	_	O
242	(	_	_	O
243	IV	_	_	O
244	arm	_	_	O
245	:	_	_	O
246	male	_	_	O
247	/	_	_	O
248	female	_	_	O
249	=	_	_	O
250	45	_	_	O
251	/	_	_	O
252	29	_	_	O
253	,	_	_	O
254	oral	_	_	O
255	arm	_	_	O
256	:	_	_	O
257	male	_	_	O
258	/	_	_	O
259	female	_	_	O
260	=	_	_	O
261	59	_	_	O
262	/	_	_	O
263	33	_	_	O
264	)	_	_	O
265	.	_	_	O

266	The	_	_	O
267	mean	_	_	O
268	age	_	_	O
269	was	_	_	O
270	52	_	_	O
271	.	_	_	O

272	3	_	_	O
273	vs	_	_	O
274	.	_	_	O

275	59	_	_	O
276	.	_	_	O

277	5	_	_	O
278	,	_	_	O
279	respectively	_	_	O
280	.	_	_	O

281	There	_	_	O
282	was	_	_	O
283	also	_	_	O
284	no	_	_	O
285	difference	_	_	O
286	of	_	_	O
287	TNM	_	_	O
288	stage	_	_	O
289	distribution	_	_	O
290	and	_	_	O
291	type	_	_	O
292	of	_	_	O
293	operation	_	_	O
294	between	_	_	O
295	groups	_	_	O
296	(	_	_	O
297	P	_	_	O
298	>	_	_	O
299	.	_	_	O

300	05	_	_	O
301	)	_	_	O
302	.	_	_	O

303	Mean	_	_	B-Premise
304	numbers	_	_	I-Premise
305	of	_	_	I-Premise
306	chemotherapy	_	_	I-Premise
307	cycles	_	_	I-Premise
308	were	_	_	I-Premise
309	6	_	_	I-Premise
310	.	_	_	I-Premise

311	5	_	_	I-Premise
312	+	_	_	I-Premise
313	/	_	_	I-Premise
314	-	_	_	I-Premise
315	3	_	_	I-Premise
316	.	_	_	I-Premise

317	7	_	_	I-Premise
318	(	_	_	I-Premise
319	IV	_	_	I-Premise
320	arm	_	_	I-Premise
321	)	_	_	I-Premise
322	vs	_	_	I-Premise
323	.	_	_	I-Premise

324	7	_	_	I-Premise
325	.	_	_	I-Premise

326	2	_	_	I-Premise
327	+	_	_	I-Premise
328	/	_	_	I-Premise
329	-	_	_	I-Premise
330	4	_	_	I-Premise
331	.	_	_	I-Premise

332	3	_	_	I-Premise
333	(	_	_	I-Premise
334	oral	_	_	I-Premise
335	arm	_	_	I-Premise
336	)	_	_	I-Premise
337	,	_	_	I-Premise
338	respectively	_	_	I-Premise
339	.	_	_	I-Premise

340	The	_	_	B-Premise
341	rate	_	_	I-Premise
342	of	_	_	I-Premise
343	recurrence	_	_	I-Premise
344	was	_	_	I-Premise
345	9	_	_	I-Premise
346	/	_	_	I-Premise
347	74	_	_	I-Premise
348	(	_	_	I-Premise
349	12	_	_	I-Premise
350	.	_	_	I-Premise

351	1	_	_	I-Premise
352	%	_	_	I-Premise
353	)	_	_	I-Premise
354	in	_	_	I-Premise
355	the	_	_	I-Premise
356	IV	_	_	I-Premise
357	arm	_	_	I-Premise
358	and	_	_	I-Premise
359	6	_	_	I-Premise
360	/	_	_	I-Premise
361	92	_	_	I-Premise
362	(	_	_	I-Premise
363	6	_	_	I-Premise
364	.	_	_	I-Premise

365	5	_	_	I-Premise
366	%	_	_	I-Premise
367	)	_	_	I-Premise
368	in	_	_	I-Premise
369	the	_	_	I-Premise
370	oral	_	_	I-Premise
371	arm	_	_	I-Premise
372	,	_	_	I-Premise
373	respectively	_	_	I-Premise
374	(	_	_	I-Premise
375	P	_	_	I-Premise
376	=	_	_	I-Premise
377	.	_	_	I-Premise

378	937	_	_	I-Premise
379	)	_	_	I-Premise
380	.	_	_	I-Premise

381	Local	_	_	B-Premise
382	recurrence	_	_	I-Premise
383	was	_	_	I-Premise
384	2	_	_	I-Premise
385	/	_	_	I-Premise
386	74	_	_	I-Premise
387	(	_	_	I-Premise
388	stage	_	_	I-Premise
389	III	_	_	I-Premise
390	;	_	_	I-Premise
391	2	_	_	I-Premise
392	.	_	_	I-Premise

393	7	_	_	I-Premise
394	%	_	_	I-Premise
395	)	_	_	I-Premise
396	in	_	_	I-Premise
397	the	_	_	I-Premise
398	IV	_	_	I-Premise
399	arm	_	_	I-Premise
400	and	_	_	I-Premise
401	1	_	_	I-Premise
402	/	_	_	I-Premise
403	92	_	_	I-Premise
404	(	_	_	I-Premise
405	stage	_	_	I-Premise
406	II	_	_	I-Premise
407	;	_	_	I-Premise
408	1	_	_	I-Premise
409	.	_	_	I-Premise

410	1	_	_	I-Premise
411	%	_	_	I-Premise
412	)	_	_	I-Premise
413	in	_	_	I-Premise
414	the	_	_	I-Premise
415	oral	_	_	I-Premise
416	arm	_	_	I-Premise
417	,	_	_	I-Premise
418	respectively	_	_	I-Premise
419	.	_	_	I-Premise

420	Systemic	_	_	B-Premise
421	recurrence	_	_	I-Premise
422	was	_	_	I-Premise
423	7	_	_	I-Premise
424	/	_	_	I-Premise
425	74	_	_	I-Premise
426	(	_	_	I-Premise
427	stage	_	_	I-Premise
428	III	_	_	I-Premise
429	;	_	_	I-Premise
430	9	_	_	I-Premise
431	.	_	_	I-Premise

432	4	_	_	I-Premise
433	%	_	_	I-Premise
434	)	_	_	I-Premise
435	in	_	_	I-Premise
436	the	_	_	I-Premise
437	IV	_	_	I-Premise
438	arm	_	_	I-Premise
439	and	_	_	I-Premise
440	5	_	_	I-Premise
441	/	_	_	I-Premise
442	92	_	_	I-Premise
443	(	_	_	I-Premise
444	stage	_	_	I-Premise
445	III	_	_	I-Premise
446	;	_	_	I-Premise
447	5	_	_	I-Premise
448	.	_	_	I-Premise

449	4	_	_	I-Premise
450	%	_	_	I-Premise
451	)	_	_	I-Premise
452	in	_	_	I-Premise
453	the	_	_	I-Premise
454	oral	_	_	I-Premise
455	arm	_	_	I-Premise
456	,	_	_	I-Premise
457	respectively	_	_	I-Premise
458	.	_	_	I-Premise

459	The	_	_	B-Premise
460	most	_	_	I-Premise
461	common	_	_	I-Premise
462	site	_	_	I-Premise
463	of	_	_	I-Premise
464	systemic	_	_	I-Premise
465	recurrence	_	_	I-Premise
466	was	_	_	I-Premise
467	the	_	_	I-Premise
468	liver	_	_	I-Premise
469	.	_	_	I-Premise

470	Toxicity	_	_	B-Premise
471	profile	_	_	I-Premise
472	was	_	_	I-Premise
473	as	_	_	I-Premise
474	follows	_	_	I-Premise
475	:	_	_	I-Premise
476	leukopenia	_	_	I-Premise
477	(	_	_	I-Premise
478	30	_	_	I-Premise
479	/	_	_	I-Premise
480	74	_	_	I-Premise
481	vs	_	_	I-Premise
482	.	_	_	I-Premise

483	17	_	_	I-Premise
484	/	_	_	I-Premise
485	92	_	_	I-Premise
486	)	_	_	I-Premise
487	and	_	_	I-Premise
488	alopecia	_	_	I-Premise
489	(	_	_	I-Premise
490	21	_	_	I-Premise
491	/	_	_	I-Premise
492	74	_	_	I-Premise
493	vs	_	_	I-Premise
494	.	_	_	I-Premise

495	13	_	_	I-Premise
496	/	_	_	I-Premise
497	92	_	_	I-Premise
498	)	_	_	I-Premise
499	were	_	_	I-Premise
500	statistically	_	_	I-Premise
501	more	_	_	I-Premise
502	common	_	_	I-Premise
503	in	_	_	I-Premise
504	the	_	_	I-Premise
505	IV	_	_	I-Premise
506	arm	_	_	I-Premise
507	.	_	_	I-Premise

508	Diarrhea	_	_	B-Premise
509	was	_	_	I-Premise
510	more	_	_	I-Premise
511	common	_	_	I-Premise
512	in	_	_	I-Premise
513	the	_	_	I-Premise
514	oral	_	_	I-Premise
515	arm	_	_	I-Premise
516	.	_	_	I-Premise

517	Poor	_	_	B-Premise
518	quality	_	_	I-Premise
519	of	_	_	I-Premise
520	life	_	_	I-Premise
521	score	_	_	I-Premise
522	between	_	_	I-Premise
523	two	_	_	I-Premise
524	groups	_	_	I-Premise
525	was	_	_	I-Premise
526	observed	_	_	I-Premise
527	at	_	_	I-Premise
528	1	_	_	I-Premise
529	month	_	_	I-Premise
530	(	_	_	I-Premise
531	23	_	_	I-Premise
532	.	_	_	I-Premise

533	9	_	_	I-Premise
534	%	_	_	I-Premise
535	vs	_	_	I-Premise
536	.	_	_	I-Premise

537	13	_	_	I-Premise
538	%	_	_	I-Premise
539	)	_	_	I-Premise
540	and	_	_	I-Premise
541	2	_	_	I-Premise
542	months	_	_	I-Premise
543	(	_	_	I-Premise
544	15	_	_	I-Premise
545	.	_	_	I-Premise

546	8	_	_	I-Premise
547	%	_	_	I-Premise
548	vs	_	_	I-Premise
549	.	_	_	I-Premise

550	3	_	_	I-Premise
551	.	_	_	I-Premise

552	7	_	_	I-Premise
553	%	_	_	I-Premise
554	)	_	_	I-Premise
555	after	_	_	I-Premise
556	chemotherapy	_	_	I-Premise
557	.	_	_	I-Premise

558	Good	_	_	B-Premise
559	quality	_	_	I-Premise
560	of	_	_	I-Premise
561	life	_	_	I-Premise
562	score	_	_	I-Premise
563	was	_	_	I-Premise
564	observed	_	_	I-Premise
565	at	_	_	I-Premise
566	1	_	_	I-Premise
567	month	_	_	I-Premise
568	(	_	_	I-Premise
569	19	_	_	I-Premise
570	.	_	_	I-Premise

571	5	_	_	I-Premise
572	%	_	_	I-Premise
573	vs	_	_	I-Premise
574	.	_	_	I-Premise

575	49	_	_	I-Premise
576	%	_	_	I-Premise
577	)	_	_	I-Premise
578	and	_	_	I-Premise
579	2	_	_	I-Premise
580	months	_	_	I-Premise
581	(	_	_	I-Premise
582	47	_	_	I-Premise
583	%	_	_	I-Premise
584	vs	_	_	I-Premise
585	.	_	_	I-Premise

586	72	_	_	I-Premise
587	%	_	_	I-Premise
588	)	_	_	I-Premise
589	,	_	_	I-Premise
590	respectively	_	_	I-Premise
591	(	_	_	I-Premise
592	P	_	_	I-Premise
593	<	_	_	I-Premise
594	.	_	_	I-Premise

595	05	_	_	I-Premise
596	)	_	_	I-Premise
597	.	_	_	I-Premise

598	Oral	_	_	B-Claim
599	doxifluridine	_	_	I-Claim
600	with	_	_	I-Claim
601	leucovorin	_	_	I-Claim
602	shows	_	_	I-Claim
603	a	_	_	I-Claim
604	comparable	_	_	I-Claim
605	therapeutic	_	_	I-Claim
606	efficacy	_	_	I-Claim
607	to	_	_	I-Claim
608	intravenous	_	_	I-Claim
609	5	_	_	I-Claim
610	-	_	_	I-Claim
611	FU	_	_	I-Claim
612	regimen	_	_	I-Claim
613	with	_	_	I-Claim
614	high	_	_	I-Claim
615	quality	_	_	I-Claim
616	of	_	_	I-Claim
617	life	_	_	I-Claim
618	as	_	_	I-Claim
619	postoperative	_	_	I-Claim
620	adjuvant	_	_	I-Claim
621	therapy	_	_	I-Claim
622	.	_	_	I-Claim

623	The	_	_	B-Claim
624	oral	_	_	I-Claim
625	regimen	_	_	I-Claim
626	also	_	_	I-Claim
627	can	_	_	I-Claim
628	be	_	_	I-Claim
629	safely	_	_	I-Claim
630	given	_	_	I-Claim
631	with	_	_	I-Claim
632	appropriate	_	_	I-Claim
633	toxicity	_	_	I-Claim
634	and	_	_	I-Claim
635	tolerability	_	_	I-Claim
636	.	_	_	I-Claim


0	Compared	_	_	O
1	with	_	_	O
2	placebo	_	_	O
3	,	_	_	O
4	prophylactic	_	_	O
5	treatment	_	_	O
6	with	_	_	O
7	bisphosphonates	_	_	O
8	reduces	_	_	O
9	risk	_	_	O
10	of	_	_	O
11	skeletal	_	_	O
12	events	_	_	O
13	in	_	_	O
14	patients	_	_	O
15	with	_	_	O
16	multiple	_	_	O
17	myeloma	_	_	O
18	.	_	_	O

19	However	_	_	O
20	,	_	_	O
21	because	_	_	O
22	of	_	_	O
23	toxicity	_	_	O
24	associated	_	_	O
25	with	_	_	O
26	long	_	_	O
27	-	_	_	O
28	term	_	_	O
29	bisphosphonate	_	_	O
30	treatment	_	_	O
31	,	_	_	O
32	establishing	_	_	O
33	the	_	_	O
34	lowest	_	_	O
35	effective	_	_	O
36	dose	_	_	O
37	is	_	_	O
38	important	_	_	O
39	.	_	_	O

40	This	_	_	O
41	study	_	_	O
42	compared	_	_	O
43	the	_	_	O
44	effect	_	_	O
45	of	_	_	O
46	two	_	_	O
47	doses	_	_	O
48	of	_	_	O
49	pamidronate	_	_	O
50	on	_	_	O
51	health	_	_	O
52	-	_	_	O
53	related	_	_	O
54	quality	_	_	O
55	of	_	_	O
56	life	_	_	O
57	and	_	_	O
58	skeletal	_	_	O
59	morbidity	_	_	O
60	in	_	_	O
61	patients	_	_	O
62	with	_	_	O
63	newly	_	_	O
64	diagnosed	_	_	O
65	multiple	_	_	O
66	myeloma	_	_	O
67	.	_	_	O

68	This	_	_	O
69	double	_	_	O
70	-	_	_	O
71	blind	_	_	O
72	,	_	_	O
73	randomised	_	_	O
74	,	_	_	O
75	phase	_	_	O
76	3	_	_	O
77	trial	_	_	O
78	was	_	_	O
79	undertaken	_	_	O
80	at	_	_	O
81	37	_	_	O
82	clinics	_	_	O
83	in	_	_	O
84	Denmark	_	_	O
85	,	_	_	O
86	Norway	_	_	O
87	,	_	_	O
88	and	_	_	O
89	Sweden	_	_	O
90	.	_	_	O

91	Patients	_	_	O
92	with	_	_	O
93	multiple	_	_	O
94	myeloma	_	_	O
95	who	_	_	O
96	were	_	_	O
97	starting	_	_	O
98	antimyeloma	_	_	O
99	treatment	_	_	O
100	were	_	_	O
101	randomly	_	_	O
102	assigned	_	_	O
103	in	_	_	O
104	a	_	_	O
105	1	_	_	O
106	:	_	_	O
107	1	_	_	O
108	ratio	_	_	O
109	to	_	_	O
110	receive	_	_	O
111	one	_	_	O
112	of	_	_	O
113	two	_	_	O
114	doses	_	_	O
115	of	_	_	O
116	pamidronate	_	_	O
117	(	_	_	O
118	30	_	_	O
119	mg	_	_	O
120	or	_	_	O
121	90	_	_	O
122	mg	_	_	O
123	)	_	_	O
124	given	_	_	O
125	by	_	_	O
126	intravenous	_	_	O
127	infusion	_	_	O
128	once	_	_	O
129	a	_	_	O
130	month	_	_	O
131	for	_	_	O
132	at	_	_	O
133	least	_	_	O
134	3	_	_	O
135	years	_	_	O
136	.	_	_	O

137	Randomisation	_	_	O
138	was	_	_	O
139	done	_	_	O
140	by	_	_	O
141	use	_	_	O
142	of	_	_	O
143	a	_	_	O
144	central	_	_	O
145	,	_	_	O
146	computerised	_	_	O
147	minimisation	_	_	O
148	system	_	_	O
149	.	_	_	O

150	Primary	_	_	O
151	outcome	_	_	O
152	was	_	_	O
153	physical	_	_	O
154	function	_	_	O
155	after	_	_	O
156	12	_	_	O
157	months	_	_	O
158	estimated	_	_	O
159	by	_	_	O
160	the	_	_	O
161	European	_	_	O
162	Organisation	_	_	O
163	for	_	_	O
164	Research	_	_	O
165	and	_	_	O
166	Treatment	_	_	O
167	of	_	_	O
168	Cancer	_	_	O
169	(	_	_	O
170	EORTC	_	_	O
171	)	_	_	O
172	QLQ	_	_	O
173	-	_	_	O
174	C30	_	_	O
175	questionnaire	_	_	O
176	(	_	_	O
177	scale	_	_	O
178	0	_	_	O
179	-	_	_	O
180	100	_	_	O
181	)	_	_	O
182	.	_	_	O

183	All	_	_	O
184	patients	_	_	O
185	who	_	_	O
186	returned	_	_	O
187	questionnaires	_	_	O
188	at	_	_	O
189	12	_	_	O
190	months	_	_	O
191	and	_	_	O
192	were	_	_	O
193	still	_	_	O
194	on	_	_	O
195	study	_	_	O
196	treatment	_	_	O
197	were	_	_	O
198	included	_	_	O
199	in	_	_	O
200	the	_	_	O
201	analysis	_	_	O
202	of	_	_	O
203	the	_	_	O
204	primary	_	_	O
205	endpoint	_	_	O
206	.	_	_	O

207	From	_	_	O
208	January	_	_	O
209	,	_	_	O
210	2001	_	_	O
211	,	_	_	O
212	until	_	_	O
213	August	_	_	O
214	,	_	_	O
215	2005	_	_	O
216	,	_	_	O
217	504	_	_	O
218	patients	_	_	O
219	were	_	_	O
220	randomly	_	_	O
221	assigned	_	_	O
222	to	_	_	O
223	pamidronate	_	_	O
224	30	_	_	O
225	mg	_	_	O
226	or	_	_	O
227	90	_	_	O
228	mg	_	_	O
229	(	_	_	O
230	252	_	_	O
231	in	_	_	O
232	each	_	_	O
233	group	_	_	O
234	)	_	_	O
235	.	_	_	O

236	157	_	_	O
237	patients	_	_	O
238	in	_	_	O
239	the	_	_	O
240	90	_	_	O
241	mg	_	_	O
242	group	_	_	O
243	and	_	_	O
244	156	_	_	O
245	in	_	_	O
246	the	_	_	O
247	30	_	_	O
248	mg	_	_	O
249	group	_	_	O
250	were	_	_	O
251	included	_	_	O
252	in	_	_	O
253	the	_	_	O
254	primary	_	_	O
255	analysis	_	_	O
256	.	_	_	O

257	Mean	_	_	B-Premise
258	physical	_	_	I-Premise
259	function	_	_	I-Premise
260	at	_	_	I-Premise
261	12	_	_	I-Premise
262	months	_	_	I-Premise
263	was	_	_	I-Premise
264	66	_	_	I-Premise
265	points	_	_	I-Premise
266	(	_	_	I-Premise
267	95	_	_	I-Premise
268	%	_	_	I-Premise
269	CI	_	_	I-Premise
270	62	_	_	I-Premise
271	·	_	_	I-Premise
272	9	_	_	I-Premise
273	-	_	_	I-Premise
274	70	_	_	I-Premise
275	·	_	_	I-Premise
276	0	_	_	I-Premise
277	)	_	_	I-Premise
278	in	_	_	I-Premise
279	the	_	_	I-Premise
280	90	_	_	I-Premise
281	mg	_	_	I-Premise
282	group	_	_	I-Premise
283	and	_	_	I-Premise
284	68	_	_	I-Premise
285	points	_	_	I-Premise
286	(	_	_	I-Premise
287	64	_	_	I-Premise
288	·	_	_	I-Premise
289	6	_	_	I-Premise
290	-	_	_	I-Premise
291	71	_	_	I-Premise
292	·	_	_	I-Premise
293	4	_	_	I-Premise
294	)	_	_	I-Premise
295	in	_	_	I-Premise
296	the	_	_	I-Premise
297	30	_	_	I-Premise
298	mg	_	_	I-Premise
299	group	_	_	I-Premise
300	(	_	_	I-Premise
301	95	_	_	I-Premise
302	%	_	_	I-Premise
303	CI	_	_	I-Premise
304	of	_	_	I-Premise
305	difference	_	_	I-Premise
306	-	_	_	I-Premise
307	6	_	_	I-Premise
308	·	_	_	I-Premise
309	6	_	_	I-Premise
310	to	_	_	I-Premise
311	3	_	_	I-Premise
312	·	_	_	I-Premise
313	3	_	_	I-Premise
314	;	_	_	I-Premise
315	p	_	_	I-Premise
316	=	_	_	I-Premise
317	0	_	_	I-Premise
318	·	_	_	I-Premise
319	52	_	_	I-Premise
320	)	_	_	I-Premise
321	.	_	_	I-Premise

322	Median	_	_	B-Premise
323	time	_	_	I-Premise
324	to	_	_	I-Premise
325	first	_	_	I-Premise
326	skeletal	_	_	I-Premise
327	-	_	_	I-Premise
328	related	_	_	I-Premise
329	event	_	_	I-Premise
330	in	_	_	I-Premise
331	patients	_	_	I-Premise
332	who	_	_	I-Premise
333	had	_	_	I-Premise
334	such	_	_	I-Premise
335	an	_	_	I-Premise
336	event	_	_	I-Premise
337	was	_	_	I-Premise
338	9	_	_	I-Premise
339	·	_	_	I-Premise
340	2	_	_	I-Premise
341	months	_	_	I-Premise
342	(	_	_	I-Premise
343	8	_	_	I-Premise
344	·	_	_	I-Premise
345	1	_	_	I-Premise
346	-	_	_	I-Premise
347	10	_	_	I-Premise
348	·	_	_	I-Premise
349	7	_	_	I-Premise
350	)	_	_	I-Premise
351	in	_	_	I-Premise
352	the	_	_	I-Premise
353	90	_	_	I-Premise
354	mg	_	_	I-Premise
355	group	_	_	I-Premise
356	and	_	_	I-Premise
357	10	_	_	I-Premise
358	·	_	_	I-Premise
359	2	_	_	I-Premise
360	months	_	_	I-Premise
361	(	_	_	I-Premise
362	7	_	_	I-Premise
363	·	_	_	I-Premise
364	3	_	_	I-Premise
365	-	_	_	I-Premise
366	14	_	_	I-Premise
367	·	_	_	I-Premise
368	0	_	_	I-Premise
369	)	_	_	I-Premise
370	in	_	_	I-Premise
371	the	_	_	I-Premise
372	30	_	_	I-Premise
373	mg	_	_	I-Premise
374	group	_	_	I-Premise
375	(	_	_	I-Premise
376	p	_	_	I-Premise
377	=	_	_	I-Premise
378	0	_	_	I-Premise
379	·	_	_	I-Premise
380	63	_	_	I-Premise
381	)	_	_	I-Premise
382	.	_	_	I-Premise

383	In	_	_	O
384	a	_	_	O
385	retrospective	_	_	O
386	analysis	_	_	O
387	,	_	_	O
388	eight	_	_	B-Premise
389	patients	_	_	I-Premise
390	in	_	_	I-Premise
391	the	_	_	I-Premise
392	pamidronate	_	_	I-Premise
393	90	_	_	I-Premise
394	mg	_	_	I-Premise
395	group	_	_	I-Premise
396	developed	_	_	I-Premise
397	osteonecrosis	_	_	I-Premise
398	of	_	_	I-Premise
399	the	_	_	I-Premise
400	jaw	_	_	I-Premise
401	compared	_	_	I-Premise
402	with	_	_	I-Premise
403	two	_	_	I-Premise
404	patients	_	_	I-Premise
405	in	_	_	I-Premise
406	the	_	_	I-Premise
407	30	_	_	I-Premise
408	mg	_	_	I-Premise
409	group	_	_	I-Premise
410	.	_	_	I-Premise

411	Monthly	_	_	B-Claim
412	infusion	_	_	I-Claim
413	of	_	_	I-Claim
414	pamidronate	_	_	I-Claim
415	30	_	_	I-Claim
416	mg	_	_	I-Claim
417	should	_	_	I-Claim
418	be	_	_	I-Claim
419	the	_	_	I-Claim
420	recommended	_	_	I-Claim
421	dose	_	_	I-Claim
422	for	_	_	I-Claim
423	prevention	_	_	I-Claim
424	of	_	_	I-Claim
425	bone	_	_	I-Claim
426	disease	_	_	I-Claim
427	in	_	_	I-Claim
428	patients	_	_	I-Claim
429	with	_	_	I-Claim
430	multiple	_	_	I-Claim
431	myeloma	_	_	I-Claim
432	.	_	_	I-Claim


0	A	_	_	O
1	multicenter	_	_	O
2	trial	_	_	O
3	was	_	_	O
4	conducted	_	_	O
5	to	_	_	O
6	determine	_	_	O
7	the	_	_	O
8	efficacy	_	_	O
9	and	_	_	O
10	toxicity	_	_	O
11	of	_	_	O
12	escalating	_	_	O
13	dosages	_	_	O
14	of	_	_	O
15	liposomal	_	_	O
16	tretinoin	_	_	O
17	(	_	_	O
18	all	_	_	O
19	-	_	_	O
20	trans	_	_	O
21	-	_	_	O
22	retinoic	_	_	O
23	acid	_	_	O
24	)	_	_	O
25	administered	_	_	O
26	once	_	_	O
27	or	_	_	O
28	three	_	_	O
29	times	_	_	O
30	weekly	_	_	O
31	in	_	_	O
32	patients	_	_	O
33	with	_	_	O
34	acquired	_	_	O
35	immunodeficiency	_	_	O
36	syndrome	_	_	O
37	(	_	_	O
38	AIDS	_	_	O
39	)	_	_	O
40	-	_	_	O
41	associated	_	_	O
42	Kaposi	_	_	O
43	sarcoma	_	_	O
44	.	_	_	O

45	Seventy	_	_	O
46	-	_	_	O
47	six	_	_	O
48	patients	_	_	O
49	with	_	_	O
50	acquired	_	_	O
51	immunodeficiency	_	_	O
52	syndrome	_	_	O
53	(	_	_	O
54	AIDS	_	_	O
55	)	_	_	O
56	-	_	_	O
57	associated	_	_	O
58	Kaposi	_	_	O
59	sarcoma	_	_	O
60	were	_	_	O
61	randomized	_	_	O
62	to	_	_	O
63	receive	_	_	O
64	the	_	_	O
65	study	_	_	O
66	drug	_	_	O
67	either	_	_	O
68	once	_	_	O
69	(	_	_	O
70	n	_	_	O
71	=	_	_	O
72	30	_	_	O
73	)	_	_	O
74	or	_	_	O
75	3	_	_	O
76	times	_	_	O
77	weekly	_	_	O
78	(	_	_	O
79	n	_	_	O
80	=	_	_	O
81	46	_	_	O
82	)	_	_	O
83	.	_	_	O

84	The	_	_	O
85	starting	_	_	O
86	dosage	_	_	O
87	was	_	_	O
88	60	_	_	O
89	mg	_	_	O
90	/	_	_	O
91	m	_	_	O
92	(	_	_	O
93	2	_	_	O
94	)	_	_	O
95	,	_	_	O
96	which	_	_	O
97	was	_	_	O
98	escalated	_	_	O
99	to	_	_	O
100	90	_	_	O
101	mg	_	_	O
102	/	_	_	O
103	m	_	_	O
104	(	_	_	O
105	2	_	_	O
106	)	_	_	O
107	and	_	_	O
108	then	_	_	O
109	120	_	_	O
110	mg	_	_	O
111	/	_	_	O
112	m	_	_	O
113	(	_	_	O
114	2	_	_	O
115	)	_	_	O
116	if	_	_	O
117	the	_	_	O
118	drug	_	_	O
119	was	_	_	O
120	well	_	_	O
121	tolerated	_	_	O
122	(	_	_	O
123	<	_	_	O
124	or	_	_	O
125	=	_	_	O
126	Grade	_	_	O
127	2	_	_	O
128	toxicities	_	_	O
129	[	_	_	O
130	according	_	_	O
131	to	_	_	O
132	the	_	_	O
133	Southwest	_	_	O
134	Oncology	_	_	O
135	Group	_	_	O
136	toxicity	_	_	O
137	scale	_	_	O
138	]	_	_	O
139	)	_	_	O
140	.	_	_	O

141	Four	_	_	O
142	weeks	_	_	O
143	of	_	_	O
144	therapy	_	_	O
145	constituted	_	_	O
146	1	_	_	O
147	cycle	_	_	O
148	;	_	_	O
149	patients	_	_	O
150	could	_	_	O
151	receive	_	_	O
152	up	_	_	O
153	to	_	_	O
154	8	_	_	O
155	cycles	_	_	O
156	and	_	_	O
157	those	_	_	O
158	who	_	_	O
159	completed	_	_	O
160	8	_	_	O
161	cycles	_	_	O
162	were	_	_	O
163	given	_	_	O
164	the	_	_	O
165	option	_	_	O
166	of	_	_	O
167	receiving	_	_	O
168	extended	_	_	O
169	therapy	_	_	O
170	.	_	_	O

171	Clinical	_	_	O
172	response	_	_	O
173	was	_	_	O
174	defined	_	_	O
175	as	_	_	O
176	complete	_	_	O
177	response	_	_	O
178	(	_	_	O
179	CR	_	_	O
180	)	_	_	O
181	,	_	_	O
182	partial	_	_	O
183	response	_	_	O
184	(	_	_	O
185	PR	_	_	O
186	)	_	_	O
187	,	_	_	O
188	or	_	_	O
189	stable	_	_	O
190	disease	_	_	O
191	(	_	_	O
192	SD	_	_	O
193	)	_	_	O
194	.	_	_	O

195	Efficacy	_	_	O
196	was	_	_	O
197	assessed	_	_	O
198	after	_	_	O
199	the	_	_	O
200	completion	_	_	O
201	of	_	_	O
202	3	_	_	O
203	treatment	_	_	O
204	cycles	_	_	O
205	;	_	_	O
206	28	_	_	O
207	.	_	_	O

208	9	_	_	O
209	%	_	_	O
210	of	_	_	O
211	patients	_	_	O
212	(	_	_	O
213	22	_	_	O
214	of	_	_	O
215	76	_	_	O
216	patients	_	_	O
217	)	_	_	O
218	responded	_	_	O
219	(	_	_	O
220	no	_	_	O
221	CRs	_	_	O
222	,	_	_	O
223	1	_	_	O
224	PR	_	_	O
225	,	_	_	O
226	and	_	_	O
227	21	_	_	O
228	SDs	_	_	O
229	)	_	_	O
230	.	_	_	O

231	Among	_	_	B-Premise
232	the	_	_	I-Premise
233	patients	_	_	I-Premise
234	receiving	_	_	I-Premise
235	treatment	_	_	I-Premise
236	3	_	_	I-Premise
237	times	_	_	I-Premise
238	weekly	_	_	I-Premise
239	,	_	_	I-Premise
240	16	_	_	I-Premise
241	of	_	_	I-Premise
242	49	_	_	I-Premise
243	patients	_	_	I-Premise
244	(	_	_	I-Premise
245	32	_	_	I-Premise
246	.	_	_	I-Premise

247	7	_	_	I-Premise
248	%	_	_	I-Premise
249	)	_	_	I-Premise
250	achieved	_	_	I-Premise
251	a	_	_	I-Premise
252	clinical	_	_	I-Premise
253	response	_	_	I-Premise
254	at	_	_	I-Premise
255	the	_	_	I-Premise
256	end	_	_	I-Premise
257	of	_	_	I-Premise
258	the	_	_	I-Premise
259	third	_	_	I-Premise
260	treatment	_	_	I-Premise
261	cycle	_	_	I-Premise
262	(	_	_	I-Premise
263	no	_	_	I-Premise
264	CRs	_	_	I-Premise
265	,	_	_	I-Premise
266	1	_	_	I-Premise
267	PR	_	_	I-Premise
268	,	_	_	I-Premise
269	and	_	_	I-Premise
270	15	_	_	I-Premise
271	SDs	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	Concomitant	_	_	B-Premise
275	or	_	_	I-Premise
276	prior	_	_	I-Premise
277	use	_	_	I-Premise
278	of	_	_	I-Premise
279	protease	_	_	I-Premise
280	inhibitors	_	_	I-Premise
281	did	_	_	I-Premise
282	not	_	_	I-Premise
283	appear	_	_	I-Premise
284	to	_	_	I-Premise
285	affect	_	_	I-Premise
286	the	_	_	I-Premise
287	patient	_	_	I-Premise
288	'	_	_	I-Premise
289	s	_	_	I-Premise
290	response	_	_	I-Premise
291	to	_	_	I-Premise
292	treatment	_	_	I-Premise
293	(	_	_	I-Premise
294	P	_	_	I-Premise
295	=	_	_	I-Premise
296	0	_	_	I-Premise
297	.	_	_	I-Premise

298	183	_	_	I-Premise
299	)	_	_	I-Premise
300	.	_	_	I-Premise

301	Liposomal	_	_	B-Premise
302	tretinoin	_	_	I-Premise
303	is	_	_	I-Premise
304	a	_	_	I-Premise
305	new	_	_	I-Premise
306	therapeutic	_	_	I-Premise
307	agent	_	_	I-Premise
308	that	_	_	I-Premise
309	has	_	_	I-Premise
310	been	_	_	I-Premise
311	reported	_	_	I-Premise
312	to	_	_	I-Premise
313	have	_	_	I-Premise
314	some	_	_	I-Premise
315	clinical	_	_	I-Premise
316	activity	_	_	I-Premise
317	in	_	_	I-Premise
318	patients	_	_	I-Premise
319	with	_	_	I-Premise
320	AIDS	_	_	I-Premise
321	-	_	_	I-Premise
322	associated	_	_	I-Premise
323	Kaposi	_	_	I-Premise
324	sarcoma	_	_	I-Premise
325	.	_	_	I-Premise

326	A	_	_	B-Claim
327	three	_	_	I-Claim
328	-	_	_	I-Claim
329	times	_	_	I-Claim
330	-	_	_	I-Claim
331	per	_	_	I-Claim
332	-	_	_	I-Claim
333	week	_	_	I-Claim
334	dosing	_	_	I-Claim
335	schedule	_	_	I-Claim
336	was	_	_	I-Claim
337	noted	_	_	I-Claim
338	to	_	_	I-Claim
339	be	_	_	I-Claim
340	more	_	_	I-Claim
341	effective	_	_	I-Claim
342	compared	_	_	I-Claim
343	with	_	_	I-Claim
344	a	_	_	I-Claim
345	once	_	_	I-Claim
346	-	_	_	I-Claim
347	a	_	_	I-Claim
348	-	_	_	I-Claim
349	week	_	_	I-Claim
350	schedule	_	_	I-Claim
351	without	_	_	I-Claim
352	any	_	_	I-Claim
353	significant	_	_	I-Claim
354	difference	_	_	I-Claim
355	in	_	_	I-Claim
356	toxicity	_	_	I-Claim
357	reported	_	_	I-Claim
358	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	effectiveness	_	_	O
4	of	_	_	O
5	mindfulness	_	_	O
6	-	_	_	O
7	based	_	_	O
8	stress	_	_	O
9	reduction	_	_	O
10	(	_	_	O
11	MBSR	_	_	O
12	)	_	_	O
13	for	_	_	O
14	mood	_	_	O
15	,	_	_	O
16	breast	_	_	O
17	-	_	_	O
18	and	_	_	O
19	endocrine	_	_	O
20	-	_	_	O
21	specific	_	_	O
22	quality	_	_	O
23	of	_	_	O
24	life	_	_	O
25	,	_	_	O
26	and	_	_	O
27	well	_	_	O
28	-	_	_	O
29	being	_	_	O
30	after	_	_	O
31	hospital	_	_	O
32	treatment	_	_	O
33	in	_	_	O
34	women	_	_	O
35	with	_	_	O
36	stage	_	_	O
37	0	_	_	O
38	to	_	_	O
39	III	_	_	O
40	breast	_	_	O
41	cancer	_	_	O
42	.	_	_	O

43	A	_	_	O
44	randomized	_	_	O
45	,	_	_	O
46	wait	_	_	O
47	-	_	_	O
48	listed	_	_	O
49	,	_	_	O
50	controlled	_	_	O
51	trial	_	_	O
52	was	_	_	O
53	carried	_	_	O
54	out	_	_	O
55	in	_	_	O
56	229	_	_	O
57	women	_	_	O
58	after	_	_	O
59	surgery	_	_	O
60	,	_	_	O
61	chemotherapy	_	_	O
62	,	_	_	O
63	and	_	_	O
64	radiotherapy	_	_	O
65	for	_	_	O
66	breast	_	_	O
67	cancer	_	_	O
68	.	_	_	O

69	Patients	_	_	O
70	were	_	_	O
71	randomly	_	_	O
72	assigned	_	_	O
73	to	_	_	O
74	the	_	_	O
75	8	_	_	O
76	-	_	_	O
77	week	_	_	O
78	MBSR	_	_	O
79	program	_	_	O
80	or	_	_	O
81	standard	_	_	O
82	care	_	_	O
83	.	_	_	O

84	Profile	_	_	O
85	of	_	_	O
86	Mood	_	_	O
87	States	_	_	O
88	(	_	_	O
89	POMS	_	_	O
90	;	_	_	O
91	primary	_	_	O
92	outcome	_	_	O
93	)	_	_	O
94	,	_	_	O
95	Functional	_	_	O
96	Assessment	_	_	O
97	of	_	_	O
98	Cancer	_	_	O
99	Therapy	_	_	O
100	-	_	_	O
101	Breast	_	_	O
102	(	_	_	O
103	FACT	_	_	O
104	-	_	_	O
105	B	_	_	O
106	)	_	_	O
107	,	_	_	O
108	Functional	_	_	O
109	Assessment	_	_	O
110	of	_	_	O
111	Cancer	_	_	O
112	Therapy	_	_	O
113	-	_	_	O
114	Endocrine	_	_	O
115	Symptoms	_	_	O
116	(	_	_	O
117	FACT	_	_	O
118	-	_	_	O
119	ES	_	_	O
120	)	_	_	O
121	scales	_	_	O
122	and	_	_	O
123	the	_	_	O
124	WHO	_	_	O
125	five	_	_	O
126	-	_	_	O
127	item	_	_	O
128	well	_	_	O
129	-	_	_	O
130	being	_	_	O
131	questionnaire	_	_	O
132	(	_	_	O
133	WHO	_	_	O
134	-	_	_	O
135	5	_	_	O
136	)	_	_	O
137	evaluated	_	_	O
138	mood	_	_	O
139	,	_	_	O
140	quality	_	_	O
141	of	_	_	O
142	life	_	_	O
143	,	_	_	O
144	and	_	_	O
145	well	_	_	O
146	-	_	_	O
147	being	_	_	O
148	at	_	_	O
149	weeks	_	_	O
150	0	_	_	O
151	,	_	_	O
152	8	_	_	O
153	,	_	_	O
154	and	_	_	O
155	12	_	_	O
156	.	_	_	O

157	For	_	_	O
158	each	_	_	O
159	outcome	_	_	O
160	measure	_	_	O
161	,	_	_	O
162	a	_	_	O
163	repeated	_	_	O
164	-	_	_	O
165	measures	_	_	O
166	analysis	_	_	O
167	of	_	_	O
168	variance	_	_	O
169	model	_	_	O
170	,	_	_	O
171	which	_	_	O
172	incorporated	_	_	O
173	week	_	_	O
174	0	_	_	O
175	measurements	_	_	O
176	as	_	_	O
177	a	_	_	O
178	covariate	_	_	O
179	,	_	_	O
180	was	_	_	O
181	used	_	_	O
182	to	_	_	O
183	compare	_	_	O
184	treatment	_	_	O
185	groups	_	_	O
186	at	_	_	O
187	8	_	_	O
188	and	_	_	O
189	12	_	_	O
190	weeks	_	_	O
191	.	_	_	O

192	There	_	_	B-Premise
193	were	_	_	I-Premise
194	statistically	_	_	I-Premise
195	significant	_	_	I-Premise
196	improvements	_	_	I-Premise
197	in	_	_	I-Premise
198	outcome	_	_	I-Premise
199	in	_	_	I-Premise
200	the	_	_	I-Premise
201	experimental	_	_	I-Premise
202	group	_	_	I-Premise
203	compared	_	_	I-Premise
204	with	_	_	I-Premise
205	control	_	_	I-Premise
206	group	_	_	I-Premise
207	at	_	_	I-Premise
208	both	_	_	I-Premise
209	8	_	_	I-Premise
210	and	_	_	I-Premise
211	12	_	_	I-Premise
212	weeks	_	_	I-Premise
213	(	_	_	I-Premise
214	except	_	_	I-Premise
215	as	_	_	I-Premise
216	indicated	_	_	I-Premise
217	)	_	_	I-Premise
218	for	_	_	I-Premise
219	POMS	_	_	I-Premise
220	total	_	_	I-Premise
221	mood	_	_	I-Premise
222	disturbance	_	_	I-Premise
223	(	_	_	I-Premise
224	and	_	_	I-Premise
225	its	_	_	I-Premise
226	subscales	_	_	I-Premise
227	of	_	_	I-Premise
228	anxiety	_	_	I-Premise
229	,	_	_	I-Premise
230	depression	_	_	I-Premise
231	[	_	_	I-Premise
232	8	_	_	I-Premise
233	weeks	_	_	I-Premise
234	only	_	_	I-Premise
235	]	_	_	I-Premise
236	,	_	_	I-Premise
237	anger	_	_	I-Premise
238	[	_	_	I-Premise
239	12	_	_	I-Premise
240	weeks	_	_	I-Premise
241	only	_	_	I-Premise
242	]	_	_	I-Premise
243	,	_	_	I-Premise
244	vigor	_	_	I-Premise
245	,	_	_	I-Premise
246	fatigue	_	_	I-Premise
247	,	_	_	I-Premise
248	and	_	_	I-Premise
249	confusion	_	_	I-Premise
250	[	_	_	I-Premise
251	8	_	_	I-Premise
252	weeks	_	_	I-Premise
253	only	_	_	I-Premise
254	]	_	_	I-Premise
255	)	_	_	I-Premise
256	,	_	_	I-Premise
257	FACT	_	_	I-Premise
258	-	_	_	I-Premise
259	B	_	_	I-Premise
260	,	_	_	I-Premise
261	FACT	_	_	I-Premise
262	-	_	_	I-Premise
263	ES	_	_	I-Premise
264	,	_	_	I-Premise
265	(	_	_	I-Premise
266	and	_	_	I-Premise
267	Functional	_	_	I-Premise
268	Assessment	_	_	I-Premise
269	of	_	_	I-Premise
270	Cancer	_	_	I-Premise
271	Therapy	_	_	I-Premise
272	subscales	_	_	I-Premise
273	of	_	_	I-Premise
274	physical	_	_	I-Premise
275	,	_	_	I-Premise
276	social	_	_	I-Premise
277	[	_	_	I-Premise
278	8	_	_	I-Premise
279	weeks	_	_	I-Premise
280	only	_	_	I-Premise
281	]	_	_	I-Premise
282	,	_	_	I-Premise
283	emotional	_	_	I-Premise
284	,	_	_	I-Premise
285	and	_	_	I-Premise
286	functional	_	_	I-Premise
287	well	_	_	I-Premise
288	-	_	_	I-Premise
289	being	_	_	I-Premise
290	)	_	_	I-Premise
291	,	_	_	I-Premise
292	and	_	_	I-Premise
293	WHO	_	_	I-Premise
294	-	_	_	I-Premise
295	5	_	_	I-Premise
296	.	_	_	I-Premise

297	MSBR	_	_	B-Premise
298	improved	_	_	I-Premise
299	mood	_	_	I-Premise
300	,	_	_	I-Premise
301	breast	_	_	I-Premise
302	-	_	_	I-Premise
303	and	_	_	I-Premise
304	endocrine	_	_	I-Premise
305	-	_	_	I-Premise
306	related	_	_	I-Premise
307	quality	_	_	I-Premise
308	of	_	_	I-Premise
309	life	_	_	I-Premise
310	,	_	_	I-Premise
311	and	_	_	I-Premise
312	well	_	_	I-Premise
313	-	_	_	I-Premise
314	being	_	_	I-Premise
315	more	_	_	I-Premise
316	effectively	_	_	I-Premise
317	than	_	_	I-Premise
318	standard	_	_	I-Premise
319	care	_	_	I-Premise
320	in	_	_	I-Premise
321	women	_	_	I-Premise
322	with	_	_	I-Premise
323	stage	_	_	I-Premise
324	0	_	_	I-Premise
325	to	_	_	I-Premise
326	III	_	_	I-Premise
327	breast	_	_	I-Premise
328	cancer	_	_	I-Premise
329	,	_	_	I-Premise
330	and	_	_	I-Premise
331	these	_	_	I-Premise
332	results	_	_	I-Premise
333	persisted	_	_	I-Premise
334	at	_	_	I-Premise
335	three	_	_	I-Premise
336	months	_	_	I-Premise
337	.	_	_	I-Premise

338	To	_	_	B-Claim
339	our	_	_	I-Claim
340	knowledge	_	_	I-Claim
341	,	_	_	I-Claim
342	this	_	_	I-Claim
343	study	_	_	I-Claim
344	provided	_	_	I-Claim
345	novel	_	_	I-Claim
346	evidence	_	_	I-Claim
347	that	_	_	I-Claim
348	MBSR	_	_	I-Claim
349	can	_	_	I-Claim
350	help	_	_	I-Claim
351	alleviate	_	_	I-Claim
352	long	_	_	I-Claim
353	-	_	_	I-Claim
354	term	_	_	I-Claim
355	emotional	_	_	I-Claim
356	and	_	_	I-Claim
357	physical	_	_	I-Claim
358	adverse	_	_	I-Claim
359	effects	_	_	I-Claim
360	of	_	_	I-Claim
361	medical	_	_	I-Claim
362	treatments	_	_	I-Claim
363	,	_	_	I-Claim
364	including	_	_	I-Claim
365	endocrine	_	_	I-Claim
366	treatments	_	_	I-Claim
367	.	_	_	I-Claim

368	MBSR	_	_	B-Claim
369	is	_	_	I-Claim
370	recommended	_	_	I-Claim
371	to	_	_	I-Claim
372	support	_	_	I-Claim
373	survivors	_	_	I-Claim
374	of	_	_	I-Claim
375	breast	_	_	I-Claim
376	cancer	_	_	I-Claim
377	.	_	_	I-Claim


0	In	_	_	B-Claim
1	vivo	_	_	I-Claim
2	data	_	_	I-Claim
3	have	_	_	I-Claim
4	shown	_	_	I-Claim
5	a	_	_	I-Claim
6	more	_	_	I-Claim
7	potent	_	_	I-Claim
8	antiangiogenic	_	_	I-Claim
9	effect	_	_	I-Claim
10	and	_	_	I-Claim
11	a	_	_	I-Claim
12	higher	_	_	I-Claim
13	antitumor	_	_	I-Claim
14	activity	_	_	I-Claim
15	of	_	_	I-Claim
16	low	_	_	I-Claim
17	-	_	_	I-Claim
18	dose	_	_	I-Claim
19	interferon	_	_	I-Claim
20	(	_	_	I-Claim
21	IFN	_	_	I-Claim
22	)	_	_	I-Claim
23	given	_	_	I-Claim
24	twice	_	_	I-Claim
25	daily	_	_	I-Claim
26	.	_	_	I-Claim

27	In	_	_	O
28	a	_	_	O
29	randomized	_	_	O
30	Phase	_	_	O
31	II	_	_	O
32	trial	_	_	O
33	,	_	_	O
34	the	_	_	O
35	authors	_	_	O
36	tested	_	_	O
37	the	_	_	O
38	hypothesis	_	_	O
39	that	_	_	O
40	twice	_	_	O
41	-	_	_	O
42	daily	_	_	O
43	low	_	_	O
44	-	_	_	O
45	dose	_	_	O
46	IFN	_	_	O
47	is	_	_	O
48	more	_	_	O
49	effective	_	_	O
50	than	_	_	O
51	daily	_	_	O
52	intermediate	_	_	O
53	-	_	_	O
54	dose	_	_	O
55	IFN	_	_	O
56	in	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	metastatic	_	_	O
60	renal	_	_	O
61	cell	_	_	O
62	cancer	_	_	O
63	(	_	_	O
64	MRCC	_	_	O
65	)	_	_	O
66	.	_	_	O

67	A	_	_	O
68	total	_	_	O
69	of	_	_	O
70	118	_	_	O
71	patients	_	_	O
72	(	_	_	O
73	59	_	_	O
74	per	_	_	O
75	arm	_	_	O
76	)	_	_	O
77	were	_	_	O
78	randomly	_	_	O
79	assigned	_	_	O
80	to	_	_	O
81	receive	_	_	O
82	IFN	_	_	O
83	at	_	_	O
84	a	_	_	O
85	dose	_	_	O
86	of	_	_	O
87	0	_	_	O
88	.	_	_	O

89	5	_	_	O
90	million	_	_	O
91	units	_	_	O
92	(	_	_	O
93	MU	_	_	O
94	)	_	_	O
95	given	_	_	O
96	subcutaneously	_	_	O
97	twice	_	_	O
98	daily	_	_	O
99	(	_	_	O
100	IFN1	_	_	O
101	)	_	_	O
102	or	_	_	O
103	IFN	_	_	O
104	at	_	_	O
105	a	_	_	O
106	dose	_	_	O
107	of	_	_	O
108	5	_	_	O
109	MU	_	_	O
110	given	_	_	O
111	subcutaneously	_	_	O
112	daily	_	_	O
113	(	_	_	O
114	IFN5	_	_	O
115	)	_	_	O
116	.	_	_	O

117	The	_	_	O
118	primary	_	_	O
119	endpoint	_	_	O
120	was	_	_	O
121	progression	_	_	O
122	-	_	_	O
123	free	_	_	O
124	survival	_	_	O
125	(	_	_	O
126	PFS	_	_	O
127	)	_	_	O
128	.	_	_	O

129	Secondary	_	_	O
130	endpoints	_	_	O
131	included	_	_	O
132	response	_	_	O
133	rate	_	_	O
134	(	_	_	O
135	RR	_	_	O
136	)	_	_	O
137	,	_	_	O
138	overall	_	_	O
139	survival	_	_	O
140	(	_	_	O
141	OS	_	_	O
142	)	_	_	O
143	,	_	_	O
144	toxicity	_	_	O
145	,	_	_	O
146	and	_	_	O
147	quality	_	_	O
148	of	_	_	O
149	life	_	_	O
150	(	_	_	O
151	QOL	_	_	O
152	)	_	_	O
153	.	_	_	O

154	There	_	_	B-Premise
155	were	_	_	I-Premise
156	no	_	_	I-Premise
157	significant	_	_	I-Premise
158	differences	_	_	I-Premise
159	in	_	_	I-Premise
160	either	_	_	I-Premise
161	PFS	_	_	I-Premise
162	or	_	_	I-Premise
163	OS	_	_	I-Premise
164	between	_	_	I-Premise
165	IFN1	_	_	I-Premise
166	and	_	_	I-Premise
167	IFN5	_	_	I-Premise
168	(	_	_	I-Premise
169	median	_	_	I-Premise
170	of	_	_	I-Premise
171	3	_	_	I-Premise
172	.	_	_	I-Premise

173	7	_	_	I-Premise
174	months	_	_	I-Premise
175	and	_	_	I-Premise
176	median	_	_	I-Premise
177	of	_	_	I-Premise
178	3	_	_	I-Premise
179	.	_	_	I-Premise

180	4	_	_	I-Premise
181	months	_	_	I-Premise
182	PFS	_	_	I-Premise
183	,	_	_	I-Premise
184	respectively	_	_	I-Premise
185	;	_	_	I-Premise
186	median	_	_	I-Premise
187	of	_	_	I-Premise
188	25	_	_	I-Premise
189	.	_	_	I-Premise

190	5	_	_	I-Premise
191	months	_	_	I-Premise
192	and	_	_	I-Premise
193	median	_	_	I-Premise
194	of	_	_	I-Premise
195	17	_	_	I-Premise
196	.	_	_	I-Premise

197	5	_	_	I-Premise
198	months	_	_	I-Premise
199	OS	_	_	I-Premise
200	,	_	_	I-Premise
201	respectively	_	_	I-Premise
202	)	_	_	I-Premise
203	.	_	_	I-Premise

204	The	_	_	B-Premise
205	RRs	_	_	I-Premise
206	were	_	_	I-Premise
207	identical	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	2	_	_	I-Premise
211	arms	_	_	I-Premise
212	(	_	_	I-Premise
213	6	_	_	I-Premise
214	.	_	_	I-Premise

215	7	_	_	I-Premise
216	%	_	_	I-Premise
217	;	_	_	I-Premise
218	95	_	_	I-Premise
219	%	_	_	I-Premise
220	confidence	_	_	I-Premise
221	interval	_	_	I-Premise
222	[	_	_	I-Premise
223	95	_	_	I-Premise
224	%	_	_	I-Premise
225	CI	_	_	I-Premise
226	]	_	_	I-Premise
227	,	_	_	I-Premise
228	1	_	_	I-Premise
229	.	_	_	I-Premise

230	8	_	_	I-Premise
231	-	_	_	I-Premise
232	16	_	_	I-Premise
233	.	_	_	I-Premise

234	5	_	_	I-Premise
235	%	_	_	I-Premise
236	)	_	_	I-Premise
237	.	_	_	I-Premise

238	Two	_	_	B-Premise
239	patients	_	_	I-Premise
240	,	_	_	I-Premise
241	1	_	_	I-Premise
242	in	_	_	I-Premise
243	each	_	_	I-Premise
244	arm	_	_	I-Premise
245	,	_	_	I-Premise
246	remained	_	_	I-Premise
247	in	_	_	I-Premise
248	complete	_	_	I-Premise
249	remission	_	_	I-Premise
250	at	_	_	I-Premise
251	the	_	_	I-Premise
252	time	_	_	I-Premise
253	of	_	_	I-Premise
254	last	_	_	I-Premise
255	follow	_	_	I-Premise
256	-	_	_	I-Premise
257	up	_	_	I-Premise
258	,	_	_	I-Premise
259	at	_	_	I-Premise
260	45	_	_	I-Premise
261	+	_	_	I-Premise
262	and	_	_	I-Premise
263	38	_	_	I-Premise
264	+	_	_	I-Premise
265	months	_	_	I-Premise
266	from	_	_	I-Premise
267	treatment	_	_	I-Premise
268	.	_	_	I-Premise

269	Thirty	_	_	B-Premise
270	-	_	_	I-Premise
271	two	_	_	I-Premise
272	patients	_	_	I-Premise
273	receiving	_	_	I-Premise
274	IFN5	_	_	I-Premise
275	and	_	_	I-Premise
276	19	_	_	I-Premise
277	patients	_	_	I-Premise
278	receiving	_	_	I-Premise
279	IFN1	_	_	I-Premise
280	experienced	_	_	I-Premise
281	Grade	_	_	I-Premise
282	3	_	_	I-Premise
283	or	_	_	I-Premise
284	higher	_	_	I-Premise
285	adverse	_	_	I-Premise
286	events	_	_	I-Premise
287	(	_	_	I-Premise
288	graded	_	_	I-Premise
289	using	_	_	I-Premise
290	the	_	_	I-Premise
291	National	_	_	I-Premise
292	Cancer	_	_	I-Premise
293	Institute	_	_	I-Premise
294	Common	_	_	I-Premise
295	Toxicity	_	_	I-Premise
296	Criteria	_	_	I-Premise
297	[	_	_	I-Premise
298	version	_	_	I-Premise
299	2	_	_	I-Premise
300	.	_	_	I-Premise

301	0	_	_	I-Premise
302	]	_	_	I-Premise
303	)	_	_	I-Premise
304	(	_	_	I-Premise
305	P	_	_	I-Premise
306	=	_	_	I-Premise
307	.	_	_	I-Premise

308	025	_	_	I-Premise
309	)	_	_	I-Premise
310	.	_	_	I-Premise

311	Eighteen	_	_	B-Premise
312	patients	_	_	I-Premise
313	receiving	_	_	I-Premise
314	IFN5	_	_	I-Premise
315	and	_	_	I-Premise
316	4	_	_	I-Premise
317	patients	_	_	I-Premise
318	receiving	_	_	I-Premise
319	IFN1	_	_	I-Premise
320	had	_	_	I-Premise
321	dose	_	_	I-Premise
322	reductions	_	_	I-Premise
323	(	_	_	I-Premise
324	P	_	_	I-Premise
325	=	_	_	I-Premise
326	.	_	_	I-Premise

327	002	_	_	I-Premise
328	)	_	_	I-Premise
329	.	_	_	I-Premise

330	There	_	_	B-Premise
331	was	_	_	I-Premise
332	a	_	_	I-Premise
333	significant	_	_	I-Premise
334	deterioration	_	_	I-Premise
335	in	_	_	I-Premise
336	QOL	_	_	I-Premise
337	and	_	_	I-Premise
338	an	_	_	I-Premise
339	increase	_	_	I-Premise
340	in	_	_	I-Premise
341	depression	_	_	I-Premise
342	associated	_	_	I-Premise
343	with	_	_	I-Premise
344	IFN5	_	_	I-Premise
345	but	_	_	I-Premise
346	no	_	_	I-Premise
347	change	_	_	I-Premise
348	was	_	_	I-Premise
349	noted	_	_	I-Premise
350	with	_	_	I-Premise
351	IFN1	_	_	I-Premise
352	.	_	_	I-Premise

353	Compared	_	_	B-Claim
354	with	_	_	I-Claim
355	IFN5	_	_	I-Claim
356	,	_	_	I-Claim
357	IFN1	_	_	I-Claim
358	is	_	_	I-Claim
359	neither	_	_	I-Claim
360	more	_	_	I-Claim
361	nor	_	_	I-Claim
362	less	_	_	I-Claim
363	effective	_	_	I-Claim
364	but	_	_	I-Claim
365	is	_	_	I-Claim
366	less	_	_	I-Claim
367	toxic	_	_	I-Claim
368	,	_	_	I-Claim
369	with	_	_	I-Claim
370	a	_	_	I-Claim
371	better	_	_	I-Claim
372	reported	_	_	I-Claim
373	QOL	_	_	I-Claim
374	.	_	_	I-Claim

375	These	_	_	B-Claim
376	results	_	_	I-Claim
377	may	_	_	I-Claim
378	have	_	_	I-Claim
379	implications	_	_	I-Claim
380	for	_	_	I-Claim
381	the	_	_	I-Claim
382	design	_	_	I-Claim
383	of	_	_	I-Claim
384	combination	_	_	I-Claim
385	regimens	_	_	I-Claim
386	incorporating	_	_	I-Claim
387	IFN	_	_	I-Claim
388	with	_	_	I-Claim
389	targeted	_	_	I-Claim
390	agents	_	_	I-Claim
391	.	_	_	I-Claim


0	Spiritual	_	_	O
1	well	_	_	O
2	-	_	_	O
3	being	_	_	O
4	and	_	_	O
5	sense	_	_	O
6	of	_	_	O
7	meaning	_	_	O
8	are	_	_	O
9	important	_	_	O
10	concerns	_	_	O
11	for	_	_	O
12	clinicians	_	_	O
13	who	_	_	O
14	care	_	_	O
15	for	_	_	O
16	patients	_	_	O
17	with	_	_	O
18	cancer	_	_	O
19	.	_	_	O

20	We	_	_	O
21	developed	_	_	O
22	Individual	_	_	O
23	Meaning	_	_	O
24	-	_	_	O
25	Centered	_	_	O
26	Psychotherapy	_	_	O
27	(	_	_	O
28	IMCP	_	_	O
29	)	_	_	O
30	to	_	_	O
31	address	_	_	O
32	the	_	_	O
33	need	_	_	O
34	for	_	_	O
35	brief	_	_	O
36	interventions	_	_	O
37	targeting	_	_	O
38	spiritual	_	_	O
39	well	_	_	O
40	-	_	_	O
41	being	_	_	O
42	and	_	_	O
43	meaning	_	_	O
44	for	_	_	O
45	patients	_	_	O
46	with	_	_	O
47	advanced	_	_	O
48	cancer	_	_	O
49	.	_	_	O

50	Patients	_	_	O
51	with	_	_	O
52	stage	_	_	O
53	III	_	_	O
54	or	_	_	O
55	IV	_	_	O
56	cancer	_	_	O
57	(	_	_	O
58	N	_	_	O
59	=	_	_	O
60	120	_	_	O
61	)	_	_	O
62	were	_	_	O
63	randomly	_	_	O
64	assigned	_	_	O
65	to	_	_	O
66	seven	_	_	O
67	sessions	_	_	O
68	of	_	_	O
69	either	_	_	O
70	IMCP	_	_	O
71	or	_	_	O
72	therapeutic	_	_	O
73	massage	_	_	O
74	(	_	_	O
75	TM	_	_	O
76	)	_	_	O
77	.	_	_	O

78	Patients	_	_	O
79	were	_	_	O
80	assessed	_	_	O
81	before	_	_	O
82	and	_	_	O
83	after	_	_	O
84	completing	_	_	O
85	the	_	_	O
86	intervention	_	_	O
87	and	_	_	O
88	2	_	_	O
89	months	_	_	O
90	postintervention	_	_	O
91	.	_	_	O

92	Primary	_	_	O
93	outcome	_	_	O
94	measures	_	_	O
95	assessed	_	_	O
96	spiritual	_	_	O
97	well	_	_	O
98	-	_	_	O
99	being	_	_	O
100	and	_	_	O
101	quality	_	_	O
102	of	_	_	O
103	life	_	_	O
104	;	_	_	O
105	secondary	_	_	O
106	outcomes	_	_	O
107	included	_	_	O
108	anxiety	_	_	O
109	,	_	_	O
110	depression	_	_	O
111	,	_	_	O
112	hopelessness	_	_	O
113	,	_	_	O
114	symptom	_	_	O
115	burden	_	_	O
116	,	_	_	O
117	and	_	_	O
118	symptom	_	_	O
119	-	_	_	O
120	related	_	_	O
121	distress	_	_	O
122	.	_	_	O

123	Of	_	_	O
124	the	_	_	O
125	120	_	_	O
126	participants	_	_	O
127	randomly	_	_	O
128	assigned	_	_	O
129	,	_	_	O
130	78	_	_	O
131	(	_	_	O
132	65	_	_	O
133	%	_	_	O
134	)	_	_	O
135	completed	_	_	O
136	the	_	_	O
137	post	_	_	O
138	-	_	_	O
139	treatment	_	_	O
140	assessment	_	_	O
141	and	_	_	O
142	67	_	_	O
143	(	_	_	O
144	56	_	_	O
145	%	_	_	O
146	)	_	_	O
147	completed	_	_	O
148	the	_	_	O
149	2	_	_	O
150	-	_	_	O
151	month	_	_	O
152	follow	_	_	O
153	-	_	_	O
154	up	_	_	O
155	.	_	_	O

156	At	_	_	B-Premise
157	the	_	_	I-Premise
158	post	_	_	I-Premise
159	-	_	_	I-Premise
160	treatment	_	_	I-Premise
161	assessment	_	_	I-Premise
162	,	_	_	I-Premise
163	IMCP	_	_	I-Premise
164	participants	_	_	I-Premise
165	demonstrated	_	_	I-Premise
166	significantly	_	_	I-Premise
167	greater	_	_	I-Premise
168	improvement	_	_	I-Premise
169	than	_	_	I-Premise
170	the	_	_	I-Premise
171	control	_	_	I-Premise
172	condition	_	_	I-Premise
173	for	_	_	I-Premise
174	the	_	_	I-Premise
175	primary	_	_	I-Premise
176	outcomes	_	_	I-Premise
177	of	_	_	I-Premise
178	spiritual	_	_	I-Premise
179	well	_	_	I-Premise
180	-	_	_	I-Premise
181	being	_	_	I-Premise
182	(	_	_	I-Premise
183	b	_	_	I-Premise
184	=	_	_	I-Premise
185	0	_	_	I-Premise
186	.	_	_	I-Premise

187	39	_	_	I-Premise
188	;	_	_	I-Premise
189	P	_	_	I-Premise
190	<	_	_	I-Premise
191	.	_	_	I-Premise

192	001	_	_	I-Premise
193	,	_	_	I-Premise
194	including	_	_	I-Premise
195	both	_	_	I-Premise
196	components	_	_	I-Premise
197	of	_	_	I-Premise
198	spiritual	_	_	I-Premise
199	well	_	_	I-Premise
200	-	_	_	I-Premise
201	being	_	_	I-Premise
202	(	_	_	I-Premise
203	sense	_	_	I-Premise
204	of	_	_	I-Premise
205	meaning	_	_	I-Premise
206	:	_	_	I-Premise
207	b	_	_	I-Premise
208	=	_	_	I-Premise
209	0	_	_	I-Premise
210	.	_	_	I-Premise

211	34	_	_	I-Premise
212	;	_	_	I-Premise
213	P	_	_	I-Premise
214	=	_	_	I-Premise
215	.	_	_	I-Premise

216	003	_	_	I-Premise
217	and	_	_	I-Premise
218	faith	_	_	I-Premise
219	:	_	_	I-Premise
220	b	_	_	I-Premise
221	=	_	_	I-Premise
222	0	_	_	I-Premise
223	.	_	_	I-Premise

224	42	_	_	I-Premise
225	;	_	_	I-Premise
226	P	_	_	I-Premise
227	=	_	_	I-Premise
228	.	_	_	I-Premise

229	03	_	_	I-Premise
230	)	_	_	I-Premise
231	,	_	_	I-Premise
232	and	_	_	I-Premise
233	quality	_	_	I-Premise
234	of	_	_	I-Premise
235	life	_	_	I-Premise
236	(	_	_	I-Premise
237	b	_	_	I-Premise
238	=	_	_	I-Premise
239	0	_	_	I-Premise
240	.	_	_	I-Premise

241	76	_	_	I-Premise
242	;	_	_	I-Premise
243	P	_	_	I-Premise
244	=	_	_	I-Premise
245	.	_	_	I-Premise

246	013	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	Significantly	_	_	B-Premise
250	greater	_	_	I-Premise
251	improvements	_	_	I-Premise
252	for	_	_	I-Premise
253	IMCP	_	_	I-Premise
254	patients	_	_	I-Premise
255	were	_	_	I-Premise
256	also	_	_	I-Premise
257	observed	_	_	I-Premise
258	for	_	_	I-Premise
259	the	_	_	I-Premise
260	secondary	_	_	I-Premise
261	outcomes	_	_	I-Premise
262	of	_	_	I-Premise
263	symptom	_	_	I-Premise
264	burden	_	_	I-Premise
265	(	_	_	I-Premise
266	b	_	_	I-Premise
267	=	_	_	I-Premise
268	-	_	_	I-Premise
269	6	_	_	I-Premise
270	.	_	_	I-Premise

271	56	_	_	I-Premise
272	;	_	_	I-Premise
273	P	_	_	I-Premise
274	<	_	_	I-Premise
275	.	_	_	I-Premise

276	001	_	_	I-Premise
277	)	_	_	I-Premise
278	and	_	_	I-Premise
279	symptom	_	_	I-Premise
280	-	_	_	I-Premise
281	related	_	_	I-Premise
282	distress	_	_	I-Premise
283	(	_	_	I-Premise
284	b	_	_	I-Premise
285	=	_	_	I-Premise
286	-	_	_	I-Premise
287	0	_	_	I-Premise
288	.	_	_	I-Premise

289	47	_	_	I-Premise
290	;	_	_	I-Premise
291	P	_	_	I-Premise
292	<	_	_	I-Premise
293	.	_	_	I-Premise

294	001	_	_	I-Premise
295	)	_	_	I-Premise
296	but	_	_	I-Premise
297	not	_	_	I-Premise
298	for	_	_	I-Premise
299	anxiety	_	_	I-Premise
300	,	_	_	I-Premise
301	depression	_	_	I-Premise
302	,	_	_	I-Premise
303	or	_	_	I-Premise
304	hopelessness	_	_	I-Premise
305	.	_	_	I-Premise

306	At	_	_	B-Premise
307	the	_	_	I-Premise
308	2	_	_	I-Premise
309	-	_	_	I-Premise
310	month	_	_	I-Premise
311	follow	_	_	I-Premise
312	-	_	_	I-Premise
313	up	_	_	I-Premise
314	assessment	_	_	I-Premise
315	,	_	_	I-Premise
316	the	_	_	I-Premise
317	improvements	_	_	I-Premise
318	observed	_	_	I-Premise
319	for	_	_	I-Premise
320	the	_	_	I-Premise
321	IMCP	_	_	I-Premise
322	group	_	_	I-Premise
323	were	_	_	I-Premise
324	no	_	_	I-Premise
325	longer	_	_	I-Premise
326	significantly	_	_	I-Premise
327	greater	_	_	I-Premise
328	than	_	_	I-Premise
329	those	_	_	I-Premise
330	observed	_	_	I-Premise
331	for	_	_	I-Premise
332	the	_	_	I-Premise
333	TM	_	_	I-Premise
334	group	_	_	I-Premise
335	.	_	_	I-Premise

336	IMCP	_	_	B-Claim
337	has	_	_	I-Claim
338	clear	_	_	I-Claim
339	short	_	_	I-Claim
340	-	_	_	I-Claim
341	term	_	_	I-Claim
342	benefits	_	_	I-Claim
343	for	_	_	I-Claim
344	spiritual	_	_	I-Claim
345	suffering	_	_	I-Claim
346	and	_	_	I-Claim
347	quality	_	_	I-Claim
348	of	_	_	I-Claim
349	life	_	_	I-Claim
350	in	_	_	I-Claim
351	patients	_	_	I-Claim
352	with	_	_	I-Claim
353	advanced	_	_	I-Claim
354	cancer	_	_	I-Claim
355	.	_	_	I-Claim

356	Clinicians	_	_	O
357	working	_	_	O
358	with	_	_	O
359	patients	_	_	O
360	who	_	_	O
361	have	_	_	O
362	advanced	_	_	O
363	cancer	_	_	O
364	should	_	_	O
365	consider	_	_	O
366	IMCP	_	_	O
367	as	_	_	O
368	an	_	_	O
369	approach	_	_	O
370	to	_	_	O
371	enhance	_	_	O
372	quality	_	_	O
373	of	_	_	O
374	life	_	_	O
375	and	_	_	O
376	spiritual	_	_	O
377	well	_	_	O
378	-	_	_	O
379	being	_	_	O
380	.	_	_	O


0	It	_	_	O
1	is	_	_	O
2	not	_	_	O
3	clear	_	_	O
4	whether	_	_	O
5	the	_	_	O
6	administration	_	_	O
7	of	_	_	O
8	radioiodine	_	_	O
9	provides	_	_	O
10	any	_	_	O
11	benefit	_	_	O
12	to	_	_	O
13	patients	_	_	O
14	with	_	_	O
15	low	_	_	O
16	-	_	_	O
17	risk	_	_	O
18	thyroid	_	_	O
19	cancer	_	_	O
20	after	_	_	O
21	a	_	_	O
22	complete	_	_	O
23	surgical	_	_	O
24	resection	_	_	O
25	.	_	_	O

26	The	_	_	O
27	administration	_	_	O
28	of	_	_	O
29	the	_	_	O
30	smallest	_	_	O
31	possible	_	_	O
32	amount	_	_	O
33	of	_	_	O
34	radioiodine	_	_	O
35	would	_	_	O
36	improve	_	_	O
37	care	_	_	O
38	.	_	_	O

39	In	_	_	O
40	our	_	_	O
41	randomized	_	_	O
42	,	_	_	O
43	phase	_	_	O
44	3	_	_	O
45	trial	_	_	O
46	,	_	_	O
47	we	_	_	O
48	compared	_	_	O
49	two	_	_	O
50	thyrotropin	_	_	O
51	-	_	_	O
52	stimulation	_	_	O
53	methods	_	_	O
54	(	_	_	O
55	thyroid	_	_	O
56	hormone	_	_	O
57	withdrawal	_	_	O
58	and	_	_	O
59	use	_	_	O
60	of	_	_	O
61	recombinant	_	_	O
62	human	_	_	O
63	thyrotropin	_	_	O
64	)	_	_	O
65	and	_	_	O
66	two	_	_	O
67	radioiodine	_	_	O
68	(	_	_	O
69	(	_	_	O
70	131	_	_	O
71	)	_	_	O
72	I	_	_	O
73	)	_	_	O
74	doses	_	_	O
75	(	_	_	O
76	i	_	_	O
77	.	_	_	O

78	e	_	_	O
79	.	_	_	O

80	,	_	_	O
81	administered	_	_	O
82	activities	_	_	O
83	)	_	_	O
84	(	_	_	O
85	1	_	_	O
86	.	_	_	O

87	1	_	_	O
88	GBq	_	_	O
89	and	_	_	O
90	3	_	_	O
91	.	_	_	O

92	7	_	_	O
93	GBq	_	_	O
94	)	_	_	O
95	in	_	_	O
96	a	_	_	O
97	2	_	_	O
98	-	_	_	O
99	by	_	_	O
100	-	_	_	O
101	2	_	_	O
102	design	_	_	O
103	.	_	_	O

104	Inclusion	_	_	O
105	criteria	_	_	O
106	were	_	_	O
107	an	_	_	O
108	age	_	_	O
109	of	_	_	O
110	18	_	_	O
111	years	_	_	O
112	or	_	_	O
113	older	_	_	O
114	;	_	_	O
115	total	_	_	O
116	thyroidectomy	_	_	O
117	for	_	_	O
118	differentiated	_	_	O
119	thyroid	_	_	O
120	carcinoma	_	_	O
121	;	_	_	O
122	tumor	_	_	O
123	-	_	_	O
124	node	_	_	O
125	-	_	_	O
126	metastasis	_	_	O
127	(	_	_	O
128	TNM	_	_	O
129	)	_	_	O
130	stage	_	_	O
131	,	_	_	O
132	ascertained	_	_	O
133	on	_	_	O
134	pathological	_	_	O
135	examination	_	_	O
136	(	_	_	O
137	p	_	_	O
138	)	_	_	O
139	of	_	_	O
140	a	_	_	O
141	surgical	_	_	O
142	specimen	_	_	O
143	,	_	_	O
144	of	_	_	O
145	pT1	_	_	O
146	(	_	_	O
147	with	_	_	O
148	tumor	_	_	O
149	diameter	_	_	O
150	≤	_	_	O
151	1	_	_	O
152	cm	_	_	O
153	)	_	_	O
154	and	_	_	O
155	N1	_	_	O
156	or	_	_	O
157	Nx	_	_	O
158	,	_	_	O
159	pT1	_	_	O
160	(	_	_	O
161	with	_	_	O
162	tumor	_	_	O
163	diameter	_	_	O
164	>	_	_	O
165	1	_	_	O
166	to	_	_	O
167	2	_	_	O
168	cm	_	_	O
169	)	_	_	O
170	and	_	_	O
171	any	_	_	O
172	N	_	_	O
173	stage	_	_	O
174	,	_	_	O
175	or	_	_	O
176	pT2N0	_	_	O
177	;	_	_	O
178	absence	_	_	O
179	of	_	_	O
180	distant	_	_	O
181	metastasis	_	_	O
182	;	_	_	O
183	and	_	_	O
184	no	_	_	O
185	iodine	_	_	O
186	contamination	_	_	O
187	.	_	_	O

188	Thyroid	_	_	O
189	ablation	_	_	O
190	was	_	_	O
191	assessed	_	_	O
192	8	_	_	O
193	months	_	_	O
194	after	_	_	O
195	radioiodine	_	_	O
196	administration	_	_	O
197	by	_	_	O
198	neck	_	_	O
199	ultrasonography	_	_	O
200	and	_	_	O
201	measurement	_	_	O
202	of	_	_	O
203	recombinant	_	_	O
204	human	_	_	O
205	thyrotropin	_	_	O
206	-	_	_	O
207	stimulated	_	_	O
208	thyroglobulin	_	_	O
209	.	_	_	O

210	Comparisons	_	_	O
211	were	_	_	O
212	based	_	_	O
213	on	_	_	O
214	an	_	_	O
215	equivalence	_	_	O
216	framework	_	_	O
217	.	_	_	O

218	There	_	_	O
219	were	_	_	O
220	752	_	_	O
221	patients	_	_	O
222	enrolled	_	_	O
223	between	_	_	O
224	2007	_	_	O
225	and	_	_	O
226	2010	_	_	O
227	;	_	_	O
228	92	_	_	O
229	%	_	_	O
230	had	_	_	O
231	papillary	_	_	O
232	cancer	_	_	O
233	.	_	_	O

234	There	_	_	B-Premise
235	were	_	_	I-Premise
236	no	_	_	I-Premise
237	unexpected	_	_	I-Premise
238	serious	_	_	I-Premise
239	adverse	_	_	I-Premise
240	events	_	_	I-Premise
241	.	_	_	I-Premise

242	In	_	_	B-Premise
243	the	_	_	I-Premise
244	684	_	_	I-Premise
245	patients	_	_	I-Premise
246	with	_	_	I-Premise
247	data	_	_	I-Premise
248	that	_	_	I-Premise
249	could	_	_	I-Premise
250	be	_	_	I-Premise
251	evaluated	_	_	I-Premise
252	,	_	_	I-Premise
253	ultrasonography	_	_	I-Premise
254	of	_	_	I-Premise
255	the	_	_	I-Premise
256	neck	_	_	I-Premise
257	was	_	_	I-Premise
258	normal	_	_	I-Premise
259	in	_	_	I-Premise
260	652	_	_	I-Premise
261	(	_	_	I-Premise
262	95	_	_	I-Premise
263	%	_	_	I-Premise
264	)	_	_	I-Premise
265	,	_	_	I-Premise
266	and	_	_	I-Premise
267	the	_	_	I-Premise
268	stimulated	_	_	I-Premise
269	thyroglobulin	_	_	I-Premise
270	level	_	_	I-Premise
271	was	_	_	I-Premise
272	1	_	_	I-Premise
273	.	_	_	I-Premise

274	0	_	_	I-Premise
275	ng	_	_	I-Premise
276	per	_	_	I-Premise
277	milliliter	_	_	I-Premise
278	or	_	_	I-Premise
279	less	_	_	I-Premise
280	in	_	_	I-Premise
281	621	_	_	I-Premise
282	of	_	_	I-Premise
283	the	_	_	I-Premise
284	652	_	_	I-Premise
285	patients	_	_	I-Premise
286	(	_	_	I-Premise
287	95	_	_	I-Premise
288	%	_	_	I-Premise
289	)	_	_	I-Premise
290	without	_	_	I-Premise
291	detectable	_	_	I-Premise
292	thyroglobulin	_	_	I-Premise
293	antibodies	_	_	I-Premise
294	.	_	_	I-Premise

295	Thyroid	_	_	B-Premise
296	ablation	_	_	I-Premise
297	was	_	_	I-Premise
298	complete	_	_	I-Premise
299	in	_	_	I-Premise
300	631	_	_	I-Premise
301	of	_	_	I-Premise
302	the	_	_	I-Premise
303	684	_	_	I-Premise
304	patients	_	_	I-Premise
305	(	_	_	I-Premise
306	92	_	_	I-Premise
307	%	_	_	I-Premise
308	)	_	_	I-Premise
309	.	_	_	I-Premise

310	The	_	_	B-Premise
311	ablation	_	_	I-Premise
312	rate	_	_	I-Premise
313	was	_	_	I-Premise
314	equivalent	_	_	I-Premise
315	between	_	_	I-Premise
316	the	_	_	I-Premise
317	(	_	_	I-Premise
318	131	_	_	I-Premise
319	)	_	_	I-Premise
320	I	_	_	I-Premise
321	doses	_	_	I-Premise
322	and	_	_	I-Premise
323	between	_	_	I-Premise
324	the	_	_	I-Premise
325	thyrotropin	_	_	I-Premise
326	-	_	_	I-Premise
327	stimulation	_	_	I-Premise
328	methods	_	_	I-Premise
329	.	_	_	I-Premise

330	The	_	_	B-Claim
331	use	_	_	I-Claim
332	of	_	_	I-Claim
333	recombinant	_	_	I-Claim
334	human	_	_	I-Claim
335	thyrotropin	_	_	I-Claim
336	and	_	_	I-Claim
337	low	_	_	I-Claim
338	-	_	_	I-Claim
339	dose	_	_	I-Claim
340	(	_	_	I-Claim
341	1	_	_	I-Claim
342	.	_	_	I-Claim

343	1	_	_	I-Claim
344	GBq	_	_	I-Claim
345	)	_	_	I-Claim
346	postoperative	_	_	I-Claim
347	radioiodine	_	_	I-Claim
348	ablation	_	_	I-Claim
349	may	_	_	I-Claim
350	be	_	_	I-Claim
351	sufficient	_	_	I-Claim
352	for	_	_	I-Claim
353	the	_	_	I-Claim
354	management	_	_	I-Claim
355	of	_	_	I-Claim
356	low	_	_	I-Claim
357	-	_	_	I-Claim
358	risk	_	_	I-Claim
359	thyroid	_	_	I-Claim
360	cancer	_	_	I-Claim
361	.	_	_	I-Claim


0	Insomnia	_	_	B-Claim
1	is	_	_	I-Claim
2	a	_	_	I-Claim
3	common	_	_	I-Claim
4	complaint	_	_	I-Claim
5	among	_	_	I-Claim
6	cancer	_	_	I-Claim
7	survivors	_	_	I-Claim
8	.	_	_	I-Claim

9	Fortunately	_	_	O
10	,	_	_	O
11	cognitive	_	_	O
12	-	_	_	O
13	behavioral	_	_	O
14	therapy	_	_	O
15	for	_	_	O
16	insomnia	_	_	O
17	(	_	_	O
18	CBT	_	_	O
19	-	_	_	O
20	I	_	_	O
21	)	_	_	O
22	has	_	_	O
23	been	_	_	O
24	shown	_	_	O
25	to	_	_	O
26	be	_	_	O
27	an	_	_	O
28	effective	_	_	O
29	treatment	_	_	O
30	in	_	_	O
31	this	_	_	O
32	population	_	_	O
33	.	_	_	O

34	However	_	_	O
35	,	_	_	O
36	it	_	_	O
37	is	_	_	O
38	rarely	_	_	O
39	implemented	_	_	O
40	given	_	_	O
41	its	_	_	O
42	limited	_	_	O
43	availability	_	_	O
44	.	_	_	O

45	To	_	_	O
46	address	_	_	O
47	this	_	_	O
48	barrier	_	_	O
49	,	_	_	O
50	we	_	_	O
51	examined	_	_	O
52	the	_	_	O
53	ability	_	_	O
54	of	_	_	O
55	an	_	_	O
56	easily	_	_	O
57	accessible	_	_	O
58	online	_	_	O
59	CBT	_	_	O
60	-	_	_	O
61	I	_	_	O
62	program	_	_	O
63	to	_	_	O
64	improve	_	_	O
65	insomnia	_	_	O
66	symptoms	_	_	O
67	in	_	_	O
68	cancer	_	_	O
69	survivors	_	_	O
70	.	_	_	O

71	Twenty	_	_	O
72	-	_	_	O
73	eight	_	_	O
74	cancer	_	_	O
75	survivors	_	_	O
76	with	_	_	O
77	insomnia	_	_	O
78	were	_	_	O
79	randomly	_	_	O
80	assigned	_	_	O
81	to	_	_	O
82	either	_	_	O
83	an	_	_	O
84	Internet	_	_	O
85	insomnia	_	_	O
86	intervention	_	_	O
87	(	_	_	O
88	n	_	_	O
89	=	_	_	O
90	14	_	_	O
91	)	_	_	O
92	or	_	_	O
93	to	_	_	O
94	a	_	_	O
95	waitlist	_	_	O
96	control	_	_	O
97	group	_	_	O
98	(	_	_	O
99	n	_	_	O
100	=	_	_	O
101	14	_	_	O
102	)	_	_	O
103	.	_	_	O

104	The	_	_	O
105	online	_	_	O
106	program	_	_	O
107	,	_	_	O
108	Sleep	_	_	O
109	Healthy	_	_	O
110	Using	_	_	O
111	The	_	_	O
112	Internet	_	_	O
113	,	_	_	O
114	delivers	_	_	O
115	the	_	_	O
116	primary	_	_	O
117	components	_	_	O
118	of	_	_	O
119	CBT	_	_	O
120	-	_	_	O
121	I	_	_	O
122	(	_	_	O
123	sleep	_	_	O
124	restriction	_	_	O
125	,	_	_	O
126	stimulus	_	_	O
127	control	_	_	O
128	,	_	_	O
129	cognitive	_	_	O
130	restructuring	_	_	O
131	,	_	_	O
132	sleep	_	_	O
133	hygiene	_	_	O
134	,	_	_	O
135	and	_	_	O
136	relapse	_	_	O
137	prevention	_	_	O
138	)	_	_	O
139	.	_	_	O

140	Pre	_	_	O
141	-	_	_	O
142	and	_	_	O
143	post	_	_	O
144	-	_	_	O
145	assessment	_	_	O
146	data	_	_	O
147	were	_	_	O
148	collected	_	_	O
149	via	_	_	O
150	online	_	_	O
151	questionnaires	_	_	O
152	and	_	_	O
153	daily	_	_	O
154	sleep	_	_	O
155	diaries	_	_	O
156	.	_	_	O

157	Participants	_	_	B-Premise
158	in	_	_	I-Premise
159	the	_	_	I-Premise
160	Internet	_	_	I-Premise
161	group	_	_	I-Premise
162	showed	_	_	I-Premise
163	significant	_	_	I-Premise
164	improvements	_	_	I-Premise
165	at	_	_	I-Premise
166	post	_	_	I-Premise
167	-	_	_	I-Premise
168	assessment	_	_	I-Premise
169	compared	_	_	I-Premise
170	with	_	_	I-Premise
171	those	_	_	I-Premise
172	in	_	_	I-Premise
173	the	_	_	I-Premise
174	control	_	_	I-Premise
175	group	_	_	I-Premise
176	in	_	_	I-Premise
177	overall	_	_	I-Premise
178	insomnia	_	_	I-Premise
179	severity	_	_	I-Premise
180	(	_	_	I-Premise
181	F	_	_	I-Premise
182	(	_	_	I-Premise
183	1	_	_	I-Premise
184	,	_	_	I-Premise
185	26	_	_	I-Premise
186	)	_	_	I-Premise
187	=	_	_	I-Premise
188	22	_	_	I-Premise
189	.	_	_	I-Premise

190	8	_	_	I-Premise
191	;	_	_	I-Premise
192	p	_	_	I-Premise
193	<	_	_	I-Premise
194	0	_	_	I-Premise
195	.	_	_	I-Premise

196	001	_	_	I-Premise
197	)	_	_	I-Premise
198	,	_	_	I-Premise
199	sleep	_	_	I-Premise
200	efficiency	_	_	I-Premise
201	(	_	_	I-Premise
202	F	_	_	I-Premise
203	(	_	_	I-Premise
204	1	_	_	I-Premise
205	,	_	_	I-Premise
206	24	_	_	I-Premise
207	)	_	_	I-Premise
208	=	_	_	I-Premise
209	11	_	_	I-Premise
210	.	_	_	I-Premise

211	45	_	_	I-Premise
212	;	_	_	I-Premise
213	P	_	_	I-Premise
214	=	_	_	I-Premise
215	0	_	_	I-Premise
216	.	_	_	I-Premise

217	002	_	_	I-Premise
218	)	_	_	I-Premise
219	,	_	_	I-Premise
220	sleep	_	_	I-Premise
221	onset	_	_	I-Premise
222	latency	_	_	I-Premise
223	(	_	_	I-Premise
224	F	_	_	I-Premise
225	(	_	_	I-Premise
226	1	_	_	I-Premise
227	,	_	_	I-Premise
228	24	_	_	I-Premise
229	)	_	_	I-Premise
230	=	_	_	I-Premise
231	5	_	_	I-Premise
232	.	_	_	I-Premise

233	18	_	_	I-Premise
234	;	_	_	I-Premise
235	P	_	_	I-Premise
236	=	_	_	I-Premise
237	0	_	_	I-Premise
238	.	_	_	I-Premise

239	03	_	_	I-Premise
240	)	_	_	I-Premise
241	,	_	_	I-Premise
242	soundness	_	_	I-Premise
243	of	_	_	I-Premise
244	sleep	_	_	I-Premise
245	(	_	_	I-Premise
246	F	_	_	I-Premise
247	(	_	_	I-Premise
248	1	_	_	I-Premise
249	,	_	_	I-Premise
250	24	_	_	I-Premise
251	)	_	_	I-Premise
252	=	_	_	I-Premise
253	9	_	_	I-Premise
254	.	_	_	I-Premise

255	34	_	_	I-Premise
256	;	_	_	I-Premise
257	P	_	_	I-Premise
258	=	_	_	I-Premise
259	0	_	_	I-Premise
260	.	_	_	I-Premise

261	005	_	_	I-Premise
262	)	_	_	I-Premise
263	,	_	_	I-Premise
264	restored	_	_	I-Premise
265	feeling	_	_	I-Premise
266	upon	_	_	I-Premise
267	awakening	_	_	I-Premise
268	(	_	_	I-Premise
269	F	_	_	I-Premise
270	(	_	_	I-Premise
271	1	_	_	I-Premise
272	,	_	_	I-Premise
273	24	_	_	I-Premise
274	)	_	_	I-Premise
275	=	_	_	I-Premise
276	11	_	_	I-Premise
277	.	_	_	I-Premise

278	95	_	_	I-Premise
279	;	_	_	I-Premise
280	P	_	_	I-Premise
281	=	_	_	I-Premise
282	0	_	_	I-Premise
283	.	_	_	I-Premise

284	002	_	_	I-Premise
285	)	_	_	I-Premise
286	,	_	_	I-Premise
287	and	_	_	I-Premise
288	general	_	_	I-Premise
289	fatigue	_	_	I-Premise
290	(	_	_	I-Premise
291	F	_	_	I-Premise
292	(	_	_	I-Premise
293	1	_	_	I-Premise
294	,	_	_	I-Premise
295	26	_	_	I-Premise
296	)	_	_	I-Premise
297	=	_	_	I-Premise
298	13	_	_	I-Premise
299	.	_	_	I-Premise

300	88	_	_	I-Premise
301	;	_	_	I-Premise
302	P	_	_	I-Premise
303	=	_	_	I-Premise
304	0	_	_	I-Premise
305	.	_	_	I-Premise

306	001	_	_	I-Premise
307	)	_	_	I-Premise
308	.	_	_	I-Premise

309	Although	_	_	B-Premise
310	other	_	_	I-Premise
311	group	_	_	I-Premise
312	×	_	_	I-Premise
313	time	_	_	I-Premise
314	interactions	_	_	I-Premise
315	were	_	_	I-Premise
316	not	_	_	I-Premise
317	significant	_	_	I-Premise
318	,	_	_	I-Premise
319	overall	_	_	I-Premise
320	adjusted	_	_	I-Premise
321	effect	_	_	I-Premise
322	sizes	_	_	I-Premise
323	for	_	_	I-Premise
324	all	_	_	I-Premise
325	sleep	_	_	I-Premise
326	variables	_	_	I-Premise
327	as	_	_	I-Premise
328	well	_	_	I-Premise
329	as	_	_	I-Premise
330	for	_	_	I-Premise
331	fatigue	_	_	I-Premise
332	,	_	_	I-Premise
333	depression	_	_	I-Premise
334	,	_	_	I-Premise
335	anxiety	_	_	I-Premise
336	,	_	_	I-Premise
337	and	_	_	I-Premise
338	quality	_	_	I-Premise
339	of	_	_	I-Premise
340	life	_	_	I-Premise
341	ranged	_	_	I-Premise
342	from	_	_	I-Premise
343	small	_	_	I-Premise
344	to	_	_	I-Premise
345	large	_	_	I-Premise
346	.	_	_	I-Premise

347	CBT	_	_	B-Claim
348	-	_	_	I-Claim
349	I	_	_	I-Claim
350	delivered	_	_	I-Claim
351	through	_	_	I-Claim
352	an	_	_	I-Claim
353	interactive	_	_	I-Claim
354	,	_	_	I-Claim
355	individually	_	_	I-Claim
356	tailored	_	_	I-Claim
357	Internet	_	_	I-Claim
358	intervention	_	_	I-Claim
359	may	_	_	I-Claim
360	be	_	_	I-Claim
361	a	_	_	I-Claim
362	viable	_	_	I-Claim
363	treatment	_	_	I-Claim
364	option	_	_	I-Claim
365	for	_	_	I-Claim
366	cancer	_	_	I-Claim
367	survivors	_	_	I-Claim
368	experiencing	_	_	I-Claim
369	insomnia	_	_	I-Claim
370	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	an	_	_	O
6	expressive	_	_	O
7	writing	_	_	O
8	(	_	_	O
9	EW	_	_	O
10	)	_	_	O
11	intervention	_	_	O
12	on	_	_	O
13	perceptions	_	_	O
14	of	_	_	O
15	emotional	_	_	O
16	support	_	_	O
17	in	_	_	O
18	women	_	_	O
19	completing	_	_	O
20	treatment	_	_	O
21	for	_	_	O
22	early	_	_	O
23	stage	_	_	O
24	breast	_	_	O
25	cancer	_	_	O
26	.	_	_	O

27	Women	_	_	O
28	were	_	_	O
29	recruited	_	_	O
30	to	_	_	O
31	the	_	_	O
32	study	_	_	O
33	during	_	_	O
34	their	_	_	O
35	final	_	_	O
36	week	_	_	O
37	of	_	_	O
38	treatment	_	_	O
39	.	_	_	O

40	Of	_	_	O
41	260	_	_	O
42	eligible	_	_	O
43	patients	_	_	O
44	,	_	_	O
45	104	_	_	O
46	(	_	_	O
47	40	_	_	O
48	%	_	_	O
49	)	_	_	O
50	agreed	_	_	O
51	to	_	_	O
52	participate	_	_	O
53	,	_	_	O
54	and	_	_	O
55	93	_	_	O
56	were	_	_	O
57	randomised	_	_	O
58	.	_	_	O

59	Women	_	_	O
60	in	_	_	O
61	the	_	_	O
62	writing	_	_	O
63	group	_	_	O
64	wrote	_	_	O
65	for	_	_	O
66	20	_	_	O
67	min	_	_	O
68	on	_	_	O
69	four	_	_	O
70	consecutive	_	_	O
71	days	_	_	O
72	.	_	_	O

73	The	_	_	O
74	control	_	_	O
75	group	_	_	O
76	received	_	_	O
77	normal	_	_	O
78	care	_	_	O
79	.	_	_	O

80	Women	_	_	O
81	'	_	_	O
82	s	_	_	O
83	perceptions	_	_	O
84	of	_	_	O
85	emotional	_	_	O
86	support	_	_	O
87	,	_	_	O
88	quality	_	_	O
89	of	_	_	O
90	life	_	_	O
91	(	_	_	O
92	QOL	_	_	O
93	)	_	_	O
94	,	_	_	O
95	mood	_	_	O
96	,	_	_	O
97	and	_	_	O
98	healthcare	_	_	O
99	utilisation	_	_	O
100	were	_	_	O
101	assessed	_	_	O
102	at	_	_	O
103	baseline	_	_	O
104	,	_	_	O
105	1	_	_	O
106	month	_	_	O
107	,	_	_	O
108	3	_	_	O
109	months	_	_	O
110	and	_	_	O
111	6	_	_	O
112	months	_	_	O
113	.	_	_	O

114	Interviews	_	_	O
115	were	_	_	O
116	conducted	_	_	O
117	to	_	_	O
118	explore	_	_	O
119	women	_	_	O
120	'	_	_	O
121	s	_	_	O
122	experience	_	_	O
123	of	_	_	O
124	writing	_	_	O
125	.	_	_	O

126	Eighty	_	_	O
127	participants	_	_	O
128	completed	_	_	O
129	all	_	_	O
130	follow	_	_	O
131	-	_	_	O
132	ups	_	_	O
133	.	_	_	O

134	There	_	_	B-Premise
135	was	_	_	I-Premise
136	a	_	_	I-Premise
137	significant	_	_	I-Premise
138	effect	_	_	I-Premise
139	of	_	_	I-Premise
140	group	_	_	I-Premise
141	on	_	_	I-Premise
142	women	_	_	I-Premise
143	'	_	_	I-Premise
144	s	_	_	I-Premise
145	perceptions	_	_	I-Premise
146	of	_	_	I-Premise
147	social	_	_	I-Premise
148	support	_	_	I-Premise
149	with	_	_	I-Premise
150	those	_	_	I-Premise
151	in	_	_	I-Premise
152	the	_	_	I-Premise
153	intervention	_	_	I-Premise
154	group	_	_	I-Premise
155	being	_	_	I-Premise
156	more	_	_	I-Premise
157	satisfied	_	_	I-Premise
158	with	_	_	I-Premise
159	the	_	_	I-Premise
160	emotional	_	_	I-Premise
161	support	_	_	I-Premise
162	they	_	_	I-Premise
163	received	_	_	I-Premise
164	(	_	_	I-Premise
165	p	_	_	I-Premise
166	<	_	_	I-Premise
167	0	_	_	I-Premise
168	.	_	_	I-Premise

169	05	_	_	I-Premise
170	)	_	_	I-Premise
171	.	_	_	I-Premise

172	Satisfaction	_	_	B-Premise
173	with	_	_	I-Premise
174	emotional	_	_	I-Premise
175	support	_	_	I-Premise
176	was	_	_	I-Premise
177	negatively	_	_	I-Premise
178	correlated	_	_	I-Premise
179	with	_	_	I-Premise
180	depression	_	_	I-Premise
181	/	_	_	I-Premise
182	dejection	_	_	I-Premise
183	(	_	_	I-Premise
184	p	_	_	I-Premise
185	<	_	_	I-Premise
186	0	_	_	I-Premise
187	.	_	_	I-Premise

188	05	_	_	I-Premise
189	)	_	_	I-Premise
190	and	_	_	I-Premise
191	anger	_	_	I-Premise
192	/	_	_	I-Premise
193	hostility	_	_	I-Premise
194	(	_	_	I-Premise
195	p	_	_	I-Premise
196	<	_	_	I-Premise
197	0	_	_	I-Premise
198	.	_	_	I-Premise

199	05	_	_	I-Premise
200	)	_	_	I-Premise
201	and	_	_	I-Premise
202	positively	_	_	I-Premise
203	correlated	_	_	I-Premise
204	with	_	_	I-Premise
205	social	_	_	I-Premise
206	and	_	_	I-Premise
207	family	_	_	I-Premise
208	well	_	_	I-Premise
209	-	_	_	I-Premise
210	being	_	_	I-Premise
211	(	_	_	I-Premise
212	p	_	_	I-Premise
213	<	_	_	I-Premise
214	0	_	_	I-Premise
215	.	_	_	I-Premise

216	001	_	_	I-Premise
217	)	_	_	I-Premise
218	6	_	_	I-Premise
219	months	_	_	I-Premise
220	post	_	_	I-Premise
221	intervention	_	_	I-Premise
222	.	_	_	I-Premise

223	There	_	_	B-Premise
224	were	_	_	I-Premise
225	no	_	_	I-Premise
226	significant	_	_	I-Premise
227	effects	_	_	I-Premise
228	of	_	_	I-Premise
229	the	_	_	I-Premise
230	intervention	_	_	I-Premise
231	on	_	_	I-Premise
232	mood	_	_	I-Premise
233	,	_	_	I-Premise
234	QOL	_	_	I-Premise
235	or	_	_	I-Premise
236	healthcare	_	_	I-Premise
237	utilisation	_	_	I-Premise
238	.	_	_	I-Premise

239	Most	_	_	B-Premise
240	participants	_	_	I-Premise
241	found	_	_	I-Premise
242	writing	_	_	I-Premise
243	valuable	_	_	I-Premise
244	and	_	_	I-Premise
245	did	_	_	I-Premise
246	not	_	_	I-Premise
247	report	_	_	I-Premise
248	any	_	_	I-Premise
249	long	_	_	I-Premise
250	-	_	_	I-Premise
251	term	_	_	I-Premise
252	negative	_	_	I-Premise
253	effects	_	_	I-Premise
254	.	_	_	I-Premise

255	EW	_	_	B-Claim
256	was	_	_	I-Claim
257	associated	_	_	I-Claim
258	with	_	_	I-Claim
259	a	_	_	I-Claim
260	higher	_	_	I-Claim
261	level	_	_	I-Claim
262	of	_	_	I-Claim
263	satisfaction	_	_	I-Claim
264	with	_	_	I-Claim
265	emotional	_	_	I-Claim
266	support	_	_	I-Claim
267	compared	_	_	I-Claim
268	with	_	_	I-Claim
269	controls	_	_	I-Claim
270	.	_	_	I-Claim

271	Given	_	_	O
272	the	_	_	O
273	existing	_	_	O
274	evidence	_	_	O
275	supporting	_	_	O
276	the	_	_	O
277	importance	_	_	O
278	of	_	_	O
279	social	_	_	O
280	support	_	_	O
281	in	_	_	O
282	adjustment	_	_	O
283	to	_	_	O
284	breast	_	_	O
285	cancer	_	_	O
286	,	_	_	O
287	it	_	_	B-Claim
288	seems	_	_	I-Claim
289	feasible	_	_	I-Claim
290	to	_	_	I-Claim
291	suggest	_	_	I-Claim
292	that	_	_	I-Claim
293	EW	_	_	I-Claim
294	may	_	_	I-Claim
295	be	_	_	I-Claim
296	a	_	_	I-Claim
297	cost	_	_	I-Claim
298	effective	_	_	I-Claim
299	accessible	_	_	I-Claim
300	treatment	_	_	I-Claim
301	that	_	_	I-Claim
302	could	_	_	I-Claim
303	be	_	_	I-Claim
304	incorporated	_	_	I-Claim
305	into	_	_	I-Claim
306	the	_	_	I-Claim
307	ongoing	_	_	I-Claim
308	care	_	_	I-Claim
309	of	_	_	I-Claim
310	women	_	_	I-Claim
311	.	_	_	I-Claim


0	Experimental	_	_	B-Claim
1	and	_	_	I-Claim
2	early	_	_	I-Claim
3	clinical	_	_	I-Claim
4	investigations	_	_	I-Claim
5	have	_	_	I-Claim
6	demonstrated	_	_	I-Claim
7	encouraging	_	_	I-Claim
8	results	_	_	I-Claim
9	for	_	_	I-Claim
10	estramustine	_	_	I-Claim
11	in	_	_	I-Claim
12	the	_	_	I-Claim
13	treatment	_	_	I-Claim
14	of	_	_	I-Claim
15	malignant	_	_	I-Claim
16	glioma	_	_	I-Claim
17	.	_	_	O

18	The	_	_	O
19	present	_	_	O
20	study	_	_	O
21	is	_	_	O
22	an	_	_	O
23	open	_	_	O
24	randomized	_	_	O
25	clinical	_	_	O
26	trial	_	_	O
27	comparing	_	_	O
28	estramustine	_	_	O
29	phosphate	_	_	O
30	(	_	_	O
31	Estracyt	_	_	O
32	)	_	_	O
33	in	_	_	O
34	addition	_	_	O
35	to	_	_	O
36	radiotherapy	_	_	O
37	with	_	_	O
38	radiotherapy	_	_	O
39	alone	_	_	O
40	as	_	_	O
41	first	_	_	O
42	line	_	_	O
43	treatment	_	_	O
44	of	_	_	O
45	astrocytoma	_	_	O
46	grade	_	_	O
47	III	_	_	O
48	and	_	_	O
49	IV	_	_	O
50	.	_	_	O

51	The	_	_	O
52	140	_	_	O
53	patients	_	_	O
54	included	_	_	O
55	were	_	_	O
56	in	_	_	O
57	a	_	_	O
58	good	_	_	O
59	clinical	_	_	O
60	condition	_	_	O
61	with	_	_	O
62	a	_	_	O
63	median	_	_	O
64	age	_	_	O
65	of	_	_	O
66	55	_	_	O
67	years	_	_	O
68	(	_	_	O
69	range	_	_	O
70	22	_	_	O
71	-	_	_	O
72	87	_	_	O
73	)	_	_	O
74	.	_	_	O

75	Estramustine	_	_	O
76	was	_	_	O
77	given	_	_	O
78	orally	_	_	O
79	,	_	_	O
80	280	_	_	O
81	mg	_	_	O
82	twice	_	_	O
83	daily	_	_	O
84	,	_	_	O
85	as	_	_	O
86	soon	_	_	O
87	as	_	_	O
88	the	_	_	O
89	diagnosis	_	_	O
90	was	_	_	O
91	established	_	_	O
92	,	_	_	O
93	during	_	_	O
94	and	_	_	O
95	after	_	_	O
96	the	_	_	O
97	radiotherapy	_	_	O
98	for	_	_	O
99	a	_	_	O
100	period	_	_	O
101	of	_	_	O
102	in	_	_	O
103	total	_	_	O
104	3	_	_	O
105	months	_	_	O
106	.	_	_	O

107	Radiotherapy	_	_	O
108	was	_	_	O
109	delivered	_	_	O
110	on	_	_	O
111	weekdays	_	_	O
112	2	_	_	O
113	Gy	_	_	O
114	daily	_	_	O
115	up	_	_	O
116	to	_	_	O
117	56	_	_	O
118	Gy	_	_	O
119	.	_	_	O

120	Eighteen	_	_	O
121	patients	_	_	O
122	were	_	_	O
123	excluded	_	_	O
124	due	_	_	O
125	to	_	_	O
126	misclassification	_	_	O
127	,	_	_	O
128	leaving	_	_	O
129	122	_	_	O
130	patients	_	_	O
131	eligible	_	_	O
132	for	_	_	O
133	evaluation	_	_	O
134	.	_	_	O

135	Overall	_	_	B-Premise
136	the	_	_	I-Premise
137	treatment	_	_	I-Premise
138	was	_	_	I-Premise
139	well	_	_	I-Premise
140	tolerated	_	_	I-Premise
141	.	_	_	O

142	Mild	_	_	B-Premise
143	or	_	_	I-Premise
144	moderate	_	_	I-Premise
145	nausea	_	_	I-Premise
146	was	_	_	I-Premise
147	the	_	_	I-Premise
148	most	_	_	I-Premise
149	common	_	_	I-Premise
150	side	_	_	I-Premise
151	effect	_	_	I-Premise
152	of	_	_	I-Premise
153	estramustine	_	_	I-Premise
154	.	_	_	I-Premise

155	The	_	_	O
156	minimum	_	_	O
157	follow	_	_	O
158	-	_	_	O
159	up	_	_	O
160	time	_	_	O
161	was	_	_	O
162	5	_	_	O
163	.	_	_	O

164	2	_	_	O
165	years	_	_	O
166	for	_	_	O
167	the	_	_	O
168	surviving	_	_	O
169	patients	_	_	O
170	.	_	_	O

171	For	_	_	B-Premise
172	astrocytoma	_	_	I-Premise
173	grade	_	_	I-Premise
174	III	_	_	I-Premise
175	the	_	_	I-Premise
176	median	_	_	I-Premise
177	survival	_	_	I-Premise
178	time	_	_	I-Premise
179	was	_	_	I-Premise
180	10	_	_	I-Premise
181	.	_	_	I-Premise

182	6	_	_	I-Premise
183	(	_	_	I-Premise
184	1	_	_	I-Premise
185	.	_	_	I-Premise

186	3	_	_	I-Premise
187	-	_	_	I-Premise
188	92	_	_	I-Premise
189	.	_	_	I-Premise

190	7	_	_	I-Premise
191	)	_	_	I-Premise
192	months	_	_	I-Premise
193	for	_	_	I-Premise
194	the	_	_	I-Premise
195	radiotherapy	_	_	I-Premise
196	only	_	_	I-Premise
197	group	_	_	I-Premise
198	and	_	_	I-Premise
199	17	_	_	I-Premise
200	.	_	_	I-Premise

201	3	_	_	I-Premise
202	(	_	_	I-Premise
203	0	_	_	I-Premise
204	.	_	_	I-Premise

205	4	_	_	I-Premise
206	-	_	_	I-Premise
207	96	_	_	I-Premise
208	.	_	_	I-Premise

209	9	_	_	I-Premise
210	+	_	_	I-Premise
211	)	_	_	I-Premise
212	months	_	_	I-Premise
213	for	_	_	I-Premise
214	the	_	_	I-Premise
215	estramustine	_	_	I-Premise
216	+	_	_	I-Premise
217	radiotherapy	_	_	I-Premise
218	group	_	_	I-Premise
219	.	_	_	I-Premise

220	In	_	_	B-Premise
221	grade	_	_	I-Premise
222	IV	_	_	I-Premise
223	the	_	_	I-Premise
224	corresponding	_	_	I-Premise
225	median	_	_	I-Premise
226	survival	_	_	I-Premise
227	time	_	_	I-Premise
228	was	_	_	I-Premise
229	12	_	_	I-Premise
230	.	_	_	I-Premise

231	3	_	_	I-Premise
232	(	_	_	I-Premise
233	2	_	_	I-Premise
234	.	_	_	I-Premise

235	1	_	_	I-Premise
236	-	_	_	I-Premise
237	89	_	_	I-Premise
238	.	_	_	I-Premise

239	2	_	_	I-Premise
240	)	_	_	I-Premise
241	and	_	_	I-Premise
242	10	_	_	I-Premise
243	.	_	_	I-Premise

244	3	_	_	I-Premise
245	(	_	_	I-Premise
246	0	_	_	I-Premise
247	.	_	_	I-Premise

248	3	_	_	I-Premise
249	-	_	_	I-Premise
250	91	_	_	I-Premise
251	.	_	_	I-Premise

252	7	_	_	I-Premise
253	+	_	_	I-Premise
254	)	_	_	I-Premise
255	months	_	_	I-Premise
256	,	_	_	I-Premise
257	respectively	_	_	I-Premise
258	.	_	_	I-Premise

259	Median	_	_	B-Premise
260	time	_	_	I-Premise
261	to	_	_	I-Premise
262	progress	_	_	I-Premise
263	for	_	_	I-Premise
264	radiotherapy	_	_	I-Premise
265	only	_	_	I-Premise
266	and	_	_	I-Premise
267	radiotherapy	_	_	I-Premise
268	and	_	_	I-Premise
269	estramustin	_	_	I-Premise
270	group	_	_	I-Premise
271	in	_	_	I-Premise
272	grade	_	_	I-Premise
273	III	_	_	I-Premise
274	tumours	_	_	I-Premise
275	was	_	_	I-Premise
276	6	_	_	I-Premise
277	.	_	_	I-Premise

278	5	_	_	I-Premise
279	and	_	_	I-Premise
280	10	_	_	I-Premise
281	.	_	_	I-Premise

282	1	_	_	I-Premise
283	months	_	_	I-Premise
284	,	_	_	I-Premise
285	respectively	_	_	I-Premise
286	.	_	_	I-Premise

287	In	_	_	B-Premise
288	grade	_	_	I-Premise
289	IV	_	_	I-Premise
290	tumours	_	_	I-Premise
291	the	_	_	I-Premise
292	corresponding	_	_	I-Premise
293	figures	_	_	I-Premise
294	were	_	_	I-Premise
295	5	_	_	I-Premise
296	.	_	_	I-Premise

297	1	_	_	I-Premise
298	and	_	_	I-Premise
299	3	_	_	I-Premise
300	.	_	_	I-Premise

301	3	_	_	I-Premise
302	months	_	_	I-Premise
303	,	_	_	I-Premise
304	respectively	_	_	I-Premise
305	.	_	_	I-Premise

306	Although	_	_	B-Premise
307	there	_	_	I-Premise
308	was	_	_	I-Premise
309	a	_	_	I-Premise
310	tendency	_	_	I-Premise
311	for	_	_	I-Premise
312	improved	_	_	I-Premise
313	survival	_	_	I-Premise
314	in	_	_	I-Premise
315	grade	_	_	I-Premise
316	III	_	_	I-Premise
317	,	_	_	I-Premise
318	no	_	_	I-Premise
319	statistical	_	_	I-Premise
320	significant	_	_	I-Premise
321	differences	_	_	I-Premise
322	were	_	_	I-Premise
323	found	_	_	I-Premise
324	between	_	_	I-Premise
325	the	_	_	I-Premise
326	treatment	_	_	I-Premise
327	groups	_	_	I-Premise
328	.	_	_	I-Premise

329	No	_	_	B-Premise
330	differences	_	_	I-Premise
331	between	_	_	I-Premise
332	the	_	_	I-Premise
333	two	_	_	I-Premise
334	treatment	_	_	I-Premise
335	groups	_	_	I-Premise
336	were	_	_	I-Premise
337	evident	_	_	I-Premise
338	with	_	_	I-Premise
339	respect	_	_	I-Premise
340	to	_	_	I-Premise
341	quality	_	_	I-Premise
342	of	_	_	I-Premise
343	life	_	_	I-Premise
344	according	_	_	I-Premise
345	to	_	_	I-Premise
346	the	_	_	I-Premise
347	EORTC	_	_	I-Premise
348	QLQ	_	_	I-Premise
349	-	_	_	I-Premise
350	protocol	_	_	I-Premise
351	.	_	_	I-Premise

352	In	_	_	B-Claim
353	conclusion	_	_	I-Claim
354	,	_	_	I-Claim
355	this	_	_	I-Claim
356	first	_	_	I-Claim
357	randomized	_	_	I-Claim
358	study	_	_	I-Claim
359	did	_	_	I-Claim
360	not	_	_	I-Claim
361	demonstrate	_	_	I-Claim
362	any	_	_	I-Claim
363	significant	_	_	I-Claim
364	improvement	_	_	I-Claim
365	of	_	_	I-Claim
366	using	_	_	I-Claim
367	estramustine	_	_	I-Claim
368	in	_	_	I-Claim
369	addition	_	_	I-Claim
370	to	_	_	I-Claim
371	conventional	_	_	I-Claim
372	radiotherapy	_	_	I-Claim
373	,	_	_	I-Claim
374	however	_	_	B-Claim
375	,	_	_	I-Claim
376	a	_	_	I-Claim
377	trend	_	_	I-Claim
378	for	_	_	I-Claim
379	a	_	_	I-Claim
380	positive	_	_	I-Claim
381	response	_	_	I-Claim
382	for	_	_	I-Claim
383	the	_	_	I-Claim
384	estramustine	_	_	I-Claim
385	group	_	_	I-Claim
386	was	_	_	I-Claim
387	found	_	_	I-Claim
388	in	_	_	I-Claim
389	patients	_	_	I-Claim
390	with	_	_	I-Claim
391	grade	_	_	I-Claim
392	III	_	_	I-Claim
393	glioma	_	_	I-Claim
394	.	_	_	I-Claim


0	Gefitinib	_	_	O
1	and	_	_	O
2	Pemetrexed	_	_	O
3	are	_	_	O
4	drugs	_	_	O
5	used	_	_	O
6	as	_	_	O
7	second	_	_	O
8	-	_	_	O
9	line	_	_	O
10	therapy	_	_	O
11	for	_	_	O
12	advanced	_	_	O
13	non	_	_	O
14	-	_	_	O
15	small	_	_	O
16	cell	_	_	O
17	lung	_	_	O
18	cancer	_	_	O
19	(	_	_	O
20	NSCLC	_	_	O
21	)	_	_	O
22	,	_	_	O
23	although	_	_	O
24	studies	_	_	O
25	comparing	_	_	O
26	the	_	_	O
27	two	_	_	O
28	drugs	_	_	O
29	are	_	_	O
30	limited	_	_	O
31	.	_	_	O

32	The	_	_	O
33	aim	_	_	O
34	of	_	_	O
35	this	_	_	O
36	study	_	_	O
37	is	_	_	O
38	to	_	_	O
39	explore	_	_	O
40	the	_	_	O
41	effects	_	_	O
42	,	_	_	O
43	safety	_	_	O
44	,	_	_	O
45	and	_	_	O
46	quality	_	_	O
47	of	_	_	O
48	life	_	_	O
49	(	_	_	O
50	QoL	_	_	O
51	)	_	_	O
52	of	_	_	O
53	Gefitinib	_	_	O
54	and	_	_	O
55	Pemetrexed	_	_	O
56	on	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	advanced	_	_	O
60	non	_	_	O
61	-	_	_	O
62	squamous	_	_	O
63	NSCLC	_	_	O
64	.	_	_	O

65	Forty	_	_	O
66	-	_	_	O
67	six	_	_	O
68	advanced	_	_	O
69	non	_	_	O
70	-	_	_	O
71	squamous	_	_	O
72	NSCLC	_	_	O
73	patients	_	_	O
74	who	_	_	O
75	failed	_	_	O
76	to	_	_	O
77	first	_	_	O
78	-	_	_	O
79	line	_	_	O
80	therapy	_	_	O
81	were	_	_	O
82	randomly	_	_	O
83	divided	_	_	O
84	into	_	_	O
85	two	_	_	O
86	groups	_	_	O
87	with	_	_	O
88	23	_	_	O
89	patients	_	_	O
90	each	_	_	O
91	,	_	_	O
92	one	_	_	O
93	using	_	_	O
94	oral	_	_	O
95	Gefitinib	_	_	O
96	(	_	_	O
97	Gefitinib	_	_	O
98	group	_	_	O
99	)	_	_	O
100	and	_	_	O
101	the	_	_	O
102	other	_	_	O
103	using	_	_	O
104	intravenous	_	_	O
105	injection	_	_	O
106	Pemetrexed	_	_	O
107	(	_	_	O
108	Pemetrexed	_	_	O
109	group	_	_	O
110	)	_	_	O
111	.	_	_	O

112	The	_	_	O
113	effects	_	_	O
114	,	_	_	O
115	safety	_	_	O
116	,	_	_	O
117	and	_	_	O
118	QoL	_	_	O
119	were	_	_	O
120	determined	_	_	O
121	and	_	_	O
122	analyzed	_	_	O
123	.	_	_	O

124	For	_	_	B-Premise
125	the	_	_	I-Premise
126	Pemetrexed	_	_	I-Premise
127	group	_	_	I-Premise
128	,	_	_	I-Premise
129	objective	_	_	I-Premise
130	response	_	_	I-Premise
131	rate	_	_	I-Premise
132	(	_	_	I-Premise
133	ORR	_	_	I-Premise
134	)	_	_	I-Premise
135	was	_	_	I-Premise
136	13	_	_	I-Premise
137	.	_	_	I-Premise

138	0	_	_	I-Premise
139	%	_	_	I-Premise
140	(	_	_	I-Premise
141	3	_	_	I-Premise
142	/	_	_	I-Premise
143	23	_	_	I-Premise
144	)	_	_	I-Premise
145	,	_	_	I-Premise
146	disease	_	_	I-Premise
147	control	_	_	I-Premise
148	rate	_	_	I-Premise
149	(	_	_	I-Premise
150	DCR	_	_	I-Premise
151	)	_	_	I-Premise
152	was	_	_	I-Premise
153	30	_	_	I-Premise
154	.	_	_	I-Premise

155	4	_	_	I-Premise
156	%	_	_	I-Premise
157	(	_	_	I-Premise
158	7	_	_	I-Premise
159	/	_	_	I-Premise
160	23	_	_	I-Premise
161	)	_	_	I-Premise
162	,	_	_	I-Premise
163	and	_	_	I-Premise
164	median	_	_	I-Premise
165	progression	_	_	I-Premise
166	-	_	_	I-Premise
167	free	_	_	I-Premise
168	survival	_	_	I-Premise
169	(	_	_	I-Premise
170	mPFS	_	_	I-Premise
171	)	_	_	I-Premise
172	was	_	_	I-Premise
173	3	_	_	I-Premise
174	.	_	_	I-Premise

175	1	_	_	I-Premise
176	months	_	_	I-Premise
177	.	_	_	I-Premise

178	In	_	_	B-Premise
179	the	_	_	I-Premise
180	Gefitinib	_	_	I-Premise
181	group	_	_	I-Premise
182	,	_	_	I-Premise
183	ORR	_	_	I-Premise
184	was	_	_	I-Premise
185	17	_	_	I-Premise
186	.	_	_	I-Premise

187	3	_	_	I-Premise
188	%	_	_	I-Premise
189	(	_	_	I-Premise
190	4	_	_	I-Premise
191	/	_	_	I-Premise
192	23	_	_	I-Premise
193	)	_	_	I-Premise
194	,	_	_	I-Premise
195	DCR	_	_	I-Premise
196	was	_	_	I-Premise
197	39	_	_	I-Premise
198	.	_	_	I-Premise

199	1	_	_	I-Premise
200	%	_	_	I-Premise
201	(	_	_	I-Premise
202	9	_	_	I-Premise
203	/	_	_	I-Premise
204	23	_	_	I-Premise
205	)	_	_	I-Premise
206	,	_	_	I-Premise
207	and	_	_	I-Premise
208	mPFS	_	_	I-Premise
209	was	_	_	I-Premise
210	4	_	_	I-Premise
211	.	_	_	I-Premise

212	4	_	_	I-Premise
213	months	_	_	I-Premise
214	.	_	_	I-Premise

215	Compared	_	_	B-Premise
216	with	_	_	I-Premise
217	the	_	_	I-Premise
218	Pemetrexed	_	_	I-Premise
219	group	_	_	I-Premise
220	,	_	_	I-Premise
221	the	_	_	I-Premise
222	ORR	_	_	I-Premise
223	,	_	_	I-Premise
224	DCR	_	_	I-Premise
225	,	_	_	I-Premise
226	and	_	_	I-Premise
227	mPFS	_	_	I-Premise
228	in	_	_	I-Premise
229	the	_	_	I-Premise
230	Gefitinib	_	_	I-Premise
231	group	_	_	I-Premise
232	exhibited	_	_	I-Premise
233	no	_	_	I-Premise
234	statistical	_	_	I-Premise
235	significance	_	_	I-Premise
236	(	_	_	I-Premise
237	P	_	_	I-Premise
238	>	_	_	I-Premise
239	0	_	_	I-Premise
240	.	_	_	I-Premise

241	05	_	_	I-Premise
242	)	_	_	I-Premise
243	.	_	_	I-Premise

244	Furthermore	_	_	O
245	,	_	_	O
246	the	_	_	B-Premise
247	most	_	_	I-Premise
248	common	_	_	I-Premise
249	toxicities	_	_	I-Premise
250	in	_	_	I-Premise
251	the	_	_	I-Premise
252	Pemetrexed	_	_	I-Premise
253	group	_	_	I-Premise
254	were	_	_	I-Premise
255	neutropenia	_	_	I-Premise
256	(	_	_	I-Premise
257	n	_	_	I-Premise
258	=	_	_	I-Premise
259	9	_	_	I-Premise
260	,	_	_	I-Premise
261	39	_	_	I-Premise
262	.	_	_	I-Premise

263	13	_	_	I-Premise
264	%	_	_	I-Premise
265	)	_	_	I-Premise
266	and	_	_	I-Premise
267	fatigue	_	_	I-Premise
268	(	_	_	I-Premise
269	n	_	_	I-Premise
270	=	_	_	I-Premise
271	8	_	_	I-Premise
272	,	_	_	I-Premise
273	34	_	_	I-Premise
274	.	_	_	I-Premise

275	78	_	_	I-Premise
276	%	_	_	I-Premise
277	)	_	_	I-Premise
278	,	_	_	I-Premise
279	whereas	_	_	I-Premise
280	those	_	_	I-Premise
281	in	_	_	I-Premise
282	the	_	_	I-Premise
283	in	_	_	I-Premise
284	Gefitinib	_	_	I-Premise
285	group	_	_	I-Premise
286	were	_	_	I-Premise
287	skin	_	_	I-Premise
288	rash	_	_	I-Premise
289	(	_	_	I-Premise
290	n	_	_	I-Premise
291	=	_	_	I-Premise
292	8	_	_	I-Premise
293	,	_	_	I-Premise
294	34	_	_	I-Premise
295	.	_	_	I-Premise

296	78	_	_	I-Premise
297	%	_	_	I-Premise
298	)	_	_	I-Premise
299	and	_	_	I-Premise
300	diarrhea	_	_	I-Premise
301	(	_	_	I-Premise
302	n	_	_	I-Premise
303	=	_	_	I-Premise
304	4	_	_	I-Premise
305	,	_	_	I-Premise
306	17	_	_	I-Premise
307	.	_	_	I-Premise

308	39	_	_	I-Premise
309	%	_	_	I-Premise
310	)	_	_	I-Premise
311	.	_	_	I-Premise

312	Compared	_	_	B-Premise
313	with	_	_	I-Premise
314	baseline	_	_	I-Premise
315	,	_	_	I-Premise
316	the	_	_	I-Premise
317	QoL	_	_	I-Premise
318	improved	_	_	I-Premise
319	in	_	_	I-Premise
320	both	_	_	I-Premise
321	groups	_	_	I-Premise
322	but	_	_	I-Premise
323	to	_	_	I-Premise
324	different	_	_	I-Premise
325	degrees	_	_	I-Premise
326	.	_	_	I-Premise

327	Likewise	_	_	O
328	,	_	_	O
329	emotional	_	_	B-Premise
330	,	_	_	I-Premise
331	functional	_	_	I-Premise
332	well	_	_	I-Premise
333	-	_	_	I-Premise
334	being	_	_	I-Premise
335	,	_	_	I-Premise
336	and	_	_	I-Premise
337	QoL	_	_	I-Premise
338	aspects	_	_	I-Premise
339	specifically	_	_	I-Premise
340	related	_	_	I-Premise
341	to	_	_	I-Premise
342	lung	_	_	I-Premise
343	cancer	_	_	I-Premise
344	were	_	_	I-Premise
345	better	_	_	I-Premise
346	improved	_	_	I-Premise
347	in	_	_	I-Premise
348	the	_	_	I-Premise
349	Gefitinib	_	_	I-Premise
350	group	_	_	I-Premise
351	than	_	_	I-Premise
352	in	_	_	I-Premise
353	the	_	_	I-Premise
354	Pemetrexed	_	_	I-Premise
355	group	_	_	I-Premise
356	(	_	_	I-Premise
357	P	_	_	I-Premise
358	<	_	_	I-Premise
359	0	_	_	I-Premise
360	.	_	_	I-Premise

361	05	_	_	I-Premise
362	)	_	_	I-Premise
363	.	_	_	I-Premise

364	The	_	_	B-Claim
365	effects	_	_	I-Claim
366	of	_	_	I-Claim
367	Pemetrexed	_	_	I-Claim
368	and	_	_	I-Claim
369	Gefitinib	_	_	I-Claim
370	as	_	_	I-Claim
371	second	_	_	I-Claim
372	line	_	_	I-Claim
373	therapy	_	_	I-Claim
374	were	_	_	I-Claim
375	similar	_	_	I-Claim
376	,	_	_	I-Claim
377	although	_	_	B-Premise
378	with	_	_	I-Premise
379	different	_	_	I-Premise
380	AEs	_	_	I-Premise
381	.	_	_	I-Premise

382	Both	_	_	B-Claim
383	drugs	_	_	I-Claim
384	could	_	_	I-Claim
385	improve	_	_	I-Claim
386	the	_	_	I-Claim
387	QoL	_	_	I-Claim
388	,	_	_	I-Claim
389	but	_	_	O
390	Gefitinib	_	_	B-Claim
391	showed	_	_	I-Claim
392	better	_	_	I-Claim
393	overall	_	_	I-Claim
394	results	_	_	I-Claim
395	than	_	_	I-Claim
396	Pemetrexed	_	_	I-Claim
397	.	_	_	I-Claim


0	This	_	_	O
1	phase	_	_	O
2	III	_	_	O
3	,	_	_	O
4	double	_	_	O
5	-	_	_	O
6	blind	_	_	O
7	,	_	_	O
8	randomized	_	_	O
9	,	_	_	O
10	multicenter	_	_	O
11	study	_	_	O
12	evaluated	_	_	O
13	the	_	_	O
14	efficacy	_	_	O
15	,	_	_	O
16	pharmacodynamics	_	_	O
17	,	_	_	O
18	and	_	_	O
19	safety	_	_	O
20	of	_	_	O
21	the	_	_	O
22	oral	_	_	O
23	aromatase	_	_	O
24	inactivator	_	_	O
25	exemestane	_	_	O
26	(	_	_	O
27	EXE	_	_	O
28	)	_	_	O
29	versus	_	_	O
30	megestrol	_	_	O
31	acetate	_	_	O
32	(	_	_	O
33	MA	_	_	O
34	)	_	_	O
35	in	_	_	O
36	postmenopausal	_	_	O
37	women	_	_	O
38	with	_	_	O
39	progressive	_	_	O
40	advanced	_	_	O
41	breast	_	_	O
42	cancer	_	_	O
43	who	_	_	O
44	experienced	_	_	O
45	failure	_	_	O
46	of	_	_	O
47	tamoxifen	_	_	O
48	.	_	_	O

49	A	_	_	O
50	total	_	_	O
51	of	_	_	O
52	769	_	_	O
53	patients	_	_	O
54	were	_	_	O
55	randomized	_	_	O
56	to	_	_	O
57	EXE	_	_	O
58	25	_	_	O
59	mg	_	_	O
60	/	_	_	O
61	d	_	_	O
62	(	_	_	O
63	n	_	_	O
64	=	_	_	O
65	366	_	_	O
66	)	_	_	O
67	or	_	_	O
68	MA	_	_	O
69	(	_	_	O
70	n	_	_	O
71	=	_	_	O
72	403	_	_	O
73	)	_	_	O
74	40	_	_	O
75	mg	_	_	O
76	four	_	_	O
77	times	_	_	O
78	daily	_	_	O
79	.	_	_	O

80	Tumor	_	_	O
81	response	_	_	O
82	,	_	_	O
83	duration	_	_	O
84	of	_	_	O
85	tumor	_	_	O
86	control	_	_	O
87	,	_	_	O
88	tumor	_	_	O
89	-	_	_	O
90	related	_	_	O
91	signs	_	_	O
92	and	_	_	O
93	symptoms	_	_	O
94	(	_	_	O
95	TRSS	_	_	O
96	)	_	_	O
97	,	_	_	O
98	quality	_	_	O
99	of	_	_	O
100	life	_	_	O
101	(	_	_	O
102	QOL	_	_	O
103	)	_	_	O
104	,	_	_	O
105	survival	_	_	O
106	,	_	_	O
107	and	_	_	O
108	tolerability	_	_	O
109	were	_	_	O
110	evaluated	_	_	O
111	.	_	_	O

112	Overall	_	_	B-Premise
113	objective	_	_	I-Premise
114	response	_	_	I-Premise
115	(	_	_	I-Premise
116	OR	_	_	I-Premise
117	)	_	_	I-Premise
118	rates	_	_	I-Premise
119	were	_	_	I-Premise
120	higher	_	_	I-Premise
121	in	_	_	I-Premise
122	patients	_	_	I-Premise
123	treated	_	_	I-Premise
124	with	_	_	I-Premise
125	EXE	_	_	I-Premise
126	than	_	_	I-Premise
127	in	_	_	I-Premise
128	those	_	_	I-Premise
129	treated	_	_	I-Premise
130	with	_	_	I-Premise
131	MA	_	_	I-Premise
132	(	_	_	I-Premise
133	15	_	_	I-Premise
134	.	_	_	I-Premise

135	0	_	_	I-Premise
136	%	_	_	I-Premise
137	v	_	_	I-Premise
138	12	_	_	I-Premise
139	.	_	_	I-Premise

140	4	_	_	I-Premise
141	%	_	_	I-Premise
142	)	_	_	I-Premise
143	;	_	_	I-Premise
144	a	_	_	B-Premise
145	similar	_	_	I-Premise
146	trend	_	_	I-Premise
147	was	_	_	I-Premise
148	noted	_	_	I-Premise
149	in	_	_	I-Premise
150	patients	_	_	I-Premise
151	with	_	_	I-Premise
152	visceral	_	_	I-Premise
153	metastases	_	_	I-Premise
154	(	_	_	I-Premise
155	13	_	_	I-Premise
156	.	_	_	I-Premise

157	5	_	_	I-Premise
158	%	_	_	I-Premise
159	v	_	_	I-Premise
160	10	_	_	I-Premise
161	.	_	_	I-Premise

162	5	_	_	I-Premise
163	%	_	_	I-Premise
164	)	_	_	I-Premise
165	.	_	_	I-Premise

166	Median	_	_	B-Premise
167	survival	_	_	I-Premise
168	time	_	_	I-Premise
169	was	_	_	I-Premise
170	significantly	_	_	I-Premise
171	longer	_	_	I-Premise
172	with	_	_	I-Premise
173	EXE	_	_	I-Premise
174	(	_	_	I-Premise
175	median	_	_	I-Premise
176	not	_	_	I-Premise
177	reached	_	_	I-Premise
178	)	_	_	I-Premise
179	than	_	_	I-Premise
180	with	_	_	I-Premise
181	MA	_	_	I-Premise
182	(	_	_	I-Premise
183	123	_	_	I-Premise
184	.	_	_	I-Premise

185	4	_	_	I-Premise
186	weeks	_	_	I-Premise
187	;	_	_	I-Premise
188	P	_	_	I-Premise
189	=	_	_	I-Premise
190	.	_	_	I-Premise

191	039	_	_	I-Premise
192	)	_	_	I-Premise
193	,	_	_	I-Premise
194	as	_	_	I-Premise
195	were	_	_	I-Premise
196	the	_	_	I-Premise
197	median	_	_	I-Premise
198	duration	_	_	I-Premise
199	of	_	_	I-Premise
200	overall	_	_	I-Premise
201	success	_	_	I-Premise
202	(	_	_	I-Premise
203	OR	_	_	I-Premise
204	or	_	_	I-Premise
205	stable	_	_	I-Premise
206	disease	_	_	I-Premise
207	>	_	_	I-Premise
208	or	_	_	I-Premise
209	=	_	_	I-Premise
210	24	_	_	I-Premise
211	weeks	_	_	I-Premise
212	;	_	_	I-Premise
213	60	_	_	I-Premise
214	.	_	_	I-Premise

215	1	_	_	I-Premise
216	v	_	_	I-Premise
217	49	_	_	I-Premise
218	.	_	_	I-Premise

219	1	_	_	I-Premise
220	weeks	_	_	I-Premise
221	;	_	_	I-Premise
222	P	_	_	I-Premise
223	=	_	_	I-Premise
224	.	_	_	I-Premise

225	025	_	_	I-Premise
226	)	_	_	I-Premise
227	,	_	_	I-Premise
228	time	_	_	I-Premise
229	to	_	_	I-Premise
230	tumor	_	_	I-Premise
231	progression	_	_	I-Premise
232	(	_	_	I-Premise
233	20	_	_	I-Premise
234	.	_	_	I-Premise

235	3	_	_	I-Premise
236	v	_	_	I-Premise
237	16	_	_	I-Premise
238	.	_	_	I-Premise

239	6	_	_	I-Premise
240	weeks	_	_	I-Premise
241	;	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	.	_	_	I-Premise

245	037	_	_	I-Premise
246	)	_	_	I-Premise
247	,	_	_	I-Premise
248	and	_	_	I-Premise
249	time	_	_	I-Premise
250	to	_	_	I-Premise
251	treatment	_	_	I-Premise
252	failure	_	_	I-Premise
253	(	_	_	I-Premise
254	16	_	_	I-Premise
255	.	_	_	I-Premise

256	3	_	_	I-Premise
257	v	_	_	I-Premise
258	15	_	_	I-Premise
259	.	_	_	I-Premise

260	7	_	_	I-Premise
261	weeks	_	_	I-Premise
262	;	_	_	I-Premise
263	P	_	_	I-Premise
264	=	_	_	I-Premise
265	.	_	_	I-Premise

266	042	_	_	I-Premise
267	)	_	_	I-Premise
268	.	_	_	I-Premise

269	Compared	_	_	B-Premise
270	with	_	_	I-Premise
271	MA	_	_	I-Premise
272	,	_	_	I-Premise
273	there	_	_	I-Premise
274	were	_	_	I-Premise
275	similar	_	_	I-Premise
276	or	_	_	I-Premise
277	greater	_	_	I-Premise
278	improvements	_	_	I-Premise
279	in	_	_	I-Premise
280	pain	_	_	I-Premise
281	,	_	_	I-Premise
282	TRSS	_	_	I-Premise
283	,	_	_	I-Premise
284	and	_	_	I-Premise
285	QOL	_	_	I-Premise
286	with	_	_	I-Premise
287	EXE	_	_	I-Premise
288	.	_	_	I-Premise

289	Both	_	_	B-Claim
290	drugs	_	_	I-Claim
291	were	_	_	I-Claim
292	well	_	_	I-Claim
293	tolerated	_	_	I-Claim
294	.	_	_	I-Claim

295	Grade	_	_	B-Premise
296	3	_	_	I-Premise
297	or	_	_	I-Premise
298	4	_	_	I-Premise
299	weight	_	_	I-Premise
300	changes	_	_	I-Premise
301	were	_	_	I-Premise
302	more	_	_	I-Premise
303	common	_	_	I-Premise
304	with	_	_	I-Premise
305	MA	_	_	I-Premise
306	(	_	_	I-Premise
307	17	_	_	I-Premise
308	.	_	_	I-Premise

309	1	_	_	I-Premise
310	%	_	_	I-Premise
311	v	_	_	I-Premise
312	7	_	_	I-Premise
313	.	_	_	I-Premise

314	6	_	_	I-Premise
315	%	_	_	I-Premise
316	;	_	_	I-Premise
317	P	_	_	I-Premise
318	=	_	_	I-Premise
319	.	_	_	I-Premise

320	001	_	_	I-Premise
321	)	_	_	I-Premise
322	.	_	_	I-Premise

323	EXE	_	_	B-Claim
324	prolongs	_	_	I-Claim
325	survival	_	_	I-Claim
326	time	_	_	I-Claim
327	,	_	_	I-Claim
328	time	_	_	I-Claim
329	to	_	_	I-Claim
330	tumor	_	_	I-Claim
331	progression	_	_	I-Claim
332	,	_	_	I-Claim
333	and	_	_	I-Claim
334	time	_	_	I-Claim
335	to	_	_	I-Claim
336	treatment	_	_	I-Claim
337	failure	_	_	I-Claim
338	compared	_	_	I-Claim
339	with	_	_	I-Claim
340	MA	_	_	I-Claim
341	and	_	_	I-Claim
342	offers	_	_	I-Claim
343	a	_	_	I-Claim
344	well	_	_	I-Claim
345	-	_	_	I-Claim
346	tolerated	_	_	I-Claim
347	treatment	_	_	I-Claim
348	option	_	_	I-Claim
349	for	_	_	I-Claim
350	postmenopausal	_	_	I-Claim
351	women	_	_	I-Claim
352	with	_	_	I-Claim
353	progressive	_	_	I-Claim
354	advanced	_	_	I-Claim
355	breast	_	_	I-Claim
356	cancer	_	_	I-Claim
357	who	_	_	I-Claim
358	experienced	_	_	I-Claim
359	failure	_	_	I-Claim
360	of	_	_	I-Claim
361	tamoxifen	_	_	I-Claim
362	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	if	_	_	O
3	the	_	_	O
4	type	_	_	O
5	of	_	_	O
6	embolic	_	_	O
7	material	_	_	O
8	used	_	_	O
9	for	_	_	O
10	uterine	_	_	O
11	artery	_	_	O
12	embolization	_	_	O
13	(	_	_	O
14	UAE	_	_	O
15	)	_	_	O
16	for	_	_	O
17	leiomyomas	_	_	O
18	has	_	_	O
19	an	_	_	O
20	impact	_	_	O
21	on	_	_	O
22	short	_	_	O
23	-	_	_	O
24	term	_	_	O
25	recovery	_	_	O
26	or	_	_	O
27	the	_	_	O
28	effectiveness	_	_	O
29	of	_	_	O
30	embolization	_	_	O
31	.	_	_	O

32	One	_	_	O
33	hundred	_	_	O
34	patients	_	_	O
35	were	_	_	O
36	randomly	_	_	O
37	assigned	_	_	O
38	to	_	_	O
39	undergo	_	_	O
40	UAE	_	_	O
41	with	_	_	O
42	polyvinyl	_	_	O
43	alcohol	_	_	O
44	(	_	_	O
45	PVA	_	_	O
46	)	_	_	O
47	particles	_	_	O
48	or	_	_	O
49	tris	_	_	O
50	-	_	_	O
51	acryl	_	_	O
52	gelatin	_	_	O
53	microspheres	_	_	O
54	.	_	_	O

55	Short	_	_	O
56	-	_	_	O
57	term	_	_	O
58	,	_	_	O
59	in	_	_	O
60	-	_	_	O
61	hospital	_	_	O
62	medication	_	_	O
63	use	_	_	O
64	and	_	_	O
65	pain	_	_	O
66	levels	_	_	O
67	were	_	_	O
68	recorded	_	_	O
69	.	_	_	O

70	After	_	_	O
71	discharge	_	_	O
72	,	_	_	O
73	symptom	_	_	O
74	severity	_	_	O
75	,	_	_	O
76	temperature	_	_	O
77	,	_	_	O
78	and	_	_	O
79	medications	_	_	O
80	used	_	_	O
81	were	_	_	O
82	recorded	_	_	O
83	daily	_	_	O
84	for	_	_	O
85	1	_	_	O
86	week	_	_	O
87	and	_	_	O
88	symptom	_	_	O
89	levels	_	_	O
90	were	_	_	O
91	measured	_	_	O
92	for	_	_	O
93	weeks	_	_	O
94	2	_	_	O
95	-	_	_	O
96	4	_	_	O
97	.	_	_	O

98	Three	_	_	O
99	months	_	_	O
100	after	_	_	O
101	embolization	_	_	O
102	,	_	_	O
103	contrast	_	_	O
104	material	_	_	O
105	-	_	_	O
106	enhanced	_	_	O
107	magnetic	_	_	O
108	resonance	_	_	O
109	imaging	_	_	O
110	examinations	_	_	O
111	were	_	_	O
112	evaluated	_	_	O
113	blindly	_	_	O
114	to	_	_	O
115	determine	_	_	O
116	the	_	_	O
117	extent	_	_	O
118	of	_	_	O
119	leiomyoma	_	_	O
120	infarction	_	_	O
121	.	_	_	O

122	Symptom	_	_	O
123	and	_	_	O
124	quality	_	_	O
125	of	_	_	O
126	life	_	_	O
127	(	_	_	O
128	QOL	_	_	O
129	)	_	_	O
130	status	_	_	O
131	was	_	_	O
132	determined	_	_	O
133	with	_	_	O
134	use	_	_	O
135	of	_	_	O
136	questionnaires	_	_	O
137	.	_	_	O

138	Analysis	_	_	O
139	was	_	_	O
140	completed	_	_	O
141	with	_	_	O
142	use	_	_	O
143	of	_	_	O
144	chi	_	_	O
145	(	_	_	O
146	2	_	_	O
147	)	_	_	O
148	analysis	_	_	O
149	,	_	_	O
150	Fisher	_	_	O
151	exact	_	_	O
152	tests	_	_	O
153	,	_	_	O
154	Student	_	_	O
155	t	_	_	O
156	tests	_	_	O
157	,	_	_	O
158	and	_	_	O
159	analysis	_	_	O
160	of	_	_	O
161	variance	_	_	O
162	as	_	_	O
163	appropriate	_	_	O
164	.	_	_	O

165	Regression	_	_	O
166	analysis	_	_	O
167	was	_	_	O
168	used	_	_	O
169	to	_	_	O
170	analyze	_	_	O
171	the	_	_	O
172	impact	_	_	O
173	on	_	_	O
174	outcome	_	_	O
175	of	_	_	O
176	baseline	_	_	O
177	factors	_	_	O
178	(	_	_	O
179	other	_	_	O
180	than	_	_	O
181	type	_	_	O
182	of	_	_	O
183	embolic	_	_	O
184	agent	_	_	O
185	)	_	_	O
186	.	_	_	O

187	No	_	_	O
188	significant	_	_	O
189	differences	_	_	O
190	were	_	_	O
191	noted	_	_	O
192	at	_	_	O
193	baseline	_	_	O
194	between	_	_	O
195	the	_	_	O
196	two	_	_	O
197	treatment	_	_	O
198	groups	_	_	O
199	.	_	_	O

200	On	_	_	B-Premise
201	average	_	_	I-Premise
202	,	_	_	I-Premise
203	there	_	_	I-Premise
204	were	_	_	I-Premise
205	significantly	_	_	I-Premise
206	higher	_	_	I-Premise
207	volumes	_	_	I-Premise
208	of	_	_	I-Premise
209	tris	_	_	I-Premise
210	-	_	_	I-Premise
211	acryl	_	_	I-Premise
212	microspheres	_	_	I-Premise
213	used	_	_	I-Premise
214	(	_	_	I-Premise
215	9	_	_	I-Premise
216	.	_	_	I-Premise

217	0	_	_	I-Premise
218	mL	_	_	I-Premise
219	vs	_	_	I-Premise
220	3	_	_	I-Premise
221	.	_	_	I-Premise

222	0	_	_	I-Premise
223	mL	_	_	I-Premise
224	;	_	_	I-Premise
225	P	_	_	I-Premise
226	=	_	_	I-Premise
227	.	_	_	I-Premise

228	0001	_	_	I-Premise
229	)	_	_	I-Premise
230	,	_	_	I-Premise
231	whereas	_	_	O
232	microcatheter	_	_	B-Premise
233	occlusion	_	_	I-Premise
234	was	_	_	I-Premise
235	more	_	_	I-Premise
236	common	_	_	I-Premise
237	with	_	_	I-Premise
238	PVA	_	_	I-Premise
239	(	_	_	I-Premise
240	28	_	_	I-Premise
241	%	_	_	I-Premise
242	vs	_	_	I-Premise
243	4	_	_	I-Premise
244	%	_	_	I-Premise
245	,	_	_	I-Premise
246	P	_	_	I-Premise
247	=	_	_	I-Premise
248	.	_	_	I-Premise

249	001	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	There	_	_	B-Premise
253	were	_	_	I-Premise
254	no	_	_	I-Premise
255	differences	_	_	I-Premise
256	in	_	_	I-Premise
257	pain	_	_	I-Premise
258	severity	_	_	I-Premise
259	,	_	_	I-Premise
260	other	_	_	I-Premise
261	postprocedural	_	_	I-Premise
262	symptoms	_	_	I-Premise
263	,	_	_	I-Premise
264	or	_	_	I-Premise
265	medication	_	_	I-Premise
266	use	_	_	I-Premise
267	between	_	_	I-Premise
268	the	_	_	I-Premise
269	two	_	_	I-Premise
270	treatment	_	_	I-Premise
271	groups	_	_	I-Premise
272	.	_	_	I-Premise

273	There	_	_	B-Premise
274	were	_	_	I-Premise
275	also	_	_	I-Premise
276	no	_	_	I-Premise
277	differences	_	_	I-Premise
278	in	_	_	I-Premise
279	the	_	_	I-Premise
280	frequency	_	_	I-Premise
281	of	_	_	I-Premise
282	incompletely	_	_	I-Premise
283	infarcted	_	_	I-Premise
284	leiomyomas	_	_	I-Premise
285	,	_	_	I-Premise
286	degree	_	_	I-Premise
287	of	_	_	I-Premise
288	improvement	_	_	I-Premise
289	in	_	_	I-Premise
290	symptom	_	_	I-Premise
291	score	_	_	I-Premise
292	,	_	_	I-Premise
293	patient	_	_	I-Premise
294	satisfaction	_	_	I-Premise
295	,	_	_	I-Premise
296	or	_	_	I-Premise
297	QOL	_	_	I-Premise
298	.	_	_	I-Premise

299	No	_	_	B-Claim
300	substantive	_	_	I-Claim
301	differences	_	_	I-Claim
302	were	_	_	I-Claim
303	detected	_	_	I-Claim
304	between	_	_	I-Claim
305	outcomes	_	_	I-Claim
306	of	_	_	I-Claim
307	embolization	_	_	I-Claim
308	with	_	_	I-Claim
309	PVA	_	_	I-Claim
310	particles	_	_	I-Claim
311	or	_	_	I-Claim
312	tris	_	_	I-Claim
313	-	_	_	I-Claim
314	acryl	_	_	I-Claim
315	gelatin	_	_	I-Claim
316	microspheres	_	_	I-Claim
317	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	examined	_	_	O
3	the	_	_	O
4	feasibility	_	_	O
5	and	_	_	O
6	acceptability	_	_	O
7	of	_	_	O
8	an	_	_	O
9	Individual	_	_	O
10	Internet	_	_	O
11	Intervention	_	_	O
12	(	_	_	O
13	III	_	_	O
14	)	_	_	O
15	embedded	_	_	O
16	and	_	_	O
17	integrated	_	_	O
18	into	_	_	O
19	an	_	_	O
20	Internet	_	_	O
21	Support	_	_	O
22	Group	_	_	O
23	(	_	_	O
24	ISG	_	_	O
25	)	_	_	O
26	with	_	_	O
27	the	_	_	O
28	ultimate	_	_	O
29	goal	_	_	O
30	of	_	_	O
31	enhancing	_	_	O
32	adherence	_	_	O
33	and	_	_	O
34	learning	_	_	O
35	,	_	_	O
36	compared	_	_	O
37	with	_	_	O
38	an	_	_	O
39	individual	_	_	O
40	internet	_	_	O
41	invention	_	_	O
42	alone	_	_	O
43	.	_	_	O

44	Thirty	_	_	O
45	-	_	_	O
46	one	_	_	O
47	posttreatment	_	_	O
48	cancer	_	_	O
49	survivors	_	_	O
50	were	_	_	O
51	randomized	_	_	O
52	in	_	_	O
53	groups	_	_	O
54	of	_	_	O
55	seven	_	_	O
56	to	_	_	O
57	nine	_	_	O
58	to	_	_	O
59	either	_	_	O
60	the	_	_	O
61	8	_	_	O
62	-	_	_	O
63	week	_	_	O
64	III	_	_	O
65	+	_	_	O
66	ISG	_	_	O
67	intervention	_	_	O
68	or	_	_	O
69	the	_	_	O
70	8	_	_	O
71	-	_	_	O
72	week	_	_	O
73	III	_	_	O
74	condition	_	_	O
75	.	_	_	O

76	Seventeen	_	_	O
77	participants	_	_	O
78	met	_	_	O
79	the	_	_	O
80	Hospital	_	_	O
81	Anxiety	_	_	O
82	and	_	_	O
83	Depression	_	_	O
84	Scale	_	_	O
85	(	_	_	O
86	HADS	_	_	O
87	)	_	_	O
88	criteria	_	_	O
89	for	_	_	O
90	depressive	_	_	O
91	symptoms	_	_	O
92	(	_	_	O
93	HADS	_	_	O
94	≥	_	_	O
95	8	_	_	O
96	)	_	_	O
97	.	_	_	O

98	Among	_	_	O
99	all	_	_	O
100	participants	_	_	O
101	,	_	_	O
102	the	_	_	O
103	mean	_	_	O
104	number	_	_	O
105	of	_	_	O
106	logins	_	_	O
107	over	_	_	O
108	8	_	_	O
109	weeks	_	_	O
110	was	_	_	O
111	20	_	_	O
112	.	_	_	O

113	8	_	_	O
114	±	_	_	O
115	17	_	_	O
116	.	_	_	O

117	7	_	_	O
118	logins	_	_	O
119	for	_	_	O
120	the	_	_	O
121	III	_	_	O
122	+	_	_	O
123	ISG	_	_	O
124	compared	_	_	O
125	with	_	_	O
126	12	_	_	O
127	.	_	_	O

128	5	_	_	O
129	±	_	_	O
130	12	_	_	O
131	.	_	_	O

132	5	_	_	O
133	in	_	_	O
134	III	_	_	O
135	-	_	_	O
136	only	_	_	O
137	(	_	_	O
138	p	_	_	O
139	=	_	_	O
140	0	_	_	O
141	.	_	_	O

142	15	_	_	O
143	)	_	_	O
144	.	_	_	O

145	Two	_	_	O
146	participants	_	_	O
147	in	_	_	O
148	the	_	_	O
149	III	_	_	O
150	+	_	_	O
151	ISG	_	_	O
152	dropped	_	_	O
153	out	_	_	O
154	,	_	_	O
155	compared	_	_	O
156	with	_	_	O
157	five	_	_	O
158	in	_	_	O
159	III	_	_	O
160	(	_	_	O
161	p	_	_	O
162	=	_	_	O
163	0	_	_	O
164	.	_	_	O

165	39	_	_	O
166	)	_	_	O
167	.	_	_	O

168	Among	_	_	B-Premise
169	the	_	_	I-Premise
170	17	_	_	I-Premise
171	participants	_	_	I-Premise
172	with	_	_	I-Premise
173	depressive	_	_	I-Premise
174	symptoms	_	_	I-Premise
175	at	_	_	I-Premise
176	baseline	_	_	I-Premise
177	,	_	_	I-Premise
178	both	_	_	I-Premise
179	the	_	_	I-Premise
180	Onward	_	_	I-Premise
181	and	_	_	I-Premise
182	the	_	_	I-Premise
183	III	_	_	I-Premise
184	-	_	_	I-Premise
185	only	_	_	I-Premise
186	condition	_	_	I-Premise
187	showed	_	_	I-Premise
188	large	_	_	I-Premise
189	reductions	_	_	I-Premise
190	in	_	_	I-Premise
191	the	_	_	I-Premise
192	depression	_	_	I-Premise
193	scale	_	_	I-Premise
194	of	_	_	I-Premise
195	HADS	_	_	I-Premise
196	(	_	_	I-Premise
197	d	_	_	I-Premise
198	=	_	_	I-Premise
199	1	_	_	I-Premise
200	.	_	_	I-Premise

201	27	_	_	I-Premise
202	and	_	_	I-Premise
203	0	_	_	I-Premise
204	.	_	_	I-Premise

205	89	_	_	I-Premise
206	,	_	_	I-Premise
207	respectively	_	_	I-Premise
208	)	_	_	I-Premise
209	.	_	_	I-Premise

210	Improvement	_	_	B-Premise
211	over	_	_	I-Premise
212	time	_	_	I-Premise
213	and	_	_	I-Premise
214	time	_	_	I-Premise
215	x	_	_	I-Premise
216	treatment	_	_	I-Premise
217	effects	_	_	I-Premise
218	only	_	_	I-Premise
219	reached	_	_	I-Premise
220	trend	_	_	I-Premise
221	significance	_	_	I-Premise
222	levels	_	_	I-Premise
223	(	_	_	I-Premise
224	ps	_	_	I-Premise
225	=	_	_	I-Premise
226	0	_	_	I-Premise
227	.	_	_	I-Premise

228	07	_	_	I-Premise
229	&	_	_	I-Premise
230	amp	_	_	I-Premise
231	;	_	_	I-Premise
232	0	_	_	I-Premise
233	.	_	_	I-Premise

234	12	_	_	I-Premise
235	)	_	_	I-Premise
236	as	_	_	I-Premise
237	this	_	_	I-Premise
238	pilot	_	_	I-Premise
239	was	_	_	I-Premise
240	not	_	_	I-Premise
241	powered	_	_	I-Premise
242	to	_	_	I-Premise
243	detect	_	_	I-Premise
244	these	_	_	I-Premise
245	differences	_	_	I-Premise
246	.	_	_	I-Premise

247	Both	_	_	B-Claim
248	the	_	_	I-Claim
249	III	_	_	I-Claim
250	+	_	_	I-Claim
251	ISG	_	_	I-Claim
252	and	_	_	I-Claim
253	III	_	_	I-Claim
254	-	_	_	I-Claim
255	only	_	_	I-Claim
256	demonstrated	_	_	I-Claim
257	pre	_	_	I-Claim
258	-	_	_	I-Claim
259	post	_	_	I-Claim
260	reductions	_	_	I-Claim
261	in	_	_	I-Claim
262	depressive	_	_	I-Claim
263	symptoms	_	_	I-Claim
264	and	_	_	I-Claim
265	high	_	_	I-Claim
266	rates	_	_	I-Claim
267	of	_	_	I-Claim
268	utilization	_	_	I-Claim
269	compared	_	_	I-Claim
270	with	_	_	I-Claim
271	other	_	_	I-Claim
272	web	_	_	I-Claim
273	-	_	_	I-Claim
274	based	_	_	I-Claim
275	treatments	_	_	I-Claim
276	for	_	_	I-Claim
277	depression	_	_	I-Claim
278	.	_	_	I-Claim

279	Although	_	_	B-Claim
280	it	_	_	I-Claim
281	is	_	_	I-Claim
282	premature	_	_	I-Claim
283	to	_	_	I-Claim
284	make	_	_	I-Claim
285	any	_	_	I-Claim
286	determination	_	_	I-Claim
287	as	_	_	I-Claim
288	to	_	_	I-Claim
289	the	_	_	I-Claim
290	efficacy	_	_	I-Claim
291	of	_	_	I-Claim
292	the	_	_	I-Claim
293	interventions	_	_	I-Claim
294	tested	_	_	I-Claim
295	in	_	_	I-Claim
296	this	_	_	I-Claim
297	feasibility	_	_	I-Claim
298	study	_	_	I-Claim
299	,	_	_	I-Claim
300	these	_	_	B-Claim
301	results	_	_	I-Claim
302	indicate	_	_	I-Claim
303	that	_	_	I-Claim
304	pursuing	_	_	I-Claim
305	the	_	_	I-Claim
306	III	_	_	I-Claim
307	+	_	_	I-Claim
308	ISG	_	_	I-Claim
309	model	_	_	I-Claim
310	,	_	_	I-Claim
311	as	_	_	I-Claim
312	well	_	_	I-Claim
313	as	_	_	I-Claim
314	standard	_	_	I-Claim
315	IIIs	_	_	I-Claim
316	,	_	_	I-Claim
317	may	_	_	I-Claim
318	be	_	_	I-Claim
319	fruitful	_	_	I-Claim
320	areas	_	_	I-Claim
321	of	_	_	I-Claim
322	future	_	_	I-Claim
323	research	_	_	I-Claim
324	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	whether	_	_	O
3	weekly	_	_	O
4	epoetin	_	_	O
5	alfa	_	_	O
6	could	_	_	O
7	improve	_	_	O
8	hemoglobin	_	_	O
9	(	_	_	O
10	HgB	_	_	O
11	)	_	_	O
12	levels	_	_	O
13	,	_	_	O
14	reduce	_	_	O
15	RBC	_	_	O
16	transfusions	_	_	O
17	,	_	_	O
18	and	_	_	O
19	improve	_	_	O
20	quality	_	_	O
21	of	_	_	O
22	life	_	_	O
23	(	_	_	O
24	QOL	_	_	O
25	)	_	_	O
26	in	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	advanced	_	_	O
30	cancer	_	_	O
31	and	_	_	O
32	with	_	_	O
33	anemia	_	_	O
34	after	_	_	O
35	receiving	_	_	O
36	myelosuppressive	_	_	O
37	chemotherapy	_	_	O
38	.	_	_	O

39	This	_	_	O
40	double	_	_	O
41	-	_	_	O
42	blind	_	_	O
43	,	_	_	O
44	placebo	_	_	O
45	-	_	_	O
46	controlled	_	_	O
47	study	_	_	O
48	randomly	_	_	O
49	assigned	_	_	O
50	patients	_	_	O
51	to	_	_	O
52	placebo	_	_	O
53	or	_	_	O
54	epoetin	_	_	O
55	alfa	_	_	O
56	(	_	_	O
57	Ortho	_	_	O
58	Biotech	_	_	O
59	,	_	_	O
60	Bridgewater	_	_	O
61	,	_	_	O
62	NJ	_	_	O
63	)	_	_	O
64	40	_	_	O
65	,	_	_	O
66	000	_	_	O
67	U	_	_	O
68	subcutaneous	_	_	O
69	weekly	_	_	O
70	for	_	_	O
71	16	_	_	O
72	weeks	_	_	O
73	.	_	_	O

74	QOL	_	_	O
75	,	_	_	O
76	HgB	_	_	O
77	,	_	_	O
78	and	_	_	O
79	RBC	_	_	O
80	transfusions	_	_	O
81	were	_	_	O
82	measured	_	_	O
83	pretreatment	_	_	O
84	and	_	_	O
85	monthly	_	_	O
86	.	_	_	O

87	The	_	_	O
88	study	_	_	O
89	accrued	_	_	O
90	344	_	_	O
91	patients	_	_	O
92	;	_	_	O
93	330	_	_	O
94	were	_	_	O
95	assessable	_	_	O
96	for	_	_	O
97	efficacy	_	_	O
98	and	_	_	O
99	305	_	_	O
100	were	_	_	O
101	assessable	_	_	O
102	for	_	_	O
103	QOL	_	_	O
104	.	_	_	O

105	Placebo	_	_	B-Premise
106	-	_	_	I-Premise
107	treated	_	_	I-Premise
108	patients	_	_	I-Premise
109	had	_	_	I-Premise
110	a	_	_	I-Premise
111	mean	_	_	I-Premise
112	increase	_	_	I-Premise
113	in	_	_	I-Premise
114	HgB	_	_	I-Premise
115	of	_	_	I-Premise
116	0	_	_	I-Premise
117	.	_	_	I-Premise

118	9	_	_	I-Premise
119	g	_	_	I-Premise
120	/	_	_	I-Premise
121	dL	_	_	I-Premise
122	(	_	_	I-Premise
123	range	_	_	I-Premise
124	,	_	_	I-Premise
125	-	_	_	I-Premise
126	3	_	_	I-Premise
127	.	_	_	I-Premise

128	8	_	_	I-Premise
129	to	_	_	I-Premise
130	+	_	_	I-Premise
131	5	_	_	I-Premise
132	.	_	_	I-Premise

133	3	_	_	I-Premise
134	)	_	_	I-Premise
135	compared	_	_	I-Premise
136	with	_	_	I-Premise
137	2	_	_	I-Premise
138	.	_	_	I-Premise

139	8	_	_	I-Premise
140	g	_	_	I-Premise
141	/	_	_	I-Premise
142	dL	_	_	I-Premise
143	(	_	_	I-Premise
144	range	_	_	I-Premise
145	,	_	_	I-Premise
146	-	_	_	I-Premise
147	2	_	_	I-Premise
148	.	_	_	I-Premise

149	2	_	_	I-Premise
150	to	_	_	I-Premise
151	+	_	_	I-Premise
152	7	_	_	I-Premise
153	.	_	_	I-Premise

154	5	_	_	I-Premise
155	)	_	_	I-Premise
156	for	_	_	I-Premise
157	epoetin	_	_	I-Premise
158	-	_	_	I-Premise
159	treated	_	_	I-Premise
160	patients	_	_	I-Premise
161	(	_	_	I-Premise
162	P	_	_	I-Premise
163	<	_	_	I-Premise
164	.	_	_	I-Premise

165	0001	_	_	I-Premise
166	)	_	_	I-Premise
167	.	_	_	I-Premise

168	During	_	_	B-Premise
169	the	_	_	I-Premise
170	study	_	_	I-Premise
171	,	_	_	I-Premise
172	31	_	_	I-Premise
173	.	_	_	I-Premise

174	7	_	_	I-Premise
175	%	_	_	I-Premise
176	of	_	_	I-Premise
177	placebo	_	_	I-Premise
178	-	_	_	I-Premise
179	treated	_	_	I-Premise
180	patients	_	_	I-Premise
181	achieved	_	_	I-Premise
182	a	_	_	I-Premise
183	>	_	_	I-Premise
184	or	_	_	I-Premise
185	=	_	_	I-Premise
186	2	_	_	I-Premise
187	g	_	_	I-Premise
188	/	_	_	I-Premise
189	dL	_	_	I-Premise
190	HgB	_	_	I-Premise
191	increase	_	_	I-Premise
192	compared	_	_	I-Premise
193	with	_	_	I-Premise
194	72	_	_	I-Premise
195	.	_	_	I-Premise

196	7	_	_	I-Premise
197	%	_	_	I-Premise
198	of	_	_	I-Premise
199	epoetin	_	_	I-Premise
200	-	_	_	I-Premise
201	treated	_	_	I-Premise
202	patients	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	<	_	_	I-Premise
206	.	_	_	I-Premise

207	0001	_	_	I-Premise
208	)	_	_	I-Premise
209	.	_	_	I-Premise

210	The	_	_	B-Premise
211	incidence	_	_	I-Premise
212	of	_	_	I-Premise
213	RBC	_	_	I-Premise
214	transfusion	_	_	I-Premise
215	for	_	_	I-Premise
216	placebo	_	_	I-Premise
217	and	_	_	I-Premise
218	epoetin	_	_	I-Premise
219	treatment	_	_	I-Premise
220	arms	_	_	I-Premise
221	was	_	_	I-Premise
222	39	_	_	I-Premise
223	.	_	_	I-Premise

224	6	_	_	I-Premise
225	%	_	_	I-Premise
226	and	_	_	I-Premise
227	25	_	_	I-Premise
228	.	_	_	I-Premise

229	3	_	_	I-Premise
230	%	_	_	I-Premise
231	(	_	_	I-Premise
232	P	_	_	I-Premise
233	=	_	_	I-Premise
234	.	_	_	I-Premise

235	005	_	_	I-Premise
236	)	_	_	I-Premise
237	,	_	_	I-Premise
238	respectively	_	_	I-Premise
239	.	_	_	I-Premise

240	The	_	_	O
241	placebo	_	_	O
242	group	_	_	O
243	received	_	_	O
244	256	_	_	O
245	units	_	_	O
246	of	_	_	O
247	RBCs	_	_	O
248	compared	_	_	O
249	with	_	_	O
250	127	_	_	O
251	units	_	_	O
252	in	_	_	O
253	the	_	_	O
254	epoetin	_	_	O
255	group	_	_	O
256	(	_	_	O
257	P	_	_	O
258	<	_	_	O
259	.	_	_	O

260	0001	_	_	O
261	)	_	_	O
262	.	_	_	O

263	The	_	_	B-Premise
264	incidence	_	_	I-Premise
265	of	_	_	I-Premise
266	toxicity	_	_	I-Premise
267	in	_	_	I-Premise
268	the	_	_	I-Premise
269	groups	_	_	I-Premise
270	was	_	_	I-Premise
271	similar	_	_	I-Premise
272	.	_	_	I-Premise

273	Changes	_	_	B-Premise
274	in	_	_	I-Premise
275	the	_	_	I-Premise
276	average	_	_	I-Premise
277	QOL	_	_	I-Premise
278	scores	_	_	I-Premise
279	from	_	_	I-Premise
280	baseline	_	_	I-Premise
281	to	_	_	I-Premise
282	the	_	_	I-Premise
283	end	_	_	I-Premise
284	of	_	_	I-Premise
285	the	_	_	I-Premise
286	study	_	_	I-Premise
287	were	_	_	I-Premise
288	similar	_	_	I-Premise
289	in	_	_	I-Premise
290	the	_	_	I-Premise
291	two	_	_	I-Premise
292	groups	_	_	I-Premise
293	(	_	_	I-Premise
294	P	_	_	I-Premise
295	=	_	_	I-Premise
296	not	_	_	I-Premise
297	significant	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	The	_	_	B-Premise
301	HgB	_	_	I-Premise
302	responders	_	_	I-Premise
303	(	_	_	I-Premise
304	irrespective	_	_	I-Premise
305	of	_	_	I-Premise
306	treatment	_	_	I-Premise
307	arm	_	_	I-Premise
308	)	_	_	I-Premise
309	had	_	_	I-Premise
310	a	_	_	I-Premise
311	mean	_	_	I-Premise
312	change	_	_	I-Premise
313	in	_	_	I-Premise
314	Functional	_	_	I-Premise
315	Assessment	_	_	I-Premise
316	of	_	_	I-Premise
317	Cancer	_	_	I-Premise
318	Therapy	_	_	I-Premise
319	(	_	_	I-Premise
320	FACT	_	_	I-Premise
321	)	_	_	I-Premise
322	fatigue	_	_	I-Premise
323	score	_	_	I-Premise
324	from	_	_	I-Premise
325	a	_	_	I-Premise
326	baseline	_	_	I-Premise
327	of	_	_	I-Premise
328	+	_	_	I-Premise
329	5	_	_	I-Premise
330	.	_	_	I-Premise

331	1	_	_	I-Premise
332	compared	_	_	I-Premise
333	with	_	_	I-Premise
334	-	_	_	I-Premise
335	2	_	_	I-Premise
336	.	_	_	I-Premise

337	1	_	_	I-Premise
338	for	_	_	I-Premise
339	the	_	_	I-Premise
340	nonresponders	_	_	I-Premise
341	(	_	_	I-Premise
342	P	_	_	I-Premise
343	=	_	_	I-Premise
344	.	_	_	I-Premise

345	006	_	_	I-Premise
346	)	_	_	I-Premise
347	.	_	_	I-Premise

348	Epoetin	_	_	B-Claim
349	alfa	_	_	I-Claim
350	significantly	_	_	I-Claim
351	improved	_	_	I-Claim
352	HgB	_	_	I-Claim
353	and	_	_	I-Claim
354	reduced	_	_	I-Claim
355	transfusions	_	_	I-Claim
356	in	_	_	I-Claim
357	this	_	_	I-Claim
358	patient	_	_	I-Claim
359	population	_	_	I-Claim
360	.	_	_	I-Claim

361	These	_	_	B-Claim
362	results	_	_	I-Claim
363	support	_	_	I-Claim
364	the	_	_	I-Claim
365	use	_	_	I-Claim
366	of	_	_	I-Claim
367	weekly	_	_	I-Claim
368	epoetin	_	_	I-Claim
369	alfa	_	_	I-Claim
370	as	_	_	I-Claim
371	an	_	_	I-Claim
372	ameliorative	_	_	I-Claim
373	agent	_	_	I-Claim
374	for	_	_	I-Claim
375	cancer	_	_	I-Claim
376	-	_	_	I-Claim
377	related	_	_	I-Claim
378	anemia	_	_	I-Claim
379	.	_	_	I-Claim


0	This	_	_	O
1	randomized	_	_	O
2	phase	_	_	O
3	II	_	_	O
4	study	_	_	O
5	compared	_	_	O
6	two	_	_	O
7	treatment	_	_	O
8	schedules	_	_	O
9	of	_	_	O
10	gemcitabine	_	_	O
11	in	_	_	O
12	patients	_	_	O
13	with	_	_	O
14	non	_	_	O
15	-	_	_	O
16	small	_	_	O
17	-	_	_	O
18	cell	_	_	O
19	lung	_	_	O
20	cancer	_	_	O
21	(	_	_	O
22	NSCLC	_	_	O
23	)	_	_	O
24	and	_	_	O
25	impaired	_	_	O
26	Karnofsky	_	_	O
27	performance	_	_	O
28	status	_	_	O
29	(	_	_	O
30	KP	_	_	O
31	)	_	_	O
32	.	_	_	O

33	Primary	_	_	O
34	objectives	_	_	O
35	were	_	_	O
36	to	_	_	O
37	record	_	_	O
38	changes	_	_	O
39	from	_	_	O
40	baseline	_	_	O
41	KP	_	_	O
42	and	_	_	O
43	to	_	_	O
44	assess	_	_	O
45	symptom	_	_	O
46	palliation	_	_	O
47	.	_	_	O

48	Secondary	_	_	O
49	objectives	_	_	O
50	were	_	_	O
51	overall	_	_	O
52	survival	_	_	O
53	,	_	_	O
54	tumor	_	_	O
55	response	_	_	O
56	,	_	_	O
57	and	_	_	O
58	toxicity	_	_	O
59	.	_	_	O

60	Patients	_	_	O
61	with	_	_	O
62	stage	_	_	O
63	IIIb	_	_	O
64	and	_	_	O
65	IV	_	_	O
66	NSCLC	_	_	O
67	and	_	_	O
68	KP	_	_	O
69	<	_	_	O
70	/	_	_	O
71	=	_	_	O
72	70	_	_	O
73	were	_	_	O
74	randomly	_	_	O
75	assigned	_	_	O
76	to	_	_	O
77	receive	_	_	O
78	gemcitabine	_	_	O
79	1	_	_	O
80	,	_	_	O
81	000	_	_	O
82	mg	_	_	O
83	/	_	_	O
84	m	_	_	O
85	(	_	_	O
86	2	_	_	O
87	)	_	_	O
88	on	_	_	O
89	days	_	_	O
90	1	_	_	O
91	,	_	_	O
92	8	_	_	O
93	,	_	_	O
94	and	_	_	O
95	15	_	_	O
96	of	_	_	O
97	each	_	_	O
98	28	_	_	O
99	-	_	_	O
100	day	_	_	O
101	cycle	_	_	O
102	(	_	_	O
103	3w4	_	_	O
104	)	_	_	O
105	or	_	_	O
106	gemcitabine	_	_	O
107	1	_	_	O
108	,	_	_	O
109	500	_	_	O
110	mg	_	_	O
111	/	_	_	O
112	m	_	_	O
113	(	_	_	O
114	2	_	_	O
115	)	_	_	O
116	on	_	_	O
117	days	_	_	O
118	1	_	_	O
119	and	_	_	O
120	8	_	_	O
121	of	_	_	O
122	each	_	_	O
123	21	_	_	O
124	-	_	_	O
125	day	_	_	O
126	cycle	_	_	O
127	(	_	_	O
128	2w3	_	_	O
129	)	_	_	O
130	,	_	_	O
131	both	_	_	O
132	for	_	_	O
133	up	_	_	O
134	to	_	_	O
135	six	_	_	O
136	cycles	_	_	O
137	.	_	_	O

138	KP	_	_	O
139	,	_	_	O
140	toxicity	_	_	O
141	,	_	_	O
142	and	_	_	O
143	SS14	_	_	O
144	lung	_	_	O
145	cancer	_	_	O
146	specific	_	_	O
147	questions	_	_	O
148	were	_	_	O
149	recorded	_	_	O
150	before	_	_	O
151	each	_	_	O
152	cycle	_	_	O
153	of	_	_	O
154	treatment	_	_	O
155	.	_	_	O

156	Response	_	_	O
157	was	_	_	O
158	evaluated	_	_	O
159	4	_	_	O
160	weeks	_	_	O
161	after	_	_	O
162	the	_	_	O
163	last	_	_	O
164	cycle	_	_	O
165	.	_	_	O

166	One	_	_	O
167	hundred	_	_	O
168	seventy	_	_	O
169	-	_	_	O
170	four	_	_	O
171	patients	_	_	O
172	were	_	_	O
173	enrolled	_	_	O
174	.	_	_	O

175	There	_	_	B-Premise
176	was	_	_	I-Premise
177	significant	_	_	I-Premise
178	early	_	_	I-Premise
179	attrition	_	_	I-Premise
180	due	_	_	I-Premise
181	to	_	_	I-Premise
182	disease	_	_	I-Premise
183	progression	_	_	I-Premise
184	;	_	_	I-Premise
185	only	_	_	I-Premise
186	61	_	_	I-Premise
187	.	_	_	I-Premise

188	5	_	_	I-Premise
189	%	_	_	I-Premise
190	of	_	_	I-Premise
191	patients	_	_	I-Premise
192	were	_	_	I-Premise
193	alive	_	_	I-Premise
194	at	_	_	I-Premise
195	2	_	_	I-Premise
196	months	_	_	I-Premise
197	.	_	_	I-Premise

198	There	_	_	B-Premise
199	was	_	_	I-Premise
200	a	_	_	I-Premise
201	significant	_	_	I-Premise
202	improvement	_	_	I-Premise
203	in	_	_	I-Premise
204	KP	_	_	I-Premise
205	from	_	_	I-Premise
206	baseline	_	_	I-Premise
207	to	_	_	I-Premise
208	pre	_	_	I-Premise
209	-	_	_	I-Premise
210	cycle	_	_	I-Premise
211	3	_	_	I-Premise
212	in	_	_	I-Premise
213	both	_	_	I-Premise
214	arms	_	_	I-Premise
215	,	_	_	I-Premise
216	with	_	_	I-Premise
217	a	_	_	I-Premise
218	trend	_	_	I-Premise
219	in	_	_	I-Premise
220	favor	_	_	I-Premise
221	of	_	_	I-Premise
222	the	_	_	I-Premise
223	3w4	_	_	I-Premise
224	regimen	_	_	I-Premise
225	for	_	_	I-Premise
226	duration	_	_	I-Premise
227	and	_	_	I-Premise
228	faster	_	_	I-Premise
229	onset	_	_	I-Premise
230	of	_	_	I-Premise
231	improvement	_	_	I-Premise
232	.	_	_	I-Premise

233	Eight	_	_	B-Premise
234	of	_	_	I-Premise
235	the	_	_	I-Premise
236	17	_	_	I-Premise
237	quality	_	_	I-Premise
238	-	_	_	I-Premise
239	of	_	_	I-Premise
240	-	_	_	I-Premise
241	life	_	_	I-Premise
242	(	_	_	I-Premise
243	QOL	_	_	I-Premise
244	)	_	_	I-Premise
245	variables	_	_	I-Premise
246	assessed	_	_	I-Premise
247	showed	_	_	I-Premise
248	an	_	_	I-Premise
249	improvement	_	_	I-Premise
250	of	_	_	I-Premise
251	more	_	_	I-Premise
252	than	_	_	I-Premise
253	10	_	_	I-Premise
254	%	_	_	I-Premise
255	between	_	_	I-Premise
256	baseline	_	_	I-Premise
257	and	_	_	I-Premise
258	the	_	_	I-Premise
259	start	_	_	I-Premise
260	of	_	_	I-Premise
261	the	_	_	I-Premise
262	third	_	_	I-Premise
263	cycle	_	_	I-Premise
264	of	_	_	I-Premise
265	treatment	_	_	I-Premise
266	.	_	_	I-Premise

267	Response	_	_	B-Premise
268	rate	_	_	I-Premise
269	,	_	_	I-Premise
270	survival	_	_	I-Premise
271	,	_	_	I-Premise
272	and	_	_	I-Premise
273	duration	_	_	I-Premise
274	were	_	_	I-Premise
275	similar	_	_	I-Premise
276	in	_	_	I-Premise
277	both	_	_	I-Premise
278	arms	_	_	I-Premise
279	.	_	_	I-Premise

280	There	_	_	B-Claim
281	was	_	_	I-Claim
282	no	_	_	I-Claim
283	significant	_	_	I-Claim
284	difference	_	_	I-Claim
285	between	_	_	I-Claim
286	the	_	_	I-Claim
287	two	_	_	I-Claim
288	schedules	_	_	I-Claim
289	examined	_	_	I-Claim
290	in	_	_	I-Claim
291	terms	_	_	I-Claim
292	of	_	_	I-Claim
293	improvement	_	_	I-Claim
294	in	_	_	I-Claim
295	KP	_	_	I-Claim
296	or	_	_	I-Claim
297	QOL	_	_	I-Claim
298	,	_	_	I-Claim
299	but	_	_	I-Claim
300	there	_	_	I-Claim
301	seemed	_	_	I-Claim
302	to	_	_	I-Claim
303	be	_	_	I-Claim
304	a	_	_	I-Claim
305	trend	_	_	I-Claim
306	in	_	_	I-Claim
307	favor	_	_	I-Claim
308	of	_	_	I-Claim
309	the	_	_	I-Claim
310	3w4	_	_	I-Claim
311	schedule	_	_	I-Claim
312	.	_	_	I-Claim


0	Thalidomide	_	_	O
1	with	_	_	O
2	melphalan	_	_	O
3	/	_	_	O
4	prednisone	_	_	O
5	(	_	_	O
6	MPT	_	_	O
7	)	_	_	O
8	was	_	_	O
9	defined	_	_	O
10	as	_	_	O
11	standard	_	_	O
12	treatment	_	_	O
13	in	_	_	O
14	elderly	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	multiple	_	_	O
18	myeloma	_	_	O
19	(	_	_	O
20	MM	_	_	O
21	)	_	_	O
22	based	_	_	O
23	on	_	_	O
24	five	_	_	O
25	randomized	_	_	O
26	trials	_	_	O
27	.	_	_	O

28	In	_	_	O
29	one	_	_	O
30	of	_	_	O
31	these	_	_	O
32	trials	_	_	O
33	,	_	_	O
34	HOVON49	_	_	O
35	,	_	_	O
36	a	_	_	O
37	prospective	_	_	O
38	health	_	_	O
39	-	_	_	O
40	related	_	_	O
41	quality	_	_	O
42	-	_	_	O
43	of	_	_	O
44	-	_	_	O
45	life	_	_	O
46	(	_	_	O
47	HRQoL	_	_	O
48	)	_	_	O
49	study	_	_	O
50	was	_	_	O
51	initiated	_	_	O
52	in	_	_	O
53	order	_	_	O
54	to	_	_	O
55	assess	_	_	O
56	the	_	_	O
57	impact	_	_	O
58	of	_	_	O
59	thalidomide	_	_	O
60	on	_	_	O
61	QoL	_	_	O
62	.	_	_	O

63	Patients	_	_	O
64	aged	_	_	O
65	>	_	_	O
66	65	_	_	O
67	years	_	_	O
68	with	_	_	O
69	newly	_	_	O
70	diagnosed	_	_	O
71	MM	_	_	O
72	were	_	_	O
73	randomized	_	_	O
74	to	_	_	O
75	receive	_	_	O
76	melphalan	_	_	O
77	plus	_	_	O
78	prednisone	_	_	O
79	(	_	_	O
80	MP	_	_	O
81	)	_	_	O
82	or	_	_	O
83	MPT	_	_	O
84	,	_	_	O
85	followed	_	_	O
86	by	_	_	O
87	thalidomide	_	_	O
88	maintenance	_	_	O
89	in	_	_	O
90	the	_	_	O
91	MPT	_	_	O
92	arm	_	_	O
93	.	_	_	O

94	Two	_	_	O
95	hundred	_	_	O
96	eighty	_	_	O
97	-	_	_	O
98	four	_	_	O
99	patients	_	_	O
100	were	_	_	O
101	included	_	_	O
102	in	_	_	O
103	this	_	_	O
104	side	_	_	O
105	study	_	_	O
106	(	_	_	O
107	MP	_	_	O
108	,	_	_	O
109	n	_	_	O
110	=	_	_	O
111	149	_	_	O
112	;	_	_	O
113	MPT	_	_	O
114	n	_	_	O
115	=	_	_	O
116	135	_	_	O
117	)	_	_	O
118	.	_	_	O

119	HRQoL	_	_	O
120	was	_	_	O
121	assessed	_	_	O
122	with	_	_	O
123	the	_	_	O
124	EORTC	_	_	O
125	Core	_	_	O
126	QoL	_	_	O
127	Questionnaire	_	_	O
128	(	_	_	O
129	QLQ	_	_	O
130	-	_	_	O
131	C30	_	_	O
132	)	_	_	O
133	and	_	_	O
134	the	_	_	O
135	myeloma	_	_	O
136	-	_	_	O
137	specific	_	_	O
138	module	_	_	O
139	(	_	_	O
140	QLQ	_	_	O
141	-	_	_	O
142	MY24	_	_	O
143	)	_	_	O
144	at	_	_	O
145	baseline	_	_	O
146	and	_	_	O
147	at	_	_	O
148	predetermined	_	_	O
149	intervals	_	_	O
150	during	_	_	O
151	treatment	_	_	O
152	.	_	_	O

153	The	_	_	B-Premise
154	QLQ	_	_	I-Premise
155	-	_	_	I-Premise
156	C30	_	_	I-Premise
157	subscales	_	_	I-Premise
158	physical	_	_	I-Premise
159	function	_	_	I-Premise
160	(	_	_	I-Premise
161	P	_	_	I-Premise
162	=	_	_	I-Premise
163	0	_	_	I-Premise
164	.	_	_	I-Premise

165	044	_	_	I-Premise
166	)	_	_	I-Premise
167	and	_	_	I-Premise
168	constipation	_	_	I-Premise
169	(	_	_	I-Premise
170	P	_	_	I-Premise
171	<	_	_	I-Premise
172	0	_	_	I-Premise
173	.	_	_	I-Premise

174	001	_	_	I-Premise
175	)	_	_	I-Premise
176	showed	_	_	I-Premise
177	an	_	_	I-Premise
178	improvement	_	_	I-Premise
179	during	_	_	I-Premise
180	induction	_	_	I-Premise
181	in	_	_	I-Premise
182	favour	_	_	I-Premise
183	of	_	_	I-Premise
184	the	_	_	I-Premise
185	MP	_	_	I-Premise
186	arm	_	_	I-Premise
187	.	_	_	I-Premise

188	During	_	_	B-Premise
189	thalidomide	_	_	I-Premise
190	maintenance	_	_	I-Premise
191	,	_	_	I-Premise
192	the	_	_	I-Premise
193	scores	_	_	I-Premise
194	for	_	_	I-Premise
195	the	_	_	I-Premise
196	QLQ	_	_	I-Premise
197	-	_	_	I-Premise
198	MY24	_	_	I-Premise
199	paraesthesia	_	_	I-Premise
200	became	_	_	I-Premise
201	significantly	_	_	I-Premise
202	higher	_	_	I-Premise
203	in	_	_	I-Premise
204	the	_	_	I-Premise
205	MPT	_	_	I-Premise
206	arm	_	_	I-Premise
207	(	_	_	I-Premise
208	P	_	_	I-Premise
209	<	_	_	I-Premise
210	0	_	_	I-Premise
211	.	_	_	I-Premise

212	001	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	The	_	_	B-Premise
216	QLQ	_	_	I-Premise
217	-	_	_	I-Premise
218	C30	_	_	I-Premise
219	subscales	_	_	I-Premise
220	pain	_	_	I-Premise
221	(	_	_	I-Premise
222	P	_	_	I-Premise
223	=	_	_	I-Premise
224	0	_	_	I-Premise
225	.	_	_	I-Premise

226	12	_	_	I-Premise
227	)	_	_	I-Premise
228	,	_	_	I-Premise
229	insomnia	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	0	_	_	I-Premise
234	.	_	_	I-Premise

235	068	_	_	I-Premise
236	)	_	_	I-Premise
237	,	_	_	I-Premise
238	appetite	_	_	I-Premise
239	loss	_	_	I-Premise
240	(	_	_	I-Premise
241	P	_	_	I-Premise
242	=	_	_	I-Premise
243	0	_	_	I-Premise
244	.	_	_	I-Premise

245	074	_	_	I-Premise
246	)	_	_	I-Premise
247	and	_	_	I-Premise
248	the	_	_	I-Premise
249	QLQ	_	_	I-Premise
250	-	_	_	I-Premise
251	MY24	_	_	I-Premise
252	item	_	_	I-Premise
253	sick	_	_	I-Premise
254	(	_	_	I-Premise
255	P	_	_	I-Premise
256	=	_	_	I-Premise
257	0	_	_	I-Premise
258	.	_	_	I-Premise

259	086	_	_	I-Premise
260	)	_	_	I-Premise
261	scored	_	_	I-Premise
262	marginally	_	_	I-Premise
263	better	_	_	I-Premise
264	during	_	_	I-Premise
265	thalidomide	_	_	I-Premise
266	maintenance	_	_	I-Premise
267	.	_	_	I-Premise

268	The	_	_	B-Premise
269	overall	_	_	I-Premise
270	QoL	_	_	I-Premise
271	-	_	_	I-Premise
272	scale	_	_	I-Premise
273	QLQ	_	_	I-Premise
274	-	_	_	I-Premise
275	C30	_	_	I-Premise
276	-	_	_	I-Premise
277	HRQoL	_	_	I-Premise
278	showed	_	_	I-Premise
279	a	_	_	I-Premise
280	significant	_	_	I-Premise
281	time	_	_	I-Premise
282	trend	_	_	I-Premise
283	towards	_	_	I-Premise
284	more	_	_	I-Premise
285	favourable	_	_	I-Premise
286	mean	_	_	I-Premise
287	values	_	_	I-Premise
288	during	_	_	I-Premise
289	protocol	_	_	I-Premise
290	treatment	_	_	I-Premise
291	without	_	_	I-Premise
292	differences	_	_	I-Premise
293	between	_	_	I-Premise
294	MP	_	_	I-Premise
295	and	_	_	I-Premise
296	MPT	_	_	I-Premise
297	.	_	_	I-Premise

298	For	_	_	B-Premise
299	the	_	_	I-Premise
300	QLQ	_	_	I-Premise
301	-	_	_	I-Premise
302	C30	_	_	I-Premise
303	subscales	_	_	I-Premise
304	emotional	_	_	I-Premise
305	function	_	_	I-Premise
306	and	_	_	I-Premise
307	future	_	_	I-Premise
308	perspectives	_	_	I-Premise
309	,	_	_	I-Premise
310	difference	_	_	I-Premise
311	in	_	_	I-Premise
312	favour	_	_	I-Premise
313	of	_	_	I-Premise
314	the	_	_	I-Premise
315	MPT	_	_	I-Premise
316	arm	_	_	I-Premise
317	from	_	_	I-Premise
318	the	_	_	I-Premise
319	start	_	_	I-Premise
320	of	_	_	I-Premise
321	treatment	_	_	I-Premise
322	was	_	_	I-Premise
323	observed	_	_	I-Premise
324	(	_	_	I-Premise
325	P	_	_	I-Premise
326	=	_	_	I-Premise
327	0	_	_	I-Premise
328	.	_	_	I-Premise

329	018	_	_	I-Premise
330	and	_	_	I-Premise
331	P	_	_	I-Premise
332	=	_	_	I-Premise
333	0	_	_	I-Premise
334	.	_	_	I-Premise

335	045	_	_	I-Premise
336	,	_	_	I-Premise
337	respectively	_	_	I-Premise
338	)	_	_	I-Premise
339	with	_	_	I-Premise
340	no	_	_	I-Premise
341	significant	_	_	I-Premise
342	'	_	_	I-Premise
343	time	_	_	I-Premise
344	×	_	_	I-Premise
345	arm	_	_	I-Premise
346	'	_	_	I-Premise
347	interaction	_	_	I-Premise
348	,	_	_	I-Premise
349	indicating	_	_	I-Premise
350	a	_	_	I-Premise
351	persistent	_	_	I-Premise
352	better	_	_	I-Premise
353	patient	_	_	I-Premise
354	perspective	_	_	I-Premise
355	with	_	_	I-Premise
356	MPT	_	_	I-Premise
357	treatment	_	_	I-Premise
358	.	_	_	I-Premise

359	This	_	_	B-Claim
360	study	_	_	I-Claim
361	shows	_	_	I-Claim
362	that	_	_	I-Claim
363	the	_	_	I-Claim
364	higher	_	_	I-Claim
365	frequency	_	_	I-Claim
366	of	_	_	I-Claim
367	toxicity	_	_	I-Claim
368	associated	_	_	I-Claim
369	with	_	_	I-Claim
370	MPT	_	_	I-Claim
371	does	_	_	I-Claim
372	not	_	_	I-Claim
373	translate	_	_	I-Claim
374	into	_	_	I-Claim
375	a	_	_	I-Claim
376	negative	_	_	I-Claim
377	effect	_	_	I-Claim
378	on	_	_	I-Claim
379	HRQoL	_	_	I-Claim
380	and	_	_	I-Claim
381	that	_	_	I-Claim
382	MPT	_	_	I-Claim
383	holds	_	_	I-Claim
384	a	_	_	I-Claim
385	better	_	_	I-Claim
386	patient	_	_	I-Claim
387	perspective	_	_	I-Claim
388	.	_	_	I-Claim


0	Chemotherapy	_	_	O
1	with	_	_	O
2	a	_	_	O
3	platinum	_	_	O
4	agent	_	_	O
5	and	_	_	O
6	a	_	_	O
7	taxane	_	_	O
8	(	_	_	O
9	paclitaxel	_	_	O
10	)	_	_	O
11	is	_	_	O
12	considered	_	_	O
13	the	_	_	O
14	standard	_	_	O
15	of	_	_	O
16	care	_	_	O
17	for	_	_	O
18	treatment	_	_	O
19	of	_	_	O
20	ovarian	_	_	O
21	carcinoma	_	_	O
22	.	_	_	O

23	We	_	_	O
24	compared	_	_	O
25	the	_	_	O
26	combination	_	_	O
27	of	_	_	O
28	docetaxel	_	_	O
29	-	_	_	O
30	carboplatin	_	_	O
31	with	_	_	O
32	the	_	_	O
33	combination	_	_	O
34	of	_	_	O
35	paclitaxel	_	_	O
36	-	_	_	O
37	carboplatin	_	_	O
38	as	_	_	O
39	first	_	_	O
40	-	_	_	O
41	line	_	_	O
42	chemotherapy	_	_	O
43	for	_	_	O
44	stage	_	_	O
45	Ic	_	_	O
46	-	_	_	O
47	IV	_	_	O
48	epithelial	_	_	O
49	ovarian	_	_	O
50	or	_	_	O
51	primary	_	_	O
52	peritoneal	_	_	O
53	cancer	_	_	O
54	.	_	_	O

55	We	_	_	O
56	randomly	_	_	O
57	assigned	_	_	O
58	1077	_	_	O
59	patients	_	_	O
60	to	_	_	O
61	receive	_	_	O
62	docetaxel	_	_	O
63	at	_	_	O
64	75	_	_	O
65	mg	_	_	O
66	/	_	_	O
67	m2	_	_	O
68	of	_	_	O
69	body	_	_	O
70	surface	_	_	O
71	area	_	_	O
72	(	_	_	O
73	1	_	_	O
74	-	_	_	O
75	hour	_	_	O
76	intravenous	_	_	O
77	infusion	_	_	O
78	)	_	_	O
79	or	_	_	O
80	paclitaxel	_	_	O
81	at	_	_	O
82	175	_	_	O
83	mg	_	_	O
84	/	_	_	O
85	m2	_	_	O
86	(	_	_	O
87	3	_	_	O
88	-	_	_	O
89	hour	_	_	O
90	intravenous	_	_	O
91	infusion	_	_	O
92	)	_	_	O
93	.	_	_	O

94	Both	_	_	O
95	treatments	_	_	O
96	then	_	_	O
97	were	_	_	O
98	followed	_	_	O
99	by	_	_	O
100	carboplatin	_	_	O
101	to	_	_	O
102	an	_	_	O
103	area	_	_	O
104	under	_	_	O
105	the	_	_	O
106	plasma	_	_	O
107	concentration	_	_	O
108	-	_	_	O
109	time	_	_	O
110	curve	_	_	O
111	of	_	_	O
112	5	_	_	O
113	.	_	_	O

114	The	_	_	O
115	treatments	_	_	O
116	were	_	_	O
117	repeated	_	_	O
118	every	_	_	O
119	3	_	_	O
120	weeks	_	_	O
121	for	_	_	O
122	six	_	_	O
123	cycles	_	_	O
124	;	_	_	O
125	in	_	_	O
126	responding	_	_	O
127	patients	_	_	O
128	,	_	_	O
129	an	_	_	O
130	additional	_	_	O
131	three	_	_	O
132	cycles	_	_	O
133	of	_	_	O
134	single	_	_	O
135	-	_	_	O
136	agent	_	_	O
137	carboplatin	_	_	O
138	was	_	_	O
139	permitted	_	_	O
140	.	_	_	O

141	Survival	_	_	O
142	curves	_	_	O
143	were	_	_	O
144	calculated	_	_	O
145	by	_	_	O
146	the	_	_	O
147	Kaplan	_	_	O
148	-	_	_	O
149	Meier	_	_	O
150	method	_	_	O
151	,	_	_	O
152	and	_	_	O
153	hazard	_	_	O
154	ratios	_	_	O
155	were	_	_	O
156	estimated	_	_	O
157	with	_	_	O
158	the	_	_	O
159	Cox	_	_	O
160	proportional	_	_	O
161	hazards	_	_	O
162	model	_	_	O
163	.	_	_	O

164	All	_	_	O
165	statistical	_	_	O
166	tests	_	_	O
167	were	_	_	O
168	two	_	_	O
169	-	_	_	O
170	sided	_	_	O
171	.	_	_	O

172	After	_	_	B-Premise
173	a	_	_	I-Premise
174	median	_	_	I-Premise
175	follow	_	_	I-Premise
176	-	_	_	I-Premise
177	up	_	_	I-Premise
178	of	_	_	I-Premise
179	23	_	_	I-Premise
180	months	_	_	I-Premise
181	,	_	_	I-Premise
182	both	_	_	I-Premise
183	groups	_	_	I-Premise
184	had	_	_	I-Premise
185	similar	_	_	I-Premise
186	progression	_	_	I-Premise
187	-	_	_	I-Premise
188	free	_	_	I-Premise
189	survival	_	_	I-Premise
190	(	_	_	I-Premise
191	medians	_	_	I-Premise
192	of	_	_	I-Premise
193	15	_	_	I-Premise
194	.	_	_	I-Premise

195	0	_	_	I-Premise
196	months	_	_	I-Premise
197	for	_	_	I-Premise
198	docetaxel	_	_	I-Premise
199	-	_	_	I-Premise
200	carboplatin	_	_	I-Premise
201	and	_	_	I-Premise
202	14	_	_	I-Premise
203	.	_	_	I-Premise

204	8	_	_	I-Premise
205	months	_	_	I-Premise
206	for	_	_	I-Premise
207	paclitaxel	_	_	I-Premise
208	-	_	_	I-Premise
209	carboplatin	_	_	I-Premise
210	;	_	_	I-Premise
211	hazard	_	_	I-Premise
212	ratio	_	_	I-Premise
213	[	_	_	I-Premise
214	HR	_	_	I-Premise
215	]	_	_	I-Premise
216	docetaxel	_	_	I-Premise
217	-	_	_	I-Premise
218	paclitaxel	_	_	I-Premise
219	=	_	_	I-Premise
220	0	_	_	I-Premise
221	.	_	_	I-Premise

222	97	_	_	I-Premise
223	,	_	_	I-Premise
224	95	_	_	I-Premise
225	%	_	_	I-Premise
226	confidence	_	_	I-Premise
227	interval	_	_	I-Premise
228	[	_	_	I-Premise
229	CI	_	_	I-Premise
230	]	_	_	I-Premise
231	=	_	_	I-Premise
232	0	_	_	I-Premise
233	.	_	_	I-Premise

234	83	_	_	I-Premise
235	to	_	_	I-Premise
236	1	_	_	I-Premise
237	.	_	_	I-Premise

238	13	_	_	I-Premise
239	;	_	_	I-Premise
240	P	_	_	I-Premise
241	=	_	_	I-Premise
242	.	_	_	I-Premise

243	707	_	_	I-Premise
244	)	_	_	I-Premise
245	,	_	_	I-Premise
246	overall	_	_	I-Premise
247	survival	_	_	I-Premise
248	rates	_	_	I-Premise
249	at	_	_	I-Premise
250	2	_	_	I-Premise
251	years	_	_	I-Premise
252	(	_	_	I-Premise
253	64	_	_	I-Premise
254	.	_	_	I-Premise

255	2	_	_	I-Premise
256	%	_	_	I-Premise
257	and	_	_	I-Premise
258	68	_	_	I-Premise
259	.	_	_	I-Premise

260	9	_	_	I-Premise
261	%	_	_	I-Premise
262	,	_	_	I-Premise
263	respectively	_	_	I-Premise
264	;	_	_	I-Premise
265	HR	_	_	I-Premise
266	=	_	_	I-Premise
267	1	_	_	I-Premise
268	.	_	_	I-Premise

269	13	_	_	I-Premise
270	,	_	_	I-Premise
271	95	_	_	I-Premise
272	%	_	_	I-Premise
273	CI	_	_	I-Premise
274	=	_	_	I-Premise
275	0	_	_	I-Premise
276	.	_	_	I-Premise

277	92	_	_	I-Premise
278	to	_	_	I-Premise
279	1	_	_	I-Premise
280	.	_	_	I-Premise

281	39	_	_	I-Premise
282	;	_	_	I-Premise
283	P	_	_	I-Premise
284	=	_	_	I-Premise
285	.	_	_	I-Premise

286	238	_	_	I-Premise
287	)	_	_	I-Premise
288	,	_	_	I-Premise
289	and	_	_	I-Premise
290	objective	_	_	I-Premise
291	tumor	_	_	I-Premise
292	(	_	_	I-Premise
293	58	_	_	I-Premise
294	.	_	_	I-Premise

295	7	_	_	I-Premise
296	%	_	_	I-Premise
297	and	_	_	I-Premise
298	59	_	_	I-Premise
299	.	_	_	I-Premise

300	5	_	_	I-Premise
301	%	_	_	I-Premise
302	,	_	_	I-Premise
303	respectively	_	_	I-Premise
304	;	_	_	I-Premise
305	difference	_	_	I-Premise
306	between	_	_	I-Premise
307	docetaxel	_	_	I-Premise
308	and	_	_	I-Premise
309	paclitaxel	_	_	I-Premise
310	=	_	_	I-Premise
311	-	_	_	I-Premise
312	0	_	_	I-Premise
313	.	_	_	I-Premise

314	8	_	_	I-Premise
315	%	_	_	I-Premise
316	,	_	_	I-Premise
317	95	_	_	I-Premise
318	%	_	_	I-Premise
319	CI	_	_	I-Premise
320	=	_	_	I-Premise
321	-	_	_	I-Premise
322	8	_	_	I-Premise
323	.	_	_	I-Premise

324	6	_	_	I-Premise
325	%	_	_	I-Premise
326	to	_	_	I-Premise
327	7	_	_	I-Premise
328	.	_	_	I-Premise

329	1	_	_	I-Premise
330	%	_	_	I-Premise
331	;	_	_	I-Premise
332	P	_	_	I-Premise
333	=	_	_	I-Premise
334	.	_	_	I-Premise

335	868	_	_	I-Premise
336	)	_	_	I-Premise
337	and	_	_	I-Premise
338	CA	_	_	I-Premise
339	-	_	_	I-Premise
340	125	_	_	I-Premise
341	(	_	_	I-Premise
342	75	_	_	I-Premise
343	.	_	_	I-Premise

344	8	_	_	I-Premise
345	%	_	_	I-Premise
346	and	_	_	I-Premise
347	76	_	_	I-Premise
348	.	_	_	I-Premise

349	8	_	_	I-Premise
350	%	_	_	I-Premise
351	,	_	_	I-Premise
352	respectively	_	_	I-Premise
353	;	_	_	I-Premise
354	difference	_	_	I-Premise
355	docetaxel	_	_	I-Premise
356	-	_	_	I-Premise
357	paclitaxel	_	_	I-Premise
358	=	_	_	I-Premise
359	-	_	_	I-Premise
360	1	_	_	I-Premise
361	.	_	_	I-Premise

362	0	_	_	I-Premise
363	%	_	_	I-Premise
364	,	_	_	I-Premise
365	95	_	_	I-Premise
366	%	_	_	I-Premise
367	CI	_	_	I-Premise
368	=	_	_	I-Premise
369	-	_	_	I-Premise
370	7	_	_	I-Premise
371	.	_	_	I-Premise

372	2	_	_	I-Premise
373	%	_	_	I-Premise
374	to	_	_	I-Premise
375	5	_	_	I-Premise
376	.	_	_	I-Premise

377	1	_	_	I-Premise
378	%	_	_	I-Premise
379	;	_	_	I-Premise
380	P	_	_	I-Premise
381	=	_	_	I-Premise
382	.	_	_	I-Premise

383	794	_	_	I-Premise
384	)	_	_	I-Premise
385	response	_	_	I-Premise
386	rates	_	_	I-Premise
387	.	_	_	I-Premise

388	However	_	_	B-Premise
389	,	_	_	I-Premise
390	docetaxel	_	_	I-Premise
391	-	_	_	I-Premise
392	carboplatin	_	_	I-Premise
393	was	_	_	I-Premise
394	associated	_	_	I-Premise
395	with	_	_	I-Premise
396	substantially	_	_	I-Premise
397	less	_	_	I-Premise
398	overall	_	_	I-Premise
399	and	_	_	I-Premise
400	grade	_	_	I-Premise
401	2	_	_	I-Premise
402	or	_	_	I-Premise
403	higher	_	_	I-Premise
404	neurotoxicity	_	_	I-Premise
405	than	_	_	I-Premise
406	paclitaxel	_	_	I-Premise
407	-	_	_	I-Premise
408	carboplatin	_	_	I-Premise
409	(	_	_	I-Premise
410	grade	_	_	I-Premise
411	>	_	_	I-Premise
412	or	_	_	I-Premise
413	=	_	_	I-Premise
414	2	_	_	I-Premise
415	neurosensory	_	_	I-Premise
416	toxicity	_	_	I-Premise
417	in	_	_	I-Premise
418	11	_	_	I-Premise
419	%	_	_	I-Premise
420	versus	_	_	I-Premise
421	30	_	_	I-Premise
422	%	_	_	I-Premise
423	,	_	_	I-Premise
424	difference	_	_	I-Premise
425	=	_	_	I-Premise
426	19	_	_	I-Premise
427	%	_	_	I-Premise
428	,	_	_	I-Premise
429	95	_	_	I-Premise
430	%	_	_	I-Premise
431	CI	_	_	I-Premise
432	=	_	_	I-Premise
433	15	_	_	I-Premise
434	%	_	_	I-Premise
435	to	_	_	I-Premise
436	24	_	_	I-Premise
437	%	_	_	I-Premise
438	;	_	_	I-Premise
439	P	_	_	I-Premise
440	<	_	_	I-Premise
441	.	_	_	I-Premise

442	001	_	_	I-Premise
443	;	_	_	I-Premise
444	grade	_	_	I-Premise
445	>	_	_	I-Premise
446	or	_	_	I-Premise
447	=	_	_	I-Premise
448	2	_	_	I-Premise
449	neuromotor	_	_	I-Premise
450	toxicity	_	_	I-Premise
451	in	_	_	I-Premise
452	3	_	_	I-Premise
453	%	_	_	I-Premise
454	versus	_	_	I-Premise
455	7	_	_	I-Premise
456	%	_	_	I-Premise
457	,	_	_	I-Premise
458	difference	_	_	I-Premise
459	=	_	_	I-Premise
460	4	_	_	I-Premise
461	%	_	_	I-Premise
462	,	_	_	I-Premise
463	95	_	_	I-Premise
464	%	_	_	I-Premise
465	CI	_	_	I-Premise
466	=	_	_	I-Premise
467	1	_	_	I-Premise
468	%	_	_	I-Premise
469	to	_	_	I-Premise
470	7	_	_	I-Premise
471	%	_	_	I-Premise
472	;	_	_	I-Premise
473	P	_	_	I-Premise
474	<	_	_	I-Premise
475	.	_	_	I-Premise

476	001	_	_	I-Premise
477	)	_	_	I-Premise
478	.	_	_	I-Premise

479	Treatment	_	_	B-Premise
480	with	_	_	I-Premise
481	docetaxel	_	_	I-Premise
482	-	_	_	I-Premise
483	carboplatin	_	_	I-Premise
484	was	_	_	I-Premise
485	associated	_	_	I-Premise
486	with	_	_	I-Premise
487	statistically	_	_	I-Premise
488	significantly	_	_	I-Premise
489	more	_	_	I-Premise
490	grade	_	_	I-Premise
491	3	_	_	I-Premise
492	-	_	_	I-Premise
493	4	_	_	I-Premise
494	neutropenia	_	_	I-Premise
495	(	_	_	I-Premise
496	94	_	_	I-Premise
497	%	_	_	I-Premise
498	versus	_	_	I-Premise
499	84	_	_	I-Premise
500	%	_	_	I-Premise
501	,	_	_	I-Premise
502	difference	_	_	I-Premise
503	=	_	_	I-Premise
504	11	_	_	I-Premise
505	%	_	_	I-Premise
506	,	_	_	I-Premise
507	95	_	_	I-Premise
508	%	_	_	I-Premise
509	CI	_	_	I-Premise
510	=	_	_	I-Premise
511	7	_	_	I-Premise
512	%	_	_	I-Premise
513	to	_	_	I-Premise
514	14	_	_	I-Premise
515	%	_	_	I-Premise
516	;	_	_	I-Premise
517	P	_	_	I-Premise
518	<	_	_	I-Premise
519	.	_	_	I-Premise

520	001	_	_	I-Premise
521	)	_	_	I-Premise
522	and	_	_	I-Premise
523	neutropenic	_	_	I-Premise
524	complications	_	_	I-Premise
525	than	_	_	I-Premise
526	treatment	_	_	I-Premise
527	with	_	_	I-Premise
528	paclitaxel	_	_	I-Premise
529	-	_	_	I-Premise
530	carboplatin	_	_	I-Premise
531	,	_	_	I-Premise
532	although	_	_	B-Premise
533	myelosuppression	_	_	I-Premise
534	did	_	_	I-Premise
535	not	_	_	I-Premise
536	influence	_	_	I-Premise
537	dose	_	_	I-Premise
538	delivery	_	_	I-Premise
539	or	_	_	I-Premise
540	patient	_	_	I-Premise
541	safety	_	_	I-Premise
542	.	_	_	I-Premise

543	Global	_	_	B-Premise
544	quality	_	_	I-Premise
545	of	_	_	I-Premise
546	life	_	_	I-Premise
547	was	_	_	I-Premise
548	similar	_	_	I-Premise
549	in	_	_	I-Premise
550	both	_	_	I-Premise
551	arms	_	_	I-Premise
552	,	_	_	I-Premise
553	but	_	_	B-Premise
554	substantive	_	_	I-Premise
555	differences	_	_	I-Premise
556	in	_	_	I-Premise
557	many	_	_	I-Premise
558	symptom	_	_	I-Premise
559	scores	_	_	I-Premise
560	favored	_	_	I-Premise
561	docetaxel	_	_	I-Premise
562	.	_	_	I-Premise

563	Docetaxel	_	_	B-Claim
564	-	_	_	I-Claim
565	carboplatin	_	_	I-Claim
566	appears	_	_	I-Claim
567	to	_	_	I-Claim
568	be	_	_	I-Claim
569	similar	_	_	I-Claim
570	to	_	_	I-Claim
571	paclitaxel	_	_	I-Claim
572	-	_	_	I-Claim
573	carboplatin	_	_	I-Claim
574	in	_	_	I-Claim
575	terms	_	_	I-Claim
576	of	_	_	I-Claim
577	progression	_	_	I-Claim
578	-	_	_	I-Claim
579	free	_	_	I-Claim
580	survival	_	_	I-Claim
581	and	_	_	I-Claim
582	response	_	_	I-Claim
583	,	_	_	I-Claim
584	although	_	_	B-Claim
585	longer	_	_	I-Claim
586	follow	_	_	I-Claim
587	-	_	_	I-Claim
588	up	_	_	I-Claim
589	is	_	_	I-Claim
590	required	_	_	I-Claim
591	for	_	_	I-Claim
592	a	_	_	I-Claim
593	definitive	_	_	I-Claim
594	statement	_	_	I-Claim
595	on	_	_	I-Claim
596	survival	_	_	I-Claim
597	.	_	_	I-Claim

598	Thus	_	_	B-Claim
599	,	_	_	I-Claim
600	docetaxel	_	_	I-Claim
601	-	_	_	I-Claim
602	carboplatin	_	_	I-Claim
603	represents	_	_	I-Claim
604	an	_	_	I-Claim
605	alternative	_	_	I-Claim
606	first	_	_	I-Claim
607	-	_	_	I-Claim
608	line	_	_	I-Claim
609	chemotherapy	_	_	I-Claim
610	regimen	_	_	I-Claim
611	for	_	_	I-Claim
612	patients	_	_	I-Claim
613	with	_	_	I-Claim
614	newly	_	_	I-Claim
615	diagnosed	_	_	I-Claim
616	ovarian	_	_	I-Claim
617	cancer	_	_	I-Claim
618	.	_	_	I-Claim


0	Pain	_	_	O
1	is	_	_	O
2	1	_	_	O
3	of	_	_	O
4	the	_	_	O
5	most	_	_	O
6	common	_	_	O
7	symptoms	_	_	O
8	that	_	_	O
9	a	_	_	O
10	cancer	_	_	O
11	patient	_	_	O
12	would	_	_	O
13	experience	_	_	O
14	.	_	_	O

15	A	_	_	O
16	significant	_	_	O
17	barrier	_	_	O
18	to	_	_	O
19	positive	_	_	O
20	pain	_	_	O
21	management	_	_	O
22	is	_	_	O
23	patients	_	_	O
24	'	_	_	O
25	misconceptions	_	_	O
26	regarding	_	_	O
27	analgesics	_	_	O
28	and	_	_	O
29	inadequate	_	_	O
30	use	_	_	O
31	of	_	_	O
32	nonpharmacological	_	_	O
33	strategies	_	_	O
34	as	_	_	O
35	pain	_	_	O
36	relief	_	_	O
37	.	_	_	O

38	The	_	_	O
39	purpose	_	_	O
40	of	_	_	O
41	this	_	_	O
42	study	_	_	O
43	was	_	_	O
44	to	_	_	O
45	investigate	_	_	O
46	the	_	_	O
47	effectiveness	_	_	O
48	of	_	_	O
49	a	_	_	O
50	pain	_	_	O
51	management	_	_	O
52	program	_	_	O
53	(	_	_	O
54	PMP	_	_	O
55	)	_	_	O
56	on	_	_	O
57	pain	_	_	O
58	intensity	_	_	O
59	,	_	_	O
60	use	_	_	O
61	of	_	_	O
62	PRN	_	_	O
63	drugs	_	_	O
64	and	_	_	O
65	nonpharmacological	_	_	O
66	strategies	_	_	O
67	as	_	_	O
68	pain	_	_	O
69	relief	_	_	O
70	,	_	_	O
71	and	_	_	O
72	barriers	_	_	O
73	to	_	_	O
74	managing	_	_	O
75	pain	_	_	O
76	in	_	_	O
77	cancer	_	_	O
78	patients	_	_	O
79	.	_	_	O

80	The	_	_	O
81	study	_	_	O
82	was	_	_	O
83	conducted	_	_	O
84	in	_	_	O
85	the	_	_	O
86	palliative	_	_	O
87	care	_	_	O
88	and	_	_	O
89	hospice	_	_	O
90	ward	_	_	O
91	of	_	_	O
92	a	_	_	O
93	public	_	_	O
94	hospital	_	_	O
95	in	_	_	O
96	Hong	_	_	O
97	Kong	_	_	O
98	.	_	_	O

99	Patients	_	_	O
100	were	_	_	O
101	randomized	_	_	O
102	to	_	_	O
103	either	_	_	O
104	an	_	_	O
105	experimental	_	_	O
106	group	_	_	O
107	(	_	_	O
108	receiving	_	_	O
109	the	_	_	O
110	PMP	_	_	O
111	)	_	_	O
112	or	_	_	O
113	a	_	_	O
114	control	_	_	O
115	group	_	_	O
116	(	_	_	O
117	routine	_	_	O
118	care	_	_	O
119	)	_	_	O
120	.	_	_	O

121	There	_	_	O
122	were	_	_	O
123	38	_	_	O
124	hospitalized	_	_	O
125	patients	_	_	O
126	,	_	_	O
127	with	_	_	O
128	20	_	_	O
129	(	_	_	O
130	13	_	_	O
131	males	_	_	O
132	and	_	_	O
133	7	_	_	O
134	females	_	_	O
135	)	_	_	O
136	in	_	_	O
137	the	_	_	O
138	experimental	_	_	O
139	group	_	_	O
140	and	_	_	O
141	18	_	_	O
142	(	_	_	O
143	11	_	_	O
144	males	_	_	O
145	and	_	_	O
146	7	_	_	O
147	females	_	_	O
148	)	_	_	O
149	in	_	_	O
150	the	_	_	O
151	control	_	_	O
152	group	_	_	O
153	;	_	_	O
154	mean	_	_	O
155	age	_	_	O
156	was	_	_	O
157	61	_	_	O
158	.	_	_	O

159	95	_	_	O
160	years	_	_	O
161	(	_	_	O
162	experimental	_	_	O
163	group	_	_	O
164	)	_	_	O
165	to	_	_	O
166	63	_	_	O
167	.	_	_	O

168	94	_	_	O
169	years	_	_	O
170	(	_	_	O
171	control	_	_	O
172	group	_	_	O
173	)	_	_	O
174	.	_	_	O

175	Upon	_	_	B-Premise
176	the	_	_	I-Premise
177	completion	_	_	I-Premise
178	of	_	_	I-Premise
179	PMP	_	_	I-Premise
180	,	_	_	I-Premise
181	pain	_	_	I-Premise
182	scores	_	_	I-Premise
183	were	_	_	I-Premise
184	significantly	_	_	I-Premise
185	reduced	_	_	I-Premise
186	in	_	_	I-Premise
187	both	_	_	I-Premise
188	groups	_	_	I-Premise
189	,	_	_	I-Premise
190	yet	_	_	B-Premise
191	patients	_	_	I-Premise
192	in	_	_	I-Premise
193	the	_	_	I-Premise
194	experimental	_	_	I-Premise
195	group	_	_	I-Premise
196	showed	_	_	I-Premise
197	a	_	_	I-Premise
198	significant	_	_	I-Premise
199	increase	_	_	I-Premise
200	in	_	_	I-Premise
201	the	_	_	I-Premise
202	use	_	_	I-Premise
203	of	_	_	I-Premise
204	PRN	_	_	I-Premise
205	analgesics	_	_	I-Premise
206	and	_	_	I-Premise
207	nonpharmacological	_	_	I-Premise
208	strategies	_	_	I-Premise
209	to	_	_	I-Premise
210	relieve	_	_	I-Premise
211	pain	_	_	I-Premise
212	(	_	_	I-Premise
213	P	_	_	I-Premise
214	<	_	_	I-Premise
215	.	_	_	I-Premise

216	05	_	_	I-Premise
217	)	_	_	I-Premise
218	and	_	_	I-Premise
219	significantly	_	_	I-Premise
220	reduce	_	_	I-Premise
221	barriers	_	_	I-Premise
222	to	_	_	I-Premise
223	managing	_	_	I-Premise
224	their	_	_	I-Premise
225	cancer	_	_	I-Premise
226	pain	_	_	I-Premise
227	(	_	_	I-Premise
228	P	_	_	I-Premise
229	<	_	_	I-Premise
230	.	_	_	I-Premise

231	05	_	_	I-Premise
232	)	_	_	I-Premise
233	compared	_	_	I-Premise
234	with	_	_	I-Premise
235	the	_	_	I-Premise
236	control	_	_	I-Premise
237	group	_	_	I-Premise
238	.	_	_	I-Premise

239	Cancer	_	_	B-Claim
240	patients	_	_	I-Claim
241	should	_	_	I-Claim
242	be	_	_	I-Claim
243	empowered	_	_	I-Claim
244	with	_	_	I-Claim
245	pain	_	_	I-Claim
246	management	_	_	I-Claim
247	education	_	_	I-Claim
248	to	_	_	I-Claim
249	gain	_	_	I-Claim
250	knowledge	_	_	I-Claim
251	and	_	_	I-Claim
252	correct	_	_	I-Claim
253	misconceptions	_	_	I-Claim
254	in	_	_	I-Claim
255	managing	_	_	I-Claim
256	their	_	_	I-Claim
257	cancer	_	_	I-Claim
258	pain	_	_	I-Claim
259	.	_	_	I-Claim

260	Integration	_	_	B-Claim
261	of	_	_	I-Claim
262	the	_	_	I-Claim
263	PMP	_	_	I-Claim
264	into	_	_	I-Claim
265	routine	_	_	I-Claim
266	clinical	_	_	I-Claim
267	work	_	_	I-Claim
268	may	_	_	I-Claim
269	help	_	_	I-Claim
270	to	_	_	I-Claim
271	improve	_	_	I-Claim
272	the	_	_	I-Claim
273	standard	_	_	I-Claim
274	of	_	_	I-Claim
275	care	_	_	I-Claim
276	for	_	_	I-Claim
277	cancer	_	_	I-Claim
278	patients	_	_	I-Claim
279	.	_	_	I-Claim

280	It	_	_	O
281	is	_	_	O
282	recommended	_	_	O
283	to	_	_	O
284	provide	_	_	O
285	pain	_	_	O
286	management	_	_	O
287	education	_	_	O
288	to	_	_	O
289	all	_	_	O
290	cancer	_	_	O
291	patients	_	_	O
292	.	_	_	O


0	Anaemia	_	_	O
1	is	_	_	O
2	common	_	_	O
3	in	_	_	O
4	patients	_	_	O
5	receiving	_	_	O
6	chemotherapy	_	_	O
7	,	_	_	O
8	causing	_	_	O
9	symptoms	_	_	O
10	that	_	_	O
11	have	_	_	O
12	a	_	_	O
13	major	_	_	O
14	impact	_	_	O
15	on	_	_	O
16	quality	_	_	O
17	of	_	_	O
18	life	_	_	O
19	(	_	_	O
20	QoL	_	_	O
21	)	_	_	O
22	.	_	_	O

23	Epoetin	_	_	O
24	beta	_	_	O
25	rapidly	_	_	O
26	increases	_	_	O
27	haemoglobin	_	_	O
28	(	_	_	O
29	Hb	_	_	O
30	)	_	_	O
31	levels	_	_	O
32	and	_	_	O
33	improves	_	_	O
34	QoL	_	_	O
35	in	_	_	O
36	anaemic	_	_	O
37	patients	_	_	O
38	with	_	_	O
39	a	_	_	O
40	variety	_	_	O
41	of	_	_	O
42	tumours	_	_	O
43	.	_	_	O

44	This	_	_	O
45	was	_	_	O
46	a	_	_	O
47	randomized	_	_	O
48	,	_	_	O
49	double	_	_	O
50	-	_	_	O
51	blind	_	_	O
52	,	_	_	O
53	parallel	_	_	O
54	-	_	_	O
55	group	_	_	O
56	,	_	_	O
57	dose	_	_	O
58	-	_	_	O
59	finding	_	_	O
60	study	_	_	O
61	assessing	_	_	O
62	the	_	_	O
63	efficacy	_	_	O
64	and	_	_	O
65	safety	_	_	O
66	of	_	_	O
67	once	_	_	O
68	-	_	_	O
69	weekly	_	_	O
70	epoetin	_	_	O
71	beta	_	_	O
72	in	_	_	O
73	patients	_	_	O
74	with	_	_	O
75	solid	_	_	O
76	tumours	_	_	O
77	receiving	_	_	O
78	chemotherapy	_	_	O
79	.	_	_	O

80	Adult	_	_	O
81	patients	_	_	O
82	with	_	_	O
83	anaemia	_	_	O
84	(	_	_	O
85	Hb	_	_	O
86	<	_	_	O
87	11	_	_	O
88	g	_	_	O
89	/	_	_	O
90	dL	_	_	O
91	)	_	_	O
92	were	_	_	O
93	randomized	_	_	O
94	to	_	_	O
95	receive	_	_	O
96	epoetin	_	_	O
97	beta	_	_	O
98	30	_	_	O
99	,	_	_	O
100	000	_	_	O
101	IU	_	_	O
102	or	_	_	O
103	20	_	_	O
104	,	_	_	O
105	000	_	_	O
106	IU	_	_	O
107	once	_	_	O
108	weekly	_	_	O
109	for	_	_	O
110	12	_	_	O
111	weeks	_	_	O
112	.	_	_	O

113	All	_	_	O
114	patients	_	_	O
115	received	_	_	O
116	oral	_	_	O
117	iron	_	_	O
118	supplementation	_	_	O
119	.	_	_	O

120	Haemoglobin	_	_	O
121	levels	_	_	O
122	,	_	_	O
123	transfusion	_	_	O
124	need	_	_	O
125	and	_	_	O
126	QoL	_	_	O
127	[	_	_	O
128	Functional	_	_	O
129	Assessment	_	_	O
130	of	_	_	O
131	Cancer	_	_	O
132	Therapy	_	_	O
133	-	_	_	O
134	fatigue	_	_	O
135	(	_	_	O
136	FACT	_	_	O
137	-	_	_	O
138	F	_	_	O
139	)	_	_	O
140	subscale	_	_	O
141	score	_	_	O
142	]	_	_	O
143	were	_	_	O
144	assessed	_	_	O
145	at	_	_	O
146	regular	_	_	O
147	intervals	_	_	O
148	.	_	_	O

149	Fifty	_	_	O
150	patients	_	_	O
151	were	_	_	O
152	randomized	_	_	O
153	;	_	_	O
154	30	_	_	O
155	patients	_	_	O
156	received	_	_	O
157	epoetin	_	_	O
158	beta	_	_	O
159	30	_	_	O
160	,	_	_	O
161	000	_	_	O
162	IU	_	_	O
163	once	_	_	O
164	weekly	_	_	O
165	and	_	_	O
166	20	_	_	O
167	received	_	_	O
168	20	_	_	O
169	,	_	_	O
170	000	_	_	O
171	IU	_	_	O
172	once	_	_	O
173	weekly	_	_	O
174	.	_	_	O

175	Mean	_	_	B-Premise
176	(	_	_	I-Premise
177	+	_	_	I-Premise
178	/	_	_	I-Premise
179	-	_	_	I-Premise
180	SD	_	_	I-Premise
181	)	_	_	I-Premise
182	increase	_	_	I-Premise
183	in	_	_	I-Premise
184	Hb	_	_	I-Premise
185	from	_	_	I-Premise
186	baseline	_	_	I-Premise
187	to	_	_	I-Premise
188	week	_	_	I-Premise
189	12	_	_	I-Premise
190	was	_	_	I-Premise
191	1	_	_	I-Premise
192	.	_	_	I-Premise

193	75	_	_	I-Premise
194	+	_	_	I-Premise
195	/	_	_	I-Premise
196	-	_	_	I-Premise
197	2	_	_	I-Premise
198	.	_	_	I-Premise

199	15	_	_	I-Premise
200	g	_	_	I-Premise
201	/	_	_	I-Premise
202	dL	_	_	I-Premise
203	in	_	_	I-Premise
204	the	_	_	I-Premise
205	30	_	_	I-Premise
206	,	_	_	I-Premise
207	000	_	_	I-Premise
208	IU	_	_	I-Premise
209	group	_	_	I-Premise
210	(	_	_	I-Premise
211	P	_	_	I-Premise
212	=	_	_	I-Premise
213	0	_	_	I-Premise
214	.	_	_	I-Premise

215	008	_	_	I-Premise
216	vs	_	_	I-Premise
217	.	_	_	I-Premise

218	baseline	_	_	I-Premise
219	)	_	_	I-Premise
220	and	_	_	I-Premise
221	1	_	_	I-Premise
222	.	_	_	I-Premise

223	04	_	_	I-Premise
224	+	_	_	I-Premise
225	/	_	_	I-Premise
226	-	_	_	I-Premise
227	1	_	_	I-Premise
228	.	_	_	I-Premise

229	75	_	_	I-Premise
230	g	_	_	I-Premise
231	/	_	_	I-Premise
232	dL	_	_	I-Premise
233	in	_	_	I-Premise
234	the	_	_	I-Premise
235	20	_	_	I-Premise
236	,	_	_	I-Premise
237	000	_	_	I-Premise
238	IU	_	_	I-Premise
239	group	_	_	I-Premise
240	(	_	_	I-Premise
241	non	_	_	I-Premise
242	-	_	_	I-Premise
243	significant	_	_	I-Premise
244	)	_	_	I-Premise
245	.	_	_	I-Premise

246	Haemoglobin	_	_	B-Premise
247	response	_	_	I-Premise
248	(	_	_	I-Premise
249	increase	_	_	I-Premise
250	in	_	_	I-Premise
251	Hb	_	_	I-Premise
252	>	_	_	I-Premise
253	or	_	_	I-Premise
254	=	_	_	I-Premise
255	2	_	_	I-Premise
256	g	_	_	I-Premise
257	/	_	_	I-Premise
258	dL	_	_	I-Premise
259	from	_	_	I-Premise
260	baseline	_	_	I-Premise
261	)	_	_	I-Premise
262	was	_	_	I-Premise
263	observed	_	_	I-Premise
264	in	_	_	I-Premise
265	78	_	_	I-Premise
266	.	_	_	I-Premise

267	3	_	_	I-Premise
268	%	_	_	I-Premise
269	of	_	_	I-Premise
270	patients	_	_	I-Premise
271	receiving	_	_	I-Premise
272	epoetin	_	_	I-Premise
273	beta	_	_	I-Premise
274	30	_	_	I-Premise
275	,	_	_	I-Premise
276	000	_	_	I-Premise
277	IU	_	_	I-Premise
278	and	_	_	I-Premise
279	66	_	_	I-Premise
280	.	_	_	I-Premise

281	7	_	_	I-Premise
282	%	_	_	I-Premise
283	receiving	_	_	I-Premise
284	epoetin	_	_	I-Premise
285	beta	_	_	I-Premise
286	20	_	_	I-Premise
287	,	_	_	I-Premise
288	000	_	_	I-Premise
289	IU	_	_	I-Premise
290	.	_	_	I-Premise

291	Improvements	_	_	O
292	in	_	_	O
293	FACT	_	_	O
294	-	_	_	O
295	F	_	_	O
296	subscale	_	_	O
297	score	_	_	O
298	were	_	_	O
299	significantly	_	_	O
300	(	_	_	O
301	P	_	_	O
302	<	_	_	O
303	0	_	_	O
304	.	_	_	O

305	001	_	_	O
306	)	_	_	O
307	correlated	_	_	O
308	with	_	_	O
309	increases	_	_	O
310	in	_	_	O
311	Hb	_	_	O
312	level	_	_	O
313	.	_	_	O

314	Transfusion	_	_	O
315	use	_	_	O
316	was	_	_	O
317	low	_	_	O
318	during	_	_	O
319	the	_	_	O
320	study	_	_	O
321	in	_	_	O
322	both	_	_	O
323	groups	_	_	O
324	.	_	_	O

325	Both	_	_	B-Premise
326	epoetin	_	_	I-Premise
327	beta	_	_	I-Premise
328	regiments	_	_	I-Premise
329	were	_	_	I-Premise
330	well	_	_	I-Premise
331	tolerated	_	_	I-Premise
332	and	_	_	I-Premise
333	there	_	_	I-Premise
334	were	_	_	I-Premise
335	no	_	_	I-Premise
336	dose	_	_	I-Premise
337	-	_	_	I-Premise
338	dependent	_	_	I-Premise
339	adverse	_	_	I-Premise
340	events	_	_	I-Premise
341	.	_	_	I-Premise

342	Epoetin	_	_	B-Claim
343	beta	_	_	I-Claim
344	30	_	_	I-Claim
345	,	_	_	I-Claim
346	000	_	_	I-Claim
347	IU	_	_	I-Claim
348	once	_	_	I-Claim
349	weekly	_	_	I-Claim
350	is	_	_	I-Claim
351	an	_	_	I-Claim
352	effective	_	_	I-Claim
353	and	_	_	I-Claim
354	well	_	_	I-Claim
355	-	_	_	I-Claim
356	tolerated	_	_	I-Claim
357	treatment	_	_	I-Claim
358	of	_	_	I-Claim
359	anaemia	_	_	I-Claim
360	in	_	_	I-Claim
361	patients	_	_	I-Claim
362	with	_	_	I-Claim
363	solid	_	_	I-Claim
364	tumours	_	_	I-Claim
365	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	the	_	_	O
4	study	_	_	O
5	is	_	_	O
6	to	_	_	O
7	demonstrate	_	_	O
8	that	_	_	O
9	intrapatient	_	_	O
10	dose	_	_	O
11	escalation	_	_	O
12	of	_	_	O
13	carboplatin	_	_	O
14	would	_	_	O
15	improve	_	_	O
16	the	_	_	O
17	outcome	_	_	O
18	in	_	_	O
19	ovarian	_	_	O
20	cancer	_	_	O
21	compared	_	_	O
22	with	_	_	O
23	flat	_	_	O
24	dosing	_	_	O
25	.	_	_	O

26	Patients	_	_	O
27	with	_	_	O
28	untreated	_	_	O
29	stage	_	_	O
30	IC	_	_	O
31	-	_	_	O
32	IV	_	_	O
33	ovarian	_	_	O
34	cancer	_	_	O
35	received	_	_	O
36	six	_	_	O
37	cycles	_	_	O
38	of	_	_	O
39	carboplatin	_	_	O
40	area	_	_	O
41	under	_	_	O
42	the	_	_	O
43	curve	_	_	O
44	6	_	_	O
45	(	_	_	O
46	AUC	_	_	O
47	6	_	_	O
48	)	_	_	O
49	3	_	_	O
50	weekly	_	_	O
51	either	_	_	O
52	with	_	_	O
53	no	_	_	O
54	dose	_	_	O
55	modification	_	_	O
56	except	_	_	O
57	for	_	_	O
58	toxicity	_	_	O
59	(	_	_	O
60	Arm	_	_	O
61	A	_	_	O
62	)	_	_	O
63	or	_	_	O
64	with	_	_	O
65	dose	_	_	O
66	escalations	_	_	O
67	in	_	_	O
68	cycles	_	_	O
69	2	_	_	O
70	-	_	_	O
71	6	_	_	O
72	based	_	_	O
73	on	_	_	O
74	nadir	_	_	O
75	neutrophil	_	_	O
76	and	_	_	O
77	platelet	_	_	O
78	counts	_	_	O
79	(	_	_	O
80	Arm	_	_	O
81	B	_	_	O
82	)	_	_	O
83	.	_	_	O

84	The	_	_	O
85	primary	_	_	O
86	end	_	_	O
87	-	_	_	O
88	point	_	_	O
89	was	_	_	O
90	progression	_	_	O
91	-	_	_	O
92	free	_	_	O
93	survival	_	_	O
94	(	_	_	O
95	PFS	_	_	O
96	)	_	_	O
97	.	_	_	O

98	Nine	_	_	O
99	hundred	_	_	O
100	and	_	_	O
101	sixty	_	_	O
102	-	_	_	O
103	four	_	_	O
104	patients	_	_	O
105	were	_	_	O
106	recruited	_	_	O
107	from	_	_	O
108	71	_	_	O
109	centers	_	_	O
110	.	_	_	O

111	Dose	_	_	O
112	escalation	_	_	O
113	was	_	_	O
114	achieved	_	_	O
115	in	_	_	O
116	77	_	_	O
117	%	_	_	O
118	of	_	_	O
119	patients	_	_	O
120	who	_	_	O
121	had	_	_	O
122	≥	_	_	O
123	1	_	_	O
124	cycle	_	_	O
125	.	_	_	O

126	The	_	_	B-Premise
127	median	_	_	I-Premise
128	AUCs	_	_	I-Premise
129	(	_	_	I-Premise
130	cycle	_	_	I-Premise
131	2	_	_	I-Premise
132	-	_	_	I-Premise
133	6	_	_	I-Premise
134	)	_	_	I-Premise
135	received	_	_	I-Premise
136	were	_	_	I-Premise
137	6	_	_	I-Premise
138	.	_	_	I-Premise

139	0	_	_	I-Premise
140	(	_	_	I-Premise
141	Arm	_	_	I-Premise
142	A	_	_	I-Premise
143	)	_	_	I-Premise
144	and	_	_	I-Premise
145	7	_	_	I-Premise
146	.	_	_	I-Premise

147	2	_	_	I-Premise
148	(	_	_	I-Premise
149	Arm	_	_	I-Premise
150	B	_	_	I-Premise
151	)	_	_	I-Premise
152	(	_	_	I-Premise
153	P	_	_	I-Premise
154	<	_	_	I-Premise
155	0	_	_	I-Premise
156	.	_	_	I-Premise

157	001	_	_	I-Premise
158	)	_	_	I-Premise
159	.	_	_	I-Premise

160	Grade	_	_	B-Premise
161	3	_	_	I-Premise
162	/	_	_	I-Premise
163	4	_	_	I-Premise
164	non	_	_	I-Premise
165	-	_	_	I-Premise
166	hematological	_	_	I-Premise
167	toxicity	_	_	I-Premise
168	was	_	_	I-Premise
169	higher	_	_	I-Premise
170	in	_	_	I-Premise
171	Arm	_	_	I-Premise
172	B	_	_	I-Premise
173	(	_	_	I-Premise
174	31	_	_	I-Premise
175	%	_	_	I-Premise
176	versus	_	_	I-Premise
177	22	_	_	I-Premise
178	%	_	_	I-Premise
179	P	_	_	I-Premise
180	=	_	_	I-Premise
181	0	_	_	I-Premise
182	.	_	_	I-Premise

183	001	_	_	I-Premise
184	)	_	_	I-Premise
185	.	_	_	I-Premise

186	The	_	_	B-Premise
187	median	_	_	I-Premise
188	PFS	_	_	I-Premise
189	was	_	_	I-Premise
190	12	_	_	I-Premise
191	.	_	_	I-Premise

192	1	_	_	I-Premise
193	months	_	_	I-Premise
194	in	_	_	I-Premise
195	Arm	_	_	I-Premise
196	A	_	_	I-Premise
197	and	_	_	I-Premise
198	B	_	_	I-Premise
199	[	_	_	I-Premise
200	hazard	_	_	I-Premise
201	ratio	_	_	I-Premise
202	(	_	_	I-Premise
203	HR	_	_	I-Premise
204	)	_	_	I-Premise
205	0	_	_	I-Premise
206	.	_	_	I-Premise

207	99	_	_	I-Premise
208	;	_	_	I-Premise
209	95	_	_	I-Premise
210	%	_	_	I-Premise
211	confidence	_	_	I-Premise
212	interval	_	_	I-Premise
213	(	_	_	I-Premise
214	CI	_	_	I-Premise
215	)	_	_	I-Premise
216	0	_	_	I-Premise
217	.	_	_	I-Premise

218	85	_	_	I-Premise
219	-	_	_	I-Premise
220	1	_	_	I-Premise
221	.	_	_	I-Premise

222	15	_	_	I-Premise
223	;	_	_	I-Premise
224	P	_	_	I-Premise
225	=	_	_	I-Premise
226	0	_	_	I-Premise
227	.	_	_	I-Premise

228	93	_	_	I-Premise
229	]	_	_	I-Premise
230	.	_	_	I-Premise

231	The	_	_	B-Premise
232	median	_	_	I-Premise
233	overall	_	_	I-Premise
234	survival	_	_	I-Premise
235	(	_	_	I-Premise
236	OS	_	_	I-Premise
237	)	_	_	I-Premise
238	was	_	_	I-Premise
239	34	_	_	I-Premise
240	.	_	_	I-Premise

241	1	_	_	I-Premise
242	and	_	_	I-Premise
243	30	_	_	I-Premise
244	.	_	_	I-Premise

245	7	_	_	I-Premise
246	months	_	_	I-Premise
247	in	_	_	I-Premise
248	Arms	_	_	I-Premise
249	A	_	_	I-Premise
250	and	_	_	I-Premise
251	B	_	_	I-Premise
252	,	_	_	I-Premise
253	respectively	_	_	I-Premise
254	(	_	_	I-Premise
255	HR	_	_	I-Premise
256	0	_	_	I-Premise
257	.	_	_	I-Premise

258	98	_	_	I-Premise
259	;	_	_	I-Premise
260	95	_	_	I-Premise
261	%	_	_	I-Premise
262	CI	_	_	I-Premise
263	0	_	_	I-Premise
264	.	_	_	I-Premise

265	81	_	_	I-Premise
266	-	_	_	I-Premise
267	1	_	_	I-Premise
268	.	_	_	I-Premise

269	18	_	_	I-Premise
270	,	_	_	I-Premise
271	P	_	_	I-Premise
272	=	_	_	I-Premise
273	0	_	_	I-Premise
274	.	_	_	I-Premise

275	82	_	_	I-Premise
276	)	_	_	I-Premise
277	.	_	_	I-Premise

278	In	_	_	B-Premise
279	multivariate	_	_	I-Premise
280	analysis	_	_	I-Premise
281	,	_	_	I-Premise
282	baseline	_	_	I-Premise
283	neutrophil	_	_	I-Premise
284	(	_	_	I-Premise
285	P	_	_	I-Premise
286	<	_	_	I-Premise
287	0	_	_	I-Premise
288	.	_	_	I-Premise

289	001	_	_	I-Premise
290	)	_	_	I-Premise
291	,	_	_	I-Premise
292	baseline	_	_	I-Premise
293	platelet	_	_	I-Premise
294	counts	_	_	I-Premise
295	(	_	_	I-Premise
296	P	_	_	I-Premise
297	<	_	_	I-Premise
298	0	_	_	I-Premise
299	.	_	_	I-Premise

300	001	_	_	I-Premise
301	)	_	_	I-Premise
302	and	_	_	I-Premise
303	the	_	_	I-Premise
304	difference	_	_	I-Premise
305	between	_	_	I-Premise
306	white	_	_	I-Premise
307	blood	_	_	I-Premise
308	cell	_	_	I-Premise
309	(	_	_	I-Premise
310	WBC	_	_	I-Premise
311	)	_	_	I-Premise
312	and	_	_	I-Premise
313	neutrophil	_	_	I-Premise
314	count	_	_	I-Premise
315	(	_	_	I-Premise
316	P	_	_	I-Premise
317	=	_	_	I-Premise
318	0	_	_	I-Premise
319	.	_	_	I-Premise

320	009	_	_	I-Premise
321	)	_	_	I-Premise
322	had	_	_	I-Premise
323	a	_	_	I-Premise
324	significant	_	_	I-Premise
325	adverse	_	_	I-Premise
326	prognostic	_	_	I-Premise
327	value	_	_	I-Premise
328	.	_	_	I-Premise

329	Intrapatient	_	_	B-Claim
330	dose	_	_	I-Claim
331	escalation	_	_	I-Claim
332	of	_	_	I-Claim
333	carboplatin	_	_	I-Claim
334	based	_	_	I-Claim
335	on	_	_	I-Claim
336	nadir	_	_	I-Claim
337	blood	_	_	I-Claim
338	counts	_	_	I-Claim
339	is	_	_	I-Claim
340	feasible	_	_	I-Claim
341	and	_	_	I-Claim
342	safe	_	_	I-Claim
343	.	_	_	I-Claim

344	However	_	_	B-Claim
345	,	_	_	I-Claim
346	it	_	_	I-Claim
347	provided	_	_	I-Claim
348	no	_	_	I-Claim
349	improvement	_	_	I-Claim
350	in	_	_	I-Claim
351	PFS	_	_	I-Claim
352	or	_	_	I-Claim
353	OS	_	_	I-Claim
354	compared	_	_	I-Claim
355	with	_	_	I-Claim
356	flat	_	_	I-Claim
357	dosing	_	_	I-Claim
358	.	_	_	I-Claim

359	Baseline	_	_	O
360	neutrophils	_	_	O
361	over	_	_	O
362	-	_	_	O
363	ride	_	_	O
364	nadir	_	_	O
365	counts	_	_	O
366	in	_	_	O
367	prognostic	_	_	O
368	significance	_	_	O
369	.	_	_	O

370	These	_	_	O
371	data	_	_	O
372	may	_	_	O
373	have	_	_	O
374	wider	_	_	O
375	implications	_	_	O
376	particularly	_	_	O
377	in	_	_	O
378	respect	_	_	O
379	of	_	_	O
380	the	_	_	O
381	management	_	_	O
382	of	_	_	O
383	chemotherapy	_	_	O
384	-	_	_	O
385	induced	_	_	O
386	neutropenia	_	_	O
387	.	_	_	O


0	The	_	_	O
1	objective	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	is	_	_	O
6	to	_	_	O
7	explore	_	_	O
8	the	_	_	O
9	inflammatory	_	_	O
10	modulation	_	_	O
11	effect	_	_	O
12	of	_	_	O
13	glutamine	_	_	O
14	-	_	_	O
15	enriched	_	_	O
16	total	_	_	O
17	parenteral	_	_	O
18	nutrition	_	_	O
19	(	_	_	O
20	TPN	_	_	O
21	)	_	_	O
22	by	_	_	O
23	investigating	_	_	O
24	the	_	_	O
25	alterations	_	_	O
26	of	_	_	O
27	inflammation	_	_	O
28	-	_	_	O
29	related	_	_	O
30	cytokines	_	_	O
31	in	_	_	O
32	gastrointestinal	_	_	O
33	(	_	_	O
34	GI	_	_	O
35	)	_	_	O
36	cancer	_	_	O
37	patients	_	_	O
38	postoperatively	_	_	O
39	.	_	_	O

40	Fifty	_	_	O
41	GI	_	_	O
42	cancer	_	_	O
43	patients	_	_	O
44	received	_	_	O
45	postoperative	_	_	O
46	7	_	_	O
47	days	_	_	O
48	of	_	_	O
49	isocaloric	_	_	O
50	and	_	_	O
51	isonitrogenous	_	_	O
52	TPN	_	_	O
53	after	_	_	O
54	operation	_	_	O
55	.	_	_	O

56	They	_	_	O
57	were	_	_	O
58	randomly	_	_	O
59	divided	_	_	O
60	to	_	_	O
61	receive	_	_	O
62	either	_	_	O
63	glutamine	_	_	O
64	-	_	_	O
65	enriched	_	_	O
66	TPN	_	_	O
67	or	_	_	O
68	standard	_	_	O
69	TPN	_	_	O
70	.	_	_	O

71	The	_	_	O
72	inflammation	_	_	O
73	-	_	_	O
74	related	_	_	O
75	cytokines	_	_	O
76	including	_	_	O
77	interleukin	_	_	O
78	-	_	_	O
79	6	_	_	O
80	,	_	_	O
81	interleukin	_	_	O
82	-	_	_	O
83	10	_	_	O
84	,	_	_	O
85	and	_	_	O
86	tumor	_	_	O
87	necrosis	_	_	O
88	factor	_	_	O
89	-	_	_	O
90	α	_	_	O
91	were	_	_	O
92	also	_	_	O
93	determined	_	_	O
94	.	_	_	O

95	Records	_	_	O
96	of	_	_	O
97	nutritional	_	_	O
98	assessments	_	_	O
99	,	_	_	O
100	inflammatory	_	_	O
101	status	_	_	O
102	,	_	_	O
103	and	_	_	O
104	postoperative	_	_	O
105	complications	_	_	O
106	were	_	_	O
107	compared	_	_	O
108	between	_	_	O
109	the	_	_	O
110	two	_	_	O
111	groups	_	_	O
112	.	_	_	O

113	Of	_	_	O
114	50	_	_	O
115	enrolled	_	_	O
116	patients	_	_	O
117	,	_	_	O
118	25	_	_	O
119	patients	_	_	O
120	were	_	_	O
121	classified	_	_	O
122	as	_	_	O
123	the	_	_	O
124	intervention	_	_	O
125	group	_	_	O
126	,	_	_	O
127	and	_	_	O
128	the	_	_	O
129	control	_	_	O
130	group	_	_	O
131	also	_	_	O
132	comprised	_	_	O
133	25	_	_	O
134	patients	_	_	O
135	.	_	_	O

136	The	_	_	O
137	differences	_	_	O
138	of	_	_	O
139	gender	_	_	O
140	,	_	_	O
141	age	_	_	O
142	,	_	_	O
143	primary	_	_	O
144	GI	_	_	O
145	malignancies	_	_	O
146	,	_	_	O
147	and	_	_	O
148	hematological	_	_	O
149	and	_	_	O
150	biochemical	_	_	O
151	data	_	_	O
152	between	_	_	O
153	the	_	_	O
154	two	_	_	O
155	compared	_	_	O
156	groups	_	_	O
157	were	_	_	O
158	not	_	_	O
159	statistically	_	_	O
160	significant	_	_	O
161	(	_	_	O
162	all	_	_	O
163	P	_	_	O
164	>	_	_	O
165	0	_	_	O
166	.	_	_	O

167	05	_	_	O
168	)	_	_	O
169	.	_	_	O

170	Compared	_	_	B-Premise
171	with	_	_	I-Premise
172	standard	_	_	I-Premise
173	TPN	_	_	I-Premise
174	,	_	_	I-Premise
175	a	_	_	I-Premise
176	higher	_	_	I-Premise
177	serum	_	_	I-Premise
178	prealbumin	_	_	I-Premise
179	level	_	_	I-Premise
180	and	_	_	I-Premise
181	better	_	_	I-Premise
182	nitrogen	_	_	I-Premise
183	balance	_	_	I-Premise
184	were	_	_	I-Premise
185	observed	_	_	I-Premise
186	in	_	_	I-Premise
187	glutamine	_	_	I-Premise
188	-	_	_	I-Premise
189	enriched	_	_	I-Premise
190	TPN	_	_	I-Premise
191	(	_	_	I-Premise
192	P	_	_	I-Premise
193	=	_	_	I-Premise
194	0	_	_	I-Premise
195	.	_	_	I-Premise

196	039	_	_	I-Premise
197	and	_	_	I-Premise
198	0	_	_	I-Premise
199	.	_	_	I-Premise

200	048	_	_	I-Premise
201	respectively	_	_	I-Premise
202	)	_	_	I-Premise
203	.	_	_	I-Premise

204	A	_	_	B-Premise
205	significantly	_	_	I-Premise
206	lower	_	_	I-Premise
207	serum	_	_	I-Premise
208	interleukin	_	_	I-Premise
209	-	_	_	I-Premise
210	6	_	_	I-Premise
211	level	_	_	I-Premise
212	was	_	_	I-Premise
213	found	_	_	I-Premise
214	in	_	_	I-Premise
215	comparing	_	_	I-Premise
216	glutamine	_	_	I-Premise
217	-	_	_	I-Premise
218	enriched	_	_	I-Premise
219	with	_	_	I-Premise
220	standard	_	_	I-Premise
221	TPN	_	_	I-Premise
222	(	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	0	_	_	I-Premise
226	.	_	_	I-Premise

227	01	_	_	I-Premise
228	)	_	_	I-Premise
229	,	_	_	I-Premise
230	but	_	_	B-Premise
231	not	_	_	I-Premise
232	in	_	_	I-Premise
233	interleukin	_	_	I-Premise
234	-	_	_	I-Premise
235	10	_	_	I-Premise
236	(	_	_	I-Premise
237	P	_	_	I-Premise
238	=	_	_	I-Premise
239	0	_	_	I-Premise
240	.	_	_	I-Premise

241	374	_	_	I-Premise
242	)	_	_	I-Premise
243	and	_	_	I-Premise
244	tumor	_	_	I-Premise
245	necrosis	_	_	I-Premise
246	factor	_	_	I-Premise
247	-	_	_	I-Premise
248	α	_	_	I-Premise
249	levels	_	_	I-Premise
250	(	_	_	I-Premise
251	P	_	_	I-Premise
252	=	_	_	I-Premise
253	0	_	_	I-Premise
254	.	_	_	I-Premise

255	653	_	_	I-Premise
256	)	_	_	I-Premise
257	.	_	_	I-Premise

258	Moreover	_	_	O
259	,	_	_	O
260	a	_	_	B-Premise
261	significant	_	_	I-Premise
262	lower	_	_	I-Premise
263	serum	_	_	I-Premise
264	C	_	_	I-Premise
265	-	_	_	I-Premise
266	reactive	_	_	I-Premise
267	protein	_	_	I-Premise
268	level	_	_	I-Premise
269	was	_	_	I-Premise
270	detected	_	_	I-Premise
271	in	_	_	I-Premise
272	glutamine	_	_	I-Premise
273	-	_	_	I-Premise
274	enriched	_	_	I-Premise
275	TPN	_	_	I-Premise
276	compared	_	_	I-Premise
277	with	_	_	I-Premise
278	standard	_	_	I-Premise
279	TPN	_	_	I-Premise
280	(	_	_	I-Premise
281	P	_	_	I-Premise
282	=	_	_	I-Premise
283	0	_	_	I-Premise
284	.	_	_	I-Premise

285	013	_	_	I-Premise
286	)	_	_	I-Premise
287	.	_	_	I-Premise

288	Indeed	_	_	O
289	,	_	_	O
290	four	_	_	B-Premise
291	cases	_	_	I-Premise
292	of	_	_	I-Premise
293	postoperative	_	_	I-Premise
294	infectious	_	_	I-Premise
295	complications	_	_	I-Premise
296	were	_	_	I-Premise
297	noted	_	_	I-Premise
298	in	_	_	I-Premise
299	the	_	_	I-Premise
300	control	_	_	I-Premise
301	group	_	_	I-Premise
302	,	_	_	I-Premise
303	but	_	_	I-Premise
304	no	_	_	I-Premise
305	postoperative	_	_	I-Premise
306	infectious	_	_	I-Premise
307	complications	_	_	I-Premise
308	were	_	_	I-Premise
309	observed	_	_	I-Premise
310	in	_	_	I-Premise
311	the	_	_	I-Premise
312	interventional	_	_	I-Premise
313	group	_	_	I-Premise
314	(	_	_	I-Premise
315	P	_	_	I-Premise
316	=	_	_	I-Premise
317	0	_	_	I-Premise
318	.	_	_	I-Premise

319	037	_	_	I-Premise
320	)	_	_	I-Premise
321	.	_	_	I-Premise

322	Our	_	_	B-Claim
323	present	_	_	I-Claim
324	study	_	_	I-Claim
325	shows	_	_	I-Claim
326	that	_	_	I-Claim
327	glutamine	_	_	I-Claim
328	-	_	_	I-Claim
329	enriched	_	_	I-Claim
330	TPN	_	_	I-Claim
331	may	_	_	I-Claim
332	be	_	_	I-Claim
333	beneficial	_	_	I-Claim
334	in	_	_	I-Claim
335	improving	_	_	I-Claim
336	the	_	_	I-Claim
337	inflammatory	_	_	I-Claim
338	status	_	_	I-Claim
339	and	_	_	I-Claim
340	decreasing	_	_	I-Claim
341	the	_	_	I-Claim
342	infectious	_	_	I-Claim
343	morbidity	_	_	I-Claim
344	in	_	_	I-Claim
345	postoperative	_	_	I-Claim
346	GI	_	_	I-Claim
347	cancer	_	_	I-Claim
348	patients	_	_	I-Claim
349	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	whether	_	_	O
3	frequent	_	_	O
4	hospital	_	_	O
5	follow	_	_	O
6	-	_	_	O
7	up	_	_	O
8	in	_	_	O
9	the	_	_	O
10	first	_	_	O
11	year	_	_	O
12	after	_	_	O
13	breast	_	_	O
14	cancer	_	_	O
15	treatment	_	_	O
16	might	_	_	O
17	partly	_	_	O
18	be	_	_	O
19	replaced	_	_	O
20	by	_	_	O
21	nurse	_	_	O
22	-	_	_	O
23	led	_	_	O
24	telephone	_	_	O
25	follow	_	_	O
26	-	_	_	O
27	up	_	_	O
28	without	_	_	O
29	deteriorating	_	_	O
30	health	_	_	O
31	-	_	_	O
32	related	_	_	O
33	quality	_	_	O
34	of	_	_	O
35	life	_	_	O
36	(	_	_	O
37	HRQoL	_	_	O
38	)	_	_	O
39	,	_	_	O
40	and	_	_	O
41	whether	_	_	O
42	a	_	_	O
43	short	_	_	O
44	educational	_	_	O
45	group	_	_	O
46	programme	_	_	O
47	(	_	_	O
48	EGP	_	_	O
49	)	_	_	O
50	would	_	_	O
51	enhance	_	_	O
52	HRQoL	_	_	O
53	.	_	_	O

54	A	_	_	O
55	multicentre	_	_	O
56	pragmatic	_	_	O
57	randomised	_	_	O
58	controlled	_	_	O
59	trial	_	_	O
60	(	_	_	O
61	RCT	_	_	O
62	)	_	_	O
63	with	_	_	O
64	a	_	_	O
65	2	_	_	O
66	×	_	_	O
67	2	_	_	O
68	factorial	_	_	O
69	design	_	_	O
70	was	_	_	O
71	performed	_	_	O
72	among	_	_	O
73	320	_	_	O
74	breast	_	_	O
75	cancer	_	_	O
76	patients	_	_	O
77	who	_	_	O
78	were	_	_	O
79	treated	_	_	O
80	with	_	_	O
81	curative	_	_	O
82	intent	_	_	O
83	.	_	_	O

84	Participants	_	_	O
85	were	_	_	O
86	randomised	_	_	O
87	to	_	_	O
88	follow	_	_	O
89	-	_	_	O
90	up	_	_	O
91	care	_	_	O
92	as	_	_	O
93	usual	_	_	O
94	(	_	_	O
95	3	_	_	O
96	-	_	_	O
97	monthly	_	_	O
98	outpatient	_	_	O
99	clinic	_	_	O
100	visits	_	_	O
101	)	_	_	O
102	,	_	_	O
103	nurse	_	_	O
104	-	_	_	O
105	led	_	_	O
106	telephone	_	_	O
107	follow	_	_	O
108	-	_	_	O
109	up	_	_	O
110	,	_	_	O
111	or	_	_	O
112	the	_	_	O
113	former	_	_	O
114	strategies	_	_	O
115	combined	_	_	O
116	with	_	_	O
117	an	_	_	O
118	educational	_	_	O
119	group	_	_	O
120	programme	_	_	O
121	.	_	_	O

122	The	_	_	O
123	primary	_	_	O
124	outcome	_	_	O
125	for	_	_	O
126	both	_	_	O
127	interventions	_	_	O
128	was	_	_	O
129	HRQoL	_	_	O
130	,	_	_	O
131	measured	_	_	O
132	by	_	_	O
133	EORTC	_	_	O
134	QLQ	_	_	O
135	-	_	_	O
136	C30	_	_	O
137	.	_	_	O

138	Secondary	_	_	O
139	outcomes	_	_	O
140	were	_	_	O
141	role	_	_	O
142	and	_	_	O
143	emotional	_	_	O
144	functioning	_	_	O
145	and	_	_	O
146	feelings	_	_	O
147	of	_	_	O
148	control	_	_	O
149	and	_	_	O
150	anxiety	_	_	O
151	.	_	_	O

152	Data	_	_	O
153	of	_	_	O
154	299	_	_	O
155	patients	_	_	O
156	were	_	_	O
157	available	_	_	O
158	for	_	_	O
159	evaluation	_	_	O
160	.	_	_	O

161	There	_	_	B-Premise
162	was	_	_	I-Premise
163	no	_	_	I-Premise
164	significant	_	_	I-Premise
165	difference	_	_	I-Premise
166	in	_	_	I-Premise
167	HRQoL	_	_	I-Premise
168	between	_	_	I-Premise
169	nurse	_	_	I-Premise
170	-	_	_	I-Premise
171	led	_	_	I-Premise
172	telephone	_	_	I-Premise
173	and	_	_	I-Premise
174	hospital	_	_	I-Premise
175	follow	_	_	I-Premise
176	-	_	_	I-Premise
177	up	_	_	I-Premise
178	at	_	_	I-Premise
179	12	_	_	I-Premise
180	months	_	_	I-Premise
181	after	_	_	I-Premise
182	treatment	_	_	I-Premise
183	(	_	_	I-Premise
184	p	_	_	I-Premise
185	=	_	_	I-Premise
186	0	_	_	I-Premise
187	.	_	_	I-Premise

188	42	_	_	I-Premise
189	;	_	_	I-Premise
190	95	_	_	I-Premise
191	%	_	_	I-Premise
192	confidence	_	_	I-Premise
193	interval	_	_	I-Premise
194	(	_	_	I-Premise
195	CI	_	_	I-Premise
196	)	_	_	I-Premise
197	for	_	_	I-Premise
198	difference	_	_	I-Premise
199	:	_	_	I-Premise
200	-	_	_	I-Premise
201	1	_	_	I-Premise
202	.	_	_	I-Premise

203	93	_	_	I-Premise
204	-	_	_	I-Premise
205	4	_	_	I-Premise
206	.	_	_	I-Premise

207	64	_	_	I-Premise
208	)	_	_	I-Premise
209	and	_	_	I-Premise
210	neither	_	_	I-Premise
211	between	_	_	I-Premise
212	follow	_	_	I-Premise
213	-	_	_	I-Premise
214	up	_	_	I-Premise
215	with	_	_	I-Premise
216	or	_	_	I-Premise
217	without	_	_	I-Premise
218	EGP	_	_	I-Premise
219	(	_	_	I-Premise
220	p	_	_	I-Premise
221	=	_	_	I-Premise
222	0	_	_	I-Premise
223	.	_	_	I-Premise

224	86	_	_	I-Premise
225	;	_	_	I-Premise
226	95	_	_	I-Premise
227	%	_	_	I-Premise
228	CI	_	_	I-Premise
229	for	_	_	I-Premise
230	difference	_	_	I-Premise
231	:	_	_	I-Premise
232	-	_	_	I-Premise
233	3	_	_	I-Premise
234	.	_	_	I-Premise

235	59	_	_	I-Premise
236	-	_	_	I-Premise
237	3	_	_	I-Premise
238	.	_	_	I-Premise

239	00	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	Furthermore	_	_	O
243	,	_	_	O
244	no	_	_	B-Premise
245	differences	_	_	I-Premise
246	between	_	_	I-Premise
247	the	_	_	I-Premise
248	intervention	_	_	I-Premise
249	groups	_	_	I-Premise
250	and	_	_	I-Premise
251	their	_	_	I-Premise
252	corresponding	_	_	I-Premise
253	control	_	_	I-Premise
254	groups	_	_	I-Premise
255	were	_	_	I-Premise
256	found	_	_	I-Premise
257	in	_	_	I-Premise
258	role	_	_	I-Premise
259	and	_	_	I-Premise
260	emotional	_	_	I-Premise
261	functioning	_	_	I-Premise
262	,	_	_	I-Premise
263	and	_	_	I-Premise
264	feelings	_	_	I-Premise
265	of	_	_	I-Premise
266	control	_	_	I-Premise
267	and	_	_	I-Premise
268	anxiety	_	_	I-Premise
269	(	_	_	I-Premise
270	all	_	_	I-Premise
271	p	_	_	I-Premise
272	-	_	_	I-Premise
273	values	_	_	I-Premise
274	>	_	_	I-Premise
275	0	_	_	I-Premise
276	.	_	_	I-Premise

277	05	_	_	I-Premise
278	)	_	_	I-Premise
279	.	_	_	I-Premise

280	Replacement	_	_	B-Claim
281	of	_	_	I-Claim
282	most	_	_	I-Claim
283	hospital	_	_	I-Claim
284	follow	_	_	I-Claim
285	-	_	_	I-Claim
286	up	_	_	I-Claim
287	visits	_	_	I-Claim
288	in	_	_	I-Claim
289	the	_	_	I-Claim
290	first	_	_	I-Claim
291	year	_	_	I-Claim
292	after	_	_	I-Claim
293	breast	_	_	I-Claim
294	cancer	_	_	I-Claim
295	treatment	_	_	I-Claim
296	by	_	_	I-Claim
297	nurse	_	_	I-Claim
298	-	_	_	I-Claim
299	led	_	_	I-Claim
300	telephone	_	_	I-Claim
301	follow	_	_	I-Claim
302	-	_	_	I-Claim
303	up	_	_	I-Claim
304	does	_	_	I-Claim
305	not	_	_	I-Claim
306	impede	_	_	I-Claim
307	patient	_	_	I-Claim
308	outcomes	_	_	I-Claim
309	.	_	_	I-Claim

310	Hence	_	_	O
311	,	_	_	O
312	nurse	_	_	B-Claim
313	-	_	_	I-Claim
314	led	_	_	I-Claim
315	telephone	_	_	I-Claim
316	follow	_	_	I-Claim
317	-	_	_	I-Claim
318	up	_	_	I-Claim
319	seems	_	_	I-Claim
320	an	_	_	I-Claim
321	appropriate	_	_	I-Claim
322	way	_	_	I-Claim
323	to	_	_	I-Claim
324	reduce	_	_	I-Claim
325	clinic	_	_	I-Claim
326	visits	_	_	I-Claim
327	and	_	_	I-Claim
328	represents	_	_	I-Claim
329	an	_	_	I-Claim
330	accepted	_	_	I-Claim
331	alternative	_	_	I-Claim
332	strategy	_	_	I-Claim
333	.	_	_	I-Claim

334	An	_	_	O
335	EGP	_	_	O
336	does	_	_	O
337	not	_	_	O
338	unequivocally	_	_	O
339	affect	_	_	O
340	positive	_	_	O
341	HRQoL	_	_	O
342	outcomes	_	_	O
343	.	_	_	O


0	Exercise	_	_	O
1	training	_	_	O
2	improves	_	_	O
3	supportive	_	_	O
4	care	_	_	O
5	outcomes	_	_	O
6	in	_	_	O
7	patients	_	_	O
8	with	_	_	O
9	breast	_	_	O
10	cancer	_	_	O
11	who	_	_	O
12	are	_	_	O
13	receiving	_	_	O
14	adjuvant	_	_	O
15	therapy	_	_	O
16	,	_	_	O
17	but	_	_	O
18	the	_	_	O
19	responses	_	_	O
20	are	_	_	O
21	heterogeneous	_	_	O
22	.	_	_	O

23	In	_	_	O
24	this	_	_	O
25	study	_	_	O
26	,	_	_	O
27	the	_	_	O
28	authors	_	_	O
29	examined	_	_	O
30	personal	_	_	O
31	and	_	_	O
32	clinical	_	_	O
33	factors	_	_	O
34	that	_	_	O
35	may	_	_	O
36	predict	_	_	O
37	exercise	_	_	O
38	training	_	_	O
39	responses	_	_	O
40	.	_	_	O

41	Breast	_	_	O
42	cancer	_	_	O
43	patients	_	_	O
44	who	_	_	O
45	were	_	_	O
46	initiating	_	_	O
47	adjuvant	_	_	O
48	chemotherapy	_	_	O
49	(	_	_	O
50	N	_	_	O
51	=	_	_	O
52	242	_	_	O
53	)	_	_	O
54	were	_	_	O
55	assigned	_	_	O
56	randomly	_	_	O
57	to	_	_	O
58	receive	_	_	O
59	usual	_	_	O
60	care	_	_	O
61	(	_	_	O
62	UC	_	_	O
63	)	_	_	O
64	(	_	_	O
65	n	_	_	O
66	=	_	_	O
67	82	_	_	O
68	)	_	_	O
69	,	_	_	O
70	resistance	_	_	O
71	exercise	_	_	O
72	training	_	_	O
73	(	_	_	O
74	RET	_	_	O
75	)	_	_	O
76	(	_	_	O
77	n	_	_	O
78	=	_	_	O
79	82	_	_	O
80	)	_	_	O
81	,	_	_	O
82	or	_	_	O
83	aerobic	_	_	O
84	exercise	_	_	O
85	training	_	_	O
86	(	_	_	O
87	AET	_	_	O
88	)	_	_	O
89	(	_	_	O
90	n	_	_	O
91	=	_	_	O
92	78	_	_	O
93	)	_	_	O
94	for	_	_	O
95	the	_	_	O
96	duration	_	_	O
97	of	_	_	O
98	chemotherapy	_	_	O
99	.	_	_	O

100	Endpoints	_	_	O
101	were	_	_	O
102	quality	_	_	O
103	of	_	_	O
104	life	_	_	O
105	(	_	_	O
106	QoL	_	_	O
107	)	_	_	O
108	,	_	_	O
109	aerobic	_	_	O
110	fitness	_	_	O
111	,	_	_	O
112	muscular	_	_	O
113	strength	_	_	O
114	,	_	_	O
115	lean	_	_	O
116	body	_	_	O
117	mass	_	_	O
118	,	_	_	O
119	and	_	_	O
120	body	_	_	O
121	fat	_	_	O
122	.	_	_	O

123	Moderators	_	_	O
124	were	_	_	O
125	patient	_	_	O
126	preference	_	_	O
127	for	_	_	O
128	group	_	_	O
129	assignment	_	_	O
130	,	_	_	O
131	marital	_	_	O
132	status	_	_	O
133	,	_	_	O
134	age	_	_	O
135	,	_	_	O
136	disease	_	_	O
137	stage	_	_	O
138	,	_	_	O
139	and	_	_	O
140	chemotherapy	_	_	O
141	regimen	_	_	O
142	.	_	_	O

143	Adjusted	_	_	O
144	linear	_	_	O
145	mixed	_	_	O
146	-	_	_	O
147	model	_	_	O
148	analyses	_	_	O
149	demonstrated	_	_	O
150	that	_	_	O
151	patient	_	_	O
152	preference	_	_	O
153	moderated	_	_	O
154	QoL	_	_	O
155	response	_	_	O
156	(	_	_	O
157	P	_	_	O
158	=	_	_	O
159	.	_	_	O

160	005	_	_	O
161	)	_	_	O
162	.	_	_	O

163	Patients	_	_	B-Premise
164	who	_	_	I-Premise
165	preferred	_	_	I-Premise
166	RET	_	_	I-Premise
167	improved	_	_	I-Premise
168	QoL	_	_	I-Premise
169	when	_	_	I-Premise
170	they	_	_	I-Premise
171	were	_	_	I-Premise
172	assigned	_	_	I-Premise
173	to	_	_	I-Premise
174	receive	_	_	I-Premise
175	RET	_	_	I-Premise
176	compared	_	_	I-Premise
177	with	_	_	I-Premise
178	UC	_	_	I-Premise
179	(	_	_	I-Premise
180	mean	_	_	I-Premise
181	difference	_	_	I-Premise
182	,	_	_	I-Premise
183	16	_	_	I-Premise
184	.	_	_	I-Premise

185	5	_	_	I-Premise
186	;	_	_	I-Premise
187	95	_	_	I-Premise
188	%	_	_	I-Premise
189	confidence	_	_	I-Premise
190	interval	_	_	I-Premise
191	[	_	_	I-Premise
192	95	_	_	I-Premise
193	%	_	_	I-Premise
194	CI	_	_	I-Premise
195	]	_	_	I-Premise
196	,	_	_	I-Premise
197	4	_	_	I-Premise
198	.	_	_	I-Premise

199	3	_	_	I-Premise
200	-	_	_	I-Premise
201	28	_	_	I-Premise
202	.	_	_	I-Premise

203	7	_	_	I-Premise
204	;	_	_	I-Premise
205	P	_	_	I-Premise
206	=	_	_	I-Premise
207	.	_	_	I-Premise

208	008	_	_	I-Premise
209	)	_	_	I-Premise
210	or	_	_	I-Premise
211	AET	_	_	I-Premise
212	(	_	_	I-Premise
213	mean	_	_	I-Premise
214	difference	_	_	I-Premise
215	,	_	_	I-Premise
216	11	_	_	I-Premise
217	;	_	_	I-Premise
218	95	_	_	I-Premise
219	%	_	_	I-Premise
220	CI	_	_	I-Premise
221	,	_	_	I-Premise
222	-	_	_	I-Premise
223	1	_	_	I-Premise
224	.	_	_	I-Premise

225	1	_	_	I-Premise
226	-	_	_	I-Premise
227	23	_	_	I-Premise
228	.	_	_	I-Premise

229	4	_	_	I-Premise
230	;	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	.	_	_	I-Premise

234	076	_	_	I-Premise
235	)	_	_	I-Premise
236	.	_	_	I-Premise

237	Patients	_	_	B-Premise
238	who	_	_	I-Premise
239	had	_	_	I-Premise
240	no	_	_	I-Premise
241	preference	_	_	I-Premise
242	had	_	_	I-Premise
243	improved	_	_	I-Premise
244	QoL	_	_	I-Premise
245	when	_	_	I-Premise
246	they	_	_	I-Premise
247	were	_	_	I-Premise
248	assigned	_	_	I-Premise
249	to	_	_	I-Premise
250	receive	_	_	I-Premise
251	AET	_	_	I-Premise
252	compared	_	_	I-Premise
253	with	_	_	I-Premise
254	RET	_	_	I-Premise
255	(	_	_	I-Premise
256	mean	_	_	I-Premise
257	difference	_	_	I-Premise
258	,	_	_	I-Premise
259	23	_	_	I-Premise
260	;	_	_	I-Premise
261	95	_	_	I-Premise
262	%	_	_	I-Premise
263	CI	_	_	I-Premise
264	,	_	_	I-Premise
265	4	_	_	I-Premise
266	.	_	_	I-Premise

267	9	_	_	I-Premise
268	-	_	_	I-Premise
269	41	_	_	I-Premise
270	;	_	_	I-Premise
271	P	_	_	I-Premise
272	=	_	_	I-Premise
273	.	_	_	I-Premise

274	014	_	_	I-Premise
275	)	_	_	I-Premise
276	.	_	_	I-Premise

277	Marital	_	_	B-Premise
278	status	_	_	I-Premise
279	also	_	_	I-Premise
280	moderated	_	_	I-Premise
281	QoL	_	_	I-Premise
282	response	_	_	I-Premise
283	(	_	_	I-Premise
284	P	_	_	I-Premise
285	=	_	_	I-Premise
286	.	_	_	I-Premise

287	026	_	_	I-Premise
288	)	_	_	I-Premise
289	,	_	_	I-Premise
290	age	_	_	I-Premise
291	moderated	_	_	I-Premise
292	aerobic	_	_	I-Premise
293	fitness	_	_	I-Premise
294	response	_	_	I-Premise
295	(	_	_	I-Premise
296	P	_	_	I-Premise
297	=	_	_	I-Premise
298	.	_	_	I-Premise

299	029	_	_	I-Premise
300	)	_	_	I-Premise
301	,	_	_	I-Premise
302	chemotherapy	_	_	I-Premise
303	regimen	_	_	I-Premise
304	moderated	_	_	I-Premise
305	strength	_	_	I-Premise
306	gain	_	_	I-Premise
307	(	_	_	I-Premise
308	P	_	_	I-Premise
309	=	_	_	I-Premise
310	.	_	_	I-Premise

311	009	_	_	I-Premise
312	)	_	_	I-Premise
313	,	_	_	I-Premise
314	and	_	_	I-Premise
315	disease	_	_	I-Premise
316	stage	_	_	I-Premise
317	moderated	_	_	I-Premise
318	both	_	_	I-Premise
319	lean	_	_	I-Premise
320	body	_	_	I-Premise
321	mass	_	_	I-Premise
322	gain	_	_	I-Premise
323	(	_	_	I-Premise
324	P	_	_	I-Premise
325	<	_	_	I-Premise
326	.	_	_	I-Premise

327	001	_	_	I-Premise
328	)	_	_	I-Premise
329	and	_	_	I-Premise
330	fat	_	_	I-Premise
331	loss	_	_	I-Premise
332	(	_	_	I-Premise
333	P	_	_	I-Premise
334	=	_	_	I-Premise
335	.	_	_	I-Premise

336	059	_	_	I-Premise
337	)	_	_	I-Premise
338	.	_	_	I-Premise

339	Unmarried	_	_	B-Premise
340	,	_	_	I-Premise
341	younger	_	_	I-Premise
342	patients	_	_	I-Premise
343	who	_	_	I-Premise
344	were	_	_	I-Premise
345	receiving	_	_	I-Premise
346	nontaxane	_	_	I-Premise
347	-	_	_	I-Premise
348	based	_	_	I-Premise
349	therapies	_	_	I-Premise
350	and	_	_	I-Premise
351	had	_	_	I-Premise
352	more	_	_	I-Premise
353	advanced	_	_	I-Premise
354	disease	_	_	I-Premise
355	stage	_	_	I-Premise
356	experienced	_	_	I-Premise
357	better	_	_	I-Premise
358	outcomes	_	_	I-Premise
359	.	_	_	I-Premise

360	The	_	_	O
361	findings	_	_	O
362	were	_	_	O
363	not	_	_	O
364	explained	_	_	O
365	by	_	_	O
366	differences	_	_	O
367	in	_	_	O
368	adherence	_	_	O
369	.	_	_	O

370	Patient	_	_	B-Claim
371	preference	_	_	I-Claim
372	,	_	_	I-Claim
373	demographic	_	_	I-Claim
374	variables	_	_	I-Claim
375	,	_	_	I-Claim
376	and	_	_	I-Claim
377	medical	_	_	I-Claim
378	variables	_	_	I-Claim
379	moderated	_	_	I-Claim
380	the	_	_	I-Claim
381	effects	_	_	I-Claim
382	of	_	_	I-Claim
383	exercise	_	_	I-Claim
384	training	_	_	I-Claim
385	in	_	_	I-Claim
386	breast	_	_	I-Claim
387	cancer	_	_	I-Claim
388	patients	_	_	I-Claim
389	who	_	_	I-Claim
390	were	_	_	I-Claim
391	receiving	_	_	I-Claim
392	chemotherapy	_	_	I-Claim
393	.	_	_	I-Claim

394	If	_	_	O
395	replicated	_	_	O
396	,	_	_	O
397	these	_	_	O
398	results	_	_	O
399	may	_	_	O
400	inform	_	_	O
401	clinical	_	_	O
402	practice	_	_	O
403	.	_	_	O


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	a	_	_	O
6	psychoeducational	_	_	O
7	intervention	_	_	O
8	in	_	_	O
9	improving	_	_	O
10	cancer	_	_	O
11	-	_	_	O
12	related	_	_	O
13	fatigue	_	_	O
14	.	_	_	O

15	This	_	_	O
16	randomized	_	_	O
17	controlled	_	_	O
18	trial	_	_	O
19	involved	_	_	O
20	109	_	_	O
21	women	_	_	O
22	commencing	_	_	O
23	adjuvant	_	_	O
24	chemotherapy	_	_	O
25	for	_	_	O
26	stage	_	_	O
27	I	_	_	O
28	or	_	_	O
29	II	_	_	O
30	breast	_	_	O
31	cancer	_	_	O
32	in	_	_	O
33	five	_	_	O
34	chemotherapy	_	_	O
35	treatment	_	_	O
36	centers	_	_	O
37	.	_	_	O

38	Intervention	_	_	O
39	group	_	_	O
40	patients	_	_	O
41	received	_	_	O
42	an	_	_	O
43	individualized	_	_	O
44	fatigue	_	_	O
45	education	_	_	O
46	and	_	_	O
47	support	_	_	O
48	program	_	_	O
49	delivered	_	_	O
50	in	_	_	O
51	the	_	_	O
52	clinic	_	_	O
53	and	_	_	O
54	by	_	_	O
55	phone	_	_	O
56	over	_	_	O
57	three	_	_	O
58	10	_	_	O
59	-	_	_	O
60	to	_	_	O
61	20	_	_	O
62	-	_	_	O
63	minute	_	_	O
64	sessions	_	_	O
65	1	_	_	O
66	week	_	_	O
67	apart	_	_	O
68	.	_	_	O

69	Instruments	_	_	O
70	included	_	_	O
71	a	_	_	O
72	numeric	_	_	O
73	rating	_	_	O
74	scale	_	_	O
75	assessing	_	_	O
76	confidence	_	_	O
77	with	_	_	O
78	managing	_	_	O
79	fatigue	_	_	O
80	;	_	_	O
81	11	_	_	O
82	-	_	_	O
83	point	_	_	O
84	numeric	_	_	O
85	rating	_	_	O
86	scales	_	_	O
87	measuring	_	_	O
88	fatigue	_	_	O
89	at	_	_	O
90	worst	_	_	O
91	,	_	_	O
92	average	_	_	O
93	,	_	_	O
94	and	_	_	O
95	best	_	_	O
96	;	_	_	O
97	the	_	_	O
98	Functional	_	_	O
99	Assessment	_	_	O
100	of	_	_	O
101	Cancer	_	_	O
102	Therapy	_	_	O
103	-	_	_	O
104	Fatigue	_	_	O
105	and	_	_	O
106	Piper	_	_	O
107	Fatigue	_	_	O
108	Scales	_	_	O
109	;	_	_	O
110	the	_	_	O
111	Cancer	_	_	O
112	Self	_	_	O
113	-	_	_	O
114	Efficacy	_	_	O
115	Scale	_	_	O
116	;	_	_	O
117	the	_	_	O
118	European	_	_	O
119	Organisation	_	_	O
120	for	_	_	O
121	Research	_	_	O
122	and	_	_	O
123	Treatment	_	_	O
124	of	_	_	O
125	Cancer	_	_	O
126	Quality	_	_	O
127	of	_	_	O
128	Life	_	_	O
129	Questionnaire	_	_	O
130	C30	_	_	O
131	;	_	_	O
132	and	_	_	O
133	the	_	_	O
134	Hospital	_	_	O
135	Anxiety	_	_	O
136	and	_	_	O
137	Depression	_	_	O
138	Scale	_	_	O
139	.	_	_	O

140	For	_	_	O
141	each	_	_	O
142	outcome	_	_	O
143	,	_	_	O
144	separate	_	_	O
145	analyses	_	_	O
146	of	_	_	O
147	covariance	_	_	O
148	of	_	_	O
149	change	_	_	O
150	scores	_	_	O
151	between	_	_	O
152	baseline	_	_	O
153	(	_	_	O
154	T1	_	_	O
155	)	_	_	O
156	and	_	_	O
157	the	_	_	O
158	three	_	_	O
159	follow	_	_	O
160	-	_	_	O
161	up	_	_	O
162	time	_	_	O
163	points	_	_	O
164	(	_	_	O
165	T2	_	_	O
166	,	_	_	O
167	T3	_	_	O
168	,	_	_	O
169	and	_	_	O
170	T4	_	_	O
171	)	_	_	O
172	were	_	_	O
173	conducted	_	_	O
174	,	_	_	O
175	controlling	_	_	O
176	for	_	_	O
177	the	_	_	O
178	variable	_	_	O
179	'	_	_	O
180	s	_	_	O
181	corresponding	_	_	O
182	baseline	_	_	O
183	value	_	_	O
184	.	_	_	O

185	Compared	_	_	B-Premise
186	with	_	_	I-Premise
187	the	_	_	I-Premise
188	intervention	_	_	I-Premise
189	group	_	_	I-Premise
190	,	_	_	I-Premise
191	mean	_	_	I-Premise
192	difference	_	_	I-Premise
193	scores	_	_	I-Premise
194	between	_	_	I-Premise
195	the	_	_	I-Premise
196	baseline	_	_	I-Premise
197	(	_	_	I-Premise
198	T1	_	_	I-Premise
199	)	_	_	I-Premise
200	and	_	_	I-Premise
201	immediate	_	_	I-Premise
202	after	_	_	I-Premise
203	the	_	_	I-Premise
204	test	_	_	I-Premise
205	(	_	_	I-Premise
206	T2	_	_	I-Premise
207	)	_	_	I-Premise
208	assessments	_	_	I-Premise
209	increased	_	_	I-Premise
210	significantly	_	_	I-Premise
211	more	_	_	I-Premise
212	for	_	_	I-Premise
213	the	_	_	I-Premise
214	control	_	_	I-Premise
215	group	_	_	I-Premise
216	for	_	_	I-Premise
217	worst	_	_	I-Premise
218	and	_	_	I-Premise
219	average	_	_	I-Premise
220	fatigue	_	_	I-Premise
221	,	_	_	I-Premise
222	Functional	_	_	I-Premise
223	Assessment	_	_	I-Premise
224	of	_	_	I-Premise
225	Cancer	_	_	I-Premise
226	Therapy	_	_	I-Premise
227	-	_	_	I-Premise
228	Fatigue	_	_	I-Premise
229	,	_	_	I-Premise
230	and	_	_	I-Premise
231	Piper	_	_	I-Premise
232	fatigue	_	_	I-Premise
233	severity	_	_	I-Premise
234	and	_	_	I-Premise
235	interference	_	_	I-Premise
236	measures	_	_	I-Premise
237	.	_	_	I-Premise

238	These	_	_	B-Premise
239	differences	_	_	I-Premise
240	were	_	_	I-Premise
241	not	_	_	I-Premise
242	observed	_	_	I-Premise
243	between	_	_	I-Premise
244	baseline	_	_	I-Premise
245	and	_	_	I-Premise
246	T3	_	_	I-Premise
247	and	_	_	I-Premise
248	T4	_	_	I-Premise
249	assessments	_	_	I-Premise
250	.	_	_	I-Premise

251	No	_	_	B-Premise
252	significant	_	_	I-Premise
253	differences	_	_	I-Premise
254	were	_	_	I-Premise
255	identified	_	_	I-Premise
256	for	_	_	I-Premise
257	any	_	_	I-Premise
258	pre	_	_	I-Premise
259	-	_	_	I-Premise
260	or	_	_	I-Premise
261	post	_	_	I-Premise
262	-	_	_	I-Premise
263	test	_	_	I-Premise
264	change	_	_	I-Premise
265	scores	_	_	I-Premise
266	for	_	_	I-Premise
267	confidence	_	_	I-Premise
268	with	_	_	I-Premise
269	managing	_	_	I-Premise
270	fatigue	_	_	I-Premise
271	,	_	_	I-Premise
272	cancer	_	_	I-Premise
273	self	_	_	I-Premise
274	-	_	_	I-Premise
275	efficacy	_	_	I-Premise
276	,	_	_	I-Premise
277	anxiety	_	_	I-Premise
278	,	_	_	I-Premise
279	depression	_	_	I-Premise
280	,	_	_	I-Premise
281	or	_	_	I-Premise
282	quality	_	_	I-Premise
283	of	_	_	I-Premise
284	life	_	_	I-Premise
285	.	_	_	I-Premise

286	Preparatory	_	_	B-Claim
287	education	_	_	I-Claim
288	and	_	_	I-Claim
289	support	_	_	I-Claim
290	has	_	_	I-Claim
291	the	_	_	I-Claim
292	potential	_	_	I-Claim
293	to	_	_	I-Claim
294	assist	_	_	I-Claim
295	women	_	_	I-Claim
296	to	_	_	I-Claim
297	cope	_	_	I-Claim
298	with	_	_	I-Claim
299	cancer	_	_	I-Claim
300	-	_	_	I-Claim
301	related	_	_	I-Claim
302	fatigue	_	_	I-Claim
303	in	_	_	I-Claim
304	the	_	_	I-Claim
305	short	_	_	I-Claim
306	term	_	_	I-Claim
307	.	_	_	I-Claim

308	However	_	_	B-Claim
309	,	_	_	I-Claim
310	further	_	_	I-Claim
311	research	_	_	I-Claim
312	is	_	_	I-Claim
313	needed	_	_	I-Claim
314	to	_	_	I-Claim
315	identify	_	_	I-Claim
316	ways	_	_	I-Claim
317	to	_	_	I-Claim
318	improve	_	_	I-Claim
319	the	_	_	I-Claim
320	potency	_	_	I-Claim
321	and	_	_	I-Claim
322	sustainability	_	_	I-Claim
323	of	_	_	I-Claim
324	psychoeducational	_	_	I-Claim
325	interventions	_	_	I-Claim
326	for	_	_	I-Claim
327	managing	_	_	I-Claim
328	cancer	_	_	I-Claim
329	-	_	_	I-Claim
330	related	_	_	I-Claim
331	fatigue	_	_	I-Claim
332	.	_	_	I-Claim


0	In	_	_	B-Premise
1	a	_	_	I-Premise
2	multinational	_	_	I-Premise
3	trial	_	_	I-Premise
4	of	_	_	I-Premise
5	anaemic	_	_	I-Premise
6	patients	_	_	I-Premise
7	with	_	_	I-Premise
8	cancer	_	_	I-Premise
9	receiving	_	_	I-Premise
10	nonplatinum	_	_	I-Premise
11	-	_	_	I-Premise
12	containing	_	_	I-Premise
13	chemotherapy	_	_	I-Premise
14	,	_	_	I-Premise
15	epoetin	_	_	I-Premise
16	-	_	_	I-Premise
17	alfa	_	_	I-Premise
18	effectively	_	_	I-Premise
19	increased	_	_	I-Premise
20	haemoglobin	_	_	I-Premise
21	levels	_	_	I-Premise
22	,	_	_	I-Premise
23	reduced	_	_	I-Premise
24	red	_	_	I-Premise
25	blood	_	_	I-Premise
26	cell	_	_	I-Premise
27	transfusion	_	_	I-Premise
28	requirements	_	_	I-Premise
29	,	_	_	I-Premise
30	and	_	_	I-Premise
31	improved	_	_	I-Premise
32	QOL	_	_	I-Premise
33	.	_	_	I-Premise

34	Although	_	_	O
35	the	_	_	O
36	study	_	_	O
37	was	_	_	O
38	not	_	_	O
39	designed	_	_	O
40	or	_	_	O
41	powered	_	_	O
42	to	_	_	O
43	evaluate	_	_	O
44	survival	_	_	O
45	,	_	_	O
46	a	_	_	B-Premise
47	survival	_	_	I-Premise
48	trend	_	_	I-Premise
49	was	_	_	I-Premise
50	noted	_	_	I-Premise
51	favouring	_	_	I-Premise
52	epoetin	_	_	I-Premise
53	-	_	_	I-Premise
54	alfa	_	_	I-Premise
55	compared	_	_	I-Premise
56	with	_	_	I-Premise
57	placebo	_	_	I-Premise
58	(	_	_	I-Premise
59	median	_	_	I-Premise
60	survival	_	_	I-Premise
61	17	_	_	I-Premise
62	vs	_	_	I-Premise
63	11	_	_	I-Premise
64	months	_	_	I-Premise
65	[	_	_	I-Premise
66	p	_	_	I-Premise
67	=	_	_	I-Premise
68	0	_	_	I-Premise
69	.	_	_	I-Premise

70	126	_	_	I-Premise
71	]	_	_	I-Premise
72	)	_	_	I-Premise
73	.	_	_	I-Premise

74	To	_	_	O
75	determine	_	_	O
76	the	_	_	O
77	incremental	_	_	O
78	cost	_	_	O
79	utility	_	_	O
80	of	_	_	O
81	epoetin	_	_	O
82	-	_	_	O
83	alfa	_	_	O
84	versus	_	_	O
85	placebo	_	_	O
86	in	_	_	O
87	anaemic	_	_	O
88	patients	_	_	O
89	with	_	_	O
90	stage	_	_	O
91	IV	_	_	O
92	breast	_	_	O
93	cancer	_	_	O
94	from	_	_	O
95	a	_	_	O
96	UK	_	_	O
97	National	_	_	O
98	Health	_	_	O
99	Service	_	_	O
100	perspective	_	_	O
101	.	_	_	O

102	Patient	_	_	O
103	data	_	_	O
104	regarding	_	_	O
105	transfusions	_	_	O
106	,	_	_	O
107	epoetin	_	_	O
108	-	_	_	O
109	alfa	_	_	O
110	usage	_	_	O
111	,	_	_	O
112	chemotherapy	_	_	O
113	treatment	_	_	O
114	cycles	_	_	O
115	,	_	_	O
116	and	_	_	O
117	adverse	_	_	O
118	events	_	_	O
119	were	_	_	O
120	recorded	_	_	O
121	,	_	_	O
122	with	_	_	O
123	survival	_	_	O
124	follow	_	_	O
125	-	_	_	O
126	up	_	_	O
127	for	_	_	O
128	12	_	_	O
129	-	_	_	O
130	36	_	_	O
131	months	_	_	O
132	post	_	_	O
133	-	_	_	O
134	study	_	_	O
135	.	_	_	O

136	Stage	_	_	O
137	IV	_	_	O
138	breast	_	_	O
139	cancer	_	_	O
140	therapy	_	_	O
141	costs	_	_	O
142	were	_	_	O
143	collected	_	_	O
144	by	_	_	O
145	surveying	_	_	O
146	UK	_	_	O
147	oncologists	_	_	O
148	,	_	_	O
149	and	_	_	O
150	utilities	_	_	O
151	for	_	_	O
152	associated	_	_	O
153	health	_	_	O
154	states	_	_	O
155	were	_	_	O
156	from	_	_	O
157	published	_	_	O
158	sources	_	_	O
159	.	_	_	O

160	Costs	_	_	O
161	were	_	_	O
162	in	_	_	O
163	British	_	_	O
164	pounds	_	_	O
165	and	_	_	O
166	year	_	_	O
167	2000	_	_	O
168	values	_	_	O
169	.	_	_	O

170	Costs	_	_	O
171	and	_	_	O
172	benefits	_	_	O
173	were	_	_	O
174	jointly	_	_	O
175	determined	_	_	O
176	for	_	_	O
177	the	_	_	O
178	stage	_	_	O
179	IV	_	_	O
180	breast	_	_	O
181	cancer	_	_	O
182	subgroup	_	_	O
183	(	_	_	O
184	n	_	_	O
185	=	_	_	O
186	55	_	_	O
187	)	_	_	O
188	.	_	_	O

189	Incremental	_	_	O
190	cost	_	_	O
191	-	_	_	O
192	utility	_	_	O
193	ratios	_	_	O
194	(	_	_	O
195	ICURs	_	_	O
196	)	_	_	O
197	were	_	_	O
198	calculated	_	_	O
199	assuming	_	_	O
200	a	_	_	O
201	6	_	_	O
202	%	_	_	O
203	annual	_	_	O
204	discount	_	_	O
205	rate	_	_	O
206	for	_	_	O
207	costs	_	_	O
208	and	_	_	O
209	a	_	_	O
210	1	_	_	O
211	.	_	_	O

212	5	_	_	O
213	%	_	_	O
214	annual	_	_	O
215	discount	_	_	O
216	rate	_	_	O
217	for	_	_	O
218	benefits	_	_	O
219	.	_	_	O

220	Bootstrap	_	_	O
221	simulations	_	_	O
222	(	_	_	O
223	10	_	_	O
224	,	_	_	O
225	000	_	_	O
226	iterations	_	_	O
227	)	_	_	O
228	were	_	_	O
229	conducted	_	_	O
230	to	_	_	O
231	account	_	_	O
232	for	_	_	O
233	uncertainty	_	_	O
234	,	_	_	O
235	and	_	_	O
236	sensitivity	_	_	O
237	analyses	_	_	O
238	were	_	_	O
239	conducted	_	_	O
240	to	_	_	O
241	establish	_	_	O
242	robustness	_	_	O
243	.	_	_	O

244	The	_	_	B-Premise
245	ICUR	_	_	I-Premise
246	for	_	_	I-Premise
247	epoetin	_	_	I-Premise
248	-	_	_	I-Premise
249	alfa	_	_	I-Premise
250	treatment	_	_	I-Premise
251	was	_	_	I-Premise
252	pounds	_	_	I-Premise
253	8	_	_	I-Premise
254	,	_	_	I-Premise
255	851	_	_	I-Premise
256	per	_	_	I-Premise
257	QALY	_	_	I-Premise
258	,	_	_	I-Premise
259	with	_	_	I-Premise
260	a	_	_	I-Premise
261	99	_	_	I-Premise
262	%	_	_	I-Premise
263	probability	_	_	I-Premise
264	of	_	_	I-Premise
265	a	_	_	I-Premise
266	positive	_	_	I-Premise
267	net	_	_	I-Premise
268	benefit	_	_	I-Premise
269	in	_	_	I-Premise
270	QALYs	_	_	I-Premise
271	(	_	_	I-Premise
272	net	_	_	I-Premise
273	benefit	_	_	I-Premise
274	=	_	_	I-Premise
275	0	_	_	I-Premise
276	.	_	_	I-Premise

277	4805	_	_	I-Premise
278	years	_	_	I-Premise
279	of	_	_	I-Premise
280	perfect	_	_	I-Premise
281	life	_	_	I-Premise
282	)	_	_	I-Premise
283	and	_	_	I-Premise
284	a	_	_	I-Premise
285	94	_	_	I-Premise
286	%	_	_	I-Premise
287	probability	_	_	I-Premise
288	of	_	_	I-Premise
289	being	_	_	I-Premise
290	acceptable	_	_	I-Premise
291	using	_	_	I-Premise
292	a	_	_	I-Premise
293	threshold	_	_	I-Premise
294	ICUR	_	_	I-Premise
295	of	_	_	I-Premise
296	pounds	_	_	I-Premise
297	30	_	_	I-Premise
298	,	_	_	I-Premise
299	000	_	_	I-Premise
300	/	_	_	I-Premise
301	QALY	_	_	I-Premise
302	.	_	_	I-Premise

303	The	_	_	B-Premise
304	main	_	_	I-Premise
305	cost	_	_	I-Premise
306	drivers	_	_	I-Premise
307	distinguishing	_	_	I-Premise
308	epoetin	_	_	I-Premise
309	-	_	_	I-Premise
310	alfa	_	_	I-Premise
311	from	_	_	I-Premise
312	placebo	_	_	I-Premise
313	were	_	_	I-Premise
314	the	_	_	I-Premise
315	costs	_	_	I-Premise
316	of	_	_	I-Premise
317	drug	_	_	I-Premise
318	and	_	_	I-Premise
319	patient	_	_	I-Premise
320	care	_	_	I-Premise
321	due	_	_	I-Premise
322	to	_	_	I-Premise
323	increased	_	_	I-Premise
324	survival	_	_	I-Premise
325	.	_	_	I-Premise

326	The	_	_	B-Claim
327	available	_	_	I-Claim
328	data	_	_	I-Claim
329	suggest	_	_	I-Claim
330	a	_	_	I-Claim
331	high	_	_	I-Claim
332	probability	_	_	I-Claim
333	of	_	_	I-Claim
334	favourable	_	_	I-Claim
335	cost	_	_	I-Claim
336	-	_	_	I-Claim
337	utility	_	_	I-Claim
338	outcomes	_	_	I-Claim
339	with	_	_	I-Claim
340	epoetin	_	_	I-Claim
341	-	_	_	I-Claim
342	alfa	_	_	I-Claim
343	treatment	_	_	I-Claim
344	for	_	_	I-Claim
345	anaemia	_	_	I-Claim
346	in	_	_	I-Claim
347	patients	_	_	I-Claim
348	with	_	_	I-Claim
349	stage	_	_	I-Claim
350	IV	_	_	I-Claim
351	breast	_	_	I-Claim
352	cancer	_	_	I-Claim
353	receiving	_	_	I-Claim
354	nonplatinum	_	_	I-Claim
355	-	_	_	I-Claim
356	containing	_	_	I-Claim
357	chemotherapy	_	_	I-Claim
358	.	_	_	I-Claim

359	Additional	_	_	B-Claim
360	studies	_	_	I-Claim
361	are	_	_	I-Claim
362	warranted	_	_	I-Claim
363	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	whether	_	_	O
3	an	_	_	O
4	Internet	_	_	B-Claim
5	-	_	_	I-Claim
6	based	_	_	I-Claim
7	tailored	_	_	I-Claim
8	education	_	_	I-Claim
9	program	_	_	I-Claim
10	is	_	_	I-Claim
11	effective	_	_	I-Claim
12	for	_	_	I-Claim
13	disease	_	_	I-Claim
14	-	_	_	I-Claim
15	free	_	_	I-Claim
16	cancer	_	_	I-Claim
17	survivors	_	_	I-Claim
18	with	_	_	I-Claim
19	cancer	_	_	I-Claim
20	-	_	_	I-Claim
21	related	_	_	I-Claim
22	fatigue	_	_	I-Claim
23	(	_	_	I-Claim
24	CRF	_	_	I-Claim
25	)	_	_	I-Claim
26	.	_	_	I-Claim

27	We	_	_	O
28	randomly	_	_	O
29	assigned	_	_	O
30	patients	_	_	O
31	who	_	_	O
32	had	_	_	O
33	completed	_	_	O
34	primary	_	_	O
35	cancer	_	_	O
36	treatment	_	_	O
37	within	_	_	O
38	the	_	_	O
39	past	_	_	O
40	24	_	_	O
41	months	_	_	O
42	in	_	_	O
43	any	_	_	O
44	of	_	_	O
45	four	_	_	O
46	Korean	_	_	O
47	hospitals	_	_	O
48	and	_	_	O
49	had	_	_	O
50	reported	_	_	O
51	moderate	_	_	O
52	to	_	_	O
53	severe	_	_	O
54	fatigue	_	_	O
55	for	_	_	O
56	at	_	_	O
57	least	_	_	O
58	1	_	_	O
59	week	_	_	O
60	to	_	_	O
61	participate	_	_	O
62	in	_	_	O
63	a	_	_	O
64	12	_	_	O
65	-	_	_	O
66	week	_	_	O
67	,	_	_	O
68	Internet	_	_	O
69	-	_	_	O
70	based	_	_	O
71	,	_	_	O
72	individually	_	_	O
73	tailored	_	_	O
74	CRF	_	_	O
75	education	_	_	O
76	program	_	_	O
77	or	_	_	O
78	to	_	_	O
79	receive	_	_	O
80	routine	_	_	O
81	care	_	_	O
82	.	_	_	O

83	We	_	_	O
84	based	_	_	O
85	the	_	_	O
86	program	_	_	O
87	on	_	_	O
88	the	_	_	O
89	CRF	_	_	O
90	guidelines	_	_	O
91	of	_	_	O
92	the	_	_	O
93	National	_	_	O
94	Comprehensive	_	_	O
95	Cancer	_	_	O
96	Network	_	_	O
97	(	_	_	O
98	NCCN	_	_	O
99	)	_	_	O
100	and	_	_	O
101	incorporated	_	_	O
102	the	_	_	O
103	transtheoretic	_	_	O
104	model	_	_	O
105	(	_	_	O
106	TTM	_	_	O
107	)	_	_	O
108	.	_	_	O

109	At	_	_	O
110	baseline	_	_	O
111	and	_	_	O
112	12	_	_	O
113	weeks	_	_	O
114	,	_	_	O
115	we	_	_	O
116	used	_	_	O
117	the	_	_	O
118	Brief	_	_	O
119	Fatigue	_	_	O
120	Inventory	_	_	O
121	(	_	_	O
122	BFI	_	_	O
123	)	_	_	O
124	and	_	_	O
125	Fatigue	_	_	O
126	Severity	_	_	O
127	Scale	_	_	O
128	(	_	_	O
129	FSS	_	_	O
130	)	_	_	O
131	as	_	_	O
132	primary	_	_	O
133	outcomes	_	_	O
134	and	_	_	O
135	the	_	_	O
136	Hospital	_	_	O
137	Anxiety	_	_	O
138	and	_	_	O
139	Depression	_	_	O
140	Scale	_	_	O
141	(	_	_	O
142	HADS	_	_	O
143	)	_	_	O
144	and	_	_	O
145	European	_	_	O
146	Organisation	_	_	O
147	for	_	_	O
148	Research	_	_	O
149	and	_	_	O
150	Treatment	_	_	O
151	of	_	_	O
152	Cancer	_	_	O
153	Quality	_	_	O
154	of	_	_	O
155	Life	_	_	O
156	Questionnaire	_	_	O
157	C30	_	_	O
158	(	_	_	O
159	EORTC	_	_	O
160	QLQ	_	_	O
161	-	_	_	O
162	C30	_	_	O
163	)	_	_	O
164	for	_	_	O
165	secondary	_	_	O
166	outcomes	_	_	O
167	.	_	_	O

168	We	_	_	O
169	recruited	_	_	O
170	273	_	_	O
171	participants	_	_	O
172	and	_	_	O
173	randomly	_	_	O
174	assigned	_	_	O
175	136	_	_	O
176	to	_	_	O
177	the	_	_	O
178	intervention	_	_	O
179	group	_	_	O
180	.	_	_	O

181	Compared	_	_	B-Premise
182	with	_	_	I-Premise
183	the	_	_	I-Premise
184	control	_	_	I-Premise
185	group	_	_	I-Premise
186	,	_	_	I-Premise
187	the	_	_	I-Premise
188	intervention	_	_	I-Premise
189	group	_	_	I-Premise
190	had	_	_	I-Premise
191	an	_	_	I-Premise
192	improvement	_	_	I-Premise
193	in	_	_	I-Premise
194	fatigue	_	_	I-Premise
195	as	_	_	I-Premise
196	shown	_	_	I-Premise
197	by	_	_	I-Premise
198	a	_	_	I-Premise
199	significantly	_	_	I-Premise
200	greater	_	_	I-Premise
201	decrease	_	_	I-Premise
202	in	_	_	I-Premise
203	BFI	_	_	I-Premise
204	global	_	_	I-Premise
205	score	_	_	I-Premise
206	(	_	_	I-Premise
207	-	_	_	I-Premise
208	0	_	_	I-Premise
209	.	_	_	I-Premise

210	66	_	_	I-Premise
211	points	_	_	I-Premise
212	;	_	_	I-Premise
213	95	_	_	I-Premise
214	%	_	_	I-Premise
215	CI	_	_	I-Premise
216	-	_	_	I-Premise
217	1	_	_	I-Premise
218	.	_	_	I-Premise

219	04	_	_	I-Premise
220	to	_	_	I-Premise
221	-	_	_	I-Premise
222	0	_	_	I-Premise
223	.	_	_	I-Premise

224	27	_	_	I-Premise
225	)	_	_	I-Premise
226	and	_	_	I-Premise
227	FSS	_	_	I-Premise
228	total	_	_	I-Premise
229	score	_	_	I-Premise
230	(	_	_	I-Premise
231	-	_	_	I-Premise
232	0	_	_	I-Premise
233	.	_	_	I-Premise

234	49	_	_	I-Premise
235	;	_	_	I-Premise
236	95	_	_	I-Premise
237	%	_	_	I-Premise
238	CI	_	_	I-Premise
239	,	_	_	I-Premise
240	-	_	_	I-Premise
241	0	_	_	I-Premise
242	.	_	_	I-Premise

243	78	_	_	I-Premise
244	to	_	_	I-Premise
245	-	_	_	I-Premise
246	0	_	_	I-Premise
247	.	_	_	I-Premise

248	21	_	_	I-Premise
249	)	_	_	I-Premise
250	.	_	_	I-Premise

251	In	_	_	B-Premise
252	secondary	_	_	I-Premise
253	outcomes	_	_	I-Premise
254	,	_	_	I-Premise
255	the	_	_	I-Premise
256	intervention	_	_	I-Premise
257	group	_	_	I-Premise
258	experienced	_	_	I-Premise
259	a	_	_	I-Premise
260	significantly	_	_	I-Premise
261	greater	_	_	I-Premise
262	decrease	_	_	I-Premise
263	in	_	_	I-Premise
264	HADS	_	_	I-Premise
265	anxiety	_	_	I-Premise
266	score	_	_	I-Premise
267	(	_	_	I-Premise
268	-	_	_	I-Premise
269	0	_	_	I-Premise
270	.	_	_	I-Premise

271	90	_	_	I-Premise
272	;	_	_	I-Premise
273	95	_	_	I-Premise
274	%	_	_	I-Premise
275	CI	_	_	I-Premise
276	,	_	_	I-Premise
277	-	_	_	I-Premise
278	1	_	_	I-Premise
279	.	_	_	I-Premise

280	51	_	_	I-Premise
281	to	_	_	I-Premise
282	-	_	_	I-Premise
283	0	_	_	I-Premise
284	.	_	_	I-Premise

285	29	_	_	I-Premise
286	)	_	_	I-Premise
287	as	_	_	I-Premise
288	well	_	_	I-Premise
289	as	_	_	I-Premise
290	global	_	_	I-Premise
291	quality	_	_	I-Premise
292	of	_	_	I-Premise
293	life	_	_	I-Premise
294	(	_	_	I-Premise
295	5	_	_	I-Premise
296	.	_	_	I-Premise

297	22	_	_	I-Premise
298	;	_	_	I-Premise
299	95	_	_	I-Premise
300	%	_	_	I-Premise
301	CI	_	_	I-Premise
302	,	_	_	I-Premise
303	0	_	_	I-Premise
304	.	_	_	I-Premise

305	93	_	_	I-Premise
306	to	_	_	I-Premise
307	9	_	_	I-Premise
308	.	_	_	I-Premise

309	50	_	_	I-Premise
310	)	_	_	I-Premise
311	and	_	_	I-Premise
312	several	_	_	I-Premise
313	functioning	_	_	I-Premise
314	scores	_	_	I-Premise
315	of	_	_	I-Premise
316	the	_	_	I-Premise
317	EORTC	_	_	I-Premise
318	QLQ	_	_	I-Premise
319	-	_	_	I-Premise
320	C30	_	_	I-Premise
321	.	_	_	I-Premise

322	An	_	_	B-Claim
323	Internet	_	_	I-Claim
324	-	_	_	I-Claim
325	based	_	_	I-Claim
326	education	_	_	I-Claim
327	program	_	_	I-Claim
328	based	_	_	I-Claim
329	on	_	_	I-Claim
330	NCCN	_	_	I-Claim
331	guidelines	_	_	I-Claim
332	and	_	_	I-Claim
333	TTM	_	_	I-Claim
334	may	_	_	I-Claim
335	help	_	_	I-Claim
336	patients	_	_	I-Claim
337	manage	_	_	I-Claim
338	CRF	_	_	I-Claim
339	.	_	_	I-Claim


0	Axillary	_	_	B-Claim
1	clearance	_	_	I-Claim
2	in	_	_	I-Claim
3	early	_	_	I-Claim
4	breast	_	_	I-Claim
5	cancer	_	_	I-Claim
6	aims	_	_	I-Claim
7	to	_	_	I-Claim
8	improve	_	_	I-Claim
9	locoregional	_	_	I-Claim
10	control	_	_	I-Claim
11	and	_	_	I-Claim
12	provide	_	_	I-Claim
13	staging	_	_	I-Claim
14	information	_	_	I-Claim
15	but	_	_	O
16	is	_	_	O
17	associated	_	_	O
18	with	_	_	O
19	undesirable	_	_	O
20	morbidity	_	_	O
21	.	_	_	O

22	We	_	_	O
23	therefore	_	_	O
24	investigated	_	_	O
25	whether	_	_	O
26	avoiding	_	_	O
27	axillary	_	_	O
28	surgery	_	_	O
29	in	_	_	O
30	older	_	_	O
31	women	_	_	O
32	would	_	_	O
33	result	_	_	O
34	in	_	_	O
35	improved	_	_	O
36	quality	_	_	O
37	of	_	_	O
38	life	_	_	O
39	(	_	_	O
40	QL	_	_	O
41	)	_	_	O
42	with	_	_	O
43	similar	_	_	O
44	disease	_	_	O
45	-	_	_	O
46	free	_	_	O
47	survival	_	_	O
48	(	_	_	O
49	DFS	_	_	O
50	)	_	_	O
51	and	_	_	O
52	overall	_	_	O
53	survival	_	_	O
54	(	_	_	O
55	OS	_	_	O
56	)	_	_	O
57	.	_	_	O

58	Between	_	_	O
59	1993	_	_	O
60	and	_	_	O
61	2002	_	_	O
62	,	_	_	O
63	women	_	_	O
64	>	_	_	O
65	or	_	_	O
66	=	_	_	O
67	60	_	_	O
68	years	_	_	O
69	old	_	_	O
70	with	_	_	O
71	clinically	_	_	O
72	node	_	_	O
73	-	_	_	O
74	negative	_	_	O
75	operable	_	_	O
76	breast	_	_	O
77	cancer	_	_	O
78	in	_	_	O
79	whom	_	_	O
80	adjuvant	_	_	O
81	tamoxifen	_	_	O
82	was	_	_	O
83	considered	_	_	O
84	indicated	_	_	O
85	regardless	_	_	O
86	of	_	_	O
87	pathologic	_	_	O
88	nodal	_	_	O
89	status	_	_	O
90	were	_	_	O
91	randomly	_	_	O
92	assigned	_	_	O
93	to	_	_	O
94	primary	_	_	O
95	surgery	_	_	O
96	plus	_	_	O
97	axillary	_	_	O
98	clearance	_	_	O
99	(	_	_	O
100	Sx	_	_	O
101	+	_	_	O
102	Ax	_	_	O
103	)	_	_	O
104	followed	_	_	O
105	by	_	_	O
106	tamoxifen	_	_	O
107	(	_	_	O
108	Tam	_	_	O
109	)	_	_	O
110	versus	_	_	O
111	Sx	_	_	O
112	without	_	_	O
113	Ax	_	_	O
114	followed	_	_	O
115	by	_	_	O
116	Tam	_	_	O
117	for	_	_	O
118	5	_	_	O
119	consecutive	_	_	O
120	years	_	_	O
121	.	_	_	O

122	The	_	_	O
123	primary	_	_	O
124	end	_	_	O
125	point	_	_	O
126	was	_	_	O
127	QL	_	_	O
128	reported	_	_	O
129	by	_	_	O
130	the	_	_	O
131	patient	_	_	O
132	and	_	_	O
133	by	_	_	O
134	physician	_	_	O
135	assessment	_	_	O
136	.	_	_	O

137	A	_	_	O
138	total	_	_	O
139	of	_	_	O
140	473	_	_	O
141	patients	_	_	O
142	(	_	_	O
143	234	_	_	O
144	to	_	_	O
145	Sx	_	_	O
146	+	_	_	O
147	Ax	_	_	O
148	,	_	_	O
149	239	_	_	O
150	to	_	_	O
151	Sx	_	_	O
152	)	_	_	O
153	were	_	_	O
154	randomly	_	_	O
155	assigned	_	_	O
156	.	_	_	O

157	The	_	_	O
158	median	_	_	O
159	age	_	_	O
160	was	_	_	O
161	74	_	_	O
162	years	_	_	O
163	;	_	_	O
164	80	_	_	O
165	%	_	_	O
166	had	_	_	O
167	estrogen	_	_	O
168	receptor	_	_	O
169	-	_	_	O
170	positive	_	_	O
171	disease	_	_	O
172	.	_	_	O

173	In	_	_	B-Premise
174	both	_	_	I-Premise
175	the	_	_	I-Premise
176	patients	_	_	I-Premise
177	'	_	_	I-Premise
178	subjective	_	_	I-Premise
179	assessment	_	_	I-Premise
180	of	_	_	I-Premise
181	their	_	_	I-Premise
182	QL	_	_	I-Premise
183	and	_	_	I-Premise
184	the	_	_	I-Premise
185	physicians	_	_	I-Premise
186	'	_	_	I-Premise
187	perception	_	_	I-Premise
188	of	_	_	I-Premise
189	the	_	_	I-Premise
190	patients	_	_	I-Premise
191	'	_	_	I-Premise
192	QL	_	_	I-Premise
193	,	_	_	I-Premise
194	the	_	_	I-Premise
195	largest	_	_	I-Premise
196	adverse	_	_	I-Premise
197	QL	_	_	I-Premise
198	effects	_	_	I-Premise
199	of	_	_	I-Premise
200	Ax	_	_	I-Premise
201	were	_	_	I-Premise
202	observed	_	_	I-Premise
203	from	_	_	I-Premise
204	baseline	_	_	I-Premise
205	to	_	_	I-Premise
206	the	_	_	I-Premise
207	first	_	_	I-Premise
208	postoperative	_	_	I-Premise
209	assessment	_	_	I-Premise
210	,	_	_	I-Premise
211	but	_	_	B-Premise
212	the	_	_	I-Premise
213	differences	_	_	I-Premise
214	tended	_	_	I-Premise
215	to	_	_	I-Premise
216	disappear	_	_	I-Premise
217	in	_	_	I-Premise
218	6	_	_	I-Premise
219	to	_	_	I-Premise
220	12	_	_	I-Premise
221	months	_	_	I-Premise
222	.	_	_	I-Premise

223	At	_	_	B-Premise
224	a	_	_	I-Premise
225	median	_	_	I-Premise
226	follow	_	_	I-Premise
227	-	_	_	I-Premise
228	up	_	_	I-Premise
229	of	_	_	I-Premise
230	6	_	_	I-Premise
231	.	_	_	I-Premise

232	6	_	_	I-Premise
233	years	_	_	I-Premise
234	,	_	_	I-Premise
235	results	_	_	I-Premise
236	for	_	_	I-Premise
237	Sx	_	_	I-Premise
238	+	_	_	I-Premise
239	Ax	_	_	I-Premise
240	and	_	_	I-Premise
241	Sx	_	_	I-Premise
242	yielded	_	_	I-Premise
243	similar	_	_	I-Premise
244	DFS	_	_	I-Premise
245	(	_	_	I-Premise
246	6	_	_	I-Premise
247	-	_	_	I-Premise
248	year	_	_	I-Premise
249	DFS	_	_	I-Premise
250	,	_	_	I-Premise
251	67	_	_	I-Premise
252	%	_	_	I-Premise
253	v	_	_	I-Premise
254	66	_	_	I-Premise
255	%	_	_	I-Premise
256	;	_	_	I-Premise
257	hazard	_	_	I-Premise
258	ratio	_	_	I-Premise
259	[	_	_	I-Premise
260	HR	_	_	I-Premise
261	]	_	_	I-Premise
262	Sx	_	_	I-Premise
263	+	_	_	I-Premise
264	Ax	_	_	I-Premise
265	/	_	_	I-Premise
266	Sx	_	_	I-Premise
267	,	_	_	I-Premise
268	1	_	_	I-Premise
269	.	_	_	I-Premise

270	06	_	_	I-Premise
271	;	_	_	I-Premise
272	95	_	_	I-Premise
273	%	_	_	I-Premise
274	CI	_	_	I-Premise
275	,	_	_	I-Premise
276	0	_	_	I-Premise
277	.	_	_	I-Premise

278	79	_	_	I-Premise
279	to	_	_	I-Premise
280	1	_	_	I-Premise
281	.	_	_	I-Premise

282	42	_	_	I-Premise
283	;	_	_	I-Premise
284	P	_	_	I-Premise
285	=	_	_	I-Premise
286	.	_	_	I-Premise

287	69	_	_	I-Premise
288	)	_	_	I-Premise
289	and	_	_	I-Premise
290	OS	_	_	I-Premise
291	(	_	_	I-Premise
292	6	_	_	I-Premise
293	-	_	_	I-Premise
294	year	_	_	I-Premise
295	OS	_	_	I-Premise
296	,	_	_	I-Premise
297	75	_	_	I-Premise
298	%	_	_	I-Premise
299	v	_	_	I-Premise
300	73	_	_	I-Premise
301	%	_	_	I-Premise
302	;	_	_	I-Premise
303	HR	_	_	I-Premise
304	Sx	_	_	I-Premise
305	+	_	_	I-Premise
306	Ax	_	_	I-Premise
307	/	_	_	I-Premise
308	Sx	_	_	I-Premise
309	,	_	_	I-Premise
310	1	_	_	I-Premise
311	.	_	_	I-Premise

312	05	_	_	I-Premise
313	;	_	_	I-Premise
314	95	_	_	I-Premise
315	%	_	_	I-Premise
316	CI	_	_	I-Premise
317	,	_	_	I-Premise
318	0	_	_	I-Premise
319	.	_	_	I-Premise

320	76	_	_	I-Premise
321	to	_	_	I-Premise
322	1	_	_	I-Premise
323	.	_	_	I-Premise

324	46	_	_	I-Premise
325	;	_	_	I-Premise
326	P	_	_	I-Premise
327	=	_	_	I-Premise
328	.	_	_	I-Premise

329	77	_	_	I-Premise
330	)	_	_	I-Premise
331	.	_	_	I-Premise

332	Avoiding	_	_	B-Claim
333	axillary	_	_	I-Claim
334	clearance	_	_	I-Claim
335	for	_	_	I-Claim
336	women	_	_	I-Claim
337	>	_	_	I-Claim
338	or	_	_	I-Claim
339	=	_	_	I-Claim
340	60	_	_	I-Claim
341	years	_	_	I-Claim
342	old	_	_	I-Claim
343	who	_	_	I-Claim
344	have	_	_	I-Claim
345	clinically	_	_	I-Claim
346	node	_	_	I-Claim
347	-	_	_	I-Claim
348	negative	_	_	I-Claim
349	disease	_	_	I-Claim
350	and	_	_	I-Claim
351	receive	_	_	I-Claim
352	Tam	_	_	I-Claim
353	for	_	_	I-Claim
354	endocrine	_	_	I-Claim
355	-	_	_	I-Claim
356	responsive	_	_	I-Claim
357	disease	_	_	I-Claim
358	yields	_	_	I-Claim
359	similar	_	_	I-Claim
360	efficacy	_	_	I-Claim
361	with	_	_	I-Claim
362	better	_	_	I-Claim
363	early	_	_	I-Claim
364	QL	_	_	I-Claim
365	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	dose	_	_	O
3	-	_	_	O
4	volume	_	_	O
5	histogram	_	_	O
6	variables	_	_	O
7	for	_	_	O
8	the	_	_	O
9	internal	_	_	O
10	and	_	_	O
11	external	_	_	O
12	urinary	_	_	O
13	sphincters	_	_	O
14	(	_	_	O
15	IUS	_	_	O
16	/	_	_	O
17	EUS	_	_	O
18	)	_	_	O
19	with	_	_	O
20	urinary	_	_	O
21	quality	_	_	O
22	of	_	_	O
23	life	_	_	O
24	after	_	_	O
25	prostate	_	_	O
26	brachytherapy	_	_	O
27	.	_	_	O

28	Subjects	_	_	O
29	were	_	_	O
30	42	_	_	O
31	consecutive	_	_	O
32	men	_	_	O
33	from	_	_	O
34	a	_	_	O
35	prospective	_	_	O
36	study	_	_	O
37	of	_	_	O
38	brachytherapy	_	_	O
39	as	_	_	O
40	monotherapy	_	_	O
41	with	_	_	O
42	(	_	_	O
43	125	_	_	O
44	)	_	_	O
45	I	_	_	O
46	for	_	_	O
47	intermediate	_	_	O
48	-	_	_	O
49	risk	_	_	O
50	localized	_	_	O
51	prostate	_	_	O
52	cancer	_	_	O
53	.	_	_	O

54	No	_	_	O
55	patient	_	_	O
56	received	_	_	O
57	hormonal	_	_	O
58	therapy	_	_	O
59	.	_	_	O

60	Preplanning	_	_	O
61	constraints	_	_	O
62	included	_	_	O
63	prostate	_	_	O
64	V100	_	_	O
65	higher	_	_	O
66	than	_	_	O
67	95	_	_	O
68	%	_	_	O
69	,	_	_	O
70	V150	_	_	O
71	lower	_	_	O
72	than	_	_	O
73	60	_	_	O
74	%	_	_	O
75	,	_	_	O
76	and	_	_	O
77	V200	_	_	O
78	lower	_	_	O
79	than	_	_	O
80	20	_	_	O
81	%	_	_	O
82	and	_	_	O
83	rectal	_	_	O
84	R100	_	_	O
85	less	_	_	O
86	than	_	_	O
87	1cm	_	_	O
88	(	_	_	O
89	3	_	_	O
90	)	_	_	O
91	.	_	_	O

92	Patients	_	_	O
93	completed	_	_	O
94	the	_	_	O
95	Expanded	_	_	O
96	Prostate	_	_	O
97	Cancer	_	_	O
98	Index	_	_	O
99	Composite	_	_	O
100	quality	_	_	O
101	-	_	_	O
102	of	_	_	O
103	-	_	_	O
104	life	_	_	O
105	questionnaire	_	_	O
106	before	_	_	O
107	and	_	_	O
108	at	_	_	O
109	1	_	_	O
110	,	_	_	O
111	4	_	_	O
112	,	_	_	O
113	8	_	_	O
114	,	_	_	O
115	and	_	_	O
116	12	_	_	O
117	months	_	_	O
118	after	_	_	O
119	implantation	_	_	O
120	,	_	_	O
121	and	_	_	O
122	urinary	_	_	O
123	domain	_	_	O
124	scores	_	_	O
125	were	_	_	O
126	analyzed	_	_	O
127	.	_	_	O

128	All	_	_	O
129	structures	_	_	O
130	including	_	_	O
131	the	_	_	O
132	IUS	_	_	O
133	and	_	_	O
134	EUS	_	_	O
135	were	_	_	O
136	contoured	_	_	O
137	on	_	_	O
138	T2	_	_	O
139	-	_	_	O
140	weighted	_	_	O
141	MRI	_	_	O
142	at	_	_	O
143	day	_	_	O
144	30	_	_	O
145	,	_	_	O
146	and	_	_	O
147	doses	_	_	O
148	received	_	_	O
149	were	_	_	O
150	calculated	_	_	O
151	from	_	_	O
152	identification	_	_	O
153	of	_	_	O
154	seeds	_	_	O
155	on	_	_	O
156	CT	_	_	O
157	.	_	_	O

158	Spearman	_	_	O
159	'	_	_	O
160	s	_	_	O
161	(	_	_	O
162	nonparametric	_	_	O
163	)	_	_	O
164	rank	_	_	O
165	correlation	_	_	O
166	coefficient	_	_	O
167	(	_	_	O
168	ρ	_	_	O
169	)	_	_	O
170	was	_	_	O
171	used	_	_	O
172	for	_	_	O
173	statistical	_	_	O
174	analyses	_	_	O
175	.	_	_	O

176	Overall	_	_	O
177	urinary	_	_	O
178	morbidity	_	_	O
179	was	_	_	O
180	worst	_	_	O
181	at	_	_	O
182	1	_	_	O
183	month	_	_	O
184	after	_	_	O
185	the	_	_	O
186	implant	_	_	O
187	.	_	_	O

188	Urinary	_	_	B-Premise
189	function	_	_	I-Premise
190	declined	_	_	I-Premise
191	when	_	_	I-Premise
192	the	_	_	I-Premise
193	IUS	_	_	I-Premise
194	V285	_	_	I-Premise
195	was	_	_	I-Premise
196	0	_	_	I-Premise
197	.	_	_	I-Premise

198	4	_	_	I-Premise
199	%	_	_	I-Premise
200	(	_	_	I-Premise
201	ρ	_	_	I-Premise
202	=	_	_	I-Premise
203	-	_	_	I-Premise
204	0	_	_	I-Premise
205	.	_	_	I-Premise

206	32	_	_	I-Premise
207	,	_	_	I-Premise
208	p	_	_	I-Premise
209	=	_	_	I-Premise
210	0	_	_	I-Premise
211	.	_	_	I-Premise

212	04	_	_	I-Premise
213	)	_	_	I-Premise
214	;	_	_	I-Premise
215	bother	_	_	B-Premise
216	worsened	_	_	I-Premise
217	when	_	_	I-Premise
218	the	_	_	I-Premise
219	IUS	_	_	I-Premise
220	V35	_	_	I-Premise
221	was	_	_	I-Premise
222	99	_	_	I-Premise
223	%	_	_	I-Premise
224	(	_	_	I-Premise
225	ρ	_	_	I-Premise
226	=	_	_	I-Premise
227	-	_	_	I-Premise
228	0	_	_	I-Premise
229	.	_	_	I-Premise

230	31	_	_	I-Premise
231	,	_	_	I-Premise
232	p	_	_	I-Premise
233	=	_	_	I-Premise
234	0	_	_	I-Premise
235	.	_	_	I-Premise

236	05	_	_	I-Premise
237	)	_	_	I-Premise
238	or	_	_	I-Premise
239	the	_	_	I-Premise
240	EUS	_	_	I-Premise
241	V240	_	_	I-Premise
242	was	_	_	I-Premise
243	63	_	_	I-Premise
244	%	_	_	I-Premise
245	(	_	_	I-Premise
246	ρ	_	_	I-Premise
247	=	_	_	I-Premise
248	-	_	_	I-Premise
249	0	_	_	I-Premise
250	.	_	_	I-Premise

251	31	_	_	I-Premise
252	,	_	_	I-Premise
253	p	_	_	I-Premise
254	=	_	_	I-Premise
255	0	_	_	I-Premise
256	.	_	_	I-Premise

257	05	_	_	I-Premise
258	)	_	_	I-Premise
259	;	_	_	I-Premise
260	irritation	_	_	B-Premise
261	increased	_	_	I-Premise
262	when	_	_	I-Premise
263	the	_	_	I-Premise
264	IUS	_	_	I-Premise
265	V35	_	_	I-Premise
266	was	_	_	I-Premise
267	95	_	_	I-Premise
268	%	_	_	I-Premise
269	(	_	_	I-Premise
270	ρ	_	_	I-Premise
271	=	_	_	I-Premise
272	-	_	_	I-Premise
273	0	_	_	I-Premise
274	.	_	_	I-Premise

275	37	_	_	I-Premise
276	,	_	_	I-Premise
277	p	_	_	I-Premise
278	=	_	_	I-Premise
279	0	_	_	I-Premise
280	.	_	_	I-Premise

281	02	_	_	I-Premise
282	)	_	_	I-Premise
283	and	_	_	I-Premise
284	the	_	_	I-Premise
285	EUS	_	_	I-Premise
286	V265	_	_	I-Premise
287	was	_	_	I-Premise
288	24	_	_	I-Premise
289	%	_	_	I-Premise
290	(	_	_	I-Premise
291	ρ	_	_	I-Premise
292	=	_	_	I-Premise
293	-	_	_	I-Premise
294	0	_	_	I-Premise
295	.	_	_	I-Premise

296	32	_	_	I-Premise
297	,	_	_	I-Premise
298	p	_	_	I-Premise
299	=	_	_	I-Premise
300	0	_	_	I-Premise
301	.	_	_	I-Premise

302	04	_	_	I-Premise
303	)	_	_	I-Premise
304	;	_	_	I-Premise
305	and	_	_	O
306	urgency	_	_	B-Premise
307	worsened	_	_	I-Premise
308	when	_	_	I-Premise
309	the	_	_	I-Premise
310	IUS	_	_	I-Premise
311	V35	_	_	I-Premise
312	was	_	_	I-Premise
313	99	_	_	I-Premise
314	.	_	_	I-Premise

315	5	_	_	I-Premise
316	%	_	_	I-Premise
317	(	_	_	I-Premise
318	ρ	_	_	I-Premise
319	=	_	_	I-Premise
320	-	_	_	I-Premise
321	0	_	_	I-Premise
322	.	_	_	I-Premise

323	38	_	_	I-Premise
324	,	_	_	I-Premise
325	p	_	_	I-Premise
326	=	_	_	I-Premise
327	0	_	_	I-Premise
328	.	_	_	I-Premise

329	02	_	_	I-Premise
330	)	_	_	I-Premise
331	.	_	_	I-Premise

332	Incontinence	_	_	B-Premise
333	did	_	_	I-Premise
334	not	_	_	I-Premise
335	correlate	_	_	I-Premise
336	with	_	_	I-Premise
337	EUS	_	_	I-Premise
338	or	_	_	I-Premise
339	IUS	_	_	I-Premise
340	dose	_	_	I-Premise
341	.	_	_	I-Premise

342	Doses	_	_	B-Claim
343	to	_	_	I-Claim
344	the	_	_	I-Claim
345	IUS	_	_	I-Claim
346	and	_	_	I-Claim
347	EUS	_	_	I-Claim
348	on	_	_	I-Claim
349	MRI	_	_	I-Claim
350	/	_	_	I-Claim
351	CT	_	_	I-Claim
352	predicted	_	_	I-Claim
353	worse	_	_	I-Claim
354	urinary	_	_	I-Claim
355	function	_	_	I-Claim
356	,	_	_	I-Claim
357	with	_	_	I-Claim
358	greater	_	_	I-Claim
359	bother	_	_	I-Claim
360	,	_	_	I-Claim
361	irritative	_	_	I-Claim
362	symptoms	_	_	I-Claim
363	,	_	_	I-Claim
364	and	_	_	I-Claim
365	urgency	_	_	I-Claim
366	.	_	_	I-Claim

367	Incorporating	_	_	B-Claim
368	MRI	_	_	I-Claim
369	-	_	_	I-Claim
370	based	_	_	I-Claim
371	dose	_	_	I-Claim
372	-	_	_	I-Claim
373	volume	_	_	I-Claim
374	histogram	_	_	I-Claim
375	analysis	_	_	I-Claim
376	into	_	_	I-Claim
377	the	_	_	I-Claim
378	treatment	_	_	I-Claim
379	planning	_	_	I-Claim
380	process	_	_	I-Claim
381	may	_	_	I-Claim
382	reduce	_	_	I-Claim
383	acute	_	_	I-Claim
384	urinary	_	_	I-Claim
385	morbidity	_	_	I-Claim
386	after	_	_	I-Claim
387	brachytherapy	_	_	I-Claim
388	.	_	_	I-Claim


0	Temozolomide	_	_	O
1	(	_	_	O
2	TMZ	_	_	O
3	)	_	_	O
4	is	_	_	O
5	an	_	_	O
6	alkylating	_	_	O
7	agent	_	_	O
8	licensed	_	_	O
9	for	_	_	O
10	treatment	_	_	O
11	of	_	_	O
12	high	_	_	O
13	-	_	_	O
14	grade	_	_	O
15	glioma	_	_	O
16	(	_	_	O
17	HGG	_	_	O
18	)	_	_	O
19	.	_	_	O

20	No	_	_	O
21	prospective	_	_	O
22	comparison	_	_	O
23	with	_	_	O
24	nitrosourea	_	_	O
25	-	_	_	O
26	based	_	_	O
27	chemotherapy	_	_	O
28	exists	_	_	O
29	.	_	_	O

30	We	_	_	O
31	report	_	_	O
32	,	_	_	O
33	to	_	_	O
34	our	_	_	O
35	knowledge	_	_	O
36	,	_	_	O
37	the	_	_	O
38	first	_	_	O
39	randomized	_	_	O
40	trial	_	_	O
41	of	_	_	O
42	procarbazine	_	_	O
43	,	_	_	O
44	lomustine	_	_	O
45	,	_	_	O
46	and	_	_	O
47	vincristine	_	_	O
48	(	_	_	O
49	PCV	_	_	O
50	)	_	_	O
51	versus	_	_	O
52	TMZ	_	_	O
53	in	_	_	O
54	chemotherapy	_	_	O
55	-	_	_	O
56	naive	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	recurrent	_	_	O
60	HGG	_	_	O
61	.	_	_	O

62	Four	_	_	O
63	hundred	_	_	O
64	forty	_	_	O
65	-	_	_	O
66	seven	_	_	O
67	patients	_	_	O
68	were	_	_	O
69	randomly	_	_	O
70	assigned	_	_	O
71	to	_	_	O
72	PCV	_	_	O
73	(	_	_	O
74	224	_	_	O
75	patients	_	_	O
76	)	_	_	O
77	or	_	_	O
78	TMZ	_	_	O
79	(	_	_	O
80	sub	_	_	O
81	-	_	_	O
82	random	_	_	O
83	assignment	_	_	O
84	:	_	_	O
85	TMZ	_	_	O
86	-	_	_	O
87	5	_	_	O
88	[	_	_	O
89	200	_	_	O
90	mg	_	_	O
91	/	_	_	O
92	m	_	_	O
93	(	_	_	O
94	2	_	_	O
95	)	_	_	O
96	for	_	_	O
97	5	_	_	O
98	days	_	_	O
99	,	_	_	O
100	112	_	_	O
101	patients	_	_	O
102	]	_	_	O
103	or	_	_	O
104	TMZ	_	_	O
105	-	_	_	O
106	21	_	_	O
107	[	_	_	O
108	100	_	_	O
109	mg	_	_	O
110	/	_	_	O
111	m	_	_	O
112	(	_	_	O
113	2	_	_	O
114	)	_	_	O
115	for	_	_	O
116	21	_	_	O
117	days	_	_	O
118	,	_	_	O
119	111	_	_	O
120	patients	_	_	O
121	]	_	_	O
122	)	_	_	O
123	for	_	_	O
124	up	_	_	O
125	to	_	_	O
126	9	_	_	O
127	months	_	_	O
128	or	_	_	O
129	until	_	_	O
130	progression	_	_	O
131	.	_	_	O

132	The	_	_	O
133	primary	_	_	O
134	outcomes	_	_	O
135	were	_	_	O
136	survival	_	_	O
137	(	_	_	O
138	PCV	_	_	O
139	v	_	_	O
140	TMZ	_	_	O
141	)	_	_	O
142	and	_	_	O
143	12	_	_	O
144	-	_	_	O
145	week	_	_	O
146	progression	_	_	O
147	-	_	_	O
148	free	_	_	O
149	survival	_	_	O
150	(	_	_	O
151	PFS	_	_	O
152	;	_	_	O
153	TMZ	_	_	O
154	-	_	_	O
155	5	_	_	O
156	v	_	_	O
157	TMZ	_	_	O
158	-	_	_	O
159	21	_	_	O
160	)	_	_	O
161	.	_	_	O

162	This	_	_	O
163	study	_	_	O
164	is	_	_	O
165	registered	_	_	O
166	as	_	_	O
167	ISRCTN83176944	_	_	O
168	.	_	_	O

169	Percentages	_	_	O
170	of	_	_	O
171	patients	_	_	O
172	completing	_	_	O
173	9	_	_	O
174	months	_	_	O
175	of	_	_	O
176	treatment	_	_	O
177	in	_	_	O
178	the	_	_	O
179	PCV	_	_	O
180	,	_	_	O
181	TMZ	_	_	O
182	-	_	_	O
183	5	_	_	O
184	,	_	_	O
185	and	_	_	O
186	TMZ	_	_	O
187	-	_	_	O
188	21	_	_	O
189	arms	_	_	O
190	were	_	_	O
191	17	_	_	O
192	%	_	_	O
193	,	_	_	O
194	26	_	_	O
195	%	_	_	O
196	,	_	_	O
197	and	_	_	O
198	13	_	_	O
199	%	_	_	O
200	,	_	_	O
201	respectively	_	_	O
202	.	_	_	O

203	Major	_	_	B-Premise
204	toxicity	_	_	I-Premise
205	was	_	_	I-Premise
206	similar	_	_	I-Premise
207	across	_	_	I-Premise
208	all	_	_	I-Premise
209	three	_	_	I-Premise
210	groups	_	_	I-Premise
211	.	_	_	I-Premise

212	With	_	_	B-Premise
213	a	_	_	I-Premise
214	median	_	_	I-Premise
215	follow	_	_	I-Premise
216	-	_	_	I-Premise
217	up	_	_	I-Premise
218	time	_	_	I-Premise
219	of	_	_	I-Premise
220	12	_	_	I-Premise
221	months	_	_	I-Premise
222	and	_	_	I-Premise
223	382	_	_	I-Premise
224	deaths	_	_	I-Premise
225	,	_	_	I-Premise
226	there	_	_	I-Premise
227	was	_	_	I-Premise
228	no	_	_	I-Premise
229	clear	_	_	I-Premise
230	survival	_	_	I-Premise
231	benefit	_	_	I-Premise
232	when	_	_	I-Premise
233	comparing	_	_	I-Premise
234	PCV	_	_	I-Premise
235	with	_	_	I-Premise
236	TMZ	_	_	I-Premise
237	(	_	_	I-Premise
238	hazard	_	_	I-Premise
239	ratio	_	_	I-Premise
240	[	_	_	I-Premise
241	HR	_	_	I-Premise
242	]	_	_	I-Premise
243	,	_	_	I-Premise
244	0	_	_	I-Premise
245	.	_	_	I-Premise

246	91	_	_	I-Premise
247	;	_	_	I-Premise
248	95	_	_	I-Premise
249	%	_	_	I-Premise
250	CI	_	_	I-Premise
251	,	_	_	I-Premise
252	0	_	_	I-Premise
253	.	_	_	I-Premise

254	74	_	_	I-Premise
255	to	_	_	I-Premise
256	1	_	_	I-Premise
257	.	_	_	I-Premise

258	11	_	_	I-Premise
259	;	_	_	I-Premise
260	P	_	_	I-Premise
261	=	_	_	I-Premise
262	.	_	_	I-Premise

263	350	_	_	I-Premise
264	)	_	_	I-Premise
265	.	_	_	I-Premise

266	For	_	_	B-Premise
267	TMZ	_	_	I-Premise
268	-	_	_	I-Premise
269	5	_	_	I-Premise
270	versus	_	_	I-Premise
271	TMZ	_	_	I-Premise
272	-	_	_	I-Premise
273	21	_	_	I-Premise
274	,	_	_	I-Premise
275	12	_	_	I-Premise
276	-	_	_	I-Premise
277	week	_	_	I-Premise
278	PFS	_	_	I-Premise
279	rates	_	_	I-Premise
280	were	_	_	I-Premise
281	similar	_	_	I-Premise
282	(	_	_	I-Premise
283	63	_	_	I-Premise
284	.	_	_	I-Premise

285	6	_	_	I-Premise
286	%	_	_	I-Premise
287	and	_	_	I-Premise
288	65	_	_	I-Premise
289	.	_	_	I-Premise

290	7	_	_	I-Premise
291	%	_	_	I-Premise
292	,	_	_	I-Premise
293	respectively	_	_	I-Premise
294	;	_	_	I-Premise
295	P	_	_	I-Premise
296	=	_	_	I-Premise
297	.	_	_	I-Premise

298	745	_	_	I-Premise
299	)	_	_	I-Premise
300	,	_	_	I-Premise
301	but	_	_	B-Premise
302	TMZ	_	_	I-Premise
303	-	_	_	I-Premise
304	5	_	_	I-Premise
305	improved	_	_	I-Premise
306	overall	_	_	I-Premise
307	PFS	_	_	I-Premise
308	(	_	_	I-Premise
309	HR	_	_	I-Premise
310	,	_	_	I-Premise
311	1	_	_	I-Premise
312	.	_	_	I-Premise

313	38	_	_	I-Premise
314	;	_	_	I-Premise
315	95	_	_	I-Premise
316	%	_	_	I-Premise
317	CI	_	_	I-Premise
318	,	_	_	I-Premise
319	1	_	_	I-Premise
320	.	_	_	I-Premise

321	05	_	_	I-Premise
322	to	_	_	I-Premise
323	1	_	_	I-Premise
324	.	_	_	I-Premise

325	82	_	_	I-Premise
326	;	_	_	I-Premise
327	P	_	_	I-Premise
328	=	_	_	I-Premise
329	.	_	_	I-Premise

330	023	_	_	I-Premise
331	)	_	_	I-Premise
332	,	_	_	I-Premise
333	survival	_	_	I-Premise
334	(	_	_	I-Premise
335	HR	_	_	I-Premise
336	,	_	_	I-Premise
337	1	_	_	I-Premise
338	.	_	_	I-Premise

339	32	_	_	I-Premise
340	;	_	_	I-Premise
341	95	_	_	I-Premise
342	%	_	_	I-Premise
343	CI	_	_	I-Premise
344	,	_	_	I-Premise
345	0	_	_	I-Premise
346	.	_	_	I-Premise

347	99	_	_	I-Premise
348	to	_	_	I-Premise
349	1	_	_	I-Premise
350	.	_	_	I-Premise

351	75	_	_	I-Premise
352	;	_	_	I-Premise
353	P	_	_	I-Premise
354	=	_	_	I-Premise
355	.	_	_	I-Premise

356	056	_	_	I-Premise
357	)	_	_	I-Premise
358	,	_	_	I-Premise
359	and	_	_	I-Premise
360	global	_	_	I-Premise
361	quality	_	_	I-Premise
362	of	_	_	I-Premise
363	life	_	_	I-Premise
364	(	_	_	I-Premise
365	49	_	_	I-Premise
366	%	_	_	I-Premise
367	v	_	_	I-Premise
368	19	_	_	I-Premise
369	%	_	_	I-Premise
370	improved	_	_	I-Premise
371	>	_	_	I-Premise
372	10	_	_	I-Premise
373	points	_	_	I-Premise
374	at	_	_	I-Premise
375	6	_	_	I-Premise
376	months	_	_	I-Premise
377	,	_	_	I-Premise
378	respectively	_	_	I-Premise
379	;	_	_	I-Premise
380	P	_	_	I-Premise
381	=	_	_	I-Premise
382	.	_	_	I-Premise

383	005	_	_	I-Premise
384	)	_	_	I-Premise
385	.	_	_	I-Premise

386	Although	_	_	B-Claim
387	TMZ	_	_	I-Claim
388	(	_	_	I-Claim
389	both	_	_	I-Claim
390	arms	_	_	I-Claim
391	combined	_	_	I-Claim
392	)	_	_	I-Claim
393	did	_	_	I-Claim
394	not	_	_	I-Claim
395	show	_	_	I-Claim
396	a	_	_	I-Claim
397	clear	_	_	I-Claim
398	benefit	_	_	I-Claim
399	compared	_	_	I-Claim
400	with	_	_	I-Claim
401	PCV	_	_	I-Claim
402	,	_	_	I-Claim
403	comparison	_	_	I-Claim
404	of	_	_	I-Claim
405	the	_	_	I-Claim
406	TMZ	_	_	I-Claim
407	schedules	_	_	I-Claim
408	demonstrated	_	_	I-Claim
409	that	_	_	I-Claim
410	the	_	_	I-Claim
411	21	_	_	I-Claim
412	-	_	_	I-Claim
413	day	_	_	I-Claim
414	schedule	_	_	I-Claim
415	was	_	_	I-Claim
416	inferior	_	_	I-Claim
417	to	_	_	I-Claim
418	the	_	_	I-Claim
419	5	_	_	I-Claim
420	-	_	_	I-Claim
421	day	_	_	I-Claim
422	schedule	_	_	I-Claim
423	in	_	_	I-Claim
424	this	_	_	I-Claim
425	setting	_	_	I-Claim
426	.	_	_	I-Claim

427	This	_	_	B-Claim
428	challenges	_	_	I-Claim
429	the	_	_	I-Claim
430	current	_	_	I-Claim
431	understanding	_	_	I-Claim
432	of	_	_	I-Claim
433	increasing	_	_	I-Claim
434	TMZ	_	_	I-Claim
435	dose	_	_	I-Claim
436	-	_	_	I-Claim
437	intensity	_	_	I-Claim
438	by	_	_	I-Claim
439	prolonged	_	_	I-Claim
440	scheduling	_	_	I-Claim
441	.	_	_	I-Claim


0	In	_	_	O
1	the	_	_	O
2	randomized	_	_	O
3	,	_	_	O
4	multinational	_	_	O
5	phase	_	_	O
6	II	_	_	O
7	/	_	_	O
8	III	_	_	O
9	trial	_	_	O
10	(	_	_	O
11	V325	_	_	O
12	)	_	_	O
13	of	_	_	O
14	untreated	_	_	O
15	advanced	_	_	O
16	gastric	_	_	O
17	cancer	_	_	O
18	patients	_	_	O
19	,	_	_	O
20	the	_	_	O
21	phase	_	_	O
22	II	_	_	O
23	part	_	_	O
24	selected	_	_	O
25	docetaxel	_	_	O
26	,	_	_	O
27	cisplatin	_	_	O
28	,	_	_	O
29	and	_	_	O
30	fluorouracil	_	_	O
31	(	_	_	O
32	DCF	_	_	O
33	)	_	_	O
34	over	_	_	O
35	docetaxel	_	_	O
36	and	_	_	O
37	cisplatin	_	_	O
38	for	_	_	O
39	comparison	_	_	O
40	against	_	_	O
41	cisplatin	_	_	O
42	and	_	_	O
43	fluorouracil	_	_	O
44	(	_	_	O
45	CF	_	_	O
46	;	_	_	O
47	reference	_	_	O
48	regimen	_	_	O
49	)	_	_	O
50	in	_	_	O
51	the	_	_	O
52	phase	_	_	O
53	III	_	_	O
54	part	_	_	O
55	.	_	_	O

56	Advanced	_	_	O
57	gastric	_	_	O
58	cancer	_	_	O
59	patients	_	_	O
60	were	_	_	O
61	randomly	_	_	O
62	assigned	_	_	O
63	to	_	_	O
64	docetaxel	_	_	O
65	75	_	_	O
66	mg	_	_	O
67	/	_	_	O
68	m2	_	_	O
69	and	_	_	O
70	cisplatin	_	_	O
71	75	_	_	O
72	mg	_	_	O
73	/	_	_	O
74	m2	_	_	O
75	(	_	_	O
76	day	_	_	O
77	1	_	_	O
78	)	_	_	O
79	plus	_	_	O
80	fluorouracil	_	_	O
81	750	_	_	O
82	mg	_	_	O
83	/	_	_	O
84	m2	_	_	O
85	/	_	_	O
86	d	_	_	O
87	(	_	_	O
88	days	_	_	O
89	1	_	_	O
90	to	_	_	O
91	5	_	_	O
92	)	_	_	O
93	every	_	_	O
94	3	_	_	O
95	weeks	_	_	O
96	or	_	_	O
97	cisplatin	_	_	O
98	100	_	_	O
99	mg	_	_	O
100	/	_	_	O
101	m2	_	_	O
102	(	_	_	O
103	day	_	_	O
104	1	_	_	O
105	)	_	_	O
106	plus	_	_	O
107	fluorouracil	_	_	O
108	1	_	_	O
109	,	_	_	O
110	000	_	_	O
111	mg	_	_	O
112	/	_	_	O
113	m2	_	_	O
114	/	_	_	O
115	d	_	_	O
116	(	_	_	O
117	days	_	_	O
118	1	_	_	O
119	to	_	_	O
120	5	_	_	O
121	)	_	_	O
122	every	_	_	O
123	4	_	_	O
124	weeks	_	_	O
125	.	_	_	O

126	The	_	_	O
127	primary	_	_	O
128	end	_	_	O
129	point	_	_	O
130	was	_	_	O
131	time	_	_	O
132	-	_	_	O
133	to	_	_	O
134	-	_	_	O
135	progression	_	_	O
136	(	_	_	O
137	TTP	_	_	O
138	)	_	_	O
139	.	_	_	O

140	In	_	_	O
141	445	_	_	O
142	randomly	_	_	O
143	assigned	_	_	O
144	and	_	_	O
145	treated	_	_	O
146	patients	_	_	O
147	(	_	_	O
148	DCF	_	_	O
149	=	_	_	O
150	221	_	_	O
151	;	_	_	O
152	CF	_	_	O
153	=	_	_	O
154	224	_	_	O
155	)	_	_	O
156	,	_	_	O
157	TTP	_	_	O
158	was	_	_	O
159	longer	_	_	O
160	with	_	_	O
161	DCF	_	_	O
162	versus	_	_	O
163	CF	_	_	O
164	(	_	_	O
165	32	_	_	O
166	%	_	_	O
167	risk	_	_	O
168	reduction	_	_	O
169	;	_	_	O
170	log	_	_	O
171	-	_	_	O
172	rank	_	_	O
173	P	_	_	O
174	<	_	_	O
175	.	_	_	O

176	001	_	_	O
177	)	_	_	O
178	.	_	_	O

179	Overall	_	_	B-Premise
180	survival	_	_	I-Premise
181	was	_	_	I-Premise
182	longer	_	_	I-Premise
183	with	_	_	I-Premise
184	DCF	_	_	I-Premise
185	versus	_	_	I-Premise
186	CF	_	_	I-Premise
187	(	_	_	I-Premise
188	23	_	_	I-Premise
189	%	_	_	I-Premise
190	risk	_	_	I-Premise
191	reduction	_	_	I-Premise
192	;	_	_	I-Premise
193	log	_	_	I-Premise
194	-	_	_	I-Premise
195	rank	_	_	I-Premise
196	P	_	_	I-Premise
197	=	_	_	I-Premise
198	.	_	_	I-Premise

199	02	_	_	I-Premise
200	)	_	_	I-Premise
201	.	_	_	I-Premise

202	Two	_	_	B-Premise
203	-	_	_	I-Premise
204	year	_	_	I-Premise
205	survival	_	_	I-Premise
206	rate	_	_	I-Premise
207	was	_	_	I-Premise
208	18	_	_	I-Premise
209	%	_	_	I-Premise
210	with	_	_	I-Premise
211	DCF	_	_	I-Premise
212	and	_	_	I-Premise
213	9	_	_	I-Premise
214	%	_	_	I-Premise
215	with	_	_	I-Premise
216	CF	_	_	I-Premise
217	.	_	_	I-Premise

218	Overall	_	_	B-Premise
219	response	_	_	I-Premise
220	rate	_	_	I-Premise
221	was	_	_	I-Premise
222	higher	_	_	I-Premise
223	with	_	_	I-Premise
224	DCF	_	_	I-Premise
225	(	_	_	I-Premise
226	chi2	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	.	_	_	I-Premise

230	01	_	_	I-Premise
231	)	_	_	I-Premise
232	.	_	_	I-Premise

233	Grade	_	_	B-Premise
234	3	_	_	I-Premise
235	to	_	_	I-Premise
236	4	_	_	I-Premise
237	treatment	_	_	I-Premise
238	-	_	_	I-Premise
239	related	_	_	I-Premise
240	adverse	_	_	I-Premise
241	events	_	_	I-Premise
242	occurred	_	_	I-Premise
243	in	_	_	I-Premise
244	69	_	_	I-Premise
245	%	_	_	I-Premise
246	(	_	_	I-Premise
247	DCF	_	_	I-Premise
248	)	_	_	I-Premise
249	v	_	_	I-Premise
250	59	_	_	I-Premise
251	%	_	_	I-Premise
252	(	_	_	I-Premise
253	CF	_	_	I-Premise
254	)	_	_	I-Premise
255	of	_	_	I-Premise
256	patients	_	_	I-Premise
257	.	_	_	I-Premise

258	Frequent	_	_	B-Premise
259	grade	_	_	I-Premise
260	3	_	_	I-Premise
261	to	_	_	I-Premise
262	4	_	_	I-Premise
263	toxicities	_	_	I-Premise
264	for	_	_	I-Premise
265	DCF	_	_	I-Premise
266	v	_	_	I-Premise
267	CF	_	_	I-Premise
268	were	_	_	I-Premise
269	:	_	_	I-Premise
270	neutropenia	_	_	I-Premise
271	(	_	_	I-Premise
272	82	_	_	I-Premise
273	%	_	_	I-Premise
274	v	_	_	I-Premise
275	57	_	_	I-Premise
276	%	_	_	I-Premise
277	)	_	_	I-Premise
278	,	_	_	I-Premise
279	stomatitis	_	_	I-Premise
280	(	_	_	I-Premise
281	21	_	_	I-Premise
282	%	_	_	I-Premise
283	v	_	_	I-Premise
284	27	_	_	I-Premise
285	%	_	_	I-Premise
286	)	_	_	I-Premise
287	,	_	_	I-Premise
288	diarrhea	_	_	I-Premise
289	(	_	_	I-Premise
290	19	_	_	I-Premise
291	%	_	_	I-Premise
292	v	_	_	I-Premise
293	8	_	_	I-Premise
294	%	_	_	I-Premise
295	)	_	_	I-Premise
296	,	_	_	I-Premise
297	lethargy	_	_	I-Premise
298	(	_	_	I-Premise
299	19	_	_	I-Premise
300	%	_	_	I-Premise
301	v	_	_	I-Premise
302	14	_	_	I-Premise
303	%	_	_	I-Premise
304	)	_	_	I-Premise
305	.	_	_	I-Premise

306	Complicated	_	_	B-Premise
307	neutropenia	_	_	I-Premise
308	was	_	_	I-Premise
309	more	_	_	I-Premise
310	frequent	_	_	I-Premise
311	with	_	_	I-Premise
312	DCF	_	_	I-Premise
313	than	_	_	I-Premise
314	CF	_	_	I-Premise
315	(	_	_	I-Premise
316	29	_	_	I-Premise
317	%	_	_	I-Premise
318	v	_	_	I-Premise
319	12	_	_	I-Premise
320	%	_	_	I-Premise
321	)	_	_	I-Premise
322	.	_	_	I-Premise

323	Adding	_	_	B-Claim
324	docetaxel	_	_	I-Claim
325	to	_	_	I-Claim
326	CF	_	_	I-Claim
327	significantly	_	_	I-Claim
328	improved	_	_	I-Claim
329	TTP	_	_	I-Claim
330	,	_	_	I-Claim
331	survival	_	_	I-Claim
332	,	_	_	I-Claim
333	and	_	_	I-Claim
334	response	_	_	I-Claim
335	rate	_	_	I-Claim
336	in	_	_	I-Claim
337	gastric	_	_	I-Claim
338	cancer	_	_	I-Claim
339	patients	_	_	I-Claim
340	,	_	_	I-Claim
341	but	_	_	I-Claim
342	resulted	_	_	I-Claim
343	in	_	_	I-Claim
344	some	_	_	I-Claim
345	increase	_	_	I-Claim
346	in	_	_	I-Claim
347	toxicity	_	_	I-Claim
348	.	_	_	I-Claim

349	Incorporation	_	_	B-Claim
350	of	_	_	I-Claim
351	docetaxel	_	_	I-Claim
352	,	_	_	I-Claim
353	as	_	_	I-Claim
354	in	_	_	I-Claim
355	DCF	_	_	I-Claim
356	or	_	_	I-Claim
357	with	_	_	I-Claim
358	other	_	_	I-Claim
359	active	_	_	I-Claim
360	drug	_	_	I-Claim
361	(	_	_	I-Claim
362	s	_	_	I-Claim
363	)	_	_	I-Claim
364	,	_	_	I-Claim
365	is	_	_	I-Claim
366	a	_	_	I-Claim
367	new	_	_	I-Claim
368	therapy	_	_	I-Claim
369	option	_	_	I-Claim
370	for	_	_	I-Claim
371	patients	_	_	I-Claim
372	with	_	_	I-Claim
373	untreated	_	_	I-Claim
374	advanced	_	_	I-Claim
375	gastric	_	_	I-Claim
376	cancer	_	_	I-Claim
377	.	_	_	I-Claim


0	A	_	_	O
1	randomized	_	_	O
2	phase	_	_	O
3	III	_	_	O
4	trial	_	_	O
5	was	_	_	O
6	conducted	_	_	O
7	to	_	_	O
8	determine	_	_	O
9	whether	_	_	O
10	combination	_	_	O
11	therapy	_	_	O
12	with	_	_	O
13	13	_	_	O
14	-	_	_	O
15	cis	_	_	O
16	-	_	_	O
17	retinoic	_	_	O
18	acid	_	_	O
19	(	_	_	O
20	13	_	_	O
21	-	_	_	O
22	CRA	_	_	O
23	)	_	_	O
24	plus	_	_	O
25	interferon	_	_	O
26	alfa	_	_	O
27	-	_	_	O
28	2a	_	_	O
29	(	_	_	O
30	IFNalpha2a	_	_	O
31	)	_	_	O
32	is	_	_	O
33	superior	_	_	O
34	to	_	_	O
35	IFNalpha2a	_	_	O
36	alone	_	_	O
37	in	_	_	O
38	patients	_	_	O
39	with	_	_	O
40	advanced	_	_	O
41	renal	_	_	O
42	cell	_	_	O
43	carcinoma	_	_	O
44	(	_	_	O
45	RCC	_	_	O
46	)	_	_	O
47	.	_	_	O

48	Two	_	_	O
49	hundred	_	_	O
50	eighty	_	_	O
51	-	_	_	O
52	four	_	_	O
53	patients	_	_	O
54	were	_	_	O
55	randomized	_	_	O
56	to	_	_	O
57	treatment	_	_	O
58	with	_	_	O
59	IFNalpha2a	_	_	O
60	plus	_	_	O
61	13	_	_	O
62	-	_	_	O
63	CRA	_	_	O
64	or	_	_	O
65	treatment	_	_	O
66	with	_	_	O
67	IFNalpha2a	_	_	O
68	alone	_	_	O
69	.	_	_	O

70	IFNalpha2a	_	_	O
71	was	_	_	O
72	given	_	_	O
73	daily	_	_	O
74	subcutaneously	_	_	O
75	,	_	_	O
76	starting	_	_	O
77	at	_	_	O
78	a	_	_	O
79	dose	_	_	O
80	of	_	_	O
81	3	_	_	O
82	million	_	_	O
83	units	_	_	O
84	(	_	_	O
85	MU	_	_	O
86	)	_	_	O
87	.	_	_	O

88	The	_	_	O
89	dose	_	_	O
90	was	_	_	O
91	escalated	_	_	O
92	every	_	_	O
93	7	_	_	O
94	days	_	_	O
95	from	_	_	O
96	3	_	_	O
97	to	_	_	O
98	9	_	_	O
99	MU	_	_	O
100	(	_	_	O
101	by	_	_	O
102	increments	_	_	O
103	of	_	_	O
104	3	_	_	O
105	MU	_	_	O
106	)	_	_	O
107	,	_	_	O
108	unless	_	_	O
109	>	_	_	O
110	/	_	_	O
111	=	_	_	O
112	grade	_	_	O
113	2	_	_	O
114	toxicity	_	_	O
115	occurred	_	_	O
116	,	_	_	O
117	in	_	_	O
118	which	_	_	O
119	case	_	_	O
120	dose	_	_	O
121	escalation	_	_	O
122	was	_	_	O
123	stopped	_	_	O
124	.	_	_	O

125	Patients	_	_	O
126	randomized	_	_	O
127	to	_	_	O
128	combination	_	_	O
129	therapy	_	_	O
130	were	_	_	O
131	given	_	_	O
132	oral	_	_	O
133	13	_	_	O
134	-	_	_	O
135	CRA	_	_	O
136	1	_	_	O
137	mg	_	_	O
138	/	_	_	O
139	kg	_	_	O
140	/	_	_	O
141	d	_	_	O
142	plus	_	_	O
143	IFNalpha2a	_	_	O
144	.	_	_	O

145	Quality	_	_	O
146	of	_	_	O
147	life	_	_	O
148	(	_	_	O
149	QOL	_	_	O
150	)	_	_	O
151	was	_	_	O
152	assessed	_	_	O
153	.	_	_	O

154	Complete	_	_	B-Premise
155	or	_	_	I-Premise
156	partial	_	_	I-Premise
157	responses	_	_	I-Premise
158	were	_	_	I-Premise
159	achieved	_	_	I-Premise
160	by	_	_	I-Premise
161	12	_	_	I-Premise
162	%	_	_	I-Premise
163	of	_	_	I-Premise
164	patients	_	_	I-Premise
165	treated	_	_	I-Premise
166	with	_	_	I-Premise
167	IFNalpha2a	_	_	I-Premise
168	plus	_	_	I-Premise
169	13	_	_	I-Premise
170	-	_	_	I-Premise
171	CRA	_	_	I-Premise
172	and	_	_	I-Premise
173	6	_	_	I-Premise
174	%	_	_	I-Premise
175	of	_	_	I-Premise
176	patients	_	_	I-Premise
177	treated	_	_	I-Premise
178	with	_	_	I-Premise
179	IFNalpha2a	_	_	I-Premise
180	(	_	_	I-Premise
181	P	_	_	I-Premise
182	=	_	_	I-Premise
183	.	_	_	I-Premise

184	14	_	_	I-Premise
185	)	_	_	I-Premise
186	.	_	_	I-Premise

187	Median	_	_	B-Premise
188	duration	_	_	I-Premise
189	of	_	_	I-Premise
190	response	_	_	I-Premise
191	(	_	_	I-Premise
192	complete	_	_	I-Premise
193	and	_	_	I-Premise
194	partial	_	_	I-Premise
195	combined	_	_	I-Premise
196	)	_	_	I-Premise
197	in	_	_	I-Premise
198	the	_	_	I-Premise
199	group	_	_	I-Premise
200	treated	_	_	I-Premise
201	with	_	_	I-Premise
202	the	_	_	I-Premise
203	combination	_	_	I-Premise
204	was	_	_	I-Premise
205	33	_	_	I-Premise
206	months	_	_	I-Premise
207	(	_	_	I-Premise
208	range	_	_	I-Premise
209	,	_	_	I-Premise
210	9	_	_	I-Premise
211	to	_	_	I-Premise
212	50	_	_	I-Premise
213	months	_	_	I-Premise
214	)	_	_	I-Premise
215	,	_	_	I-Premise
216	versus	_	_	I-Premise
217	22	_	_	I-Premise
218	months	_	_	I-Premise
219	(	_	_	I-Premise
220	range	_	_	I-Premise
221	,	_	_	I-Premise
222	5	_	_	I-Premise
223	to	_	_	I-Premise
224	38	_	_	I-Premise
225	months	_	_	I-Premise
226	)	_	_	I-Premise
227	for	_	_	I-Premise
228	the	_	_	I-Premise
229	second	_	_	I-Premise
230	group	_	_	I-Premise
231	(	_	_	I-Premise
232	P	_	_	I-Premise
233	=	_	_	I-Premise
234	.	_	_	I-Premise

235	03	_	_	I-Premise
236	)	_	_	I-Premise
237	.	_	_	I-Premise

238	Nineteen	_	_	B-Premise
239	percent	_	_	I-Premise
240	of	_	_	I-Premise
241	patients	_	_	I-Premise
242	treated	_	_	I-Premise
243	with	_	_	I-Premise
244	IFNalpha2a	_	_	I-Premise
245	plus	_	_	I-Premise
246	13	_	_	I-Premise
247	-	_	_	I-Premise
248	CRA	_	_	I-Premise
249	were	_	_	I-Premise
250	progression	_	_	I-Premise
251	-	_	_	I-Premise
252	free	_	_	I-Premise
253	at	_	_	I-Premise
254	24	_	_	I-Premise
255	months	_	_	I-Premise
256	,	_	_	I-Premise
257	compared	_	_	I-Premise
258	with	_	_	I-Premise
259	10	_	_	I-Premise
260	%	_	_	I-Premise
261	of	_	_	I-Premise
262	patients	_	_	I-Premise
263	treated	_	_	I-Premise
264	with	_	_	I-Premise
265	IFNalpha2a	_	_	I-Premise
266	alone	_	_	I-Premise
267	(	_	_	I-Premise
268	P	_	_	I-Premise
269	=	_	_	I-Premise
270	.	_	_	I-Premise

271	05	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	Median	_	_	B-Premise
275	survival	_	_	I-Premise
276	time	_	_	I-Premise
277	for	_	_	I-Premise
278	all	_	_	I-Premise
279	patients	_	_	I-Premise
280	was	_	_	I-Premise
281	15	_	_	I-Premise
282	months	_	_	I-Premise
283	,	_	_	I-Premise
284	with	_	_	I-Premise
285	no	_	_	I-Premise
286	difference	_	_	I-Premise
287	in	_	_	I-Premise
288	survival	_	_	I-Premise
289	between	_	_	I-Premise
290	the	_	_	I-Premise
291	two	_	_	I-Premise
292	treatment	_	_	I-Premise
293	arms	_	_	I-Premise
294	(	_	_	I-Premise
295	P	_	_	I-Premise
296	=	_	_	I-Premise
297	.	_	_	I-Premise

298	26	_	_	I-Premise
299	)	_	_	I-Premise
300	.	_	_	I-Premise

301	QOL	_	_	B-Premise
302	decreased	_	_	I-Premise
303	during	_	_	I-Premise
304	the	_	_	I-Premise
305	first	_	_	I-Premise
306	8	_	_	I-Premise
307	weeks	_	_	I-Premise
308	of	_	_	I-Premise
309	treatment	_	_	I-Premise
310	,	_	_	I-Premise
311	and	_	_	I-Premise
312	a	_	_	I-Premise
313	partial	_	_	I-Premise
314	recovery	_	_	I-Premise
315	followed	_	_	I-Premise
316	.	_	_	I-Premise

317	Lower	_	_	B-Premise
318	scores	_	_	I-Premise
319	were	_	_	I-Premise
320	associated	_	_	I-Premise
321	with	_	_	I-Premise
322	the	_	_	I-Premise
323	combination	_	_	I-Premise
324	therapy	_	_	I-Premise
325	.	_	_	I-Premise

326	Response	_	_	B-Claim
327	proportion	_	_	I-Claim
328	and	_	_	I-Claim
329	survival	_	_	I-Claim
330	did	_	_	I-Claim
331	not	_	_	I-Claim
332	improve	_	_	I-Claim
333	significantly	_	_	I-Claim
334	with	_	_	I-Claim
335	the	_	_	I-Claim
336	addition	_	_	I-Claim
337	of	_	_	I-Claim
338	13	_	_	I-Claim
339	-	_	_	I-Claim
340	CRA	_	_	I-Claim
341	to	_	_	I-Claim
342	IFNalpha2a	_	_	I-Claim
343	therapy	_	_	I-Claim
344	in	_	_	I-Claim
345	patients	_	_	I-Claim
346	with	_	_	I-Claim
347	advanced	_	_	I-Claim
348	RCC	_	_	I-Claim
349	.	_	_	I-Claim

350	13	_	_	B-Claim
351	-	_	_	I-Claim
352	CRA	_	_	I-Claim
353	may	_	_	I-Claim
354	lengthen	_	_	I-Claim
355	response	_	_	I-Claim
356	to	_	_	I-Claim
357	IFNalpha2a	_	_	I-Claim
358	therapy	_	_	I-Claim
359	in	_	_	I-Claim
360	patients	_	_	I-Claim
361	with	_	_	I-Claim
362	IFNalpha2a	_	_	I-Claim
363	-	_	_	I-Claim
364	sensitive	_	_	I-Claim
365	tumors	_	_	I-Claim
366	.	_	_	I-Claim

367	Treatment	_	_	B-Claim
368	,	_	_	I-Claim
369	particularly	_	_	I-Claim
370	the	_	_	I-Claim
371	combination	_	_	I-Claim
372	therapy	_	_	I-Claim
373	,	_	_	I-Claim
374	was	_	_	I-Claim
375	associated	_	_	I-Claim
376	with	_	_	I-Claim
377	a	_	_	I-Claim
378	decrease	_	_	I-Claim
379	in	_	_	I-Claim
380	QOL	_	_	I-Claim
381	.	_	_	I-Claim


0	A	_	_	O
1	phase	_	_	O
2	III	_	_	O
3	randomized	_	_	O
4	trial	_	_	O
5	was	_	_	O
6	carried	_	_	O
7	out	_	_	O
8	to	_	_	O
9	compare	_	_	O
10	two	_	_	O
11	schedules	_	_	O
12	of	_	_	O
13	the	_	_	O
14	vinorelbine	_	_	O
15	(	_	_	O
16	VNR	_	_	O
17	)	_	_	O
18	-	_	_	O
19	cisplatin	_	_	O
20	(	_	_	O
21	CDDP	_	_	O
22	)	_	_	O
23	regimen	_	_	O
24	in	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	locally	_	_	O
28	advanced	_	_	O
29	unresectable	_	_	O
30	poor	_	_	O
31	prognosis	_	_	O
32	stage	_	_	O
33	IIIB	_	_	O
34	or	_	_	O
35	metastatic	_	_	O
36	stage	_	_	O
37	IV	_	_	O
38	non	_	_	O
39	-	_	_	O
40	small	_	_	O
41	cell	_	_	O
42	lung	_	_	O
43	cancer	_	_	O
44	.	_	_	O

45	The	_	_	O
46	primary	_	_	O
47	endpoints	_	_	O
48	were	_	_	O
49	overall	_	_	O
50	survival	_	_	O
51	(	_	_	O
52	OS	_	_	O
53	)	_	_	O
54	and	_	_	O
55	analysis	_	_	O
56	of	_	_	O
57	toxicity	_	_	O
58	,	_	_	O
59	while	_	_	O
60	secondary	_	_	O
61	endpoints	_	_	O
62	included	_	_	O
63	response	_	_	O
64	rates	_	_	O
65	,	_	_	O
66	time	_	_	O
67	-	_	_	O
68	to	_	_	O
69	-	_	_	O
70	progression	_	_	O
71	(	_	_	O
72	TTP	_	_	O
73	)	_	_	O
74	and	_	_	O
75	quality	_	_	O
76	of	_	_	O
77	life	_	_	O
78	(	_	_	O
79	QoL	_	_	O
80	)	_	_	O
81	.	_	_	O

82	Eligible	_	_	O
83	patients	_	_	O
84	were	_	_	O
85	randomized	_	_	O
86	to	_	_	O
87	receive	_	_	O
88	:	_	_	O
89	(	_	_	O
90	a	_	_	O
91	)	_	_	O
92	VNR	_	_	O
93	25mg	_	_	O
94	/	_	_	O
95	m	_	_	O
96	(	_	_	O
97	2	_	_	O
98	)	_	_	O
99	on	_	_	O
100	day	_	_	O
101	1	_	_	O
102	,	_	_	O
103	8	_	_	O
104	and	_	_	O
105	15	_	_	O
106	plus	_	_	O
107	CDDP	_	_	O
108	100mg	_	_	O
109	/	_	_	O
110	m	_	_	O
111	(	_	_	O
112	2	_	_	O
113	)	_	_	O
114	on	_	_	O
115	day	_	_	O
116	1	_	_	O
117	every	_	_	O
118	4	_	_	O
119	weeks	_	_	O
120	or	_	_	O
121	(	_	_	O
122	b	_	_	O
123	)	_	_	O
124	VNR	_	_	O
125	30	_	_	O
126	mg	_	_	O
127	/	_	_	O
128	m	_	_	O
129	(	_	_	O
130	2	_	_	O
131	)	_	_	O
132	on	_	_	O
133	day	_	_	O
134	1	_	_	O
135	and	_	_	O
136	8	_	_	O
137	plus	_	_	O
138	CDDP	_	_	O
139	80	_	_	O
140	mg	_	_	O
141	/	_	_	O
142	m	_	_	O
143	(	_	_	O
144	2	_	_	O
145	)	_	_	O
146	on	_	_	O
147	day	_	_	O
148	1	_	_	O
149	every	_	_	O
150	3	_	_	O
151	weeks	_	_	O
152	.	_	_	O

153	All	_	_	O
154	patients	_	_	O
155	were	_	_	O
156	chemotherapy	_	_	O
157	-	_	_	O
158	naïve	_	_	O
159	and	_	_	O
160	had	_	_	O
161	an	_	_	O
162	ECOG	_	_	O
163	performance	_	_	O
164	status	_	_	O
165	(	_	_	O
166	PS	_	_	O
167	)	_	_	O
168	of	_	_	O
169	0	_	_	O
170	-	_	_	O
171	1	_	_	O
172	.	_	_	O

173	Overall	_	_	O
174	278	_	_	O
175	patients	_	_	O
176	were	_	_	O
177	enrolled	_	_	O
178	into	_	_	O
179	the	_	_	O
180	trial	_	_	O
181	.	_	_	O

182	Overall	_	_	O
183	response	_	_	O
184	rate	_	_	O
185	was	_	_	O
186	34	_	_	O
187	%	_	_	O
188	(	_	_	O
189	95	_	_	O
190	%	_	_	O
191	CL	_	_	O
192	26	_	_	O
193	-	_	_	O
194	42	_	_	O
195	%	_	_	O
196	)	_	_	O
197	in	_	_	O
198	the	_	_	O
199	weekly	_	_	O
200	VNR	_	_	O
201	/	_	_	O
202	CDDP	_	_	O
203	arm	_	_	O
204	,	_	_	O
205	and	_	_	O
206	32	_	_	O
207	%	_	_	O
208	(	_	_	O
209	95	_	_	O
210	%	_	_	O
211	CL	_	_	O
212	24	_	_	O
213	-	_	_	O
214	40	_	_	O
215	%	_	_	O
216	)	_	_	O
217	in	_	_	O
218	patients	_	_	O
219	treated	_	_	O
220	with	_	_	O
221	day	_	_	O
222	1	_	_	O
223	-	_	_	O
224	8	_	_	O
225	VNR	_	_	O
226	/	_	_	O
227	CDDP	_	_	O
228	without	_	_	O
229	any	_	_	O
230	statistically	_	_	O
231	significant	_	_	O
232	difference	_	_	O
233	.	_	_	O

234	Median	_	_	B-Premise
235	TTP	_	_	I-Premise
236	was	_	_	I-Premise
237	4	_	_	I-Premise
238	.	_	_	I-Premise

239	5	_	_	I-Premise
240	and	_	_	I-Premise
241	4	_	_	I-Premise
242	.	_	_	I-Premise

243	6	_	_	I-Premise
244	months	_	_	I-Premise
245	respectively	_	_	I-Premise
246	for	_	_	I-Premise
247	weekly	_	_	I-Premise
248	VNR	_	_	I-Premise
249	/	_	_	I-Premise
250	CDDP	_	_	I-Premise
251	arm	_	_	I-Premise
252	and	_	_	I-Premise
253	the	_	_	I-Premise
254	day	_	_	I-Premise
255	1	_	_	I-Premise
256	-	_	_	I-Premise
257	8	_	_	I-Premise
258	VNR	_	_	I-Premise
259	/	_	_	I-Premise
260	CDDP	_	_	I-Premise
261	one	_	_	I-Premise
262	.	_	_	I-Premise

263	This	_	_	B-Premise
264	difference	_	_	I-Premise
265	was	_	_	I-Premise
266	not	_	_	I-Premise
267	statistically	_	_	I-Premise
268	significant	_	_	I-Premise
269	(	_	_	I-Premise
270	log	_	_	I-Premise
271	-	_	_	I-Premise
272	rank	_	_	I-Premise
273	test	_	_	I-Premise
274	,	_	_	I-Premise
275	p	_	_	I-Premise
276	=	_	_	I-Premise
277	0	_	_	I-Premise
278	.	_	_	I-Premise

279	818	_	_	I-Premise
280	)	_	_	I-Premise
281	.	_	_	I-Premise

282	Median	_	_	B-Premise
283	OS	_	_	I-Premise
284	was	_	_	I-Premise
285	9	_	_	I-Premise
286	.	_	_	I-Premise

287	45	_	_	I-Premise
288	and	_	_	I-Premise
289	10	_	_	I-Premise
290	months	_	_	I-Premise
291	respectively	_	_	I-Premise
292	for	_	_	I-Premise
293	weekly	_	_	I-Premise
294	VNR	_	_	I-Premise
295	/	_	_	I-Premise
296	CDDP	_	_	I-Premise
297	arm	_	_	I-Premise
298	and	_	_	I-Premise
299	the	_	_	I-Premise
300	day	_	_	I-Premise
301	1	_	_	I-Premise
302	-	_	_	I-Premise
303	8	_	_	I-Premise
304	VNR	_	_	I-Premise
305	/	_	_	I-Premise
306	CDDP	_	_	I-Premise
307	one	_	_	I-Premise
308	without	_	_	I-Premise
309	statistically	_	_	I-Premise
310	a	_	_	I-Premise
311	significant	_	_	I-Premise
312	difference	_	_	I-Premise
313	(	_	_	I-Premise
314	log	_	_	I-Premise
315	-	_	_	I-Premise
316	rank	_	_	I-Premise
317	test	_	_	I-Premise
318	,	_	_	I-Premise
319	p	_	_	I-Premise
320	=	_	_	I-Premise
321	0	_	_	I-Premise
322	.	_	_	I-Premise

323	259	_	_	I-Premise
324	)	_	_	I-Premise
325	.	_	_	I-Premise

326	The	_	_	B-Premise
327	1	_	_	I-Premise
328	-	_	_	I-Premise
329	and	_	_	I-Premise
330	2	_	_	I-Premise
331	-	_	_	I-Premise
332	year	_	_	I-Premise
333	survival	_	_	I-Premise
334	rates	_	_	I-Premise
335	were	_	_	I-Premise
336	31	_	_	I-Premise
337	and	_	_	I-Premise
338	36	_	_	I-Premise
339	%	_	_	I-Premise
340	,	_	_	I-Premise
341	and	_	_	I-Premise
342	10	_	_	I-Premise
343	and	_	_	I-Premise
344	11	_	_	I-Premise
345	%	_	_	I-Premise
346	respectively	_	_	I-Premise
347	.	_	_	I-Premise

348	The	_	_	B-Premise
349	incidence	_	_	I-Premise
350	of	_	_	I-Premise
351	severe	_	_	I-Premise
352	neutropenia	_	_	I-Premise
353	(	_	_	I-Premise
354	34	_	_	I-Premise
355	%	_	_	I-Premise
356	versus	_	_	I-Premise
357	68	_	_	I-Premise
358	%	_	_	I-Premise
359	;	_	_	I-Premise
360	p	_	_	I-Premise
361	=	_	_	I-Premise
362	0	_	_	I-Premise
363	.	_	_	I-Premise

364	0001	_	_	I-Premise
365	)	_	_	I-Premise
366	and	_	_	I-Premise
367	of	_	_	I-Premise
368	febrile	_	_	I-Premise
369	neutropenia	_	_	I-Premise
370	(	_	_	I-Premise
371	5	_	_	I-Premise
372	%	_	_	I-Premise
373	versus	_	_	I-Premise
374	12	_	_	I-Premise
375	%	_	_	I-Premise
376	;	_	_	I-Premise
377	p	_	_	I-Premise
378	=	_	_	I-Premise
379	0	_	_	I-Premise
380	.	_	_	I-Premise

381	026	_	_	I-Premise
382	)	_	_	I-Premise
383	,	_	_	I-Premise
384	as	_	_	I-Premise
385	well	_	_	I-Premise
386	as	_	_	I-Premise
387	the	_	_	I-Premise
388	rate	_	_	I-Premise
389	of	_	_	I-Premise
390	therapy	_	_	I-Premise
391	omissions	_	_	I-Premise
392	(	_	_	I-Premise
393	10	_	_	I-Premise
394	%	_	_	I-Premise
395	versus	_	_	I-Premise
396	24	_	_	I-Premise
397	%	_	_	I-Premise
398	;	_	_	I-Premise
399	p	_	_	I-Premise
400	=	_	_	I-Premise
401	0	_	_	I-Premise
402	.	_	_	I-Premise

403	0037	_	_	I-Premise
404	)	_	_	I-Premise
405	were	_	_	I-Premise
406	higher	_	_	I-Premise
407	in	_	_	I-Premise
408	the	_	_	I-Premise
409	weekly	_	_	I-Premise
410	VNR	_	_	I-Premise
411	/	_	_	I-Premise
412	CDDP	_	_	I-Premise
413	arm	_	_	I-Premise
414	than	_	_	I-Premise
415	in	_	_	I-Premise
416	the	_	_	I-Premise
417	day	_	_	I-Premise
418	1	_	_	I-Premise
419	-	_	_	I-Premise
420	8	_	_	I-Premise
421	VNR	_	_	I-Premise
422	/	_	_	I-Premise
423	CDDP	_	_	I-Premise
424	one	_	_	I-Premise
425	.	_	_	I-Premise

426	The	_	_	B-Premise
427	weekly	_	_	I-Premise
428	VNR	_	_	I-Premise
429	/	_	_	I-Premise
430	CDDP	_	_	I-Premise
431	regimen	_	_	I-Premise
432	was	_	_	I-Premise
433	associated	_	_	I-Premise
434	with	_	_	I-Premise
435	a	_	_	I-Premise
436	lower	_	_	I-Premise
437	received	_	_	I-Premise
438	dose	_	_	I-Premise
439	intensity	_	_	I-Premise
440	in	_	_	I-Premise
441	a	_	_	I-Premise
442	statistically	_	_	I-Premise
443	significant	_	_	I-Premise
444	fashion	_	_	I-Premise
445	(	_	_	I-Premise
446	9	_	_	I-Premise
447	%	_	_	I-Premise
448	versus	_	_	I-Premise
449	22	_	_	I-Premise
450	%	_	_	I-Premise
451	;	_	_	I-Premise
452	p	_	_	I-Premise
453	=	_	_	I-Premise
454	0	_	_	I-Premise
455	.	_	_	I-Premise

456	0001	_	_	I-Premise
457	)	_	_	I-Premise
458	and	_	_	I-Premise
459	with	_	_	I-Premise
460	a	_	_	I-Premise
461	lower	_	_	I-Premise
462	non	_	_	I-Premise
463	-	_	_	I-Premise
464	statistically	_	_	I-Premise
465	significant	_	_	I-Premise
466	quality	_	_	I-Premise
467	of	_	_	I-Premise
468	life	_	_	I-Premise
469	score	_	_	I-Premise
470	as	_	_	I-Premise
471	compared	_	_	I-Premise
472	to	_	_	I-Premise
473	the	_	_	I-Premise
474	day	_	_	I-Premise
475	1	_	_	I-Premise
476	-	_	_	I-Premise
477	8	_	_	I-Premise
478	VNR	_	_	I-Premise
479	/	_	_	I-Premise
480	CDDP	_	_	I-Premise
481	schedule	_	_	I-Premise
482	.	_	_	I-Premise

483	The	_	_	B-Claim
484	combination	_	_	I-Claim
485	of	_	_	I-Claim
486	day	_	_	I-Claim
487	1	_	_	I-Claim
488	-	_	_	I-Claim
489	8	_	_	I-Claim
490	VNR	_	_	I-Claim
491	plus	_	_	I-Claim
492	CDDP	_	_	I-Claim
493	every	_	_	I-Claim
494	3	_	_	I-Claim
495	weeks	_	_	I-Claim
496	is	_	_	I-Claim
497	less	_	_	I-Claim
498	toxic	_	_	I-Claim
499	and	_	_	I-Claim
500	better	_	_	I-Claim
501	tolerated	_	_	I-Claim
502	than	_	_	I-Claim
503	the	_	_	I-Claim
504	regimen	_	_	I-Claim
505	of	_	_	I-Claim
506	weekly	_	_	I-Claim
507	VNR	_	_	I-Claim
508	plus	_	_	I-Claim
509	CDDP	_	_	I-Claim
510	every	_	_	I-Claim
511	4	_	_	I-Claim
512	weeks	_	_	I-Claim
513	.	_	_	I-Claim

514	The	_	_	B-Claim
515	two	_	_	I-Claim
516	schedules	_	_	I-Claim
517	are	_	_	I-Claim
518	equivalent	_	_	I-Claim
519	in	_	_	I-Claim
520	terms	_	_	I-Claim
521	of	_	_	I-Claim
522	overall	_	_	I-Claim
523	response	_	_	I-Claim
524	rate	_	_	I-Claim
525	,	_	_	I-Claim
526	median	_	_	I-Claim
527	time	_	_	I-Claim
528	-	_	_	I-Claim
529	to	_	_	I-Claim
530	-	_	_	I-Claim
531	progression	_	_	I-Claim
532	and	_	_	I-Claim
533	overall	_	_	I-Claim
534	survival	_	_	I-Claim
535	.	_	_	I-Claim

536	The	_	_	B-Claim
537	combination	_	_	I-Claim
538	of	_	_	I-Claim
539	VNR	_	_	I-Claim
540	on	_	_	I-Claim
541	day	_	_	I-Claim
542	1	_	_	I-Claim
543	-	_	_	I-Claim
544	8	_	_	I-Claim
545	plus	_	_	I-Claim
546	CDDP	_	_	I-Claim
547	every	_	_	I-Claim
548	3	_	_	I-Claim
549	weeks	_	_	I-Claim
550	may	_	_	I-Claim
551	be	_	_	I-Claim
552	considered	_	_	I-Claim
553	as	_	_	I-Claim
554	a	_	_	I-Claim
555	reference	_	_	I-Claim
556	regimen	_	_	I-Claim
557	for	_	_	I-Claim
558	the	_	_	I-Claim
559	treatment	_	_	I-Claim
560	of	_	_	I-Claim
561	patients	_	_	I-Claim
562	with	_	_	I-Claim
563	advanced	_	_	I-Claim
564	disease	_	_	I-Claim
565	and	_	_	I-Claim
566	those	_	_	I-Claim
567	who	_	_	I-Claim
568	deserve	_	_	I-Claim
569	a	_	_	I-Claim
570	postoperative	_	_	I-Claim
571	therapy	_	_	I-Claim
572	,	_	_	I-Claim
573	and	_	_	I-Claim
574	for	_	_	I-Claim
575	future	_	_	I-Claim
576	studies	_	_	I-Claim
577	.	_	_	I-Claim


0	Bevacizumab	_	_	B-Claim
1	,	_	_	I-Claim
2	a	_	_	I-Claim
3	monoclonal	_	_	I-Claim
4	antibody	_	_	I-Claim
5	against	_	_	I-Claim
6	vascular	_	_	I-Claim
7	endothelial	_	_	I-Claim
8	growth	_	_	I-Claim
9	factor	_	_	I-Claim
10	,	_	_	I-Claim
11	increases	_	_	I-Claim
12	survival	_	_	I-Claim
13	when	_	_	I-Claim
14	combined	_	_	I-Claim
15	with	_	_	I-Claim
16	irinotecan	_	_	I-Claim
17	-	_	_	I-Claim
18	based	_	_	I-Claim
19	chemotherapy	_	_	I-Claim
20	in	_	_	I-Claim
21	first	_	_	I-Claim
22	-	_	_	I-Claim
23	line	_	_	I-Claim
24	treatment	_	_	I-Claim
25	of	_	_	I-Claim
26	metastatic	_	_	I-Claim
27	colorectal	_	_	I-Claim
28	cancer	_	_	I-Claim
29	(	_	_	I-Claim
30	CRC	_	_	I-Claim
31	)	_	_	I-Claim
32	.	_	_	I-Claim

33	This	_	_	O
34	randomized	_	_	O
35	,	_	_	O
36	phase	_	_	O
37	II	_	_	O
38	trial	_	_	O
39	compared	_	_	O
40	bevacizumab	_	_	O
41	plus	_	_	O
42	fluorouracil	_	_	O
43	and	_	_	O
44	leucovorin	_	_	O
45	(	_	_	O
46	FU	_	_	O
47	/	_	_	O
48	LV	_	_	O
49	)	_	_	O
50	versus	_	_	O
51	placebo	_	_	O
52	plus	_	_	O
53	FU	_	_	O
54	/	_	_	O
55	LV	_	_	O
56	as	_	_	O
57	first	_	_	O
58	-	_	_	O
59	line	_	_	O
60	therapy	_	_	O
61	in	_	_	O
62	patients	_	_	O
63	considered	_	_	O
64	nonoptimal	_	_	O
65	candidates	_	_	O
66	for	_	_	O
67	first	_	_	O
68	-	_	_	O
69	line	_	_	O
70	irinotecan	_	_	O
71	.	_	_	O

72	Patients	_	_	O
73	had	_	_	O
74	metastatic	_	_	O
75	CRC	_	_	O
76	and	_	_	O
77	one	_	_	O
78	of	_	_	O
79	the	_	_	O
80	following	_	_	O
81	characteristics	_	_	O
82	:	_	_	O
83	age	_	_	O
84	>	_	_	O
85	or	_	_	O
86	=	_	_	O
87	65	_	_	O
88	years	_	_	O
89	,	_	_	O
90	Eastern	_	_	O
91	Cooperative	_	_	O
92	Oncology	_	_	O
93	Group	_	_	O
94	performance	_	_	O
95	status	_	_	O
96	1	_	_	O
97	or	_	_	O
98	2	_	_	O
99	,	_	_	O
100	serum	_	_	O
101	albumin	_	_	O
102	<	_	_	O
103	or	_	_	O
104	=	_	_	O
105	3	_	_	O
106	.	_	_	O

107	5	_	_	O
108	g	_	_	O
109	/	_	_	O
110	dL	_	_	O
111	,	_	_	O
112	or	_	_	O
113	prior	_	_	O
114	abdominal	_	_	O
115	/	_	_	O
116	pelvic	_	_	O
117	radiotherapy	_	_	O
118	.	_	_	O

119	Patients	_	_	O
120	were	_	_	O
121	randomly	_	_	O
122	assigned	_	_	O
123	to	_	_	O
124	FU	_	_	O
125	/	_	_	O
126	LV	_	_	O
127	/	_	_	O
128	placebo	_	_	O
129	(	_	_	O
130	n	_	_	O
131	=	_	_	O
132	105	_	_	O
133	)	_	_	O
134	or	_	_	O
135	FU	_	_	O
136	/	_	_	O
137	LV	_	_	O
138	/	_	_	O
139	bevacizumab	_	_	O
140	(	_	_	O
141	n	_	_	O
142	=	_	_	O
143	104	_	_	O
144	)	_	_	O
145	.	_	_	O

146	The	_	_	O
147	primary	_	_	O
148	end	_	_	O
149	point	_	_	O
150	was	_	_	O
151	overall	_	_	O
152	survival	_	_	O
153	.	_	_	O

154	Secondary	_	_	O
155	end	_	_	O
156	points	_	_	O
157	were	_	_	O
158	progression	_	_	O
159	-	_	_	O
160	free	_	_	O
161	survival	_	_	O
162	,	_	_	O
163	response	_	_	O
164	rate	_	_	O
165	,	_	_	O
166	response	_	_	O
167	duration	_	_	O
168	,	_	_	O
169	and	_	_	O
170	quality	_	_	O
171	of	_	_	O
172	life	_	_	O
173	.	_	_	O

174	Safety	_	_	O
175	was	_	_	O
176	also	_	_	O
177	assessed	_	_	O
178	.	_	_	O

179	Median	_	_	B-Premise
180	survival	_	_	I-Premise
181	was	_	_	I-Premise
182	16	_	_	I-Premise
183	.	_	_	I-Premise

184	6	_	_	I-Premise
185	months	_	_	I-Premise
186	for	_	_	I-Premise
187	the	_	_	I-Premise
188	FU	_	_	I-Premise
189	/	_	_	I-Premise
190	LV	_	_	I-Premise
191	/	_	_	I-Premise
192	bevacizumab	_	_	I-Premise
193	group	_	_	I-Premise
194	and	_	_	I-Premise
195	12	_	_	I-Premise
196	.	_	_	I-Premise

197	9	_	_	I-Premise
198	months	_	_	I-Premise
199	for	_	_	I-Premise
200	the	_	_	I-Premise
201	FU	_	_	I-Premise
202	/	_	_	I-Premise
203	LV	_	_	I-Premise
204	/	_	_	I-Premise
205	placebo	_	_	I-Premise
206	group	_	_	I-Premise
207	(	_	_	I-Premise
208	hazard	_	_	I-Premise
209	ratio	_	_	I-Premise
210	,	_	_	I-Premise
211	0	_	_	I-Premise
212	.	_	_	I-Premise

213	79	_	_	I-Premise
214	;	_	_	I-Premise
215	P	_	_	I-Premise
216	=	_	_	I-Premise
217	.	_	_	I-Premise

218	16	_	_	I-Premise
219	)	_	_	I-Premise
220	.	_	_	I-Premise

221	Median	_	_	B-Premise
222	progression	_	_	I-Premise
223	-	_	_	I-Premise
224	free	_	_	I-Premise
225	survival	_	_	I-Premise
226	was	_	_	I-Premise
227	9	_	_	I-Premise
228	.	_	_	I-Premise

229	2	_	_	I-Premise
230	months	_	_	I-Premise
231	(	_	_	I-Premise
232	FU	_	_	I-Premise
233	/	_	_	I-Premise
234	LV	_	_	I-Premise
235	/	_	_	I-Premise
236	bevacizumab	_	_	I-Premise
237	)	_	_	I-Premise
238	and	_	_	I-Premise
239	5	_	_	I-Premise
240	.	_	_	I-Premise

241	5	_	_	I-Premise
242	months	_	_	I-Premise
243	(	_	_	I-Premise
244	FU	_	_	I-Premise
245	/	_	_	I-Premise
246	LV	_	_	I-Premise
247	/	_	_	I-Premise
248	placebo	_	_	I-Premise
249	)	_	_	I-Premise
250	;	_	_	I-Premise
251	hazard	_	_	B-Premise
252	ratio	_	_	I-Premise
253	was	_	_	I-Premise
254	0	_	_	I-Premise
255	.	_	_	I-Premise

256	50	_	_	I-Premise
257	;	_	_	I-Premise
258	P	_	_	I-Premise
259	=	_	_	I-Premise
260	.	_	_	I-Premise

261	0002	_	_	I-Premise
262	.	_	_	O

263	Response	_	_	B-Premise
264	rates	_	_	I-Premise
265	were	_	_	I-Premise
266	26	_	_	I-Premise
267	.	_	_	I-Premise

268	0	_	_	I-Premise
269	%	_	_	I-Premise
270	(	_	_	I-Premise
271	FU	_	_	I-Premise
272	/	_	_	I-Premise
273	LV	_	_	I-Premise
274	/	_	_	I-Premise
275	bevacizumab	_	_	I-Premise
276	)	_	_	I-Premise
277	and	_	_	I-Premise
278	15	_	_	I-Premise
279	.	_	_	I-Premise

280	2	_	_	I-Premise
281	%	_	_	I-Premise
282	(	_	_	I-Premise
283	FU	_	_	I-Premise
284	/	_	_	I-Premise
285	LV	_	_	I-Premise
286	/	_	_	I-Premise
287	placebo	_	_	I-Premise
288	)	_	_	I-Premise
289	(	_	_	I-Premise
290	P	_	_	I-Premise
291	=	_	_	I-Premise
292	.	_	_	I-Premise

293	055	_	_	I-Premise
294	)	_	_	I-Premise
295	;	_	_	I-Premise
296	duration	_	_	B-Premise
297	of	_	_	I-Premise
298	response	_	_	I-Premise
299	was	_	_	I-Premise
300	9	_	_	I-Premise
301	.	_	_	I-Premise

302	2	_	_	I-Premise
303	months	_	_	I-Premise
304	(	_	_	I-Premise
305	FU	_	_	I-Premise
306	/	_	_	I-Premise
307	LV	_	_	I-Premise
308	/	_	_	I-Premise
309	bevacizumab	_	_	I-Premise
310	)	_	_	I-Premise
311	and	_	_	I-Premise
312	6	_	_	I-Premise
313	.	_	_	I-Premise

314	8	_	_	I-Premise
315	months	_	_	I-Premise
316	(	_	_	I-Premise
317	FU	_	_	I-Premise
318	/	_	_	I-Premise
319	LV	_	_	I-Premise
320	/	_	_	I-Premise
321	placebo	_	_	I-Premise
322	)	_	_	I-Premise
323	;	_	_	I-Premise
324	hazard	_	_	B-Premise
325	ratio	_	_	I-Premise
326	was	_	_	I-Premise
327	0	_	_	I-Premise
328	.	_	_	I-Premise

329	42	_	_	I-Premise
330	;	_	_	I-Premise
331	P	_	_	I-Premise
332	=	_	_	I-Premise
333	.	_	_	I-Premise

334	088	_	_	I-Premise
335	.	_	_	I-Premise

336	Grade	_	_	B-Premise
337	3	_	_	I-Premise
338	hypertension	_	_	I-Premise
339	was	_	_	I-Premise
340	more	_	_	I-Premise
341	common	_	_	I-Premise
342	with	_	_	I-Premise
343	bevacizumab	_	_	I-Premise
344	treatment	_	_	I-Premise
345	(	_	_	I-Premise
346	16	_	_	I-Premise
347	%	_	_	I-Premise
348	v	_	_	I-Premise
349	3	_	_	I-Premise
350	%	_	_	I-Premise
351	)	_	_	I-Premise
352	but	_	_	B-Premise
353	was	_	_	I-Premise
354	controlled	_	_	I-Premise
355	with	_	_	I-Premise
356	oral	_	_	I-Premise
357	medication	_	_	I-Premise
358	and	_	_	I-Premise
359	did	_	_	I-Premise
360	not	_	_	I-Premise
361	cause	_	_	I-Premise
362	study	_	_	I-Premise
363	drug	_	_	I-Premise
364	discontinuation	_	_	I-Premise
365	.	_	_	I-Premise

366	Addition	_	_	B-Claim
367	of	_	_	I-Claim
368	bevacizumab	_	_	I-Claim
369	to	_	_	I-Claim
370	FU	_	_	I-Claim
371	/	_	_	I-Claim
372	LV	_	_	I-Claim
373	as	_	_	I-Claim
374	first	_	_	I-Claim
375	-	_	_	I-Claim
376	line	_	_	I-Claim
377	therapy	_	_	I-Claim
378	in	_	_	I-Claim
379	CRC	_	_	I-Claim
380	patients	_	_	I-Claim
381	who	_	_	I-Claim
382	were	_	_	I-Claim
383	not	_	_	I-Claim
384	considered	_	_	I-Claim
385	optimal	_	_	I-Claim
386	candidates	_	_	I-Claim
387	for	_	_	I-Claim
388	first	_	_	I-Claim
389	-	_	_	I-Claim
390	line	_	_	I-Claim
391	irinotecan	_	_	I-Claim
392	treatment	_	_	I-Claim
393	provided	_	_	I-Claim
394	clinically	_	_	I-Claim
395	significant	_	_	I-Claim
396	patient	_	_	I-Claim
397	benefit	_	_	I-Claim
398	,	_	_	I-Claim
399	including	_	_	I-Claim
400	statistically	_	_	I-Claim
401	significant	_	_	I-Claim
402	improvement	_	_	I-Claim
403	in	_	_	I-Claim
404	progression	_	_	I-Claim
405	-	_	_	I-Claim
406	free	_	_	I-Claim
407	survival	_	_	I-Claim
408	.	_	_	I-Claim


0	Recombinant	_	_	O
1	human	_	_	O
2	TSH	_	_	O
3	(	_	_	O
4	rhTSH	_	_	O
5	)	_	_	O
6	has	_	_	O
7	become	_	_	O
8	the	_	_	O
9	modality	_	_	O
10	of	_	_	O
11	choice	_	_	O
12	for	_	_	O
13	radioiodine	_	_	O
14	remnant	_	_	O
15	ablation	_	_	O
16	(	_	_	O
17	RRA	_	_	O
18	)	_	_	O
19	in	_	_	O
20	low	_	_	O
21	-	_	_	O
22	risk	_	_	O
23	thyroid	_	_	O
24	cancer	_	_	O
25	patients	_	_	O
26	.	_	_	O

27	The	_	_	O
28	aims	_	_	O
29	of	_	_	O
30	the	_	_	O
31	present	_	_	O
32	prospective	_	_	O
33	randomized	_	_	O
34	study	_	_	O
35	were	_	_	O
36	to	_	_	O
37	evaluate	_	_	O
38	the	_	_	O
39	impact	_	_	O
40	of	_	_	O
41	TSH	_	_	O
42	stimulation	_	_	O
43	procedure	_	_	O
44	(	_	_	O
45	hypothyroidism	_	_	O
46	vs	_	_	O
47	.	_	_	O

48	rhTSH	_	_	O
49	)	_	_	O
50	on	_	_	O
51	quality	_	_	O
52	of	_	_	O
53	life	_	_	O
54	(	_	_	O
55	QoL	_	_	O
56	)	_	_	O
57	of	_	_	O
58	thyroid	_	_	O
59	cancer	_	_	O
60	patients	_	_	O
61	undergoing	_	_	O
62	RRA	_	_	O
63	and	_	_	O
64	to	_	_	O
65	evaluate	_	_	O
66	efficacy	_	_	O
67	of	_	_	O
68	both	_	_	O
69	procedures	_	_	O
70	.	_	_	O

71	L	_	_	O
72	-	_	_	O
73	T4	_	_	O
74	was	_	_	O
75	initiated	_	_	O
76	in	_	_	O
77	both	_	_	O
78	groups	_	_	O
79	after	_	_	O
80	thyroidectomy	_	_	O
81	.	_	_	O

82	After	_	_	O
83	randomization	_	_	O
84	,	_	_	O
85	L	_	_	O
86	-	_	_	O
87	T4	_	_	O
88	was	_	_	O
89	discontinued	_	_	O
90	in	_	_	O
91	hypothyroid	_	_	O
92	(	_	_	O
93	hypo	_	_	O
94	)	_	_	O
95	group	_	_	O
96	and	_	_	O
97	continued	_	_	O
98	in	_	_	O
99	rhTSH	_	_	O
100	group	_	_	O
101	.	_	_	O

102	A	_	_	O
103	measure	_	_	O
104	of	_	_	O
105	3	_	_	O
106	.	_	_	O

107	7	_	_	O
108	GBq	_	_	O
109	of	_	_	O
110	radioiodine	_	_	O
111	was	_	_	O
112	given	_	_	O
113	to	_	_	O
114	both	_	_	O
115	groups	_	_	O
116	.	_	_	O

117	The	_	_	O
118	functional	_	_	O
119	assessment	_	_	O
120	of	_	_	O
121	chronic	_	_	O
122	illness	_	_	O
123	therapy	_	_	O
124	-	_	_	O
125	fatigue	_	_	O
126	(	_	_	O
127	FACIT	_	_	O
128	-	_	_	O
129	F	_	_	O
130	)	_	_	O
131	was	_	_	O
132	administered	_	_	O
133	from	_	_	O
134	the	_	_	O
135	early	_	_	O
136	postoperative	_	_	O
137	period	_	_	O
138	to	_	_	O
139	9	_	_	O
140	months	_	_	O
141	.	_	_	O

142	Socio	_	_	O
143	-	_	_	O
144	demographic	_	_	O
145	parameters	_	_	O
146	,	_	_	O
147	anxiety	_	_	O
148	and	_	_	O
149	depression	_	_	O
150	scales	_	_	O
151	were	_	_	O
152	also	_	_	O
153	evaluated	_	_	O
154	(	_	_	O
155	CES	_	_	O
156	-	_	_	O
157	D	_	_	O
158	,	_	_	O
159	BDI	_	_	O
160	and	_	_	O
161	Spielberger	_	_	O
162	state	_	_	O
163	-	_	_	O
164	trait	_	_	O
165	questionnaires	_	_	O
166	)	_	_	O
167	.	_	_	O

168	At	_	_	O
169	9	_	_	O
170	months	_	_	O
171	,	_	_	O
172	patients	_	_	O
173	underwent	_	_	O
174	an	_	_	O
175	rhTSH	_	_	O
176	stimulation	_	_	O
177	test	_	_	O
178	,	_	_	O
179	diagnostic	_	_	O
180	(	_	_	O
181	131	_	_	O
182	)	_	_	O
183	I	_	_	O
184	whole	_	_	O
185	body	_	_	O
186	scan	_	_	O
187	(	_	_	O
188	dxWBS	_	_	O
189	)	_	_	O
190	and	_	_	O
191	neck	_	_	O
192	ultrasonography	_	_	O
193	.	_	_	O

194	A	_	_	O
195	total	_	_	O
196	of	_	_	O
197	74	_	_	O
198	patients	_	_	O
199	were	_	_	O
200	enrolled	_	_	O
201	for	_	_	O
202	the	_	_	O
203	study	_	_	O
204	.	_	_	O

205	There	_	_	B-Premise
206	was	_	_	I-Premise
207	a	_	_	I-Premise
208	significant	_	_	I-Premise
209	decrease	_	_	I-Premise
210	in	_	_	I-Premise
211	QoL	_	_	I-Premise
212	from	_	_	I-Premise
213	baseline	_	_	I-Premise
214	(	_	_	I-Premise
215	t0	_	_	I-Premise
216	)	_	_	I-Premise
217	to	_	_	I-Premise
218	t1	_	_	I-Premise
219	(	_	_	I-Premise
220	RRA	_	_	I-Premise
221	period	_	_	I-Premise
222	)	_	_	I-Premise
223	in	_	_	I-Premise
224	the	_	_	I-Premise
225	hypothyroid	_	_	I-Premise
226	group	_	_	I-Premise
227	with	_	_	I-Premise
228	significant	_	_	I-Premise
229	differences	_	_	I-Premise
230	in	_	_	I-Premise
231	FACIT	_	_	I-Premise
232	-	_	_	I-Premise
233	F	_	_	I-Premise
234	TOI	_	_	I-Premise
235	(	_	_	I-Premise
236	P	_	_	I-Premise
237	<	_	_	I-Premise
238	10	_	_	I-Premise
239	(	_	_	I-Premise
240	-	_	_	I-Premise
241	3	_	_	I-Premise
242	)	_	_	I-Premise
243	)	_	_	I-Premise
244	,	_	_	I-Premise
245	FACT	_	_	I-Premise
246	-	_	_	I-Premise
247	G	_	_	I-Premise
248	total	_	_	I-Premise
249	score	_	_	I-Premise
250	(	_	_	I-Premise
251	P	_	_	I-Premise
252	=	_	_	I-Premise
253	0	_	_	I-Premise
254	.	_	_	I-Premise

255	005	_	_	I-Premise
256	)	_	_	I-Premise
257	and	_	_	I-Premise
258	FACIT	_	_	I-Premise
259	-	_	_	I-Premise
260	F	_	_	I-Premise
261	total	_	_	I-Premise
262	score	_	_	I-Premise
263	(	_	_	I-Premise
264	P	_	_	I-Premise
265	=	_	_	I-Premise
266	0	_	_	I-Premise
267	.	_	_	I-Premise

268	003	_	_	I-Premise
269	)	_	_	I-Premise
270	.	_	_	I-Premise

271	By	_	_	B-Premise
272	contrast	_	_	I-Premise
273	,	_	_	I-Premise
274	QoL	_	_	I-Premise
275	was	_	_	I-Premise
276	preserved	_	_	I-Premise
277	in	_	_	I-Premise
278	the	_	_	I-Premise
279	rhTSH	_	_	I-Premise
280	group	_	_	I-Premise
281	.	_	_	I-Premise

282	In	_	_	O
283	the	_	_	O
284	multivariate	_	_	O
285	analysis	_	_	O
286	,	_	_	O
287	FACIT	_	_	O
288	-	_	_	O
289	TOI	_	_	O
290	changes	_	_	O
291	were	_	_	O
292	only	_	_	O
293	affected	_	_	O
294	by	_	_	O
295	the	_	_	O
296	modality	_	_	O
297	of	_	_	O
298	TSH	_	_	O
299	stimulation	_	_	O
300	performed	_	_	O
301	for	_	_	O
302	RRA	_	_	O
303	.	_	_	O

304	From	_	_	B-Premise
305	3	_	_	I-Premise
306	to	_	_	I-Premise
307	9	_	_	I-Premise
308	months	_	_	I-Premise
309	,	_	_	I-Premise
310	changes	_	_	I-Premise
311	of	_	_	I-Premise
312	QoL	_	_	I-Premise
313	scales	_	_	I-Premise
314	and	_	_	I-Premise
315	subscales	_	_	I-Premise
316	were	_	_	I-Premise
317	no	_	_	I-Premise
318	longer	_	_	I-Premise
319	statistically	_	_	I-Premise
320	different	_	_	I-Premise
321	in	_	_	I-Premise
322	both	_	_	I-Premise
323	groups	_	_	I-Premise
324	of	_	_	I-Premise
325	patients	_	_	I-Premise
326	.	_	_	I-Premise

327	Based	_	_	B-Premise
328	on	_	_	I-Premise
329	serum	_	_	I-Premise
330	rhTSH	_	_	I-Premise
331	-	_	_	I-Premise
332	stimulated	_	_	I-Premise
333	Tg	_	_	I-Premise
334	alone	_	_	I-Premise
335	(	_	_	I-Premise
336	Tg	_	_	I-Premise
337	<	_	_	I-Premise
338	0	_	_	I-Premise
339	.	_	_	I-Premise

340	8	_	_	I-Premise
341	microg	_	_	I-Premise
342	/	_	_	I-Premise
343	l	_	_	I-Premise
344	,	_	_	I-Premise
345	BRAHMS	_	_	I-Premise
346	Tg	_	_	I-Premise
347	Kryptor	_	_	I-Premise
348	)	_	_	I-Premise
349	,	_	_	I-Premise
350	no	_	_	I-Premise
351	difference	_	_	I-Premise
352	in	_	_	I-Premise
353	ablation	_	_	I-Premise
354	success	_	_	I-Premise
355	was	_	_	I-Premise
356	observed	_	_	I-Premise
357	between	_	_	I-Premise
358	rhTSH	_	_	I-Premise
359	and	_	_	I-Premise
360	hypothyroidism	_	_	I-Premise
361	groups	_	_	I-Premise
362	,	_	_	I-Premise
363	91	_	_	I-Premise
364	.	_	_	I-Premise

365	7	_	_	I-Premise
366	%	_	_	I-Premise
367	and	_	_	I-Premise
368	97	_	_	I-Premise
369	.	_	_	I-Premise

370	1	_	_	I-Premise
371	%	_	_	I-Premise
372	,	_	_	I-Premise
373	respectively	_	_	I-Premise
374	.	_	_	I-Premise

375	A	_	_	B-Premise
376	higher	_	_	I-Premise
377	rate	_	_	I-Premise
378	of	_	_	I-Premise
379	persistent	_	_	I-Premise
380	thyroid	_	_	I-Premise
381	remnants	_	_	I-Premise
382	was	_	_	I-Premise
383	observed	_	_	I-Premise
384	in	_	_	I-Premise
385	the	_	_	I-Premise
386	rhTSH	_	_	I-Premise
387	arm	_	_	I-Premise
388	,	_	_	I-Premise
389	although	_	_	B-Premise
390	in	_	_	I-Premise
391	most	_	_	I-Premise
392	cases	_	_	I-Premise
393	uptake	_	_	I-Premise
394	was	_	_	I-Premise
395	<	_	_	I-Premise
396	0	_	_	I-Premise
397	.	_	_	I-Premise

398	1	_	_	I-Premise
399	%	_	_	I-Premise
400	and	_	_	I-Premise
401	of	_	_	I-Premise
402	no	_	_	I-Premise
403	clinical	_	_	I-Premise
404	significance	_	_	I-Premise
405	.	_	_	I-Premise

406	rhTSH	_	_	B-Claim
407	preserves	_	_	I-Claim
408	QoL	_	_	I-Claim
409	of	_	_	I-Claim
410	patients	_	_	I-Claim
411	undergoing	_	_	I-Claim
412	RRA	_	_	I-Claim
413	with	_	_	I-Claim
414	similar	_	_	I-Claim
415	rates	_	_	I-Claim
416	of	_	_	I-Claim
417	ablation	_	_	I-Claim
418	success	_	_	I-Claim
419	compared	_	_	I-Claim
420	to	_	_	I-Claim
421	hypothyrodism	_	_	I-Claim
422	.	_	_	I-Claim

423	However	_	_	O
424	,	_	_	O
425	there	_	_	O
426	is	_	_	O
427	a	_	_	O
428	wide	_	_	O
429	heterogeneity	_	_	O
430	in	_	_	O
431	the	_	_	O
432	clinical	_	_	O
433	impact	_	_	O
434	of	_	_	O
435	hypothyroidism	_	_	O
436	.	_	_	O


0	Health	_	_	O
1	-	_	_	O
2	related	_	_	O
3	quality	_	_	O
4	of	_	_	O
5	life	_	_	O
6	(	_	_	O
7	HRQOL	_	_	O
8	)	_	_	O
9	,	_	_	O
10	symptoms	_	_	O
11	of	_	_	O
12	depression	_	_	O
13	,	_	_	O
14	and	_	_	O
15	adverse	_	_	O
16	events	_	_	O
17	(	_	_	O
18	AEs	_	_	O
19	)	_	_	O
20	were	_	_	O
21	compared	_	_	O
22	between	_	_	O
23	Japanese	_	_	O
24	postmenopausal	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	hormone	_	_	O
28	-	_	_	O
29	sensitive	_	_	O
30	breast	_	_	O
31	cancer	_	_	O
32	(	_	_	O
33	BC	_	_	O
34	)	_	_	O
35	who	_	_	O
36	received	_	_	O
37	adjuvant	_	_	O
38	tamoxifen	_	_	O
39	,	_	_	O
40	exemestane	_	_	O
41	,	_	_	O
42	or	_	_	O
43	anastrozole	_	_	O
44	in	_	_	O
45	an	_	_	O
46	open	_	_	O
47	-	_	_	O
48	labeled	_	_	O
49	,	_	_	O
50	randomized	_	_	O
51	,	_	_	O
52	multicenter	_	_	O
53	trial	_	_	O
54	designated	_	_	O
55	as	_	_	O
56	the	_	_	O
57	National	_	_	O
58	Surgical	_	_	O
59	Adjuvant	_	_	O
60	Study	_	_	O
61	of	_	_	O
62	Breast	_	_	O
63	Cancer	_	_	O
64	(	_	_	O
65	N	_	_	O
66	-	_	_	O
67	SAS	_	_	O
68	BC	_	_	O
69	)	_	_	O
70	04	_	_	O
71	substudy	_	_	O
72	of	_	_	O
73	the	_	_	O
74	Tamoxifen	_	_	O
75	Exemestane	_	_	O
76	Adjuvant	_	_	O
77	Multinational	_	_	O
78	(	_	_	O
79	TEAM	_	_	O
80	)	_	_	O
81	trial	_	_	O
82	.	_	_	O

83	During	_	_	O
84	the	_	_	O
85	first	_	_	O
86	year	_	_	O
87	of	_	_	O
88	treatment	_	_	O
89	,	_	_	O
90	HRQOL	_	_	O
91	and	_	_	O
92	symptoms	_	_	O
93	of	_	_	O
94	depression	_	_	O
95	were	_	_	O
96	analyzed	_	_	O
97	using	_	_	O
98	the	_	_	O
99	Functional	_	_	O
100	Assessment	_	_	O
101	of	_	_	O
102	Cancer	_	_	O
103	Therapy	_	_	O
104	-	_	_	O
105	Breast	_	_	O
106	(	_	_	O
107	FACT	_	_	O
108	-	_	_	O
109	B	_	_	O
110	)	_	_	O
111	and	_	_	O
112	its	_	_	O
113	Endocrine	_	_	O
114	Symptom	_	_	O
115	Subscale	_	_	O
116	(	_	_	O
117	ES	_	_	O
118	)	_	_	O
119	,	_	_	O
120	and	_	_	O
121	the	_	_	O
122	Center	_	_	O
123	for	_	_	O
124	Epidemiologic	_	_	O
125	Studies	_	_	O
126	Depression	_	_	O
127	Scale	_	_	O
128	(	_	_	O
129	CES	_	_	O
130	-	_	_	O
131	D	_	_	O
132	)	_	_	O
133	,	_	_	O
134	respectively	_	_	O
135	.	_	_	O

136	In	_	_	O
137	addition	_	_	O
138	,	_	_	O
139	predefined	_	_	O
140	AEs	_	_	O
141	were	_	_	O
142	analyzed	_	_	O
143	.	_	_	O

144	A	_	_	O
145	total	_	_	O
146	of	_	_	O
147	166	_	_	O
148	eligible	_	_	O
149	patients	_	_	O
150	were	_	_	O
151	randomly	_	_	O
152	assigned	_	_	O
153	to	_	_	O
154	receive	_	_	O
155	adjuvant	_	_	O
156	tamoxifen	_	_	O
157	,	_	_	O
158	exemestane	_	_	O
159	,	_	_	O
160	or	_	_	O
161	anastrozole	_	_	O
162	.	_	_	O

163	FACT	_	_	B-Premise
164	-	_	_	I-Premise
165	B	_	_	I-Premise
166	scores	_	_	I-Premise
167	increased	_	_	I-Premise
168	after	_	_	I-Premise
169	treatment	_	_	I-Premise
170	began	_	_	I-Premise
171	and	_	_	I-Premise
172	remained	_	_	I-Premise
173	significantly	_	_	I-Premise
174	higher	_	_	I-Premise
175	in	_	_	I-Premise
176	the	_	_	I-Premise
177	tamoxifen	_	_	I-Premise
178	group	_	_	I-Premise
179	than	_	_	I-Premise
180	in	_	_	I-Premise
181	the	_	_	I-Premise
182	exemestane	_	_	I-Premise
183	group	_	_	I-Premise
184	or	_	_	I-Premise
185	anastrozole	_	_	I-Premise
186	group	_	_	I-Premise
187	during	_	_	I-Premise
188	the	_	_	I-Premise
189	first	_	_	I-Premise
190	year	_	_	I-Premise
191	(	_	_	I-Premise
192	P	_	_	I-Premise
193	=	_	_	I-Premise
194	0	_	_	I-Premise
195	.	_	_	I-Premise

196	045	_	_	I-Premise
197	)	_	_	I-Premise
198	.	_	_	I-Premise

199	FACT	_	_	B-Premise
200	-	_	_	I-Premise
201	B	_	_	I-Premise
202	scores	_	_	I-Premise
203	were	_	_	I-Premise
204	similar	_	_	I-Premise
205	in	_	_	I-Premise
206	the	_	_	I-Premise
207	exemestane	_	_	I-Premise
208	group	_	_	I-Premise
209	and	_	_	I-Premise
210	anastrozole	_	_	I-Premise
211	group	_	_	I-Premise
212	.	_	_	I-Premise

213	ES	_	_	B-Premise
214	scores	_	_	I-Premise
215	and	_	_	I-Premise
216	CES	_	_	I-Premise
217	-	_	_	I-Premise
218	D	_	_	I-Premise
219	scores	_	_	I-Premise
220	were	_	_	I-Premise
221	similar	_	_	I-Premise
222	in	_	_	I-Premise
223	all	_	_	I-Premise
224	treatment	_	_	I-Premise
225	groups	_	_	I-Premise
226	.	_	_	I-Premise

227	Arthralgia	_	_	B-Premise
228	and	_	_	I-Premise
229	fatigue	_	_	I-Premise
230	were	_	_	I-Premise
231	less	_	_	I-Premise
232	frequent	_	_	I-Premise
233	,	_	_	I-Premise
234	but	_	_	I-Premise
235	vaginal	_	_	I-Premise
236	discharge	_	_	I-Premise
237	was	_	_	I-Premise
238	more	_	_	I-Premise
239	frequent	_	_	I-Premise
240	in	_	_	I-Premise
241	the	_	_	I-Premise
242	tamoxifen	_	_	I-Premise
243	group	_	_	I-Premise
244	than	_	_	I-Premise
245	in	_	_	I-Premise
246	the	_	_	I-Premise
247	exemestane	_	_	I-Premise
248	group	_	_	I-Premise
249	or	_	_	I-Premise
250	anastrozole	_	_	I-Premise
251	group	_	_	I-Premise
252	.	_	_	I-Premise

253	HRQOL	_	_	B-Claim
254	was	_	_	I-Claim
255	better	_	_	I-Claim
256	in	_	_	I-Claim
257	Japanese	_	_	I-Claim
258	postmenopausal	_	_	I-Claim
259	women	_	_	I-Claim
260	treated	_	_	I-Claim
261	with	_	_	I-Claim
262	tamoxifen	_	_	I-Claim
263	than	_	_	I-Claim
264	those	_	_	I-Claim
265	treated	_	_	I-Claim
266	with	_	_	I-Claim
267	exemestane	_	_	I-Claim
268	or	_	_	I-Claim
269	anastrozole	_	_	I-Claim
270	.	_	_	I-Claim

271	HRQOL	_	_	B-Claim
272	and	_	_	I-Claim
273	AEs	_	_	I-Claim
274	were	_	_	I-Claim
275	similar	_	_	I-Claim
276	with	_	_	I-Claim
277	exemestane	_	_	I-Claim
278	and	_	_	I-Claim
279	anastrozole	_	_	I-Claim
280	.	_	_	I-Claim

281	Given	_	_	B-Claim
282	the	_	_	I-Claim
283	results	_	_	I-Claim
284	of	_	_	I-Claim
285	the	_	_	I-Claim
286	TEAM	_	_	I-Claim
287	trial	_	_	I-Claim
288	,	_	_	I-Claim
289	upfront	_	_	I-Claim
290	use	_	_	I-Claim
291	of	_	_	I-Claim
292	tamoxifen	_	_	I-Claim
293	followed	_	_	I-Claim
294	by	_	_	I-Claim
295	an	_	_	I-Claim
296	aromatase	_	_	I-Claim
297	inhibitor	_	_	I-Claim
298	(	_	_	I-Claim
299	AI	_	_	I-Claim
300	)	_	_	I-Claim
301	may	_	_	I-Claim
302	be	_	_	I-Claim
303	an	_	_	I-Claim
304	important	_	_	I-Claim
305	option	_	_	I-Claim
306	for	_	_	I-Claim
307	adjuvant	_	_	I-Claim
308	endocrine	_	_	I-Claim
309	therapy	_	_	I-Claim
310	in	_	_	I-Claim
311	Japanese	_	_	I-Claim
312	postmenopausal	_	_	I-Claim
313	women	_	_	I-Claim
314	.	_	_	I-Claim


0	Anti	_	_	B-Claim
1	-	_	_	I-Claim
2	aromatase	_	_	I-Claim
3	therapy	_	_	I-Claim
4	is	_	_	I-Claim
5	important	_	_	I-Claim
6	in	_	_	I-Claim
7	the	_	_	I-Claim
8	treatment	_	_	I-Claim
9	of	_	_	I-Claim
10	breast	_	_	I-Claim
11	cancer	_	_	I-Claim
12	in	_	_	I-Claim
13	postmenopausal	_	_	I-Claim
14	women	_	_	I-Claim
15	but	_	_	O
16	they	_	_	O
17	have	_	_	O
18	effects	_	_	O
19	on	_	_	O
20	the	_	_	O
21	bone	_	_	O
22	mineral	_	_	O
23	density	_	_	O
24	(	_	_	O
25	BMD	_	_	O
26	)	_	_	O
27	and	_	_	O
28	osteoporosis	_	_	O
29	.	_	_	O

30	Cyclooxygenase	_	_	B-Claim
31	-	_	_	I-Claim
32	2	_	_	I-Claim
33	(	_	_	I-Claim
34	COX	_	_	I-Claim
35	-	_	_	I-Claim
36	2	_	_	I-Claim
37	)	_	_	I-Claim
38	inhibitors	_	_	I-Claim
39	have	_	_	I-Claim
40	been	_	_	I-Claim
41	shown	_	_	I-Claim
42	to	_	_	I-Claim
43	be	_	_	I-Claim
44	effective	_	_	I-Claim
45	in	_	_	I-Claim
46	chemoprevention	_	_	I-Claim
47	in	_	_	I-Claim
48	animal	_	_	I-Claim
49	and	_	_	I-Claim
50	clinical	_	_	I-Claim
51	studies	_	_	I-Claim
52	.	_	_	I-Claim

53	A	_	_	O
54	proof	_	_	O
55	of	_	_	O
56	principle	_	_	O
57	study	_	_	O
58	was	_	_	O
59	performed	_	_	O
60	to	_	_	O
61	investigate	_	_	O
62	the	_	_	O
63	efficacy	_	_	O
64	of	_	_	O
65	combing	_	_	O
66	anti	_	_	O
67	-	_	_	O
68	aromatase	_	_	O
69	therapy	_	_	O
70	(	_	_	O
71	exemestane	_	_	O
72	)	_	_	O
73	and	_	_	O
74	COX	_	_	O
75	-	_	_	O
76	2	_	_	O
77	inhibitors	_	_	O
78	neoadjuvantly	_	_	O
79	.	_	_	O

80	The	_	_	O
81	changes	_	_	O
82	in	_	_	O
83	the	_	_	O
84	BMD	_	_	O
85	,	_	_	O
86	bone	_	_	O
87	turnover	_	_	O
88	proteins	_	_	O
89	and	_	_	O
90	quality	_	_	O
91	-	_	_	O
92	of	_	_	O
93	-	_	_	O
94	life	_	_	O
95	(	_	_	O
96	QoL	_	_	O
97	)	_	_	O
98	were	_	_	O
99	analyzed	_	_	O
100	and	_	_	O
101	presented	_	_	O
102	here	_	_	O
103	.	_	_	O

104	82	_	_	O
105	postmenopausal	_	_	O
106	patients	_	_	O
107	with	_	_	O
108	histologically	_	_	O
109	confirmed	_	_	O
110	invasive	_	_	O
111	hormone	_	_	O
112	-	_	_	O
113	sensitive	_	_	O
114	breast	_	_	O
115	cancers	_	_	O
116	were	_	_	O
117	included	_	_	O
118	for	_	_	O
119	the	_	_	O
120	neoadjuvant	_	_	O
121	therapy	_	_	O
122	(	_	_	O
123	NHT	_	_	O
124	)	_	_	O
125	.	_	_	O

126	30	_	_	O
127	patients	_	_	O
128	received	_	_	O
129	exemestane	_	_	O
130	(	_	_	O
131	EXE	_	_	O
132	)	_	_	O
133	25	_	_	O
134	mg	_	_	O
135	daily	_	_	O
136	and	_	_	O
137	celecoxib	_	_	O
138	(	_	_	O
139	CXB	_	_	O
140	)	_	_	O
141	400	_	_	O
142	mg	_	_	O
143	twice	_	_	O
144	daily	_	_	O
145	(	_	_	O
146	group	_	_	O
147	A	_	_	O
148	)	_	_	O
149	,	_	_	O
150	24	_	_	O
151	patients	_	_	O
152	received	_	_	O
153	EXE	_	_	O
154	25	_	_	O
155	mg	_	_	O
156	daily	_	_	O
157	(	_	_	O
158	group	_	_	O
159	B	_	_	O
160	)	_	_	O
161	and	_	_	O
162	28	_	_	O
163	patients	_	_	O
164	received	_	_	O
165	letrozole	_	_	O
166	(	_	_	O
167	LET	_	_	O
168	)	_	_	O
169	2	_	_	O
170	.	_	_	O

171	5	_	_	O
172	mg	_	_	O
173	daily	_	_	O
174	(	_	_	O
175	group	_	_	O
176	C	_	_	O
177	)	_	_	O
178	.	_	_	O

179	The	_	_	O
180	same	_	_	O
181	assigned	_	_	O
182	treatment	_	_	O
183	was	_	_	O
184	intended	_	_	O
185	to	_	_	O
186	continue	_	_	O
187	for	_	_	O
188	2	_	_	O
189	years	_	_	O
190	to	_	_	O
191	study	_	_	O
192	the	_	_	O
193	changes	_	_	O
194	in	_	_	O
195	the	_	_	O
196	bone	_	_	O
197	metabolism	_	_	O
198	.	_	_	O

199	BMD	_	_	O
200	of	_	_	O
201	48	_	_	O
202	patients	_	_	O
203	were	_	_	O
204	analyzed	_	_	O
205	;	_	_	O
206	23	_	_	O
207	belongs	_	_	O
208	to	_	_	O
209	group	_	_	O
210	A	_	_	O
211	,	_	_	O
212	10	_	_	O
213	to	_	_	O
214	group	_	_	O
215	B	_	_	O
216	and	_	_	O
217	15	_	_	O
218	to	_	_	O
219	group	_	_	O
220	C	_	_	O
221	.	_	_	O

222	The	_	_	O
223	serum	_	_	O
224	bone	_	_	O
225	turnover	_	_	O
226	proteins	_	_	O
227	bone	_	_	O
228	-	_	_	O
229	specific	_	_	O
230	alkaline	_	_	O
231	phosphatase	_	_	O
232	(	_	_	O
233	BAP	_	_	O
234	)	_	_	O
235	and	_	_	O
236	carboxyterminal	_	_	O
237	crosslinked	_	_	O
238	telopeptide	_	_	O
239	of	_	_	O
240	type	_	_	O
241	I	_	_	O
242	collagen	_	_	O
243	(	_	_	O
244	ICTP	_	_	O
245	)	_	_	O
246	,	_	_	O
247	were	_	_	O
248	measured	_	_	O
249	with	_	_	O
250	commercially	_	_	O
251	available	_	_	O
252	test	_	_	O
253	kits	_	_	O
254	before	_	_	O
255	treatment	_	_	O
256	,	_	_	O
257	3	_	_	O
258	months	_	_	O
259	and	_	_	O
260	15	_	_	O
261	months	_	_	O
262	after	_	_	O
263	treatment	_	_	O
264	.	_	_	O

265	Functional	_	_	O
266	Assessment	_	_	O
267	of	_	_	O
268	Cancer	_	_	O
269	Therapy	_	_	O
270	core	_	_	O
271	questionnaire	_	_	O
272	(	_	_	O
273	FACT	_	_	O
274	-	_	_	O
275	G	_	_	O
276	)	_	_	O
277	with	_	_	O
278	its	_	_	O
279	additional	_	_	O
280	breast	_	_	O
281	cancer	_	_	O
282	subscale	_	_	O
283	were	_	_	O
284	performed	_	_	O
285	at	_	_	O
286	baseline	_	_	O
287	,	_	_	O
288	4	_	_	O
289	,	_	_	O
290	8	_	_	O
291	,	_	_	O
292	and	_	_	O
293	12	_	_	O
294	weeks	_	_	O
295	after	_	_	O
296	NHT	_	_	O
297	.	_	_	O

298	Difference	_	_	B-Premise
299	between	_	_	I-Premise
300	groups	_	_	I-Premise
301	(	_	_	I-Premise
302	p	_	_	I-Premise
303	=	_	_	I-Premise
304	0	_	_	I-Premise
305	.	_	_	I-Premise

306	007	_	_	I-Premise
307	)	_	_	I-Premise
308	for	_	_	I-Premise
309	BMD	_	_	I-Premise
310	at	_	_	I-Premise
311	femur	_	_	I-Premise
312	was	_	_	I-Premise
313	significant	_	_	I-Premise
314	.	_	_	I-Premise

315	The	_	_	B-Premise
316	changes	_	_	I-Premise
317	of	_	_	I-Premise
318	BMD	_	_	I-Premise
319	in	_	_	I-Premise
320	group	_	_	I-Premise
321	B	_	_	I-Premise
322	patients	_	_	I-Premise
323	were	_	_	I-Premise
324	significantly	_	_	I-Premise
325	greater	_	_	I-Premise
326	than	_	_	I-Premise
327	patients	_	_	I-Premise
328	in	_	_	I-Premise
329	group	_	_	I-Premise
330	A	_	_	I-Premise
331	(	_	_	I-Premise
332	p	_	_	I-Premise
333	=	_	_	I-Premise
334	0	_	_	I-Premise
335	.	_	_	I-Premise

336	011	_	_	I-Premise
337	,	_	_	I-Premise
338	CI	_	_	I-Premise
339	=	_	_	I-Premise
340	0	_	_	I-Premise
341	.	_	_	I-Premise

342	063	_	_	I-Premise
343	-	_	_	I-Premise
344	0	_	_	I-Premise
345	.	_	_	I-Premise

346	437	_	_	I-Premise
347	)	_	_	I-Premise
348	,	_	_	I-Premise
349	and	_	_	I-Premise
350	group	_	_	I-Premise
351	C	_	_	I-Premise
352	(	_	_	I-Premise
353	p	_	_	I-Premise
354	=	_	_	I-Premise
355	0	_	_	I-Premise
356	.	_	_	I-Premise

357	003	_	_	I-Premise
358	,	_	_	I-Premise
359	CI	_	_	I-Premise
360	=	_	_	I-Premise
361	0	_	_	I-Premise
362	.	_	_	I-Premise

363	146	_	_	I-Premise
364	-	_	_	I-Premise
365	0	_	_	I-Premise
366	.	_	_	I-Premise

367	620	_	_	I-Premise
368	)	_	_	I-Premise
369	.	_	_	I-Premise

370	The	_	_	B-Premise
371	mean	_	_	I-Premise
372	BAP	_	_	I-Premise
373	increased	_	_	I-Premise
374	from	_	_	I-Premise
375	baseline	_	_	I-Premise
376	in	_	_	I-Premise
377	group	_	_	I-Premise
378	B	_	_	I-Premise
379	patients	_	_	I-Premise
380	but	_	_	I-Premise
381	decreased	_	_	I-Premise
382	from	_	_	I-Premise
383	baseline	_	_	I-Premise
384	in	_	_	I-Premise
385	group	_	_	I-Premise
386	C	_	_	I-Premise
387	patients	_	_	I-Premise
388	at	_	_	I-Premise
389	3	_	_	I-Premise
390	months	_	_	I-Premise
391	and	_	_	I-Premise
392	15	_	_	I-Premise
393	months	_	_	I-Premise
394	.	_	_	I-Premise

395	No	_	_	B-Premise
396	statistical	_	_	I-Premise
397	significance	_	_	I-Premise
398	was	_	_	I-Premise
399	found	_	_	I-Premise
400	in	_	_	I-Premise
401	the	_	_	I-Premise
402	FACT	_	_	I-Premise
403	-	_	_	I-Premise
404	G	_	_	I-Premise
405	scores	_	_	I-Premise
406	and	_	_	I-Premise
407	FACT	_	_	I-Premise
408	-	_	_	I-Premise
409	B	_	_	I-Premise
410	scores	_	_	I-Premise
411	among	_	_	I-Premise
412	different	_	_	I-Premise
413	groups	_	_	I-Premise
414	at	_	_	I-Premise
415	baseline	_	_	I-Premise
416	,	_	_	I-Premise
417	week	_	_	I-Premise
418	4	_	_	I-Premise
419	,	_	_	I-Premise
420	week	_	_	I-Premise
421	8	_	_	I-Premise
422	and	_	_	I-Premise
423	week	_	_	I-Premise
424	12	_	_	I-Premise
425	after	_	_	I-Premise
426	NHT	_	_	I-Premise
427	.	_	_	I-Premise

428	The	_	_	B-Premise
429	Breast	_	_	I-Premise
430	Cancer	_	_	I-Premise
431	Subscale	_	_	I-Premise
432	scores	_	_	I-Premise
433	in	_	_	I-Premise
434	group	_	_	I-Premise
435	A	_	_	I-Premise
436	patients	_	_	I-Premise
437	were	_	_	I-Premise
438	significantly	_	_	I-Premise
439	higher	_	_	I-Premise
440	than	_	_	I-Premise
441	that	_	_	I-Premise
442	of	_	_	I-Premise
443	group	_	_	I-Premise
444	C	_	_	I-Premise
445	patients	_	_	I-Premise
446	(	_	_	I-Premise
447	p	_	_	I-Premise
448	=	_	_	I-Premise
449	0	_	_	I-Premise
450	.	_	_	I-Premise

451	021	_	_	I-Premise
452	)	_	_	I-Premise
453	.	_	_	I-Premise

454	After	_	_	B-Premise
455	4	_	_	I-Premise
456	weeks	_	_	I-Premise
457	of	_	_	I-Premise
458	NHT	_	_	I-Premise
459	,	_	_	I-Premise
460	negative	_	_	I-Premise
461	changes	_	_	I-Premise
462	of	_	_	I-Premise
463	FACT	_	_	I-Premise
464	-	_	_	I-Premise
465	B	_	_	I-Premise
466	and	_	_	I-Premise
467	FACT	_	_	I-Premise
468	-	_	_	I-Premise
469	G	_	_	I-Premise
470	scores	_	_	I-Premise
471	were	_	_	I-Premise
472	found	_	_	I-Premise
473	in	_	_	I-Premise
474	group	_	_	I-Premise
475	B	_	_	I-Premise
476	and	_	_	I-Premise
477	C	_	_	I-Premise
478	patients	_	_	I-Premise
479	,	_	_	I-Premise
480	but	_	_	B-Premise
481	there	_	_	I-Premise
482	were	_	_	I-Premise
483	positive	_	_	I-Premise
484	changes	_	_	I-Premise
485	in	_	_	I-Premise
486	group	_	_	I-Premise
487	A	_	_	I-Premise
488	patients	_	_	I-Premise
489	.	_	_	I-Premise

490	Significant	_	_	B-Premise
491	differences	_	_	I-Premise
492	of	_	_	I-Premise
493	FACT	_	_	I-Premise
494	-	_	_	I-Premise
495	B	_	_	I-Premise
496	score	_	_	I-Premise
497	(	_	_	I-Premise
498	p	_	_	I-Premise
499	=	_	_	I-Premise
500	0	_	_	I-Premise
501	.	_	_	I-Premise

502	008	_	_	I-Premise
503	)	_	_	I-Premise
504	and	_	_	I-Premise
505	FACT	_	_	I-Premise
506	-	_	_	I-Premise
507	G	_	_	I-Premise
508	score	_	_	I-Premise
509	(	_	_	I-Premise
510	p	_	_	I-Premise
511	=	_	_	I-Premise
512	0	_	_	I-Premise
513	.	_	_	I-Premise

514	019	_	_	I-Premise
515	)	_	_	I-Premise
516	were	_	_	I-Premise
517	observed	_	_	I-Premise
518	at	_	_	I-Premise
519	that	_	_	I-Premise
520	time	_	_	I-Premise
521	point	_	_	I-Premise
522	.	_	_	I-Premise

523	Article	_	_	O
524	from	_	_	O
525	the	_	_	O
526	Special	_	_	O
527	issue	_	_	O
528	on	_	_	O
529	Targeted	_	_	O
530	Inhibitors	_	_	O
531	.	_	_	O


0	The	_	_	B-Claim
1	postoperative	_	_	I-Claim
2	clinical	_	_	I-Claim
3	superiority	_	_	I-Claim
4	of	_	_	I-Claim
5	the	_	_	I-Claim
6	interposition	_	_	I-Claim
7	of	_	_	I-Claim
8	jejunum	_	_	I-Claim
9	reconstruction	_	_	I-Claim
10	(	_	_	I-Claim
11	INT	_	_	I-Claim
12	)	_	_	I-Claim
13	to	_	_	I-Claim
14	Roux	_	_	I-Claim
15	-	_	_	I-Claim
16	en	_	_	I-Claim
17	-	_	_	I-Claim
18	Y	_	_	I-Claim
19	reconstruction	_	_	I-Claim
20	(	_	_	I-Claim
21	RY	_	_	I-Claim
22	)	_	_	I-Claim
23	after	_	_	I-Claim
24	total	_	_	I-Claim
25	gastrectomy	_	_	I-Claim
26	has	_	_	I-Claim
27	not	_	_	I-Claim
28	been	_	_	I-Claim
29	clarified	_	_	I-Claim
30	.	_	_	I-Claim

31	Postoperative	_	_	O
32	quality	_	_	O
33	of	_	_	O
34	life	_	_	O
35	(	_	_	O
36	QOL	_	_	O
37	)	_	_	O
38	was	_	_	O
39	evaluated	_	_	O
40	between	_	_	O
41	the	_	_	O
42	2	_	_	O
43	methods	_	_	O
44	by	_	_	O
45	a	_	_	O
46	multi	_	_	O
47	-	_	_	O
48	institutional	_	_	O
49	prospective	_	_	O
50	randomized	_	_	O
51	trial	_	_	O
52	.	_	_	O

53	A	_	_	O
54	total	_	_	O
55	of	_	_	O
56	103	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	gastric	_	_	O
60	cancer	_	_	O
61	were	_	_	O
62	prospectively	_	_	O
63	randomly	_	_	O
64	divided	_	_	O
65	into	_	_	O
66	groups	_	_	O
67	for	_	_	O
68	RY	_	_	O
69	(	_	_	O
70	n	_	_	O
71	=	_	_	O
72	51	_	_	O
73	)	_	_	O
74	or	_	_	O
75	INT	_	_	O
76	reconstruction	_	_	O
77	(	_	_	O
78	n	_	_	O
79	=	_	_	O
80	52	_	_	O
81	)	_	_	O
82	after	_	_	O
83	total	_	_	O
84	gastrectomy	_	_	O
85	.	_	_	O

86	They	_	_	O
87	were	_	_	O
88	stratified	_	_	O
89	by	_	_	O
90	sex	_	_	O
91	,	_	_	O
92	age	_	_	O
93	,	_	_	O
94	institute	_	_	O
95	,	_	_	O
96	histology	_	_	O
97	,	_	_	O
98	and	_	_	O
99	degree	_	_	O
100	of	_	_	O
101	lymph	_	_	O
102	node	_	_	O
103	dissection	_	_	O
104	.	_	_	O

105	Postoperatively	_	_	O
106	,	_	_	O
107	body	_	_	O
108	mass	_	_	O
109	index	_	_	O
110	(	_	_	O
111	BMI	_	_	O
112	)	_	_	O
113	and	_	_	O
114	nutritional	_	_	O
115	conditions	_	_	O
116	were	_	_	O
117	measured	_	_	O
118	serially	_	_	O
119	,	_	_	O
120	and	_	_	O
121	QOL	_	_	O
122	and	_	_	O
123	postoperative	_	_	O
124	squalor	_	_	O
125	scores	_	_	O
126	were	_	_	O
127	evaluated	_	_	O
128	at	_	_	O
129	3	_	_	O
130	,	_	_	O
131	12	_	_	O
132	,	_	_	O
133	and	_	_	O
134	60	_	_	O
135	months	_	_	O
136	and	_	_	O
137	compared	_	_	O
138	between	_	_	O
139	the	_	_	O
140	2	_	_	O
141	groups	_	_	O
142	.	_	_	O

143	After	_	_	O
144	removing	_	_	O
145	patients	_	_	O
146	who	_	_	O
147	did	_	_	O
148	not	_	_	O
149	complete	_	_	O
150	the	_	_	O
151	follow	_	_	O
152	-	_	_	O
153	up	_	_	O
154	survey	_	_	O
155	or	_	_	O
156	censured	_	_	O
157	cases	_	_	O
158	,	_	_	O
159	24	_	_	O
160	patients	_	_	O
161	in	_	_	O
162	the	_	_	O
163	RY	_	_	O
164	group	_	_	O
165	and	_	_	O
166	18	_	_	O
167	patients	_	_	O
168	in	_	_	O
169	the	_	_	O
170	INT	_	_	O
171	group	_	_	O
172	were	_	_	O
173	clinically	_	_	O
174	available	_	_	O
175	and	_	_	O
176	their	_	_	O
177	postoperative	_	_	O
178	status	_	_	O
179	was	_	_	O
180	assessed	_	_	O
181	.	_	_	O

182	QOL	_	_	B-Premise
183	scores	_	_	I-Premise
184	were	_	_	I-Premise
185	increased	_	_	I-Premise
186	and	_	_	I-Premise
187	complication	_	_	I-Premise
188	scores	_	_	I-Premise
189	were	_	_	I-Premise
190	improved	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	postoperative	_	_	I-Premise
194	periods	_	_	I-Premise
195	(	_	_	I-Premise
196	P	_	_	I-Premise
197	<	_	_	I-Premise
198	.	_	_	I-Premise

199	01	_	_	I-Premise
200	)	_	_	I-Premise
201	.	_	_	I-Premise

202	Postoperative	_	_	B-Premise
203	BMI	_	_	I-Premise
204	significantly	_	_	I-Premise
205	deteriorated	_	_	I-Premise
206	compared	_	_	I-Premise
207	with	_	_	I-Premise
208	preoperative	_	_	I-Premise
209	BMI	_	_	I-Premise
210	in	_	_	I-Premise
211	each	_	_	I-Premise
212	group	_	_	I-Premise
213	.	_	_	I-Premise

214	The	_	_	B-Premise
215	postoperative	_	_	I-Premise
216	QOL	_	_	I-Premise
217	and	_	_	I-Premise
218	complication	_	_	I-Premise
219	scores	_	_	I-Premise
220	at	_	_	I-Premise
221	60	_	_	I-Premise
222	months	_	_	I-Premise
223	after	_	_	I-Premise
224	surgery	_	_	I-Premise
225	were	_	_	I-Premise
226	significantly	_	_	I-Premise
227	better	_	_	I-Premise
228	than	_	_	I-Premise
229	those	_	_	I-Premise
230	at	_	_	I-Premise
231	3	_	_	I-Premise
232	months	_	_	I-Premise
233	after	_	_	I-Premise
234	surgery	_	_	I-Premise
235	in	_	_	I-Premise
236	each	_	_	I-Premise
237	group	_	_	I-Premise
238	(	_	_	I-Premise
239	P	_	_	I-Premise
240	<	_	_	I-Premise
241	.	_	_	I-Premise

242	01	_	_	I-Premise
243	)	_	_	I-Premise
244	.	_	_	I-Premise

245	However	_	_	O
246	,	_	_	O
247	there	_	_	B-Premise
248	was	_	_	I-Premise
249	no	_	_	I-Premise
250	significant	_	_	I-Premise
251	difference	_	_	I-Premise
252	of	_	_	I-Premise
253	QOL	_	_	I-Premise
254	scores	_	_	I-Premise
255	and	_	_	I-Premise
256	postoperative	_	_	I-Premise
257	complication	_	_	I-Premise
258	scores	_	_	I-Premise
259	between	_	_	I-Premise
260	the	_	_	I-Premise
261	2	_	_	I-Premise
262	reconstruction	_	_	I-Premise
263	groups	_	_	I-Premise
264	.	_	_	I-Premise

265	The	_	_	B-Premise
266	nutritional	_	_	I-Premise
267	condition	_	_	I-Premise
268	in	_	_	I-Premise
269	the	_	_	I-Premise
270	INT	_	_	I-Premise
271	group	_	_	I-Premise
272	was	_	_	I-Premise
273	nearly	_	_	I-Premise
274	the	_	_	I-Premise
275	same	_	_	I-Premise
276	as	_	_	I-Premise
277	that	_	_	I-Premise
278	in	_	_	I-Premise
279	the	_	_	I-Premise
280	RY	_	_	I-Premise
281	group	_	_	I-Premise
282	.	_	_	I-Premise

283	Although	_	_	B-Premise
284	our	_	_	I-Premise
285	patient	_	_	I-Premise
286	sample	_	_	I-Premise
287	was	_	_	I-Premise
288	small	_	_	I-Premise
289	and	_	_	I-Premise
290	patients	_	_	I-Premise
291	who	_	_	I-Premise
292	did	_	_	I-Premise
293	not	_	_	I-Premise
294	complete	_	_	I-Premise
295	the	_	_	I-Premise
296	follow	_	_	I-Premise
297	-	_	_	I-Premise
298	up	_	_	I-Premise
299	survey	_	_	I-Premise
300	were	_	_	I-Premise
301	present	_	_	I-Premise
302	,	_	_	I-Premise
303	we	_	_	B-Claim
304	could	_	_	I-Claim
305	not	_	_	I-Claim
306	identify	_	_	I-Claim
307	any	_	_	I-Claim
308	clinical	_	_	I-Claim
309	difference	_	_	I-Claim
310	between	_	_	I-Claim
311	INT	_	_	I-Claim
312	and	_	_	I-Claim
313	RY	_	_	I-Claim
314	after	_	_	I-Claim
315	total	_	_	I-Claim
316	gastrectomy	_	_	I-Claim
317	60	_	_	I-Claim
318	months	_	_	I-Claim
319	after	_	_	I-Claim
320	surgery	_	_	I-Claim
321	.	_	_	I-Claim

322	The	_	_	B-Claim
323	safer	_	_	I-Claim
324	and	_	_	I-Claim
325	simpler	_	_	I-Claim
326	RY	_	_	I-Claim
327	method	_	_	I-Claim
328	may	_	_	I-Claim
329	be	_	_	I-Claim
330	a	_	_	I-Claim
331	more	_	_	I-Claim
332	suitable	_	_	I-Claim
333	reconstruction	_	_	I-Claim
334	method	_	_	I-Claim
335	than	_	_	I-Claim
336	INT	_	_	I-Claim
337	after	_	_	I-Claim
338	total	_	_	I-Claim
339	gastrectomy	_	_	I-Claim
340	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	whether	_	_	O
3	the	_	_	O
4	effect	_	_	O
5	of	_	_	O
6	hypofractionated	_	_	O
7	thoracic	_	_	O
8	radiotherapy	_	_	O
9	(	_	_	O
10	TRT	_	_	O
11	)	_	_	O
12	is	_	_	O
13	comparable	_	_	O
14	to	_	_	O
15	more	_	_	O
16	standard	_	_	O
17	fractionated	_	_	O
18	radiotherapy	_	_	O
19	(	_	_	O
20	RT	_	_	O
21	)	_	_	O
22	in	_	_	O
23	advanced	_	_	O
24	non	_	_	O
25	-	_	_	O
26	small	_	_	O
27	-	_	_	O
28	cell	_	_	O
29	lung	_	_	O
30	cancer	_	_	O
31	(	_	_	O
32	NSCLC	_	_	O
33	)	_	_	O
34	.	_	_	O

35	A	_	_	O
36	total	_	_	O
37	of	_	_	O
38	421	_	_	O
39	patients	_	_	O
40	with	_	_	O
41	locally	_	_	O
42	advanced	_	_	O
43	stage	_	_	O
44	III	_	_	O
45	or	_	_	O
46	stage	_	_	O
47	IV	_	_	O
48	NSCLC	_	_	O
49	tumors	_	_	O
50	were	_	_	O
51	included	_	_	O
52	.	_	_	O

53	Inclusion	_	_	O
54	criteria	_	_	O
55	were	_	_	O
56	inoperable	_	_	O
57	,	_	_	O
58	disease	_	_	O
59	too	_	_	O
60	advanced	_	_	O
61	for	_	_	O
62	curative	_	_	O
63	radiotherapy	_	_	O
64	,	_	_	O
65	and	_	_	O
66	chest	_	_	O
67	symptoms	_	_	O
68	or	_	_	O
69	central	_	_	O
70	tumor	_	_	O
71	threatening	_	_	O
72	the	_	_	O
73	airways	_	_	O
74	.	_	_	O

75	Patients	_	_	O
76	were	_	_	O
77	randomly	_	_	O
78	assigned	_	_	O
79	to	_	_	O
80	three	_	_	O
81	arms	_	_	O
82	:	_	_	O
83	A	_	_	O
84	,	_	_	O
85	17	_	_	O
86	Gy	_	_	O
87	per	_	_	O
88	two	_	_	O
89	fractions	_	_	O
90	(	_	_	O
91	n	_	_	O
92	=	_	_	O
93	146	_	_	O
94	)	_	_	O
95	;	_	_	O
96	B	_	_	O
97	,	_	_	O
98	42	_	_	O
99	Gy	_	_	O
100	per	_	_	O
101	15	_	_	O
102	fractions	_	_	O
103	(	_	_	O
104	n	_	_	O
105	=	_	_	O
106	145	_	_	O
107	)	_	_	O
108	;	_	_	O
109	and	_	_	O
110	C	_	_	O
111	,	_	_	O
112	50	_	_	O
113	Gy	_	_	O
114	per	_	_	O
115	25	_	_	O
116	fractions	_	_	O
117	(	_	_	O
118	n	_	_	O
119	=	_	_	O
120	130	_	_	O
121	)	_	_	O
122	.	_	_	O

123	Four	_	_	O
124	hundred	_	_	O
125	seven	_	_	O
126	patients	_	_	O
127	were	_	_	O
128	eligible	_	_	O
129	for	_	_	O
130	the	_	_	O
131	study	_	_	O
132	;	_	_	O
133	395	_	_	O
134	patients	_	_	O
135	(	_	_	O
136	97	_	_	O
137	%	_	_	O
138	)	_	_	O
139	participated	_	_	O
140	in	_	_	O
141	the	_	_	O
142	health	_	_	O
143	-	_	_	O
144	related	_	_	O
145	quality	_	_	O
146	-	_	_	O
147	of	_	_	O
148	-	_	_	O
149	life	_	_	O
150	(	_	_	O
151	HRQOL	_	_	O
152	)	_	_	O
153	study	_	_	O
154	.	_	_	O

155	The	_	_	O
156	European	_	_	O
157	Organization	_	_	O
158	for	_	_	O
159	Research	_	_	O
160	and	_	_	O
161	Treatment	_	_	O
162	of	_	_	O
163	Cancer	_	_	O
164	(	_	_	O
165	EORTC	_	_	O
166	)	_	_	O
167	Quality	_	_	O
168	of	_	_	O
169	Life	_	_	O
170	Questionnaire	_	_	O
171	(	_	_	O
172	QLQ	_	_	O
173	)	_	_	O
174	-	_	_	O
175	C30	_	_	O
176	and	_	_	O
177	EORTC	_	_	O
178	QLQ	_	_	O
179	-	_	_	O
180	lung	_	_	O
181	cancer	_	_	O
182	-	_	_	O
183	specific	_	_	O
184	module	_	_	O
185	(	_	_	O
186	LC13	_	_	O
187	)	_	_	O
188	were	_	_	O
189	used	_	_	O
190	to	_	_	O
191	investigate	_	_	O
192	airway	_	_	O
193	symptom	_	_	O
194	relief	_	_	O
195	and	_	_	O
196	changes	_	_	O
197	in	_	_	O
198	HRQOL	_	_	O
199	.	_	_	O

200	Assessments	_	_	O
201	were	_	_	O
202	performed	_	_	O
203	before	_	_	O
204	TRT	_	_	O
205	and	_	_	O
206	until	_	_	O
207	week	_	_	O
208	54	_	_	O
209	.	_	_	O

210	Clinicians	_	_	O
211	'	_	_	O
212	assessments	_	_	O
213	of	_	_	O
214	symptom	_	_	O
215	improvement	_	_	O
216	were	_	_	O
217	at	_	_	O
218	2	_	_	O
219	,	_	_	O
220	6	_	_	O
221	,	_	_	O
222	and	_	_	O
223	14	_	_	O
224	weeks	_	_	O
225	after	_	_	O
226	completion	_	_	O
227	of	_	_	O
228	TRT	_	_	O
229	.	_	_	O

230	The	_	_	O
231	patients	_	_	O
232	were	_	_	O
233	observed	_	_	O
234	for	_	_	O
235	a	_	_	O
236	minimum	_	_	O
237	of	_	_	O
238	3	_	_	O
239	years	_	_	O
240	.	_	_	O

241	Results	_	_	O
242	Baseline	_	_	O
243	prognostic	_	_	O
244	data	_	_	O
245	were	_	_	O
246	equally	_	_	O
247	distributed	_	_	O
248	in	_	_	O
249	the	_	_	O
250	treatment	_	_	O
251	groups	_	_	O
252	.	_	_	O

253	Patient	_	_	O
254	compliance	_	_	O
255	with	_	_	O
256	respect	_	_	O
257	to	_	_	O
258	the	_	_	O
259	HRQOL	_	_	O
260	investigation	_	_	O
261	was	_	_	O
262	minimum	_	_	O
263	74	_	_	O
264	%	_	_	O
265	.	_	_	O

266	HRQOL	_	_	B-Premise
267	and	_	_	I-Premise
268	symptom	_	_	I-Premise
269	relief	_	_	I-Premise
270	were	_	_	I-Premise
271	equivalent	_	_	I-Premise
272	in	_	_	I-Premise
273	the	_	_	I-Premise
274	treatment	_	_	I-Premise
275	arms	_	_	I-Premise
276	.	_	_	I-Premise

277	No	_	_	B-Premise
278	significant	_	_	I-Premise
279	difference	_	_	I-Premise
280	in	_	_	I-Premise
281	survival	_	_	I-Premise
282	among	_	_	I-Premise
283	arms	_	_	I-Premise
284	A	_	_	I-Premise
285	,	_	_	I-Premise
286	B	_	_	I-Premise
287	,	_	_	I-Premise
288	and	_	_	I-Premise
289	C	_	_	I-Premise
290	was	_	_	I-Premise
291	found	_	_	I-Premise
292	,	_	_	I-Premise
293	with	_	_	I-Premise
294	median	_	_	I-Premise
295	survival	_	_	I-Premise
296	8	_	_	I-Premise
297	.	_	_	I-Premise

298	2	_	_	I-Premise
299	,	_	_	I-Premise
300	7	_	_	I-Premise
301	.	_	_	I-Premise

302	0	_	_	I-Premise
303	,	_	_	I-Premise
304	and	_	_	I-Premise
305	6	_	_	I-Premise
306	.	_	_	I-Premise

307	8	_	_	I-Premise
308	months	_	_	I-Premise
309	,	_	_	I-Premise
310	respectively	_	_	I-Premise
311	.	_	_	I-Premise

312	Our	_	_	B-Claim
313	data	_	_	I-Claim
314	indicate	_	_	I-Claim
315	that	_	_	I-Claim
316	protracted	_	_	I-Claim
317	palliative	_	_	I-Claim
318	TRT	_	_	I-Claim
319	renders	_	_	I-Claim
320	no	_	_	I-Claim
321	improvement	_	_	I-Claim
322	in	_	_	I-Claim
323	symptom	_	_	I-Claim
324	relief	_	_	I-Claim
325	,	_	_	I-Claim
326	HRQOL	_	_	I-Claim
327	,	_	_	I-Claim
328	or	_	_	I-Claim
329	survival	_	_	I-Claim
330	when	_	_	I-Claim
331	compared	_	_	I-Claim
332	with	_	_	I-Claim
333	short	_	_	I-Claim
334	-	_	_	I-Claim
335	term	_	_	I-Claim
336	hypofractionated	_	_	I-Claim
337	treatment	_	_	I-Claim
338	in	_	_	I-Claim
339	advanced	_	_	I-Claim
340	NSCLC	_	_	I-Claim
341	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	long	_	_	O
4	-	_	_	O
5	term	_	_	O
6	outcome	_	_	O
7	and	_	_	O
8	health	_	_	O
9	-	_	_	O
10	related	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	(	_	_	O
15	HRQL	_	_	O
16	)	_	_	O
17	of	_	_	O
18	patients	_	_	O
19	with	_	_	O
20	endometrial	_	_	O
21	carcinoma	_	_	O
22	(	_	_	O
23	EC	_	_	O
24	)	_	_	O
25	treated	_	_	O
26	with	_	_	O
27	or	_	_	O
28	without	_	_	O
29	pelvic	_	_	O
30	radiotherapy	_	_	O
31	in	_	_	O
32	the	_	_	O
33	Post	_	_	O
34	Operative	_	_	O
35	Radiation	_	_	O
36	Therapy	_	_	O
37	in	_	_	O
38	Endometrial	_	_	O
39	Carcinoma	_	_	O
40	1	_	_	O
41	(	_	_	O
42	PORTEC	_	_	O
43	-	_	_	O
44	1	_	_	O
45	)	_	_	O
46	trial	_	_	O
47	.	_	_	O

48	Between	_	_	O
49	1990	_	_	O
50	and	_	_	O
51	1997	_	_	O
52	,	_	_	O
53	714	_	_	O
54	patients	_	_	O
55	with	_	_	O
56	stage	_	_	O
57	IC	_	_	O
58	grade	_	_	O
59	1	_	_	O
60	to	_	_	O
61	2	_	_	O
62	or	_	_	O
63	IB	_	_	O
64	grade	_	_	O
65	2	_	_	O
66	to	_	_	O
67	3	_	_	O
68	EC	_	_	O
69	were	_	_	O
70	randomly	_	_	O
71	allocated	_	_	O
72	to	_	_	O
73	pelvic	_	_	O
74	external	_	_	O
75	-	_	_	O
76	beam	_	_	O
77	radiotherapy	_	_	O
78	(	_	_	O
79	EBRT	_	_	O
80	)	_	_	O
81	or	_	_	O
82	no	_	_	O
83	additional	_	_	O
84	treatment	_	_	O
85	(	_	_	O
86	NAT	_	_	O
87	)	_	_	O
88	.	_	_	O

89	HRQL	_	_	O
90	was	_	_	O
91	evaluated	_	_	O
92	with	_	_	O
93	the	_	_	O
94	Short	_	_	O
95	Form	_	_	O
96	36	_	_	O
97	-	_	_	O
98	Item	_	_	O
99	(	_	_	O
100	SF	_	_	O
101	-	_	_	O
102	36	_	_	O
103	)	_	_	O
104	questionnaire	_	_	O
105	;	_	_	O
106	subscales	_	_	O
107	from	_	_	O
108	the	_	_	O
109	European	_	_	O
110	Organisation	_	_	O
111	for	_	_	O
112	Research	_	_	O
113	and	_	_	O
114	Treatment	_	_	O
115	of	_	_	O
116	Cancer	_	_	O
117	(	_	_	O
118	EORTC	_	_	O
119	)	_	_	O
120	PR25	_	_	O
121	module	_	_	O
122	for	_	_	O
123	bowel	_	_	O
124	and	_	_	O
125	bladder	_	_	O
126	symptoms	_	_	O
127	and	_	_	O
128	the	_	_	O
129	OV28	_	_	O
130	and	_	_	O
131	CX24	_	_	O
132	modules	_	_	O
133	for	_	_	O
134	sexual	_	_	O
135	symptoms	_	_	O
136	;	_	_	O
137	and	_	_	O
138	demographic	_	_	O
139	questions	_	_	O
140	.	_	_	O

141	Analysis	_	_	O
142	was	_	_	O
143	by	_	_	O
144	intention	_	_	O
145	-	_	_	O
146	to	_	_	O
147	-	_	_	O
148	treat	_	_	O
149	.	_	_	O

150	Median	_	_	O
151	follow	_	_	O
152	-	_	_	O
153	up	_	_	O
154	was	_	_	O
155	13	_	_	O
156	.	_	_	O

157	3	_	_	O
158	years	_	_	O
159	.	_	_	O

160	The	_	_	B-Premise
161	15	_	_	I-Premise
162	-	_	_	I-Premise
163	year	_	_	I-Premise
164	actuarial	_	_	I-Premise
165	locoregional	_	_	I-Premise
166	recurrence	_	_	I-Premise
167	rates	_	_	I-Premise
168	were	_	_	I-Premise
169	5	_	_	I-Premise
170	.	_	_	I-Premise

171	8	_	_	I-Premise
172	%	_	_	I-Premise
173	for	_	_	I-Premise
174	EBRT	_	_	I-Premise
175	versus	_	_	I-Premise
176	15	_	_	I-Premise
177	.	_	_	I-Premise

178	5	_	_	I-Premise
179	%	_	_	I-Premise
180	for	_	_	I-Premise
181	NAT	_	_	I-Premise
182	(	_	_	I-Premise
183	P	_	_	I-Premise
184	<	_	_	I-Premise
185	.	_	_	I-Premise

186	001	_	_	I-Premise
187	)	_	_	I-Premise
188	,	_	_	I-Premise
189	and	_	_	I-Premise
190	15	_	_	I-Premise
191	-	_	_	I-Premise
192	year	_	_	I-Premise
193	overall	_	_	I-Premise
194	survival	_	_	I-Premise
195	was	_	_	I-Premise
196	52	_	_	I-Premise
197	%	_	_	I-Premise
198	versus	_	_	I-Premise
199	60	_	_	I-Premise
200	%	_	_	I-Premise
201	(	_	_	I-Premise
202	P	_	_	I-Premise
203	=	_	_	I-Premise
204	.	_	_	I-Premise

205	14	_	_	I-Premise
206	)	_	_	I-Premise
207	.	_	_	I-Premise

208	Of	_	_	O
209	the	_	_	O
210	351	_	_	O
211	patients	_	_	O
212	confirmed	_	_	O
213	to	_	_	O
214	be	_	_	O
215	alive	_	_	O
216	with	_	_	O
217	correct	_	_	O
218	address	_	_	O
219	,	_	_	O
220	246	_	_	O
221	(	_	_	O
222	70	_	_	O
223	%	_	_	O
224	)	_	_	O
225	returned	_	_	O
226	the	_	_	O
227	questionnaire	_	_	O
228	.	_	_	O

229	Patients	_	_	B-Premise
230	treated	_	_	I-Premise
231	with	_	_	I-Premise
232	EBRT	_	_	I-Premise
233	reported	_	_	I-Premise
234	significant	_	_	I-Premise
235	(	_	_	I-Premise
236	P	_	_	I-Premise
237	<	_	_	I-Premise
238	.	_	_	I-Premise

239	01	_	_	I-Premise
240	)	_	_	I-Premise
241	and	_	_	I-Premise
242	clinically	_	_	I-Premise
243	relevant	_	_	I-Premise
244	higher	_	_	I-Premise
245	rates	_	_	I-Premise
246	of	_	_	I-Premise
247	urinary	_	_	I-Premise
248	incontinence	_	_	I-Premise
249	,	_	_	I-Premise
250	diarrhea	_	_	I-Premise
251	,	_	_	I-Premise
252	and	_	_	I-Premise
253	fecal	_	_	I-Premise
254	leakage	_	_	I-Premise
255	leading	_	_	I-Premise
256	to	_	_	I-Premise
257	more	_	_	I-Premise
258	limitations	_	_	I-Premise
259	in	_	_	I-Premise
260	daily	_	_	I-Premise
261	activities	_	_	I-Premise
262	.	_	_	I-Premise

263	Increased	_	_	B-Premise
264	symptoms	_	_	I-Premise
265	were	_	_	I-Premise
266	reflected	_	_	I-Premise
267	by	_	_	I-Premise
268	the	_	_	I-Premise
269	frequent	_	_	I-Premise
270	use	_	_	I-Premise
271	of	_	_	I-Premise
272	incontinence	_	_	I-Premise
273	materials	_	_	I-Premise
274	after	_	_	I-Premise
275	EBRT	_	_	I-Premise
276	(	_	_	I-Premise
277	day	_	_	I-Premise
278	and	_	_	I-Premise
279	night	_	_	I-Premise
280	use	_	_	I-Premise
281	,	_	_	I-Premise
282	42	_	_	I-Premise
283	.	_	_	I-Premise

284	9	_	_	I-Premise
285	%	_	_	I-Premise
286	v	_	_	I-Premise
287	15	_	_	I-Premise
288	.	_	_	I-Premise

289	2	_	_	I-Premise
290	%	_	_	I-Premise
291	for	_	_	I-Premise
292	NAT	_	_	I-Premise
293	;	_	_	I-Premise
294	P	_	_	I-Premise
295	<	_	_	I-Premise
296	.	_	_	I-Premise

297	001	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	Patients	_	_	B-Premise
301	treated	_	_	I-Premise
302	with	_	_	I-Premise
303	EBRT	_	_	I-Premise
304	reported	_	_	I-Premise
305	lower	_	_	I-Premise
306	scores	_	_	I-Premise
307	on	_	_	I-Premise
308	the	_	_	I-Premise
309	SF	_	_	I-Premise
310	-	_	_	I-Premise
311	36	_	_	I-Premise
312	scales	_	_	I-Premise
313	"	_	_	I-Premise
314	physical	_	_	I-Premise
315	functioning	_	_	I-Premise
316	"	_	_	I-Premise
317	(	_	_	I-Premise
318	P	_	_	I-Premise
319	=	_	_	I-Premise
320	.	_	_	I-Premise

321	004	_	_	I-Premise
322	)	_	_	I-Premise
323	and	_	_	I-Premise
324	"	_	_	I-Premise
325	role	_	_	I-Premise
326	-	_	_	I-Premise
327	physical	_	_	I-Premise
328	"	_	_	I-Premise
329	(	_	_	I-Premise
330	P	_	_	I-Premise
331	=	_	_	I-Premise
332	.	_	_	I-Premise

333	003	_	_	I-Premise
334	)	_	_	I-Premise
335	.	_	_	I-Premise

336	EBRT	_	_	B-Claim
337	for	_	_	I-Claim
338	endometrial	_	_	I-Claim
339	cancer	_	_	I-Claim
340	is	_	_	I-Claim
341	associated	_	_	I-Claim
342	with	_	_	I-Claim
343	long	_	_	I-Claim
344	-	_	_	I-Claim
345	term	_	_	I-Claim
346	urinary	_	_	I-Claim
347	and	_	_	I-Claim
348	bowel	_	_	I-Claim
349	symptoms	_	_	I-Claim
350	and	_	_	I-Claim
351	lower	_	_	I-Claim
352	physical	_	_	I-Claim
353	and	_	_	I-Claim
354	role	_	_	I-Claim
355	-	_	_	I-Claim
356	physical	_	_	I-Claim
357	functioning	_	_	I-Claim
358	,	_	_	I-Claim
359	even	_	_	I-Claim
360	15	_	_	I-Claim
361	years	_	_	I-Claim
362	after	_	_	I-Claim
363	treatment	_	_	I-Claim
364	.	_	_	I-Claim

365	Despite	_	_	B-Claim
366	its	_	_	I-Claim
367	efficacy	_	_	I-Claim
368	in	_	_	I-Claim
369	reducing	_	_	I-Claim
370	locoregional	_	_	I-Claim
371	recurrence	_	_	I-Claim
372	,	_	_	I-Claim
373	EBRT	_	_	I-Claim
374	should	_	_	I-Claim
375	be	_	_	I-Claim
376	avoided	_	_	I-Claim
377	in	_	_	I-Claim
378	patients	_	_	I-Claim
379	with	_	_	I-Claim
380	low	_	_	I-Claim
381	-	_	_	I-Claim
382	and	_	_	I-Claim
383	intermediate	_	_	I-Claim
384	-	_	_	I-Claim
385	risk	_	_	I-Claim
386	EC	_	_	I-Claim
387	.	_	_	I-Claim


0	Premenopausal	_	_	O
1	women	_	_	O
2	with	_	_	O
3	breast	_	_	O
4	cancer	_	_	O
5	receiving	_	_	O
6	adjuvant	_	_	O
7	chemotherapy	_	_	O
8	are	_	_	O
9	at	_	_	O
10	risk	_	_	O
11	for	_	_	O
12	amenorrhea	_	_	O
13	.	_	_	O

14	The	_	_	O
15	National	_	_	O
16	Surgical	_	_	O
17	Adjuvant	_	_	O
18	Breast	_	_	O
19	and	_	_	O
20	Bowel	_	_	O
21	Project	_	_	O
22	B	_	_	O
23	-	_	_	O
24	30	_	_	O
25	trial	_	_	O
26	included	_	_	O
27	menstrual	_	_	O
28	history	_	_	O
29	(	_	_	O
30	MH	_	_	O
31	)	_	_	O
32	and	_	_	O
33	quality	_	_	O
34	-	_	_	O
35	of	_	_	O
36	-	_	_	O
37	life	_	_	O
38	(	_	_	O
39	QOL	_	_	O
40	)	_	_	O
41	studies	_	_	O
42	to	_	_	O
43	compare	_	_	O
44	treatments	_	_	O
45	on	_	_	O
46	these	_	_	O
47	outcomes	_	_	O
48	.	_	_	O

49	Patients	_	_	O
50	were	_	_	O
51	randomly	_	_	O
52	assigned	_	_	O
53	to	_	_	O
54	sequential	_	_	O
55	doxorubicin	_	_	O
56	(	_	_	O
57	A	_	_	O
58	)	_	_	O
59	and	_	_	O
60	cyclophosphamide	_	_	O
61	(	_	_	O
62	C	_	_	O
63	)	_	_	O
64	followed	_	_	O
65	by	_	_	O
66	docetaxel	_	_	O
67	(	_	_	O
68	T	_	_	O
69	;	_	_	O
70	AC	_	_	O
71	→	_	_	O
72	T	_	_	O
73	)	_	_	O
74	,	_	_	O
75	concurrent	_	_	O
76	TAC	_	_	O
77	,	_	_	O
78	or	_	_	O
79	AT	_	_	O
80	,	_	_	O
81	which	_	_	O
82	varied	_	_	O
83	in	_	_	O
84	duration	_	_	O
85	(	_	_	O
86	24	_	_	O
87	,	_	_	O
88	12	_	_	O
89	,	_	_	O
90	12	_	_	O
91	weeks	_	_	O
92	,	_	_	O
93	respectively	_	_	O
94	)	_	_	O
95	,	_	_	O
96	and	_	_	O
97	use	_	_	O
98	of	_	_	O
99	C	_	_	O
100	.	_	_	O

101	Endocrine	_	_	O
102	therapy	_	_	O
103	was	_	_	O
104	prescribed	_	_	O
105	for	_	_	O
106	women	_	_	O
107	with	_	_	O
108	hormone	_	_	O
109	receptor	_	_	O
110	-	_	_	O
111	positive	_	_	O
112	tumors	_	_	O
113	.	_	_	O

114	MH	_	_	O
115	and	_	_	O
116	QOL	_	_	O
117	were	_	_	O
118	assessed	_	_	O
119	with	_	_	O
120	standardized	_	_	O
121	questionnaires	_	_	O
122	at	_	_	O
123	baseline	_	_	O
124	;	_	_	O
125	cycle	_	_	O
126	4	_	_	O
127	,	_	_	O
128	day	_	_	O
129	1	_	_	O
130	;	_	_	O
131	and	_	_	O
132	every	_	_	O
133	6	_	_	O
134	months	_	_	O
135	through	_	_	O
136	24	_	_	O
137	months	_	_	O
138	.	_	_	O

139	Prespecified	_	_	O
140	analyses	_	_	O
141	examined	_	_	O
142	rates	_	_	O
143	of	_	_	O
144	amenorrhea	_	_	O
145	by	_	_	O
146	treatment	_	_	O
147	arm	_	_	O
148	,	_	_	O
149	the	_	_	O
150	relationship	_	_	O
151	between	_	_	O
152	amenorrhea	_	_	O
153	and	_	_	O
154	QOL	_	_	O
155	,	_	_	O
156	and	_	_	O
157	QOL	_	_	O
158	by	_	_	O
159	treatment	_	_	O
160	arm	_	_	O
161	.	_	_	O

162	Amenorrhea	_	_	B-Premise
163	12	_	_	I-Premise
164	months	_	_	I-Premise
165	after	_	_	I-Premise
166	random	_	_	I-Premise
167	assignment	_	_	I-Premise
168	was	_	_	I-Premise
169	significantly	_	_	I-Premise
170	different	_	_	I-Premise
171	between	_	_	I-Premise
172	treatment	_	_	I-Premise
173	groups	_	_	I-Premise
174	:	_	_	I-Premise
175	69	_	_	I-Premise
176	.	_	_	I-Premise

177	8	_	_	I-Premise
178	%	_	_	I-Premise
179	for	_	_	I-Premise
180	AC	_	_	I-Premise
181	→	_	_	I-Premise
182	T	_	_	I-Premise
183	,	_	_	I-Premise
184	57	_	_	I-Premise
185	.	_	_	I-Premise

186	7	_	_	I-Premise
187	%	_	_	I-Premise
188	for	_	_	I-Premise
189	TAC	_	_	I-Premise
190	,	_	_	I-Premise
191	and	_	_	I-Premise
192	37	_	_	I-Premise
193	.	_	_	I-Premise

194	9	_	_	I-Premise
195	%	_	_	I-Premise
196	for	_	_	I-Premise
197	AT	_	_	I-Premise
198	(	_	_	I-Premise
199	P	_	_	I-Premise
200	<	_	_	I-Premise
201	.	_	_	I-Premise

202	001	_	_	I-Premise
203	)	_	_	I-Premise
204	.	_	_	I-Premise

205	The	_	_	B-Premise
206	AT	_	_	I-Premise
207	group	_	_	I-Premise
208	without	_	_	I-Premise
209	tamoxifen	_	_	I-Premise
210	had	_	_	I-Premise
211	the	_	_	I-Premise
212	lowest	_	_	I-Premise
213	rate	_	_	I-Premise
214	of	_	_	I-Premise
215	amenorrhea	_	_	I-Premise
216	.	_	_	I-Premise

217	QOL	_	_	B-Premise
218	was	_	_	I-Premise
219	poorer	_	_	I-Premise
220	for	_	_	I-Premise
221	patients	_	_	I-Premise
222	receiving	_	_	I-Premise
223	AC	_	_	I-Premise
224	→	_	_	I-Premise
225	T	_	_	I-Premise
226	at	_	_	I-Premise
227	6	_	_	I-Premise
228	months	_	_	I-Premise
229	but	_	_	I-Premise
230	similar	_	_	I-Premise
231	to	_	_	I-Premise
232	others	_	_	I-Premise
233	by	_	_	I-Premise
234	12	_	_	I-Premise
235	months	_	_	I-Premise
236	.	_	_	I-Premise

237	Post	_	_	B-Premise
238	-	_	_	I-Premise
239	treatment	_	_	I-Premise
240	symptoms	_	_	I-Premise
241	were	_	_	I-Premise
242	increased	_	_	I-Premise
243	above	_	_	I-Premise
244	baseline	_	_	I-Premise
245	for	_	_	I-Premise
246	all	_	_	I-Premise
247	treatments	_	_	I-Premise
248	.	_	_	I-Premise

249	Multivariable	_	_	B-Premise
250	repeated	_	_	I-Premise
251	measures	_	_	I-Premise
252	modeling	_	_	I-Premise
253	demonstrated	_	_	I-Premise
254	that	_	_	I-Premise
255	treatment	_	_	I-Premise
256	arm	_	_	I-Premise
257	,	_	_	I-Premise
258	time	_	_	I-Premise
259	point	_	_	I-Premise
260	,	_	_	I-Premise
261	age	_	_	I-Premise
262	,	_	_	I-Premise
263	and	_	_	I-Premise
264	tamoxifen	_	_	I-Premise
265	use	_	_	I-Premise
266	were	_	_	I-Premise
267	significantly	_	_	I-Premise
268	associated	_	_	I-Premise
269	with	_	_	I-Premise
270	symptom	_	_	I-Premise
271	severity	_	_	I-Premise
272	(	_	_	I-Premise
273	all	_	_	I-Premise
274	P	_	_	I-Premise
275	values	_	_	I-Premise
276	<	_	_	I-Premise
277	.	_	_	I-Premise

278	002	_	_	I-Premise
279	)	_	_	I-Premise
280	.	_	_	I-Premise

281	Amenorrhea	_	_	B-Claim
282	rates	_	_	I-Claim
283	differed	_	_	I-Claim
284	significantly	_	_	I-Claim
285	by	_	_	I-Claim
286	treatment	_	_	I-Claim
287	arm	_	_	I-Claim
288	,	_	_	I-Claim
289	with	_	_	I-Claim
290	the	_	_	I-Claim
291	AT	_	_	I-Claim
292	arm	_	_	I-Claim
293	having	_	_	I-Claim
294	the	_	_	I-Claim
295	lowest	_	_	I-Claim
296	rate	_	_	I-Claim
297	.	_	_	I-Claim

298	Patients	_	_	B-Claim
299	treated	_	_	I-Claim
300	with	_	_	I-Claim
301	longer	_	_	I-Claim
302	duration	_	_	I-Claim
303	therapy	_	_	I-Claim
304	(	_	_	I-Claim
305	AC	_	_	I-Claim
306	→	_	_	I-Claim
307	T	_	_	I-Claim
308	)	_	_	I-Claim
309	had	_	_	I-Claim
310	greater	_	_	I-Claim
311	symptom	_	_	I-Claim
312	severity	_	_	I-Claim
313	and	_	_	I-Claim
314	poorer	_	_	I-Claim
315	QOL	_	_	I-Claim
316	at	_	_	I-Claim
317	6	_	_	I-Claim
318	months	_	_	I-Claim
319	,	_	_	I-Claim
320	but	_	_	I-Claim
321	did	_	_	I-Claim
322	not	_	_	I-Claim
323	differ	_	_	I-Claim
324	from	_	_	I-Claim
325	shorter	_	_	I-Claim
326	duration	_	_	I-Claim
327	treatments	_	_	I-Claim
328	at	_	_	I-Claim
329	12	_	_	I-Claim
330	months	_	_	I-Claim
331	.	_	_	I-Claim


0	On	_	_	O
1	March	_	_	O
2	15	_	_	O
3	,	_	_	O
4	2005	_	_	O
5	,	_	_	O
6	the	_	_	O
7	US	_	_	O
8	Food	_	_	O
9	and	_	_	O
10	Drug	_	_	O
11	Administration	_	_	O
12	approved	_	_	O
13	temozolomide	_	_	O
14	(	_	_	O
15	Temodar	_	_	O
16	capsules	_	_	O
17	,	_	_	O
18	Schering	_	_	O
19	-	_	_	O
20	Plough	_	_	O
21	Research	_	_	O
22	Institute	_	_	O
23	)	_	_	O
24	for	_	_	O
25	the	_	_	O
26	treatment	_	_	O
27	of	_	_	O
28	adult	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	newly	_	_	O
32	diagnosed	_	_	O
33	glioblastoma	_	_	O
34	multiforme	_	_	O
35	concomitantly	_	_	O
36	with	_	_	O
37	radiotherapy	_	_	O
38	and	_	_	O
39	then	_	_	O
40	as	_	_	O
41	maintenance	_	_	O
42	treatment	_	_	O
43	.	_	_	O

44	Five	_	_	O
45	hundred	_	_	O
46	seventy	_	_	O
47	-	_	_	O
48	three	_	_	O
49	glioblastoma	_	_	O
50	multiforme	_	_	O
51	patients	_	_	O
52	were	_	_	O
53	randomized	_	_	O
54	to	_	_	O
55	receive	_	_	O
56	either	_	_	O
57	temozolomide	_	_	O
58	+	_	_	O
59	radiotherapy	_	_	O
60	(	_	_	O
61	n	_	_	O
62	=	_	_	O
63	287	_	_	O
64	)	_	_	O
65	or	_	_	O
66	radiotherapy	_	_	O
67	alone	_	_	O
68	(	_	_	O
69	n	_	_	O
70	=	_	_	O
71	286	_	_	O
72	)	_	_	O
73	.	_	_	O

74	Patients	_	_	O
75	in	_	_	O
76	the	_	_	O
77	temozolomide	_	_	O
78	+	_	_	O
79	radiotherapy	_	_	O
80	arm	_	_	O
81	received	_	_	O
82	concomitant	_	_	O
83	temozolomide	_	_	O
84	(	_	_	O
85	75	_	_	O
86	mg	_	_	O
87	/	_	_	O
88	m2	_	_	O
89	)	_	_	O
90	once	_	_	O
91	daily	_	_	O
92	for	_	_	O
93	the	_	_	O
94	duration	_	_	O
95	of	_	_	O
96	radiation	_	_	O
97	therapy	_	_	O
98	(	_	_	O
99	42	_	_	O
100	-	_	_	O
101	49	_	_	O
102	days	_	_	O
103	)	_	_	O
104	.	_	_	O

105	This	_	_	O
106	was	_	_	O
107	followed	_	_	O
108	,	_	_	O
109	4	_	_	O
110	weeks	_	_	O
111	later	_	_	O
112	,	_	_	O
113	by	_	_	O
114	six	_	_	O
115	cycles	_	_	O
116	of	_	_	O
117	temozolomide	_	_	O
118	,	_	_	O
119	150	_	_	O
120	or	_	_	O
121	200	_	_	O
122	mg	_	_	O
123	/	_	_	O
124	m2	_	_	O
125	daily	_	_	O
126	for	_	_	O
127	5	_	_	O
128	days	_	_	O
129	,	_	_	O
130	every	_	_	O
131	4	_	_	O
132	weeks	_	_	O
133	.	_	_	O

134	Patients	_	_	O
135	in	_	_	O
136	the	_	_	O
137	control	_	_	O
138	arm	_	_	O
139	received	_	_	O
140	radiotherapy	_	_	O
141	only	_	_	O
142	.	_	_	O

143	In	_	_	O
144	both	_	_	O
145	arms	_	_	O
146	,	_	_	O
147	radiotherapy	_	_	O
148	was	_	_	O
149	delivered	_	_	O
150	as	_	_	O
151	60	_	_	O
152	Gy	_	_	O
153	/	_	_	O
154	30	_	_	O
155	fractions	_	_	O
156	to	_	_	O
157	the	_	_	O
158	tumor	_	_	O
159	site	_	_	O
160	with	_	_	O
161	a	_	_	O
162	2	_	_	O
163	to	_	_	O
164	3	_	_	O
165	cm	_	_	O
166	margin	_	_	O
167	.	_	_	O

168	Pneumocystis	_	_	O
169	carinii	_	_	O
170	pneumonia	_	_	O
171	prophylaxis	_	_	O
172	was	_	_	O
173	required	_	_	O
174	during	_	_	O
175	temozolomide	_	_	O
176	+	_	_	O
177	radiotherapy	_	_	O
178	treatment	_	_	O
179	and	_	_	O
180	was	_	_	O
181	continued	_	_	O
182	until	_	_	O
183	recovery	_	_	O
184	of	_	_	O
185	lymphocytopenia	_	_	O
186	(	_	_	O
187	Common	_	_	O
188	Toxicity	_	_	O
189	Criteria	_	_	O
190	grade	_	_	O
191	<	_	_	O
192	1	_	_	O
193	)	_	_	O
194	.	_	_	O

195	At	_	_	O
196	disease	_	_	O
197	progression	_	_	O
198	,	_	_	O
199	temozolomide	_	_	O
200	salvage	_	_	O
201	treatment	_	_	O
202	was	_	_	O
203	given	_	_	O
204	to	_	_	O
205	161	_	_	O
206	of	_	_	O
207	282	_	_	O
208	patients	_	_	O
209	(	_	_	O
210	57	_	_	O
211	%	_	_	O
212	)	_	_	O
213	in	_	_	O
214	the	_	_	O
215	radiotherapy	_	_	O
216	alone	_	_	O
217	arm	_	_	O
218	,	_	_	O
219	and	_	_	O
220	to	_	_	O
221	62	_	_	O
222	of	_	_	O
223	277	_	_	O
224	patients	_	_	O
225	(	_	_	O
226	22	_	_	O
227	%	_	_	O
228	)	_	_	O
229	in	_	_	O
230	the	_	_	O
231	temozolomide	_	_	O
232	+	_	_	O
233	radiotherapy	_	_	O
234	arm	_	_	O
235	.	_	_	O

236	Patients	_	_	B-Claim
237	receiving	_	_	I-Claim
238	concomitant	_	_	I-Claim
239	and	_	_	I-Claim
240	maintenance	_	_	I-Claim
241	temozolomide	_	_	I-Claim
242	+	_	_	I-Claim
243	radiotherapy	_	_	I-Claim
244	had	_	_	I-Claim
245	significantly	_	_	I-Claim
246	improved	_	_	I-Claim
247	overall	_	_	I-Claim
248	survival	_	_	I-Claim
249	.	_	_	I-Claim

250	The	_	_	B-Premise
251	hazard	_	_	I-Premise
252	ratio	_	_	I-Premise
253	was	_	_	I-Premise
254	0	_	_	I-Premise
255	.	_	_	I-Premise

256	63	_	_	I-Premise
257	(	_	_	I-Premise
258	95	_	_	I-Premise
259	%	_	_	I-Premise
260	confidence	_	_	I-Premise
261	interval	_	_	I-Premise
262	,	_	_	I-Premise
263	0	_	_	I-Premise
264	.	_	_	I-Premise

265	52	_	_	I-Premise
266	-	_	_	I-Premise
267	0	_	_	I-Premise
268	.	_	_	I-Premise

269	75	_	_	I-Premise
270	;	_	_	I-Premise
271	log	_	_	I-Premise
272	-	_	_	I-Premise
273	rank	_	_	I-Premise
274	,	_	_	I-Premise
275	P	_	_	I-Premise
276	<	_	_	I-Premise
277	0	_	_	I-Premise
278	.	_	_	I-Premise

279	0001	_	_	I-Premise
280	)	_	_	I-Premise
281	.	_	_	I-Premise

282	Median	_	_	B-Premise
283	survival	_	_	I-Premise
284	was	_	_	I-Premise
285	14	_	_	I-Premise
286	.	_	_	I-Premise

287	6	_	_	I-Premise
288	months	_	_	I-Premise
289	(	_	_	I-Premise
290	temozolomide	_	_	I-Premise
291	+	_	_	I-Premise
292	radiotherapy	_	_	I-Premise
293	)	_	_	I-Premise
294	versus	_	_	I-Premise
295	12	_	_	I-Premise
296	.	_	_	I-Premise

297	1	_	_	I-Premise
298	months	_	_	I-Premise
299	(	_	_	I-Premise
300	radiotherapy	_	_	I-Premise
301	alone	_	_	I-Premise
302	)	_	_	I-Premise
303	.	_	_	I-Premise

304	Adverse	_	_	B-Claim
305	events	_	_	I-Claim
306	during	_	_	I-Claim
307	temozolomide	_	_	I-Claim
308	treatment	_	_	I-Claim
309	included	_	_	I-Claim
310	thrombocytopenia	_	_	I-Claim
311	,	_	_	I-Claim
312	nausea	_	_	I-Claim
313	,	_	_	I-Claim
314	vomiting	_	_	I-Claim
315	,	_	_	I-Claim
316	anorexia	_	_	I-Claim
317	,	_	_	I-Claim
318	constipation	_	_	I-Claim
319	,	_	_	I-Claim
320	alopecia	_	_	I-Claim
321	,	_	_	I-Claim
322	headache	_	_	I-Claim
323	,	_	_	I-Claim
324	fatigue	_	_	I-Claim
325	,	_	_	I-Claim
326	and	_	_	I-Claim
327	convulsions	_	_	I-Claim
328	.	_	_	I-Claim


0	As	_	_	O
1	patients	_	_	O
2	with	_	_	O
3	pancreas	_	_	O
4	and	_	_	O
5	periampullary	_	_	O
6	cancer	_	_	O
7	(	_	_	O
8	PPC	_	_	O
9	)	_	_	O
10	experience	_	_	O
11	improved	_	_	O
12	survival	_	_	O
13	rates	_	_	O
14	and	_	_	O
15	longevity	_	_	O
16	,	_	_	O
17	the	_	_	O
18	focus	_	_	O
19	shifts	_	_	O
20	toward	_	_	O
21	living	_	_	O
22	life	_	_	O
23	while	_	_	O
24	surviving	_	_	O
25	cancer	_	_	O
26	.	_	_	O

27	Fatigue	_	_	O
28	is	_	_	O
29	the	_	_	O
30	most	_	_	O
31	commonly	_	_	O
32	reported	_	_	O
33	symptom	_	_	O
34	in	_	_	O
35	all	_	_	O
36	cancer	_	_	O
37	patients	_	_	O
38	.	_	_	O

39	Exercise	_	_	O
40	has	_	_	O
41	been	_	_	O
42	found	_	_	O
43	to	_	_	O
44	effectively	_	_	O
45	decrease	_	_	O
46	fatigue	_	_	O
47	levels	_	_	O
48	and	_	_	O
49	improve	_	_	O
50	physical	_	_	O
51	functioning	_	_	O
52	in	_	_	O
53	cancer	_	_	O
54	patients	_	_	O
55	.	_	_	O

56	One	_	_	O
57	hundred	_	_	O
58	two	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	resected	_	_	O
62	PPC	_	_	O
63	consented	_	_	O
64	to	_	_	O
65	participate	_	_	O
66	in	_	_	O
67	this	_	_	O
68	study	_	_	O
69	and	_	_	O
70	were	_	_	O
71	randomized	_	_	O
72	to	_	_	O
73	either	_	_	O
74	an	_	_	O
75	intervention	_	_	O
76	group	_	_	O
77	(	_	_	O
78	IG	_	_	O
79	)	_	_	O
80	or	_	_	O
81	a	_	_	O
82	usual	_	_	O
83	care	_	_	O
84	group	_	_	O
85	(	_	_	O
86	UCG	_	_	O
87	)	_	_	O
88	.	_	_	O

89	Subjects	_	_	O
90	completed	_	_	O
91	visual	_	_	O
92	analog	_	_	O
93	scales	_	_	O
94	,	_	_	O
95	the	_	_	O
96	FACIT	_	_	O
97	-	_	_	O
98	Fatigue	_	_	O
99	Scale	_	_	O
100	and	_	_	O
101	the	_	_	O
102	Short	_	_	O
103	Form	_	_	O
104	-	_	_	O
105	36v2	_	_	O
106	after	_	_	O
107	surgery	_	_	O
108	and	_	_	O
109	again	_	_	O
110	3	_	_	O
111	to	_	_	O
112	6	_	_	O
113	months	_	_	O
114	after	_	_	O
115	hospital	_	_	O
116	discharge	_	_	O
117	.	_	_	O

118	Patients	_	_	O
119	in	_	_	O
120	the	_	_	O
121	IG	_	_	O
122	and	_	_	O
123	UCG	_	_	O
124	were	_	_	O
125	comparable	_	_	O
126	with	_	_	O
127	regard	_	_	O
128	to	_	_	O
129	demographics	_	_	O
130	,	_	_	O
131	comorbidities	_	_	O
132	,	_	_	O
133	cancer	_	_	O
134	type	_	_	O
135	and	_	_	O
136	staging	_	_	O
137	,	_	_	O
138	type	_	_	O
139	of	_	_	O
140	resection	_	_	O
141	,	_	_	O
142	preoperative	_	_	O
143	fatigue	_	_	O
144	and	_	_	O
145	pain	_	_	O
146	levels	_	_	O
147	,	_	_	O
148	adjuvant	_	_	O
149	therapy	_	_	O
150	,	_	_	O
151	and	_	_	O
152	baseline	_	_	O
153	walking	_	_	O
154	distance	_	_	O
155	.	_	_	O

156	Patients	_	_	B-Premise
157	in	_	_	I-Premise
158	the	_	_	I-Premise
159	IG	_	_	I-Premise
160	had	_	_	I-Premise
161	significantly	_	_	I-Premise
162	improved	_	_	I-Premise
163	scores	_	_	I-Premise
164	on	_	_	I-Premise
165	the	_	_	I-Premise
166	FACIT	_	_	I-Premise
167	-	_	_	I-Premise
168	Fatigue	_	_	I-Premise
169	Scale	_	_	I-Premise
170	at	_	_	I-Premise
171	study	_	_	I-Premise
172	completion	_	_	I-Premise
173	,	_	_	I-Premise
174	improved	_	_	I-Premise
175	fatigue	_	_	I-Premise
176	and	_	_	I-Premise
177	pain	_	_	I-Premise
178	scores	_	_	I-Premise
179	,	_	_	I-Premise
180	as	_	_	I-Premise
181	well	_	_	I-Premise
182	as	_	_	I-Premise
183	overall	_	_	I-Premise
184	physical	_	_	I-Premise
185	functioning	_	_	I-Premise
186	and	_	_	I-Premise
187	mental	_	_	I-Premise
188	health	_	_	I-Premise
189	composite	_	_	I-Premise
190	scores	_	_	I-Premise
191	.	_	_	I-Premise

192	At	_	_	B-Premise
193	study	_	_	I-Premise
194	completion	_	_	I-Premise
195	,	_	_	I-Premise
196	participants	_	_	I-Premise
197	in	_	_	I-Premise
198	the	_	_	I-Premise
199	IG	_	_	I-Premise
200	were	_	_	I-Premise
201	walking	_	_	I-Premise
202	twice	_	_	I-Premise
203	as	_	_	I-Premise
204	far	_	_	I-Premise
205	and	_	_	I-Premise
206	were	_	_	I-Premise
207	significantly	_	_	I-Premise
208	more	_	_	I-Premise
209	likely	_	_	I-Premise
210	to	_	_	I-Premise
211	have	_	_	I-Premise
212	continued	_	_	I-Premise
213	walking	_	_	I-Premise
214	or	_	_	I-Premise
215	another	_	_	I-Premise
216	form	_	_	I-Premise
217	of	_	_	I-Premise
218	exercise	_	_	I-Premise
219	as	_	_	I-Premise
220	compared	_	_	I-Premise
221	with	_	_	I-Premise
222	the	_	_	I-Premise
223	UCG	_	_	I-Premise
224	.	_	_	I-Premise

225	Using	_	_	O
226	hierarchical	_	_	O
227	cluster	_	_	O
228	analysis	_	_	O
229	,	_	_	O
230	3	_	_	O
231	mutually	_	_	O
232	exclusive	_	_	O
233	symptom	_	_	O
234	groupings	_	_	O
235	were	_	_	O
236	identified	_	_	O
237	in	_	_	O
238	the	_	_	O
239	cohort	_	_	O
240	.	_	_	O

241	Kaplan	_	_	B-Premise
242	-	_	_	I-Premise
243	Meier	_	_	I-Premise
244	survival	_	_	I-Premise
245	analysis	_	_	I-Premise
246	did	_	_	I-Premise
247	not	_	_	I-Premise
248	indicate	_	_	I-Premise
249	an	_	_	I-Premise
250	overall	_	_	I-Premise
251	survival	_	_	I-Premise
252	benefit	_	_	I-Premise
253	for	_	_	I-Premise
254	the	_	_	I-Premise
255	IG	_	_	I-Premise
256	.	_	_	I-Premise

257	This	_	_	B-Claim
258	is	_	_	I-Claim
259	the	_	_	I-Claim
260	first	_	_	I-Claim
261	prospective	_	_	I-Claim
262	,	_	_	I-Claim
263	randomized	_	_	I-Claim
264	controlled	_	_	I-Claim
265	trial	_	_	I-Claim
266	to	_	_	I-Claim
267	report	_	_	I-Claim
268	that	_	_	I-Claim
269	participation	_	_	I-Claim
270	in	_	_	I-Claim
271	a	_	_	I-Claim
272	home	_	_	I-Claim
273	walking	_	_	I-Claim
274	program	_	_	I-Claim
275	confers	_	_	I-Claim
276	a	_	_	I-Claim
277	significant	_	_	I-Claim
278	benefit	_	_	I-Claim
279	in	_	_	I-Claim
280	resected	_	_	I-Claim
281	PPC	_	_	I-Claim
282	patients	_	_	I-Claim
283	with	_	_	I-Claim
284	regard	_	_	I-Claim
285	to	_	_	I-Claim
286	fatigue	_	_	I-Claim
287	levels	_	_	I-Claim
288	,	_	_	I-Claim
289	physical	_	_	I-Claim
290	functioning	_	_	I-Claim
291	,	_	_	I-Claim
292	and	_	_	I-Claim
293	health	_	_	I-Claim
294	-	_	_	I-Claim
295	related	_	_	I-Claim
296	quality	_	_	I-Claim
297	of	_	_	I-Claim
298	life	_	_	I-Claim
299	.	_	_	I-Claim


0	Everolimus	_	_	O
1	(	_	_	O
2	EVE	_	_	O
3	)	_	_	O
4	+	_	_	O
5	exemestane	_	_	O
6	(	_	_	O
7	EXE	_	_	O
8	;	_	_	O
9	n	_	_	O
10	=	_	_	O
11	485	_	_	O
12	)	_	_	O
13	more	_	_	O
14	than	_	_	O
15	doubled	_	_	O
16	median	_	_	O
17	progression	_	_	O
18	-	_	_	O
19	free	_	_	O
20	survival	_	_	O
21	versus	_	_	O
22	placebo	_	_	O
23	(	_	_	O
24	PBO	_	_	O
25	)	_	_	O
26	+	_	_	O
27	EXE	_	_	O
28	(	_	_	O
29	n	_	_	O
30	=	_	_	O
31	239	_	_	O
32	)	_	_	O
33	,	_	_	O
34	with	_	_	O
35	a	_	_	O
36	manageable	_	_	O
37	safety	_	_	O
38	profile	_	_	O
39	and	_	_	O
40	no	_	_	O
41	deterioration	_	_	O
42	in	_	_	O
43	health	_	_	O
44	-	_	_	O
45	related	_	_	O
46	quality	_	_	O
47	-	_	_	O
48	of	_	_	O
49	-	_	_	O
50	life	_	_	O
51	(	_	_	O
52	HRQOL	_	_	O
53	)	_	_	O
54	in	_	_	O
55	patients	_	_	O
56	with	_	_	O
57	hormone	_	_	O
58	-	_	_	O
59	receptor	_	_	O
60	-	_	_	O
61	positive	_	_	O
62	(	_	_	O
63	HR	_	_	O
64	(	_	_	O
65	+	_	_	O
66	)	_	_	O
67	)	_	_	O
68	advanced	_	_	O
69	breast	_	_	O
70	cancer	_	_	O
71	(	_	_	O
72	ABC	_	_	O
73	)	_	_	O
74	who	_	_	O
75	recurred	_	_	O
76	or	_	_	O
77	progressed	_	_	O
78	on	_	_	O
79	/	_	_	O
80	after	_	_	O
81	nonsteroidal	_	_	O
82	aromatase	_	_	O
83	inhibitor	_	_	O
84	(	_	_	O
85	NSAI	_	_	O
86	)	_	_	O
87	therapy	_	_	O
88	.	_	_	O

89	To	_	_	O
90	further	_	_	O
91	evaluate	_	_	O
92	EVE	_	_	O
93	+	_	_	O
94	EXE	_	_	O
95	impact	_	_	O
96	on	_	_	O
97	disease	_	_	O
98	burden	_	_	O
99	,	_	_	O
100	we	_	_	O
101	conducted	_	_	O
102	additional	_	_	O
103	post	_	_	O
104	-	_	_	O
105	hoc	_	_	O
106	analyses	_	_	O
107	of	_	_	O
108	patient	_	_	O
109	-	_	_	O
110	reported	_	_	O
111	HRQOL	_	_	O
112	.	_	_	O

113	HRQOL	_	_	O
114	was	_	_	O
115	assessed	_	_	O
116	using	_	_	O
117	EORTC	_	_	O
118	QLQ	_	_	O
119	-	_	_	O
120	C30	_	_	O
121	and	_	_	O
122	QLQ	_	_	O
123	-	_	_	O
124	BR23	_	_	O
125	questionnaires	_	_	O
126	at	_	_	O
127	baseline	_	_	O
128	and	_	_	O
129	every	_	_	O
130	6	_	_	O
131	weeks	_	_	O
132	thereafter	_	_	O
133	until	_	_	O
134	treatment	_	_	O
135	discontinuation	_	_	O
136	because	_	_	O
137	of	_	_	O
138	disease	_	_	O
139	progression	_	_	O
140	,	_	_	O
141	toxicity	_	_	O
142	,	_	_	O
143	or	_	_	O
144	consent	_	_	O
145	withdrawal	_	_	O
146	.	_	_	O

147	Endpoints	_	_	O
148	included	_	_	O
149	the	_	_	O
150	QLQ	_	_	O
151	-	_	_	O
152	C30	_	_	O
153	Global	_	_	O
154	Health	_	_	O
155	Status	_	_	O
156	(	_	_	O
157	QL2	_	_	O
158	)	_	_	O
159	scale	_	_	O
160	,	_	_	O
161	the	_	_	O
162	QLQ	_	_	O
163	-	_	_	O
164	BR23	_	_	O
165	breast	_	_	O
166	symptom	_	_	O
167	(	_	_	O
168	BRBS	_	_	O
169	)	_	_	O
170	,	_	_	O
171	and	_	_	O
172	arm	_	_	O
173	symptom	_	_	O
174	(	_	_	O
175	BRAS	_	_	O
176	)	_	_	O
177	scales	_	_	O
178	.	_	_	O

179	Between	_	_	O
180	-	_	_	O
181	group	_	_	O
182	differences	_	_	O
183	in	_	_	O
184	change	_	_	O
185	from	_	_	O
186	baseline	_	_	O
187	were	_	_	O
188	assessed	_	_	O
189	using	_	_	O
190	linear	_	_	O
191	mixed	_	_	O
192	models	_	_	O
193	with	_	_	O
194	selected	_	_	O
195	covariates	_	_	O
196	.	_	_	O

197	Sensitivity	_	_	O
198	analysis	_	_	O
199	using	_	_	O
200	pattern	_	_	O
201	-	_	_	O
202	mixture	_	_	O
203	models	_	_	O
204	determined	_	_	O
205	the	_	_	O
206	effect	_	_	O
207	of	_	_	O
208	study	_	_	O
209	discontinuation	_	_	O
210	on	_	_	O
211	/	_	_	O
212	before	_	_	O
213	week	_	_	O
214	24	_	_	O
215	.	_	_	O

216	Treatment	_	_	O
217	arms	_	_	O
218	were	_	_	O
219	compared	_	_	O
220	using	_	_	O
221	differences	_	_	O
222	of	_	_	O
223	least	_	_	O
224	squares	_	_	O
225	mean	_	_	O
226	(	_	_	O
227	LSM	_	_	O
228	)	_	_	O
229	changes	_	_	O
230	from	_	_	O
231	baseline	_	_	O
232	and	_	_	O
233	95	_	_	O
234	%	_	_	O
235	confidence	_	_	O
236	intervals	_	_	O
237	(	_	_	O
238	CIs	_	_	O
239	)	_	_	O
240	at	_	_	O
241	each	_	_	O
242	timepoint	_	_	O
243	and	_	_	O
244	overall	_	_	O
245	.	_	_	O

246	Progression	_	_	O
247	-	_	_	O
248	free	_	_	O
249	survival	_	_	O
250	,	_	_	O
251	survival	_	_	O
252	,	_	_	O
253	response	_	_	O
254	rate	_	_	O
255	,	_	_	O
256	safety	_	_	O
257	,	_	_	O
258	and	_	_	O
259	HRQOL	_	_	O
260	.	_	_	O

261	Linear	_	_	B-Premise
262	mixed	_	_	I-Premise
263	models	_	_	I-Premise
264	(	_	_	I-Premise
265	primary	_	_	I-Premise
266	model	_	_	I-Premise
267	)	_	_	I-Premise
268	demonstrated	_	_	I-Premise
269	no	_	_	I-Premise
270	statistically	_	_	I-Premise
271	significant	_	_	I-Premise
272	overall	_	_	I-Premise
273	difference	_	_	I-Premise
274	between	_	_	I-Premise
275	EVE	_	_	I-Premise
276	+	_	_	I-Premise
277	EXE	_	_	I-Premise
278	and	_	_	I-Premise
279	PBO	_	_	I-Premise
280	+	_	_	I-Premise
281	EXE	_	_	I-Premise
282	for	_	_	I-Premise
283	QL2	_	_	I-Premise
284	(	_	_	I-Premise
285	LSM	_	_	I-Premise
286	difference	_	_	I-Premise
287	=	_	_	I-Premise
288	-	_	_	I-Premise
289	1	_	_	I-Premise
290	.	_	_	I-Premise

291	91	_	_	I-Premise
292	;	_	_	I-Premise
293	95	_	_	I-Premise
294	%	_	_	I-Premise
295	CI	_	_	I-Premise
296	=	_	_	I-Premise
297	-	_	_	I-Premise
298	4	_	_	I-Premise
299	.	_	_	I-Premise

300	61	_	_	I-Premise
301	,	_	_	I-Premise
302	0	_	_	I-Premise
303	.	_	_	I-Premise

304	78	_	_	I-Premise
305	)	_	_	I-Premise
306	,	_	_	I-Premise
307	BRBS	_	_	I-Premise
308	(	_	_	I-Premise
309	LSM	_	_	I-Premise
310	difference	_	_	I-Premise
311	=	_	_	I-Premise
312	-	_	_	I-Premise
313	0	_	_	I-Premise
314	.	_	_	I-Premise

315	18	_	_	I-Premise
316	;	_	_	I-Premise
317	95	_	_	I-Premise
318	%	_	_	I-Premise
319	CI	_	_	I-Premise
320	=	_	_	I-Premise
321	-	_	_	I-Premise
322	1	_	_	I-Premise
323	.	_	_	I-Premise

324	98	_	_	I-Premise
325	,	_	_	I-Premise
326	1	_	_	I-Premise
327	.	_	_	I-Premise

328	62	_	_	I-Premise
329	)	_	_	I-Premise
330	,	_	_	I-Premise
331	or	_	_	I-Premise
332	BRAS	_	_	I-Premise
333	(	_	_	I-Premise
334	LSM	_	_	I-Premise
335	difference	_	_	I-Premise
336	=	_	_	I-Premise
337	-	_	_	I-Premise
338	0	_	_	I-Premise
339	.	_	_	I-Premise

340	42	_	_	I-Premise
341	;	_	_	I-Premise
342	95	_	_	I-Premise
343	%	_	_	I-Premise
344	CI	_	_	I-Premise
345	=	_	_	I-Premise
346	-	_	_	I-Premise
347	2	_	_	I-Premise
348	.	_	_	I-Premise

349	94	_	_	I-Premise
350	,	_	_	I-Premise
351	2	_	_	I-Premise
352	.	_	_	I-Premise

353	10	_	_	I-Premise
354	)	_	_	I-Premise
355	.	_	_	I-Premise

356	Based	_	_	O
357	on	_	_	O
358	pattern	_	_	O
359	-	_	_	O
360	mixture	_	_	O
361	models	_	_	O
362	,	_	_	O
363	patients	_	_	O
364	who	_	_	O
365	dropped	_	_	O
366	out	_	_	O
367	early	_	_	O
368	had	_	_	O
369	worse	_	_	O
370	QL2	_	_	O
371	decline	_	_	O
372	on	_	_	O
373	both	_	_	O
374	treatments	_	_	O
375	.	_	_	O

376	In	_	_	B-Premise
377	the	_	_	I-Premise
378	expanded	_	_	I-Premise
379	pattern	_	_	I-Premise
380	-	_	_	I-Premise
381	mixture	_	_	I-Premise
382	model	_	_	I-Premise
383	,	_	_	I-Premise
384	EVE	_	_	I-Premise
385	+	_	_	I-Premise
386	EXE	_	_	I-Premise
387	-	_	_	I-Premise
388	treated	_	_	I-Premise
389	patients	_	_	I-Premise
390	who	_	_	I-Premise
391	did	_	_	I-Premise
392	not	_	_	I-Premise
393	drop	_	_	I-Premise
394	out	_	_	I-Premise
395	early	_	_	I-Premise
396	had	_	_	I-Premise
397	stable	_	_	I-Premise
398	BRBS	_	_	I-Premise
399	and	_	_	I-Premise
400	BRAS	_	_	I-Premise
401	relative	_	_	I-Premise
402	to	_	_	I-Premise
403	PBO	_	_	I-Premise
404	+	_	_	I-Premise
405	EXE	_	_	I-Premise
406	.	_	_	I-Premise

407	HRQOL	_	_	O
408	data	_	_	O
409	were	_	_	O
410	not	_	_	O
411	collected	_	_	O
412	after	_	_	O
413	disease	_	_	O
414	progression	_	_	O
415	.	_	_	O

416	These	_	_	B-Claim
417	analyses	_	_	I-Claim
418	confirm	_	_	I-Claim
419	that	_	_	I-Claim
420	EVE	_	_	I-Claim
421	+	_	_	I-Claim
422	EXE	_	_	I-Claim
423	provides	_	_	I-Claim
424	clinical	_	_	I-Claim
425	benefit	_	_	I-Claim
426	without	_	_	I-Claim
427	adversely	_	_	I-Claim
428	impacting	_	_	I-Claim
429	HRQOL	_	_	I-Claim
430	in	_	_	I-Claim
431	patients	_	_	I-Claim
432	with	_	_	I-Claim
433	HR	_	_	I-Claim
434	(	_	_	I-Claim
435	+	_	_	I-Claim
436	)	_	_	I-Claim
437	ABC	_	_	I-Claim
438	who	_	_	I-Claim
439	recurred	_	_	I-Claim
440	/	_	_	I-Claim
441	progressed	_	_	I-Claim
442	on	_	_	I-Claim
443	prior	_	_	I-Claim
444	NSAIs	_	_	I-Claim
445	versus	_	_	I-Claim
446	endocrine	_	_	I-Claim
447	therapy	_	_	I-Claim
448	alone	_	_	I-Claim
449	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	low	_	_	O
6	-	_	_	O
7	frequency	_	_	O
8	low	_	_	O
9	-	_	_	O
10	intensity	_	_	O
11	electrotherapy	_	_	O
12	and	_	_	O
13	manual	_	_	O
14	lymphatic	_	_	O
15	drainage	_	_	O
16	in	_	_	O
17	the	_	_	O
18	treatment	_	_	O
19	of	_	_	O
20	chronic	_	_	O
21	upper	_	_	O
22	limb	_	_	O
23	breast	_	_	O
24	cancer	_	_	O
25	-	_	_	O
26	related	_	_	O
27	lymphoedema	_	_	O
28	.	_	_	O

29	Cross	_	_	O
30	-	_	_	O
31	over	_	_	O
32	single	_	_	O
33	-	_	_	O
34	blind	_	_	O
35	random	_	_	O
36	clinical	_	_	O
37	trial	_	_	O
38	.	_	_	O

39	Rehabilitation	_	_	O
40	service	_	_	O
41	.	_	_	O

42	Thirty	_	_	O
43	-	_	_	O
44	six	_	_	O
45	women	_	_	O
46	with	_	_	O
47	chronic	_	_	O
48	upper	_	_	O
49	limb	_	_	O
50	breast	_	_	O
51	cancer	_	_	O
52	-	_	_	O
53	related	_	_	O
54	lymphoedema	_	_	O
55	.	_	_	O

56	Patients	_	_	O
57	were	_	_	O
58	randomized	_	_	O
59	to	_	_	O
60	undergo	_	_	O
61	10	_	_	O
62	sessions	_	_	O
63	of	_	_	O
64	manual	_	_	O
65	lymphatic	_	_	O
66	drainage	_	_	O
67	followed	_	_	O
68	by	_	_	O
69	10	_	_	O
70	sessions	_	_	O
71	of	_	_	O
72	low	_	_	O
73	-	_	_	O
74	frequency	_	_	O
75	low	_	_	O
76	-	_	_	O
77	intensity	_	_	O
78	electrotherapy	_	_	O
79	or	_	_	O
80	to	_	_	O
81	undergo	_	_	O
82	first	_	_	O
83	low	_	_	O
84	-	_	_	O
85	frequency	_	_	O
86	low	_	_	O
87	-	_	_	O
88	intensity	_	_	O
89	electrotherapy	_	_	O
90	followed	_	_	O
91	by	_	_	O
92	manual	_	_	O
93	lymphatic	_	_	O
94	drainage	_	_	O
95	.	_	_	O

96	There	_	_	O
97	was	_	_	O
98	a	_	_	O
99	month	_	_	O
100	of	_	_	O
101	washout	_	_	O
102	time	_	_	O
103	between	_	_	O
104	treatments	_	_	O
105	.	_	_	O

106	Each	_	_	O
107	patient	_	_	O
108	was	_	_	O
109	examined	_	_	O
110	just	_	_	O
111	before	_	_	O
112	and	_	_	O
113	after	_	_	O
114	each	_	_	O
115	treatment	_	_	O
116	.	_	_	O

117	Researchers	_	_	O
118	and	_	_	O
119	outcome	_	_	O
120	assessors	_	_	O
121	were	_	_	O
122	blinded	_	_	O
123	for	_	_	O
124	assigned	_	_	O
125	treatment	_	_	O
126	.	_	_	O

127	Outcomes	_	_	O
128	were	_	_	O
129	lymphoedema	_	_	O
130	volume	_	_	O
131	,	_	_	O
132	pain	_	_	O
133	,	_	_	O
134	heaviness	_	_	O
135	and	_	_	O
136	tightness	_	_	O
137	,	_	_	O
138	and	_	_	O
139	health	_	_	O
140	-	_	_	O
141	related	_	_	O
142	quality	_	_	O
143	of	_	_	O
144	life	_	_	O
145	measured	_	_	O
146	with	_	_	O
147	the	_	_	O
148	Functional	_	_	O
149	Assessment	_	_	O
150	of	_	_	O
151	Cancer	_	_	O
152	Therapy	_	_	O
153	Questionnaire	_	_	O
154	for	_	_	O
155	Breast	_	_	O
156	Cancer	_	_	O
157	version	_	_	O
158	4	_	_	O
159	(	_	_	O
160	FACT	_	_	O
161	-	_	_	O
162	B	_	_	O
163	+	_	_	O
164	4	_	_	O
165	)	_	_	O
166	.	_	_	O

167	Carry	_	_	O
168	-	_	_	O
169	over	_	_	O
170	,	_	_	O
171	period	_	_	O
172	and	_	_	O
173	treatment	_	_	O
174	effects	_	_	O
175	were	_	_	O
176	analysed	_	_	O
177	.	_	_	O

178	Treatment	_	_	O
179	effect	_	_	O
180	was	_	_	O
181	assessed	_	_	O
182	using	_	_	O
183	paired	_	_	O
184	t	_	_	O
185	-	_	_	O
186	test	_	_	O
187	.	_	_	O

188	Thirty	_	_	O
189	patients	_	_	O
190	finalized	_	_	O
191	treatment	_	_	O
192	.	_	_	O

193	Comparing	_	_	B-Premise
194	the	_	_	I-Premise
195	changes	_	_	I-Premise
196	in	_	_	I-Premise
197	low	_	_	I-Premise
198	-	_	_	I-Premise
199	frequency	_	_	I-Premise
200	low	_	_	I-Premise
201	-	_	_	I-Premise
202	intensity	_	_	I-Premise
203	electrotherapy	_	_	I-Premise
204	with	_	_	I-Premise
205	manual	_	_	I-Premise
206	lymphatic	_	_	I-Premise
207	drainage	_	_	I-Premise
208	changes	_	_	I-Premise
209	,	_	_	I-Premise
210	there	_	_	I-Premise
211	were	_	_	I-Premise
212	no	_	_	I-Premise
213	significant	_	_	I-Premise
214	differences	_	_	I-Premise
215	.	_	_	I-Premise

216	Low	_	_	B-Premise
217	-	_	_	I-Premise
218	frequency	_	_	I-Premise
219	low	_	_	I-Premise
220	-	_	_	I-Premise
221	intensity	_	_	I-Premise
222	electrotherapy	_	_	I-Premise
223	did	_	_	I-Premise
224	not	_	_	I-Premise
225	reduce	_	_	I-Premise
226	lymphoedema	_	_	I-Premise
227	volume	_	_	I-Premise
228	(	_	_	I-Premise
229	mean	_	_	I-Premise
230	of	_	_	I-Premise
231	change	_	_	I-Premise
232	=	_	_	I-Premise
233	19	_	_	I-Premise
234	.	_	_	I-Premise

235	77	_	_	I-Premise
236	mL	_	_	I-Premise
237	,	_	_	I-Premise
238	P	_	_	I-Premise
239	=	_	_	I-Premise
240	0	_	_	I-Premise
241	.	_	_	I-Premise

242	36	_	_	I-Premise
243	)	_	_	I-Premise
244	,	_	_	I-Premise
245	but	_	_	O
246	significant	_	_	B-Premise
247	reductions	_	_	I-Premise
248	were	_	_	I-Premise
249	observed	_	_	I-Premise
250	in	_	_	I-Premise
251	pain	_	_	I-Premise
252	,	_	_	I-Premise
253	heaviness	_	_	I-Premise
254	and	_	_	I-Premise
255	tightness	_	_	I-Premise
256	(	_	_	I-Premise
257	mean	_	_	I-Premise
258	of	_	_	I-Premise
259	change	_	_	I-Premise
260	=	_	_	I-Premise
261	13	_	_	I-Premise
262	.	_	_	I-Premise

263	1	_	_	I-Premise
264	,	_	_	I-Premise
265	16	_	_	I-Premise
266	.	_	_	I-Premise

267	2	_	_	I-Premise
268	and	_	_	I-Premise
269	6	_	_	I-Premise
270	.	_	_	I-Premise

271	4	_	_	I-Premise
272	mm	_	_	I-Premise
273	,	_	_	I-Premise
274	respectively	_	_	I-Premise
275	)	_	_	I-Premise
276	,	_	_	I-Premise
277	and	_	_	I-Premise
278	FACT	_	_	I-Premise
279	-	_	_	I-Premise
280	B	_	_	I-Premise
281	+	_	_	I-Premise
282	4	_	_	I-Premise
283	summaries	_	_	I-Premise
284	improved	_	_	I-Premise
285	significantly	_	_	I-Premise
286	(	_	_	I-Premise
287	Trial	_	_	I-Premise
288	Outcome	_	_	I-Premise
289	Index	_	_	I-Premise
290	mean	_	_	I-Premise
291	of	_	_	I-Premise
292	change	_	_	I-Premise
293	=	_	_	I-Premise
294	5	_	_	I-Premise
295	.	_	_	I-Premise

296	4	_	_	I-Premise
297	,	_	_	I-Premise
298	P	_	_	I-Premise
299	=	_	_	I-Premise
300	0	_	_	I-Premise
301	.	_	_	I-Premise

302	015	_	_	I-Premise
303	)	_	_	I-Premise
304	.	_	_	I-Premise

305	Manual	_	_	B-Premise
306	lymphatic	_	_	I-Premise
307	drainage	_	_	I-Premise
308	showed	_	_	I-Premise
309	no	_	_	I-Premise
310	significant	_	_	I-Premise
311	changes	_	_	I-Premise
312	in	_	_	I-Premise
313	any	_	_	I-Premise
314	of	_	_	I-Premise
315	the	_	_	I-Premise
316	outcomes	_	_	I-Premise
317	.	_	_	I-Premise

318	Although	_	_	B-Claim
319	there	_	_	I-Claim
320	are	_	_	I-Claim
321	no	_	_	I-Claim
322	significant	_	_	I-Claim
323	differences	_	_	I-Claim
324	between	_	_	I-Claim
325	treatment	_	_	I-Claim
326	changes	_	_	I-Claim
327	,	_	_	I-Claim
328	the	_	_	B-Claim
329	observed	_	_	I-Claim
330	trend	_	_	I-Claim
331	towards	_	_	I-Claim
332	a	_	_	I-Claim
333	better	_	_	I-Claim
334	health	_	_	I-Claim
335	-	_	_	I-Claim
336	related	_	_	I-Claim
337	quality	_	_	I-Claim
338	of	_	_	I-Claim
339	life	_	_	I-Claim
340	is	_	_	I-Claim
341	remarkable	_	_	I-Claim
342	in	_	_	I-Claim
343	low	_	_	I-Claim
344	-	_	_	I-Claim
345	frequency	_	_	I-Claim
346	low	_	_	I-Claim
347	-	_	_	I-Claim
348	intensity	_	_	I-Claim
349	electrotherapy	_	_	I-Claim
350	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	aimed	_	_	O
3	to	_	_	O
4	compare	_	_	O
5	quality	_	_	O
6	of	_	_	O
7	life	_	_	O
8	(	_	_	O
9	QOL	_	_	O
10	)	_	_	O
11	,	_	_	O
12	functional	_	_	O
13	outcome	_	_	O
14	,	_	_	O
15	body	_	_	O
16	image	_	_	O
17	,	_	_	O
18	and	_	_	O
19	cosmesis	_	_	O
20	after	_	_	O
21	hand	_	_	O
22	-	_	_	O
23	assisted	_	_	O
24	laparoscopic	_	_	O
25	(	_	_	O
26	LRP	_	_	O
27	)	_	_	O
28	versus	_	_	O
29	open	_	_	O
30	restorative	_	_	O
31	proctocolectomy	_	_	O
32	(	_	_	O
33	ORP	_	_	O
34	)	_	_	O
35	.	_	_	O

36	The	_	_	O
37	potential	_	_	O
38	long	_	_	O
39	-	_	_	O
40	term	_	_	O
41	advantages	_	_	O
42	of	_	_	O
43	LRP	_	_	O
44	over	_	_	O
45	ORP	_	_	O
46	remain	_	_	O
47	to	_	_	O
48	be	_	_	O
49	determined	_	_	O
50	.	_	_	O

51	The	_	_	O
52	most	_	_	O
53	likely	_	_	O
54	advantage	_	_	O
55	of	_	_	O
56	LRP	_	_	O
57	is	_	_	O
58	the	_	_	O
59	superior	_	_	O
60	cosmetic	_	_	O
61	result	_	_	O
62	.	_	_	O

63	It	_	_	O
64	is	_	_	O
65	,	_	_	O
66	however	_	_	O
67	,	_	_	O
68	unclear	_	_	O
69	whether	_	_	O
70	the	_	_	O
71	size	_	_	O
72	and	_	_	O
73	location	_	_	O
74	of	_	_	O
75	incisions	_	_	O
76	affect	_	_	O
77	body	_	_	O
78	image	_	_	O
79	and	_	_	O
80	QOL	_	_	O
81	.	_	_	O

82	In	_	_	O
83	a	_	_	O
84	previously	_	_	O
85	conducted	_	_	O
86	randomized	_	_	O
87	trial	_	_	O
88	comparing	_	_	O
89	LRP	_	_	O
90	with	_	_	O
91	ORP	_	_	O
92	,	_	_	O
93	60	_	_	O
94	patients	_	_	O
95	were	_	_	O
96	prospectively	_	_	O
97	evaluated	_	_	O
98	.	_	_	O

99	The	_	_	O
100	primary	_	_	O
101	end	_	_	O
102	points	_	_	O
103	were	_	_	O
104	body	_	_	O
105	image	_	_	O
106	and	_	_	O
107	cosmesis	_	_	O
108	.	_	_	O

109	The	_	_	O
110	secondary	_	_	O
111	end	_	_	O
112	points	_	_	O
113	were	_	_	O
114	morbidity	_	_	O
115	,	_	_	O
116	QOL	_	_	O
117	,	_	_	O
118	and	_	_	O
119	functional	_	_	O
120	outcome	_	_	O
121	.	_	_	O

122	A	_	_	O
123	body	_	_	O
124	image	_	_	O
125	questionnaire	_	_	O
126	was	_	_	O
127	used	_	_	O
128	to	_	_	O
129	evaluate	_	_	O
130	body	_	_	O
131	image	_	_	O
132	and	_	_	O
133	cosmesis	_	_	O
134	.	_	_	O

135	The	_	_	O
136	Short	_	_	O
137	Form	_	_	O
138	-	_	_	O
139	36	_	_	O
140	Health	_	_	O
141	Survey	_	_	O
142	and	_	_	O
143	the	_	_	O
144	Gastrointestinal	_	_	O
145	Quality	_	_	O
146	of	_	_	O
147	Life	_	_	O
148	Inventory	_	_	O
149	were	_	_	O
150	used	_	_	O
151	to	_	_	O
152	assess	_	_	O
153	QOL	_	_	O
154	.	_	_	O

155	Body	_	_	O
156	image	_	_	O
157	and	_	_	O
158	QOL	_	_	O
159	also	_	_	O
160	were	_	_	O
161	assessed	_	_	O
162	preoperatively	_	_	O
163	.	_	_	O

164	A	_	_	O
165	total	_	_	O
166	of	_	_	O
167	53	_	_	O
168	patients	_	_	O
169	completed	_	_	O
170	the	_	_	O
171	QOL	_	_	O
172	and	_	_	O
173	functional	_	_	O
174	outcome	_	_	O
175	questionnaires	_	_	O
176	.	_	_	O

177	There	_	_	B-Premise
178	were	_	_	I-Premise
179	no	_	_	I-Premise
180	differences	_	_	I-Premise
181	in	_	_	I-Premise
182	functional	_	_	I-Premise
183	outcome	_	_	I-Premise
184	,	_	_	I-Premise
185	morbidity	_	_	I-Premise
186	,	_	_	I-Premise
187	or	_	_	I-Premise
188	QOL	_	_	I-Premise
189	between	_	_	I-Premise
190	LRP	_	_	I-Premise
191	and	_	_	I-Premise
192	ORP	_	_	I-Premise
193	.	_	_	I-Premise

194	At	_	_	O
195	a	_	_	O
196	median	_	_	O
197	of	_	_	O
198	2	_	_	O
199	.	_	_	O

200	7	_	_	O
201	years	_	_	O
202	after	_	_	O
203	surgery	_	_	O
204	,	_	_	O
205	46	_	_	O
206	patients	_	_	O
207	returned	_	_	O
208	the	_	_	O
209	questionnaires	_	_	O
210	regarding	_	_	O
211	body	_	_	O
212	image	_	_	O
213	,	_	_	O
214	cosmesis	_	_	O
215	,	_	_	O
216	and	_	_	O
217	morbidity	_	_	O
218	.	_	_	O

219	The	_	_	B-Premise
220	body	_	_	I-Premise
221	image	_	_	I-Premise
222	and	_	_	I-Premise
223	cosmesis	_	_	I-Premise
224	scores	_	_	I-Premise
225	of	_	_	I-Premise
226	female	_	_	I-Premise
227	patients	_	_	I-Premise
228	were	_	_	I-Premise
229	significantly	_	_	I-Premise
230	higher	_	_	I-Premise
231	in	_	_	I-Premise
232	the	_	_	I-Premise
233	LRP	_	_	I-Premise
234	group	_	_	I-Premise
235	than	_	_	I-Premise
236	in	_	_	I-Premise
237	the	_	_	I-Premise
238	ORP	_	_	I-Premise
239	group	_	_	I-Premise
240	(	_	_	I-Premise
241	body	_	_	I-Premise
242	image	_	_	I-Premise
243	,	_	_	I-Premise
244	17	_	_	I-Premise
245	.	_	_	I-Premise

246	4	_	_	I-Premise
247	vs	_	_	I-Premise
248	14	_	_	I-Premise
249	.	_	_	I-Premise

250	9	_	_	I-Premise
251	;	_	_	I-Premise
252	cosmesis	_	_	I-Premise
253	,	_	_	I-Premise
254	19	_	_	I-Premise
255	.	_	_	I-Premise

256	1	_	_	I-Premise
257	vs	_	_	I-Premise
258	13	_	_	I-Premise
259	.	_	_	I-Premise

260	0	_	_	I-Premise
261	,	_	_	I-Premise
262	respectively	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	The	_	_	B-Premise
266	female	_	_	I-Premise
267	patients	_	_	I-Premise
268	in	_	_	I-Premise
269	the	_	_	I-Premise
270	ORP	_	_	I-Premise
271	group	_	_	I-Premise
272	had	_	_	I-Premise
273	significantly	_	_	I-Premise
274	lower	_	_	I-Premise
275	body	_	_	I-Premise
276	image	_	_	I-Premise
277	scores	_	_	I-Premise
278	than	_	_	I-Premise
279	the	_	_	I-Premise
280	male	_	_	I-Premise
281	patients	_	_	I-Premise
282	(	_	_	I-Premise
283	14	_	_	I-Premise
284	.	_	_	I-Premise

285	9	_	_	I-Premise
286	vs	_	_	I-Premise
287	18	_	_	I-Premise
288	.	_	_	I-Premise

289	3	_	_	I-Premise
290	)	_	_	I-Premise
291	.	_	_	I-Premise

292	This	_	_	B-Claim
293	study	_	_	I-Claim
294	is	_	_	I-Claim
295	the	_	_	I-Claim
296	first	_	_	I-Claim
297	to	_	_	I-Claim
298	show	_	_	I-Claim
299	that	_	_	I-Claim
300	ORP	_	_	I-Claim
301	has	_	_	I-Claim
302	a	_	_	I-Claim
303	negative	_	_	I-Claim
304	impact	_	_	I-Claim
305	on	_	_	I-Claim
306	body	_	_	I-Claim
307	image	_	_	I-Claim
308	and	_	_	I-Claim
309	cosmesis	_	_	I-Claim
310	as	_	_	I-Claim
311	compared	_	_	I-Claim
312	with	_	_	I-Claim
313	LRP	_	_	I-Claim
314	.	_	_	I-Claim

315	Functional	_	_	B-Claim
316	outcome	_	_	I-Claim
317	,	_	_	I-Claim
318	QOL	_	_	I-Claim
319	,	_	_	I-Claim
320	and	_	_	I-Claim
321	morbidity	_	_	I-Claim
322	are	_	_	I-Claim
323	similar	_	_	I-Claim
324	for	_	_	I-Claim
325	the	_	_	I-Claim
326	two	_	_	I-Claim
327	approaches	_	_	I-Claim
328	.	_	_	I-Claim

329	The	_	_	B-Claim
330	advantages	_	_	I-Claim
331	of	_	_	I-Claim
332	a	_	_	I-Claim
333	long	_	_	I-Claim
334	-	_	_	I-Claim
335	lasting	_	_	I-Claim
336	improved	_	_	I-Claim
337	body	_	_	I-Claim
338	image	_	_	I-Claim
339	and	_	_	I-Claim
340	cosmesis	_	_	I-Claim
341	for	_	_	I-Claim
342	this	_	_	I-Claim
343	relatively	_	_	I-Claim
344	young	_	_	I-Claim
345	patient	_	_	I-Claim
346	population	_	_	I-Claim
347	may	_	_	I-Claim
348	compensate	_	_	I-Claim
349	for	_	_	I-Claim
350	the	_	_	I-Claim
351	longer	_	_	I-Claim
352	operating	_	_	I-Claim
353	times	_	_	I-Claim
354	and	_	_	I-Claim
355	higher	_	_	I-Claim
356	costs	_	_	I-Claim
357	,	_	_	I-Claim
358	particularly	_	_	I-Claim
359	for	_	_	I-Claim
360	women	_	_	I-Claim
361	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	feasibility	_	_	O
4	of	_	_	O
5	administering	_	_	O
6	a	_	_	O
7	flavonoid	_	_	O
8	-	_	_	O
9	rich	_	_	O
10	adjunctive	_	_	O
11	treatment	_	_	O
12	(	_	_	O
13	Concord	_	_	O
14	grape	_	_	O
15	juice	_	_	O
16	)	_	_	O
17	for	_	_	O
18	the	_	_	O
19	management	_	_	O
20	of	_	_	O
21	chemotherapy	_	_	O
22	-	_	_	O
23	induced	_	_	O
24	nausea	_	_	O
25	and	_	_	O
26	vomiting	_	_	O
27	(	_	_	O
28	CINV	_	_	O
29	)	_	_	O
30	;	_	_	O
31	to	_	_	O
32	evaluate	_	_	O
33	the	_	_	O
34	usefulness	_	_	O
35	of	_	_	O
36	existing	_	_	O
37	measures	_	_	O
38	for	_	_	O
39	assessing	_	_	O
40	CINV	_	_	O
41	frequency	_	_	O
42	and	_	_	O
43	severity	_	_	O
44	,	_	_	O
45	quality	_	_	O
46	of	_	_	O
47	life	_	_	O
48	,	_	_	O
49	control	_	_	O
50	over	_	_	O
51	life	_	_	O
52	events	_	_	O
53	,	_	_	O
54	and	_	_	O
55	psychological	_	_	O
56	state	_	_	O
57	;	_	_	O
58	to	_	_	O
59	identify	_	_	O
60	any	_	_	O
61	actual	_	_	O
62	or	_	_	O
63	potential	_	_	O
64	adverse	_	_	O
65	events	_	_	O
66	associated	_	_	O
67	with	_	_	O
68	frequent	_	_	O
69	grape	_	_	O
70	juice	_	_	O
71	intake	_	_	O
72	;	_	_	O
73	and	_	_	O
74	to	_	_	O
75	provide	_	_	O
76	preliminary	_	_	O
77	data	_	_	O
78	concerning	_	_	O
79	the	_	_	O
80	effect	_	_	O
81	of	_	_	O
82	Concord	_	_	O
83	grape	_	_	O
84	juice	_	_	O
85	on	_	_	O
86	CINV	_	_	O
87	,	_	_	O
88	quality	_	_	O
89	of	_	_	O
90	life	_	_	O
91	,	_	_	O
92	perceived	_	_	O
93	control	_	_	O
94	over	_	_	O
95	life	_	_	O
96	events	_	_	O
97	,	_	_	O
98	and	_	_	O
99	psychological	_	_	O
100	state	_	_	O
101	.	_	_	O

102	Double	_	_	O
103	-	_	_	O
104	blind	_	_	O
105	,	_	_	O
106	randomized	_	_	O
107	clinical	_	_	O
108	trial	_	_	O
109	.	_	_	O

110	A	_	_	O
111	cancer	_	_	O
112	center	_	_	O
113	in	_	_	O
114	an	_	_	O
115	academic	_	_	O
116	health	_	_	O
117	science	_	_	O
118	center	_	_	O
119	in	_	_	O
120	the	_	_	O
121	northeastern	_	_	O
122	United	_	_	O
123	States	_	_	O
124	.	_	_	O

125	77	_	_	O
126	adult	_	_	O
127	patients	_	_	O
128	with	_	_	O
129	cancer	_	_	O
130	receiving	_	_	O
131	moderately	_	_	O
132	or	_	_	O
133	highly	_	_	O
134	emetogenic	_	_	O
135	chemotherapy	_	_	O
136	agents	_	_	O
137	.	_	_	O

138	Participants	_	_	O
139	drank	_	_	O
140	4	_	_	O
141	oz	_	_	O
142	.	_	_	O

143	of	_	_	O
144	grape	_	_	O
145	juice	_	_	O
146	or	_	_	O
147	placebo	_	_	O
148	prior	_	_	O
149	to	_	_	O
150	meals	_	_	O
151	for	_	_	O
152	one	_	_	O
153	week	_	_	O
154	following	_	_	O
155	each	_	_	O
156	of	_	_	O
157	four	_	_	O
158	chemotherapy	_	_	O
159	treatment	_	_	O
160	cycles	_	_	O
161	.	_	_	O

162	They	_	_	O
163	recorded	_	_	O
164	frequency	_	_	O
165	,	_	_	O
166	duration	_	_	O
167	,	_	_	O
168	and	_	_	O
169	distress	_	_	O
170	of	_	_	O
171	nausea	_	_	O
172	,	_	_	O
173	vomiting	_	_	O
174	,	_	_	O
175	and	_	_	O
176	retching	_	_	O
177	daily	_	_	O
178	,	_	_	O
179	beginning	_	_	O
180	the	_	_	O
181	evening	_	_	O
182	of	_	_	O
183	chemotherapy	_	_	O
184	administration	_	_	O
185	and	_	_	O
186	continuing	_	_	O
187	for	_	_	O
188	seven	_	_	O
189	days	_	_	O
190	.	_	_	O

191	Data	_	_	O
192	were	_	_	O
193	analyzed	_	_	O
194	with	_	_	O
195	generalized	_	_	O
196	estimating	_	_	O
197	equations	_	_	O
198	methodology	_	_	O
199	to	_	_	O
200	model	_	_	O
201	differences	_	_	O
202	between	_	_	O
203	groups	_	_	O
204	over	_	_	O
205	time	_	_	O
206	.	_	_	O

207	Nausea	_	_	B-Premise
208	and	_	_	I-Premise
209	vomiting	_	_	I-Premise
210	frequency	_	_	I-Premise
211	,	_	_	I-Premise
212	duration	_	_	I-Premise
213	,	_	_	I-Premise
214	and	_	_	I-Premise
215	distress	_	_	I-Premise
216	were	_	_	I-Premise
217	lower	_	_	I-Premise
218	for	_	_	I-Premise
219	experimental	_	_	I-Premise
220	group	_	_	I-Premise
221	members	_	_	I-Premise
222	,	_	_	I-Premise
223	although	_	_	B-Premise
224	a	_	_	I-Premise
225	high	_	_	I-Premise
226	attrition	_	_	I-Premise
227	rate	_	_	I-Premise
228	(	_	_	I-Premise
229	50	_	_	I-Premise
230	%	_	_	I-Premise
231	)	_	_	I-Premise
232	resulted	_	_	I-Premise
233	in	_	_	I-Premise
234	insufficient	_	_	I-Premise
235	power	_	_	I-Premise
236	to	_	_	I-Premise
237	detect	_	_	I-Premise
238	statistically	_	_	I-Premise
239	significant	_	_	I-Premise
240	differences	_	_	I-Premise
241	over	_	_	I-Premise
242	time	_	_	I-Premise
243	.	_	_	I-Premise

244	Greater	_	_	O
245	levels	_	_	O
246	of	_	_	O
247	anxiety	_	_	O
248	,	_	_	O
249	depression	_	_	O
250	,	_	_	O
251	and	_	_	O
252	hostility	_	_	O
253	at	_	_	O
254	baseline	_	_	O
255	were	_	_	O
256	related	_	_	O
257	to	_	_	O
258	nausea	_	_	O
259	and	_	_	O
260	vomiting	_	_	O
261	,	_	_	O
262	quality	_	_	O
263	of	_	_	O
264	life	_	_	O
265	,	_	_	O
266	and	_	_	O
267	perceived	_	_	O
268	control	_	_	O
269	over	_	_	O
270	decision	_	_	O
271	making	_	_	O
272	.	_	_	O

273	The	_	_	B-Claim
274	effect	_	_	I-Claim
275	of	_	_	I-Claim
276	grape	_	_	I-Claim
277	juice	_	_	I-Claim
278	flavonoids	_	_	I-Claim
279	on	_	_	I-Claim
280	CINV	_	_	I-Claim
281	should	_	_	I-Claim
282	be	_	_	I-Claim
283	investigated	_	_	I-Claim
284	further	_	_	I-Claim
285	with	_	_	I-Claim
286	a	_	_	I-Claim
287	larger	_	_	I-Claim
288	sample	_	_	I-Claim
289	to	_	_	I-Claim
290	determine	_	_	I-Claim
291	whether	_	_	I-Claim
292	preliminary	_	_	I-Claim
293	findings	_	_	I-Claim
294	are	_	_	I-Claim
295	supported	_	_	I-Claim
296	.	_	_	I-Claim

297	Alterations	_	_	O
298	to	_	_	O
299	the	_	_	O
300	study	_	_	O
301	protocol	_	_	O
302	will	_	_	O
303	be	_	_	O
304	necessary	_	_	O
305	to	_	_	O
306	decrease	_	_	O
307	attrition	_	_	O
308	.	_	_	O

309	Flavonoid	_	_	B-Claim
310	-	_	_	I-Claim
311	rich	_	_	I-Claim
312	fruits	_	_	I-Claim
313	and	_	_	I-Claim
314	vegetables	_	_	I-Claim
315	may	_	_	I-Claim
316	provide	_	_	I-Claim
317	additional	_	_	I-Claim
318	protection	_	_	I-Claim
319	against	_	_	I-Claim
320	CINV	_	_	I-Claim
321	.	_	_	I-Claim

322	If	_	_	O
323	the	_	_	O
324	compounds	_	_	O
325	work	_	_	O
326	,	_	_	O
327	they	_	_	O
328	would	_	_	O
329	offer	_	_	O
330	a	_	_	O
331	low	_	_	O
332	-	_	_	O
333	cost	_	_	O
334	,	_	_	O
335	readily	_	_	O
336	available	_	_	O
337	adjunctive	_	_	O
338	treatment	_	_	O
339	for	_	_	O
340	the	_	_	O
341	management	_	_	O
342	of	_	_	O
343	CINV	_	_	O
344	.	_	_	O


0	Studies	_	_	O
1	on	_	_	O
2	quality	_	_	O
3	of	_	_	O
4	life	_	_	O
5	(	_	_	O
6	QOL	_	_	O
7	)	_	_	O
8	among	_	_	O
9	women	_	_	O
10	with	_	_	O
11	endometrial	_	_	O
12	cancer	_	_	O
13	have	_	_	O
14	shown	_	_	O
15	that	_	_	O
16	patients	_	_	O
17	who	_	_	O
18	undergo	_	_	O
19	pelvic	_	_	O
20	radiotherapy	_	_	O
21	report	_	_	O
22	lower	_	_	O
23	role	_	_	O
24	functioning	_	_	O
25	and	_	_	O
26	more	_	_	O
27	diarrhea	_	_	O
28	and	_	_	O
29	fatigue	_	_	O
30	.	_	_	O

31	In	_	_	O
32	the	_	_	O
33	Post	_	_	O
34	Operative	_	_	O
35	Radiation	_	_	O
36	Therapy	_	_	O
37	in	_	_	O
38	Endometrial	_	_	O
39	Cancer	_	_	O
40	(	_	_	O
41	PORTEC	_	_	O
42	)	_	_	O
43	trial	_	_	O
44	,	_	_	O
45	patients	_	_	O
46	with	_	_	O
47	endometrial	_	_	O
48	carcinoma	_	_	O
49	were	_	_	O
50	randomly	_	_	O
51	assigned	_	_	O
52	to	_	_	O
53	receive	_	_	O
54	external	_	_	O
55	-	_	_	O
56	beam	_	_	O
57	radiotherapy	_	_	O
58	(	_	_	O
59	EBRT	_	_	O
60	)	_	_	O
61	or	_	_	O
62	vaginal	_	_	O
63	brachytherapy	_	_	O
64	(	_	_	O
65	VBT	_	_	O
66	)	_	_	O
67	.	_	_	O

68	QOL	_	_	O
69	was	_	_	O
70	evaluated	_	_	O
71	by	_	_	O
72	using	_	_	O
73	the	_	_	O
74	European	_	_	O
75	Organisation	_	_	O
76	for	_	_	O
77	Research	_	_	O
78	and	_	_	O
79	Treatment	_	_	O
80	of	_	_	O
81	Cancer	_	_	O
82	Quality	_	_	O
83	of	_	_	O
84	Life	_	_	O
85	Questionnaire	_	_	O
86	C30	_	_	O
87	and	_	_	O
88	subscales	_	_	O
89	from	_	_	O
90	the	_	_	O
91	prostate	_	_	O
92	cancer	_	_	O
93	module	_	_	O
94	,	_	_	O
95	PR	_	_	O
96	-	_	_	O
97	25	_	_	O
98	,	_	_	O
99	and	_	_	O
100	the	_	_	O
101	ovarian	_	_	O
102	cancer	_	_	O
103	module	_	_	O
104	,	_	_	O
105	OV	_	_	O
106	-	_	_	O
107	28	_	_	O
108	.	_	_	O

109	PORTEC	_	_	O
110	-	_	_	O
111	2	_	_	O
112	accrued	_	_	O
113	427	_	_	O
114	patients	_	_	O
115	between	_	_	O
116	2002	_	_	O
117	and	_	_	O
118	2006	_	_	O
119	,	_	_	O
120	of	_	_	O
121	whom	_	_	O
122	214	_	_	O
123	were	_	_	O
124	randomly	_	_	O
125	assigned	_	_	O
126	to	_	_	O
127	EBRT	_	_	O
128	,	_	_	O
129	and	_	_	O
130	213	_	_	O
131	were	_	_	O
132	randomly	_	_	O
133	assigned	_	_	O
134	to	_	_	O
135	VBT	_	_	O
136	.	_	_	O

137	Three	_	_	O
138	-	_	_	O
139	hundred	_	_	O
140	forty	_	_	O
141	-	_	_	O
142	eight	_	_	O
143	patients	_	_	O
144	(	_	_	O
145	81	_	_	O
146	%	_	_	O
147	)	_	_	O
148	were	_	_	O
149	evaluable	_	_	O
150	for	_	_	O
151	QOL	_	_	O
152	.	_	_	O

153	QOL	_	_	O
154	outcomes	_	_	O
155	were	_	_	O
156	analyzed	_	_	O
157	at	_	_	O
158	a	_	_	O
159	median	_	_	O
160	follow	_	_	O
161	-	_	_	O
162	up	_	_	O
163	of	_	_	O
164	2	_	_	O
165	years	_	_	O
166	.	_	_	O

167	At	_	_	O
168	baseline	_	_	O
169	after	_	_	O
170	surgery	_	_	O
171	,	_	_	O
172	patient	_	_	O
173	functioning	_	_	O
174	was	_	_	O
175	at	_	_	O
176	the	_	_	O
177	lowest	_	_	O
178	level	_	_	O
179	,	_	_	O
180	and	_	_	O
181	it	_	_	O
182	increased	_	_	O
183	during	_	_	O
184	and	_	_	O
185	after	_	_	O
186	radiotherapy	_	_	O
187	to	_	_	O
188	reach	_	_	O
189	a	_	_	O
190	plateau	_	_	O
191	after	_	_	O
192	12	_	_	O
193	months	_	_	O
194	.	_	_	O

195	Patients	_	_	B-Premise
196	in	_	_	I-Premise
197	the	_	_	I-Premise
198	VBT	_	_	I-Premise
199	group	_	_	I-Premise
200	reported	_	_	I-Premise
201	better	_	_	I-Premise
202	social	_	_	I-Premise
203	functioning	_	_	I-Premise
204	(	_	_	I-Premise
205	P	_	_	I-Premise
206	<	_	_	I-Premise
207	.	_	_	I-Premise

208	002	_	_	I-Premise
209	)	_	_	I-Premise
210	and	_	_	I-Premise
211	lower	_	_	I-Premise
212	symptom	_	_	I-Premise
213	scores	_	_	I-Premise
214	for	_	_	I-Premise
215	diarrhea	_	_	I-Premise
216	,	_	_	I-Premise
217	fecal	_	_	I-Premise
218	leakage	_	_	I-Premise
219	,	_	_	I-Premise
220	the	_	_	I-Premise
221	need	_	_	I-Premise
222	to	_	_	I-Premise
223	stay	_	_	I-Premise
224	close	_	_	I-Premise
225	to	_	_	I-Premise
226	the	_	_	I-Premise
227	toilet	_	_	I-Premise
228	,	_	_	I-Premise
229	and	_	_	I-Premise
230	limitation	_	_	I-Premise
231	in	_	_	I-Premise
232	daily	_	_	I-Premise
233	activities	_	_	I-Premise
234	because	_	_	I-Premise
235	of	_	_	I-Premise
236	bowel	_	_	I-Premise
237	symptoms	_	_	I-Premise
238	(	_	_	I-Premise
239	P	_	_	I-Premise
240	<	_	_	I-Premise
241	.	_	_	I-Premise

242	001	_	_	I-Premise
243	)	_	_	I-Premise
244	.	_	_	I-Premise

245	At	_	_	O
246	baseline	_	_	O
247	,	_	_	O
248	15	_	_	O
249	%	_	_	O
250	of	_	_	O
251	patients	_	_	O
252	were	_	_	O
253	sexually	_	_	O
254	active	_	_	O
255	;	_	_	O
256	this	_	_	O
257	increased	_	_	O
258	significantly	_	_	O
259	to	_	_	O
260	39	_	_	O
261	%	_	_	O
262	during	_	_	O
263	the	_	_	O
264	first	_	_	O
265	year	_	_	O
266	(	_	_	O
267	P	_	_	O
268	<	_	_	O
269	.	_	_	O

270	001	_	_	O
271	)	_	_	O
272	.	_	_	O

273	Sexual	_	_	B-Premise
274	functioning	_	_	I-Premise
275	and	_	_	I-Premise
276	symptoms	_	_	I-Premise
277	did	_	_	I-Premise
278	not	_	_	I-Premise
279	differ	_	_	I-Premise
280	between	_	_	I-Premise
281	the	_	_	I-Premise
282	treatment	_	_	I-Premise
283	groups	_	_	I-Premise
284	.	_	_	I-Premise

285	Patients	_	_	B-Premise
286	who	_	_	I-Premise
287	received	_	_	I-Premise
288	EBRT	_	_	I-Premise
289	reported	_	_	I-Premise
290	significantly	_	_	I-Premise
291	higher	_	_	I-Premise
292	levels	_	_	I-Premise
293	of	_	_	I-Premise
294	diarrhea	_	_	I-Premise
295	and	_	_	I-Premise
296	bowel	_	_	I-Premise
297	symptoms	_	_	I-Premise
298	.	_	_	I-Premise

299	This	_	_	O
300	resulted	_	_	O
301	in	_	_	O
302	a	_	_	O
303	higher	_	_	O
304	need	_	_	O
305	to	_	_	O
306	remain	_	_	O
307	close	_	_	O
308	to	_	_	O
309	a	_	_	O
310	toilet	_	_	O
311	and	_	_	O
312	,	_	_	O
313	as	_	_	O
314	a	_	_	O
315	consequence	_	_	O
316	,	_	_	O
317	more	_	_	O
318	limitation	_	_	O
319	of	_	_	O
320	daily	_	_	O
321	activities	_	_	O
322	because	_	_	O
323	of	_	_	O
324	bowel	_	_	O
325	symptoms	_	_	O
326	and	_	_	O
327	decreased	_	_	O
328	social	_	_	O
329	functioning	_	_	O
330	.	_	_	O

331	Vaginal	_	_	B-Claim
332	brachytherapy	_	_	I-Claim
333	provides	_	_	I-Claim
334	a	_	_	I-Claim
335	better	_	_	I-Claim
336	QOL	_	_	I-Claim
337	,	_	_	I-Claim
338	and	_	_	I-Claim
339	should	_	_	I-Claim
340	be	_	_	I-Claim
341	the	_	_	I-Claim
342	preferred	_	_	I-Claim
343	treatment	_	_	I-Claim
344	from	_	_	I-Claim
345	a	_	_	I-Claim
346	QOL	_	_	I-Claim
347	perspective	_	_	I-Claim
348	.	_	_	I-Claim


0	To	_	_	O
1	analyze	_	_	O
2	and	_	_	O
3	compare	_	_	O
4	radiologic	_	_	O
5	lung	_	_	O
6	expansion	_	_	O
7	after	_	_	O
8	talc	_	_	O
9	pleurodesis	_	_	O
10	performed	_	_	O
11	either	_	_	O
12	by	_	_	O
13	videothoracoscopy	_	_	O
14	or	_	_	O
15	chest	_	_	O
16	tube	_	_	O
17	and	_	_	O
18	correlate	_	_	O
19	it	_	_	O
20	with	_	_	O
21	clinical	_	_	O
22	outcome	_	_	O
23	.	_	_	O

24	Secondary	_	_	O
25	end	_	_	O
26	points	_	_	O
27	evaluated	_	_	O
28	were	_	_	O
29	as	_	_	O
30	follows	_	_	O
31	:	_	_	O
32	clinical	_	_	O
33	efficacy	_	_	O
34	;	_	_	O
35	quality	_	_	O
36	of	_	_	O
37	life	_	_	O
38	;	_	_	O
39	safety	_	_	O
40	;	_	_	O
41	and	_	_	O
42	survival	_	_	O
43	.	_	_	O

44	Prospective	_	_	O
45	randomized	_	_	O
46	study	_	_	O
47	that	_	_	O
48	included	_	_	O
49	60	_	_	O
50	patients	_	_	O
51	(	_	_	O
52	45	_	_	O
53	women	_	_	O
54	,	_	_	O
55	15	_	_	O
56	men	_	_	O
57	;	_	_	O
58	mean	_	_	O
59	age	_	_	O
60	,	_	_	O
61	55	_	_	O
62	.	_	_	O

63	2	_	_	O
64	years	_	_	O
65	)	_	_	O
66	with	_	_	O
67	recurrent	_	_	O
68	malignant	_	_	O
69	pleural	_	_	O
70	effusion	_	_	O
71	between	_	_	O
72	January	_	_	O
73	2005	_	_	O
74	and	_	_	O
75	January	_	_	O
76	2008	_	_	O
77	.	_	_	O

78	They	_	_	O
79	were	_	_	O
80	randomized	_	_	O
81	into	_	_	O
82	the	_	_	O
83	following	_	_	O
84	two	_	_	O
85	groups	_	_	O
86	:	_	_	O
87	video	_	_	O
88	-	_	_	O
89	assisted	_	_	O
90	thoracic	_	_	O
91	surgery	_	_	O
92	(	_	_	O
93	VATS	_	_	O
94	)	_	_	O
95	talc	_	_	O
96	poudrage	_	_	O
97	;	_	_	O
98	and	_	_	O
99	talc	_	_	O
100	slurry	_	_	O
101	(	_	_	O
102	TS	_	_	O
103	)	_	_	O
104	administered	_	_	O
105	through	_	_	O
106	a	_	_	O
107	chest	_	_	O
108	tube	_	_	O
109	.	_	_	O

110	Lung	_	_	O
111	expansion	_	_	O
112	was	_	_	O
113	evaluated	_	_	O
114	through	_	_	O
115	chest	_	_	O
116	CT	_	_	O
117	scans	_	_	O
118	obtained	_	_	O
119	0	_	_	O
120	,	_	_	O
121	1	_	_	O
122	,	_	_	O
123	3	_	_	O
124	and	_	_	O
125	6	_	_	O
126	months	_	_	O
127	after	_	_	O
128	pleurodesis	_	_	O
129	.	_	_	O

130	Complications	_	_	O
131	,	_	_	O
132	drainage	_	_	O
133	time	_	_	O
134	,	_	_	O
135	hospital	_	_	O
136	stay	_	_	O
137	,	_	_	O
138	and	_	_	O
139	quality	_	_	O
140	of	_	_	O
141	life	_	_	O
142	(	_	_	O
143	Medical	_	_	O
144	Outcomes	_	_	O
145	Study	_	_	O
146	36	_	_	O
147	-	_	_	O
148	item	_	_	O
149	short	_	_	O
150	form	_	_	O
151	and	_	_	O
152	World	_	_	O
153	Health	_	_	O
154	Organization	_	_	O
155	quality	_	_	O
156	-	_	_	O
157	of	_	_	O
158	-	_	_	O
159	life	_	_	O
160	questionnaires	_	_	O
161	)	_	_	O
162	were	_	_	O
163	also	_	_	O
164	analyzed	_	_	O
165	.	_	_	O

166	There	_	_	O
167	were	_	_	O
168	no	_	_	O
169	significant	_	_	O
170	differences	_	_	O
171	in	_	_	O
172	preprocedure	_	_	O
173	clinical	_	_	O
174	and	_	_	O
175	pathologic	_	_	O
176	variables	_	_	O
177	between	_	_	O
178	groups	_	_	O
179	.	_	_	O

180	The	_	_	O
181	immediate	_	_	O
182	total	_	_	O
183	(	_	_	O
184	ie	_	_	O
185	,	_	_	O
186	>	_	_	O
187	90	_	_	O
188	%	_	_	O
189	)	_	_	O
190	lung	_	_	O
191	expansion	_	_	O
192	was	_	_	O
193	observed	_	_	O
194	in	_	_	O
195	27	_	_	O
196	patients	_	_	O
197	(	_	_	O
198	45	_	_	O
199	%	_	_	O
200	)	_	_	O
201	and	_	_	O
202	was	_	_	O
203	more	_	_	O
204	frequent	_	_	O
205	in	_	_	O
206	the	_	_	O
207	VATS	_	_	O
208	group	_	_	O
209	(	_	_	O
210	60	_	_	O
211	%	_	_	O
212	vs	_	_	O
213	30	_	_	O
214	%	_	_	O
215	,	_	_	O
216	respectively	_	_	O
217	;	_	_	O
218	p	_	_	O
219	=	_	_	O
220	0	_	_	O
221	.	_	_	O

222	027	_	_	O
223	)	_	_	O
224	.	_	_	O

225	During	_	_	B-Premise
226	follow	_	_	I-Premise
227	-	_	_	I-Premise
228	up	_	_	I-Premise
229	,	_	_	I-Premise
230	71	_	_	I-Premise
231	%	_	_	I-Premise
232	of	_	_	I-Premise
233	the	_	_	I-Premise
234	patients	_	_	I-Premise
235	showed	_	_	I-Premise
236	unaltered	_	_	I-Premise
237	or	_	_	I-Premise
238	improved	_	_	I-Premise
239	lung	_	_	I-Premise
240	expansion	_	_	I-Premise
241	and	_	_	I-Premise
242	9	_	_	I-Premise
243	patients	_	_	I-Premise
244	(	_	_	I-Premise
245	15	_	_	I-Premise
246	%	_	_	I-Premise
247	)	_	_	I-Premise
248	needed	_	_	I-Premise
249	new	_	_	I-Premise
250	pleural	_	_	I-Premise
251	procedures	_	_	I-Premise
252	(	_	_	I-Premise
253	VATS	_	_	I-Premise
254	group	_	_	I-Premise
255	,	_	_	I-Premise
256	5	_	_	I-Premise
257	recurrences	_	_	I-Premise
258	;	_	_	I-Premise
259	TS	_	_	I-Premise
260	group	_	_	I-Premise
261	,	_	_	I-Premise
262	4	_	_	I-Premise
263	recurrences	_	_	I-Premise
264	;	_	_	I-Premise
265	p	_	_	I-Premise
266	=	_	_	I-Premise
267	0	_	_	I-Premise
268	.	_	_	I-Premise

269	999	_	_	I-Premise
270	)	_	_	I-Premise
271	.	_	_	I-Premise

272	No	_	_	B-Premise
273	differences	_	_	I-Premise
274	were	_	_	I-Premise
275	found	_	_	I-Premise
276	between	_	_	I-Premise
277	groups	_	_	I-Premise
278	regarding	_	_	I-Premise
279	quality	_	_	I-Premise
280	of	_	_	I-Premise
281	life	_	_	I-Premise
282	,	_	_	I-Premise
283	complications	_	_	I-Premise
284	,	_	_	I-Premise
285	drainage	_	_	I-Premise
286	time	_	_	I-Premise
287	,	_	_	I-Premise
288	hospital	_	_	I-Premise
289	stay	_	_	I-Premise
290	,	_	_	I-Premise
291	and	_	_	I-Premise
292	survival	_	_	I-Premise
293	.	_	_	I-Premise

294	Immediate	_	_	B-Premise
295	lung	_	_	I-Premise
296	expansion	_	_	I-Premise
297	did	_	_	I-Premise
298	not	_	_	I-Premise
299	correlate	_	_	I-Premise
300	with	_	_	I-Premise
301	radiologic	_	_	I-Premise
302	recurrence	_	_	I-Premise
303	,	_	_	I-Premise
304	clinical	_	_	I-Premise
305	recurrence	_	_	I-Premise
306	,	_	_	I-Premise
307	or	_	_	I-Premise
308	complications	_	_	I-Premise
309	(	_	_	I-Premise
310	p	_	_	I-Premise
311	=	_	_	I-Premise
312	0	_	_	I-Premise
313	.	_	_	I-Premise

314	60	_	_	I-Premise
315	,	_	_	I-Premise
316	0	_	_	I-Premise
317	.	_	_	I-Premise

318	15	_	_	I-Premise
319	,	_	_	I-Premise
320	and	_	_	I-Premise
321	0	_	_	I-Premise
322	.	_	_	I-Premise

323	20	_	_	I-Premise
324	,	_	_	I-Premise
325	respectively	_	_	I-Premise
326	)	_	_	I-Premise
327	.	_	_	I-Premise

328	Immediate	_	_	B-Premise
329	partial	_	_	I-Premise
330	lung	_	_	I-Premise
331	expansion	_	_	I-Premise
332	was	_	_	I-Premise
333	a	_	_	I-Premise
334	frequent	_	_	I-Premise
335	finding	_	_	I-Premise
336	and	_	_	I-Premise
337	was	_	_	I-Premise
338	more	_	_	I-Premise
339	frequent	_	_	I-Premise
340	after	_	_	I-Premise
341	TS	_	_	I-Premise
342	.	_	_	I-Premise

343	Nonetheless	_	_	O
344	,	_	_	O
345	no	_	_	B-Claim
346	correlation	_	_	I-Claim
347	between	_	_	I-Claim
348	immediate	_	_	I-Claim
349	lung	_	_	I-Claim
350	expansion	_	_	I-Claim
351	and	_	_	I-Claim
352	clinical	_	_	I-Claim
353	outcome	_	_	I-Claim
354	was	_	_	I-Claim
355	found	_	_	I-Claim
356	in	_	_	I-Claim
357	this	_	_	I-Claim
358	study	_	_	I-Claim
359	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	safety	_	_	O
4	and	_	_	O
5	efficacy	_	_	O
6	of	_	_	O
7	abatacept	_	_	O
8	during	_	_	O
9	2	_	_	O
10	years	_	_	O
11	of	_	_	O
12	the	_	_	O
13	ATTAIN	_	_	O
14	(	_	_	O
15	Abatacept	_	_	O
16	Trial	_	_	O
17	in	_	_	O
18	Treatment	_	_	O
19	of	_	_	O
20	Anti	_	_	O
21	-	_	_	O
22	TNF	_	_	O
23	INadequate	_	_	O
24	responders	_	_	O
25	)	_	_	O
26	trial	_	_	O
27	in	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	rheumatoid	_	_	O
31	arthritis	_	_	O
32	.	_	_	O

33	Patients	_	_	O
34	completing	_	_	O
35	the	_	_	O
36	6	_	_	O
37	-	_	_	O
38	month	_	_	O
39	,	_	_	O
40	double	_	_	O
41	-	_	_	O
42	blind	_	_	O
43	period	_	_	O
44	were	_	_	O
45	eligible	_	_	O
46	to	_	_	O
47	enter	_	_	O
48	the	_	_	O
49	long	_	_	O
50	-	_	_	O
51	term	_	_	O
52	extension	_	_	O
53	;	_	_	O
54	patients	_	_	O
55	received	_	_	O
56	abatacept	_	_	O
57	approximately	_	_	O
58	10	_	_	O
59	mg	_	_	O
60	/	_	_	O
61	kg	_	_	O
62	,	_	_	O
63	plus	_	_	O
64	disease	_	_	O
65	-	_	_	O
66	modifying	_	_	O
67	antirheumatic	_	_	O
68	drugs	_	_	O
69	.	_	_	O

70	Safety	_	_	O
71	and	_	_	O
72	efficacy	_	_	O
73	(	_	_	O
74	American	_	_	O
75	College	_	_	O
76	of	_	_	O
77	Rheumatology	_	_	O
78	(	_	_	O
79	ACR	_	_	O
80	)	_	_	O
81	criteria	_	_	O
82	responses	_	_	O
83	,	_	_	O
84	DAS28	_	_	O
85	(	_	_	O
86	C	_	_	O
87	-	_	_	O
88	reactive	_	_	O
89	protein	_	_	O
90	)	_	_	O
91	,	_	_	O
92	HAQ	_	_	O
93	-	_	_	O
94	DI	_	_	O
95	,	_	_	O
96	SF	_	_	O
97	-	_	_	O
98	36	_	_	O
99	,	_	_	O
100	Medical	_	_	O
101	Outcomes	_	_	O
102	Study	_	_	O
103	Sleep	_	_	O
104	Problems	_	_	O
105	Index	_	_	O
106	,	_	_	O
107	fatigue	_	_	O
108	VAS	_	_	O
109	)	_	_	O
110	were	_	_	O
111	assessed	_	_	O
112	through	_	_	O
113	2	_	_	O
114	years	_	_	O
115	.	_	_	O

116	317	_	_	O
117	patients	_	_	O
118	(	_	_	O
119	218	_	_	O
120	from	_	_	O
121	the	_	_	O
122	abatacept	_	_	O
123	and	_	_	O
124	99	_	_	O
125	from	_	_	O
126	the	_	_	O
127	placebo	_	_	O
128	group	_	_	O
129	)	_	_	O
130	entered	_	_	O
131	and	_	_	O
132	222	_	_	O
133	(	_	_	O
134	70	_	_	O
135	%	_	_	O
136	)	_	_	O
137	completed	_	_	O
138	18	_	_	O
139	months	_	_	O
140	of	_	_	O
141	long	_	_	O
142	-	_	_	O
143	term	_	_	O
144	extension	_	_	O
145	treatment	_	_	O
146	.	_	_	O

147	The	_	_	B-Premise
148	incidence	_	_	I-Premise
149	and	_	_	I-Premise
150	type	_	_	I-Premise
151	of	_	_	I-Premise
152	adverse	_	_	I-Premise
153	events	_	_	I-Premise
154	were	_	_	I-Premise
155	consistent	_	_	I-Premise
156	between	_	_	I-Premise
157	the	_	_	I-Premise
158	double	_	_	I-Premise
159	-	_	_	I-Premise
160	blind	_	_	I-Premise
161	and	_	_	I-Premise
162	cumulative	_	_	I-Premise
163	(	_	_	I-Premise
164	double	_	_	I-Premise
165	-	_	_	I-Premise
166	blind	_	_	I-Premise
167	plus	_	_	I-Premise
168	long	_	_	I-Premise
169	-	_	_	I-Premise
170	term	_	_	I-Premise
171	extension	_	_	I-Premise
172	)	_	_	I-Premise
173	periods	_	_	I-Premise
174	.	_	_	I-Premise

175	Rates	_	_	B-Premise
176	of	_	_	I-Premise
177	serious	_	_	I-Premise
178	adverse	_	_	I-Premise
179	events	_	_	I-Premise
180	were	_	_	I-Premise
181	25	_	_	I-Premise
182	.	_	_	I-Premise

183	6	_	_	I-Premise
184	and	_	_	I-Premise
185	23	_	_	I-Premise
186	.	_	_	I-Premise

187	4	_	_	I-Premise
188	per	_	_	I-Premise
189	100	_	_	I-Premise
190	patient	_	_	I-Premise
191	-	_	_	I-Premise
192	years	_	_	I-Premise
193	in	_	_	I-Premise
194	the	_	_	I-Premise
195	double	_	_	I-Premise
196	-	_	_	I-Premise
197	blind	_	_	I-Premise
198	versus	_	_	I-Premise
199	cumulative	_	_	I-Premise
200	period	_	_	I-Premise
201	.	_	_	I-Premise

202	At	_	_	B-Premise
203	6	_	_	I-Premise
204	months	_	_	I-Premise
205	and	_	_	I-Premise
206	2	_	_	I-Premise
207	years	_	_	I-Premise
208	,	_	_	I-Premise
209	using	_	_	I-Premise
210	non	_	_	I-Premise
211	-	_	_	I-Premise
212	responder	_	_	I-Premise
213	analyses	_	_	I-Premise
214	,	_	_	I-Premise
215	ACR	_	_	I-Premise
216	responses	_	_	I-Premise
217	in	_	_	I-Premise
218	abatacept	_	_	I-Premise
219	-	_	_	I-Premise
220	treated	_	_	I-Premise
221	patients	_	_	I-Premise
222	were	_	_	I-Premise
223	:	_	_	I-Premise
224	ACR	_	_	I-Premise
225	20	_	_	I-Premise
226	,	_	_	I-Premise
227	59	_	_	I-Premise
228	.	_	_	I-Premise

229	4	_	_	I-Premise
230	%	_	_	I-Premise
231	and	_	_	I-Premise
232	56	_	_	I-Premise
233	.	_	_	I-Premise

234	2	_	_	I-Premise
235	%	_	_	I-Premise
236	;	_	_	I-Premise
237	ACR	_	_	I-Premise
238	50	_	_	I-Premise
239	,	_	_	I-Premise
240	23	_	_	I-Premise
241	.	_	_	I-Premise

242	5	_	_	I-Premise
243	%	_	_	I-Premise
244	and	_	_	I-Premise
245	33	_	_	I-Premise
246	.	_	_	I-Premise

247	2	_	_	I-Premise
248	%	_	_	I-Premise
249	;	_	_	I-Premise
250	ACR	_	_	I-Premise
251	70	_	_	I-Premise
252	,	_	_	I-Premise
253	11	_	_	I-Premise
254	.	_	_	I-Premise

255	5	_	_	I-Premise
256	%	_	_	I-Premise
257	and	_	_	I-Premise
258	16	_	_	I-Premise
259	.	_	_	I-Premise

260	1	_	_	I-Premise
261	%	_	_	I-Premise
262	;	_	_	I-Premise
263	HAQ	_	_	I-Premise
264	-	_	_	I-Premise
265	DI	_	_	I-Premise
266	responses	_	_	I-Premise
267	were	_	_	I-Premise
268	54	_	_	I-Premise
269	.	_	_	I-Premise

270	4	_	_	I-Premise
271	%	_	_	I-Premise
272	and	_	_	I-Premise
273	47	_	_	I-Premise
274	.	_	_	I-Premise

275	9	_	_	I-Premise
276	%	_	_	I-Premise
277	.	_	_	I-Premise

278	At	_	_	B-Premise
279	6	_	_	I-Premise
280	months	_	_	I-Premise
281	and	_	_	I-Premise
282	2	_	_	I-Premise
283	years	_	_	I-Premise
284	,	_	_	I-Premise
285	using	_	_	I-Premise
286	post	_	_	I-Premise
287	-	_	_	I-Premise
288	hoc	_	_	I-Premise
289	as	_	_	I-Premise
290	-	_	_	I-Premise
291	observed	_	_	I-Premise
292	analyses	_	_	I-Premise
293	,	_	_	I-Premise
294	the	_	_	I-Premise
295	percentage	_	_	I-Premise
296	of	_	_	I-Premise
297	patients	_	_	I-Premise
298	(	_	_	I-Premise
299	95	_	_	I-Premise
300	%	_	_	I-Premise
301	confidence	_	_	I-Premise
302	interval	_	_	I-Premise
303	)	_	_	I-Premise
304	achieving	_	_	I-Premise
305	DAS28	_	_	I-Premise
306	(	_	_	I-Premise
307	C	_	_	I-Premise
308	-	_	_	I-Premise
309	reactive	_	_	I-Premise
310	protein	_	_	I-Premise
311	)	_	_	I-Premise
312	low	_	_	I-Premise
313	disease	_	_	I-Premise
314	activity	_	_	I-Premise
315	score	_	_	I-Premise
316	(	_	_	I-Premise
317	<	_	_	I-Premise
318	or	_	_	I-Premise
319	=	_	_	I-Premise
320	3	_	_	I-Premise
321	.	_	_	I-Premise

322	2	_	_	I-Premise
323	)	_	_	I-Premise
324	and	_	_	I-Premise
325	DAS28	_	_	I-Premise
326	(	_	_	I-Premise
327	C	_	_	I-Premise
328	-	_	_	I-Premise
329	reactive	_	_	I-Premise
330	protein	_	_	I-Premise
331	)	_	_	I-Premise
332	-	_	_	I-Premise
333	defined	_	_	I-Premise
334	remission	_	_	I-Premise
335	(	_	_	I-Premise
336	<	_	_	I-Premise
337	2	_	_	I-Premise
338	.	_	_	I-Premise

339	6	_	_	I-Premise
340	)	_	_	I-Premise
341	increased	_	_	I-Premise
342	from	_	_	I-Premise
343	18	_	_	I-Premise
344	.	_	_	I-Premise

345	3	_	_	I-Premise
346	%	_	_	I-Premise
347	(	_	_	I-Premise
348	13	_	_	I-Premise
349	.	_	_	I-Premise

350	0	_	_	I-Premise
351	,	_	_	I-Premise
352	23	_	_	I-Premise
353	.	_	_	I-Premise

354	5	_	_	I-Premise
355	)	_	_	I-Premise
356	to	_	_	I-Premise
357	32	_	_	I-Premise
358	.	_	_	I-Premise

359	0	_	_	I-Premise
360	%	_	_	I-Premise
361	(	_	_	I-Premise
362	24	_	_	I-Premise
363	.	_	_	I-Premise

364	6	_	_	I-Premise
365	,	_	_	I-Premise
366	39	_	_	I-Premise
367	.	_	_	I-Premise

368	4	_	_	I-Premise
369	)	_	_	I-Premise
370	and	_	_	I-Premise
371	11	_	_	I-Premise
372	.	_	_	I-Premise

373	1	_	_	I-Premise
374	%	_	_	I-Premise
375	(	_	_	I-Premise
376	6	_	_	I-Premise
377	.	_	_	I-Premise

378	8	_	_	I-Premise
379	,	_	_	I-Premise
380	15	_	_	I-Premise
381	.	_	_	I-Premise

382	3	_	_	I-Premise
383	)	_	_	I-Premise
384	to	_	_	I-Premise
385	20	_	_	I-Premise
386	.	_	_	I-Premise

387	3	_	_	I-Premise
388	%	_	_	I-Premise
389	(	_	_	I-Premise
390	13	_	_	I-Premise
391	.	_	_	I-Premise

392	9	_	_	I-Premise
393	,	_	_	I-Premise
394	26	_	_	I-Premise
395	.	_	_	I-Premise

396	6	_	_	I-Premise
397	)	_	_	I-Premise
398	.	_	_	I-Premise

399	Clinically	_	_	B-Premise
400	meaningful	_	_	I-Premise
401	improvements	_	_	I-Premise
402	in	_	_	I-Premise
403	SF	_	_	I-Premise
404	-	_	_	I-Premise
405	36	_	_	I-Premise
406	,	_	_	I-Premise
407	pain	_	_	I-Premise
408	,	_	_	I-Premise
409	fatigue	_	_	I-Premise
410	and	_	_	I-Premise
411	sleep	_	_	I-Premise
412	problems	_	_	I-Premise
413	were	_	_	I-Premise
414	also	_	_	I-Premise
415	maintained	_	_	I-Premise
416	throughout	_	_	I-Premise
417	the	_	_	I-Premise
418	2	_	_	I-Premise
419	years	_	_	I-Premise
420	of	_	_	I-Premise
421	abatacept	_	_	I-Premise
422	treatment	_	_	I-Premise
423	.	_	_	I-Premise

424	No	_	_	B-Premise
425	unique	_	_	I-Premise
426	safety	_	_	I-Premise
427	observations	_	_	I-Premise
428	were	_	_	I-Premise
429	reported	_	_	I-Premise
430	during	_	_	I-Premise
431	open	_	_	I-Premise
432	-	_	_	I-Premise
433	label	_	_	I-Premise
434	exposure	_	_	I-Premise
435	.	_	_	I-Premise

436	Improvements	_	_	B-Premise
437	in	_	_	I-Premise
438	the	_	_	I-Premise
439	signs	_	_	I-Premise
440	and	_	_	I-Premise
441	symptoms	_	_	I-Premise
442	of	_	_	I-Premise
443	rheumatoid	_	_	I-Premise
444	arthritis	_	_	I-Premise
445	,	_	_	I-Premise
446	physical	_	_	I-Premise
447	function	_	_	I-Premise
448	and	_	_	I-Premise
449	health	_	_	I-Premise
450	-	_	_	I-Premise
451	related	_	_	I-Premise
452	quality	_	_	I-Premise
453	of	_	_	I-Premise
454	life	_	_	I-Premise
455	observed	_	_	I-Premise
456	after	_	_	I-Premise
457	6	_	_	I-Premise
458	months	_	_	I-Premise
459	,	_	_	I-Premise
460	were	_	_	I-Premise
461	maintained	_	_	I-Premise
462	throughout	_	_	I-Premise
463	the	_	_	I-Premise
464	2	_	_	I-Premise
465	years	_	_	I-Premise
466	in	_	_	I-Premise
467	this	_	_	I-Premise
468	population	_	_	I-Premise
469	with	_	_	I-Premise
470	difficult	_	_	I-Premise
471	-	_	_	I-Premise
472	to	_	_	I-Premise
473	-	_	_	I-Premise
474	treat	_	_	I-Premise
475	disease	_	_	I-Premise
476	.	_	_	I-Premise


0	The	_	_	O
1	American	_	_	O
2	College	_	_	O
3	of	_	_	O
4	Surgeons	_	_	O
5	Oncology	_	_	O
6	Group	_	_	O
7	phase	_	_	O
8	III	_	_	O
9	Surgical	_	_	O
10	Prostatectomy	_	_	O
11	Versus	_	_	O
12	Interstitial	_	_	O
13	Radiation	_	_	O
14	Intervention	_	_	O
15	Trial	_	_	O
16	comparing	_	_	O
17	radical	_	_	O
18	prostatectomy	_	_	O
19	(	_	_	O
20	RP	_	_	O
21	)	_	_	O
22	and	_	_	O
23	brachytherapy	_	_	O
24	(	_	_	O
25	BT	_	_	O
26	)	_	_	O
27	closed	_	_	O
28	after	_	_	O
29	2	_	_	O
30	years	_	_	O
31	due	_	_	O
32	to	_	_	O
33	poor	_	_	O
34	accrual	_	_	O
35	.	_	_	O

36	We	_	_	O
37	report	_	_	O
38	health	_	_	O
39	-	_	_	O
40	related	_	_	O
41	quality	_	_	O
42	of	_	_	O
43	life	_	_	O
44	(	_	_	O
45	HRQOL	_	_	O
46	)	_	_	O
47	at	_	_	O
48	a	_	_	O
49	mean	_	_	O
50	of	_	_	O
51	5	_	_	O
52	.	_	_	O

53	3	_	_	O
54	years	_	_	O
55	for	_	_	O
56	168	_	_	O
57	trial	_	_	O
58	-	_	_	O
59	eligible	_	_	O
60	men	_	_	O
61	who	_	_	O
62	either	_	_	O
63	chose	_	_	O
64	or	_	_	O
65	were	_	_	O
66	randomly	_	_	O
67	assigned	_	_	O
68	to	_	_	O
69	RP	_	_	O
70	or	_	_	O
71	BT	_	_	O
72	following	_	_	O
73	a	_	_	O
74	multidisciplinary	_	_	O
75	educational	_	_	O
76	session	_	_	O
77	.	_	_	O

78	After	_	_	O
79	initial	_	_	O
80	lack	_	_	O
81	of	_	_	O
82	accrual	_	_	O
83	,	_	_	O
84	a	_	_	O
85	multidisciplinary	_	_	O
86	educational	_	_	O
87	session	_	_	O
88	was	_	_	O
89	introduced	_	_	O
90	for	_	_	O
91	eligible	_	_	O
92	patients	_	_	O
93	.	_	_	O

94	In	_	_	O
95	all	_	_	O
96	,	_	_	O
97	263	_	_	O
98	men	_	_	O
99	attended	_	_	O
100	47	_	_	O
101	sessions	_	_	O
102	.	_	_	O

103	Of	_	_	O
104	those	_	_	O
105	,	_	_	O
106	34	_	_	O
107	consented	_	_	O
108	to	_	_	O
109	random	_	_	O
110	assignment	_	_	O
111	,	_	_	O
112	62	_	_	O
113	chose	_	_	O
114	RP	_	_	O
115	,	_	_	O
116	and	_	_	O
117	94	_	_	O
118	chose	_	_	O
119	BT	_	_	O
120	.	_	_	O

121	Five	_	_	O
122	years	_	_	O
123	later	_	_	O
124	,	_	_	O
125	these	_	_	O
126	190	_	_	O
127	men	_	_	O
128	underwent	_	_	O
129	HRQOL	_	_	O
130	evaluation	_	_	O
131	by	_	_	O
132	using	_	_	O
133	the	_	_	O
134	cancer	_	_	O
135	-	_	_	O
136	specific	_	_	O
137	50	_	_	O
138	-	_	_	O
139	item	_	_	O
140	Expanded	_	_	O
141	Prostate	_	_	O
142	Cancer	_	_	O
143	Index	_	_	O
144	Composite	_	_	O
145	,	_	_	O
146	the	_	_	O
147	Short	_	_	O
148	Form	_	_	O
149	12	_	_	O
150	Physical	_	_	O
151	Component	_	_	O
152	Score	_	_	O
153	,	_	_	O
154	and	_	_	O
155	Short	_	_	O
156	Form	_	_	O
157	12	_	_	O
158	Mental	_	_	O
159	Component	_	_	O
160	Score	_	_	O
161	.	_	_	O

162	Response	_	_	O
163	rate	_	_	O
164	was	_	_	O
165	88	_	_	O
166	.	_	_	O

167	4	_	_	O
168	%	_	_	O
169	.	_	_	O

170	The	_	_	O
171	Wilcoxon	_	_	O
172	rank	_	_	O
173	sum	_	_	O
174	test	_	_	O
175	was	_	_	O
176	used	_	_	O
177	to	_	_	O
178	compare	_	_	O
179	summary	_	_	O
180	scores	_	_	O
181	between	_	_	O
182	the	_	_	O
183	two	_	_	O
184	interventions	_	_	O
185	.	_	_	O

186	Of	_	_	O
187	168	_	_	O
188	survey	_	_	O
189	responders	_	_	O
190	,	_	_	O
191	60	_	_	O
192	.	_	_	O

193	7	_	_	O
194	%	_	_	O
195	had	_	_	O
196	BT	_	_	O
197	(	_	_	O
198	9	_	_	O
199	.	_	_	O

200	5	_	_	O
201	%	_	_	O
202	randomly	_	_	O
203	assigned	_	_	O
204	)	_	_	O
205	and	_	_	O
206	39	_	_	O
207	.	_	_	O

208	3	_	_	O
209	%	_	_	O
210	had	_	_	O
211	RP	_	_	O
212	(	_	_	O
213	9	_	_	O
214	.	_	_	O

215	5	_	_	O
216	%	_	_	O
217	randomly	_	_	O
218	assigned	_	_	O
219	)	_	_	O
220	.	_	_	O

221	Median	_	_	O
222	age	_	_	O
223	was	_	_	O
224	61	_	_	O
225	.	_	_	O

226	4	_	_	O
227	years	_	_	O
228	for	_	_	O
229	BT	_	_	O
230	and	_	_	O
231	59	_	_	O
232	.	_	_	O

233	4	_	_	O
234	for	_	_	O
235	RP	_	_	O
236	(	_	_	O
237	P	_	_	O
238	=	_	_	O
239	.	_	_	O

240	05	_	_	O
241	)	_	_	O
242	.	_	_	O

243	Median	_	_	O
244	follow	_	_	O
245	-	_	_	O
246	up	_	_	O
247	was	_	_	O
248	5	_	_	O
249	.	_	_	O

250	2	_	_	O
251	years	_	_	O
252	(	_	_	O
253	range	_	_	O
254	,	_	_	O
255	3	_	_	O
256	.	_	_	O

257	2	_	_	O
258	to	_	_	O
259	6	_	_	O
260	.	_	_	O

261	5	_	_	O
262	years	_	_	O
263	)	_	_	O
264	.	_	_	O

265	For	_	_	B-Premise
266	BT	_	_	I-Premise
267	versus	_	_	I-Premise
268	RP	_	_	I-Premise
269	,	_	_	I-Premise
270	there	_	_	I-Premise
271	was	_	_	I-Premise
272	no	_	_	I-Premise
273	difference	_	_	I-Premise
274	in	_	_	I-Premise
275	bowel	_	_	I-Premise
276	or	_	_	I-Premise
277	hormonal	_	_	I-Premise
278	domains	_	_	I-Premise
279	,	_	_	I-Premise
280	but	_	_	O
281	men	_	_	B-Premise
282	treated	_	_	I-Premise
283	with	_	_	I-Premise
284	BT	_	_	I-Premise
285	scored	_	_	I-Premise
286	better	_	_	I-Premise
287	in	_	_	I-Premise
288	urinary	_	_	I-Premise
289	(	_	_	I-Premise
290	91	_	_	I-Premise
291	.	_	_	I-Premise

292	8	_	_	I-Premise
293	v	_	_	I-Premise
294	88	_	_	I-Premise
295	.	_	_	I-Premise

296	1	_	_	I-Premise
297	;	_	_	I-Premise
298	P	_	_	I-Premise
299	=	_	_	I-Premise
300	.	_	_	I-Premise

301	02	_	_	I-Premise
302	)	_	_	I-Premise
303	and	_	_	I-Premise
304	sexual	_	_	I-Premise
305	(	_	_	I-Premise
306	52	_	_	I-Premise
307	.	_	_	I-Premise

308	5	_	_	I-Premise
309	v	_	_	I-Premise
310	39	_	_	I-Premise
311	.	_	_	I-Premise

312	2	_	_	I-Premise
313	;	_	_	I-Premise
314	P	_	_	I-Premise
315	=	_	_	I-Premise
316	.	_	_	I-Premise

317	001	_	_	I-Premise
318	)	_	_	I-Premise
319	domains	_	_	I-Premise
320	,	_	_	I-Premise
321	and	_	_	I-Premise
322	in	_	_	I-Premise
323	patient	_	_	I-Premise
324	satisfaction	_	_	I-Premise
325	(	_	_	I-Premise
326	93	_	_	I-Premise
327	.	_	_	I-Premise

328	6	_	_	I-Premise
329	v	_	_	I-Premise
330	76	_	_	I-Premise
331	.	_	_	I-Premise

332	9	_	_	I-Premise
333	;	_	_	I-Premise
334	P	_	_	I-Premise
335	<	_	_	I-Premise
336	.	_	_	I-Premise

337	001	_	_	I-Premise
338	)	_	_	I-Premise
339	.	_	_	I-Premise

340	Although	_	_	O
341	treatment	_	_	O
342	allocation	_	_	O
343	was	_	_	O
344	random	_	_	O
345	in	_	_	O
346	only	_	_	O
347	19	_	_	O
348	%	_	_	O
349	,	_	_	O
350	all	_	_	O
351	patients	_	_	O
352	received	_	_	O
353	identical	_	_	O
354	information	_	_	O
355	in	_	_	O
356	a	_	_	O
357	multidisciplinary	_	_	O
358	setting	_	_	O
359	before	_	_	O
360	selecting	_	_	O
361	RP	_	_	O
362	,	_	_	O
363	BT	_	_	O
364	,	_	_	O
365	or	_	_	O
366	random	_	_	O
367	assignment	_	_	O
368	.	_	_	O

369	HRQOL	_	_	B-Claim
370	evaluated	_	_	I-Claim
371	3	_	_	I-Claim
372	.	_	_	I-Claim

373	2	_	_	I-Claim
374	to	_	_	I-Claim
375	6	_	_	I-Claim
376	.	_	_	I-Claim

377	5	_	_	I-Claim
378	years	_	_	I-Claim
379	after	_	_	I-Claim
380	treatment	_	_	I-Claim
381	showed	_	_	I-Claim
382	an	_	_	I-Claim
383	advantage	_	_	I-Claim
384	for	_	_	I-Claim
385	BT	_	_	I-Claim
386	in	_	_	I-Claim
387	urinary	_	_	I-Claim
388	and	_	_	I-Claim
389	sexual	_	_	I-Claim
390	domains	_	_	I-Claim
391	and	_	_	I-Claim
392	in	_	_	I-Claim
393	patient	_	_	I-Claim
394	satisfaction	_	_	I-Claim
395	.	_	_	I-Claim


0	Bone	_	_	O
1	-	_	_	O
2	cancer	_	_	O
3	pain	_	_	O
4	is	_	_	O
5	a	_	_	O
6	common	_	_	O
7	and	_	_	O
8	refractory	_	_	O
9	cancer	_	_	O
10	pain	_	_	O
11	.	_	_	O

12	Opioids	_	_	O
13	,	_	_	O
14	on	_	_	O
15	their	_	_	O
16	own	_	_	O
17	,	_	_	O
18	do	_	_	O
19	not	_	_	O
20	control	_	_	O
21	this	_	_	O
22	type	_	_	O
23	of	_	_	O
24	pain	_	_	O
25	well	_	_	O
26	enough	_	_	O
27	,	_	_	O
28	and	_	_	O
29	co	_	_	O
30	-	_	_	O
31	analgesics	_	_	O
32	are	_	_	O
33	necessary	_	_	O
34	.	_	_	O

35	Patients	_	_	O
36	with	_	_	O
37	bone	_	_	O
38	metastasis	_	_	O
39	-	_	_	O
40	related	_	_	O
41	pain	_	_	O
42	at	_	_	O
43	Numeric	_	_	O
44	Rating	_	_	O
45	Scale	_	_	O
46	≥	_	_	O
47	4	_	_	O
48	were	_	_	O
49	enrolled	_	_	O
50	to	_	_	O
51	this	_	_	O
52	randomized	_	_	O
53	placebo	_	_	O
54	-	_	_	O
55	controlled	_	_	O
56	trial	_	_	O
57	.	_	_	O

58	They	_	_	O
59	had	_	_	O
60	also	_	_	O
61	received	_	_	O
62	morphine	_	_	O
63	or	_	_	O
64	transdermal	_	_	O
65	fentanyl	_	_	O
66	patches	_	_	O
67	for	_	_	O
68	at	_	_	O
69	least	_	_	O
70	1	_	_	O
71	week	_	_	O
72	.	_	_	O

73	During	_	_	O
74	the	_	_	O
75	3	_	_	O
76	-	_	_	O
77	day	_	_	O
78	efficacy	_	_	O
79	phase	_	_	O
80	,	_	_	O
81	patients	_	_	O
82	received	_	_	O
83	placebo	_	_	O
84	or	_	_	O
85	1	_	_	O
86	-	_	_	O
87	3	_	_	O
88	tablets	_	_	O
89	of	_	_	O
90	oxycodone	_	_	O
91	/	_	_	O
92	paracetamol	_	_	O
93	(	_	_	O
94	5	_	_	O
95	/	_	_	O
96	325	_	_	O
97	mg	_	_	O
98	)	_	_	O
99	,	_	_	O
100	four	_	_	O
101	times	_	_	O
102	daily	_	_	O
103	for	_	_	O
104	3	_	_	O
105	days	_	_	O
106	.	_	_	O

107	All	_	_	O
108	patients	_	_	O
109	kept	_	_	O
110	a	_	_	O
111	daily	_	_	O
112	pain	_	_	O
113	diary	_	_	O
114	.	_	_	O

115	The	_	_	O
116	primary	_	_	O
117	endpoint	_	_	O
118	was	_	_	O
119	the	_	_	O
120	Pain	_	_	O
121	Intensity	_	_	O
122	Difference	_	_	O
123	(	_	_	O
124	PID	_	_	O
125	)	_	_	O
126	.	_	_	O

127	Secondary	_	_	O
128	endpoints	_	_	O
129	were	_	_	O
130	cases	_	_	O
131	of	_	_	O
132	breakthrough	_	_	O
133	pain	_	_	O
134	and	_	_	O
135	rescue	_	_	O
136	morphine	_	_	O
137	consumption	_	_	O
138	.	_	_	O

139	Additional	_	_	O
140	analyses	_	_	O
141	included	_	_	O
142	the	_	_	O
143	Short	_	_	O
144	Form	_	_	O
145	-	_	_	O
146	6	_	_	O
147	Dimensions	_	_	O
148	(	_	_	O
149	SF	_	_	O
150	-	_	_	O
151	6D	_	_	O
152	)	_	_	O
153	quality	_	_	O
154	-	_	_	O
155	of	_	_	O
156	-	_	_	O
157	life	_	_	O
158	scale	_	_	O
159	and	_	_	O
160	a	_	_	O
161	general	_	_	O
162	impression	_	_	O
163	(	_	_	O
164	GI	_	_	O
165	)	_	_	O
166	of	_	_	O
167	patient	_	_	O
168	satisfaction	_	_	O
169	with	_	_	O
170	treatment	_	_	O
171	at	_	_	O
172	the	_	_	O
173	end	_	_	O
174	of	_	_	O
175	the	_	_	O
176	phase	_	_	O
177	.	_	_	O

178	Of	_	_	O
179	the	_	_	O
180	246	_	_	O
181	patients	_	_	O
182	in	_	_	O
183	the	_	_	O
184	intent	_	_	O
185	-	_	_	O
186	to	_	_	O
187	-	_	_	O
188	treat	_	_	O
189	set	_	_	O
190	,	_	_	O
191	89	_	_	O
192	·	_	_	O
193	4	_	_	O
194	%	_	_	O
195	completed	_	_	O
196	the	_	_	O
197	3	_	_	O
198	-	_	_	O
199	day	_	_	O
200	efficacy	_	_	O
201	phase	_	_	O
202	.	_	_	O

203	PIDs	_	_	B-Premise
204	were	_	_	I-Premise
205	0	_	_	I-Premise
206	·	_	_	I-Premise
207	9	_	_	I-Premise
208	and	_	_	I-Premise
209	0	_	_	I-Premise
210	·	_	_	I-Premise
211	3	_	_	I-Premise
212	in	_	_	I-Premise
213	the	_	_	I-Premise
214	oxycodone	_	_	I-Premise
215	/	_	_	I-Premise
216	paracetamol	_	_	I-Premise
217	and	_	_	I-Premise
218	placebo	_	_	I-Premise
219	groups	_	_	I-Premise
220	respectively	_	_	I-Premise
221	,	_	_	I-Premise
222	on	_	_	I-Premise
223	day	_	_	I-Premise
224	1	_	_	I-Premise
225	(	_	_	I-Premise
226	P	_	_	I-Premise
227	<	_	_	I-Premise
228	0	_	_	I-Premise
229	·	_	_	I-Premise
230	001	_	_	I-Premise
231	)	_	_	I-Premise
232	,	_	_	I-Premise
233	and	_	_	I-Premise
234	1	_	_	I-Premise
235	·	_	_	I-Premise
236	5	_	_	I-Premise
237	and	_	_	I-Premise
238	0	_	_	I-Premise
239	·	_	_	I-Premise
240	3	_	_	I-Premise
241	respectively	_	_	I-Premise
242	on	_	_	I-Premise
243	day	_	_	I-Premise
244	3	_	_	I-Premise
245	(	_	_	I-Premise
246	P	_	_	I-Premise
247	<	_	_	I-Premise
248	0	_	_	I-Premise
249	·	_	_	I-Premise
250	001	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	Thirty	_	_	B-Premise
254	-	_	_	I-Premise
255	eight	_	_	I-Premise
256	patients	_	_	I-Premise
257	in	_	_	I-Premise
258	the	_	_	I-Premise
259	treatment	_	_	I-Premise
260	group	_	_	I-Premise
261	,	_	_	I-Premise
262	and	_	_	I-Premise
263	58	_	_	I-Premise
264	in	_	_	I-Premise
265	the	_	_	I-Premise
266	placebo	_	_	I-Premise
267	group	_	_	I-Premise
268	,	_	_	I-Premise
269	suffered	_	_	I-Premise
270	breakthrough	_	_	I-Premise
271	pain	_	_	I-Premise
272	on	_	_	I-Premise
273	day	_	_	I-Premise
274	3	_	_	I-Premise
275	(	_	_	I-Premise
276	P	_	_	I-Premise
277	<	_	_	I-Premise
278	0	_	_	I-Premise
279	·	_	_	I-Premise
280	001	_	_	I-Premise
281	)	_	_	I-Premise
282	.	_	_	I-Premise

283	The	_	_	B-Premise
284	SF	_	_	I-Premise
285	-	_	_	I-Premise
286	6D	_	_	I-Premise
287	score	_	_	I-Premise
288	decreased	_	_	I-Premise
289	to	_	_	I-Premise
290	21	_	_	I-Premise
291	·	_	_	I-Premise
292	2	_	_	I-Premise
293	±	_	_	I-Premise
294	2	_	_	I-Premise
295	·	_	_	I-Premise
296	5	_	_	I-Premise
297	in	_	_	I-Premise
298	the	_	_	I-Premise
299	oxycodone	_	_	I-Premise
300	/	_	_	I-Premise
301	paracetamol	_	_	I-Premise
302	group	_	_	I-Premise
303	at	_	_	I-Premise
304	the	_	_	I-Premise
305	end	_	_	I-Premise
306	of	_	_	I-Premise
307	the	_	_	I-Premise
308	phase	_	_	I-Premise
309	(	_	_	I-Premise
310	P	_	_	I-Premise
311	=	_	_	I-Premise
312	0	_	_	I-Premise
313	·	_	_	I-Premise
314	001	_	_	I-Premise
315	)	_	_	I-Premise
316	.	_	_	I-Premise

317	In	_	_	B-Premise
318	the	_	_	I-Premise
319	oxycodone	_	_	I-Premise
320	/	_	_	I-Premise
321	paracetamol	_	_	I-Premise
322	group	_	_	I-Premise
323	,	_	_	I-Premise
324	67	_	_	I-Premise
325	%	_	_	I-Premise
326	rated	_	_	I-Premise
327	GI	_	_	I-Premise
328	as	_	_	I-Premise
329	good	_	_	I-Premise
330	,	_	_	I-Premise
331	very	_	_	I-Premise
332	good	_	_	I-Premise
333	,	_	_	I-Premise
334	or	_	_	I-Premise
335	excellent	_	_	I-Premise
336	.	_	_	I-Premise

337	Patients	_	_	B-Claim
338	with	_	_	I-Claim
339	bone	_	_	I-Claim
340	-	_	_	I-Claim
341	cancer	_	_	I-Claim
342	pain	_	_	I-Claim
343	,	_	_	I-Claim
344	already	_	_	I-Claim
345	on	_	_	I-Claim
346	opioids	_	_	I-Claim
347	,	_	_	I-Claim
348	obtain	_	_	I-Claim
349	clinically	_	_	I-Claim
350	important	_	_	I-Claim
351	,	_	_	I-Claim
352	additional	_	_	I-Claim
353	pain	_	_	I-Claim
354	-	_	_	I-Claim
355	control	_	_	I-Claim
356	,	_	_	I-Claim
357	with	_	_	I-Claim
358	regular	_	_	I-Claim
359	oxycodone	_	_	I-Claim
360	/	_	_	I-Claim
361	paracetamol	_	_	I-Claim
362	dosing	_	_	I-Claim
363	.	_	_	I-Claim


0	We	_	_	O
1	conducted	_	_	O
2	a	_	_	O
3	prospective	_	_	O
4	,	_	_	O
5	randomized	_	_	O
6	,	_	_	O
7	multicentre	_	_	O
8	clinical	_	_	O
9	trial	_	_	O
10	comparing	_	_	O
11	the	_	_	O
12	effects	_	_	O
13	and	_	_	O
14	costs	_	_	O
15	of	_	_	O
16	GM	_	_	O
17	-	_	_	O
18	CSF	_	_	O
19	as	_	_	O
20	an	_	_	O
21	adjunct	_	_	O
22	to	_	_	O
23	intensive	_	_	O
24	chemotherapy	_	_	O
25	in	_	_	O
26	elderly	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	acute	_	_	O
30	myeloid	_	_	O
31	leukaemia	_	_	O
32	(	_	_	O
33	AML	_	_	O
34	)	_	_	O
35	.	_	_	O

36	The	_	_	O
37	patients	_	_	O
38	were	_	_	O
39	randomized	_	_	O
40	to	_	_	O
41	either	_	_	O
42	daunomycin	_	_	O
43	-	_	_	O
44	cytosine	_	_	O
45	arabinoside	_	_	O
46	(	_	_	O
47	control	_	_	O
48	arm	_	_	O
49	:	_	_	O
50	n	_	_	O
51	=	_	_	O
52	161	_	_	O
53	)	_	_	O
54	or	_	_	O
55	daunomycin	_	_	O
56	-	_	_	O
57	cytosine	_	_	O
58	arabinoside	_	_	O
59	with	_	_	O
60	GM	_	_	O
61	-	_	_	O
62	CSF	_	_	O
63	(	_	_	O
64	GM	_	_	O
65	-	_	_	O
66	CSF	_	_	O
67	arm	_	_	O
68	:	_	_	O
69	n	_	_	O
70	=	_	_	O
71	157	_	_	O
72	)	_	_	O
73	.	_	_	O

74	The	_	_	O
75	primary	_	_	O
76	end	_	_	O
77	-	_	_	O
78	point	_	_	O
79	was	_	_	O
80	the	_	_	O
81	effect	_	_	O
82	of	_	_	O
83	GM	_	_	O
84	-	_	_	O
85	CSF	_	_	O
86	on	_	_	O
87	the	_	_	O
88	percentage	_	_	O
89	of	_	_	O
90	complete	_	_	O
91	remissions	_	_	O
92	(	_	_	O
93	CR	_	_	O
94	)	_	_	O
95	.	_	_	O

96	Survival	_	_	O
97	duration	_	_	O
98	,	_	_	O
99	disease	_	_	O
100	-	_	_	O
101	free	_	_	O
102	survival	_	_	O
103	,	_	_	O
104	quality	_	_	O
105	of	_	_	O
106	life	_	_	O
107	and	_	_	O
108	costs	_	_	O
109	were	_	_	O
110	evaluated	_	_	O
111	separately	_	_	O
112	.	_	_	O

113	CR	_	_	B-Premise
114	after	_	_	I-Premise
115	remission	_	_	I-Premise
116	induction	_	_	I-Premise
117	treatment	_	_	I-Premise
118	was	_	_	I-Premise
119	achieved	_	_	I-Premise
120	in	_	_	I-Premise
121	55	_	_	I-Premise
122	%	_	_	I-Premise
123	of	_	_	I-Premise
124	the	_	_	I-Premise
125	patients	_	_	I-Premise
126	in	_	_	I-Premise
127	the	_	_	I-Premise
128	control	_	_	I-Premise
129	group	_	_	I-Premise
130	and	_	_	I-Premise
131	in	_	_	I-Premise
132	56	_	_	I-Premise
133	%	_	_	I-Premise
134	of	_	_	I-Premise
135	the	_	_	I-Premise
136	patients	_	_	I-Premise
137	in	_	_	I-Premise
138	the	_	_	I-Premise
139	GM	_	_	I-Premise
140	-	_	_	I-Premise
141	CSF	_	_	I-Premise
142	group	_	_	I-Premise
143	(	_	_	I-Premise
144	P	_	_	I-Premise
145	=	_	_	I-Premise
146	NS	_	_	I-Premise
147	)	_	_	I-Premise
148	.	_	_	I-Premise

149	The	_	_	B-Premise
150	duration	_	_	I-Premise
151	of	_	_	I-Premise
152	survival	_	_	I-Premise
153	and	_	_	I-Premise
154	disease	_	_	I-Premise
155	-	_	_	I-Premise
156	free	_	_	I-Premise
157	survival	_	_	I-Premise
158	at	_	_	I-Premise
159	2	_	_	I-Premise
160	years	_	_	I-Premise
161	after	_	_	I-Premise
162	randomization	_	_	I-Premise
163	were	_	_	I-Premise
164	estimated	_	_	I-Premise
165	at	_	_	I-Premise
166	22	_	_	I-Premise
167	%	_	_	I-Premise
168	and	_	_	I-Premise
169	19	_	_	I-Premise
170	%	_	_	I-Premise
171	for	_	_	I-Premise
172	the	_	_	I-Premise
173	control	_	_	I-Premise
174	group	_	_	I-Premise
175	and	_	_	I-Premise
176	22	_	_	I-Premise
177	%	_	_	I-Premise
178	and	_	_	I-Premise
179	14	_	_	I-Premise
180	%	_	_	I-Premise
181	for	_	_	I-Premise
182	the	_	_	I-Premise
183	GM	_	_	I-Premise
184	-	_	_	I-Premise
185	CSF	_	_	I-Premise
186	group	_	_	I-Premise
187	(	_	_	I-Premise
188	P	_	_	I-Premise
189	=	_	_	I-Premise
190	NS	_	_	I-Premise
191	)	_	_	I-Premise
192	.	_	_	I-Premise

193	Considering	_	_	B-Premise
194	the	_	_	I-Premise
195	short	_	_	I-Premise
196	-	_	_	I-Premise
197	term	_	_	I-Premise
198	quality	_	_	I-Premise
199	of	_	_	I-Premise
200	life	_	_	I-Premise
201	,	_	_	I-Premise
202	the	_	_	I-Premise
203	administration	_	_	I-Premise
204	of	_	_	I-Premise
205	GM	_	_	I-Premise
206	-	_	_	I-Premise
207	CSF	_	_	I-Premise
208	resulted	_	_	I-Premise
209	in	_	_	I-Premise
210	more	_	_	I-Premise
211	problems	_	_	I-Premise
212	with	_	_	I-Premise
213	regard	_	_	I-Premise
214	to	_	_	I-Premise
215	depressed	_	_	I-Premise
216	mood	_	_	I-Premise
217	,	_	_	I-Premise
218	diarrhoea	_	_	I-Premise
219	and	_	_	I-Premise
220	rash	_	_	I-Premise
221	/	_	_	I-Premise
222	eczema	_	_	I-Premise
223	.	_	_	I-Premise

224	With	_	_	B-Premise
225	regard	_	_	I-Premise
226	to	_	_	I-Premise
227	the	_	_	I-Premise
228	long	_	_	I-Premise
229	-	_	_	I-Premise
230	term	_	_	I-Premise
231	quality	_	_	I-Premise
232	of	_	_	I-Premise
233	life	_	_	I-Premise
234	there	_	_	I-Premise
235	were	_	_	I-Premise
236	no	_	_	I-Premise
237	significant	_	_	I-Premise
238	differences	_	_	I-Premise
239	between	_	_	I-Premise
240	the	_	_	I-Premise
241	two	_	_	I-Premise
242	groups	_	_	I-Premise
243	.	_	_	I-Premise

244	The	_	_	B-Premise
245	average	_	_	I-Premise
246	costs	_	_	I-Premise
247	of	_	_	I-Premise
248	the	_	_	I-Premise
249	primary	_	_	I-Premise
250	treatment	_	_	I-Premise
251	were	_	_	I-Premise
252	higher	_	_	I-Premise
253	in	_	_	I-Premise
254	GM	_	_	I-Premise
255	-	_	_	I-Premise
256	CSF	_	_	I-Premise
257	-	_	_	I-Premise
258	treated	_	_	I-Premise
259	patients	_	_	I-Premise
260	than	_	_	I-Premise
261	in	_	_	I-Premise
262	the	_	_	I-Premise
263	control	_	_	I-Premise
264	group	_	_	I-Premise
265	,	_	_	I-Premise
266	i	_	_	I-Premise
267	.	_	_	I-Premise

268	e	_	_	I-Premise
269	.	_	_	I-Premise

270	US	_	_	I-Premise
271	$	_	_	I-Premise
272	40782	_	_	I-Premise
273	and	_	_	I-Premise
274	US	_	_	I-Premise
275	$	_	_	I-Premise
276	34465	_	_	I-Premise
277	,	_	_	I-Premise
278	respectively	_	_	I-Premise
279	(	_	_	I-Premise
280	P	_	_	I-Premise
281	<	_	_	I-Premise
282	0	_	_	I-Premise
283	.	_	_	I-Premise

284	01	_	_	I-Premise
285	)	_	_	I-Premise
286	.	_	_	I-Premise

287	The	_	_	B-Premise
288	costs	_	_	I-Premise
289	during	_	_	I-Premise
290	the	_	_	I-Premise
291	follow	_	_	I-Premise
292	-	_	_	I-Premise
293	up	_	_	I-Premise
294	period	_	_	I-Premise
295	did	_	_	I-Premise
296	not	_	_	I-Premise
297	differ	_	_	I-Premise
298	between	_	_	I-Premise
299	the	_	_	I-Premise
300	two	_	_	I-Premise
301	groups	_	_	I-Premise
302	.	_	_	I-Premise

303	The	_	_	B-Claim
304	results	_	_	I-Claim
305	of	_	_	I-Claim
306	this	_	_	I-Claim
307	randomized	_	_	I-Claim
308	clinical	_	_	I-Claim
309	trial	_	_	I-Claim
310	indicate	_	_	I-Claim
311	that	_	_	I-Claim
312	daunomycin	_	_	I-Claim
313	-	_	_	I-Claim
314	cytosine	_	_	I-Claim
315	arabinoside	_	_	I-Claim
316	plus	_	_	I-Claim
317	GM	_	_	I-Claim
318	-	_	_	I-Claim
319	CSF	_	_	I-Claim
320	is	_	_	I-Claim
321	not	_	_	I-Claim
322	a	_	_	I-Claim
323	cost	_	_	I-Claim
324	-	_	_	I-Claim
325	effective	_	_	I-Claim
326	treatment	_	_	I-Claim
327	strategy	_	_	I-Claim
328	when	_	_	I-Claim
329	compared	_	_	I-Claim
330	with	_	_	I-Claim
331	daunomycin	_	_	I-Claim
332	-	_	_	I-Claim
333	cytosine	_	_	I-Claim
334	arabinoside	_	_	I-Claim
335	alone	_	_	I-Claim
336	.	_	_	I-Claim


0	Numerous	_	_	O
1	studies	_	_	O
2	have	_	_	O
3	examined	_	_	O
4	the	_	_	O
5	comorbidity	_	_	O
6	of	_	_	O
7	depression	_	_	O
8	with	_	_	O
9	cancer	_	_	O
10	,	_	_	O
11	and	_	_	O
12	some	_	_	O
13	have	_	_	O
14	indicated	_	_	O
15	that	_	_	O
16	depression	_	_	O
17	may	_	_	O
18	be	_	_	O
19	associated	_	_	O
20	with	_	_	O
21	cancer	_	_	O
22	progression	_	_	O
23	or	_	_	O
24	survival	_	_	O
25	.	_	_	O

26	However	_	_	O
27	,	_	_	O
28	few	_	_	O
29	studies	_	_	O
30	have	_	_	O
31	assessed	_	_	O
32	whether	_	_	O
33	changes	_	_	O
34	in	_	_	O
35	depression	_	_	O
36	symptoms	_	_	O
37	are	_	_	O
38	associated	_	_	O
39	with	_	_	O
40	survival	_	_	O
41	.	_	_	O

42	In	_	_	O
43	a	_	_	O
44	secondary	_	_	O
45	analysis	_	_	O
46	of	_	_	O
47	a	_	_	O
48	randomized	_	_	O
49	trial	_	_	O
50	of	_	_	O
51	supportive	_	_	O
52	-	_	_	O
53	expressive	_	_	O
54	group	_	_	O
55	therapy	_	_	O
56	,	_	_	O
57	125	_	_	O
58	women	_	_	O
59	with	_	_	O
60	metastatic	_	_	O
61	breast	_	_	O
62	cancer	_	_	O
63	(	_	_	O
64	MBC	_	_	O
65	)	_	_	O
66	completed	_	_	O
67	a	_	_	O
68	depression	_	_	O
69	symptom	_	_	O
70	measure	_	_	O
71	(	_	_	O
72	Center	_	_	O
73	for	_	_	O
74	Epidemiologic	_	_	O
75	Studies	_	_	O
76	-	_	_	O
77	Depression	_	_	O
78	Scale	_	_	O
79	[	_	_	O
80	CES	_	_	O
81	-	_	_	O
82	D	_	_	O
83	]	_	_	O
84	)	_	_	O
85	at	_	_	O
86	baseline	_	_	O
87	and	_	_	O
88	were	_	_	O
89	randomly	_	_	O
90	assigned	_	_	O
91	to	_	_	O
92	a	_	_	O
93	treatment	_	_	O
94	group	_	_	O
95	or	_	_	O
96	to	_	_	O
97	a	_	_	O
98	control	_	_	O
99	group	_	_	O
100	that	_	_	O
101	received	_	_	O
102	educational	_	_	O
103	materials	_	_	O
104	.	_	_	O

105	At	_	_	O
106	baseline	_	_	O
107	and	_	_	O
108	three	_	_	O
109	follow	_	_	O
110	-	_	_	O
111	up	_	_	O
112	points	_	_	O
113	,	_	_	O
114	101	_	_	O
115	of	_	_	O
116	125	_	_	O
117	women	_	_	O
118	completed	_	_	O
119	a	_	_	O
120	depression	_	_	O
121	symptom	_	_	O
122	measure	_	_	O
123	.	_	_	O

124	We	_	_	O
125	used	_	_	O
126	these	_	_	O
127	data	_	_	O
128	in	_	_	O
129	a	_	_	O
130	Cox	_	_	O
131	proportional	_	_	O
132	hazards	_	_	O
133	analysis	_	_	O
134	to	_	_	O
135	examine	_	_	O
136	whether	_	_	O
137	decreasing	_	_	O
138	depression	_	_	O
139	symptoms	_	_	O
140	over	_	_	O
141	the	_	_	O
142	first	_	_	O
143	year	_	_	O
144	of	_	_	O
145	the	_	_	O
146	study	_	_	O
147	(	_	_	O
148	the	_	_	O
149	length	_	_	O
150	of	_	_	O
151	the	_	_	O
152	intervention	_	_	O
153	)	_	_	O
154	would	_	_	O
155	be	_	_	O
156	associated	_	_	O
157	with	_	_	O
158	longer	_	_	O
159	survival	_	_	O
160	.	_	_	O

161	Median	_	_	B-Premise
162	survival	_	_	I-Premise
163	time	_	_	I-Premise
164	was	_	_	I-Premise
165	53	_	_	I-Premise
166	.	_	_	I-Premise

167	6	_	_	I-Premise
168	months	_	_	I-Premise
169	for	_	_	I-Premise
170	women	_	_	I-Premise
171	with	_	_	I-Premise
172	decreasing	_	_	I-Premise
173	CES	_	_	I-Premise
174	-	_	_	I-Premise
175	D	_	_	I-Premise
176	scores	_	_	I-Premise
177	over	_	_	I-Premise
178	1	_	_	I-Premise
179	year	_	_	I-Premise
180	and	_	_	I-Premise
181	25	_	_	I-Premise
182	.	_	_	I-Premise

183	1	_	_	I-Premise
184	months	_	_	I-Premise
185	for	_	_	I-Premise
186	women	_	_	I-Premise
187	with	_	_	I-Premise
188	increasing	_	_	I-Premise
189	CES	_	_	I-Premise
190	-	_	_	I-Premise
191	D	_	_	I-Premise
192	scores	_	_	I-Premise
193	.	_	_	I-Premise

194	There	_	_	B-Premise
195	was	_	_	I-Premise
196	a	_	_	I-Premise
197	significant	_	_	I-Premise
198	effect	_	_	I-Premise
199	of	_	_	I-Premise
200	change	_	_	I-Premise
201	in	_	_	I-Premise
202	CES	_	_	I-Premise
203	-	_	_	I-Premise
204	D	_	_	I-Premise
205	over	_	_	I-Premise
206	the	_	_	I-Premise
207	first	_	_	I-Premise
208	year	_	_	I-Premise
209	on	_	_	I-Premise
210	survival	_	_	I-Premise
211	out	_	_	I-Premise
212	to	_	_	I-Premise
213	14	_	_	I-Premise
214	years	_	_	I-Premise
215	(	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	.	_	_	I-Premise

219	007	_	_	I-Premise
220	)	_	_	I-Premise
221	but	_	_	B-Premise
222	no	_	_	I-Premise
223	significant	_	_	I-Premise
224	interaction	_	_	I-Premise
225	between	_	_	I-Premise
226	treatment	_	_	I-Premise
227	condition	_	_	I-Premise
228	and	_	_	I-Premise
229	CES	_	_	I-Premise
230	-	_	_	I-Premise
231	D	_	_	I-Premise
232	change	_	_	I-Premise
233	on	_	_	I-Premise
234	survival	_	_	I-Premise
235	.	_	_	I-Premise

236	Neither	_	_	O
237	demographic	_	_	O
238	nor	_	_	O
239	medical	_	_	O
240	variables	_	_	O
241	explained	_	_	O
242	this	_	_	O
243	association	_	_	O
244	.	_	_	O

245	Decreasing	_	_	B-Claim
246	depression	_	_	I-Claim
247	symptoms	_	_	I-Claim
248	over	_	_	I-Claim
249	the	_	_	I-Claim
250	first	_	_	I-Claim
251	year	_	_	I-Claim
252	were	_	_	I-Claim
253	associated	_	_	I-Claim
254	with	_	_	I-Claim
255	longer	_	_	I-Claim
256	subsequent	_	_	I-Claim
257	survival	_	_	I-Claim
258	for	_	_	I-Claim
259	women	_	_	I-Claim
260	with	_	_	I-Claim
261	MBC	_	_	I-Claim
262	in	_	_	I-Claim
263	this	_	_	I-Claim
264	sample	_	_	I-Claim
265	.	_	_	I-Claim

266	Further	_	_	B-Claim
267	research	_	_	I-Claim
268	is	_	_	I-Claim
269	necessary	_	_	I-Claim
270	to	_	_	I-Claim
271	confirm	_	_	I-Claim
272	this	_	_	I-Claim
273	hypothesis	_	_	I-Claim
274	in	_	_	I-Claim
275	other	_	_	I-Claim
276	samples	_	_	I-Claim
277	,	_	_	I-Claim
278	and	_	_	I-Claim
279	causation	_	_	I-Claim
280	cannot	_	_	I-Claim
281	be	_	_	I-Claim
282	assumed	_	_	I-Claim
283	based	_	_	I-Claim
284	on	_	_	I-Claim
285	this	_	_	I-Claim
286	analysis	_	_	I-Claim
287	.	_	_	I-Claim


0	Few	_	_	O
1	intervention	_	_	O
2	programs	_	_	O
3	assist	_	_	O
4	patients	_	_	O
5	and	_	_	O
6	their	_	_	O
7	family	_	_	O
8	caregivers	_	_	O
9	to	_	_	O
10	manage	_	_	O
11	advanced	_	_	O
12	cancer	_	_	O
13	and	_	_	O
14	maintain	_	_	O
15	their	_	_	O
16	quality	_	_	O
17	of	_	_	O
18	life	_	_	O
19	(	_	_	O
20	QOL	_	_	O
21	)	_	_	O
22	.	_	_	O

23	This	_	_	O
24	study	_	_	O
25	examined	_	_	O
26	(	_	_	O
27	i	_	_	O
28	)	_	_	O
29	whether	_	_	O
30	patient	_	_	O
31	-	_	_	O
32	caregiver	_	_	O
33	dyads	_	_	O
34	(	_	_	O
35	i	_	_	O
36	.	_	_	O

37	e	_	_	O
38	.	_	_	O

39	,	_	_	O
40	pairs	_	_	O
41	)	_	_	O
42	randomly	_	_	O
43	assigned	_	_	O
44	to	_	_	O
45	a	_	_	O
46	brief	_	_	O
47	or	_	_	O
48	extensive	_	_	O
49	dyadic	_	_	O
50	intervention	_	_	O
51	(	_	_	O
52	the	_	_	O
53	FOCUS	_	_	O
54	Program	_	_	O
55	)	_	_	O
56	had	_	_	O
57	better	_	_	O
58	outcomes	_	_	O
59	than	_	_	O
60	dyads	_	_	O
61	randomly	_	_	O
62	assigned	_	_	O
63	to	_	_	O
64	usual	_	_	O
65	care	_	_	O
66	and	_	_	O
67	(	_	_	O
68	ii	_	_	O
69	)	_	_	O
70	whether	_	_	O
71	patients	_	_	O
72	'	_	_	O
73	risk	_	_	O
74	for	_	_	O
75	distress	_	_	O
76	and	_	_	O
77	other	_	_	O
78	factors	_	_	O
79	moderated	_	_	O
80	the	_	_	O
81	effect	_	_	O
82	of	_	_	O
83	the	_	_	O
84	brief	_	_	O
85	or	_	_	O
86	extensive	_	_	O
87	program	_	_	O
88	on	_	_	O
89	outcomes	_	_	O
90	.	_	_	O

91	Advanced	_	_	O
92	cancer	_	_	O
93	patients	_	_	O
94	and	_	_	O
95	their	_	_	O
96	caregivers	_	_	O
97	(	_	_	O
98	N	_	_	O
99	=	_	_	O
100	484	_	_	O
101	dyads	_	_	O
102	)	_	_	O
103	were	_	_	O
104	stratified	_	_	O
105	by	_	_	O
106	patients	_	_	O
107	'	_	_	O
108	baseline	_	_	O
109	risk	_	_	O
110	for	_	_	O
111	distress	_	_	O
112	(	_	_	O
113	high	_	_	O
114	versus	_	_	O
115	low	_	_	O
116	)	_	_	O
117	,	_	_	O
118	cancer	_	_	O
119	type	_	_	O
120	(	_	_	O
121	lung	_	_	O
122	,	_	_	O
123	colorectal	_	_	O
124	,	_	_	O
125	breast	_	_	O
126	,	_	_	O
127	or	_	_	O
128	prostate	_	_	O
129	)	_	_	O
130	,	_	_	O
131	and	_	_	O
132	research	_	_	O
133	site	_	_	O
134	and	_	_	O
135	then	_	_	O
136	randomly	_	_	O
137	assigned	_	_	O
138	to	_	_	O
139	a	_	_	O
140	brief	_	_	O
141	(	_	_	O
142	three	_	_	O
143	-	_	_	O
144	session	_	_	O
145	)	_	_	O
146	or	_	_	O
147	extensive	_	_	O
148	(	_	_	O
149	six	_	_	O
150	-	_	_	O
151	session	_	_	O
152	)	_	_	O
153	intervention	_	_	O
154	or	_	_	O
155	control	_	_	O
156	.	_	_	O

157	The	_	_	O
158	interventions	_	_	O
159	offered	_	_	O
160	dyads	_	_	O
161	information	_	_	O
162	and	_	_	O
163	support	_	_	O
164	.	_	_	O

165	Intermediary	_	_	O
166	outcomes	_	_	O
167	were	_	_	O
168	appraisals	_	_	O
169	(	_	_	O
170	i	_	_	O
171	.	_	_	O

172	e	_	_	O
173	.	_	_	O

174	,	_	_	O
175	appraisal	_	_	O
176	of	_	_	O
177	illness	_	_	O
178	/	_	_	O
179	caregiving	_	_	O
180	,	_	_	O
181	uncertainty	_	_	O
182	,	_	_	O
183	and	_	_	O
184	hopelessness	_	_	O
185	)	_	_	O
186	and	_	_	O
187	resources	_	_	O
188	(	_	_	O
189	i	_	_	O
190	.	_	_	O

191	e	_	_	O
192	.	_	_	O

193	,	_	_	O
194	coping	_	_	O
195	,	_	_	O
196	interpersonal	_	_	O
197	relationships	_	_	O
198	,	_	_	O
199	and	_	_	O
200	self	_	_	O
201	-	_	_	O
202	efficacy	_	_	O
203	)	_	_	O
204	.	_	_	O

205	The	_	_	O
206	primary	_	_	O
207	outcome	_	_	O
208	was	_	_	O
209	QOL	_	_	O
210	.	_	_	O

211	Data	_	_	O
212	were	_	_	O
213	collected	_	_	O
214	prior	_	_	O
215	to	_	_	O
216	intervention	_	_	O
217	and	_	_	O
218	post	_	_	O
219	-	_	_	O
220	intervention	_	_	O
221	(	_	_	O
222	3	_	_	O
223	and	_	_	O
224	6	_	_	O
225	months	_	_	O
226	from	_	_	O
227	baseline	_	_	O
228	)	_	_	O
229	.	_	_	O

230	The	_	_	O
231	final	_	_	O
232	sample	_	_	O
233	was	_	_	O
234	302	_	_	O
235	dyads	_	_	O
236	.	_	_	O

237	Repeated	_	_	O
238	measures	_	_	O
239	MANCOVA	_	_	O
240	was	_	_	O
241	used	_	_	O
242	to	_	_	O
243	evaluate	_	_	O
244	outcomes	_	_	O
245	.	_	_	O

246	Significant	_	_	B-Premise
247	group	_	_	I-Premise
248	by	_	_	I-Premise
249	time	_	_	I-Premise
250	interactions	_	_	I-Premise
251	showed	_	_	I-Premise
252	that	_	_	I-Premise
253	there	_	_	I-Premise
254	was	_	_	I-Premise
255	an	_	_	I-Premise
256	improvement	_	_	I-Premise
257	in	_	_	I-Premise
258	dyads	_	_	I-Premise
259	'	_	_	I-Premise
260	coping	_	_	I-Premise
261	(	_	_	I-Premise
262	p	_	_	I-Premise
263	<	_	_	I-Premise
264	0	_	_	I-Premise
265	.	_	_	I-Premise

266	05	_	_	I-Premise
267	)	_	_	I-Premise
268	,	_	_	I-Premise
269	self	_	_	I-Premise
270	-	_	_	I-Premise
271	efficacy	_	_	I-Premise
272	(	_	_	I-Premise
273	p	_	_	I-Premise
274	<	_	_	I-Premise
275	0	_	_	I-Premise
276	.	_	_	I-Premise

277	05	_	_	I-Premise
278	)	_	_	I-Premise
279	,	_	_	I-Premise
280	and	_	_	I-Premise
281	social	_	_	I-Premise
282	QOL	_	_	I-Premise
283	(	_	_	I-Premise
284	p	_	_	I-Premise
285	<	_	_	I-Premise
286	0	_	_	I-Premise
287	.	_	_	I-Premise

288	01	_	_	I-Premise
289	)	_	_	I-Premise
290	and	_	_	I-Premise
291	in	_	_	I-Premise
292	caregivers	_	_	I-Premise
293	'	_	_	I-Premise
294	emotional	_	_	I-Premise
295	QOL	_	_	I-Premise
296	(	_	_	I-Premise
297	p	_	_	I-Premise
298	<	_	_	I-Premise
299	0	_	_	I-Premise
300	.	_	_	I-Premise

301	05	_	_	I-Premise
302	)	_	_	I-Premise
303	.	_	_	I-Premise

304	Effects	_	_	O
305	varied	_	_	O
306	by	_	_	O
307	intervention	_	_	O
308	dose	_	_	O
309	.	_	_	O

310	Most	_	_	O
311	effects	_	_	O
312	were	_	_	O
313	found	_	_	O
314	at	_	_	O
315	3	_	_	O
316	months	_	_	O
317	only	_	_	O
318	.	_	_	O

319	Risk	_	_	B-Premise
320	for	_	_	I-Premise
321	distress	_	_	I-Premise
322	accounted	_	_	I-Premise
323	for	_	_	I-Premise
324	very	_	_	I-Premise
325	few	_	_	I-Premise
326	moderation	_	_	I-Premise
327	effects	_	_	I-Premise
328	.	_	_	I-Premise

329	Both	_	_	B-Premise
330	brief	_	_	I-Premise
331	and	_	_	I-Premise
332	extensive	_	_	I-Premise
333	programs	_	_	I-Premise
334	had	_	_	I-Premise
335	positive	_	_	I-Premise
336	outcomes	_	_	I-Premise
337	for	_	_	I-Premise
338	patient	_	_	I-Premise
339	-	_	_	I-Premise
340	caregiver	_	_	I-Premise
341	dyads	_	_	I-Premise
342	,	_	_	I-Premise
343	but	_	_	B-Premise
344	few	_	_	I-Premise
345	sustained	_	_	I-Premise
346	effects	_	_	I-Premise
347	.	_	_	I-Premise

348	Patient	_	_	B-Claim
349	-	_	_	I-Claim
350	caregiver	_	_	I-Claim
351	dyads	_	_	I-Claim
352	benefit	_	_	I-Claim
353	when	_	_	I-Claim
354	viewed	_	_	I-Claim
355	as	_	_	I-Claim
356	the	_	_	I-Claim
357	'	_	_	I-Claim
358	unit	_	_	I-Claim
359	of	_	_	I-Claim
360	care	_	_	I-Claim
361	'	_	_	I-Claim
362	.	_	_	I-Claim


0	Few	_	_	O
1	randomized	_	_	O
2	trials	_	_	O
3	have	_	_	O
4	compared	_	_	O
5	the	_	_	O
6	survival	_	_	O
7	benefit	_	_	O
8	of	_	_	O
9	interferon	_	_	O
10	-	_	_	O
11	alfa	_	_	O
12	over	_	_	O
13	controls	_	_	O
14	in	_	_	O
15	metastatic	_	_	O
16	renal	_	_	O
17	cell	_	_	O
18	carcinoma	_	_	O
19	,	_	_	O
20	and	_	_	O
21	none	_	_	O
22	has	_	_	O
23	been	_	_	O
24	performed	_	_	O
25	using	_	_	O
26	interleukin	_	_	O
27	-	_	_	O
28	2	_	_	O
29	.	_	_	O

30	The	_	_	O
31	Programme	_	_	O
32	Etude	_	_	O
33	Rein	_	_	O
34	Cytokines	_	_	O
35	(	_	_	O
36	PERCY	_	_	O
37	)	_	_	O
38	Quattro	_	_	O
39	trial	_	_	O
40	was	_	_	O
41	designed	_	_	O
42	to	_	_	O
43	evaluate	_	_	O
44	both	_	_	O
45	cytokines	_	_	O
46	for	_	_	O
47	their	_	_	O
48	survival	_	_	O
49	benefit	_	_	O
50	to	_	_	O
51	intermediate	_	_	O
52	prognosis	_	_	O
53	patients	_	_	O
54	,	_	_	O
55	who	_	_	O
56	represent	_	_	O
57	the	_	_	O
58	majority	_	_	O
59	of	_	_	O
60	candidates	_	_	O
61	for	_	_	O
62	these	_	_	O
63	treatments	_	_	O
64	.	_	_	O

65	Patients	_	_	O
66	were	_	_	O
67	randomized	_	_	O
68	in	_	_	O
69	a	_	_	O
70	2	_	_	O
71	-	_	_	O
72	by	_	_	O
73	-	_	_	O
74	2	_	_	O
75	factorial	_	_	O
76	design	_	_	O
77	to	_	_	O
78	medroxyprogesterone	_	_	O
79	acetate	_	_	O
80	200	_	_	O
81	mg	_	_	O
82	daily	_	_	O
83	,	_	_	O
84	interferon	_	_	O
85	-	_	_	O
86	alfa	_	_	O
87	9	_	_	O
88	million	_	_	O
89	IU	_	_	O
90	3	_	_	O
91	times	_	_	O
92	a	_	_	O
93	week	_	_	O
94	,	_	_	O
95	subcutaneous	_	_	O
96	interleukin	_	_	O
97	-	_	_	O
98	2	_	_	O
99	9	_	_	O
100	million	_	_	O
101	IU	_	_	O
102	daily	_	_	O
103	,	_	_	O
104	or	_	_	O
105	a	_	_	O
106	combination	_	_	O
107	of	_	_	O
108	both	_	_	O
109	cytokines	_	_	O
110	.	_	_	O

111	Tumor	_	_	O
112	response	_	_	O
113	was	_	_	O
114	evaluated	_	_	O
115	at	_	_	O
116	Week	_	_	O
117	12	_	_	O
118	and	_	_	O
119	Month	_	_	O
120	6	_	_	O
121	;	_	_	O
122	progression	_	_	O
123	-	_	_	O
124	free	_	_	O
125	patients	_	_	O
126	received	_	_	O
127	further	_	_	O
128	identical	_	_	O
129	treatment	_	_	O
130	for	_	_	O
131	a	_	_	O
132	maximum	_	_	O
133	of	_	_	O
134	3	_	_	O
135	additional	_	_	O
136	months	_	_	O
137	.	_	_	O

138	Primary	_	_	O
139	endpoint	_	_	O
140	was	_	_	O
141	overall	_	_	O
142	survival	_	_	O
143	;	_	_	O
144	secondary	_	_	O
145	endpoints	_	_	O
146	were	_	_	O
147	disease	_	_	O
148	-	_	_	O
149	free	_	_	O
150	survival	_	_	O
151	,	_	_	O
152	response	_	_	O
153	rate	_	_	O
154	,	_	_	O
155	toxicity	_	_	O
156	,	_	_	O
157	and	_	_	O
158	quality	_	_	O
159	of	_	_	O
160	life	_	_	O
161	.	_	_	O

162	Survival	_	_	O
163	was	_	_	O
164	analyzed	_	_	O
165	on	_	_	O
166	an	_	_	O
167	intent	_	_	O
168	-	_	_	O
169	to	_	_	O
170	-	_	_	O
171	treat	_	_	O
172	basis	_	_	O
173	.	_	_	O

174	From	_	_	O
175	January	_	_	O
176	2000	_	_	O
177	to	_	_	O
178	July	_	_	O
179	2004	_	_	O
180	,	_	_	O
181	492	_	_	O
182	patients	_	_	O
183	were	_	_	O
184	enrolled	_	_	O
185	.	_	_	O

186	Analysis	_	_	O
187	was	_	_	O
188	performed	_	_	O
189	after	_	_	O
190	a	_	_	O
191	29	_	_	O
192	.	_	_	O

193	2	_	_	O
194	-	_	_	O
195	month	_	_	O
196	median	_	_	O
197	follow	_	_	O
198	-	_	_	O
199	up	_	_	O
200	(	_	_	O
201	range	_	_	O
202	,	_	_	O
203	0	_	_	O
204	months	_	_	O
205	to	_	_	O
206	54	_	_	O
207	.	_	_	O

208	6	_	_	O
209	months	_	_	O
210	)	_	_	O
211	.	_	_	O

212	There	_	_	B-Premise
213	were	_	_	I-Premise
214	no	_	_	I-Premise
215	significant	_	_	I-Premise
216	survival	_	_	I-Premise
217	differences	_	_	I-Premise
218	between	_	_	I-Premise
219	the	_	_	I-Premise
220	244	_	_	I-Premise
221	interferon	_	_	I-Premise
222	-	_	_	I-Premise
223	alfa	_	_	I-Premise
224	-	_	_	I-Premise
225	treated	_	_	I-Premise
226	patients	_	_	I-Premise
227	and	_	_	I-Premise
228	248	_	_	I-Premise
229	noninterferon	_	_	I-Premise
230	-	_	_	I-Premise
231	alfa	_	_	I-Premise
232	patients	_	_	I-Premise
233	(	_	_	I-Premise
234	hazard	_	_	I-Premise
235	ratio	_	_	I-Premise
236	,	_	_	I-Premise
237	1	_	_	I-Premise
238	.	_	_	I-Premise

239	00	_	_	I-Premise
240	;	_	_	I-Premise
241	95	_	_	I-Premise
242	%	_	_	I-Premise
243	CI	_	_	I-Premise
244	,	_	_	I-Premise
245	0	_	_	I-Premise
246	.	_	_	I-Premise

247	81	_	_	I-Premise
248	-	_	_	I-Premise
249	1	_	_	I-Premise
250	.	_	_	I-Premise

251	24	_	_	I-Premise
252	)	_	_	I-Premise
253	or	_	_	I-Premise
254	between	_	_	I-Premise
255	the	_	_	I-Premise
256	247	_	_	I-Premise
257	interleukin	_	_	I-Premise
258	-	_	_	I-Premise
259	2	_	_	I-Premise
260	and	_	_	I-Premise
261	245	_	_	I-Premise
262	noninterleukin	_	_	I-Premise
263	-	_	_	I-Premise
264	2	_	_	I-Premise
265	-	_	_	I-Premise
266	treated	_	_	I-Premise
267	patients	_	_	I-Premise
268	(	_	_	I-Premise
269	hazard	_	_	I-Premise
270	ratio	_	_	I-Premise
271	,	_	_	I-Premise
272	1	_	_	I-Premise
273	.	_	_	I-Premise

274	07	_	_	I-Premise
275	;	_	_	I-Premise
276	95	_	_	I-Premise
277	%	_	_	I-Premise
278	CI	_	_	I-Premise
279	,	_	_	I-Premise
280	0	_	_	I-Premise
281	.	_	_	I-Premise

282	87	_	_	I-Premise
283	-	_	_	I-Premise
284	1	_	_	I-Premise
285	.	_	_	I-Premise

286	33	_	_	I-Premise
287	;	_	_	I-Premise
288	log	_	_	I-Premise
289	rank	_	_	I-Premise
290	,	_	_	I-Premise
291	0	_	_	I-Premise
292	.	_	_	I-Premise

293	99	_	_	I-Premise
294	and	_	_	I-Premise
295	0	_	_	I-Premise
296	.	_	_	I-Premise

297	52	_	_	I-Premise
298	,	_	_	I-Premise
299	respectively	_	_	I-Premise
300	)	_	_	I-Premise
301	.	_	_	I-Premise

302	Grade	_	_	B-Premise
303	3	_	_	I-Premise
304	-	_	_	I-Premise
305	4	_	_	I-Premise
306	toxicities	_	_	I-Premise
307	were	_	_	I-Premise
308	significantly	_	_	I-Premise
309	more	_	_	I-Premise
310	frequent	_	_	I-Premise
311	in	_	_	I-Premise
312	cytokine	_	_	I-Premise
313	-	_	_	I-Premise
314	treated	_	_	I-Premise
315	patients	_	_	I-Premise
316	than	_	_	I-Premise
317	in	_	_	I-Premise
318	medroxyprogesterone	_	_	I-Premise
319	-	_	_	I-Premise
320	treated	_	_	I-Premise
321	patients	_	_	I-Premise
322	.	_	_	I-Premise

323	Subcutaneous	_	_	B-Claim
324	interleukin	_	_	I-Claim
325	-	_	_	I-Claim
326	2	_	_	I-Claim
327	and	_	_	I-Claim
328	/	_	_	I-Claim
329	or	_	_	I-Claim
330	interferon	_	_	I-Claim
331	-	_	_	I-Claim
332	alfa	_	_	I-Claim
333	provide	_	_	I-Claim
334	no	_	_	I-Claim
335	survival	_	_	I-Claim
336	benefit	_	_	I-Claim
337	in	_	_	I-Claim
338	metastatic	_	_	I-Claim
339	renal	_	_	I-Claim
340	cancers	_	_	I-Claim
341	of	_	_	I-Claim
342	intermediate	_	_	I-Claim
343	prognosis	_	_	I-Claim
344	,	_	_	I-Claim
345	and	_	_	I-Claim
346	they	_	_	I-Claim
347	induce	_	_	I-Claim
348	a	_	_	I-Claim
349	significant	_	_	I-Claim
350	risk	_	_	I-Claim
351	of	_	_	I-Claim
352	toxicity	_	_	I-Claim
353	.	_	_	I-Claim

354	Newly	_	_	B-Claim
355	available	_	_	I-Claim
356	angiogenesis	_	_	I-Claim
357	inhibitors	_	_	I-Claim
358	should	_	_	I-Claim
359	be	_	_	I-Claim
360	preferred	_	_	I-Claim
361	for	_	_	I-Claim
362	these	_	_	I-Claim
363	patients	_	_	I-Claim
364	.	_	_	I-Claim


0	There	_	_	O
1	are	_	_	O
2	few	_	_	O
3	randomized	_	_	O
4	controlled	_	_	O
5	trials	_	_	O
6	on	_	_	O
7	the	_	_	O
8	effectiveness	_	_	O
9	of	_	_	O
10	palliative	_	_	O
11	care	_	_	O
12	interventions	_	_	O
13	to	_	_	O
14	improve	_	_	O
15	the	_	_	O
16	care	_	_	O
17	of	_	_	O
18	patients	_	_	O
19	with	_	_	O
20	advanced	_	_	O
21	cancer	_	_	O
22	.	_	_	O

23	To	_	_	O
24	determine	_	_	O
25	the	_	_	O
26	effect	_	_	O
27	of	_	_	O
28	a	_	_	O
29	nursing	_	_	O
30	-	_	_	O
31	led	_	_	O
32	intervention	_	_	O
33	on	_	_	O
34	quality	_	_	O
35	of	_	_	O
36	life	_	_	O
37	,	_	_	O
38	symptom	_	_	O
39	intensity	_	_	O
40	,	_	_	O
41	mood	_	_	O
42	,	_	_	O
43	and	_	_	O
44	resource	_	_	O
45	use	_	_	O
46	in	_	_	O
47	patients	_	_	O
48	with	_	_	O
49	advanced	_	_	O
50	cancer	_	_	O
51	.	_	_	O

52	Randomized	_	_	O
53	controlled	_	_	O
54	trial	_	_	O
55	conducted	_	_	O
56	from	_	_	O
57	November	_	_	O
58	2003	_	_	O
59	through	_	_	O
60	May	_	_	O
61	2008	_	_	O
62	of	_	_	O
63	322	_	_	O
64	patients	_	_	O
65	with	_	_	O
66	advanced	_	_	O
67	cancer	_	_	O
68	in	_	_	O
69	a	_	_	O
70	rural	_	_	O
71	,	_	_	O
72	National	_	_	O
73	Cancer	_	_	O
74	Institute	_	_	O
75	-	_	_	O
76	designated	_	_	O
77	comprehensive	_	_	O
78	cancer	_	_	O
79	center	_	_	O
80	in	_	_	O
81	New	_	_	O
82	Hampshire	_	_	O
83	and	_	_	O
84	affiliated	_	_	O
85	outreach	_	_	O
86	clinics	_	_	O
87	and	_	_	O
88	a	_	_	O
89	VA	_	_	O
90	medical	_	_	O
91	center	_	_	O
92	in	_	_	O
93	Vermont	_	_	O
94	.	_	_	O

95	A	_	_	O
96	multicomponent	_	_	O
97	,	_	_	O
98	psychoeducational	_	_	O
99	intervention	_	_	O
100	(	_	_	O
101	Project	_	_	O
102	ENABLE	_	_	O
103	[	_	_	O
104	Educate	_	_	O
105	,	_	_	O
106	Nurture	_	_	O
107	,	_	_	O
108	Advise	_	_	O
109	,	_	_	O
110	Before	_	_	O
111	Life	_	_	O
112	Ends	_	_	O
113	]	_	_	O
114	)	_	_	O
115	conducted	_	_	O
116	by	_	_	O
117	advanced	_	_	O
118	practice	_	_	O
119	nurses	_	_	O
120	consisting	_	_	O
121	of	_	_	O
122	4	_	_	O
123	weekly	_	_	O
124	educational	_	_	O
125	sessions	_	_	O
126	and	_	_	O
127	monthly	_	_	O
128	follow	_	_	O
129	-	_	_	O
130	up	_	_	O
131	sessions	_	_	O
132	until	_	_	O
133	death	_	_	O
134	or	_	_	O
135	study	_	_	O
136	completion	_	_	O
137	(	_	_	O
138	n	_	_	O
139	=	_	_	O
140	161	_	_	O
141	)	_	_	O
142	vs	_	_	O
143	usual	_	_	O
144	care	_	_	O
145	(	_	_	O
146	n	_	_	O
147	=	_	_	O
148	161	_	_	O
149	)	_	_	O
150	.	_	_	O

151	Quality	_	_	O
152	of	_	_	O
153	life	_	_	O
154	was	_	_	O
155	measured	_	_	O
156	by	_	_	O
157	the	_	_	O
158	Functional	_	_	O
159	Assessment	_	_	O
160	of	_	_	O
161	Chronic	_	_	O
162	Illness	_	_	O
163	Therapy	_	_	O
164	for	_	_	O
165	Palliative	_	_	O
166	Care	_	_	O
167	(	_	_	O
168	score	_	_	O
169	range	_	_	O
170	,	_	_	O
171	0	_	_	O
172	-	_	_	O
173	184	_	_	O
174	)	_	_	O
175	.	_	_	O

176	Symptom	_	_	O
177	intensity	_	_	O
178	was	_	_	O
179	measured	_	_	O
180	by	_	_	O
181	the	_	_	O
182	Edmonton	_	_	O
183	Symptom	_	_	O
184	Assessment	_	_	O
185	Scale	_	_	O
186	(	_	_	O
187	score	_	_	O
188	range	_	_	O
189	,	_	_	O
190	0	_	_	O
191	-	_	_	O
192	900	_	_	O
193	)	_	_	O
194	.	_	_	O

195	Mood	_	_	O
196	was	_	_	O
197	measured	_	_	O
198	by	_	_	O
199	the	_	_	O
200	Center	_	_	O
201	for	_	_	O
202	Epidemiological	_	_	O
203	Studies	_	_	O
204	Depression	_	_	O
205	Scale	_	_	O
206	(	_	_	O
207	range	_	_	O
208	,	_	_	O
209	0	_	_	O
210	-	_	_	O
211	60	_	_	O
212	)	_	_	O
213	.	_	_	O

214	These	_	_	O
215	measures	_	_	O
216	were	_	_	O
217	assessed	_	_	O
218	at	_	_	O
219	baseline	_	_	O
220	,	_	_	O
221	1	_	_	O
222	month	_	_	O
223	,	_	_	O
224	and	_	_	O
225	every	_	_	O
226	3	_	_	O
227	months	_	_	O
228	until	_	_	O
229	death	_	_	O
230	or	_	_	O
231	study	_	_	O
232	completion	_	_	O
233	.	_	_	O

234	Intensity	_	_	O
235	of	_	_	O
236	service	_	_	O
237	was	_	_	O
238	measured	_	_	O
239	as	_	_	O
240	the	_	_	O
241	number	_	_	O
242	of	_	_	O
243	days	_	_	O
244	in	_	_	O
245	the	_	_	O
246	hospital	_	_	O
247	and	_	_	O
248	in	_	_	O
249	the	_	_	O
250	intensive	_	_	O
251	care	_	_	O
252	unit	_	_	O
253	(	_	_	O
254	ICU	_	_	O
255	)	_	_	O
256	and	_	_	O
257	the	_	_	O
258	number	_	_	O
259	of	_	_	O
260	emergency	_	_	O
261	department	_	_	O
262	visits	_	_	O
263	recorded	_	_	O
264	in	_	_	O
265	the	_	_	O
266	electronic	_	_	O
267	medical	_	_	O
268	record	_	_	O
269	.	_	_	O

270	A	_	_	O
271	total	_	_	O
272	of	_	_	O
273	322	_	_	O
274	participants	_	_	O
275	with	_	_	O
276	cancer	_	_	O
277	of	_	_	O
278	the	_	_	O
279	gastrointestinal	_	_	O
280	tract	_	_	O
281	(	_	_	O
282	41	_	_	O
283	%	_	_	O
284	;	_	_	O
285	67	_	_	O
286	in	_	_	O
287	the	_	_	O
288	usual	_	_	O
289	care	_	_	O
290	group	_	_	O
291	vs	_	_	O
292	66	_	_	O
293	in	_	_	O
294	the	_	_	O
295	intervention	_	_	O
296	group	_	_	O
297	)	_	_	O
298	,	_	_	O
299	lung	_	_	O
300	(	_	_	O
301	36	_	_	O
302	%	_	_	O
303	;	_	_	O
304	58	_	_	O
305	vs	_	_	O
306	59	_	_	O
307	)	_	_	O
308	,	_	_	O
309	genitourinary	_	_	O
310	tract	_	_	O
311	(	_	_	O
312	12	_	_	O
313	%	_	_	O
314	;	_	_	O
315	20	_	_	O
316	vs	_	_	O
317	19	_	_	O
318	)	_	_	O
319	,	_	_	O
320	and	_	_	O
321	breast	_	_	O
322	(	_	_	O
323	10	_	_	O
324	%	_	_	O
325	;	_	_	O
326	16	_	_	O
327	vs	_	_	O
328	17	_	_	O
329	)	_	_	O
330	were	_	_	O
331	randomized	_	_	O
332	.	_	_	O

333	The	_	_	B-Premise
334	estimated	_	_	I-Premise
335	treatment	_	_	I-Premise
336	effects	_	_	I-Premise
337	(	_	_	I-Premise
338	intervention	_	_	I-Premise
339	minus	_	_	I-Premise
340	usual	_	_	I-Premise
341	care	_	_	I-Premise
342	)	_	_	I-Premise
343	for	_	_	I-Premise
344	all	_	_	I-Premise
345	participants	_	_	I-Premise
346	were	_	_	I-Premise
347	a	_	_	I-Premise
348	mean	_	_	I-Premise
349	(	_	_	I-Premise
350	SE	_	_	I-Premise
351	)	_	_	I-Premise
352	of	_	_	I-Premise
353	4	_	_	I-Premise
354	.	_	_	I-Premise

355	6	_	_	I-Premise
356	(	_	_	I-Premise
357	2	_	_	I-Premise
358	)	_	_	I-Premise
359	for	_	_	I-Premise
360	quality	_	_	I-Premise
361	of	_	_	I-Premise
362	life	_	_	I-Premise
363	(	_	_	I-Premise
364	P	_	_	I-Premise
365	=	_	_	I-Premise
366	.	_	_	I-Premise

367	02	_	_	I-Premise
368	)	_	_	I-Premise
369	,	_	_	I-Premise
370	-	_	_	I-Premise
371	27	_	_	I-Premise
372	.	_	_	I-Premise

373	8	_	_	I-Premise
374	(	_	_	I-Premise
375	15	_	_	I-Premise
376	)	_	_	I-Premise
377	for	_	_	I-Premise
378	symptom	_	_	I-Premise
379	intensity	_	_	I-Premise
380	(	_	_	I-Premise
381	P	_	_	I-Premise
382	=	_	_	I-Premise
383	.	_	_	I-Premise

384	06	_	_	I-Premise
385	)	_	_	I-Premise
386	,	_	_	I-Premise
387	and	_	_	I-Premise
388	-	_	_	I-Premise
389	1	_	_	I-Premise
390	.	_	_	I-Premise

391	8	_	_	I-Premise
392	(	_	_	I-Premise
393	0	_	_	I-Premise
394	.	_	_	I-Premise

395	81	_	_	I-Premise
396	)	_	_	I-Premise
397	for	_	_	I-Premise
398	depressed	_	_	I-Premise
399	mood	_	_	I-Premise
400	(	_	_	I-Premise
401	P	_	_	I-Premise
402	=	_	_	I-Premise
403	.	_	_	I-Premise

404	02	_	_	I-Premise
405	)	_	_	I-Premise
406	.	_	_	I-Premise

407	The	_	_	B-Premise
408	estimated	_	_	I-Premise
409	treatment	_	_	I-Premise
410	effects	_	_	I-Premise
411	in	_	_	I-Premise
412	participants	_	_	I-Premise
413	who	_	_	I-Premise
414	died	_	_	I-Premise
415	during	_	_	I-Premise
416	the	_	_	I-Premise
417	study	_	_	I-Premise
418	were	_	_	I-Premise
419	a	_	_	I-Premise
420	mean	_	_	I-Premise
421	(	_	_	I-Premise
422	SE	_	_	I-Premise
423	)	_	_	I-Premise
424	of	_	_	I-Premise
425	8	_	_	I-Premise
426	.	_	_	I-Premise

427	6	_	_	I-Premise
428	(	_	_	I-Premise
429	3	_	_	I-Premise
430	.	_	_	I-Premise

431	6	_	_	I-Premise
432	)	_	_	I-Premise
433	for	_	_	I-Premise
434	quality	_	_	I-Premise
435	of	_	_	I-Premise
436	life	_	_	I-Premise
437	(	_	_	I-Premise
438	P	_	_	I-Premise
439	=	_	_	I-Premise
440	.	_	_	I-Premise

441	02	_	_	I-Premise
442	)	_	_	I-Premise
443	,	_	_	I-Premise
444	-	_	_	I-Premise
445	24	_	_	I-Premise
446	.	_	_	I-Premise

447	2	_	_	I-Premise
448	(	_	_	I-Premise
449	20	_	_	I-Premise
450	.	_	_	I-Premise

451	5	_	_	I-Premise
452	)	_	_	I-Premise
453	for	_	_	I-Premise
454	symptom	_	_	I-Premise
455	intensity	_	_	I-Premise
456	(	_	_	I-Premise
457	P	_	_	I-Premise
458	=	_	_	I-Premise
459	.	_	_	I-Premise

460	24	_	_	I-Premise
461	)	_	_	I-Premise
462	,	_	_	I-Premise
463	and	_	_	I-Premise
464	-	_	_	I-Premise
465	2	_	_	I-Premise
466	.	_	_	I-Premise

467	7	_	_	I-Premise
468	(	_	_	I-Premise
469	1	_	_	I-Premise
470	.	_	_	I-Premise

471	2	_	_	I-Premise
472	)	_	_	I-Premise
473	for	_	_	I-Premise
474	depressed	_	_	I-Premise
475	mood	_	_	I-Premise
476	(	_	_	I-Premise
477	P	_	_	I-Premise
478	=	_	_	I-Premise
479	.	_	_	I-Premise

480	03	_	_	I-Premise
481	)	_	_	I-Premise
482	.	_	_	I-Premise

483	Intensity	_	_	O
484	of	_	_	O
485	service	_	_	O
486	did	_	_	O
487	not	_	_	O
488	differ	_	_	O
489	between	_	_	O
490	the	_	_	O
491	2	_	_	O
492	groups	_	_	O
493	.	_	_	O

494	Compared	_	_	B-Claim
495	with	_	_	I-Claim
496	participants	_	_	I-Claim
497	receiving	_	_	I-Claim
498	usual	_	_	I-Claim
499	oncology	_	_	I-Claim
500	care	_	_	I-Claim
501	,	_	_	I-Claim
502	those	_	_	I-Claim
503	receiving	_	_	I-Claim
504	a	_	_	I-Claim
505	nurse	_	_	I-Claim
506	-	_	_	I-Claim
507	led	_	_	I-Claim
508	,	_	_	I-Claim
509	palliative	_	_	I-Claim
510	care	_	_	I-Claim
511	-	_	_	I-Claim
512	focused	_	_	I-Claim
513	intervention	_	_	I-Claim
514	addressing	_	_	I-Claim
515	physical	_	_	I-Claim
516	,	_	_	I-Claim
517	psychosocial	_	_	I-Claim
518	,	_	_	I-Claim
519	and	_	_	I-Claim
520	care	_	_	I-Claim
521	coordination	_	_	I-Claim
522	provided	_	_	I-Claim
523	concurrently	_	_	I-Claim
524	with	_	_	I-Claim
525	oncology	_	_	I-Claim
526	care	_	_	I-Claim
527	had	_	_	I-Claim
528	higher	_	_	I-Claim
529	scores	_	_	I-Claim
530	for	_	_	I-Claim
531	quality	_	_	I-Claim
532	of	_	_	I-Claim
533	life	_	_	I-Claim
534	and	_	_	I-Claim
535	mood	_	_	I-Claim
536	,	_	_	I-Claim
537	but	_	_	B-Claim
538	did	_	_	I-Claim
539	not	_	_	I-Claim
540	have	_	_	I-Claim
541	improvements	_	_	I-Claim
542	in	_	_	I-Claim
543	symptom	_	_	I-Claim
544	intensity	_	_	I-Claim
545	scores	_	_	I-Claim
546	or	_	_	I-Claim
547	reduced	_	_	I-Claim
548	days	_	_	I-Claim
549	in	_	_	I-Claim
550	the	_	_	I-Claim
551	hospital	_	_	I-Claim
552	or	_	_	I-Claim
553	ICU	_	_	I-Claim
554	or	_	_	I-Claim
555	emergency	_	_	I-Claim
556	department	_	_	I-Claim
557	visits	_	_	I-Claim
558	.	_	_	I-Claim


0	Before	_	_	O
1	the	_	_	O
2	knowledge	_	_	O
3	that	_	_	O
4	5	_	_	O
5	years	_	_	O
6	of	_	_	O
7	adjuvant	_	_	O
8	tamoxifen	_	_	O
9	is	_	_	O
10	less	_	_	O
11	efficacious	_	_	O
12	than	_	_	O
13	2	_	_	O
14	to	_	_	O
15	3	_	_	O
16	years	_	_	O
17	of	_	_	O
18	tamoxifen	_	_	O
19	followed	_	_	O
20	by	_	_	O
21	2	_	_	O
22	to	_	_	O
23	3	_	_	O
24	years	_	_	O
25	of	_	_	O
26	anastrozole	_	_	O
27	/	_	_	O
28	exemestane	_	_	O
29	,	_	_	O
30	we	_	_	O
31	designed	_	_	O
32	a	_	_	O
33	multicenter	_	_	O
34	double	_	_	O
35	-	_	_	O
36	blind	_	_	O
37	randomized	_	_	O
38	controlled	_	_	O
39	trial	_	_	O
40	in	_	_	O
41	women	_	_	O
42	taking	_	_	O
43	tamoxifen	_	_	O
44	with	_	_	O
45	a	_	_	O
46	thickened	_	_	O
47	endometrium	_	_	O
48	to	_	_	O
49	compare	_	_	O
50	uterine	_	_	O
51	and	_	_	O
52	quality	_	_	O
53	-	_	_	O
54	of	_	_	O
55	-	_	_	O
56	life	_	_	O
57	parameters	_	_	O
58	between	_	_	O
59	those	_	_	O
60	switching	_	_	O
61	to	_	_	O
62	anastrozole	_	_	O
63	and	_	_	O
64	those	_	_	O
65	continuing	_	_	O
66	tamoxifen	_	_	O
67	.	_	_	O

68	Asymptomatic	_	_	O
69	postmenopausal	_	_	O
70	women	_	_	O
71	who	_	_	O
72	took	_	_	O
73	adjuvant	_	_	O
74	tamoxifen	_	_	O
75	for	_	_	O
76	2	_	_	O
77	to	_	_	O
78	3	_	_	O
79	years	_	_	O
80	for	_	_	O
81	operable	_	_	O
82	breast	_	_	O
83	cancer	_	_	O
84	with	_	_	O
85	a	_	_	O
86	double	_	_	O
87	endometrial	_	_	O
88	thickness	_	_	O
89	greater	_	_	O
90	than	_	_	O
91	7	_	_	O
92	mm	_	_	O
93	were	_	_	O
94	randomized	_	_	O
95	to	_	_	O
96	20	_	_	O
97	mg	_	_	O
98	tamoxifen	_	_	O
99	or	_	_	O
100	1	_	_	O
101	mg	_	_	O
102	anastrozole	_	_	O
103	for	_	_	O
104	the	_	_	O
105	remaining	_	_	O
106	duration	_	_	O
107	,	_	_	O
108	totaling	_	_	O
109	5	_	_	O
110	years	_	_	O
111	.	_	_	O

112	Tablets	_	_	O
113	were	_	_	O
114	unrecognizable	_	_	O
115	for	_	_	O
116	drug	_	_	O
117	assignment	_	_	O
118	.	_	_	O

119	The	_	_	O
120	primary	_	_	O
121	endpoints	_	_	O
122	were	_	_	O
123	the	_	_	O
124	differences	_	_	O
125	in	_	_	O
126	double	_	_	O
127	endometrial	_	_	O
128	thickness	_	_	O
129	and	_	_	O
130	uterine	_	_	O
131	volume	_	_	O
132	after	_	_	O
133	1	_	_	O
134	year	_	_	O
135	.	_	_	O

136	Uterine	_	_	O
137	and	_	_	O
138	quality	_	_	O
139	-	_	_	O
140	of	_	_	O
141	-	_	_	O
142	life	_	_	O
143	data	_	_	O
144	were	_	_	O
145	analyzed	_	_	O
146	using	_	_	O
147	regression	_	_	O
148	methods	_	_	O
149	,	_	_	O
150	and	_	_	O
151	missing	_	_	O
152	values	_	_	O
153	were	_	_	O
154	handled	_	_	O
155	using	_	_	O
156	multiple	_	_	O
157	imputation	_	_	O
158	.	_	_	O

159	Seventy	_	_	O
160	-	_	_	O
161	two	_	_	O
162	women	_	_	O
163	(	_	_	O
164	median	_	_	O
165	age	_	_	O
166	,	_	_	O
167	60	_	_	O
168	y	_	_	O
169	)	_	_	O
170	were	_	_	O
171	randomized	_	_	O
172	in	_	_	O
173	five	_	_	O
174	hospitals	_	_	O
175	.	_	_	O

176	Relative	_	_	B-Premise
177	to	_	_	I-Premise
178	women	_	_	I-Premise
179	continuing	_	_	I-Premise
180	tamoxifen	_	_	I-Premise
181	,	_	_	I-Premise
182	women	_	_	I-Premise
183	switching	_	_	I-Premise
184	to	_	_	I-Premise
185	anastrozole	_	_	I-Premise
186	experienced	_	_	I-Premise
187	a	_	_	I-Premise
188	decrease	_	_	I-Premise
189	of	_	_	I-Premise
190	53	_	_	I-Premise
191	%	_	_	I-Premise
192	(	_	_	I-Premise
193	95	_	_	I-Premise
194	%	_	_	I-Premise
195	CI	_	_	I-Premise
196	,	_	_	I-Premise
197	41	_	_	I-Premise
198	%	_	_	I-Premise
199	-	_	_	I-Premise
200	63	_	_	I-Premise
201	%	_	_	I-Premise
202	)	_	_	I-Premise
203	in	_	_	I-Premise
204	double	_	_	I-Premise
205	endometrial	_	_	I-Premise
206	thickness	_	_	I-Premise
207	and	_	_	I-Premise
208	a	_	_	I-Premise
209	decrease	_	_	I-Premise
210	of	_	_	I-Premise
211	51	_	_	I-Premise
212	%	_	_	I-Premise
213	(	_	_	I-Premise
214	95	_	_	I-Premise
215	%	_	_	I-Premise
216	CI	_	_	I-Premise
217	,	_	_	I-Premise
218	39	_	_	I-Premise
219	%	_	_	I-Premise
220	-	_	_	I-Premise
221	60	_	_	I-Premise
222	%	_	_	I-Premise
223	)	_	_	I-Premise
224	in	_	_	I-Premise
225	uterine	_	_	I-Premise
226	volume	_	_	I-Premise
227	.	_	_	I-Premise

228	Vaginal	_	_	B-Premise
229	dryness	_	_	I-Premise
230	(	_	_	I-Premise
231	b	_	_	I-Premise
232	=	_	_	I-Premise
233	0	_	_	I-Premise
234	.	_	_	I-Premise

235	064	_	_	I-Premise
236	;	_	_	I-Premise
237	95	_	_	I-Premise
238	%	_	_	I-Premise
239	CI	_	_	I-Premise
240	,	_	_	I-Premise
241	0	_	_	I-Premise
242	.	_	_	I-Premise

243	016	_	_	I-Premise
244	-	_	_	I-Premise
245	0	_	_	I-Premise
246	.	_	_	I-Premise

247	112	_	_	I-Premise
248	)	_	_	I-Premise
249	and	_	_	I-Premise
250	sexual	_	_	I-Premise
251	problems	_	_	I-Premise
252	(	_	_	I-Premise
253	b	_	_	I-Premise
254	=	_	_	I-Premise
255	0	_	_	I-Premise
256	.	_	_	I-Premise

257	054	_	_	I-Premise
258	;	_	_	I-Premise
259	95	_	_	I-Premise
260	%	_	_	I-Premise
261	CI	_	_	I-Premise
262	,	_	_	I-Premise
263	0	_	_	I-Premise
264	.	_	_	I-Premise

265	007	_	_	I-Premise
266	-	_	_	I-Premise
267	0	_	_	I-Premise
268	.	_	_	I-Premise

269	102	_	_	I-Premise
270	)	_	_	I-Premise
271	increased	_	_	I-Premise
272	in	_	_	I-Premise
273	women	_	_	I-Premise
274	taking	_	_	I-Premise
275	anastrozole	_	_	I-Premise
276	compared	_	_	I-Premise
277	with	_	_	I-Premise
278	women	_	_	I-Premise
279	taking	_	_	I-Premise
280	tamoxifen	_	_	I-Premise
281	.	_	_	I-Premise

282	Treatment	_	_	B-Premise
283	arms	_	_	I-Premise
284	did	_	_	I-Premise
285	not	_	_	I-Premise
286	differ	_	_	I-Premise
287	regarding	_	_	I-Premise
288	withdrawal	_	_	I-Premise
289	rate	_	_	I-Premise
290	and	_	_	I-Premise
291	the	_	_	I-Premise
292	experience	_	_	I-Premise
293	of	_	_	I-Premise
294	(	_	_	I-Premise
295	serious	_	_	I-Premise
296	)	_	_	I-Premise
297	adverse	_	_	I-Premise
298	events	_	_	I-Premise
299	.	_	_	I-Premise

300	Despite	_	_	O
301	premature	_	_	O
302	trial	_	_	O
303	closure	_	_	O
304	,	_	_	O
305	our	_	_	O
306	data	_	_	O
307	provided	_	_	O
308	valuable	_	_	O
309	insights	_	_	O
310	.	_	_	O

311	Switching	_	_	B-Claim
312	to	_	_	I-Claim
313	anastrozole	_	_	I-Claim
314	strongly	_	_	I-Claim
315	decreased	_	_	I-Claim
316	the	_	_	I-Claim
317	endometrial	_	_	I-Claim
318	thickness	_	_	I-Claim
319	and	_	_	I-Claim
320	uterine	_	_	I-Claim
321	volume	_	_	I-Claim
322	but	_	_	I-Claim
323	increased	_	_	I-Claim
324	sexual	_	_	I-Claim
325	disturbances	_	_	I-Claim
326	.	_	_	I-Claim

327	Safe	_	_	B-Claim
328	and	_	_	I-Claim
329	effective	_	_	I-Claim
330	interventions	_	_	I-Claim
331	are	_	_	I-Claim
332	needed	_	_	I-Claim
333	to	_	_	I-Claim
334	alleviate	_	_	I-Claim
335	sexual	_	_	I-Claim
336	dysfunction	_	_	I-Claim
337	.	_	_	I-Claim


0	Molecular	_	_	O
1	markers	_	_	O
2	to	_	_	O
3	predict	_	_	O
4	response	_	_	O
5	to	_	_	O
6	5	_	_	O
7	-	_	_	O
8	fluorouracil	_	_	O
9	(	_	_	O
10	FU	_	_	O
11	)	_	_	O
12	-	_	_	O
13	based	_	_	O
14	treatment	_	_	O
15	of	_	_	O
16	recurrent	_	_	O
17	or	_	_	O
18	metastasised	_	_	O
19	colorectal	_	_	O
20	cancer	_	_	O
21	(	_	_	O
22	mCRC	_	_	O
23	)	_	_	O
24	are	_	_	O
25	not	_	_	O
26	established	_	_	O
27	.	_	_	O

28	The	_	_	O
29	aim	_	_	O
30	of	_	_	O
31	this	_	_	O
32	trial	_	_	O
33	was	_	_	O
34	to	_	_	O
35	determine	_	_	O
36	the	_	_	O
37	value	_	_	O
38	of	_	_	O
39	thymidylate	_	_	O
40	synthase	_	_	O
41	(	_	_	O
42	TS	_	_	O
43	)	_	_	O
44	,	_	_	O
45	a	_	_	O
46	key	_	_	O
47	enzyme	_	_	O
48	of	_	_	O
49	DNA	_	_	O
50	synthesis	_	_	O
51	and	_	_	O
52	target	_	_	O
53	of	_	_	O
54	5	_	_	O
55	-	_	_	O
56	FU	_	_	O
57	,	_	_	O
58	to	_	_	O
59	predict	_	_	O
60	response	_	_	O
61	to	_	_	O
62	chemotherapy	_	_	O
63	of	_	_	O
64	mCRC	_	_	O
65	.	_	_	O

66	Tumour	_	_	O
67	tissue	_	_	O
68	was	_	_	O
69	obtained	_	_	O
70	from	_	_	O
71	168	_	_	O
72	patients	_	_	O
73	with	_	_	O
74	mCRC	_	_	O
75	for	_	_	O
76	relative	_	_	O
77	thymidylate	_	_	O
78	synthase	_	_	O
79	(	_	_	O
80	TS	_	_	O
81	)	_	_	O
82	mRNA	_	_	O
83	quantitation	_	_	O
84	.	_	_	O

85	Patients	_	_	O
86	were	_	_	O
87	randomised	_	_	O
88	to	_	_	O
89	receive	_	_	O
90	either	_	_	O
91	5	_	_	O
92	-	_	_	O
93	FU	_	_	O
94	/	_	_	O
95	folinic	_	_	O
96	acid	_	_	O
97	(	_	_	O
98	FA	_	_	O
99	,	_	_	O
100	FUFA	_	_	O
101	)	_	_	O
102	alone	_	_	O
103	or	_	_	O
104	in	_	_	O
105	combination	_	_	O
106	with	_	_	O
107	irinotecan	_	_	O
108	5	_	_	O
109	-	_	_	O
110	fluorouracil	_	_	O
111	/	_	_	O
112	folinic	_	_	O
113	acid	_	_	O
114	and	_	_	O
115	irinotecan	_	_	O
116	(	_	_	O
117	FOLFIRI	_	_	O
118	)	_	_	O
119	stratified	_	_	O
120	by	_	_	O
121	TS	_	_	O
122	(	_	_	O
123	low	_	_	O
124	versus	_	_	O
125	high	_	_	O
126	)	_	_	O
127	.	_	_	O

128	Primary	_	_	O
129	end	_	_	O
130	-	_	_	O
131	point	_	_	O
132	was	_	_	O
133	overall	_	_	O
134	response	_	_	O
135	to	_	_	O
136	first	_	_	O
137	-	_	_	O
138	line	_	_	O
139	treatment	_	_	O
140	among	_	_	O
141	TS	_	_	O
142	high	_	_	O
143	patients	_	_	O
144	.	_	_	O

145	All	_	_	O
146	parties	_	_	O
147	,	_	_	O
148	except	_	_	O
149	for	_	_	O
150	the	_	_	O
151	randomisation	_	_	O
152	centre	_	_	O
153	,	_	_	O
154	were	_	_	O
155	blinded	_	_	O
156	for	_	_	O
157	TS	_	_	O
158	status	_	_	O
159	.	_	_	O

160	Biopsies	_	_	O
161	(	_	_	O
162	n	_	_	O
163	=	_	_	O
164	168	_	_	O
165	)	_	_	O
166	were	_	_	O
167	taken	_	_	O
168	without	_	_	O
169	complications	_	_	O
170	.	_	_	O

171	TS	_	_	O
172	levels	_	_	O
173	were	_	_	O
174	available	_	_	O
175	for	_	_	O
176	147	_	_	O
177	patients	_	_	O
178	(	_	_	O
179	87	_	_	O
180	.	_	_	O

181	5	_	_	O
182	%	_	_	O
183	)	_	_	O
184	.	_	_	O

185	Analysing	_	_	B-Premise
186	response	_	_	I-Premise
187	to	_	_	I-Premise
188	FUFA	_	_	I-Premise
189	and	_	_	I-Premise
190	FOLFIRI	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	per	_	_	I-Premise
194	protocol	_	_	I-Premise
195	set	_	_	I-Premise
196	(	_	_	I-Premise
197	n	_	_	I-Premise
198	=	_	_	I-Premise
199	119	_	_	I-Premise
200	)	_	_	I-Premise
201	after	_	_	I-Premise
202	un	_	_	I-Premise
203	-	_	_	I-Premise
204	blinding	_	_	I-Premise
205	TS	_	_	I-Premise
206	in	_	_	I-Premise
207	the	_	_	I-Premise
208	data	_	_	I-Premise
209	base	_	_	I-Premise
210	revealed	_	_	I-Premise
211	a	_	_	I-Premise
212	trend	_	_	I-Premise
213	to	_	_	I-Premise
214	better	_	_	I-Premise
215	overall	_	_	I-Premise
216	response	_	_	I-Premise
217	to	_	_	I-Premise
218	FOLFIRI	_	_	I-Premise
219	(	_	_	I-Premise
220	9	_	_	I-Premise
221	/	_	_	I-Premise
222	19	_	_	I-Premise
223	,	_	_	I-Premise
224	47	_	_	I-Premise
225	%	_	_	I-Premise
226	)	_	_	I-Premise
227	in	_	_	I-Premise
228	TS	_	_	I-Premise
229	high	_	_	I-Premise
230	compared	_	_	I-Premise
231	to	_	_	I-Premise
232	FUFA	_	_	I-Premise
233	(	_	_	I-Premise
234	5	_	_	I-Premise
235	/	_	_	I-Premise
236	23	_	_	I-Premise
237	,	_	_	I-Premise
238	22	_	_	I-Premise
239	%	_	_	I-Premise
240	,	_	_	I-Premise
241	p	_	_	I-Premise
242	=	_	_	I-Premise
243	0	_	_	I-Premise
244	.	_	_	I-Premise

245	077	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	In	_	_	B-Premise
249	patients	_	_	I-Premise
250	with	_	_	I-Premise
251	biopsies	_	_	I-Premise
252	taken	_	_	I-Premise
253	from	_	_	I-Premise
254	liver	_	_	I-Premise
255	lesions	_	_	I-Premise
256	(	_	_	I-Premise
257	n	_	_	I-Premise
258	=	_	_	I-Premise
259	91	_	_	I-Premise
260	)	_	_	I-Premise
261	overall	_	_	I-Premise
262	response	_	_	I-Premise
263	to	_	_	I-Premise
264	FOLFIRI	_	_	I-Premise
265	and	_	_	I-Premise
266	FUFA	_	_	I-Premise
267	in	_	_	I-Premise
268	TS	_	_	I-Premise
269	high	_	_	I-Premise
270	was	_	_	I-Premise
271	53	_	_	I-Premise
272	%	_	_	I-Premise
273	(	_	_	I-Premise
274	9	_	_	I-Premise
275	/	_	_	I-Premise
276	17	_	_	I-Premise
277	)	_	_	I-Premise
278	and	_	_	I-Premise
279	18	_	_	I-Premise
280	%	_	_	I-Premise
281	(	_	_	I-Premise
282	3	_	_	I-Premise
283	/	_	_	I-Premise
284	17	_	_	I-Premise
285	)	_	_	I-Premise
286	,	_	_	I-Premise
287	respectively	_	_	I-Premise
288	(	_	_	I-Premise
289	p	_	_	I-Premise
290	=	_	_	I-Premise
291	0	_	_	I-Premise
292	.	_	_	I-Premise

293	035	_	_	I-Premise
294	)	_	_	I-Premise
295	.	_	_	I-Premise

296	In	_	_	B-Premise
297	patients	_	_	I-Premise
298	with	_	_	I-Premise
299	low	_	_	I-Premise
300	TS	_	_	I-Premise
301	,	_	_	I-Premise
302	no	_	_	I-Premise
303	remarkable	_	_	I-Premise
304	difference	_	_	I-Premise
305	in	_	_	I-Premise
306	overall	_	_	I-Premise
307	response	_	_	I-Premise
308	to	_	_	I-Premise
309	FOLFIRI	_	_	I-Premise
310	and	_	_	I-Premise
311	FUFA	_	_	I-Premise
312	was	_	_	I-Premise
313	observed	_	_	I-Premise
314	.	_	_	I-Premise

315	Taking	_	_	B-Claim
316	a	_	_	I-Claim
317	pre	_	_	I-Claim
318	-	_	_	I-Claim
319	treatment	_	_	I-Claim
320	biopsy	_	_	I-Claim
321	is	_	_	I-Claim
322	a	_	_	I-Claim
323	safe	_	_	I-Claim
324	and	_	_	I-Claim
325	feasible	_	_	I-Claim
326	procedure	_	_	I-Claim
327	in	_	_	I-Claim
328	mCRC	_	_	I-Claim
329	.	_	_	I-Claim

330	After	_	_	B-Claim
331	validation	_	_	I-Claim
332	of	_	_	I-Claim
333	our	_	_	I-Claim
334	data	_	_	I-Claim
335	in	_	_	I-Claim
336	a	_	_	I-Claim
337	larger	_	_	I-Claim
338	group	_	_	I-Claim
339	TS	_	_	I-Claim
340	determination	_	_	I-Claim
341	may	_	_	I-Claim
342	have	_	_	I-Claim
343	the	_	_	I-Claim
344	potential	_	_	I-Claim
345	to	_	_	I-Claim
346	better	_	_	I-Claim
347	help	_	_	I-Claim
348	direct	_	_	I-Claim
349	systemic	_	_	I-Claim
350	treatment	_	_	I-Claim
351	in	_	_	I-Claim
352	patients	_	_	I-Claim
353	with	_	_	I-Claim
354	primarily	_	_	I-Claim
355	non	_	_	I-Claim
356	-	_	_	I-Claim
357	resectable	_	_	I-Claim
358	mCRC	_	_	I-Claim
359	.	_	_	I-Claim


0	Chemoradiotherapy	_	_	O
1	(	_	_	O
2	CRT	_	_	O
3	)	_	_	O
4	-	_	_	O
5	induced	_	_	O
6	oral	_	_	O
7	mucositis	_	_	O
8	(	_	_	O
9	OM	_	_	O
10	)	_	_	O
11	adversely	_	_	O
12	affects	_	_	O
13	a	_	_	O
14	patient	_	_	O
15	'	_	_	O
16	s	_	_	O
17	oral	_	_	O
18	functions	_	_	O
19	and	_	_	O
20	quality	_	_	O
21	of	_	_	O
22	life	_	_	O
23	(	_	_	O
24	QOL	_	_	O
25	)	_	_	O
26	.	_	_	O

27	Low	_	_	O
28	-	_	_	O
29	level	_	_	O
30	laser	_	_	O
31	therapy	_	_	O
32	(	_	_	O
33	LLLT	_	_	O
34	)	_	_	O
35	showed	_	_	O
36	some	_	_	O
37	preventive	_	_	O
38	and	_	_	O
39	curative	_	_	O
40	effects	_	_	O
41	against	_	_	O
42	clinically	_	_	O
43	reported	_	_	O
44	objective	_	_	O
45	measures	_	_	O
46	of	_	_	O
47	OM	_	_	O
48	in	_	_	O
49	few	_	_	O
50	trials	_	_	O
51	including	_	_	O
52	our	_	_	O
53	recently	_	_	O
54	published	_	_	O
55	study	_	_	O
56	.	_	_	O

57	There	_	_	O
58	is	_	_	O
59	dearth	_	_	O
60	of	_	_	O
61	evidence	_	_	O
62	regarding	_	_	O
63	the	_	_	O
64	effects	_	_	O
65	of	_	_	O
66	LLLT	_	_	O
67	on	_	_	O
68	patient	_	_	O
69	'	_	_	O
70	s	_	_	O
71	subjective	_	_	O
72	experience	_	_	O
73	of	_	_	O
74	OM	_	_	O
75	and	_	_	O
76	QOL	_	_	O
77	.	_	_	O

78	Hence	_	_	O
79	,	_	_	O
80	we	_	_	O
81	did	_	_	O
82	this	_	_	O
83	study	_	_	O
84	to	_	_	O
85	evaluate	_	_	O
86	the	_	_	O
87	effects	_	_	O
88	of	_	_	O
89	LLLT	_	_	O
90	on	_	_	O
91	a	_	_	O
92	patient	_	_	O
93	'	_	_	O
94	s	_	_	O
95	reported	_	_	O
96	measures	_	_	O
97	of	_	_	O
98	OM	_	_	O
99	and	_	_	O
100	QOL	_	_	O
101	in	_	_	O
102	head	_	_	O
103	and	_	_	O
104	neck	_	_	O
105	cancer	_	_	O
106	(	_	_	O
107	HNC	_	_	O
108	)	_	_	O
109	patients	_	_	O
110	receiving	_	_	O
111	CRT	_	_	O
112	.	_	_	O

113	This	_	_	O
114	triple	_	_	O
115	blinded	_	_	O
116	study	_	_	O
117	randomized	_	_	O
118	220	_	_	O
119	HNC	_	_	O
120	patients	_	_	O
121	scheduled	_	_	O
122	for	_	_	O
123	CRT	_	_	O
124	(	_	_	O
125	three	_	_	O
126	weekly	_	_	O
127	Cisplatin	_	_	O
128	+	_	_	O
129	RT	_	_	O
130	=	_	_	O
131	66	_	_	O
132	Gray	_	_	O
133	(	_	_	O
134	2	_	_	O
135	Gy	_	_	O
136	/	_	_	O
137	session	_	_	O
138	)	_	_	O
139	,	_	_	O
140	five	_	_	O
141	fractions	_	_	O
142	/	_	_	O
143	week	_	_	O
144	for	_	_	O
145	6	_	_	O
146	.	_	_	O

147	5	_	_	O
148	weeks	_	_	O
149	,	_	_	O
150	total	_	_	O
151	33	_	_	O
152	fractions	_	_	O
153	)	_	_	O
154	into	_	_	O
155	laser	_	_	O
156	(	_	_	O
157	110	_	_	O
158	)	_	_	O
159	and	_	_	O
160	placebo	_	_	O
161	(	_	_	O
162	110	_	_	O
163	)	_	_	O
164	groups	_	_	O
165	.	_	_	O

166	The	_	_	O
167	laser	_	_	O
168	group	_	_	O
169	received	_	_	O
170	LLLT	_	_	O
171	(	_	_	O
172	Technomed	_	_	O
173	Electronics	_	_	O
174	Advanced	_	_	O
175	Laser	_	_	O
176	Therapy	_	_	O
177	1000	_	_	O
178	,	_	_	O
179	He	_	_	O
180	-	_	_	O
181	Ne	_	_	O
182	,	_	_	O
183	λ	_	_	O
184	=	_	_	O
185	632	_	_	O
186	.	_	_	O

187	8	_	_	O
188	nm	_	_	O
189	,	_	_	O
190	power	_	_	O
191	density	_	_	O
192	=	_	_	O
193	24	_	_	O
194	mW	_	_	O
195	/	_	_	O
196	cm	_	_	O
197	(	_	_	O
198	2	_	_	O
199	)	_	_	O
200	,	_	_	O
201	dosage	_	_	O
202	=	_	_	O
203	3	_	_	O
204	.	_	_	O

205	0	_	_	O
206	J	_	_	O
207	at	_	_	O
208	each	_	_	O
209	point	_	_	O
210	,	_	_	O
211	total	_	_	O
212	dose	_	_	O
213	/	_	_	O
214	session	_	_	O
215	=	_	_	O
216	36	_	_	O
217	-	_	_	O
218	40	_	_	O
219	J	_	_	O
220	,	_	_	O
221	spot	_	_	O
222	size	_	_	O
223	1	_	_	O
224	cm	_	_	O
225	(	_	_	O
226	2	_	_	O
227	)	_	_	O
228	,	_	_	O
229	irradiation	_	_	O
230	time	_	_	O
231	/	_	_	O
232	point	_	_	O
233	125	_	_	O
234	s	_	_	O
235	)	_	_	O
236	before	_	_	O
237	each	_	_	O
238	radiation	_	_	O
239	session	_	_	O
240	,	_	_	O
241	while	_	_	O
242	the	_	_	O
243	placebo	_	_	O
244	group	_	_	O
245	did	_	_	O
246	not	_	_	O
247	receive	_	_	O
248	laser	_	_	O
249	therapy	_	_	O
250	.	_	_	O

251	Methodology	_	_	O
252	was	_	_	O
253	similar	_	_	O
254	to	_	_	O
255	our	_	_	O
256	recently	_	_	O
257	published	_	_	O
258	study	_	_	O
259	(	_	_	O
260	Gautam	_	_	O
261	et	_	_	O
262	al	_	_	O
263	.	_	_	O

264	Radiother	_	_	O
265	Oncol	_	_	O
266	104	_	_	O
267	:	_	_	O
268	349	_	_	O
269	-	_	_	O
270	354	_	_	O
271	,	_	_	O
272	2012	_	_	O
273	)	_	_	O
274	.	_	_	O

275	In	_	_	O
276	this	_	_	O
277	part	_	_	O
278	of	_	_	O
279	our	_	_	O
280	study	_	_	O
281	,	_	_	O
282	a	_	_	O
283	blinded	_	_	O
284	assessor	_	_	O
285	collected	_	_	O
286	subjective	_	_	O
287	outcomes	_	_	O
288	of	_	_	O
289	the	_	_	O
290	patient	_	_	O
291	'	_	_	O
292	s	_	_	O
293	reported	_	_	O
294	measures	_	_	O
295	of	_	_	O
296	OM	_	_	O
297	using	_	_	O
298	Oral	_	_	O
299	Mucositis	_	_	O
300	Weekly	_	_	O
301	Questionnaire	_	_	O
302	-	_	_	O
303	Head	_	_	O
304	and	_	_	O
305	Neck	_	_	O
306	(	_	_	O
307	OMWQ	_	_	O
308	-	_	_	O
309	HN	_	_	O
310	)	_	_	O
311	and	_	_	O
312	QOL	_	_	O
313	using	_	_	O
314	Functional	_	_	O
315	Assessment	_	_	O
316	of	_	_	O
317	Cancer	_	_	O
318	Treatment	_	_	O
319	-	_	_	O
320	Head	_	_	O
321	and	_	_	O
322	Neck	_	_	O
323	(	_	_	O
324	FACT	_	_	O
325	-	_	_	O
326	HN	_	_	O
327	)	_	_	O
328	Questionnaire	_	_	O
329	.	_	_	O

330	Data	_	_	O
331	were	_	_	O
332	analyzed	_	_	O
333	using	_	_	O
334	repeated	_	_	O
335	measure	_	_	O
336	ANOVA	_	_	O
337	through	_	_	O
338	general	_	_	O
339	linear	_	_	O
340	model	_	_	O
341	.	_	_	O

342	Statistical	_	_	O
343	significance	_	_	O
344	was	_	_	O
345	kept	_	_	O
346	at	_	_	O
347	p	_	_	O
348	<	_	_	O
349	0	_	_	O
350	.	_	_	O

351	05	_	_	O
352	.	_	_	O

353	Results	_	_	B-Premise
354	analysis	_	_	I-Premise
355	revealed	_	_	I-Premise
356	that	_	_	I-Premise
357	OMWQ	_	_	I-Premise
358	-	_	_	I-Premise
359	HN	_	_	I-Premise
360	(	_	_	I-Premise
361	F	_	_	I-Premise
362	=	_	_	I-Premise
363	12	_	_	I-Premise
364	.	_	_	I-Premise

365	199	_	_	I-Premise
366	,	_	_	I-Premise
367	df	_	_	I-Premise
368	=	_	_	I-Premise
369	6	_	_	I-Premise
370	,	_	_	I-Premise
371	1314	_	_	I-Premise
372	,	_	_	I-Premise
373	p	_	_	I-Premise
374	<	_	_	I-Premise
375	0	_	_	I-Premise
376	.	_	_	I-Premise

377	001	_	_	I-Premise
378	)	_	_	I-Premise
379	and	_	_	I-Premise
380	FACT	_	_	I-Premise
381	-	_	_	I-Premise
382	HN	_	_	I-Premise
383	(	_	_	I-Premise
384	p	_	_	I-Premise
385	<	_	_	I-Premise
386	0	_	_	I-Premise
387	.	_	_	I-Premise

388	05	_	_	I-Premise
389	)	_	_	I-Premise
390	scores	_	_	I-Premise
391	were	_	_	I-Premise
392	significantly	_	_	I-Premise
393	lower	_	_	I-Premise
394	in	_	_	I-Premise
395	LLLT	_	_	I-Premise
396	than	_	_	I-Premise
397	placebo	_	_	I-Premise
398	group	_	_	I-Premise
399	patients	_	_	I-Premise
400	.	_	_	I-Premise

401	Also	_	_	O
402	,	_	_	O
403	a	_	_	B-Premise
404	significant	_	_	I-Premise
405	reduction	_	_	I-Premise
406	(	_	_	I-Premise
407	p	_	_	I-Premise
408	<	_	_	I-Premise
409	0	_	_	I-Premise
410	.	_	_	I-Premise

411	001	_	_	I-Premise
412	)	_	_	I-Premise
413	in	_	_	I-Premise
414	incidence	_	_	I-Premise
415	of	_	_	I-Premise
416	severe	_	_	I-Premise
417	OM	_	_	I-Premise
418	,	_	_	I-Premise
419	need	_	_	I-Premise
420	for	_	_	I-Premise
421	opioid	_	_	I-Premise
422	analgesics	_	_	I-Premise
423	,	_	_	I-Premise
424	and	_	_	I-Premise
425	total	_	_	I-Premise
426	parenteral	_	_	I-Premise
427	nutrition	_	_	I-Premise
428	was	_	_	I-Premise
429	observed	_	_	I-Premise
430	.	_	_	I-Premise

431	LLLT	_	_	B-Claim
432	was	_	_	I-Claim
433	effective	_	_	I-Claim
434	in	_	_	I-Claim
435	improving	_	_	I-Claim
436	the	_	_	I-Claim
437	patient	_	_	I-Claim
438	'	_	_	I-Claim
439	s	_	_	I-Claim
440	subjective	_	_	I-Claim
441	experience	_	_	I-Claim
442	of	_	_	I-Claim
443	OM	_	_	I-Claim
444	and	_	_	I-Claim
445	QOL	_	_	I-Claim
446	in	_	_	I-Claim
447	HNC	_	_	I-Claim
448	patients	_	_	I-Claim
449	receiving	_	_	I-Claim
450	CRT	_	_	I-Claim
451	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	the	_	_	O
3	impact	_	_	O
4	of	_	_	O
5	dietary	_	_	O
6	counseling	_	_	O
7	or	_	_	O
8	nutritional	_	_	O
9	supplements	_	_	O
10	on	_	_	O
11	outcomes	_	_	O
12	in	_	_	O
13	cancer	_	_	O
14	patients	_	_	O
15	:	_	_	O
16	nutritional	_	_	O
17	,	_	_	O
18	morbidity	_	_	O
19	,	_	_	O
20	and	_	_	O
21	quality	_	_	O
22	of	_	_	O
23	life	_	_	O
24	(	_	_	O
25	QoL	_	_	O
26	)	_	_	O
27	during	_	_	O
28	and	_	_	O
29	3	_	_	O
30	months	_	_	O
31	after	_	_	O
32	radiotherapy	_	_	O
33	.	_	_	O

34	A	_	_	O
35	total	_	_	O
36	of	_	_	O
37	111	_	_	O
38	colorectal	_	_	O
39	cancer	_	_	O
40	outpatients	_	_	O
41	referred	_	_	O
42	for	_	_	O
43	radiotherapy	_	_	O
44	,	_	_	O
45	stratified	_	_	O
46	by	_	_	O
47	staging	_	_	O
48	,	_	_	O
49	were	_	_	O
50	randomly	_	_	O
51	assigned	_	_	O
52	:	_	_	O
53	group	_	_	O
54	1	_	_	O
55	(	_	_	O
56	G1	_	_	O
57	;	_	_	O
58	n	_	_	O
59	=	_	_	O
60	37	_	_	O
61	)	_	_	O
62	,	_	_	O
63	dietary	_	_	O
64	counseling	_	_	O
65	(	_	_	O
66	regular	_	_	O
67	foods	_	_	O
68	)	_	_	O
69	;	_	_	O
70	group	_	_	O
71	2	_	_	O
72	(	_	_	O
73	G2	_	_	O
74	;	_	_	O
75	n	_	_	O
76	=	_	_	O
77	37	_	_	O
78	)	_	_	O
79	,	_	_	O
80	protein	_	_	O
81	supplements	_	_	O
82	;	_	_	O
83	and	_	_	O
84	group	_	_	O
85	3	_	_	O
86	(	_	_	O
87	G3	_	_	O
88	;	_	_	O
89	n	_	_	O
90	=	_	_	O
91	37	_	_	O
92	)	_	_	O
93	,	_	_	O
94	ad	_	_	O
95	libitum	_	_	O
96	intake	_	_	O
97	.	_	_	O

98	Nutritional	_	_	O
99	intake	_	_	O
100	(	_	_	O
101	diet	_	_	O
102	history	_	_	O
103	)	_	_	O
104	,	_	_	O
105	status	_	_	O
106	(	_	_	O
107	Ottery	_	_	O
108	'	_	_	O
109	s	_	_	O
110	Subjective	_	_	O
111	Global	_	_	O
112	Assessment	_	_	O
113	)	_	_	O
114	,	_	_	O
115	and	_	_	O
116	QoL	_	_	O
117	(	_	_	O
118	European	_	_	O
119	Organisation	_	_	O
120	for	_	_	O
121	Research	_	_	O
122	and	_	_	O
123	Treatment	_	_	O
124	of	_	_	O
125	Cancer	_	_	O
126	Quality	_	_	O
127	of	_	_	O
128	Life	_	_	O
129	Questionnaire	_	_	O
130	version	_	_	O
131	3	_	_	O
132	.	_	_	O

133	0	_	_	O
134	)	_	_	O
135	were	_	_	O
136	evaluated	_	_	O
137	at	_	_	O
138	baseline	_	_	O
139	,	_	_	O
140	at	_	_	O
141	the	_	_	O
142	end	_	_	O
143	,	_	_	O
144	and	_	_	O
145	3	_	_	O
146	months	_	_	O
147	after	_	_	O
148	radiotherapy	_	_	O
149	.	_	_	O

150	At	_	_	B-Premise
151	radiotherapy	_	_	I-Premise
152	completion	_	_	I-Premise
153	,	_	_	I-Premise
154	energy	_	_	I-Premise
155	intake	_	_	I-Premise
156	increased	_	_	I-Premise
157	in	_	_	I-Premise
158	G1	_	_	I-Premise
159	/	_	_	I-Premise
160	G2	_	_	I-Premise
161	(	_	_	I-Premise
162	P	_	_	I-Premise
163	<	_	_	I-Premise
164	or	_	_	I-Premise
165	=	_	_	I-Premise
166	.	_	_	I-Premise

167	04	_	_	I-Premise
168	)	_	_	I-Premise
169	,	_	_	I-Premise
170	G1	_	_	I-Premise
171	more	_	_	I-Premise
172	than	_	_	I-Premise
173	G2	_	_	I-Premise
174	(	_	_	I-Premise
175	P	_	_	I-Premise
176	=	_	_	I-Premise
177	.	_	_	I-Premise

178	001	_	_	I-Premise
179	)	_	_	I-Premise
180	,	_	_	I-Premise
181	and	_	_	I-Premise
182	decreased	_	_	I-Premise
183	in	_	_	I-Premise
184	G3	_	_	I-Premise
185	(	_	_	I-Premise
186	P	_	_	I-Premise
187	<	_	_	I-Premise
188	.	_	_	I-Premise

189	01	_	_	I-Premise
190	)	_	_	I-Premise
191	.	_	_	I-Premise

192	Protein	_	_	B-Premise
193	intake	_	_	I-Premise
194	increased	_	_	I-Premise
195	in	_	_	I-Premise
196	G1	_	_	I-Premise
197	/	_	_	I-Premise
198	G2	_	_	I-Premise
199	(	_	_	I-Premise
200	P	_	_	I-Premise
201	<	_	_	I-Premise
202	or	_	_	I-Premise
203	=	_	_	I-Premise
204	.	_	_	I-Premise

205	007	_	_	I-Premise
206	)	_	_	I-Premise
207	,	_	_	I-Premise
208	G1	_	_	I-Premise
209	less	_	_	I-Premise
210	than	_	_	I-Premise
211	G2	_	_	I-Premise
212	(	_	_	I-Premise
213	not	_	_	I-Premise
214	significant	_	_	I-Premise
215	)	_	_	I-Premise
216	,	_	_	I-Premise
217	and	_	_	I-Premise
218	decreased	_	_	I-Premise
219	in	_	_	I-Premise
220	G3	_	_	I-Premise
221	(	_	_	I-Premise
222	P	_	_	I-Premise
223	<	_	_	I-Premise
224	.	_	_	I-Premise

225	01	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	At	_	_	B-Premise
229	3	_	_	I-Premise
230	months	_	_	I-Premise
231	,	_	_	I-Premise
232	G1	_	_	I-Premise
233	maintained	_	_	I-Premise
234	nutritional	_	_	I-Premise
235	intake	_	_	I-Premise
236	and	_	_	I-Premise
237	G2	_	_	I-Premise
238	/	_	_	I-Premise
239	G3	_	_	I-Premise
240	returned	_	_	I-Premise
241	to	_	_	I-Premise
242	baseline	_	_	I-Premise
243	.	_	_	I-Premise

244	After	_	_	B-Premise
245	radiotherapy	_	_	I-Premise
246	and	_	_	I-Premise
247	at	_	_	I-Premise
248	3	_	_	I-Premise
249	months	_	_	I-Premise
250	,	_	_	I-Premise
251	rates	_	_	I-Premise
252	of	_	_	I-Premise
253	anorexia	_	_	I-Premise
254	,	_	_	I-Premise
255	nausea	_	_	I-Premise
256	,	_	_	I-Premise
257	vomiting	_	_	I-Premise
258	,	_	_	I-Premise
259	and	_	_	I-Premise
260	diarrhea	_	_	I-Premise
261	were	_	_	I-Premise
262	higher	_	_	I-Premise
263	in	_	_	I-Premise
264	G3	_	_	I-Premise
265	(	_	_	I-Premise
266	P	_	_	I-Premise
267	<	_	_	I-Premise
268	.	_	_	I-Premise

269	05	_	_	I-Premise
270	)	_	_	I-Premise
271	.	_	_	I-Premise

272	At	_	_	B-Premise
273	radiotherapy	_	_	I-Premise
274	completion	_	_	I-Premise
275	,	_	_	I-Premise
276	in	_	_	I-Premise
277	G1	_	_	I-Premise
278	all	_	_	I-Premise
279	QoL	_	_	I-Premise
280	function	_	_	I-Premise
281	scores	_	_	I-Premise
282	improved	_	_	I-Premise
283	proportionally	_	_	I-Premise
284	to	_	_	I-Premise
285	adequate	_	_	I-Premise
286	intake	_	_	I-Premise
287	or	_	_	I-Premise
288	nutritional	_	_	I-Premise
289	status	_	_	I-Premise
290	(	_	_	I-Premise
291	P	_	_	I-Premise
292	<	_	_	I-Premise
293	.	_	_	I-Premise

294	05	_	_	I-Premise
295	)	_	_	I-Premise
296	;	_	_	I-Premise
297	whereas	_	_	I-Premise
298	in	_	_	I-Premise
299	G2	_	_	I-Premise
300	only	_	_	I-Premise
301	three	_	_	I-Premise
302	of	_	_	I-Premise
303	six	_	_	I-Premise
304	function	_	_	I-Premise
305	scores	_	_	I-Premise
306	improved	_	_	I-Premise
307	proportionally	_	_	I-Premise
308	to	_	_	I-Premise
309	protein	_	_	I-Premise
310	intake	_	_	I-Premise
311	(	_	_	I-Premise
312	P	_	_	I-Premise
313	=	_	_	I-Premise
314	.	_	_	I-Premise

315	04	_	_	I-Premise
316	)	_	_	I-Premise
317	,	_	_	I-Premise
318	and	_	_	I-Premise
319	in	_	_	I-Premise
320	G3	_	_	I-Premise
321	all	_	_	I-Premise
322	scores	_	_	I-Premise
323	worsened	_	_	I-Premise
324	(	_	_	I-Premise
325	P	_	_	I-Premise
326	<	_	_	I-Premise
327	.	_	_	I-Premise

328	05	_	_	I-Premise
329	)	_	_	I-Premise
330	.	_	_	I-Premise

331	At	_	_	B-Premise
332	3	_	_	I-Premise
333	months	_	_	I-Premise
334	,	_	_	I-Premise
335	G1	_	_	I-Premise
336	patients	_	_	I-Premise
337	maintained	_	_	I-Premise
338	/	_	_	I-Premise
339	improved	_	_	I-Premise
340	function	_	_	I-Premise
341	,	_	_	I-Premise
342	symptoms	_	_	I-Premise
343	,	_	_	I-Premise
344	and	_	_	I-Premise
345	single	_	_	I-Premise
346	-	_	_	I-Premise
347	item	_	_	I-Premise
348	scores	_	_	I-Premise
349	(	_	_	I-Premise
350	P	_	_	I-Premise
351	<	_	_	I-Premise
352	.	_	_	I-Premise

353	02	_	_	I-Premise
354	)	_	_	I-Premise
355	;	_	_	I-Premise
356	in	_	_	I-Premise
357	G2	_	_	I-Premise
358	,	_	_	I-Premise
359	only	_	_	I-Premise
360	few	_	_	I-Premise
361	function	_	_	I-Premise
362	and	_	_	I-Premise
363	symptom	_	_	I-Premise
364	scales	_	_	I-Premise
365	improved	_	_	I-Premise
366	(	_	_	I-Premise
367	P	_	_	I-Premise
368	<	_	_	I-Premise
369	.	_	_	I-Premise

370	05	_	_	I-Premise
371	)	_	_	I-Premise
372	;	_	_	I-Premise
373	in	_	_	I-Premise
374	G3	_	_	I-Premise
375	,	_	_	I-Premise
376	QoL	_	_	I-Premise
377	remained	_	_	I-Premise
378	as	_	_	I-Premise
379	poor	_	_	I-Premise
380	as	_	_	I-Premise
381	after	_	_	I-Premise
382	radiotherapy	_	_	I-Premise
383	.	_	_	I-Premise

384	In	_	_	B-Premise
385	G1	_	_	I-Premise
386	/	_	_	I-Premise
387	G2	_	_	I-Premise
388	,	_	_	I-Premise
389	respectively	_	_	I-Premise
390	,	_	_	I-Premise
391	improvement	_	_	I-Premise
392	/	_	_	I-Premise
393	deterioration	_	_	I-Premise
394	of	_	_	I-Premise
395	QoL	_	_	I-Premise
396	correlated	_	_	I-Premise
397	with	_	_	I-Premise
398	better	_	_	I-Premise
399	or	_	_	I-Premise
400	poorer	_	_	I-Premise
401	intake	_	_	I-Premise
402	or	_	_	I-Premise
403	nutritional	_	_	I-Premise
404	status	_	_	I-Premise
405	(	_	_	I-Premise
406	P	_	_	I-Premise
407	<	_	_	I-Premise
408	.	_	_	I-Premise

409	003	_	_	I-Premise
410	)	_	_	I-Premise
411	.	_	_	I-Premise

412	During	_	_	B-Claim
413	radiotherapy	_	_	I-Claim
414	,	_	_	I-Claim
415	both	_	_	I-Claim
416	interventions	_	_	I-Claim
417	positively	_	_	I-Claim
418	influenced	_	_	I-Claim
419	outcomes	_	_	I-Claim
420	;	_	_	I-Claim
421	dietary	_	_	B-Claim
422	counseling	_	_	I-Claim
423	was	_	_	I-Claim
424	of	_	_	I-Claim
425	similar	_	_	I-Claim
426	or	_	_	I-Claim
427	higher	_	_	I-Claim
428	benefit	_	_	I-Claim
429	,	_	_	I-Claim
430	whereas	_	_	I-Claim
431	even	_	_	I-Claim
432	3	_	_	I-Claim
433	months	_	_	I-Claim
434	after	_	_	I-Claim
435	RT	_	_	I-Claim
436	,	_	_	I-Claim
437	it	_	_	I-Claim
438	was	_	_	I-Claim
439	the	_	_	I-Claim
440	only	_	_	I-Claim
441	method	_	_	I-Claim
442	to	_	_	I-Claim
443	sustain	_	_	I-Claim
444	a	_	_	I-Claim
445	significant	_	_	I-Claim
446	impact	_	_	I-Claim
447	on	_	_	I-Claim
448	patient	_	_	I-Claim
449	outcomes	_	_	I-Claim
450	.	_	_	I-Claim


0	Gefitinib	_	_	O
1	has	_	_	O
2	shown	_	_	O
3	high	_	_	O
4	response	_	_	O
5	rate	_	_	O
6	and	_	_	O
7	improved	_	_	O
8	progression	_	_	O
9	-	_	_	O
10	free	_	_	O
11	survival	_	_	O
12	(	_	_	O
13	PFS	_	_	O
14	)	_	_	O
15	in	_	_	O
16	never	_	_	O
17	-	_	_	O
18	smokers	_	_	O
19	with	_	_	O
20	lung	_	_	O
21	adenocarcinoma	_	_	O
22	(	_	_	O
23	NSLAs	_	_	O
24	)	_	_	O
25	.	_	_	O

26	We	_	_	O
27	compared	_	_	O
28	efficacy	_	_	O
29	of	_	_	O
30	gefitinib	_	_	O
31	with	_	_	O
32	gemcitabine	_	_	O
33	and	_	_	O
34	cisplatin	_	_	O
35	(	_	_	O
36	GP	_	_	O
37	)	_	_	O
38	chemotherapy	_	_	O
39	in	_	_	O
40	this	_	_	O
41	group	_	_	O
42	of	_	_	O
43	patients	_	_	O
44	as	_	_	O
45	first	_	_	O
46	-	_	_	O
47	line	_	_	O
48	therapy	_	_	O
49	.	_	_	O

50	In	_	_	O
51	this	_	_	O
52	randomized	_	_	O
53	phase	_	_	O
54	III	_	_	O
55	trial	_	_	O
56	,	_	_	O
57	a	_	_	O
58	total	_	_	O
59	of	_	_	O
60	313	_	_	O
61	Korean	_	_	O
62	never	_	_	O
63	-	_	_	O
64	smokers	_	_	O
65	with	_	_	O
66	stage	_	_	O
67	IIIB	_	_	O
68	or	_	_	O
69	IV	_	_	O
70	lung	_	_	O
71	adenocarcinoma	_	_	O
72	,	_	_	O
73	Eastern	_	_	O
74	Cooperative	_	_	O
75	Oncology	_	_	O
76	Group	_	_	O
77	performance	_	_	O
78	status	_	_	O
79	0	_	_	O
80	to	_	_	O
81	2	_	_	O
82	,	_	_	O
83	and	_	_	O
84	adequate	_	_	O
85	organ	_	_	O
86	function	_	_	O
87	were	_	_	O
88	randomly	_	_	O
89	assigned	_	_	O
90	to	_	_	O
91	receive	_	_	O
92	either	_	_	O
93	gefitinib	_	_	O
94	(	_	_	O
95	250	_	_	O
96	mg	_	_	O
97	daily	_	_	O
98	)	_	_	O
99	or	_	_	O
100	GP	_	_	O
101	chemotherapy	_	_	O
102	(	_	_	O
103	gemcitabine	_	_	O
104	1	_	_	O
105	,	_	_	O
106	250	_	_	O
107	mg	_	_	O
108	/	_	_	O
109	m	_	_	O
110	(	_	_	O
111	2	_	_	O
112	)	_	_	O
113	on	_	_	O
114	days	_	_	O
115	1	_	_	O
116	and	_	_	O
117	8	_	_	O
118	;	_	_	O
119	cisplatin	_	_	O
120	80	_	_	O
121	mg	_	_	O
122	/	_	_	O
123	m	_	_	O
124	(	_	_	O
125	2	_	_	O
126	)	_	_	O
127	on	_	_	O
128	day	_	_	O
129	1	_	_	O
130	every	_	_	O
131	3	_	_	O
132	weeks	_	_	O
133	,	_	_	O
134	for	_	_	O
135	up	_	_	O
136	to	_	_	O
137	nine	_	_	O
138	courses	_	_	O
139	)	_	_	O
140	.	_	_	O

141	The	_	_	O
142	primary	_	_	O
143	objective	_	_	O
144	was	_	_	O
145	to	_	_	O
146	demonstrate	_	_	O
147	better	_	_	O
148	overall	_	_	O
149	survival	_	_	O
150	(	_	_	O
151	OS	_	_	O
152	)	_	_	O
153	for	_	_	O
154	gefitinib	_	_	O
155	compared	_	_	O
156	with	_	_	O
157	GP	_	_	O
158	in	_	_	O
159	chemotherapy	_	_	O
160	-	_	_	O
161	naive	_	_	O
162	NSLAs	_	_	O
163	.	_	_	O

164	Three	_	_	O
165	hundred	_	_	O
166	nine	_	_	O
167	patients	_	_	O
168	were	_	_	O
169	analyzed	_	_	O
170	per	_	_	O
171	protocol	_	_	O
172	(	_	_	O
173	gefitinib	_	_	O
174	arm	_	_	O
175	,	_	_	O
176	n	_	_	O
177	=	_	_	O
178	159	_	_	O
179	;	_	_	O
180	GP	_	_	O
181	arm	_	_	O
182	,	_	_	O
183	n	_	_	O
184	=	_	_	O
185	150	_	_	O
186	)	_	_	O
187	.	_	_	O

188	Gefitinib	_	_	B-Premise
189	did	_	_	I-Premise
190	not	_	_	I-Premise
191	show	_	_	I-Premise
192	better	_	_	I-Premise
193	OS	_	_	I-Premise
194	compared	_	_	I-Premise
195	with	_	_	I-Premise
196	GP	_	_	I-Premise
197	(	_	_	I-Premise
198	hazard	_	_	I-Premise
199	ratio	_	_	I-Premise
200	[	_	_	I-Premise
201	HR	_	_	I-Premise
202	]	_	_	I-Premise
203	,	_	_	I-Premise
204	0	_	_	I-Premise
205	.	_	_	I-Premise

206	932	_	_	I-Premise
207	;	_	_	I-Premise
208	95	_	_	I-Premise
209	%	_	_	I-Premise
210	CI	_	_	I-Premise
211	,	_	_	I-Premise
212	0	_	_	I-Premise
213	.	_	_	I-Premise

214	716	_	_	I-Premise
215	to	_	_	I-Premise
216	1	_	_	I-Premise
217	.	_	_	I-Premise

218	213	_	_	I-Premise
219	;	_	_	I-Premise
220	P	_	_	I-Premise
221	=	_	_	I-Premise
222	.	_	_	I-Premise

223	604	_	_	I-Premise
224	;	_	_	I-Premise
225	median	_	_	I-Premise
226	OS	_	_	I-Premise
227	,	_	_	I-Premise
228	22	_	_	I-Premise
229	.	_	_	I-Premise

230	3	_	_	I-Premise
231	v	_	_	I-Premise
232	22	_	_	I-Premise
233	.	_	_	I-Premise

234	9	_	_	I-Premise
235	months	_	_	I-Premise
236	,	_	_	I-Premise
237	respectively	_	_	I-Premise
238	)	_	_	I-Premise
239	.	_	_	I-Premise

240	The	_	_	B-Premise
241	1	_	_	I-Premise
242	-	_	_	I-Premise
243	year	_	_	I-Premise
244	PFS	_	_	I-Premise
245	rates	_	_	I-Premise
246	were	_	_	I-Premise
247	16	_	_	I-Premise
248	.	_	_	I-Premise

249	7	_	_	I-Premise
250	%	_	_	I-Premise
251	with	_	_	I-Premise
252	gefitinib	_	_	I-Premise
253	and	_	_	I-Premise
254	2	_	_	I-Premise
255	.	_	_	I-Premise

256	8	_	_	I-Premise
257	%	_	_	I-Premise
258	with	_	_	I-Premise
259	GP	_	_	I-Premise
260	(	_	_	I-Premise
261	HR	_	_	I-Premise
262	,	_	_	I-Premise
263	1	_	_	I-Premise
264	.	_	_	I-Premise

265	198	_	_	I-Premise
266	;	_	_	I-Premise
267	95	_	_	I-Premise
268	%	_	_	I-Premise
269	CI	_	_	I-Premise
270	,	_	_	I-Premise
271	0	_	_	I-Premise
272	.	_	_	I-Premise

273	944	_	_	I-Premise
274	to	_	_	I-Premise
275	1	_	_	I-Premise
276	.	_	_	I-Premise

277	520	_	_	I-Premise
278	)	_	_	I-Premise
279	.	_	_	I-Premise

280	Response	_	_	B-Premise
281	rates	_	_	I-Premise
282	were	_	_	I-Premise
283	55	_	_	I-Premise
284	%	_	_	I-Premise
285	with	_	_	I-Premise
286	gefitinib	_	_	I-Premise
287	and	_	_	I-Premise
288	46	_	_	I-Premise
289	%	_	_	I-Premise
290	with	_	_	I-Premise
291	GP	_	_	I-Premise
292	(	_	_	I-Premise
293	P	_	_	I-Premise
294	=	_	_	I-Premise
295	.	_	_	I-Premise

296	101	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	Myelosuppression	_	_	B-Premise
300	,	_	_	I-Premise
301	renal	_	_	I-Premise
302	insufficiency	_	_	I-Premise
303	,	_	_	I-Premise
304	and	_	_	I-Premise
305	fatigue	_	_	I-Premise
306	were	_	_	I-Premise
307	more	_	_	I-Premise
308	common	_	_	I-Premise
309	in	_	_	I-Premise
310	the	_	_	I-Premise
311	GP	_	_	I-Premise
312	arm	_	_	I-Premise
313	,	_	_	I-Premise
314	but	_	_	O
315	skin	_	_	B-Premise
316	toxicities	_	_	I-Premise
317	and	_	_	I-Premise
318	liver	_	_	I-Premise
319	dysfunction	_	_	I-Premise
320	were	_	_	I-Premise
321	more	_	_	I-Premise
322	common	_	_	I-Premise
323	in	_	_	I-Premise
324	the	_	_	I-Premise
325	gefitinib	_	_	I-Premise
326	arm	_	_	I-Premise
327	.	_	_	I-Premise

328	Two	_	_	B-Premise
329	patients	_	_	I-Premise
330	(	_	_	I-Premise
331	1	_	_	I-Premise
332	.	_	_	I-Premise

333	3	_	_	I-Premise
334	%	_	_	I-Premise
335	)	_	_	I-Premise
336	in	_	_	I-Premise
337	the	_	_	I-Premise
338	gefitinib	_	_	I-Premise
339	arm	_	_	I-Premise
340	developed	_	_	I-Premise
341	interstitial	_	_	I-Premise
342	lung	_	_	I-Premise
343	disease	_	_	I-Premise
344	and	_	_	I-Premise
345	died	_	_	I-Premise
346	.	_	_	I-Premise

347	Gefitinib	_	_	B-Claim
348	failed	_	_	I-Claim
349	to	_	_	I-Claim
350	demonstrate	_	_	I-Claim
351	superior	_	_	I-Claim
352	OS	_	_	I-Claim
353	compared	_	_	I-Claim
354	with	_	_	I-Claim
355	GP	_	_	I-Claim
356	as	_	_	I-Claim
357	first	_	_	I-Claim
358	-	_	_	I-Claim
359	line	_	_	I-Claim
360	therapy	_	_	I-Claim
361	for	_	_	I-Claim
362	NSLAs	_	_	I-Claim
363	.	_	_	I-Claim


0	Anemia	_	_	B-Claim
1	,	_	_	I-Claim
2	highly	_	_	I-Claim
3	common	_	_	I-Claim
4	among	_	_	I-Claim
5	cancer	_	_	I-Claim
6	patients	_	_	I-Claim
7	,	_	_	I-Claim
8	is	_	_	I-Claim
9	often	_	_	I-Claim
10	an	_	_	I-Claim
11	underlying	_	_	I-Claim
12	cause	_	_	I-Claim
13	of	_	_	I-Claim
14	cancer	_	_	I-Claim
15	-	_	_	I-Claim
16	related	_	_	I-Claim
17	fatigue	_	_	I-Claim
18	and	_	_	I-Claim
19	other	_	_	I-Claim
20	quality	_	_	I-Claim
21	-	_	_	I-Claim
22	of	_	_	I-Claim
23	-	_	_	I-Claim
24	life	_	_	I-Claim
25	(	_	_	I-Claim
26	QOL	_	_	I-Claim
27	)	_	_	I-Claim
28	deficits	_	_	I-Claim
29	.	_	_	I-Claim

30	Although	_	_	O
31	randomized	_	_	O
32	clinical	_	_	O
33	trials	_	_	O
34	have	_	_	O
35	shown	_	_	O
36	that	_	_	O
37	treatment	_	_	O
38	with	_	_	O
39	epoetin	_	_	O
40	alfa	_	_	O
41	increases	_	_	O
42	hemoglobin	_	_	O
43	levels	_	_	O
44	,	_	_	O
45	reduces	_	_	O
46	fatigue	_	_	O
47	,	_	_	O
48	lessens	_	_	O
49	transfusion	_	_	O
50	requirements	_	_	O
51	,	_	_	O
52	and	_	_	O
53	improves	_	_	O
54	overall	_	_	O
55	QOL	_	_	O
56	,	_	_	O
57	cancer	_	_	O
58	-	_	_	O
59	related	_	_	O
60	anemia	_	_	O
61	and	_	_	O
62	fatigue	_	_	O
63	remain	_	_	O
64	undertreated	_	_	O
65	.	_	_	O

66	This	_	_	O
67	is	_	_	O
68	,	_	_	O
69	in	_	_	O
70	part	_	_	O
71	,	_	_	O
72	because	_	_	O
73	scales	_	_	O
74	and	_	_	O
75	measures	_	_	O
76	of	_	_	O
77	QOL	_	_	O
78	are	_	_	O
79	still	_	_	O
80	relatively	_	_	O
81	unfamiliar	_	_	O
82	to	_	_	O
83	most	_	_	O
84	clinicians	_	_	O
85	and	_	_	O
86	because	_	_	O
87	population	_	_	O
88	-	_	_	O
89	based	_	_	O
90	reference	_	_	O
91	ranges	_	_	O
92	are	_	_	O
93	lacking	_	_	O
94	,	_	_	O
95	thus	_	_	O
96	making	_	_	O
97	clinical	_	_	O
98	trial	_	_	O
99	results	_	_	O
100	difficult	_	_	O
101	to	_	_	O
102	interpret	_	_	O
103	.	_	_	O

104	To	_	_	O
105	aid	_	_	O
106	in	_	_	O
107	the	_	_	O
108	interpretation	_	_	O
109	of	_	_	O
110	QOL	_	_	O
111	results	_	_	O
112	from	_	_	O
113	clinical	_	_	O
114	trials	_	_	O
115	,	_	_	O
116	we	_	_	O
117	administered	_	_	O
118	the	_	_	O
119	Functional	_	_	O
120	Assessment	_	_	O
121	of	_	_	O
122	Cancer	_	_	O
123	Therapy	_	_	O
124	-	_	_	O
125	Anemia	_	_	O
126	(	_	_	O
127	FACT	_	_	O
128	-	_	_	O
129	An	_	_	O
130	)	_	_	O
131	QOL	_	_	O
132	instrument	_	_	O
133	to	_	_	O
134	a	_	_	O
135	nationally	_	_	O
136	representative	_	_	O
137	sample	_	_	O
138	of	_	_	O
139	1	_	_	O
140	,	_	_	O
141	400	_	_	O
142	people	_	_	O
143	using	_	_	O
144	an	_	_	O
145	Internet	_	_	O
146	survey	_	_	O
147	panel	_	_	O
148	in	_	_	O
149	the	_	_	O
150	United	_	_	O
151	States	_	_	O
152	.	_	_	O

153	We	_	_	O
154	then	_	_	O
155	compared	_	_	O
156	the	_	_	O
157	FACT	_	_	O
158	-	_	_	O
159	An	_	_	O
160	data	_	_	O
161	from	_	_	O
162	the	_	_	O
163	Internet	_	_	O
164	survey	_	_	O
165	with	_	_	O
166	the	_	_	O
167	QOL	_	_	O
168	data	_	_	O
169	of	_	_	O
170	a	_	_	O
171	375	_	_	O
172	-	_	_	O
173	patient	_	_	O
174	randomized	_	_	O
175	,	_	_	O
176	double	_	_	O
177	-	_	_	O
178	blind	_	_	O
179	clinical	_	_	O
180	trial	_	_	O
181	evaluating	_	_	O
182	epoetin	_	_	O
183	alfa	_	_	O
184	versus	_	_	O
185	placebo	_	_	O
186	in	_	_	O
187	anemic	_	_	O
188	cancer	_	_	O
189	patients	_	_	O
190	.	_	_	O

191	FACT	_	_	O
192	-	_	_	O
193	An	_	_	O
194	,	_	_	O
195	as	_	_	O
196	administered	_	_	O
197	to	_	_	O
198	the	_	_	O
199	survey	_	_	O
200	population	_	_	O
201	,	_	_	O
202	displayed	_	_	O
203	good	_	_	O
204	psychometric	_	_	O
205	properties	_	_	O
206	and	_	_	O
207	was	_	_	O
208	able	_	_	O
209	to	_	_	O
210	discriminate	_	_	O
211	between	_	_	O
212	respondents	_	_	O
213	with	_	_	O
214	histories	_	_	O
215	of	_	_	O
216	specified	_	_	O
217	illnesses	_	_	O
218	,	_	_	O
219	including	_	_	O
220	anemia	_	_	O
221	and	_	_	O
222	cancer	_	_	O
223	,	_	_	O
224	and	_	_	O
225	those	_	_	O
226	without	_	_	O
227	.	_	_	O

228	Comparison	_	_	B-Premise
229	of	_	_	I-Premise
230	the	_	_	I-Premise
231	population	_	_	I-Premise
232	norm	_	_	I-Premise
233	and	_	_	I-Premise
234	clinical	_	_	I-Premise
235	trial	_	_	I-Premise
236	data	_	_	I-Premise
237	showed	_	_	I-Premise
238	that	_	_	I-Premise
239	treatment	_	_	I-Premise
240	with	_	_	I-Premise
241	epoetin	_	_	I-Premise
242	alfa	_	_	I-Premise
243	resulted	_	_	I-Premise
244	in	_	_	I-Premise
245	clinically	_	_	I-Premise
246	meaningful	_	_	I-Premise
247	as	_	_	I-Premise
248	well	_	_	I-Premise
249	as	_	_	I-Premise
250	statistically	_	_	I-Premise
251	significant	_	_	I-Premise
252	improvements	_	_	I-Premise
253	in	_	_	I-Premise
254	QOL	_	_	I-Premise
255	(	_	_	I-Premise
256	P	_	_	I-Premise
257	<	_	_	I-Premise
258	.	_	_	I-Premise

259	01	_	_	I-Premise
260	)	_	_	I-Premise
261	.	_	_	I-Premise

262	Reliable	_	_	O
263	population	_	_	O
264	norm	_	_	O
265	data	_	_	O
266	are	_	_	O
267	now	_	_	O
268	available	_	_	O
269	to	_	_	O
270	aid	_	_	O
271	in	_	_	O
272	the	_	_	O
273	interpretation	_	_	O
274	of	_	_	O
275	clinical	_	_	O
276	trial	_	_	O
277	results	_	_	O
278	where	_	_	O
279	the	_	_	O
280	FACT	_	_	O
281	-	_	_	O
282	An	_	_	O
283	questionnaire	_	_	O
284	is	_	_	O
285	administered	_	_	O
286	.	_	_	O

287	In	_	_	B-Claim
288	the	_	_	I-Claim
289	clinical	_	_	I-Claim
290	trial	_	_	I-Claim
291	,	_	_	I-Claim
292	treatment	_	_	I-Claim
293	with	_	_	I-Claim
294	epoetin	_	_	I-Claim
295	alfa	_	_	I-Claim
296	overcame	_	_	I-Claim
297	much	_	_	I-Claim
298	of	_	_	I-Claim
299	the	_	_	I-Claim
300	QOL	_	_	I-Claim
301	deficit	_	_	I-Claim
302	seen	_	_	I-Claim
303	in	_	_	I-Claim
304	anemic	_	_	I-Claim
305	cancer	_	_	I-Claim
306	patients	_	_	I-Claim
307	compared	_	_	I-Claim
308	with	_	_	I-Claim
309	the	_	_	I-Claim
310	norm	_	_	I-Claim
311	population	_	_	I-Claim
312	sample	_	_	I-Claim
313	.	_	_	I-Claim


0	Research	_	_	O
1	has	_	_	O
2	shown	_	_	O
3	that	_	_	O
4	self	_	_	O
5	-	_	_	O
6	directed	_	_	O
7	stress	_	_	O
8	management	_	_	O
9	training	_	_	O
10	improves	_	_	O
11	mental	_	_	O
12	well	_	_	O
13	-	_	_	O
14	being	_	_	O
15	in	_	_	O
16	patients	_	_	O
17	undergoing	_	_	O
18	chemotherapy	_	_	O
19	.	_	_	O

20	The	_	_	O
21	present	_	_	O
22	study	_	_	O
23	extends	_	_	O
24	this	_	_	O
25	work	_	_	O
26	by	_	_	O
27	evaluating	_	_	O
28	separate	_	_	O
29	and	_	_	O
30	combined	_	_	O
31	effects	_	_	O
32	of	_	_	O
33	stress	_	_	O
34	management	_	_	O
35	training	_	_	O
36	and	_	_	O
37	home	_	_	O
38	-	_	_	O
39	based	_	_	O
40	exercise	_	_	O
41	.	_	_	O

42	Following	_	_	O
43	assessment	_	_	O
44	of	_	_	O
45	mental	_	_	O
46	and	_	_	O
47	physical	_	_	O
48	well	_	_	O
49	-	_	_	O
50	being	_	_	O
51	,	_	_	O
52	depression	_	_	O
53	,	_	_	O
54	anxiety	_	_	O
55	,	_	_	O
56	exercise	_	_	O
57	,	_	_	O
58	and	_	_	O
59	stress	_	_	O
60	reduction	_	_	O
61	activity	_	_	O
62	before	_	_	O
63	chemotherapy	_	_	O
64	started	_	_	O
65	,	_	_	O
66	patients	_	_	O
67	were	_	_	O
68	randomized	_	_	O
69	to	_	_	O
70	stress	_	_	O
71	management	_	_	O
72	training	_	_	O
73	(	_	_	O
74	SM	_	_	O
75	)	_	_	O
76	,	_	_	O
77	exercise	_	_	O
78	(	_	_	O
79	EX	_	_	O
80	)	_	_	O
81	,	_	_	O
82	combined	_	_	O
83	stress	_	_	O
84	management	_	_	O
85	and	_	_	O
86	exercise	_	_	O
87	(	_	_	O
88	SMEX	_	_	O
89	)	_	_	O
90	,	_	_	O
91	or	_	_	O
92	usual	_	_	O
93	care	_	_	O
94	only	_	_	O
95	(	_	_	O
96	UCO	_	_	O
97	)	_	_	O
98	.	_	_	O

99	Outcomes	_	_	O
100	were	_	_	O
101	reassessed	_	_	O
102	6	_	_	O
103	and	_	_	O
104	12	_	_	O
105	weeks	_	_	O
106	after	_	_	O
107	chemotherapy	_	_	O
108	started	_	_	O
109	.	_	_	O

110	Significance	_	_	O
111	testing	_	_	O
112	of	_	_	O
113	group	_	_	O
114	-	_	_	O
115	by	_	_	O
116	-	_	_	O
117	time	_	_	O
118	interactions	_	_	O
119	in	_	_	O
120	286	_	_	O
121	patients	_	_	O
122	who	_	_	O
123	completed	_	_	O
124	all	_	_	O
125	assessments	_	_	O
126	was	_	_	O
127	used	_	_	O
128	to	_	_	O
129	evaluate	_	_	O
130	intervention	_	_	O
131	efficacy	_	_	O
132	.	_	_	O

133	Interaction	_	_	B-Premise
134	effects	_	_	I-Premise
135	for	_	_	I-Premise
136	mental	_	_	I-Premise
137	and	_	_	I-Premise
138	physical	_	_	I-Premise
139	well	_	_	I-Premise
140	-	_	_	I-Premise
141	being	_	_	I-Premise
142	scores	_	_	I-Premise
143	were	_	_	I-Premise
144	not	_	_	I-Premise
145	significant	_	_	I-Premise
146	.	_	_	I-Premise

147	Depression	_	_	B-Premise
148	scores	_	_	I-Premise
149	yielded	_	_	I-Premise
150	a	_	_	I-Premise
151	linear	_	_	I-Premise
152	interaction	_	_	I-Premise
153	comparing	_	_	I-Premise
154	UCO	_	_	I-Premise
155	and	_	_	I-Premise
156	SMEX	_	_	I-Premise
157	(	_	_	I-Premise
158	p	_	_	I-Premise
159	=	_	_	I-Premise
160	0	_	_	I-Premise
161	.	_	_	I-Premise

162	019	_	_	I-Premise
163	)	_	_	I-Premise
164	,	_	_	I-Premise
165	with	_	_	I-Premise
166	decreases	_	_	I-Premise
167	in	_	_	I-Premise
168	SMEX	_	_	I-Premise
169	but	_	_	I-Premise
170	not	_	_	I-Premise
171	UCO	_	_	I-Premise
172	.	_	_	I-Premise

173	Anxiety	_	_	B-Premise
174	scores	_	_	I-Premise
175	yielded	_	_	I-Premise
176	a	_	_	I-Premise
177	quadratic	_	_	I-Premise
178	interaction	_	_	I-Premise
179	comparing	_	_	I-Premise
180	UCO	_	_	I-Premise
181	and	_	_	I-Premise
182	SMEX	_	_	I-Premise
183	(	_	_	I-Premise
184	p	_	_	I-Premise
185	=	_	_	I-Premise
186	0	_	_	I-Premise
187	.	_	_	I-Premise

188	049	_	_	I-Premise
189	)	_	_	I-Premise
190	,	_	_	I-Premise
191	with	_	_	I-Premise
192	trends	_	_	I-Premise
193	for	_	_	I-Premise
194	changes	_	_	I-Premise
195	in	_	_	I-Premise
196	SMEX	_	_	I-Premise
197	but	_	_	I-Premise
198	not	_	_	I-Premise
199	UCO	_	_	I-Premise
200	.	_	_	I-Premise

201	Additional	_	_	B-Premise
202	analyses	_	_	I-Premise
203	yielded	_	_	I-Premise
204	quadratic	_	_	I-Premise
205	interactions	_	_	I-Premise
206	for	_	_	I-Premise
207	exercise	_	_	I-Premise
208	activity	_	_	I-Premise
209	comparing	_	_	I-Premise
210	UCO	_	_	I-Premise
211	and	_	_	I-Premise
212	SMEX	_	_	I-Premise
213	(	_	_	I-Premise
214	p	_	_	I-Premise
215	=	_	_	I-Premise
216	0	_	_	I-Premise
217	.	_	_	I-Premise

218	022	_	_	I-Premise
219	)	_	_	I-Premise
220	,	_	_	I-Premise
221	with	_	_	I-Premise
222	positive	_	_	I-Premise
223	changes	_	_	I-Premise
224	in	_	_	I-Premise
225	SMEX	_	_	I-Premise
226	but	_	_	I-Premise
227	not	_	_	I-Premise
228	UCO	_	_	I-Premise
229	,	_	_	I-Premise
230	and	_	_	I-Premise
231	for	_	_	I-Premise
232	stress	_	_	I-Premise
233	management	_	_	I-Premise
234	activity	_	_	I-Premise
235	comparing	_	_	I-Premise
236	UCO	_	_	I-Premise
237	and	_	_	I-Premise
238	SM	_	_	I-Premise
239	(	_	_	I-Premise
240	p	_	_	I-Premise
241	<	_	_	I-Premise
242	0	_	_	I-Premise
243	.	_	_	I-Premise

244	001	_	_	I-Premise
245	)	_	_	I-Premise
246	and	_	_	I-Premise
247	UCO	_	_	I-Premise
248	and	_	_	I-Premise
249	SMEX	_	_	I-Premise
250	(	_	_	I-Premise
251	p	_	_	I-Premise
252	=	_	_	I-Premise
253	0	_	_	I-Premise
254	.	_	_	I-Premise

255	013	_	_	I-Premise
256	)	_	_	I-Premise
257	,	_	_	I-Premise
258	with	_	_	I-Premise
259	positive	_	_	I-Premise
260	changes	_	_	I-Premise
261	in	_	_	I-Premise
262	SM	_	_	I-Premise
263	and	_	_	I-Premise
264	SMEX	_	_	I-Premise
265	but	_	_	I-Premise
266	not	_	_	I-Premise
267	UCO	_	_	I-Premise
268	.	_	_	I-Premise

269	Only	_	_	B-Claim
270	the	_	_	I-Claim
271	combined	_	_	I-Claim
272	intervention	_	_	I-Claim
273	yielded	_	_	I-Claim
274	effects	_	_	I-Claim
275	on	_	_	I-Claim
276	quality	_	_	I-Claim
277	of	_	_	I-Claim
278	life	_	_	I-Claim
279	outcomes	_	_	I-Claim
280	,	_	_	I-Claim
281	and	_	_	I-Claim
282	these	_	_	I-Claim
283	were	_	_	I-Claim
284	limited	_	_	I-Claim
285	to	_	_	I-Claim
286	anxiety	_	_	I-Claim
287	and	_	_	I-Claim
288	depression	_	_	I-Claim
289	.	_	_	I-Claim

290	These	_	_	B-Premise
291	findings	_	_	I-Premise
292	are	_	_	I-Premise
293	consistent	_	_	I-Premise
294	with	_	_	I-Premise
295	evidence	_	_	I-Premise
296	that	_	_	I-Premise
297	only	_	_	I-Premise
298	the	_	_	I-Premise
299	combined	_	_	I-Premise
300	intervention	_	_	I-Premise
301	yielded	_	_	I-Premise
302	increases	_	_	I-Premise
303	in	_	_	I-Premise
304	both	_	_	I-Premise
305	exercise	_	_	I-Premise
306	and	_	_	I-Premise
307	stress	_	_	I-Premise
308	management	_	_	I-Premise
309	activity	_	_	I-Premise
310	.	_	_	I-Premise

311	Future	_	_	O
312	research	_	_	O
313	should	_	_	O
314	investigate	_	_	O
315	ways	_	_	O
316	to	_	_	O
317	augment	_	_	O
318	this	_	_	O
319	intervention	_	_	O
320	to	_	_	O
321	enhance	_	_	O
322	its	_	_	O
323	benefits	_	_	O
324	.	_	_	O


0	Nocturnal	_	_	O
1	administration	_	_	O
2	of	_	_	O
3	branched	_	_	O
4	-	_	_	O
5	chain	_	_	O
6	amino	_	_	O
7	acid	_	_	O
8	(	_	_	O
9	BCAA	_	_	O
10	)	_	_	O
11	granules	_	_	O
12	improves	_	_	O
13	serum	_	_	O
14	albumin	_	_	O
15	levels	_	_	O
16	in	_	_	O
17	patients	_	_	O
18	with	_	_	O
19	cirrhosis	_	_	O
20	.	_	_	O

21	However	_	_	O
22	,	_	_	O
23	it	_	_	O
24	is	_	_	O
25	unclear	_	_	O
26	whether	_	_	O
27	or	_	_	O
28	not	_	_	O
29	this	_	_	O
30	administration	_	_	O
31	method	_	_	O
32	can	_	_	O
33	improve	_	_	O
34	the	_	_	O
35	patients	_	_	O
36	'	_	_	O
37	quality	_	_	O
38	of	_	_	O
39	life	_	_	O
40	(	_	_	O
41	QOL	_	_	O
42	)	_	_	O
43	.	_	_	O

44	In	_	_	O
45	this	_	_	O
46	study	_	_	O
47	,	_	_	O
48	we	_	_	O
49	aimed	_	_	O
50	to	_	_	O
51	investigate	_	_	O
52	the	_	_	O
53	efficacy	_	_	O
54	of	_	_	O
55	BCAA	_	_	O
56	granules	_	_	O
57	,	_	_	O
58	given	_	_	O
59	nocturnally	_	_	O
60	,	_	_	O
61	in	_	_	O
62	improving	_	_	O
63	QOL	_	_	O
64	in	_	_	O
65	these	_	_	O
66	patients	_	_	O
67	.	_	_	O

68	We	_	_	O
69	performed	_	_	O
70	a	_	_	O
71	multicenter	_	_	O
72	,	_	_	O
73	randomized	_	_	O
74	controlled	_	_	O
75	trial	_	_	O
76	examining	_	_	O
77	the	_	_	O
78	comparative	_	_	O
79	effects	_	_	O
80	of	_	_	O
81	BCAA	_	_	O
82	granules	_	_	O
83	given	_	_	O
84	orally	_	_	O
85	for	_	_	O
86	3	_	_	O
87	months	_	_	O
88	with	_	_	O
89	daytime	_	_	O
90	or	_	_	O
91	nocturnal	_	_	O
92	administration	_	_	O
93	in	_	_	O
94	patients	_	_	O
95	with	_	_	O
96	compensated	_	_	O
97	cirrhosis	_	_	O
98	.	_	_	O

99	Health	_	_	O
100	-	_	_	O
101	related	_	_	O
102	QOL	_	_	O
103	was	_	_	O
104	measured	_	_	O
105	by	_	_	O
106	a	_	_	O
107	Japanese	_	_	O
108	version	_	_	O
109	of	_	_	O
110	the	_	_	O
111	questionnaire	_	_	O
112	on	_	_	O
113	subjective	_	_	O
114	and	_	_	O
115	objective	_	_	O
116	symptoms	_	_	O
117	,	_	_	O
118	and	_	_	O
119	the	_	_	O
120	Short	_	_	O
121	Form	_	_	O
122	-	_	_	O
123	8	_	_	O
124	(	_	_	O
125	SF	_	_	O
126	-	_	_	O
127	8	_	_	O
128	)	_	_	O
129	questionnaire	_	_	O
130	.	_	_	O

131	Twenty	_	_	O
132	-	_	_	O
133	one	_	_	O
134	patients	_	_	O
135	received	_	_	O
136	BCAA	_	_	O
137	granules	_	_	O
138	three	_	_	O
139	times	_	_	O
140	a	_	_	O
141	day	_	_	O
142	(	_	_	O
143	one	_	_	O
144	sachet	_	_	O
145	after	_	_	O
146	each	_	_	O
147	meal	_	_	O
148	:	_	_	O
149	the	_	_	O
150	daytime	_	_	O
151	group	_	_	O
152	)	_	_	O
153	,	_	_	O
154	and	_	_	O
155	16	_	_	O
156	patients	_	_	O
157	received	_	_	O
158	the	_	_	O
159	granules	_	_	O
160	twice	_	_	O
161	a	_	_	O
162	day	_	_	O
163	(	_	_	O
164	one	_	_	O
165	sachet	_	_	O
166	after	_	_	O
167	breakfast	_	_	O
168	,	_	_	O
169	and	_	_	O
170	two	_	_	O
171	sachets	_	_	O
172	before	_	_	O
173	bedtime	_	_	O
174	:	_	_	O
175	the	_	_	O
176	nocturnal	_	_	O
177	group	_	_	O
178	)	_	_	O
179	.	_	_	O

180	Baseline	_	_	O
181	characteristics	_	_	O
182	did	_	_	O
183	not	_	_	O
184	differ	_	_	O
185	between	_	_	O
186	the	_	_	O
187	groups	_	_	O
188	(	_	_	O
189	whole	_	_	O
190	cohort	_	_	O
191	:	_	_	O
192	Child	_	_	O
193	-	_	_	O
194	Pugh	_	_	O
195	grade	_	_	O
196	A	_	_	O
197	/	_	_	O
198	B	_	_	O
199	,	_	_	O
200	21	_	_	O
201	/	_	_	O
202	16	_	_	O
203	;	_	_	O
204	mean	_	_	O
205	age	_	_	O
206	,	_	_	O
207	68	_	_	O
208	.	_	_	O

209	2	_	_	O
210	years	_	_	O
211	)	_	_	O
212	.	_	_	O

213	There	_	_	B-Premise
214	was	_	_	I-Premise
215	no	_	_	I-Premise
216	significant	_	_	I-Premise
217	difference	_	_	I-Premise
218	in	_	_	I-Premise
219	any	_	_	I-Premise
220	of	_	_	I-Premise
221	the	_	_	I-Premise
222	subjects	_	_	I-Premise
223	revealed	_	_	I-Premise
224	by	_	_	I-Premise
225	the	_	_	I-Premise
226	questionnaire	_	_	I-Premise
227	regarding	_	_	I-Premise
228	subjective	_	_	I-Premise
229	or	_	_	I-Premise
230	objective	_	_	I-Premise
231	symptoms	_	_	I-Premise
232	,	_	_	I-Premise
233	or	_	_	I-Premise
234	by	_	_	I-Premise
235	the	_	_	I-Premise
236	SF	_	_	I-Premise
237	-	_	_	I-Premise
238	8	_	_	I-Premise
239	between	_	_	I-Premise
240	the	_	_	I-Premise
241	daytime	_	_	I-Premise
242	group	_	_	I-Premise
243	and	_	_	I-Premise
244	the	_	_	I-Premise
245	nocturnal	_	_	I-Premise
246	group	_	_	I-Premise
247	after	_	_	I-Premise
248	3	_	_	I-Premise
249	months	_	_	I-Premise
250	of	_	_	I-Premise
251	treatment	_	_	I-Premise
252	.	_	_	I-Premise

253	The	_	_	B-Premise
254	daytime	_	_	I-Premise
255	group	_	_	I-Premise
256	showed	_	_	I-Premise
257	a	_	_	I-Premise
258	significant	_	_	I-Premise
259	effect	_	_	I-Premise
260	on	_	_	I-Premise
261	general	_	_	I-Premise
262	health	_	_	I-Premise
263	,	_	_	I-Premise
264	vitality	_	_	I-Premise
265	,	_	_	I-Premise
266	social	_	_	I-Premise
267	functioning	_	_	I-Premise
268	,	_	_	I-Premise
269	mental	_	_	I-Premise
270	health	_	_	I-Premise
271	,	_	_	I-Premise
272	and	_	_	I-Premise
273	role	_	_	I-Premise
274	emotional	_	_	I-Premise
275	as	_	_	I-Premise
276	revealed	_	_	I-Premise
277	on	_	_	I-Premise
278	the	_	_	I-Premise
279	SF	_	_	I-Premise
280	-	_	_	I-Premise
281	8	_	_	I-Premise
282	.	_	_	I-Premise

283	Conversely	_	_	B-Premise
284	,	_	_	I-Premise
285	the	_	_	I-Premise
286	nocturnal	_	_	I-Premise
287	group	_	_	I-Premise
288	exhibited	_	_	I-Premise
289	a	_	_	I-Premise
290	significant	_	_	I-Premise
291	decrease	_	_	I-Premise
292	in	_	_	I-Premise
293	the	_	_	I-Premise
294	occurrence	_	_	I-Premise
295	of	_	_	I-Premise
296	muscle	_	_	I-Premise
297	cramps	_	_	I-Premise
298	in	_	_	I-Premise
299	the	_	_	I-Premise
300	legs	_	_	I-Premise
301	(	_	_	I-Premise
302	P	_	_	I-Premise
303	=	_	_	I-Premise
304	0	_	_	I-Premise
305	.	_	_	I-Premise

306	014	_	_	I-Premise
307	)	_	_	I-Premise
308	and	_	_	I-Premise
309	significantly	_	_	I-Premise
310	improved	_	_	I-Premise
311	Fisher	_	_	I-Premise
312	'	_	_	I-Premise
313	s	_	_	I-Premise
314	ratio	_	_	I-Premise
315	after	_	_	I-Premise
316	3	_	_	I-Premise
317	months	_	_	I-Premise
318	(	_	_	I-Premise
319	P	_	_	I-Premise
320	=	_	_	I-Premise
321	0	_	_	I-Premise
322	.	_	_	I-Premise

323	04	_	_	I-Premise
324	)	_	_	I-Premise
325	.	_	_	I-Premise

326	Nocturnal	_	_	B-Claim
327	administration	_	_	I-Claim
328	of	_	_	I-Claim
329	BCAA	_	_	I-Claim
330	granules	_	_	I-Claim
331	in	_	_	I-Claim
332	patients	_	_	I-Claim
333	with	_	_	I-Claim
334	cirrhosis	_	_	I-Claim
335	reduced	_	_	I-Claim
336	the	_	_	I-Claim
337	occurrence	_	_	I-Claim
338	of	_	_	I-Claim
339	muscle	_	_	I-Claim
340	cramps	_	_	I-Claim
341	in	_	_	I-Claim
342	the	_	_	I-Claim
343	leg	_	_	I-Claim
344	but	_	_	I-Claim
345	did	_	_	I-Claim
346	not	_	_	I-Claim
347	improve	_	_	I-Claim
348	the	_	_	I-Claim
349	patients	_	_	I-Claim
350	'	_	_	I-Claim
351	QOL	_	_	I-Claim
352	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	whether	_	_	O
3	the	_	_	O
4	impact	_	_	O
5	of	_	_	O
6	"	_	_	O
7	laying	_	_	O
8	on	_	_	O
9	of	_	_	O
10	hands	_	_	O
11	"	_	_	O
12	on	_	_	O
13	the	_	_	O
14	well	_	_	O
15	-	_	_	O
16	being	_	_	O
17	of	_	_	O
18	patients	_	_	O
19	with	_	_	O
20	advanced	_	_	O
21	cancer	_	_	O
22	is	_	_	O
23	more	_	_	O
24	efficient	_	_	O
25	when	_	_	O
26	performed	_	_	O
27	by	_	_	O
28	a	_	_	O
29	person	_	_	O
30	with	_	_	O
31	self	_	_	O
32	-	_	_	O
33	declared	_	_	O
34	"	_	_	O
35	healing	_	_	O
36	powers	_	_	O
37	"	_	_	O
38	as	_	_	O
39	compared	_	_	O
40	to	_	_	O
41	an	_	_	O
42	actor	_	_	O
43	mimicking	_	_	O
44	the	_	_	O
45	healer	_	_	O
46	in	_	_	O
47	close	_	_	O
48	detail	_	_	O
49	.	_	_	O

50	A	_	_	O
51	total	_	_	O
52	of	_	_	O
53	80	_	_	O
54	patients	_	_	O
55	were	_	_	O
56	registered	_	_	O
57	to	_	_	O
58	participate	_	_	O
59	in	_	_	O
60	a	_	_	O
61	randomized	_	_	O
62	,	_	_	O
63	single	_	_	O
64	-	_	_	O
65	blind	_	_	O
66	phase	_	_	O
67	III	_	_	O
68	trial	_	_	O
69	to	_	_	O
70	evaluate	_	_	O
71	the	_	_	O
72	difference	_	_	O
73	in	_	_	O
74	efficacy	_	_	O
75	of	_	_	O
76	"	_	_	O
77	laying	_	_	O
78	on	_	_	O
79	of	_	_	O
80	hands	_	_	O
81	"	_	_	O
82	by	_	_	O
83	either	_	_	O
84	a	_	_	O
85	"	_	_	O
86	healer	_	_	O
87	"	_	_	O
88	or	_	_	O
89	an	_	_	O
90	actor	_	_	O
91	.	_	_	O

92	Each	_	_	O
93	group	_	_	O
94	consisted	_	_	O
95	of	_	_	O
96	40	_	_	O
97	patients	_	_	O
98	,	_	_	O
99	scheduled	_	_	O
100	to	_	_	O
101	receive	_	_	O
102	treatment	_	_	O
103	for	_	_	O
104	5	_	_	O
105	min	_	_	O
106	,	_	_	O
107	three	_	_	O
108	times	_	_	O
109	a	_	_	O
110	week	_	_	O
111	.	_	_	O

112	The	_	_	O
113	effect	_	_	O
114	of	_	_	O
115	treatment	_	_	O
116	was	_	_	O
117	measured	_	_	O
118	using	_	_	O
119	a	_	_	O
120	"	_	_	O
121	Well	_	_	O
122	-	_	_	O
123	Being	_	_	O
124	scale	_	_	O
125	"	_	_	O
126	,	_	_	O
127	with	_	_	O
128	the	_	_	O
129	difference	_	_	O
130	of	_	_	O
131	the	_	_	O
132	average	_	_	O
133	score	_	_	O
134	of	_	_	O
135	the	_	_	O
136	"	_	_	O
137	Well	_	_	O
138	-	_	_	O
139	Being	_	_	O
140	scale	_	_	O
141	"	_	_	O
142	on	_	_	O
143	day	_	_	O
144	10	_	_	O
145	being	_	_	O
146	defined	_	_	O
147	as	_	_	O
148	primary	_	_	O
149	and	_	_	O
150	that	_	_	O
151	on	_	_	O
152	day	_	_	O
153	5	_	_	O
154	as	_	_	O
155	secondary	_	_	O
156	endpoint	_	_	O
157	.	_	_	O

158	There	_	_	B-Premise
159	was	_	_	I-Premise
160	no	_	_	I-Premise
161	significant	_	_	I-Premise
162	difference	_	_	I-Premise
163	in	_	_	I-Premise
164	average	_	_	I-Premise
165	score	_	_	I-Premise
166	values	_	_	I-Premise
167	between	_	_	I-Premise
168	the	_	_	I-Premise
169	"	_	_	I-Premise
170	healer	_	_	I-Premise
171	"	_	_	I-Premise
172	and	_	_	I-Premise
173	the	_	_	I-Premise
174	actor	_	_	I-Premise
175	with	_	_	I-Premise
176	regard	_	_	I-Premise
177	to	_	_	I-Premise
178	the	_	_	I-Premise
179	primary	_	_	I-Premise
180	(	_	_	I-Premise
181	p	_	_	I-Premise
182	=	_	_	I-Premise
183	0	_	_	I-Premise
184	.	_	_	I-Premise

185	34	_	_	I-Premise
186	)	_	_	I-Premise
187	or	_	_	I-Premise
188	the	_	_	I-Premise
189	secondary	_	_	I-Premise
190	endpoint	_	_	I-Premise
191	(	_	_	I-Premise
192	p	_	_	I-Premise
193	=	_	_	I-Premise
194	0	_	_	I-Premise
195	.	_	_	I-Premise

196	94	_	_	I-Premise
197	)	_	_	I-Premise
198	,	_	_	I-Premise
199	but	_	_	B-Premise
200	the	_	_	I-Premise
201	comparison	_	_	I-Premise
202	was	_	_	I-Premise
203	limited	_	_	I-Premise
204	due	_	_	I-Premise
205	to	_	_	I-Premise
206	major	_	_	I-Premise
207	protocol	_	_	I-Premise
208	violations	_	_	I-Premise
209	by	_	_	I-Premise
210	the	_	_	I-Premise
211	"	_	_	I-Premise
212	healer	_	_	I-Premise
213	"	_	_	I-Premise
214	who	_	_	I-Premise
215	unblinded	_	_	I-Premise
216	his	_	_	I-Premise
217	status	_	_	I-Premise
218	after	_	_	I-Premise
219	the	_	_	I-Premise
220	first	_	_	I-Premise
221	run	_	_	I-Premise
222	and	_	_	I-Premise
223	quit	_	_	I-Premise
224	the	_	_	I-Premise
225	study	_	_	I-Premise
226	.	_	_	I-Premise

227	The	_	_	O
228	study	_	_	O
229	was	_	_	O
230	completed	_	_	O
231	by	_	_	O
232	the	_	_	O
233	actor	_	_	O
234	as	_	_	O
235	a	_	_	O
236	descriptive	_	_	O
237	,	_	_	O
238	explorative	_	_	O
239	study	_	_	O
240	on	_	_	O
241	the	_	_	O
242	impact	_	_	O
243	of	_	_	O
244	"	_	_	O
245	laying	_	_	O
246	on	_	_	O
247	of	_	_	O
248	hands	_	_	O
249	"	_	_	O
250	.	_	_	O

251	A	_	_	B-Premise
252	significant	_	_	I-Premise
253	improvement	_	_	I-Premise
254	in	_	_	I-Premise
255	symptoms	_	_	I-Premise
256	after	_	_	I-Premise
257	treatment	_	_	I-Premise
258	was	_	_	I-Premise
259	found	_	_	I-Premise
260	on	_	_	I-Premise
261	day	_	_	I-Premise
262	5	_	_	I-Premise
263	(	_	_	I-Premise
264	p	_	_	I-Premise
265	<	_	_	I-Premise
266	0	_	_	I-Premise
267	.	_	_	I-Premise

268	001	_	_	I-Premise
269	)	_	_	I-Premise
270	and	_	_	I-Premise
271	on	_	_	I-Premise
272	day	_	_	I-Premise
273	10	_	_	I-Premise
274	(	_	_	I-Premise
275	p	_	_	I-Premise
276	=	_	_	I-Premise
277	0	_	_	I-Premise
278	.	_	_	I-Premise

279	0002	_	_	I-Premise
280	)	_	_	I-Premise
281	.	_	_	I-Premise

282	"	_	_	B-Claim
283	Laying	_	_	I-Claim
284	on	_	_	I-Claim
285	of	_	_	I-Claim
286	hands	_	_	I-Claim
287	"	_	_	I-Claim
288	resulted	_	_	I-Claim
289	in	_	_	I-Claim
290	a	_	_	I-Claim
291	significant	_	_	I-Claim
292	improvement	_	_	I-Claim
293	of	_	_	I-Claim
294	cancer	_	_	I-Claim
295	-	_	_	I-Claim
296	or	_	_	I-Claim
297	cancer	_	_	I-Claim
298	-	_	_	I-Claim
299	therapy	_	_	I-Claim
300	-	_	_	I-Claim
301	associated	_	_	I-Claim
302	symptoms	_	_	I-Claim
303	.	_	_	I-Claim

304	The	_	_	B-Claim
305	magnitude	_	_	I-Claim
306	of	_	_	I-Claim
307	improvement	_	_	I-Claim
308	obtained	_	_	I-Claim
309	was	_	_	I-Claim
310	similar	_	_	I-Claim
311	whether	_	_	I-Claim
312	on	_	_	I-Claim
313	a	_	_	I-Claim
314	self	_	_	I-Claim
315	-	_	_	I-Claim
316	declared	_	_	I-Claim
317	-	_	_	I-Claim
318	healer	_	_	I-Claim
319	-	_	_	I-Claim
320	or	_	_	I-Claim
321	an	_	_	I-Claim
322	actor	_	_	I-Claim
323	-	_	_	I-Claim
324	provided	_	_	I-Claim
325	"	_	_	I-Claim
326	treatment	_	_	I-Claim
327	"	_	_	I-Claim
328	.	_	_	I-Claim


0	The	_	_	O
1	current	_	_	O
2	study	_	_	O
3	examined	_	_	O
4	the	_	_	O
5	effect	_	_	O
6	of	_	_	O
7	recombinant	_	_	O
8	human	_	_	O
9	deoxyribonuclease	_	_	O
10	(	_	_	O
11	rhDNase	_	_	O
12	)	_	_	O
13	on	_	_	O
14	quality	_	_	O
15	of	_	_	O
16	life	_	_	O
17	(	_	_	O
18	QOL	_	_	O
19	)	_	_	O
20	measures	_	_	O
21	,	_	_	O
22	clinical	_	_	O
23	improvement	_	_	O
24	,	_	_	O
25	and	_	_	O
26	DNA	_	_	O
27	content	_	_	O
28	of	_	_	O
29	thick	_	_	O
30	oropharyngeal	_	_	O
31	secretions	_	_	O
32	(	_	_	O
33	OPS	_	_	O
34	)	_	_	O
35	in	_	_	O
36	patients	_	_	O
37	with	_	_	O
38	head	_	_	O
39	-	_	_	O
40	and	_	_	O
41	-	_	_	O
42	neck	_	_	O
43	(	_	_	O
44	H	_	_	O
45	&	_	_	O
46	N	_	_	O
47	)	_	_	O
48	cancers	_	_	O
49	.	_	_	O

50	Thirty	_	_	O
51	-	_	_	O
52	six	_	_	O
53	patients	_	_	O
54	with	_	_	O
55	local	_	_	O
56	-	_	_	O
57	regional	_	_	O
58	advanced	_	_	O
59	H	_	_	O
60	&	_	_	O
61	amp	_	_	O
62	;	_	_	O
63	N	_	_	O
64	cancer	_	_	O
65	receiving	_	_	O
66	chemoradiationtherapy	_	_	O
67	(	_	_	O
68	CRT	_	_	O
69	)	_	_	O
70	were	_	_	O
71	randomized	_	_	O
72	to	_	_	O
73	receive	_	_	O
74	either	_	_	O
75	placebo	_	_	O
76	or	_	_	O
77	rhDNase	_	_	O
78	.	_	_	O

79	Endpoints	_	_	O
80	included	_	_	O
81	MD	_	_	O
82	Anderson	_	_	O
83	Symptom	_	_	O
84	Inventory	_	_	O
85	-	_	_	O
86	Head	_	_	O
87	and	_	_	O
88	Neck	_	_	O
89	(	_	_	O
90	MDASI	_	_	O
91	-	_	_	O
92	HN	_	_	O
93	)	_	_	O
94	and	_	_	O
95	Functional	_	_	O
96	Assessment	_	_	O
97	of	_	_	O
98	Cancer	_	_	O
99	Therapy	_	_	O
100	-	_	_	O
101	Head	_	_	O
102	and	_	_	O
103	Neck	_	_	O
104	(	_	_	O
105	FACT	_	_	O
106	-	_	_	O
107	NH	_	_	O
108	)	_	_	O
109	scores	_	_	O
110	,	_	_	O
111	along	_	_	O
112	with	_	_	O
113	clinical	_	_	O
114	assessment	_	_	O
115	and	_	_	O
116	DNA	_	_	O
117	concentration	_	_	O
118	of	_	_	O
119	OPS	_	_	O
120	.	_	_	O

121	There	_	_	B-Premise
122	were	_	_	I-Premise
123	no	_	_	I-Premise
124	statistically	_	_	I-Premise
125	significant	_	_	I-Premise
126	differences	_	_	I-Premise
127	in	_	_	I-Premise
128	patients	_	_	I-Premise
129	'	_	_	I-Premise
130	QOL	_	_	I-Premise
131	outcomes	_	_	I-Premise
132	over	_	_	I-Premise
133	the	_	_	I-Premise
134	study	_	_	I-Premise
135	period	_	_	I-Premise
136	.	_	_	I-Premise

137	Both	_	_	B-Premise
138	groups	_	_	I-Premise
139	showed	_	_	I-Premise
140	an	_	_	I-Premise
141	increase	_	_	I-Premise
142	in	_	_	I-Premise
143	symptom	_	_	I-Premise
144	and	_	_	I-Premise
145	interference	_	_	I-Premise
146	scores	_	_	I-Premise
147	,	_	_	I-Premise
148	although	_	_	O
149	patients	_	_	B-Premise
150	in	_	_	I-Premise
151	the	_	_	I-Premise
152	rhDNase	_	_	I-Premise
153	group	_	_	I-Premise
154	showed	_	_	I-Premise
155	a	_	_	I-Premise
156	greater	_	_	I-Premise
157	decline	_	_	I-Premise
158	in	_	_	I-Premise
159	both	_	_	I-Premise
160	scores	_	_	I-Premise
161	during	_	_	I-Premise
162	the	_	_	I-Premise
163	3	_	_	I-Premise
164	months	_	_	I-Premise
165	posttreatment	_	_	I-Premise
166	.	_	_	I-Premise

167	Similarly	_	_	B-Premise
168	,	_	_	I-Premise
169	both	_	_	I-Premise
170	groups	_	_	I-Premise
171	showed	_	_	I-Premise
172	a	_	_	I-Premise
173	decline	_	_	I-Premise
174	in	_	_	I-Premise
175	physical	_	_	I-Premise
176	and	_	_	I-Premise
177	functional	_	_	I-Premise
178	well	_	_	I-Premise
179	being	_	_	I-Premise
180	but	_	_	I-Premise
181	recovered	_	_	I-Premise
182	in	_	_	I-Premise
183	the	_	_	I-Premise
184	3	_	_	I-Premise
185	months	_	_	I-Premise
186	posttreatment	_	_	I-Premise
187	follow	_	_	I-Premise
188	-	_	_	I-Premise
189	up	_	_	I-Premise
190	,	_	_	I-Premise
191	with	_	_	I-Premise
192	the	_	_	I-Premise
193	rhDNase	_	_	I-Premise
194	group	_	_	I-Premise
195	exhibiting	_	_	I-Premise
196	speedier	_	_	I-Premise
197	recovery	_	_	I-Premise
198	.	_	_	I-Premise

199	Patients	_	_	B-Premise
200	in	_	_	I-Premise
201	the	_	_	I-Premise
202	rhDNase	_	_	I-Premise
203	group	_	_	I-Premise
204	exhibited	_	_	I-Premise
205	significant	_	_	I-Premise
206	clinical	_	_	I-Premise
207	improvement	_	_	I-Premise
208	in	_	_	I-Premise
209	OPS	_	_	I-Premise
210	,	_	_	I-Premise
211	blindly	_	_	I-Premise
212	assessed	_	_	I-Premise
213	by	_	_	I-Premise
214	a	_	_	I-Premise
215	physician	_	_	I-Premise
216	,	_	_	I-Premise
217	compared	_	_	I-Premise
218	with	_	_	I-Premise
219	the	_	_	I-Premise
220	placebo	_	_	I-Premise
221	group	_	_	I-Premise
222	(	_	_	I-Premise
223	67	_	_	I-Premise
224	%	_	_	I-Premise
225	vs	_	_	I-Premise
226	27	_	_	I-Premise
227	%	_	_	I-Premise
228	,	_	_	I-Premise
229	respectively	_	_	I-Premise
230	;	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	.	_	_	I-Premise

234	046	_	_	I-Premise
235	)	_	_	I-Premise
236	.	_	_	I-Premise

237	The	_	_	B-Premise
238	rhDNase	_	_	I-Premise
239	group	_	_	I-Premise
240	showed	_	_	I-Premise
241	no	_	_	I-Premise
242	change	_	_	I-Premise
243	in	_	_	I-Premise
244	OPS	_	_	I-Premise
245	-	_	_	I-Premise
246	DNA	_	_	I-Premise
247	concentration	_	_	I-Premise
248	,	_	_	I-Premise
249	although	_	_	O
250	the	_	_	B-Premise
251	placebo	_	_	I-Premise
252	group	_	_	I-Premise
253	showed	_	_	I-Premise
254	a	_	_	I-Premise
255	significant	_	_	I-Premise
256	increase	_	_	I-Premise
257	in	_	_	I-Premise
258	DNA	_	_	I-Premise
259	concentration	_	_	I-Premise
260	during	_	_	I-Premise
261	the	_	_	I-Premise
262	drug	_	_	I-Premise
263	trial	_	_	I-Premise
264	(	_	_	I-Premise
265	P	_	_	I-Premise
266	=	_	_	I-Premise
267	.	_	_	I-Premise

268	045	_	_	I-Premise
269	)	_	_	I-Premise
270	.	_	_	I-Premise

271	There	_	_	B-Claim
272	was	_	_	I-Claim
273	no	_	_	I-Claim
274	differences	_	_	I-Claim
275	in	_	_	I-Claim
276	acute	_	_	I-Claim
277	toxicities	_	_	I-Claim
278	between	_	_	I-Claim
279	the	_	_	I-Claim
280	2	_	_	I-Claim
281	groups	_	_	I-Claim
282	.	_	_	I-Claim

283	Our	_	_	B-Claim
284	preliminary	_	_	I-Claim
285	data	_	_	I-Claim
286	suggest	_	_	I-Claim
287	that	_	_	I-Claim
288	rhDNase	_	_	I-Claim
289	did	_	_	I-Claim
290	not	_	_	I-Claim
291	significantly	_	_	I-Claim
292	improve	_	_	I-Claim
293	study	_	_	I-Claim
294	primary	_	_	I-Claim
295	endpoints	_	_	I-Claim
296	of	_	_	I-Claim
297	QOL	_	_	I-Claim
298	measures	_	_	I-Claim
299	compared	_	_	I-Claim
300	with	_	_	I-Claim
301	the	_	_	I-Claim
302	placebo	_	_	I-Claim
303	group	_	_	I-Claim
304	.	_	_	I-Claim

305	However	_	_	O
306	,	_	_	O
307	there	_	_	B-Claim
308	was	_	_	I-Claim
309	a	_	_	I-Claim
310	significant	_	_	I-Claim
311	improvement	_	_	I-Claim
312	in	_	_	I-Claim
313	secondary	_	_	I-Claim
314	endpoints	_	_	I-Claim
315	of	_	_	I-Claim
316	clinically	_	_	I-Claim
317	assessed	_	_	I-Claim
318	OPS	_	_	I-Claim
319	and	_	_	I-Claim
320	DNA	_	_	I-Claim
321	concentration	_	_	I-Claim
322	compared	_	_	I-Claim
323	with	_	_	I-Claim
324	placebo	_	_	I-Claim
325	in	_	_	I-Claim
326	H	_	_	I-Claim
327	&	_	_	I-Claim
328	N	_	_	I-Claim
329	cancer	_	_	I-Claim
330	patients	_	_	I-Claim
331	treated	_	_	I-Claim
332	with	_	_	I-Claim
333	CRT	_	_	I-Claim
334	.	_	_	I-Claim

335	Further	_	_	O
336	investigation	_	_	O
337	in	_	_	O
338	larger	_	_	O
339	numbers	_	_	O
340	of	_	_	O
341	patients	_	_	O
342	is	_	_	O
343	warranted	_	_	O
344	.	_	_	O


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	prospective	_	_	O
5	controlled	_	_	O
6	study	_	_	O
7	was	_	_	O
8	to	_	_	O
9	assess	_	_	O
10	the	_	_	O
11	efficacy	_	_	O
12	of	_	_	O
13	two	_	_	O
14	different	_	_	O
15	combination	_	_	O
16	treatment	_	_	O
17	modalities	_	_	O
18	of	_	_	O
19	lymphedema	_	_	O
20	(	_	_	O
21	LE	_	_	O
22	)	_	_	O
23	.	_	_	O

24	Manual	_	_	O
25	lymphatic	_	_	O
26	drainage	_	_	O
27	(	_	_	O
28	MLD	_	_	O
29	)	_	_	O
30	and	_	_	O
31	compression	_	_	O
32	bandage	_	_	O
33	combination	_	_	O
34	(	_	_	O
35	complex	_	_	O
36	decongestive	_	_	O
37	therapy	_	_	O
38	)	_	_	O
39	have	_	_	O
40	been	_	_	O
41	compared	_	_	O
42	with	_	_	O
43	intermittent	_	_	O
44	pneumatic	_	_	O
45	compression	_	_	O
46	(	_	_	O
47	IPC	_	_	O
48	)	_	_	O
49	plus	_	_	O
50	self	_	_	O
51	-	_	_	O
52	lymphatic	_	_	O
53	drainage	_	_	O
54	(	_	_	O
55	SLD	_	_	O
56	)	_	_	O
57	.	_	_	O

58	Both	_	_	O
59	MLD	_	_	O
60	with	_	_	O
61	compression	_	_	O
62	bandage	_	_	O
63	(	_	_	O
64	complex	_	_	O
65	decongestive	_	_	O
66	therapy	_	_	O
67	)	_	_	O
68	group	_	_	O
69	(	_	_	O
70	Group	_	_	O
71	I	_	_	O
72	,	_	_	O
73	n	_	_	O
74	=	_	_	O
75	15	_	_	O
76	)	_	_	O
77	and	_	_	O
78	IPC	_	_	O
79	with	_	_	O
80	SLD	_	_	O
81	group	_	_	O
82	(	_	_	O
83	Group	_	_	O
84	II	_	_	O
85	,	_	_	O
86	n	_	_	O
87	=	_	_	O
88	15	_	_	O
89	)	_	_	O
90	received	_	_	O
91	treatment	_	_	O
92	for	_	_	O
93	LE	_	_	O
94	3	_	_	O
95	days	_	_	O
96	in	_	_	O
97	a	_	_	O
98	week	_	_	O
99	and	_	_	O
100	every	_	_	O
101	other	_	_	O
102	day	_	_	O
103	for	_	_	O
104	6	_	_	O
105	weeks	_	_	O
106	.	_	_	O

107	Arm	_	_	O
108	circumferences	_	_	O
109	were	_	_	O
110	measured	_	_	O
111	before	_	_	O
112	and	_	_	O
113	the	_	_	O
114	1st	_	_	O
115	,	_	_	O
116	3rd	_	_	O
117	,	_	_	O
118	and	_	_	O
119	6th	_	_	O
120	weeks	_	_	O
121	of	_	_	O
122	the	_	_	O
123	treatment	_	_	O
124	.	_	_	O

125	EORTC	_	_	O
126	-	_	_	O
127	QLQ	_	_	O
128	and	_	_	O
129	ASES	_	_	O
130	-	_	_	O
131	tests	_	_	O
132	were	_	_	O
133	performed	_	_	O
134	to	_	_	O
135	assess	_	_	O
136	the	_	_	O
137	quality	_	_	O
138	of	_	_	O
139	life	_	_	O
140	before	_	_	O
141	and	_	_	O
142	after	_	_	O
143	6	_	_	O
144	week	_	_	O
145	-	_	_	O
146	treatment	_	_	O
147	.	_	_	O

148	Patients	_	_	O
149	in	_	_	O
150	both	_	_	O
151	groups	_	_	O
152	had	_	_	O
153	similar	_	_	O
154	demographic	_	_	O
155	and	_	_	O
156	clinical	_	_	O
157	characteristics	_	_	O
158	.	_	_	O

159	Even	_	_	O
160	though	_	_	O
161	both	_	_	B-Premise
162	treatment	_	_	I-Premise
163	modalities	_	_	I-Premise
164	resulted	_	_	I-Premise
165	in	_	_	I-Premise
166	significant	_	_	I-Premise
167	decrease	_	_	I-Premise
168	in	_	_	I-Premise
169	the	_	_	I-Premise
170	total	_	_	I-Premise
171	arm	_	_	I-Premise
172	volume	_	_	I-Premise
173	(	_	_	I-Premise
174	12	_	_	I-Premise
175	.	_	_	I-Premise

176	2	_	_	I-Premise
177	%	_	_	I-Premise
178	decrease	_	_	I-Premise
179	in	_	_	I-Premise
180	Group	_	_	I-Premise
181	II	_	_	I-Premise
182	and	_	_	I-Premise
183	14	_	_	I-Premise
184	.	_	_	I-Premise

185	9	_	_	I-Premise
186	%	_	_	I-Premise
187	decrease	_	_	I-Premise
188	in	_	_	I-Premise
189	Group	_	_	I-Premise
190	I	_	_	I-Premise
191	)	_	_	I-Premise
192	(	_	_	I-Premise
193	p	_	_	I-Premise
194	<	_	_	I-Premise
195	0	_	_	I-Premise
196	.	_	_	I-Premise

197	001	_	_	I-Premise
198	)	_	_	I-Premise
199	,	_	_	I-Premise
200	no	_	_	B-Premise
201	significant	_	_	I-Premise
202	difference	_	_	I-Premise
203	(	_	_	I-Premise
204	p	_	_	I-Premise
205	=	_	_	I-Premise
206	0	_	_	I-Premise
207	.	_	_	I-Premise

208	582	_	_	I-Premise
209	)	_	_	I-Premise
210	was	_	_	I-Premise
211	found	_	_	I-Premise
212	between	_	_	I-Premise
213	those	_	_	I-Premise
214	two	_	_	I-Premise
215	groups	_	_	I-Premise
216	.	_	_	I-Premise

217	Similarly	_	_	B-Premise
218	,	_	_	I-Premise
219	ASES	_	_	I-Premise
220	scores	_	_	I-Premise
221	were	_	_	I-Premise
222	significantly	_	_	I-Premise
223	(	_	_	I-Premise
224	p	_	_	I-Premise
225	=	_	_	I-Premise
226	0	_	_	I-Premise
227	.	_	_	I-Premise

228	001	_	_	I-Premise
229	)	_	_	I-Premise
230	improved	_	_	I-Premise
231	in	_	_	I-Premise
232	both	_	_	I-Premise
233	Group	_	_	I-Premise
234	I	_	_	I-Premise
235	and	_	_	I-Premise
236	II	_	_	I-Premise
237	without	_	_	I-Premise
238	any	_	_	I-Premise
239	significant	_	_	I-Premise
240	difference	_	_	I-Premise
241	between	_	_	I-Premise
242	the	_	_	I-Premise
243	groups	_	_	I-Premise
244	.	_	_	I-Premise

245	While	_	_	B-Premise
246	emotional	_	_	I-Premise
247	functioning	_	_	I-Premise
248	,	_	_	I-Premise
249	fatigue	_	_	I-Premise
250	,	_	_	I-Premise
251	and	_	_	I-Premise
252	pain	_	_	I-Premise
253	scores	_	_	I-Premise
254	were	_	_	I-Premise
255	significantly	_	_	I-Premise
256	improved	_	_	I-Premise
257	in	_	_	I-Premise
258	both	_	_	I-Premise
259	groups	_	_	I-Premise
260	,	_	_	I-Premise
261	global	_	_	I-Premise
262	health	_	_	I-Premise
263	status	_	_	I-Premise
264	,	_	_	I-Premise
265	functional	_	_	I-Premise
266	and	_	_	I-Premise
267	cognitive	_	_	I-Premise
268	functioning	_	_	I-Premise
269	scores	_	_	I-Premise
270	appeared	_	_	I-Premise
271	to	_	_	I-Premise
272	be	_	_	I-Premise
273	improved	_	_	I-Premise
274	only	_	_	I-Premise
275	in	_	_	I-Premise
276	patients	_	_	I-Premise
277	of	_	_	I-Premise
278	group	_	_	I-Premise
279	I	_	_	I-Premise
280	.	_	_	I-Premise

281	Different	_	_	B-Claim
282	treatment	_	_	I-Claim
283	modalities	_	_	I-Claim
284	consisting	_	_	I-Claim
285	of	_	_	I-Claim
286	MLD	_	_	I-Claim
287	and	_	_	I-Claim
288	compression	_	_	I-Claim
289	bandage	_	_	I-Claim
290	(	_	_	I-Claim
291	complex	_	_	I-Claim
292	decongestive	_	_	I-Claim
293	therapy	_	_	I-Claim
294	)	_	_	I-Claim
295	or	_	_	I-Claim
296	IPC	_	_	I-Claim
297	and	_	_	I-Claim
298	SLD	_	_	I-Claim
299	appear	_	_	I-Claim
300	to	_	_	I-Claim
301	be	_	_	I-Claim
302	effective	_	_	I-Claim
303	in	_	_	I-Claim
304	the	_	_	I-Claim
305	treatment	_	_	I-Claim
306	of	_	_	I-Claim
307	LE	_	_	I-Claim
308	with	_	_	I-Claim
309	similar	_	_	I-Claim
310	therapeutic	_	_	I-Claim
311	efficacy	_	_	I-Claim
312	in	_	_	I-Claim
313	patients	_	_	I-Claim
314	with	_	_	I-Claim
315	breast	_	_	I-Claim
316	cancer	_	_	I-Claim
317	.	_	_	I-Claim

318	However	_	_	B-Claim
319	,	_	_	I-Claim
320	combination	_	_	I-Claim
321	modalities	_	_	I-Claim
322	including	_	_	I-Claim
323	IPC	_	_	I-Claim
324	and	_	_	I-Claim
325	SLD	_	_	I-Claim
326	may	_	_	I-Claim
327	be	_	_	I-Claim
328	the	_	_	I-Claim
329	preferred	_	_	I-Claim
330	choices	_	_	I-Claim
331	for	_	_	I-Claim
332	their	_	_	I-Claim
333	applicability	_	_	I-Claim
334	at	_	_	I-Claim
335	home	_	_	I-Claim
336	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	the	_	_	O
4	present	_	_	O
5	trial	_	_	O
6	was	_	_	O
7	to	_	_	O
8	evaluate	_	_	O
9	the	_	_	O
10	effects	_	_	O
11	of	_	_	O
12	chemotherapy	_	_	O
13	on	_	_	O
14	the	_	_	O
15	quality	_	_	O
16	of	_	_	O
17	life	_	_	O
18	and	_	_	O
19	survival	_	_	O
20	of	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	advanced	_	_	O
24	non	_	_	O
25	-	_	_	O
26	small	_	_	O
27	cell	_	_	O
28	lung	_	_	O
29	cancer	_	_	O
30	(	_	_	O
31	NSCLC	_	_	O
32	)	_	_	O
33	(	_	_	O
34	stage	_	_	O
35	IIIB	_	_	O
36	or	_	_	O
37	IV	_	_	O
38	)	_	_	O
39	.	_	_	O

40	In	_	_	O
41	a	_	_	O
42	controlled	_	_	O
43	multicentre	_	_	O
44	trial	_	_	O
45	,	_	_	O
46	patients	_	_	O
47	were	_	_	O
48	randomised	_	_	O
49	to	_	_	O
50	receive	_	_	O
51	supportive	_	_	O
52	care	_	_	O
53	only	_	_	O
54	or	_	_	O
55	supportive	_	_	O
56	care	_	_	O
57	plus	_	_	O
58	chemotherapy	_	_	O
59	.	_	_	O

60	Chemotherapy	_	_	O
61	consisted	_	_	O
62	of	_	_	O
63	intravenous	_	_	O
64	(	_	_	O
65	i	_	_	O
66	.	_	_	O

67	v	_	_	O
68	.	_	_	O

69	)	_	_	O
70	carboplatin	_	_	O
71	300	_	_	O
72	mg	_	_	O
73	/	_	_	O
74	m2	_	_	O
75	on	_	_	O
76	day	_	_	O
77	1	_	_	O
78	and	_	_	O
79	etoposide	_	_	O
80	120	_	_	O
81	mg	_	_	O
82	/	_	_	O
83	m2	_	_	O
84	orally	_	_	O
85	on	_	_	O
86	days	_	_	O
87	1	_	_	O
88	-	_	_	O
89	5	_	_	O
90	every	_	_	O
91	4	_	_	O
92	weeks	_	_	O
93	for	_	_	O
94	a	_	_	O
95	maximum	_	_	O
96	of	_	_	O
97	eight	_	_	O
98	courses	_	_	O
99	.	_	_	O

100	Quality	_	_	O
101	of	_	_	O
102	life	_	_	O
103	was	_	_	O
104	measured	_	_	O
105	at	_	_	O
106	randomisation	_	_	O
107	and	_	_	O
108	prior	_	_	O
109	to	_	_	O
110	each	_	_	O
111	treatment	_	_	O
112	course	_	_	O
113	and	_	_	O
114	at	_	_	O
115	corresponding	_	_	O
116	4	_	_	O
117	-	_	_	O
118	week	_	_	O
119	intervals	_	_	O
120	in	_	_	O
121	the	_	_	O
122	control	_	_	O
123	arm	_	_	O
124	,	_	_	O
125	using	_	_	O
126	the	_	_	O
127	EORTC	_	_	O
128	QLQ	_	_	O
129	-	_	_	O
130	C30	_	_	O
131	+	_	_	O
132	LC13	_	_	O
133	questionnaire	_	_	O
134	.	_	_	O

135	48	_	_	O
136	patients	_	_	O
137	were	_	_	O
138	randomised	_	_	O
139	(	_	_	O
140	supportive	_	_	O
141	care	_	_	O
142	26	_	_	O
143	,	_	_	O
144	chemotherapy	_	_	O
145	22	_	_	O
146	)	_	_	O
147	,	_	_	O
148	being	_	_	O
149	eligible	_	_	O
150	for	_	_	O
151	comparative	_	_	O
152	analyses	_	_	O
153	.	_	_	O

154	Another	_	_	O
155	102	_	_	O
156	patients	_	_	O
157	,	_	_	O
158	97	_	_	O
159	of	_	_	O
160	which	_	_	O
161	received	_	_	O
162	chemotherapy	_	_	O
163	,	_	_	O
164	were	_	_	O
165	subsequently	_	_	O
166	included	_	_	O
167	in	_	_	O
168	the	_	_	O
169	study	_	_	O
170	on	_	_	O
171	an	_	_	O
172	individual	_	_	O
173	treatment	_	_	O
174	preference	_	_	O
175	basis	_	_	O
176	.	_	_	O

177	Data	_	_	O
178	from	_	_	O
179	these	_	_	O
180	patients	_	_	O
181	were	_	_	O
182	used	_	_	O
183	for	_	_	O
184	confirmative	_	_	O
185	purposes	_	_	O
186	.	_	_	O

187	Patients	_	_	B-Premise
188	in	_	_	I-Premise
189	the	_	_	I-Premise
190	chemotherapy	_	_	I-Premise
191	group	_	_	I-Premise
192	reported	_	_	I-Premise
193	better	_	_	I-Premise
194	overall	_	_	I-Premise
195	physical	_	_	I-Premise
196	functioning	_	_	I-Premise
197	and	_	_	I-Premise
198	symptom	_	_	I-Premise
199	control	_	_	I-Premise
200	compared	_	_	I-Premise
201	with	_	_	I-Premise
202	the	_	_	I-Premise
203	supportive	_	_	I-Premise
204	care	_	_	I-Premise
205	group	_	_	I-Premise
206	.	_	_	I-Premise

207	Group	_	_	B-Premise
208	differences	_	_	I-Premise
209	were	_	_	I-Premise
210	smaller	_	_	I-Premise
211	within	_	_	I-Premise
212	the	_	_	I-Premise
213	psychosocial	_	_	I-Premise
214	domain	_	_	I-Premise
215	,	_	_	I-Premise
216	although	_	_	B-Premise
217	trends	_	_	I-Premise
218	were	_	_	I-Premise
219	seen	_	_	I-Premise
220	in	_	_	I-Premise
221	favour	_	_	I-Premise
222	of	_	_	I-Premise
223	the	_	_	I-Premise
224	chemotherapy	_	_	I-Premise
225	group	_	_	I-Premise
226	.	_	_	I-Premise

227	No	_	_	B-Premise
228	significant	_	_	I-Premise
229	differences	_	_	I-Premise
230	were	_	_	I-Premise
231	seen	_	_	I-Premise
232	in	_	_	I-Premise
233	favour	_	_	I-Premise
234	of	_	_	I-Premise
235	the	_	_	I-Premise
236	supportive	_	_	I-Premise
237	care	_	_	I-Premise
238	group	_	_	I-Premise
239	,	_	_	I-Premise
240	except	_	_	B-Premise
241	for	_	_	I-Premise
242	hair	_	_	I-Premise
243	loss	_	_	I-Premise
244	.	_	_	I-Premise

245	Median	_	_	B-Premise
246	survival	_	_	I-Premise
247	times	_	_	I-Premise
248	were	_	_	I-Premise
249	29	_	_	I-Premise
250	weeks	_	_	I-Premise
251	in	_	_	I-Premise
252	the	_	_	I-Premise
253	chemotherapy	_	_	I-Premise
254	group	_	_	I-Premise
255	versus	_	_	I-Premise
256	11	_	_	I-Premise
257	weeks	_	_	I-Premise
258	in	_	_	I-Premise
259	the	_	_	I-Premise
260	supportive	_	_	I-Premise
261	care	_	_	I-Premise
262	group	_	_	I-Premise
263	,	_	_	I-Premise
264	and	_	_	I-Premise
265	1	_	_	I-Premise
266	-	_	_	I-Premise
267	year	_	_	I-Premise
268	survival	_	_	I-Premise
269	rates	_	_	I-Premise
270	were	_	_	I-Premise
271	28	_	_	I-Premise
272	%	_	_	I-Premise
273	versus	_	_	I-Premise
274	8	_	_	I-Premise
275	%	_	_	I-Premise
276	.	_	_	I-Premise

277	Quality	_	_	B-Premise
278	of	_	_	I-Premise
279	life	_	_	I-Premise
280	and	_	_	I-Premise
281	survival	_	_	I-Premise
282	outcomes	_	_	I-Premise
283	were	_	_	I-Premise
284	similar	_	_	I-Premise
285	in	_	_	I-Premise
286	the	_	_	I-Premise
287	randomised	_	_	I-Premise
288	and	_	_	I-Premise
289	non	_	_	I-Premise
290	-	_	_	I-Premise
291	randomised	_	_	I-Premise
292	patients	_	_	I-Premise
293	receiving	_	_	I-Premise
294	chemotherapy	_	_	I-Premise
295	.	_	_	I-Premise

296	No	_	_	B-Premise
297	treatment	_	_	I-Premise
298	-	_	_	I-Premise
299	related	_	_	I-Premise
300	deaths	_	_	I-Premise
301	occurred	_	_	I-Premise
302	.	_	_	I-Premise

303	In	_	_	B-Claim
304	conclusion	_	_	I-Claim
305	,	_	_	I-Claim
306	treatment	_	_	I-Claim
307	with	_	_	I-Claim
308	carboplatin	_	_	I-Claim
309	and	_	_	I-Claim
310	etoposide	_	_	I-Claim
311	can	_	_	I-Claim
312	improve	_	_	I-Claim
313	both	_	_	I-Claim
314	the	_	_	I-Claim
315	quality	_	_	I-Claim
316	of	_	_	I-Claim
317	life	_	_	I-Claim
318	and	_	_	I-Claim
319	the	_	_	I-Claim
320	survival	_	_	I-Claim
321	of	_	_	I-Claim
322	patients	_	_	I-Claim
323	with	_	_	I-Claim
324	advanced	_	_	I-Claim
325	NSCLC	_	_	I-Claim
326	.	_	_	I-Claim


0	We	_	_	O
1	have	_	_	O
2	recently	_	_	O
3	suggested	_	_	O
4	that	_	_	O
5	bolus	_	_	O
6	5	_	_	O
7	-	_	_	O
8	fluorouracil	_	_	O
9	(	_	_	O
10	5	_	_	O
11	-	_	_	O
12	FU	_	_	O
13	)	_	_	O
14	may	_	_	O
15	work	_	_	O
16	via	_	_	O
17	a	_	_	O
18	RNA	_	_	O
19	directed	_	_	O
20	mechanism	_	_	O
21	while	_	_	O
22	continuous	_	_	O
23	infusion	_	_	O
24	5	_	_	O
25	-	_	_	O
26	FU	_	_	O
27	may	_	_	O
28	kill	_	_	O
29	cells	_	_	O
30	via	_	_	O
31	a	_	_	O
32	thymidylate	_	_	O
33	synthase	_	_	O
34	related	_	_	O
35	pathway	_	_	O
36	.	_	_	O

37	It	_	_	O
38	may	_	_	O
39	thus	_	_	O
40	be	_	_	O
41	possible	_	_	O
42	to	_	_	O
43	selectively	_	_	O
44	modulate	_	_	O
45	each	_	_	O
46	schedule	_	_	O
47	biochemically	_	_	O
48	.	_	_	O

49	We	_	_	O
50	have	_	_	O
51	compared	_	_	O
52	an	_	_	O
53	alternating	_	_	O
54	regimen	_	_	O
55	of	_	_	O
56	bolus	_	_	O
57	and	_	_	O
58	continuous	_	_	O
59	infusion	_	_	O
60	5	_	_	O
61	-	_	_	O
62	FU	_	_	O
63	,	_	_	O
64	selectively	_	_	O
65	modulated	_	_	O
66	for	_	_	O
67	the	_	_	O
68	schedule	_	_	O
69	of	_	_	O
70	administration	_	_	O
71	,	_	_	O
72	with	_	_	O
73	modulated	_	_	O
74	bolus	_	_	O
75	5	_	_	O
76	-	_	_	O
77	FU	_	_	O
78	in	_	_	O
79	advanced	_	_	O
80	colorectal	_	_	O
81	cancer	_	_	O
82	patients	_	_	O
83	.	_	_	O

84	Two	_	_	O
85	hundred	_	_	O
86	fourteen	_	_	O
87	patients	_	_	O
88	from	_	_	O
89	nineteen	_	_	O
90	Italian	_	_	O
91	centers	_	_	O
92	were	_	_	O
93	randomized	_	_	O
94	to	_	_	O
95	the	_	_	O
96	control	_	_	O
97	arm	_	_	O
98	consisting	_	_	O
99	of	_	_	O
100	biweekly	_	_	O
101	cycles	_	_	O
102	of	_	_	O
103	MTX	_	_	O
104	,	_	_	O
105	200	_	_	O
106	mg	_	_	O
107	/	_	_	O
108	m2	_	_	O
109	on	_	_	O
110	day	_	_	O
111	1	_	_	O
112	,	_	_	O
113	followed	_	_	O
114	by	_	_	O
115	bolus	_	_	O
116	5	_	_	O
117	-	_	_	O
118	FU	_	_	O
119	600	_	_	O
120	mg	_	_	O
121	/	_	_	O
122	m2	_	_	O
123	on	_	_	O
124	day	_	_	O
125	2	_	_	O
126	and	_	_	O
127	6	_	_	O
128	-	_	_	O
129	S	_	_	O
130	-	_	_	O
131	leucovorin	_	_	O
132	rescue	_	_	O
133	,	_	_	O
134	or	_	_	O
135	to	_	_	O
136	the	_	_	O
137	experimental	_	_	O
138	arm	_	_	O
139	consisting	_	_	O
140	of	_	_	O
141	two	_	_	O
142	biweekly	_	_	O
143	cycles	_	_	O
144	of	_	_	O
145	the	_	_	O
146	same	_	_	O
147	regimen	_	_	O
148	as	_	_	O
149	in	_	_	O
150	the	_	_	O
151	control	_	_	O
152	arm	_	_	O
153	alternated	_	_	O
154	to	_	_	O
155	three	_	_	O
156	weeks	_	_	O
157	of	_	_	O
158	continuous	_	_	O
159	infusion	_	_	O
160	5	_	_	O
161	-	_	_	O
162	FU	_	_	O
163	(	_	_	O
164	200	_	_	O
165	mg	_	_	O
166	/	_	_	O
167	m2	_	_	O
168	day	_	_	O
169	)	_	_	O
170	+	_	_	O
171	weekly	_	_	O
172	bolus	_	_	O
173	6	_	_	O
174	-	_	_	O
175	S	_	_	O
176	-	_	_	O
177	leucovorin	_	_	O
178	,	_	_	O
179	20	_	_	O
180	mg	_	_	O
181	/	_	_	O
182	m2	_	_	O
183	.	_	_	O

184	Nine	_	_	B-Premise
185	CR	_	_	I-Premise
186	and	_	_	I-Premise
187	twenty	_	_	I-Premise
188	-	_	_	I-Premise
189	seven	_	_	I-Premise
190	PR	_	_	I-Premise
191	were	_	_	I-Premise
192	obtained	_	_	I-Premise
193	on	_	_	I-Premise
194	one	_	_	I-Premise
195	hundred	_	_	I-Premise
196	eleven	_	_	I-Premise
197	evaluable	_	_	I-Premise
198	patients	_	_	I-Premise
199	treated	_	_	I-Premise
200	in	_	_	I-Premise
201	experimental	_	_	I-Premise
202	arm	_	_	I-Premise
203	(	_	_	I-Premise
204	RR	_	_	I-Premise
205	=	_	_	I-Premise
206	32	_	_	I-Premise
207	%	_	_	I-Premise
208	,	_	_	I-Premise
209	95	_	_	I-Premise
210	%	_	_	I-Premise
211	confidence	_	_	I-Premise
212	interval	_	_	I-Premise
213	(	_	_	I-Premise
214	95	_	_	I-Premise
215	%	_	_	I-Premise
216	CI	_	_	I-Premise
217	)	_	_	I-Premise
218	:	_	_	I-Premise
219	24	_	_	I-Premise
220	%	_	_	I-Premise
221	-	_	_	I-Premise
222	42	_	_	I-Premise
223	%	_	_	I-Premise
224	)	_	_	I-Premise
225	,	_	_	I-Premise
226	while	_	_	I-Premise
227	two	_	_	I-Premise
228	CR	_	_	I-Premise
229	and	_	_	I-Premise
230	eleven	_	_	I-Premise
231	PR	_	_	I-Premise
232	were	_	_	I-Premise
233	observed	_	_	I-Premise
234	among	_	_	I-Premise
235	one	_	_	I-Premise
236	hundred	_	_	I-Premise
237	three	_	_	I-Premise
238	evaluable	_	_	I-Premise
239	patients	_	_	I-Premise
240	in	_	_	I-Premise
241	control	_	_	I-Premise
242	arm	_	_	I-Premise
243	(	_	_	I-Premise
244	RR	_	_	I-Premise
245	=	_	_	I-Premise
246	13	_	_	I-Premise
247	%	_	_	I-Premise
248	,	_	_	I-Premise
249	95	_	_	I-Premise
250	%	_	_	I-Premise
251	CI	_	_	I-Premise
252	:	_	_	I-Premise
253	7	_	_	I-Premise
254	%	_	_	I-Premise
255	-	_	_	I-Premise
256	21	_	_	I-Premise
257	%	_	_	I-Premise
258	)	_	_	I-Premise
259	.	_	_	I-Premise

260	WHO	_	_	B-Premise
261	grade	_	_	I-Premise
262	3	_	_	I-Premise
263	-	_	_	I-Premise
264	4	_	_	I-Premise
265	toxicity	_	_	I-Premise
266	occurred	_	_	I-Premise
267	in	_	_	I-Premise
268	13	_	_	I-Premise
269	%	_	_	I-Premise
270	of	_	_	I-Premise
271	cycles	_	_	I-Premise
272	of	_	_	I-Premise
273	experimental	_	_	I-Premise
274	arm	_	_	I-Premise
275	and	_	_	I-Premise
276	in	_	_	I-Premise
277	8	_	_	I-Premise
278	%	_	_	I-Premise
279	of	_	_	I-Premise
280	cycles	_	_	I-Premise
281	in	_	_	I-Premise
282	control	_	_	I-Premise
283	arm	_	_	I-Premise
284	.	_	_	I-Premise

285	The	_	_	B-Premise
286	PFS	_	_	I-Premise
287	was	_	_	I-Premise
288	significantly	_	_	I-Premise
289	longer	_	_	I-Premise
290	in	_	_	I-Premise
291	experimental	_	_	I-Premise
292	arm	_	_	I-Premise
293	(	_	_	I-Premise
294	6	_	_	I-Premise
295	.	_	_	I-Premise

296	2	_	_	I-Premise
297	vs	_	_	I-Premise
298	.	_	_	I-Premise

299	4	_	_	I-Premise
300	.	_	_	I-Premise

301	3	_	_	I-Premise
302	months	_	_	I-Premise
303	,	_	_	I-Premise
304	odds	_	_	I-Premise
305	ratio	_	_	I-Premise
306	0	_	_	I-Premise
307	.	_	_	I-Premise

308	66	_	_	I-Premise
309	,	_	_	I-Premise
310	P	_	_	I-Premise
311	=	_	_	I-Premise
312	0	_	_	I-Premise
313	.	_	_	I-Premise

314	003	_	_	I-Premise
315	)	_	_	I-Premise
316	,	_	_	I-Premise
317	while	_	_	O
318	the	_	_	B-Premise
319	overall	_	_	I-Premise
320	survival	_	_	I-Premise
321	was	_	_	I-Premise
322	similar	_	_	I-Premise
323	in	_	_	I-Premise
324	both	_	_	I-Premise
325	arms	_	_	I-Premise
326	(	_	_	I-Premise
327	14	_	_	I-Premise
328	.	_	_	I-Premise

329	8	_	_	I-Premise
330	months	_	_	I-Premise
331	in	_	_	I-Premise
332	experimental	_	_	I-Premise
333	arm	_	_	I-Premise
334	vs	_	_	I-Premise
335	.	_	_	I-Premise

336	14	_	_	I-Premise
337	.	_	_	I-Premise

338	1	_	_	I-Premise
339	months	_	_	I-Premise
340	in	_	_	I-Premise
341	control	_	_	I-Premise
342	arm	_	_	I-Premise
343	)	_	_	I-Premise
344	;	_	_	I-Premise
345	quality	_	_	B-Claim
346	of	_	_	I-Claim
347	life	_	_	I-Claim
348	was	_	_	I-Claim
349	similar	_	_	I-Claim
350	as	_	_	I-Claim
351	well	_	_	I-Claim
352	.	_	_	I-Claim

353	Eighty	_	_	B-Premise
354	percent	_	_	I-Premise
355	of	_	_	I-Premise
356	patients	_	_	I-Premise
357	receiving	_	_	I-Premise
358	second	_	_	I-Premise
359	-	_	_	I-Premise
360	line	_	_	I-Premise
361	chemotherapy	_	_	I-Premise
362	in	_	_	I-Premise
363	control	_	_	I-Premise
364	arm	_	_	I-Premise
365	were	_	_	I-Premise
366	treated	_	_	I-Premise
367	with	_	_	I-Premise
368	continuous	_	_	I-Premise
369	infusion	_	_	I-Premise
370	5	_	_	I-Premise
371	-	_	_	I-Premise
372	FU	_	_	I-Premise
373	.	_	_	I-Premise

374	Alternating	_	_	O
375	,	_	_	O
376	schedule	_	_	B-Claim
377	-	_	_	I-Claim
378	specific	_	_	I-Claim
379	biochemical	_	_	I-Claim
380	modulation	_	_	I-Claim
381	of	_	_	I-Claim
382	FU	_	_	I-Claim
383	is	_	_	I-Claim
384	more	_	_	I-Claim
385	active	_	_	I-Claim
386	than	_	_	I-Claim
387	MTX	_	_	I-Claim
388	-	_	_	I-Claim
389	-	_	_	I-Claim
390	>	_	_	I-Claim
391	5	_	_	I-Claim
392	-	_	_	I-Claim
393	FU	_	_	I-Claim
394	as	_	_	I-Claim
395	first	_	_	I-Claim
396	-	_	_	I-Claim
397	line	_	_	I-Claim
398	treatment	_	_	I-Claim
399	of	_	_	I-Claim
400	advanced	_	_	I-Claim
401	colorectal	_	_	I-Claim
402	cancer	_	_	I-Claim
403	.	_	_	I-Claim

404	However	_	_	B-Claim
405	,	_	_	I-Claim
406	the	_	_	I-Claim
407	overall	_	_	I-Claim
408	survival	_	_	I-Claim
409	was	_	_	I-Claim
410	similar	_	_	I-Claim
411	suggesting	_	_	I-Claim
412	that	_	_	I-Claim
413	alternating	_	_	I-Claim
414	bolus	_	_	I-Claim
415	and	_	_	I-Claim
416	infusional	_	_	I-Claim
417	5	_	_	I-Claim
418	-	_	_	I-Claim
419	FU	_	_	I-Claim
420	upfront	_	_	I-Claim
421	may	_	_	I-Claim
422	be	_	_	I-Claim
423	as	_	_	I-Claim
424	effective	_	_	I-Claim
425	as	_	_	I-Claim
426	giving	_	_	I-Claim
427	them	_	_	I-Claim
428	in	_	_	I-Claim
429	sequence	_	_	I-Claim
430	as	_	_	I-Claim
431	first	_	_	I-Claim
432	-	_	_	I-Claim
433	and	_	_	I-Claim
434	second	_	_	I-Claim
435	-	_	_	I-Claim
436	line	_	_	I-Claim
437	treatment	_	_	I-Claim
438	.	_	_	I-Claim


0	The	_	_	O
1	management	_	_	O
2	of	_	_	O
3	cancer	_	_	O
4	-	_	_	O
5	related	_	_	O
6	anorexia	_	_	O
7	/	_	_	O
8	cachexia	_	_	O
9	syndrome	_	_	O
10	(	_	_	O
11	CACS	_	_	O
12	)	_	_	O
13	is	_	_	O
14	a	_	_	O
15	great	_	_	O
16	challenge	_	_	O
17	in	_	_	O
18	clinical	_	_	O
19	practice	_	_	O
20	.	_	_	O

21	To	_	_	O
22	date	_	_	O
23	,	_	_	O
24	practice	_	_	O
25	guidelines	_	_	O
26	for	_	_	O
27	the	_	_	O
28	prevention	_	_	O
29	and	_	_	O
30	treatment	_	_	O
31	of	_	_	O
32	CACS	_	_	O
33	are	_	_	O
34	lacking	_	_	O
35	.	_	_	O

36	The	_	_	O
37	authors	_	_	O
38	conducted	_	_	O
39	a	_	_	O
40	randomized	_	_	O
41	study	_	_	O
42	to	_	_	O
43	confirm	_	_	O
44	the	_	_	O
45	effectiveness	_	_	O
46	and	_	_	O
47	safety	_	_	O
48	of	_	_	O
49	treatment	_	_	O
50	of	_	_	O
51	CACS	_	_	O
52	utilizing	_	_	O
53	megestrol	_	_	O
54	acetate	_	_	O
55	(	_	_	O
56	MA	_	_	O
57	)	_	_	O
58	plus	_	_	O
59	thalidomide	_	_	O
60	.	_	_	O

61	One	_	_	O
62	hundred	_	_	O
63	and	_	_	O
64	two	_	_	O
65	candidates	_	_	O
66	with	_	_	O
67	CACS	_	_	O
68	were	_	_	O
69	randomly	_	_	O
70	assigned	_	_	O
71	to	_	_	O
72	two	_	_	O
73	treatment	_	_	O
74	groups	_	_	O
75	(	_	_	O
76	trial	_	_	O
77	group	_	_	O
78	and	_	_	O
79	control	_	_	O
80	group	_	_	O
81	)	_	_	O
82	:	_	_	O
83	the	_	_	O
84	trial	_	_	O
85	group	_	_	O
86	received	_	_	O
87	MA	_	_	O
88	(	_	_	O
89	160	_	_	O
90	mg	_	_	O
91	po	_	_	O
92	,	_	_	O
93	bid	_	_	O
94	)	_	_	O
95	plus	_	_	O
96	thalidomide	_	_	O
97	(	_	_	O
98	50	_	_	O
99	mg	_	_	O
100	po	_	_	O
101	,	_	_	O
102	bid	_	_	O
103	)	_	_	O
104	,	_	_	O
105	while	_	_	O
106	the	_	_	O
107	control	_	_	O
108	group	_	_	O
109	received	_	_	O
110	MA	_	_	O
111	(	_	_	O
112	160	_	_	O
113	mg	_	_	O
114	po	_	_	O
115	,	_	_	O
116	bid	_	_	O
117	)	_	_	O
118	alone	_	_	O
119	.	_	_	O

120	Treatment	_	_	O
121	duration	_	_	O
122	was	_	_	O
123	8	_	_	O
124	weeks	_	_	O
125	.	_	_	O

126	Analysis	_	_	B-Premise
127	of	_	_	I-Premise
128	the	_	_	I-Premise
129	trial	_	_	I-Premise
130	group	_	_	I-Premise
131	demonstrated	_	_	I-Premise
132	a	_	_	I-Premise
133	significant	_	_	I-Premise
134	increase	_	_	I-Premise
135	from	_	_	I-Premise
136	baseline	_	_	I-Premise
137	in	_	_	I-Premise
138	body	_	_	I-Premise
139	weight	_	_	I-Premise
140	(	_	_	I-Premise
141	<	_	_	I-Premise
142	0	_	_	I-Premise
143	.	_	_	I-Premise

144	01	_	_	I-Premise
145	)	_	_	I-Premise
146	,	_	_	I-Premise
147	quality	_	_	I-Premise
148	of	_	_	I-Premise
149	life	_	_	I-Premise
150	(	_	_	I-Premise
151	p	_	_	I-Premise
152	=	_	_	I-Premise
153	0	_	_	I-Premise
154	.	_	_	I-Premise

155	02	_	_	I-Premise
156	)	_	_	I-Premise
157	,	_	_	I-Premise
158	appetite	_	_	I-Premise
159	(	_	_	I-Premise
160	p	_	_	I-Premise
161	=	_	_	I-Premise
162	0	_	_	I-Premise
163	.	_	_	I-Premise

164	01	_	_	I-Premise
165	)	_	_	I-Premise
166	,	_	_	I-Premise
167	and	_	_	I-Premise
168	grip	_	_	I-Premise
169	strength	_	_	I-Premise
170	(	_	_	I-Premise
171	p	_	_	I-Premise
172	=	_	_	I-Premise
173	0	_	_	I-Premise
174	.	_	_	I-Premise

175	01	_	_	I-Premise
176	)	_	_	I-Premise
177	,	_	_	I-Premise
178	and	_	_	I-Premise
179	a	_	_	I-Premise
180	significant	_	_	I-Premise
181	decrease	_	_	I-Premise
182	in	_	_	I-Premise
183	fatigue	_	_	I-Premise
184	,	_	_	I-Premise
185	Glasgow	_	_	I-Premise
186	Prognostic	_	_	I-Premise
187	Score	_	_	I-Premise
188	(	_	_	I-Premise
189	p	_	_	I-Premise
190	=	_	_	I-Premise
191	0	_	_	I-Premise
192	.	_	_	I-Premise

193	05	_	_	I-Premise
194	)	_	_	I-Premise
195	,	_	_	I-Premise
196	Eastern	_	_	I-Premise
197	Cooperative	_	_	I-Premise
198	Oncology	_	_	I-Premise
199	Group	_	_	I-Premise
200	performance	_	_	I-Premise
201	status	_	_	I-Premise
202	(	_	_	I-Premise
203	p	_	_	I-Premise
204	=	_	_	I-Premise
205	0	_	_	I-Premise
206	.	_	_	I-Premise

207	03	_	_	I-Premise
208	)	_	_	I-Premise
209	,	_	_	I-Premise
210	IL	_	_	I-Premise
211	-	_	_	I-Premise
212	6	_	_	I-Premise
213	(	_	_	I-Premise
214	p	_	_	I-Premise
215	<	_	_	I-Premise
216	0	_	_	I-Premise
217	.	_	_	I-Premise

218	01	_	_	I-Premise
219	)	_	_	I-Premise
220	,	_	_	I-Premise
221	and	_	_	I-Premise
222	tumor	_	_	I-Premise
223	necrosis	_	_	I-Premise
224	factor	_	_	I-Premise
225	-	_	_	I-Premise
226	α	_	_	I-Premise
227	(	_	_	I-Premise
228	p	_	_	I-Premise
229	=	_	_	I-Premise
230	0	_	_	I-Premise
231	.	_	_	I-Premise

232	02	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	In	_	_	B-Premise
236	contrast	_	_	I-Premise
237	,	_	_	I-Premise
238	in	_	_	I-Premise
239	the	_	_	I-Premise
240	control	_	_	I-Premise
241	group	_	_	I-Premise
242	,	_	_	I-Premise
243	endpoints	_	_	I-Premise
244	with	_	_	I-Premise
245	a	_	_	I-Premise
246	significant	_	_	I-Premise
247	improvement	_	_	I-Premise
248	from	_	_	I-Premise
249	baseline	_	_	I-Premise
250	included	_	_	I-Premise
251	body	_	_	I-Premise
252	weight	_	_	I-Premise
253	(	_	_	I-Premise
254	p	_	_	I-Premise
255	<	_	_	I-Premise
256	0	_	_	I-Premise
257	.	_	_	I-Premise

258	02	_	_	I-Premise
259	)	_	_	I-Premise
260	and	_	_	I-Premise
261	appetite	_	_	I-Premise
262	(	_	_	I-Premise
263	p	_	_	I-Premise
264	=	_	_	I-Premise
265	0	_	_	I-Premise
266	.	_	_	I-Premise

267	02	_	_	I-Premise
268	)	_	_	I-Premise
269	.	_	_	I-Premise

270	The	_	_	B-Premise
271	mean	_	_	I-Premise
272	changes	_	_	I-Premise
273	in	_	_	I-Premise
274	the	_	_	I-Premise
275	endpoints	_	_	I-Premise
276	from	_	_	I-Premise
277	baseline	_	_	I-Premise
278	in	_	_	I-Premise
279	the	_	_	I-Premise
280	trial	_	_	I-Premise
281	group	_	_	I-Premise
282	were	_	_	I-Premise
283	significantly	_	_	I-Premise
284	greater	_	_	I-Premise
285	compared	_	_	I-Premise
286	with	_	_	I-Premise
287	the	_	_	I-Premise
288	control	_	_	I-Premise
289	group	_	_	I-Premise
290	:	_	_	I-Premise
291	in	_	_	I-Premise
292	the	_	_	I-Premise
293	primary	_	_	I-Premise
294	endpoints	_	_	I-Premise
295	,	_	_	I-Premise
296	body	_	_	I-Premise
297	weight	_	_	I-Premise
298	(	_	_	I-Premise
299	p	_	_	I-Premise
300	=	_	_	I-Premise
301	0	_	_	I-Premise
302	.	_	_	I-Premise

303	05	_	_	I-Premise
304	)	_	_	I-Premise
305	,	_	_	I-Premise
306	fatigue	_	_	I-Premise
307	(	_	_	I-Premise
308	p	_	_	I-Premise
309	<	_	_	I-Premise
310	0	_	_	I-Premise
311	.	_	_	I-Premise

312	01	_	_	I-Premise
313	)	_	_	I-Premise
314	and	_	_	I-Premise
315	quality	_	_	I-Premise
316	of	_	_	I-Premise
317	life	_	_	I-Premise
318	(	_	_	I-Premise
319	p	_	_	I-Premise
320	=	_	_	I-Premise
321	0	_	_	I-Premise
322	.	_	_	I-Premise

323	01	_	_	I-Premise
324	)	_	_	I-Premise
325	,	_	_	I-Premise
326	and	_	_	I-Premise
327	in	_	_	I-Premise
328	the	_	_	I-Premise
329	secondary	_	_	I-Premise
330	endpoints	_	_	I-Premise
331	,	_	_	I-Premise
332	grip	_	_	I-Premise
333	strength	_	_	I-Premise
334	(	_	_	I-Premise
335	p	_	_	I-Premise
336	=	_	_	I-Premise
337	0	_	_	I-Premise
338	.	_	_	I-Premise

339	05	_	_	I-Premise
340	)	_	_	I-Premise
341	,	_	_	I-Premise
342	Glasgow	_	_	I-Premise
343	Prognostic	_	_	I-Premise
344	Score	_	_	I-Premise
345	(	_	_	I-Premise
346	p	_	_	I-Premise
347	=	_	_	I-Premise
348	0	_	_	I-Premise
349	.	_	_	I-Premise

350	02	_	_	I-Premise
351	)	_	_	I-Premise
352	,	_	_	I-Premise
353	Eastern	_	_	I-Premise
354	Cooperative	_	_	I-Premise
355	Oncology	_	_	I-Premise
356	Group	_	_	I-Premise
357	performance	_	_	I-Premise
358	status	_	_	I-Premise
359	(	_	_	I-Premise
360	p	_	_	I-Premise
361	=	_	_	I-Premise
362	0	_	_	I-Premise
363	.	_	_	I-Premise

364	02	_	_	I-Premise
365	)	_	_	I-Premise
366	,	_	_	I-Premise
367	IL	_	_	I-Premise
368	-	_	_	I-Premise
369	6	_	_	I-Premise
370	(	_	_	I-Premise
371	p	_	_	I-Premise
372	<	_	_	I-Premise
373	0	_	_	I-Premise
374	.	_	_	I-Premise

375	01	_	_	I-Premise
376	)	_	_	I-Premise
377	and	_	_	I-Premise
378	tumor	_	_	I-Premise
379	necrosis	_	_	I-Premise
380	factor	_	_	I-Premise
381	-	_	_	I-Premise
382	α	_	_	I-Premise
383	(	_	_	I-Premise
384	p	_	_	I-Premise
385	=	_	_	I-Premise
386	0	_	_	I-Premise
387	.	_	_	I-Premise

388	01	_	_	I-Premise
389	)	_	_	I-Premise
390	.	_	_	I-Premise

391	Toxicity	_	_	B-Premise
392	was	_	_	I-Premise
393	found	_	_	I-Premise
394	to	_	_	I-Premise
395	be	_	_	I-Premise
396	relatively	_	_	I-Premise
397	negligible	_	_	I-Premise
398	in	_	_	I-Premise
399	both	_	_	I-Premise
400	groups	_	_	I-Premise
401	.	_	_	I-Premise

402	A	_	_	B-Claim
403	combination	_	_	I-Claim
404	regimen	_	_	I-Claim
405	of	_	_	I-Claim
406	MA	_	_	I-Claim
407	and	_	_	I-Claim
408	thalidomide	_	_	I-Claim
409	is	_	_	I-Claim
410	more	_	_	I-Claim
411	effective	_	_	I-Claim
412	than	_	_	I-Claim
413	MA	_	_	I-Claim
414	alone	_	_	I-Claim
415	in	_	_	I-Claim
416	the	_	_	I-Claim
417	treatment	_	_	I-Claim
418	of	_	_	I-Claim
419	CACS	_	_	I-Claim
420	.	_	_	I-Claim


0	Sentinel	_	_	B-Claim
1	lymph	_	_	I-Claim
2	node	_	_	I-Claim
3	biopsy	_	_	I-Claim
4	in	_	_	I-Claim
5	women	_	_	I-Claim
6	with	_	_	I-Claim
7	operable	_	_	I-Claim
8	breast	_	_	I-Claim
9	cancer	_	_	I-Claim
10	is	_	_	I-Claim
11	routinely	_	_	I-Claim
12	used	_	_	I-Claim
13	in	_	_	I-Claim
14	some	_	_	I-Claim
15	countries	_	_	I-Claim
16	for	_	_	I-Claim
17	staging	_	_	I-Claim
18	the	_	_	I-Claim
19	axilla	_	_	I-Claim
20	despite	_	_	I-Claim
21	limited	_	_	I-Claim
22	data	_	_	I-Claim
23	from	_	_	I-Claim
24	randomized	_	_	I-Claim
25	trials	_	_	I-Claim
26	on	_	_	I-Claim
27	morbidity	_	_	I-Claim
28	and	_	_	I-Claim
29	mortality	_	_	I-Claim
30	outcomes	_	_	I-Claim
31	.	_	_	I-Claim

32	We	_	_	O
33	conducted	_	_	O
34	a	_	_	O
35	multicenter	_	_	O
36	randomized	_	_	O
37	trial	_	_	O
38	to	_	_	O
39	compare	_	_	O
40	quality	_	_	O
41	-	_	_	O
42	of	_	_	O
43	-	_	_	O
44	life	_	_	O
45	outcomes	_	_	O
46	between	_	_	O
47	patients	_	_	O
48	with	_	_	O
49	clinically	_	_	O
50	node	_	_	O
51	-	_	_	O
52	negative	_	_	O
53	invasive	_	_	O
54	breast	_	_	O
55	cancer	_	_	O
56	who	_	_	O
57	received	_	_	O
58	sentinel	_	_	O
59	lymph	_	_	O
60	node	_	_	O
61	biopsy	_	_	O
62	and	_	_	O
63	patients	_	_	O
64	who	_	_	O
65	received	_	_	O
66	standard	_	_	O
67	axillary	_	_	O
68	treatment	_	_	O
69	.	_	_	O

70	The	_	_	O
71	primary	_	_	O
72	outcome	_	_	O
73	measures	_	_	O
74	were	_	_	O
75	arm	_	_	O
76	and	_	_	O
77	shoulder	_	_	O
78	morbidity	_	_	O
79	and	_	_	O
80	quality	_	_	O
81	of	_	_	O
82	life	_	_	O
83	.	_	_	O

84	From	_	_	O
85	November	_	_	O
86	1999	_	_	O
87	to	_	_	O
88	October	_	_	O
89	2003	_	_	O
90	,	_	_	O
91	1031	_	_	O
92	patients	_	_	O
93	were	_	_	O
94	randomly	_	_	O
95	assigned	_	_	O
96	to	_	_	O
97	undergo	_	_	O
98	sentinel	_	_	O
99	lymph	_	_	O
100	node	_	_	O
101	biopsy	_	_	O
102	(	_	_	O
103	n	_	_	O
104	=	_	_	O
105	515	_	_	O
106	)	_	_	O
107	or	_	_	O
108	standard	_	_	O
109	axillary	_	_	O
110	surgery	_	_	O
111	(	_	_	O
112	n	_	_	O
113	=	_	_	O
114	516	_	_	O
115	)	_	_	O
116	.	_	_	O

117	Patients	_	_	O
118	with	_	_	O
119	sentinel	_	_	O
120	lymph	_	_	O
121	node	_	_	O
122	metastases	_	_	O
123	proceeded	_	_	O
124	to	_	_	O
125	delayed	_	_	O
126	axillary	_	_	O
127	clearance	_	_	O
128	or	_	_	O
129	received	_	_	O
130	axillary	_	_	O
131	radiotherapy	_	_	O
132	(	_	_	O
133	depending	_	_	O
134	on	_	_	O
135	the	_	_	O
136	protocol	_	_	O
137	at	_	_	O
138	the	_	_	O
139	treating	_	_	O
140	institution	_	_	O
141	)	_	_	O
142	.	_	_	O

143	Intention	_	_	O
144	-	_	_	O
145	to	_	_	O
146	-	_	_	O
147	treat	_	_	O
148	analyses	_	_	O
149	of	_	_	O
150	data	_	_	O
151	at	_	_	O
152	1	_	_	O
153	,	_	_	O
154	3	_	_	O
155	,	_	_	O
156	6	_	_	O
157	,	_	_	O
158	and	_	_	O
159	12	_	_	O
160	months	_	_	O
161	after	_	_	O
162	surgery	_	_	O
163	are	_	_	O
164	presented	_	_	O
165	.	_	_	O

166	All	_	_	O
167	statistical	_	_	O
168	tests	_	_	O
169	were	_	_	O
170	two	_	_	O
171	-	_	_	O
172	sided	_	_	O
173	.	_	_	O

174	The	_	_	B-Premise
175	relative	_	_	I-Premise
176	risks	_	_	I-Premise
177	of	_	_	I-Premise
178	any	_	_	I-Premise
179	lymphedema	_	_	I-Premise
180	and	_	_	I-Premise
181	sensory	_	_	I-Premise
182	loss	_	_	I-Premise
183	for	_	_	I-Premise
184	the	_	_	I-Premise
185	sentinel	_	_	I-Premise
186	lymph	_	_	I-Premise
187	node	_	_	I-Premise
188	biopsy	_	_	I-Premise
189	group	_	_	I-Premise
190	compared	_	_	I-Premise
191	with	_	_	I-Premise
192	the	_	_	I-Premise
193	standard	_	_	I-Premise
194	axillary	_	_	I-Premise
195	treatment	_	_	I-Premise
196	group	_	_	I-Premise
197	at	_	_	I-Premise
198	12	_	_	I-Premise
199	months	_	_	I-Premise
200	were	_	_	I-Premise
201	0	_	_	I-Premise
202	.	_	_	I-Premise

203	37	_	_	I-Premise
204	(	_	_	I-Premise
205	95	_	_	I-Premise
206	%	_	_	I-Premise
207	confidence	_	_	I-Premise
208	interval	_	_	I-Premise
209	[	_	_	I-Premise
210	CI	_	_	I-Premise
211	]	_	_	I-Premise
212	=	_	_	I-Premise
213	0	_	_	I-Premise
214	.	_	_	I-Premise

215	23	_	_	I-Premise
216	to	_	_	I-Premise
217	0	_	_	I-Premise
218	.	_	_	I-Premise

219	60	_	_	I-Premise
220	;	_	_	I-Premise
221	absolute	_	_	I-Premise
222	rates	_	_	I-Premise
223	:	_	_	I-Premise
224	5	_	_	I-Premise
225	%	_	_	I-Premise
226	versus	_	_	I-Premise
227	13	_	_	I-Premise
228	%	_	_	I-Premise
229	)	_	_	I-Premise
230	and	_	_	I-Premise
231	0	_	_	I-Premise
232	.	_	_	I-Premise

233	37	_	_	I-Premise
234	(	_	_	I-Premise
235	95	_	_	I-Premise
236	%	_	_	I-Premise
237	CI	_	_	I-Premise
238	=	_	_	I-Premise
239	0	_	_	I-Premise
240	.	_	_	I-Premise

241	27	_	_	I-Premise
242	to	_	_	I-Premise
243	0	_	_	I-Premise
244	.	_	_	I-Premise

245	50	_	_	I-Premise
246	;	_	_	I-Premise
247	absolute	_	_	I-Premise
248	rates	_	_	I-Premise
249	:	_	_	I-Premise
250	11	_	_	I-Premise
251	%	_	_	I-Premise
252	versus	_	_	I-Premise
253	31	_	_	I-Premise
254	%	_	_	I-Premise
255	)	_	_	I-Premise
256	,	_	_	I-Premise
257	respectively	_	_	I-Premise
258	.	_	_	I-Premise

259	Drain	_	_	B-Premise
260	usage	_	_	I-Premise
261	,	_	_	I-Premise
262	length	_	_	I-Premise
263	of	_	_	I-Premise
264	hospital	_	_	I-Premise
265	stay	_	_	I-Premise
266	,	_	_	I-Premise
267	and	_	_	I-Premise
268	time	_	_	I-Premise
269	to	_	_	I-Premise
270	resumption	_	_	I-Premise
271	of	_	_	I-Premise
272	normal	_	_	I-Premise
273	day	_	_	I-Premise
274	-	_	_	I-Premise
275	to	_	_	I-Premise
276	-	_	_	I-Premise
277	day	_	_	I-Premise
278	activities	_	_	I-Premise
279	after	_	_	I-Premise
280	surgery	_	_	I-Premise
281	were	_	_	I-Premise
282	statistically	_	_	I-Premise
283	significantly	_	_	I-Premise
284	lower	_	_	I-Premise
285	in	_	_	I-Premise
286	the	_	_	I-Premise
287	sentinel	_	_	I-Premise
288	lymph	_	_	I-Premise
289	node	_	_	I-Premise
290	biopsy	_	_	I-Premise
291	group	_	_	I-Premise
292	(	_	_	I-Premise
293	all	_	_	I-Premise
294	P	_	_	I-Premise
295	<	_	_	I-Premise
296	.	_	_	I-Premise

297	001	_	_	I-Premise
298	)	_	_	I-Premise
299	,	_	_	I-Premise
300	and	_	_	I-Premise
301	axillary	_	_	I-Premise
302	operative	_	_	I-Premise
303	time	_	_	I-Premise
304	was	_	_	I-Premise
305	reduced	_	_	I-Premise
306	(	_	_	I-Premise
307	P	_	_	I-Premise
308	=	_	_	I-Premise
309	.	_	_	I-Premise

310	055	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	Overall	_	_	B-Premise
314	patient	_	_	I-Premise
315	-	_	_	I-Premise
316	recorded	_	_	I-Premise
317	quality	_	_	I-Premise
318	of	_	_	I-Premise
319	life	_	_	I-Premise
320	and	_	_	I-Premise
321	arm	_	_	I-Premise
322	functioning	_	_	I-Premise
323	scores	_	_	I-Premise
324	were	_	_	I-Premise
325	statistically	_	_	I-Premise
326	significantly	_	_	I-Premise
327	better	_	_	I-Premise
328	in	_	_	I-Premise
329	the	_	_	I-Premise
330	sentinel	_	_	I-Premise
331	lymph	_	_	I-Premise
332	node	_	_	I-Premise
333	biopsy	_	_	I-Premise
334	group	_	_	I-Premise
335	throughout	_	_	I-Premise
336	(	_	_	I-Premise
337	all	_	_	I-Premise
338	P	_	_	I-Premise
339	<	_	_	I-Premise
340	or	_	_	I-Premise
341	=	_	_	I-Premise
342	.	_	_	I-Premise

343	003	_	_	I-Premise
344	)	_	_	I-Premise
345	.	_	_	I-Premise

346	These	_	_	B-Premise
347	benefits	_	_	I-Premise
348	were	_	_	I-Premise
349	seen	_	_	I-Premise
350	with	_	_	I-Premise
351	no	_	_	I-Premise
352	increase	_	_	I-Premise
353	in	_	_	I-Premise
354	anxiety	_	_	I-Premise
355	levels	_	_	I-Premise
356	in	_	_	I-Premise
357	the	_	_	I-Premise
358	sentinel	_	_	I-Premise
359	lymph	_	_	I-Premise
360	node	_	_	I-Premise
361	biopsy	_	_	I-Premise
362	group	_	_	I-Premise
363	(	_	_	I-Premise
364	P	_	_	I-Premise
365	>	_	_	I-Premise
366	.	_	_	I-Premise

367	05	_	_	I-Premise
368	)	_	_	I-Premise
369	.	_	_	I-Premise

370	Sentinel	_	_	B-Claim
371	lymph	_	_	I-Claim
372	node	_	_	I-Claim
373	biopsy	_	_	I-Claim
374	is	_	_	I-Claim
375	associated	_	_	I-Claim
376	with	_	_	I-Claim
377	reduced	_	_	I-Claim
378	arm	_	_	I-Claim
379	morbidity	_	_	I-Claim
380	and	_	_	I-Claim
381	better	_	_	I-Claim
382	quality	_	_	I-Claim
383	of	_	_	I-Claim
384	life	_	_	I-Claim
385	than	_	_	I-Claim
386	standard	_	_	I-Claim
387	axillary	_	_	I-Claim
388	treatment	_	_	I-Claim
389	and	_	_	I-Claim
390	should	_	_	I-Claim
391	be	_	_	I-Claim
392	the	_	_	I-Claim
393	treatment	_	_	I-Claim
394	of	_	_	I-Claim
395	choice	_	_	I-Claim
396	for	_	_	I-Claim
397	patients	_	_	I-Claim
398	who	_	_	I-Claim
399	have	_	_	I-Claim
400	early	_	_	I-Claim
401	-	_	_	I-Claim
402	stage	_	_	I-Claim
403	breast	_	_	I-Claim
404	cancer	_	_	I-Claim
405	with	_	_	I-Claim
406	clinically	_	_	I-Claim
407	negative	_	_	I-Claim
408	nodes	_	_	I-Claim
409	.	_	_	I-Claim


0	For	_	_	B-Claim
1	patients	_	_	I-Claim
2	with	_	_	I-Claim
3	metastatic	_	_	I-Claim
4	prostate	_	_	I-Claim
5	cancer	_	_	I-Claim
6	,	_	_	I-Claim
7	treatment	_	_	I-Claim
8	is	_	_	I-Claim
9	primarily	_	_	I-Claim
10	palliative	_	_	I-Claim
11	,	_	_	I-Claim
12	relying	_	_	I-Claim
13	mainly	_	_	I-Claim
14	on	_	_	I-Claim
15	the	_	_	I-Claim
16	suppression	_	_	I-Claim
17	of	_	_	I-Claim
18	systemic	_	_	I-Claim
19	androgen	_	_	I-Claim
20	hormone	_	_	I-Claim
21	levels	_	_	I-Claim
22	.	_	_	I-Claim

23	To	_	_	O
24	help	_	_	O
25	document	_	_	O
26	the	_	_	O
27	achievement	_	_	O
28	of	_	_	O
29	palliation	_	_	O
30	and	_	_	O
31	to	_	_	O
32	characterize	_	_	O
33	positive	_	_	O
34	and	_	_	O
35	negative	_	_	O
36	effects	_	_	O
37	of	_	_	O
38	treatment	_	_	O
39	,	_	_	O
40	we	_	_	O
41	evaluated	_	_	O
42	quality	_	_	O
43	-	_	_	O
44	of	_	_	O
45	-	_	_	O
46	life	_	_	O
47	(	_	_	O
48	QOL	_	_	O
49	)	_	_	O
50	parameters	_	_	O
51	in	_	_	O
52	patients	_	_	O
53	with	_	_	O
54	metastatic	_	_	O
55	prostate	_	_	O
56	cancer	_	_	O
57	who	_	_	O
58	were	_	_	O
59	randomly	_	_	O
60	assigned	_	_	O
61	to	_	_	O
62	two	_	_	O
63	methods	_	_	O
64	of	_	_	O
65	androgen	_	_	O
66	deprivation	_	_	O
67	.	_	_	O

68	Patients	_	_	O
69	(	_	_	O
70	n	_	_	O
71	=	_	_	O
72	739	_	_	O
73	)	_	_	O
74	with	_	_	O
75	stage	_	_	O
76	M1	_	_	O
77	(	_	_	O
78	bone	_	_	O
79	or	_	_	O
80	soft	_	_	O
81	tissue	_	_	O
82	metastasis	_	_	O
83	)	_	_	O
84	prostate	_	_	O
85	cancer	_	_	O
86	were	_	_	O
87	enrolled	_	_	O
88	in	_	_	O
89	a	_	_	O
90	QOL	_	_	O
91	protocol	_	_	O
92	that	_	_	O
93	was	_	_	O
94	a	_	_	O
95	companion	_	_	O
96	to	_	_	O
97	Southwest	_	_	O
98	Oncology	_	_	O
99	Group	_	_	O
100	INT	_	_	O
101	-	_	_	O
102	0105	_	_	O
103	,	_	_	O
104	a	_	_	O
105	randomized	_	_	O
106	double	_	_	O
107	-	_	_	O
108	blind	_	_	O
109	trial	_	_	O
110	comparing	_	_	O
111	treatment	_	_	O
112	with	_	_	O
113	bilateral	_	_	O
114	orchiectomy	_	_	O
115	(	_	_	O
116	surgical	_	_	O
117	castration	_	_	O
118	)	_	_	O
119	plus	_	_	O
120	either	_	_	O
121	flutamide	_	_	O
122	or	_	_	O
123	placebo	_	_	O
124	.	_	_	O

125	Patients	_	_	O
126	completed	_	_	O
127	a	_	_	O
128	comprehensive	_	_	O
129	battery	_	_	O
130	of	_	_	O
131	QOL	_	_	O
132	questionnaires	_	_	O
133	at	_	_	O
134	random	_	_	O
135	assignment	_	_	O
136	to	_	_	O
137	treatment	_	_	O
138	and	_	_	O
139	at	_	_	O
140	1	_	_	O
141	,	_	_	O
142	3	_	_	O
143	,	_	_	O
144	and	_	_	O
145	6	_	_	O
146	months	_	_	O
147	later	_	_	O
148	.	_	_	O

149	Data	_	_	O
150	were	_	_	O
151	collected	_	_	O
152	on	_	_	O
153	three	_	_	O
154	treatment	_	_	O
155	-	_	_	O
156	specific	_	_	O
157	symptoms	_	_	O
158	(	_	_	O
159	diarrhea	_	_	O
160	,	_	_	O
161	gas	_	_	O
162	pain	_	_	O
163	,	_	_	O
164	and	_	_	O
165	body	_	_	O
166	image	_	_	O
167	)	_	_	O
168	,	_	_	O
169	on	_	_	O
170	physical	_	_	O
171	functioning	_	_	O
172	,	_	_	O
173	and	_	_	O
174	on	_	_	O
175	emotional	_	_	O
176	functioning	_	_	O
177	.	_	_	O

178	All	_	_	O
179	P	_	_	O
180	values	_	_	O
181	are	_	_	O
182	two	_	_	O
183	-	_	_	O
184	sided	_	_	O
185	.	_	_	O

186	Questionnaire	_	_	O
187	return	_	_	O
188	rates	_	_	O
189	for	_	_	O
190	this	_	_	O
191	study	_	_	O
192	never	_	_	O
193	dropped	_	_	O
194	below	_	_	O
195	80	_	_	O
196	%	_	_	O
197	;	_	_	O
198	only	_	_	O
199	2	_	_	O
200	%	_	_	O
201	of	_	_	O
202	the	_	_	O
203	patients	_	_	O
204	did	_	_	O
205	not	_	_	O
206	submit	_	_	O
207	baseline	_	_	O
208	QOL	_	_	O
209	assessments	_	_	O
210	.	_	_	O

211	Cross	_	_	B-Premise
212	-	_	_	I-Premise
213	sectional	_	_	I-Premise
214	analyses	_	_	I-Premise
215	(	_	_	I-Premise
216	corrected	_	_	I-Premise
217	for	_	_	I-Premise
218	multiple	_	_	I-Premise
219	testing	_	_	I-Premise
220	)	_	_	I-Premise
221	identified	_	_	I-Premise
222	statistically	_	_	I-Premise
223	significant	_	_	I-Premise
224	differences	_	_	I-Premise
225	that	_	_	I-Premise
226	favored	_	_	I-Premise
227	orchiectomy	_	_	I-Premise
228	plus	_	_	I-Premise
229	placebo	_	_	I-Premise
230	for	_	_	I-Premise
231	two	_	_	I-Premise
232	of	_	_	I-Premise
233	the	_	_	I-Premise
234	five	_	_	I-Premise
235	primary	_	_	I-Premise
236	QOL	_	_	I-Premise
237	parameters	_	_	I-Premise
238	as	_	_	I-Premise
239	follows	_	_	I-Premise
240	:	_	_	I-Premise
241	patients	_	_	I-Premise
242	receiving	_	_	I-Premise
243	flutamide	_	_	I-Premise
244	reported	_	_	I-Premise
245	more	_	_	I-Premise
246	diarrhea	_	_	I-Premise
247	at	_	_	I-Premise
248	3	_	_	I-Premise
249	months	_	_	I-Premise
250	(	_	_	I-Premise
251	P	_	_	I-Premise
252	=	_	_	I-Premise
253	.	_	_	I-Premise

254	001	_	_	I-Premise
255	)	_	_	I-Premise
256	and	_	_	I-Premise
257	worse	_	_	I-Premise
258	emotional	_	_	I-Premise
259	functioning	_	_	I-Premise
260	at	_	_	I-Premise
261	3	_	_	I-Premise
262	and	_	_	I-Premise
263	6	_	_	I-Premise
264	months	_	_	I-Premise
265	(	_	_	I-Premise
266	both	_	_	I-Premise
267	P	_	_	I-Premise
268	<	_	_	I-Premise
269	.	_	_	I-Premise

270	003	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	Longitudinal	_	_	B-Premise
274	analyses	_	_	I-Premise
275	replicated	_	_	I-Premise
276	these	_	_	I-Premise
277	findings	_	_	I-Premise
278	.	_	_	I-Premise

279	Other	_	_	B-Premise
280	analyzed	_	_	I-Premise
281	QOL	_	_	I-Premise
282	parameters	_	_	I-Premise
283	favored	_	_	I-Premise
284	the	_	_	I-Premise
285	group	_	_	I-Premise
286	receiving	_	_	I-Premise
287	placebo	_	_	I-Premise
288	but	_	_	B-Premise
289	were	_	_	I-Premise
290	not	_	_	I-Premise
291	statistically	_	_	I-Premise
292	significant	_	_	I-Premise
293	after	_	_	I-Premise
294	adjustment	_	_	I-Premise
295	for	_	_	I-Premise
296	multiple	_	_	I-Premise
297	testing	_	_	I-Premise
298	.	_	_	I-Premise

299	We	_	_	B-Claim
300	found	_	_	I-Claim
301	a	_	_	I-Claim
302	consistent	_	_	I-Claim
303	pattern	_	_	I-Claim
304	of	_	_	I-Claim
305	better	_	_	I-Claim
306	QOL	_	_	I-Claim
307	outcomes	_	_	I-Claim
308	at	_	_	I-Claim
309	each	_	_	I-Claim
310	follow	_	_	I-Claim
311	-	_	_	I-Claim
312	up	_	_	I-Claim
313	assessment	_	_	I-Claim
314	during	_	_	I-Claim
315	the	_	_	I-Claim
316	first	_	_	I-Claim
317	6	_	_	I-Claim
318	months	_	_	I-Claim
319	of	_	_	I-Claim
320	treatment	_	_	I-Claim
321	for	_	_	I-Claim
322	orchiectomized	_	_	I-Claim
323	patients	_	_	I-Claim
324	with	_	_	I-Claim
325	metastatic	_	_	I-Claim
326	prostate	_	_	I-Claim
327	cancer	_	_	I-Claim
328	who	_	_	I-Claim
329	received	_	_	I-Claim
330	placebo	_	_	I-Claim
331	versus	_	_	I-Claim
332	flutamide	_	_	I-Claim
333	.	_	_	I-Claim

334	Improvement	_	_	B-Claim
335	over	_	_	I-Claim
336	time	_	_	I-Claim
337	was	_	_	I-Claim
338	evident	_	_	I-Claim
339	in	_	_	I-Claim
340	both	_	_	I-Claim
341	treatment	_	_	I-Claim
342	groups	_	_	I-Claim
343	but	_	_	I-Claim
344	more	_	_	I-Claim
345	so	_	_	I-Claim
346	for	_	_	I-Claim
347	patients	_	_	I-Claim
348	receiving	_	_	I-Claim
349	placebo	_	_	I-Claim
350	.	_	_	I-Claim


0	Taxol	_	_	B-Premise
1	(	_	_	I-Premise
2	paclitaxel	_	_	I-Premise
3	;	_	_	I-Premise
4	Bristol	_	_	I-Premise
5	-	_	_	I-Premise
6	Myers	_	_	I-Premise
7	Squibb	_	_	I-Premise
8	,	_	_	I-Premise
9	Wallingford	_	_	I-Premise
10	,	_	_	I-Premise
11	CT	_	_	I-Premise
12	)	_	_	I-Premise
13	is	_	_	I-Premise
14	a	_	_	I-Premise
15	new	_	_	I-Premise
16	anticancer	_	_	I-Premise
17	agent	_	_	I-Premise
18	with	_	_	I-Premise
19	activity	_	_	I-Premise
20	in	_	_	I-Premise
21	a	_	_	I-Premise
22	number	_	_	I-Premise
23	of	_	_	I-Premise
24	human	_	_	I-Premise
25	tumors	_	_	I-Premise
26	,	_	_	I-Premise
27	including	_	_	I-Premise
28	epithelial	_	_	I-Premise
29	ovarian	_	_	I-Premise
30	cancer	_	_	I-Premise
31	.	_	_	I-Premise

32	In	_	_	O
33	nonrandomized	_	_	O
34	trials	_	_	O
35	,	_	_	O
36	doses	_	_	O
37	studied	_	_	O
38	have	_	_	O
39	ranged	_	_	O
40	from	_	_	O
41	135	_	_	O
42	mg	_	_	O
43	/	_	_	O
44	m2	_	_	O
45	to	_	_	O
46	250	_	_	O
47	mg	_	_	O
48	/	_	_	O
49	m2	_	_	O
50	administered	_	_	O
51	over	_	_	O
52	24	_	_	O
53	hours	_	_	O
54	with	_	_	O
55	premedication	_	_	O
56	to	_	_	O
57	avoid	_	_	O
58	hypersensitivity	_	_	O
59	reactions	_	_	O
60	(	_	_	O
61	HSRs	_	_	O
62	)	_	_	O
63	.	_	_	O

64	This	_	_	O
65	study	_	_	O
66	addressed	_	_	O
67	two	_	_	O
68	questions	_	_	O
69	:	_	_	O
70	the	_	_	O
71	dose	_	_	O
72	-	_	_	O
73	response	_	_	O
74	relationship	_	_	O
75	of	_	_	O
76	Taxol	_	_	O
77	in	_	_	O
78	relapsed	_	_	O
79	ovarian	_	_	O
80	cancer	_	_	O
81	and	_	_	O
82	the	_	_	O
83	safety	_	_	O
84	of	_	_	O
85	a	_	_	O
86	short	_	_	O
87	infusion	_	_	O
88	given	_	_	O
89	with	_	_	O
90	premedication	_	_	O
91	.	_	_	O

92	Women	_	_	O
93	with	_	_	O
94	platinum	_	_	O
95	-	_	_	O
96	pretreated	_	_	O
97	epithelial	_	_	O
98	ovarian	_	_	O
99	cancer	_	_	O
100	and	_	_	O
101	measurable	_	_	O
102	recurrent	_	_	O
103	disease	_	_	O
104	were	_	_	O
105	randomized	_	_	O
106	in	_	_	O
107	a	_	_	O
108	bifactorial	_	_	O
109	design	_	_	O
110	to	_	_	O
111	receive	_	_	O
112	either	_	_	O
113	175	_	_	O
114	or	_	_	O
115	135	_	_	O
116	mg	_	_	O
117	/	_	_	O
118	m2	_	_	O
119	of	_	_	O
120	Taxol	_	_	O
121	over	_	_	O
122	either	_	_	O
123	24	_	_	O
124	or	_	_	O
125	3	_	_	O
126	hours	_	_	O
127	.	_	_	O

128	Major	_	_	O
129	end	_	_	O
130	points	_	_	O
131	were	_	_	O
132	the	_	_	O
133	frequency	_	_	O
134	of	_	_	O
135	significant	_	_	O
136	HSRs	_	_	O
137	and	_	_	O
138	objective	_	_	O
139	response	_	_	O
140	rate	_	_	O
141	.	_	_	O

142	Secondary	_	_	O
143	end	_	_	O
144	points	_	_	O
145	were	_	_	O
146	progression	_	_	O
147	-	_	_	O
148	free	_	_	O
149	and	_	_	O
150	overall	_	_	O
151	survival	_	_	O
152	.	_	_	O

153	Of	_	_	O
154	407	_	_	O
155	patients	_	_	O
156	randomized	_	_	O
157	,	_	_	O
158	391	_	_	O
159	were	_	_	O
160	eligible	_	_	O
161	and	_	_	O
162	382	_	_	O
163	assessable	_	_	O
164	for	_	_	O
165	response	_	_	O
166	.	_	_	O

167	Analysis	_	_	O
168	was	_	_	O
169	performed	_	_	O
170	according	_	_	O
171	to	_	_	O
172	the	_	_	O
173	bifactorial	_	_	O
174	design	_	_	O
175	.	_	_	O

176	Severe	_	_	B-Premise
177	HSRs	_	_	I-Premise
178	were	_	_	I-Premise
179	rare	_	_	I-Premise
180	(	_	_	I-Premise
181	1	_	_	I-Premise
182	.	_	_	I-Premise

183	5	_	_	I-Premise
184	%	_	_	I-Premise
185	patients	_	_	I-Premise
186	)	_	_	I-Premise
187	and	_	_	I-Premise
188	were	_	_	I-Premise
189	not	_	_	I-Premise
190	affected	_	_	I-Premise
191	by	_	_	I-Premise
192	either	_	_	I-Premise
193	dose	_	_	I-Premise
194	or	_	_	I-Premise
195	schedule	_	_	I-Premise
196	.	_	_	I-Premise

197	Response	_	_	B-Premise
198	was	_	_	I-Premise
199	slightly	_	_	I-Premise
200	higher	_	_	I-Premise
201	at	_	_	I-Premise
202	the	_	_	I-Premise
203	175	_	_	I-Premise
204	-	_	_	I-Premise
205	mg	_	_	I-Premise
206	/	_	_	I-Premise
207	m2	_	_	I-Premise
208	dose	_	_	I-Premise
209	(	_	_	I-Premise
210	20	_	_	I-Premise
211	%	_	_	I-Premise
212	)	_	_	I-Premise
213	than	_	_	I-Premise
214	at	_	_	I-Premise
215	135	_	_	I-Premise
216	mg	_	_	I-Premise
217	/	_	_	I-Premise
218	m2	_	_	I-Premise
219	(	_	_	I-Premise
220	15	_	_	I-Premise
221	%	_	_	I-Premise
222	)	_	_	I-Premise
223	,	_	_	I-Premise
224	but	_	_	B-Premise
225	this	_	_	I-Premise
226	was	_	_	I-Premise
227	not	_	_	I-Premise
228	statistically	_	_	I-Premise
229	significant	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	.	_	_	I-Premise

234	2	_	_	I-Premise
235	)	_	_	I-Premise
236	.	_	_	I-Premise

237	However	_	_	B-Premise
238	,	_	_	I-Premise
239	progression	_	_	I-Premise
240	-	_	_	I-Premise
241	free	_	_	I-Premise
242	survival	_	_	I-Premise
243	was	_	_	I-Premise
244	significantly	_	_	I-Premise
245	longer	_	_	I-Premise
246	in	_	_	I-Premise
247	the	_	_	I-Premise
248	high	_	_	I-Premise
249	-	_	_	I-Premise
250	dose	_	_	I-Premise
251	group	_	_	I-Premise
252	(	_	_	I-Premise
253	19	_	_	I-Premise
254	v	_	_	I-Premise
255	14	_	_	I-Premise
256	weeks	_	_	I-Premise
257	;	_	_	I-Premise
258	P	_	_	I-Premise
259	=	_	_	I-Premise
260	.	_	_	I-Premise

261	02	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	Significantly	_	_	B-Premise
265	more	_	_	I-Premise
266	neutropenia	_	_	I-Premise
267	was	_	_	I-Premise
268	seen	_	_	I-Premise
269	when	_	_	I-Premise
270	Taxol	_	_	I-Premise
271	was	_	_	I-Premise
272	administered	_	_	I-Premise
273	as	_	_	I-Premise
274	a	_	_	I-Premise
275	24	_	_	I-Premise
276	-	_	_	I-Premise
277	hour	_	_	I-Premise
278	infusion	_	_	I-Premise
279	.	_	_	I-Premise

280	Response	_	_	B-Premise
281	rates	_	_	I-Premise
282	were	_	_	I-Premise
283	similar	_	_	I-Premise
284	in	_	_	I-Premise
285	the	_	_	I-Premise
286	24	_	_	I-Premise
287	-	_	_	I-Premise
288	and	_	_	I-Premise
289	3	_	_	I-Premise
290	-	_	_	I-Premise
291	hour	_	_	I-Premise
292	groups	_	_	I-Premise
293	(	_	_	I-Premise
294	19	_	_	I-Premise
295	%	_	_	I-Premise
296	and	_	_	I-Premise
297	16	_	_	I-Premise
298	%	_	_	I-Premise
299	,	_	_	I-Premise
300	respectively	_	_	I-Premise
301	;	_	_	I-Premise
302	P	_	_	I-Premise
303	=	_	_	I-Premise
304	.	_	_	I-Premise

305	6	_	_	I-Premise
306	)	_	_	I-Premise
307	.	_	_	I-Premise

308	No	_	_	B-Premise
309	survival	_	_	I-Premise
310	differences	_	_	I-Premise
311	were	_	_	I-Premise
312	noted	_	_	I-Premise
313	.	_	_	I-Premise

314	The	_	_	B-Claim
315	3	_	_	I-Claim
316	-	_	_	I-Claim
317	hour	_	_	I-Claim
318	infusion	_	_	I-Claim
319	of	_	_	I-Claim
320	Taxol	_	_	I-Claim
321	is	_	_	I-Claim
322	safe	_	_	I-Claim
323	when	_	_	I-Claim
324	given	_	_	I-Claim
325	with	_	_	I-Claim
326	premedication	_	_	I-Claim
327	and	_	_	I-Claim
328	is	_	_	I-Claim
329	associated	_	_	I-Claim
330	with	_	_	I-Claim
331	less	_	_	I-Claim
332	neutropenia	_	_	I-Claim
333	.	_	_	I-Claim

334	There	_	_	O
335	is	_	_	O
336	a	_	_	O
337	modest	_	_	O
338	dose	_	_	O
339	effect	_	_	O
340	with	_	_	O
341	longer	_	_	O
342	time	_	_	O
343	to	_	_	O
344	progression	_	_	O
345	at	_	_	O
346	175	_	_	O
347	mg	_	_	O
348	/	_	_	O
349	m2	_	_	O
350	.	_	_	O

351	The	_	_	B-Claim
352	observation	_	_	I-Claim
353	that	_	_	I-Claim
354	longer	_	_	I-Claim
355	infusion	_	_	I-Claim
356	produces	_	_	I-Claim
357	more	_	_	I-Claim
358	myelosuppression	_	_	I-Claim
359	but	_	_	I-Claim
360	does	_	_	I-Claim
361	not	_	_	I-Claim
362	yield	_	_	I-Claim
363	higher	_	_	I-Claim
364	response	_	_	I-Claim
365	rates	_	_	I-Claim
366	should	_	_	I-Claim
367	lead	_	_	I-Claim
368	to	_	_	I-Claim
369	further	_	_	I-Claim
370	studies	_	_	I-Claim
371	to	_	_	I-Claim
372	determine	_	_	I-Claim
373	the	_	_	I-Claim
374	optimal	_	_	I-Claim
375	dose	_	_	I-Claim
376	and	_	_	I-Claim
377	schedule	_	_	I-Claim
378	of	_	_	I-Claim
379	this	_	_	I-Claim
380	interesting	_	_	I-Claim
381	new	_	_	I-Claim
382	agent	_	_	I-Claim
383	.	_	_	I-Claim


0	Treatment	_	_	O
1	-	_	_	O
2	induced	_	_	O
3	arm	_	_	O
4	lymphoedema	_	_	O
5	is	_	_	O
6	a	_	_	O
7	common	_	_	O
8	and	_	_	O
9	distressing	_	_	O
10	complication	_	_	O
11	of	_	_	O
12	curative	_	_	O
13	surgery	_	_	O
14	and	_	_	O
15	radiotherapy	_	_	O
16	for	_	_	O
17	early	_	_	O
18	breast	_	_	O
19	cancer	_	_	O
20	.	_	_	O

21	A	_	_	O
22	number	_	_	O
23	of	_	_	O
24	studies	_	_	O
25	testing	_	_	O
26	alpha	_	_	O
27	-	_	_	O
28	tocopherol	_	_	O
29	(	_	_	O
30	vitamin	_	_	O
31	E	_	_	O
32	)	_	_	O
33	and	_	_	O
34	pentoxifylline	_	_	O
35	suggest	_	_	O
36	evidence	_	_	O
37	of	_	_	O
38	clinical	_	_	O
39	regression	_	_	O
40	of	_	_	O
41	superficial	_	_	O
42	radiation	_	_	O
43	-	_	_	O
44	induced	_	_	O
45	fibrosis	_	_	O
46	but	_	_	O
47	there	_	_	O
48	is	_	_	O
49	only	_	_	O
50	very	_	_	O
51	limited	_	_	O
52	evidence	_	_	O
53	from	_	_	O
54	randomised	_	_	O
55	trials	_	_	O
56	.	_	_	O

57	Arm	_	_	O
58	lymphoedema	_	_	O
59	after	_	_	O
60	lymphatic	_	_	O
61	radiotherapy	_	_	O
62	and	_	_	O
63	surgery	_	_	O
64	has	_	_	O
65	been	_	_	O
66	used	_	_	O
67	in	_	_	O
68	the	_	_	O
69	present	_	_	O
70	study	_	_	O
71	as	_	_	O
72	a	_	_	O
73	clinical	_	_	O
74	system	_	_	O
75	for	_	_	O
76	testing	_	_	O
77	these	_	_	O
78	drugs	_	_	O
79	in	_	_	O
80	a	_	_	O
81	double	_	_	O
82	-	_	_	O
83	blind	_	_	O
84	placebo	_	_	O
85	-	_	_	O
86	controlled	_	_	O
87	randomised	_	_	O
88	phase	_	_	O
89	II	_	_	O
90	trial	_	_	O
91	.	_	_	O

92	Sixty	_	_	O
93	-	_	_	O
94	eight	_	_	O
95	eligible	_	_	O
96	research	_	_	O
97	volunteers	_	_	O
98	with	_	_	O
99	a	_	_	O
100	minimum	_	_	O
101	20	_	_	O
102	%	_	_	O
103	increase	_	_	O
104	in	_	_	O
105	arm	_	_	O
106	volume	_	_	O
107	at	_	_	O
108	a	_	_	O
109	median	_	_	O
110	15	_	_	O
111	.	_	_	O

112	5	_	_	O
113	years	_	_	O
114	(	_	_	O
115	range	_	_	O
116	2	_	_	O
117	-	_	_	O
118	41	_	_	O
119	)	_	_	O
120	after	_	_	O
121	axillary	_	_	O
122	/	_	_	O
123	supraclavicular	_	_	O
124	radiotherapy	_	_	O
125	(	_	_	O
126	plus	_	_	O
127	axillary	_	_	O
128	surgery	_	_	O
129	in	_	_	O
130	51	_	_	O
131	/	_	_	O
132	68	_	_	O
133	(	_	_	O
134	75	_	_	O
135	%	_	_	O
136	)	_	_	O
137	cases	_	_	O
138	)	_	_	O
139	were	_	_	O
140	randomised	_	_	O
141	to	_	_	O
142	active	_	_	O
143	drugs	_	_	O
144	or	_	_	O
145	placebo	_	_	O
146	.	_	_	O

147	All	_	_	O
148	volunteers	_	_	O
149	were	_	_	O
150	given	_	_	O
151	dl	_	_	O
152	-	_	_	O
153	alpha	_	_	O
154	tocopheryl	_	_	O
155	acetate	_	_	O
156	500	_	_	O
157	mg	_	_	O
158	twice	_	_	O
159	a	_	_	O
160	day	_	_	O
161	orally	_	_	O
162	plus	_	_	O
163	pentoxifylline	_	_	O
164	400	_	_	O
165	mg	_	_	O
166	twice	_	_	O
167	a	_	_	O
168	day	_	_	O
169	orally	_	_	O
170	,	_	_	O
171	or	_	_	O
172	corresponding	_	_	O
173	placebos	_	_	O
174	,	_	_	O
175	for	_	_	O
176	6	_	_	O
177	months	_	_	O
178	.	_	_	O

179	The	_	_	O
180	primary	_	_	O
181	endpoint	_	_	O
182	was	_	_	O
183	volume	_	_	O
184	of	_	_	O
185	the	_	_	O
186	ipsilateral	_	_	O
187	limb	_	_	O
188	measured	_	_	O
189	opto	_	_	O
190	-	_	_	O
191	electronically	_	_	O
192	using	_	_	O
193	a	_	_	O
194	perometer	_	_	O
195	and	_	_	O
196	expressed	_	_	O
197	as	_	_	O
198	a	_	_	O
199	percentage	_	_	O
200	of	_	_	O
201	the	_	_	O
202	contralateral	_	_	O
203	limb	_	_	O
204	volume	_	_	O
205	.	_	_	O

206	At	_	_	B-Premise
207	12	_	_	I-Premise
208	months	_	_	I-Premise
209	post	_	_	I-Premise
210	-	_	_	I-Premise
211	randomisation	_	_	I-Premise
212	,	_	_	I-Premise
213	there	_	_	I-Premise
214	was	_	_	I-Premise
215	no	_	_	I-Premise
216	significant	_	_	I-Premise
217	difference	_	_	I-Premise
218	between	_	_	I-Premise
219	treatment	_	_	I-Premise
220	and	_	_	I-Premise
221	control	_	_	I-Premise
222	groups	_	_	I-Premise
223	in	_	_	I-Premise
224	terms	_	_	I-Premise
225	of	_	_	I-Premise
226	arm	_	_	I-Premise
227	volume	_	_	I-Premise
228	.	_	_	I-Premise

229	Absolute	_	_	B-Premise
230	change	_	_	I-Premise
231	in	_	_	I-Premise
232	arm	_	_	I-Premise
233	volume	_	_	I-Premise
234	at	_	_	I-Premise
235	12	_	_	I-Premise
236	months	_	_	I-Premise
237	was	_	_	I-Premise
238	2	_	_	I-Premise
239	.	_	_	I-Premise

240	5	_	_	I-Premise
241	%	_	_	I-Premise
242	(	_	_	I-Premise
243	95	_	_	I-Premise
244	%	_	_	I-Premise
245	CI	_	_	I-Premise
246	-	_	_	I-Premise
247	0	_	_	I-Premise
248	.	_	_	I-Premise

249	40	_	_	I-Premise
250	to	_	_	I-Premise
251	5	_	_	I-Premise
252	.	_	_	I-Premise

253	3	_	_	I-Premise
254	)	_	_	I-Premise
255	in	_	_	I-Premise
256	the	_	_	I-Premise
257	treatment	_	_	I-Premise
258	group	_	_	I-Premise
259	compared	_	_	I-Premise
260	to	_	_	I-Premise
261	1	_	_	I-Premise
262	.	_	_	I-Premise

263	2	_	_	I-Premise
264	%	_	_	I-Premise
265	(	_	_	I-Premise
266	95	_	_	I-Premise
267	%	_	_	I-Premise
268	CI	_	_	I-Premise
269	-	_	_	I-Premise
270	2	_	_	I-Premise
271	.	_	_	I-Premise

272	8	_	_	I-Premise
273	to	_	_	I-Premise
274	5	_	_	I-Premise
275	.	_	_	I-Premise

276	1	_	_	I-Premise
277	)	_	_	I-Premise
278	in	_	_	I-Premise
279	the	_	_	I-Premise
280	placebo	_	_	I-Premise
281	group	_	_	I-Premise
282	.	_	_	I-Premise

283	The	_	_	B-Premise
284	difference	_	_	I-Premise
285	in	_	_	I-Premise
286	mean	_	_	I-Premise
287	volume	_	_	I-Premise
288	change	_	_	I-Premise
289	between	_	_	I-Premise
290	randomisation	_	_	I-Premise
291	groups	_	_	I-Premise
292	at	_	_	I-Premise
293	12	_	_	I-Premise
294	months	_	_	I-Premise
295	was	_	_	I-Premise
296	not	_	_	I-Premise
297	statistically	_	_	I-Premise
298	significant	_	_	I-Premise
299	(	_	_	I-Premise
300	P	_	_	I-Premise
301	=	_	_	I-Premise
302	0	_	_	I-Premise
303	.	_	_	I-Premise

304	6	_	_	I-Premise
305	)	_	_	I-Premise
306	,	_	_	I-Premise
307	-	_	_	I-Premise
308	1	_	_	I-Premise
309	.	_	_	I-Premise

310	3	_	_	I-Premise
311	%	_	_	I-Premise
312	(	_	_	I-Premise
313	95	_	_	I-Premise
314	%	_	_	I-Premise
315	CI	_	_	I-Premise
316	-	_	_	I-Premise
317	6	_	_	I-Premise
318	.	_	_	I-Premise

319	1	_	_	I-Premise
320	to	_	_	I-Premise
321	3	_	_	I-Premise
322	.	_	_	I-Premise

323	5	_	_	I-Premise
324	)	_	_	I-Premise
325	,	_	_	I-Premise
326	nor	_	_	I-Premise
327	was	_	_	I-Premise
328	there	_	_	I-Premise
329	a	_	_	I-Premise
330	significant	_	_	I-Premise
331	difference	_	_	I-Premise
332	in	_	_	I-Premise
333	response	_	_	I-Premise
334	at	_	_	I-Premise
335	6	_	_	I-Premise
336	months	_	_	I-Premise
337	(	_	_	I-Premise
338	P	_	_	I-Premise
339	=	_	_	I-Premise
340	0	_	_	I-Premise
341	.	_	_	I-Premise

342	7	_	_	I-Premise
343	)	_	_	I-Premise
344	,	_	_	I-Premise
345	where	_	_	I-Premise
346	mean	_	_	I-Premise
347	change	_	_	I-Premise
348	in	_	_	I-Premise
349	arm	_	_	I-Premise
350	volume	_	_	I-Premise
351	from	_	_	I-Premise
352	baseline	_	_	I-Premise
353	in	_	_	I-Premise
354	the	_	_	I-Premise
355	treatment	_	_	I-Premise
356	and	_	_	I-Premise
357	placebo	_	_	I-Premise
358	groups	_	_	I-Premise
359	was	_	_	I-Premise
360	-	_	_	I-Premise
361	2	_	_	I-Premise
362	.	_	_	I-Premise

363	3	_	_	I-Premise
364	%	_	_	I-Premise
365	(	_	_	I-Premise
366	95	_	_	I-Premise
367	%	_	_	I-Premise
368	CI	_	_	I-Premise
369	-	_	_	I-Premise
370	7	_	_	I-Premise
371	.	_	_	I-Premise

372	9	_	_	I-Premise
373	to	_	_	I-Premise
374	3	_	_	I-Premise
375	.	_	_	I-Premise

376	4	_	_	I-Premise
377	)	_	_	I-Premise
378	and	_	_	I-Premise
379	-	_	_	I-Premise
380	1	_	_	I-Premise
381	.	_	_	I-Premise

382	1	_	_	I-Premise
383	%	_	_	I-Premise
384	(	_	_	I-Premise
385	95	_	_	I-Premise
386	%	_	_	I-Premise
387	CI	_	_	I-Premise
388	-	_	_	I-Premise
389	3	_	_	I-Premise
390	.	_	_	I-Premise

391	9	_	_	I-Premise
392	to	_	_	I-Premise
393	1	_	_	I-Premise
394	.	_	_	I-Premise

395	7	_	_	I-Premise
396	)	_	_	I-Premise
397	,	_	_	I-Premise
398	respectively	_	_	I-Premise
399	.	_	_	I-Premise

400	There	_	_	B-Premise
401	were	_	_	I-Premise
402	no	_	_	I-Premise
403	significant	_	_	I-Premise
404	differences	_	_	I-Premise
405	between	_	_	I-Premise
406	randomised	_	_	I-Premise
407	groups	_	_	I-Premise
408	in	_	_	I-Premise
409	terms	_	_	I-Premise
410	of	_	_	I-Premise
411	secondary	_	_	I-Premise
412	endpoints	_	_	I-Premise
413	,	_	_	I-Premise
414	including	_	_	I-Premise
415	tissue	_	_	I-Premise
416	induration	_	_	I-Premise
417	(	_	_	I-Premise
418	fibrosis	_	_	I-Premise
419	)	_	_	I-Premise
420	in	_	_	I-Premise
421	the	_	_	I-Premise
422	irradiated	_	_	I-Premise
423	breast	_	_	I-Premise
424	or	_	_	I-Premise
425	chest	_	_	I-Premise
426	wall	_	_	I-Premise
427	,	_	_	I-Premise
428	pectoral	_	_	I-Premise
429	fold	_	_	I-Premise
430	or	_	_	I-Premise
431	supraclavicular	_	_	I-Premise
432	fossa	_	_	I-Premise
433	,	_	_	I-Premise
434	change	_	_	I-Premise
435	in	_	_	I-Premise
436	photographic	_	_	I-Premise
437	breast	_	_	I-Premise
438	/	_	_	I-Premise
439	chest	_	_	I-Premise
440	wall	_	_	I-Premise
441	appearance	_	_	I-Premise
442	or	_	_	I-Premise
443	patient	_	_	I-Premise
444	self	_	_	I-Premise
445	-	_	_	I-Premise
446	assessment	_	_	I-Premise
447	of	_	_	I-Premise
448	function	_	_	I-Premise
449	and	_	_	I-Premise
450	Quality	_	_	I-Premise
451	of	_	_	I-Premise
452	Life	_	_	I-Premise
453	at	_	_	I-Premise
454	either	_	_	I-Premise
455	6	_	_	I-Premise
456	or	_	_	I-Premise
457	12	_	_	I-Premise
458	months	_	_	I-Premise
459	.	_	_	I-Premise

460	The	_	_	B-Claim
461	study	_	_	I-Claim
462	fails	_	_	I-Claim
463	to	_	_	I-Claim
464	demonstrate	_	_	I-Claim
465	efficacy	_	_	I-Claim
466	of	_	_	I-Claim
467	dl	_	_	I-Claim
468	-	_	_	I-Claim
469	alpha	_	_	I-Claim
470	tocopheryl	_	_	I-Claim
471	acetate	_	_	I-Claim
472	plus	_	_	I-Claim
473	pentoxifylline	_	_	I-Claim
474	in	_	_	I-Claim
475	patients	_	_	I-Claim
476	with	_	_	I-Claim
477	arm	_	_	I-Claim
478	lymphoedema	_	_	I-Claim
479	following	_	_	I-Claim
480	axillary	_	_	I-Claim
481	surgery	_	_	I-Claim
482	and	_	_	I-Claim
483	lymphatic	_	_	I-Claim
484	radiotherapy	_	_	I-Claim
485	,	_	_	I-Claim
486	nor	_	_	I-Claim
487	does	_	_	I-Claim
488	it	_	_	I-Claim
489	suggest	_	_	I-Claim
490	any	_	_	I-Claim
491	benefits	_	_	I-Claim
492	of	_	_	I-Claim
493	these	_	_	I-Claim
494	drugs	_	_	I-Claim
495	in	_	_	I-Claim
496	radiation	_	_	I-Claim
497	-	_	_	I-Claim
498	induced	_	_	I-Claim
499	induration	_	_	I-Claim
500	(	_	_	I-Claim
501	fibrosis	_	_	I-Claim
502	)	_	_	I-Claim
503	in	_	_	I-Claim
504	the	_	_	I-Claim
505	breast	_	_	I-Claim
506	,	_	_	I-Claim
507	chest	_	_	I-Claim
508	wall	_	_	I-Claim
509	,	_	_	I-Claim
510	pectoral	_	_	I-Claim
511	fold	_	_	I-Claim
512	,	_	_	I-Claim
513	axilla	_	_	I-Claim
514	or	_	_	I-Claim
515	supraclavicular	_	_	I-Claim
516	fossa	_	_	I-Claim
517	.	_	_	I-Claim


0	Gemcitabine	_	_	O
1	(	_	_	O
2	G	_	_	O
3	)	_	_	O
4	is	_	_	O
5	standard	_	_	O
6	therapy	_	_	O
7	for	_	_	O
8	pancreatic	_	_	O
9	cancer	_	_	O
10	.	_	_	O

11	Enzastaurin	_	_	O
12	(	_	_	O
13	E	_	_	O
14	)	_	_	O
15	inhibits	_	_	O
16	PKCβ	_	_	O
17	and	_	_	O
18	PI3K	_	_	O
19	/	_	_	O
20	AKT	_	_	O
21	signaling	_	_	O
22	pathways	_	_	O
23	with	_	_	O
24	a	_	_	O
25	dose	_	_	O
26	-	_	_	O
27	dependent	_	_	O
28	effect	_	_	O
29	on	_	_	O
30	growth	_	_	O
31	of	_	_	O
32	pancreatic	_	_	O
33	carcinoma	_	_	O
34	xenografts	_	_	O
35	.	_	_	O

36	Data	_	_	B-Claim
37	suggest	_	_	I-Claim
38	that	_	_	I-Claim
39	the	_	_	I-Claim
40	GE	_	_	I-Claim
41	combination	_	_	I-Claim
42	may	_	_	I-Claim
43	improve	_	_	I-Claim
44	clinical	_	_	I-Claim
45	outcomes	_	_	I-Claim
46	.	_	_	I-Claim

47	Primary	_	_	O
48	objective	_	_	O
49	was	_	_	O
50	overall	_	_	O
51	survival	_	_	O
52	(	_	_	O
53	OS	_	_	O
54	)	_	_	O
55	;	_	_	O
56	secondary	_	_	O
57	objectives	_	_	O
58	assessed	_	_	O
59	progression	_	_	O
60	-	_	_	O
61	free	_	_	O
62	survival	_	_	O
63	(	_	_	O
64	PFS	_	_	O
65	)	_	_	O
66	,	_	_	O
67	response	_	_	O
68	rate	_	_	O
69	(	_	_	O
70	RR	_	_	O
71	)	_	_	O
72	,	_	_	O
73	quality	_	_	O
74	of	_	_	O
75	life	_	_	O
76	(	_	_	O
77	QOL	_	_	O
78	)	_	_	O
79	,	_	_	O
80	toxicity	_	_	O
81	,	_	_	O
82	and	_	_	O
83	relationships	_	_	O
84	between	_	_	O
85	biomarker	_	_	O
86	expression	_	_	O
87	and	_	_	O
88	clinical	_	_	O
89	outcomes	_	_	O
90	.	_	_	O

91	Patients	_	_	O
92	were	_	_	O
93	randomly	_	_	O
94	assigned	_	_	O
95	(	_	_	O
96	2	_	_	O
97	:	_	_	O
98	1	_	_	O
99	)	_	_	O
100	to	_	_	O
101	GE	_	_	O
102	or	_	_	O
103	G	_	_	O
104	treatment	_	_	O
105	;	_	_	O
106	GE	_	_	O
107	arm	_	_	O
108	:	_	_	O
109	E	_	_	O
110	500	_	_	O
111	mg	_	_	O
112	p	_	_	O
113	.	_	_	O

114	o	_	_	O
115	.	_	_	O

116	daily	_	_	O
117	;	_	_	O
118	loading	_	_	O
119	-	_	_	O
120	dose	_	_	O
121	(	_	_	O
122	1200	_	_	O
123	mg	_	_	O
124	;	_	_	O
125	Day	_	_	O
126	1	_	_	O
127	Cycle	_	_	O
128	1	_	_	O
129	only	_	_	O
130	)	_	_	O
131	and	_	_	O
132	G	_	_	O
133	1000	_	_	O
134	mg	_	_	O
135	/	_	_	O
136	m	_	_	O
137	(	_	_	O
138	2	_	_	O
139	)	_	_	O
140	i	_	_	O
141	.	_	_	O

142	v	_	_	O
143	.	_	_	O

144	Days	_	_	O
145	1	_	_	O
146	,	_	_	O
147	8	_	_	O
148	,	_	_	O
149	and	_	_	O
150	15	_	_	O
151	in	_	_	O
152	28	_	_	O
153	-	_	_	O
154	day	_	_	O
155	cycles	_	_	O
156	;	_	_	O
157	G	_	_	O
158	arm	_	_	O
159	:	_	_	O
160	G	_	_	O
161	as	_	_	O
162	in	_	_	O
163	GE	_	_	O
164	.	_	_	O

165	Biomarker	_	_	O
166	expression	_	_	O
167	was	_	_	O
168	assessed	_	_	O
169	by	_	_	O
170	immunohistochemistry	_	_	O
171	.	_	_	O

172	Randomization	_	_	O
173	totaled	_	_	O
174	130	_	_	O
175	patients	_	_	O
176	(	_	_	O
177	GE	_	_	O
178	=	_	_	O
179	86	_	_	O
180	,	_	_	O
181	G	_	_	O
182	=	_	_	O
183	44	_	_	O
184	)	_	_	O
185	;	_	_	O
186	121	_	_	O
187	patients	_	_	O
188	were	_	_	O
189	treated	_	_	O
190	(	_	_	O
191	GE	_	_	O
192	=	_	_	O
193	82	_	_	O
194	,	_	_	O
195	G	_	_	O
196	=	_	_	O
197	39	_	_	O
198	)	_	_	O
199	.	_	_	O

200	GE	_	_	O
201	/	_	_	O
202	G	_	_	O
203	median	_	_	O
204	OS	_	_	O
205	was	_	_	O
206	5	_	_	O
207	.	_	_	O

208	6	_	_	O
209	/	_	_	O
210	5	_	_	O
211	.	_	_	O

212	1	_	_	O
213	months	_	_	O
214	;	_	_	O
215	median	_	_	O
216	PFS	_	_	O
217	was	_	_	O
218	3	_	_	O
219	.	_	_	O

220	4	_	_	O
221	/	_	_	O
222	3	_	_	O
223	.	_	_	O

224	0	_	_	O
225	months	_	_	O
226	.	_	_	O

227	GE	_	_	O
228	responses	_	_	O
229	:	_	_	O
230	1	_	_	O
231	complete	_	_	O
232	response	_	_	O
233	(	_	_	O
234	CR	_	_	O
235	,	_	_	O
236	1	_	_	O
237	.	_	_	O

238	2	_	_	O
239	%	_	_	O
240	)	_	_	O
241	,	_	_	O
242	6	_	_	O
243	partial	_	_	O
244	response	_	_	O
245	(	_	_	O
246	PR	_	_	O
247	,	_	_	O
248	7	_	_	O
249	.	_	_	O

250	4	_	_	O
251	%	_	_	O
252	)	_	_	O
253	,	_	_	O
254	and	_	_	O
255	33	_	_	O
256	stable	_	_	O
257	disease	_	_	O
258	(	_	_	O
259	SD	_	_	O
260	,	_	_	O
261	40	_	_	O
262	.	_	_	O

263	7	_	_	O
264	%	_	_	O
265	)	_	_	O
266	;	_	_	O
267	disease	_	_	O
268	control	_	_	O
269	rate	_	_	O
270	(	_	_	O
271	DCR	_	_	O
272	=	_	_	O
273	CR	_	_	O
274	+	_	_	O
275	PR	_	_	O
276	+	_	_	O
277	SD	_	_	O
278	,	_	_	O
279	49	_	_	O
280	.	_	_	O

281	4	_	_	O
282	%	_	_	O
283	)	_	_	O
284	.	_	_	O

285	G	_	_	O
286	responses	_	_	O
287	:	_	_	O
288	2	_	_	O
289	PR	_	_	O
290	(	_	_	O
291	5	_	_	O
292	.	_	_	O

293	3	_	_	O
294	%	_	_	O
295	)	_	_	O
296	and	_	_	O
297	16	_	_	O
298	SD	_	_	O
299	(	_	_	O
300	42	_	_	O
301	.	_	_	O

302	1	_	_	O
303	%	_	_	O
304	)	_	_	O
305	;	_	_	O
306	DCR	_	_	O
307	(	_	_	O
308	47	_	_	O
309	.	_	_	O

310	4	_	_	O
311	%	_	_	O
312	)	_	_	O
313	.	_	_	O

314	No	_	_	B-Premise
315	QOL	_	_	I-Premise
316	differences	_	_	I-Premise
317	were	_	_	I-Premise
318	noted	_	_	I-Premise
319	between	_	_	I-Premise
320	arms	_	_	I-Premise
321	.	_	_	I-Premise

322	GE	_	_	B-Premise
323	/	_	_	I-Premise
324	G	_	_	I-Premise
325	Grade	_	_	I-Premise
326	3	_	_	I-Premise
327	-	_	_	I-Premise
328	4	_	_	I-Premise
329	toxicities	_	_	I-Premise
330	included	_	_	I-Premise
331	:	_	_	I-Premise
332	neutropenia	_	_	I-Premise
333	(	_	_	I-Premise
334	18	_	_	I-Premise
335	.	_	_	I-Premise

336	3	_	_	I-Premise
337	%	_	_	I-Premise
338	/	_	_	I-Premise
339	28	_	_	I-Premise
340	.	_	_	I-Premise

341	2	_	_	I-Premise
342	%	_	_	I-Premise
343	)	_	_	I-Premise
344	;	_	_	I-Premise
345	thrombocytopenia	_	_	I-Premise
346	(	_	_	I-Premise
347	14	_	_	I-Premise
348	.	_	_	I-Premise

349	6	_	_	I-Premise
350	%	_	_	I-Premise
351	/	_	_	I-Premise
352	25	_	_	I-Premise
353	.	_	_	I-Premise

354	6	_	_	I-Premise
355	%	_	_	I-Premise
356	)	_	_	I-Premise
357	;	_	_	I-Premise
358	and	_	_	I-Premise
359	fatigue	_	_	I-Premise
360	(	_	_	I-Premise
361	11	_	_	I-Premise
362	.	_	_	I-Premise

363	0	_	_	I-Premise
364	%	_	_	I-Premise
365	/	_	_	I-Premise
366	7	_	_	I-Premise
367	.	_	_	I-Premise

368	7	_	_	I-Premise
369	%	_	_	I-Premise
370	)	_	_	I-Premise
371	.	_	_	I-Premise

372	No	_	_	B-Premise
373	statistically	_	_	I-Premise
374	significant	_	_	I-Premise
375	relationships	_	_	I-Premise
376	between	_	_	I-Premise
377	biomarker	_	_	I-Premise
378	expression	_	_	I-Premise
379	and	_	_	I-Premise
380	outcomes	_	_	I-Premise
381	were	_	_	I-Premise
382	observed	_	_	I-Premise
383	.	_	_	I-Premise

384	However	_	_	O
385	,	_	_	O
386	patients	_	_	B-Premise
387	with	_	_	I-Premise
388	low	_	_	I-Premise
389	expression	_	_	I-Premise
390	of	_	_	I-Premise
391	cytoplasmic	_	_	I-Premise
392	pGSK	_	_	I-Premise
393	-	_	_	I-Premise
394	3β	_	_	I-Premise
395	trended	_	_	I-Premise
396	toward	_	_	I-Premise
397	greater	_	_	I-Premise
398	OS	_	_	I-Premise
399	with	_	_	I-Premise
400	GE	_	_	I-Premise
401	treatment	_	_	I-Premise
402	.	_	_	I-Premise

403	OS	_	_	B-Premise
404	,	_	_	I-Premise
405	PFS	_	_	I-Premise
406	,	_	_	I-Premise
407	QOL	_	_	I-Premise
408	,	_	_	I-Premise
409	and	_	_	I-Premise
410	RR	_	_	I-Premise
411	were	_	_	I-Premise
412	comparable	_	_	I-Premise
413	between	_	_	I-Premise
414	arms	_	_	I-Premise
415	.	_	_	I-Premise

416	Adding	_	_	B-Claim
417	E	_	_	I-Claim
418	to	_	_	I-Claim
419	G	_	_	I-Claim
420	did	_	_	I-Claim
421	not	_	_	I-Claim
422	increase	_	_	I-Claim
423	hematologic	_	_	I-Claim
424	toxicities	_	_	I-Claim
425	.	_	_	I-Claim

426	GE	_	_	O
427	does	_	_	O
428	not	_	_	O
429	warrant	_	_	O
430	further	_	_	O
431	investigation	_	_	O
432	in	_	_	O
433	unselected	_	_	O
434	pancreatic	_	_	O
435	cancer	_	_	O
436	patients	_	_	O
437	.	_	_	O


0	The	_	_	O
1	Intergroup	_	_	O
2	conducted	_	_	O
3	this	_	_	O
4	breast	_	_	O
5	cancer	_	_	O
6	adjuvant	_	_	O
7	trial	_	_	O
8	to	_	_	O
9	compare	_	_	O
10	an	_	_	O
11	investigational	_	_	O
12	16	_	_	O
13	-	_	_	O
14	week	_	_	O
15	regimen	_	_	O
16	with	_	_	O
17	cyclophosphamide	_	_	O
18	,	_	_	O
19	doxorubicin	_	_	O
20	,	_	_	O
21	and	_	_	O
22	fluorouracil	_	_	O
23	(	_	_	O
24	5	_	_	O
25	-	_	_	O
26	FU	_	_	O
27	;	_	_	O
28	CAF	_	_	O
29	)	_	_	O
30	.	_	_	O

31	The	_	_	O
32	16	_	_	O
33	-	_	_	O
34	week	_	_	O
35	regimen	_	_	O
36	features	_	_	O
37	greater	_	_	O
38	doxorubicin	_	_	O
39	and	_	_	O
40	5	_	_	O
41	-	_	_	O
42	FU	_	_	O
43	dose	_	_	O
44	-	_	_	O
45	intensity	_	_	O
46	than	_	_	O
47	CAF	_	_	O
48	and	_	_	O
49	improved	_	_	O
50	scheduling	_	_	O
51	of	_	_	O
52	antimetabolites	_	_	O
53	with	_	_	O
54	sequential	_	_	O
55	methotrexate	_	_	O
56	and	_	_	O
57	5	_	_	O
58	-	_	_	O
59	FU	_	_	O
60	,	_	_	O
61	as	_	_	O
62	well	_	_	O
63	as	_	_	O
64	infusion	_	_	O
65	5	_	_	O
66	-	_	_	O
67	FU	_	_	O
68	.	_	_	O

69	A	_	_	O
70	total	_	_	O
71	of	_	_	O
72	646	_	_	O
73	node	_	_	O
74	-	_	_	O
75	positive	_	_	O
76	,	_	_	O
77	receptor	_	_	O
78	-	_	_	O
79	negative	_	_	O
80	patients	_	_	O
81	were	_	_	O
82	randomly	_	_	O
83	assigned	_	_	O
84	to	_	_	O
85	receive	_	_	O
86	either	_	_	O
87	the	_	_	O
88	1	_	_	O
89	6	_	_	O
90	-	_	_	O
91	week	_	_	O
92	regimen	_	_	O
93	or	_	_	O
94	six	_	_	O
95	cycles	_	_	O
96	of	_	_	O
97	CAF	_	_	O
98	.	_	_	O

99	Breast	_	_	O
100	cancer	_	_	O
101	outcomes	_	_	O
102	included	_	_	O
103	recurrence	_	_	O
104	as	_	_	O
105	well	_	_	O
106	as	_	_	O
107	disease	_	_	O
108	-	_	_	O
109	free	_	_	O
110	and	_	_	O
111	overall	_	_	O
112	survival	_	_	O
113	.	_	_	O

114	Toxicity	_	_	O
115	was	_	_	O
116	evaluated	_	_	O
117	by	_	_	O
118	the	_	_	O
119	Common	_	_	O
120	Toxicity	_	_	O
121	Criteria	_	_	O
122	(	_	_	O
123	CTC	_	_	O
124	)	_	_	O
125	.	_	_	O

126	Treatment	_	_	O
127	-	_	_	O
128	related	_	_	O
129	quality	_	_	O
130	of	_	_	O
131	life	_	_	O
132	was	_	_	O
133	assessed	_	_	O
134	by	_	_	O
135	the	_	_	O
136	Breast	_	_	O
137	Chemotherapy	_	_	O
138	Questionnaire	_	_	O
139	(	_	_	O
140	BCQ	_	_	O
141	)	_	_	O
142	before	_	_	O
143	,	_	_	O
144	during	_	_	O
145	,	_	_	O
146	and	_	_	O
147	4	_	_	O
148	months	_	_	O
149	after	_	_	O
150	treatment	_	_	O
151	in	_	_	O
152	163	_	_	O
153	patients	_	_	O
154	.	_	_	O

155	The	_	_	O
156	trial	_	_	O
157	was	_	_	O
158	designed	_	_	O
159	to	_	_	O
160	use	_	_	O
161	one	_	_	O
162	-	_	_	O
163	sided	_	_	O
164	tests	_	_	O
165	of	_	_	O
166	significance	_	_	O
167	for	_	_	O
168	power	_	_	O
169	calculations	_	_	O
170	,	_	_	O
171	but	_	_	O
172	is	_	_	O
173	now	_	_	O
174	reported	_	_	O
175	with	_	_	O
176	both	_	_	O
177	one	_	_	O
178	-	_	_	O
179	sided	_	_	O
180	and	_	_	O
181	the	_	_	O
182	traditional	_	_	O
183	two	_	_	O
184	-	_	_	O
185	sided	_	_	O
186	tests	_	_	O
187	of	_	_	O
188	significance	_	_	O
189	.	_	_	O

190	At	_	_	B-Premise
191	a	_	_	I-Premise
192	median	_	_	I-Premise
193	follow	_	_	I-Premise
194	-	_	_	I-Premise
195	up	_	_	I-Premise
196	of	_	_	I-Premise
197	3	_	_	I-Premise
198	.	_	_	I-Premise

199	9	_	_	I-Premise
200	years	_	_	I-Premise
201	,	_	_	I-Premise
202	the	_	_	I-Premise
203	estimated	_	_	I-Premise
204	4	_	_	I-Premise
205	-	_	_	I-Premise
206	year	_	_	I-Premise
207	recurrence	_	_	I-Premise
208	-	_	_	I-Premise
209	free	_	_	I-Premise
210	survival	_	_	I-Premise
211	rate	_	_	I-Premise
212	was	_	_	I-Premise
213	67	_	_	I-Premise
214	.	_	_	I-Premise

215	5	_	_	I-Premise
216	%	_	_	I-Premise
217	with	_	_	I-Premise
218	the	_	_	I-Premise
219	16	_	_	I-Premise
220	-	_	_	I-Premise
221	week	_	_	I-Premise
222	regimen	_	_	I-Premise
223	versus	_	_	I-Premise
224	62	_	_	I-Premise
225	.	_	_	I-Premise

226	7	_	_	I-Premise
227	%	_	_	I-Premise
228	with	_	_	I-Premise
229	CAF	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	.	_	_	I-Premise

234	19	_	_	I-Premise
235	,	_	_	I-Premise
236	two	_	_	I-Premise
237	-	_	_	I-Premise
238	sided	_	_	I-Premise
239	;	_	_	I-Premise
240	P	_	_	I-Premise
241	=	_	_	I-Premise
242	.	_	_	I-Premise

243	095	_	_	I-Premise
244	,	_	_	I-Premise
245	one	_	_	I-Premise
246	-	_	_	I-Premise
247	sided	_	_	I-Premise
248	)	_	_	I-Premise
249	.	_	_	I-Premise

250	The	_	_	B-Premise
251	estimated	_	_	I-Premise
252	4	_	_	I-Premise
253	-	_	_	I-Premise
254	year	_	_	I-Premise
255	survival	_	_	I-Premise
256	rate	_	_	I-Premise
257	was	_	_	I-Premise
258	78	_	_	I-Premise
259	.	_	_	I-Premise

260	1	_	_	I-Premise
261	%	_	_	I-Premise
262	with	_	_	I-Premise
263	the	_	_	I-Premise
264	16	_	_	I-Premise
265	-	_	_	I-Premise
266	week	_	_	I-Premise
267	regimen	_	_	I-Premise
268	versus	_	_	I-Premise
269	71	_	_	I-Premise
270	.	_	_	I-Premise

271	4	_	_	I-Premise
272	%	_	_	I-Premise
273	with	_	_	I-Premise
274	CAF	_	_	I-Premise
275	(	_	_	I-Premise
276	P	_	_	I-Premise
277	=	_	_	I-Premise
278	.	_	_	I-Premise

279	10	_	_	I-Premise
280	,	_	_	I-Premise
281	two	_	_	I-Premise
282	-	_	_	I-Premise
283	sided	_	_	I-Premise
284	;	_	_	I-Premise
285	P	_	_	I-Premise
286	=	_	_	I-Premise
287	.	_	_	I-Premise

288	05	_	_	I-Premise
289	,	_	_	I-Premise
290	one	_	_	I-Premise
291	-	_	_	I-Premise
292	sided	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	CAF	_	_	B-Premise
296	produced	_	_	I-Premise
297	significantly	_	_	I-Premise
298	higher	_	_	I-Premise
299	grades	_	_	I-Premise
300	of	_	_	I-Premise
301	leukopenia	_	_	I-Premise
302	,	_	_	I-Premise
303	granulocytopenia	_	_	I-Premise
304	,	_	_	I-Premise
305	and	_	_	I-Premise
306	thrombocytopenia	_	_	I-Premise
307	,	_	_	I-Premise
308	as	_	_	I-Premise
309	well	_	_	I-Premise
310	as	_	_	I-Premise
311	liver	_	_	I-Premise
312	and	_	_	I-Premise
313	cardiac	_	_	I-Premise
314	toxicity	_	_	I-Premise
315	,	_	_	I-Premise
316	whereas	_	_	O
317	the	_	_	B-Premise
318	16	_	_	I-Premise
319	-	_	_	I-Premise
320	week	_	_	I-Premise
321	regimen	_	_	I-Premise
322	produced	_	_	I-Premise
323	significantly	_	_	I-Premise
324	higher	_	_	I-Premise
325	grades	_	_	I-Premise
326	of	_	_	I-Premise
327	anemia	_	_	I-Premise
328	,	_	_	I-Premise
329	nausea	_	_	I-Premise
330	,	_	_	I-Premise
331	stomatitis	_	_	I-Premise
332	,	_	_	I-Premise
333	and	_	_	I-Premise
334	weight	_	_	I-Premise
335	loss	_	_	I-Premise
336	,	_	_	I-Premise
337	as	_	_	I-Premise
338	well	_	_	I-Premise
339	as	_	_	I-Premise
340	skin	_	_	I-Premise
341	and	_	_	I-Premise
342	neurotoxicity	_	_	I-Premise
343	.	_	_	I-Premise

344	There	_	_	B-Premise
345	were	_	_	I-Premise
346	three	_	_	I-Premise
347	treatment	_	_	I-Premise
348	-	_	_	I-Premise
349	related	_	_	I-Premise
350	deaths	_	_	I-Premise
351	with	_	_	I-Premise
352	CAF	_	_	I-Premise
353	but	_	_	B-Premise
354	none	_	_	I-Premise
355	with	_	_	I-Premise
356	the	_	_	I-Premise
357	16	_	_	I-Premise
358	-	_	_	I-Premise
359	week	_	_	I-Premise
360	regimen	_	_	I-Premise
361	.	_	_	I-Premise

362	During	_	_	B-Premise
363	treatment	_	_	I-Premise
364	,	_	_	I-Premise
365	quality	_	_	I-Premise
366	of	_	_	I-Premise
367	life	_	_	I-Premise
368	declined	_	_	I-Premise
369	significantly	_	_	I-Premise
370	more	_	_	I-Premise
371	with	_	_	I-Premise
372	the	_	_	I-Premise
373	16	_	_	I-Premise
374	-	_	_	I-Premise
375	week	_	_	I-Premise
376	regimen	_	_	I-Premise
377	than	_	_	I-Premise
378	CAF	_	_	I-Premise
379	,	_	_	I-Premise
380	but	_	_	B-Premise
381	by	_	_	I-Premise
382	4	_	_	I-Premise
383	months	_	_	I-Premise
384	posttreatment	_	_	I-Premise
385	,	_	_	I-Premise
386	there	_	_	I-Premise
387	was	_	_	I-Premise
388	no	_	_	I-Premise
389	difference	_	_	I-Premise
390	.	_	_	I-Premise

391	The	_	_	B-Premise
392	16	_	_	I-Premise
393	-	_	_	I-Premise
394	week	_	_	I-Premise
395	regimen	_	_	I-Premise
396	produced	_	_	I-Premise
397	marginally	_	_	I-Premise
398	better	_	_	I-Premise
399	breast	_	_	I-Premise
400	cancer	_	_	I-Premise
401	outcomes	_	_	I-Premise
402	than	_	_	I-Premise
403	CAF	_	_	I-Premise
404	with	_	_	I-Premise
405	similar	_	_	I-Premise
406	toxicity	_	_	I-Premise
407	but	_	_	I-Premise
408	a	_	_	I-Premise
409	greater	_	_	I-Premise
410	reduction	_	_	I-Premise
411	in	_	_	I-Premise
412	during	_	_	I-Premise
413	-	_	_	I-Premise
414	treatment	_	_	I-Premise
415	quality	_	_	I-Premise
416	of	_	_	I-Premise
417	life	_	_	I-Premise
418	.	_	_	I-Premise

419	The	_	_	B-Claim
420	16	_	_	I-Claim
421	-	_	_	I-Claim
422	week	_	_	I-Claim
423	regimen	_	_	I-Claim
424	should	_	_	I-Claim
425	not	_	_	I-Claim
426	be	_	_	I-Claim
427	used	_	_	I-Claim
428	instead	_	_	I-Claim
429	of	_	_	I-Claim
430	a	_	_	I-Claim
431	standard	_	_	I-Claim
432	-	_	_	I-Claim
433	dose	_	_	I-Claim
434	regimen	_	_	I-Claim
435	without	_	_	I-Claim
436	careful	_	_	I-Claim
437	consideration	_	_	I-Claim
438	of	_	_	I-Claim
439	the	_	_	I-Claim
440	16	_	_	I-Claim
441	-	_	_	I-Claim
442	week	_	_	I-Claim
443	regimen	_	_	I-Claim
444	'	_	_	I-Claim
445	s	_	_	I-Claim
446	pros	_	_	I-Claim
447	and	_	_	I-Claim
448	cons	_	_	I-Claim
449	,	_	_	I-Claim
450	which	_	_	I-Claim
451	include	_	_	I-Claim
452	its	_	_	I-Claim
453	complicated	_	_	I-Claim
454	schedule	_	_	I-Claim
455	.	_	_	I-Claim

456	It	_	_	B-Claim
457	should	_	_	I-Claim
458	probably	_	_	I-Claim
459	not	_	_	I-Claim
460	be	_	_	I-Claim
461	tested	_	_	I-Claim
462	further	_	_	I-Claim
463	,	_	_	I-Claim
464	but	_	_	B-Claim
465	its	_	_	I-Claim
466	antimetabolite	_	_	I-Claim
467	schedules	_	_	I-Claim
468	and	_	_	I-Claim
469	frequent	_	_	I-Claim
470	drug	_	_	I-Claim
471	administration	_	_	I-Claim
472	(	_	_	I-Claim
473	ie	_	_	I-Claim
474	,	_	_	I-Claim
475	dose	_	_	I-Claim
476	density	_	_	I-Claim
477	)	_	_	I-Claim
478	should	_	_	I-Claim
479	be	_	_	I-Claim
480	considered	_	_	I-Claim
481	in	_	_	I-Claim
482	the	_	_	I-Claim
483	development	_	_	I-Claim
484	of	_	_	I-Claim
485	new	_	_	I-Claim
486	regimens	_	_	I-Claim
487	.	_	_	I-Claim


0	Proinflammatory	_	_	O
1	cytokines	_	_	O
2	,	_	_	O
3	especially	_	_	O
4	tumour	_	_	O
5	necrosis	_	_	O
6	factor	_	_	O
7	alpha	_	_	O
8	(	_	_	O
9	TNF	_	_	O
10	-	_	_	O
11	alpha	_	_	O
12	)	_	_	O
13	,	_	_	O
14	play	_	_	O
15	a	_	_	O
16	prominent	_	_	O
17	role	_	_	O
18	in	_	_	O
19	the	_	_	O
20	pathogenesis	_	_	O
21	of	_	_	O
22	cancer	_	_	O
23	cachexia	_	_	O
24	.	_	_	O

25	Thalidomide	_	_	B-Claim
26	,	_	_	I-Claim
27	which	_	_	I-Claim
28	is	_	_	I-Claim
29	an	_	_	I-Claim
30	inhibitor	_	_	I-Claim
31	of	_	_	I-Claim
32	TNF	_	_	I-Claim
33	-	_	_	I-Claim
34	alpha	_	_	I-Claim
35	synthesis	_	_	I-Claim
36	,	_	_	I-Claim
37	may	_	_	I-Claim
38	represent	_	_	I-Claim
39	a	_	_	I-Claim
40	novel	_	_	I-Claim
41	and	_	_	I-Claim
42	rational	_	_	I-Claim
43	approach	_	_	I-Claim
44	to	_	_	I-Claim
45	the	_	_	I-Claim
46	treatment	_	_	I-Claim
47	of	_	_	I-Claim
48	cancer	_	_	I-Claim
49	cachexia	_	_	I-Claim
50	.	_	_	I-Claim

51	To	_	_	O
52	assess	_	_	O
53	the	_	_	O
54	safety	_	_	O
55	and	_	_	O
56	efficacy	_	_	O
57	of	_	_	O
58	thalidomide	_	_	O
59	in	_	_	O
60	attenuating	_	_	O
61	weight	_	_	O
62	loss	_	_	O
63	in	_	_	O
64	patients	_	_	O
65	with	_	_	O
66	cachexia	_	_	O
67	secondary	_	_	O
68	to	_	_	O
69	advanced	_	_	O
70	pancreatic	_	_	O
71	cancer	_	_	O
72	.	_	_	O

73	Fifty	_	_	O
74	patients	_	_	O
75	with	_	_	O
76	advanced	_	_	O
77	pancreatic	_	_	O
78	cancer	_	_	O
79	who	_	_	O
80	had	_	_	O
81	lost	_	_	O
82	at	_	_	O
83	least	_	_	O
84	10	_	_	O
85	%	_	_	O
86	of	_	_	O
87	their	_	_	O
88	body	_	_	O
89	weight	_	_	O
90	were	_	_	O
91	randomised	_	_	O
92	to	_	_	O
93	receive	_	_	O
94	thalidomide	_	_	O
95	200	_	_	O
96	mg	_	_	O
97	daily	_	_	O
98	or	_	_	O
99	placebo	_	_	O
100	for	_	_	O
101	24	_	_	O
102	weeks	_	_	O
103	in	_	_	O
104	a	_	_	O
105	single	_	_	O
106	centre	_	_	O
107	,	_	_	O
108	double	_	_	O
109	blind	_	_	O
110	,	_	_	O
111	randomised	_	_	O
112	controlled	_	_	O
113	trial	_	_	O
114	.	_	_	O

115	The	_	_	O
116	primary	_	_	O
117	outcome	_	_	O
118	was	_	_	O
119	change	_	_	O
120	in	_	_	O
121	weight	_	_	O
122	and	_	_	O
123	nutritional	_	_	O
124	status	_	_	O
125	.	_	_	O

126	Thirty	_	_	O
127	three	_	_	O
128	patients	_	_	O
129	(	_	_	O
130	16	_	_	O
131	control	_	_	O
132	,	_	_	O
133	17	_	_	O
134	thalidomide	_	_	O
135	)	_	_	O
136	were	_	_	O
137	evaluated	_	_	O
138	at	_	_	O
139	four	_	_	O
140	weeks	_	_	O
141	,	_	_	O
142	and	_	_	O
143	20	_	_	O
144	patients	_	_	O
145	(	_	_	O
146	eight	_	_	O
147	control	_	_	O
148	,	_	_	O
149	12	_	_	O
150	thalidomide	_	_	O
151	)	_	_	O
152	at	_	_	O
153	eight	_	_	O
154	weeks	_	_	O
155	.	_	_	O

156	At	_	_	B-Premise
157	four	_	_	I-Premise
158	weeks	_	_	I-Premise
159	,	_	_	I-Premise
160	patients	_	_	I-Premise
161	who	_	_	I-Premise
162	received	_	_	I-Premise
163	thalidomide	_	_	I-Premise
164	had	_	_	I-Premise
165	gained	_	_	I-Premise
166	on	_	_	I-Premise
167	average	_	_	I-Premise
168	0	_	_	I-Premise
169	.	_	_	I-Premise

170	37	_	_	I-Premise
171	kg	_	_	I-Premise
172	in	_	_	I-Premise
173	weight	_	_	I-Premise
174	and	_	_	I-Premise
175	1	_	_	I-Premise
176	.	_	_	I-Premise

177	0	_	_	I-Premise
178	cm	_	_	I-Premise
179	(	_	_	I-Premise
180	3	_	_	I-Premise
181	)	_	_	I-Premise
182	in	_	_	I-Premise
183	arm	_	_	I-Premise
184	muscle	_	_	I-Premise
185	mass	_	_	I-Premise
186	(	_	_	I-Premise
187	AMA	_	_	I-Premise
188	)	_	_	I-Premise
189	compared	_	_	I-Premise
190	with	_	_	I-Premise
191	a	_	_	I-Premise
192	loss	_	_	I-Premise
193	of	_	_	I-Premise
194	2	_	_	I-Premise
195	.	_	_	I-Premise

196	21	_	_	I-Premise
197	kg	_	_	I-Premise
198	(	_	_	I-Premise
199	absolute	_	_	I-Premise
200	difference	_	_	I-Premise
201	-	_	_	I-Premise
202	2	_	_	I-Premise
203	.	_	_	I-Premise

204	59	_	_	I-Premise
205	kg	_	_	I-Premise
206	(	_	_	I-Premise
207	95	_	_	I-Premise
208	%	_	_	I-Premise
209	confidence	_	_	I-Premise
210	interval	_	_	I-Premise
211	(	_	_	I-Premise
212	CI	_	_	I-Premise
213	)	_	_	I-Premise
214	-	_	_	I-Premise
215	4	_	_	I-Premise
216	.	_	_	I-Premise

217	3	_	_	I-Premise
218	to	_	_	I-Premise
219	-	_	_	I-Premise
220	0	_	_	I-Premise
221	.	_	_	I-Premise

222	8	_	_	I-Premise
223	)	_	_	I-Premise
224	;	_	_	I-Premise
225	p	_	_	I-Premise
226	=	_	_	I-Premise
227	0	_	_	I-Premise
228	.	_	_	I-Premise

229	005	_	_	I-Premise
230	)	_	_	I-Premise
231	and	_	_	I-Premise
232	4	_	_	I-Premise
233	.	_	_	I-Premise

234	46	_	_	I-Premise
235	cm	_	_	I-Premise
236	(	_	_	I-Premise
237	3	_	_	I-Premise
238	)	_	_	I-Premise
239	(	_	_	I-Premise
240	absolute	_	_	I-Premise
241	difference	_	_	I-Premise
242	-	_	_	I-Premise
243	5	_	_	I-Premise
244	.	_	_	I-Premise

245	6	_	_	I-Premise
246	cm	_	_	I-Premise
247	(	_	_	I-Premise
248	3	_	_	I-Premise
249	)	_	_	I-Premise
250	(	_	_	I-Premise
251	95	_	_	I-Premise
252	%	_	_	I-Premise
253	CI	_	_	I-Premise
254	-	_	_	I-Premise
255	8	_	_	I-Premise
256	.	_	_	I-Premise

257	9	_	_	I-Premise
258	to	_	_	I-Premise
259	-	_	_	I-Premise
260	2	_	_	I-Premise
261	.	_	_	I-Premise

262	2	_	_	I-Premise
263	)	_	_	I-Premise
264	;	_	_	I-Premise
265	p	_	_	I-Premise
266	=	_	_	I-Premise
267	0	_	_	I-Premise
268	.	_	_	I-Premise

269	002	_	_	I-Premise
270	)	_	_	I-Premise
271	in	_	_	I-Premise
272	the	_	_	I-Premise
273	placebo	_	_	I-Premise
274	group	_	_	I-Premise
275	.	_	_	I-Premise

276	At	_	_	B-Premise
277	eight	_	_	I-Premise
278	weeks	_	_	I-Premise
279	,	_	_	I-Premise
280	patients	_	_	I-Premise
281	in	_	_	I-Premise
282	the	_	_	I-Premise
283	thalidomide	_	_	I-Premise
284	group	_	_	I-Premise
285	had	_	_	I-Premise
286	lost	_	_	I-Premise
287	0	_	_	I-Premise
288	.	_	_	I-Premise

289	06	_	_	I-Premise
290	kg	_	_	I-Premise
291	in	_	_	I-Premise
292	weight	_	_	I-Premise
293	and	_	_	I-Premise
294	0	_	_	I-Premise
295	.	_	_	I-Premise

296	5	_	_	I-Premise
297	cm	_	_	I-Premise
298	(	_	_	I-Premise
299	3	_	_	I-Premise
300	)	_	_	I-Premise
301	in	_	_	I-Premise
302	AMA	_	_	I-Premise
303	compared	_	_	I-Premise
304	with	_	_	I-Premise
305	a	_	_	I-Premise
306	loss	_	_	I-Premise
307	of	_	_	I-Premise
308	3	_	_	I-Premise
309	.	_	_	I-Premise

310	62	_	_	I-Premise
311	kg	_	_	I-Premise
312	(	_	_	I-Premise
313	absolute	_	_	I-Premise
314	difference	_	_	I-Premise
315	-	_	_	I-Premise
316	3	_	_	I-Premise
317	.	_	_	I-Premise

318	57	_	_	I-Premise
319	kg	_	_	I-Premise
320	(	_	_	I-Premise
321	95	_	_	I-Premise
322	%	_	_	I-Premise
323	CI	_	_	I-Premise
324	-	_	_	I-Premise
325	6	_	_	I-Premise
326	.	_	_	I-Premise

327	8	_	_	I-Premise
328	to	_	_	I-Premise
329	-	_	_	I-Premise
330	0	_	_	I-Premise
331	.	_	_	I-Premise

332	3	_	_	I-Premise
333	)	_	_	I-Premise
334	;	_	_	I-Premise
335	p	_	_	I-Premise
336	=	_	_	I-Premise
337	0	_	_	I-Premise
338	.	_	_	I-Premise

339	034	_	_	I-Premise
340	)	_	_	I-Premise
341	and	_	_	I-Premise
342	8	_	_	I-Premise
343	.	_	_	I-Premise

344	4	_	_	I-Premise
345	cm	_	_	I-Premise
346	(	_	_	I-Premise
347	3	_	_	I-Premise
348	)	_	_	I-Premise
349	(	_	_	I-Premise
350	absolute	_	_	I-Premise
351	difference	_	_	I-Premise
352	-	_	_	I-Premise
353	7	_	_	I-Premise
354	.	_	_	I-Premise

355	9	_	_	I-Premise
356	cm	_	_	I-Premise
357	(	_	_	I-Premise
358	3	_	_	I-Premise
359	)	_	_	I-Premise
360	(	_	_	I-Premise
361	95	_	_	I-Premise
362	%	_	_	I-Premise
363	CI	_	_	I-Premise
364	-	_	_	I-Premise
365	14	_	_	I-Premise
366	.	_	_	I-Premise

367	0	_	_	I-Premise
368	to	_	_	I-Premise
369	-	_	_	I-Premise
370	1	_	_	I-Premise
371	.	_	_	I-Premise

372	8	_	_	I-Premise
373	)	_	_	I-Premise
374	;	_	_	I-Premise
375	p	_	_	I-Premise
376	=	_	_	I-Premise
377	0	_	_	I-Premise
378	.	_	_	I-Premise

379	014	_	_	I-Premise
380	)	_	_	I-Premise
381	in	_	_	I-Premise
382	the	_	_	I-Premise
383	placebo	_	_	I-Premise
384	group	_	_	I-Premise
385	.	_	_	I-Premise

386	Improvement	_	_	B-Premise
387	in	_	_	I-Premise
388	physical	_	_	I-Premise
389	functioning	_	_	I-Premise
390	correlated	_	_	I-Premise
391	positively	_	_	I-Premise
392	with	_	_	I-Premise
393	weight	_	_	I-Premise
394	gain	_	_	I-Premise
395	(	_	_	I-Premise
396	r	_	_	I-Premise
397	=	_	_	I-Premise
398	0	_	_	I-Premise
399	.	_	_	I-Premise

400	56	_	_	I-Premise
401	,	_	_	I-Premise
402	p	_	_	I-Premise
403	=	_	_	I-Premise
404	0	_	_	I-Premise
405	.	_	_	I-Premise

406	001	_	_	I-Premise
407	)	_	_	I-Premise
408	.	_	_	I-Premise

409	Thalidomide	_	_	B-Claim
410	was	_	_	I-Claim
411	well	_	_	I-Claim
412	tolerated	_	_	I-Claim
413	and	_	_	I-Claim
414	effective	_	_	I-Claim
415	at	_	_	I-Claim
416	attenuating	_	_	I-Claim
417	loss	_	_	I-Claim
418	of	_	_	I-Claim
419	weight	_	_	I-Claim
420	and	_	_	I-Claim
421	lean	_	_	I-Claim
422	body	_	_	I-Claim
423	mass	_	_	I-Claim
424	in	_	_	I-Claim
425	patients	_	_	I-Claim
426	with	_	_	I-Claim
427	cachexia	_	_	I-Claim
428	due	_	_	I-Claim
429	to	_	_	I-Claim
430	advanced	_	_	I-Claim
431	pancreatic	_	_	I-Claim
432	cancer	_	_	I-Claim
433	.	_	_	I-Claim


0	DPPE	_	_	B-Claim
1	(	_	_	I-Claim
2	tesmilifene	_	_	I-Claim
3	)	_	_	I-Claim
4	plus	_	_	I-Claim
5	doxorubicin	_	_	I-Claim
6	(	_	_	I-Claim
7	DOX	_	_	I-Claim
8	)	_	_	I-Claim
9	demonstrated	_	_	I-Claim
10	a	_	_	I-Claim
11	significant	_	_	I-Claim
12	improvement	_	_	I-Claim
13	in	_	_	I-Claim
14	survival	_	_	I-Claim
15	versus	_	_	I-Claim
16	DOX	_	_	I-Claim
17	in	_	_	I-Claim
18	a	_	_	I-Claim
19	phase	_	_	I-Claim
20	III	_	_	I-Claim
21	clinical	_	_	I-Claim
22	trial	_	_	I-Claim
23	in	_	_	I-Claim
24	advanced	_	_	I-Claim
25	breast	_	_	I-Claim
26	cancer	_	_	I-Claim
27	.	_	_	I-Claim

28	However	_	_	B-Premise
29	,	_	_	I-Premise
30	DPPE	_	_	I-Premise
31	is	_	_	I-Premise
32	associated	_	_	I-Premise
33	with	_	_	I-Premise
34	unusual	_	_	I-Premise
35	toxicity	_	_	I-Premise
36	in	_	_	I-Premise
37	the	_	_	I-Premise
38	form	_	_	I-Premise
39	of	_	_	I-Premise
40	hallucinations	_	_	I-Premise
41	,	_	_	I-Premise
42	nausea	_	_	I-Premise
43	and	_	_	I-Premise
44	vomiting	_	_	I-Premise
45	which	_	_	I-Premise
46	were	_	_	I-Premise
47	anticipated	_	_	I-Premise
48	to	_	_	I-Premise
49	impact	_	_	I-Premise
50	on	_	_	I-Premise
51	short	_	_	I-Premise
52	-	_	_	I-Premise
53	term	_	_	I-Premise
54	quality	_	_	I-Premise
55	of	_	_	I-Premise
56	life	_	_	I-Premise
57	(	_	_	I-Premise
58	QOL	_	_	I-Premise
59	)	_	_	I-Premise
60	.	_	_	I-Premise

61	Standard	_	_	O
62	National	_	_	O
63	Cancer	_	_	O
64	Institute	_	_	O
65	of	_	_	O
66	Canada	_	_	O
67	Clinical	_	_	O
68	Trials	_	_	O
69	Group	_	_	O
70	(	_	_	O
71	NCIC	_	_	O
72	CTG	_	_	O
73	)	_	_	O
74	approaches	_	_	O
75	were	_	_	O
76	applied	_	_	O
77	as	_	_	O
78	the	_	_	O
79	primary	_	_	O
80	method	_	_	O
81	to	_	_	O
82	analyze	_	_	O
83	the	_	_	O
84	QOL	_	_	O
85	data	_	_	O
86	from	_	_	O
87	this	_	_	O
88	trial	_	_	O
89	.	_	_	O

90	This	_	_	O
91	includes	_	_	O
92	cross	_	_	O
93	-	_	_	O
94	sectional	_	_	O
95	comparisons	_	_	O
96	,	_	_	O
97	together	_	_	O
98	with	_	_	O
99	a	_	_	O
100	global	_	_	O
101	test	_	_	O
102	for	_	_	O
103	the	_	_	O
104	QOL	_	_	O
105	response	_	_	O
106	rate	_	_	O
107	.	_	_	O

108	Sensitivity	_	_	O
109	analyses	_	_	O
110	were	_	_	O
111	also	_	_	O
112	performed	_	_	O
113	for	_	_	O
114	selected	_	_	O
115	QOL	_	_	O
116	domains	_	_	O
117	and	_	_	O
118	items	_	_	O
119	,	_	_	O
120	using	_	_	O
121	other	_	_	O
122	types	_	_	O
123	of	_	_	O
124	summary	_	_	O
125	measures	_	_	O
126	and	_	_	O
127	statistics	_	_	O
128	.	_	_	O

129	Two	_	_	O
130	hundred	_	_	O
131	seventy	_	_	O
132	one	_	_	O
133	patients	_	_	O
134	(	_	_	O
135	89	_	_	O
136	%	_	_	O
137	of	_	_	O
138	randomized	_	_	O
139	)	_	_	O
140	submitted	_	_	O
141	the	_	_	O
142	baseline	_	_	O
143	QOL	_	_	O
144	questionnaires	_	_	O
145	and	_	_	O
146	were	_	_	O
147	included	_	_	O
148	in	_	_	O
149	the	_	_	O
150	QOL	_	_	O
151	analysis	_	_	O
152	.	_	_	O

153	No	_	_	B-Premise
154	statistically	_	_	I-Premise
155	significant	_	_	I-Premise
156	difference	_	_	I-Premise
157	in	_	_	I-Premise
158	QOL	_	_	I-Premise
159	response	_	_	I-Premise
160	between	_	_	I-Premise
161	treatment	_	_	I-Premise
162	arms	_	_	I-Premise
163	was	_	_	I-Premise
164	found	_	_	I-Premise
165	for	_	_	I-Premise
166	any	_	_	I-Premise
167	domain	_	_	I-Premise
168	or	_	_	I-Premise
169	item	_	_	I-Premise
170	except	_	_	I-Premise
171	nausea	_	_	I-Premise
172	and	_	_	I-Premise
173	vomiting	_	_	I-Premise
174	(	_	_	I-Premise
175	P	_	_	I-Premise
176	=	_	_	I-Premise
177	0	_	_	I-Premise
178	.	_	_	I-Premise

179	04	_	_	I-Premise
180	)	_	_	I-Premise
181	.	_	_	I-Premise

182	Cross	_	_	B-Premise
183	-	_	_	I-Premise
184	sectional	_	_	I-Premise
185	comparisons	_	_	I-Premise
186	showed	_	_	I-Premise
187	statistically	_	_	I-Premise
188	significant	_	_	I-Premise
189	differences	_	_	I-Premise
190	for	_	_	I-Premise
191	some	_	_	I-Premise
192	domains	_	_	I-Premise
193	/	_	_	I-Premise
194	items	_	_	I-Premise
195	at	_	_	I-Premise
196	specific	_	_	I-Premise
197	assessment	_	_	I-Premise
198	times	_	_	I-Premise
199	with	_	_	I-Premise
200	all	_	_	I-Premise
201	differences	_	_	I-Premise
202	favoring	_	_	I-Premise
203	the	_	_	I-Premise
204	DOX	_	_	I-Premise
205	alone	_	_	I-Premise
206	arm	_	_	I-Premise
207	.	_	_	I-Premise

208	Patients	_	_	B-Premise
209	on	_	_	I-Premise
210	DPPE	_	_	I-Premise
211	/	_	_	I-Premise
212	DOX	_	_	I-Premise
213	arm	_	_	I-Premise
214	were	_	_	I-Premise
215	significantly	_	_	I-Premise
216	worse	_	_	I-Premise
217	in	_	_	I-Premise
218	terms	_	_	I-Premise
219	of	_	_	I-Premise
220	average	_	_	I-Premise
221	and	_	_	I-Premise
222	median	_	_	I-Premise
223	pain	_	_	I-Premise
224	change	_	_	I-Premise
225	scores	_	_	I-Premise
226	.	_	_	I-Premise

227	Different	_	_	B-Claim
228	analyses	_	_	I-Claim
229	yielded	_	_	I-Claim
230	slightly	_	_	I-Claim
231	different	_	_	I-Claim
232	conclusions	_	_	I-Claim
233	but	_	_	O
234	,	_	_	O
235	in	_	_	B-Claim
236	general	_	_	I-Claim
237	,	_	_	I-Claim
238	the	_	_	I-Claim
239	QOL	_	_	I-Claim
240	analyses	_	_	I-Claim
241	were	_	_	I-Claim
242	concordant	_	_	I-Claim
243	and	_	_	I-Claim
244	showed	_	_	I-Claim
245	that	_	_	I-Claim
246	patients	_	_	I-Claim
247	on	_	_	I-Claim
248	DOX	_	_	I-Claim
249	alone	_	_	I-Claim
250	had	_	_	I-Claim
251	fewer	_	_	I-Claim
252	disease	_	_	I-Claim
253	and	_	_	I-Claim
254	treatment	_	_	I-Claim
255	related	_	_	I-Claim
256	adverse	_	_	I-Claim
257	events	_	_	I-Claim
258	and	_	_	I-Claim
259	better	_	_	I-Claim
260	QOL	_	_	I-Claim
261	.	_	_	I-Claim

262	Interestingly	_	_	B-Claim
263	,	_	_	I-Claim
264	the	_	_	I-Claim
265	QOL	_	_	I-Claim
266	response	_	_	I-Claim
267	analysis	_	_	I-Claim
268	also	_	_	I-Claim
269	showed	_	_	I-Claim
270	that	_	_	I-Claim
271	aggressive	_	_	I-Claim
272	premedication	_	_	I-Claim
273	regimens	_	_	I-Claim
274	appear	_	_	I-Claim
275	to	_	_	I-Claim
276	ameliorate	_	_	I-Claim
277	potential	_	_	I-Claim
278	negative	_	_	I-Claim
279	effects	_	_	I-Claim
280	of	_	_	I-Claim
281	DPPE	_	_	I-Claim
282	on	_	_	I-Claim
283	emesis	_	_	I-Claim
284	and	_	_	I-Claim
285	nausea	_	_	I-Claim
286	as	_	_	I-Claim
287	measured	_	_	I-Claim
288	by	_	_	I-Claim
289	patient	_	_	I-Claim
290	assessed	_	_	I-Claim
291	QOL	_	_	I-Claim
292	.	_	_	I-Claim


0	Malignant	_	_	B-Claim
1	pleural	_	_	I-Claim
2	effusion	_	_	I-Claim
3	(	_	_	I-Claim
4	MPE	_	_	I-Claim
5	)	_	_	I-Claim
6	is	_	_	I-Claim
7	a	_	_	I-Claim
8	common	_	_	I-Claim
9	complication	_	_	I-Claim
10	of	_	_	I-Claim
11	advanced	_	_	I-Claim
12	non	_	_	I-Claim
13	-	_	_	I-Claim
14	small	_	_	I-Claim
15	cell	_	_	I-Claim
16	lung	_	_	I-Claim
17	cancer	_	_	I-Claim
18	(	_	_	I-Claim
19	NSCLC	_	_	I-Claim
20	)	_	_	I-Claim
21	.	_	_	I-Claim

22	Bevacizumab	_	_	B-Claim
23	,	_	_	I-Claim
24	a	_	_	I-Claim
25	humanized	_	_	I-Claim
26	monoclonal	_	_	I-Claim
27	antibody	_	_	I-Claim
28	against	_	_	I-Claim
29	vascular	_	_	I-Claim
30	endothelial	_	_	I-Claim
31	growth	_	_	I-Claim
32	factor	_	_	I-Claim
33	(	_	_	I-Claim
34	VEGF	_	_	I-Claim
35	)	_	_	I-Claim
36	,	_	_	I-Claim
37	has	_	_	I-Claim
38	been	_	_	I-Claim
39	shown	_	_	I-Claim
40	to	_	_	I-Claim
41	be	_	_	I-Claim
42	efficient	_	_	I-Claim
43	in	_	_	I-Claim
44	suppressing	_	_	I-Claim
45	the	_	_	I-Claim
46	accumulation	_	_	I-Claim
47	of	_	_	I-Claim
48	pleural	_	_	I-Claim
49	fluid	_	_	I-Claim
50	.	_	_	I-Claim

51	However	_	_	O
52	,	_	_	O
53	whether	_	_	O
54	intrapleural	_	_	O
55	delivery	_	_	O
56	of	_	_	O
57	bevacizumab	_	_	O
58	can	_	_	O
59	be	_	_	O
60	used	_	_	O
61	to	_	_	O
62	treat	_	_	O
63	MPE	_	_	O
64	remains	_	_	O
65	unknown	_	_	O
66	.	_	_	O

67	The	_	_	O
68	aim	_	_	O
69	of	_	_	O
70	the	_	_	O
71	present	_	_	O
72	study	_	_	O
73	was	_	_	O
74	to	_	_	O
75	evaluate	_	_	O
76	the	_	_	O
77	efficacy	_	_	O
78	and	_	_	O
79	safety	_	_	O
80	of	_	_	O
81	combined	_	_	O
82	intrapleural	_	_	O
83	therapy	_	_	O
84	with	_	_	O
85	bevacizumab	_	_	O
86	and	_	_	O
87	cisplatin	_	_	O
88	,	_	_	O
89	an	_	_	O
90	antineoplastic	_	_	O
91	agent	_	_	O
92	,	_	_	O
93	in	_	_	O
94	controlling	_	_	O
95	MPE	_	_	O
96	.	_	_	O

97	A	_	_	O
98	total	_	_	O
99	of	_	_	O
100	72	_	_	O
101	NSCLC	_	_	O
102	study	_	_	O
103	subjects	_	_	O
104	with	_	_	O
105	MPE	_	_	O
106	were	_	_	O
107	randomly	_	_	O
108	assigned	_	_	O
109	to	_	_	O
110	one	_	_	O
111	of	_	_	O
112	two	_	_	O
113	groups	_	_	O
114	.	_	_	O

115	The	_	_	O
116	first	_	_	O
117	group	_	_	O
118	received	_	_	O
119	intrapleural	_	_	O
120	bevacizumab	_	_	O
121	(	_	_	O
122	300	_	_	O
123	mg	_	_	O
124	)	_	_	O
125	with	_	_	O
126	cisplatin	_	_	O
127	(	_	_	O
128	30	_	_	O
129	mg	_	_	O
130	)	_	_	O
131	therapy	_	_	O
132	and	_	_	O
133	the	_	_	O
134	second	_	_	O
135	group	_	_	O
136	received	_	_	O
137	intrapleural	_	_	O
138	cisplatin	_	_	O
139	(	_	_	O
140	30	_	_	O
141	mg	_	_	O
142	)	_	_	O
143	therapy	_	_	O
144	alone	_	_	O
145	.	_	_	O

146	Pleural	_	_	O
147	fluid	_	_	O
148	was	_	_	O
149	collected	_	_	O
150	from	_	_	O
151	both	_	_	O
152	groups	_	_	O
153	prior	_	_	O
154	to	_	_	O
155	and	_	_	O
156	following	_	_	O
157	treatment	_	_	O
158	.	_	_	O

159	The	_	_	O
160	levels	_	_	O
161	of	_	_	O
162	VEGF	_	_	O
163	and	_	_	O
164	carcinoembryonic	_	_	O
165	antigen	_	_	O
166	(	_	_	O
167	CEA	_	_	O
168	)	_	_	O
169	in	_	_	O
170	the	_	_	O
171	pleural	_	_	O
172	fluid	_	_	O
173	were	_	_	O
174	determined	_	_	O
175	by	_	_	O
176	ELISA	_	_	O
177	.	_	_	O

178	In	_	_	B-Premise
179	70	_	_	I-Premise
180	evaluable	_	_	I-Premise
181	study	_	_	I-Premise
182	subjects	_	_	I-Premise
183	,	_	_	I-Premise
184	the	_	_	I-Premise
185	curative	_	_	I-Premise
186	efficacy	_	_	I-Premise
187	in	_	_	I-Premise
188	the	_	_	I-Premise
189	bevacizumab	_	_	I-Premise
190	group	_	_	I-Premise
191	was	_	_	I-Premise
192	significantly	_	_	I-Premise
193	higher	_	_	I-Premise
194	than	_	_	I-Premise
195	that	_	_	I-Premise
196	found	_	_	I-Premise
197	in	_	_	I-Premise
198	the	_	_	I-Premise
199	cisplatin	_	_	I-Premise
200	group	_	_	I-Premise
201	(	_	_	I-Premise
202	83	_	_	I-Premise
203	.	_	_	I-Premise

204	33	_	_	I-Premise
205	vs	_	_	I-Premise
206	.	_	_	I-Premise

207	50	_	_	I-Premise
208	.	_	_	I-Premise

209	00	_	_	I-Premise
210	%	_	_	I-Premise
211	,	_	_	I-Premise
212	respectively	_	_	I-Premise
213	;	_	_	I-Premise
214	p	_	_	I-Premise
215	<	_	_	I-Premise
216	0	_	_	I-Premise
217	.	_	_	I-Premise

218	05	_	_	I-Premise
219	)	_	_	I-Premise
220	.	_	_	I-Premise

221	Therapy	_	_	B-Premise
222	with	_	_	I-Premise
223	combined	_	_	I-Premise
224	bevacizumab	_	_	I-Premise
225	plus	_	_	I-Premise
226	cisplatin	_	_	I-Premise
227	significantly	_	_	I-Premise
228	reduced	_	_	I-Premise
229	VEGF	_	_	I-Premise
230	levels	_	_	I-Premise
231	in	_	_	I-Premise
232	the	_	_	I-Premise
233	pleural	_	_	I-Premise
234	fluid	_	_	I-Premise
235	(	_	_	I-Premise
236	p	_	_	I-Premise
237	<	_	_	I-Premise
238	0	_	_	I-Premise
239	.	_	_	I-Premise

240	01	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	In	_	_	B-Premise
244	the	_	_	I-Premise
245	bevacizumab	_	_	I-Premise
246	group	_	_	I-Premise
247	,	_	_	I-Premise
248	the	_	_	I-Premise
249	levels	_	_	I-Premise
250	of	_	_	I-Premise
251	VEGF	_	_	I-Premise
252	in	_	_	I-Premise
253	the	_	_	I-Premise
254	pleural	_	_	I-Premise
255	fluid	_	_	I-Premise
256	were	_	_	I-Premise
257	significantly	_	_	I-Premise
258	lower	_	_	I-Premise
259	compared	_	_	I-Premise
260	to	_	_	I-Premise
261	those	_	_	I-Premise
262	of	_	_	I-Premise
263	the	_	_	I-Premise
264	cisplatin	_	_	I-Premise
265	group	_	_	I-Premise
266	after	_	_	I-Premise
267	treatment	_	_	I-Premise
268	,	_	_	I-Premise
269	which	_	_	I-Premise
270	showed	_	_	I-Premise
271	greater	_	_	I-Premise
272	efficacy	_	_	I-Premise
273	(	_	_	I-Premise
274	p	_	_	I-Premise
275	<	_	_	I-Premise
276	0	_	_	I-Premise
277	.	_	_	I-Premise

278	01	_	_	I-Premise
279	)	_	_	I-Premise
280	.	_	_	I-Premise

281	In	_	_	B-Premise
282	addition	_	_	I-Premise
283	,	_	_	I-Premise
284	combination	_	_	I-Premise
285	therapy	_	_	I-Premise
286	showed	_	_	I-Premise
287	greater	_	_	I-Premise
288	efficacy	_	_	I-Premise
289	in	_	_	I-Premise
290	the	_	_	I-Premise
291	patients	_	_	I-Premise
292	with	_	_	I-Premise
293	high	_	_	I-Premise
294	levels	_	_	I-Premise
295	of	_	_	I-Premise
296	VEGF	_	_	I-Premise
297	expression	_	_	I-Premise
298	(	_	_	I-Premise
299	p	_	_	I-Premise
300	<	_	_	I-Premise
301	0	_	_	I-Premise
302	.	_	_	I-Premise

303	01	_	_	I-Premise
304	)	_	_	I-Premise
305	.	_	_	I-Premise

306	There	_	_	B-Premise
307	was	_	_	I-Premise
308	no	_	_	I-Premise
309	significant	_	_	I-Premise
310	difference	_	_	I-Premise
311	in	_	_	I-Premise
312	grade	_	_	I-Premise
313	III	_	_	I-Premise
314	/	_	_	I-Premise
315	IV	_	_	I-Premise
316	adverse	_	_	I-Premise
317	events	_	_	I-Premise
318	between	_	_	I-Premise
319	the	_	_	I-Premise
320	two	_	_	I-Premise
321	groups	_	_	I-Premise
322	.	_	_	I-Premise

323	All	_	_	B-Premise
324	procedures	_	_	I-Premise
325	were	_	_	I-Premise
326	well	_	_	I-Premise
327	tolerated	_	_	I-Premise
328	by	_	_	I-Premise
329	the	_	_	I-Premise
330	patients	_	_	I-Premise
331	.	_	_	I-Premise

332	Combined	_	_	B-Claim
333	intrapleural	_	_	I-Claim
334	therapy	_	_	I-Claim
335	with	_	_	I-Claim
336	bevacizumab	_	_	I-Claim
337	and	_	_	I-Claim
338	cisplatin	_	_	I-Claim
339	was	_	_	I-Claim
340	effective	_	_	I-Claim
341	and	_	_	I-Claim
342	safe	_	_	I-Claim
343	in	_	_	I-Claim
344	managing	_	_	I-Claim
345	NSCLC	_	_	I-Claim
346	-	_	_	I-Claim
347	mediated	_	_	I-Claim
348	MPE	_	_	I-Claim
349	.	_	_	I-Claim

350	We	_	_	B-Claim
351	propose	_	_	I-Claim
352	that	_	_	I-Claim
353	VEGF	_	_	I-Claim
354	expression	_	_	I-Claim
355	levels	_	_	I-Claim
356	in	_	_	I-Claim
357	MPE	_	_	I-Claim
358	could	_	_	I-Claim
359	serve	_	_	I-Claim
360	as	_	_	I-Claim
361	a	_	_	I-Claim
362	prognostic	_	_	I-Claim
363	marker	_	_	I-Claim
364	for	_	_	I-Claim
365	bevacizumab	_	_	I-Claim
366	therapy	_	_	I-Claim
367	.	_	_	I-Claim


0	Observational	_	_	O
1	studies	_	_	O
2	demonstrate	_	_	O
3	an	_	_	O
4	association	_	_	O
5	between	_	_	O
6	physical	_	_	O
7	activity	_	_	O
8	and	_	_	O
9	improved	_	_	O
10	outcomes	_	_	O
11	in	_	_	O
12	breast	_	_	O
13	and	_	_	O
14	colon	_	_	O
15	cancer	_	_	O
16	survivors	_	_	O
17	.	_	_	O

18	To	_	_	O
19	test	_	_	O
20	these	_	_	O
21	observations	_	_	O
22	with	_	_	O
23	a	_	_	O
24	large	_	_	O
25	,	_	_	O
26	randomized	_	_	O
27	clinical	_	_	O
28	trial	_	_	O
29	,	_	_	O
30	an	_	_	O
31	intervention	_	_	O
32	that	_	_	O
33	significantly	_	_	O
34	impacts	_	_	O
35	physical	_	_	O
36	activity	_	_	O
37	in	_	_	O
38	these	_	_	O
39	patients	_	_	O
40	is	_	_	O
41	needed	_	_	O
42	.	_	_	O

43	The	_	_	O
44	Active	_	_	O
45	After	_	_	O
46	Cancer	_	_	O
47	Trial	_	_	O
48	(	_	_	O
49	AACT	_	_	O
50	)	_	_	O
51	was	_	_	O
52	a	_	_	O
53	multicenter	_	_	O
54	pilot	_	_	O
55	study	_	_	O
56	evaluating	_	_	O
57	the	_	_	O
58	feasibility	_	_	O
59	of	_	_	O
60	a	_	_	O
61	telephone	_	_	O
62	-	_	_	O
63	based	_	_	O
64	exercise	_	_	O
65	intervention	_	_	O
66	in	_	_	O
67	a	_	_	O
68	cooperative	_	_	O
69	group	_	_	O
70	setting	_	_	O
71	.	_	_	O

72	Sedentary	_	_	O
73	(	_	_	O
74	engaging	_	_	O
75	in	_	_	O
76	<	_	_	O
77	60	_	_	O
78	min	_	_	O
79	of	_	_	O
80	recreational	_	_	O
81	activity	_	_	O
82	/	_	_	O
83	week	_	_	O
84	)	_	_	O
85	breast	_	_	O
86	and	_	_	O
87	colorectal	_	_	O
88	cancer	_	_	O
89	survivors	_	_	O
90	were	_	_	O
91	randomized	_	_	O
92	to	_	_	O
93	a	_	_	O
94	telephone	_	_	O
95	-	_	_	O
96	based	_	_	O
97	exercise	_	_	O
98	intervention	_	_	O
99	or	_	_	O
100	usual	_	_	O
101	care	_	_	O
102	control	_	_	O
103	group	_	_	O
104	.	_	_	O

105	The	_	_	O
106	intervention	_	_	O
107	was	_	_	O
108	delivered	_	_	O
109	through	_	_	O
110	the	_	_	O
111	University	_	_	O
112	of	_	_	O
113	California	_	_	O
114	at	_	_	O
115	San	_	_	O
116	Diego	_	_	O
117	;	_	_	O
118	participants	_	_	O
119	received	_	_	O
120	ten	_	_	O
121	phone	_	_	O
122	calls	_	_	O
123	over	_	_	O
124	the	_	_	O
125	course	_	_	O
126	of	_	_	O
127	the	_	_	O
128	16	_	_	O
129	-	_	_	O
130	week	_	_	O
131	intervention	_	_	O
132	.	_	_	O

133	All	_	_	O
134	participants	_	_	O
135	underwent	_	_	O
136	assessment	_	_	O
137	of	_	_	O
138	physical	_	_	O
139	activity	_	_	O
140	,	_	_	O
141	fitness	_	_	O
142	,	_	_	O
143	physical	_	_	O
144	functioning	_	_	O
145	,	_	_	O
146	fatigue	_	_	O
147	and	_	_	O
148	exercise	_	_	O
149	self	_	_	O
150	-	_	_	O
151	efficacy	_	_	O
152	at	_	_	O
153	baseline	_	_	O
154	and	_	_	O
155	after	_	_	O
156	the	_	_	O
157	16	_	_	O
158	-	_	_	O
159	week	_	_	O
160	intervention	_	_	O
161	.	_	_	O

162	One	_	_	O
163	hundred	_	_	O
164	and	_	_	O
165	twenty	_	_	O
166	-	_	_	O
167	one	_	_	O
168	patients	_	_	O
169	were	_	_	O
170	enrolled	_	_	O
171	through	_	_	O
172	ten	_	_	O
173	Cancer	_	_	O
174	and	_	_	O
175	Leukemia	_	_	O
176	Group	_	_	O
177	B	_	_	O
178	(	_	_	O
179	CALGB	_	_	O
180	)	_	_	O
181	institutions	_	_	O
182	;	_	_	O
183	100	_	_	O
184	patients	_	_	O
185	had	_	_	O
186	breast	_	_	O
187	cancer	_	_	O
188	and	_	_	O
189	21	_	_	O
190	had	_	_	O
191	colorectal	_	_	O
192	cancer	_	_	O
193	.	_	_	O

194	Participants	_	_	B-Premise
195	randomized	_	_	I-Premise
196	to	_	_	I-Premise
197	the	_	_	I-Premise
198	exercise	_	_	I-Premise
199	group	_	_	I-Premise
200	increased	_	_	I-Premise
201	physical	_	_	I-Premise
202	activity	_	_	I-Premise
203	by	_	_	I-Premise
204	more	_	_	I-Premise
205	than	_	_	I-Premise
206	100	_	_	I-Premise
207	versus	_	_	I-Premise
208	22	_	_	I-Premise
209	%	_	_	I-Premise
210	in	_	_	I-Premise
211	controls	_	_	I-Premise
212	(	_	_	I-Premise
213	54	_	_	I-Premise
214	.	_	_	I-Premise

215	5	_	_	I-Premise
216	vs	_	_	I-Premise
217	.	_	_	I-Premise

218	14	_	_	I-Premise
219	.	_	_	I-Premise

220	6	_	_	I-Premise
221	min	_	_	I-Premise
222	,	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	0	_	_	I-Premise
226	.	_	_	I-Premise

227	13	_	_	I-Premise
228	)	_	_	I-Premise
229	,	_	_	I-Premise
230	and	_	_	I-Premise
231	experienced	_	_	I-Premise
232	significant	_	_	I-Premise
233	increases	_	_	I-Premise
234	in	_	_	I-Premise
235	fitness	_	_	I-Premise
236	(	_	_	I-Premise
237	increased	_	_	I-Premise
238	6	_	_	I-Premise
239	-	_	_	I-Premise
240	min	_	_	I-Premise
241	walk	_	_	I-Premise
242	test	_	_	I-Premise
243	distance	_	_	I-Premise
244	by	_	_	I-Premise
245	186	_	_	I-Premise
246	.	_	_	I-Premise

247	9	_	_	I-Premise
248	vs	_	_	I-Premise
249	.	_	_	I-Premise

250	81	_	_	I-Premise
251	.	_	_	I-Premise

252	9	_	_	I-Premise
253	feet	_	_	I-Premise
254	,	_	_	I-Premise
255	P	_	_	I-Premise
256	=	_	_	I-Premise
257	0	_	_	I-Premise
258	.	_	_	I-Premise

259	006	_	_	I-Premise
260	)	_	_	I-Premise
261	and	_	_	I-Premise
262	physical	_	_	I-Premise
263	functioning	_	_	I-Premise
264	(	_	_	I-Premise
265	7	_	_	I-Premise
266	.	_	_	I-Premise

267	1	_	_	I-Premise
268	vs	_	_	I-Premise
269	.	_	_	I-Premise

270	2	_	_	I-Premise
271	.	_	_	I-Premise

272	6	_	_	I-Premise
273	,	_	_	I-Premise
274	P	_	_	I-Premise
275	=	_	_	I-Premise
276	0	_	_	I-Premise
277	.	_	_	I-Premise

278	04	_	_	I-Premise
279	)	_	_	I-Premise
280	as	_	_	I-Premise
281	compared	_	_	I-Premise
282	to	_	_	I-Premise
283	the	_	_	I-Premise
284	control	_	_	I-Premise
285	group	_	_	I-Premise
286	.	_	_	I-Premise

287	Breast	_	_	B-Claim
288	and	_	_	I-Claim
289	colorectal	_	_	I-Claim
290	cancer	_	_	I-Claim
291	survivors	_	_	I-Claim
292	enrolled	_	_	I-Claim
293	in	_	_	I-Claim
294	a	_	_	I-Claim
295	multicenter	_	_	I-Claim
296	,	_	_	I-Claim
297	telephone	_	_	I-Claim
298	-	_	_	I-Claim
299	based	_	_	I-Claim
300	physical	_	_	I-Claim
301	activity	_	_	I-Claim
302	intervention	_	_	I-Claim
303	increased	_	_	I-Claim
304	physical	_	_	I-Claim
305	activity	_	_	I-Claim
306	and	_	_	I-Claim
307	experienced	_	_	I-Claim
308	significant	_	_	I-Claim
309	improvements	_	_	I-Claim
310	in	_	_	I-Claim
311	fitness	_	_	I-Claim
312	and	_	_	I-Claim
313	physical	_	_	I-Claim
314	functioning	_	_	I-Claim
315	.	_	_	I-Claim

316	Lifestyle	_	_	B-Claim
317	intervention	_	_	I-Claim
318	research	_	_	I-Claim
319	is	_	_	I-Claim
320	feasible	_	_	I-Claim
321	in	_	_	I-Claim
322	a	_	_	I-Claim
323	cooperative	_	_	I-Claim
324	group	_	_	I-Claim
325	setting	_	_	I-Claim
326	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	cannabis	_	_	O
6	extract	_	_	O
7	(	_	_	O
8	CE	_	_	O
9	)	_	_	O
10	,	_	_	O
11	delta	_	_	O
12	-	_	_	O
13	9	_	_	O
14	-	_	_	O
15	tetrahydrocannabinol	_	_	O
16	(	_	_	O
17	THC	_	_	O
18	)	_	_	O
19	,	_	_	O
20	and	_	_	O
21	placebo	_	_	O
22	(	_	_	O
23	PL	_	_	O
24	)	_	_	O
25	on	_	_	O
26	appetite	_	_	O
27	and	_	_	O
28	quality	_	_	O
29	of	_	_	O
30	life	_	_	O
31	(	_	_	O
32	QOL	_	_	O
33	)	_	_	O
34	in	_	_	O
35	patients	_	_	O
36	with	_	_	O
37	cancer	_	_	O
38	-	_	_	O
39	related	_	_	O
40	anorexia	_	_	O
41	-	_	_	O
42	cachexia	_	_	O
43	syndrome	_	_	O
44	(	_	_	O
45	CACS	_	_	O
46	)	_	_	O
47	.	_	_	O

48	Adult	_	_	O
49	patients	_	_	O
50	with	_	_	O
51	advanced	_	_	O
52	cancer	_	_	O
53	,	_	_	O
54	CACS	_	_	O
55	,	_	_	O
56	weight	_	_	O
57	loss	_	_	O
58	(	_	_	O
59	>	_	_	O
60	or	_	_	O
61	=	_	_	O
62	5	_	_	O
63	%	_	_	O
64	over	_	_	O
65	6	_	_	O
66	months	_	_	O
67	)	_	_	O
68	,	_	_	O
69	and	_	_	O
70	Eastern	_	_	O
71	Cooperative	_	_	O
72	Oncology	_	_	O
73	Group	_	_	O
74	(	_	_	O
75	ECOG	_	_	O
76	)	_	_	O
77	performance	_	_	O
78	status	_	_	O
79	(	_	_	O
80	PS	_	_	O
81	)	_	_	O
82	<	_	_	O
83	or	_	_	O
84	=	_	_	O
85	2	_	_	O
86	were	_	_	O
87	randomly	_	_	O
88	assigned	_	_	O
89	(	_	_	O
90	2	_	_	O
91	:	_	_	O
92	2	_	_	O
93	:	_	_	O
94	1	_	_	O
95	)	_	_	O
96	to	_	_	O
97	receive	_	_	O
98	CE	_	_	O
99	(	_	_	O
100	standardized	_	_	O
101	for	_	_	O
102	2	_	_	O
103	.	_	_	O

104	5	_	_	O
105	mg	_	_	O
106	THC	_	_	O
107	and	_	_	O
108	1	_	_	O
109	mg	_	_	O
110	cannabidiol	_	_	O
111	)	_	_	O
112	or	_	_	O
113	THC	_	_	O
114	(	_	_	O
115	2	_	_	O
116	.	_	_	O

117	5	_	_	O
118	mg	_	_	O
119	)	_	_	O
120	or	_	_	O
121	PL	_	_	O
122	orally	_	_	O
123	,	_	_	O
124	twice	_	_	O
125	daily	_	_	O
126	for	_	_	O
127	6	_	_	O
128	weeks	_	_	O
129	.	_	_	O

130	Appetite	_	_	O
131	,	_	_	O
132	mood	_	_	O
133	,	_	_	O
134	and	_	_	O
135	nausea	_	_	O
136	were	_	_	O
137	monitored	_	_	O
138	daily	_	_	O
139	with	_	_	O
140	a	_	_	O
141	visual	_	_	O
142	analog	_	_	O
143	scale	_	_	O
144	(	_	_	O
145	VAS	_	_	O
146	)	_	_	O
147	;	_	_	O
148	QOL	_	_	O
149	was	_	_	O
150	assessed	_	_	O
151	with	_	_	O
152	the	_	_	O
153	European	_	_	O
154	Organisation	_	_	O
155	for	_	_	O
156	Research	_	_	O
157	and	_	_	O
158	Treatment	_	_	O
159	of	_	_	O
160	Cancer	_	_	O
161	Quality	_	_	O
162	of	_	_	O
163	Life	_	_	O
164	Questionnaire	_	_	O
165	C30	_	_	O
166	(	_	_	O
167	composite	_	_	O
168	score	_	_	O
169	:	_	_	O
170	questions	_	_	O
171	29	_	_	O
172	and	_	_	O
173	30	_	_	O
174	)	_	_	O
175	.	_	_	O

176	Cannabinoid	_	_	O
177	-	_	_	O
178	related	_	_	O
179	toxicity	_	_	O
180	was	_	_	O
181	assessed	_	_	O
182	every	_	_	O
183	2	_	_	O
184	weeks	_	_	O
185	.	_	_	O

186	Of	_	_	O
187	289	_	_	O
188	patients	_	_	O
189	screened	_	_	O
190	,	_	_	O
191	243	_	_	O
192	were	_	_	O
193	randomly	_	_	O
194	assigned	_	_	O
195	and	_	_	O
196	164	_	_	O
197	(	_	_	O
198	CE	_	_	O
199	,	_	_	O
200	66	_	_	O
201	of	_	_	O
202	95	_	_	O
203	patients	_	_	O
204	;	_	_	O
205	THC	_	_	O
206	,	_	_	O
207	65	_	_	O
208	of	_	_	O
209	100	_	_	O
210	patients	_	_	O
211	;	_	_	O
212	and	_	_	O
213	PL	_	_	O
214	,	_	_	O
215	33	_	_	O
216	of	_	_	O
217	48	_	_	O
218	patients	_	_	O
219	)	_	_	O
220	completed	_	_	O
221	treatment	_	_	O
222	.	_	_	O

223	At	_	_	O
224	baseline	_	_	O
225	,	_	_	O
226	groups	_	_	O
227	were	_	_	O
228	comparable	_	_	O
229	for	_	_	O
230	age	_	_	O
231	(	_	_	O
232	mean	_	_	O
233	,	_	_	O
234	61	_	_	O
235	years	_	_	O
236	)	_	_	O
237	,	_	_	O
238	sex	_	_	O
239	(	_	_	O
240	54	_	_	O
241	%	_	_	O
242	men	_	_	O
243	)	_	_	O
244	,	_	_	O
245	weight	_	_	O
246	loss	_	_	O
247	(	_	_	O
248	32	_	_	O
249	%	_	_	O
250	>	_	_	O
251	or	_	_	O
252	=	_	_	O
253	10	_	_	O
254	%	_	_	O
255	)	_	_	O
256	,	_	_	O
257	PS	_	_	O
258	(	_	_	O
259	13	_	_	O
260	%	_	_	O
261	ECOG	_	_	O
262	=	_	_	O
263	2	_	_	O
264	)	_	_	O
265	,	_	_	O
266	antineoplastic	_	_	O
267	treatment	_	_	O
268	(	_	_	O
269	50	_	_	O
270	%	_	_	O
271	)	_	_	O
272	,	_	_	O
273	appetite	_	_	O
274	(	_	_	O
275	mean	_	_	O
276	VAS	_	_	O
277	score	_	_	O
278	,	_	_	O
279	31	_	_	O
280	/	_	_	O
281	100	_	_	O
282	mm	_	_	O
283	)	_	_	O
284	,	_	_	O
285	and	_	_	O
286	QOL	_	_	O
287	(	_	_	O
288	mean	_	_	O
289	score	_	_	O
290	,	_	_	O
291	30	_	_	O
292	/	_	_	O
293	100	_	_	O
294	)	_	_	O
295	.	_	_	O

296	Intent	_	_	B-Premise
297	-	_	_	I-Premise
298	to	_	_	I-Premise
299	-	_	_	I-Premise
300	treat	_	_	I-Premise
301	analysis	_	_	I-Premise
302	showed	_	_	I-Premise
303	no	_	_	I-Premise
304	significant	_	_	I-Premise
305	differences	_	_	I-Premise
306	between	_	_	I-Premise
307	the	_	_	I-Premise
308	three	_	_	I-Premise
309	arms	_	_	I-Premise
310	for	_	_	I-Premise
311	appetite	_	_	I-Premise
312	,	_	_	I-Premise
313	QOL	_	_	I-Premise
314	,	_	_	I-Premise
315	or	_	_	I-Premise
316	cannabinoid	_	_	I-Premise
317	-	_	_	I-Premise
318	related	_	_	I-Premise
319	toxicity	_	_	I-Premise
320	.	_	_	I-Premise

321	Increased	_	_	B-Premise
322	appetite	_	_	I-Premise
323	was	_	_	I-Premise
324	reported	_	_	I-Premise
325	by	_	_	I-Premise
326	73	_	_	I-Premise
327	%	_	_	I-Premise
328	,	_	_	I-Premise
329	58	_	_	I-Premise
330	%	_	_	I-Premise
331	,	_	_	I-Premise
332	and	_	_	I-Premise
333	69	_	_	I-Premise
334	%	_	_	I-Premise
335	of	_	_	I-Premise
336	patients	_	_	I-Premise
337	receiving	_	_	I-Premise
338	CE	_	_	I-Premise
339	,	_	_	I-Premise
340	THC	_	_	I-Premise
341	,	_	_	I-Premise
342	or	_	_	I-Premise
343	PL	_	_	I-Premise
344	,	_	_	I-Premise
345	respectively	_	_	I-Premise
346	.	_	_	I-Premise

347	An	_	_	O
348	independent	_	_	O
349	data	_	_	O
350	review	_	_	O
351	board	_	_	O
352	recommended	_	_	O
353	termination	_	_	O
354	of	_	_	O
355	recruitment	_	_	O
356	because	_	_	O
357	of	_	_	O
358	insufficient	_	_	O
359	differences	_	_	O
360	between	_	_	O
361	study	_	_	O
362	arms	_	_	O
363	.	_	_	O

364	CE	_	_	B-Premise
365	at	_	_	I-Premise
366	the	_	_	I-Premise
367	oral	_	_	I-Premise
368	dose	_	_	I-Premise
369	administered	_	_	I-Premise
370	was	_	_	I-Premise
371	well	_	_	I-Premise
372	tolerated	_	_	I-Premise
373	by	_	_	I-Premise
374	these	_	_	I-Premise
375	patients	_	_	I-Premise
376	with	_	_	I-Premise
377	CACS	_	_	I-Premise
378	.	_	_	I-Premise

379	No	_	_	B-Claim
380	differences	_	_	I-Claim
381	in	_	_	I-Claim
382	patients	_	_	I-Claim
383	'	_	_	I-Claim
384	appetite	_	_	I-Claim
385	or	_	_	I-Claim
386	QOL	_	_	I-Claim
387	were	_	_	I-Claim
388	found	_	_	I-Claim
389	either	_	_	I-Claim
390	between	_	_	I-Claim
391	CE	_	_	I-Claim
392	,	_	_	I-Claim
393	THC	_	_	I-Claim
394	,	_	_	I-Claim
395	and	_	_	I-Claim
396	PL	_	_	I-Claim
397	or	_	_	I-Claim
398	between	_	_	I-Claim
399	CE	_	_	I-Claim
400	and	_	_	I-Claim
401	THC	_	_	I-Claim
402	at	_	_	I-Claim
403	the	_	_	I-Claim
404	dosages	_	_	I-Claim
405	investigated	_	_	I-Claim
406	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	assess	_	_	O
8	efficacy	_	_	O
9	and	_	_	O
10	safety	_	_	O
11	of	_	_	O
12	association	_	_	O
13	of	_	_	O
14	duloxetine	_	_	O
15	and	_	_	O
16	rehabilitation	_	_	O
17	compared	_	_	O
18	with	_	_	O
19	rehabilitation	_	_	O
20	alone	_	_	O
21	in	_	_	O
22	men	_	_	O
23	with	_	_	O
24	SUI	_	_	O
25	after	_	_	O
26	radical	_	_	O
27	retropubic	_	_	O
28	prostatectomy	_	_	O
29	(	_	_	O
30	RRP	_	_	O
31	)	_	_	O
32	,	_	_	O
33	and	_	_	O
34	to	_	_	O
35	compare	_	_	O
36	continence	_	_	O
37	rate	_	_	O
38	even	_	_	O
39	after	_	_	O
40	planned	_	_	O
41	duloxetine	_	_	O
42	suspension	_	_	O
43	.	_	_	O

44	After	_	_	O
45	catheter	_	_	O
46	removal	_	_	O
47	,	_	_	O
48	112	_	_	O
49	patients	_	_	O
50	were	_	_	O
51	randomized	_	_	O
52	to	_	_	O
53	receive	_	_	O
54	rehabilitation	_	_	O
55	and	_	_	O
56	duloxetine	_	_	O
57	(	_	_	O
58	group	_	_	O
59	A	_	_	O
60	)	_	_	O
61	or	_	_	O
62	rehabilitation	_	_	O
63	alone	_	_	O
64	(	_	_	O
65	group	_	_	O
66	B	_	_	O
67	)	_	_	O
68	,	_	_	O
69	for	_	_	O
70	16	_	_	O
71	wk	_	_	O
72	.	_	_	O

73	postprostatectomy	_	_	O
74	SUI	_	_	O
75	with	_	_	O
76	daily	_	_	O
77	incontinent	_	_	O
78	episodes	_	_	O
79	frequency	_	_	O
80	(	_	_	O
81	IEF	_	_	O
82	)	_	_	O
83	of	_	_	O
84	four	_	_	O
85	or	_	_	O
86	greater	_	_	O
87	.	_	_	O

88	After	_	_	O
89	16	_	_	O
90	wk	_	_	O
91	both	_	_	O
92	groups	_	_	O
93	suspended	_	_	O
94	duloxetine	_	_	O
95	/	_	_	O
96	placebo	_	_	O
97	and	_	_	O
98	continued	_	_	O
99	rehabilitation	_	_	O
100	.	_	_	O

101	All	_	_	O
102	patients	_	_	O
103	completed	_	_	O
104	incontinence	_	_	O
105	quality	_	_	O
106	of	_	_	O
107	life	_	_	O
108	(	_	_	O
109	I	_	_	O
110	-	_	_	O
111	QoL	_	_	O
112	)	_	_	O
113	questionnaire	_	_	O
114	and	_	_	O
115	bladder	_	_	O
116	diary	_	_	O
117	.	_	_	O

118	Wilcoxon	_	_	O
119	test	_	_	O
120	was	_	_	O
121	used	_	_	O
122	to	_	_	O
123	analyse	_	_	O
124	changes	_	_	O
125	in	_	_	O
126	IEF	_	_	O
127	and	_	_	O
128	in	_	_	O
129	I	_	_	O
130	-	_	_	O
131	QoL	_	_	O
132	score	_	_	O
133	;	_	_	O
134	Fisher	_	_	O
135	exact	_	_	O
136	test	_	_	O
137	was	_	_	O
138	used	_	_	O
139	to	_	_	O
140	compare	_	_	O
141	continent	_	_	O
142	patients	_	_	O
143	between	_	_	O
144	the	_	_	O
145	groups	_	_	O
146	.	_	_	O

147	Adverse	_	_	O
148	events	_	_	O
149	for	_	_	O
150	duloxetine	_	_	O
151	was	_	_	O
152	15	_	_	O
153	.	_	_	O

154	2	_	_	O
155	%	_	_	O
156	.	_	_	O

157	102	_	_	O
158	men	_	_	O
159	completed	_	_	O
160	the	_	_	O
161	study	_	_	O
162	.	_	_	O

163	There	_	_	B-Premise
164	was	_	_	I-Premise
165	a	_	_	I-Premise
166	significant	_	_	I-Premise
167	decrease	_	_	I-Premise
168	in	_	_	I-Premise
169	pad	_	_	I-Premise
170	use	_	_	I-Premise
171	in	_	_	I-Premise
172	group	_	_	I-Premise
173	A	_	_	I-Premise
174	.	_	_	I-Premise

175	After	_	_	B-Premise
176	16	_	_	I-Premise
177	wk	_	_	I-Premise
178	,	_	_	I-Premise
179	39	_	_	I-Premise
180	patients	_	_	I-Premise
181	versus	_	_	I-Premise
182	27	_	_	I-Premise
183	were	_	_	I-Premise
184	dry	_	_	I-Premise
185	(	_	_	I-Premise
186	p	_	_	I-Premise
187	=	_	_	I-Premise
188	0	_	_	I-Premise
189	.	_	_	I-Premise

190	007	_	_	I-Premise
191	)	_	_	I-Premise
192	.	_	_	I-Premise

193	At	_	_	B-Premise
194	20	_	_	I-Premise
195	wk	_	_	I-Premise
196	,	_	_	I-Premise
197	4	_	_	I-Premise
198	wk	_	_	I-Premise
199	after	_	_	I-Premise
200	planned	_	_	I-Premise
201	interruption	_	_	I-Premise
202	of	_	_	I-Premise
203	duloxetine	_	_	I-Premise
204	,	_	_	I-Premise
205	we	_	_	I-Premise
206	observed	_	_	I-Premise
207	a	_	_	I-Premise
208	U	_	_	I-Premise
209	-	_	_	I-Premise
210	turn	_	_	I-Premise
211	,	_	_	I-Premise
212	23	_	_	I-Premise
213	patients	_	_	I-Premise
214	were	_	_	I-Premise
215	completely	_	_	I-Premise
216	dry	_	_	I-Premise
217	in	_	_	I-Premise
218	group	_	_	I-Premise
219	A	_	_	I-Premise
220	versus	_	_	I-Premise
221	38	_	_	I-Premise
222	in	_	_	I-Premise
223	group	_	_	I-Premise
224	B	_	_	I-Premise
225	(	_	_	I-Premise
226	p	_	_	I-Premise
227	=	_	_	I-Premise
228	0	_	_	I-Premise
229	.	_	_	I-Premise

230	008	_	_	I-Premise
231	)	_	_	I-Premise
232	.	_	_	I-Premise

233	Whereas	_	_	B-Premise
234	,	_	_	I-Premise
235	after	_	_	I-Premise
236	24	_	_	I-Premise
237	wk	_	_	I-Premise
238	,	_	_	I-Premise
239	31	_	_	I-Premise
240	in	_	_	I-Premise
241	group	_	_	I-Premise
242	A	_	_	I-Premise
243	versus	_	_	I-Premise
244	41	_	_	I-Premise
245	in	_	_	I-Premise
246	group	_	_	I-Premise
247	B	_	_	I-Premise
248	were	_	_	I-Premise
249	dry	_	_	I-Premise
250	(	_	_	I-Premise
251	p	_	_	I-Premise
252	=	_	_	I-Premise
253	0	_	_	I-Premise
254	.	_	_	I-Premise

255	08	_	_	I-Premise
256	)	_	_	I-Premise
257	.	_	_	O

258	The	_	_	B-Claim
259	decrease	_	_	I-Claim
260	in	_	_	I-Claim
261	IEF	_	_	I-Claim
262	and	_	_	I-Claim
263	improvements	_	_	I-Claim
264	in	_	_	I-Claim
265	I	_	_	I-Claim
266	-	_	_	I-Claim
267	QoL	_	_	I-Claim
268	scores	_	_	I-Claim
269	were	_	_	I-Claim
270	significantly	_	_	I-Claim
271	greater	_	_	I-Claim
272	in	_	_	I-Claim
273	group	_	_	I-Claim
274	A	_	_	I-Claim
275	for	_	_	I-Claim
276	the	_	_	I-Claim
277	first	_	_	I-Claim
278	16	_	_	I-Claim
279	wk	_	_	I-Claim
280	.	_	_	I-Claim

281	The	_	_	B-Claim
282	data	_	_	I-Claim
283	suggest	_	_	I-Claim
284	that	_	_	I-Claim
285	combination	_	_	I-Claim
286	therapy	_	_	I-Claim
287	might	_	_	I-Claim
288	provide	_	_	I-Claim
289	another	_	_	I-Claim
290	treatment	_	_	I-Claim
291	option	_	_	I-Claim
292	for	_	_	I-Claim
293	SUI	_	_	I-Claim
294	in	_	_	I-Claim
295	men	_	_	I-Claim
296	that	_	_	I-Claim
297	might	_	_	I-Claim
298	increase	_	_	I-Claim
299	the	_	_	I-Claim
300	percentage	_	_	I-Claim
301	of	_	_	I-Claim
302	early	_	_	I-Claim
303	postsurgery	_	_	I-Claim
304	continence	_	_	I-Claim
305	.	_	_	I-Claim


0	To	_	_	O
1	study	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	Fuzheng	_	_	O
6	Jianpi	_	_	O
7	Decoction	_	_	O
8	(	_	_	O
9	FJD	_	_	O
10	)	_	_	O
11	combined	_	_	O
12	chemotherapy	_	_	O
13	on	_	_	O
14	the	_	_	O
15	quality	_	_	O
16	of	_	_	O
17	life	_	_	O
18	(	_	_	O
19	QOL	_	_	O
20	)	_	_	O
21	and	_	_	O
22	the	_	_	O
23	survival	_	_	O
24	time	_	_	O
25	of	_	_	O
26	children	_	_	O
27	with	_	_	O
28	solid	_	_	O
29	tumor	_	_	O
30	.	_	_	O

31	Recruited	_	_	O
32	were	_	_	O
33	167	_	_	O
34	solid	_	_	O
35	tumor	_	_	O
36	children	_	_	O
37	patients	_	_	O
38	at	_	_	O
39	Department	_	_	O
40	of	_	_	O
41	Tumor	_	_	O
42	,	_	_	O
43	Beijing	_	_	O
44	Children	_	_	O
45	'	_	_	O
46	s	_	_	O
47	Hospital	_	_	O
48	.	_	_	O

49	They	_	_	O
50	were	_	_	O
51	randomly	_	_	O
52	assigned	_	_	O
53	to	_	_	O
54	the	_	_	O
55	treatment	_	_	O
56	group	_	_	O
57	(	_	_	O
58	83	_	_	O
59	cases	_	_	O
60	)	_	_	O
61	and	_	_	O
62	the	_	_	O
63	control	_	_	O
64	group	_	_	O
65	(	_	_	O
66	84	_	_	O
67	cases	_	_	O
68	)	_	_	O
69	according	_	_	O
70	to	_	_	O
71	the	_	_	O
72	random	_	_	O
73	digit	_	_	O
74	table	_	_	O
75	.	_	_	O

76	All	_	_	O
77	had	_	_	O
78	chemotherapy	_	_	O
79	.	_	_	O

80	Those	_	_	O
81	in	_	_	O
82	the	_	_	O
83	treatment	_	_	O
84	group	_	_	O
85	additionally	_	_	O
86	took	_	_	O
87	FJD	_	_	O
88	,	_	_	O
89	50	_	_	O
90	-	_	_	O
91	100	_	_	O
92	mL	_	_	O
93	each	_	_	O
94	time	_	_	O
95	,	_	_	O
96	twice	_	_	O
97	daily	_	_	O
98	.	_	_	O

99	After	_	_	O
100	chemotherapy	_	_	O
101	those	_	_	O
102	in	_	_	O
103	the	_	_	O
104	treatment	_	_	O
105	group	_	_	O
106	took	_	_	O
107	modified	_	_	O
108	FJD	_	_	O
109	.	_	_	O

110	The	_	_	O
111	WBC	_	_	O
112	,	_	_	O
113	Hb	_	_	O
114	,	_	_	O
115	and	_	_	O
116	PLT	_	_	O
117	were	_	_	O
118	detected	_	_	O
119	in	_	_	O
120	all	_	_	O
121	patients	_	_	O
122	before	_	_	O
123	treatment	_	_	O
124	,	_	_	O
125	6	_	_	O
126	months	_	_	O
127	after	_	_	O
128	treatment	_	_	O
129	,	_	_	O
130	and	_	_	O
131	1	_	_	O
132	year	_	_	O
133	after	_	_	O
134	treatment	_	_	O
135	.	_	_	O

136	The	_	_	O
137	1	_	_	O
138	-	_	_	O
139	,	_	_	O
140	2	_	_	O
141	-	_	_	O
142	,	_	_	O
143	and	_	_	O
144	3	_	_	O
145	-	_	_	O
146	year	_	_	O
147	QOL	_	_	O
148	,	_	_	O
149	3	_	_	O
150	-	_	_	O
151	year	_	_	O
152	survival	_	_	O
153	rate	_	_	O
154	,	_	_	O
155	and	_	_	O
156	the	_	_	O
157	survival	_	_	O
158	life	_	_	O
159	of	_	_	O
160	dead	_	_	O
161	children	_	_	O
162	patients	_	_	O
163	were	_	_	O
164	observed	_	_	O
165	.	_	_	O

166	Compared	_	_	B-Premise
167	with	_	_	I-Premise
168	the	_	_	I-Premise
169	control	_	_	I-Premise
170	group	_	_	I-Premise
171	of	_	_	I-Premise
172	the	_	_	I-Premise
173	same	_	_	I-Premise
174	period	_	_	I-Premise
175	,	_	_	I-Premise
176	the	_	_	I-Premise
177	6	_	_	I-Premise
178	-	_	_	I-Premise
179	month	_	_	I-Premise
180	and	_	_	I-Premise
181	1	_	_	I-Premise
182	-	_	_	I-Premise
183	year	_	_	I-Premise
184	WBC	_	_	I-Premise
185	and	_	_	I-Premise
186	Hb	_	_	I-Premise
187	increased	_	_	I-Premise
188	,	_	_	I-Premise
189	the	_	_	I-Premise
190	1	_	_	I-Premise
191	-	_	_	I-Premise
192	year	_	_	I-Premise
193	PLT	_	_	I-Premise
194	increased	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	treatment	_	_	I-Premise
198	group	_	_	I-Premise
199	,	_	_	I-Premise
200	showing	_	_	I-Premise
201	statistical	_	_	I-Premise
202	difference	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	<	_	_	I-Premise
206	0	_	_	I-Premise
207	.	_	_	I-Premise

208	05	_	_	I-Premise
209	,	_	_	I-Premise
210	P	_	_	I-Premise
211	<	_	_	I-Premise
212	0	_	_	I-Premise
213	.	_	_	I-Premise

214	01	_	_	I-Premise
215	)	_	_	I-Premise
216	.	_	_	I-Premise

217	Compared	_	_	B-Premise
218	with	_	_	I-Premise
219	1	_	_	I-Premise
220	-	_	_	I-Premise
221	year	_	_	I-Premise
222	treatment	_	_	I-Premise
223	in	_	_	I-Premise
224	the	_	_	I-Premise
225	treatment	_	_	I-Premise
226	group	_	_	I-Premise
227	,	_	_	I-Premise
228	the	_	_	I-Premise
229	2	_	_	I-Premise
230	-	_	_	I-Premise
231	and	_	_	I-Premise
232	3	_	_	I-Premise
233	-	_	_	I-Premise
234	year	_	_	I-Premise
235	psychological	_	_	I-Premise
236	functions	_	_	I-Premise
237	and	_	_	I-Premise
238	the	_	_	I-Premise
239	general	_	_	I-Premise
240	symptoms	_	_	I-Premise
241	scores	_	_	I-Premise
242	decreased	_	_	I-Premise
243	(	_	_	I-Premise
244	P	_	_	I-Premise
245	<	_	_	I-Premise
246	0	_	_	I-Premise
247	.	_	_	I-Premise

248	05	_	_	I-Premise
249	,	_	_	I-Premise
250	P	_	_	I-Premise
251	<	_	_	I-Premise
252	0	_	_	I-Premise
253	.	_	_	I-Premise

254	01	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	Compared	_	_	B-Premise
258	with	_	_	I-Premise
259	the	_	_	I-Premise
260	control	_	_	I-Premise
261	group	_	_	I-Premise
262	of	_	_	I-Premise
263	the	_	_	I-Premise
264	same	_	_	I-Premise
265	period	_	_	I-Premise
266	,	_	_	I-Premise
267	the	_	_	I-Premise
268	2	_	_	I-Premise
269	-	_	_	I-Premise
270	and	_	_	I-Premise
271	3	_	_	I-Premise
272	-	_	_	I-Premise
273	year	_	_	I-Premise
274	somatic	_	_	I-Premise
275	functions	_	_	I-Premise
276	,	_	_	I-Premise
277	psychological	_	_	I-Premise
278	functions	_	_	I-Premise
279	,	_	_	I-Premise
280	and	_	_	I-Premise
281	the	_	_	I-Premise
282	general	_	_	I-Premise
283	symptoms	_	_	I-Premise
284	scores	_	_	I-Premise
285	decreased	_	_	I-Premise
286	in	_	_	I-Premise
287	the	_	_	I-Premise
288	treatment	_	_	I-Premise
289	group	_	_	I-Premise
290	;	_	_	I-Premise
291	the	_	_	B-Premise
292	2	_	_	I-Premise
293	-	_	_	I-Premise
294	year	_	_	I-Premise
295	somatic	_	_	I-Premise
296	functions	_	_	I-Premise
297	and	_	_	I-Premise
298	psychological	_	_	I-Premise
299	functions	_	_	I-Premise
300	decreased	_	_	I-Premise
301	in	_	_	I-Premise
302	the	_	_	I-Premise
303	treatment	_	_	I-Premise
304	group	_	_	I-Premise
305	;	_	_	I-Premise
306	the	_	_	B-Premise
307	3	_	_	I-Premise
308	-	_	_	I-Premise
309	year	_	_	I-Premise
310	psychological	_	_	I-Premise
311	functions	_	_	I-Premise
312	and	_	_	I-Premise
313	the	_	_	I-Premise
314	general	_	_	I-Premise
315	symptoms	_	_	I-Premise
316	scores	_	_	I-Premise
317	decreased	_	_	I-Premise
318	in	_	_	I-Premise
319	the	_	_	I-Premise
320	treatment	_	_	I-Premise
321	group	_	_	I-Premise
322	,	_	_	I-Premise
323	all	_	_	I-Premise
324	with	_	_	I-Premise
325	statistical	_	_	I-Premise
326	difference	_	_	I-Premise
327	(	_	_	I-Premise
328	all	_	_	I-Premise
329	P	_	_	I-Premise
330	<	_	_	I-Premise
331	0	_	_	I-Premise
332	.	_	_	I-Premise

333	05	_	_	I-Premise
334	)	_	_	I-Premise
335	.	_	_	I-Premise

336	Compared	_	_	B-Premise
337	with	_	_	I-Premise
338	the	_	_	I-Premise
339	control	_	_	I-Premise
340	group	_	_	I-Premise
341	,	_	_	I-Premise
342	the	_	_	I-Premise
343	death	_	_	I-Premise
344	number	_	_	I-Premise
345	decreased	_	_	I-Premise
346	,	_	_	I-Premise
347	the	_	_	I-Premise
348	survival	_	_	I-Premise
349	rate	_	_	I-Premise
350	increased	_	_	I-Premise
351	,	_	_	I-Premise
352	the	_	_	I-Premise
353	life	_	_	I-Premise
354	span	_	_	I-Premise
355	of	_	_	I-Premise
356	dead	_	_	I-Premise
357	children	_	_	I-Premise
358	was	_	_	I-Premise
359	prolonged	_	_	I-Premise
360	in	_	_	I-Premise
361	the	_	_	I-Premise
362	treatment	_	_	I-Premise
363	group	_	_	I-Premise
364	,	_	_	I-Premise
365	showing	_	_	I-Premise
366	statistical	_	_	I-Premise
367	difference	_	_	I-Premise
368	(	_	_	I-Premise
369	P	_	_	I-Premise
370	<	_	_	I-Premise
371	0	_	_	I-Premise
372	.	_	_	I-Premise

373	05	_	_	I-Premise
374	)	_	_	I-Premise
375	.	_	_	I-Premise

376	FJD	_	_	B-Claim
377	combined	_	_	I-Claim
378	chemotherapy	_	_	I-Claim
379	could	_	_	I-Claim
380	effectively	_	_	I-Claim
381	improve	_	_	I-Claim
382	the	_	_	I-Claim
383	QOL	_	_	I-Claim
384	of	_	_	I-Claim
385	solid	_	_	I-Claim
386	tumor	_	_	I-Claim
387	children	_	_	I-Claim
388	patients	_	_	I-Claim
389	,	_	_	I-Claim
390	elevate	_	_	I-Claim
391	their	_	_	I-Claim
392	survival	_	_	I-Claim
393	rate	_	_	I-Claim
394	,	_	_	I-Claim
395	and	_	_	I-Claim
396	prolong	_	_	I-Claim
397	their	_	_	I-Claim
398	life	_	_	I-Claim
399	spans	_	_	I-Claim
400	.	_	_	I-Claim


0	We	_	_	O
1	aimed	_	_	O
2	at	_	_	O
3	investigating	_	_	O
4	the	_	_	O
5	efficacy	_	_	O
6	,	_	_	O
7	tolerability	_	_	O
8	,	_	_	O
9	and	_	_	O
10	quality	_	_	O
11	of	_	_	O
12	life	_	_	O
13	(	_	_	O
14	QOL	_	_	O
15	)	_	_	O
16	of	_	_	O
17	gemcitabine	_	_	O
18	(	_	_	O
19	GEM	_	_	O
20	)	_	_	O
21	compared	_	_	O
22	with	_	_	O
23	pegylated	_	_	O
24	liposomal	_	_	O
25	doxorubicin	_	_	O
26	(	_	_	O
27	PLD	_	_	O
28	)	_	_	O
29	in	_	_	O
30	the	_	_	O
31	salvage	_	_	O
32	treatment	_	_	O
33	of	_	_	O
34	recurrent	_	_	O
35	ovarian	_	_	O
36	cancer	_	_	O
37	.	_	_	O

38	A	_	_	O
39	phase	_	_	O
40	III	_	_	O
41	randomized	_	_	O
42	multicenter	_	_	O
43	trial	_	_	O
44	was	_	_	O
45	planned	_	_	O
46	to	_	_	O
47	compare	_	_	O
48	GEM	_	_	O
49	(	_	_	O
50	1	_	_	O
51	,	_	_	O
52	000	_	_	O
53	mg	_	_	O
54	/	_	_	O
55	m	_	_	O
56	(	_	_	O
57	2	_	_	O
58	)	_	_	O
59	on	_	_	O
60	days	_	_	O
61	1	_	_	O
62	,	_	_	O
63	8	_	_	O
64	,	_	_	O
65	and	_	_	O
66	15	_	_	O
67	every	_	_	O
68	28	_	_	O
69	days	_	_	O
70	)	_	_	O
71	with	_	_	O
72	PLD	_	_	O
73	(	_	_	O
74	40	_	_	O
75	mg	_	_	O
76	/	_	_	O
77	m	_	_	O
78	(	_	_	O
79	2	_	_	O
80	)	_	_	O
81	every	_	_	O
82	28	_	_	O
83	days	_	_	O
84	)	_	_	O
85	in	_	_	O
86	ovarian	_	_	O
87	cancer	_	_	O
88	patients	_	_	O
89	who	_	_	O
90	experienced	_	_	O
91	treatment	_	_	O
92	failure	_	_	O
93	with	_	_	O
94	only	_	_	O
95	one	_	_	O
96	platinum	_	_	O
97	/	_	_	O
98	paclitaxel	_	_	O
99	regimen	_	_	O
100	and	_	_	O
101	who	_	_	O
102	experienced	_	_	O
103	recurrence	_	_	O
104	or	_	_	O
105	progression	_	_	O
106	within	_	_	O
107	12	_	_	O
108	months	_	_	O
109	after	_	_	O
110	completion	_	_	O
111	of	_	_	O
112	primary	_	_	O
113	treatment	_	_	O
114	.	_	_	O

115	One	_	_	O
116	hundred	_	_	O
117	fifty	_	_	O
118	-	_	_	O
119	three	_	_	O
120	patients	_	_	O
121	were	_	_	O
122	randomly	_	_	O
123	assigned	_	_	O
124	to	_	_	O
125	PLD	_	_	O
126	(	_	_	O
127	n	_	_	O
128	=	_	_	O
129	76	_	_	O
130	)	_	_	O
131	or	_	_	O
132	GEM	_	_	O
133	(	_	_	O
134	n	_	_	O
135	=	_	_	O
136	77	_	_	O
137	)	_	_	O
138	.	_	_	O

139	Treatment	_	_	O
140	arms	_	_	O
141	were	_	_	O
142	well	_	_	O
143	balanced	_	_	O
144	for	_	_	O
145	clinicopathologic	_	_	O
146	characteristics	_	_	O
147	.	_	_	O

148	Grade	_	_	O
149	3	_	_	O
150	or	_	_	O
151	4	_	_	O
152	neutropenia	_	_	O
153	was	_	_	O
154	more	_	_	O
155	frequent	_	_	O
156	in	_	_	O
157	GEM	_	_	O
158	-	_	_	O
159	treated	_	_	O
160	patients	_	_	O
161	versus	_	_	O
162	PLD	_	_	O
163	-	_	_	O
164	treated	_	_	O
165	patients	_	_	O
166	(	_	_	O
167	P	_	_	O
168	=	_	_	O
169	.	_	_	O

170	007	_	_	O
171	)	_	_	O
172	.	_	_	O

173	Grade	_	_	O
174	3	_	_	O
175	or	_	_	O
176	4	_	_	O
177	palmar	_	_	O
178	-	_	_	O
179	plantar	_	_	O
180	erythrodysesthesia	_	_	O
181	was	_	_	O
182	documented	_	_	O
183	in	_	_	O
184	a	_	_	O
185	higher	_	_	O
186	proportion	_	_	O
187	of	_	_	O
188	PLD	_	_	O
189	patients	_	_	O
190	(	_	_	O
191	6	_	_	O
192	%	_	_	O
193	)	_	_	O
194	versus	_	_	O
195	GEM	_	_	O
196	patients	_	_	O
197	(	_	_	O
198	0	_	_	O
199	%	_	_	O
200	;	_	_	O
201	P	_	_	O
202	=	_	_	O
203	.	_	_	O

204	061	_	_	O
205	)	_	_	O
206	.	_	_	O

207	The	_	_	B-Premise
208	overall	_	_	I-Premise
209	response	_	_	I-Premise
210	rate	_	_	I-Premise
211	was	_	_	I-Premise
212	16	_	_	I-Premise
213	%	_	_	I-Premise
214	in	_	_	I-Premise
215	the	_	_	I-Premise
216	PLD	_	_	I-Premise
217	arm	_	_	I-Premise
218	compared	_	_	I-Premise
219	with	_	_	I-Premise
220	29	_	_	I-Premise
221	%	_	_	I-Premise
222	in	_	_	I-Premise
223	the	_	_	I-Premise
224	GEM	_	_	I-Premise
225	arm	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	.	_	_	I-Premise

230	056	_	_	I-Premise
231	)	_	_	I-Premise
232	.	_	_	I-Premise

233	No	_	_	B-Premise
234	statistically	_	_	I-Premise
235	significant	_	_	I-Premise
236	difference	_	_	I-Premise
237	in	_	_	I-Premise
238	time	_	_	I-Premise
239	to	_	_	I-Premise
240	progression	_	_	I-Premise
241	(	_	_	I-Premise
242	TTP	_	_	I-Premise
243	)	_	_	I-Premise
244	curves	_	_	I-Premise
245	according	_	_	I-Premise
246	to	_	_	I-Premise
247	treatment	_	_	I-Premise
248	allocation	_	_	I-Premise
249	was	_	_	I-Premise
250	documented	_	_	I-Premise
251	(	_	_	I-Premise
252	P	_	_	I-Premise
253	=	_	_	I-Premise
254	.	_	_	I-Premise

255	411	_	_	I-Premise
256	)	_	_	I-Premise
257	.	_	_	I-Premise

258	However	_	_	B-Premise
259	,	_	_	I-Premise
260	a	_	_	I-Premise
261	trend	_	_	I-Premise
262	for	_	_	I-Premise
263	more	_	_	I-Premise
264	favorable	_	_	I-Premise
265	overall	_	_	I-Premise
266	survival	_	_	I-Premise
267	was	_	_	I-Premise
268	documented	_	_	I-Premise
269	in	_	_	I-Premise
270	the	_	_	I-Premise
271	PLD	_	_	I-Premise
272	arm	_	_	I-Premise
273	compared	_	_	I-Premise
274	with	_	_	I-Premise
275	the	_	_	I-Premise
276	GEM	_	_	I-Premise
277	arm	_	_	I-Premise
278	,	_	_	I-Premise
279	although	_	_	B-Premise
280	the	_	_	I-Premise
281	P	_	_	I-Premise
282	value	_	_	I-Premise
283	was	_	_	I-Premise
284	of	_	_	I-Premise
285	borderline	_	_	I-Premise
286	statistical	_	_	I-Premise
287	significance	_	_	I-Premise
288	(	_	_	I-Premise
289	P	_	_	I-Premise
290	=	_	_	I-Premise
291	.	_	_	I-Premise

292	048	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	Statistically	_	_	B-Premise
296	significantly	_	_	I-Premise
297	higher	_	_	I-Premise
298	global	_	_	I-Premise
299	QOL	_	_	I-Premise
300	scores	_	_	I-Premise
301	were	_	_	I-Premise
302	found	_	_	I-Premise
303	in	_	_	I-Premise
304	PLD	_	_	I-Premise
305	-	_	_	I-Premise
306	treated	_	_	I-Premise
307	patients	_	_	I-Premise
308	at	_	_	I-Premise
309	the	_	_	I-Premise
310	first	_	_	I-Premise
311	and	_	_	I-Premise
312	second	_	_	I-Premise
313	postbaseline	_	_	I-Premise
314	QOL	_	_	I-Premise
315	assessments	_	_	I-Premise
316	.	_	_	I-Premise

317	GEM	_	_	B-Claim
318	does	_	_	I-Claim
319	not	_	_	I-Claim
320	provide	_	_	I-Claim
321	an	_	_	I-Claim
322	advantage	_	_	I-Claim
323	compared	_	_	I-Claim
324	with	_	_	I-Claim
325	PLD	_	_	I-Claim
326	in	_	_	I-Claim
327	terms	_	_	I-Claim
328	of	_	_	I-Claim
329	TTP	_	_	I-Claim
330	in	_	_	I-Claim
331	ovarian	_	_	I-Claim
332	cancer	_	_	I-Claim
333	patients	_	_	I-Claim
334	who	_	_	I-Claim
335	experience	_	_	I-Claim
336	recurrence	_	_	I-Claim
337	within	_	_	I-Claim
338	12	_	_	I-Claim
339	months	_	_	I-Claim
340	after	_	_	I-Claim
341	primary	_	_	I-Claim
342	treatment	_	_	I-Claim
343	but	_	_	I-Claim
344	should	_	_	I-Claim
345	be	_	_	I-Claim
346	considered	_	_	I-Claim
347	in	_	_	I-Claim
348	the	_	_	I-Claim
349	spectrum	_	_	I-Claim
350	of	_	_	I-Claim
351	drugs	_	_	I-Claim
352	to	_	_	I-Claim
353	be	_	_	I-Claim
354	possibly	_	_	I-Claim
355	used	_	_	I-Claim
356	in	_	_	I-Claim
357	the	_	_	I-Claim
358	salvage	_	_	I-Claim
359	setting	_	_	I-Claim
360	.	_	_	I-Claim


0	We	_	_	O
1	investigated	_	_	O
2	the	_	_	O
3	role	_	_	O
4	of	_	_	O
5	tamoxifen	_	_	O
6	and	_	_	O
7	radiotherapy	_	_	O
8	(	_	_	O
9	RT	_	_	O
10	)	_	_	O
11	for	_	_	O
12	the	_	_	O
13	prevention	_	_	O
14	and	_	_	O
15	treatment	_	_	O
16	of	_	_	O
17	gynecomastia	_	_	O
18	and	_	_	O
19	breast	_	_	O
20	pain	_	_	O
21	during	_	_	O
22	adjuvant	_	_	O
23	bicalutamide	_	_	O
24	monotherapy	_	_	O
25	after	_	_	O
26	radical	_	_	O
27	prostatectomy	_	_	O
28	(	_	_	O
29	RP	_	_	O
30	)	_	_	O
31	in	_	_	O
32	patients	_	_	O
33	with	_	_	O
34	prostate	_	_	O
35	cancer	_	_	O
36	.	_	_	O

37	Also	_	_	O
38	,	_	_	O
39	we	_	_	O
40	evaluated	_	_	O
41	their	_	_	O
42	effects	_	_	O
43	on	_	_	O
44	patient	_	_	O
45	hormonal	_	_	O
46	status	_	_	O
47	,	_	_	O
48	quality	_	_	O
49	of	_	_	O
50	life	_	_	O
51	(	_	_	O
52	QOL	_	_	O
53	)	_	_	O
54	,	_	_	O
55	sexual	_	_	O
56	function	_	_	O
57	and	_	_	O
58	prostate	_	_	O
59	specific	_	_	O
60	antigen	_	_	O
61	relapse	_	_	O
62	-	_	_	O
63	free	_	_	O
64	survival	_	_	O
65	.	_	_	O

66	This	_	_	O
67	was	_	_	O
68	a	_	_	O
69	multicenter	_	_	O
70	prospective	_	_	O
71	trial	_	_	O
72	.	_	_	O

73	From	_	_	O
74	January	_	_	O
75	2002	_	_	O
76	to	_	_	O
77	February	_	_	O
78	2004	_	_	O
79	,	_	_	O
80	102	_	_	O
81	patients	_	_	O
82	who	_	_	O
83	had	_	_	O
84	undergone	_	_	O
85	RP	_	_	O
86	for	_	_	O
87	localized	_	_	O
88	or	_	_	O
89	locally	_	_	O
90	advanced	_	_	O
91	prostate	_	_	O
92	cancer	_	_	O
93	were	_	_	O
94	recruited	_	_	O
95	and	_	_	O
96	randomized	_	_	O
97	into	_	_	O
98	3	_	_	O
99	groups	_	_	O
100	,	_	_	O
101	namely	_	_	O
102	group	_	_	O
103	1	_	_	O
104	-	_	_	O
105	those	_	_	O
106	receiving	_	_	O
107	only	_	_	O
108	150	_	_	O
109	mg	_	_	O
110	bicalutamide	_	_	O
111	as	_	_	O
112	adjuvant	_	_	O
113	hormonal	_	_	O
114	therapy	_	_	O
115	,	_	_	O
116	group	_	_	O
117	2	_	_	O
118	-	_	_	O
119	those	_	_	O
120	receiving	_	_	O
121	bicalutamide	_	_	O
122	and	_	_	O
123	10	_	_	O
124	mg	_	_	O
125	tamoxifen	_	_	O
126	,	_	_	O
127	and	_	_	O
128	group	_	_	O
129	3	_	_	O
130	-	_	_	O
131	those	_	_	O
132	receiving	_	_	O
133	bicalutamide	_	_	O
134	and	_	_	O
135	RT	_	_	O
136	.	_	_	O

137	Patients	_	_	O
138	in	_	_	O
139	group	_	_	O
140	1	_	_	O
141	in	_	_	O
142	whom	_	_	O
143	gynecomastia	_	_	O
144	or	_	_	O
145	breast	_	_	O
146	pain	_	_	O
147	developed	_	_	O
148	were	_	_	O
149	subsequently	_	_	O
150	randomized	_	_	O
151	to	_	_	O
152	receive	_	_	O
153	tamoxifen	_	_	O
154	or	_	_	O
155	RT	_	_	O
156	soon	_	_	O
157	after	_	_	O
158	symptoms	_	_	O
159	started	_	_	O
160	.	_	_	O

161	Gynecomastia	_	_	O
162	,	_	_	O
163	breast	_	_	O
164	pain	_	_	O
165	,	_	_	O
166	prostate	_	_	O
167	specific	_	_	O
168	antigen	_	_	O
169	,	_	_	O
170	QOL	_	_	O
171	,	_	_	O
172	sexual	_	_	O
173	function	_	_	O
174	and	_	_	O
175	hormonal	_	_	O
176	levels	_	_	O
177	were	_	_	O
178	assessed	_	_	O
179	.	_	_	O

180	Minimum	_	_	O
181	followup	_	_	O
182	was	_	_	O
183	12	_	_	O
184	months	_	_	O
185	.	_	_	O

186	Of	_	_	B-Premise
187	group	_	_	I-Premise
188	1	_	_	I-Premise
189	patients	_	_	I-Premise
190	67	_	_	I-Premise
191	%	_	_	I-Premise
192	had	_	_	I-Premise
193	gynecomastia	_	_	I-Premise
194	compared	_	_	I-Premise
195	with	_	_	I-Premise
196	8	_	_	I-Premise
197	%	_	_	I-Premise
198	in	_	_	I-Premise
199	group	_	_	I-Premise
200	2	_	_	I-Premise
201	and	_	_	I-Premise
202	34	_	_	I-Premise
203	%	_	_	I-Premise
204	in	_	_	I-Premise
205	group	_	_	I-Premise
206	3	_	_	I-Premise
207	.	_	_	I-Premise

208	Breast	_	_	B-Premise
209	pain	_	_	I-Premise
210	was	_	_	I-Premise
211	more	_	_	I-Premise
212	frequent	_	_	I-Premise
213	in	_	_	I-Premise
214	group	_	_	I-Premise
215	1	_	_	I-Premise
216	than	_	_	I-Premise
217	in	_	_	I-Premise
218	groups	_	_	I-Premise
219	2	_	_	I-Premise
220	and	_	_	I-Premise
221	3	_	_	I-Premise
222	(	_	_	I-Premise
223	58	_	_	I-Premise
224	%	_	_	I-Premise
225	vs	_	_	I-Premise
226	7	_	_	I-Premise
227	%	_	_	I-Premise
228	and	_	_	I-Premise
229	30	_	_	I-Premise
230	%	_	_	I-Premise
231	,	_	_	I-Premise
232	respectively	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	Differences	_	_	B-Premise
236	were	_	_	I-Premise
237	significant	_	_	I-Premise
238	between	_	_	I-Premise
239	groups	_	_	I-Premise
240	1	_	_	I-Premise
241	and	_	_	I-Premise
242	2	_	_	I-Premise
243	(	_	_	I-Premise
244	OR	_	_	I-Premise
245	0	_	_	I-Premise
246	.	_	_	I-Premise

247	12	_	_	I-Premise
248	p	_	_	I-Premise
249	<	_	_	I-Premise
250	0	_	_	I-Premise
251	.	_	_	I-Premise

252	001	_	_	I-Premise
253	)	_	_	I-Premise
254	,	_	_	I-Premise
255	and	_	_	I-Premise
256	groups	_	_	I-Premise
257	1	_	_	I-Premise
258	and	_	_	I-Premise
259	3	_	_	I-Premise
260	(	_	_	I-Premise
261	OR	_	_	I-Premise
262	0	_	_	I-Premise
263	.	_	_	I-Premise

264	52	_	_	I-Premise
265	p	_	_	I-Premise
266	<	_	_	I-Premise
267	0	_	_	I-Premise
268	.	_	_	I-Premise

269	01	_	_	I-Premise
270	)	_	_	I-Premise
271	.	_	_	I-Premise

272	In	_	_	B-Premise
273	patients	_	_	I-Premise
274	in	_	_	I-Premise
275	group	_	_	I-Premise
276	1	_	_	I-Premise
277	who	_	_	I-Premise
278	had	_	_	I-Premise
279	gynecomastia	_	_	I-Premise
280	or	_	_	I-Premise
281	breast	_	_	I-Premise
282	pain	_	_	I-Premise
283	a	_	_	I-Premise
284	significant	_	_	I-Premise
285	decrease	_	_	I-Premise
286	in	_	_	I-Premise
287	symptoms	_	_	I-Premise
288	was	_	_	I-Premise
289	achieved	_	_	I-Premise
290	in	_	_	I-Premise
291	those	_	_	I-Premise
292	receiving	_	_	I-Premise
293	tamoxifen	_	_	I-Premise
294	(	_	_	I-Premise
295	p	_	_	I-Premise
296	<	_	_	I-Premise
297	0	_	_	I-Premise
298	.	_	_	I-Premise

299	05	_	_	I-Premise
300	)	_	_	I-Premise
301	.	_	_	I-Premise

302	Treatments	_	_	B-Premise
303	were	_	_	I-Premise
304	well	_	_	I-Premise
305	tolerated	_	_	I-Premise
306	in	_	_	I-Premise
307	the	_	_	I-Premise
308	3	_	_	I-Premise
309	groups	_	_	I-Premise
310	.	_	_	I-Premise

311	No	_	_	B-Premise
312	differences	_	_	I-Premise
313	in	_	_	I-Premise
314	QOL	_	_	I-Premise
315	between	_	_	I-Premise
316	groups	_	_	I-Premise
317	2	_	_	I-Premise
318	and	_	_	I-Premise
319	3	_	_	I-Premise
320	were	_	_	I-Premise
321	found	_	_	I-Premise
322	.	_	_	I-Premise

323	At	_	_	B-Premise
324	a	_	_	I-Premise
325	median	_	_	I-Premise
326	followup	_	_	I-Premise
327	of	_	_	I-Premise
328	26	_	_	I-Premise
329	months	_	_	I-Premise
330	we	_	_	I-Premise
331	observed	_	_	I-Premise
332	12	_	_	I-Premise
333	biochemical	_	_	I-Premise
334	relapses	_	_	I-Premise
335	.	_	_	I-Premise

336	Gynecomastia	_	_	B-Claim
337	and	_	_	I-Claim
338	breast	_	_	I-Claim
339	pain	_	_	I-Claim
340	induced	_	_	I-Claim
341	by	_	_	I-Claim
342	bicalutamide	_	_	I-Claim
343	monotherapy	_	_	I-Claim
344	after	_	_	I-Claim
345	RP	_	_	I-Claim
346	can	_	_	I-Claim
347	be	_	_	I-Claim
348	prevented	_	_	I-Claim
349	and	_	_	I-Claim
350	treated	_	_	I-Claim
351	.	_	_	I-Claim

352	Tamoxifen	_	_	B-Claim
353	has	_	_	I-Claim
354	been	_	_	I-Claim
355	shown	_	_	I-Claim
356	to	_	_	I-Claim
357	be	_	_	I-Claim
358	more	_	_	I-Claim
359	effective	_	_	I-Claim
360	and	_	_	I-Claim
361	safe	_	_	I-Claim
362	than	_	_	I-Claim
363	RT	_	_	I-Claim
364	in	_	_	I-Claim
365	this	_	_	I-Claim
366	setting	_	_	I-Claim
367	.	_	_	I-Claim

368	QOL	_	_	B-Claim
369	and	_	_	I-Claim
370	sexual	_	_	I-Claim
371	function	_	_	I-Claim
372	are	_	_	I-Claim
373	not	_	_	I-Claim
374	negatively	_	_	I-Claim
375	influenced	_	_	I-Claim
376	by	_	_	I-Claim
377	these	_	_	I-Claim
378	2	_	_	I-Claim
379	treatment	_	_	I-Claim
380	options	_	_	I-Claim
381	.	_	_	O


0	Treatment	_	_	B-Claim
1	with	_	_	I-Claim
2	cisplatin	_	_	I-Claim
3	-	_	_	I-Claim
4	based	_	_	I-Claim
5	chemotherapy	_	_	I-Claim
6	provides	_	_	I-Claim
7	a	_	_	I-Claim
8	modest	_	_	I-Claim
9	survival	_	_	I-Claim
10	advantage	_	_	I-Claim
11	over	_	_	I-Claim
12	supportive	_	_	I-Claim
13	care	_	_	I-Claim
14	alone	_	_	I-Claim
15	in	_	_	I-Claim
16	advanced	_	_	I-Claim
17	non	_	_	I-Claim
18	-	_	_	I-Claim
19	small	_	_	I-Claim
20	-	_	_	I-Claim
21	cell	_	_	I-Claim
22	lung	_	_	I-Claim
23	cancer	_	_	I-Claim
24	(	_	_	I-Claim
25	NSCLC	_	_	I-Claim
26	)	_	_	I-Claim
27	.	_	_	I-Claim

28	To	_	_	O
29	determine	_	_	O
30	whether	_	_	O
31	a	_	_	O
32	new	_	_	O
33	agent	_	_	O
34	,	_	_	O
35	paclitaxel	_	_	O
36	,	_	_	O
37	would	_	_	O
38	further	_	_	O
39	improve	_	_	O
40	survival	_	_	O
41	in	_	_	O
42	NSCLC	_	_	O
43	,	_	_	O
44	the	_	_	O
45	Eastern	_	_	O
46	Cooperative	_	_	O
47	Oncology	_	_	O
48	Group	_	_	O
49	conducted	_	_	O
50	a	_	_	O
51	randomized	_	_	O
52	trial	_	_	O
53	comparing	_	_	O
54	paclitaxel	_	_	O
55	plus	_	_	O
56	cisplatin	_	_	O
57	to	_	_	O
58	a	_	_	O
59	standard	_	_	O
60	chemotherapy	_	_	O
61	regimen	_	_	O
62	consisting	_	_	O
63	of	_	_	O
64	cisplatin	_	_	O
65	and	_	_	O
66	etoposide	_	_	O
67	.	_	_	O

68	The	_	_	O
69	study	_	_	O
70	was	_	_	O
71	carried	_	_	O
72	out	_	_	O
73	by	_	_	O
74	a	_	_	O
75	multi	_	_	O
76	-	_	_	O
77	institutional	_	_	O
78	cooperative	_	_	O
79	group	_	_	O
80	in	_	_	O
81	chemotherapy	_	_	O
82	-	_	_	O
83	naive	_	_	O
84	stage	_	_	O
85	IIIB	_	_	O
86	to	_	_	O
87	IV	_	_	O
88	NSCLC	_	_	O
89	patients	_	_	O
90	randomized	_	_	O
91	to	_	_	O
92	receive	_	_	O
93	paclitaxel	_	_	O
94	plus	_	_	O
95	cisplatin	_	_	O
96	or	_	_	O
97	etoposide	_	_	O
98	plus	_	_	O
99	cisplatin	_	_	O
100	.	_	_	O

101	Paclitaxel	_	_	O
102	was	_	_	O
103	administered	_	_	O
104	at	_	_	O
105	two	_	_	O
106	different	_	_	O
107	dose	_	_	O
108	levels	_	_	O
109	(	_	_	O
110	135	_	_	O
111	mg	_	_	O
112	/	_	_	O
113	m	_	_	O
114	(	_	_	O
115	2	_	_	O
116	)	_	_	O
117	and	_	_	O
118	250	_	_	O
119	mg	_	_	O
120	/	_	_	O
121	m	_	_	O
122	(	_	_	O
123	2	_	_	O
124	)	_	_	O
125	)	_	_	O
126	,	_	_	O
127	and	_	_	O
128	etoposide	_	_	O
129	was	_	_	O
130	given	_	_	O
131	at	_	_	O
132	a	_	_	O
133	dose	_	_	O
134	of	_	_	O
135	100	_	_	O
136	mg	_	_	O
137	/	_	_	O
138	m	_	_	O
139	(	_	_	O
140	2	_	_	O
141	)	_	_	O
142	daily	_	_	O
143	on	_	_	O
144	days	_	_	O
145	1	_	_	O
146	to	_	_	O
147	3	_	_	O
148	.	_	_	O

149	Each	_	_	O
150	regimen	_	_	O
151	was	_	_	O
152	repeated	_	_	O
153	every	_	_	O
154	21	_	_	O
155	days	_	_	O
156	and	_	_	O
157	each	_	_	O
158	included	_	_	O
159	cisplatin	_	_	O
160	(	_	_	O
161	75	_	_	O
162	mg	_	_	O
163	/	_	_	O
164	m	_	_	O
165	(	_	_	O
166	2	_	_	O
167	)	_	_	O
168	)	_	_	O
169	.	_	_	O

170	The	_	_	O
171	characteristics	_	_	O
172	of	_	_	O
173	the	_	_	O
174	599	_	_	O
175	patients	_	_	O
176	were	_	_	O
177	well	_	_	O
178	-	_	_	O
179	balanced	_	_	O
180	across	_	_	O
181	the	_	_	O
182	three	_	_	O
183	treatment	_	_	O
184	groups	_	_	O
185	.	_	_	O

186	Superior	_	_	B-Premise
187	survival	_	_	I-Premise
188	was	_	_	I-Premise
189	observed	_	_	I-Premise
190	with	_	_	I-Premise
191	the	_	_	I-Premise
192	combined	_	_	I-Premise
193	paclitaxel	_	_	I-Premise
194	regimens	_	_	I-Premise
195	(	_	_	I-Premise
196	median	_	_	I-Premise
197	survival	_	_	I-Premise
198	time	_	_	I-Premise
199	,	_	_	I-Premise
200	9	_	_	I-Premise
201	.	_	_	I-Premise

202	9	_	_	I-Premise
203	months	_	_	I-Premise
204	;	_	_	I-Premise
205	1	_	_	I-Premise
206	-	_	_	I-Premise
207	year	_	_	I-Premise
208	survival	_	_	I-Premise
209	rate	_	_	I-Premise
210	,	_	_	I-Premise
211	38	_	_	I-Premise
212	.	_	_	I-Premise

213	9	_	_	I-Premise
214	%	_	_	I-Premise
215	)	_	_	I-Premise
216	compared	_	_	I-Premise
217	with	_	_	I-Premise
218	etoposide	_	_	I-Premise
219	plus	_	_	I-Premise
220	cisplatin	_	_	I-Premise
221	(	_	_	I-Premise
222	median	_	_	I-Premise
223	survival	_	_	I-Premise
224	time	_	_	I-Premise
225	,	_	_	I-Premise
226	7	_	_	I-Premise
227	.	_	_	I-Premise

228	6	_	_	I-Premise
229	months	_	_	I-Premise
230	;	_	_	I-Premise
231	1	_	_	I-Premise
232	-	_	_	I-Premise
233	year	_	_	I-Premise
234	survival	_	_	I-Premise
235	rate	_	_	I-Premise
236	,	_	_	I-Premise
237	31	_	_	I-Premise
238	.	_	_	I-Premise

239	8	_	_	I-Premise
240	%	_	_	I-Premise
241	;	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	.	_	_	I-Premise

245	048	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	Comparing	_	_	B-Premise
249	survival	_	_	I-Premise
250	for	_	_	I-Premise
251	the	_	_	I-Premise
252	two	_	_	I-Premise
253	dose	_	_	I-Premise
254	levels	_	_	I-Premise
255	of	_	_	I-Premise
256	paclitaxel	_	_	I-Premise
257	revealed	_	_	I-Premise
258	no	_	_	I-Premise
259	significant	_	_	I-Premise
260	difference	_	_	I-Premise
261	.	_	_	I-Premise

262	The	_	_	B-Premise
263	median	_	_	I-Premise
264	survival	_	_	I-Premise
265	duration	_	_	I-Premise
266	for	_	_	I-Premise
267	the	_	_	I-Premise
268	stage	_	_	I-Premise
269	IIIB	_	_	I-Premise
270	subgroup	_	_	I-Premise
271	was	_	_	I-Premise
272	7	_	_	I-Premise
273	.	_	_	I-Premise

274	9	_	_	I-Premise
275	months	_	_	I-Premise
276	for	_	_	I-Premise
277	etoposide	_	_	I-Premise
278	plus	_	_	I-Premise
279	cisplatin	_	_	I-Premise
280	patients	_	_	I-Premise
281	versus	_	_	I-Premise
282	13	_	_	I-Premise
283	.	_	_	I-Premise

284	1	_	_	I-Premise
285	months	_	_	I-Premise
286	for	_	_	I-Premise
287	all	_	_	I-Premise
288	paclitaxel	_	_	I-Premise
289	patients	_	_	I-Premise
290	(	_	_	I-Premise
291	P	_	_	I-Premise
292	=	_	_	I-Premise
293	.	_	_	I-Premise

294	152	_	_	I-Premise
295	)	_	_	I-Premise
296	.	_	_	I-Premise

297	For	_	_	B-Premise
298	the	_	_	I-Premise
299	stage	_	_	I-Premise
300	IV	_	_	I-Premise
301	subgroup	_	_	I-Premise
302	,	_	_	I-Premise
303	the	_	_	I-Premise
304	median	_	_	I-Premise
305	survival	_	_	I-Premise
306	time	_	_	I-Premise
307	for	_	_	I-Premise
308	etoposide	_	_	I-Premise
309	plus	_	_	I-Premise
310	cisplatin	_	_	I-Premise
311	was	_	_	I-Premise
312	7	_	_	I-Premise
313	.	_	_	I-Premise

314	6	_	_	I-Premise
315	months	_	_	I-Premise
316	compared	_	_	I-Premise
317	with	_	_	I-Premise
318	8	_	_	I-Premise
319	.	_	_	I-Premise

320	9	_	_	I-Premise
321	months	_	_	I-Premise
322	for	_	_	I-Premise
323	paclitaxel	_	_	I-Premise
324	(	_	_	I-Premise
325	P	_	_	I-Premise
326	=	_	_	I-Premise
327	.	_	_	I-Premise

328	246	_	_	I-Premise
329	)	_	_	I-Premise
330	.	_	_	I-Premise

331	With	_	_	B-Premise
332	the	_	_	I-Premise
333	exceptions	_	_	I-Premise
334	of	_	_	I-Premise
335	increased	_	_	I-Premise
336	granulocytopenia	_	_	I-Premise
337	on	_	_	I-Premise
338	the	_	_	I-Premise
339	low	_	_	I-Premise
340	-	_	_	I-Premise
341	dose	_	_	I-Premise
342	paclitaxel	_	_	I-Premise
343	regimen	_	_	I-Premise
344	and	_	_	I-Premise
345	increased	_	_	I-Premise
346	myalgias	_	_	I-Premise
347	,	_	_	I-Premise
348	neurotoxicity	_	_	I-Premise
349	,	_	_	I-Premise
350	and	_	_	I-Premise
351	,	_	_	I-Premise
352	possibly	_	_	I-Premise
353	,	_	_	I-Premise
354	increased	_	_	I-Premise
355	treatment	_	_	I-Premise
356	-	_	_	I-Premise
357	related	_	_	I-Premise
358	cardiac	_	_	I-Premise
359	events	_	_	I-Premise
360	with	_	_	I-Premise
361	high	_	_	I-Premise
362	-	_	_	I-Premise
363	dose	_	_	I-Premise
364	paclitaxel	_	_	I-Premise
365	,	_	_	I-Premise
366	toxicity	_	_	I-Premise
367	was	_	_	I-Premise
368	similar	_	_	I-Premise
369	across	_	_	I-Premise
370	all	_	_	I-Premise
371	three	_	_	I-Premise
372	arms	_	_	I-Premise
373	.	_	_	I-Premise

374	Quality	_	_	B-Premise
375	of	_	_	I-Premise
376	life	_	_	I-Premise
377	(	_	_	I-Premise
378	QOL	_	_	I-Premise
379	)	_	_	I-Premise
380	declined	_	_	I-Premise
381	significantly	_	_	I-Premise
382	over	_	_	I-Premise
383	the	_	_	I-Premise
384	6	_	_	I-Premise
385	months	_	_	I-Premise
386	.	_	_	I-Premise

387	However	_	_	O
388	,	_	_	O
389	QOL	_	_	B-Claim
390	scores	_	_	I-Claim
391	were	_	_	I-Claim
392	not	_	_	I-Claim
393	significantly	_	_	I-Claim
394	different	_	_	I-Claim
395	among	_	_	I-Claim
396	the	_	_	I-Claim
397	regimens	_	_	I-Claim
398	.	_	_	I-Claim

399	As	_	_	O
400	a	_	_	O
401	result	_	_	O
402	of	_	_	O
403	these	_	_	O
404	observations	_	_	O
405	,	_	_	O
406	paclitaxel	_	_	B-Claim
407	(	_	_	I-Claim
408	135	_	_	I-Claim
409	mg	_	_	I-Claim
410	/	_	_	I-Claim
411	m	_	_	I-Claim
412	(	_	_	I-Claim
413	2	_	_	I-Claim
414	)	_	_	I-Claim
415	)	_	_	I-Claim
416	combined	_	_	I-Claim
417	with	_	_	I-Claim
418	cisplatin	_	_	I-Claim
419	has	_	_	I-Claim
420	replaced	_	_	I-Claim
421	etoposide	_	_	I-Claim
422	plus	_	_	I-Claim
423	cisplatin	_	_	I-Claim
424	as	_	_	I-Claim
425	the	_	_	I-Claim
426	reference	_	_	I-Claim
427	regimen	_	_	I-Claim
428	in	_	_	I-Claim
429	our	_	_	I-Claim
430	recently	_	_	I-Claim
431	completed	_	_	I-Claim
432	phase	_	_	I-Claim
433	III	_	_	I-Claim
434	trial	_	_	I-Claim
435	.	_	_	I-Claim


0	The	_	_	O
1	AVEREL	_	_	O
2	trial	_	_	O
3	[	_	_	O
4	A	_	_	O
5	Study	_	_	O
6	of	_	_	O
7	Avastin	_	_	O
8	(	_	_	O
9	Bevacizumab	_	_	O
10	)	_	_	O
11	in	_	_	O
12	Combination	_	_	O
13	With	_	_	O
14	Herceptin	_	_	O
15	(	_	_	O
16	Trastuzumab	_	_	O
17	)	_	_	O
18	/	_	_	O
19	Docetaxel	_	_	O
20	in	_	_	O
21	Patients	_	_	O
22	With	_	_	O
23	HER2	_	_	O
24	-	_	_	O
25	Positive	_	_	O
26	Metastatic	_	_	O
27	Breast	_	_	O
28	Cancer	_	_	O
29	]	_	_	O
30	evaluated	_	_	O
31	first	_	_	O
32	-	_	_	O
33	line	_	_	O
34	bevacizumab	_	_	O
35	-	_	_	O
36	containing	_	_	O
37	therapy	_	_	O
38	for	_	_	O
39	human	_	_	O
40	epidermal	_	_	O
41	growth	_	_	O
42	factor	_	_	O
43	receptor	_	_	O
44	2	_	_	O
45	(	_	_	O
46	HER2	_	_	O
47	)	_	_	O
48	-	_	_	O
49	positive	_	_	O
50	locally	_	_	O
51	recurrent	_	_	O
52	/	_	_	O
53	metastatic	_	_	O
54	breast	_	_	O
55	cancer	_	_	O
56	(	_	_	O
57	LR	_	_	O
58	/	_	_	O
59	MBC	_	_	O
60	)	_	_	O
61	.	_	_	O

62	Patients	_	_	O
63	with	_	_	O
64	measurable	_	_	O
65	/	_	_	O
66	evaluable	_	_	O
67	HER2	_	_	O
68	-	_	_	O
69	positive	_	_	O
70	LR	_	_	O
71	/	_	_	O
72	MBC	_	_	O
73	who	_	_	O
74	had	_	_	O
75	not	_	_	O
76	received	_	_	O
77	trastuzumab	_	_	O
78	or	_	_	O
79	chemotherapy	_	_	O
80	for	_	_	O
81	LR	_	_	O
82	/	_	_	O
83	MBC	_	_	O
84	were	_	_	O
85	stratified	_	_	O
86	by	_	_	O
87	prior	_	_	O
88	adjuvant	_	_	O
89	trastuzumab	_	_	O
90	,	_	_	O
91	prior	_	_	O
92	(	_	_	O
93	neo	_	_	O
94	)	_	_	O
95	adjuvant	_	_	O
96	taxane	_	_	O
97	,	_	_	O
98	hormone	_	_	O
99	receptor	_	_	O
100	status	_	_	O
101	,	_	_	O
102	and	_	_	O
103	measurable	_	_	O
104	disease	_	_	O
105	and	_	_	O
106	were	_	_	O
107	randomly	_	_	O
108	assigned	_	_	O
109	to	_	_	O
110	receive	_	_	O
111	docetaxel	_	_	O
112	100	_	_	O
113	mg	_	_	O
114	/	_	_	O
115	m	_	_	O
116	(	_	_	O
117	2	_	_	O
118	)	_	_	O
119	plus	_	_	O
120	trastuzumab	_	_	O
121	8	_	_	O
122	mg	_	_	O
123	/	_	_	O
124	kg	_	_	O
125	loading	_	_	O
126	dose	_	_	O
127	followed	_	_	O
128	by	_	_	O
129	6	_	_	O
130	mg	_	_	O
131	/	_	_	O
132	kg	_	_	O
133	either	_	_	O
134	with	_	_	O
135	bevacizumab	_	_	O
136	15	_	_	O
137	mg	_	_	O
138	/	_	_	O
139	kg	_	_	O
140	or	_	_	O
141	without	_	_	O
142	bevacizumab	_	_	O
143	,	_	_	O
144	all	_	_	O
145	administered	_	_	O
146	every	_	_	O
147	3	_	_	O
148	weeks	_	_	O
149	.	_	_	O

150	The	_	_	O
151	primary	_	_	O
152	end	_	_	O
153	point	_	_	O
154	was	_	_	O
155	progression	_	_	O
156	-	_	_	O
157	free	_	_	O
158	survival	_	_	O
159	(	_	_	O
160	PFS	_	_	O
161	)	_	_	O
162	.	_	_	O

163	Additional	_	_	O
164	end	_	_	O
165	points	_	_	O
166	included	_	_	O
167	overall	_	_	O
168	survival	_	_	O
169	,	_	_	O
170	response	_	_	O
171	rate	_	_	O
172	(	_	_	O
173	RR	_	_	O
174	)	_	_	O
175	,	_	_	O
176	safety	_	_	O
177	,	_	_	O
178	quality	_	_	O
179	of	_	_	O
180	life	_	_	O
181	,	_	_	O
182	and	_	_	O
183	translational	_	_	O
184	research	_	_	O
185	.	_	_	O

186	Results	_	_	O
187	Baseline	_	_	O
188	characteristics	_	_	O
189	of	_	_	O
190	the	_	_	O
191	424	_	_	O
192	patients	_	_	O
193	were	_	_	O
194	balanced	_	_	O
195	between	_	_	O
196	treatment	_	_	O
197	arms	_	_	O
198	.	_	_	O

199	Most	_	_	O
200	patients	_	_	O
201	had	_	_	O
202	visceral	_	_	O
203	metastases	_	_	O
204	,	_	_	O
205	43	_	_	O
206	%	_	_	O
207	had	_	_	O
208	a	_	_	O
209	disease	_	_	O
210	-	_	_	O
211	free	_	_	O
212	interval	_	_	O
213	less	_	_	O
214	than	_	_	O
215	12	_	_	O
216	months	_	_	O
217	,	_	_	O
218	and	_	_	O
219	85	_	_	O
220	%	_	_	O
221	had	_	_	O
222	measurable	_	_	O
223	disease	_	_	O
224	.	_	_	O

225	Median	_	_	O
226	follow	_	_	O
227	-	_	_	O
228	up	_	_	O
229	was	_	_	O
230	26	_	_	O
231	months	_	_	O
232	.	_	_	O

233	The	_	_	B-Premise
234	hazard	_	_	I-Premise
235	ratio	_	_	I-Premise
236	for	_	_	I-Premise
237	investigator	_	_	I-Premise
238	-	_	_	I-Premise
239	assessed	_	_	I-Premise
240	PFS	_	_	I-Premise
241	was	_	_	I-Premise
242	0	_	_	I-Premise
243	.	_	_	I-Premise

244	82	_	_	I-Premise
245	(	_	_	I-Premise
246	95	_	_	I-Premise
247	%	_	_	I-Premise
248	CI	_	_	I-Premise
249	,	_	_	I-Premise
250	0	_	_	I-Premise
251	.	_	_	I-Premise

252	65	_	_	I-Premise
253	to	_	_	I-Premise
254	1	_	_	I-Premise
255	.	_	_	I-Premise

256	02	_	_	I-Premise
257	;	_	_	I-Premise
258	P	_	_	I-Premise
259	=	_	_	I-Premise
260	.	_	_	I-Premise

261	0775	_	_	I-Premise
262	;	_	_	I-Premise
263	median	_	_	I-Premise
264	PFS	_	_	I-Premise
265	,	_	_	I-Premise
266	13	_	_	I-Premise
267	.	_	_	I-Premise

268	7	_	_	I-Premise
269	v	_	_	I-Premise
270	16	_	_	I-Premise
271	.	_	_	I-Premise

272	5	_	_	I-Premise
273	months	_	_	I-Premise
274	in	_	_	I-Premise
275	the	_	_	I-Premise
276	non	_	_	I-Premise
277	-	_	_	I-Premise
278	bevacizumab	_	_	I-Premise
279	and	_	_	I-Premise
280	bevacizumab	_	_	I-Premise
281	arms	_	_	I-Premise
282	,	_	_	I-Premise
283	respectively	_	_	I-Premise
284	;	_	_	I-Premise
285	PFS	_	_	I-Premise
286	events	_	_	I-Premise
287	in	_	_	I-Premise
288	72	_	_	I-Premise
289	%	_	_	I-Premise
290	)	_	_	I-Premise
291	.	_	_	I-Premise

292	The	_	_	B-Premise
293	Independent	_	_	I-Premise
294	Review	_	_	I-Premise
295	Committee	_	_	I-Premise
296	-	_	_	I-Premise
297	assessed	_	_	I-Premise
298	PFS	_	_	I-Premise
299	hazard	_	_	I-Premise
300	ratio	_	_	I-Premise
301	was	_	_	I-Premise
302	0	_	_	I-Premise
303	.	_	_	I-Premise

304	72	_	_	I-Premise
305	(	_	_	I-Premise
306	95	_	_	I-Premise
307	%	_	_	I-Premise
308	CI	_	_	I-Premise
309	,	_	_	I-Premise
310	0	_	_	I-Premise
311	.	_	_	I-Premise

312	54	_	_	I-Premise
313	to	_	_	I-Premise
314	0	_	_	I-Premise
315	.	_	_	I-Premise

316	94	_	_	I-Premise
317	;	_	_	I-Premise
318	P	_	_	I-Premise
319	=	_	_	I-Premise
320	.	_	_	I-Premise

321	0162	_	_	I-Premise
322	;	_	_	I-Premise
323	median	_	_	I-Premise
324	PFS	_	_	I-Premise
325	,	_	_	I-Premise
326	13	_	_	I-Premise
327	.	_	_	I-Premise

328	9	_	_	I-Premise
329	v	_	_	I-Premise
330	16	_	_	I-Premise
331	.	_	_	I-Premise

332	8	_	_	I-Premise
333	months	_	_	I-Premise
334	,	_	_	I-Premise
335	respectively	_	_	I-Premise
336	;	_	_	I-Premise
337	PFS	_	_	I-Premise
338	events	_	_	I-Premise
339	in	_	_	I-Premise
340	53	_	_	I-Premise
341	%	_	_	I-Premise
342	)	_	_	I-Premise
343	.	_	_	I-Premise

344	The	_	_	B-Premise
345	RR	_	_	I-Premise
346	was	_	_	I-Premise
347	70	_	_	I-Premise
348	%	_	_	I-Premise
349	versus	_	_	I-Premise
350	74	_	_	I-Premise
351	%	_	_	I-Premise
352	,	_	_	I-Premise
353	respectively	_	_	I-Premise
354	(	_	_	I-Premise
355	P	_	_	I-Premise
356	=	_	_	I-Premise
357	.	_	_	I-Premise

358	3492	_	_	I-Premise
359	)	_	_	I-Premise
360	.	_	_	I-Premise

361	Grade	_	_	B-Claim
362	≥	_	_	I-Claim
363	3	_	_	I-Claim
364	febrile	_	_	I-Claim
365	neutropenia	_	_	I-Claim
366	and	_	_	I-Claim
367	hypertension	_	_	I-Claim
368	were	_	_	I-Claim
369	more	_	_	I-Claim
370	common	_	_	I-Claim
371	with	_	_	I-Claim
372	bevacizumab	_	_	I-Claim
373	-	_	_	I-Claim
374	containing	_	_	I-Claim
375	therapy	_	_	I-Claim
376	.	_	_	I-Claim

377	High	_	_	B-Premise
378	baseline	_	_	I-Premise
379	plasma	_	_	I-Premise
380	vascular	_	_	I-Premise
381	endothelial	_	_	I-Premise
382	growth	_	_	I-Premise
383	factor	_	_	I-Premise
384	A	_	_	I-Premise
385	(	_	_	I-Premise
386	VEGF	_	_	I-Premise
387	-	_	_	I-Premise
388	A	_	_	I-Premise
389	)	_	_	I-Premise
390	concentrations	_	_	I-Premise
391	were	_	_	I-Premise
392	associated	_	_	I-Premise
393	with	_	_	I-Premise
394	greater	_	_	I-Premise
395	bevacizumab	_	_	I-Premise
396	benefit	_	_	I-Premise
397	(	_	_	I-Premise
398	not	_	_	I-Premise
399	statistically	_	_	I-Premise
400	significant	_	_	I-Premise
401	)	_	_	I-Premise
402	.	_	_	I-Premise

403	Combining	_	_	B-Claim
404	bevacizumab	_	_	I-Claim
405	with	_	_	I-Claim
406	docetaxel	_	_	I-Claim
407	and	_	_	I-Claim
408	trastuzumab	_	_	I-Claim
409	did	_	_	I-Claim
410	not	_	_	I-Claim
411	significantly	_	_	I-Claim
412	improve	_	_	I-Claim
413	investigator	_	_	I-Claim
414	-	_	_	I-Claim
415	assessed	_	_	I-Claim
416	PFS	_	_	I-Claim
417	.	_	_	I-Claim

418	The	_	_	O
419	potential	_	_	O
420	predictive	_	_	O
421	value	_	_	O
422	of	_	_	O
423	plasma	_	_	O
424	VEGF	_	_	O
425	-	_	_	O
426	A	_	_	O
427	is	_	_	O
428	consistent	_	_	O
429	with	_	_	O
430	findings	_	_	O
431	in	_	_	O
432	HER2	_	_	O
433	-	_	_	O
434	negative	_	_	O
435	LR	_	_	O
436	/	_	_	O
437	MBC	_	_	O
438	,	_	_	O
439	warranting	_	_	O
440	prospective	_	_	O
441	evaluation	_	_	O
442	.	_	_	O


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	long	_	_	O
4	term	_	_	O
5	risks	_	_	O
6	and	_	_	O
7	benefits	_	_	O
8	of	_	_	O
9	hormone	_	_	O
10	replacement	_	_	O
11	therapy	_	_	O
12	(	_	_	O
13	combined	_	_	O
14	hormone	_	_	O
15	therapy	_	_	O
16	versus	_	_	O
17	placebo	_	_	O
18	,	_	_	O
19	and	_	_	O
20	oestrogen	_	_	O
21	alone	_	_	O
22	versus	_	_	O
23	combined	_	_	O
24	hormone	_	_	O
25	therapy	_	_	O
26	)	_	_	O
27	.	_	_	O

28	Multicentre	_	_	O
29	,	_	_	O
30	randomised	_	_	O
31	,	_	_	O
32	placebo	_	_	O
33	controlled	_	_	O
34	,	_	_	O
35	double	_	_	O
36	blind	_	_	O
37	trial	_	_	O
38	.	_	_	O

39	General	_	_	O
40	practices	_	_	O
41	in	_	_	O
42	UK	_	_	O
43	(	_	_	O
44	384	_	_	O
45	)	_	_	O
46	,	_	_	O
47	Australia	_	_	O
48	(	_	_	O
49	91	_	_	O
50	)	_	_	O
51	,	_	_	O
52	and	_	_	O
53	New	_	_	O
54	Zealand	_	_	O
55	(	_	_	O
56	24	_	_	O
57	)	_	_	O
58	.	_	_	O

59	Postmenopausal	_	_	O
60	women	_	_	O
61	aged	_	_	O
62	50	_	_	O
63	-	_	_	O
64	69	_	_	O
65	years	_	_	O
66	at	_	_	O
67	randomisation	_	_	O
68	.	_	_	O

69	At	_	_	O
70	early	_	_	O
71	closure	_	_	O
72	of	_	_	O
73	the	_	_	O
74	trial	_	_	O
75	,	_	_	O
76	56	_	_	O
77	,	_	_	O
78	583	_	_	O
79	had	_	_	O
80	been	_	_	O
81	screened	_	_	O
82	,	_	_	O
83	8980	_	_	O
84	entered	_	_	O
85	run	_	_	O
86	-	_	_	O
87	in	_	_	O
88	,	_	_	O
89	and	_	_	O
90	5692	_	_	O
91	(	_	_	O
92	26	_	_	O
93	%	_	_	O
94	of	_	_	O
95	target	_	_	O
96	of	_	_	O
97	22	_	_	O
98	,	_	_	O
99	300	_	_	O
100	)	_	_	O
101	started	_	_	O
102	treatment	_	_	O
103	.	_	_	O

104	Oestrogen	_	_	O
105	only	_	_	O
106	therapy	_	_	O
107	(	_	_	O
108	conjugated	_	_	O
109	equine	_	_	O
110	oestrogens	_	_	O
111	0	_	_	O
112	.	_	_	O

113	625	_	_	O
114	mg	_	_	O
115	orally	_	_	O
116	daily	_	_	O
117	)	_	_	O
118	or	_	_	O
119	combined	_	_	O
120	hormone	_	_	O
121	therapy	_	_	O
122	(	_	_	O
123	conjugated	_	_	O
124	equine	_	_	O
125	oestrogens	_	_	O
126	plus	_	_	O
127	medroxyprogesterone	_	_	O
128	acetate	_	_	O
129	2	_	_	O
130	.	_	_	O

131	5	_	_	O
132	/	_	_	O
133	5	_	_	O
134	.	_	_	O

135	0	_	_	O
136	mg	_	_	O
137	orally	_	_	O
138	daily	_	_	O
139	)	_	_	O
140	.	_	_	O

141	Ten	_	_	O
142	years	_	_	O
143	of	_	_	O
144	treatment	_	_	O
145	planned	_	_	O
146	.	_	_	O

147	major	_	_	O
148	cardiovascular	_	_	O
149	disease	_	_	O
150	,	_	_	O
151	osteoporotic	_	_	O
152	fractures	_	_	O
153	,	_	_	O
154	and	_	_	O
155	breast	_	_	O
156	cancer	_	_	O
157	.	_	_	O

158	other	_	_	O
159	cancers	_	_	O
160	,	_	_	O
161	death	_	_	O
162	from	_	_	O
163	all	_	_	O
164	causes	_	_	O
165	,	_	_	O
166	venous	_	_	O
167	thromboembolism	_	_	O
168	,	_	_	O
169	cerebrovascular	_	_	O
170	disease	_	_	O
171	,	_	_	O
172	dementia	_	_	O
173	,	_	_	O
174	and	_	_	O
175	quality	_	_	O
176	of	_	_	O
177	life	_	_	O
178	.	_	_	O

179	The	_	_	O
180	trial	_	_	O
181	was	_	_	O
182	prematurely	_	_	O
183	closed	_	_	O
184	during	_	_	O
185	recruitment	_	_	O
186	,	_	_	O
187	after	_	_	O
188	a	_	_	O
189	median	_	_	O
190	follow	_	_	O
191	-	_	_	O
192	up	_	_	O
193	of	_	_	O
194	11	_	_	O
195	.	_	_	O

196	9	_	_	O
197	months	_	_	O
198	(	_	_	O
199	interquartile	_	_	O
200	range	_	_	O
201	7	_	_	O
202	.	_	_	O

203	1	_	_	O
204	-	_	_	O
205	19	_	_	O
206	.	_	_	O

207	6	_	_	O
208	,	_	_	O
209	total	_	_	O
210	6498	_	_	O
211	women	_	_	O
212	years	_	_	O
213	)	_	_	O
214	in	_	_	O
215	those	_	_	O
216	enrolled	_	_	O
217	,	_	_	O
218	after	_	_	O
219	the	_	_	O
220	publication	_	_	O
221	of	_	_	O
222	early	_	_	O
223	results	_	_	O
224	from	_	_	O
225	the	_	_	O
226	women	_	_	O
227	'	_	_	O
228	s	_	_	O
229	health	_	_	O
230	initiative	_	_	O
231	study	_	_	O
232	.	_	_	O

233	The	_	_	O
234	mean	_	_	O
235	age	_	_	O
236	of	_	_	O
237	randomised	_	_	O
238	women	_	_	O
239	was	_	_	O
240	62	_	_	O
241	.	_	_	O

242	8	_	_	O
243	(	_	_	O
244	SD	_	_	O
245	4	_	_	O
246	.	_	_	O

247	8	_	_	O
248	)	_	_	O
249	years	_	_	O
250	.	_	_	O

251	When	_	_	B-Premise
252	combined	_	_	I-Premise
253	hormone	_	_	I-Premise
254	therapy	_	_	I-Premise
255	(	_	_	I-Premise
256	n	_	_	I-Premise
257	=	_	_	I-Premise
258	2196	_	_	I-Premise
259	)	_	_	I-Premise
260	was	_	_	I-Premise
261	compared	_	_	I-Premise
262	with	_	_	I-Premise
263	placebo	_	_	I-Premise
264	(	_	_	I-Premise
265	n	_	_	I-Premise
266	=	_	_	I-Premise
267	2189	_	_	I-Premise
268	)	_	_	I-Premise
269	,	_	_	I-Premise
270	there	_	_	I-Premise
271	was	_	_	I-Premise
272	a	_	_	I-Premise
273	significant	_	_	I-Premise
274	increase	_	_	I-Premise
275	in	_	_	I-Premise
276	the	_	_	I-Premise
277	number	_	_	I-Premise
278	of	_	_	I-Premise
279	major	_	_	I-Premise
280	cardiovascular	_	_	I-Premise
281	events	_	_	I-Premise
282	(	_	_	I-Premise
283	7	_	_	I-Premise
284	v	_	_	I-Premise
285	0	_	_	I-Premise
286	,	_	_	I-Premise
287	P	_	_	I-Premise
288	=	_	_	I-Premise
289	0	_	_	I-Premise
290	.	_	_	I-Premise

291	016	_	_	I-Premise
292	)	_	_	I-Premise
293	and	_	_	I-Premise
294	venous	_	_	I-Premise
295	thromboembolisms	_	_	I-Premise
296	(	_	_	I-Premise
297	22	_	_	I-Premise
298	v	_	_	I-Premise
299	3	_	_	I-Premise
300	,	_	_	I-Premise
301	hazard	_	_	I-Premise
302	ratio	_	_	I-Premise
303	7	_	_	I-Premise
304	.	_	_	I-Premise

305	36	_	_	I-Premise
306	(	_	_	I-Premise
307	95	_	_	I-Premise
308	%	_	_	I-Premise
309	CI	_	_	I-Premise
310	2	_	_	I-Premise
311	.	_	_	I-Premise

312	20	_	_	I-Premise
313	to	_	_	I-Premise
314	24	_	_	I-Premise
315	.	_	_	I-Premise

316	60	_	_	I-Premise
317	)	_	_	I-Premise
318	)	_	_	I-Premise
319	.	_	_	I-Premise

320	There	_	_	B-Premise
321	were	_	_	I-Premise
322	no	_	_	I-Premise
323	statistically	_	_	I-Premise
324	significant	_	_	I-Premise
325	differences	_	_	I-Premise
326	in	_	_	I-Premise
327	numbers	_	_	I-Premise
328	of	_	_	I-Premise
329	breast	_	_	I-Premise
330	or	_	_	I-Premise
331	other	_	_	I-Premise
332	cancers	_	_	I-Premise
333	(	_	_	I-Premise
334	22	_	_	I-Premise
335	v	_	_	I-Premise
336	25	_	_	I-Premise
337	,	_	_	I-Premise
338	hazard	_	_	I-Premise
339	ratio	_	_	I-Premise
340	0	_	_	I-Premise
341	.	_	_	I-Premise

342	88	_	_	I-Premise
343	(	_	_	I-Premise
344	0	_	_	I-Premise
345	.	_	_	I-Premise

346	49	_	_	I-Premise
347	to	_	_	I-Premise
348	1	_	_	I-Premise
349	.	_	_	I-Premise

350	56	_	_	I-Premise
351	)	_	_	I-Premise
352	)	_	_	I-Premise
353	,	_	_	I-Premise
354	cerebrovascular	_	_	I-Premise
355	events	_	_	I-Premise
356	(	_	_	I-Premise
357	14	_	_	I-Premise
358	v	_	_	I-Premise
359	19	_	_	I-Premise
360	,	_	_	I-Premise
361	0	_	_	I-Premise
362	.	_	_	I-Premise

363	73	_	_	I-Premise
364	(	_	_	I-Premise
365	0	_	_	I-Premise
366	.	_	_	I-Premise

367	37	_	_	I-Premise
368	to	_	_	I-Premise
369	1	_	_	I-Premise
370	.	_	_	I-Premise

371	46	_	_	I-Premise
372	)	_	_	I-Premise
373	)	_	_	I-Premise
374	,	_	_	I-Premise
375	fractures	_	_	I-Premise
376	(	_	_	I-Premise
377	40	_	_	I-Premise
378	v	_	_	I-Premise
379	58	_	_	I-Premise
380	,	_	_	I-Premise
381	0	_	_	I-Premise
382	.	_	_	I-Premise

383	69	_	_	I-Premise
384	(	_	_	I-Premise
385	0	_	_	I-Premise
386	.	_	_	I-Premise

387	46	_	_	I-Premise
388	to	_	_	I-Premise
389	1	_	_	I-Premise
390	.	_	_	I-Premise

391	03	_	_	I-Premise
392	)	_	_	I-Premise
393	)	_	_	I-Premise
394	,	_	_	I-Premise
395	and	_	_	I-Premise
396	overall	_	_	I-Premise
397	deaths	_	_	I-Premise
398	(	_	_	I-Premise
399	8	_	_	I-Premise
400	v	_	_	I-Premise
401	5	_	_	I-Premise
402	,	_	_	I-Premise
403	1	_	_	I-Premise
404	.	_	_	I-Premise

405	60	_	_	I-Premise
406	(	_	_	I-Premise
407	0	_	_	I-Premise
408	.	_	_	I-Premise

409	52	_	_	I-Premise
410	to	_	_	I-Premise
411	4	_	_	I-Premise
412	.	_	_	I-Premise

413	89	_	_	I-Premise
414	)	_	_	I-Premise
415	)	_	_	I-Premise
416	.	_	_	I-Premise

417	Comparison	_	_	B-Premise
418	of	_	_	I-Premise
419	combined	_	_	I-Premise
420	hormone	_	_	I-Premise
421	therapy	_	_	I-Premise
422	(	_	_	I-Premise
423	n	_	_	I-Premise
424	=	_	_	I-Premise
425	815	_	_	I-Premise
426	)	_	_	I-Premise
427	versus	_	_	I-Premise
428	oestrogen	_	_	I-Premise
429	therapy	_	_	I-Premise
430	(	_	_	I-Premise
431	n	_	_	I-Premise
432	=	_	_	I-Premise
433	826	_	_	I-Premise
434	)	_	_	I-Premise
435	outcomes	_	_	I-Premise
436	revealed	_	_	I-Premise
437	no	_	_	I-Premise
438	significant	_	_	I-Premise
439	differences	_	_	I-Premise
440	.	_	_	I-Premise

441	Hormone	_	_	B-Claim
442	replacement	_	_	I-Claim
443	therapy	_	_	I-Claim
444	increases	_	_	I-Claim
445	cardiovascular	_	_	I-Claim
446	and	_	_	I-Claim
447	thromboembolic	_	_	I-Claim
448	risk	_	_	I-Claim
449	when	_	_	I-Claim
450	started	_	_	I-Claim
451	many	_	_	I-Claim
452	years	_	_	I-Claim
453	after	_	_	I-Claim
454	the	_	_	I-Claim
455	menopause	_	_	I-Claim
456	.	_	_	I-Claim

457	The	_	_	B-Claim
458	results	_	_	I-Claim
459	are	_	_	I-Claim
460	consistent	_	_	I-Claim
461	with	_	_	I-Claim
462	the	_	_	I-Claim
463	findings	_	_	I-Claim
464	of	_	_	I-Claim
465	the	_	_	I-Claim
466	women	_	_	I-Claim
467	'	_	_	I-Claim
468	s	_	_	I-Claim
469	health	_	_	I-Claim
470	initiative	_	_	I-Claim
471	study	_	_	I-Claim
472	and	_	_	I-Claim
473	secondary	_	_	I-Claim
474	prevention	_	_	I-Claim
475	studies	_	_	I-Claim
476	.	_	_	I-Claim

477	Research	_	_	B-Claim
478	is	_	_	I-Claim
479	needed	_	_	I-Claim
480	to	_	_	I-Claim
481	assess	_	_	I-Claim
482	the	_	_	I-Claim
483	long	_	_	I-Claim
484	term	_	_	I-Claim
485	risks	_	_	I-Claim
486	and	_	_	I-Claim
487	benefits	_	_	I-Claim
488	of	_	_	I-Claim
489	starting	_	_	I-Claim
490	hormone	_	_	I-Claim
491	replacement	_	_	I-Claim
492	therapy	_	_	I-Claim
493	near	_	_	I-Claim
494	the	_	_	I-Claim
495	menopause	_	_	I-Claim
496	,	_	_	I-Claim
497	when	_	_	I-Claim
498	the	_	_	I-Claim
499	effect	_	_	I-Claim
500	may	_	_	I-Claim
501	be	_	_	I-Claim
502	different	_	_	I-Claim
503	.	_	_	I-Claim


0	For	_	_	O
1	patients	_	_	O
2	undergoing	_	_	O
3	oncologic	_	_	O
4	surgery	_	_	O
5	,	_	_	O
6	the	_	_	O
7	quality	_	_	O
8	of	_	_	O
9	life	_	_	O
10	(	_	_	O
11	QoL	_	_	O
12	)	_	_	O
13	is	_	_	O
14	generally	_	_	O
15	accepted	_	_	O
16	as	_	_	O
17	an	_	_	O
18	important	_	_	O
19	outcome	_	_	O
20	parameter	_	_	O
21	in	_	_	O
22	addition	_	_	O
23	to	_	_	O
24	long	_	_	O
25	-	_	_	O
26	term	_	_	O
27	survival	_	_	O
28	,	_	_	O
29	mortality	_	_	O
30	and	_	_	O
31	complication	_	_	O
32	rates	_	_	O
33	.	_	_	O

34	This	_	_	O
35	study	_	_	O
36	focussed	_	_	O
37	on	_	_	O
38	the	_	_	O
39	QoL	_	_	O
40	in	_	_	O
41	patients	_	_	O
42	after	_	_	O
43	oesophagectomy	_	_	O
44	for	_	_	O
45	cancer	_	_	O
46	,	_	_	O
47	comparing	_	_	O
48	the	_	_	O
49	method	_	_	O
50	of	_	_	O
51	reconstruction	_	_	O
52	(	_	_	O
53	narrow	_	_	O
54	gastric	_	_	O
55	tube	_	_	O
56	vs	_	_	O
57	whole	_	_	O
58	stomach	_	_	O
59	)	_	_	O
60	.	_	_	O

61	In	_	_	O
62	a	_	_	O
63	prospective	_	_	O
64	randomised	_	_	O
65	single	_	_	O
66	-	_	_	O
67	centre	_	_	O
68	study	_	_	O
69	from	_	_	O
70	2007	_	_	O
71	to	_	_	O
72	2008	_	_	O
73	,	_	_	O
74	104	_	_	O
75	patients	_	_	O
76	underwent	_	_	O
77	oesophagectomy	_	_	O
78	for	_	_	O
79	cancer	_	_	O
80	.	_	_	O

81	To	_	_	O
82	assess	_	_	O
83	the	_	_	O
84	QoL	_	_	O
85	,	_	_	O
86	a	_	_	O
87	questionnaire	_	_	O
88	in	_	_	O
89	reference	_	_	O
90	to	_	_	O
91	the	_	_	O
92	EORTC	_	_	O
93	-	_	_	O
94	QLQ	_	_	O
95	-	_	_	O
96	C30	_	_	O
97	and	_	_	O
98	the	_	_	O
99	QLQ	_	_	O
100	-	_	_	O
101	OES24	_	_	O
102	was	_	_	O
103	administered	_	_	O
104	at	_	_	O
105	3	_	_	O
106	weeks	_	_	O
107	,	_	_	O
108	6	_	_	O
109	months	_	_	O
110	and	_	_	O
111	1	_	_	O
112	year	_	_	O
113	after	_	_	O
114	surgery	_	_	O
115	.	_	_	O

116	Clinical	_	_	O
117	data	_	_	O
118	were	_	_	O
119	collected	_	_	O
120	prospectively	_	_	O
121	,	_	_	O
122	and	_	_	O
123	follow	_	_	O
124	-	_	_	O
125	up	_	_	O
126	was	_	_	O
127	performed	_	_	O
128	regularly	_	_	O
129	.	_	_	O

130	There	_	_	B-Premise
131	were	_	_	I-Premise
132	no	_	_	I-Premise
133	significant	_	_	I-Premise
134	differences	_	_	I-Premise
135	between	_	_	I-Premise
136	the	_	_	I-Premise
137	narrow	_	_	I-Premise
138	gastric	_	_	I-Premise
139	tube	_	_	I-Premise
140	group	_	_	I-Premise
141	(	_	_	I-Premise
142	NGT	_	_	I-Premise
143	group	_	_	I-Premise
144	,	_	_	I-Premise
145	n	_	_	I-Premise
146	=	_	_	I-Premise
147	52	_	_	I-Premise
148	)	_	_	I-Premise
149	and	_	_	I-Premise
150	the	_	_	I-Premise
151	whole	_	_	I-Premise
152	-	_	_	I-Premise
153	stomach	_	_	I-Premise
154	group	_	_	I-Premise
155	(	_	_	I-Premise
156	WS	_	_	I-Premise
157	group	_	_	I-Premise
158	,	_	_	I-Premise
159	n	_	_	I-Premise
160	=	_	_	I-Premise
161	52	_	_	I-Premise
162	)	_	_	I-Premise
163	with	_	_	I-Premise
164	regard	_	_	I-Premise
165	to	_	_	I-Premise
166	patient	_	_	I-Premise
167	and	_	_	I-Premise
168	cancer	_	_	I-Premise
169	characteristics	_	_	I-Premise
170	,	_	_	I-Premise
171	operative	_	_	I-Premise
172	procedure	_	_	I-Premise
173	,	_	_	I-Premise
174	postoperative	_	_	I-Premise
175	intensive	_	_	I-Premise
176	care	_	_	I-Premise
177	unit	_	_	I-Premise
178	(	_	_	I-Premise
179	ICU	_	_	I-Premise
180	)	_	_	I-Premise
181	hospitalisation	_	_	I-Premise
182	,	_	_	I-Premise
183	and	_	_	I-Premise
184	overall	_	_	I-Premise
185	survival	_	_	I-Premise
186	at	_	_	I-Premise
187	1	_	_	I-Premise
188	year	_	_	I-Premise
189	.	_	_	I-Premise

190	Regarding	_	_	B-Premise
191	the	_	_	I-Premise
192	postoperative	_	_	I-Premise
193	complication	_	_	I-Premise
194	,	_	_	I-Premise
195	there	_	_	I-Premise
196	were	_	_	I-Premise
197	more	_	_	I-Premise
198	cases	_	_	I-Premise
199	of	_	_	I-Premise
200	postoperative	_	_	I-Premise
201	reflux	_	_	I-Premise
202	oesophagitis	_	_	I-Premise
203	and	_	_	I-Premise
204	impairment	_	_	I-Premise
205	of	_	_	I-Premise
206	pulmonary	_	_	I-Premise
207	function	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	WS	_	_	I-Premise
211	group	_	_	I-Premise
212	(	_	_	I-Premise
213	P	_	_	I-Premise
214	<	_	_	I-Premise
215	0	_	_	I-Premise
216	.	_	_	I-Premise

217	05	_	_	I-Premise
218	)	_	_	I-Premise
219	.	_	_	I-Premise

220	Regarding	_	_	B-Premise
221	the	_	_	I-Premise
222	QoL	_	_	I-Premise
223	investigation	_	_	I-Premise
224	,	_	_	I-Premise
225	the	_	_	I-Premise
226	scores	_	_	I-Premise
227	of	_	_	I-Premise
228	QoL	_	_	I-Premise
229	dropped	_	_	I-Premise
230	for	_	_	I-Premise
231	all	_	_	I-Premise
232	patients	_	_	I-Premise
233	at	_	_	I-Premise
234	3	_	_	I-Premise
235	weeks	_	_	I-Premise
236	after	_	_	I-Premise
237	surgery	_	_	I-Premise
238	.	_	_	I-Premise

239	Slowly	_	_	O
240	,	_	_	O
241	recovery	_	_	B-Premise
242	was	_	_	I-Premise
243	found	_	_	I-Premise
244	at	_	_	I-Premise
245	both	_	_	I-Premise
246	6	_	_	I-Premise
247	months	_	_	I-Premise
248	and	_	_	I-Premise
249	1	_	_	I-Premise
250	year	_	_	I-Premise
251	in	_	_	I-Premise
252	both	_	_	I-Premise
253	groups	_	_	I-Premise
254	.	_	_	I-Premise

255	Patients	_	_	B-Premise
256	in	_	_	I-Premise
257	the	_	_	I-Premise
258	NGT	_	_	I-Premise
259	group	_	_	I-Premise
260	reported	_	_	I-Premise
261	significantly	_	_	I-Premise
262	(	_	_	I-Premise
263	P	_	_	I-Premise
264	<	_	_	I-Premise
265	0	_	_	I-Premise
266	.	_	_	I-Premise

267	05	_	_	I-Premise
268	)	_	_	I-Premise
269	better	_	_	I-Premise
270	scores	_	_	I-Premise
271	of	_	_	I-Premise
272	QoL	_	_	I-Premise
273	at	_	_	I-Premise
274	both	_	_	I-Premise
275	6	_	_	I-Premise
276	months	_	_	I-Premise
277	and	_	_	I-Premise
278	1	_	_	I-Premise
279	year	_	_	I-Premise
280	.	_	_	I-Premise

281	Patients	_	_	B-Claim
282	who	_	_	I-Claim
283	underwent	_	_	I-Claim
284	gastric	_	_	I-Claim
285	tube	_	_	I-Claim
286	reconstruction	_	_	I-Claim
287	develop	_	_	I-Claim
288	less	_	_	I-Claim
289	postoperative	_	_	I-Claim
290	digestive	_	_	I-Claim
291	tract	_	_	I-Claim
292	complications	_	_	I-Claim
293	,	_	_	I-Claim
294	and	_	_	I-Claim
295	have	_	_	I-Claim
296	a	_	_	I-Claim
297	quicker	_	_	I-Claim
298	recovery	_	_	I-Claim
299	and	_	_	I-Claim
300	a	_	_	I-Claim
301	better	_	_	I-Claim
302	QoL	_	_	I-Claim
303	during	_	_	I-Claim
304	the	_	_	I-Claim
305	follow	_	_	I-Claim
306	-	_	_	I-Claim
307	up	_	_	I-Claim
308	period	_	_	I-Claim
309	.	_	_	I-Claim

310	Further	_	_	O
311	investigation	_	_	O
312	and	_	_	O
313	data	_	_	O
314	collection	_	_	O
315	will	_	_	O
316	allow	_	_	O
317	the	_	_	O
318	assessment	_	_	O
319	of	_	_	O
320	this	_	_	O
321	procedure	_	_	O
322	beyond	_	_	O
323	1	_	_	O
324	year	_	_	O
325	after	_	_	O
326	operation	_	_	O
327	.	_	_	O


0	This	_	_	O
1	phase	_	_	O
2	III	_	_	O
3	study	_	_	O
4	was	_	_	O
5	performed	_	_	O
6	to	_	_	O
7	determine	_	_	O
8	the	_	_	O
9	superiority	_	_	O
10	of	_	_	O
11	doxorubicin	_	_	O
12	(	_	_	O
13	DOX	_	_	O
14	)	_	_	O
15	and	_	_	O
16	vinorelbine	_	_	O
17	(	_	_	O
18	VNB	_	_	O
19	)	_	_	O
20	(	_	_	O
21	arm	_	_	O
22	1	_	_	O
23	)	_	_	O
24	versus	_	_	O
25	DOX	_	_	O
26	alone	_	_	O
27	(	_	_	O
28	arm	_	_	O
29	2	_	_	O
30	)	_	_	O
31	in	_	_	O
32	metastatic	_	_	O
33	breast	_	_	O
34	cancer	_	_	O
35	(	_	_	O
36	MBC	_	_	O
37	)	_	_	O
38	for	_	_	O
39	overall	_	_	O
40	survival	_	_	O
41	(	_	_	O
42	OS	_	_	O
43	)	_	_	O
44	,	_	_	O
45	time	_	_	O
46	to	_	_	O
47	treatment	_	_	O
48	failure	_	_	O
49	(	_	_	O
50	TTF	_	_	O
51	)	_	_	O
52	,	_	_	O
53	toxicity	_	_	O
54	,	_	_	O
55	and	_	_	O
56	quality	_	_	O
57	of	_	_	O
58	life	_	_	O
59	(	_	_	O
60	QOL	_	_	O
61	)	_	_	O
62	.	_	_	O

63	Three	_	_	O
64	hundred	_	_	O
65	three	_	_	O
66	patients	_	_	O
67	were	_	_	O
68	randomized	_	_	O
69	to	_	_	O
70	DOX	_	_	O
71	50	_	_	O
72	mg	_	_	O
73	/	_	_	O
74	m	_	_	O
75	(	_	_	O
76	2	_	_	O
77	)	_	_	O
78	intravenously	_	_	O
79	(	_	_	O
80	IV	_	_	O
81	)	_	_	O
82	on	_	_	O
83	day	_	_	O
84	1	_	_	O
85	and	_	_	O
86	VNB	_	_	O
87	25	_	_	O
88	mg	_	_	O
89	/	_	_	O
90	m	_	_	O
91	(	_	_	O
92	2	_	_	O
93	)	_	_	O
94	IV	_	_	O
95	on	_	_	O
96	days	_	_	O
97	1	_	_	O
98	and	_	_	O
99	8	_	_	O
100	(	_	_	O
101	arm	_	_	O
102	1	_	_	O
103	)	_	_	O
104	or	_	_	O
105	DOX	_	_	O
106	70	_	_	O
107	mg	_	_	O
108	/	_	_	O
109	m	_	_	O
110	(	_	_	O
111	2	_	_	O
112	)	_	_	O
113	IV	_	_	O
114	on	_	_	O
115	day	_	_	O
116	1	_	_	O
117	(	_	_	O
118	arm	_	_	O
119	2	_	_	O
120	)	_	_	O
121	.	_	_	O

122	Both	_	_	O
123	regimens	_	_	O
124	were	_	_	O
125	given	_	_	O
126	every	_	_	O
127	3	_	_	O
128	weeks	_	_	O
129	until	_	_	O
130	a	_	_	O
131	cumulative	_	_	O
132	DOX	_	_	O
133	dose	_	_	O
134	of	_	_	O
135	450	_	_	O
136	mg	_	_	O
137	/	_	_	O
138	m	_	_	O
139	(	_	_	O
140	2	_	_	O
141	)	_	_	O
142	.	_	_	O

143	After	_	_	O
144	16	_	_	O
145	of	_	_	O
146	the	_	_	O
147	first	_	_	O
148	65	_	_	O
149	randomized	_	_	O
150	patients	_	_	O
151	experienced	_	_	O
152	febrile	_	_	O
153	neutropenia	_	_	O
154	(	_	_	O
155	FN	_	_	O
156	)	_	_	O
157	,	_	_	O
158	the	_	_	O
159	doses	_	_	O
160	were	_	_	O
161	reduced	_	_	O
162	to	_	_	O
163	DOX	_	_	O
164	40	_	_	O
165	mg	_	_	O
166	/	_	_	O
167	m	_	_	O
168	(	_	_	O
169	2	_	_	O
170	)	_	_	O
171	on	_	_	O
172	day	_	_	O
173	1	_	_	O
174	and	_	_	O
175	VNB	_	_	O
176	20	_	_	O
177	mg	_	_	O
178	/	_	_	O
179	m	_	_	O
180	(	_	_	O
181	2	_	_	O
182	)	_	_	O
183	on	_	_	O
184	days	_	_	O
185	1	_	_	O
186	and	_	_	O
187	8	_	_	O
188	versus	_	_	O
189	DOX	_	_	O
190	60	_	_	O
191	mg	_	_	O
192	/	_	_	O
193	m	_	_	O
194	(	_	_	O
195	2	_	_	O
196	)	_	_	O
197	on	_	_	O
198	day	_	_	O
199	1	_	_	O
200	.	_	_	O

201	Eligible	_	_	O
202	patients	_	_	O
203	were	_	_	O
204	vinca	_	_	O
205	alkaloid	_	_	O
206	and	_	_	O
207	anthracycline	_	_	O
208	naive	_	_	O
209	.	_	_	O

210	Chemotherapy	_	_	O
211	was	_	_	O
212	first	_	_	O
213	-	_	_	O
214	line	_	_	O
215	or	_	_	O
216	second	_	_	O
217	-	_	_	O
218	line	_	_	O
219	for	_	_	O
220	MBC	_	_	O
221	.	_	_	O

222	Three	_	_	O
223	patients	_	_	O
224	were	_	_	O
225	ineligible	_	_	O
226	.	_	_	O

227	Thus	_	_	O
228	,	_	_	O
229	300	_	_	O
230	patients	_	_	O
231	were	_	_	O
232	assessable	_	_	O
233	for	_	_	O
234	toxicity	_	_	O
235	and	_	_	O
236	to	_	_	O
237	determine	_	_	O
238	time	_	_	O
239	to	_	_	O
240	disease	_	_	O
241	progression	_	_	O
242	(	_	_	O
243	TTP	_	_	O
244	)	_	_	O
245	,	_	_	O
246	TTF	_	_	O
247	,	_	_	O
248	and	_	_	O
249	OS	_	_	O
250	.	_	_	O

251	Two	_	_	O
252	hundred	_	_	O
253	eighty	_	_	O
254	-	_	_	O
255	nine	_	_	O
256	patients	_	_	O
257	were	_	_	O
258	assessable	_	_	O
259	for	_	_	O
260	response	_	_	O
261	,	_	_	O
262	and	_	_	O
263	99	_	_	O
264	responders	_	_	O
265	were	_	_	O
266	assessable	_	_	O
267	for	_	_	O
268	response	_	_	O
269	duration	_	_	O
270	(	_	_	O
271	RD	_	_	O
272	)	_	_	O
273	.	_	_	O

274	The	_	_	B-Premise
275	response	_	_	I-Premise
276	rates	_	_	I-Premise
277	,	_	_	I-Premise
278	QOL	_	_	I-Premise
279	,	_	_	I-Premise
280	and	_	_	I-Premise
281	median	_	_	I-Premise
282	RD	_	_	I-Premise
283	,	_	_	I-Premise
284	TTP	_	_	I-Premise
285	,	_	_	I-Premise
286	and	_	_	I-Premise
287	TTF	_	_	I-Premise
288	were	_	_	I-Premise
289	not	_	_	I-Premise
290	significantly	_	_	I-Premise
291	different	_	_	I-Premise
292	between	_	_	I-Premise
293	the	_	_	I-Premise
294	arms	_	_	I-Premise
295	.	_	_	I-Premise

296	Median	_	_	B-Premise
297	OS	_	_	I-Premise
298	was	_	_	I-Premise
299	13	_	_	I-Premise
300	.	_	_	I-Premise

301	8	_	_	I-Premise
302	months	_	_	I-Premise
303	for	_	_	I-Premise
304	arm	_	_	I-Premise
305	1	_	_	I-Premise
306	versus	_	_	I-Premise
307	14	_	_	I-Premise
308	.	_	_	I-Premise

309	4	_	_	I-Premise
310	months	_	_	I-Premise
311	for	_	_	I-Premise
312	arm	_	_	I-Premise
313	2	_	_	I-Premise
314	(	_	_	I-Premise
315	P	_	_	I-Premise
316	=	_	_	I-Premise
317	.	_	_	I-Premise

318	4	_	_	I-Premise
319	)	_	_	I-Premise
320	.	_	_	I-Premise

321	Grade	_	_	B-Premise
322	3	_	_	I-Premise
323	or	_	_	I-Premise
324	4	_	_	I-Premise
325	granulocytopenia	_	_	I-Premise
326	was	_	_	I-Premise
327	equivalent	_	_	I-Premise
328	in	_	_	I-Premise
329	both	_	_	I-Premise
330	arms	_	_	I-Premise
331	but	_	_	I-Premise
332	more	_	_	I-Premise
333	grade	_	_	I-Premise
334	3	_	_	I-Premise
335	/	_	_	I-Premise
336	4	_	_	I-Premise
337	neurotoxicity	_	_	I-Premise
338	,	_	_	I-Premise
339	mild	_	_	I-Premise
340	venous	_	_	I-Premise
341	toxicity	_	_	I-Premise
342	,	_	_	I-Premise
343	and	_	_	I-Premise
344	FN	_	_	I-Premise
345	were	_	_	I-Premise
346	seen	_	_	I-Premise
347	on	_	_	I-Premise
348	arm	_	_	I-Premise
349	1	_	_	I-Premise
350	.	_	_	I-Premise

351	The	_	_	B-Claim
352	survival	_	_	I-Claim
353	with	_	_	I-Claim
354	DOX	_	_	I-Claim
355	and	_	_	I-Claim
356	VNB	_	_	I-Claim
357	is	_	_	I-Claim
358	not	_	_	I-Claim
359	superior	_	_	I-Claim
360	to	_	_	I-Claim
361	DOX	_	_	I-Claim
362	alone	_	_	I-Claim
363	in	_	_	I-Claim
364	MBC	_	_	I-Claim
365	.	_	_	I-Claim


0	To	_	_	O
1	prospectively	_	_	O
2	evaluate	_	_	O
3	and	_	_	O
4	compare	_	_	O
5	health	_	_	O
6	-	_	_	O
7	related	_	_	O
8	quality	_	_	O
9	-	_	_	O
10	of	_	_	O
11	-	_	_	O
12	life	_	_	O
13	(	_	_	O
14	QOL	_	_	O
15	)	_	_	O
16	outcomes	_	_	O
17	in	_	_	O
18	patients	_	_	O
19	with	_	_	O
20	head	_	_	O
21	-	_	_	O
22	neck	_	_	O
23	squamous	_	_	O
24	cell	_	_	O
25	carcinoma	_	_	O
26	randomized	_	_	O
27	to	_	_	O
28	either	_	_	O
29	intensity	_	_	O
30	-	_	_	O
31	modulated	_	_	O
32	radiation	_	_	O
33	therapy	_	_	O
34	(	_	_	O
35	IMRT	_	_	O
36	)	_	_	O
37	or	_	_	O
38	three	_	_	O
39	-	_	_	O
40	dimensional	_	_	O
41	conformal	_	_	O
42	radiotherapy	_	_	O
43	(	_	_	O
44	3D	_	_	O
45	-	_	_	O
46	CRT	_	_	O
47	)	_	_	O
48	and	_	_	O
49	assess	_	_	O
50	serial	_	_	O
51	longitudinal	_	_	O
52	change	_	_	O
53	in	_	_	O
54	QOL	_	_	O
55	over	_	_	O
56	time	_	_	O
57	.	_	_	O

58	QOL	_	_	O
59	outcomes	_	_	O
60	were	_	_	O
61	assessed	_	_	O
62	using	_	_	O
63	the	_	_	O
64	European	_	_	O
65	Organization	_	_	O
66	for	_	_	O
67	Research	_	_	O
68	and	_	_	O
69	Treatment	_	_	O
70	of	_	_	O
71	Cancer	_	_	O
72	(	_	_	O
73	EORTC	_	_	O
74	)	_	_	O
75	QOL	_	_	O
76	questionnaire	_	_	O
77	(	_	_	O
78	QLQ	_	_	O
79	-	_	_	O
80	C30	_	_	O
81	)	_	_	O
82	and	_	_	O
83	Head	_	_	O
84	-	_	_	O
85	Neck	_	_	O
86	module	_	_	O
87	(	_	_	O
88	HN	_	_	O
89	-	_	_	O
90	35	_	_	O
91	)	_	_	O
92	at	_	_	O
93	baseline	_	_	O
94	(	_	_	O
95	pre	_	_	O
96	-	_	_	O
97	treatment	_	_	O
98	)	_	_	O
99	and	_	_	O
100	subsequently	_	_	O
101	periodically	_	_	O
102	on	_	_	O
103	follow	_	_	O
104	-	_	_	O
105	up	_	_	O
106	.	_	_	O

107	Mean	_	_	O
108	scores	_	_	O
109	of	_	_	O
110	individual	_	_	O
111	domains	_	_	O
112	/	_	_	O
113	scales	_	_	O
114	of	_	_	O
115	3D	_	_	O
116	-	_	_	O
117	CRT	_	_	O
118	and	_	_	O
119	IMRT	_	_	O
120	were	_	_	O
121	compared	_	_	O
122	using	_	_	O
123	'	_	_	O
124	t	_	_	O
125	'	_	_	O
126	test	_	_	O
127	at	_	_	O
128	each	_	_	O
129	time	_	_	O
130	point	_	_	O
131	;	_	_	O
132	while	_	_	O
133	longitudinal	_	_	O
134	change	_	_	O
135	in	_	_	O
136	mean	_	_	O
137	scores	_	_	O
138	of	_	_	O
139	both	_	_	O
140	groups	_	_	O
141	over	_	_	O
142	time	_	_	O
143	was	_	_	O
144	evaluated	_	_	O
145	by	_	_	O
146	repeated	_	_	O
147	measurement	_	_	O
148	analysis	_	_	O
149	of	_	_	O
150	variance	_	_	O
151	.	_	_	O

152	Fifty	_	_	O
153	eight	_	_	O
154	of	_	_	O
155	the	_	_	O
156	60	_	_	O
157	randomized	_	_	O
158	patients	_	_	O
159	who	_	_	O
160	filled	_	_	O
161	the	_	_	O
162	QOL	_	_	O
163	questionnaire	_	_	O
164	at	_	_	O
165	least	_	_	O
166	at	_	_	O
167	one	_	_	O
168	time	_	_	O
169	point	_	_	O
170	were	_	_	O
171	included	_	_	O
172	in	_	_	O
173	the	_	_	O
174	analysis	_	_	O
175	.	_	_	O

176	Several	_	_	O
177	general	_	_	O
178	(	_	_	O
179	emotional	_	_	O
180	functioning	_	_	O
181	,	_	_	O
182	role	_	_	O
183	functioning	_	_	O
184	,	_	_	O
185	social	_	_	O
186	contact	_	_	O
187	)	_	_	O
188	as	_	_	O
189	well	_	_	O
190	as	_	_	O
191	head	_	_	O
192	and	_	_	O
193	neck	_	_	O
194	cancer	_	_	O
195	-	_	_	O
196	specific	_	_	O
197	(	_	_	O
198	dry	_	_	O
199	mouth	_	_	O
200	,	_	_	O
201	opening	_	_	O
202	mouth	_	_	O
203	,	_	_	O
204	sticky	_	_	O
205	saliva	_	_	O
206	,	_	_	O
207	pain	_	_	O
208	,	_	_	O
209	senses	_	_	O
210	)	_	_	O
211	QOL	_	_	O
212	domains	_	_	O
213	were	_	_	O
214	better	_	_	O
215	preserved	_	_	O
216	with	_	_	O
217	IMRT	_	_	O
218	compared	_	_	O
219	to	_	_	O
220	3D	_	_	O
221	-	_	_	O
222	CRT	_	_	O
223	at	_	_	O
224	different	_	_	O
225	time	_	_	O
226	points	_	_	O
227	.	_	_	O

228	Importantly	_	_	O
229	,	_	_	O
230	none	_	_	O
231	of	_	_	O
232	the	_	_	O
233	QOL	_	_	O
234	domains	_	_	O
235	were	_	_	O
236	worse	_	_	O
237	with	_	_	O
238	IMRT	_	_	O
239	at	_	_	O
240	any	_	_	O
241	time	_	_	O
242	point	_	_	O
243	.	_	_	O

244	There	_	_	B-Premise
245	was	_	_	I-Premise
246	substantial	_	_	I-Premise
247	deterioration	_	_	I-Premise
248	in	_	_	I-Premise
249	QOL	_	_	I-Premise
250	scores	_	_	I-Premise
251	immediate	_	_	I-Premise
252	post	_	_	I-Premise
253	-	_	_	I-Premise
254	treatment	_	_	I-Premise
255	(	_	_	I-Premise
256	3	_	_	I-Premise
257	-	_	_	I-Premise
258	months	_	_	I-Premise
259	)	_	_	I-Premise
260	in	_	_	I-Premise
261	both	_	_	I-Premise
262	arms	_	_	I-Premise
263	.	_	_	I-Premise

264	However	_	_	B-Premise
265	,	_	_	I-Premise
266	QOL	_	_	I-Premise
267	scores	_	_	I-Premise
268	gradually	_	_	I-Premise
269	but	_	_	I-Premise
270	definitely	_	_	I-Premise
271	improved	_	_	I-Premise
272	over	_	_	I-Premise
273	time	_	_	I-Premise
274	for	_	_	I-Premise
275	most	_	_	I-Premise
276	domains	_	_	I-Premise
277	.	_	_	I-Premise

278	Global	_	_	B-Premise
279	QOL	_	_	I-Premise
280	,	_	_	I-Premise
281	emotional	_	_	I-Premise
282	/	_	_	I-Premise
283	role	_	_	I-Premise
284	functioning	_	_	I-Premise
285	,	_	_	I-Premise
286	nausea	_	_	I-Premise
287	/	_	_	I-Premise
288	vomiting	_	_	I-Premise
289	,	_	_	I-Premise
290	pain	_	_	I-Premise
291	,	_	_	I-Premise
292	swallowing	_	_	I-Premise
293	,	_	_	I-Premise
294	speech	_	_	I-Premise
295	,	_	_	I-Premise
296	social	_	_	I-Premise
297	contact	_	_	I-Premise
298	/	_	_	I-Premise
299	eating	_	_	I-Premise
300	,	_	_	I-Premise
301	insomnia	_	_	I-Premise
302	showed	_	_	I-Premise
303	rapid	_	_	I-Premise
304	recovery	_	_	I-Premise
305	(	_	_	I-Premise
306	<	_	_	I-Premise
307	6months	_	_	I-Premise
308	)	_	_	I-Premise
309	while	_	_	I-Premise
310	physical	_	_	I-Premise
311	/	_	_	I-Premise
312	cognitive	_	_	I-Premise
313	functioning	_	_	I-Premise
314	,	_	_	I-Premise
315	dry	_	_	I-Premise
316	mouth	_	_	I-Premise
317	,	_	_	I-Premise
318	sticky	_	_	I-Premise
319	saliva	_	_	I-Premise
320	,	_	_	I-Premise
321	fatigue	_	_	I-Premise
322	,	_	_	I-Premise
323	senses	_	_	I-Premise
324	showed	_	_	I-Premise
325	delayed	_	_	I-Premise
326	recovery	_	_	I-Premise
327	(	_	_	I-Premise
328	>	_	_	I-Premise
329	6months	_	_	I-Premise
330	)	_	_	I-Premise
331	.	_	_	I-Premise

332	There	_	_	B-Premise
333	were	_	_	I-Premise
334	no	_	_	I-Premise
335	significant	_	_	I-Premise
336	differences	_	_	I-Premise
337	in	_	_	I-Premise
338	loco	_	_	I-Premise
339	-	_	_	I-Premise
340	regional	_	_	I-Premise
341	or	_	_	I-Premise
342	survival	_	_	I-Premise
343	between	_	_	I-Premise
344	the	_	_	I-Premise
345	two	_	_	I-Premise
346	arms	_	_	I-Premise
347	.	_	_	I-Premise

348	There	_	_	B-Claim
349	is	_	_	I-Claim
350	substantial	_	_	I-Claim
351	deterioration	_	_	I-Claim
352	in	_	_	I-Claim
353	QOL	_	_	I-Claim
354	after	_	_	I-Claim
355	curative	_	_	I-Claim
356	-	_	_	I-Claim
357	intent	_	_	I-Claim
358	head	_	_	I-Claim
359	-	_	_	I-Claim
360	neck	_	_	I-Claim
361	irradiation	_	_	I-Claim
362	that	_	_	I-Claim
363	gradually	_	_	I-Claim
364	improves	_	_	I-Claim
365	over	_	_	I-Claim
366	time	_	_	I-Claim
367	.	_	_	I-Claim

368	IMRT	_	_	B-Claim
369	results	_	_	I-Claim
370	in	_	_	I-Claim
371	clinically	_	_	I-Claim
372	meaningful	_	_	I-Claim
373	and	_	_	I-Claim
374	statistically	_	_	I-Claim
375	better	_	_	I-Claim
376	QOL	_	_	I-Claim
377	scores	_	_	I-Claim
378	for	_	_	I-Claim
379	some	_	_	I-Claim
380	domains	_	_	I-Claim
381	compared	_	_	I-Claim
382	to	_	_	I-Claim
383	3D	_	_	I-Claim
384	-	_	_	I-Claim
385	CRT	_	_	I-Claim
386	at	_	_	I-Claim
387	several	_	_	I-Claim
388	time	_	_	I-Claim
389	points	_	_	I-Claim
390	with	_	_	I-Claim
391	comparable	_	_	I-Claim
392	disease	_	_	I-Claim
393	outcomes	_	_	I-Claim
394	that	_	_	I-Claim
395	could	_	_	I-Claim
396	support	_	_	I-Claim
397	its	_	_	I-Claim
398	widespread	_	_	I-Claim
399	adoption	_	_	I-Claim
400	in	_	_	I-Claim
401	routine	_	_	I-Claim
402	clinical	_	_	I-Claim
403	practice	_	_	I-Claim
404	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	a	_	_	O
6	novel	_	_	O
7	coloplasty	_	_	O
8	colonic	_	_	O
9	pouch	_	_	O
10	design	_	_	O
11	in	_	_	O
12	optimizing	_	_	O
13	bowel	_	_	O
14	function	_	_	O
15	after	_	_	O
16	ultralow	_	_	O
17	anterior	_	_	O
18	resection	_	_	O
19	.	_	_	O

20	A	_	_	B-Claim
21	colonic	_	_	I-Claim
22	J	_	_	I-Claim
23	-	_	_	I-Claim
24	pouch	_	_	I-Claim
25	may	_	_	I-Claim
26	reduce	_	_	I-Claim
27	excessive	_	_	I-Claim
28	stool	_	_	I-Claim
29	frequency	_	_	I-Claim
30	and	_	_	I-Claim
31	incontinence	_	_	I-Claim
32	after	_	_	I-Claim
33	anterior	_	_	I-Claim
34	resection	_	_	I-Claim
35	,	_	_	I-Claim
36	but	_	_	I-Claim
37	at	_	_	I-Claim
38	the	_	_	I-Claim
39	risk	_	_	I-Claim
40	of	_	_	I-Claim
41	evacuation	_	_	I-Claim
42	problems	_	_	I-Claim
43	.	_	_	I-Claim

44	Experimental	_	_	B-Claim
45	surgery	_	_	I-Claim
46	on	_	_	I-Claim
47	pigs	_	_	I-Claim
48	has	_	_	I-Claim
49	suggested	_	_	I-Claim
50	that	_	_	I-Claim
51	a	_	_	I-Claim
52	coloplasty	_	_	I-Claim
53	pouch	_	_	I-Claim
54	(	_	_	I-Claim
55	CP	_	_	I-Claim
56	)	_	_	I-Claim
57	may	_	_	I-Claim
58	be	_	_	I-Claim
59	a	_	_	I-Claim
60	useful	_	_	I-Claim
61	alternative	_	_	I-Claim
62	.	_	_	O

63	Although	_	_	O
64	CP	_	_	O
65	has	_	_	O
66	recently	_	_	O
67	been	_	_	O
68	shown	_	_	O
69	to	_	_	O
70	be	_	_	O
71	feasible	_	_	O
72	in	_	_	O
73	patients	_	_	O
74	,	_	_	O
75	there	_	_	O
76	is	_	_	O
77	no	_	_	O
78	randomized	_	_	O
79	controlled	_	_	O
80	trial	_	_	O
81	comparing	_	_	O
82	bowel	_	_	O
83	function	_	_	O
84	with	_	_	O
85	the	_	_	O
86	J	_	_	O
87	-	_	_	O
88	pouch	_	_	O
89	.	_	_	O

90	After	_	_	O
91	anterior	_	_	O
92	resection	_	_	O
93	for	_	_	O
94	cancer	_	_	O
95	,	_	_	O
96	patients	_	_	O
97	were	_	_	O
98	allocated	_	_	O
99	to	_	_	O
100	either	_	_	O
101	J	_	_	O
102	-	_	_	O
103	pouch	_	_	O
104	or	_	_	O
105	CP	_	_	O
106	-	_	_	O
107	anal	_	_	O
108	anastomoses	_	_	O
109	.	_	_	O

110	Continence	_	_	O
111	scoring	_	_	O
112	,	_	_	O
113	anorectal	_	_	O
114	manometry	_	_	O
115	,	_	_	O
116	and	_	_	O
117	endoanal	_	_	O
118	ultrasound	_	_	O
119	assessments	_	_	O
120	were	_	_	O
121	made	_	_	O
122	before	_	_	O
123	surgery	_	_	O
124	.	_	_	O

125	All	_	_	O
126	complications	_	_	O
127	were	_	_	O
128	recorded	_	_	O
129	,	_	_	O
130	and	_	_	O
131	these	_	_	O
132	preoperative	_	_	O
133	assessments	_	_	O
134	were	_	_	O
135	repeated	_	_	O
136	at	_	_	O
137	4	_	_	O
138	months	_	_	O
139	.	_	_	O

140	The	_	_	O
141	assessments	_	_	O
142	were	_	_	O
143	repeated	_	_	O
144	again	_	_	O
145	at	_	_	O
146	1	_	_	O
147	year	_	_	O
148	,	_	_	O
149	and	_	_	O
150	a	_	_	O
151	quality	_	_	O
152	of	_	_	O
153	life	_	_	O
154	questionnaire	_	_	O
155	was	_	_	O
156	added	_	_	O
157	.	_	_	O

158	Eighty	_	_	O
159	-	_	_	O
160	eight	_	_	O
161	patients	_	_	O
162	were	_	_	O
163	recruited	_	_	O
164	from	_	_	O
165	October	_	_	O
166	1998	_	_	O
167	to	_	_	O
168	April	_	_	O
169	2000	_	_	O
170	.	_	_	O

171	Both	_	_	O
172	groups	_	_	O
173	were	_	_	O
174	well	_	_	O
175	matched	_	_	O
176	for	_	_	O
177	age	_	_	O
178	,	_	_	O
179	gender	_	_	O
180	,	_	_	O
181	staging	_	_	O
182	,	_	_	O
183	adjuvant	_	_	O
184	therapy	_	_	O
185	,	_	_	O
186	and	_	_	O
187	mean	_	_	O
188	follow	_	_	O
189	-	_	_	O
190	up	_	_	O
191	.	_	_	O

192	There	_	_	O
193	were	_	_	O
194	no	_	_	O
195	differences	_	_	O
196	in	_	_	O
197	the	_	_	O
198	intraoperative	_	_	O
199	time	_	_	O
200	and	_	_	O
201	hospital	_	_	O
202	stay	_	_	O
203	.	_	_	O

204	CP	_	_	B-Premise
205	resulted	_	_	I-Premise
206	in	_	_	I-Premise
207	more	_	_	I-Premise
208	anastomotic	_	_	I-Premise
209	leaks	_	_	I-Premise
210	.	_	_	I-Premise

211	At	_	_	B-Premise
212	4	_	_	I-Premise
213	months	_	_	I-Premise
214	,	_	_	I-Premise
215	J	_	_	I-Premise
216	-	_	_	I-Premise
217	pouch	_	_	I-Premise
218	patients	_	_	I-Premise
219	had	_	_	I-Premise
220	10	_	_	I-Premise
221	.	_	_	I-Premise

222	3	_	_	I-Premise
223	%	_	_	I-Premise
224	less	_	_	I-Premise
225	stool	_	_	I-Premise
226	fragmentation	_	_	I-Premise
227	but	_	_	I-Premise
228	poorer	_	_	I-Premise
229	stool	_	_	I-Premise
230	deferment	_	_	I-Premise
231	and	_	_	I-Premise
232	more	_	_	I-Premise
233	nocturnal	_	_	I-Premise
234	leakage	_	_	I-Premise
235	.	_	_	I-Premise

236	However	_	_	O
237	,	_	_	O
238	there	_	_	B-Premise
239	were	_	_	I-Premise
240	no	_	_	I-Premise
241	differences	_	_	I-Premise
242	in	_	_	I-Premise
243	the	_	_	I-Premise
244	bowel	_	_	I-Premise
245	function	_	_	I-Premise
246	,	_	_	I-Premise
247	continence	_	_	I-Premise
248	score	_	_	I-Premise
249	,	_	_	I-Premise
250	and	_	_	I-Premise
251	quality	_	_	I-Premise
252	of	_	_	I-Premise
253	life	_	_	I-Premise
254	at	_	_	I-Premise
255	1	_	_	I-Premise
256	year	_	_	I-Premise
257	.	_	_	I-Premise

258	There	_	_	B-Premise
259	were	_	_	I-Premise
260	no	_	_	I-Premise
261	differences	_	_	I-Premise
262	in	_	_	I-Premise
263	the	_	_	I-Premise
264	anorectal	_	_	I-Premise
265	manometry	_	_	I-Premise
266	and	_	_	I-Premise
267	endoanal	_	_	I-Premise
268	ultrasound	_	_	I-Premise
269	findings	_	_	I-Premise
270	.	_	_	I-Premise

271	Coloplasty	_	_	B-Claim
272	pouches	_	_	I-Claim
273	resulted	_	_	I-Claim
274	in	_	_	I-Claim
275	more	_	_	I-Claim
276	anastomotic	_	_	I-Claim
277	leaks	_	_	I-Claim
278	and	_	_	I-Claim
279	minimal	_	_	I-Claim
280	differences	_	_	I-Claim
281	in	_	_	I-Claim
282	bowel	_	_	I-Claim
283	function	_	_	I-Claim
284	.	_	_	I-Claim

285	At	_	_	O
286	present	_	_	O
287	,	_	_	O
288	the	_	_	B-Claim
289	J	_	_	I-Claim
290	-	_	_	I-Claim
291	pouch	_	_	I-Claim
292	remains	_	_	I-Claim
293	the	_	_	I-Claim
294	benchmark	_	_	I-Claim
295	for	_	_	I-Claim
296	routine	_	_	I-Claim
297	clinical	_	_	I-Claim
298	practice	_	_	I-Claim
299	,	_	_	I-Claim
300	and	_	_	O
301	due	_	_	B-Claim
302	care	_	_	I-Claim
303	(	_	_	I-Claim
304	including	_	_	I-Claim
305	defunctioning	_	_	I-Claim
306	stoma	_	_	I-Claim
307	)	_	_	I-Claim
308	should	_	_	I-Claim
309	be	_	_	I-Claim
310	exercised	_	_	I-Claim
311	in	_	_	I-Claim
312	situations	_	_	I-Claim
313	requiring	_	_	I-Claim
314	CP	_	_	I-Claim
315	.	_	_	I-Claim


0	We	_	_	O
1	aimed	_	_	O
2	to	_	_	O
3	determine	_	_	O
4	the	_	_	O
5	effectiveness	_	_	O
6	of	_	_	O
7	a	_	_	O
8	lay	_	_	O
9	-	_	_	O
10	administered	_	_	O
11	tailored	_	_	O
12	education	_	_	O
13	and	_	_	O
14	coaching	_	_	O
15	(	_	_	O
16	TEC	_	_	O
17	)	_	_	O
18	intervention	_	_	O
19	(	_	_	O
20	aimed	_	_	O
21	at	_	_	O
22	reducing	_	_	O
23	pain	_	_	O
24	misconceptions	_	_	O
25	and	_	_	O
26	enhancing	_	_	O
27	self	_	_	O
28	-	_	_	O
29	efficacy	_	_	O
30	for	_	_	O
31	communicating	_	_	O
32	with	_	_	O
33	physicians	_	_	O
34	)	_	_	O
35	on	_	_	O
36	cancer	_	_	O
37	pain	_	_	O
38	severity	_	_	O
39	,	_	_	O
40	pain	_	_	O
41	-	_	_	O
42	related	_	_	O
43	impairment	_	_	O
44	,	_	_	O
45	and	_	_	O
46	quality	_	_	O
47	of	_	_	O
48	life	_	_	O
49	.	_	_	O

50	Cancer	_	_	O
51	patients	_	_	O
52	with	_	_	O
53	baseline	_	_	O
54	"	_	_	O
55	worst	_	_	O
56	pain	_	_	O
57	"	_	_	O
58	of	_	_	O
59	≥	_	_	O
60	4	_	_	O
61	on	_	_	O
62	a	_	_	O
63	0	_	_	O
64	-	_	_	O
65	10	_	_	O
66	scale	_	_	O
67	or	_	_	O
68	at	_	_	O
69	least	_	_	O
70	moderate	_	_	O
71	functional	_	_	O
72	impairment	_	_	O
73	due	_	_	O
74	to	_	_	O
75	pain	_	_	O
76	were	_	_	O
77	randomly	_	_	O
78	assigned	_	_	O
79	to	_	_	O
80	TEC	_	_	O
81	or	_	_	O
82	enhanced	_	_	O
83	usual	_	_	O
84	care	_	_	O
85	(	_	_	O
86	EUC	_	_	O
87	)	_	_	O
88	during	_	_	O
89	a	_	_	O
90	telephone	_	_	O
91	interview	_	_	O
92	conducted	_	_	O
93	in	_	_	O
94	advance	_	_	O
95	of	_	_	O
96	a	_	_	O
97	planned	_	_	O
98	oncology	_	_	O
99	office	_	_	O
100	visit	_	_	O
101	(	_	_	O
102	265	_	_	O
103	patients	_	_	O
104	randomized	_	_	O
105	to	_	_	O
106	TEC	_	_	O
107	or	_	_	O
108	EUC	_	_	O
109	;	_	_	O
110	258	_	_	O
111	completed	_	_	O
112	at	_	_	O
113	least	_	_	O
114	one	_	_	O
115	follow	_	_	O
116	-	_	_	O
117	up	_	_	O
118	)	_	_	O
119	.	_	_	O

120	Patients	_	_	O
121	completed	_	_	O
122	questionnaires	_	_	O
123	before	_	_	O
124	and	_	_	O
125	after	_	_	O
126	the	_	_	O
127	visit	_	_	O
128	and	_	_	O
129	were	_	_	O
130	interviewed	_	_	O
131	by	_	_	O
132	telephone	_	_	O
133	at	_	_	O
134	2	_	_	O
135	,	_	_	O
136	6	_	_	O
137	,	_	_	O
138	and	_	_	O
139	12	_	_	O
140	weeks	_	_	O
141	.	_	_	O

142	Mixed	_	_	O
143	effects	_	_	O
144	regressions	_	_	O
145	were	_	_	O
146	used	_	_	O
147	to	_	_	O
148	evaluate	_	_	O
149	the	_	_	O
150	intervention	_	_	O
151	adjusting	_	_	O
152	for	_	_	O
153	patient	_	_	O
154	,	_	_	O
155	practice	_	_	O
156	,	_	_	O
157	and	_	_	O
158	site	_	_	O
159	characteristics	_	_	O
160	.	_	_	O

161	Compared	_	_	B-Premise
162	to	_	_	I-Premise
163	EUC	_	_	I-Premise
164	,	_	_	I-Premise
165	TEC	_	_	I-Premise
166	was	_	_	I-Premise
167	associated	_	_	I-Premise
168	with	_	_	I-Premise
169	increased	_	_	I-Premise
170	pain	_	_	I-Premise
171	communication	_	_	I-Premise
172	self	_	_	I-Premise
173	-	_	_	I-Premise
174	efficacy	_	_	I-Premise
175	after	_	_	I-Premise
176	the	_	_	I-Premise
177	intervention	_	_	I-Premise
178	(	_	_	I-Premise
179	P	_	_	I-Premise
180	<	_	_	I-Premise
181	.	_	_	I-Premise

182	001	_	_	I-Premise
183	)	_	_	I-Premise
184	;	_	_	I-Premise
185	both	_	_	B-Premise
186	groups	_	_	I-Premise
187	showed	_	_	I-Premise
188	significant	_	_	I-Premise
189	(	_	_	I-Premise
190	P	_	_	I-Premise
191	<	_	_	I-Premise
192	.	_	_	I-Premise

193	0001	_	_	I-Premise
194	)	_	_	I-Premise
195	,	_	_	I-Premise
196	similar	_	_	I-Premise
197	,	_	_	I-Premise
198	reductions	_	_	I-Premise
199	in	_	_	I-Premise
200	pain	_	_	I-Premise
201	misconceptions	_	_	I-Premise
202	.	_	_	I-Premise

203	At	_	_	B-Premise
204	2	_	_	I-Premise
205	weeks	_	_	I-Premise
206	,	_	_	I-Premise
207	assignment	_	_	I-Premise
208	to	_	_	I-Premise
209	TEC	_	_	I-Premise
210	was	_	_	I-Premise
211	associated	_	_	I-Premise
212	with	_	_	I-Premise
213	improvement	_	_	I-Premise
214	in	_	_	I-Premise
215	pain	_	_	I-Premise
216	-	_	_	I-Premise
217	related	_	_	I-Premise
218	impairment	_	_	I-Premise
219	(	_	_	I-Premise
220	-	_	_	I-Premise
221	0	_	_	I-Premise
222	.	_	_	I-Premise

223	25	_	_	I-Premise
224	points	_	_	I-Premise
225	on	_	_	I-Premise
226	a	_	_	I-Premise
227	5	_	_	I-Premise
228	-	_	_	I-Premise
229	point	_	_	I-Premise
230	scale	_	_	I-Premise
231	,	_	_	I-Premise
232	95	_	_	I-Premise
233	%	_	_	I-Premise
234	confidence	_	_	I-Premise
235	interval	_	_	I-Premise
236	-	_	_	I-Premise
237	0	_	_	I-Premise
238	.	_	_	I-Premise

239	43	_	_	I-Premise
240	to	_	_	I-Premise
241	-	_	_	I-Premise
242	0	_	_	I-Premise
243	.	_	_	I-Premise

244	06	_	_	I-Premise
245	,	_	_	I-Premise
246	P	_	_	I-Premise
247	=	_	_	I-Premise
248	.	_	_	I-Premise

249	01	_	_	I-Premise
250	)	_	_	I-Premise
251	but	_	_	B-Premise
252	not	_	_	I-Premise
253	in	_	_	I-Premise
254	pain	_	_	I-Premise
255	severity	_	_	I-Premise
256	(	_	_	I-Premise
257	-	_	_	I-Premise
258	0	_	_	I-Premise
259	.	_	_	I-Premise

260	21	_	_	I-Premise
261	points	_	_	I-Premise
262	on	_	_	I-Premise
263	an	_	_	I-Premise
264	11	_	_	I-Premise
265	-	_	_	I-Premise
266	point	_	_	I-Premise
267	scale	_	_	I-Premise
268	,	_	_	I-Premise
269	-	_	_	I-Premise
270	0	_	_	I-Premise
271	.	_	_	I-Premise

272	60	_	_	I-Premise
273	to	_	_	I-Premise
274	0	_	_	I-Premise
275	.	_	_	I-Premise

276	17	_	_	I-Premise
277	,	_	_	I-Premise
278	P	_	_	I-Premise
279	=	_	_	I-Premise
280	.	_	_	I-Premise

281	27	_	_	I-Premise
282	)	_	_	I-Premise
283	.	_	_	I-Premise

284	The	_	_	B-Premise
285	improvement	_	_	I-Premise
286	in	_	_	I-Premise
287	pain	_	_	I-Premise
288	-	_	_	I-Premise
289	related	_	_	I-Premise
290	impairment	_	_	I-Premise
291	was	_	_	I-Premise
292	not	_	_	I-Premise
293	sustained	_	_	I-Premise
294	at	_	_	I-Premise
295	6	_	_	I-Premise
296	and	_	_	I-Premise
297	12	_	_	I-Premise
298	weeks	_	_	I-Premise
299	.	_	_	I-Premise

300	There	_	_	B-Premise
301	were	_	_	I-Premise
302	no	_	_	I-Premise
303	significant	_	_	I-Premise
304	intervention	_	_	I-Premise
305	by	_	_	I-Premise
306	subgroup	_	_	I-Premise
307	interactions	_	_	I-Premise
308	(	_	_	I-Premise
309	P	_	_	I-Premise
310	>	_	_	I-Premise
311	.	_	_	I-Premise

312	10	_	_	I-Premise
313	)	_	_	I-Premise
314	.	_	_	I-Premise

315	We	_	_	B-Claim
316	conclude	_	_	I-Claim
317	that	_	_	I-Claim
318	TEC	_	_	I-Claim
319	,	_	_	I-Claim
320	compared	_	_	I-Claim
321	with	_	_	I-Claim
322	EUC	_	_	I-Claim
323	,	_	_	I-Claim
324	resulted	_	_	I-Claim
325	in	_	_	I-Claim
326	improved	_	_	I-Claim
327	pain	_	_	I-Claim
328	communication	_	_	I-Claim
329	self	_	_	I-Claim
330	-	_	_	I-Claim
331	efficacy	_	_	I-Claim
332	and	_	_	I-Claim
333	temporary	_	_	I-Claim
334	improvement	_	_	I-Claim
335	in	_	_	I-Claim
336	pain	_	_	I-Claim
337	-	_	_	I-Claim
338	related	_	_	I-Claim
339	impairment	_	_	I-Claim
340	,	_	_	I-Claim
341	but	_	_	I-Claim
342	no	_	_	I-Claim
343	improvement	_	_	I-Claim
344	in	_	_	I-Claim
345	pain	_	_	I-Claim
346	severity	_	_	I-Claim
347	.	_	_	I-Claim


0	For	_	_	B-Claim
1	malignant	_	_	I-Claim
2	pleural	_	_	I-Claim
3	mesothelioma	_	_	I-Claim
4	(	_	_	I-Claim
5	MPM	_	_	I-Claim
6	)	_	_	I-Claim
7	patients	_	_	I-Claim
8	with	_	_	I-Claim
9	a	_	_	I-Claim
10	poor	_	_	I-Claim
11	prognosis	_	_	I-Claim
12	,	_	_	I-Claim
13	maintaining	_	_	I-Claim
14	health	_	_	I-Claim
15	-	_	_	I-Claim
16	related	_	_	I-Claim
17	quality	_	_	I-Claim
18	of	_	_	I-Claim
19	life	_	_	I-Claim
20	(	_	_	I-Claim
21	HRQOL	_	_	I-Claim
22	)	_	_	I-Claim
23	is	_	_	I-Claim
24	important	_	_	I-Claim
25	.	_	_	I-Claim

26	This	_	_	O
27	article	_	_	O
28	compares	_	_	O
29	the	_	_	O
30	impact	_	_	O
31	on	_	_	O
32	HRQOL	_	_	O
33	of	_	_	O
34	first	_	_	O
35	-	_	_	O
36	line	_	_	O
37	treatment	_	_	O
38	with	_	_	O
39	cisplatin	_	_	O
40	versus	_	_	O
41	raltitrexed	_	_	O
42	and	_	_	O
43	cisplatin	_	_	O
44	.	_	_	O

45	Patients	_	_	O
46	with	_	_	O
47	histologically	_	_	O
48	-	_	_	O
49	proven	_	_	O
50	unresectable	_	_	O
51	MPM	_	_	O
52	,	_	_	O
53	not	_	_	O
54	pretreated	_	_	O
55	with	_	_	O
56	chemotherapy	_	_	O
57	were	_	_	O
58	randomly	_	_	O
59	assigned	_	_	O
60	to	_	_	O
61	receive	_	_	O
62	cisplatin	_	_	O
63	80	_	_	O
64	mg	_	_	O
65	/	_	_	O
66	m2	_	_	O
67	intravenously	_	_	O
68	on	_	_	O
69	day	_	_	O
70	1	_	_	O
71	,	_	_	O
72	with	_	_	O
73	or	_	_	O
74	without	_	_	O
75	preceding	_	_	O
76	infusion	_	_	O
77	of	_	_	O
78	raltitrexed	_	_	O
79	3	_	_	O
80	mg	_	_	O
81	/	_	_	O
82	m2	_	_	O
83	.	_	_	O

84	HRQOL	_	_	O
85	was	_	_	O
86	assessed	_	_	O
87	with	_	_	O
88	the	_	_	O
89	European	_	_	O
90	Organisation	_	_	O
91	for	_	_	O
92	Research	_	_	O
93	and	_	_	O
94	Treatment	_	_	O
95	of	_	_	O
96	Cancer	_	_	O
97	Core	_	_	O
98	Quality	_	_	O
99	of	_	_	O
100	Life	_	_	O
101	Questionnaire	_	_	O
102	C30	_	_	O
103	(	_	_	O
104	EORTC	_	_	O
105	QLQ	_	_	O
106	-	_	_	O
107	C30	_	_	O
108	)	_	_	O
109	and	_	_	O
110	EORTC	_	_	O
111	Lung	_	_	O
112	Cancer	_	_	O
113	Module	_	_	O
114	(	_	_	O
115	QLQ	_	_	O
116	-	_	_	O
117	LC13	_	_	O
118	)	_	_	O
119	tools	_	_	O
120	.	_	_	O

121	Assessments	_	_	O
122	were	_	_	O
123	conducted	_	_	O
124	at	_	_	O
125	baseline	_	_	O
126	,	_	_	O
127	immediately	_	_	O
128	before	_	_	O
129	every	_	_	O
130	treatment	_	_	O
131	cycle	_	_	O
132	,	_	_	O
133	at	_	_	O
134	the	_	_	O
135	end	_	_	O
136	of	_	_	O
137	treatment	_	_	O
138	,	_	_	O
139	and	_	_	O
140	every	_	_	O
141	six	_	_	O
142	weeks	_	_	O
143	for	_	_	O
144	12	_	_	O
145	months	_	_	O
146	.	_	_	O

147	Two	_	_	O
148	hundred	_	_	O
149	fifty	_	_	O
150	patients	_	_	O
151	were	_	_	O
152	randomly	_	_	O
153	assigned	_	_	O
154	,	_	_	O
155	80	_	_	O
156	%	_	_	O
157	were	_	_	O
158	male	_	_	O
159	with	_	_	O
160	a	_	_	O
161	median	_	_	O
162	age	_	_	O
163	of	_	_	O
164	58	_	_	O
165	years	_	_	O
166	,	_	_	O
167	WHO	_	_	O
168	performance	_	_	O
169	status	_	_	O
170	0	_	_	O
171	,	_	_	O
172	1	_	_	O
173	,	_	_	O
174	and	_	_	O
175	2	_	_	O
176	,	_	_	O
177	in	_	_	O
178	25	_	_	O
179	%	_	_	O
180	,	_	_	O
181	62	_	_	O
182	%	_	_	O
183	,	_	_	O
184	and	_	_	O
185	13	_	_	O
186	%	_	_	O
187	of	_	_	O
188	cases	_	_	O
189	.	_	_	O

190	The	_	_	B-Premise
191	clinical	_	_	I-Premise
192	results	_	_	I-Premise
193	found	_	_	I-Premise
194	raltitrexed	_	_	I-Premise
195	and	_	_	I-Premise
196	cisplatin	_	_	I-Premise
197	to	_	_	I-Premise
198	be	_	_	I-Premise
199	superior	_	_	I-Premise
200	to	_	_	I-Premise
201	cisplatin	_	_	I-Premise
202	with	_	_	I-Premise
203	regard	_	_	I-Premise
204	to	_	_	I-Premise
205	overall	_	_	I-Premise
206	survival	_	_	I-Premise
207	(	_	_	I-Premise
208	P	_	_	I-Premise
209	=	_	_	I-Premise
210	.	_	_	I-Premise

211	048	_	_	I-Premise
212	)	_	_	I-Premise
213	.	_	_	I-Premise

214	The	_	_	B-Premise
215	global	_	_	I-Premise
216	HRQOL	_	_	I-Premise
217	scale	_	_	I-Premise
218	was	_	_	I-Premise
219	comparable	_	_	I-Premise
220	at	_	_	I-Premise
221	baseline	_	_	I-Premise
222	on	_	_	I-Premise
223	both	_	_	I-Premise
224	treatment	_	_	I-Premise
225	arms	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	.	_	_	I-Premise

230	848	_	_	I-Premise
231	)	_	_	I-Premise
232	;	_	_	I-Premise
233	at	_	_	B-Premise
234	no	_	_	I-Premise
235	point	_	_	I-Premise
236	was	_	_	I-Premise
237	any	_	_	I-Premise
238	significant	_	_	I-Premise
239	difference	_	_	I-Premise
240	apparent	_	_	I-Premise
241	on	_	_	I-Premise
242	this	_	_	I-Premise
243	end	_	_	I-Premise
244	point	_	_	I-Premise
245	.	_	_	I-Premise

246	Both	_	_	B-Premise
247	treatments	_	_	I-Premise
248	led	_	_	I-Premise
249	to	_	_	I-Premise
250	an	_	_	I-Premise
251	improvement	_	_	I-Premise
252	,	_	_	I-Premise
253	over	_	_	I-Premise
254	time	_	_	I-Premise
255	,	_	_	I-Premise
256	in	_	_	I-Premise
257	dyspnoea	_	_	I-Premise
258	.	_	_	I-Premise

259	This	_	_	B-Claim
260	effect	_	_	I-Claim
261	is	_	_	I-Claim
262	an	_	_	I-Claim
263	important	_	_	I-Claim
264	clinically	_	_	I-Claim
265	meaningful	_	_	I-Claim
266	reduction	_	_	I-Claim
267	from	_	_	I-Claim
268	baseline	_	_	I-Claim
269	in	_	_	I-Claim
270	the	_	_	I-Claim
271	cisplatin	_	_	I-Claim
272	/	_	_	I-Claim
273	raltitrexed	_	_	I-Claim
274	arm	_	_	I-Claim
275	.	_	_	I-Claim

276	However	_	_	B-Premise
277	,	_	_	I-Premise
278	the	_	_	I-Premise
279	majority	_	_	I-Premise
280	of	_	_	I-Premise
281	scales	_	_	I-Premise
282	of	_	_	I-Premise
283	the	_	_	I-Premise
284	EORTC	_	_	I-Premise
285	QLQ	_	_	I-Premise
286	-	_	_	I-Premise
287	C30	_	_	I-Premise
288	or	_	_	I-Premise
289	LC13	_	_	I-Premise
290	showed	_	_	I-Premise
291	stabilization	_	_	I-Premise
292	of	_	_	I-Premise
293	HRQOL	_	_	I-Premise
294	with	_	_	I-Premise
295	few	_	_	I-Premise
296	clinically	_	_	I-Premise
297	significant	_	_	I-Premise
298	differences	_	_	I-Premise
299	between	_	_	I-Premise
300	the	_	_	I-Premise
301	treatment	_	_	I-Premise
302	arms	_	_	I-Premise
303	.	_	_	I-Premise

304	This	_	_	B-Claim
305	study	_	_	I-Claim
306	provides	_	_	I-Claim
307	important	_	_	I-Claim
308	information	_	_	I-Claim
309	about	_	_	I-Claim
310	the	_	_	I-Claim
311	HRQOL	_	_	I-Claim
312	of	_	_	I-Claim
313	chemotherapy	_	_	I-Claim
314	-	_	_	I-Claim
315	treated	_	_	I-Claim
316	MPM	_	_	I-Claim
317	patients	_	_	I-Claim
318	.	_	_	I-Claim


0	The	_	_	O
1	combination	_	_	O
2	of	_	_	O
3	radiotherapy	_	_	O
4	plus	_	_	O
5	long	_	_	O
6	-	_	_	O
7	term	_	_	O
8	medical	_	_	O
9	suppression	_	_	O
10	of	_	_	O
11	androgens	_	_	O
12	(	_	_	O
13	>	_	_	O
14	or	_	_	O
15	=	_	_	O
16	2	_	_	O
17	years	_	_	O
18	)	_	_	O
19	improves	_	_	O
20	overall	_	_	O
21	survival	_	_	O
22	in	_	_	O
23	patients	_	_	O
24	with	_	_	O
25	locally	_	_	O
26	advanced	_	_	O
27	prostate	_	_	O
28	cancer	_	_	O
29	.	_	_	O

30	We	_	_	O
31	compared	_	_	O
32	the	_	_	O
33	use	_	_	O
34	of	_	_	O
35	radiotherapy	_	_	O
36	plus	_	_	O
37	short	_	_	O
38	-	_	_	O
39	term	_	_	O
40	androgen	_	_	O
41	suppression	_	_	O
42	with	_	_	O
43	the	_	_	O
44	use	_	_	O
45	of	_	_	O
46	radiotherapy	_	_	O
47	plus	_	_	O
48	long	_	_	O
49	-	_	_	O
50	term	_	_	O
51	androgen	_	_	O
52	suppression	_	_	O
53	in	_	_	O
54	the	_	_	O
55	treatment	_	_	O
56	of	_	_	O
57	locally	_	_	O
58	advanced	_	_	O
59	prostate	_	_	O
60	cancer	_	_	O
61	.	_	_	O

62	We	_	_	O
63	randomly	_	_	O
64	assigned	_	_	O
65	patients	_	_	O
66	with	_	_	O
67	locally	_	_	O
68	advanced	_	_	O
69	prostate	_	_	O
70	cancer	_	_	O
71	who	_	_	O
72	had	_	_	O
73	received	_	_	O
74	external	_	_	O
75	-	_	_	O
76	beam	_	_	O
77	radiotherapy	_	_	O
78	plus	_	_	O
79	6	_	_	O
80	months	_	_	O
81	of	_	_	O
82	androgen	_	_	O
83	suppression	_	_	O
84	to	_	_	O
85	two	_	_	O
86	groups	_	_	O
87	,	_	_	O
88	one	_	_	O
89	to	_	_	O
90	receive	_	_	O
91	no	_	_	O
92	further	_	_	O
93	treatment	_	_	O
94	(	_	_	O
95	short	_	_	O
96	-	_	_	O
97	term	_	_	O
98	suppression	_	_	O
99	)	_	_	O
100	and	_	_	O
101	the	_	_	O
102	other	_	_	O
103	to	_	_	O
104	receive	_	_	O
105	2	_	_	O
106	.	_	_	O

107	5	_	_	O
108	years	_	_	O
109	of	_	_	O
110	further	_	_	O
111	treatment	_	_	O
112	with	_	_	O
113	a	_	_	O
114	luteinizing	_	_	O
115	hormone	_	_	O
116	-	_	_	O
117	releasing	_	_	O
118	hormone	_	_	O
119	agonist	_	_	O
120	(	_	_	O
121	long	_	_	O
122	-	_	_	O
123	term	_	_	O
124	suppression	_	_	O
125	)	_	_	O
126	.	_	_	O

127	An	_	_	O
128	outcome	_	_	O
129	of	_	_	O
130	noninferiority	_	_	O
131	of	_	_	O
132	short	_	_	O
133	-	_	_	O
134	term	_	_	O
135	androgen	_	_	O
136	suppression	_	_	O
137	as	_	_	O
138	compared	_	_	O
139	with	_	_	O
140	long	_	_	O
141	-	_	_	O
142	term	_	_	O
143	suppression	_	_	O
144	required	_	_	O
145	a	_	_	O
146	hazard	_	_	O
147	ratio	_	_	O
148	of	_	_	O
149	more	_	_	O
150	than	_	_	O
151	1	_	_	O
152	.	_	_	O

153	35	_	_	O
154	for	_	_	O
155	overall	_	_	O
156	survival	_	_	O
157	,	_	_	O
158	with	_	_	O
159	a	_	_	O
160	one	_	_	O
161	-	_	_	O
162	sided	_	_	O
163	alpha	_	_	O
164	level	_	_	O
165	of	_	_	O
166	0	_	_	O
167	.	_	_	O

168	05	_	_	O
169	.	_	_	O

170	An	_	_	O
171	interim	_	_	O
172	analysis	_	_	O
173	showed	_	_	O
174	futility	_	_	O
175	,	_	_	O
176	and	_	_	O
177	the	_	_	O
178	results	_	_	O
179	are	_	_	O
180	presented	_	_	O
181	with	_	_	O
182	an	_	_	O
183	adjusted	_	_	O
184	one	_	_	O
185	-	_	_	O
186	sided	_	_	O
187	alpha	_	_	O
188	level	_	_	O
189	of	_	_	O
190	0	_	_	O
191	.	_	_	O

192	0429	_	_	O
193	.	_	_	O

194	A	_	_	O
195	total	_	_	O
196	of	_	_	O
197	1113	_	_	O
198	men	_	_	O
199	were	_	_	O
200	registered	_	_	O
201	,	_	_	O
202	of	_	_	O
203	whom	_	_	O
204	970	_	_	O
205	were	_	_	O
206	randomly	_	_	O
207	assigned	_	_	O
208	,	_	_	O
209	483	_	_	O
210	to	_	_	O
211	short	_	_	O
212	-	_	_	O
213	term	_	_	O
214	suppression	_	_	O
215	and	_	_	O
216	487	_	_	O
217	to	_	_	O
218	long	_	_	O
219	-	_	_	O
220	term	_	_	O
221	suppression	_	_	O
222	.	_	_	O

223	After	_	_	B-Premise
224	a	_	_	I-Premise
225	median	_	_	I-Premise
226	follow	_	_	I-Premise
227	-	_	_	I-Premise
228	up	_	_	I-Premise
229	of	_	_	I-Premise
230	6	_	_	I-Premise
231	.	_	_	I-Premise

232	4	_	_	I-Premise
233	years	_	_	I-Premise
234	,	_	_	I-Premise
235	132	_	_	I-Premise
236	patients	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	short	_	_	I-Premise
240	-	_	_	I-Premise
241	term	_	_	I-Premise
242	group	_	_	I-Premise
243	and	_	_	I-Premise
244	98	_	_	I-Premise
245	in	_	_	I-Premise
246	the	_	_	I-Premise
247	long	_	_	I-Premise
248	-	_	_	I-Premise
249	term	_	_	I-Premise
250	group	_	_	I-Premise
251	had	_	_	I-Premise
252	died	_	_	I-Premise
253	;	_	_	I-Premise
254	the	_	_	B-Premise
255	number	_	_	I-Premise
256	of	_	_	I-Premise
257	deaths	_	_	I-Premise
258	due	_	_	I-Premise
259	to	_	_	I-Premise
260	prostate	_	_	I-Premise
261	cancer	_	_	I-Premise
262	was	_	_	I-Premise
263	47	_	_	I-Premise
264	in	_	_	I-Premise
265	the	_	_	I-Premise
266	short	_	_	I-Premise
267	-	_	_	I-Premise
268	term	_	_	I-Premise
269	group	_	_	I-Premise
270	and	_	_	I-Premise
271	29	_	_	I-Premise
272	in	_	_	I-Premise
273	the	_	_	I-Premise
274	long	_	_	I-Premise
275	-	_	_	I-Premise
276	term	_	_	I-Premise
277	group	_	_	I-Premise
278	.	_	_	I-Premise

279	The	_	_	B-Premise
280	5	_	_	I-Premise
281	-	_	_	I-Premise
282	year	_	_	I-Premise
283	overall	_	_	I-Premise
284	mortality	_	_	I-Premise
285	for	_	_	I-Premise
286	short	_	_	I-Premise
287	-	_	_	I-Premise
288	term	_	_	I-Premise
289	and	_	_	I-Premise
290	long	_	_	I-Premise
291	-	_	_	I-Premise
292	term	_	_	I-Premise
293	suppression	_	_	I-Premise
294	was	_	_	I-Premise
295	19	_	_	I-Premise
296	.	_	_	I-Premise

297	0	_	_	I-Premise
298	%	_	_	I-Premise
299	and	_	_	I-Premise
300	15	_	_	I-Premise
301	.	_	_	I-Premise

302	2	_	_	I-Premise
303	%	_	_	I-Premise
304	,	_	_	I-Premise
305	respectively	_	_	I-Premise
306	;	_	_	I-Premise
307	the	_	_	O
308	observed	_	_	O
309	hazard	_	_	O
310	ratio	_	_	O
311	was	_	_	O
312	1	_	_	O
313	.	_	_	O

314	42	_	_	O
315	(	_	_	O
316	upper	_	_	O
317	95	_	_	O
318	.	_	_	O

319	71	_	_	O
320	%	_	_	O
321	confidence	_	_	O
322	limit	_	_	O
323	,	_	_	O
324	1	_	_	O
325	.	_	_	O

326	79	_	_	O
327	;	_	_	O
328	P	_	_	O
329	=	_	_	O
330	0	_	_	O
331	.	_	_	O

332	65	_	_	O
333	for	_	_	O
334	noninferiority	_	_	O
335	)	_	_	O
336	.	_	_	O

337	Adverse	_	_	B-Premise
338	events	_	_	I-Premise
339	in	_	_	I-Premise
340	both	_	_	I-Premise
341	groups	_	_	I-Premise
342	included	_	_	I-Premise
343	fatigue	_	_	I-Premise
344	,	_	_	I-Premise
345	diminished	_	_	I-Premise
346	sexual	_	_	I-Premise
347	function	_	_	I-Premise
348	,	_	_	I-Premise
349	and	_	_	I-Premise
350	hot	_	_	I-Premise
351	flushes	_	_	I-Premise
352	.	_	_	I-Premise

353	The	_	_	B-Claim
354	combination	_	_	I-Claim
355	of	_	_	I-Claim
356	radiotherapy	_	_	I-Claim
357	plus	_	_	I-Claim
358	6	_	_	I-Claim
359	months	_	_	I-Claim
360	of	_	_	I-Claim
361	androgen	_	_	I-Claim
362	suppression	_	_	I-Claim
363	provides	_	_	I-Claim
364	inferior	_	_	I-Claim
365	survival	_	_	I-Claim
366	as	_	_	I-Claim
367	compared	_	_	I-Claim
368	with	_	_	I-Claim
369	radiotherapy	_	_	I-Claim
370	plus	_	_	I-Claim
371	3	_	_	I-Claim
372	years	_	_	I-Claim
373	of	_	_	I-Claim
374	androgen	_	_	I-Claim
375	suppression	_	_	I-Claim
376	in	_	_	I-Claim
377	the	_	_	I-Claim
378	treatment	_	_	I-Claim
379	of	_	_	I-Claim
380	locally	_	_	I-Claim
381	advanced	_	_	I-Claim
382	prostate	_	_	I-Claim
383	cancer	_	_	I-Claim
384	.	_	_	I-Claim


0	Few	_	_	O
1	reports	_	_	O
2	have	_	_	O
3	examined	_	_	O
4	the	_	_	O
5	use	_	_	O
6	of	_	_	O
7	recombinant	_	_	O
8	human	_	_	O
9	thyroid	_	_	O
10	-	_	_	O
11	stimulating	_	_	O
12	hormone	_	_	O
13	(	_	_	O
14	rhTSH	_	_	O
15	)	_	_	O
16	for	_	_	O
17	ablation	_	_	O
18	of	_	_	O
19	postsurgical	_	_	O
20	thyroid	_	_	O
21	remnants	_	_	O
22	after	_	_	O
23	low	_	_	O
24	-	_	_	O
25	dose	_	_	O
26	radioactive	_	_	O
27	iodine	_	_	O
28	(	_	_	O
29	RI	_	_	O
30	)	_	_	O
31	therapy	_	_	O
32	,	_	_	O
33	compared	_	_	O
34	with	_	_	O
35	conventional	_	_	O
36	thyroid	_	_	O
37	hormone	_	_	O
38	withdrawal	_	_	O
39	.	_	_	O

40	We	_	_	O
41	investigated	_	_	O
42	whether	_	_	O
43	patient	_	_	O
44	preparation	_	_	O
45	using	_	_	O
46	rhTSH	_	_	O
47	was	_	_	O
48	comparable	_	_	O
49	to	_	_	O
50	conventional	_	_	O
51	thyroid	_	_	O
52	hormone	_	_	O
53	withdrawal	_	_	O
54	with	_	_	O
55	respect	_	_	O
56	to	_	_	O
57	efficacy	_	_	O
58	of	_	_	O
59	postsurgical	_	_	O
60	remnant	_	_	O
61	ablation	_	_	O
62	in	_	_	O
63	low	_	_	O
64	-	_	_	O
65	risk	_	_	O
66	patients	_	_	O
67	receiving	_	_	O
68	a	_	_	O
69	30	_	_	O
70	mCi	_	_	O
71	RI	_	_	O
72	.	_	_	O

73	In	_	_	O
74	addition	_	_	O
75	,	_	_	O
76	we	_	_	O
77	also	_	_	O
78	evaluated	_	_	O
79	the	_	_	O
80	impact	_	_	O
81	of	_	_	O
82	rhTSH	_	_	O
83	(	_	_	O
84	rhTSH	_	_	O
85	vs	_	_	O
86	.	_	_	O

87	conventional	_	_	O
88	thyroid	_	_	O
89	hormone	_	_	O
90	withdrawal	_	_	O
91	)	_	_	O
92	on	_	_	O
93	quality	_	_	O
94	of	_	_	O
95	life	_	_	O
96	(	_	_	O
97	QoL	_	_	O
98	)	_	_	O
99	of	_	_	O
100	thyroid	_	_	O
101	cancer	_	_	O
102	patients	_	_	O
103	undergoing	_	_	O
104	RI	_	_	O
105	ablation	_	_	O
106	.	_	_	O

107	This	_	_	O
108	study	_	_	O
109	included	_	_	O
110	three	_	_	O
111	groups	_	_	O
112	of	_	_	O
113	patients	_	_	O
114	,	_	_	O
115	enrolled	_	_	O
116	consecutively	_	_	O
117	.	_	_	O

118	From	_	_	O
119	February	_	_	O
120	2006	_	_	O
121	to	_	_	O
122	March	_	_	O
123	2007	_	_	O
124	,	_	_	O
125	291	_	_	O
126	patients	_	_	O
127	were	_	_	O
128	enrolled	_	_	O
129	and	_	_	O
130	randomized	_	_	O
131	,	_	_	O
132	after	_	_	O
133	total	_	_	O
134	thyroidectomy	_	_	O
135	:	_	_	O
136	(	_	_	O
137	1	_	_	O
138	)	_	_	O
139	withdrawal	_	_	O
140	of	_	_	O
141	levothyroxine	_	_	O
142	(	_	_	O
143	LT4	_	_	O
144	)	_	_	O
145	for	_	_	O
146	4	_	_	O
147	weeks	_	_	O
148	(	_	_	O
149	T4	_	_	O
150	-	_	_	O
151	WD	_	_	O
152	Group	_	_	O
153	,	_	_	O
154	n	_	_	O
155	=	_	_	O
156	89	_	_	O
157	)	_	_	O
158	,	_	_	O
159	(	_	_	O
160	2	_	_	O
161	)	_	_	O
162	withdrawal	_	_	O
163	of	_	_	O
164	LT4	_	_	O
165	for	_	_	O
166	4	_	_	O
167	weeks	_	_	O
168	plus	_	_	O
169	2	_	_	O
170	weeks	_	_	O
171	on	_	_	O
172	and	_	_	O
173	then	_	_	O
174	2	_	_	O
175	weeks	_	_	O
176	off	_	_	O
177	liothyronine	_	_	O
178	(	_	_	O
179	LT3	_	_	O
180	)	_	_	O
181	(	_	_	O
182	T3	_	_	O
183	-	_	_	O
184	WD	_	_	O
185	Group	_	_	O
186	,	_	_	O
187	n	_	_	O
188	=	_	_	O
189	133	_	_	O
190	)	_	_	O
191	,	_	_	O
192	and	_	_	O
193	(	_	_	O
194	3	_	_	O
195	)	_	_	O
196	rhTSH	_	_	O
197	administration	_	_	O
198	(	_	_	O
199	rhTSH	_	_	O
200	Group	_	_	O
201	,	_	_	O
202	n	_	_	O
203	=	_	_	O
204	69	_	_	O
205	)	_	_	O
206	.	_	_	O

207	QoL	_	_	O
208	was	_	_	O
209	determined	_	_	O
210	at	_	_	O
211	the	_	_	O
212	time	_	_	O
213	of	_	_	O
214	ablation	_	_	O
215	.	_	_	O

216	Patients	_	_	O
217	in	_	_	O
218	the	_	_	O
219	three	_	_	O
220	groups	_	_	O
221	did	_	_	O
222	not	_	_	O
223	differ	_	_	O
224	significantly	_	_	O
225	in	_	_	O
226	baseline	_	_	O
227	characteristics	_	_	O
228	or	_	_	O
229	tumor	_	_	O
230	,	_	_	O
231	node	_	_	O
232	and	_	_	O
233	metastasis	_	_	O
234	(	_	_	O
235	TNM	_	_	O
236	)	_	_	O
237	staging	_	_	O
238	.	_	_	O

239	In	_	_	B-Premise
240	all	_	_	I-Premise
241	study	_	_	I-Premise
242	groups	_	_	I-Premise
243	,	_	_	I-Premise
244	serum	_	_	I-Premise
245	TSH	_	_	I-Premise
246	levels	_	_	I-Premise
247	showed	_	_	I-Premise
248	very	_	_	I-Premise
249	good	_	_	I-Premise
250	stimulation	_	_	I-Premise
251	(	_	_	I-Premise
252	mean	_	_	I-Premise
253	,	_	_	I-Premise
254	82	_	_	I-Premise
255	.	_	_	I-Premise

256	24	_	_	I-Premise
257	+	_	_	I-Premise
258	/	_	_	I-Premise
259	-	_	_	I-Premise
260	18	_	_	I-Premise
261	.	_	_	I-Premise

262	21	_	_	I-Premise
263	mU	_	_	I-Premise
264	/	_	_	I-Premise
265	L	_	_	I-Premise
266	)	_	_	I-Premise
267	,	_	_	I-Premise
268	without	_	_	I-Premise
269	significant	_	_	I-Premise
270	between	_	_	I-Premise
271	-	_	_	I-Premise
272	group	_	_	I-Premise
273	differences	_	_	I-Premise
274	(	_	_	I-Premise
275	p	_	_	I-Premise
276	=	_	_	I-Premise
277	0	_	_	I-Premise
278	.	_	_	I-Premise

279	5213	_	_	I-Premise
280	)	_	_	I-Premise
281	.	_	_	I-Premise

282	Follow	_	_	O
283	-	_	_	O
284	up	_	_	O
285	examinations	_	_	O
286	were	_	_	O
287	performed	_	_	O
288	12	_	_	O
289	months	_	_	O
290	after	_	_	O
291	ablation	_	_	O
292	to	_	_	O
293	assess	_	_	O
294	ablation	_	_	O
295	outcome	_	_	O
296	in	_	_	O
297	each	_	_	O
298	group	_	_	O
299	by	_	_	O
300	131	_	_	O
301	whole	_	_	O
302	body	_	_	O
303	scans	_	_	O
304	(	_	_	O
305	WBSs	_	_	O
306	)	_	_	O
307	,	_	_	O
308	serum	_	_	O
309	thyroglobulin	_	_	O
310	measurement	_	_	O
311	after	_	_	O
312	TSH	_	_	O
313	stimulation	_	_	O
314	,	_	_	O
315	and	_	_	O
316	neck	_	_	O
317	ultrasonography	_	_	O
318	.	_	_	O

319	The	_	_	B-Premise
320	successful	_	_	I-Premise
321	ablation	_	_	I-Premise
322	rate	_	_	I-Premise
323	was	_	_	I-Premise
324	91	_	_	I-Premise
325	.	_	_	I-Premise

326	0	_	_	I-Premise
327	%	_	_	I-Premise
328	in	_	_	I-Premise
329	T4	_	_	I-Premise
330	-	_	_	I-Premise
331	WD	_	_	I-Premise
332	Group	_	_	I-Premise
333	,	_	_	I-Premise
334	91	_	_	I-Premise
335	.	_	_	I-Premise

336	7	_	_	I-Premise
337	%	_	_	I-Premise
338	in	_	_	I-Premise
339	T3	_	_	I-Premise
340	-	_	_	I-Premise
341	WD	_	_	I-Premise
342	Group	_	_	I-Premise
343	,	_	_	I-Premise
344	and	_	_	I-Premise
345	91	_	_	I-Premise
346	.	_	_	I-Premise

347	3	_	_	I-Premise
348	%	_	_	I-Premise
349	in	_	_	I-Premise
350	rhTSH	_	_	I-Premise
351	Group	_	_	I-Premise
352	,	_	_	I-Premise
353	without	_	_	I-Premise
354	significant	_	_	I-Premise
355	between	_	_	I-Premise
356	-	_	_	I-Premise
357	preparation	_	_	I-Premise
358	differences	_	_	I-Premise
359	(	_	_	I-Premise
360	p	_	_	I-Premise
361	=	_	_	I-Premise
362	0	_	_	I-Premise
363	.	_	_	I-Premise

364	2061	_	_	I-Premise
365	)	_	_	I-Premise
366	.	_	_	I-Premise

367	QoL	_	_	B-Premise
368	was	_	_	I-Premise
369	better	_	_	I-Premise
370	preserved	_	_	I-Premise
371	in	_	_	I-Premise
372	rhTSH	_	_	I-Premise
373	Group	_	_	I-Premise
374	than	_	_	I-Premise
375	in	_	_	I-Premise
376	T4	_	_	I-Premise
377	-	_	_	I-Premise
378	WD	_	_	I-Premise
379	and	_	_	I-Premise
380	T3	_	_	I-Premise
381	-	_	_	I-Premise
382	WD	_	_	I-Premise
383	Groups	_	_	I-Premise
384	(	_	_	I-Premise
385	p	_	_	I-Premise
386	<	_	_	I-Premise
387	0	_	_	I-Premise
388	.	_	_	I-Premise

389	0001	_	_	I-Premise
390	)	_	_	I-Premise
391	.	_	_	I-Premise

392	However	_	_	B-Premise
393	,	_	_	I-Premise
394	there	_	_	I-Premise
395	was	_	_	I-Premise
396	no	_	_	I-Premise
397	QoL	_	_	I-Premise
398	difference	_	_	I-Premise
399	at	_	_	I-Premise
400	the	_	_	I-Premise
401	time	_	_	I-Premise
402	of	_	_	I-Premise
403	ablation	_	_	I-Premise
404	between	_	_	I-Premise
405	T4	_	_	I-Premise
406	-	_	_	I-Premise
407	WD	_	_	I-Premise
408	and	_	_	I-Premise
409	T3	_	_	I-Premise
410	-	_	_	I-Premise
411	WD	_	_	I-Premise
412	Groups	_	_	I-Premise
413	.	_	_	I-Premise

414	Our	_	_	B-Claim
415	study	_	_	I-Claim
416	indicates	_	_	I-Claim
417	that	_	_	I-Claim
418	use	_	_	I-Claim
419	of	_	_	I-Claim
420	rhTSH	_	_	I-Claim
421	preserves	_	_	I-Claim
422	QoL	_	_	I-Claim
423	in	_	_	I-Claim
424	patients	_	_	I-Claim
425	undergoing	_	_	I-Claim
426	RI	_	_	I-Claim
427	ablation	_	_	I-Claim
428	and	_	_	I-Claim
429	affords	_	_	I-Claim
430	an	_	_	I-Claim
431	ablation	_	_	I-Claim
432	success	_	_	I-Claim
433	rate	_	_	I-Claim
434	comparable	_	_	I-Claim
435	to	_	_	I-Claim
436	that	_	_	I-Claim
437	seen	_	_	I-Claim
438	after	_	_	I-Claim
439	thyroid	_	_	I-Claim
440	hormone	_	_	I-Claim
441	withdrawal	_	_	I-Claim
442	.	_	_	I-Claim

443	Notably	_	_	O
444	,	_	_	O
445	ablation	_	_	O
446	preparation	_	_	O
447	using	_	_	O
448	withdrawal	_	_	O
449	of	_	_	O
450	LT3	_	_	O
451	for	_	_	O
452	2	_	_	O
453	weeks	_	_	O
454	did	_	_	O
455	not	_	_	O
456	prevent	_	_	O
457	development	_	_	O
458	of	_	_	O
459	profound	_	_	O
460	hypothyroidism	_	_	O
461	,	_	_	O
462	as	_	_	O
463	also	_	_	O
464	occurred	_	_	O
465	when	_	_	O
466	LT4	_	_	O
467	alone	_	_	O
468	was	_	_	O
469	withdrawn	_	_	O
470	for	_	_	O
471	4	_	_	O
472	weeks	_	_	O
473	.	_	_	O


0	The	_	_	O
1	effectiveness	_	_	O
2	of	_	_	O
3	a	_	_	O
4	Pain	_	_	O
5	Education	_	_	O
6	Program	_	_	O
7	in	_	_	O
8	cancer	_	_	O
9	patients	_	_	O
10	with	_	_	O
11	chronic	_	_	O
12	pain	_	_	O
13	offered	_	_	O
14	by	_	_	O
15	nurses	_	_	O
16	was	_	_	O
17	investigated	_	_	O
18	in	_	_	O
19	a	_	_	O
20	randomized	_	_	O
21	controlled	_	_	O
22	clinical	_	_	O
23	trial	_	_	O
24	.	_	_	O

25	A	_	_	O
26	multi	_	_	O
27	-	_	_	O
28	method	_	_	O
29	approach	_	_	O
30	was	_	_	O
31	used	_	_	O
32	in	_	_	O
33	which	_	_	O
34	verbal	_	_	O
35	instruction	_	_	O
36	,	_	_	O
37	written	_	_	O
38	material	_	_	O
39	,	_	_	O
40	an	_	_	O
41	audio	_	_	O
42	cassette	_	_	O
43	tape	_	_	O
44	,	_	_	O
45	and	_	_	O
46	the	_	_	O
47	use	_	_	O
48	of	_	_	O
49	a	_	_	O
50	pain	_	_	O
51	diary	_	_	O
52	were	_	_	O
53	combined	_	_	O
54	to	_	_	O
55	inform	_	_	O
56	and	_	_	O
57	instruct	_	_	O
58	patients	_	_	O
59	about	_	_	O
60	pain	_	_	O
61	and	_	_	O
62	pain	_	_	O
63	management	_	_	O
64	.	_	_	O

65	The	_	_	O
66	Pain	_	_	O
67	Education	_	_	O
68	Program	_	_	O
69	was	_	_	O
70	tailored	_	_	O
71	to	_	_	O
72	the	_	_	O
73	needs	_	_	O
74	of	_	_	O
75	the	_	_	O
76	individual	_	_	O
77	patient	_	_	O
78	and	_	_	O
79	consisted	_	_	O
80	of	_	_	O
81	three	_	_	O
82	elements	_	_	O
83	:	_	_	O
84	(	_	_	O
85	1	_	_	O
86	)	_	_	O
87	educating	_	_	O
88	patients	_	_	O
89	about	_	_	O
90	the	_	_	O
91	basic	_	_	O
92	principles	_	_	O
93	regarding	_	_	O
94	pain	_	_	O
95	and	_	_	O
96	pain	_	_	O
97	management	_	_	O
98	;	_	_	O
99	(	_	_	O
100	2	_	_	O
101	)	_	_	O
102	instructing	_	_	O
103	patients	_	_	O
104	how	_	_	O
105	to	_	_	O
106	report	_	_	O
107	their	_	_	O
108	pain	_	_	O
109	in	_	_	O
110	a	_	_	O
111	pain	_	_	O
112	diary	_	_	O
113	;	_	_	O
114	and	_	_	O
115	(	_	_	O
116	3	_	_	O
117	)	_	_	O
118	instructing	_	_	O
119	patients	_	_	O
120	how	_	_	O
121	to	_	_	O
122	communicate	_	_	O
123	about	_	_	O
124	pain	_	_	O
125	and	_	_	O
126	how	_	_	O
127	to	_	_	O
128	contact	_	_	O
129	health	_	_	O
130	care	_	_	O
131	providers	_	_	O
132	.	_	_	O

133	Following	_	_	O
134	pretesting	_	_	O
135	in	_	_	O
136	313	_	_	O
137	patients	_	_	O
138	,	_	_	O
139	patients	_	_	O
140	who	_	_	O
141	needed	_	_	O
142	district	_	_	O
143	nursing	_	_	O
144	and	_	_	O
145	who	_	_	O
146	did	_	_	O
147	not	_	_	O
148	need	_	_	O
149	district	_	_	O
150	nursing	_	_	O
151	at	_	_	O
152	home	_	_	O
153	were	_	_	O
154	randomly	_	_	O
155	assigned	_	_	O
156	to	_	_	O
157	a	_	_	O
158	control	_	_	O
159	or	_	_	O
160	intervention	_	_	O
161	group	_	_	O
162	.	_	_	O

163	Intervention	_	_	O
164	group	_	_	O
165	patients	_	_	O
166	received	_	_	O
167	the	_	_	O
168	Pain	_	_	O
169	Education	_	_	O
170	Program	_	_	O
171	in	_	_	O
172	the	_	_	O
173	hospital	_	_	O
174	,	_	_	O
175	and	_	_	O
176	3	_	_	O
177	and	_	_	O
178	7	_	_	O
179	days	_	_	O
180	postdischarge	_	_	O
181	by	_	_	O
182	telephone	_	_	O
183	;	_	_	O
184	this	_	_	O
185	was	_	_	O
186	done	_	_	O
187	by	_	_	O
188	nurses	_	_	O
189	who	_	_	O
190	were	_	_	O
191	specially	_	_	O
192	trained	_	_	O
193	as	_	_	O
194	pain	_	_	O
195	counselors	_	_	O
196	.	_	_	O

197	Follow	_	_	O
198	-	_	_	O
199	up	_	_	O
200	assessments	_	_	O
201	were	_	_	O
202	at	_	_	O
203	2	_	_	O
204	,	_	_	O
205	4	_	_	O
206	and	_	_	O
207	8	_	_	O
208	weeks	_	_	O
209	postdischarge	_	_	O
210	.	_	_	O

211	Results	_	_	O
212	of	_	_	O
213	the	_	_	O
214	pretest	_	_	O
215	showed	_	_	O
216	that	_	_	O
217	many	_	_	O
218	patients	_	_	O
219	lacked	_	_	O
220	knowledge	_	_	O
221	about	_	_	O
222	pain	_	_	O
223	and	_	_	O
224	pain	_	_	O
225	management	_	_	O
226	.	_	_	O

227	The	_	_	O
228	majority	_	_	O
229	of	_	_	O
230	pain	_	_	O
231	topics	_	_	O
232	had	_	_	O
233	to	_	_	O
234	be	_	_	O
235	discussed	_	_	O
236	.	_	_	O

237	The	_	_	B-Claim
238	Pain	_	_	I-Claim
239	Education	_	_	I-Claim
240	Program	_	_	I-Claim
241	proved	_	_	I-Claim
242	to	_	_	I-Claim
243	be	_	_	I-Claim
244	feasible	_	_	I-Claim
245	:	_	_	I-Claim
246	75	_	_	B-Premise
247	.	_	_	I-Premise

248	0	_	_	I-Premise
249	%	_	_	I-Premise
250	of	_	_	I-Premise
251	the	_	_	I-Premise
252	patients	_	_	I-Premise
253	had	_	_	I-Premise
254	read	_	_	I-Premise
255	the	_	_	I-Premise
256	entire	_	_	I-Premise
257	pain	_	_	I-Premise
258	brochure	_	_	I-Premise
259	,	_	_	I-Premise
260	55	_	_	I-Premise
261	.	_	_	I-Premise

262	7	_	_	I-Premise
263	%	_	_	I-Premise
264	had	_	_	I-Premise
265	listened	_	_	I-Premise
266	to	_	_	I-Premise
267	the	_	_	I-Premise
268	audio	_	_	I-Premise
269	cassette	_	_	I-Premise
270	,	_	_	I-Premise
271	and	_	_	I-Premise
272	85	_	_	I-Premise
273	.	_	_	I-Premise

274	6	_	_	I-Premise
275	%	_	_	I-Premise
276	of	_	_	I-Premise
277	pain	_	_	I-Premise
278	scores	_	_	I-Premise
279	were	_	_	I-Premise
280	completed	_	_	I-Premise
281	in	_	_	I-Premise
282	the	_	_	I-Premise
283	pain	_	_	I-Premise
284	diary	_	_	I-Premise
285	.	_	_	I-Premise

286	Results	_	_	B-Claim
287	showed	_	_	I-Claim
288	a	_	_	I-Claim
289	significant	_	_	I-Claim
290	increase	_	_	I-Claim
291	in	_	_	I-Claim
292	pain	_	_	I-Claim
293	knowledge	_	_	I-Claim
294	in	_	_	I-Claim
295	patients	_	_	I-Claim
296	who	_	_	I-Claim
297	received	_	_	I-Claim
298	the	_	_	I-Claim
299	Pain	_	_	I-Claim
300	Education	_	_	I-Claim
301	Program	_	_	I-Claim
302	and	_	_	I-Claim
303	a	_	_	I-Claim
304	significant	_	_	I-Claim
305	decrease	_	_	I-Claim
306	in	_	_	I-Claim
307	pain	_	_	I-Claim
308	intensity	_	_	I-Claim
309	.	_	_	I-Claim

310	However	_	_	B-Premise
311	,	_	_	I-Premise
312	pain	_	_	I-Premise
313	relief	_	_	I-Premise
314	was	_	_	I-Premise
315	mainly	_	_	I-Premise
316	found	_	_	I-Premise
317	in	_	_	I-Premise
318	the	_	_	I-Premise
319	intervention	_	_	I-Premise
320	group	_	_	I-Premise
321	patients	_	_	I-Premise
322	without	_	_	I-Premise
323	district	_	_	I-Premise
324	nursing	_	_	I-Premise
325	.	_	_	I-Premise

326	It	_	_	B-Claim
327	can	_	_	I-Claim
328	be	_	_	I-Claim
329	concluded	_	_	I-Claim
330	that	_	_	I-Claim
331	the	_	_	I-Claim
332	tailored	_	_	I-Claim
333	Pain	_	_	I-Claim
334	Education	_	_	I-Claim
335	Program	_	_	I-Claim
336	is	_	_	I-Claim
337	effective	_	_	I-Claim
338	for	_	_	I-Claim
339	cancer	_	_	I-Claim
340	patients	_	_	I-Claim
341	in	_	_	I-Claim
342	chronic	_	_	I-Claim
343	pain	_	_	I-Claim
344	.	_	_	I-Claim

345	The	_	_	B-Claim
346	use	_	_	I-Claim
347	of	_	_	I-Claim
348	the	_	_	I-Claim
349	Pain	_	_	I-Claim
350	Education	_	_	I-Claim
351	Program	_	_	I-Claim
352	by	_	_	I-Claim
353	nurses	_	_	I-Claim
354	should	_	_	I-Claim
355	be	_	_	I-Claim
356	seriously	_	_	I-Claim
357	considered	_	_	I-Claim
358	on	_	_	I-Claim
359	oncology	_	_	I-Claim
360	units	_	_	I-Claim
361	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	,	_	_	O
5	impact	_	_	O
6	on	_	_	O
7	quality	_	_	O
8	-	_	_	O
9	of	_	_	O
10	-	_	_	O
11	life	_	_	O
12	(	_	_	O
13	QoL	_	_	O
14	)	_	_	O
15	and	_	_	O
16	tolerability	_	_	O
17	of	_	_	O
18	two	_	_	O
19	different	_	_	O
20	irinotecan	_	_	O
21	administration	_	_	O
22	schedules	_	_	O
23	in	_	_	O
24	combination	_	_	O
25	with	_	_	O
26	capecitabine	_	_	O
27	as	_	_	O
28	first	_	_	O
29	-	_	_	O
30	line	_	_	O
31	treatment	_	_	O
32	of	_	_	O
33	metastatic	_	_	O
34	colorectal	_	_	O
35	cancer	_	_	O
36	.	_	_	O

37	We	_	_	O
38	carried	_	_	O
39	out	_	_	O
40	a	_	_	O
41	randomized	_	_	O
42	phase	_	_	O
43	II	_	_	O
44	trial	_	_	O
45	to	_	_	O
46	select	_	_	O
47	one	_	_	O
48	of	_	_	O
49	the	_	_	O
50	following	_	_	O
51	treatment	_	_	O
52	regimens	_	_	O
53	for	_	_	O
54	further	_	_	O
55	investigation	_	_	O
56	:	_	_	O
57	weekly	_	_	O
58	irinotecan	_	_	O
59	at	_	_	O
60	a	_	_	O
61	dose	_	_	O
62	of	_	_	O
63	70	_	_	O
64	mg	_	_	O
65	/	_	_	O
66	m	_	_	O
67	(	_	_	O
68	2	_	_	O
69	)	_	_	O
70	days	_	_	O
71	1	_	_	O
72	,	_	_	O
73	8	_	_	O
74	,	_	_	O
75	15	_	_	O
76	,	_	_	O
77	22	_	_	O
78	,	_	_	O
79	29	_	_	O
80	(	_	_	O
81	arm	_	_	O
82	A	_	_	O
83	)	_	_	O
84	or	_	_	O
85	3	_	_	O
86	-	_	_	O
87	weekly	_	_	O
88	irinotecan	_	_	O
89	at	_	_	O
90	a	_	_	O
91	dose	_	_	O
92	of	_	_	O
93	300	_	_	O
94	/	_	_	O
95	240	_	_	O
96	mg	_	_	O
97	/	_	_	O
98	m	_	_	O
99	(	_	_	O
100	2	_	_	O
101	)	_	_	O
102	day	_	_	O
103	1	_	_	O
104	and	_	_	O
105	days	_	_	O
106	22	_	_	O
107	(	_	_	O
108	arm	_	_	O
109	B	_	_	O
110	)	_	_	O
111	in	_	_	O
112	combination	_	_	O
113	with	_	_	O
114	capecitabine	_	_	O
115	1000	_	_	O
116	mg	_	_	O
117	/	_	_	O
118	m	_	_	O
119	(	_	_	O
120	2	_	_	O
121	)	_	_	O
122	twice	_	_	O
123	daily	_	_	O
124	days	_	_	O
125	1	_	_	O
126	-	_	_	O
127	14	_	_	O
128	and	_	_	O
129	days	_	_	O
130	22	_	_	O
131	-	_	_	O
132	35	_	_	O
133	every	_	_	O
134	6	_	_	O
135	weeks	_	_	O
136	.	_	_	O

137	Seventy	_	_	O
138	-	_	_	O
139	five	_	_	O
140	patients	_	_	O
141	with	_	_	O
142	good	_	_	O
143	performance	_	_	O
144	status	_	_	O
145	entered	_	_	O
146	the	_	_	O
147	trial	_	_	O
148	.	_	_	O

149	The	_	_	O
150	two	_	_	O
151	arms	_	_	O
152	were	_	_	O
153	well	_	_	O
154	balanced	_	_	O
155	for	_	_	O
156	relevant	_	_	O
157	patient	_	_	O
158	and	_	_	O
159	disease	_	_	O
160	characteristics	_	_	O
161	.	_	_	O

162	The	_	_	B-Premise
163	most	_	_	I-Premise
164	frequent	_	_	I-Premise
165	toxic	_	_	I-Premise
166	effects	_	_	I-Premise
167	were	_	_	I-Premise
168	grade	_	_	I-Premise
169	3	_	_	I-Premise
170	/	_	_	I-Premise
171	4	_	_	I-Premise
172	diarrhea	_	_	I-Premise
173	(	_	_	I-Premise
174	arm	_	_	I-Premise
175	A	_	_	I-Premise
176	:	_	_	I-Premise
177	34	_	_	I-Premise
178	%	_	_	I-Premise
179	,	_	_	I-Premise
180	B	_	_	I-Premise
181	:	_	_	I-Premise
182	19	_	_	I-Premise
183	%	_	_	I-Premise
184	)	_	_	I-Premise
185	,	_	_	I-Premise
186	grade	_	_	I-Premise
187	3	_	_	I-Premise
188	/	_	_	I-Premise
189	4	_	_	I-Premise
190	neutropenia	_	_	I-Premise
191	(	_	_	I-Premise
192	A	_	_	I-Premise
193	:	_	_	I-Premise
194	5	_	_	I-Premise
195	%	_	_	I-Premise
196	,	_	_	I-Premise
197	B	_	_	I-Premise
198	:	_	_	I-Premise
199	19	_	_	I-Premise
200	%	_	_	I-Premise
201	)	_	_	I-Premise
202	and	_	_	I-Premise
203	grade	_	_	I-Premise
204	2	_	_	I-Premise
205	/	_	_	I-Premise
206	3	_	_	I-Premise
207	alopecia	_	_	I-Premise
208	(	_	_	I-Premise
209	A	_	_	I-Premise
210	:	_	_	I-Premise
211	26	_	_	I-Premise
212	%	_	_	I-Premise
213	,	_	_	I-Premise
214	B	_	_	I-Premise
215	:	_	_	I-Premise
216	65	_	_	I-Premise
217	%	_	_	I-Premise
218	)	_	_	I-Premise
219	.	_	_	I-Premise

220	Other	_	_	B-Premise
221	grade	_	_	I-Premise
222	3	_	_	I-Premise
223	/	_	_	I-Premise
224	4	_	_	I-Premise
225	toxic	_	_	I-Premise
226	effects	_	_	I-Premise
227	were	_	_	I-Premise
228	rare	_	_	I-Premise
229	(	_	_	I-Premise
230	<	_	_	I-Premise
231	5	_	_	I-Premise
232	%	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	Response	_	_	B-Premise
236	rates	_	_	I-Premise
237	were	_	_	I-Premise
238	34	_	_	I-Premise
239	%	_	_	I-Premise
240	[	_	_	I-Premise
241	95	_	_	I-Premise
242	%	_	_	I-Premise
243	confidence	_	_	I-Premise
244	interval	_	_	I-Premise
245	(	_	_	I-Premise
246	CI	_	_	I-Premise
247	)	_	_	I-Premise
248	20	_	_	I-Premise
249	%	_	_	I-Premise
250	to	_	_	I-Premise
251	51	_	_	I-Premise
252	%	_	_	I-Premise
253	]	_	_	I-Premise
254	in	_	_	I-Premise
255	arm	_	_	I-Premise
256	A	_	_	I-Premise
257	and	_	_	I-Premise
258	35	_	_	I-Premise
259	%	_	_	I-Premise
260	(	_	_	I-Premise
261	95	_	_	I-Premise
262	%	_	_	I-Premise
263	CI	_	_	I-Premise
264	:	_	_	I-Premise
265	20	_	_	I-Premise
266	%	_	_	I-Premise
267	to	_	_	I-Premise
268	53	_	_	I-Premise
269	%	_	_	I-Premise
270	)	_	_	I-Premise
271	in	_	_	I-Premise
272	arm	_	_	I-Premise
273	B	_	_	I-Premise
274	.	_	_	I-Premise

275	Median	_	_	B-Premise
276	time	_	_	I-Premise
277	to	_	_	I-Premise
278	progression	_	_	I-Premise
279	was	_	_	I-Premise
280	6	_	_	I-Premise
281	.	_	_	I-Premise

282	9	_	_	I-Premise
283	(	_	_	I-Premise
284	4	_	_	I-Premise
285	.	_	_	I-Premise

286	6	_	_	I-Premise
287	-	_	_	I-Premise
288	10	_	_	I-Premise
289	.	_	_	I-Premise

290	1	_	_	I-Premise
291	)	_	_	I-Premise
292	and	_	_	I-Premise
293	9	_	_	I-Premise
294	.	_	_	I-Premise

295	2	_	_	I-Premise
296	(	_	_	I-Premise
297	7	_	_	I-Premise
298	.	_	_	I-Premise

299	9	_	_	I-Premise
300	-	_	_	I-Premise
301	11	_	_	I-Premise
302	.	_	_	I-Premise

303	5	_	_	I-Premise
304	)	_	_	I-Premise
305	months	_	_	I-Premise
306	and	_	_	I-Premise
307	median	_	_	I-Premise
308	overall	_	_	I-Premise
309	survival	_	_	I-Premise
310	was	_	_	I-Premise
311	17	_	_	I-Premise
312	.	_	_	I-Premise

313	4	_	_	I-Premise
314	(	_	_	I-Premise
315	12	_	_	I-Premise
316	.	_	_	I-Premise

317	6	_	_	I-Premise
318	-	_	_	I-Premise
319	23	_	_	I-Premise
320	.	_	_	I-Premise

321	0	_	_	I-Premise
322	+	_	_	I-Premise
323	)	_	_	I-Premise
324	and	_	_	I-Premise
325	24	_	_	I-Premise
326	.	_	_	I-Premise

327	7	_	_	I-Premise
328	(	_	_	I-Premise
329	16	_	_	I-Premise
330	.	_	_	I-Premise

331	3	_	_	I-Premise
332	-	_	_	I-Premise
333	26	_	_	I-Premise
334	.	_	_	I-Premise

335	4	_	_	I-Premise
336	+	_	_	I-Premise
337	)	_	_	I-Premise
338	months	_	_	I-Premise
339	.	_	_	I-Premise

340	Patients	_	_	B-Premise
341	with	_	_	I-Premise
342	an	_	_	I-Premise
343	objective	_	_	I-Premise
344	tumor	_	_	I-Premise
345	response	_	_	I-Premise
346	reported	_	_	I-Premise
347	better	_	_	I-Premise
348	physical	_	_	I-Premise
349	well	_	_	I-Premise
350	-	_	_	I-Premise
351	being	_	_	I-Premise
352	(	_	_	I-Premise
353	P	_	_	I-Premise
354	<	_	_	I-Premise
355	0	_	_	I-Premise
356	.	_	_	I-Premise

357	01	_	_	I-Premise
358	)	_	_	I-Premise
359	,	_	_	I-Premise
360	mood	_	_	I-Premise
361	(	_	_	I-Premise
362	P	_	_	I-Premise
363	<	_	_	I-Premise
364	0	_	_	I-Premise
365	.	_	_	I-Premise

366	05	_	_	I-Premise
367	)	_	_	I-Premise
368	,	_	_	I-Premise
369	functional	_	_	I-Premise
370	performance	_	_	I-Premise
371	(	_	_	I-Premise
372	P	_	_	I-Premise
373	<	_	_	I-Premise
374	0	_	_	I-Premise
375	.	_	_	I-Premise

376	05	_	_	I-Premise
377	)	_	_	I-Premise
378	and	_	_	I-Premise
379	less	_	_	I-Premise
380	effort	_	_	I-Premise
381	to	_	_	I-Premise
382	cope	_	_	I-Premise
383	(	_	_	I-Premise
384	P	_	_	I-Premise
385	<	_	_	I-Premise
386	0	_	_	I-Premise
387	.	_	_	I-Premise

388	05	_	_	I-Premise
389	)	_	_	I-Premise
390	compared	_	_	I-Premise
391	with	_	_	I-Premise
392	the	_	_	I-Premise
393	non	_	_	I-Premise
394	-	_	_	I-Premise
395	responders	_	_	I-Premise
396	and	_	_	I-Premise
397	stable	_	_	I-Premise
398	disease	_	_	I-Premise
399	patients	_	_	I-Premise
400	.	_	_	I-Premise

401	The	_	_	O
402	primary	_	_	O
403	end	_	_	O
404	point	_	_	O
405	of	_	_	O
406	this	_	_	O
407	study	_	_	O
408	was	_	_	O
409	the	_	_	O
410	objective	_	_	O
411	response	_	_	O
412	rate	_	_	O
413	and	_	_	O
414	based	_	_	O
415	on	_	_	O
416	the	_	_	O
417	statistical	_	_	O
418	design	_	_	O
419	of	_	_	O
420	the	_	_	O
421	trial	_	_	O
422	,	_	_	O
423	the	_	_	O
424	3	_	_	O
425	-	_	_	O
426	weekly	_	_	O
427	irinotecan	_	_	O
428	schedule	_	_	O
429	was	_	_	O
430	selected	_	_	O
431	over	_	_	O
432	weekly	_	_	O
433	irinotecan	_	_	O
434	administration	_	_	O
435	.	_	_	O

436	The	_	_	B-Claim
437	3	_	_	I-Claim
438	-	_	_	I-Claim
439	weekly	_	_	I-Claim
440	irinotecan	_	_	I-Claim
441	schedule	_	_	I-Claim
442	also	_	_	I-Claim
443	seemed	_	_	I-Claim
444	advantageous	_	_	I-Claim
445	in	_	_	I-Claim
446	terms	_	_	I-Claim
447	of	_	_	I-Claim
448	grade	_	_	I-Claim
449	3	_	_	I-Claim
450	/	_	_	I-Claim
451	4	_	_	I-Claim
452	diarrhea	_	_	I-Claim
453	,	_	_	I-Claim
454	time	_	_	I-Claim
455	to	_	_	I-Claim
456	progression	_	_	I-Claim
457	,	_	_	I-Claim
458	overall	_	_	I-Claim
459	survival	_	_	I-Claim
460	and	_	_	I-Claim
461	patient	_	_	I-Claim
462	convenience	_	_	I-Claim
463	,	_	_	I-Claim
464	but	_	_	B-Claim
465	the	_	_	I-Claim
466	study	_	_	I-Claim
467	was	_	_	I-Claim
468	not	_	_	I-Claim
469	designed	_	_	I-Claim
470	to	_	_	I-Claim
471	detect	_	_	I-Claim
472	differences	_	_	I-Claim
473	in	_	_	I-Claim
474	these	_	_	I-Claim
475	parameters	_	_	I-Claim
476	.	_	_	I-Claim

477	In	_	_	O
478	addition	_	_	O
479	,	_	_	O
480	tumor	_	_	B-Claim
481	response	_	_	I-Claim
482	was	_	_	I-Claim
483	shown	_	_	I-Claim
484	to	_	_	I-Claim
485	have	_	_	I-Claim
486	a	_	_	I-Claim
487	beneficial	_	_	I-Claim
488	effect	_	_	I-Claim
489	on	_	_	I-Claim
490	QoL	_	_	I-Claim
491	indicators	_	_	I-Claim
492	.	_	_	I-Claim


0	The	_	_	O
1	second	_	_	O
2	International	_	_	O
3	Society	_	_	O
4	of	_	_	O
5	Paediatric	_	_	O
6	Oncology	_	_	O
7	(	_	_	O
8	SIOP	_	_	O
9	)	_	_	O
10	study	_	_	O
11	for	_	_	O
12	rhabdomyosarcoma	_	_	O
13	(	_	_	O
14	MMT84	_	_	O
15	)	_	_	O
16	had	_	_	O
17	several	_	_	O
18	goals	_	_	O
19	.	_	_	O

20	The	_	_	O
21	two	_	_	O
22	principal	_	_	O
23	aims	_	_	O
24	were	_	_	O
25	:	_	_	O
26	(	_	_	O
27	1	_	_	O
28	)	_	_	O
29	to	_	_	O
30	improve	_	_	O
31	the	_	_	O
32	survival	_	_	O
33	of	_	_	O
34	children	_	_	O
35	with	_	_	O
36	rhabdomyosarcoma	_	_	O
37	;	_	_	O
38	and	_	_	O
39	(	_	_	O
40	2	_	_	O
41	)	_	_	O
42	to	_	_	O
43	reduce	_	_	O
44	the	_	_	O
45	late	_	_	O
46	effects	_	_	O
47	from	_	_	O
48	therapy	_	_	O
49	by	_	_	O
50	restricting	_	_	O
51	the	_	_	O
52	indications	_	_	O
53	for	_	_	O
54	surgery	_	_	O
55	and	_	_	O
56	/	_	_	O
57	or	_	_	O
58	radiotherapy	_	_	O
59	after	_	_	O
60	good	_	_	O
61	response	_	_	O
62	to	_	_	O
63	initial	_	_	O
64	chemotherapy	_	_	O
65	.	_	_	O

66	A	_	_	O
67	further	_	_	O
68	aim	_	_	O
69	was	_	_	O
70	to	_	_	O
71	investigate	_	_	O
72	the	_	_	O
73	role	_	_	O
74	of	_	_	O
75	high	_	_	O
76	-	_	_	O
77	dose	_	_	O
78	chemotherapy	_	_	O
79	in	_	_	O
80	young	_	_	O
81	patients	_	_	O
82	with	_	_	O
83	parameningeal	_	_	O
84	primary	_	_	O
85	tumours	_	_	O
86	.	_	_	O

87	186	_	_	O
88	previously	_	_	O
89	untreated	_	_	O
90	eligible	_	_	O
91	patients	_	_	O
92	entered	_	_	O
93	the	_	_	O
94	study	_	_	O
95	.	_	_	O

96	Patients	_	_	O
97	with	_	_	O
98	completely	_	_	O
99	resected	_	_	O
100	primary	_	_	O
101	tumour	_	_	O
102	received	_	_	O
103	three	_	_	O
104	courses	_	_	O
105	of	_	_	O
106	IVA	_	_	O
107	(	_	_	O
108	ifosfamide	_	_	O
109	,	_	_	O
110	vincristine	_	_	O
111	and	_	_	O
112	actinomycin	_	_	O
113	D	_	_	O
114	)	_	_	O
115	.	_	_	O

116	Patients	_	_	O
117	with	_	_	O
118	incompletely	_	_	O
119	resected	_	_	O
120	tumour	_	_	O
121	received	_	_	O
122	six	_	_	O
123	to	_	_	O
124	10	_	_	O
125	courses	_	_	O
126	of	_	_	O
127	IVA	_	_	O
128	according	_	_	O
129	to	_	_	O
130	stage	_	_	O
131	.	_	_	O

132	Patients	_	_	O
133	achieving	_	_	O
134	complete	_	_	O
135	remission	_	_	O
136	with	_	_	O
137	chemotherapy	_	_	O
138	alone	_	_	O
139	did	_	_	O
140	not	_	_	O
141	usually	_	_	O
142	receive	_	_	O
143	radiotherapy	_	_	O
144	or	_	_	O
145	undergo	_	_	O
146	extensive	_	_	O
147	surgery	_	_	O
148	,	_	_	O
149	but	_	_	O
150	patients	_	_	O
151	remaining	_	_	O
152	in	_	_	O
153	partial	_	_	O
154	remission	_	_	O
155	received	_	_	O
156	local	_	_	O
157	therapy	_	_	O
158	with	_	_	O
159	surgery	_	_	O
160	and	_	_	O
161	/	_	_	O
162	or	_	_	O
163	radiotherapy	_	_	O
164	.	_	_	O

165	Only	_	_	O
166	patients	_	_	O
167	over	_	_	O
168	5	_	_	O
169	years	_	_	O
170	of	_	_	O
171	age	_	_	O
172	with	_	_	O
173	parameningeal	_	_	O
174	disease	_	_	O
175	and	_	_	O
176	patients	_	_	O
177	over	_	_	O
178	12	_	_	O
179	years	_	_	O
180	with	_	_	O
181	tumours	_	_	O
182	at	_	_	O
183	any	_	_	O
184	site	_	_	O
185	were	_	_	O
186	given	_	_	O
187	systematic	_	_	O
188	irradiation	_	_	O
189	.	_	_	O

190	Complete	_	_	B-Premise
191	remission	_	_	I-Premise
192	was	_	_	I-Premise
193	achieved	_	_	I-Premise
194	in	_	_	I-Premise
195	91	_	_	I-Premise
196	%	_	_	I-Premise
197	(	_	_	I-Premise
198	170	_	_	I-Premise
199	/	_	_	I-Premise
200	186	_	_	I-Premise
201	)	_	_	I-Premise
202	of	_	_	I-Premise
203	all	_	_	I-Premise
204	patients	_	_	I-Premise
205	.	_	_	I-Premise

206	With	_	_	B-Premise
207	a	_	_	I-Premise
208	median	_	_	I-Premise
209	follow	_	_	I-Premise
210	-	_	_	I-Premise
211	up	_	_	I-Premise
212	of	_	_	I-Premise
213	8	_	_	I-Premise
214	years	_	_	I-Premise
215	,	_	_	I-Premise
216	the	_	_	I-Premise
217	5	_	_	I-Premise
218	-	_	_	I-Premise
219	year	_	_	I-Premise
220	overall	_	_	I-Premise
221	survival	_	_	I-Premise
222	was	_	_	I-Premise
223	68	_	_	I-Premise
224	%	_	_	I-Premise
225	(	_	_	I-Premise
226	+	_	_	I-Premise
227	/	_	_	I-Premise
228	-	_	_	I-Premise
229	3	_	_	I-Premise
230	%	_	_	I-Premise
231	standard	_	_	I-Premise
232	error	_	_	I-Premise
233	of	_	_	I-Premise
234	the	_	_	I-Premise
235	mean	_	_	I-Premise
236	(	_	_	I-Premise
237	SEM	_	_	I-Premise
238	)	_	_	I-Premise
239	and	_	_	I-Premise
240	the	_	_	I-Premise
241	5	_	_	I-Premise
242	-	_	_	I-Premise
243	year	_	_	I-Premise
244	event	_	_	I-Premise
245	-	_	_	I-Premise
246	free	_	_	I-Premise
247	survival	_	_	I-Premise
248	53	_	_	I-Premise
249	%	_	_	I-Premise
250	(	_	_	I-Premise
251	+	_	_	I-Premise
252	/	_	_	I-Premise
253	-	_	_	I-Premise
254	4	_	_	I-Premise
255	%	_	_	I-Premise
256	SEM	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	These	_	_	B-Premise
260	results	_	_	I-Premise
261	show	_	_	I-Premise
262	an	_	_	I-Premise
263	improvement	_	_	I-Premise
264	over	_	_	I-Premise
265	previous	_	_	I-Premise
266	SIOP	_	_	I-Premise
267	study	_	_	I-Premise
268	(	_	_	I-Premise
269	RMS75	_	_	I-Premise
270	)	_	_	I-Premise
271	in	_	_	I-Premise
272	which	_	_	I-Premise
273	survival	_	_	I-Premise
274	was	_	_	I-Premise
275	52	_	_	I-Premise
276	%	_	_	I-Premise
277	and	_	_	I-Premise
278	event	_	_	I-Premise
279	-	_	_	I-Premise
280	free	_	_	I-Premise
281	survival	_	_	I-Premise
282	was	_	_	I-Premise
283	47	_	_	I-Premise
284	%	_	_	I-Premise
285	.	_	_	I-Premise

286	Among	_	_	B-Premise
287	the	_	_	I-Premise
288	54	_	_	I-Premise
289	patients	_	_	I-Premise
290	who	_	_	I-Premise
291	exhibited	_	_	I-Premise
292	isolated	_	_	I-Premise
293	local	_	_	I-Premise
294	relapse	_	_	I-Premise
295	,	_	_	I-Premise
296	35	_	_	I-Premise
297	%	_	_	I-Premise
298	(	_	_	I-Premise
299	19	_	_	I-Premise
300	/	_	_	I-Premise
301	54	_	_	I-Premise
302	)	_	_	I-Premise
303	survived	_	_	I-Premise
304	in	_	_	I-Premise
305	further	_	_	I-Premise
306	remission	_	_	I-Premise
307	longer	_	_	I-Premise
308	than	_	_	I-Premise
309	2	_	_	I-Premise
310	years	_	_	I-Premise
311	after	_	_	I-Premise
312	retreatment	_	_	I-Premise
313	,	_	_	I-Premise
314	including	_	_	I-Premise
315	local	_	_	I-Premise
316	therapy	_	_	I-Premise
317	(	_	_	I-Premise
318	surgery	_	_	I-Premise
319	+	_	_	I-Premise
320	/	_	_	I-Premise
321	-	_	_	I-Premise
322	radiotherapy	_	_	I-Premise
323	)	_	_	I-Premise
324	.	_	_	I-Premise

325	Analysis	_	_	O
326	of	_	_	O
327	the	_	_	O
328	overall	_	_	O
329	burden	_	_	O
330	of	_	_	O
331	therapy	_	_	O
332	received	_	_	O
333	by	_	_	O
334	all	_	_	O
335	surviving	_	_	O
336	children	_	_	O
337	(	_	_	O
338	including	_	_	O
339	primary	_	_	O
340	treatment	_	_	O
341	and	_	_	O
342	treatment	_	_	O
343	for	_	_	O
344	relapse	_	_	O
345	if	_	_	O
346	required	_	_	O
347	)	_	_	O
348	showed	_	_	O
349	that	_	_	O
350	24	_	_	O
351	%	_	_	O
352	(	_	_	O
353	28	_	_	O
354	/	_	_	O
355	116	_	_	O
356	)	_	_	O
357	were	_	_	O
358	treated	_	_	O
359	by	_	_	O
360	limited	_	_	O
361	surgery	_	_	O
362	followed	_	_	O
363	by	_	_	O
364	three	_	_	O
365	courses	_	_	O
366	of	_	_	O
367	IVA	_	_	O
368	,	_	_	O
369	29	_	_	O
370	%	_	_	O
371	(	_	_	O
372	34	_	_	O
373	/	_	_	O
374	116	_	_	O
375	)	_	_	O
376	were	_	_	O
377	treated	_	_	O
378	by	_	_	O
379	chemotherapy	_	_	O
380	alone	_	_	O
381	(	_	_	O
382	after	_	_	O
383	initial	_	_	O
384	biopsy	_	_	O
385	)	_	_	O
386	and	_	_	O
387	13	_	_	O
388	%	_	_	O
389	(	_	_	O
390	15	_	_	O
391	/	_	_	O
392	116	_	_	O
393	)	_	_	O
394	received	_	_	O
395	chemotherapy	_	_	O
396	plus	_	_	O
397	conservative	_	_	O
398	local	_	_	O
399	treatment	_	_	O
400	(	_	_	O
401	limited	_	_	O
402	surgery	_	_	O
403	or	_	_	O
404	radiotherapy	_	_	O
405	for	_	_	O
406	residual	_	_	O
407	disease	_	_	O
408	)	_	_	O
409	.	_	_	O

410	Only	_	_	O
411	34	_	_	O
412	%	_	_	O
413	(	_	_	O
414	39	_	_	O
415	/	_	_	O
416	116	_	_	O
417	)	_	_	O
418	received	_	_	O
419	intensive	_	_	O
420	local	_	_	O
421	therapy	_	_	O
422	defined	_	_	O
423	as	_	_	O
424	radical	_	_	O
425	wide	_	_	O
426	field	_	_	O
427	radiotherapy	_	_	O
428	or	_	_	O
429	radical	_	_	O
430	surgery	_	_	O
431	or	_	_	O
432	both	_	_	O
433	.	_	_	O

434	Compared	_	_	B-Claim
435	with	_	_	I-Claim
436	the	_	_	I-Claim
437	results	_	_	I-Claim
438	obtained	_	_	I-Claim
439	in	_	_	I-Claim
440	the	_	_	I-Claim
441	previous	_	_	I-Claim
442	SIOP	_	_	I-Claim
443	study	_	_	I-Claim
444	,	_	_	I-Claim
445	treatment	_	_	I-Claim
446	in	_	_	I-Claim
447	MMT84	_	_	I-Claim
448	was	_	_	I-Claim
449	based	_	_	I-Claim
450	on	_	_	I-Claim
451	response	_	_	I-Claim
452	to	_	_	I-Claim
453	initial	_	_	I-Claim
454	chemotherapy	_	_	I-Claim
455	and	_	_	I-Claim
456	,	_	_	I-Claim
457	despite	_	_	I-Claim
458	an	_	_	I-Claim
459	overall	_	_	I-Claim
460	reduction	_	_	I-Claim
461	of	_	_	I-Claim
462	the	_	_	I-Claim
463	use	_	_	I-Claim
464	of	_	_	I-Claim
465	local	_	_	I-Claim
466	therapy	_	_	I-Claim
467	,	_	_	I-Claim
468	significantly	_	_	I-Claim
469	improved	_	_	I-Claim
470	survival	_	_	I-Claim
471	for	_	_	I-Claim
472	patients	_	_	I-Claim
473	with	_	_	I-Claim
474	non	_	_	I-Claim
475	-	_	_	I-Claim
476	metastatic	_	_	I-Claim
477	disease	_	_	I-Claim
478	.	_	_	I-Claim

479	This	_	_	B-Claim
480	trial	_	_	I-Claim
481	,	_	_	I-Claim
482	also	_	_	I-Claim
483	for	_	_	I-Claim
484	the	_	_	I-Claim
485	first	_	_	I-Claim
486	time	_	_	I-Claim
487	,	_	_	I-Claim
488	provides	_	_	I-Claim
489	evidence	_	_	I-Claim
490	that	_	_	I-Claim
491	retreatment	_	_	I-Claim
492	after	_	_	I-Claim
493	local	_	_	I-Claim
494	relapse	_	_	I-Claim
495	can	_	_	I-Claim
496	achieve	_	_	I-Claim
497	long	_	_	I-Claim
498	-	_	_	I-Claim
499	term	_	_	I-Claim
500	second	_	_	I-Claim
501	remissions	_	_	I-Claim
502	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	multicenter	_	_	O
5	randomized	_	_	O
6	trial	_	_	O
7	was	_	_	O
8	to	_	_	O
9	assess	_	_	O
10	the	_	_	O
11	efficacy	_	_	O
12	and	_	_	O
13	safety	_	_	O
14	of	_	_	O
15	sentinel	_	_	O
16	lymph	_	_	O
17	node	_	_	O
18	(	_	_	O
19	SLN	_	_	O
20	)	_	_	O
21	biopsy	_	_	O
22	compared	_	_	O
23	with	_	_	O
24	axillary	_	_	O
25	lymph	_	_	O
26	node	_	_	O
27	dissection	_	_	O
28	(	_	_	O
29	ALND	_	_	O
30	)	_	_	O
31	.	_	_	O

32	All	_	_	O
33	studies	_	_	O
34	on	_	_	O
35	SLN	_	_	O
36	biopsy	_	_	O
37	in	_	_	O
38	breast	_	_	O
39	cancer	_	_	O
40	report	_	_	O
41	a	_	_	O
42	variable	_	_	O
43	false	_	_	O
44	negative	_	_	O
45	rate	_	_	O
46	,	_	_	O
47	whose	_	_	O
48	prognostic	_	_	O
49	consequences	_	_	O
50	are	_	_	O
51	still	_	_	O
52	unclear	_	_	O
53	.	_	_	O

54	From	_	_	O
55	May	_	_	O
56	1999	_	_	O
57	to	_	_	O
58	December	_	_	O
59	2004	_	_	O
60	,	_	_	O
61	patients	_	_	O
62	with	_	_	O
63	breast	_	_	O
64	cancer	_	_	O
65	<	_	_	O
66	or	_	_	O
67	=	_	_	O
68	3	_	_	O
69	cm	_	_	O
70	were	_	_	O
71	randomly	_	_	O
72	assigned	_	_	O
73	to	_	_	O
74	receive	_	_	O
75	SLN	_	_	O
76	biopsy	_	_	O
77	associated	_	_	O
78	with	_	_	O
79	ALND	_	_	O
80	(	_	_	O
81	ALND	_	_	O
82	arm	_	_	O
83	)	_	_	O
84	or	_	_	O
85	SLN	_	_	O
86	biopsy	_	_	O
87	followed	_	_	O
88	by	_	_	O
89	ALND	_	_	O
90	only	_	_	O
91	if	_	_	O
92	the	_	_	O
93	SLN	_	_	O
94	was	_	_	O
95	metastatic	_	_	O
96	(	_	_	O
97	SLN	_	_	O
98	arm	_	_	O
99	)	_	_	O
100	.	_	_	O

101	The	_	_	O
102	main	_	_	O
103	aim	_	_	O
104	was	_	_	O
105	the	_	_	O
106	comparison	_	_	O
107	of	_	_	O
108	disease	_	_	O
109	-	_	_	O
110	free	_	_	O
111	survival	_	_	O
112	in	_	_	O
113	the	_	_	O
114	2	_	_	O
115	arms	_	_	O
116	.	_	_	O

117	A	_	_	O
118	total	_	_	O
119	of	_	_	O
120	749	_	_	O
121	patients	_	_	O
122	were	_	_	O
123	randomized	_	_	O
124	and	_	_	O
125	697	_	_	O
126	were	_	_	O
127	available	_	_	O
128	for	_	_	O
129	analysis	_	_	O
130	.	_	_	O

131	SLNs	_	_	O
132	were	_	_	O
133	identified	_	_	O
134	in	_	_	O
135	662	_	_	O
136	of	_	_	O
137	697	_	_	O
138	patients	_	_	O
139	(	_	_	O
140	95	_	_	O
141	%	_	_	O
142	)	_	_	O
143	and	_	_	O
144	positive	_	_	O
145	SLNs	_	_	O
146	were	_	_	O
147	found	_	_	O
148	in	_	_	O
149	189	_	_	O
150	of	_	_	O
151	662	_	_	O
152	patients	_	_	O
153	(	_	_	O
154	28	_	_	O
155	.	_	_	O

156	5	_	_	O
157	%	_	_	O
158	)	_	_	O
159	.	_	_	O

160	In	_	_	O
161	the	_	_	O
162	ALND	_	_	O
163	group	_	_	O
164	,	_	_	O
165	positive	_	_	O
166	non	_	_	O
167	-	_	_	O
168	SLNs	_	_	O
169	were	_	_	O
170	found	_	_	O
171	in	_	_	O
172	18	_	_	O
173	patients	_	_	O
174	with	_	_	O
175	negative	_	_	O
176	SLN	_	_	O
177	,	_	_	O
178	giving	_	_	O
179	a	_	_	O
180	false	_	_	O
181	negative	_	_	O
182	rate	_	_	O
183	of	_	_	O
184	16	_	_	O
185	.	_	_	O

186	7	_	_	O
187	%	_	_	O
188	(	_	_	O
189	18	_	_	O
190	of	_	_	O
191	108	_	_	O
192	)	_	_	O
193	.	_	_	O

194	Postoperative	_	_	B-Premise
195	side	_	_	I-Premise
196	effects	_	_	I-Premise
197	were	_	_	I-Premise
198	significantly	_	_	I-Premise
199	less	_	_	I-Premise
200	in	_	_	I-Premise
201	the	_	_	I-Premise
202	SLN	_	_	I-Premise
203	group	_	_	I-Premise
204	and	_	_	I-Premise
205	there	_	_	I-Premise
206	was	_	_	I-Premise
207	no	_	_	I-Premise
208	negative	_	_	I-Premise
209	impact	_	_	I-Premise
210	of	_	_	I-Premise
211	the	_	_	I-Premise
212	SLN	_	_	I-Premise
213	procedure	_	_	I-Premise
214	on	_	_	I-Premise
215	psychologic	_	_	I-Premise
216	well	_	_	I-Premise
217	being	_	_	I-Premise
218	.	_	_	I-Premise

219	At	_	_	O
220	a	_	_	O
221	median	_	_	O
222	follow	_	_	O
223	-	_	_	O
224	up	_	_	O
225	of	_	_	O
226	56	_	_	O
227	months	_	_	O
228	,	_	_	O
229	there	_	_	O
230	were	_	_	O
231	more	_	_	O
232	locoregional	_	_	O
233	recurrences	_	_	O
234	in	_	_	O
235	the	_	_	O
236	SLN	_	_	O
237	arm	_	_	O
238	,	_	_	O
239	and	_	_	O
240	the	_	_	O
241	5	_	_	O
242	-	_	_	O
243	year	_	_	O
244	disease	_	_	O
245	-	_	_	O
246	free	_	_	O
247	survival	_	_	O
248	was	_	_	O
249	89	_	_	O
250	.	_	_	O

251	9	_	_	O
252	%	_	_	O
253	in	_	_	O
254	the	_	_	O
255	ALND	_	_	O
256	arm	_	_	O
257	and	_	_	O
258	87	_	_	O
259	.	_	_	O

260	6	_	_	O
261	%	_	_	O
262	in	_	_	O
263	the	_	_	O
264	SLN	_	_	O
265	arm	_	_	O
266	,	_	_	O
267	with	_	_	O
268	a	_	_	O
269	difference	_	_	O
270	of	_	_	O
271	2	_	_	O
272	.	_	_	O

273	3	_	_	O
274	%	_	_	O
275	(	_	_	O
276	95	_	_	O
277	%	_	_	O
278	confidence	_	_	O
279	interval	_	_	O
280	:	_	_	O
281	-	_	_	O
282	3	_	_	O
283	.	_	_	O

284	1	_	_	O
285	%	_	_	O
286	to	_	_	O
287	7	_	_	O
288	.	_	_	O

289	6	_	_	O
290	%	_	_	O
291	)	_	_	O
292	.	_	_	O

293	However	_	_	B-Premise
294	,	_	_	I-Premise
295	the	_	_	I-Premise
296	number	_	_	I-Premise
297	of	_	_	I-Premise
298	enrolled	_	_	I-Premise
299	patients	_	_	I-Premise
300	was	_	_	I-Premise
301	not	_	_	I-Premise
302	sufficient	_	_	I-Premise
303	to	_	_	I-Premise
304	draw	_	_	I-Premise
305	definitive	_	_	I-Premise
306	conclusions	_	_	I-Premise
307	.	_	_	I-Premise

308	SLN	_	_	B-Claim
309	biopsy	_	_	I-Claim
310	is	_	_	I-Claim
311	an	_	_	I-Claim
312	effective	_	_	I-Claim
313	and	_	_	I-Claim
314	well	_	_	I-Claim
315	-	_	_	I-Claim
316	tolerated	_	_	I-Claim
317	procedure	_	_	I-Claim
318	.	_	_	I-Claim

319	However	_	_	B-Claim
320	,	_	_	I-Claim
321	its	_	_	I-Claim
322	safety	_	_	I-Claim
323	should	_	_	I-Claim
324	be	_	_	I-Claim
325	confirmed	_	_	I-Claim
326	by	_	_	I-Claim
327	the	_	_	I-Claim
328	results	_	_	I-Claim
329	of	_	_	I-Claim
330	larger	_	_	I-Claim
331	randomized	_	_	I-Claim
332	trials	_	_	I-Claim
333	and	_	_	I-Claim
334	meta	_	_	I-Claim
335	-	_	_	I-Claim
336	analyses	_	_	I-Claim
337	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	a	_	_	O
8	biweekly	_	_	O
9	regimen	_	_	O
10	of	_	_	O
11	leucovorin	_	_	O
12	(	_	_	O
13	LV	_	_	O
14	)	_	_	O
15	plus	_	_	O
16	fluorouracil	_	_	O
17	(	_	_	O
18	FU	_	_	O
19	)	_	_	O
20	alone	_	_	O
21	or	_	_	O
22	in	_	_	O
23	combination	_	_	O
24	with	_	_	O
25	cisplatin	_	_	O
26	or	_	_	O
27	irinotecan	_	_	O
28	in	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	previously	_	_	O
32	untreated	_	_	O
33	metastatic	_	_	O
34	gastric	_	_	O
35	adenocarcinoma	_	_	O
36	and	_	_	O
37	to	_	_	O
38	select	_	_	O
39	the	_	_	O
40	best	_	_	O
41	arm	_	_	O
42	for	_	_	O
43	a	_	_	O
44	phase	_	_	O
45	III	_	_	O
46	study	_	_	O
47	.	_	_	O

48	One	_	_	O
49	hundred	_	_	O
50	thirty	_	_	O
51	-	_	_	O
52	six	_	_	O
53	patients	_	_	O
54	(	_	_	O
55	two	_	_	O
56	were	_	_	O
57	ineligible	_	_	O
58	)	_	_	O
59	were	_	_	O
60	enrolled	_	_	O
61	onto	_	_	O
62	the	_	_	O
63	randomized	_	_	O
64	multicenter	_	_	O
65	phase	_	_	O
66	II	_	_	O
67	trial	_	_	O
68	.	_	_	O

69	Patients	_	_	O
70	received	_	_	O
71	LV	_	_	O
72	200	_	_	O
73	mg	_	_	O
74	/	_	_	O
75	m	_	_	O
76	(	_	_	O
77	2	_	_	O
78	)	_	_	O
79	(	_	_	O
80	2	_	_	O
81	-	_	_	O
82	hour	_	_	O
83	infusion	_	_	O
84	)	_	_	O
85	followed	_	_	O
86	by	_	_	O
87	FU	_	_	O
88	400	_	_	O
89	mg	_	_	O
90	/	_	_	O
91	m	_	_	O
92	(	_	_	O
93	2	_	_	O
94	)	_	_	O
95	(	_	_	O
96	bolus	_	_	O
97	)	_	_	O
98	and	_	_	O
99	FU	_	_	O
100	600	_	_	O
101	mg	_	_	O
102	/	_	_	O
103	m	_	_	O
104	(	_	_	O
105	2	_	_	O
106	)	_	_	O
107	(	_	_	O
108	22	_	_	O
109	-	_	_	O
110	hour	_	_	O
111	continuous	_	_	O
112	infusion	_	_	O
113	)	_	_	O
114	on	_	_	O
115	days	_	_	O
116	1	_	_	O
117	and	_	_	O
118	2	_	_	O
119	every	_	_	O
120	14	_	_	O
121	days	_	_	O
122	(	_	_	O
123	LV5FU2	_	_	O
124	;	_	_	O
125	arm	_	_	O
126	A	_	_	O
127	)	_	_	O
128	,	_	_	O
129	LV5FU2	_	_	O
130	plus	_	_	O
131	cisplatin	_	_	O
132	50	_	_	O
133	mg	_	_	O
134	/	_	_	O
135	m	_	_	O
136	(	_	_	O
137	2	_	_	O
138	)	_	_	O
139	(	_	_	O
140	1	_	_	O
141	-	_	_	O
142	hour	_	_	O
143	infusion	_	_	O
144	)	_	_	O
145	on	_	_	O
146	day	_	_	O
147	1	_	_	O
148	or	_	_	O
149	2	_	_	O
150	(	_	_	O
151	arm	_	_	O
152	B	_	_	O
153	)	_	_	O
154	,	_	_	O
155	or	_	_	O
156	LV5FU2	_	_	O
157	plus	_	_	O
158	irinotecan	_	_	O
159	180	_	_	O
160	mg	_	_	O
161	/	_	_	O
162	m	_	_	O
163	(	_	_	O
164	2	_	_	O
165	)	_	_	O
166	(	_	_	O
167	2	_	_	O
168	-	_	_	O
169	hour	_	_	O
170	infusion	_	_	O
171	)	_	_	O
172	on	_	_	O
173	day	_	_	O
174	1	_	_	O
175	(	_	_	O
176	arm	_	_	O
177	C	_	_	O
178	)	_	_	O
179	.	_	_	O

180	The	_	_	B-Premise
181	overall	_	_	I-Premise
182	response	_	_	I-Premise
183	rates	_	_	I-Premise
184	,	_	_	I-Premise
185	which	_	_	I-Premise
186	were	_	_	I-Premise
187	confirmed	_	_	I-Premise
188	by	_	_	I-Premise
189	an	_	_	I-Premise
190	independent	_	_	I-Premise
191	expert	_	_	I-Premise
192	panel	_	_	I-Premise
193	,	_	_	I-Premise
194	were	_	_	I-Premise
195	13	_	_	I-Premise
196	%	_	_	I-Premise
197	(	_	_	I-Premise
198	95	_	_	I-Premise
199	%	_	_	I-Premise
200	CI	_	_	I-Premise
201	,	_	_	I-Premise
202	3	_	_	I-Premise
203	.	_	_	I-Premise

204	4	_	_	I-Premise
205	%	_	_	I-Premise
206	to	_	_	I-Premise
207	23	_	_	I-Premise
208	.	_	_	I-Premise

209	3	_	_	I-Premise
210	%	_	_	I-Premise
211	)	_	_	I-Premise
212	,	_	_	I-Premise
213	27	_	_	I-Premise
214	%	_	_	I-Premise
215	(	_	_	I-Premise
216	95	_	_	I-Premise
217	%	_	_	I-Premise
218	CI	_	_	I-Premise
219	,	_	_	I-Premise
220	14	_	_	I-Premise
221	.	_	_	I-Premise

222	1	_	_	I-Premise
223	%	_	_	I-Premise
224	to	_	_	I-Premise
225	40	_	_	I-Premise
226	.	_	_	I-Premise

227	4	_	_	I-Premise
228	%	_	_	I-Premise
229	)	_	_	I-Premise
230	,	_	_	I-Premise
231	and	_	_	I-Premise
232	40	_	_	I-Premise
233	%	_	_	I-Premise
234	(	_	_	I-Premise
235	95	_	_	I-Premise
236	%	_	_	I-Premise
237	CI	_	_	I-Premise
238	,	_	_	I-Premise
239	25	_	_	I-Premise
240	.	_	_	I-Premise

241	7	_	_	I-Premise
242	%	_	_	I-Premise
243	to	_	_	I-Premise
244	54	_	_	I-Premise
245	.	_	_	I-Premise

246	3	_	_	I-Premise
247	%	_	_	I-Premise
248	)	_	_	I-Premise
249	for	_	_	I-Premise
250	arms	_	_	I-Premise
251	A	_	_	I-Premise
252	,	_	_	I-Premise
253	B	_	_	I-Premise
254	,	_	_	I-Premise
255	and	_	_	I-Premise
256	C	_	_	I-Premise
257	,	_	_	I-Premise
258	respectively	_	_	I-Premise
259	.	_	_	I-Premise

260	Median	_	_	B-Premise
261	progression	_	_	I-Premise
262	-	_	_	I-Premise
263	free	_	_	I-Premise
264	survival	_	_	I-Premise
265	and	_	_	I-Premise
266	overall	_	_	I-Premise
267	survival	_	_	I-Premise
268	times	_	_	I-Premise
269	were	_	_	I-Premise
270	3	_	_	I-Premise
271	.	_	_	I-Premise

272	2	_	_	I-Premise
273	months	_	_	I-Premise
274	(	_	_	I-Premise
275	95	_	_	I-Premise
276	%	_	_	I-Premise
277	CI	_	_	I-Premise
278	,	_	_	I-Premise
279	1	_	_	I-Premise
280	.	_	_	I-Premise

281	8	_	_	I-Premise
282	to	_	_	I-Premise
283	4	_	_	I-Premise
284	.	_	_	I-Premise

285	6	_	_	I-Premise
286	months	_	_	I-Premise
287	)	_	_	I-Premise
288	and	_	_	I-Premise
289	6	_	_	I-Premise
290	.	_	_	I-Premise

291	8	_	_	I-Premise
292	months	_	_	I-Premise
293	(	_	_	I-Premise
294	95	_	_	I-Premise
295	%	_	_	I-Premise
296	CI	_	_	I-Premise
297	,	_	_	I-Premise
298	2	_	_	I-Premise
299	.	_	_	I-Premise

300	6	_	_	I-Premise
301	to	_	_	I-Premise
302	11	_	_	I-Premise
303	.	_	_	I-Premise

304	1	_	_	I-Premise
305	months	_	_	I-Premise
306	)	_	_	I-Premise
307	with	_	_	I-Premise
308	LV5FU2	_	_	I-Premise
309	,	_	_	I-Premise
310	respectively	_	_	I-Premise
311	;	_	_	I-Premise
312	4	_	_	I-Premise
313	.	_	_	I-Premise

314	9	_	_	I-Premise
315	months	_	_	I-Premise
316	(	_	_	I-Premise
317	95	_	_	I-Premise
318	%	_	_	I-Premise
319	CI	_	_	I-Premise
320	,	_	_	I-Premise
321	3	_	_	I-Premise
322	.	_	_	I-Premise

323	5	_	_	I-Premise
324	to	_	_	I-Premise
325	6	_	_	I-Premise
326	.	_	_	I-Premise

327	3	_	_	I-Premise
328	months	_	_	I-Premise
329	)	_	_	I-Premise
330	and	_	_	I-Premise
331	9	_	_	I-Premise
332	.	_	_	I-Premise

333	5	_	_	I-Premise
334	months	_	_	I-Premise
335	(	_	_	I-Premise
336	95	_	_	I-Premise
337	%	_	_	I-Premise
338	CI	_	_	I-Premise
339	,	_	_	I-Premise
340	6	_	_	I-Premise
341	.	_	_	I-Premise

342	9	_	_	I-Premise
343	to	_	_	I-Premise
344	12	_	_	I-Premise
345	.	_	_	I-Premise

346	2	_	_	I-Premise
347	months	_	_	I-Premise
348	)	_	_	I-Premise
349	with	_	_	I-Premise
350	LV5FU2	_	_	I-Premise
351	-	_	_	I-Premise
352	cisplatin	_	_	I-Premise
353	,	_	_	I-Premise
354	respectively	_	_	I-Premise
355	;	_	_	I-Premise
356	and	_	_	I-Premise
357	6	_	_	I-Premise
358	.	_	_	I-Premise

359	9	_	_	I-Premise
360	months	_	_	I-Premise
361	(	_	_	I-Premise
362	95	_	_	I-Premise
363	%	_	_	I-Premise
364	CI	_	_	I-Premise
365	,	_	_	I-Premise
366	5	_	_	I-Premise
367	.	_	_	I-Premise

368	5	_	_	I-Premise
369	to	_	_	I-Premise
370	8	_	_	I-Premise
371	.	_	_	I-Premise

372	3	_	_	I-Premise
373	months	_	_	I-Premise
374	)	_	_	I-Premise
375	and	_	_	I-Premise
376	11	_	_	I-Premise
377	.	_	_	I-Premise

378	3	_	_	I-Premise
379	months	_	_	I-Premise
380	(	_	_	I-Premise
381	95	_	_	I-Premise
382	%	_	_	I-Premise
383	CI	_	_	I-Premise
384	,	_	_	I-Premise
385	9	_	_	I-Premise
386	.	_	_	I-Premise

387	3	_	_	I-Premise
388	to	_	_	I-Premise
389	13	_	_	I-Premise
390	.	_	_	I-Premise

391	3	_	_	I-Premise
392	months	_	_	I-Premise
393	)	_	_	I-Premise
394	with	_	_	I-Premise
395	LV5FU2	_	_	I-Premise
396	-	_	_	I-Premise
397	irinotecan	_	_	I-Premise
398	,	_	_	I-Premise
399	respectively	_	_	I-Premise
400	.	_	_	I-Premise

401	Of	_	_	B-Claim
402	the	_	_	I-Claim
403	three	_	_	I-Claim
404	regimens	_	_	I-Claim
405	tested	_	_	I-Claim
406	,	_	_	I-Claim
407	the	_	_	I-Claim
408	combination	_	_	I-Claim
409	of	_	_	I-Claim
410	LV5FU2	_	_	I-Claim
411	-	_	_	I-Claim
412	irinotecan	_	_	I-Claim
413	is	_	_	I-Claim
414	the	_	_	I-Claim
415	most	_	_	I-Claim
416	promising	_	_	I-Claim
417	and	_	_	I-Claim
418	will	_	_	I-Claim
419	be	_	_	I-Claim
420	assessed	_	_	I-Claim
421	in	_	_	I-Claim
422	a	_	_	I-Claim
423	phase	_	_	I-Claim
424	III	_	_	I-Claim
425	trial	_	_	I-Claim
426	.	_	_	I-Claim


0	Several	_	_	O
1	multicomponent	_	_	O
2	regimens	_	_	O
3	have	_	_	O
4	been	_	_	O
5	reported	_	_	O
6	to	_	_	O
7	be	_	_	O
8	useful	_	_	O
9	in	_	_	O
10	advanced	_	_	O
11	androgen	_	_	O
12	-	_	_	O
13	independent	_	_	O
14	prostate	_	_	O
15	cancer	_	_	O
16	.	_	_	O

17	We	_	_	O
18	used	_	_	O
19	a	_	_	O
20	randomized	_	_	O
21	phase	_	_	O
22	II	_	_	O
23	design	_	_	O
24	to	_	_	O
25	evaluate	_	_	O
26	and	_	_	O
27	compare	_	_	O
28	two	_	_	O
29	such	_	_	O
30	regimens	_	_	O
31	.	_	_	O

32	Patients	_	_	O
33	were	_	_	O
34	accrued	_	_	O
35	primarily	_	_	O
36	in	_	_	O
37	the	_	_	O
38	community	_	_	O
39	setting	_	_	O
40	.	_	_	O

41	Patients	_	_	O
42	with	_	_	O
43	progressive	_	_	O
44	,	_	_	O
45	androgen	_	_	O
46	-	_	_	O
47	independent	_	_	O
48	prostate	_	_	O
49	cancer	_	_	O
50	were	_	_	O
51	randomly	_	_	O
52	assigned	_	_	O
53	to	_	_	O
54	one	_	_	O
55	of	_	_	O
56	two	_	_	O
57	treatments	_	_	O
58	:	_	_	O
59	either	_	_	O
60	ketoconazole	_	_	O
61	/	_	_	O
62	doxorubicin	_	_	O
63	alternating	_	_	O
64	with	_	_	O
65	vinblastine	_	_	O
66	/	_	_	O
67	estramustine	_	_	O
68	(	_	_	O
69	KA	_	_	O
70	/	_	_	O
71	VE	_	_	O
72	)	_	_	O
73	or	_	_	O
74	paclitaxel	_	_	O
75	,	_	_	O
76	estramustine	_	_	O
77	,	_	_	O
78	and	_	_	O
79	oral	_	_	O
80	etoposide	_	_	O
81	(	_	_	O
82	TEE	_	_	O
83	)	_	_	O
84	.	_	_	O

85	Patients	_	_	O
86	were	_	_	O
87	prospectively	_	_	O
88	stratified	_	_	O
89	on	_	_	O
90	the	_	_	O
91	basis	_	_	O
92	of	_	_	O
93	disease	_	_	O
94	volume	_	_	O
95	.	_	_	O

96	The	_	_	O
97	primary	_	_	O
98	end	_	_	O
99	points	_	_	O
100	were	_	_	O
101	response	_	_	O
102	and	_	_	O
103	overall	_	_	O
104	survival	_	_	O
105	time	_	_	O
106	.	_	_	O

107	A	_	_	O
108	total	_	_	O
109	of	_	_	O
110	75	_	_	O
111	patients	_	_	O
112	were	_	_	O
113	registered	_	_	O
114	;	_	_	O
115	71	_	_	O
116	are	_	_	O
117	included	_	_	O
118	in	_	_	O
119	the	_	_	O
120	analysis	_	_	O
121	.	_	_	O

122	By	_	_	O
123	the	_	_	O
124	criterion	_	_	O
125	of	_	_	O
126	an	_	_	O
127	80	_	_	O
128	%	_	_	O
129	prostate	_	_	O
130	-	_	_	O
131	specific	_	_	O
132	antigen	_	_	O
133	reduction	_	_	O
134	maintained	_	_	O
135	for	_	_	O
136	at	_	_	O
137	least	_	_	O
138	8	_	_	O
139	weeks	_	_	O
140	,	_	_	O
141	11	_	_	O
142	(	_	_	O
143	30	_	_	O
144	%	_	_	O
145	)	_	_	O
146	of	_	_	O
147	37	_	_	O
148	patients	_	_	O
149	in	_	_	O
150	the	_	_	O
151	TEE	_	_	O
152	arm	_	_	O
153	responded	_	_	O
154	,	_	_	O
155	whereas	_	_	O
156	11	_	_	O
157	(	_	_	O
158	32	_	_	O
159	%	_	_	O
160	)	_	_	O
161	of	_	_	O
162	34	_	_	O
163	assigned	_	_	O
164	to	_	_	O
165	KA	_	_	O
166	/	_	_	O
167	VE	_	_	O
168	responded	_	_	O
169	.	_	_	O

170	Median	_	_	B-Premise
171	survival	_	_	I-Premise
172	was	_	_	I-Premise
173	16	_	_	I-Premise
174	.	_	_	I-Premise

175	9	_	_	I-Premise
176	months	_	_	I-Premise
177	(	_	_	I-Premise
178	95	_	_	I-Premise
179	%	_	_	I-Premise
180	confidence	_	_	I-Premise
181	interval	_	_	I-Premise
182	[	_	_	I-Premise
183	CI	_	_	I-Premise
184	]	_	_	I-Premise
185	,	_	_	I-Premise
186	10	_	_	I-Premise
187	.	_	_	I-Premise

188	5	_	_	I-Premise
189	to	_	_	I-Premise
190	21	_	_	I-Premise
191	.	_	_	I-Premise

192	2	_	_	I-Premise
193	months	_	_	I-Premise
194	)	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	TEE	_	_	I-Premise
198	arm	_	_	I-Premise
199	and	_	_	I-Premise
200	23	_	_	I-Premise
201	.	_	_	I-Premise

202	4	_	_	I-Premise
203	months	_	_	I-Premise
204	(	_	_	I-Premise
205	95	_	_	I-Premise
206	%	_	_	I-Premise
207	CI	_	_	I-Premise
208	,	_	_	I-Premise
209	12	_	_	I-Premise
210	.	_	_	I-Premise

211	9	_	_	I-Premise
212	to	_	_	I-Premise
213	30	_	_	I-Premise
214	.	_	_	I-Premise

215	6	_	_	I-Premise
216	months	_	_	I-Premise
217	)	_	_	I-Premise
218	for	_	_	I-Premise
219	patients	_	_	I-Premise
220	treated	_	_	I-Premise
221	with	_	_	I-Premise
222	KA	_	_	I-Premise
223	/	_	_	I-Premise
224	VE	_	_	I-Premise
225	.	_	_	I-Premise

226	Many	_	_	B-Premise
227	patients	_	_	I-Premise
228	(	_	_	I-Premise
229	24	_	_	I-Premise
230	%	_	_	I-Premise
231	)	_	_	I-Premise
232	failed	_	_	I-Premise
233	to	_	_	I-Premise
234	complete	_	_	I-Premise
235	at	_	_	I-Premise
236	least	_	_	I-Premise
237	6	_	_	I-Premise
238	weeks	_	_	I-Premise
239	of	_	_	I-Premise
240	therapy	_	_	I-Premise
241	,	_	_	I-Premise
242	including	_	_	I-Premise
243	five	_	_	I-Premise
244	(	_	_	I-Premise
245	8	_	_	I-Premise
246	%	_	_	I-Premise
247	)	_	_	I-Premise
248	treatment	_	_	I-Premise
249	-	_	_	I-Premise
250	related	_	_	I-Premise
251	early	_	_	I-Premise
252	deaths	_	_	I-Premise
253	.	_	_	I-Premise

254	Each	_	_	B-Claim
255	of	_	_	I-Claim
256	these	_	_	I-Claim
257	regimens	_	_	I-Claim
258	produced	_	_	I-Claim
259	clinically	_	_	I-Claim
260	significant	_	_	I-Claim
261	responses	_	_	I-Claim
262	,	_	_	I-Claim
263	and	_	_	O
264	the	_	_	B-Claim
265	observed	_	_	I-Claim
266	median	_	_	I-Claim
267	survival	_	_	I-Claim
268	(	_	_	I-Claim
269	18	_	_	I-Claim
270	.	_	_	I-Claim

271	9	_	_	I-Claim
272	months	_	_	I-Claim
273	for	_	_	I-Claim
274	all	_	_	I-Claim
275	71	_	_	I-Claim
276	patients	_	_	I-Claim
277	)	_	_	I-Claim
278	compares	_	_	I-Claim
279	favorably	_	_	I-Claim
280	with	_	_	I-Claim
281	previously	_	_	I-Claim
282	published	_	_	I-Claim
283	results	_	_	I-Claim
284	,	_	_	I-Claim
285	especially	_	_	I-Claim
286	in	_	_	I-Claim
287	the	_	_	I-Claim
288	community	_	_	I-Claim
289	setting	_	_	I-Claim
290	.	_	_	I-Claim

291	Nonetheless	_	_	B-Claim
292	,	_	_	I-Claim
293	it	_	_	I-Claim
294	is	_	_	I-Claim
295	apparent	_	_	I-Claim
296	that	_	_	I-Claim
297	these	_	_	I-Claim
298	first	_	_	I-Claim
299	-	_	_	I-Claim
300	generation	_	_	I-Claim
301	regimens	_	_	I-Claim
302	must	_	_	I-Claim
303	be	_	_	I-Claim
304	applied	_	_	I-Claim
305	judiciously	_	_	I-Claim
306	,	_	_	I-Claim
307	and	_	_	O
308	thus	_	_	B-Claim
309	we	_	_	I-Claim
310	view	_	_	I-Claim
311	efforts	_	_	I-Claim
312	at	_	_	I-Claim
313	better	_	_	I-Claim
314	patient	_	_	I-Claim
315	selection	_	_	I-Claim
316	and	_	_	I-Claim
317	the	_	_	I-Claim
318	development	_	_	I-Claim
319	of	_	_	I-Claim
320	more	_	_	I-Claim
321	tolerable	_	_	I-Claim
322	therapies	_	_	I-Claim
323	as	_	_	I-Claim
324	higher	_	_	I-Claim
325	priorities	_	_	I-Claim
326	than	_	_	I-Claim
327	carrying	_	_	I-Claim
328	either	_	_	I-Claim
329	of	_	_	I-Claim
330	these	_	_	I-Claim
331	regimens	_	_	I-Claim
332	to	_	_	I-Claim
333	phase	_	_	I-Claim
334	III	_	_	I-Claim
335	evaluation	_	_	I-Claim
336	in	_	_	I-Claim
337	the	_	_	I-Claim
338	cooperative	_	_	I-Claim
339	group	_	_	I-Claim
340	setting	_	_	I-Claim
341	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	safety	_	_	O
4	and	_	_	O
5	health	_	_	O
6	-	_	_	O
7	related	_	_	O
8	quality	_	_	O
9	of	_	_	O
10	life	_	_	O
11	(	_	_	O
12	HRQOL	_	_	O
13	)	_	_	O
14	of	_	_	O
15	continuous	_	_	O
16	combined	_	_	O
17	hormone	_	_	O
18	replacement	_	_	O
19	therapy	_	_	O
20	(	_	_	O
21	ccHRT	_	_	O
22	)	_	_	O
23	with	_	_	O
24	estradiol	_	_	O
25	valerate	_	_	O
26	/	_	_	O
27	medroxyprogesterone	_	_	O
28	acetate	_	_	O
29	(	_	_	O
30	E	_	_	O
31	(	_	_	O
32	2	_	_	O
33	)	_	_	O
34	V	_	_	O
35	/	_	_	O
36	MPA	_	_	O
37	)	_	_	O
38	over	_	_	O
39	nine	_	_	O
40	years	_	_	O
41	and	_	_	O
42	at	_	_	O
43	follow	_	_	O
44	-	_	_	O
45	up	_	_	O
46	one	_	_	O
47	year	_	_	O
48	after	_	_	O
49	discontinuation	_	_	O
50	.	_	_	O

51	A	_	_	O
52	total	_	_	O
53	of	_	_	O
54	419	_	_	O
55	women	_	_	O
56	were	_	_	O
57	randomized	_	_	O
58	to	_	_	O
59	one	_	_	O
60	of	_	_	O
61	four	_	_	O
62	treatments	_	_	O
63	:	_	_	O
64	once	_	_	O
65	-	_	_	O
66	daily	_	_	O
67	1	_	_	O
68	mg	_	_	O
69	E2V	_	_	O
70	/	_	_	O
71	2	_	_	O
72	.	_	_	O

73	5	_	_	O
74	mg	_	_	O
75	MPA	_	_	O
76	(	_	_	O
77	1	_	_	O
78	+	_	_	O
79	2	_	_	O
80	.	_	_	O

81	5	_	_	O
82	group	_	_	O
83	)	_	_	O
84	;	_	_	O
85	1	_	_	O
86	mg	_	_	O
87	E2V	_	_	O
88	/	_	_	O
89	5	_	_	O
90	mg	_	_	O
91	MPA	_	_	O
92	daily	_	_	O
93	(	_	_	O
94	1	_	_	O
95	+	_	_	O
96	5	_	_	O
97	group	_	_	O
98	)	_	_	O
99	;	_	_	O
100	2	_	_	O
101	mg	_	_	O
102	E2V	_	_	O
103	/	_	_	O
104	2	_	_	O
105	.	_	_	O

106	5	_	_	O
107	mg	_	_	O
108	MPA	_	_	O
109	daily	_	_	O
110	(	_	_	O
111	2	_	_	O
112	+	_	_	O
113	2	_	_	O
114	.	_	_	O

115	5	_	_	O
116	group	_	_	O
117	)	_	_	O
118	;	_	_	O
119	2	_	_	O
120	mg	_	_	O
121	E2V	_	_	O
122	/	_	_	O
123	5	_	_	O
124	mg	_	_	O
125	MPA	_	_	O
126	daily	_	_	O
127	(	_	_	O
128	2	_	_	O
129	+	_	_	O
130	5	_	_	O
131	group	_	_	O
132	)	_	_	O
133	(	_	_	O
134	Indivina	_	_	O
135	,	_	_	O
136	Orion	_	_	O
137	Pharma	_	_	O
138	)	_	_	O
139	.	_	_	O

140	For	_	_	O
141	the	_	_	O
142	last	_	_	O
143	six	_	_	O
144	months	_	_	O
145	,	_	_	O
146	all	_	_	O
147	received	_	_	O
148	the	_	_	O
149	1	_	_	O
150	+	_	_	O
151	2	_	_	O
152	.	_	_	O

153	5	_	_	O
154	dosage	_	_	O
155	.	_	_	O

156	The	_	_	O
157	2	_	_	O
158	+	_	_	O
159	2	_	_	O
160	.	_	_	O

161	5	_	_	O
162	dosage	_	_	O
163	was	_	_	O
164	discontinued	_	_	O
165	at	_	_	O
166	the	_	_	O
167	end	_	_	O
168	of	_	_	O
169	year	_	_	O
170	7	_	_	O
171	.	_	_	O

172	A	_	_	O
173	total	_	_	O
174	of	_	_	O
175	198	_	_	O
176	women	_	_	O
177	continued	_	_	O
178	after	_	_	O
179	year	_	_	O
180	7	_	_	O
181	.	_	_	O

182	Annualized	_	_	O
183	percentage	_	_	O
184	rates	_	_	O
185	for	_	_	O
186	cardiovascular	_	_	O
187	events	_	_	O
188	[	_	_	O
189	corrected	_	_	O
190	]	_	_	O
191	and	_	_	O
192	endometrial	_	_	O
193	cancers	_	_	O
194	[	_	_	O
195	corrected	_	_	O
196	]	_	_	O
197	were	_	_	O
198	below	_	_	O
199	national	_	_	O
200	rates	_	_	O
201	for	_	_	O
202	Finland	_	_	O
203	and	_	_	O
204	those	_	_	O
205	reported	_	_	O
206	for	_	_	O
207	the	_	_	O
208	Women	_	_	O
209	'	_	_	O
210	s	_	_	O
211	Health	_	_	O
212	Initiative	_	_	O
213	.	_	_	O

214	There	_	_	B-Premise
215	were	_	_	I-Premise
216	no	_	_	I-Premise
217	serious	_	_	I-Premise
218	events	_	_	I-Premise
219	with	_	_	I-Premise
220	the	_	_	I-Premise
221	1	_	_	I-Premise
222	+	_	_	I-Premise
223	2	_	_	I-Premise
224	.	_	_	I-Premise

225	5	_	_	I-Premise
226	dosage	_	_	I-Premise
227	or	_	_	I-Premise
228	after	_	_	I-Premise
229	ccHRT	_	_	I-Premise
230	discontinuation	_	_	I-Premise
231	.	_	_	I-Premise

232	Climacteric	_	_	B-Premise
233	symptoms	_	_	I-Premise
234	remained	_	_	I-Premise
235	significantly	_	_	I-Premise
236	below	_	_	I-Premise
237	baseline	_	_	I-Premise
238	values	_	_	I-Premise
239	after	_	_	I-Premise
240	dosage	_	_	I-Premise
241	reduction	_	_	I-Premise
242	;	_	_	I-Premise
243	some	_	_	B-Premise
244	symptoms	_	_	I-Premise
245	recurred	_	_	I-Premise
246	after	_	_	I-Premise
247	discontinuation	_	_	I-Premise
248	of	_	_	I-Premise
249	ccHRT	_	_	I-Premise
250	.	_	_	I-Premise

251	HRQOL	_	_	B-Premise
252	ratings	_	_	I-Premise
253	improved	_	_	I-Premise
254	with	_	_	I-Premise
255	ccHRT	_	_	I-Premise
256	,	_	_	I-Premise
257	irrespective	_	_	I-Premise
258	of	_	_	I-Premise
259	dosage	_	_	I-Premise
260	,	_	_	I-Premise
261	including	_	_	I-Premise
262	depressed	_	_	I-Premise
263	mood	_	_	I-Premise
264	,	_	_	I-Premise
265	anxiety	_	_	I-Premise
266	,	_	_	I-Premise
267	health	_	_	I-Premise
268	perception	_	_	I-Premise
269	and	_	_	I-Premise
270	sexual	_	_	I-Premise
271	interest	_	_	I-Premise
272	.	_	_	I-Premise

273	Scores	_	_	B-Premise
274	on	_	_	I-Premise
275	a	_	_	I-Premise
276	scale	_	_	I-Premise
277	assessing	_	_	I-Premise
278	daily	_	_	I-Premise
279	functioning	_	_	I-Premise
280	and	_	_	I-Premise
281	enjoyment	_	_	I-Premise
282	(	_	_	I-Premise
283	Q	_	_	I-Premise
284	-	_	_	I-Premise
285	LES	_	_	I-Premise
286	-	_	_	I-Premise
287	Q	_	_	I-Premise
288	)	_	_	I-Premise
289	improved	_	_	I-Premise
290	from	_	_	I-Premise
291	year	_	_	I-Premise
292	7	_	_	I-Premise
293	to	_	_	I-Premise
294	year	_	_	I-Premise
295	9	_	_	I-Premise
296	.	_	_	I-Premise

297	They	_	_	B-Premise
298	deteriorated	_	_	I-Premise
299	during	_	_	I-Premise
300	follow	_	_	I-Premise
301	-	_	_	I-Premise
302	up	_	_	I-Premise
303	in	_	_	I-Premise
304	women	_	_	I-Premise
305	not	_	_	I-Premise
306	continuing	_	_	I-Premise
307	ccHRT	_	_	I-Premise
308	.	_	_	I-Premise

309	Lower	_	_	B-Claim
310	dosages	_	_	I-Claim
311	of	_	_	I-Claim
312	HRT	_	_	I-Claim
313	were	_	_	I-Claim
314	as	_	_	I-Claim
315	effective	_	_	I-Claim
316	as	_	_	I-Claim
317	higher	_	_	I-Claim
318	doses	_	_	I-Claim
319	in	_	_	I-Claim
320	improving	_	_	I-Claim
321	climacteric	_	_	I-Claim
322	symptoms	_	_	I-Claim
323	and	_	_	I-Claim
324	HRQOL	_	_	I-Claim
325	ratings	_	_	I-Claim
326	and	_	_	I-Claim
327	had	_	_	I-Claim
328	fewer	_	_	I-Claim
329	safety	_	_	I-Claim
330	concerns	_	_	I-Claim
331	.	_	_	I-Claim

332	Following	_	_	B-Premise
333	discontinuation	_	_	I-Premise
334	of	_	_	I-Premise
335	ccHRT	_	_	I-Premise
336	,	_	_	I-Premise
337	patient	_	_	I-Premise
338	satisfaction	_	_	I-Premise
339	was	_	_	I-Premise
340	variable	_	_	I-Premise
341	,	_	_	I-Premise
342	with	_	_	I-Premise
343	15	_	_	I-Premise
344	%	_	_	I-Premise
345	electing	_	_	I-Premise
346	to	_	_	I-Premise
347	continue	_	_	I-Premise
348	or	_	_	I-Premise
349	restart	_	_	I-Premise
350	HRT	_	_	I-Premise
351	and	_	_	I-Premise
352	7	_	_	I-Premise
353	%	_	_	I-Premise
354	resuming	_	_	I-Premise
355	at	_	_	I-Premise
356	follow	_	_	I-Premise
357	-	_	_	I-Premise
358	up	_	_	I-Premise
359	.	_	_	I-Premise

360	This	_	_	B-Claim
361	supports	_	_	I-Claim
362	the	_	_	I-Claim
363	need	_	_	I-Claim
364	for	_	_	I-Claim
365	an	_	_	I-Claim
366	individualized	_	_	I-Claim
367	approach	_	_	I-Claim
368	to	_	_	I-Claim
369	therapy	_	_	I-Claim
370	recommendations	_	_	I-Claim
371	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	directly	_	_	O
3	the	_	_	O
4	effect	_	_	O
5	of	_	_	O
6	intensity	_	_	O
7	-	_	_	O
8	modulated	_	_	O
9	radiotherapy	_	_	O
10	(	_	_	O
11	IMRT	_	_	O
12	)	_	_	O
13	vs	_	_	O
14	.	_	_	O

15	conventional	_	_	O
16	radiotherapy	_	_	O
17	(	_	_	O
18	CRT	_	_	O
19	)	_	_	O
20	on	_	_	O
21	salivary	_	_	O
22	flow	_	_	O
23	and	_	_	O
24	quality	_	_	O
25	of	_	_	O
26	life	_	_	O
27	(	_	_	O
28	QoL	_	_	O
29	)	_	_	O
30	in	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	early	_	_	O
34	-	_	_	O
35	stage	_	_	O
36	nasopharyngeal	_	_	O
37	carcinoma	_	_	O
38	(	_	_	O
39	NPC	_	_	O
40	)	_	_	O
41	.	_	_	O

42	Fifty	_	_	O
43	-	_	_	O
44	one	_	_	O
45	patients	_	_	O
46	with	_	_	O
47	T2	_	_	O
48	,	_	_	O
49	N0	_	_	O
50	/	_	_	O
51	N1	_	_	O
52	,	_	_	O
53	M0	_	_	O
54	NPC	_	_	O
55	took	_	_	O
56	part	_	_	O
57	in	_	_	O
58	a	_	_	O
59	randomized	_	_	O
60	controlled	_	_	O
61	clinical	_	_	O
62	study	_	_	O
63	and	_	_	O
64	received	_	_	O
65	IMRT	_	_	O
66	or	_	_	O
67	CRT	_	_	O
68	.	_	_	O

69	Stimulated	_	_	O
70	whole	_	_	O
71	(	_	_	O
72	SWS	_	_	O
73	)	_	_	O
74	and	_	_	O
75	parotid	_	_	O
76	(	_	_	O
77	SPS	_	_	O
78	)	_	_	O
79	saliva	_	_	O
80	flow	_	_	O
81	were	_	_	O
82	measured	_	_	O
83	and	_	_	O
84	Medical	_	_	O
85	Outcomes	_	_	O
86	Short	_	_	O
87	Form	_	_	O
88	36	_	_	O
89	(	_	_	O
90	SF	_	_	O
91	-	_	_	O
92	36	_	_	O
93	)	_	_	O
94	,	_	_	O
95	European	_	_	O
96	Organization	_	_	O
97	for	_	_	O
98	Research	_	_	O
99	and	_	_	O
100	Treatment	_	_	O
101	of	_	_	O
102	Cancer	_	_	O
103	(	_	_	O
104	EORTC	_	_	O
105	)	_	_	O
106	core	_	_	O
107	quetionnaire	_	_	O
108	,	_	_	O
109	and	_	_	O
110	EORTC	_	_	O
111	head	_	_	O
112	-	_	_	O
113	and	_	_	O
114	-	_	_	O
115	neck	_	_	O
116	module	_	_	O
117	(	_	_	O
118	QLQ	_	_	O
119	-	_	_	O
120	H	_	_	O
121	&	_	_	O
122	amp	_	_	O
123	;	_	_	O
124	N35	_	_	O
125	)	_	_	O
126	were	_	_	O
127	completed	_	_	O
128	at	_	_	O
129	baseline	_	_	O
130	and	_	_	O
131	2	_	_	O
132	,	_	_	O
133	6	_	_	O
134	,	_	_	O
135	and	_	_	O
136	12	_	_	O
137	months	_	_	O
138	after	_	_	O
139	radiotherapy	_	_	O
140	.	_	_	O

141	Forty	_	_	B-Premise
142	-	_	_	I-Premise
143	six	_	_	I-Premise
144	patients	_	_	I-Premise
145	(	_	_	I-Premise
146	88	_	_	I-Premise
147	%	_	_	I-Premise
148	)	_	_	I-Premise
149	were	_	_	I-Premise
150	in	_	_	I-Premise
151	disease	_	_	I-Premise
152	remission	_	_	I-Premise
153	12	_	_	I-Premise
154	months	_	_	I-Premise
155	after	_	_	I-Premise
156	radiotherapy	_	_	I-Premise
157	.	_	_	I-Premise

158	At	_	_	B-Premise
159	12	_	_	I-Premise
160	months	_	_	I-Premise
161	postradiotherapy	_	_	I-Premise
162	,	_	_	I-Premise
163	12	_	_	I-Premise
164	(	_	_	I-Premise
165	50	_	_	I-Premise
166	.	_	_	I-Premise

167	0	_	_	I-Premise
168	%	_	_	I-Premise
169	)	_	_	I-Premise
170	and	_	_	I-Premise
171	20	_	_	I-Premise
172	patients	_	_	I-Premise
173	(	_	_	I-Premise
174	83	_	_	I-Premise
175	.	_	_	I-Premise

176	3	_	_	I-Premise
177	%	_	_	I-Premise
178	)	_	_	I-Premise
179	in	_	_	I-Premise
180	the	_	_	I-Premise
181	IMRT	_	_	I-Premise
182	group	_	_	I-Premise
183	had	_	_	I-Premise
184	recovered	_	_	I-Premise
185	at	_	_	I-Premise
186	least	_	_	I-Premise
187	25	_	_	I-Premise
188	%	_	_	I-Premise
189	of	_	_	I-Premise
190	preradiotherapy	_	_	I-Premise
191	SWS	_	_	I-Premise
192	and	_	_	I-Premise
193	SPS	_	_	I-Premise
194	flow	_	_	I-Premise
195	respectively	_	_	I-Premise
196	,	_	_	I-Premise
197	compared	_	_	I-Premise
198	with	_	_	I-Premise
199	1	_	_	I-Premise
200	(	_	_	I-Premise
201	4	_	_	I-Premise
202	.	_	_	I-Premise

203	8	_	_	I-Premise
204	%	_	_	I-Premise
205	)	_	_	I-Premise
206	and	_	_	I-Premise
207	2	_	_	I-Premise
208	patients	_	_	I-Premise
209	(	_	_	I-Premise
210	9	_	_	I-Premise
211	.	_	_	I-Premise

212	5	_	_	I-Premise
213	%	_	_	I-Premise
214	)	_	_	I-Premise
215	,	_	_	I-Premise
216	respectively	_	_	I-Premise
217	,	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	CRT	_	_	I-Premise
221	group	_	_	I-Premise
222	.	_	_	I-Premise

223	Global	_	_	B-Premise
224	health	_	_	I-Premise
225	scores	_	_	I-Premise
226	showed	_	_	I-Premise
227	continuous	_	_	I-Premise
228	improvement	_	_	I-Premise
229	in	_	_	I-Premise
230	QoL	_	_	I-Premise
231	after	_	_	I-Premise
232	both	_	_	I-Premise
233	treatments	_	_	I-Premise
234	(	_	_	I-Premise
235	p	_	_	I-Premise
236	<	_	_	I-Premise
237	0	_	_	I-Premise
238	.	_	_	I-Premise

239	001	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	However	_	_	B-Premise
243	,	_	_	I-Premise
244	after	_	_	I-Premise
245	12	_	_	I-Premise
246	months	_	_	I-Premise
247	subscale	_	_	I-Premise
248	scores	_	_	I-Premise
249	for	_	_	I-Premise
250	role	_	_	I-Premise
251	-	_	_	I-Premise
252	physical	_	_	I-Premise
253	,	_	_	I-Premise
254	bodily	_	_	I-Premise
255	pain	_	_	I-Premise
256	,	_	_	I-Premise
257	and	_	_	I-Premise
258	physical	_	_	I-Premise
259	function	_	_	I-Premise
260	were	_	_	I-Premise
261	significantly	_	_	I-Premise
262	higher	_	_	I-Premise
263	in	_	_	I-Premise
264	the	_	_	I-Premise
265	IMRT	_	_	I-Premise
266	group	_	_	I-Premise
267	,	_	_	I-Premise
268	indicating	_	_	I-Premise
269	a	_	_	I-Premise
270	better	_	_	I-Premise
271	condition	_	_	I-Premise
272	(	_	_	I-Premise
273	p	_	_	I-Premise
274	<	_	_	I-Premise
275	0	_	_	I-Premise
276	.	_	_	I-Premise

277	05	_	_	I-Premise
278	)	_	_	I-Premise
279	.	_	_	I-Premise

280	Dry	_	_	B-Premise
281	mouth	_	_	I-Premise
282	and	_	_	I-Premise
283	sticky	_	_	I-Premise
284	saliva	_	_	I-Premise
285	were	_	_	I-Premise
286	problems	_	_	I-Premise
287	in	_	_	I-Premise
288	both	_	_	I-Premise
289	groups	_	_	I-Premise
290	2	_	_	I-Premise
291	months	_	_	I-Premise
292	after	_	_	I-Premise
293	treatment	_	_	I-Premise
294	.	_	_	I-Premise

295	In	_	_	B-Premise
296	the	_	_	I-Premise
297	IMRT	_	_	I-Premise
298	group	_	_	I-Premise
299	,	_	_	I-Premise
300	there	_	_	I-Premise
301	was	_	_	I-Premise
302	consistent	_	_	I-Premise
303	improvement	_	_	I-Premise
304	over	_	_	I-Premise
305	time	_	_	I-Premise
306	with	_	_	I-Premise
307	xerostomia	_	_	I-Premise
308	-	_	_	I-Premise
309	related	_	_	I-Premise
310	symptoms	_	_	I-Premise
311	significantly	_	_	I-Premise
312	less	_	_	I-Premise
313	common	_	_	I-Premise
314	than	_	_	I-Premise
315	in	_	_	I-Premise
316	the	_	_	I-Premise
317	CRT	_	_	I-Premise
318	group	_	_	I-Premise
319	at	_	_	I-Premise
320	12	_	_	I-Premise
321	months	_	_	I-Premise
322	postradiotherapy	_	_	I-Premise
323	.	_	_	I-Premise

324	IMRT	_	_	B-Claim
325	was	_	_	I-Claim
326	significantly	_	_	I-Claim
327	better	_	_	I-Claim
328	than	_	_	I-Claim
329	CRT	_	_	I-Claim
330	in	_	_	I-Claim
331	terms	_	_	I-Claim
332	of	_	_	I-Claim
333	parotid	_	_	I-Claim
334	sparing	_	_	I-Claim
335	and	_	_	I-Claim
336	improved	_	_	I-Claim
337	QoL	_	_	I-Claim
338	for	_	_	I-Claim
339	early	_	_	I-Claim
340	-	_	_	I-Claim
341	stage	_	_	I-Claim
342	disease	_	_	I-Claim
343	.	_	_	I-Claim

344	The	_	_	B-Claim
345	findings	_	_	I-Claim
346	support	_	_	I-Claim
347	the	_	_	I-Claim
348	case	_	_	I-Claim
349	for	_	_	I-Claim
350	assessment	_	_	I-Claim
351	of	_	_	I-Claim
352	health	_	_	I-Claim
353	-	_	_	I-Claim
354	related	_	_	I-Claim
355	QoL	_	_	I-Claim
356	in	_	_	I-Claim
357	relation	_	_	I-Claim
358	to	_	_	I-Claim
359	head	_	_	I-Claim
360	-	_	_	I-Claim
361	and	_	_	I-Claim
362	-	_	_	I-Claim
363	neck	_	_	I-Claim
364	cancer	_	_	I-Claim
365	using	_	_	I-Claim
366	a	_	_	I-Claim
367	site	_	_	I-Claim
368	-	_	_	I-Claim
369	specific	_	_	I-Claim
370	approach	_	_	I-Claim
371	.	_	_	O


0	Regularly	_	_	O
1	collecting	_	_	O
2	patient	_	_	O
3	-	_	_	O
4	reported	_	_	O
5	outcomes	_	_	O
6	(	_	_	O
7	PROs	_	_	O
8	)	_	_	O
9	of	_	_	O
10	health	_	_	O
11	-	_	_	O
12	related	_	_	O
13	quality	_	_	O
14	of	_	_	O
15	life	_	_	O
16	with	_	_	O
17	feedback	_	_	O
18	to	_	_	O
19	oncologists	_	_	O
20	may	_	_	O
21	assist	_	_	O
22	in	_	_	O
23	eliciting	_	_	O
24	and	_	_	O
25	monitoring	_	_	O
26	patients	_	_	O
27	'	_	_	O
28	problems	_	_	O
29	during	_	_	O
30	cancer	_	_	O
31	treatment	_	_	O
32	.	_	_	O

33	This	_	_	O
34	study	_	_	O
35	examined	_	_	O
36	how	_	_	O
37	PRO	_	_	O
38	feedback	_	_	O
39	had	_	_	O
40	an	_	_	O
41	impact	_	_	O
42	on	_	_	O
43	patient	_	_	O
44	-	_	_	O
45	physician	_	_	O
46	communication	_	_	O
47	over	_	_	O
48	time	_	_	O
49	to	_	_	O
50	gain	_	_	O
51	a	_	_	O
52	better	_	_	O
53	understanding	_	_	O
54	of	_	_	O
55	how	_	_	O
56	it	_	_	O
57	may	_	_	O
58	influence	_	_	O
59	patient	_	_	O
60	care	_	_	O
61	.	_	_	O

62	Exploratory	_	_	O
63	analyses	_	_	O
64	were	_	_	O
65	performed	_	_	O
66	on	_	_	O
67	a	_	_	O
68	data	_	_	O
69	set	_	_	O
70	from	_	_	O
71	a	_	_	O
72	previous	_	_	O
73	study	_	_	O
74	.	_	_	O

75	Patients	_	_	O
76	were	_	_	O
77	randomly	_	_	O
78	assigned	_	_	O
79	to	_	_	O
80	intervention	_	_	O
81	(	_	_	O
82	regular	_	_	O
83	completion	_	_	O
84	of	_	_	O
85	European	_	_	O
86	Organisation	_	_	O
87	for	_	_	O
88	Research	_	_	O
89	and	_	_	O
90	Treatment	_	_	O
91	of	_	_	O
92	Cancer	_	_	O
93	Quality	_	_	O
94	of	_	_	O
95	Life	_	_	O
96	Questionnaire	_	_	O
97	-	_	_	O
98	Core	_	_	O
99	30	_	_	O
100	and	_	_	O
101	Hospital	_	_	O
102	Anxiety	_	_	O
103	and	_	_	O
104	Depression	_	_	O
105	Scale	_	_	O
106	with	_	_	O
107	feedback	_	_	O
108	to	_	_	O
109	oncologists	_	_	O
110	)	_	_	O
111	,	_	_	O
112	attention	_	_	O
113	-	_	_	O
114	control	_	_	O
115	(	_	_	O
116	completion	_	_	O
117	of	_	_	O
118	same	_	_	O
119	questionnaires	_	_	O
120	without	_	_	O
121	feedback	_	_	O
122	)	_	_	O
123	,	_	_	O
124	and	_	_	O
125	control	_	_	O
126	(	_	_	O
127	standard	_	_	O
128	care	_	_	O
129	)	_	_	O
130	arms	_	_	O
131	.	_	_	O

132	The	_	_	O
133	content	_	_	O
134	of	_	_	O
135	consultation	_	_	O
136	audio	_	_	O
137	recordings	_	_	O
138	between	_	_	O
139	28	_	_	O
140	oncologists	_	_	O
141	and	_	_	O
142	198	_	_	O
143	patients	_	_	O
144	over	_	_	O
145	four	_	_	O
146	consecutive	_	_	O
147	visits	_	_	O
148	(	_	_	O
149	792	_	_	O
150	consultations	_	_	O
151	)	_	_	O
152	was	_	_	O
153	analyzed	_	_	O
154	.	_	_	O

155	Mixed	_	_	O
156	-	_	_	O
157	effects	_	_	O
158	models	_	_	O
159	and	_	_	O
160	multivariate	_	_	O
161	regressions	_	_	O
162	were	_	_	O
163	used	_	_	O
164	to	_	_	O
165	examine	_	_	O
166	the	_	_	O
167	longitudinal	_	_	O
168	impact	_	_	O
169	of	_	_	O
170	the	_	_	O
171	intervention	_	_	O
172	on	_	_	O
173	patient	_	_	O
174	-	_	_	O
175	physician	_	_	O
176	communication	_	_	O
177	,	_	_	O
178	dynamics	_	_	O
179	of	_	_	O
180	patient	_	_	O
181	-	_	_	O
182	physician	_	_	O
183	interaction	_	_	O
184	,	_	_	O
185	and	_	_	O
186	the	_	_	O
187	association	_	_	O
188	between	_	_	O
189	PROs	_	_	O
190	and	_	_	O
191	the	_	_	O
192	content	_	_	O
193	of	_	_	O
194	clinic	_	_	O
195	discussion	_	_	O
196	.	_	_	O

197	Patients	_	_	B-Premise
198	in	_	_	I-Premise
199	the	_	_	I-Premise
200	intervention	_	_	I-Premise
201	arm	_	_	I-Premise
202	discussed	_	_	I-Premise
203	more	_	_	I-Premise
204	symptoms	_	_	I-Premise
205	over	_	_	I-Premise
206	time	_	_	I-Premise
207	compared	_	_	I-Premise
208	with	_	_	I-Premise
209	patients	_	_	I-Premise
210	in	_	_	I-Premise
211	the	_	_	I-Premise
212	attention	_	_	I-Premise
213	-	_	_	I-Premise
214	control	_	_	I-Premise
215	(	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	.	_	_	I-Premise

219	008	_	_	I-Premise
220	)	_	_	I-Premise
221	and	_	_	I-Premise
222	control	_	_	I-Premise
223	(	_	_	I-Premise
224	P	_	_	I-Premise
225	=	_	_	I-Premise
226	.	_	_	I-Premise

227	04	_	_	I-Premise
228	)	_	_	I-Premise
229	arms	_	_	I-Premise
230	.	_	_	I-Premise

231	No	_	_	B-Premise
232	study	_	_	I-Premise
233	arm	_	_	I-Premise
234	effect	_	_	I-Premise
235	was	_	_	I-Premise
236	observed	_	_	I-Premise
237	for	_	_	I-Premise
238	function	_	_	I-Premise
239	discussions	_	_	I-Premise
240	.	_	_	I-Premise

241	Discussion	_	_	O
242	topics	_	_	O
243	were	_	_	O
244	predominantly	_	_	O
245	raised	_	_	O
246	by	_	_	O
247	patients	_	_	O
248	/	_	_	O
249	relatives	_	_	O
250	,	_	_	O
251	regardless	_	_	O
252	of	_	_	O
253	arm	_	_	O
254	allocation	_	_	O
255	.	_	_	O

256	Clinic	_	_	B-Premise
257	discussions	_	_	I-Premise
258	were	_	_	I-Premise
259	associated	_	_	I-Premise
260	with	_	_	I-Premise
261	severity	_	_	I-Premise
262	of	_	_	I-Premise
263	patient	_	_	I-Premise
264	-	_	_	I-Premise
265	reported	_	_	I-Premise
266	symptoms	_	_	I-Premise
267	but	_	_	I-Premise
268	not	_	_	I-Premise
269	with	_	_	I-Premise
270	patient	_	_	I-Premise
271	-	_	_	I-Premise
272	reported	_	_	I-Premise
273	functional	_	_	I-Premise
274	concerns	_	_	I-Premise
275	.	_	_	I-Premise

276	A	_	_	B-Premise
277	positive	_	_	I-Premise
278	longitudinal	_	_	I-Premise
279	impact	_	_	I-Premise
280	of	_	_	I-Premise
281	the	_	_	I-Premise
282	intervention	_	_	I-Premise
283	on	_	_	I-Premise
284	symptom	_	_	I-Premise
285	discussion	_	_	I-Premise
286	was	_	_	I-Premise
287	observed	_	_	I-Premise
288	,	_	_	I-Premise
289	but	_	_	B-Premise
290	not	_	_	I-Premise
291	for	_	_	I-Premise
292	function	_	_	I-Premise
293	discussion	_	_	I-Premise
294	,	_	_	I-Premise
295	suggesting	_	_	I-Premise
296	that	_	_	I-Premise
297	potentially	_	_	I-Premise
298	serious	_	_	I-Premise
299	problems	_	_	I-Premise
300	may	_	_	I-Premise
301	remain	_	_	I-Premise
302	unaddressed	_	_	I-Premise
303	.	_	_	I-Premise

304	Training	_	_	B-Claim
305	oncologists	_	_	I-Claim
306	in	_	_	I-Claim
307	responding	_	_	I-Claim
308	to	_	_	I-Claim
309	patient	_	_	I-Claim
310	-	_	_	I-Claim
311	reported	_	_	I-Claim
312	functional	_	_	I-Claim
313	concerns	_	_	I-Claim
314	may	_	_	I-Claim
315	increase	_	_	I-Claim
316	the	_	_	I-Claim
317	impact	_	_	I-Claim
318	of	_	_	I-Claim
319	this	_	_	I-Claim
320	intervention	_	_	I-Claim
321	.	_	_	I-Claim


0	The	_	_	O
1	optimal	_	_	O
2	duration	_	_	O
3	over	_	_	O
4	which	_	_	O
5	lung	_	_	O
6	SBRT	_	_	O
7	should	_	_	O
8	be	_	_	O
9	delivered	_	_	O
10	is	_	_	O
11	unknown	_	_	O
12	.	_	_	O

13	We	_	_	O
14	conducted	_	_	O
15	a	_	_	O
16	randomized	_	_	O
17	pilot	_	_	O
18	study	_	_	O
19	in	_	_	O
20	patients	_	_	O
21	treated	_	_	O
22	with	_	_	O
23	four	_	_	O
24	fractions	_	_	O
25	of	_	_	O
26	lung	_	_	O
27	SBRT	_	_	O
28	delivered	_	_	O
29	over	_	_	O
30	4	_	_	O
31	or	_	_	O
32	over	_	_	O
33	11	_	_	O
34	days	_	_	O
35	.	_	_	O

36	Patients	_	_	O
37	with	_	_	O
38	a	_	_	O
39	peripheral	_	_	O
40	solitary	_	_	O
41	lung	_	_	O
42	tumor	_	_	O
43	(	_	_	O
44	NSCLC	_	_	O
45	or	_	_	O
46	pulmonary	_	_	O
47	metastasis	_	_	O
48	)	_	_	O
49	≤	_	_	O
50	5	_	_	O
51	cm	_	_	O
52	were	_	_	O
53	eligible	_	_	O
54	.	_	_	O

55	For	_	_	O
56	NSCLC	_	_	O
57	lung	_	_	O
58	tumors	_	_	O
59	≤	_	_	O
60	3	_	_	O
61	cm	_	_	O
62	,	_	_	O
63	a	_	_	O
64	dose	_	_	O
65	of	_	_	O
66	48	_	_	O
67	Gy	_	_	O
68	in	_	_	O
69	4	_	_	O
70	fractions	_	_	O
71	was	_	_	O
72	used	_	_	O
73	,	_	_	O
74	otherwise	_	_	O
75	52	_	_	O
76	Gy	_	_	O
77	in	_	_	O
78	4	_	_	O
79	fractions	_	_	O
80	was	_	_	O
81	delivered	_	_	O
82	.	_	_	O

83	Patients	_	_	O
84	were	_	_	O
85	randomized	_	_	O
86	to	_	_	O
87	receive	_	_	O
88	treatment	_	_	O
89	over	_	_	O
90	4	_	_	O
91	consecutive	_	_	O
92	days	_	_	O
93	or	_	_	O
94	over	_	_	O
95	11	_	_	O
96	days	_	_	O
97	.	_	_	O

98	The	_	_	O
99	primary	_	_	O
100	end	_	_	O
101	-	_	_	O
102	point	_	_	O
103	was	_	_	O
104	acute	_	_	O
105	grade	_	_	O
106	≥	_	_	O
107	2	_	_	O
108	toxicity	_	_	O
109	.	_	_	O

110	Secondary	_	_	O
111	end	_	_	O
112	-	_	_	O
113	points	_	_	O
114	included	_	_	O
115	quality	_	_	O
116	of	_	_	O
117	life	_	_	O
118	(	_	_	O
119	QOL	_	_	O
120	)	_	_	O
121	assessed	_	_	O
122	using	_	_	O
123	the	_	_	O
124	EORTC	_	_	O
125	QLQ	_	_	O
126	-	_	_	O
127	C30	_	_	O
128	and	_	_	O
129	QLQ	_	_	O
130	-	_	_	O
131	LC13	_	_	O
132	questionnaires	_	_	O
133	.	_	_	O

134	Fifty	_	_	O
135	four	_	_	O
136	patients	_	_	O
137	were	_	_	O
138	enrolled	_	_	O
139	.	_	_	O

140	More	_	_	O
141	patients	_	_	O
142	in	_	_	O
143	the	_	_	O
144	11	_	_	O
145	day	_	_	O
146	group	_	_	O
147	had	_	_	O
148	respiratory	_	_	O
149	symptoms	_	_	O
150	at	_	_	O
151	baseline	_	_	O
152	.	_	_	O

153	55	_	_	B-Premise
154	.	_	_	I-Premise

155	6	_	_	I-Premise
156	%	_	_	I-Premise
157	patients	_	_	I-Premise
158	treated	_	_	I-Premise
159	over	_	_	I-Premise
160	4	_	_	I-Premise
161	days	_	_	I-Premise
162	and	_	_	I-Premise
163	33	_	_	I-Premise
164	.	_	_	I-Premise

165	3	_	_	I-Premise
166	%	_	_	I-Premise
167	of	_	_	I-Premise
168	patients	_	_	I-Premise
169	treated	_	_	I-Premise
170	over	_	_	I-Premise
171	11	_	_	I-Premise
172	days	_	_	I-Premise
173	experienced	_	_	I-Premise
174	acute	_	_	I-Premise
175	grade	_	_	I-Premise
176	≥	_	_	I-Premise
177	2	_	_	I-Premise
178	toxicity	_	_	I-Premise
179	(	_	_	I-Premise
180	p	_	_	I-Premise
181	=	_	_	I-Premise
182	0	_	_	I-Premise
183	.	_	_	I-Premise

184	085	_	_	I-Premise
185	)	_	_	I-Premise
186	.	_	_	I-Premise

187	Dyspnea	_	_	B-Premise
188	,	_	_	I-Premise
189	fatigue	_	_	I-Premise
190	and	_	_	I-Premise
191	coughing	_	_	I-Premise
192	domains	_	_	I-Premise
193	were	_	_	I-Premise
194	worse	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	11	_	_	I-Premise
198	day	_	_	I-Premise
199	group	_	_	I-Premise
200	at	_	_	I-Premise
201	baseline	_	_	I-Premise
202	.	_	_	I-Premise

203	At	_	_	B-Premise
204	1	_	_	I-Premise
205	and	_	_	I-Premise
206	4	_	_	I-Premise
207	months	_	_	I-Premise
208	,	_	_	I-Premise
209	more	_	_	I-Premise
210	patients	_	_	I-Premise
211	in	_	_	I-Premise
212	the	_	_	I-Premise
213	4	_	_	I-Premise
214	day	_	_	I-Premise
215	group	_	_	I-Premise
216	experienced	_	_	I-Premise
217	a	_	_	I-Premise
218	clinically	_	_	I-Premise
219	meaningful	_	_	I-Premise
220	worsening	_	_	I-Premise
221	in	_	_	I-Premise
222	the	_	_	I-Premise
223	dyspnea	_	_	I-Premise
224	QOL	_	_	I-Premise
225	domain	_	_	I-Premise
226	compared	_	_	I-Premise
227	to	_	_	I-Premise
228	the	_	_	I-Premise
229	11	_	_	I-Premise
230	day	_	_	I-Premise
231	group	_	_	I-Premise
232	(	_	_	I-Premise
233	44	_	_	I-Premise
234	.	_	_	I-Premise

235	5	_	_	I-Premise
236	%	_	_	I-Premise
237	vs	_	_	I-Premise
238	15	_	_	I-Premise
239	.	_	_	I-Premise

240	4	_	_	I-Premise
241	%	_	_	I-Premise
242	,	_	_	I-Premise
243	p	_	_	I-Premise
244	=	_	_	I-Premise
245	0	_	_	I-Premise
246	.	_	_	I-Premise

247	02	_	_	I-Premise
248	;	_	_	I-Premise
249	38	_	_	I-Premise
250	.	_	_	I-Premise

251	5	_	_	I-Premise
252	%	_	_	I-Premise
253	vs	_	_	I-Premise
254	12	_	_	I-Premise
255	.	_	_	I-Premise

256	0	_	_	I-Premise
257	%	_	_	I-Premise
258	,	_	_	I-Premise
259	p	_	_	I-Premise
260	=	_	_	I-Premise
261	0	_	_	I-Premise
262	.	_	_	I-Premise

263	03	_	_	I-Premise
264	,	_	_	I-Premise
265	respectively	_	_	I-Premise
266	)	_	_	I-Premise
267	.	_	_	I-Premise

268	However	_	_	B-Premise
269	,	_	_	I-Premise
270	raw	_	_	I-Premise
271	QOL	_	_	I-Premise
272	scores	_	_	I-Premise
273	were	_	_	I-Premise
274	not	_	_	I-Premise
275	different	_	_	I-Premise
276	at	_	_	I-Premise
277	these	_	_	I-Premise
278	time	_	_	I-Premise
279	-	_	_	I-Premise
280	points	_	_	I-Premise
281	between	_	_	I-Premise
282	treatment	_	_	I-Premise
283	groups	_	_	I-Premise
284	.	_	_	I-Premise

285	Grade	_	_	B-Claim
286	2	_	_	I-Claim
287	or	_	_	I-Claim
288	higher	_	_	I-Claim
289	acute	_	_	I-Claim
290	toxicity	_	_	I-Claim
291	was	_	_	I-Claim
292	more	_	_	I-Claim
293	common	_	_	I-Claim
294	in	_	_	I-Claim
295	the	_	_	I-Claim
296	4	_	_	I-Claim
297	day	_	_	I-Claim
298	group	_	_	I-Claim
299	,	_	_	I-Claim
300	approaching	_	_	I-Claim
301	statistical	_	_	I-Claim
302	significance	_	_	I-Claim
303	.	_	_	I-Claim

304	More	_	_	B-Claim
305	patients	_	_	I-Claim
306	treated	_	_	I-Claim
307	on	_	_	I-Claim
308	4	_	_	I-Claim
309	consecutive	_	_	I-Claim
310	days	_	_	I-Claim
311	reported	_	_	I-Claim
312	a	_	_	I-Claim
313	clinically	_	_	I-Claim
314	meaningful	_	_	I-Claim
315	increase	_	_	I-Claim
316	in	_	_	I-Claim
317	dyspnea	_	_	I-Claim
318	,	_	_	I-Claim
319	although	_	_	B-Claim
320	interpretation	_	_	I-Claim
321	of	_	_	I-Claim
322	these	_	_	I-Claim
323	results	_	_	I-Claim
324	is	_	_	I-Claim
325	challenging	_	_	I-Claim
326	due	_	_	I-Claim
327	to	_	_	I-Claim
328	baseline	_	_	I-Claim
329	imbalance	_	_	I-Claim
330	between	_	_	I-Claim
331	treatment	_	_	I-Claim
332	groups	_	_	I-Claim
333	.	_	_	I-Claim

334	Larger	_	_	B-Claim
335	studies	_	_	I-Claim
336	are	_	_	I-Claim
337	required	_	_	I-Claim
338	to	_	_	I-Claim
339	validate	_	_	I-Claim
340	these	_	_	I-Claim
341	results	_	_	I-Claim
342	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	analgesic	_	_	O
10	and	_	_	O
11	adverse	_	_	O
12	effects	_	_	O
13	,	_	_	O
14	doses	_	_	O
15	,	_	_	O
16	as	_	_	O
17	well	_	_	O
18	as	_	_	O
19	cost	_	_	O
20	of	_	_	O
21	opioid	_	_	O
22	drugs	_	_	O
23	,	_	_	O
24	supportive	_	_	O
25	drug	_	_	O
26	therapy	_	_	O
27	and	_	_	O
28	other	_	_	O
29	analgesic	_	_	O
30	drugs	_	_	O
31	in	_	_	O
32	patients	_	_	O
33	treated	_	_	O
34	with	_	_	O
35	oral	_	_	O
36	sustained	_	_	O
37	-	_	_	O
38	release	_	_	O
39	morphine	_	_	O
40	,	_	_	O
41	transdermal	_	_	O
42	fentanyl	_	_	O
43	,	_	_	O
44	and	_	_	O
45	oral	_	_	O
46	methadone	_	_	O
47	.	_	_	O

48	One	_	_	O
49	hundred	_	_	O
50	and	_	_	O
51	eight	_	_	O
52	cancer	_	_	O
53	patients	_	_	O
54	,	_	_	O
55	no	_	_	O
56	longer	_	_	O
57	responsive	_	_	O
58	to	_	_	O
59	opioids	_	_	O
60	for	_	_	O
61	moderate	_	_	O
62	pain	_	_	O
63	,	_	_	O
64	were	_	_	O
65	selected	_	_	O
66	to	_	_	O
67	randomly	_	_	O
68	receive	_	_	O
69	initial	_	_	O
70	daily	_	_	O
71	doses	_	_	O
72	of	_	_	O
73	60	_	_	O
74	mg	_	_	O
75	of	_	_	O
76	oral	_	_	O
77	sustained	_	_	O
78	-	_	_	O
79	release	_	_	O
80	morphine	_	_	O
81	,	_	_	O
82	15	_	_	O
83	mg	_	_	O
84	of	_	_	O
85	oral	_	_	O
86	methadone	_	_	O
87	,	_	_	O
88	or	_	_	O
89	0	_	_	O
90	.	_	_	O

91	6	_	_	O
92	mg	_	_	O
93	(	_	_	O
94	25	_	_	O
95	microg	_	_	O
96	/	_	_	O
97	h	_	_	O
98	)	_	_	O
99	of	_	_	O
100	transdermal	_	_	O
101	fentanyl	_	_	O
102	.	_	_	O

103	Oral	_	_	O
104	morphine	_	_	O
105	was	_	_	O
106	used	_	_	O
107	as	_	_	O
108	breakthrough	_	_	O
109	pain	_	_	O
110	medication	_	_	O
111	during	_	_	O
112	opioid	_	_	O
113	titration	_	_	O
114	.	_	_	O

115	Opioid	_	_	O
116	doses	_	_	O
117	,	_	_	O
118	pain	_	_	O
119	intensity	_	_	O
120	,	_	_	O
121	adverse	_	_	O
122	effects	_	_	O
123	,	_	_	O
124	symptomatic	_	_	O
125	drugs	_	_	O
126	,	_	_	O
127	were	_	_	O
128	recorded	_	_	O
129	at	_	_	O
130	week	_	_	O
131	intervals	_	_	O
132	for	_	_	O
133	4	_	_	O
134	weeks	_	_	O
135	.	_	_	O

136	Costs	_	_	O
137	of	_	_	O
138	opioid	_	_	O
139	therapy	_	_	O
140	,	_	_	O
141	supportive	_	_	O
142	drugs	_	_	O
143	,	_	_	O
144	and	_	_	O
145	other	_	_	O
146	analgesic	_	_	O
147	drugs	_	_	O
148	were	_	_	O
149	also	_	_	O
150	evaluated	_	_	O
151	.	_	_	O

152	Seventy	_	_	O
153	patients	_	_	O
154	completed	_	_	O
155	the	_	_	O
156	4	_	_	O
157	weeks	_	_	O
158	period	_	_	O
159	of	_	_	O
160	study	_	_	O
161	.	_	_	O

162	Five	_	_	O
163	,	_	_	O
164	five	_	_	O
165	,	_	_	O
166	and	_	_	O
167	four	_	_	O
168	patients	_	_	O
169	,	_	_	O
170	treated	_	_	O
171	with	_	_	O
172	oral	_	_	O
173	morphine	_	_	O
174	,	_	_	O
175	transdermal	_	_	O
176	fentanyl	_	_	O
177	,	_	_	O
178	and	_	_	O
179	oral	_	_	O
180	methadone	_	_	O
181	,	_	_	O
182	respectively	_	_	O
183	,	_	_	O
184	required	_	_	O
185	opioid	_	_	O
186	switching	_	_	O
187	.	_	_	O

188	No	_	_	B-Premise
189	differences	_	_	I-Premise
190	in	_	_	I-Premise
191	pain	_	_	I-Premise
192	and	_	_	I-Premise
193	symptom	_	_	I-Premise
194	intensity	_	_	I-Premise
195	were	_	_	I-Premise
196	observed	_	_	I-Premise
197	.	_	_	I-Premise

198	Opioid	_	_	B-Premise
199	escalation	_	_	I-Premise
200	index	_	_	I-Premise
201	was	_	_	I-Premise
202	significantly	_	_	I-Premise
203	lower	_	_	I-Premise
204	in	_	_	I-Premise
205	patients	_	_	I-Premise
206	receiving	_	_	I-Premise
207	methadone	_	_	I-Premise
208	(	_	_	I-Premise
209	p	_	_	I-Premise
210	<	_	_	I-Premise
211	0	_	_	I-Premise
212	.	_	_	I-Premise

213	0001	_	_	I-Premise
214	)	_	_	I-Premise
215	,	_	_	I-Premise
216	although	_	_	I-Premise
217	requiring	_	_	I-Premise
218	up	_	_	I-Premise
219	and	_	_	I-Premise
220	down	_	_	I-Premise
221	changes	_	_	I-Premise
222	in	_	_	I-Premise
223	doses	_	_	I-Premise
224	.	_	_	I-Premise

225	At	_	_	B-Premise
226	the	_	_	I-Premise
227	doses	_	_	I-Premise
228	used	_	_	I-Premise
229	,	_	_	I-Premise
230	methadone	_	_	I-Premise
231	was	_	_	I-Premise
232	significantly	_	_	I-Premise
233	less	_	_	I-Premise
234	expensive	_	_	I-Premise
235	(	_	_	I-Premise
236	p	_	_	I-Premise
237	<	_	_	I-Premise
238	0	_	_	I-Premise
239	.	_	_	I-Premise

240	0001	_	_	I-Premise
241	)	_	_	I-Premise
242	,	_	_	I-Premise
243	while	_	_	I-Premise
244	the	_	_	I-Premise
245	use	_	_	I-Premise
246	and	_	_	I-Premise
247	costs	_	_	I-Premise
248	of	_	_	I-Premise
249	supportive	_	_	I-Premise
250	drugs	_	_	I-Premise
251	and	_	_	I-Premise
252	other	_	_	I-Premise
253	analgesics	_	_	I-Premise
254	were	_	_	I-Premise
255	similar	_	_	I-Premise
256	in	_	_	I-Premise
257	the	_	_	I-Premise
258	three	_	_	I-Premise
259	groups	_	_	I-Premise
260	.	_	_	I-Premise

261	No	_	_	B-Premise
262	relevant	_	_	I-Premise
263	differences	_	_	I-Premise
264	in	_	_	I-Premise
265	adverse	_	_	I-Premise
266	effects	_	_	I-Premise
267	were	_	_	I-Premise
268	observed	_	_	I-Premise
269	among	_	_	I-Premise
270	the	_	_	I-Premise
271	groups	_	_	I-Premise
272	during	_	_	I-Premise
273	either	_	_	I-Premise
274	the	_	_	I-Premise
275	titration	_	_	I-Premise
276	phase	_	_	I-Premise
277	and	_	_	I-Premise
278	chronic	_	_	I-Premise
279	treatment	_	_	I-Premise
280	.	_	_	I-Premise

281	All	_	_	B-Claim
282	the	_	_	I-Claim
283	three	_	_	I-Claim
284	opioids	_	_	I-Claim
285	used	_	_	I-Claim
286	as	_	_	I-Claim
287	first	_	_	I-Claim
288	-	_	_	I-Claim
289	line	_	_	I-Claim
290	therapy	_	_	I-Claim
291	were	_	_	I-Claim
292	effective	_	_	I-Claim
293	,	_	_	I-Claim
294	well	_	_	I-Claim
295	tolerated	_	_	I-Claim
296	,	_	_	I-Claim
297	and	_	_	I-Claim
298	required	_	_	I-Claim
299	similar	_	_	I-Claim
300	amounts	_	_	I-Claim
301	of	_	_	I-Claim
302	symptomatic	_	_	I-Claim
303	drugs	_	_	I-Claim
304	or	_	_	I-Claim
305	co	_	_	I-Claim
306	-	_	_	I-Claim
307	analgesics	_	_	I-Claim
308	.	_	_	I-Claim

309	Methadone	_	_	B-Claim
310	was	_	_	I-Claim
311	significantly	_	_	I-Claim
312	less	_	_	I-Claim
313	expensive	_	_	I-Claim
314	,	_	_	I-Claim
315	but	_	_	I-Claim
316	required	_	_	I-Claim
317	more	_	_	I-Claim
318	changes	_	_	I-Claim
319	,	_	_	I-Claim
320	up	_	_	I-Claim
321	and	_	_	I-Claim
322	down	_	_	I-Claim
323	,	_	_	I-Claim
324	of	_	_	I-Claim
325	the	_	_	I-Claim
326	doses	_	_	I-Claim
327	,	_	_	I-Claim
328	suggesting	_	_	I-Claim
329	that	_	_	I-Claim
330	dose	_	_	I-Claim
331	titration	_	_	I-Claim
332	of	_	_	I-Claim
333	this	_	_	I-Claim
334	drug	_	_	I-Claim
335	requires	_	_	I-Claim
336	major	_	_	I-Claim
337	clinical	_	_	I-Claim
338	expertise	_	_	I-Claim
339	.	_	_	I-Claim


0	This	_	_	O
1	randomized	_	_	O
2	controlled	_	_	O
3	trial	_	_	O
4	assessed	_	_	O
5	the	_	_	O
6	effect	_	_	O
7	of	_	_	O
8	a	_	_	O
9	SMART	_	_	O
10	(	_	_	O
11	Stress	_	_	O
12	Management	_	_	O
13	and	_	_	O
14	Resiliency	_	_	O
15	Training	_	_	O
16	)	_	_	O
17	program	_	_	O
18	among	_	_	O
19	25	_	_	O
20	women	_	_	O
21	diagnosed	_	_	O
22	with	_	_	O
23	breast	_	_	O
24	cancer	_	_	O
25	.	_	_	O

26	Resilience	_	_	O
27	,	_	_	O
28	perceived	_	_	O
29	stress	_	_	O
30	,	_	_	O
31	anxiety	_	_	O
32	,	_	_	O
33	and	_	_	O
34	quality	_	_	O
35	of	_	_	O
36	life	_	_	O
37	improved	_	_	O
38	at	_	_	O
39	12	_	_	O
40	weeks	_	_	O
41	in	_	_	O
42	the	_	_	O
43	active	_	_	O
44	but	_	_	O
45	not	_	_	O
46	the	_	_	O
47	control	_	_	O
48	arm	_	_	O
49	.	_	_	O

50	A	_	_	O
51	brief	_	_	O
52	training	_	_	O
53	in	_	_	O
54	the	_	_	O
55	SMART	_	_	O
56	program	_	_	O
57	can	_	_	O
58	enhance	_	_	O
59	resilience	_	_	O
60	and	_	_	O
61	quality	_	_	O
62	of	_	_	O
63	life	_	_	O
64	and	_	_	O
65	decrease	_	_	O
66	stress	_	_	O
67	and	_	_	O
68	anxiety	_	_	O
69	.	_	_	O

70	Patients	_	_	O
71	with	_	_	O
72	breast	_	_	O
73	cancer	_	_	O
74	experience	_	_	O
75	stress	_	_	O
76	and	_	_	O
77	anxiety	_	_	O
78	related	_	_	O
79	to	_	_	O
80	their	_	_	O
81	diagnosis	_	_	O
82	,	_	_	O
83	with	_	_	O
84	resulting	_	_	O
85	lower	_	_	O
86	quality	_	_	O
87	of	_	_	O
88	life	_	_	O
89	.	_	_	O

90	The	_	_	O
91	purpose	_	_	O
92	of	_	_	O
93	this	_	_	O
94	study	_	_	O
95	was	_	_	O
96	to	_	_	O
97	assess	_	_	O
98	the	_	_	O
99	effect	_	_	O
100	of	_	_	O
101	a	_	_	O
102	SMART	_	_	O
103	(	_	_	O
104	Stress	_	_	O
105	Management	_	_	O
106	and	_	_	O
107	Resiliency	_	_	O
108	Training	_	_	O
109	)	_	_	O
110	program	_	_	O
111	for	_	_	O
112	increasing	_	_	O
113	resiliency	_	_	O
114	and	_	_	O
115	for	_	_	O
116	decreasing	_	_	O
117	stress	_	_	O
118	and	_	_	O
119	anxiety	_	_	O
120	among	_	_	O
121	mentors	_	_	O
122	who	_	_	O
123	themselves	_	_	O
124	were	_	_	O
125	previously	_	_	O
126	diagnosed	_	_	O
127	with	_	_	O
128	breast	_	_	O
129	cancer	_	_	O
130	.	_	_	O

131	The	_	_	O
132	program	_	_	O
133	consisted	_	_	O
134	of	_	_	O
135	two	_	_	O
136	90	_	_	O
137	-	_	_	O
138	minute	_	_	O
139	group	_	_	O
140	training	_	_	O
141	sessions	_	_	O
142	,	_	_	O
143	a	_	_	O
144	brief	_	_	O
145	individual	_	_	O
146	session	_	_	O
147	,	_	_	O
148	and	_	_	O
149	3	_	_	O
150	follow	_	_	O
151	-	_	_	O
152	up	_	_	O
153	telephone	_	_	O
154	calls	_	_	O
155	.	_	_	O

156	Twenty	_	_	O
157	-	_	_	O
158	four	_	_	O
159	mentors	_	_	O
160	at	_	_	O
161	Mayo	_	_	O
162	Clinic	_	_	O
163	in	_	_	O
164	Rochester	_	_	O
165	,	_	_	O
166	Minnesota	_	_	O
167	,	_	_	O
168	were	_	_	O
169	randomized	_	_	O
170	in	_	_	O
171	a	_	_	O
172	single	_	_	O
173	-	_	_	O
174	blind	_	_	O
175	,	_	_	O
176	wait	_	_	O
177	-	_	_	O
178	list	_	_	O
179	controlled	_	_	O
180	clinical	_	_	O
181	trial	_	_	O
182	to	_	_	O
183	either	_	_	O
184	the	_	_	O
185	SMART	_	_	O
186	intervention	_	_	O
187	or	_	_	O
188	a	_	_	O
189	control	_	_	O
190	group	_	_	O
191	for	_	_	O
192	12	_	_	O
193	weeks	_	_	O
194	.	_	_	O

195	Primary	_	_	O
196	outcome	_	_	O
197	measures	_	_	O
198	assessed	_	_	O
199	at	_	_	O
200	baseline	_	_	O
201	and	_	_	O
202	at	_	_	O
203	week	_	_	O
204	12	_	_	O
205	included	_	_	O
206	the	_	_	O
207	Connor	_	_	O
208	Davidson	_	_	O
209	Resilience	_	_	O
210	Scale	_	_	O
211	,	_	_	O
212	Perceived	_	_	O
213	Stress	_	_	O
214	Scale	_	_	O
215	,	_	_	O
216	Smith	_	_	O
217	Anxiety	_	_	O
218	Scale	_	_	O
219	,	_	_	O
220	and	_	_	O
221	Linear	_	_	O
222	Analog	_	_	O
223	Self	_	_	O
224	Assessment	_	_	O
225	Scale	_	_	O
226	.	_	_	O

227	Twenty	_	_	O
228	patients	_	_	O
229	completed	_	_	O
230	the	_	_	O
231	study	_	_	O
232	.	_	_	O

233	A	_	_	B-Premise
234	statistically	_	_	I-Premise
235	significant	_	_	I-Premise
236	improvement	_	_	I-Premise
237	in	_	_	I-Premise
238	resilience	_	_	I-Premise
239	,	_	_	I-Premise
240	perceived	_	_	I-Premise
241	stress	_	_	I-Premise
242	,	_	_	I-Premise
243	anxiety	_	_	I-Premise
244	,	_	_	I-Premise
245	and	_	_	I-Premise
246	overall	_	_	I-Premise
247	quality	_	_	I-Premise
248	of	_	_	I-Premise
249	life	_	_	I-Premise
250	at	_	_	I-Premise
251	12	_	_	I-Premise
252	weeks	_	_	I-Premise
253	,	_	_	I-Premise
254	compared	_	_	I-Premise
255	with	_	_	I-Premise
256	baseline	_	_	I-Premise
257	was	_	_	I-Premise
258	observed	_	_	I-Premise
259	in	_	_	I-Premise
260	the	_	_	I-Premise
261	study	_	_	I-Premise
262	arm	_	_	I-Premise
263	.	_	_	I-Premise

264	No	_	_	B-Premise
265	significant	_	_	I-Premise
266	difference	_	_	I-Premise
267	in	_	_	I-Premise
268	any	_	_	I-Premise
269	of	_	_	I-Premise
270	these	_	_	I-Premise
271	measures	_	_	I-Premise
272	was	_	_	I-Premise
273	noted	_	_	I-Premise
274	in	_	_	I-Premise
275	the	_	_	I-Premise
276	control	_	_	I-Premise
277	group	_	_	I-Premise
278	.	_	_	I-Premise

279	This	_	_	B-Claim
280	study	_	_	I-Claim
281	demonstrates	_	_	I-Claim
282	that	_	_	I-Claim
283	a	_	_	I-Claim
284	brief	_	_	I-Claim
285	,	_	_	I-Claim
286	predominantly	_	_	I-Claim
287	group	_	_	I-Claim
288	-	_	_	I-Claim
289	based	_	_	I-Claim
290	resilience	_	_	I-Claim
291	training	_	_	I-Claim
292	intervention	_	_	I-Claim
293	is	_	_	I-Claim
294	feasible	_	_	I-Claim
295	in	_	_	I-Claim
296	patients	_	_	I-Claim
297	with	_	_	I-Claim
298	previous	_	_	I-Claim
299	breast	_	_	I-Claim
300	cancer	_	_	I-Claim
301	;	_	_	I-Claim
302	also	_	_	I-Claim
303	,	_	_	I-Claim
304	it	_	_	I-Claim
305	may	_	_	I-Claim
306	be	_	_	I-Claim
307	efficacious	_	_	I-Claim
308	.	_	_	I-Claim


0	The	_	_	O
1	TAX	_	_	O
2	327	_	_	O
3	study	_	_	O
4	compared	_	_	O
5	docetaxel	_	_	O
6	administered	_	_	O
7	every	_	_	O
8	3	_	_	O
9	weeks	_	_	O
10	(	_	_	O
11	D3	_	_	O
12	)	_	_	O
13	,	_	_	O
14	weekly	_	_	O
15	docetaxel	_	_	O
16	(	_	_	O
17	D1	_	_	O
18	)	_	_	O
19	,	_	_	O
20	and	_	_	O
21	mitoxantrone	_	_	O
22	(	_	_	O
23	M	_	_	O
24	)	_	_	O
25	,	_	_	O
26	each	_	_	O
27	with	_	_	O
28	prednisone	_	_	O
29	(	_	_	O
30	P	_	_	O
31	)	_	_	O
32	,	_	_	O
33	in	_	_	O
34	1	_	_	O
35	,	_	_	O
36	006	_	_	O
37	men	_	_	O
38	with	_	_	O
39	metastatic	_	_	O
40	hormone	_	_	O
41	-	_	_	O
42	resistant	_	_	O
43	prostate	_	_	O
44	cancer	_	_	O
45	(	_	_	O
46	HRPC	_	_	O
47	)	_	_	O
48	.	_	_	O

49	The	_	_	O
50	original	_	_	O
51	analysis	_	_	O
52	,	_	_	O
53	undertaken	_	_	O
54	in	_	_	O
55	August	_	_	O
56	2003	_	_	O
57	when	_	_	O
58	557	_	_	O
59	deaths	_	_	O
60	had	_	_	O
61	occurred	_	_	O
62	,	_	_	O
63	showed	_	_	O
64	significantly	_	_	O
65	better	_	_	O
66	survival	_	_	O
67	and	_	_	O
68	response	_	_	O
69	rates	_	_	O
70	for	_	_	O
71	pain	_	_	O
72	,	_	_	O
73	prostate	_	_	O
74	-	_	_	O
75	specific	_	_	O
76	antigen	_	_	O
77	(	_	_	O
78	PSA	_	_	O
79	)	_	_	O
80	,	_	_	O
81	and	_	_	O
82	quality	_	_	O
83	of	_	_	O
84	life	_	_	O
85	for	_	_	O
86	D3P	_	_	O
87	when	_	_	O
88	compared	_	_	O
89	with	_	_	O
90	MP	_	_	O
91	.	_	_	O

92	Here	_	_	O
93	,	_	_	O
94	we	_	_	O
95	report	_	_	O
96	an	_	_	O
97	updated	_	_	O
98	analysis	_	_	O
99	of	_	_	O
100	survival	_	_	O
101	.	_	_	O

102	Investigators	_	_	O
103	were	_	_	O
104	asked	_	_	O
105	to	_	_	O
106	provide	_	_	O
107	the	_	_	O
108	date	_	_	O
109	of	_	_	O
110	death	_	_	O
111	or	_	_	O
112	last	_	_	O
113	follow	_	_	O
114	-	_	_	O
115	up	_	_	O
116	for	_	_	O
117	all	_	_	O
118	participants	_	_	O
119	who	_	_	O
120	were	_	_	O
121	alive	_	_	O
122	in	_	_	O
123	August	_	_	O
124	2003	_	_	O
125	.	_	_	O

126	By	_	_	O
127	March	_	_	O
128	2007	_	_	O
129	,	_	_	O
130	data	_	_	O
131	on	_	_	O
132	310	_	_	O
133	additional	_	_	O
134	deaths	_	_	O
135	were	_	_	O
136	obtained	_	_	O
137	(	_	_	O
138	total	_	_	O
139	=	_	_	O
140	867	_	_	O
141	deaths	_	_	O
142	)	_	_	O
143	.	_	_	O

144	The	_	_	B-Premise
145	survival	_	_	I-Premise
146	benefit	_	_	I-Premise
147	of	_	_	I-Premise
148	D3P	_	_	I-Premise
149	compared	_	_	I-Premise
150	with	_	_	I-Premise
151	MP	_	_	I-Premise
152	has	_	_	I-Premise
153	persisted	_	_	I-Premise
154	with	_	_	I-Premise
155	extended	_	_	I-Premise
156	follow	_	_	I-Premise
157	-	_	_	I-Premise
158	up	_	_	I-Premise
159	(	_	_	I-Premise
160	P	_	_	I-Premise
161	=	_	_	I-Premise
162	.	_	_	I-Premise

163	004	_	_	I-Premise
164	)	_	_	I-Premise
165	.	_	_	I-Premise

166	Median	_	_	O
167	survival	_	_	O
168	time	_	_	O
169	was	_	_	O
170	19	_	_	O
171	.	_	_	O

172	2	_	_	O
173	months	_	_	O
174	(	_	_	O
175	95	_	_	O
176	%	_	_	O
177	CI	_	_	O
178	,	_	_	O
179	17	_	_	O
180	.	_	_	O

181	5	_	_	O
182	to	_	_	O
183	21	_	_	O
184	.	_	_	O

185	3	_	_	O
186	months	_	_	O
187	)	_	_	O
188	in	_	_	O
189	the	_	_	O
190	D3P	_	_	O
191	arm	_	_	O
192	,	_	_	O
193	17	_	_	O
194	.	_	_	O

195	8	_	_	O
196	months	_	_	O
197	(	_	_	O
198	95	_	_	O
199	%	_	_	O
200	CI	_	_	O
201	,	_	_	O
202	16	_	_	O
203	.	_	_	O

204	2	_	_	O
205	to	_	_	O
206	19	_	_	O
207	.	_	_	O

208	2	_	_	O
209	months	_	_	O
210	)	_	_	O
211	in	_	_	O
212	the	_	_	O
213	D1P	_	_	O
214	arm	_	_	O
215	,	_	_	O
216	and	_	_	O
217	16	_	_	O
218	.	_	_	O

219	3	_	_	O
220	months	_	_	O
221	(	_	_	O
222	95	_	_	O
223	%	_	_	O
224	CI	_	_	O
225	,	_	_	O
226	14	_	_	O
227	.	_	_	O

228	3	_	_	O
229	to	_	_	O
230	17	_	_	O
231	.	_	_	O

232	9	_	_	O
233	months	_	_	O
234	)	_	_	O
235	in	_	_	O
236	the	_	_	O
237	MP	_	_	O
238	arm	_	_	O
239	.	_	_	O

240	More	_	_	B-Premise
241	patients	_	_	I-Premise
242	survived	_	_	I-Premise
243	>	_	_	I-Premise
244	/	_	_	I-Premise
245	=	_	_	I-Premise
246	3	_	_	I-Premise
247	years	_	_	I-Premise
248	in	_	_	I-Premise
249	the	_	_	I-Premise
250	D3P	_	_	I-Premise
251	and	_	_	I-Premise
252	D1P	_	_	I-Premise
253	arms	_	_	I-Premise
254	(	_	_	I-Premise
255	18	_	_	I-Premise
256	.	_	_	I-Premise

257	6	_	_	I-Premise
258	%	_	_	I-Premise
259	and	_	_	I-Premise
260	16	_	_	I-Premise
261	.	_	_	I-Premise

262	6	_	_	I-Premise
263	%	_	_	I-Premise
264	,	_	_	I-Premise
265	respectively	_	_	I-Premise
266	)	_	_	I-Premise
267	compared	_	_	I-Premise
268	with	_	_	I-Premise
269	the	_	_	I-Premise
270	MP	_	_	I-Premise
271	arm	_	_	I-Premise
272	(	_	_	I-Premise
273	13	_	_	I-Premise
274	.	_	_	I-Premise

275	5	_	_	I-Premise
276	%	_	_	I-Premise
277	)	_	_	I-Premise
278	.	_	_	I-Premise

279	Similar	_	_	B-Premise
280	trends	_	_	I-Premise
281	in	_	_	I-Premise
282	survival	_	_	I-Premise
283	between	_	_	I-Premise
284	treatment	_	_	I-Premise
285	arms	_	_	I-Premise
286	were	_	_	I-Premise
287	seen	_	_	I-Premise
288	for	_	_	I-Premise
289	men	_	_	I-Premise
290	greater	_	_	I-Premise
291	than	_	_	I-Premise
292	and	_	_	I-Premise
293	less	_	_	I-Premise
294	than	_	_	I-Premise
295	65	_	_	I-Premise
296	years	_	_	I-Premise
297	of	_	_	I-Premise
298	age	_	_	I-Premise
299	,	_	_	I-Premise
300	for	_	_	I-Premise
301	those	_	_	I-Premise
302	with	_	_	I-Premise
303	and	_	_	I-Premise
304	without	_	_	I-Premise
305	pain	_	_	I-Premise
306	at	_	_	I-Premise
307	baseline	_	_	I-Premise
308	,	_	_	I-Premise
309	and	_	_	I-Premise
310	for	_	_	I-Premise
311	those	_	_	I-Premise
312	with	_	_	I-Premise
313	baseline	_	_	I-Premise
314	PSA	_	_	I-Premise
315	greater	_	_	I-Premise
316	than	_	_	I-Premise
317	and	_	_	I-Premise
318	less	_	_	I-Premise
319	than	_	_	I-Premise
320	the	_	_	I-Premise
321	median	_	_	I-Premise
322	value	_	_	I-Premise
323	of	_	_	I-Premise
324	115	_	_	I-Premise
325	ng	_	_	I-Premise
326	/	_	_	I-Premise
327	mL	_	_	I-Premise
328	.	_	_	I-Premise

329	The	_	_	B-Claim
330	present	_	_	I-Claim
331	analysis	_	_	I-Claim
332	confirms	_	_	I-Claim
333	that	_	_	I-Claim
334	survival	_	_	I-Claim
335	of	_	_	I-Claim
336	men	_	_	I-Claim
337	with	_	_	I-Claim
338	metastatic	_	_	I-Claim
339	HRPC	_	_	I-Claim
340	is	_	_	I-Claim
341	significantly	_	_	I-Claim
342	longer	_	_	I-Claim
343	after	_	_	I-Claim
344	treatment	_	_	I-Claim
345	with	_	_	I-Claim
346	D3P	_	_	I-Claim
347	than	_	_	I-Claim
348	with	_	_	I-Claim
349	MP	_	_	I-Claim
350	.	_	_	I-Claim

351	Consistent	_	_	O
352	results	_	_	O
353	are	_	_	O
354	observed	_	_	O
355	across	_	_	O
356	subgroups	_	_	O
357	of	_	_	O
358	patients	_	_	O
359	.	_	_	O


0	Both	_	_	O
1	gastrojejunostomy	_	_	O
2	(	_	_	O
3	GJJ	_	_	O
4	)	_	_	O
5	and	_	_	O
6	stent	_	_	O
7	placement	_	_	O
8	are	_	_	O
9	commonly	_	_	O
10	used	_	_	O
11	palliative	_	_	O
12	treatments	_	_	O
13	of	_	_	O
14	obstructive	_	_	O
15	symptoms	_	_	O
16	caused	_	_	O
17	by	_	_	O
18	malignant	_	_	O
19	gastric	_	_	O
20	outlet	_	_	O
21	obstruction	_	_	O
22	(	_	_	O
23	GOO	_	_	O
24	)	_	_	O
25	.	_	_	O

26	Compare	_	_	O
27	GJJ	_	_	O
28	and	_	_	O
29	stent	_	_	O
30	placement	_	_	O
31	.	_	_	O

32	Multicenter	_	_	O
33	,	_	_	O
34	randomized	_	_	O
35	trial	_	_	O
36	.	_	_	O

37	Twenty	_	_	O
38	-	_	_	O
39	one	_	_	O
40	centers	_	_	O
41	in	_	_	O
42	The	_	_	O
43	Netherlands	_	_	O
44	.	_	_	O

45	Patients	_	_	O
46	with	_	_	O
47	GOO	_	_	O
48	.	_	_	O

49	GJJ	_	_	O
50	and	_	_	O
51	stent	_	_	O
52	placement	_	_	O
53	.	_	_	O

54	Outcomes	_	_	O
55	were	_	_	O
56	medical	_	_	O
57	effects	_	_	O
58	,	_	_	O
59	quality	_	_	O
60	of	_	_	O
61	life	_	_	O
62	,	_	_	O
63	and	_	_	O
64	costs	_	_	O
65	.	_	_	O

66	Analysis	_	_	O
67	was	_	_	O
68	by	_	_	O
69	intent	_	_	O
70	to	_	_	O
71	treat	_	_	O
72	.	_	_	O

73	Eighteen	_	_	O
74	patients	_	_	O
75	were	_	_	O
76	randomized	_	_	O
77	to	_	_	O
78	GJJ	_	_	O
79	and	_	_	O
80	21	_	_	O
81	to	_	_	O
82	stent	_	_	O
83	placement	_	_	O
84	.	_	_	O

85	Food	_	_	B-Premise
86	intake	_	_	I-Premise
87	improved	_	_	I-Premise
88	more	_	_	I-Premise
89	rapidly	_	_	I-Premise
90	after	_	_	I-Premise
91	stent	_	_	I-Premise
92	placement	_	_	I-Premise
93	than	_	_	I-Premise
94	after	_	_	I-Premise
95	GJJ	_	_	I-Premise
96	(	_	_	I-Premise
97	GOO	_	_	I-Premise
98	Scoring	_	_	I-Premise
99	System	_	_	I-Premise
100	score	_	_	I-Premise
101	>	_	_	I-Premise
102	or	_	_	I-Premise
103	=	_	_	I-Premise
104	2	_	_	I-Premise
105	:	_	_	I-Premise
106	median	_	_	I-Premise
107	5	_	_	I-Premise
108	vs	_	_	I-Premise
109	8	_	_	I-Premise
110	days	_	_	I-Premise
111	,	_	_	I-Premise
112	respectively	_	_	I-Premise
113	;	_	_	I-Premise
114	P	_	_	I-Premise
115	<	_	_	I-Premise
116	.	_	_	I-Premise

117	01	_	_	I-Premise
118	)	_	_	I-Premise
119	but	_	_	B-Premise
120	long	_	_	I-Premise
121	-	_	_	I-Premise
122	term	_	_	I-Premise
123	relief	_	_	I-Premise
124	was	_	_	I-Premise
125	better	_	_	I-Premise
126	after	_	_	I-Premise
127	GJJ	_	_	I-Premise
128	,	_	_	I-Premise
129	with	_	_	I-Premise
130	more	_	_	I-Premise
131	patients	_	_	I-Premise
132	living	_	_	I-Premise
133	more	_	_	I-Premise
134	days	_	_	I-Premise
135	with	_	_	I-Premise
136	a	_	_	I-Premise
137	GOO	_	_	I-Premise
138	Scoring	_	_	I-Premise
139	System	_	_	I-Premise
140	score	_	_	I-Premise
141	of	_	_	I-Premise
142	2	_	_	I-Premise
143	or	_	_	I-Premise
144	more	_	_	I-Premise
145	than	_	_	I-Premise
146	after	_	_	I-Premise
147	stent	_	_	I-Premise
148	placement	_	_	I-Premise
149	(	_	_	I-Premise
150	72	_	_	I-Premise
151	vs	_	_	I-Premise
152	50	_	_	I-Premise
153	days	_	_	I-Premise
154	,	_	_	I-Premise
155	respectively	_	_	I-Premise
156	;	_	_	I-Premise
157	P	_	_	I-Premise
158	=	_	_	I-Premise
159	.	_	_	I-Premise

160	05	_	_	I-Premise
161	)	_	_	I-Premise
162	.	_	_	I-Premise

163	More	_	_	B-Premise
164	major	_	_	I-Premise
165	complications	_	_	I-Premise
166	(	_	_	I-Premise
167	stent	_	_	I-Premise
168	:	_	_	I-Premise
169	6	_	_	I-Premise
170	in	_	_	I-Premise
171	4	_	_	I-Premise
172	patients	_	_	I-Premise
173	vs	_	_	I-Premise
174	GJJ	_	_	I-Premise
175	:	_	_	I-Premise
176	0	_	_	I-Premise
177	;	_	_	I-Premise
178	P	_	_	I-Premise
179	=	_	_	I-Premise
180	.	_	_	I-Premise

181	02	_	_	I-Premise
182	)	_	_	I-Premise
183	,	_	_	I-Premise
184	recurrent	_	_	I-Premise
185	obstructive	_	_	I-Premise
186	symptoms	_	_	I-Premise
187	(	_	_	I-Premise
188	stent	_	_	I-Premise
189	:	_	_	I-Premise
190	8	_	_	I-Premise
191	in	_	_	I-Premise
192	5	_	_	I-Premise
193	patients	_	_	I-Premise
194	vs	_	_	I-Premise
195	GJJ	_	_	I-Premise
196	:	_	_	I-Premise
197	1	_	_	I-Premise
198	in	_	_	I-Premise
199	1	_	_	I-Premise
200	patient	_	_	I-Premise
201	;	_	_	I-Premise
202	P	_	_	I-Premise
203	=	_	_	I-Premise
204	.	_	_	I-Premise

205	02	_	_	I-Premise
206	)	_	_	I-Premise
207	,	_	_	I-Premise
208	and	_	_	I-Premise
209	reinterventions	_	_	I-Premise
210	(	_	_	I-Premise
211	stent	_	_	I-Premise
212	:	_	_	I-Premise
213	10	_	_	I-Premise
214	in	_	_	I-Premise
215	7	_	_	I-Premise
216	patients	_	_	I-Premise
217	vs	_	_	I-Premise
218	GJJ	_	_	I-Premise
219	:	_	_	I-Premise
220	2	_	_	I-Premise
221	in	_	_	I-Premise
222	2	_	_	I-Premise
223	patients	_	_	I-Premise
224	;	_	_	I-Premise
225	P	_	_	I-Premise
226	<	_	_	I-Premise
227	.	_	_	I-Premise

228	01	_	_	I-Premise
229	)	_	_	I-Premise
230	were	_	_	I-Premise
231	observed	_	_	I-Premise
232	after	_	_	I-Premise
233	stent	_	_	I-Premise
234	placement	_	_	I-Premise
235	compared	_	_	I-Premise
236	with	_	_	I-Premise
237	GJJ	_	_	I-Premise
238	.	_	_	I-Premise

239	When	_	_	B-Premise
240	stent	_	_	I-Premise
241	obstruction	_	_	I-Premise
242	was	_	_	I-Premise
243	not	_	_	I-Premise
244	regarded	_	_	I-Premise
245	as	_	_	I-Premise
246	a	_	_	I-Premise
247	major	_	_	I-Premise
248	complication	_	_	I-Premise
249	,	_	_	I-Premise
250	no	_	_	I-Premise
251	differences	_	_	I-Premise
252	in	_	_	I-Premise
253	complications	_	_	I-Premise
254	were	_	_	I-Premise
255	found	_	_	I-Premise
256	(	_	_	I-Premise
257	P	_	_	I-Premise
258	=	_	_	I-Premise
259	.	_	_	I-Premise

260	4	_	_	I-Premise
261	)	_	_	I-Premise
262	.	_	_	I-Premise

263	There	_	_	B-Premise
264	were	_	_	I-Premise
265	also	_	_	I-Premise
266	no	_	_	I-Premise
267	differences	_	_	I-Premise
268	in	_	_	I-Premise
269	median	_	_	I-Premise
270	survival	_	_	I-Premise
271	(	_	_	I-Premise
272	stent	_	_	I-Premise
273	:	_	_	I-Premise
274	56	_	_	I-Premise
275	days	_	_	I-Premise
276	vs	_	_	I-Premise
277	GJJ	_	_	I-Premise
278	:	_	_	I-Premise
279	78	_	_	I-Premise
280	days	_	_	I-Premise
281	)	_	_	I-Premise
282	and	_	_	I-Premise
283	quality	_	_	I-Premise
284	of	_	_	I-Premise
285	life	_	_	I-Premise
286	.	_	_	I-Premise

287	Mean	_	_	B-Premise
288	total	_	_	I-Premise
289	costs	_	_	I-Premise
290	of	_	_	I-Premise
291	GJJ	_	_	I-Premise
292	were	_	_	I-Premise
293	higher	_	_	I-Premise
294	compared	_	_	I-Premise
295	with	_	_	I-Premise
296	stent	_	_	I-Premise
297	placement	_	_	I-Premise
298	(	_	_	I-Premise
299	$	_	_	I-Premise
300	16	_	_	I-Premise
301	,	_	_	I-Premise
302	535	_	_	I-Premise
303	vs	_	_	I-Premise
304	$	_	_	I-Premise
305	11	_	_	I-Premise
306	,	_	_	I-Premise
307	720	_	_	I-Premise
308	,	_	_	I-Premise
309	respectively	_	_	I-Premise
310	;	_	_	I-Premise
311	P	_	_	I-Premise
312	=	_	_	I-Premise
313	.	_	_	I-Premise

314	049	_	_	I-Premise
315	[	_	_	I-Premise
316	comparing	_	_	I-Premise
317	medians	_	_	I-Premise
318	]	_	_	I-Premise
319	)	_	_	I-Premise
320	.	_	_	I-Premise

321	Because	_	_	O
322	of	_	_	O
323	the	_	_	O
324	small	_	_	O
325	study	_	_	O
326	population	_	_	O
327	,	_	_	O
328	only	_	_	O
329	initial	_	_	O
330	hospital	_	_	O
331	costs	_	_	O
332	would	_	_	O
333	have	_	_	O
334	been	_	_	O
335	statistically	_	_	O
336	significant	_	_	O
337	if	_	_	O
338	the	_	_	O
339	Bonferroni	_	_	O
340	correction	_	_	O
341	for	_	_	O
342	multiple	_	_	O
343	testing	_	_	O
344	had	_	_	O
345	been	_	_	O
346	applied	_	_	O
347	.	_	_	O

348	Relatively	_	_	O
349	small	_	_	O
350	patient	_	_	O
351	population	_	_	O
352	.	_	_	O

353	Despite	_	_	B-Premise
354	slow	_	_	I-Premise
355	initial	_	_	I-Premise
356	symptom	_	_	I-Premise
357	improvement	_	_	I-Premise
358	,	_	_	I-Premise
359	GJJ	_	_	B-Claim
360	was	_	_	I-Claim
361	associated	_	_	I-Claim
362	with	_	_	I-Claim
363	better	_	_	I-Claim
364	long	_	_	I-Claim
365	-	_	_	I-Claim
366	term	_	_	I-Claim
367	results	_	_	I-Claim
368	and	_	_	I-Claim
369	is	_	_	I-Claim
370	therefore	_	_	I-Claim
371	the	_	_	I-Claim
372	treatment	_	_	I-Claim
373	of	_	_	I-Claim
374	choice	_	_	I-Claim
375	in	_	_	I-Claim
376	patients	_	_	I-Claim
377	with	_	_	I-Claim
378	a	_	_	I-Claim
379	life	_	_	I-Claim
380	expectancy	_	_	I-Claim
381	of	_	_	I-Claim
382	2	_	_	I-Claim
383	months	_	_	I-Claim
384	or	_	_	I-Claim
385	longer	_	_	I-Claim
386	.	_	_	I-Claim

387	Because	_	_	B-Claim
388	stent	_	_	I-Claim
389	placement	_	_	I-Claim
390	was	_	_	I-Claim
391	associated	_	_	I-Claim
392	with	_	_	I-Claim
393	better	_	_	I-Claim
394	short	_	_	I-Claim
395	-	_	_	I-Claim
396	term	_	_	I-Claim
397	outcomes	_	_	I-Claim
398	,	_	_	I-Claim
399	this	_	_	B-Claim
400	treatment	_	_	I-Claim
401	is	_	_	I-Claim
402	preferable	_	_	I-Claim
403	for	_	_	I-Claim
404	patients	_	_	I-Claim
405	expected	_	_	I-Claim
406	to	_	_	I-Claim
407	live	_	_	I-Claim
408	less	_	_	I-Claim
409	than	_	_	I-Claim
410	2	_	_	I-Claim
411	months	_	_	I-Claim
412	.	_	_	I-Claim


0	Topical	_	_	O
1	photodynamic	_	_	O
2	therapy	_	_	O
3	(	_	_	O
4	PDT	_	_	O
5	)	_	_	O
6	with	_	_	O
7	aminolevulinic	_	_	O
8	acid	_	_	O
9	(	_	_	O
10	ALA	_	_	O
11	)	_	_	O
12	and	_	_	O
13	5	_	_	O
14	%	_	_	O
15	imiquimod	_	_	O
16	cream	_	_	O
17	are	_	_	O
18	effective	_	_	O
19	therapies	_	_	O
20	for	_	_	O
21	the	_	_	O
22	treatment	_	_	O
23	of	_	_	O
24	actinic	_	_	O
25	keratoses	_	_	O
26	(	_	_	O
27	AKs	_	_	O
28	)	_	_	O
29	,	_	_	O
30	but	_	_	O
31	no	_	_	O
32	split	_	_	O
33	-	_	_	O
34	face	_	_	O
35	studies	_	_	O
36	directly	_	_	O
37	comparing	_	_	O
38	these	_	_	O
39	treatment	_	_	O
40	options	_	_	O
41	are	_	_	O
42	available	_	_	O
43	in	_	_	O
44	the	_	_	O
45	literature	_	_	O
46	.	_	_	O

47	To	_	_	O
48	compare	_	_	O
49	the	_	_	O
50	efficacy	_	_	O
51	and	_	_	O
52	tolerability	_	_	O
53	of	_	_	O
54	ALA	_	_	O
55	-	_	_	O
56	PDT	_	_	O
57	and	_	_	O
58	imiquimod	_	_	O
59	5	_	_	O
60	%	_	_	O
61	cream	_	_	O
62	for	_	_	O
63	the	_	_	O
64	treatment	_	_	O
65	of	_	_	O
66	AKs	_	_	O
67	.	_	_	O

68	Sixty	_	_	O
69	-	_	_	O
70	one	_	_	O
71	patients	_	_	O
72	were	_	_	O
73	enrolled	_	_	O
74	from	_	_	O
75	the	_	_	O
76	Salt	_	_	O
77	Lake	_	_	O
78	City	_	_	O
79	Veterans	_	_	O
80	Affairs	_	_	O
81	Hospital	_	_	O
82	;	_	_	O
83	51	_	_	O
84	completed	_	_	O
85	the	_	_	O
86	study	_	_	O
87	and	_	_	O
88	were	_	_	O
89	included	_	_	O
90	in	_	_	O
91	the	_	_	O
92	analysis	_	_	O
93	.	_	_	O

94	All	_	_	O
95	patients	_	_	O
96	were	_	_	O
97	randomized	_	_	O
98	to	_	_	O
99	receive	_	_	O
100	half	_	_	O
101	of	_	_	O
102	a	_	_	O
103	sachet	_	_	O
104	of	_	_	O
105	imiquimod	_	_	O
106	5	_	_	O
107	%	_	_	O
108	cream	_	_	O
109	twice	_	_	O
110	weekly	_	_	O
111	on	_	_	O
112	half	_	_	O
113	of	_	_	O
114	their	_	_	O
115	face	_	_	O
116	and	_	_	O
117	two	_	_	O
118	sessions	_	_	O
119	of	_	_	O
120	PDT	_	_	O
121	with	_	_	O
122	20	_	_	O
123	%	_	_	O
124	solution	_	_	O
125	of	_	_	O
126	ALA	_	_	O
127	applied	_	_	O
128	for	_	_	O
129	1	_	_	O
130	hour	_	_	O
131	to	_	_	O
132	the	_	_	O
133	other	_	_	O
134	side	_	_	O
135	of	_	_	O
136	the	_	_	O
137	face	_	_	O
138	.	_	_	O

139	The	_	_	B-Premise
140	75	_	_	I-Premise
141	%	_	_	I-Premise
142	AK	_	_	I-Premise
143	clearance	_	_	I-Premise
144	rate	_	_	I-Premise
145	was	_	_	I-Premise
146	34	_	_	I-Premise
147	.	_	_	I-Premise

148	6	_	_	I-Premise
149	%	_	_	I-Premise
150	for	_	_	I-Premise
151	ALA	_	_	I-Premise
152	-	_	_	I-Premise
153	PDT	_	_	I-Premise
154	and	_	_	I-Premise
155	25	_	_	I-Premise
156	%	_	_	I-Premise
157	for	_	_	I-Premise
158	imiquimod	_	_	I-Premise
159	5	_	_	I-Premise
160	%	_	_	I-Premise
161	cream	_	_	I-Premise
162	(	_	_	I-Premise
163	p	_	_	I-Premise
164	=	_	_	I-Premise
165	.	_	_	I-Premise

166	30	_	_	I-Premise
167	)	_	_	I-Premise
168	.	_	_	I-Premise

169	The	_	_	B-Premise
170	mean	_	_	I-Premise
171	reduction	_	_	I-Premise
172	in	_	_	I-Premise
173	AK	_	_	I-Premise
174	count	_	_	I-Premise
175	was	_	_	I-Premise
176	59	_	_	I-Premise
177	.	_	_	I-Premise

178	2	_	_	I-Premise
179	%	_	_	I-Premise
180	for	_	_	I-Premise
181	ALA	_	_	I-Premise
182	-	_	_	I-Premise
183	PDT	_	_	I-Premise
184	and	_	_	I-Premise
185	41	_	_	I-Premise
186	.	_	_	I-Premise

187	4	_	_	I-Premise
188	%	_	_	I-Premise
189	for	_	_	I-Premise
190	imiquimod	_	_	I-Premise
191	5	_	_	I-Premise
192	%	_	_	I-Premise
193	cream	_	_	I-Premise
194	(	_	_	I-Premise
195	p	_	_	I-Premise
196	=	_	_	I-Premise
197	.	_	_	I-Premise

198	002	_	_	I-Premise
199	)	_	_	I-Premise
200	.	_	_	I-Premise

201	Dermatology	_	_	B-Premise
202	Life	_	_	I-Premise
203	Quality	_	_	I-Premise
204	Index	_	_	I-Premise
205	(	_	_	I-Premise
206	DLQI	_	_	I-Premise
207	)	_	_	I-Premise
208	scores	_	_	I-Premise
209	were	_	_	I-Premise
210	assessed	_	_	I-Premise
211	for	_	_	I-Premise
212	each	_	_	I-Premise
213	treatment	_	_	I-Premise
214	modality	_	_	I-Premise
215	at	_	_	I-Premise
216	week	_	_	I-Premise
217	4	_	_	I-Premise
218	and	_	_	I-Premise
219	were	_	_	I-Premise
220	1	_	_	I-Premise
221	.	_	_	I-Premise

222	95	_	_	I-Premise
223	and	_	_	I-Premise
224	1	_	_	I-Premise
225	.	_	_	I-Premise

226	38	_	_	I-Premise
227	,	_	_	I-Premise
228	respectively	_	_	I-Premise
229	(	_	_	I-Premise
230	p	_	_	I-Premise
231	=	_	_	I-Premise
232	.	_	_	I-Premise

233	20	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	The	_	_	B-Premise
237	sample	_	_	I-Premise
238	size	_	_	I-Premise
239	was	_	_	I-Premise
240	small	_	_	I-Premise
241	,	_	_	I-Premise
242	and	_	_	I-Premise
243	patients	_	_	I-Premise
244	applied	_	_	I-Premise
245	a	_	_	I-Premise
246	small	_	_	I-Premise
247	amount	_	_	I-Premise
248	of	_	_	I-Premise
249	imiquimod	_	_	I-Premise
250	5	_	_	I-Premise
251	%	_	_	I-Premise
252	cream	_	_	I-Premise
253	(	_	_	I-Premise
254	half	_	_	I-Premise
255	a	_	_	I-Premise
256	sachet	_	_	I-Premise
257	)	_	_	I-Premise
258	to	_	_	I-Premise
259	a	_	_	I-Premise
260	large	_	_	I-Premise
261	surface	_	_	I-Premise
262	area	_	_	I-Premise
263	.	_	_	I-Premise

264	There	_	_	B-Claim
265	was	_	_	I-Claim
266	no	_	_	I-Claim
267	statistically	_	_	I-Claim
268	significant	_	_	I-Claim
269	difference	_	_	I-Claim
270	in	_	_	I-Claim
271	treatment	_	_	I-Claim
272	response	_	_	I-Claim
273	when	_	_	I-Claim
274	the	_	_	I-Claim
275	100	_	_	I-Claim
276	%	_	_	I-Claim
277	or	_	_	I-Claim
278	75	_	_	I-Claim
279	%	_	_	I-Claim
280	clearance	_	_	I-Claim
281	rate	_	_	I-Claim
282	cutoff	_	_	I-Claim
283	was	_	_	I-Claim
284	used	_	_	I-Claim
285	,	_	_	I-Claim
286	but	_	_	B-Claim
287	our	_	_	I-Claim
288	secondary	_	_	I-Claim
289	outcome	_	_	I-Claim
290	suggests	_	_	I-Claim
291	that	_	_	I-Claim
292	two	_	_	I-Claim
293	sessions	_	_	I-Claim
294	of	_	_	I-Claim
295	ALA	_	_	I-Claim
296	-	_	_	I-Claim
297	PDT	_	_	I-Claim
298	is	_	_	I-Claim
299	superior	_	_	I-Claim
300	to	_	_	I-Claim
301	imiquimod	_	_	I-Claim
302	5	_	_	I-Claim
303	%	_	_	I-Claim
304	cream	_	_	I-Claim
305	for	_	_	I-Claim
306	the	_	_	I-Claim
307	treatment	_	_	I-Claim
308	of	_	_	I-Claim
309	AKs	_	_	I-Claim
310	.	_	_	I-Claim

311	There	_	_	B-Claim
312	was	_	_	I-Claim
313	no	_	_	I-Claim
314	statistically	_	_	I-Claim
315	significant	_	_	I-Claim
316	difference	_	_	I-Claim
317	in	_	_	I-Claim
318	effect	_	_	I-Claim
319	on	_	_	I-Claim
320	quality	_	_	I-Claim
321	of	_	_	I-Claim
322	life	_	_	I-Claim
323	as	_	_	I-Claim
324	assessed	_	_	I-Claim
325	using	_	_	I-Claim
326	the	_	_	I-Claim
327	DLQI	_	_	I-Claim
328	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	short	_	_	O
3	-	_	_	O
4	and	_	_	O
5	long	_	_	O
6	-	_	_	O
7	term	_	_	O
8	effects	_	_	O
9	of	_	_	O
10	adjuvant	_	_	O
11	treatment	_	_	O
12	versus	_	_	O
13	observation	_	_	O
14	after	_	_	O
15	surgery	_	_	O
16	on	_	_	O
17	health	_	_	O
18	-	_	_	O
19	related	_	_	O
20	quality	_	_	O
21	of	_	_	O
22	life	_	_	O
23	(	_	_	O
24	HRQL	_	_	O
25	)	_	_	O
26	of	_	_	O
27	prostate	_	_	O
28	cancer	_	_	O
29	patients	_	_	O
30	.	_	_	O

31	The	_	_	O
32	Southwest	_	_	O
33	Oncology	_	_	O
34	Group	_	_	O
35	(	_	_	O
36	SWOG	_	_	O
37	)	_	_	O
38	intergroup	_	_	O
39	trial	_	_	O
40	compared	_	_	O
41	radical	_	_	O
42	prostatectomy	_	_	O
43	(	_	_	O
44	RP	_	_	O
45	)	_	_	O
46	plus	_	_	O
47	observation	_	_	O
48	versus	_	_	O
49	RP	_	_	O
50	plus	_	_	O
51	adjuvant	_	_	O
52	radiation	_	_	O
53	therapy	_	_	O
54	(	_	_	O
55	RT	_	_	O
56	)	_	_	O
57	.	_	_	O

58	Two	_	_	O
59	-	_	_	O
60	hundred	_	_	O
61	seventeen	_	_	O
62	of	_	_	O
63	425	_	_	O
64	therapeutic	_	_	O
65	trial	_	_	O
66	patients	_	_	O
67	were	_	_	O
68	eligible	_	_	O
69	and	_	_	O
70	registered	_	_	O
71	to	_	_	O
72	the	_	_	O
73	HRQL	_	_	O
74	study	_	_	O
75	.	_	_	O

76	Patients	_	_	O
77	completed	_	_	O
78	the	_	_	O
79	SWOG	_	_	O
80	Quality	_	_	O
81	of	_	_	O
82	Life	_	_	O
83	Questionnaire	_	_	O
84	(	_	_	O
85	emotional	_	_	O
86	,	_	_	O
87	physical	_	_	O
88	,	_	_	O
89	social	_	_	O
90	,	_	_	O
91	and	_	_	O
92	role	_	_	O
93	function	_	_	O
94	;	_	_	O
95	general	_	_	O
96	symptom	_	_	O
97	status	_	_	O
98	;	_	_	O
99	treatment	_	_	O
100	/	_	_	O
101	disease	_	_	O
102	-	_	_	O
103	specific	_	_	O
104	symptoms	_	_	O
105	;	_	_	O
106	and	_	_	O
107	global	_	_	O
108	HRQL	_	_	O
109	[	_	_	O
110	GHRQL	_	_	O
111	]	_	_	O
112	)	_	_	O
113	at	_	_	O
114	baseline	_	_	O
115	,	_	_	O
116	6	_	_	O
117	weeks	_	_	O
118	,	_	_	O
119	6	_	_	O
120	months	_	_	O
121	,	_	_	O
122	and	_	_	O
123	annually	_	_	O
124	for	_	_	O
125	5	_	_	O
126	years	_	_	O
127	.	_	_	O

128	Prespecified	_	_	O
129	outcomes	_	_	O
130	were	_	_	O
131	three	_	_	O
132	genitourinary	_	_	O
133	symptoms	_	_	O
134	(	_	_	O
135	bowel	_	_	O
136	function	_	_	O
137	tenderness	_	_	O
138	,	_	_	O
139	frequent	_	_	O
140	urination	_	_	O
141	,	_	_	O
142	and	_	_	O
143	erectile	_	_	O
144	dysfunction	_	_	O
145	[	_	_	O
146	ED	_	_	O
147	]	_	_	O
148	)	_	_	O
149	and	_	_	O
150	measures	_	_	O
151	of	_	_	O
152	physical	_	_	O
153	and	_	_	O
154	emotional	_	_	O
155	function	_	_	O
156	.	_	_	O

157	Adjustments	_	_	O
158	were	_	_	O
159	made	_	_	O
160	for	_	_	O
161	the	_	_	O
162	baseline	_	_	O
163	score	_	_	O
164	.	_	_	O

165	Patients	_	_	O
166	receiving	_	_	O
167	adjuvant	_	_	O
168	RT	_	_	O
169	reported	_	_	O
170	worse	_	_	O
171	bowel	_	_	O
172	function	_	_	O
173	(	_	_	O
174	through	_	_	O
175	approximately	_	_	O
176	2	_	_	O
177	years	_	_	O
178	)	_	_	O
179	and	_	_	O
180	worse	_	_	O
181	urinary	_	_	O
182	function	_	_	O
183	.	_	_	O

184	There	_	_	O
185	were	_	_	O
186	no	_	_	O
187	statistically	_	_	O
188	significant	_	_	O
189	differences	_	_	O
190	for	_	_	O
191	ED	_	_	O
192	.	_	_	O

193	GHRQL	_	_	B-Premise
194	was	_	_	I-Premise
195	initially	_	_	I-Premise
196	worse	_	_	I-Premise
197	for	_	_	I-Premise
198	the	_	_	I-Premise
199	RP	_	_	I-Premise
200	+	_	_	I-Premise
201	RT	_	_	I-Premise
202	arm	_	_	I-Premise
203	but	_	_	I-Premise
204	improved	_	_	I-Premise
205	over	_	_	I-Premise
206	time	_	_	I-Premise
207	and	_	_	I-Premise
208	was	_	_	I-Premise
209	better	_	_	I-Premise
210	at	_	_	I-Premise
211	the	_	_	I-Premise
212	end	_	_	I-Premise
213	of	_	_	I-Premise
214	the	_	_	I-Premise
215	period	_	_	I-Premise
216	than	_	_	I-Premise
217	the	_	_	I-Premise
218	GHRQL	_	_	I-Premise
219	reported	_	_	I-Premise
220	for	_	_	I-Premise
221	RP	_	_	I-Premise
222	alone	_	_	I-Premise
223	(	_	_	I-Premise
224	treatment	_	_	I-Premise
225	arm	_	_	I-Premise
226	x	_	_	I-Premise
227	time	_	_	I-Premise
228	interaction	_	_	I-Premise
229	,	_	_	I-Premise
230	P	_	_	I-Premise
231	=	_	_	I-Premise
232	.	_	_	I-Premise

233	0004	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	Symptom	_	_	B-Premise
237	distress	_	_	I-Premise
238	was	_	_	I-Premise
239	significantly	_	_	I-Premise
240	worse	_	_	I-Premise
241	for	_	_	I-Premise
242	the	_	_	I-Premise
243	RP	_	_	I-Premise
244	+	_	_	I-Premise
245	RT	_	_	I-Premise
246	arm	_	_	I-Premise
247	compared	_	_	I-Premise
248	with	_	_	I-Premise
249	the	_	_	I-Premise
250	RP	_	_	I-Premise
251	alone	_	_	I-Premise
252	arm	_	_	I-Premise
253	,	_	_	O
254	but	_	_	B-Premise
255	the	_	_	I-Premise
256	treatment	_	_	I-Premise
257	arms	_	_	I-Premise
258	did	_	_	I-Premise
259	not	_	_	I-Premise
260	differ	_	_	I-Premise
261	with	_	_	I-Premise
262	respect	_	_	I-Premise
263	to	_	_	I-Premise
264	other	_	_	I-Premise
265	general	_	_	I-Premise
266	measures	_	_	I-Premise
267	of	_	_	I-Premise
268	HRQL	_	_	I-Premise
269	.	_	_	I-Premise

270	The	_	_	B-Premise
271	addition	_	_	I-Premise
272	of	_	_	I-Premise
273	RT	_	_	I-Premise
274	to	_	_	I-Premise
275	surgery	_	_	I-Premise
276	resulted	_	_	I-Premise
277	in	_	_	I-Premise
278	more	_	_	I-Premise
279	frequent	_	_	I-Premise
280	urination	_	_	I-Premise
281	,	_	_	I-Premise
282	as	_	_	I-Premise
283	well	_	_	I-Premise
284	as	_	_	I-Premise
285	early	_	_	I-Premise
286	report	_	_	I-Premise
287	of	_	_	I-Premise
288	more	_	_	I-Premise
289	bowel	_	_	I-Premise
290	dysfunction	_	_	I-Premise
291	,	_	_	O
292	although	_	_	B-Premise
293	bowel	_	_	I-Premise
294	function	_	_	I-Premise
295	differences	_	_	I-Premise
296	disappeared	_	_	I-Premise
297	over	_	_	I-Premise
298	the	_	_	I-Premise
299	5	_	_	I-Premise
300	-	_	_	I-Premise
301	year	_	_	I-Premise
302	period	_	_	I-Premise
303	.	_	_	I-Premise

304	The	_	_	B-Claim
305	addition	_	_	I-Claim
306	of	_	_	I-Claim
307	RT	_	_	I-Claim
308	did	_	_	I-Claim
309	not	_	_	I-Claim
310	negatively	_	_	I-Claim
311	impact	_	_	I-Claim
312	ED	_	_	I-Claim
313	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	was	_	_	O
3	designed	_	_	O
4	to	_	_	O
5	evaluate	_	_	O
6	efficacy	_	_	O
7	,	_	_	O
8	toxicity	_	_	O
9	,	_	_	O
10	and	_	_	O
11	adverse	_	_	O
12	effects	_	_	O
13	of	_	_	O
14	combination	_	_	O
15	of	_	_	O
16	chemotherapy	_	_	O
17	drugs	_	_	O
18	and	_	_	O
19	intraperitoneal	_	_	O
20	perfusion	_	_	O
21	of	_	_	O
22	verapamil	_	_	O
23	in	_	_	O
24	the	_	_	O
25	treatment	_	_	O
26	of	_	_	O
27	malignant	_	_	O
28	ascites	_	_	O
29	.	_	_	O

30	Seventy	_	_	O
31	-	_	_	O
32	two	_	_	O
33	patients	_	_	O
34	with	_	_	O
35	malignant	_	_	O
36	ascites	_	_	O
37	were	_	_	O
38	divided	_	_	O
39	into	_	_	O
40	two	_	_	O
41	study	_	_	O
42	groups	_	_	O
43	.	_	_	O

44	Patients	_	_	O
45	in	_	_	O
46	control	_	_	O
47	group	_	_	O
48	(	_	_	O
49	31	_	_	O
50	cases	_	_	O
51	)	_	_	O
52	received	_	_	O
53	conventional	_	_	O
54	chemotherapy	_	_	O
55	,	_	_	O
56	whereas	_	_	O
57	patients	_	_	O
58	in	_	_	O
59	the	_	_	O
60	combined	_	_	O
61	treatment	_	_	O
62	group	_	_	O
63	(	_	_	O
64	41	_	_	O
65	cases	_	_	O
66	)	_	_	O
67	were	_	_	O
68	given	_	_	O
69	verapamil	_	_	O
70	intraperitoneally	_	_	O
71	in	_	_	O
72	addition	_	_	O
73	to	_	_	O
74	chemotherapy	_	_	O
75	drugs	_	_	O
76	.	_	_	O

77	Thirty	_	_	O
78	days	_	_	O
79	after	_	_	O
80	the	_	_	O
81	treatment	_	_	O
82	,	_	_	O
83	efficacy	_	_	O
84	,	_	_	O
85	toxicity	_	_	O
86	,	_	_	O
87	and	_	_	O
88	adverse	_	_	O
89	effects	_	_	O
90	were	_	_	O
91	assessed	_	_	O
92	in	_	_	O
93	both	_	_	O
94	study	_	_	O
95	groups	_	_	O
96	.	_	_	O

97	The	_	_	B-Premise
98	treatment	_	_	I-Premise
99	of	_	_	I-Premise
100	control	_	_	I-Premise
101	group	_	_	I-Premise
102	led	_	_	I-Premise
103	to	_	_	I-Premise
104	1	_	_	I-Premise
105	case	_	_	I-Premise
106	of	_	_	I-Premise
107	complete	_	_	I-Premise
108	remission	_	_	I-Premise
109	and	_	_	I-Premise
110	2	_	_	I-Premise
111	cases	_	_	I-Premise
112	of	_	_	I-Premise
113	partial	_	_	I-Premise
114	remission	_	_	I-Premise
115	,	_	_	I-Premise
116	making	_	_	I-Premise
117	the	_	_	I-Premise
118	rate	_	_	I-Premise
119	of	_	_	I-Premise
120	efficacy	_	_	I-Premise
121	(	_	_	I-Premise
122	complete	_	_	I-Premise
123	+	_	_	I-Premise
124	partial	_	_	I-Premise
125	remission	_	_	I-Premise
126	)	_	_	I-Premise
127	of	_	_	I-Premise
128	9	_	_	I-Premise
129	.	_	_	I-Premise

130	7	_	_	I-Premise
131	%	_	_	I-Premise
132	.	_	_	I-Premise

133	The	_	_	B-Premise
134	combined	_	_	I-Premise
135	treatment	_	_	I-Premise
136	group	_	_	I-Premise
137	demonstrated	_	_	I-Premise
138	13	_	_	I-Premise
139	cases	_	_	I-Premise
140	of	_	_	I-Premise
141	complete	_	_	I-Premise
142	remission	_	_	I-Premise
143	and	_	_	I-Premise
144	22	_	_	I-Premise
145	cases	_	_	I-Premise
146	of	_	_	I-Premise
147	partial	_	_	I-Premise
148	remission	_	_	I-Premise
149	.	_	_	I-Premise

150	Thus	_	_	O
151	,	_	_	O
152	the	_	_	B-Premise
153	rate	_	_	I-Premise
154	of	_	_	I-Premise
155	efficacy	_	_	I-Premise
156	was	_	_	I-Premise
157	significantly	_	_	I-Premise
158	higher	_	_	I-Premise
159	in	_	_	I-Premise
160	the	_	_	I-Premise
161	combined	_	_	I-Premise
162	treatment	_	_	I-Premise
163	group	_	_	I-Premise
164	(	_	_	I-Premise
165	85	_	_	I-Premise
166	.	_	_	I-Premise

167	36	_	_	I-Premise
168	%	_	_	I-Premise
169	;	_	_	I-Premise
170	p	_	_	I-Premise
171	<	_	_	I-Premise
172	0	_	_	I-Premise
173	.	_	_	I-Premise

174	05	_	_	I-Premise
175	vs	_	_	I-Premise
176	.	_	_	I-Premise

177	control	_	_	I-Premise
178	group	_	_	I-Premise
179	)	_	_	I-Premise
180	.	_	_	I-Premise

181	Using	_	_	O
182	KPS	_	_	O
183	scores	_	_	O
184	,	_	_	O
185	changes	_	_	O
186	in	_	_	O
187	quality	_	_	O
188	of	_	_	O
189	life	_	_	O
190	were	_	_	O
191	compared	_	_	O
192	before	_	_	O
193	and	_	_	O
194	after	_	_	O
195	the	_	_	O
196	treatment	_	_	O
197	.	_	_	O

198	The	_	_	B-Premise
199	quality	_	_	I-Premise
200	of	_	_	I-Premise
201	life	_	_	I-Premise
202	improved	_	_	I-Premise
203	in	_	_	I-Premise
204	control	_	_	I-Premise
205	group	_	_	I-Premise
206	by	_	_	I-Premise
207	13	_	_	I-Premise
208	.	_	_	I-Premise

209	7	_	_	I-Premise
210	%	_	_	I-Premise
211	,	_	_	I-Premise
212	while	_	_	I-Premise
213	combined	_	_	I-Premise
214	treatment	_	_	I-Premise
215	group	_	_	I-Premise
216	showed	_	_	I-Premise
217	improvement	_	_	I-Premise
218	of	_	_	I-Premise
219	83	_	_	I-Premise
220	.	_	_	I-Premise

221	5	_	_	I-Premise
222	%	_	_	I-Premise
223	(	_	_	I-Premise
224	p	_	_	I-Premise
225	<	_	_	I-Premise
226	0	_	_	I-Premise
227	.	_	_	I-Premise

228	05	_	_	I-Premise
229	vs	_	_	I-Premise
230	.	_	_	I-Premise

231	control	_	_	I-Premise
232	group	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	Further	_	_	O
236	,	_	_	O
237	cumulative	_	_	B-Premise
238	survival	_	_	I-Premise
239	rate	_	_	I-Premise
240	was	_	_	I-Premise
241	also	_	_	I-Premise
242	significantly	_	_	I-Premise
243	higher	_	_	I-Premise
244	in	_	_	I-Premise
245	the	_	_	I-Premise
246	combined	_	_	I-Premise
247	treatment	_	_	I-Premise
248	group	_	_	I-Premise
249	.	_	_	I-Premise

250	Treatment	_	_	B-Premise
251	toxicity	_	_	I-Premise
252	and	_	_	I-Premise
253	the	_	_	I-Premise
254	rate	_	_	I-Premise
255	of	_	_	I-Premise
256	adverse	_	_	I-Premise
257	effects	_	_	I-Premise
258	and	_	_	I-Premise
259	intestinal	_	_	I-Premise
260	adhesion	_	_	I-Premise
261	were	_	_	I-Premise
262	not	_	_	I-Premise
263	significantly	_	_	I-Premise
264	different	_	_	I-Premise
265	between	_	_	I-Premise
266	study	_	_	I-Premise
267	groups	_	_	I-Premise
268	.	_	_	I-Premise

269	Intraperitoneal	_	_	B-Claim
270	perfusion	_	_	I-Claim
271	of	_	_	I-Claim
272	verapamil	_	_	I-Claim
273	enhances	_	_	I-Claim
274	the	_	_	I-Claim
275	efficacy	_	_	I-Claim
276	of	_	_	I-Claim
277	chemotherapy	_	_	I-Claim
278	drugs	_	_	I-Claim
279	,	_	_	I-Claim
280	prolongs	_	_	I-Claim
281	survival	_	_	I-Claim
282	,	_	_	I-Claim
283	and	_	_	I-Claim
284	improves	_	_	I-Claim
285	the	_	_	I-Claim
286	quality	_	_	I-Claim
287	of	_	_	I-Claim
288	life	_	_	I-Claim
289	.	_	_	I-Claim

290	Intraperitoneal	_	_	B-Claim
291	administration	_	_	I-Claim
292	limits	_	_	I-Claim
293	cardiotoxicity	_	_	I-Claim
294	of	_	_	I-Claim
295	verapamil	_	_	I-Claim
296	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	investigate	_	_	O
8	whether	_	_	O
9	specialized	_	_	O
10	supportive	_	_	O
11	enteral	_	_	O
12	and	_	_	O
13	parenteral	_	_	O
14	feeding	_	_	O
15	have	_	_	O
16	superior	_	_	O
17	effects	_	_	O
18	compared	_	_	O
19	to	_	_	O
20	oral	_	_	O
21	nutrition	_	_	O
22	on	_	_	O
23	recovery	_	_	O
24	during	_	_	O
25	long	_	_	O
26	-	_	_	O
27	term	_	_	O
28	postoperative	_	_	O
29	treatment	_	_	O
30	of	_	_	O
31	cancer	_	_	O
32	patients	_	_	O
33	with	_	_	O
34	preoperative	_	_	O
35	weight	_	_	O
36	loss	_	_	O
37	and	_	_	O
38	reduced	_	_	O
39	maximum	_	_	O
40	exercise	_	_	O
41	capacity	_	_	O
42	.	_	_	O

43	One	_	_	O
44	hundred	_	_	O
45	twenty	_	_	O
46	-	_	_	O
47	six	_	_	O
48	patients	_	_	O
49	referred	_	_	O
50	for	_	_	O
51	resection	_	_	O
52	of	_	_	O
53	the	_	_	O
54	esophagus	_	_	O
55	(	_	_	O
56	n	_	_	O
57	=	_	_	O
58	48	_	_	O
59	)	_	_	O
60	,	_	_	O
61	stomach	_	_	O
62	(	_	_	O
63	n	_	_	O
64	=	_	_	O
65	28	_	_	O
66	)	_	_	O
67	,	_	_	O
68	or	_	_	O
69	pancreas	_	_	O
70	(	_	_	O
71	n	_	_	O
72	=	_	_	O
73	50	_	_	O
74	)	_	_	O
75	were	_	_	O
76	considered	_	_	O
77	to	_	_	O
78	be	_	_	O
79	included	_	_	O
80	before	_	_	O
81	operation	_	_	O
82	.	_	_	O

83	Included	_	_	O
84	patients	_	_	O
85	(	_	_	O
86	n	_	_	O
87	=	_	_	O
88	80	_	_	O
89	)	_	_	O
90	received	_	_	O
91	supportive	_	_	O
92	enteral	_	_	O
93	or	_	_	O
94	parenteral	_	_	O
95	nutrition	_	_	O
96	postoperatively	_	_	O
97	at	_	_	O
98	home	_	_	O
99	corresponding	_	_	O
100	to	_	_	O
101	1000	_	_	O
102	kcal	_	_	O
103	/	_	_	O
104	d	_	_	O
105	until	_	_	O
106	the	_	_	O
107	patients	_	_	O
108	did	_	_	O
109	not	_	_	O
110	wish	_	_	O
111	to	_	_	O
112	continue	_	_	O
113	with	_	_	O
114	artificial	_	_	O
115	nutrition	_	_	O
116	for	_	_	O
117	any	_	_	O
118	reason	_	_	O
119	.	_	_	O

120	Patients	_	_	O
121	randomized	_	_	O
122	to	_	_	O
123	oral	_	_	O
124	nutrition	_	_	O
125	only	_	_	O
126	served	_	_	O
127	as	_	_	O
128	control	_	_	O
129	subjects	_	_	O
130	.	_	_	O

131	Caloric	_	_	O
132	intake	_	_	O
133	,	_	_	O
134	body	_	_	O
135	composition	_	_	O
136	(	_	_	O
137	dual	_	_	O
138	-	_	_	O
139	energy	_	_	O
140	x	_	_	O
141	-	_	_	O
142	ray	_	_	O
143	absorptiometry	_	_	O
144	)	_	_	O
145	,	_	_	O
146	and	_	_	O
147	respiratory	_	_	O
148	gas	_	_	O
149	exchanges	_	_	O
150	at	_	_	O
151	rest	_	_	O
152	and	_	_	O
153	during	_	_	O
154	exercise	_	_	O
155	were	_	_	O
156	measured	_	_	O
157	including	_	_	O
158	health	_	_	O
159	-	_	_	O
160	related	_	_	O
161	quality	_	_	O
162	of	_	_	O
163	life	_	_	O
164	.	_	_	O

165	Survival	_	_	B-Premise
166	and	_	_	I-Premise
167	hospital	_	_	I-Premise
168	stay	_	_	I-Premise
169	did	_	_	I-Premise
170	not	_	_	I-Premise
171	differ	_	_	I-Premise
172	among	_	_	I-Premise
173	the	_	_	I-Premise
174	groups	_	_	I-Premise
175	,	_	_	I-Premise
176	whereas	_	_	I-Premise
177	overall	_	_	I-Premise
178	complications	_	_	I-Premise
179	were	_	_	I-Premise
180	higher	_	_	I-Premise
181	on	_	_	I-Premise
182	artificial	_	_	I-Premise
183	nutrition	_	_	I-Premise
184	(	_	_	I-Premise
185	P	_	_	I-Premise
186	<	_	_	I-Premise
187	.	_	_	I-Premise

188	05	_	_	I-Premise
189	)	_	_	I-Premise
190	.	_	_	I-Premise

191	Changes	_	_	B-Premise
192	in	_	_	I-Premise
193	resting	_	_	I-Premise
194	energy	_	_	I-Premise
195	expenditure	_	_	I-Premise
196	and	_	_	I-Premise
197	biochemical	_	_	I-Premise
198	tests	_	_	I-Premise
199	did	_	_	I-Premise
200	not	_	_	I-Premise
201	differ	_	_	I-Premise
202	during	_	_	I-Premise
203	follow	_	_	I-Premise
204	-	_	_	I-Premise
205	up	_	_	I-Premise
206	among	_	_	I-Premise
207	the	_	_	I-Premise
208	groups	_	_	I-Premise
209	.	_	_	I-Premise

210	Body	_	_	B-Premise
211	weight	_	_	I-Premise
212	and	_	_	I-Premise
213	whole	_	_	I-Premise
214	body	_	_	I-Premise
215	fat	_	_	I-Premise
216	declined	_	_	I-Premise
217	similarly	_	_	I-Premise
218	over	_	_	I-Premise
219	time	_	_	I-Premise
220	in	_	_	I-Premise
221	all	_	_	I-Premise
222	groups	_	_	I-Premise
223	(	_	_	I-Premise
224	P	_	_	I-Premise
225	<	_	_	I-Premise
226	.	_	_	I-Premise

227	005	_	_	I-Premise
228	)	_	_	I-Premise
229	,	_	_	I-Premise
230	whereas	_	_	O
231	lean	_	_	B-Premise
232	body	_	_	I-Premise
233	mass	_	_	I-Premise
234	was	_	_	I-Premise
235	unchanged	_	_	I-Premise
236	during	_	_	I-Premise
237	follow	_	_	I-Premise
238	-	_	_	I-Premise
239	up	_	_	I-Premise
240	compared	_	_	I-Premise
241	to	_	_	I-Premise
242	preoperative	_	_	I-Premise
243	values	_	_	I-Premise
244	.	_	_	I-Premise

245	Maximum	_	_	B-Premise
246	exercise	_	_	I-Premise
247	capacity	_	_	I-Premise
248	and	_	_	I-Premise
249	maximum	_	_	I-Premise
250	oxygen	_	_	I-Premise
251	consumption	_	_	I-Premise
252	were	_	_	I-Premise
253	normalized	_	_	I-Premise
254	within	_	_	I-Premise
255	6	_	_	I-Premise
256	months	_	_	I-Premise
257	postoperatively	_	_	I-Premise
258	in	_	_	I-Premise
259	all	_	_	I-Premise
260	groups	_	_	I-Premise
261	.	_	_	I-Premise

262	There	_	_	B-Premise
263	was	_	_	I-Premise
264	no	_	_	I-Premise
265	difference	_	_	I-Premise
266	in	_	_	I-Premise
267	recovery	_	_	I-Premise
268	of	_	_	I-Premise
269	food	_	_	I-Premise
270	intake	_	_	I-Premise
271	among	_	_	I-Premise
272	the	_	_	I-Premise
273	groups	_	_	I-Premise
274	.	_	_	I-Premise

275	Parenteral	_	_	B-Claim
276	feeding	_	_	I-Claim
277	was	_	_	I-Claim
278	associated	_	_	I-Claim
279	with	_	_	I-Claim
280	the	_	_	I-Claim
281	highest	_	_	I-Claim
282	rate	_	_	I-Claim
283	of	_	_	I-Claim
284	nutrition	_	_	I-Claim
285	-	_	_	I-Claim
286	related	_	_	I-Claim
287	complications	_	_	I-Claim
288	,	_	_	I-Claim
289	whereas	_	_	O
290	enteral	_	_	B-Claim
291	feeding	_	_	I-Claim
292	reduced	_	_	I-Claim
293	quality	_	_	I-Claim
294	of	_	_	I-Claim
295	life	_	_	I-Claim
296	most	_	_	I-Claim
297	extensively	_	_	I-Claim
298	.	_	_	I-Claim

299	After	_	_	B-Claim
300	major	_	_	I-Claim
301	surgery	_	_	I-Claim
302	,	_	_	I-Claim
303	specialized	_	_	I-Claim
304	supportive	_	_	I-Claim
305	enteral	_	_	I-Claim
306	and	_	_	I-Claim
307	parenteral	_	_	I-Claim
308	nutrition	_	_	I-Claim
309	are	_	_	I-Claim
310	not	_	_	I-Claim
311	superior	_	_	I-Claim
312	to	_	_	I-Claim
313	oral	_	_	I-Claim
314	nutrition	_	_	I-Claim
315	only	_	_	I-Claim
316	when	_	_	I-Claim
317	guided	_	_	I-Claim
318	by	_	_	I-Claim
319	a	_	_	I-Claim
320	dietitian	_	_	I-Claim
321	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	outcome	_	_	O
4	of	_	_	O
5	treatment	_	_	O
6	of	_	_	O
7	mediastinoscopy	_	_	O
8	-	_	_	O
9	verified	_	_	O
10	N2	_	_	O
11	non	_	_	O
12	-	_	_	O
13	small	_	_	O
14	-	_	_	O
15	cell	_	_	O
16	lung	_	_	O
17	cancer	_	_	O
18	treated	_	_	O
19	with	_	_	O
20	induction	_	_	O
21	chemotherapy	_	_	O
22	followed	_	_	O
23	by	_	_	O
24	either	_	_	O
25	surgery	_	_	O
26	or	_	_	O
27	radiotherapy	_	_	O
28	(	_	_	O
29	RT	_	_	O
30	)	_	_	O
31	,	_	_	O
32	with	_	_	O
33	both	_	_	O
34	options	_	_	O
35	followed	_	_	O
36	by	_	_	O
37	consolidation	_	_	O
38	chemotherapy	_	_	O
39	.	_	_	O

40	A	_	_	O
41	randomized	_	_	O
42	Phase	_	_	O
43	III	_	_	O
44	trial	_	_	O
45	for	_	_	O
46	Stage	_	_	O
47	IIIA	_	_	O
48	(	_	_	O
49	T1	_	_	O
50	-	_	_	O
51	T3N2M0	_	_	O
52	)	_	_	O
53	non	_	_	O
54	-	_	_	O
55	small	_	_	O
56	cell	_	_	O
57	lung	_	_	O
58	cancer	_	_	O
59	was	_	_	O
60	conducted	_	_	O
61	by	_	_	O
62	the	_	_	O
63	Radiation	_	_	O
64	Therapy	_	_	O
65	Oncology	_	_	O
66	Group	_	_	O
67	(	_	_	O
68	RTOG	_	_	O
69	)	_	_	O
70	and	_	_	O
71	Eastern	_	_	O
72	Cooperative	_	_	O
73	Oncology	_	_	O
74	Group	_	_	O
75	between	_	_	O
76	April	_	_	O
77	1990	_	_	O
78	and	_	_	O
79	April	_	_	O
80	1994	_	_	O
81	.	_	_	O

82	After	_	_	O
83	documentation	_	_	O
84	of	_	_	O
85	N2	_	_	O
86	disease	_	_	O
87	by	_	_	O
88	mediastinoscopy	_	_	O
89	or	_	_	O
90	anterior	_	_	O
91	mediastinotomy	_	_	O
92	,	_	_	O
93	patients	_	_	O
94	received	_	_	O
95	induction	_	_	O
96	chemotherapy	_	_	O
97	with	_	_	O
98	cisplatin	_	_	O
99	,	_	_	O
100	vinblastine	_	_	O
101	,	_	_	O
102	and	_	_	O
103	mitomycin	_	_	O
104	-	_	_	O
105	C	_	_	O
106	.	_	_	O

107	Mitomycin	_	_	O
108	-	_	_	O
109	C	_	_	O
110	was	_	_	O
111	later	_	_	O
112	dropped	_	_	O
113	from	_	_	O
114	the	_	_	O
115	induction	_	_	O
116	regimen	_	_	O
117	.	_	_	O

118	Patients	_	_	O
119	were	_	_	O
120	then	_	_	O
121	randomized	_	_	O
122	to	_	_	O
123	surgery	_	_	O
124	or	_	_	O
125	RT	_	_	O
126	(	_	_	O
127	64	_	_	O
128	Gy	_	_	O
129	in	_	_	O
130	7	_	_	O
131	weeks	_	_	O
132	)	_	_	O
133	followed	_	_	O
134	by	_	_	O
135	cisplatin	_	_	O
136	and	_	_	O
137	vinblastine	_	_	O
138	.	_	_	O

139	RTOG	_	_	O
140	89	_	_	O
141	-	_	_	O
142	01	_	_	O
143	accrued	_	_	O
144	75	_	_	O
145	patients	_	_	O
146	,	_	_	O
147	of	_	_	O
148	whom	_	_	O
149	73	_	_	O
150	were	_	_	O
151	eligible	_	_	O
152	and	_	_	O
153	analyzable	_	_	O
154	.	_	_	O

155	Twelve	_	_	O
156	patients	_	_	O
157	received	_	_	O
158	induction	_	_	O
159	chemotherapy	_	_	O
160	but	_	_	O
161	were	_	_	O
162	not	_	_	O
163	randomized	_	_	O
164	to	_	_	O
165	RT	_	_	O
166	or	_	_	O
167	surgery	_	_	O
168	thereafter	_	_	O
169	.	_	_	O

170	Forty	_	_	O
171	-	_	_	O
172	five	_	_	O
173	patients	_	_	O
174	were	_	_	O
175	randomized	_	_	O
176	to	_	_	O
177	postinduction	_	_	O
178	RT	_	_	O
179	or	_	_	O
180	surgery	_	_	O
181	.	_	_	O

182	Of	_	_	O
183	the	_	_	O
184	analyzable	_	_	O
185	patients	_	_	O
186	,	_	_	O
187	90	_	_	O
188	%	_	_	O
189	had	_	_	O
190	a	_	_	O
191	Karnofsky	_	_	O
192	performance	_	_	O
193	score	_	_	O
194	of	_	_	O
195	90	_	_	O
196	-	_	_	O
197	100	_	_	O
198	,	_	_	O
199	18	_	_	O
200	%	_	_	O
201	had	_	_	O
202	weight	_	_	O
203	loss	_	_	O
204	>	_	_	O
205	5	_	_	O
206	%	_	_	O
207	,	_	_	O
208	37	_	_	O
209	%	_	_	O
210	had	_	_	O
211	squamous	_	_	O
212	cell	_	_	O
213	histologic	_	_	O
214	features	_	_	O
215	,	_	_	O
216	and	_	_	O
217	54	_	_	O
218	%	_	_	O
219	had	_	_	O
220	bulky	_	_	O
221	N2	_	_	O
222	disease	_	_	O
223	.	_	_	O

224	The	_	_	O
225	distribution	_	_	O
226	of	_	_	O
227	bulky	_	_	O
228	N2	_	_	O
229	disease	_	_	O
230	was	_	_	O
231	uniform	_	_	O
232	among	_	_	O
233	the	_	_	O
234	treatment	_	_	O
235	arms	_	_	O
236	.	_	_	O

237	The	_	_	B-Premise
238	incidence	_	_	I-Premise
239	of	_	_	I-Premise
240	Grade	_	_	I-Premise
241	4	_	_	I-Premise
242	toxicity	_	_	I-Premise
243	was	_	_	I-Premise
244	56	_	_	I-Premise
245	%	_	_	I-Premise
246	in	_	_	I-Premise
247	patients	_	_	I-Premise
248	receiving	_	_	I-Premise
249	mitomycin	_	_	I-Premise
250	-	_	_	I-Premise
251	C	_	_	I-Premise
252	and	_	_	I-Premise
253	29	_	_	I-Premise
254	%	_	_	I-Premise
255	in	_	_	I-Premise
256	those	_	_	I-Premise
257	who	_	_	I-Premise
258	did	_	_	I-Premise
259	not	_	_	I-Premise
260	.	_	_	I-Premise

261	Only	_	_	B-Premise
262	1	_	_	I-Premise
263	patient	_	_	I-Premise
264	in	_	_	I-Premise
265	each	_	_	I-Premise
266	group	_	_	I-Premise
267	had	_	_	I-Premise
268	acute	_	_	I-Premise
269	nonhematologic	_	_	I-Premise
270	toxicity	_	_	I-Premise
271	greater	_	_	I-Premise
272	than	_	_	I-Premise
273	Grade	_	_	I-Premise
274	3	_	_	I-Premise
275	(	_	_	I-Premise
276	nausea	_	_	I-Premise
277	and	_	_	I-Premise
278	vomiting	_	_	I-Premise
279	)	_	_	I-Premise
280	.	_	_	I-Premise

281	No	_	_	B-Premise
282	acute	_	_	I-Premise
283	Grade	_	_	I-Premise
284	4	_	_	I-Premise
285	radiation	_	_	I-Premise
286	toxicity	_	_	I-Premise
287	developed	_	_	I-Premise
288	.	_	_	I-Premise

289	The	_	_	B-Premise
290	incidences	_	_	I-Premise
291	of	_	_	I-Premise
292	long	_	_	I-Premise
293	-	_	_	I-Premise
294	term	_	_	I-Premise
295	toxicity	_	_	I-Premise
296	were	_	_	I-Premise
297	equivalent	_	_	I-Premise
298	across	_	_	I-Premise
299	the	_	_	I-Premise
300	arms	_	_	I-Premise
301	.	_	_	I-Premise

302	Three	_	_	B-Premise
303	treatment	_	_	I-Premise
304	-	_	_	I-Premise
305	related	_	_	I-Premise
306	deaths	_	_	I-Premise
307	occurred	_	_	I-Premise
308	:	_	_	I-Premise
309	2	_	_	I-Premise
310	patients	_	_	I-Premise
311	in	_	_	I-Premise
312	the	_	_	I-Premise
313	surgical	_	_	I-Premise
314	arms	_	_	I-Premise
315	(	_	_	I-Premise
316	one	_	_	I-Premise
317	late	_	_	I-Premise
318	pulmonary	_	_	I-Premise
319	toxicity	_	_	I-Premise
320	and	_	_	I-Premise
321	one	_	_	I-Premise
322	pulmonary	_	_	I-Premise
323	embolus	_	_	I-Premise
324	)	_	_	I-Premise
325	,	_	_	I-Premise
326	and	_	_	I-Premise
327	1	_	_	I-Premise
328	patient	_	_	I-Premise
329	in	_	_	I-Premise
330	the	_	_	I-Premise
331	radiation	_	_	I-Premise
332	arm	_	_	I-Premise
333	(	_	_	I-Premise
334	radiation	_	_	I-Premise
335	pneumonitis	_	_	I-Premise
336	)	_	_	I-Premise
337	.	_	_	I-Premise

338	Induction	_	_	B-Premise
339	chemotherapy	_	_	I-Premise
340	was	_	_	I-Premise
341	completed	_	_	I-Premise
342	in	_	_	I-Premise
343	78	_	_	I-Premise
344	%	_	_	I-Premise
345	of	_	_	I-Premise
346	the	_	_	I-Premise
347	patients	_	_	I-Premise
348	.	_	_	I-Premise

349	Complete	_	_	B-Premise
350	resection	_	_	I-Premise
351	was	_	_	I-Premise
352	performed	_	_	I-Premise
353	in	_	_	I-Premise
354	73	_	_	I-Premise
355	%	_	_	I-Premise
356	of	_	_	I-Premise
357	26	_	_	I-Premise
358	patients	_	_	I-Premise
359	undergoing	_	_	I-Premise
360	thoracotomy	_	_	I-Premise
361	.	_	_	I-Premise

362	Consolidation	_	_	B-Premise
363	chemotherapy	_	_	I-Premise
364	was	_	_	I-Premise
365	completed	_	_	I-Premise
366	in	_	_	I-Premise
367	75	_	_	I-Premise
368	%	_	_	I-Premise
369	of	_	_	I-Premise
370	the	_	_	I-Premise
371	patients	_	_	I-Premise
372	.	_	_	I-Premise

373	No	_	_	B-Premise
374	statistically	_	_	I-Premise
375	significant	_	_	I-Premise
376	difference	_	_	I-Premise
377	was	_	_	I-Premise
378	found	_	_	I-Premise
379	among	_	_	I-Premise
380	the	_	_	I-Premise
381	treatment	_	_	I-Premise
382	arms	_	_	I-Premise
383	.	_	_	I-Premise

384	The	_	_	B-Premise
385	overall	_	_	I-Premise
386	progression	_	_	I-Premise
387	-	_	_	I-Premise
388	free	_	_	I-Premise
389	survival	_	_	I-Premise
390	rate	_	_	I-Premise
391	was	_	_	I-Premise
392	53	_	_	I-Premise
393	%	_	_	I-Premise
394	at	_	_	I-Premise
395	1	_	_	I-Premise
396	year	_	_	I-Premise
397	and	_	_	I-Premise
398	17	_	_	I-Premise
399	%	_	_	I-Premise
400	at	_	_	I-Premise
401	3	_	_	I-Premise
402	years	_	_	I-Premise
403	.	_	_	I-Premise

404	The	_	_	B-Premise
405	median	_	_	I-Premise
406	progression	_	_	I-Premise
407	-	_	_	I-Premise
408	free	_	_	I-Premise
409	survival	_	_	I-Premise
410	was	_	_	I-Premise
411	14	_	_	I-Premise
412	months	_	_	I-Premise
413	.	_	_	I-Premise

414	No	_	_	B-Premise
415	difference	_	_	I-Premise
416	in	_	_	I-Premise
417	the	_	_	I-Premise
418	1	_	_	I-Premise
419	-	_	_	I-Premise
420	year	_	_	I-Premise
421	survival	_	_	I-Premise
422	rate	_	_	I-Premise
423	(	_	_	I-Premise
424	70	_	_	I-Premise
425	%	_	_	I-Premise
426	vs	_	_	I-Premise
427	.	_	_	I-Premise

428	66	_	_	I-Premise
429	%	_	_	I-Premise
430	)	_	_	I-Premise
431	or	_	_	I-Premise
432	median	_	_	I-Premise
433	survival	_	_	I-Premise
434	time	_	_	I-Premise
435	(	_	_	I-Premise
436	19	_	_	I-Premise
437	.	_	_	I-Premise

438	4	_	_	I-Premise
439	vs	_	_	I-Premise
440	.	_	_	I-Premise

441	17	_	_	I-Premise
442	.	_	_	I-Premise

443	4	_	_	I-Premise
444	months	_	_	I-Premise
445	)	_	_	I-Premise
446	between	_	_	I-Premise
447	the	_	_	I-Premise
448	surgery	_	_	I-Premise
449	and	_	_	I-Premise
450	RT	_	_	I-Premise
451	arms	_	_	I-Premise
452	.	_	_	I-Premise

453	The	_	_	B-Premise
454	median	_	_	I-Premise
455	survival	_	_	I-Premise
456	in	_	_	I-Premise
457	the	_	_	I-Premise
458	patients	_	_	I-Premise
459	receiving	_	_	I-Premise
460	induction	_	_	I-Premise
461	chemotherapy	_	_	I-Premise
462	only	_	_	I-Premise
463	was	_	_	I-Premise
464	8	_	_	I-Premise
465	.	_	_	I-Premise

466	9	_	_	I-Premise
467	months	_	_	I-Premise
468	.	_	_	I-Premise

469	Mitomycin	_	_	B-Premise
470	-	_	_	I-Premise
471	C	_	_	I-Premise
472	had	_	_	I-Premise
473	no	_	_	I-Premise
474	impact	_	_	I-Premise
475	on	_	_	I-Premise
476	survival	_	_	I-Premise
477	(	_	_	I-Premise
478	p	_	_	I-Premise
479	=	_	_	I-Premise
480	0	_	_	I-Premise
481	.	_	_	I-Premise

482	75	_	_	I-Premise
483	)	_	_	I-Premise
484	.	_	_	I-Premise

485	No	_	_	B-Premise
486	statistically	_	_	I-Premise
487	significant	_	_	I-Premise
488	difference	_	_	I-Premise
489	was	_	_	I-Premise
490	noted	_	_	I-Premise
491	in	_	_	I-Premise
492	the	_	_	I-Premise
493	time	_	_	I-Premise
494	to	_	_	I-Premise
495	local	_	_	I-Premise
496	failure	_	_	I-Premise
497	between	_	_	I-Premise
498	the	_	_	I-Premise
499	surgical	_	_	I-Premise
500	and	_	_	I-Premise
501	RT	_	_	I-Premise
502	arms	_	_	I-Premise
503	.	_	_	I-Premise

504	The	_	_	B-Claim
505	patient	_	_	I-Claim
506	accrual	_	_	I-Claim
507	to	_	_	I-Claim
508	this	_	_	I-Claim
509	trial	_	_	I-Claim
510	made	_	_	I-Claim
511	its	_	_	I-Claim
512	results	_	_	I-Claim
513	inconclusive	_	_	I-Claim
514	,	_	_	I-Claim
515	but	_	_	O
516	several	_	_	O
517	observations	_	_	O
518	are	_	_	O
519	notable	_	_	O
520	.	_	_	O

521	In	_	_	O
522	this	_	_	O
523	trial	_	_	O
524	,	_	_	O
525	histologic	_	_	B-Claim
526	confirmation	_	_	I-Claim
527	of	_	_	I-Claim
528	N2	_	_	I-Claim
529	disease	_	_	I-Claim
530	in	_	_	I-Claim
531	the	_	_	I-Claim
532	surgical	_	_	I-Claim
533	and	_	_	I-Claim
534	nonsurgical	_	_	I-Claim
535	arms	_	_	I-Claim
536	eliminated	_	_	I-Claim
537	the	_	_	I-Claim
538	usual	_	_	I-Claim
539	biases	_	_	I-Claim
540	from	_	_	I-Claim
541	clinical	_	_	I-Claim
542	staging	_	_	I-Claim
543	.	_	_	I-Claim

544	In	_	_	O
545	this	_	_	O
546	setting	_	_	O
547	,	_	_	O
548	local	_	_	B-Claim
549	control	_	_	I-Claim
550	and	_	_	I-Claim
551	survival	_	_	I-Claim
552	were	_	_	I-Claim
553	essentially	_	_	I-Claim
554	equal	_	_	I-Claim
555	between	_	_	I-Claim
556	the	_	_	I-Claim
557	surgical	_	_	I-Claim
558	and	_	_	I-Claim
559	RT	_	_	I-Claim
560	arms	_	_	I-Claim
561	.	_	_	I-Claim

562	The	_	_	B-Claim
563	3	_	_	I-Claim
564	-	_	_	I-Claim
565	and	_	_	I-Claim
566	5	_	_	I-Claim
567	-	_	_	I-Claim
568	year	_	_	I-Claim
569	survival	_	_	I-Claim
570	rates	_	_	I-Claim
571	of	_	_	I-Claim
572	nonsurgical	_	_	I-Claim
573	therapy	_	_	I-Claim
574	were	_	_	I-Claim
575	comparable	_	_	I-Claim
576	to	_	_	I-Claim
577	published	_	_	I-Claim
578	surgical	_	_	I-Claim
579	trials	_	_	I-Claim
580	of	_	_	I-Claim
581	N2	_	_	I-Claim
582	disease	_	_	I-Claim
583	.	_	_	I-Claim


0	During	_	_	B-Premise
1	the	_	_	I-Premise
2	last	_	_	I-Premise
3	decade	_	_	I-Premise
4	,	_	_	I-Premise
5	survival	_	_	I-Premise
6	rates	_	_	I-Premise
7	for	_	_	I-Premise
8	breast	_	_	I-Premise
9	cancer	_	_	I-Premise
10	have	_	_	I-Premise
11	increased	_	_	I-Premise
12	as	_	_	I-Premise
13	a	_	_	I-Premise
14	result	_	_	I-Premise
15	of	_	_	I-Premise
16	earlier	_	_	I-Premise
17	detection	_	_	I-Premise
18	and	_	_	I-Premise
19	increased	_	_	I-Premise
20	use	_	_	I-Premise
21	of	_	_	I-Premise
22	adjuvant	_	_	I-Premise
23	therapy	_	_	I-Premise
24	.	_	_	I-Premise

25	Limited	_	_	O
26	data	_	_	O
27	exist	_	_	O
28	on	_	_	O
29	the	_	_	O
30	psychosocial	_	_	O
31	aspects	_	_	O
32	of	_	_	O
33	the	_	_	O
34	transitional	_	_	O
35	period	_	_	O
36	between	_	_	O
37	the	_	_	O
38	end	_	_	O
39	of	_	_	O
40	primary	_	_	O
41	treatment	_	_	O
42	and	_	_	O
43	survivorship	_	_	O
44	.	_	_	O

45	We	_	_	O
46	investigated	_	_	O
47	the	_	_	O
48	baseline	_	_	O
49	psychosocial	_	_	O
50	status	_	_	O
51	of	_	_	O
52	women	_	_	O
53	enrolled	_	_	O
54	in	_	_	O
55	a	_	_	O
56	randomized	_	_	O
57	trial	_	_	O
58	testing	_	_	O
59	two	_	_	O
60	psychosocial	_	_	O
61	interventions	_	_	O
62	for	_	_	O
63	women	_	_	O
64	at	_	_	O
65	the	_	_	O
66	end	_	_	O
67	of	_	_	O
68	primary	_	_	O
69	treatment	_	_	O
70	.	_	_	O

71	Participants	_	_	O
72	,	_	_	O
73	identified	_	_	O
74	within	_	_	O
75	1	_	_	O
76	month	_	_	O
77	after	_	_	O
78	surgery	_	_	O
79	(	_	_	O
80	registration	_	_	O
81	)	_	_	O
82	,	_	_	O
83	provided	_	_	O
84	demographic	_	_	O
85	information	_	_	O
86	and	_	_	O
87	limited	_	_	O
88	measures	_	_	O
89	of	_	_	O
90	quality	_	_	O
91	of	_	_	O
92	life	_	_	O
93	.	_	_	O

94	They	_	_	O
95	were	_	_	O
96	followed	_	_	O
97	until	_	_	O
98	they	_	_	O
99	finished	_	_	O
100	primary	_	_	O
101	treatment	_	_	O
102	(	_	_	O
103	enrollment	_	_	O
104	)	_	_	O
105	,	_	_	O
106	at	_	_	O
107	which	_	_	O
108	time	_	_	O
109	they	_	_	O
110	completed	_	_	O
111	a	_	_	O
112	mailed	_	_	O
113	baseline	_	_	O
114	survey	_	_	O
115	that	_	_	O
116	included	_	_	O
117	standardized	_	_	O
118	measures	_	_	O
119	of	_	_	O
120	quality	_	_	O
121	of	_	_	O
122	life	_	_	O
123	(	_	_	O
124	including	_	_	O
125	standardized	_	_	O
126	scales	_	_	O
127	of	_	_	O
128	physical	_	_	O
129	and	_	_	O
130	emotional	_	_	O
131	functioning	_	_	O
132	)	_	_	O
133	,	_	_	O
134	mood	_	_	O
135	,	_	_	O
136	symptoms	_	_	O
137	,	_	_	O
138	and	_	_	O
139	sexual	_	_	O
140	functioning	_	_	O
141	.	_	_	O

142	A	_	_	O
143	total	_	_	O
144	of	_	_	O
145	558	_	_	O
146	patients	_	_	O
147	(	_	_	O
148	mean	_	_	O
149	age	_	_	O
150	=	_	_	O
151	56	_	_	O
152	.	_	_	O

153	9	_	_	O
154	years	_	_	O
155	)	_	_	O
156	were	_	_	O
157	enrolled	_	_	O
158	in	_	_	O
159	the	_	_	O
160	study	_	_	O
161	between	_	_	O
162	July	_	_	O
163	1	_	_	O
164	,	_	_	O
165	1999	_	_	O
166	,	_	_	O
167	and	_	_	O
168	June	_	_	O
169	30	_	_	O
170	,	_	_	O
171	2002	_	_	O
172	.	_	_	O

173	Health	_	_	O
174	outcomes	_	_	O
175	were	_	_	O
176	examined	_	_	O
177	according	_	_	O
178	to	_	_	O
179	treatment	_	_	O
180	received	_	_	O
181	:	_	_	O
182	mastectomy	_	_	O
183	with	_	_	O
184	and	_	_	O
185	without	_	_	O
186	chemotherapy	_	_	O
187	,	_	_	O
188	and	_	_	O
189	lumpectomy	_	_	O
190	with	_	_	O
191	and	_	_	O
192	without	_	_	O
193	chemotherapy	_	_	O
194	.	_	_	O

195	All	_	_	O
196	statistical	_	_	O
197	tests	_	_	O
198	were	_	_	O
199	two	_	_	O
200	-	_	_	O
201	sided	_	_	O
202	.	_	_	O

203	Among	_	_	B-Premise
204	all	_	_	I-Premise
205	treatment	_	_	I-Premise
206	groups	_	_	I-Premise
207	,	_	_	I-Premise
208	patients	_	_	I-Premise
209	who	_	_	I-Premise
210	had	_	_	I-Premise
211	a	_	_	I-Premise
212	mastectomy	_	_	I-Premise
213	had	_	_	I-Premise
214	the	_	_	I-Premise
215	poorest	_	_	I-Premise
216	physical	_	_	I-Premise
217	functioning	_	_	I-Premise
218	at	_	_	I-Premise
219	registration	_	_	I-Premise
220	(	_	_	I-Premise
221	P	_	_	I-Premise
222	<	_	_	I-Premise
223	.	_	_	I-Premise

224	001	_	_	I-Premise
225	)	_	_	I-Premise
226	and	_	_	I-Premise
227	at	_	_	I-Premise
228	enrollment	_	_	I-Premise
229	(	_	_	I-Premise
230	P	_	_	I-Premise
231	=	_	_	I-Premise
232	.	_	_	I-Premise

233	05	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	At	_	_	B-Premise
237	enrollment	_	_	I-Premise
238	,	_	_	I-Premise
239	mood	_	_	I-Premise
240	and	_	_	I-Premise
241	emotional	_	_	I-Premise
242	functioning	_	_	I-Premise
243	were	_	_	I-Premise
244	similar	_	_	I-Premise
245	among	_	_	I-Premise
246	all	_	_	I-Premise
247	patients	_	_	I-Premise
248	,	_	_	I-Premise
249	with	_	_	I-Premise
250	no	_	_	I-Premise
251	differences	_	_	I-Premise
252	by	_	_	I-Premise
253	type	_	_	I-Premise
254	of	_	_	I-Premise
255	treatment	_	_	I-Premise
256	received	_	_	I-Premise
257	.	_	_	I-Premise

258	At	_	_	B-Premise
259	enrollment	_	_	I-Premise
260	,	_	_	I-Premise
261	symptoms	_	_	I-Premise
262	,	_	_	I-Premise
263	including	_	_	I-Premise
264	muscle	_	_	I-Premise
265	stiffness	_	_	I-Premise
266	,	_	_	I-Premise
267	breast	_	_	I-Premise
268	sensitivity	_	_	I-Premise
269	,	_	_	I-Premise
270	aches	_	_	I-Premise
271	and	_	_	I-Premise
272	pains	_	_	I-Premise
273	,	_	_	I-Premise
274	tendency	_	_	I-Premise
275	to	_	_	I-Premise
276	take	_	_	I-Premise
277	naps	_	_	I-Premise
278	,	_	_	I-Premise
279	and	_	_	I-Premise
280	difficulty	_	_	I-Premise
281	concentrating	_	_	I-Premise
282	,	_	_	I-Premise
283	were	_	_	I-Premise
284	common	_	_	I-Premise
285	among	_	_	I-Premise
286	patients	_	_	I-Premise
287	in	_	_	I-Premise
288	all	_	_	I-Premise
289	groups	_	_	I-Premise
290	and	_	_	I-Premise
291	were	_	_	I-Premise
292	statistically	_	_	I-Premise
293	significantly	_	_	I-Premise
294	associated	_	_	I-Premise
295	with	_	_	I-Premise
296	poor	_	_	I-Premise
297	physical	_	_	I-Premise
298	functioning	_	_	I-Premise
299	and	_	_	I-Premise
300	emotional	_	_	I-Premise
301	well	_	_	I-Premise
302	-	_	_	I-Premise
303	being	_	_	I-Premise
304	.	_	_	I-Premise

305	Sexual	_	_	B-Premise
306	functioning	_	_	I-Premise
307	was	_	_	I-Premise
308	worse	_	_	I-Premise
309	for	_	_	I-Premise
310	women	_	_	I-Premise
311	who	_	_	I-Premise
312	received	_	_	I-Premise
313	chemotherapy	_	_	I-Premise
314	than	_	_	I-Premise
315	for	_	_	I-Premise
316	those	_	_	I-Premise
317	who	_	_	I-Premise
318	did	_	_	I-Premise
319	not	_	_	I-Premise
320	,	_	_	I-Premise
321	regardless	_	_	I-Premise
322	of	_	_	I-Premise
323	type	_	_	I-Premise
324	of	_	_	I-Premise
325	surgery	_	_	I-Premise
326	(	_	_	I-Premise
327	P	_	_	I-Premise
328	<	_	_	I-Premise
329	.	_	_	I-Premise

330	001	_	_	I-Premise
331	)	_	_	I-Premise
332	.	_	_	I-Premise

333	At	_	_	B-Claim
334	the	_	_	I-Claim
335	end	_	_	I-Claim
336	of	_	_	I-Claim
337	primary	_	_	I-Claim
338	treatment	_	_	I-Claim
339	for	_	_	I-Claim
340	breast	_	_	I-Claim
341	cancer	_	_	I-Claim
342	,	_	_	I-Claim
343	women	_	_	I-Claim
344	in	_	_	I-Claim
345	all	_	_	I-Claim
346	treatment	_	_	I-Claim
347	groups	_	_	I-Claim
348	report	_	_	I-Claim
349	good	_	_	I-Claim
350	emotional	_	_	I-Claim
351	functioning	_	_	I-Claim
352	but	_	_	I-Claim
353	report	_	_	I-Claim
354	decreased	_	_	I-Claim
355	physical	_	_	I-Claim
356	functioning	_	_	I-Claim
357	,	_	_	I-Claim
358	particularly	_	_	I-Claim
359	among	_	_	I-Claim
360	women	_	_	I-Claim
361	who	_	_	I-Claim
362	have	_	_	I-Claim
363	a	_	_	I-Claim
364	mastectomy	_	_	I-Claim
365	or	_	_	I-Claim
366	receive	_	_	I-Claim
367	chemotherapy	_	_	I-Claim
368	.	_	_	I-Claim

369	Clinical	_	_	B-Claim
370	interventions	_	_	I-Claim
371	to	_	_	I-Claim
372	address	_	_	I-Claim
373	common	_	_	I-Claim
374	symptoms	_	_	I-Claim
375	associated	_	_	I-Claim
376	with	_	_	I-Claim
377	treatment	_	_	I-Claim
378	should	_	_	I-Claim
379	be	_	_	I-Claim
380	considered	_	_	I-Claim
381	to	_	_	I-Claim
382	improve	_	_	I-Claim
383	physical	_	_	I-Claim
384	and	_	_	I-Claim
385	emotional	_	_	I-Claim
386	functioning	_	_	I-Claim
387	at	_	_	I-Claim
388	the	_	_	I-Claim
389	end	_	_	I-Claim
390	of	_	_	I-Claim
391	primary	_	_	I-Claim
392	treatment	_	_	I-Claim
393	for	_	_	I-Claim
394	breast	_	_	I-Claim
395	cancer	_	_	I-Claim
396	.	_	_	I-Claim


0	We	_	_	O
1	evaluated	_	_	O
2	the	_	_	O
3	role	_	_	O
4	of	_	_	O
5	glutathione	_	_	O
6	-	_	_	O
7	related	_	_	O
8	genotypes	_	_	O
9	on	_	_	O
10	overall	_	_	O
11	survival	_	_	O
12	,	_	_	O
13	time	_	_	O
14	to	_	_	O
15	progression	_	_	O
16	,	_	_	O
17	adverse	_	_	O
18	events	_	_	O
19	,	_	_	O
20	and	_	_	O
21	quality	_	_	O
22	of	_	_	O
23	life	_	_	O
24	(	_	_	O
25	QOL	_	_	O
26	)	_	_	O
27	in	_	_	O
28	stage	_	_	O
29	IIIB	_	_	O
30	/	_	_	O
31	IV	_	_	O
32	non	_	_	O
33	-	_	_	O
34	small	_	_	O
35	cell	_	_	O
36	lung	_	_	O
37	cancer	_	_	O
38	patients	_	_	O
39	who	_	_	O
40	were	_	_	O
41	stable	_	_	O
42	or	_	_	O
43	responding	_	_	O
44	from	_	_	O
45	initial	_	_	O
46	treatment	_	_	O
47	with	_	_	O
48	platinum	_	_	O
49	-	_	_	O
50	based	_	_	O
51	chemotherapy	_	_	O
52	and	_	_	O
53	subsequently	_	_	O
54	randomized	_	_	O
55	to	_	_	O
56	receive	_	_	O
57	daily	_	_	O
58	oral	_	_	O
59	carboxyaminoimidazole	_	_	O
60	or	_	_	O
61	a	_	_	O
62	placebo	_	_	O
63	.	_	_	O

64	Of	_	_	O
65	the	_	_	O
66	186	_	_	O
67	total	_	_	O
68	patients	_	_	O
69	,	_	_	O
70	113	_	_	O
71	had	_	_	O
72	initial	_	_	O
73	treatment	_	_	O
74	with	_	_	O
75	platinum	_	_	O
76	therapy	_	_	O
77	and	_	_	O
78	DNA	_	_	O
79	samples	_	_	O
80	of	_	_	O
81	whom	_	_	O
82	46	_	_	O
83	also	_	_	O
84	had	_	_	O
85	QOL	_	_	O
86	data	_	_	O
87	.	_	_	O

88	These	_	_	O
89	samples	_	_	O
90	were	_	_	O
91	analyzed	_	_	O
92	using	_	_	O
93	six	_	_	O
94	polymorphic	_	_	O
95	DNA	_	_	O
96	markers	_	_	O
97	that	_	_	O
98	encode	_	_	O
99	five	_	_	O
100	important	_	_	O
101	enzymes	_	_	O
102	in	_	_	O
103	the	_	_	O
104	glutathione	_	_	O
105	metabolic	_	_	O
106	pathway	_	_	O
107	.	_	_	O

108	Patient	_	_	O
109	QOL	_	_	O
110	was	_	_	O
111	assessed	_	_	O
112	using	_	_	O
113	the	_	_	O
114	Functional	_	_	O
115	Assessment	_	_	O
116	of	_	_	O
117	Cancer	_	_	O
118	Therapy	_	_	O
119	-	_	_	O
120	Lung	_	_	O
121	and	_	_	O
122	the	_	_	O
123	UNISCALE	_	_	O
124	QOL	_	_	O
125	questionnaires	_	_	O
126	.	_	_	O

127	A	_	_	O
128	clinically	_	_	O
129	significant	_	_	O
130	decline	_	_	O
131	in	_	_	O
132	QOL	_	_	O
133	was	_	_	O
134	defined	_	_	O
135	as	_	_	O
136	a	_	_	O
137	10	_	_	O
138	%	_	_	O
139	decrease	_	_	O
140	from	_	_	O
141	baseline	_	_	O
142	to	_	_	O
143	week	_	_	O
144	-	_	_	O
145	8	_	_	O
146	.	_	_	O

147	Multivariate	_	_	O
148	analyses	_	_	O
149	were	_	_	O
150	used	_	_	O
151	to	_	_	O
152	evaluate	_	_	O
153	the	_	_	O
154	association	_	_	O
155	of	_	_	O
156	the	_	_	O
157	genotypes	_	_	O
158	on	_	_	O
159	the	_	_	O
160	four	_	_	O
161	endpoints	_	_	O
162	.	_	_	O

163	Patients	_	_	B-Premise
164	carrying	_	_	I-Premise
165	a	_	_	I-Premise
166	GCLC	_	_	I-Premise
167	77	_	_	I-Premise
168	genotype	_	_	I-Premise
169	had	_	_	I-Premise
170	a	_	_	I-Premise
171	worse	_	_	I-Premise
172	overall	_	_	I-Premise
173	survival	_	_	I-Premise
174	(	_	_	I-Premise
175	hazard	_	_	I-Premise
176	ratio	_	_	I-Premise
177	(	_	_	I-Premise
178	HR	_	_	I-Premise
179	)	_	_	I-Premise
180	=	_	_	I-Premise
181	1	_	_	I-Premise
182	.	_	_	I-Premise

183	5	_	_	I-Premise
184	,	_	_	I-Premise
185	p	_	_	I-Premise
186	=	_	_	I-Premise
187	0	_	_	I-Premise
188	.	_	_	I-Premise

189	05	_	_	I-Premise
190	)	_	_	I-Premise
191	.	_	_	I-Premise

192	Patients	_	_	B-Premise
193	carrying	_	_	I-Premise
194	the	_	_	I-Premise
195	GPX1	_	_	I-Premise
196	-	_	_	I-Premise
197	CC	_	_	I-Premise
198	genotype	_	_	I-Premise
199	had	_	_	I-Premise
200	a	_	_	I-Premise
201	clinically	_	_	I-Premise
202	significant	_	_	I-Premise
203	decline	_	_	I-Premise
204	in	_	_	I-Premise
205	the	_	_	I-Premise
206	UNISCALE	_	_	I-Premise
207	(	_	_	I-Premise
208	odds	_	_	I-Premise
209	ratio	_	_	I-Premise
210	(	_	_	I-Premise
211	OR	_	_	I-Premise
212	)	_	_	I-Premise
213	:	_	_	I-Premise
214	7	_	_	I-Premise
215	.	_	_	I-Premise

216	5	_	_	I-Premise
217	;	_	_	I-Premise
218	p	_	_	I-Premise
219	=	_	_	I-Premise
220	0	_	_	I-Premise
221	.	_	_	I-Premise

222	04	_	_	I-Premise
223	)	_	_	I-Premise
224	,	_	_	I-Premise
225	total	_	_	I-Premise
226	Functional	_	_	I-Premise
227	Assessment	_	_	I-Premise
228	of	_	_	I-Premise
229	Cancer	_	_	I-Premise
230	Therapy	_	_	I-Premise
231	-	_	_	I-Premise
232	Lung	_	_	I-Premise
233	score	_	_	I-Premise
234	(	_	_	I-Premise
235	OR	_	_	I-Premise
236	:	_	_	I-Premise
237	11	_	_	I-Premise
238	.	_	_	I-Premise

239	0	_	_	I-Premise
240	;	_	_	I-Premise
241	p	_	_	I-Premise
242	=	_	_	I-Premise
243	0	_	_	I-Premise
244	.	_	_	I-Premise

245	04	_	_	I-Premise
246	)	_	_	I-Premise
247	,	_	_	I-Premise
248	physical	_	_	I-Premise
249	(	_	_	I-Premise
250	OR	_	_	I-Premise
251	:	_	_	I-Premise
252	7	_	_	I-Premise
253	.	_	_	I-Premise

254	1	_	_	I-Premise
255	;	_	_	I-Premise
256	p	_	_	I-Premise
257	=	_	_	I-Premise
258	0	_	_	I-Premise
259	.	_	_	I-Premise

260	03	_	_	I-Premise
261	)	_	_	I-Premise
262	,	_	_	I-Premise
263	functional	_	_	I-Premise
264	(	_	_	I-Premise
265	OR	_	_	I-Premise
266	:	_	_	I-Premise
267	5	_	_	I-Premise
268	.	_	_	I-Premise

269	2	_	_	I-Premise
270	;	_	_	I-Premise
271	p	_	_	I-Premise
272	=	_	_	I-Premise
273	0	_	_	I-Premise
274	.	_	_	I-Premise

275	04	_	_	I-Premise
276	)	_	_	I-Premise
277	,	_	_	I-Premise
278	and	_	_	I-Premise
279	emotional	_	_	I-Premise
280	well	_	_	I-Premise
281	-	_	_	I-Premise
282	being	_	_	I-Premise
283	constructs	_	_	I-Premise
284	(	_	_	I-Premise
285	OR	_	_	I-Premise
286	:	_	_	I-Premise
287	23	_	_	I-Premise
288	.	_	_	I-Premise

289	8	_	_	I-Premise
290	;	_	_	I-Premise
291	p	_	_	I-Premise
292	=	_	_	I-Premise
293	0	_	_	I-Premise
294	.	_	_	I-Premise

295	01	_	_	I-Premise
296	)	_	_	I-Premise
297	.	_	_	I-Premise

298	Genotypes	_	_	B-Claim
299	of	_	_	I-Claim
300	glutathione	_	_	I-Claim
301	-	_	_	I-Claim
302	related	_	_	I-Claim
303	enzymes	_	_	I-Claim
304	,	_	_	I-Claim
305	especially	_	_	I-Claim
306	GCLC	_	_	I-Claim
307	,	_	_	I-Claim
308	may	_	_	I-Claim
309	be	_	_	I-Claim
310	used	_	_	I-Claim
311	as	_	_	I-Claim
312	host	_	_	I-Claim
313	factors	_	_	I-Claim
314	in	_	_	I-Claim
315	predicting	_	_	I-Claim
316	patients	_	_	I-Claim
317	'	_	_	I-Claim
318	survival	_	_	I-Claim
319	after	_	_	I-Claim
320	platinum	_	_	I-Claim
321	-	_	_	I-Claim
322	based	_	_	I-Claim
323	chemotherapy	_	_	I-Claim
324	.	_	_	I-Claim

325	GPX1	_	_	B-Claim
326	may	_	_	I-Claim
327	be	_	_	I-Claim
328	an	_	_	I-Claim
329	inherited	_	_	I-Claim
330	factor	_	_	I-Claim
331	in	_	_	I-Claim
332	predicting	_	_	I-Claim
333	patients	_	_	I-Claim
334	'	_	_	I-Claim
335	QOL	_	_	I-Claim
336	.	_	_	I-Claim

337	Further	_	_	B-Claim
338	investigation	_	_	I-Claim
339	to	_	_	I-Claim
340	define	_	_	I-Claim
341	and	_	_	I-Claim
342	measure	_	_	I-Claim
343	the	_	_	I-Claim
344	effects	_	_	I-Claim
345	of	_	_	I-Claim
346	these	_	_	I-Claim
347	genes	_	_	I-Claim
348	in	_	_	I-Claim
349	chemotherapeutic	_	_	I-Claim
350	regimens	_	_	I-Claim
351	,	_	_	I-Claim
352	drug	_	_	I-Claim
353	toxicities	_	_	I-Claim
354	,	_	_	I-Claim
355	disease	_	_	I-Claim
356	progression	_	_	I-Claim
357	,	_	_	I-Claim
358	and	_	_	I-Claim
359	QOL	_	_	I-Claim
360	are	_	_	I-Claim
361	critical	_	_	I-Claim
362	.	_	_	I-Claim


0	Transthoracic	_	_	O
1	and	_	_	O
2	transhiatal	_	_	O
3	esophagectomy	_	_	O
4	are	_	_	O
5	two	_	_	O
6	common	_	_	O
7	procedures	_	_	O
8	for	_	_	O
9	esophageal	_	_	O
10	cancer	_	_	O
11	resection	_	_	O
12	.	_	_	O

13	Prospective	_	_	O
14	studies	_	_	O
15	comparing	_	_	O
16	the	_	_	O
17	two	_	_	O
18	methods	_	_	O
19	in	_	_	O
20	Asian	_	_	O
21	people	_	_	O
22	are	_	_	O
23	few	_	_	O
24	.	_	_	O

25	In	_	_	O
26	addition	_	_	O
27	,	_	_	O
28	the	_	_	O
29	data	_	_	O
30	comparing	_	_	O
31	their	_	_	O
32	effects	_	_	O
33	on	_	_	O
34	the	_	_	O
35	quality	_	_	O
36	of	_	_	O
37	life	_	_	O
38	are	_	_	O
39	lacking	_	_	O
40	.	_	_	O

41	A	_	_	O
42	prospective	_	_	O
43	randomized	_	_	O
44	study	_	_	O
45	was	_	_	O
46	conducted	_	_	O
47	from	_	_	O
48	January	_	_	O
49	2003	_	_	O
50	.	_	_	O

51	Patients	_	_	O
52	of	_	_	O
53	resectable	_	_	O
54	esophageal	_	_	O
55	cancer	_	_	O
56	of	_	_	O
57	comparable	_	_	O
58	stage	_	_	O
59	were	_	_	O
60	allocated	_	_	O
61	to	_	_	O
62	undergo	_	_	O
63	the	_	_	O
64	transthoracic	_	_	O
65	or	_	_	O
66	transhiatal	_	_	O
67	procedure	_	_	O
68	in	_	_	O
69	turn	_	_	O
70	.	_	_	O

71	They	_	_	O
72	were	_	_	O
73	all	_	_	O
74	reconstructed	_	_	O
75	with	_	_	O
76	stomach	_	_	O
77	interposition	_	_	O
78	through	_	_	O
79	the	_	_	O
80	retrosternal	_	_	O
81	route	_	_	O
82	.	_	_	O

83	Discharged	_	_	O
84	patients	_	_	O
85	were	_	_	O
86	followed	_	_	O
87	-	_	_	O
88	up	_	_	O
89	in	_	_	O
90	the	_	_	O
91	outpatient	_	_	O
92	clinic	_	_	O
93	.	_	_	O

94	They	_	_	O
95	were	_	_	O
96	questioned	_	_	O
97	on	_	_	O
98	the	_	_	O
99	topics	_	_	O
100	of	_	_	O
101	(	_	_	O
102	i	_	_	O
103	)	_	_	O
104	severity	_	_	O
105	of	_	_	O
106	pain	_	_	O
107	,	_	_	O
108	(	_	_	O
109	ii	_	_	O
110	)	_	_	O
111	ease	_	_	O
112	of	_	_	O
113	swallowing	_	_	O
114	,	_	_	O
115	(	_	_	O
116	iii	_	_	O
117	)	_	_	O
118	satisfaction	_	_	O
119	of	_	_	O
120	daily	_	_	O
121	activities	_	_	O
122	,	_	_	O
123	(	_	_	O
124	iv	_	_	O
125	)	_	_	O
126	dependence	_	_	O
127	on	_	_	O
128	medications	_	_	O
129	,	_	_	O
130	(	_	_	O
131	v	_	_	O
132	)	_	_	O
133	working	_	_	O
134	ability	_	_	O
135	,	_	_	O
136	(	_	_	O
137	vi	_	_	O
138	)	_	_	O
139	fatigue	_	_	O
140	,	_	_	O
141	(	_	_	O
142	vii	_	_	O
143	)	_	_	O
144	appetite	_	_	O
145	,	_	_	O
146	(	_	_	O
147	viii	_	_	O
148	)	_	_	O
149	sociality	_	_	O
150	,	_	_	O
151	(	_	_	O
152	ix	_	_	O
153	)	_	_	O
154	happiness	_	_	O
155	and	_	_	O
156	(	_	_	O
157	x	_	_	O
158	)	_	_	O
159	self	_	_	O
160	respect	_	_	O
161	,	_	_	O
162	in	_	_	O
163	the	_	_	O
164	third	_	_	O
165	,	_	_	O
166	sixth	_	_	O
167	and	_	_	O
168	twelfth	_	_	O
169	month	_	_	O
170	.	_	_	O

171	Also	_	_	O
172	the	_	_	O
173	demographic	_	_	O
174	data	_	_	O
175	,	_	_	O
176	operative	_	_	O
177	results	_	_	O
178	and	_	_	O
179	survival	_	_	O
180	were	_	_	O
181	recorded	_	_	O
182	.	_	_	O

183	Up	_	_	O
184	to	_	_	O
185	December	_	_	O
186	2006	_	_	O
187	,	_	_	O
188	eighty	_	_	O
189	-	_	_	O
190	seven	_	_	O
191	patients	_	_	O
192	of	_	_	O
193	stage	_	_	O
194	II	_	_	O
195	and	_	_	O
196	III	_	_	O
197	,	_	_	O
198	including	_	_	O
199	71	_	_	O
200	patients	_	_	O
201	of	_	_	O
202	middle	_	_	O
203	third	_	_	O
204	lesions	_	_	O
205	and	_	_	O
206	16	_	_	O
207	lower	_	_	O
208	third	_	_	O
209	lesions	_	_	O
210	were	_	_	O
211	enrolled	_	_	O
212	.	_	_	O

213	The	_	_	B-Premise
214	operation	_	_	I-Premise
215	time	_	_	I-Premise
216	was	_	_	I-Premise
217	significantly	_	_	I-Premise
218	longer	_	_	I-Premise
219	,	_	_	I-Premise
220	and	_	_	I-Premise
221	the	_	_	I-Premise
222	leakage	_	_	I-Premise
223	rate	_	_	I-Premise
224	was	_	_	I-Premise
225	higher	_	_	I-Premise
226	in	_	_	I-Premise
227	the	_	_	I-Premise
228	transthoracic	_	_	I-Premise
229	group	_	_	I-Premise
230	(	_	_	I-Premise
231	Student	_	_	I-Premise
232	'	_	_	I-Premise
233	s	_	_	I-Premise
234	t	_	_	I-Premise
235	-	_	_	I-Premise
236	test	_	_	I-Premise
237	and	_	_	I-Premise
238	Fischer	_	_	I-Premise
239	'	_	_	I-Premise
240	s	_	_	I-Premise
241	exact	_	_	I-Premise
242	test	_	_	I-Premise
243	,	_	_	I-Premise
244	respectively	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	However	_	_	O
248	,	_	_	O
249	intraoperative	_	_	B-Premise
250	blood	_	_	I-Premise
251	loss	_	_	I-Premise
252	and	_	_	I-Premise
253	postoperative	_	_	I-Premise
254	hospital	_	_	I-Premise
255	stay	_	_	I-Premise
256	were	_	_	I-Premise
257	not	_	_	I-Premise
258	significantly	_	_	I-Premise
259	different	_	_	I-Premise
260	(	_	_	I-Premise
261	Student	_	_	I-Premise
262	t	_	_	I-Premise
263	-	_	_	I-Premise
264	test	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	Also	_	_	O
268	,	_	_	O
269	the	_	_	B-Premise
270	Kaplan	_	_	I-Premise
271	-	_	_	I-Premise
272	Meier	_	_	I-Premise
273	survival	_	_	I-Premise
274	curves	_	_	I-Premise
275	of	_	_	I-Premise
276	these	_	_	I-Premise
277	two	_	_	I-Premise
278	groups	_	_	I-Premise
279	were	_	_	I-Premise
280	not	_	_	I-Premise
281	significantly	_	_	I-Premise
282	different	_	_	I-Premise
283	by	_	_	I-Premise
284	log	_	_	I-Premise
285	-	_	_	I-Premise
286	rank	_	_	I-Premise
287	test	_	_	I-Premise
288	(	_	_	I-Premise
289	p	_	_	I-Premise
290	=	_	_	I-Premise
291	0	_	_	I-Premise
292	.	_	_	I-Premise

293	286	_	_	I-Premise
294	)	_	_	I-Premise
295	.	_	_	I-Premise

296	The	_	_	B-Premise
297	score	_	_	I-Premise
298	on	_	_	I-Premise
299	the	_	_	I-Premise
300	quality	_	_	I-Premise
301	of	_	_	I-Premise
302	life	_	_	I-Premise
303	of	_	_	I-Premise
304	transhiatal	_	_	I-Premise
305	patients	_	_	I-Premise
306	was	_	_	I-Premise
307	significantly	_	_	I-Premise
308	higher	_	_	I-Premise
309	than	_	_	I-Premise
310	that	_	_	I-Premise
311	of	_	_	I-Premise
312	transthoracic	_	_	I-Premise
313	patients	_	_	I-Premise
314	in	_	_	I-Premise
315	the	_	_	I-Premise
316	third	_	_	I-Premise
317	,	_	_	I-Premise
318	sixth	_	_	I-Premise
319	and	_	_	I-Premise
320	twelfth	_	_	I-Premise
321	month	_	_	I-Premise
322	.	_	_	I-Premise

323	Transhiatal	_	_	B-Claim
324	esophagectomy	_	_	I-Claim
325	is	_	_	I-Claim
326	a	_	_	I-Claim
327	safe	_	_	I-Claim
328	and	_	_	I-Claim
329	fast	_	_	I-Claim
330	procedure	_	_	I-Claim
331	.	_	_	I-Claim

332	The	_	_	B-Claim
333	survival	_	_	I-Claim
334	was	_	_	I-Claim
335	similar	_	_	I-Claim
336	to	_	_	I-Claim
337	that	_	_	I-Claim
338	of	_	_	I-Claim
339	transthoracic	_	_	I-Claim
340	approach	_	_	I-Claim
341	.	_	_	I-Claim

342	Its	_	_	B-Claim
343	leakage	_	_	I-Claim
344	rate	_	_	I-Claim
345	was	_	_	I-Claim
346	lower	_	_	I-Claim
347	and	_	_	I-Claim
348	quality	_	_	I-Claim
349	of	_	_	I-Claim
350	life	_	_	I-Claim
351	was	_	_	I-Claim
352	better	_	_	I-Claim
353	.	_	_	I-Claim


0	Despite	_	_	B-Claim
1	considerable	_	_	I-Claim
2	improvement	_	_	I-Claim
3	in	_	_	I-Claim
4	the	_	_	I-Claim
5	treatment	_	_	I-Claim
6	of	_	_	I-Claim
7	advanced	_	_	I-Claim
8	ovarian	_	_	I-Claim
9	cancer	_	_	I-Claim
10	,	_	_	I-Claim
11	the	_	_	I-Claim
12	optimization	_	_	I-Claim
13	of	_	_	I-Claim
14	efficacy	_	_	I-Claim
15	and	_	_	I-Claim
16	tolerability	_	_	I-Claim
17	remains	_	_	I-Claim
18	an	_	_	I-Claim
19	important	_	_	I-Claim
20	issue	_	_	I-Claim
21	.	_	_	I-Claim

22	Therefore	_	_	O
23	,	_	_	O
24	we	_	_	O
25	performed	_	_	O
26	a	_	_	O
27	randomized	_	_	O
28	,	_	_	O
29	phase	_	_	O
30	III	_	_	O
31	non	_	_	O
32	-	_	_	O
33	inferiority	_	_	O
34	trial	_	_	O
35	comparing	_	_	O
36	paclitaxel	_	_	O
37	plus	_	_	O
38	cisplatin	_	_	O
39	(	_	_	O
40	PT	_	_	O
41	)	_	_	O
42	with	_	_	O
43	paclitaxel	_	_	O
44	plus	_	_	O
45	carboplatin	_	_	O
46	(	_	_	O
47	TC	_	_	O
48	)	_	_	O
49	in	_	_	O
50	patients	_	_	O
51	with	_	_	O
52	advanced	_	_	O
53	ovarian	_	_	O
54	cancer	_	_	O
55	.	_	_	O

56	A	_	_	O
57	total	_	_	O
58	of	_	_	O
59	798	_	_	O
60	patients	_	_	O
61	with	_	_	O
62	International	_	_	O
63	Federation	_	_	O
64	of	_	_	O
65	Gynecology	_	_	O
66	and	_	_	O
67	Obstetrics	_	_	O
68	stage	_	_	O
69	IIB	_	_	O
70	-	_	_	O
71	IV	_	_	O
72	were	_	_	O
73	randomly	_	_	O
74	assigned	_	_	O
75	to	_	_	O
76	receive	_	_	O
77	six	_	_	O
78	courses	_	_	O
79	of	_	_	O
80	either	_	_	O
81	PT	_	_	O
82	or	_	_	O
83	TC	_	_	O
84	at	_	_	O
85	3	_	_	O
86	-	_	_	O
87	week	_	_	O
88	intervals	_	_	O
89	.	_	_	O

90	The	_	_	O
91	primary	_	_	O
92	endpoint	_	_	O
93	was	_	_	O
94	the	_	_	O
95	proportion	_	_	O
96	of	_	_	O
97	patients	_	_	O
98	without	_	_	O
99	progression	_	_	O
100	at	_	_	O
101	2	_	_	O
102	years	_	_	O
103	.	_	_	O

104	Secondary	_	_	O
105	endpoints	_	_	O
106	included	_	_	O
107	toxicity	_	_	O
108	,	_	_	O
109	response	_	_	O
110	to	_	_	O
111	treatment	_	_	O
112	,	_	_	O
113	quality	_	_	O
114	of	_	_	O
115	life	_	_	O
116	,	_	_	O
117	and	_	_	O
118	overall	_	_	O
119	and	_	_	O
120	progression	_	_	O
121	-	_	_	O
122	free	_	_	O
123	survival	_	_	O
124	time	_	_	O
125	.	_	_	O

126	Quality	_	_	O
127	of	_	_	O
128	life	_	_	O
129	was	_	_	O
130	evaluated	_	_	O
131	using	_	_	O
132	the	_	_	O
133	European	_	_	O
134	Organization	_	_	O
135	for	_	_	O
136	Research	_	_	O
137	and	_	_	O
138	Treatment	_	_	O
139	of	_	_	O
140	Cancer	_	_	O
141	quality	_	_	O
142	-	_	_	O
143	of	_	_	O
144	-	_	_	O
145	life	_	_	O
146	questionnaire	_	_	O
147	(	_	_	O
148	QLQ	_	_	O
149	)	_	_	O
150	-	_	_	O
151	C30	_	_	O
152	,	_	_	O
153	version	_	_	O
154	2	_	_	O
155	.	_	_	O

156	0	_	_	O
157	.	_	_	O

158	Survival	_	_	O
159	curves	_	_	O
160	were	_	_	O
161	calculated	_	_	O
162	using	_	_	O
163	the	_	_	O
164	Kaplan	_	_	O
165	-	_	_	O
166	Meier	_	_	O
167	method	_	_	O
168	,	_	_	O
169	and	_	_	O
170	hazard	_	_	O
171	ratios	_	_	O
172	were	_	_	O
173	estimated	_	_	O
174	using	_	_	O
175	the	_	_	O
176	Cox	_	_	O
177	proportional	_	_	O
178	hazards	_	_	O
179	model	_	_	O
180	.	_	_	O

181	The	_	_	B-Premise
182	proportion	_	_	I-Premise
183	of	_	_	I-Premise
184	patients	_	_	I-Premise
185	without	_	_	I-Premise
186	progression	_	_	I-Premise
187	at	_	_	I-Premise
188	2	_	_	I-Premise
189	years	_	_	I-Premise
190	was	_	_	I-Premise
191	not	_	_	I-Premise
192	statistically	_	_	I-Premise
193	significantly	_	_	I-Premise
194	different	_	_	I-Premise
195	between	_	_	I-Premise
196	the	_	_	I-Premise
197	two	_	_	I-Premise
198	treatment	_	_	I-Premise
199	arms	_	_	I-Premise
200	(	_	_	I-Premise
201	40	_	_	I-Premise
202	.	_	_	I-Premise

203	0	_	_	I-Premise
204	%	_	_	I-Premise
205	for	_	_	I-Premise
206	PT	_	_	I-Premise
207	versus	_	_	I-Premise
208	37	_	_	I-Premise
209	.	_	_	I-Premise

210	5	_	_	I-Premise
211	%	_	_	I-Premise
212	for	_	_	I-Premise
213	TC	_	_	I-Premise
214	,	_	_	I-Premise
215	difference	_	_	I-Premise
216	=	_	_	I-Premise
217	2	_	_	I-Premise
218	.	_	_	I-Premise

219	5	_	_	I-Premise
220	%	_	_	I-Premise
221	,	_	_	I-Premise
222	one	_	_	I-Premise
223	-	_	_	I-Premise
224	sided	_	_	I-Premise
225	95	_	_	I-Premise
226	%	_	_	I-Premise
227	confidence	_	_	I-Premise
228	interval	_	_	I-Premise
229	[	_	_	I-Premise
230	CI	_	_	I-Premise
231	]	_	_	I-Premise
232	=	_	_	I-Premise
233	-	_	_	I-Premise
234	infinity	_	_	I-Premise
235	to	_	_	I-Premise
236	8	_	_	I-Premise
237	.	_	_	I-Premise

238	2	_	_	I-Premise
239	%	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	Median	_	_	B-Premise
243	progression	_	_	I-Premise
244	-	_	_	I-Premise
245	free	_	_	I-Premise
246	survival	_	_	I-Premise
247	time	_	_	I-Premise
248	in	_	_	I-Premise
249	the	_	_	I-Premise
250	TC	_	_	I-Premise
251	arm	_	_	I-Premise
252	(	_	_	I-Premise
253	17	_	_	I-Premise
254	.	_	_	I-Premise

255	2	_	_	I-Premise
256	months	_	_	I-Premise
257	,	_	_	I-Premise
258	95	_	_	I-Premise
259	%	_	_	I-Premise
260	CI	_	_	I-Premise
261	=	_	_	I-Premise
262	15	_	_	I-Premise
263	.	_	_	I-Premise

264	2	_	_	I-Premise
265	to	_	_	I-Premise
266	19	_	_	I-Premise
267	.	_	_	I-Premise

268	3	_	_	I-Premise
269	months	_	_	I-Premise
270	)	_	_	I-Premise
271	and	_	_	I-Premise
272	the	_	_	I-Premise
273	PT	_	_	I-Premise
274	arm	_	_	I-Premise
275	(	_	_	I-Premise
276	19	_	_	I-Premise
277	.	_	_	I-Premise

278	1	_	_	I-Premise
279	months	_	_	I-Premise
280	,	_	_	I-Premise
281	95	_	_	I-Premise
282	%	_	_	I-Premise
283	CI	_	_	I-Premise
284	=	_	_	I-Premise
285	16	_	_	I-Premise
286	.	_	_	I-Premise

287	7	_	_	I-Premise
288	to	_	_	I-Premise
289	21	_	_	I-Premise
290	.	_	_	I-Premise

291	5	_	_	I-Premise
292	months	_	_	I-Premise
293	)	_	_	I-Premise
294	were	_	_	I-Premise
295	also	_	_	I-Premise
296	not	_	_	I-Premise
297	statistically	_	_	I-Premise
298	significantly	_	_	I-Premise
299	different	_	_	I-Premise
300	;	_	_	I-Premise
301	the	_	_	B-Premise
302	same	_	_	I-Premise
303	was	_	_	I-Premise
304	true	_	_	I-Premise
305	of	_	_	I-Premise
306	median	_	_	I-Premise
307	overall	_	_	I-Premise
308	survival	_	_	I-Premise
309	time	_	_	I-Premise
310	(	_	_	I-Premise
311	43	_	_	I-Premise
312	.	_	_	I-Premise

313	3	_	_	I-Premise
314	months	_	_	I-Premise
315	,	_	_	I-Premise
316	95	_	_	I-Premise
317	%	_	_	I-Premise
318	CI	_	_	I-Premise
319	=	_	_	I-Premise
320	37	_	_	I-Premise
321	.	_	_	I-Premise

322	2	_	_	I-Premise
323	to	_	_	I-Premise
324	47	_	_	I-Premise
325	.	_	_	I-Premise

326	8	_	_	I-Premise
327	months	_	_	I-Premise
328	versus	_	_	I-Premise
329	44	_	_	I-Premise
330	.	_	_	I-Premise

331	1	_	_	I-Premise
332	months	_	_	I-Premise
333	,	_	_	I-Premise
334	95	_	_	I-Premise
335	%	_	_	I-Premise
336	CI	_	_	I-Premise
337	=	_	_	I-Premise
338	40	_	_	I-Premise
339	.	_	_	I-Premise

340	2	_	_	I-Premise
341	to	_	_	I-Premise
342	49	_	_	I-Premise
343	.	_	_	I-Premise

344	4	_	_	I-Premise
345	months	_	_	I-Premise
346	,	_	_	I-Premise
347	for	_	_	I-Premise
348	the	_	_	I-Premise
349	TC	_	_	I-Premise
350	and	_	_	I-Premise
351	PT	_	_	I-Premise
352	arms	_	_	I-Premise
353	,	_	_	I-Premise
354	respectively	_	_	I-Premise
355	)	_	_	I-Premise
356	.	_	_	I-Premise

357	The	_	_	B-Premise
358	TC	_	_	I-Premise
359	regimen	_	_	I-Premise
360	was	_	_	I-Premise
361	associated	_	_	I-Premise
362	with	_	_	I-Premise
363	a	_	_	I-Premise
364	higher	_	_	I-Premise
365	frequency	_	_	I-Premise
366	of	_	_	I-Premise
367	hematologic	_	_	I-Premise
368	toxicity	_	_	I-Premise
369	,	_	_	I-Premise
370	but	_	_	B-Premise
371	a	_	_	I-Premise
372	lower	_	_	I-Premise
373	frequency	_	_	I-Premise
374	of	_	_	I-Premise
375	gastrointestinal	_	_	I-Premise
376	and	_	_	I-Premise
377	neurologic	_	_	I-Premise
378	toxicity	_	_	I-Premise
379	,	_	_	I-Premise
380	than	_	_	I-Premise
381	the	_	_	I-Premise
382	PT	_	_	I-Premise
383	regimen	_	_	I-Premise
384	.	_	_	I-Premise

385	Mean	_	_	B-Premise
386	global	_	_	I-Premise
387	quality	_	_	I-Premise
388	-	_	_	I-Premise
389	of	_	_	I-Premise
390	-	_	_	I-Premise
391	life	_	_	I-Premise
392	scores	_	_	I-Premise
393	at	_	_	I-Premise
394	the	_	_	I-Premise
395	end	_	_	I-Premise
396	of	_	_	I-Premise
397	treatment	_	_	I-Premise
398	were	_	_	I-Premise
399	statistically	_	_	I-Premise
400	significantly	_	_	I-Premise
401	better	_	_	I-Premise
402	in	_	_	I-Premise
403	the	_	_	I-Premise
404	TC	_	_	I-Premise
405	arm	_	_	I-Premise
406	than	_	_	I-Premise
407	in	_	_	I-Premise
408	the	_	_	I-Premise
409	PT	_	_	I-Premise
410	arm	_	_	I-Premise
411	(	_	_	I-Premise
412	65	_	_	I-Premise
413	.	_	_	I-Premise

414	25	_	_	I-Premise
415	versus	_	_	I-Premise
416	51	_	_	I-Premise
417	.	_	_	I-Premise

418	97	_	_	I-Premise
419	,	_	_	I-Premise
420	respectively	_	_	I-Premise
421	;	_	_	I-Premise
422	difference	_	_	I-Premise
423	=	_	_	I-Premise
424	-	_	_	I-Premise
425	13	_	_	I-Premise
426	.	_	_	I-Premise

427	28	_	_	I-Premise
428	,	_	_	I-Premise
429	95	_	_	I-Premise
430	%	_	_	I-Premise
431	CI	_	_	I-Premise
432	=	_	_	I-Premise
433	-	_	_	I-Premise
434	18	_	_	I-Premise
435	.	_	_	I-Premise

436	88	_	_	I-Premise
437	to	_	_	I-Premise
438	-	_	_	I-Premise
439	7	_	_	I-Premise
440	.	_	_	I-Premise

441	68	_	_	I-Premise
442	)	_	_	I-Premise
443	.	_	_	I-Premise

444	The	_	_	B-Claim
445	TC	_	_	I-Claim
446	regimen	_	_	I-Claim
447	achieved	_	_	I-Claim
448	comparable	_	_	I-Claim
449	efficacy	_	_	I-Claim
450	to	_	_	I-Claim
451	the	_	_	I-Claim
452	PT	_	_	I-Claim
453	regimen	_	_	I-Claim
454	but	_	_	I-Claim
455	was	_	_	I-Claim
456	associated	_	_	I-Claim
457	with	_	_	I-Claim
458	better	_	_	I-Claim
459	tolerability	_	_	I-Claim
460	and	_	_	I-Claim
461	quality	_	_	I-Claim
462	of	_	_	I-Claim
463	life	_	_	I-Claim
464	,	_	_	I-Claim
465	and	_	_	I-Claim
466	should	_	_	I-Claim
467	,	_	_	I-Claim
468	therefore	_	_	I-Claim
469	,	_	_	I-Claim
470	be	_	_	I-Claim
471	considered	_	_	I-Claim
472	as	_	_	I-Claim
473	an	_	_	I-Claim
474	important	_	_	I-Claim
475	alternative	_	_	I-Claim
476	for	_	_	I-Claim
477	standard	_	_	I-Claim
478	first	_	_	I-Claim
479	-	_	_	I-Claim
480	line	_	_	I-Claim
481	chemotherapy	_	_	I-Claim
482	in	_	_	I-Claim
483	patients	_	_	I-Claim
484	with	_	_	I-Claim
485	advanced	_	_	I-Claim
486	ovarian	_	_	I-Claim
487	cancer	_	_	I-Claim
488	.	_	_	I-Claim


0	Anemia	_	_	B-Claim
1	is	_	_	I-Claim
2	an	_	_	I-Claim
3	expected	_	_	I-Claim
4	consequence	_	_	I-Claim
5	of	_	_	I-Claim
6	intensive	_	_	I-Claim
7	chemotherapy	_	_	I-Claim
8	regimens	_	_	I-Claim
9	administered	_	_	I-Claim
10	to	_	_	I-Claim
11	patients	_	_	I-Claim
12	with	_	_	I-Claim
13	acute	_	_	I-Claim
14	leukemia	_	_	I-Claim
15	.	_	_	I-Claim

16	This	_	_	O
17	study	_	_	O
18	was	_	_	O
19	designed	_	_	O
20	to	_	_	O
21	determine	_	_	O
22	whether	_	_	O
23	epoetin	_	_	O
24	alpha	_	_	O
25	would	_	_	O
26	decrease	_	_	O
27	the	_	_	O
28	number	_	_	O
29	of	_	_	O
30	transfusion	_	_	O
31	events	_	_	O
32	and	_	_	O
33	units	_	_	O
34	of	_	_	O
35	packed	_	_	O
36	erythrocytes	_	_	O
37	(	_	_	O
38	PRBCs	_	_	O
39	)	_	_	O
40	transfused	_	_	O
41	,	_	_	O
42	and	_	_	O
43	the	_	_	O
44	secondary	_	_	O
45	objective	_	_	O
46	was	_	_	O
47	to	_	_	O
48	study	_	_	O
49	the	_	_	O
50	effects	_	_	O
51	of	_	_	O
52	epoetin	_	_	O
53	alpha	_	_	O
54	on	_	_	O
55	quality	_	_	O
56	of	_	_	O
57	life	_	_	O
58	(	_	_	O
59	QOL	_	_	O
60	)	_	_	O
61	and	_	_	O
62	complete	_	_	O
63	remission	_	_	O
64	(	_	_	O
65	CR	_	_	O
66	)	_	_	O
67	rates	_	_	O
68	.	_	_	O

69	Patients	_	_	O
70	with	_	_	O
71	acute	_	_	O
72	lymphoblastic	_	_	O
73	leukemia	_	_	O
74	(	_	_	O
75	ALL	_	_	O
76	)	_	_	O
77	,	_	_	O
78	lymphoblastic	_	_	O
79	lymphoma	_	_	O
80	(	_	_	O
81	LL	_	_	O
82	)	_	_	O
83	,	_	_	O
84	or	_	_	O
85	Burkitt	_	_	O
86	lymphoma	_	_	O
87	(	_	_	O
88	BL	_	_	O
89	)	_	_	O
90	who	_	_	O
91	were	_	_	O
92	receiving	_	_	O
93	frontline	_	_	O
94	myelosuppressive	_	_	O
95	chemotherapy	_	_	O
96	were	_	_	O
97	randomized	_	_	O
98	to	_	_	O
99	receive	_	_	O
100	epoetin	_	_	O
101	alpha	_	_	O
102	or	_	_	O
103	no	_	_	O
104	epoetin	_	_	O
105	during	_	_	O
106	the	_	_	O
107	first	_	_	O
108	6	_	_	O
109	cycles	_	_	O
110	of	_	_	O
111	their	_	_	O
112	planned	_	_	O
113	chemotherapy	_	_	O
114	.	_	_	O

115	QOL	_	_	O
116	was	_	_	O
117	assessed	_	_	O
118	by	_	_	O
119	using	_	_	O
120	the	_	_	O
121	Edmonton	_	_	O
122	Symptom	_	_	O
123	Assessment	_	_	O
124	Scale	_	_	O
125	(	_	_	O
126	ESAS	_	_	O
127	)	_	_	O
128	and	_	_	O
129	the	_	_	O
130	Functional	_	_	O
131	Assessment	_	_	O
132	of	_	_	O
133	Cancer	_	_	O
134	Therapy	_	_	O
135	(	_	_	O
136	FACT	_	_	O
137	)	_	_	O
138	-	_	_	O
139	Anemia	_	_	O
140	questionnaires	_	_	O
141	.	_	_	O

142	Fifty	_	_	O
143	-	_	_	O
144	five	_	_	O
145	patients	_	_	O
146	were	_	_	O
147	randomized	_	_	O
148	to	_	_	O
149	receive	_	_	O
150	epoetin	_	_	O
151	alpha	_	_	O
152	,	_	_	O
153	and	_	_	O
154	54	_	_	O
155	patients	_	_	O
156	received	_	_	O
157	no	_	_	O
158	epoetin	_	_	O
159	.	_	_	O

160	Transfusion	_	_	O
161	data	_	_	O
162	were	_	_	O
163	available	_	_	O
164	for	_	_	O
165	79	_	_	O
166	of	_	_	O
167	81	_	_	O
168	evaluable	_	_	O
169	patients	_	_	O
170	(	_	_	O
171	98	_	_	O
172	%	_	_	O
173	)	_	_	O
174	who	_	_	O
175	completed	_	_	O
176	the	_	_	O
177	treatment	_	_	O
178	/	_	_	O
179	observation	_	_	O
180	period	_	_	O
181	.	_	_	O

182	The	_	_	B-Premise
183	trial	_	_	I-Premise
184	was	_	_	I-Premise
185	stopped	_	_	I-Premise
186	early	_	_	I-Premise
187	because	_	_	I-Premise
188	of	_	_	I-Premise
189	poor	_	_	I-Premise
190	accrual	_	_	I-Premise
191	before	_	_	I-Premise
192	the	_	_	I-Premise
193	target	_	_	I-Premise
194	of	_	_	I-Premise
195	123	_	_	I-Premise
196	evaluable	_	_	I-Premise
197	patients	_	_	I-Premise
198	was	_	_	I-Premise
199	met	_	_	I-Premise
200	.	_	_	I-Premise

201	A	_	_	B-Premise
202	mean	_	_	I-Premise
203	of	_	_	I-Premise
204	10	_	_	I-Premise
205	.	_	_	I-Premise

206	6	_	_	I-Premise
207	units	_	_	I-Premise
208	of	_	_	I-Premise
209	PRBCs	_	_	I-Premise
210	over	_	_	I-Premise
211	5	_	_	I-Premise
212	months	_	_	I-Premise
213	were	_	_	I-Premise
214	administered	_	_	I-Premise
215	to	_	_	I-Premise
216	those	_	_	I-Premise
217	who	_	_	I-Premise
218	received	_	_	I-Premise
219	epoetin	_	_	I-Premise
220	alpha	_	_	I-Premise
221	compared	_	_	I-Premise
222	with	_	_	I-Premise
223	13	_	_	I-Premise
224	units	_	_	I-Premise
225	for	_	_	I-Premise
226	those	_	_	I-Premise
227	who	_	_	I-Premise
228	did	_	_	I-Premise
229	not	_	_	I-Premise
230	receive	_	_	I-Premise
231	epoetin	_	_	I-Premise
232	(	_	_	I-Premise
233	P	_	_	I-Premise
234	=	_	_	I-Premise
235	.	_	_	I-Premise

236	04	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	There	_	_	B-Premise
240	was	_	_	I-Premise
241	no	_	_	I-Premise
242	significant	_	_	I-Premise
243	difference	_	_	I-Premise
244	in	_	_	I-Premise
245	QOL	_	_	I-Premise
246	as	_	_	I-Premise
247	assessed	_	_	I-Premise
248	by	_	_	I-Premise
249	the	_	_	I-Premise
250	FACT	_	_	I-Premise
251	-	_	_	I-Premise
252	Anemia	_	_	I-Premise
253	or	_	_	I-Premise
254	ESAS	_	_	I-Premise
255	instruments	_	_	I-Premise
256	.	_	_	I-Premise

257	The	_	_	B-Premise
258	CR	_	_	I-Premise
259	rate	_	_	I-Premise
260	and	_	_	I-Premise
261	the	_	_	I-Premise
262	3	_	_	I-Premise
263	-	_	_	I-Premise
264	year	_	_	I-Premise
265	CR	_	_	I-Premise
266	duration	_	_	I-Premise
267	were	_	_	I-Premise
268	not	_	_	I-Premise
269	affected	_	_	I-Premise
270	adversely	_	_	I-Premise
271	by	_	_	I-Premise
272	use	_	_	I-Premise
273	of	_	_	I-Premise
274	epoetin	_	_	I-Premise
275	alpha	_	_	I-Premise
276	.	_	_	I-Premise

277	Epoetin	_	_	B-Claim
278	alpha	_	_	I-Claim
279	decreased	_	_	I-Claim
280	the	_	_	I-Claim
281	number	_	_	I-Claim
282	of	_	_	I-Claim
283	PRBC	_	_	I-Claim
284	transfusions	_	_	I-Claim
285	and	_	_	I-Claim
286	did	_	_	I-Claim
287	not	_	_	I-Claim
288	appear	_	_	I-Claim
289	to	_	_	I-Claim
290	have	_	_	I-Claim
291	a	_	_	I-Claim
292	negative	_	_	I-Claim
293	impact	_	_	I-Claim
294	on	_	_	I-Claim
295	remission	_	_	I-Claim
296	duration	_	_	I-Claim
297	.	_	_	I-Claim

298	No	_	_	B-Claim
299	difference	_	_	I-Claim
300	in	_	_	I-Claim
301	QOL	_	_	I-Claim
302	was	_	_	I-Claim
303	observed	_	_	I-Claim
304	.	_	_	I-Claim


0	Many	_	_	O
1	patients	_	_	O
2	with	_	_	O
3	cancer	_	_	O
4	experience	_	_	O
5	depression	_	_	O
6	and	_	_	O
7	anxiety	_	_	O
8	,	_	_	O
9	and	_	_	O
10	an	_	_	O
11	associated	_	_	O
12	decrease	_	_	O
13	in	_	_	O
14	quality	_	_	O
15	of	_	_	O
16	life	_	_	O
17	(	_	_	O
18	QOL	_	_	O
19	)	_	_	O
20	during	_	_	O
21	radiation	_	_	O
22	therapy	_	_	O
23	(	_	_	O
24	RT	_	_	O
25	)	_	_	O
26	.	_	_	O

27	The	_	_	O
28	main	_	_	O
29	objective	_	_	O
30	of	_	_	O
31	the	_	_	O
32	study	_	_	O
33	was	_	_	O
34	to	_	_	O
35	determine	_	_	O
36	the	_	_	O
37	benefits	_	_	O
38	of	_	_	O
39	psychosocial	_	_	O
40	interventions	_	_	O
41	for	_	_	O
42	cancer	_	_	O
43	patients	_	_	O
44	who	_	_	O
45	received	_	_	O
46	RT	_	_	O
47	.	_	_	O

48	Patients	_	_	O
49	with	_	_	O
50	cancer	_	_	O
51	(	_	_	O
52	n	_	_	O
53	=	_	_	O
54	178	_	_	O
55	)	_	_	O
56	who	_	_	O
57	agreed	_	_	O
58	to	_	_	O
59	participate	_	_	O
60	in	_	_	O
61	the	_	_	O
62	study	_	_	O
63	were	_	_	O
64	randomized	_	_	O
65	to	_	_	O
66	the	_	_	O
67	intervention	_	_	O
68	arm	_	_	O
69	(	_	_	O
70	n	_	_	O
71	=	_	_	O
72	89	_	_	O
73	)	_	_	O
74	or	_	_	O
75	the	_	_	O
76	control	_	_	O
77	arm	_	_	O
78	(	_	_	O
79	n	_	_	O
80	=	_	_	O
81	89	_	_	O
82	)	_	_	O
83	.	_	_	O

84	Patients	_	_	O
85	in	_	_	O
86	the	_	_	O
87	intervention	_	_	O
88	group	_	_	O
89	received	_	_	O
90	psychosocial	_	_	O
91	care	_	_	O
92	during	_	_	O
93	RT	_	_	O
94	,	_	_	O
95	whereas	_	_	O
96	the	_	_	O
97	control	_	_	O
98	group	_	_	O
99	received	_	_	O
100	RT	_	_	O
101	only	_	_	O
102	.	_	_	O

103	The	_	_	O
104	benefits	_	_	O
105	of	_	_	O
106	the	_	_	O
107	intervention	_	_	O
108	were	_	_	O
109	evaluated	_	_	O
110	using	_	_	O
111	the	_	_	O
112	Zung	_	_	O
113	Self	_	_	O
114	-	_	_	O
115	rating	_	_	O
116	Depression	_	_	O
117	Scale	_	_	O
118	(	_	_	O
119	SDS	_	_	O
120	)	_	_	O
121	to	_	_	O
122	measure	_	_	O
123	depression	_	_	O
124	,	_	_	O
125	the	_	_	O
126	Self	_	_	O
127	-	_	_	O
128	rating	_	_	O
129	Anxiety	_	_	O
130	Scale	_	_	O
131	(	_	_	O
132	SAS	_	_	O
133	)	_	_	O
134	to	_	_	O
135	assess	_	_	O
136	anxiety	_	_	O
137	,	_	_	O
138	and	_	_	O
139	the	_	_	O
140	European	_	_	O
141	Organization	_	_	O
142	for	_	_	O
143	Research	_	_	O
144	and	_	_	O
145	Treatment	_	_	O
146	of	_	_	O
147	Cancer	_	_	O
148	Quality	_	_	O
149	of	_	_	O
150	Life	_	_	O
151	Questionnaire	_	_	O
152	-	_	_	O
153	Core	_	_	O
154	30	_	_	O
155	(	_	_	O
156	EORTC	_	_	O
157	QLQ	_	_	O
158	-	_	_	O
159	C30	_	_	O
160	)	_	_	O
161	to	_	_	O
162	survey	_	_	O
163	health	_	_	O
164	-	_	_	O
165	related	_	_	O
166	QOL	_	_	O
167	.	_	_	O

168	The	_	_	O
169	association	_	_	O
170	between	_	_	O
171	intervention	_	_	O
172	and	_	_	O
173	survival	_	_	O
174	was	_	_	O
175	also	_	_	O
176	assessed	_	_	O
177	.	_	_	O

178	Patients	_	_	B-Premise
179	randomly	_	_	I-Premise
180	assigned	_	_	I-Premise
181	to	_	_	I-Premise
182	the	_	_	I-Premise
183	intervention	_	_	I-Premise
184	arm	_	_	I-Premise
185	showed	_	_	I-Premise
186	significant	_	_	I-Premise
187	improvements	_	_	I-Premise
188	on	_	_	I-Premise
189	symptoms	_	_	I-Premise
190	of	_	_	I-Premise
191	depression	_	_	I-Premise
192	(	_	_	I-Premise
193	p	_	_	I-Premise
194	<	_	_	I-Premise
195	0	_	_	I-Premise
196	.	_	_	I-Premise

197	05	_	_	I-Premise
198	)	_	_	I-Premise
199	and	_	_	I-Premise
200	anxiety	_	_	I-Premise
201	(	_	_	I-Premise
202	p	_	_	I-Premise
203	<	_	_	I-Premise
204	0	_	_	I-Premise
205	.	_	_	I-Premise

206	05	_	_	I-Premise
207	)	_	_	I-Premise
208	,	_	_	I-Premise
209	health	_	_	I-Premise
210	-	_	_	I-Premise
211	related	_	_	I-Premise
212	QOL	_	_	I-Premise
213	(	_	_	I-Premise
214	p	_	_	I-Premise
215	<	_	_	I-Premise
216	0	_	_	I-Premise
217	.	_	_	I-Premise

218	05	_	_	I-Premise
219	)	_	_	I-Premise
220	(	_	_	I-Premise
221	i	_	_	I-Premise
222	.	_	_	I-Premise

223	e	_	_	I-Premise
224	.	_	_	I-Premise

225	better	_	_	I-Premise
226	global	_	_	I-Premise
227	health	_	_	I-Premise
228	status	_	_	I-Premise
229	,	_	_	I-Premise
230	and	_	_	I-Premise
231	physical	_	_	I-Premise
232	and	_	_	I-Premise
233	emotional	_	_	I-Premise
234	functioning	_	_	I-Premise
235	,	_	_	I-Premise
236	and	_	_	I-Premise
237	less	_	_	I-Premise
238	insomnia	_	_	I-Premise
239	)	_	_	I-Premise
240	when	_	_	I-Premise
241	compared	_	_	I-Premise
242	with	_	_	I-Premise
243	controls	_	_	I-Premise
244	.	_	_	I-Premise

245	In	_	_	B-Claim
246	the	_	_	I-Claim
247	subset	_	_	I-Claim
248	analysis	_	_	I-Claim
249	,	_	_	I-Claim
250	female	_	_	I-Claim
251	patients	_	_	I-Claim
252	,	_	_	I-Claim
253	those	_	_	I-Claim
254	that	_	_	I-Claim
255	received	_	_	I-Claim
256	high	_	_	I-Claim
257	dose	_	_	I-Claim
258	irradiation	_	_	I-Claim
259	,	_	_	I-Claim
260	and	_	_	I-Claim
261	those	_	_	I-Claim
262	that	_	_	I-Claim
263	underwent	_	_	I-Claim
264	adjuvant	_	_	I-Claim
265	chemotherapy	_	_	I-Claim
266	could	_	_	I-Claim
267	benefit	_	_	I-Claim
268	more	_	_	I-Claim
269	from	_	_	I-Claim
270	psychosocial	_	_	I-Claim
271	intervention	_	_	I-Claim
272	.	_	_	I-Claim

273	There	_	_	B-Premise
274	was	_	_	I-Premise
275	no	_	_	I-Premise
276	difference	_	_	I-Premise
277	between	_	_	I-Premise
278	the	_	_	I-Premise
279	two	_	_	I-Premise
280	groups	_	_	I-Premise
281	in	_	_	I-Premise
282	disease	_	_	I-Premise
283	-	_	_	I-Premise
284	free	_	_	I-Premise
285	survival	_	_	I-Premise
286	(	_	_	I-Premise
287	DFS	_	_	I-Premise
288	)	_	_	I-Premise
289	(	_	_	I-Premise
290	2	_	_	I-Premise
291	-	_	_	I-Premise
292	year	_	_	I-Premise
293	DFS	_	_	I-Premise
294	79	_	_	I-Premise
295	.	_	_	I-Premise

296	8	_	_	I-Premise
297	%	_	_	I-Premise
298	in	_	_	I-Premise
299	the	_	_	I-Premise
300	intervention	_	_	I-Premise
301	arm	_	_	I-Premise
302	and	_	_	I-Premise
303	76	_	_	I-Premise
304	.	_	_	I-Premise

305	4	_	_	I-Premise
306	%	_	_	I-Premise
307	in	_	_	I-Premise
308	the	_	_	I-Premise
309	control	_	_	I-Premise
310	arm	_	_	I-Premise
311	;	_	_	I-Premise
312	p	_	_	I-Premise
313	=	_	_	I-Premise
314	0	_	_	I-Premise
315	.	_	_	I-Premise

316	527	_	_	I-Premise
317	)	_	_	I-Premise
318	and	_	_	I-Premise
319	overall	_	_	I-Premise
320	survival	_	_	I-Premise
321	(	_	_	I-Premise
322	OS	_	_	I-Premise
323	)	_	_	I-Premise
324	(	_	_	I-Premise
325	2	_	_	I-Premise
326	-	_	_	I-Premise
327	year	_	_	I-Premise
328	OS	_	_	I-Premise
329	83	_	_	I-Premise
330	.	_	_	I-Premise

331	1	_	_	I-Premise
332	%	_	_	I-Premise
333	in	_	_	I-Premise
334	the	_	_	I-Premise
335	intervention	_	_	I-Premise
336	arm	_	_	I-Premise
337	and	_	_	I-Premise
338	84	_	_	I-Premise
339	.	_	_	I-Premise

340	3	_	_	I-Premise
341	%	_	_	I-Premise
342	in	_	_	I-Premise
343	the	_	_	I-Premise
344	control	_	_	I-Premise
345	arm	_	_	I-Premise
346	;	_	_	I-Premise
347	p	_	_	I-Premise
348	=	_	_	I-Premise
349	0	_	_	I-Premise
350	.	_	_	I-Premise

351	925	_	_	I-Premise
352	)	_	_	I-Premise
353	.	_	_	I-Premise

354	Psychosocial	_	_	B-Claim
355	intervention	_	_	I-Claim
356	is	_	_	I-Claim
357	a	_	_	I-Claim
358	cost	_	_	I-Claim
359	-	_	_	I-Claim
360	effective	_	_	I-Claim
361	approach	_	_	I-Claim
362	that	_	_	I-Claim
363	can	_	_	I-Claim
364	improve	_	_	I-Claim
365	a	_	_	I-Claim
366	patient	_	_	I-Claim
367	'	_	_	I-Claim
368	s	_	_	I-Claim
369	mood	_	_	I-Claim
370	and	_	_	I-Claim
371	QOL	_	_	I-Claim
372	both	_	_	I-Claim
373	during	_	_	I-Claim
374	and	_	_	I-Claim
375	after	_	_	I-Claim
376	RT	_	_	I-Claim
377	.	_	_	I-Claim

378	However	_	_	B-Claim
379	,	_	_	I-Claim
380	the	_	_	I-Claim
381	intervention	_	_	I-Claim
382	was	_	_	I-Claim
383	not	_	_	I-Claim
384	found	_	_	I-Claim
385	to	_	_	I-Claim
386	reduce	_	_	I-Claim
387	the	_	_	I-Claim
388	risk	_	_	I-Claim
389	of	_	_	I-Claim
390	cancer	_	_	I-Claim
391	recurrence	_	_	I-Claim
392	and	_	_	I-Claim
393	death	_	_	I-Claim
394	.	_	_	I-Claim


0	To	_	_	O
1	examine	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	a	_	_	O
6	progressive	_	_	O
7	upper	_	_	O
8	-	_	_	O
9	body	_	_	O
10	exercise	_	_	O
11	program	_	_	O
12	on	_	_	O
13	lymphedema	_	_	O
14	secondary	_	_	O
15	to	_	_	O
16	breast	_	_	O
17	cancer	_	_	O
18	treatment	_	_	O
19	.	_	_	O

20	Fourteen	_	_	O
21	breast	_	_	O
22	cancer	_	_	O
23	survivors	_	_	O
24	with	_	_	O
25	unilateral	_	_	O
26	upper	_	_	O
27	extremity	_	_	O
28	lymphedema	_	_	O
29	were	_	_	O
30	randomly	_	_	O
31	assigned	_	_	O
32	to	_	_	O
33	an	_	_	O
34	exercise	_	_	O
35	(	_	_	O
36	n	_	_	O
37	=	_	_	O
38	7	_	_	O
39	)	_	_	O
40	or	_	_	O
41	control	_	_	O
42	group	_	_	O
43	(	_	_	O
44	n	_	_	O
45	=	_	_	O
46	7	_	_	O
47	)	_	_	O
48	.	_	_	O

49	The	_	_	O
50	exercise	_	_	O
51	group	_	_	O
52	followed	_	_	O
53	a	_	_	O
54	progressive	_	_	O
55	,	_	_	O
56	8	_	_	O
57	-	_	_	O
58	week	_	_	O
59	upper	_	_	O
60	-	_	_	O
61	body	_	_	O
62	exercise	_	_	O
63	program	_	_	O
64	consisting	_	_	O
65	of	_	_	O
66	resistance	_	_	O
67	training	_	_	O
68	plus	_	_	O
69	aerobic	_	_	O
70	exercise	_	_	O
71	using	_	_	O
72	a	_	_	O
73	Monark	_	_	O
74	Rehab	_	_	O
75	Trainer	_	_	O
76	arm	_	_	O
77	ergometer	_	_	O
78	.	_	_	O

79	Lymphedema	_	_	O
80	was	_	_	O
81	assessed	_	_	O
82	by	_	_	O
83	arm	_	_	O
84	circumference	_	_	O
85	and	_	_	O
86	measurement	_	_	O
87	of	_	_	O
88	arm	_	_	O
89	volume	_	_	O
90	by	_	_	O
91	water	_	_	O
92	displacement	_	_	O
93	.	_	_	O

94	Patients	_	_	O
95	were	_	_	O
96	evaluated	_	_	O
97	on	_	_	O
98	five	_	_	O
99	occasions	_	_	O
100	over	_	_	O
101	the	_	_	O
102	experimental	_	_	O
103	period	_	_	O
104	.	_	_	O

105	The	_	_	O
106	Medical	_	_	O
107	Outcomes	_	_	O
108	Trust	_	_	O
109	Short	_	_	O
110	-	_	_	O
111	Form	_	_	O
112	36	_	_	O
113	Survey	_	_	O
114	was	_	_	O
115	used	_	_	O
116	to	_	_	O
117	measure	_	_	O
118	quality	_	_	O
119	of	_	_	O
120	life	_	_	O
121	before	_	_	O
122	and	_	_	O
123	after	_	_	O
124	the	_	_	O
125	intervention	_	_	O
126	.	_	_	O

127	Significance	_	_	O
128	was	_	_	O
129	set	_	_	O
130	at	_	_	O
131	alpha	_	_	O
132	<	_	_	O
133	or	_	_	O
134	=	_	_	O
135	0	_	_	O
136	.	_	_	O

137	01	_	_	O
138	.	_	_	O

139	No	_	_	B-Premise
140	changes	_	_	I-Premise
141	were	_	_	I-Premise
142	found	_	_	I-Premise
143	in	_	_	I-Premise
144	arm	_	_	I-Premise
145	circumference	_	_	I-Premise
146	or	_	_	I-Premise
147	arm	_	_	I-Premise
148	volume	_	_	I-Premise
149	as	_	_	I-Premise
150	a	_	_	I-Premise
151	result	_	_	I-Premise
152	of	_	_	I-Premise
153	the	_	_	I-Premise
154	exercise	_	_	I-Premise
155	program	_	_	I-Premise
156	.	_	_	I-Premise

157	Three	_	_	B-Premise
158	of	_	_	I-Premise
159	the	_	_	I-Premise
160	quality	_	_	I-Premise
161	-	_	_	I-Premise
162	of	_	_	I-Premise
163	-	_	_	I-Premise
164	life	_	_	I-Premise
165	domains	_	_	I-Premise
166	showed	_	_	I-Premise
167	trends	_	_	I-Premise
168	toward	_	_	I-Premise
169	increases	_	_	I-Premise
170	in	_	_	I-Premise
171	the	_	_	I-Premise
172	exercise	_	_	I-Premise
173	group	_	_	I-Premise
174	:	_	_	I-Premise
175	physical	_	_	I-Premise
176	functioning	_	_	I-Premise
177	(	_	_	I-Premise
178	P	_	_	I-Premise
179	=	_	_	I-Premise
180	.	_	_	I-Premise

181	050	_	_	I-Premise
182	)	_	_	I-Premise
183	,	_	_	I-Premise
184	general	_	_	I-Premise
185	health	_	_	I-Premise
186	(	_	_	I-Premise
187	P	_	_	I-Premise
188	=	_	_	I-Premise
189	.	_	_	I-Premise

190	048	_	_	I-Premise
191	)	_	_	I-Premise
192	,	_	_	I-Premise
193	and	_	_	I-Premise
194	vitality	_	_	I-Premise
195	(	_	_	I-Premise
196	P	_	_	I-Premise
197	=	_	_	I-Premise
198	.	_	_	I-Premise

199	023	_	_	I-Premise
200	)	_	_	I-Premise
201	.	_	_	I-Premise

202	Mental	_	_	B-Premise
203	health	_	_	I-Premise
204	increased	_	_	I-Premise
205	,	_	_	I-Premise
206	although	_	_	I-Premise
207	not	_	_	I-Premise
208	significantly	_	_	I-Premise
209	,	_	_	I-Premise
210	for	_	_	I-Premise
211	all	_	_	I-Premise
212	subjects	_	_	I-Premise
213	(	_	_	I-Premise
214	P	_	_	I-Premise
215	=	_	_	I-Premise
216	.	_	_	I-Premise

217	019	_	_	I-Premise
218	)	_	_	I-Premise
219	.	_	_	I-Premise

220	Arm	_	_	B-Premise
221	volume	_	_	I-Premise
222	measured	_	_	I-Premise
223	by	_	_	I-Premise
224	water	_	_	I-Premise
225	displacement	_	_	I-Premise
226	was	_	_	I-Premise
227	correlated	_	_	I-Premise
228	with	_	_	I-Premise
229	calculated	_	_	I-Premise
230	arm	_	_	I-Premise
231	volume	_	_	I-Premise
232	(	_	_	I-Premise
233	r	_	_	I-Premise
234	=	_	_	I-Premise
235	.	_	_	I-Premise

236	973	_	_	I-Premise
237	,	_	_	I-Premise
238	P	_	_	I-Premise
239	<	_	_	I-Premise
240	.	_	_	I-Premise

241	001	_	_	I-Premise
242	)	_	_	I-Premise
243	,	_	_	I-Premise
244	although	_	_	B-Premise
245	the	_	_	I-Premise
246	exercise	_	_	I-Premise
247	and	_	_	I-Premise
248	control	_	_	I-Premise
249	group	_	_	I-Premise
250	means	_	_	I-Premise
251	were	_	_	I-Premise
252	significantly	_	_	I-Premise
253	different	_	_	I-Premise
254	(	_	_	I-Premise
255	P	_	_	I-Premise
256	<	_	_	I-Premise
257	.	_	_	I-Premise

258	001	_	_	I-Premise
259	)	_	_	I-Premise
260	.	_	_	I-Premise

261	Participation	_	_	B-Claim
262	in	_	_	I-Claim
263	an	_	_	I-Claim
264	upper	_	_	I-Claim
265	-	_	_	I-Claim
266	body	_	_	I-Claim
267	exercise	_	_	I-Claim
268	program	_	_	I-Claim
269	caused	_	_	I-Claim
270	no	_	_	I-Claim
271	changes	_	_	I-Claim
272	in	_	_	I-Claim
273	arm	_	_	I-Claim
274	circumference	_	_	I-Claim
275	or	_	_	I-Claim
276	arm	_	_	I-Claim
277	volume	_	_	I-Claim
278	in	_	_	I-Claim
279	women	_	_	I-Claim
280	with	_	_	I-Claim
281	lymphedema	_	_	I-Claim
282	after	_	_	I-Claim
283	breast	_	_	I-Claim
284	cancer	_	_	I-Claim
285	,	_	_	I-Claim
286	and	_	_	I-Claim
287	they	_	_	I-Claim
288	may	_	_	I-Claim
289	have	_	_	I-Claim
290	experienced	_	_	I-Claim
291	an	_	_	I-Claim
292	increase	_	_	I-Claim
293	in	_	_	I-Claim
294	quality	_	_	I-Claim
295	of	_	_	I-Claim
296	life	_	_	I-Claim
297	.	_	_	I-Claim

298	Additional	_	_	B-Claim
299	studies	_	_	I-Claim
300	should	_	_	I-Claim
301	be	_	_	I-Claim
302	done	_	_	I-Claim
303	in	_	_	I-Claim
304	this	_	_	I-Claim
305	area	_	_	I-Claim
306	to	_	_	I-Claim
307	determine	_	_	I-Claim
308	the	_	_	I-Claim
309	optimum	_	_	I-Claim
310	training	_	_	I-Claim
311	program	_	_	I-Claim
312	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	article	_	_	O
5	is	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	quality	_	_	O
9	of	_	_	O
10	life	_	_	O
11	(	_	_	O
12	QOL	_	_	O
13	)	_	_	O
14	and	_	_	O
15	menopausal	_	_	O
16	symptoms	_	_	O
17	among	_	_	O
18	premenopausal	_	_	O
19	patients	_	_	O
20	with	_	_	O
21	lymph	_	_	O
22	node	_	_	O
23	-	_	_	O
24	negative	_	_	O
25	breast	_	_	O
26	cancer	_	_	O
27	receiving	_	_	O
28	chemotherapy	_	_	O
29	,	_	_	O
30	goserelin	_	_	O
31	,	_	_	O
32	or	_	_	O
33	their	_	_	O
34	sequential	_	_	O
35	combination	_	_	O
36	,	_	_	O
37	and	_	_	O
38	to	_	_	O
39	investigate	_	_	O
40	differential	_	_	O
41	effects	_	_	O
42	by	_	_	O
43	age	_	_	O
44	.	_	_	O

45	We	_	_	O
46	evaluated	_	_	O
47	QOL	_	_	O
48	data	_	_	O
49	from	_	_	O
50	874	_	_	O
51	pre	_	_	O
52	-	_	_	O
53	and	_	_	O
54	perimenopausal	_	_	O
55	women	_	_	O
56	with	_	_	O
57	lymph	_	_	O
58	node	_	_	O
59	-	_	_	O
60	negative	_	_	O
61	breast	_	_	O
62	cancer	_	_	O
63	who	_	_	O
64	were	_	_	O
65	randomly	_	_	O
66	assigned	_	_	O
67	to	_	_	O
68	receive	_	_	O
69	six	_	_	O
70	courses	_	_	O
71	of	_	_	O
72	classical	_	_	O
73	cyclophosphamide	_	_	O
74	,	_	_	O
75	methotrexate	_	_	O
76	,	_	_	O
77	and	_	_	O
78	fluorouracil	_	_	O
79	(	_	_	O
80	CMF	_	_	O
81	)	_	_	O
82	chemotherapy	_	_	O
83	,	_	_	O
84	ovarian	_	_	O
85	suppression	_	_	O
86	with	_	_	O
87	goserelin	_	_	O
88	for	_	_	O
89	24	_	_	O
90	months	_	_	O
91	,	_	_	O
92	or	_	_	O
93	six	_	_	O
94	courses	_	_	O
95	of	_	_	O
96	classical	_	_	O
97	CMF	_	_	O
98	followed	_	_	O
99	by	_	_	O
100	18	_	_	O
101	months	_	_	O
102	of	_	_	O
103	goserelin	_	_	O
104	.	_	_	O

105	We	_	_	O
106	report	_	_	O
107	QOL	_	_	O
108	data	_	_	O
109	collected	_	_	O
110	during	_	_	O
111	3	_	_	O
112	years	_	_	O
113	after	_	_	O
114	random	_	_	O
115	assignment	_	_	O
116	in	_	_	O
117	patients	_	_	O
118	without	_	_	O
119	disease	_	_	O
120	recurrence	_	_	O
121	.	_	_	O

122	Overall	_	_	B-Premise
123	,	_	_	I-Premise
124	patients	_	_	I-Premise
125	receiving	_	_	I-Premise
126	goserelin	_	_	I-Premise
127	alone	_	_	I-Premise
128	showed	_	_	I-Premise
129	a	_	_	I-Premise
130	marked	_	_	I-Premise
131	improvement	_	_	I-Premise
132	or	_	_	I-Premise
133	less	_	_	I-Premise
134	deterioration	_	_	I-Premise
135	in	_	_	I-Premise
136	QOL	_	_	I-Premise
137	measures	_	_	I-Premise
138	over	_	_	I-Premise
139	the	_	_	I-Premise
140	first	_	_	I-Premise
141	6	_	_	I-Premise
142	months	_	_	I-Premise
143	than	_	_	I-Premise
144	those	_	_	I-Premise
145	patients	_	_	I-Premise
146	treated	_	_	I-Premise
147	with	_	_	I-Premise
148	CMF	_	_	I-Premise
149	.	_	_	I-Premise

150	There	_	_	B-Premise
151	were	_	_	I-Premise
152	no	_	_	I-Premise
153	differences	_	_	I-Premise
154	at	_	_	I-Premise
155	3	_	_	I-Premise
156	years	_	_	I-Premise
157	after	_	_	I-Premise
158	random	_	_	I-Premise
159	assignment	_	_	I-Premise
160	according	_	_	I-Premise
161	to	_	_	I-Premise
162	treatment	_	_	I-Premise
163	except	_	_	I-Premise
164	for	_	_	I-Premise
165	hot	_	_	I-Premise
166	flashes	_	_	I-Premise
167	.	_	_	I-Premise

168	As	_	_	B-Premise
169	reflected	_	_	I-Premise
170	in	_	_	I-Premise
171	the	_	_	I-Premise
172	hot	_	_	I-Premise
173	flashes	_	_	I-Premise
174	scores	_	_	I-Premise
175	,	_	_	I-Premise
176	patients	_	_	I-Premise
177	in	_	_	I-Premise
178	all	_	_	I-Premise
179	three	_	_	I-Premise
180	treatment	_	_	I-Premise
181	groups	_	_	I-Premise
182	experienced	_	_	I-Premise
183	induced	_	_	I-Premise
184	amenorrhea	_	_	I-Premise
185	,	_	_	I-Premise
186	but	_	_	B-Premise
187	the	_	_	I-Premise
188	onset	_	_	I-Premise
189	of	_	_	I-Premise
190	ovarian	_	_	I-Premise
191	function	_	_	I-Premise
192	suppression	_	_	I-Premise
193	was	_	_	I-Premise
194	slightly	_	_	I-Premise
195	delayed	_	_	I-Premise
196	for	_	_	I-Premise
197	patients	_	_	I-Premise
198	receiving	_	_	I-Premise
199	chemotherapy	_	_	I-Premise
200	.	_	_	I-Premise

201	Younger	_	_	B-Premise
202	patients	_	_	I-Premise
203	(	_	_	I-Premise
204	<	_	_	I-Premise
205	40	_	_	I-Premise
206	years	_	_	I-Premise
207	)	_	_	I-Premise
208	who	_	_	I-Premise
209	received	_	_	I-Premise
210	goserelin	_	_	I-Premise
211	alone	_	_	I-Premise
212	returned	_	_	I-Premise
213	to	_	_	I-Premise
214	their	_	_	I-Premise
215	premenopausal	_	_	I-Premise
216	status	_	_	I-Premise
217	at	_	_	I-Premise
218	6	_	_	I-Premise
219	months	_	_	I-Premise
220	after	_	_	I-Premise
221	the	_	_	I-Premise
222	cessation	_	_	I-Premise
223	of	_	_	I-Premise
224	therapy	_	_	I-Premise
225	,	_	_	I-Premise
226	while	_	_	I-Premise
227	those	_	_	I-Premise
228	who	_	_	I-Premise
229	received	_	_	I-Premise
230	CMF	_	_	I-Premise
231	showed	_	_	I-Premise
232	marginal	_	_	I-Premise
233	changes	_	_	I-Premise
234	from	_	_	I-Premise
235	their	_	_	I-Premise
236	baseline	_	_	I-Premise
237	hot	_	_	I-Premise
238	flashes	_	_	I-Premise
239	scores	_	_	I-Premise
240	.	_	_	I-Premise

241	Age	_	_	B-Claim
242	-	_	_	I-Claim
243	adjusted	_	_	I-Claim
244	risk	_	_	I-Claim
245	profiles	_	_	I-Claim
246	that	_	_	I-Claim
247	consider	_	_	I-Claim
248	patient	_	_	I-Claim
249	-	_	_	I-Claim
250	reported	_	_	I-Claim
251	outcomes	_	_	I-Claim
252	enable	_	_	I-Claim
253	patients	_	_	I-Claim
254	to	_	_	I-Claim
255	adapt	_	_	I-Claim
256	to	_	_	I-Claim
257	their	_	_	I-Claim
258	disease	_	_	I-Claim
259	and	_	_	I-Claim
260	treatment	_	_	I-Claim
261	,	_	_	I-Claim
262	such	_	_	I-Claim
263	as	_	_	I-Claim
264	considering	_	_	I-Claim
265	the	_	_	I-Claim
266	trade	_	_	I-Claim
267	-	_	_	I-Claim
268	offs	_	_	I-Claim
269	between	_	_	I-Claim
270	delayed	_	_	I-Claim
271	endocrine	_	_	I-Claim
272	symptoms	_	_	I-Claim
273	,	_	_	I-Claim
274	but	_	_	I-Claim
275	higher	_	_	I-Claim
276	risk	_	_	I-Claim
277	of	_	_	I-Claim
278	permanent	_	_	I-Claim
279	menopause	_	_	I-Claim
280	with	_	_	I-Claim
281	chemotherapy	_	_	I-Claim
282	,	_	_	I-Claim
283	and	_	_	I-Claim
284	immediate	_	_	I-Claim
285	but	_	_	I-Claim
286	reversible	_	_	I-Claim
287	endocrine	_	_	I-Claim
288	symptoms	_	_	I-Claim
289	with	_	_	I-Claim
290	goserelin	_	_	I-Claim
291	,	_	_	I-Claim
292	in	_	_	I-Claim
293	younger	_	_	I-Claim
294	premenopausal	_	_	I-Claim
295	patients	_	_	I-Claim
296	.	_	_	I-Claim


0	To	_	_	O
1	describe	_	_	O
2	the	_	_	O
3	Food	_	_	O
4	and	_	_	O
5	Drug	_	_	O
6	Administration	_	_	O
7	(	_	_	O
8	FDA	_	_	O
9	)	_	_	O
10	review	_	_	O
11	and	_	_	O
12	approval	_	_	O
13	of	_	_	O
14	erlotinib	_	_	O
15	(	_	_	O
16	Tarceva	_	_	O
17	,	_	_	O
18	OSI	_	_	O
19	Pharmaceuticals	_	_	O
20	,	_	_	O
21	Melville	_	_	O
22	,	_	_	O
23	NY	_	_	O
24	)	_	_	O
25	for	_	_	O
26	treatment	_	_	O
27	of	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	locally	_	_	O
31	advanced	_	_	O
32	or	_	_	O
33	metastatic	_	_	O
34	non	_	_	O
35	-	_	_	O
36	small	_	_	O
37	cell	_	_	O
38	lung	_	_	O
39	cancer	_	_	O
40	(	_	_	O
41	NSCLC	_	_	O
42	)	_	_	O
43	after	_	_	O
44	failure	_	_	O
45	of	_	_	O
46	at	_	_	O
47	least	_	_	O
48	one	_	_	O
49	prior	_	_	O
50	chemotherapy	_	_	O
51	regimen	_	_	O
52	.	_	_	O

53	The	_	_	O
54	FDA	_	_	O
55	reviewed	_	_	O
56	raw	_	_	O
57	data	_	_	O
58	in	_	_	O
59	electronic	_	_	O
60	format	_	_	O
61	from	_	_	O
62	a	_	_	O
63	randomized	_	_	O
64	controlled	_	_	O
65	clinical	_	_	O
66	trial	_	_	O
67	comparing	_	_	O
68	erlotinib	_	_	O
69	with	_	_	O
70	placebo	_	_	O
71	in	_	_	O
72	patients	_	_	O
73	with	_	_	O
74	locally	_	_	O
75	advanced	_	_	O
76	or	_	_	O
77	metastatic	_	_	O
78	NSCLC	_	_	O
79	after	_	_	O
80	failure	_	_	O
81	of	_	_	O
82	at	_	_	O
83	least	_	_	O
84	one	_	_	O
85	prior	_	_	O
86	chemotherapy	_	_	O
87	regimen	_	_	O
88	.	_	_	O

89	Patients	_	_	O
90	were	_	_	O
91	randomized	_	_	O
92	in	_	_	O
93	a	_	_	O
94	2	_	_	O
95	:	_	_	O
96	1	_	_	O
97	ratio	_	_	O
98	(	_	_	O
99	erlotinib	_	_	O
100	,	_	_	O
101	n	_	_	O
102	=	_	_	O
103	488	_	_	O
104	and	_	_	O
105	placebo	_	_	O
106	,	_	_	O
107	n	_	_	O
108	=	_	_	O
109	243	_	_	O
110	)	_	_	O
111	.	_	_	O

112	Erlotinib	_	_	B-Claim
113	was	_	_	I-Claim
114	superior	_	_	I-Claim
115	to	_	_	I-Claim
116	placebo	_	_	I-Claim
117	for	_	_	I-Claim
118	survival	_	_	I-Claim
119	,	_	_	I-Claim
120	progression	_	_	I-Claim
121	-	_	_	I-Claim
122	free	_	_	I-Claim
123	survival	_	_	I-Claim
124	,	_	_	I-Claim
125	and	_	_	I-Claim
126	tumor	_	_	I-Claim
127	response	_	_	I-Claim
128	rate	_	_	I-Claim
129	.	_	_	I-Claim

130	Exploratory	_	_	B-Claim
131	analyses	_	_	I-Claim
132	indicate	_	_	I-Claim
133	that	_	_	I-Claim
134	epidermal	_	_	I-Claim
135	growth	_	_	I-Claim
136	factor	_	_	I-Claim
137	receptor	_	_	I-Claim
138	status	_	_	I-Claim
139	may	_	_	I-Claim
140	be	_	_	I-Claim
141	an	_	_	I-Claim
142	important	_	_	I-Claim
143	predictor	_	_	I-Claim
144	of	_	_	I-Claim
145	the	_	_	I-Claim
146	erlotinib	_	_	I-Claim
147	survival	_	_	I-Claim
148	effect	_	_	I-Claim
149	.	_	_	I-Claim

150	Rash	_	_	B-Premise
151	(	_	_	I-Premise
152	75	_	_	I-Premise
153	%	_	_	I-Premise
154	versus	_	_	I-Premise
155	17	_	_	I-Premise
156	%	_	_	I-Premise
157	)	_	_	I-Premise
158	and	_	_	I-Premise
159	diarrhea	_	_	I-Premise
160	(	_	_	I-Premise
161	54	_	_	I-Premise
162	%	_	_	I-Premise
163	versus	_	_	I-Premise
164	18	_	_	I-Premise
165	%	_	_	I-Premise
166	)	_	_	I-Premise
167	in	_	_	I-Premise
168	the	_	_	I-Premise
169	erlotnib	_	_	I-Premise
170	and	_	_	I-Premise
171	placebo	_	_	I-Premise
172	group	_	_	I-Premise
173	respectively	_	_	I-Premise
174	were	_	_	I-Premise
175	the	_	_	I-Premise
176	most	_	_	I-Premise
177	common	_	_	I-Premise
178	adverse	_	_	I-Premise
179	events	_	_	I-Premise
180	.	_	_	I-Premise

181	Severe	_	_	B-Premise
182	rash	_	_	I-Premise
183	occurred	_	_	I-Premise
184	in	_	_	I-Premise
185	9	_	_	I-Premise
186	%	_	_	I-Premise
187	and	_	_	I-Premise
188	severe	_	_	I-Premise
189	diarrhea	_	_	I-Premise
190	in	_	_	I-Premise
191	6	_	_	I-Premise
192	%	_	_	I-Premise
193	of	_	_	I-Premise
194	erlotinib	_	_	I-Premise
195	-	_	_	I-Premise
196	treated	_	_	I-Premise
197	patients	_	_	I-Premise
198	and	_	_	I-Premise
199	each	_	_	I-Premise
200	resulted	_	_	I-Premise
201	in	_	_	I-Premise
202	study	_	_	I-Premise
203	discontinuation	_	_	I-Premise
204	in	_	_	I-Premise
205	1	_	_	I-Premise
206	%	_	_	I-Premise
207	of	_	_	I-Premise
208	patients	_	_	I-Premise
209	.	_	_	I-Premise

210	Dose	_	_	B-Premise
211	reductions	_	_	I-Premise
212	were	_	_	I-Premise
213	required	_	_	I-Premise
214	for	_	_	I-Premise
215	10	_	_	I-Premise
216	%	_	_	I-Premise
217	of	_	_	I-Premise
218	patients	_	_	I-Premise
219	with	_	_	I-Premise
220	rash	_	_	I-Premise
221	and	_	_	I-Premise
222	4	_	_	I-Premise
223	%	_	_	I-Premise
224	of	_	_	I-Premise
225	patients	_	_	I-Premise
226	with	_	_	I-Premise
227	diarrhea	_	_	I-Premise
228	.	_	_	I-Premise

229	On	_	_	O
230	November	_	_	O
231	18	_	_	O
232	,	_	_	O
233	2004	_	_	O
234	,	_	_	O
235	the	_	_	O
236	FDA	_	_	O
237	granted	_	_	O
238	erlotinib	_	_	O
239	regular	_	_	O
240	approval	_	_	O
241	for	_	_	O
242	treatment	_	_	O
243	of	_	_	O
244	patients	_	_	O
245	with	_	_	O
246	locally	_	_	O
247	advanced	_	_	O
248	or	_	_	O
249	metastatic	_	_	O
250	NSCLC	_	_	O
251	after	_	_	O
252	failure	_	_	O
253	of	_	_	O
254	at	_	_	O
255	least	_	_	O
256	one	_	_	O
257	prior	_	_	O
258	chemotherapy	_	_	O
259	regimen	_	_	O
260	.	_	_	O

261	The	_	_	O
262	applicant	_	_	O
263	has	_	_	O
264	committed	_	_	O
265	to	_	_	O
266	conduct	_	_	O
267	post	_	_	O
268	-	_	_	O
269	marketing	_	_	O
270	clinical	_	_	O
271	trials	_	_	O
272	to	_	_	O
273	assess	_	_	O
274	further	_	_	O
275	the	_	_	O
276	effect	_	_	O
277	of	_	_	O
278	epidermal	_	_	O
279	growth	_	_	O
280	factor	_	_	O
281	receptor	_	_	O
282	expression	_	_	O
283	,	_	_	O
284	measured	_	_	O
285	with	_	_	O
286	immunohistochemical	_	_	O
287	staining	_	_	O
288	,	_	_	O
289	on	_	_	O
290	erlotinib	_	_	O
291	treatment	_	_	O
292	effect	_	_	O
293	.	_	_	O


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	the	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	clinical	_	_	O
9	outcomes	_	_	O
10	and	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	in	_	_	O
15	patients	_	_	O
16	undergoing	_	_	O
17	surgery	_	_	O
18	for	_	_	O
19	pilonidal	_	_	O
20	disease	_	_	O
21	with	_	_	O
22	unroofing	_	_	O
23	and	_	_	O
24	marsupialization	_	_	O
25	(	_	_	O
26	UM	_	_	O
27	)	_	_	O
28	or	_	_	O
29	rhomboid	_	_	O
30	excision	_	_	O
31	and	_	_	O
32	Limberg	_	_	O
33	flap	_	_	O
34	(	_	_	O
35	RELP	_	_	O
36	)	_	_	O
37	procedures	_	_	O
38	.	_	_	O

39	One	_	_	O
40	hundred	_	_	O
41	forty	_	_	O
42	consecutive	_	_	O
43	patients	_	_	O
44	with	_	_	O
45	pilonidal	_	_	O
46	sinus	_	_	O
47	were	_	_	O
48	randomly	_	_	O
49	assigned	_	_	O
50	to	_	_	O
51	receive	_	_	O
52	either	_	_	O
53	UM	_	_	O
54	or	_	_	O
55	RELP	_	_	O
56	procedures	_	_	O
57	.	_	_	O

58	A	_	_	O
59	specifically	_	_	O
60	designed	_	_	O
61	questionnaire	_	_	O
62	was	_	_	O
63	administered	_	_	O
64	at	_	_	O
65	three	_	_	O
66	months	_	_	O
67	to	_	_	O
68	assess	_	_	O
69	time	_	_	O
70	from	_	_	O
71	the	_	_	O
72	operation	_	_	O
73	until	_	_	O
74	the	_	_	O
75	patient	_	_	O
76	was	_	_	O
77	able	_	_	O
78	to	_	_	O
79	walk	_	_	O
80	,	_	_	O
81	return	_	_	O
82	to	_	_	O
83	daily	_	_	O
84	activities	_	_	O
85	,	_	_	O
86	or	_	_	O
87	sit	_	_	O
88	without	_	_	O
89	pain	_	_	O
90	,	_	_	O
91	time	_	_	O
92	to	_	_	O
93	return	_	_	O
94	to	_	_	O
95	work	_	_	O
96	or	_	_	O
97	school	_	_	O
98	,	_	_	O
99	and	_	_	O
100	time	_	_	O
101	to	_	_	O
102	healing	_	_	O
103	.	_	_	O

104	Postoperative	_	_	O
105	pain	_	_	O
106	was	_	_	O
107	assessed	_	_	O
108	with	_	_	O
109	a	_	_	O
110	visual	_	_	O
111	analog	_	_	O
112	scale	_	_	O
113	and	_	_	O
114	the	_	_	O
115	McGill	_	_	O
116	Pain	_	_	O
117	Questionnaire	_	_	O
118	.	_	_	O

119	Patients	_	_	O
120	'	_	_	O
121	quality	_	_	O
122	of	_	_	O
123	life	_	_	O
124	was	_	_	O
125	evaluated	_	_	O
126	with	_	_	O
127	the	_	_	O
128	Cardiff	_	_	O
129	Wound	_	_	O
130	Impact	_	_	O
131	Schedule	_	_	O
132	(	_	_	O
133	CWIS	_	_	O
134	)	_	_	O
135	.	_	_	O

136	Questionnaires	_	_	O
137	were	_	_	O
138	administered	_	_	O
139	by	_	_	O
140	a	_	_	O
141	clinician	_	_	O
142	blinded	_	_	O
143	to	_	_	O
144	treatment	_	_	O
145	.	_	_	O

146	Compared	_	_	B-Premise
147	with	_	_	I-Premise
148	RELP	_	_	I-Premise
149	,	_	_	I-Premise
150	patients	_	_	I-Premise
151	receiving	_	_	I-Premise
152	UM	_	_	I-Premise
153	had	_	_	I-Premise
154	significantly	_	_	I-Premise
155	shorter	_	_	I-Premise
156	duration	_	_	I-Premise
157	of	_	_	I-Premise
158	operation	_	_	I-Premise
159	and	_	_	I-Premise
160	hospital	_	_	I-Premise
161	stay	_	_	I-Premise
162	,	_	_	I-Premise
163	shorter	_	_	I-Premise
164	time	_	_	I-Premise
165	periods	_	_	I-Premise
166	to	_	_	I-Premise
167	walk	_	_	I-Premise
168	,	_	_	I-Premise
169	return	_	_	I-Premise
170	to	_	_	I-Premise
171	daily	_	_	I-Premise
172	activities	_	_	I-Premise
173	,	_	_	I-Premise
174	or	_	_	I-Premise
175	sit	_	_	I-Premise
176	without	_	_	I-Premise
177	pain	_	_	I-Premise
178	and	_	_	I-Premise
179	to	_	_	I-Premise
180	return	_	_	I-Premise
181	to	_	_	I-Premise
182	work	_	_	I-Premise
183	or	_	_	I-Premise
184	school	_	_	I-Premise
185	,	_	_	I-Premise
186	and	_	_	I-Premise
187	fewer	_	_	I-Premise
188	complications	_	_	I-Premise
189	.	_	_	I-Premise

190	Time	_	_	B-Premise
191	to	_	_	I-Premise
192	final	_	_	I-Premise
193	healing	_	_	I-Premise
194	was	_	_	I-Premise
195	significantly	_	_	I-Premise
196	shorter	_	_	I-Premise
197	and	_	_	I-Premise
198	quality	_	_	I-Premise
199	of	_	_	I-Premise
200	life	_	_	I-Premise
201	scores	_	_	I-Premise
202	on	_	_	I-Premise
203	the	_	_	I-Premise
204	CWIS	_	_	I-Premise
205	were	_	_	I-Premise
206	higher	_	_	I-Premise
207	in	_	_	I-Premise
208	patients	_	_	I-Premise
209	receiving	_	_	I-Premise
210	RELP	_	_	I-Premise
211	than	_	_	I-Premise
212	in	_	_	I-Premise
213	those	_	_	I-Premise
214	receiving	_	_	I-Premise
215	UM	_	_	I-Premise
216	.	_	_	I-Premise

217	Patients	_	_	B-Premise
218	with	_	_	I-Premise
219	UM	_	_	I-Premise
220	had	_	_	I-Premise
221	lower	_	_	I-Premise
222	levels	_	_	I-Premise
223	of	_	_	I-Premise
224	pain	_	_	I-Premise
225	one	_	_	I-Premise
226	week	_	_	I-Premise
227	after	_	_	I-Premise
228	surgery	_	_	I-Premise
229	.	_	_	I-Premise

230	The	_	_	B-Claim
231	unroofing	_	_	I-Claim
232	and	_	_	I-Claim
233	marsupialization	_	_	I-Claim
234	procedure	_	_	I-Claim
235	provides	_	_	I-Claim
236	more	_	_	I-Claim
237	clinical	_	_	I-Claim
238	benefits	_	_	I-Claim
239	in	_	_	I-Claim
240	the	_	_	I-Claim
241	treatment	_	_	I-Claim
242	of	_	_	I-Claim
243	pilonidal	_	_	I-Claim
244	disease	_	_	I-Claim
245	than	_	_	I-Claim
246	rhomboid	_	_	I-Claim
247	excision	_	_	I-Claim
248	and	_	_	I-Claim
249	Limberg	_	_	I-Claim
250	flap	_	_	I-Claim
251	and	_	_	I-Claim
252	should	_	_	I-Claim
253	be	_	_	I-Claim
254	considered	_	_	I-Claim
255	the	_	_	I-Claim
256	procedure	_	_	I-Claim
257	of	_	_	I-Claim
258	choice	_	_	I-Claim
259	.	_	_	I-Claim

260	However	_	_	B-Claim
261	,	_	_	I-Claim
262	it	_	_	I-Claim
263	may	_	_	I-Claim
264	be	_	_	I-Claim
265	associated	_	_	I-Claim
266	with	_	_	I-Claim
267	more	_	_	I-Claim
268	inconvenience	_	_	I-Claim
269	in	_	_	I-Claim
270	wound	_	_	I-Claim
271	care	_	_	I-Claim
272	and	_	_	I-Claim
273	longer	_	_	I-Claim
274	healing	_	_	I-Claim
275	time	_	_	I-Claim
276	than	_	_	I-Claim
277	rhomboid	_	_	I-Claim
278	excision	_	_	I-Claim
279	and	_	_	I-Claim
280	Lindberg	_	_	I-Claim
281	flap	_	_	I-Claim
282	.	_	_	I-Claim


0	Therapy	_	_	B-Claim
1	of	_	_	I-Claim
2	patients	_	_	I-Claim
3	with	_	_	I-Claim
4	advanced	_	_	I-Claim
5	gastric	_	_	I-Claim
6	or	_	_	I-Claim
7	gastroesophageal	_	_	I-Claim
8	junction	_	_	I-Claim
9	cancer	_	_	I-Claim
10	should	_	_	I-Claim
11	provide	_	_	I-Claim
12	symptom	_	_	I-Claim
13	relief	_	_	I-Claim
14	and	_	_	I-Claim
15	improve	_	_	I-Claim
16	quality	_	_	I-Claim
17	of	_	_	I-Claim
18	life	_	_	I-Claim
19	(	_	_	I-Claim
20	QOL	_	_	I-Claim
21	)	_	_	I-Claim
22	because	_	_	I-Claim
23	most	_	_	I-Claim
24	patients	_	_	I-Claim
25	are	_	_	I-Claim
26	symptomatic	_	_	I-Claim
27	at	_	_	I-Claim
28	baseline	_	_	I-Claim
29	.	_	_	I-Claim

30	Using	_	_	O
31	validated	_	_	O
32	instruments	_	_	O
33	,	_	_	O
34	we	_	_	O
35	prospectively	_	_	O
36	assessed	_	_	O
37	QOL	_	_	O
38	(	_	_	O
39	even	_	_	O
40	after	_	_	O
41	completion	_	_	O
42	of	_	_	O
43	protocol	_	_	O
44	treatment	_	_	O
45	)	_	_	O
46	as	_	_	O
47	one	_	_	O
48	of	_	_	O
49	the	_	_	O
50	secondary	_	_	O
51	end	_	_	O
52	points	_	_	O
53	of	_	_	O
54	the	_	_	O
55	V325	_	_	O
56	phase	_	_	O
57	III	_	_	O
58	trial	_	_	O
59	.	_	_	O

60	Four	_	_	O
61	hundred	_	_	O
62	forty	_	_	O
63	-	_	_	O
64	five	_	_	O
65	patients	_	_	O
66	randomly	_	_	O
67	received	_	_	O
68	either	_	_	O
69	docetaxel	_	_	O
70	75	_	_	O
71	mg	_	_	O
72	/	_	_	O
73	m	_	_	O
74	(	_	_	O
75	2	_	_	O
76	)	_	_	O
77	and	_	_	O
78	cisplatin	_	_	O
79	75	_	_	O
80	mg	_	_	O
81	/	_	_	O
82	m	_	_	O
83	(	_	_	O
84	2	_	_	O
85	)	_	_	O
86	each	_	_	O
87	on	_	_	O
88	day	_	_	O
89	1	_	_	O
90	plus	_	_	O
91	fluorouracil	_	_	O
92	750	_	_	O
93	mg	_	_	O
94	/	_	_	O
95	m	_	_	O
96	(	_	_	O
97	2	_	_	O
98	)	_	_	O
99	/	_	_	O
100	d	_	_	O
101	continuous	_	_	O
102	infusion	_	_	O
103	on	_	_	O
104	days	_	_	O
105	1	_	_	O
106	to	_	_	O
107	5	_	_	O
108	every	_	_	O
109	3	_	_	O
110	weeks	_	_	O
111	(	_	_	O
112	DCF	_	_	O
113	)	_	_	O
114	or	_	_	O
115	cisplatin	_	_	O
116	100	_	_	O
117	mg	_	_	O
118	/	_	_	O
119	m	_	_	O
120	(	_	_	O
121	2	_	_	O
122	)	_	_	O
123	on	_	_	O
124	day	_	_	O
125	1	_	_	O
126	plus	_	_	O
127	fluorouracil	_	_	O
128	1	_	_	O
129	,	_	_	O
130	000	_	_	O
131	mg	_	_	O
132	/	_	_	O
133	m	_	_	O
134	(	_	_	O
135	2	_	_	O
136	)	_	_	O
137	/	_	_	O
138	d	_	_	O
139	continuous	_	_	O
140	infusion	_	_	O
141	on	_	_	O
142	days	_	_	O
143	1	_	_	O
144	to	_	_	O
145	5	_	_	O
146	every	_	_	O
147	4	_	_	O
148	weeks	_	_	O
149	(	_	_	O
150	CF	_	_	O
151	)	_	_	O
152	.	_	_	O

153	The	_	_	O
154	European	_	_	O
155	Organisation	_	_	O
156	for	_	_	O
157	Research	_	_	O
158	and	_	_	O
159	Treatment	_	_	O
160	of	_	_	O
161	Cancer	_	_	O
162	Quality	_	_	O
163	of	_	_	O
164	Life	_	_	O
165	Questionnaire	_	_	O
166	C30	_	_	O
167	(	_	_	O
168	EORTC	_	_	O
169	QLQ	_	_	O
170	-	_	_	O
171	C30	_	_	O
172	)	_	_	O
173	and	_	_	O
174	,	_	_	O
175	where	_	_	O
176	available	_	_	O
177	,	_	_	O
178	the	_	_	O
179	EuroQOL	_	_	O
180	EQ	_	_	O
181	-	_	_	O
182	5D	_	_	O
183	questionnaire	_	_	O
184	were	_	_	O
185	administered	_	_	O
186	every	_	_	O
187	8	_	_	O
188	weeks	_	_	O
189	from	_	_	O
190	baseline	_	_	O
191	until	_	_	O
192	progression	_	_	O
193	and	_	_	O
194	then	_	_	O
195	every	_	_	O
196	3	_	_	O
197	months	_	_	O
198	.	_	_	O

199	Time	_	_	O
200	to	_	_	O
201	definitive	_	_	O
202	deterioration	_	_	O
203	of	_	_	O
204	QOL	_	_	O
205	parameters	_	_	O
206	was	_	_	O
207	analyzed	_	_	O
208	.	_	_	O

209	The	_	_	O
210	proportions	_	_	O
211	of	_	_	O
212	patients	_	_	O
213	having	_	_	O
214	assessable	_	_	O
215	EORTC	_	_	O
216	QLQ	_	_	O
217	-	_	_	O
218	C30	_	_	O
219	and	_	_	O
220	EQ	_	_	O
221	-	_	_	O
222	5D	_	_	O
223	questionnaires	_	_	O
224	at	_	_	O
225	baseline	_	_	O
226	were	_	_	O
227	86	_	_	O
228	.	_	_	O

229	0	_	_	O
230	%	_	_	O
231	and	_	_	O
232	78	_	_	O
233	.	_	_	O

234	7	_	_	O
235	%	_	_	O
236	with	_	_	O
237	DCF	_	_	O
238	,	_	_	O
239	respectively	_	_	O
240	,	_	_	O
241	and	_	_	O
242	89	_	_	O
243	.	_	_	O

244	7	_	_	O
245	%	_	_	O
246	and	_	_	O
247	92	_	_	O
248	.	_	_	O

249	8	_	_	O
250	%	_	_	O
251	with	_	_	O
252	CF	_	_	O
253	,	_	_	O
254	respectively	_	_	O
255	.	_	_	O

256	Time	_	_	B-Premise
257	to	_	_	I-Premise
258	5	_	_	I-Premise
259	%	_	_	I-Premise
260	deterioration	_	_	I-Premise
261	of	_	_	I-Premise
262	global	_	_	I-Premise
263	health	_	_	I-Premise
264	status	_	_	I-Premise
265	(	_	_	I-Premise
266	primary	_	_	I-Premise
267	end	_	_	I-Premise
268	point	_	_	I-Premise
269	)	_	_	I-Premise
270	significantly	_	_	I-Premise
271	favored	_	_	I-Premise
272	DCF	_	_	I-Premise
273	over	_	_	I-Premise
274	CF	_	_	I-Premise
275	(	_	_	I-Premise
276	log	_	_	I-Premise
277	-	_	_	I-Premise
278	rank	_	_	I-Premise
279	test	_	_	I-Premise
280	,	_	_	I-Premise
281	P	_	_	I-Premise
282	=	_	_	I-Premise
283	.	_	_	I-Premise

284	01	_	_	I-Premise
285	)	_	_	I-Premise
286	.	_	_	I-Premise

287	QOL	_	_	B-Premise
288	was	_	_	I-Premise
289	preserved	_	_	I-Premise
290	longer	_	_	I-Premise
291	for	_	_	I-Premise
292	patients	_	_	I-Premise
293	on	_	_	I-Premise
294	DCF	_	_	I-Premise
295	than	_	_	I-Premise
296	those	_	_	I-Premise
297	on	_	_	I-Premise
298	CF	_	_	I-Premise
299	for	_	_	I-Premise
300	all	_	_	I-Premise
301	time	_	_	I-Premise
302	to	_	_	I-Premise
303	deterioration	_	_	I-Premise
304	analyses	_	_	I-Premise
305	,	_	_	I-Premise
306	demonstrating	_	_	I-Premise
307	the	_	_	I-Premise
308	statistical	_	_	I-Premise
309	superiority	_	_	I-Premise
310	of	_	_	I-Premise
311	DCF	_	_	I-Premise
312	compared	_	_	I-Premise
313	with	_	_	I-Premise
314	CF	_	_	I-Premise
315	.	_	_	I-Premise

316	V325	_	_	O
317	represents	_	_	O
318	the	_	_	O
319	largest	_	_	O
320	trial	_	_	O
321	with	_	_	O
322	the	_	_	O
323	longest	_	_	O
324	prospectively	_	_	O
325	controlled	_	_	O
326	evaluations	_	_	O
327	of	_	_	O
328	QOL	_	_	O
329	during	_	_	O
330	protocol	_	_	O
331	chemotherapy	_	_	O
332	and	_	_	O
333	follow	_	_	O
334	-	_	_	O
335	up	_	_	O
336	in	_	_	O
337	patients	_	_	O
338	with	_	_	O
339	advanced	_	_	O
340	gastric	_	_	O
341	or	_	_	O
342	gastroesophageal	_	_	O
343	junction	_	_	O
344	cancer	_	_	O
345	.	_	_	O

346	In	_	_	B-Claim
347	V325	_	_	I-Claim
348	,	_	_	I-Claim
349	advanced	_	_	I-Claim
350	gastric	_	_	I-Claim
351	or	_	_	I-Claim
352	gastroesophageal	_	_	I-Claim
353	junction	_	_	I-Claim
354	cancer	_	_	I-Claim
355	patients	_	_	I-Claim
356	receiving	_	_	I-Claim
357	DCF	_	_	I-Claim
358	not	_	_	I-Claim
359	only	_	_	I-Claim
360	had	_	_	I-Claim
361	statistically	_	_	I-Claim
362	improved	_	_	I-Claim
363	overall	_	_	I-Claim
364	survival	_	_	I-Claim
365	and	_	_	I-Claim
366	time	_	_	I-Claim
367	to	_	_	I-Claim
368	tumor	_	_	I-Claim
369	-	_	_	I-Claim
370	progression	_	_	I-Claim
371	,	_	_	I-Claim
372	but	_	_	I-Claim
373	they	_	_	I-Claim
374	also	_	_	I-Claim
375	had	_	_	I-Claim
376	better	_	_	I-Claim
377	preservation	_	_	I-Claim
378	of	_	_	I-Claim
379	QOL	_	_	I-Claim
380	compared	_	_	I-Claim
381	with	_	_	I-Claim
382	patients	_	_	I-Claim
383	receiving	_	_	I-Claim
384	CF	_	_	I-Claim
385	.	_	_	I-Claim


0	The	_	_	B-Claim
1	combination	_	_	I-Claim
2	of	_	_	I-Claim
3	interferon	_	_	I-Claim
4	alfa	_	_	I-Claim
5	(	_	_	I-Claim
6	IFNalpha	_	_	I-Claim
7	)	_	_	I-Claim
8	and	_	_	I-Claim
9	isotretinoin	_	_	I-Claim
10	has	_	_	I-Claim
11	shown	_	_	I-Claim
12	a	_	_	I-Claim
13	direct	_	_	I-Claim
14	antiproliferative	_	_	I-Claim
15	effect	_	_	I-Claim
16	on	_	_	I-Claim
17	human	_	_	I-Claim
18	melanoma	_	_	I-Claim
19	cell	_	_	I-Claim
20	lines	_	_	I-Claim
21	,	_	_	I-Claim
22	but	_	_	B-Claim
23	it	_	_	I-Claim
24	remained	_	_	I-Claim
25	unclear	_	_	I-Claim
26	whether	_	_	I-Claim
27	this	_	_	I-Claim
28	combination	_	_	I-Claim
29	is	_	_	I-Claim
30	more	_	_	I-Claim
31	effective	_	_	I-Claim
32	than	_	_	I-Claim
33	IFNalpha	_	_	I-Claim
34	alone	_	_	I-Claim
35	in	_	_	I-Claim
36	patients	_	_	I-Claim
37	with	_	_	I-Claim
38	metastatic	_	_	I-Claim
39	melanoma	_	_	I-Claim
40	.	_	_	I-Claim

41	We	_	_	O
42	evaluated	_	_	O
43	safety	_	_	O
44	and	_	_	O
45	efficacy	_	_	O
46	of	_	_	O
47	IFNalpha	_	_	O
48	and	_	_	O
49	isotretinoin	_	_	O
50	compared	_	_	O
51	with	_	_	O
52	IFNalpha	_	_	O
53	alone	_	_	O
54	as	_	_	O
55	adjuvant	_	_	O
56	treatment	_	_	O
57	in	_	_	O
58	patients	_	_	O
59	with	_	_	O
60	primary	_	_	O
61	malignant	_	_	O
62	melanoma	_	_	O
63	stage	_	_	O
64	IIA	_	_	O
65	and	_	_	O
66	IIB	_	_	O
67	.	_	_	O

68	In	_	_	O
69	a	_	_	O
70	prospective	_	_	O
71	,	_	_	O
72	randomized	_	_	O
73	,	_	_	O
74	double	_	_	O
75	-	_	_	O
76	blind	_	_	O
77	,	_	_	O
78	placebo	_	_	O
79	-	_	_	O
80	controlled	_	_	O
81	trial	_	_	O
82	,	_	_	O
83	407	_	_	O
84	melanoma	_	_	O
85	patients	_	_	O
86	in	_	_	O
87	stage	_	_	O
88	IIA	_	_	O
89	(	_	_	O
90	301	_	_	O
91	patients	_	_	O
92	)	_	_	O
93	and	_	_	O
94	IIB	_	_	O
95	(	_	_	O
96	106	_	_	O
97	patients	_	_	O
98	)	_	_	O
99	were	_	_	O
100	randomly	_	_	O
101	assigned	_	_	O
102	to	_	_	O
103	either	_	_	O
104	IFNalpha	_	_	O
105	and	_	_	O
106	isotretinoin	_	_	O
107	(	_	_	O
108	isotretinoin	_	_	O
109	group	_	_	O
110	;	_	_	O
111	206	_	_	O
112	patients	_	_	O
113	)	_	_	O
114	or	_	_	O
115	IFNalpha	_	_	O
116	and	_	_	O
117	placebo	_	_	O
118	(	_	_	O
119	placebo	_	_	O
120	group	_	_	O
121	;	_	_	O
122	201	_	_	O
123	patients	_	_	O
124	)	_	_	O
125	after	_	_	O
126	excision	_	_	O
127	of	_	_	O
128	the	_	_	O
129	primary	_	_	O
130	tumor	_	_	O
131	.	_	_	O

132	IFNalpha	_	_	O
133	was	_	_	O
134	administered	_	_	O
135	three	_	_	O
136	times	_	_	O
137	a	_	_	O
138	week	_	_	O
139	at	_	_	O
140	a	_	_	O
141	dose	_	_	O
142	of	_	_	O
143	3	_	_	O
144	million	_	_	O
145	units	_	_	O
146	subcutaneously	_	_	O
147	for	_	_	O
148	24	_	_	O
149	months	_	_	O
150	.	_	_	O

151	Isotretinoin	_	_	O
152	at	_	_	O
153	a	_	_	O
154	dose	_	_	O
155	of	_	_	O
156	20	_	_	O
157	mg	_	_	O
158	for	_	_	O
159	patients	_	_	O
160	<	_	_	O
161	or	_	_	O
162	=	_	_	O
163	73	_	_	O
164	kg	_	_	O
165	,	_	_	O
166	30	_	_	O
167	mg	_	_	O
168	for	_	_	O
169	patients	_	_	O
170	greater	_	_	O
171	than	_	_	O
172	73	_	_	O
173	kg	_	_	O
174	,	_	_	O
175	or	_	_	O
176	placebo	_	_	O
177	daily	_	_	O
178	for	_	_	O
179	24	_	_	O
180	months	_	_	O
181	.	_	_	O

182	A	_	_	B-Premise
183	scheduled	_	_	I-Premise
184	interim	_	_	I-Premise
185	analysis	_	_	I-Premise
186	revealed	_	_	I-Premise
187	no	_	_	I-Premise
188	significant	_	_	I-Premise
189	differences	_	_	I-Premise
190	in	_	_	I-Premise
191	survival	_	_	I-Premise
192	rates	_	_	I-Premise
193	,	_	_	I-Premise
194	with	_	_	I-Premise
195	the	_	_	I-Premise
196	isotretinoin	_	_	I-Premise
197	group	_	_	I-Premise
198	and	_	_	I-Premise
199	the	_	_	I-Premise
200	placebo	_	_	I-Premise
201	group	_	_	I-Premise
202	showing	_	_	I-Premise
203	5	_	_	I-Premise
204	-	_	_	I-Premise
205	year	_	_	I-Premise
206	disease	_	_	I-Premise
207	-	_	_	I-Premise
208	free	_	_	I-Premise
209	survival	_	_	I-Premise
210	rates	_	_	I-Premise
211	of	_	_	I-Premise
212	55	_	_	I-Premise
213	%	_	_	I-Premise
214	(	_	_	I-Premise
215	95	_	_	I-Premise
216	%	_	_	I-Premise
217	CI	_	_	I-Premise
218	,	_	_	I-Premise
219	46	_	_	I-Premise
220	%	_	_	I-Premise
221	to	_	_	I-Premise
222	65	_	_	I-Premise
223	%	_	_	I-Premise
224	)	_	_	I-Premise
225	and	_	_	I-Premise
226	67	_	_	I-Premise
227	%	_	_	I-Premise
228	(	_	_	I-Premise
229	95	_	_	I-Premise
230	%	_	_	I-Premise
231	CI	_	_	I-Premise
232	,	_	_	I-Premise
233	59	_	_	I-Premise
234	%	_	_	I-Premise
235	to	_	_	I-Premise
236	75	_	_	I-Premise
237	%	_	_	I-Premise
238	)	_	_	I-Premise
239	,	_	_	I-Premise
240	respectively	_	_	I-Premise
241	,	_	_	I-Premise
242	and	_	_	I-Premise
243	overall	_	_	I-Premise
244	5	_	_	I-Premise
245	-	_	_	I-Premise
246	year	_	_	I-Premise
247	survival	_	_	I-Premise
248	rates	_	_	I-Premise
249	of	_	_	I-Premise
250	76	_	_	I-Premise
251	%	_	_	I-Premise
252	(	_	_	I-Premise
253	95	_	_	I-Premise
254	%	_	_	I-Premise
255	CI	_	_	I-Premise
256	,	_	_	I-Premise
257	67	_	_	I-Premise
258	%	_	_	I-Premise
259	to	_	_	I-Premise
260	84	_	_	I-Premise
261	%	_	_	I-Premise
262	)	_	_	I-Premise
263	and	_	_	I-Premise
264	81	_	_	I-Premise
265	%	_	_	I-Premise
266	(	_	_	I-Premise
267	95	_	_	I-Premise
268	%	_	_	I-Premise
269	CI	_	_	I-Premise
270	,	_	_	I-Premise
271	74	_	_	I-Premise
272	%	_	_	I-Premise
273	to	_	_	I-Premise
274	88	_	_	I-Premise
275	%	_	_	I-Premise
276	)	_	_	I-Premise
277	,	_	_	I-Premise
278	respectively	_	_	I-Premise
279	.	_	_	I-Premise

280	The	_	_	O
281	trial	_	_	O
282	was	_	_	O
283	stopped	_	_	O
284	for	_	_	O
285	futility	_	_	O
286	.	_	_	O

287	The	_	_	B-Claim
288	addition	_	_	I-Claim
289	of	_	_	I-Claim
290	isotretinoin	_	_	I-Claim
291	to	_	_	I-Claim
292	an	_	_	I-Claim
293	adjuvant	_	_	I-Claim
294	treatment	_	_	I-Claim
295	of	_	_	I-Claim
296	low	_	_	I-Claim
297	-	_	_	I-Claim
298	dose	_	_	I-Claim
299	IFNalpha	_	_	I-Claim
300	in	_	_	I-Claim
301	patients	_	_	I-Claim
302	with	_	_	I-Claim
303	stage	_	_	I-Claim
304	IIA	_	_	I-Claim
305	and	_	_	I-Claim
306	IIB	_	_	I-Claim
307	melanoma	_	_	I-Claim
308	had	_	_	I-Claim
309	no	_	_	I-Claim
310	significant	_	_	I-Claim
311	effect	_	_	I-Claim
312	on	_	_	I-Claim
313	disease	_	_	I-Claim
314	-	_	_	I-Claim
315	free	_	_	I-Claim
316	or	_	_	I-Claim
317	overall	_	_	I-Claim
318	survival	_	_	I-Claim
319	and	_	_	I-Claim
320	is	_	_	I-Claim
321	therefore	_	_	I-Claim
322	not	_	_	I-Claim
323	recommended	_	_	I-Claim
324	.	_	_	I-Claim


0	Amitriptyline	_	_	B-Claim
1	is	_	_	I-Claim
2	the	_	_	I-Claim
3	most	_	_	I-Claim
4	common	_	_	I-Claim
5	analgesic	_	_	I-Claim
6	adjuvant	_	_	I-Claim
7	used	_	_	I-Claim
8	in	_	_	I-Claim
9	cancer	_	_	I-Claim
10	patients	_	_	I-Claim
11	with	_	_	I-Claim
12	neuropathic	_	_	I-Claim
13	pain	_	_	I-Claim
14	,	_	_	I-Claim
15	even	_	_	O
16	though	_	_	O
17	no	_	_	B-Claim
18	specific	_	_	I-Claim
19	studies	_	_	I-Claim
20	have	_	_	I-Claim
21	demonstrated	_	_	I-Claim
22	a	_	_	I-Claim
23	benefit	_	_	I-Claim
24	.	_	_	I-Claim

25	A	_	_	O
26	randomized	_	_	O
27	placebo	_	_	O
28	-	_	_	O
29	controlled	_	_	O
30	,	_	_	O
31	double	_	_	O
32	-	_	_	O
33	blind	_	_	O
34	crossover	_	_	O
35	study	_	_	O
36	was	_	_	O
37	designed	_	_	O
38	to	_	_	O
39	evidence	_	_	O
40	the	_	_	O
41	effects	_	_	O
42	of	_	_	O
43	amitriptyline	_	_	O
44	in	_	_	O
45	patients	_	_	O
46	with	_	_	O
47	neuropathic	_	_	O
48	cancer	_	_	O
49	pain	_	_	O
50	.	_	_	O

51	Sixteen	_	_	O
52	advanced	_	_	O
53	cancer	_	_	O
54	patients	_	_	O
55	with	_	_	O
56	neuropathic	_	_	O
57	pain	_	_	O
58	on	_	_	O
59	systemic	_	_	O
60	morphine	_	_	O
61	therapy	_	_	O
62	,	_	_	O
63	no	_	_	O
64	longer	_	_	O
65	receiving	_	_	O
66	oncologic	_	_	O
67	treatment	_	_	O
68	,	_	_	O
69	presenting	_	_	O
70	moderate	_	_	O
71	pain	_	_	O
72	(	_	_	O
73	about	_	_	O
74	4	_	_	O
75	or	_	_	O
76	more	_	_	O
77	,	_	_	O
78	but	_	_	O
79	less	_	_	O
80	than	_	_	O
81	7	_	_	O
82	,	_	_	O
83	on	_	_	O
84	a	_	_	O
85	numerical	_	_	O
86	scale	_	_	O
87	of	_	_	O
88	0	_	_	O
89	-	_	_	O
90	10	_	_	O
91	)	_	_	O
92	in	_	_	O
93	the	_	_	O
94	last	_	_	O
95	week	_	_	O
96	,	_	_	O
97	and	_	_	O
98	given	_	_	O
99	a	_	_	O
100	stable	_	_	O
101	morphine	_	_	O
102	dose	_	_	O
103	in	_	_	O
104	the	_	_	O
105	last	_	_	O
106	2	_	_	O
107	days	_	_	O
108	were	_	_	O
109	admitted	_	_	O
110	to	_	_	O
111	the	_	_	O
112	study	_	_	O
113	.	_	_	O

114	During	_	_	O
115	the	_	_	O
116	first	_	_	O
117	week	_	_	O
118	of	_	_	O
119	study	_	_	O
120	,	_	_	O
121	patients	_	_	O
122	were	_	_	O
123	administered	_	_	O
124	25	_	_	O
125	mg	_	_	O
126	of	_	_	O
127	amitriptyline	_	_	O
128	or	_	_	O
129	equivalent	_	_	O
130	drops	_	_	O
131	of	_	_	O
132	placebo	_	_	O
133	at	_	_	O
134	night	_	_	O
135	for	_	_	O
136	3	_	_	O
137	days	_	_	O
138	and	_	_	O
139	50	_	_	O
140	mg	_	_	O
141	for	_	_	O
142	the	_	_	O
143	following	_	_	O
144	4	_	_	O
145	days	_	_	O
146	.	_	_	O

147	Doses	_	_	O
148	for	_	_	O
149	patients	_	_	O
150	aged	_	_	O
151	more	_	_	O
152	than	_	_	O
153	65	_	_	O
154	years	_	_	O
155	were	_	_	O
156	15	_	_	O
157	mg	_	_	O
158	(	_	_	O
159	first	_	_	O
160	3	_	_	O
161	days	_	_	O
162	)	_	_	O
163	and	_	_	O
164	30	_	_	O
165	mg	_	_	O
166	(	_	_	O
167	3	_	_	O
168	days	_	_	O
169	after	_	_	O
170	)	_	_	O
171	.	_	_	O

172	After	_	_	O
173	a	_	_	O
174	week	_	_	O
175	,	_	_	O
176	a	_	_	O
177	crossover	_	_	O
178	took	_	_	O
179	place	_	_	O
180	for	_	_	O
181	the	_	_	O
182	second	_	_	O
183	week	_	_	O
184	,	_	_	O
185	with	_	_	O
186	the	_	_	O
187	other	_	_	O
188	treatment	_	_	O
189	at	_	_	O
190	an	_	_	O
191	inverse	_	_	O
192	sequence	_	_	O
193	.	_	_	O

194	Opioid	_	_	O
195	consumption	_	_	O
196	,	_	_	O
197	pain	_	_	O
198	intensity	_	_	O
199	,	_	_	O
200	symptoms	_	_	O
201	and	_	_	O
202	adverse	_	_	O
203	effects	_	_	O
204	,	_	_	O
205	mood	_	_	O
206	,	_	_	O
207	sleep	_	_	O
208	,	_	_	O
209	patient	_	_	O
210	'	_	_	O
211	s	_	_	O
212	preference	_	_	O
213	,	_	_	O
214	quality	_	_	O
215	of	_	_	O
216	life	_	_	O
217	before	_	_	O
218	starting	_	_	O
219	the	_	_	O
220	study	_	_	O
221	,	_	_	O
222	the	_	_	O
223	first	_	_	O
224	week	_	_	O
225	after	_	_	O
226	and	_	_	O
227	the	_	_	O
228	second	_	_	O
229	week	_	_	O
230	after	_	_	O
231	were	_	_	O
232	recorded	_	_	O
233	.	_	_	O

234	No	_	_	B-Premise
235	significant	_	_	I-Premise
236	benefits	_	_	I-Premise
237	in	_	_	I-Premise
238	analgesia	_	_	I-Premise
239	were	_	_	I-Premise
240	found	_	_	I-Premise
241	in	_	_	I-Premise
242	the	_	_	I-Premise
243	global	_	_	I-Premise
244	pain	_	_	I-Premise
245	intensity	_	_	I-Premise
246	of	_	_	I-Premise
247	the	_	_	I-Premise
248	previous	_	_	I-Premise
249	week	_	_	I-Premise
250	of	_	_	I-Premise
251	treatment	_	_	I-Premise
252	,	_	_	I-Premise
253	the	_	_	I-Premise
254	least	_	_	I-Premise
255	pain	_	_	I-Premise
256	intensity	_	_	I-Premise
257	or	_	_	I-Premise
258	the	_	_	I-Premise
259	pain	_	_	I-Premise
260	evaluated	_	_	I-Premise
261	just	_	_	I-Premise
262	after	_	_	I-Premise
263	a	_	_	I-Premise
264	week	_	_	I-Premise
265	of	_	_	I-Premise
266	treatment	_	_	I-Premise
267	,	_	_	I-Premise
268	at	_	_	I-Premise
269	the	_	_	I-Premise
270	moment	_	_	I-Premise
271	of	_	_	I-Premise
272	the	_	_	I-Premise
273	visit	_	_	I-Premise
274	,	_	_	I-Premise
275	when	_	_	I-Premise
276	amitriptyline	_	_	I-Premise
277	was	_	_	I-Premise
278	compared	_	_	I-Premise
279	with	_	_	I-Premise
280	placebo	_	_	I-Premise
281	.	_	_	I-Premise

282	A	_	_	B-Premise
283	significant	_	_	I-Premise
284	difference	_	_	I-Premise
285	was	_	_	I-Premise
286	evidenced	_	_	I-Premise
287	for	_	_	I-Premise
288	the	_	_	I-Premise
289	worst	_	_	I-Premise
290	pain	_	_	I-Premise
291	(	_	_	I-Premise
292	P	_	_	I-Premise
293	<	_	_	I-Premise
294	0	_	_	I-Premise
295	.	_	_	I-Premise

296	035	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	No	_	_	B-Premise
300	differences	_	_	I-Premise
301	in	_	_	I-Premise
302	opioid	_	_	I-Premise
303	doses	_	_	I-Premise
304	during	_	_	I-Premise
305	the	_	_	I-Premise
306	period	_	_	I-Premise
307	of	_	_	I-Premise
308	study	_	_	I-Premise
309	were	_	_	I-Premise
310	found	_	_	I-Premise
311	.	_	_	I-Premise

312	Drowsiness	_	_	B-Premise
313	,	_	_	I-Premise
314	confusion	_	_	I-Premise
315	and	_	_	I-Premise
316	dry	_	_	I-Premise
317	mouth	_	_	I-Premise
318	were	_	_	I-Premise
319	significantly	_	_	I-Premise
320	more	_	_	I-Premise
321	intense	_	_	I-Premise
322	with	_	_	I-Premise
323	amitriptyline	_	_	I-Premise
324	than	_	_	I-Premise
325	with	_	_	I-Premise
326	placebo	_	_	I-Premise
327	(	_	_	I-Premise
328	P	_	_	I-Premise
329	<	_	_	I-Premise
330	0	_	_	I-Premise
331	.	_	_	I-Premise

332	036	_	_	I-Premise
333	,	_	_	I-Premise
334	0	_	_	I-Premise
335	.	_	_	I-Premise

336	003	_	_	I-Premise
337	,	_	_	I-Premise
338	and	_	_	I-Premise
339	0	_	_	I-Premise
340	.	_	_	I-Premise

341	034	_	_	I-Premise
342	,	_	_	I-Premise
343	respectively	_	_	I-Premise
344	)	_	_	I-Premise
345	.	_	_	I-Premise

346	There	_	_	B-Premise
347	were	_	_	I-Premise
348	no	_	_	I-Premise
349	substantial	_	_	I-Premise
350	differences	_	_	I-Premise
351	between	_	_	I-Premise
352	the	_	_	I-Premise
353	two	_	_	I-Premise
354	treatments	_	_	I-Premise
355	in	_	_	I-Premise
356	Spitzer	_	_	I-Premise
357	'	_	_	I-Premise
358	s	_	_	I-Premise
359	quality	_	_	I-Premise
360	of	_	_	I-Premise
361	life	_	_	I-Premise
362	score	_	_	I-Premise
363	and	_	_	I-Premise
364	for	_	_	I-Premise
365	each	_	_	I-Premise
366	item	_	_	I-Premise
367	.	_	_	I-Premise

368	No	_	_	B-Premise
369	differences	_	_	I-Premise
370	in	_	_	I-Premise
371	patients	_	_	I-Premise
372	'	_	_	I-Premise
373	preference	_	_	I-Premise
374	for	_	_	I-Premise
375	the	_	_	I-Premise
376	two	_	_	I-Premise
377	treatment	_	_	I-Premise
378	periods	_	_	I-Premise
379	were	_	_	I-Premise
380	found	_	_	I-Premise
381	.	_	_	I-Premise

382	The	_	_	B-Claim
383	analgesic	_	_	I-Claim
384	effects	_	_	I-Claim
385	of	_	_	I-Claim
386	amitriptyline	_	_	I-Claim
387	were	_	_	I-Claim
388	slight	_	_	I-Claim
389	and	_	_	I-Claim
390	associated	_	_	I-Claim
391	with	_	_	I-Claim
392	adverse	_	_	I-Claim
393	effects	_	_	I-Claim
394	.	_	_	I-Claim

395	In	_	_	O
396	light	_	_	O
397	of	_	_	O
398	the	_	_	O
399	results	_	_	O
400	obtained	_	_	O
401	in	_	_	O
402	the	_	_	O
403	study	_	_	O
404	,	_	_	O
405	the	_	_	B-Claim
406	extensive	_	_	I-Claim
407	use	_	_	I-Claim
408	of	_	_	I-Claim
409	the	_	_	I-Claim
410	drug	_	_	I-Claim
411	for	_	_	I-Claim
412	cancer	_	_	I-Claim
413	pain	_	_	I-Claim
414	should	_	_	I-Claim
415	be	_	_	I-Claim
416	questioned	_	_	I-Claim
417	.	_	_	I-Claim


0	The	_	_	O
1	World	_	_	O
2	Health	_	_	O
3	Organization	_	_	O
4	(	_	_	O
5	WHO	_	_	O
6	)	_	_	O
7	guidelines	_	_	O
8	for	_	_	O
9	the	_	_	O
10	treatment	_	_	O
11	of	_	_	O
12	cancer	_	_	O
13	pain	_	_	O
14	recommend	_	_	O
15	nonopioid	_	_	O
16	analgesics	_	_	O
17	as	_	_	O
18	first	_	_	O
19	-	_	_	O
20	line	_	_	O
21	therapy	_	_	O
22	,	_	_	O
23	so	_	_	O
24	-	_	_	O
25	called	_	_	O
26	"	_	_	O
27	weak	_	_	O
28	"	_	_	O
29	analgesics	_	_	O
30	combined	_	_	O
31	with	_	_	O
32	nonopioid	_	_	O
33	analgesics	_	_	O
34	as	_	_	O
35	second	_	_	O
36	-	_	_	O
37	line	_	_	O
38	therapy	_	_	O
39	,	_	_	O
40	and	_	_	O
41	so	_	_	O
42	-	_	_	O
43	called	_	_	O
44	"	_	_	O
45	strong	_	_	O
46	"	_	_	O
47	opioids	_	_	O
48	(	_	_	O
49	with	_	_	O
50	nonopioid	_	_	O
51	analgesics	_	_	O
52	)	_	_	O
53	only	_	_	O
54	as	_	_	O
55	third	_	_	O
56	-	_	_	O
57	line	_	_	O
58	therapy	_	_	O
59	.	_	_	O

60	However	_	_	O
61	,	_	_	O
62	these	_	_	O
63	guidelines	_	_	O
64	can	_	_	O
65	be	_	_	O
66	questioned	_	_	O
67	with	_	_	O
68	regard	_	_	O
69	to	_	_	O
70	the	_	_	O
71	extent	_	_	O
72	of	_	_	O
73	efficacy	_	_	O
74	as	_	_	O
75	well	_	_	O
76	as	_	_	O
77	the	_	_	O
78	rationale	_	_	O
79	for	_	_	O
80	not	_	_	O
81	using	_	_	O
82	strong	_	_	O
83	opioids	_	_	O
84	as	_	_	O
85	first	_	_	O
86	-	_	_	O
87	line	_	_	O
88	treatment	_	_	O
89	,	_	_	O
90	especially	_	_	O
91	in	_	_	O
92	terminal	_	_	O
93	cancer	_	_	O
94	patients	_	_	O
95	.	_	_	O

96	The	_	_	O
97	purpose	_	_	O
98	of	_	_	O
99	this	_	_	O
100	randomized	_	_	O
101	study	_	_	O
102	was	_	_	O
103	to	_	_	O
104	prospectively	_	_	O
105	compare	_	_	O
106	the	_	_	O
107	efficacy	_	_	O
108	and	_	_	O
109	tolerability	_	_	O
110	of	_	_	O
111	strong	_	_	O
112	opioids	_	_	O
113	as	_	_	O
114	first	_	_	O
115	-	_	_	O
116	line	_	_	O
117	agents	_	_	O
118	with	_	_	O
119	the	_	_	O
120	recommendations	_	_	O
121	of	_	_	O
122	the	_	_	O
123	WHO	_	_	O
124	in	_	_	O
125	terminal	_	_	O
126	cancer	_	_	O
127	patients	_	_	O
128	.	_	_	O

129	One	_	_	O
130	hundred	_	_	O
131	patients	_	_	O
132	with	_	_	O
133	mild	_	_	O
134	-	_	_	O
135	moderate	_	_	O
136	pain	_	_	O
137	were	_	_	O
138	randomized	_	_	O
139	to	_	_	O
140	treatment	_	_	O
141	according	_	_	O
142	to	_	_	O
143	WHO	_	_	O
144	guidelines	_	_	O
145	or	_	_	O
146	to	_	_	O
147	treatment	_	_	O
148	with	_	_	O
149	strong	_	_	O
150	opioids	_	_	O
151	.	_	_	O

152	Evaluated	_	_	O
153	outcomes	_	_	O
154	included	_	_	O
155	pain	_	_	O
156	intensity	_	_	O
157	,	_	_	O
158	need	_	_	O
159	for	_	_	O
160	change	_	_	O
161	in	_	_	O
162	therapy	_	_	O
163	,	_	_	O
164	quality	_	_	O
165	of	_	_	O
166	life	_	_	O
167	,	_	_	O
168	Karnofsky	_	_	O
169	Performance	_	_	O
170	Status	_	_	O
171	,	_	_	O
172	general	_	_	O
173	condition	_	_	O
174	of	_	_	O
175	the	_	_	O
176	patient	_	_	O
177	,	_	_	O
178	and	_	_	O
179	adverse	_	_	O
180	events	_	_	O
181	.	_	_	O

182	No	_	_	B-Premise
183	between	_	_	I-Premise
184	-	_	_	I-Premise
185	treatment	_	_	I-Premise
186	differences	_	_	I-Premise
187	were	_	_	I-Premise
188	observed	_	_	I-Premise
189	for	_	_	I-Premise
190	changes	_	_	I-Premise
191	in	_	_	I-Premise
192	quality	_	_	I-Premise
193	of	_	_	I-Premise
194	life	_	_	I-Premise
195	or	_	_	I-Premise
196	performance	_	_	I-Premise
197	status	_	_	I-Premise
198	,	_	_	I-Premise
199	but	_	_	O
200	patients	_	_	B-Premise
201	started	_	_	I-Premise
202	on	_	_	I-Premise
203	strong	_	_	I-Premise
204	opioids	_	_	I-Premise
205	had	_	_	I-Premise
206	significantly	_	_	I-Premise
207	better	_	_	I-Premise
208	pain	_	_	I-Premise
209	relief	_	_	I-Premise
210	than	_	_	I-Premise
211	patients	_	_	I-Premise
212	treated	_	_	I-Premise
213	according	_	_	I-Premise
214	to	_	_	I-Premise
215	WHO	_	_	I-Premise
216	guidelines	_	_	I-Premise
217	(	_	_	I-Premise
218	P	_	_	I-Premise
219	=	_	_	I-Premise
220	0	_	_	I-Premise
221	.	_	_	I-Premise

222	041	_	_	I-Premise
223	)	_	_	I-Premise
224	.	_	_	I-Premise

225	Additionally	_	_	B-Premise
226	,	_	_	I-Premise
227	patients	_	_	I-Premise
228	started	_	_	I-Premise
229	on	_	_	I-Premise
230	strong	_	_	I-Premise
231	opioids	_	_	I-Premise
232	required	_	_	I-Premise
233	significantly	_	_	I-Premise
234	fewer	_	_	I-Premise
235	changes	_	_	I-Premise
236	in	_	_	I-Premise
237	therapy	_	_	I-Premise
238	,	_	_	I-Premise
239	had	_	_	I-Premise
240	greater	_	_	I-Premise
241	reduction	_	_	I-Premise
242	in	_	_	I-Premise
243	pain	_	_	I-Premise
244	when	_	_	I-Premise
245	a	_	_	I-Premise
246	change	_	_	I-Premise
247	was	_	_	I-Premise
248	initiated	_	_	I-Premise
249	,	_	_	I-Premise
250	and	_	_	I-Premise
251	reported	_	_	I-Premise
252	greater	_	_	I-Premise
253	satisfaction	_	_	I-Premise
254	with	_	_	I-Premise
255	treatment	_	_	I-Premise
256	than	_	_	I-Premise
257	the	_	_	I-Premise
258	comparator	_	_	I-Premise
259	group	_	_	I-Premise
260	(	_	_	I-Premise
261	P	_	_	I-Premise
262	=	_	_	I-Premise
263	0	_	_	I-Premise
264	.	_	_	I-Premise

265	041	_	_	I-Premise
266	)	_	_	I-Premise
267	.	_	_	I-Premise

268	Strong	_	_	B-Claim
269	opioids	_	_	I-Claim
270	were	_	_	I-Claim
271	safe	_	_	I-Claim
272	and	_	_	I-Claim
273	well	_	_	I-Claim
274	-	_	_	I-Claim
275	tolerated	_	_	I-Claim
276	,	_	_	I-Claim
277	with	_	_	I-Claim
278	no	_	_	I-Claim
279	development	_	_	I-Claim
280	of	_	_	I-Claim
281	tolerance	_	_	I-Claim
282	or	_	_	I-Claim
283	serious	_	_	I-Claim
284	adverse	_	_	I-Claim
285	events	_	_	I-Claim
286	.	_	_	I-Claim

287	These	_	_	B-Claim
288	data	_	_	I-Claim
289	suggest	_	_	I-Claim
290	the	_	_	I-Claim
291	utility	_	_	I-Claim
292	of	_	_	I-Claim
293	strong	_	_	I-Claim
294	opioids	_	_	I-Claim
295	for	_	_	I-Claim
296	first	_	_	I-Claim
297	-	_	_	I-Claim
298	line	_	_	I-Claim
299	treatment	_	_	I-Claim
300	of	_	_	I-Claim
301	pain	_	_	I-Claim
302	in	_	_	I-Claim
303	patients	_	_	I-Claim
304	with	_	_	I-Claim
305	terminal	_	_	I-Claim
306	cancer	_	_	I-Claim
307	.	_	_	I-Claim


0	Treosulfan	_	_	O
1	,	_	_	O
2	an	_	_	O
3	alkylating	_	_	O
4	agent	_	_	O
5	,	_	_	O
6	has	_	_	O
7	demonstrated	_	_	O
8	activity	_	_	O
9	in	_	_	O
10	recurrent	_	_	O
11	ovarian	_	_	O
12	carcinoma	_	_	O
13	.	_	_	O

14	It	_	_	O
15	is	_	_	O
16	equieffective	_	_	O
17	as	_	_	O
18	oral	_	_	O
19	(	_	_	O
20	p	_	_	O
21	.	_	_	O

22	o	_	_	O
23	.	_	_	O

24	)	_	_	O
25	and	_	_	O
26	intravenous	_	_	O
27	(	_	_	O
28	i	_	_	O
29	.	_	_	O

30	v	_	_	O
31	.	_	_	O

32	)	_	_	O
33	formulation	_	_	O
34	.	_	_	O

35	To	_	_	O
36	explore	_	_	O
37	the	_	_	O
38	preference	_	_	O
39	and	_	_	O
40	compliance	_	_	O
41	of	_	_	O
42	elderly	_	_	O
43	patients	_	_	O
44	regarding	_	_	O
45	p	_	_	O
46	.	_	_	O

47	o	_	_	O
48	.	_	_	O

49	or	_	_	O
50	i	_	_	O
51	.	_	_	O

52	v	_	_	O
53	.	_	_	O

54	treosulfan	_	_	O
55	for	_	_	O
56	the	_	_	O
57	treatment	_	_	O
58	of	_	_	O
59	relapsed	_	_	O
60	ovarian	_	_	O
61	carcinoma	_	_	O
62	,	_	_	O
63	women	_	_	O
64	aged	_	_	O
65	65	_	_	O
66	years	_	_	O
67	or	_	_	O
68	older	_	_	O
69	were	_	_	O
70	included	_	_	O
71	in	_	_	O
72	this	_	_	O
73	prospective	_	_	O
74	multicenter	_	_	O
75	study	_	_	O
76	.	_	_	O

77	Since	_	_	O
78	elderly	_	_	O
79	patients	_	_	O
80	usually	_	_	O
81	have	_	_	O
82	several	_	_	O
83	concomitant	_	_	O
84	diseases	_	_	O
85	and	_	_	O
86	experience	_	_	O
87	more	_	_	O
88	treatment	_	_	O
89	toxicity	_	_	O
90	,	_	_	O
91	an	_	_	O
92	interim	_	_	O
93	safety	_	_	O
94	analysis	_	_	O
95	was	_	_	O
96	planned	_	_	O
97	and	_	_	O
98	performed	_	_	O
99	after	_	_	O
100	25	_	_	O
101	patients	_	_	O
102	finished	_	_	O
103	therapy	_	_	O
104	to	_	_	O
105	assess	_	_	O
106	the	_	_	O
107	tolerability	_	_	O
108	of	_	_	O
109	the	_	_	O
110	treatment	_	_	O
111	regimens	_	_	O
112	.	_	_	O

113	Patients	_	_	O
114	had	_	_	O
115	a	_	_	O
116	free	_	_	O
117	choice	_	_	O
118	of	_	_	O
119	treosulfan	_	_	O
120	i	_	_	O
121	.	_	_	O

122	v	_	_	O
123	.	_	_	O

124	(	_	_	O
125	7	_	_	O
126	,	_	_	O
127	000	_	_	O
128	mg	_	_	O
129	/	_	_	O
130	m	_	_	O
131	(	_	_	O
132	2	_	_	O
133	)	_	_	O
134	day	_	_	O
135	1	_	_	O
136	of	_	_	O
137	a	_	_	O
138	28	_	_	O
139	-	_	_	O
140	day	_	_	O
141	cycle	_	_	O
142	)	_	_	O
143	or	_	_	O
144	p	_	_	O
145	.	_	_	O

146	o	_	_	O
147	.	_	_	O

148	(	_	_	O
149	600	_	_	O
150	mg	_	_	O
151	/	_	_	O
152	m	_	_	O
153	(	_	_	O
154	2	_	_	O
155	)	_	_	O
156	day	_	_	O
157	1	_	_	O
158	-	_	_	O
159	28	_	_	O
160	of	_	_	O
161	a	_	_	O
162	56	_	_	O
163	-	_	_	O
164	day	_	_	O
165	cycle	_	_	O
166	)	_	_	O
167	for	_	_	O
168	a	_	_	O
169	maximum	_	_	O
170	of	_	_	O
171	12	_	_	O
172	cycles	_	_	O
173	(	_	_	O
174	i	_	_	O
175	.	_	_	O

176	v	_	_	O
177	.	_	_	O

178	)	_	_	O
179	or	_	_	O
180	12	_	_	O
181	months	_	_	O
182	(	_	_	O
183	p	_	_	O
184	.	_	_	O

185	o	_	_	O
186	.	_	_	O

187	)	_	_	O
188	.	_	_	O

189	Indecisive	_	_	O
190	patients	_	_	O
191	were	_	_	O
192	randomized	_	_	O
193	.	_	_	O

194	Toxicity	_	_	O
195	was	_	_	O
196	evaluated	_	_	O
197	according	_	_	O
198	to	_	_	O
199	the	_	_	O
200	NCI	_	_	O
201	-	_	_	O
202	CTC	_	_	O
203	version	_	_	O
204	2	_	_	O
205	.	_	_	O

206	0	_	_	O
207	.	_	_	O

208	Twenty	_	_	O
209	-	_	_	O
210	five	_	_	O
211	of	_	_	O
212	51	_	_	O
213	recruited	_	_	O
214	patients	_	_	O
215	completed	_	_	O
216	therapy	_	_	O
217	at	_	_	O
218	the	_	_	O
219	time	_	_	O
220	of	_	_	O
221	the	_	_	O
222	planned	_	_	O
223	interim	_	_	O
224	analysis	_	_	O
225	(	_	_	O
226	median	_	_	O
227	age	_	_	O
228	,	_	_	O
229	75	_	_	O
230	years	_	_	O
231	;	_	_	O
232	range	_	_	O
233	,	_	_	O
234	70	_	_	O
235	-	_	_	O
236	82	_	_	O
237	)	_	_	O
238	.	_	_	O

239	Median	_	_	O
240	ECOG	_	_	O
241	was	_	_	O
242	1	_	_	O
243	,	_	_	O
244	and	_	_	O
245	median	_	_	O
246	number	_	_	O
247	of	_	_	O
248	prior	_	_	O
249	chemotherapy	_	_	O
250	regimens	_	_	O
251	was	_	_	O
252	2	_	_	O
253	.	_	_	O

254	A	_	_	O
255	median	_	_	O
256	number	_	_	O
257	of	_	_	O
258	4	_	_	O
259	cycles	_	_	O
260	(	_	_	O
261	range	_	_	O
262	,	_	_	O
263	1	_	_	O
264	-	_	_	O
265	12	_	_	O
266	)	_	_	O
267	were	_	_	O
268	administered	_	_	O
269	per	_	_	O
270	patient	_	_	O
271	.	_	_	O

272	Anemia	_	_	B-Premise
273	was	_	_	I-Premise
274	the	_	_	I-Premise
275	most	_	_	I-Premise
276	common	_	_	I-Premise
277	hematological	_	_	I-Premise
278	toxicity	_	_	I-Premise
279	(	_	_	I-Premise
280	88	_	_	I-Premise
281	%	_	_	I-Premise
282	of	_	_	I-Premise
283	patients	_	_	I-Premise
284	)	_	_	I-Premise
285	.	_	_	I-Premise

286	Most	_	_	B-Premise
287	frequent	_	_	I-Premise
288	non	_	_	I-Premise
289	-	_	_	I-Premise
290	hematological	_	_	I-Premise
291	toxicities	_	_	I-Premise
292	were	_	_	I-Premise
293	nausea	_	_	I-Premise
294	(	_	_	I-Premise
295	76	_	_	I-Premise
296	%	_	_	I-Premise
297	)	_	_	I-Premise
298	,	_	_	I-Premise
299	constipation	_	_	I-Premise
300	(	_	_	I-Premise
301	68	_	_	I-Premise
302	%	_	_	I-Premise
303	)	_	_	I-Premise
304	,	_	_	I-Premise
305	and	_	_	I-Premise
306	fatigue	_	_	I-Premise
307	(	_	_	I-Premise
308	64	_	_	I-Premise
309	%	_	_	I-Premise
310	)	_	_	I-Premise
311	.	_	_	I-Premise

312	Treatment	_	_	B-Claim
313	was	_	_	I-Claim
314	generally	_	_	I-Claim
315	well	_	_	I-Claim
316	tolerated	_	_	I-Claim
317	despite	_	_	I-Claim
318	the	_	_	I-Claim
319	fact	_	_	I-Claim
320	that	_	_	I-Claim
321	most	_	_	I-Claim
322	patients	_	_	I-Claim
323	suffered	_	_	I-Claim
324	from	_	_	I-Claim
325	multiple	_	_	I-Claim
326	comorbidities	_	_	I-Claim
327	and	_	_	I-Claim
328	were	_	_	I-Claim
329	heavily	_	_	I-Claim
330	pretreated	_	_	I-Claim
331	.	_	_	I-Claim

332	There	_	_	B-Claim
333	were	_	_	I-Claim
334	no	_	_	I-Claim
335	unexpected	_	_	I-Claim
336	hematological	_	_	I-Claim
337	or	_	_	I-Claim
338	non	_	_	I-Claim
339	-	_	_	I-Claim
340	hematological	_	_	I-Claim
341	toxicities	_	_	I-Claim
342	.	_	_	I-Claim

343	Based	_	_	O
344	on	_	_	O
345	this	_	_	O
346	safety	_	_	O
347	analysis	_	_	O
348	,	_	_	O
349	the	_	_	O
350	next	_	_	O
351	step	_	_	O
352	of	_	_	O
353	study	_	_	O
354	recruitment	_	_	O
355	was	_	_	O
356	continued	_	_	O
357	.	_	_	O


0	Adjuvant	_	_	O
1	chemotherapy	_	_	O
2	for	_	_	O
3	early	_	_	O
4	stage	_	_	O
5	non	_	_	O
6	-	_	_	O
7	small	_	_	O
8	-	_	_	O
9	cell	_	_	O
10	lung	_	_	O
11	cancer	_	_	O
12	(	_	_	O
13	NSCLC	_	_	O
14	)	_	_	O
15	is	_	_	O
16	now	_	_	O
17	the	_	_	O
18	standard	_	_	O
19	of	_	_	O
20	care	_	_	O
21	,	_	_	O
22	but	_	_	O
23	there	_	_	O
24	is	_	_	O
25	little	_	_	O
26	information	_	_	O
27	regarding	_	_	O
28	its	_	_	O
29	impact	_	_	O
30	on	_	_	O
31	quality	_	_	O
32	of	_	_	O
33	life	_	_	O
34	(	_	_	O
35	QOL	_	_	O
36	)	_	_	O
37	.	_	_	O

38	We	_	_	O
39	report	_	_	O
40	the	_	_	O
41	QOL	_	_	O
42	results	_	_	O
43	of	_	_	O
44	JBR	_	_	O
45	.	_	_	O

46	10	_	_	O
47	,	_	_	O
48	a	_	_	O
49	North	_	_	O
50	American	_	_	O
51	,	_	_	O
52	intergroup	_	_	O
53	,	_	_	O
54	randomized	_	_	O
55	trial	_	_	O
56	of	_	_	O
57	adjuvant	_	_	O
58	cisplatin	_	_	O
59	and	_	_	O
60	vinorelbine	_	_	O
61	compared	_	_	O
62	with	_	_	O
63	observation	_	_	O
64	in	_	_	O
65	patients	_	_	O
66	who	_	_	O
67	have	_	_	O
68	completely	_	_	O
69	resected	_	_	O
70	,	_	_	O
71	stages	_	_	O
72	IB	_	_	O
73	to	_	_	O
74	II	_	_	O
75	NSCLC	_	_	O
76	.	_	_	O

77	QOL	_	_	O
78	was	_	_	O
79	assessed	_	_	O
80	with	_	_	O
81	the	_	_	O
82	European	_	_	O
83	Organisation	_	_	O
84	for	_	_	O
85	Research	_	_	O
86	and	_	_	O
87	Treatment	_	_	O
88	of	_	_	O
89	Cancer	_	_	O
90	Quality	_	_	O
91	of	_	_	O
92	Life	_	_	O
93	Questionnaire	_	_	O
94	C30	_	_	O
95	and	_	_	O
96	a	_	_	O
97	trial	_	_	O
98	-	_	_	O
99	specific	_	_	O
100	checklist	_	_	O
101	at	_	_	O
102	baseline	_	_	O
103	and	_	_	O
104	at	_	_	O
105	weeks	_	_	O
106	5	_	_	O
107	and	_	_	O
108	9	_	_	O
109	for	_	_	O
110	those	_	_	O
111	who	_	_	O
112	received	_	_	O
113	chemotherapy	_	_	O
114	and	_	_	O
115	at	_	_	O
116	follow	_	_	O
117	-	_	_	O
118	up	_	_	O
119	months	_	_	O
120	3	_	_	O
121	,	_	_	O
122	6	_	_	O
123	,	_	_	O
124	9	_	_	O
125	,	_	_	O
126	12	_	_	O
127	,	_	_	O
128	18	_	_	O
129	,	_	_	O
130	24	_	_	O
131	,	_	_	O
132	30	_	_	O
133	and	_	_	O
134	36	_	_	O
135	.	_	_	O

136	A	_	_	O
137	10	_	_	O
138	-	_	_	O
139	point	_	_	O
140	change	_	_	O
141	in	_	_	O
142	QOL	_	_	O
143	scores	_	_	O
144	from	_	_	O
145	baseline	_	_	O
146	was	_	_	O
147	considered	_	_	O
148	clinically	_	_	O
149	significant	_	_	O
150	.	_	_	O

151	Four	_	_	O
152	hundred	_	_	O
153	eighty	_	_	O
154	-	_	_	O
155	two	_	_	O
156	patients	_	_	O
157	were	_	_	O
158	randomly	_	_	O
159	assigned	_	_	O
160	on	_	_	O
161	JBR	_	_	O
162	.	_	_	O

163	10	_	_	O
164	.	_	_	O

165	A	_	_	O
166	total	_	_	O
167	of	_	_	O
168	173	_	_	O
169	patients	_	_	O
170	(	_	_	O
171	82	_	_	O
172	%	_	_	O
173	of	_	_	O
174	the	_	_	O
175	expected	_	_	O
176	)	_	_	O
177	in	_	_	O
178	the	_	_	O
179	observation	_	_	O
180	arm	_	_	O
181	and	_	_	O
182	186	_	_	O
183	(	_	_	O
184	85	_	_	O
185	%	_	_	O
186	of	_	_	O
187	expected	_	_	O
188	)	_	_	O
189	in	_	_	O
190	the	_	_	O
191	chemotherapy	_	_	O
192	arm	_	_	O
193	completed	_	_	O
194	baseline	_	_	O
195	QOL	_	_	O
196	assessments	_	_	O
197	.	_	_	O

198	The	_	_	B-Premise
199	two	_	_	I-Premise
200	groups	_	_	I-Premise
201	were	_	_	I-Premise
202	comparable	_	_	I-Premise
203	,	_	_	I-Premise
204	with	_	_	I-Premise
205	low	_	_	I-Premise
206	global	_	_	I-Premise
207	QOL	_	_	I-Premise
208	scores	_	_	I-Premise
209	and	_	_	I-Premise
210	significant	_	_	I-Premise
211	symptom	_	_	I-Premise
212	burden	_	_	I-Premise
213	,	_	_	I-Premise
214	especially	_	_	I-Premise
215	pain	_	_	I-Premise
216	and	_	_	I-Premise
217	fatigue	_	_	I-Premise
218	,	_	_	I-Premise
219	after	_	_	I-Premise
220	thoracotomy	_	_	I-Premise
221	.	_	_	I-Premise

222	Changes	_	_	O
223	in	_	_	O
224	QOL	_	_	O
225	during	_	_	O
226	chemotherapy	_	_	O
227	were	_	_	O
228	relatively	_	_	O
229	modest	_	_	O
230	;	_	_	O
231	fatigue	_	_	B-Premise
232	,	_	_	I-Premise
233	nausea	_	_	I-Premise
234	,	_	_	I-Premise
235	and	_	_	I-Premise
236	vomiting	_	_	I-Premise
237	worsened	_	_	I-Premise
238	,	_	_	I-Premise
239	but	_	_	B-Premise
240	there	_	_	I-Premise
241	was	_	_	I-Premise
242	a	_	_	I-Premise
243	reduction	_	_	I-Premise
244	in	_	_	I-Premise
245	pain	_	_	I-Premise
246	and	_	_	I-Premise
247	no	_	_	I-Premise
248	change	_	_	I-Premise
249	in	_	_	I-Premise
250	global	_	_	I-Premise
251	QOL	_	_	I-Premise
252	.	_	_	I-Premise

253	Patients	_	_	B-Premise
254	in	_	_	I-Premise
255	the	_	_	I-Premise
256	observation	_	_	I-Premise
257	arm	_	_	I-Premise
258	showed	_	_	I-Premise
259	considerable	_	_	I-Premise
260	improvements	_	_	I-Premise
261	in	_	_	I-Premise
262	QOL	_	_	I-Premise
263	by	_	_	I-Premise
264	3	_	_	I-Premise
265	months	_	_	I-Premise
266	.	_	_	I-Premise

267	QOL	_	_	B-Premise
268	,	_	_	I-Premise
269	except	_	_	I-Premise
270	for	_	_	I-Premise
271	symptoms	_	_	I-Premise
272	of	_	_	I-Premise
273	sensory	_	_	I-Premise
274	neuropathy	_	_	I-Premise
275	and	_	_	I-Premise
276	hearing	_	_	I-Premise
277	loss	_	_	I-Premise
278	,	_	_	I-Premise
279	in	_	_	I-Premise
280	those	_	_	I-Premise
281	treated	_	_	I-Premise
282	with	_	_	I-Premise
283	chemotherapy	_	_	I-Premise
284	returned	_	_	I-Premise
285	to	_	_	I-Premise
286	baseline	_	_	I-Premise
287	by	_	_	I-Premise
288	9	_	_	I-Premise
289	months	_	_	I-Premise
290	.	_	_	I-Premise

291	The	_	_	B-Claim
292	findings	_	_	I-Claim
293	of	_	_	I-Claim
294	this	_	_	I-Claim
295	trial	_	_	I-Claim
296	indicate	_	_	I-Claim
297	that	_	_	I-Claim
298	the	_	_	I-Claim
299	negative	_	_	I-Claim
300	effects	_	_	I-Claim
301	of	_	_	I-Claim
302	adjuvant	_	_	I-Claim
303	chemotherapy	_	_	I-Claim
304	on	_	_	I-Claim
305	QOL	_	_	I-Claim
306	appear	_	_	I-Claim
307	to	_	_	I-Claim
308	be	_	_	I-Claim
309	temporary	_	_	I-Claim
310	,	_	_	I-Claim
311	and	_	_	I-Claim
312	that	_	_	I-Claim
313	improvements	_	_	I-Claim
314	(	_	_	I-Claim
315	with	_	_	I-Claim
316	a	_	_	I-Claim
317	return	_	_	I-Claim
318	to	_	_	I-Claim
319	baseline	_	_	I-Claim
320	function	_	_	I-Claim
321	)	_	_	I-Claim
322	are	_	_	I-Claim
323	likely	_	_	I-Claim
324	in	_	_	I-Claim
325	most	_	_	I-Claim
326	patients	_	_	I-Claim
327	.	_	_	I-Claim


0	The	_	_	O
1	combination	_	_	O
2	of	_	_	O
3	carboplatin	_	_	O
4	and	_	_	O
5	paclitaxel	_	_	O
6	is	_	_	O
7	the	_	_	O
8	standard	_	_	O
9	of	_	_	O
10	care	_	_	O
11	for	_	_	O
12	the	_	_	O
13	treatment	_	_	O
14	of	_	_	O
15	ovarian	_	_	O
16	cancer	_	_	O
17	,	_	_	O
18	yet	_	_	O
19	rates	_	_	O
20	of	_	_	O
21	recurrence	_	_	O
22	and	_	_	O
23	death	_	_	O
24	remain	_	_	O
25	high	_	_	O
26	.	_	_	O

27	We	_	_	O
28	performed	_	_	O
29	a	_	_	O
30	prospective	_	_	O
31	randomized	_	_	O
32	phase	_	_	O
33	III	_	_	O
34	study	_	_	O
35	to	_	_	O
36	examine	_	_	O
37	whether	_	_	O
38	sequential	_	_	O
39	administration	_	_	O
40	of	_	_	O
41	topotecan	_	_	O
42	can	_	_	O
43	improve	_	_	O
44	the	_	_	O
45	efficacy	_	_	O
46	of	_	_	O
47	carboplatin	_	_	O
48	and	_	_	O
49	paclitaxel	_	_	O
50	in	_	_	O
51	first	_	_	O
52	-	_	_	O
53	line	_	_	O
54	treatment	_	_	O
55	of	_	_	O
56	advanced	_	_	O
57	epithelial	_	_	O
58	ovarian	_	_	O
59	cancer	_	_	O
60	.	_	_	O

61	A	_	_	O
62	total	_	_	O
63	of	_	_	O
64	1308	_	_	O
65	patients	_	_	O
66	with	_	_	O
67	previously	_	_	O
68	untreated	_	_	O
69	ovarian	_	_	O
70	cancer	_	_	O
71	(	_	_	O
72	International	_	_	O
73	Federation	_	_	O
74	of	_	_	O
75	Gynecology	_	_	O
76	and	_	_	O
77	Obstetrics	_	_	O
78	stages	_	_	O
79	IIB	_	_	O
80	-	_	_	O
81	IV	_	_	O
82	)	_	_	O
83	were	_	_	O
84	randomly	_	_	O
85	assigned	_	_	O
86	to	_	_	O
87	receive	_	_	O
88	six	_	_	O
89	cycles	_	_	O
90	of	_	_	O
91	paclitaxel	_	_	O
92	and	_	_	O
93	carboplatin	_	_	O
94	followed	_	_	O
95	by	_	_	O
96	either	_	_	O
97	four	_	_	O
98	cycles	_	_	O
99	of	_	_	O
100	topotecan	_	_	O
101	(	_	_	O
102	TC	_	_	O
103	-	_	_	O
104	Top	_	_	O
105	;	_	_	O
106	658	_	_	O
107	patients	_	_	O
108	)	_	_	O
109	or	_	_	O
110	surveillance	_	_	O
111	(	_	_	O
112	TC	_	_	O
113	;	_	_	O
114	650	_	_	O
115	patients	_	_	O
116	)	_	_	O
117	on	_	_	O
118	a	_	_	O
119	3	_	_	O
120	-	_	_	O
121	week	_	_	O
122	per	_	_	O
123	cycle	_	_	O
124	schedule	_	_	O
125	.	_	_	O

126	The	_	_	O
127	primary	_	_	O
128	endpoint	_	_	O
129	was	_	_	O
130	overall	_	_	O
131	survival	_	_	O
132	,	_	_	O
133	and	_	_	O
134	secondary	_	_	O
135	endpoints	_	_	O
136	were	_	_	O
137	progression	_	_	O
138	-	_	_	O
139	free	_	_	O
140	survival	_	_	O
141	,	_	_	O
142	response	_	_	O
143	rate	_	_	O
144	,	_	_	O
145	toxicity	_	_	O
146	,	_	_	O
147	and	_	_	O
148	quality	_	_	O
149	of	_	_	O
150	life	_	_	O
151	.	_	_	O

152	Time	_	_	O
153	-	_	_	O
154	to	_	_	O
155	-	_	_	O
156	event	_	_	O
157	data	_	_	O
158	were	_	_	O
159	analyzed	_	_	O
160	using	_	_	O
161	the	_	_	O
162	Kaplan	_	_	O
163	-	_	_	O
164	Meier	_	_	O
165	method	_	_	O
166	,	_	_	O
167	and	_	_	O
168	a	_	_	O
169	stratified	_	_	O
170	log	_	_	O
171	-	_	_	O
172	rank	_	_	O
173	test	_	_	O
174	was	_	_	O
175	used	_	_	O
176	to	_	_	O
177	compare	_	_	O
178	distributions	_	_	O
179	between	_	_	O
180	treatment	_	_	O
181	groups	_	_	O
182	.	_	_	O

183	Hazard	_	_	O
184	ratios	_	_	O
185	(	_	_	O
186	HRs	_	_	O
187	)	_	_	O
188	with	_	_	O
189	95	_	_	O
190	%	_	_	O
191	confidence	_	_	O
192	intervals	_	_	O
193	(	_	_	O
194	CIs	_	_	O
195	)	_	_	O
196	were	_	_	O
197	estimated	_	_	O
198	using	_	_	O
199	a	_	_	O
200	Cox	_	_	O
201	proportional	_	_	O
202	hazards	_	_	O
203	model	_	_	O
204	.	_	_	O

205	Categorical	_	_	O
206	data	_	_	O
207	were	_	_	O
208	compared	_	_	O
209	using	_	_	O
210	a	_	_	O
211	stratified	_	_	O
212	Cochran	_	_	O
213	-	_	_	O
214	Mantel	_	_	O
215	-	_	_	O
216	Haenszel	_	_	O
217	test	_	_	O
218	.	_	_	O

219	All	_	_	O
220	statistical	_	_	O
221	tests	_	_	O
222	were	_	_	O
223	two	_	_	O
224	-	_	_	O
225	sided	_	_	O
226	.	_	_	O

227	Median	_	_	B-Premise
228	progression	_	_	I-Premise
229	-	_	_	I-Premise
230	free	_	_	I-Premise
231	survival	_	_	I-Premise
232	was	_	_	I-Premise
233	18	_	_	I-Premise
234	.	_	_	I-Premise

235	2	_	_	I-Premise
236	months	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	TC	_	_	I-Premise
240	-	_	_	I-Premise
241	Top	_	_	I-Premise
242	arm	_	_	I-Premise
243	versus	_	_	I-Premise
244	18	_	_	I-Premise
245	.	_	_	I-Premise

246	5	_	_	I-Premise
247	months	_	_	I-Premise
248	in	_	_	I-Premise
249	the	_	_	I-Premise
250	TC	_	_	I-Premise
251	arm	_	_	I-Premise
252	(	_	_	I-Premise
253	stratum	_	_	I-Premise
254	-	_	_	I-Premise
255	adjusted	_	_	I-Premise
256	HR	_	_	I-Premise
257	=	_	_	I-Premise
258	0	_	_	I-Premise
259	.	_	_	I-Premise

260	97	_	_	I-Premise
261	[	_	_	I-Premise
262	95	_	_	I-Premise
263	%	_	_	I-Premise
264	CI	_	_	I-Premise
265	=	_	_	I-Premise
266	0	_	_	I-Premise
267	.	_	_	I-Premise

268	85	_	_	I-Premise
269	to	_	_	I-Premise
270	1	_	_	I-Premise
271	.	_	_	I-Premise

272	10	_	_	I-Premise
273	]	_	_	I-Premise
274	;	_	_	I-Premise
275	P	_	_	I-Premise
276	=	_	_	I-Premise
277	.	_	_	I-Premise

278	688	_	_	I-Premise
279	)	_	_	I-Premise
280	.	_	_	I-Premise

281	Median	_	_	B-Premise
282	overall	_	_	I-Premise
283	survival	_	_	I-Premise
284	was	_	_	I-Premise
285	43	_	_	I-Premise
286	.	_	_	I-Premise

287	1	_	_	I-Premise
288	months	_	_	I-Premise
289	for	_	_	I-Premise
290	the	_	_	I-Premise
291	TC	_	_	I-Premise
292	-	_	_	I-Premise
293	Top	_	_	I-Premise
294	arm	_	_	I-Premise
295	versus	_	_	I-Premise
296	44	_	_	I-Premise
297	.	_	_	I-Premise

298	5	_	_	I-Premise
299	months	_	_	I-Premise
300	for	_	_	I-Premise
301	the	_	_	I-Premise
302	TC	_	_	I-Premise
303	arm	_	_	I-Premise
304	(	_	_	I-Premise
305	stratum	_	_	I-Premise
306	-	_	_	I-Premise
307	adjusted	_	_	I-Premise
308	HR	_	_	I-Premise
309	=	_	_	I-Premise
310	1	_	_	I-Premise
311	.	_	_	I-Premise

312	01	_	_	I-Premise
313	[	_	_	I-Premise
314	95	_	_	I-Premise
315	%	_	_	I-Premise
316	CI	_	_	I-Premise
317	=	_	_	I-Premise
318	0	_	_	I-Premise
319	.	_	_	I-Premise

320	86	_	_	I-Premise
321	to	_	_	I-Premise
322	1	_	_	I-Premise
323	.	_	_	I-Premise

324	18	_	_	I-Premise
325	]	_	_	I-Premise
326	;	_	_	I-Premise
327	P	_	_	I-Premise
328	=	_	_	I-Premise
329	.	_	_	I-Premise

330	885	_	_	I-Premise
331	)	_	_	I-Premise
332	.	_	_	I-Premise

333	At	_	_	B-Premise
334	3	_	_	I-Premise
335	years	_	_	I-Premise
336	,	_	_	I-Premise
337	overall	_	_	I-Premise
338	survival	_	_	I-Premise
339	in	_	_	I-Premise
340	both	_	_	I-Premise
341	arms	_	_	I-Premise
342	was	_	_	I-Premise
343	57	_	_	I-Premise
344	%	_	_	I-Premise
345	(	_	_	I-Premise
346	58	_	_	I-Premise
347	.	_	_	I-Premise

348	5	_	_	I-Premise
349	%	_	_	I-Premise
350	in	_	_	I-Premise
351	the	_	_	I-Premise
352	TC	_	_	I-Premise
353	arm	_	_	I-Premise
354	and	_	_	I-Premise
355	55	_	_	I-Premise
356	.	_	_	I-Premise

357	7	_	_	I-Premise
358	%	_	_	I-Premise
359	in	_	_	I-Premise
360	the	_	_	I-Premise
361	TC	_	_	I-Premise
362	-	_	_	I-Premise
363	Top	_	_	I-Premise
364	arm	_	_	I-Premise
365	)	_	_	I-Premise
366	.	_	_	I-Premise

367	Compared	_	_	B-Premise
368	with	_	_	I-Premise
369	patients	_	_	I-Premise
370	in	_	_	I-Premise
371	the	_	_	I-Premise
372	TC	_	_	I-Premise
373	arm	_	_	I-Premise
374	,	_	_	I-Premise
375	patients	_	_	I-Premise
376	in	_	_	I-Premise
377	the	_	_	I-Premise
378	TC	_	_	I-Premise
379	-	_	_	I-Premise
380	Top	_	_	I-Premise
381	arm	_	_	I-Premise
382	had	_	_	I-Premise
383	more	_	_	I-Premise
384	grade	_	_	I-Premise
385	3	_	_	I-Premise
386	-	_	_	I-Premise
387	4	_	_	I-Premise
388	hematologic	_	_	I-Premise
389	toxic	_	_	I-Premise
390	effects	_	_	I-Premise
391	(	_	_	I-Premise
392	requiring	_	_	I-Premise
393	more	_	_	I-Premise
394	supportive	_	_	I-Premise
395	care	_	_	I-Premise
396	)	_	_	I-Premise
397	and	_	_	I-Premise
398	more	_	_	I-Premise
399	grade	_	_	I-Premise
400	3	_	_	I-Premise
401	-	_	_	I-Premise
402	4	_	_	I-Premise
403	infections	_	_	I-Premise
404	(	_	_	I-Premise
405	5	_	_	I-Premise
406	.	_	_	I-Premise

407	1	_	_	I-Premise
408	%	_	_	I-Premise
409	versus	_	_	I-Premise
410	2	_	_	I-Premise
411	.	_	_	I-Premise

412	7	_	_	I-Premise
413	%	_	_	I-Premise
414	;	_	_	I-Premise
415	P	_	_	I-Premise
416	=	_	_	I-Premise
417	.	_	_	I-Premise

418	034	_	_	I-Premise
419	)	_	_	I-Premise
420	but	_	_	I-Premise
421	did	_	_	I-Premise
422	not	_	_	I-Premise
423	have	_	_	I-Premise
424	a	_	_	I-Premise
425	statistically	_	_	I-Premise
426	significant	_	_	I-Premise
427	increase	_	_	I-Premise
428	in	_	_	I-Premise
429	febrile	_	_	I-Premise
430	neutropenia	_	_	I-Premise
431	(	_	_	I-Premise
432	3	_	_	I-Premise
433	.	_	_	I-Premise

434	3	_	_	I-Premise
435	%	_	_	I-Premise
436	versus	_	_	I-Premise
437	3	_	_	I-Premise
438	.	_	_	I-Premise

439	1	_	_	I-Premise
440	%	_	_	I-Premise
441	;	_	_	I-Premise
442	P	_	_	I-Premise
443	=	_	_	I-Premise
444	.	_	_	I-Premise

445	80	_	_	I-Premise
446	)	_	_	I-Premise
447	.	_	_	I-Premise

448	Among	_	_	B-Premise
449	patients	_	_	I-Premise
450	who	_	_	I-Premise
451	had	_	_	I-Premise
452	measurable	_	_	I-Premise
453	disease	_	_	I-Premise
454	(	_	_	I-Premise
455	TC	_	_	I-Premise
456	,	_	_	I-Premise
457	n	_	_	I-Premise
458	=	_	_	I-Premise
459	147	_	_	I-Premise
460	;	_	_	I-Premise
461	TC	_	_	I-Premise
462	-	_	_	I-Premise
463	Top	_	_	I-Premise
464	,	_	_	I-Premise
465	n	_	_	I-Premise
466	=	_	_	I-Premise
467	145	_	_	I-Premise
468	)	_	_	I-Premise
469	,	_	_	I-Premise
470	overall	_	_	I-Premise
471	(	_	_	I-Premise
472	i	_	_	I-Premise
473	.	_	_	I-Premise

474	e	_	_	I-Premise
475	.	_	_	I-Premise

476	,	_	_	I-Premise
477	complete	_	_	I-Premise
478	or	_	_	I-Premise
479	partial	_	_	I-Premise
480	)	_	_	I-Premise
481	response	_	_	I-Premise
482	was	_	_	I-Premise
483	69	_	_	I-Premise
484	.	_	_	I-Premise

485	0	_	_	I-Premise
486	%	_	_	I-Premise
487	(	_	_	I-Premise
488	95	_	_	I-Premise
489	%	_	_	I-Premise
490	CI	_	_	I-Premise
491	=	_	_	I-Premise
492	61	_	_	I-Premise
493	.	_	_	I-Premise

494	4	_	_	I-Premise
495	%	_	_	I-Premise
496	to	_	_	I-Premise
497	76	_	_	I-Premise
498	.	_	_	I-Premise

499	5	_	_	I-Premise
500	%	_	_	I-Premise
501	)	_	_	I-Premise
502	in	_	_	I-Premise
503	the	_	_	I-Premise
504	TC	_	_	I-Premise
505	-	_	_	I-Premise
506	Top	_	_	I-Premise
507	arm	_	_	I-Premise
508	and	_	_	I-Premise
509	76	_	_	I-Premise
510	.	_	_	I-Premise

511	2	_	_	I-Premise
512	%	_	_	I-Premise
513	(	_	_	I-Premise
514	95	_	_	I-Premise
515	%	_	_	I-Premise
516	CI	_	_	I-Premise
517	=	_	_	I-Premise
518	69	_	_	I-Premise
519	.	_	_	I-Premise

520	3	_	_	I-Premise
521	%	_	_	I-Premise
522	to	_	_	I-Premise
523	83	_	_	I-Premise
524	.	_	_	I-Premise

525	1	_	_	I-Premise
526	%	_	_	I-Premise
527	)	_	_	I-Premise
528	in	_	_	I-Premise
529	the	_	_	I-Premise
530	TC	_	_	I-Premise
531	arm	_	_	I-Premise
532	(	_	_	I-Premise
533	P	_	_	I-Premise
534	=	_	_	I-Premise
535	.	_	_	I-Premise

536	166	_	_	I-Premise
537	)	_	_	I-Premise
538	.	_	_	I-Premise

539	The	_	_	B-Claim
540	sequential	_	_	I-Claim
541	addition	_	_	I-Claim
542	of	_	_	I-Claim
543	topotecan	_	_	I-Claim
544	to	_	_	I-Claim
545	carboplatin	_	_	I-Claim
546	-	_	_	I-Claim
547	paclitaxel	_	_	I-Claim
548	did	_	_	I-Claim
549	not	_	_	I-Claim
550	result	_	_	I-Claim
551	in	_	_	I-Claim
552	superior	_	_	I-Claim
553	overall	_	_	I-Claim
554	response	_	_	I-Claim
555	or	_	_	I-Claim
556	progression	_	_	I-Claim
557	-	_	_	I-Claim
558	free	_	_	I-Claim
559	or	_	_	I-Claim
560	overall	_	_	I-Claim
561	survival	_	_	I-Claim
562	.	_	_	I-Claim

563	Therefore	_	_	B-Claim
564	,	_	_	I-Claim
565	this	_	_	I-Claim
566	regimen	_	_	I-Claim
567	is	_	_	I-Claim
568	not	_	_	I-Claim
569	recommended	_	_	I-Claim
570	as	_	_	I-Claim
571	standard	_	_	I-Claim
572	of	_	_	I-Claim
573	care	_	_	I-Claim
574	treatment	_	_	I-Claim
575	for	_	_	I-Claim
576	ovarian	_	_	I-Claim
577	cancer	_	_	I-Claim
578	.	_	_	I-Claim


0	Two	_	_	O
1	million	_	_	O
2	people	_	_	O
3	across	_	_	O
4	the	_	_	O
5	U	_	_	O
6	.	_	_	O

7	K	_	_	O
8	.	_	_	O

9	are	_	_	O
10	living	_	_	O
11	with	_	_	O
12	cancer	_	_	O
13	,	_	_	O
14	often	_	_	O
15	experienced	_	_	O
16	as	_	_	O
17	a	_	_	O
18	long	_	_	O
19	-	_	_	O
20	term	_	_	O
21	condition	_	_	O
22	.	_	_	O

23	They	_	_	O
24	may	_	_	O
25	have	_	_	O
26	unmet	_	_	O
27	needs	_	_	O
28	after	_	_	O
29	active	_	_	O
30	treatment	_	_	O
31	.	_	_	O

32	Rehabilitation	_	_	O
33	aims	_	_	O
34	to	_	_	O
35	address	_	_	O
36	these	_	_	O
37	needs	_	_	O
38	,	_	_	O
39	maximize	_	_	O
40	psychological	_	_	O
41	and	_	_	O
42	physical	_	_	O
43	function	_	_	O
44	,	_	_	O
45	and	_	_	O
46	enable	_	_	O
47	minimum	_	_	O
48	dependency	_	_	O
49	regardless	_	_	O
50	of	_	_	O
51	life	_	_	O
52	expectancy	_	_	O
53	.	_	_	O

54	We	_	_	O
55	aimed	_	_	O
56	to	_	_	O
57	test	_	_	O
58	,	_	_	O
59	in	_	_	O
60	a	_	_	O
61	randomized	_	_	O
62	controlled	_	_	O
63	trial	_	_	O
64	,	_	_	O
65	the	_	_	O
66	clinical	_	_	O
67	and	_	_	O
68	cost	_	_	O
69	effectiveness	_	_	O
70	of	_	_	O
71	a	_	_	O
72	rehabilitation	_	_	O
73	intervention	_	_	O
74	for	_	_	O
75	patients	_	_	O
76	with	_	_	O
77	advanced	_	_	O
78	,	_	_	O
79	recurrent	_	_	O
80	cancer	_	_	O
81	.	_	_	O

82	We	_	_	O
83	conducted	_	_	O
84	a	_	_	O
85	two	_	_	O
86	-	_	_	O
87	arm	_	_	O
88	,	_	_	O
89	wait	_	_	O
90	-	_	_	O
91	list	_	_	O
92	control	_	_	O
93	,	_	_	O
94	randomized	_	_	O
95	trial	_	_	O
96	of	_	_	O
97	a	_	_	O
98	complex	_	_	O
99	rehabilitation	_	_	O
100	intervention	_	_	O
101	delivered	_	_	O
102	by	_	_	O
103	a	_	_	O
104	hospice	_	_	O
105	-	_	_	O
106	based	_	_	O
107	multidisciplinary	_	_	O
108	team	_	_	O
109	vs	_	_	O
110	.	_	_	O

111	usual	_	_	O
112	care	_	_	O
113	for	_	_	O
114	active	_	_	O
115	,	_	_	O
116	progressive	_	_	O
117	,	_	_	O
118	recurrent	_	_	O
119	hematological	_	_	O
120	and	_	_	O
121	breast	_	_	O
122	malignancies	_	_	O
123	,	_	_	O
124	with	_	_	O
125	a	_	_	O
126	follow	_	_	O
127	-	_	_	O
128	up	_	_	O
129	at	_	_	O
130	three	_	_	O
131	months	_	_	O
132	.	_	_	O

133	The	_	_	O
134	primary	_	_	O
135	outcome	_	_	O
136	was	_	_	O
137	the	_	_	O
138	psychological	_	_	O
139	subscale	_	_	O
140	of	_	_	O
141	the	_	_	O
142	Supportive	_	_	O
143	Care	_	_	O
144	Needs	_	_	O
145	Survey	_	_	O
146	(	_	_	O
147	SCNS	_	_	O
148	)	_	_	O
149	.	_	_	O

150	Secondary	_	_	O
151	outcomes	_	_	O
152	were	_	_	O
153	other	_	_	O
154	domains	_	_	O
155	of	_	_	O
156	the	_	_	O
157	SCNS	_	_	O
158	,	_	_	O
159	psychological	_	_	O
160	status	_	_	O
161	,	_	_	O
162	continuity	_	_	O
163	of	_	_	O
164	care	_	_	O
165	,	_	_	O
166	quality	_	_	O
167	of	_	_	O
168	life	_	_	O
169	,	_	_	O
170	and	_	_	O
171	resource	_	_	O
172	use	_	_	O
173	.	_	_	O

174	Forty	_	_	O
175	-	_	_	O
176	one	_	_	O
177	participants	_	_	O
178	were	_	_	O
179	enrolled	_	_	O
180	and	_	_	O
181	36	_	_	O
182	completed	_	_	O
183	the	_	_	O
184	trial	_	_	O
185	.	_	_	O

186	The	_	_	B-Premise
187	primary	_	_	I-Premise
188	outcome	_	_	I-Premise
189	was	_	_	I-Premise
190	significantly	_	_	I-Premise
191	lower	_	_	I-Premise
192	in	_	_	I-Premise
193	the	_	_	I-Premise
194	intervention	_	_	I-Premise
195	arm	_	_	I-Premise
196	(	_	_	I-Premise
197	adjusted	_	_	I-Premise
198	difference	_	_	I-Premise
199	-	_	_	I-Premise
200	16	_	_	I-Premise
201	.	_	_	I-Premise

202	8	_	_	I-Premise
203	,	_	_	I-Premise
204	95	_	_	I-Premise
205	%	_	_	I-Premise
206	CI	_	_	I-Premise
207	-	_	_	I-Premise
208	28	_	_	I-Premise
209	.	_	_	I-Premise

210	34	_	_	I-Premise
211	to	_	_	I-Premise
212	-	_	_	I-Premise
213	5	_	_	I-Premise
214	.	_	_	I-Premise

215	3	_	_	I-Premise
216	;	_	_	I-Premise
217	P	_	_	I-Premise
218	=	_	_	I-Premise
219	0	_	_	I-Premise
220	.	_	_	I-Premise

221	006	_	_	I-Premise
222	)	_	_	I-Premise
223	.	_	_	I-Premise

224	The	_	_	B-Premise
225	SCNS	_	_	I-Premise
226	physical	_	_	I-Premise
227	and	_	_	I-Premise
228	patient	_	_	I-Premise
229	care	_	_	I-Premise
230	subscales	_	_	I-Premise
231	(	_	_	I-Premise
232	-	_	_	I-Premise
233	14	_	_	I-Premise
234	.	_	_	I-Premise

235	2	_	_	I-Premise
236	,	_	_	I-Premise
237	95	_	_	I-Premise
238	%	_	_	I-Premise
239	CI	_	_	I-Premise
240	-	_	_	I-Premise
241	26	_	_	I-Premise
242	.	_	_	I-Premise

243	2	_	_	I-Premise
244	to	_	_	I-Premise
245	-	_	_	I-Premise
246	2	_	_	I-Premise
247	.	_	_	I-Premise

248	2	_	_	I-Premise
249	;	_	_	I-Premise
250	P	_	_	I-Premise
251	=	_	_	I-Premise
252	0	_	_	I-Premise
253	.	_	_	I-Premise

254	02	_	_	I-Premise
255	and	_	_	I-Premise
256	-	_	_	I-Premise
257	7	_	_	I-Premise
258	.	_	_	I-Premise

259	4	_	_	I-Premise
260	,	_	_	I-Premise
261	95	_	_	I-Premise
262	%	_	_	I-Premise
263	CI	_	_	I-Premise
264	-	_	_	I-Premise
265	13	_	_	I-Premise
266	.	_	_	I-Premise

267	7	_	_	I-Premise
268	to	_	_	I-Premise
269	-	_	_	I-Premise
270	1	_	_	I-Premise
271	.	_	_	I-Premise

272	1	_	_	I-Premise
273	;	_	_	I-Premise
274	P	_	_	I-Premise
275	=	_	_	I-Premise
276	0	_	_	I-Premise
277	.	_	_	I-Premise

278	02	_	_	I-Premise
279	,	_	_	I-Premise
280	respectively	_	_	I-Premise
281	)	_	_	I-Premise
282	and	_	_	I-Premise
283	self	_	_	I-Premise
284	-	_	_	I-Premise
285	reported	_	_	I-Premise
286	health	_	_	I-Premise
287	state	_	_	I-Premise
288	(	_	_	I-Premise
289	12	_	_	I-Premise
290	.	_	_	I-Premise

291	8	_	_	I-Premise
292	,	_	_	I-Premise
293	95	_	_	I-Premise
294	%	_	_	I-Premise
295	CI	_	_	I-Premise
296	3	_	_	I-Premise
297	.	_	_	I-Premise

298	2	_	_	I-Premise
299	to	_	_	I-Premise
300	22	_	_	I-Premise
301	.	_	_	I-Premise

302	4	_	_	I-Premise
303	;	_	_	I-Premise
304	P	_	_	I-Premise
305	=	_	_	I-Premise
306	0	_	_	I-Premise
307	.	_	_	I-Premise

308	01	_	_	I-Premise
309	)	_	_	I-Premise
310	also	_	_	I-Premise
311	differed	_	_	I-Premise
312	significantly	_	_	I-Premise
313	.	_	_	I-Premise

314	The	_	_	B-Premise
315	incremental	_	_	I-Premise
316	cost	_	_	I-Premise
317	-	_	_	I-Premise
318	effectiveness	_	_	I-Premise
319	ratio	_	_	I-Premise
320	was	_	_	I-Premise
321	£	_	_	I-Premise
322	19	_	_	I-Premise
323	,	_	_	I-Premise
324	390	_	_	I-Premise
325	per	_	_	I-Premise
326	quality	_	_	I-Premise
327	-	_	_	I-Premise
328	adjusted	_	_	I-Premise
329	life	_	_	I-Premise
330	year	_	_	I-Premise
331	.	_	_	I-Premise

332	This	_	_	B-Claim
333	intervention	_	_	I-Claim
334	significantly	_	_	I-Claim
335	reduced	_	_	I-Claim
336	the	_	_	I-Claim
337	unmet	_	_	I-Claim
338	needs	_	_	I-Claim
339	of	_	_	I-Claim
340	cancer	_	_	I-Claim
341	survivors	_	_	I-Claim
342	and	_	_	I-Claim
343	it	_	_	I-Claim
344	is	_	_	I-Claim
345	likely	_	_	I-Claim
346	that	_	_	I-Claim
347	it	_	_	I-Claim
348	is	_	_	I-Claim
349	cost	_	_	I-Claim
350	-	_	_	I-Claim
351	effective	_	_	I-Claim
352	.	_	_	I-Claim

353	Despite	_	_	B-Claim
354	small	_	_	I-Claim
355	numbers	_	_	I-Claim
356	,	_	_	I-Claim
357	the	_	_	I-Claim
358	main	_	_	I-Claim
359	effect	_	_	I-Claim
360	size	_	_	I-Claim
361	was	_	_	I-Claim
362	robust	_	_	I-Claim
363	.	_	_	I-Claim

364	We	_	_	B-Claim
365	recommend	_	_	I-Claim
366	implementation	_	_	I-Claim
367	alongside	_	_	I-Claim
368	evaluation	_	_	I-Claim
369	in	_	_	I-Claim
370	wider	_	_	I-Claim
371	clinical	_	_	I-Claim
372	settings	_	_	I-Claim
373	and	_	_	I-Claim
374	patient	_	_	I-Claim
375	populations	_	_	I-Claim
376	.	_	_	I-Claim


0	Vasomotor	_	_	O
1	symptoms	_	_	O
2	are	_	_	O
3	common	_	_	O
4	adverse	_	_	O
5	effects	_	_	O
6	of	_	_	O
7	antiestrogen	_	_	O
8	hormone	_	_	O
9	treatment	_	_	O
10	in	_	_	O
11	conventional	_	_	O
12	breast	_	_	O
13	cancer	_	_	O
14	care	_	_	O
15	.	_	_	O

16	Hormone	_	_	O
17	replacement	_	_	O
18	therapy	_	_	O
19	is	_	_	O
20	contraindicated	_	_	O
21	in	_	_	O
22	patients	_	_	O
23	with	_	_	O
24	breast	_	_	O
25	cancer	_	_	O
26	.	_	_	O

27	Venlafaxine	_	_	O
28	(	_	_	O
29	Effexor	_	_	O
30	)	_	_	O
31	,	_	_	O
32	the	_	_	O
33	therapy	_	_	O
34	of	_	_	O
35	choice	_	_	O
36	for	_	_	O
37	these	_	_	O
38	symptoms	_	_	O
39	,	_	_	O
40	has	_	_	O
41	numerous	_	_	O
42	adverse	_	_	O
43	effects	_	_	O
44	.	_	_	O

45	Recent	_	_	O
46	studies	_	_	O
47	suggest	_	_	O
48	acupuncture	_	_	O
49	may	_	_	O
50	be	_	_	O
51	effective	_	_	O
52	in	_	_	O
53	reducing	_	_	O
54	vasomotor	_	_	O
55	symptoms	_	_	O
56	in	_	_	O
57	menopausal	_	_	O
58	women	_	_	O
59	.	_	_	O

60	This	_	_	O
61	randomized	_	_	O
62	controlled	_	_	O
63	trial	_	_	O
64	tested	_	_	O
65	whether	_	_	O
66	acupuncture	_	_	O
67	reduces	_	_	O
68	vasomotor	_	_	O
69	symptoms	_	_	O
70	and	_	_	O
71	produces	_	_	O
72	fewer	_	_	O
73	adverse	_	_	O
74	effects	_	_	O
75	than	_	_	O
76	venlafaxine	_	_	O
77	.	_	_	O

78	Fifty	_	_	O
79	patients	_	_	O
80	were	_	_	O
81	randomly	_	_	O
82	assigned	_	_	O
83	to	_	_	O
84	receive	_	_	O
85	12	_	_	O
86	weeks	_	_	O
87	of	_	_	O
88	acupuncture	_	_	O
89	(	_	_	O
90	n	_	_	O
91	=	_	_	O
92	25	_	_	O
93	)	_	_	O
94	or	_	_	O
95	venlafaxine	_	_	O
96	(	_	_	O
97	n	_	_	O
98	=	_	_	O
99	25	_	_	O
100	)	_	_	O
101	treatment	_	_	O
102	.	_	_	O

103	Health	_	_	O
104	outcomes	_	_	O
105	were	_	_	O
106	measured	_	_	O
107	for	_	_	O
108	up	_	_	O
109	to	_	_	O
110	1	_	_	O
111	year	_	_	O
112	post	_	_	O
113	-	_	_	O
114	treatment	_	_	O
115	.	_	_	O

116	Both	_	_	B-Premise
117	groups	_	_	I-Premise
118	exhibited	_	_	I-Premise
119	significant	_	_	I-Premise
120	decreases	_	_	I-Premise
121	in	_	_	I-Premise
122	hot	_	_	I-Premise
123	flashes	_	_	I-Premise
124	,	_	_	I-Premise
125	depressive	_	_	I-Premise
126	symptoms	_	_	I-Premise
127	,	_	_	I-Premise
128	and	_	_	I-Premise
129	other	_	_	I-Premise
130	quality	_	_	I-Premise
131	-	_	_	I-Premise
132	of	_	_	I-Premise
133	-	_	_	I-Premise
134	life	_	_	I-Premise
135	symptoms	_	_	I-Premise
136	,	_	_	I-Premise
137	including	_	_	I-Premise
138	significant	_	_	I-Premise
139	improvements	_	_	I-Premise
140	in	_	_	I-Premise
141	mental	_	_	I-Premise
142	health	_	_	I-Premise
143	from	_	_	I-Premise
144	pre	_	_	I-Premise
145	-	_	_	I-Premise
146	to	_	_	I-Premise
147	post	_	_	I-Premise
148	-	_	_	I-Premise
149	treatment	_	_	I-Premise
150	.	_	_	I-Premise

151	These	_	_	B-Premise
152	changes	_	_	I-Premise
153	were	_	_	I-Premise
154	similar	_	_	I-Premise
155	in	_	_	I-Premise
156	both	_	_	I-Premise
157	groups	_	_	I-Premise
158	,	_	_	I-Premise
159	indicating	_	_	I-Premise
160	that	_	_	I-Premise
161	acupuncture	_	_	I-Premise
162	was	_	_	I-Premise
163	as	_	_	I-Premise
164	effective	_	_	I-Premise
165	as	_	_	I-Premise
166	venlafaxine	_	_	I-Premise
167	.	_	_	I-Premise

168	By	_	_	B-Premise
169	2	_	_	I-Premise
170	weeks	_	_	I-Premise
171	post	_	_	I-Premise
172	-	_	_	I-Premise
173	treatment	_	_	I-Premise
174	,	_	_	I-Premise
175	the	_	_	I-Premise
176	venlafaxine	_	_	I-Premise
177	group	_	_	I-Premise
178	experienced	_	_	I-Premise
179	significant	_	_	I-Premise
180	increases	_	_	I-Premise
181	in	_	_	I-Premise
182	hot	_	_	I-Premise
183	flashes	_	_	I-Premise
184	,	_	_	I-Premise
185	whereas	_	_	I-Premise
186	hot	_	_	I-Premise
187	flashes	_	_	I-Premise
188	in	_	_	I-Premise
189	the	_	_	I-Premise
190	acupuncture	_	_	I-Premise
191	group	_	_	I-Premise
192	remained	_	_	I-Premise
193	at	_	_	I-Premise
194	low	_	_	I-Premise
195	levels	_	_	I-Premise
196	.	_	_	I-Premise

197	The	_	_	B-Premise
198	venlafaxine	_	_	I-Premise
199	group	_	_	I-Premise
200	experienced	_	_	I-Premise
201	18	_	_	I-Premise
202	incidences	_	_	I-Premise
203	of	_	_	I-Premise
204	adverse	_	_	I-Premise
205	effects	_	_	I-Premise
206	(	_	_	I-Premise
207	eg	_	_	I-Premise
208	,	_	_	I-Premise
209	nausea	_	_	I-Premise
210	,	_	_	I-Premise
211	dry	_	_	I-Premise
212	mouth	_	_	I-Premise
213	,	_	_	I-Premise
214	dizziness	_	_	I-Premise
215	,	_	_	I-Premise
216	anxiety	_	_	I-Premise
217	)	_	_	I-Premise
218	,	_	_	I-Premise
219	whereas	_	_	I-Premise
220	the	_	_	I-Premise
221	acupuncture	_	_	I-Premise
222	group	_	_	I-Premise
223	experienced	_	_	I-Premise
224	no	_	_	I-Premise
225	negative	_	_	I-Premise
226	adverse	_	_	I-Premise
227	effects	_	_	I-Premise
228	.	_	_	I-Premise

229	Acupuncture	_	_	B-Premise
230	had	_	_	I-Premise
231	the	_	_	I-Premise
232	additional	_	_	I-Premise
233	benefit	_	_	I-Premise
234	of	_	_	I-Premise
235	increased	_	_	I-Premise
236	sex	_	_	I-Premise
237	drive	_	_	I-Premise
238	in	_	_	I-Premise
239	some	_	_	I-Premise
240	women	_	_	I-Premise
241	,	_	_	I-Premise
242	and	_	_	I-Premise
243	most	_	_	I-Premise
244	reported	_	_	I-Premise
245	an	_	_	I-Premise
246	improvement	_	_	I-Premise
247	in	_	_	I-Premise
248	their	_	_	I-Premise
249	energy	_	_	I-Premise
250	,	_	_	I-Premise
251	clarity	_	_	I-Premise
252	of	_	_	I-Premise
253	thought	_	_	I-Premise
254	,	_	_	I-Premise
255	and	_	_	I-Premise
256	sense	_	_	I-Premise
257	of	_	_	I-Premise
258	well	_	_	I-Premise
259	-	_	_	I-Premise
260	being	_	_	I-Premise
261	.	_	_	I-Premise

262	Acupuncture	_	_	B-Claim
263	appears	_	_	I-Claim
264	to	_	_	I-Claim
265	be	_	_	I-Claim
266	equivalent	_	_	I-Claim
267	to	_	_	I-Claim
268	drug	_	_	I-Claim
269	therapy	_	_	I-Claim
270	in	_	_	I-Claim
271	these	_	_	I-Claim
272	patients	_	_	I-Claim
273	.	_	_	I-Claim

274	It	_	_	B-Claim
275	is	_	_	I-Claim
276	a	_	_	I-Claim
277	safe	_	_	I-Claim
278	,	_	_	I-Claim
279	effective	_	_	I-Claim
280	and	_	_	I-Claim
281	durable	_	_	I-Claim
282	treatment	_	_	I-Claim
283	for	_	_	I-Claim
284	vasomotor	_	_	I-Claim
285	symptoms	_	_	I-Claim
286	secondary	_	_	I-Claim
287	to	_	_	I-Claim
288	long	_	_	I-Claim
289	-	_	_	I-Claim
290	term	_	_	I-Claim
291	antiestrogen	_	_	I-Claim
292	hormone	_	_	I-Claim
293	use	_	_	I-Claim
294	in	_	_	I-Claim
295	patients	_	_	I-Claim
296	with	_	_	I-Claim
297	breast	_	_	I-Claim
298	cancer	_	_	I-Claim
299	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	1	_	_	O
3	-	_	_	O
4	year	_	_	O
5	outcomes	_	_	O
6	of	_	_	O
7	a	_	_	O
8	four	_	_	O
9	-	_	_	O
10	component	_	_	O
11	behavioral	_	_	O
12	therapy	_	_	O
13	(	_	_	O
14	BT	_	_	O
15	)	_	_	O
16	sleep	_	_	O
17	intervention	_	_	O
18	(	_	_	O
19	Individualized	_	_	O
20	Sleep	_	_	O
21	Promotion	_	_	O
22	Plan	_	_	O
23	[	_	_	O
24	ISPP	_	_	O
25	]	_	_	O
26	)	_	_	O
27	versus	_	_	O
28	a	_	_	O
29	healthy	_	_	O
30	eating	_	_	O
31	control	_	_	O
32	(	_	_	O
33	HEC	_	_	O
34	)	_	_	O
35	on	_	_	O
36	cancer	_	_	O
37	-	_	_	O
38	related	_	_	O
39	fatigue	_	_	O
40	in	_	_	O
41	women	_	_	O
42	receiving	_	_	O
43	breast	_	_	O
44	cancer	_	_	O
45	adjuvant	_	_	O
46	chemotherapy	_	_	O
47	treatment	_	_	O
48	(	_	_	O
49	CTX	_	_	O
50	)	_	_	O
51	.	_	_	O

52	A	_	_	O
53	total	_	_	O
54	of	_	_	O
55	219	_	_	O
56	participants	_	_	O
57	from	_	_	O
58	12	_	_	O
59	oncology	_	_	O
60	clinics	_	_	O
61	were	_	_	O
62	randomly	_	_	O
63	assigned	_	_	O
64	in	_	_	O
65	a	_	_	O
66	clinical	_	_	O
67	trial	_	_	O
68	.	_	_	O

69	Before	_	_	O
70	CTX	_	_	O
71	,	_	_	O
72	research	_	_	O
73	nurses	_	_	O
74	coached	_	_	O
75	intervention	_	_	O
76	participants	_	_	O
77	to	_	_	O
78	develop	_	_	O
79	a	_	_	O
80	BT	_	_	O
81	plan	_	_	O
82	including	_	_	O
83	stimulus	_	_	O
84	control	_	_	O
85	,	_	_	O
86	modified	_	_	O
87	sleep	_	_	O
88	restriction	_	_	O
89	,	_	_	O
90	relaxation	_	_	O
91	therapy	_	_	O
92	,	_	_	O
93	and	_	_	O
94	sleep	_	_	O
95	hygiene	_	_	O
96	.	_	_	O

97	BT	_	_	O
98	plans	_	_	O
99	were	_	_	O
100	revised	_	_	O
101	before	_	_	O
102	each	_	_	O
103	CTX	_	_	O
104	and	_	_	O
105	30	_	_	O
106	,	_	_	O
107	60	_	_	O
108	,	_	_	O
109	and	_	_	O
110	90	_	_	O
111	days	_	_	O
112	after	_	_	O
113	the	_	_	O
114	last	_	_	O
115	CTX	_	_	O
116	and	_	_	O
117	reinforced	_	_	O
118	7	_	_	O
119	to	_	_	O
120	9	_	_	O
121	days	_	_	O
122	later	_	_	O
123	.	_	_	O

124	HEC	_	_	O
125	participants	_	_	O
126	received	_	_	O
127	nutritional	_	_	O
128	information	_	_	O
129	and	_	_	O
130	equal	_	_	O
131	attention	_	_	O
132	.	_	_	O

133	Pittsburgh	_	_	O
134	Sleep	_	_	O
135	Quality	_	_	O
136	Index	_	_	O
137	(	_	_	O
138	PSQI	_	_	O
139	)	_	_	O
140	,	_	_	O
141	Daily	_	_	O
142	Diary	_	_	O
143	,	_	_	O
144	Wrist	_	_	O
145	Actigraph	_	_	O
146	,	_	_	O
147	and	_	_	O
148	Piper	_	_	O
149	Fatigue	_	_	O
150	Scale	_	_	O
151	measures	_	_	O
152	and	_	_	O
153	Repeated	_	_	O
154	Linear	_	_	O
155	Mixed	_	_	O
156	Model	_	_	O
157	analysis	_	_	O
158	following	_	_	O
159	the	_	_	O
160	Intent	_	_	O
161	to	_	_	O
162	Treat	_	_	O
163	paradigm	_	_	O
164	were	_	_	O
165	used	_	_	O
166	.	_	_	O

167	Sleep	_	_	B-Premise
168	quality	_	_	I-Premise
169	differed	_	_	I-Premise
170	over	_	_	I-Premise
171	1	_	_	I-Premise
172	years	_	_	I-Premise
173	time	_	_	I-Premise
174	(	_	_	I-Premise
175	F	_	_	I-Premise
176	[	_	_	I-Premise
177	4	_	_	I-Premise
178	,	_	_	I-Premise
179	162	_	_	I-Premise
180	]	_	_	I-Premise
181	=	_	_	I-Premise
182	7	_	_	I-Premise
183	.	_	_	I-Premise

184	7	_	_	I-Premise
185	,	_	_	I-Premise
186	P	_	_	I-Premise
187	<	_	_	I-Premise
188	.	_	_	I-Premise

189	001	_	_	I-Premise
190	;	_	_	I-Premise
191	by	_	_	I-Premise
192	group	_	_	I-Premise
193	,	_	_	I-Premise
194	F	_	_	I-Premise
195	[	_	_	I-Premise
196	1	_	_	I-Premise
197	,	_	_	I-Premise
198	173	_	_	I-Premise
199	]	_	_	I-Premise
200	=	_	_	I-Premise
201	4	_	_	I-Premise
202	.	_	_	I-Premise

203	8	_	_	I-Premise
204	,	_	_	I-Premise
205	P	_	_	I-Premise
206	=	_	_	I-Premise
207	.	_	_	I-Premise

208	029	_	_	I-Premise
209	;	_	_	I-Premise
210	and	_	_	I-Premise
211	over	_	_	I-Premise
212	time	_	_	I-Premise
213	by	_	_	I-Premise
214	group	_	_	I-Premise
215	,	_	_	I-Premise
216	F	_	_	I-Premise
217	[	_	_	I-Premise
218	4	_	_	I-Premise
219	,	_	_	I-Premise
220	162	_	_	I-Premise
221	]	_	_	I-Premise
222	=	_	_	I-Premise
223	3	_	_	I-Premise
224	.	_	_	I-Premise

225	3	_	_	I-Premise
226	,	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	.	_	_	I-Premise

230	013	_	_	I-Premise
231	)	_	_	I-Premise
232	.	_	_	I-Premise

233	Pairwise	_	_	B-Premise
234	comparisons	_	_	I-Premise
235	revealed	_	_	I-Premise
236	significant	_	_	I-Premise
237	differences	_	_	I-Premise
238	between	_	_	I-Premise
239	groups	_	_	I-Premise
240	at	_	_	I-Premise
241	90	_	_	I-Premise
242	days	_	_	I-Premise
243	(	_	_	I-Premise
244	P	_	_	I-Premise
245	=	_	_	I-Premise
246	.	_	_	I-Premise

247	002	_	_	I-Premise
248	)	_	_	I-Premise
249	but	_	_	B-Premise
250	not	_	_	I-Premise
251	at	_	_	I-Premise
252	1	_	_	I-Premise
253	year	_	_	I-Premise
254	(	_	_	I-Premise
255	P	_	_	I-Premise
256	=	_	_	I-Premise
257	.	_	_	I-Premise

258	052	_	_	I-Premise
259	)	_	_	I-Premise
260	.	_	_	I-Premise

261	Seven	_	_	O
262	days	_	_	O
263	of	_	_	O
264	diary	_	_	O
265	and	_	_	O
266	actigraphy	_	_	O
267	data	_	_	O
268	did	_	_	O
269	not	_	_	O
270	corroborate	_	_	O
271	with	_	_	O
272	monthly	_	_	O
273	reflections	_	_	O
274	(	_	_	O
275	PSQI	_	_	O
276	)	_	_	O
277	.	_	_	O

278	The	_	_	B-Premise
279	night	_	_	I-Premise
280	awakenings	_	_	I-Premise
281	(	_	_	I-Premise
282	Actigraph	_	_	I-Premise
283	)	_	_	I-Premise
284	pattern	_	_	I-Premise
285	was	_	_	I-Premise
286	significantly	_	_	I-Premise
287	different	_	_	I-Premise
288	by	_	_	I-Premise
289	group	_	_	I-Premise
290	over	_	_	I-Premise
291	time	_	_	I-Premise
292	(	_	_	I-Premise
293	P	_	_	I-Premise
294	=	_	_	I-Premise
295	.	_	_	I-Premise

296	046	_	_	I-Premise
297	)	_	_	I-Premise
298	,	_	_	I-Premise
299	with	_	_	I-Premise
300	no	_	_	I-Premise
301	differences	_	_	I-Premise
302	between	_	_	I-Premise
303	groups	_	_	I-Premise
304	at	_	_	I-Premise
305	90	_	_	I-Premise
306	days	_	_	I-Premise
307	or	_	_	I-Premise
308	at	_	_	I-Premise
309	1	_	_	I-Premise
310	year	_	_	I-Premise
311	.	_	_	I-Premise

312	Fatigue	_	_	B-Premise
313	was	_	_	I-Premise
314	lower	_	_	I-Premise
315	at	_	_	I-Premise
316	1	_	_	I-Premise
317	year	_	_	I-Premise
318	than	_	_	I-Premise
319	before	_	_	I-Premise
320	CTX	_	_	I-Premise
321	;	_	_	I-Premise
322	no	_	_	B-Premise
323	group	_	_	I-Premise
324	effects	_	_	I-Premise
325	were	_	_	I-Premise
326	found	_	_	I-Premise
327	.	_	_	I-Premise

328	The	_	_	B-Claim
329	BT	_	_	I-Claim
330	group	_	_	I-Claim
331	,	_	_	I-Claim
332	on	_	_	I-Claim
333	average	_	_	I-Claim
334	,	_	_	I-Claim
335	experienced	_	_	I-Claim
336	significant	_	_	I-Claim
337	improvement	_	_	I-Claim
338	on	_	_	I-Claim
339	global	_	_	I-Claim
340	sleep	_	_	I-Claim
341	quality	_	_	I-Claim
342	compared	_	_	I-Claim
343	with	_	_	I-Claim
344	the	_	_	I-Claim
345	HEC	_	_	I-Claim
346	group	_	_	I-Claim
347	,	_	_	I-Claim
348	but	_	_	B-Claim
349	not	_	_	I-Claim
350	on	_	_	I-Claim
351	objective	_	_	I-Claim
352	sleep	_	_	I-Claim
353	or	_	_	I-Claim
354	fatigue	_	_	I-Claim
355	outcomes	_	_	I-Claim
356	.	_	_	I-Claim


0	The	_	_	O
1	majority	_	_	O
2	of	_	_	O
3	prostate	_	_	O
4	carcinoma	_	_	O
5	survivors	_	_	O
6	experience	_	_	O
7	enduring	_	_	O
8	sexual	_	_	O
9	difficulties	_	_	O
10	and	_	_	O
11	associated	_	_	O
12	distress	_	_	O
13	in	_	_	O
14	the	_	_	O
15	years	_	_	O
16	after	_	_	O
17	definitive	_	_	O
18	treatment	_	_	O
19	.	_	_	O

20	A	_	_	O
21	counseling	_	_	O
22	intervention	_	_	O
23	aimed	_	_	O
24	at	_	_	O
25	improving	_	_	O
26	levels	_	_	O
27	of	_	_	O
28	sexual	_	_	O
29	satisfaction	_	_	O
30	and	_	_	O
31	increasing	_	_	O
32	successful	_	_	O
33	utilization	_	_	O
34	of	_	_	O
35	medical	_	_	O
36	treatment	_	_	O
37	for	_	_	O
38	erectile	_	_	O
39	dysfunction	_	_	O
40	(	_	_	O
41	ED	_	_	O
42	)	_	_	O
43	was	_	_	O
44	developed	_	_	O
45	and	_	_	O
46	pilot	_	_	O
47	-	_	_	O
48	tested	_	_	O
49	for	_	_	O
50	both	_	_	O
51	the	_	_	O
52	survivor	_	_	O
53	of	_	_	O
54	prostate	_	_	O
55	carcinoma	_	_	O
56	and	_	_	O
57	his	_	_	O
58	partner	_	_	O
59	.	_	_	O

60	All	_	_	O
61	male	_	_	O
62	participants	_	_	O
63	were	_	_	O
64	3	_	_	O
65	-	_	_	O
66	month	_	_	O
67	to	_	_	O
68	5	_	_	O
69	-	_	_	O
70	year	_	_	O
71	survivors	_	_	O
72	of	_	_	O
73	localized	_	_	O
74	prostate	_	_	O
75	carcinoma	_	_	O
76	who	_	_	O
77	had	_	_	O
78	been	_	_	O
79	treated	_	_	O
80	with	_	_	O
81	radical	_	_	O
82	prostatectomy	_	_	O
83	or	_	_	O
84	radiation	_	_	O
85	therapy	_	_	O
86	,	_	_	O
87	and	_	_	O
88	were	_	_	O
89	married	_	_	O
90	or	_	_	O
91	in	_	_	O
92	a	_	_	O
93	committed	_	_	O
94	relationship	_	_	O
95	.	_	_	O

96	Couples	_	_	O
97	were	_	_	O
98	randomized	_	_	O
99	to	_	_	O
100	attend	_	_	O
101	four	_	_	O
102	sessions	_	_	O
103	of	_	_	O
104	counseling	_	_	O
105	together	_	_	O
106	or	_	_	O
107	to	_	_	O
108	have	_	_	O
109	the	_	_	O
110	man	_	_	O
111	attend	_	_	O
112	alone	_	_	O
113	.	_	_	O

114	In	_	_	O
115	both	_	_	O
116	groups	_	_	O
117	,	_	_	O
118	partners	_	_	O
119	completed	_	_	O
120	behavioral	_	_	O
121	homework	_	_	O
122	.	_	_	O

123	The	_	_	O
124	sessions	_	_	O
125	included	_	_	O
126	education	_	_	O
127	on	_	_	O
128	prostate	_	_	O
129	carcinoma	_	_	O
130	and	_	_	O
131	sexual	_	_	O
132	function	_	_	O
133	and	_	_	O
134	options	_	_	O
135	to	_	_	O
136	treat	_	_	O
137	ED	_	_	O
138	as	_	_	O
139	well	_	_	O
140	as	_	_	O
141	sexual	_	_	O
142	communication	_	_	O
143	and	_	_	O
144	stimulation	_	_	O
145	skills	_	_	O
146	.	_	_	O

147	Standardized	_	_	O
148	questionnaires	_	_	O
149	at	_	_	O
150	baseline	_	_	O
151	,	_	_	O
152	posttreatment	_	_	O
153	,	_	_	O
154	and	_	_	O
155	at	_	_	O
156	3	_	_	O
157	-	_	_	O
158	month	_	_	O
159	and	_	_	O
160	6	_	_	O
161	-	_	_	O
162	month	_	_	O
163	follow	_	_	O
164	-	_	_	O
165	up	_	_	O
166	assessed	_	_	O
167	sexual	_	_	O
168	function	_	_	O
169	,	_	_	O
170	marital	_	_	O
171	adjustment	_	_	O
172	,	_	_	O
173	psychologic	_	_	O
174	distress	_	_	O
175	,	_	_	O
176	and	_	_	O
177	utilization	_	_	O
178	of	_	_	O
179	treatments	_	_	O
180	for	_	_	O
181	ED	_	_	O
182	.	_	_	O

183	Fifty	_	_	O
184	-	_	_	O
185	one	_	_	O
186	of	_	_	O
187	84	_	_	O
188	couples	_	_	O
189	randomized	_	_	O
190	to	_	_	O
191	treatment	_	_	O
192	completed	_	_	O
193	the	_	_	O
194	intervention	_	_	O
195	(	_	_	O
196	61	_	_	O
197	%	_	_	O
198	)	_	_	O
199	.	_	_	O

200	Attendance	_	_	O
201	by	_	_	O
202	the	_	_	O
203	partner	_	_	O
204	did	_	_	O
205	not	_	_	O
206	affect	_	_	O
207	outcomes	_	_	O
208	.	_	_	O

209	Participants	_	_	B-Premise
210	completing	_	_	I-Premise
211	the	_	_	I-Premise
212	intervention	_	_	I-Premise
213	demonstrated	_	_	I-Premise
214	improvement	_	_	I-Premise
215	in	_	_	I-Premise
216	male	_	_	I-Premise
217	overall	_	_	I-Premise
218	distress	_	_	I-Premise
219	(	_	_	I-Premise
220	P	_	_	I-Premise
221	<	_	_	I-Premise
222	0	_	_	I-Premise
223	.	_	_	I-Premise

224	01	_	_	I-Premise
225	)	_	_	I-Premise
226	,	_	_	I-Premise
227	male	_	_	I-Premise
228	global	_	_	I-Premise
229	sexual	_	_	I-Premise
230	function	_	_	I-Premise
231	(	_	_	I-Premise
232	P	_	_	I-Premise
233	<	_	_	I-Premise
234	0	_	_	I-Premise
235	.	_	_	I-Premise

236	0001	_	_	I-Premise
237	)	_	_	I-Premise
238	,	_	_	I-Premise
239	and	_	_	I-Premise
240	female	_	_	I-Premise
241	global	_	_	I-Premise
242	sexual	_	_	I-Premise
243	function	_	_	I-Premise
244	(	_	_	I-Premise
245	P	_	_	I-Premise
246	<	_	_	I-Premise
247	0	_	_	I-Premise
248	.	_	_	I-Premise

249	05	_	_	I-Premise
250	)	_	_	I-Premise
251	at	_	_	I-Premise
252	3	_	_	I-Premise
253	-	_	_	I-Premise
254	month	_	_	I-Premise
255	follow	_	_	I-Premise
256	-	_	_	I-Premise
257	up	_	_	I-Premise
258	,	_	_	I-Premise
259	but	_	_	B-Premise
260	regression	_	_	I-Premise
261	toward	_	_	I-Premise
262	baseline	_	_	I-Premise
263	was	_	_	I-Premise
264	noted	_	_	I-Premise
265	at	_	_	I-Premise
266	6	_	_	I-Premise
267	-	_	_	I-Premise
268	month	_	_	I-Premise
269	follow	_	_	I-Premise
270	-	_	_	I-Premise
271	up	_	_	I-Premise
272	.	_	_	I-Premise

273	However	_	_	B-Premise
274	,	_	_	I-Premise
275	utilization	_	_	I-Premise
276	of	_	_	I-Premise
277	ED	_	_	I-Premise
278	treatments	_	_	I-Premise
279	increased	_	_	I-Premise
280	from	_	_	I-Premise
281	31	_	_	I-Premise
282	%	_	_	I-Premise
283	at	_	_	I-Premise
284	the	_	_	I-Premise
285	time	_	_	I-Premise
286	of	_	_	I-Premise
287	study	_	_	I-Premise
288	entry	_	_	I-Premise
289	to	_	_	I-Premise
290	49	_	_	I-Premise
291	%	_	_	I-Premise
292	at	_	_	I-Premise
293	the	_	_	I-Premise
294	6	_	_	I-Premise
295	-	_	_	I-Premise
296	month	_	_	I-Premise
297	follow	_	_	I-Premise
298	-	_	_	I-Premise
299	up	_	_	I-Premise
300	(	_	_	I-Premise
301	P	_	_	I-Premise
302	=	_	_	I-Premise
303	0	_	_	I-Premise
304	.	_	_	I-Premise

305	003	_	_	I-Premise
306	)	_	_	I-Premise
307	.	_	_	I-Premise

308	The	_	_	B-Claim
309	results	_	_	I-Claim
310	of	_	_	I-Claim
311	this	_	_	I-Claim
312	brief	_	_	I-Claim
313	pilot	_	_	I-Claim
314	counseling	_	_	I-Claim
315	intervention	_	_	I-Claim
316	demonstrated	_	_	I-Claim
317	significant	_	_	I-Claim
318	gains	_	_	I-Claim
319	in	_	_	I-Claim
320	sexual	_	_	I-Claim
321	function	_	_	I-Claim
322	and	_	_	I-Claim
323	satisfaction	_	_	I-Claim
324	and	_	_	I-Claim
325	increased	_	_	I-Claim
326	utilization	_	_	I-Claim
327	of	_	_	I-Claim
328	treatments	_	_	I-Claim
329	for	_	_	I-Claim
330	ED	_	_	I-Claim
331	.	_	_	I-Claim

332	However	_	_	B-Claim
333	,	_	_	I-Claim
334	modifications	_	_	I-Claim
335	are	_	_	I-Claim
336	needed	_	_	I-Claim
337	in	_	_	I-Claim
338	future	_	_	I-Claim
339	randomized	_	_	I-Claim
340	trials	_	_	I-Claim
341	to	_	_	I-Claim
342	reduce	_	_	I-Claim
343	the	_	_	I-Claim
344	rate	_	_	I-Claim
345	of	_	_	I-Claim
346	premature	_	_	I-Claim
347	termination	_	_	I-Claim
348	and	_	_	I-Claim
349	to	_	_	I-Claim
350	improve	_	_	I-Claim
351	long	_	_	I-Claim
352	-	_	_	I-Claim
353	term	_	_	I-Claim
354	maintenance	_	_	I-Claim
355	of	_	_	I-Claim
356	gains	_	_	I-Claim
357	.	_	_	I-Claim


0	Both	_	_	O
1	gemcitabine	_	_	O
2	(	_	_	O
3	GEM	_	_	O
4	)	_	_	O
5	and	_	_	O
6	fluoropyrimidines	_	_	O
7	are	_	_	O
8	valuable	_	_	O
9	treatment	_	_	O
10	for	_	_	O
11	advanced	_	_	O
12	pancreatic	_	_	O
13	cancer	_	_	O
14	.	_	_	O

15	This	_	_	O
16	open	_	_	O
17	-	_	_	O
18	label	_	_	O
19	study	_	_	O
20	was	_	_	O
21	designed	_	_	O
22	to	_	_	O
23	compare	_	_	O
24	the	_	_	O
25	overall	_	_	O
26	survival	_	_	O
27	(	_	_	O
28	OS	_	_	O
29	)	_	_	O
30	of	_	_	O
31	patients	_	_	O
32	randomly	_	_	O
33	assigned	_	_	O
34	to	_	_	O
35	GEM	_	_	O
36	alone	_	_	O
37	or	_	_	O
38	GEM	_	_	O
39	plus	_	_	O
40	capecitabine	_	_	O
41	(	_	_	O
42	GEM	_	_	O
43	-	_	_	O
44	CAP	_	_	O
45	)	_	_	O
46	.	_	_	O

47	Patients	_	_	O
48	with	_	_	O
49	previously	_	_	O
50	untreated	_	_	O
51	histologically	_	_	O
52	or	_	_	O
53	cytologically	_	_	O
54	proven	_	_	O
55	locally	_	_	O
56	advanced	_	_	O
57	or	_	_	O
58	metastatic	_	_	O
59	carcinoma	_	_	O
60	of	_	_	O
61	the	_	_	O
62	pancreas	_	_	O
63	with	_	_	O
64	a	_	_	O
65	performance	_	_	O
66	status	_	_	O
67	<	_	_	O
68	or	_	_	O
69	=	_	_	O
70	2	_	_	O
71	were	_	_	O
72	recruited	_	_	O
73	.	_	_	O

74	Patients	_	_	O
75	were	_	_	O
76	randomly	_	_	O
77	assigned	_	_	O
78	to	_	_	O
79	GEM	_	_	O
80	or	_	_	O
81	GEM	_	_	O
82	-	_	_	O
83	CAP	_	_	O
84	.	_	_	O

85	The	_	_	O
86	primary	_	_	O
87	outcome	_	_	O
88	measure	_	_	O
89	was	_	_	O
90	survival	_	_	O
91	.	_	_	O

92	Meta	_	_	O
93	-	_	_	O
94	analysis	_	_	O
95	of	_	_	O
96	published	_	_	O
97	studies	_	_	O
98	was	_	_	O
99	also	_	_	O
100	conducted	_	_	O
101	.	_	_	O

102	Between	_	_	O
103	May	_	_	O
104	2002	_	_	O
105	and	_	_	O
106	January	_	_	O
107	2005	_	_	O
108	,	_	_	O
109	533	_	_	O
110	patients	_	_	O
111	were	_	_	O
112	randomly	_	_	O
113	assigned	_	_	O
114	to	_	_	O
115	GEM	_	_	O
116	(	_	_	O
117	n	_	_	O
118	=	_	_	O
119	266	_	_	O
120	)	_	_	O
121	and	_	_	O
122	GEM	_	_	O
123	-	_	_	O
124	CAP	_	_	O
125	(	_	_	O
126	n	_	_	O
127	=	_	_	O
128	267	_	_	O
129	)	_	_	O
130	arms	_	_	O
131	.	_	_	O

132	GEM	_	_	B-Premise
133	-	_	_	I-Premise
134	CAP	_	_	I-Premise
135	significantly	_	_	I-Premise
136	improved	_	_	I-Premise
137	objective	_	_	I-Premise
138	response	_	_	I-Premise
139	rate	_	_	I-Premise
140	(	_	_	I-Premise
141	19	_	_	I-Premise
142	.	_	_	I-Premise

143	1	_	_	I-Premise
144	%	_	_	I-Premise
145	v	_	_	I-Premise
146	12	_	_	I-Premise
147	.	_	_	I-Premise

148	4	_	_	I-Premise
149	%	_	_	I-Premise
150	;	_	_	I-Premise
151	P	_	_	I-Premise
152	=	_	_	I-Premise
153	.	_	_	I-Premise

154	034	_	_	I-Premise
155	)	_	_	I-Premise
156	and	_	_	I-Premise
157	progression	_	_	I-Premise
158	-	_	_	I-Premise
159	free	_	_	I-Premise
160	survival	_	_	I-Premise
161	(	_	_	I-Premise
162	hazard	_	_	I-Premise
163	ratio	_	_	I-Premise
164	[	_	_	I-Premise
165	HR	_	_	I-Premise
166	]	_	_	I-Premise
167	,	_	_	I-Premise
168	0	_	_	I-Premise
169	.	_	_	I-Premise

170	78	_	_	I-Premise
171	;	_	_	I-Premise
172	95	_	_	I-Premise
173	%	_	_	I-Premise
174	CI	_	_	I-Premise
175	,	_	_	I-Premise
176	0	_	_	I-Premise
177	.	_	_	I-Premise

178	66	_	_	I-Premise
179	to	_	_	I-Premise
180	0	_	_	I-Premise
181	.	_	_	I-Premise

182	93	_	_	I-Premise
183	;	_	_	I-Premise
184	P	_	_	I-Premise
185	=	_	_	I-Premise
186	.	_	_	I-Premise

187	004	_	_	I-Premise
188	)	_	_	I-Premise
189	and	_	_	I-Premise
190	was	_	_	I-Premise
191	associated	_	_	I-Premise
192	with	_	_	I-Premise
193	a	_	_	I-Premise
194	trend	_	_	I-Premise
195	toward	_	_	I-Premise
196	improved	_	_	I-Premise
197	OS	_	_	I-Premise
198	(	_	_	I-Premise
199	HR	_	_	I-Premise
200	,	_	_	I-Premise
201	0	_	_	I-Premise
202	.	_	_	I-Premise

203	86	_	_	I-Premise
204	;	_	_	I-Premise
205	95	_	_	I-Premise
206	%	_	_	I-Premise
207	CI	_	_	I-Premise
208	,	_	_	I-Premise
209	0	_	_	I-Premise
210	.	_	_	I-Premise

211	72	_	_	I-Premise
212	to	_	_	I-Premise
213	1	_	_	I-Premise
214	.	_	_	I-Premise

215	02	_	_	I-Premise
216	;	_	_	I-Premise
217	P	_	_	I-Premise
218	=	_	_	I-Premise
219	.	_	_	I-Premise

220	08	_	_	I-Premise
221	)	_	_	I-Premise
222	compared	_	_	I-Premise
223	with	_	_	I-Premise
224	GEM	_	_	I-Premise
225	alone	_	_	I-Premise
226	.	_	_	I-Premise

227	This	_	_	B-Premise
228	trend	_	_	I-Premise
229	for	_	_	I-Premise
230	OS	_	_	I-Premise
231	benefit	_	_	I-Premise
232	for	_	_	I-Premise
233	GEM	_	_	I-Premise
234	-	_	_	I-Premise
235	CAP	_	_	I-Premise
236	was	_	_	I-Premise
237	consistent	_	_	I-Premise
238	across	_	_	I-Premise
239	different	_	_	I-Premise
240	prognostic	_	_	I-Premise
241	subgroups	_	_	I-Premise
242	according	_	_	I-Premise
243	to	_	_	I-Premise
244	baseline	_	_	I-Premise
245	stratification	_	_	I-Premise
246	factors	_	_	I-Premise
247	(	_	_	I-Premise
248	stage	_	_	I-Premise
249	and	_	_	I-Premise
250	performance	_	_	I-Premise
251	status	_	_	I-Premise
252	)	_	_	I-Premise
253	and	_	_	I-Premise
254	remained	_	_	I-Premise
255	after	_	_	I-Premise
256	adjusting	_	_	I-Premise
257	for	_	_	I-Premise
258	these	_	_	I-Premise
259	stratification	_	_	I-Premise
260	factors	_	_	I-Premise
261	(	_	_	I-Premise
262	P	_	_	I-Premise
263	=	_	_	I-Premise
264	.	_	_	I-Premise

265	077	_	_	I-Premise
266	)	_	_	I-Premise
267	.	_	_	I-Premise

268	Moreover	_	_	O
269	,	_	_	O
270	the	_	_	B-Premise
271	meta	_	_	I-Premise
272	-	_	_	I-Premise
273	analysis	_	_	I-Premise
274	of	_	_	I-Premise
275	two	_	_	I-Premise
276	additional	_	_	I-Premise
277	studies	_	_	I-Premise
278	involving	_	_	I-Premise
279	935	_	_	I-Premise
280	patients	_	_	I-Premise
281	showed	_	_	I-Premise
282	a	_	_	I-Premise
283	significant	_	_	I-Premise
284	survival	_	_	I-Premise
285	benefit	_	_	I-Premise
286	in	_	_	I-Premise
287	favor	_	_	I-Premise
288	of	_	_	I-Premise
289	GEM	_	_	I-Premise
290	-	_	_	I-Premise
291	CAP	_	_	I-Premise
292	(	_	_	I-Premise
293	HR	_	_	I-Premise
294	,	_	_	I-Premise
295	0	_	_	I-Premise
296	.	_	_	I-Premise

297	86	_	_	I-Premise
298	;	_	_	I-Premise
299	95	_	_	I-Premise
300	%	_	_	I-Premise
301	CI	_	_	I-Premise
302	,	_	_	I-Premise
303	0	_	_	I-Premise
304	.	_	_	I-Premise

305	75	_	_	I-Premise
306	to	_	_	I-Premise
307	0	_	_	I-Premise
308	.	_	_	I-Premise

309	98	_	_	I-Premise
310	;	_	_	I-Premise
311	P	_	_	I-Premise
312	=	_	_	I-Premise
313	.	_	_	I-Premise

314	02	_	_	I-Premise
315	)	_	_	I-Premise
316	with	_	_	I-Premise
317	no	_	_	I-Premise
318	intertrial	_	_	I-Premise
319	heterogeneity	_	_	I-Premise
320	.	_	_	I-Premise

321	On	_	_	B-Claim
322	the	_	_	I-Claim
323	basis	_	_	I-Claim
324	of	_	_	I-Claim
325	our	_	_	I-Claim
326	trial	_	_	I-Claim
327	and	_	_	I-Claim
328	the	_	_	I-Claim
329	meta	_	_	I-Claim
330	-	_	_	I-Claim
331	analysis	_	_	I-Claim
332	,	_	_	I-Claim
333	GEM	_	_	I-Claim
334	-	_	_	I-Claim
335	CAP	_	_	I-Claim
336	should	_	_	I-Claim
337	be	_	_	I-Claim
338	considered	_	_	I-Claim
339	as	_	_	I-Claim
340	one	_	_	I-Claim
341	of	_	_	I-Claim
342	the	_	_	I-Claim
343	standard	_	_	I-Claim
344	first	_	_	I-Claim
345	-	_	_	I-Claim
346	line	_	_	I-Claim
347	options	_	_	I-Claim
348	in	_	_	I-Claim
349	locally	_	_	I-Claim
350	advanced	_	_	I-Claim
351	and	_	_	I-Claim
352	metastatic	_	_	I-Claim
353	pancreatic	_	_	I-Claim
354	cancer	_	_	I-Claim
355	.	_	_	I-Claim


0	A	_	_	O
1	multidimensional	_	_	O
2	rehabilitation	_	_	O
3	program	_	_	O
4	for	_	_	O
5	cancer	_	_	O
6	survivors	_	_	O
7	was	_	_	O
8	developed	_	_	O
9	to	_	_	O
10	overcome	_	_	O
11	cancer	_	_	O
12	-	_	_	O
13	related	_	_	O
14	problems	_	_	O
15	and	_	_	O
16	to	_	_	O
17	improve	_	_	O
18	quality	_	_	O
19	of	_	_	O
20	life	_	_	O
21	.	_	_	O

22	The	_	_	O
23	two	_	_	O
24	purposes	_	_	O
25	of	_	_	O
26	the	_	_	O
27	study	_	_	O
28	were	_	_	O
29	to	_	_	O
30	describe	_	_	O
31	the	_	_	O
32	effectiveness	_	_	O
33	of	_	_	O
34	the	_	_	O
35	program	_	_	O
36	and	_	_	O
37	to	_	_	O
38	obtain	_	_	O
39	information	_	_	O
40	about	_	_	O
41	patient	_	_	O
42	preferences	_	_	O
43	for	_	_	O
44	multi	_	_	O
45	or	_	_	O
46	mono	_	_	O
47	dimensional	_	_	O
48	rehabilitation	_	_	O
49	programs	_	_	O
50	.	_	_	O

51	cancer	_	_	O
52	survivors	_	_	O
53	with	_	_	O
54	different	_	_	O
55	diagnoses	_	_	O
56	,	_	_	O
57	and	_	_	O
58	cancer	_	_	O
59	-	_	_	O
60	related	_	_	O
61	physical	_	_	O
62	and	_	_	O
63	psychosocial	_	_	O
64	problems	_	_	O
65	.	_	_	O

66	a	_	_	O
67	15	_	_	O
68	-	_	_	O
69	week	_	_	O
70	rehabilitation	_	_	O
71	program	_	_	O
72	including	_	_	O
73	individual	_	_	O
74	exercise	_	_	O
75	,	_	_	O
76	sports	_	_	O
77	,	_	_	O
78	psycho	_	_	O
79	-	_	_	O
80	education	_	_	O
81	,	_	_	O
82	and	_	_	O
83	information	_	_	O
84	.	_	_	O

85	Group	_	_	O
86	-	_	_	O
87	wise	_	_	O
88	randomization	_	_	O
89	was	_	_	O
90	implemented	_	_	O
91	by	_	_	O
92	assigning	_	_	O
93	one	_	_	O
94	half	_	_	O
95	of	_	_	O
96	the	_	_	O
97	patients	_	_	O
98	to	_	_	O
99	the	_	_	O
100	complete	_	_	O
101	program	_	_	O
102	while	_	_	O
103	the	_	_	O
104	other	_	_	O
105	half	_	_	O
106	were	_	_	O
107	allowed	_	_	O
108	to	_	_	O
109	choose	_	_	O
110	which	_	_	O
111	program	_	_	O
112	components	_	_	O
113	they	_	_	O
114	considered	_	_	O
115	relevant	_	_	O
116	.	_	_	O

117	Health	_	_	O
118	-	_	_	O
119	Related	_	_	O
120	Quality	_	_	O
121	of	_	_	O
122	Life	_	_	O
123	[	_	_	O
124	RAND	_	_	O
125	-	_	_	O
126	36	_	_	O
127	and	_	_	O
128	Rotterdam	_	_	O
129	Symptom	_	_	O
130	Check	_	_	O
131	List	_	_	O
132	(	_	_	O
133	RSCL	_	_	O
134	)	_	_	O
135	]	_	_	O
136	,	_	_	O
137	exercise	_	_	O
138	capacity	_	_	O
139	(	_	_	O
140	symptom	_	_	O
141	limited	_	_	O
142	bicycle	_	_	O
143	ergometry	_	_	O
144	)	_	_	O
145	,	_	_	O
146	muscle	_	_	O
147	force	_	_	O
148	(	_	_	O
149	hand	_	_	O
150	-	_	_	O
151	held	_	_	O
152	dynamometry	_	_	O
153	)	_	_	O
154	,	_	_	O
155	and	_	_	O
156	patient	_	_	O
157	preferences	_	_	O
158	.	_	_	O

159	Measurements	_	_	O
160	were	_	_	O
161	performed	_	_	O
162	before	_	_	O
163	(	_	_	O
164	T0	_	_	O
165	)	_	_	O
166	and	_	_	O
167	after	_	_	O
168	the	_	_	O
169	rehabilitation	_	_	O
170	program	_	_	O
171	(	_	_	O
172	T1	_	_	O
173	)	_	_	O
174	,	_	_	O
175	and	_	_	O
176	at	_	_	O
177	a	_	_	O
178	3	_	_	O
179	-	_	_	O
180	month	_	_	O
181	follow	_	_	O
182	-	_	_	O
183	up	_	_	O
184	(	_	_	O
185	T2	_	_	O
186	)	_	_	O
187	.	_	_	O

188	After	_	_	B-Premise
189	the	_	_	I-Premise
190	rehabilitation	_	_	I-Premise
191	program	_	_	I-Premise
192	,	_	_	I-Premise
193	cancer	_	_	I-Premise
194	survivors	_	_	I-Premise
195	(	_	_	I-Premise
196	n	_	_	I-Premise
197	=	_	_	I-Premise
198	63	_	_	I-Premise
199	)	_	_	I-Premise
200	displayed	_	_	I-Premise
201	statistically	_	_	I-Premise
202	significant	_	_	I-Premise
203	improvements	_	_	I-Premise
204	on	_	_	I-Premise
205	health	_	_	I-Premise
206	-	_	_	I-Premise
207	related	_	_	I-Premise
208	quality	_	_	I-Premise
209	of	_	_	I-Premise
210	life	_	_	I-Premise
211	with	_	_	I-Premise
212	effect	_	_	I-Premise
213	sizes	_	_	I-Premise
214	(	_	_	I-Premise
215	ES	_	_	I-Premise
216	)	_	_	I-Premise
217	varying	_	_	I-Premise
218	from	_	_	I-Premise
219	0	_	_	I-Premise
220	.	_	_	I-Premise

221	38	_	_	I-Premise
222	to	_	_	I-Premise
223	0	_	_	I-Premise
224	.	_	_	I-Premise

225	99	_	_	I-Premise
226	(	_	_	I-Premise
227	RAND	_	_	I-Premise
228	-	_	_	I-Premise
229	36	_	_	I-Premise
230	)	_	_	I-Premise
231	and	_	_	I-Premise
232	from	_	_	I-Premise
233	-	_	_	I-Premise
234	0	_	_	I-Premise
235	.	_	_	I-Premise

236	34	_	_	I-Premise
237	to	_	_	I-Premise
238	-	_	_	I-Premise
239	0	_	_	I-Premise
240	.	_	_	I-Premise

241	57	_	_	I-Premise
242	(	_	_	I-Premise
243	RSCL	_	_	I-Premise
244	)	_	_	I-Premise
245	,	_	_	I-Premise
246	most	_	_	I-Premise
247	persistent	_	_	I-Premise
248	at	_	_	I-Premise
249	3	_	_	I-Premise
250	-	_	_	I-Premise
251	month	_	_	I-Premise
252	follow	_	_	I-Premise
253	-	_	_	I-Premise
254	up	_	_	I-Premise
255	.	_	_	I-Premise

256	Furthermore	_	_	B-Premise
257	,	_	_	I-Premise
258	statistically	_	_	I-Premise
259	significant	_	_	I-Premise
260	improvements	_	_	I-Premise
261	in	_	_	I-Premise
262	exercise	_	_	I-Premise
263	capacity	_	_	I-Premise
264	and	_	_	I-Premise
265	muscle	_	_	I-Premise
266	force	_	_	I-Premise
267	of	_	_	I-Premise
268	upper	_	_	I-Premise
269	and	_	_	I-Premise
270	lower	_	_	I-Premise
271	extremities	_	_	I-Premise
272	were	_	_	I-Premise
273	displayed	_	_	I-Premise
274	after	_	_	I-Premise
275	rehabilitation	_	_	I-Premise
276	.	_	_	I-Premise

277	If	_	_	B-Premise
278	offered	_	_	I-Premise
279	a	_	_	I-Premise
280	choice	_	_	I-Premise
281	,	_	_	I-Premise
282	80	_	_	I-Premise
283	%	_	_	I-Premise
284	of	_	_	I-Premise
285	the	_	_	I-Premise
286	patients	_	_	I-Premise
287	prior	_	_	I-Premise
288	to	_	_	I-Premise
289	start	_	_	I-Premise
290	and	_	_	I-Premise
291	58	_	_	I-Premise
292	%	_	_	I-Premise
293	of	_	_	I-Premise
294	the	_	_	I-Premise
295	patients	_	_	I-Premise
296	after	_	_	I-Premise
297	completion	_	_	I-Premise
298	of	_	_	I-Premise
299	the	_	_	I-Premise
300	program	_	_	I-Premise
301	indicated	_	_	I-Premise
302	that	_	_	I-Premise
303	they	_	_	I-Premise
304	preferred	_	_	I-Premise
305	the	_	_	I-Premise
306	entire	_	_	I-Premise
307	multidimensional	_	_	I-Premise
308	program	_	_	I-Premise
309	.	_	_	I-Premise

310	A	_	_	B-Claim
311	multidimensional	_	_	I-Claim
312	rehabilitation	_	_	I-Claim
313	program	_	_	I-Claim
314	has	_	_	I-Claim
315	statistically	_	_	I-Claim
316	and	_	_	I-Claim
317	clinically	_	_	I-Claim
318	relevant	_	_	I-Claim
319	beneficial	_	_	I-Claim
320	effects	_	_	I-Claim
321	on	_	_	I-Claim
322	health	_	_	I-Claim
323	-	_	_	I-Claim
324	related	_	_	I-Claim
325	quality	_	_	I-Claim
326	of	_	_	I-Claim
327	life	_	_	I-Claim
328	,	_	_	I-Claim
329	exercise	_	_	I-Claim
330	capacity	_	_	I-Claim
331	,	_	_	I-Claim
332	and	_	_	I-Claim
333	muscle	_	_	I-Claim
334	force	_	_	I-Claim
335	in	_	_	I-Claim
336	cancer	_	_	I-Claim
337	patients	_	_	I-Claim
338	with	_	_	I-Claim
339	different	_	_	I-Claim
340	diagnoses	_	_	I-Claim
341	.	_	_	I-Claim

342	Furthermore	_	_	O
343	,	_	_	O
344	if	_	_	B-Claim
345	offered	_	_	I-Claim
346	the	_	_	I-Claim
347	choice	_	_	I-Claim
348	,	_	_	I-Claim
349	the	_	_	I-Claim
350	majority	_	_	I-Claim
351	of	_	_	I-Claim
352	cancer	_	_	I-Claim
353	survivors	_	_	I-Claim
354	seem	_	_	I-Claim
355	to	_	_	I-Claim
356	prefer	_	_	I-Claim
357	multidimensional	_	_	I-Claim
358	programs	_	_	I-Claim
359	to	_	_	I-Claim
360	programs	_	_	I-Claim
361	with	_	_	I-Claim
362	only	_	_	I-Claim
363	one	_	_	I-Claim
364	component	_	_	I-Claim
365	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	is	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	treatment	_	_	O
10	and	_	_	O
11	retention	_	_	O
12	effects	_	_	O
13	between	_	_	O
14	standard	_	_	O
15	decongestive	_	_	O
16	lymphatic	_	_	O
17	therapy	_	_	O
18	(	_	_	O
19	DLT	_	_	O
20	)	_	_	O
21	combined	_	_	O
22	with	_	_	O
23	pneumatic	_	_	O
24	compression	_	_	O
25	(	_	_	O
26	PC	_	_	O
27	)	_	_	O
28	and	_	_	O
29	modified	_	_	O
30	DLT	_	_	O
31	,	_	_	O
32	in	_	_	O
33	which	_	_	O
34	the	_	_	O
35	use	_	_	O
36	of	_	_	O
37	a	_	_	O
38	short	_	_	O
39	-	_	_	O
40	stretch	_	_	O
41	bandage	_	_	O
42	is	_	_	O
43	replaced	_	_	O
44	with	_	_	O
45	the	_	_	O
46	use	_	_	O
47	of	_	_	O
48	Kinesio	_	_	O
49	tape	_	_	O
50	(	_	_	O
51	K	_	_	O
52	-	_	_	O
53	tape	_	_	O
54	)	_	_	O
55	combined	_	_	O
56	with	_	_	O
57	PC	_	_	O
58	.	_	_	O

59	Forty	_	_	O
60	-	_	_	O
61	one	_	_	O
62	patients	_	_	O
63	with	_	_	O
64	unilateral	_	_	O
65	breast	_	_	O
66	-	_	_	O
67	cancer	_	_	O
68	-	_	_	O
69	related	_	_	O
70	lymphedema	_	_	O
71	for	_	_	O
72	at	_	_	O
73	least	_	_	O
74	3	_	_	O
75	months	_	_	O
76	were	_	_	O
77	randomly	_	_	O
78	grouped	_	_	O
79	into	_	_	O
80	the	_	_	O
81	DLT	_	_	O
82	group	_	_	O
83	(	_	_	O
84	bandage	_	_	O
85	group	_	_	O
86	,	_	_	O
87	N	_	_	O
88	=	_	_	O
89	21	_	_	O
90	)	_	_	O
91	or	_	_	O
92	the	_	_	O
93	modified	_	_	O
94	DLT	_	_	O
95	group	_	_	O
96	(	_	_	O
97	K	_	_	O
98	-	_	_	O
99	tape	_	_	O
100	group	_	_	O
101	,	_	_	O
102	N	_	_	O
103	=	_	_	O
104	20	_	_	O
105	)	_	_	O
106	.	_	_	O

107	Skin	_	_	O
108	care	_	_	O
109	,	_	_	O
110	30	_	_	O
111	-	_	_	O
112	min	_	_	O
113	manual	_	_	O
114	lymphatic	_	_	O
115	drainage	_	_	O
116	,	_	_	O
117	1	_	_	O
118	-	_	_	O
119	h	_	_	O
120	pneumatic	_	_	O
121	compression	_	_	O
122	therapy	_	_	O
123	,	_	_	O
124	application	_	_	O
125	of	_	_	O
126	a	_	_	O
127	short	_	_	O
128	-	_	_	O
129	stretch	_	_	O
130	bandage	_	_	O
131	or	_	_	O
132	K	_	_	O
133	-	_	_	O
134	tape	_	_	O
135	for	_	_	O
136	each	_	_	O
137	group	_	_	O
138	,	_	_	O
139	and	_	_	O
140	a	_	_	O
141	20	_	_	O
142	-	_	_	O
143	min	_	_	O
144	physical	_	_	O
145	therapy	_	_	O
146	exercise	_	_	O
147	were	_	_	O
148	given	_	_	O
149	during	_	_	O
150	every	_	_	O
151	treatment	_	_	O
152	session	_	_	O
153	.	_	_	O

154	Patient	_	_	O
155	evaluation	_	_	O
156	items	_	_	O
157	included	_	_	O
158	physical	_	_	O
159	therapy	_	_	O
160	assessment	_	_	O
161	,	_	_	O
162	limb	_	_	O
163	size	_	_	O
164	,	_	_	O
165	water	_	_	O
166	composition	_	_	O
167	of	_	_	O
168	the	_	_	O
169	upper	_	_	O
170	extremity	_	_	O
171	,	_	_	O
172	lymphedema	_	_	O
173	-	_	_	O
174	related	_	_	O
175	symptoms	_	_	O
176	,	_	_	O
177	quality	_	_	O
178	of	_	_	O
179	life	_	_	O
180	,	_	_	O
181	and	_	_	O
182	patients	_	_	O
183	'	_	_	O
184	acceptance	_	_	O
185	to	_	_	O
186	the	_	_	O
187	bandage	_	_	O
188	or	_	_	O
189	tape	_	_	O
190	.	_	_	O

191	There	_	_	B-Premise
192	was	_	_	I-Premise
193	no	_	_	I-Premise
194	significant	_	_	I-Premise
195	difference	_	_	I-Premise
196	between	_	_	I-Premise
197	groups	_	_	I-Premise
198	in	_	_	I-Premise
199	all	_	_	I-Premise
200	outcome	_	_	I-Premise
201	variables	_	_	I-Premise
202	(	_	_	I-Premise
203	P	_	_	I-Premise
204	>	_	_	I-Premise
205	0	_	_	I-Premise
206	.	_	_	I-Premise

207	05	_	_	I-Premise
208	)	_	_	I-Premise
209	through	_	_	I-Premise
210	the	_	_	I-Premise
211	whole	_	_	I-Premise
212	study	_	_	I-Premise
213	period	_	_	I-Premise
214	.	_	_	I-Premise

215	Excess	_	_	B-Premise
216	limb	_	_	I-Premise
217	size	_	_	I-Premise
218	(	_	_	I-Premise
219	circumference	_	_	I-Premise
220	and	_	_	I-Premise
221	water	_	_	I-Premise
222	displacement	_	_	I-Premise
223	)	_	_	I-Premise
224	and	_	_	I-Premise
225	excess	_	_	I-Premise
226	water	_	_	I-Premise
227	composition	_	_	I-Premise
228	were	_	_	I-Premise
229	reduced	_	_	I-Premise
230	significantly	_	_	I-Premise
231	in	_	_	I-Premise
232	the	_	_	I-Premise
233	bandage	_	_	I-Premise
234	group	_	_	I-Premise
235	;	_	_	I-Premise
236	excess	_	_	B-Premise
237	circumference	_	_	I-Premise
238	and	_	_	I-Premise
239	excess	_	_	I-Premise
240	water	_	_	I-Premise
241	composition	_	_	I-Premise
242	were	_	_	I-Premise
243	reduced	_	_	I-Premise
244	significantly	_	_	I-Premise
245	in	_	_	I-Premise
246	the	_	_	I-Premise
247	tape	_	_	I-Premise
248	group	_	_	I-Premise
249	.	_	_	I-Premise

250	The	_	_	B-Premise
251	acceptance	_	_	I-Premise
252	of	_	_	I-Premise
253	K	_	_	I-Premise
254	-	_	_	I-Premise
255	tape	_	_	I-Premise
256	was	_	_	I-Premise
257	better	_	_	I-Premise
258	than	_	_	I-Premise
259	the	_	_	I-Premise
260	bandage	_	_	I-Premise
261	,	_	_	I-Premise
262	and	_	_	I-Premise
263	benefits	_	_	I-Premise
264	included	_	_	I-Premise
265	longer	_	_	I-Premise
266	wearing	_	_	I-Premise
267	time	_	_	I-Premise
268	,	_	_	I-Premise
269	less	_	_	I-Premise
270	difficulty	_	_	I-Premise
271	in	_	_	I-Premise
272	usage	_	_	I-Premise
273	,	_	_	I-Premise
274	and	_	_	I-Premise
275	increased	_	_	I-Premise
276	comfort	_	_	I-Premise
277	and	_	_	I-Premise
278	convenience	_	_	I-Premise
279	(	_	_	I-Premise
280	P	_	_	I-Premise
281	<	_	_	I-Premise
282	0	_	_	I-Premise
283	.	_	_	I-Premise

284	05	_	_	I-Premise
285	)	_	_	I-Premise
286	.	_	_	I-Premise

287	The	_	_	B-Claim
288	study	_	_	I-Claim
289	results	_	_	I-Claim
290	suggest	_	_	I-Claim
291	that	_	_	I-Claim
292	K	_	_	I-Claim
293	-	_	_	I-Claim
294	tape	_	_	I-Claim
295	could	_	_	I-Claim
296	replace	_	_	I-Claim
297	the	_	_	I-Claim
298	bandage	_	_	I-Claim
299	in	_	_	I-Claim
300	DLT	_	_	I-Claim
301	,	_	_	I-Claim
302	and	_	_	I-Claim
303	it	_	_	I-Claim
304	could	_	_	I-Claim
305	be	_	_	I-Claim
306	an	_	_	I-Claim
307	alternative	_	_	I-Claim
308	choice	_	_	I-Claim
309	for	_	_	I-Claim
310	the	_	_	I-Claim
311	breast	_	_	I-Claim
312	-	_	_	I-Claim
313	cancer	_	_	I-Claim
314	-	_	_	I-Claim
315	related	_	_	I-Claim
316	lymphedema	_	_	I-Claim
317	patient	_	_	I-Claim
318	with	_	_	I-Claim
319	poor	_	_	I-Claim
320	short	_	_	I-Claim
321	-	_	_	I-Claim
322	stretch	_	_	I-Claim
323	bandage	_	_	I-Claim
324	compliance	_	_	I-Claim
325	after	_	_	I-Claim
326	1	_	_	I-Claim
327	-	_	_	I-Claim
328	month	_	_	I-Claim
329	intervention	_	_	I-Claim
330	.	_	_	I-Claim

331	If	_	_	O
332	the	_	_	O
333	intervention	_	_	O
334	period	_	_	O
335	was	_	_	O
336	prolonged	_	_	O
337	,	_	_	O
338	we	_	_	O
339	might	_	_	O
340	get	_	_	O
341	different	_	_	O
342	conclusion	_	_	O
343	.	_	_	O

344	Moreover	_	_	O
345	,	_	_	O
346	these	_	_	B-Claim
347	two	_	_	I-Claim
348	treatment	_	_	I-Claim
349	protocols	_	_	I-Claim
350	are	_	_	I-Claim
351	inefficient	_	_	I-Claim
352	and	_	_	I-Claim
353	cost	_	_	I-Claim
354	time	_	_	I-Claim
355	in	_	_	I-Claim
356	application	_	_	I-Claim
357	.	_	_	I-Claim

358	More	_	_	B-Claim
359	efficient	_	_	I-Claim
360	treatment	_	_	I-Claim
361	protocol	_	_	I-Claim
362	is	_	_	I-Claim
363	needed	_	_	I-Claim
364	for	_	_	I-Claim
365	clinical	_	_	I-Claim
366	practice	_	_	I-Claim
367	.	_	_	I-Claim


0	It	_	_	B-Claim
1	has	_	_	I-Claim
2	been	_	_	I-Claim
3	shown	_	_	I-Claim
4	that	_	_	I-Claim
5	nonpharmacologic	_	_	I-Claim
6	interventions	_	_	I-Claim
7	are	_	_	I-Claim
8	effective	_	_	I-Claim
9	management	_	_	I-Claim
10	techniques	_	_	I-Claim
11	for	_	_	I-Claim
12	cancer	_	_	I-Claim
13	-	_	_	I-Claim
14	related	_	_	I-Claim
15	fatigue	_	_	I-Claim
16	(	_	_	I-Claim
17	CRF	_	_	I-Claim
18	)	_	_	I-Claim
19	in	_	_	I-Claim
20	cancer	_	_	I-Claim
21	survivors	_	_	I-Claim
22	.	_	_	I-Claim

23	However	_	_	O
24	,	_	_	O
25	few	_	_	O
26	studies	_	_	O
27	have	_	_	O
28	investigated	_	_	O
29	their	_	_	O
30	effectiveness	_	_	O
31	in	_	_	O
32	patients	_	_	O
33	who	_	_	O
34	are	_	_	O
35	receiving	_	_	O
36	chemotherapy	_	_	O
37	.	_	_	O

38	In	_	_	O
39	this	_	_	O
40	study	_	_	O
41	,	_	_	O
42	the	_	_	O
43	authors	_	_	O
44	tested	_	_	O
45	the	_	_	O
46	effectiveness	_	_	O
47	of	_	_	O
48	a	_	_	O
49	brief	_	_	O
50	behaviorally	_	_	O
51	oriented	_	_	O
52	intervention	_	_	O
53	in	_	_	O
54	reducing	_	_	O
55	CRF	_	_	O
56	and	_	_	O
57	improving	_	_	O
58	physical	_	_	O
59	function	_	_	O
60	and	_	_	O
61	associated	_	_	O
62	distress	_	_	O
63	in	_	_	O
64	individuals	_	_	O
65	who	_	_	O
66	were	_	_	O
67	receiving	_	_	O
68	chemotherapy	_	_	O
69	.	_	_	O

70	For	_	_	O
71	this	_	_	O
72	randomized	_	_	O
73	controlled	_	_	O
74	trial	_	_	O
75	,	_	_	O
76	60	_	_	O
77	patients	_	_	O
78	with	_	_	O
79	cancer	_	_	O
80	were	_	_	O
81	recruited	_	_	O
82	and	_	_	O
83	received	_	_	O
84	either	_	_	O
85	usual	_	_	O
86	care	_	_	O
87	or	_	_	O
88	the	_	_	O
89	intervention	_	_	O
90	.	_	_	O

91	The	_	_	O
92	intervention	_	_	O
93	was	_	_	O
94	delivered	_	_	O
95	on	_	_	O
96	an	_	_	O
97	individual	_	_	O
98	basis	_	_	O
99	on	_	_	O
100	3	_	_	O
101	occasions	_	_	O
102	over	_	_	O
103	a	_	_	O
104	period	_	_	O
105	from	_	_	O
106	9	_	_	O
107	weeks	_	_	O
108	to	_	_	O
109	12	_	_	O
110	weeks	_	_	O
111	,	_	_	O
112	and	_	_	O
113	the	_	_	O
114	objective	_	_	O
115	of	_	_	O
116	the	_	_	O
117	intervention	_	_	O
118	was	_	_	O
119	to	_	_	O
120	alter	_	_	O
121	fatigue	_	_	O
122	-	_	_	O
123	related	_	_	O
124	thoughts	_	_	O
125	and	_	_	O
126	behavior	_	_	O
127	.	_	_	O

128	Primary	_	_	O
129	outcomes	_	_	O
130	were	_	_	O
131	assessed	_	_	O
132	as	_	_	O
133	follows	_	_	O
134	:	_	_	O
135	CRF	_	_	O
136	using	_	_	O
137	the	_	_	O
138	Visual	_	_	O
139	Analogue	_	_	O
140	Scale	_	_	O
141	-	_	_	O
142	Global	_	_	O
143	Fatigue	_	_	O
144	;	_	_	O
145	physical	_	_	O
146	functioning	_	_	O
147	using	_	_	O
148	the	_	_	O
149	European	_	_	O
150	Organization	_	_	O
151	for	_	_	O
152	Research	_	_	O
153	and	_	_	O
154	Treatment	_	_	O
155	of	_	_	O
156	Cancer	_	_	O
157	Quality	_	_	O
158	-	_	_	O
159	of	_	_	O
160	-	_	_	O
161	Life	_	_	O
162	Core	_	_	O
163	30	_	_	O
164	Questionnaire	_	_	O
165	,	_	_	O
166	and	_	_	O
167	CRF	_	_	O
168	-	_	_	O
169	associated	_	_	O
170	distress	_	_	O
171	using	_	_	O
172	the	_	_	O
173	Fatigue	_	_	O
174	Outcome	_	_	O
175	Measure	_	_	O
176	.	_	_	O

177	Assessments	_	_	O
178	were	_	_	O
179	made	_	_	O
180	on	_	_	O
181	4	_	_	O
182	occasions	_	_	O
183	:	_	_	O
184	at	_	_	O
185	baseline	_	_	O
186	(	_	_	O
187	T0	_	_	O
188	)	_	_	O
189	,	_	_	O
190	at	_	_	O
191	the	_	_	O
192	end	_	_	O
193	of	_	_	O
194	chemotherapy	_	_	O
195	(	_	_	O
196	T1	_	_	O
197	)	_	_	O
198	,	_	_	O
199	1	_	_	O
200	month	_	_	O
201	after	_	_	O
202	chemotherapy	_	_	O
203	(	_	_	O
204	T2	_	_	O
205	)	_	_	O
206	,	_	_	O
207	and	_	_	O
208	9	_	_	O
209	months	_	_	O
210	after	_	_	O
211	recruitment	_	_	O
212	(	_	_	O
213	T3	_	_	O
214	)	_	_	O
215	.	_	_	O

216	Normally	_	_	O
217	distributed	_	_	O
218	data	_	_	O
219	were	_	_	O
220	analyzed	_	_	O
221	using	_	_	O
222	t	_	_	O
223	tests	_	_	O
224	and	_	_	O
225	random	_	_	O
226	-	_	_	O
227	slope	_	_	O
228	/	_	_	O
229	random	_	_	O
230	-	_	_	O
231	intercept	_	_	O
232	mixed	_	_	O
233	models	_	_	O
234	.	_	_	O

235	The	_	_	B-Premise
236	intervention	_	_	I-Premise
237	demonstrated	_	_	I-Premise
238	a	_	_	I-Premise
239	trend	_	_	I-Premise
240	toward	_	_	I-Premise
241	improved	_	_	I-Premise
242	CRF	_	_	I-Premise
243	,	_	_	I-Premise
244	although	_	_	B-Premise
245	this	_	_	I-Premise
246	effect	_	_	I-Premise
247	was	_	_	I-Premise
248	reduced	_	_	I-Premise
249	once	_	_	I-Premise
250	confounders	_	_	I-Premise
251	had	_	_	I-Premise
252	been	_	_	I-Premise
253	controlled	_	_	I-Premise
254	statistically	_	_	I-Premise
255	.	_	_	I-Premise

256	There	_	_	B-Premise
257	was	_	_	I-Premise
258	a	_	_	I-Premise
259	significant	_	_	I-Premise
260	improvement	_	_	I-Premise
261	in	_	_	I-Premise
262	physical	_	_	I-Premise
263	functioning	_	_	I-Premise
264	(	_	_	I-Premise
265	coefficient	_	_	I-Premise
266	,	_	_	I-Premise
267	10	_	_	I-Premise
268	.	_	_	I-Premise

269	0	_	_	I-Premise
270	;	_	_	I-Premise
271	95	_	_	I-Premise
272	%	_	_	I-Premise
273	confidence	_	_	I-Premise
274	interval	_	_	I-Premise
275	,	_	_	I-Premise
276	2	_	_	I-Premise
277	.	_	_	I-Premise

278	5	_	_	I-Premise
279	-	_	_	I-Premise
280	17	_	_	I-Premise
281	.	_	_	I-Premise

282	5	_	_	I-Premise
283	;	_	_	I-Premise
284	P	_	_	I-Premise
285	=	_	_	I-Premise
286	.	_	_	I-Premise

287	009	_	_	I-Premise
288	)	_	_	I-Premise
289	,	_	_	I-Premise
290	and	_	_	I-Premise
291	this	_	_	I-Premise
292	effect	_	_	I-Premise
293	remained	_	_	I-Premise
294	once	_	_	I-Premise
295	the	_	_	I-Premise
296	confounding	_	_	I-Premise
297	effects	_	_	I-Premise
298	of	_	_	I-Premise
299	mood	_	_	I-Premise
300	disturbance	_	_	I-Premise
301	and	_	_	I-Premise
302	comorbid	_	_	I-Premise
303	disorders	_	_	I-Premise
304	were	_	_	I-Premise
305	controlled	_	_	I-Premise
306	statistically	_	_	I-Premise
307	.	_	_	I-Premise

308	No	_	_	B-Premise
309	decrease	_	_	I-Premise
310	in	_	_	I-Premise
311	fatigue	_	_	I-Premise
312	-	_	_	I-Premise
313	related	_	_	I-Premise
314	distress	_	_	I-Premise
315	was	_	_	I-Premise
316	detected	_	_	I-Premise
317	.	_	_	I-Premise

318	The	_	_	B-Claim
319	behaviorally	_	_	I-Claim
320	oriented	_	_	I-Claim
321	intervention	_	_	I-Claim
322	brought	_	_	I-Claim
323	about	_	_	I-Claim
324	significant	_	_	I-Claim
325	improvements	_	_	I-Claim
326	in	_	_	I-Claim
327	physical	_	_	I-Claim
328	functioning	_	_	I-Claim
329	,	_	_	I-Claim
330	indicated	_	_	I-Claim
331	a	_	_	I-Claim
332	trend	_	_	I-Claim
333	toward	_	_	I-Claim
334	improved	_	_	I-Claim
335	CRF	_	_	I-Claim
336	,	_	_	I-Claim
337	but	_	_	I-Claim
338	detected	_	_	I-Claim
339	no	_	_	I-Claim
340	effect	_	_	I-Claim
341	for	_	_	I-Claim
342	fatigue	_	_	I-Claim
343	-	_	_	I-Claim
344	related	_	_	I-Claim
345	distress	_	_	I-Claim
346	.	_	_	I-Claim


0	The	_	_	O
1	primary	_	_	O
2	objective	_	_	O
3	of	_	_	O
4	this	_	_	O
5	study	_	_	O
6	was	_	_	O
7	to	_	_	O
8	compare	_	_	O
9	the	_	_	O
10	response	_	_	O
11	rates	_	_	O
12	of	_	_	O
13	elderly	_	_	O
14	,	_	_	O
15	chemonaive	_	_	O
16	patients	_	_	O
17	with	_	_	O
18	advanced	_	_	O
19	non	_	_	O
20	-	_	_	O
21	small	_	_	O
22	cell	_	_	O
23	lung	_	_	O
24	cancer	_	_	O
25	(	_	_	O
26	NSCLC	_	_	O
27	)	_	_	O
28	treated	_	_	O
29	with	_	_	O
30	daily	_	_	O
31	oral	_	_	O
32	erlotinib	_	_	O
33	versus	_	_	O
34	oral	_	_	O
35	vinorelbine	_	_	O
36	.	_	_	O

37	Chemonaive	_	_	O
38	Taiwanese	_	_	O
39	patients	_	_	O
40	aged	_	_	O
41	70	_	_	O
42	years	_	_	O
43	or	_	_	O
44	older	_	_	O
45	who	_	_	O
46	had	_	_	O
47	advanced	_	_	O
48	NSCLC	_	_	O
49	were	_	_	O
50	randomized	_	_	O
51	to	_	_	O
52	receive	_	_	O
53	either	_	_	O
54	oral	_	_	O
55	erlotinib	_	_	O
56	150	_	_	O
57	mg	_	_	O
58	(	_	_	O
59	E	_	_	O
60	)	_	_	O
61	daily	_	_	O
62	or	_	_	O
63	oral	_	_	O
64	vinorelbine	_	_	O
65	60	_	_	O
66	mg	_	_	O
67	/	_	_	O
68	m	_	_	O
69	(	_	_	O
70	V	_	_	O
71	)	_	_	O
72	on	_	_	O
73	days	_	_	O
74	1	_	_	O
75	and	_	_	O
76	8	_	_	O
77	every	_	_	O
78	3	_	_	O
79	weeks	_	_	O
80	.	_	_	O

81	From	_	_	O
82	February	_	_	O
83	2007	_	_	O
84	to	_	_	O
85	July	_	_	O
86	2008	_	_	O
87	,	_	_	O
88	116	_	_	O
89	patients	_	_	O
90	were	_	_	O
91	enrolled	_	_	O
92	and	_	_	O
93	113	_	_	O
94	were	_	_	O
95	included	_	_	O
96	in	_	_	O
97	the	_	_	O
98	intent	_	_	O
99	-	_	_	O
100	to	_	_	O
101	-	_	_	O
102	treat	_	_	O
103	population	_	_	O
104	:	_	_	O
105	57	_	_	O
106	patients	_	_	O
107	in	_	_	O
108	the	_	_	O
109	E	_	_	O
110	group	_	_	O
111	and	_	_	O
112	56	_	_	O
113	patients	_	_	O
114	in	_	_	O
115	the	_	_	O
116	V	_	_	O
117	group	_	_	O
118	.	_	_	O

119	Objective	_	_	B-Premise
120	response	_	_	I-Premise
121	rates	_	_	I-Premise
122	were	_	_	I-Premise
123	22	_	_	I-Premise
124	.	_	_	I-Premise

125	8	_	_	I-Premise
126	%	_	_	I-Premise
127	(	_	_	I-Premise
128	13	_	_	I-Premise
129	of	_	_	I-Premise
130	57	_	_	I-Premise
131	)	_	_	I-Premise
132	in	_	_	I-Premise
133	E	_	_	I-Premise
134	and	_	_	I-Premise
135	8	_	_	I-Premise
136	.	_	_	I-Premise

137	9	_	_	I-Premise
138	%	_	_	I-Premise
139	(	_	_	I-Premise
140	5	_	_	I-Premise
141	of	_	_	I-Premise
142	56	_	_	I-Premise
143	)	_	_	I-Premise
144	in	_	_	I-Premise
145	V	_	_	I-Premise
146	(	_	_	I-Premise
147	p	_	_	I-Premise
148	=	_	_	I-Premise
149	0	_	_	I-Premise
150	.	_	_	I-Premise

151	0388	_	_	I-Premise
152	)	_	_	I-Premise
153	.	_	_	I-Premise

154	Median	_	_	B-Premise
155	progression	_	_	I-Premise
156	-	_	_	I-Premise
157	free	_	_	I-Premise
158	survival	_	_	I-Premise
159	(	_	_	I-Premise
160	PFS	_	_	I-Premise
161	)	_	_	I-Premise
162	was	_	_	I-Premise
163	4	_	_	I-Premise
164	.	_	_	I-Premise

165	57	_	_	I-Premise
166	months	_	_	I-Premise
167	in	_	_	I-Premise
168	E	_	_	I-Premise
169	and	_	_	I-Premise
170	2	_	_	I-Premise
171	.	_	_	I-Premise

172	53	_	_	I-Premise
173	months	_	_	I-Premise
174	in	_	_	I-Premise
175	V	_	_	I-Premise
176	(	_	_	I-Premise
177	p	_	_	I-Premise
178	=	_	_	I-Premise
179	0	_	_	I-Premise
180	.	_	_	I-Premise

181	0287	_	_	I-Premise
182	)	_	_	I-Premise
183	,	_	_	I-Premise
184	with	_	_	I-Premise
185	an	_	_	I-Premise
186	80	_	_	I-Premise
187	.	_	_	I-Premise

188	6	_	_	I-Premise
189	%	_	_	I-Premise
190	increase	_	_	I-Premise
191	in	_	_	I-Premise
192	median	_	_	I-Premise
193	PFS	_	_	I-Premise
194	for	_	_	I-Premise
195	E	_	_	I-Premise
196	compared	_	_	I-Premise
197	with	_	_	I-Premise
198	V	_	_	I-Premise
199	.	_	_	I-Premise

200	Median	_	_	B-Premise
201	survival	_	_	I-Premise
202	time	_	_	I-Premise
203	was	_	_	I-Premise
204	11	_	_	I-Premise
205	.	_	_	I-Premise

206	67	_	_	I-Premise
207	months	_	_	I-Premise
208	in	_	_	I-Premise
209	E	_	_	I-Premise
210	and	_	_	I-Premise
211	9	_	_	I-Premise
212	.	_	_	I-Premise

213	3	_	_	I-Premise
214	months	_	_	I-Premise
215	in	_	_	I-Premise
216	V	_	_	I-Premise
217	(	_	_	I-Premise
218	p	_	_	I-Premise
219	=	_	_	I-Premise
220	0	_	_	I-Premise
221	.	_	_	I-Premise

222	6975	_	_	I-Premise
223	)	_	_	I-Premise
224	.	_	_	I-Premise

225	Toxicities	_	_	B-Premise
226	were	_	_	I-Premise
227	generally	_	_	I-Premise
228	mild	_	_	I-Premise
229	in	_	_	I-Premise
230	both	_	_	I-Premise
231	groups	_	_	I-Premise
232	.	_	_	I-Premise

233	Median	_	_	B-Premise
234	PFS	_	_	I-Premise
235	was	_	_	I-Premise
236	longest	_	_	I-Premise
237	for	_	_	I-Premise
238	epidermal	_	_	I-Premise
239	growth	_	_	I-Premise
240	factor	_	_	I-Premise
241	receptor	_	_	I-Premise
242	gene	_	_	I-Premise
243	(	_	_	I-Premise
244	EGFR	_	_	I-Premise
245	)	_	_	I-Premise
246	-	_	_	I-Premise
247	mutated	_	_	I-Premise
248	patients	_	_	I-Premise
249	in	_	_	I-Premise
250	the	_	_	I-Premise
251	E	_	_	I-Premise
252	group	_	_	I-Premise
253	,	_	_	I-Premise
254	followed	_	_	I-Premise
255	by	_	_	I-Premise
256	EGFR	_	_	I-Premise
257	-	_	_	I-Premise
258	mutated	_	_	I-Premise
259	patients	_	_	I-Premise
260	in	_	_	I-Premise
261	V	_	_	I-Premise
262	,	_	_	I-Premise
263	EGFR	_	_	I-Premise
264	wild	_	_	I-Premise
265	type	_	_	I-Premise
266	in	_	_	I-Premise
267	E	_	_	I-Premise
268	,	_	_	I-Premise
269	and	_	_	I-Premise
270	EGFR	_	_	I-Premise
271	wild	_	_	I-Premise
272	type	_	_	I-Premise
273	in	_	_	I-Premise
274	V	_	_	I-Premise
275	(	_	_	I-Premise
276	p	_	_	I-Premise
277	=	_	_	I-Premise
278	0	_	_	I-Premise
279	.	_	_	I-Premise

280	0034	_	_	I-Premise
281	)	_	_	I-Premise
282	.	_	_	I-Premise

283	Overall	_	_	B-Premise
284	survival	_	_	I-Premise
285	was	_	_	I-Premise
286	longer	_	_	I-Premise
287	for	_	_	I-Premise
288	EGFR	_	_	I-Premise
289	-	_	_	I-Premise
290	mutated	_	_	I-Premise
291	patients	_	_	I-Premise
292	than	_	_	I-Premise
293	for	_	_	I-Premise
294	EGFR	_	_	I-Premise
295	wild	_	_	I-Premise
296	-	_	_	I-Premise
297	type	_	_	I-Premise
298	patients	_	_	I-Premise
299	(	_	_	I-Premise
300	p	_	_	I-Premise
301	<	_	_	I-Premise
302	0	_	_	I-Premise
303	.	_	_	I-Premise

304	0001	_	_	I-Premise
305	)	_	_	I-Premise
306	.	_	_	I-Premise

307	Erlotinib	_	_	B-Claim
308	is	_	_	I-Claim
309	highly	_	_	I-Claim
310	effective	_	_	I-Claim
311	compared	_	_	I-Claim
312	with	_	_	I-Claim
313	oral	_	_	I-Claim
314	vinorelbine	_	_	I-Claim
315	in	_	_	I-Claim
316	elderly	_	_	I-Claim
317	,	_	_	I-Claim
318	chemonaive	_	_	I-Claim
319	,	_	_	I-Claim
320	Taiwanese	_	_	I-Claim
321	patients	_	_	I-Claim
322	with	_	_	I-Claim
323	NSCLC	_	_	I-Claim
324	.	_	_	I-Claim

325	EGFR	_	_	B-Claim
326	-	_	_	I-Claim
327	mutated	_	_	I-Claim
328	patients	_	_	I-Claim
329	had	_	_	I-Claim
330	better	_	_	I-Claim
331	survival	_	_	I-Claim
332	than	_	_	I-Claim
333	those	_	_	I-Claim
334	with	_	_	I-Claim
335	EGFR	_	_	I-Claim
336	wild	_	_	I-Claim
337	-	_	_	I-Claim
338	type	_	_	I-Claim
339	disease	_	_	I-Claim
340	,	_	_	I-Claim
341	regardless	_	_	I-Claim
342	of	_	_	I-Claim
343	the	_	_	I-Claim
344	treatment	_	_	I-Claim
345	received	_	_	I-Claim
346	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	immediate	_	_	O
4	and	_	_	O
5	long	_	_	O
6	-	_	_	O
7	term	_	_	O
8	effects	_	_	O
9	of	_	_	O
10	true	_	_	O
11	acupuncture	_	_	O
12	versus	_	_	O
13	sham	_	_	O
14	acupuncture	_	_	O
15	on	_	_	O
16	hot	_	_	O
17	flash	_	_	O
18	frequency	_	_	O
19	in	_	_	O
20	women	_	_	O
21	with	_	_	O
22	breast	_	_	O
23	cancer	_	_	O
24	.	_	_	O

25	Seventy	_	_	O
26	-	_	_	O
27	two	_	_	O
28	women	_	_	O
29	with	_	_	O
30	breast	_	_	O
31	cancer	_	_	O
32	experiencing	_	_	O
33	three	_	_	O
34	or	_	_	O
35	more	_	_	O
36	hot	_	_	O
37	flashes	_	_	O
38	per	_	_	O
39	day	_	_	O
40	were	_	_	O
41	randomly	_	_	O
42	assigned	_	_	O
43	to	_	_	O
44	receive	_	_	O
45	either	_	_	O
46	true	_	_	O
47	or	_	_	O
48	sham	_	_	O
49	acupuncture	_	_	O
50	.	_	_	O

51	Interventions	_	_	O
52	were	_	_	O
53	given	_	_	O
54	twice	_	_	O
55	weekly	_	_	O
56	for	_	_	O
57	4	_	_	O
58	consecutive	_	_	O
59	weeks	_	_	O
60	.	_	_	O

61	Hot	_	_	O
62	flash	_	_	O
63	frequency	_	_	O
64	was	_	_	O
65	evaluated	_	_	O
66	at	_	_	O
67	baseline	_	_	O
68	,	_	_	O
69	at	_	_	O
70	6	_	_	O
71	weeks	_	_	O
72	,	_	_	O
73	and	_	_	O
74	at	_	_	O
75	6	_	_	O
76	months	_	_	O
77	after	_	_	O
78	initiation	_	_	O
79	of	_	_	O
80	treatment	_	_	O
81	.	_	_	O

82	Patients	_	_	O
83	initially	_	_	O
84	randomly	_	_	O
85	assigned	_	_	O
86	to	_	_	O
87	the	_	_	O
88	sham	_	_	O
89	group	_	_	O
90	were	_	_	O
91	crossed	_	_	O
92	over	_	_	O
93	to	_	_	O
94	true	_	_	O
95	acupuncture	_	_	O
96	starting	_	_	O
97	at	_	_	O
98	week	_	_	O
99	7	_	_	O
100	.	_	_	O

101	The	_	_	O
102	mean	_	_	O
103	number	_	_	O
104	of	_	_	O
105	hot	_	_	O
106	flashes	_	_	O
107	per	_	_	O
108	day	_	_	O
109	was	_	_	O
110	reduced	_	_	O
111	from	_	_	O
112	8	_	_	O
113	.	_	_	O

114	7	_	_	O
115	(	_	_	O
116	standard	_	_	O
117	deviation	_	_	O
118	[	_	_	O
119	SD	_	_	O
120	]	_	_	O
121	,	_	_	O
122	3	_	_	O
123	.	_	_	O

124	9	_	_	O
125	)	_	_	O
126	to	_	_	O
127	6	_	_	O
128	.	_	_	O

129	2	_	_	O
130	(	_	_	O
131	SD	_	_	O
132	,	_	_	O
133	4	_	_	O
134	.	_	_	O

135	2	_	_	O
136	)	_	_	O
137	in	_	_	O
138	the	_	_	O
139	true	_	_	O
140	acupuncture	_	_	O
141	group	_	_	O
142	and	_	_	O
143	from	_	_	O
144	10	_	_	O
145	.	_	_	O

146	0	_	_	O
147	(	_	_	O
148	SD	_	_	O
149	,	_	_	O
150	6	_	_	O
151	.	_	_	O

152	1	_	_	O
153	)	_	_	O
154	to	_	_	O
155	7	_	_	O
156	.	_	_	O

157	6	_	_	O
158	(	_	_	O
159	SD	_	_	O
160	,	_	_	O
161	5	_	_	O
162	.	_	_	O

163	7	_	_	O
164	)	_	_	O
165	in	_	_	O
166	the	_	_	O
167	sham	_	_	O
168	group	_	_	O
169	.	_	_	O

170	True	_	_	B-Premise
171	acupuncture	_	_	I-Premise
172	was	_	_	I-Premise
173	associated	_	_	I-Premise
174	with	_	_	I-Premise
175	0	_	_	I-Premise
176	.	_	_	I-Premise

177	8	_	_	I-Premise
178	fewer	_	_	I-Premise
179	hot	_	_	I-Premise
180	flashes	_	_	I-Premise
181	per	_	_	I-Premise
182	day	_	_	I-Premise
183	than	_	_	I-Premise
184	sham	_	_	I-Premise
185	at	_	_	I-Premise
186	6	_	_	I-Premise
187	weeks	_	_	I-Premise
188	,	_	_	O
189	but	_	_	B-Premise
190	the	_	_	I-Premise
191	difference	_	_	I-Premise
192	did	_	_	I-Premise
193	not	_	_	I-Premise
194	reach	_	_	I-Premise
195	statistical	_	_	I-Premise
196	significance	_	_	I-Premise
197	(	_	_	I-Premise
198	95	_	_	I-Premise
199	%	_	_	I-Premise
200	CI	_	_	I-Premise
201	,	_	_	I-Premise
202	-	_	_	I-Premise
203	0	_	_	I-Premise
204	.	_	_	I-Premise

205	7	_	_	I-Premise
206	to	_	_	I-Premise
207	2	_	_	I-Premise
208	.	_	_	I-Premise

209	4	_	_	I-Premise
210	;	_	_	I-Premise
211	P	_	_	I-Premise
212	=	_	_	I-Premise
213	.	_	_	I-Premise

214	3	_	_	I-Premise
215	)	_	_	I-Premise
216	.	_	_	I-Premise

217	When	_	_	B-Premise
218	participants	_	_	I-Premise
219	in	_	_	I-Premise
220	the	_	_	I-Premise
221	sham	_	_	I-Premise
222	acupuncture	_	_	I-Premise
223	group	_	_	I-Premise
224	were	_	_	I-Premise
225	crossed	_	_	I-Premise
226	over	_	_	I-Premise
227	to	_	_	I-Premise
228	true	_	_	I-Premise
229	acupuncture	_	_	I-Premise
230	,	_	_	I-Premise
231	a	_	_	I-Premise
232	further	_	_	I-Premise
233	reduction	_	_	I-Premise
234	in	_	_	I-Premise
235	the	_	_	I-Premise
236	frequency	_	_	I-Premise
237	of	_	_	I-Premise
238	hot	_	_	I-Premise
239	flashes	_	_	I-Premise
240	was	_	_	I-Premise
241	seen	_	_	I-Premise
242	.	_	_	I-Premise

243	This	_	_	O
244	reduction	_	_	O
245	in	_	_	O
246	hot	_	_	O
247	flash	_	_	O
248	frequency	_	_	O
249	persisted	_	_	O
250	for	_	_	O
251	up	_	_	O
252	to	_	_	O
253	6	_	_	O
254	months	_	_	O
255	after	_	_	O
256	the	_	_	O
257	completion	_	_	O
258	of	_	_	O
259	treatment	_	_	O
260	.	_	_	O

261	Hot	_	_	B-Claim
262	flash	_	_	I-Claim
263	frequency	_	_	I-Claim
264	in	_	_	I-Claim
265	breast	_	_	I-Claim
266	cancer	_	_	I-Claim
267	patients	_	_	I-Claim
268	was	_	_	I-Claim
269	reduced	_	_	I-Claim
270	following	_	_	I-Claim
271	acupuncture	_	_	I-Claim
272	.	_	_	I-Claim

273	However	_	_	O
274	,	_	_	O
275	when	_	_	B-Premise
276	compared	_	_	I-Premise
277	with	_	_	I-Premise
278	sham	_	_	I-Premise
279	acupuncture	_	_	I-Premise
280	,	_	_	I-Premise
281	the	_	_	I-Premise
282	reduction	_	_	I-Premise
283	by	_	_	I-Premise
284	the	_	_	I-Premise
285	acupuncture	_	_	I-Premise
286	regimen	_	_	I-Premise
287	as	_	_	I-Premise
288	provided	_	_	I-Premise
289	in	_	_	I-Premise
290	the	_	_	I-Premise
291	current	_	_	I-Premise
292	study	_	_	I-Premise
293	did	_	_	I-Premise
294	not	_	_	I-Premise
295	reach	_	_	I-Premise
296	statistical	_	_	I-Premise
297	significance	_	_	I-Premise
298	.	_	_	I-Premise

299	We	_	_	B-Claim
300	cannot	_	_	I-Claim
301	exclude	_	_	I-Claim
302	the	_	_	I-Claim
303	possibility	_	_	I-Claim
304	that	_	_	I-Claim
305	a	_	_	I-Claim
306	longer	_	_	I-Claim
307	and	_	_	I-Claim
308	more	_	_	I-Claim
309	intense	_	_	I-Claim
310	acupuncture	_	_	I-Claim
311	intervention	_	_	I-Claim
312	could	_	_	I-Claim
313	produce	_	_	I-Claim
314	a	_	_	I-Claim
315	larger	_	_	I-Claim
316	reduction	_	_	I-Claim
317	of	_	_	I-Claim
318	these	_	_	I-Claim
319	symptoms	_	_	I-Claim
320	.	_	_	I-Claim


0	Due	_	_	O
1	to	_	_	O
2	the	_	_	O
3	various	_	_	O
4	inter	_	_	O
5	-	_	_	O
6	individual	_	_	O
7	differences	_	_	O
8	in	_	_	O
9	the	_	_	O
10	biological	_	_	O
11	characteristics	_	_	O
12	of	_	_	O
13	tumor	_	_	O
14	cells	_	_	O
15	,	_	_	O
16	as	_	_	O
17	well	_	_	O
18	as	_	_	O
19	issues	_	_	O
20	on	_	_	O
21	the	_	_	O
22	efficacy	_	_	O
23	,	_	_	O
24	adverse	_	_	O
25	reactions	_	_	O
26	,	_	_	O
27	and	_	_	O
28	defects	_	_	O
29	of	_	_	O
30	existing	_	_	O
31	drugs	_	_	O
32	,	_	_	O
33	we	_	_	O
34	compared	_	_	O
35	the	_	_	O
36	clinical	_	_	O
37	efficacy	_	_	O
38	and	_	_	O
39	toxicity	_	_	O
40	of	_	_	O
41	pemetrexed	_	_	O
42	and	_	_	O
43	gemcitabine	_	_	O
44	combined	_	_	O
45	with	_	_	O
46	cisplatin	_	_	O
47	for	_	_	O
48	the	_	_	O
49	treatment	_	_	O
50	of	_	_	O
51	previously	_	_	O
52	untreated	_	_	O
53	advanced	_	_	O
54	non	_	_	O
55	-	_	_	O
56	small	_	_	O
57	cell	_	_	O
58	lung	_	_	O
59	cancer	_	_	O
60	(	_	_	O
61	NSCLC	_	_	O
62	)	_	_	O
63	.	_	_	O

64	251	_	_	O
65	patients	_	_	O
66	were	_	_	O
67	randomly	_	_	O
68	divided	_	_	O
69	into	_	_	O
70	pemetrexed	_	_	O
71	combined	_	_	O
72	with	_	_	O
73	cisplatin	_	_	O
74	group	_	_	O
75	(	_	_	O
76	PP	_	_	O
77	group	_	_	O
78	)	_	_	O
79	with	_	_	O
80	127	_	_	O
81	cases	_	_	O
82	and	_	_	O
83	gemcitabine	_	_	O
84	combined	_	_	O
85	with	_	_	O
86	cisplatin	_	_	O
87	group	_	_	O
88	(	_	_	O
89	GP	_	_	O
90	group	_	_	O
91	)	_	_	O
92	with	_	_	O
93	124	_	_	O
94	cases	_	_	O
95	.	_	_	O

96	PP	_	_	O
97	group	_	_	O
98	received	_	_	O
99	pemetrexed	_	_	O
100	500	_	_	O
101	mg	_	_	O
102	/	_	_	O
103	m²	_	_	O
104	iv	_	_	O
105	infusion	_	_	O
106	d1	_	_	O
107	and	_	_	O
108	cisplatin	_	_	O
109	75	_	_	O
110	mg	_	_	O
111	/	_	_	O
112	m²	_	_	O
113	iv	_	_	O
114	infusion	_	_	O
115	d1	_	_	O
116	,	_	_	O
117	whereas	_	_	O
118	GP	_	_	O
119	group	_	_	O
120	received	_	_	O
121	gemcitabine	_	_	O
122	1	_	_	O
123	,	_	_	O
124	000	_	_	O
125	mg	_	_	O
126	/	_	_	O
127	m²	_	_	O
128	iv	_	_	O
129	infusion	_	_	O
130	d1	_	_	O
131	,	_	_	O
132	8	_	_	O
133	and	_	_	O
134	cisplatin	_	_	O
135	75	_	_	O
136	mg	_	_	O
137	/	_	_	O
138	m²	_	_	O
139	iv	_	_	O
140	infusion	_	_	O
141	d1	_	_	O
142	.	_	_	O

143	The	_	_	O
144	treatment	_	_	O
145	cycle	_	_	O
146	was	_	_	O
147	once	_	_	O
148	every	_	_	O
149	three	_	_	O
150	weeks	_	_	O
151	.	_	_	O

152	In	_	_	O
153	addition	_	_	O
154	,	_	_	O
155	folic	_	_	O
156	acid	_	_	O
157	,	_	_	O
158	vitamin	_	_	O
159	B12	_	_	O
160	,	_	_	O
161	and	_	_	O
162	dexamethasone	_	_	O
163	were	_	_	O
164	administered	_	_	O
165	in	_	_	O
166	both	_	_	O
167	groups	_	_	O
168	.	_	_	O

169	The	_	_	B-Premise
170	total	_	_	I-Premise
171	clinical	_	_	I-Premise
172	effective	_	_	I-Premise
173	rates	_	_	I-Premise
174	in	_	_	I-Premise
175	PP	_	_	I-Premise
176	group	_	_	I-Premise
177	and	_	_	I-Premise
178	GP	_	_	I-Premise
179	group	_	_	I-Premise
180	were	_	_	I-Premise
181	25	_	_	I-Premise
182	.	_	_	I-Premise

183	20	_	_	I-Premise
184	%	_	_	I-Premise
185	and	_	_	I-Premise
186	17	_	_	I-Premise
187	.	_	_	I-Premise

188	74	_	_	I-Premise
189	%	_	_	I-Premise
190	,	_	_	I-Premise
191	respectively	_	_	I-Premise
192	.	_	_	I-Premise

193	The	_	_	B-Premise
194	total	_	_	I-Premise
195	efficiencies	_	_	I-Premise
196	of	_	_	I-Premise
197	non	_	_	I-Premise
198	-	_	_	I-Premise
199	squamous	_	_	I-Premise
200	cell	_	_	I-Premise
201	carcinoma	_	_	I-Premise
202	were	_	_	I-Premise
203	27	_	_	I-Premise
204	.	_	_	I-Premise

205	62	_	_	I-Premise
206	%	_	_	I-Premise
207	and	_	_	I-Premise
208	16	_	_	I-Premise
209	.	_	_	I-Premise

210	00	_	_	I-Premise
211	%	_	_	I-Premise
212	.	_	_	I-Premise

213	The	_	_	B-Premise
214	tumor	_	_	I-Premise
215	progression	_	_	I-Premise
216	duration	_	_	I-Premise
217	in	_	_	I-Premise
218	these	_	_	I-Premise
219	two	_	_	I-Premise
220	groups	_	_	I-Premise
221	was	_	_	I-Premise
222	6	_	_	I-Premise
223	.	_	_	I-Premise

224	5	_	_	I-Premise
225	and	_	_	I-Premise
226	5	_	_	I-Premise
227	.	_	_	I-Premise

228	6	_	_	I-Premise
229	months	_	_	I-Premise
230	,	_	_	I-Premise
231	respectively	_	_	I-Premise
232	.	_	_	I-Premise

233	The	_	_	B-Premise
234	median	_	_	I-Premise
235	survival	_	_	I-Premise
236	time	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	two	_	_	I-Premise
240	groups	_	_	I-Premise
241	was	_	_	I-Premise
242	16	_	_	I-Premise
243	.	_	_	I-Premise

244	9	_	_	I-Premise
245	and	_	_	I-Premise
246	17	_	_	I-Premise
247	.	_	_	I-Premise

248	0	_	_	I-Premise
249	months	_	_	I-Premise
250	,	_	_	I-Premise
251	respectively	_	_	I-Premise
252	,	_	_	I-Premise
253	with	_	_	I-Premise
254	59	_	_	I-Premise
255	.	_	_	I-Premise

256	62	_	_	I-Premise
257	%	_	_	I-Premise
258	and	_	_	I-Premise
259	65	_	_	I-Premise
260	.	_	_	I-Premise

261	87	_	_	I-Premise
262	%	_	_	I-Premise
263	survival	_	_	I-Premise
264	rates	_	_	I-Premise
265	of	_	_	I-Premise
266	1	_	_	I-Premise
267	year	_	_	I-Premise
268	and	_	_	I-Premise
269	27	_	_	I-Premise
270	.	_	_	I-Premise

271	28	_	_	I-Premise
272	%	_	_	I-Premise
273	and	_	_	I-Premise
274	27	_	_	I-Premise
275	.	_	_	I-Premise

276	93	_	_	I-Premise
277	%	_	_	I-Premise
278	survival	_	_	I-Premise
279	rates	_	_	I-Premise
280	of	_	_	I-Premise
281	2	_	_	I-Premise
282	years	_	_	I-Premise
283	,	_	_	I-Premise
284	respectively	_	_	I-Premise
285	.	_	_	I-Premise

286	The	_	_	B-Premise
287	total	_	_	I-Premise
288	efficacy	_	_	I-Premise
289	of	_	_	I-Premise
290	non	_	_	I-Premise
291	-	_	_	I-Premise
292	squamous	_	_	I-Premise
293	cell	_	_	I-Premise
294	carcinoma	_	_	I-Premise
295	in	_	_	I-Premise
296	the	_	_	I-Premise
297	PP	_	_	I-Premise
298	group	_	_	I-Premise
299	was	_	_	I-Premise
300	significantly	_	_	I-Premise
301	higher	_	_	I-Premise
302	than	_	_	I-Premise
303	that	_	_	I-Premise
304	in	_	_	I-Premise
305	GP	_	_	I-Premise
306	group	_	_	I-Premise
307	.	_	_	I-Premise

308	The	_	_	B-Premise
309	results	_	_	I-Premise
310	were	_	_	I-Premise
311	statistically	_	_	I-Premise
312	significant	_	_	I-Premise
313	.	_	_	I-Premise

314	However	_	_	O
315	,	_	_	O
316	there	_	_	O
317	were	_	_	O
318	no	_	_	O
319	significant	_	_	O
320	differences	_	_	O
321	in	_	_	O
322	total	_	_	O
323	response	_	_	O
324	rates	_	_	O
325	,	_	_	O
326	tumor	_	_	O
327	progression	_	_	O
328	duration	_	_	O
329	,	_	_	O
330	and	_	_	O
331	median	_	_	O
332	survival	_	_	O
333	rates	_	_	O
334	of	_	_	O
335	1	_	_	O
336	and	_	_	O
337	2	_	_	O
338	years	_	_	O
339	.	_	_	O

340	The	_	_	B-Premise
341	rate	_	_	I-Premise
342	of	_	_	I-Premise
343	adverse	_	_	I-Premise
344	reactions	_	_	I-Premise
345	,	_	_	I-Premise
346	including	_	_	I-Premise
347	white	_	_	I-Premise
348	blood	_	_	I-Premise
349	cell	_	_	I-Premise
350	reduction	_	_	I-Premise
351	,	_	_	I-Premise
352	lower	_	_	I-Premise
353	platelet	_	_	I-Premise
354	count	_	_	I-Premise
355	,	_	_	I-Premise
356	lower	_	_	I-Premise
357	hemoglobin	_	_	I-Premise
358	,	_	_	I-Premise
359	and	_	_	I-Premise
360	hair	_	_	I-Premise
361	loss	_	_	I-Premise
362	in	_	_	I-Premise
363	the	_	_	I-Premise
364	PP	_	_	I-Premise
365	group	_	_	I-Premise
366	was	_	_	I-Premise
367	significantly	_	_	I-Premise
368	lower	_	_	I-Premise
369	than	_	_	I-Premise
370	that	_	_	I-Premise
371	in	_	_	I-Premise
372	the	_	_	I-Premise
373	GP	_	_	I-Premise
374	group	_	_	I-Premise
375	.	_	_	I-Premise

376	The	_	_	B-Premise
377	results	_	_	I-Premise
378	were	_	_	I-Premise
379	statistically	_	_	I-Premise
380	significant	_	_	I-Premise
381	.	_	_	I-Premise

382	The	_	_	B-Claim
383	clinical	_	_	I-Claim
384	efficacy	_	_	I-Claim
385	of	_	_	I-Claim
386	pemetrexed	_	_	I-Claim
387	and	_	_	I-Claim
388	gemcitabine	_	_	I-Claim
389	combined	_	_	I-Claim
390	with	_	_	I-Claim
391	cisplatin	_	_	I-Claim
392	for	_	_	I-Claim
393	the	_	_	I-Claim
394	treatment	_	_	I-Claim
395	of	_	_	I-Claim
396	previously	_	_	I-Claim
397	untreated	_	_	I-Claim
398	advanced	_	_	I-Claim
399	NSCLC	_	_	I-Claim
400	was	_	_	I-Claim
401	roughly	_	_	I-Claim
402	the	_	_	I-Claim
403	same	_	_	I-Claim
404	,	_	_	I-Claim
405	but	_	_	B-Claim
406	the	_	_	I-Claim
407	adverse	_	_	I-Claim
408	reactions	_	_	I-Claim
409	decreased	_	_	I-Claim
410	significantly	_	_	I-Claim
411	in	_	_	I-Claim
412	the	_	_	I-Claim
413	PP	_	_	I-Claim
414	group	_	_	I-Claim
415	compared	_	_	I-Claim
416	with	_	_	I-Claim
417	those	_	_	I-Claim
418	in	_	_	I-Claim
419	the	_	_	I-Claim
420	GP	_	_	I-Claim
421	group	_	_	I-Claim
422	.	_	_	I-Claim

423	Therefore	_	_	B-Claim
424	,	_	_	I-Claim
425	pemetrexed	_	_	I-Claim
426	combined	_	_	I-Claim
427	with	_	_	I-Claim
428	cisplatin	_	_	I-Claim
429	can	_	_	I-Claim
430	be	_	_	I-Claim
431	used	_	_	I-Claim
432	as	_	_	I-Claim
433	a	_	_	I-Claim
434	safe	_	_	I-Claim
435	and	_	_	I-Claim
436	effective	_	_	I-Claim
437	drug	_	_	I-Claim
438	for	_	_	I-Claim
439	clinical	_	_	I-Claim
440	first	_	_	I-Claim
441	-	_	_	I-Claim
442	line	_	_	I-Claim
443	treatment	_	_	I-Claim
444	for	_	_	I-Claim
445	previously	_	_	I-Claim
446	untreated	_	_	I-Claim
447	NSCLC	_	_	I-Claim
448	.	_	_	I-Claim


0	Lymphedema	_	_	O
1	is	_	_	O
2	an	_	_	O
3	adverse	_	_	O
4	effect	_	_	O
5	of	_	_	O
6	breast	_	_	O
7	cancer	_	_	O
8	surgery	_	_	O
9	.	_	_	O

10	Aqua	_	_	O
11	lymphatic	_	_	O
12	therapy	_	_	O
13	(	_	_	O
14	ALT	_	_	O
15	)	_	_	O
16	is	_	_	O
17	a	_	_	O
18	novel	_	_	O
19	treatment	_	_	O
20	for	_	_	O
21	limb	_	_	O
22	volume	_	_	O
23	reduction	_	_	O
24	.	_	_	O

25	The	_	_	O
26	aim	_	_	O
27	of	_	_	O
28	this	_	_	O
29	study	_	_	O
30	was	_	_	O
31	to	_	_	O
32	examine	_	_	O
33	whether	_	_	O
34	ALT	_	_	O
35	is	_	_	O
36	a	_	_	O
37	safe	_	_	O
38	method	_	_	O
39	and	_	_	O
40	whether	_	_	O
41	there	_	_	O
42	are	_	_	O
43	differences	_	_	O
44	in	_	_	O
45	adherence	_	_	O
46	,	_	_	O
47	limb	_	_	O
48	volume	_	_	O
49	,	_	_	O
50	and	_	_	O
51	quality	_	_	O
52	of	_	_	O
53	life	_	_	O
54	between	_	_	O
55	women	_	_	O
56	who	_	_	O
57	perform	_	_	O
58	only	_	_	O
59	self	_	_	O
60	-	_	_	O
61	management	_	_	O
62	treatment	_	_	O
63	and	_	_	O
64	women	_	_	O
65	who	_	_	O
66	participate	_	_	O
67	as	_	_	O
68	well	_	_	O
69	in	_	_	O
70	ALT	_	_	O
71	.	_	_	O

72	Design	_	_	O
73	of	_	_	O
74	the	_	_	O
75	study	_	_	O
76	was	_	_	O
77	single	_	_	O
78	-	_	_	O
79	blind	_	_	O
80	randomized	_	_	O
81	clinical	_	_	O
82	trial	_	_	O
83	.	_	_	O

84	The	_	_	O
85	setting	_	_	O
86	was	_	_	O
87	in	_	_	O
88	a	_	_	O
89	hydrotherapy	_	_	O
90	pool	_	_	O
91	,	_	_	O
92	1	_	_	O
93	.	_	_	O

94	2	_	_	O
95	m	_	_	O
96	depth	_	_	O
97	,	_	_	O
98	and	_	_	O
99	a	_	_	O
100	temperature	_	_	O
101	of	_	_	O
102	32	_	_	O
103	-	_	_	O
104	33	_	_	O
105	degrees	_	_	O
106	capital	_	_	O
107	ES	_	_	O
108	,	_	_	O
109	Cyrillic	_	_	O
110	.	_	_	O

111	Forty	_	_	O
112	-	_	_	O
113	eight	_	_	O
114	women	_	_	O
115	(	_	_	O
116	56	_	_	O
117	+	_	_	O
118	/	_	_	O
119	-	_	_	O
120	10	_	_	O
121	years	_	_	O
122	)	_	_	O
123	,	_	_	O
124	with	_	_	O
125	a	_	_	O
126	12	_	_	O
127	.	_	_	O

128	8	_	_	O
129	%	_	_	O
130	lymphedema	_	_	O
131	relative	_	_	O
132	volume	_	_	O
133	,	_	_	O
134	participated	_	_	O
135	in	_	_	O
136	the	_	_	O
137	study	_	_	O
138	.	_	_	O

139	The	_	_	O
140	control	_	_	O
141	group	_	_	O
142	was	_	_	O
143	instructed	_	_	O
144	to	_	_	O
145	perform	_	_	O
146	the	_	_	O
147	self	_	_	O
148	-	_	_	O
149	management	_	_	O
150	treatment	_	_	O
151	.	_	_	O

152	The	_	_	O
153	study	_	_	O
154	group	_	_	O
155	joined	_	_	O
156	a	_	_	O
157	weekly	_	_	O
158	session	_	_	O
159	of	_	_	O
160	ALT	_	_	O
161	for	_	_	O
162	3	_	_	O
163	months	_	_	O
164	in	_	_	O
165	addition	_	_	O
166	to	_	_	O
167	the	_	_	O
168	self	_	_	O
169	-	_	_	O
170	management	_	_	O
171	therapy	_	_	O
172	.	_	_	O

173	Adherence	_	_	O
174	was	_	_	O
175	assessed	_	_	O
176	by	_	_	O
177	a	_	_	O
178	self	_	_	O
179	-	_	_	O
180	reported	_	_	O
181	diary	_	_	O
182	,	_	_	O
183	limb	_	_	O
184	volume	_	_	O
185	by	_	_	O
186	a	_	_	O
187	water	_	_	O
188	displacement	_	_	O
189	device	_	_	O
190	,	_	_	O
191	quality	_	_	O
192	of	_	_	O
193	life	_	_	O
194	by	_	_	O
195	the	_	_	O
196	Upper	_	_	O
197	Limb	_	_	O
198	Lymphedema	_	_	O
199	Questionnaire	_	_	O
200	(	_	_	O
201	ULL27	_	_	O
202	)	_	_	O
203	,	_	_	O
204	prior	_	_	O
205	to	_	_	O
206	,	_	_	O
207	and	_	_	O
208	after	_	_	O
209	the	_	_	O
210	intervention	_	_	O
211	period	_	_	O
212	.	_	_	O

213	There	_	_	B-Premise
214	was	_	_	I-Premise
215	no	_	_	I-Premise
216	episode	_	_	I-Premise
217	of	_	_	I-Premise
218	arm	_	_	I-Premise
219	infection	_	_	I-Premise
220	or	_	_	I-Premise
221	aggravation	_	_	I-Premise
222	in	_	_	I-Premise
223	limb	_	_	I-Premise
224	volume	_	_	I-Premise
225	during	_	_	I-Premise
226	the	_	_	I-Premise
227	study	_	_	I-Premise
228	period	_	_	I-Premise
229	.	_	_	I-Premise

230	ALT	_	_	B-Premise
231	had	_	_	I-Premise
232	a	_	_	I-Premise
233	positive	_	_	I-Premise
234	,	_	_	I-Premise
235	statistically	_	_	I-Premise
236	and	_	_	I-Premise
237	clinically	_	_	I-Premise
238	significant	_	_	I-Premise
239	immediate	_	_	I-Premise
240	effect	_	_	I-Premise
241	on	_	_	I-Premise
242	limb	_	_	I-Premise
243	volume	_	_	I-Premise
244	but	_	_	B-Premise
245	no	_	_	I-Premise
246	long	_	_	I-Premise
247	-	_	_	I-Premise
248	term	_	_	I-Premise
249	effect	_	_	I-Premise
250	was	_	_	I-Premise
251	noted	_	_	I-Premise
252	.	_	_	I-Premise

253	The	_	_	B-Premise
254	adherence	_	_	I-Premise
255	rate	_	_	I-Premise
256	to	_	_	I-Premise
257	ALT	_	_	I-Premise
258	was	_	_	I-Premise
259	significantly	_	_	I-Premise
260	higher	_	_	I-Premise
261	than	_	_	I-Premise
262	the	_	_	I-Premise
263	adherence	_	_	I-Premise
264	to	_	_	I-Premise
265	self	_	_	I-Premise
266	-	_	_	I-Premise
267	management	_	_	I-Premise
268	therapy	_	_	I-Premise
269	.	_	_	I-Premise

270	QOL	_	_	B-Premise
271	improved	_	_	I-Premise
272	in	_	_	I-Premise
273	the	_	_	I-Premise
274	study	_	_	I-Premise
275	group	_	_	I-Premise
276	.	_	_	I-Premise

277	ALT	_	_	B-Claim
278	was	_	_	I-Claim
279	found	_	_	I-Claim
280	to	_	_	I-Claim
281	be	_	_	I-Claim
282	a	_	_	I-Claim
283	safe	_	_	I-Claim
284	method	_	_	I-Claim
285	,	_	_	I-Claim
286	with	_	_	I-Claim
287	high	_	_	I-Claim
288	adherence	_	_	I-Claim
289	,	_	_	I-Claim
290	in	_	_	I-Claim
291	treating	_	_	I-Claim
292	women	_	_	I-Claim
293	who	_	_	I-Claim
294	suffer	_	_	I-Claim
295	from	_	_	I-Claim
296	mild	_	_	I-Claim
297	to	_	_	I-Claim
298	moderate	_	_	I-Claim
299	lymphedema	_	_	I-Claim
300	.	_	_	I-Claim

301	A	_	_	B-Claim
302	significant	_	_	I-Claim
303	immediate	_	_	I-Claim
304	and	_	_	I-Claim
305	insignificant	_	_	I-Claim
306	long	_	_	I-Claim
307	-	_	_	I-Claim
308	term	_	_	I-Claim
309	effect	_	_	I-Claim
310	on	_	_	I-Claim
311	limb	_	_	I-Claim
312	volume	_	_	I-Claim
313	was	_	_	I-Claim
314	noted	_	_	I-Claim
315	.	_	_	I-Claim


0	The	_	_	B-Claim
1	generalizability	_	_	I-Claim
2	of	_	_	I-Claim
3	palliative	_	_	I-Claim
4	care	_	_	I-Claim
5	intervention	_	_	I-Claim
6	research	_	_	I-Claim
7	is	_	_	I-Claim
8	often	_	_	I-Claim
9	limited	_	_	I-Claim
10	by	_	_	I-Claim
11	high	_	_	I-Claim
12	rates	_	_	I-Claim
13	of	_	_	I-Claim
14	study	_	_	I-Claim
15	attrition	_	_	I-Claim
16	.	_	_	I-Claim

17	This	_	_	O
18	study	_	_	O
19	examined	_	_	O
20	factors	_	_	O
21	associated	_	_	O
22	with	_	_	O
23	attrition	_	_	O
24	from	_	_	O
25	a	_	_	O
26	randomized	_	_	O
27	controlled	_	_	O
28	trial	_	_	O
29	comparing	_	_	O
30	meaning	_	_	O
31	-	_	_	O
32	centered	_	_	O
33	group	_	_	O
34	psychotherapy	_	_	O
35	(	_	_	O
36	MCGP	_	_	O
37	)	_	_	O
38	,	_	_	O
39	an	_	_	O
40	intervention	_	_	O
41	designed	_	_	O
42	to	_	_	O
43	help	_	_	O
44	advanced	_	_	O
45	cancer	_	_	O
46	patients	_	_	O
47	sustain	_	_	O
48	or	_	_	O
49	enhance	_	_	O
50	their	_	_	O
51	sense	_	_	O
52	of	_	_	O
53	meaning	_	_	O
54	to	_	_	O
55	the	_	_	O
56	supportive	_	_	O
57	group	_	_	O
58	psychotherapy	_	_	O
59	(	_	_	O
60	SGP	_	_	O
61	)	_	_	O
62	,	_	_	O
63	a	_	_	O
64	standardized	_	_	O
65	support	_	_	O
66	group	_	_	O
67	.	_	_	O

68	Patients	_	_	O
69	with	_	_	O
70	advanced	_	_	O
71	solid	_	_	O
72	tumor	_	_	O
73	cancers	_	_	O
74	(	_	_	O
75	n	_	_	O
76	=	_	_	O
77	153	_	_	O
78	)	_	_	O
79	were	_	_	O
80	randomized	_	_	O
81	to	_	_	O
82	eight	_	_	O
83	sessions	_	_	O
84	of	_	_	O
85	either	_	_	O
86	the	_	_	O
87	MCGP	_	_	O
88	or	_	_	O
89	SGP	_	_	O
90	.	_	_	O

91	They	_	_	O
92	completed	_	_	O
93	assessments	_	_	O
94	of	_	_	O
95	psychosocial	_	_	O
96	,	_	_	O
97	spiritual	_	_	O
98	,	_	_	O
99	and	_	_	O
100	physical	_	_	O
101	well	_	_	O
102	-	_	_	O
103	being	_	_	O
104	pretreatment	_	_	O
105	,	_	_	O
106	midtreatment	_	_	O
107	,	_	_	O
108	and	_	_	O
109	2	_	_	O
110	months	_	_	O
111	post	_	_	O
112	-	_	_	O
113	treatment	_	_	O
114	.	_	_	O

115	Attrition	_	_	O
116	was	_	_	O
117	assessed	_	_	O
118	in	_	_	O
119	terms	_	_	O
120	of	_	_	O
121	the	_	_	O
122	percent	_	_	O
123	of	_	_	O
124	participants	_	_	O
125	who	_	_	O
126	failed	_	_	O
127	to	_	_	O
128	complete	_	_	O
129	these	_	_	O
130	assessments	_	_	O
131	,	_	_	O
132	and	_	_	O
133	demographic	_	_	O
134	,	_	_	O
135	psychiatric	_	_	O
136	,	_	_	O
137	medical	_	_	O
138	,	_	_	O
139	and	_	_	O
140	study	_	_	O
141	-	_	_	O
142	related	_	_	O
143	correlates	_	_	O
144	of	_	_	O
145	attrition	_	_	O
146	were	_	_	O
147	examined	_	_	O
148	for	_	_	O
149	the	_	_	O
150	participants	_	_	O
151	in	_	_	O
152	each	_	_	O
153	of	_	_	O
154	these	_	_	O
155	categories	_	_	O
156	.	_	_	O

157	The	_	_	B-Premise
158	rates	_	_	I-Premise
159	of	_	_	I-Premise
160	attrition	_	_	I-Premise
161	at	_	_	I-Premise
162	these	_	_	I-Premise
163	time	_	_	I-Premise
164	points	_	_	I-Premise
165	were	_	_	I-Premise
166	28	_	_	I-Premise
167	.	_	_	I-Premise

168	1	_	_	I-Premise
169	%	_	_	I-Premise
170	,	_	_	I-Premise
171	17	_	_	I-Premise
172	.	_	_	I-Premise

173	7	_	_	I-Premise
174	%	_	_	I-Premise
175	,	_	_	I-Premise
176	and	_	_	I-Premise
177	11	_	_	I-Premise
178	.	_	_	I-Premise

179	1	_	_	I-Premise
180	%	_	_	I-Premise
181	,	_	_	I-Premise
182	respectively	_	_	I-Premise
183	;	_	_	I-Premise
184	43	_	_	I-Premise
185	.	_	_	I-Premise

186	1	_	_	I-Premise
187	%	_	_	I-Premise
188	of	_	_	I-Premise
189	the	_	_	I-Premise
190	participants	_	_	I-Premise
191	(	_	_	I-Premise
192	66	_	_	I-Premise
193	of	_	_	I-Premise
194	153	_	_	I-Premise
195	)	_	_	I-Premise
196	completed	_	_	I-Premise
197	the	_	_	I-Premise
198	entire	_	_	I-Premise
199	study	_	_	I-Premise
200	.	_	_	I-Premise

201	The	_	_	B-Premise
202	most	_	_	I-Premise
203	common	_	_	I-Premise
204	reason	_	_	I-Premise
205	for	_	_	I-Premise
206	dropout	_	_	I-Premise
207	was	_	_	I-Premise
208	patients	_	_	I-Premise
209	feeling	_	_	I-Premise
210	too	_	_	I-Premise
211	ill	_	_	I-Premise
212	.	_	_	I-Premise

213	Attrition	_	_	B-Premise
214	rates	_	_	I-Premise
215	did	_	_	I-Premise
216	not	_	_	I-Premise
217	vary	_	_	I-Premise
218	significantly	_	_	I-Premise
219	between	_	_	I-Premise
220	study	_	_	I-Premise
221	arms	_	_	I-Premise
222	.	_	_	I-Premise

223	The	_	_	O
224	participants	_	_	O
225	who	_	_	O
226	dropped	_	_	O
227	out	_	_	O
228	pretreatment	_	_	O
229	reported	_	_	O
230	less	_	_	O
231	financial	_	_	O
232	concerns	_	_	O
233	than	_	_	O
234	post	_	_	O
235	-	_	_	O
236	treatment	_	_	O
237	dropouts	_	_	O
238	,	_	_	O
239	and	_	_	O
240	the	_	_	O
241	participants	_	_	O
242	who	_	_	O
243	dropped	_	_	O
244	out	_	_	O
245	of	_	_	O
246	the	_	_	O
247	study	_	_	O
248	midtreatment	_	_	O
249	had	_	_	O
250	poorer	_	_	O
251	physical	_	_	O
252	health	_	_	O
253	than	_	_	O
254	treatment	_	_	O
255	completers	_	_	O
256	.	_	_	O

257	There	_	_	B-Premise
258	were	_	_	I-Premise
259	no	_	_	I-Premise
260	other	_	_	I-Premise
261	significant	_	_	I-Premise
262	associations	_	_	I-Premise
263	between	_	_	I-Premise
264	attrition	_	_	I-Premise
265	and	_	_	I-Premise
266	any	_	_	I-Premise
267	demographic	_	_	I-Premise
268	,	_	_	I-Premise
269	medical	_	_	I-Premise
270	,	_	_	I-Premise
271	psychiatric	_	_	I-Premise
272	,	_	_	I-Premise
273	or	_	_	I-Premise
274	study	_	_	I-Premise
275	-	_	_	I-Premise
276	related	_	_	I-Premise
277	variables	_	_	I-Premise
278	.	_	_	I-Premise

279	These	_	_	B-Claim
280	findings	_	_	I-Claim
281	highlight	_	_	I-Claim
282	the	_	_	I-Claim
283	challenge	_	_	I-Claim
284	of	_	_	I-Claim
285	maintaining	_	_	I-Claim
286	advanced	_	_	I-Claim
287	cancer	_	_	I-Claim
288	patients	_	_	I-Claim
289	in	_	_	I-Claim
290	longitudinal	_	_	I-Claim
291	research	_	_	I-Claim
292	and	_	_	I-Claim
293	suggest	_	_	I-Claim
294	the	_	_	I-Claim
295	need	_	_	I-Claim
296	to	_	_	I-Claim
297	consider	_	_	I-Claim
298	alternative	_	_	I-Claim
299	approaches	_	_	I-Claim
300	(	_	_	I-Claim
301	e	_	_	I-Claim
302	.	_	_	I-Claim

303	g	_	_	I-Claim
304	.	_	_	I-Claim

305	,	_	_	I-Claim
306	telemedicine	_	_	I-Claim
307	)	_	_	I-Claim
308	for	_	_	I-Claim
309	patients	_	_	I-Claim
310	who	_	_	I-Claim
311	might	_	_	I-Claim
312	benefit	_	_	I-Claim
313	from	_	_	I-Claim
314	group	_	_	I-Claim
315	interventions	_	_	I-Claim
316	but	_	_	I-Claim
317	are	_	_	I-Claim
318	too	_	_	I-Claim
319	ill	_	_	I-Claim
320	to	_	_	I-Claim
321	travel	_	_	I-Claim
322	.	_	_	I-Claim


0	Previous	_	_	B-Claim
1	trials	_	_	I-Claim
2	have	_	_	I-Claim
3	suggested	_	_	I-Claim
4	a	_	_	I-Claim
5	quality	_	_	I-Claim
6	-	_	_	I-Claim
7	of	_	_	I-Claim
8	-	_	_	I-Claim
9	life	_	_	I-Claim
10	(	_	_	I-Claim
11	QOL	_	_	I-Claim
12	)	_	_	I-Claim
13	improvement	_	_	I-Claim
14	for	_	_	I-Claim
15	anemic	_	_	I-Claim
16	cancer	_	_	I-Claim
17	patients	_	_	I-Claim
18	treated	_	_	I-Claim
19	with	_	_	I-Claim
20	erythropoietin	_	_	I-Claim
21	,	_	_	I-Claim
22	but	_	_	I-Claim
23	few	_	_	I-Claim
24	used	_	_	I-Claim
25	QOL	_	_	I-Claim
26	as	_	_	I-Claim
27	the	_	_	I-Claim
28	primary	_	_	I-Claim
29	outcome	_	_	I-Claim
30	.	_	_	I-Claim

31	We	_	_	O
32	designed	_	_	O
33	a	_	_	O
34	trial	_	_	O
35	to	_	_	O
36	investigate	_	_	O
37	the	_	_	O
38	effects	_	_	O
39	of	_	_	O
40	epoetin	_	_	O
41	alfa	_	_	O
42	therapy	_	_	O
43	on	_	_	O
44	the	_	_	O
45	QOL	_	_	O
46	of	_	_	O
47	anemic	_	_	O
48	patients	_	_	O
49	with	_	_	O
50	advanced	_	_	O
51	non	_	_	O
52	-	_	_	O
53	small	_	_	O
54	-	_	_	O
55	cell	_	_	O
56	carcinoma	_	_	O
57	of	_	_	O
58	the	_	_	O
59	lung	_	_	O
60	(	_	_	O
61	NSCLC	_	_	O
62	)	_	_	O
63	.	_	_	O

64	A	_	_	O
65	multicenter	_	_	O
66	,	_	_	O
67	randomized	_	_	O
68	,	_	_	O
69	double	_	_	O
70	-	_	_	O
71	blind	_	_	O
72	,	_	_	O
73	placebo	_	_	O
74	-	_	_	O
75	controlled	_	_	O
76	trial	_	_	O
77	was	_	_	O
78	conducted	_	_	O
79	.	_	_	O

80	The	_	_	O
81	proposed	_	_	O
82	sample	_	_	O
83	size	_	_	O
84	was	_	_	O
85	300	_	_	O
86	patients	_	_	O
87	.	_	_	O

88	Eligible	_	_	O
89	patients	_	_	O
90	were	_	_	O
91	required	_	_	O
92	to	_	_	O
93	have	_	_	O
94	NSCLC	_	_	O
95	unsuitable	_	_	O
96	for	_	_	O
97	curative	_	_	O
98	therapy	_	_	O
99	and	_	_	O
100	baseline	_	_	O
101	hemoglobin	_	_	O
102	(	_	_	O
103	Hgb	_	_	O
104	)	_	_	O
105	levels	_	_	O
106	less	_	_	O
107	than	_	_	O
108	121	_	_	O
109	g	_	_	O
110	/	_	_	O
111	L	_	_	O
112	.	_	_	O

113	Patients	_	_	O
114	were	_	_	O
115	assigned	_	_	O
116	to	_	_	O
117	12	_	_	O
118	weekly	_	_	O
119	injections	_	_	O
120	of	_	_	O
121	subcutaneous	_	_	O
122	epoetin	_	_	O
123	alpha	_	_	O
124	or	_	_	O
125	placebo	_	_	O
126	,	_	_	O
127	targeting	_	_	O
128	Hgb	_	_	O
129	levels	_	_	O
130	between	_	_	O
131	120	_	_	O
132	and	_	_	O
133	140	_	_	O
134	g	_	_	O
135	/	_	_	O
136	L	_	_	O
137	.	_	_	O

138	The	_	_	O
139	primary	_	_	O
140	outcome	_	_	O
141	was	_	_	O
142	the	_	_	O
143	difference	_	_	O
144	in	_	_	O
145	the	_	_	O
146	change	_	_	O
147	in	_	_	O
148	Functional	_	_	O
149	Assessment	_	_	O
150	of	_	_	O
151	Cancer	_	_	O
152	Therapy	_	_	O
153	-	_	_	O
154	Anemia	_	_	O
155	scores	_	_	O
156	between	_	_	O
157	baseline	_	_	O
158	and	_	_	O
159	12	_	_	O
160	weeks	_	_	O
161	.	_	_	O

162	Reports	_	_	O
163	of	_	_	O
164	thrombotic	_	_	O
165	events	_	_	O
166	in	_	_	O
167	other	_	_	O
168	epoetin	_	_	O
169	trials	_	_	O
170	prompted	_	_	O
171	an	_	_	O
172	unplanned	_	_	O
173	safety	_	_	O
174	analysis	_	_	O
175	after	_	_	O
176	70	_	_	O
177	patients	_	_	O
178	had	_	_	O
179	been	_	_	O
180	randomly	_	_	O
181	assigned	_	_	O
182	(	_	_	O
183	33	_	_	O
184	to	_	_	O
185	the	_	_	O
186	active	_	_	O
187	arm	_	_	O
188	and	_	_	O
189	37	_	_	O
190	to	_	_	O
191	the	_	_	O
192	placebo	_	_	O
193	arm	_	_	O
194	)	_	_	O
195	.	_	_	O

196	This	_	_	B-Premise
197	revealed	_	_	I-Premise
198	a	_	_	I-Premise
199	significant	_	_	I-Premise
200	difference	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	median	_	_	I-Premise
204	survival	_	_	I-Premise
205	in	_	_	I-Premise
206	favor	_	_	I-Premise
207	of	_	_	I-Premise
208	the	_	_	I-Premise
209	patients	_	_	I-Premise
210	on	_	_	I-Premise
211	the	_	_	I-Premise
212	placebo	_	_	I-Premise
213	arm	_	_	I-Premise
214	of	_	_	I-Premise
215	the	_	_	I-Premise
216	trial	_	_	I-Premise
217	(	_	_	I-Premise
218	63	_	_	I-Premise
219	v	_	_	I-Premise
220	129	_	_	I-Premise
221	days	_	_	I-Premise
222	;	_	_	I-Premise
223	hazard	_	_	I-Premise
224	ratio	_	_	I-Premise
225	,	_	_	I-Premise
226	1	_	_	I-Premise
227	.	_	_	I-Premise

228	84	_	_	I-Premise
229	;	_	_	I-Premise
230	P	_	_	I-Premise
231	=	_	_	I-Premise
232	.	_	_	I-Premise

233	04	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	The	_	_	O
237	Steering	_	_	O
238	Committee	_	_	O
239	closed	_	_	O
240	the	_	_	O
241	trial	_	_	O
242	.	_	_	O

243	Patient	_	_	B-Premise
244	numbers	_	_	I-Premise
245	compromised	_	_	I-Premise
246	the	_	_	I-Premise
247	interpretation	_	_	I-Premise
248	of	_	_	I-Premise
249	the	_	_	I-Premise
250	QOL	_	_	I-Premise
251	analysis	_	_	I-Premise
252	,	_	_	I-Premise
253	but	_	_	O
254	a	_	_	B-Premise
255	positive	_	_	I-Premise
256	Hgb	_	_	I-Premise
257	response	_	_	I-Premise
258	was	_	_	I-Premise
259	noted	_	_	I-Premise
260	with	_	_	I-Premise
261	epoetin	_	_	I-Premise
262	alfa	_	_	I-Premise
263	treatment	_	_	I-Premise
264	.	_	_	I-Premise

265	An	_	_	B-Claim
266	unplanned	_	_	I-Claim
267	safety	_	_	I-Claim
268	analysis	_	_	I-Claim
269	suggested	_	_	I-Claim
270	decreased	_	_	I-Claim
271	overall	_	_	I-Claim
272	survival	_	_	I-Claim
273	in	_	_	I-Claim
274	patients	_	_	I-Claim
275	with	_	_	I-Claim
276	advanced	_	_	I-Claim
277	NSCLC	_	_	I-Claim
278	treated	_	_	I-Claim
279	with	_	_	I-Claim
280	epoetin	_	_	I-Claim
281	alfa	_	_	I-Claim
282	.	_	_	I-Claim

283	Although	_	_	O
284	infrequent	_	_	O
285	,	_	_	O
286	other	_	_	O
287	similar	_	_	O
288	reports	_	_	O
289	highlight	_	_	O
290	the	_	_	O
291	need	_	_	O
292	for	_	_	O
293	ongoing	_	_	O
294	trials	_	_	O
295	evaluating	_	_	O
296	erythropoietin	_	_	O
297	receptor	_	_	O
298	agonists	_	_	O
299	to	_	_	O
300	ensure	_	_	O
301	that	_	_	O
302	overall	_	_	O
303	survival	_	_	O
304	is	_	_	O
305	monitored	_	_	O
306	closely	_	_	O
307	.	_	_	O


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	analysis	_	_	O
5	was	_	_	O
6	to	_	_	O
7	assess	_	_	O
8	the	_	_	O
9	impact	_	_	O
10	of	_	_	O
11	pretreatment	_	_	O
12	factors	_	_	O
13	on	_	_	O
14	quality	_	_	O
15	of	_	_	O
16	life	_	_	O
17	(	_	_	O
18	QOL	_	_	O
19	)	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	locally	_	_	O
24	advanced	_	_	O
25	nonsmall	_	_	O
26	cell	_	_	O
27	lung	_	_	O
28	cancer	_	_	O
29	(	_	_	O
30	NSCLC	_	_	O
31	)	_	_	O
32	.	_	_	O

33	In	_	_	O
34	particular	_	_	O
35	,	_	_	O
36	this	_	_	O
37	study	_	_	O
38	focused	_	_	O
39	on	_	_	O
40	the	_	_	O
41	possible	_	_	O
42	interaction	_	_	O
43	between	_	_	O
44	gender	_	_	O
45	-	_	_	O
46	specific	_	_	O
47	baseline	_	_	O
48	health	_	_	O
49	-	_	_	O
50	related	_	_	O
51	QOL	_	_	O
52	and	_	_	O
53	Karnofsky	_	_	O
54	performance	_	_	O
55	score	_	_	O
56	(	_	_	O
57	KPS	_	_	O
58	)	_	_	O
59	in	_	_	O
60	a	_	_	O
61	prospective	_	_	O
62	randomized	_	_	O
63	lung	_	_	O
64	cancer	_	_	O
65	trial	_	_	O
66	.	_	_	O

67	QOL	_	_	O
68	information	_	_	O
69	,	_	_	O
70	using	_	_	O
71	validated	_	_	O
72	instruments	_	_	O
73	(	_	_	O
74	Functional	_	_	O
75	Assessment	_	_	O
76	of	_	_	O
77	Cancer	_	_	O
78	Therapy	_	_	O
79	-	_	_	O
80	Lung	_	_	O
81	[	_	_	O
82	FACT	_	_	O
83	-	_	_	O
84	L	_	_	O
85	]	_	_	O
86	,	_	_	O
87	version	_	_	O
88	2	_	_	O
89	,	_	_	O
90	and	_	_	O
91	Functional	_	_	O
92	Living	_	_	O
93	Index	_	_	O
94	-	_	_	O
95	Cancer	_	_	O
96	[	_	_	O
97	FLIC	_	_	O
98	]	_	_	O
99	)	_	_	O
100	,	_	_	O
101	was	_	_	O
102	prospectively	_	_	O
103	collected	_	_	O
104	in	_	_	O
105	patients	_	_	O
106	with	_	_	O
107	locally	_	_	O
108	advanced	_	_	O
109	NSCLC	_	_	O
110	treated	_	_	O
111	on	_	_	O
112	Radiation	_	_	O
113	Therapy	_	_	O
114	Oncology	_	_	O
115	Group	_	_	O
116	(	_	_	O
117	RTOG	_	_	O
118	)	_	_	O
119	trial	_	_	O
120	89	_	_	O
121	-	_	_	O
122	01	_	_	O
123	.	_	_	O

124	Between	_	_	O
125	April	_	_	O
126	1990	_	_	O
127	and	_	_	O
128	April	_	_	O
129	1994	_	_	O
130	,	_	_	O
131	70	_	_	O
132	eligible	_	_	O
133	patients	_	_	O
134	participated	_	_	O
135	in	_	_	O
136	a	_	_	O
137	phase	_	_	O
138	III	_	_	O
139	trial	_	_	O
140	comparing	_	_	O
141	a	_	_	O
142	regimen	_	_	O
143	containing	_	_	O
144	sequential	_	_	O
145	chemotherapy	_	_	O
146	and	_	_	O
147	radiation	_	_	O
148	therapy	_	_	O
149	versus	_	_	O
150	sequential	_	_	O
151	chemotherapy	_	_	O
152	plus	_	_	O
153	surgery	_	_	O
154	.	_	_	O

155	Of	_	_	O
156	these	_	_	O
157	70	_	_	O
158	patients	_	_	O
159	,	_	_	O
160	46	_	_	O
161	underwent	_	_	O
162	pretreatment	_	_	O
163	FLIC	_	_	O
164	and	_	_	O
165	49	_	_	O
166	underwent	_	_	O
167	pretreatment	_	_	O
168	FACT	_	_	O
169	-	_	_	O
170	L	_	_	O
171	.	_	_	O

172	There	_	_	B-Premise
173	was	_	_	I-Premise
174	a	_	_	I-Premise
175	significant	_	_	I-Premise
176	interaction	_	_	I-Premise
177	between	_	_	I-Premise
178	gender	_	_	I-Premise
179	and	_	_	I-Premise
180	KPS	_	_	I-Premise
181	using	_	_	I-Premise
182	FLIC	_	_	I-Premise
183	(	_	_	I-Premise
184	P	_	_	I-Premise
185	=	_	_	I-Premise
186	0	_	_	I-Premise
187	.	_	_	I-Premise

188	009	_	_	I-Premise
189	)	_	_	I-Premise
190	,	_	_	I-Premise
191	which	_	_	I-Premise
192	also	_	_	I-Premise
193	showed	_	_	I-Premise
194	a	_	_	I-Premise
195	trend	_	_	I-Premise
196	toward	_	_	I-Premise
197	significance	_	_	I-Premise
198	with	_	_	I-Premise
199	FACT	_	_	I-Premise
200	(	_	_	I-Premise
201	P	_	_	I-Premise
202	=	_	_	I-Premise
203	0	_	_	I-Premise
204	.	_	_	I-Premise

205	09	_	_	I-Premise
206	)	_	_	I-Premise
207	.	_	_	I-Premise

208	Significant	_	_	B-Premise
209	KPS	_	_	I-Premise
210	-	_	_	I-Premise
211	by	_	_	I-Premise
212	-	_	_	I-Premise
213	gender	_	_	I-Premise
214	interactions	_	_	I-Premise
215	were	_	_	I-Premise
216	noted	_	_	I-Premise
217	for	_	_	I-Premise
218	FACT	_	_	I-Premise
219	-	_	_	I-Premise
220	L	_	_	I-Premise
221	in	_	_	I-Premise
222	the	_	_	I-Premise
223	physical	_	_	I-Premise
224	well	_	_	I-Premise
225	-	_	_	I-Premise
226	being	_	_	I-Premise
227	and	_	_	I-Premise
228	additional	_	_	I-Premise
229	concerns	_	_	I-Premise
230	-	_	_	I-Premise
231	lung	_	_	I-Premise
232	subscales	_	_	I-Premise
233	(	_	_	I-Premise
234	P	_	_	I-Premise
235	=	_	_	I-Premise
236	0	_	_	I-Premise
237	.	_	_	I-Premise

238	012	_	_	I-Premise
239	and	_	_	I-Premise
240	P	_	_	I-Premise
241	=	_	_	I-Premise
242	0	_	_	I-Premise
243	.	_	_	I-Premise

244	0003	_	_	I-Premise
245	,	_	_	I-Premise
246	respectively	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	The	_	_	B-Premise
250	results	_	_	I-Premise
251	of	_	_	I-Premise
252	both	_	_	I-Premise
253	the	_	_	I-Premise
254	FLIC	_	_	I-Premise
255	and	_	_	I-Premise
256	FACT	_	_	I-Premise
257	-	_	_	I-Premise
258	L	_	_	I-Premise
259	demonstrated	_	_	I-Premise
260	significantly	_	_	I-Premise
261	lower	_	_	I-Premise
262	scores	_	_	I-Premise
263	corresponding	_	_	I-Premise
264	to	_	_	I-Premise
265	lower	_	_	I-Premise
266	KPS	_	_	I-Premise
267	values	_	_	I-Premise
268	(	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	0	_	_	I-Premise
272	.	_	_	I-Premise

273	009	_	_	I-Premise
274	and	_	_	I-Premise
275	P	_	_	I-Premise
276	=	_	_	I-Premise
277	0	_	_	I-Premise
278	.	_	_	I-Premise

279	016	_	_	I-Premise
280	,	_	_	I-Premise
281	respectively	_	_	I-Premise
282	)	_	_	I-Premise
283	.	_	_	I-Premise

284	Results	_	_	B-Claim
285	of	_	_	I-Claim
286	this	_	_	I-Claim
287	randomized	_	_	I-Claim
288	study	_	_	I-Claim
289	incorporating	_	_	I-Claim
290	prospective	_	_	I-Claim
291	QOL	_	_	I-Claim
292	measurements	_	_	I-Claim
293	suggested	_	_	I-Claim
294	that	_	_	I-Claim
295	in	_	_	I-Claim
296	patients	_	_	I-Claim
297	with	_	_	I-Claim
298	locally	_	_	I-Claim
299	advanced	_	_	I-Claim
300	NSCLC	_	_	I-Claim
301	,	_	_	I-Claim
302	analyzing	_	_	I-Claim
303	QOL	_	_	I-Claim
304	data	_	_	I-Claim
305	by	_	_	I-Claim
306	either	_	_	I-Claim
307	gender	_	_	I-Claim
308	or	_	_	I-Claim
309	performance	_	_	I-Claim
310	status	_	_	I-Claim
311	alone	_	_	I-Claim
312	may	_	_	I-Claim
313	not	_	_	I-Claim
314	accurately	_	_	I-Claim
315	reflect	_	_	I-Claim
316	how	_	_	I-Claim
317	these	_	_	I-Claim
318	factors	_	_	I-Claim
319	depend	_	_	I-Claim
320	upon	_	_	I-Claim
321	each	_	_	I-Claim
322	another	_	_	I-Claim
323	.	_	_	I-Claim

324	Understanding	_	_	O
325	the	_	_	O
326	interaction	_	_	O
327	between	_	_	O
328	gender	_	_	O
329	and	_	_	O
330	performance	_	_	O
331	status	_	_	O
332	could	_	_	O
333	lead	_	_	O
334	to	_	_	O
335	better	_	_	O
336	prognosticators	_	_	O
337	and	_	_	O
338	potentially	_	_	O
339	could	_	_	O
340	tailor	_	_	O
341	interventions	_	_	O
342	for	_	_	O
343	specific	_	_	O
344	groups	_	_	O
345	of	_	_	O
346	patients	_	_	O
347	with	_	_	O
348	lung	_	_	O
349	cancer	_	_	O
350	.	_	_	O


0	Care	_	_	O
1	closer	_	_	O
2	to	_	_	O
3	home	_	_	O
4	is	_	_	O
5	being	_	_	O
6	explored	_	_	O
7	as	_	_	O
8	a	_	_	O
9	means	_	_	O
10	of	_	_	O
11	improving	_	_	O
12	patient	_	_	O
13	experience	_	_	O
14	as	_	_	O
15	well	_	_	O
16	as	_	_	O
17	efficiency	_	_	O
18	in	_	_	O
19	terms	_	_	O
20	of	_	_	O
21	cost	_	_	O
22	savings	_	_	O
23	.	_	_	O

24	Evidence	_	_	O
25	that	_	_	O
26	community	_	_	O
27	cancer	_	_	O
28	services	_	_	O
29	improve	_	_	O
30	care	_	_	O
31	quality	_	_	O
32	and	_	_	O
33	/	_	_	O
34	or	_	_	O
35	generate	_	_	O
36	cost	_	_	O
37	savings	_	_	O
38	is	_	_	O
39	currently	_	_	O
40	limited	_	_	O
41	.	_	_	O

42	A	_	_	O
43	randomised	_	_	O
44	study	_	_	O
45	was	_	_	O
46	undertaken	_	_	O
47	to	_	_	O
48	compare	_	_	O
49	delivery	_	_	O
50	of	_	_	O
51	cancer	_	_	O
52	treatment	_	_	O
53	in	_	_	O
54	the	_	_	O
55	hospital	_	_	O
56	with	_	_	O
57	two	_	_	O
58	different	_	_	O
59	community	_	_	O
60	settings	_	_	O
61	.	_	_	O

62	Ninety	_	_	O
63	-	_	_	O
64	seven	_	_	O
65	patients	_	_	O
66	being	_	_	O
67	offered	_	_	O
68	outpatient	_	_	O
69	-	_	_	O
70	based	_	_	O
71	cancer	_	_	O
72	treatment	_	_	O
73	were	_	_	O
74	randomised	_	_	O
75	to	_	_	O
76	treatment	_	_	O
77	delivered	_	_	O
78	in	_	_	O
79	a	_	_	O
80	hospital	_	_	O
81	day	_	_	O
82	unit	_	_	O
83	,	_	_	O
84	at	_	_	O
85	the	_	_	O
86	patient	_	_	O
87	'	_	_	O
88	s	_	_	O
89	home	_	_	O
90	or	_	_	O
91	in	_	_	O
92	local	_	_	O
93	general	_	_	O
94	practice	_	_	O
95	(	_	_	O
96	GP	_	_	O
97	)	_	_	O
98	surgeries	_	_	O
99	.	_	_	O

100	The	_	_	O
101	primary	_	_	O
102	outcome	_	_	O
103	was	_	_	O
104	patient	_	_	O
105	-	_	_	O
106	perceived	_	_	O
107	benefits	_	_	O
108	,	_	_	O
109	using	_	_	O
110	the	_	_	O
111	emotional	_	_	O
112	function	_	_	O
113	domain	_	_	O
114	of	_	_	O
115	the	_	_	O
116	EORTC	_	_	O
117	quality	_	_	O
118	of	_	_	O
119	life	_	_	O
120	(	_	_	O
121	QOL	_	_	O
122	)	_	_	O
123	QLQC30	_	_	O
124	questionnaire	_	_	O
125	evaluated	_	_	O
126	after	_	_	O
127	12	_	_	O
128	weeks	_	_	O
129	.	_	_	O

130	Secondary	_	_	O
131	outcomes	_	_	O
132	included	_	_	O
133	additional	_	_	O
134	QOL	_	_	O
135	measures	_	_	O
136	,	_	_	O
137	patient	_	_	O
138	satisfaction	_	_	O
139	,	_	_	O
140	safety	_	_	O
141	and	_	_	O
142	health	_	_	O
143	economics	_	_	O
144	.	_	_	O

145	There	_	_	B-Premise
146	was	_	_	I-Premise
147	no	_	_	I-Premise
148	statistically	_	_	I-Premise
149	significant	_	_	I-Premise
150	QOL	_	_	I-Premise
151	difference	_	_	I-Premise
152	between	_	_	I-Premise
153	treatment	_	_	I-Premise
154	in	_	_	I-Premise
155	the	_	_	I-Premise
156	combined	_	_	I-Premise
157	community	_	_	I-Premise
158	locations	_	_	I-Premise
159	relative	_	_	I-Premise
160	to	_	_	I-Premise
161	hospital	_	_	I-Premise
162	(	_	_	I-Premise
163	difference	_	_	I-Premise
164	of	_	_	I-Premise
165	-	_	_	I-Premise
166	7	_	_	I-Premise
167	.	_	_	I-Premise

168	2	_	_	I-Premise
169	,	_	_	I-Premise
170	95	_	_	I-Premise
171	%	_	_	I-Premise
172	confidence	_	_	I-Premise
173	interval	_	_	I-Premise
174	:	_	_	I-Premise
175	-	_	_	I-Premise
176	19	_	_	I-Premise
177	·	_	_	I-Premise
178	5	_	_	I-Premise
179	to	_	_	I-Premise
180	+	_	_	I-Premise
181	5	_	_	I-Premise
182	·	_	_	I-Premise
183	2	_	_	I-Premise
184	,	_	_	I-Premise
185	P	_	_	I-Premise
186	=	_	_	I-Premise
187	0	_	_	I-Premise
188	.	_	_	I-Premise

189	25	_	_	I-Premise
190	)	_	_	I-Premise
191	.	_	_	I-Premise

192	There	_	_	B-Premise
193	was	_	_	I-Premise
194	a	_	_	I-Premise
195	significant	_	_	I-Premise
196	difference	_	_	I-Premise
197	between	_	_	I-Premise
198	the	_	_	I-Premise
199	two	_	_	I-Premise
200	community	_	_	I-Premise
201	locations	_	_	I-Premise
202	in	_	_	I-Premise
203	favour	_	_	I-Premise
204	of	_	_	I-Premise
205	home	_	_	I-Premise
206	(	_	_	I-Premise
207	+	_	_	I-Premise
208	15	_	_	I-Premise
209	·	_	_	I-Premise
210	2	_	_	I-Premise
211	,	_	_	I-Premise
212	1	_	_	I-Premise
213	·	_	_	I-Premise
214	3	_	_	I-Premise
215	to	_	_	I-Premise
216	29	_	_	I-Premise
217	·	_	_	I-Premise
218	1	_	_	I-Premise
219	,	_	_	I-Premise
220	P	_	_	I-Premise
221	=	_	_	I-Premise
222	0	_	_	I-Premise
223	.	_	_	I-Premise

224	033	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	Hospital	_	_	O
228	anxiety	_	_	O
229	and	_	_	O
230	depression	_	_	O
231	scale	_	_	O
232	scores	_	_	O
233	were	_	_	O
234	consistent	_	_	O
235	with	_	_	O
236	the	_	_	O
237	primary	_	_	O
238	outcome	_	_	O
239	measure	_	_	O
240	.	_	_	O

241	There	_	_	B-Premise
242	was	_	_	I-Premise
243	no	_	_	I-Premise
244	evidence	_	_	I-Premise
245	that	_	_	I-Premise
246	community	_	_	I-Premise
247	treatment	_	_	I-Premise
248	compromised	_	_	I-Premise
249	patient	_	_	I-Premise
250	safety	_	_	I-Premise
251	and	_	_	O
252	no	_	_	B-Premise
253	significant	_	_	I-Premise
254	difference	_	_	I-Premise
255	between	_	_	I-Premise
256	treatment	_	_	I-Premise
257	arms	_	_	I-Premise
258	in	_	_	I-Premise
259	terms	_	_	I-Premise
260	of	_	_	I-Premise
261	overall	_	_	I-Premise
262	costs	_	_	I-Premise
263	or	_	_	I-Premise
264	Quality	_	_	I-Premise
265	Adjusted	_	_	I-Premise
266	Life	_	_	I-Premise
267	Year	_	_	I-Premise
268	.	_	_	I-Premise

269	Seventy	_	_	B-Premise
270	-	_	_	I-Premise
271	eight	_	_	I-Premise
272	percent	_	_	I-Premise
273	of	_	_	I-Premise
274	patients	_	_	I-Premise
275	expressed	_	_	I-Premise
276	satisfaction	_	_	I-Premise
277	with	_	_	I-Premise
278	their	_	_	I-Premise
279	treatment	_	_	I-Premise
280	whatever	_	_	I-Premise
281	their	_	_	I-Premise
282	location	_	_	I-Premise
283	,	_	_	I-Premise
284	whereas	_	_	I-Premise
285	57	_	_	I-Premise
286	%	_	_	I-Premise
287	of	_	_	I-Premise
288	patients	_	_	I-Premise
289	preferred	_	_	I-Premise
290	future	_	_	I-Premise
291	treatment	_	_	I-Premise
292	to	_	_	I-Premise
293	continue	_	_	I-Premise
294	at	_	_	I-Premise
295	the	_	_	I-Premise
296	hospital	_	_	I-Premise
297	,	_	_	I-Premise
298	81	_	_	I-Premise
299	%	_	_	I-Premise
300	at	_	_	I-Premise
301	GP	_	_	I-Premise
302	surgeries	_	_	I-Premise
303	and	_	_	I-Premise
304	90	_	_	I-Premise
305	%	_	_	I-Premise
306	at	_	_	I-Premise
307	home	_	_	I-Premise
308	.	_	_	I-Premise

309	Although	_	_	O
310	initial	_	_	O
311	pre	_	_	O
312	-	_	_	O
313	trial	_	_	O
314	interviews	_	_	O
315	revealed	_	_	O
316	concerns	_	_	O
317	among	_	_	O
318	health	_	_	O
319	-	_	_	O
320	care	_	_	O
321	professionals	_	_	O
322	and	_	_	O
323	some	_	_	O
324	patients	_	_	O
325	regarding	_	_	O
326	community	_	_	O
327	treatment	_	_	O
328	,	_	_	O
329	opinions	_	_	O
330	were	_	_	O
331	largely	_	_	O
332	more	_	_	O
333	favourable	_	_	O
334	in	_	_	O
335	post	_	_	O
336	-	_	_	O
337	trial	_	_	O
338	interviews	_	_	O
339	.	_	_	O

340	Patient	_	_	B-Claim
341	QOL	_	_	I-Claim
342	favours	_	_	I-Claim
343	delivering	_	_	I-Claim
344	cancer	_	_	I-Claim
345	treatment	_	_	I-Claim
346	in	_	_	I-Claim
347	the	_	_	I-Claim
348	home	_	_	I-Claim
349	rather	_	_	I-Claim
350	than	_	_	I-Claim
351	GP	_	_	I-Claim
352	surgeries	_	_	I-Claim
353	.	_	_	I-Claim

354	Nevertheless	_	_	B-Claim
355	,	_	_	I-Claim
356	both	_	_	I-Claim
357	community	_	_	I-Claim
358	settings	_	_	I-Claim
359	were	_	_	I-Claim
360	acceptable	_	_	I-Claim
361	to	_	_	I-Claim
362	and	_	_	I-Claim
363	preferred	_	_	I-Claim
364	by	_	_	I-Claim
365	patients	_	_	I-Claim
366	compared	_	_	I-Claim
367	with	_	_	I-Claim
368	hospital	_	_	I-Claim
369	,	_	_	I-Claim
370	were	_	_	I-Claim
371	safe	_	_	I-Claim
372	,	_	_	I-Claim
373	with	_	_	I-Claim
374	no	_	_	I-Claim
375	detrimental	_	_	I-Claim
376	impact	_	_	I-Claim
377	on	_	_	I-Claim
378	overall	_	_	I-Claim
379	health	_	_	I-Claim
380	-	_	_	I-Claim
381	care	_	_	I-Claim
382	costs	_	_	I-Claim
383	.	_	_	I-Claim


0	A	_	_	O
1	randomized	_	_	O
2	controlled	_	_	O
3	trial	_	_	O
4	previously	_	_	O
5	conducted	_	_	O
6	in	_	_	O
7	radiation	_	_	O
8	oncology	_	_	O
9	patients	_	_	O
10	demonstrated	_	_	O
11	that	_	_	O
12	nutrition	_	_	O
13	intervention	_	_	O
14	had	_	_	O
15	a	_	_	O
16	beneficial	_	_	O
17	impact	_	_	O
18	on	_	_	O
19	body	_	_	O
20	weight	_	_	O
21	,	_	_	O
22	nutritional	_	_	O
23	status	_	_	O
24	,	_	_	O
25	and	_	_	O
26	quality	_	_	O
27	of	_	_	O
28	life	_	_	O
29	compared	_	_	O
30	with	_	_	O
31	standard	_	_	O
32	practice	_	_	O
33	,	_	_	O
34	but	_	_	O
35	it	_	_	O
36	did	_	_	O
37	not	_	_	O
38	report	_	_	O
39	on	_	_	O
40	dietary	_	_	O
41	intake	_	_	O
42	data	_	_	O
43	.	_	_	O

44	To	_	_	O
45	determine	_	_	O
46	the	_	_	O
47	impact	_	_	O
48	of	_	_	O
49	nutrition	_	_	O
50	intervention	_	_	O
51	compared	_	_	O
52	with	_	_	O
53	standard	_	_	O
54	practice	_	_	O
55	on	_	_	O
56	dietary	_	_	O
57	intake	_	_	O
58	in	_	_	O
59	outpatients	_	_	O
60	receiving	_	_	O
61	radiotherapy	_	_	O
62	.	_	_	O

63	Prospective	_	_	O
64	,	_	_	O
65	randomized	_	_	O
66	,	_	_	O
67	controlled	_	_	O
68	trial	_	_	O
69	.	_	_	O

70	Sixty	_	_	O
71	consecutive	_	_	O
72	radiation	_	_	O
73	oncology	_	_	O
74	outpatients	_	_	O
75	(	_	_	O
76	51	_	_	O
77	men	_	_	O
78	and	_	_	O
79	nine	_	_	O
80	women	_	_	O
81	;	_	_	O
82	age	_	_	O
83	61	_	_	O
84	.	_	_	O

85	9	_	_	O
86	+	_	_	O
87	/	_	_	O
88	-	_	_	O
89	14	_	_	O
90	years	_	_	O
91	[	_	_	O
92	mean	_	_	O
93	+	_	_	O
94	/	_	_	O
95	-	_	_	O
96	standard	_	_	O
97	deviation	_	_	O
98	]	_	_	O
99	)	_	_	O
100	.	_	_	O

101	Australian	_	_	O
102	private	_	_	O
103	radiotherapy	_	_	O
104	facility	_	_	O
105	.	_	_	O

106	Patients	_	_	O
107	were	_	_	O
108	randomly	_	_	O
109	assigned	_	_	O
110	to	_	_	O
111	receive	_	_	O
112	either	_	_	O
113	nutrition	_	_	O
114	intervention	_	_	O
115	(	_	_	O
116	n	_	_	O
117	=	_	_	O
118	29	_	_	O
119	)	_	_	O
120	(	_	_	O
121	nutrition	_	_	O
122	counseling	_	_	O
123	following	_	_	O
124	the	_	_	O
125	American	_	_	O
126	Dietetic	_	_	O
127	Association	_	_	O
128	[	_	_	O
129	ADA	_	_	O
130	]	_	_	O
131	medical	_	_	O
132	nutrition	_	_	O
133	therapy	_	_	O
134	[	_	_	O
135	MNT	_	_	O
136	]	_	_	O
137	protocol	_	_	O
138	for	_	_	O
139	radiation	_	_	O
140	oncology	_	_	O
141	)	_	_	O
142	or	_	_	O
143	standard	_	_	O
144	practice	_	_	O
145	(	_	_	O
146	n	_	_	O
147	=	_	_	O
148	31	_	_	O
149	)	_	_	O
150	(	_	_	O
151	general	_	_	O
152	nutrition	_	_	O
153	talk	_	_	O
154	and	_	_	O
155	booklet	_	_	O
156	)	_	_	O
157	.	_	_	O

158	Dietary	_	_	O
159	intake	_	_	O
160	(	_	_	O
161	protein	_	_	O
162	,	_	_	O
163	energy	_	_	O
164	,	_	_	O
165	fiber	_	_	O
166	)	_	_	O
167	assessed	_	_	O
168	at	_	_	O
169	baseline	_	_	O
170	and	_	_	O
171	at	_	_	O
172	4	_	_	O
173	,	_	_	O
174	8	_	_	O
175	,	_	_	O
176	and	_	_	O
177	12	_	_	O
178	weeks	_	_	O
179	after	_	_	O
180	starting	_	_	O
181	radiotherapy	_	_	O
182	.	_	_	O

183	Repeated	_	_	O
184	-	_	_	O
185	measures	_	_	O
186	analysis	_	_	O
187	of	_	_	O
188	variance	_	_	O
189	done	_	_	O
190	on	_	_	O
191	an	_	_	O
192	intention	_	_	O
193	to	_	_	O
194	treat	_	_	O
195	basis	_	_	O
196	.	_	_	O

197	The	_	_	B-Premise
198	nutrition	_	_	I-Premise
199	intervention	_	_	I-Premise
200	group	_	_	I-Premise
201	had	_	_	I-Premise
202	a	_	_	I-Premise
203	higher	_	_	I-Premise
204	mean	_	_	I-Premise
205	total	_	_	I-Premise
206	energy	_	_	I-Premise
207	(	_	_	I-Premise
208	P	_	_	I-Premise
209	=	_	_	I-Premise
210	0	_	_	I-Premise
211	.	_	_	I-Premise

212	029	_	_	I-Premise
213	)	_	_	I-Premise
214	and	_	_	I-Premise
215	protein	_	_	I-Premise
216	intake	_	_	I-Premise
217	(	_	_	I-Premise
218	P	_	_	I-Premise
219	<	_	_	I-Premise
220	0	_	_	I-Premise
221	.	_	_	I-Premise

222	001	_	_	I-Premise
223	)	_	_	I-Premise
224	compared	_	_	I-Premise
225	with	_	_	I-Premise
226	the	_	_	I-Premise
227	standard	_	_	I-Premise
228	practice	_	_	I-Premise
229	group	_	_	I-Premise
230	.	_	_	I-Premise

231	Mean	_	_	B-Premise
232	intake	_	_	I-Premise
233	per	_	_	I-Premise
234	kilogram	_	_	I-Premise
235	of	_	_	I-Premise
236	body	_	_	I-Premise
237	weight	_	_	I-Premise
238	for	_	_	I-Premise
239	the	_	_	I-Premise
240	nutrition	_	_	I-Premise
241	intervention	_	_	I-Premise
242	group	_	_	I-Premise
243	ranged	_	_	I-Premise
244	from	_	_	I-Premise
245	28	_	_	I-Premise
246	to	_	_	I-Premise
247	31	_	_	I-Premise
248	kcal	_	_	I-Premise
249	/	_	_	I-Premise
250	kg	_	_	I-Premise
251	/	_	_	I-Premise
252	day	_	_	I-Premise
253	compared	_	_	I-Premise
254	with	_	_	I-Premise
255	25	_	_	I-Premise
256	to	_	_	I-Premise
257	29	_	_	I-Premise
258	kcal	_	_	I-Premise
259	/	_	_	I-Premise
260	kg	_	_	I-Premise
261	/	_	_	I-Premise
262	day	_	_	I-Premise
263	for	_	_	I-Premise
264	the	_	_	I-Premise
265	standard	_	_	I-Premise
266	practice	_	_	I-Premise
267	group	_	_	I-Premise
268	(	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	0	_	_	I-Premise
272	.	_	_	I-Premise

273	022	_	_	I-Premise
274	)	_	_	I-Premise
275	.	_	_	I-Premise

276	The	_	_	B-Premise
277	nutrition	_	_	I-Premise
278	intervention	_	_	I-Premise
279	group	_	_	I-Premise
280	had	_	_	I-Premise
281	a	_	_	I-Premise
282	higher	_	_	I-Premise
283	mean	_	_	I-Premise
284	protein	_	_	I-Premise
285	intake	_	_	I-Premise
286	(	_	_	I-Premise
287	1	_	_	I-Premise
288	.	_	_	I-Premise

289	1	_	_	I-Premise
290	to	_	_	I-Premise
291	1	_	_	I-Premise
292	.	_	_	I-Premise

293	3	_	_	I-Premise
294	g	_	_	I-Premise
295	/	_	_	I-Premise
296	kg	_	_	I-Premise
297	/	_	_	I-Premise
298	day	_	_	I-Premise
299	)	_	_	I-Premise
300	compared	_	_	I-Premise
301	with	_	_	I-Premise
302	the	_	_	I-Premise
303	standard	_	_	I-Premise
304	practice	_	_	I-Premise
305	group	_	_	I-Premise
306	(	_	_	I-Premise
307	1	_	_	I-Premise
308	.	_	_	I-Premise

309	0	_	_	I-Premise
310	to	_	_	I-Premise
311	1	_	_	I-Premise
312	.	_	_	I-Premise

313	1	_	_	I-Premise
314	g	_	_	I-Premise
315	/	_	_	I-Premise
316	kg	_	_	I-Premise
317	/	_	_	I-Premise
318	day	_	_	I-Premise
319	)	_	_	I-Premise
320	(	_	_	I-Premise
321	P	_	_	I-Premise
322	=	_	_	I-Premise
323	0	_	_	I-Premise
324	.	_	_	I-Premise

325	001	_	_	I-Premise
326	)	_	_	I-Premise
327	.	_	_	I-Premise

328	Although	_	_	B-Premise
329	the	_	_	I-Premise
330	change	_	_	I-Premise
331	in	_	_	I-Premise
332	fiber	_	_	I-Premise
333	intake	_	_	I-Premise
334	between	_	_	I-Premise
335	the	_	_	I-Premise
336	groups	_	_	I-Premise
337	was	_	_	I-Premise
338	not	_	_	I-Premise
339	significant	_	_	I-Premise
340	,	_	_	I-Premise
341	there	_	_	B-Premise
342	was	_	_	I-Premise
343	a	_	_	I-Premise
344	trend	_	_	I-Premise
345	in	_	_	I-Premise
346	the	_	_	I-Premise
347	anticipated	_	_	I-Premise
348	direction	_	_	I-Premise
349	(	_	_	I-Premise
350	P	_	_	I-Premise
351	=	_	_	I-Premise
352	0	_	_	I-Premise
353	.	_	_	I-Premise

354	083	_	_	I-Premise
355	)	_	_	I-Premise
356	.	_	_	I-Premise

357	Intensive	_	_	B-Claim
358	nutrition	_	_	I-Claim
359	intervention	_	_	I-Claim
360	following	_	_	I-Claim
361	the	_	_	I-Claim
362	ADA	_	_	I-Claim
363	MNT	_	_	I-Claim
364	protocol	_	_	I-Claim
365	results	_	_	I-Claim
366	in	_	_	I-Claim
367	improved	_	_	I-Claim
368	dietary	_	_	I-Claim
369	intake	_	_	I-Claim
370	compared	_	_	I-Claim
371	with	_	_	I-Claim
372	standard	_	_	I-Claim
373	practice	_	_	I-Claim
374	and	_	_	I-Claim
375	seems	_	_	I-Claim
376	to	_	_	I-Claim
377	beneficially	_	_	I-Claim
378	impact	_	_	I-Claim
379	nutrition	_	_	I-Claim
380	-	_	_	I-Claim
381	related	_	_	I-Claim
382	outcomes	_	_	I-Claim
383	previously	_	_	I-Claim
384	observed	_	_	I-Claim
385	in	_	_	I-Claim
386	oncology	_	_	I-Claim
387	outpatients	_	_	I-Claim
388	receiving	_	_	I-Claim
389	radiotherapy	_	_	I-Claim
390	.	_	_	I-Claim

391	The	_	_	B-Claim
392	ADA	_	_	I-Claim
393	MNT	_	_	I-Claim
394	protocol	_	_	I-Claim
395	for	_	_	I-Claim
396	radiation	_	_	I-Claim
397	oncology	_	_	I-Claim
398	is	_	_	I-Claim
399	a	_	_	I-Claim
400	useful	_	_	I-Claim
401	guide	_	_	I-Claim
402	to	_	_	I-Claim
403	the	_	_	I-Claim
404	level	_	_	I-Claim
405	of	_	_	I-Claim
406	nutrition	_	_	I-Claim
407	support	_	_	I-Claim
408	required	_	_	I-Claim
409	.	_	_	I-Claim


0	This	_	_	O
1	randomized	_	_	O
2	phase	_	_	O
3	II	_	_	O
4	trial	_	_	O
5	evaluated	_	_	O
6	two	_	_	O
7	docetaxel	_	_	O
8	-	_	_	O
9	based	_	_	O
10	regimens	_	_	O
11	to	_	_	O
12	see	_	_	O
13	which	_	_	O
14	would	_	_	O
15	be	_	_	O
16	most	_	_	O
17	promising	_	_	O
18	according	_	_	O
19	to	_	_	O
20	overall	_	_	O
21	response	_	_	O
22	rate	_	_	O
23	(	_	_	O
24	ORR	_	_	O
25	)	_	_	O
26	for	_	_	O
27	comparison	_	_	O
28	in	_	_	O
29	a	_	_	O
30	phase	_	_	O
31	III	_	_	O
32	trial	_	_	O
33	with	_	_	O
34	epirubicin	_	_	O
35	-	_	_	O
36	cisplatin	_	_	O
37	-	_	_	O
38	fluorouracil	_	_	O
39	(	_	_	O
40	ECF	_	_	O
41	)	_	_	O
42	as	_	_	O
43	first	_	_	O
44	-	_	_	O
45	line	_	_	O
46	advanced	_	_	O
47	gastric	_	_	O
48	cancer	_	_	O
49	therapy	_	_	O
50	.	_	_	O

51	Chemotherapy	_	_	O
52	-	_	_	O
53	naïve	_	_	O
54	patients	_	_	O
55	with	_	_	O
56	measurable	_	_	O
57	unresectable	_	_	O
58	and	_	_	O
59	/	_	_	O
60	or	_	_	O
61	metastatic	_	_	O
62	gastric	_	_	O
63	carcinoma	_	_	O
64	,	_	_	O
65	a	_	_	O
66	performance	_	_	O
67	status	_	_	O
68	<	_	_	O
69	or	_	_	O
70	=	_	_	O
71	1	_	_	O
72	,	_	_	O
73	and	_	_	O
74	adequate	_	_	O
75	hematologic	_	_	O
76	,	_	_	O
77	hepatic	_	_	O
78	,	_	_	O
79	and	_	_	O
80	renal	_	_	O
81	function	_	_	O
82	randomly	_	_	O
83	received	_	_	O
84	<	_	_	O
85	or	_	_	O
86	=	_	_	O
87	eight	_	_	O
88	3	_	_	O
89	-	_	_	O
90	weekly	_	_	O
91	cycles	_	_	O
92	of	_	_	O
93	ECF	_	_	O
94	(	_	_	O
95	epirubicin	_	_	O
96	50	_	_	O
97	mg	_	_	O
98	/	_	_	O
99	m	_	_	O
100	(	_	_	O
101	2	_	_	O
102	)	_	_	O
103	on	_	_	O
104	day	_	_	O
105	1	_	_	O
106	,	_	_	O
107	cisplatin	_	_	O
108	60	_	_	O
109	mg	_	_	O
110	/	_	_	O
111	m	_	_	O
112	(	_	_	O
113	2	_	_	O
114	)	_	_	O
115	on	_	_	O
116	day	_	_	O
117	1	_	_	O
118	,	_	_	O
119	and	_	_	O
120	fluorouracil	_	_	O
121	[	_	_	O
122	FU	_	_	O
123	]	_	_	O
124	200	_	_	O
125	mg	_	_	O
126	/	_	_	O
127	m	_	_	O
128	(	_	_	O
129	2	_	_	O
130	)	_	_	O
131	/	_	_	O
132	d	_	_	O
133	on	_	_	O
134	days	_	_	O
135	1	_	_	O
136	to	_	_	O
137	21	_	_	O
138	)	_	_	O
139	,	_	_	O
140	TC	_	_	O
141	(	_	_	O
142	docetaxel	_	_	O
143	initially	_	_	O
144	85	_	_	O
145	mg	_	_	O
146	/	_	_	O
147	m	_	_	O
148	(	_	_	O
149	2	_	_	O
150	)	_	_	O
151	on	_	_	O
152	day	_	_	O
153	1	_	_	O
154	[	_	_	O
155	later	_	_	O
156	reduced	_	_	O
157	to	_	_	O
158	75	_	_	O
159	mg	_	_	O
160	/	_	_	O
161	m	_	_	O
162	(	_	_	O
163	2	_	_	O
164	)	_	_	O
165	as	_	_	O
166	a	_	_	O
167	result	_	_	O
168	of	_	_	O
169	toxicity	_	_	O
170	]	_	_	O
171	and	_	_	O
172	cisplatin	_	_	O
173	75	_	_	O
174	mg	_	_	O
175	/	_	_	O
176	m	_	_	O
177	(	_	_	O
178	2	_	_	O
179	)	_	_	O
180	on	_	_	O
181	day	_	_	O
182	1	_	_	O
183	)	_	_	O
184	,	_	_	O
185	or	_	_	O
186	TCF	_	_	O
187	(	_	_	O
188	TC	_	_	O
189	plus	_	_	O
190	FU	_	_	O
191	300	_	_	O
192	mg	_	_	O
193	/	_	_	O
194	m	_	_	O
195	(	_	_	O
196	2	_	_	O
197	)	_	_	O
198	/	_	_	O
199	d	_	_	O
200	on	_	_	O
201	days	_	_	O
202	1	_	_	O
203	to	_	_	O
204	14	_	_	O
205	)	_	_	O
206	.	_	_	O

207	Study	_	_	O
208	objectives	_	_	O
209	included	_	_	O
210	response	_	_	O
211	(	_	_	O
212	primary	_	_	O
213	)	_	_	O
214	,	_	_	O
215	survival	_	_	O
216	,	_	_	O
217	toxicity	_	_	O
218	,	_	_	O
219	and	_	_	O
220	quality	_	_	O
221	of	_	_	O
222	life	_	_	O
223	(	_	_	O
224	QOL	_	_	O
225	)	_	_	O
226	.	_	_	O

227	ORR	_	_	B-Premise
228	was	_	_	I-Premise
229	25	_	_	I-Premise
230	.	_	_	I-Premise

231	0	_	_	I-Premise
232	%	_	_	I-Premise
233	(	_	_	I-Premise
234	95	_	_	I-Premise
235	%	_	_	I-Premise
236	CI	_	_	I-Premise
237	,	_	_	I-Premise
238	13	_	_	I-Premise
239	%	_	_	I-Premise
240	to	_	_	I-Premise
241	41	_	_	I-Premise
242	%	_	_	I-Premise
243	)	_	_	I-Premise
244	for	_	_	I-Premise
245	ECF	_	_	I-Premise
246	,	_	_	I-Premise
247	18	_	_	I-Premise
248	.	_	_	I-Premise

249	5	_	_	I-Premise
250	%	_	_	I-Premise
251	(	_	_	I-Premise
252	95	_	_	I-Premise
253	%	_	_	I-Premise
254	CI	_	_	I-Premise
255	,	_	_	I-Premise
256	9	_	_	I-Premise
257	%	_	_	I-Premise
258	to	_	_	I-Premise
259	34	_	_	I-Premise
260	%	_	_	I-Premise
261	)	_	_	I-Premise
262	for	_	_	I-Premise
263	TC	_	_	I-Premise
264	,	_	_	I-Premise
265	and	_	_	I-Premise
266	36	_	_	I-Premise
267	.	_	_	I-Premise

268	6	_	_	I-Premise
269	%	_	_	I-Premise
270	(	_	_	I-Premise
271	95	_	_	I-Premise
272	%	_	_	I-Premise
273	CI	_	_	I-Premise
274	,	_	_	I-Premise
275	23	_	_	I-Premise
276	%	_	_	I-Premise
277	to	_	_	I-Premise
278	53	_	_	I-Premise
279	%	_	_	I-Premise
280	)	_	_	I-Premise
281	for	_	_	I-Premise
282	TCF	_	_	I-Premise
283	(	_	_	I-Premise
284	n	_	_	I-Premise
285	=	_	_	I-Premise
286	119	_	_	I-Premise
287	)	_	_	I-Premise
288	.	_	_	I-Premise

289	Median	_	_	B-Premise
290	overall	_	_	I-Premise
291	survival	_	_	I-Premise
292	times	_	_	I-Premise
293	were	_	_	I-Premise
294	8	_	_	I-Premise
295	.	_	_	I-Premise

296	3	_	_	I-Premise
297	,	_	_	I-Premise
298	11	_	_	I-Premise
299	.	_	_	I-Premise

300	0	_	_	I-Premise
301	,	_	_	I-Premise
302	and	_	_	I-Premise
303	10	_	_	I-Premise
304	.	_	_	I-Premise

305	4	_	_	I-Premise
306	months	_	_	I-Premise
307	for	_	_	I-Premise
308	ECF	_	_	I-Premise
309	,	_	_	I-Premise
310	TC	_	_	I-Premise
311	,	_	_	I-Premise
312	and	_	_	I-Premise
313	TCF	_	_	I-Premise
314	,	_	_	I-Premise
315	respectively	_	_	I-Premise
316	.	_	_	I-Premise

317	Toxicity	_	_	B-Premise
318	was	_	_	I-Premise
319	acceptable	_	_	I-Premise
320	,	_	_	I-Premise
321	with	_	_	I-Premise
322	one	_	_	I-Premise
323	toxic	_	_	I-Premise
324	death	_	_	I-Premise
325	(	_	_	I-Premise
326	TC	_	_	I-Premise
327	arm	_	_	I-Premise
328	)	_	_	I-Premise
329	.	_	_	I-Premise

330	Grade	_	_	B-Premise
331	3	_	_	I-Premise
332	or	_	_	I-Premise
333	4	_	_	I-Premise
334	neutropenia	_	_	I-Premise
335	occurred	_	_	I-Premise
336	in	_	_	I-Premise
337	more	_	_	I-Premise
338	treatment	_	_	I-Premise
339	cycles	_	_	I-Premise
340	with	_	_	I-Premise
341	docetaxel	_	_	I-Premise
342	(	_	_	I-Premise
343	TC	_	_	I-Premise
344	,	_	_	I-Premise
345	49	_	_	I-Premise
346	%	_	_	I-Premise
347	;	_	_	I-Premise
348	TCF	_	_	I-Premise
349	,	_	_	I-Premise
350	57	_	_	I-Premise
351	%	_	_	I-Premise
352	;	_	_	I-Premise
353	ECF	_	_	I-Premise
354	,	_	_	I-Premise
355	34	_	_	I-Premise
356	%	_	_	I-Premise
357	)	_	_	I-Premise
358	.	_	_	I-Premise

359	Global	_	_	B-Claim
360	health	_	_	I-Claim
361	status	_	_	I-Claim
362	/	_	_	I-Claim
363	QOL	_	_	I-Claim
364	substantially	_	_	I-Claim
365	improved	_	_	I-Claim
366	with	_	_	I-Claim
367	ECF	_	_	I-Claim
368	and	_	_	I-Claim
369	remained	_	_	I-Claim
370	similar	_	_	I-Claim
371	to	_	_	I-Claim
372	baseline	_	_	I-Claim
373	with	_	_	I-Claim
374	both	_	_	I-Claim
375	docetaxel	_	_	I-Claim
376	regimens	_	_	I-Claim
377	.	_	_	I-Claim

378	Time	_	_	B-Premise
379	to	_	_	I-Premise
380	response	_	_	I-Premise
381	and	_	_	I-Premise
382	ORR	_	_	I-Premise
383	favor	_	_	I-Premise
384	TCF	_	_	I-Premise
385	over	_	_	I-Premise
386	TC	_	_	I-Premise
387	for	_	_	I-Premise
388	further	_	_	I-Premise
389	evaluation	_	_	I-Premise
390	,	_	_	I-Premise
391	particularly	_	_	I-Premise
392	in	_	_	I-Premise
393	the	_	_	I-Premise
394	neoadjuvant	_	_	I-Premise
395	setting	_	_	I-Premise
396	.	_	_	I-Premise

397	A	_	_	B-Premise
398	trend	_	_	I-Premise
399	towards	_	_	I-Premise
400	increased	_	_	I-Premise
401	myelosuppression	_	_	I-Premise
402	and	_	_	I-Premise
403	infectious	_	_	I-Premise
404	complications	_	_	I-Premise
405	with	_	_	I-Premise
406	TCF	_	_	I-Premise
407	versus	_	_	I-Premise
408	TC	_	_	I-Premise
409	or	_	_	I-Premise
410	ECF	_	_	I-Premise
411	was	_	_	I-Premise
412	observed	_	_	I-Premise
413	.	_	_	I-Premise


0	Morbidity	_	_	B-Claim
1	associated	_	_	I-Claim
2	with	_	_	I-Claim
3	wound	_	_	I-Claim
4	complications	_	_	I-Claim
5	may	_	_	I-Claim
6	translate	_	_	I-Claim
7	into	_	_	I-Claim
8	disability	_	_	I-Claim
9	and	_	_	I-Claim
10	quality	_	_	I-Claim
11	-	_	_	I-Claim
12	of	_	_	I-Claim
13	-	_	_	I-Claim
14	life	_	_	I-Claim
15	disadvantages	_	_	I-Claim
16	for	_	_	I-Claim
17	patients	_	_	I-Claim
18	treated	_	_	I-Claim
19	with	_	_	I-Claim
20	radiotherapy	_	_	I-Claim
21	(	_	_	I-Claim
22	RT	_	_	I-Claim
23	)	_	_	I-Claim
24	for	_	_	I-Claim
25	soft	_	_	I-Claim
26	tissue	_	_	I-Claim
27	sarcoma	_	_	I-Claim
28	(	_	_	I-Claim
29	STS	_	_	I-Claim
30	)	_	_	I-Claim
31	of	_	_	I-Claim
32	the	_	_	I-Claim
33	extremities	_	_	I-Claim
34	.	_	_	I-Claim

35	Functional	_	_	O
36	outcome	_	_	O
37	and	_	_	O
38	health	_	_	O
39	status	_	_	O
40	of	_	_	O
41	extremity	_	_	O
42	STS	_	_	O
43	patients	_	_	O
44	randomized	_	_	O
45	in	_	_	O
46	a	_	_	O
47	phase	_	_	O
48	III	_	_	O
49	trial	_	_	O
50	comparing	_	_	O
51	preoperative	_	_	O
52	versus	_	_	O
53	postoperative	_	_	O
54	RT	_	_	O
55	is	_	_	O
56	described	_	_	O
57	.	_	_	O

58	One	_	_	O
59	hundred	_	_	O
60	ninety	_	_	O
61	patients	_	_	O
62	with	_	_	O
63	extremity	_	_	O
64	STS	_	_	O
65	were	_	_	O
66	randomized	_	_	O
67	after	_	_	O
68	stratification	_	_	O
69	by	_	_	O
70	tumor	_	_	O
71	size	_	_	O
72	dichotomized	_	_	O
73	at	_	_	O
74	10	_	_	O
75	cm	_	_	O
76	.	_	_	O

77	Function	_	_	O
78	and	_	_	O
79	quality	_	_	O
80	of	_	_	O
81	life	_	_	O
82	were	_	_	O
83	measured	_	_	O
84	by	_	_	O
85	the	_	_	O
86	Musculoskeletal	_	_	O
87	Tumor	_	_	O
88	Society	_	_	O
89	Rating	_	_	O
90	Scale	_	_	O
91	(	_	_	O
92	MSTS	_	_	O
93	)	_	_	O
94	,	_	_	O
95	the	_	_	O
96	Toronto	_	_	O
97	Extremity	_	_	O
98	Salvage	_	_	O
99	Score	_	_	O
100	(	_	_	O
101	TESS	_	_	O
102	)	_	_	O
103	,	_	_	O
104	and	_	_	O
105	the	_	_	O
106	Short	_	_	O
107	Form	_	_	O
108	-	_	_	O
109	36	_	_	O
110	(	_	_	O
111	SF	_	_	O
112	-	_	_	O
113	36	_	_	O
114	)	_	_	O
115	at	_	_	O
116	randomization	_	_	O
117	,	_	_	O
118	6	_	_	O
119	weeks	_	_	O
120	,	_	_	O
121	and	_	_	O
122	3	_	_	O
123	,	_	_	O
124	6	_	_	O
125	,	_	_	O
126	12	_	_	O
127	,	_	_	O
128	and	_	_	O
129	24	_	_	O
130	months	_	_	O
131	after	_	_	O
132	surgery	_	_	O
133	.	_	_	O

134	One	_	_	O
135	hundred	_	_	O
136	eighty	_	_	O
137	-	_	_	O
138	five	_	_	O
139	patients	_	_	O
140	had	_	_	O
141	function	_	_	O
142	data	_	_	O
143	.	_	_	O

144	Patients	_	_	B-Premise
145	treated	_	_	I-Premise
146	with	_	_	I-Premise
147	postoperative	_	_	I-Premise
148	RT	_	_	I-Premise
149	had	_	_	I-Premise
150	better	_	_	I-Premise
151	function	_	_	I-Premise
152	with	_	_	I-Premise
153	higher	_	_	I-Premise
154	MSTS	_	_	I-Premise
155	(	_	_	I-Premise
156	25	_	_	I-Premise
157	.	_	_	I-Premise

158	8	_	_	I-Premise
159	v	_	_	I-Premise
160	21	_	_	I-Premise
161	.	_	_	I-Premise

162	3	_	_	I-Premise
163	,	_	_	I-Premise
164	P	_	_	I-Premise
165	<	_	_	I-Premise
166	.	_	_	I-Premise

167	01	_	_	I-Premise
168	)	_	_	I-Premise
169	,	_	_	I-Premise
170	TESS	_	_	I-Premise
171	(	_	_	I-Premise
172	69	_	_	I-Premise
173	.	_	_	I-Premise

174	8	_	_	I-Premise
175	v	_	_	I-Premise
176	60	_	_	I-Premise
177	.	_	_	I-Premise

178	6	_	_	I-Premise
179	,	_	_	I-Premise
180	P	_	_	I-Premise
181	=	_	_	I-Premise
182	.	_	_	I-Premise

183	01	_	_	I-Premise
184	)	_	_	I-Premise
185	,	_	_	I-Premise
186	and	_	_	I-Premise
187	SF	_	_	I-Premise
188	-	_	_	I-Premise
189	36	_	_	I-Premise
190	bodily	_	_	I-Premise
191	pain	_	_	I-Premise
192	(	_	_	I-Premise
193	67	_	_	I-Premise
194	.	_	_	I-Premise

195	7	_	_	I-Premise
196	v	_	_	I-Premise
197	58	_	_	I-Premise
198	.	_	_	I-Premise

199	5	_	_	I-Premise
200	,	_	_	I-Premise
201	P	_	_	I-Premise
202	=	_	_	I-Premise
203	.	_	_	I-Premise

204	03	_	_	I-Premise
205	)	_	_	I-Premise
206	scores	_	_	I-Premise
207	at	_	_	I-Premise
208	6	_	_	I-Premise
209	weeks	_	_	I-Premise
210	after	_	_	I-Premise
211	surgery	_	_	I-Premise
212	.	_	_	I-Premise

213	There	_	_	O
214	were	_	_	O
215	no	_	_	O
216	differences	_	_	O
217	at	_	_	O
218	later	_	_	O
219	time	_	_	O
220	points	_	_	O
221	.	_	_	O

222	Scores	_	_	B-Premise
223	on	_	_	I-Premise
224	the	_	_	I-Premise
225	physical	_	_	I-Premise
226	function	_	_	I-Premise
227	,	_	_	I-Premise
228	role	_	_	I-Premise
229	-	_	_	I-Premise
230	physical	_	_	I-Premise
231	,	_	_	I-Premise
232	and	_	_	I-Premise
233	general	_	_	I-Premise
234	health	_	_	I-Premise
235	subscales	_	_	I-Premise
236	of	_	_	I-Premise
237	the	_	_	I-Premise
238	SF	_	_	I-Premise
239	-	_	_	I-Premise
240	36	_	_	I-Premise
241	were	_	_	I-Premise
242	significantly	_	_	I-Premise
243	lower	_	_	I-Premise
244	than	_	_	I-Premise
245	Canadian	_	_	I-Premise
246	normative	_	_	I-Premise
247	data	_	_	I-Premise
248	at	_	_	I-Premise
249	all	_	_	I-Premise
250	time	_	_	I-Premise
251	points	_	_	I-Premise
252	.	_	_	I-Premise

253	After	_	_	O
254	treatment	_	_	O
255	arm	_	_	O
256	was	_	_	O
257	controlled	_	_	O
258	for	_	_	O
259	,	_	_	O
260	MSTS	_	_	O
261	change	_	_	O
262	scores	_	_	O
263	were	_	_	O
264	predicted	_	_	O
265	by	_	_	O
266	a	_	_	O
267	lower	_	_	O
268	-	_	_	O
269	extremity	_	_	O
270	tumor	_	_	O
271	,	_	_	O
272	a	_	_	O
273	large	_	_	O
274	resection	_	_	O
275	specimen	_	_	O
276	,	_	_	O
277	and	_	_	O
278	motor	_	_	O
279	nerve	_	_	O
280	sacrifice	_	_	O
281	;	_	_	O
282	TESS	_	_	O
283	change	_	_	O
284	scores	_	_	O
285	were	_	_	O
286	predicted	_	_	O
287	by	_	_	O
288	lower	_	_	O
289	-	_	_	O
290	extremity	_	_	O
291	tumor	_	_	O
292	and	_	_	O
293	prior	_	_	O
294	incomplete	_	_	O
295	excision	_	_	O
296	.	_	_	O

297	When	_	_	B-Premise
298	wound	_	_	I-Premise
299	complication	_	_	I-Premise
300	was	_	_	I-Premise
301	included	_	_	I-Premise
302	in	_	_	I-Premise
303	the	_	_	I-Premise
304	model	_	_	I-Premise
305	,	_	_	I-Premise
306	patients	_	_	I-Premise
307	with	_	_	I-Premise
308	complications	_	_	I-Premise
309	had	_	_	I-Premise
310	lower	_	_	I-Premise
311	MSTS	_	_	I-Premise
312	and	_	_	I-Premise
313	TESS	_	_	I-Premise
314	scores	_	_	I-Premise
315	in	_	_	I-Premise
316	the	_	_	I-Premise
317	first	_	_	I-Premise
318	2	_	_	I-Premise
319	years	_	_	I-Premise
320	after	_	_	I-Premise
321	treatment	_	_	I-Premise
322	.	_	_	I-Premise

323	The	_	_	B-Claim
324	timing	_	_	I-Claim
325	of	_	_	I-Claim
326	RT	_	_	I-Claim
327	has	_	_	I-Claim
328	minimal	_	_	I-Claim
329	impact	_	_	I-Claim
330	on	_	_	I-Claim
331	the	_	_	I-Claim
332	function	_	_	I-Claim
333	of	_	_	I-Claim
334	STS	_	_	I-Claim
335	patients	_	_	I-Claim
336	in	_	_	I-Claim
337	the	_	_	I-Claim
338	first	_	_	I-Claim
339	year	_	_	I-Claim
340	after	_	_	I-Claim
341	surgery	_	_	I-Claim
342	.	_	_	O

343	Tumor	_	_	B-Claim
344	characteristics	_	_	I-Claim
345	and	_	_	I-Claim
346	wound	_	_	I-Claim
347	complications	_	_	I-Claim
348	have	_	_	I-Claim
349	a	_	_	I-Claim
350	detrimental	_	_	I-Claim
351	effect	_	_	I-Claim
352	on	_	_	I-Claim
353	patient	_	_	I-Claim
354	function	_	_	I-Claim
355	.	_	_	I-Claim


0	The	_	_	O
1	goal	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	assess	_	_	O
8	the	_	_	O
9	impact	_	_	O
10	of	_	_	O
11	neuronavigation	_	_	O
12	on	_	_	O
13	the	_	_	O
14	cytoreductive	_	_	O
15	treatment	_	_	O
16	of	_	_	O
17	solitary	_	_	O
18	contrast	_	_	O
19	-	_	_	O
20	enhancing	_	_	O
21	intracerebral	_	_	O
22	tumors	_	_	O
23	and	_	_	O
24	outcomes	_	_	O
25	of	_	_	O
26	this	_	_	O
27	treatment	_	_	O
28	in	_	_	O
29	cases	_	_	O
30	in	_	_	O
31	which	_	_	O
32	neuronavigation	_	_	O
33	was	_	_	O
34	preoperatively	_	_	O
35	judged	_	_	O
36	to	_	_	O
37	be	_	_	O
38	redundant	_	_	O
39	.	_	_	O

40	The	_	_	O
41	authors	_	_	O
42	conducted	_	_	O
43	a	_	_	O
44	prospective	_	_	O
45	randomized	_	_	O
46	study	_	_	O
47	in	_	_	O
48	which	_	_	O
49	45	_	_	O
50	patients	_	_	O
51	,	_	_	O
52	each	_	_	O
53	harboring	_	_	O
54	a	_	_	O
55	solitary	_	_	O
56	contrast	_	_	O
57	-	_	_	O
58	enhancing	_	_	O
59	intracerebral	_	_	O
60	tumor	_	_	O
61	,	_	_	O
62	were	_	_	O
63	randomized	_	_	O
64	for	_	_	O
65	surgery	_	_	O
66	with	_	_	O
67	or	_	_	O
68	without	_	_	O
69	neuronavigation	_	_	O
70	.	_	_	O

71	Peri	_	_	O
72	-	_	_	O
73	and	_	_	O
74	postoperative	_	_	O
75	parameters	_	_	O
76	under	_	_	O
77	investigation	_	_	O
78	included	_	_	O
79	the	_	_	O
80	following	_	_	O
81	:	_	_	O
82	duration	_	_	O
83	of	_	_	O
84	the	_	_	O
85	procedure	_	_	O
86	;	_	_	O
87	surgeon	_	_	O
88	'	_	_	O
89	s	_	_	O
90	estimate	_	_	O
91	of	_	_	O
92	the	_	_	O
93	usefulness	_	_	O
94	of	_	_	O
95	neuronavigation	_	_	O
96	;	_	_	O
97	quantification	_	_	O
98	of	_	_	O
99	the	_	_	O
100	extent	_	_	O
101	of	_	_	O
102	resection	_	_	O
103	,	_	_	O
104	determined	_	_	O
105	using	_	_	O
106	magnetic	_	_	O
107	resonance	_	_	O
108	imaging	_	_	O
109	;	_	_	O
110	and	_	_	O
111	the	_	_	O
112	postoperative	_	_	O
113	course	_	_	O
114	,	_	_	O
115	as	_	_	O
116	evaluated	_	_	O
117	by	_	_	O
118	neurological	_	_	O
119	examinations	_	_	O
120	,	_	_	O
121	the	_	_	O
122	patient	_	_	O
123	'	_	_	O
124	s	_	_	O
125	quality	_	_	O
126	-	_	_	O
127	of	_	_	O
128	-	_	_	O
129	life	_	_	O
130	self	_	_	O
131	-	_	_	O
132	assessment	_	_	O
133	,	_	_	O
134	application	_	_	O
135	of	_	_	O
136	the	_	_	O
137	Barthel	_	_	O
138	index	_	_	O
139	and	_	_	O
140	the	_	_	O
141	Karnofsky	_	_	O
142	Performance	_	_	O
143	Scale	_	_	O
144	score	_	_	O
145	,	_	_	O
146	and	_	_	O
147	the	_	_	O
148	patient	_	_	O
149	'	_	_	O
150	s	_	_	O
151	time	_	_	O
152	of	_	_	O
153	death	_	_	O
154	.	_	_	O

155	The	_	_	B-Premise
156	mean	_	_	I-Premise
157	amount	_	_	I-Premise
158	of	_	_	I-Premise
159	residual	_	_	I-Premise
160	tumor	_	_	I-Premise
161	tissue	_	_	I-Premise
162	was	_	_	I-Premise
163	28	_	_	I-Premise
164	.	_	_	I-Premise

165	9	_	_	I-Premise
166	%	_	_	I-Premise
167	for	_	_	I-Premise
168	standard	_	_	I-Premise
169	surgery	_	_	I-Premise
170	(	_	_	I-Premise
171	SS	_	_	I-Premise
172	)	_	_	I-Premise
173	and	_	_	I-Premise
174	13	_	_	I-Premise
175	.	_	_	I-Premise

176	8	_	_	I-Premise
177	%	_	_	I-Premise
178	for	_	_	I-Premise
179	surgery	_	_	I-Premise
180	involving	_	_	I-Premise
181	neuronavigation	_	_	I-Premise
182	(	_	_	I-Premise
183	SN	_	_	I-Premise
184	)	_	_	I-Premise
185	.	_	_	I-Premise

186	The	_	_	B-Premise
187	corresponding	_	_	I-Premise
188	mean	_	_	I-Premise
189	amounts	_	_	I-Premise
190	of	_	_	I-Premise
191	residual	_	_	I-Premise
192	contrast	_	_	I-Premise
193	-	_	_	I-Premise
194	enhancing	_	_	I-Premise
195	tumor	_	_	I-Premise
196	tissue	_	_	I-Premise
197	were	_	_	I-Premise
198	29	_	_	I-Premise
199	.	_	_	I-Premise

200	2	_	_	I-Premise
201	and	_	_	I-Premise
202	24	_	_	I-Premise
203	.	_	_	I-Premise

204	4	_	_	I-Premise
205	%	_	_	I-Premise
206	,	_	_	I-Premise
207	respectively	_	_	I-Premise
208	.	_	_	I-Premise

209	These	_	_	B-Premise
210	differences	_	_	I-Premise
211	were	_	_	I-Premise
212	not	_	_	I-Premise
213	significant	_	_	I-Premise
214	.	_	_	I-Premise

215	Gross	_	_	B-Premise
216	-	_	_	I-Premise
217	total	_	_	I-Premise
218	removal	_	_	I-Premise
219	(	_	_	I-Premise
220	GTR	_	_	I-Premise
221	)	_	_	I-Premise
222	was	_	_	I-Premise
223	achieved	_	_	I-Premise
224	in	_	_	I-Premise
225	five	_	_	I-Premise
226	patients	_	_	I-Premise
227	who	_	_	I-Premise
228	underwent	_	_	I-Premise
229	SS	_	_	I-Premise
230	and	_	_	I-Premise
231	in	_	_	I-Premise
232	three	_	_	I-Premise
233	who	_	_	I-Premise
234	underwent	_	_	I-Premise
235	SN	_	_	I-Premise
236	.	_	_	I-Premise

237	Median	_	_	B-Premise
238	survival	_	_	I-Premise
239	was	_	_	I-Premise
240	significantly	_	_	I-Premise
241	shorter	_	_	I-Premise
242	in	_	_	I-Premise
243	the	_	_	I-Premise
244	SN	_	_	I-Premise
245	group	_	_	I-Premise
246	(	_	_	I-Premise
247	5	_	_	I-Premise
248	.	_	_	I-Premise

249	6	_	_	I-Premise
250	months	_	_	I-Premise
251	compared	_	_	I-Premise
252	with	_	_	I-Premise
253	9	_	_	I-Premise
254	months	_	_	I-Premise
255	,	_	_	I-Premise
256	unadjusted	_	_	I-Premise
257	hazard	_	_	I-Premise
258	ratio	_	_	I-Premise
259	=	_	_	I-Premise
260	1	_	_	I-Premise
261	.	_	_	I-Premise

262	6	_	_	I-Premise
263	)	_	_	I-Premise
264	;	_	_	I-Premise
265	however	_	_	B-Premise
266	,	_	_	I-Premise
267	this	_	_	I-Premise
268	difference	_	_	I-Premise
269	may	_	_	I-Premise
270	be	_	_	I-Premise
271	attributable	_	_	I-Premise
272	to	_	_	I-Premise
273	the	_	_	I-Premise
274	coincidental	_	_	I-Premise
275	early	_	_	I-Premise
276	death	_	_	I-Premise
277	of	_	_	I-Premise
278	three	_	_	I-Premise
279	patients	_	_	I-Premise
280	in	_	_	I-Premise
281	the	_	_	I-Premise
282	SN	_	_	I-Premise
283	group	_	_	I-Premise
284	.	_	_	I-Premise

285	No	_	_	B-Premise
286	discernible	_	_	I-Premise
287	important	_	_	I-Premise
288	effect	_	_	I-Premise
289	on	_	_	I-Premise
290	the	_	_	I-Premise
291	patients	_	_	I-Premise
292	'	_	_	I-Premise
293	3	_	_	I-Premise
294	-	_	_	I-Premise
295	month	_	_	I-Premise
296	postoperative	_	_	I-Premise
297	course	_	_	I-Premise
298	was	_	_	I-Premise
299	identified	_	_	I-Premise
300	.	_	_	I-Premise

301	There	_	_	B-Claim
302	is	_	_	I-Claim
303	no	_	_	I-Claim
304	rationale	_	_	I-Claim
305	for	_	_	I-Claim
306	the	_	_	I-Claim
307	routine	_	_	I-Claim
308	use	_	_	I-Claim
309	of	_	_	I-Claim
310	neuronavigation	_	_	I-Claim
311	to	_	_	I-Claim
312	improve	_	_	I-Claim
313	the	_	_	I-Claim
314	extent	_	_	I-Claim
315	of	_	_	I-Claim
316	tumor	_	_	I-Claim
317	resection	_	_	I-Claim
318	and	_	_	I-Claim
319	prognosis	_	_	I-Claim
320	in	_	_	I-Claim
321	patients	_	_	I-Claim
322	harboring	_	_	I-Claim
323	a	_	_	I-Claim
324	solitary	_	_	I-Claim
325	enhancing	_	_	I-Claim
326	intracerebral	_	_	I-Claim
327	lesion	_	_	I-Claim
328	when	_	_	I-Claim
329	neuronavigation	_	_	I-Claim
330	is	_	_	I-Claim
331	not	_	_	I-Claim
332	already	_	_	I-Claim
333	deemed	_	_	I-Claim
334	advantageous	_	_	I-Claim
335	because	_	_	I-Claim
336	of	_	_	I-Claim
337	the	_	_	I-Claim
338	size	_	_	I-Claim
339	or	_	_	I-Claim
340	location	_	_	I-Claim
341	of	_	_	I-Claim
342	the	_	_	I-Claim
343	lesion	_	_	I-Claim
344	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	toxicity	_	_	O
10	and	_	_	O
11	efficacy	_	_	O
12	of	_	_	O
13	radiation	_	_	O
14	therapy	_	_	O
15	(	_	_	O
16	RT	_	_	O
17	)	_	_	O
18	for	_	_	O
19	localized	_	_	O
20	carcinoma	_	_	O
21	of	_	_	O
22	the	_	_	O
23	prostate	_	_	O
24	,	_	_	O
25	using	_	_	O
26	a	_	_	O
27	hypofractionated	_	_	O
28	(	_	_	O
29	55	_	_	O
30	Gy	_	_	O
31	/	_	_	O
32	20	_	_	O
33	fractions	_	_	O
34	/	_	_	O
35	4	_	_	O
36	weeks	_	_	O
37	)	_	_	O
38	vs	_	_	O
39	.	_	_	O

40	a	_	_	O
41	conventionally	_	_	O
42	fractionated	_	_	O
43	(	_	_	O
44	64	_	_	O
45	Gy	_	_	O
46	/	_	_	O
47	32	_	_	O
48	fractions	_	_	O
49	/	_	_	O
50	6	_	_	O
51	.	_	_	O

52	5	_	_	O
53	weeks	_	_	O
54	)	_	_	O
55	dose	_	_	O
56	schedule	_	_	O
57	.	_	_	O

58	A	_	_	O
59	total	_	_	O
60	of	_	_	O
61	217	_	_	O
62	patients	_	_	O
63	were	_	_	O
64	randomized	_	_	O
65	to	_	_	O
66	either	_	_	O
67	the	_	_	O
68	hypofractionated	_	_	O
69	(	_	_	O
70	108	_	_	O
71	patients	_	_	O
72	)	_	_	O
73	or	_	_	O
74	the	_	_	O
75	conventional	_	_	O
76	(	_	_	O
77	109	_	_	O
78	patients	_	_	O
79	)	_	_	O
80	dose	_	_	O
81	schedule	_	_	O
82	,	_	_	O
83	with	_	_	O
84	planning	_	_	O
85	with	_	_	O
86	two	_	_	O
87	-	_	_	O
88	dimensional	_	_	O
89	(	_	_	O
90	2D	_	_	O
91	)	_	_	O
92	CT	_	_	O
93	scan	_	_	O
94	planning	_	_	O
95	methodology	_	_	O
96	in	_	_	O
97	the	_	_	O
98	majority	_	_	O
99	of	_	_	O
100	cases	_	_	O
101	.	_	_	O

102	All	_	_	O
103	patients	_	_	O
104	were	_	_	O
105	followed	_	_	O
106	for	_	_	O
107	a	_	_	O
108	median	_	_	O
109	of	_	_	O
110	48	_	_	O
111	(	_	_	O
112	6	_	_	O
113	-	_	_	O
114	108	_	_	O
115	)	_	_	O
116	months	_	_	O
117	.	_	_	O

118	Gastrointestinal	_	_	O
119	(	_	_	O
120	GI	_	_	O
121	)	_	_	O
122	and	_	_	O
123	genitourinary	_	_	O
124	(	_	_	O
125	GU	_	_	O
126	)	_	_	O
127	toxicity	_	_	O
128	was	_	_	O
129	evaluated	_	_	O
130	before	_	_	O
131	RT	_	_	O
132	and	_	_	O
133	after	_	_	O
134	its	_	_	O
135	completion	_	_	O
136	using	_	_	O
137	modified	_	_	O
138	late	_	_	O
139	effects	_	_	O
140	of	_	_	O
141	normal	_	_	O
142	tissue	_	_	O
143	-	_	_	O
144	subjective	_	_	O
145	,	_	_	O
146	objective	_	_	O
147	,	_	_	O
148	management	_	_	O
149	,	_	_	O
150	analytic	_	_	O
151	(	_	_	O
152	LENT	_	_	O
153	-	_	_	O
154	SOMA	_	_	O
155	)	_	_	O
156	scales	_	_	O
157	and	_	_	O
158	the	_	_	O
159	European	_	_	O
160	Organization	_	_	O
161	for	_	_	O
162	Research	_	_	O
163	and	_	_	O
164	Treatment	_	_	O
165	of	_	_	O
166	Cancer	_	_	O
167	sexual	_	_	O
168	function	_	_	O
169	questionnaire	_	_	O
170	.	_	_	O

171	Efficacy	_	_	O
172	of	_	_	O
173	RT	_	_	O
174	based	_	_	O
175	on	_	_	O
176	clinical	_	_	O
177	,	_	_	O
178	radiologic	_	_	O
179	,	_	_	O
180	and	_	_	O
181	prostate	_	_	O
182	-	_	_	O
183	specific	_	_	O
184	antigen	_	_	O
185	data	_	_	O
186	were	_	_	O
187	also	_	_	O
188	evaluated	_	_	O
189	at	_	_	O
190	baseline	_	_	O
191	and	_	_	O
192	after	_	_	O
193	RT	_	_	O
194	.	_	_	O

195	Gastrointestinal	_	_	B-Premise
196	and	_	_	I-Premise
197	GU	_	_	I-Premise
198	toxicity	_	_	I-Premise
199	persisted	_	_	I-Premise
200	5	_	_	I-Premise
201	years	_	_	I-Premise
202	after	_	_	I-Premise
203	RT	_	_	I-Premise
204	and	_	_	I-Premise
205	did	_	_	I-Premise
206	not	_	_	I-Premise
207	differ	_	_	I-Premise
208	between	_	_	I-Premise
209	the	_	_	I-Premise
210	two	_	_	I-Premise
211	dose	_	_	I-Premise
212	schedules	_	_	I-Premise
213	other	_	_	I-Premise
214	than	_	_	I-Premise
215	in	_	_	I-Premise
216	regard	_	_	I-Premise
217	to	_	_	I-Premise
218	urgency	_	_	I-Premise
219	of	_	_	I-Premise
220	defecation	_	_	I-Premise
221	.	_	_	I-Premise

222	However	_	_	B-Premise
223	,	_	_	I-Premise
224	1	_	_	I-Premise
225	-	_	_	I-Premise
226	month	_	_	I-Premise
227	GI	_	_	I-Premise
228	toxicity	_	_	I-Premise
229	was	_	_	I-Premise
230	not	_	_	I-Premise
231	only	_	_	I-Premise
232	worse	_	_	I-Premise
233	in	_	_	I-Premise
234	patients	_	_	I-Premise
235	with	_	_	I-Premise
236	the	_	_	I-Premise
237	hypofractionated	_	_	I-Premise
238	RT	_	_	I-Premise
239	schedule	_	_	I-Premise
240	but	_	_	I-Premise
241	also	_	_	I-Premise
242	adversely	_	_	I-Premise
243	affected	_	_	I-Premise
244	daily	_	_	I-Premise
245	activities	_	_	I-Premise
246	.	_	_	I-Premise

247	Nadir	_	_	B-Premise
248	prostate	_	_	I-Premise
249	-	_	_	I-Premise
250	specific	_	_	I-Premise
251	antigen	_	_	I-Premise
252	values	_	_	I-Premise
253	occurred	_	_	I-Premise
254	at	_	_	I-Premise
255	a	_	_	I-Premise
256	median	_	_	I-Premise
257	of	_	_	I-Premise
258	18	_	_	I-Premise
259	.	_	_	I-Premise

260	0	_	_	I-Premise
261	(	_	_	I-Premise
262	3	_	_	I-Premise
263	.	_	_	I-Premise

264	0	_	_	I-Premise
265	-	_	_	I-Premise
266	54	_	_	I-Premise
267	.	_	_	I-Premise

268	0	_	_	I-Premise
269	)	_	_	I-Premise
270	months	_	_	I-Premise
271	after	_	_	I-Premise
272	RT	_	_	I-Premise
273	.	_	_	I-Premise

274	A	_	_	B-Premise
275	total	_	_	I-Premise
276	of	_	_	I-Premise
277	76	_	_	I-Premise
278	biochemical	_	_	I-Premise
279	relapses	_	_	I-Premise
280	,	_	_	I-Premise
281	with	_	_	I-Premise
282	or	_	_	I-Premise
283	without	_	_	I-Premise
284	clinical	_	_	I-Premise
285	relapses	_	_	I-Premise
286	,	_	_	I-Premise
287	have	_	_	I-Premise
288	occurred	_	_	I-Premise
289	since	_	_	I-Premise
290	;	_	_	I-Premise
291	of	_	_	I-Premise
292	these	_	_	I-Premise
293	,	_	_	I-Premise
294	37	_	_	I-Premise
295	were	_	_	I-Premise
296	in	_	_	I-Premise
297	the	_	_	I-Premise
298	hypofractionated	_	_	I-Premise
299	and	_	_	I-Premise
300	39	_	_	I-Premise
301	in	_	_	I-Premise
302	the	_	_	I-Premise
303	conventional	_	_	I-Premise
304	schedule	_	_	I-Premise
305	.	_	_	I-Premise

306	The	_	_	B-Premise
307	5	_	_	I-Premise
308	-	_	_	I-Premise
309	year	_	_	I-Premise
310	biochemical	_	_	I-Premise
311	+	_	_	I-Premise
312	/	_	_	I-Premise
313	-	_	_	I-Premise
314	clinical	_	_	I-Premise
315	relapse	_	_	I-Premise
316	-	_	_	I-Premise
317	free	_	_	I-Premise
318	and	_	_	I-Premise
319	overall	_	_	I-Premise
320	survival	_	_	I-Premise
321	was	_	_	I-Premise
322	55	_	_	I-Premise
323	.	_	_	I-Premise

324	9	_	_	I-Premise
325	%	_	_	I-Premise
326	and	_	_	I-Premise
327	85	_	_	I-Premise
328	.	_	_	I-Premise

329	3	_	_	I-Premise
330	%	_	_	I-Premise
331	respectively	_	_	I-Premise
332	for	_	_	I-Premise
333	all	_	_	I-Premise
334	patients	_	_	I-Premise
335	,	_	_	I-Premise
336	and	_	_	I-Premise
337	did	_	_	I-Premise
338	not	_	_	I-Premise
339	differ	_	_	I-Premise
340	between	_	_	I-Premise
341	the	_	_	I-Premise
342	two	_	_	I-Premise
343	schedules	_	_	I-Premise
344	.	_	_	I-Premise

345	Radiation	_	_	B-Claim
346	therapy	_	_	I-Claim
347	for	_	_	I-Claim
348	prostate	_	_	I-Claim
349	carcinoma	_	_	I-Claim
350	causes	_	_	I-Claim
351	persistent	_	_	I-Claim
352	GI	_	_	I-Claim
353	toxicity	_	_	I-Claim
354	that	_	_	I-Claim
355	is	_	_	I-Claim
356	largely	_	_	I-Claim
357	independent	_	_	I-Claim
358	of	_	_	I-Claim
359	the	_	_	I-Claim
360	two	_	_	I-Claim
361	dose	_	_	I-Claim
362	schedules	_	_	I-Claim
363	.	_	_	I-Claim

364	The	_	_	B-Claim
365	hypofractionated	_	_	I-Claim
366	schedule	_	_	I-Claim
367	is	_	_	I-Claim
368	equivalent	_	_	I-Claim
369	in	_	_	I-Claim
370	efficacy	_	_	I-Claim
371	to	_	_	I-Claim
372	the	_	_	I-Claim
373	conventional	_	_	I-Claim
374	schedule	_	_	I-Claim
375	.	_	_	I-Claim


0	Many	_	_	O
1	patients	_	_	O
2	with	_	_	O
3	advanced	_	_	O
4	ovarian	_	_	O
5	cancer	_	_	O
6	will	_	_	O
7	develop	_	_	O
8	recurrent	_	_	O
9	disease	_	_	O
10	.	_	_	O

11	For	_	_	B-Premise
12	those	_	_	I-Premise
13	patients	_	_	I-Premise
14	who	_	_	I-Premise
15	have	_	_	I-Premise
16	recurrence	_	_	I-Premise
17	of	_	_	I-Premise
18	disease	_	_	I-Premise
19	at	_	_	I-Premise
20	least	_	_	I-Premise
21	6	_	_	I-Premise
22	months	_	_	I-Premise
23	after	_	_	I-Premise
24	initial	_	_	I-Premise
25	therapy	_	_	I-Premise
26	,	_	_	I-Premise
27	the	_	_	I-Premise
28	paclitaxel	_	_	I-Premise
29	-	_	_	I-Premise
30	platinum	_	_	I-Premise
31	combination	_	_	I-Premise
32	has	_	_	I-Premise
33	been	_	_	I-Premise
34	shown	_	_	I-Premise
35	to	_	_	I-Premise
36	be	_	_	I-Premise
37	a	_	_	I-Premise
38	superior	_	_	I-Premise
39	treatment	_	_	I-Premise
40	to	_	_	I-Premise
41	platinum	_	_	I-Premise
42	monotherapy	_	_	I-Premise
43	.	_	_	I-Premise

44	However	_	_	B-Claim
45	,	_	_	I-Claim
46	many	_	_	I-Claim
47	patients	_	_	I-Claim
48	develop	_	_	I-Claim
49	clinically	_	_	I-Claim
50	relevant	_	_	I-Claim
51	neurotoxicity	_	_	I-Claim
52	,	_	_	I-Claim
53	frequently	_	_	I-Claim
54	resulting	_	_	I-Claim
55	in	_	_	I-Claim
56	treatment	_	_	I-Claim
57	discontinuation	_	_	I-Claim
58	.	_	_	I-Claim

59	The	_	_	O
60	efficacy	_	_	O
61	and	_	_	O
62	safety	_	_	O
63	of	_	_	O
64	an	_	_	O
65	alternative	_	_	O
66	regimen	_	_	O
67	that	_	_	O
68	does	_	_	O
69	not	_	_	O
70	show	_	_	O
71	significant	_	_	O
72	neurotoxicity	_	_	O
73	were	_	_	O
74	evaluated	_	_	O
75	by	_	_	O
76	comparing	_	_	O
77	gemcitabine	_	_	O
78	-	_	_	O
79	carboplatin	_	_	O
80	with	_	_	O
81	carboplatin	_	_	O
82	in	_	_	O
83	platinum	_	_	O
84	-	_	_	O
85	sensitive	_	_	O
86	recurrent	_	_	O
87	ovarian	_	_	O
88	cancer	_	_	O
89	patients	_	_	O
90	in	_	_	O
91	a	_	_	O
92	Gynecologic	_	_	O
93	Cancer	_	_	O
94	InterGroup	_	_	O
95	trial	_	_	O
96	of	_	_	O
97	the	_	_	O
98	Arbeitsgemeinschaft	_	_	O
99	Gynakologische	_	_	O
100	Onkologie	_	_	O
101	Ovarian	_	_	O
102	Cancer	_	_	O
103	Study	_	_	O
104	Group	_	_	O
105	,	_	_	O
106	the	_	_	O
107	National	_	_	O
108	Cancer	_	_	O
109	Institute	_	_	O
110	of	_	_	O
111	Canada	_	_	O
112	Clinical	_	_	O
113	Trials	_	_	O
114	Group	_	_	O
115	,	_	_	O
116	and	_	_	O
117	the	_	_	O
118	European	_	_	O
119	Organisation	_	_	O
120	for	_	_	O
121	Research	_	_	O
122	and	_	_	O
123	Treatment	_	_	O
124	of	_	_	O
125	Cancer	_	_	O
126	Gynaecological	_	_	O
127	Cancer	_	_	O
128	Group	_	_	O
129	.	_	_	O

130	Participants	_	_	O
131	with	_	_	O
132	recurrent	_	_	O
133	platinum	_	_	O
134	-	_	_	O
135	sensitive	_	_	O
136	ovarian	_	_	O
137	cancer	_	_	O
138	were	_	_	O
139	randomly	_	_	O
140	assigned	_	_	O
141	to	_	_	O
142	receive	_	_	O
143	either	_	_	O
144	gemcitabine	_	_	O
145	-	_	_	O
146	carboplatin	_	_	O
147	or	_	_	O
148	carboplatin	_	_	O
149	every	_	_	O
150	21	_	_	O
151	days	_	_	O
152	.	_	_	O

153	The	_	_	O
154	primary	_	_	O
155	objective	_	_	O
156	was	_	_	O
157	to	_	_	O
158	compare	_	_	O
159	progression	_	_	O
160	-	_	_	O
161	free	_	_	O
162	survival	_	_	O
163	(	_	_	O
164	PFS	_	_	O
165	)	_	_	O
166	between	_	_	O
167	the	_	_	O
168	groups	_	_	O
169	.	_	_	O

170	From	_	_	O
171	September	_	_	O
172	1999	_	_	O
173	to	_	_	O
174	April	_	_	O
175	2002	_	_	O
176	,	_	_	O
177	356	_	_	O
178	patients	_	_	O
179	(	_	_	O
180	178	_	_	O
181	participants	_	_	O
182	received	_	_	O
183	gemcitabine	_	_	O
184	-	_	_	O
185	carboplatin	_	_	O
186	,	_	_	O
187	178	_	_	O
188	received	_	_	O
189	carboplatin	_	_	O
190	only	_	_	O
191	)	_	_	O
192	were	_	_	O
193	randomized	_	_	O
194	to	_	_	O
195	treatment	_	_	O
196	.	_	_	O

197	Patients	_	_	O
198	received	_	_	O
199	six	_	_	O
200	cycles	_	_	O
201	of	_	_	O
202	either	_	_	O
203	gemcitabine	_	_	O
204	-	_	_	O
205	carboplatin	_	_	O
206	or	_	_	O
207	carboplatin	_	_	O
208	.	_	_	O

209	With	_	_	B-Premise
210	a	_	_	I-Premise
211	median	_	_	I-Premise
212	follow	_	_	I-Premise
213	-	_	_	I-Premise
214	up	_	_	I-Premise
215	of	_	_	I-Premise
216	17	_	_	I-Premise
217	months	_	_	I-Premise
218	,	_	_	I-Premise
219	median	_	_	I-Premise
220	PFS	_	_	I-Premise
221	was	_	_	I-Premise
222	8	_	_	I-Premise
223	.	_	_	I-Premise

224	6	_	_	I-Premise
225	months	_	_	I-Premise
226	for	_	_	I-Premise
227	gemcitabine	_	_	I-Premise
228	-	_	_	I-Premise
229	carboplatin	_	_	I-Premise
230	(	_	_	I-Premise
231	95	_	_	I-Premise
232	%	_	_	I-Premise
233	confidence	_	_	I-Premise
234	interval	_	_	I-Premise
235	[	_	_	I-Premise
236	CI	_	_	I-Premise
237	]	_	_	I-Premise
238	7	_	_	I-Premise
239	.	_	_	I-Premise

240	9	_	_	I-Premise
241	-	_	_	I-Premise
242	9	_	_	I-Premise
243	.	_	_	I-Premise

244	7	_	_	I-Premise
245	months	_	_	I-Premise
246	)	_	_	I-Premise
247	and	_	_	I-Premise
248	5	_	_	I-Premise
249	.	_	_	I-Premise

250	8	_	_	I-Premise
251	months	_	_	I-Premise
252	for	_	_	I-Premise
253	carboplatin	_	_	I-Premise
254	(	_	_	I-Premise
255	95	_	_	I-Premise
256	%	_	_	I-Premise
257	CI	_	_	I-Premise
258	5	_	_	I-Premise
259	.	_	_	I-Premise

260	2	_	_	I-Premise
261	-	_	_	I-Premise
262	7	_	_	I-Premise
263	.	_	_	I-Premise

264	1	_	_	I-Premise
265	months	_	_	I-Premise
266	;	_	_	I-Premise
267	hazard	_	_	I-Premise
268	ratio	_	_	I-Premise
269	[	_	_	I-Premise
270	HR	_	_	I-Premise
271	]	_	_	I-Premise
272	0	_	_	I-Premise
273	.	_	_	I-Premise

274	72	_	_	I-Premise
275	[	_	_	I-Premise
276	95	_	_	I-Premise
277	%	_	_	I-Premise
278	CI	_	_	I-Premise
279	0	_	_	I-Premise
280	.	_	_	I-Premise

281	58	_	_	I-Premise
282	-	_	_	I-Premise
283	0	_	_	I-Premise
284	.	_	_	I-Premise

285	90	_	_	I-Premise
286	;	_	_	I-Premise
287	P	_	_	I-Premise
288	=	_	_	I-Premise
289	0	_	_	I-Premise
290	.	_	_	I-Premise

291	0032	_	_	I-Premise
292	]	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	The	_	_	B-Premise
296	response	_	_	I-Premise
297	rate	_	_	I-Premise
298	for	_	_	I-Premise
299	the	_	_	I-Premise
300	gemcitabine	_	_	I-Premise
301	-	_	_	I-Premise
302	carboplatin	_	_	I-Premise
303	group	_	_	I-Premise
304	was	_	_	I-Premise
305	47	_	_	I-Premise
306	.	_	_	I-Premise

307	2	_	_	I-Premise
308	%	_	_	I-Premise
309	(	_	_	I-Premise
310	95	_	_	I-Premise
311	%	_	_	I-Premise
312	CI	_	_	I-Premise
313	39	_	_	I-Premise
314	.	_	_	I-Premise

315	9	_	_	I-Premise
316	-	_	_	I-Premise
317	54	_	_	I-Premise
318	.	_	_	I-Premise

319	5	_	_	I-Premise
320	%	_	_	I-Premise
321	)	_	_	I-Premise
322	and	_	_	I-Premise
323	30	_	_	I-Premise
324	.	_	_	I-Premise

325	9	_	_	I-Premise
326	%	_	_	I-Premise
327	for	_	_	I-Premise
328	carboplatin	_	_	I-Premise
329	group	_	_	I-Premise
330	(	_	_	I-Premise
331	95	_	_	I-Premise
332	%	_	_	I-Premise
333	CI	_	_	I-Premise
334	24	_	_	I-Premise
335	.	_	_	I-Premise

336	1	_	_	I-Premise
337	-	_	_	I-Premise
338	37	_	_	I-Premise
339	.	_	_	I-Premise

340	7	_	_	I-Premise
341	%	_	_	I-Premise
342	;	_	_	I-Premise
343	P	_	_	I-Premise
344	=	_	_	I-Premise
345	0	_	_	I-Premise
346	.	_	_	I-Premise

347	0016	_	_	I-Premise
348	)	_	_	I-Premise
349	.	_	_	I-Premise

350	The	_	_	B-Premise
351	HR	_	_	I-Premise
352	for	_	_	I-Premise
353	overall	_	_	I-Premise
354	survival	_	_	I-Premise
355	was	_	_	I-Premise
356	0	_	_	I-Premise
357	.	_	_	I-Premise

358	96	_	_	I-Premise
359	(	_	_	I-Premise
360	95	_	_	I-Premise
361	%	_	_	I-Premise
362	CI	_	_	I-Premise
363	0	_	_	I-Premise
364	.	_	_	I-Premise

365	75	_	_	I-Premise
366	-	_	_	I-Premise
367	1	_	_	I-Premise
368	.	_	_	I-Premise

369	23	_	_	I-Premise
370	;	_	_	I-Premise
371	P	_	_	I-Premise
372	=	_	_	I-Premise
373	0	_	_	I-Premise
374	.	_	_	I-Premise

375	7349	_	_	I-Premise
376	)	_	_	I-Premise
377	.	_	_	I-Premise

378	Patients	_	_	B-Premise
379	treated	_	_	I-Premise
380	with	_	_	I-Premise
381	gemcitabine	_	_	I-Premise
382	-	_	_	I-Premise
383	carboplatin	_	_	I-Premise
384	reported	_	_	I-Premise
385	significantly	_	_	I-Premise
386	faster	_	_	I-Premise
387	palliation	_	_	I-Premise
388	of	_	_	I-Premise
389	abdominal	_	_	I-Premise
390	symptoms	_	_	I-Premise
391	and	_	_	I-Premise
392	a	_	_	I-Premise
393	significantly	_	_	I-Premise
394	improved	_	_	I-Premise
395	global	_	_	I-Premise
396	quality	_	_	I-Premise
397	of	_	_	I-Premise
398	life	_	_	I-Premise
399	.	_	_	I-Premise

400	Gemcitabine	_	_	B-Claim
401	-	_	_	I-Claim
402	carboplatin	_	_	I-Claim
403	treatment	_	_	I-Claim
404	significantly	_	_	I-Claim
405	improves	_	_	I-Claim
406	the	_	_	I-Claim
407	PFS	_	_	I-Claim
408	of	_	_	I-Claim
409	patients	_	_	I-Claim
410	with	_	_	I-Claim
411	platinum	_	_	I-Claim
412	-	_	_	I-Claim
413	sensitive	_	_	I-Claim
414	recurrent	_	_	I-Claim
415	ovarian	_	_	I-Claim
416	cancer	_	_	I-Claim
417	.	_	_	I-Claim


0	Approximately	_	_	O
1	30	_	_	O
2	%	_	_	O
3	of	_	_	O
4	lung	_	_	O
5	cancer	_	_	O
6	cases	_	_	O
7	are	_	_	O
8	diagnosed	_	_	O
9	in	_	_	O
10	patients	_	_	O
11	>	_	_	O
12	70	_	_	O
13	years	_	_	O
14	of	_	_	O
15	age	_	_	O
16	.	_	_	O

17	Standard	_	_	B-Claim
18	chemotherapy	_	_	I-Claim
19	regimens	_	_	I-Claim
20	are	_	_	I-Claim
21	generally	_	_	I-Claim
22	considered	_	_	I-Claim
23	too	_	_	I-Claim
24	toxic	_	_	I-Claim
25	for	_	_	I-Claim
26	elderly	_	_	I-Claim
27	patients	_	_	I-Claim
28	.	_	_	I-Claim

29	We	_	_	O
30	conducted	_	_	O
31	a	_	_	O
32	multicenter	_	_	O
33	phase	_	_	O
34	II	_	_	O
35	trial	_	_	O
36	to	_	_	O
37	determine	_	_	O
38	the	_	_	O
39	efficacy	_	_	O
40	and	_	_	O
41	safety	_	_	O
42	of	_	_	O
43	carboplatin	_	_	O
44	combined	_	_	O
45	with	_	_	O
46	vinorelbine	_	_	O
47	every	_	_	O
48	4	_	_	O
49	weeks	_	_	O
50	as	_	_	O
51	first	_	_	O
52	-	_	_	O
53	line	_	_	O
54	treatment	_	_	O
55	for	_	_	O
56	advanced	_	_	O
57	non	_	_	O
58	-	_	_	O
59	small	_	_	O
60	-	_	_	O
61	cell	_	_	O
62	lung	_	_	O
63	cancer	_	_	O
64	(	_	_	O
65	NSCLC	_	_	O
66	)	_	_	O
67	in	_	_	O
68	elderly	_	_	O
69	patients	_	_	O
70	.	_	_	O

71	Patients	_	_	O
72	were	_	_	O
73	eligible	_	_	O
74	if	_	_	O
75	they	_	_	O
76	were	_	_	O
77	aged	_	_	O
78	>	_	_	O
79	OR	_	_	O
80	=	_	_	O
81	70	_	_	O
82	years	_	_	O
83	,	_	_	O
84	had	_	_	O
85	stage	_	_	O
86	IIIB	_	_	O
87	(	_	_	O
88	with	_	_	O
89	pleural	_	_	O
90	effusion	_	_	O
91	)	_	_	O
92	or	_	_	O
93	stage	_	_	O
94	IV	_	_	O
95	NSCLC	_	_	O
96	,	_	_	O
97	had	_	_	O
98	a	_	_	O
99	performance	_	_	O
100	status	_	_	O
101	of	_	_	O
102	0	_	_	O
103	/	_	_	O
104	1	_	_	O
105	,	_	_	O
106	had	_	_	O
107	not	_	_	O
108	previously	_	_	O
109	received	_	_	O
110	chemotherapy	_	_	O
111	,	_	_	O
112	and	_	_	O
113	had	_	_	O
114	normal	_	_	O
115	organ	_	_	O
116	function	_	_	O
117	.	_	_	O

118	Forty	_	_	O
119	patients	_	_	O
120	(	_	_	O
121	31	_	_	O
122	men	_	_	O
123	and	_	_	O
124	9	_	_	O
125	women	_	_	O
126	)	_	_	O
127	were	_	_	O
128	enrolled	_	_	O
129	and	_	_	O
130	received	_	_	O
131	3	_	_	O
132	-	_	_	O
133	5	_	_	O
134	courses	_	_	O
135	of	_	_	O
136	treatment	_	_	O
137	.	_	_	O

138	Median	_	_	O
139	age	_	_	O
140	was	_	_	O
141	72	_	_	O
142	years	_	_	O
143	(	_	_	O
144	range	_	_	O
145	,	_	_	O
146	70	_	_	O
147	-	_	_	O
148	82	_	_	O
149	years	_	_	O
150	)	_	_	O
151	.	_	_	O

152	Eighty	_	_	O
153	percent	_	_	O
154	of	_	_	O
155	patients	_	_	O
156	had	_	_	O
157	stage	_	_	O
158	IV	_	_	O
159	NSCLC	_	_	O
160	,	_	_	O
161	with	_	_	O
162	squamous	_	_	O
163	cell	_	_	O
164	(	_	_	O
165	n	_	_	O
166	=	_	_	O
167	21	_	_	O
168	)	_	_	O
169	,	_	_	O
170	adenocarcinoma	_	_	O
171	(	_	_	O
172	n	_	_	O
173	=	_	_	O
174	12	_	_	O
175	)	_	_	O
176	,	_	_	O
177	and	_	_	O
178	undifferentiated	_	_	O
179	(	_	_	O
180	n	_	_	O
181	=	_	_	O
182	7	_	_	O
183	)	_	_	O
184	histologies	_	_	O
185	.	_	_	O

186	Forty	_	_	O
187	patients	_	_	O
188	were	_	_	O
189	assessable	_	_	O
190	for	_	_	O
191	toxicity	_	_	O
192	and	_	_	O
193	32	_	_	O
194	for	_	_	O
195	treatment	_	_	O
196	response	_	_	O
197	.	_	_	O

198	Among	_	_	B-Premise
199	these	_	_	I-Premise
200	32	_	_	I-Premise
201	patients	_	_	I-Premise
202	,	_	_	I-Premise
203	8	_	_	I-Premise
204	had	_	_	I-Premise
205	a	_	_	I-Premise
206	partial	_	_	I-Premise
207	response	_	_	I-Premise
208	(	_	_	I-Premise
209	intent	_	_	I-Premise
210	-	_	_	I-Premise
211	to	_	_	I-Premise
212	-	_	_	I-Premise
213	treat	_	_	I-Premise
214	response	_	_	I-Premise
215	rate	_	_	I-Premise
216	,	_	_	I-Premise
217	20	_	_	I-Premise
218	%	_	_	I-Premise
219	)	_	_	I-Premise
220	,	_	_	I-Premise
221	and	_	_	I-Premise
222	10	_	_	I-Premise
223	(	_	_	I-Premise
224	25	_	_	I-Premise
225	%	_	_	I-Premise
226	)	_	_	I-Premise
227	had	_	_	I-Premise
228	stable	_	_	I-Premise
229	disease	_	_	I-Premise
230	.	_	_	I-Premise

231	The	_	_	B-Premise
232	median	_	_	I-Premise
233	survival	_	_	I-Premise
234	was	_	_	I-Premise
235	7	_	_	I-Premise
236	.	_	_	I-Premise

237	8	_	_	I-Premise
238	months	_	_	I-Premise
239	(	_	_	I-Premise
240	range	_	_	I-Premise
241	,	_	_	I-Premise
242	4	_	_	I-Premise
243	-	_	_	I-Premise
244	11	_	_	I-Premise
245	.	_	_	I-Premise

246	6	_	_	I-Premise
247	months	_	_	I-Premise
248	)	_	_	I-Premise
249	.	_	_	I-Premise

250	The	_	_	B-Premise
251	1	_	_	I-Premise
252	-	_	_	I-Premise
253	and	_	_	I-Premise
254	2	_	_	I-Premise
255	-	_	_	I-Premise
256	year	_	_	I-Premise
257	survival	_	_	I-Premise
258	rates	_	_	I-Premise
259	were	_	_	I-Premise
260	25	_	_	I-Premise
261	%	_	_	I-Premise
262	and	_	_	I-Premise
263	7	_	_	I-Premise
264	%	_	_	I-Premise
265	,	_	_	I-Premise
266	respectively	_	_	I-Premise
267	;	_	_	I-Premise
268	median	_	_	B-Premise
269	time	_	_	I-Premise
270	to	_	_	I-Premise
271	progression	_	_	I-Premise
272	was	_	_	I-Premise
273	4	_	_	I-Premise
274	.	_	_	I-Premise

275	3	_	_	I-Premise
276	months	_	_	I-Premise
277	(	_	_	I-Premise
278	range	_	_	I-Premise
279	,	_	_	I-Premise
280	0	_	_	I-Premise
281	.	_	_	I-Premise

282	2	_	_	I-Premise
283	-	_	_	I-Premise
284	13	_	_	I-Premise
285	.	_	_	I-Premise

286	8	_	_	I-Premise
287	months	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	Grade	_	_	B-Premise
291	3	_	_	I-Premise
292	/	_	_	I-Premise
293	4	_	_	I-Premise
294	neutropenia	_	_	I-Premise
295	was	_	_	I-Premise
296	seen	_	_	I-Premise
297	in	_	_	I-Premise
298	27	_	_	I-Premise
299	patients	_	_	I-Premise
300	(	_	_	I-Premise
301	68	_	_	I-Premise
302	%	_	_	I-Premise
303	)	_	_	I-Premise
304	,	_	_	I-Premise
305	and	_	_	I-Premise
306	grade	_	_	I-Premise
307	3	_	_	I-Premise
308	/	_	_	I-Premise
309	4	_	_	I-Premise
310	anemia	_	_	I-Premise
311	was	_	_	I-Premise
312	seen	_	_	I-Premise
313	in	_	_	I-Premise
314	5	_	_	I-Premise
315	patients	_	_	I-Premise
316	(	_	_	I-Premise
317	13	_	_	I-Premise
318	%	_	_	I-Premise
319	)	_	_	I-Premise
320	.	_	_	I-Premise

321	One	_	_	B-Premise
322	patient	_	_	I-Premise
323	died	_	_	I-Premise
324	of	_	_	I-Premise
325	febrile	_	_	I-Premise
326	neutropenia	_	_	I-Premise
327	during	_	_	I-Premise
328	treatment	_	_	I-Premise
329	.	_	_	I-Premise

330	The	_	_	B-Premise
331	main	_	_	I-Premise
332	nonhematologic	_	_	I-Premise
333	adverse	_	_	I-Premise
334	effect	_	_	I-Premise
335	was	_	_	I-Premise
336	fatigue	_	_	I-Premise
337	(	_	_	I-Premise
338	grade	_	_	I-Premise
339	3	_	_	I-Premise
340	/	_	_	I-Premise
341	4	_	_	I-Premise
342	in	_	_	I-Premise
343	18	_	_	I-Premise
344	%	_	_	I-Premise
345	of	_	_	I-Premise
346	patients	_	_	I-Premise
347	)	_	_	I-Premise
348	.	_	_	I-Premise

349	Carboplatin	_	_	B-Claim
350	/	_	_	I-Claim
351	vinorelbine	_	_	I-Claim
352	is	_	_	I-Claim
353	well	_	_	I-Claim
354	tolerated	_	_	I-Claim
355	by	_	_	I-Claim
356	elderly	_	_	I-Claim
357	patients	_	_	I-Claim
358	with	_	_	I-Claim
359	extensive	_	_	I-Claim
360	-	_	_	I-Claim
361	stage	_	_	I-Claim
362	NSCLC	_	_	I-Claim
363	.	_	_	I-Claim

364	Efficacy	_	_	B-Claim
365	is	_	_	I-Claim
366	low	_	_	I-Claim
367	but	_	_	I-Claim
368	similar	_	_	I-Claim
369	to	_	_	I-Claim
370	that	_	_	I-Claim
371	of	_	_	I-Claim
372	other	_	_	I-Claim
373	treatments	_	_	I-Claim
374	used	_	_	I-Claim
375	in	_	_	I-Claim
376	this	_	_	I-Claim
377	setting	_	_	I-Claim
378	.	_	_	I-Claim


0	Psychological	_	_	B-Claim
1	interventions	_	_	I-Claim
2	are	_	_	I-Claim
3	efficacious	_	_	I-Claim
4	in	_	_	I-Claim
5	reducing	_	_	I-Claim
6	emotional	_	_	I-Claim
7	distress	_	_	I-Claim
8	for	_	_	I-Claim
9	cancer	_	_	I-Claim
10	patients	_	_	I-Claim
11	.	_	_	I-Claim

12	However	_	_	B-Claim
13	,	_	_	I-Claim
14	it	_	_	I-Claim
15	is	_	_	I-Claim
16	not	_	_	I-Claim
17	clear	_	_	I-Claim
18	whether	_	_	I-Claim
19	psychological	_	_	I-Claim
20	improvements	_	_	I-Claim
21	are	_	_	I-Claim
22	,	_	_	I-Claim
23	in	_	_	I-Claim
24	turn	_	_	I-Claim
25	,	_	_	I-Claim
26	related	_	_	I-Claim
27	to	_	_	I-Claim
28	improved	_	_	I-Claim
29	health	_	_	I-Claim
30	.	_	_	I-Claim

31	A	_	_	O
32	clinical	_	_	O
33	trial	_	_	O
34	tests	_	_	O
35	whether	_	_	O
36	a	_	_	O
37	psychological	_	_	O
38	intervention	_	_	O
39	for	_	_	O
40	cancer	_	_	O
41	patients	_	_	O
42	can	_	_	O
43	do	_	_	O
44	so	_	_	O
45	,	_	_	O
46	and	_	_	O
47	also	_	_	O
48	tests	_	_	O
49	two	_	_	O
50	routes	_	_	O
51	to	_	_	O
52	achieve	_	_	O
53	better	_	_	O
54	health	_	_	O
55	:	_	_	O
56	(	_	_	O
57	a	_	_	O
58	)	_	_	O
59	reducing	_	_	O
60	patients	_	_	O
61	'	_	_	O
62	Emotional	_	_	O
63	Distress	_	_	O
64	,	_	_	O
65	and	_	_	O
66	/	_	_	O
67	or	_	_	O
68	(	_	_	O
69	b	_	_	O
70	)	_	_	O
71	enhancing	_	_	O
72	their	_	_	O
73	functional	_	_	O
74	immunity	_	_	O
75	.	_	_	O

76	Post	_	_	O
77	-	_	_	O
78	surgery	_	_	O
79	,	_	_	O
80	227	_	_	O
81	breast	_	_	O
82	cancer	_	_	O
83	patients	_	_	O
84	were	_	_	O
85	randomized	_	_	O
86	to	_	_	O
87	intervention	_	_	O
88	or	_	_	O
89	assessment	_	_	O
90	only	_	_	O
91	Study	_	_	O
92	Arms	_	_	O
93	.	_	_	O

94	Conducted	_	_	O
95	in	_	_	O
96	small	_	_	O
97	groups	_	_	O
98	,	_	_	O
99	intervention	_	_	O
100	sessions	_	_	O
101	were	_	_	O
102	offered	_	_	O
103	weekly	_	_	O
104	for	_	_	O
105	4	_	_	O
106	months	_	_	O
107	and	_	_	O
108	followed	_	_	O
109	by	_	_	O
110	monthly	_	_	O
111	sessions	_	_	O
112	for	_	_	O
113	8	_	_	O
114	months	_	_	O
115	.	_	_	O

116	Measures	_	_	O
117	included	_	_	O
118	psychological	_	_	O
119	(	_	_	O
120	distress	_	_	O
121	)	_	_	O
122	,	_	_	O
123	biological	_	_	O
124	(	_	_	O
125	immune	_	_	O
126	)	_	_	O
127	,	_	_	O
128	and	_	_	O
129	health	_	_	O
130	outcomes	_	_	O
131	(	_	_	O
132	performance	_	_	O
133	status	_	_	O
134	and	_	_	O
135	evaluations	_	_	O
136	of	_	_	O
137	patient	_	_	O
138	'	_	_	O
139	s	_	_	O
140	symptomatology	_	_	O
141	,	_	_	O
142	including	_	_	O
143	toxicity	_	_	O
144	from	_	_	O
145	cancer	_	_	O
146	treatment	_	_	O
147	,	_	_	O
148	lab	_	_	O
149	values	_	_	O
150	)	_	_	O
151	collected	_	_	O
152	at	_	_	O
153	baseline	_	_	O
154	,	_	_	O
155	4	_	_	O
156	months	_	_	O
157	,	_	_	O
158	and	_	_	O
159	12	_	_	O
160	months	_	_	O
161	.	_	_	O

162	A	_	_	B-Premise
163	path	_	_	I-Premise
164	model	_	_	I-Premise
165	revealed	_	_	I-Premise
166	that	_	_	I-Premise
167	intervention	_	_	I-Premise
168	participation	_	_	I-Premise
169	directly	_	_	I-Premise
170	improved	_	_	I-Premise
171	health	_	_	I-Premise
172	(	_	_	I-Premise
173	p	_	_	I-Premise
174	<	_	_	I-Premise
175	.	_	_	I-Premise

176	05	_	_	I-Premise
177	)	_	_	I-Premise
178	at	_	_	I-Premise
179	12	_	_	I-Premise
180	months	_	_	I-Premise
181	.	_	_	I-Premise

182	These	_	_	B-Premise
183	effects	_	_	I-Premise
184	remained	_	_	I-Premise
185	when	_	_	I-Premise
186	statistically	_	_	I-Premise
187	controlling	_	_	I-Premise
188	for	_	_	I-Premise
189	baseline	_	_	I-Premise
190	levels	_	_	I-Premise
191	of	_	_	I-Premise
192	distress	_	_	I-Premise
193	,	_	_	I-Premise
194	immunity	_	_	I-Premise
195	,	_	_	I-Premise
196	and	_	_	I-Premise
197	health	_	_	I-Premise
198	as	_	_	I-Premise
199	well	_	_	I-Premise
200	as	_	_	I-Premise
201	sociodemographic	_	_	I-Premise
202	,	_	_	I-Premise
203	disease	_	_	I-Premise
204	,	_	_	I-Premise
205	and	_	_	I-Premise
206	cancer	_	_	I-Premise
207	treatment	_	_	I-Premise
208	variables	_	_	I-Premise
209	.	_	_	I-Premise

210	Regarding	_	_	B-Premise
211	the	_	_	I-Premise
212	mechanisms	_	_	I-Premise
213	for	_	_	I-Premise
214	achieving	_	_	I-Premise
215	better	_	_	I-Premise
216	health	_	_	I-Premise
217	,	_	_	I-Premise
218	support	_	_	I-Premise
219	was	_	_	I-Premise
220	found	_	_	I-Premise
221	for	_	_	I-Premise
222	an	_	_	I-Premise
223	indirect	_	_	I-Premise
224	effect	_	_	I-Premise
225	of	_	_	I-Premise
226	distress	_	_	I-Premise
227	reduction	_	_	I-Premise
228	.	_	_	I-Premise

229	That	_	_	B-Premise
230	is	_	_	I-Premise
231	,	_	_	I-Premise
232	by	_	_	I-Premise
233	specifically	_	_	I-Premise
234	lowering	_	_	I-Premise
235	intervention	_	_	I-Premise
236	patients	_	_	I-Premise
237	'	_	_	I-Premise
238	distress	_	_	I-Premise
239	at	_	_	I-Premise
240	4	_	_	I-Premise
241	months	_	_	I-Premise
242	,	_	_	I-Premise
243	their	_	_	I-Premise
244	health	_	_	I-Premise
245	was	_	_	I-Premise
246	improved	_	_	I-Premise
247	at	_	_	I-Premise
248	12	_	_	I-Premise
249	months	_	_	I-Premise
250	(	_	_	I-Premise
251	p	_	_	I-Premise
252	<	_	_	I-Premise
253	.	_	_	I-Premise

254	05	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	Although	_	_	B-Premise
258	the	_	_	I-Premise
259	intervention	_	_	I-Premise
260	simultaneously	_	_	I-Premise
261	improved	_	_	I-Premise
262	patients	_	_	I-Premise
263	'	_	_	I-Premise
264	T	_	_	I-Premise
265	-	_	_	I-Premise
266	cell	_	_	I-Premise
267	blastogenesis	_	_	I-Premise
268	in	_	_	I-Premise
269	response	_	_	I-Premise
270	to	_	_	I-Premise
271	phytohemagglutinin	_	_	I-Premise
272	(	_	_	I-Premise
273	PHA	_	_	I-Premise
274	)	_	_	I-Premise
275	,	_	_	I-Premise
276	the	_	_	B-Premise
277	latter	_	_	I-Premise
278	increases	_	_	I-Premise
279	were	_	_	I-Premise
280	unrelated	_	_	I-Premise
281	to	_	_	I-Premise
282	improved	_	_	I-Premise
283	health	_	_	I-Premise
284	.	_	_	I-Premise

285	A	_	_	B-Premise
286	convergence	_	_	I-Premise
287	of	_	_	I-Premise
288	biobehavioral	_	_	I-Premise
289	effects	_	_	I-Premise
290	and	_	_	I-Premise
291	health	_	_	I-Premise
292	improvements	_	_	I-Premise
293	were	_	_	I-Premise
294	observed	_	_	I-Premise
295	.	_	_	I-Premise

296	Behavioral	_	_	B-Claim
297	change	_	_	I-Claim
298	,	_	_	I-Claim
299	rather	_	_	I-Claim
300	than	_	_	I-Claim
301	immunity	_	_	I-Claim
302	change	_	_	I-Claim
303	,	_	_	I-Claim
304	was	_	_	I-Claim
305	influential	_	_	I-Claim
306	in	_	_	I-Claim
307	achieving	_	_	I-Claim
308	lower	_	_	I-Claim
309	levels	_	_	I-Claim
310	of	_	_	I-Claim
311	symptomatology	_	_	I-Claim
312	and	_	_	I-Claim
313	higher	_	_	I-Claim
314	functional	_	_	I-Claim
315	status	_	_	I-Claim
316	.	_	_	I-Claim

317	Distress	_	_	B-Claim
318	reduction	_	_	I-Claim
319	is	_	_	I-Claim
320	highlighted	_	_	I-Claim
321	as	_	_	I-Claim
322	an	_	_	I-Claim
323	important	_	_	I-Claim
324	mechanism	_	_	I-Claim
325	by	_	_	I-Claim
326	which	_	_	I-Claim
327	health	_	_	I-Claim
328	can	_	_	I-Claim
329	be	_	_	I-Claim
330	improved	_	_	I-Claim
331	.	_	_	I-Claim


0	A	_	_	O
1	randomised	_	_	O
2	controlled	_	_	O
3	trial	_	_	O
4	(	_	_	O
5	RCT	_	_	O
6	)	_	_	O
7	demonstrated	_	_	O
8	that	_	_	O
9	cognitive	_	_	O
10	behaviour	_	_	O
11	therapy	_	_	O
12	(	_	_	O
13	CBT	_	_	O
14	)	_	_	O
15	for	_	_	O
16	fatigue	_	_	O
17	during	_	_	O
18	curative	_	_	O
19	cancer	_	_	O
20	treatment	_	_	O
21	was	_	_	O
22	effective	_	_	O
23	shortly	_	_	O
24	after	_	_	O
25	cancer	_	_	O
26	treatment	_	_	O
27	.	_	_	O

28	This	_	_	O
29	study	_	_	O
30	aimed	_	_	O
31	to	_	_	O
32	identify	_	_	O
33	which	_	_	O
34	patient	_	_	O
35	characteristics	_	_	O
36	predict	_	_	O
37	fatigue	_	_	O
38	improvement	_	_	O
39	after	_	_	O
40	CBT	_	_	O
41	.	_	_	O

42	In	_	_	O
43	addition	_	_	O
44	,	_	_	O
45	the	_	_	O
46	long	_	_	O
47	-	_	_	O
48	term	_	_	O
49	effectiveness	_	_	O
50	was	_	_	O
51	investigated	_	_	O
52	.	_	_	O

53	Patients	_	_	O
54	with	_	_	O
55	various	_	_	O
56	malignancies	_	_	O
57	participated	_	_	O
58	in	_	_	O
59	the	_	_	O
60	RCT	_	_	O
61	(	_	_	O
62	n	_	_	O
63	=	_	_	O
64	210	_	_	O
65	)	_	_	O
66	.	_	_	O

67	Participants	_	_	O
68	were	_	_	O
69	assessed	_	_	O
70	before	_	_	O
71	cancer	_	_	O
72	treatment	_	_	O
73	(	_	_	O
74	T1	_	_	O
75	)	_	_	O
76	,	_	_	O
77	postintervention	_	_	O
78	(	_	_	O
79	T2	_	_	O
80	)	_	_	O
81	,	_	_	O
82	which	_	_	O
83	was	_	_	O
84	at	_	_	O
85	least	_	_	O
86	2	_	_	O
87	months	_	_	O
88	after	_	_	O
89	cancer	_	_	O
90	treatment	_	_	O
91	,	_	_	O
92	and	_	_	O
93	after	_	_	O
94	1	_	_	O
95	-	_	_	O
96	year	_	_	O
97	follow	_	_	O
98	-	_	_	O
99	up	_	_	O
100	(	_	_	O
101	T3	_	_	O
102	)	_	_	O
103	.	_	_	O

104	Monthly	_	_	O
105	fatigue	_	_	O
106	assessments	_	_	O
107	were	_	_	O
108	completed	_	_	O
109	between	_	_	O
110	T2	_	_	O
111	and	_	_	O
112	T3	_	_	O
113	.	_	_	O

114	A	_	_	O
115	regression	_	_	O
116	analysis	_	_	O
117	with	_	_	O
118	interactions	_	_	O
119	was	_	_	O
120	performed	_	_	O
121	to	_	_	O
122	determine	_	_	O
123	if	_	_	O
124	domains	_	_	O
125	of	_	_	O
126	quality	_	_	O
127	of	_	_	O
128	life	_	_	O
129	(	_	_	O
130	EORTC	_	_	O
131	-	_	_	O
132	QLQ	_	_	O
133	-	_	_	O
134	C30	_	_	O
135	)	_	_	O
136	functioning	_	_	O
137	(	_	_	O
138	Health	_	_	O
139	Survey	_	_	O
140	Short	_	_	O
141	Form	_	_	O
142	-	_	_	O
143	36	_	_	O
144	)	_	_	O
145	or	_	_	O
146	psychological	_	_	O
147	distress	_	_	O
148	(	_	_	O
149	Symptom	_	_	O
150	Checklist	_	_	O
151	-	_	_	O
152	90	_	_	O
153	)	_	_	O
154	moderated	_	_	O
155	the	_	_	O
156	effect	_	_	O
157	of	_	_	O
158	CBT	_	_	O
159	on	_	_	O
160	fatigue	_	_	O
161	.	_	_	O

162	Analyses	_	_	O
163	of	_	_	O
164	covariance	_	_	O
165	were	_	_	O
166	used	_	_	O
167	to	_	_	O
168	study	_	_	O
169	the	_	_	O
170	long	_	_	O
171	-	_	_	O
172	term	_	_	O
173	effectiveness	_	_	O
174	of	_	_	O
175	CBT	_	_	O
176	.	_	_	O

177	Fatigue	_	_	B-Premise
178	at	_	_	I-Premise
179	T2	_	_	I-Premise
180	was	_	_	I-Premise
181	predicted	_	_	I-Premise
182	by	_	_	I-Premise
183	a	_	_	I-Premise
184	significant	_	_	I-Premise
185	interaction	_	_	I-Premise
186	between	_	_	I-Premise
187	self	_	_	I-Premise
188	-	_	_	I-Premise
189	reported	_	_	I-Premise
190	cognitive	_	_	I-Premise
191	functioning	_	_	I-Premise
192	and	_	_	I-Premise
193	CBT	_	_	I-Premise
194	.	_	_	I-Premise

195	No	_	_	B-Premise
196	interactions	_	_	I-Premise
197	were	_	_	I-Premise
198	found	_	_	I-Premise
199	between	_	_	I-Premise
200	other	_	_	I-Premise
201	domains	_	_	I-Premise
202	of	_	_	I-Premise
203	quality	_	_	I-Premise
204	of	_	_	I-Premise
205	life	_	_	I-Premise
206	,	_	_	I-Premise
207	functioning	_	_	I-Premise
208	,	_	_	I-Premise
209	psychological	_	_	I-Premise
210	distress	_	_	I-Premise
211	and	_	_	I-Premise
212	CBT	_	_	I-Premise
213	.	_	_	I-Premise

214	At	_	_	B-Premise
215	T3	_	_	I-Premise
216	,	_	_	I-Premise
217	no	_	_	I-Premise
218	significant	_	_	I-Premise
219	difference	_	_	I-Premise
220	on	_	_	I-Premise
221	fatigue	_	_	I-Premise
222	was	_	_	I-Premise
223	found	_	_	I-Premise
224	between	_	_	I-Premise
225	CBT	_	_	I-Premise
226	and	_	_	I-Premise
227	usual	_	_	I-Premise
228	care	_	_	I-Premise
229	.	_	_	I-Premise

230	Exploratory	_	_	B-Premise
231	analyses	_	_	I-Premise
232	showed	_	_	I-Premise
233	that	_	_	I-Premise
234	the	_	_	I-Premise
235	difference	_	_	I-Premise
236	nearly	_	_	I-Premise
237	reached	_	_	I-Premise
238	significance	_	_	I-Premise
239	until	_	_	I-Premise
240	7	_	_	I-Premise
241	months	_	_	I-Premise
242	postintervention	_	_	I-Premise
243	.	_	_	I-Premise

244	Patients	_	_	B-Premise
245	who	_	_	I-Premise
246	experienced	_	_	I-Premise
247	more	_	_	I-Premise
248	concentration	_	_	I-Premise
249	and	_	_	I-Premise
250	memory	_	_	I-Premise
251	problems	_	_	I-Premise
252	at	_	_	I-Premise
253	T1	_	_	I-Premise
254	benefited	_	_	I-Premise
255	more	_	_	I-Premise
256	from	_	_	I-Premise
257	CBT	_	_	I-Premise
258	for	_	_	I-Premise
259	fatigue	_	_	I-Premise
260	and	_	_	I-Premise
261	are	_	_	I-Premise
262	indicators	_	_	I-Premise
263	.	_	_	I-Premise

264	After	_	_	B-Premise
265	a	_	_	I-Premise
266	year	_	_	I-Premise
267	of	_	_	I-Premise
268	follow	_	_	I-Premise
269	-	_	_	I-Premise
270	up	_	_	I-Premise
271	,	_	_	I-Premise
272	the	_	_	I-Premise
273	effect	_	_	I-Premise
274	of	_	_	I-Premise
275	CBT	_	_	I-Premise
276	for	_	_	I-Premise
277	fatigue	_	_	I-Premise
278	was	_	_	I-Premise
279	no	_	_	I-Premise
280	longer	_	_	I-Premise
281	observed	_	_	I-Premise
282	,	_	_	I-Premise
283	and	_	_	I-Premise
284	the	_	_	I-Premise
285	effect	_	_	I-Premise
286	on	_	_	I-Premise
287	fatigue	_	_	I-Premise
288	seemed	_	_	I-Premise
289	to	_	_	I-Premise
290	be	_	_	I-Premise
291	diminished	_	_	I-Premise
292	7	_	_	I-Premise
293	months	_	_	I-Premise
294	postintervention	_	_	I-Premise
295	.	_	_	I-Premise

296	The	_	_	B-Claim
297	implication	_	_	I-Claim
298	is	_	_	I-Claim
299	that	_	_	I-Claim
300	CBT	_	_	I-Claim
301	for	_	_	I-Claim
302	fatigue	_	_	I-Claim
303	should	_	_	I-Claim
304	be	_	_	I-Claim
305	offered	_	_	I-Claim
306	to	_	_	I-Claim
307	patients	_	_	I-Claim
308	with	_	_	I-Claim
309	cancer	_	_	I-Claim
310	with	_	_	I-Claim
311	the	_	_	I-Claim
312	highest	_	_	I-Claim
313	chance	_	_	I-Claim
314	to	_	_	I-Claim
315	benefit	_	_	I-Claim
316	.	_	_	I-Claim


0	Surgical	_	_	O
1	resection	_	_	O
2	is	_	_	O
3	regarded	_	_	O
4	as	_	_	O
5	the	_	_	O
6	only	_	_	O
7	curative	_	_	O
8	option	_	_	O
9	for	_	_	O
10	resectable	_	_	O
11	oesophageal	_	_	O
12	cancer	_	_	O
13	,	_	_	O
14	but	_	_	O
15	pulmonary	_	_	O
16	complications	_	_	O
17	occurring	_	_	O
18	in	_	_	O
19	more	_	_	O
20	than	_	_	O
21	half	_	_	O
22	of	_	_	O
23	patients	_	_	O
24	after	_	_	O
25	open	_	_	O
26	oesophagectomy	_	_	O
27	are	_	_	O
28	a	_	_	O
29	great	_	_	O
30	concern	_	_	O
31	.	_	_	O

32	We	_	_	O
33	assessed	_	_	O
34	whether	_	_	O
35	minimally	_	_	O
36	invasive	_	_	O
37	oesophagectomy	_	_	O
38	reduces	_	_	O
39	morbidity	_	_	O
40	compared	_	_	O
41	with	_	_	O
42	open	_	_	O
43	oesophagectomy	_	_	O
44	.	_	_	O

45	We	_	_	O
46	did	_	_	O
47	a	_	_	O
48	multicentre	_	_	O
49	,	_	_	O
50	open	_	_	O
51	-	_	_	O
52	label	_	_	O
53	,	_	_	O
54	randomised	_	_	O
55	controlled	_	_	O
56	trial	_	_	O
57	at	_	_	O
58	five	_	_	O
59	study	_	_	O
60	centres	_	_	O
61	in	_	_	O
62	three	_	_	O
63	countries	_	_	O
64	between	_	_	O
65	June	_	_	O
66	1	_	_	O
67	,	_	_	O
68	2009	_	_	O
69	,	_	_	O
70	and	_	_	O
71	March	_	_	O
72	31	_	_	O
73	,	_	_	O
74	2011	_	_	O
75	.	_	_	O

76	Patients	_	_	O
77	aged	_	_	O
78	18	_	_	O
79	-	_	_	O
80	75	_	_	O
81	years	_	_	O
82	with	_	_	O
83	resectable	_	_	O
84	cancer	_	_	O
85	of	_	_	O
86	the	_	_	O
87	oesophagus	_	_	O
88	or	_	_	O
89	gastro	_	_	O
90	-	_	_	O
91	oesophageal	_	_	O
92	junction	_	_	O
93	were	_	_	O
94	randomly	_	_	O
95	assigned	_	_	O
96	via	_	_	O
97	a	_	_	O
98	computer	_	_	O
99	-	_	_	O
100	generated	_	_	O
101	randomisation	_	_	O
102	sequence	_	_	O
103	to	_	_	O
104	receive	_	_	O
105	either	_	_	O
106	open	_	_	O
107	transthoracic	_	_	O
108	or	_	_	O
109	minimally	_	_	O
110	invasive	_	_	O
111	transthoracic	_	_	O
112	oesophagectomy	_	_	O
113	.	_	_	O

114	Randomisation	_	_	O
115	was	_	_	O
116	stratified	_	_	O
117	by	_	_	O
118	centre	_	_	O
119	.	_	_	O

120	Patients	_	_	O
121	,	_	_	O
122	and	_	_	O
123	investigators	_	_	O
124	undertaking	_	_	O
125	interventions	_	_	O
126	,	_	_	O
127	assessing	_	_	O
128	outcomes	_	_	O
129	,	_	_	O
130	and	_	_	O
131	analysing	_	_	O
132	data	_	_	O
133	,	_	_	O
134	were	_	_	O
135	not	_	_	O
136	masked	_	_	O
137	to	_	_	O
138	group	_	_	O
139	assignment	_	_	O
140	.	_	_	O

141	The	_	_	O
142	primary	_	_	O
143	outcome	_	_	O
144	was	_	_	O
145	pulmonary	_	_	O
146	infection	_	_	O
147	within	_	_	O
148	the	_	_	O
149	first	_	_	O
150	2	_	_	O
151	weeks	_	_	O
152	after	_	_	O
153	surgery	_	_	O
154	and	_	_	O
155	during	_	_	O
156	the	_	_	O
157	whole	_	_	O
158	stay	_	_	O
159	in	_	_	O
160	hospital	_	_	O
161	.	_	_	O

162	Analysis	_	_	O
163	was	_	_	O
164	by	_	_	O
165	intention	_	_	O
166	to	_	_	O
167	treat	_	_	O
168	.	_	_	O

169	This	_	_	O
170	trial	_	_	O
171	is	_	_	O
172	registered	_	_	O
173	with	_	_	O
174	the	_	_	O
175	Netherlands	_	_	O
176	Trial	_	_	O
177	Register	_	_	O
178	,	_	_	O
179	NTR	_	_	O
180	TC	_	_	O
181	2452	_	_	O
182	.	_	_	O

183	We	_	_	O
184	randomly	_	_	O
185	assigned	_	_	O
186	56	_	_	O
187	patients	_	_	O
188	to	_	_	O
189	the	_	_	O
190	open	_	_	O
191	oesophagectomy	_	_	O
192	group	_	_	O
193	and	_	_	O
194	59	_	_	O
195	to	_	_	O
196	the	_	_	O
197	minimally	_	_	O
198	invasive	_	_	O
199	oesophagectomy	_	_	O
200	group	_	_	O
201	.	_	_	O

202	16	_	_	B-Premise
203	(	_	_	I-Premise
204	29	_	_	I-Premise
205	%	_	_	I-Premise
206	)	_	_	I-Premise
207	patients	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	open	_	_	I-Premise
211	oesophagectomy	_	_	I-Premise
212	group	_	_	I-Premise
213	had	_	_	I-Premise
214	pulmonary	_	_	I-Premise
215	infection	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	first	_	_	I-Premise
219	2	_	_	I-Premise
220	weeks	_	_	I-Premise
221	compared	_	_	I-Premise
222	with	_	_	I-Premise
223	five	_	_	I-Premise
224	(	_	_	I-Premise
225	9	_	_	I-Premise
226	%	_	_	I-Premise
227	)	_	_	I-Premise
228	in	_	_	I-Premise
229	the	_	_	I-Premise
230	minimally	_	_	I-Premise
231	invasive	_	_	I-Premise
232	group	_	_	I-Premise
233	(	_	_	I-Premise
234	relative	_	_	I-Premise
235	risk	_	_	I-Premise
236	[	_	_	I-Premise
237	RR	_	_	I-Premise
238	]	_	_	I-Premise
239	0	_	_	I-Premise
240	·	_	_	I-Premise
241	30	_	_	I-Premise
242	,	_	_	I-Premise
243	95	_	_	I-Premise
244	%	_	_	I-Premise
245	CI	_	_	I-Premise
246	0	_	_	I-Premise
247	·	_	_	I-Premise
248	12	_	_	I-Premise
249	-	_	_	I-Premise
250	0	_	_	I-Premise
251	·	_	_	I-Premise
252	76	_	_	I-Premise
253	;	_	_	I-Premise
254	p	_	_	I-Premise
255	=	_	_	I-Premise
256	0	_	_	I-Premise
257	·	_	_	I-Premise
258	005	_	_	I-Premise
259	)	_	_	I-Premise
260	.	_	_	I-Premise

261	19	_	_	B-Premise
262	(	_	_	I-Premise
263	34	_	_	I-Premise
264	%	_	_	I-Premise
265	)	_	_	I-Premise
266	patients	_	_	I-Premise
267	in	_	_	I-Premise
268	the	_	_	I-Premise
269	open	_	_	I-Premise
270	oesophagectomy	_	_	I-Premise
271	group	_	_	I-Premise
272	had	_	_	I-Premise
273	pulmonary	_	_	I-Premise
274	infection	_	_	I-Premise
275	in	_	_	I-Premise
276	-	_	_	I-Premise
277	hospital	_	_	I-Premise
278	compared	_	_	I-Premise
279	with	_	_	I-Premise
280	seven	_	_	I-Premise
281	(	_	_	I-Premise
282	12	_	_	I-Premise
283	%	_	_	I-Premise
284	)	_	_	I-Premise
285	in	_	_	I-Premise
286	the	_	_	I-Premise
287	minimally	_	_	I-Premise
288	invasive	_	_	I-Premise
289	group	_	_	I-Premise
290	(	_	_	I-Premise
291	0	_	_	I-Premise
292	·	_	_	I-Premise
293	35	_	_	I-Premise
294	,	_	_	I-Premise
295	0	_	_	I-Premise
296	·	_	_	I-Premise
297	16	_	_	I-Premise
298	-	_	_	I-Premise
299	0	_	_	I-Premise
300	·	_	_	I-Premise
301	78	_	_	I-Premise
302	;	_	_	I-Premise
303	p	_	_	I-Premise
304	=	_	_	I-Premise
305	0	_	_	I-Premise
306	·	_	_	I-Premise
307	005	_	_	I-Premise
308	)	_	_	I-Premise
309	.	_	_	I-Premise

310	For	_	_	B-Premise
311	in	_	_	I-Premise
312	-	_	_	I-Premise
313	hospital	_	_	I-Premise
314	mortality	_	_	I-Premise
315	,	_	_	I-Premise
316	one	_	_	I-Premise
317	patient	_	_	I-Premise
318	in	_	_	I-Premise
319	the	_	_	I-Premise
320	open	_	_	I-Premise
321	oesophagectomy	_	_	I-Premise
322	group	_	_	I-Premise
323	died	_	_	I-Premise
324	from	_	_	I-Premise
325	anastomotic	_	_	I-Premise
326	leakage	_	_	I-Premise
327	and	_	_	I-Premise
328	two	_	_	I-Premise
329	in	_	_	I-Premise
330	the	_	_	I-Premise
331	minimally	_	_	I-Premise
332	invasive	_	_	I-Premise
333	group	_	_	I-Premise
334	from	_	_	I-Premise
335	aspiration	_	_	I-Premise
336	and	_	_	I-Premise
337	mediastinitis	_	_	I-Premise
338	after	_	_	I-Premise
339	anastomotic	_	_	I-Premise
340	leakage	_	_	I-Premise
341	.	_	_	I-Premise

342	These	_	_	B-Claim
343	findings	_	_	I-Claim
344	provide	_	_	I-Claim
345	evidence	_	_	I-Claim
346	for	_	_	I-Claim
347	the	_	_	I-Claim
348	short	_	_	I-Claim
349	-	_	_	I-Claim
350	term	_	_	I-Claim
351	benefits	_	_	I-Claim
352	of	_	_	I-Claim
353	minimally	_	_	I-Claim
354	invasive	_	_	I-Claim
355	oesophagectomy	_	_	I-Claim
356	for	_	_	I-Claim
357	patients	_	_	I-Claim
358	with	_	_	I-Claim
359	resectable	_	_	I-Claim
360	oesophageal	_	_	I-Claim
361	cancer	_	_	I-Claim
362	.	_	_	I-Claim


0	Serum	_	_	O
1	CA125	_	_	O
2	concentration	_	_	O
3	often	_	_	O
4	rises	_	_	O
5	several	_	_	O
6	months	_	_	O
7	before	_	_	O
8	clinical	_	_	O
9	or	_	_	O
10	symptomatic	_	_	O
11	relapse	_	_	O
12	in	_	_	O
13	women	_	_	O
14	with	_	_	O
15	ovarian	_	_	O
16	cancer	_	_	O
17	.	_	_	O

18	In	_	_	O
19	the	_	_	O
20	MRC	_	_	O
21	OV05	_	_	O
22	/	_	_	O
23	EORTC	_	_	O
24	55955	_	_	O
25	collaborative	_	_	O
26	trial	_	_	O
27	,	_	_	O
28	we	_	_	O
29	aimed	_	_	O
30	to	_	_	O
31	establish	_	_	O
32	the	_	_	O
33	benefits	_	_	O
34	of	_	_	O
35	early	_	_	O
36	treatment	_	_	O
37	on	_	_	O
38	the	_	_	O
39	basis	_	_	O
40	of	_	_	O
41	increased	_	_	O
42	CA125	_	_	O
43	concentrations	_	_	O
44	compared	_	_	O
45	with	_	_	O
46	delayed	_	_	O
47	treatment	_	_	O
48	on	_	_	O
49	the	_	_	O
50	basis	_	_	O
51	of	_	_	O
52	clinical	_	_	O
53	recurrence	_	_	O
54	.	_	_	O

55	Women	_	_	O
56	with	_	_	O
57	ovarian	_	_	O
58	cancer	_	_	O
59	in	_	_	O
60	complete	_	_	O
61	remission	_	_	O
62	after	_	_	O
63	first	_	_	O
64	-	_	_	O
65	line	_	_	O
66	platinum	_	_	O
67	-	_	_	O
68	based	_	_	O
69	chemotherapy	_	_	O
70	and	_	_	O
71	a	_	_	O
72	normal	_	_	O
73	CA125	_	_	O
74	concentration	_	_	O
75	were	_	_	O
76	registered	_	_	O
77	for	_	_	O
78	this	_	_	O
79	randomised	_	_	O
80	controlled	_	_	O
81	trial	_	_	O
82	.	_	_	O

83	Clinical	_	_	O
84	examination	_	_	O
85	and	_	_	O
86	CA125	_	_	O
87	measurement	_	_	O
88	were	_	_	O
89	done	_	_	O
90	every	_	_	O
91	3	_	_	O
92	months	_	_	O
93	.	_	_	O

94	Patients	_	_	O
95	and	_	_	O
96	investigators	_	_	O
97	were	_	_	O
98	masked	_	_	O
99	to	_	_	O
100	CA125	_	_	O
101	results	_	_	O
102	,	_	_	O
103	which	_	_	O
104	were	_	_	O
105	monitored	_	_	O
106	by	_	_	O
107	coordinating	_	_	O
108	centres	_	_	O
109	.	_	_	O

110	If	_	_	O
111	CA125	_	_	O
112	concentration	_	_	O
113	exceeded	_	_	O
114	twice	_	_	O
115	the	_	_	O
116	upper	_	_	O
117	limit	_	_	O
118	of	_	_	O
119	normal	_	_	O
120	,	_	_	O
121	patients	_	_	O
122	were	_	_	O
123	randomly	_	_	O
124	assigned	_	_	O
125	(	_	_	O
126	1	_	_	O
127	:	_	_	O
128	1	_	_	O
129	)	_	_	O
130	by	_	_	O
131	minimisation	_	_	O
132	to	_	_	O
133	early	_	_	O
134	or	_	_	O
135	delayed	_	_	O
136	chemotherapy	_	_	O
137	.	_	_	O

138	Patients	_	_	O
139	and	_	_	O
140	clinical	_	_	O
141	sites	_	_	O
142	were	_	_	O
143	informed	_	_	O
144	of	_	_	O
145	allocation	_	_	O
146	to	_	_	O
147	early	_	_	O
148	treatment	_	_	O
149	,	_	_	O
150	and	_	_	O
151	treatment	_	_	O
152	was	_	_	O
153	started	_	_	O
154	as	_	_	O
155	soon	_	_	O
156	as	_	_	O
157	possible	_	_	O
158	within	_	_	O
159	28	_	_	O
160	days	_	_	O
161	of	_	_	O
162	the	_	_	O
163	increased	_	_	O
164	CA125	_	_	O
165	measurement	_	_	O
166	.	_	_	O

167	Patients	_	_	O
168	assigned	_	_	O
169	to	_	_	O
170	delayed	_	_	O
171	treatment	_	_	O
172	continued	_	_	O
173	masked	_	_	O
174	CA125	_	_	O
175	measurements	_	_	O
176	,	_	_	O
177	with	_	_	O
178	treatment	_	_	O
179	commencing	_	_	O
180	at	_	_	O
181	clinical	_	_	O
182	or	_	_	O
183	symptomatic	_	_	O
184	relapse	_	_	O
185	.	_	_	O

186	All	_	_	O
187	patients	_	_	O
188	were	_	_	O
189	treated	_	_	O
190	according	_	_	O
191	to	_	_	O
192	standard	_	_	O
193	local	_	_	O
194	practice	_	_	O
195	.	_	_	O

196	The	_	_	O
197	primary	_	_	O
198	outcome	_	_	O
199	was	_	_	O
200	overall	_	_	O
201	survival	_	_	O
202	.	_	_	O

203	Analysis	_	_	O
204	was	_	_	O
205	by	_	_	O
206	intention	_	_	O
207	to	_	_	O
208	treat	_	_	O
209	.	_	_	O

210	This	_	_	O
211	study	_	_	O
212	is	_	_	O
213	registered	_	_	O
214	,	_	_	O
215	ISRCTN87786644	_	_	O
216	.	_	_	O

217	1442	_	_	O
218	patients	_	_	O
219	were	_	_	O
220	registered	_	_	O
221	for	_	_	O
222	the	_	_	O
223	trial	_	_	O
224	,	_	_	O
225	of	_	_	O
226	whom	_	_	O
227	529	_	_	O
228	were	_	_	O
229	randomly	_	_	O
230	assigned	_	_	O
231	to	_	_	O
232	treatment	_	_	O
233	groups	_	_	O
234	and	_	_	O
235	were	_	_	O
236	included	_	_	O
237	in	_	_	O
238	our	_	_	O
239	analysis	_	_	O
240	(	_	_	O
241	265	_	_	O
242	early	_	_	O
243	,	_	_	O
244	264	_	_	O
245	delayed	_	_	O
246	)	_	_	O
247	.	_	_	O

248	With	_	_	B-Premise
249	a	_	_	I-Premise
250	median	_	_	I-Premise
251	follow	_	_	I-Premise
252	-	_	_	I-Premise
253	up	_	_	I-Premise
254	of	_	_	I-Premise
255	56	_	_	I-Premise
256	·	_	_	I-Premise
257	9	_	_	I-Premise
258	months	_	_	I-Premise
259	(	_	_	I-Premise
260	IQR	_	_	I-Premise
261	37	_	_	I-Premise
262	·	_	_	I-Premise
263	4	_	_	I-Premise
264	-	_	_	I-Premise
265	81	_	_	I-Premise
266	·	_	_	I-Premise
267	8	_	_	I-Premise
268	)	_	_	I-Premise
269	from	_	_	I-Premise
270	randomisation	_	_	I-Premise
271	and	_	_	I-Premise
272	370	_	_	I-Premise
273	deaths	_	_	I-Premise
274	(	_	_	I-Premise
275	186	_	_	I-Premise
276	early	_	_	I-Premise
277	,	_	_	I-Premise
278	184	_	_	I-Premise
279	delayed	_	_	I-Premise
280	)	_	_	I-Premise
281	,	_	_	I-Premise
282	there	_	_	I-Premise
283	was	_	_	I-Premise
284	no	_	_	I-Premise
285	evidence	_	_	I-Premise
286	of	_	_	I-Premise
287	a	_	_	I-Premise
288	difference	_	_	I-Premise
289	in	_	_	I-Premise
290	overall	_	_	I-Premise
291	survival	_	_	I-Premise
292	between	_	_	I-Premise
293	early	_	_	I-Premise
294	and	_	_	I-Premise
295	delayed	_	_	I-Premise
296	treatment	_	_	I-Premise
297	(	_	_	I-Premise
298	HR	_	_	I-Premise
299	0	_	_	I-Premise
300	·	_	_	I-Premise
301	98	_	_	I-Premise
302	,	_	_	I-Premise
303	95	_	_	I-Premise
304	%	_	_	I-Premise
305	CI	_	_	I-Premise
306	0	_	_	I-Premise
307	·	_	_	I-Premise
308	80	_	_	I-Premise
309	-	_	_	I-Premise
310	1	_	_	I-Premise
311	·	_	_	I-Premise
312	20	_	_	I-Premise
313	,	_	_	I-Premise
314	p	_	_	I-Premise
315	=	_	_	I-Premise
316	0	_	_	I-Premise
317	·	_	_	I-Premise
318	85	_	_	I-Premise
319	)	_	_	I-Premise
320	.	_	_	I-Premise

321	Median	_	_	B-Premise
322	survival	_	_	I-Premise
323	from	_	_	I-Premise
324	randomisation	_	_	I-Premise
325	was	_	_	I-Premise
326	25	_	_	I-Premise
327	·	_	_	I-Premise
328	7	_	_	I-Premise
329	months	_	_	I-Premise
330	(	_	_	I-Premise
331	95	_	_	I-Premise
332	%	_	_	I-Premise
333	CI	_	_	I-Premise
334	23	_	_	I-Premise
335	·	_	_	I-Premise
336	0	_	_	I-Premise
337	-	_	_	I-Premise
338	27	_	_	I-Premise
339	·	_	_	I-Premise
340	9	_	_	I-Premise
341	)	_	_	I-Premise
342	for	_	_	I-Premise
343	patients	_	_	I-Premise
344	on	_	_	I-Premise
345	early	_	_	I-Premise
346	treatment	_	_	I-Premise
347	and	_	_	I-Premise
348	27	_	_	I-Premise
349	·	_	_	I-Premise
350	1	_	_	I-Premise
351	months	_	_	I-Premise
352	(	_	_	I-Premise
353	22	_	_	I-Premise
354	·	_	_	I-Premise
355	8	_	_	I-Premise
356	-	_	_	I-Premise
357	30	_	_	I-Premise
358	·	_	_	I-Premise
359	9	_	_	I-Premise
360	)	_	_	I-Premise
361	for	_	_	I-Premise
362	those	_	_	I-Premise
363	on	_	_	I-Premise
364	delayed	_	_	I-Premise
365	treatment	_	_	I-Premise
366	.	_	_	I-Premise

367	Our	_	_	B-Claim
368	findings	_	_	I-Claim
369	showed	_	_	I-Claim
370	no	_	_	I-Claim
371	evidence	_	_	I-Claim
372	of	_	_	I-Claim
373	a	_	_	I-Claim
374	survival	_	_	I-Claim
375	benefit	_	_	I-Claim
376	with	_	_	I-Claim
377	early	_	_	I-Claim
378	treatment	_	_	I-Claim
379	of	_	_	I-Claim
380	relapse	_	_	I-Claim
381	on	_	_	I-Claim
382	the	_	_	I-Claim
383	basis	_	_	I-Claim
384	of	_	_	I-Claim
385	a	_	_	I-Claim
386	raised	_	_	I-Claim
387	CA125	_	_	I-Claim
388	concentration	_	_	I-Claim
389	alone	_	_	I-Claim
390	,	_	_	I-Claim
391	and	_	_	B-Claim
392	therefore	_	_	I-Claim
393	the	_	_	I-Claim
394	value	_	_	I-Claim
395	of	_	_	I-Claim
396	routine	_	_	I-Claim
397	measurement	_	_	I-Claim
398	of	_	_	I-Claim
399	CA125	_	_	I-Claim
400	in	_	_	I-Claim
401	the	_	_	I-Claim
402	follow	_	_	I-Claim
403	-	_	_	I-Claim
404	up	_	_	I-Claim
405	of	_	_	I-Claim
406	patients	_	_	I-Claim
407	with	_	_	I-Claim
408	ovarian	_	_	I-Claim
409	cancer	_	_	I-Claim
410	who	_	_	I-Claim
411	attain	_	_	I-Claim
412	a	_	_	I-Claim
413	complete	_	_	I-Claim
414	response	_	_	I-Claim
415	after	_	_	I-Claim
416	first	_	_	I-Claim
417	-	_	_	I-Claim
418	line	_	_	I-Claim
419	treatment	_	_	I-Claim
420	is	_	_	I-Claim
421	not	_	_	I-Claim
422	proven	_	_	I-Claim
423	.	_	_	I-Claim


0	To	_	_	O
1	examine	_	_	O
2	health	_	_	O
3	-	_	_	O
4	related	_	_	O
5	quality	_	_	O
6	of	_	_	O
7	life	_	_	O
8	,	_	_	O
9	we	_	_	O
10	investigated	_	_	O
11	the	_	_	O
12	effect	_	_	O
13	of	_	_	O
14	adjuvant	_	_	O
15	chemotherapy	_	_	O
16	regimens	_	_	O
17	on	_	_	O
18	utility	_	_	O
19	scores	_	_	O
20	assessed	_	_	O
21	by	_	_	O
22	the	_	_	O
23	EuroQoL	_	_	O
24	-	_	_	O
25	5D	_	_	O
26	(	_	_	O
27	EQ	_	_	O
28	-	_	_	O
29	5D	_	_	O
30	)	_	_	O
31	instrument	_	_	O
32	in	_	_	O
33	a	_	_	O
34	randomized	_	_	O
35	,	_	_	O
36	controlled	_	_	O
37	trial	_	_	O
38	for	_	_	O
39	breast	_	_	O
40	cancer	_	_	O
41	patients	_	_	O
42	after	_	_	O
43	surgery	_	_	O
44	.	_	_	O

45	We	_	_	O
46	also	_	_	O
47	investigated	_	_	O
48	the	_	_	O
49	relationship	_	_	O
50	between	_	_	O
51	Functional	_	_	O
52	Assessment	_	_	O
53	of	_	_	O
54	Cancer	_	_	O
55	Therapy	_	_	O
56	(	_	_	O
57	FACT	_	_	O
58	)	_	_	O
59	scale	_	_	O
60	scores	_	_	O
61	and	_	_	O
62	EQ	_	_	O
63	-	_	_	O
64	5D	_	_	O
65	utilities	_	_	O
66	.	_	_	O

67	Patients	_	_	O
68	were	_	_	O
69	randomly	_	_	O
70	assigned	_	_	O
71	to	_	_	O
72	the	_	_	O
73	following	_	_	O
74	four	_	_	O
75	chemotherapy	_	_	O
76	regimens	_	_	O
77	:	_	_	O
78	four	_	_	O
79	cycles	_	_	O
80	of	_	_	O
81	anthracycline	_	_	O
82	followed	_	_	O
83	by	_	_	O
84	paclitaxel	_	_	O
85	(	_	_	O
86	ACP	_	_	O
87	)	_	_	O
88	,	_	_	O
89	four	_	_	O
90	cycles	_	_	O
91	of	_	_	O
92	anthracycline	_	_	O
93	-	_	_	O
94	containing	_	_	O
95	regimens	_	_	O
96	followed	_	_	O
97	by	_	_	O
98	docetaxel	_	_	O
99	(	_	_	O
100	ACD	_	_	O
101	)	_	_	O
102	,	_	_	O
103	eight	_	_	O
104	cycles	_	_	O
105	of	_	_	O
106	paclitaxel	_	_	O
107	(	_	_	O
108	PTX	_	_	O
109	)	_	_	O
110	,	_	_	O
111	and	_	_	O
112	eight	_	_	O
113	cycles	_	_	O
114	of	_	_	O
115	docetaxel	_	_	O
116	(	_	_	O
117	DTX	_	_	O
118	)	_	_	O
119	.	_	_	O

120	Of	_	_	O
121	1060	_	_	O
122	registered	_	_	O
123	,	_	_	O
124	the	_	_	O
125	first	_	_	O
126	300	_	_	O
127	consecutive	_	_	O
128	patients	_	_	O
129	were	_	_	O
130	included	_	_	O
131	in	_	_	O
132	the	_	_	O
133	current	_	_	O
134	utility	_	_	O
135	study	_	_	O
136	.	_	_	O

137	Utility	_	_	O
138	scores	_	_	O
139	were	_	_	O
140	assessed	_	_	O
141	using	_	_	O
142	the	_	_	O
143	EQ	_	_	O
144	-	_	_	O
145	5D	_	_	O
146	instrument	_	_	O
147	at	_	_	O
148	baseline	_	_	O
149	;	_	_	O
150	cycles	_	_	O
151	3	_	_	O
152	,	_	_	O
153	5	_	_	O
154	,	_	_	O
155	and	_	_	O
156	7	_	_	O
157	;	_	_	O
158	7	_	_	O
159	months	_	_	O
160	;	_	_	O
161	and	_	_	O
162	1	_	_	O
163	year	_	_	O
164	.	_	_	O

165	We	_	_	O
166	also	_	_	O
167	evaluated	_	_	O
168	the	_	_	O
169	correlation	_	_	O
170	between	_	_	O
171	these	_	_	O
172	scores	_	_	O
173	and	_	_	O
174	FACT	_	_	O
175	-	_	_	O
176	G	_	_	O
177	,	_	_	O
178	-	_	_	O
179	B	_	_	O
180	,	_	_	O
181	and	_	_	O
182	-	_	_	O
183	Taxane	_	_	O
184	scores	_	_	O
185	at	_	_	O
186	each	_	_	O
187	time	_	_	O
188	point	_	_	O
189	.	_	_	O

190	Utility	_	_	B-Premise
191	scores	_	_	I-Premise
192	were	_	_	I-Premise
193	significantly	_	_	I-Premise
194	lower	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	DTX	_	_	I-Premise
198	group	_	_	I-Premise
199	than	_	_	I-Premise
200	in	_	_	I-Premise
201	the	_	_	I-Premise
202	ACP	_	_	I-Premise
203	and	_	_	I-Premise
204	ACD	_	_	I-Premise
205	groups	_	_	I-Premise
206	.	_	_	I-Premise

207	Mean	_	_	B-Premise
208	utility	_	_	I-Premise
209	scores	_	_	I-Premise
210	in	_	_	I-Premise
211	the	_	_	I-Premise
212	DTX	_	_	I-Premise
213	group	_	_	I-Premise
214	were	_	_	I-Premise
215	lowest	_	_	I-Premise
216	at	_	_	I-Premise
217	7	_	_	I-Premise
218	months	_	_	I-Premise
219	and	_	_	I-Premise
220	tended	_	_	I-Premise
221	to	_	_	I-Premise
222	remain	_	_	I-Premise
223	low	_	_	I-Premise
224	for	_	_	I-Premise
225	a	_	_	I-Premise
226	long	_	_	I-Premise
227	time	_	_	I-Premise
228	.	_	_	I-Premise

229	The	_	_	B-Premise
230	combined	_	_	I-Premise
231	anthracycline	_	_	I-Premise
232	followed	_	_	I-Premise
233	by	_	_	I-Premise
234	taxane	_	_	I-Premise
235	group	_	_	I-Premise
236	had	_	_	I-Premise
237	significantly	_	_	I-Premise
238	higher	_	_	I-Premise
239	utility	_	_	I-Premise
240	scores	_	_	I-Premise
241	that	_	_	I-Premise
242	the	_	_	I-Premise
243	taxane	_	_	I-Premise
244	-	_	_	I-Premise
245	alone	_	_	I-Premise
246	group	_	_	I-Premise
247	,	_	_	I-Premise
248	with	_	_	I-Premise
249	no	_	_	I-Premise
250	significant	_	_	I-Premise
251	difference	_	_	I-Premise
252	depending	_	_	I-Premise
253	on	_	_	I-Premise
254	the	_	_	I-Premise
255	type	_	_	I-Premise
256	of	_	_	I-Premise
257	taxane	_	_	I-Premise
258	.	_	_	I-Premise

259	Only	_	_	B-Premise
260	the	_	_	I-Premise
261	FACT	_	_	I-Premise
262	-	_	_	I-Premise
263	G	_	_	I-Premise
264	social	_	_	I-Premise
265	/	_	_	I-Premise
266	family	_	_	I-Premise
267	well	_	_	I-Premise
268	-	_	_	I-Premise
269	being	_	_	I-Premise
270	subscale	_	_	I-Premise
271	had	_	_	I-Premise
272	no	_	_	I-Premise
273	relationship	_	_	I-Premise
274	with	_	_	I-Premise
275	EQ	_	_	I-Premise
276	-	_	_	I-Premise
277	5D	_	_	I-Premise
278	responses	_	_	I-Premise
279	and	_	_	I-Premise
280	utility	_	_	I-Premise
281	scores	_	_	I-Premise
282	.	_	_	I-Premise

283	Although	_	_	B-Claim
284	the	_	_	I-Claim
285	regimens	_	_	I-Claim
286	in	_	_	I-Claim
287	this	_	_	I-Claim
288	study	_	_	I-Claim
289	were	_	_	I-Claim
290	similar	_	_	I-Claim
291	in	_	_	I-Claim
292	that	_	_	I-Claim
293	they	_	_	I-Claim
294	included	_	_	I-Claim
295	taxane	_	_	I-Claim
296	,	_	_	I-Claim
297	the	_	_	I-Claim
298	mean	_	_	I-Claim
299	utility	_	_	I-Claim
300	scores	_	_	I-Claim
301	and	_	_	I-Claim
302	longitudinal	_	_	I-Claim
303	patterns	_	_	I-Claim
304	of	_	_	I-Claim
305	utility	_	_	I-Claim
306	scores	_	_	I-Claim
307	were	_	_	I-Claim
308	different	_	_	I-Claim
309	among	_	_	I-Claim
310	regimens	_	_	I-Claim
311	.	_	_	I-Claim


0	Chronic	_	_	O
1	gastrointestinal	_	_	O
2	symptoms	_	_	O
3	after	_	_	O
4	pelvic	_	_	O
5	radiotherapy	_	_	O
6	are	_	_	O
7	common	_	_	O
8	,	_	_	O
9	multifactorial	_	_	O
10	in	_	_	O
11	cause	_	_	O
12	,	_	_	O
13	and	_	_	O
14	affect	_	_	O
15	patients	_	_	O
16	'	_	_	O
17	quality	_	_	O
18	of	_	_	O
19	life	_	_	O
20	.	_	_	O

21	We	_	_	O
22	assessed	_	_	O
23	whether	_	_	O
24	such	_	_	O
25	patients	_	_	O
26	could	_	_	O
27	be	_	_	O
28	helped	_	_	O
29	if	_	_	O
30	a	_	_	O
31	practitioner	_	_	O
32	followed	_	_	O
33	an	_	_	O
34	investigative	_	_	O
35	and	_	_	O
36	management	_	_	O
37	algorithm	_	_	O
38	,	_	_	O
39	and	_	_	O
40	whether	_	_	O
41	outcomes	_	_	O
42	differed	_	_	O
43	by	_	_	O
44	whether	_	_	O
45	a	_	_	O
46	nurse	_	_	O
47	or	_	_	O
48	a	_	_	O
49	gastroenterologist	_	_	O
50	led	_	_	O
51	this	_	_	O
52	algorithm	_	_	O
53	-	_	_	O
54	based	_	_	O
55	care	_	_	O
56	.	_	_	O

57	For	_	_	O
58	this	_	_	O
59	three	_	_	O
60	-	_	_	O
61	arm	_	_	O
62	randomised	_	_	O
63	controlled	_	_	O
64	trial	_	_	O
65	we	_	_	O
66	recruited	_	_	O
67	patients	_	_	O
68	(	_	_	O
69	aged	_	_	O
70	≥	_	_	O
71	18	_	_	O
72	years	_	_	O
73	)	_	_	O
74	from	_	_	O
75	clinics	_	_	O
76	in	_	_	O
77	London	_	_	O
78	,	_	_	O
79	UK	_	_	O
80	,	_	_	O
81	with	_	_	O
82	new	_	_	O
83	-	_	_	O
84	onset	_	_	O
85	gastrointestinal	_	_	O
86	symptoms	_	_	O
87	persisting	_	_	O
88	6	_	_	O
89	months	_	_	O
90	after	_	_	O
91	pelvic	_	_	O
92	radiotherapy	_	_	O
93	.	_	_	O

94	Using	_	_	O
95	a	_	_	O
96	computer	_	_	O
97	-	_	_	O
98	generated	_	_	O
99	randomisation	_	_	O
100	sequence	_	_	O
101	,	_	_	O
102	we	_	_	O
103	randomly	_	_	O
104	allocated	_	_	O
105	patients	_	_	O
106	to	_	_	O
107	one	_	_	O
108	of	_	_	O
109	three	_	_	O
110	groups	_	_	O
111	(	_	_	O
112	1	_	_	O
113	:	_	_	O
114	1	_	_	O
115	:	_	_	O
116	1	_	_	O
117	;	_	_	O
118	stratified	_	_	O
119	by	_	_	O
120	tumour	_	_	O
121	site	_	_	O
122	[	_	_	O
123	urological	_	_	O
124	,	_	_	O
125	gynaecological	_	_	O
126	,	_	_	O
127	or	_	_	O
128	gastrointestinal	_	_	O
129	]	_	_	O
130	,	_	_	O
131	and	_	_	O
132	degree	_	_	O
133	of	_	_	O
134	bowel	_	_	O
135	dysfunction	_	_	O
136	[	_	_	O
137	IBDQ	_	_	O
138	-	_	_	O
139	B	_	_	O
140	score	_	_	O
141	<	_	_	O
142	60	_	_	O
143	vs	_	_	O
144	60	_	_	O
145	-	_	_	O
146	70	_	_	O
147	]	_	_	O
148	)	_	_	O
149	:	_	_	O
150	usual	_	_	O
151	care	_	_	O
152	(	_	_	O
153	a	_	_	O
154	detailed	_	_	O
155	self	_	_	O
156	-	_	_	O
157	help	_	_	O
158	booklet	_	_	O
159	)	_	_	O
160	,	_	_	O
161	gastroenterologist	_	_	O
162	-	_	_	O
163	led	_	_	O
164	algorithm	_	_	O
165	-	_	_	O
166	based	_	_	O
167	treatment	_	_	O
168	,	_	_	O
169	or	_	_	O
170	nurse	_	_	O
171	-	_	_	O
172	led	_	_	O
173	algorithm	_	_	O
174	-	_	_	O
175	based	_	_	O
176	treatment	_	_	O
177	.	_	_	O

178	The	_	_	O
179	primary	_	_	O
180	endpoint	_	_	O
181	was	_	_	O
182	change	_	_	O
183	in	_	_	O
184	Inflammatory	_	_	O
185	Bowel	_	_	O
186	Disease	_	_	O
187	Questionnaire	_	_	O
188	-	_	_	O
189	Bowel	_	_	O
190	subset	_	_	O
191	score	_	_	O
192	(	_	_	O
193	IBDQ	_	_	O
194	-	_	_	O
195	B	_	_	O
196	)	_	_	O
197	at	_	_	O
198	6	_	_	O
199	months	_	_	O
200	,	_	_	O
201	analysed	_	_	O
202	by	_	_	O
203	intention	_	_	O
204	to	_	_	O
205	treat	_	_	O
206	.	_	_	O

207	Between	_	_	O
208	Nov	_	_	O
209	26	_	_	O
210	,	_	_	O
211	2007	_	_	O
212	,	_	_	O
213	and	_	_	O
214	Dec	_	_	O
215	12	_	_	O
216	,	_	_	O
217	2011	_	_	O
218	,	_	_	O
219	we	_	_	O
220	enrolled	_	_	O
221	and	_	_	O
222	randomly	_	_	O
223	allocated	_	_	O
224	218	_	_	O
225	patients	_	_	O
226	to	_	_	O
227	treatment	_	_	O
228	:	_	_	O
229	80	_	_	O
230	to	_	_	O
231	the	_	_	O
232	nurse	_	_	O
233	group	_	_	O
234	,	_	_	O
235	70	_	_	O
236	to	_	_	O
237	the	_	_	O
238	gastroenterologist	_	_	O
239	group	_	_	O
240	,	_	_	O
241	and	_	_	O
242	68	_	_	O
243	to	_	_	O
244	the	_	_	O
245	booklet	_	_	O
246	group	_	_	O
247	(	_	_	O
248	figure	_	_	O
249	)	_	_	O
250	.	_	_	O

251	Most	_	_	O
252	had	_	_	O
253	a	_	_	O
254	baseline	_	_	O
255	IBDQ	_	_	O
256	-	_	_	O
257	B	_	_	O
258	score	_	_	O
259	indicating	_	_	O
260	moderate	_	_	O
261	-	_	_	O
262	to	_	_	O
263	-	_	_	O
264	severe	_	_	O
265	symptoms	_	_	O
266	.	_	_	O

267	We	_	_	B-Premise
268	recorded	_	_	I-Premise
269	the	_	_	I-Premise
270	following	_	_	I-Premise
271	pair	_	_	I-Premise
272	-	_	_	I-Premise
273	wise	_	_	I-Premise
274	mean	_	_	I-Premise
275	difference	_	_	I-Premise
276	in	_	_	I-Premise
277	change	_	_	I-Premise
278	in	_	_	I-Premise
279	IBDQ	_	_	I-Premise
280	-	_	_	I-Premise
281	B	_	_	I-Premise
282	score	_	_	I-Premise
283	between	_	_	I-Premise
284	groups	_	_	I-Premise
285	:	_	_	I-Premise
286	nurse	_	_	I-Premise
287	versus	_	_	I-Premise
288	booklet	_	_	I-Premise
289	4	_	_	I-Premise
290	·	_	_	I-Premise
291	12	_	_	I-Premise
292	(	_	_	I-Premise
293	95	_	_	I-Premise
294	%	_	_	I-Premise
295	CI	_	_	I-Premise
296	0	_	_	I-Premise
297	·	_	_	I-Premise
298	04	_	_	I-Premise
299	-	_	_	I-Premise
300	8	_	_	I-Premise
301	·	_	_	I-Premise
302	19	_	_	I-Premise
303	;	_	_	I-Premise
304	p	_	_	I-Premise
305	=	_	_	I-Premise
306	0	_	_	I-Premise
307	·	_	_	I-Premise
308	04	_	_	I-Premise
309	)	_	_	I-Premise
310	,	_	_	I-Premise
311	gastroenterologist	_	_	I-Premise
312	versus	_	_	I-Premise
313	booklet	_	_	I-Premise
314	5	_	_	I-Premise
315	·	_	_	I-Premise
316	47	_	_	I-Premise
317	(	_	_	I-Premise
318	1	_	_	I-Premise
319	·	_	_	I-Premise
320	14	_	_	I-Premise
321	-	_	_	I-Premise
322	9	_	_	I-Premise
323	·	_	_	I-Premise
324	81	_	_	I-Premise
325	;	_	_	I-Premise
326	p	_	_	I-Premise
327	=	_	_	I-Premise
328	0	_	_	I-Premise
329	·	_	_	I-Premise
330	01	_	_	I-Premise
331	)	_	_	I-Premise
332	.	_	_	I-Premise

333	Outcomes	_	_	B-Premise
334	in	_	_	I-Premise
335	the	_	_	I-Premise
336	nurse	_	_	I-Premise
337	group	_	_	I-Premise
338	were	_	_	I-Premise
339	not	_	_	I-Premise
340	inferior	_	_	I-Premise
341	to	_	_	I-Premise
342	outcomes	_	_	I-Premise
343	in	_	_	I-Premise
344	the	_	_	I-Premise
345	gastroenterologist	_	_	I-Premise
346	group	_	_	I-Premise
347	(	_	_	I-Premise
348	mean	_	_	I-Premise
349	difference	_	_	I-Premise
350	1	_	_	I-Premise
351	·	_	_	I-Premise
352	36	_	_	I-Premise
353	,	_	_	I-Premise
354	one	_	_	I-Premise
355	sided	_	_	I-Premise
356	95	_	_	I-Premise
357	%	_	_	I-Premise
358	CI	_	_	I-Premise
359	-	_	_	I-Premise
360	1	_	_	I-Premise
361	·	_	_	I-Premise
362	48	_	_	I-Premise
363	)	_	_	I-Premise
364	.	_	_	I-Premise

365	Patients	_	_	B-Claim
366	given	_	_	I-Claim
367	targeted	_	_	I-Claim
368	intervention	_	_	I-Claim
369	following	_	_	I-Claim
370	a	_	_	I-Claim
371	detailed	_	_	I-Claim
372	clinical	_	_	I-Claim
373	algorithm	_	_	I-Claim
374	had	_	_	I-Claim
375	better	_	_	I-Claim
376	improvements	_	_	I-Claim
377	in	_	_	I-Claim
378	radiotherapy	_	_	I-Claim
379	-	_	_	I-Claim
380	induced	_	_	I-Claim
381	gastrointestinal	_	_	I-Claim
382	symptoms	_	_	I-Claim
383	than	_	_	I-Claim
384	did	_	_	I-Claim
385	patients	_	_	I-Claim
386	given	_	_	I-Claim
387	usual	_	_	I-Claim
388	care	_	_	I-Claim
389	.	_	_	I-Claim

390	Our	_	_	B-Claim
391	findings	_	_	I-Claim
392	suggest	_	_	I-Claim
393	that	_	_	I-Claim
394	,	_	_	I-Claim
395	for	_	_	I-Claim
396	most	_	_	I-Claim
397	patients	_	_	I-Claim
398	,	_	_	I-Claim
399	this	_	_	I-Claim
400	algorithm	_	_	I-Claim
401	-	_	_	I-Claim
402	based	_	_	I-Claim
403	care	_	_	I-Claim
404	can	_	_	I-Claim
405	be	_	_	I-Claim
406	given	_	_	I-Claim
407	by	_	_	I-Claim
408	a	_	_	I-Claim
409	trained	_	_	I-Claim
410	nurse	_	_	I-Claim
411	.	_	_	I-Claim


0	Lymphoma	_	_	O
1	patients	_	_	O
2	commonly	_	_	O
3	experience	_	_	O
4	declines	_	_	O
5	in	_	_	O
6	physical	_	_	O
7	functioning	_	_	O
8	and	_	_	O
9	quality	_	_	O
10	of	_	_	O
11	life	_	_	O
12	(	_	_	O
13	QoL	_	_	O
14	)	_	_	O
15	that	_	_	O
16	may	_	_	O
17	be	_	_	O
18	reversed	_	_	O
19	with	_	_	O
20	exercise	_	_	O
21	training	_	_	O
22	.	_	_	O

23	We	_	_	O
24	conducted	_	_	O
25	a	_	_	O
26	randomized	_	_	O
27	controlled	_	_	O
28	trial	_	_	O
29	in	_	_	O
30	Edmonton	_	_	O
31	,	_	_	O
32	Alberta	_	_	O
33	,	_	_	O
34	Canada	_	_	O
35	,	_	_	O
36	between	_	_	O
37	2005	_	_	O
38	and	_	_	O
39	2008	_	_	O
40	that	_	_	O
41	stratified	_	_	O
42	122	_	_	O
43	lymphoma	_	_	O
44	patients	_	_	O
45	by	_	_	O
46	major	_	_	O
47	disease	_	_	O
48	type	_	_	O
49	and	_	_	O
50	current	_	_	O
51	treatment	_	_	O
52	status	_	_	O
53	and	_	_	O
54	randomly	_	_	O
55	assigned	_	_	O
56	them	_	_	O
57	to	_	_	O
58	usual	_	_	O
59	care	_	_	O
60	(	_	_	O
61	UC	_	_	O
62	;	_	_	O
63	n	_	_	O
64	=	_	_	O
65	62	_	_	O
66	)	_	_	O
67	or	_	_	O
68	12	_	_	O
69	weeks	_	_	O
70	of	_	_	O
71	supervised	_	_	O
72	aerobic	_	_	O
73	exercise	_	_	O
74	training	_	_	O
75	(	_	_	O
76	AET	_	_	O
77	;	_	_	O
78	n	_	_	O
79	=	_	_	O
80	60	_	_	O
81	)	_	_	O
82	.	_	_	O

83	Our	_	_	O
84	primary	_	_	O
85	end	_	_	O
86	point	_	_	O
87	was	_	_	O
88	patient	_	_	O
89	-	_	_	O
90	rated	_	_	O
91	physical	_	_	O
92	functioning	_	_	O
93	assessed	_	_	O
94	by	_	_	O
95	the	_	_	O
96	Trial	_	_	O
97	Outcome	_	_	O
98	Index	_	_	O
99	-	_	_	O
100	Anemia	_	_	O
101	.	_	_	O

102	Secondary	_	_	O
103	end	_	_	O
104	points	_	_	O
105	were	_	_	O
106	overall	_	_	O
107	QoL	_	_	O
108	,	_	_	O
109	psychosocial	_	_	O
110	functioning	_	_	O
111	,	_	_	O
112	cardiovascular	_	_	O
113	fitness	_	_	O
114	,	_	_	O
115	and	_	_	O
116	body	_	_	O
117	composition	_	_	O
118	.	_	_	O

119	Follow	_	_	O
120	-	_	_	O
121	up	_	_	O
122	assessment	_	_	O
123	for	_	_	O
124	our	_	_	O
125	primary	_	_	O
126	end	_	_	O
127	point	_	_	O
128	was	_	_	O
129	96	_	_	O
130	%	_	_	O
131	(	_	_	O
132	117	_	_	O
133	of	_	_	O
134	122	_	_	O
135	)	_	_	O
136	at	_	_	O
137	postintervention	_	_	O
138	and	_	_	O
139	90	_	_	O
140	%	_	_	O
141	(	_	_	O
142	110	_	_	O
143	of	_	_	O
144	122	_	_	O
145	)	_	_	O
146	at	_	_	O
147	6	_	_	O
148	-	_	_	O
149	month	_	_	O
150	follow	_	_	O
151	-	_	_	O
152	up	_	_	O
153	.	_	_	O

154	Median	_	_	O
155	adherence	_	_	O
156	to	_	_	O
157	the	_	_	O
158	supervised	_	_	O
159	exercise	_	_	O
160	program	_	_	O
161	was	_	_	O
162	92	_	_	O
163	%	_	_	O
164	.	_	_	O

165	At	_	_	B-Premise
166	postintervention	_	_	I-Premise
167	,	_	_	I-Premise
168	AET	_	_	I-Premise
169	was	_	_	I-Premise
170	superior	_	_	I-Premise
171	to	_	_	I-Premise
172	UC	_	_	I-Premise
173	for	_	_	I-Premise
174	patient	_	_	I-Premise
175	-	_	_	I-Premise
176	rated	_	_	I-Premise
177	physical	_	_	I-Premise
178	functioning	_	_	I-Premise
179	(	_	_	I-Premise
180	mean	_	_	I-Premise
181	group	_	_	I-Premise
182	difference	_	_	I-Premise
183	,	_	_	I-Premise
184	+	_	_	I-Premise
185	9	_	_	I-Premise
186	.	_	_	I-Premise

187	0	_	_	I-Premise
188	;	_	_	I-Premise
189	95	_	_	I-Premise
190	%	_	_	I-Premise
191	CI	_	_	I-Premise
192	,	_	_	I-Premise
193	2	_	_	I-Premise
194	.	_	_	I-Premise

195	0	_	_	I-Premise
196	to	_	_	I-Premise
197	16	_	_	I-Premise
198	.	_	_	I-Premise

199	0	_	_	I-Premise
200	;	_	_	I-Premise
201	P	_	_	I-Premise
202	=	_	_	I-Premise
203	.	_	_	I-Premise

204	012	_	_	I-Premise
205	)	_	_	I-Premise
206	,	_	_	I-Premise
207	overall	_	_	I-Premise
208	QoL	_	_	I-Premise
209	(	_	_	I-Premise
210	P	_	_	I-Premise
211	=	_	_	I-Premise
212	.	_	_	I-Premise

213	021	_	_	I-Premise
214	)	_	_	I-Premise
215	,	_	_	I-Premise
216	fatigue	_	_	I-Premise
217	(	_	_	I-Premise
218	P	_	_	I-Premise
219	=	_	_	I-Premise
220	.	_	_	I-Premise

221	013	_	_	I-Premise
222	)	_	_	I-Premise
223	,	_	_	I-Premise
224	happiness	_	_	I-Premise
225	(	_	_	I-Premise
226	P	_	_	I-Premise
227	=	_	_	I-Premise
228	.	_	_	I-Premise

229	004	_	_	I-Premise
230	)	_	_	I-Premise
231	,	_	_	I-Premise
232	depression	_	_	I-Premise
233	(	_	_	I-Premise
234	P	_	_	I-Premise
235	=	_	_	I-Premise
236	.	_	_	I-Premise

237	005	_	_	I-Premise
238	)	_	_	I-Premise
239	,	_	_	I-Premise
240	general	_	_	I-Premise
241	health	_	_	I-Premise
242	(	_	_	I-Premise
243	P	_	_	I-Premise
244	<	_	_	I-Premise
245	.	_	_	I-Premise

246	001	_	_	I-Premise
247	)	_	_	I-Premise
248	,	_	_	I-Premise
249	cardiovascular	_	_	I-Premise
250	fitness	_	_	I-Premise
251	(	_	_	I-Premise
252	P	_	_	I-Premise
253	<	_	_	I-Premise
254	.	_	_	I-Premise

255	001	_	_	I-Premise
256	)	_	_	I-Premise
257	,	_	_	I-Premise
258	and	_	_	I-Premise
259	lean	_	_	I-Premise
260	body	_	_	I-Premise
261	mass	_	_	I-Premise
262	(	_	_	I-Premise
263	P	_	_	I-Premise
264	=	_	_	I-Premise
265	.	_	_	I-Premise

266	008	_	_	I-Premise
267	)	_	_	I-Premise
268	.	_	_	I-Premise

269	Change	_	_	O
270	in	_	_	O
271	peak	_	_	O
272	cardiovascular	_	_	O
273	fitness	_	_	O
274	mediated	_	_	O
275	the	_	_	O
276	change	_	_	O
277	in	_	_	O
278	patient	_	_	O
279	-	_	_	O
280	rated	_	_	O
281	physical	_	_	O
282	functioning	_	_	O
283	.	_	_	O

284	AET	_	_	B-Premise
285	did	_	_	I-Premise
286	not	_	_	I-Premise
287	interfere	_	_	I-Premise
288	with	_	_	I-Premise
289	chemotherapy	_	_	I-Premise
290	completion	_	_	I-Premise
291	rate	_	_	I-Premise
292	or	_	_	I-Premise
293	treatment	_	_	I-Premise
294	response	_	_	I-Premise
295	.	_	_	I-Premise

296	At	_	_	B-Premise
297	6	_	_	I-Premise
298	-	_	_	I-Premise
299	month	_	_	I-Premise
300	follow	_	_	I-Premise
301	-	_	_	I-Premise
302	up	_	_	I-Premise
303	,	_	_	I-Premise
304	AET	_	_	I-Premise
305	was	_	_	I-Premise
306	still	_	_	I-Premise
307	borderline	_	_	I-Premise
308	or	_	_	I-Premise
309	significantly	_	_	I-Premise
310	superior	_	_	I-Premise
311	to	_	_	I-Premise
312	UC	_	_	I-Premise
313	for	_	_	I-Premise
314	overall	_	_	I-Premise
315	QoL	_	_	I-Premise
316	(	_	_	I-Premise
317	P	_	_	I-Premise
318	=	_	_	I-Premise
319	.	_	_	I-Premise

320	054	_	_	I-Premise
321	)	_	_	I-Premise
322	,	_	_	I-Premise
323	happiness	_	_	I-Premise
324	(	_	_	I-Premise
325	P	_	_	I-Premise
326	=	_	_	I-Premise
327	.	_	_	I-Premise

328	034	_	_	I-Premise
329	)	_	_	I-Premise
330	,	_	_	I-Premise
331	and	_	_	I-Premise
332	depression	_	_	I-Premise
333	(	_	_	I-Premise
334	P	_	_	I-Premise
335	=	_	_	I-Premise
336	.	_	_	I-Premise

337	009	_	_	I-Premise
338	)	_	_	I-Premise
339	without	_	_	I-Premise
340	an	_	_	I-Premise
341	increased	_	_	I-Premise
342	risk	_	_	I-Premise
343	of	_	_	I-Premise
344	disease	_	_	I-Premise
345	recurrence	_	_	I-Premise
346	/	_	_	I-Premise
347	progression	_	_	I-Premise
348	.	_	_	I-Premise

349	AET	_	_	B-Claim
350	significantly	_	_	I-Claim
351	improved	_	_	I-Claim
352	important	_	_	I-Claim
353	patient	_	_	I-Claim
354	-	_	_	I-Claim
355	rated	_	_	I-Claim
356	outcomes	_	_	I-Claim
357	and	_	_	I-Claim
358	objective	_	_	I-Claim
359	physical	_	_	I-Claim
360	functioning	_	_	I-Claim
361	in	_	_	I-Claim
362	lymphoma	_	_	I-Claim
363	patients	_	_	I-Claim
364	without	_	_	I-Claim
365	interfering	_	_	I-Claim
366	with	_	_	I-Claim
367	medical	_	_	I-Claim
368	treatments	_	_	I-Claim
369	or	_	_	I-Claim
370	response	_	_	I-Claim
371	.	_	_	I-Claim

372	Exercise	_	_	B-Claim
373	training	_	_	I-Claim
374	to	_	_	I-Claim
375	improve	_	_	I-Claim
376	cardiovascular	_	_	I-Claim
377	fitness	_	_	I-Claim
378	should	_	_	I-Claim
379	be	_	_	I-Claim
380	considered	_	_	I-Claim
381	in	_	_	I-Claim
382	the	_	_	I-Claim
383	management	_	_	I-Claim
384	of	_	_	I-Claim
385	lymphoma	_	_	I-Claim
386	patients	_	_	I-Claim
387	.	_	_	I-Claim


0	Older	_	_	O
1	breast	_	_	O
2	cancer	_	_	O
3	survivors	_	_	O
4	(	_	_	O
5	BCSs	_	_	O
6	)	_	_	O
7	are	_	_	O
8	at	_	_	O
9	risk	_	_	O
10	for	_	_	O
11	late	_	_	O
12	and	_	_	O
13	long	_	_	O
14	-	_	_	O
15	term	_	_	O
16	treatment	_	_	O
17	effects	_	_	O
18	on	_	_	O
19	quality	_	_	O
20	of	_	_	O
21	life	_	_	O
22	(	_	_	O
23	QOL	_	_	O
24	)	_	_	O
25	,	_	_	O
26	including	_	_	O
27	lower	_	_	O
28	physical	_	_	O
29	functioning	_	_	O
30	and	_	_	O
31	fear	_	_	O
32	of	_	_	O
33	recurrence	_	_	O
34	.	_	_	O

35	Two	_	_	O
36	promising	_	_	O
37	approaches	_	_	O
38	to	_	_	O
39	address	_	_	O
40	this	_	_	O
41	include	_	_	O
42	dance	_	_	O
43	/	_	_	O
44	movement	_	_	O
45	therapy	_	_	O
46	and	_	_	O
47	mindfulness	_	_	O
48	.	_	_	O

49	The	_	_	O
50	purpose	_	_	O
51	of	_	_	O
52	this	_	_	O
53	2	_	_	O
54	-	_	_	O
55	group	_	_	O
56	randomized	_	_	O
57	controlled	_	_	O
58	pilot	_	_	O
59	feasibility	_	_	O
60	study	_	_	O
61	was	_	_	O
62	to	_	_	O
63	test	_	_	O
64	short	_	_	O
65	-	_	_	O
66	term	_	_	O
67	effects	_	_	O
68	of	_	_	O
69	a	_	_	O
70	12	_	_	O
71	-	_	_	O
72	week	_	_	O
73	Mindful	_	_	O
74	Movement	_	_	O
75	Program	_	_	O
76	(	_	_	O
77	MMP	_	_	O
78	)	_	_	O
79	intervention	_	_	O
80	combining	_	_	O
81	mindfulness	_	_	O
82	with	_	_	O
83	self	_	_	O
84	-	_	_	O
85	directed	_	_	O
86	movement	_	_	O
87	on	_	_	O
88	QOL	_	_	O
89	and	_	_	O
90	mindfulness	_	_	O
91	in	_	_	O
92	female	_	_	O
93	BCSs	_	_	O
94	50	_	_	O
95	years	_	_	O
96	or	_	_	O
97	older	_	_	O
98	and	_	_	O
99	at	_	_	O
100	12	_	_	O
101	months	_	_	O
102	or	_	_	O
103	more	_	_	O
104	following	_	_	O
105	treatment	_	_	O
106	.	_	_	O

107	Consented	_	_	O
108	participants	_	_	O
109	were	_	_	O
110	randomized	_	_	O
111	to	_	_	O
112	an	_	_	O
113	experimental	_	_	O
114	group	_	_	O
115	(	_	_	O
116	EG	_	_	O
117	)	_	_	O
118	(	_	_	O
119	12	_	_	O
120	weekly	_	_	O
121	MMP	_	_	O
122	sessions	_	_	O
123	)	_	_	O
124	or	_	_	O
125	a	_	_	O
126	control	_	_	O
127	group	_	_	O
128	(	_	_	O
129	no	_	_	O
130	sessions	_	_	O
131	)	_	_	O
132	.	_	_	O

133	All	_	_	O
134	completed	_	_	O
135	questionnaires	_	_	O
136	3	_	_	O
137	times	_	_	O
138	.	_	_	O

139	The	_	_	O
140	EG	_	_	O
141	participants	_	_	O
142	kept	_	_	O
143	home	_	_	O
144	practice	_	_	O
145	diaries	_	_	O
146	.	_	_	O

147	Analysis	_	_	O
148	was	_	_	O
149	conducted	_	_	O
150	after	_	_	O
151	intervention	_	_	O
152	for	_	_	O
153	immediate	_	_	O
154	effects	_	_	O
155	on	_	_	O
156	outcome	_	_	O
157	variables	_	_	O
158	and	_	_	O
159	6	_	_	O
160	weeks	_	_	O
161	later	_	_	O
162	for	_	_	O
163	maintenance	_	_	O
164	of	_	_	O
165	effects	_	_	O
166	.	_	_	O

167	Participants	_	_	O
168	(	_	_	O
169	n	_	_	O
170	=	_	_	O
171	49	_	_	O
172	)	_	_	O
173	ranged	_	_	O
174	in	_	_	O
175	age	_	_	O
176	from	_	_	O
177	50	_	_	O
178	to	_	_	O
179	90	_	_	O
180	years	_	_	O
181	(	_	_	O
182	average	_	_	O
183	,	_	_	O
184	65	_	_	O
185	.	_	_	O

186	6	_	_	O
187	years	_	_	O
188	)	_	_	O
189	and	_	_	O
190	were	_	_	O
191	at	_	_	O
192	9	_	_	O
193	.	_	_	O

194	8	_	_	O
195	years	_	_	O
196	since	_	_	O
197	diagnosis	_	_	O
198	(	_	_	O
199	range	_	_	O
200	,	_	_	O
201	1	_	_	O
202	-	_	_	O
203	32	_	_	O
204	years	_	_	O
205	)	_	_	O
206	,	_	_	O
207	and	_	_	O
208	the	_	_	O
209	majority	_	_	O
210	were	_	_	O
211	white	_	_	O
212	,	_	_	O
213	unpartnered	_	_	O
214	,	_	_	O
215	and	_	_	O
216	retired	_	_	O
217	.	_	_	O

218	After	_	_	B-Premise
219	intervention	_	_	I-Premise
220	,	_	_	I-Premise
221	EG	_	_	I-Premise
222	participants	_	_	I-Premise
223	showed	_	_	I-Premise
224	improved	_	_	I-Premise
225	QOL	_	_	I-Premise
226	via	_	_	I-Premise
227	decreased	_	_	I-Premise
228	fear	_	_	I-Premise
229	of	_	_	I-Premise
230	recurrence	_	_	I-Premise
231	and	_	_	I-Premise
232	increased	_	_	I-Premise
233	mindfulness	_	_	I-Premise
234	attitude	_	_	I-Premise
235	.	_	_	I-Premise

236	At	_	_	B-Premise
237	6	_	_	I-Premise
238	weeks	_	_	I-Premise
239	,	_	_	I-Premise
240	initial	_	_	I-Premise
241	effects	_	_	I-Premise
242	were	_	_	I-Premise
243	retained	_	_	I-Premise
244	.	_	_	I-Premise

245	The	_	_	B-Premise
246	MMP	_	_	I-Premise
247	appears	_	_	I-Premise
248	to	_	_	I-Premise
249	benefit	_	_	I-Premise
250	older	_	_	I-Premise
251	BCSs	_	_	I-Premise
252	by	_	_	I-Premise
253	reducing	_	_	I-Premise
254	fear	_	_	I-Premise
255	of	_	_	I-Premise
256	recurrence	_	_	I-Premise
257	and	_	_	I-Premise
258	improving	_	_	I-Premise
259	mindfulness	_	_	I-Premise
260	attitude	_	_	I-Premise
261	.	_	_	I-Premise

262	Although	_	_	B-Claim
263	these	_	_	I-Claim
264	findings	_	_	I-Claim
265	are	_	_	I-Claim
266	promising	_	_	I-Claim
267	,	_	_	I-Claim
268	a	_	_	I-Claim
269	larger	_	_	I-Claim
270	study	_	_	I-Claim
271	is	_	_	I-Claim
272	needed	_	_	I-Claim
273	to	_	_	I-Claim
274	determine	_	_	I-Claim
275	more	_	_	I-Claim
276	specifically	_	_	I-Claim
277	what	_	_	I-Claim
278	short	_	_	I-Claim
279	-	_	_	I-Claim
280	and	_	_	I-Claim
281	long	_	_	I-Claim
282	-	_	_	I-Claim
283	term	_	_	I-Claim
284	effects	_	_	I-Claim
285	are	_	_	I-Claim
286	possible	_	_	I-Claim
287	.	_	_	I-Claim

288	The	_	_	B-Claim
289	combination	_	_	I-Claim
290	of	_	_	I-Claim
291	self	_	_	I-Claim
292	-	_	_	I-Claim
293	directed	_	_	I-Claim
294	movement	_	_	I-Claim
295	and	_	_	I-Claim
296	mindfulness	_	_	I-Claim
297	,	_	_	I-Claim
298	as	_	_	I-Claim
299	tested	_	_	I-Claim
300	here	_	_	I-Claim
301	,	_	_	I-Claim
302	may	_	_	I-Claim
303	be	_	_	I-Claim
304	a	_	_	I-Claim
305	valuable	_	_	I-Claim
306	tool	_	_	I-Claim
307	for	_	_	I-Claim
308	promoting	_	_	I-Claim
309	health	_	_	I-Claim
310	and	_	_	I-Claim
311	well	_	_	I-Claim
312	-	_	_	I-Claim
313	being	_	_	I-Claim
314	in	_	_	I-Claim
315	older	_	_	I-Claim
316	long	_	_	I-Claim
317	-	_	_	I-Claim
318	term	_	_	I-Claim
319	survivors	_	_	I-Claim
320	of	_	_	I-Claim
321	breast	_	_	I-Claim
322	cancer	_	_	I-Claim
323	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	functional	_	_	O
3	and	_	_	O
4	psychological	_	_	O
5	benefits	_	_	O
6	of	_	_	O
7	a	_	_	O
8	12	_	_	O
9	week	_	_	O
10	supervised	_	_	O
11	group	_	_	O
12	exercise	_	_	O
13	programme	_	_	O
14	during	_	_	O
15	treatment	_	_	O
16	for	_	_	O
17	early	_	_	O
18	stage	_	_	O
19	breast	_	_	O
20	cancer	_	_	O
21	,	_	_	O
22	with	_	_	O
23	six	_	_	O
24	month	_	_	O
25	follow	_	_	O
26	-	_	_	O
27	up	_	_	O
28	.	_	_	O

29	Pragmatic	_	_	O
30	randomised	_	_	O
31	controlled	_	_	O
32	prospective	_	_	O
33	open	_	_	O
34	trial	_	_	O
35	.	_	_	O

36	Three	_	_	O
37	National	_	_	O
38	Health	_	_	O
39	Service	_	_	O
40	oncology	_	_	O
41	clinics	_	_	O
42	in	_	_	O
43	Scotland	_	_	O
44	and	_	_	O
45	community	_	_	O
46	exercise	_	_	O
47	facilities	_	_	O
48	.	_	_	O

49	203	_	_	O
50	women	_	_	O
51	entered	_	_	O
52	the	_	_	O
53	study	_	_	O
54	;	_	_	O
55	177	_	_	O
56	completed	_	_	O
57	the	_	_	O
58	six	_	_	O
59	month	_	_	O
60	follow	_	_	O
61	-	_	_	O
62	up	_	_	O
63	.	_	_	O

64	Supervised	_	_	O
65	12	_	_	O
66	week	_	_	O
67	group	_	_	O
68	exercise	_	_	O
69	programme	_	_	O
70	in	_	_	O
71	addition	_	_	O
72	to	_	_	O
73	usual	_	_	O
74	care	_	_	O
75	,	_	_	O
76	compared	_	_	O
77	with	_	_	O
78	usual	_	_	O
79	care	_	_	O
80	.	_	_	O

81	Functional	_	_	O
82	assessment	_	_	O
83	of	_	_	O
84	cancer	_	_	O
85	therapy	_	_	O
86	(	_	_	O
87	FACT	_	_	O
88	)	_	_	O
89	questionnaire	_	_	O
90	,	_	_	O
91	Beck	_	_	O
92	depression	_	_	O
93	inventory	_	_	O
94	,	_	_	O
95	positive	_	_	O
96	and	_	_	O
97	negative	_	_	O
98	affect	_	_	O
99	scale	_	_	O
100	,	_	_	O
101	body	_	_	O
102	mass	_	_	O
103	index	_	_	O
104	,	_	_	O
105	seven	_	_	O
106	day	_	_	O
107	recall	_	_	O
108	of	_	_	O
109	physical	_	_	O
110	activity	_	_	O
111	,	_	_	O
112	12	_	_	O
113	minute	_	_	O
114	walk	_	_	O
115	test	_	_	O
116	,	_	_	O
117	and	_	_	O
118	assessment	_	_	O
119	of	_	_	O
120	shoulder	_	_	O
121	mobility	_	_	O
122	.	_	_	O

123	Mixed	_	_	B-Premise
124	effects	_	_	I-Premise
125	models	_	_	I-Premise
126	with	_	_	I-Premise
127	adjustment	_	_	I-Premise
128	for	_	_	I-Premise
129	baseline	_	_	I-Premise
130	values	_	_	I-Premise
131	,	_	_	I-Premise
132	study	_	_	I-Premise
133	site	_	_	I-Premise
134	,	_	_	I-Premise
135	treatment	_	_	I-Premise
136	at	_	_	I-Premise
137	baseline	_	_	I-Premise
138	,	_	_	I-Premise
139	and	_	_	I-Premise
140	age	_	_	I-Premise
141	gave	_	_	I-Premise
142	intervention	_	_	I-Premise
143	effect	_	_	I-Premise
144	estimates	_	_	I-Premise
145	(	_	_	I-Premise
146	intervention	_	_	I-Premise
147	minus	_	_	I-Premise
148	control	_	_	I-Premise
149	)	_	_	I-Premise
150	at	_	_	I-Premise
151	12	_	_	I-Premise
152	weeks	_	_	I-Premise
153	of	_	_	I-Premise
154	129	_	_	I-Premise
155	(	_	_	I-Premise
156	95	_	_	I-Premise
157	%	_	_	I-Premise
158	confidence	_	_	I-Premise
159	interval	_	_	I-Premise
160	83	_	_	I-Premise
161	to	_	_	I-Premise
162	176	_	_	I-Premise
163	)	_	_	I-Premise
164	for	_	_	I-Premise
165	metres	_	_	I-Premise
166	walked	_	_	I-Premise
167	in	_	_	I-Premise
168	12	_	_	I-Premise
169	minutes	_	_	I-Premise
170	,	_	_	I-Premise
171	182	_	_	I-Premise
172	(	_	_	I-Premise
173	75	_	_	I-Premise
174	to	_	_	I-Premise
175	289	_	_	I-Premise
176	)	_	_	I-Premise
177	for	_	_	I-Premise
178	minutes	_	_	I-Premise
179	of	_	_	I-Premise
180	moderate	_	_	I-Premise
181	intensity	_	_	I-Premise
182	activity	_	_	I-Premise
183	reported	_	_	I-Premise
184	in	_	_	I-Premise
185	a	_	_	I-Premise
186	week	_	_	I-Premise
187	,	_	_	I-Premise
188	2	_	_	I-Premise
189	.	_	_	I-Premise

190	6	_	_	I-Premise
191	(	_	_	I-Premise
192	1	_	_	I-Premise
193	.	_	_	I-Premise

194	6	_	_	I-Premise
195	to	_	_	I-Premise
196	3	_	_	I-Premise
197	.	_	_	I-Premise

198	7	_	_	I-Premise
199	)	_	_	I-Premise
200	for	_	_	I-Premise
201	shoulder	_	_	I-Premise
202	mobility	_	_	I-Premise
203	,	_	_	I-Premise
204	2	_	_	I-Premise
205	.	_	_	I-Premise

206	5	_	_	I-Premise
207	(	_	_	I-Premise
208	1	_	_	I-Premise
209	.	_	_	I-Premise

210	0	_	_	I-Premise
211	to	_	_	I-Premise
212	3	_	_	I-Premise
213	.	_	_	I-Premise

214	9	_	_	I-Premise
215	)	_	_	I-Premise
216	for	_	_	I-Premise
217	breast	_	_	I-Premise
218	cancer	_	_	I-Premise
219	specific	_	_	I-Premise
220	subscale	_	_	I-Premise
221	of	_	_	I-Premise
222	quality	_	_	I-Premise
223	of	_	_	I-Premise
224	life	_	_	I-Premise
225	,	_	_	I-Premise
226	and	_	_	I-Premise
227	4	_	_	I-Premise
228	.	_	_	I-Premise

229	0	_	_	I-Premise
230	(	_	_	I-Premise
231	1	_	_	I-Premise
232	.	_	_	I-Premise

233	8	_	_	I-Premise
234	to	_	_	I-Premise
235	6	_	_	I-Premise
236	.	_	_	I-Premise

237	3	_	_	I-Premise
238	)	_	_	I-Premise
239	for	_	_	I-Premise
240	positive	_	_	I-Premise
241	mood	_	_	I-Premise
242	.	_	_	I-Premise

243	No	_	_	B-Premise
244	significant	_	_	I-Premise
245	effect	_	_	I-Premise
246	was	_	_	I-Premise
247	seen	_	_	I-Premise
248	for	_	_	I-Premise
249	general	_	_	I-Premise
250	quality	_	_	I-Premise
251	of	_	_	I-Premise
252	life	_	_	I-Premise
253	(	_	_	I-Premise
254	FACT	_	_	I-Premise
255	-	_	_	I-Premise
256	G	_	_	I-Premise
257	)	_	_	I-Premise
258	,	_	_	I-Premise
259	which	_	_	I-Premise
260	was	_	_	I-Premise
261	the	_	_	I-Premise
262	primary	_	_	I-Premise
263	outcome	_	_	I-Premise
264	.	_	_	I-Premise

265	At	_	_	B-Premise
266	the	_	_	I-Premise
267	six	_	_	I-Premise
268	month	_	_	I-Premise
269	follow	_	_	I-Premise
270	-	_	_	I-Premise
271	up	_	_	I-Premise
272	,	_	_	I-Premise
273	most	_	_	I-Premise
274	of	_	_	I-Premise
275	these	_	_	I-Premise
276	effects	_	_	I-Premise
277	were	_	_	I-Premise
278	maintained	_	_	I-Premise
279	and	_	_	I-Premise
280	an	_	_	I-Premise
281	intervention	_	_	I-Premise
282	effect	_	_	I-Premise
283	for	_	_	I-Premise
284	breast	_	_	I-Premise
285	cancer	_	_	I-Premise
286	specific	_	_	I-Premise
287	quality	_	_	I-Premise
288	of	_	_	I-Premise
289	life	_	_	I-Premise
290	emerged	_	_	I-Premise
291	.	_	_	I-Premise

292	No	_	_	B-Premise
293	adverse	_	_	I-Premise
294	effects	_	_	I-Premise
295	were	_	_	I-Premise
296	noted	_	_	I-Premise
297	.	_	_	I-Premise

298	Supervised	_	_	B-Claim
299	group	_	_	I-Claim
300	exercise	_	_	I-Claim
301	provided	_	_	I-Claim
302	functional	_	_	I-Claim
303	and	_	_	I-Claim
304	psychological	_	_	I-Claim
305	benefit	_	_	I-Claim
306	after	_	_	I-Claim
307	a	_	_	I-Claim
308	12	_	_	I-Claim
309	week	_	_	I-Claim
310	intervention	_	_	I-Claim
311	and	_	_	I-Claim
312	six	_	_	I-Claim
313	months	_	_	I-Claim
314	later	_	_	I-Claim
315	.	_	_	I-Claim

316	Clinicians	_	_	B-Claim
317	should	_	_	I-Claim
318	encourage	_	_	I-Claim
319	activity	_	_	I-Claim
320	for	_	_	I-Claim
321	their	_	_	I-Claim
322	patients	_	_	I-Claim
323	.	_	_	I-Claim

324	Policy	_	_	B-Claim
325	makers	_	_	I-Claim
326	should	_	_	I-Claim
327	consider	_	_	I-Claim
328	the	_	_	I-Claim
329	inclusion	_	_	I-Claim
330	of	_	_	I-Claim
331	exercise	_	_	I-Claim
332	opportunities	_	_	I-Claim
333	in	_	_	I-Claim
334	cancer	_	_	I-Claim
335	rehabilitation	_	_	I-Claim
336	services	_	_	I-Claim
337	.	_	_	I-Claim


0	Evidence	_	_	B-Claim
1	suggests	_	_	I-Claim
2	that	_	_	I-Claim
3	the	_	_	I-Claim
4	re	_	_	I-Claim
5	-	_	_	I-Claim
6	entry	_	_	I-Claim
7	phase	_	_	I-Claim
8	(	_	_	I-Claim
9	ie	_	_	I-Claim
10	,	_	_	I-Claim
11	early	_	_	I-Claim
12	period	_	_	I-Claim
13	after	_	_	I-Claim
14	medical	_	_	I-Claim
15	treatment	_	_	I-Claim
16	completion	_	_	I-Claim
17	)	_	_	I-Claim
18	presents	_	_	I-Claim
19	distinct	_	_	I-Claim
20	challenges	_	_	I-Claim
21	for	_	_	I-Claim
22	cancer	_	_	I-Claim
23	patients	_	_	I-Claim
24	.	_	_	I-Claim

25	To	_	_	O
26	facilitate	_	_	O
27	the	_	_	O
28	transition	_	_	O
29	to	_	_	O
30	recovery	_	_	O
31	,	_	_	O
32	we	_	_	O
33	conducted	_	_	O
34	the	_	_	O
35	Moving	_	_	O
36	Beyond	_	_	O
37	Cancer	_	_	O
38	(	_	_	O
39	MBC	_	_	O
40	)	_	_	O
41	trial	_	_	O
42	,	_	_	O
43	a	_	_	O
44	multisite	_	_	O
45	,	_	_	O
46	randomized	_	_	O
47	,	_	_	O
48	controlled	_	_	O
49	trial	_	_	O
50	of	_	_	O
51	psychoeducational	_	_	O
52	interventions	_	_	O
53	for	_	_	O
54	breast	_	_	O
55	cancer	_	_	O
56	patients	_	_	O
57	.	_	_	O

58	Breast	_	_	O
59	cancer	_	_	O
60	patients	_	_	O
61	were	_	_	O
62	registered	_	_	O
63	within	_	_	O
64	6	_	_	O
65	weeks	_	_	O
66	after	_	_	O
67	surgery	_	_	O
68	.	_	_	O

69	After	_	_	O
70	medical	_	_	O
71	treatment	_	_	O
72	,	_	_	O
73	they	_	_	O
74	completed	_	_	O
75	baseline	_	_	O
76	measures	_	_	O
77	and	_	_	O
78	were	_	_	O
79	randomly	_	_	O
80	assigned	_	_	O
81	to	_	_	O
82	standard	_	_	O
83	National	_	_	O
84	Cancer	_	_	O
85	Institute	_	_	O
86	print	_	_	O
87	material	_	_	O
88	(	_	_	O
89	CTL	_	_	O
90	)	_	_	O
91	;	_	_	O
92	standard	_	_	O
93	print	_	_	O
94	material	_	_	O
95	and	_	_	O
96	peer	_	_	O
97	-	_	_	O
98	modeling	_	_	O
99	videotape	_	_	O
100	(	_	_	O
101	VID	_	_	O
102	)	_	_	O
103	;	_	_	O
104	or	_	_	O
105	standard	_	_	O
106	print	_	_	O
107	material	_	_	O
108	,	_	_	O
109	videotape	_	_	O
110	,	_	_	O
111	two	_	_	O
112	sessions	_	_	O
113	with	_	_	O
114	a	_	_	O
115	trained	_	_	O
116	cancer	_	_	O
117	educator	_	_	O
118	,	_	_	O
119	and	_	_	O
120	informational	_	_	O
121	workbook	_	_	O
122	(	_	_	O
123	EDU	_	_	O
124	)	_	_	O
125	.	_	_	O

126	Two	_	_	O
127	primary	_	_	O
128	end	_	_	O
129	points	_	_	O
130	were	_	_	O
131	examined	_	_	O
132	:	_	_	O
133	energy	_	_	O
134	/	_	_	O
135	fatigue	_	_	O
136	and	_	_	O
137	cancer	_	_	O
138	-	_	_	O
139	specific	_	_	O
140	distress	_	_	O
141	.	_	_	O

142	Secondary	_	_	O
143	end	_	_	O
144	points	_	_	O
145	were	_	_	O
146	depressive	_	_	O
147	symptoms	_	_	O
148	and	_	_	O
149	post	_	_	O
150	-	_	_	O
151	traumatic	_	_	O
152	growth	_	_	O
153	.	_	_	O

154	Perceived	_	_	O
155	preparedness	_	_	O
156	for	_	_	O
157	re	_	_	O
158	-	_	_	O
159	entry	_	_	O
160	was	_	_	O
161	analyzed	_	_	O
162	as	_	_	O
163	a	_	_	O
164	moderator	_	_	O
165	of	_	_	O
166	effects	_	_	O
167	.	_	_	O

168	Of	_	_	O
169	558	_	_	O
170	women	_	_	O
171	randomly	_	_	O
172	assigned	_	_	O
173	to	_	_	O
174	treatment	_	_	O
175	,	_	_	O
176	418	_	_	O
177	completed	_	_	O
178	the	_	_	O
179	6	_	_	O
180	-	_	_	O
181	month	_	_	O
182	assessment	_	_	O
183	and	_	_	O
184	399	_	_	O
185	completed	_	_	O
186	the	_	_	O
187	12	_	_	O
188	-	_	_	O
189	month	_	_	O
190	assessment	_	_	O
191	.	_	_	O

192	In	_	_	B-Premise
193	analyses	_	_	I-Premise
194	controlling	_	_	I-Premise
195	for	_	_	I-Premise
196	study	_	_	I-Premise
197	site	_	_	I-Premise
198	and	_	_	I-Premise
199	baseline	_	_	I-Premise
200	depressive	_	_	I-Premise
201	symptoms	_	_	I-Premise
202	,	_	_	I-Premise
203	VID	_	_	I-Premise
204	produced	_	_	I-Premise
205	significant	_	_	I-Premise
206	improvement	_	_	I-Premise
207	in	_	_	I-Premise
208	energy	_	_	I-Premise
209	/	_	_	I-Premise
210	fatigue	_	_	I-Premise
211	at	_	_	I-Premise
212	6	_	_	I-Premise
213	months	_	_	I-Premise
214	relative	_	_	I-Premise
215	to	_	_	I-Premise
216	CTL	_	_	I-Premise
217	,	_	_	I-Premise
218	particularly	_	_	I-Premise
219	among	_	_	I-Premise
220	women	_	_	I-Premise
221	who	_	_	I-Premise
222	felt	_	_	I-Premise
223	less	_	_	I-Premise
224	prepared	_	_	I-Premise
225	for	_	_	I-Premise
226	re	_	_	I-Premise
227	-	_	_	I-Premise
228	entry	_	_	I-Premise
229	at	_	_	I-Premise
230	baseline	_	_	I-Premise
231	.	_	_	I-Premise

232	No	_	_	B-Premise
233	significant	_	_	I-Premise
234	main	_	_	I-Premise
235	effect	_	_	I-Premise
236	of	_	_	I-Premise
237	the	_	_	I-Premise
238	interventions	_	_	I-Premise
239	emerged	_	_	I-Premise
240	on	_	_	I-Premise
241	cancer	_	_	I-Premise
242	-	_	_	I-Premise
243	specific	_	_	I-Premise
244	distress	_	_	I-Premise
245	,	_	_	I-Premise
246	but	_	_	B-Premise
247	EDU	_	_	I-Premise
248	prompted	_	_	I-Premise
249	greater	_	_	I-Premise
250	reduction	_	_	I-Premise
251	in	_	_	I-Premise
252	this	_	_	I-Premise
253	outcome	_	_	I-Premise
254	relative	_	_	I-Premise
255	to	_	_	I-Premise
256	CTL	_	_	I-Premise
257	at	_	_	I-Premise
258	6	_	_	I-Premise
259	months	_	_	I-Premise
260	for	_	_	I-Premise
261	patients	_	_	I-Premise
262	who	_	_	I-Premise
263	felt	_	_	I-Premise
264	more	_	_	I-Premise
265	prepared	_	_	I-Premise
266	for	_	_	I-Premise
267	re	_	_	I-Premise
268	-	_	_	I-Premise
269	entry	_	_	I-Premise
270	.	_	_	I-Premise

271	Between	_	_	B-Premise
272	-	_	_	I-Premise
273	group	_	_	I-Premise
274	differences	_	_	I-Premise
275	in	_	_	I-Premise
276	the	_	_	I-Premise
277	primary	_	_	I-Premise
278	outcomes	_	_	I-Premise
279	were	_	_	I-Premise
280	not	_	_	I-Premise
281	significant	_	_	I-Premise
282	at	_	_	I-Premise
283	12	_	_	I-Premise
284	months	_	_	I-Premise
285	,	_	_	I-Premise
286	and	_	_	B-Premise
287	no	_	_	I-Premise
288	significant	_	_	I-Premise
289	effects	_	_	I-Premise
290	emerged	_	_	I-Premise
291	on	_	_	I-Premise
292	the	_	_	I-Premise
293	secondary	_	_	I-Premise
294	end	_	_	I-Premise
295	points	_	_	I-Premise
296	.	_	_	I-Premise

297	A	_	_	B-Claim
298	peer	_	_	I-Claim
299	-	_	_	I-Claim
300	modeling	_	_	I-Claim
301	videotape	_	_	I-Claim
302	can	_	_	I-Claim
303	accelerate	_	_	I-Claim
304	the	_	_	I-Claim
305	recovery	_	_	I-Claim
306	of	_	_	I-Claim
307	energy	_	_	I-Claim
308	during	_	_	I-Claim
309	the	_	_	I-Claim
310	re	_	_	I-Claim
311	-	_	_	I-Claim
312	entry	_	_	I-Claim
313	phase	_	_	I-Claim
314	in	_	_	I-Claim
315	women	_	_	I-Claim
316	treated	_	_	I-Claim
317	for	_	_	I-Claim
318	breast	_	_	I-Claim
319	cancer	_	_	I-Claim
320	,	_	_	I-Claim
321	particularly	_	_	I-Claim
322	among	_	_	I-Claim
323	those	_	_	I-Claim
324	who	_	_	I-Claim
325	feel	_	_	I-Claim
326	less	_	_	I-Claim
327	prepared	_	_	I-Claim
328	for	_	_	I-Claim
329	re	_	_	I-Claim
330	-	_	_	I-Claim
331	entry	_	_	I-Claim
332	.	_	_	I-Claim


0	The	_	_	B-Claim
1	combination	_	_	I-Claim
2	of	_	_	I-Claim
3	etoposide	_	_	I-Claim
4	plus	_	_	I-Claim
5	cisplatin	_	_	I-Claim
6	(	_	_	I-Claim
7	EP	_	_	I-Claim
8	)	_	_	I-Claim
9	is	_	_	I-Claim
10	considered	_	_	I-Claim
11	to	_	_	I-Claim
12	be	_	_	I-Claim
13	standard	_	_	I-Claim
14	therapy	_	_	I-Claim
15	for	_	_	I-Claim
16	small	_	_	I-Claim
17	-	_	_	I-Claim
18	cell	_	_	I-Claim
19	lung	_	_	I-Claim
20	cancer	_	_	I-Claim
21	(	_	_	I-Claim
22	SCLC	_	_	I-Claim
23	)	_	_	I-Claim
24	.	_	_	I-Claim

25	To	_	_	O
26	determine	_	_	O
27	whether	_	_	O
28	drug	_	_	O
29	intensification	_	_	O
30	improves	_	_	O
31	survival	_	_	O
32	of	_	_	O
33	patients	_	_	O
34	with	_	_	O
35	extensive	_	_	O
36	SCLC	_	_	O
37	,	_	_	O
38	we	_	_	O
39	compared	_	_	O
40	this	_	_	O
41	treatment	_	_	O
42	with	_	_	O
43	a	_	_	O
44	four	_	_	O
45	-	_	_	O
46	drug	_	_	O
47	regimen	_	_	O
48	containing	_	_	O
49	EP	_	_	O
50	plus	_	_	O
51	cyclophosphamide	_	_	O
52	and	_	_	O
53	4	_	_	O
54	'	_	_	O
55	-	_	_	O
56	epidoxorubicin	_	_	O
57	(	_	_	O
58	PCDE	_	_	O
59	)	_	_	O
60	.	_	_	O

61	In	_	_	O
62	a	_	_	O
63	phase	_	_	O
64	III	_	_	O
65	clinical	_	_	O
66	trial	_	_	O
67	organized	_	_	O
68	by	_	_	O
69	the	_	_	O
70	French	_	_	O
71	Federation	_	_	O
72	of	_	_	O
73	Cancer	_	_	O
74	Institutes	_	_	O
75	,	_	_	O
76	patients	_	_	O
77	were	_	_	O
78	randomly	_	_	O
79	assigned	_	_	O
80	to	_	_	O
81	receive	_	_	O
82	either	_	_	O
83	EP	_	_	O
84	(	_	_	O
85	n	_	_	O
86	=	_	_	O
87	109	_	_	O
88	;	_	_	O
89	etoposide	_	_	O
90	at	_	_	O
91	a	_	_	O
92	dose	_	_	O
93	of	_	_	O
94	100	_	_	O
95	mg	_	_	O
96	/	_	_	O
97	m	_	_	O
98	(	_	_	O
99	2	_	_	O
100	)	_	_	O
101	on	_	_	O
102	days	_	_	O
103	1	_	_	O
104	-	_	_	O
105	3	_	_	O
106	plus	_	_	O
107	cisplatin	_	_	O
108	at	_	_	O
109	100	_	_	O
110	mg	_	_	O
111	/	_	_	O
112	m	_	_	O
113	(	_	_	O
114	2	_	_	O
115	)	_	_	O
116	on	_	_	O
117	day	_	_	O
118	2	_	_	O
119	)	_	_	O
120	or	_	_	O
121	PCDE	_	_	O
122	(	_	_	O
123	n	_	_	O
124	=	_	_	O
125	117	_	_	O
126	;	_	_	O
127	etoposide	_	_	O
128	and	_	_	O
129	cisplatin	_	_	O
130	given	_	_	O
131	as	_	_	O
132	in	_	_	O
133	EP	_	_	O
134	plus	_	_	O
135	cyclophosphamide	_	_	O
136	at	_	_	O
137	400	_	_	O
138	mg	_	_	O
139	/	_	_	O
140	m	_	_	O
141	(	_	_	O
142	2	_	_	O
143	)	_	_	O
144	on	_	_	O
145	days	_	_	O
146	1	_	_	O
147	-	_	_	O
148	3	_	_	O
149	and	_	_	O
150	4	_	_	O
151	'	_	_	O
152	-	_	_	O
153	epidoxorubicin	_	_	O
154	at	_	_	O
155	40	_	_	O
156	mg	_	_	O
157	/	_	_	O
158	m	_	_	O
159	(	_	_	O
160	2	_	_	O
161	)	_	_	O
162	on	_	_	O
163	day	_	_	O
164	1	_	_	O
165	)	_	_	O
166	every	_	_	O
167	4	_	_	O
168	weeks	_	_	O
169	.	_	_	O

170	Both	_	_	O
171	groups	_	_	O
172	received	_	_	O
173	a	_	_	O
174	total	_	_	O
175	of	_	_	O
176	six	_	_	O
177	cycles	_	_	O
178	.	_	_	O

179	Survival	_	_	O
180	differences	_	_	O
181	were	_	_	O
182	analyzed	_	_	O
183	by	_	_	O
184	Wilcoxon	_	_	O
185	and	_	_	O
186	log	_	_	O
187	-	_	_	O
188	rank	_	_	O
189	tests	_	_	O
190	.	_	_	O

191	Associations	_	_	O
192	of	_	_	O
193	treatment	_	_	O
194	group	_	_	O
195	and	_	_	O
196	putative	_	_	O
197	prognostic	_	_	O
198	variables	_	_	O
199	with	_	_	O
200	survival	_	_	O
201	were	_	_	O
202	tested	_	_	O
203	in	_	_	O
204	the	_	_	O
205	Cox	_	_	O
206	proportional	_	_	O
207	hazards	_	_	O
208	model	_	_	O
209	.	_	_	O

210	Quality	_	_	O
211	of	_	_	O
212	life	_	_	O
213	was	_	_	O
214	assessed	_	_	O
215	from	_	_	O
216	the	_	_	O
217	responses	_	_	O
218	to	_	_	O
219	the	_	_	O
220	European	_	_	O
221	Organization	_	_	O
222	for	_	_	O
223	Research	_	_	O
224	and	_	_	O
225	Treatment	_	_	O
226	of	_	_	O
227	Cancer	_	_	O
228	quality	_	_	O
229	-	_	_	O
230	of	_	_	O
231	-	_	_	O
232	life	_	_	O
233	questionnaire	_	_	O
234	(	_	_	O
235	C30	_	_	O
236	,	_	_	O
237	health	_	_	O
238	status	_	_	O
239	and	_	_	O
240	lung	_	_	O
241	cancer	_	_	O
242	module	_	_	O
243	13	_	_	O
244	)	_	_	O
245	.	_	_	O

246	All	_	_	O
247	statistical	_	_	O
248	tests	_	_	O
249	were	_	_	O
250	two	_	_	O
251	-	_	_	O
252	sided	_	_	O
253	.	_	_	O

254	Patients	_	_	B-Premise
255	in	_	_	I-Premise
256	the	_	_	I-Premise
257	PCDE	_	_	I-Premise
258	arm	_	_	I-Premise
259	had	_	_	I-Premise
260	a	_	_	I-Premise
261	statistically	_	_	I-Premise
262	significant	_	_	I-Premise
263	higher	_	_	I-Premise
264	frequency	_	_	I-Premise
265	of	_	_	I-Premise
266	combined	_	_	I-Premise
267	complete	_	_	I-Premise
268	plus	_	_	I-Premise
269	partial	_	_	I-Premise
270	responses	_	_	I-Premise
271	compared	_	_	I-Premise
272	with	_	_	I-Premise
273	those	_	_	I-Premise
274	in	_	_	I-Premise
275	the	_	_	I-Premise
276	EP	_	_	I-Premise
277	arm	_	_	I-Premise
278	(	_	_	I-Premise
279	21	_	_	I-Premise
280	%	_	_	I-Premise
281	plus	_	_	I-Premise
282	55	_	_	I-Premise
283	%	_	_	I-Premise
284	versus	_	_	I-Premise
285	13	_	_	I-Premise
286	%	_	_	I-Premise
287	plus	_	_	I-Premise
288	48	_	_	I-Premise
289	%	_	_	I-Premise
290	,	_	_	I-Premise
291	respectively	_	_	I-Premise
292	;	_	_	I-Premise
293	P	_	_	I-Premise
294	=	_	_	I-Premise
295	.	_	_	I-Premise

296	02	_	_	I-Premise
297	for	_	_	I-Premise
298	difference	_	_	I-Premise
299	in	_	_	I-Premise
300	combined	_	_	I-Premise
301	objective	_	_	I-Premise
302	responses	_	_	I-Premise
303	)	_	_	I-Premise
304	.	_	_	I-Premise

305	Patients	_	_	B-Premise
306	in	_	_	I-Premise
307	the	_	_	I-Premise
308	PCDE	_	_	I-Premise
309	arm	_	_	I-Premise
310	survived	_	_	I-Premise
311	longer	_	_	I-Premise
312	than	_	_	I-Premise
313	those	_	_	I-Premise
314	in	_	_	I-Premise
315	the	_	_	I-Premise
316	EP	_	_	I-Premise
317	arm	_	_	I-Premise
318	(	_	_	I-Premise
319	1	_	_	I-Premise
320	-	_	_	I-Premise
321	year	_	_	I-Premise
322	survival	_	_	I-Premise
323	rate	_	_	I-Premise
324	:	_	_	I-Premise
325	40	_	_	I-Premise
326	%	_	_	I-Premise
327	and	_	_	I-Premise
328	29	_	_	I-Premise
329	%	_	_	I-Premise
330	,	_	_	I-Premise
331	respectively	_	_	I-Premise
332	;	_	_	I-Premise
333	median	_	_	I-Premise
334	survival	_	_	I-Premise
335	:	_	_	I-Premise
336	10	_	_	I-Premise
337	.	_	_	I-Premise

338	5	_	_	I-Premise
339	and	_	_	I-Premise
340	9	_	_	I-Premise
341	.	_	_	I-Premise

342	3	_	_	I-Premise
343	months	_	_	I-Premise
344	,	_	_	I-Premise
345	respectively	_	_	I-Premise
346	;	_	_	I-Premise
347	log	_	_	I-Premise
348	-	_	_	I-Premise
349	rank	_	_	I-Premise
350	P	_	_	I-Premise
351	=	_	_	I-Premise
352	.	_	_	I-Premise

353	0067	_	_	I-Premise
354	)	_	_	I-Premise
355	.	_	_	I-Premise

356	In	_	_	B-Premise
357	the	_	_	I-Premise
358	Cox	_	_	I-Premise
359	model	_	_	I-Premise
360	,	_	_	I-Premise
361	the	_	_	I-Premise
362	relative	_	_	I-Premise
363	risk	_	_	I-Premise
364	of	_	_	I-Premise
365	death	_	_	I-Premise
366	for	_	_	I-Premise
367	patients	_	_	I-Premise
368	in	_	_	I-Premise
369	the	_	_	I-Premise
370	PCDE	_	_	I-Premise
371	arm	_	_	I-Premise
372	compared	_	_	I-Premise
373	with	_	_	I-Premise
374	those	_	_	I-Premise
375	in	_	_	I-Premise
376	the	_	_	I-Premise
377	EP	_	_	I-Premise
378	arm	_	_	I-Premise
379	was	_	_	I-Premise
380	0	_	_	I-Premise
381	.	_	_	I-Premise

382	70	_	_	I-Premise
383	(	_	_	I-Premise
384	95	_	_	I-Premise
385	%	_	_	I-Premise
386	confidence	_	_	I-Premise
387	interval	_	_	I-Premise
388	=	_	_	I-Premise
389	0	_	_	I-Premise
390	.	_	_	I-Premise

391	51	_	_	I-Premise
392	to	_	_	I-Premise
393	0	_	_	I-Premise
394	.	_	_	I-Premise

395	95	_	_	I-Premise
396	)	_	_	I-Premise
397	;	_	_	I-Premise
398	the	_	_	B-Premise
399	disease	_	_	I-Premise
400	also	_	_	I-Premise
401	progressed	_	_	I-Premise
402	more	_	_	I-Premise
403	slowly	_	_	I-Premise
404	in	_	_	I-Premise
405	patients	_	_	I-Premise
406	in	_	_	I-Premise
407	the	_	_	I-Premise
408	PCDE	_	_	I-Premise
409	arm	_	_	I-Premise
410	.	_	_	I-Premise

411	Hematologic	_	_	B-Premise
412	toxicity	_	_	I-Premise
413	was	_	_	I-Premise
414	higher	_	_	I-Premise
415	in	_	_	I-Premise
416	the	_	_	I-Premise
417	PCDE	_	_	I-Premise
418	arm	_	_	I-Premise
419	(	_	_	I-Premise
420	22	_	_	I-Premise
421	%	_	_	I-Premise
422	with	_	_	I-Premise
423	documented	_	_	I-Premise
424	infections	_	_	I-Premise
425	compared	_	_	I-Premise
426	with	_	_	I-Premise
427	8	_	_	I-Premise
428	%	_	_	I-Premise
429	in	_	_	I-Premise
430	the	_	_	I-Premise
431	EP	_	_	I-Premise
432	arm	_	_	I-Premise
433	;	_	_	I-Premise
434	P	_	_	I-Premise
435	=	_	_	I-Premise
436	.	_	_	I-Premise

437	0038	_	_	I-Premise
438	)	_	_	I-Premise
439	,	_	_	I-Premise
440	and	_	_	O
441	the	_	_	B-Premise
442	toxicity	_	_	I-Premise
443	-	_	_	I-Premise
444	related	_	_	I-Premise
445	death	_	_	I-Premise
446	rate	_	_	I-Premise
447	was	_	_	I-Premise
448	9	_	_	I-Premise
449	%	_	_	I-Premise
450	in	_	_	I-Premise
451	the	_	_	I-Premise
452	PCDE	_	_	I-Premise
453	arm	_	_	I-Premise
454	versus	_	_	I-Premise
455	5	_	_	I-Premise
456	.	_	_	I-Premise

457	5	_	_	I-Premise
458	%	_	_	I-Premise
459	in	_	_	I-Premise
460	the	_	_	I-Premise
461	EP	_	_	I-Premise
462	arm	_	_	I-Premise
463	(	_	_	I-Premise
464	P	_	_	I-Premise
465	=	_	_	I-Premise
466	.	_	_	I-Premise

467	22	_	_	I-Premise
468	)	_	_	I-Premise
469	.	_	_	I-Premise

470	The	_	_	B-Claim
471	global	_	_	I-Claim
472	health	_	_	I-Claim
473	status	_	_	I-Claim
474	showed	_	_	I-Claim
475	similar	_	_	I-Claim
476	improvement	_	_	I-Claim
477	in	_	_	I-Claim
478	both	_	_	I-Claim
479	arms	_	_	I-Claim
480	during	_	_	I-Claim
481	treatment	_	_	I-Claim
482	.	_	_	I-Claim

483	Compared	_	_	B-Claim
484	with	_	_	I-Claim
485	the	_	_	I-Claim
486	EP	_	_	I-Claim
487	regimen	_	_	I-Claim
488	,	_	_	I-Claim
489	the	_	_	I-Claim
490	PCDE	_	_	I-Claim
491	regimen	_	_	I-Claim
492	yielded	_	_	I-Claim
493	higher	_	_	I-Claim
494	response	_	_	I-Claim
495	rates	_	_	I-Claim
496	and	_	_	I-Claim
497	better	_	_	I-Claim
498	survival	_	_	I-Claim
499	rates	_	_	I-Claim
500	in	_	_	I-Claim
501	patients	_	_	I-Claim
502	with	_	_	I-Claim
503	extensive	_	_	I-Claim
504	SCLC	_	_	I-Claim
505	without	_	_	I-Claim
506	affecting	_	_	I-Claim
507	the	_	_	I-Claim
508	quality	_	_	I-Claim
509	of	_	_	I-Claim
510	life	_	_	I-Claim
511	of	_	_	I-Claim
512	the	_	_	I-Claim
513	patients	_	_	I-Claim
514	during	_	_	I-Claim
515	chemotherapy	_	_	I-Claim
516	.	_	_	I-Claim


0	Behavioral	_	_	O
1	symptoms	_	_	O
2	are	_	_	O
3	common	_	_	O
4	in	_	_	O
5	breast	_	_	O
6	cancer	_	_	O
7	survivors	_	_	O
8	,	_	_	O
9	including	_	_	O
10	disturbances	_	_	O
11	in	_	_	O
12	energy	_	_	O
13	,	_	_	O
14	sleep	_	_	O
15	,	_	_	O
16	and	_	_	O
17	mood	_	_	O
18	,	_	_	O
19	though	_	_	O
20	few	_	_	O
21	risk	_	_	O
22	factors	_	_	O
23	for	_	_	O
24	these	_	_	O
25	negative	_	_	O
26	outcomes	_	_	O
27	have	_	_	O
28	been	_	_	O
29	identified	_	_	O
30	.	_	_	O

31	Our	_	_	O
32	study	_	_	O
33	examined	_	_	O
34	intrusive	_	_	O
35	thoughts	_	_	O
36	as	_	_	O
37	a	_	_	O
38	predictor	_	_	O
39	of	_	_	O
40	lingering	_	_	O
41	symptoms	_	_	O
42	in	_	_	O
43	breast	_	_	O
44	cancer	_	_	O
45	survivors	_	_	O
46	in	_	_	O
47	the	_	_	O
48	year	_	_	O
49	following	_	_	O
50	treatment	_	_	O
51	.	_	_	O

52	Data	_	_	O
53	come	_	_	O
54	from	_	_	O
55	the	_	_	O
56	Moving	_	_	O
57	Beyond	_	_	O
58	Cancer	_	_	O
59	psychoeducational	_	_	O
60	intervention	_	_	O
61	trial	_	_	O
62	,	_	_	O
63	aimed	_	_	O
64	at	_	_	O
65	easing	_	_	O
66	the	_	_	O
67	transition	_	_	O
68	from	_	_	O
69	patient	_	_	O
70	to	_	_	O
71	survivor	_	_	O
72	.	_	_	O

73	Women	_	_	O
74	(	_	_	O
75	n	_	_	O
76	=	_	_	O
77	558	_	_	O
78	)	_	_	O
79	completed	_	_	O
80	psychosocial	_	_	O
81	questionnaires	_	_	O
82	within	_	_	O
83	4	_	_	O
84	weeks	_	_	O
85	posttreatment	_	_	O
86	and	_	_	O
87	again	_	_	O
88	2	_	_	O
89	,	_	_	O
90	6	_	_	O
91	,	_	_	O
92	and	_	_	O
93	12	_	_	O
94	months	_	_	O
95	later	_	_	O
96	.	_	_	O

97	We	_	_	O
98	examined	_	_	O
99	intrusive	_	_	O
100	thoughts	_	_	O
101	about	_	_	O
102	cancer	_	_	O
103	at	_	_	O
104	the	_	_	O
105	baseline	_	_	O
106	assessment	_	_	O
107	as	_	_	O
108	a	_	_	O
109	predictor	_	_	O
110	of	_	_	O
111	fatigue	_	_	O
112	,	_	_	O
113	sleep	_	_	O
114	problems	_	_	O
115	,	_	_	O
116	pain	_	_	O
117	,	_	_	O
118	breast	_	_	O
119	cancer	_	_	O
120	-	_	_	O
121	specific	_	_	O
122	symptoms	_	_	O
123	,	_	_	O
124	depressive	_	_	O
125	symptoms	_	_	O
126	,	_	_	O
127	negative	_	_	O
128	affect	_	_	O
129	,	_	_	O
130	and	_	_	O
131	quality	_	_	O
132	of	_	_	O
133	life	_	_	O
134	using	_	_	O
135	growth	_	_	O
136	curve	_	_	O
137	modeling	_	_	O
138	,	_	_	O
139	controlling	_	_	O
140	for	_	_	O
141	study	_	_	O
142	condition	_	_	O
143	and	_	_	O
144	other	_	_	O
145	covariates	_	_	O
146	.	_	_	O

147	Intrusive	_	_	B-Premise
148	thoughts	_	_	I-Premise
149	were	_	_	I-Premise
150	associated	_	_	I-Premise
151	with	_	_	I-Premise
152	higher	_	_	I-Premise
153	levels	_	_	I-Premise
154	of	_	_	I-Premise
155	all	_	_	I-Premise
156	symptoms	_	_	I-Premise
157	at	_	_	I-Premise
158	baseline	_	_	I-Premise
159	and	_	_	I-Premise
160	at	_	_	I-Premise
161	the	_	_	I-Premise
162	12	_	_	I-Premise
163	-	_	_	I-Premise
164	month	_	_	I-Premise
165	assessment	_	_	I-Premise
166	.	_	_	I-Premise

167	Intrusive	_	_	B-Premise
168	thoughts	_	_	I-Premise
169	also	_	_	I-Premise
170	influenced	_	_	I-Premise
171	the	_	_	I-Premise
172	trajectory	_	_	I-Premise
173	of	_	_	I-Premise
174	pain	_	_	I-Premise
175	,	_	_	I-Premise
176	depressive	_	_	I-Premise
177	symptoms	_	_	I-Premise
178	,	_	_	I-Premise
179	negative	_	_	I-Premise
180	affect	_	_	I-Premise
181	,	_	_	I-Premise
182	and	_	_	I-Premise
183	physical	_	_	I-Premise
184	functioning	_	_	I-Premise
185	over	_	_	I-Premise
186	time	_	_	I-Premise
187	;	_	_	I-Premise
188	women	_	_	B-Premise
189	with	_	_	I-Premise
190	higher	_	_	I-Premise
191	intrusions	_	_	I-Premise
192	at	_	_	I-Premise
193	baseline	_	_	I-Premise
194	started	_	_	I-Premise
195	worse	_	_	I-Premise
196	and	_	_	I-Premise
197	improved	_	_	I-Premise
198	over	_	_	I-Premise
199	time	_	_	I-Premise
200	,	_	_	I-Premise
201	whereas	_	_	I-Premise
202	those	_	_	I-Premise
203	with	_	_	I-Premise
204	lower	_	_	I-Premise
205	intrusions	_	_	I-Premise
206	remained	_	_	I-Premise
207	at	_	_	I-Premise
208	a	_	_	I-Premise
209	constant	_	_	I-Premise
210	,	_	_	I-Premise
211	lower	_	_	I-Premise
212	level	_	_	I-Premise
213	over	_	_	I-Premise
214	time	_	_	I-Premise
215	.	_	_	I-Premise

216	Intrusions	_	_	B-Premise
217	were	_	_	I-Premise
218	not	_	_	I-Premise
219	associated	_	_	I-Premise
220	with	_	_	I-Premise
221	the	_	_	I-Premise
222	trajectory	_	_	I-Premise
223	of	_	_	I-Premise
224	fatigue	_	_	I-Premise
225	,	_	_	I-Premise
226	sleep	_	_	I-Premise
227	,	_	_	I-Premise
228	breast	_	_	I-Premise
229	cancer	_	_	I-Premise
230	-	_	_	I-Premise
231	specific	_	_	I-Premise
232	symptoms	_	_	I-Premise
233	,	_	_	I-Premise
234	or	_	_	I-Premise
235	mental	_	_	I-Premise
236	functioning	_	_	I-Premise
237	;	_	_	I-Premise
238	women	_	_	B-Premise
239	with	_	_	I-Premise
240	higher	_	_	I-Premise
241	intrusions	_	_	I-Premise
242	at	_	_	I-Premise
243	baseline	_	_	I-Premise
244	started	_	_	I-Premise
245	worse	_	_	I-Premise
246	and	_	_	I-Premise
247	remained	_	_	I-Premise
248	worse	_	_	I-Premise
249	over	_	_	I-Premise
250	time	_	_	I-Premise
251	.	_	_	I-Premise

252	Intrusive	_	_	B-Claim
253	thoughts	_	_	I-Claim
254	are	_	_	I-Claim
255	associated	_	_	I-Claim
256	with	_	_	I-Claim
257	enduring	_	_	I-Claim
258	elevations	_	_	I-Claim
259	in	_	_	I-Claim
260	behavioral	_	_	I-Claim
261	symptoms	_	_	I-Claim
262	and	_	_	I-Claim
263	impaired	_	_	I-Claim
264	quality	_	_	I-Claim
265	of	_	_	I-Claim
266	life	_	_	I-Claim
267	in	_	_	I-Claim
268	the	_	_	I-Claim
269	year	_	_	I-Claim
270	after	_	_	I-Claim
271	breast	_	_	I-Claim
272	cancer	_	_	I-Claim
273	treatment	_	_	I-Claim
274	and	_	_	I-Claim
275	may	_	_	I-Claim
276	be	_	_	I-Claim
277	a	_	_	I-Claim
278	risk	_	_	I-Claim
279	factor	_	_	I-Claim
280	for	_	_	I-Claim
281	poor	_	_	I-Claim
282	outcomes	_	_	I-Claim
283	.	_	_	I-Claim


0	The	_	_	B-Claim
1	role	_	_	I-Claim
2	of	_	_	I-Claim
3	high	_	_	I-Claim
4	-	_	_	I-Claim
5	dose	_	_	I-Claim
6	chemotherapy	_	_	I-Claim
7	(	_	_	I-Claim
8	HDCT	_	_	I-Claim
9	)	_	_	I-Claim
10	in	_	_	I-Claim
11	metastatic	_	_	I-Claim
12	breast	_	_	I-Claim
13	cancer	_	_	I-Claim
14	remains	_	_	I-Claim
15	controversial	_	_	I-Claim
16	.	_	_	I-Claim

17	Trials	_	_	B-Claim
18	with	_	_	I-Claim
19	late	_	_	I-Claim
20	intensification	_	_	I-Claim
21	HDCT	_	_	I-Claim
22	have	_	_	I-Claim
23	failed	_	_	I-Claim
24	to	_	_	I-Claim
25	show	_	_	I-Claim
26	an	_	_	I-Claim
27	advantage	_	_	I-Claim
28	in	_	_	I-Claim
29	overall	_	_	I-Claim
30	survival	_	_	I-Claim
31	.	_	_	I-Claim

32	This	_	_	O
33	study	_	_	O
34	was	_	_	O
35	initiated	_	_	O
36	to	_	_	O
37	compare	_	_	O
38	up	_	_	O
39	-	_	_	O
40	front	_	_	O
41	tandem	_	_	O
42	HDCT	_	_	O
43	and	_	_	O
44	standard	_	_	O
45	combination	_	_	O
46	therapy	_	_	O
47	in	_	_	O
48	patients	_	_	O
49	with	_	_	O
50	metastatic	_	_	O
51	breast	_	_	O
52	cancer	_	_	O
53	.	_	_	O

54	Patients	_	_	O
55	without	_	_	O
56	prior	_	_	O
57	chemotherapy	_	_	O
58	for	_	_	O
59	metastatic	_	_	O
60	disease	_	_	O
61	were	_	_	O
62	randomly	_	_	O
63	assigned	_	_	O
64	to	_	_	O
65	standard	_	_	O
66	combination	_	_	O
67	therapy	_	_	O
68	with	_	_	O
69	doxorubicin	_	_	O
70	and	_	_	O
71	paclitaxel	_	_	O
72	(	_	_	O
73	AT	_	_	O
74	)	_	_	O
75	or	_	_	O
76	double	_	_	O
77	HDCT	_	_	O
78	with	_	_	O
79	cyclophosphamide	_	_	O
80	,	_	_	O
81	mitoxantrone	_	_	O
82	,	_	_	O
83	and	_	_	O
84	etoposide	_	_	O
85	followed	_	_	O
86	by	_	_	O
87	peripheral	_	_	O
88	-	_	_	O
89	blood	_	_	O
90	stem	_	_	O
91	-	_	_	O
92	cell	_	_	O
93	transplantation	_	_	O
94	.	_	_	O

95	HDCT	_	_	O
96	was	_	_	O
97	repeated	_	_	O
98	after	_	_	O
99	6	_	_	O
100	weeks	_	_	O
101	.	_	_	O

102	Patients	_	_	O
103	were	_	_	O
104	stratified	_	_	O
105	by	_	_	O
106	menopausal	_	_	O
107	and	_	_	O
108	hormone	_	_	O
109	-	_	_	O
110	receptor	_	_	O
111	status	_	_	O
112	.	_	_	O

113	The	_	_	O
114	primary	_	_	O
115	objective	_	_	O
116	was	_	_	O
117	to	_	_	O
118	compare	_	_	O
119	complete	_	_	O
120	response	_	_	O
121	(	_	_	O
122	CR	_	_	O
123	)	_	_	O
124	rates	_	_	O
125	.	_	_	O

126	A	_	_	O
127	total	_	_	O
128	of	_	_	O
129	93	_	_	O
130	patients	_	_	O
131	were	_	_	O
132	enrolled	_	_	O
133	onto	_	_	O
134	the	_	_	O
135	trial	_	_	O
136	.	_	_	O

137	Intent	_	_	B-Premise
138	-	_	_	I-Premise
139	to	_	_	I-Premise
140	-	_	_	I-Premise
141	treat	_	_	I-Premise
142	CR	_	_	I-Premise
143	rates	_	_	I-Premise
144	for	_	_	I-Premise
145	patients	_	_	I-Premise
146	randomized	_	_	I-Premise
147	to	_	_	I-Premise
148	HDCT	_	_	I-Premise
149	and	_	_	I-Premise
150	AT	_	_	I-Premise
151	were	_	_	I-Premise
152	12	_	_	I-Premise
153	.	_	_	I-Premise

154	5	_	_	I-Premise
155	%	_	_	I-Premise
156	and	_	_	I-Premise
157	11	_	_	I-Premise
158	.	_	_	I-Premise

159	1	_	_	I-Premise
160	%	_	_	I-Premise
161	,	_	_	I-Premise
162	respectively	_	_	I-Premise
163	(	_	_	I-Premise
164	P	_	_	I-Premise
165	=	_	_	I-Premise
166	.	_	_	I-Premise

167	84	_	_	I-Premise
168	)	_	_	I-Premise
169	.	_	_	I-Premise

170	Objective	_	_	B-Premise
171	response	_	_	I-Premise
172	rates	_	_	I-Premise
173	were	_	_	I-Premise
174	66	_	_	I-Premise
175	.	_	_	I-Premise

176	7	_	_	I-Premise
177	%	_	_	I-Premise
178	for	_	_	I-Premise
179	patients	_	_	I-Premise
180	in	_	_	I-Premise
181	the	_	_	I-Premise
182	high	_	_	I-Premise
183	-	_	_	I-Premise
184	dose	_	_	I-Premise
185	group	_	_	I-Premise
186	and	_	_	I-Premise
187	64	_	_	I-Premise
188	.	_	_	I-Premise

189	4	_	_	I-Premise
190	%	_	_	I-Premise
191	for	_	_	I-Premise
192	patients	_	_	I-Premise
193	in	_	_	I-Premise
194	the	_	_	I-Premise
195	AT	_	_	I-Premise
196	arm	_	_	I-Premise
197	(	_	_	I-Premise
198	P	_	_	I-Premise
199	=	_	_	I-Premise
200	.	_	_	I-Premise

201	82	_	_	I-Premise
202	)	_	_	I-Premise
203	.	_	_	I-Premise

204	In	_	_	B-Premise
205	an	_	_	I-Premise
206	intent	_	_	I-Premise
207	-	_	_	I-Premise
208	to	_	_	I-Premise
209	-	_	_	I-Premise
210	treat	_	_	I-Premise
211	analysis	_	_	I-Premise
212	,	_	_	I-Premise
213	there	_	_	I-Premise
214	were	_	_	I-Premise
215	no	_	_	I-Premise
216	significant	_	_	I-Premise
217	differences	_	_	I-Premise
218	between	_	_	I-Premise
219	the	_	_	I-Premise
220	two	_	_	I-Premise
221	treatments	_	_	I-Premise
222	in	_	_	I-Premise
223	median	_	_	I-Premise
224	time	_	_	I-Premise
225	to	_	_	I-Premise
226	progression	_	_	I-Premise
227	(	_	_	I-Premise
228	HDCT	_	_	I-Premise
229	,	_	_	I-Premise
230	11	_	_	I-Premise
231	.	_	_	I-Premise

232	1	_	_	I-Premise
233	months	_	_	I-Premise
234	;	_	_	I-Premise
235	AT	_	_	I-Premise
236	,	_	_	I-Premise
237	10	_	_	I-Premise
238	.	_	_	I-Premise

239	6	_	_	I-Premise
240	months	_	_	I-Premise
241	;	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	.	_	_	I-Premise

245	67	_	_	I-Premise
246	)	_	_	I-Premise
247	,	_	_	I-Premise
248	duration	_	_	I-Premise
249	of	_	_	I-Premise
250	response	_	_	I-Premise
251	(	_	_	I-Premise
252	HDCT	_	_	I-Premise
253	,	_	_	I-Premise
254	13	_	_	I-Premise
255	.	_	_	I-Premise

256	9	_	_	I-Premise
257	months	_	_	I-Premise
258	;	_	_	I-Premise
259	AT	_	_	I-Premise
260	,	_	_	I-Premise
261	14	_	_	I-Premise
262	.	_	_	I-Premise

263	3	_	_	I-Premise
264	months	_	_	I-Premise
265	;	_	_	I-Premise
266	P	_	_	I-Premise
267	=	_	_	I-Premise
268	.	_	_	I-Premise

269	98	_	_	I-Premise
270	)	_	_	I-Premise
271	,	_	_	I-Premise
272	and	_	_	I-Premise
273	overall	_	_	I-Premise
274	survival	_	_	I-Premise
275	(	_	_	I-Premise
276	HDCT	_	_	I-Premise
277	,	_	_	I-Premise
278	26	_	_	I-Premise
279	.	_	_	I-Premise

280	9	_	_	I-Premise
281	months	_	_	I-Premise
282	;	_	_	I-Premise
283	AT	_	_	I-Premise
284	,	_	_	I-Premise
285	23	_	_	I-Premise
286	.	_	_	I-Premise

287	4	_	_	I-Premise
288	months	_	_	I-Premise
289	;	_	_	I-Premise
290	P	_	_	I-Premise
291	=	_	_	I-Premise
292	.	_	_	I-Premise

293	60	_	_	I-Premise
294	)	_	_	I-Premise
295	.	_	_	I-Premise

296	HDCT	_	_	B-Premise
297	was	_	_	I-Premise
298	associated	_	_	I-Premise
299	with	_	_	I-Premise
300	significantly	_	_	I-Premise
301	more	_	_	I-Premise
302	myelosuppression	_	_	I-Premise
303	,	_	_	I-Premise
304	infection	_	_	I-Premise
305	,	_	_	I-Premise
306	diarrhea	_	_	I-Premise
307	,	_	_	I-Premise
308	stomatitis	_	_	I-Premise
309	,	_	_	I-Premise
310	and	_	_	I-Premise
311	nausea	_	_	I-Premise
312	and	_	_	I-Premise
313	vomiting	_	_	I-Premise
314	,	_	_	I-Premise
315	whereas	_	_	I-Premise
316	patients	_	_	I-Premise
317	treated	_	_	I-Premise
318	with	_	_	I-Premise
319	AT	_	_	I-Premise
320	developed	_	_	I-Premise
321	more	_	_	I-Premise
322	neurotoxicity	_	_	I-Premise
323	.	_	_	I-Premise

324	This	_	_	B-Claim
325	trial	_	_	I-Claim
326	failed	_	_	I-Claim
327	to	_	_	I-Claim
328	show	_	_	I-Claim
329	a	_	_	I-Claim
330	benefit	_	_	I-Claim
331	for	_	_	I-Claim
332	up	_	_	I-Claim
333	-	_	_	I-Claim
334	front	_	_	I-Claim
335	tandem	_	_	I-Claim
336	HDCT	_	_	I-Claim
337	compared	_	_	I-Claim
338	with	_	_	I-Claim
339	standard	_	_	I-Claim
340	combination	_	_	I-Claim
341	therapy	_	_	I-Claim
342	.	_	_	I-Claim

343	HDCT	_	_	B-Claim
344	was	_	_	I-Claim
345	associated	_	_	I-Claim
346	with	_	_	I-Claim
347	more	_	_	I-Claim
348	acute	_	_	I-Claim
349	adverse	_	_	I-Claim
350	effects	_	_	I-Claim
351	.	_	_	I-Claim


0	Impaired	_	_	B-Claim
1	cognition	_	_	I-Claim
2	,	_	_	I-Claim
3	fatigue	_	_	I-Claim
4	,	_	_	I-Claim
5	and	_	_	I-Claim
6	diminished	_	_	I-Claim
7	quality	_	_	I-Claim
8	of	_	_	I-Claim
9	life	_	_	I-Claim
10	(	_	_	I-Claim
11	QOL	_	_	I-Claim
12	)	_	_	I-Claim
13	are	_	_	I-Claim
14	commonly	_	_	I-Claim
15	associated	_	_	I-Claim
16	with	_	_	I-Claim
17	breast	_	_	I-Claim
18	cancer	_	_	I-Claim
19	chemotherapy	_	_	I-Claim
20	.	_	_	I-Claim

21	This	_	_	O
22	randomized	_	_	O
23	,	_	_	O
24	double	_	_	O
25	-	_	_	O
26	blind	_	_	O
27	,	_	_	O
28	placebo	_	_	O
29	-	_	_	O
30	controlled	_	_	O
31	pilot	_	_	O
32	trial	_	_	O
33	assessed	_	_	O
34	the	_	_	O
35	feasibility	_	_	O
36	of	_	_	O
37	quantifying	_	_	O
38	the	_	_	O
39	effects	_	_	O
40	of	_	_	O
41	epoetin	_	_	O
42	alfa	_	_	O
43	on	_	_	O
44	cognitive	_	_	O
45	function	_	_	O
46	and	_	_	O
47	mood	_	_	O
48	,	_	_	O
49	and	_	_	O
50	evaluated	_	_	O
51	its	_	_	O
52	effects	_	_	O
53	on	_	_	O
54	fatigue	_	_	O
55	and	_	_	O
56	QOL	_	_	O
57	in	_	_	O
58	patients	_	_	O
59	with	_	_	O
60	breast	_	_	O
61	cancer	_	_	O
62	treated	_	_	O
63	with	_	_	O
64	anthracycline	_	_	O
65	-	_	_	O
66	based	_	_	O
67	adjuvant	_	_	O
68	or	_	_	O
69	neoadjuvant	_	_	O
70	chemotherapy	_	_	O
71	.	_	_	O

72	Patients	_	_	O
73	were	_	_	O
74	randomized	_	_	O
75	to	_	_	O
76	receive	_	_	O
77	epoetin	_	_	O
78	alfa	_	_	O
79	40	_	_	O
80	,	_	_	O
81	000	_	_	O
82	U	_	_	O
83	subcutaneously	_	_	O
84	once	_	_	O
85	weekly	_	_	O
86	or	_	_	O
87	placebo	_	_	O
88	at	_	_	O
89	the	_	_	O
90	beginning	_	_	O
91	of	_	_	O
92	4	_	_	O
93	cycles	_	_	O
94	of	_	_	O
95	chemotherapy	_	_	O
96	administered	_	_	O
97	over	_	_	O
98	12	_	_	O
99	weeks	_	_	O
100	.	_	_	O

101	Cognitive	_	_	O
102	function	_	_	O
103	was	_	_	O
104	assessed	_	_	O
105	by	_	_	O
106	Executive	_	_	O
107	Interview	_	_	O
108	(	_	_	O
109	EXIT25	_	_	O
110	)	_	_	O
111	and	_	_	O
112	Clock	_	_	O
113	Drawing	_	_	O
114	Tasks	_	_	O
115	;	_	_	O
116	mood	_	_	O
117	by	_	_	O
118	Profile	_	_	O
119	of	_	_	O
120	Mood	_	_	O
121	States	_	_	O
122	;	_	_	O
123	anemia	_	_	O
124	-	_	_	O
125	related	_	_	O
126	symptoms	_	_	O
127	,	_	_	O
128	including	_	_	O
129	fatigue	_	_	O
130	,	_	_	O
131	by	_	_	O
132	the	_	_	O
133	Functional	_	_	O
134	Assessment	_	_	O
135	of	_	_	O
136	Cancer	_	_	O
137	Therapy	_	_	O
138	-	_	_	O
139	Anemia	_	_	O
140	(	_	_	O
141	FACT	_	_	O
142	-	_	_	O
143	An	_	_	O
144	)	_	_	O
145	subscale	_	_	O
146	;	_	_	O
147	and	_	_	O
148	QOL	_	_	O
149	by	_	_	O
150	Linear	_	_	O
151	Analog	_	_	O
152	Scale	_	_	O
153	Assessment	_	_	O
154	.	_	_	O

155	Ninety	_	_	O
156	-	_	_	O
157	four	_	_	O
158	patients	_	_	O
159	were	_	_	O
160	evaluable	_	_	O
161	for	_	_	O
162	efficacy	_	_	O
163	and	_	_	O
164	safety	_	_	O
165	.	_	_	O

166	Mean	_	_	B-Premise
167	change	_	_	I-Premise
168	in	_	_	I-Premise
169	EXIT25	_	_	I-Premise
170	scores	_	_	I-Premise
171	from	_	_	I-Premise
172	baseline	_	_	I-Premise
173	to	_	_	I-Premise
174	cycle	_	_	I-Premise
175	4	_	_	I-Premise
176	in	_	_	I-Premise
177	the	_	_	I-Premise
178	epoetin	_	_	I-Premise
179	alfa	_	_	I-Premise
180	group	_	_	I-Premise
181	was	_	_	I-Premise
182	1	_	_	I-Premise
183	.	_	_	I-Premise

184	3	_	_	I-Premise
185	+	_	_	I-Premise
186	/	_	_	I-Premise
187	-	_	_	I-Premise
188	3	_	_	I-Premise
189	.	_	_	I-Premise

190	3	_	_	I-Premise
191	;	_	_	I-Premise
192	the	_	_	B-Premise
193	mean	_	_	I-Premise
194	change	_	_	I-Premise
195	was	_	_	I-Premise
196	0	_	_	I-Premise
197	.	_	_	I-Premise

198	3	_	_	I-Premise
199	+	_	_	I-Premise
200	/	_	_	I-Premise
201	-	_	_	I-Premise
202	2	_	_	I-Premise
203	.	_	_	I-Premise

204	4	_	_	I-Premise
205	in	_	_	I-Premise
206	the	_	_	I-Premise
207	placebo	_	_	I-Premise
208	group	_	_	I-Premise
209	(	_	_	I-Premise
210	a	_	_	I-Premise
211	negative	_	_	I-Premise
212	change	_	_	I-Premise
213	indicates	_	_	I-Premise
214	improved	_	_	I-Premise
215	executive	_	_	I-Premise
216	function	_	_	I-Premise
217	)	_	_	I-Premise
218	.	_	_	I-Premise

219	There	_	_	B-Premise
220	was	_	_	I-Premise
221	no	_	_	I-Premise
222	difference	_	_	I-Premise
223	between	_	_	I-Premise
224	groups	_	_	I-Premise
225	in	_	_	I-Premise
226	mean	_	_	I-Premise
227	change	_	_	I-Premise
228	in	_	_	I-Premise
229	EXIT25	_	_	I-Premise
230	score	_	_	I-Premise
231	from	_	_	I-Premise
232	baseline	_	_	I-Premise
233	to	_	_	I-Premise
234	6	_	_	I-Premise
235	-	_	_	I-Premise
236	month	_	_	I-Premise
237	follow	_	_	I-Premise
238	-	_	_	I-Premise
239	up	_	_	I-Premise
240	assessment	_	_	I-Premise
241	.	_	_	I-Premise

242	Mean	_	_	B-Premise
243	hemoglobin	_	_	I-Premise
244	levels	_	_	I-Premise
245	were	_	_	I-Premise
246	higher	_	_	I-Premise
247	in	_	_	I-Premise
248	the	_	_	I-Premise
249	epoetin	_	_	I-Premise
250	alfa	_	_	I-Premise
251	group	_	_	I-Premise
252	compared	_	_	I-Premise
253	with	_	_	I-Premise
254	the	_	_	I-Premise
255	placebo	_	_	I-Premise
256	group	_	_	I-Premise
257	after	_	_	I-Premise
258	4	_	_	I-Premise
259	cycles	_	_	I-Premise
260	of	_	_	I-Premise
261	chemotherapy	_	_	I-Premise
262	.	_	_	I-Premise

263	Epoetin	_	_	B-Premise
264	alfa	_	_	I-Premise
265	recipients	_	_	I-Premise
266	had	_	_	I-Premise
267	less	_	_	I-Premise
268	of	_	_	I-Premise
269	a	_	_	I-Premise
270	decrease	_	_	I-Premise
271	in	_	_	I-Premise
272	FACT	_	_	I-Premise
273	-	_	_	I-Premise
274	An	_	_	I-Premise
275	subscale	_	_	I-Premise
276	scores	_	_	I-Premise
277	from	_	_	I-Premise
278	baseline	_	_	I-Premise
279	to	_	_	I-Premise
280	cycle	_	_	I-Premise
281	4	_	_	I-Premise
282	and	_	_	I-Premise
283	improvement	_	_	I-Premise
284	in	_	_	I-Premise
285	FACT	_	_	I-Premise
286	-	_	_	I-Premise
287	An	_	_	I-Premise
288	subscale	_	_	I-Premise
289	scores	_	_	I-Premise
290	at	_	_	I-Premise
291	6	_	_	I-Premise
292	-	_	_	I-Premise
293	month	_	_	I-Premise
294	follow	_	_	I-Premise
295	-	_	_	I-Premise
296	up	_	_	I-Premise
297	assessment	_	_	I-Premise
298	compared	_	_	I-Premise
299	with	_	_	I-Premise
300	placebo	_	_	I-Premise
301	.	_	_	I-Premise

302	Epoetin	_	_	B-Claim
303	alfa	_	_	I-Claim
304	therapy	_	_	I-Claim
305	was	_	_	I-Claim
306	well	_	_	I-Claim
307	tolerated	_	_	I-Claim
308	.	_	_	I-Claim

309	These	_	_	B-Claim
310	data	_	_	I-Claim
311	suggest	_	_	I-Claim
312	that	_	_	I-Claim
313	epoetin	_	_	I-Claim
314	alfa	_	_	I-Claim
315	may	_	_	I-Claim
316	have	_	_	I-Claim
317	attenuated	_	_	I-Claim
318	the	_	_	I-Claim
319	cognitive	_	_	I-Claim
320	impairment	_	_	I-Claim
321	and	_	_	I-Claim
322	fatigue	_	_	I-Claim
323	that	_	_	I-Claim
324	occurred	_	_	I-Claim
325	during	_	_	I-Claim
326	adjuvant	_	_	I-Claim
327	breast	_	_	I-Claim
328	cancer	_	_	I-Claim
329	chemotherapy	_	_	I-Claim
330	.	_	_	I-Claim


0	Recently	_	_	B-Claim
1	,	_	_	I-Claim
2	the	_	_	I-Claim
3	treatment	_	_	I-Claim
4	of	_	_	I-Claim
5	advanced	_	_	I-Claim
6	gastric	_	_	I-Claim
7	cancer	_	_	I-Claim
8	by	_	_	I-Claim
9	continuous	_	_	I-Claim
10	infusion	_	_	I-Claim
11	of	_	_	I-Claim
12	5	_	_	I-Claim
13	-	_	_	I-Claim
14	fluorouracil	_	_	I-Claim
15	(	_	_	I-Claim
16	5	_	_	I-Claim
17	-	_	_	I-Claim
18	FU	_	_	I-Claim
19	)	_	_	I-Claim
20	with	_	_	I-Claim
21	low	_	_	I-Claim
22	-	_	_	I-Claim
23	dose	_	_	I-Claim
24	cisplatin	_	_	I-Claim
25	(	_	_	I-Claim
26	CDDP	_	_	I-Claim
27	)	_	_	I-Claim
28	has	_	_	I-Claim
29	improved	_	_	I-Claim
30	efficacy	_	_	I-Claim
31	without	_	_	I-Claim
32	severe	_	_	I-Claim
33	toxicities	_	_	I-Claim
34	.	_	_	I-Claim

35	The	_	_	B-Claim
36	possible	_	_	I-Claim
37	effectiveness	_	_	I-Claim
38	of	_	_	I-Claim
39	5	_	_	I-Claim
40	-	_	_	I-Claim
41	FU	_	_	I-Claim
42	+	_	_	I-Claim
43	low	_	_	I-Claim
44	-	_	_	I-Claim
45	dose	_	_	I-Claim
46	CDDP	_	_	I-Claim
47	for	_	_	I-Claim
48	colorectal	_	_	I-Claim
49	cancer	_	_	I-Claim
50	(	_	_	I-Claim
51	CRC	_	_	I-Claim
52	)	_	_	I-Claim
53	is	_	_	I-Claim
54	intriguing	_	_	I-Claim
55	.	_	_	I-Claim

56	One	_	_	O
57	hundred	_	_	O
58	fifty	_	_	O
59	-	_	_	O
60	five	_	_	O
61	patients	_	_	O
62	with	_	_	O
63	far	_	_	O
64	-	_	_	O
65	advanced	_	_	O
66	CRC	_	_	O
67	including	_	_	O
68	at	_	_	O
69	least	_	_	O
70	one	_	_	O
71	measurable	_	_	O
72	lesion	_	_	O
73	were	_	_	O
74	enrolled	_	_	O
75	in	_	_	O
76	a	_	_	O
77	prospective	_	_	O
78	randomized	_	_	O
79	clinical	_	_	O
80	trial	_	_	O
81	funded	_	_	O
82	by	_	_	O
83	the	_	_	O
84	Japanese	_	_	O
85	Foundation	_	_	O
86	for	_	_	O
87	Multidisciplinary	_	_	O
88	Treatment	_	_	O
89	of	_	_	O
90	Cancer	_	_	O
91	.	_	_	O

92	These	_	_	O
93	patients	_	_	O
94	were	_	_	O
95	assigned	_	_	O
96	to	_	_	O
97	the	_	_	O
98	two	_	_	O
99	arms	_	_	O
100	to	_	_	O
101	assess	_	_	O
102	the	_	_	O
103	value	_	_	O
104	of	_	_	O
105	low	_	_	O
106	-	_	_	O
107	dose	_	_	O
108	CDDP	_	_	O
109	when	_	_	O
110	added	_	_	O
111	to	_	_	O
112	a	_	_	O
113	continuous	_	_	O
114	intravenous	_	_	O
115	infusion	_	_	O
116	of	_	_	O
117	5	_	_	O
118	-	_	_	O
119	FU	_	_	O
120	at	_	_	O
121	a	_	_	O
122	dose	_	_	O
123	of	_	_	O
124	300	_	_	O
125	mg	_	_	O
126	/	_	_	O
127	m	_	_	O
128	(	_	_	O
129	2	_	_	O
130	)	_	_	O
131	/	_	_	O
132	24	_	_	O
133	hrs	_	_	O
134	in	_	_	O
135	a	_	_	O
136	one	_	_	O
137	-	_	_	O
138	week	_	_	O
139	cycle	_	_	O
140	consisting	_	_	O
141	of	_	_	O
142	5	_	_	O
143	days	_	_	O
144	of	_	_	O
145	treatment	_	_	O
146	and	_	_	O
147	2	_	_	O
148	days	_	_	O
149	of	_	_	O
150	rest	_	_	O
151	for	_	_	O
152	at	_	_	O
153	least	_	_	O
154	12	_	_	O
155	weeks	_	_	O
156	.	_	_	O

157	CD	_	_	O
158	-	_	_	O
159	DP	_	_	O
160	was	_	_	O
161	given	_	_	O
162	intravenously	_	_	O
163	at	_	_	O
164	a	_	_	O
165	dose	_	_	O
166	of	_	_	O
167	3	_	_	O
168	mg	_	_	O
169	/	_	_	O
170	m	_	_	O
171	(	_	_	O
172	2	_	_	O
173	)	_	_	O
174	on	_	_	O
175	days	_	_	O
176	1	_	_	O
177	-	_	_	O
178	5	_	_	O
179	and	_	_	O
180	days	_	_	O
181	8	_	_	O
182	-	_	_	O
183	12	_	_	O
184	,	_	_	O
185	and	_	_	O
186	then	_	_	O
187	at	_	_	O
188	a	_	_	O
189	dose	_	_	O
190	of	_	_	O
191	7	_	_	O
192	mg	_	_	O
193	/	_	_	O
194	m	_	_	O
195	(	_	_	O
196	2	_	_	O
197	)	_	_	O
198	twice	_	_	O
199	a	_	_	O
200	week	_	_	O
201	.	_	_	O

202	Three	_	_	O
203	patients	_	_	O
204	were	_	_	O
205	excluded	_	_	O
206	from	_	_	O
207	the	_	_	O
208	trial	_	_	O
209	.	_	_	O

210	The	_	_	B-Premise
211	response	_	_	I-Premise
212	rate	_	_	I-Premise
213	in	_	_	I-Premise
214	the	_	_	I-Premise
215	5	_	_	I-Premise
216	-	_	_	I-Premise
217	FU	_	_	I-Premise
218	+	_	_	I-Premise
219	low	_	_	I-Premise
220	-	_	_	I-Premise
221	dose	_	_	I-Premise
222	CDDP	_	_	I-Premise
223	arm	_	_	I-Premise
224	(	_	_	I-Premise
225	n	_	_	I-Premise
226	=	_	_	I-Premise
227	75	_	_	I-Premise
228	)	_	_	I-Premise
229	was	_	_	I-Premise
230	significantly	_	_	I-Premise
231	higher	_	_	I-Premise
232	than	_	_	I-Premise
233	that	_	_	I-Premise
234	in	_	_	I-Premise
235	the	_	_	I-Premise
236	5	_	_	I-Premise
237	-	_	_	I-Premise
238	FU	_	_	I-Premise
239	arm	_	_	I-Premise
240	(	_	_	I-Premise
241	n	_	_	I-Premise
242	=	_	_	I-Premise
243	77	_	_	I-Premise
244	)	_	_	I-Premise
245	(	_	_	I-Premise
246	25	_	_	I-Premise
247	.	_	_	I-Premise

248	3	_	_	I-Premise
249	%	_	_	I-Premise
250	vs	_	_	I-Premise
251	.	_	_	I-Premise

252	11	_	_	I-Premise
253	.	_	_	I-Premise

254	7	_	_	I-Premise
255	%	_	_	I-Premise
256	;	_	_	I-Premise
257	P	_	_	I-Premise
258	=	_	_	I-Premise
259	0	_	_	I-Premise
260	.	_	_	I-Premise

261	037	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	There	_	_	B-Premise
265	was	_	_	I-Premise
266	no	_	_	I-Premise
267	significant	_	_	I-Premise
268	difference	_	_	I-Premise
269	in	_	_	I-Premise
270	the	_	_	I-Premise
271	median	_	_	I-Premise
272	overall	_	_	I-Premise
273	survival	_	_	I-Premise
274	time	_	_	I-Premise
275	between	_	_	I-Premise
276	the	_	_	I-Premise
277	5	_	_	I-Premise
278	-	_	_	I-Premise
279	FU	_	_	I-Premise
280	+	_	_	I-Premise
281	low	_	_	I-Premise
282	-	_	_	I-Premise
283	dose	_	_	I-Premise
284	CDDP	_	_	I-Premise
285	arm	_	_	I-Premise
286	and	_	_	I-Premise
287	the	_	_	I-Premise
288	5	_	_	I-Premise
289	-	_	_	I-Premise
290	FU	_	_	I-Premise
291	arm	_	_	I-Premise
292	(	_	_	I-Premise
293	479	_	_	I-Premise
294	and	_	_	I-Premise
295	491	_	_	I-Premise
296	days	_	_	I-Premise
297	,	_	_	I-Premise
298	respectively	_	_	I-Premise
299	)	_	_	I-Premise
300	.	_	_	I-Premise

301	Grades	_	_	B-Premise
302	3	_	_	I-Premise
303	/	_	_	I-Premise
304	4	_	_	I-Premise
305	toxicities	_	_	I-Premise
306	occurred	_	_	I-Premise
307	infrequently	_	_	I-Premise
308	in	_	_	I-Premise
309	both	_	_	I-Premise
310	arms	_	_	I-Premise
311	.	_	_	I-Premise

312	The	_	_	B-Premise
313	quality	_	_	I-Premise
314	of	_	_	I-Premise
315	life	_	_	I-Premise
316	was	_	_	I-Premise
317	almost	_	_	I-Premise
318	the	_	_	I-Premise
319	same	_	_	I-Premise
320	between	_	_	I-Premise
321	the	_	_	I-Premise
322	arms	_	_	I-Premise
323	.	_	_	O

324	Low	_	_	B-Claim
325	-	_	_	I-Claim
326	dose	_	_	I-Claim
327	CDDP	_	_	I-Claim
328	improved	_	_	I-Claim
329	the	_	_	I-Claim
330	response	_	_	I-Claim
331	rate	_	_	I-Claim
332	while	_	_	I-Claim
333	keeping	_	_	I-Claim
334	toxicities	_	_	I-Claim
335	within	_	_	I-Claim
336	clinically	_	_	I-Claim
337	acceptable	_	_	I-Claim
338	limits	_	_	I-Claim
339	.	_	_	I-Claim

340	However	_	_	B-Claim
341	,	_	_	I-Claim
342	this	_	_	I-Claim
343	combined	_	_	I-Claim
344	treatment	_	_	I-Claim
345	did	_	_	I-Claim
346	not	_	_	I-Claim
347	confer	_	_	I-Claim
348	a	_	_	I-Claim
349	survival	_	_	I-Claim
350	advantage	_	_	I-Claim
351	over	_	_	I-Claim
352	treatment	_	_	I-Claim
353	with	_	_	I-Claim
354	continuous	_	_	I-Claim
355	infusion	_	_	I-Claim
356	of	_	_	I-Claim
357	5	_	_	I-Claim
358	-	_	_	I-Claim
359	FU	_	_	I-Claim
360	alone	_	_	I-Claim
361	for	_	_	I-Claim
362	patients	_	_	I-Claim
363	with	_	_	I-Claim
364	far	_	_	I-Claim
365	-	_	_	I-Claim
366	advanced	_	_	I-Claim
367	CRC	_	_	I-Claim
368	;	_	_	I-Claim
369	that	_	_	I-Claim
370	might	_	_	I-Claim
371	be	_	_	I-Claim
372	attributable	_	_	I-Claim
373	to	_	_	I-Claim
374	the	_	_	I-Claim
375	short	_	_	I-Claim
376	CDDP	_	_	I-Claim
377	administration	_	_	I-Claim
378	setting	_	_	I-Claim
379	of	_	_	I-Claim
380	12	_	_	I-Claim
381	weeks	_	_	I-Claim
382	.	_	_	I-Claim


0	An	_	_	O
1	open	_	_	O
2	,	_	_	O
3	randomized	_	_	O
4	study	_	_	O
5	was	_	_	O
6	performed	_	_	O
7	to	_	_	O
8	assess	_	_	O
9	the	_	_	O
10	effects	_	_	O
11	of	_	_	O
12	supportive	_	_	O
13	pamidronate	_	_	O
14	treatment	_	_	O
15	on	_	_	O
16	morbidity	_	_	O
17	from	_	_	O
18	bone	_	_	O
19	metastases	_	_	O
20	in	_	_	O
21	breast	_	_	O
22	cancer	_	_	O
23	patients	_	_	O
24	.	_	_	O

25	Eighty	_	_	O
26	-	_	_	O
27	one	_	_	O
28	pamidronate	_	_	O
29	patients	_	_	O
30	and	_	_	O
31	80	_	_	O
32	control	_	_	O
33	patients	_	_	O
34	were	_	_	O
35	monitored	_	_	O
36	for	_	_	O
37	a	_	_	O
38	median	_	_	O
39	of	_	_	O
40	18	_	_	O
41	and	_	_	O
42	21	_	_	O
43	months	_	_	O
44	,	_	_	O
45	respectively	_	_	O
46	,	_	_	O
47	for	_	_	O
48	events	_	_	O
49	of	_	_	O
50	skeletal	_	_	O
51	morbidity	_	_	O
52	and	_	_	O
53	the	_	_	O
54	radiologic	_	_	O
55	course	_	_	O
56	of	_	_	O
57	metastatic	_	_	O
58	bone	_	_	O
59	disease	_	_	O
60	.	_	_	O

61	The	_	_	O
62	oral	_	_	O
63	pamidronate	_	_	O
64	dose	_	_	O
65	was	_	_	O
66	600	_	_	O
67	mg	_	_	O
68	/	_	_	O
69	d	_	_	O
70	(	_	_	O
71	high	_	_	O
72	dose	_	_	O
73	[	_	_	O
74	HD	_	_	O
75	]	_	_	O
76	)	_	_	O
77	during	_	_	O
78	the	_	_	O
79	earliest	_	_	O
80	study	_	_	O
81	years	_	_	O
82	,	_	_	O
83	then	_	_	O
84	changed	_	_	O
85	to	_	_	O
86	300	_	_	O
87	mg	_	_	O
88	/	_	_	O
89	d	_	_	O
90	(	_	_	O
91	low	_	_	O
92	dose	_	_	O
93	[	_	_	O
94	LD	_	_	O
95	]	_	_	O
96	)	_	_	O
97	because	_	_	O
98	of	_	_	O
99	gastrointestinal	_	_	O
100	toxicity	_	_	O
101	.	_	_	O

102	Twenty	_	_	O
103	-	_	_	O
104	nine	_	_	O
105	of	_	_	O
106	81	_	_	O
107	pamidronate	_	_	O
108	(	_	_	O
109	HD	_	_	O
110	/	_	_	O
111	LD	_	_	O
112	)	_	_	O
113	patients	_	_	O
114	first	_	_	O
115	received	_	_	O
116	600	_	_	O
117	mg	_	_	O
118	/	_	_	O
119	d	_	_	O
120	and	_	_	O
121	were	_	_	O
122	then	_	_	O
123	changed	_	_	O
124	to	_	_	O
125	300	_	_	O
126	mg	_	_	O
127	/	_	_	O
128	d	_	_	O
129	;	_	_	O
130	52	_	_	O
131	of	_	_	O
132	81	_	_	O
133	pamidronate	_	_	O
134	LD	_	_	O
135	patients	_	_	O
136	received	_	_	O
137	300	_	_	O
138	mg	_	_	O
139	/	_	_	O
140	d	_	_	O
141	throughout	_	_	O
142	the	_	_	O
143	study	_	_	O
144	.	_	_	O

145	Tumor	_	_	O
146	treatment	_	_	O
147	was	_	_	O
148	unrestricted	_	_	O
149	.	_	_	O

150	An	_	_	O
151	overall	_	_	O
152	intent	_	_	O
153	-	_	_	O
154	to	_	_	O
155	-	_	_	O
156	treat	_	_	O
157	analysis	_	_	O
158	was	_	_	O
159	performed	_	_	O
160	.	_	_	O

161	In	_	_	B-Premise
162	the	_	_	I-Premise
163	pamidronate	_	_	I-Premise
164	group	_	_	I-Premise
165	,	_	_	I-Premise
166	the	_	_	I-Premise
167	occurrence	_	_	I-Premise
168	of	_	_	I-Premise
169	hypercalcemia	_	_	I-Premise
170	,	_	_	I-Premise
171	severe	_	_	I-Premise
172	bone	_	_	I-Premise
173	pain	_	_	I-Premise
174	,	_	_	I-Premise
175	and	_	_	I-Premise
176	symptomatic	_	_	I-Premise
177	impending	_	_	I-Premise
178	fractures	_	_	I-Premise
179	decreased	_	_	I-Premise
180	by	_	_	I-Premise
181	65	_	_	I-Premise
182	%	_	_	I-Premise
183	,	_	_	I-Premise
184	30	_	_	I-Premise
185	%	_	_	I-Premise
186	,	_	_	I-Premise
187	and	_	_	I-Premise
188	50	_	_	I-Premise
189	%	_	_	I-Premise
190	,	_	_	I-Premise
191	respectively	_	_	I-Premise
192	;	_	_	I-Premise
193	event	_	_	I-Premise
194	-	_	_	I-Premise
195	rates	_	_	I-Premise
196	of	_	_	I-Premise
197	systemic	_	_	I-Premise
198	treatment	_	_	I-Premise
199	and	_	_	I-Premise
200	radiotherapy	_	_	I-Premise
201	decreased	_	_	I-Premise
202	by	_	_	I-Premise
203	35	_	_	I-Premise
204	%	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	<	_	_	I-Premise
208	or	_	_	I-Premise
209	=	_	_	I-Premise
210	.	_	_	I-Premise

211	02	_	_	I-Premise
212	)	_	_	I-Premise
213	.	_	_	I-Premise

214	The	_	_	B-Premise
215	event	_	_	I-Premise
216	-	_	_	I-Premise
217	free	_	_	I-Premise
218	period	_	_	I-Premise
219	(	_	_	I-Premise
220	EFP	_	_	I-Premise
221	)	_	_	I-Premise
222	,	_	_	I-Premise
223	radiologic	_	_	I-Premise
224	course	_	_	I-Premise
225	of	_	_	I-Premise
226	disease	_	_	I-Premise
227	,	_	_	I-Premise
228	and	_	_	I-Premise
229	survival	_	_	I-Premise
230	did	_	_	I-Premise
231	not	_	_	I-Premise
232	improve	_	_	I-Premise
233	.	_	_	I-Premise

234	Subgroup	_	_	B-Claim
235	analyses	_	_	I-Claim
236	suggested	_	_	I-Claim
237	a	_	_	I-Claim
238	dose	_	_	I-Claim
239	-	_	_	I-Claim
240	dependent	_	_	I-Claim
241	treatment	_	_	I-Claim
242	effect	_	_	I-Claim
243	.	_	_	I-Claim

244	Compared	_	_	B-Premise
245	with	_	_	I-Premise
246	their	_	_	I-Premise
247	controls	_	_	I-Premise
248	,	_	_	I-Premise
249	in	_	_	I-Premise
250	pamidronate	_	_	I-Premise
251	HD	_	_	I-Premise
252	/	_	_	I-Premise
253	LD	_	_	I-Premise
254	patients	_	_	I-Premise
255	,	_	_	I-Premise
256	events	_	_	I-Premise
257	occurred	_	_	I-Premise
258	60	_	_	I-Premise
259	%	_	_	I-Premise
260	to	_	_	I-Premise
261	90	_	_	I-Premise
262	%	_	_	I-Premise
263	less	_	_	I-Premise
264	frequently	_	_	I-Premise
265	(	_	_	I-Premise
266	P	_	_	I-Premise
267	<	_	_	I-Premise
268	or	_	_	I-Premise
269	=	_	_	I-Premise
270	.	_	_	I-Premise

271	03	_	_	I-Premise
272	)	_	_	I-Premise
273	and	_	_	I-Premise
274	the	_	_	I-Premise
275	EFP	_	_	I-Premise
276	was	_	_	I-Premise
277	prolonged	_	_	I-Premise
278	(	_	_	I-Premise
279	P	_	_	I-Premise
280	=	_	_	I-Premise
281	.	_	_	I-Premise

282	002	_	_	I-Premise
283	)	_	_	I-Premise
284	.	_	_	I-Premise

285	In	_	_	B-Premise
286	pamidronate	_	_	I-Premise
287	LD	_	_	I-Premise
288	patients	_	_	I-Premise
289	,	_	_	I-Premise
290	event	_	_	I-Premise
291	-	_	_	I-Premise
292	rates	_	_	I-Premise
293	decreased	_	_	I-Premise
294	by	_	_	I-Premise
295	15	_	_	I-Premise
296	%	_	_	I-Premise
297	to	_	_	I-Premise
298	45	_	_	I-Premise
299	%	_	_	I-Premise
300	(	_	_	I-Premise
301	P	_	_	I-Premise
302	<	_	_	I-Premise
303	or	_	_	I-Premise
304	=	_	_	I-Premise
305	.	_	_	I-Premise

306	04	_	_	I-Premise
307	)	_	_	I-Premise
308	.	_	_	I-Premise

309	Gastrointestinal	_	_	B-Premise
310	toxicity	_	_	I-Premise
311	of	_	_	I-Premise
312	pamidronate	_	_	I-Premise
313	caused	_	_	I-Premise
314	a	_	_	I-Premise
315	23	_	_	I-Premise
316	%	_	_	I-Premise
317	drop	_	_	I-Premise
318	-	_	_	I-Premise
319	out	_	_	I-Premise
320	rate	_	_	I-Premise
321	,	_	_	I-Premise
322	but	_	_	B-Claim
323	other	_	_	I-Claim
324	cancer	_	_	I-Claim
325	-	_	_	I-Claim
326	associated	_	_	I-Claim
327	factors	_	_	I-Claim
328	seemed	_	_	I-Claim
329	to	_	_	I-Claim
330	contribute	_	_	I-Claim
331	to	_	_	I-Claim
332	this	_	_	I-Claim
333	toxicity	_	_	I-Claim
334	.	_	_	I-Claim

335	Pamidronate	_	_	B-Claim
336	treatment	_	_	I-Claim
337	of	_	_	I-Claim
338	breast	_	_	I-Claim
339	cancer	_	_	I-Claim
340	patients	_	_	I-Claim
341	efficaciously	_	_	I-Claim
342	reduced	_	_	I-Claim
343	skeletal	_	_	I-Claim
344	morbidity	_	_	I-Claim
345	.	_	_	I-Claim

346	The	_	_	B-Claim
347	effect	_	_	I-Claim
348	appeared	_	_	I-Claim
349	to	_	_	I-Claim
350	be	_	_	I-Claim
351	dose	_	_	I-Claim
352	-	_	_	I-Claim
353	dependent	_	_	I-Claim
354	.	_	_	I-Claim

355	Further	_	_	B-Claim
356	research	_	_	I-Claim
357	on	_	_	I-Claim
358	dose	_	_	I-Claim
359	and	_	_	I-Claim
360	mode	_	_	I-Claim
361	of	_	_	I-Claim
362	treatment	_	_	I-Claim
363	is	_	_	I-Claim
364	mandatory	_	_	I-Claim
365	.	_	_	I-Claim


0	To	_	_	O
1	perform	_	_	O
2	a	_	_	O
3	randomized	_	_	O
4	trial	_	_	O
5	comparing	_	_	O
6	70	_	_	O
7	and	_	_	O
8	80	_	_	O
9	Gy	_	_	O
10	radiotherapy	_	_	O
11	for	_	_	O
12	prostate	_	_	O
13	cancer	_	_	O
14	.	_	_	O

15	A	_	_	O
16	total	_	_	O
17	of	_	_	O
18	306	_	_	O
19	patients	_	_	O
20	with	_	_	O
21	localized	_	_	O
22	prostate	_	_	O
23	cancer	_	_	O
24	were	_	_	O
25	randomized	_	_	O
26	.	_	_	O

27	No	_	_	O
28	androgen	_	_	O
29	deprivation	_	_	O
30	was	_	_	O
31	allowed	_	_	O
32	.	_	_	O

33	The	_	_	O
34	primary	_	_	O
35	endpoint	_	_	O
36	was	_	_	O
37	biochemical	_	_	O
38	relapse	_	_	O
39	according	_	_	O
40	to	_	_	O
41	the	_	_	O
42	modified	_	_	O
43	1997	_	_	O
44	-	_	_	O
45	American	_	_	O
46	Society	_	_	O
47	for	_	_	O
48	Therapeutic	_	_	O
49	Radiology	_	_	O
50	and	_	_	O
51	Oncology	_	_	O
52	and	_	_	O
53	Phoenix	_	_	O
54	definitions	_	_	O
55	.	_	_	O

56	Toxicity	_	_	O
57	was	_	_	O
58	graded	_	_	O
59	using	_	_	O
60	the	_	_	O
61	Radiation	_	_	O
62	Therapy	_	_	O
63	Oncology	_	_	O
64	Group	_	_	O
65	1991	_	_	O
66	criteria	_	_	O
67	and	_	_	O
68	the	_	_	O
69	late	_	_	O
70	effects	_	_	O
71	on	_	_	O
72	normal	_	_	O
73	tissues	_	_	O
74	-	_	_	O
75	subjective	_	_	O
76	,	_	_	O
77	objective	_	_	O
78	,	_	_	O
79	management	_	_	O
80	,	_	_	O
81	analytic	_	_	O
82	scales	_	_	O
83	(	_	_	O
84	LENT	_	_	O
85	-	_	_	O
86	SOMA	_	_	O
87	)	_	_	O
88	scales	_	_	O
89	.	_	_	O

90	The	_	_	O
91	patients	_	_	O
92	'	_	_	O
93	quality	_	_	O
94	of	_	_	O
95	life	_	_	O
96	was	_	_	O
97	scored	_	_	O
98	using	_	_	O
99	the	_	_	O
100	European	_	_	O
101	Organization	_	_	O
102	for	_	_	O
103	Research	_	_	O
104	and	_	_	O
105	Treatment	_	_	O
106	of	_	_	O
107	Cancer	_	_	O
108	Quality	_	_	O
109	of	_	_	O
110	Life	_	_	O
111	Questionnaire	_	_	O
112	30	_	_	O
113	-	_	_	O
114	item	_	_	O
115	cancer	_	_	O
116	-	_	_	O
117	specific	_	_	O
118	and	_	_	O
119	25	_	_	O
120	-	_	_	O
121	item	_	_	O
122	prostate	_	_	O
123	-	_	_	O
124	specific	_	_	O
125	modules	_	_	O
126	.	_	_	O

127	The	_	_	O
128	median	_	_	O
129	follow	_	_	O
130	-	_	_	O
131	up	_	_	O
132	was	_	_	O
133	61	_	_	O
134	months	_	_	O
135	.	_	_	O

136	According	_	_	O
137	to	_	_	O
138	the	_	_	O
139	1997	_	_	O
140	-	_	_	O
141	American	_	_	O
142	Society	_	_	O
143	for	_	_	O
144	Therapeutic	_	_	O
145	Radiology	_	_	O
146	and	_	_	O
147	Oncology	_	_	O
148	definition	_	_	O
149	,	_	_	O
150	the	_	_	O
151	5	_	_	O
152	-	_	_	O
153	year	_	_	O
154	biochemical	_	_	O
155	relapse	_	_	O
156	rate	_	_	O
157	was	_	_	O
158	39	_	_	O
159	%	_	_	O
160	and	_	_	O
161	28	_	_	O
162	%	_	_	O
163	in	_	_	O
164	the	_	_	O
165	70	_	_	O
166	-	_	_	O
167	and	_	_	O
168	80	_	_	O
169	-	_	_	O
170	Gy	_	_	O
171	arms	_	_	O
172	,	_	_	O
173	respectively	_	_	O
174	(	_	_	O
175	p	_	_	O
176	=	_	_	O
177	.	_	_	O

178	036	_	_	O
179	)	_	_	O
180	.	_	_	O

181	Using	_	_	O
182	the	_	_	O
183	Phoenix	_	_	O
184	definition	_	_	O
185	,	_	_	O
186	the	_	_	O
187	5	_	_	O
188	-	_	_	O
189	year	_	_	O
190	biochemical	_	_	O
191	relapse	_	_	O
192	rate	_	_	O
193	was	_	_	O
194	32	_	_	O
195	%	_	_	O
196	and	_	_	O
197	23	_	_	O
198	.	_	_	O

199	5	_	_	O
200	%	_	_	O
201	,	_	_	O
202	respectively	_	_	O
203	(	_	_	O
204	p	_	_	O
205	=	_	_	O
206	.	_	_	O

207	09	_	_	O
208	)	_	_	O
209	.	_	_	O

210	The	_	_	O
211	subgroup	_	_	O
212	analysis	_	_	O
213	showed	_	_	O
214	a	_	_	O
215	better	_	_	O
216	biochemical	_	_	O
217	outcome	_	_	O
218	for	_	_	O
219	the	_	_	O
220	higher	_	_	O
221	dose	_	_	O
222	group	_	_	O
223	with	_	_	O
224	an	_	_	O
225	initial	_	_	O
226	prostate	_	_	O
227	-	_	_	O
228	specific	_	_	O
229	antigen	_	_	O
230	level	_	_	O
231	>	_	_	O
232	15	_	_	O
233	ng	_	_	O
234	/	_	_	O
235	mL	_	_	O
236	.	_	_	O

237	At	_	_	O
238	the	_	_	O
239	last	_	_	O
240	follow	_	_	O
241	-	_	_	O
242	up	_	_	O
243	date	_	_	O
244	,	_	_	O
245	26	_	_	O
246	patients	_	_	O
247	had	_	_	O
248	died	_	_	O
249	,	_	_	O
250	10	_	_	O
251	of	_	_	O
252	their	_	_	O
253	disease	_	_	O
254	and	_	_	O
255	none	_	_	O
256	of	_	_	O
257	toxicity	_	_	O
258	,	_	_	O
259	with	_	_	O
260	no	_	_	O
261	differences	_	_	O
262	between	_	_	O
263	the	_	_	O
264	two	_	_	O
265	arms	_	_	O
266	.	_	_	O

267	According	_	_	B-Premise
268	to	_	_	I-Premise
269	the	_	_	I-Premise
270	Radiation	_	_	I-Premise
271	Therapy	_	_	I-Premise
272	Oncology	_	_	I-Premise
273	Group	_	_	I-Premise
274	scale	_	_	I-Premise
275	,	_	_	I-Premise
276	the	_	_	I-Premise
277	Grade	_	_	I-Premise
278	2	_	_	I-Premise
279	or	_	_	I-Premise
280	greater	_	_	I-Premise
281	rectal	_	_	I-Premise
282	toxicity	_	_	I-Premise
283	rate	_	_	I-Premise
284	was	_	_	I-Premise
285	14	_	_	I-Premise
286	%	_	_	I-Premise
287	and	_	_	I-Premise
288	19	_	_	I-Premise
289	.	_	_	I-Premise

290	5	_	_	I-Premise
291	%	_	_	I-Premise
292	for	_	_	I-Premise
293	the	_	_	I-Premise
294	70	_	_	I-Premise
295	-	_	_	I-Premise
296	and	_	_	I-Premise
297	80	_	_	I-Premise
298	-	_	_	I-Premise
299	Gy	_	_	I-Premise
300	arms	_	_	I-Premise
301	(	_	_	I-Premise
302	p	_	_	I-Premise
303	=	_	_	I-Premise
304	.	_	_	I-Premise

305	22	_	_	I-Premise
306	)	_	_	I-Premise
307	,	_	_	I-Premise
308	respectively	_	_	I-Premise
309	.	_	_	I-Premise

310	The	_	_	B-Premise
311	Grade	_	_	I-Premise
312	2	_	_	I-Premise
313	or	_	_	I-Premise
314	greater	_	_	I-Premise
315	urinary	_	_	I-Premise
316	toxicity	_	_	I-Premise
317	was	_	_	I-Premise
318	10	_	_	I-Premise
319	%	_	_	I-Premise
320	at	_	_	I-Premise
321	70	_	_	I-Premise
322	Gy	_	_	I-Premise
323	and	_	_	I-Premise
324	17	_	_	I-Premise
325	.	_	_	I-Premise

326	5	_	_	I-Premise
327	%	_	_	I-Premise
328	at	_	_	I-Premise
329	80	_	_	I-Premise
330	Gy	_	_	I-Premise
331	(	_	_	I-Premise
332	p	_	_	I-Premise
333	=	_	_	I-Premise
334	.	_	_	I-Premise

335	046	_	_	I-Premise
336	)	_	_	I-Premise
337	.	_	_	I-Premise

338	Similar	_	_	B-Premise
339	results	_	_	I-Premise
340	were	_	_	I-Premise
341	observed	_	_	I-Premise
342	using	_	_	I-Premise
343	the	_	_	I-Premise
344	LENT	_	_	I-Premise
345	-	_	_	I-Premise
346	SOMA	_	_	I-Premise
347	scale	_	_	I-Premise
348	.	_	_	I-Premise

349	Bladder	_	_	B-Premise
350	toxicity	_	_	I-Premise
351	was	_	_	I-Premise
352	more	_	_	I-Premise
353	frequent	_	_	I-Premise
354	at	_	_	I-Premise
355	80	_	_	I-Premise
356	Gy	_	_	I-Premise
357	than	_	_	I-Premise
358	at	_	_	I-Premise
359	70	_	_	I-Premise
360	Gy	_	_	I-Premise
361	(	_	_	I-Premise
362	p	_	_	I-Premise
363	=	_	_	I-Premise
364	.	_	_	I-Premise

365	039	_	_	I-Premise
366	)	_	_	I-Premise
367	.	_	_	I-Premise

368	The	_	_	B-Premise
369	quality	_	_	I-Premise
370	-	_	_	I-Premise
371	of	_	_	I-Premise
372	-	_	_	I-Premise
373	life	_	_	I-Premise
374	questionnaire	_	_	I-Premise
375	results	_	_	I-Premise
376	before	_	_	I-Premise
377	and	_	_	I-Premise
378	5	_	_	I-Premise
379	years	_	_	I-Premise
380	after	_	_	I-Premise
381	treatment	_	_	I-Premise
382	were	_	_	I-Premise
383	available	_	_	I-Premise
384	for	_	_	I-Premise
385	103	_	_	I-Premise
386	patients	_	_	I-Premise
387	with	_	_	I-Premise
388	no	_	_	I-Premise
389	differences	_	_	I-Premise
390	found	_	_	I-Premise
391	between	_	_	I-Premise
392	the	_	_	I-Premise
393	70	_	_	I-Premise
394	-	_	_	I-Premise
395	and	_	_	I-Premise
396	80	_	_	I-Premise
397	-	_	_	I-Premise
398	Gy	_	_	I-Premise
399	arms	_	_	I-Premise
400	.	_	_	I-Premise

401	High	_	_	B-Claim
402	-	_	_	I-Claim
403	dose	_	_	I-Claim
404	radiotherapy	_	_	I-Claim
405	provided	_	_	I-Claim
406	a	_	_	I-Claim
407	better	_	_	I-Claim
408	5	_	_	I-Claim
409	-	_	_	I-Claim
410	year	_	_	I-Claim
411	biochemical	_	_	I-Claim
412	outcome	_	_	I-Claim
413	with	_	_	I-Claim
414	slightly	_	_	I-Claim
415	greater	_	_	I-Claim
416	toxicity	_	_	I-Claim
417	.	_	_	I-Claim


0	For	_	_	B-Claim
1	men	_	_	I-Claim
2	with	_	_	I-Claim
3	localised	_	_	I-Claim
4	prostate	_	_	I-Claim
5	cancer	_	_	I-Claim
6	,	_	_	I-Claim
7	surgery	_	_	I-Claim
8	provides	_	_	I-Claim
9	a	_	_	I-Claim
10	survival	_	_	I-Claim
11	benefit	_	_	I-Claim
12	compared	_	_	I-Claim
13	with	_	_	I-Claim
14	watchful	_	_	I-Claim
15	waiting	_	_	I-Claim
16	.	_	_	I-Claim

17	Treatments	_	_	O
18	are	_	_	O
19	associated	_	_	O
20	with	_	_	O
21	morbidity	_	_	O
22	.	_	_	O

23	Results	_	_	O
24	for	_	_	O
25	functional	_	_	O
26	outcome	_	_	O
27	and	_	_	O
28	quality	_	_	O
29	of	_	_	O
30	life	_	_	O
31	are	_	_	O
32	rarely	_	_	O
33	reported	_	_	O
34	beyond	_	_	O
35	10	_	_	O
36	years	_	_	O
37	and	_	_	O
38	are	_	_	O
39	lacking	_	_	O
40	from	_	_	O
41	randomised	_	_	O
42	settings	_	_	O
43	.	_	_	O

44	We	_	_	O
45	report	_	_	O
46	results	_	_	O
47	for	_	_	O
48	quality	_	_	O
49	of	_	_	O
50	life	_	_	O
51	for	_	_	O
52	men	_	_	O
53	in	_	_	O
54	the	_	_	O
55	Scandinavian	_	_	O
56	Prostate	_	_	O
57	Cancer	_	_	O
58	Group	_	_	O
59	Study	_	_	O
60	Number	_	_	O
61	4	_	_	O
62	(	_	_	O
63	SPCG	_	_	O
64	-	_	_	O
65	4	_	_	O
66	)	_	_	O
67	after	_	_	O
68	a	_	_	O
69	median	_	_	O
70	follow	_	_	O
71	-	_	_	O
72	up	_	_	O
73	of	_	_	O
74	more	_	_	O
75	than	_	_	O
76	12	_	_	O
77	years	_	_	O
78	.	_	_	O

79	All	_	_	O
80	living	_	_	O
81	Swedish	_	_	O
82	and	_	_	O
83	Finnish	_	_	O
84	men	_	_	O
85	(	_	_	O
86	400	_	_	O
87	of	_	_	O
88	695	_	_	O
89	)	_	_	O
90	randomly	_	_	O
91	assigned	_	_	O
92	to	_	_	O
93	radical	_	_	O
94	prostatectomy	_	_	O
95	or	_	_	O
96	watchful	_	_	O
97	waiting	_	_	O
98	in	_	_	O
99	SPCG	_	_	O
100	-	_	_	O
101	4	_	_	O
102	from	_	_	O
103	1989	_	_	O
104	to	_	_	O
105	1999	_	_	O
106	were	_	_	O
107	included	_	_	O
108	in	_	_	O
109	our	_	_	O
110	analysis	_	_	O
111	.	_	_	O

112	An	_	_	O
113	additional	_	_	O
114	281	_	_	O
115	men	_	_	O
116	were	_	_	O
117	included	_	_	O
118	in	_	_	O
119	a	_	_	O
120	population	_	_	O
121	-	_	_	O
122	based	_	_	O
123	control	_	_	O
124	group	_	_	O
125	matched	_	_	O
126	for	_	_	O
127	region	_	_	O
128	and	_	_	O
129	age	_	_	O
130	.	_	_	O

131	Physical	_	_	O
132	symptoms	_	_	O
133	,	_	_	O
134	symptom	_	_	O
135	-	_	_	O
136	induced	_	_	O
137	stress	_	_	O
138	,	_	_	O
139	and	_	_	O
140	self	_	_	O
141	-	_	_	O
142	assessed	_	_	O
143	quality	_	_	O
144	of	_	_	O
145	life	_	_	O
146	were	_	_	O
147	evaluated	_	_	O
148	with	_	_	O
149	a	_	_	O
150	study	_	_	O
151	-	_	_	O
152	specific	_	_	O
153	questionnaire	_	_	O
154	.	_	_	O

155	Longitudinal	_	_	O
156	data	_	_	O
157	were	_	_	O
158	available	_	_	O
159	for	_	_	O
160	166	_	_	O
161	Swedish	_	_	O
162	men	_	_	O
163	who	_	_	O
164	had	_	_	O
165	answered	_	_	O
166	quality	_	_	O
167	-	_	_	O
168	of	_	_	O
169	-	_	_	O
170	life	_	_	O
171	questionnaires	_	_	O
172	at	_	_	O
173	an	_	_	O
174	earlier	_	_	O
175	timepoint	_	_	O
176	.	_	_	O

177	182	_	_	O
178	(	_	_	O
179	88	_	_	O
180	%	_	_	O
181	)	_	_	O
182	of	_	_	O
183	208	_	_	O
184	men	_	_	O
185	in	_	_	O
186	the	_	_	O
187	radical	_	_	O
188	prostatectomy	_	_	O
189	group	_	_	O
190	,	_	_	O
191	167	_	_	O
192	(	_	_	O
193	87	_	_	O
194	%	_	_	O
195	)	_	_	O
196	of	_	_	O
197	192	_	_	O
198	men	_	_	O
199	in	_	_	O
200	the	_	_	O
201	watchful	_	_	O
202	-	_	_	O
203	waiting	_	_	O
204	group	_	_	O
205	,	_	_	O
206	and	_	_	O
207	214	_	_	O
208	(	_	_	O
209	76	_	_	O
210	%	_	_	O
211	)	_	_	O
212	of	_	_	O
213	281	_	_	O
214	men	_	_	O
215	in	_	_	O
216	the	_	_	O
217	population	_	_	O
218	-	_	_	O
219	based	_	_	O
220	control	_	_	O
221	group	_	_	O
222	answered	_	_	O
223	the	_	_	O
224	questionnaire	_	_	O
225	.	_	_	O

226	Men	_	_	O
227	in	_	_	O
228	SPCG	_	_	O
229	-	_	_	O
230	4	_	_	O
231	had	_	_	O
232	a	_	_	O
233	median	_	_	O
234	follow	_	_	O
235	-	_	_	O
236	up	_	_	O
237	of	_	_	O
238	12	_	_	O
239	·	_	_	O
240	2	_	_	O
241	years	_	_	O
242	(	_	_	O
243	range	_	_	O
244	7	_	_	O
245	-	_	_	O
246	17	_	_	O
247	)	_	_	O
248	and	_	_	O
249	a	_	_	O
250	median	_	_	O
251	age	_	_	O
252	of	_	_	O
253	77	_	_	O
254	·	_	_	O
255	0	_	_	O
256	years	_	_	O
257	(	_	_	O
258	range	_	_	O
259	61	_	_	O
260	-	_	_	O
261	88	_	_	O
262	)	_	_	O
263	.	_	_	O

264	High	_	_	B-Premise
265	self	_	_	I-Premise
266	-	_	_	I-Premise
267	assessed	_	_	I-Premise
268	quality	_	_	I-Premise
269	of	_	_	I-Premise
270	life	_	_	I-Premise
271	was	_	_	I-Premise
272	reported	_	_	I-Premise
273	by	_	_	I-Premise
274	62	_	_	I-Premise
275	(	_	_	I-Premise
276	35	_	_	I-Premise
277	%	_	_	I-Premise
278	)	_	_	I-Premise
279	of	_	_	I-Premise
280	179	_	_	I-Premise
281	men	_	_	I-Premise
282	allocated	_	_	I-Premise
283	radical	_	_	I-Premise
284	prostatectomy	_	_	I-Premise
285	,	_	_	I-Premise
286	55	_	_	I-Premise
287	(	_	_	I-Premise
288	34	_	_	I-Premise
289	%	_	_	I-Premise
290	)	_	_	I-Premise
291	of	_	_	I-Premise
292	160	_	_	I-Premise
293	men	_	_	I-Premise
294	assigned	_	_	I-Premise
295	to	_	_	I-Premise
296	watchful	_	_	I-Premise
297	waiting	_	_	I-Premise
298	,	_	_	I-Premise
299	and	_	_	I-Premise
300	93	_	_	I-Premise
301	(	_	_	I-Premise
302	45	_	_	I-Premise
303	%	_	_	I-Premise
304	)	_	_	I-Premise
305	of	_	_	I-Premise
306	208	_	_	I-Premise
307	men	_	_	I-Premise
308	in	_	_	I-Premise
309	the	_	_	I-Premise
310	control	_	_	I-Premise
311	group	_	_	I-Premise
312	.	_	_	I-Premise

313	Anxiety	_	_	B-Premise
314	was	_	_	I-Premise
315	higher	_	_	I-Premise
316	in	_	_	I-Premise
317	the	_	_	I-Premise
318	SPCG	_	_	I-Premise
319	-	_	_	I-Premise
320	4	_	_	I-Premise
321	groups	_	_	I-Premise
322	(	_	_	I-Premise
323	77	_	_	I-Premise
324	[	_	_	I-Premise
325	43	_	_	I-Premise
326	%	_	_	I-Premise
327	]	_	_	I-Premise
328	of	_	_	I-Premise
329	178	_	_	I-Premise
330	and	_	_	I-Premise
331	69	_	_	I-Premise
332	[	_	_	I-Premise
333	43	_	_	I-Premise
334	%	_	_	I-Premise
335	]	_	_	I-Premise
336	of	_	_	I-Premise
337	161	_	_	I-Premise
338	men	_	_	I-Premise
339	)	_	_	I-Premise
340	than	_	_	I-Premise
341	in	_	_	I-Premise
342	the	_	_	I-Premise
343	control	_	_	I-Premise
344	group	_	_	I-Premise
345	(	_	_	I-Premise
346	68	_	_	I-Premise
347	[	_	_	I-Premise
348	33	_	_	I-Premise
349	%	_	_	I-Premise
350	]	_	_	I-Premise
351	of	_	_	I-Premise
352	208	_	_	I-Premise
353	men	_	_	I-Premise
354	;	_	_	I-Premise
355	relative	_	_	I-Premise
356	risk	_	_	I-Premise
357	1	_	_	I-Premise
358	·	_	_	I-Premise
359	42	_	_	I-Premise
360	,	_	_	I-Premise
361	95	_	_	I-Premise
362	%	_	_	I-Premise
363	CI	_	_	I-Premise
364	1	_	_	I-Premise
365	·	_	_	I-Premise
366	07	_	_	I-Premise
367	-	_	_	I-Premise
368	1	_	_	I-Premise
369	·	_	_	I-Premise
370	88	_	_	I-Premise
371	)	_	_	I-Premise
372	.	_	_	I-Premise

373	Prevalence	_	_	B-Premise
374	of	_	_	I-Premise
375	erectile	_	_	I-Premise
376	dysfunction	_	_	I-Premise
377	was	_	_	I-Premise
378	84	_	_	I-Premise
379	%	_	_	I-Premise
380	(	_	_	I-Premise
381	146	_	_	I-Premise
382	of	_	_	I-Premise
383	173	_	_	I-Premise
384	men	_	_	I-Premise
385	)	_	_	I-Premise
386	in	_	_	I-Premise
387	the	_	_	I-Premise
388	radical	_	_	I-Premise
389	prostatectomy	_	_	I-Premise
390	group	_	_	I-Premise
391	,	_	_	I-Premise
392	80	_	_	I-Premise
393	%	_	_	I-Premise
394	(	_	_	I-Premise
395	122	_	_	I-Premise
396	of	_	_	I-Premise
397	153	_	_	I-Premise
398	)	_	_	I-Premise
399	in	_	_	I-Premise
400	the	_	_	I-Premise
401	watchful	_	_	I-Premise
402	-	_	_	I-Premise
403	waiting	_	_	I-Premise
404	group	_	_	I-Premise
405	,	_	_	I-Premise
406	and	_	_	I-Premise
407	46	_	_	I-Premise
408	%	_	_	I-Premise
409	(	_	_	I-Premise
410	95	_	_	I-Premise
411	of	_	_	I-Premise
412	208	_	_	I-Premise
413	)	_	_	I-Premise
414	in	_	_	I-Premise
415	the	_	_	I-Premise
416	control	_	_	I-Premise
417	group	_	_	I-Premise
418	and	_	_	I-Premise
419	prevalence	_	_	I-Premise
420	of	_	_	I-Premise
421	urinary	_	_	I-Premise
422	leakage	_	_	I-Premise
423	was	_	_	I-Premise
424	41	_	_	I-Premise
425	%	_	_	I-Premise
426	(	_	_	I-Premise
427	71	_	_	I-Premise
428	of	_	_	I-Premise
429	173	_	_	I-Premise
430	)	_	_	I-Premise
431	,	_	_	I-Premise
432	11	_	_	I-Premise
433	%	_	_	I-Premise
434	(	_	_	I-Premise
435	18	_	_	I-Premise
436	of	_	_	I-Premise
437	164	_	_	I-Premise
438	)	_	_	I-Premise
439	,	_	_	I-Premise
440	and	_	_	I-Premise
441	3	_	_	I-Premise
442	%	_	_	I-Premise
443	(	_	_	I-Premise
444	six	_	_	I-Premise
445	of	_	_	I-Premise
446	209	_	_	I-Premise
447	)	_	_	I-Premise
448	,	_	_	I-Premise
449	respectively	_	_	I-Premise
450	.	_	_	I-Premise

451	Distress	_	_	B-Premise
452	caused	_	_	I-Premise
453	by	_	_	I-Premise
454	these	_	_	I-Premise
455	symptoms	_	_	I-Premise
456	was	_	_	I-Premise
457	reported	_	_	I-Premise
458	significantly	_	_	I-Premise
459	more	_	_	I-Premise
460	often	_	_	I-Premise
461	by	_	_	I-Premise
462	men	_	_	I-Premise
463	allocated	_	_	I-Premise
464	radical	_	_	I-Premise
465	prostatectomy	_	_	I-Premise
466	than	_	_	I-Premise
467	by	_	_	I-Premise
468	men	_	_	I-Premise
469	assigned	_	_	I-Premise
470	to	_	_	I-Premise
471	watchful	_	_	I-Premise
472	waiting	_	_	I-Premise
473	.	_	_	I-Premise

474	In	_	_	B-Premise
475	a	_	_	I-Premise
476	longitudinal	_	_	I-Premise
477	analysis	_	_	I-Premise
478	of	_	_	I-Premise
479	men	_	_	I-Premise
480	in	_	_	I-Premise
481	SPCG	_	_	I-Premise
482	-	_	_	I-Premise
483	4	_	_	I-Premise
484	who	_	_	I-Premise
485	provided	_	_	I-Premise
486	information	_	_	I-Premise
487	at	_	_	I-Premise
488	two	_	_	I-Premise
489	follow	_	_	I-Premise
490	-	_	_	I-Premise
491	up	_	_	I-Premise
492	points	_	_	I-Premise
493	9	_	_	I-Premise
494	years	_	_	I-Premise
495	apart	_	_	I-Premise
496	,	_	_	I-Premise
497	38	_	_	I-Premise
498	(	_	_	I-Premise
499	45	_	_	I-Premise
500	%	_	_	I-Premise
501	)	_	_	I-Premise
502	of	_	_	I-Premise
503	85	_	_	I-Premise
504	men	_	_	I-Premise
505	allocated	_	_	I-Premise
506	radical	_	_	I-Premise
507	prostatectomy	_	_	I-Premise
508	and	_	_	I-Premise
509	48	_	_	I-Premise
510	(	_	_	I-Premise
511	60	_	_	I-Premise
512	%	_	_	I-Premise
513	)	_	_	I-Premise
514	of	_	_	I-Premise
515	80	_	_	I-Premise
516	men	_	_	I-Premise
517	allocated	_	_	I-Premise
518	watchful	_	_	I-Premise
519	waiting	_	_	I-Premise
520	reported	_	_	I-Premise
521	an	_	_	I-Premise
522	increase	_	_	I-Premise
523	in	_	_	I-Premise
524	number	_	_	I-Premise
525	of	_	_	I-Premise
526	physical	_	_	I-Premise
527	symptoms	_	_	I-Premise
528	;	_	_	I-Premise
529	50	_	_	I-Premise
530	(	_	_	I-Premise
531	61	_	_	I-Premise
532	%	_	_	I-Premise
533	)	_	_	I-Premise
534	of	_	_	I-Premise
535	82	_	_	I-Premise
536	and	_	_	I-Premise
537	47	_	_	I-Premise
538	(	_	_	I-Premise
539	64	_	_	I-Premise
540	%	_	_	I-Premise
541	)	_	_	I-Premise
542	of	_	_	I-Premise
543	74	_	_	I-Premise
544	men	_	_	I-Premise
545	,	_	_	I-Premise
546	respectively	_	_	I-Premise
547	,	_	_	I-Premise
548	reported	_	_	I-Premise
549	a	_	_	I-Premise
550	reduction	_	_	I-Premise
551	in	_	_	I-Premise
552	quality	_	_	I-Premise
553	of	_	_	I-Premise
554	life	_	_	I-Premise
555	.	_	_	I-Premise

556	For	_	_	B-Premise
557	men	_	_	I-Premise
558	in	_	_	I-Premise
559	SPCG	_	_	I-Premise
560	-	_	_	I-Premise
561	4	_	_	I-Premise
562	,	_	_	I-Premise
563	negative	_	_	I-Premise
564	side	_	_	I-Premise
565	-	_	_	I-Premise
566	effects	_	_	I-Premise
567	were	_	_	I-Premise
568	common	_	_	I-Premise
569	and	_	_	I-Premise
570	added	_	_	I-Premise
571	more	_	_	I-Premise
572	stress	_	_	I-Premise
573	than	_	_	I-Premise
574	was	_	_	I-Premise
575	reported	_	_	I-Premise
576	in	_	_	I-Premise
577	the	_	_	I-Premise
578	control	_	_	I-Premise
579	population	_	_	I-Premise
580	.	_	_	I-Premise

581	In	_	_	B-Claim
582	the	_	_	I-Claim
583	radical	_	_	I-Claim
584	prostatectomy	_	_	I-Claim
585	group	_	_	I-Claim
586	,	_	_	I-Claim
587	erectile	_	_	I-Claim
588	dysfunction	_	_	I-Claim
589	and	_	_	I-Claim
590	urinary	_	_	I-Claim
591	leakage	_	_	I-Claim
592	were	_	_	I-Claim
593	often	_	_	I-Claim
594	consequences	_	_	I-Claim
595	of	_	_	I-Claim
596	surgery	_	_	I-Claim
597	.	_	_	I-Claim

598	In	_	_	B-Claim
599	the	_	_	I-Claim
600	watchful	_	_	I-Claim
601	-	_	_	I-Claim
602	waiting	_	_	I-Claim
603	group	_	_	I-Claim
604	,	_	_	I-Claim
605	side	_	_	I-Claim
606	-	_	_	I-Claim
607	effects	_	_	I-Claim
608	can	_	_	I-Claim
609	be	_	_	I-Claim
610	caused	_	_	I-Claim
611	by	_	_	I-Claim
612	tumour	_	_	I-Claim
613	progression	_	_	I-Claim
614	.	_	_	I-Claim

615	The	_	_	B-Claim
616	number	_	_	I-Claim
617	and	_	_	I-Claim
618	severity	_	_	I-Claim
619	of	_	_	I-Claim
620	side	_	_	I-Claim
621	-	_	_	I-Claim
622	effects	_	_	I-Claim
623	changes	_	_	I-Claim
624	over	_	_	I-Claim
625	time	_	_	I-Claim
626	at	_	_	I-Claim
627	a	_	_	I-Claim
628	higher	_	_	I-Claim
629	rate	_	_	I-Claim
630	than	_	_	I-Claim
631	is	_	_	I-Claim
632	caused	_	_	I-Claim
633	by	_	_	I-Claim
634	normal	_	_	I-Claim
635	ageing	_	_	I-Claim
636	and	_	_	I-Claim
637	a	_	_	I-Claim
638	loss	_	_	I-Claim
639	of	_	_	I-Claim
640	sexual	_	_	I-Claim
641	ability	_	_	I-Claim
642	is	_	_	I-Claim
643	a	_	_	I-Claim
644	persistent	_	_	I-Claim
645	psychological	_	_	I-Claim
646	problem	_	_	I-Claim
647	for	_	_	I-Claim
648	both	_	_	I-Claim
649	interventions	_	_	I-Claim
650	.	_	_	I-Claim

651	An	_	_	O
652	understanding	_	_	O
653	of	_	_	O
654	the	_	_	O
655	patterns	_	_	O
656	of	_	_	O
657	side	_	_	O
658	-	_	_	O
659	effects	_	_	O
660	and	_	_	O
661	time	_	_	O
662	dimension	_	_	O
663	of	_	_	O
664	their	_	_	O
665	occurrence	_	_	O
666	for	_	_	O
667	each	_	_	O
668	treatment	_	_	O
669	is	_	_	O
670	important	_	_	O
671	for	_	_	O
672	full	_	_	O
673	patient	_	_	O
674	information	_	_	O
675	.	_	_	O


0	Assess	_	_	O
1	toxicity	_	_	O
2	and	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	cisplatin	_	_	O
6	(	_	_	O
7	Cis	_	_	O
8	)	_	_	O
9	doublet	_	_	O
10	combinations	_	_	O
11	in	_	_	O
12	advanced	_	_	O
13	and	_	_	O
14	recurrent	_	_	O
15	cervical	_	_	O
16	carcinoma	_	_	O
17	.	_	_	O

18	Patients	_	_	O
19	were	_	_	O
20	randomly	_	_	O
21	assigned	_	_	O
22	to	_	_	O
23	paclitaxel	_	_	O
24	135	_	_	O
25	mg	_	_	O
26	/	_	_	O
27	m	_	_	O
28	(	_	_	O
29	2	_	_	O
30	)	_	_	O
31	over	_	_	O
32	24	_	_	O
33	hours	_	_	O
34	plus	_	_	O
35	Cis	_	_	O
36	50	_	_	O
37	mg	_	_	O
38	/	_	_	O
39	m	_	_	O
40	(	_	_	O
41	2	_	_	O
42	)	_	_	O
43	day	_	_	O
44	2	_	_	O
45	every	_	_	O
46	3	_	_	O
47	weeks	_	_	O
48	(	_	_	O
49	PC	_	_	O
50	,	_	_	O
51	reference	_	_	O
52	arm	_	_	O
53	)	_	_	O
54	;	_	_	O
55	vinorelbine	_	_	O
56	30	_	_	O
57	mg	_	_	O
58	/	_	_	O
59	m	_	_	O
60	(	_	_	O
61	2	_	_	O
62	)	_	_	O
63	days	_	_	O
64	1	_	_	O
65	and	_	_	O
66	8	_	_	O
67	plus	_	_	O
68	Cis	_	_	O
69	50	_	_	O
70	mg	_	_	O
71	/	_	_	O
72	m	_	_	O
73	(	_	_	O
74	2	_	_	O
75	)	_	_	O
76	day	_	_	O
77	1	_	_	O
78	every	_	_	O
79	3	_	_	O
80	weeks	_	_	O
81	(	_	_	O
82	VC	_	_	O
83	)	_	_	O
84	;	_	_	O
85	gemcitabine	_	_	O
86	1	_	_	O
87	,	_	_	O
88	000	_	_	O
89	mg	_	_	O
90	/	_	_	O
91	m	_	_	O
92	(	_	_	O
93	2	_	_	O
94	)	_	_	O
95	day	_	_	O
96	1	_	_	O
97	and	_	_	O
98	8	_	_	O
99	plus	_	_	O
100	Cis	_	_	O
101	50	_	_	O
102	mg	_	_	O
103	/	_	_	O
104	m	_	_	O
105	(	_	_	O
106	2	_	_	O
107	)	_	_	O
108	day	_	_	O
109	1	_	_	O
110	every	_	_	O
111	3	_	_	O
112	weeks	_	_	O
113	(	_	_	O
114	GC	_	_	O
115	)	_	_	O
116	;	_	_	O
117	or	_	_	O
118	topotecan	_	_	O
119	0	_	_	O
120	.	_	_	O

121	75	_	_	O
122	mg	_	_	O
123	/	_	_	O
124	m	_	_	O
125	(	_	_	O
126	2	_	_	O
127	)	_	_	O
128	days	_	_	O
129	1	_	_	O
130	,	_	_	O
131	2	_	_	O
132	,	_	_	O
133	and	_	_	O
134	3	_	_	O
135	plus	_	_	O
136	Cis	_	_	O
137	50	_	_	O
138	mg	_	_	O
139	/	_	_	O
140	m	_	_	O
141	(	_	_	O
142	2	_	_	O
143	)	_	_	O
144	day	_	_	O
145	1	_	_	O
146	every	_	_	O
147	3	_	_	O
148	weeks	_	_	O
149	(	_	_	O
150	TC	_	_	O
151	)	_	_	O
152	.	_	_	O

153	Survival	_	_	O
154	was	_	_	O
155	the	_	_	O
156	primary	_	_	O
157	end	_	_	O
158	point	_	_	O
159	with	_	_	O
160	a	_	_	O
161	33	_	_	O
162	%	_	_	O
163	improvement	_	_	O
164	relative	_	_	O
165	to	_	_	O
166	PC	_	_	O
167	considered	_	_	O
168	important	_	_	O
169	(	_	_	O
170	85	_	_	O
171	%	_	_	O
172	power	_	_	O
173	,	_	_	O
174	alpha	_	_	O
175	=	_	_	O
176	5	_	_	O
177	%	_	_	O
178	)	_	_	O
179	.	_	_	O

180	Quality	_	_	O
181	-	_	_	O
182	of	_	_	O
183	-	_	_	O
184	life	_	_	O
185	data	_	_	O
186	were	_	_	O
187	prospectively	_	_	O
188	collected	_	_	O
189	.	_	_	O

190	A	_	_	O
191	total	_	_	O
192	of	_	_	O
193	513	_	_	O
194	patients	_	_	O
195	were	_	_	O
196	enrolled	_	_	O
197	when	_	_	O
198	a	_	_	O
199	planned	_	_	O
200	interim	_	_	O
201	analysis	_	_	O
202	recommended	_	_	O
203	early	_	_	O
204	closure	_	_	O
205	for	_	_	O
206	futility	_	_	O
207	.	_	_	O

208	The	_	_	B-Premise
209	experimental	_	_	I-Premise
210	-	_	_	I-Premise
211	to	_	_	I-Premise
212	-	_	_	I-Premise
213	PC	_	_	I-Premise
214	hazard	_	_	I-Premise
215	ratios	_	_	I-Premise
216	of	_	_	I-Premise
217	death	_	_	I-Premise
218	were	_	_	I-Premise
219	1	_	_	I-Premise
220	.	_	_	I-Premise

221	15	_	_	I-Premise
222	(	_	_	I-Premise
223	95	_	_	I-Premise
224	%	_	_	I-Premise
225	CI	_	_	I-Premise
226	,	_	_	I-Premise
227	0	_	_	I-Premise
228	.	_	_	I-Premise

229	79	_	_	I-Premise
230	to	_	_	I-Premise
231	1	_	_	I-Premise
232	.	_	_	I-Premise

233	67	_	_	I-Premise
234	)	_	_	I-Premise
235	for	_	_	I-Premise
236	VC	_	_	I-Premise
237	,	_	_	I-Premise
238	1	_	_	I-Premise
239	.	_	_	I-Premise

240	32	_	_	I-Premise
241	(	_	_	I-Premise
242	95	_	_	I-Premise
243	%	_	_	I-Premise
244	CI	_	_	I-Premise
245	,	_	_	I-Premise
246	0	_	_	I-Premise
247	.	_	_	I-Premise

248	91	_	_	I-Premise
249	to	_	_	I-Premise
250	1	_	_	I-Premise
251	.	_	_	I-Premise

252	92	_	_	I-Premise
253	)	_	_	I-Premise
254	for	_	_	I-Premise
255	GC	_	_	I-Premise
256	,	_	_	I-Premise
257	and	_	_	I-Premise
258	1	_	_	I-Premise
259	.	_	_	I-Premise

260	26	_	_	I-Premise
261	(	_	_	I-Premise
262	95	_	_	I-Premise
263	%	_	_	I-Premise
264	CI	_	_	I-Premise
265	,	_	_	I-Premise
266	0	_	_	I-Premise
267	.	_	_	I-Premise

268	86	_	_	I-Premise
269	to	_	_	I-Premise
270	1	_	_	I-Premise
271	.	_	_	I-Premise

272	82	_	_	I-Premise
273	)	_	_	I-Premise
274	for	_	_	I-Premise
275	TC	_	_	I-Premise
276	.	_	_	I-Premise

277	The	_	_	B-Premise
278	hazard	_	_	I-Premise
279	ratios	_	_	I-Premise
280	for	_	_	I-Premise
281	progression	_	_	I-Premise
282	-	_	_	I-Premise
283	free	_	_	I-Premise
284	survival	_	_	I-Premise
285	(	_	_	I-Premise
286	PFS	_	_	I-Premise
287	)	_	_	I-Premise
288	were	_	_	I-Premise
289	1	_	_	I-Premise
290	.	_	_	I-Premise

291	36	_	_	I-Premise
292	(	_	_	I-Premise
293	95	_	_	I-Premise
294	%	_	_	I-Premise
295	CI	_	_	I-Premise
296	,	_	_	I-Premise
297	0	_	_	I-Premise
298	.	_	_	I-Premise

299	97	_	_	I-Premise
300	to	_	_	I-Premise
301	1	_	_	I-Premise
302	.	_	_	I-Premise

303	90	_	_	I-Premise
304	)	_	_	I-Premise
305	for	_	_	I-Premise
306	VC	_	_	I-Premise
307	,	_	_	I-Premise
308	1	_	_	I-Premise
309	.	_	_	I-Premise

310	39	_	_	I-Premise
311	(	_	_	I-Premise
312	95	_	_	I-Premise
313	%	_	_	I-Premise
314	CI	_	_	I-Premise
315	,	_	_	I-Premise
316	0	_	_	I-Premise
317	.	_	_	I-Premise

318	99	_	_	I-Premise
319	to	_	_	I-Premise
320	1	_	_	I-Premise
321	.	_	_	I-Premise

322	96	_	_	I-Premise
323	)	_	_	I-Premise
324	for	_	_	I-Premise
325	GC	_	_	I-Premise
326	,	_	_	I-Premise
327	and	_	_	I-Premise
328	1	_	_	I-Premise
329	.	_	_	I-Premise

330	27	_	_	I-Premise
331	(	_	_	I-Premise
332	95	_	_	I-Premise
333	%	_	_	I-Premise
334	CI	_	_	I-Premise
335	,	_	_	I-Premise
336	0	_	_	I-Premise
337	.	_	_	I-Premise

338	90	_	_	I-Premise
339	to	_	_	I-Premise
340	1	_	_	I-Premise
341	.	_	_	I-Premise

342	78	_	_	I-Premise
343	)	_	_	I-Premise
344	for	_	_	I-Premise
345	TC	_	_	I-Premise
346	.	_	_	I-Premise

347	Response	_	_	B-Premise
348	rates	_	_	I-Premise
349	(	_	_	I-Premise
350	RRs	_	_	I-Premise
351	)	_	_	I-Premise
352	for	_	_	I-Premise
353	PC	_	_	I-Premise
354	,	_	_	I-Premise
355	VC	_	_	I-Premise
356	,	_	_	I-Premise
357	GC	_	_	I-Premise
358	,	_	_	I-Premise
359	and	_	_	I-Premise
360	TC	_	_	I-Premise
361	were	_	_	I-Premise
362	29	_	_	I-Premise
363	.	_	_	I-Premise

364	1	_	_	I-Premise
365	%	_	_	I-Premise
366	,	_	_	I-Premise
367	25	_	_	I-Premise
368	.	_	_	I-Premise

369	9	_	_	I-Premise
370	%	_	_	I-Premise
371	,	_	_	I-Premise
372	22	_	_	I-Premise
373	.	_	_	I-Premise

374	3	_	_	I-Premise
375	%	_	_	I-Premise
376	,	_	_	I-Premise
377	and	_	_	I-Premise
378	23	_	_	I-Premise
379	.	_	_	I-Premise

380	4	_	_	I-Premise
381	%	_	_	I-Premise
382	,	_	_	I-Premise
383	respectively	_	_	I-Premise
384	.	_	_	I-Premise

385	The	_	_	B-Premise
386	arms	_	_	I-Premise
387	were	_	_	I-Premise
388	comparable	_	_	I-Premise
389	with	_	_	I-Premise
390	respect	_	_	I-Premise
391	to	_	_	I-Premise
392	toxicity	_	_	I-Premise
393	except	_	_	I-Premise
394	for	_	_	I-Premise
395	leucopenia	_	_	I-Premise
396	,	_	_	I-Premise
397	neutropenia	_	_	I-Premise
398	,	_	_	I-Premise
399	infection	_	_	I-Premise
400	,	_	_	I-Premise
401	and	_	_	I-Premise
402	alopecia	_	_	I-Premise
403	.	_	_	I-Premise

404	VC	_	_	B-Claim
405	,	_	_	I-Claim
406	GC	_	_	I-Claim
407	,	_	_	I-Claim
408	and	_	_	I-Claim
409	TC	_	_	I-Claim
410	are	_	_	I-Claim
411	not	_	_	I-Claim
412	superior	_	_	I-Claim
413	to	_	_	I-Claim
414	PC	_	_	I-Claim
415	in	_	_	I-Claim
416	terms	_	_	I-Claim
417	of	_	_	I-Claim
418	overall	_	_	I-Claim
419	survival	_	_	I-Claim
420	(	_	_	I-Claim
421	OS	_	_	I-Claim
422	)	_	_	I-Claim
423	.	_	_	I-Claim

424	However	_	_	B-Claim
425	,	_	_	I-Claim
426	the	_	_	I-Claim
427	trend	_	_	I-Claim
428	in	_	_	I-Claim
429	RR	_	_	I-Claim
430	,	_	_	I-Claim
431	PFS	_	_	I-Claim
432	,	_	_	I-Claim
433	and	_	_	I-Claim
434	OS	_	_	I-Claim
435	favors	_	_	I-Claim
436	PC	_	_	I-Claim
437	.	_	_	I-Claim

438	Differences	_	_	B-Claim
439	in	_	_	I-Claim
440	chemotherapy	_	_	I-Claim
441	scheduling	_	_	I-Claim
442	,	_	_	I-Claim
443	pre	_	_	I-Claim
444	-	_	_	I-Claim
445	existing	_	_	I-Claim
446	morbidity	_	_	I-Claim
447	,	_	_	I-Claim
448	and	_	_	I-Claim
449	toxicity	_	_	I-Claim
450	are	_	_	I-Claim
451	important	_	_	I-Claim
452	in	_	_	I-Claim
453	individualizing	_	_	I-Claim
454	therapy	_	_	I-Claim
455	.	_	_	I-Claim


0	Gynecological	_	_	O
1	neoplastic	_	_	O
2	disease	_	_	O
3	progression	_	_	O
4	is	_	_	O
5	characterized	_	_	O
6	by	_	_	O
7	specific	_	_	O
8	energy	_	_	O
9	metabolism	_	_	O
10	alterations	_	_	O
11	and	_	_	O
12	by	_	_	O
13	symptoms	_	_	O
14	including	_	_	O
15	fatigue	_	_	O
16	,	_	_	O
17	anorexia	_	_	O
18	,	_	_	O
19	nausea	_	_	O
20	,	_	_	O
21	anemia	_	_	O
22	,	_	_	O
23	and	_	_	O
24	immunodepression	_	_	O
25	,	_	_	O
26	which	_	_	O
27	result	_	_	O
28	in	_	_	O
29	a	_	_	O
30	cachexia	_	_	O
31	syndrome	_	_	O
32	and	_	_	O
33	a	_	_	O
34	marked	_	_	O
35	decrease	_	_	O
36	in	_	_	O
37	patient	_	_	O
38	quality	_	_	O
39	of	_	_	O
40	life	_	_	O
41	(	_	_	O
42	QoL	_	_	O
43	)	_	_	O
44	.	_	_	O

45	Therapeutic	_	_	O
46	protocols	_	_	O
47	associated	_	_	O
48	with	_	_	O
49	appropriate	_	_	O
50	and	_	_	O
51	effective	_	_	O
52	psychological	_	_	O
53	and	_	_	O
54	social	_	_	O
55	support	_	_	O
56	systems	_	_	O
57	are	_	_	O
58	essential	_	_	O
59	to	_	_	O
60	counteract	_	_	O
61	the	_	_	O
62	symptoms	_	_	O
63	of	_	_	O
64	neoplastic	_	_	O
65	disease	_	_	O
66	in	_	_	O
67	incurable	_	_	O
68	patients	_	_	O
69	.	_	_	O

70	A	_	_	O
71	phase	_	_	O
72	III	_	_	O
73	randomized	_	_	O
74	study	_	_	O
75	was	_	_	O
76	performed	_	_	O
77	to	_	_	O
78	establish	_	_	O
79	the	_	_	O
80	most	_	_	O
81	effective	_	_	O
82	and	_	_	O
83	safest	_	_	O
84	treatment	_	_	O
85	to	_	_	O
86	improve	_	_	O
87	the	_	_	O
88	key	_	_	O
89	symptoms	_	_	O
90	in	_	_	O
91	advanced	_	_	O
92	gynecological	_	_	O
93	cancer	_	_	O
94	patients	_	_	O
95	,	_	_	O
96	i	_	_	O
97	.	_	_	O

98	e	_	_	O
99	.	_	_	O

100	,	_	_	O
101	lean	_	_	O
102	body	_	_	O
103	mass	_	_	O
104	(	_	_	O
105	LBM	_	_	O
106	)	_	_	O
107	,	_	_	O
108	resting	_	_	O
109	energy	_	_	O
110	expenditure	_	_	O
111	(	_	_	O
112	REE	_	_	O
113	)	_	_	O
114	,	_	_	O
115	fatigue	_	_	O
116	,	_	_	O
117	and	_	_	O
118	QoL	_	_	O
119	.	_	_	O

120	In	_	_	O
121	addition	_	_	O
122	,	_	_	O
123	the	_	_	O
124	impact	_	_	O
125	of	_	_	O
126	the	_	_	O
127	treatment	_	_	O
128	arms	_	_	O
129	on	_	_	O
130	the	_	_	O
131	main	_	_	O
132	metabolic	_	_	O
133	and	_	_	O
134	inflammatory	_	_	O
135	parameters	_	_	O
136	,	_	_	O
137	including	_	_	O
138	C	_	_	O
139	-	_	_	O
140	reactive	_	_	O
141	protein	_	_	O
142	(	_	_	O
143	CRP	_	_	O
144	)	_	_	O
145	,	_	_	O
146	interleukin	_	_	O
147	(	_	_	O
148	IL	_	_	O
149	)	_	_	O
150	-	_	_	O
151	6	_	_	O
152	,	_	_	O
153	tumor	_	_	O
154	necrosis	_	_	O
155	factor	_	_	O
156	(	_	_	O
157	TNF	_	_	O
158	)	_	_	O
159	-	_	_	O
160	α	_	_	O
161	,	_	_	O
162	leptin	_	_	O
163	,	_	_	O
164	reactive	_	_	O
165	oxygen	_	_	O
166	species	_	_	O
167	(	_	_	O
168	ROS	_	_	O
169	)	_	_	O
170	,	_	_	O
171	and	_	_	O
172	glutathione	_	_	O
173	peroxidase	_	_	O
174	,	_	_	O
175	was	_	_	O
176	evaluated	_	_	O
177	.	_	_	O

178	The	_	_	O
179	change	_	_	O
180	in	_	_	O
181	the	_	_	O
182	Glasgow	_	_	O
183	Prognostic	_	_	O
184	Score	_	_	O
185	(	_	_	O
186	GPS	_	_	O
187	)	_	_	O
188	during	_	_	O
189	treatment	_	_	O
190	was	_	_	O
191	also	_	_	O
192	assessed	_	_	O
193	.	_	_	O

194	A	_	_	O
195	total	_	_	O
196	of	_	_	O
197	104	_	_	O
198	advanced	_	_	O
199	-	_	_	O
200	stage	_	_	O
201	gynecological	_	_	O
202	cancer	_	_	O
203	patients	_	_	O
204	were	_	_	O
205	enrolled	_	_	O
206	and	_	_	O
207	randomly	_	_	O
208	assigned	_	_	O
209	to	_	_	O
210	receive	_	_	O
211	either	_	_	O
212	megestrol	_	_	O
213	acetate	_	_	O
214	(	_	_	O
215	MA	_	_	O
216	)	_	_	O
217	plus	_	_	O
218	l	_	_	O
219	-	_	_	O
220	carnitine	_	_	O
221	,	_	_	O
222	celecoxib	_	_	O
223	,	_	_	O
224	and	_	_	O
225	antioxidants	_	_	O
226	(	_	_	O
227	arm	_	_	O
228	1	_	_	O
229	)	_	_	O
230	or	_	_	O
231	MA	_	_	O
232	alone	_	_	O
233	(	_	_	O
234	arm	_	_	O
235	2	_	_	O
236	)	_	_	O
237	.	_	_	O

238	The	_	_	O
239	treatment	_	_	O
240	duration	_	_	O
241	was	_	_	O
242	4	_	_	O
243	months	_	_	O
244	.	_	_	O

245	The	_	_	B-Premise
246	combination	_	_	I-Premise
247	arm	_	_	I-Premise
248	was	_	_	I-Premise
249	more	_	_	I-Premise
250	effective	_	_	I-Premise
251	than	_	_	I-Premise
252	arm	_	_	I-Premise
253	2	_	_	I-Premise
254	with	_	_	I-Premise
255	respect	_	_	I-Premise
256	to	_	_	I-Premise
257	LBM	_	_	I-Premise
258	,	_	_	I-Premise
259	REE	_	_	I-Premise
260	,	_	_	I-Premise
261	fatigue	_	_	I-Premise
262	,	_	_	I-Premise
263	and	_	_	I-Premise
264	global	_	_	I-Premise
265	QoL	_	_	I-Premise
266	.	_	_	I-Premise

267	As	_	_	B-Premise
268	for	_	_	I-Premise
269	the	_	_	I-Premise
270	secondary	_	_	I-Premise
271	efficacy	_	_	I-Premise
272	endpoints	_	_	I-Premise
273	,	_	_	I-Premise
274	patient	_	_	I-Premise
275	appetite	_	_	I-Premise
276	increased	_	_	I-Premise
277	,	_	_	I-Premise
278	and	_	_	I-Premise
279	ECOG	_	_	I-Premise
280	PS	_	_	I-Premise
281	decreased	_	_	I-Premise
282	significantly	_	_	I-Premise
283	in	_	_	I-Premise
284	both	_	_	I-Premise
285	arms	_	_	I-Premise
286	.	_	_	I-Premise

287	The	_	_	B-Premise
288	inflammation	_	_	I-Premise
289	and	_	_	I-Premise
290	oxidative	_	_	I-Premise
291	stress	_	_	I-Premise
292	parameters	_	_	I-Premise
293	IL	_	_	I-Premise
294	-	_	_	I-Premise
295	6	_	_	I-Premise
296	,	_	_	I-Premise
297	TNF	_	_	I-Premise
298	-	_	_	I-Premise
299	α	_	_	I-Premise
300	,	_	_	I-Premise
301	CRP	_	_	I-Premise
302	,	_	_	I-Premise
303	and	_	_	I-Premise
304	ROS	_	_	I-Premise
305	decreased	_	_	I-Premise
306	significantly	_	_	I-Premise
307	in	_	_	I-Premise
308	arm	_	_	I-Premise
309	1	_	_	I-Premise
310	,	_	_	I-Premise
311	while	_	_	I-Premise
312	no	_	_	I-Premise
313	significant	_	_	I-Premise
314	change	_	_	I-Premise
315	was	_	_	I-Premise
316	observed	_	_	I-Premise
317	in	_	_	I-Premise
318	arm	_	_	I-Premise
319	2	_	_	I-Premise
320	.	_	_	I-Premise

321	The	_	_	B-Claim
322	combined	_	_	I-Claim
323	treatment	_	_	I-Claim
324	improved	_	_	I-Claim
325	both	_	_	I-Claim
326	immunometabolic	_	_	I-Claim
327	alterations	_	_	I-Claim
328	and	_	_	I-Claim
329	patient	_	_	I-Claim
330	QoL	_	_	I-Claim
331	.	_	_	I-Claim

332	Multimodality	_	_	B-Claim
333	therapies	_	_	I-Claim
334	for	_	_	I-Claim
335	cachexia	_	_	I-Claim
336	ideally	_	_	I-Claim
337	should	_	_	I-Claim
338	be	_	_	I-Claim
339	introduced	_	_	I-Claim
340	within	_	_	I-Claim
341	a	_	_	I-Claim
342	context	_	_	I-Claim
343	of	_	_	I-Claim
344	"	_	_	I-Claim
345	best	_	_	I-Claim
346	supportive	_	_	I-Claim
347	care	_	_	I-Claim
348	"	_	_	I-Claim
349	that	_	_	I-Claim
350	includes	_	_	I-Claim
351	optimal	_	_	I-Claim
352	symptom	_	_	I-Claim
353	management	_	_	I-Claim
354	and	_	_	I-Claim
355	careful	_	_	I-Claim
356	psychosocial	_	_	I-Claim
357	counseling	_	_	I-Claim
358	.	_	_	I-Claim


0	In	_	_	O
1	phase	_	_	O
2	II	_	_	O
3	studies	_	_	O
4	,	_	_	O
5	irinotecan	_	_	O
6	is	_	_	O
7	active	_	_	O
8	in	_	_	O
9	metastatic	_	_	O
10	colorectal	_	_	O
11	cancer	_	_	O
12	,	_	_	O
13	but	_	_	O
14	the	_	_	O
15	overall	_	_	O
16	benefit	_	_	O
17	has	_	_	O
18	not	_	_	O
19	been	_	_	O
20	assessed	_	_	O
21	in	_	_	O
22	a	_	_	O
23	randomised	_	_	O
24	clinical	_	_	O
25	trial	_	_	O
26	.	_	_	O

27	Patients	_	_	O
28	with	_	_	O
29	proven	_	_	O
30	metastatic	_	_	O
31	colorectal	_	_	O
32	cancer	_	_	O
33	,	_	_	O
34	which	_	_	O
35	had	_	_	O
36	progressed	_	_	O
37	within	_	_	O
38	6	_	_	O
39	months	_	_	O
40	of	_	_	O
41	treatment	_	_	O
42	with	_	_	O
43	fluorouracil	_	_	O
44	,	_	_	O
45	were	_	_	O
46	randomly	_	_	O
47	assigned	_	_	O
48	either	_	_	O
49	300	_	_	O
50	-	_	_	O
51	350	_	_	O
52	mg	_	_	O
53	/	_	_	O
54	m2	_	_	O
55	irinotecan	_	_	O
56	every	_	_	O
57	3	_	_	O
58	weeks	_	_	O
59	with	_	_	O
60	supportive	_	_	O
61	care	_	_	O
62	or	_	_	O
63	supportive	_	_	O
64	care	_	_	O
65	alone	_	_	O
66	,	_	_	O
67	in	_	_	O
68	a	_	_	O
69	2	_	_	O
70	:	_	_	O
71	1	_	_	O
72	ratio	_	_	O
73	.	_	_	O

74	189	_	_	O
75	patients	_	_	O
76	were	_	_	O
77	allocated	_	_	O
78	irinotecan	_	_	O
79	and	_	_	O
80	supportive	_	_	O
81	care	_	_	O
82	and	_	_	O
83	90	_	_	O
84	supportive	_	_	O
85	care	_	_	O
86	alone	_	_	O
87	.	_	_	O

88	The	_	_	O
89	mean	_	_	O
90	age	_	_	O
91	of	_	_	O
92	the	_	_	O
93	participants	_	_	O
94	was	_	_	O
95	58	_	_	O
96	.	_	_	O

97	8	_	_	O
98	years	_	_	O
99	;	_	_	O
100	181	_	_	O
101	(	_	_	O
102	65	_	_	O
103	%	_	_	O
104	)	_	_	O
105	were	_	_	O
106	men	_	_	O
107	and	_	_	O
108	98	_	_	O
109	(	_	_	O
110	35	_	_	O
111	%	_	_	O
112	)	_	_	O
113	were	_	_	O
114	women	_	_	O
115	.	_	_	O

116	WHO	_	_	O
117	performance	_	_	O
118	status	_	_	O
119	was	_	_	O
120	0	_	_	O
121	in	_	_	O
122	79	_	_	O
123	(	_	_	O
124	42	_	_	O
125	%	_	_	O
126	)	_	_	O
127	patients	_	_	O
128	,	_	_	O
129	1	_	_	O
130	in	_	_	O
131	77	_	_	O
132	(	_	_	O
133	41	_	_	O
134	%	_	_	O
135	)	_	_	O
136	patients	_	_	O
137	,	_	_	O
138	and	_	_	O
139	2	_	_	O
140	in	_	_	O
141	32	_	_	O
142	(	_	_	O
143	17	_	_	O
144	%	_	_	O
145	)	_	_	O
146	patients	_	_	O
147	.	_	_	O

148	Tumour	_	_	O
149	-	_	_	O
150	related	_	_	O
151	symptoms	_	_	O
152	were	_	_	O
153	present	_	_	O
154	in	_	_	O
155	134	_	_	O
156	(	_	_	O
157	71	_	_	O
158	%	_	_	O
159	)	_	_	O
160	patients	_	_	O
161	and	_	_	O
162	weight	_	_	O
163	loss	_	_	O
164	of	_	_	O
165	more	_	_	O
166	than	_	_	O
167	5	_	_	O
168	%	_	_	O
169	was	_	_	O
170	seen	_	_	O
171	in	_	_	O
172	15	_	_	O
173	(	_	_	O
174	8	_	_	O
175	%	_	_	O
176	)	_	_	O
177	patients	_	_	O
178	.	_	_	O

179	With	_	_	B-Premise
180	a	_	_	I-Premise
181	median	_	_	I-Premise
182	follow	_	_	I-Premise
183	-	_	_	I-Premise
184	up	_	_	I-Premise
185	of	_	_	I-Premise
186	13	_	_	I-Premise
187	months	_	_	I-Premise
188	,	_	_	I-Premise
189	the	_	_	I-Premise
190	overall	_	_	I-Premise
191	survival	_	_	I-Premise
192	was	_	_	I-Premise
193	significantly	_	_	I-Premise
194	better	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	irinotecan	_	_	I-Premise
198	group	_	_	I-Premise
199	(	_	_	I-Premise
200	p	_	_	I-Premise
201	=	_	_	I-Premise
202	0	_	_	I-Premise
203	.	_	_	I-Premise

204	0001	_	_	I-Premise
205	)	_	_	I-Premise
206	,	_	_	I-Premise
207	with	_	_	I-Premise
208	36	_	_	I-Premise
209	.	_	_	I-Premise

210	2	_	_	I-Premise
211	%	_	_	I-Premise
212	1	_	_	I-Premise
213	-	_	_	I-Premise
214	year	_	_	I-Premise
215	survival	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	irinotecan	_	_	I-Premise
219	group	_	_	I-Premise
220	versus	_	_	I-Premise
221	13	_	_	I-Premise
222	.	_	_	I-Premise

223	8	_	_	I-Premise
224	%	_	_	I-Premise
225	in	_	_	I-Premise
226	the	_	_	I-Premise
227	supportive	_	_	I-Premise
228	-	_	_	I-Premise
229	care	_	_	I-Premise
230	group	_	_	I-Premise
231	.	_	_	I-Premise

232	The	_	_	B-Premise
233	survival	_	_	I-Premise
234	benefit	_	_	I-Premise
235	,	_	_	I-Premise
236	adjusted	_	_	I-Premise
237	for	_	_	I-Premise
238	prognostic	_	_	I-Premise
239	factors	_	_	I-Premise
240	in	_	_	I-Premise
241	a	_	_	I-Premise
242	multivariate	_	_	I-Premise
243	analysis	_	_	I-Premise
244	,	_	_	I-Premise
245	remained	_	_	I-Premise
246	significant	_	_	I-Premise
247	(	_	_	I-Premise
248	p	_	_	I-Premise
249	=	_	_	I-Premise
250	0	_	_	I-Premise
251	.	_	_	I-Premise

252	001	_	_	I-Premise
253	)	_	_	I-Premise
254	.	_	_	I-Premise

255	Survival	_	_	B-Premise
256	without	_	_	I-Premise
257	performance	_	_	I-Premise
258	-	_	_	I-Premise
259	status	_	_	I-Premise
260	deterioration	_	_	I-Premise
261	(	_	_	I-Premise
262	p	_	_	I-Premise
263	=	_	_	I-Premise
264	0	_	_	I-Premise
265	.	_	_	I-Premise

266	0001	_	_	I-Premise
267	)	_	_	I-Premise
268	,	_	_	I-Premise
269	without	_	_	I-Premise
270	weight	_	_	I-Premise
271	loss	_	_	I-Premise
272	of	_	_	I-Premise
273	more	_	_	I-Premise
274	than	_	_	I-Premise
275	5	_	_	I-Premise
276	%	_	_	I-Premise
277	(	_	_	I-Premise
278	p	_	_	I-Premise
279	=	_	_	I-Premise
280	0	_	_	I-Premise
281	.	_	_	I-Premise

282	018	_	_	I-Premise
283	)	_	_	I-Premise
284	,	_	_	I-Premise
285	and	_	_	I-Premise
286	pain	_	_	I-Premise
287	-	_	_	I-Premise
288	free	_	_	I-Premise
289	survival	_	_	I-Premise
290	(	_	_	I-Premise
291	p	_	_	I-Premise
292	=	_	_	I-Premise
293	0	_	_	I-Premise
294	.	_	_	I-Premise

295	003	_	_	I-Premise
296	)	_	_	I-Premise
297	were	_	_	I-Premise
298	significantly	_	_	I-Premise
299	better	_	_	I-Premise
300	in	_	_	I-Premise
301	the	_	_	I-Premise
302	patients	_	_	I-Premise
303	given	_	_	I-Premise
304	irinotecan	_	_	I-Premise
305	.	_	_	I-Premise

306	In	_	_	B-Premise
307	a	_	_	I-Premise
308	quality	_	_	I-Premise
309	-	_	_	I-Premise
310	of	_	_	I-Premise
311	-	_	_	I-Premise
312	life	_	_	I-Premise
313	analysis	_	_	I-Premise
314	,	_	_	I-Premise
315	all	_	_	I-Premise
316	significant	_	_	I-Premise
317	differences	_	_	I-Premise
318	,	_	_	I-Premise
319	except	_	_	I-Premise
320	on	_	_	I-Premise
321	diarrhoea	_	_	I-Premise
322	score	_	_	I-Premise
323	,	_	_	I-Premise
324	were	_	_	I-Premise
325	in	_	_	I-Premise
326	favour	_	_	I-Premise
327	of	_	_	I-Premise
328	the	_	_	I-Premise
329	irinotecan	_	_	I-Premise
330	group	_	_	I-Premise
331	.	_	_	I-Premise

332	Our	_	_	B-Claim
333	study	_	_	I-Claim
334	shows	_	_	I-Claim
335	that	_	_	I-Claim
336	despite	_	_	I-Claim
337	the	_	_	I-Claim
338	side	_	_	I-Claim
339	-	_	_	I-Claim
340	effects	_	_	I-Claim
341	of	_	_	I-Claim
342	treatment	_	_	I-Claim
343	,	_	_	I-Claim
344	patients	_	_	I-Claim
345	who	_	_	I-Claim
346	have	_	_	I-Claim
347	metastatic	_	_	I-Claim
348	colorectal	_	_	I-Claim
349	cancer	_	_	I-Claim
350	,	_	_	I-Claim
351	and	_	_	I-Claim
352	for	_	_	I-Claim
353	whom	_	_	I-Claim
354	fluorouracil	_	_	I-Claim
355	has	_	_	I-Claim
356	failed	_	_	I-Claim
357	,	_	_	I-Claim
358	have	_	_	I-Claim
359	a	_	_	I-Claim
360	longer	_	_	I-Claim
361	survival	_	_	I-Claim
362	,	_	_	I-Claim
363	fewer	_	_	I-Claim
364	tumour	_	_	I-Claim
365	-	_	_	I-Claim
366	related	_	_	I-Claim
367	symptoms	_	_	I-Claim
368	,	_	_	I-Claim
369	and	_	_	I-Claim
370	a	_	_	I-Claim
371	better	_	_	I-Claim
372	quality	_	_	I-Claim
373	of	_	_	I-Claim
374	life	_	_	I-Claim
375	when	_	_	I-Claim
376	treated	_	_	I-Claim
377	with	_	_	I-Claim
378	irinotecan	_	_	I-Claim
379	than	_	_	I-Claim
380	with	_	_	I-Claim
381	supportive	_	_	I-Claim
382	care	_	_	I-Claim
383	alone	_	_	I-Claim
384	.	_	_	I-Claim


0	In	_	_	O
1	a	_	_	O
2	previous	_	_	O
3	study	_	_	O
4	of	_	_	O
5	treatment	_	_	O
6	for	_	_	O
7	advanced	_	_	O
8	colorectal	_	_	O
9	cancer	_	_	O
10	,	_	_	O
11	the	_	_	O
12	LV5FU2	_	_	O
13	regimen	_	_	O
14	,	_	_	O
15	comprising	_	_	O
16	leucovorin	_	_	O
17	(	_	_	O
18	LV	_	_	O
19	)	_	_	O
20	plus	_	_	O
21	bolus	_	_	O
22	and	_	_	O
23	infusional	_	_	O
24	fluorouracil	_	_	O
25	(	_	_	O
26	5FU	_	_	O
27	)	_	_	O
28	every	_	_	O
29	2	_	_	O
30	weeks	_	_	O
31	,	_	_	O
32	was	_	_	O
33	superior	_	_	O
34	to	_	_	O
35	the	_	_	O
36	standard	_	_	O
37	North	_	_	O
38	Central	_	_	O
39	Cancer	_	_	O
40	Treatment	_	_	O
41	Group	_	_	O
42	/	_	_	O
43	Mayo	_	_	O
44	Clinic	_	_	O
45	5	_	_	O
46	-	_	_	O
47	day	_	_	O
48	bolus	_	_	O
49	5FU	_	_	O
50	/	_	_	O
51	LV	_	_	O
52	regimen	_	_	O
53	.	_	_	O

54	This	_	_	O
55	phase	_	_	O
56	III	_	_	O
57	study	_	_	O
58	investigated	_	_	O
59	the	_	_	O
60	effect	_	_	O
61	of	_	_	O
62	combining	_	_	O
63	oxaliplatin	_	_	O
64	with	_	_	O
65	LV5FU2	_	_	O
66	,	_	_	O
67	with	_	_	O
68	progression	_	_	O
69	-	_	_	O
70	free	_	_	O
71	survival	_	_	O
72	as	_	_	O
73	the	_	_	O
74	primary	_	_	O
75	end	_	_	O
76	point	_	_	O
77	.	_	_	O

78	Four	_	_	O
79	hundred	_	_	O
80	twenty	_	_	O
81	previously	_	_	O
82	untreated	_	_	O
83	patients	_	_	O
84	with	_	_	O
85	measurable	_	_	O
86	disease	_	_	O
87	were	_	_	O
88	randomized	_	_	O
89	to	_	_	O
90	receive	_	_	O
91	a	_	_	O
92	2	_	_	O
93	-	_	_	O
94	hour	_	_	O
95	infusion	_	_	O
96	of	_	_	O
97	LV	_	_	O
98	(	_	_	O
99	200	_	_	O
100	mg	_	_	O
101	/	_	_	O
102	m	_	_	O
103	(	_	_	O
104	2	_	_	O
105	)	_	_	O
106	/	_	_	O
107	d	_	_	O
108	)	_	_	O
109	followed	_	_	O
110	by	_	_	O
111	a	_	_	O
112	5FU	_	_	O
113	bolus	_	_	O
114	(	_	_	O
115	400	_	_	O
116	mg	_	_	O
117	/	_	_	O
118	m	_	_	O
119	(	_	_	O
120	2	_	_	O
121	)	_	_	O
122	/	_	_	O
123	d	_	_	O
124	)	_	_	O
125	and	_	_	O
126	22	_	_	O
127	-	_	_	O
128	hour	_	_	O
129	infusion	_	_	O
130	(	_	_	O
131	600	_	_	O
132	mg	_	_	O
133	/	_	_	O
134	m	_	_	O
135	(	_	_	O
136	2	_	_	O
137	)	_	_	O
138	/	_	_	O
139	d	_	_	O
140	)	_	_	O
141	for	_	_	O
142	2	_	_	O
143	consecutive	_	_	O
144	days	_	_	O
145	every	_	_	O
146	2	_	_	O
147	weeks	_	_	O
148	,	_	_	O
149	either	_	_	O
150	alone	_	_	O
151	or	_	_	O
152	together	_	_	O
153	with	_	_	O
154	oxaliplatin	_	_	O
155	85	_	_	O
156	mg	_	_	O
157	/	_	_	O
158	m	_	_	O
159	(	_	_	O
160	2	_	_	O
161	)	_	_	O
162	as	_	_	O
163	a	_	_	O
164	2	_	_	O
165	-	_	_	O
166	hour	_	_	O
167	infusion	_	_	O
168	on	_	_	O
169	day	_	_	O
170	1	_	_	O
171	.	_	_	O

172	Patients	_	_	B-Premise
173	allocated	_	_	I-Premise
174	to	_	_	I-Premise
175	oxaliplatin	_	_	I-Premise
176	plus	_	_	I-Premise
177	LV5FU2	_	_	I-Premise
178	had	_	_	I-Premise
179	significantly	_	_	I-Premise
180	longer	_	_	I-Premise
181	progression	_	_	I-Premise
182	-	_	_	I-Premise
183	free	_	_	I-Premise
184	survival	_	_	I-Premise
185	(	_	_	I-Premise
186	median	_	_	I-Premise
187	,	_	_	I-Premise
188	9	_	_	I-Premise
189	.	_	_	I-Premise

190	0	_	_	I-Premise
191	v	_	_	I-Premise
192	6	_	_	I-Premise
193	.	_	_	I-Premise

194	2	_	_	I-Premise
195	months	_	_	I-Premise
196	;	_	_	I-Premise
197	P	_	_	I-Premise
198	=	_	_	I-Premise
199	.	_	_	I-Premise

200	0003	_	_	I-Premise
201	)	_	_	I-Premise
202	and	_	_	I-Premise
203	better	_	_	I-Premise
204	response	_	_	I-Premise
205	rate	_	_	I-Premise
206	(	_	_	I-Premise
207	50	_	_	I-Premise
208	.	_	_	I-Premise

209	7	_	_	I-Premise
210	%	_	_	I-Premise
211	v	_	_	I-Premise
212	22	_	_	I-Premise
213	.	_	_	I-Premise

214	3	_	_	I-Premise
215	%	_	_	I-Premise
216	;	_	_	I-Premise
217	P	_	_	I-Premise
218	=	_	_	I-Premise
219	.	_	_	I-Premise

220	0001	_	_	I-Premise
221	)	_	_	I-Premise
222	when	_	_	I-Premise
223	compared	_	_	I-Premise
224	with	_	_	I-Premise
225	the	_	_	I-Premise
226	control	_	_	I-Premise
227	arm	_	_	I-Premise
228	.	_	_	I-Premise

229	The	_	_	B-Premise
230	improvement	_	_	I-Premise
231	in	_	_	I-Premise
232	overall	_	_	I-Premise
233	survival	_	_	I-Premise
234	did	_	_	I-Premise
235	not	_	_	I-Premise
236	reach	_	_	I-Premise
237	significance	_	_	I-Premise
238	(	_	_	I-Premise
239	median	_	_	I-Premise
240	,	_	_	I-Premise
241	16	_	_	I-Premise
242	.	_	_	I-Premise

243	2	_	_	I-Premise
244	v	_	_	I-Premise
245	14	_	_	I-Premise
246	.	_	_	I-Premise

247	7	_	_	I-Premise
248	months	_	_	I-Premise
249	;	_	_	I-Premise
250	P	_	_	I-Premise
251	=	_	_	I-Premise
252	.	_	_	I-Premise

253	12	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	LV5FU2	_	_	B-Premise
257	plus	_	_	I-Premise
258	oxaliplatin	_	_	I-Premise
259	gave	_	_	I-Premise
260	higher	_	_	I-Premise
261	frequencies	_	_	I-Premise
262	of	_	_	I-Premise
263	National	_	_	I-Premise
264	Cancer	_	_	I-Premise
265	Institute	_	_	I-Premise
266	common	_	_	I-Premise
267	toxicity	_	_	I-Premise
268	criteria	_	_	I-Premise
269	grade	_	_	I-Premise
270	3	_	_	I-Premise
271	/	_	_	I-Premise
272	4	_	_	I-Premise
273	neutropenia	_	_	I-Premise
274	(	_	_	I-Premise
275	41	_	_	I-Premise
276	.	_	_	I-Premise

277	7	_	_	I-Premise
278	%	_	_	I-Premise
279	v	_	_	I-Premise
280	5	_	_	I-Premise
281	.	_	_	I-Premise

282	3	_	_	I-Premise
283	%	_	_	I-Premise
284	of	_	_	I-Premise
285	patients	_	_	I-Premise
286	)	_	_	I-Premise
287	,	_	_	I-Premise
288	grade	_	_	I-Premise
289	3	_	_	I-Premise
290	/	_	_	I-Premise
291	4	_	_	I-Premise
292	diarrhea	_	_	I-Premise
293	(	_	_	I-Premise
294	11	_	_	I-Premise
295	.	_	_	I-Premise

296	9	_	_	I-Premise
297	%	_	_	I-Premise
298	v	_	_	I-Premise
299	5	_	_	I-Premise
300	.	_	_	I-Premise

301	3	_	_	I-Premise
302	%	_	_	I-Premise
303	)	_	_	I-Premise
304	,	_	_	I-Premise
305	and	_	_	I-Premise
306	grade	_	_	I-Premise
307	3	_	_	I-Premise
308	neurosensory	_	_	I-Premise
309	toxicity	_	_	I-Premise
310	(	_	_	I-Premise
311	18	_	_	I-Premise
312	.	_	_	I-Premise

313	2	_	_	I-Premise
314	%	_	_	I-Premise
315	v	_	_	I-Premise
316	0	_	_	I-Premise
317	%	_	_	I-Premise
318	)	_	_	I-Premise
319	,	_	_	I-Premise
320	but	_	_	I-Premise
321	this	_	_	I-Premise
322	did	_	_	I-Premise
323	not	_	_	I-Premise
324	result	_	_	I-Premise
325	in	_	_	I-Premise
326	impairment	_	_	I-Premise
327	of	_	_	I-Premise
328	quality	_	_	I-Premise
329	of	_	_	I-Premise
330	life	_	_	I-Premise
331	(	_	_	I-Premise
332	QoL	_	_	I-Premise
333	)	_	_	I-Premise
334	.	_	_	I-Premise

335	Survival	_	_	B-Premise
336	without	_	_	I-Premise
337	disease	_	_	I-Premise
338	progression	_	_	I-Premise
339	or	_	_	I-Premise
340	deterioration	_	_	I-Premise
341	in	_	_	I-Premise
342	global	_	_	I-Premise
343	health	_	_	I-Premise
344	status	_	_	I-Premise
345	was	_	_	I-Premise
346	longer	_	_	I-Premise
347	in	_	_	I-Premise
348	patients	_	_	I-Premise
349	allocated	_	_	I-Premise
350	to	_	_	I-Premise
351	oxaliplatin	_	_	I-Premise
352	treatment	_	_	I-Premise
353	(	_	_	I-Premise
354	P	_	_	I-Premise
355	=	_	_	I-Premise
356	.	_	_	I-Premise

357	004	_	_	I-Premise
358	)	_	_	I-Premise
359	.	_	_	I-Premise

360	The	_	_	B-Claim
361	LV5FU2	_	_	I-Claim
362	-	_	_	I-Claim
363	oxaliplatin	_	_	I-Claim
364	combination	_	_	I-Claim
365	seems	_	_	I-Claim
366	beneficial	_	_	I-Claim
367	as	_	_	I-Claim
368	first	_	_	I-Claim
369	-	_	_	I-Claim
370	line	_	_	I-Claim
371	therapy	_	_	I-Claim
372	in	_	_	I-Claim
373	advanced	_	_	I-Claim
374	colorectal	_	_	I-Claim
375	cancer	_	_	I-Claim
376	,	_	_	I-Claim
377	demonstrating	_	_	I-Claim
378	a	_	_	I-Claim
379	prolonged	_	_	I-Claim
380	progression	_	_	I-Claim
381	-	_	_	I-Claim
382	free	_	_	I-Claim
383	survival	_	_	I-Claim
384	with	_	_	I-Claim
385	acceptable	_	_	I-Claim
386	tolerability	_	_	I-Claim
387	and	_	_	I-Claim
388	maintenance	_	_	I-Claim
389	of	_	_	I-Claim
390	QoL	_	_	I-Claim
391	.	_	_	I-Claim


0	Standard	_	_	O
1	guidelines	_	_	O
2	for	_	_	O
3	cancer	_	_	O
4	pain	_	_	O
5	treatment	_	_	O
6	routinely	_	_	O
7	recommend	_	_	O
8	training	_	_	O
9	patients	_	_	O
10	to	_	_	O
11	reduce	_	_	O
12	barriers	_	_	O
13	to	_	_	O
14	pain	_	_	O
15	relief	_	_	O
16	,	_	_	O
17	use	_	_	O
18	medications	_	_	O
19	appropriately	_	_	O
20	,	_	_	O
21	and	_	_	O
22	communicate	_	_	O
23	their	_	_	O
24	pain	_	_	O
25	-	_	_	O
26	related	_	_	O
27	needs	_	_	O
28	.	_	_	O

29	Methods	_	_	B-Claim
30	are	_	_	I-Claim
31	needed	_	_	I-Claim
32	to	_	_	I-Claim
33	reduce	_	_	I-Claim
34	professional	_	_	I-Claim
35	time	_	_	I-Claim
36	required	_	_	I-Claim
37	while	_	_	I-Claim
38	achieving	_	_	I-Claim
39	sustained	_	_	I-Claim
40	intervention	_	_	I-Claim
41	effectiveness	_	_	I-Claim
42	.	_	_	I-Claim

43	In	_	_	O
44	a	_	_	O
45	multisite	_	_	O
46	,	_	_	O
47	randomized	_	_	O
48	controlled	_	_	O
49	trial	_	_	O
50	,	_	_	O
51	this	_	_	O
52	study	_	_	O
53	tested	_	_	O
54	a	_	_	O
55	pain	_	_	O
56	training	_	_	O
57	method	_	_	O
58	versus	_	_	O
59	a	_	_	O
60	nutrition	_	_	O
61	control	_	_	O
62	.	_	_	O

63	At	_	_	O
64	six	_	_	O
65	oncology	_	_	O
66	clinics	_	_	O
67	,	_	_	O
68	physicians	_	_	O
69	(	_	_	O
70	N	_	_	O
71	=	_	_	O
72	22	_	_	O
73	)	_	_	O
74	and	_	_	O
75	nurses	_	_	O
76	(	_	_	O
77	N	_	_	O
78	=	_	_	O
79	23	_	_	O
80	)	_	_	O
81	enrolled	_	_	O
82	patients	_	_	O
83	(	_	_	O
84	N	_	_	O
85	=	_	_	O
86	93	_	_	O
87	)	_	_	O
88	who	_	_	O
89	were	_	_	O
90	over	_	_	O
91	18	_	_	O
92	years	_	_	O
93	of	_	_	O
94	age	_	_	O
95	,	_	_	O
96	with	_	_	O
97	cancer	_	_	O
98	diagnoses	_	_	O
99	,	_	_	O
100	pain	_	_	O
101	,	_	_	O
102	and	_	_	O
103	a	_	_	O
104	life	_	_	O
105	expectancy	_	_	O
106	of	_	_	O
107	at	_	_	O
108	least	_	_	O
109	6	_	_	O
110	months	_	_	O
111	.	_	_	O

112	Pain	_	_	O
113	training	_	_	O
114	and	_	_	O
115	control	_	_	O
116	interventions	_	_	O
117	were	_	_	O
118	matched	_	_	O
119	for	_	_	O
120	materials	_	_	O
121	and	_	_	O
122	method	_	_	O
123	.	_	_	O

124	Patients	_	_	O
125	watched	_	_	O
126	a	_	_	O
127	video	_	_	O
128	followed	_	_	O
129	by	_	_	O
130	about	_	_	O
131	20	_	_	O
132	min	_	_	O
133	of	_	_	O
134	manual	_	_	O
135	-	_	_	O
136	standardized	_	_	O
137	training	_	_	O
138	with	_	_	O
139	an	_	_	O
140	oncology	_	_	O
141	nurse	_	_	O
142	focused	_	_	O
143	on	_	_	O
144	reviewing	_	_	O
145	the	_	_	O
146	printed	_	_	O
147	material	_	_	O
148	and	_	_	O
149	adapted	_	_	O
150	to	_	_	O
151	individual	_	_	O
152	concerns	_	_	O
153	of	_	_	O
154	patients	_	_	O
155	.	_	_	O

156	A	_	_	O
157	follow	_	_	O
158	-	_	_	O
159	up	_	_	O
160	phone	_	_	O
161	call	_	_	O
162	after	_	_	O
163	72	_	_	O
164	h	_	_	O
165	addressed	_	_	O
166	individualized	_	_	O
167	treatment	_	_	O
168	content	_	_	O
169	and	_	_	O
170	pain	_	_	O
171	communication	_	_	O
172	.	_	_	O

173	Assessments	_	_	O
174	at	_	_	O
175	baseline	_	_	O
176	,	_	_	O
177	one	_	_	O
178	,	_	_	O
179	three	_	_	O
180	,	_	_	O
181	and	_	_	O
182	6	_	_	O
183	months	_	_	O
184	included	_	_	O
185	barriers	_	_	O
186	,	_	_	O
187	the	_	_	O
188	Brief	_	_	O
189	Pain	_	_	O
190	Inventory	_	_	O
191	,	_	_	O
192	opioid	_	_	O
193	use	_	_	O
194	,	_	_	O
195	and	_	_	O
196	physician	_	_	O
197	and	_	_	O
198	nurse	_	_	O
199	ratings	_	_	O
200	of	_	_	O
201	their	_	_	O
202	patients	_	_	O
203	'	_	_	O
204	pain	_	_	O
205	.	_	_	O

206	Trained	_	_	B-Premise
207	versus	_	_	I-Premise
208	control	_	_	I-Premise
209	patients	_	_	I-Premise
210	reported	_	_	I-Premise
211	reduced	_	_	I-Premise
212	barriers	_	_	I-Premise
213	to	_	_	I-Premise
214	pain	_	_	I-Premise
215	relief	_	_	I-Premise
216	(	_	_	I-Premise
217	P	_	_	I-Premise
218	<	_	_	I-Premise
219	.	_	_	I-Premise

220	001	_	_	I-Premise
221	)	_	_	I-Premise
222	,	_	_	I-Premise
223	lower	_	_	I-Premise
224	usual	_	_	I-Premise
225	pain	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	.	_	_	I-Premise

230	03	_	_	I-Premise
231	)	_	_	I-Premise
232	,	_	_	I-Premise
233	and	_	_	I-Premise
234	greater	_	_	I-Premise
235	opioid	_	_	I-Premise
236	use	_	_	I-Premise
237	(	_	_	I-Premise
238	P	_	_	I-Premise
239	<	_	_	I-Premise
240	.	_	_	I-Premise

241	001	_	_	I-Premise
242	)	_	_	I-Premise
243	.	_	_	I-Premise

244	No	_	_	B-Premise
245	pain	_	_	I-Premise
246	training	_	_	I-Premise
247	patients	_	_	I-Premise
248	reported	_	_	I-Premise
249	severe	_	_	I-Premise
250	pain	_	_	I-Premise
251	(	_	_	I-Premise
252	>	_	_	I-Premise
253	6	_	_	I-Premise
254	on	_	_	I-Premise
255	a	_	_	I-Premise
256	0	_	_	I-Premise
257	-	_	_	I-Premise
258	10	_	_	I-Premise
259	scale	_	_	I-Premise
260	)	_	_	I-Premise
261	at	_	_	I-Premise
262	1	_	_	I-Premise
263	-	_	_	I-Premise
264	month	_	_	I-Premise
265	outcomes	_	_	I-Premise
266	(	_	_	I-Premise
267	P	_	_	I-Premise
268	=	_	_	I-Premise
269	.	_	_	I-Premise

270	03	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	Physician	_	_	O
274	and	_	_	O
275	nurse	_	_	O
276	ratings	_	_	O
277	were	_	_	O
278	closer	_	_	O
279	to	_	_	O
280	patients	_	_	O
281	'	_	_	O
282	ratings	_	_	O
283	of	_	_	O
284	pain	_	_	O
285	for	_	_	O
286	trained	_	_	O
287	versus	_	_	O
288	nutrition	_	_	O
289	groups	_	_	O
290	(	_	_	O
291	P	_	_	O
292	=	_	_	O
293	.	_	_	O

294	04	_	_	O
295	and	_	_	O
296	<	_	_	O
297	.	_	_	O

298	001	_	_	O
299	,	_	_	O
300	respectively	_	_	O
301	)	_	_	O
302	.	_	_	O

303	Training	_	_	O
304	efficacy	_	_	O
305	was	_	_	O
306	not	_	_	O
307	modified	_	_	O
308	by	_	_	O
309	patient	_	_	O
310	characteristics	_	_	O
311	.	_	_	O

312	Using	_	_	B-Claim
313	video	_	_	I-Claim
314	and	_	_	I-Claim
315	print	_	_	I-Claim
316	materials	_	_	I-Claim
317	,	_	_	I-Claim
318	with	_	_	I-Claim
319	brief	_	_	I-Claim
320	individualized	_	_	I-Claim
321	training	_	_	I-Claim
322	,	_	_	I-Claim
323	effectively	_	_	I-Claim
324	improved	_	_	I-Claim
325	pain	_	_	I-Claim
326	management	_	_	I-Claim
327	over	_	_	I-Claim
328	time	_	_	I-Claim
329	for	_	_	I-Claim
330	cancer	_	_	I-Claim
331	patients	_	_	I-Claim
332	of	_	_	I-Claim
333	varying	_	_	I-Claim
334	diagnostic	_	_	I-Claim
335	and	_	_	I-Claim
336	demographic	_	_	I-Claim
337	groups	_	_	I-Claim
338	.	_	_	I-Claim


0	Kaposi	_	_	O
1	'	_	_	O
2	s	_	_	O
3	sarcoma	_	_	O
4	is	_	_	O
5	currently	_	_	O
6	the	_	_	O
7	most	_	_	O
8	common	_	_	O
9	tumor	_	_	O
10	in	_	_	O
11	Zimbabwe	_	_	O
12	.	_	_	O

13	The	_	_	O
14	purpose	_	_	O
15	of	_	_	O
16	our	_	_	O
17	study	_	_	O
18	is	_	_	O
19	to	_	_	O
20	compare	_	_	O
21	the	_	_	O
22	effectiveness	_	_	O
23	of	_	_	O
24	supportive	_	_	O
25	care	_	_	O
26	vs	_	_	O
27	.	_	_	O

28	3	_	_	O
29	intervention	_	_	O
30	approaches	_	_	O
31	,	_	_	O
32	namely	_	_	O
33	oral	_	_	O
34	Etoposide	_	_	O
35	,	_	_	O
36	a	_	_	O
37	3	_	_	O
38	-	_	_	O
39	drug	_	_	O
40	combination	_	_	O
41	,	_	_	O
42	and	_	_	O
43	radiotherapy	_	_	O
44	using	_	_	O
45	quality	_	_	O
46	of	_	_	O
47	life	_	_	O
48	(	_	_	O
49	QOL	_	_	O
50	)	_	_	O
51	as	_	_	O
52	the	_	_	O
53	primary	_	_	O
54	measure	_	_	O
55	of	_	_	O
56	success	_	_	O
57	.	_	_	O

58	In	_	_	O
59	addition	_	_	O
60	,	_	_	O
61	our	_	_	O
62	study	_	_	O
63	was	_	_	O
64	to	_	_	O
65	determine	_	_	O
66	whether	_	_	O
67	a	_	_	O
68	disease	_	_	O
69	-	_	_	O
70	specific	_	_	O
71	module	_	_	O
72	has	_	_	O
73	greater	_	_	O
74	sensitivity	_	_	O
75	to	_	_	O
76	group	_	_	O
77	differences	_	_	O
78	than	_	_	O
79	a	_	_	O
80	generic	_	_	O
81	QOL	_	_	O
82	questionnaire	_	_	O
83	and	_	_	O
84	to	_	_	O
85	determine	_	_	O
86	the	_	_	O
87	most	_	_	O
88	pragmatic	_	_	O
89	approach	_	_	O
90	to	_	_	O
91	treating	_	_	O
92	epidemic	_	_	O
93	Kaposi	_	_	O
94	'	_	_	O
95	s	_	_	O
96	sarcoma	_	_	O
97	(	_	_	O
98	EKS	_	_	O
99	)	_	_	O
100	in	_	_	O
101	Zimbabwe	_	_	O
102	.	_	_	O

103	Histologically	_	_	O
104	confirmed	_	_	O
105	HIV	_	_	O
106	-	_	_	O
107	positive	_	_	O
108	patients	_	_	O
109	with	_	_	O
110	Kaposi	_	_	O
111	'	_	_	O
112	s	_	_	O
113	sarcoma	_	_	O
114	were	_	_	O
115	randomized	_	_	O
116	to	_	_	O
117	receive	_	_	O
118	supportive	_	_	O
119	care	_	_	O
120	only	_	_	O
121	or	_	_	O
122	supportive	_	_	O
123	care	_	_	O
124	plus	_	_	O
125	either	_	_	O
126	radiotherapy	_	_	O
127	,	_	_	O
128	oral	_	_	O
129	Etoposide	_	_	O
130	or	_	_	O
131	a	_	_	O
132	3	_	_	O
133	-	_	_	O
134	drug	_	_	O
135	combination	_	_	O
136	consisting	_	_	O
137	of	_	_	O
138	actinomycin	_	_	O
139	-	_	_	O
140	D	_	_	O
141	,	_	_	O
142	vincristine	_	_	O
143	and	_	_	O
144	bleomycin	_	_	O
145	.	_	_	O

146	No	_	_	O
147	patient	_	_	O
148	received	_	_	O
149	antiretroviral	_	_	O
150	therapy	_	_	O
151	.	_	_	O

152	The	_	_	O
153	primary	_	_	O
154	outcome	_	_	O
155	was	_	_	O
156	QOL	_	_	O
157	measured	_	_	O
158	by	_	_	O
159	the	_	_	O
160	functional	_	_	O
161	living	_	_	O
162	index	_	_	O
163	-	_	_	O
164	cancer	_	_	O
165	(	_	_	O
166	FLI	_	_	O
167	-	_	_	O
168	C	_	_	O
169	)	_	_	O
170	and	_	_	O
171	supplemented	_	_	O
172	by	_	_	O
173	the	_	_	O
174	Kaposi	_	_	O
175	'	_	_	O
176	s	_	_	O
177	sarcoma	_	_	O
178	module	_	_	O
179	(	_	_	O
180	KSM	_	_	O
181	)	_	_	O
182	.	_	_	O

183	From	_	_	O
184	1994	_	_	O
185	-	_	_	O
186	1999	_	_	O
187	,	_	_	O
188	495	_	_	O
189	EKS	_	_	O
190	patients	_	_	O
191	were	_	_	O
192	accrued	_	_	O
193	,	_	_	O
194	and	_	_	O
195	470	_	_	O
196	were	_	_	O
197	evaluable	_	_	O
198	.	_	_	O

199	Of	_	_	O
200	these	_	_	O
201	,	_	_	O
202	433	_	_	O
203	are	_	_	O
204	known	_	_	O
205	to	_	_	O
206	be	_	_	O
207	dead	_	_	O
208	,	_	_	O
209	26	_	_	O
210	are	_	_	O
211	lost	_	_	O
212	to	_	_	O
213	follow	_	_	O
214	-	_	_	O
215	up	_	_	O
216	and	_	_	O
217	11	_	_	O
218	are	_	_	O
219	still	_	_	O
220	alive	_	_	O
221	.	_	_	O

222	The	_	_	B-Premise
223	group	_	_	I-Premise
224	treated	_	_	I-Premise
225	with	_	_	I-Premise
226	oral	_	_	I-Premise
227	Etoposide	_	_	I-Premise
228	had	_	_	I-Premise
229	a	_	_	I-Premise
230	significantly	_	_	I-Premise
231	better	_	_	I-Premise
232	QOL	_	_	I-Premise
233	than	_	_	I-Premise
234	the	_	_	I-Premise
235	radiotherapy	_	_	I-Premise
236	group	_	_	I-Premise
237	for	_	_	I-Premise
238	the	_	_	I-Premise
239	total	_	_	I-Premise
240	FLI	_	_	I-Premise
241	-	_	_	I-Premise
242	C	_	_	I-Premise
243	score	_	_	I-Premise
244	(	_	_	I-Premise
245	adjusted	_	_	I-Premise
246	mean	_	_	I-Premise
247	plus	_	_	I-Premise
248	standard	_	_	I-Premise
249	error	_	_	I-Premise
250	at	_	_	I-Premise
251	3	_	_	I-Premise
252	-	_	_	I-Premise
253	months	_	_	I-Premise
254	89	_	_	I-Premise
255	+	_	_	I-Premise
256	/	_	_	I-Premise
257	-	_	_	I-Premise
258	3	_	_	I-Premise
259	vs	_	_	I-Premise
260	.	_	_	I-Premise

261	76	_	_	I-Premise
262	+	_	_	I-Premise
263	/	_	_	I-Premise
264	-	_	_	I-Premise
265	3	_	_	I-Premise
266	;	_	_	I-Premise
267	p	_	_	I-Premise
268	=	_	_	I-Premise
269	0	_	_	I-Premise
270	.	_	_	I-Premise

271	004	_	_	I-Premise
272	)	_	_	I-Premise
273	and	_	_	I-Premise
274	for	_	_	I-Premise
275	the	_	_	I-Premise
276	hardship	_	_	I-Premise
277	(	_	_	I-Premise
278	11	_	_	I-Premise
279	+	_	_	I-Premise
280	/	_	_	I-Premise
281	-	_	_	I-Premise
282	0	_	_	I-Premise
283	.	_	_	I-Premise

284	4	_	_	I-Premise
285	vs	_	_	I-Premise
286	.	_	_	I-Premise

287	9	_	_	I-Premise
288	+	_	_	I-Premise
289	/	_	_	I-Premise
290	-	_	_	I-Premise
291	0	_	_	I-Premise
292	.	_	_	I-Premise

293	4	_	_	I-Premise
294	;	_	_	I-Premise
295	p	_	_	I-Premise
296	=	_	_	I-Premise
297	0	_	_	I-Premise
298	.	_	_	I-Premise

299	001	_	_	I-Premise
300	)	_	_	I-Premise
301	;	_	_	I-Premise
302	social	_	_	I-Premise
303	(	_	_	I-Premise
304	10	_	_	I-Premise
305	+	_	_	I-Premise
306	/	_	_	I-Premise
307	-	_	_	I-Premise
308	0	_	_	I-Premise
309	.	_	_	I-Premise

310	4	_	_	I-Premise
311	vs	_	_	I-Premise
312	.	_	_	I-Premise

313	8	_	_	I-Premise
314	+	_	_	I-Premise
315	/	_	_	I-Premise
316	-	_	_	I-Premise
317	0	_	_	I-Premise
318	.	_	_	I-Premise

319	4	_	_	I-Premise
320	;	_	_	I-Premise
321	p	_	_	I-Premise
322	=	_	_	I-Premise
323	0	_	_	I-Premise
324	.	_	_	I-Premise

325	001	_	_	I-Premise
326	)	_	_	I-Premise
327	and	_	_	I-Premise
328	nausea	_	_	I-Premise
329	(	_	_	I-Premise
330	9	_	_	I-Premise
331	+	_	_	I-Premise
332	/	_	_	I-Premise
333	-	_	_	I-Premise
334	0	_	_	I-Premise
335	.	_	_	I-Premise

336	4	_	_	I-Premise
337	vs	_	_	I-Premise
338	.	_	_	I-Premise

339	8	_	_	I-Premise
340	+	_	_	I-Premise
341	/	_	_	I-Premise
342	-	_	_	I-Premise
343	0	_	_	I-Premise
344	.	_	_	I-Premise

345	4	_	_	I-Premise
346	;	_	_	I-Premise
347	p	_	_	I-Premise
348	=	_	_	I-Premise
349	0	_	_	I-Premise
350	.	_	_	I-Premise

351	002	_	_	I-Premise
352	)	_	_	I-Premise
353	subscales	_	_	I-Premise
354	.	_	_	I-Premise

355	In	_	_	B-Premise
356	addition	_	_	I-Premise
357	,	_	_	I-Premise
358	on	_	_	I-Premise
359	the	_	_	I-Premise
360	physical	_	_	I-Premise
361	and	_	_	I-Premise
362	psychological	_	_	I-Premise
363	subscales	_	_	I-Premise
364	,	_	_	I-Premise
365	the	_	_	I-Premise
366	Etoposide	_	_	I-Premise
367	group	_	_	I-Premise
368	had	_	_	I-Premise
369	a	_	_	I-Premise
370	significantly	_	_	I-Premise
371	better	_	_	I-Premise
372	QOL	_	_	I-Premise
373	than	_	_	I-Premise
374	the	_	_	I-Premise
375	other	_	_	I-Premise
376	3	_	_	I-Premise
377	treatment	_	_	I-Premise
378	groups	_	_	I-Premise
379	(	_	_	I-Premise
380	p	_	_	I-Premise
381	<	_	_	I-Premise
382	0	_	_	I-Premise
383	.	_	_	I-Premise

384	04	_	_	I-Premise
385	)	_	_	I-Premise
386	.	_	_	I-Premise

387	The	_	_	B-Premise
388	3	_	_	I-Premise
389	-	_	_	I-Premise
390	drug	_	_	I-Premise
391	combination	_	_	I-Premise
392	,	_	_	I-Premise
393	supportive	_	_	I-Premise
394	care	_	_	I-Premise
395	and	_	_	I-Premise
396	radiotherapy	_	_	I-Premise
397	groups	_	_	I-Premise
398	did	_	_	I-Premise
399	not	_	_	I-Premise
400	differ	_	_	I-Premise
401	significantly	_	_	I-Premise
402	from	_	_	I-Premise
403	each	_	_	I-Premise
404	other	_	_	I-Premise
405	with	_	_	I-Premise
406	respect	_	_	I-Premise
407	to	_	_	I-Premise
408	the	_	_	I-Premise
409	total	_	_	I-Premise
410	FLI	_	_	I-Premise
411	-	_	_	I-Premise
412	C	_	_	I-Premise
413	score	_	_	I-Premise
414	or	_	_	I-Premise
415	its	_	_	I-Premise
416	subscales	_	_	I-Premise
417	.	_	_	I-Premise

418	There	_	_	B-Premise
419	were	_	_	I-Premise
420	no	_	_	I-Premise
421	group	_	_	I-Premise
422	differences	_	_	I-Premise
423	with	_	_	I-Premise
424	respect	_	_	I-Premise
425	to	_	_	I-Premise
426	survival	_	_	I-Premise
427	.	_	_	I-Premise

428	Oral	_	_	B-Claim
429	Etoposide	_	_	I-Claim
430	therapy	_	_	I-Claim
431	resulted	_	_	I-Claim
432	in	_	_	I-Claim
433	better	_	_	I-Claim
434	total	_	_	I-Claim
435	FLI	_	_	I-Claim
436	-	_	_	I-Claim
437	C	_	_	I-Claim
438	QOL	_	_	I-Claim
439	score	_	_	I-Claim
440	than	_	_	I-Claim
441	radiotherapy	_	_	I-Claim
442	.	_	_	I-Claim

443	As	_	_	O
444	well	_	_	O
445	,	_	_	O
446	Etoposide	_	_	B-Claim
447	resulted	_	_	I-Claim
448	in	_	_	I-Claim
449	better	_	_	I-Claim
450	physical	_	_	I-Claim
451	and	_	_	I-Claim
452	psychological	_	_	I-Claim
453	subscale	_	_	I-Claim
454	scores	_	_	I-Claim
455	than	_	_	I-Claim
456	radiotherapy	_	_	I-Claim
457	,	_	_	I-Claim
458	3	_	_	I-Claim
459	-	_	_	I-Claim
460	drugs	_	_	I-Claim
461	and	_	_	I-Claim
462	supportive	_	_	I-Claim
463	care	_	_	I-Claim
464	.	_	_	I-Claim

465	Thus	_	_	B-Claim
466	,	_	_	I-Claim
467	funds	_	_	I-Claim
468	permitting	_	_	I-Claim
469	,	_	_	I-Claim
470	oral	_	_	I-Claim
471	Etoposide	_	_	I-Claim
472	is	_	_	I-Claim
473	a	_	_	I-Claim
474	pragmatic	_	_	I-Claim
475	approach	_	_	I-Claim
476	to	_	_	I-Claim
477	treating	_	_	I-Claim
478	EKS	_	_	I-Claim
479	in	_	_	I-Claim
480	an	_	_	I-Claim
481	environment	_	_	I-Claim
482	where	_	_	I-Claim
483	antiretroviral	_	_	I-Claim
484	drugs	_	_	I-Claim
485	are	_	_	I-Claim
486	not	_	_	I-Claim
487	universally	_	_	I-Claim
488	available	_	_	I-Claim
489	.	_	_	I-Claim

490	The	_	_	B-Claim
491	study	_	_	I-Claim
492	underscores	_	_	I-Claim
493	the	_	_	I-Claim
494	value	_	_	I-Claim
495	of	_	_	I-Claim
496	undertaking	_	_	I-Claim
497	studies	_	_	I-Claim
498	in	_	_	I-Claim
499	areas	_	_	I-Claim
500	of	_	_	I-Claim
501	disease	_	_	I-Claim
502	prevalence	_	_	I-Claim
503	and	_	_	I-Claim
504	the	_	_	I-Claim
505	necessity	_	_	I-Claim
506	of	_	_	I-Claim
507	selecting	_	_	I-Claim
508	appropriate	_	_	I-Claim
509	outcome	_	_	I-Claim
510	measures	_	_	I-Claim
511	.	_	_	I-Claim


0	This	_	_	O
1	trial	_	_	O
2	was	_	_	O
3	conducted	_	_	O
4	to	_	_	O
5	determine	_	_	O
6	whether	_	_	O
7	high	_	_	O
8	-	_	_	O
9	dose	_	_	O
10	fluorouracil	_	_	O
11	(	_	_	O
12	FU	_	_	O
13	)	_	_	O
14	given	_	_	O
15	as	_	_	O
16	a	_	_	O
17	weekly	_	_	O
18	24	_	_	O
19	-	_	_	O
20	hour	_	_	O
21	infusion	_	_	O
22	is	_	_	O
23	more	_	_	O
24	active	_	_	O
25	than	_	_	O
26	bolus	_	_	O
27	FU	_	_	O
28	+	_	_	O
29	leucovorin	_	_	O
30	(	_	_	O
31	LV	_	_	O
32	)	_	_	O
33	,	_	_	O
34	and	_	_	O
35	whether	_	_	O
36	high	_	_	O
37	-	_	_	O
38	dose	_	_	O
39	infusional	_	_	O
40	FU	_	_	O
41	can	_	_	O
42	be	_	_	O
43	modulated	_	_	O
44	by	_	_	O
45	LV	_	_	O
46	.	_	_	O

47	A	_	_	O
48	total	_	_	O
49	of	_	_	O
50	497	_	_	O
51	patients	_	_	O
52	with	_	_	O
53	previously	_	_	O
54	untreated	_	_	O
55	metastatic	_	_	O
56	colorectal	_	_	O
57	cancer	_	_	O
58	were	_	_	O
59	randomly	_	_	O
60	assigned	_	_	O
61	to	_	_	O
62	receive	_	_	O
63	bolus	_	_	O
64	FU	_	_	O
65	425	_	_	O
66	mg	_	_	O
67	/	_	_	O
68	m2	_	_	O
69	intravenously	_	_	O
70	+	_	_	O
71	LV	_	_	O
72	20	_	_	O
73	mg	_	_	O
74	/	_	_	O
75	m2	_	_	O
76	on	_	_	O
77	days	_	_	O
78	1	_	_	O
79	to	_	_	O
80	5	_	_	O
81	and	_	_	O
82	repeated	_	_	O
83	on	_	_	O
84	day	_	_	O
85	28	_	_	O
86	(	_	_	O
87	FU	_	_	O
88	+	_	_	O
89	LV	_	_	O
90	)	_	_	O
91	,	_	_	O
92	or	_	_	O
93	FU	_	_	O
94	2600	_	_	O
95	mg	_	_	O
96	/	_	_	O
97	m2	_	_	O
98	as	_	_	O
99	a	_	_	O
100	24	_	_	O
101	-	_	_	O
102	hour	_	_	O
103	infusion	_	_	O
104	alone	_	_	O
105	(	_	_	O
106	FU24h	_	_	O
107	)	_	_	O
108	or	_	_	O
109	in	_	_	O
110	combination	_	_	O
111	with	_	_	O
112	500	_	_	O
113	mg	_	_	O
114	/	_	_	O
115	m2	_	_	O
116	LV	_	_	O
117	(	_	_	O
118	FU24h	_	_	O
119	+	_	_	O
120	LV	_	_	O
121	)	_	_	O
122	-	_	_	O
123	all	_	_	O
124	given	_	_	O
125	weekly	_	_	O
126	x6	_	_	O
127	followed	_	_	O
128	by	_	_	O
129	a	_	_	O
130	2	_	_	O
131	-	_	_	O
132	week	_	_	O
133	rest	_	_	O
134	period	_	_	O
135	.	_	_	O

136	Survival	_	_	O
137	was	_	_	O
138	the	_	_	O
139	major	_	_	O
140	study	_	_	O
141	end	_	_	O
142	point	_	_	O
143	.	_	_	O

144	With	_	_	B-Premise
145	a	_	_	I-Premise
146	median	_	_	I-Premise
147	follow	_	_	I-Premise
148	-	_	_	I-Premise
149	up	_	_	I-Premise
150	of	_	_	I-Premise
151	more	_	_	I-Premise
152	than	_	_	I-Premise
153	3	_	_	I-Premise
154	years	_	_	I-Premise
155	,	_	_	I-Premise
156	survival	_	_	I-Premise
157	did	_	_	I-Premise
158	not	_	_	I-Premise
159	differ	_	_	I-Premise
160	among	_	_	I-Premise
161	the	_	_	I-Premise
162	treatment	_	_	I-Premise
163	groups	_	_	I-Premise
164	(	_	_	I-Premise
165	median	_	_	I-Premise
166	FU	_	_	I-Premise
167	+	_	_	I-Premise
168	LV	_	_	I-Premise
169	,	_	_	I-Premise
170	11	_	_	I-Premise
171	.	_	_	I-Premise

172	1	_	_	I-Premise
173	months	_	_	I-Premise
174	[	_	_	I-Premise
175	95	_	_	I-Premise
176	%	_	_	I-Premise
177	CI	_	_	I-Premise
178	,	_	_	I-Premise
179	10	_	_	I-Premise
180	.	_	_	I-Premise

181	2	_	_	I-Premise
182	to	_	_	I-Premise
183	15	_	_	I-Premise
184	.	_	_	I-Premise

185	0	_	_	I-Premise
186	months	_	_	I-Premise
187	]	_	_	I-Premise
188	;	_	_	I-Premise
189	FU24h	_	_	I-Premise
190	,	_	_	I-Premise
191	13	_	_	I-Premise
192	.	_	_	I-Premise

193	0	_	_	I-Premise
194	months	_	_	I-Premise
195	[	_	_	I-Premise
196	95	_	_	I-Premise
197	%	_	_	I-Premise
198	CI	_	_	I-Premise
199	,	_	_	I-Premise
200	10	_	_	I-Premise
201	.	_	_	I-Premise

202	4	_	_	I-Premise
203	to	_	_	I-Premise
204	15	_	_	I-Premise
205	.	_	_	I-Premise

206	4	_	_	I-Premise
207	months	_	_	I-Premise
208	]	_	_	I-Premise
209	;	_	_	I-Premise
210	FU24h	_	_	I-Premise
211	+	_	_	I-Premise
212	LV	_	_	I-Premise
213	,	_	_	I-Premise
214	13	_	_	I-Premise
215	.	_	_	I-Premise

216	7	_	_	I-Premise
217	months	_	_	I-Premise
218	[	_	_	I-Premise
219	95	_	_	I-Premise
220	%	_	_	I-Premise
221	CI	_	_	I-Premise
222	,	_	_	I-Premise
223	12	_	_	I-Premise
224	.	_	_	I-Premise

225	0	_	_	I-Premise
226	to	_	_	I-Premise
227	16	_	_	I-Premise
228	.	_	_	I-Premise

229	4	_	_	I-Premise
230	months	_	_	I-Premise
231	]	_	_	I-Premise
232	;	_	_	I-Premise
233	P	_	_	I-Premise
234	=	_	_	I-Premise
235	.	_	_	I-Premise

236	724	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	Progression	_	_	B-Premise
240	-	_	_	I-Premise
241	free	_	_	I-Premise
242	survival	_	_	I-Premise
243	(	_	_	I-Premise
244	PFS	_	_	I-Premise
245	)	_	_	I-Premise
246	was	_	_	I-Premise
247	significantly	_	_	I-Premise
248	longer	_	_	I-Premise
249	for	_	_	I-Premise
250	FU24h	_	_	I-Premise
251	+	_	_	I-Premise
252	LV	_	_	I-Premise
253	(	_	_	I-Premise
254	median	_	_	I-Premise
255	FU	_	_	I-Premise
256	+	_	_	I-Premise
257	LV	_	_	I-Premise
258	,	_	_	I-Premise
259	4	_	_	I-Premise
260	.	_	_	I-Premise

261	0	_	_	I-Premise
262	months	_	_	I-Premise
263	[	_	_	I-Premise
264	95	_	_	I-Premise
265	%	_	_	I-Premise
266	CI	_	_	I-Premise
267	,	_	_	I-Premise
268	3	_	_	I-Premise
269	.	_	_	I-Premise

270	4	_	_	I-Premise
271	to	_	_	I-Premise
272	4	_	_	I-Premise
273	.	_	_	I-Premise

274	9	_	_	I-Premise
275	]	_	_	I-Premise
276	;	_	_	I-Premise
277	FU24h	_	_	I-Premise
278	,	_	_	I-Premise
279	4	_	_	I-Premise
280	.	_	_	I-Premise

281	1	_	_	I-Premise
282	months	_	_	I-Premise
283	[	_	_	I-Premise
284	95	_	_	I-Premise
285	%	_	_	I-Premise
286	CI	_	_	I-Premise
287	,	_	_	I-Premise
288	3	_	_	I-Premise
289	.	_	_	I-Premise

290	4	_	_	I-Premise
291	to	_	_	I-Premise
292	5	_	_	I-Premise
293	.	_	_	I-Premise

294	0	_	_	I-Premise
295	]	_	_	I-Premise
296	;	_	_	I-Premise
297	FU24h	_	_	I-Premise
298	+	_	_	I-Premise
299	LV	_	_	I-Premise
300	5	_	_	I-Premise
301	.	_	_	I-Premise

302	6	_	_	I-Premise
303	months	_	_	I-Premise
304	[	_	_	I-Premise
305	95	_	_	I-Premise
306	%	_	_	I-Premise
307	CI	_	_	I-Premise
308	,	_	_	I-Premise
309	4	_	_	I-Premise
310	.	_	_	I-Premise

311	4	_	_	I-Premise
312	to	_	_	I-Premise
313	6	_	_	I-Premise
314	.	_	_	I-Premise

315	7	_	_	I-Premise
316	]	_	_	I-Premise
317	;	_	_	I-Premise
318	P	_	_	I-Premise
319	=	_	_	I-Premise
320	.	_	_	I-Premise

321	029	_	_	I-Premise
322	)	_	_	I-Premise
323	.	_	_	I-Premise

324	The	_	_	B-Premise
325	response	_	_	I-Premise
326	rates	_	_	I-Premise
327	in	_	_	I-Premise
328	the	_	_	I-Premise
329	subgroup	_	_	I-Premise
330	of	_	_	I-Premise
331	patients	_	_	I-Premise
332	with	_	_	I-Premise
333	measurable	_	_	I-Premise
334	disease	_	_	I-Premise
335	were	_	_	I-Premise
336	12	_	_	I-Premise
337	%	_	_	I-Premise
338	,	_	_	I-Premise
339	10	_	_	I-Premise
340	%	_	_	I-Premise
341	,	_	_	I-Premise
342	and	_	_	I-Premise
343	17	_	_	I-Premise
344	%	_	_	I-Premise
345	for	_	_	I-Premise
346	FU	_	_	I-Premise
347	+	_	_	I-Premise
348	LV	_	_	I-Premise
349	,	_	_	I-Premise
350	FU24h	_	_	I-Premise
351	,	_	_	I-Premise
352	and	_	_	I-Premise
353	FU24h	_	_	I-Premise
354	+	_	_	I-Premise
355	LV	_	_	I-Premise
356	,	_	_	I-Premise
357	respectively	_	_	I-Premise
358	(	_	_	I-Premise
359	not	_	_	I-Premise
360	significant	_	_	I-Premise
361	)	_	_	I-Premise
362	.	_	_	I-Premise

363	Occurrence	_	_	B-Premise
364	of	_	_	I-Premise
365	grade	_	_	I-Premise
366	3	_	_	I-Premise
367	and	_	_	I-Premise
368	4	_	_	I-Premise
369	diarrhea	_	_	I-Premise
370	was	_	_	I-Premise
371	higher	_	_	I-Premise
372	in	_	_	I-Premise
373	the	_	_	I-Premise
374	FU24h	_	_	I-Premise
375	+	_	_	I-Premise
376	LV	_	_	I-Premise
377	arm	_	_	I-Premise
378	(	_	_	I-Premise
379	22	_	_	I-Premise
380	%	_	_	I-Premise
381	)	_	_	I-Premise
382	compared	_	_	I-Premise
383	with	_	_	I-Premise
384	the	_	_	I-Premise
385	FU24h	_	_	I-Premise
386	(	_	_	I-Premise
387	6	_	_	I-Premise
388	%	_	_	I-Premise
389	)	_	_	I-Premise
390	or	_	_	I-Premise
391	FU	_	_	I-Premise
392	+	_	_	I-Premise
393	LV	_	_	I-Premise
394	(	_	_	I-Premise
395	9	_	_	I-Premise
396	%	_	_	I-Premise
397	)	_	_	I-Premise
398	arms	_	_	I-Premise
399	;	_	_	I-Premise
400	however	_	_	B-Premise
401	,	_	_	I-Premise
402	stomatitis	_	_	I-Premise
403	(	_	_	I-Premise
404	11	_	_	I-Premise
405	%	_	_	I-Premise
406	in	_	_	I-Premise
407	FU	_	_	I-Premise
408	+	_	_	I-Premise
409	LV	_	_	I-Premise
410	v	_	_	I-Premise
411	3	_	_	I-Premise
412	%	_	_	I-Premise
413	in	_	_	I-Premise
414	FU24h	_	_	I-Premise
415	v	_	_	I-Premise
416	5	_	_	I-Premise
417	%	_	_	I-Premise
418	in	_	_	I-Premise
419	FU24h	_	_	I-Premise
420	+	_	_	I-Premise
421	LV	_	_	I-Premise
422	arms	_	_	I-Premise
423	)	_	_	I-Premise
424	and	_	_	I-Premise
425	hematologic	_	_	I-Premise
426	toxicity	_	_	I-Premise
427	were	_	_	I-Premise
428	higher	_	_	I-Premise
429	in	_	_	I-Premise
430	the	_	_	I-Premise
431	bolus	_	_	I-Premise
432	FU	_	_	I-Premise
433	+	_	_	I-Premise
434	LV	_	_	I-Premise
435	arm	_	_	I-Premise
436	.	_	_	I-Premise

437	Global	_	_	B-Claim
438	quality	_	_	I-Claim
439	of	_	_	I-Claim
440	life	_	_	I-Claim
441	did	_	_	I-Claim
442	not	_	_	I-Claim
443	differ	_	_	I-Claim
444	within	_	_	I-Claim
445	the	_	_	I-Claim
446	three	_	_	I-Claim
447	arms	_	_	I-Claim
448	.	_	_	I-Claim

449	Neither	_	_	B-Claim
450	FU24h	_	_	I-Claim
451	+	_	_	I-Claim
452	LV	_	_	I-Claim
453	nor	_	_	I-Claim
454	FU24h	_	_	I-Claim
455	prolong	_	_	I-Claim
456	survival	_	_	I-Claim
457	,	_	_	I-Claim
458	relative	_	_	I-Claim
459	to	_	_	I-Claim
460	bolus	_	_	I-Claim
461	FU	_	_	I-Claim
462	+	_	_	I-Claim
463	LV	_	_	I-Claim
464	.	_	_	I-Claim

465	Leucovorin	_	_	B-Claim
466	increases	_	_	I-Claim
467	PFS	_	_	I-Claim
468	if	_	_	I-Claim
469	added	_	_	I-Claim
470	to	_	_	I-Claim
471	FU24h	_	_	I-Claim
472	,	_	_	I-Claim
473	but	_	_	I-Claim
474	increases	_	_	I-Claim
475	toxicity	_	_	I-Claim
476	.	_	_	I-Claim


0	Maintenance	_	_	O
1	therapy	_	_	O
2	,	_	_	O
3	commenced	_	_	O
4	immediately	_	_	O
5	after	_	_	O
6	the	_	_	O
7	completion	_	_	O
8	of	_	_	O
9	first	_	_	O
10	-	_	_	O
11	line	_	_	O
12	chemotherapy	_	_	O
13	,	_	_	O
14	is	_	_	O
15	a	_	_	O
16	promising	_	_	O
17	strategy	_	_	O
18	for	_	_	O
19	improving	_	_	O
20	treatment	_	_	O
21	outcomes	_	_	O
22	in	_	_	O
23	patients	_	_	O
24	with	_	_	O
25	non	_	_	O
26	-	_	_	O
27	small	_	_	O
28	-	_	_	O
29	cell	_	_	O
30	lung	_	_	O
31	cancer	_	_	O
32	(	_	_	O
33	NSCLC	_	_	O
34	)	_	_	O
35	.	_	_	O

36	The	_	_	O
37	global	_	_	O
38	phase	_	_	O
39	III	_	_	O
40	SequentiAl	_	_	O
41	Tarceva	_	_	O
42	in	_	_	O
43	UnResectable	_	_	O
44	NSCLC	_	_	O
45	(	_	_	O
46	SATURN	_	_	O
47	)	_	_	O
48	study	_	_	O
49	evaluated	_	_	O
50	the	_	_	O
51	efficacy	_	_	O
52	and	_	_	O
53	safety	_	_	O
54	of	_	_	O
55	the	_	_	O
56	epidermal	_	_	O
57	growth	_	_	O
58	factor	_	_	O
59	receptor	_	_	O
60	(	_	_	O
61	EGFR	_	_	O
62	)	_	_	O
63	tyrosine	_	_	O
64	-	_	_	O
65	kinase	_	_	O
66	inhibitor	_	_	O
67	erlotinib	_	_	O
68	as	_	_	O
69	maintenance	_	_	O
70	treatment	_	_	O
71	in	_	_	O
72	NSCLC	_	_	O
73	patients	_	_	O
74	without	_	_	O
75	progression	_	_	O
76	after	_	_	O
77	first	_	_	O
78	-	_	_	O
79	line	_	_	O
80	chemotherapy	_	_	O
81	.	_	_	O

82	We	_	_	O
83	report	_	_	O
84	a	_	_	O
85	retrospective	_	_	O
86	subanalysis	_	_	O
87	of	_	_	O
88	Asian	_	_	O
89	patients	_	_	O
90	enrolled	_	_	O
91	in	_	_	O
92	SATURN	_	_	O
93	.	_	_	O

94	Patients	_	_	O
95	with	_	_	O
96	advanced	_	_	O
97	NSCLC	_	_	O
98	with	_	_	O
99	no	_	_	O
100	evidence	_	_	O
101	of	_	_	O
102	progression	_	_	O
103	after	_	_	O
104	four	_	_	O
105	cycles	_	_	O
106	of	_	_	O
107	chemotherapy	_	_	O
108	were	_	_	O
109	randomized	_	_	O
110	to	_	_	O
111	receive	_	_	O
112	erlotinib	_	_	O
113	150	_	_	O
114	mg	_	_	O
115	/	_	_	O
116	day	_	_	O
117	or	_	_	O
118	placebo	_	_	O
119	,	_	_	O
120	until	_	_	O
121	progressive	_	_	O
122	disease	_	_	O
123	or	_	_	O
124	limiting	_	_	O
125	toxicity	_	_	O
126	.	_	_	O

127	The	_	_	O
128	co	_	_	O
129	-	_	_	O
130	primary	_	_	O
131	endpoints	_	_	O
132	of	_	_	O
133	SATURN	_	_	O
134	were	_	_	O
135	progression	_	_	O
136	-	_	_	O
137	free	_	_	O
138	survival	_	_	O
139	(	_	_	O
140	PFS	_	_	O
141	)	_	_	O
142	in	_	_	O
143	all	_	_	O
144	patients	_	_	O
145	and	_	_	O
146	in	_	_	O
147	those	_	_	O
148	with	_	_	O
149	positive	_	_	O
150	EGFR	_	_	O
151	immunohistochemistry	_	_	O
152	(	_	_	O
153	IHC	_	_	O
154	)	_	_	O
155	status	_	_	O
156	.	_	_	O

157	Secondary	_	_	O
158	endpoints	_	_	O
159	included	_	_	O
160	overall	_	_	O
161	survival	_	_	O
162	(	_	_	O
163	OS	_	_	O
164	)	_	_	O
165	,	_	_	O
166	disease	_	_	O
167	control	_	_	O
168	rate	_	_	O
169	,	_	_	O
170	safety	_	_	O
171	,	_	_	O
172	quality	_	_	O
173	of	_	_	O
174	life	_	_	O
175	(	_	_	O
176	QoL	_	_	O
177	)	_	_	O
178	and	_	_	O
179	biomarker	_	_	O
180	analyses	_	_	O
181	.	_	_	O

182	In	_	_	O
183	total	_	_	O
184	,	_	_	O
185	126	_	_	O
186	patients	_	_	O
187	from	_	_	O
188	East	_	_	O
189	and	_	_	O
190	South	_	_	O
191	-	_	_	O
192	East	_	_	O
193	Asian	_	_	O
194	centers	_	_	O
195	were	_	_	O
196	randomized	_	_	O
197	(	_	_	O
198	14	_	_	O
199	%	_	_	O
200	of	_	_	O
201	the	_	_	O
202	intent	_	_	O
203	-	_	_	O
204	to	_	_	O
205	-	_	_	O
206	treat	_	_	O
207	population	_	_	O
208	)	_	_	O
209	:	_	_	O
210	88	_	_	O
211	from	_	_	O
212	Korea	_	_	O
213	,	_	_	O
214	28	_	_	O
215	from	_	_	O
216	China	_	_	O
217	and	_	_	O
218	10	_	_	O
219	from	_	_	O
220	Malaysia	_	_	O
221	;	_	_	O
222	one	_	_	O
223	patient	_	_	O
224	was	_	_	O
225	excluded	_	_	O
226	from	_	_	O
227	this	_	_	O
228	analysis	_	_	O
229	due	_	_	O
230	to	_	_	O
231	Indian	_	_	O
232	ethnicity	_	_	O
233	.	_	_	O

234	PFS	_	_	B-Premise
235	was	_	_	I-Premise
236	significantly	_	_	I-Premise
237	prolonged	_	_	I-Premise
238	in	_	_	I-Premise
239	the	_	_	I-Premise
240	erlotinib	_	_	I-Premise
241	treatment	_	_	I-Premise
242	arm	_	_	I-Premise
243	,	_	_	I-Premise
244	both	_	_	I-Premise
245	overall	_	_	I-Premise
246	(	_	_	I-Premise
247	hazard	_	_	I-Premise
248	ratio	_	_	I-Premise
249	[	_	_	I-Premise
250	HR	_	_	I-Premise
251	]	_	_	I-Premise
252	:	_	_	I-Premise
253	0	_	_	I-Premise
254	.	_	_	I-Premise

255	57	_	_	I-Premise
256	;	_	_	I-Premise
257	p	_	_	I-Premise
258	=	_	_	I-Premise
259	0	_	_	I-Premise
260	.	_	_	I-Premise

261	0067	_	_	I-Premise
262	)	_	_	I-Premise
263	and	_	_	I-Premise
264	in	_	_	I-Premise
265	patients	_	_	I-Premise
266	with	_	_	I-Premise
267	EGFR	_	_	I-Premise
268	IHC	_	_	I-Premise
269	-	_	_	I-Premise
270	positive	_	_	I-Premise
271	disease	_	_	I-Premise
272	(	_	_	I-Premise
273	HR	_	_	I-Premise
274	=	_	_	I-Premise
275	0	_	_	I-Premise
276	.	_	_	I-Premise

277	50	_	_	I-Premise
278	;	_	_	I-Premise
279	p	_	_	I-Premise
280	=	_	_	I-Premise
281	0	_	_	I-Premise
282	.	_	_	I-Premise

283	0057	_	_	I-Premise
284	)	_	_	I-Premise
285	.	_	_	I-Premise

286	There	_	_	B-Premise
287	was	_	_	I-Premise
288	a	_	_	I-Premise
289	trend	_	_	I-Premise
290	towards	_	_	I-Premise
291	an	_	_	I-Premise
292	increase	_	_	I-Premise
293	in	_	_	I-Premise
294	OS	_	_	I-Premise
295	,	_	_	I-Premise
296	which	_	_	I-Premise
297	reached	_	_	I-Premise
298	statistical	_	_	I-Premise
299	significance	_	_	I-Premise
300	in	_	_	I-Premise
301	the	_	_	I-Premise
302	EGFR	_	_	I-Premise
303	IHC	_	_	I-Premise
304	-	_	_	I-Premise
305	positive	_	_	I-Premise
306	subgroup	_	_	I-Premise
307	(	_	_	I-Premise
308	p	_	_	I-Premise
309	=	_	_	I-Premise
310	0	_	_	I-Premise
311	.	_	_	I-Premise

312	0233	_	_	I-Premise
313	)	_	_	I-Premise
314	.	_	_	I-Premise

315	The	_	_	B-Premise
316	overall	_	_	I-Premise
317	response	_	_	I-Premise
318	rate	_	_	I-Premise
319	was	_	_	I-Premise
320	significantly	_	_	I-Premise
321	higher	_	_	I-Premise
322	with	_	_	I-Premise
323	erlotinib	_	_	I-Premise
324	compared	_	_	I-Premise
325	with	_	_	I-Premise
326	placebo	_	_	I-Premise
327	(	_	_	I-Premise
328	24	_	_	I-Premise
329	%	_	_	I-Premise
330	versus	_	_	I-Premise
331	5	_	_	I-Premise
332	%	_	_	I-Premise
333	;	_	_	I-Premise
334	p	_	_	I-Premise
335	=	_	_	I-Premise
336	0	_	_	I-Premise
337	.	_	_	I-Premise

338	0025	_	_	I-Premise
339	)	_	_	I-Premise
340	.	_	_	I-Premise

341	Erlotinib	_	_	B-Claim
342	was	_	_	I-Claim
343	generally	_	_	I-Claim
344	well	_	_	I-Claim
345	tolerated	_	_	I-Claim
346	and	_	_	I-Claim
347	had	_	_	I-Claim
348	no	_	_	I-Claim
349	negative	_	_	I-Claim
350	impact	_	_	I-Claim
351	on	_	_	I-Claim
352	QoL	_	_	I-Claim
353	in	_	_	I-Claim
354	this	_	_	I-Claim
355	subpopulation	_	_	I-Claim
356	.	_	_	I-Claim

357	The	_	_	B-Premise
358	most	_	_	I-Premise
359	common	_	_	I-Premise
360	treatment	_	_	I-Premise
361	-	_	_	I-Premise
362	related	_	_	I-Premise
363	adverse	_	_	I-Premise
364	events	_	_	I-Premise
365	were	_	_	I-Premise
366	rash	_	_	I-Premise
367	,	_	_	I-Premise
368	diarrhea	_	_	I-Premise
369	and	_	_	I-Premise
370	pruritus	_	_	I-Premise
371	.	_	_	I-Premise

372	Erlotinib	_	_	B-Claim
373	was	_	_	I-Claim
374	effective	_	_	I-Claim
375	and	_	_	I-Claim
376	well	_	_	I-Claim
377	tolerated	_	_	I-Claim
378	in	_	_	I-Claim
379	Asian	_	_	I-Claim
380	patients	_	_	I-Claim
381	,	_	_	I-Claim
382	producing	_	_	I-Claim
383	benefits	_	_	I-Claim
384	consistent	_	_	I-Claim
385	with	_	_	I-Claim
386	those	_	_	I-Claim
387	observed	_	_	I-Claim
388	in	_	_	I-Claim
389	the	_	_	I-Claim
390	overall	_	_	I-Claim
391	SATURN	_	_	I-Claim
392	population	_	_	I-Claim
393	.	_	_	I-Claim

394	Maintenance	_	_	B-Claim
395	treatment	_	_	I-Claim
396	with	_	_	I-Claim
397	erlotinib	_	_	I-Claim
398	appears	_	_	I-Claim
399	to	_	_	I-Claim
400	be	_	_	I-Claim
401	a	_	_	I-Claim
402	useful	_	_	I-Claim
403	option	_	_	I-Claim
404	for	_	_	I-Claim
405	the	_	_	I-Claim
406	management	_	_	I-Claim
407	of	_	_	I-Claim
408	Asian	_	_	I-Claim
409	patients	_	_	I-Claim
410	with	_	_	I-Claim
411	advanced	_	_	I-Claim
412	NSCLC	_	_	I-Claim
413	without	_	_	I-Claim
414	progression	_	_	I-Claim
415	after	_	_	I-Claim
416	first	_	_	I-Claim
417	-	_	_	I-Claim
418	line	_	_	I-Claim
419	chemotherapy	_	_	I-Claim
420	.	_	_	I-Claim


0	A	_	_	O
1	recent	_	_	O
2	randomized	_	_	O
3	trial	_	_	O
4	to	_	_	O
5	compare	_	_	O
6	external	_	_	O
7	beam	_	_	O
8	radiation	_	_	O
9	therapy	_	_	O
10	(	_	_	O
11	EBRT	_	_	O
12	)	_	_	O
13	to	_	_	O
14	cryoablation	_	_	O
15	for	_	_	O
16	localized	_	_	O
17	disease	_	_	O
18	showed	_	_	O
19	cryoablation	_	_	O
20	to	_	_	O
21	be	_	_	O
22	noninferior	_	_	O
23	to	_	_	O
24	external	_	_	O
25	beam	_	_	O
26	EBRT	_	_	O
27	in	_	_	O
28	disease	_	_	O
29	progression	_	_	O
30	and	_	_	O
31	overall	_	_	O
32	and	_	_	O
33	disease	_	_	O
34	-	_	_	O
35	specific	_	_	O
36	survival	_	_	O
37	.	_	_	O

38	We	_	_	O
39	report	_	_	O
40	on	_	_	O
41	the	_	_	O
42	quality	_	_	O
43	of	_	_	O
44	life	_	_	O
45	(	_	_	O
46	QOL	_	_	O
47	)	_	_	O
48	outcomes	_	_	O
49	for	_	_	O
50	this	_	_	O
51	trial	_	_	O
52	.	_	_	O

53	From	_	_	O
54	December	_	_	O
55	1997	_	_	O
56	through	_	_	O
57	February	_	_	O
58	2003	_	_	O
59	,	_	_	O
60	244	_	_	O
61	men	_	_	O
62	with	_	_	O
63	newly	_	_	O
64	diagnosed	_	_	O
65	localized	_	_	O
66	prostate	_	_	O
67	cancer	_	_	O
68	were	_	_	O
69	randomly	_	_	O
70	assigned	_	_	O
71	to	_	_	O
72	cryoablation	_	_	O
73	or	_	_	O
74	EBRT	_	_	O
75	(	_	_	O
76	median	_	_	O
77	dose	_	_	O
78	68	_	_	O
79	Gy	_	_	O
80	)	_	_	O
81	.	_	_	O

82	All	_	_	O
83	patients	_	_	O
84	received	_	_	O
85	neoadjuvant	_	_	O
86	antiandrogen	_	_	O
87	therapy	_	_	O
88	.	_	_	O

89	Patients	_	_	O
90	completed	_	_	O
91	the	_	_	O
92	EORTC	_	_	O
93	QLQ	_	_	O
94	C30	_	_	O
95	and	_	_	O
96	the	_	_	O
97	Prostate	_	_	O
98	Cancer	_	_	O
99	Index	_	_	O
100	(	_	_	O
101	PCI	_	_	O
102	)	_	_	O
103	before	_	_	O
104	treatment	_	_	O
105	and	_	_	O
106	at	_	_	O
107	1	_	_	O
108	.	_	_	O

109	5	_	_	O
110	,	_	_	O
111	3	_	_	O
112	,	_	_	O
113	6	_	_	O
114	,	_	_	O
115	12	_	_	O
116	,	_	_	O
117	18	_	_	O
118	,	_	_	O
119	24	_	_	O
120	,	_	_	O
121	and	_	_	O
122	36	_	_	O
123	months	_	_	O
124	post	_	_	O
125	-	_	_	O
126	treatment	_	_	O
127	.	_	_	O

128	Regardless	_	_	B-Premise
129	of	_	_	I-Premise
130	treatment	_	_	I-Premise
131	arm	_	_	I-Premise
132	,	_	_	I-Premise
133	participants	_	_	I-Premise
134	reported	_	_	I-Premise
135	high	_	_	I-Premise
136	levels	_	_	I-Premise
137	of	_	_	I-Premise
138	QOL	_	_	I-Premise
139	with	_	_	I-Premise
140	few	_	_	I-Premise
141	exceptions	_	_	I-Premise
142	.	_	_	I-Premise

143	cryoablation	_	_	B-Premise
144	was	_	_	I-Premise
145	associated	_	_	I-Premise
146	with	_	_	I-Premise
147	more	_	_	I-Premise
148	acute	_	_	I-Premise
149	urinary	_	_	I-Premise
150	dysfunction	_	_	I-Premise
151	(	_	_	I-Premise
152	mean	_	_	I-Premise
153	PCI	_	_	I-Premise
154	urinary	_	_	I-Premise
155	function	_	_	I-Premise
156	cryoablation	_	_	I-Premise
157	=	_	_	I-Premise
158	69	_	_	I-Premise
159	.	_	_	I-Premise

160	4	_	_	I-Premise
161	;	_	_	I-Premise
162	mean	_	_	I-Premise
163	EBRT	_	_	I-Premise
164	=	_	_	I-Premise
165	90	_	_	I-Premise
166	.	_	_	I-Premise

167	7	_	_	I-Premise
168	;	_	_	I-Premise
169	P	_	_	I-Premise
170	<	_	_	I-Premise
171	.	_	_	I-Premise

172	001	_	_	I-Premise
173	)	_	_	I-Premise
174	,	_	_	I-Premise
175	which	_	_	I-Premise
176	resolved	_	_	I-Premise
177	over	_	_	I-Premise
178	time	_	_	I-Premise
179	.	_	_	I-Premise

180	No	_	_	B-Premise
181	late	_	_	I-Premise
182	arising	_	_	I-Premise
183	QOL	_	_	I-Premise
184	issues	_	_	I-Premise
185	were	_	_	I-Premise
186	observed	_	_	I-Premise
187	.	_	_	I-Premise

188	Both	_	_	B-Premise
189	EBRT	_	_	I-Premise
190	and	_	_	I-Premise
191	cryoablation	_	_	I-Premise
192	participants	_	_	I-Premise
193	reported	_	_	I-Premise
194	decreases	_	_	I-Premise
195	in	_	_	I-Premise
196	sexual	_	_	I-Premise
197	function	_	_	I-Premise
198	at	_	_	I-Premise
199	3	_	_	I-Premise
200	months	_	_	I-Premise
201	with	_	_	I-Premise
202	the	_	_	I-Premise
203	cryoablation	_	_	I-Premise
204	patients	_	_	I-Premise
205	reporting	_	_	I-Premise
206	poorer	_	_	I-Premise
207	functioning	_	_	I-Premise
208	(	_	_	I-Premise
209	mean	_	_	I-Premise
210	cryoablation	_	_	I-Premise
211	=	_	_	I-Premise
212	7	_	_	I-Premise
213	.	_	_	I-Premise

214	2	_	_	I-Premise
215	:	_	_	I-Premise
216	mean	_	_	I-Premise
217	EBRT	_	_	I-Premise
218	=	_	_	I-Premise
219	32	_	_	I-Premise
220	.	_	_	I-Premise

221	9	_	_	I-Premise
222	;	_	_	I-Premise
223	P	_	_	I-Premise
224	<	_	_	I-Premise
225	.	_	_	I-Premise

226	001	_	_	I-Premise
227	)	_	_	I-Premise
228	.	_	_	I-Premise

229	Mean	_	_	B-Premise
230	sexual	_	_	I-Premise
231	function	_	_	I-Premise
232	score	_	_	I-Premise
233	was	_	_	I-Premise
234	15	_	_	I-Premise
235	points	_	_	I-Premise
236	lower	_	_	I-Premise
237	at	_	_	I-Premise
238	3	_	_	I-Premise
239	years	_	_	I-Premise
240	for	_	_	I-Premise
241	the	_	_	I-Premise
242	cryoablation	_	_	I-Premise
243	group	_	_	I-Premise
244	and	_	_	I-Premise
245	13	_	_	I-Premise
246	%	_	_	I-Premise
247	more	_	_	I-Premise
248	of	_	_	I-Premise
249	the	_	_	I-Premise
250	cryoablation	_	_	I-Premise
251	men	_	_	I-Premise
252	said	_	_	I-Premise
253	that	_	_	I-Premise
254	sexuality	_	_	I-Premise
255	was	_	_	I-Premise
256	a	_	_	I-Premise
257	moderate	_	_	I-Premise
258	or	_	_	I-Premise
259	big	_	_	I-Premise
260	problem	_	_	I-Premise
261	.	_	_	I-Premise

262	In	_	_	B-Claim
263	this	_	_	I-Claim
264	randomized	_	_	I-Claim
265	trial	_	_	I-Claim
266	,	_	_	I-Claim
267	no	_	_	I-Claim
268	long	_	_	I-Claim
269	-	_	_	I-Claim
270	term	_	_	I-Claim
271	QOL	_	_	I-Claim
272	advantage	_	_	I-Claim
273	for	_	_	I-Claim
274	either	_	_	I-Claim
275	treatment	_	_	I-Claim
276	was	_	_	I-Claim
277	apparent	_	_	I-Claim
278	with	_	_	B-Claim
279	the	_	_	I-Claim
280	exception	_	_	I-Claim
281	of	_	_	I-Claim
282	poorer	_	_	I-Claim
283	sexual	_	_	I-Claim
284	function	_	_	I-Claim
285	reported	_	_	I-Claim
286	by	_	_	I-Claim
287	those	_	_	I-Claim
288	treated	_	_	I-Claim
289	with	_	_	I-Claim
290	cryoablation	_	_	I-Claim
291	.	_	_	I-Claim

292	Men	_	_	O
293	who	_	_	O
294	wish	_	_	O
295	to	_	_	O
296	increase	_	_	O
297	their	_	_	O
298	odds	_	_	O
299	of	_	_	O
300	retaining	_	_	O
301	sexual	_	_	O
302	function	_	_	O
303	might	_	_	O
304	be	_	_	O
305	counseled	_	_	O
306	to	_	_	O
307	choose	_	_	O
308	EBRT	_	_	O
309	over	_	_	O
310	cryoablation	_	_	O
311	.	_	_	O


0	Hot	_	_	O
1	flushes	_	_	O
2	and	_	_	O
3	night	_	_	O
4	sweats	_	_	O
5	(	_	_	O
6	HFNS	_	_	O
7	)	_	_	O
8	affect	_	_	O
9	65	_	_	O
10	-	_	_	O
11	85	_	_	O
12	%	_	_	O
13	of	_	_	O
14	women	_	_	O
15	after	_	_	O
16	breast	_	_	O
17	cancer	_	_	O
18	treatment	_	_	O
19	;	_	_	O
20	they	_	_	O
21	are	_	_	O
22	distressing	_	_	O
23	,	_	_	O
24	causing	_	_	O
25	sleep	_	_	O
26	problems	_	_	O
27	and	_	_	O
28	decreased	_	_	O
29	quality	_	_	O
30	of	_	_	O
31	life	_	_	O
32	.	_	_	O

33	Hormone	_	_	B-Claim
34	replacement	_	_	I-Claim
35	therapy	_	_	I-Claim
36	is	_	_	I-Claim
37	often	_	_	I-Claim
38	either	_	_	I-Claim
39	undesirable	_	_	I-Claim
40	or	_	_	I-Claim
41	contraindicated	_	_	I-Claim
42	.	_	_	I-Claim

43	Safe	_	_	B-Claim
44	,	_	_	I-Claim
45	effective	_	_	I-Claim
46	non	_	_	I-Claim
47	-	_	_	I-Claim
48	hormonal	_	_	I-Claim
49	treatments	_	_	I-Claim
50	are	_	_	I-Claim
51	needed	_	_	I-Claim
52	.	_	_	I-Claim

53	We	_	_	O
54	investigated	_	_	O
55	whether	_	_	O
56	cognitive	_	_	O
57	behavioural	_	_	O
58	therapy	_	_	O
59	(	_	_	O
60	CBT	_	_	O
61	)	_	_	O
62	can	_	_	O
63	help	_	_	O
64	breast	_	_	O
65	cancer	_	_	O
66	survivors	_	_	O
67	to	_	_	O
68	effectively	_	_	O
69	manage	_	_	O
70	HFNS	_	_	O
71	.	_	_	O

72	In	_	_	O
73	this	_	_	O
74	randomised	_	_	O
75	controlled	_	_	O
76	trial	_	_	O
77	,	_	_	O
78	we	_	_	O
79	recruited	_	_	O
80	women	_	_	O
81	from	_	_	O
82	breast	_	_	O
83	clinics	_	_	O
84	in	_	_	O
85	London	_	_	O
86	,	_	_	O
87	UK	_	_	O
88	,	_	_	O
89	who	_	_	O
90	had	_	_	O
91	problematic	_	_	O
92	HFNS	_	_	O
93	(	_	_	O
94	minimum	_	_	O
95	ten	_	_	O
96	problematic	_	_	O
97	episodes	_	_	O
98	a	_	_	O
99	week	_	_	O
100	)	_	_	O
101	after	_	_	O
102	breast	_	_	O
103	-	_	_	O
104	cancer	_	_	O
105	treatment	_	_	O
106	.	_	_	O

107	Participants	_	_	O
108	were	_	_	O
109	randomly	_	_	O
110	allocated	_	_	O
111	to	_	_	O
112	receive	_	_	O
113	either	_	_	O
114	usual	_	_	O
115	care	_	_	O
116	or	_	_	O
117	usual	_	_	O
118	care	_	_	O
119	plus	_	_	O
120	group	_	_	O
121	CBT	_	_	O
122	(	_	_	O
123	1	_	_	O
124	:	_	_	O
125	1	_	_	O
126	)	_	_	O
127	.	_	_	O

128	Randomisation	_	_	O
129	was	_	_	O
130	done	_	_	O
131	in	_	_	O
132	blocks	_	_	O
133	of	_	_	O
134	12	_	_	O
135	-	_	_	O
136	20	_	_	O
137	participants	_	_	O
138	,	_	_	O
139	stratifying	_	_	O
140	by	_	_	O
141	age	_	_	O
142	(	_	_	O
143	younger	_	_	O
144	than	_	_	O
145	50	_	_	O
146	years	_	_	O
147	,	_	_	O
148	50	_	_	O
149	years	_	_	O
150	or	_	_	O
151	older	_	_	O
152	)	_	_	O
153	,	_	_	O
154	and	_	_	O
155	was	_	_	O
156	done	_	_	O
157	with	_	_	O
158	a	_	_	O
159	computer	_	_	O
160	-	_	_	O
161	generated	_	_	O
162	sequence	_	_	O
163	.	_	_	O

164	The	_	_	O
165	trial	_	_	O
166	statistician	_	_	O
167	and	_	_	O
168	researchers	_	_	O
169	collecting	_	_	O
170	outcome	_	_	O
171	measures	_	_	O
172	were	_	_	O
173	masked	_	_	O
174	to	_	_	O
175	group	_	_	O
176	allocation	_	_	O
177	.	_	_	O

178	Group	_	_	O
179	CBT	_	_	O
180	comprised	_	_	O
181	one	_	_	O
182	90	_	_	O
183	min	_	_	O
184	session	_	_	O
185	a	_	_	O
186	week	_	_	O
187	for	_	_	O
188	6	_	_	O
189	weeks	_	_	O
190	,	_	_	O
191	and	_	_	O
192	included	_	_	O
193	psycho	_	_	O
194	-	_	_	O
195	education	_	_	O
196	,	_	_	O
197	paced	_	_	O
198	breathing	_	_	O
199	,	_	_	O
200	and	_	_	O
201	cognitive	_	_	O
202	and	_	_	O
203	behavioural	_	_	O
204	strategies	_	_	O
205	to	_	_	O
206	manage	_	_	O
207	HFNS	_	_	O
208	.	_	_	O

209	Assessments	_	_	O
210	were	_	_	O
211	done	_	_	O
212	at	_	_	O
213	baseline	_	_	O
214	,	_	_	O
215	9	_	_	O
216	weeks	_	_	O
217	,	_	_	O
218	and	_	_	O
219	26	_	_	O
220	weeks	_	_	O
221	after	_	_	O
222	randomisation	_	_	O
223	.	_	_	O

224	The	_	_	O
225	primary	_	_	O
226	outcome	_	_	O
227	was	_	_	O
228	the	_	_	O
229	adjusted	_	_	O
230	mean	_	_	O
231	difference	_	_	O
232	in	_	_	O
233	HFNS	_	_	O
234	problem	_	_	O
235	rating	_	_	O
236	(	_	_	O
237	1	_	_	O
238	-	_	_	O
239	10	_	_	O
240	)	_	_	O
241	between	_	_	O
242	CBT	_	_	O
243	and	_	_	O
244	usual	_	_	O
245	care	_	_	O
246	groups	_	_	O
247	at	_	_	O
248	9	_	_	O
249	weeks	_	_	O
250	after	_	_	O
251	randomisation	_	_	O
252	.	_	_	O

253	Analysis	_	_	O
254	of	_	_	O
255	the	_	_	O
256	primary	_	_	O
257	endpoint	_	_	O
258	was	_	_	O
259	done	_	_	O
260	by	_	_	O
261	modified	_	_	O
262	intention	_	_	O
263	to	_	_	O
264	treat	_	_	O
265	.	_	_	O

266	The	_	_	O
267	trial	_	_	O
268	is	_	_	O
269	registered	_	_	O
270	,	_	_	O
271	ISRCTN13771934	_	_	O
272	,	_	_	O
273	and	_	_	O
274	was	_	_	O
275	closed	_	_	O
276	March	_	_	O
277	15	_	_	O
278	,	_	_	O
279	2011	_	_	O
280	.	_	_	O

281	Between	_	_	O
282	May	_	_	O
283	5	_	_	O
284	,	_	_	O
285	2009	_	_	O
286	,	_	_	O
287	and	_	_	O
288	Aug	_	_	O
289	27	_	_	O
290	,	_	_	O
291	2010	_	_	O
292	,	_	_	O
293	96	_	_	O
294	women	_	_	O
295	were	_	_	O
296	randomly	_	_	O
297	allocated	_	_	O
298	to	_	_	O
299	group	_	_	O
300	CBT	_	_	O
301	(	_	_	O
302	n	_	_	O
303	=	_	_	O
304	47	_	_	O
305	)	_	_	O
306	or	_	_	O
307	usual	_	_	O
308	care	_	_	O
309	(	_	_	O
310	n	_	_	O
311	=	_	_	O
312	49	_	_	O
313	)	_	_	O
314	.	_	_	O

315	Group	_	_	B-Premise
316	CBT	_	_	I-Premise
317	significantly	_	_	I-Premise
318	reduced	_	_	I-Premise
319	HFNS	_	_	I-Premise
320	problem	_	_	I-Premise
321	rating	_	_	I-Premise
322	at	_	_	I-Premise
323	9	_	_	I-Premise
324	weeks	_	_	I-Premise
325	after	_	_	I-Premise
326	randomisation	_	_	I-Premise
327	compared	_	_	I-Premise
328	with	_	_	I-Premise
329	usual	_	_	I-Premise
330	care	_	_	I-Premise
331	(	_	_	I-Premise
332	mean	_	_	I-Premise
333	difference	_	_	I-Premise
334	-	_	_	I-Premise
335	1	_	_	I-Premise
336	·	_	_	I-Premise
337	67	_	_	I-Premise
338	,	_	_	I-Premise
339	95	_	_	I-Premise
340	%	_	_	I-Premise
341	CI	_	_	I-Premise
342	-	_	_	I-Premise
343	2	_	_	I-Premise
344	·	_	_	I-Premise
345	43	_	_	I-Premise
346	to	_	_	I-Premise
347	-	_	_	I-Premise
348	0	_	_	I-Premise
349	·	_	_	I-Premise
350	91	_	_	I-Premise
351	;	_	_	I-Premise
352	p	_	_	I-Premise
353	<	_	_	I-Premise
354	0	_	_	I-Premise
355	·	_	_	I-Premise
356	0001	_	_	I-Premise
357	)	_	_	I-Premise
358	and	_	_	I-Premise
359	improvements	_	_	I-Premise
360	were	_	_	I-Premise
361	maintained	_	_	I-Premise
362	at	_	_	I-Premise
363	26	_	_	I-Premise
364	weeks	_	_	I-Premise
365	(	_	_	I-Premise
366	mean	_	_	I-Premise
367	difference	_	_	I-Premise
368	-	_	_	I-Premise
369	1	_	_	I-Premise
370	·	_	_	I-Premise
371	76	_	_	I-Premise
372	,	_	_	I-Premise
373	-	_	_	I-Premise
374	2	_	_	I-Premise
375	·	_	_	I-Premise
376	54	_	_	I-Premise
377	to	_	_	I-Premise
378	-	_	_	I-Premise
379	0	_	_	I-Premise
380	·	_	_	I-Premise
381	99	_	_	I-Premise
382	;	_	_	I-Premise
383	p	_	_	I-Premise
384	<	_	_	I-Premise
385	0	_	_	I-Premise
386	·	_	_	I-Premise
387	0001	_	_	I-Premise
388	)	_	_	I-Premise
389	.	_	_	I-Premise

390	We	_	_	B-Premise
391	recorded	_	_	I-Premise
392	no	_	_	I-Premise
393	CBT	_	_	I-Premise
394	-	_	_	I-Premise
395	related	_	_	I-Premise
396	adverse	_	_	I-Premise
397	events	_	_	I-Premise
398	.	_	_	I-Premise

399	Group	_	_	B-Claim
400	CBT	_	_	I-Claim
401	seems	_	_	I-Claim
402	to	_	_	I-Claim
403	be	_	_	I-Claim
404	a	_	_	I-Claim
405	safe	_	_	I-Claim
406	and	_	_	I-Claim
407	effective	_	_	I-Claim
408	treatment	_	_	I-Claim
409	for	_	_	I-Claim
410	women	_	_	I-Claim
411	who	_	_	I-Claim
412	have	_	_	I-Claim
413	problematic	_	_	I-Claim
414	HFNS	_	_	I-Claim
415	after	_	_	I-Claim
416	breast	_	_	I-Claim
417	cancer	_	_	I-Claim
418	treatment	_	_	I-Claim
419	with	_	_	I-Claim
420	additional	_	_	I-Claim
421	benefits	_	_	I-Claim
422	to	_	_	I-Claim
423	mood	_	_	I-Claim
424	,	_	_	I-Claim
425	sleep	_	_	I-Claim
426	,	_	_	I-Claim
427	and	_	_	I-Claim
428	quality	_	_	I-Claim
429	of	_	_	I-Claim
430	life	_	_	I-Claim
431	.	_	_	I-Claim

432	The	_	_	O
433	treatment	_	_	O
434	could	_	_	O
435	be	_	_	O
436	incorporated	_	_	O
437	into	_	_	O
438	breast	_	_	O
439	cancer	_	_	O
440	survivorship	_	_	O
441	programmes	_	_	O
442	and	_	_	O
443	delivered	_	_	O
444	by	_	_	O
445	trained	_	_	O
446	breast	_	_	O
447	cancer	_	_	O
448	nurses	_	_	O
449	.	_	_	O


0	We	_	_	O
1	report	_	_	O
2	results	_	_	O
3	of	_	_	O
4	a	_	_	O
5	randomized	_	_	O
6	prospective	_	_	O
7	study	_	_	O
8	that	_	_	O
9	compared	_	_	O
10	single	_	_	O
11	agents	_	_	O
12	of	_	_	O
13	low	_	_	O
14	toxicity	_	_	O
15	given	_	_	O
16	both	_	_	O
17	as	_	_	O
18	the	_	_	O
19	first	_	_	O
20	-	_	_	O
21	line	_	_	O
22	and	_	_	O
23	second	_	_	O
24	-	_	_	O
25	line	_	_	O
26	chemotherapy	_	_	O
27	with	_	_	O
28	combination	_	_	O
29	chemotherapy	_	_	O
30	in	_	_	O
31	advanced	_	_	O
32	breast	_	_	O
33	cancer	_	_	O
34	with	_	_	O
35	distant	_	_	O
36	metastases	_	_	O
37	.	_	_	O

38	Patients	_	_	O
39	in	_	_	O
40	the	_	_	O
41	single	_	_	O
42	-	_	_	O
43	agent	_	_	O
44	arm	_	_	O
45	(	_	_	O
46	n	_	_	O
47	=	_	_	O
48	153	_	_	O
49	)	_	_	O
50	received	_	_	O
51	weekly	_	_	O
52	epirubicin	_	_	O
53	(	_	_	O
54	E	_	_	O
55	)	_	_	O
56	20	_	_	O
57	mg	_	_	O
58	/	_	_	O
59	m2	_	_	O
60	until	_	_	O
61	progression	_	_	O
62	or	_	_	O
63	until	_	_	O
64	the	_	_	O
65	cumulative	_	_	O
66	dose	_	_	O
67	of	_	_	O
68	1	_	_	O
69	,	_	_	O
70	000	_	_	O
71	mg	_	_	O
72	/	_	_	O
73	m2	_	_	O
74	,	_	_	O
75	followed	_	_	O
76	by	_	_	O
77	mitomycin	_	_	O
78	(	_	_	O
79	M	_	_	O
80	)	_	_	O
81	8	_	_	O
82	mg	_	_	O
83	/	_	_	O
84	m2	_	_	O
85	every	_	_	O
86	4	_	_	O
87	weeks	_	_	O
88	,	_	_	O
89	and	_	_	O
90	those	_	_	O
91	in	_	_	O
92	the	_	_	O
93	combination	_	_	O
94	chemotherapy	_	_	O
95	arm	_	_	O
96	(	_	_	O
97	n	_	_	O
98	=	_	_	O
99	150	_	_	O
100	)	_	_	O
101	were	_	_	O
102	first	_	_	O
103	given	_	_	O
104	cyclophosphamide	_	_	O
105	500	_	_	O
106	mg	_	_	O
107	/	_	_	O
108	m2	_	_	O
109	,	_	_	O
110	E	_	_	O
111	60	_	_	O
112	mg	_	_	O
113	/	_	_	O
114	m2	_	_	O
115	,	_	_	O
116	and	_	_	O
117	fluorouracil	_	_	O
118	500	_	_	O
119	mg	_	_	O
120	/	_	_	O
121	m2	_	_	O
122	three	_	_	O
123	times	_	_	O
124	per	_	_	O
125	week	_	_	O
126	(	_	_	O
127	CEF	_	_	O
128	)	_	_	O
129	followed	_	_	O
130	by	_	_	O
131	M	_	_	O
132	8	_	_	O
133	mg	_	_	O
134	/	_	_	O
135	m2	_	_	O
136	plus	_	_	O
137	vinblastine	_	_	O
138	(	_	_	O
139	V	_	_	O
140	)	_	_	O
141	6	_	_	O
142	mg	_	_	O
143	/	_	_	O
144	m2	_	_	O
145	every	_	_	O
146	4	_	_	O
147	weeks	_	_	O
148	.	_	_	O

149	Exclusion	_	_	O
150	criteria	_	_	O
151	included	_	_	O
152	age	_	_	O
153	greater	_	_	O
154	than	_	_	O
155	70	_	_	O
156	years	_	_	O
157	,	_	_	O
158	World	_	_	O
159	Health	_	_	O
160	Organization	_	_	O
161	(	_	_	O
162	WHO	_	_	O
163	)	_	_	O
164	performance	_	_	O
165	status	_	_	O
166	greater	_	_	O
167	than	_	_	O
168	2	_	_	O
169	,	_	_	O
170	prior	_	_	O
171	chemotherapy	_	_	O
172	for	_	_	O
173	metastatic	_	_	O
174	disease	_	_	O
175	,	_	_	O
176	and	_	_	O
177	presence	_	_	O
178	of	_	_	O
179	liver	_	_	O
180	metastases	_	_	O
181	in	_	_	O
182	patients	_	_	O
183	younger	_	_	O
184	than	_	_	O
185	50	_	_	O
186	.	_	_	O

187	An	_	_	B-Premise
188	objective	_	_	I-Premise
189	response	_	_	I-Premise
190	(	_	_	I-Premise
191	complete	_	_	I-Premise
192	[	_	_	I-Premise
193	CR	_	_	I-Premise
194	]	_	_	I-Premise
195	or	_	_	I-Premise
196	partial	_	_	I-Premise
197	[	_	_	I-Premise
198	PR	_	_	I-Premise
199	]	_	_	I-Premise
200	)	_	_	I-Premise
201	was	_	_	I-Premise
202	obtained	_	_	I-Premise
203	in	_	_	I-Premise
204	55	_	_	I-Premise
205	%	_	_	I-Premise
206	,	_	_	I-Premise
207	48	_	_	I-Premise
208	%	_	_	I-Premise
209	,	_	_	I-Premise
210	16	_	_	I-Premise
211	%	_	_	I-Premise
212	,	_	_	I-Premise
213	and	_	_	I-Premise
214	7	_	_	I-Premise
215	%	_	_	I-Premise
216	of	_	_	I-Premise
217	patients	_	_	I-Premise
218	treated	_	_	I-Premise
219	with	_	_	I-Premise
220	CEF	_	_	I-Premise
221	,	_	_	I-Premise
222	E	_	_	I-Premise
223	,	_	_	I-Premise
224	M	_	_	I-Premise
225	,	_	_	I-Premise
226	and	_	_	I-Premise
227	MV	_	_	I-Premise
228	,	_	_	I-Premise
229	respectively	_	_	I-Premise
230	.	_	_	I-Premise

231	A	_	_	B-Premise
232	response	_	_	I-Premise
233	to	_	_	I-Premise
234	CEF	_	_	I-Premise
235	tended	_	_	I-Premise
236	to	_	_	I-Premise
237	last	_	_	I-Premise
238	longer	_	_	I-Premise
239	than	_	_	I-Premise
240	a	_	_	I-Premise
241	response	_	_	I-Premise
242	to	_	_	I-Premise
243	E	_	_	I-Premise
244	(	_	_	I-Premise
245	median	_	_	I-Premise
246	,	_	_	I-Premise
247	12	_	_	I-Premise
248	v	_	_	I-Premise
249	10	_	_	I-Premise
250	.	_	_	I-Premise

251	5	_	_	I-Premise
252	months	_	_	I-Premise
253	;	_	_	I-Premise
254	P	_	_	I-Premise
255	=	_	_	I-Premise
256	.	_	_	I-Premise

257	07	_	_	I-Premise
258	)	_	_	I-Premise
259	.	_	_	I-Premise

260	Treatment	_	_	B-Premise
261	-	_	_	I-Premise
262	related	_	_	I-Premise
263	toxicity	_	_	I-Premise
264	was	_	_	I-Premise
265	less	_	_	I-Premise
266	in	_	_	I-Premise
267	the	_	_	I-Premise
268	single	_	_	I-Premise
269	-	_	_	I-Premise
270	agent	_	_	I-Premise
271	arm	_	_	I-Premise
272	and	_	_	I-Premise
273	quality	_	_	I-Premise
274	-	_	_	I-Premise
275	of	_	_	I-Premise
276	-	_	_	I-Premise
277	life	_	_	I-Premise
278	(	_	_	I-Premise
279	QOL	_	_	I-Premise
280	)	_	_	I-Premise
281	analysis	_	_	I-Premise
282	favored	_	_	I-Premise
283	the	_	_	I-Premise
284	single	_	_	I-Premise
285	-	_	_	I-Premise
286	agent	_	_	I-Premise
287	arm	_	_	I-Premise
288	.	_	_	I-Premise

289	No	_	_	B-Premise
290	significant	_	_	I-Premise
291	difference	_	_	I-Premise
292	in	_	_	I-Premise
293	time	_	_	I-Premise
294	to	_	_	I-Premise
295	progression	_	_	I-Premise
296	or	_	_	I-Premise
297	survival	_	_	I-Premise
298	was	_	_	I-Premise
299	found	_	_	I-Premise
300	between	_	_	I-Premise
301	the	_	_	I-Premise
302	two	_	_	I-Premise
303	arms	_	_	I-Premise
304	.	_	_	I-Premise

305	Similarly	_	_	B-Premise
306	,	_	_	I-Premise
307	no	_	_	I-Premise
308	difference	_	_	I-Premise
309	in	_	_	I-Premise
310	survival	_	_	I-Premise
311	was	_	_	I-Premise
312	found	_	_	I-Premise
313	when	_	_	I-Premise
314	the	_	_	I-Premise
315	patients	_	_	I-Premise
316	who	_	_	I-Premise
317	received	_	_	I-Premise
318	both	_	_	I-Premise
319	the	_	_	I-Premise
320	planned	_	_	I-Premise
321	first	_	_	I-Premise
322	-	_	_	I-Premise
323	and	_	_	I-Premise
324	second	_	_	I-Premise
325	-	_	_	I-Premise
326	line	_	_	I-Premise
327	treatments	_	_	I-Premise
328	were	_	_	I-Premise
329	compared	_	_	I-Premise
330	or	_	_	I-Premise
331	when	_	_	I-Premise
332	survival	_	_	I-Premise
333	was	_	_	I-Premise
334	calculated	_	_	I-Premise
335	from	_	_	I-Premise
336	the	_	_	I-Premise
337	beginning	_	_	I-Premise
338	of	_	_	I-Premise
339	the	_	_	I-Premise
340	second	_	_	I-Premise
341	-	_	_	I-Premise
342	line	_	_	I-Premise
343	therapy	_	_	I-Premise
344	.	_	_	I-Premise

345	Patients	_	_	B-Claim
346	treated	_	_	I-Claim
347	with	_	_	I-Claim
348	single	_	_	I-Claim
349	-	_	_	I-Claim
350	agent	_	_	I-Claim
351	E	_	_	I-Claim
352	followed	_	_	I-Claim
353	by	_	_	I-Claim
354	single	_	_	I-Claim
355	-	_	_	I-Claim
356	agent	_	_	I-Claim
357	M	_	_	I-Claim
358	had	_	_	I-Claim
359	similar	_	_	I-Claim
360	survival	_	_	I-Claim
361	,	_	_	I-Claim
362	but	_	_	I-Claim
363	less	_	_	I-Claim
364	treatment	_	_	I-Claim
365	-	_	_	I-Claim
366	related	_	_	I-Claim
367	toxicity	_	_	I-Claim
368	and	_	_	I-Claim
369	better	_	_	I-Claim
370	QOL	_	_	I-Claim
371	as	_	_	I-Claim
372	compared	_	_	I-Claim
373	with	_	_	I-Claim
374	those	_	_	I-Claim
375	treated	_	_	I-Claim
376	with	_	_	I-Claim
377	CEF	_	_	I-Claim
378	followed	_	_	I-Claim
379	by	_	_	I-Claim
380	MV	_	_	I-Claim
381	.	_	_	I-Claim


0	This	_	_	O
1	double	_	_	O
2	-	_	_	O
3	blind	_	_	O
4	randomized	_	_	O
5	phase	_	_	O
6	II	_	_	O
7	trial	_	_	O
8	examined	_	_	O
9	whether	_	_	O
10	vandetanib	_	_	O
11	,	_	_	O
12	an	_	_	O
13	inhibitor	_	_	O
14	of	_	_	O
15	vascular	_	_	O
16	endothelial	_	_	O
17	and	_	_	O
18	epidermal	_	_	O
19	growth	_	_	O
20	factor	_	_	O
21	receptors	_	_	O
22	,	_	_	O
23	could	_	_	O
24	prolong	_	_	O
25	progression	_	_	O
26	-	_	_	O
27	free	_	_	O
28	survival	_	_	O
29	in	_	_	O
30	responding	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	small	_	_	O
34	-	_	_	O
35	cell	_	_	O
36	lung	_	_	O
37	cancer	_	_	O
38	.	_	_	O

39	Eligible	_	_	O
40	patients	_	_	O
41	with	_	_	O
42	complete	_	_	O
43	response	_	_	O
44	(	_	_	O
45	CR	_	_	O
46	)	_	_	O
47	or	_	_	O
48	partial	_	_	O
49	response	_	_	O
50	(	_	_	O
51	PR	_	_	O
52	)	_	_	O
53	to	_	_	O
54	combination	_	_	O
55	chemotherapy	_	_	O
56	(	_	_	O
57	+	_	_	O
58	/	_	_	O
59	-	_	_	O
60	thoracic	_	_	O
61	or	_	_	O
62	prophylactic	_	_	O
63	cranial	_	_	O
64	radiation	_	_	O
65	)	_	_	O
66	received	_	_	O
67	oral	_	_	O
68	vandetanib	_	_	O
69	300	_	_	O
70	mg	_	_	O
71	/	_	_	O
72	d	_	_	O
73	or	_	_	O
74	matched	_	_	O
75	placebo	_	_	O
76	.	_	_	O

77	With	_	_	O
78	100	_	_	O
79	patients	_	_	O
80	and	_	_	O
81	77	_	_	O
82	events	_	_	O
83	,	_	_	O
84	the	_	_	O
85	study	_	_	O
86	had	_	_	O
87	80	_	_	O
88	%	_	_	O
89	power	_	_	O
90	to	_	_	O
91	detect	_	_	O
92	an	_	_	O
93	improvement	_	_	O
94	in	_	_	O
95	median	_	_	O
96	progression	_	_	O
97	-	_	_	O
98	free	_	_	O
99	survival	_	_	O
100	from	_	_	O
101	4	_	_	O
102	to	_	_	O
103	6	_	_	O
104	.	_	_	O

105	5	_	_	O
106	months	_	_	O
107	(	_	_	O
108	one	_	_	O
109	-	_	_	O
110	sided	_	_	O
111	,	_	_	O
112	10	_	_	O
113	%	_	_	O
114	-	_	_	O
115	level	_	_	O
116	test	_	_	O
117	)	_	_	O
118	.	_	_	O

119	Between	_	_	O
120	May	_	_	O
121	2003	_	_	O
122	and	_	_	O
123	March	_	_	O
124	2006	_	_	O
125	,	_	_	O
126	107	_	_	O
127	patients	_	_	O
128	were	_	_	O
129	accrued	_	_	O
130	;	_	_	O
131	46	_	_	O
132	had	_	_	O
133	limited	_	_	O
134	disease	_	_	O
135	and	_	_	O
136	61	_	_	O
137	extensive	_	_	O
138	disease	_	_	O
139	.	_	_	O

140	There	_	_	O
141	were	_	_	O
142	fewer	_	_	O
143	patients	_	_	O
144	with	_	_	O
145	a	_	_	O
146	performance	_	_	O
147	status	_	_	O
148	of	_	_	O
149	0	_	_	O
150	(	_	_	O
151	n	_	_	O
152	=	_	_	O
153	11	_	_	O
154	v	_	_	O
155	20	_	_	O
156	)	_	_	O
157	,	_	_	O
158	and	_	_	O
159	fewer	_	_	O
160	had	_	_	O
161	CR	_	_	O
162	to	_	_	O
163	initial	_	_	O
164	therapy	_	_	O
165	(	_	_	O
166	n	_	_	O
167	=	_	_	O
168	4	_	_	O
169	v	_	_	O
170	8	_	_	O
171	)	_	_	O
172	in	_	_	O
173	the	_	_	O
174	vandetanib	_	_	O
175	arm	_	_	O
176	.	_	_	O

177	Vandetanib	_	_	B-Premise
178	patients	_	_	I-Premise
179	had	_	_	I-Premise
180	more	_	_	I-Premise
181	toxicity	_	_	I-Premise
182	and	_	_	I-Premise
183	required	_	_	I-Premise
184	more	_	_	I-Premise
185	dose	_	_	I-Premise
186	modifications	_	_	I-Premise
187	for	_	_	I-Premise
188	gastrointestinal	_	_	I-Premise
189	toxicity	_	_	I-Premise
190	and	_	_	I-Premise
191	rash	_	_	I-Premise
192	.	_	_	I-Premise

193	Asymptomatic	_	_	B-Premise
194	Corrected	_	_	I-Premise
195	QT	_	_	I-Premise
196	interval	_	_	I-Premise
197	(	_	_	I-Premise
198	QTC	_	_	I-Premise
199	)	_	_	I-Premise
200	prolongation	_	_	I-Premise
201	was	_	_	I-Premise
202	observed	_	_	I-Premise
203	in	_	_	I-Premise
204	eight	_	_	I-Premise
205	vandetanib	_	_	I-Premise
206	patients	_	_	I-Premise
207	.	_	_	I-Premise

208	Median	_	_	B-Premise
209	progression	_	_	I-Premise
210	-	_	_	I-Premise
211	free	_	_	I-Premise
212	survival	_	_	I-Premise
213	for	_	_	I-Premise
214	vandetanib	_	_	I-Premise
215	and	_	_	I-Premise
216	placebo	_	_	I-Premise
217	was	_	_	I-Premise
218	2	_	_	I-Premise
219	.	_	_	I-Premise

220	7	_	_	I-Premise
221	and	_	_	I-Premise
222	2	_	_	I-Premise
223	.	_	_	I-Premise

224	8	_	_	I-Premise
225	months	_	_	I-Premise
226	,	_	_	I-Premise
227	respectively	_	_	I-Premise
228	(	_	_	I-Premise
229	hazard	_	_	I-Premise
230	ratio	_	_	I-Premise
231	[	_	_	I-Premise
232	HR	_	_	I-Premise
233	]	_	_	I-Premise
234	,	_	_	I-Premise
235	1	_	_	I-Premise
236	.	_	_	I-Premise

237	01	_	_	I-Premise
238	;	_	_	I-Premise
239	80	_	_	I-Premise
240	%	_	_	I-Premise
241	CI	_	_	I-Premise
242	,	_	_	I-Premise
243	0	_	_	I-Premise
244	.	_	_	I-Premise

245	75	_	_	I-Premise
246	to	_	_	I-Premise
247	1	_	_	I-Premise
248	.	_	_	I-Premise

249	36	_	_	I-Premise
250	;	_	_	I-Premise
251	one	_	_	I-Premise
252	-	_	_	I-Premise
253	sided	_	_	I-Premise
254	P	_	_	I-Premise
255	=	_	_	I-Premise
256	.	_	_	I-Premise

257	51	_	_	I-Premise
258	)	_	_	I-Premise
259	.	_	_	I-Premise

260	Overall	_	_	B-Premise
261	survival	_	_	I-Premise
262	for	_	_	I-Premise
263	vandetanib	_	_	I-Premise
264	was	_	_	I-Premise
265	10	_	_	I-Premise
266	.	_	_	I-Premise

267	6	_	_	I-Premise
268	versus	_	_	I-Premise
269	11	_	_	I-Premise
270	.	_	_	I-Premise

271	9	_	_	I-Premise
272	months	_	_	I-Premise
273	for	_	_	I-Premise
274	placebo	_	_	I-Premise
275	(	_	_	I-Premise
276	HR	_	_	I-Premise
277	,	_	_	I-Premise
278	1	_	_	I-Premise
279	.	_	_	I-Premise

280	43	_	_	I-Premise
281	;	_	_	I-Premise
282	80	_	_	I-Premise
283	%	_	_	I-Premise
284	CI	_	_	I-Premise
285	,	_	_	I-Premise
286	1	_	_	I-Premise
287	.	_	_	I-Premise

288	00	_	_	I-Premise
289	to	_	_	I-Premise
290	2	_	_	I-Premise
291	.	_	_	I-Premise

292	05	_	_	I-Premise
293	;	_	_	I-Premise
294	one	_	_	I-Premise
295	-	_	_	I-Premise
296	sided	_	_	I-Premise
297	P	_	_	I-Premise
298	=	_	_	I-Premise
299	0	_	_	I-Premise
300	.	_	_	I-Premise

301	9	_	_	I-Premise
302	)	_	_	I-Premise
303	.	_	_	I-Premise

304	In	_	_	B-Premise
305	planned	_	_	I-Premise
306	subgroup	_	_	I-Premise
307	analyses	_	_	I-Premise
308	,	_	_	I-Premise
309	a	_	_	I-Premise
310	significant	_	_	I-Premise
311	interaction	_	_	I-Premise
312	was	_	_	I-Premise
313	noted	_	_	I-Premise
314	(	_	_	I-Premise
315	P	_	_	I-Premise
316	=	_	_	I-Premise
317	.	_	_	I-Premise

318	01	_	_	I-Premise
319	)	_	_	I-Premise
320	:	_	_	I-Premise
321	limited	_	_	I-Premise
322	-	_	_	I-Premise
323	stage	_	_	I-Premise
324	vandetanib	_	_	I-Premise
325	patients	_	_	I-Premise
326	had	_	_	I-Premise
327	longer	_	_	I-Premise
328	overall	_	_	I-Premise
329	survival	_	_	I-Premise
330	(	_	_	I-Premise
331	HR	_	_	I-Premise
332	,	_	_	I-Premise
333	0	_	_	I-Premise
334	.	_	_	I-Premise

335	45	_	_	I-Premise
336	;	_	_	I-Premise
337	one	_	_	I-Premise
338	-	_	_	I-Premise
339	sided	_	_	I-Premise
340	P	_	_	I-Premise
341	=	_	_	I-Premise
342	.	_	_	I-Premise

343	07	_	_	I-Premise
344	)	_	_	I-Premise
345	and	_	_	I-Premise
346	extensive	_	_	I-Premise
347	-	_	_	I-Premise
348	stage	_	_	I-Premise
349	vandetanib	_	_	I-Premise
350	patients	_	_	I-Premise
351	shorter	_	_	I-Premise
352	survival	_	_	I-Premise
353	compared	_	_	I-Premise
354	with	_	_	I-Premise
355	placebo	_	_	I-Premise
356	(	_	_	I-Premise
357	HR	_	_	I-Premise
358	,	_	_	I-Premise
359	2	_	_	I-Premise
360	.	_	_	I-Premise

361	27	_	_	I-Premise
362	;	_	_	I-Premise
363	one	_	_	I-Premise
364	-	_	_	I-Premise
365	sided	_	_	I-Premise
366	P	_	_	I-Premise
367	=	_	_	I-Premise
368	.	_	_	I-Premise

369	996	_	_	I-Premise
370	)	_	_	I-Premise
371	.	_	_	I-Premise

372	Vandetanib	_	_	B-Claim
373	failed	_	_	I-Claim
374	to	_	_	I-Claim
375	demonstrate	_	_	I-Claim
376	efficacy	_	_	I-Claim
377	as	_	_	I-Claim
378	maintenance	_	_	I-Claim
379	therapy	_	_	I-Claim
380	for	_	_	I-Claim
381	small	_	_	I-Claim
382	-	_	_	I-Claim
383	cell	_	_	I-Claim
384	lung	_	_	I-Claim
385	cancer	_	_	I-Claim
386	.	_	_	I-Claim


0	In	_	_	B-Claim
1	endocrine	_	_	I-Claim
2	therapy	_	_	I-Claim
3	trials	_	_	I-Claim
4	in	_	_	I-Claim
5	advanced	_	_	I-Claim
6	breast	_	_	I-Claim
7	cancer	_	_	I-Claim
8	,	_	_	I-Claim
9	patients	_	_	I-Claim
10	with	_	_	I-Claim
11	response	_	_	I-Claim
12	(	_	_	I-Claim
13	complete	_	_	I-Claim
14	response	_	_	I-Claim
15	/	_	_	I-Claim
16	partial	_	_	I-Claim
17	response	_	_	I-Claim
18	[	_	_	I-Claim
19	CR	_	_	I-Claim
20	/	_	_	I-Claim
21	PR	_	_	I-Claim
22	]	_	_	I-Claim
23	)	_	_	I-Claim
24	and	_	_	I-Claim
25	patients	_	_	I-Claim
26	with	_	_	I-Claim
27	stable	_	_	I-Claim
28	disease	_	_	I-Claim
29	for	_	_	I-Claim
30	at	_	_	I-Claim
31	least	_	_	I-Claim
32	6	_	_	I-Claim
33	months	_	_	I-Claim
34	(	_	_	I-Claim
35	SD	_	_	I-Claim
36	(	_	_	I-Claim
37	6m	_	_	I-Claim
38	)	_	_	I-Claim
39	)	_	_	I-Claim
40	have	_	_	I-Claim
41	shown	_	_	I-Claim
42	similar	_	_	I-Claim
43	survival	_	_	I-Claim
44	and	_	_	I-Claim
45	therefore	_	_	I-Claim
46	are	_	_	I-Claim
47	often	_	_	I-Claim
48	defined	_	_	I-Claim
49	as	_	_	I-Claim
50	a	_	_	I-Claim
51	population	_	_	I-Claim
52	with	_	_	I-Claim
53	clinical	_	_	I-Claim
54	benefit	_	_	I-Claim
55	(	_	_	I-Claim
56	patients	_	_	I-Claim
57	with	_	_	I-Claim
58	CR	_	_	I-Claim
59	/	_	_	I-Claim
60	PR	_	_	I-Claim
61	or	_	_	I-Claim
62	SD	_	_	I-Claim
63	(	_	_	I-Claim
64	6m	_	_	I-Claim
65	)	_	_	I-Claim
66	)	_	_	I-Claim
67	.	_	_	I-Claim

68	We	_	_	O
69	evaluated	_	_	O
70	the	_	_	O
71	impact	_	_	O
72	of	_	_	O
73	response	_	_	O
74	and	_	_	O
75	/	_	_	O
76	or	_	_	O
77	clinical	_	_	O
78	benefit	_	_	O
79	on	_	_	O
80	quality	_	_	O
81	of	_	_	O
82	life	_	_	O
83	(	_	_	O
84	QL	_	_	O
85	)	_	_	O
86	in	_	_	O
87	postmenopausal	_	_	O
88	patients	_	_	O
89	under	_	_	O
90	second	_	_	O
91	-	_	_	O
92	line	_	_	O
93	endocrine	_	_	O
94	treatment	_	_	O
95	after	_	_	O
96	failure	_	_	O
97	of	_	_	O
98	tamoxifen	_	_	O
99	.	_	_	O

100	One	_	_	O
101	hundred	_	_	O
102	twenty	_	_	O
103	-	_	_	O
104	eight	_	_	O
105	of	_	_	O
106	177	_	_	O
107	eligible	_	_	O
108	patients	_	_	O
109	of	_	_	O
110	a	_	_	O
111	randomized	_	_	O
112	trial	_	_	O
113	(	_	_	O
114	Swiss	_	_	O
115	Group	_	_	O
116	for	_	_	O
117	Clinical	_	_	O
118	Cancer	_	_	O
119	Research	_	_	O
120	20	_	_	O
121	/	_	_	O
122	90	_	_	O
123	)	_	_	O
124	receiving	_	_	O
125	either	_	_	O
126	formestane	_	_	O
127	(	_	_	O
128	250	_	_	O
129	mg	_	_	O
130	intramuscularly	_	_	O
131	biweekly	_	_	O
132	)	_	_	O
133	or	_	_	O
134	megestrol	_	_	O
135	acetate	_	_	O
136	(	_	_	O
137	160	_	_	O
138	mg	_	_	O
139	orally	_	_	O
140	daily	_	_	O
141	)	_	_	O
142	were	_	_	O
143	analyzed	_	_	O
144	.	_	_	O

145	The	_	_	O
146	baseline	_	_	O
147	characteristics	_	_	O
148	(	_	_	O
149	with	_	_	O
150	the	_	_	O
151	exception	_	_	O
152	of	_	_	O
153	site	_	_	O
154	of	_	_	O
155	metastases	_	_	O
156	)	_	_	O
157	were	_	_	O
158	balanced	_	_	O
159	among	_	_	O
160	patients	_	_	O
161	with	_	_	O
162	CR	_	_	O
163	/	_	_	O
164	PR	_	_	O
165	,	_	_	O
166	SD	_	_	O
167	(	_	_	O
168	6m	_	_	O
169	)	_	_	O
170	,	_	_	O
171	and	_	_	O
172	progressive	_	_	O
173	disease	_	_	O
174	(	_	_	O
175	PD	_	_	O
176	)	_	_	O
177	.	_	_	O

178	Patients	_	_	O
179	completed	_	_	O
180	QL	_	_	O
181	indicators	_	_	O
182	at	_	_	O
183	baseline	_	_	O
184	and	_	_	O
185	at	_	_	O
186	1	_	_	O
187	,	_	_	O
188	3	_	_	O
189	,	_	_	O
190	5	_	_	O
191	,	_	_	O
192	7	_	_	O
193	,	_	_	O
194	9	_	_	O
195	,	_	_	O
196	and	_	_	O
197	11	_	_	O
198	months	_	_	O
199	.	_	_	O

200	Responders	_	_	O
201	were	_	_	O
202	separately	_	_	O
203	compared	_	_	O
204	with	_	_	O
205	nonresponders	_	_	O
206	(	_	_	O
207	patients	_	_	O
208	with	_	_	O
209	SD	_	_	O
210	(	_	_	O
211	6m	_	_	O
212	)	_	_	O
213	or	_	_	O
214	PD	_	_	O
215	)	_	_	O
216	and	_	_	O
217	with	_	_	O
218	patients	_	_	O
219	with	_	_	O
220	SD	_	_	O
221	(	_	_	O
222	6m	_	_	O
223	)	_	_	O
224	,	_	_	O
225	and	_	_	O
226	patients	_	_	O
227	with	_	_	O
228	clinical	_	_	O
229	benefit	_	_	O
230	were	_	_	O
231	compared	_	_	O
232	with	_	_	O
233	patients	_	_	O
234	with	_	_	O
235	PD	_	_	O
236	by	_	_	O
237	analysis	_	_	O
238	of	_	_	O
239	covariance	_	_	O
240	with	_	_	O
241	adjustment	_	_	O
242	for	_	_	O
243	baseline	_	_	O
244	scores	_	_	O
245	.	_	_	O

246	Overall	_	_	O
247	,	_	_	O
248	88	_	_	O
249	%	_	_	O
250	(	_	_	O
251	557	_	_	O
252	of	_	_	O
253	634	_	_	O
254	)	_	_	O
255	of	_	_	O
256	expected	_	_	O
257	QL	_	_	O
258	forms	_	_	O
259	were	_	_	O
260	received	_	_	O
261	.	_	_	O

262	In	_	_	O
263	the	_	_	O
264	comparison	_	_	O
265	of	_	_	O
266	responders	_	_	O
267	versus	_	_	O
268	patients	_	_	O
269	with	_	_	O
270	both	_	_	O
271	SD	_	_	O
272	(	_	_	O
273	6m	_	_	O
274	)	_	_	O
275	and	_	_	O
276	PD	_	_	O
277	,	_	_	O
278	responders	_	_	B-Premise
279	indicated	_	_	I-Premise
280	better	_	_	I-Premise
281	physical	_	_	I-Premise
282	well	_	_	I-Premise
283	-	_	_	I-Premise
284	being	_	_	I-Premise
285	(	_	_	I-Premise
286	P	_	_	I-Premise
287	=	_	_	I-Premise
288	.	_	_	I-Premise

289	004	_	_	I-Premise
290	)	_	_	I-Premise
291	and	_	_	I-Premise
292	mood	_	_	I-Premise
293	(	_	_	I-Premise
294	P	_	_	I-Premise
295	=	_	_	I-Premise
296	.	_	_	I-Premise

297	02	_	_	I-Premise
298	)	_	_	I-Premise
299	at	_	_	I-Premise
300	month	_	_	I-Premise
301	3	_	_	I-Premise
302	.	_	_	I-Premise

303	Compared	_	_	B-Premise
304	only	_	_	I-Premise
305	with	_	_	I-Premise
306	patients	_	_	I-Premise
307	with	_	_	I-Premise
308	SD	_	_	I-Premise
309	(	_	_	I-Premise
310	6m	_	_	I-Premise
311	)	_	_	I-Premise
312	,	_	_	I-Premise
313	responders	_	_	I-Premise
314	showed	_	_	I-Premise
315	no	_	_	I-Premise
316	significant	_	_	I-Premise
317	difference	_	_	I-Premise
318	in	_	_	I-Premise
319	baseline	_	_	I-Premise
320	QL	_	_	I-Premise
321	and	_	_	I-Premise
322	time	_	_	I-Premise
323	to	_	_	I-Premise
324	treatment	_	_	I-Premise
325	failure	_	_	I-Premise
326	(	_	_	I-Premise
327	328	_	_	I-Premise
328	.	_	_	I-Premise

329	5	_	_	I-Premise
330	v	_	_	I-Premise
331	340	_	_	I-Premise
332	days	_	_	I-Premise
333	)	_	_	I-Premise
334	.	_	_	I-Premise

335	While	_	_	B-Premise
336	under	_	_	I-Premise
337	treatment	_	_	I-Premise
338	,	_	_	I-Premise
339	responders	_	_	I-Premise
340	reported	_	_	I-Premise
341	significantly	_	_	I-Premise
342	better	_	_	I-Premise
343	physical	_	_	I-Premise
344	well	_	_	I-Premise
345	-	_	_	I-Premise
346	being	_	_	I-Premise
347	(	_	_	I-Premise
348	months	_	_	I-Premise
349	3	_	_	I-Premise
350	to	_	_	I-Premise
351	11	_	_	I-Premise
352	)	_	_	I-Premise
353	,	_	_	I-Premise
354	mood	_	_	I-Premise
355	(	_	_	I-Premise
356	months	_	_	I-Premise
357	5	_	_	I-Premise
358	to	_	_	I-Premise
359	11	_	_	I-Premise
360	)	_	_	I-Premise
361	,	_	_	I-Premise
362	coping	_	_	I-Premise
363	(	_	_	I-Premise
364	months	_	_	I-Premise
365	5	_	_	I-Premise
366	to	_	_	I-Premise
367	9	_	_	I-Premise
368	)	_	_	I-Premise
369	,	_	_	I-Premise
370	and	_	_	I-Premise
371	appetite	_	_	I-Premise
372	(	_	_	I-Premise
373	months	_	_	I-Premise
374	7	_	_	I-Premise
375	to	_	_	I-Premise
376	11	_	_	I-Premise
377	)	_	_	I-Premise
378	and	_	_	I-Premise
379	less	_	_	I-Premise
380	dizziness	_	_	I-Premise
381	(	_	_	I-Premise
382	month	_	_	I-Premise
383	9	_	_	I-Premise
384	)	_	_	I-Premise
385	than	_	_	I-Premise
386	patients	_	_	I-Premise
387	with	_	_	I-Premise
388	SD	_	_	I-Premise
389	(	_	_	I-Premise
390	6m	_	_	I-Premise
391	)	_	_	I-Premise
392	.	_	_	I-Premise

393	The	_	_	B-Premise
394	changes	_	_	I-Premise
395	between	_	_	I-Premise
396	baseline	_	_	I-Premise
397	and	_	_	I-Premise
398	months	_	_	I-Premise
399	5	_	_	I-Premise
400	and	_	_	I-Premise
401	7	_	_	I-Premise
402	,	_	_	I-Premise
403	respectively	_	_	I-Premise
404	,	_	_	I-Premise
405	indicated	_	_	I-Premise
406	improvement	_	_	I-Premise
407	in	_	_	I-Premise
408	responders	_	_	I-Premise
409	but	_	_	I-Premise
410	heterogeneous	_	_	I-Premise
411	patterns	_	_	I-Premise
412	in	_	_	I-Premise
413	patients	_	_	I-Premise
414	with	_	_	I-Premise
415	SD	_	_	I-Premise
416	(	_	_	I-Premise
417	6m	_	_	I-Premise
418	)	_	_	I-Premise
419	.	_	_	I-Premise

420	Although	_	_	B-Premise
421	the	_	_	I-Premise
422	CR	_	_	I-Premise
423	/	_	_	I-Premise
424	PR	_	_	I-Premise
425	and	_	_	I-Premise
426	SD	_	_	I-Premise
427	(	_	_	I-Premise
428	6m	_	_	I-Premise
429	)	_	_	I-Premise
430	groups	_	_	I-Premise
431	had	_	_	I-Premise
432	similar	_	_	I-Premise
433	times	_	_	I-Premise
434	to	_	_	I-Premise
435	treatment	_	_	I-Premise
436	failure	_	_	I-Premise
437	,	_	_	I-Premise
438	patients	_	_	B-Claim
439	with	_	_	I-Claim
440	CR	_	_	I-Claim
441	/	_	_	I-Claim
442	PR	_	_	I-Claim
443	reported	_	_	I-Claim
444	better	_	_	I-Claim
445	QL	_	_	I-Claim
446	,	_	_	I-Claim
447	suggesting	_	_	I-Claim
448	more	_	_	I-Claim
449	beneficial	_	_	I-Claim
450	response	_	_	I-Claim
451	to	_	_	I-Claim
452	second	_	_	I-Claim
453	-	_	_	I-Claim
454	line	_	_	I-Claim
455	endocrine	_	_	I-Claim
456	treatment	_	_	I-Claim
457	.	_	_	I-Claim

458	Patients	_	_	O
459	'	_	_	O
460	subjective	_	_	O
461	perspective	_	_	O
462	should	_	_	O
463	be	_	_	O
464	taken	_	_	O
465	into	_	_	O
466	account	_	_	O
467	in	_	_	O
468	this	_	_	O
469	mainly	_	_	O
470	palliative	_	_	O
471	setting	_	_	O
472	.	_	_	O

473	Future	_	_	O
474	trials	_	_	O
475	should	_	_	O
476	be	_	_	O
477	designed	_	_	O
478	so	_	_	O
479	that	_	_	O
480	the	_	_	O
481	CR	_	_	O
482	/	_	_	O
483	PR	_	_	O
484	and	_	_	O
485	SD	_	_	O
486	(	_	_	O
487	6m	_	_	O
488	)	_	_	O
489	groups	_	_	O
490	are	_	_	O
491	investigated	_	_	O
492	separately	_	_	O
493	.	_	_	O


0	To	_	_	O
1	compare	_	_	O
2	survival	_	_	O
3	in	_	_	O
4	patients	_	_	O
5	with	_	_	O
6	recurrent	_	_	O
7	or	_	_	O
8	metastatic	_	_	O
9	squamous	_	_	O
10	cell	_	_	O
11	carcinoma	_	_	O
12	of	_	_	O
13	the	_	_	O
14	head	_	_	O
15	and	_	_	O
16	neck	_	_	O
17	(	_	_	O
18	SCCHN	_	_	O
19	)	_	_	O
20	treated	_	_	O
21	with	_	_	O
22	gefitinib	_	_	O
23	250	_	_	O
24	or	_	_	O
25	500	_	_	O
26	mg	_	_	O
27	/	_	_	O
28	day	_	_	O
29	or	_	_	O
30	standard	_	_	O
31	methotrexate	_	_	O
32	.	_	_	O

33	Four	_	_	O
34	hundred	_	_	O
35	eighty	_	_	O
36	-	_	_	O
37	six	_	_	O
38	patients	_	_	O
39	with	_	_	O
40	recurrent	_	_	O
41	SCCHN	_	_	O
42	were	_	_	O
43	randomly	_	_	O
44	assigned	_	_	O
45	to	_	_	O
46	oral	_	_	O
47	gefitinib	_	_	O
48	250	_	_	O
49	mg	_	_	O
50	/	_	_	O
51	day	_	_	O
52	,	_	_	O
53	gefitinib	_	_	O
54	500	_	_	O
55	mg	_	_	O
56	/	_	_	O
57	day	_	_	O
58	,	_	_	O
59	or	_	_	O
60	methotrexate	_	_	O
61	40	_	_	O
62	mg	_	_	O
63	/	_	_	O
64	m	_	_	O
65	(	_	_	O
66	2	_	_	O
67	)	_	_	O
68	intravenously	_	_	O
69	weekly	_	_	O
70	.	_	_	O

71	Primary	_	_	O
72	end	_	_	O
73	point	_	_	O
74	was	_	_	O
75	overall	_	_	O
76	survival	_	_	O
77	,	_	_	O
78	secondary	_	_	O
79	end	_	_	O
80	points	_	_	O
81	were	_	_	O
82	objective	_	_	O
83	response	_	_	O
84	rate	_	_	O
85	(	_	_	O
86	ORR	_	_	O
87	)	_	_	O
88	,	_	_	O
89	safety	_	_	O
90	,	_	_	O
91	symptom	_	_	O
92	improvement	_	_	O
93	,	_	_	O
94	and	_	_	O
95	quality	_	_	O
96	of	_	_	O
97	life	_	_	O
98	(	_	_	O
99	QOL	_	_	O
100	)	_	_	O
101	.	_	_	O

102	Exploratory	_	_	O
103	end	_	_	O
104	points	_	_	O
105	included	_	_	O
106	association	_	_	O
107	of	_	_	O
108	efficacy	_	_	O
109	with	_	_	O
110	epidermal	_	_	O
111	growth	_	_	O
112	factor	_	_	O
113	receptor	_	_	O
114	gene	_	_	O
115	copy	_	_	O
116	number	_	_	O
117	and	_	_	O
118	other	_	_	O
119	biomarkers	_	_	O
120	.	_	_	O

121	Neither	_	_	B-Premise
122	gefitinib	_	_	I-Premise
123	250	_	_	I-Premise
124	nor	_	_	I-Premise
125	500	_	_	I-Premise
126	mg	_	_	I-Premise
127	/	_	_	I-Premise
128	day	_	_	I-Premise
129	improved	_	_	I-Premise
130	overall	_	_	I-Premise
131	survival	_	_	I-Premise
132	compared	_	_	I-Premise
133	with	_	_	I-Premise
134	methotrexate	_	_	I-Premise
135	(	_	_	I-Premise
136	hazard	_	_	I-Premise
137	ratio	_	_	I-Premise
138	[	_	_	I-Premise
139	HR	_	_	I-Premise
140	]	_	_	I-Premise
141	,	_	_	I-Premise
142	1	_	_	I-Premise
143	.	_	_	I-Premise

144	22	_	_	I-Premise
145	;	_	_	I-Premise
146	95	_	_	I-Premise
147	%	_	_	I-Premise
148	CI	_	_	I-Premise
149	,	_	_	I-Premise
150	0	_	_	I-Premise
151	.	_	_	I-Premise

152	95	_	_	I-Premise
153	to	_	_	I-Premise
154	1	_	_	I-Premise
155	.	_	_	I-Premise

156	57	_	_	I-Premise
157	;	_	_	I-Premise
158	P	_	_	I-Premise
159	=	_	_	I-Premise
160	.	_	_	I-Premise

161	12	_	_	I-Premise
162	;	_	_	I-Premise
163	and	_	_	I-Premise
164	HR	_	_	I-Premise
165	,	_	_	I-Premise
166	1	_	_	I-Premise
167	.	_	_	I-Premise

168	12	_	_	I-Premise
169	;	_	_	I-Premise
170	95	_	_	I-Premise
171	%	_	_	I-Premise
172	CI	_	_	I-Premise
173	,	_	_	I-Premise
174	0	_	_	I-Premise
175	.	_	_	I-Premise

176	87	_	_	I-Premise
177	to	_	_	I-Premise
178	1	_	_	I-Premise
179	.	_	_	I-Premise

180	43	_	_	I-Premise
181	;	_	_	I-Premise
182	P	_	_	I-Premise
183	=	_	_	I-Premise
184	.	_	_	I-Premise

185	39	_	_	I-Premise
186	,	_	_	I-Premise
187	respectively	_	_	I-Premise
188	)	_	_	I-Premise
189	.	_	_	I-Premise

190	In	_	_	B-Premise
191	the	_	_	I-Premise
192	gefitinib	_	_	I-Premise
193	250	_	_	I-Premise
194	mg	_	_	I-Premise
195	/	_	_	I-Premise
196	day	_	_	I-Premise
197	,	_	_	I-Premise
198	500	_	_	I-Premise
199	mg	_	_	I-Premise
200	/	_	_	I-Premise
201	day	_	_	I-Premise
202	,	_	_	I-Premise
203	and	_	_	I-Premise
204	methotrexate	_	_	I-Premise
205	groups	_	_	I-Premise
206	,	_	_	I-Premise
207	respectively	_	_	I-Premise
208	,	_	_	I-Premise
209	median	_	_	I-Premise
210	overall	_	_	I-Premise
211	survival	_	_	I-Premise
212	was	_	_	I-Premise
213	5	_	_	I-Premise
214	.	_	_	I-Premise

215	6	_	_	I-Premise
216	,	_	_	I-Premise
217	6	_	_	I-Premise
218	.	_	_	I-Premise

219	0	_	_	I-Premise
220	,	_	_	I-Premise
221	and	_	_	I-Premise
222	6	_	_	I-Premise
223	.	_	_	I-Premise

224	7	_	_	I-Premise
225	months	_	_	I-Premise
226	;	_	_	I-Premise
227	ORRs	_	_	I-Premise
228	(	_	_	I-Premise
229	Response	_	_	I-Premise
230	Evaluation	_	_	I-Premise
231	Criteria	_	_	I-Premise
232	in	_	_	I-Premise
233	Solid	_	_	I-Premise
234	Tumors	_	_	I-Premise
235	)	_	_	I-Premise
236	were	_	_	I-Premise
237	2	_	_	I-Premise
238	.	_	_	I-Premise

239	7	_	_	I-Premise
240	%	_	_	I-Premise
241	,	_	_	I-Premise
242	7	_	_	I-Premise
243	.	_	_	I-Premise

244	6	_	_	I-Premise
245	%	_	_	I-Premise
246	and	_	_	I-Premise
247	3	_	_	I-Premise
248	.	_	_	I-Premise

249	9	_	_	I-Premise
250	%	_	_	I-Premise
251	,	_	_	I-Premise
252	with	_	_	I-Premise
253	no	_	_	I-Premise
254	statistically	_	_	I-Premise
255	significant	_	_	I-Premise
256	difference	_	_	I-Premise
257	between	_	_	I-Premise
258	either	_	_	I-Premise
259	gefitinib	_	_	I-Premise
260	arm	_	_	I-Premise
261	and	_	_	I-Premise
262	methotrexate	_	_	I-Premise
263	.	_	_	I-Premise

264	No	_	_	B-Premise
265	unexpected	_	_	I-Premise
266	adverse	_	_	I-Premise
267	events	_	_	I-Premise
268	were	_	_	I-Premise
269	observed	_	_	I-Premise
270	,	_	_	I-Premise
271	except	_	_	B-Premise
272	for	_	_	I-Premise
273	tumor	_	_	I-Premise
274	hemorrhage	_	_	I-Premise
275	-	_	_	I-Premise
276	type	_	_	I-Premise
277	events	_	_	I-Premise
278	with	_	_	I-Premise
279	gefitinib	_	_	I-Premise
280	(	_	_	I-Premise
281	8	_	_	I-Premise
282	.	_	_	I-Premise

283	9	_	_	I-Premise
284	%	_	_	I-Premise
285	,	_	_	I-Premise
286	gefitinib	_	_	I-Premise
287	250	_	_	I-Premise
288	mg	_	_	I-Premise
289	/	_	_	I-Premise
290	day	_	_	I-Premise
291	;	_	_	I-Premise
292	11	_	_	I-Premise
293	.	_	_	I-Premise

294	4	_	_	I-Premise
295	%	_	_	I-Premise
296	,	_	_	I-Premise
297	gefitinib	_	_	I-Premise
298	500	_	_	I-Premise
299	mg	_	_	I-Premise
300	/	_	_	I-Premise
301	day	_	_	I-Premise
302	;	_	_	I-Premise
303	1	_	_	I-Premise
304	.	_	_	I-Premise

305	9	_	_	I-Premise
306	%	_	_	I-Premise
307	,	_	_	I-Premise
308	methotrexate	_	_	I-Premise
309	)	_	_	I-Premise
310	.	_	_	I-Premise

311	QOL	_	_	B-Premise
312	improvement	_	_	I-Premise
313	rates	_	_	I-Premise
314	(	_	_	I-Premise
315	Functional	_	_	I-Premise
316	Assessment	_	_	I-Premise
317	of	_	_	I-Premise
318	Cancer	_	_	I-Premise
319	Therapy	_	_	I-Premise
320	-	_	_	I-Premise
321	Head	_	_	I-Premise
322	&	_	_	I-Premise
323	amp	_	_	I-Premise
324	;	_	_	I-Premise
325	Neck	_	_	I-Premise
326	total	_	_	I-Premise
327	score	_	_	I-Premise
328	)	_	_	I-Premise
329	were	_	_	I-Premise
330	13	_	_	I-Premise
331	.	_	_	I-Premise

332	4	_	_	I-Premise
333	%	_	_	I-Premise
334	,	_	_	I-Premise
335	18	_	_	I-Premise
336	.	_	_	I-Premise

337	0	_	_	I-Premise
338	%	_	_	I-Premise
339	,	_	_	I-Premise
340	and	_	_	I-Premise
341	6	_	_	I-Premise
342	.	_	_	I-Premise

343	0	_	_	I-Premise
344	%	_	_	I-Premise
345	for	_	_	I-Premise
346	gefitinib	_	_	I-Premise
347	250	_	_	I-Premise
348	mg	_	_	I-Premise
349	/	_	_	I-Premise
350	day	_	_	I-Premise
351	,	_	_	I-Premise
352	500	_	_	I-Premise
353	mg	_	_	I-Premise
354	/	_	_	I-Premise
355	day	_	_	I-Premise
356	,	_	_	I-Premise
357	and	_	_	I-Premise
358	methotrexate	_	_	I-Premise
359	,	_	_	I-Premise
360	respectively	_	_	I-Premise
361	.	_	_	I-Premise

362	In	_	_	B-Claim
363	patients	_	_	I-Claim
364	with	_	_	I-Claim
365	recurrent	_	_	I-Claim
366	or	_	_	I-Claim
367	metastatic	_	_	I-Claim
368	SCCHN	_	_	I-Claim
369	,	_	_	I-Claim
370	while	_	_	I-Claim
371	responses	_	_	I-Claim
372	with	_	_	I-Claim
373	gefitinib	_	_	I-Claim
374	were	_	_	I-Claim
375	seen	_	_	I-Claim
376	,	_	_	I-Claim
377	neither	_	_	I-Claim
378	gefitinib	_	_	I-Claim
379	250	_	_	I-Claim
380	nor	_	_	I-Claim
381	500	_	_	I-Claim
382	mg	_	_	I-Claim
383	/	_	_	I-Claim
384	day	_	_	I-Claim
385	improved	_	_	I-Claim
386	overall	_	_	I-Claim
387	survival	_	_	I-Claim
388	compared	_	_	I-Claim
389	with	_	_	I-Claim
390	methotrexate	_	_	I-Claim
391	.	_	_	I-Claim

392	With	_	_	B-Claim
393	the	_	_	I-Claim
394	exception	_	_	I-Claim
395	of	_	_	I-Claim
396	tumor	_	_	I-Claim
397	hemorrhage	_	_	I-Claim
398	-	_	_	I-Claim
399	type	_	_	I-Claim
400	events	_	_	I-Claim
401	with	_	_	I-Claim
402	gefitinib	_	_	I-Claim
403	,	_	_	I-Claim
404	the	_	_	I-Claim
405	adverse	_	_	I-Claim
406	event	_	_	I-Claim
407	profiles	_	_	I-Claim
408	were	_	_	I-Claim
409	generally	_	_	I-Claim
410	consistent	_	_	I-Claim
411	with	_	_	I-Claim
412	those	_	_	I-Claim
413	previously	_	_	I-Claim
414	observed	_	_	I-Claim
415	.	_	_	I-Claim


0	The	_	_	B-Claim
1	impact	_	_	I-Claim
2	of	_	_	I-Claim
3	treatment	_	_	I-Claim
4	on	_	_	I-Claim
5	health	_	_	I-Claim
6	-	_	_	I-Claim
7	related	_	_	I-Claim
8	quality	_	_	I-Claim
9	of	_	_	I-Claim
10	life	_	_	I-Claim
11	(	_	_	I-Claim
12	HRQoL	_	_	I-Claim
13	)	_	_	I-Claim
14	is	_	_	I-Claim
15	an	_	_	I-Claim
16	important	_	_	I-Claim
17	consideration	_	_	I-Claim
18	in	_	_	I-Claim
19	the	_	_	I-Claim
20	adjuvant	_	_	I-Claim
21	treatment	_	_	I-Claim
22	of	_	_	I-Claim
23	operable	_	_	I-Claim
24	breast	_	_	I-Claim
25	cancer	_	_	I-Claim
26	.	_	_	I-Claim

27	Here	_	_	O
28	we	_	_	O
29	report	_	_	O
30	mature	_	_	O
31	HRQoL	_	_	O
32	outcomes	_	_	O
33	from	_	_	O
34	the	_	_	O
35	ATAC	_	_	O
36	trial	_	_	O
37	,	_	_	O
38	comparing	_	_	O
39	anastrozole	_	_	O
40	with	_	_	O
41	tamoxifen	_	_	O
42	as	_	_	O
43	primary	_	_	O
44	adjuvant	_	_	O
45	therapy	_	_	O
46	for	_	_	O
47	postmenopausal	_	_	O
48	women	_	_	O
49	with	_	_	O
50	localized	_	_	O
51	breast	_	_	O
52	cancer	_	_	O
53	.	_	_	O

54	Patients	_	_	O
55	completed	_	_	O
56	the	_	_	O
57	Functional	_	_	O
58	Assessment	_	_	O
59	of	_	_	O
60	Cancer	_	_	O
61	Therapy	_	_	O
62	-	_	_	O
63	Breast	_	_	O
64	(	_	_	O
65	FACT	_	_	O
66	-	_	_	O
67	B	_	_	O
68	)	_	_	O
69	questionnaire	_	_	O
70	plus	_	_	O
71	endocrine	_	_	O
72	subscale	_	_	O
73	(	_	_	O
74	ES	_	_	O
75	)	_	_	O
76	at	_	_	O
77	baseline	_	_	O
78	,	_	_	O
79	3	_	_	O
80	and	_	_	O
81	6	_	_	O
82	months	_	_	O
83	,	_	_	O
84	and	_	_	O
85	every	_	_	O
86	6	_	_	O
87	months	_	_	O
88	thereafter	_	_	O
89	.	_	_	O

90	Baseline	_	_	O
91	characteristics	_	_	O
92	in	_	_	O
93	the	_	_	O
94	HRQoL	_	_	O
95	sub	_	_	O
96	-	_	_	O
97	protocol	_	_	O
98	were	_	_	O
99	well	_	_	O
100	balanced	_	_	O
101	between	_	_	O
102	the	_	_	O
103	anastrozole	_	_	O
104	(	_	_	O
105	n	_	_	O
106	=	_	_	O
107	335	_	_	O
108	)	_	_	O
109	and	_	_	O
110	tamoxifen	_	_	O
111	(	_	_	O
112	n	_	_	O
113	=	_	_	O
114	347	_	_	O
115	)	_	_	O
116	groups	_	_	O
117	in	_	_	O
118	the	_	_	O
119	primary	_	_	O
120	analysis	_	_	O
121	population	_	_	O
122	.	_	_	O

123	As	_	_	B-Premise
124	with	_	_	I-Premise
125	previously	_	_	I-Premise
126	published	_	_	I-Premise
127	results	_	_	I-Premise
128	at	_	_	I-Premise
129	2	_	_	I-Premise
130	years	_	_	I-Premise
131	,	_	_	I-Premise
132	there	_	_	I-Premise
133	was	_	_	I-Premise
134	no	_	_	I-Premise
135	statistically	_	_	I-Premise
136	significant	_	_	I-Premise
137	difference	_	_	I-Premise
138	in	_	_	I-Premise
139	the	_	_	I-Premise
140	Trial	_	_	I-Premise
141	Outcome	_	_	I-Premise
142	Index	_	_	I-Premise
143	of	_	_	I-Premise
144	the	_	_	I-Premise
145	FACT	_	_	I-Premise
146	-	_	_	I-Premise
147	B	_	_	I-Premise
148	,	_	_	I-Premise
149	the	_	_	I-Premise
150	primary	_	_	I-Premise
151	endpoint	_	_	I-Premise
152	of	_	_	I-Premise
153	the	_	_	I-Premise
154	study	_	_	I-Premise
155	,	_	_	I-Premise
156	between	_	_	I-Premise
157	treatments	_	_	I-Premise
158	at	_	_	I-Premise
159	5	_	_	I-Premise
160	years	_	_	I-Premise
161	.	_	_	I-Premise

162	There	_	_	B-Premise
163	were	_	_	I-Premise
164	no	_	_	I-Premise
165	statistically	_	_	I-Premise
166	significant	_	_	I-Premise
167	differences	_	_	I-Premise
168	between	_	_	I-Premise
169	treatment	_	_	I-Premise
170	groups	_	_	I-Premise
171	in	_	_	I-Premise
172	ES	_	_	I-Premise
173	total	_	_	I-Premise
174	scores	_	_	I-Premise
175	.	_	_	I-Premise

176	Consistent	_	_	O
177	with	_	_	O
178	the	_	_	O
179	2	_	_	O
180	-	_	_	O
181	year	_	_	O
182	analysis	_	_	O
183	,	_	_	O
184	there	_	_	B-Claim
185	were	_	_	I-Claim
186	differences	_	_	I-Claim
187	between	_	_	I-Claim
188	treatment	_	_	I-Claim
189	groups	_	_	I-Claim
190	in	_	_	I-Claim
191	patient	_	_	I-Claim
192	-	_	_	I-Claim
193	reported	_	_	I-Claim
194	side	_	_	I-Claim
195	effects	_	_	I-Claim
196	:	_	_	I-Claim
197	diarrhea	_	_	B-Premise
198	(	_	_	I-Premise
199	anastrozole	_	_	I-Premise
200	3	_	_	I-Premise
201	.	_	_	I-Premise

202	1	_	_	I-Premise
203	%	_	_	I-Premise
204	vs	_	_	I-Premise
205	.	_	_	I-Premise

206	tamoxifen	_	_	I-Premise
207	1	_	_	I-Premise
208	.	_	_	I-Premise

209	3	_	_	I-Premise
210	%	_	_	I-Premise
211	)	_	_	I-Premise
212	,	_	_	I-Premise
213	vaginal	_	_	I-Premise
214	dryness	_	_	I-Premise
215	(	_	_	I-Premise
216	18	_	_	I-Premise
217	.	_	_	I-Premise

218	5	_	_	I-Premise
219	%	_	_	I-Premise
220	vs	_	_	I-Premise
221	.	_	_	I-Premise

222	9	_	_	I-Premise
223	.	_	_	I-Premise

224	1	_	_	I-Premise
225	%	_	_	I-Premise
226	)	_	_	I-Premise
227	,	_	_	I-Premise
228	diminished	_	_	I-Premise
229	libido	_	_	I-Premise
230	(	_	_	I-Premise
231	34	_	_	I-Premise
232	.	_	_	I-Premise

233	0	_	_	I-Premise
234	%	_	_	I-Premise
235	vs	_	_	I-Premise
236	.	_	_	I-Premise

237	26	_	_	I-Premise
238	.	_	_	I-Premise

239	1	_	_	I-Premise
240	%	_	_	I-Premise
241	)	_	_	I-Premise
242	,	_	_	I-Premise
243	and	_	_	I-Premise
244	dyspareunia	_	_	I-Premise
245	(	_	_	I-Premise
246	17	_	_	I-Premise
247	.	_	_	I-Premise

248	3	_	_	I-Premise
249	%	_	_	I-Premise
250	vs	_	_	I-Premise
251	.	_	_	I-Premise

252	8	_	_	I-Premise
253	.	_	_	I-Premise

254	1	_	_	I-Premise
255	%	_	_	I-Premise
256	)	_	_	I-Premise
257	were	_	_	I-Premise
258	significantly	_	_	I-Premise
259	more	_	_	I-Premise
260	frequent	_	_	I-Premise
261	with	_	_	I-Premise
262	anastrozole	_	_	I-Premise
263	compared	_	_	I-Premise
264	to	_	_	I-Premise
265	tamoxifen	_	_	I-Premise
266	.	_	_	I-Premise

267	Dizziness	_	_	B-Premise
268	(	_	_	I-Premise
269	3	_	_	I-Premise
270	.	_	_	I-Premise

271	1	_	_	I-Premise
272	%	_	_	I-Premise
273	vs	_	_	I-Premise
274	.	_	_	I-Premise

275	5	_	_	I-Premise
276	.	_	_	I-Premise

277	4	_	_	I-Premise
278	%	_	_	I-Premise
279	)	_	_	I-Premise
280	and	_	_	I-Premise
281	vaginal	_	_	I-Premise
282	discharge	_	_	I-Premise
283	(	_	_	I-Premise
284	1	_	_	I-Premise
285	.	_	_	I-Premise

286	2	_	_	I-Premise
287	%	_	_	I-Premise
288	vs	_	_	I-Premise
289	.	_	_	I-Premise

290	5	_	_	I-Premise
291	.	_	_	I-Premise

292	2	_	_	I-Premise
293	%	_	_	I-Premise
294	)	_	_	I-Premise
295	were	_	_	I-Premise
296	significantly	_	_	I-Premise
297	less	_	_	I-Premise
298	frequent	_	_	I-Premise
299	with	_	_	I-Premise
300	anastrozole	_	_	I-Premise
301	compared	_	_	I-Premise
302	to	_	_	I-Premise
303	tamoxifen	_	_	I-Premise
304	.	_	_	I-Premise

305	In	_	_	B-Claim
306	this	_	_	I-Claim
307	,	_	_	I-Claim
308	the	_	_	I-Claim
309	first	_	_	I-Claim
310	report	_	_	I-Claim
311	of	_	_	I-Claim
312	HRQoL	_	_	I-Claim
313	over	_	_	I-Claim
314	5	_	_	I-Claim
315	years	_	_	I-Claim
316	of	_	_	I-Claim
317	initial	_	_	I-Claim
318	adjuvant	_	_	I-Claim
319	therapy	_	_	I-Claim
320	with	_	_	I-Claim
321	an	_	_	I-Claim
322	aromatase	_	_	I-Claim
323	inhibitor	_	_	I-Claim
324	,	_	_	I-Claim
325	we	_	_	I-Claim
326	conclude	_	_	I-Claim
327	that	_	_	I-Claim
328	anastrozole	_	_	I-Claim
329	and	_	_	I-Claim
330	tamoxifen	_	_	I-Claim
331	had	_	_	I-Claim
332	similar	_	_	I-Claim
333	impacts	_	_	I-Claim
334	on	_	_	I-Claim
335	HRQoL	_	_	I-Claim
336	,	_	_	I-Claim
337	which	_	_	I-Claim
338	was	_	_	I-Claim
339	maintained	_	_	I-Claim
340	or	_	_	I-Claim
341	slightly	_	_	I-Claim
342	improved	_	_	I-Claim
343	during	_	_	I-Claim
344	the	_	_	I-Claim
345	treatment	_	_	I-Claim
346	period	_	_	I-Claim
347	for	_	_	I-Claim
348	both	_	_	I-Claim
349	groups	_	_	I-Claim
350	.	_	_	I-Claim


0	Mucositis	_	_	B-Premise
1	occurs	_	_	I-Premise
2	in	_	_	I-Premise
3	almost	_	_	I-Premise
4	all	_	_	I-Premise
5	patients	_	_	I-Premise
6	treated	_	_	I-Premise
7	with	_	_	I-Premise
8	radiotherapy	_	_	I-Premise
9	for	_	_	I-Premise
10	head	_	_	I-Premise
11	and	_	_	I-Premise
12	neck	_	_	I-Premise
13	cancer	_	_	I-Premise
14	.	_	_	I-Premise

15	The	_	_	O
16	aim	_	_	O
17	of	_	_	O
18	this	_	_	O
19	multicenter	_	_	O
20	,	_	_	O
21	double	_	_	O
22	-	_	_	O
23	blind	_	_	O
24	,	_	_	O
25	prospective	_	_	O
26	,	_	_	O
27	randomized	_	_	O
28	trial	_	_	O
29	was	_	_	O
30	to	_	_	O
31	evaluate	_	_	O
32	the	_	_	O
33	clinical	_	_	O
34	efficacy	_	_	O
35	of	_	_	O
36	an	_	_	O
37	economically	_	_	O
38	viable	_	_	O
39	antimicrobial	_	_	O
40	lozenge	_	_	O
41	(	_	_	O
42	bacitracin	_	_	O
43	,	_	_	O
44	clotrimazole	_	_	O
45	,	_	_	O
46	and	_	_	O
47	gentamicin	_	_	O
48	[	_	_	O
49	BcoG	_	_	O
50	]	_	_	O
51	)	_	_	O
52	in	_	_	O
53	the	_	_	O
54	alleviation	_	_	O
55	of	_	_	O
56	radiation	_	_	O
57	-	_	_	O
58	induced	_	_	O
59	mucositis	_	_	O
60	in	_	_	O
61	patients	_	_	O
62	with	_	_	O
63	head	_	_	O
64	and	_	_	O
65	neck	_	_	O
66	cancer	_	_	O
67	.	_	_	O

68	One	_	_	O
69	hundred	_	_	O
70	thirty	_	_	O
71	-	_	_	O
72	seven	_	_	O
73	eligible	_	_	O
74	patients	_	_	O
75	were	_	_	O
76	randomized	_	_	O
77	to	_	_	O
78	treatment	_	_	O
79	with	_	_	O
80	either	_	_	O
81	antimicrobial	_	_	O
82	lozenge	_	_	O
83	(	_	_	O
84	69	_	_	O
85	patients	_	_	O
86	)	_	_	O
87	or	_	_	O
88	placebo	_	_	O
89	lozenge	_	_	O
90	(	_	_	O
91	68	_	_	O
92	patients	_	_	O
93	)	_	_	O
94	.	_	_	O

95	The	_	_	O
96	primary	_	_	O
97	end	_	_	O
98	point	_	_	O
99	of	_	_	O
100	the	_	_	O
101	study	_	_	O
102	was	_	_	O
103	the	_	_	O
104	time	_	_	O
105	to	_	_	O
106	development	_	_	O
107	of	_	_	O
108	severe	_	_	O
109	mucositis	_	_	O
110	from	_	_	O
111	the	_	_	O
112	start	_	_	O
113	of	_	_	O
114	radiotherapy	_	_	O
115	.	_	_	O

116	Secondary	_	_	O
117	end	_	_	O
118	points	_	_	O
119	included	_	_	O
120	severity	_	_	O
121	and	_	_	O
122	duration	_	_	O
123	of	_	_	O
124	mucositis	_	_	O
125	,	_	_	O
126	pain	_	_	O
127	measurement	_	_	O
128	,	_	_	O
129	radiation	_	_	O
130	therapy	_	_	O
131	interruption	_	_	O
132	,	_	_	O
133	and	_	_	O
134	quality	_	_	O
135	of	_	_	O
136	life	_	_	O
137	.	_	_	O

138	Mucositis	_	_	O
139	was	_	_	O
140	scored	_	_	O
141	using	_	_	O
142	a	_	_	O
143	validated	_	_	O
144	mucositis	_	_	O
145	scoring	_	_	O
146	system	_	_	O
147	.	_	_	O

148	Toxicity	_	_	B-Premise
149	profiles	_	_	I-Premise
150	were	_	_	I-Premise
151	similar	_	_	I-Premise
152	between	_	_	I-Premise
153	the	_	_	I-Premise
154	two	_	_	I-Premise
155	arms	_	_	I-Premise
156	of	_	_	I-Premise
157	the	_	_	I-Premise
158	study	_	_	I-Premise
159	.	_	_	I-Premise

160	The	_	_	B-Premise
161	median	_	_	I-Premise
162	time	_	_	I-Premise
163	to	_	_	I-Premise
164	development	_	_	I-Premise
165	of	_	_	I-Premise
166	severe	_	_	I-Premise
167	mucositis	_	_	I-Premise
168	from	_	_	I-Premise
169	the	_	_	I-Premise
170	start	_	_	I-Premise
171	of	_	_	I-Premise
172	radiotherapy	_	_	I-Premise
173	was	_	_	I-Premise
174	3	_	_	I-Premise
175	.	_	_	I-Premise

176	61	_	_	I-Premise
177	weeks	_	_	I-Premise
178	on	_	_	I-Premise
179	BCoG	_	_	I-Premise
180	and	_	_	I-Premise
181	3	_	_	I-Premise
182	.	_	_	I-Premise

183	96	_	_	I-Premise
184	weeks	_	_	I-Premise
185	on	_	_	I-Premise
186	placebo	_	_	I-Premise
187	(	_	_	I-Premise
188	P	_	_	I-Premise
189	=	_	_	I-Premise
190	.	_	_	I-Premise

191	61	_	_	I-Premise
192	)	_	_	I-Premise
193	.	_	_	I-Premise

194	There	_	_	B-Premise
195	were	_	_	I-Premise
196	no	_	_	I-Premise
197	statistically	_	_	I-Premise
198	significant	_	_	I-Premise
199	differences	_	_	I-Premise
200	between	_	_	I-Premise
201	the	_	_	I-Premise
202	arms	_	_	I-Premise
203	in	_	_	I-Premise
204	the	_	_	I-Premise
205	extent	_	_	I-Premise
206	of	_	_	I-Premise
207	severe	_	_	I-Premise
208	mucositis	_	_	I-Premise
209	as	_	_	I-Premise
210	measured	_	_	I-Premise
211	by	_	_	I-Premise
212	physician	_	_	I-Premise
213	,	_	_	I-Premise
214	in	_	_	I-Premise
215	oral	_	_	I-Premise
216	toxicities	_	_	I-Premise
217	as	_	_	I-Premise
218	recorded	_	_	I-Premise
219	by	_	_	I-Premise
220	patients	_	_	I-Premise
221	,	_	_	I-Premise
222	or	_	_	I-Premise
223	in	_	_	I-Premise
224	radiotherapy	_	_	I-Premise
225	delays	_	_	I-Premise
226	.	_	_	I-Premise

227	This	_	_	O
228	study	_	_	O
229	was	_	_	O
230	conducted	_	_	O
231	on	_	_	O
232	the	_	_	O
233	basis	_	_	O
234	of	_	_	O
235	a	_	_	O
236	pilot	_	_	O
237	study	_	_	O
238	that	_	_	O
239	demonstrated	_	_	O
240	the	_	_	O
241	BCoG	_	_	O
242	lozenge	_	_	O
243	to	_	_	O
244	be	_	_	O
245	tolerable	_	_	O
246	and	_	_	O
247	microbiologically	_	_	O
248	efficacious	_	_	O
249	.	_	_	O

250	A	_	_	O
251	validated	_	_	O
252	mucositis	_	_	O
253	scoring	_	_	O
254	system	_	_	O
255	was	_	_	O
256	used	_	_	O
257	.	_	_	O

258	However	_	_	O
259	,	_	_	O
260	in	_	_	B-Claim
261	this	_	_	I-Claim
262	group	_	_	I-Claim
263	of	_	_	I-Claim
264	patients	_	_	I-Claim
265	treated	_	_	I-Claim
266	with	_	_	I-Claim
267	conventional	_	_	I-Claim
268	radiotherapy	_	_	I-Claim
269	,	_	_	I-Claim
270	the	_	_	I-Claim
271	lozenge	_	_	I-Claim
272	did	_	_	I-Claim
273	not	_	_	I-Claim
274	impact	_	_	I-Claim
275	significantly	_	_	I-Claim
276	on	_	_	I-Claim
277	the	_	_	I-Claim
278	severity	_	_	I-Claim
279	of	_	_	I-Claim
280	mucositis	_	_	I-Claim
281	.	_	_	I-Claim

282	Whether	_	_	B-Claim
283	such	_	_	I-Claim
284	a	_	_	I-Claim
285	lozenge	_	_	I-Claim
286	would	_	_	I-Claim
287	be	_	_	I-Claim
288	beneficial	_	_	I-Claim
289	in	_	_	I-Claim
290	treatment	_	_	I-Claim
291	situations	_	_	I-Claim
292	where	_	_	I-Claim
293	rate	_	_	I-Claim
294	of	_	_	I-Claim
295	severe	_	_	I-Claim
296	mucositis	_	_	I-Claim
297	is	_	_	I-Claim
298	higher	_	_	I-Claim
299	(	_	_	I-Claim
300	ie	_	_	I-Claim
301	,	_	_	I-Claim
302	in	_	_	I-Claim
303	patients	_	_	I-Claim
304	treated	_	_	I-Claim
305	with	_	_	I-Claim
306	unconventional	_	_	I-Claim
307	fractionation	_	_	I-Claim
308	or	_	_	I-Claim
309	with	_	_	I-Claim
310	concomitant	_	_	I-Claim
311	chemotherapy	_	_	I-Claim
312	)	_	_	I-Claim
313	is	_	_	I-Claim
314	unknown	_	_	I-Claim
315	.	_	_	I-Claim


0	Patients	_	_	O
1	experience	_	_	O
2	reductions	_	_	O
3	in	_	_	O
4	quality	_	_	O
5	of	_	_	O
6	life	_	_	O
7	(	_	_	O
8	QOL	_	_	O
9	)	_	_	O
10	while	_	_	O
11	receiving	_	_	O
12	cancer	_	_	O
13	treatment	_	_	O
14	and	_	_	O
15	several	_	_	O
16	approaches	_	_	O
17	have	_	_	O
18	been	_	_	O
19	proposed	_	_	O
20	to	_	_	O
21	address	_	_	O
22	QOL	_	_	O
23	issues	_	_	O
24	.	_	_	O

25	In	_	_	O
26	this	_	_	O
27	project	_	_	O
28	,	_	_	O
29	the	_	_	O
30	QOL	_	_	O
31	differences	_	_	O
32	between	_	_	O
33	older	_	_	O
34	adult	_	_	O
35	(	_	_	O
36	age	_	_	O
37	65	_	_	O
38	+	_	_	O
39	)	_	_	O
40	and	_	_	O
41	younger	_	_	O
42	adult	_	_	O
43	(	_	_	O
44	age	_	_	O
45	18	_	_	O
46	-	_	_	O
47	64	_	_	O
48	)	_	_	O
49	advanced	_	_	O
50	cancer	_	_	O
51	patients	_	_	O
52	in	_	_	O
53	response	_	_	O
54	to	_	_	O
55	a	_	_	O
56	multidisciplinary	_	_	O
57	intervention	_	_	O
58	designed	_	_	O
59	to	_	_	O
60	improve	_	_	O
61	QOL	_	_	O
62	were	_	_	O
63	examined	_	_	O
64	.	_	_	O

65	This	_	_	O
66	study	_	_	O
67	was	_	_	O
68	registered	_	_	O
69	on	_	_	O
70	ClinicalTrials	_	_	O
71	.	_	_	O

72	gov	_	_	O
73	.	_	_	O

74	Newly	_	_	O
75	diagnosed	_	_	O
76	advanced	_	_	O
77	cancer	_	_	O
78	patients	_	_	O
79	undergoing	_	_	O
80	radiation	_	_	O
81	therapy	_	_	O
82	were	_	_	O
83	randomized	_	_	O
84	to	_	_	O
85	active	_	_	O
86	QOL	_	_	O
87	intervention	_	_	O
88	or	_	_	O
89	control	_	_	O
90	groups	_	_	O
91	.	_	_	O

92	Those	_	_	O
93	in	_	_	O
94	the	_	_	O
95	intervention	_	_	O
96	group	_	_	O
97	received	_	_	O
98	six	_	_	O
99	multidisciplinary	_	_	O
100	90	_	_	O
101	-	_	_	O
102	minute	_	_	O
103	sessions	_	_	O
104	designed	_	_	O
105	to	_	_	O
106	address	_	_	O
107	the	_	_	O
108	five	_	_	O
109	major	_	_	O
110	domains	_	_	O
111	of	_	_	O
112	QOL	_	_	O
113	.	_	_	O

114	Outcomes	_	_	O
115	measured	_	_	O
116	at	_	_	O
117	baseline	_	_	O
118	and	_	_	O
119	weeks	_	_	O
120	4	_	_	O
121	,	_	_	O
122	27	_	_	O
123	,	_	_	O
124	and	_	_	O
125	52	_	_	O
126	included	_	_	O
127	QOL	_	_	O
128	(	_	_	O
129	Linear	_	_	O
130	Analogue	_	_	O
131	Self	_	_	O
132	-	_	_	O
133	Assessment	_	_	O
134	(	_	_	O
135	LASA	_	_	O
136	)	_	_	O
137	,	_	_	O
138	Functional	_	_	O
139	Assessment	_	_	O
140	of	_	_	O
141	Cancer	_	_	O
142	Therapy	_	_	O
143	-	_	_	O
144	General	_	_	O
145	(	_	_	O
146	FACT	_	_	O
147	-	_	_	O
148	G	_	_	O
149	)	_	_	O
150	)	_	_	O
151	and	_	_	O
152	mood	_	_	O
153	(	_	_	O
154	Profile	_	_	O
155	of	_	_	O
156	Mood	_	_	O
157	States	_	_	O
158	(	_	_	O
159	POMS	_	_	O
160	)	_	_	O
161	)	_	_	O
162	.	_	_	O

163	Kruskall	_	_	O
164	-	_	_	O
165	Wallis	_	_	O
166	methodology	_	_	O
167	was	_	_	O
168	used	_	_	O
169	to	_	_	O
170	compare	_	_	O
171	scores	_	_	O
172	between	_	_	O
173	older	_	_	O
174	and	_	_	O
175	younger	_	_	O
176	adult	_	_	O
177	patients	_	_	O
178	randomized	_	_	O
179	to	_	_	O
180	the	_	_	O
181	intervention	_	_	O
182	.	_	_	O

183	Of	_	_	O
184	131	_	_	O
185	patients	_	_	O
186	in	_	_	O
187	the	_	_	O
188	larger	_	_	O
189	randomized	_	_	O
190	controlled	_	_	O
191	study	_	_	O
192	,	_	_	O
193	we	_	_	O
194	report	_	_	O
195	data	_	_	O
196	on	_	_	O
197	54	_	_	O
198	evaluable	_	_	O
199	patients	_	_	O
200	(	_	_	O
201	16	_	_	O
202	older	_	_	O
203	adults	_	_	O
204	and	_	_	O
205	38	_	_	O
206	younger	_	_	O
207	adults	_	_	O
208	)	_	_	O
209	randomized	_	_	O
210	to	_	_	O
211	the	_	_	O
212	intervention	_	_	O
213	.	_	_	O

214	Older	_	_	B-Premise
215	adult	_	_	I-Premise
216	patients	_	_	I-Premise
217	reported	_	_	I-Premise
218	better	_	_	I-Premise
219	overall	_	_	I-Premise
220	QOL	_	_	I-Premise
221	(	_	_	I-Premise
222	LASA	_	_	I-Premise
223	74	_	_	I-Premise
224	.	_	_	I-Premise

225	4	_	_	I-Premise
226	vs	_	_	I-Premise
227	.	_	_	I-Premise

228	62	_	_	I-Premise
229	.	_	_	I-Premise

230	9	_	_	I-Premise
231	,	_	_	I-Premise
232	p	_	_	I-Premise
233	=	_	_	I-Premise
234	0	_	_	I-Premise
235	.	_	_	I-Premise

236	040	_	_	I-Premise
237	)	_	_	I-Premise
238	,	_	_	I-Premise
239	higher	_	_	I-Premise
240	social	_	_	I-Premise
241	well	_	_	I-Premise
242	-	_	_	I-Premise
243	being	_	_	I-Premise
244	(	_	_	I-Premise
245	FACT	_	_	I-Premise
246	-	_	_	I-Premise
247	G	_	_	I-Premise
248	91	_	_	I-Premise
249	.	_	_	I-Premise

250	1	_	_	I-Premise
251	vs	_	_	I-Premise
252	.	_	_	I-Premise

253	83	_	_	I-Premise
254	.	_	_	I-Premise

255	3	_	_	I-Premise
256	,	_	_	I-Premise
257	p	_	_	I-Premise
258	=	_	_	I-Premise
259	0	_	_	I-Premise
260	.	_	_	I-Premise

261	045	_	_	I-Premise
262	)	_	_	I-Premise
263	,	_	_	I-Premise
264	and	_	_	I-Premise
265	fewer	_	_	I-Premise
266	problems	_	_	I-Premise
267	with	_	_	I-Premise
268	anger	_	_	I-Premise
269	(	_	_	I-Premise
270	POMS	_	_	I-Premise
271	anger	_	_	I-Premise
272	-	_	_	I-Premise
273	hostility	_	_	I-Premise
274	95	_	_	I-Premise
275	.	_	_	I-Premise

276	0	_	_	I-Premise
277	vs	_	_	I-Premise
278	.	_	_	I-Premise

279	86	_	_	I-Premise
280	.	_	_	I-Premise

281	4	_	_	I-Premise
282	,	_	_	I-Premise
283	p	_	_	I-Premise
284	=	_	_	I-Premise
285	0	_	_	I-Premise
286	.	_	_	I-Premise

287	028	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	Long	_	_	B-Premise
291	-	_	_	I-Premise
292	term	_	_	I-Premise
293	benefits	_	_	I-Premise
294	for	_	_	I-Premise
295	older	_	_	I-Premise
296	patients	_	_	I-Premise
297	were	_	_	I-Premise
298	seen	_	_	I-Premise
299	in	_	_	I-Premise
300	the	_	_	I-Premise
301	anger	_	_	I-Premise
302	-	_	_	I-Premise
303	hostility	_	_	I-Premise
304	scale	_	_	I-Premise
305	at	_	_	I-Premise
306	week	_	_	I-Premise
307	27	_	_	I-Premise
308	(	_	_	I-Premise
309	92	_	_	I-Premise
310	.	_	_	I-Premise

311	2	_	_	I-Premise
312	vs	_	_	I-Premise
313	.	_	_	I-Premise

314	84	_	_	I-Premise
315	.	_	_	I-Premise

316	2	_	_	I-Premise
317	,	_	_	I-Premise
318	p	_	_	I-Premise
319	=	_	_	I-Premise
320	0	_	_	I-Premise
321	.	_	_	I-Premise

322	027	_	_	I-Premise
323	)	_	_	I-Premise
324	and	_	_	I-Premise
325	week	_	_	I-Premise
326	52	_	_	I-Premise
327	(	_	_	I-Premise
328	96	_	_	I-Premise
329	.	_	_	I-Premise

330	3	_	_	I-Premise
331	vs	_	_	I-Premise
332	.	_	_	I-Premise

333	85	_	_	I-Premise
334	.	_	_	I-Premise

335	9	_	_	I-Premise
336	,	_	_	I-Premise
337	p	_	_	I-Premise
338	=	_	_	I-Premise
339	0	_	_	I-Premise
340	.	_	_	I-Premise

341	005	_	_	I-Premise
342	)	_	_	I-Premise
343	.	_	_	I-Premise

344	Older	_	_	B-Claim
345	adult	_	_	I-Claim
346	patients	_	_	I-Claim
347	who	_	_	I-Claim
348	received	_	_	I-Claim
349	a	_	_	I-Claim
350	multidisciplinary	_	_	I-Claim
351	intervention	_	_	I-Claim
352	to	_	_	I-Claim
353	improve	_	_	I-Claim
354	QOL	_	_	I-Claim
355	while	_	_	I-Claim
356	undergoing	_	_	I-Claim
357	advanced	_	_	I-Claim
358	cancer	_	_	I-Claim
359	treatments	_	_	I-Claim
360	benefited	_	_	I-Claim
361	differently	_	_	I-Claim
362	in	_	_	I-Claim
363	some	_	_	I-Claim
364	QOL	_	_	I-Claim
365	domains	_	_	I-Claim
366	,	_	_	I-Claim
367	compared	_	_	I-Claim
368	to	_	_	I-Claim
369	younger	_	_	I-Claim
370	adult	_	_	I-Claim
371	patients	_	_	I-Claim
372	.	_	_	I-Claim

373	Future	_	_	O
374	studies	_	_	O
375	can	_	_	O
376	provide	_	_	O
377	further	_	_	O
378	insight	_	_	O
379	on	_	_	O
380	how	_	_	O
381	to	_	_	O
382	tailor	_	_	O
383	QOL	_	_	O
384	interventions	_	_	O
385	for	_	_	O
386	these	_	_	O
387	age	_	_	O
388	groups	_	_	O
389	.	_	_	O


0	A	_	_	O
1	dramatic	_	_	O
2	rise	_	_	O
3	in	_	_	O
4	incidence	_	_	O
5	,	_	_	O
6	an	_	_	O
7	aging	_	_	O
8	population	_	_	O
9	,	_	_	O
10	and	_	_	O
11	expensive	_	_	O
12	palliative	_	_	O
13	treatments	_	_	O
14	have	_	_	O
15	led	_	_	O
16	to	_	_	O
17	an	_	_	O
18	escalating	_	_	O
19	burden	_	_	O
20	on	_	_	O
21	clinicians	_	_	O
22	managing	_	_	O
23	inoperable	_	_	O
24	esophageal	_	_	O
25	cancer	_	_	O
26	with	_	_	O
27	only	_	_	O
28	limited	_	_	O
29	evidence	_	_	O
30	of	_	_	O
31	effectiveness	_	_	O
32	.	_	_	O

33	This	_	_	O
34	study	_	_	O
35	compares	_	_	O
36	the	_	_	O
37	clinical	_	_	O
38	effectiveness	_	_	O
39	and	_	_	O
40	cost	_	_	O
41	-	_	_	O
42	effectiveness	_	_	O
43	of	_	_	O
44	self	_	_	O
45	-	_	_	O
46	expanding	_	_	O
47	metal	_	_	O
48	stents	_	_	O
49	(	_	_	O
50	SEMSs	_	_	O
51	)	_	_	O
52	with	_	_	O
53	other	_	_	O
54	palliative	_	_	O
55	therapies	_	_	O
56	to	_	_	O
57	aid	_	_	O
58	clinicians	_	_	O
59	in	_	_	O
60	making	_	_	O
61	an	_	_	O
62	evidence	_	_	O
63	-	_	_	O
64	based	_	_	O
65	treatment	_	_	O
66	choice	_	_	O
67	.	_	_	O

68	We	_	_	O
69	conducted	_	_	O
70	a	_	_	O
71	prospective	_	_	O
72	,	_	_	O
73	multicenter	_	_	O
74	,	_	_	O
75	randomized	_	_	O
76	,	_	_	O
77	controlled	_	_	O
78	,	_	_	O
79	clinical	_	_	O
80	trial	_	_	O
81	with	_	_	O
82	215	_	_	O
83	patients	_	_	O
84	followed	_	_	O
85	until	_	_	O
86	death	_	_	O
87	or	_	_	O
88	study	_	_	O
89	closure	_	_	O
90	.	_	_	O

91	The	_	_	O
92	primary	_	_	O
93	outcome	_	_	O
94	measures	_	_	O
95	were	_	_	O
96	dysphagia	_	_	O
97	,	_	_	O
98	quality	_	_	O
99	of	_	_	O
100	life	_	_	O
101	(	_	_	O
102	QL	_	_	O
103	)	_	_	O
104	6	_	_	O
105	weeks	_	_	O
106	following	_	_	O
107	treatment	_	_	O
108	,	_	_	O
109	and	_	_	O
110	total	_	_	O
111	cost	_	_	O
112	of	_	_	O
113	treatment	_	_	O
114	.	_	_	O

115	Secondary	_	_	O
116	outcome	_	_	O
117	measures	_	_	O
118	included	_	_	O
119	treatment	_	_	O
120	-	_	_	O
121	associated	_	_	O
122	morbidity	_	_	O
123	,	_	_	O
124	mortality	_	_	O
125	,	_	_	O
126	survival	_	_	O
127	,	_	_	O
128	and	_	_	O
129	cost	_	_	O
130	-	_	_	O
131	effectiveness	_	_	O
132	.	_	_	O

133	An	_	_	O
134	intention	_	_	O
135	-	_	_	O
136	to	_	_	O
137	-	_	_	O
138	treat	_	_	O
139	analysis	_	_	O
140	was	_	_	O
141	carried	_	_	O
142	out	_	_	O
143	.	_	_	O

144	There	_	_	B-Premise
145	was	_	_	I-Premise
146	a	_	_	I-Premise
147	significant	_	_	I-Premise
148	difference	_	_	I-Premise
149	in	_	_	I-Premise
150	mean	_	_	I-Premise
151	dysphagia	_	_	I-Premise
152	grade	_	_	I-Premise
153	between	_	_	I-Premise
154	treatment	_	_	I-Premise
155	arms	_	_	I-Premise
156	6	_	_	I-Premise
157	weeks	_	_	I-Premise
158	following	_	_	I-Premise
159	treatment	_	_	I-Premise
160	(	_	_	I-Premise
161	P	_	_	I-Premise
162	=	_	_	I-Premise
163	0	_	_	I-Premise
164	.	_	_	I-Premise

165	046	_	_	I-Premise
166	)	_	_	I-Premise
167	,	_	_	I-Premise
168	with	_	_	I-Premise
169	worse	_	_	I-Premise
170	swallowing	_	_	I-Premise
171	reported	_	_	I-Premise
172	by	_	_	I-Premise
173	rigid	_	_	I-Premise
174	stent	_	_	I-Premise
175	-	_	_	I-Premise
176	treated	_	_	I-Premise
177	patients	_	_	I-Premise
178	(	_	_	I-Premise
179	mean	_	_	I-Premise
180	dysphagia	_	_	I-Premise
181	score	_	_	I-Premise
182	difference	_	_	I-Premise
183	=	_	_	I-Premise
184	-	_	_	I-Premise
185	0	_	_	I-Premise
186	.	_	_	I-Premise

187	49	_	_	I-Premise
188	;	_	_	I-Premise
189	95	_	_	I-Premise
190	%	_	_	I-Premise
191	confidence	_	_	I-Premise
192	interval	_	_	I-Premise
193	(	_	_	I-Premise
194	CI	_	_	I-Premise
195	)	_	_	I-Premise
196	-	_	_	I-Premise
197	0	_	_	I-Premise
198	.	_	_	I-Premise

199	10	_	_	I-Premise
200	to	_	_	I-Premise
201	-	_	_	I-Premise
202	0	_	_	I-Premise
203	.	_	_	I-Premise

204	89	_	_	I-Premise
205	,	_	_	I-Premise
206	P	_	_	I-Premise
207	=	_	_	I-Premise
208	0	_	_	I-Premise
209	.	_	_	I-Premise

210	014	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	Global	_	_	B-Premise
214	QL	_	_	I-Premise
215	scores	_	_	I-Premise
216	were	_	_	I-Premise
217	lower	_	_	I-Premise
218	at	_	_	I-Premise
219	both	_	_	I-Premise
220	1	_	_	I-Premise
221	and	_	_	I-Premise
222	6	_	_	I-Premise
223	weeks	_	_	I-Premise
224	following	_	_	I-Premise
225	treatment	_	_	I-Premise
226	for	_	_	I-Premise
227	patients	_	_	I-Premise
228	treated	_	_	I-Premise
229	by	_	_	I-Premise
230	SEMSs	_	_	I-Premise
231	(	_	_	I-Premise
232	mean	_	_	I-Premise
233	difference	_	_	I-Premise
234	QL	_	_	I-Premise
235	index	_	_	I-Premise
236	week	_	_	I-Premise
237	1	_	_	I-Premise
238	=	_	_	I-Premise
239	-	_	_	I-Premise
240	0	_	_	I-Premise
241	.	_	_	I-Premise

242	66	_	_	I-Premise
243	;	_	_	I-Premise
244	95	_	_	I-Premise
245	%	_	_	I-Premise
246	CI	_	_	I-Premise
247	:	_	_	I-Premise
248	-	_	_	I-Premise
249	0	_	_	I-Premise
250	.	_	_	I-Premise

251	02	_	_	I-Premise
252	to	_	_	I-Premise
253	-	_	_	I-Premise
254	1	_	_	I-Premise
255	.	_	_	I-Premise

256	30	_	_	I-Premise
257	,	_	_	I-Premise
258	P	_	_	I-Premise
259	=	_	_	I-Premise
260	0	_	_	I-Premise
261	.	_	_	I-Premise

262	04	_	_	I-Premise
263	;	_	_	I-Premise
264	mean	_	_	I-Premise
265	difference	_	_	I-Premise
266	QL	_	_	I-Premise
267	index	_	_	I-Premise
268	week	_	_	I-Premise
269	6	_	_	I-Premise
270	=	_	_	I-Premise
271	-	_	_	I-Premise
272	1	_	_	I-Premise
273	.	_	_	I-Premise

274	01	_	_	I-Premise
275	;	_	_	I-Premise
276	95	_	_	I-Premise
277	%	_	_	I-Premise
278	CI	_	_	I-Premise
279	-	_	_	I-Premise
280	0	_	_	I-Premise
281	.	_	_	I-Premise

282	30	_	_	I-Premise
283	to	_	_	I-Premise
284	-	_	_	I-Premise
285	1	_	_	I-Premise
286	.	_	_	I-Premise

287	72	_	_	I-Premise
288	,	_	_	I-Premise
289	P	_	_	I-Premise
290	=	_	_	I-Premise
291	0	_	_	I-Premise
292	.	_	_	I-Premise

293	006	_	_	I-Premise
294	)	_	_	I-Premise
295	.	_	_	I-Premise

296	These	_	_	B-Premise
297	findings	_	_	I-Premise
298	were	_	_	I-Premise
299	associated	_	_	I-Premise
300	with	_	_	I-Premise
301	higher	_	_	I-Premise
302	post	_	_	I-Premise
303	-	_	_	I-Premise
304	procedure	_	_	I-Premise
305	pain	_	_	I-Premise
306	scores	_	_	I-Premise
307	in	_	_	I-Premise
308	the	_	_	I-Premise
309	SEMS	_	_	I-Premise
310	patient	_	_	I-Premise
311	group	_	_	I-Premise
312	(	_	_	I-Premise
313	mean	_	_	I-Premise
314	difference	_	_	I-Premise
315	of	_	_	I-Premise
316	the	_	_	I-Premise
317	European	_	_	I-Premise
318	Organisation	_	_	I-Premise
319	for	_	_	I-Premise
320	Research	_	_	I-Premise
321	and	_	_	I-Premise
322	Treatment	_	_	I-Premise
323	of	_	_	I-Premise
324	Cancer	_	_	I-Premise
325	QLQ	_	_	I-Premise
326	C	_	_	I-Premise
327	-	_	_	I-Premise
328	30	_	_	I-Premise
329	pain	_	_	I-Premise
330	symptom	_	_	I-Premise
331	score	_	_	I-Premise
332	at	_	_	I-Premise
333	week	_	_	I-Premise
334	1	_	_	I-Premise
335	=	_	_	I-Premise
336	11	_	_	I-Premise
337	.	_	_	I-Premise

338	13	_	_	I-Premise
339	;	_	_	I-Premise
340	95	_	_	I-Premise
341	%	_	_	I-Premise
342	CI	_	_	I-Premise
343	:	_	_	I-Premise
344	2	_	_	I-Premise
345	.	_	_	I-Premise

346	89	_	_	I-Premise
347	-	_	_	I-Premise
348	19	_	_	I-Premise
349	.	_	_	I-Premise

350	4	_	_	I-Premise
351	;	_	_	I-Premise
352	P	_	_	I-Premise
353	=	_	_	I-Premise
354	0	_	_	I-Premise
355	.	_	_	I-Premise

356	01	_	_	I-Premise
357	)	_	_	I-Premise
358	.	_	_	I-Premise

359	Although	_	_	B-Premise
360	mean	_	_	I-Premise
361	EQ	_	_	I-Premise
362	-	_	_	I-Premise
363	5D	_	_	I-Premise
364	QL	_	_	I-Premise
365	values	_	_	I-Premise
366	differed	_	_	I-Premise
367	between	_	_	I-Premise
368	the	_	_	I-Premise
369	treatments	_	_	I-Premise
370	(	_	_	I-Premise
371	P	_	_	I-Premise
372	<	_	_	I-Premise
373	0	_	_	I-Premise
374	.	_	_	I-Premise

375	001	_	_	I-Premise
376	)	_	_	I-Premise
377	,	_	_	I-Premise
378	this	_	_	I-Premise
379	difference	_	_	I-Premise
380	dissipated	_	_	I-Premise
381	following	_	_	I-Premise
382	generation	_	_	I-Premise
383	of	_	_	I-Premise
384	quality	_	_	I-Premise
385	-	_	_	I-Premise
386	adjusted	_	_	I-Premise
387	life	_	_	I-Premise
388	year	_	_	I-Premise
389	values	_	_	I-Premise
390	.	_	_	I-Premise

391	Total	_	_	O
392	costs	_	_	O
393	varied	_	_	O
394	between	_	_	O
395	treatment	_	_	O
396	arms	_	_	O
397	but	_	_	O
398	these	_	_	O
399	findings	_	_	O
400	canceled	_	_	O
401	out	_	_	O
402	when	_	_	O
403	SEMSs	_	_	O
404	were	_	_	O
405	compared	_	_	O
406	with	_	_	O
407	non	_	_	O
408	-	_	_	O
409	SEMS	_	_	O
410	therapies	_	_	O
411	(	_	_	O
412	95	_	_	O
413	%	_	_	O
414	CI	_	_	O
415	-	_	_	O
416	845	_	_	O
417	.	_	_	O

418	15	_	_	O
419	-	_	_	O
420	1	_	_	O
421	,	_	_	O
422	332	_	_	O
423	.	_	_	O

424	62	_	_	O
425	)	_	_	O
426	.	_	_	O

427	These	_	_	O
428	results	_	_	O
429	were	_	_	O
430	robust	_	_	O
431	to	_	_	O
432	sensitivity	_	_	O
433	analysis	_	_	O
434	.	_	_	O

435	There	_	_	B-Premise
436	were	_	_	I-Premise
437	no	_	_	I-Premise
438	differences	_	_	I-Premise
439	in	_	_	I-Premise
440	the	_	_	I-Premise
441	in	_	_	I-Premise
442	-	_	_	I-Premise
443	hospital	_	_	I-Premise
444	mortality	_	_	I-Premise
445	or	_	_	I-Premise
446	early	_	_	I-Premise
447	complication	_	_	I-Premise
448	rates	_	_	I-Premise
449	,	_	_	I-Premise
450	but	_	_	B-Premise
451	late	_	_	I-Premise
452	complications	_	_	I-Premise
453	were	_	_	I-Premise
454	more	_	_	I-Premise
455	frequent	_	_	I-Premise
456	after	_	_	I-Premise
457	rigid	_	_	I-Premise
458	stenting	_	_	I-Premise
459	(	_	_	I-Premise
460	risk	_	_	I-Premise
461	ratio	_	_	I-Premise
462	=	_	_	I-Premise
463	2	_	_	I-Premise
464	.	_	_	I-Premise

465	47	_	_	I-Premise
466	;	_	_	I-Premise
467	95	_	_	I-Premise
468	%	_	_	I-Premise
469	CI	_	_	I-Premise
470	1	_	_	I-Premise
471	.	_	_	I-Premise

472	88	_	_	I-Premise
473	-	_	_	I-Premise
474	3	_	_	I-Premise
475	.	_	_	I-Premise

476	04	_	_	I-Premise
477	)	_	_	I-Premise
478	.	_	_	I-Premise

479	There	_	_	B-Premise
480	was	_	_	I-Premise
481	a	_	_	I-Premise
482	survival	_	_	I-Premise
483	advantage	_	_	I-Premise
484	for	_	_	I-Premise
485	non	_	_	I-Premise
486	-	_	_	I-Premise
487	stent	_	_	I-Premise
488	-	_	_	I-Premise
489	treated	_	_	I-Premise
490	patients	_	_	I-Premise
491	(	_	_	I-Premise
492	log	_	_	I-Premise
493	-	_	_	I-Premise
494	rank	_	_	I-Premise
495	statistic	_	_	I-Premise
496	=	_	_	I-Premise
497	4	_	_	I-Premise
498	.	_	_	I-Premise

499	21	_	_	I-Premise
500	,	_	_	I-Premise
501	P	_	_	I-Premise
502	=	_	_	I-Premise
503	0	_	_	I-Premise
504	.	_	_	I-Premise

505	04	_	_	I-Premise
506	)	_	_	I-Premise
507	.	_	_	I-Premise

508	The	_	_	B-Claim
509	treatment	_	_	I-Claim
510	choice	_	_	I-Claim
511	for	_	_	I-Claim
512	patients	_	_	I-Claim
513	with	_	_	I-Claim
514	inoperable	_	_	I-Claim
515	esophageal	_	_	I-Claim
516	cancer	_	_	I-Claim
517	should	_	_	I-Claim
518	be	_	_	I-Claim
519	between	_	_	I-Claim
520	a	_	_	I-Claim
521	SEMS	_	_	I-Claim
522	or	_	_	I-Claim
523	a	_	_	I-Claim
524	non	_	_	I-Claim
525	-	_	_	I-Claim
526	stent	_	_	I-Claim
527	treatment	_	_	I-Claim
528	after	_	_	I-Claim
529	consideration	_	_	I-Claim
530	has	_	_	I-Claim
531	been	_	_	I-Claim
532	given	_	_	I-Claim
533	to	_	_	I-Claim
534	both	_	_	I-Claim
535	patient	_	_	I-Claim
536	and	_	_	I-Claim
537	tumor	_	_	I-Claim
538	characteristics	_	_	I-Claim
539	and	_	_	I-Claim
540	clinician	_	_	I-Claim
541	and	_	_	I-Claim
542	patient	_	_	I-Claim
543	preferences	_	_	I-Claim
544	.	_	_	I-Claim


0	LV5FU2	_	_	O
1	with	_	_	O
2	high	_	_	O
3	-	_	_	O
4	dose	_	_	O
5	leucovorin	_	_	O
6	(	_	_	O
7	LV	_	_	O
8	)	_	_	O
9	,	_	_	O
10	weekly	_	_	O
11	infusional	_	_	O
12	5	_	_	O
13	-	_	_	O
14	fluorouracil	_	_	O
15	(	_	_	O
16	5FU	_	_	O
17	)	_	_	O
18	(	_	_	O
19	AIO	_	_	O
20	schedule	_	_	O
21	)	_	_	O
22	and	_	_	O
23	raltitrexed	_	_	O
24	have	_	_	O
25	been	_	_	O
26	demonstrated	_	_	O
27	to	_	_	O
28	be	_	_	O
29	active	_	_	O
30	agents	_	_	O
31	in	_	_	O
32	first	_	_	O
33	-	_	_	O
34	line	_	_	O
35	treatment	_	_	O
36	of	_	_	O
37	colorectal	_	_	O
38	cancer	_	_	O
39	.	_	_	O

40	We	_	_	O
41	performed	_	_	O
42	a	_	_	O
43	4	_	_	O
44	-	_	_	O
45	arm	_	_	O
46	randomised	_	_	O
47	trial	_	_	O
48	to	_	_	O
49	compare	_	_	O
50	(	_	_	O
51	1	_	_	O
52	)	_	_	O
53	a	_	_	O
54	low	_	_	O
55	-	_	_	O
56	dose	_	_	O
57	intravenous	_	_	O
58	bolus	_	_	O
59	of	_	_	O
60	LV	_	_	O
61	(	_	_	O
62	20	_	_	O
63	mg	_	_	O
64	/	_	_	O
65	m2	_	_	O
66	)	_	_	O
67	,	_	_	O
68	followed	_	_	O
69	by	_	_	O
70	an	_	_	O
71	intravenous	_	_	O
72	bolus	_	_	O
73	of	_	_	O
74	5FU	_	_	O
75	(	_	_	O
76	400	_	_	O
77	mg	_	_	O
78	/	_	_	O
79	m2	_	_	O
80	)	_	_	O
81	,	_	_	O
82	followed	_	_	O
83	by	_	_	O
84	a	_	_	O
85	22	_	_	O
86	-	_	_	O
87	hour	_	_	O
88	continuous	_	_	O
89	infusion	_	_	O
90	of	_	_	O
91	5FU	_	_	O
92	(	_	_	O
93	600	_	_	O
94	mg	_	_	O
95	/	_	_	O
96	m2	_	_	O
97	)	_	_	O
98	on	_	_	O
99	day	_	_	O
100	1	_	_	O
101	and	_	_	O
102	day	_	_	O
103	2	_	_	O
104	/	_	_	O
105	2	_	_	O
106	weeks	_	_	O
107	(	_	_	O
108	ldLV5FU2	_	_	O
109	arm	_	_	O
110	)	_	_	O
111	,	_	_	O
112	(	_	_	O
113	2	_	_	O
114	)	_	_	O
115	a	_	_	O
116	weekly	_	_	O
117	continuous	_	_	O
118	infusion	_	_	O
119	of	_	_	O
120	high	_	_	O
121	-	_	_	O
122	dose	_	_	O
123	5FU	_	_	O
124	(	_	_	O
125	2	_	_	O
126	.	_	_	O

127	6	_	_	O
128	g	_	_	O
129	/	_	_	O
130	m2	_	_	O
131	/	_	_	O
132	week	_	_	O
133	)	_	_	O
134	for	_	_	O
135	6	_	_	O
136	weeks	_	_	O
137	followed	_	_	O
138	by	_	_	O
139	a	_	_	O
140	rest	_	_	O
141	week	_	_	O
142	(	_	_	O
143	HD	_	_	O
144	-	_	_	O
145	FU	_	_	O
146	arm	_	_	O
147	)	_	_	O
148	and	_	_	O
149	(	_	_	O
150	3	_	_	O
151	)	_	_	O
152	raltitrexed	_	_	O
153	(	_	_	O
154	Tomudex	_	_	O
155	arm	_	_	O
156	;	_	_	O
157	3	_	_	O
158	mg	_	_	O
159	/	_	_	O
160	m2	_	_	O
161	/	_	_	O
162	3	_	_	O
163	weeks	_	_	O
164	)	_	_	O
165	to	_	_	O
166	standard	_	_	O
167	LV5FU2	_	_	O
168	.	_	_	O

169	From	_	_	O
170	1997	_	_	O
171	to	_	_	O
172	2001	_	_	O
173	,	_	_	O
174	294	_	_	O
175	patients	_	_	O
176	were	_	_	O
177	included	_	_	O
178	.	_	_	O

179	The	_	_	O
180	4	_	_	O
181	arms	_	_	O
182	were	_	_	O
183	well	_	_	O
184	balanced	_	_	O
185	for	_	_	O
186	sex	_	_	O
187	ratio	_	_	O
188	,	_	_	O
189	age	_	_	O
190	,	_	_	O
191	WHO	_	_	O
192	performance	_	_	O
193	status	_	_	O
194	,	_	_	O
195	the	_	_	O
196	primary	_	_	O
197	tumour	_	_	O
198	site	_	_	O
199	and	_	_	O
200	prior	_	_	O
201	adjuvant	_	_	O
202	chemotherapy	_	_	O
203	.	_	_	O

204	Treatment	_	_	O
205	was	_	_	O
206	stopped	_	_	O
207	due	_	_	O
208	to	_	_	O
209	low	_	_	O
210	accrual	_	_	O
211	.	_	_	O

212	Two	_	_	B-Premise
213	toxicity	_	_	I-Premise
214	-	_	_	I-Premise
215	related	_	_	I-Premise
216	deaths	_	_	I-Premise
217	were	_	_	I-Premise
218	observed	_	_	I-Premise
219	in	_	_	I-Premise
220	the	_	_	I-Premise
221	Tomudex	_	_	I-Premise
222	arm	_	_	I-Premise
223	.	_	_	I-Premise

224	The	_	_	B-Premise
225	treatments	_	_	I-Premise
226	gave	_	_	I-Premise
227	rise	_	_	I-Premise
228	to	_	_	I-Premise
229	different	_	_	I-Premise
230	rates	_	_	I-Premise
231	of	_	_	I-Premise
232	grade	_	_	I-Premise
233	3	_	_	I-Premise
234	-	_	_	I-Premise
235	4	_	_	I-Premise
236	neutropenia	_	_	I-Premise
237	(	_	_	I-Premise
238	3	_	_	I-Premise
239	,	_	_	I-Premise
240	4	_	_	I-Premise
241	,	_	_	I-Premise
242	11	_	_	I-Premise
243	and	_	_	I-Premise
244	14	_	_	I-Premise
245	%	_	_	I-Premise
246	of	_	_	I-Premise
247	the	_	_	I-Premise
248	patients	_	_	I-Premise
249	in	_	_	I-Premise
250	the	_	_	I-Premise
251	LV5FU2	_	_	I-Premise
252	,	_	_	I-Premise
253	ldLV5FU2	_	_	I-Premise
254	,	_	_	I-Premise
255	HD	_	_	I-Premise
256	-	_	_	I-Premise
257	FU	_	_	I-Premise
258	and	_	_	I-Premise
259	Tomudex	_	_	I-Premise
260	arms	_	_	I-Premise
261	,	_	_	I-Premise
262	respectively	_	_	I-Premise
263	,	_	_	I-Premise
264	p	_	_	I-Premise
265	=	_	_	I-Premise
266	0	_	_	I-Premise
267	.	_	_	I-Premise

268	028	_	_	I-Premise
269	)	_	_	I-Premise
270	,	_	_	I-Premise
271	leucopenia	_	_	I-Premise
272	and	_	_	I-Premise
273	vomiting	_	_	I-Premise
274	.	_	_	I-Premise

275	At	_	_	B-Premise
276	least	_	_	I-Premise
277	one	_	_	I-Premise
278	episode	_	_	I-Premise
279	of	_	_	I-Premise
280	grade	_	_	I-Premise
281	3	_	_	I-Premise
282	-	_	_	I-Premise
283	4	_	_	I-Premise
284	toxicity	_	_	I-Premise
285	was	_	_	I-Premise
286	observed	_	_	I-Premise
287	in	_	_	I-Premise
288	27	_	_	I-Premise
289	,	_	_	I-Premise
290	25	_	_	I-Premise
291	,	_	_	I-Premise
292	38	_	_	I-Premise
293	and	_	_	I-Premise
294	47	_	_	I-Premise
295	%	_	_	I-Premise
296	of	_	_	I-Premise
297	the	_	_	I-Premise
298	patients	_	_	I-Premise
299	in	_	_	I-Premise
300	the	_	_	I-Premise
301	LV5FU2	_	_	I-Premise
302	,	_	_	I-Premise
303	ldLV5FU2	_	_	I-Premise
304	,	_	_	I-Premise
305	HD	_	_	I-Premise
306	-	_	_	I-Premise
307	FU	_	_	I-Premise
308	and	_	_	I-Premise
309	Tomudex	_	_	I-Premise
310	arms	_	_	I-Premise
311	,	_	_	I-Premise
312	respectively	_	_	I-Premise
313	(	_	_	I-Premise
314	p	_	_	I-Premise
315	=	_	_	I-Premise
316	0	_	_	I-Premise
317	.	_	_	I-Premise

318	016	_	_	I-Premise
319	)	_	_	I-Premise
320	.	_	_	I-Premise

321	An	_	_	B-Premise
322	objective	_	_	I-Premise
323	response	_	_	I-Premise
324	was	_	_	I-Premise
325	observed	_	_	I-Premise
326	in	_	_	I-Premise
327	28	_	_	I-Premise
328	,	_	_	I-Premise
329	21	_	_	I-Premise
330	,	_	_	I-Premise
331	22	_	_	I-Premise
332	and	_	_	I-Premise
333	10	_	_	I-Premise
334	%	_	_	I-Premise
335	of	_	_	I-Premise
336	the	_	_	I-Premise
337	patients	_	_	I-Premise
338	in	_	_	I-Premise
339	the	_	_	I-Premise
340	LV5FU2	_	_	I-Premise
341	,	_	_	I-Premise
342	ldLV5FU2	_	_	I-Premise
343	,	_	_	I-Premise
344	HD	_	_	I-Premise
345	-	_	_	I-Premise
346	FU	_	_	I-Premise
347	and	_	_	I-Premise
348	Tomudex	_	_	I-Premise
349	arms	_	_	I-Premise
350	,	_	_	I-Premise
351	respectively	_	_	I-Premise
352	(	_	_	I-Premise
353	p	_	_	I-Premise
354	=	_	_	I-Premise
355	0	_	_	I-Premise
356	.	_	_	I-Premise

357	04	_	_	I-Premise
358	)	_	_	I-Premise
359	.	_	_	I-Premise

360	Progression	_	_	B-Premise
361	-	_	_	I-Premise
362	free	_	_	I-Premise
363	survival	_	_	I-Premise
364	(	_	_	I-Premise
365	PFS	_	_	I-Premise
366	)	_	_	I-Premise
367	of	_	_	I-Premise
368	the	_	_	I-Premise
369	patients	_	_	I-Premise
370	in	_	_	I-Premise
371	the	_	_	I-Premise
372	Tomudex	_	_	I-Premise
373	arm	_	_	I-Premise
374	was	_	_	I-Premise
375	statistically	_	_	I-Premise
376	lower	_	_	I-Premise
377	compared	_	_	I-Premise
378	to	_	_	I-Premise
379	that	_	_	I-Premise
380	of	_	_	I-Premise
381	patients	_	_	I-Premise
382	treated	_	_	I-Premise
383	with	_	_	I-Premise
384	LV5FU2	_	_	I-Premise
385	or	_	_	I-Premise
386	ldLV5FU2	_	_	I-Premise
387	(	_	_	I-Premise
388	combined	_	_	I-Premise
389	group	_	_	I-Premise
390	;	_	_	I-Premise
391	p	_	_	I-Premise
392	=	_	_	I-Premise
393	0	_	_	I-Premise
394	.	_	_	I-Premise

395	013	_	_	I-Premise
396	,	_	_	I-Premise
397	log	_	_	I-Premise
398	rank	_	_	I-Premise
399	test	_	_	I-Premise
400	)	_	_	I-Premise
401	.	_	_	I-Premise

402	In	_	_	B-Claim
403	conclusion	_	_	I-Claim
404	,	_	_	I-Claim
405	Tomudex	_	_	I-Claim
406	is	_	_	I-Claim
407	more	_	_	I-Claim
408	toxic	_	_	I-Claim
409	and	_	_	I-Claim
410	yields	_	_	I-Claim
411	shorter	_	_	I-Claim
412	PFS	_	_	I-Claim
413	than	_	_	I-Claim
414	infusional	_	_	I-Claim
415	5FU	_	_	I-Claim
416	.	_	_	I-Claim

417	Despite	_	_	B-Claim
418	the	_	_	I-Claim
419	early	_	_	I-Claim
420	closure	_	_	I-Claim
421	of	_	_	I-Claim
422	the	_	_	I-Claim
423	study	_	_	I-Claim
424	and	_	_	I-Claim
425	the	_	_	I-Claim
426	lack	_	_	I-Claim
427	of	_	_	I-Claim
428	power	_	_	I-Claim
429	of	_	_	I-Claim
430	the	_	_	I-Claim
431	comparison	_	_	I-Claim
432	,	_	_	I-Claim
433	it	_	_	I-Claim
434	seems	_	_	I-Claim
435	that	_	_	I-Claim
436	ldLV5FU2	_	_	I-Claim
437	could	_	_	I-Claim
438	be	_	_	I-Claim
439	considered	_	_	I-Claim
440	as	_	_	I-Claim
441	an	_	_	I-Claim
442	active	_	_	I-Claim
443	,	_	_	I-Claim
444	easier	_	_	I-Claim
445	and	_	_	I-Claim
446	less	_	_	I-Claim
447	expensive	_	_	I-Claim
448	option	_	_	I-Claim
449	for	_	_	I-Claim
450	the	_	_	I-Claim
451	treatment	_	_	I-Claim
452	of	_	_	I-Claim
453	metastatic	_	_	I-Claim
454	colorectal	_	_	I-Claim
455	cancer	_	_	I-Claim
456	compared	_	_	I-Claim
457	to	_	_	I-Claim
458	classic	_	_	I-Claim
459	LV5FU2	_	_	I-Claim
460	or	_	_	I-Claim
461	weekly	_	_	I-Claim
462	HD	_	_	I-Claim
463	-	_	_	I-Claim
464	FU	_	_	I-Claim
465	.	_	_	I-Claim


0	Patients	_	_	O
1	with	_	_	O
2	cancer	_	_	O
3	are	_	_	O
4	characterized	_	_	O
5	by	_	_	O
6	a	_	_	O
7	profound	_	_	O
8	impairment	_	_	O
9	of	_	_	O
10	glucose	_	_	O
11	utilization	_	_	O
12	,	_	_	O
13	with	_	_	O
14	lipids	_	_	O
15	being	_	_	O
16	the	_	_	O
17	preferred	_	_	O
18	metabolic	_	_	O
19	fuel	_	_	O
20	.	_	_	O

21	In	_	_	O
22	contrast	_	_	O
23	,	_	_	O
24	the	_	_	O
25	energy	_	_	O
26	needs	_	_	O
27	of	_	_	O
28	malignant	_	_	O
29	tumors	_	_	O
30	are	_	_	O
31	almost	_	_	O
32	entirely	_	_	O
33	met	_	_	O
34	by	_	_	O
35	glucose	_	_	O
36	.	_	_	O

37	We	_	_	O
38	therefore	_	_	O
39	studied	_	_	O
40	the	_	_	O
41	effects	_	_	O
42	of	_	_	O
43	a	_	_	O
44	high	_	_	O
45	-	_	_	O
46	fat	_	_	O
47	diet	_	_	O
48	,	_	_	O
49	particularly	_	_	O
50	on	_	_	O
51	body	_	_	O
52	composition	_	_	O
53	.	_	_	O

54	Twenty	_	_	O
55	-	_	_	O
56	three	_	_	O
57	moderately	_	_	O
58	malnourished	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	gastrointestinal	_	_	O
62	carcinomas	_	_	O
63	were	_	_	O
64	randomized	_	_	O
65	to	_	_	O
66	receive	_	_	O
67	either	_	_	O
68	a	_	_	O
69	conventional	_	_	O
70	diet	_	_	O
71	supplying	_	_	O
72	35	_	_	O
73	nonprotein	_	_	O
74	kcal	_	_	O
75	and	_	_	O
76	1	_	_	O
77	.	_	_	O

78	1	_	_	O
79	g	_	_	O
80	of	_	_	O
81	protein	_	_	O
82	/	_	_	O
83	kg	_	_	O
84	per	_	_	O
85	day	_	_	O
86	(	_	_	O
87	group	_	_	O
88	A	_	_	O
89	,	_	_	O
90	n	_	_	O
91	=	_	_	O
92	11	_	_	O
93	)	_	_	O
94	or	_	_	O
95	a	_	_	O
96	fat	_	_	O
97	-	_	_	O
98	enriched	_	_	O
99	artificial	_	_	O
100	liquid	_	_	O
101	diet	_	_	O
102	(	_	_	O
103	20	_	_	O
104	nonprotein	_	_	O
105	kcal	_	_	O
106	/	_	_	O
107	kg	_	_	O
108	per	_	_	O
109	day	_	_	O
110	)	_	_	O
111	plus	_	_	O
112	normal	_	_	O
113	meals	_	_	O
114	(	_	_	O
115	group	_	_	O
116	B	_	_	O
117	,	_	_	O
118	n	_	_	O
119	=	_	_	O
120	12	_	_	O
121	)	_	_	O
122	for	_	_	O
123	a	_	_	O
124	period	_	_	O
125	of	_	_	O
126	eight	_	_	O
127	weeks	_	_	O
128	,	_	_	O
129	i	_	_	O
130	.	_	_	O

131	e	_	_	O
132	.	_	_	O

133	,	_	_	O
134	from	_	_	O
135	the	_	_	O
136	first	_	_	O
137	to	_	_	O
138	the	_	_	O
139	third	_	_	O
140	chemotherapy	_	_	O
141	cycle	_	_	O
142	.	_	_	O

143	The	_	_	O
144	fat	_	_	O
145	content	_	_	O
146	of	_	_	O
147	the	_	_	O
148	artificial	_	_	O
149	diet	_	_	O
150	was	_	_	O
151	66	_	_	O
152	%	_	_	O
153	of	_	_	O
154	the	_	_	O
155	nonprotein	_	_	O
156	calories	_	_	O
157	.	_	_	O

158	The	_	_	O
159	day	_	_	O
160	before	_	_	O
161	the	_	_	O
162	nutritional	_	_	O
163	interventions	_	_	O
164	,	_	_	O
165	and	_	_	O
166	again	_	_	O
167	after	_	_	O
168	four	_	_	O
169	and	_	_	O
170	eight	_	_	O
171	weeks	_	_	O
172	,	_	_	O
173	body	_	_	O
174	compartments	_	_	O
175	were	_	_	O
176	determined	_	_	O
177	using	_	_	O
178	bioelectrical	_	_	O
179	impedance	_	_	O
180	analysis	_	_	O
181	,	_	_	O
182	lymphocyte	_	_	O
183	subpopulations	_	_	O
184	were	_	_	O
185	quantified	_	_	O
186	using	_	_	O
187	flow	_	_	O
188	cytometry	_	_	O
189	,	_	_	O
190	and	_	_	O
191	some	_	_	O
192	aspects	_	_	O
193	of	_	_	O
194	the	_	_	O
195	quality	_	_	O
196	of	_	_	O
197	life	_	_	O
198	were	_	_	O
199	rated	_	_	O
200	using	_	_	O
201	four	_	_	O
202	linear	_	_	O
203	analog	_	_	O
204	self	_	_	O
205	-	_	_	O
206	assessment	_	_	O
207	(	_	_	O
208	LASA	_	_	O
209	)	_	_	O
210	scales	_	_	O
211	.	_	_	O

212	The	_	_	O
213	statistical	_	_	O
214	calculations	_	_	O
215	were	_	_	O
216	done	_	_	O
217	as	_	_	O
218	an	_	_	O
219	exploratory	_	_	O
220	data	_	_	O
221	analysis	_	_	O
222	.	_	_	O

223	The	_	_	O
224	consumption	_	_	O
225	of	_	_	O
226	non	_	_	O
227	-	_	_	O
228	protein	_	_	O
229	calories	_	_	O
230	did	_	_	O
231	not	_	_	O
232	differ	_	_	O
233	significantly	_	_	O
234	between	_	_	O
235	the	_	_	O
236	two	_	_	O
237	patient	_	_	O
238	groups	_	_	O
239	.	_	_	O

240	An	_	_	B-Premise
241	average	_	_	I-Premise
242	weight	_	_	I-Premise
243	gain	_	_	I-Premise
244	in	_	_	I-Premise
245	group	_	_	I-Premise
246	B	_	_	I-Premise
247	contrasted	_	_	I-Premise
248	with	_	_	I-Premise
249	an	_	_	I-Premise
250	average	_	_	I-Premise
251	weight	_	_	I-Premise
252	loss	_	_	I-Premise
253	in	_	_	I-Premise
254	group	_	_	I-Premise
255	A	_	_	I-Premise
256	after	_	_	I-Premise
257	four	_	_	I-Premise
258	(	_	_	I-Premise
259	P	_	_	I-Premise
260	<	_	_	I-Premise
261	0	_	_	I-Premise
262	.	_	_	I-Premise

263	01	_	_	I-Premise
264	)	_	_	I-Premise
265	and	_	_	I-Premise
266	eight	_	_	I-Premise
267	weeks	_	_	I-Premise
268	(	_	_	I-Premise
269	P	_	_	I-Premise
270	<	_	_	I-Premise
271	0	_	_	I-Premise
272	.	_	_	I-Premise

273	05	_	_	I-Premise
274	)	_	_	I-Premise
275	.	_	_	I-Premise

276	Fat	_	_	B-Premise
277	-	_	_	I-Premise
278	free	_	_	I-Premise
279	mass	_	_	I-Premise
280	showed	_	_	I-Premise
281	an	_	_	I-Premise
282	intergroup	_	_	I-Premise
283	difference	_	_	I-Premise
284	in	_	_	I-Premise
285	favor	_	_	I-Premise
286	of	_	_	I-Premise
287	group	_	_	I-Premise
288	B	_	_	I-Premise
289	after	_	_	I-Premise
290	eight	_	_	I-Premise
291	weeks	_	_	I-Premise
292	(	_	_	I-Premise
293	P	_	_	I-Premise
294	<	_	_	I-Premise
295	0	_	_	I-Premise
296	.	_	_	I-Premise

297	05	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	Body	_	_	B-Premise
301	cell	_	_	I-Premise
302	mass	_	_	I-Premise
303	was	_	_	I-Premise
304	maintained	_	_	I-Premise
305	throughout	_	_	I-Premise
306	the	_	_	I-Premise
307	study	_	_	I-Premise
308	in	_	_	I-Premise
309	group	_	_	I-Premise
310	B	_	_	I-Premise
311	,	_	_	I-Premise
312	but	_	_	I-Premise
313	declined	_	_	I-Premise
314	significantly	_	_	I-Premise
315	up	_	_	I-Premise
316	to	_	_	I-Premise
317	weeks	_	_	I-Premise
318	4	_	_	I-Premise
319	and	_	_	I-Premise
320	8	_	_	I-Premise
321	in	_	_	I-Premise
322	group	_	_	I-Premise
323	A	_	_	I-Premise
324	(	_	_	I-Premise
325	intergroup	_	_	I-Premise
326	difference	_	_	I-Premise
327	:	_	_	I-Premise
328	P	_	_	I-Premise
329	<	_	_	I-Premise
330	0	_	_	I-Premise
331	.	_	_	I-Premise

332	05	_	_	I-Premise
333	and	_	_	I-Premise
334	0	_	_	I-Premise
335	.	_	_	I-Premise

336	01	_	_	I-Premise
337	,	_	_	I-Premise
338	respectively	_	_	I-Premise
339	)	_	_	I-Premise
340	.	_	_	I-Premise

341	A	_	_	B-Premise
342	decrease	_	_	I-Premise
343	in	_	_	I-Premise
344	the	_	_	I-Premise
345	total	_	_	I-Premise
346	lymphocyte	_	_	I-Premise
347	count	_	_	I-Premise
348	by	_	_	I-Premise
349	559	_	_	I-Premise
350	cells	_	_	I-Premise
351	/	_	_	I-Premise
352	mul	_	_	I-Premise
353	occurred	_	_	I-Premise
354	with	_	_	I-Premise
355	the	_	_	I-Premise
356	fat	_	_	I-Premise
357	-	_	_	I-Premise
358	enriched	_	_	I-Premise
359	diet	_	_	I-Premise
360	(	_	_	I-Premise
361	P	_	_	I-Premise
362	<	_	_	I-Premise
363	0	_	_	I-Premise
364	.	_	_	I-Premise

365	05	_	_	I-Premise
366	)	_	_	I-Premise
367	.	_	_	I-Premise

368	Several	_	_	B-Premise
369	aspects	_	_	I-Premise
370	of	_	_	I-Premise
371	the	_	_	I-Premise
372	quality	_	_	I-Premise
373	of	_	_	I-Premise
374	life	_	_	I-Premise
375	were	_	_	I-Premise
376	rated	_	_	I-Premise
377	to	_	_	I-Premise
378	be	_	_	I-Premise
379	better	_	_	I-Premise
380	in	_	_	I-Premise
381	group	_	_	I-Premise
382	B	_	_	I-Premise
383	than	_	_	I-Premise
384	in	_	_	I-Premise
385	group	_	_	I-Premise
386	A	_	_	I-Premise
387	,	_	_	I-Premise
388	although	_	_	B-Premise
389	not	_	_	I-Premise
390	all	_	_	I-Premise
391	differences	_	_	I-Premise
392	reached	_	_	I-Premise
393	statistical	_	_	I-Premise
394	significance	_	_	I-Premise
395	.	_	_	I-Premise

396	In	_	_	B-Claim
397	patients	_	_	I-Claim
398	with	_	_	I-Claim
399	cancer	_	_	I-Claim
400	,	_	_	I-Claim
401	a	_	_	I-Claim
402	high	_	_	I-Claim
403	-	_	_	I-Claim
404	fat	_	_	I-Claim
405	diet	_	_	I-Claim
406	may	_	_	I-Claim
407	possibly	_	_	I-Claim
408	support	_	_	I-Claim
409	the	_	_	I-Claim
410	maintenance	_	_	I-Claim
411	of	_	_	I-Claim
412	both	_	_	I-Claim
413	body	_	_	I-Claim
414	weight	_	_	I-Claim
415	and	_	_	I-Claim
416	body	_	_	I-Claim
417	cell	_	_	I-Claim
418	mass	_	_	I-Claim
419	.	_	_	I-Claim

420	However	_	_	B-Claim
421	,	_	_	I-Claim
422	monitoring	_	_	I-Claim
423	the	_	_	I-Claim
424	lymphocyte	_	_	I-Claim
425	count	_	_	I-Claim
426	is	_	_	I-Claim
427	advisable	_	_	I-Claim
428	.	_	_	I-Claim


0	To	_	_	O
1	test	_	_	O
2	the	_	_	O
3	ability	_	_	O
4	of	_	_	O
5	the	_	_	O
6	cytoprotectant	_	_	O
7	,	_	_	O
8	amifostine	_	_	O
9	,	_	_	O
10	to	_	_	O
11	reduce	_	_	O
12	chemoradiotherapy	_	_	O
13	-	_	_	O
14	induced	_	_	O
15	esophagitis	_	_	O
16	and	_	_	O
17	evaluate	_	_	O
18	its	_	_	O
19	influence	_	_	O
20	on	_	_	O
21	quality	_	_	O
22	of	_	_	O
23	life	_	_	O
24	(	_	_	O
25	QOL	_	_	O
26	)	_	_	O
27	and	_	_	O
28	swallowing	_	_	O
29	symptoms	_	_	O
30	.	_	_	O

31	A	_	_	O
32	total	_	_	O
33	of	_	_	O
34	243	_	_	O
35	patients	_	_	O
36	with	_	_	O
37	stage	_	_	O
38	II	_	_	O
39	to	_	_	O
40	IIIA	_	_	O
41	/	_	_	O
42	B	_	_	O
43	non	_	_	O
44	-	_	_	O
45	small	_	_	O
46	-	_	_	O
47	cell	_	_	O
48	lung	_	_	O
49	cancer	_	_	O
50	received	_	_	O
51	induction	_	_	O
52	paclitaxel	_	_	O
53	225	_	_	O
54	mg	_	_	O
55	/	_	_	O
56	m	_	_	O
57	(	_	_	O
58	2	_	_	O
59	)	_	_	O
60	intravenously	_	_	O
61	(	_	_	O
62	IV	_	_	O
63	)	_	_	O
64	days	_	_	O
65	1	_	_	O
66	and	_	_	O
67	22	_	_	O
68	and	_	_	O
69	carboplatin	_	_	O
70	area	_	_	O
71	under	_	_	O
72	the	_	_	O
73	curve	_	_	O
74	(	_	_	O
75	AUC	_	_	O
76	)	_	_	O
77	days	_	_	O
78	1	_	_	O
79	and	_	_	O
80	22	_	_	O
81	,	_	_	O
82	followed	_	_	O
83	by	_	_	O
84	concurrent	_	_	O
85	weekly	_	_	O
86	paclitaxel	_	_	O
87	(	_	_	O
88	50	_	_	O
89	mg	_	_	O
90	/	_	_	O
91	m	_	_	O
92	(	_	_	O
93	2	_	_	O
94	)	_	_	O
95	IV	_	_	O
96	)	_	_	O
97	and	_	_	O
98	carboplatin	_	_	O
99	(	_	_	O
100	AUC	_	_	O
101	2	_	_	O
102	)	_	_	O
103	,	_	_	O
104	and	_	_	O
105	hyperfractionated	_	_	O
106	radiation	_	_	O
107	therapy	_	_	O
108	(	_	_	O
109	69	_	_	O
110	.	_	_	O

111	6	_	_	O
112	Gy	_	_	O
113	at	_	_	O
114	1	_	_	O
115	.	_	_	O

116	2	_	_	O
117	Gy	_	_	O
118	bid	_	_	O
119	)	_	_	O
120	.	_	_	O

121	Patients	_	_	O
122	were	_	_	O
123	randomly	_	_	O
124	assigned	_	_	O
125	at	_	_	O
126	registration	_	_	O
127	to	_	_	O
128	amifostine	_	_	O
129	(	_	_	O
130	AM	_	_	O
131	)	_	_	O
132	500	_	_	O
133	mg	_	_	O
134	IV	_	_	O
135	four	_	_	O
136	times	_	_	O
137	per	_	_	O
138	week	_	_	O
139	or	_	_	O
140	no	_	_	O
141	AM	_	_	O
142	during	_	_	O
143	chemoradiotherapy	_	_	O
144	.	_	_	O

145	Beyond	_	_	O
146	standard	_	_	O
147	toxicity	_	_	O
148	end	_	_	O
149	points	_	_	O
150	,	_	_	O
151	physician	_	_	O
152	dysphagia	_	_	O
153	logs	_	_	O
154	(	_	_	O
155	PDLs	_	_	O
156	)	_	_	O
157	,	_	_	O
158	daily	_	_	O
159	patient	_	_	O
160	swallowing	_	_	O
161	diaries	_	_	O
162	,	_	_	O
163	and	_	_	O
164	QOL	_	_	O
165	(	_	_	O
166	EORTC	_	_	O
167	QLQ	_	_	O
168	-	_	_	O
169	C30	_	_	O
170	/	_	_	O
171	LC	_	_	O
172	-	_	_	O
173	13	_	_	O
174	)	_	_	O
175	were	_	_	O
176	also	_	_	O
177	collected	_	_	O
178	.	_	_	O

179	Swallowing	_	_	O
180	AUC	_	_	O
181	analyses	_	_	O
182	were	_	_	O
183	calculated	_	_	O
184	from	_	_	O
185	patient	_	_	O
186	diaries	_	_	O
187	and	_	_	O
188	PDLs	_	_	O
189	.	_	_	O

190	A	_	_	O
191	total	_	_	O
192	of	_	_	O
193	120	_	_	O
194	patients	_	_	O
195	were	_	_	O
196	randomly	_	_	O
197	assigned	_	_	O
198	to	_	_	O
199	receive	_	_	O
200	AM	_	_	O
201	,	_	_	O
202	and	_	_	O
203	122	_	_	O
204	,	_	_	O
205	to	_	_	O
206	receive	_	_	O
207	no	_	_	O
208	AM	_	_	O
209	(	_	_	O
210	one	_	_	O
211	patient	_	_	O
212	was	_	_	O
213	ineligible	_	_	O
214	)	_	_	O
215	;	_	_	O
216	72	_	_	O
217	%	_	_	O
218	received	_	_	O
219	AM	_	_	O
220	per	_	_	O
221	protocol	_	_	O
222	or	_	_	O
223	with	_	_	O
224	a	_	_	O
225	minor	_	_	O
226	deviation	_	_	O
227	.	_	_	O

228	AM	_	_	B-Premise
229	was	_	_	I-Premise
230	associated	_	_	I-Premise
231	with	_	_	I-Premise
232	higher	_	_	I-Premise
233	rates	_	_	I-Premise
234	of	_	_	I-Premise
235	acute	_	_	I-Premise
236	nausea	_	_	I-Premise
237	(	_	_	I-Premise
238	P	_	_	I-Premise
239	=	_	_	I-Premise
240	.	_	_	I-Premise

241	03	_	_	I-Premise
242	)	_	_	I-Premise
243	,	_	_	I-Premise
244	vomiting	_	_	I-Premise
245	(	_	_	I-Premise
246	P	_	_	I-Premise
247	=	_	_	I-Premise
248	.	_	_	I-Premise

249	007	_	_	I-Premise
250	)	_	_	I-Premise
251	,	_	_	I-Premise
252	cardiovascular	_	_	I-Premise
253	toxicity	_	_	I-Premise
254	(	_	_	I-Premise
255	P	_	_	I-Premise
256	=	_	_	I-Premise
257	.	_	_	I-Premise

258	0001	_	_	I-Premise
259	)	_	_	I-Premise
260	,	_	_	I-Premise
261	and	_	_	I-Premise
262	infection	_	_	I-Premise
263	or	_	_	I-Premise
264	febrile	_	_	I-Premise
265	neutropenia	_	_	I-Premise
266	(	_	_	I-Premise
267	P	_	_	I-Premise
268	=	_	_	I-Premise
269	.	_	_	I-Premise

270	03	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	The	_	_	B-Premise
274	rate	_	_	I-Premise
275	of	_	_	I-Premise
276	>	_	_	I-Premise
277	/	_	_	I-Premise
278	=	_	_	I-Premise
279	grade	_	_	I-Premise
280	3	_	_	I-Premise
281	esophagitis	_	_	I-Premise
282	was	_	_	I-Premise
283	30	_	_	I-Premise
284	%	_	_	I-Premise
285	with	_	_	I-Premise
286	AM	_	_	I-Premise
287	versus	_	_	I-Premise
288	34	_	_	I-Premise
289	%	_	_	I-Premise
290	without	_	_	I-Premise
291	AM	_	_	I-Premise
292	(	_	_	I-Premise
293	P	_	_	I-Premise
294	=	_	_	I-Premise
295	.	_	_	I-Premise

296	9	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	Patient	_	_	B-Premise
300	diaries	_	_	I-Premise
301	demonstrated	_	_	I-Premise
302	lower	_	_	I-Premise
303	swallowing	_	_	I-Premise
304	dysfunction	_	_	I-Premise
305	AUC	_	_	I-Premise
306	with	_	_	I-Premise
307	amifostine	_	_	I-Premise
308	(	_	_	I-Premise
309	z	_	_	I-Premise
310	test	_	_	I-Premise
311	P	_	_	I-Premise
312	=	_	_	I-Premise
313	.	_	_	I-Premise

314	025	_	_	I-Premise
315	)	_	_	I-Premise
316	.	_	_	I-Premise

317	QOL	_	_	B-Premise
318	was	_	_	I-Premise
319	not	_	_	I-Premise
320	significantly	_	_	I-Premise
321	different	_	_	I-Premise
322	between	_	_	I-Premise
323	the	_	_	I-Premise
324	two	_	_	I-Premise
325	arms	_	_	I-Premise
326	,	_	_	I-Premise
327	except	_	_	I-Premise
328	for	_	_	I-Premise
329	pain	_	_	I-Premise
330	,	_	_	I-Premise
331	which	_	_	I-Premise
332	showed	_	_	I-Premise
333	more	_	_	I-Premise
334	clinically	_	_	I-Premise
335	meaningful	_	_	I-Premise
336	improvement	_	_	I-Premise
337	and	_	_	I-Premise
338	less	_	_	I-Premise
339	deterioration	_	_	I-Premise
340	at	_	_	I-Premise
341	6	_	_	I-Premise
342	weeks	_	_	I-Premise
343	follow	_	_	I-Premise
344	-	_	_	I-Premise
345	up	_	_	I-Premise
346	(	_	_	I-Premise
347	v	_	_	I-Premise
348	pretreatment	_	_	I-Premise
349	)	_	_	I-Premise
350	in	_	_	I-Premise
351	the	_	_	I-Premise
352	AM	_	_	I-Premise
353	arm	_	_	I-Premise
354	(	_	_	I-Premise
355	P	_	_	I-Premise
356	=	_	_	I-Premise
357	.	_	_	I-Premise

358	003	_	_	I-Premise
359	)	_	_	I-Premise
360	.	_	_	I-Premise

361	The	_	_	B-Premise
362	median	_	_	I-Premise
363	survival	_	_	I-Premise
364	rates	_	_	I-Premise
365	for	_	_	I-Premise
366	both	_	_	I-Premise
367	arms	_	_	I-Premise
368	were	_	_	I-Premise
369	comparable	_	_	I-Premise
370	(	_	_	I-Premise
371	AM	_	_	I-Premise
372	,	_	_	I-Premise
373	17	_	_	I-Premise
374	.	_	_	I-Premise

375	3	_	_	I-Premise
376	v	_	_	I-Premise
377	no	_	_	I-Premise
378	AM	_	_	I-Premise
379	,	_	_	I-Premise
380	17	_	_	I-Premise
381	.	_	_	I-Premise

382	9	_	_	I-Premise
383	months	_	_	I-Premise
384	;	_	_	I-Premise
385	P	_	_	I-Premise
386	=	_	_	I-Premise
387	.	_	_	I-Premise

388	87	_	_	I-Premise
389	)	_	_	I-Premise
390	.	_	_	I-Premise

391	AM	_	_	B-Claim
392	did	_	_	I-Claim
393	not	_	_	I-Claim
394	significantly	_	_	I-Claim
395	reduce	_	_	I-Claim
396	esophagitis	_	_	I-Claim
397	>	_	_	I-Claim
398	/	_	_	I-Claim
399	=	_	_	I-Claim
400	grade	_	_	I-Claim
401	3	_	_	I-Claim
402	in	_	_	I-Claim
403	patients	_	_	I-Claim
404	receiving	_	_	I-Claim
405	hyperfractionated	_	_	I-Claim
406	radiation	_	_	I-Claim
407	and	_	_	I-Claim
408	chemotherapy	_	_	I-Claim
409	.	_	_	I-Claim

410	However	_	_	B-Claim
411	,	_	_	I-Claim
412	patient	_	_	I-Claim
413	self	_	_	I-Claim
414	-	_	_	I-Claim
415	assessments	_	_	I-Claim
416	suggested	_	_	I-Claim
417	a	_	_	I-Claim
418	possible	_	_	I-Claim
419	advantage	_	_	I-Claim
420	to	_	_	I-Claim
421	AM	_	_	I-Claim
422	that	_	_	I-Claim
423	is	_	_	I-Claim
424	being	_	_	I-Claim
425	explored	_	_	I-Claim
426	with	_	_	I-Claim
427	modified	_	_	I-Claim
428	dosing	_	_	I-Claim
429	route	_	_	I-Claim
430	strategies	_	_	I-Claim
431	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	tested	_	_	O
3	hyperbaric	_	_	O
4	oxygen	_	_	O
5	(	_	_	O
6	HBO	_	_	O
7	)	_	_	O
8	as	_	_	O
9	an	_	_	O
10	adjunct	_	_	O
11	to	_	_	O
12	surgery	_	_	O
13	and	_	_	O
14	antibiotics	_	_	O
15	in	_	_	O
16	the	_	_	O
17	treatment	_	_	O
18	of	_	_	O
19	bisphosphonate	_	_	O
20	-	_	_	O
21	related	_	_	O
22	osteonecrosis	_	_	O
23	of	_	_	O
24	the	_	_	O
25	jaw	_	_	O
26	(	_	_	O
27	ONJ	_	_	O
28	)	_	_	O
29	and	_	_	O
30	evaluated	_	_	O
31	its	_	_	O
32	effects	_	_	O
33	on	_	_	O
34	gingival	_	_	O
35	healing	_	_	O
36	,	_	_	O
37	pain	_	_	O
38	,	_	_	O
39	and	_	_	O
40	quality	_	_	O
41	of	_	_	O
42	life	_	_	O
43	.	_	_	O

44	The	_	_	O
45	investigators	_	_	O
46	implemented	_	_	O
47	a	_	_	O
48	randomized	_	_	O
49	controlled	_	_	O
50	trial	_	_	O
51	and	_	_	O
52	enrolled	_	_	O
53	a	_	_	O
54	sample	_	_	O
55	composed	_	_	O
56	of	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	ONJ	_	_	O
60	,	_	_	O
61	where	_	_	O
62	the	_	_	O
63	predictor	_	_	O
64	variable	_	_	O
65	was	_	_	O
66	HBO	_	_	O
67	administered	_	_	O
68	at	_	_	O
69	2	_	_	O
70	atm	_	_	O
71	twice	_	_	O
72	a	_	_	O
73	day	_	_	O
74	for	_	_	O
75	40	_	_	O
76	treatments	_	_	O
77	as	_	_	O
78	an	_	_	O
79	adjunct	_	_	O
80	to	_	_	O
81	conventional	_	_	O
82	therapy	_	_	O
83	of	_	_	O
84	surgery	_	_	O
85	and	_	_	O
86	antibiotics	_	_	O
87	versus	_	_	O
88	conventional	_	_	O
89	therapy	_	_	O
90	alone	_	_	O
91	.	_	_	O

92	Over	_	_	O
93	the	_	_	O
94	next	_	_	O
95	24	_	_	O
96	months	_	_	O
97	,	_	_	O
98	oral	_	_	O
99	lesion	_	_	O
100	size	_	_	O
101	and	_	_	O
102	number	_	_	O
103	,	_	_	O
104	pain	_	_	O
105	,	_	_	O
106	and	_	_	O
107	quality	_	_	O
108	of	_	_	O
109	life	_	_	O
110	were	_	_	O
111	assessed	_	_	O
112	.	_	_	O

113	Forty	_	_	O
114	-	_	_	O
115	six	_	_	O
116	patients	_	_	O
117	(	_	_	O
118	mean	_	_	O
119	age	_	_	O
120	,	_	_	O
121	66	_	_	O
122	yrs	_	_	O
123	;	_	_	O
124	57	_	_	O
125	%	_	_	O
126	women	_	_	O
127	)	_	_	O
128	contributed	_	_	O
129	data	_	_	O
130	to	_	_	O
131	the	_	_	O
132	trial	_	_	O
133	.	_	_	O

134	There	_	_	O
135	were	_	_	O
136	no	_	_	O
137	statistically	_	_	O
138	significant	_	_	O
139	differences	_	_	O
140	in	_	_	O
141	the	_	_	O
142	distribution	_	_	O
143	of	_	_	O
144	variables	_	_	O
145	used	_	_	O
146	to	_	_	O
147	assess	_	_	O
148	randomization	_	_	O
149	success	_	_	O
150	between	_	_	O
151	the	_	_	O
152	HBO	_	_	O
153	and	_	_	O
154	standard	_	_	O
155	treatment	_	_	O
156	groups	_	_	O
157	.	_	_	O

158	Seventeen	_	_	B-Premise
159	of	_	_	I-Premise
160	25	_	_	I-Premise
161	HBO	_	_	I-Premise
162	-	_	_	I-Premise
163	treated	_	_	I-Premise
164	patients	_	_	I-Premise
165	(	_	_	I-Premise
166	68	_	_	I-Premise
167	%	_	_	I-Premise
168	)	_	_	I-Premise
169	improved	_	_	I-Premise
170	versus	_	_	I-Premise
171	8	_	_	I-Premise
172	of	_	_	I-Premise
173	21	_	_	I-Premise
174	controls	_	_	I-Premise
175	(	_	_	I-Premise
176	38	_	_	I-Premise
177	.	_	_	I-Premise

178	1	_	_	I-Premise
179	%	_	_	I-Premise
180	;	_	_	I-Premise
181	P	_	_	I-Premise
182	=	_	_	I-Premise
183	.	_	_	I-Premise

184	043	_	_	I-Premise
185	,	_	_	I-Premise
186	χ	_	_	I-Premise
187	(	_	_	I-Premise
188	2	_	_	I-Premise
189	)	_	_	I-Premise
190	test	_	_	I-Premise
191	)	_	_	I-Premise
192	.	_	_	I-Premise

193	Mean	_	_	B-Premise
194	time	_	_	I-Premise
195	to	_	_	I-Premise
196	improvement	_	_	I-Premise
197	was	_	_	I-Premise
198	39	_	_	I-Premise
199	.	_	_	I-Premise

200	7	_	_	I-Premise
201	weeks	_	_	I-Premise
202	(	_	_	I-Premise
203	95	_	_	I-Premise
204	%	_	_	I-Premise
205	confidence	_	_	I-Premise
206	interval	_	_	I-Premise
207	[	_	_	I-Premise
208	CI	_	_	I-Premise
209	]	_	_	I-Premise
210	,	_	_	I-Premise
211	22	_	_	I-Premise
212	.	_	_	I-Premise

213	4	_	_	I-Premise
214	to	_	_	I-Premise
215	57	_	_	I-Premise
216	.	_	_	I-Premise

217	0	_	_	I-Premise
218	weeks	_	_	I-Premise
219	)	_	_	I-Premise
220	for	_	_	I-Premise
221	HBO	_	_	I-Premise
222	-	_	_	I-Premise
223	treated	_	_	I-Premise
224	patients	_	_	I-Premise
225	versus	_	_	I-Premise
226	67	_	_	I-Premise
227	.	_	_	I-Premise

228	9	_	_	I-Premise
229	weeks	_	_	I-Premise
230	(	_	_	I-Premise
231	95	_	_	I-Premise
232	CI	_	_	I-Premise
233	,	_	_	I-Premise
234	48	_	_	I-Premise
235	.	_	_	I-Premise

236	4	_	_	I-Premise
237	to	_	_	I-Premise
238	87	_	_	I-Premise
239	.	_	_	I-Premise

240	5	_	_	I-Premise
241	weeks	_	_	I-Premise
242	)	_	_	I-Premise
243	for	_	_	I-Premise
244	controls	_	_	I-Premise
245	(	_	_	I-Premise
246	P	_	_	I-Premise
247	=	_	_	I-Premise
248	.	_	_	I-Premise

249	03	_	_	I-Premise
250	,	_	_	I-Premise
251	log	_	_	I-Premise
252	-	_	_	I-Premise
253	rank	_	_	I-Premise
254	test	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	However	_	_	B-Premise
258	,	_	_	I-Premise
259	complete	_	_	I-Premise
260	gingival	_	_	I-Premise
261	healing	_	_	I-Premise
262	occurred	_	_	I-Premise
263	in	_	_	I-Premise
264	only	_	_	I-Premise
265	14	_	_	I-Premise
266	of	_	_	I-Premise
267	25	_	_	I-Premise
268	HBO	_	_	I-Premise
269	-	_	_	I-Premise
270	treated	_	_	I-Premise
271	patients	_	_	I-Premise
272	(	_	_	I-Premise
273	52	_	_	I-Premise
274	%	_	_	I-Premise
275	)	_	_	I-Premise
276	versus	_	_	I-Premise
277	7	_	_	I-Premise
278	of	_	_	I-Premise
279	21	_	_	I-Premise
280	controls	_	_	I-Premise
281	(	_	_	I-Premise
282	33	_	_	I-Premise
283	.	_	_	I-Premise

284	3	_	_	I-Premise
285	%	_	_	I-Premise
286	;	_	_	I-Premise
287	P	_	_	I-Premise
288	=	_	_	I-Premise
289	.	_	_	I-Premise

290	203	_	_	I-Premise
291	,	_	_	I-Premise
292	χ	_	_	I-Premise
293	(	_	_	I-Premise
294	2	_	_	I-Premise
295	)	_	_	I-Premise
296	test	_	_	I-Premise
297	)	_	_	I-Premise
298	,	_	_	I-Premise
299	and	_	_	I-Premise
300	time	_	_	I-Premise
301	to	_	_	I-Premise
302	healing	_	_	I-Premise
303	was	_	_	I-Premise
304	59	_	_	I-Premise
305	weeks	_	_	I-Premise
306	(	_	_	I-Premise
307	95	_	_	I-Premise
308	%	_	_	I-Premise
309	CI	_	_	I-Premise
310	,	_	_	I-Premise
311	42	_	_	I-Premise
312	.	_	_	I-Premise

313	8	_	_	I-Premise
314	%	_	_	I-Premise
315	to	_	_	I-Premise
316	75	_	_	I-Premise
317	.	_	_	I-Premise

318	8	_	_	I-Premise
319	%	_	_	I-Premise
320	)	_	_	I-Premise
321	for	_	_	I-Premise
322	HBO	_	_	I-Premise
323	-	_	_	I-Premise
324	treated	_	_	I-Premise
325	patients	_	_	I-Premise
326	versus	_	_	I-Premise
327	70	_	_	I-Premise
328	weeks	_	_	I-Premise
329	(	_	_	I-Premise
330	95	_	_	I-Premise
331	CI	_	_	I-Premise
332	,	_	_	I-Premise
333	52	_	_	I-Premise
334	.	_	_	I-Premise

335	2	_	_	I-Premise
336	%	_	_	I-Premise
337	to	_	_	I-Premise
338	88	_	_	I-Premise
339	.	_	_	I-Premise

340	36	_	_	I-Premise
341	%	_	_	I-Premise
342	)	_	_	I-Premise
343	for	_	_	I-Premise
344	controls	_	_	I-Premise
345	(	_	_	I-Premise
346	P	_	_	I-Premise
347	=	_	_	I-Premise
348	.	_	_	I-Premise

349	32	_	_	I-Premise
350	,	_	_	I-Premise
351	log	_	_	I-Premise
352	-	_	_	I-Premise
353	rank	_	_	I-Premise
354	test	_	_	I-Premise
355	)	_	_	I-Premise
356	.	_	_	I-Premise

357	Pain	_	_	B-Premise
358	decreased	_	_	I-Premise
359	faster	_	_	I-Premise
360	for	_	_	I-Premise
361	HBO	_	_	I-Premise
362	-	_	_	I-Premise
363	treated	_	_	I-Premise
364	subjects	_	_	I-Premise
365	(	_	_	I-Premise
366	P	_	_	I-Premise
367	<	_	_	I-Premise
368	.	_	_	I-Premise

369	01	_	_	I-Premise
370	,	_	_	I-Premise
371	linear	_	_	I-Premise
372	regression	_	_	I-Premise
373	)	_	_	I-Premise
374	.	_	_	I-Premise

375	Quality	_	_	B-Premise
376	-	_	_	I-Premise
377	of	_	_	I-Premise
378	-	_	_	I-Premise
379	life	_	_	I-Premise
380	scores	_	_	I-Premise
381	for	_	_	I-Premise
382	physical	_	_	I-Premise
383	health	_	_	I-Premise
384	(	_	_	I-Premise
385	P	_	_	I-Premise
386	=	_	_	I-Premise
387	.	_	_	I-Premise

388	002	_	_	I-Premise
389	)	_	_	I-Premise
390	and	_	_	I-Premise
391	perceived	_	_	I-Premise
392	health	_	_	I-Premise
393	(	_	_	I-Premise
394	P	_	_	I-Premise
395	=	_	_	I-Premise
396	.	_	_	I-Premise

397	043	_	_	I-Premise
398	)	_	_	I-Premise
399	decreased	_	_	I-Premise
400	at	_	_	I-Premise
401	6	_	_	I-Premise
402	months	_	_	I-Premise
403	for	_	_	I-Premise
404	control	_	_	I-Premise
405	group	_	_	I-Premise
406	but	_	_	I-Premise
407	for	_	_	I-Premise
408	not	_	_	I-Premise
409	the	_	_	I-Premise
410	HBO	_	_	I-Premise
411	group	_	_	I-Premise
412	.	_	_	I-Premise

413	ONJ	_	_	B-Claim
414	is	_	_	I-Claim
415	multifactorial	_	_	I-Claim
416	and	_	_	I-Claim
417	no	_	_	I-Claim
418	single	_	_	I-Claim
419	treatment	_	_	I-Claim
420	modality	_	_	I-Claim
421	is	_	_	I-Claim
422	likely	_	_	I-Claim
423	to	_	_	I-Claim
424	reverse	_	_	I-Claim
425	it	_	_	I-Claim
426	;	_	_	I-Claim
427	however	_	_	B-Claim
428	,	_	_	I-Claim
429	it	_	_	I-Claim
430	is	_	_	I-Claim
431	treatable	_	_	I-Claim
432	and	_	_	I-Claim
433	even	_	_	I-Claim
434	advanced	_	_	I-Claim
435	presentations	_	_	I-Claim
436	can	_	_	I-Claim
437	improve	_	_	I-Claim
438	with	_	_	I-Claim
439	intensive	_	_	I-Claim
440	multimodal	_	_	I-Claim
441	therapy	_	_	I-Claim
442	.	_	_	I-Claim

443	Clinically	_	_	B-Claim
444	,	_	_	I-Claim
445	HBO	_	_	I-Claim
446	appears	_	_	I-Claim
447	to	_	_	I-Claim
448	be	_	_	I-Claim
449	a	_	_	I-Claim
450	useful	_	_	I-Claim
451	adjunct	_	_	I-Claim
452	to	_	_	I-Claim
453	ONJ	_	_	I-Claim
454	treatment	_	_	I-Claim
455	,	_	_	I-Claim
456	particularly	_	_	I-Claim
457	for	_	_	I-Claim
458	more	_	_	I-Claim
459	severe	_	_	I-Claim
460	cases	_	_	I-Claim
461	,	_	_	I-Claim
462	although	_	_	I-Claim
463	this	_	_	I-Claim
464	study	_	_	I-Claim
465	was	_	_	I-Claim
466	underpowered	_	_	I-Claim
467	to	_	_	I-Claim
468	fully	_	_	I-Claim
469	support	_	_	I-Claim
470	this	_	_	I-Claim
471	claim	_	_	I-Claim
472	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	evaluate	_	_	O
8	pamidronate	_	_	O
9	for	_	_	O
10	bone	_	_	O
11	pain	_	_	O
12	in	_	_	O
13	a	_	_	O
14	randomised	_	_	O
15	double	_	_	O
16	-	_	_	O
17	blind	_	_	O
18	trial	_	_	O
19	and	_	_	O
20	to	_	_	O
21	evaluate	_	_	O
22	the	_	_	O
23	contribution	_	_	O
24	of	_	_	O
25	new	_	_	O
26	markers	_	_	O
27	of	_	_	O
28	bone	_	_	O
29	resorption	_	_	O
30	in	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	bone	_	_	O
34	metastases	_	_	O
35	.	_	_	O

36	Fifty	_	_	O
37	-	_	_	O
38	two	_	_	O
39	patients	_	_	O
40	with	_	_	O
41	painful	_	_	O
42	bone	_	_	O
43	metastases	_	_	O
44	were	_	_	O
45	randomised	_	_	O
46	to	_	_	O
47	receive	_	_	O
48	a	_	_	O
49	two	_	_	O
50	-	_	_	O
51	hour	_	_	O
52	infusion	_	_	O
53	of	_	_	O
54	pamidronate	_	_	O
55	120	_	_	O
56	mg	_	_	O
57	or	_	_	O
58	an	_	_	O
59	identical	_	_	O
60	infusion	_	_	O
61	of	_	_	O
62	saline	_	_	O
63	.	_	_	O

64	Four	_	_	O
65	weeks	_	_	O
66	later	_	_	O
67	,	_	_	O
68	all	_	_	O
69	patients	_	_	O
70	received	_	_	O
71	pamidronate	_	_	O
72	120	_	_	O
73	mg	_	_	O
74	.	_	_	O

75	Bone	_	_	O
76	resorption	_	_	O
77	markers	_	_	O
78	measured	_	_	O
79	included	_	_	O
80	urinary	_	_	O
81	calcium	_	_	O
82	(	_	_	O
83	uCa	_	_	O
84	)	_	_	O
85	,	_	_	O
86	hydroxyproline	_	_	O
87	(	_	_	O
88	Hyp	_	_	O
89	)	_	_	O
90	,	_	_	O
91	and	_	_	O
92	the	_	_	O
93	collagen	_	_	O
94	breakdown	_	_	O
95	products	_	_	O
96	:	_	_	O
97	NTx	_	_	O
98	,	_	_	O
99	Crosslaps	_	_	O
100	and	_	_	O
101	Free	_	_	O
102	Dpd	_	_	O
103	.	_	_	O

104	Symptomatic	_	_	B-Premise
105	response	_	_	I-Premise
106	during	_	_	I-Premise
107	the	_	_	I-Premise
108	first	_	_	I-Premise
109	four	_	_	I-Premise
110	weeks	_	_	I-Premise
111	was	_	_	I-Premise
112	seen	_	_	I-Premise
113	after	_	_	I-Premise
114	pamidronate	_	_	I-Premise
115	,	_	_	I-Premise
116	but	_	_	I-Premise
117	not	_	_	I-Premise
118	with	_	_	I-Premise
119	placebo	_	_	I-Premise
120	(	_	_	I-Premise
121	P	_	_	I-Premise
122	<	_	_	I-Premise
123	0	_	_	I-Premise
124	.	_	_	I-Premise

125	05	_	_	I-Premise
126	)	_	_	I-Premise
127	.	_	_	I-Premise

128	Quality	_	_	B-Premise
129	of	_	_	I-Premise
130	life	_	_	I-Premise
131	was	_	_	I-Premise
132	maintained	_	_	I-Premise
133	with	_	_	I-Premise
134	pamidronate	_	_	I-Premise
135	and	_	_	I-Premise
136	deteriorated	_	_	I-Premise
137	after	_	_	I-Premise
138	placebo	_	_	I-Premise
139	(	_	_	I-Premise
140	P	_	_	I-Premise
141	<	_	_	I-Premise
142	0	_	_	I-Premise
143	.	_	_	I-Premise

144	05	_	_	I-Premise
145	)	_	_	I-Premise
146	.	_	_	I-Premise

147	Resorption	_	_	B-Premise
148	markers	_	_	I-Premise
149	did	_	_	I-Premise
150	not	_	_	I-Premise
151	decrease	_	_	I-Premise
152	after	_	_	I-Premise
153	placebo	_	_	I-Premise
154	,	_	_	I-Premise
155	but	_	_	B-Premise
156	NTx	_	_	I-Premise
157	and	_	_	I-Premise
158	Crosslaps	_	_	I-Premise
159	both	_	_	I-Premise
160	decreased	_	_	I-Premise
161	by	_	_	I-Premise
162	70	_	_	I-Premise
163	%	_	_	I-Premise
164	after	_	_	I-Premise
165	pamidronate	_	_	I-Premise
166	(	_	_	I-Premise
167	P	_	_	I-Premise
168	=	_	_	I-Premise
169	0	_	_	I-Premise
170	.	_	_	I-Premise

171	001	_	_	I-Premise
172	)	_	_	I-Premise
173	.	_	_	I-Premise

174	A	_	_	B-Premise
175	second	_	_	I-Premise
176	infusion	_	_	I-Premise
177	of	_	_	I-Premise
178	pamidronate	_	_	I-Premise
179	did	_	_	I-Premise
180	not	_	_	I-Premise
181	decrease	_	_	I-Premise
182	resorption	_	_	I-Premise
183	further	_	_	I-Premise
184	,	_	_	I-Premise
185	but	_	_	B-Premise
186	maintained	_	_	I-Premise
187	the	_	_	I-Premise
188	suppression	_	_	I-Premise
189	of	_	_	I-Premise
190	resorption	_	_	I-Premise
191	at	_	_	I-Premise
192	similar	_	_	I-Premise
193	levels	_	_	I-Premise
194	for	_	_	I-Premise
195	a	_	_	I-Premise
196	further	_	_	I-Premise
197	four	_	_	I-Premise
198	weeks	_	_	I-Premise
199	.	_	_	I-Premise

200	Symptomatic	_	_	B-Premise
201	response	_	_	I-Premise
202	to	_	_	I-Premise
203	pamidronate	_	_	I-Premise
204	correlated	_	_	I-Premise
205	closely	_	_	I-Premise
206	with	_	_	I-Premise
207	the	_	_	I-Premise
208	rate	_	_	I-Premise
209	of	_	_	I-Premise
210	bone	_	_	I-Premise
211	resorption	_	_	I-Premise
212	;	_	_	I-Premise
213	it	_	_	B-Premise
214	was	_	_	I-Premise
215	more	_	_	I-Premise
216	frequent	_	_	I-Premise
217	in	_	_	I-Premise
218	those	_	_	I-Premise
219	patients	_	_	I-Premise
220	with	_	_	I-Premise
221	an	_	_	I-Premise
222	initial	_	_	I-Premise
223	NTx	_	_	I-Premise
224	value	_	_	I-Premise
225	of	_	_	I-Premise
226	<	_	_	I-Premise
227	2	_	_	I-Premise
228	times	_	_	I-Premise
229	the	_	_	I-Premise
230	upper	_	_	I-Premise
231	limit	_	_	I-Premise
232	of	_	_	I-Premise
233	normal	_	_	I-Premise
234	(	_	_	I-Premise
235	17	_	_	I-Premise
236	of	_	_	I-Premise
237	27	_	_	I-Premise
238	,	_	_	I-Premise
239	62	_	_	I-Premise
240	%	_	_	I-Premise
241	)	_	_	I-Premise
242	and	_	_	I-Premise
243	in	_	_	I-Premise
244	those	_	_	I-Premise
245	where	_	_	I-Premise
246	the	_	_	I-Premise
247	level	_	_	I-Premise
248	of	_	_	I-Premise
249	Ntx	_	_	I-Premise
250	returned	_	_	I-Premise
251	to	_	_	I-Premise
252	normal	_	_	I-Premise
253	(	_	_	I-Premise
254	19	_	_	I-Premise
255	of	_	_	I-Premise
256	32	_	_	I-Premise
257	,	_	_	I-Premise
258	59	_	_	I-Premise
259	%	_	_	I-Premise
260	)	_	_	I-Premise
261	,	_	_	I-Premise
262	than	_	_	I-Premise
263	in	_	_	I-Premise
264	the	_	_	I-Premise
265	patients	_	_	I-Premise
266	with	_	_	I-Premise
267	either	_	_	I-Premise
268	high	_	_	I-Premise
269	baseline	_	_	I-Premise
270	values	_	_	I-Premise
271	of	_	_	I-Premise
272	NTx	_	_	I-Premise
273	(	_	_	I-Premise
274	>	_	_	I-Premise
275	2	_	_	I-Premise
276	times	_	_	I-Premise
277	the	_	_	I-Premise
278	upper	_	_	I-Premise
279	limit	_	_	I-Premise
280	of	_	_	I-Premise
281	normal	_	_	I-Premise
282	)	_	_	I-Premise
283	or	_	_	I-Premise
284	Ntx	_	_	I-Premise
285	levels	_	_	I-Premise
286	which	_	_	I-Premise
287	failed	_	_	I-Premise
288	to	_	_	I-Premise
289	normalise	_	_	I-Premise
290	for	_	_	I-Premise
291	whom	_	_	I-Premise
292	the	_	_	I-Premise
293	response	_	_	I-Premise
294	frequencies	_	_	I-Premise
295	were	_	_	I-Premise
296	2	_	_	I-Premise
297	of	_	_	I-Premise
298	16	_	_	I-Premise
299	(	_	_	I-Premise
300	13	_	_	I-Premise
301	%	_	_	I-Premise
302	)	_	_	I-Premise
303	and	_	_	I-Premise
304	0	_	_	I-Premise
305	of	_	_	I-Premise
306	11	_	_	I-Premise
307	(	_	_	I-Premise
308	0	_	_	I-Premise
309	%	_	_	I-Premise
310	)	_	_	I-Premise
311	,	_	_	I-Premise
312	respectively	_	_	I-Premise
313	.	_	_	I-Premise

314	Subjective	_	_	B-Claim
315	benefit	_	_	I-Claim
316	after	_	_	I-Claim
317	intravenous	_	_	I-Claim
318	pamidronate	_	_	I-Claim
319	is	_	_	I-Claim
320	confirmed	_	_	I-Claim
321	in	_	_	I-Claim
322	this	_	_	I-Claim
323	placebo	_	_	I-Claim
324	-	_	_	I-Claim
325	controlled	_	_	I-Claim
326	study	_	_	I-Claim
327	.	_	_	I-Claim

328	The	_	_	B-Claim
329	new	_	_	I-Claim
330	bone	_	_	I-Claim
331	resorption	_	_	I-Claim
332	markers	_	_	I-Claim
333	of	_	_	I-Claim
334	collagen	_	_	I-Claim
335	breakdown	_	_	I-Claim
336	were	_	_	I-Claim
337	able	_	_	I-Claim
338	to	_	_	I-Claim
339	predict	_	_	I-Claim
340	clinical	_	_	I-Claim
341	response	_	_	I-Claim
342	to	_	_	I-Claim
343	pamidronate	_	_	I-Claim
344	.	_	_	I-Claim


0	Docetaxel	_	_	B-Claim
1	has	_	_	I-Claim
2	shown	_	_	I-Claim
3	activity	_	_	I-Claim
4	in	_	_	I-Claim
5	elderly	_	_	I-Claim
6	patients	_	_	I-Claim
7	with	_	_	I-Claim
8	advanced	_	_	I-Claim
9	non	_	_	I-Claim
10	-	_	_	I-Claim
11	small	_	_	I-Claim
12	-	_	_	I-Claim
13	cell	_	_	I-Claim
14	lung	_	_	I-Claim
15	cancer	_	_	I-Claim
16	(	_	_	I-Claim
17	NSCLC	_	_	I-Claim
18	)	_	_	I-Claim
19	.	_	_	I-Claim

20	This	_	_	O
21	randomized	_	_	O
22	phase	_	_	O
23	III	_	_	O
24	trial	_	_	O
25	evaluated	_	_	O
26	the	_	_	O
27	efficacy	_	_	O
28	and	_	_	O
29	safety	_	_	O
30	of	_	_	O
31	docetaxel	_	_	O
32	versus	_	_	O
33	vinorelbine	_	_	O
34	(	_	_	O
35	the	_	_	O
36	current	_	_	O
37	standard	_	_	O
38	treatment	_	_	O
39	)	_	_	O
40	in	_	_	O
41	elderly	_	_	O
42	patients	_	_	O
43	.	_	_	O

44	Chemotherapy	_	_	O
45	-	_	_	O
46	naïve	_	_	O
47	patients	_	_	O
48	age	_	_	O
49	70	_	_	O
50	years	_	_	O
51	or	_	_	O
52	older	_	_	O
53	with	_	_	O
54	stage	_	_	O
55	IIIB	_	_	O
56	/	_	_	O
57	IV	_	_	O
58	NSCLC	_	_	O
59	and	_	_	O
60	performance	_	_	O
61	status	_	_	O
62	2	_	_	O
63	or	_	_	O
64	lower	_	_	O
65	were	_	_	O
66	eligible	_	_	O
67	.	_	_	O

68	Patients	_	_	O
69	randomly	_	_	O
70	received	_	_	O
71	docetaxel	_	_	O
72	60	_	_	O
73	mg	_	_	O
74	/	_	_	O
75	m2	_	_	O
76	(	_	_	O
77	day	_	_	O
78	1	_	_	O
79	)	_	_	O
80	or	_	_	O
81	vinorelbine	_	_	O
82	25	_	_	O
83	mg	_	_	O
84	/	_	_	O
85	m2	_	_	O
86	(	_	_	O
87	days	_	_	O
88	1	_	_	O
89	and	_	_	O
90	8	_	_	O
91	)	_	_	O
92	every	_	_	O
93	21	_	_	O
94	days	_	_	O
95	for	_	_	O
96	four	_	_	O
97	cycles	_	_	O
98	.	_	_	O

99	The	_	_	O
100	primary	_	_	O
101	end	_	_	O
102	point	_	_	O
103	was	_	_	O
104	overall	_	_	O
105	survival	_	_	O
106	.	_	_	O

107	Overall	_	_	O
108	disease	_	_	O
109	-	_	_	O
110	related	_	_	O
111	symptom	_	_	O
112	improvement	_	_	O
113	was	_	_	O
114	assessed	_	_	O
115	using	_	_	O
116	an	_	_	O
117	eight	_	_	O
118	-	_	_	O
119	item	_	_	O
120	questionnaire	_	_	O
121	.	_	_	O

122	In	_	_	O
123	total	_	_	O
124	,	_	_	O
125	182	_	_	O
126	patients	_	_	O
127	were	_	_	O
128	enrolled	_	_	O
129	.	_	_	O

130	Median	_	_	O
131	age	_	_	O
132	was	_	_	O
133	76	_	_	O
134	years	_	_	O
135	(	_	_	O
136	range	_	_	O
137	,	_	_	O
138	70	_	_	O
139	years	_	_	O
140	to	_	_	O
141	86	_	_	O
142	years	_	_	O
143	)	_	_	O
144	.	_	_	O

145	There	_	_	B-Premise
146	was	_	_	I-Premise
147	no	_	_	I-Premise
148	statistical	_	_	I-Premise
149	difference	_	_	I-Premise
150	in	_	_	I-Premise
151	median	_	_	I-Premise
152	overall	_	_	I-Premise
153	survival	_	_	I-Premise
154	with	_	_	I-Premise
155	docetaxel	_	_	I-Premise
156	versus	_	_	I-Premise
157	vinorelbine	_	_	I-Premise
158	(	_	_	I-Premise
159	14	_	_	I-Premise
160	.	_	_	I-Premise

161	3	_	_	I-Premise
162	months	_	_	I-Premise
163	v	_	_	I-Premise
164	9	_	_	I-Premise
165	.	_	_	I-Premise

166	9	_	_	I-Premise
167	months	_	_	I-Premise
168	;	_	_	I-Premise
169	hazard	_	_	I-Premise
170	ratio	_	_	I-Premise
171	,	_	_	I-Premise
172	0	_	_	I-Premise
173	.	_	_	I-Premise

174	780	_	_	I-Premise
175	;	_	_	I-Premise
176	95	_	_	I-Premise
177	%	_	_	I-Premise
178	CI	_	_	I-Premise
179	,	_	_	I-Premise
180	0	_	_	I-Premise
181	.	_	_	I-Premise

182	561	_	_	I-Premise
183	to	_	_	I-Premise
184	1	_	_	I-Premise
185	.	_	_	I-Premise

186	085	_	_	I-Premise
187	;	_	_	I-Premise
188	P	_	_	I-Premise
189	=	_	_	I-Premise
190	.	_	_	I-Premise

191	138	_	_	I-Premise
192	)	_	_	I-Premise
193	.	_	_	I-Premise

194	There	_	_	B-Premise
195	was	_	_	I-Premise
196	a	_	_	I-Premise
197	significant	_	_	I-Premise
198	difference	_	_	I-Premise
199	in	_	_	I-Premise
200	median	_	_	I-Premise
201	progression	_	_	I-Premise
202	-	_	_	I-Premise
203	free	_	_	I-Premise
204	survival	_	_	I-Premise
205	(	_	_	I-Premise
206	5	_	_	I-Premise
207	.	_	_	I-Premise

208	5	_	_	I-Premise
209	months	_	_	I-Premise
210	v	_	_	I-Premise
211	3	_	_	I-Premise
212	.	_	_	I-Premise

213	1	_	_	I-Premise
214	months	_	_	I-Premise
215	;	_	_	I-Premise
216	P	_	_	I-Premise
217	<	_	_	I-Premise
218	.	_	_	I-Premise

219	001	_	_	I-Premise
220	)	_	_	I-Premise
221	.	_	_	I-Premise

222	Response	_	_	B-Premise
223	rates	_	_	I-Premise
224	were	_	_	I-Premise
225	also	_	_	I-Premise
226	significantly	_	_	I-Premise
227	improved	_	_	I-Premise
228	with	_	_	I-Premise
229	docetaxel	_	_	I-Premise
230	versus	_	_	I-Premise
231	vinorelbine	_	_	I-Premise
232	(	_	_	I-Premise
233	22	_	_	I-Premise
234	.	_	_	I-Premise

235	7	_	_	I-Premise
236	%	_	_	I-Premise
237	v	_	_	I-Premise
238	9	_	_	I-Premise
239	.	_	_	I-Premise

240	9	_	_	I-Premise
241	%	_	_	I-Premise
242	;	_	_	I-Premise
243	P	_	_	I-Premise
244	=	_	_	I-Premise
245	.	_	_	I-Premise

246	019	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	The	_	_	B-Premise
250	most	_	_	I-Premise
251	common	_	_	I-Premise
252	grade	_	_	I-Premise
253	3	_	_	I-Premise
254	to	_	_	I-Premise
255	4	_	_	I-Premise
256	toxicities	_	_	I-Premise
257	were	_	_	I-Premise
258	neutropenia	_	_	I-Premise
259	(	_	_	I-Premise
260	82	_	_	I-Premise
261	.	_	_	I-Premise

262	9	_	_	I-Premise
263	%	_	_	I-Premise
264	for	_	_	I-Premise
265	docetaxel	_	_	I-Premise
266	;	_	_	I-Premise
267	69	_	_	I-Premise
268	.	_	_	I-Premise

269	2	_	_	I-Premise
270	%	_	_	I-Premise
271	for	_	_	I-Premise
272	vinorelbine	_	_	I-Premise
273	;	_	_	I-Premise
274	P	_	_	I-Premise
275	=	_	_	I-Premise
276	.	_	_	I-Premise

277	031	_	_	I-Premise
278	)	_	_	I-Premise
279	and	_	_	I-Premise
280	leukopenia	_	_	I-Premise
281	(	_	_	I-Premise
282	58	_	_	I-Premise
283	.	_	_	I-Premise

284	0	_	_	I-Premise
285	%	_	_	I-Premise
286	for	_	_	I-Premise
287	docetaxel	_	_	I-Premise
288	;	_	_	I-Premise
289	51	_	_	I-Premise
290	.	_	_	I-Premise

291	7	_	_	I-Premise
292	%	_	_	I-Premise
293	for	_	_	I-Premise
294	vinorelbine	_	_	I-Premise
295	)	_	_	I-Premise
296	.	_	_	I-Premise

297	Other	_	_	B-Premise
298	toxicities	_	_	I-Premise
299	were	_	_	I-Premise
300	mild	_	_	I-Premise
301	and	_	_	I-Premise
302	generally	_	_	I-Premise
303	well	_	_	I-Premise
304	tolerated	_	_	I-Premise
305	.	_	_	I-Premise

306	Docetaxel	_	_	B-Premise
307	improved	_	_	I-Premise
308	overall	_	_	I-Premise
309	disease	_	_	I-Premise
310	-	_	_	I-Premise
311	related	_	_	I-Premise
312	symptoms	_	_	I-Premise
313	over	_	_	I-Premise
314	vinorelbine	_	_	I-Premise
315	(	_	_	I-Premise
316	odds	_	_	I-Premise
317	ratio	_	_	I-Premise
318	,	_	_	I-Premise
319	1	_	_	I-Premise
320	.	_	_	I-Premise

321	86	_	_	I-Premise
322	;	_	_	I-Premise
323	95	_	_	I-Premise
324	%	_	_	I-Premise
325	CI	_	_	I-Premise
326	,	_	_	I-Premise
327	1	_	_	I-Premise
328	.	_	_	I-Premise

329	09	_	_	I-Premise
330	to	_	_	I-Premise
331	3	_	_	I-Premise
332	.	_	_	I-Premise

333	20	_	_	I-Premise
334	)	_	_	I-Premise
335	.	_	_	I-Premise

336	Docetaxel	_	_	B-Premise
337	improved	_	_	I-Premise
338	progression	_	_	I-Premise
339	-	_	_	I-Premise
340	free	_	_	I-Premise
341	survival	_	_	I-Premise
342	,	_	_	I-Premise
343	response	_	_	I-Premise
344	rate	_	_	I-Premise
345	,	_	_	I-Premise
346	and	_	_	I-Premise
347	disease	_	_	I-Premise
348	-	_	_	I-Premise
349	related	_	_	I-Premise
350	symptoms	_	_	I-Premise
351	versus	_	_	I-Premise
352	vinorelbine	_	_	I-Premise
353	.	_	_	I-Premise

354	Overall	_	_	B-Claim
355	survival	_	_	I-Claim
356	was	_	_	I-Claim
357	not	_	_	I-Claim
358	statistically	_	_	I-Claim
359	significantly	_	_	I-Claim
360	improved	_	_	I-Claim
361	at	_	_	I-Claim
362	this	_	_	I-Claim
363	time	_	_	I-Claim
364	.	_	_	I-Claim

365	Docetaxel	_	_	B-Claim
366	monotherapy	_	_	I-Claim
367	may	_	_	I-Claim
368	be	_	_	I-Claim
369	considered	_	_	I-Claim
370	as	_	_	I-Claim
371	an	_	_	I-Claim
372	option	_	_	I-Claim
373	in	_	_	I-Claim
374	the	_	_	I-Claim
375	standard	_	_	I-Claim
376	treatment	_	_	I-Claim
377	of	_	_	I-Claim
378	elderly	_	_	I-Claim
379	patients	_	_	I-Claim
380	with	_	_	I-Claim
381	advanced	_	_	I-Claim
382	NSCLC	_	_	I-Claim
383	.	_	_	I-Claim


0	Cancer	_	_	O
1	related	_	_	O
2	fatigue	_	_	O
3	(	_	_	O
4	CRF	_	_	O
5	)	_	_	O
6	is	_	_	O
7	a	_	_	O
8	common	_	_	O
9	problem	_	_	O
10	for	_	_	O
11	cancer	_	_	O
12	patients	_	_	O
13	across	_	_	O
14	diagnoses	_	_	O
15	during	_	_	O
16	chemotherapy	_	_	O
17	and	_	_	O
18	is	_	_	O
19	associated	_	_	O
20	with	_	_	O
21	physical	_	_	O
22	inactivity	_	_	O
23	,	_	_	O
24	lower	_	_	O
25	functional	_	_	O
26	level	_	_	O
27	and	_	_	O
28	lack	_	_	O
29	of	_	_	O
30	energy	_	_	O
31	.	_	_	O

32	Few	_	_	O
33	RCT	_	_	O
34	exercise	_	_	O
35	intervention	_	_	O
36	studies	_	_	O
37	have	_	_	O
38	included	_	_	O
39	cancer	_	_	O
40	patients	_	_	O
41	undergoing	_	_	O
42	chemotherapy	_	_	O
43	.	_	_	O

44	The	_	_	O
45	objective	_	_	O
46	of	_	_	O
47	this	_	_	O
48	study	_	_	O
49	is	_	_	O
50	to	_	_	O
51	evaluate	_	_	O
52	whether	_	_	O
53	a	_	_	O
54	six	_	_	O
55	-	_	_	O
56	week	_	_	O
57	supervised	_	_	O
58	multimodal	_	_	O
59	exercise	_	_	O
60	intervention	_	_	O
61	,	_	_	O
62	adjunct	_	_	O
63	to	_	_	O
64	chemotherapy	_	_	O
65	and	_	_	O
66	standard	_	_	O
67	care	_	_	O
68	,	_	_	O
69	can	_	_	O
70	reduce	_	_	O
71	the	_	_	O
72	patient	_	_	O
73	'	_	_	O
74	s	_	_	O
75	CRF	_	_	O
76	level	_	_	O
77	.	_	_	O

78	Data	_	_	O
79	is	_	_	O
80	based	_	_	O
81	on	_	_	O
82	analyses	_	_	O
83	of	_	_	O
84	a	_	_	O
85	prospective	_	_	O
86	randomised	_	_	O
87	controlled	_	_	O
88	trial	_	_	O
89	'	_	_	O
90	The	_	_	O
91	Body	_	_	O
92	Cancer	_	_	O
93	Trial	_	_	O
94	'	_	_	O
95	.	_	_	O

96	213	_	_	O
97	cancer	_	_	O
98	patients	_	_	O
99	with	_	_	O
100	different	_	_	O
101	diagnoses	_	_	O
102	were	_	_	O
103	randomised	_	_	O
104	into	_	_	O
105	an	_	_	O
106	intervention	_	_	O
107	group	_	_	O
108	or	_	_	O
109	wait	_	_	O
110	-	_	_	O
111	list	_	_	O
112	control	_	_	O
113	group	_	_	O
114	.	_	_	O

115	The	_	_	O
116	primary	_	_	O
117	outcome	_	_	O
118	,	_	_	O
119	Fatigue	_	_	O
120	score	_	_	O
121	(	_	_	O
122	CRF	_	_	O
123	)	_	_	O
124	,	_	_	O
125	was	_	_	O
126	evaluated	_	_	O
127	by	_	_	O
128	the	_	_	O
129	Functional	_	_	O
130	Assessment	_	_	O
131	of	_	_	O
132	Cancer	_	_	O
133	Therapy	_	_	O
134	-	_	_	O
135	Anaemia	_	_	O
136	Questionnaire	_	_	O
137	(	_	_	O
138	FACT	_	_	O
139	-	_	_	O
140	An	_	_	O
141	-	_	_	O
142	)	_	_	O
143	(	_	_	O
144	FACT	_	_	O
145	-	_	_	O
146	G	_	_	O
147	score	_	_	O
148	&	_	_	O
149	FACT	_	_	O
150	-	_	_	O
151	An	_	_	O
152	Anemia	_	_	O
153	subscale	_	_	O
154	)	_	_	O
155	.	_	_	O

156	Supervised	_	_	O
157	exercise	_	_	O
158	,	_	_	O
159	comprising	_	_	O
160	high	_	_	O
161	-	_	_	O
162	intensity	_	_	O
163	cardiovascular	_	_	O
164	and	_	_	O
165	heavy	_	_	O
166	resistance	_	_	O
167	training	_	_	O
168	,	_	_	O
169	relaxation	_	_	O
170	-	_	_	O
171	and	_	_	O
172	body	_	_	O
173	awareness	_	_	O
174	training	_	_	O
175	and	_	_	O
176	massage	_	_	O
177	,	_	_	O
178	9	_	_	O
179	h	_	_	O
180	weekly	_	_	O
181	for	_	_	O
182	6	_	_	O
183	weeks	_	_	O
184	.	_	_	O

185	CRF	_	_	B-Premise
186	was	_	_	I-Premise
187	significantly	_	_	I-Premise
188	reduced	_	_	I-Premise
189	in	_	_	I-Premise
190	the	_	_	I-Premise
191	intervention	_	_	I-Premise
192	group	_	_	I-Premise
193	,	_	_	I-Premise
194	corresponding	_	_	I-Premise
195	to	_	_	I-Premise
196	a	_	_	I-Premise
197	Fatigue	_	_	I-Premise
198	score	_	_	I-Premise
199	reduction	_	_	I-Premise
200	of	_	_	I-Premise
201	3	_	_	I-Premise
202	.	_	_	I-Premise

203	04	_	_	I-Premise
204	(	_	_	I-Premise
205	effect	_	_	I-Premise
206	size	_	_	I-Premise
207	of	_	_	I-Premise
208	0	_	_	I-Premise
209	.	_	_	I-Premise

210	44	_	_	I-Premise
211	,	_	_	I-Premise
212	95	_	_	I-Premise
213	%	_	_	I-Premise
214	CI	_	_	I-Premise
215	0	_	_	I-Premise
216	.	_	_	I-Premise

217	17	_	_	I-Premise
218	-	_	_	I-Premise
219	0	_	_	I-Premise
220	.	_	_	I-Premise

221	72	_	_	I-Premise
222	)	_	_	I-Premise
223	(	_	_	I-Premise
224	P	_	_	I-Premise
225	=	_	_	I-Premise
226	.	_	_	I-Premise

227	002	_	_	I-Premise
228	)	_	_	I-Premise
229	,	_	_	I-Premise
230	the	_	_	I-Premise
231	FACT	_	_	I-Premise
232	-	_	_	I-Premise
233	An	_	_	I-Premise
234	score	_	_	I-Premise
235	by	_	_	I-Premise
236	5	_	_	I-Premise
237	.	_	_	I-Premise

238	40	_	_	I-Premise
239	(	_	_	I-Premise
240	P	_	_	I-Premise
241	=	_	_	I-Premise
242	.	_	_	I-Premise

243	015	_	_	I-Premise
244	)	_	_	I-Premise
245	,	_	_	I-Premise
246	the	_	_	I-Premise
247	FACT	_	_	I-Premise
248	-	_	_	I-Premise
249	An	_	_	I-Premise
250	Toi	_	_	I-Premise
251	score	_	_	I-Premise
252	by	_	_	I-Premise
253	5	_	_	I-Premise
254	.	_	_	I-Premise

255	22	_	_	I-Premise
256	(	_	_	I-Premise
257	P	_	_	I-Premise
258	=	_	_	I-Premise
259	.	_	_	I-Premise

260	009	_	_	I-Premise
261	)	_	_	I-Premise
262	and	_	_	I-Premise
263	the	_	_	I-Premise
264	Anaemia	_	_	I-Premise
265	-	_	_	I-Premise
266	ANS	_	_	I-Premise
267	by	_	_	I-Premise
268	3	_	_	I-Premise
269	.	_	_	I-Premise

270	76	_	_	I-Premise
271	(	_	_	I-Premise
272	P	_	_	I-Premise
273	=	_	_	I-Premise
274	.	_	_	I-Premise

275	002	_	_	I-Premise
276	)	_	_	I-Premise
277	.	_	_	I-Premise

278	There	_	_	B-Premise
279	was	_	_	I-Premise
280	no	_	_	I-Premise
281	statistically	_	_	I-Premise
282	significant	_	_	I-Premise
283	effect	_	_	I-Premise
284	on	_	_	I-Premise
285	the	_	_	I-Premise
286	General	_	_	I-Premise
287	Quality	_	_	I-Premise
288	of	_	_	I-Premise
289	Life	_	_	I-Premise
290	score	_	_	I-Premise
291	(	_	_	I-Premise
292	FACT	_	_	I-Premise
293	-	_	_	I-Premise
294	G	_	_	I-Premise
295	)	_	_	I-Premise
296	or	_	_	I-Premise
297	on	_	_	I-Premise
298	any	_	_	I-Premise
299	of	_	_	I-Premise
300	the	_	_	I-Premise
301	individual	_	_	I-Premise
302	wellbeing	_	_	I-Premise
303	scores	_	_	I-Premise
304	;	_	_	I-Premise
305	Physical	_	_	I-Premise
306	(	_	_	I-Premise
307	P	_	_	I-Premise
308	=	_	_	I-Premise
309	.	_	_	I-Premise

310	13	_	_	I-Premise
311	)	_	_	I-Premise
312	,	_	_	I-Premise
313	Emotional	_	_	I-Premise
314	(	_	_	I-Premise
315	P	_	_	I-Premise
316	=	_	_	I-Premise
317	.	_	_	I-Premise

318	87	_	_	I-Premise
319	)	_	_	I-Premise
320	,	_	_	I-Premise
321	Social	_	_	I-Premise
322	(	_	_	I-Premise
323	P	_	_	I-Premise
324	=	_	_	I-Premise
325	.	_	_	I-Premise

326	83	_	_	I-Premise
327	)	_	_	I-Premise
328	and	_	_	I-Premise
329	Functional	_	_	I-Premise
330	(	_	_	I-Premise
331	P	_	_	I-Premise
332	=	_	_	I-Premise
333	.	_	_	I-Premise

334	26	_	_	I-Premise
335	)	_	_	I-Premise
336	.	_	_	I-Premise

337	In	_	_	B-Claim
338	summary	_	_	I-Claim
339	,	_	_	I-Claim
340	this	_	_	I-Claim
341	six	_	_	I-Claim
342	-	_	_	I-Claim
343	week	_	_	I-Claim
344	supervised	_	_	I-Claim
345	multimodal	_	_	I-Claim
346	exercise	_	_	I-Claim
347	intervention	_	_	I-Claim
348	can	_	_	I-Claim
349	lead	_	_	I-Claim
350	to	_	_	I-Claim
351	significant	_	_	I-Claim
352	reduction	_	_	I-Claim
353	in	_	_	I-Claim
354	self	_	_	I-Claim
355	-	_	_	I-Claim
356	reported	_	_	I-Claim
357	CRF	_	_	I-Claim
358	in	_	_	I-Claim
359	cancer	_	_	I-Claim
360	patients	_	_	I-Claim
361	undergoing	_	_	I-Claim
362	chemotherapy	_	_	I-Claim
363	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	whether	_	_	O
3	patients	_	_	O
4	with	_	_	O
5	locally	_	_	O
6	advanced	_	_	O
7	non	_	_	O
8	-	_	_	O
9	small	_	_	O
10	cell	_	_	O
11	lung	_	_	O
12	cancer	_	_	O
13	unsuitable	_	_	O
14	for	_	_	O
15	resection	_	_	O
16	or	_	_	O
17	radical	_	_	O
18	radiotherapy	_	_	O
19	,	_	_	O
20	and	_	_	O
21	with	_	_	O
22	minimal	_	_	O
23	thoracic	_	_	O
24	symptoms	_	_	O
25	,	_	_	O
26	should	_	_	O
27	be	_	_	O
28	given	_	_	O
29	palliative	_	_	O
30	thoracic	_	_	O
31	radiotherapy	_	_	O
32	immediately	_	_	O
33	or	_	_	O
34	as	_	_	O
35	needed	_	_	O
36	to	_	_	O
37	treat	_	_	O
38	symptoms	_	_	O
39	.	_	_	O

40	Multicentre	_	_	O
41	randomised	_	_	O
42	controlled	_	_	O
43	trial	_	_	O
44	.	_	_	O

45	23	_	_	O
46	centres	_	_	O
47	in	_	_	O
48	the	_	_	O
49	United	_	_	O
50	Kingdom	_	_	O
51	,	_	_	O
52	Ireland	_	_	O
53	,	_	_	O
54	and	_	_	O
55	South	_	_	O
56	Africa	_	_	O
57	.	_	_	O

58	230	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	previously	_	_	O
62	untreated	_	_	O
63	,	_	_	O
64	non	_	_	O
65	-	_	_	O
66	small	_	_	O
67	cell	_	_	O
68	lung	_	_	O
69	cancer	_	_	O
70	that	_	_	O
71	is	_	_	O
72	locally	_	_	O
73	too	_	_	O
74	advanced	_	_	O
75	for	_	_	O
76	resection	_	_	O
77	or	_	_	O
78	radical	_	_	O
79	radiotherapy	_	_	O
80	with	_	_	O
81	curative	_	_	O
82	intent	_	_	O
83	,	_	_	O
84	with	_	_	O
85	minimal	_	_	O
86	thoracic	_	_	O
87	symptoms	_	_	O
88	,	_	_	O
89	and	_	_	O
90	with	_	_	O
91	no	_	_	O
92	indication	_	_	O
93	for	_	_	O
94	immediate	_	_	O
95	thoracic	_	_	O
96	radiotherapy	_	_	O
97	.	_	_	O

98	All	_	_	O
99	patients	_	_	O
100	were	_	_	O
101	given	_	_	O
102	supportive	_	_	O
103	treatment	_	_	O
104	and	_	_	O
105	were	_	_	O
106	randomised	_	_	O
107	to	_	_	O
108	receive	_	_	O
109	palliative	_	_	O
110	thoracic	_	_	O
111	radiotherapy	_	_	O
112	either	_	_	O
113	immediately	_	_	O
114	or	_	_	O
115	delayed	_	_	O
116	until	_	_	O
117	needed	_	_	O
118	to	_	_	O
119	treat	_	_	O
120	symptoms	_	_	O
121	.	_	_	O

122	The	_	_	O
123	recommended	_	_	O
124	regimens	_	_	O
125	were	_	_	O
126	17	_	_	O
127	Gy	_	_	O
128	in	_	_	O
129	two	_	_	O
130	fractions	_	_	O
131	one	_	_	O
132	week	_	_	O
133	apart	_	_	O
134	or	_	_	O
135	10	_	_	O
136	Gy	_	_	O
137	as	_	_	O
138	a	_	_	O
139	single	_	_	O
140	dose	_	_	O
141	.	_	_	O

142	Primary	_	_	O
143	-	_	_	O
144	-	_	_	O
145	patients	_	_	O
146	alive	_	_	O
147	and	_	_	O
148	without	_	_	O
149	moderate	_	_	O
150	or	_	_	O
151	severe	_	_	O
152	cough	_	_	O
153	,	_	_	O
154	chest	_	_	O
155	pain	_	_	O
156	,	_	_	O
157	haemoptysis	_	_	O
158	,	_	_	O
159	or	_	_	O
160	dyspnoea	_	_	O
161	six	_	_	O
162	months	_	_	O
163	from	_	_	O
164	randomisation	_	_	O
165	,	_	_	O
166	as	_	_	O
167	recorded	_	_	O
168	by	_	_	O
169	clinicians	_	_	O
170	.	_	_	O

171	Secondary	_	_	O
172	-	_	_	O
173	-	_	_	O
174	quality	_	_	O
175	of	_	_	O
176	life	_	_	O
177	,	_	_	O
178	adverse	_	_	O
179	events	_	_	O
180	,	_	_	O
181	survival	_	_	O
182	.	_	_	O

183	From	_	_	O
184	December	_	_	O
185	1992	_	_	O
186	to	_	_	O
187	May	_	_	O
188	1999	_	_	O
189	,	_	_	O
190	230	_	_	O
191	patients	_	_	O
192	were	_	_	O
193	randomised	_	_	O
194	.	_	_	O

195	104	_	_	O
196	/	_	_	O
197	115	_	_	O
198	of	_	_	O
199	the	_	_	O
200	patients	_	_	O
201	in	_	_	O
202	the	_	_	O
203	immediate	_	_	O
204	treatment	_	_	O
205	group	_	_	O
206	received	_	_	O
207	thoracic	_	_	O
208	radiotherapy	_	_	O
209	(	_	_	O
210	90	_	_	O
211	received	_	_	O
212	one	_	_	O
213	of	_	_	O
214	the	_	_	O
215	recommended	_	_	O
216	regimens	_	_	O
217	)	_	_	O
218	.	_	_	O

219	In	_	_	O
220	the	_	_	O
221	delayed	_	_	O
222	treatment	_	_	O
223	group	_	_	O
224	,	_	_	O
225	48	_	_	O
226	/	_	_	O
227	115	_	_	O
228	(	_	_	O
229	42	_	_	O
230	%	_	_	O
231	)	_	_	O
232	patients	_	_	O
233	received	_	_	O
234	thoracic	_	_	O
235	radiotherapy	_	_	O
236	(	_	_	O
237	29	_	_	O
238	received	_	_	O
239	one	_	_	O
240	of	_	_	O
241	the	_	_	O
242	recommended	_	_	O
243	regimens	_	_	O
244	)	_	_	O
245	;	_	_	O
246	64	_	_	O
247	(	_	_	O
248	56	_	_	O
249	%	_	_	O
250	)	_	_	O
251	died	_	_	O
252	without	_	_	O
253	receiving	_	_	O
254	thoracic	_	_	O
255	radiotherapy	_	_	O
256	;	_	_	O
257	the	_	_	O
258	remaining	_	_	O
259	three	_	_	O
260	(	_	_	O
261	3	_	_	O
262	%	_	_	O
263	)	_	_	O
264	were	_	_	O
265	alive	_	_	O
266	at	_	_	O
267	the	_	_	O
268	end	_	_	O
269	of	_	_	O
270	the	_	_	O
271	study	_	_	O
272	without	_	_	O
273	having	_	_	O
274	received	_	_	O
275	the	_	_	O
276	treatment	_	_	O
277	.	_	_	O

278	For	_	_	O
279	patients	_	_	O
280	who	_	_	O
281	received	_	_	O
282	thoracic	_	_	O
283	radiotherapy	_	_	O
284	,	_	_	O
285	the	_	_	O
286	median	_	_	O
287	time	_	_	O
288	to	_	_	O
289	start	_	_	O
290	was	_	_	O
291	15	_	_	O
292	days	_	_	O
293	in	_	_	O
294	the	_	_	O
295	immediate	_	_	O
296	treatment	_	_	O
297	group	_	_	O
298	and	_	_	O
299	125	_	_	O
300	days	_	_	O
301	in	_	_	O
302	the	_	_	O
303	delayed	_	_	O
304	treatment	_	_	O
305	group	_	_	O
306	.	_	_	O

307	The	_	_	B-Premise
308	primary	_	_	I-Premise
309	outcome	_	_	I-Premise
310	measure	_	_	I-Premise
311	was	_	_	I-Premise
312	achieved	_	_	I-Premise
313	in	_	_	I-Premise
314	28	_	_	I-Premise
315	%	_	_	I-Premise
316	of	_	_	I-Premise
317	the	_	_	I-Premise
318	immediate	_	_	I-Premise
319	treatment	_	_	I-Premise
320	group	_	_	I-Premise
321	and	_	_	I-Premise
322	26	_	_	I-Premise
323	%	_	_	I-Premise
324	of	_	_	I-Premise
325	patients	_	_	I-Premise
326	from	_	_	I-Premise
327	the	_	_	I-Premise
328	delayed	_	_	I-Premise
329	treatment	_	_	I-Premise
330	group	_	_	I-Premise
331	(	_	_	I-Premise
332	27	_	_	I-Premise
333	/	_	_	I-Premise
334	97	_	_	I-Premise
335	and	_	_	I-Premise
336	27	_	_	I-Premise
337	/	_	_	I-Premise
338	103	_	_	I-Premise
339	,	_	_	I-Premise
340	respectively	_	_	I-Premise
341	;	_	_	I-Premise
342	absolute	_	_	I-Premise
343	difference	_	_	I-Premise
344	1	_	_	I-Premise
345	.	_	_	I-Premise

346	6	_	_	I-Premise
347	%	_	_	I-Premise
348	,	_	_	I-Premise
349	95	_	_	I-Premise
350	%	_	_	I-Premise
351	confidence	_	_	I-Premise
352	interval	_	_	I-Premise
353	-	_	_	I-Premise
354	10	_	_	I-Premise
355	.	_	_	I-Premise

356	7	_	_	I-Premise
357	%	_	_	I-Premise
358	to	_	_	I-Premise
359	13	_	_	I-Premise
360	.	_	_	I-Premise

361	9	_	_	I-Premise
362	%	_	_	I-Premise
363	)	_	_	I-Premise
364	.	_	_	I-Premise

365	No	_	_	B-Premise
366	evidence	_	_	I-Premise
367	of	_	_	I-Premise
368	a	_	_	I-Premise
369	difference	_	_	I-Premise
370	was	_	_	I-Premise
371	observed	_	_	I-Premise
372	between	_	_	I-Premise
373	the	_	_	I-Premise
374	two	_	_	I-Premise
375	treatment	_	_	I-Premise
376	groups	_	_	I-Premise
377	in	_	_	I-Premise
378	terms	_	_	I-Premise
379	of	_	_	I-Premise
380	activity	_	_	I-Premise
381	level	_	_	I-Premise
382	,	_	_	I-Premise
383	anxiety	_	_	I-Premise
384	,	_	_	I-Premise
385	depression	_	_	I-Premise
386	,	_	_	I-Premise
387	and	_	_	I-Premise
388	psychological	_	_	I-Premise
389	distress	_	_	I-Premise
390	,	_	_	I-Premise
391	as	_	_	I-Premise
392	recorded	_	_	I-Premise
393	by	_	_	I-Premise
394	the	_	_	I-Premise
395	patients	_	_	I-Premise
396	.	_	_	I-Premise

397	Adverse	_	_	B-Premise
398	events	_	_	I-Premise
399	were	_	_	I-Premise
400	more	_	_	I-Premise
401	common	_	_	I-Premise
402	in	_	_	I-Premise
403	the	_	_	I-Premise
404	immediate	_	_	I-Premise
405	treatment	_	_	I-Premise
406	group	_	_	I-Premise
407	.	_	_	I-Premise

408	Neither	_	_	B-Premise
409	group	_	_	I-Premise
410	had	_	_	I-Premise
411	a	_	_	I-Premise
412	survival	_	_	I-Premise
413	advantage	_	_	I-Premise
414	(	_	_	I-Premise
415	hazard	_	_	I-Premise
416	ratio	_	_	I-Premise
417	0	_	_	I-Premise
418	.	_	_	I-Premise

419	95	_	_	I-Premise
420	,	_	_	I-Premise
421	0	_	_	I-Premise
422	.	_	_	I-Premise

423	73	_	_	I-Premise
424	to	_	_	I-Premise
425	1	_	_	I-Premise
426	.	_	_	I-Premise

427	24	_	_	I-Premise
428	;	_	_	I-Premise
429	P	_	_	I-Premise
430	=	_	_	I-Premise
431	0	_	_	I-Premise
432	.	_	_	I-Premise

433	71	_	_	I-Premise
434	)	_	_	I-Premise
435	.	_	_	I-Premise

436	Median	_	_	B-Premise
437	survival	_	_	I-Premise
438	was	_	_	I-Premise
439	8	_	_	I-Premise
440	.	_	_	I-Premise

441	3	_	_	I-Premise
442	months	_	_	I-Premise
443	and	_	_	I-Premise
444	7	_	_	I-Premise
445	.	_	_	I-Premise

446	9	_	_	I-Premise
447	months	_	_	I-Premise
448	,	_	_	I-Premise
449	and	_	_	O
450	the	_	_	B-Premise
451	survival	_	_	I-Premise
452	rates	_	_	I-Premise
453	were	_	_	I-Premise
454	31	_	_	I-Premise
455	%	_	_	I-Premise
456	and	_	_	I-Premise
457	29	_	_	I-Premise
458	%	_	_	I-Premise
459	at	_	_	I-Premise
460	12	_	_	I-Premise
461	months	_	_	I-Premise
462	,	_	_	I-Premise
463	for	_	_	I-Premise
464	the	_	_	I-Premise
465	immediate	_	_	I-Premise
466	and	_	_	I-Premise
467	delayed	_	_	I-Premise
468	treatment	_	_	I-Premise
469	groups	_	_	I-Premise
470	,	_	_	I-Premise
471	respectively	_	_	I-Premise
472	.	_	_	I-Premise

473	In	_	_	B-Claim
474	minimally	_	_	I-Claim
475	symptomatic	_	_	I-Claim
476	patients	_	_	I-Claim
477	with	_	_	I-Claim
478	locally	_	_	I-Claim
479	advanced	_	_	I-Claim
480	non	_	_	I-Claim
481	-	_	_	I-Claim
482	small	_	_	I-Claim
483	cell	_	_	I-Claim
484	lung	_	_	I-Claim
485	cancer	_	_	I-Claim
486	,	_	_	I-Claim
487	no	_	_	I-Claim
488	persuasive	_	_	I-Claim
489	evidence	_	_	I-Claim
490	was	_	_	I-Claim
491	found	_	_	I-Claim
492	to	_	_	I-Claim
493	indicate	_	_	I-Claim
494	that	_	_	I-Claim
495	giving	_	_	I-Claim
496	immediate	_	_	I-Claim
497	palliative	_	_	I-Claim
498	thoracic	_	_	I-Claim
499	radiotherapy	_	_	I-Claim
500	improves	_	_	I-Claim
501	symptom	_	_	I-Claim
502	control	_	_	I-Claim
503	,	_	_	I-Claim
504	quality	_	_	I-Claim
505	of	_	_	I-Claim
506	life	_	_	I-Claim
507	,	_	_	I-Claim
508	or	_	_	I-Claim
509	survival	_	_	I-Claim
510	when	_	_	I-Claim
511	compared	_	_	I-Claim
512	with	_	_	I-Claim
513	delaying	_	_	I-Claim
514	until	_	_	I-Claim
515	symptoms	_	_	I-Claim
516	require	_	_	I-Claim
517	treatment	_	_	I-Claim
518	.	_	_	I-Claim


0	A	_	_	O
1	randomized	_	_	O
2	controlled	_	_	O
3	trial	_	_	O
4	was	_	_	O
5	performed	_	_	O
6	to	_	_	O
7	assess	_	_	O
8	the	_	_	O
9	outcome	_	_	O
10	of	_	_	O
11	early	_	_	O
12	oral	_	_	O
13	postoperative	_	_	O
14	feeding	_	_	O
15	(	_	_	O
16	EOF	_	_	O
17	)	_	_	O
18	compared	_	_	O
19	with	_	_	O
20	traditional	_	_	O
21	oral	_	_	O
22	feeding	_	_	O
23	(	_	_	O
24	TOF	_	_	O
25	)	_	_	O
26	in	_	_	O
27	gynecologic	_	_	O
28	oncology	_	_	O
29	patients	_	_	O
30	undergoing	_	_	O
31	a	_	_	O
32	complex	_	_	O
33	laparotomy	_	_	O
34	,	_	_	O
35	including	_	_	O
36	upper	_	_	O
37	abdominal	_	_	O
38	surgery	_	_	O
39	.	_	_	O

40	Patients	_	_	O
41	aged	_	_	O
42	18	_	_	O
43	-	_	_	O
44	75	_	_	O
45	years	_	_	O
46	,	_	_	O
47	undergoing	_	_	O
48	an	_	_	O
49	elective	_	_	O
50	laparotomy	_	_	O
51	and	_	_	O
52	with	_	_	O
53	a	_	_	O
54	preoperative	_	_	O
55	suspicion	_	_	O
56	of	_	_	O
57	gynecologic	_	_	O
58	malignancy	_	_	O
59	,	_	_	O
60	were	_	_	O
61	eligible	_	_	O
62	.	_	_	O

63	Exclusion	_	_	O
64	criteria	_	_	O
65	included	_	_	O
66	infectious	_	_	O
67	conditions	_	_	O
68	,	_	_	O
69	intestinal	_	_	O
70	obstruction	_	_	O
71	,	_	_	O
72	severe	_	_	O
73	malnutrition	_	_	O
74	,	_	_	O
75	American	_	_	O
76	Society	_	_	O
77	of	_	_	O
78	Anesthesiologists	_	_	O
79	score	_	_	O
80	C4	_	_	O
81	,	_	_	O
82	intestinal	_	_	O
83	resection	_	_	O
84	,	_	_	O
85	and	_	_	O
86	postoperative	_	_	O
87	stay	_	_	O
88	in	_	_	O
89	the	_	_	O
90	intensive	_	_	O
91	care	_	_	O
92	unit	_	_	O
93	lasting	_	_	O
94	24	_	_	O
95	h	_	_	O
96	.	_	_	O

97	Patients	_	_	O
98	allocated	_	_	O
99	to	_	_	O
100	EOF	_	_	O
101	received	_	_	O
102	liquid	_	_	O
103	diet	_	_	O
104	in	_	_	O
105	the	_	_	O
106	first	_	_	O
107	postoperative	_	_	O
108	day	_	_	O
109	and	_	_	O
110	then	_	_	O
111	regular	_	_	O
112	diet	_	_	O
113	.	_	_	O

114	Patients	_	_	O
115	received	_	_	O
116	traditional	_	_	O
117	feeding	_	_	O
118	scheme	_	_	O
119	until	_	_	O
120	resolution	_	_	O
121	of	_	_	O
122	postoperative	_	_	O
123	ileus	_	_	O
124	to	_	_	O
125	start	_	_	O
126	liquid	_	_	O
127	diet	_	_	O
128	.	_	_	O

129	The	_	_	O
130	primary	_	_	O
131	end	_	_	O
132	-	_	_	O
133	point	_	_	O
134	of	_	_	O
135	the	_	_	O
136	trial	_	_	O
137	was	_	_	O
138	length	_	_	O
139	of	_	_	O
140	hospital	_	_	O
141	stay	_	_	O
142	.	_	_	O

143	Between	_	_	O
144	January	_	_	O
145	1	_	_	O
146	,	_	_	O
147	2007	_	_	O
148	,	_	_	O
149	and	_	_	O
150	November	_	_	O
151	17	_	_	O
152	,	_	_	O
153	2007	_	_	O
154	,	_	_	O
155	a	_	_	O
156	total	_	_	O
157	of	_	_	O
158	143	_	_	O
159	patients	_	_	O
160	were	_	_	O
161	randomized	_	_	O
162	to	_	_	O
163	receive	_	_	O
164	either	_	_	O
165	EOF	_	_	O
166	or	_	_	O
167	TOF	_	_	O
168	.	_	_	O

169	Hospital	_	_	B-Premise
170	stay	_	_	I-Premise
171	for	_	_	I-Premise
172	patients	_	_	I-Premise
173	who	_	_	I-Premise
174	received	_	_	I-Premise
175	EOF	_	_	I-Premise
176	(	_	_	I-Premise
177	n	_	_	I-Premise
178	=	_	_	I-Premise
179	71	_	_	I-Premise
180	)	_	_	I-Premise
181	was	_	_	I-Premise
182	4	_	_	I-Premise
183	.	_	_	I-Premise

184	7	_	_	I-Premise
185	vs	_	_	I-Premise
186	.	_	_	I-Premise

187	5	_	_	I-Premise
188	.	_	_	I-Premise

189	8	_	_	I-Premise
190	days	_	_	I-Premise
191	for	_	_	I-Premise
192	the	_	_	I-Premise
193	TOF	_	_	I-Premise
194	group	_	_	I-Premise
195	(	_	_	I-Premise
196	n	_	_	I-Premise
197	=	_	_	I-Premise
198	72	_	_	I-Premise
199	)	_	_	I-Premise
200	(	_	_	I-Premise
201	P	_	_	I-Premise
202	=	_	_	I-Premise
203	0	_	_	I-Premise
204	.	_	_	I-Premise

205	006	_	_	I-Premise
206	)	_	_	I-Premise
207	.	_	_	I-Premise

208	The	_	_	B-Premise
209	mean	_	_	I-Premise
210	level	_	_	I-Premise
211	of	_	_	I-Premise
212	postoperative	_	_	I-Premise
213	satisfaction	_	_	I-Premise
214	was	_	_	I-Premise
215	significantly	_	_	I-Premise
216	higher	_	_	I-Premise
217	in	_	_	I-Premise
218	the	_	_	I-Premise
219	EOF	_	_	I-Premise
220	group	_	_	I-Premise
221	(	_	_	I-Premise
222	82	_	_	I-Premise
223	.	_	_	I-Premise

224	8	_	_	I-Premise
225	vs	_	_	I-Premise
226	.	_	_	I-Premise

227	71	_	_	I-Premise
228	.	_	_	I-Premise

229	7	_	_	I-Premise
230	mm	_	_	I-Premise
231	,	_	_	I-Premise
232	P	_	_	I-Premise
233	B	_	_	I-Premise
234	0	_	_	I-Premise
235	.	_	_	I-Premise

236	001	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	Patients	_	_	B-Premise
240	who	_	_	I-Premise
241	received	_	_	I-Premise
242	the	_	_	I-Premise
243	TOF	_	_	I-Premise
244	scheme	_	_	I-Premise
245	had	_	_	I-Premise
246	significantly	_	_	I-Premise
247	higher	_	_	I-Premise
248	overall	_	_	I-Premise
249	postoperative	_	_	I-Premise
250	complications	_	_	I-Premise
251	(	_	_	I-Premise
252	39	_	_	I-Premise
253	vs	_	_	I-Premise
254	.	_	_	I-Premise

255	17	_	_	I-Premise
256	%	_	_	I-Premise
257	in	_	_	I-Premise
258	EOF	_	_	I-Premise
259	group	_	_	I-Premise
260	,	_	_	I-Premise
261	P	_	_	I-Premise
262	=	_	_	I-Premise
263	0	_	_	I-Premise
264	.	_	_	I-Premise

265	003	_	_	I-Premise
266	)	_	_	I-Premise
267	and	_	_	I-Premise
268	infective	_	_	I-Premise
269	complications	_	_	I-Premise
270	(	_	_	I-Premise
271	14	_	_	I-Premise
272	%	_	_	I-Premise
273	in	_	_	I-Premise
274	TOF	_	_	I-Premise
275	group	_	_	I-Premise
276	vs	_	_	I-Premise
277	.	_	_	I-Premise

278	3	_	_	I-Premise
279	%	_	_	I-Premise
280	in	_	_	I-Premise
281	EOF	_	_	I-Premise
282	group	_	_	I-Premise
283	,	_	_	I-Premise
284	P	_	_	I-Premise
285	=	_	_	I-Premise
286	0	_	_	I-Premise
287	.	_	_	I-Premise

288	017	_	_	I-Premise
289	)	_	_	I-Premise
290	.	_	_	I-Premise

291	Variables	_	_	B-Premise
292	such	_	_	I-Premise
293	as	_	_	I-Premise
294	nausea	_	_	I-Premise
295	and	_	_	I-Premise
296	vomiting	_	_	I-Premise
297	,	_	_	I-Premise
298	analgesic	_	_	I-Premise
299	and	_	_	I-Premise
300	antiemetic	_	_	I-Premise
301	requirement	_	_	I-Premise
302	as	_	_	I-Premise
303	well	_	_	I-Premise
304	as	_	_	I-Premise
305	level	_	_	I-Premise
306	of	_	_	I-Premise
307	pain	_	_	I-Premise
308	and	_	_	I-Premise
309	quality	_	_	I-Premise
310	of	_	_	I-Premise
311	life	_	_	I-Premise
312	were	_	_	I-Premise
313	not	_	_	I-Premise
314	different	_	_	I-Premise
315	between	_	_	I-Premise
316	groups	_	_	I-Premise
317	.	_	_	I-Premise

318	On	_	_	B-Claim
319	the	_	_	I-Claim
320	basis	_	_	I-Claim
321	of	_	_	I-Claim
322	these	_	_	I-Claim
323	findings	_	_	I-Claim
324	,	_	_	I-Claim
325	the	_	_	I-Claim
326	policy	_	_	I-Claim
327	of	_	_	I-Claim
328	EOF	_	_	I-Claim
329	should	_	_	I-Claim
330	be	_	_	I-Claim
331	used	_	_	I-Claim
332	after	_	_	I-Claim
333	a	_	_	I-Claim
334	complex	_	_	I-Claim
335	gynecologic	_	_	I-Claim
336	oncologic	_	_	I-Claim
337	laparotomy	_	_	I-Claim
338	.	_	_	I-Claim


0	Many	_	_	O
1	women	_	_	O
2	with	_	_	O
3	breast	_	_	O
4	cancer	_	_	O
5	need	_	_	O
6	psychological	_	_	O
7	help	_	_	O
8	to	_	_	O
9	cope	_	_	O
10	more	_	_	O
11	effectively	_	_	O
12	after	_	_	O
13	treatment	_	_	O
14	.	_	_	O

15	Cognitive	_	_	O
16	and	_	_	O
17	behavioural	_	_	O
18	techniques	_	_	O
19	are	_	_	O
20	not	_	_	O
21	yet	_	_	O
22	well	_	_	O
23	established	_	_	O
24	in	_	_	O
25	France	_	_	O
26	.	_	_	O

27	A	_	_	O
28	multi	_	_	O
29	-	_	_	O
30	site	_	_	O
31	randomized	_	_	O
32	study	_	_	O
33	was	_	_	O
34	conducted	_	_	O
35	to	_	_	O
36	evaluate	_	_	O
37	the	_	_	O
38	effects	_	_	O
39	of	_	_	O
40	a	_	_	O
41	psycho	_	_	O
42	-	_	_	O
43	educational	_	_	O
44	group	_	_	O
45	intervention	_	_	O
46	in	_	_	O
47	this	_	_	O
48	population	_	_	O
49	.	_	_	O

50	Two	_	_	O
51	hundred	_	_	O
52	and	_	_	O
53	three	_	_	O
54	patients	_	_	O
55	,	_	_	O
56	recruited	_	_	O
57	after	_	_	O
58	primary	_	_	O
59	treatment	_	_	O
60	,	_	_	O
61	were	_	_	O
62	randomly	_	_	O
63	assigned	_	_	O
64	either	_	_	O
65	to	_	_	O
66	a	_	_	O
67	treatment	_	_	O
68	group	_	_	O
69	(	_	_	O
70	psycho	_	_	O
71	-	_	_	O
72	educational	_	_	O
73	intervention	_	_	O
74	)	_	_	O
75	or	_	_	O
76	to	_	_	O
77	a	_	_	O
78	waiting	_	_	O
79	-	_	_	O
80	list	_	_	O
81	control	_	_	O
82	group	_	_	O
83	.	_	_	O

84	The	_	_	O
85	8	_	_	O
86	-	_	_	O
87	week	_	_	O
88	programme	_	_	O
89	of	_	_	O
90	2	_	_	O
91	h	_	_	O
92	sessions	_	_	O
93	comprised	_	_	O
94	of	_	_	O
95	thematic	_	_	O
96	discussions	_	_	O
97	,	_	_	O
98	information	_	_	O
99	and	_	_	O
100	training	_	_	O
101	in	_	_	O
102	stress	_	_	O
103	management	_	_	O
104	techniques	_	_	O
105	.	_	_	O

106	Evaluation	_	_	O
107	at	_	_	O
108	baseline	_	_	O
109	,	_	_	O
110	after	_	_	O
111	8	_	_	O
112	sessions	_	_	O
113	,	_	_	O
114	and	_	_	O
115	1	_	_	O
116	month	_	_	O
117	after	_	_	O
118	programme	_	_	O
119	completion	_	_	O
120	,	_	_	O
121	included	_	_	O
122	evaluations	_	_	O
123	using	_	_	O
124	the	_	_	O
125	STAI	_	_	O
126	,	_	_	O
127	POMS	_	_	O
128	,	_	_	O
129	MAC	_	_	O
130	,	_	_	O
131	EORTC	_	_	O
132	QLQ	_	_	O
133	-	_	_	O
134	C30	_	_	O
135	and	_	_	O
136	EORTC	_	_	O
137	QLQ	_	_	O
138	-	_	_	O
139	BR23	_	_	O
140	breast	_	_	O
141	module	_	_	O
142	scales	_	_	O
143	.	_	_	O

144	We	_	_	B-Premise
145	observed	_	_	I-Premise
146	a	_	_	I-Premise
147	significant	_	_	I-Premise
148	reduction	_	_	I-Premise
149	in	_	_	I-Premise
150	anxiety	_	_	I-Premise
151	(	_	_	I-Premise
152	STAI	_	_	I-Premise
153	,	_	_	I-Premise
154	POMS	_	_	I-Premise
155	)	_	_	I-Premise
156	among	_	_	I-Premise
157	group	_	_	I-Premise
158	participants	_	_	I-Premise
159	,	_	_	I-Premise
160	a	_	_	I-Premise
161	reduction	_	_	I-Premise
162	in	_	_	I-Premise
163	anger	_	_	I-Premise
164	,	_	_	I-Premise
165	depression	_	_	I-Premise
166	and	_	_	I-Premise
167	fatigue	_	_	I-Premise
168	(	_	_	I-Premise
169	POMS	_	_	I-Premise
170	)	_	_	I-Premise
171	,	_	_	I-Premise
172	a	_	_	I-Premise
173	significant	_	_	I-Premise
174	improvement	_	_	I-Premise
175	in	_	_	I-Premise
176	vigor	_	_	I-Premise
177	and	_	_	I-Premise
178	interpersonal	_	_	I-Premise
179	relationships	_	_	I-Premise
180	(	_	_	I-Premise
181	POMS	_	_	I-Premise
182	)	_	_	I-Premise
183	,	_	_	I-Premise
184	in	_	_	I-Premise
185	emotional	_	_	I-Premise
186	and	_	_	I-Premise
187	role	_	_	I-Premise
188	functioning	_	_	I-Premise
189	,	_	_	I-Premise
190	in	_	_	I-Premise
191	health	_	_	I-Premise
192	status	_	_	I-Premise
193	and	_	_	I-Premise
194	fatigue	_	_	I-Premise
195	level	_	_	I-Premise
196	(	_	_	I-Premise
197	EORTC	_	_	I-Premise
198	QLQ	_	_	I-Premise
199	-	_	_	I-Premise
200	C30	_	_	I-Premise
201	)	_	_	I-Premise
202	.	_	_	I-Premise

203	In	_	_	O
204	contrast	_	_	O
205	,	_	_	O
206	coping	_	_	B-Premise
207	strategies	_	_	I-Premise
208	(	_	_	I-Premise
209	MAC	_	_	I-Premise
210	)	_	_	I-Premise
211	were	_	_	I-Premise
212	not	_	_	I-Premise
213	significantly	_	_	I-Premise
214	different	_	_	I-Premise
215	between	_	_	I-Premise
216	groups	_	_	I-Premise
217	.	_	_	I-Premise

218	No	_	_	B-Premise
219	group	_	_	I-Premise
220	-	_	_	I-Premise
221	related	_	_	I-Premise
222	negative	_	_	I-Premise
223	effects	_	_	I-Premise
224	were	_	_	I-Premise
225	observed	_	_	I-Premise
226	and	_	_	I-Premise
227	the	_	_	I-Premise
228	global	_	_	I-Premise
229	satisfaction	_	_	I-Premise
230	levels	_	_	I-Premise
231	were	_	_	I-Premise
232	very	_	_	I-Premise
233	high	_	_	I-Premise
234	.	_	_	I-Premise

235	This	_	_	B-Claim
236	study	_	_	I-Claim
237	demonstrates	_	_	I-Claim
238	the	_	_	I-Claim
239	feasibility	_	_	I-Claim
240	and	_	_	I-Claim
241	effectiveness	_	_	I-Claim
242	of	_	_	I-Claim
243	a	_	_	I-Claim
244	psycho	_	_	I-Claim
245	-	_	_	I-Claim
246	educational	_	_	I-Claim
247	intervention	_	_	I-Claim
248	,	_	_	I-Claim
249	which	_	_	I-Claim
250	can	_	_	I-Claim
251	accelerate	_	_	I-Claim
252	the	_	_	I-Claim
253	reduction	_	_	I-Claim
254	of	_	_	I-Claim
255	those	_	_	I-Claim
256	negative	_	_	I-Claim
257	affects	_	_	I-Claim
258	which	_	_	I-Claim
259	are	_	_	I-Claim
260	present	_	_	I-Claim
261	at	_	_	I-Claim
262	the	_	_	I-Claim
263	end	_	_	I-Claim
264	of	_	_	I-Claim
265	treatment	_	_	I-Claim
266	.	_	_	I-Claim

267	It	_	_	B-Claim
268	represents	_	_	I-Claim
269	an	_	_	I-Claim
270	excellent	_	_	I-Claim
271	complement	_	_	I-Claim
272	or	_	_	I-Claim
273	an	_	_	I-Claim
274	alternative	_	_	I-Claim
275	to	_	_	I-Claim
276	individual	_	_	I-Claim
277	psycho	_	_	I-Claim
278	-	_	_	I-Claim
279	oncologic	_	_	I-Claim
280	therapeutic	_	_	I-Claim
281	support	_	_	I-Claim
282	,	_	_	I-Claim
283	widely	_	_	O
284	proposed	_	_	O
285	in	_	_	O
286	France	_	_	O
287	,	_	_	O
288	and	_	_	O
289	should	_	_	O
290	now	_	_	O
291	be	_	_	O
292	tested	_	_	O
293	in	_	_	O
294	groups	_	_	O
295	with	_	_	O
296	other	_	_	O
297	types	_	_	O
298	of	_	_	O
299	cancer	_	_	O
300	and	_	_	O
301	at	_	_	O
302	other	_	_	O
303	disease	_	_	O
304	phases	_	_	O
305	.	_	_	O


0	The	_	_	B-Claim
1	addition	_	_	I-Claim
2	of	_	_	I-Claim
3	bevacizumab	_	_	I-Claim
4	to	_	_	I-Claim
5	paclitaxel	_	_	I-Claim
6	improved	_	_	I-Claim
7	progression	_	_	I-Claim
8	-	_	_	I-Claim
9	free	_	_	I-Claim
10	survival	_	_	I-Claim
11	(	_	_	I-Claim
12	PFS	_	_	I-Claim
13	)	_	_	I-Claim
14	of	_	_	I-Claim
15	patients	_	_	I-Claim
16	with	_	_	I-Claim
17	metastatic	_	_	I-Claim
18	breast	_	_	I-Claim
19	cancer	_	_	I-Claim
20	(	_	_	I-Claim
21	MBC	_	_	I-Claim
22	)	_	_	I-Claim
23	.	_	_	I-Claim

24	We	_	_	O
25	examined	_	_	O
26	the	_	_	O
27	efficacy	_	_	O
28	and	_	_	O
29	safety	_	_	O
30	of	_	_	O
31	adding	_	_	O
32	gemcitabine	_	_	O
33	to	_	_	O
34	paclitaxel	_	_	O
35	/	_	_	O
36	bevacizumab	_	_	O
37	(	_	_	O
38	PB	_	_	O
39	)	_	_	O
40	.	_	_	O

41	In	_	_	O
42	this	_	_	O
43	multicenter	_	_	O
44	,	_	_	O
45	open	_	_	O
46	-	_	_	O
47	label	_	_	O
48	,	_	_	O
49	randomized	_	_	O
50	phase	_	_	O
51	II	_	_	O
52	trial	_	_	O
53	,	_	_	O
54	women	_	_	O
55	with	_	_	O
56	locally	_	_	O
57	advanced	_	_	O
58	or	_	_	O
59	MBC	_	_	O
60	were	_	_	O
61	randomly	_	_	O
62	assigned	_	_	O
63	to	_	_	O
64	receive	_	_	O
65	paclitaxel	_	_	O
66	90	_	_	O
67	mg	_	_	O
68	/	_	_	O
69	m	_	_	O
70	(	_	_	O
71	2	_	_	O
72	)	_	_	O
73	(	_	_	O
74	days	_	_	O
75	1	_	_	O
76	,	_	_	O
77	8	_	_	O
78	,	_	_	O
79	15	_	_	O
80	)	_	_	O
81	and	_	_	O
82	bevacizumab	_	_	O
83	10	_	_	O
84	mg	_	_	O
85	/	_	_	O
86	kg	_	_	O
87	(	_	_	O
88	days	_	_	O
89	1	_	_	O
90	,	_	_	O
91	15	_	_	O
92	)	_	_	O
93	with	_	_	O
94	or	_	_	O
95	without	_	_	O
96	gemcitabine	_	_	O
97	1500	_	_	O
98	mg	_	_	O
99	/	_	_	O
100	m	_	_	O
101	(	_	_	O
102	2	_	_	O
103	)	_	_	O
104	(	_	_	O
105	days	_	_	O
106	1	_	_	O
107	,	_	_	O
108	15	_	_	O
109	)	_	_	O
110	in	_	_	O
111	28	_	_	O
112	-	_	_	O
113	day	_	_	O
114	cycles	_	_	O
115	.	_	_	O

116	Patients	_	_	O
117	with	_	_	O
118	prior	_	_	O
119	cytotoxic	_	_	O
120	therapy	_	_	O
121	for	_	_	O
122	MBC	_	_	O
123	were	_	_	O
124	ineligible	_	_	O
125	.	_	_	O

126	The	_	_	O
127	primary	_	_	O
128	endpoint	_	_	O
129	was	_	_	O
130	investigator	_	_	O
131	-	_	_	O
132	assessed	_	_	O
133	overall	_	_	O
134	response	_	_	O
135	rate	_	_	O
136	(	_	_	O
137	ORR	_	_	O
138	)	_	_	O
139	;	_	_	O
140	secondary	_	_	O
141	endpoints	_	_	O
142	were	_	_	O
143	PFS	_	_	O
144	,	_	_	O
145	overall	_	_	O
146	survival	_	_	O
147	(	_	_	O
148	OS	_	_	O
149	)	_	_	O
150	,	_	_	O
151	safety	_	_	O
152	,	_	_	O
153	and	_	_	O
154	quality	_	_	O
155	of	_	_	O
156	life	_	_	O
157	.	_	_	O

158	Ninety	_	_	O
159	-	_	_	O
160	four	_	_	O
161	patients	_	_	O
162	received	_	_	O
163	PB	_	_	O
164	,	_	_	O
165	and	_	_	O
166	93	_	_	O
167	received	_	_	O
168	paclitaxel	_	_	O
169	/	_	_	O
170	bevacizumab	_	_	O
171	/	_	_	O
172	gemcitabine	_	_	O
173	(	_	_	O
174	PB	_	_	O
175	+	_	_	O
176	G	_	_	O
177	)	_	_	O
178	.	_	_	O

179	The	_	_	B-Premise
180	ORRs	_	_	I-Premise
181	were	_	_	I-Premise
182	48	_	_	I-Premise
183	.	_	_	I-Premise

184	9	_	_	I-Premise
185	%	_	_	I-Premise
186	(	_	_	I-Premise
187	95	_	_	I-Premise
188	%	_	_	I-Premise
189	confidence	_	_	I-Premise
190	interval	_	_	I-Premise
191	[	_	_	I-Premise
192	CI	_	_	I-Premise
193	]	_	_	I-Premise
194	,	_	_	I-Premise
195	38	_	_	I-Premise
196	.	_	_	I-Premise

197	5	_	_	I-Premise
198	%	_	_	I-Premise
199	-	_	_	I-Premise
200	59	_	_	I-Premise
201	.	_	_	I-Premise

202	5	_	_	I-Premise
203	%	_	_	I-Premise
204	)	_	_	I-Premise
205	and	_	_	I-Premise
206	58	_	_	I-Premise
207	.	_	_	I-Premise

208	7	_	_	I-Premise
209	%	_	_	I-Premise
210	(	_	_	I-Premise
211	95	_	_	I-Premise
212	%	_	_	I-Premise
213	CI	_	_	I-Premise
214	,	_	_	I-Premise
215	47	_	_	I-Premise
216	.	_	_	I-Premise

217	9	_	_	I-Premise
218	%	_	_	I-Premise
219	-	_	_	I-Premise
220	68	_	_	I-Premise
221	.	_	_	I-Premise

222	9	_	_	I-Premise
223	%	_	_	I-Premise
224	;	_	_	I-Premise
225	P	_	_	I-Premise
226	=	_	_	I-Premise
227	.	_	_	I-Premise

228	117	_	_	I-Premise
229	)	_	_	I-Premise
230	with	_	_	I-Premise
231	PB	_	_	I-Premise
232	and	_	_	I-Premise
233	PB	_	_	I-Premise
234	+	_	_	I-Premise
235	G	_	_	I-Premise
236	,	_	_	I-Premise
237	respectively	_	_	I-Premise
238	.	_	_	I-Premise

239	The	_	_	B-Premise
240	median	_	_	I-Premise
241	PFS	_	_	I-Premise
242	was	_	_	I-Premise
243	8	_	_	I-Premise
244	.	_	_	I-Premise

245	8	_	_	I-Premise
246	months	_	_	I-Premise
247	(	_	_	I-Premise
248	95	_	_	I-Premise
249	%	_	_	I-Premise
250	CI	_	_	I-Premise
251	,	_	_	I-Premise
252	8	_	_	I-Premise
253	.	_	_	I-Premise

254	1	_	_	I-Premise
255	-	_	_	I-Premise
256	10	_	_	I-Premise
257	.	_	_	I-Premise

258	4	_	_	I-Premise
259	months	_	_	I-Premise
260	)	_	_	I-Premise
261	and	_	_	I-Premise
262	11	_	_	I-Premise
263	.	_	_	I-Premise

264	3	_	_	I-Premise
265	months	_	_	I-Premise
266	(	_	_	I-Premise
267	95	_	_	I-Premise
268	%	_	_	I-Premise
269	CI	_	_	I-Premise
270	,	_	_	I-Premise
271	9	_	_	I-Premise
272	.	_	_	I-Premise

273	7	_	_	I-Premise
274	-	_	_	I-Premise
275	12	_	_	I-Premise
276	.	_	_	I-Premise

277	7	_	_	I-Premise
278	months	_	_	I-Premise
279	;	_	_	I-Premise
280	P	_	_	I-Premise
281	=	_	_	I-Premise
282	.	_	_	I-Premise

283	247	_	_	I-Premise
284	;	_	_	I-Premise
285	hazard	_	_	I-Premise
286	ratio	_	_	I-Premise
287	,	_	_	I-Premise
288	0	_	_	I-Premise
289	.	_	_	I-Premise

290	82	_	_	I-Premise
291	)	_	_	I-Premise
292	;	_	_	I-Premise
293	the	_	_	I-Premise
294	median	_	_	I-Premise
295	OS	_	_	I-Premise
296	was	_	_	I-Premise
297	25	_	_	I-Premise
298	.	_	_	I-Premise

299	0	_	_	I-Premise
300	months	_	_	I-Premise
301	(	_	_	I-Premise
302	95	_	_	I-Premise
303	%	_	_	I-Premise
304	CI	_	_	I-Premise
305	,	_	_	I-Premise
306	18	_	_	I-Premise
307	.	_	_	I-Premise

308	8	_	_	I-Premise
309	-	_	_	I-Premise
310	not	_	_	I-Premise
311	assessable	_	_	I-Premise
312	[	_	_	I-Premise
313	N	_	_	I-Premise
314	/	_	_	I-Premise
315	A	_	_	I-Premise
316	]	_	_	I-Premise
317	months	_	_	I-Premise
318	)	_	_	I-Premise
319	and	_	_	I-Premise
320	24	_	_	I-Premise
321	.	_	_	I-Premise

322	3	_	_	I-Premise
323	months	_	_	I-Premise
324	(	_	_	I-Premise
325	95	_	_	I-Premise
326	%	_	_	I-Premise
327	CI	_	_	I-Premise
328	,	_	_	I-Premise
329	20	_	_	I-Premise
330	.	_	_	I-Premise

331	3	_	_	I-Premise
332	-	_	_	I-Premise
333	N	_	_	I-Premise
334	/	_	_	I-Premise
335	A	_	_	I-Premise
336	months	_	_	I-Premise
337	;	_	_	I-Premise
338	P	_	_	I-Premise
339	=	_	_	I-Premise
340	.	_	_	I-Premise

341	475	_	_	I-Premise
342	;	_	_	I-Premise
343	hazard	_	_	I-Premise
344	ratio	_	_	I-Premise
345	,	_	_	I-Premise
346	0	_	_	I-Premise
347	.	_	_	I-Premise

348	84	_	_	I-Premise
349	)	_	_	I-Premise
350	,	_	_	I-Premise
351	with	_	_	I-Premise
352	PB	_	_	I-Premise
353	and	_	_	I-Premise
354	PB	_	_	I-Premise
355	+	_	_	I-Premise
356	G	_	_	I-Premise
357	,	_	_	I-Premise
358	respectively	_	_	I-Premise
359	.	_	_	I-Premise

360	There	_	_	B-Premise
361	was	_	_	I-Premise
362	significantly	_	_	I-Premise
363	more	_	_	I-Premise
364	grade	_	_	I-Premise
365	3	_	_	I-Premise
366	-	_	_	I-Premise
367	4	_	_	I-Premise
368	neutropenia	_	_	I-Premise
369	(	_	_	I-Premise
370	P	_	_	I-Premise
371	=	_	_	I-Premise
372	.	_	_	I-Premise

373	001	_	_	I-Premise
374	)	_	_	I-Premise
375	and	_	_	I-Premise
376	dyspnea	_	_	I-Premise
377	(	_	_	I-Premise
378	P	_	_	I-Premise
379	=	_	_	I-Premise
380	.	_	_	I-Premise

381	014	_	_	I-Premise
382	)	_	_	I-Premise
383	with	_	_	I-Premise
384	PB	_	_	I-Premise
385	+	_	_	I-Premise
386	G	_	_	I-Premise
387	.	_	_	I-Premise

388	Patients	_	_	B-Premise
389	treated	_	_	I-Premise
390	with	_	_	I-Premise
391	PB	_	_	I-Premise
392	experienced	_	_	I-Premise
393	more	_	_	I-Premise
394	improvement	_	_	I-Premise
395	in	_	_	I-Premise
396	total	_	_	I-Premise
397	FACT	_	_	I-Premise
398	-	_	_	I-Premise
399	B	_	_	I-Premise
400	(	_	_	I-Premise
401	Functional	_	_	I-Premise
402	Assessment	_	_	I-Premise
403	of	_	_	I-Premise
404	Cancer	_	_	I-Premise
405	Therapy	_	_	I-Premise
406	-	_	_	I-Premise
407	Breast	_	_	I-Premise
408	)	_	_	I-Premise
409	(	_	_	I-Premise
410	P	_	_	I-Premise
411	=	_	_	I-Premise
412	.	_	_	I-Premise

413	021	_	_	I-Premise
414	)	_	_	I-Premise
415	,	_	_	I-Premise
416	FACT	_	_	I-Premise
417	-	_	_	I-Premise
418	B	_	_	I-Premise
419	Social	_	_	I-Premise
420	/	_	_	I-Premise
421	Family	_	_	I-Premise
422	Well	_	_	I-Premise
423	-	_	_	I-Premise
424	being	_	_	I-Premise
425	(	_	_	I-Premise
426	P	_	_	I-Premise
427	=	_	_	I-Premise
428	.	_	_	I-Premise

429	041	_	_	I-Premise
430	)	_	_	I-Premise
431	,	_	_	I-Premise
432	and	_	_	I-Premise
433	Breast	_	_	I-Premise
434	Cancer	_	_	I-Premise
435	-	_	_	I-Premise
436	Additional	_	_	I-Premise
437	Concerns	_	_	I-Premise
438	(	_	_	I-Premise
439	P	_	_	I-Premise
440	=	_	_	I-Premise
441	.	_	_	I-Premise

442	008	_	_	I-Premise
443	)	_	_	I-Premise
444	scores	_	_	I-Premise
445	than	_	_	I-Premise
446	patients	_	_	I-Premise
447	treated	_	_	I-Premise
448	with	_	_	I-Premise
449	PB	_	_	I-Premise
450	+	_	_	I-Premise
451	G	_	_	I-Premise
452	.	_	_	I-Premise

453	The	_	_	B-Claim
454	addition	_	_	I-Claim
455	of	_	_	I-Claim
456	gemcitabine	_	_	I-Claim
457	to	_	_	I-Claim
458	PB	_	_	I-Claim
459	was	_	_	I-Claim
460	not	_	_	I-Claim
461	associated	_	_	I-Claim
462	with	_	_	I-Claim
463	a	_	_	I-Claim
464	statistically	_	_	I-Claim
465	significant	_	_	I-Claim
466	improvement	_	_	I-Claim
467	in	_	_	I-Claim
468	ORR	_	_	I-Claim
469	.	_	_	I-Claim

470	Treatment	_	_	B-Claim
471	with	_	_	I-Claim
472	PB	_	_	I-Claim
473	+	_	_	I-Claim
474	G	_	_	I-Claim
475	increased	_	_	I-Claim
476	the	_	_	I-Claim
477	incidence	_	_	I-Claim
478	of	_	_	I-Claim
479	severe	_	_	I-Claim
480	neutropenia	_	_	I-Claim
481	and	_	_	I-Claim
482	dyspnea	_	_	I-Claim
483	,	_	_	I-Claim
484	although	_	_	B-Claim
485	the	_	_	I-Claim
486	regimen	_	_	I-Claim
487	generally	_	_	I-Claim
488	was	_	_	I-Claim
489	well	_	_	I-Claim
490	tolerated	_	_	I-Claim
491	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	whether	_	_	O
3	the	_	_	O
4	administration	_	_	O
5	of	_	_	O
6	recombinant	_	_	O
7	human	_	_	O
8	erythropoietin	_	_	O
9	(	_	_	O
10	r	_	_	O
11	-	_	_	O
12	HuEPO	_	_	O
13	)	_	_	O
14	would	_	_	O
15	increase	_	_	O
16	the	_	_	O
17	hematocrit	_	_	O
18	,	_	_	O
19	reduce	_	_	O
20	the	_	_	O
21	requirement	_	_	O
22	for	_	_	O
23	transfusion	_	_	O
24	,	_	_	O
25	and	_	_	O
26	improve	_	_	O
27	the	_	_	O
28	quality	_	_	O
29	of	_	_	O
30	life	_	_	O
31	in	_	_	O
32	anemic	_	_	O
33	cancer	_	_	O
34	patients	_	_	O
35	receiving	_	_	O
36	myelosuppressive	_	_	O
37	,	_	_	O
38	cisplatin	_	_	O
39	-	_	_	O
40	based	_	_	O
41	chemotherapy	_	_	O
42	.	_	_	O

43	One	_	_	O
44	hundred	_	_	O
45	thirty	_	_	O
46	-	_	_	O
47	two	_	_	O
48	anemic	_	_	O
49	cancer	_	_	O
50	patients	_	_	O
51	receiving	_	_	O
52	cyclic	_	_	O
53	,	_	_	O
54	cisplatin	_	_	O
55	-	_	_	O
56	containing	_	_	O
57	,	_	_	O
58	myelosuppressive	_	_	O
59	chemotherapy	_	_	O
60	were	_	_	O
61	evaluated	_	_	O
62	.	_	_	O

63	Patients	_	_	O
64	received	_	_	O
65	either	_	_	O
66	r	_	_	O
67	-	_	_	O
68	HuEPO	_	_	O
69	(	_	_	O
70	150	_	_	O
71	U	_	_	O
72	/	_	_	O
73	kg	_	_	O
74	)	_	_	O
75	or	_	_	O
76	placebo	_	_	O
77	,	_	_	O
78	subcutaneously	_	_	O
79	,	_	_	O
80	three	_	_	O
81	times	_	_	O
82	a	_	_	O
83	week	_	_	O
84	for	_	_	O
85	3	_	_	O
86	months	_	_	O
87	.	_	_	O

88	Responses	_	_	O
89	were	_	_	O
90	assessed	_	_	O
91	by	_	_	O
92	measuring	_	_	O
93	changes	_	_	O
94	in	_	_	O
95	hemoglobin	_	_	O
96	/	_	_	O
97	hematocrit	_	_	O
98	,	_	_	O
99	transfusion	_	_	O
100	requirement	_	_	O
101	,	_	_	O
102	and	_	_	O
103	quality	_	_	O
104	of	_	_	O
105	life	_	_	O
106	.	_	_	O

107	The	_	_	B-Premise
108	mean	_	_	I-Premise
109	hematocrit	_	_	I-Premise
110	increased	_	_	I-Premise
111	by	_	_	I-Premise
112	6	_	_	I-Premise
113	.	_	_	I-Premise

114	0	_	_	I-Premise
115	percentage	_	_	I-Premise
116	points	_	_	I-Premise
117	in	_	_	I-Premise
118	the	_	_	I-Premise
119	r	_	_	I-Premise
120	-	_	_	I-Premise
121	HuEPO	_	_	I-Premise
122	group	_	_	I-Premise
123	versus	_	_	I-Premise
124	1	_	_	I-Premise
125	.	_	_	I-Premise

126	3	_	_	I-Premise
127	in	_	_	I-Premise
128	the	_	_	I-Premise
129	placebo	_	_	I-Premise
130	group	_	_	I-Premise
131	.	_	_	I-Premise

132	A	_	_	B-Premise
133	decrease	_	_	I-Premise
134	in	_	_	I-Premise
135	transfusion	_	_	I-Premise
136	requirement	_	_	I-Premise
137	did	_	_	I-Premise
138	not	_	_	I-Premise
139	reach	_	_	I-Premise
140	significance	_	_	I-Premise
141	over	_	_	I-Premise
142	all	_	_	I-Premise
143	3	_	_	I-Premise
144	months	_	_	I-Premise
145	,	_	_	I-Premise
146	but	_	_	I-Premise
147	there	_	_	I-Premise
148	was	_	_	I-Premise
149	a	_	_	I-Premise
150	significant	_	_	I-Premise
151	reduction	_	_	I-Premise
152	in	_	_	I-Premise
153	the	_	_	I-Premise
154	percentage	_	_	I-Premise
155	of	_	_	I-Premise
156	patients	_	_	I-Premise
157	transfused	_	_	I-Premise
158	in	_	_	I-Premise
159	the	_	_	I-Premise
160	second	_	_	I-Premise
161	and	_	_	I-Premise
162	third	_	_	I-Premise
163	months	_	_	I-Premise
164	(	_	_	I-Premise
165	27	_	_	I-Premise
166	%	_	_	I-Premise
167	r	_	_	I-Premise
168	-	_	_	I-Premise
169	HuEPO	_	_	I-Premise
170	vs	_	_	I-Premise
171	.	_	_	I-Premise

172	56	_	_	I-Premise
173	%	_	_	I-Premise
174	placebo	_	_	I-Premise
175	)	_	_	I-Premise
176	and	_	_	I-Premise
177	a	_	_	I-Premise
178	trend	_	_	I-Premise
179	toward	_	_	I-Premise
180	reduction	_	_	I-Premise
181	in	_	_	I-Premise
182	the	_	_	I-Premise
183	mean	_	_	I-Premise
184	total	_	_	I-Premise
185	number	_	_	I-Premise
186	of	_	_	I-Premise
187	units	_	_	I-Premise
188	transfused	_	_	I-Premise
189	(	_	_	I-Premise
190	1	_	_	I-Premise
191	.	_	_	I-Premise

192	20	_	_	I-Premise
193	units	_	_	I-Premise
194	r	_	_	I-Premise
195	-	_	_	I-Premise
196	HuEPO	_	_	I-Premise
197	vs	_	_	I-Premise
198	.	_	_	I-Premise

199	2	_	_	I-Premise
200	.	_	_	I-Premise

201	02	_	_	I-Premise
202	units	_	_	I-Premise
203	placebo	_	_	I-Premise
204	)	_	_	I-Premise
205	,	_	_	I-Premise
206	suggesting	_	_	I-Premise
207	a	_	_	I-Premise
208	lag	_	_	I-Premise
209	of	_	_	I-Premise
210	1	_	_	I-Premise
211	month	_	_	I-Premise
212	before	_	_	I-Premise
213	r	_	_	I-Premise
214	-	_	_	I-Premise
215	HuEPO	_	_	I-Premise
216	can	_	_	I-Premise
217	affect	_	_	I-Premise
218	the	_	_	I-Premise
219	transfusion	_	_	I-Premise
220	requirement	_	_	I-Premise
221	.	_	_	I-Premise

222	Pretreatment	_	_	B-Premise
223	serum	_	_	I-Premise
224	erythropoietin	_	_	I-Premise
225	levels	_	_	I-Premise
226	were	_	_	I-Premise
227	lower	_	_	I-Premise
228	in	_	_	I-Premise
229	responders	_	_	I-Premise
230	than	_	_	I-Premise
231	in	_	_	I-Premise
232	nonresponders	_	_	I-Premise
233	(	_	_	I-Premise
234	73	_	_	I-Premise
235	.	_	_	I-Premise

236	5	_	_	I-Premise
237	IU	_	_	I-Premise
238	/	_	_	I-Premise
239	L	_	_	I-Premise
240	and	_	_	I-Premise
241	86	_	_	I-Premise
242	.	_	_	I-Premise

243	3	_	_	I-Premise
244	IU	_	_	I-Premise
245	/	_	_	I-Premise
246	L	_	_	I-Premise
247	means	_	_	I-Premise
248	,	_	_	I-Premise
249	respectively	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	However	_	_	B-Premise
253	,	_	_	I-Premise
254	the	_	_	I-Premise
255	magnitude	_	_	I-Premise
256	of	_	_	I-Premise
257	this	_	_	I-Premise
258	difference	_	_	I-Premise
259	was	_	_	I-Premise
260	not	_	_	I-Premise
261	helpful	_	_	I-Premise
262	in	_	_	I-Premise
263	defining	_	_	I-Premise
264	which	_	_	I-Premise
265	patients	_	_	I-Premise
266	were	_	_	I-Premise
267	likely	_	_	I-Premise
268	to	_	_	I-Premise
269	respond	_	_	I-Premise
270	.	_	_	I-Premise

271	There	_	_	B-Premise
272	was	_	_	I-Premise
273	a	_	_	I-Premise
274	significant	_	_	I-Premise
275	improvement	_	_	I-Premise
276	in	_	_	I-Premise
277	overall	_	_	I-Premise
278	quality	_	_	I-Premise
279	of	_	_	I-Premise
280	life	_	_	I-Premise
281	between	_	_	I-Premise
282	the	_	_	I-Premise
283	two	_	_	I-Premise
284	treatment	_	_	I-Premise
285	arms	_	_	I-Premise
286	in	_	_	I-Premise
287	favor	_	_	I-Premise
288	of	_	_	I-Premise
289	the	_	_	I-Premise
290	r	_	_	I-Premise
291	-	_	_	I-Premise
292	HuEPO	_	_	I-Premise
293	-	_	_	I-Premise
294	treated	_	_	I-Premise
295	group	_	_	I-Premise
296	.	_	_	I-Premise

297	There	_	_	B-Premise
298	were	_	_	I-Premise
299	no	_	_	I-Premise
300	significant	_	_	I-Premise
301	adverse	_	_	I-Premise
302	effects	_	_	I-Premise
303	associated	_	_	I-Premise
304	with	_	_	I-Premise
305	r	_	_	I-Premise
306	-	_	_	I-Premise
307	HuEPO	_	_	I-Premise
308	.	_	_	I-Premise

309	r	_	_	B-Claim
310	-	_	_	I-Claim
311	HuEPO	_	_	I-Claim
312	is	_	_	I-Claim
313	safe	_	_	I-Claim
314	and	_	_	I-Claim
315	can	_	_	I-Claim
316	cause	_	_	I-Claim
317	a	_	_	I-Claim
318	significant	_	_	I-Claim
319	improvement	_	_	I-Claim
320	in	_	_	I-Claim
321	the	_	_	I-Claim
322	hematocrit	_	_	I-Claim
323	and	_	_	I-Claim
324	quality	_	_	I-Claim
325	of	_	_	I-Claim
326	life	_	_	I-Claim
327	of	_	_	I-Claim
328	anemic	_	_	I-Claim
329	cancer	_	_	I-Claim
330	patients	_	_	I-Claim
331	receiving	_	_	I-Claim
332	myelosuppressive	_	_	I-Claim
333	,	_	_	I-Claim
334	cisplatin	_	_	I-Claim
335	-	_	_	I-Claim
336	based	_	_	I-Claim
337	chemotherapy	_	_	I-Claim
338	.	_	_	I-Claim

339	After	_	_	B-Claim
340	1	_	_	I-Claim
341	month	_	_	I-Claim
342	of	_	_	I-Claim
343	r	_	_	I-Claim
344	-	_	_	I-Claim
345	HuEPO	_	_	I-Claim
346	,	_	_	I-Claim
347	there	_	_	I-Claim
348	is	_	_	I-Claim
349	also	_	_	I-Claim
350	a	_	_	I-Claim
351	reduction	_	_	I-Claim
352	in	_	_	I-Claim
353	transfusion	_	_	I-Claim
354	requirement	_	_	I-Claim
355	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	in	_	_	O
3	a	_	_	O
4	phase	_	_	O
5	III	_	_	O
6	study	_	_	O
7	the	_	_	O
8	safety	_	_	O
9	and	_	_	O
10	efficacy	_	_	O
11	of	_	_	O
12	fludarabine	_	_	O
13	to	_	_	O
14	that	_	_	O
15	of	_	_	O
16	cyclophosphamide	_	_	O
17	,	_	_	O
18	vincristine	_	_	O
19	,	_	_	O
20	and	_	_	O
21	prednisone	_	_	O
22	(	_	_	O
23	CVP	_	_	O
24	)	_	_	O
25	in	_	_	O
26	recurrent	_	_	O
27	,	_	_	O
28	low	_	_	O
29	-	_	_	O
30	grade	_	_	O
31	,	_	_	O
32	non	_	_	O
33	-	_	_	O
34	Hodgkin	_	_	O
35	'	_	_	O
36	s	_	_	O
37	lymphoma	_	_	O
38	after	_	_	O
39	previous	_	_	O
40	response	_	_	O
41	to	_	_	O
42	systemic	_	_	O
43	treatment	_	_	O
44	.	_	_	O

45	Patients	_	_	O
46	were	_	_	O
47	randomized	_	_	O
48	to	_	_	O
49	fludarabine	_	_	O
50	(	_	_	O
51	25	_	_	O
52	mg	_	_	O
53	/	_	_	O
54	m	_	_	O
55	(	_	_	O
56	2	_	_	O
57	)	_	_	O
58	intravenously	_	_	O
59	on	_	_	O
60	days	_	_	O
61	1	_	_	O
62	to	_	_	O
63	5	_	_	O
64	,	_	_	O
65	every	_	_	O
66	28	_	_	O
67	days	_	_	O
68	)	_	_	O
69	or	_	_	O
70	CVP	_	_	O
71	(	_	_	O
72	cyclophosphamide	_	_	O
73	750	_	_	O
74	mg	_	_	O
75	/	_	_	O
76	m	_	_	O
77	(	_	_	O
78	2	_	_	O
79	)	_	_	O
80	and	_	_	O
81	vincristine	_	_	O
82	1	_	_	O
83	.	_	_	O

84	2	_	_	O
85	mg	_	_	O
86	/	_	_	O
87	m	_	_	O
88	(	_	_	O
89	2	_	_	O
90	)	_	_	O
91	both	_	_	O
92	intravenously	_	_	O
93	on	_	_	O
94	day	_	_	O
95	1	_	_	O
96	and	_	_	O
97	prednisone	_	_	O
98	40	_	_	O
99	mg	_	_	O
100	/	_	_	O
101	m	_	_	O
102	(	_	_	O
103	2	_	_	O
104	)	_	_	O
105	orally	_	_	O
106	on	_	_	O
107	days	_	_	O
108	1	_	_	O
109	to	_	_	O
110	5	_	_	O
111	,	_	_	O
112	every	_	_	O
113	21	_	_	O
114	days	_	_	O
115	)	_	_	O
116	.	_	_	O

117	The	_	_	O
118	primary	_	_	O
119	outcome	_	_	O
120	assessed	_	_	O
121	was	_	_	O
122	progression	_	_	O
123	-	_	_	O
124	free	_	_	O
125	survival	_	_	O
126	(	_	_	O
127	PFS	_	_	O
128	)	_	_	O
129	;	_	_	O
130	secondary	_	_	O
131	outcomes	_	_	O
132	included	_	_	O
133	treatment	_	_	O
134	-	_	_	O
135	free	_	_	O
136	survival	_	_	O
137	(	_	_	O
138	TFS	_	_	O
139	)	_	_	O
140	,	_	_	O
141	overall	_	_	O
142	survival	_	_	O
143	(	_	_	O
144	OS	_	_	O
145	)	_	_	O
146	,	_	_	O
147	treatment	_	_	O
148	-	_	_	O
149	related	_	_	O
150	toxicity	_	_	O
151	,	_	_	O
152	and	_	_	O
153	quality	_	_	O
154	of	_	_	O
155	life	_	_	O
156	(	_	_	O
157	QoL	_	_	O
158	)	_	_	O
159	according	_	_	O
160	to	_	_	O
161	the	_	_	O
162	European	_	_	O
163	Organization	_	_	O
164	for	_	_	O
165	Research	_	_	O
166	and	_	_	O
167	Treatment	_	_	O
168	of	_	_	O
169	Cancer	_	_	O
170	'	_	_	O
171	s	_	_	O
172	Quality	_	_	O
173	of	_	_	O
174	Life	_	_	O
175	Questionnaire	_	_	O
176	C	_	_	O
177	-	_	_	O
178	30	_	_	O
179	version	_	_	O
180	1	_	_	O
181	.	_	_	O

182	0	_	_	O
183	instrument	_	_	O
184	.	_	_	O

185	Ninety	_	_	O
186	-	_	_	O
187	one	_	_	O
188	patients	_	_	O
189	were	_	_	O
190	randomized	_	_	O
191	,	_	_	O
192	47	_	_	O
193	to	_	_	O
194	fludarabine	_	_	O
195	and	_	_	O
196	44	_	_	O
197	to	_	_	O
198	CVP	_	_	O
199	.	_	_	O

200	There	_	_	B-Premise
201	was	_	_	I-Premise
202	no	_	_	I-Premise
203	difference	_	_	I-Premise
204	in	_	_	I-Premise
205	response	_	_	I-Premise
206	rates	_	_	I-Premise
207	,	_	_	I-Premise
208	with	_	_	I-Premise
209	64	_	_	I-Premise
210	%	_	_	I-Premise
211	(	_	_	I-Premise
212	complete	_	_	I-Premise
213	response	_	_	I-Premise
214	[	_	_	I-Premise
215	CR	_	_	I-Premise
216	]	_	_	I-Premise
217	,	_	_	I-Premise
218	9	_	_	I-Premise
219	%	_	_	I-Premise
220	)	_	_	I-Premise
221	for	_	_	I-Premise
222	fludarabine	_	_	I-Premise
223	versus	_	_	I-Premise
224	52	_	_	I-Premise
225	%	_	_	I-Premise
226	(	_	_	I-Premise
227	CR	_	_	I-Premise
228	,	_	_	I-Premise
229	7	_	_	I-Premise
230	%	_	_	I-Premise
231	)	_	_	I-Premise
232	for	_	_	I-Premise
233	CVP	_	_	I-Premise
234	(	_	_	I-Premise
235	P	_	_	I-Premise
236	=	_	_	I-Premise
237	.	_	_	I-Premise

238	72	_	_	I-Premise
239	)	_	_	I-Premise
240	.	_	_	I-Premise

241	With	_	_	B-Premise
242	a	_	_	I-Premise
243	median	_	_	I-Premise
244	follow	_	_	I-Premise
245	-	_	_	I-Premise
246	up	_	_	I-Premise
247	of	_	_	I-Premise
248	42	_	_	I-Premise
249	months	_	_	I-Premise
250	,	_	_	I-Premise
251	median	_	_	I-Premise
252	PFS	_	_	I-Premise
253	(	_	_	I-Premise
254	11	_	_	I-Premise
255	months	_	_	I-Premise
256	v	_	_	I-Premise
257	9	_	_	I-Premise
258	.	_	_	I-Premise

259	1	_	_	I-Premise
260	months	_	_	I-Premise
261	;	_	_	I-Premise
262	P	_	_	I-Premise
263	=	_	_	I-Premise
264	.	_	_	I-Premise

265	03	_	_	I-Premise
266	)	_	_	I-Premise
267	and	_	_	I-Premise
268	TFS	_	_	I-Premise
269	(	_	_	I-Premise
270	15	_	_	I-Premise
271	months	_	_	I-Premise
272	v	_	_	I-Premise
273	11	_	_	I-Premise
274	months	_	_	I-Premise
275	;	_	_	I-Premise
276	P	_	_	I-Premise
277	=	_	_	I-Premise
278	.	_	_	I-Premise

279	02	_	_	I-Premise
280	)	_	_	I-Premise
281	were	_	_	I-Premise
282	superior	_	_	I-Premise
283	in	_	_	I-Premise
284	patients	_	_	I-Premise
285	receiving	_	_	I-Premise
286	fludarabine	_	_	I-Premise
287	.	_	_	I-Premise

288	No	_	_	B-Premise
289	difference	_	_	I-Premise
290	in	_	_	I-Premise
291	median	_	_	I-Premise
292	overall	_	_	I-Premise
293	survival	_	_	I-Premise
294	was	_	_	I-Premise
295	detected	_	_	I-Premise
296	(	_	_	I-Premise
297	57	_	_	I-Premise
298	months	_	_	I-Premise
299	for	_	_	I-Premise
300	fludarabine	_	_	I-Premise
301	v	_	_	I-Premise
302	44	_	_	I-Premise
303	months	_	_	I-Premise
304	for	_	_	I-Premise
305	CVP	_	_	I-Premise
306	;	_	_	I-Premise
307	P	_	_	I-Premise
308	=	_	_	I-Premise
309	.	_	_	I-Premise

310	95	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	Three	_	_	B-Premise
314	patients	_	_	I-Premise
315	receiving	_	_	I-Premise
316	fludarabine	_	_	I-Premise
317	died	_	_	I-Premise
318	of	_	_	I-Premise
319	treatment	_	_	I-Premise
320	-	_	_	I-Premise
321	related	_	_	I-Premise
322	toxicity	_	_	I-Premise
323	compared	_	_	I-Premise
324	with	_	_	I-Premise
325	none	_	_	I-Premise
326	of	_	_	I-Premise
327	the	_	_	I-Premise
328	patients	_	_	I-Premise
329	receiving	_	_	I-Premise
330	CVP	_	_	I-Premise
331	.	_	_	I-Premise

332	Peripheral	_	_	B-Premise
333	neuropathy	_	_	I-Premise
334	and	_	_	I-Premise
335	alopecia	_	_	I-Premise
336	were	_	_	I-Premise
337	more	_	_	I-Premise
338	common	_	_	I-Premise
339	with	_	_	I-Premise
340	CVP	_	_	I-Premise
341	.	_	_	I-Premise

342	Patients	_	_	B-Premise
343	receiving	_	_	I-Premise
344	fludarabine	_	_	I-Premise
345	had	_	_	I-Premise
346	higher	_	_	I-Premise
347	scores	_	_	I-Premise
348	for	_	_	I-Premise
349	social	_	_	I-Premise
350	function	_	_	I-Premise
351	(	_	_	I-Premise
352	P	_	_	I-Premise
353	=	_	_	I-Premise
354	.	_	_	I-Premise

355	008	_	_	I-Premise
356	)	_	_	I-Premise
357	;	_	_	I-Premise
358	no	_	_	B-Premise
359	other	_	_	I-Premise
360	differences	_	_	I-Premise
361	in	_	_	I-Premise
362	QoL	_	_	I-Premise
363	were	_	_	I-Premise
364	detected	_	_	I-Premise
365	.	_	_	I-Premise

366	In	_	_	B-Claim
367	recurrent	_	_	I-Claim
368	low	_	_	I-Claim
369	-	_	_	I-Claim
370	grade	_	_	I-Claim
371	lymphoma	_	_	I-Claim
372	,	_	_	I-Claim
373	fludarabine	_	_	I-Claim
374	improves	_	_	I-Claim
375	PFS	_	_	I-Claim
376	,	_	_	I-Claim
377	TFS	_	_	I-Claim
378	,	_	_	I-Claim
379	and	_	_	I-Claim
380	social	_	_	I-Claim
381	function	_	_	I-Claim
382	scores	_	_	I-Claim
383	in	_	_	I-Claim
384	comparison	_	_	I-Claim
385	with	_	_	I-Claim
386	CVP	_	_	I-Claim
387	but	_	_	I-Claim
388	does	_	_	I-Claim
389	not	_	_	I-Claim
390	improve	_	_	I-Claim
391	OS	_	_	I-Claim
392	.	_	_	I-Claim


0	The	_	_	O
1	standard	_	_	O
2	doublet	_	_	O
3	,	_	_	O
4	vinorelbine	_	_	O
5	-	_	_	O
6	cisplatin	_	_	O
7	,	_	_	O
8	was	_	_	O
9	compared	_	_	O
10	with	_	_	O
11	a	_	_	O
12	triplet	_	_	O
13	of	_	_	O
14	vinorelbine	_	_	O
15	-	_	_	O
16	ifosfamide	_	_	O
17	-	_	_	O
18	cisplatin	_	_	O
19	,	_	_	O
20	in	_	_	O
21	terms	_	_	O
22	of	_	_	O
23	survival	_	_	O
24	,	_	_	O
25	in	_	_	O
26	patients	_	_	O
27	with	_	_	O
28	advanced	_	_	O
29	non	_	_	O
30	-	_	_	O
31	small	_	_	O
32	-	_	_	O
33	cell	_	_	O
34	lung	_	_	O
35	cancer	_	_	O
36	(	_	_	O
37	NSCLC	_	_	O
38	)	_	_	O
39	.	_	_	O

40	From	_	_	O
41	February	_	_	O
42	1998	_	_	O
43	to	_	_	O
44	June	_	_	O
45	1999	_	_	O
46	,	_	_	O
47	259	_	_	O
48	chemonaïve	_	_	O
49	patients	_	_	O
50	entered	_	_	O
51	the	_	_	O
52	study	_	_	O
53	and	_	_	O
54	were	_	_	O
55	randomised	_	_	O
56	to	_	_	O
57	receive	_	_	O
58	either	_	_	O
59	vinorelbine	_	_	O
60	-	_	_	O
61	cisplatin	_	_	O
62	(	_	_	O
63	NP	_	_	O
64	;	_	_	O
65	vinorelbine	_	_	O
66	30	_	_	O
67	mg	_	_	O
68	/	_	_	O
69	m	_	_	O
70	(	_	_	O
71	2	_	_	O
72	)	_	_	O
73	on	_	_	O
74	days	_	_	O
75	1	_	_	O
76	,	_	_	O
77	8	_	_	O
78	and	_	_	O
79	15	_	_	O
80	with	_	_	O
81	cisplatin	_	_	O
82	80	_	_	O
83	mg	_	_	O
84	/	_	_	O
85	m	_	_	O
86	(	_	_	O
87	2	_	_	O
88	)	_	_	O
89	on	_	_	O
90	day	_	_	O
91	1	_	_	O
92	)	_	_	O
93	or	_	_	O
94	vinorelbine	_	_	O
95	-	_	_	O
96	ifosfamide	_	_	O
97	-	_	_	O
98	cisplatin	_	_	O
99	(	_	_	O
100	NIP	_	_	O
101	;	_	_	O
102	vinorelbine	_	_	O
103	25	_	_	O
104	mg	_	_	O
105	/	_	_	O
106	m	_	_	O
107	(	_	_	O
108	2	_	_	O
109	)	_	_	O
110	on	_	_	O
111	days	_	_	O
112	1	_	_	O
113	and	_	_	O
114	8	_	_	O
115	,	_	_	O
116	ifosfamide	_	_	O
117	3	_	_	O
118	g	_	_	O
119	/	_	_	O
120	m	_	_	O
121	(	_	_	O
122	2	_	_	O
123	)	_	_	O
124	on	_	_	O
125	day	_	_	O
126	1	_	_	O
127	and	_	_	O
128	cisplatin	_	_	O
129	75	_	_	O
130	mg	_	_	O
131	/	_	_	O
132	m	_	_	O
133	(	_	_	O
134	2	_	_	O
135	)	_	_	O
136	on	_	_	O
137	day	_	_	O
138	1	_	_	O
139	)	_	_	O
140	,	_	_	O
141	with	_	_	O
142	both	_	_	O
143	regimens	_	_	O
144	being	_	_	O
145	repeated	_	_	O
146	every	_	_	O
147	3	_	_	O
148	weeks	_	_	O
149	.	_	_	O

150	All	_	_	O
151	patients	_	_	O
152	had	_	_	O
153	stage	_	_	O
154	IV	_	_	O
155	or	_	_	O
156	relapsed	_	_	O
157	disease	_	_	O
158	and	_	_	O
159	a	_	_	O
160	performance	_	_	O
161	score	_	_	O
162	of	_	_	O
163	0	_	_	O
164	or	_	_	O
165	1	_	_	O
166	.	_	_	O

167	The	_	_	B-Premise
168	overall	_	_	I-Premise
169	response	_	_	I-Premise
170	rate	_	_	I-Premise
171	was	_	_	I-Premise
172	34	_	_	I-Premise
173	.	_	_	I-Premise

174	6	_	_	I-Premise
175	%	_	_	I-Premise
176	for	_	_	I-Premise
177	NP	_	_	I-Premise
178	and	_	_	I-Premise
179	35	_	_	I-Premise
180	.	_	_	I-Premise

181	7	_	_	I-Premise
182	%	_	_	I-Premise
183	for	_	_	I-Premise
184	NIP	_	_	I-Premise
185	.	_	_	I-Premise

186	Median	_	_	B-Premise
187	and	_	_	I-Premise
188	1	_	_	I-Premise
189	-	_	_	I-Premise
190	year	_	_	I-Premise
191	survival	_	_	I-Premise
192	rates	_	_	I-Premise
193	were	_	_	I-Premise
194	10	_	_	I-Premise
195	.	_	_	I-Premise

196	0	_	_	I-Premise
197	months	_	_	I-Premise
198	and	_	_	I-Premise
199	38	_	_	I-Premise
200	.	_	_	I-Premise

201	4	_	_	I-Premise
202	%	_	_	I-Premise
203	for	_	_	I-Premise
204	NP	_	_	I-Premise
205	,	_	_	I-Premise
206	and	_	_	I-Premise
207	8	_	_	I-Premise
208	.	_	_	I-Premise

209	2	_	_	I-Premise
210	months	_	_	I-Premise
211	and	_	_	I-Premise
212	33	_	_	I-Premise
213	.	_	_	I-Premise

214	7	_	_	I-Premise
215	%	_	_	I-Premise
216	for	_	_	I-Premise
217	NIP	_	_	I-Premise
218	,	_	_	I-Premise
219	respectively	_	_	I-Premise
220	.	_	_	I-Premise

221	A	_	_	O
222	median	_	_	O
223	of	_	_	O
224	four	_	_	O
225	cycles	_	_	O
226	was	_	_	O
227	administered	_	_	O
228	in	_	_	O
229	each	_	_	O
230	arm	_	_	O
231	.	_	_	O

232	The	_	_	B-Premise
233	major	_	_	I-Premise
234	World	_	_	I-Premise
235	Health	_	_	I-Premise
236	Organization	_	_	I-Premise
237	grade	_	_	I-Premise
238	3	_	_	I-Premise
239	-	_	_	I-Premise
240	4	_	_	I-Premise
241	toxicities	_	_	I-Premise
242	for	_	_	I-Premise
243	NP	_	_	I-Premise
244	and	_	_	I-Premise
245	NIP	_	_	I-Premise
246	,	_	_	I-Premise
247	respectively	_	_	I-Premise
248	,	_	_	I-Premise
249	were	_	_	I-Premise
250	:	_	_	I-Premise
251	neutropenia	_	_	I-Premise
252	(	_	_	I-Premise
253	20	_	_	I-Premise
254	.	_	_	I-Premise

255	3	_	_	I-Premise
256	%	_	_	I-Premise
257	compared	_	_	I-Premise
258	with	_	_	I-Premise
259	9	_	_	I-Premise
260	%	_	_	I-Premise
261	of	_	_	I-Premise
262	cycles	_	_	I-Premise
263	)	_	_	I-Premise
264	,	_	_	I-Premise
265	anaemia	_	_	I-Premise
266	(	_	_	I-Premise
267	4	_	_	I-Premise
268	.	_	_	I-Premise

269	1	_	_	I-Premise
270	%	_	_	I-Premise
271	compared	_	_	I-Premise
272	with	_	_	I-Premise
273	5	_	_	I-Premise
274	%	_	_	I-Premise
275	of	_	_	I-Premise
276	cycles	_	_	I-Premise
277	)	_	_	I-Premise
278	,	_	_	I-Premise
279	nausea	_	_	I-Premise
280	and	_	_	I-Premise
281	vomiting	_	_	I-Premise
282	(	_	_	I-Premise
283	22	_	_	I-Premise
284	.	_	_	I-Premise

285	2	_	_	I-Premise
286	%	_	_	I-Premise
287	compared	_	_	I-Premise
288	with	_	_	I-Premise
289	19	_	_	I-Premise
290	.	_	_	I-Premise

291	4	_	_	I-Premise
292	%	_	_	I-Premise
293	of	_	_	I-Premise
294	patients	_	_	I-Premise
295	)	_	_	I-Premise
296	and	_	_	I-Premise
297	alopecia	_	_	I-Premise
298	(	_	_	I-Premise
299	5	_	_	I-Premise
300	.	_	_	I-Premise

301	6	_	_	I-Premise
302	%	_	_	I-Premise
303	compared	_	_	I-Premise
304	with	_	_	I-Premise
305	29	_	_	I-Premise
306	.	_	_	I-Premise

307	8	_	_	I-Premise
308	%	_	_	I-Premise
309	of	_	_	I-Premise
310	patients	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	Four	_	_	B-Premise
314	toxic	_	_	I-Premise
315	deaths	_	_	I-Premise
316	occurred	_	_	I-Premise
317	in	_	_	I-Premise
318	the	_	_	I-Premise
319	NP	_	_	I-Premise
320	arm	_	_	I-Premise
321	and	_	_	I-Premise
322	eight	_	_	I-Premise
323	in	_	_	I-Premise
324	the	_	_	I-Premise
325	NIP	_	_	I-Premise
326	arm	_	_	I-Premise
327	.	_	_	I-Premise

328	The	_	_	B-Premise
329	different	_	_	I-Premise
330	schedules	_	_	I-Premise
331	of	_	_	I-Premise
332	vinorelbine	_	_	I-Premise
333	in	_	_	I-Premise
334	the	_	_	I-Premise
335	two	_	_	I-Premise
336	arms	_	_	I-Premise
337	led	_	_	I-Premise
338	to	_	_	I-Premise
339	a	_	_	I-Premise
340	greater	_	_	I-Premise
341	survival	_	_	I-Premise
342	in	_	_	I-Premise
343	the	_	_	I-Premise
344	NP	_	_	I-Premise
345	arm	_	_	I-Premise
346	without	_	_	I-Premise
347	impairing	_	_	I-Premise
348	the	_	_	I-Premise
349	tolerance	_	_	I-Premise
350	profile	_	_	I-Premise
351	,	_	_	I-Premise
352	although	_	_	B-Premise
353	this	_	_	I-Premise
354	is	_	_	I-Premise
355	not	_	_	I-Premise
356	statistically	_	_	I-Premise
357	significant	_	_	I-Premise
358	.	_	_	I-Premise

359	This	_	_	B-Claim
360	confirms	_	_	I-Claim
361	that	_	_	I-Claim
362	the	_	_	I-Claim
363	two	_	_	I-Claim
364	-	_	_	I-Claim
365	drug	_	_	I-Claim
366	combination	_	_	I-Claim
367	NP	_	_	I-Claim
368	is	_	_	I-Claim
369	a	_	_	I-Claim
370	reference	_	_	I-Claim
371	treatment	_	_	I-Claim
372	for	_	_	I-Claim
373	metastatic	_	_	I-Claim
374	NSCLC	_	_	I-Claim
375	.	_	_	I-Claim

376	The	_	_	B-Claim
377	role	_	_	I-Claim
378	of	_	_	I-Claim
379	three	_	_	I-Claim
380	-	_	_	I-Claim
381	drug	_	_	I-Claim
382	combinations	_	_	I-Claim
383	remains	_	_	I-Claim
384	questionable	_	_	I-Claim
385	in	_	_	I-Claim
386	this	_	_	I-Claim
387	subset	_	_	I-Claim
388	of	_	_	I-Claim
389	patients	_	_	I-Claim
390	.	_	_	I-Claim


0	We	_	_	O
1	compared	_	_	O
2	fulvestrant	_	_	O
3	500	_	_	O
4	mg	_	_	O
5	regimen	_	_	O
6	with	_	_	O
7	the	_	_	O
8	approved	_	_	O
9	dose	_	_	O
10	of	_	_	O
11	fulvestrant	_	_	O
12	250	_	_	O
13	mg	_	_	O
14	per	_	_	O
15	month	_	_	O
16	for	_	_	O
17	treatment	_	_	O
18	of	_	_	O
19	postmenopausal	_	_	O
20	women	_	_	O
21	with	_	_	O
22	estrogen	_	_	O
23	receptor	_	_	O
24	-	_	_	O
25	positive	_	_	O
26	advanced	_	_	O
27	breast	_	_	O
28	cancer	_	_	O
29	who	_	_	O
30	experienced	_	_	O
31	progression	_	_	O
32	after	_	_	O
33	prior	_	_	O
34	endocrine	_	_	O
35	therapy	_	_	O
36	.	_	_	O

37	Comparison	_	_	O
38	of	_	_	O
39	Faslodex	_	_	O
40	in	_	_	O
41	Recurrent	_	_	O
42	or	_	_	O
43	Metastatic	_	_	O
44	Breast	_	_	O
45	Cancer	_	_	O
46	(	_	_	O
47	CONFIRM	_	_	O
48	)	_	_	O
49	is	_	_	O
50	a	_	_	O
51	double	_	_	O
52	-	_	_	O
53	blind	_	_	O
54	,	_	_	O
55	parallel	_	_	O
56	-	_	_	O
57	group	_	_	O
58	,	_	_	O
59	multicenter	_	_	O
60	,	_	_	O
61	phase	_	_	O
62	III	_	_	O
63	study	_	_	O
64	.	_	_	O

65	Patients	_	_	O
66	were	_	_	O
67	randomly	_	_	O
68	assigned	_	_	O
69	to	_	_	O
70	fulvestrant	_	_	O
71	500	_	_	O
72	mg	_	_	O
73	(	_	_	O
74	500	_	_	O
75	mg	_	_	O
76	intramuscularly	_	_	O
77	[	_	_	O
78	IM	_	_	O
79	]	_	_	O
80	on	_	_	O
81	day	_	_	O
82	0	_	_	O
83	,	_	_	O
84	then	_	_	O
85	500	_	_	O
86	mg	_	_	O
87	IM	_	_	O
88	on	_	_	O
89	days	_	_	O
90	14	_	_	O
91	and	_	_	O
92	28	_	_	O
93	and	_	_	O
94	every	_	_	O
95	28	_	_	O
96	days	_	_	O
97	thereafter	_	_	O
98	)	_	_	O
99	or	_	_	O
100	250	_	_	O
101	mg	_	_	O
102	every	_	_	O
103	28	_	_	O
104	days	_	_	O
105	.	_	_	O

106	Primary	_	_	O
107	end	_	_	O
108	point	_	_	O
109	was	_	_	O
110	progression	_	_	O
111	-	_	_	O
112	free	_	_	O
113	survival	_	_	O
114	(	_	_	O
115	PFS	_	_	O
116	)	_	_	O
117	.	_	_	O

118	Secondary	_	_	O
119	end	_	_	O
120	points	_	_	O
121	included	_	_	O
122	objective	_	_	O
123	response	_	_	O
124	rate	_	_	O
125	,	_	_	O
126	clinical	_	_	O
127	benefit	_	_	O
128	rate	_	_	O
129	(	_	_	O
130	CBR	_	_	O
131	)	_	_	O
132	,	_	_	O
133	duration	_	_	O
134	of	_	_	O
135	clinical	_	_	O
136	benefit	_	_	O
137	(	_	_	O
138	DoCB	_	_	O
139	)	_	_	O
140	,	_	_	O
141	overall	_	_	O
142	survival	_	_	O
143	(	_	_	O
144	OS	_	_	O
145	)	_	_	O
146	,	_	_	O
147	and	_	_	O
148	quality	_	_	O
149	of	_	_	O
150	life	_	_	O
151	(	_	_	O
152	QOL	_	_	O
153	)	_	_	O
154	.	_	_	O

155	PFS	_	_	B-Premise
156	was	_	_	I-Premise
157	significantly	_	_	I-Premise
158	longer	_	_	I-Premise
159	for	_	_	I-Premise
160	fulvestrant	_	_	I-Premise
161	500	_	_	I-Premise
162	mg	_	_	I-Premise
163	(	_	_	I-Premise
164	n	_	_	I-Premise
165	=	_	_	I-Premise
166	362	_	_	I-Premise
167	)	_	_	I-Premise
168	than	_	_	I-Premise
169	250	_	_	I-Premise
170	mg	_	_	I-Premise
171	(	_	_	I-Premise
172	n	_	_	I-Premise
173	=	_	_	I-Premise
174	374	_	_	I-Premise
175	)	_	_	I-Premise
176	(	_	_	I-Premise
177	hazard	_	_	I-Premise
178	ratio	_	_	I-Premise
179	[	_	_	I-Premise
180	HR	_	_	I-Premise
181	]	_	_	I-Premise
182	=	_	_	I-Premise
183	0	_	_	I-Premise
184	.	_	_	I-Premise

185	80	_	_	I-Premise
186	;	_	_	I-Premise
187	95	_	_	I-Premise
188	%	_	_	I-Premise
189	CI	_	_	I-Premise
190	,	_	_	I-Premise
191	0	_	_	I-Premise
192	.	_	_	I-Premise

193	68	_	_	I-Premise
194	to	_	_	I-Premise
195	0	_	_	I-Premise
196	.	_	_	I-Premise

197	94	_	_	I-Premise
198	;	_	_	I-Premise
199	P	_	_	I-Premise
200	=	_	_	I-Premise
201	.	_	_	I-Premise

202	006	_	_	I-Premise
203	)	_	_	I-Premise
204	,	_	_	I-Premise
205	corresponding	_	_	I-Premise
206	to	_	_	I-Premise
207	a	_	_	I-Premise
208	20	_	_	I-Premise
209	%	_	_	I-Premise
210	reduction	_	_	I-Premise
211	in	_	_	I-Premise
212	risk	_	_	I-Premise
213	of	_	_	I-Premise
214	progression	_	_	I-Premise
215	.	_	_	I-Premise

216	Objective	_	_	B-Premise
217	response	_	_	I-Premise
218	rate	_	_	I-Premise
219	was	_	_	I-Premise
220	similar	_	_	I-Premise
221	for	_	_	I-Premise
222	fulvestrant	_	_	I-Premise
223	500	_	_	I-Premise
224	mg	_	_	I-Premise
225	and	_	_	I-Premise
226	250	_	_	I-Premise
227	mg	_	_	I-Premise
228	(	_	_	I-Premise
229	9	_	_	I-Premise
230	.	_	_	I-Premise

231	1	_	_	I-Premise
232	%	_	_	I-Premise
233	v	_	_	I-Premise
234	10	_	_	I-Premise
235	.	_	_	I-Premise

236	2	_	_	I-Premise
237	%	_	_	I-Premise
238	,	_	_	I-Premise
239	respectively	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	CBR	_	_	B-Premise
243	was	_	_	I-Premise
244	45	_	_	I-Premise
245	.	_	_	I-Premise

246	6	_	_	I-Premise
247	%	_	_	I-Premise
248	for	_	_	I-Premise
249	fulvestrant	_	_	I-Premise
250	500	_	_	I-Premise
251	mg	_	_	I-Premise
252	and	_	_	I-Premise
253	39	_	_	I-Premise
254	.	_	_	I-Premise

255	6	_	_	I-Premise
256	%	_	_	I-Premise
257	for	_	_	I-Premise
258	fulvestrant	_	_	I-Premise
259	250	_	_	I-Premise
260	mg	_	_	I-Premise
261	.	_	_	I-Premise

262	DoCB	_	_	B-Premise
263	and	_	_	I-Premise
264	OS	_	_	I-Premise
265	were	_	_	I-Premise
266	16	_	_	I-Premise
267	.	_	_	I-Premise

268	6	_	_	I-Premise
269	and	_	_	I-Premise
270	25	_	_	I-Premise
271	.	_	_	I-Premise

272	1	_	_	I-Premise
273	months	_	_	I-Premise
274	,	_	_	I-Premise
275	respectively	_	_	I-Premise
276	,	_	_	I-Premise
277	for	_	_	I-Premise
278	the	_	_	I-Premise
279	500	_	_	I-Premise
280	-	_	_	I-Premise
281	mg	_	_	I-Premise
282	group	_	_	I-Premise
283	,	_	_	I-Premise
284	whereas	_	_	I-Premise
285	DoCB	_	_	I-Premise
286	and	_	_	I-Premise
287	OS	_	_	I-Premise
288	were	_	_	I-Premise
289	13	_	_	I-Premise
290	.	_	_	I-Premise

291	9	_	_	I-Premise
292	and	_	_	I-Premise
293	22	_	_	I-Premise
294	.	_	_	I-Premise

295	8	_	_	I-Premise
296	months	_	_	I-Premise
297	,	_	_	I-Premise
298	respectively	_	_	I-Premise
299	,	_	_	I-Premise
300	in	_	_	I-Premise
301	the	_	_	I-Premise
302	250	_	_	I-Premise
303	-	_	_	I-Premise
304	mg	_	_	I-Premise
305	group	_	_	I-Premise
306	.	_	_	I-Premise

307	Fulvestrant	_	_	B-Claim
308	500	_	_	I-Claim
309	mg	_	_	I-Claim
310	was	_	_	I-Claim
311	well	_	_	I-Claim
312	tolerated	_	_	I-Claim
313	with	_	_	I-Claim
314	no	_	_	I-Claim
315	dose	_	_	I-Claim
316	-	_	_	I-Claim
317	dependent	_	_	I-Claim
318	adverse	_	_	I-Claim
319	events	_	_	I-Claim
320	.	_	_	I-Claim

321	QOL	_	_	B-Claim
322	was	_	_	I-Claim
323	similar	_	_	I-Claim
324	for	_	_	I-Claim
325	both	_	_	I-Claim
326	arms	_	_	I-Claim
327	.	_	_	I-Claim

328	Fulvestrant	_	_	B-Claim
329	500	_	_	I-Claim
330	mg	_	_	I-Claim
331	was	_	_	I-Claim
332	associated	_	_	I-Claim
333	with	_	_	I-Claim
334	a	_	_	I-Claim
335	statistically	_	_	I-Claim
336	significant	_	_	I-Claim
337	increase	_	_	I-Claim
338	in	_	_	I-Claim
339	PFS	_	_	I-Claim
340	and	_	_	I-Claim
341	not	_	_	I-Claim
342	associated	_	_	I-Claim
343	with	_	_	I-Claim
344	increased	_	_	I-Claim
345	toxicity	_	_	I-Claim
346	,	_	_	I-Claim
347	corresponding	_	_	O
348	to	_	_	O
349	a	_	_	O
350	clinically	_	_	O
351	meaningful	_	_	O
352	improvement	_	_	O
353	in	_	_	O
354	benefit	_	_	O
355	versus	_	_	O
356	risk	_	_	O
357	compared	_	_	O
358	with	_	_	O
359	fulvestrant	_	_	O
360	250	_	_	O
361	mg	_	_	O
362	.	_	_	O


0	Cisplatin	_	_	B-Claim
1	reduces	_	_	I-Claim
2	plasma	_	_	I-Claim
3	ghrelin	_	_	I-Claim
4	levels	_	_	I-Claim
5	through	_	_	I-Claim
6	the	_	_	I-Claim
7	5	_	_	I-Claim
8	-	_	_	I-Claim
9	hydroxytryptamine	_	_	I-Claim
10	(	_	_	I-Claim
11	5	_	_	I-Claim
12	-	_	_	I-Claim
13	HT	_	_	I-Claim
14	)	_	_	I-Claim
15	receptor	_	_	I-Claim
16	.	_	_	I-Claim

17	This	_	_	O
18	may	_	_	O
19	cause	_	_	O
20	cisplatin	_	_	O
21	-	_	_	O
22	induced	_	_	O
23	gastrointestinal	_	_	O
24	disorders	_	_	O
25	and	_	_	O
26	hinders	_	_	O
27	the	_	_	O
28	continuation	_	_	O
29	of	_	_	O
30	chemotherapy	_	_	O
31	.	_	_	O

32	The	_	_	O
33	authors	_	_	O
34	of	_	_	O
35	this	_	_	O
36	report	_	_	O
37	conducted	_	_	O
38	a	_	_	O
39	prospective	_	_	O
40	,	_	_	O
41	randomized	_	_	O
42	phase	_	_	O
43	2	_	_	O
44	trial	_	_	O
45	to	_	_	O
46	evaluate	_	_	O
47	the	_	_	O
48	effects	_	_	O
49	of	_	_	O
50	exogenous	_	_	O
51	ghrelin	_	_	O
52	during	_	_	O
53	cisplatin	_	_	O
54	-	_	_	O
55	based	_	_	O
56	chemotherapy	_	_	O
57	.	_	_	O

58	Forty	_	_	O
59	-	_	_	O
60	two	_	_	O
61	patients	_	_	O
62	with	_	_	O
63	esophageal	_	_	O
64	cancer	_	_	O
65	who	_	_	O
66	were	_	_	O
67	receiving	_	_	O
68	cisplatin	_	_	O
69	-	_	_	O
70	based	_	_	O
71	neoadjuvant	_	_	O
72	chemotherapy	_	_	O
73	were	_	_	O
74	assigned	_	_	O
75	to	_	_	O
76	either	_	_	O
77	a	_	_	O
78	ghrelin	_	_	O
79	group	_	_	O
80	(	_	_	O
81	n	_	_	O
82	=	_	_	O
83	21	_	_	O
84	)	_	_	O
85	or	_	_	O
86	a	_	_	O
87	placebo	_	_	O
88	group	_	_	O
89	(	_	_	O
90	n	_	_	O
91	=	_	_	O
92	21	_	_	O
93	)	_	_	O
94	.	_	_	O

95	They	_	_	O
96	received	_	_	O
97	either	_	_	O
98	intravenous	_	_	O
99	infusions	_	_	O
100	of	_	_	O
101	synthetic	_	_	O
102	human	_	_	O
103	ghrelin	_	_	O
104	(	_	_	O
105	3	_	_	O
106	μg	_	_	O
107	/	_	_	O
108	kg	_	_	O
109	)	_	_	O
110	or	_	_	O
111	saline	_	_	O
112	twice	_	_	O
113	daily	_	_	O
114	for	_	_	O
115	1	_	_	O
116	week	_	_	O
117	with	_	_	O
118	cisplatin	_	_	O
119	administration	_	_	O
120	.	_	_	O

121	The	_	_	O
122	primary	_	_	O
123	endpoint	_	_	O
124	was	_	_	O
125	changes	_	_	O
126	in	_	_	O
127	oral	_	_	O
128	calorie	_	_	O
129	intake	_	_	O
130	,	_	_	O
131	and	_	_	O
132	the	_	_	O
133	secondary	_	_	O
134	endpoints	_	_	O
135	were	_	_	O
136	chemotherapy	_	_	O
137	-	_	_	O
138	related	_	_	O
139	adverse	_	_	O
140	events	_	_	O
141	;	_	_	O
142	appetite	_	_	O
143	visual	_	_	O
144	analog	_	_	O
145	scale	_	_	O
146	(	_	_	O
147	VAS	_	_	O
148	)	_	_	O
149	scores	_	_	O
150	;	_	_	O
151	changes	_	_	O
152	in	_	_	O
153	gastrointestinal	_	_	O
154	hormones	_	_	O
155	and	_	_	O
156	nutritional	_	_	O
157	status	_	_	O
158	,	_	_	O
159	including	_	_	O
160	rapid	_	_	O
161	turnover	_	_	O
162	proteins	_	_	O
163	,	_	_	O
164	and	_	_	O
165	quality	_	_	O
166	of	_	_	O
167	life	_	_	O
168	(	_	_	O
169	QoL	_	_	O
170	)	_	_	O
171	estimated	_	_	O
172	with	_	_	O
173	the	_	_	O
174	European	_	_	O
175	Organization	_	_	O
176	for	_	_	O
177	Research	_	_	O
178	and	_	_	O
179	Treatment	_	_	O
180	of	_	_	O
181	Cancer	_	_	O
182	QoL	_	_	O
183	core	_	_	O
184	questionnaire	_	_	O
185	(	_	_	O
186	QLQ	_	_	O
187	-	_	_	O
188	C30	_	_	O
189	)	_	_	O
190	.	_	_	O

191	Two	_	_	O
192	patients	_	_	O
193	were	_	_	O
194	excluded	_	_	O
195	from	_	_	O
196	the	_	_	O
197	final	_	_	O
198	analysis	_	_	O
199	:	_	_	O
200	One	_	_	O
201	patient	_	_	O
202	suspended	_	_	O
203	ghrelin	_	_	O
204	administration	_	_	O
205	because	_	_	O
206	of	_	_	O
207	excessive	_	_	O
208	diaphoresis	_	_	O
209	,	_	_	O
210	and	_	_	O
211	another	_	_	O
212	patient	_	_	O
213	in	_	_	O
214	the	_	_	O
215	placebo	_	_	O
216	group	_	_	O
217	failed	_	_	O
218	to	_	_	O
219	monitor	_	_	O
220	the	_	_	O
221	self	_	_	O
222	-	_	_	O
223	questionnaire	_	_	O
224	.	_	_	O

225	Food	_	_	B-Premise
226	intake	_	_	I-Premise
227	and	_	_	I-Premise
228	appetite	_	_	I-Premise
229	VAS	_	_	I-Premise
230	scores	_	_	I-Premise
231	were	_	_	I-Premise
232	significantly	_	_	I-Premise
233	higher	_	_	I-Premise
234	in	_	_	I-Premise
235	the	_	_	I-Premise
236	ghrelin	_	_	I-Premise
237	group	_	_	I-Premise
238	than	_	_	I-Premise
239	in	_	_	I-Premise
240	the	_	_	I-Premise
241	placebo	_	_	I-Premise
242	group	_	_	I-Premise
243	(	_	_	I-Premise
244	18	_	_	I-Premise
245	.	_	_	I-Premise

246	2	_	_	I-Premise
247	±	_	_	I-Premise
248	5	_	_	I-Premise
249	.	_	_	I-Premise

250	2	_	_	I-Premise
251	kcal	_	_	I-Premise
252	/	_	_	I-Premise
253	kg	_	_	I-Premise
254	/	_	_	I-Premise
255	day	_	_	I-Premise
256	vs	_	_	I-Premise
257	12	_	_	I-Premise
258	.	_	_	I-Premise

259	7	_	_	I-Premise
260	±	_	_	I-Premise
261	3	_	_	I-Premise
262	.	_	_	I-Premise

263	4	_	_	I-Premise
264	kcal	_	_	I-Premise
265	/	_	_	I-Premise
266	kg	_	_	I-Premise
267	/	_	_	I-Premise
268	day	_	_	I-Premise
269	[	_	_	I-Premise
270	P	_	_	I-Premise
271	=	_	_	I-Premise
272	.	_	_	I-Premise

273	001	_	_	I-Premise
274	]	_	_	I-Premise
275	and	_	_	I-Premise
276	6	_	_	I-Premise
277	.	_	_	I-Premise

278	2	_	_	I-Premise
279	±	_	_	I-Premise
280	0	_	_	I-Premise
281	.	_	_	I-Premise

282	9	_	_	I-Premise
283	vs	_	_	I-Premise
284	4	_	_	I-Premise
285	.	_	_	I-Premise

286	1	_	_	I-Premise
287	±	_	_	I-Premise
288	0	_	_	I-Premise
289	.	_	_	I-Premise

290	9	_	_	I-Premise
291	[	_	_	I-Premise
292	P	_	_	I-Premise
293	<	_	_	I-Premise
294	.	_	_	I-Premise

295	0001	_	_	I-Premise
296	]	_	_	I-Premise
297	,	_	_	I-Premise
298	respectively	_	_	I-Premise
299	)	_	_	I-Premise
300	.	_	_	I-Premise

301	Patients	_	_	B-Premise
302	in	_	_	I-Premise
303	the	_	_	I-Premise
304	ghrelin	_	_	I-Premise
305	group	_	_	I-Premise
306	had	_	_	I-Premise
307	fewer	_	_	I-Premise
308	adverse	_	_	I-Premise
309	events	_	_	I-Premise
310	during	_	_	I-Premise
311	chemotherapy	_	_	I-Premise
312	related	_	_	I-Premise
313	to	_	_	I-Premise
314	anorexia	_	_	I-Premise
315	and	_	_	I-Premise
316	nausea	_	_	I-Premise
317	than	_	_	I-Premise
318	patients	_	_	I-Premise
319	in	_	_	I-Premise
320	the	_	_	I-Premise
321	control	_	_	I-Premise
322	group	_	_	I-Premise
323	.	_	_	I-Premise

324	Significant	_	_	B-Premise
325	deterioration	_	_	I-Premise
326	was	_	_	I-Premise
327	noted	_	_	I-Premise
328	after	_	_	I-Premise
329	chemotherapy	_	_	I-Premise
330	in	_	_	I-Premise
331	the	_	_	I-Premise
332	placebo	_	_	I-Premise
333	group	_	_	I-Premise
334	in	_	_	I-Premise
335	QoL	_	_	I-Premise
336	scores	_	_	I-Premise
337	,	_	_	I-Premise
338	appetite	_	_	I-Premise
339	,	_	_	I-Premise
340	nausea	_	_	I-Premise
341	and	_	_	I-Premise
342	vomiting	_	_	I-Premise
343	,	_	_	I-Premise
344	and	_	_	I-Premise
345	global	_	_	I-Premise
346	health	_	_	I-Premise
347	status	_	_	I-Premise
348	.	_	_	I-Premise

349	Short	_	_	B-Claim
350	-	_	_	I-Claim
351	term	_	_	I-Claim
352	administration	_	_	I-Claim
353	of	_	_	I-Claim
354	exogenous	_	_	I-Claim
355	ghrelin	_	_	I-Claim
356	at	_	_	I-Claim
357	the	_	_	I-Claim
358	start	_	_	I-Claim
359	of	_	_	I-Claim
360	cisplatin	_	_	I-Claim
361	-	_	_	I-Claim
362	based	_	_	I-Claim
363	chemotherapy	_	_	I-Claim
364	stimulated	_	_	I-Claim
365	food	_	_	I-Claim
366	intake	_	_	I-Claim
367	and	_	_	I-Claim
368	minimized	_	_	I-Claim
369	adverse	_	_	I-Claim
370	events	_	_	I-Claim
371	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	whether	_	_	O
3	omission	_	_	O
4	of	_	_	O
5	postoperative	_	_	O
6	radiotherapy	_	_	O
7	in	_	_	O
8	women	_	_	O
9	with	_	_	O
10	'	_	_	O
11	low	_	_	O
12	-	_	_	O
13	risk	_	_	O
14	'	_	_	O
15	axillary	_	_	O
16	node	_	_	O
17	negative	_	_	O
18	breast	_	_	O
19	cancer	_	_	O
20	(	_	_	O
21	T0	_	_	O
22	-	_	_	O
23	2	_	_	O
24	)	_	_	O
25	treated	_	_	O
26	by	_	_	O
27	breast	_	_	O
28	-	_	_	O
29	conserving	_	_	O
30	surgery	_	_	O
31	and	_	_	O
32	endocrine	_	_	O
33	therapy	_	_	O
34	improves	_	_	O
35	quality	_	_	O
36	of	_	_	O
37	life	_	_	O
38	and	_	_	O
39	is	_	_	O
40	more	_	_	O
41	cost	_	_	O
42	-	_	_	O
43	effective	_	_	O
44	.	_	_	O

45	A	_	_	O
46	randomised	_	_	O
47	controlled	_	_	O
48	clinical	_	_	O
49	trial	_	_	O
50	,	_	_	O
51	using	_	_	O
52	a	_	_	O
53	method	_	_	O
54	of	_	_	O
55	minimisation	_	_	O
56	balanced	_	_	O
57	by	_	_	O
58	centre	_	_	O
59	,	_	_	O
60	grade	_	_	O
61	of	_	_	O
62	cancer	_	_	O
63	,	_	_	O
64	age	_	_	O
65	,	_	_	O
66	lymphatic	_	_	O
67	/	_	_	O
68	vascular	_	_	O
69	invasion	_	_	O
70	and	_	_	O
71	preoperative	_	_	O
72	endocrine	_	_	O
73	therapy	_	_	O
74	,	_	_	O
75	was	_	_	O
76	performed	_	_	O
77	.	_	_	O

78	A	_	_	O
79	non	_	_	O
80	-	_	_	O
81	randomised	_	_	O
82	cohort	_	_	O
83	was	_	_	O
84	also	_	_	O
85	recruited	_	_	O
86	,	_	_	O
87	in	_	_	O
88	order	_	_	O
89	to	_	_	O
90	complete	_	_	O
91	a	_	_	O
92	comprehensive	_	_	O
93	cohort	_	_	O
94	study	_	_	O
95	.	_	_	O

96	The	_	_	O
97	setting	_	_	O
98	was	_	_	O
99	breast	_	_	O
100	cancer	_	_	O
101	clinics	_	_	O
102	in	_	_	O
103	cancer	_	_	O
104	centres	_	_	O
105	in	_	_	O
106	the	_	_	O
107	UK	_	_	O
108	.	_	_	O

109	Patients	_	_	O
110	aged	_	_	O
111	65	_	_	O
112	years	_	_	O
113	or	_	_	O
114	more	_	_	O
115	were	_	_	O
116	eligible	_	_	O
117	provided	_	_	O
118	that	_	_	O
119	their	_	_	O
120	cancers	_	_	O
121	were	_	_	O
122	considered	_	_	O
123	to	_	_	O
124	be	_	_	O
125	at	_	_	O
126	low	_	_	O
127	risk	_	_	O
128	of	_	_	O
129	local	_	_	O
130	recurrence	_	_	O
131	,	_	_	O
132	were	_	_	O
133	suitable	_	_	O
134	for	_	_	O
135	breast	_	_	O
136	-	_	_	O
137	conservation	_	_	O
138	surgery	_	_	O
139	,	_	_	O
140	were	_	_	O
141	receiving	_	_	O
142	endocrine	_	_	O
143	therapy	_	_	O
144	and	_	_	O
145	were	_	_	O
146	able	_	_	O
147	and	_	_	O
148	willing	_	_	O
149	to	_	_	O
150	give	_	_	O
151	informed	_	_	O
152	consent	_	_	O
153	.	_	_	O

154	The	_	_	O
155	standard	_	_	O
156	treatment	_	_	O
157	of	_	_	O
158	postoperative	_	_	O
159	breast	_	_	O
160	irradiation	_	_	O
161	or	_	_	O
162	the	_	_	O
163	omission	_	_	O
164	of	_	_	O
165	radiotherapy	_	_	O
166	.	_	_	O

167	Quality	_	_	O
168	of	_	_	O
169	life	_	_	O
170	was	_	_	O
171	the	_	_	O
172	primary	_	_	O
173	outcome	_	_	O
174	measure	_	_	O
175	,	_	_	O
176	together	_	_	O
177	with	_	_	O
178	anxiety	_	_	O
179	and	_	_	O
180	depression	_	_	O
181	and	_	_	O
182	cost	_	_	O
183	-	_	_	O
184	effectiveness	_	_	O
185	.	_	_	O

186	Secondary	_	_	O
187	outcome	_	_	O
188	measures	_	_	O
189	were	_	_	O
190	recurrence	_	_	O
191	rates	_	_	O
192	,	_	_	O
193	functional	_	_	O
194	status	_	_	O
195	,	_	_	O
196	treatment	_	_	O
197	-	_	_	O
198	related	_	_	O
199	morbidity	_	_	O
200	and	_	_	O
201	cosmesis	_	_	O
202	.	_	_	O

203	The	_	_	O
204	principal	_	_	O
205	method	_	_	O
206	of	_	_	O
207	data	_	_	O
208	collection	_	_	O
209	was	_	_	O
210	by	_	_	O
211	questionnaire	_	_	O
212	,	_	_	O
213	completed	_	_	O
214	at	_	_	O
215	home	_	_	O
216	with	_	_	O
217	a	_	_	O
218	research	_	_	O
219	nurse	_	_	O
220	at	_	_	O
221	four	_	_	O
222	times	_	_	O
223	over	_	_	O
224	15	_	_	O
225	months	_	_	O
226	.	_	_	O

227	The	_	_	B-Claim
228	hypothesised	_	_	I-Claim
229	improvement	_	_	I-Claim
230	in	_	_	I-Claim
231	overall	_	_	I-Claim
232	quality	_	_	I-Claim
233	of	_	_	I-Claim
234	life	_	_	I-Claim
235	with	_	_	I-Claim
236	the	_	_	I-Claim
237	omission	_	_	I-Claim
238	of	_	_	I-Claim
239	radiotherapy	_	_	I-Claim
240	was	_	_	I-Claim
241	not	_	_	I-Claim
242	seen	_	_	I-Claim
243	in	_	_	I-Claim
244	the	_	_	I-Claim
245	EuroQol	_	_	I-Claim
246	assessment	_	_	I-Claim
247	or	_	_	I-Claim
248	in	_	_	I-Claim
249	the	_	_	I-Claim
250	functionality	_	_	I-Claim
251	and	_	_	I-Claim
252	symptoms	_	_	I-Claim
253	summary	_	_	I-Claim
254	domains	_	_	I-Claim
255	of	_	_	I-Claim
256	the	_	_	I-Claim
257	European	_	_	I-Claim
258	Organisation	_	_	I-Claim
259	for	_	_	I-Claim
260	Research	_	_	I-Claim
261	in	_	_	I-Claim
262	the	_	_	I-Claim
263	Treatment	_	_	I-Claim
264	of	_	_	I-Claim
265	Cancer	_	_	I-Claim
266	(	_	_	I-Claim
267	EORTC	_	_	I-Claim
268	)	_	_	I-Claim
269	scales	_	_	I-Claim
270	.	_	_	I-Claim

271	Some	_	_	O
272	differences	_	_	O
273	were	_	_	O
274	apparent	_	_	O
275	within	_	_	O
276	subscales	_	_	O
277	of	_	_	O
278	the	_	_	O
279	EORTC	_	_	O
280	questionnaires	_	_	O
281	,	_	_	O
282	and	_	_	O
283	insights	_	_	O
284	into	_	_	O
285	the	_	_	O
286	impact	_	_	O
287	of	_	_	O
288	treatment	_	_	O
289	were	_	_	O
290	also	_	_	O
291	provided	_	_	O
292	by	_	_	O
293	the	_	_	O
294	qualitative	_	_	O
295	data	_	_	O
296	obtained	_	_	O
297	by	_	_	O
298	open	_	_	O
299	-	_	_	O
300	ended	_	_	O
301	questions	_	_	O
302	.	_	_	O

303	Differences	_	_	B-Premise
304	were	_	_	I-Premise
305	most	_	_	I-Premise
306	apparent	_	_	I-Premise
307	shortly	_	_	I-Premise
308	after	_	_	I-Premise
309	the	_	_	I-Premise
310	time	_	_	I-Premise
311	of	_	_	I-Premise
312	completion	_	_	I-Premise
313	of	_	_	I-Premise
314	radiotherapy	_	_	I-Premise
315	.	_	_	I-Premise

316	Radiotherapy	_	_	B-Claim
317	was	_	_	I-Claim
318	then	_	_	I-Claim
319	associated	_	_	I-Claim
320	with	_	_	I-Claim
321	increased	_	_	I-Claim
322	breast	_	_	I-Claim
323	symptoms	_	_	I-Claim
324	and	_	_	I-Claim
325	with	_	_	I-Claim
326	greater	_	_	I-Claim
327	fatigue	_	_	I-Claim
328	but	_	_	I-Claim
329	with	_	_	I-Claim
330	less	_	_	I-Claim
331	insomnia	_	_	I-Claim
332	and	_	_	I-Claim
333	endocrine	_	_	I-Claim
334	side	_	_	I-Claim
335	-	_	_	I-Claim
336	effects	_	_	I-Claim
337	.	_	_	I-Claim

338	Patients	_	_	B-Premise
339	had	_	_	I-Premise
340	significant	_	_	I-Premise
341	concerns	_	_	I-Premise
342	about	_	_	I-Premise
343	the	_	_	I-Premise
344	delivery	_	_	I-Premise
345	of	_	_	I-Premise
346	radiotherapy	_	_	I-Premise
347	services	_	_	I-Premise
348	,	_	_	I-Premise
349	such	_	_	I-Premise
350	as	_	_	I-Premise
351	transport	_	_	I-Premise
352	,	_	_	I-Premise
353	accommodation	_	_	I-Premise
354	and	_	_	I-Premise
355	travel	_	_	I-Premise
356	costs	_	_	I-Premise
357	associated	_	_	I-Premise
358	with	_	_	I-Premise
359	receiving	_	_	I-Premise
360	radiotherapy	_	_	I-Premise
361	.	_	_	I-Premise

362	By	_	_	B-Premise
363	the	_	_	I-Premise
364	end	_	_	I-Premise
365	of	_	_	I-Premise
366	follow	_	_	I-Premise
367	-	_	_	I-Premise
368	up	_	_	I-Premise
369	,	_	_	I-Premise
370	patients	_	_	I-Premise
371	receiving	_	_	I-Premise
372	radiotherapy	_	_	I-Premise
373	were	_	_	I-Premise
374	expressing	_	_	I-Premise
375	less	_	_	I-Premise
376	anxiety	_	_	I-Premise
377	about	_	_	I-Premise
378	recurrence	_	_	I-Premise
379	than	_	_	I-Premise
380	those	_	_	I-Premise
381	who	_	_	I-Premise
382	had	_	_	I-Premise
383	not	_	_	I-Premise
384	received	_	_	I-Premise
385	radiotherapy	_	_	I-Premise
386	.	_	_	I-Premise

387	Functionality	_	_	B-Premise
388	was	_	_	I-Premise
389	not	_	_	I-Premise
390	greatly	_	_	I-Premise
391	affected	_	_	I-Premise
392	by	_	_	I-Premise
393	treatment	_	_	I-Premise
394	.	_	_	I-Premise

395	Within	_	_	B-Premise
396	the	_	_	I-Premise
397	randomised	_	_	I-Premise
398	controlled	_	_	I-Premise
399	trial	_	_	I-Premise
400	,	_	_	I-Premise
401	the	_	_	I-Premise
402	Barthel	_	_	I-Premise
403	Index	_	_	I-Premise
404	demonstrated	_	_	I-Premise
405	a	_	_	I-Premise
406	small	_	_	I-Premise
407	but	_	_	I-Premise
408	significant	_	_	I-Premise
409	fall	_	_	I-Premise
410	in	_	_	I-Premise
411	functionality	_	_	I-Premise
412	with	_	_	I-Premise
413	radiotherapy	_	_	I-Premise
414	compared	_	_	I-Premise
415	with	_	_	I-Premise
416	the	_	_	I-Premise
417	no	_	_	I-Premise
418	radiotherapy	_	_	I-Premise
419	arm	_	_	I-Premise
420	of	_	_	I-Premise
421	the	_	_	I-Premise
422	trial	_	_	I-Premise
423	.	_	_	I-Premise

424	Results	_	_	B-Premise
425	from	_	_	I-Premise
426	the	_	_	I-Premise
427	non	_	_	I-Premise
428	-	_	_	I-Premise
429	randomised	_	_	I-Premise
430	patients	_	_	I-Premise
431	did	_	_	I-Premise
432	not	_	_	I-Premise
433	confirm	_	_	I-Premise
434	this	_	_	I-Premise
435	effect	_	_	I-Premise
436	,	_	_	I-Premise
437	however	_	_	I-Premise
438	.	_	_	I-Premise

439	Cosmetic	_	_	B-Premise
440	results	_	_	I-Premise
441	were	_	_	I-Premise
442	better	_	_	I-Premise
443	in	_	_	I-Premise
444	those	_	_	I-Premise
445	not	_	_	I-Premise
446	receiving	_	_	I-Premise
447	radiotherapy	_	_	I-Premise
448	but	_	_	B-Premise
449	this	_	_	I-Premise
450	did	_	_	I-Premise
451	not	_	_	I-Premise
452	appear	_	_	I-Premise
453	to	_	_	I-Premise
454	be	_	_	I-Premise
455	an	_	_	I-Premise
456	important	_	_	I-Premise
457	issue	_	_	I-Premise
458	to	_	_	I-Premise
459	the	_	_	I-Premise
460	patients	_	_	I-Premise
461	.	_	_	I-Premise

462	The	_	_	B-Claim
463	use	_	_	I-Claim
464	of	_	_	I-Claim
465	home	_	_	I-Claim
466	-	_	_	I-Claim
467	based	_	_	I-Claim
468	assessments	_	_	I-Claim
469	by	_	_	I-Claim
470	a	_	_	I-Claim
471	research	_	_	I-Claim
472	nurse	_	_	I-Claim
473	proved	_	_	I-Claim
474	to	_	_	I-Claim
475	be	_	_	I-Claim
476	an	_	_	I-Claim
477	effective	_	_	I-Claim
478	way	_	_	I-Claim
479	of	_	_	I-Claim
480	obtaining	_	_	I-Claim
481	high	_	_	I-Claim
482	-	_	_	I-Claim
483	quality	_	_	I-Claim
484	data	_	_	I-Claim
485	.	_	_	I-Claim

486	Costs	_	_	O
487	to	_	_	O
488	the	_	_	O
489	NHS	_	_	O
490	associated	_	_	O
491	with	_	_	O
492	postoperative	_	_	O
493	radiotherapy	_	_	O
494	were	_	_	O
495	calculated	_	_	O
496	to	_	_	O
497	be	_	_	O
498	of	_	_	O
499	the	_	_	O
500	order	_	_	O
501	of	_	_	O
502	2000	_	_	O
503	pounds	_	_	O
504	per	_	_	O
505	patient	_	_	O
506	.	_	_	O

507	In	_	_	B-Premise
508	the	_	_	I-Premise
509	follow	_	_	I-Premise
510	-	_	_	I-Premise
511	up	_	_	I-Premise
512	in	_	_	I-Premise
513	this	_	_	I-Premise
514	study	_	_	I-Premise
515	,	_	_	I-Premise
516	there	_	_	I-Premise
517	were	_	_	I-Premise
518	no	_	_	I-Premise
519	recurrences	_	_	I-Premise
520	,	_	_	I-Premise
521	and	_	_	I-Premise
522	the	_	_	I-Premise
523	quality	_	_	I-Premise
524	of	_	_	I-Premise
525	life	_	_	I-Premise
526	utilities	_	_	I-Premise
527	from	_	_	I-Premise
528	EuroQol	_	_	I-Premise
529	were	_	_	I-Premise
530	almost	_	_	I-Premise
531	identical	_	_	I-Premise
532	.	_	_	I-Premise

533	Although	_	_	B-Premise
534	there	_	_	I-Premise
535	are	_	_	I-Premise
536	no	_	_	I-Premise
537	differences	_	_	I-Premise
538	in	_	_	I-Premise
539	overall	_	_	I-Premise
540	quality	_	_	I-Premise
541	of	_	_	I-Premise
542	life	_	_	I-Premise
543	scores	_	_	I-Premise
544	between	_	_	I-Premise
545	the	_	_	I-Premise
546	patients	_	_	I-Premise
547	treated	_	_	I-Premise
548	with	_	_	I-Premise
549	and	_	_	I-Premise
550	without	_	_	I-Premise
551	radiotherapy	_	_	I-Premise
552	,	_	_	I-Premise
553	there	_	_	I-Premise
554	are	_	_	I-Premise
555	several	_	_	I-Premise
556	dimensions	_	_	I-Premise
557	that	_	_	I-Premise
558	exhibit	_	_	I-Premise
559	significant	_	_	I-Premise
560	advantage	_	_	I-Premise
561	to	_	_	I-Premise
562	the	_	_	I-Premise
563	omission	_	_	I-Premise
564	of	_	_	I-Premise
565	irradiation	_	_	I-Premise
566	.	_	_	I-Premise

567	Over	_	_	B-Premise
568	the	_	_	I-Premise
569	first	_	_	I-Premise
570	15	_	_	I-Premise
571	months	_	_	I-Premise
572	,	_	_	I-Premise
573	radiotherapy	_	_	I-Premise
574	for	_	_	I-Premise
575	this	_	_	I-Premise
576	population	_	_	I-Premise
577	is	_	_	I-Premise
578	not	_	_	I-Premise
579	a	_	_	I-Premise
580	cost	_	_	I-Premise
581	-	_	_	I-Premise
582	effective	_	_	I-Premise
583	treatment	_	_	I-Premise
584	.	_	_	I-Premise

585	However	_	_	O
586	,	_	_	O
587	the	_	_	O
588	early	_	_	B-Claim
589	postoperative	_	_	I-Claim
590	outcome	_	_	I-Claim
591	does	_	_	I-Claim
592	not	_	_	I-Claim
593	give	_	_	I-Claim
594	a	_	_	I-Claim
595	complete	_	_	I-Claim
596	answer	_	_	I-Claim
597	and	_	_	O
598	the	_	_	B-Claim
599	eventual	_	_	I-Claim
600	cost	_	_	I-Claim
601	-	_	_	I-Claim
602	effectiveness	_	_	I-Claim
603	will	_	_	I-Claim
604	only	_	_	I-Claim
605	become	_	_	I-Claim
606	clear	_	_	I-Claim
607	after	_	_	I-Claim
608	long	_	_	I-Claim
609	-	_	_	I-Claim
610	term	_	_	I-Claim
611	follow	_	_	I-Claim
612	-	_	_	I-Claim
613	up	_	_	I-Claim
614	.	_	_	I-Claim

615	Extrapolations	_	_	B-Claim
616	from	_	_	I-Claim
617	these	_	_	I-Claim
618	data	_	_	I-Claim
619	suggest	_	_	I-Claim
620	that	_	_	I-Claim
621	radiotherapy	_	_	I-Claim
622	may	_	_	I-Claim
623	not	_	_	I-Claim
624	be	_	_	I-Claim
625	a	_	_	I-Claim
626	cost	_	_	I-Claim
627	-	_	_	I-Claim
628	effective	_	_	I-Claim
629	treatment	_	_	I-Claim
630	unless	_	_	I-Claim
631	it	_	_	I-Claim
632	results	_	_	I-Claim
633	in	_	_	I-Claim
634	a	_	_	I-Claim
635	recurrence	_	_	I-Claim
636	rate	_	_	I-Claim
637	that	_	_	I-Claim
638	is	_	_	I-Claim
639	at	_	_	I-Claim
640	least	_	_	I-Claim
641	5	_	_	I-Claim
642	%	_	_	I-Claim
643	lower	_	_	I-Claim
644	in	_	_	I-Claim
645	absolute	_	_	I-Claim
646	terms	_	_	I-Claim
647	than	_	_	I-Claim
648	those	_	_	I-Claim
649	treated	_	_	I-Claim
650	without	_	_	I-Claim
651	radiotherapy	_	_	I-Claim
652	.	_	_	I-Claim

653	Further	_	_	B-Claim
654	research	_	_	I-Claim
655	is	_	_	I-Claim
656	needed	_	_	I-Claim
657	into	_	_	I-Claim
658	a	_	_	I-Claim
659	number	_	_	I-Claim
660	of	_	_	I-Claim
661	areas	_	_	I-Claim
662	including	_	_	I-Claim
663	the	_	_	I-Claim
664	long	_	_	I-Claim
665	-	_	_	I-Claim
666	term	_	_	I-Claim
667	aspects	_	_	I-Claim
668	of	_	_	I-Claim
669	quality	_	_	I-Claim
670	of	_	_	I-Claim
671	life	_	_	I-Claim
672	,	_	_	I-Claim
673	clinical	_	_	I-Claim
674	outcomes	_	_	I-Claim
675	,	_	_	I-Claim
676	costs	_	_	I-Claim
677	and	_	_	I-Claim
678	consequences	_	_	I-Claim
679	of	_	_	I-Claim
680	omitting	_	_	I-Claim
681	radiotherapy	_	_	I-Claim
682	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	whether	_	_	O
3	palliation	_	_	O
4	of	_	_	O
5	chest	_	_	O
6	symptoms	_	_	O
7	from	_	_	O
8	a	_	_	O
9	10	_	_	O
10	Gy	_	_	O
11	single	_	_	O
12	fraction	_	_	O
13	(	_	_	O
14	regimen	_	_	O
15	1	_	_	O
16	)	_	_	O
17	was	_	_	O
18	equivalent	_	_	O
19	to	_	_	O
20	that	_	_	O
21	from	_	_	O
22	30	_	_	O
23	Gy	_	_	O
24	in	_	_	O
25	10	_	_	O
26	fractions	_	_	O
27	(	_	_	O
28	regimen	_	_	O
29	2	_	_	O
30	)	_	_	O
31	.	_	_	O

32	Patients	_	_	O
33	with	_	_	O
34	cytologically	_	_	O
35	proven	_	_	O
36	,	_	_	O
37	symptomatic	_	_	O
38	lung	_	_	O
39	cancer	_	_	O
40	not	_	_	O
41	amenable	_	_	O
42	to	_	_	O
43	curative	_	_	O
44	therapy	_	_	O
45	,	_	_	O
46	with	_	_	O
47	performance	_	_	O
48	status	_	_	O
49	0	_	_	O
50	-	_	_	O
51	3	_	_	O
52	,	_	_	O
53	were	_	_	O
54	randomised	_	_	O
55	to	_	_	O
56	receive	_	_	O
57	either	_	_	O
58	30	_	_	O
59	Gy	_	_	O
60	in	_	_	O
61	10	_	_	O
62	fractions	_	_	O
63	or	_	_	O
64	a	_	_	O
65	10	_	_	O
66	Gy	_	_	O
67	single	_	_	O
68	fraction	_	_	O
69	.	_	_	O

70	Local	_	_	O
71	symptoms	_	_	O
72	were	_	_	O
73	scored	_	_	O
74	on	_	_	O
75	a	_	_	O
76	physician	_	_	O
77	-	_	_	O
78	assessed	_	_	O
79	,	_	_	O
80	five	_	_	O
81	-	_	_	O
82	point	_	_	O
83	categorical	_	_	O
84	scale	_	_	O
85	and	_	_	O
86	summed	_	_	O
87	to	_	_	O
88	produce	_	_	O
89	a	_	_	O
90	total	_	_	O
91	symptom	_	_	O
92	score	_	_	O
93	(	_	_	O
94	TSS	_	_	O
95	)	_	_	O
96	.	_	_	O

97	This	_	_	O
98	,	_	_	O
99	performance	_	_	O
100	status	_	_	O
101	,	_	_	O
102	Hospital	_	_	O
103	Anxiety	_	_	O
104	and	_	_	O
105	Depression	_	_	O
106	(	_	_	O
107	HAD	_	_	O
108	)	_	_	O
109	score	_	_	O
110	and	_	_	O
111	Spitzer	_	_	O
112	'	_	_	O
113	s	_	_	O
114	quality	_	_	O
115	-	_	_	O
116	of	_	_	O
117	-	_	_	O
118	life	_	_	O
119	index	_	_	O
120	were	_	_	O
121	noted	_	_	O
122	before	_	_	O
123	treatment	_	_	O
124	,	_	_	O
125	at	_	_	O
126	1	_	_	O
127	month	_	_	O
128	after	_	_	O
129	treatment	_	_	O
130	and	_	_	O
131	every	_	_	O
132	2	_	_	O
133	months	_	_	O
134	thereafter	_	_	O
135	.	_	_	O

136	Palliation	_	_	O
137	was	_	_	O
138	defined	_	_	O
139	as	_	_	O
140	an	_	_	O
141	improvement	_	_	O
142	of	_	_	O
143	one	_	_	O
144	point	_	_	O
145	or	_	_	O
146	more	_	_	O
147	in	_	_	O
148	the	_	_	O
149	categorical	_	_	O
150	scale	_	_	O
151	.	_	_	O

152	Equivalence	_	_	O
153	was	_	_	O
154	defined	_	_	O
155	as	_	_	O
156	less	_	_	O
157	than	_	_	O
158	20	_	_	O
159	%	_	_	O
160	difference	_	_	O
161	in	_	_	O
162	the	_	_	O
163	number	_	_	O
164	achieving	_	_	O
165	an	_	_	O
166	improvement	_	_	O
167	in	_	_	O
168	the	_	_	O
169	TSS	_	_	O
170	.	_	_	O

171	We	_	_	O
172	randomised	_	_	O
173	149	_	_	O
174	patients	_	_	O
175	and	_	_	O
176	analysed	_	_	O
177	74	_	_	O
178	in	_	_	O
179	each	_	_	O
180	arm	_	_	O
181	.	_	_	O

182	According	_	_	O
183	to	_	_	O
184	the	_	_	O
185	design	_	_	O
186	criteria	_	_	O
187	,	_	_	O
188	palliation	_	_	O
189	was	_	_	O
190	equivalent	_	_	O
191	between	_	_	O
192	the	_	_	O
193	two	_	_	O
194	arms	_	_	O
195	.	_	_	O

196	TSS	_	_	B-Premise
197	improved	_	_	I-Premise
198	in	_	_	I-Premise
199	49	_	_	I-Premise
200	patients	_	_	I-Premise
201	(	_	_	I-Premise
202	77	_	_	I-Premise
203	%	_	_	I-Premise
204	)	_	_	I-Premise
205	on	_	_	I-Premise
206	regimen	_	_	I-Premise
207	1	_	_	I-Premise
208	,	_	_	I-Premise
209	and	_	_	I-Premise
210	in	_	_	I-Premise
211	57	_	_	I-Premise
212	(	_	_	I-Premise
213	92	_	_	I-Premise
214	%	_	_	I-Premise
215	)	_	_	I-Premise
216	patients	_	_	I-Premise
217	on	_	_	I-Premise
218	regimen	_	_	I-Premise
219	2	_	_	I-Premise
220	,	_	_	I-Premise
221	a	_	_	I-Premise
222	difference	_	_	I-Premise
223	of	_	_	I-Premise
224	15	_	_	I-Premise
225	%	_	_	I-Premise
226	(	_	_	I-Premise
227	95	_	_	I-Premise
228	%	_	_	I-Premise
229	confidence	_	_	I-Premise
230	interval	_	_	I-Premise
231	[	_	_	I-Premise
232	CI	_	_	I-Premise
233	]	_	_	I-Premise
234	3	_	_	I-Premise
235	-	_	_	I-Premise
236	28	_	_	I-Premise
237	)	_	_	I-Premise
238	in	_	_	I-Premise
239	the	_	_	I-Premise
240	proportion	_	_	I-Premise
241	improving	_	_	I-Premise
242	between	_	_	I-Premise
243	the	_	_	I-Premise
244	two	_	_	I-Premise
245	regimens	_	_	I-Premise
246	.	_	_	I-Premise

247	A	_	_	B-Premise
248	complete	_	_	I-Premise
249	resolution	_	_	I-Premise
250	of	_	_	I-Premise
251	all	_	_	I-Premise
252	symptoms	_	_	I-Premise
253	was	_	_	I-Premise
254	achieved	_	_	I-Premise
255	in	_	_	I-Premise
256	three	_	_	I-Premise
257	(	_	_	I-Premise
258	5	_	_	I-Premise
259	%	_	_	I-Premise
260	)	_	_	I-Premise
261	on	_	_	I-Premise
262	regimen	_	_	I-Premise
263	1	_	_	I-Premise
264	,	_	_	I-Premise
265	and	_	_	I-Premise
266	in	_	_	I-Premise
267	14	_	_	I-Premise
268	(	_	_	I-Premise
269	23	_	_	I-Premise
270	%	_	_	I-Premise
271	)	_	_	I-Premise
272	patients	_	_	I-Premise
273	on	_	_	I-Premise
274	regimen	_	_	I-Premise
275	2	_	_	I-Premise
276	(	_	_	I-Premise
277	P	_	_	I-Premise
278	<	_	_	I-Premise
279	0	_	_	I-Premise
280	.	_	_	I-Premise

281	001	_	_	I-Premise
282	)	_	_	I-Premise
283	,	_	_	I-Premise
284	a	_	_	I-Premise
285	difference	_	_	I-Premise
286	in	_	_	I-Premise
287	the	_	_	I-Premise
288	proportion	_	_	I-Premise
289	between	_	_	I-Premise
290	the	_	_	I-Premise
291	two	_	_	I-Premise
292	regimens	_	_	I-Premise
293	of	_	_	I-Premise
294	21	_	_	I-Premise
295	%	_	_	I-Premise
296	(	_	_	I-Premise
297	95	_	_	I-Premise
298	%	_	_	I-Premise
299	CI	_	_	I-Premise
300	10	_	_	I-Premise
301	-	_	_	I-Premise
302	33	_	_	I-Premise
303	)	_	_	I-Premise
304	.	_	_	I-Premise

305	A	_	_	B-Premise
306	significantly	_	_	I-Premise
307	higher	_	_	I-Premise
308	proportion	_	_	I-Premise
309	of	_	_	I-Premise
310	patients	_	_	I-Premise
311	experienced	_	_	I-Premise
312	palliation	_	_	I-Premise
313	and	_	_	I-Premise
314	complete	_	_	I-Premise
315	resolution	_	_	I-Premise
316	of	_	_	I-Premise
317	chest	_	_	I-Premise
318	pain	_	_	I-Premise
319	and	_	_	I-Premise
320	dyspnoea	_	_	I-Premise
321	with	_	_	I-Premise
322	regimen	_	_	I-Premise
323	2	_	_	I-Premise
324	.	_	_	I-Premise

325	No	_	_	B-Premise
326	differences	_	_	I-Premise
327	were	_	_	I-Premise
328	observed	_	_	I-Premise
329	in	_	_	I-Premise
330	toxicity	_	_	I-Premise
331	.	_	_	I-Premise

332	The	_	_	B-Premise
333	median	_	_	I-Premise
334	survival	_	_	I-Premise
335	was	_	_	I-Premise
336	22	_	_	I-Premise
337	.	_	_	I-Premise

338	7	_	_	I-Premise
339	weeks	_	_	I-Premise
340	for	_	_	I-Premise
341	regimen	_	_	I-Premise
342	1	_	_	I-Premise
343	and	_	_	I-Premise
344	28	_	_	I-Premise
345	.	_	_	I-Premise

346	3	_	_	I-Premise
347	weeks	_	_	I-Premise
348	for	_	_	I-Premise
349	regimen	_	_	I-Premise
350	2	_	_	I-Premise
351	(	_	_	I-Premise
352	P	_	_	I-Premise
353	=	_	_	I-Premise
354	0	_	_	I-Premise
355	.	_	_	I-Premise

356	197	_	_	I-Premise
357	)	_	_	I-Premise
358	.	_	_	I-Premise

359	Although	_	_	B-Claim
360	this	_	_	I-Claim
361	trial	_	_	I-Claim
362	met	_	_	I-Claim
363	the	_	_	I-Claim
364	pre	_	_	I-Claim
365	-	_	_	I-Claim
366	determined	_	_	I-Claim
367	criteria	_	_	I-Claim
368	for	_	_	I-Claim
369	equivalence	_	_	I-Claim
370	between	_	_	I-Claim
371	the	_	_	I-Claim
372	two	_	_	I-Claim
373	palliative	_	_	I-Claim
374	regimens	_	_	I-Claim
375	,	_	_	I-Claim
376	significantly	_	_	B-Claim
377	more	_	_	I-Claim
378	patients	_	_	I-Claim
379	achieved	_	_	I-Claim
380	complete	_	_	I-Claim
381	resolution	_	_	I-Claim
382	of	_	_	I-Claim
383	symptoms	_	_	I-Claim
384	and	_	_	I-Claim
385	palliation	_	_	I-Claim
386	of	_	_	I-Claim
387	chest	_	_	I-Claim
388	pain	_	_	I-Claim
389	and	_	_	I-Claim
390	dyspnoea	_	_	I-Claim
391	with	_	_	I-Claim
392	the	_	_	I-Claim
393	fractionated	_	_	I-Claim
394	regimen	_	_	I-Claim
395	.	_	_	I-Claim


0	The	_	_	B-Claim
1	incidence	_	_	I-Claim
2	and	_	_	I-Claim
3	development	_	_	I-Claim
4	of	_	_	I-Claim
5	cancer	_	_	I-Claim
6	are	_	_	I-Claim
7	closely	_	_	I-Claim
8	related	_	_	I-Claim
9	to	_	_	I-Claim
10	dysfunction	_	_	I-Claim
11	of	_	_	I-Claim
12	immune	_	_	I-Claim
13	function	_	_	I-Claim
14	.	_	_	I-Claim

15	The	_	_	O
16	immune	_	_	O
17	system	_	_	O
18	cannot	_	_	O
19	identify	_	_	O
20	and	_	_	O
21	remove	_	_	O
22	malignant	_	_	O
23	and	_	_	O
24	mutant	_	_	O
25	cells	_	_	O
26	,	_	_	O
27	which	_	_	O
28	cause	_	_	O
29	tumor	_	_	O
30	cells	_	_	O
31	to	_	_	O
32	escape	_	_	O
33	from	_	_	O
34	surveillance	_	_	O
35	and	_	_	O
36	clearance	_	_	O
37	of	_	_	O
38	the	_	_	O
39	immune	_	_	O
40	system	_	_	O
41	.	_	_	O

42	Immunobiological	_	_	O
43	cancer	_	_	O
44	therapy	_	_	O
45	plays	_	_	O
46	an	_	_	O
47	important	_	_	O
48	role	_	_	O
49	in	_	_	O
50	strengthening	_	_	O
51	body	_	_	O
52	immunological	_	_	O
53	surveillance	_	_	O
54	function	_	_	O
55	and	_	_	O
56	killing	_	_	O
57	remaining	_	_	O
58	tumor	_	_	O
59	cells	_	_	O
60	in	_	_	O
61	the	_	_	O
62	body	_	_	O
63	.	_	_	O

64	We	_	_	O
65	investigated	_	_	O
66	the	_	_	O
67	role	_	_	O
68	of	_	_	O
69	DC	_	_	O
70	/	_	_	O
71	CIK	_	_	O
72	(	_	_	O
73	dendritic	_	_	O
74	cell	_	_	O
75	/	_	_	O
76	cytokine	_	_	O
77	-	_	_	O
78	induced	_	_	O
79	killer	_	_	O
80	cells	_	_	O
81	)	_	_	O
82	immunobiological	_	_	O
83	cancer	_	_	O
84	therapy	_	_	O
85	in	_	_	O
86	maintenance	_	_	O
87	therapy	_	_	O
88	of	_	_	O
89	advanced	_	_	O
90	non	_	_	O
91	-	_	_	O
92	small	_	_	O
93	cell	_	_	O
94	lung	_	_	O
95	cancer	_	_	O
96	.	_	_	O

97	When	_	_	O
98	60	_	_	O
99	cases	_	_	O
100	of	_	_	O
101	non	_	_	O
102	-	_	_	O
103	small	_	_	O
104	cell	_	_	O
105	lung	_	_	O
106	cancer	_	_	O
107	patients	_	_	O
108	in	_	_	O
109	stage	_	_	O
110	IIIb	_	_	O
111	and	_	_	O
112	IV	_	_	O
113	reached	_	_	O
114	stable	_	_	O
115	disease	_	_	O
116	after	_	_	O
117	treatment	_	_	O
118	with	_	_	O
119	4	_	_	O
120	cycles	_	_	O
121	of	_	_	O
122	a	_	_	O
123	two	_	_	O
124	-	_	_	O
125	drug	_	_	O
126	regimen	_	_	O
127	with	_	_	O
128	platinum	_	_	O
129	,	_	_	O
130	they	_	_	O
131	were	_	_	O
132	randomly	_	_	O
133	divided	_	_	O
134	into	_	_	O
135	two	_	_	O
136	groups	_	_	O
137	.	_	_	O

138	One	_	_	O
139	group	_	_	O
140	was	_	_	O
141	treated	_	_	O
142	with	_	_	O
143	DC	_	_	O
144	/	_	_	O
145	CIK	_	_	O
146	immunobiological	_	_	O
147	cancer	_	_	O
148	therapy	_	_	O
149	,	_	_	O
150	and	_	_	O
151	the	_	_	O
152	other	_	_	O
153	was	_	_	O
154	taken	_	_	O
155	as	_	_	O
156	a	_	_	O
157	control	_	_	O
158	group	_	_	O
159	.	_	_	O

160	Finally	_	_	O
161	,	_	_	O
162	cancer	_	_	O
163	progression	_	_	O
164	time	_	_	O
165	and	_	_	O
166	toxicity	_	_	O
167	reaction	_	_	O
168	of	_	_	O
169	the	_	_	O
170	two	_	_	O
171	groups	_	_	O
172	were	_	_	O
173	evaluated	_	_	O
174	.	_	_	O

175	DC	_	_	B-Premise
176	/	_	_	I-Premise
177	CIK	_	_	I-Premise
178	treatment	_	_	I-Premise
179	prolongs	_	_	I-Premise
180	progression	_	_	I-Premise
181	-	_	_	I-Premise
182	free	_	_	I-Premise
183	survival	_	_	I-Premise
184	(	_	_	I-Premise
185	3	_	_	I-Premise
186	.	_	_	I-Premise

187	20	_	_	I-Premise
188	months	_	_	I-Premise
189	[	_	_	I-Premise
190	95	_	_	I-Premise
191	%	_	_	I-Premise
192	CI	_	_	I-Premise
193	,	_	_	I-Premise
194	2	_	_	I-Premise
195	.	_	_	I-Premise

196	94	_	_	I-Premise
197	-	_	_	I-Premise
198	3	_	_	I-Premise
199	.	_	_	I-Premise

200	50	_	_	I-Premise
201	]	_	_	I-Premise
202	vs	_	_	I-Premise
203	2	_	_	I-Premise
204	.	_	_	I-Premise

205	56	_	_	I-Premise
206	months	_	_	I-Premise
207	[	_	_	I-Premise
208	95	_	_	I-Premise
209	%	_	_	I-Premise
210	CI	_	_	I-Premise
211	,	_	_	I-Premise
212	2	_	_	I-Premise
213	.	_	_	I-Premise

214	39	_	_	I-Premise
215	-	_	_	I-Premise
216	2	_	_	I-Premise
217	.	_	_	I-Premise

218	73	_	_	I-Premise
219	]	_	_	I-Premise
220	;	_	_	I-Premise
221	P	_	_	I-Premise
222	<	_	_	I-Premise
223	0	_	_	I-Premise
224	.	_	_	I-Premise

225	05	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	In	_	_	B-Premise
229	the	_	_	I-Premise
230	treatment	_	_	I-Premise
231	group	_	_	I-Premise
232	,	_	_	I-Premise
233	the	_	_	I-Premise
234	proportion	_	_	I-Premise
235	of	_	_	I-Premise
236	NK	_	_	I-Premise
237	cells	_	_	I-Premise
238	,	_	_	I-Premise
239	T	_	_	I-Premise
240	-	_	_	I-Premise
241	cell	_	_	I-Premise
242	subgroups	_	_	I-Premise
243	CD3	_	_	I-Premise
244	+	_	_	I-Premise
245	,	_	_	I-Premise
246	CD4	_	_	I-Premise
247	+	_	_	I-Premise
248	and	_	_	I-Premise
249	CD8	_	_	I-Premise
250	+	_	_	I-Premise
251	had	_	_	I-Premise
252	a	_	_	I-Premise
253	significant	_	_	I-Premise
254	change	_	_	I-Premise
255	before	_	_	I-Premise
256	and	_	_	I-Premise
257	after	_	_	I-Premise
258	treatment	_	_	I-Premise
259	.	_	_	I-Premise

260	Liver	_	_	B-Premise
261	and	_	_	I-Premise
262	kidney	_	_	I-Premise
263	function	_	_	I-Premise
264	and	_	_	I-Premise
265	blood	_	_	I-Premise
266	tests	_	_	I-Premise
267	of	_	_	I-Premise
268	the	_	_	I-Premise
269	treatment	_	_	I-Premise
270	group	_	_	I-Premise
271	were	_	_	I-Premise
272	within	_	_	I-Premise
273	the	_	_	I-Premise
274	normal	_	_	I-Premise
275	range	_	_	I-Premise
276	before	_	_	I-Premise
277	and	_	_	I-Premise
278	after	_	_	I-Premise
279	treatment	_	_	I-Premise
280	.	_	_	I-Premise

281	In	_	_	B-Premise
282	the	_	_	I-Premise
283	treatment	_	_	I-Premise
284	group	_	_	I-Premise
285	,	_	_	I-Premise
286	1	_	_	I-Premise
287	case	_	_	I-Premise
288	suffered	_	_	I-Premise
289	from	_	_	I-Premise
290	chest	_	_	I-Premise
291	distress	_	_	I-Premise
292	,	_	_	I-Premise
293	3	_	_	I-Premise
294	cases	_	_	I-Premise
295	suffered	_	_	I-Premise
296	from	_	_	I-Premise
297	acratia	_	_	I-Premise
298	,	_	_	I-Premise
299	and	_	_	I-Premise
300	4	_	_	I-Premise
301	cases	_	_	I-Premise
302	suffered	_	_	I-Premise
303	from	_	_	I-Premise
304	pyrexia	_	_	I-Premise
305	.	_	_	I-Premise

306	DC	_	_	B-Claim
307	/	_	_	I-Claim
308	CIK	_	_	I-Claim
309	treatment	_	_	I-Claim
310	had	_	_	I-Claim
311	potential	_	_	I-Claim
312	benefit	_	_	I-Claim
313	for	_	_	I-Claim
314	patients	_	_	I-Claim
315	with	_	_	I-Claim
316	advanced	_	_	I-Claim
317	non	_	_	I-Claim
318	-	_	_	I-Claim
319	small	_	_	I-Claim
320	cell	_	_	I-Claim
321	lung	_	_	I-Claim
322	cancer	_	_	I-Claim
323	compared	_	_	I-Claim
324	with	_	_	I-Claim
325	the	_	_	I-Claim
326	control	_	_	I-Claim
327	group	_	_	I-Claim
328	and	_	_	I-Claim
329	had	_	_	I-Claim
330	no	_	_	I-Claim
331	obvious	_	_	I-Claim
332	side	_	_	I-Claim
333	effects	_	_	I-Claim
334	.	_	_	I-Claim

335	DC	_	_	B-Claim
336	/	_	_	I-Claim
337	CIK	_	_	I-Claim
338	treatment	_	_	I-Claim
339	is	_	_	I-Claim
340	a	_	_	I-Claim
341	safe	_	_	I-Claim
342	and	_	_	I-Claim
343	effective	_	_	I-Claim
344	method	_	_	I-Claim
345	for	_	_	I-Claim
346	maintenance	_	_	I-Claim
347	therapy	_	_	I-Claim
348	of	_	_	I-Claim
349	advanced	_	_	I-Claim
350	non	_	_	I-Claim
351	-	_	_	I-Claim
352	small	_	_	I-Claim
353	cell	_	_	I-Claim
354	lung	_	_	I-Claim
355	cancer	_	_	I-Claim
356	.	_	_	I-Claim


0	Cancer	_	_	O
1	cachexia	_	_	O
2	is	_	_	O
3	a	_	_	O
4	common	_	_	O
5	problem	_	_	O
6	among	_	_	O
7	advanced	_	_	O
8	cancer	_	_	O
9	patients	_	_	O
10	.	_	_	O

11	A	_	_	O
12	mixture	_	_	O
13	of	_	_	O
14	beta	_	_	O
15	-	_	_	O
16	hydroxyl	_	_	O
17	beta	_	_	O
18	-	_	_	O
19	methyl	_	_	O
20	butyrate	_	_	O
21	,	_	_	O
22	glutamine	_	_	O
23	,	_	_	O
24	and	_	_	O
25	arginine	_	_	O
26	(	_	_	O
27	HMB	_	_	O
28	/	_	_	O
29	Arg	_	_	O
30	/	_	_	O
31	Gln	_	_	O
32	)	_	_	O
33	previously	_	_	O
34	showed	_	_	O
35	activity	_	_	O
36	for	_	_	O
37	increasing	_	_	O
38	lean	_	_	O
39	body	_	_	O
40	mass	_	_	O
41	(	_	_	O
42	LBM	_	_	O
43	)	_	_	O
44	among	_	_	O
45	patients	_	_	O
46	with	_	_	O
47	cancer	_	_	O
48	cachexia	_	_	O
49	.	_	_	O

50	Therefore	_	_	O
51	a	_	_	O
52	phase	_	_	O
53	III	_	_	O
54	trial	_	_	O
55	was	_	_	O
56	implemented	_	_	O
57	to	_	_	O
58	confirm	_	_	O
59	this	_	_	O
60	activity	_	_	O
61	.	_	_	O

62	Four	_	_	O
63	hundred	_	_	O
64	seventy	_	_	O
65	-	_	_	O
66	two	_	_	O
67	advanced	_	_	O
68	cancer	_	_	O
69	patients	_	_	O
70	with	_	_	O
71	between	_	_	O
72	2	_	_	O
73	%	_	_	O
74	and	_	_	O
75	10	_	_	O
76	%	_	_	O
77	weight	_	_	O
78	loss	_	_	O
79	were	_	_	O
80	randomized	_	_	O
81	to	_	_	O
82	a	_	_	O
83	mixture	_	_	O
84	of	_	_	O
85	beta	_	_	O
86	-	_	_	O
87	hydroxyl	_	_	O
88	beta	_	_	O
89	-	_	_	O
90	methyl	_	_	O
91	butyrate	_	_	O
92	,	_	_	O
93	glutamine	_	_	O
94	,	_	_	O
95	and	_	_	O
96	arginine	_	_	O
97	or	_	_	O
98	an	_	_	O
99	isonitrogenous	_	_	O
100	,	_	_	O
101	isocaloric	_	_	O
102	control	_	_	O
103	mixture	_	_	O
104	taken	_	_	O
105	twice	_	_	O
106	a	_	_	O
107	day	_	_	O
108	for	_	_	O
109	8	_	_	O
110	weeks	_	_	O
111	.	_	_	O

112	Lean	_	_	O
113	body	_	_	O
114	mass	_	_	O
115	was	_	_	O
116	estimated	_	_	O
117	by	_	_	O
118	bioimpedance	_	_	O
119	and	_	_	O
120	skin	_	_	O
121	-	_	_	O
122	fold	_	_	O
123	measurements	_	_	O
124	.	_	_	O

125	Body	_	_	O
126	plethysmography	_	_	O
127	was	_	_	O
128	used	_	_	O
129	when	_	_	O
130	available	_	_	O
131	.	_	_	O

132	Weight	_	_	O
133	,	_	_	O
134	the	_	_	O
135	Schwartz	_	_	O
136	Fatigue	_	_	O
137	Scale	_	_	O
138	,	_	_	O
139	and	_	_	O
140	the	_	_	O
141	Spitzer	_	_	O
142	Quality	_	_	O
143	of	_	_	O
144	Life	_	_	O
145	Scale	_	_	O
146	were	_	_	O
147	also	_	_	O
148	measured	_	_	O
149	.	_	_	O

150	Only	_	_	O
151	37	_	_	O
152	%	_	_	O
153	of	_	_	O
154	the	_	_	O
155	patients	_	_	O
156	completed	_	_	O
157	protocol	_	_	O
158	treatment	_	_	O
159	.	_	_	O

160	The	_	_	O
161	majority	_	_	O
162	of	_	_	O
163	the	_	_	O
164	patient	_	_	O
165	loss	_	_	O
166	was	_	_	O
167	because	_	_	O
168	of	_	_	O
169	patient	_	_	O
170	preference	_	_	O
171	(	_	_	O
172	45	_	_	O
173	%	_	_	O
174	of	_	_	O
175	enrolled	_	_	O
176	patients	_	_	O
177	)	_	_	O
178	.	_	_	O

179	However	_	_	O
180	,	_	_	O
181	loss	_	_	O
182	of	_	_	O
183	power	_	_	O
184	was	_	_	O
185	not	_	_	O
186	an	_	_	O
187	issue	_	_	O
188	because	_	_	O
189	of	_	_	O
190	the	_	_	O
191	planned	_	_	O
192	large	_	_	O
193	target	_	_	O
194	sample	_	_	O
195	size	_	_	O
196	.	_	_	O

197	Based	_	_	O
198	on	_	_	O
199	an	_	_	O
200	intention	_	_	O
201	to	_	_	O
202	treat	_	_	O
203	analysis	_	_	O
204	,	_	_	O
205	there	_	_	O
206	was	_	_	O
207	no	_	_	O
208	statistically	_	_	O
209	significant	_	_	O
210	difference	_	_	O
211	in	_	_	O
212	the	_	_	O
213	8	_	_	O
214	-	_	_	O
215	week	_	_	O
216	lean	_	_	O
217	body	_	_	O
218	mass	_	_	O
219	between	_	_	O
220	the	_	_	O
221	two	_	_	O
222	arms	_	_	O
223	.	_	_	O

224	The	_	_	O
225	secondary	_	_	O
226	endpoints	_	_	O
227	were	_	_	O
228	also	_	_	O
229	not	_	_	O
230	significantly	_	_	O
231	different	_	_	O
232	between	_	_	O
233	the	_	_	O
234	arms	_	_	O
235	.	_	_	O

236	Based	_	_	B-Premise
237	on	_	_	I-Premise
238	the	_	_	I-Premise
239	results	_	_	I-Premise
240	of	_	_	I-Premise
241	the	_	_	I-Premise
242	area	_	_	I-Premise
243	under	_	_	I-Premise
244	the	_	_	I-Premise
245	curve	_	_	I-Premise
246	(	_	_	I-Premise
247	AUC	_	_	I-Premise
248	)	_	_	I-Premise
249	analysis	_	_	I-Premise
250	,	_	_	I-Premise
251	patients	_	_	I-Premise
252	receiving	_	_	I-Premise
253	HMB	_	_	I-Premise
254	/	_	_	I-Premise
255	Arg	_	_	I-Premise
256	/	_	_	I-Premise
257	Gln	_	_	I-Premise
258	had	_	_	I-Premise
259	a	_	_	I-Premise
260	strong	_	_	I-Premise
261	trend	_	_	I-Premise
262	higher	_	_	I-Premise
263	LBM	_	_	I-Premise
264	throughout	_	_	I-Premise
265	the	_	_	I-Premise
266	study	_	_	I-Premise
267	as	_	_	I-Premise
268	measured	_	_	I-Premise
269	by	_	_	I-Premise
270	both	_	_	I-Premise
271	bioimpedance	_	_	I-Premise
272	(	_	_	I-Premise
273	p	_	_	I-Premise
274	=	_	_	I-Premise
275	0	_	_	I-Premise
276	.	_	_	I-Premise

277	08	_	_	I-Premise
278	)	_	_	I-Premise
279	and	_	_	I-Premise
280	skin	_	_	I-Premise
281	-	_	_	I-Premise
282	fold	_	_	I-Premise
283	measurements	_	_	I-Premise
284	(	_	_	I-Premise
285	p	_	_	I-Premise
286	=	_	_	I-Premise
287	0	_	_	I-Premise
288	.	_	_	I-Premise

289	08	_	_	I-Premise
290	)	_	_	I-Premise
291	.	_	_	I-Premise

292	Among	_	_	B-Premise
293	the	_	_	I-Premise
294	subset	_	_	I-Premise
295	of	_	_	I-Premise
296	patients	_	_	I-Premise
297	receiving	_	_	I-Premise
298	concurrent	_	_	I-Premise
299	chemotherapy	_	_	I-Premise
300	,	_	_	I-Premise
301	there	_	_	I-Premise
302	were	_	_	I-Premise
303	again	_	_	I-Premise
304	no	_	_	I-Premise
305	significant	_	_	I-Premise
306	differences	_	_	I-Premise
307	in	_	_	I-Premise
308	the	_	_	I-Premise
309	endpoints	_	_	I-Premise
310	.	_	_	I-Premise

311	The	_	_	B-Premise
312	secondary	_	_	I-Premise
313	endpoints	_	_	I-Premise
314	were	_	_	I-Premise
315	also	_	_	I-Premise
316	not	_	_	I-Premise
317	significantly	_	_	I-Premise
318	different	_	_	I-Premise
319	between	_	_	I-Premise
320	the	_	_	I-Premise
321	arms	_	_	I-Premise
322	.	_	_	I-Premise

323	This	_	_	B-Claim
324	trial	_	_	I-Claim
325	was	_	_	I-Claim
326	unable	_	_	I-Claim
327	to	_	_	I-Claim
328	adequately	_	_	I-Claim
329	test	_	_	I-Claim
330	the	_	_	I-Claim
331	ability	_	_	I-Claim
332	of	_	_	I-Claim
333	beta	_	_	I-Claim
334	-	_	_	I-Claim
335	hydroxy	_	_	I-Claim
336	beta	_	_	I-Claim
337	-	_	_	I-Claim
338	methylbutyrate	_	_	I-Claim
339	,	_	_	I-Claim
340	glutamine	_	_	I-Claim
341	,	_	_	I-Claim
342	and	_	_	I-Claim
343	arginine	_	_	I-Claim
344	to	_	_	I-Claim
345	reverse	_	_	I-Claim
346	or	_	_	I-Claim
347	prevent	_	_	I-Claim
348	lean	_	_	I-Claim
349	body	_	_	I-Claim
350	mass	_	_	I-Claim
351	wasting	_	_	I-Claim
352	among	_	_	I-Claim
353	cancer	_	_	I-Claim
354	patients	_	_	I-Claim
355	.	_	_	I-Claim

356	Possible	_	_	O
357	contributing	_	_	O
358	factors	_	_	O
359	beyond	_	_	O
360	the	_	_	O
361	efficacy	_	_	O
362	of	_	_	O
363	the	_	_	O
364	intervention	_	_	O
365	were	_	_	O
366	the	_	_	O
367	inability	_	_	O
368	of	_	_	O
369	patients	_	_	O
370	to	_	_	O
371	complete	_	_	O
372	an	_	_	O
373	8	_	_	O
374	-	_	_	O
375	week	_	_	O
376	course	_	_	O
377	of	_	_	O
378	treatment	_	_	O
379	and	_	_	O
380	return	_	_	O
381	in	_	_	O
382	a	_	_	O
383	timely	_	_	O
384	fashion	_	_	O
385	for	_	_	O
386	follow	_	_	O
387	-	_	_	O
388	up	_	_	O
389	assessment	_	_	O
390	,	_	_	O
391	and	_	_	O
392	because	_	_	O
393	the	_	_	O
394	patients	_	_	O
395	may	_	_	O
396	have	_	_	O
397	only	_	_	O
398	had	_	_	O
399	weight	_	_	O
400	loss	_	_	O
401	possible	_	_	O
402	not	_	_	O
403	related	_	_	O
404	to	_	_	O
405	cachexia	_	_	O
406	,	_	_	O
407	but	_	_	O
408	other	_	_	O
409	causes	_	_	O
410	of	_	_	O
411	weight	_	_	O
412	loss	_	_	O
413	,	_	_	O
414	such	_	_	O
415	as	_	_	O
416	decreased	_	_	O
417	appetite	_	_	O
418	.	_	_	O

419	However	_	_	O
420	,	_	_	O
421	there	_	_	O
422	was	_	_	O
423	a	_	_	O
424	strong	_	_	O
425	trend	_	_	O
426	towards	_	_	O
427	an	_	_	O
428	increased	_	_	O
429	body	_	_	O
430	mass	_	_	O
431	among	_	_	O
432	patients	_	_	O
433	taking	_	_	O
434	the	_	_	O
435	Juven	_	_	O
436	compound	_	_	O
437	using	_	_	O
438	the	_	_	O
439	secondary	_	_	O
440	endpoint	_	_	O
441	of	_	_	O
442	AUC	_	_	O
443	.	_	_	O


0	Radiation	_	_	O
1	-	_	_	O
2	induced	_	_	O
3	mucositis	_	_	O
4	is	_	_	O
5	an	_	_	O
6	acute	_	_	O
7	reaction	_	_	O
8	of	_	_	O
9	the	_	_	O
10	mucosa	_	_	O
11	of	_	_	O
12	patients	_	_	O
13	undergoing	_	_	O
14	head	_	_	O
15	and	_	_	O
16	neck	_	_	O
17	radiotherapy	_	_	O
18	.	_	_	O

19	It	_	_	O
20	can	_	_	O
21	have	_	_	O
22	debilitating	_	_	O
23	and	_	_	O
24	dose	_	_	O
25	-	_	_	O
26	limiting	_	_	O
27	consequences	_	_	O
28	.	_	_	O

29	There	_	_	B-Claim
30	is	_	_	I-Claim
31	no	_	_	I-Claim
32	consensus	_	_	I-Claim
33	on	_	_	I-Claim
34	an	_	_	I-Claim
35	accepted	_	_	I-Claim
36	intervention	_	_	I-Claim
37	that	_	_	I-Claim
38	significantly	_	_	I-Claim
39	reduces	_	_	I-Claim
40	its	_	_	I-Claim
41	severity	_	_	I-Claim
42	.	_	_	I-Claim

43	Misoprostol	_	_	O
44	is	_	_	O
45	a	_	_	O
46	synthetic	_	_	O
47	prostaglandin	_	_	O
48	E1	_	_	O
49	analogue	_	_	O
50	,	_	_	O
51	with	_	_	O
52	properties	_	_	O
53	of	_	_	O
54	a	_	_	O
55	mucosal	_	_	O
56	cytoprotectant	_	_	O
57	.	_	_	O

58	We	_	_	O
59	designed	_	_	O
60	a	_	_	O
61	randomized	_	_	O
62	,	_	_	O
63	double	_	_	O
64	-	_	_	O
65	blind	_	_	O
66	,	_	_	O
67	placebo	_	_	O
68	-	_	_	O
69	controlled	_	_	O
70	trial	_	_	O
71	of	_	_	O
72	misoprostol	_	_	O
73	in	_	_	O
74	patients	_	_	O
75	with	_	_	O
76	head	_	_	O
77	and	_	_	O
78	neck	_	_	O
79	cancer	_	_	O
80	.	_	_	O

81	The	_	_	O
82	aim	_	_	O
83	of	_	_	O
84	this	_	_	O
85	study	_	_	O
86	was	_	_	O
87	to	_	_	O
88	determine	_	_	O
89	if	_	_	O
90	topical	_	_	O
91	misoprostol	_	_	O
92	was	_	_	O
93	effective	_	_	O
94	in	_	_	O
95	reducing	_	_	O
96	the	_	_	O
97	severity	_	_	O
98	of	_	_	O
99	radiation	_	_	O
100	-	_	_	O
101	induced	_	_	O
102	mucositis	_	_	O
103	in	_	_	O
104	patients	_	_	O
105	receiving	_	_	O
106	radical	_	_	O
107	dose	_	_	O
108	radiotherapy	_	_	O
109	.	_	_	O

110	The	_	_	O
111	effect	_	_	O
112	of	_	_	O
113	this	_	_	O
114	intervention	_	_	O
115	on	_	_	O
116	a	_	_	O
117	patient	_	_	O
118	'	_	_	O
119	s	_	_	O
120	general	_	_	O
121	well	_	_	O
122	-	_	_	O
123	being	_	_	O
124	was	_	_	O
125	also	_	_	O
126	investigated	_	_	O
127	.	_	_	O

128	The	_	_	O
129	primary	_	_	O
130	end	_	_	O
131	-	_	_	O
132	point	_	_	O
133	of	_	_	O
134	the	_	_	O
135	study	_	_	O
136	was	_	_	O
137	the	_	_	O
138	incidence	_	_	O
139	of	_	_	O
140	Radiation	_	_	O
141	Therapy	_	_	O
142	Oncology	_	_	O
143	Group	_	_	O
144	grade	_	_	O
145	3	_	_	O
146	mucositis	_	_	O
147	.	_	_	O

148	Between	_	_	O
149	1999	_	_	O
150	and	_	_	O
151	2002	_	_	O
152	,	_	_	O
153	83	_	_	O
154	patients	_	_	O
155	were	_	_	O
156	recruited	_	_	O
157	into	_	_	O
158	the	_	_	O
159	study	_	_	O
160	at	_	_	O
161	Westmead	_	_	O
162	and	_	_	O
163	Nepean	_	_	O
164	Hospitals	_	_	O
165	,	_	_	O
166	Sydney	_	_	O
167	.	_	_	O

168	Forty	_	_	O
169	-	_	_	O
170	two	_	_	O
171	patients	_	_	O
172	were	_	_	O
173	randomized	_	_	O
174	to	_	_	O
175	receive	_	_	O
176	misoprostol	_	_	O
177	and	_	_	O
178	41	_	_	O
179	to	_	_	O
180	receive	_	_	O
181	a	_	_	O
182	placebo	_	_	O
183	.	_	_	O

184	Most	_	_	O
185	patients	_	_	O
186	received	_	_	O
187	radiotherapy	_	_	O
188	in	_	_	O
189	the	_	_	O
190	adjuvant	_	_	O
191	setting	_	_	O
192	(	_	_	O
193	52	_	_	O
194	of	_	_	O
195	the	_	_	O
196	83	_	_	O
197	)	_	_	O
198	and	_	_	O
199	had	_	_	O
200	either	_	_	O
201	an	_	_	O
202	oral	_	_	O
203	cavity	_	_	O
204	(	_	_	O
205	42	_	_	O
206	of	_	_	O
207	the	_	_	O
208	83	_	_	O
209	)	_	_	O
210	or	_	_	O
211	an	_	_	O
212	oropharyngeal	_	_	O
213	(	_	_	O
214	16	_	_	O
215	of	_	_	O
216	the	_	_	O
217	83	_	_	O
218	)	_	_	O
219	cancer	_	_	O
220	.	_	_	O

221	We	_	_	B-Claim
222	could	_	_	I-Claim
223	not	_	_	I-Claim
224	identify	_	_	I-Claim
225	any	_	_	I-Claim
226	significant	_	_	I-Claim
227	difference	_	_	I-Claim
228	in	_	_	I-Claim
229	the	_	_	I-Claim
230	incidence	_	_	I-Claim
231	of	_	_	I-Claim
232	severe	_	_	I-Claim
233	mucositis	_	_	I-Claim
234	based	_	_	I-Claim
235	on	_	_	I-Claim
236	whether	_	_	I-Claim
237	patients	_	_	I-Claim
238	were	_	_	I-Claim
239	allocated	_	_	I-Claim
240	to	_	_	I-Claim
241	receive	_	_	I-Claim
242	misoprostol	_	_	I-Claim
243	or	_	_	I-Claim
244	placebo	_	_	I-Claim
245	.	_	_	I-Claim

246	There	_	_	B-Premise
247	was	_	_	I-Premise
248	no	_	_	I-Premise
249	significant	_	_	I-Premise
250	difference	_	_	I-Premise
251	in	_	_	I-Premise
252	the	_	_	I-Premise
253	mean	_	_	I-Premise
254	area	_	_	I-Premise
255	under	_	_	I-Premise
256	the	_	_	I-Premise
257	mucositis	_	_	I-Premise
258	curve	_	_	I-Premise
259	(	_	_	I-Premise
260	13	_	_	I-Premise
261	.	_	_	I-Premise

262	2	_	_	I-Premise
263	vs	_	_	I-Premise
264	16	_	_	I-Premise
265	.	_	_	I-Premise

266	6	_	_	I-Premise
267	;	_	_	I-Premise
268	P	_	_	I-Premise
269	=	_	_	I-Premise
270	0	_	_	I-Premise
271	.	_	_	I-Premise

272	1	_	_	I-Premise
273	)	_	_	I-Premise
274	.	_	_	I-Premise

275	Patients	_	_	B-Premise
276	allocated	_	_	I-Premise
277	to	_	_	I-Premise
278	misoprostol	_	_	I-Premise
279	did	_	_	I-Premise
280	report	_	_	I-Premise
281	slightly	_	_	I-Premise
282	increased	_	_	I-Premise
283	soreness	_	_	I-Premise
284	(	_	_	I-Premise
285	7	_	_	I-Premise
286	.	_	_	I-Premise

287	6	_	_	I-Premise
288	vs	_	_	I-Premise
289	6	_	_	I-Premise
290	.	_	_	I-Premise

291	9	_	_	I-Premise
292	;	_	_	I-Premise
293	P	_	_	I-Premise
294	=	_	_	I-Premise
295	0	_	_	I-Premise
296	.	_	_	I-Premise

297	04	_	_	I-Premise
298	)	_	_	I-Premise
299	and	_	_	I-Premise
300	a	_	_	I-Premise
301	greater	_	_	I-Premise
302	use	_	_	I-Premise
303	of	_	_	I-Premise
304	analgesics	_	_	I-Premise
305	.	_	_	I-Premise

306	However	_	_	B-Premise
307	,	_	_	I-Premise
308	this	_	_	I-Premise
309	difference	_	_	I-Premise
310	did	_	_	I-Premise
311	not	_	_	I-Premise
312	translate	_	_	I-Premise
313	into	_	_	I-Premise
314	a	_	_	I-Premise
315	worse	_	_	I-Premise
316	feeling	_	_	I-Premise
317	of	_	_	I-Premise
318	general	_	_	I-Premise
319	well	_	_	I-Premise
320	-	_	_	I-Premise
321	being	_	_	I-Premise
322	as	_	_	I-Premise
323	measured	_	_	I-Premise
324	by	_	_	I-Premise
325	a	_	_	I-Premise
326	simple	_	_	I-Premise
327	visual	_	_	I-Premise
328	analogue	_	_	I-Premise
329	scale	_	_	I-Premise
330	(	_	_	I-Premise
331	5	_	_	I-Premise
332	.	_	_	I-Premise

333	8	_	_	I-Premise
334	vs	_	_	I-Premise
335	5	_	_	I-Premise
336	.	_	_	I-Premise

337	2	_	_	I-Premise
338	;	_	_	I-Premise
339	P	_	_	I-Premise
340	=	_	_	I-Premise
341	0	_	_	I-Premise
342	.	_	_	I-Premise

343	3	_	_	I-Premise
344	)	_	_	I-Premise
345	.	_	_	I-Premise

346	In	_	_	B-Claim
347	conclusion	_	_	I-Claim
348	,	_	_	I-Claim
349	we	_	_	I-Claim
350	were	_	_	I-Claim
351	unable	_	_	I-Claim
352	to	_	_	I-Claim
353	identify	_	_	I-Claim
354	a	_	_	I-Claim
355	reduction	_	_	I-Claim
356	in	_	_	I-Claim
357	radiation	_	_	I-Claim
358	-	_	_	I-Claim
359	induced	_	_	I-Claim
360	mucositis	_	_	I-Claim
361	in	_	_	I-Claim
362	patients	_	_	I-Claim
363	receiving	_	_	I-Claim
364	misoprostol	_	_	I-Claim
365	.	_	_	I-Claim

366	There	_	_	B-Claim
367	is	_	_	I-Claim
368	a	_	_	I-Claim
369	paucity	_	_	I-Claim
370	of	_	_	I-Claim
371	high	_	_	I-Claim
372	-	_	_	I-Claim
373	level	_	_	I-Claim
374	evidence	_	_	I-Claim
375	on	_	_	I-Claim
376	potentially	_	_	I-Claim
377	useful	_	_	I-Claim
378	interventions	_	_	I-Claim
379	and	_	_	I-Claim
380	a	_	_	I-Claim
381	continued	_	_	I-Claim
382	need	_	_	I-Claim
383	for	_	_	I-Claim
384	new	_	_	I-Claim
385	and	_	_	I-Claim
386	innovative	_	_	I-Claim
387	research	_	_	I-Claim
388	,	_	_	I-Claim
389	incorporating	_	_	I-Claim
390	quality	_	_	I-Claim
391	-	_	_	I-Claim
392	of	_	_	I-Claim
393	-	_	_	I-Claim
394	life	_	_	I-Claim
395	measurements	_	_	I-Claim
396	,	_	_	I-Claim
397	in	_	_	I-Claim
398	patients	_	_	I-Claim
399	experiencing	_	_	I-Claim
400	radiation	_	_	I-Claim
401	-	_	_	I-Claim
402	induced	_	_	I-Claim
403	mucositis	_	_	I-Claim
404	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effectiveness	_	_	O
4	and	_	_	O
5	tolerability	_	_	O
6	of	_	_	O
7	gemcitabine	_	_	O
8	plus	_	_	O
9	cisplatin	_	_	O
10	with	_	_	O
11	single	_	_	O
12	-	_	_	O
13	agent	_	_	O
14	gemcitabine	_	_	O
15	as	_	_	O
16	first	_	_	O
17	-	_	_	O
18	line	_	_	O
19	chemotherapy	_	_	O
20	for	_	_	O
21	locally	_	_	O
22	advanced	_	_	O
23	or	_	_	O
24	metastatic	_	_	O
25	pancreatic	_	_	O
26	cancer	_	_	O
27	.	_	_	O

28	Patients	_	_	O
29	with	_	_	O
30	advanced	_	_	O
31	adenocarcinoma	_	_	O
32	of	_	_	O
33	the	_	_	O
34	pancreas	_	_	O
35	were	_	_	O
36	randomly	_	_	O
37	assigned	_	_	O
38	to	_	_	O
39	receive	_	_	O
40	either	_	_	O
41	gemcitabine	_	_	O
42	1	_	_	O
43	,	_	_	O
44	000	_	_	O
45	mg	_	_	O
46	/	_	_	O
47	m2	_	_	O
48	and	_	_	O
49	cisplatin	_	_	O
50	50	_	_	O
51	mg	_	_	O
52	/	_	_	O
53	m2	_	_	O
54	given	_	_	O
55	on	_	_	O
56	days	_	_	O
57	1	_	_	O
58	and	_	_	O
59	15	_	_	O
60	of	_	_	O
61	a	_	_	O
62	4	_	_	O
63	-	_	_	O
64	week	_	_	O
65	cycle	_	_	O
66	(	_	_	O
67	GemCis	_	_	O
68	arm	_	_	O
69	)	_	_	O
70	or	_	_	O
71	gemcitabine	_	_	O
72	alone	_	_	O
73	at	_	_	O
74	a	_	_	O
75	dose	_	_	O
76	of	_	_	O
77	1	_	_	O
78	,	_	_	O
79	000	_	_	O
80	mg	_	_	O
81	/	_	_	O
82	m2	_	_	O
83	on	_	_	O
84	days	_	_	O
85	1	_	_	O
86	,	_	_	O
87	8	_	_	O
88	,	_	_	O
89	and	_	_	O
90	15	_	_	O
91	of	_	_	O
92	a	_	_	O
93	4	_	_	O
94	-	_	_	O
95	week	_	_	O
96	regimen	_	_	O
97	(	_	_	O
98	Gem	_	_	O
99	arm	_	_	O
100	)	_	_	O
101	.	_	_	O

102	The	_	_	O
103	primary	_	_	O
104	end	_	_	O
105	point	_	_	O
106	was	_	_	O
107	overall	_	_	O
108	survival	_	_	O
109	;	_	_	O
110	secondary	_	_	O
111	end	_	_	O
112	points	_	_	O
113	were	_	_	O
114	progression	_	_	O
115	-	_	_	O
116	free	_	_	O
117	survival	_	_	O
118	,	_	_	O
119	response	_	_	O
120	rate	_	_	O
121	,	_	_	O
122	safety	_	_	O
123	,	_	_	O
124	and	_	_	O
125	quality	_	_	O
126	of	_	_	O
127	life	_	_	O
128	.	_	_	O

129	One	_	_	O
130	hundred	_	_	O
131	ninety	_	_	O
132	-	_	_	O
133	five	_	_	O
134	patients	_	_	O
135	were	_	_	O
136	enrolled	_	_	O
137	and	_	_	O
138	showed	_	_	O
139	baseline	_	_	O
140	characteristics	_	_	O
141	well	_	_	O
142	balanced	_	_	O
143	between	_	_	O
144	treatment	_	_	O
145	arms	_	_	O
146	.	_	_	O

147	Combination	_	_	B-Premise
148	treatment	_	_	I-Premise
149	in	_	_	I-Premise
150	the	_	_	I-Premise
151	GemCis	_	_	I-Premise
152	arm	_	_	I-Premise
153	was	_	_	I-Premise
154	associated	_	_	I-Premise
155	with	_	_	I-Premise
156	a	_	_	I-Premise
157	prolonged	_	_	I-Premise
158	median	_	_	I-Premise
159	progression	_	_	I-Premise
160	-	_	_	I-Premise
161	free	_	_	I-Premise
162	survival	_	_	I-Premise
163	(	_	_	I-Premise
164	5	_	_	I-Premise
165	.	_	_	I-Premise

166	3	_	_	I-Premise
167	months	_	_	I-Premise
168	v	_	_	I-Premise
169	3	_	_	I-Premise
170	.	_	_	I-Premise

171	1	_	_	I-Premise
172	months	_	_	I-Premise
173	;	_	_	I-Premise
174	hazard	_	_	I-Premise
175	ratio	_	_	I-Premise
176	[	_	_	I-Premise
177	HR	_	_	I-Premise
178	]	_	_	I-Premise
179	=	_	_	I-Premise
180	0	_	_	I-Premise
181	.	_	_	I-Premise

182	75	_	_	I-Premise
183	;	_	_	I-Premise
184	P	_	_	I-Premise
185	=	_	_	I-Premise
186	.	_	_	I-Premise

187	053	_	_	I-Premise
188	)	_	_	I-Premise
189	.	_	_	I-Premise

190	Also	_	_	B-Premise
191	,	_	_	I-Premise
192	median	_	_	I-Premise
193	overall	_	_	I-Premise
194	survival	_	_	I-Premise
195	was	_	_	I-Premise
196	superior	_	_	I-Premise
197	for	_	_	I-Premise
198	patients	_	_	I-Premise
199	treated	_	_	I-Premise
200	in	_	_	I-Premise
201	the	_	_	I-Premise
202	GemCis	_	_	I-Premise
203	arm	_	_	I-Premise
204	as	_	_	I-Premise
205	compared	_	_	I-Premise
206	with	_	_	I-Premise
207	the	_	_	I-Premise
208	Gem	_	_	I-Premise
209	arm	_	_	I-Premise
210	(	_	_	I-Premise
211	7	_	_	I-Premise
212	.	_	_	I-Premise

213	5	_	_	I-Premise
214	v	_	_	I-Premise
215	6	_	_	I-Premise
216	.	_	_	I-Premise

217	0	_	_	I-Premise
218	months	_	_	I-Premise
219	)	_	_	I-Premise
220	,	_	_	I-Premise
221	an	_	_	B-Premise
222	advantage	_	_	I-Premise
223	which	_	_	I-Premise
224	did	_	_	I-Premise
225	not	_	_	I-Premise
226	,	_	_	I-Premise
227	however	_	_	I-Premise
228	,	_	_	I-Premise
229	reach	_	_	I-Premise
230	statistical	_	_	I-Premise
231	significance	_	_	I-Premise
232	(	_	_	I-Premise
233	HR	_	_	I-Premise
234	=	_	_	I-Premise
235	0	_	_	I-Premise
236	.	_	_	I-Premise

237	80	_	_	I-Premise
238	;	_	_	I-Premise
239	P	_	_	I-Premise
240	=	_	_	I-Premise
241	.	_	_	I-Premise

242	15	_	_	I-Premise
243	)	_	_	I-Premise
244	.	_	_	I-Premise

245	Tumor	_	_	B-Premise
246	response	_	_	I-Premise
247	rates	_	_	I-Premise
248	were	_	_	I-Premise
249	comparable	_	_	I-Premise
250	between	_	_	I-Premise
251	treatment	_	_	I-Premise
252	arms	_	_	I-Premise
253	(	_	_	I-Premise
254	10	_	_	I-Premise
255	.	_	_	I-Premise

256	2	_	_	I-Premise
257	%	_	_	I-Premise
258	v	_	_	I-Premise
259	8	_	_	I-Premise
260	.	_	_	I-Premise

261	2	_	_	I-Premise
262	%	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	The	_	_	B-Premise
266	rate	_	_	I-Premise
267	of	_	_	I-Premise
268	stable	_	_	I-Premise
269	disease	_	_	I-Premise
270	was	_	_	I-Premise
271	,	_	_	I-Premise
272	however	_	_	I-Premise
273	,	_	_	I-Premise
274	greater	_	_	I-Premise
275	in	_	_	I-Premise
276	the	_	_	I-Premise
277	combination	_	_	I-Premise
278	arm	_	_	I-Premise
279	(	_	_	I-Premise
280	60	_	_	I-Premise
281	.	_	_	I-Premise

282	2	_	_	I-Premise
283	%	_	_	I-Premise
284	v	_	_	I-Premise
285	40	_	_	I-Premise
286	.	_	_	I-Premise

287	2	_	_	I-Premise
288	%	_	_	I-Premise
289	;	_	_	I-Premise
290	P	_	_	I-Premise
291	<	_	_	I-Premise
292	.	_	_	I-Premise

293	001	_	_	I-Premise
294	)	_	_	I-Premise
295	.	_	_	O

296	Grade	_	_	B-Premise
297	3	_	_	I-Premise
298	to	_	_	I-Premise
299	4	_	_	I-Premise
300	hematologic	_	_	I-Premise
301	toxicity	_	_	I-Premise
302	did	_	_	I-Premise
303	not	_	_	I-Premise
304	exceed	_	_	I-Premise
305	15	_	_	I-Premise
306	%	_	_	I-Premise
307	in	_	_	I-Premise
308	both	_	_	I-Premise
309	treatment	_	_	I-Premise
310	arms	_	_	I-Premise
311	.	_	_	I-Premise

312	These	_	_	B-Claim
313	results	_	_	I-Claim
314	support	_	_	I-Claim
315	the	_	_	I-Claim
316	efficacy	_	_	I-Claim
317	and	_	_	I-Claim
318	safety	_	_	I-Claim
319	of	_	_	I-Claim
320	an	_	_	I-Claim
321	every	_	_	I-Claim
322	-	_	_	I-Claim
323	2	_	_	I-Claim
324	-	_	_	I-Claim
325	weeks	_	_	I-Claim
326	treatment	_	_	I-Claim
327	with	_	_	I-Claim
328	gemcitabine	_	_	I-Claim
329	plus	_	_	I-Claim
330	cisplatin	_	_	I-Claim
331	.	_	_	I-Claim

332	Median	_	_	B-Claim
333	overall	_	_	I-Claim
334	survival	_	_	I-Claim
335	and	_	_	I-Claim
336	progression	_	_	I-Claim
337	-	_	_	I-Claim
338	free	_	_	I-Claim
339	survival	_	_	I-Claim
340	were	_	_	I-Claim
341	more	_	_	I-Claim
342	favorable	_	_	I-Claim
343	in	_	_	I-Claim
344	the	_	_	I-Claim
345	combination	_	_	I-Claim
346	arm	_	_	I-Claim
347	as	_	_	I-Claim
348	compared	_	_	I-Claim
349	with	_	_	I-Claim
350	gemcitabine	_	_	I-Claim
351	alone	_	_	I-Claim
352	,	_	_	I-Claim
353	although	_	_	B-Premise
354	the	_	_	I-Premise
355	difference	_	_	I-Premise
356	did	_	_	I-Premise
357	not	_	_	I-Premise
358	attain	_	_	I-Premise
359	statistical	_	_	I-Premise
360	significance	_	_	I-Premise
361	.	_	_	I-Premise


0	Treatment	_	_	O
1	of	_	_	O
2	patients	_	_	O
3	with	_	_	O
4	advanced	_	_	O
5	or	_	_	O
6	metastatic	_	_	O
7	esophagogastric	_	_	O
8	adenocarcinoma	_	_	O
9	should	_	_	O
10	not	_	_	O
11	only	_	_	O
12	prolong	_	_	O
13	life	_	_	O
14	but	_	_	O
15	also	_	_	O
16	provide	_	_	O
17	relief	_	_	O
18	of	_	_	O
19	symptoms	_	_	O
20	and	_	_	O
21	improve	_	_	O
22	quality	_	_	O
23	of	_	_	O
24	life	_	_	O
25	(	_	_	O
26	QOL	_	_	O
27	)	_	_	O
28	.	_	_	O

29	Esophagogastric	_	_	O
30	adenocarcinoma	_	_	O
31	mainly	_	_	O
32	occurs	_	_	O
33	in	_	_	O
34	elderly	_	_	O
35	patients	_	_	O
36	,	_	_	O
37	but	_	_	O
38	they	_	_	O
39	are	_	_	O
40	underrepresented	_	_	O
41	in	_	_	O
42	most	_	_	O
43	clinical	_	_	O
44	trials	_	_	O
45	and	_	_	O
46	often	_	_	O
47	do	_	_	O
48	not	_	_	O
49	receive	_	_	O
50	effective	_	_	O
51	combination	_	_	O
52	chemotherapy	_	_	O
53	,	_	_	O
54	most	_	_	O
55	probably	_	_	O
56	for	_	_	O
57	fear	_	_	O
58	of	_	_	O
59	intolerance	_	_	O
60	.	_	_	O

61	Using	_	_	O
62	validated	_	_	O
63	instruments	_	_	O
64	,	_	_	O
65	we	_	_	O
66	prospectively	_	_	O
67	assessed	_	_	O
68	QOL	_	_	O
69	within	_	_	O
70	the	_	_	O
71	randomized	_	_	O
72	FLOT65	_	_	O
73	+	_	_	O
74	phase	_	_	O
75	II	_	_	O
76	trial	_	_	O
77	.	_	_	O

78	Within	_	_	O
79	the	_	_	O
80	FLOT65	_	_	O
81	+	_	_	O
82	trial	_	_	O
83	,	_	_	O
84	a	_	_	O
85	total	_	_	O
86	of	_	_	O
87	143	_	_	O
88	patients	_	_	O
89	aged	_	_	O
90	≥	_	_	O
91	65	_	_	O
92	years	_	_	O
93	were	_	_	O
94	randomly	_	_	O
95	allocated	_	_	O
96	to	_	_	O
97	receive	_	_	O
98	biweekly	_	_	O
99	oxaliplatin	_	_	O
100	plus	_	_	O
101	5	_	_	O
102	-	_	_	O
103	fluorouracil	_	_	O
104	(	_	_	O
105	5	_	_	O
106	-	_	_	O
107	FU	_	_	O
108	)	_	_	O
109	continuous	_	_	O
110	infusion	_	_	O
111	and	_	_	O
112	folinic	_	_	O
113	acid	_	_	O
114	(	_	_	O
115	FLO	_	_	O
116	)	_	_	O
117	or	_	_	O
118	the	_	_	O
119	same	_	_	O
120	regimen	_	_	O
121	in	_	_	O
122	combination	_	_	O
123	with	_	_	O
124	docetaxel	_	_	O
125	50	_	_	O
126	mg	_	_	O
127	/	_	_	O
128	m	_	_	O
129	(	_	_	O
130	2	_	_	O
131	)	_	_	O
132	(	_	_	O
133	FLOT	_	_	O
134	)	_	_	O
135	.	_	_	O

136	The	_	_	O
137	European	_	_	O
138	Organisation	_	_	O
139	for	_	_	O
140	Research	_	_	O
141	and	_	_	O
142	Treatment	_	_	O
143	of	_	_	O
144	Cancer	_	_	O
145	Quality	_	_	O
146	of	_	_	O
147	Life	_	_	O
148	Questionnaire	_	_	O
149	C30	_	_	O
150	(	_	_	O
151	EORTC	_	_	O
152	QLQ	_	_	O
153	-	_	_	O
154	C30	_	_	O
155	)	_	_	O
156	and	_	_	O
157	the	_	_	O
158	gastric	_	_	O
159	module	_	_	O
160	STO22	_	_	O
161	were	_	_	O
162	administered	_	_	O
163	every	_	_	O
164	8	_	_	O
165	weeks	_	_	O
166	until	_	_	O
167	progression	_	_	O
168	.	_	_	O

169	Time	_	_	O
170	to	_	_	O
171	definitive	_	_	O
172	deterioration	_	_	O
173	of	_	_	O
174	QOL	_	_	O
175	parameters	_	_	O
176	was	_	_	O
177	analyzed	_	_	O
178	and	_	_	O
179	compared	_	_	O
180	within	_	_	O
181	the	_	_	O
182	treatment	_	_	O
183	arms	_	_	O
184	.	_	_	O

185	The	_	_	O
186	median	_	_	O
187	age	_	_	O
188	of	_	_	O
189	patients	_	_	O
190	was	_	_	O
191	70	_	_	O
192	years	_	_	O
193	.	_	_	O

194	Patients	_	_	B-Premise
195	receiving	_	_	I-Premise
196	FLOT	_	_	I-Premise
197	exhibited	_	_	I-Premise
198	higher	_	_	I-Premise
199	response	_	_	I-Premise
200	rates	_	_	I-Premise
201	and	_	_	I-Premise
202	had	_	_	I-Premise
203	improved	_	_	I-Premise
204	disease	_	_	I-Premise
205	-	_	_	I-Premise
206	free	_	_	I-Premise
207	and	_	_	I-Premise
208	progression	_	_	I-Premise
209	-	_	_	I-Premise
210	free	_	_	I-Premise
211	survival	_	_	I-Premise
212	(	_	_	I-Premise
213	PFS	_	_	I-Premise
214	)	_	_	I-Premise
215	.	_	_	I-Premise

216	The	_	_	O
217	proportions	_	_	O
218	of	_	_	O
219	patients	_	_	O
220	with	_	_	O
221	evaluable	_	_	O
222	baseline	_	_	O
223	EORTC	_	_	O
224	QLQ	_	_	O
225	-	_	_	O
226	C30	_	_	O
227	and	_	_	O
228	STO22	_	_	O
229	questionnaires	_	_	O
230	were	_	_	O
231	balanced	_	_	O
232	(	_	_	O
233	83	_	_	O
234	%	_	_	O
235	in	_	_	O
236	FLOT	_	_	O
237	and	_	_	O
238	89	_	_	O
239	%	_	_	O
240	in	_	_	O
241	FLO	_	_	O
242	)	_	_	O
243	.	_	_	O

244	Considering	_	_	O
245	evaluable	_	_	O
246	patients	_	_	O
247	with	_	_	O
248	assessable	_	_	O
249	questionnaires	_	_	O
250	(	_	_	O
251	n	_	_	O
252	=	_	_	O
253	123	_	_	O
254	)	_	_	O
255	,	_	_	O
256	neither	_	_	O
257	functioning	_	_	O
258	nor	_	_	O
259	symptom	_	_	O
260	parameters	_	_	O
261	differed	_	_	O
262	significantly	_	_	O
263	in	_	_	O
264	favor	_	_	O
265	of	_	_	O
266	one	_	_	O
267	of	_	_	O
268	the	_	_	O
269	two	_	_	O
270	treatment	_	_	O
271	groups	_	_	O
272	.	_	_	O

273	Particularly	_	_	O
274	,	_	_	O
275	there	_	_	B-Premise
276	was	_	_	I-Premise
277	no	_	_	I-Premise
278	significant	_	_	I-Premise
279	difference	_	_	I-Premise
280	regarding	_	_	I-Premise
281	time	_	_	I-Premise
282	to	_	_	I-Premise
283	definitive	_	_	I-Premise
284	deterioration	_	_	I-Premise
285	of	_	_	I-Premise
286	global	_	_	I-Premise
287	health	_	_	I-Premise
288	status	_	_	I-Premise
289	/	_	_	I-Premise
290	quality	_	_	I-Premise
291	of	_	_	I-Premise
292	life	_	_	I-Premise
293	from	_	_	I-Premise
294	baseline	_	_	I-Premise
295	(	_	_	I-Premise
296	primary	_	_	I-Premise
297	endpoint	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	Notably	_	_	O
301	,	_	_	O
302	patients	_	_	B-Premise
303	receiving	_	_	I-Premise
304	FLO	_	_	I-Premise
305	or	_	_	I-Premise
306	FLOT	_	_	I-Premise
307	as	_	_	I-Premise
308	palliative	_	_	I-Premise
309	treatment	_	_	I-Premise
310	(	_	_	I-Premise
311	n	_	_	I-Premise
312	=	_	_	I-Premise
313	98	_	_	I-Premise
314	)	_	_	I-Premise
315	achieved	_	_	I-Premise
316	comparable	_	_	I-Premise
317	QOL	_	_	I-Premise
318	results	_	_	I-Premise
319	.	_	_	I-Premise

320	Although	_	_	B-Premise
321	toxicity	_	_	I-Premise
322	was	_	_	I-Premise
323	higher	_	_	I-Premise
324	in	_	_	I-Premise
325	patients	_	_	I-Premise
326	receiving	_	_	I-Premise
327	FLOT	_	_	I-Premise
328	,	_	_	I-Premise
329	no	_	_	B-Premise
330	negative	_	_	I-Premise
331	impact	_	_	I-Premise
332	of	_	_	I-Premise
333	the	_	_	I-Premise
334	addition	_	_	I-Premise
335	of	_	_	I-Premise
336	docetaxel	_	_	I-Premise
337	on	_	_	I-Premise
338	QOL	_	_	I-Premise
339	parameters	_	_	I-Premise
340	could	_	_	I-Premise
341	be	_	_	I-Premise
342	demonstrated	_	_	I-Premise
343	.	_	_	I-Premise

344	Thus	_	_	O
345	,	_	_	O
346	elderly	_	_	B-Claim
347	patients	_	_	I-Claim
348	in	_	_	I-Claim
349	need	_	_	I-Claim
350	of	_	_	I-Claim
351	intensified	_	_	I-Claim
352	chemotherapy	_	_	I-Claim
353	may	_	_	I-Claim
354	receive	_	_	I-Claim
355	FLOT	_	_	I-Claim
356	without	_	_	I-Claim
357	compromising	_	_	I-Claim
358	patient	_	_	I-Claim
359	-	_	_	I-Claim
360	reported	_	_	I-Claim
361	outcome	_	_	I-Claim
362	parameters	_	_	I-Claim
363	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	sought	_	_	O
3	to	_	_	O
4	evaluate	_	_	O
5	effectiveness	_	_	O
6	of	_	_	O
7	autologous	_	_	O
8	dendritic	_	_	O
9	cell	_	_	O
10	vaccine	_	_	O
11	(	_	_	O
12	immunotherapy	_	_	O
13	)	_	_	O
14	for	_	_	O
15	glioblastoma	_	_	O
16	multiforme	_	_	O
17	(	_	_	O
18	GBM	_	_	O
19	)	_	_	O
20	.	_	_	O

21	Patients	_	_	O
22	14	_	_	O
23	to	_	_	O
24	70	_	_	O
25	years	_	_	O
26	of	_	_	O
27	age	_	_	O
28	with	_	_	O
29	newly	_	_	O
30	diagnosed	_	_	O
31	GBM	_	_	O
32	and	_	_	O
33	Karnofsky	_	_	O
34	Performance	_	_	O
35	Scale	_	_	O
36	(	_	_	O
37	KPS	_	_	O
38	)	_	_	O
39	score	_	_	O
40	>	_	_	O
41	70	_	_	O
42	who	_	_	O
43	were	_	_	O
44	receiving	_	_	O
45	initial	_	_	O
46	treatment	_	_	O
47	were	_	_	O
48	enrolled	_	_	O
49	and	_	_	O
50	were	_	_	O
51	randomized	_	_	O
52	into	_	_	O
53	2	_	_	O
54	groups	_	_	O
55	during	_	_	O
56	the	_	_	O
57	5	_	_	O
58	-	_	_	O
59	year	_	_	O
60	study	_	_	O
61	period	_	_	O
62	.	_	_	O

63	Eighteen	_	_	O
64	patients	_	_	O
65	underwent	_	_	O
66	conventional	_	_	O
67	treatment	_	_	O
68	(	_	_	O
69	surgery	_	_	O
70	,	_	_	O
71	radiotherapy	_	_	O
72	,	_	_	O
73	and	_	_	O
74	chemotherapy	_	_	O
75	)	_	_	O
76	and	_	_	O
77	received	_	_	O
78	adjuvant	_	_	O
79	autologous	_	_	O
80	dendritic	_	_	O
81	cell	_	_	O
82	vaccine	_	_	O
83	,	_	_	O
84	and	_	_	O
85	16	_	_	O
86	patients	_	_	O
87	(	_	_	O
88	control	_	_	O
89	group	_	_	O
90	)	_	_	O
91	underwent	_	_	O
92	conventional	_	_	O
93	treatment	_	_	O
94	only	_	_	O
95	.	_	_	O

96	Administration	_	_	O
97	of	_	_	O
98	the	_	_	O
99	vaccine	_	_	O
100	was	_	_	O
101	begun	_	_	O
102	within	_	_	O
103	1	_	_	O
104	to	_	_	O
105	2	_	_	O
106	months	_	_	O
107	postoperatively	_	_	O
108	,	_	_	O
109	with	_	_	O
110	10	_	_	O
111	inoculations	_	_	O
112	given	_	_	O
113	over	_	_	O
114	6	_	_	O
115	months	_	_	O
116	.	_	_	O

117	Outcome	_	_	O
118	measures	_	_	O
119	were	_	_	O
120	overall	_	_	O
121	survival	_	_	O
122	(	_	_	O
123	OS	_	_	O
124	)	_	_	O
125	;	_	_	O
126	progression	_	_	O
127	-	_	_	O
128	free	_	_	O
129	survival	_	_	O
130	(	_	_	O
131	PFS	_	_	O
132	)	_	_	O
133	;	_	_	O
134	1	_	_	O
135	-	_	_	O
136	,	_	_	O
137	2	_	_	O
138	-	_	_	O
139	,	_	_	O
140	and	_	_	O
141	3	_	_	O
142	-	_	_	O
143	year	_	_	O
144	survival	_	_	O
145	rates	_	_	O
146	,	_	_	O
147	and	_	_	O
148	quality	_	_	O
149	of	_	_	O
150	life	_	_	O
151	(	_	_	O
152	QoL	_	_	O
153	)	_	_	O
154	.	_	_	O

155	Follow	_	_	O
156	-	_	_	O
157	up	_	_	O
158	time	_	_	O
159	ranged	_	_	O
160	from	_	_	O
161	14	_	_	O
162	to	_	_	O
163	56	_	_	O
164	months	_	_	O
165	(	_	_	O
166	median	_	_	O
167	,	_	_	O
168	33	_	_	O
169	months	_	_	O
170	)	_	_	O
171	.	_	_	O

172	The	_	_	B-Premise
173	1	_	_	I-Premise
174	-	_	_	I-Premise
175	,	_	_	I-Premise
176	2	_	_	I-Premise
177	-	_	_	I-Premise
178	,	_	_	I-Premise
179	and	_	_	I-Premise
180	3	_	_	I-Premise
181	-	_	_	I-Premise
182	year	_	_	I-Premise
183	survival	_	_	I-Premise
184	rates	_	_	I-Premise
185	were	_	_	I-Premise
186	88	_	_	I-Premise
187	.	_	_	I-Premise

188	9	_	_	I-Premise
189	%	_	_	I-Premise
190	,	_	_	I-Premise
191	44	_	_	I-Premise
192	.	_	_	I-Premise

193	4	_	_	I-Premise
194	%	_	_	I-Premise
195	,	_	_	I-Premise
196	and	_	_	I-Premise
197	16	_	_	I-Premise
198	.	_	_	I-Premise

199	7	_	_	I-Premise
200	%	_	_	I-Premise
201	for	_	_	I-Premise
202	the	_	_	I-Premise
203	vaccine	_	_	I-Premise
204	group	_	_	I-Premise
205	,	_	_	I-Premise
206	respectively	_	_	I-Premise
207	,	_	_	I-Premise
208	and	_	_	I-Premise
209	75	_	_	I-Premise
210	.	_	_	I-Premise

211	0	_	_	I-Premise
212	%	_	_	I-Premise
213	,	_	_	I-Premise
214	18	_	_	I-Premise
215	.	_	_	I-Premise

216	8	_	_	I-Premise
217	%	_	_	I-Premise
218	,	_	_	I-Premise
219	and	_	_	I-Premise
220	0	_	_	I-Premise
221	%	_	_	I-Premise
222	,	_	_	I-Premise
223	respectively	_	_	I-Premise
224	,	_	_	I-Premise
225	for	_	_	I-Premise
226	the	_	_	I-Premise
227	control	_	_	I-Premise
228	group	_	_	I-Premise
229	,	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	0	_	_	I-Premise
234	.	_	_	I-Premise

235	299	_	_	I-Premise
236	,	_	_	I-Premise
237	0	_	_	I-Premise
238	.	_	_	I-Premise

239	0035	_	_	I-Premise
240	,	_	_	I-Premise
241	0	_	_	I-Premise
242	.	_	_	I-Premise

243	0014	_	_	I-Premise
244	,	_	_	I-Premise
245	respectively	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	The	_	_	B-Premise
249	median	_	_	I-Premise
250	OS	_	_	I-Premise
251	for	_	_	I-Premise
252	the	_	_	I-Premise
253	vaccine	_	_	I-Premise
254	group	_	_	I-Premise
255	was	_	_	I-Premise
256	31	_	_	I-Premise
257	.	_	_	I-Premise

258	9	_	_	I-Premise
259	months	_	_	I-Premise
260	and	_	_	I-Premise
261	for	_	_	I-Premise
262	the	_	_	I-Premise
263	control	_	_	I-Premise
264	group	_	_	I-Premise
265	was	_	_	I-Premise
266	15	_	_	I-Premise
267	.	_	_	I-Premise

268	0	_	_	I-Premise
269	months	_	_	I-Premise
270	(	_	_	I-Premise
271	P	_	_	I-Premise
272	<	_	_	I-Premise
273	0	_	_	I-Premise
274	.	_	_	I-Premise

275	002	_	_	I-Premise
276	)	_	_	I-Premise
277	.	_	_	I-Premise

278	The	_	_	B-Premise
279	median	_	_	I-Premise
280	progression	_	_	I-Premise
281	-	_	_	I-Premise
282	free	_	_	I-Premise
283	survival	_	_	I-Premise
284	(	_	_	I-Premise
285	PFS	_	_	I-Premise
286	)	_	_	I-Premise
287	for	_	_	I-Premise
288	the	_	_	I-Premise
289	vaccine	_	_	I-Premise
290	group	_	_	I-Premise
291	was	_	_	I-Premise
292	8	_	_	I-Premise
293	.	_	_	I-Premise

294	5	_	_	I-Premise
295	months	_	_	I-Premise
296	,	_	_	I-Premise
297	and	_	_	I-Premise
298	8	_	_	I-Premise
299	.	_	_	I-Premise

300	0	_	_	I-Premise
301	months	_	_	I-Premise
302	for	_	_	I-Premise
303	the	_	_	I-Premise
304	control	_	_	I-Premise
305	group	_	_	I-Premise
306	(	_	_	I-Premise
307	P	_	_	I-Premise
308	=	_	_	I-Premise
309	0	_	_	I-Premise
310	.	_	_	I-Premise

311	075	_	_	I-Premise
312	)	_	_	I-Premise
313	.	_	_	I-Premise

314	The	_	_	B-Premise
315	surviving	_	_	I-Premise
316	fraction	_	_	I-Premise
317	was	_	_	I-Premise
318	significantly	_	_	I-Premise
319	higher	_	_	I-Premise
320	in	_	_	I-Premise
321	the	_	_	I-Premise
322	vaccine	_	_	I-Premise
323	group	_	_	I-Premise
324	based	_	_	I-Premise
325	on	_	_	I-Premise
326	Kaplan	_	_	I-Premise
327	-	_	_	I-Premise
328	Meier	_	_	I-Premise
329	analysis	_	_	I-Premise
330	.	_	_	I-Premise

331	Adjuvant	_	_	B-Claim
332	immunotherapy	_	_	I-Claim
333	with	_	_	I-Claim
334	whole	_	_	I-Claim
335	-	_	_	I-Claim
336	cell	_	_	I-Claim
337	lysate	_	_	I-Claim
338	dendritic	_	_	I-Claim
339	cell	_	_	I-Claim
340	vaccine	_	_	I-Claim
341	may	_	_	I-Claim
342	improve	_	_	I-Claim
343	short	_	_	I-Claim
344	-	_	_	I-Claim
345	term	_	_	I-Claim
346	survival	_	_	I-Claim
347	.	_	_	I-Claim

348	It	_	_	B-Claim
349	seems	_	_	I-Claim
350	to	_	_	I-Claim
351	be	_	_	I-Claim
352	safe	_	_	I-Claim
353	,	_	_	I-Claim
354	and	_	_	I-Claim
355	its	_	_	I-Claim
356	long	_	_	I-Claim
357	-	_	_	I-Claim
358	term	_	_	I-Claim
359	effectiveness	_	_	I-Claim
360	is	_	_	I-Claim
361	worthy	_	_	I-Claim
362	of	_	_	I-Claim
363	further	_	_	I-Claim
364	investigation	_	_	I-Claim
365	.	_	_	I-Claim


0	To	_	_	O
1	prospectively	_	_	O
2	evaluate	_	_	O
3	health	_	_	O
4	-	_	_	O
5	related	_	_	O
6	quality	_	_	O
7	of	_	_	O
8	life	_	_	O
9	(	_	_	O
10	HRQOL	_	_	O
11	)	_	_	O
12	outcomes	_	_	O
13	for	_	_	O
14	uterine	_	_	O
15	artery	_	_	O
16	embolization	_	_	O
17	(	_	_	O
18	UAE	_	_	O
19	)	_	_	O
20	and	_	_	O
21	hysterectomy	_	_	O
22	up	_	_	O
23	to	_	_	O
24	24	_	_	O
25	months	_	_	O
26	after	_	_	O
27	the	_	_	O
28	intervention	_	_	O
29	in	_	_	O
30	terms	_	_	O
31	of	_	_	O
32	mental	_	_	O
33	and	_	_	O
34	physical	_	_	O
35	health	_	_	O
36	,	_	_	O
37	urinary	_	_	O
38	and	_	_	O
39	defecatory	_	_	O
40	function	_	_	O
41	,	_	_	O
42	and	_	_	O
43	overall	_	_	O
44	patient	_	_	O
45	satisfaction	_	_	O
46	.	_	_	O

47	Ethics	_	_	O
48	committee	_	_	O
49	approval	_	_	O
50	and	_	_	O
51	informed	_	_	O
52	consent	_	_	O
53	were	_	_	O
54	obtained	_	_	O
55	for	_	_	O
56	the	_	_	O
57	Embolisation	_	_	O
58	versus	_	_	O
59	Hysterectomy	_	_	O
60	Trial	_	_	O
61	.	_	_	O

62	Women	_	_	O
63	(	_	_	O
64	n	_	_	O
65	=	_	_	O
66	177	_	_	O
67	)	_	_	O
68	with	_	_	O
69	uterine	_	_	O
70	fibroids	_	_	O
71	and	_	_	O
72	heavy	_	_	O
73	menstrual	_	_	O
74	bleeding	_	_	O
75	who	_	_	O
76	were	_	_	O
77	scheduled	_	_	O
78	to	_	_	O
79	undergo	_	_	O
80	hysterectomy	_	_	O
81	were	_	_	O
82	randomly	_	_	O
83	assigned	_	_	O
84	to	_	_	O
85	undergo	_	_	O
86	UAE	_	_	O
87	(	_	_	O
88	n	_	_	O
89	=	_	_	O
90	88	_	_	O
91	)	_	_	O
92	or	_	_	O
93	hysterectomy	_	_	O
94	(	_	_	O
95	n	_	_	O
96	=	_	_	O
97	89	_	_	O
98	)	_	_	O
99	.	_	_	O

100	HRQOL	_	_	O
101	was	_	_	O
102	measured	_	_	O
103	six	_	_	O
104	times	_	_	O
105	during	_	_	O
106	a	_	_	O
107	24	_	_	O
108	-	_	_	O
109	month	_	_	O
110	follow	_	_	O
111	-	_	_	O
112	up	_	_	O
113	period	_	_	O
114	with	_	_	O
115	the	_	_	O
116	following	_	_	O
117	validated	_	_	O
118	questionnaires	_	_	O
119	:	_	_	O
120	Medical	_	_	O
121	Outcome	_	_	O
122	Study	_	_	O
123	Short	_	_	O
124	Form	_	_	O
125	36	_	_	O
126	(	_	_	O
127	SF	_	_	O
128	-	_	_	O
129	36	_	_	O
130	)	_	_	O
131	mental	_	_	O
132	component	_	_	O
133	summary	_	_	O
134	(	_	_	O
135	MCS	_	_	O
136	)	_	_	O
137	and	_	_	O
138	physical	_	_	O
139	component	_	_	O
140	summary	_	_	O
141	(	_	_	O
142	PCS	_	_	O
143	)	_	_	O
144	,	_	_	O
145	Health	_	_	O
146	Utilities	_	_	O
147	Index	_	_	O
148	Mark	_	_	O
149	3	_	_	O
150	,	_	_	O
151	EuroQol	_	_	O
152	5D	_	_	O
153	,	_	_	O
154	urogenital	_	_	O
155	distress	_	_	O
156	inventory	_	_	O
157	(	_	_	O
158	UDI	_	_	O
159	)	_	_	O
160	,	_	_	O
161	incontinence	_	_	O
162	impact	_	_	O
163	questionnaire	_	_	O
164	,	_	_	O
165	and	_	_	O
166	defecation	_	_	O
167	distress	_	_	O
168	inventory	_	_	O
169	(	_	_	O
170	DDI	_	_	O
171	)	_	_	O
172	.	_	_	O

173	Satisfaction	_	_	O
174	was	_	_	O
175	assessed	_	_	O
176	with	_	_	O
177	a	_	_	O
178	seven	_	_	O
179	-	_	_	O
180	point	_	_	O
181	Likert	_	_	O
182	scale	_	_	O
183	.	_	_	O

184	Repeated	_	_	O
185	measurement	_	_	O
186	analysis	_	_	O
187	was	_	_	O
188	performed	_	_	O
189	for	_	_	O
190	between	_	_	O
191	-	_	_	O
192	group	_	_	O
193	analysis	_	_	O
194	.	_	_	O

195	Paired	_	_	O
196	t	_	_	O
197	tests	_	_	O
198	were	_	_	O
199	performed	_	_	O
200	for	_	_	O
201	within	_	_	O
202	-	_	_	O
203	group	_	_	O
204	analysis	_	_	O
205	.	_	_	O

206	Satisfaction	_	_	O
207	was	_	_	O
208	analyzed	_	_	O
209	with	_	_	O
210	the	_	_	O
211	Fisher	_	_	O
212	exact	_	_	O
213	test	_	_	O
214	.	_	_	O

215	The	_	_	B-Premise
216	SF	_	_	I-Premise
217	-	_	_	I-Premise
218	36	_	_	I-Premise
219	MCS	_	_	I-Premise
220	and	_	_	I-Premise
221	PCS	_	_	I-Premise
222	,	_	_	I-Premise
223	Health	_	_	I-Premise
224	Utilities	_	_	I-Premise
225	Index	_	_	I-Premise
226	Mark	_	_	I-Premise
227	3	_	_	I-Premise
228	,	_	_	I-Premise
229	EuroQol	_	_	I-Premise
230	5D	_	_	I-Premise
231	,	_	_	I-Premise
232	and	_	_	I-Premise
233	UDI	_	_	I-Premise
234	scores	_	_	I-Premise
235	were	_	_	I-Premise
236	improved	_	_	I-Premise
237	significantly	_	_	I-Premise
238	in	_	_	I-Premise
239	both	_	_	I-Premise
240	groups	_	_	I-Premise
241	at	_	_	I-Premise
242	6	_	_	I-Premise
243	months	_	_	I-Premise
244	and	_	_	I-Premise
245	afterward	_	_	I-Premise
246	(	_	_	I-Premise
247	P	_	_	I-Premise
248	<	_	_	I-Premise
249	.	_	_	I-Premise

250	05	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	The	_	_	O
254	DDI	_	_	O
255	score	_	_	O
256	was	_	_	O
257	improved	_	_	O
258	significantly	_	_	O
259	in	_	_	O
260	only	_	_	O
261	the	_	_	O
262	UAE	_	_	O
263	group	_	_	O
264	at	_	_	O
265	6	_	_	O
266	months	_	_	O
267	and	_	_	O
268	afterward	_	_	O
269	(	_	_	O
270	P	_	_	O
271	<	_	_	O
272	.	_	_	O

273	05	_	_	O
274	)	_	_	O
275	.	_	_	O

276	No	_	_	O
277	differences	_	_	O
278	between	_	_	O
279	groups	_	_	O
280	were	_	_	O
281	observed	_	_	O
282	,	_	_	O
283	with	_	_	O
284	the	_	_	O
285	exception	_	_	O
286	of	_	_	O
287	PCS	_	_	O
288	scores	_	_	O
289	at	_	_	O
290	6	_	_	O
291	-	_	_	O
292	week	_	_	O
293	follow	_	_	O
294	-	_	_	O
295	up	_	_	O
296	:	_	_	O
297	Patients	_	_	O
298	in	_	_	O
299	the	_	_	O
300	UAE	_	_	O
301	group	_	_	O
302	had	_	_	O
303	significantly	_	_	O
304	better	_	_	O
305	scores	_	_	O
306	than	_	_	O
307	did	_	_	O
308	patients	_	_	O
309	in	_	_	O
310	the	_	_	O
311	hysterectomy	_	_	O
312	group	_	_	O
313	(	_	_	O
314	P	_	_	O
315	<	_	_	O
316	.	_	_	O

317	001	_	_	O
318	)	_	_	O
319	.	_	_	O

320	Improvement	_	_	O
321	in	_	_	O
322	PCS	_	_	O
323	score	_	_	O
324	at	_	_	O
325	24	_	_	O
326	-	_	_	O
327	month	_	_	O
328	follow	_	_	O
329	-	_	_	O
330	up	_	_	O
331	was	_	_	O
332	significantly	_	_	O
333	higher	_	_	O
334	for	_	_	O
335	patients	_	_	O
336	who	_	_	O
337	were	_	_	O
338	employed	_	_	O
339	at	_	_	O
340	baseline	_	_	O
341	(	_	_	O
342	P	_	_	O
343	=	_	_	O
344	.	_	_	O

345	035	_	_	O
346	)	_	_	O
347	.	_	_	O

348	At	_	_	B-Premise
349	24	_	_	I-Premise
350	-	_	_	I-Premise
351	month	_	_	I-Premise
352	follow	_	_	I-Premise
353	-	_	_	I-Premise
354	up	_	_	I-Premise
355	,	_	_	I-Premise
356	patients	_	_	I-Premise
357	in	_	_	I-Premise
358	the	_	_	I-Premise
359	hysterectomy	_	_	I-Premise
360	group	_	_	I-Premise
361	were	_	_	I-Premise
362	significantly	_	_	I-Premise
363	more	_	_	I-Premise
364	satisfied	_	_	I-Premise
365	than	_	_	I-Premise
366	those	_	_	I-Premise
367	in	_	_	I-Premise
368	the	_	_	I-Premise
369	UAE	_	_	I-Premise
370	group	_	_	I-Premise
371	(	_	_	I-Premise
372	P	_	_	I-Premise
373	=	_	_	I-Premise
374	.	_	_	I-Premise

375	02	_	_	I-Premise
376	)	_	_	I-Premise
377	.	_	_	I-Premise

378	Both	_	_	B-Claim
379	UAE	_	_	I-Claim
380	and	_	_	I-Claim
381	hysterectomy	_	_	I-Claim
382	improved	_	_	I-Claim
383	HRQOL	_	_	I-Claim
384	.	_	_	I-Claim

385	No	_	_	B-Claim
386	differences	_	_	I-Claim
387	were	_	_	I-Claim
388	observed	_	_	I-Claim
389	between	_	_	I-Claim
390	groups	_	_	I-Claim
391	regarding	_	_	I-Claim
392	HRQOL	_	_	I-Claim
393	at	_	_	I-Claim
394	24	_	_	I-Claim
395	-	_	_	I-Claim
396	month	_	_	I-Claim
397	follow	_	_	I-Claim
398	-	_	_	I-Claim
399	up	_	_	I-Claim
400	.	_	_	I-Claim

401	On	_	_	B-Claim
402	the	_	_	I-Claim
403	basis	_	_	I-Claim
404	of	_	_	I-Claim
405	HRQOL	_	_	I-Claim
406	results	_	_	I-Claim
407	,	_	_	I-Claim
408	the	_	_	I-Claim
409	authors	_	_	I-Claim
410	determined	_	_	I-Claim
411	that	_	_	I-Claim
412	UAE	_	_	I-Claim
413	is	_	_	I-Claim
414	a	_	_	I-Claim
415	good	_	_	I-Claim
416	alternative	_	_	I-Claim
417	to	_	_	I-Claim
418	hysterectomy	_	_	I-Claim
419	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	incidence	_	_	O
4	and	_	_	O
5	temporal	_	_	O
6	resolution	_	_	O
7	of	_	_	O
8	dysuria	_	_	O
9	after	_	_	O
10	permanent	_	_	O
11	prostate	_	_	O
12	brachytherapy	_	_	O
13	,	_	_	O
14	and	_	_	O
15	to	_	_	O
16	identify	_	_	O
17	predictors	_	_	O
18	of	_	_	O
19	brachytherapy	_	_	O
20	-	_	_	O
21	related	_	_	O
22	dysuria	_	_	O
23	.	_	_	O

24	The	_	_	O
25	study	_	_	O
26	included	_	_	O
27	130	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	no	_	_	O
31	history	_	_	O
32	of	_	_	O
33	transurethral	_	_	O
34	resection	_	_	O
35	of	_	_	O
36	the	_	_	O
37	prostate	_	_	O
38	before	_	_	O
39	treatment	_	_	O
40	,	_	_	O
41	who	_	_	O
42	had	_	_	O
43	brachytherapy	_	_	O
44	on	_	_	O
45	one	_	_	O
46	of	_	_	O
47	two	_	_	O
48	prospective	_	_	O
49	randomized	_	_	O
50	trials	_	_	O
51	,	_	_	O
52	with	_	_	O
53	explicitly	_	_	O
54	planned	_	_	O
55	and	_	_	O
56	executed	_	_	O
57	urethral	_	_	O
58	-	_	_	O
59	sparing	_	_	O
60	techniques	_	_	O
61	(	_	_	O
62	100	_	_	O
63	-	_	_	O
64	150	_	_	O
65	%	_	_	O
66	minimum	_	_	O
67	peripheral	_	_	O
68	dose	_	_	O
69	)	_	_	O
70	using	_	_	O
71	either	_	_	O
72	103Pd	_	_	O
73	or	_	_	O
74	125I	_	_	O
75	for	_	_	O
76	clinical	_	_	O
77	T1c	_	_	O
78	-	_	_	O
79	T2c	_	_	O
80	prostate	_	_	O
81	cancer	_	_	O
82	.	_	_	O

83	The	_	_	O
84	median	_	_	O
85	follow	_	_	O
86	-	_	_	O
87	up	_	_	O
88	was	_	_	O
89	22	_	_	O
90	.	_	_	O

91	6	_	_	O
92	months	_	_	O
93	.	_	_	O

94	An	_	_	O
95	alpha	_	_	O
96	-	_	_	O
97	blocker	_	_	O
98	was	_	_	O
99	initiated	_	_	O
100	either	_	_	O
101	prophylactically	_	_	O
102	2	_	_	O
103	weeks	_	_	O
104	before	_	_	O
105	implantation	_	_	O
106	and	_	_	O
107	continued	_	_	O
108	at	_	_	O
109	least	_	_	O
110	until	_	_	O
111	the	_	_	O
112	International	_	_	O
113	Prostate	_	_	O
114	Symptom	_	_	O
115	Score	_	_	O
116	(	_	_	O
117	IPSS	_	_	O
118	)	_	_	O
119	returned	_	_	O
120	to	_	_	O
121	normal	_	_	O
122	,	_	_	O
123	or	_	_	O
124	withheld	_	_	O
125	until	_	_	O
126	the	_	_	O
127	onset	_	_	O
128	of	_	_	O
129	significant	_	_	O
130	brachytherapy	_	_	O
131	-	_	_	O
132	related	_	_	O
133	urinary	_	_	O
134	morbidity	_	_	O
135	.	_	_	O

136	Dysuria	_	_	O
137	was	_	_	O
138	evaluated	_	_	O
139	on	_	_	O
140	a	_	_	O
141	0	_	_	O
142	-	_	_	O
143	10	_	_	O
144	scale	_	_	O
145	,	_	_	O
146	before	_	_	O
147	brachytherapy	_	_	O
148	and	_	_	O
149	then	_	_	O
150	at	_	_	O
151	1	_	_	O
152	,	_	_	O
153	3	_	_	O
154	,	_	_	O
155	6	_	_	O
156	and	_	_	O
157	12	_	_	O
158	months	_	_	O
159	afterward	_	_	O
160	,	_	_	O
161	with	_	_	O
162	a	_	_	O
163	median	_	_	O
164	of	_	_	O
165	four	_	_	O
166	dysuria	_	_	O
167	questionnaires	_	_	O
168	per	_	_	O
169	patient	_	_	O
170	.	_	_	O

171	Clinical	_	_	O
172	,	_	_	O
173	treatment	_	_	O
174	and	_	_	O
175	dosimetric	_	_	O
176	variables	_	_	O
177	evaluated	_	_	O
178	included	_	_	O
179	alpha	_	_	O
180	-	_	_	O
181	blocker	_	_	O
182	,	_	_	O
183	age	_	_	O
184	,	_	_	O
185	IPSS	_	_	O
186	before	_	_	O
187	and	_	_	O
188	the	_	_	O
189	maximum	_	_	O
190	after	_	_	O
191	treatment	_	_	O
192	,	_	_	O
193	prostate	_	_	O
194	volume	_	_	O
195	on	_	_	O
196	ultrasonography	_	_	O
197	,	_	_	O
198	hormonal	_	_	O
199	status	_	_	O
200	,	_	_	O
201	supplemental	_	_	O
202	radiotherapy	_	_	O
203	,	_	_	O
204	isotope	_	_	O
205	,	_	_	O
206	urethral	_	_	O
207	dose	_	_	O
208	,	_	_	O
209	V	_	_	O
210	(	_	_	O
211	100	_	_	O
212	/	_	_	O
213	200	_	_	O
214	)	_	_	O
215	,	_	_	O
216	D90	_	_	O
217	,	_	_	O
218	and	_	_	O
219	time	_	_	O
220	to	_	_	O
221	obtaining	_	_	O
222	a	_	_	O
223	normal	_	_	O
224	IPSS	_	_	O
225	.	_	_	O

226	The	_	_	O
227	maximum	_	_	O
228	incidence	_	_	O
229	of	_	_	O
230	dysuria	_	_	O
231	was	_	_	O
232	85	_	_	O
233	%	_	_	O
234	at	_	_	O
235	1	_	_	O
236	month	_	_	O
237	after	_	_	O
238	brachytherapy	_	_	O
239	,	_	_	O
240	with	_	_	O
241	subsequent	_	_	O
242	resolution	_	_	O
243	over	_	_	O
244	time	_	_	O
245	.	_	_	O

246	The	_	_	B-Premise
247	use	_	_	I-Premise
248	of	_	_	I-Premise
249	prophylactic	_	_	I-Premise
250	tamsulosin	_	_	I-Premise
251	resulted	_	_	I-Premise
252	in	_	_	I-Premise
253	a	_	_	I-Premise
254	statistically	_	_	I-Premise
255	lower	_	_	I-Premise
256	dysuria	_	_	I-Premise
257	severity	_	_	I-Premise
258	score	_	_	I-Premise
259	(	_	_	I-Premise
260	difference	_	_	I-Premise
261	of	_	_	I-Premise
262	2	_	_	I-Premise
263	.	_	_	I-Premise

264	7	_	_	I-Premise
265	vs	_	_	I-Premise
266	4	_	_	I-Premise
267	.	_	_	I-Premise

268	2	_	_	I-Premise
269	,	_	_	I-Premise
270	P	_	_	I-Premise
271	<	_	_	I-Premise
272	0	_	_	I-Premise
273	.	_	_	I-Premise

274	005	_	_	I-Premise
275	)	_	_	I-Premise
276	at	_	_	I-Premise
277	1	_	_	I-Premise
278	month	_	_	I-Premise
279	,	_	_	I-Premise
280	with	_	_	I-Premise
281	no	_	_	I-Premise
282	discernible	_	_	I-Premise
283	differences	_	_	I-Premise
284	at	_	_	I-Premise
285	3	_	_	I-Premise
286	,	_	_	I-Premise
287	6	_	_	I-Premise
288	,	_	_	I-Premise
289	12	_	_	I-Premise
290	and	_	_	I-Premise
291	18	_	_	I-Premise
292	months	_	_	I-Premise
293	.	_	_	I-Premise

294	Patients	_	_	B-Premise
295	with	_	_	I-Premise
296	dysuria	_	_	I-Premise
297	had	_	_	I-Premise
298	a	_	_	I-Premise
299	statistically	_	_	I-Premise
300	higher	_	_	I-Premise
301	IPSS	_	_	I-Premise
302	.	_	_	I-Premise

303	The	_	_	B-Premise
304	dysuria	_	_	I-Premise
305	resolved	_	_	I-Premise
306	faster	_	_	I-Premise
307	in	_	_	I-Premise
308	patients	_	_	I-Premise
309	implanted	_	_	I-Premise
310	with	_	_	I-Premise
311	103Pd	_	_	I-Premise
312	but	_	_	B-Premise
313	was	_	_	I-Premise
314	unaffected	_	_	I-Premise
315	by	_	_	I-Premise
316	the	_	_	I-Premise
317	use	_	_	I-Premise
318	of	_	_	I-Premise
319	supplemental	_	_	I-Premise
320	radiotherapy	_	_	I-Premise
321	and	_	_	I-Premise
322	/	_	_	I-Premise
323	or	_	_	I-Premise
324	androgen	_	_	I-Premise
325	deprivation	_	_	I-Premise
326	therapy	_	_	I-Premise
327	.	_	_	I-Premise

328	In	_	_	B-Premise
329	multivariate	_	_	I-Premise
330	analysis	_	_	I-Premise
331	,	_	_	I-Premise
332	prophylactic	_	_	I-Premise
333	alpha	_	_	I-Premise
334	-	_	_	I-Premise
335	blockers	_	_	I-Premise
336	resulted	_	_	I-Premise
337	in	_	_	I-Premise
338	statistically	_	_	I-Premise
339	lower	_	_	I-Premise
340	maximum	_	_	I-Premise
341	dysuria	_	_	I-Premise
342	scores	_	_	I-Premise
343	,	_	_	I-Premise
344	while	_	_	B-Premise
345	the	_	_	I-Premise
346	maximum	_	_	I-Premise
347	IPSS	_	_	I-Premise
348	after	_	_	I-Premise
349	implantation	_	_	I-Premise
350	and	_	_	I-Premise
351	isotope	_	_	I-Premise
352	type	_	_	I-Premise
353	(	_	_	I-Premise
354	but	_	_	I-Premise
355	only	_	_	I-Premise
356	at	_	_	I-Premise
357	6	_	_	I-Premise
358	months	_	_	I-Premise
359	)	_	_	I-Premise
360	were	_	_	I-Premise
361	the	_	_	I-Premise
362	best	_	_	I-Premise
363	predictors	_	_	I-Premise
364	of	_	_	I-Premise
365	the	_	_	I-Premise
366	resolution	_	_	I-Premise
367	of	_	_	I-Premise
368	dysuria	_	_	I-Premise
369	.	_	_	I-Premise

370	Dysuria	_	_	B-Claim
371	is	_	_	I-Claim
372	common	_	_	I-Claim
373	after	_	_	I-Claim
374	brachytherapy	_	_	I-Claim
375	but	_	_	I-Claim
376	is	_	_	I-Claim
377	typically	_	_	I-Claim
378	mild	_	_	I-Claim
379	.	_	_	I-Claim

380	Prophylactic	_	_	B-Claim
381	alpha	_	_	I-Claim
382	-	_	_	I-Claim
383	blockers	_	_	I-Claim
384	gave	_	_	I-Claim
385	significantly	_	_	I-Claim
386	lower	_	_	I-Claim
387	maximum	_	_	I-Claim
388	dysuria	_	_	I-Claim
389	scores	_	_	I-Claim
390	but	_	_	B-Claim
391	did	_	_	I-Claim
392	not	_	_	I-Claim
393	affect	_	_	I-Claim
394	the	_	_	I-Claim
395	time	_	_	I-Claim
396	to	_	_	I-Claim
397	the	_	_	I-Claim
398	resolution	_	_	I-Claim
399	of	_	_	I-Claim
400	dysuria	_	_	I-Claim
401	.	_	_	I-Claim

402	The	_	_	B-Claim
403	maximum	_	_	I-Claim
404	IPSS	_	_	I-Claim
405	after	_	_	I-Claim
406	the	_	_	I-Claim
407	implant	_	_	I-Claim
408	was	_	_	I-Claim
409	the	_	_	I-Claim
410	best	_	_	I-Claim
411	predictor	_	_	I-Claim
412	of	_	_	I-Claim
413	the	_	_	I-Claim
414	resolution	_	_	I-Claim
415	of	_	_	I-Claim
416	dysuria	_	_	I-Claim
417	.	_	_	I-Claim


0	To	_	_	O
1	test	_	_	O
2	the	_	_	O
3	hypothesis	_	_	O
4	that	_	_	O
5	modulation	_	_	O
6	of	_	_	O
7	Bcl	_	_	O
8	-	_	_	O
9	2	_	_	O
10	with	_	_	O
11	13	_	_	O
12	-	_	_	O
13	cis	_	_	O
14	retinoic	_	_	O
15	acid	_	_	O
16	(	_	_	O
17	CRA	_	_	O
18	)	_	_	O
19	/	_	_	O
20	interferon	_	_	O
21	-	_	_	O
22	alpha2b	_	_	O
23	(	_	_	O
24	IFN	_	_	O
25	)	_	_	O
26	with	_	_	O
27	paclitaxel	_	_	O
28	(	_	_	O
29	TAX	_	_	O
30	)	_	_	O
31	,	_	_	O
32	or	_	_	O
33	mitoxantrone	_	_	O
34	,	_	_	O
35	estramustine	_	_	O
36	and	_	_	O
37	vinorelbine	_	_	O
38	(	_	_	O
39	MEV	_	_	O
40	)	_	_	O
41	will	_	_	O
42	have	_	_	O
43	clinical	_	_	O
44	activity	_	_	O
45	in	_	_	O
46	men	_	_	O
47	with	_	_	O
48	metastatic	_	_	O
49	castrate	_	_	O
50	-	_	_	O
51	resistant	_	_	O
52	prostate	_	_	O
53	cancer	_	_	O
54	(	_	_	O
55	CRPC	_	_	O
56	)	_	_	O
57	.	_	_	O

58	70	_	_	O
59	patients	_	_	O
60	were	_	_	O
61	treated	_	_	O
62	with	_	_	O
63	either	_	_	O
64	MEV	_	_	O
65	(	_	_	O
66	Arm	_	_	O
67	A	_	_	O
68	)	_	_	O
69	in	_	_	O
70	a	_	_	O
71	3	_	_	O
72	-	_	_	O
73	week	_	_	O
74	cycle	_	_	O
75	or	_	_	O
76	CRA	_	_	O
77	/	_	_	O
78	IFN	_	_	O
79	/	_	_	O
80	TAX	_	_	O
81	with	_	_	O
82	an	_	_	O
83	8	_	_	O
84	-	_	_	O
85	week	_	_	O
86	cycle	_	_	O
87	(	_	_	O
88	Arm	_	_	O
89	B	_	_	O
90	)	_	_	O
91	.	_	_	O

92	Patients	_	_	O
93	were	_	_	O
94	assessed	_	_	O
95	for	_	_	O
96	response	_	_	O
97	,	_	_	O
98	toxicity	_	_	O
99	,	_	_	O
100	quality	_	_	O
101	of	_	_	O
102	life	_	_	O
103	(	_	_	O
104	QOL	_	_	O
105	)	_	_	O
106	,	_	_	O
107	and	_	_	O
108	the	_	_	O
109	effect	_	_	O
110	of	_	_	O
111	treatment	_	_	O
112	on	_	_	O
113	Bcl	_	_	O
114	-	_	_	O
115	2	_	_	O
116	levels	_	_	O
117	in	_	_	O
118	peripheral	_	_	O
119	blood	_	_	O
120	mononuclear	_	_	O
121	cells	_	_	O
122	(	_	_	O
123	PBMC	_	_	O
124	)	_	_	O
125	.	_	_	O

126	The	_	_	B-Premise
127	PSA	_	_	I-Premise
128	response	_	_	I-Premise
129	rates	_	_	I-Premise
130	were	_	_	I-Premise
131	50	_	_	I-Premise
132	%	_	_	I-Premise
133	and	_	_	I-Premise
134	23	_	_	I-Premise
135	%	_	_	I-Premise
136	,	_	_	I-Premise
137	measurable	_	_	I-Premise
138	disease	_	_	I-Premise
139	response	_	_	I-Premise
140	rates	_	_	I-Premise
141	(	_	_	I-Premise
142	CR	_	_	I-Premise
143	+	_	_	I-Premise
144	PR	_	_	I-Premise
145	)	_	_	I-Premise
146	14	_	_	I-Premise
147	%	_	_	I-Premise
148	and	_	_	I-Premise
149	15	_	_	I-Premise
150	%	_	_	I-Premise
151	,	_	_	I-Premise
152	and	_	_	I-Premise
153	median	_	_	I-Premise
154	overall	_	_	I-Premise
155	survival	_	_	I-Premise
156	19	_	_	I-Premise
157	.	_	_	I-Premise

158	4	_	_	I-Premise
159	months	_	_	I-Premise
160	and	_	_	I-Premise
161	13	_	_	I-Premise
162	.	_	_	I-Premise

163	9	_	_	I-Premise
164	months	_	_	I-Premise
165	on	_	_	I-Premise
166	Arm	_	_	I-Premise
167	A	_	_	I-Premise
168	and	_	_	I-Premise
169	Arm	_	_	I-Premise
170	B	_	_	I-Premise
171	respectively	_	_	I-Premise
172	.	_	_	I-Premise

173	Transient	_	_	B-Premise
174	grade	_	_	I-Premise
175	4	_	_	I-Premise
176	neutropenia	_	_	I-Premise
177	occurred	_	_	I-Premise
178	in	_	_	I-Premise
179	18	_	_	I-Premise
180	and	_	_	I-Premise
181	2	_	_	I-Premise
182	patients	_	_	I-Premise
183	,	_	_	I-Premise
184	and	_	_	I-Premise
185	grade	_	_	I-Premise
186	3	_	_	I-Premise
187	to	_	_	I-Premise
188	4	_	_	I-Premise
189	thrombosis	_	_	I-Premise
190	in	_	_	I-Premise
191	7	_	_	I-Premise
192	patients	_	_	I-Premise
193	and	_	_	I-Premise
194	1	_	_	I-Premise
195	patient	_	_	I-Premise
196	in	_	_	I-Premise
197	Arm	_	_	I-Premise
198	A	_	_	I-Premise
199	and	_	_	I-Premise
200	Arm	_	_	I-Premise
201	B	_	_	I-Premise
202	respectively	_	_	I-Premise
203	.	_	_	I-Premise

204	Patients	_	_	B-Premise
205	on	_	_	I-Premise
206	Arm	_	_	I-Premise
207	B	_	_	I-Premise
208	reported	_	_	I-Premise
209	a	_	_	I-Premise
210	clinically	_	_	I-Premise
211	significant	_	_	I-Premise
212	decline	_	_	I-Premise
213	in	_	_	I-Premise
214	QOL	_	_	I-Premise
215	between	_	_	I-Premise
216	baseline	_	_	I-Premise
217	and	_	_	I-Premise
218	week	_	_	I-Premise
219	9	_	_	I-Premise
220	/	_	_	I-Premise
221	10	_	_	I-Premise
222	(	_	_	I-Premise
223	.	_	_	I-Premise

224	71	_	_	I-Premise
225	s	_	_	I-Premise
226	.	_	_	I-Premise

227	d	_	_	I-Premise
228	.	_	_	I-Premise

229	)	_	_	I-Premise
230	,	_	_	I-Premise
231	and	_	_	I-Premise
232	a	_	_	I-Premise
233	significantly	_	_	I-Premise
234	lower	_	_	I-Premise
235	level	_	_	I-Premise
236	of	_	_	I-Premise
237	QOL	_	_	I-Premise
238	than	_	_	I-Premise
239	Arm	_	_	I-Premise
240	A	_	_	I-Premise
241	(	_	_	I-Premise
242	p	_	_	I-Premise
243	=	_	_	I-Premise
244	0	_	_	I-Premise
245	.	_	_	I-Premise

246	01	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	As	_	_	B-Premise
250	hypothesized	_	_	I-Premise
251	,	_	_	I-Premise
252	Bcl	_	_	I-Premise
253	-	_	_	I-Premise
254	2	_	_	I-Premise
255	levels	_	_	I-Premise
256	decreased	_	_	I-Premise
257	with	_	_	I-Premise
258	CRA	_	_	I-Premise
259	/	_	_	I-Premise
260	IFN	_	_	I-Premise
261	therapy	_	_	I-Premise
262	only	_	_	I-Premise
263	in	_	_	I-Premise
264	Arm	_	_	I-Premise
265	B	_	_	I-Premise
266	(	_	_	I-Premise
267	p	_	_	I-Premise
268	=	_	_	I-Premise
269	0	_	_	I-Premise
270	.	_	_	I-Premise

271	03	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	Treatment	_	_	B-Claim
275	with	_	_	I-Claim
276	MEV	_	_	I-Claim
277	was	_	_	I-Claim
278	well	_	_	I-Claim
279	tolerated	_	_	I-Claim
280	and	_	_	I-Claim
281	demonstrated	_	_	I-Claim
282	clinical	_	_	I-Claim
283	activity	_	_	I-Claim
284	in	_	_	I-Claim
285	patients	_	_	I-Claim
286	with	_	_	I-Claim
287	CRPC	_	_	I-Claim
288	.	_	_	I-Claim

289	Given	_	_	B-Claim
290	the	_	_	I-Claim
291	adverse	_	_	I-Claim
292	effect	_	_	I-Claim
293	of	_	_	I-Claim
294	CRA	_	_	I-Claim
295	/	_	_	I-Claim
296	IFN	_	_	I-Claim
297	/	_	_	I-Claim
298	TAX	_	_	I-Claim
299	on	_	_	I-Claim
300	QOL	_	_	I-Claim
301	,	_	_	I-Claim
302	the	_	_	I-Claim
303	study	_	_	I-Claim
304	of	_	_	I-Claim
305	other	_	_	I-Claim
306	novel	_	_	I-Claim
307	agents	_	_	I-Claim
308	that	_	_	I-Claim
309	target	_	_	I-Claim
310	Bcl	_	_	I-Claim
311	-	_	_	I-Claim
312	2	_	_	I-Claim
313	family	_	_	I-Claim
314	proteins	_	_	I-Claim
315	is	_	_	I-Claim
316	warranted	_	_	I-Claim
317	.	_	_	I-Claim

318	The	_	_	O
319	feasibility	_	_	O
320	of	_	_	O
321	measuring	_	_	O
322	Bcl	_	_	O
323	-	_	_	O
324	2	_	_	O
325	protein	_	_	O
326	in	_	_	O
327	a	_	_	O
328	cooperative	_	_	O
329	group	_	_	O
330	setting	_	_	O
331	is	_	_	O
332	hypothesis	_	_	O
333	generating	_	_	O
334	and	_	_	O
335	supports	_	_	O
336	further	_	_	O
337	study	_	_	O
338	as	_	_	O
339	a	_	_	O
340	marker	_	_	O
341	for	_	_	O
342	Bcl	_	_	O
343	-	_	_	O
344	2	_	_	O
345	targeted	_	_	O
346	therapy	_	_	O
347	.	_	_	O


0	To	_	_	O
1	assess	_	_	O
2	patient	_	_	O
3	-	_	_	O
4	reported	_	_	O
5	prostate	_	_	O
6	cancer	_	_	O
7	-	_	_	O
8	specific	_	_	O
9	quality	_	_	O
10	of	_	_	O
11	life	_	_	O
12	2	_	_	O
13	and	_	_	O
14	3	_	_	O
15	years	_	_	O
16	after	_	_	O
17	radiotherapy	_	_	O
18	to	_	_	O
19	the	_	_	O
20	prostate	_	_	O
21	in	_	_	O
22	a	_	_	O
23	randomized	_	_	O
24	dose	_	_	O
25	-	_	_	O
26	escalation	_	_	O
27	trial	_	_	O
28	of	_	_	O
29	70	_	_	O
30	versus	_	_	O
31	78	_	_	O
32	Gy	_	_	O
33	conducted	_	_	O
34	from	_	_	O
35	1993	_	_	O
36	to	_	_	O
37	1998	_	_	O
38	.	_	_	O

39	Two	_	_	O
40	years	_	_	O
41	after	_	_	O
42	completing	_	_	O
43	radiotherapy	_	_	O
44	,	_	_	O
45	a	_	_	O
46	questionnaire	_	_	O
47	that	_	_	O
48	assessed	_	_	O
49	bladder	_	_	O
50	,	_	_	O
51	rectal	_	_	O
52	,	_	_	O
53	and	_	_	O
54	sexual	_	_	O
55	function	_	_	O
56	was	_	_	O
57	sent	_	_	O
58	to	_	_	O
59	301	_	_	O
60	patients	_	_	O
61	in	_	_	O
62	the	_	_	O
63	study	_	_	O
64	.	_	_	O

65	Three	_	_	O
66	years	_	_	O
67	after	_	_	O
68	treatment	_	_	O
69	,	_	_	O
70	a	_	_	O
71	second	_	_	O
72	questionnaire	_	_	O
73	was	_	_	O
74	sent	_	_	O
75	to	_	_	O
76	the	_	_	O
77	175	_	_	O
78	patients	_	_	O
79	with	_	_	O
80	adequate	_	_	O
81	follow	_	_	O
82	-	_	_	O
83	up	_	_	O
84	.	_	_	O

85	Three	_	_	B-Premise
86	years	_	_	I-Premise
87	after	_	_	I-Premise
88	radiotherapy	_	_	I-Premise
89	,	_	_	I-Premise
90	urinary	_	_	I-Premise
91	incontinence	_	_	I-Premise
92	was	_	_	I-Premise
93	reported	_	_	I-Premise
94	by	_	_	I-Premise
95	35	_	_	I-Premise
96	%	_	_	I-Premise
97	of	_	_	I-Premise
98	patients	_	_	I-Premise
99	,	_	_	I-Premise
100	but	_	_	I-Premise
101	only	_	_	I-Premise
102	6	_	_	I-Premise
103	%	_	_	I-Premise
104	required	_	_	I-Premise
105	the	_	_	I-Premise
106	use	_	_	I-Premise
107	of	_	_	I-Premise
108	a	_	_	I-Premise
109	pad	_	_	I-Premise
110	or	_	_	I-Premise
111	other	_	_	I-Premise
112	protective	_	_	I-Premise
113	device	_	_	I-Premise
114	.	_	_	I-Premise

115	Patients	_	_	B-Premise
116	reported	_	_	I-Premise
117	increased	_	_	I-Premise
118	leakage	_	_	I-Premise
119	with	_	_	I-Premise
120	a	_	_	I-Premise
121	full	_	_	I-Premise
122	bladder	_	_	I-Premise
123	(	_	_	I-Premise
124	urge	_	_	I-Premise
125	incontinence	_	_	I-Premise
126	)	_	_	I-Premise
127	between	_	_	I-Premise
128	the	_	_	I-Premise
129	2	_	_	I-Premise
130	and	_	_	I-Premise
131	3	_	_	I-Premise
132	-	_	_	I-Premise
133	year	_	_	I-Premise
134	questionnaires	_	_	I-Premise
135	(	_	_	I-Premise
136	42	_	_	I-Premise
137	%	_	_	I-Premise
138	versus	_	_	I-Premise
139	50	_	_	I-Premise
140	%	_	_	I-Premise
141	;	_	_	I-Premise
142	P	_	_	I-Premise
143	=	_	_	I-Premise
144	0	_	_	I-Premise
145	.	_	_	I-Premise

146	03	_	_	I-Premise
147	)	_	_	I-Premise
148	.	_	_	I-Premise

149	At	_	_	B-Premise
150	3	_	_	I-Premise
151	years	_	_	I-Premise
152	,	_	_	I-Premise
153	33	_	_	I-Premise
154	%	_	_	I-Premise
155	of	_	_	I-Premise
156	patients	_	_	I-Premise
157	reported	_	_	I-Premise
158	rectal	_	_	I-Premise
159	bleeding	_	_	I-Premise
160	compared	_	_	I-Premise
161	with	_	_	I-Premise
162	47	_	_	I-Premise
163	%	_	_	I-Premise
164	at	_	_	I-Premise
165	2	_	_	I-Premise
166	years	_	_	I-Premise
167	(	_	_	I-Premise
168	P	_	_	I-Premise
169	=	_	_	I-Premise
170	0	_	_	I-Premise
171	.	_	_	I-Premise

172	006	_	_	I-Premise
173	)	_	_	I-Premise
174	.	_	_	I-Premise

175	Patients	_	_	B-Premise
176	in	_	_	I-Premise
177	the	_	_	I-Premise
178	78	_	_	I-Premise
179	-	_	_	I-Premise
180	Gy	_	_	I-Premise
181	arm	_	_	I-Premise
182	reported	_	_	I-Premise
183	more	_	_	I-Premise
184	frequent	_	_	I-Premise
185	bowel	_	_	I-Premise
186	movements	_	_	I-Premise
187	at	_	_	I-Premise
188	3	_	_	I-Premise
189	years	_	_	I-Premise
190	and	_	_	I-Premise
191	less	_	_	I-Premise
192	change	_	_	I-Premise
193	in	_	_	I-Premise
194	bowel	_	_	I-Premise
195	function	_	_	I-Premise
196	at	_	_	I-Premise
197	2	_	_	I-Premise
198	years	_	_	I-Premise
199	than	_	_	I-Premise
200	patients	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	70	_	_	I-Premise
204	-	_	_	I-Premise
205	Gy	_	_	I-Premise
206	arm	_	_	I-Premise
207	.	_	_	I-Premise

208	Before	_	_	B-Premise
209	radiotherapy	_	_	I-Premise
210	,	_	_	I-Premise
211	84	_	_	I-Premise
212	%	_	_	I-Premise
213	of	_	_	I-Premise
214	patients	_	_	I-Premise
215	reported	_	_	I-Premise
216	erections	_	_	I-Premise
217	adequate	_	_	I-Premise
218	for	_	_	I-Premise
219	intercourse	_	_	I-Premise
220	at	_	_	I-Premise
221	least	_	_	I-Premise
222	a	_	_	I-Premise
223	few	_	_	I-Premise
224	times	_	_	I-Premise
225	during	_	_	I-Premise
226	the	_	_	I-Premise
227	previous	_	_	I-Premise
228	year	_	_	I-Premise
229	.	_	_	I-Premise

230	After	_	_	B-Premise
231	2	_	_	I-Premise
232	and	_	_	I-Premise
233	3	_	_	I-Premise
234	years	_	_	I-Premise
235	,	_	_	I-Premise
236	this	_	_	I-Premise
237	had	_	_	I-Premise
238	decreased	_	_	I-Premise
239	to	_	_	I-Premise
240	49	_	_	I-Premise
241	%	_	_	I-Premise
242	and	_	_	I-Premise
243	41	_	_	I-Premise
244	%	_	_	I-Premise
245	,	_	_	I-Premise
246	respectively	_	_	I-Premise
247	(	_	_	I-Premise
248	P	_	_	I-Premise
249	<	_	_	I-Premise
250	0	_	_	I-Premise
251	.	_	_	I-Premise

252	02	_	_	I-Premise
253	)	_	_	I-Premise
254	.	_	_	I-Premise

255	By	_	_	B-Claim
256	patient	_	_	I-Claim
257	-	_	_	I-Claim
258	reported	_	_	I-Claim
259	questionnaire	_	_	I-Claim
260	,	_	_	I-Claim
261	78	_	_	I-Claim
262	Gy	_	_	I-Claim
263	produced	_	_	I-Claim
264	an	_	_	I-Claim
265	increase	_	_	I-Claim
266	in	_	_	I-Claim
267	bowel	_	_	I-Claim
268	movement	_	_	I-Claim
269	frequency	_	_	I-Claim
270	and	_	_	I-Claim
271	no	_	_	I-Claim
272	increase	_	_	I-Claim
273	in	_	_	I-Claim
274	bladder	_	_	I-Claim
275	or	_	_	I-Claim
276	sexual	_	_	I-Claim
277	side	_	_	I-Claim
278	effects	_	_	I-Claim
279	at	_	_	I-Claim
280	3	_	_	I-Claim
281	years	_	_	I-Claim
282	compared	_	_	I-Claim
283	with	_	_	I-Claim
284	70	_	_	I-Claim
285	Gy	_	_	I-Claim
286	.	_	_	I-Claim

287	Comparing	_	_	B-Claim
288	the	_	_	I-Claim
289	results	_	_	I-Claim
290	2	_	_	I-Claim
291	and	_	_	I-Claim
292	3	_	_	I-Claim
293	years	_	_	I-Claim
294	after	_	_	I-Claim
295	radiotherapy	_	_	I-Claim
296	,	_	_	I-Claim
297	the	_	_	I-Claim
298	symptoms	_	_	I-Claim
299	of	_	_	I-Claim
300	rectal	_	_	I-Claim
301	bleeding	_	_	I-Claim
302	had	_	_	I-Claim
303	improved	_	_	I-Claim
304	,	_	_	I-Claim
305	erectile	_	_	I-Claim
306	function	_	_	I-Claim
307	had	_	_	I-Claim
308	decreased	_	_	I-Claim
309	,	_	_	I-Claim
310	and	_	_	I-Claim
311	urinary	_	_	I-Claim
312	urge	_	_	I-Claim
313	incontinence	_	_	I-Claim
314	had	_	_	I-Claim
315	increased	_	_	I-Claim
316	.	_	_	I-Claim


0	This	_	_	O
1	randomised	_	_	O
2	multicentre	_	_	O
3	trial	_	_	O
4	was	_	_	O
5	conducted	_	_	O
6	to	_	_	O
7	establish	_	_	O
8	the	_	_	O
9	optimal	_	_	O
10	duration	_	_	O
11	of	_	_	O
12	palliative	_	_	O
13	chemotherapy	_	_	O
14	in	_	_	O
15	advanced	_	_	O
16	non	_	_	O
17	-	_	_	O
18	small	_	_	O
19	-	_	_	O
20	cell	_	_	O
21	lung	_	_	O
22	cancer	_	_	O
23	(	_	_	O
24	NSCLC	_	_	O
25	)	_	_	O
26	.	_	_	O

27	We	_	_	O
28	compared	_	_	O
29	a	_	_	O
30	policy	_	_	O
31	of	_	_	O
32	three	_	_	O
33	vs	_	_	O
34	six	_	_	O
35	courses	_	_	O
36	of	_	_	O
37	new	_	_	O
38	-	_	_	O
39	generation	_	_	O
40	platinum	_	_	O
41	-	_	_	O
42	based	_	_	O
43	combination	_	_	O
44	chemotherapy	_	_	O
45	with	_	_	O
46	regard	_	_	O
47	to	_	_	O
48	effects	_	_	O
49	on	_	_	O
50	quality	_	_	O
51	of	_	_	O
52	life	_	_	O
53	(	_	_	O
54	QoL	_	_	O
55	)	_	_	O
56	and	_	_	O
57	survival	_	_	O
58	.	_	_	O

59	Patients	_	_	O
60	with	_	_	O
61	stage	_	_	O
62	IIIB	_	_	O
63	or	_	_	O
64	IV	_	_	O
65	NSCLC	_	_	O
66	and	_	_	O
67	WHO	_	_	O
68	performance	_	_	O
69	status	_	_	O
70	(	_	_	O
71	PS	_	_	O
72	)	_	_	O
73	0	_	_	O
74	-	_	_	O
75	2	_	_	O
76	were	_	_	O
77	randomised	_	_	O
78	to	_	_	O
79	receive	_	_	O
80	three	_	_	O
81	(	_	_	O
82	C3	_	_	O
83	)	_	_	O
84	or	_	_	O
85	six	_	_	O
86	(	_	_	O
87	C6	_	_	O
88	)	_	_	O
89	courses	_	_	O
90	of	_	_	O
91	carboplatin	_	_	O
92	(	_	_	O
93	area	_	_	O
94	under	_	_	O
95	the	_	_	O
96	curve	_	_	O
97	(	_	_	O
98	AUC	_	_	O
99	)	_	_	O
100	4	_	_	O
101	,	_	_	O
102	Chatelut	_	_	O
103	'	_	_	O
104	s	_	_	O
105	formula	_	_	O
106	,	_	_	O
107	equivalent	_	_	O
108	to	_	_	O
109	Calvert	_	_	O
110	'	_	_	O
111	s	_	_	O
112	AUC	_	_	O
113	5	_	_	O
114	)	_	_	O
115	on	_	_	O
116	day	_	_	O
117	1	_	_	O
118	and	_	_	O
119	vinorelbine	_	_	O
120	25	_	_	O
121	mg	_	_	O
122	m	_	_	O
123	(	_	_	O
124	-	_	_	O
125	2	_	_	O
126	)	_	_	O
127	on	_	_	O
128	days	_	_	O
129	1	_	_	O
130	and	_	_	O
131	8	_	_	O
132	of	_	_	O
133	a	_	_	O
134	3	_	_	O
135	-	_	_	O
136	week	_	_	O
137	cycle	_	_	O
138	.	_	_	O

139	Key	_	_	O
140	end	_	_	O
141	points	_	_	O
142	were	_	_	O
143	QoL	_	_	O
144	at	_	_	O
145	18	_	_	O
146	weeks	_	_	O
147	,	_	_	O
148	measured	_	_	O
149	with	_	_	O
150	EORTC	_	_	O
151	Quality	_	_	O
152	of	_	_	O
153	Life	_	_	O
154	Questionnaire	_	_	O
155	(	_	_	O
156	QLQ	_	_	O
157	)	_	_	O
158	-	_	_	O
159	C30	_	_	O
160	and	_	_	O
161	QLQ	_	_	O
162	-	_	_	O
163	LC13	_	_	O
164	,	_	_	O
165	and	_	_	O
166	overall	_	_	O
167	survival	_	_	O
168	.	_	_	O

169	Secondary	_	_	O
170	end	_	_	O
171	points	_	_	O
172	were	_	_	O
173	progression	_	_	O
174	-	_	_	O
175	free	_	_	O
176	survival	_	_	O
177	and	_	_	O
178	need	_	_	O
179	of	_	_	O
180	palliative	_	_	O
181	radiotherapy	_	_	O
182	.	_	_	O

183	Two	_	_	O
184	hundred	_	_	O
185	and	_	_	O
186	ninety	_	_	O
187	-	_	_	O
188	seven	_	_	O
189	patients	_	_	O
190	were	_	_	O
191	randomised	_	_	O
192	(	_	_	O
193	C3	_	_	O
194	150	_	_	O
195	,	_	_	O
196	C6	_	_	O
197	147	_	_	O
198	)	_	_	O
199	.	_	_	O

200	Their	_	_	O
201	median	_	_	O
202	age	_	_	O
203	was	_	_	O
204	65	_	_	O
205	years	_	_	O
206	,	_	_	O
207	30	_	_	O
208	%	_	_	O
209	had	_	_	O
210	PS	_	_	O
211	2	_	_	O
212	and	_	_	O
213	76	_	_	O
214	%	_	_	O
215	stage	_	_	O
216	IV	_	_	O
217	disease	_	_	O
218	.	_	_	O

219	Seventy	_	_	O
220	-	_	_	O
221	eight	_	_	O
222	and	_	_	O
223	54	_	_	O
224	%	_	_	O
225	of	_	_	O
226	C3	_	_	O
227	and	_	_	O
228	C6	_	_	O
229	patients	_	_	O
230	,	_	_	O
231	respectively	_	_	O
232	,	_	_	O
233	completed	_	_	O
234	all	_	_	O
235	scheduled	_	_	O
236	chemotherapy	_	_	O
237	courses	_	_	O
238	.	_	_	O

239	Compliance	_	_	O
240	with	_	_	O
241	QoL	_	_	O
242	questionnaires	_	_	O
243	was	_	_	O
244	88	_	_	O
245	%	_	_	O
246	.	_	_	O

247	There	_	_	B-Premise
248	were	_	_	I-Premise
249	no	_	_	I-Premise
250	significant	_	_	I-Premise
251	group	_	_	I-Premise
252	differences	_	_	I-Premise
253	in	_	_	I-Premise
254	global	_	_	I-Premise
255	QoL	_	_	I-Premise
256	,	_	_	I-Premise
257	pain	_	_	I-Premise
258	or	_	_	I-Premise
259	fatigue	_	_	I-Premise
260	up	_	_	I-Premise
261	to	_	_	I-Premise
262	26	_	_	I-Premise
263	weeks	_	_	I-Premise
264	.	_	_	I-Premise

265	The	_	_	B-Premise
266	dyspnoea	_	_	I-Premise
267	palliation	_	_	I-Premise
268	rate	_	_	I-Premise
269	was	_	_	I-Premise
270	lower	_	_	I-Premise
271	in	_	_	I-Premise
272	the	_	_	I-Premise
273	C3	_	_	I-Premise
274	arm	_	_	I-Premise
275	at	_	_	I-Premise
276	18	_	_	I-Premise
277	and	_	_	I-Premise
278	26	_	_	I-Premise
279	weeks	_	_	I-Premise
280	(	_	_	I-Premise
281	P	_	_	I-Premise
282	<	_	_	I-Premise
283	0	_	_	I-Premise
284	.	_	_	I-Premise

285	05	_	_	I-Premise
286	)	_	_	I-Premise
287	,	_	_	I-Premise
288	but	_	_	B-Premise
289	this	_	_	I-Premise
290	finding	_	_	I-Premise
291	was	_	_	I-Premise
292	inconsistent	_	_	I-Premise
293	across	_	_	I-Premise
294	different	_	_	I-Premise
295	methods	_	_	I-Premise
296	of	_	_	I-Premise
297	analysis	_	_	I-Premise
298	.	_	_	I-Premise

299	Median	_	_	B-Premise
300	survival	_	_	I-Premise
301	in	_	_	I-Premise
302	the	_	_	I-Premise
303	C3	_	_	I-Premise
304	group	_	_	I-Premise
305	was	_	_	I-Premise
306	28	_	_	I-Premise
307	vs	_	_	I-Premise
308	32	_	_	I-Premise
309	weeks	_	_	I-Premise
310	in	_	_	I-Premise
311	the	_	_	I-Premise
312	C6	_	_	I-Premise
313	group	_	_	I-Premise
314	(	_	_	I-Premise
315	P	_	_	I-Premise
316	=	_	_	I-Premise
317	0	_	_	I-Premise
318	.	_	_	I-Premise

319	75	_	_	I-Premise
320	,	_	_	I-Premise
321	HR	_	_	I-Premise
322	1	_	_	I-Premise
323	.	_	_	I-Premise

324	04	_	_	I-Premise
325	,	_	_	I-Premise
326	95	_	_	I-Premise
327	%	_	_	I-Premise
328	CI	_	_	I-Premise
329	0	_	_	I-Premise
330	.	_	_	I-Premise

331	82	_	_	I-Premise
332	-	_	_	I-Premise
333	1	_	_	I-Premise
334	.	_	_	I-Premise

335	31	_	_	I-Premise
336	)	_	_	I-Premise
337	.	_	_	I-Premise

338	One	_	_	B-Premise
339	-	_	_	I-Premise
340	and	_	_	I-Premise
341	2	_	_	I-Premise
342	-	_	_	I-Premise
343	year	_	_	I-Premise
344	survival	_	_	I-Premise
345	rates	_	_	I-Premise
346	were	_	_	I-Premise
347	25	_	_	I-Premise
348	and	_	_	I-Premise
349	9	_	_	I-Premise
350	%	_	_	I-Premise
351	vs	_	_	I-Premise
352	25	_	_	I-Premise
353	and	_	_	I-Premise
354	5	_	_	I-Premise
355	%	_	_	I-Premise
356	in	_	_	I-Premise
357	the	_	_	I-Premise
358	C3	_	_	I-Premise
359	and	_	_	I-Premise
360	C6	_	_	I-Premise
361	arm	_	_	I-Premise
362	,	_	_	I-Premise
363	respectively	_	_	I-Premise
364	.	_	_	I-Premise

365	Median	_	_	B-Premise
366	progression	_	_	I-Premise
367	-	_	_	I-Premise
368	free	_	_	I-Premise
369	survival	_	_	I-Premise
370	was	_	_	I-Premise
371	16	_	_	I-Premise
372	and	_	_	I-Premise
373	21	_	_	I-Premise
374	weeks	_	_	I-Premise
375	in	_	_	I-Premise
376	the	_	_	I-Premise
377	C3	_	_	I-Premise
378	and	_	_	I-Premise
379	C6	_	_	I-Premise
380	groups	_	_	I-Premise
381	,	_	_	I-Premise
382	respectively	_	_	I-Premise
383	(	_	_	I-Premise
384	P	_	_	I-Premise
385	=	_	_	I-Premise
386	0	_	_	I-Premise
387	.	_	_	I-Premise

388	21	_	_	I-Premise
389	,	_	_	I-Premise
390	HR	_	_	I-Premise
391	0	_	_	I-Premise
392	.	_	_	I-Premise

393	86	_	_	I-Premise
394	,	_	_	I-Premise
395	95	_	_	I-Premise
396	%	_	_	I-Premise
397	CI	_	_	I-Premise
398	0	_	_	I-Premise
399	.	_	_	I-Premise

400	68	_	_	I-Premise
401	-	_	_	I-Premise
402	1	_	_	I-Premise
403	.	_	_	I-Premise

404	08	_	_	I-Premise
405	)	_	_	I-Premise
406	.	_	_	I-Premise

407	In	_	_	B-Claim
408	conclusion	_	_	I-Claim
409	,	_	_	I-Claim
410	palliative	_	_	I-Claim
411	chemotherapy	_	_	I-Claim
412	with	_	_	I-Claim
413	carboplatin	_	_	I-Claim
414	and	_	_	I-Claim
415	vinorelbine	_	_	I-Claim
416	beyond	_	_	I-Claim
417	three	_	_	I-Claim
418	courses	_	_	I-Claim
419	conveys	_	_	I-Claim
420	no	_	_	I-Claim
421	survival	_	_	I-Claim
422	or	_	_	I-Claim
423	consistent	_	_	I-Claim
424	QoL	_	_	I-Claim
425	benefits	_	_	I-Claim
426	in	_	_	I-Claim
427	advanced	_	_	I-Claim
428	NSCLC	_	_	I-Claim
429	.	_	_	I-Claim


0	Patients	_	_	O
1	with	_	_	O
2	lymphoma	_	_	O
3	experience	_	_	O
4	sleep	_	_	O
5	problems	_	_	O
6	that	_	_	O
7	may	_	_	O
8	be	_	_	O
9	managed	_	_	O
10	with	_	_	O
11	aerobic	_	_	O
12	exercise	_	_	O
13	but	_	_	O
14	no	_	_	O
15	previous	_	_	O
16	study	_	_	O
17	has	_	_	O
18	examined	_	_	O
19	this	_	_	O
20	issue	_	_	O
21	.	_	_	O

22	We	_	_	O
23	randomized	_	_	O
24	122	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	lymphoma	_	_	O
28	to	_	_	O
29	usual	_	_	O
30	care	_	_	O
31	(	_	_	O
32	n	_	_	O
33	=	_	_	O
34	62	_	_	O
35	)	_	_	O
36	or	_	_	O
37	12	_	_	O
38	weeks	_	_	O
39	of	_	_	O
40	supervised	_	_	O
41	aerobic	_	_	O
42	exercise	_	_	O
43	training	_	_	O
44	(	_	_	O
45	AET	_	_	O
46	;	_	_	O
47	n	_	_	O
48	=	_	_	O
49	60	_	_	O
50	)	_	_	O
51	.	_	_	O

52	Our	_	_	O
53	primary	_	_	O
54	sleep	_	_	O
55	endpoint	_	_	O
56	was	_	_	O
57	global	_	_	O
58	sleep	_	_	O
59	quality	_	_	O
60	assessed	_	_	O
61	by	_	_	O
62	the	_	_	O
63	Pittsburgh	_	_	O
64	Sleep	_	_	O
65	Quality	_	_	O
66	Index	_	_	O
67	(	_	_	O
68	PSQI	_	_	O
69	)	_	_	O
70	.	_	_	O

71	Secondary	_	_	O
72	endpoints	_	_	O
73	were	_	_	O
74	the	_	_	O
75	PSQI	_	_	O
76	component	_	_	O
77	scores	_	_	O
78	.	_	_	O

79	Planned	_	_	O
80	subgroup	_	_	O
81	analyses	_	_	O
82	were	_	_	O
83	also	_	_	O
84	conducted	_	_	O
85	.	_	_	O

86	Intention	_	_	B-Premise
87	-	_	_	I-Premise
88	to	_	_	I-Premise
89	-	_	_	I-Premise
90	treat	_	_	I-Premise
91	analyses	_	_	I-Premise
92	indicated	_	_	I-Premise
93	that	_	_	I-Premise
94	AET	_	_	I-Premise
95	resulted	_	_	I-Premise
96	in	_	_	I-Premise
97	a	_	_	I-Premise
98	nonsignificant	_	_	I-Premise
99	(	_	_	I-Premise
100	P	_	_	I-Premise
101	=	_	_	I-Premise
102	0	_	_	I-Premise
103	.	_	_	I-Premise

104	16	_	_	I-Premise
105	)	_	_	I-Premise
106	improvement	_	_	I-Premise
107	in	_	_	I-Premise
108	global	_	_	I-Premise
109	sleep	_	_	I-Premise
110	quality	_	_	I-Premise
111	compared	_	_	I-Premise
112	with	_	_	I-Premise
113	usual	_	_	I-Premise
114	care	_	_	I-Premise
115	[	_	_	I-Premise
116	mean	_	_	I-Premise
117	group	_	_	I-Premise
118	difference	_	_	I-Premise
119	=	_	_	I-Premise
120	-	_	_	I-Premise
121	0	_	_	I-Premise
122	.	_	_	I-Premise

123	64	_	_	I-Premise
124	;	_	_	I-Premise
125	95	_	_	I-Premise
126	%	_	_	I-Premise
127	confidence	_	_	I-Premise
128	interval	_	_	I-Premise
129	(	_	_	I-Premise
130	CI	_	_	I-Premise
131	)	_	_	I-Premise
132	,	_	_	I-Premise
133	-	_	_	I-Premise
134	1	_	_	I-Premise
135	.	_	_	I-Premise

136	56	_	_	I-Premise
137	to	_	_	I-Premise
138	+	_	_	I-Premise
139	0	_	_	I-Premise
140	.	_	_	I-Premise

141	27	_	_	I-Premise
142	]	_	_	I-Premise
143	.	_	_	I-Premise

144	In	_	_	B-Premise
145	planned	_	_	I-Premise
146	subgroup	_	_	I-Premise
147	analyses	_	_	I-Premise
148	,	_	_	I-Premise
149	statistically	_	_	I-Premise
150	significant	_	_	I-Premise
151	or	_	_	I-Premise
152	borderline	_	_	I-Premise
153	significant	_	_	I-Premise
154	interactions	_	_	I-Premise
155	were	_	_	I-Premise
156	identified	_	_	I-Premise
157	for	_	_	I-Premise
158	type	_	_	I-Premise
159	of	_	_	I-Premise
160	lymphoma	_	_	I-Premise
161	(	_	_	I-Premise
162	P	_	_	I-Premise
163	(	_	_	I-Premise
164	interaction	_	_	I-Premise
165	)	_	_	I-Premise
166	=	_	_	I-Premise
167	0	_	_	I-Premise
168	.	_	_	I-Premise

169	006	_	_	I-Premise
170	)	_	_	I-Premise
171	,	_	_	I-Premise
172	current	_	_	I-Premise
173	treatment	_	_	I-Premise
174	status	_	_	I-Premise
175	(	_	_	I-Premise
176	P	_	_	I-Premise
177	(	_	_	I-Premise
178	interaction	_	_	I-Premise
179	)	_	_	I-Premise
180	=	_	_	I-Premise
181	0	_	_	I-Premise
182	.	_	_	I-Premise

183	036	_	_	I-Premise
184	)	_	_	I-Premise
185	,	_	_	I-Premise
186	time	_	_	I-Premise
187	since	_	_	I-Premise
188	diagnosis	_	_	I-Premise
189	(	_	_	I-Premise
190	P	_	_	I-Premise
191	(	_	_	I-Premise
192	interaction	_	_	I-Premise
193	)	_	_	I-Premise
194	=	_	_	I-Premise
195	0	_	_	I-Premise
196	.	_	_	I-Premise

197	010	_	_	I-Premise
198	)	_	_	I-Premise
199	,	_	_	I-Premise
200	body	_	_	I-Premise
201	mass	_	_	I-Premise
202	index	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	(	_	_	I-Premise
206	interaction	_	_	I-Premise
207	)	_	_	I-Premise
208	=	_	_	I-Premise
209	0	_	_	I-Premise
210	.	_	_	I-Premise

211	075	_	_	I-Premise
212	)	_	_	I-Premise
213	,	_	_	I-Premise
214	and	_	_	I-Premise
215	baseline	_	_	I-Premise
216	sleep	_	_	I-Premise
217	quality	_	_	I-Premise
218	(	_	_	I-Premise
219	P	_	_	I-Premise
220	(	_	_	I-Premise
221	interaction	_	_	I-Premise
222	)	_	_	I-Premise
223	=	_	_	I-Premise
224	0	_	_	I-Premise
225	.	_	_	I-Premise

226	041	_	_	I-Premise
227	)	_	_	I-Premise
228	.	_	_	I-Premise

229	Specifically	_	_	O
230	,	_	_	O
231	AET	_	_	B-Premise
232	improved	_	_	I-Premise
233	global	_	_	I-Premise
234	sleep	_	_	I-Premise
235	quality	_	_	I-Premise
236	in	_	_	I-Premise
237	patients	_	_	I-Premise
238	with	_	_	I-Premise
239	lymphoma	_	_	I-Premise
240	who	_	_	I-Premise
241	had	_	_	I-Premise
242	indolent	_	_	I-Premise
243	non	_	_	I-Premise
244	-	_	_	I-Premise
245	Hodgkin	_	_	I-Premise
246	lymphoma	_	_	I-Premise
247	(	_	_	I-Premise
248	P	_	_	I-Premise
249	=	_	_	I-Premise
250	0	_	_	I-Premise
251	.	_	_	I-Premise

252	001	_	_	I-Premise
253	)	_	_	I-Premise
254	,	_	_	I-Premise
255	were	_	_	I-Premise
256	receiving	_	_	I-Premise
257	chemotherapy	_	_	I-Premise
258	(	_	_	I-Premise
259	P	_	_	I-Premise
260	=	_	_	I-Premise
261	0	_	_	I-Premise
262	.	_	_	I-Premise

263	013	_	_	I-Premise
264	)	_	_	I-Premise
265	,	_	_	I-Premise
266	were	_	_	I-Premise
267	<	_	_	I-Premise
268	2	_	_	I-Premise
269	years	_	_	I-Premise
270	post	_	_	I-Premise
271	-	_	_	I-Premise
272	diagnosis	_	_	I-Premise
273	(	_	_	I-Premise
274	P	_	_	I-Premise
275	=	_	_	I-Premise
276	0	_	_	I-Premise
277	.	_	_	I-Premise

278	005	_	_	I-Premise
279	)	_	_	I-Premise
280	,	_	_	I-Premise
281	were	_	_	I-Premise
282	obese	_	_	I-Premise
283	(	_	_	I-Premise
284	P	_	_	I-Premise
285	=	_	_	I-Premise
286	0	_	_	I-Premise
287	.	_	_	I-Premise

288	025	_	_	I-Premise
289	)	_	_	I-Premise
290	,	_	_	I-Premise
291	and	_	_	I-Premise
292	were	_	_	I-Premise
293	poor	_	_	I-Premise
294	sleepers	_	_	I-Premise
295	at	_	_	I-Premise
296	baseline	_	_	I-Premise
297	(	_	_	I-Premise
298	P	_	_	I-Premise
299	=	_	_	I-Premise
300	0	_	_	I-Premise
301	.	_	_	I-Premise

302	007	_	_	I-Premise
303	)	_	_	I-Premise
304	.	_	_	I-Premise

305	AET	_	_	B-Claim
306	did	_	_	I-Claim
307	not	_	_	I-Claim
308	significantly	_	_	I-Claim
309	improve	_	_	I-Claim
310	sleep	_	_	I-Claim
311	quality	_	_	I-Claim
312	in	_	_	I-Claim
313	this	_	_	I-Claim
314	heterogeneous	_	_	I-Claim
315	sample	_	_	I-Claim
316	of	_	_	I-Claim
317	patients	_	_	I-Claim
318	with	_	_	I-Claim
319	lymphoma	_	_	I-Claim
320	;	_	_	I-Claim
321	however	_	_	B-Claim
322	,	_	_	I-Claim
323	clinically	_	_	I-Claim
324	identifiable	_	_	I-Claim
325	subgroups	_	_	I-Claim
326	appeared	_	_	I-Claim
327	to	_	_	I-Claim
328	benefit	_	_	I-Claim
329	.	_	_	I-Claim

330	Future	_	_	O
331	exercise	_	_	O
332	trials	_	_	O
333	targeting	_	_	O
334	these	_	_	O
335	responsive	_	_	O
336	subgroups	_	_	O
337	are	_	_	O
338	needed	_	_	O
339	to	_	_	O
340	confirm	_	_	O
341	these	_	_	O
342	findings	_	_	O
343	.	_	_	O

344	If	_	_	O
345	replicated	_	_	O
346	in	_	_	O
347	larger	_	_	O
348	and	_	_	O
349	more	_	_	O
350	focused	_	_	O
351	trials	_	_	O
352	,	_	_	O
353	aerobic	_	_	O
354	exercise	_	_	O
355	may	_	_	O
356	be	_	_	O
357	an	_	_	O
358	attractive	_	_	O
359	option	_	_	O
360	to	_	_	O
361	manage	_	_	O
362	sleep	_	_	O
363	dysfunction	_	_	O
364	in	_	_	O
365	patients	_	_	O
366	with	_	_	O
367	cancer	_	_	O
368	because	_	_	O
369	of	_	_	O
370	its	_	_	O
371	favorable	_	_	O
372	safety	_	_	O
373	profile	_	_	O
374	and	_	_	O
375	other	_	_	O
376	documented	_	_	O
377	health	_	_	O
378	benefits	_	_	O
379	.	_	_	O


0	National	_	_	O
1	Cancer	_	_	O
2	Institute	_	_	O
3	of	_	_	O
4	Canada	_	_	O
5	Clinical	_	_	O
6	Trials	_	_	O
7	Group	_	_	O
8	CO	_	_	O
9	.	_	_	O

10	17	_	_	O
11	demonstrated	_	_	O
12	the	_	_	O
13	antiepidermal	_	_	O
14	growth	_	_	O
15	factor	_	_	O
16	receptor	_	_	O
17	(	_	_	O
18	anti	_	_	O
19	-	_	_	O
20	EGFR	_	_	O
21	)	_	_	O
22	monoclonal	_	_	O
23	antibody	_	_	O
24	cetuximab	_	_	O
25	improves	_	_	O
26	overall	_	_	O
27	and	_	_	O
28	progression	_	_	O
29	-	_	_	O
30	free	_	_	O
31	survival	_	_	O
32	in	_	_	O
33	patients	_	_	O
34	with	_	_	O
35	advanced	_	_	O
36	,	_	_	O
37	chemotherapy	_	_	O
38	-	_	_	O
39	refractory	_	_	O
40	colorectal	_	_	O
41	cancer	_	_	O
42	(	_	_	O
43	CRC	_	_	O
44	)	_	_	O
45	,	_	_	O
46	particularly	_	_	O
47	in	_	_	O
48	patients	_	_	O
49	with	_	_	O
50	wild	_	_	O
51	-	_	_	O
52	type	_	_	O
53	KRAS	_	_	O
54	tumors	_	_	O
55	.	_	_	O

56	This	_	_	O
57	article	_	_	O
58	reports	_	_	O
59	the	_	_	O
60	health	_	_	O
61	-	_	_	O
62	related	_	_	O
63	quality	_	_	O
64	-	_	_	O
65	of	_	_	O
66	-	_	_	O
67	life	_	_	O
68	(	_	_	O
69	HRQL	_	_	O
70	)	_	_	O
71	outcomes	_	_	O
72	from	_	_	O
73	CO	_	_	O
74	.	_	_	O

75	17	_	_	O
76	.	_	_	O

77	Patients	_	_	O
78	(	_	_	O
79	N	_	_	O
80	=	_	_	O
81	572	_	_	O
82	)	_	_	O
83	with	_	_	O
84	pretreated	_	_	O
85	EGFR	_	_	O
86	-	_	_	O
87	detectable	_	_	O
88	advanced	_	_	O
89	CRC	_	_	O
90	were	_	_	O
91	randomly	_	_	O
92	assigned	_	_	O
93	to	_	_	O
94	cetuximab	_	_	O
95	and	_	_	O
96	best	_	_	O
97	supportive	_	_	O
98	care	_	_	O
99	(	_	_	O
100	BSC	_	_	O
101	)	_	_	O
102	or	_	_	O
103	to	_	_	O
104	BSC	_	_	O
105	alone	_	_	O
106	.	_	_	O

107	HRQL	_	_	O
108	primary	_	_	O
109	end	_	_	O
110	points	_	_	O
111	assessed	_	_	O
112	by	_	_	O
113	the	_	_	O
114	EORTC	_	_	O
115	QLQ	_	_	O
116	-	_	_	O
117	C30	_	_	O
118	were	_	_	O
119	physical	_	_	O
120	function	_	_	O
121	(	_	_	O
122	PF	_	_	O
123	)	_	_	O
124	and	_	_	O
125	global	_	_	O
126	health	_	_	O
127	status	_	_	O
128	(	_	_	O
129	GHS	_	_	O
130	)	_	_	O
131	;	_	_	O
132	mean	_	_	O
133	changes	_	_	O
134	from	_	_	O
135	baseline	_	_	O
136	to	_	_	O
137	8	_	_	O
138	and	_	_	O
139	16	_	_	O
140	weeks	_	_	O
141	were	_	_	O
142	assessed	_	_	O
143	.	_	_	O

144	Post	_	_	O
145	hoc	_	_	O
146	analysis	_	_	O
147	by	_	_	O
148	KRAS	_	_	O
149	mutation	_	_	O
150	status	_	_	O
151	was	_	_	O
152	performed	_	_	O
153	.	_	_	O

154	Questionnaire	_	_	O
155	compliance	_	_	O
156	was	_	_	O
157	94	_	_	O
158	%	_	_	O
159	at	_	_	O
160	baseline	_	_	O
161	,	_	_	O
162	but	_	_	O
163	it	_	_	O
164	declined	_	_	O
165	differentially	_	_	O
166	(	_	_	O
167	67	_	_	O
168	%	_	_	O
169	v	_	_	O
170	47	_	_	O
171	%	_	_	O
172	for	_	_	O
173	cetuximab	_	_	O
174	v	_	_	O
175	BSC	_	_	O
176	at	_	_	O
177	16	_	_	O
178	weeks	_	_	O
179	)	_	_	O
180	.	_	_	O

181	PF	_	_	B-Premise
182	change	_	_	I-Premise
183	scores	_	_	I-Premise
184	were	_	_	I-Premise
185	-	_	_	I-Premise
186	3	_	_	I-Premise
187	.	_	_	I-Premise

188	9	_	_	I-Premise
189	for	_	_	I-Premise
190	cetuximab	_	_	I-Premise
191	and	_	_	I-Premise
192	-	_	_	I-Premise
193	8	_	_	I-Premise
194	.	_	_	I-Premise

195	6	_	_	I-Premise
196	for	_	_	I-Premise
197	BSC	_	_	I-Premise
198	(	_	_	I-Premise
199	P	_	_	I-Premise
200	=	_	_	I-Premise
201	.	_	_	I-Premise

202	046	_	_	I-Premise
203	)	_	_	I-Premise
204	at	_	_	I-Premise
205	8	_	_	I-Premise
206	weeks	_	_	I-Premise
207	and	_	_	I-Premise
208	were	_	_	I-Premise
209	-	_	_	I-Premise
210	5	_	_	I-Premise
211	.	_	_	I-Premise

212	9	_	_	I-Premise
213	and	_	_	I-Premise
214	-	_	_	I-Premise
215	12	_	_	I-Premise
216	.	_	_	I-Premise

217	5	_	_	I-Premise
218	for	_	_	I-Premise
219	cetuximab	_	_	I-Premise
220	and	_	_	I-Premise
221	BSC	_	_	I-Premise
222	,	_	_	I-Premise
223	respectively	_	_	I-Premise
224	,	_	_	I-Premise
225	(	_	_	I-Premise
226	P	_	_	I-Premise
227	=	_	_	I-Premise
228	.	_	_	I-Premise

229	027	_	_	I-Premise
230	)	_	_	I-Premise
231	at	_	_	I-Premise
232	16	_	_	I-Premise
233	weeks	_	_	I-Premise
234	.	_	_	I-Premise

235	GHS	_	_	B-Premise
236	change	_	_	I-Premise
237	scores	_	_	I-Premise
238	were	_	_	I-Premise
239	-	_	_	I-Premise
240	0	_	_	I-Premise
241	.	_	_	I-Premise

242	5	_	_	I-Premise
243	and	_	_	I-Premise
244	-	_	_	I-Premise
245	7	_	_	I-Premise
246	.	_	_	I-Premise

247	1	_	_	I-Premise
248	(	_	_	I-Premise
249	P	_	_	I-Premise
250	=	_	_	I-Premise
251	.	_	_	I-Premise

252	008	_	_	I-Premise
253	)	_	_	I-Premise
254	at	_	_	I-Premise
255	8	_	_	I-Premise
256	weeks	_	_	I-Premise
257	and	_	_	I-Premise
258	were	_	_	I-Premise
259	-	_	_	I-Premise
260	3	_	_	I-Premise
261	.	_	_	I-Premise

262	6	_	_	I-Premise
263	and	_	_	I-Premise
264	-	_	_	I-Premise
265	15	_	_	I-Premise
266	.	_	_	I-Premise

267	2	_	_	I-Premise
268	(	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	.	_	_	I-Premise

272	008	_	_	I-Premise
273	)	_	_	I-Premise
274	at	_	_	I-Premise
275	16	_	_	I-Premise
276	weeks	_	_	I-Premise
277	for	_	_	I-Premise
278	cetuximab	_	_	I-Premise
279	and	_	_	I-Premise
280	BSC	_	_	I-Premise
281	,	_	_	I-Premise
282	respectively	_	_	I-Premise
283	.	_	_	I-Premise

284	In	_	_	B-Premise
285	patients	_	_	I-Premise
286	who	_	_	I-Premise
287	had	_	_	I-Premise
288	tumors	_	_	I-Premise
289	with	_	_	I-Premise
290	wild	_	_	I-Premise
291	-	_	_	I-Premise
292	type	_	_	I-Premise
293	KRAS	_	_	I-Premise
294	status	_	_	I-Premise
295	,	_	_	I-Premise
296	cetuximab	_	_	I-Premise
297	resulted	_	_	I-Premise
298	in	_	_	I-Premise
299	less	_	_	I-Premise
300	PF	_	_	I-Premise
301	deterioration	_	_	I-Premise
302	at	_	_	I-Premise
303	8	_	_	I-Premise
304	weeks	_	_	I-Premise
305	(	_	_	I-Premise
306	-	_	_	I-Premise
307	0	_	_	I-Premise
308	.	_	_	I-Premise

309	7	_	_	I-Premise
310	v	_	_	I-Premise
311	-	_	_	I-Premise
312	7	_	_	I-Premise
313	.	_	_	I-Premise

314	2	_	_	I-Premise
315	;	_	_	I-Premise
316	P	_	_	I-Premise
317	=	_	_	I-Premise
318	.	_	_	I-Premise

319	11	_	_	I-Premise
320	)	_	_	I-Premise
321	and	_	_	I-Premise
322	16	_	_	I-Premise
323	weeks	_	_	I-Premise
324	(	_	_	I-Premise
325	-	_	_	I-Premise
326	3	_	_	I-Premise
327	.	_	_	I-Premise

328	4	_	_	I-Premise
329	v	_	_	I-Premise
330	-	_	_	I-Premise
331	13	_	_	I-Premise
332	.	_	_	I-Premise

333	8	_	_	I-Premise
334	;	_	_	I-Premise
335	P	_	_	I-Premise
336	=	_	_	I-Premise
337	.	_	_	I-Premise

338	008	_	_	I-Premise
339	)	_	_	I-Premise
340	compared	_	_	I-Premise
341	with	_	_	I-Premise
342	BSC	_	_	I-Premise
343	.	_	_	I-Premise

344	Patients	_	_	B-Premise
345	with	_	_	I-Premise
346	wild	_	_	I-Premise
347	-	_	_	I-Premise
348	type	_	_	I-Premise
349	status	_	_	I-Premise
350	who	_	_	I-Premise
351	received	_	_	I-Premise
352	cetuximab	_	_	I-Premise
353	experienced	_	_	I-Premise
354	improved	_	_	I-Premise
355	GHS	_	_	I-Premise
356	at	_	_	I-Premise
357	8	_	_	I-Premise
358	weeks	_	_	I-Premise
359	,	_	_	I-Premise
360	whereas	_	_	I-Premise
361	patients	_	_	I-Premise
362	who	_	_	I-Premise
363	received	_	_	I-Premise
364	BSC	_	_	I-Premise
365	alone	_	_	I-Premise
366	deteriorated	_	_	I-Premise
367	(	_	_	I-Premise
368	3	_	_	I-Premise
369	.	_	_	I-Premise

370	2	_	_	I-Premise
371	v	_	_	I-Premise
372	-	_	_	I-Premise
373	7	_	_	I-Premise
374	.	_	_	I-Premise

375	7	_	_	I-Premise
376	;	_	_	I-Premise
377	P	_	_	I-Premise
378	=	_	_	I-Premise
379	.	_	_	I-Premise

380	002	_	_	I-Premise
381	)	_	_	I-Premise
382	.	_	_	I-Premise

383	Cetuximab	_	_	B-Premise
384	preserved	_	_	I-Premise
385	GHS	_	_	I-Premise
386	at	_	_	I-Premise
387	16	_	_	I-Premise
388	weeks	_	_	I-Premise
389	(	_	_	I-Premise
390	-	_	_	I-Premise
391	0	_	_	I-Premise
392	.	_	_	I-Premise

393	2	_	_	I-Premise
394	v	_	_	I-Premise
395	-	_	_	I-Premise
396	18	_	_	I-Premise
397	.	_	_	I-Premise

398	1	_	_	I-Premise
399	;	_	_	I-Premise
400	P	_	_	I-Premise
401	<	_	_	I-Premise
402	.	_	_	I-Premise

403	001	_	_	I-Premise
404	)	_	_	I-Premise
405	.	_	_	I-Premise

406	No	_	_	B-Premise
407	significant	_	_	I-Premise
408	differences	_	_	I-Premise
409	were	_	_	I-Premise
410	noted	_	_	I-Premise
411	between	_	_	I-Premise
412	study	_	_	I-Premise
413	arms	_	_	I-Premise
414	for	_	_	I-Premise
415	patients	_	_	I-Premise
416	with	_	_	I-Premise
417	mutated	_	_	I-Premise
418	KRAS	_	_	I-Premise
419	tumors	_	_	I-Premise
420	.	_	_	I-Premise

421	Cetuximab	_	_	B-Claim
422	offers	_	_	I-Claim
423	important	_	_	I-Claim
424	HRQL	_	_	I-Claim
425	and	_	_	I-Claim
426	survival	_	_	I-Claim
427	benefits	_	_	I-Claim
428	for	_	_	I-Claim
429	pretreated	_	_	I-Claim
430	patients	_	_	I-Claim
431	with	_	_	I-Claim
432	advanced	_	_	I-Claim
433	,	_	_	I-Claim
434	wild	_	_	I-Claim
435	-	_	_	I-Claim
436	type	_	_	I-Claim
437	KRAS	_	_	I-Claim
438	CRC	_	_	I-Claim
439	.	_	_	I-Claim


0	Dignity	_	_	O
1	therapy	_	_	O
2	is	_	_	O
3	a	_	_	O
4	unique	_	_	O
5	,	_	_	O
6	individualised	_	_	O
7	,	_	_	O
8	short	_	_	O
9	-	_	_	O
10	term	_	_	O
11	psychotherapy	_	_	O
12	that	_	_	O
13	was	_	_	O
14	developed	_	_	O
15	for	_	_	O
16	patients	_	_	O
17	(	_	_	O
18	and	_	_	O
19	their	_	_	O
20	families	_	_	O
21	)	_	_	O
22	living	_	_	O
23	with	_	_	O
24	life	_	_	O
25	-	_	_	O
26	threatening	_	_	O
27	or	_	_	O
28	life	_	_	O
29	-	_	_	O
30	limiting	_	_	O
31	illness	_	_	O
32	.	_	_	O

33	We	_	_	O
34	investigated	_	_	O
35	whether	_	_	O
36	dignity	_	_	O
37	therapy	_	_	O
38	could	_	_	O
39	mitigate	_	_	O
40	distress	_	_	O
41	or	_	_	O
42	bolster	_	_	O
43	the	_	_	O
44	experience	_	_	O
45	in	_	_	O
46	patients	_	_	O
47	nearing	_	_	O
48	the	_	_	O
49	end	_	_	O
50	of	_	_	O
51	their	_	_	O
52	lives	_	_	O
53	.	_	_	O

54	Patients	_	_	O
55	(	_	_	O
56	aged	_	_	O
57	≥	_	_	O
58	18	_	_	O
59	years	_	_	O
60	)	_	_	O
61	with	_	_	O
62	a	_	_	O
63	terminal	_	_	O
64	prognosis	_	_	O
65	(	_	_	O
66	life	_	_	O
67	expectancy	_	_	O
68	≤	_	_	O
69	6	_	_	O
70	months	_	_	O
71	)	_	_	O
72	who	_	_	O
73	were	_	_	O
74	receiving	_	_	O
75	palliative	_	_	O
76	care	_	_	O
77	in	_	_	O
78	a	_	_	O
79	hospital	_	_	O
80	or	_	_	O
81	community	_	_	O
82	setting	_	_	O
83	(	_	_	O
84	hospice	_	_	O
85	or	_	_	O
86	home	_	_	O
87	)	_	_	O
88	in	_	_	O
89	Canada	_	_	O
90	,	_	_	O
91	USA	_	_	O
92	,	_	_	O
93	and	_	_	O
94	Australia	_	_	O
95	were	_	_	O
96	randomly	_	_	O
97	assigned	_	_	O
98	to	_	_	O
99	dignity	_	_	O
100	therapy	_	_	O
101	,	_	_	O
102	client	_	_	O
103	-	_	_	O
104	centred	_	_	O
105	care	_	_	O
106	,	_	_	O
107	or	_	_	O
108	standard	_	_	O
109	palliative	_	_	O
110	care	_	_	O
111	in	_	_	O
112	a	_	_	O
113	1	_	_	O
114	:	_	_	O
115	1	_	_	O
116	:	_	_	O
117	1	_	_	O
118	ratio	_	_	O
119	.	_	_	O

120	Randomisation	_	_	O
121	was	_	_	O
122	by	_	_	O
123	use	_	_	O
124	of	_	_	O
125	a	_	_	O
126	computer	_	_	O
127	-	_	_	O
128	generated	_	_	O
129	table	_	_	O
130	of	_	_	O
131	random	_	_	O
132	numbers	_	_	O
133	in	_	_	O
134	blocks	_	_	O
135	of	_	_	O
136	30	_	_	O
137	.	_	_	O

138	Allocation	_	_	O
139	concealment	_	_	O
140	was	_	_	O
141	by	_	_	O
142	use	_	_	O
143	of	_	_	O
144	opaque	_	_	O
145	sealed	_	_	O
146	envelopes	_	_	O
147	.	_	_	O

148	The	_	_	O
149	primary	_	_	O
150	outcomes	_	_	O
151	-	_	_	O
152	-	_	_	O
153	reductions	_	_	O
154	in	_	_	O
155	various	_	_	O
156	dimensions	_	_	O
157	of	_	_	O
158	distress	_	_	O
159	before	_	_	O
160	and	_	_	O
161	after	_	_	O
162	completion	_	_	O
163	of	_	_	O
164	the	_	_	O
165	study	_	_	O
166	-	_	_	O
167	-	_	_	O
168	were	_	_	O
169	measured	_	_	O
170	with	_	_	O
171	the	_	_	O
172	Functional	_	_	O
173	Assessment	_	_	O
174	of	_	_	O
175	Chronic	_	_	O
176	Illness	_	_	O
177	Therapy	_	_	O
178	Spiritual	_	_	O
179	Well	_	_	O
180	-	_	_	O
181	Being	_	_	O
182	Scale	_	_	O
183	,	_	_	O
184	Patient	_	_	O
185	Dignity	_	_	O
186	Inventory	_	_	O
187	,	_	_	O
188	Hospital	_	_	O
189	Anxiety	_	_	O
190	and	_	_	O
191	Depression	_	_	O
192	Scale	_	_	O
193	,	_	_	O
194	items	_	_	O
195	from	_	_	O
196	the	_	_	O
197	Structured	_	_	O
198	Interview	_	_	O
199	for	_	_	O
200	Symptoms	_	_	O
201	and	_	_	O
202	Concerns	_	_	O
203	,	_	_	O
204	Quality	_	_	O
205	of	_	_	O
206	Life	_	_	O
207	Scale	_	_	O
208	,	_	_	O
209	and	_	_	O
210	modified	_	_	O
211	Edmonton	_	_	O
212	Symptom	_	_	O
213	Assessment	_	_	O
214	Scale	_	_	O
215	.	_	_	O

216	Secondary	_	_	O
217	outcomes	_	_	O
218	of	_	_	O
219	self	_	_	O
220	-	_	_	O
221	reported	_	_	O
222	end	_	_	O
223	-	_	_	O
224	of	_	_	O
225	-	_	_	O
226	life	_	_	O
227	experiences	_	_	O
228	were	_	_	O
229	assessed	_	_	O
230	in	_	_	O
231	a	_	_	O
232	survey	_	_	O
233	that	_	_	O
234	was	_	_	O
235	undertaken	_	_	O
236	after	_	_	O
237	the	_	_	O
238	completion	_	_	O
239	of	_	_	O
240	the	_	_	O
241	study	_	_	O
242	.	_	_	O

243	Outcomes	_	_	O
244	were	_	_	O
245	assessed	_	_	O
246	by	_	_	O
247	research	_	_	O
248	staff	_	_	O
249	with	_	_	O
250	whom	_	_	O
251	the	_	_	O
252	participant	_	_	O
253	had	_	_	O
254	no	_	_	O
255	previous	_	_	O
256	contact	_	_	O
257	to	_	_	O
258	avoid	_	_	O
259	any	_	_	O
260	possible	_	_	O
261	response	_	_	O
262	bias	_	_	O
263	or	_	_	O
264	contamination	_	_	O
265	.	_	_	O

266	Analyses	_	_	O
267	were	_	_	O
268	done	_	_	O
269	on	_	_	O
270	all	_	_	O
271	patients	_	_	O
272	with	_	_	O
273	available	_	_	O
274	data	_	_	O
275	at	_	_	O
276	baseline	_	_	O
277	and	_	_	O
278	at	_	_	O
279	the	_	_	O
280	end	_	_	O
281	of	_	_	O
282	the	_	_	O
283	study	_	_	O
284	intervention	_	_	O
285	.	_	_	O

286	165	_	_	O
287	of	_	_	O
288	441	_	_	O
289	patients	_	_	O
290	were	_	_	O
291	assigned	_	_	O
292	to	_	_	O
293	dignity	_	_	O
294	therapy	_	_	O
295	,	_	_	O
296	140	_	_	O
297	standard	_	_	O
298	palliative	_	_	O
299	care	_	_	O
300	,	_	_	O
301	and	_	_	O
302	136	_	_	O
303	client	_	_	O
304	-	_	_	O
305	centred	_	_	O
306	care	_	_	O
307	.	_	_	O

308	108	_	_	O
309	,	_	_	O
310	111	_	_	O
311	,	_	_	O
312	and	_	_	O
313	107	_	_	O
314	patients	_	_	O
315	,	_	_	O
316	respectively	_	_	O
317	,	_	_	O
318	were	_	_	O
319	analysed	_	_	O
320	.	_	_	O

321	No	_	_	B-Premise
322	significant	_	_	I-Premise
323	differences	_	_	I-Premise
324	were	_	_	I-Premise
325	noted	_	_	I-Premise
326	in	_	_	I-Premise
327	the	_	_	I-Premise
328	distress	_	_	I-Premise
329	levels	_	_	I-Premise
330	before	_	_	I-Premise
331	and	_	_	I-Premise
332	after	_	_	I-Premise
333	completion	_	_	I-Premise
334	of	_	_	I-Premise
335	the	_	_	I-Premise
336	study	_	_	I-Premise
337	in	_	_	I-Premise
338	the	_	_	I-Premise
339	three	_	_	I-Premise
340	groups	_	_	I-Premise
341	.	_	_	I-Premise

342	For	_	_	B-Premise
343	the	_	_	I-Premise
344	secondary	_	_	I-Premise
345	outcomes	_	_	I-Premise
346	,	_	_	I-Premise
347	patients	_	_	I-Premise
348	reported	_	_	I-Premise
349	that	_	_	I-Premise
350	dignity	_	_	I-Premise
351	therapy	_	_	I-Premise
352	was	_	_	I-Premise
353	significantly	_	_	I-Premise
354	more	_	_	I-Premise
355	likely	_	_	I-Premise
356	than	_	_	I-Premise
357	the	_	_	I-Premise
358	other	_	_	I-Premise
359	two	_	_	I-Premise
360	interventions	_	_	I-Premise
361	to	_	_	I-Premise
362	have	_	_	I-Premise
363	been	_	_	I-Premise
364	helpful	_	_	I-Premise
365	(	_	_	I-Premise
366	χ	_	_	I-Premise
367	(	_	_	I-Premise
368	2	_	_	I-Premise
369	)	_	_	I-Premise
370	=	_	_	I-Premise
371	35	_	_	I-Premise
372	·	_	_	I-Premise
373	50	_	_	I-Premise
374	,	_	_	I-Premise
375	df	_	_	I-Premise
376	=	_	_	I-Premise
377	2	_	_	I-Premise
378	;	_	_	I-Premise
379	p	_	_	I-Premise
380	<	_	_	I-Premise
381	0	_	_	I-Premise
382	·	_	_	I-Premise
383	0001	_	_	I-Premise
384	)	_	_	I-Premise
385	,	_	_	I-Premise
386	improve	_	_	I-Premise
387	quality	_	_	I-Premise
388	of	_	_	I-Premise
389	life	_	_	I-Premise
390	(	_	_	I-Premise
391	χ	_	_	I-Premise
392	(	_	_	I-Premise
393	2	_	_	I-Premise
394	)	_	_	I-Premise
395	=	_	_	I-Premise
396	14	_	_	I-Premise
397	·	_	_	I-Premise
398	52	_	_	I-Premise
399	;	_	_	I-Premise
400	p	_	_	I-Premise
401	=	_	_	I-Premise
402	0	_	_	I-Premise
403	·	_	_	I-Premise
404	001	_	_	I-Premise
405	)	_	_	I-Premise
406	,	_	_	I-Premise
407	increase	_	_	I-Premise
408	sense	_	_	I-Premise
409	of	_	_	I-Premise
410	dignity	_	_	I-Premise
411	(	_	_	I-Premise
412	χ	_	_	I-Premise
413	(	_	_	I-Premise
414	2	_	_	I-Premise
415	)	_	_	I-Premise
416	=	_	_	I-Premise
417	12	_	_	I-Premise
418	·	_	_	I-Premise
419	66	_	_	I-Premise
420	;	_	_	I-Premise
421	p	_	_	I-Premise
422	=	_	_	I-Premise
423	0	_	_	I-Premise
424	·	_	_	I-Premise
425	002	_	_	I-Premise
426	)	_	_	I-Premise
427	,	_	_	I-Premise
428	change	_	_	I-Premise
429	how	_	_	I-Premise
430	their	_	_	I-Premise
431	family	_	_	I-Premise
432	saw	_	_	I-Premise
433	and	_	_	I-Premise
434	appreciated	_	_	I-Premise
435	them	_	_	I-Premise
436	(	_	_	I-Premise
437	χ	_	_	I-Premise
438	(	_	_	I-Premise
439	2	_	_	I-Premise
440	)	_	_	I-Premise
441	=	_	_	I-Premise
442	33	_	_	I-Premise
443	·	_	_	I-Premise
444	81	_	_	I-Premise
445	;	_	_	I-Premise
446	p	_	_	I-Premise
447	<	_	_	I-Premise
448	0	_	_	I-Premise
449	·	_	_	I-Premise
450	0001	_	_	I-Premise
451	)	_	_	I-Premise
452	,	_	_	I-Premise
453	and	_	_	I-Premise
454	be	_	_	I-Premise
455	helpful	_	_	I-Premise
456	to	_	_	I-Premise
457	their	_	_	I-Premise
458	family	_	_	I-Premise
459	(	_	_	I-Premise
460	χ	_	_	I-Premise
461	(	_	_	I-Premise
462	2	_	_	I-Premise
463	)	_	_	I-Premise
464	=	_	_	I-Premise
465	33	_	_	I-Premise
466	·	_	_	I-Premise
467	86	_	_	I-Premise
468	;	_	_	I-Premise
469	p	_	_	I-Premise
470	<	_	_	I-Premise
471	0	_	_	I-Premise
472	·	_	_	I-Premise
473	0001	_	_	I-Premise
474	)	_	_	I-Premise
475	.	_	_	I-Premise

476	Dignity	_	_	B-Premise
477	therapy	_	_	I-Premise
478	was	_	_	I-Premise
479	significantly	_	_	I-Premise
480	better	_	_	I-Premise
481	than	_	_	I-Premise
482	client	_	_	I-Premise
483	-	_	_	I-Premise
484	centred	_	_	I-Premise
485	care	_	_	I-Premise
486	in	_	_	I-Premise
487	improving	_	_	I-Premise
488	spiritual	_	_	I-Premise
489	wellbeing	_	_	I-Premise
490	(	_	_	I-Premise
491	χ	_	_	I-Premise
492	(	_	_	I-Premise
493	2	_	_	I-Premise
494	)	_	_	I-Premise
495	=	_	_	I-Premise
496	10	_	_	I-Premise
497	·	_	_	I-Premise
498	35	_	_	I-Premise
499	;	_	_	I-Premise
500	p	_	_	I-Premise
501	=	_	_	I-Premise
502	0	_	_	I-Premise
503	·	_	_	I-Premise
504	006	_	_	I-Premise
505	)	_	_	I-Premise
506	,	_	_	I-Premise
507	and	_	_	I-Premise
508	was	_	_	I-Premise
509	significantly	_	_	I-Premise
510	better	_	_	I-Premise
511	than	_	_	I-Premise
512	standard	_	_	I-Premise
513	palliative	_	_	I-Premise
514	care	_	_	I-Premise
515	in	_	_	I-Premise
516	terms	_	_	I-Premise
517	of	_	_	I-Premise
518	lessening	_	_	I-Premise
519	sadness	_	_	I-Premise
520	or	_	_	I-Premise
521	depression	_	_	I-Premise
522	(	_	_	I-Premise
523	χ	_	_	I-Premise
524	(	_	_	I-Premise
525	2	_	_	I-Premise
526	)	_	_	I-Premise
527	=	_	_	I-Premise
528	9	_	_	I-Premise
529	·	_	_	I-Premise
530	38	_	_	I-Premise
531	;	_	_	I-Premise
532	p	_	_	I-Premise
533	=	_	_	I-Premise
534	0	_	_	I-Premise
535	·	_	_	I-Premise
536	009	_	_	I-Premise
537	)	_	_	I-Premise
538	;	_	_	I-Premise
539	significantly	_	_	B-Premise
540	more	_	_	I-Premise
541	patients	_	_	I-Premise
542	who	_	_	I-Premise
543	had	_	_	I-Premise
544	received	_	_	I-Premise
545	dignity	_	_	I-Premise
546	therapy	_	_	I-Premise
547	reported	_	_	I-Premise
548	that	_	_	I-Premise
549	the	_	_	I-Premise
550	study	_	_	I-Premise
551	group	_	_	I-Premise
552	had	_	_	I-Premise
553	been	_	_	I-Premise
554	satisfactory	_	_	I-Premise
555	,	_	_	I-Premise
556	compared	_	_	I-Premise
557	with	_	_	I-Premise
558	those	_	_	I-Premise
559	who	_	_	I-Premise
560	received	_	_	I-Premise
561	standard	_	_	I-Premise
562	palliative	_	_	I-Premise
563	care	_	_	I-Premise
564	(	_	_	I-Premise
565	χ	_	_	I-Premise
566	(	_	_	I-Premise
567	2	_	_	I-Premise
568	)	_	_	I-Premise
569	=	_	_	I-Premise
570	29	_	_	I-Premise
571	·	_	_	I-Premise
572	58	_	_	I-Premise
573	;	_	_	I-Premise
574	p	_	_	I-Premise
575	<	_	_	I-Premise
576	0	_	_	I-Premise
577	·	_	_	I-Premise
578	0001	_	_	I-Premise
579	)	_	_	I-Premise
580	.	_	_	I-Premise

581	Although	_	_	B-Claim
582	the	_	_	I-Claim
583	ability	_	_	I-Claim
584	of	_	_	I-Claim
585	dignity	_	_	I-Claim
586	therapy	_	_	I-Claim
587	to	_	_	I-Claim
588	mitigate	_	_	I-Claim
589	outright	_	_	I-Claim
590	distress	_	_	I-Claim
591	,	_	_	I-Claim
592	such	_	_	I-Claim
593	as	_	_	I-Claim
594	depression	_	_	I-Claim
595	,	_	_	I-Claim
596	desire	_	_	I-Claim
597	for	_	_	I-Claim
598	death	_	_	I-Claim
599	or	_	_	I-Claim
600	suicidality	_	_	I-Claim
601	,	_	_	I-Claim
602	has	_	_	I-Claim
603	yet	_	_	I-Claim
604	to	_	_	I-Claim
605	be	_	_	I-Claim
606	proven	_	_	I-Claim
607	,	_	_	I-Claim
608	its	_	_	B-Claim
609	benefits	_	_	I-Claim
610	in	_	_	I-Claim
611	terms	_	_	I-Claim
612	of	_	_	I-Claim
613	self	_	_	I-Claim
614	-	_	_	I-Claim
615	reported	_	_	I-Claim
616	end	_	_	I-Claim
617	-	_	_	I-Claim
618	of	_	_	I-Claim
619	-	_	_	I-Claim
620	life	_	_	I-Claim
621	experiences	_	_	I-Claim
622	support	_	_	I-Claim
623	its	_	_	I-Claim
624	clinical	_	_	I-Claim
625	application	_	_	I-Claim
626	for	_	_	I-Claim
627	patients	_	_	I-Claim
628	nearing	_	_	I-Claim
629	death	_	_	I-Claim
630	.	_	_	I-Claim


0	Chemotherapy	_	_	B-Claim
1	can	_	_	I-Claim
2	profoundly	_	_	I-Claim
3	affect	_	_	I-Claim
4	patients	_	_	I-Claim
5	'	_	_	I-Claim
6	quality	_	_	I-Claim
7	of	_	_	I-Claim
8	life	_	_	I-Claim
9	(	_	_	I-Claim
10	QOL	_	_	I-Claim
11	)	_	_	I-Claim
12	,	_	_	I-Claim
13	yet	_	_	O
14	few	_	_	O
15	clinical	_	_	O
16	trials	_	_	O
17	in	_	_	O
18	advanced	_	_	O
19	cervical	_	_	O
20	cancer	_	_	O
21	have	_	_	O
22	included	_	_	O
23	QOL	_	_	O
24	outcomes	_	_	O
25	.	_	_	O

26	Our	_	_	O
27	purpose	_	_	O
28	was	_	_	O
29	to	_	_	O
30	assess	_	_	O
31	the	_	_	O
32	impact	_	_	O
33	of	_	_	O
34	cisplatin	_	_	O
35	(	_	_	O
36	C	_	_	O
37	)	_	_	O
38	versus	_	_	O
39	cisplatin	_	_	O
40	plus	_	_	O
41	paclitaxel	_	_	O
42	(	_	_	O
43	CP	_	_	O
44	)	_	_	O
45	on	_	_	O
46	overall	_	_	O
47	QOL	_	_	O
48	and	_	_	O
49	pain	_	_	O
50	in	_	_	O
51	cervical	_	_	O
52	cancer	_	_	O
53	patients	_	_	O
54	.	_	_	O

55	QOL	_	_	O
56	was	_	_	O
57	assessed	_	_	O
58	using	_	_	O
59	FACT	_	_	O
60	-	_	_	O
61	Cx	_	_	O
62	,	_	_	O
63	consisting	_	_	O
64	of	_	_	O
65	the	_	_	O
66	Functional	_	_	O
67	Assessment	_	_	O
68	of	_	_	O
69	Cancer	_	_	O
70	Therapy	_	_	O
71	(	_	_	O
72	FACT	_	_	O
73	-	_	_	O
74	G	_	_	O
75	)	_	_	O
76	plus	_	_	O
77	a	_	_	O
78	cervix	_	_	O
79	cancer	_	_	O
80	-	_	_	O
81	specific	_	_	O
82	subscale	_	_	O
83	,	_	_	O
84	the	_	_	O
85	Brief	_	_	O
86	Pain	_	_	O
87	Inventory	_	_	O
88	-	_	_	O
89	Short	_	_	O
90	Form	_	_	O
91	(	_	_	O
92	BPI	_	_	O
93	-	_	_	O
94	SF	_	_	O
95	)	_	_	O
96	,	_	_	O
97	and	_	_	O
98	a	_	_	O
99	neurotoxicity	_	_	O
100	subscale	_	_	O
101	.	_	_	O

102	Time	_	_	O
103	points	_	_	O
104	were	_	_	O
105	:	_	_	O
106	baseline	_	_	O
107	(	_	_	O
108	prior	_	_	O
109	to	_	_	O
110	randomization	_	_	O
111	)	_	_	O
112	and	_	_	O
113	prior	_	_	O
114	to	_	_	O
115	chemotherapy	_	_	O
116	cycles	_	_	O
117	2	_	_	O
118	,	_	_	O
119	3	_	_	O
120	,	_	_	O
121	and	_	_	O
122	4	_	_	O
123	.	_	_	O

124	Overall	_	_	B-Premise
125	(	_	_	I-Premise
126	FACT	_	_	I-Premise
127	-	_	_	I-Premise
128	G	_	_	I-Premise
129	)	_	_	I-Premise
130	scores	_	_	I-Premise
131	did	_	_	I-Premise
132	not	_	_	I-Premise
133	differ	_	_	I-Premise
134	significantly	_	_	I-Premise
135	between	_	_	I-Premise
136	arms	_	_	I-Premise
137	at	_	_	I-Premise
138	the	_	_	I-Premise
139	fourth	_	_	I-Premise
140	assessment	_	_	I-Premise
141	(	_	_	I-Premise
142	C	_	_	I-Premise
143	=	_	_	I-Premise
144	70	_	_	I-Premise
145	.	_	_	I-Premise

146	3	_	_	I-Premise
147	(	_	_	I-Premise
148	19	_	_	I-Premise
149	.	_	_	I-Premise

150	6	_	_	I-Premise
151	)	_	_	I-Premise
152	;	_	_	I-Premise
153	CP	_	_	I-Premise
154	=	_	_	I-Premise
155	72	_	_	I-Premise
156	.	_	_	I-Premise

157	8	_	_	I-Premise
158	(	_	_	I-Premise
159	17	_	_	I-Premise
160	.	_	_	I-Premise

161	4	_	_	I-Premise
162	)	_	_	I-Premise
163	)	_	_	I-Premise
164	.	_	_	I-Premise

165	Scores	_	_	B-Premise
166	were	_	_	I-Premise
167	stable	_	_	I-Premise
168	over	_	_	I-Premise
169	time	_	_	I-Premise
170	and	_	_	I-Premise
171	considerably	_	_	I-Premise
172	lower	_	_	I-Premise
173	than	_	_	I-Premise
174	the	_	_	I-Premise
175	general	_	_	I-Premise
176	population	_	_	I-Premise
177	norms	_	_	I-Premise
178	.	_	_	I-Premise

179	The	_	_	B-Premise
180	BPI	_	_	I-Premise
181	-	_	_	I-Premise
182	SF	_	_	I-Premise
183	revealed	_	_	I-Premise
184	a	_	_	I-Premise
185	decline	_	_	I-Premise
186	in	_	_	I-Premise
187	pain	_	_	I-Premise
188	scores	_	_	I-Premise
189	in	_	_	I-Premise
190	both	_	_	I-Premise
191	arms	_	_	I-Premise
192	from	_	_	I-Premise
193	the	_	_	I-Premise
194	first	_	_	I-Premise
195	to	_	_	I-Premise
196	fourth	_	_	I-Premise
197	assessments	_	_	I-Premise
198	.	_	_	I-Premise

199	The	_	_	B-Premise
200	CP	_	_	I-Premise
201	arm	_	_	I-Premise
202	produced	_	_	I-Premise
203	a	_	_	I-Premise
204	significantly	_	_	I-Premise
205	higher	_	_	I-Premise
206	response	_	_	I-Premise
207	rate	_	_	I-Premise
208	and	_	_	I-Premise
209	progression	_	_	I-Premise
210	-	_	_	I-Premise
211	free	_	_	I-Premise
212	survival	_	_	I-Premise
213	(	_	_	I-Premise
214	PFS	_	_	I-Premise
215	)	_	_	I-Premise
216	but	_	_	B-Premise
217	not	_	_	I-Premise
218	overall	_	_	I-Premise
219	survival	_	_	I-Premise
220	(	_	_	I-Premise
221	OS	_	_	I-Premise
222	)	_	_	I-Premise
223	.	_	_	I-Premise

224	Greater	_	_	B-Premise
225	myelosuppression	_	_	I-Premise
226	was	_	_	I-Premise
227	reported	_	_	I-Premise
228	in	_	_	I-Premise
229	the	_	_	I-Premise
230	combination	_	_	I-Premise
231	arm	_	_	I-Premise
232	.	_	_	I-Premise

233	The	_	_	B-Premise
234	rate	_	_	I-Premise
235	of	_	_	I-Premise
236	QOL	_	_	I-Premise
237	drop	_	_	I-Premise
238	-	_	_	I-Premise
239	out	_	_	I-Premise
240	for	_	_	I-Premise
241	any	_	_	I-Premise
242	reason	_	_	I-Premise
243	was	_	_	I-Premise
244	higher	_	_	I-Premise
245	for	_	_	I-Premise
246	C	_	_	I-Premise
247	(	_	_	I-Premise
248	53	_	_	I-Premise
249	%	_	_	I-Premise
250	)	_	_	I-Premise
251	compared	_	_	I-Premise
252	to	_	_	I-Premise
253	CP	_	_	I-Premise
254	(	_	_	I-Premise
255	38	_	_	I-Premise
256	%	_	_	I-Premise
257	)	_	_	I-Premise
258	(	_	_	I-Premise
259	P	_	_	I-Premise
260	<	_	_	I-Premise
261	0	_	_	I-Premise
262	.	_	_	I-Premise

263	05	_	_	I-Premise
264	)	_	_	I-Premise
265	.	_	_	I-Premise

266	At	_	_	O
267	the	_	_	O
268	fourth	_	_	O
269	time	_	_	O
270	point	_	_	O
271	,	_	_	O
272	60	_	_	O
273	%	_	_	O
274	of	_	_	O
275	living	_	_	O
276	patients	_	_	O
277	in	_	_	O
278	both	_	_	O
279	arms	_	_	O
280	completed	_	_	O
281	a	_	_	O
282	QOL	_	_	O
283	assessment	_	_	O
284	.	_	_	O

285	There	_	_	B-Claim
286	was	_	_	I-Claim
287	no	_	_	I-Claim
288	significant	_	_	I-Claim
289	difference	_	_	I-Claim
290	in	_	_	I-Claim
291	overall	_	_	I-Claim
292	QOL	_	_	I-Claim
293	scores	_	_	I-Claim
294	between	_	_	I-Claim
295	treatment	_	_	I-Claim
296	arms	_	_	I-Claim
297	or	_	_	I-Claim
298	serially	_	_	I-Claim
299	.	_	_	I-Claim

300	Combined	_	_	B-Claim
301	with	_	_	I-Claim
302	QOL	_	_	I-Claim
303	results	_	_	I-Claim
304	,	_	_	I-Claim
305	the	_	_	I-Claim
306	significant	_	_	I-Claim
307	increase	_	_	I-Claim
308	in	_	_	I-Claim
309	response	_	_	I-Claim
310	and	_	_	I-Claim
311	PFS	_	_	I-Claim
312	in	_	_	I-Claim
313	the	_	_	I-Claim
314	CP	_	_	I-Claim
315	arm	_	_	I-Claim
316	and	_	_	I-Claim
317	the	_	_	I-Claim
318	higher	_	_	I-Claim
319	drop	_	_	I-Claim
320	-	_	_	I-Claim
321	out	_	_	I-Claim
322	rate	_	_	I-Claim
323	in	_	_	I-Claim
324	the	_	_	I-Claim
325	C	_	_	I-Claim
326	arm	_	_	I-Claim
327	suggest	_	_	I-Claim
328	a	_	_	I-Claim
329	better	_	_	I-Claim
330	outcome	_	_	I-Claim
331	for	_	_	I-Claim
332	the	_	_	I-Claim
333	combination	_	_	I-Claim
334	regimen	_	_	I-Claim
335	despite	_	_	I-Claim
336	its	_	_	I-Claim
337	increased	_	_	I-Claim
338	myelosuppression	_	_	I-Claim
339	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	analgesic	_	_	O
4	effect	_	_	O
5	,	_	_	O
6	safety	_	_	O
7	,	_	_	O
8	and	_	_	O
9	cost	_	_	O
10	-	_	_	O
11	effectiveness	_	_	O
12	of	_	_	O
13	controlled	_	_	O
14	-	_	_	O
15	release	_	_	O
16	oxycodone	_	_	O
17	(	_	_	O
18	CRO	_	_	O
19	)	_	_	O
20	to	_	_	O
21	control	_	_	O
22	postoperative	_	_	O
23	pain	_	_	O
24	in	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	liver	_	_	O
28	cancer	_	_	O
29	who	_	_	O
30	are	_	_	O
31	undergoing	_	_	O
32	transarterial	_	_	O
33	chemoembolization	_	_	O
34	.	_	_	O

35	This	_	_	O
36	randomized	_	_	O
37	,	_	_	O
38	double	_	_	O
39	-	_	_	O
40	blind	_	_	O
41	,	_	_	O
42	placebo	_	_	O
43	-	_	_	O
44	controlled	_	_	O
45	,	_	_	O
46	prospective	_	_	O
47	clinical	_	_	O
48	study	_	_	O
49	received	_	_	O
50	institutional	_	_	O
51	review	_	_	O
52	board	_	_	O
53	approval	_	_	O
54	.	_	_	O

55	After	_	_	O
56	written	_	_	O
57	informed	_	_	O
58	consent	_	_	O
59	was	_	_	O
60	obtained	_	_	O
61	,	_	_	O
62	210	_	_	O
63	patients	_	_	O
64	with	_	_	O
65	liver	_	_	O
66	cancer	_	_	O
67	were	_	_	O
68	randomized	_	_	O
69	into	_	_	O
70	three	_	_	O
71	groups	_	_	O
72	of	_	_	O
73	70	_	_	O
74	patients	_	_	O
75	.	_	_	O

76	Group	_	_	O
77	1	_	_	O
78	received	_	_	O
79	20	_	_	O
80	mg	_	_	O
81	of	_	_	O
82	CRO	_	_	O
83	,	_	_	O
84	group	_	_	O
85	2	_	_	O
86	received	_	_	O
87	10	_	_	O
88	mg	_	_	O
89	of	_	_	O
90	CRO	_	_	O
91	,	_	_	O
92	and	_	_	O
93	group	_	_	O
94	3	_	_	O
95	received	_	_	O
96	a	_	_	O
97	placebo	_	_	O
98	at	_	_	O
99	1	_	_	O
100	hour	_	_	O
101	before	_	_	O
102	transarterial	_	_	O
103	chemoembolization	_	_	O
104	(	_	_	O
105	T	_	_	O
106	(	_	_	O
107	0	_	_	O
108	)	_	_	O
109	)	_	_	O
110	and	_	_	O
111	12	_	_	O
112	(	_	_	O
113	T	_	_	O
114	(	_	_	O
115	12	_	_	O
116	)	_	_	O
117	)	_	_	O
118	and	_	_	O
119	24	_	_	O
120	(	_	_	O
121	T	_	_	O
122	(	_	_	O
123	24	_	_	O
124	)	_	_	O
125	)	_	_	O
126	hours	_	_	O
127	after	_	_	O
128	T	_	_	O
129	(	_	_	O
130	0	_	_	O
131	)	_	_	O
132	.	_	_	O

133	Pain	_	_	O
134	intensity	_	_	O
135	on	_	_	O
136	a	_	_	O
137	numeric	_	_	O
138	rating	_	_	O
139	scale	_	_	O
140	,	_	_	O
141	percentage	_	_	O
142	of	_	_	O
143	patients	_	_	O
144	with	_	_	O
145	each	_	_	O
146	degree	_	_	O
147	of	_	_	O
148	pain	_	_	O
149	,	_	_	O
150	quality	_	_	O
151	of	_	_	O
152	life	_	_	O
153	,	_	_	O
154	adverse	_	_	O
155	reactions	_	_	O
156	,	_	_	O
157	analgesic	_	_	O
158	costs	_	_	O
159	,	_	_	O
160	and	_	_	O
161	hospital	_	_	O
162	stays	_	_	O
163	were	_	_	O
164	evaluated	_	_	O
165	and	_	_	O
166	compared	_	_	O
167	among	_	_	O
168	the	_	_	O
169	three	_	_	O
170	groups	_	_	O
171	.	_	_	O

172	Numeric	_	_	B-Premise
173	rating	_	_	I-Premise
174	scale	_	_	I-Premise
175	scores	_	_	I-Premise
176	for	_	_	I-Premise
177	pain	_	_	I-Premise
178	intensity	_	_	I-Premise
179	in	_	_	I-Premise
180	group	_	_	I-Premise
181	1	_	_	I-Premise
182	and	_	_	I-Premise
183	group	_	_	I-Premise
184	2	_	_	I-Premise
185	were	_	_	I-Premise
186	significantly	_	_	I-Premise
187	lower	_	_	I-Premise
188	than	_	_	I-Premise
189	those	_	_	I-Premise
190	in	_	_	I-Premise
191	group	_	_	I-Premise
192	3	_	_	I-Premise
193	at	_	_	I-Premise
194	T	_	_	I-Premise
195	(	_	_	I-Premise
196	0	_	_	I-Premise
197	-	_	_	I-Premise
198	12	_	_	I-Premise
199	)	_	_	I-Premise
200	(	_	_	I-Premise
201	P	_	_	I-Premise
202	<	_	_	I-Premise
203	.	_	_	I-Premise

204	001	_	_	I-Premise
205	)	_	_	I-Premise
206	;	_	_	I-Premise
207	T	_	_	I-Premise
208	(	_	_	I-Premise
209	12	_	_	I-Premise
210	-	_	_	I-Premise
211	24	_	_	I-Premise
212	)	_	_	I-Premise
213	(	_	_	I-Premise
214	P	_	_	I-Premise
215	<	_	_	I-Premise
216	.	_	_	I-Premise

217	001	_	_	I-Premise
218	)	_	_	I-Premise
219	;	_	_	I-Premise
220	and	_	_	I-Premise
221	T	_	_	I-Premise
222	(	_	_	I-Premise
223	24	_	_	I-Premise
224	-	_	_	I-Premise
225	48	_	_	I-Premise
226	)	_	_	I-Premise
227	(	_	_	I-Premise
228	P	_	_	I-Premise
229	<	_	_	I-Premise
230	.	_	_	I-Premise

231	001	_	_	I-Premise
232	)	_	_	I-Premise
233	.	_	_	I-Premise

234	When	_	_	B-Premise
235	group	_	_	I-Premise
236	1	_	_	I-Premise
237	with	_	_	I-Premise
238	group	_	_	I-Premise
239	2	_	_	I-Premise
240	were	_	_	I-Premise
241	compared	_	_	I-Premise
242	,	_	_	I-Premise
243	numeric	_	_	I-Premise
244	rating	_	_	I-Premise
245	scale	_	_	I-Premise
246	scores	_	_	I-Premise
247	were	_	_	I-Premise
248	significantly	_	_	I-Premise
249	lower	_	_	I-Premise
250	in	_	_	I-Premise
251	group	_	_	I-Premise
252	1	_	_	I-Premise
253	than	_	_	I-Premise
254	in	_	_	I-Premise
255	group	_	_	I-Premise
256	2	_	_	I-Premise
257	during	_	_	I-Premise
258	the	_	_	I-Premise
259	period	_	_	I-Premise
260	of	_	_	I-Premise
261	T	_	_	I-Premise
262	(	_	_	I-Premise
263	0	_	_	I-Premise
264	-	_	_	I-Premise
265	12	_	_	I-Premise
266	)	_	_	I-Premise
267	(	_	_	I-Premise
268	P	_	_	I-Premise
269	<	_	_	I-Premise
270	.	_	_	I-Premise

271	001	_	_	I-Premise
272	)	_	_	I-Premise
273	but	_	_	B-Premise
274	were	_	_	I-Premise
275	not	_	_	I-Premise
276	significantly	_	_	I-Premise
277	different	_	_	I-Premise
278	at	_	_	I-Premise
279	T	_	_	I-Premise
280	(	_	_	I-Premise
281	12	_	_	I-Premise
282	-	_	_	I-Premise
283	24	_	_	I-Premise
284	)	_	_	I-Premise
285	(	_	_	I-Premise
286	P	_	_	I-Premise
287	=	_	_	I-Premise
288	.	_	_	I-Premise

289	68	_	_	I-Premise
290	)	_	_	I-Premise
291	and	_	_	I-Premise
292	T	_	_	I-Premise
293	(	_	_	I-Premise
294	24	_	_	I-Premise
295	-	_	_	I-Premise
296	48	_	_	I-Premise
297	)	_	_	I-Premise
298	(	_	_	I-Premise
299	P	_	_	I-Premise
300	=	_	_	I-Premise
301	.	_	_	I-Premise

302	10	_	_	I-Premise
303	)	_	_	I-Premise
304	.	_	_	I-Premise

305	Analgesic	_	_	B-Premise
306	cost	_	_	I-Premise
307	and	_	_	I-Premise
308	hospital	_	_	I-Premise
309	stay	_	_	I-Premise
310	were	_	_	I-Premise
311	significantly	_	_	I-Premise
312	lower	_	_	I-Premise
313	in	_	_	I-Premise
314	treated	_	_	I-Premise
315	groups	_	_	I-Premise
316	than	_	_	I-Premise
317	in	_	_	I-Premise
318	the	_	_	I-Premise
319	placebo	_	_	I-Premise
320	group	_	_	I-Premise
321	.	_	_	I-Premise

322	No	_	_	B-Premise
323	significant	_	_	I-Premise
324	difference	_	_	I-Premise
325	was	_	_	I-Premise
326	observed	_	_	I-Premise
327	in	_	_	I-Premise
328	quality	_	_	I-Premise
329	of	_	_	I-Premise
330	life	_	_	I-Premise
331	and	_	_	I-Premise
332	adverse	_	_	I-Premise
333	events	_	_	I-Premise
334	between	_	_	I-Premise
335	the	_	_	I-Premise
336	treated	_	_	I-Premise
337	groups	_	_	I-Premise
338	and	_	_	I-Premise
339	the	_	_	I-Premise
340	placebo	_	_	I-Premise
341	group	_	_	I-Premise
342	.	_	_	I-Premise

343	CRO	_	_	B-Claim
344	is	_	_	I-Claim
345	effective	_	_	I-Claim
346	,	_	_	I-Claim
347	safe	_	_	I-Claim
348	,	_	_	I-Claim
349	and	_	_	I-Claim
350	cost	_	_	I-Claim
351	-	_	_	I-Claim
352	effective	_	_	I-Claim
353	in	_	_	I-Claim
354	the	_	_	I-Claim
355	control	_	_	I-Claim
356	of	_	_	I-Claim
357	postoperative	_	_	I-Claim
358	pain	_	_	I-Claim
359	after	_	_	I-Claim
360	transarterial	_	_	I-Claim
361	chemoembolization	_	_	I-Claim
362	for	_	_	I-Claim
363	patients	_	_	I-Claim
364	with	_	_	I-Claim
365	inoperable	_	_	I-Claim
366	liver	_	_	I-Claim
367	cancer	_	_	I-Claim
368	.	_	_	I-Claim


0	Promising	_	_	O
1	results	_	_	O
2	in	_	_	O
3	a	_	_	O
4	randomized	_	_	O
5	phase	_	_	O
6	II	_	_	O
7	trial	_	_	O
8	with	_	_	O
9	the	_	_	O
10	hypoxic	_	_	O
11	cytotoxin	_	_	O
12	tirapazamine	_	_	O
13	(	_	_	O
14	TPZ	_	_	O
15	)	_	_	O
16	combined	_	_	O
17	with	_	_	O
18	cisplatin	_	_	O
19	(	_	_	O
20	CIS	_	_	O
21	)	_	_	O
22	and	_	_	O
23	radiation	_	_	O
24	led	_	_	O
25	to	_	_	O
26	this	_	_	O
27	phase	_	_	O
28	III	_	_	O
29	trial	_	_	O
30	.	_	_	O

31	Patients	_	_	O
32	with	_	_	O
33	previously	_	_	O
34	untreated	_	_	O
35	stage	_	_	O
36	III	_	_	O
37	or	_	_	O
38	IV	_	_	O
39	(	_	_	O
40	excluding	_	_	O
41	T1	_	_	O
42	-	_	_	O
43	2N1	_	_	O
44	and	_	_	O
45	M1	_	_	O
46	)	_	_	O
47	squamous	_	_	O
48	cell	_	_	O
49	carcinoma	_	_	O
50	of	_	_	O
51	the	_	_	O
52	oral	_	_	O
53	cavity	_	_	O
54	,	_	_	O
55	oropharynx	_	_	O
56	,	_	_	O
57	hypopharynx	_	_	O
58	,	_	_	O
59	or	_	_	O
60	larynx	_	_	O
61	were	_	_	O
62	randomly	_	_	O
63	assigned	_	_	O
64	to	_	_	O
65	receive	_	_	O
66	definitive	_	_	O
67	radiotherapy	_	_	O
68	(	_	_	O
69	70	_	_	O
70	Gy	_	_	O
71	in	_	_	O
72	7	_	_	O
73	weeks	_	_	O
74	)	_	_	O
75	concurrently	_	_	O
76	with	_	_	O
77	either	_	_	O
78	CIS	_	_	O
79	(	_	_	O
80	100	_	_	O
81	mg	_	_	O
82	/	_	_	O
83	m	_	_	O
84	(	_	_	O
85	2	_	_	O
86	)	_	_	O
87	)	_	_	O
88	on	_	_	O
89	day	_	_	O
90	1	_	_	O
91	of	_	_	O
92	weeks	_	_	O
93	1	_	_	O
94	,	_	_	O
95	4	_	_	O
96	,	_	_	O
97	and	_	_	O
98	7	_	_	O
99	or	_	_	O
100	CIS	_	_	O
101	(	_	_	O
102	75	_	_	O
103	mg	_	_	O
104	/	_	_	O
105	m	_	_	O
106	(	_	_	O
107	2	_	_	O
108	)	_	_	O
109	)	_	_	O
110	plus	_	_	O
111	TPZ	_	_	O
112	(	_	_	O
113	290	_	_	O
114	mg	_	_	O
115	/	_	_	O
116	m	_	_	O
117	(	_	_	O
118	2	_	_	O
119	)	_	_	O
120	/	_	_	O
121	d	_	_	O
122	)	_	_	O
123	on	_	_	O
124	day	_	_	O
125	1	_	_	O
126	of	_	_	O
127	weeks	_	_	O
128	1	_	_	O
129	,	_	_	O
130	4	_	_	O
131	,	_	_	O
132	and	_	_	O
133	7	_	_	O
134	and	_	_	O
135	TPZ	_	_	O
136	alone	_	_	O
137	(	_	_	O
138	160	_	_	O
139	mg	_	_	O
140	/	_	_	O
141	m	_	_	O
142	(	_	_	O
143	2	_	_	O
144	)	_	_	O
145	/	_	_	O
146	d	_	_	O
147	)	_	_	O
148	on	_	_	O
149	days	_	_	O
150	1	_	_	O
151	,	_	_	O
152	3	_	_	O
153	,	_	_	O
154	and	_	_	O
155	5	_	_	O
156	of	_	_	O
157	weeks	_	_	O
158	2	_	_	O
159	and	_	_	O
160	3	_	_	O
161	(	_	_	O
162	TPZ	_	_	O
163	/	_	_	O
164	CIS	_	_	O
165	)	_	_	O
166	.	_	_	O

167	The	_	_	O
168	primary	_	_	O
169	end	_	_	O
170	point	_	_	O
171	was	_	_	O
172	overall	_	_	O
173	survival	_	_	O
174	(	_	_	O
175	OS	_	_	O
176	)	_	_	O
177	.	_	_	O

178	The	_	_	O
179	planned	_	_	O
180	sample	_	_	O
181	size	_	_	O
182	was	_	_	O
183	850	_	_	O
184	,	_	_	O
185	estimated	_	_	O
186	to	_	_	O
187	result	_	_	O
188	in	_	_	O
189	334	_	_	O
190	deaths	_	_	O
191	,	_	_	O
192	which	_	_	O
193	would	_	_	O
194	provide	_	_	O
195	90	_	_	O
196	%	_	_	O
197	power	_	_	O
198	to	_	_	O
199	detect	_	_	O
200	a	_	_	O
201	difference	_	_	O
202	in	_	_	O
203	2	_	_	O
204	-	_	_	O
205	year	_	_	O
206	survival	_	_	O
207	rates	_	_	O
208	of	_	_	O
209	60	_	_	O
210	%	_	_	O
211	v	_	_	O
212	70	_	_	O
213	%	_	_	O
214	for	_	_	O
215	CIS	_	_	O
216	versus	_	_	O
217	TPZ	_	_	O
218	/	_	_	O
219	CIS	_	_	O
220	,	_	_	O
221	respectively	_	_	O
222	(	_	_	O
223	hazard	_	_	O
224	ratio	_	_	O
225	=	_	_	O
226	0	_	_	O
227	.	_	_	O

228	69	_	_	O
229	)	_	_	O
230	.	_	_	O

231	Eight	_	_	O
232	hundred	_	_	O
233	sixty	_	_	O
234	-	_	_	O
235	one	_	_	O
236	patients	_	_	O
237	were	_	_	O
238	accrued	_	_	O
239	from	_	_	O
240	89	_	_	O
241	sites	_	_	O
242	in	_	_	O
243	16	_	_	O
244	countries	_	_	O
245	.	_	_	O

246	In	_	_	B-Premise
247	an	_	_	I-Premise
248	intent	_	_	I-Premise
249	-	_	_	I-Premise
250	to	_	_	I-Premise
251	-	_	_	I-Premise
252	treat	_	_	I-Premise
253	analysis	_	_	I-Premise
254	,	_	_	I-Premise
255	the	_	_	I-Premise
256	2	_	_	I-Premise
257	-	_	_	I-Premise
258	year	_	_	I-Premise
259	OS	_	_	I-Premise
260	rates	_	_	I-Premise
261	were	_	_	I-Premise
262	65	_	_	I-Premise
263	.	_	_	I-Premise

264	7	_	_	I-Premise
265	%	_	_	I-Premise
266	for	_	_	I-Premise
267	CIS	_	_	I-Premise
268	and	_	_	I-Premise
269	66	_	_	I-Premise
270	.	_	_	I-Premise

271	2	_	_	I-Premise
272	%	_	_	I-Premise
273	for	_	_	I-Premise
274	TPZ	_	_	I-Premise
275	/	_	_	I-Premise
276	CIS	_	_	I-Premise
277	(	_	_	I-Premise
278	TPZ	_	_	I-Premise
279	/	_	_	I-Premise
280	CIS	_	_	I-Premise
281	-	_	_	I-Premise
282	-	_	_	I-Premise
283	CIS	_	_	I-Premise
284	:	_	_	I-Premise
285	95	_	_	I-Premise
286	%	_	_	I-Premise
287	CI	_	_	I-Premise
288	,	_	_	I-Premise
289	-	_	_	I-Premise
290	5	_	_	I-Premise
291	.	_	_	I-Premise

292	9	_	_	I-Premise
293	%	_	_	I-Premise
294	to	_	_	I-Premise
295	6	_	_	I-Premise
296	.	_	_	I-Premise

297	9	_	_	I-Premise
298	%	_	_	I-Premise
299	)	_	_	I-Premise
300	.	_	_	I-Premise

301	There	_	_	B-Premise
302	were	_	_	I-Premise
303	no	_	_	I-Premise
304	significant	_	_	I-Premise
305	differences	_	_	I-Premise
306	in	_	_	I-Premise
307	failure	_	_	I-Premise
308	-	_	_	I-Premise
309	free	_	_	I-Premise
310	survival	_	_	I-Premise
311	,	_	_	I-Premise
312	time	_	_	I-Premise
313	to	_	_	I-Premise
314	locoregional	_	_	I-Premise
315	failure	_	_	I-Premise
316	,	_	_	I-Premise
317	or	_	_	I-Premise
318	quality	_	_	I-Premise
319	of	_	_	I-Premise
320	life	_	_	I-Premise
321	as	_	_	I-Premise
322	measured	_	_	I-Premise
323	by	_	_	I-Premise
324	Functional	_	_	I-Premise
325	Assessment	_	_	I-Premise
326	of	_	_	I-Premise
327	Cancer	_	_	I-Premise
328	Therapy	_	_	I-Premise
329	-	_	_	I-Premise
330	Head	_	_	I-Premise
331	and	_	_	I-Premise
332	Neck	_	_	I-Premise
333	.	_	_	I-Premise

334	We	_	_	B-Claim
335	found	_	_	I-Claim
336	no	_	_	I-Claim
337	evidence	_	_	I-Claim
338	that	_	_	I-Claim
339	the	_	_	I-Claim
340	addition	_	_	I-Claim
341	of	_	_	I-Claim
342	TPZ	_	_	I-Claim
343	to	_	_	I-Claim
344	chemoradiotherapy	_	_	I-Claim
345	,	_	_	I-Claim
346	in	_	_	I-Claim
347	patients	_	_	I-Claim
348	with	_	_	I-Claim
349	advanced	_	_	I-Claim
350	head	_	_	I-Claim
351	and	_	_	I-Claim
352	neck	_	_	I-Claim
353	cancer	_	_	I-Claim
354	not	_	_	I-Claim
355	selected	_	_	I-Claim
356	for	_	_	I-Claim
357	the	_	_	I-Claim
358	presence	_	_	I-Claim
359	of	_	_	I-Claim
360	hypoxia	_	_	I-Claim
361	,	_	_	I-Claim
362	improves	_	_	I-Claim
363	OS	_	_	I-Claim
364	.	_	_	I-Claim


0	Sunitinib	_	_	O
1	has	_	_	O
2	demonstrated	_	_	O
3	antitumor	_	_	O
4	activity	_	_	O
5	in	_	_	O
6	metastatic	_	_	O
7	renal	_	_	O
8	cell	_	_	O
9	carcinoma	_	_	O
10	(	_	_	O
11	mRCC	_	_	O
12	)	_	_	O
13	when	_	_	O
14	given	_	_	O
15	at	_	_	O
16	50	_	_	O
17	mg	_	_	O
18	/	_	_	O
19	d	_	_	O
20	on	_	_	O
21	a	_	_	O
22	4	_	_	O
23	-	_	_	O
24	weeks	_	_	O
25	-	_	_	O
26	on	_	_	O
27	2	_	_	O
28	-	_	_	O
29	weeks	_	_	O
30	-	_	_	O
31	off	_	_	O
32	regimen	_	_	O
33	.	_	_	O

34	Herein	_	_	O
35	,	_	_	O
36	we	_	_	O
37	report	_	_	O
38	results	_	_	O
39	of	_	_	O
40	an	_	_	O
41	open	_	_	O
42	-	_	_	O
43	label	_	_	O
44	,	_	_	O
45	multicenter	_	_	O
46	phase	_	_	O
47	II	_	_	O
48	mRCC	_	_	O
49	study	_	_	O
50	of	_	_	O
51	sunitinib	_	_	O
52	administered	_	_	O
53	on	_	_	O
54	a	_	_	O
55	continuous	_	_	O
56	once	_	_	O
57	-	_	_	O
58	daily	_	_	O
59	dosing	_	_	O
60	regimen	_	_	O
61	.	_	_	O

62	Eligibility	_	_	O
63	criteria	_	_	O
64	included	_	_	O
65	histologically	_	_	O
66	proven	_	_	O
67	mRCC	_	_	O
68	with	_	_	O
69	measurable	_	_	O
70	disease	_	_	O
71	,	_	_	O
72	failure	_	_	O
73	of	_	_	O
74	one	_	_	O
75	prior	_	_	O
76	cytokine	_	_	O
77	regimen	_	_	O
78	,	_	_	O
79	and	_	_	O
80	good	_	_	O
81	performance	_	_	O
82	status	_	_	O
83	.	_	_	O

84	Patients	_	_	O
85	were	_	_	O
86	randomly	_	_	O
87	assigned	_	_	O
88	to	_	_	O
89	a	_	_	O
90	sunitinib	_	_	O
91	starting	_	_	O
92	dose	_	_	O
93	of	_	_	O
94	37	_	_	O
95	.	_	_	O

96	5	_	_	O
97	mg	_	_	O
98	/	_	_	O
99	d	_	_	O
100	in	_	_	O
101	the	_	_	O
102	morning	_	_	O
103	(	_	_	O
104	AM	_	_	O
105	)	_	_	O
106	or	_	_	O
107	evening	_	_	O
108	(	_	_	O
109	PM	_	_	O
110	)	_	_	O
111	.	_	_	O

112	RECIST	_	_	O
113	-	_	_	O
114	defined	_	_	O
115	objective	_	_	O
116	response	_	_	O
117	rate	_	_	O
118	(	_	_	O
119	ORR	_	_	O
120	)	_	_	O
121	was	_	_	O
122	the	_	_	O
123	primary	_	_	O
124	end	_	_	O
125	point	_	_	O
126	.	_	_	O

127	Secondary	_	_	O
128	end	_	_	O
129	points	_	_	O
130	included	_	_	O
131	progression	_	_	O
132	-	_	_	O
133	free	_	_	O
134	survival	_	_	O
135	(	_	_	O
136	PFS	_	_	O
137	)	_	_	O
138	,	_	_	O
139	overall	_	_	O
140	survival	_	_	O
141	(	_	_	O
142	OS	_	_	O
143	)	_	_	O
144	,	_	_	O
145	adverse	_	_	O
146	events	_	_	O
147	(	_	_	O
148	AEs	_	_	O
149	)	_	_	O
150	,	_	_	O
151	and	_	_	O
152	quality	_	_	O
153	-	_	_	O
154	of	_	_	O
155	-	_	_	O
156	life	_	_	O
157	measures	_	_	O
158	.	_	_	O

159	One	_	_	O
160	hundred	_	_	O
161	seven	_	_	O
162	patients	_	_	O
163	were	_	_	O
164	randomly	_	_	O
165	assigned	_	_	O
166	to	_	_	O
167	AM	_	_	O
168	(	_	_	O
169	n	_	_	O
170	=	_	_	O
171	54	_	_	O
172	)	_	_	O
173	or	_	_	O
174	PM	_	_	O
175	(	_	_	O
176	n	_	_	O
177	=	_	_	O
178	53	_	_	O
179	)	_	_	O
180	dosing	_	_	O
181	and	_	_	O
182	on	_	_	O
183	study	_	_	O
184	for	_	_	O
185	a	_	_	O
186	median	_	_	O
187	8	_	_	O
188	.	_	_	O

189	3	_	_	O
190	months	_	_	O
191	.	_	_	O

192	Eighty	_	_	O
193	-	_	_	O
194	three	_	_	O
195	patients	_	_	O
196	discontinued	_	_	O
197	,	_	_	O
198	65	_	_	O
199	due	_	_	O
200	to	_	_	O
201	disease	_	_	O
202	progression	_	_	O
203	and	_	_	O
204	16	_	_	O
205	because	_	_	O
206	of	_	_	O
207	AEs	_	_	O
208	;	_	_	O
209	two	_	_	O
210	patients	_	_	O
211	withdrew	_	_	O
212	consent	_	_	O
213	.	_	_	O

214	Dosing	_	_	O
215	was	_	_	O
216	reduced	_	_	O
217	to	_	_	O
218	25	_	_	O
219	mg	_	_	O
220	/	_	_	O
221	d	_	_	O
222	in	_	_	O
223	46	_	_	O
224	patients	_	_	O
225	(	_	_	O
226	43	_	_	O
227	%	_	_	O
228	)	_	_	O
229	due	_	_	O
230	to	_	_	O
231	grade	_	_	O
232	3	_	_	O
233	/	_	_	O
234	4	_	_	O
235	AEs	_	_	O
236	.	_	_	O

237	The	_	_	B-Premise
238	most	_	_	I-Premise
239	common	_	_	I-Premise
240	grade	_	_	I-Premise
241	3	_	_	I-Premise
242	treatment	_	_	I-Premise
243	-	_	_	I-Premise
244	related	_	_	I-Premise
245	AEs	_	_	I-Premise
246	were	_	_	I-Premise
247	asthenia	_	_	I-Premise
248	/	_	_	I-Premise
249	fatigue	_	_	I-Premise
250	(	_	_	I-Premise
251	16	_	_	I-Premise
252	%	_	_	I-Premise
253	)	_	_	I-Premise
254	,	_	_	I-Premise
255	diarrhea	_	_	I-Premise
256	(	_	_	I-Premise
257	11	_	_	I-Premise
258	%	_	_	I-Premise
259	)	_	_	I-Premise
260	,	_	_	I-Premise
261	hypertension	_	_	I-Premise
262	(	_	_	I-Premise
263	11	_	_	I-Premise
264	%	_	_	I-Premise
265	)	_	_	I-Premise
266	,	_	_	I-Premise
267	hand	_	_	I-Premise
268	-	_	_	I-Premise
269	foot	_	_	I-Premise
270	syndrome	_	_	I-Premise
271	(	_	_	I-Premise
272	9	_	_	I-Premise
273	%	_	_	I-Premise
274	)	_	_	I-Premise
275	,	_	_	I-Premise
276	and	_	_	I-Premise
277	anorexia	_	_	I-Premise
278	(	_	_	I-Premise
279	8	_	_	I-Premise
280	%	_	_	I-Premise
281	)	_	_	I-Premise
282	.	_	_	I-Premise

283	ORR	_	_	O
284	was	_	_	O
285	20	_	_	O
286	%	_	_	O
287	with	_	_	O
288	a	_	_	O
289	7	_	_	O
290	.	_	_	O

291	2	_	_	O
292	-	_	_	O
293	month	_	_	O
294	median	_	_	O
295	response	_	_	O
296	duration	_	_	O
297	.	_	_	O

298	Median	_	_	B-Premise
299	PFS	_	_	I-Premise
300	and	_	_	I-Premise
301	OS	_	_	I-Premise
302	were	_	_	I-Premise
303	8	_	_	I-Premise
304	.	_	_	I-Premise

305	2	_	_	I-Premise
306	and	_	_	I-Premise
307	19	_	_	I-Premise
308	.	_	_	I-Premise

309	8	_	_	I-Premise
310	months	_	_	I-Premise
311	,	_	_	I-Premise
312	respectively	_	_	I-Premise
313	,	_	_	I-Premise
314	at	_	_	I-Premise
315	median	_	_	I-Premise
316	follow	_	_	I-Premise
317	-	_	_	I-Premise
318	up	_	_	I-Premise
319	of	_	_	I-Premise
320	26	_	_	I-Premise
321	.	_	_	I-Premise

322	4	_	_	I-Premise
323	months	_	_	I-Premise
324	.	_	_	I-Premise

325	Efficacy	_	_	B-Premise
326	,	_	_	I-Premise
327	tolerability	_	_	I-Premise
328	,	_	_	I-Premise
329	and	_	_	I-Premise
330	quality	_	_	I-Premise
331	-	_	_	I-Premise
332	of	_	_	I-Premise
333	-	_	_	I-Premise
334	life	_	_	I-Premise
335	results	_	_	I-Premise
336	were	_	_	I-Premise
337	similar	_	_	I-Premise
338	between	_	_	I-Premise
339	patients	_	_	I-Premise
340	dosed	_	_	I-Premise
341	in	_	_	I-Premise
342	the	_	_	I-Premise
343	AM	_	_	I-Premise
344	or	_	_	I-Premise
345	PM	_	_	I-Premise
346	.	_	_	I-Premise

347	Sunitinib	_	_	B-Claim
348	37	_	_	I-Claim
349	.	_	_	I-Claim

350	5	_	_	I-Claim
351	mg	_	_	I-Claim
352	,	_	_	I-Claim
353	administered	_	_	I-Claim
354	on	_	_	I-Claim
355	a	_	_	I-Claim
356	continuous	_	_	I-Claim
357	once	_	_	I-Claim
358	-	_	_	I-Claim
359	daily	_	_	I-Claim
360	dosing	_	_	I-Claim
361	regimen	_	_	I-Claim
362	,	_	_	I-Claim
363	has	_	_	I-Claim
364	a	_	_	I-Claim
365	manageable	_	_	I-Claim
366	safety	_	_	I-Claim
367	profile	_	_	I-Claim
368	as	_	_	I-Claim
369	second	_	_	I-Claim
370	-	_	_	I-Claim
371	line	_	_	I-Claim
372	mRCC	_	_	I-Claim
373	therapy	_	_	I-Claim
374	,	_	_	I-Claim
375	providing	_	_	I-Claim
376	flexible	_	_	I-Claim
377	dosing	_	_	I-Claim
378	,	_	_	I-Claim
379	which	_	_	I-Claim
380	can	_	_	I-Claim
381	be	_	_	I-Claim
382	explored	_	_	I-Claim
383	in	_	_	I-Claim
384	combination	_	_	I-Claim
385	studies	_	_	I-Claim
386	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	our	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	evaluate	_	_	O
8	the	_	_	O
9	effect	_	_	O
10	of	_	_	O
11	cognitive	_	_	O
12	behavioral	_	_	O
13	therapy	_	_	O
14	(	_	_	O
15	CBT	_	_	O
16	)	_	_	O
17	,	_	_	O
18	physical	_	_	O
19	exercise	_	_	O
20	(	_	_	O
21	PE	_	_	O
22	)	_	_	O
23	,	_	_	O
24	and	_	_	O
25	of	_	_	O
26	these	_	_	O
27	two	_	_	O
28	interventions	_	_	O
29	combined	_	_	O
30	(	_	_	O
31	CBT	_	_	O
32	/	_	_	O
33	PE	_	_	O
34	)	_	_	O
35	on	_	_	O
36	menopausal	_	_	O
37	symptoms	_	_	O
38	(	_	_	O
39	primary	_	_	O
40	outcome	_	_	O
41	)	_	_	O
42	,	_	_	O
43	body	_	_	O
44	image	_	_	O
45	,	_	_	O
46	sexual	_	_	O
47	functioning	_	_	O
48	,	_	_	O
49	psychological	_	_	O
50	well	_	_	O
51	-	_	_	O
52	being	_	_	O
53	,	_	_	O
54	and	_	_	O
55	health	_	_	O
56	-	_	_	O
57	related	_	_	O
58	quality	_	_	O
59	of	_	_	O
60	life	_	_	O
61	(	_	_	O
62	secondary	_	_	O
63	outcomes	_	_	O
64	)	_	_	O
65	in	_	_	O
66	patients	_	_	O
67	with	_	_	O
68	breast	_	_	O
69	cancer	_	_	O
70	experiencing	_	_	O
71	treatment	_	_	O
72	-	_	_	O
73	induced	_	_	O
74	menopause	_	_	O
75	.	_	_	O

76	Patients	_	_	O
77	with	_	_	O
78	breast	_	_	O
79	cancer	_	_	O
80	reporting	_	_	O
81	treatment	_	_	O
82	-	_	_	O
83	induced	_	_	O
84	menopausal	_	_	O
85	symptoms	_	_	O
86	(	_	_	O
87	N	_	_	O
88	=	_	_	O
89	422	_	_	O
90	)	_	_	O
91	were	_	_	O
92	randomly	_	_	O
93	assigned	_	_	O
94	to	_	_	O
95	CBT	_	_	O
96	(	_	_	O
97	n	_	_	O
98	=	_	_	O
99	109	_	_	O
100	)	_	_	O
101	,	_	_	O
102	PE	_	_	O
103	(	_	_	O
104	n	_	_	O
105	=	_	_	O
106	104	_	_	O
107	)	_	_	O
108	,	_	_	O
109	CBT	_	_	O
110	/	_	_	O
111	PE	_	_	O
112	(	_	_	O
113	n	_	_	O
114	=	_	_	O
115	106	_	_	O
116	)	_	_	O
117	,	_	_	O
118	or	_	_	O
119	to	_	_	O
120	a	_	_	O
121	waiting	_	_	O
122	list	_	_	O
123	control	_	_	O
124	group	_	_	O
125	(	_	_	O
126	n	_	_	O
127	=	_	_	O
128	103	_	_	O
129	)	_	_	O
130	.	_	_	O

131	Self	_	_	O
132	-	_	_	O
133	report	_	_	O
134	questionnaires	_	_	O
135	were	_	_	O
136	completed	_	_	O
137	at	_	_	O
138	baseline	_	_	O
139	,	_	_	O
140	12	_	_	O
141	weeks	_	_	O
142	,	_	_	O
143	and	_	_	O
144	6	_	_	O
145	months	_	_	O
146	.	_	_	O

147	Multilevel	_	_	O
148	procedures	_	_	O
149	were	_	_	O
150	used	_	_	O
151	to	_	_	O
152	compare	_	_	O
153	the	_	_	O
154	intervention	_	_	O
155	groups	_	_	O
156	with	_	_	O
157	the	_	_	O
158	control	_	_	O
159	group	_	_	O
160	over	_	_	O
161	time	_	_	O
162	.	_	_	O

163	Compared	_	_	B-Premise
164	with	_	_	I-Premise
165	the	_	_	I-Premise
166	control	_	_	I-Premise
167	group	_	_	I-Premise
168	,	_	_	I-Premise
169	the	_	_	I-Premise
170	intervention	_	_	I-Premise
171	groups	_	_	I-Premise
172	had	_	_	I-Premise
173	a	_	_	I-Premise
174	significant	_	_	I-Premise
175	decrease	_	_	I-Premise
176	in	_	_	I-Premise
177	levels	_	_	I-Premise
178	of	_	_	I-Premise
179	endocrine	_	_	I-Premise
180	symptoms	_	_	I-Premise
181	(	_	_	I-Premise
182	Functional	_	_	I-Premise
183	Assessment	_	_	I-Premise
184	of	_	_	I-Premise
185	Cancer	_	_	I-Premise
186	Therapy	_	_	I-Premise
187	-	_	_	I-Premise
188	Endocrine	_	_	I-Premise
189	Symptoms	_	_	I-Premise
190	;	_	_	I-Premise
191	P	_	_	I-Premise
192	<	_	_	I-Premise
193	.	_	_	I-Premise

194	001	_	_	I-Premise
195	;	_	_	I-Premise
196	effect	_	_	I-Premise
197	size	_	_	I-Premise
198	,	_	_	I-Premise
199	0	_	_	I-Premise
200	.	_	_	I-Premise

201	31	_	_	I-Premise
202	-	_	_	I-Premise
203	0	_	_	I-Premise
204	.	_	_	I-Premise

205	52	_	_	I-Premise
206	)	_	_	I-Premise
207	and	_	_	I-Premise
208	urinary	_	_	I-Premise
209	symptoms	_	_	I-Premise
210	(	_	_	I-Premise
211	Bristol	_	_	I-Premise
212	Female	_	_	I-Premise
213	Lower	_	_	I-Premise
214	Urinary	_	_	I-Premise
215	Tract	_	_	I-Premise
216	Symptoms	_	_	I-Premise
217	Questionnaire	_	_	I-Premise
218	;	_	_	I-Premise
219	P	_	_	I-Premise
220	=	_	_	I-Premise
221	.	_	_	I-Premise

222	002	_	_	I-Premise
223	;	_	_	I-Premise
224	effect	_	_	I-Premise
225	size	_	_	I-Premise
226	,	_	_	I-Premise
227	0	_	_	I-Premise
228	.	_	_	I-Premise

229	29	_	_	I-Premise
230	-	_	_	I-Premise
231	0	_	_	I-Premise
232	.	_	_	I-Premise

233	33	_	_	I-Premise
234	)	_	_	I-Premise
235	,	_	_	I-Premise
236	and	_	_	I-Premise
237	they	_	_	I-Premise
238	showed	_	_	I-Premise
239	an	_	_	I-Premise
240	improvement	_	_	I-Premise
241	in	_	_	I-Premise
242	physical	_	_	I-Premise
243	functioning	_	_	I-Premise
244	(	_	_	I-Premise
245	36	_	_	I-Premise
246	-	_	_	I-Premise
247	Item	_	_	I-Premise
248	Short	_	_	I-Premise
249	Form	_	_	I-Premise
250	Health	_	_	I-Premise
251	Survey	_	_	I-Premise
252	physical	_	_	I-Premise
253	functioning	_	_	I-Premise
254	subscale	_	_	I-Premise
255	;	_	_	I-Premise
256	P	_	_	I-Premise
257	=	_	_	I-Premise
258	.	_	_	I-Premise

259	002	_	_	I-Premise
260	;	_	_	I-Premise
261	effect	_	_	I-Premise
262	size	_	_	I-Premise
263	,	_	_	I-Premise
264	0	_	_	I-Premise
265	.	_	_	I-Premise

266	37	_	_	I-Premise
267	-	_	_	I-Premise
268	0	_	_	I-Premise
269	.	_	_	I-Premise

270	46	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	The	_	_	B-Premise
274	groups	_	_	I-Premise
275	that	_	_	I-Premise
276	included	_	_	I-Premise
277	CBT	_	_	I-Premise
278	also	_	_	I-Premise
279	showed	_	_	I-Premise
280	a	_	_	I-Premise
281	significant	_	_	I-Premise
282	decrease	_	_	I-Premise
283	in	_	_	I-Premise
284	the	_	_	I-Premise
285	perceived	_	_	I-Premise
286	burden	_	_	I-Premise
287	of	_	_	I-Premise
288	hot	_	_	I-Premise
289	flashes	_	_	I-Premise
290	and	_	_	I-Premise
291	night	_	_	I-Premise
292	sweats	_	_	I-Premise
293	(	_	_	I-Premise
294	problem	_	_	I-Premise
295	rating	_	_	I-Premise
296	scale	_	_	I-Premise
297	of	_	_	I-Premise
298	the	_	_	I-Premise
299	Hot	_	_	I-Premise
300	Flush	_	_	I-Premise
301	Rating	_	_	I-Premise
302	Scale	_	_	I-Premise
303	;	_	_	I-Premise
304	P	_	_	I-Premise
305	<	_	_	I-Premise
306	.	_	_	I-Premise

307	001	_	_	I-Premise
308	;	_	_	I-Premise
309	effect	_	_	I-Premise
310	size	_	_	I-Premise
311	,	_	_	I-Premise
312	0	_	_	I-Premise
313	.	_	_	I-Premise

314	39	_	_	I-Premise
315	-	_	_	I-Premise
316	0	_	_	I-Premise
317	.	_	_	I-Premise

318	56	_	_	I-Premise
319	)	_	_	I-Premise
320	and	_	_	I-Premise
321	an	_	_	I-Premise
322	increase	_	_	I-Premise
323	in	_	_	I-Premise
324	sexual	_	_	I-Premise
325	activity	_	_	I-Premise
326	(	_	_	I-Premise
327	Sexual	_	_	I-Premise
328	Activity	_	_	I-Premise
329	Questionnaire	_	_	I-Premise
330	habit	_	_	I-Premise
331	subscale	_	_	I-Premise
332	;	_	_	I-Premise
333	P	_	_	I-Premise
334	=	_	_	I-Premise
335	.	_	_	I-Premise

336	027	_	_	I-Premise
337	;	_	_	I-Premise
338	effect	_	_	I-Premise
339	size	_	_	I-Premise
340	,	_	_	I-Premise
341	0	_	_	I-Premise
342	.	_	_	I-Premise

343	65	_	_	I-Premise
344	)	_	_	I-Premise
345	.	_	_	I-Premise

346	Most	_	_	O
347	of	_	_	O
348	these	_	_	O
349	effects	_	_	O
350	were	_	_	O
351	observed	_	_	O
352	at	_	_	O
353	both	_	_	O
354	the	_	_	O
355	12	_	_	O
356	-	_	_	O
357	week	_	_	O
358	and	_	_	O
359	6	_	_	O
360	-	_	_	O
361	month	_	_	O
362	follow	_	_	O
363	-	_	_	O
364	ups	_	_	O
365	.	_	_	O

366	CBT	_	_	B-Claim
367	and	_	_	I-Claim
368	PE	_	_	I-Claim
369	can	_	_	I-Claim
370	have	_	_	I-Claim
371	salutary	_	_	I-Claim
372	effects	_	_	I-Claim
373	on	_	_	I-Claim
374	endocrine	_	_	I-Claim
375	symptoms	_	_	I-Claim
376	and	_	_	I-Claim
377	,	_	_	I-Claim
378	to	_	_	I-Claim
379	a	_	_	I-Claim
380	lesser	_	_	I-Claim
381	degree	_	_	I-Claim
382	,	_	_	I-Claim
383	on	_	_	I-Claim
384	sexuality	_	_	I-Claim
385	and	_	_	I-Claim
386	physical	_	_	I-Claim
387	functioning	_	_	I-Claim
388	of	_	_	I-Claim
389	patients	_	_	I-Claim
390	with	_	_	I-Claim
391	breast	_	_	I-Claim
392	cancer	_	_	I-Claim
393	experiencing	_	_	I-Claim
394	treatment	_	_	I-Claim
395	-	_	_	I-Claim
396	induced	_	_	I-Claim
397	menopause	_	_	I-Claim
398	.	_	_	I-Claim

399	Future	_	_	B-Claim
400	work	_	_	I-Claim
401	is	_	_	I-Claim
402	needed	_	_	I-Claim
403	to	_	_	I-Claim
404	improve	_	_	I-Claim
405	the	_	_	I-Claim
406	design	_	_	I-Claim
407	and	_	_	I-Claim
408	the	_	_	I-Claim
409	planning	_	_	I-Claim
410	of	_	_	I-Claim
411	these	_	_	I-Claim
412	interventions	_	_	I-Claim
413	to	_	_	I-Claim
414	improve	_	_	I-Claim
415	program	_	_	I-Claim
416	adherence	_	_	I-Claim
417	.	_	_	I-Claim


0	This	_	_	O
1	phase	_	_	O
2	III	_	_	O
3	randomized	_	_	O
4	trial	_	_	O
5	compared	_	_	O
6	two	_	_	O
7	chemotherapy	_	_	O
8	regimens	_	_	O
9	,	_	_	O
10	gemcitabine	_	_	O
11	plus	_	_	O
12	carboplatin	_	_	O
13	and	_	_	O
14	mitomycin	_	_	O
15	,	_	_	O
16	ifosfamide	_	_	O
17	,	_	_	O
18	and	_	_	O
19	cisplatin	_	_	O
20	,	_	_	O
21	in	_	_	O
22	chemotherapy	_	_	O
23	-	_	_	O
24	naive	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	advanced	_	_	O
28	non	_	_	O
29	-	_	_	O
30	small	_	_	O
31	-	_	_	O
32	cell	_	_	O
33	lung	_	_	O
34	cancer	_	_	O
35	(	_	_	O
36	NSCLC	_	_	O
37	)	_	_	O
38	.	_	_	O

39	The	_	_	O
40	regimens	_	_	O
41	were	_	_	O
42	compared	_	_	O
43	with	_	_	O
44	regard	_	_	O
45	to	_	_	O
46	effects	_	_	O
47	on	_	_	O
48	survival	_	_	O
49	,	_	_	O
50	response	_	_	O
51	rates	_	_	O
52	,	_	_	O
53	toxicity	_	_	O
54	,	_	_	O
55	and	_	_	O
56	quality	_	_	O
57	of	_	_	O
58	life	_	_	O
59	.	_	_	O

60	Eligible	_	_	O
61	patients	_	_	O
62	had	_	_	O
63	previously	_	_	O
64	untreated	_	_	O
65	stage	_	_	O
66	IIIB	_	_	O
67	or	_	_	O
68	IV	_	_	O
69	NSCLC	_	_	O
70	suitable	_	_	O
71	for	_	_	O
72	cisplatin	_	_	O
73	-	_	_	O
74	based	_	_	O
75	chemotherapy	_	_	O
76	.	_	_	O

77	Randomly	_	_	O
78	assigned	_	_	O
79	patients	_	_	O
80	were	_	_	O
81	to	_	_	O
82	receive	_	_	O
83	four	_	_	O
84	cycles	_	_	O
85	,	_	_	O
86	each	_	_	O
87	at	_	_	O
88	3	_	_	O
89	-	_	_	O
90	week	_	_	O
91	intervals	_	_	O
92	,	_	_	O
93	of	_	_	O
94	carboplatin	_	_	O
95	area	_	_	O
96	under	_	_	O
97	the	_	_	O
98	curve	_	_	O
99	of	_	_	O
100	5	_	_	O
101	on	_	_	O
102	day	_	_	O
103	1	_	_	O
104	plus	_	_	O
105	gemcitabine	_	_	O
106	1	_	_	O
107	,	_	_	O
108	200	_	_	O
109	mg	_	_	O
110	/	_	_	O
111	m	_	_	O
112	(	_	_	O
113	2	_	_	O
114	)	_	_	O
115	on	_	_	O
116	days	_	_	O
117	1	_	_	O
118	and	_	_	O
119	8	_	_	O
120	(	_	_	O
121	GCa	_	_	O
122	)	_	_	O
123	or	_	_	O
124	mitomycin	_	_	O
125	6	_	_	O
126	mg	_	_	O
127	/	_	_	O
128	m	_	_	O
129	(	_	_	O
130	2	_	_	O
131	)	_	_	O
132	,	_	_	O
133	ifosfamide	_	_	O
134	3g	_	_	O
135	/	_	_	O
136	m	_	_	O
137	(	_	_	O
138	2	_	_	O
139	)	_	_	O
140	,	_	_	O
141	and	_	_	O
142	cisplatin	_	_	O
143	50	_	_	O
144	mg	_	_	O
145	/	_	_	O
146	m	_	_	O
147	(	_	_	O
148	2	_	_	O
149	)	_	_	O
150	on	_	_	O
151	day	_	_	O
152	1	_	_	O
153	(	_	_	O
154	MIC	_	_	O
155	)	_	_	O
156	.	_	_	O

157	Between	_	_	O
158	February	_	_	O
159	1999	_	_	O
160	and	_	_	O
161	August	_	_	O
162	2001	_	_	O
163	,	_	_	O
164	422	_	_	O
165	patients	_	_	O
166	(	_	_	O
167	GCa	_	_	O
168	,	_	_	O
169	n	_	_	O
170	=	_	_	O
171	212	_	_	O
172	;	_	_	O
173	MIC	_	_	O
174	,	_	_	O
175	n	_	_	O
176	=	_	_	O
177	210	_	_	O
178	)	_	_	O
179	were	_	_	O
180	randomly	_	_	O
181	assigned	_	_	O
182	in	_	_	O
183	the	_	_	O
184	United	_	_	O
185	Kingdom	_	_	O
186	.	_	_	O

187	The	_	_	O
188	majority	_	_	O
189	of	_	_	O
190	patients	_	_	O
191	received	_	_	O
192	the	_	_	O
193	intended	_	_	O
194	four	_	_	O
195	cycles	_	_	O
196	(	_	_	O
197	GCa	_	_	O
198	,	_	_	O
199	64	_	_	O
200	%	_	_	O
201	;	_	_	O
202	MIC	_	_	O
203	,	_	_	O
204	61	_	_	O
205	%	_	_	O
206	)	_	_	O
207	.	_	_	O

208	There	_	_	B-Premise
209	was	_	_	I-Premise
210	a	_	_	I-Premise
211	significant	_	_	I-Premise
212	survival	_	_	I-Premise
213	advantage	_	_	I-Premise
214	for	_	_	I-Premise
215	GCa	_	_	I-Premise
216	compared	_	_	I-Premise
217	with	_	_	I-Premise
218	MIC	_	_	I-Premise
219	(	_	_	I-Premise
220	hazard	_	_	I-Premise
221	ratio	_	_	I-Premise
222	,	_	_	I-Premise
223	0	_	_	I-Premise
224	.	_	_	I-Premise

225	76	_	_	I-Premise
226	;	_	_	I-Premise
227	95	_	_	I-Premise
228	%	_	_	I-Premise
229	CI	_	_	I-Premise
230	,	_	_	I-Premise
231	0	_	_	I-Premise
232	.	_	_	I-Premise

233	61	_	_	I-Premise
234	to	_	_	I-Premise
235	0	_	_	I-Premise
236	.	_	_	I-Premise

237	93	_	_	I-Premise
238	;	_	_	I-Premise
239	P	_	_	I-Premise
240	=	_	_	I-Premise
241	.	_	_	I-Premise

242	008	_	_	I-Premise
243	)	_	_	I-Premise
244	.	_	_	I-Premise

245	Median	_	_	B-Premise
246	survival	_	_	I-Premise
247	was	_	_	I-Premise
248	10	_	_	I-Premise
249	months	_	_	I-Premise
250	with	_	_	I-Premise
251	GCa	_	_	I-Premise
252	and	_	_	I-Premise
253	7	_	_	I-Premise
254	.	_	_	I-Premise

255	6	_	_	I-Premise
256	months	_	_	I-Premise
257	with	_	_	I-Premise
258	MIC	_	_	I-Premise
259	(	_	_	I-Premise
260	difference	_	_	I-Premise
261	,	_	_	I-Premise
262	2	_	_	I-Premise
263	.	_	_	I-Premise

264	4	_	_	I-Premise
265	months	_	_	I-Premise
266	;	_	_	I-Premise
267	95	_	_	I-Premise
268	%	_	_	I-Premise
269	CI	_	_	I-Premise
270	,	_	_	I-Premise
271	1	_	_	I-Premise
272	.	_	_	I-Premise

273	0	_	_	I-Premise
274	to	_	_	I-Premise
275	4	_	_	I-Premise
276	.	_	_	I-Premise

277	0	_	_	I-Premise
278	)	_	_	I-Premise
279	,	_	_	I-Premise
280	and	_	_	I-Premise
281	1	_	_	I-Premise
282	-	_	_	I-Premise
283	year	_	_	I-Premise
284	survival	_	_	I-Premise
285	was	_	_	I-Premise
286	40	_	_	I-Premise
287	%	_	_	I-Premise
288	with	_	_	I-Premise
289	GCa	_	_	I-Premise
290	and	_	_	I-Premise
291	30	_	_	I-Premise
292	%	_	_	I-Premise
293	with	_	_	I-Premise
294	MIC	_	_	I-Premise
295	(	_	_	I-Premise
296	difference	_	_	I-Premise
297	,	_	_	I-Premise
298	10	_	_	I-Premise
299	%	_	_	I-Premise
300	;	_	_	I-Premise
301	95	_	_	I-Premise
302	%	_	_	I-Premise
303	CI	_	_	I-Premise
304	,	_	_	I-Premise
305	3	_	_	I-Premise
306	%	_	_	I-Premise
307	to	_	_	I-Premise
308	18	_	_	I-Premise
309	%	_	_	I-Premise
310	)	_	_	I-Premise
311	.	_	_	I-Premise

312	Overall	_	_	B-Premise
313	response	_	_	I-Premise
314	rates	_	_	I-Premise
315	were	_	_	I-Premise
316	similar	_	_	I-Premise
317	(	_	_	I-Premise
318	42	_	_	I-Premise
319	%	_	_	I-Premise
320	for	_	_	I-Premise
321	GCa	_	_	I-Premise
322	v	_	_	I-Premise
323	41	_	_	I-Premise
324	%	_	_	I-Premise
325	for	_	_	I-Premise
326	MIC	_	_	I-Premise
327	;	_	_	I-Premise
328	P	_	_	I-Premise
329	=	_	_	I-Premise
330	.	_	_	I-Premise

331	84	_	_	I-Premise
332	)	_	_	I-Premise
333	.	_	_	I-Premise

334	More	_	_	B-Premise
335	thrombocytopenia	_	_	I-Premise
336	occurred	_	_	I-Premise
337	with	_	_	I-Premise
338	GCa	_	_	I-Premise
339	(	_	_	I-Premise
340	P	_	_	I-Premise
341	=	_	_	I-Premise
342	.	_	_	I-Premise

343	03	_	_	I-Premise
344	)	_	_	I-Premise
345	,	_	_	I-Premise
346	but	_	_	B-Premise
347	this	_	_	I-Premise
348	was	_	_	I-Premise
349	not	_	_	I-Premise
350	associated	_	_	I-Premise
351	with	_	_	I-Premise
352	increased	_	_	I-Premise
353	hospital	_	_	I-Premise
354	admission	_	_	I-Premise
355	or	_	_	I-Premise
356	fatality	_	_	I-Premise
357	.	_	_	I-Premise

358	GCa	_	_	B-Premise
359	caused	_	_	I-Premise
360	less	_	_	I-Premise
361	nausea	_	_	I-Premise
362	,	_	_	I-Premise
363	vomiting	_	_	I-Premise
364	,	_	_	I-Premise
365	constipation	_	_	I-Premise
366	,	_	_	I-Premise
367	and	_	_	I-Premise
368	alopecia	_	_	I-Premise
369	and	_	_	I-Premise
370	was	_	_	I-Premise
371	associated	_	_	I-Premise
372	with	_	_	I-Premise
373	fewer	_	_	I-Premise
374	admissions	_	_	I-Premise
375	for	_	_	I-Premise
376	administration	_	_	I-Premise
377	and	_	_	I-Premise
378	better	_	_	I-Premise
379	quality	_	_	I-Premise
380	of	_	_	I-Premise
381	life	_	_	I-Premise
382	.	_	_	I-Premise

383	In	_	_	B-Claim
384	patients	_	_	I-Claim
385	with	_	_	I-Claim
386	advanced	_	_	I-Claim
387	NSCLC	_	_	I-Claim
388	,	_	_	I-Claim
389	GCa	_	_	I-Claim
390	chemotherapy	_	_	I-Claim
391	was	_	_	I-Claim
392	shown	_	_	I-Claim
393	to	_	_	I-Claim
394	be	_	_	I-Claim
395	a	_	_	I-Claim
396	better	_	_	I-Claim
397	-	_	_	I-Claim
398	tolerated	_	_	I-Claim
399	treatment	_	_	I-Claim
400	that	_	_	I-Claim
401	conferred	_	_	I-Claim
402	a	_	_	I-Claim
403	survival	_	_	I-Claim
404	advantage	_	_	I-Claim
405	over	_	_	I-Claim
406	MIC	_	_	I-Claim
407	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	outcomes	_	_	O
4	of	_	_	O
5	uterine	_	_	O
6	artery	_	_	O
7	embolization	_	_	O
8	(	_	_	O
9	UAE	_	_	O
10	)	_	_	O
11	for	_	_	O
12	leiomyomas	_	_	O
13	with	_	_	O
14	use	_	_	O
15	of	_	_	O
16	tris	_	_	O
17	-	_	_	O
18	acryl	_	_	O
19	gelatin	_	_	O
20	microspheres	_	_	O
21	(	_	_	O
22	TAGM	_	_	O
23	)	_	_	O
24	versus	_	_	O
25	spherical	_	_	O
26	polyvinyl	_	_	O
27	alcohol	_	_	O
28	(	_	_	O
29	PVA	_	_	O
30	)	_	_	O
31	particles	_	_	O
32	.	_	_	O

33	Patients	_	_	O
34	undergoing	_	_	O
35	UAE	_	_	O
36	were	_	_	O
37	randomly	_	_	O
38	assigned	_	_	O
39	to	_	_	O
40	receive	_	_	O
41	TAGMs	_	_	O
42	or	_	_	O
43	PVA	_	_	O
44	.	_	_	O

45	Embolization	_	_	O
46	was	_	_	O
47	performed	_	_	O
48	in	_	_	O
49	a	_	_	O
50	standardized	_	_	O
51	manner	_	_	O
52	.	_	_	O

53	Outcome	_	_	O
54	data	_	_	O
55	were	_	_	O
56	collected	_	_	O
57	at	_	_	O
58	3	_	_	O
59	months	_	_	O
60	after	_	_	O
61	embolization	_	_	O
62	,	_	_	O
63	including	_	_	O
64	assessment	_	_	O
65	of	_	_	O
66	clinical	_	_	O
67	symptoms	_	_	O
68	,	_	_	O
69	scores	_	_	O
70	from	_	_	O
71	a	_	_	O
72	fibroid	_	_	O
73	tumor	_	_	O
74	-	_	_	O
75	specific	_	_	O
76	symptom	_	_	O
77	and	_	_	O
78	quality	_	_	O
79	of	_	_	O
80	life	_	_	O
81	(	_	_	O
82	QOL	_	_	O
83	)	_	_	O
84	questionnaire	_	_	O
85	,	_	_	O
86	and	_	_	O
87	findings	_	_	O
88	on	_	_	O
89	contrast	_	_	O
90	material	_	_	O
91	-	_	_	O
92	enhanced	_	_	O
93	magnetic	_	_	O
94	resonance	_	_	O
95	(	_	_	O
96	MR	_	_	O
97	)	_	_	O
98	imaging	_	_	O
99	,	_	_	O
100	including	_	_	O
101	the	_	_	O
102	degree	_	_	O
103	of	_	_	O
104	tumor	_	_	O
105	infarction	_	_	O
106	and	_	_	O
107	volume	_	_	O
108	reduction	_	_	O
109	.	_	_	O

110	Data	_	_	O
111	were	_	_	O
112	analyzed	_	_	O
113	with	_	_	O
114	use	_	_	O
115	of	_	_	O
116	t	_	_	O
117	tests	_	_	O
118	,	_	_	O
119	the	_	_	O
120	Mann	_	_	O
121	-	_	_	O
122	Whitney	_	_	O
123	U	_	_	O
124	test	_	_	O
125	,	_	_	O
126	and	_	_	O
127	chi2	_	_	O
128	tests	_	_	O
129	as	_	_	O
130	appropriate	_	_	O
131	.	_	_	O

132	Thirty	_	_	O
133	-	_	_	O
134	six	_	_	O
135	patients	_	_	O
136	were	_	_	O
137	treated	_	_	O
138	.	_	_	O

139	There	_	_	O
140	were	_	_	O
141	no	_	_	O
142	differences	_	_	O
143	in	_	_	O
144	the	_	_	O
145	two	_	_	O
146	treatment	_	_	O
147	groups	_	_	O
148	at	_	_	O
149	baseline	_	_	O
150	.	_	_	O

151	Clinical	_	_	O
152	follow	_	_	O
153	-	_	_	O
154	up	_	_	O
155	was	_	_	O
156	obtained	_	_	O
157	in	_	_	O
158	35	_	_	O
159	patients	_	_	O
160	.	_	_	O

161	Among	_	_	B-Premise
162	the	_	_	I-Premise
163	clinical	_	_	I-Premise
164	outcome	_	_	I-Premise
165	measures	_	_	I-Premise
166	,	_	_	I-Premise
167	QOL	_	_	I-Premise
168	score	_	_	I-Premise
169	improvement	_	_	I-Premise
170	was	_	_	I-Premise
171	greater	_	_	I-Premise
172	for	_	_	I-Premise
173	UAE	_	_	I-Premise
174	with	_	_	I-Premise
175	TAGMs	_	_	I-Premise
176	compared	_	_	I-Premise
177	with	_	_	I-Premise
178	PVA	_	_	I-Premise
179	(	_	_	I-Premise
180	49	_	_	I-Premise
181	.	_	_	I-Premise

182	0	_	_	I-Premise
183	vs	_	_	I-Premise
184	27	_	_	I-Premise
185	.	_	_	I-Premise

186	9	_	_	I-Premise
187	;	_	_	I-Premise
188	P	_	_	I-Premise
189	=	_	_	I-Premise
190	.	_	_	I-Premise

191	02	_	_	I-Premise
192	)	_	_	I-Premise
193	,	_	_	I-Premise
194	but	_	_	B-Premise
195	no	_	_	I-Premise
196	other	_	_	I-Premise
197	differences	_	_	I-Premise
198	were	_	_	I-Premise
199	noted	_	_	I-Premise
200	.	_	_	I-Premise

201	Of	_	_	B-Premise
202	the	_	_	I-Premise
203	25	_	_	I-Premise
204	patients	_	_	I-Premise
205	in	_	_	I-Premise
206	whom	_	_	I-Premise
207	3	_	_	I-Premise
208	-	_	_	I-Premise
209	month	_	_	I-Premise
210	MR	_	_	I-Premise
211	imaging	_	_	I-Premise
212	follow	_	_	I-Premise
213	-	_	_	I-Premise
214	up	_	_	I-Premise
215	was	_	_	I-Premise
216	completed	_	_	I-Premise
217	,	_	_	I-Premise
218	those	_	_	I-Premise
219	treated	_	_	I-Premise
220	with	_	_	I-Premise
221	TAGM	_	_	I-Premise
222	were	_	_	I-Premise
223	significantly	_	_	I-Premise
224	more	_	_	I-Premise
225	likely	_	_	I-Premise
226	to	_	_	I-Premise
227	have	_	_	I-Premise
228	complete	_	_	I-Premise
229	infarction	_	_	I-Premise
230	of	_	_	I-Premise
231	all	_	_	I-Premise
232	leiomyomas	_	_	I-Premise
233	(	_	_	I-Premise
234	six	_	_	I-Premise
235	patients	_	_	I-Premise
236	vs	_	_	I-Premise
237	one	_	_	I-Premise
238	patient	_	_	I-Premise
239	;	_	_	I-Premise
240	P	_	_	I-Premise
241	=	_	_	I-Premise
242	.	_	_	I-Premise

243	02	_	_	I-Premise
244	)	_	_	I-Premise
245	,	_	_	I-Premise
246	were	_	_	I-Premise
247	more	_	_	I-Premise
248	likely	_	_	I-Premise
249	to	_	_	I-Premise
250	have	_	_	I-Premise
251	at	_	_	I-Premise
252	least	_	_	I-Premise
253	90	_	_	I-Premise
254	%	_	_	I-Premise
255	tumor	_	_	I-Premise
256	infarction	_	_	I-Premise
257	(	_	_	I-Premise
258	eight	_	_	I-Premise
259	patients	_	_	I-Premise
260	vs	_	_	I-Premise
261	four	_	_	I-Premise
262	patients	_	_	I-Premise
263	;	_	_	I-Premise
264	P	_	_	I-Premise
265	=	_	_	I-Premise
266	.	_	_	I-Premise

267	03	_	_	I-Premise
268	)	_	_	I-Premise
269	,	_	_	I-Premise
270	and	_	_	I-Premise
271	had	_	_	I-Premise
272	a	_	_	I-Premise
273	lower	_	_	I-Premise
274	mean	_	_	I-Premise
275	percent	_	_	I-Premise
276	of	_	_	I-Premise
277	residual	_	_	I-Premise
278	perfused	_	_	I-Premise
279	fibroid	_	_	I-Premise
280	tumor	_	_	I-Premise
281	tissue	_	_	I-Premise
282	(	_	_	I-Premise
283	9	_	_	I-Premise
284	.	_	_	I-Premise

285	6	_	_	I-Premise
286	%	_	_	I-Premise
287	vs	_	_	I-Premise
288	44	_	_	I-Premise
289	.	_	_	I-Premise

290	3	_	_	I-Premise
291	%	_	_	I-Premise
292	;	_	_	I-Premise
293	P	_	_	I-Premise
294	=	_	_	I-Premise
295	.	_	_	I-Premise

296	004	_	_	I-Premise
297	)	_	_	I-Premise
298	compared	_	_	I-Premise
299	with	_	_	I-Premise
300	patients	_	_	I-Premise
301	treated	_	_	I-Premise
302	with	_	_	I-Premise
303	PVA	_	_	I-Premise
304	.	_	_	I-Premise

305	Based	_	_	O
306	on	_	_	O
307	these	_	_	O
308	differences	_	_	O
309	between	_	_	O
310	the	_	_	O
311	embolic	_	_	O
312	agents	_	_	O
313	,	_	_	O
314	enrollment	_	_	O
315	in	_	_	O
316	this	_	_	O
317	study	_	_	O
318	was	_	_	O
319	terminated	_	_	O
320	.	_	_	O

321	The	_	_	B-Claim
322	use	_	_	I-Claim
323	of	_	_	I-Claim
324	spherical	_	_	I-Claim
325	PVA	_	_	I-Claim
326	particles	_	_	I-Claim
327	in	_	_	I-Claim
328	the	_	_	I-Claim
329	manner	_	_	I-Claim
330	described	_	_	I-Claim
331	herein	_	_	I-Claim
332	results	_	_	I-Claim
333	in	_	_	I-Claim
334	an	_	_	I-Claim
335	unacceptably	_	_	I-Claim
336	high	_	_	I-Claim
337	rate	_	_	I-Claim
338	of	_	_	I-Claim
339	failed	_	_	I-Claim
340	tumor	_	_	I-Claim
341	infarction	_	_	I-Claim
342	in	_	_	I-Claim
343	UAE	_	_	I-Claim
344	.	_	_	I-Claim


0	Therapy	_	_	O
1	for	_	_	O
2	polycystic	_	_	O
3	liver	_	_	O
4	is	_	_	O
5	invasive	_	_	O
6	,	_	_	O
7	expensive	_	_	O
8	,	_	_	O
9	and	_	_	O
10	has	_	_	O
11	disappointing	_	_	O
12	long	_	_	O
13	-	_	_	O
14	term	_	_	O
15	results	_	_	O
16	.	_	_	O

17	Treatment	_	_	O
18	with	_	_	O
19	somatostatin	_	_	O
20	analogues	_	_	O
21	slowed	_	_	O
22	kidney	_	_	O
23	growth	_	_	O
24	in	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	polycystic	_	_	O
28	kidney	_	_	O
29	disease	_	_	O
30	(	_	_	O
31	PKD	_	_	O
32	)	_	_	O
33	and	_	_	O
34	reduced	_	_	O
35	liver	_	_	O
36	and	_	_	O
37	kidney	_	_	O
38	volume	_	_	O
39	in	_	_	O
40	a	_	_	O
41	PKD	_	_	O
42	rodent	_	_	O
43	model	_	_	O
44	.	_	_	O

45	We	_	_	O
46	evaluated	_	_	O
47	the	_	_	O
48	effects	_	_	O
49	of	_	_	O
50	lanreotide	_	_	O
51	,	_	_	O
52	a	_	_	O
53	somatostatin	_	_	O
54	analogue	_	_	O
55	,	_	_	O
56	in	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	polycystic	_	_	O
60	liver	_	_	O
61	because	_	_	O
62	of	_	_	O
63	autosomal	_	_	O
64	-	_	_	O
65	dominant	_	_	O
66	(	_	_	O
67	AD	_	_	O
68	)	_	_	O
69	PKD	_	_	O
70	or	_	_	O
71	autosomal	_	_	O
72	-	_	_	O
73	dominant	_	_	O
74	polycystic	_	_	O
75	liver	_	_	O
76	disease	_	_	O
77	(	_	_	O
78	PCLD	_	_	O
79	)	_	_	O
80	.	_	_	O

81	We	_	_	O
82	performed	_	_	O
83	a	_	_	O
84	randomized	_	_	O
85	,	_	_	O
86	double	_	_	O
87	-	_	_	O
88	blind	_	_	O
89	,	_	_	O
90	placebo	_	_	O
91	-	_	_	O
92	controlled	_	_	O
93	trial	_	_	O
94	in	_	_	O
95	2	_	_	O
96	tertiary	_	_	O
97	referral	_	_	O
98	centers	_	_	O
99	.	_	_	O

100	Patients	_	_	O
101	with	_	_	O
102	polycystic	_	_	O
103	liver	_	_	O
104	(	_	_	O
105	n	_	_	O
106	=	_	_	O
107	54	_	_	O
108	)	_	_	O
109	were	_	_	O
110	randomly	_	_	O
111	assigned	_	_	O
112	to	_	_	O
113	groups	_	_	O
114	given	_	_	O
115	lanreotide	_	_	O
116	(	_	_	O
117	120	_	_	O
118	mg	_	_	O
119	)	_	_	O
120	or	_	_	O
121	placebo	_	_	O
122	,	_	_	O
123	administered	_	_	O
124	every	_	_	O
125	28	_	_	O
126	days	_	_	O
127	for	_	_	O
128	24	_	_	O
129	weeks	_	_	O
130	.	_	_	O

131	The	_	_	O
132	primary	_	_	O
133	end	_	_	O
134	point	_	_	O
135	was	_	_	O
136	the	_	_	O
137	difference	_	_	O
138	in	_	_	O
139	total	_	_	O
140	liver	_	_	O
141	volume	_	_	O
142	,	_	_	O
143	measured	_	_	O
144	by	_	_	O
145	computerized	_	_	O
146	tomography	_	_	O
147	at	_	_	O
148	weeks	_	_	O
149	0	_	_	O
150	and	_	_	O
151	24	_	_	O
152	.	_	_	O

153	Analyses	_	_	O
154	were	_	_	O
155	performed	_	_	O
156	on	_	_	O
157	an	_	_	O
158	intention	_	_	O
159	-	_	_	O
160	to	_	_	O
161	-	_	_	O
162	treat	_	_	O
163	basis	_	_	O
164	.	_	_	O

165	Baseline	_	_	B-Premise
166	characteristics	_	_	I-Premise
167	were	_	_	I-Premise
168	comparable	_	_	I-Premise
169	for	_	_	I-Premise
170	both	_	_	I-Premise
171	groups	_	_	I-Premise
172	,	_	_	I-Premise
173	except	_	_	B-Premise
174	that	_	_	I-Premise
175	more	_	_	I-Premise
176	patients	_	_	I-Premise
177	with	_	_	I-Premise
178	ADPKD	_	_	I-Premise
179	were	_	_	I-Premise
180	assigned	_	_	I-Premise
181	to	_	_	I-Premise
182	the	_	_	I-Premise
183	placebo	_	_	I-Premise
184	group	_	_	I-Premise
185	(	_	_	I-Premise
186	P	_	_	I-Premise
187	=	_	_	I-Premise
188	.	_	_	I-Premise

189	03	_	_	I-Premise
190	)	_	_	I-Premise
191	.	_	_	I-Premise

192	The	_	_	B-Premise
193	mean	_	_	I-Premise
194	liver	_	_	I-Premise
195	volume	_	_	I-Premise
196	decreased	_	_	I-Premise
197	2	_	_	I-Premise
198	.	_	_	I-Premise

199	9	_	_	I-Premise
200	%	_	_	I-Premise
201	,	_	_	I-Premise
202	from	_	_	I-Premise
203	4606	_	_	I-Premise
204	mL	_	_	I-Premise
205	(	_	_	I-Premise
206	95	_	_	I-Premise
207	%	_	_	I-Premise
208	confidence	_	_	I-Premise
209	interval	_	_	I-Premise
210	(	_	_	I-Premise
211	CI	_	_	I-Premise
212	)	_	_	I-Premise
213	:	_	_	I-Premise
214	547	_	_	I-Premise
215	-	_	_	I-Premise
216	8665	_	_	I-Premise
217	)	_	_	I-Premise
218	to	_	_	I-Premise
219	4471	_	_	I-Premise
220	mL	_	_	I-Premise
221	(	_	_	I-Premise
222	95	_	_	I-Premise
223	%	_	_	I-Premise
224	CI	_	_	I-Premise
225	:	_	_	I-Premise
226	542	_	_	I-Premise
227	-	_	_	I-Premise
228	8401	_	_	I-Premise
229	mL	_	_	I-Premise
230	)	_	_	I-Premise
231	,	_	_	I-Premise
232	in	_	_	I-Premise
233	patients	_	_	I-Premise
234	given	_	_	I-Premise
235	lanreotide	_	_	I-Premise
236	.	_	_	I-Premise

237	In	_	_	B-Premise
238	the	_	_	I-Premise
239	placebo	_	_	I-Premise
240	group	_	_	I-Premise
241	,	_	_	I-Premise
242	the	_	_	I-Premise
243	mean	_	_	I-Premise
244	liver	_	_	I-Premise
245	volume	_	_	I-Premise
246	increased	_	_	I-Premise
247	1	_	_	I-Premise
248	.	_	_	I-Premise

249	6	_	_	I-Premise
250	%	_	_	I-Premise
251	,	_	_	I-Premise
252	from	_	_	I-Premise
253	4689	_	_	I-Premise
254	mL	_	_	I-Premise
255	(	_	_	I-Premise
256	95	_	_	I-Premise
257	%	_	_	I-Premise
258	CI	_	_	I-Premise
259	:	_	_	I-Premise
260	613	_	_	I-Premise
261	-	_	_	I-Premise
262	8765	_	_	I-Premise
263	mL	_	_	I-Premise
264	)	_	_	I-Premise
265	to	_	_	I-Premise
266	4895	_	_	I-Premise
267	mL	_	_	I-Premise
268	(	_	_	I-Premise
269	95	_	_	I-Premise
270	%	_	_	I-Premise
271	CI	_	_	I-Premise
272	:	_	_	I-Premise
273	739	_	_	I-Premise
274	-	_	_	I-Premise
275	9053	_	_	I-Premise
276	mL	_	_	I-Premise
277	)	_	_	I-Premise
278	(	_	_	I-Premise
279	P	_	_	I-Premise
280	<	_	_	I-Premise
281	.	_	_	I-Premise

282	01	_	_	I-Premise
283	)	_	_	I-Premise
284	.	_	_	I-Premise

285	Post	_	_	B-Premise
286	hoc	_	_	I-Premise
287	stratification	_	_	I-Premise
288	for	_	_	I-Premise
289	patients	_	_	I-Premise
290	with	_	_	I-Premise
291	ADPKD	_	_	I-Premise
292	or	_	_	I-Premise
293	PCLD	_	_	I-Premise
294	revealed	_	_	I-Premise
295	similar	_	_	I-Premise
296	changes	_	_	I-Premise
297	in	_	_	I-Premise
298	liver	_	_	I-Premise
299	volume	_	_	I-Premise
300	,	_	_	I-Premise
301	with	_	_	I-Premise
302	statistically	_	_	I-Premise
303	significant	_	_	I-Premise
304	differences	_	_	I-Premise
305	in	_	_	I-Premise
306	patients	_	_	I-Premise
307	given	_	_	I-Premise
308	lanreotide	_	_	I-Premise
309	(	_	_	I-Premise
310	P	_	_	I-Premise
311	<	_	_	I-Premise
312	.	_	_	I-Premise

313	01	_	_	I-Premise
314	for	_	_	I-Premise
315	both	_	_	I-Premise
316	diseases	_	_	I-Premise
317	)	_	_	I-Premise
318	.	_	_	I-Premise

319	In	_	_	B-Claim
320	patients	_	_	I-Claim
321	with	_	_	I-Claim
322	polycystic	_	_	I-Claim
323	liver	_	_	I-Claim
324	,	_	_	I-Claim
325	6	_	_	I-Claim
326	months	_	_	I-Claim
327	of	_	_	I-Claim
328	treatment	_	_	I-Claim
329	with	_	_	I-Claim
330	lanreotide	_	_	I-Claim
331	reduces	_	_	I-Claim
332	liver	_	_	I-Claim
333	volume	_	_	I-Claim
334	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	effectiveness	_	_	O
4	of	_	_	O
5	the	_	_	O
6	Alleviating	_	_	O
7	Depression	_	_	O
8	Among	_	_	O
9	Patients	_	_	O
10	With	_	_	O
11	Cancer	_	_	O
12	(	_	_	O
13	ADAPt	_	_	O
14	-	_	_	O
15	C	_	_	O
16	)	_	_	O
17	collaborative	_	_	O
18	care	_	_	O
19	management	_	_	O
20	for	_	_	O
21	major	_	_	O
22	depression	_	_	O
23	or	_	_	O
24	dysthymia	_	_	O
25	.	_	_	O

26	Study	_	_	O
27	patients	_	_	O
28	included	_	_	O
29	472	_	_	O
30	low	_	_	O
31	-	_	_	O
32	income	_	_	O
33	,	_	_	O
34	predominantly	_	_	O
35	female	_	_	O
36	Hispanic	_	_	O
37	patients	_	_	O
38	with	_	_	O
39	cancer	_	_	O
40	age	_	_	O
41	>	_	_	O
42	or	_	_	O
43	=	_	_	O
44	18	_	_	O
45	years	_	_	O
46	with	_	_	O
47	major	_	_	O
48	depression	_	_	O
49	(	_	_	O
50	49	_	_	O
51	%	_	_	O
52	)	_	_	O
53	,	_	_	O
54	dysthymia	_	_	O
55	(	_	_	O
56	5	_	_	O
57	%	_	_	O
58	)	_	_	O
59	,	_	_	O
60	or	_	_	O
61	both	_	_	O
62	(	_	_	O
63	46	_	_	O
64	%	_	_	O
65	)	_	_	O
66	.	_	_	O

67	Patients	_	_	O
68	were	_	_	O
69	randomly	_	_	O
70	assigned	_	_	O
71	to	_	_	O
72	intervention	_	_	O
73	(	_	_	O
74	n	_	_	O
75	=	_	_	O
76	242	_	_	O
77	)	_	_	O
78	or	_	_	O
79	enhanced	_	_	O
80	usual	_	_	O
81	care	_	_	O
82	(	_	_	O
83	EUC	_	_	O
84	;	_	_	O
85	n	_	_	O
86	=	_	_	O
87	230	_	_	O
88	)	_	_	O
89	.	_	_	O

90	Intervention	_	_	O
91	patients	_	_	O
92	had	_	_	O
93	access	_	_	O
94	for	_	_	O
95	up	_	_	O
96	to	_	_	O
97	12	_	_	O
98	months	_	_	O
99	to	_	_	O
100	a	_	_	O
101	depression	_	_	O
102	clinical	_	_	O
103	specialist	_	_	O
104	(	_	_	O
105	supervised	_	_	O
106	by	_	_	O
107	a	_	_	O
108	psychiatrist	_	_	O
109	)	_	_	O
110	who	_	_	O
111	offered	_	_	O
112	education	_	_	O
113	,	_	_	O
114	structured	_	_	O
115	psychotherapy	_	_	O
116	,	_	_	O
117	and	_	_	O
118	maintenance	_	_	O
119	/	_	_	O
120	relapse	_	_	O
121	prevention	_	_	O
122	support	_	_	O
123	.	_	_	O

124	The	_	_	O
125	psychiatrist	_	_	O
126	prescribed	_	_	O
127	antidepressant	_	_	O
128	medications	_	_	O
129	for	_	_	O
130	patients	_	_	O
131	preferring	_	_	O
132	or	_	_	O
133	assessed	_	_	O
134	to	_	_	O
135	require	_	_	O
136	medication	_	_	O
137	.	_	_	O

138	At	_	_	B-Premise
139	12	_	_	I-Premise
140	months	_	_	I-Premise
141	,	_	_	I-Premise
142	63	_	_	I-Premise
143	%	_	_	I-Premise
144	of	_	_	I-Premise
145	intervention	_	_	I-Premise
146	patients	_	_	I-Premise
147	had	_	_	I-Premise
148	a	_	_	I-Premise
149	50	_	_	I-Premise
150	%	_	_	I-Premise
151	or	_	_	I-Premise
152	greater	_	_	I-Premise
153	reduction	_	_	I-Premise
154	in	_	_	I-Premise
155	depressive	_	_	I-Premise
156	symptoms	_	_	I-Premise
157	from	_	_	I-Premise
158	baseline	_	_	I-Premise
159	as	_	_	I-Premise
160	assessed	_	_	I-Premise
161	by	_	_	I-Premise
162	the	_	_	I-Premise
163	Patient	_	_	I-Premise
164	Health	_	_	I-Premise
165	Questionnaire	_	_	I-Premise
166	-	_	_	I-Premise
167	9	_	_	I-Premise
168	(	_	_	I-Premise
169	PHQ	_	_	I-Premise
170	-	_	_	I-Premise
171	9	_	_	I-Premise
172	)	_	_	I-Premise
173	depression	_	_	I-Premise
174	scale	_	_	I-Premise
175	compared	_	_	I-Premise
176	with	_	_	I-Premise
177	50	_	_	I-Premise
178	%	_	_	I-Premise
179	of	_	_	I-Premise
180	EUC	_	_	I-Premise
181	patients	_	_	I-Premise
182	(	_	_	I-Premise
183	odds	_	_	I-Premise
184	ratio	_	_	I-Premise
185	[	_	_	I-Premise
186	OR	_	_	I-Premise
187	]	_	_	I-Premise
188	=	_	_	I-Premise
189	1	_	_	I-Premise
190	.	_	_	I-Premise

191	98	_	_	I-Premise
192	;	_	_	I-Premise
193	95	_	_	I-Premise
194	%	_	_	I-Premise
195	CI	_	_	I-Premise
196	,	_	_	I-Premise
197	1	_	_	I-Premise
198	.	_	_	I-Premise

199	16	_	_	I-Premise
200	to	_	_	I-Premise
201	3	_	_	I-Premise
202	.	_	_	I-Premise

203	38	_	_	I-Premise
204	;	_	_	I-Premise
205	P	_	_	I-Premise
206	=	_	_	I-Premise
207	.	_	_	I-Premise

208	01	_	_	I-Premise
209	)	_	_	I-Premise
210	.	_	_	I-Premise

211	Improvement	_	_	B-Premise
212	was	_	_	I-Premise
213	also	_	_	I-Premise
214	found	_	_	I-Premise
215	for	_	_	I-Premise
216	5	_	_	I-Premise
217	-	_	_	I-Premise
218	point	_	_	I-Premise
219	decrease	_	_	I-Premise
220	in	_	_	I-Premise
221	PHQ	_	_	I-Premise
222	-	_	_	I-Premise
223	9	_	_	I-Premise
224	score	_	_	I-Premise
225	among	_	_	I-Premise
226	72	_	_	I-Premise
227	.	_	_	I-Premise

228	2	_	_	I-Premise
229	%	_	_	I-Premise
230	of	_	_	I-Premise
231	intervention	_	_	I-Premise
232	patients	_	_	I-Premise
233	compared	_	_	I-Premise
234	with	_	_	I-Premise
235	59	_	_	I-Premise
236	.	_	_	I-Premise

237	7	_	_	I-Premise
238	%	_	_	I-Premise
239	of	_	_	I-Premise
240	EUC	_	_	I-Premise
241	patients	_	_	I-Premise
242	(	_	_	I-Premise
243	OR	_	_	I-Premise
244	=	_	_	I-Premise
245	1	_	_	I-Premise
246	.	_	_	I-Premise

247	99	_	_	I-Premise
248	;	_	_	I-Premise
249	95	_	_	I-Premise
250	%	_	_	I-Premise
251	CI	_	_	I-Premise
252	,	_	_	I-Premise
253	1	_	_	I-Premise
254	.	_	_	I-Premise

255	14	_	_	I-Premise
256	to	_	_	I-Premise
257	3	_	_	I-Premise
258	.	_	_	I-Premise

259	50	_	_	I-Premise
260	;	_	_	I-Premise
261	P	_	_	I-Premise
262	=	_	_	I-Premise
263	.	_	_	I-Premise

264	02	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	Intervention	_	_	B-Premise
268	patients	_	_	I-Premise
269	also	_	_	I-Premise
270	experienced	_	_	I-Premise
271	greater	_	_	I-Premise
272	rates	_	_	I-Premise
273	of	_	_	I-Premise
274	depression	_	_	I-Premise
275	treatment	_	_	I-Premise
276	(	_	_	I-Premise
277	72	_	_	I-Premise
278	.	_	_	I-Premise

279	3	_	_	I-Premise
280	%	_	_	I-Premise
281	v	_	_	I-Premise
282	10	_	_	I-Premise
283	.	_	_	I-Premise

284	4	_	_	I-Premise
285	%	_	_	I-Premise
286	of	_	_	I-Premise
287	EUC	_	_	I-Premise
288	patients	_	_	I-Premise
289	;	_	_	I-Premise
290	P	_	_	I-Premise
291	<	_	_	I-Premise
292	.	_	_	I-Premise

293	0001	_	_	I-Premise
294	)	_	_	I-Premise
295	and	_	_	I-Premise
296	significantly	_	_	I-Premise
297	better	_	_	I-Premise
298	quality	_	_	I-Premise
299	-	_	_	I-Premise
300	of	_	_	I-Premise
301	-	_	_	I-Premise
302	life	_	_	I-Premise
303	outcomes	_	_	I-Premise
304	,	_	_	I-Premise
305	including	_	_	I-Premise
306	social	_	_	I-Premise
307	/	_	_	I-Premise
308	family	_	_	I-Premise
309	(	_	_	I-Premise
310	adjusted	_	_	I-Premise
311	mean	_	_	I-Premise
312	difference	_	_	I-Premise
313	between	_	_	I-Premise
314	groups	_	_	I-Premise
315	,	_	_	I-Premise
316	2	_	_	I-Premise
317	.	_	_	I-Premise

318	7	_	_	I-Premise
319	;	_	_	I-Premise
320	95	_	_	I-Premise
321	%	_	_	I-Premise
322	CI	_	_	I-Premise
323	,	_	_	I-Premise
324	1	_	_	I-Premise
325	.	_	_	I-Premise

326	22	_	_	I-Premise
327	to	_	_	I-Premise
328	4	_	_	I-Premise
329	.	_	_	I-Premise

330	17	_	_	I-Premise
331	;	_	_	I-Premise
332	P	_	_	I-Premise
333	<	_	_	I-Premise
334	.	_	_	I-Premise

335	001	_	_	I-Premise
336	)	_	_	I-Premise
337	,	_	_	I-Premise
338	emotional	_	_	I-Premise
339	(	_	_	I-Premise
340	adjusted	_	_	I-Premise
341	mean	_	_	I-Premise
342	difference	_	_	I-Premise
343	,	_	_	I-Premise
344	1	_	_	I-Premise
345	.	_	_	I-Premise

346	29	_	_	I-Premise
347	;	_	_	I-Premise
348	95	_	_	I-Premise
349	%	_	_	I-Premise
350	CI	_	_	I-Premise
351	,	_	_	I-Premise
352	0	_	_	I-Premise
353	.	_	_	I-Premise

354	26	_	_	I-Premise
355	to	_	_	I-Premise
356	2	_	_	I-Premise
357	.	_	_	I-Premise

358	22	_	_	I-Premise
359	;	_	_	I-Premise
360	P	_	_	I-Premise
361	=	_	_	I-Premise
362	.	_	_	I-Premise

363	01	_	_	I-Premise
364	)	_	_	I-Premise
365	,	_	_	I-Premise
366	functional	_	_	I-Premise
367	(	_	_	I-Premise
368	adjusted	_	_	I-Premise
369	mean	_	_	I-Premise
370	difference	_	_	I-Premise
371	,	_	_	I-Premise
372	1	_	_	I-Premise
373	.	_	_	I-Premise

374	34	_	_	I-Premise
375	;	_	_	I-Premise
376	95	_	_	I-Premise
377	%	_	_	I-Premise
378	CI	_	_	I-Premise
379	,	_	_	I-Premise
380	0	_	_	I-Premise
381	.	_	_	I-Premise

382	08	_	_	I-Premise
383	to	_	_	I-Premise
384	2	_	_	I-Premise
385	.	_	_	I-Premise

386	59	_	_	I-Premise
387	;	_	_	I-Premise
388	P	_	_	I-Premise
389	=	_	_	I-Premise
390	.	_	_	I-Premise

391	04	_	_	I-Premise
392	)	_	_	I-Premise
393	,	_	_	I-Premise
394	and	_	_	I-Premise
395	physical	_	_	I-Premise
396	well	_	_	I-Premise
397	-	_	_	I-Premise
398	being	_	_	I-Premise
399	(	_	_	I-Premise
400	adjusted	_	_	I-Premise
401	mean	_	_	I-Premise
402	difference	_	_	I-Premise
403	,	_	_	I-Premise
404	2	_	_	I-Premise
405	.	_	_	I-Premise

406	79	_	_	I-Premise
407	;	_	_	I-Premise
408	95	_	_	I-Premise
409	%	_	_	I-Premise
410	CI	_	_	I-Premise
411	,	_	_	I-Premise
412	0	_	_	I-Premise
413	.	_	_	I-Premise

414	49	_	_	I-Premise
415	to	_	_	I-Premise
416	5	_	_	I-Premise
417	.	_	_	I-Premise

418	1	_	_	I-Premise
419	;	_	_	I-Premise
420	P	_	_	I-Premise
421	=	_	_	I-Premise
422	.	_	_	I-Premise

423	02	_	_	I-Premise
424	)	_	_	I-Premise
425	.	_	_	I-Premise

426	ADAPt	_	_	B-Claim
427	-	_	_	I-Claim
428	C	_	_	I-Claim
429	collaborative	_	_	I-Claim
430	care	_	_	I-Claim
431	is	_	_	I-Claim
432	feasible	_	_	I-Claim
433	and	_	_	I-Claim
434	results	_	_	I-Claim
435	in	_	_	I-Claim
436	significant	_	_	I-Claim
437	reduction	_	_	I-Claim
438	in	_	_	I-Claim
439	depressive	_	_	I-Claim
440	symptoms	_	_	I-Claim
441	,	_	_	I-Claim
442	improvement	_	_	I-Claim
443	in	_	_	I-Claim
444	quality	_	_	I-Claim
445	of	_	_	I-Claim
446	life	_	_	I-Claim
447	,	_	_	I-Claim
448	and	_	_	I-Claim
449	lower	_	_	I-Claim
450	pain	_	_	I-Claim
451	levels	_	_	I-Claim
452	compared	_	_	I-Claim
453	with	_	_	I-Claim
454	EUC	_	_	I-Claim
455	for	_	_	I-Claim
456	patients	_	_	I-Claim
457	with	_	_	I-Claim
458	depressive	_	_	I-Claim
459	disorders	_	_	I-Claim
460	in	_	_	I-Claim
461	a	_	_	I-Claim
462	low	_	_	I-Claim
463	-	_	_	I-Claim
464	income	_	_	I-Claim
465	,	_	_	I-Claim
466	predominantly	_	_	I-Claim
467	Hispanic	_	_	I-Claim
468	population	_	_	I-Claim
469	in	_	_	I-Claim
470	public	_	_	I-Claim
471	sector	_	_	I-Claim
472	oncology	_	_	I-Claim
473	clinics	_	_	I-Claim
474	.	_	_	I-Claim


0	Surgery	_	_	O
1	and	_	_	O
2	radiotherapy	_	_	O
3	commonly	_	_	O
4	cause	_	_	O
5	adverse	_	_	O
6	musculoskeletal	_	_	O
7	problems	_	_	O
8	,	_	_	O
9	particularly	_	_	O
10	loss	_	_	O
11	of	_	_	O
12	strength	_	_	O
13	and	_	_	O
14	range	_	_	O
15	of	_	_	O
16	motion	_	_	O
17	,	_	_	O
18	in	_	_	O
19	the	_	_	O
20	upper	_	_	O
21	quadrant	_	_	O
22	of	_	_	O
23	breast	_	_	O
24	cancer	_	_	O
25	patients	_	_	O
26	.	_	_	O

27	Few	_	_	O
28	well	_	_	O
29	-	_	_	O
30	designed	_	_	O
31	studies	_	_	O
32	have	_	_	O
33	investigated	_	_	O
34	whether	_	_	O
35	these	_	_	O
36	impairments	_	_	O
37	can	_	_	O
38	be	_	_	O
39	prevented	_	_	O
40	.	_	_	O

41	Stretching	_	_	B-Claim
42	is	_	_	I-Claim
43	an	_	_	I-Claim
44	effective	_	_	I-Claim
45	technique	_	_	I-Claim
46	for	_	_	I-Claim
47	increasing	_	_	I-Claim
48	range	_	_	I-Claim
49	of	_	_	I-Claim
50	motion	_	_	I-Claim
51	,	_	_	I-Claim
52	hence	_	_	O
53	the	_	_	O
54	aim	_	_	O
55	of	_	_	O
56	this	_	_	O
57	study	_	_	O
58	was	_	_	O
59	to	_	_	O
60	investigate	_	_	O
61	whether	_	_	O
62	a	_	_	O
63	stretching	_	_	O
64	program	_	_	O
65	reduced	_	_	O
66	acute	_	_	O
67	musculoskeletal	_	_	O
68	impairments	_	_	O
69	in	_	_	O
70	patients	_	_	O
71	undergoing	_	_	O
72	radiotherapy	_	_	O
73	for	_	_	O
74	breast	_	_	O
75	cancer	_	_	O
76	.	_	_	O

77	Sixty	_	_	O
78	-	_	_	O
79	four	_	_	O
80	women	_	_	O
81	were	_	_	O
82	recruited	_	_	O
83	prior	_	_	O
84	to	_	_	O
85	commencement	_	_	O
86	of	_	_	O
87	radiotherapy	_	_	O
88	following	_	_	O
89	breast	_	_	O
90	cancer	_	_	O
91	surgery	_	_	O
92	.	_	_	O

93	Participants	_	_	O
94	were	_	_	O
95	randomised	_	_	O
96	to	_	_	O
97	either	_	_	O
98	a	_	_	O
99	control	_	_	O
100	or	_	_	O
101	stretch	_	_	O
102	group	_	_	O
103	.	_	_	O

104	Participants	_	_	O
105	in	_	_	O
106	both	_	_	O
107	groups	_	_	O
108	were	_	_	O
109	reviewed	_	_	O
110	by	_	_	O
111	the	_	_	O
112	physical	_	_	O
113	therapist	_	_	O
114	on	_	_	O
115	a	_	_	O
116	weekly	_	_	O
117	basis	_	_	O
118	for	_	_	O
119	approximately	_	_	O
120	6	_	_	O
121	weeks	_	_	O
122	,	_	_	O
123	and	_	_	O
124	were	_	_	O
125	given	_	_	O
126	general	_	_	O
127	information	_	_	O
128	about	_	_	O
129	skin	_	_	O
130	care	_	_	O
131	and	_	_	O
132	lymphedema	_	_	O
133	.	_	_	O

134	The	_	_	O
135	control	_	_	O
136	group	_	_	O
137	received	_	_	O
138	no	_	_	O
139	advice	_	_	O
140	about	_	_	O
141	exercise	_	_	O
142	.	_	_	O

143	The	_	_	O
144	stretch	_	_	O
145	group	_	_	O
146	received	_	_	O
147	instruction	_	_	O
148	on	_	_	O
149	low	_	_	O
150	-	_	_	O
151	load	_	_	O
152	,	_	_	O
153	prolonged	_	_	O
154	pectoral	_	_	O
155	stretches	_	_	O
156	,	_	_	O
157	which	_	_	O
158	were	_	_	O
159	to	_	_	O
160	be	_	_	O
161	performed	_	_	O
162	daily	_	_	O
163	and	_	_	O
164	were	_	_	O
165	checked	_	_	O
166	at	_	_	O
167	weekly	_	_	O
168	visits	_	_	O
169	.	_	_	O

170	Shoulder	_	_	O
171	range	_	_	O
172	of	_	_	O
173	motion	_	_	O
174	,	_	_	O
175	strength	_	_	O
176	,	_	_	O
177	arm	_	_	O
178	circumference	_	_	O
179	,	_	_	O
180	and	_	_	O
181	quality	_	_	O
182	of	_	_	O
183	life	_	_	O
184	measurements	_	_	O
185	were	_	_	O
186	taken	_	_	O
187	prior	_	_	O
188	to	_	_	O
189	,	_	_	O
190	and	_	_	O
191	at	_	_	O
192	completion	_	_	O
193	of	_	_	O
194	radiotherapy	_	_	O
195	,	_	_	O
196	and	_	_	O
197	at	_	_	O
198	7	_	_	O
199	months	_	_	O
200	after	_	_	O
201	radiotherapy	_	_	O
202	.	_	_	O

203	There	_	_	B-Premise
204	was	_	_	I-Premise
205	no	_	_	I-Premise
206	difference	_	_	I-Premise
207	in	_	_	I-Premise
208	any	_	_	I-Premise
209	outcome	_	_	I-Premise
210	between	_	_	I-Premise
211	groups	_	_	I-Premise
212	.	_	_	I-Premise

213	Breast	_	_	B-Premise
214	symptoms	_	_	I-Premise
215	increased	_	_	I-Premise
216	for	_	_	I-Premise
217	both	_	_	I-Premise
218	groups	_	_	I-Premise
219	during	_	_	I-Premise
220	radiotherapy	_	_	I-Premise
221	,	_	_	I-Premise
222	without	_	_	I-Premise
223	loss	_	_	I-Premise
224	of	_	_	I-Premise
225	strength	_	_	I-Premise
226	or	_	_	I-Premise
227	range	_	_	I-Premise
228	of	_	_	I-Premise
229	movement	_	_	I-Premise
230	.	_	_	I-Premise

231	The	_	_	B-Premise
232	incidence	_	_	I-Premise
233	of	_	_	I-Premise
234	lymphedema	_	_	I-Premise
235	during	_	_	I-Premise
236	the	_	_	I-Premise
237	study	_	_	I-Premise
238	was	_	_	I-Premise
239	low	_	_	I-Premise
240	for	_	_	I-Premise
241	both	_	_	I-Premise
242	groups	_	_	I-Premise
243	and	_	_	I-Premise
244	did	_	_	I-Premise
245	not	_	_	I-Premise
246	differ	_	_	I-Premise
247	between	_	_	I-Premise
248	groups	_	_	I-Premise
249	.	_	_	I-Premise

250	The	_	_	B-Premise
251	pectoral	_	_	I-Premise
252	stretching	_	_	I-Premise
253	program	_	_	I-Premise
254	did	_	_	I-Premise
255	not	_	_	I-Premise
256	influence	_	_	I-Premise
257	the	_	_	I-Premise
258	outcomes	_	_	I-Premise
259	measured	_	_	I-Premise
260	because	_	_	I-Premise
261	the	_	_	I-Premise
262	symptoms	_	_	I-Premise
263	reported	_	_	I-Premise
264	by	_	_	I-Premise
265	patients	_	_	I-Premise
266	were	_	_	I-Premise
267	not	_	_	I-Premise
268	a	_	_	I-Premise
269	consequence	_	_	I-Premise
270	of	_	_	I-Premise
271	contracture	_	_	I-Premise
272	.	_	_	I-Premise


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	2	_	_	O
10	-	_	_	O
11	year	_	_	O
12	functional	_	_	O
13	performance	_	_	O
14	and	_	_	O
15	quality	_	_	O
16	of	_	_	O
17	life	_	_	O
18	in	_	_	O
19	patients	_	_	O
20	with	_	_	O
21	operable	_	_	O
22	squamous	_	_	O
23	cell	_	_	O
24	carcinoma	_	_	O
25	of	_	_	O
26	the	_	_	O
27	esophagus	_	_	O
28	,	_	_	O
29	who	_	_	O
30	have	_	_	O
31	received	_	_	O
32	either	_	_	O
33	surgery	_	_	O
34	or	_	_	O
35	definitive	_	_	O
36	chemoradiation	_	_	O
37	(	_	_	O
38	CRT	_	_	O
39	)	_	_	O
40	.	_	_	O

41	The	_	_	O
42	functional	_	_	O
43	outcomes	_	_	O
44	and	_	_	O
45	quality	_	_	O
46	of	_	_	O
47	life	_	_	O
48	in	_	_	O
49	patients	_	_	O
50	receiving	_	_	O
51	esophagectomy	_	_	O
52	or	_	_	O
53	definitive	_	_	O
54	CRT	_	_	O
55	is	_	_	O
56	uncertain	_	_	O
57	.	_	_	O

58	Data	_	_	O
59	were	_	_	O
60	extracted	_	_	O
61	from	_	_	O
62	the	_	_	O
63	database	_	_	O
64	of	_	_	O
65	a	_	_	O
66	prospective	_	_	O
67	randomized	_	_	O
68	controlled	_	_	O
69	trial	_	_	O
70	that	_	_	O
71	included	_	_	O
72	patients	_	_	O
73	with	_	_	O
74	resectable	_	_	O
75	mid	_	_	O
76	or	_	_	O
77	lower	_	_	O
78	thoracic	_	_	O
79	esophageal	_	_	O
80	cancers	_	_	O
81	.	_	_	O

82	The	_	_	O
83	patients	_	_	O
84	were	_	_	O
85	randomized	_	_	O
86	to	_	_	O
87	either	_	_	O
88	standard	_	_	O
89	esophagectomy	_	_	O
90	or	_	_	O
91	definitive	_	_	O
92	CRT	_	_	O
93	.	_	_	O

94	Quality	_	_	O
95	of	_	_	O
96	life	_	_	O
97	assessments	_	_	O
98	were	_	_	O
99	performed	_	_	O
100	using	_	_	O
101	the	_	_	O
102	EORTC	_	_	O
103	QLQ	_	_	O
104	-	_	_	O
105	C30	_	_	O
106	and	_	_	O
107	QLQ	_	_	O
108	-	_	_	O
109	OES24	_	_	O
110	modules	_	_	O
111	.	_	_	O

112	Other	_	_	O
113	functional	_	_	O
114	assessments	_	_	O
115	included	_	_	O
116	pulmonary	_	_	O
117	and	_	_	O
118	eating	_	_	O
119	functions	_	_	O
120	.	_	_	O

121	From	_	_	O
122	July	_	_	O
123	2000	_	_	O
124	to	_	_	O
125	December	_	_	O
126	2004	_	_	O
127	,	_	_	O
128	a	_	_	O
129	total	_	_	O
130	of	_	_	O
131	81	_	_	O
132	patients	_	_	O
133	were	_	_	O
134	enrolled	_	_	O
135	into	_	_	O
136	the	_	_	O
137	study	_	_	O
138	.	_	_	O

139	No	_	_	B-Premise
140	significant	_	_	I-Premise
141	longitudinal	_	_	I-Premise
142	changes	_	_	I-Premise
143	were	_	_	I-Premise
144	detected	_	_	I-Premise
145	in	_	_	I-Premise
146	the	_	_	I-Premise
147	global	_	_	I-Premise
148	health	_	_	I-Premise
149	status	_	_	I-Premise
150	in	_	_	I-Premise
151	both	_	_	I-Premise
152	groups	_	_	I-Premise
153	upon	_	_	I-Premise
154	available	_	_	I-Premise
155	follow	_	_	I-Premise
156	-	_	_	I-Premise
157	up	_	_	I-Premise
158	.	_	_	I-Premise

159	Surgery	_	_	B-Premise
160	was	_	_	I-Premise
161	associated	_	_	I-Premise
162	with	_	_	I-Premise
163	worsened	_	_	I-Premise
164	physical	_	_	I-Premise
165	functioning	_	_	I-Premise
166	and	_	_	I-Premise
167	fatigue	_	_	I-Premise
168	symptoms	_	_	I-Premise
169	up	_	_	I-Premise
170	to	_	_	I-Premise
171	6	_	_	I-Premise
172	months	_	_	I-Premise
173	after	_	_	I-Premise
174	treatment	_	_	I-Premise
175	(	_	_	I-Premise
176	P	_	_	I-Premise
177	<	_	_	I-Premise
178	0	_	_	I-Premise
179	.	_	_	I-Premise

180	001	_	_	I-Premise
181	and	_	_	I-Premise
182	P	_	_	I-Premise
183	=	_	_	I-Premise
184	0	_	_	I-Premise
185	.	_	_	I-Premise

186	021	_	_	I-Premise
187	,	_	_	I-Premise
188	respectively	_	_	I-Premise
189	)	_	_	I-Premise
190	and	_	_	I-Premise
191	these	_	_	I-Premise
192	scales	_	_	I-Premise
193	improved	_	_	I-Premise
194	at	_	_	I-Premise
195	2	_	_	I-Premise
196	years	_	_	I-Premise
197	.	_	_	I-Premise

198	In	_	_	B-Premise
199	terms	_	_	I-Premise
200	of	_	_	I-Premise
201	pulmonary	_	_	I-Premise
202	function	_	_	I-Premise
203	,	_	_	I-Premise
204	dyspnoic	_	_	I-Premise
205	and	_	_	I-Premise
206	coughing	_	_	I-Premise
207	symptoms	_	_	I-Premise
208	were	_	_	I-Premise
209	significantly	_	_	I-Premise
210	worsened	_	_	I-Premise
211	3	_	_	I-Premise
212	months	_	_	I-Premise
213	after	_	_	I-Premise
214	surgery	_	_	I-Premise
215	(	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	0	_	_	I-Premise
219	.	_	_	I-Premise

220	024	_	_	I-Premise
221	and	_	_	I-Premise
222	P	_	_	I-Premise
223	=	_	_	I-Premise
224	0	_	_	I-Premise
225	.	_	_	I-Premise

226	036	_	_	I-Premise
227	,	_	_	I-Premise
228	respectively	_	_	I-Premise
229	)	_	_	I-Premise
230	whereas	_	_	I-Premise
231	symptoms	_	_	I-Premise
232	in	_	_	I-Premise
233	the	_	_	I-Premise
234	CRT	_	_	I-Premise
235	group	_	_	I-Premise
236	progressively	_	_	I-Premise
237	deteriorated	_	_	I-Premise
238	over	_	_	I-Premise
239	time	_	_	I-Premise
240	.	_	_	I-Premise

241	Concerning	_	_	B-Premise
242	the	_	_	I-Premise
243	eating	_	_	I-Premise
244	function	_	_	I-Premise
245	,	_	_	I-Premise
246	both	_	_	I-Premise
247	groups	_	_	I-Premise
248	had	_	_	I-Premise
249	improvements	_	_	I-Premise
250	in	_	_	I-Premise
251	dysphagia	_	_	I-Premise
252	but	_	_	I-Premise
253	there	_	_	I-Premise
254	were	_	_	I-Premise
255	frequent	_	_	I-Premise
256	need	_	_	I-Premise
257	for	_	_	I-Premise
258	endoscopic	_	_	I-Premise
259	intervention	_	_	I-Premise
260	.	_	_	I-Premise

261	Neither	_	_	B-Premise
262	surgery	_	_	I-Premise
263	nor	_	_	I-Premise
264	definitive	_	_	I-Premise
265	CRT	_	_	I-Premise
266	significantly	_	_	I-Premise
267	impaired	_	_	I-Premise
268	the	_	_	I-Premise
269	global	_	_	I-Premise
270	health	_	_	I-Premise
271	status	_	_	I-Premise
272	of	_	_	I-Premise
273	patients	_	_	I-Premise
274	.	_	_	I-Premise

275	Surgery	_	_	B-Claim
276	was	_	_	I-Claim
277	associated	_	_	I-Claim
278	with	_	_	I-Claim
279	a	_	_	I-Claim
280	short	_	_	I-Claim
281	-	_	_	I-Claim
282	term	_	_	I-Claim
283	negative	_	_	I-Claim
284	impact	_	_	I-Claim
285	in	_	_	I-Claim
286	some	_	_	I-Claim
287	aspects	_	_	I-Claim
288	of	_	_	I-Claim
289	health	_	_	I-Claim
290	related	_	_	I-Claim
291	quality	_	_	I-Claim
292	of	_	_	I-Claim
293	life	_	_	I-Claim
294	assessments	_	_	I-Claim
295	but	_	_	B-Claim
296	these	_	_	I-Claim
297	changes	_	_	I-Claim
298	became	_	_	I-Claim
299	insignificant	_	_	I-Claim
300	2	_	_	I-Claim
301	years	_	_	I-Claim
302	after	_	_	I-Claim
303	treatment	_	_	I-Claim
304	.	_	_	I-Claim

305	However	_	_	O
306	,	_	_	O
307	CRT	_	_	B-Claim
308	was	_	_	I-Claim
309	associated	_	_	I-Claim
310	with	_	_	I-Claim
311	progressive	_	_	I-Claim
312	deteriorations	_	_	I-Claim
313	in	_	_	I-Claim
314	pulmonary	_	_	I-Claim
315	function	_	_	I-Claim
316	in	_	_	I-Claim
317	the	_	_	I-Claim
318	longer	_	_	I-Claim
319	term	_	_	I-Claim
320	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	was	_	_	O
3	designed	_	_	O
4	to	_	_	O
5	evaluate	_	_	O
6	the	_	_	O
7	impact	_	_	O
8	of	_	_	O
9	laparoscopic	_	_	O
10	rectal	_	_	O
11	resection	_	_	O
12	on	_	_	O
13	short	_	_	O
14	-	_	_	O
15	term	_	_	O
16	postoperative	_	_	O
17	morbidity	_	_	O
18	and	_	_	O
19	costs	_	_	O
20	.	_	_	O

21	A	_	_	O
22	total	_	_	O
23	of	_	_	O
24	168	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	rectal	_	_	O
28	cancer	_	_	O
29	were	_	_	O
30	randomly	_	_	O
31	assigned	_	_	O
32	to	_	_	O
33	laparoscopic	_	_	O
34	(	_	_	O
35	n	_	_	O
36	=	_	_	O
37	83	_	_	O
38	)	_	_	O
39	or	_	_	O
40	open	_	_	O
41	(	_	_	O
42	n	_	_	O
43	=	_	_	O
44	85	_	_	O
45	)	_	_	O
46	resection	_	_	O
47	.	_	_	O

48	Outcome	_	_	O
49	parameters	_	_	O
50	were	_	_	O
51	:	_	_	O
52	postoperative	_	_	O
53	morbidity	_	_	O
54	,	_	_	O
55	length	_	_	O
56	of	_	_	O
57	hospital	_	_	O
58	stay	_	_	O
59	,	_	_	O
60	quality	_	_	O
61	of	_	_	O
62	life	_	_	O
63	,	_	_	O
64	long	_	_	O
65	-	_	_	O
66	term	_	_	O
67	survival	_	_	O
68	,	_	_	O
69	and	_	_	O
70	local	_	_	O
71	recurrences	_	_	O
72	.	_	_	O

73	The	_	_	O
74	mean	_	_	O
75	follow	_	_	O
76	-	_	_	O
77	up	_	_	O
78	period	_	_	O
79	was	_	_	O
80	53	_	_	O
81	.	_	_	O

82	6	_	_	O
83	months	_	_	O
84	.	_	_	O

85	Cost	_	_	O
86	-	_	_	O
87	benefit	_	_	O
88	analysis	_	_	O
89	was	_	_	O
90	based	_	_	O
91	on	_	_	O
92	hospital	_	_	O
93	costs	_	_	O
94	.	_	_	O

95	Operative	_	_	B-Premise
96	time	_	_	I-Premise
97	was	_	_	I-Premise
98	53	_	_	I-Premise
99	minutes	_	_	I-Premise
100	longer	_	_	I-Premise
101	in	_	_	I-Premise
102	the	_	_	I-Premise
103	laparoscopic	_	_	I-Premise
104	group	_	_	I-Premise
105	(	_	_	I-Premise
106	P	_	_	I-Premise
107	<	_	_	I-Premise
108	0	_	_	I-Premise
109	.	_	_	I-Premise

110	0001	_	_	I-Premise
111	)	_	_	I-Premise
112	.	_	_	I-Premise

113	Postoperative	_	_	B-Premise
114	morbidity	_	_	I-Premise
115	rate	_	_	I-Premise
116	was	_	_	I-Premise
117	28	_	_	I-Premise
118	.	_	_	I-Premise

119	9	_	_	I-Premise
120	percent	_	_	I-Premise
121	in	_	_	I-Premise
122	the	_	_	I-Premise
123	laparoscopic	_	_	I-Premise
124	vs	_	_	I-Premise
125	.	_	_	I-Premise

126	40	_	_	I-Premise
127	percent	_	_	I-Premise
128	in	_	_	I-Premise
129	the	_	_	I-Premise
130	open	_	_	I-Premise
131	group	_	_	I-Premise
132	(	_	_	I-Premise
133	P	_	_	I-Premise
134	=	_	_	I-Premise
135	0	_	_	I-Premise
136	.	_	_	I-Premise

137	18	_	_	I-Premise
138	)	_	_	I-Premise
139	.	_	_	I-Premise

140	The	_	_	B-Premise
141	mean	_	_	I-Premise
142	length	_	_	I-Premise
143	of	_	_	I-Premise
144	hospital	_	_	I-Premise
145	stay	_	_	I-Premise
146	was	_	_	I-Premise
147	10	_	_	I-Premise
148	(	_	_	I-Premise
149	4	_	_	I-Premise
150	.	_	_	I-Premise

151	9	_	_	I-Premise
152	)	_	_	I-Premise
153	days	_	_	I-Premise
154	in	_	_	I-Premise
155	the	_	_	I-Premise
156	laparoscopic	_	_	I-Premise
157	group	_	_	I-Premise
158	and	_	_	I-Premise
159	13	_	_	I-Premise
160	.	_	_	I-Premise

161	6	_	_	I-Premise
162	(	_	_	I-Premise
163	10	_	_	I-Premise
164	)	_	_	I-Premise
165	days	_	_	I-Premise
166	in	_	_	I-Premise
167	the	_	_	I-Premise
168	open	_	_	I-Premise
169	group	_	_	I-Premise
170	(	_	_	I-Premise
171	P	_	_	I-Premise
172	=	_	_	I-Premise
173	0	_	_	I-Premise
174	.	_	_	I-Premise

175	004	_	_	I-Premise
176	)	_	_	I-Premise
177	.	_	_	I-Premise

178	Local	_	_	B-Premise
179	recurrence	_	_	I-Premise
180	rate	_	_	I-Premise
181	and	_	_	I-Premise
182	five	_	_	I-Premise
183	-	_	_	I-Premise
184	year	_	_	I-Premise
185	survival	_	_	I-Premise
186	were	_	_	I-Premise
187	similar	_	_	I-Premise
188	in	_	_	I-Premise
189	both	_	_	I-Premise
190	groups	_	_	I-Premise
191	;	_	_	I-Premise
192	however	_	_	B-Claim
193	,	_	_	I-Claim
194	the	_	_	I-Claim
195	limited	_	_	I-Claim
196	number	_	_	I-Claim
197	of	_	_	I-Claim
198	patients	_	_	I-Claim
199	does	_	_	I-Claim
200	not	_	_	I-Claim
201	allow	_	_	I-Claim
202	firm	_	_	I-Claim
203	conclusions	_	_	I-Claim
204	.	_	_	I-Claim

205	Quality	_	_	B-Premise
206	of	_	_	I-Premise
207	life	_	_	I-Premise
208	was	_	_	I-Premise
209	better	_	_	I-Premise
210	in	_	_	I-Premise
211	the	_	_	I-Premise
212	laparoscopic	_	_	I-Premise
213	group	_	_	I-Premise
214	only	_	_	I-Premise
215	in	_	_	I-Premise
216	the	_	_	I-Premise
217	first	_	_	I-Premise
218	year	_	_	I-Premise
219	after	_	_	I-Premise
220	surgery	_	_	I-Premise
221	(	_	_	I-Premise
222	P	_	_	I-Premise
223	<	_	_	I-Premise
224	0	_	_	I-Premise
225	.	_	_	I-Premise

226	0001	_	_	I-Premise
227	)	_	_	I-Premise
228	.	_	_	I-Premise

229	The	_	_	B-Premise
230	additional	_	_	I-Premise
231	charge	_	_	I-Premise
232	in	_	_	I-Premise
233	the	_	_	I-Premise
234	laparoscopic	_	_	I-Premise
235	group	_	_	I-Premise
236	was	_	_	I-Premise
237	$	_	_	I-Premise
238	1	_	_	I-Premise
239	,	_	_	I-Premise
240	748	_	_	I-Premise
241	per	_	_	I-Premise
242	patient	_	_	I-Premise
243	randomized	_	_	I-Premise
244	(	_	_	I-Premise
245	$	_	_	I-Premise
246	1	_	_	I-Premise
247	,	_	_	I-Premise
248	194	_	_	I-Premise
249	the	_	_	I-Premise
250	result	_	_	I-Premise
251	of	_	_	I-Premise
252	surgical	_	_	I-Premise
253	instruments	_	_	I-Premise
254	and	_	_	I-Premise
255	$	_	_	I-Premise
256	554	_	_	I-Premise
257	the	_	_	I-Premise
258	result	_	_	I-Premise
259	of	_	_	I-Premise
260	longer	_	_	I-Premise
261	operative	_	_	I-Premise
262	time	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	The	_	_	B-Premise
266	saving	_	_	I-Premise
267	in	_	_	I-Premise
268	the	_	_	I-Premise
269	laparoscopic	_	_	I-Premise
270	group	_	_	I-Premise
271	was	_	_	I-Premise
272	$	_	_	I-Premise
273	1	_	_	I-Premise
274	,	_	_	I-Premise
275	396	_	_	I-Premise
276	per	_	_	I-Premise
277	patient	_	_	I-Premise
278	randomized	_	_	I-Premise
279	(	_	_	I-Premise
280	$	_	_	I-Premise
281	647	_	_	I-Premise
282	the	_	_	I-Premise
283	result	_	_	I-Premise
284	of	_	_	I-Premise
285	shorter	_	_	I-Premise
286	length	_	_	I-Premise
287	of	_	_	I-Premise
288	hospital	_	_	I-Premise
289	stay	_	_	I-Premise
290	and	_	_	I-Premise
291	$	_	_	I-Premise
292	749	_	_	I-Premise
293	the	_	_	I-Premise
294	result	_	_	I-Premise
295	of	_	_	I-Premise
296	the	_	_	I-Premise
297	lower	_	_	I-Premise
298	cost	_	_	I-Premise
299	of	_	_	I-Premise
300	postoperative	_	_	I-Premise
301	complications	_	_	I-Premise
302	)	_	_	I-Premise
303	.	_	_	I-Premise

304	The	_	_	B-Premise
305	net	_	_	I-Premise
306	balance	_	_	I-Premise
307	resulted	_	_	I-Premise
308	in	_	_	I-Premise
309	$	_	_	I-Premise
310	351	_	_	I-Premise
311	extra	_	_	I-Premise
312	cost	_	_	I-Premise
313	per	_	_	I-Premise
314	patient	_	_	I-Premise
315	randomly	_	_	I-Premise
316	allocated	_	_	I-Premise
317	to	_	_	I-Premise
318	the	_	_	I-Premise
319	laparoscopic	_	_	I-Premise
320	group	_	_	I-Premise
321	.	_	_	I-Premise

322	Short	_	_	B-Claim
323	-	_	_	I-Claim
324	term	_	_	I-Claim
325	postoperative	_	_	I-Claim
326	morbidity	_	_	I-Claim
327	was	_	_	I-Claim
328	similar	_	_	I-Claim
329	in	_	_	I-Claim
330	the	_	_	I-Claim
331	two	_	_	I-Claim
332	groups	_	_	I-Claim
333	.	_	_	I-Claim

334	Laparoscopic	_	_	B-Claim
335	resection	_	_	I-Claim
336	reduced	_	_	I-Claim
337	length	_	_	I-Claim
338	of	_	_	I-Claim
339	hospital	_	_	I-Claim
340	stay	_	_	I-Claim
341	,	_	_	I-Claim
342	improved	_	_	I-Claim
343	first	_	_	I-Claim
344	-	_	_	I-Claim
345	year	_	_	I-Claim
346	quality	_	_	I-Claim
347	of	_	_	I-Claim
348	life	_	_	I-Claim
349	,	_	_	I-Claim
350	and	_	_	I-Claim
351	slightly	_	_	I-Claim
352	increased	_	_	I-Claim
353	hospital	_	_	I-Claim
354	costs	_	_	I-Claim
355	.	_	_	I-Claim


0	Although	_	_	O
1	many	_	_	O
2	drug	_	_	O
3	combination	_	_	O
4	therapies	_	_	O
5	have	_	_	O
6	been	_	_	O
7	proposed	_	_	O
8	,	_	_	O
9	there	_	_	B-Claim
10	is	_	_	I-Claim
11	no	_	_	I-Claim
12	standard	_	_	I-Claim
13	therapy	_	_	I-Claim
14	for	_	_	I-Claim
15	patients	_	_	I-Claim
16	with	_	_	I-Claim
17	advanced	_	_	I-Claim
18	gastric	_	_	I-Claim
19	carcinoma	_	_	I-Claim
20	.	_	_	I-Claim

21	The	_	_	B-Claim
22	superiority	_	_	I-Claim
23	of	_	_	I-Claim
24	combination	_	_	I-Claim
25	therapy	_	_	I-Claim
26	over	_	_	I-Claim
27	monochemotherapy	_	_	I-Claim
28	has	_	_	I-Claim
29	not	_	_	I-Claim
30	been	_	_	I-Claim
31	demonstrated	_	_	I-Claim
32	convincingly	_	_	I-Claim
33	.	_	_	I-Claim

34	To	_	_	O
35	explore	_	_	O
36	the	_	_	O
37	role	_	_	O
38	of	_	_	O
39	monochemotherapy	_	_	O
40	,	_	_	O
41	the	_	_	O
42	authors	_	_	O
43	evaluated	_	_	O
44	5	_	_	O
45	-	_	_	O
46	fluorouracil	_	_	O
47	(	_	_	O
48	5	_	_	O
49	-	_	_	O
50	FU	_	_	O
51	)	_	_	O
52	,	_	_	O
53	modulated	_	_	O
54	by	_	_	O
55	6S	_	_	O
56	-	_	_	O
57	leucovorin	_	_	O
58	(	_	_	O
59	6S	_	_	O
60	-	_	_	O
61	LV	_	_	O
62	)	_	_	O
63	and	_	_	O
64	a	_	_	O
65	cisplatin	_	_	O
66	-	_	_	O
67	containing	_	_	O
68	regimen	_	_	O
69	,	_	_	O
70	which	_	_	O
71	was	_	_	O
72	comprised	_	_	O
73	of	_	_	O
74	epirubicin	_	_	O
75	,	_	_	O
76	etoposide	_	_	O
77	,	_	_	O
78	and	_	_	O
79	cisplatin	_	_	O
80	with	_	_	O
81	the	_	_	O
82	addition	_	_	O
83	of	_	_	O
84	the	_	_	O
85	reversal	_	_	O
86	agent	_	_	O
87	lonidamine	_	_	O
88	(	_	_	O
89	EEP	_	_	O
90	-	_	_	O
91	L	_	_	O
92	)	_	_	O
93	.	_	_	O

94	After	_	_	O
95	stratification	_	_	O
96	according	_	_	O
97	to	_	_	O
98	performance	_	_	O
99	status	_	_	O
100	(	_	_	O
101	PS	_	_	O
102	)	_	_	O
103	and	_	_	O
104	resection	_	_	O
105	of	_	_	O
106	the	_	_	O
107	primary	_	_	O
108	tumor	_	_	O
109	,	_	_	O
110	72	_	_	O
111	patients	_	_	O
112	with	_	_	O
113	advanced	_	_	O
114	gastric	_	_	O
115	carcinoma	_	_	O
116	were	_	_	O
117	randomized	_	_	O
118	to	_	_	O
119	2	_	_	O
120	parallel	_	_	O
121	Phase	_	_	O
122	II	_	_	O
123	trials	_	_	O
124	with	_	_	O
125	5	_	_	O
126	-	_	_	O
127	FU	_	_	O
128	/	_	_	O
129	6S	_	_	O
130	-	_	_	O
131	LV	_	_	O
132	and	_	_	O
133	EEP	_	_	O
134	-	_	_	O
135	L	_	_	O
136	,	_	_	O
137	respectively	_	_	O
138	.	_	_	O

139	Thirty	_	_	O
140	-	_	_	O
141	six	_	_	O
142	patients	_	_	O
143	in	_	_	O
144	Study	_	_	O
145	A	_	_	O
146	received	_	_	O
147	bolus	_	_	O
148	6S	_	_	O
149	-	_	_	O
150	LV	_	_	O
151	,	_	_	O
152	100	_	_	O
153	mg	_	_	O
154	/	_	_	O
155	m2	_	_	O
156	,	_	_	O
157	followed	_	_	O
158	by	_	_	O
159	bolus	_	_	O
160	5	_	_	O
161	-	_	_	O
162	FU	_	_	O
163	,	_	_	O
164	370	_	_	O
165	mg	_	_	O
166	/	_	_	O
167	m2	_	_	O
168	,	_	_	O
169	on	_	_	O
170	Days	_	_	O
171	1	_	_	O
172	-	_	_	O
173	5	_	_	O
174	and	_	_	O
175	36	_	_	O
176	others	_	_	O
177	in	_	_	O
178	Study	_	_	O
179	B	_	_	O
180	received	_	_	O
181	epirubicin	_	_	O
182	,	_	_	O
183	30	_	_	O
184	mg	_	_	O
185	/	_	_	O
186	m2	_	_	O
187	,	_	_	O
188	on	_	_	O
189	Days	_	_	O
190	1	_	_	O
191	and	_	_	O
192	5	_	_	O
193	;	_	_	O
194	etoposide	_	_	O
195	,	_	_	O
196	100	_	_	O
197	mg	_	_	O
198	/	_	_	O
199	m2	_	_	O
200	,	_	_	O
201	on	_	_	O
202	Days	_	_	O
203	1	_	_	O
204	,	_	_	O
205	3	_	_	O
206	,	_	_	O
207	and	_	_	O
208	5	_	_	O
209	;	_	_	O
210	cisplatin	_	_	O
211	,	_	_	O
212	30	_	_	O
213	mg	_	_	O
214	/	_	_	O
215	m2	_	_	O
216	,	_	_	O
217	on	_	_	O
218	Days	_	_	O
219	2	_	_	O
220	and	_	_	O
221	4	_	_	O
222	;	_	_	O
223	and	_	_	O
224	lonidamine	_	_	O
225	,	_	_	O
226	150	_	_	O
227	mg	_	_	O
228	/	_	_	O
229	day	_	_	O
230	.	_	_	O

231	There	_	_	O
232	were	_	_	O
233	6	_	_	O
234	partial	_	_	O
235	responses	_	_	O
236	(	_	_	O
237	18	_	_	O
238	.	_	_	O

239	2	_	_	O
240	%	_	_	O
241	)	_	_	O
242	(	_	_	O
243	95	_	_	O
244	%	_	_	O
245	confidence	_	_	O
246	interval	_	_	O
247	[	_	_	O
248	CI	_	_	O
249	]	_	_	O
250	+	_	_	O
251	/	_	_	O
252	-	_	_	O
253	13	_	_	O
254	.	_	_	O

255	2	_	_	O
256	)	_	_	O
257	in	_	_	O
258	Study	_	_	O
259	A	_	_	O
260	and	_	_	O
261	7	_	_	O
262	partial	_	_	O
263	responses	_	_	O
264	(	_	_	O
265	21	_	_	O
266	.	_	_	O

267	9	_	_	O
268	%	_	_	O
269	)	_	_	O
270	(	_	_	O
271	95	_	_	O
272	%	_	_	O
273	CI	_	_	O
274	+	_	_	O
275	/	_	_	O
276	-	_	_	O
277	14	_	_	O
278	.	_	_	O

279	3	_	_	O
280	)	_	_	O
281	in	_	_	O
282	Study	_	_	O
283	B	_	_	O
284	.	_	_	O

285	Partial	_	_	O
286	responses	_	_	O
287	were	_	_	O
288	more	_	_	O
289	frequent	_	_	O
290	in	_	_	O
291	patients	_	_	O
292	with	_	_	O
293	resected	_	_	O
294	tumors	_	_	O
295	or	_	_	O
296	with	_	_	O
297	an	_	_	O
298	Eastern	_	_	O
299	Cooperative	_	_	O
300	Oncology	_	_	O
301	Group	_	_	O
302	PS	_	_	O
303	of	_	_	O
304	0	_	_	O
305	-	_	_	O
306	1	_	_	O
307	.	_	_	O

308	The	_	_	B-Premise
309	median	_	_	I-Premise
310	duration	_	_	I-Premise
311	of	_	_	I-Premise
312	response	_	_	I-Premise
313	was	_	_	I-Premise
314	8	_	_	I-Premise
315	.	_	_	I-Premise

316	8	_	_	I-Premise
317	and	_	_	I-Premise
318	8	_	_	I-Premise
319	.	_	_	I-Premise

320	3	_	_	I-Premise
321	months	_	_	I-Premise
322	,	_	_	I-Premise
323	respectively	_	_	I-Premise
324	,	_	_	I-Premise
325	in	_	_	I-Premise
326	Study	_	_	I-Premise
327	A	_	_	I-Premise
328	and	_	_	I-Premise
329	Study	_	_	I-Premise
330	B	_	_	I-Premise
331	.	_	_	I-Premise

332	The	_	_	B-Premise
333	median	_	_	I-Premise
334	survival	_	_	I-Premise
335	reached	_	_	I-Premise
336	8	_	_	I-Premise
337	months	_	_	I-Premise
338	in	_	_	I-Premise
339	Study	_	_	I-Premise
340	A	_	_	I-Premise
341	and	_	_	I-Premise
342	9	_	_	I-Premise
343	months	_	_	I-Premise
344	in	_	_	I-Premise
345	Study	_	_	I-Premise
346	B	_	_	I-Premise
347	.	_	_	I-Premise

348	In	_	_	B-Premise
349	the	_	_	I-Premise
350	whole	_	_	I-Premise
351	population	_	_	I-Premise
352	of	_	_	I-Premise
353	patients	_	_	I-Premise
354	survival	_	_	I-Premise
355	was	_	_	I-Premise
356	significantly	_	_	I-Premise
357	higher	_	_	I-Premise
358	in	_	_	I-Premise
359	patients	_	_	I-Premise
360	with	_	_	I-Premise
361	a	_	_	I-Premise
362	PS	_	_	I-Premise
363	of	_	_	I-Premise
364	0	_	_	I-Premise
365	-	_	_	I-Premise
366	1	_	_	I-Premise
367	(	_	_	I-Premise
368	P	_	_	I-Premise
369	<	_	_	I-Premise
370	0	_	_	I-Premise
371	.	_	_	I-Premise

372	05	_	_	I-Premise
373	)	_	_	I-Premise
374	.	_	_	I-Premise

375	Patients	_	_	B-Premise
376	with	_	_	I-Premise
377	a	_	_	I-Premise
378	PS	_	_	I-Premise
379	of	_	_	I-Premise
380	0	_	_	I-Premise
381	-	_	_	I-Premise
382	1	_	_	I-Premise
383	and	_	_	I-Premise
384	a	_	_	I-Premise
385	resected	_	_	I-Premise
386	tumor	_	_	I-Premise
387	had	_	_	I-Premise
388	the	_	_	I-Premise
389	significantly	_	_	I-Premise
390	longest	_	_	I-Premise
391	survival	_	_	I-Premise
392	both	_	_	I-Premise
393	in	_	_	I-Premise
394	EEP	_	_	I-Premise
395	-	_	_	I-Premise
396	L	_	_	I-Premise
397	treated	_	_	I-Premise
398	patients	_	_	I-Premise
399	and	_	_	I-Premise
400	in	_	_	I-Premise
401	all	_	_	I-Premise
402	evaluable	_	_	I-Premise
403	patients	_	_	I-Premise
404	in	_	_	I-Premise
405	the	_	_	I-Premise
406	two	_	_	I-Premise
407	studies	_	_	I-Premise
408	.	_	_	I-Premise

409	The	_	_	B-Premise
410	most	_	_	I-Premise
411	frequent	_	_	I-Premise
412	World	_	_	I-Premise
413	Health	_	_	I-Premise
414	Organization	_	_	I-Premise
415	Grade	_	_	I-Premise
416	3	_	_	I-Premise
417	-	_	_	I-Premise
418	4	_	_	I-Premise
419	toxic	_	_	I-Premise
420	effects	_	_	I-Premise
421	were	_	_	I-Premise
422	gastrointestinal	_	_	I-Premise
423	in	_	_	I-Premise
424	Study	_	_	I-Premise
425	A	_	_	I-Premise
426	and	_	_	I-Premise
427	hematologic	_	_	I-Premise
428	in	_	_	I-Premise
429	Study	_	_	I-Premise
430	B	_	_	I-Premise
431	.	_	_	I-Premise

432	No	_	_	B-Premise
433	treatment	_	_	I-Premise
434	-	_	_	I-Premise
435	related	_	_	I-Premise
436	death	_	_	I-Premise
437	was	_	_	I-Premise
438	observed	_	_	I-Premise
439	.	_	_	I-Premise

440	The	_	_	B-Claim
441	efficacy	_	_	I-Claim
442	of	_	_	I-Claim
443	5	_	_	I-Claim
444	-	_	_	I-Claim
445	FU	_	_	I-Claim
446	,	_	_	I-Claim
447	modulated	_	_	I-Claim
448	with	_	_	I-Claim
449	6S	_	_	I-Claim
450	-	_	_	I-Claim
451	LV	_	_	I-Claim
452	,	_	_	I-Claim
453	is	_	_	I-Claim
454	moderate	_	_	I-Claim
455	in	_	_	I-Claim
456	patients	_	_	I-Claim
457	with	_	_	I-Claim
458	advanced	_	_	I-Claim
459	gastric	_	_	I-Claim
460	carcinoma	_	_	I-Claim
461	,	_	_	I-Claim
462	similar	_	_	I-Claim
463	to	_	_	I-Claim
464	cisplatin	_	_	I-Claim
465	-	_	_	I-Claim
466	containing	_	_	I-Claim
467	regimens	_	_	I-Claim
468	.	_	_	I-Claim

469	PS	_	_	B-Claim
470	and	_	_	I-Claim
471	other	_	_	I-Claim
472	prognostic	_	_	I-Claim
473	factors	_	_	I-Claim
474	could	_	_	I-Claim
475	influence	_	_	I-Claim
476	the	_	_	I-Claim
477	response	_	_	I-Claim
478	rate	_	_	I-Claim
479	,	_	_	I-Claim
480	which	_	_	I-Claim
481	does	_	_	I-Claim
482	not	_	_	I-Claim
483	appear	_	_	I-Claim
484	to	_	_	I-Claim
485	be	_	_	I-Claim
486	a	_	_	I-Claim
487	reliable	_	_	I-Claim
488	parameter	_	_	I-Claim
489	for	_	_	I-Claim
490	evaluating	_	_	I-Claim
491	the	_	_	I-Claim
492	outcome	_	_	I-Claim
493	of	_	_	I-Claim
494	chemotherapy	_	_	I-Claim
495	trials	_	_	I-Claim
496	.	_	_	I-Claim


0	Chemotherapy	_	_	B-Claim
1	prolongs	_	_	I-Claim
2	survival	_	_	I-Claim
3	and	_	_	I-Claim
4	improves	_	_	I-Claim
5	quality	_	_	I-Claim
6	of	_	_	I-Claim
7	life	_	_	I-Claim
8	(	_	_	I-Claim
9	QOL	_	_	I-Claim
10	)	_	_	I-Claim
11	for	_	_	I-Claim
12	good	_	_	I-Claim
13	performance	_	_	I-Claim
14	status	_	_	I-Claim
15	(	_	_	I-Claim
16	PS	_	_	I-Claim
17	)	_	_	I-Claim
18	patients	_	_	I-Claim
19	with	_	_	I-Claim
20	advanced	_	_	I-Claim
21	non	_	_	I-Claim
22	-	_	_	I-Claim
23	small	_	_	I-Claim
24	cell	_	_	I-Claim
25	lung	_	_	I-Claim
26	cancer	_	_	I-Claim
27	(	_	_	I-Claim
28	NSCLC	_	_	I-Claim
29	)	_	_	I-Claim
30	.	_	_	I-Claim

31	Targeted	_	_	B-Claim
32	therapies	_	_	I-Claim
33	may	_	_	I-Claim
34	improve	_	_	I-Claim
35	chemotherapy	_	_	I-Claim
36	effectiveness	_	_	I-Claim
37	without	_	_	I-Claim
38	worsening	_	_	I-Claim
39	toxicity	_	_	I-Claim
40	.	_	_	I-Claim

41	SGN	_	_	O
42	-	_	_	O
43	15	_	_	O
44	is	_	_	O
45	an	_	_	O
46	antibody	_	_	O
47	-	_	_	O
48	drug	_	_	O
49	conjugate	_	_	O
50	(	_	_	O
51	ADC	_	_	O
52	)	_	_	O
53	,	_	_	O
54	consisting	_	_	O
55	of	_	_	O
56	a	_	_	O
57	chimeric	_	_	O
58	murine	_	_	O
59	monoclonal	_	_	O
60	antibody	_	_	O
61	recognizing	_	_	O
62	the	_	_	O
63	Lewis	_	_	O
64	Y	_	_	O
65	(	_	_	O
66	Le	_	_	O
67	(	_	_	O
68	y	_	_	O
69	)	_	_	O
70	)	_	_	O
71	antigen	_	_	O
72	,	_	_	O
73	conjugated	_	_	O
74	to	_	_	O
75	doxorubicin	_	_	O
76	.	_	_	O

77	Le	_	_	B-Claim
78	(	_	_	I-Claim
79	y	_	_	I-Claim
80	)	_	_	I-Claim
81	is	_	_	I-Claim
82	an	_	_	I-Claim
83	attractive	_	_	I-Claim
84	target	_	_	I-Claim
85	since	_	_	I-Claim
86	it	_	_	I-Claim
87	is	_	_	I-Claim
88	expressed	_	_	I-Claim
89	by	_	_	I-Claim
90	most	_	_	I-Claim
91	NSCLC	_	_	I-Claim
92	.	_	_	I-Claim

93	SGN	_	_	B-Premise
94	-	_	_	I-Premise
95	15	_	_	I-Premise
96	was	_	_	I-Premise
97	active	_	_	I-Premise
98	against	_	_	I-Premise
99	Le	_	_	I-Premise
100	(	_	_	I-Premise
101	y	_	_	I-Premise
102	)	_	_	I-Premise
103	-	_	_	I-Premise
104	positive	_	_	I-Premise
105	tumors	_	_	I-Premise
106	in	_	_	I-Premise
107	early	_	_	I-Premise
108	phase	_	_	I-Premise
109	clinical	_	_	I-Premise
110	trials	_	_	I-Premise
111	and	_	_	I-Premise
112	was	_	_	I-Premise
113	synergistic	_	_	I-Premise
114	with	_	_	I-Premise
115	docetaxel	_	_	I-Premise
116	in	_	_	I-Premise
117	preclinical	_	_	I-Premise
118	experiments	_	_	I-Premise
119	.	_	_	I-Premise

120	This	_	_	O
121	Phase	_	_	O
122	II	_	_	O
123	,	_	_	O
124	open	_	_	O
125	-	_	_	O
126	label	_	_	O
127	study	_	_	O
128	was	_	_	O
129	conducted	_	_	O
130	to	_	_	O
131	confirm	_	_	O
132	the	_	_	O
133	activity	_	_	O
134	of	_	_	O
135	SGN	_	_	O
136	-	_	_	O
137	15	_	_	O
138	plus	_	_	O
139	docetaxel	_	_	O
140	in	_	_	O
141	previously	_	_	O
142	treated	_	_	O
143	NSCLC	_	_	O
144	patients	_	_	O
145	.	_	_	O

146	Sixty	_	_	O
147	-	_	_	O
148	two	_	_	O
149	patients	_	_	O
150	with	_	_	O
151	recurrent	_	_	O
152	or	_	_	O
153	metastatic	_	_	O
154	NSCLC	_	_	O
155	expressing	_	_	O
156	Le	_	_	O
157	(	_	_	O
158	y	_	_	O
159	)	_	_	O
160	,	_	_	O
161	one	_	_	O
162	or	_	_	O
163	two	_	_	O
164	prior	_	_	O
165	chemotherapy	_	_	O
166	regimens	_	_	O
167	,	_	_	O
168	and	_	_	O
169	PS	_	_	O
170	<	_	_	O
171	or	_	_	O
172	=	_	_	O
173	2	_	_	O
174	were	_	_	O
175	randomized	_	_	O
176	2	_	_	O
177	:	_	_	O
178	1	_	_	O
179	to	_	_	O
180	receive	_	_	O
181	SGN	_	_	O
182	-	_	_	O
183	15	_	_	O
184	200	_	_	O
185	mg	_	_	O
186	/	_	_	O
187	m2	_	_	O
188	/	_	_	O
189	week	_	_	O
190	with	_	_	O
191	docetaxel	_	_	O
192	35	_	_	O
193	mg	_	_	O
194	/	_	_	O
195	m2	_	_	O
196	/	_	_	O
197	week	_	_	O
198	(	_	_	O
199	Arm	_	_	O
200	A	_	_	O
201	)	_	_	O
202	or	_	_	O
203	docetaxel	_	_	O
204	35	_	_	O
205	mg	_	_	O
206	/	_	_	O
207	m2	_	_	O
208	/	_	_	O
209	week	_	_	O
210	alone	_	_	O
211	(	_	_	O
212	Arm	_	_	O
213	B	_	_	O
214	)	_	_	O
215	for	_	_	O
216	6	_	_	O
217	of	_	_	O
218	8	_	_	O
219	weeks	_	_	O
220	.	_	_	O

221	Intrapatient	_	_	O
222	dose	_	_	O
223	-	_	_	O
224	escalation	_	_	O
225	of	_	_	O
226	SGN	_	_	O
227	-	_	_	O
228	15	_	_	O
229	to	_	_	O
230	350	_	_	O
231	mg	_	_	O
232	/	_	_	O
233	m2	_	_	O
234	was	_	_	O
235	permitted	_	_	O
236	in	_	_	O
237	the	_	_	O
238	second	_	_	O
239	half	_	_	O
240	of	_	_	O
241	the	_	_	O
242	study	_	_	O
243	.	_	_	O

244	Endpoints	_	_	O
245	were	_	_	O
246	survival	_	_	O
247	,	_	_	O
248	safety	_	_	O
249	,	_	_	O
250	efficacy	_	_	O
251	,	_	_	O
252	and	_	_	O
253	quality	_	_	O
254	of	_	_	O
255	life	_	_	O
256	.	_	_	O

257	Forty	_	_	O
258	patients	_	_	O
259	on	_	_	O
260	Arm	_	_	O
261	A	_	_	O
262	and	_	_	O
263	19	_	_	O
264	on	_	_	O
265	Arm	_	_	O
266	B	_	_	O
267	received	_	_	O
268	at	_	_	O
269	least	_	_	O
270	one	_	_	O
271	treatment	_	_	O
272	.	_	_	O

273	Patients	_	_	B-Premise
274	on	_	_	I-Premise
275	Arms	_	_	I-Premise
276	A	_	_	I-Premise
277	and	_	_	I-Premise
278	B	_	_	I-Premise
279	had	_	_	I-Premise
280	median	_	_	I-Premise
281	survivals	_	_	I-Premise
282	of	_	_	I-Premise
283	31	_	_	I-Premise
284	.	_	_	I-Premise

285	4	_	_	I-Premise
286	and	_	_	I-Premise
287	25	_	_	I-Premise
288	.	_	_	I-Premise

289	3	_	_	I-Premise
290	weeks	_	_	I-Premise
291	,	_	_	I-Premise
292	12	_	_	I-Premise
293	-	_	_	I-Premise
294	month	_	_	I-Premise
295	survivals	_	_	I-Premise
296	of	_	_	I-Premise
297	29	_	_	I-Premise
298	%	_	_	I-Premise
299	and	_	_	I-Premise
300	24	_	_	I-Premise
301	%	_	_	I-Premise
302	,	_	_	I-Premise
303	and	_	_	I-Premise
304	18	_	_	I-Premise
305	-	_	_	I-Premise
306	month	_	_	I-Premise
307	survivals	_	_	I-Premise
308	of	_	_	I-Premise
309	18	_	_	I-Premise
310	%	_	_	I-Premise
311	and	_	_	I-Premise
312	8	_	_	I-Premise
313	%	_	_	I-Premise
314	,	_	_	I-Premise
315	respectively	_	_	I-Premise
316	.	_	_	O

317	Toxicity	_	_	B-Premise
318	was	_	_	I-Premise
319	mild	_	_	I-Premise
320	in	_	_	I-Premise
321	both	_	_	I-Premise
322	arms	_	_	I-Premise
323	.	_	_	I-Premise

324	QOL	_	_	B-Premise
325	analyses	_	_	I-Premise
326	favored	_	_	I-Premise
327	Arm	_	_	I-Premise
328	A	_	_	I-Premise
329	.	_	_	I-Premise

330	SGN	_	_	B-Claim
331	-	_	_	I-Claim
332	15	_	_	I-Claim
333	plus	_	_	I-Claim
334	docetaxel	_	_	I-Claim
335	is	_	_	I-Claim
336	a	_	_	I-Claim
337	well	_	_	I-Claim
338	-	_	_	I-Claim
339	tolerated	_	_	I-Claim
340	and	_	_	I-Claim
341	active	_	_	I-Claim
342	second	_	_	I-Claim
343	and	_	_	I-Claim
344	third	_	_	I-Claim
345	line	_	_	I-Claim
346	treatment	_	_	I-Claim
347	for	_	_	I-Claim
348	NSCLC	_	_	I-Claim
349	patients	_	_	I-Claim
350	.	_	_	O

351	Ongoing	_	_	O
352	studies	_	_	O
353	are	_	_	O
354	exploring	_	_	O
355	alternate	_	_	O
356	schedules	_	_	O
357	to	_	_	O
358	maximize	_	_	O
359	synergy	_	_	O
360	between	_	_	O
361	these	_	_	O
362	agents	_	_	O
363	.	_	_	O


0	In	_	_	O
1	the	_	_	O
2	Asia	_	_	O
3	-	_	_	O
4	Pacific	_	_	O
5	region	_	_	O
6	and	_	_	O
7	elsewhere	_	_	O
8	,	_	_	O
9	almost	_	_	O
10	85	_	_	O
11	%	_	_	O
12	of	_	_	O
13	patients	_	_	O
14	with	_	_	O
15	hepatocellular	_	_	O
16	carcinoma	_	_	O
17	(	_	_	O
18	HCC	_	_	O
19	)	_	_	O
20	are	_	_	O
21	inoperable	_	_	O
22	at	_	_	O
23	diagnosis	_	_	O
24	and	_	_	O
25	have	_	_	O
26	a	_	_	O
27	dismal	_	_	O
28	prognosis	_	_	O
29	.	_	_	O

30	Tamoxifen	_	_	B-Claim
31	(	_	_	I-Claim
32	TMX	_	_	I-Claim
33	)	_	_	I-Claim
34	is	_	_	I-Claim
35	believed	_	_	I-Claim
36	to	_	_	I-Claim
37	inhibit	_	_	I-Claim
38	HCC	_	_	I-Claim
39	positive	_	_	I-Claim
40	for	_	_	I-Claim
41	estrogen	_	_	I-Claim
42	receptor	_	_	I-Claim
43	(	_	_	I-Claim
44	ER	_	_	I-Claim
45	)	_	_	I-Claim
46	,	_	_	I-Claim
47	but	_	_	I-Claim
48	most	_	_	I-Claim
49	HCCs	_	_	I-Claim
50	are	_	_	I-Claim
51	ER	_	_	I-Claim
52	negative	_	_	I-Claim
53	.	_	_	I-Claim

54	Results	_	_	B-Claim
55	of	_	_	I-Claim
56	previous	_	_	I-Claim
57	phase	_	_	I-Claim
58	3	_	_	I-Claim
59	trials	_	_	I-Claim
60	in	_	_	I-Claim
61	inoperable	_	_	I-Claim
62	HCC	_	_	I-Claim
63	have	_	_	I-Claim
64	been	_	_	I-Claim
65	conflicting	_	_	I-Claim
66	and	_	_	I-Claim
67	inconclusive	_	_	I-Claim
68	.	_	_	I-Claim

69	At	_	_	B-Claim
70	higher	_	_	I-Claim
71	doses	_	_	I-Claim
72	,	_	_	I-Claim
73	however	_	_	I-Claim
74	,	_	_	I-Claim
75	TMX	_	_	I-Claim
76	inhibits	_	_	I-Claim
77	HCC	_	_	I-Claim
78	through	_	_	I-Claim
79	ER	_	_	I-Claim
80	-	_	_	I-Claim
81	independent	_	_	I-Claim
82	mechanisms	_	_	I-Claim
83	.	_	_	I-Claim

84	A	_	_	O
85	multicenter	_	_	O
86	randomized	_	_	O
87	controlled	_	_	O
88	trial	_	_	O
89	was	_	_	O
90	performed	_	_	O
91	to	_	_	O
92	assess	_	_	O
93	the	_	_	O
94	role	_	_	O
95	of	_	_	O
96	high	_	_	O
97	-	_	_	O
98	dose	_	_	O
99	TMX	_	_	O
100	versus	_	_	O
101	placebo	_	_	O
102	(	_	_	O
103	P	_	_	O
104	)	_	_	O
105	in	_	_	O
106	the	_	_	O
107	treatment	_	_	O
108	of	_	_	O
109	patients	_	_	O
110	with	_	_	O
111	inoperable	_	_	O
112	HCC	_	_	O
113	with	_	_	O
114	respect	_	_	O
115	to	_	_	O
116	survival	_	_	O
117	and	_	_	O
118	quality	_	_	O
119	of	_	_	O
120	life	_	_	O
121	(	_	_	O
122	QoL	_	_	O
123	)	_	_	O
124	.	_	_	O

125	A	_	_	O
126	total	_	_	O
127	of	_	_	O
128	329	_	_	O
129	patients	_	_	O
130	from	_	_	O
131	10	_	_	O
132	centers	_	_	O
133	in	_	_	O
134	9	_	_	O
135	countries	_	_	O
136	in	_	_	O
137	the	_	_	O
138	Asia	_	_	O
139	-	_	_	O
140	Pacific	_	_	O
141	region	_	_	O
142	enrolled	_	_	O
143	in	_	_	O
144	a	_	_	O
145	double	_	_	O
146	-	_	_	O
147	blind	_	_	O
148	randomized	_	_	O
149	controlled	_	_	O
150	trial	_	_	O
151	of	_	_	O
152	TMX	_	_	O
153	120	_	_	O
154	mg	_	_	O
155	/	_	_	O
156	d	_	_	O
157	(	_	_	O
158	TMX120	_	_	O
159	)	_	_	O
160	against	_	_	O
161	P	_	_	O
162	as	_	_	O
163	a	_	_	O
164	control	_	_	O
165	arm	_	_	O
166	with	_	_	O
167	an	_	_	O
168	intermediate	_	_	O
169	dosage	_	_	O
170	of	_	_	O
171	TMX	_	_	O
172	60	_	_	O
173	mg	_	_	O
174	/	_	_	O
175	d	_	_	O
176	(	_	_	O
177	TMX60	_	_	O
178	)	_	_	O
179	to	_	_	O
180	assess	_	_	O
181	possible	_	_	O
182	dose	_	_	O
183	response	_	_	O
184	.	_	_	O

185	An	_	_	O
186	independent	_	_	O
187	data	_	_	O
188	monitoring	_	_	O
189	committee	_	_	O
190	reviewed	_	_	O
191	all	_	_	O
192	aspects	_	_	O
193	of	_	_	O
194	the	_	_	O
195	trial	_	_	O
196	.	_	_	O

197	QoL	_	_	O
198	was	_	_	O
199	assessed	_	_	O
200	using	_	_	O
201	the	_	_	O
202	European	_	_	O
203	Organization	_	_	O
204	for	_	_	O
205	Research	_	_	O
206	and	_	_	O
207	Treatment	_	_	O
208	of	_	_	O
209	Cancer	_	_	O
210	QLQ	_	_	O
211	-	_	_	O
212	C30	_	_	O
213	questionnaire	_	_	O
214	.	_	_	O

215	Three	_	_	B-Premise
216	-	_	_	I-Premise
217	month	_	_	I-Premise
218	survival	_	_	I-Premise
219	rates	_	_	I-Premise
220	for	_	_	I-Premise
221	the	_	_	I-Premise
222	P	_	_	I-Premise
223	,	_	_	I-Premise
224	TMX60	_	_	I-Premise
225	,	_	_	I-Premise
226	and	_	_	I-Premise
227	TMX120	_	_	I-Premise
228	groups	_	_	I-Premise
229	were	_	_	I-Premise
230	44	_	_	I-Premise
231	%	_	_	I-Premise
232	,	_	_	I-Premise
233	41	_	_	I-Premise
234	%	_	_	I-Premise
235	,	_	_	I-Premise
236	and	_	_	I-Premise
237	35	_	_	I-Premise
238	%	_	_	I-Premise
239	,	_	_	I-Premise
240	respectively	_	_	I-Premise
241	,	_	_	I-Premise
242	with	_	_	I-Premise
243	a	_	_	I-Premise
244	statistically	_	_	I-Premise
245	significant	_	_	I-Premise
246	trend	_	_	I-Premise
247	difference	_	_	I-Premise
248	in	_	_	I-Premise
249	survival	_	_	I-Premise
250	across	_	_	I-Premise
251	the	_	_	I-Premise
252	3	_	_	I-Premise
253	treatment	_	_	I-Premise
254	regimens	_	_	I-Premise
255	(	_	_	I-Premise
256	P	_	_	I-Premise
257	=	_	_	I-Premise
258	.	_	_	I-Premise

259	011	_	_	I-Premise
260	)	_	_	I-Premise
261	.	_	_	I-Premise

262	There	_	_	B-Premise
263	was	_	_	I-Premise
264	a	_	_	I-Premise
265	significantly	_	_	I-Premise
266	higher	_	_	I-Premise
267	risk	_	_	I-Premise
268	of	_	_	I-Premise
269	death	_	_	I-Premise
270	in	_	_	I-Premise
271	the	_	_	I-Premise
272	TMX120	_	_	I-Premise
273	group	_	_	I-Premise
274	compared	_	_	I-Premise
275	with	_	_	I-Premise
276	the	_	_	I-Premise
277	P	_	_	I-Premise
278	group	_	_	I-Premise
279	(	_	_	I-Premise
280	hazard	_	_	I-Premise
281	ratio	_	_	I-Premise
282	,	_	_	I-Premise
283	1	_	_	I-Premise
284	.	_	_	I-Premise

285	39	_	_	I-Premise
286	;	_	_	I-Premise
287	95	_	_	I-Premise
288	%	_	_	I-Premise
289	confidence	_	_	I-Premise
290	interval	_	_	I-Premise
291	,	_	_	I-Premise
292	1	_	_	I-Premise
293	.	_	_	I-Premise

294	07	_	_	I-Premise
295	-	_	_	I-Premise
296	1	_	_	I-Premise
297	.	_	_	I-Premise

298	81	_	_	I-Premise
299	)	_	_	I-Premise
300	.	_	_	I-Premise

301	Adverse	_	_	B-Premise
302	drug	_	_	I-Premise
303	reactions	_	_	I-Premise
304	were	_	_	I-Premise
305	reported	_	_	I-Premise
306	in	_	_	I-Premise
307	3	_	_	I-Premise
308	%	_	_	I-Premise
309	(	_	_	I-Premise
310	9	_	_	I-Premise
311	patients	_	_	I-Premise
312	)	_	_	I-Premise
313	,	_	_	I-Premise
314	and	_	_	O
315	8	_	_	B-Premise
316	patients	_	_	I-Premise
317	were	_	_	I-Premise
318	lost	_	_	I-Premise
319	to	_	_	I-Premise
320	follow	_	_	I-Premise
321	-	_	_	I-Premise
322	up	_	_	I-Premise
323	.	_	_	I-Premise

324	In	_	_	O
325	conclusion	_	_	O
326	,	_	_	O
327	TMX	_	_	B-Claim
328	does	_	_	I-Claim
329	not	_	_	I-Claim
330	prolong	_	_	I-Claim
331	survival	_	_	I-Claim
332	in	_	_	I-Claim
333	patients	_	_	I-Claim
334	with	_	_	I-Claim
335	inoperable	_	_	I-Claim
336	HCC	_	_	I-Claim
337	and	_	_	I-Claim
338	has	_	_	I-Claim
339	an	_	_	I-Claim
340	increasingly	_	_	I-Claim
341	negative	_	_	I-Claim
342	impact	_	_	I-Claim
343	with	_	_	I-Claim
344	increasing	_	_	I-Claim
345	dose	_	_	I-Claim
346	.	_	_	I-Claim

347	No	_	_	B-Claim
348	appreciable	_	_	I-Claim
349	advantage	_	_	I-Claim
350	to	_	_	I-Claim
351	QoL	_	_	I-Claim
352	with	_	_	I-Claim
353	TMX	_	_	I-Claim
354	was	_	_	I-Claim
355	observed	_	_	I-Claim
356	.	_	_	I-Claim


0	Lung	_	_	O
1	cancer	_	_	O
2	is	_	_	O
3	one	_	_	O
4	of	_	_	O
5	the	_	_	O
6	most	_	_	O
7	common	_	_	O
8	cancers	_	_	O
9	in	_	_	O
10	the	_	_	O
11	United	_	_	O
12	States	_	_	O
13	and	_	_	O
14	is	_	_	O
15	associated	_	_	O
16	with	_	_	O
17	high	_	_	O
18	levels	_	_	O
19	of	_	_	O
20	symptoms	_	_	O
21	,	_	_	O
22	including	_	_	O
23	pain	_	_	O
24	,	_	_	O
25	fatigue	_	_	O
26	,	_	_	O
27	shortness	_	_	O
28	of	_	_	O
29	breath	_	_	O
30	,	_	_	O
31	and	_	_	O
32	psychological	_	_	O
33	distress	_	_	O
34	.	_	_	O

35	Caregivers	_	_	O
36	and	_	_	O
37	patients	_	_	O
38	are	_	_	O
39	adversely	_	_	O
40	affected	_	_	O
41	.	_	_	O

42	However	_	_	O
43	,	_	_	O
44	previous	_	_	O
45	studies	_	_	O
46	of	_	_	O
47	coping	_	_	O
48	skills	_	_	O
49	training	_	_	O
50	(	_	_	O
51	CST	_	_	O
52	)	_	_	O
53	interventions	_	_	O
54	have	_	_	O
55	not	_	_	O
56	been	_	_	O
57	tested	_	_	O
58	in	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	lung	_	_	O
62	cancer	_	_	O
63	nor	_	_	O
64	have	_	_	O
65	systematically	_	_	O
66	included	_	_	O
67	caregivers	_	_	O
68	.	_	_	O

69	This	_	_	O
70	study	_	_	O
71	tested	_	_	O
72	the	_	_	O
73	efficacy	_	_	O
74	of	_	_	O
75	a	_	_	O
76	caregiver	_	_	O
77	-	_	_	O
78	assisted	_	_	O
79	CST	_	_	O
80	protocol	_	_	O
81	in	_	_	O
82	a	_	_	O
83	sample	_	_	O
84	of	_	_	O
85	patients	_	_	O
86	with	_	_	O
87	lung	_	_	O
88	cancer	_	_	O
89	.	_	_	O

90	Two	_	_	O
91	hundred	_	_	O
92	thirty	_	_	O
93	-	_	_	O
94	three	_	_	O
95	lung	_	_	O
96	cancer	_	_	O
97	patients	_	_	O
98	and	_	_	O
99	their	_	_	O
100	caregivers	_	_	O
101	were	_	_	O
102	randomly	_	_	O
103	assigned	_	_	O
104	to	_	_	O
105	receive	_	_	O
106	14	_	_	O
107	telephone	_	_	O
108	-	_	_	O
109	based	_	_	O
110	sessions	_	_	O
111	of	_	_	O
112	either	_	_	O
113	caregiver	_	_	O
114	-	_	_	O
115	assisted	_	_	O
116	CST	_	_	O
117	or	_	_	O
118	education	_	_	O
119	/	_	_	O
120	support	_	_	O
121	involving	_	_	O
122	the	_	_	O
123	caregiver	_	_	O
124	.	_	_	O

125	Patients	_	_	O
126	completed	_	_	O
127	measures	_	_	O
128	assessing	_	_	O
129	pain	_	_	O
130	,	_	_	O
131	psychological	_	_	O
132	distress	_	_	O
133	,	_	_	O
134	quality	_	_	O
135	of	_	_	O
136	life	_	_	O
137	(	_	_	O
138	QOL	_	_	O
139	)	_	_	O
140	,	_	_	O
141	and	_	_	O
142	self	_	_	O
143	-	_	_	O
144	efficacy	_	_	O
145	for	_	_	O
146	symptom	_	_	O
147	management	_	_	O
148	;	_	_	O
149	caregivers	_	_	O
150	completed	_	_	O
151	measures	_	_	O
152	assessing	_	_	O
153	psychological	_	_	O
154	distress	_	_	O
155	,	_	_	O
156	caregiver	_	_	O
157	strain	_	_	O
158	,	_	_	O
159	and	_	_	O
160	self	_	_	O
161	-	_	_	O
162	efficacy	_	_	O
163	for	_	_	O
164	helping	_	_	O
165	the	_	_	O
166	patient	_	_	O
167	manage	_	_	O
168	symptoms	_	_	O
169	.	_	_	O

170	Patients	_	_	B-Premise
171	in	_	_	I-Premise
172	both	_	_	I-Premise
173	treatment	_	_	I-Premise
174	conditions	_	_	I-Premise
175	showed	_	_	I-Premise
176	improvements	_	_	I-Premise
177	in	_	_	I-Premise
178	pain	_	_	I-Premise
179	,	_	_	I-Premise
180	depression	_	_	I-Premise
181	,	_	_	I-Premise
182	QOL	_	_	I-Premise
183	,	_	_	I-Premise
184	and	_	_	I-Premise
185	self	_	_	I-Premise
186	-	_	_	I-Premise
187	efficacy	_	_	I-Premise
188	,	_	_	I-Premise
189	and	_	_	I-Premise
190	caregivers	_	_	I-Premise
191	in	_	_	I-Premise
192	both	_	_	I-Premise
193	conditions	_	_	I-Premise
194	showed	_	_	I-Premise
195	improvements	_	_	I-Premise
196	in	_	_	I-Premise
197	anxiety	_	_	I-Premise
198	and	_	_	I-Premise
199	self	_	_	I-Premise
200	-	_	_	I-Premise
201	efficacy	_	_	I-Premise
202	from	_	_	I-Premise
203	baseline	_	_	I-Premise
204	to	_	_	I-Premise
205	four	_	_	I-Premise
206	-	_	_	I-Premise
207	month	_	_	I-Premise
208	follow	_	_	I-Premise
209	-	_	_	I-Premise
210	up	_	_	I-Premise
211	.	_	_	I-Premise

212	Results	_	_	B-Premise
213	of	_	_	I-Premise
214	exploratory	_	_	I-Premise
215	analyses	_	_	I-Premise
216	suggested	_	_	I-Premise
217	that	_	_	I-Premise
218	the	_	_	I-Premise
219	CST	_	_	I-Premise
220	intervention	_	_	I-Premise
221	was	_	_	I-Premise
222	more	_	_	I-Premise
223	beneficial	_	_	I-Premise
224	to	_	_	I-Premise
225	patients	_	_	I-Premise
226	/	_	_	I-Premise
227	caregivers	_	_	I-Premise
228	with	_	_	I-Premise
229	Stage	_	_	I-Premise
230	II	_	_	I-Premise
231	and	_	_	I-Premise
232	III	_	_	I-Premise
233	cancers	_	_	I-Premise
234	,	_	_	I-Premise
235	whereas	_	_	O
236	the	_	_	B-Premise
237	education	_	_	I-Premise
238	/	_	_	I-Premise
239	support	_	_	I-Premise
240	intervention	_	_	I-Premise
241	was	_	_	I-Premise
242	more	_	_	I-Premise
243	beneficial	_	_	I-Premise
244	to	_	_	I-Premise
245	patients	_	_	I-Premise
246	/	_	_	I-Premise
247	caregivers	_	_	I-Premise
248	with	_	_	I-Premise
249	Stage	_	_	I-Premise
250	I	_	_	I-Premise
251	cancer	_	_	I-Premise
252	.	_	_	I-Premise

253	Taken	_	_	B-Premise
254	together	_	_	I-Premise
255	with	_	_	I-Premise
256	the	_	_	I-Premise
257	broader	_	_	I-Premise
258	literature	_	_	I-Premise
259	in	_	_	I-Premise
260	this	_	_	I-Premise
261	area	_	_	I-Premise
262	,	_	_	I-Premise
263	results	_	_	B-Claim
264	from	_	_	I-Claim
265	this	_	_	I-Claim
266	study	_	_	I-Claim
267	suggest	_	_	I-Claim
268	that	_	_	I-Claim
269	psychosocial	_	_	I-Claim
270	interventions	_	_	I-Claim
271	can	_	_	I-Claim
272	lead	_	_	I-Claim
273	to	_	_	I-Claim
274	improvements	_	_	I-Claim
275	in	_	_	I-Claim
276	a	_	_	I-Claim
277	range	_	_	I-Claim
278	of	_	_	I-Claim
279	outcomes	_	_	I-Claim
280	for	_	_	I-Claim
281	cancer	_	_	I-Claim
282	patients	_	_	I-Claim
283	.	_	_	I-Claim

284	Suggestions	_	_	O
285	for	_	_	O
286	future	_	_	O
287	studies	_	_	O
288	include	_	_	O
289	the	_	_	O
290	use	_	_	O
291	of	_	_	O
292	three	_	_	O
293	-	_	_	O
294	group	_	_	O
295	designs	_	_	O
296	(	_	_	O
297	e	_	_	O
298	.	_	_	O

299	g	_	_	O
300	.	_	_	O

301	,	_	_	O
302	comparing	_	_	O
303	two	_	_	O
304	active	_	_	O
305	interventions	_	_	O
306	with	_	_	O
307	a	_	_	O
308	standard	_	_	O
309	-	_	_	O
310	care	_	_	O
311	control	_	_	O
312	)	_	_	O
313	and	_	_	O
314	examining	_	_	O
315	mechanisms	_	_	O
316	of	_	_	O
317	change	_	_	O
318	.	_	_	O


0	The	_	_	O
1	finding	_	_	O
2	of	_	_	O
3	a	_	_	O
4	decrease	_	_	O
5	in	_	_	O
6	contralateral	_	_	O
7	breast	_	_	O
8	cancer	_	_	O
9	incidence	_	_	O
10	following	_	_	O
11	tamoxifen	_	_	O
12	administration	_	_	O
13	for	_	_	O
14	adjuvant	_	_	O
15	therapy	_	_	O
16	led	_	_	O
17	to	_	_	O
18	the	_	_	O
19	concept	_	_	O
20	that	_	_	O
21	the	_	_	O
22	drug	_	_	O
23	might	_	_	O
24	play	_	_	O
25	a	_	_	O
26	role	_	_	O
27	in	_	_	O
28	breast	_	_	O
29	cancer	_	_	O
30	prevention	_	_	O
31	.	_	_	O

32	To	_	_	O
33	test	_	_	O
34	this	_	_	O
35	hypothesis	_	_	O
36	,	_	_	O
37	the	_	_	O
38	National	_	_	O
39	Surgical	_	_	O
40	Adjuvant	_	_	O
41	Breast	_	_	O
42	and	_	_	O
43	Bowel	_	_	O
44	Project	_	_	O
45	initiated	_	_	O
46	the	_	_	O
47	Breast	_	_	O
48	Cancer	_	_	O
49	Prevention	_	_	O
50	Trial	_	_	O
51	(	_	_	O
52	P	_	_	O
53	-	_	_	O
54	1	_	_	O
55	)	_	_	O
56	in	_	_	O
57	1992	_	_	O
58	.	_	_	O

59	Women	_	_	O
60	(	_	_	O
61	N	_	_	O
62	=	_	_	O
63	13388	_	_	O
64	)	_	_	O
65	at	_	_	O
66	increased	_	_	O
67	risk	_	_	O
68	for	_	_	O
69	breast	_	_	O
70	cancer	_	_	O
71	because	_	_	O
72	they	_	_	O
73	1	_	_	O
74	)	_	_	O
75	were	_	_	O
76	60	_	_	O
77	years	_	_	O
78	of	_	_	O
79	age	_	_	O
80	or	_	_	O
81	older	_	_	O
82	,	_	_	O
83	2	_	_	O
84	)	_	_	O
85	were	_	_	O
86	35	_	_	O
87	-	_	_	O
88	59	_	_	O
89	years	_	_	O
90	of	_	_	O
91	age	_	_	O
92	with	_	_	O
93	a	_	_	O
94	5	_	_	O
95	-	_	_	O
96	year	_	_	O
97	predicted	_	_	O
98	risk	_	_	O
99	for	_	_	O
100	breast	_	_	O
101	cancer	_	_	O
102	of	_	_	O
103	at	_	_	O
104	least	_	_	O
105	1	_	_	O
106	.	_	_	O

107	66	_	_	O
108	%	_	_	O
109	,	_	_	O
110	or	_	_	O
111	3	_	_	O
112	)	_	_	O
113	had	_	_	O
114	a	_	_	O
115	history	_	_	O
116	of	_	_	O
117	lobular	_	_	O
118	carcinoma	_	_	O
119	in	_	_	O
120	situ	_	_	O
121	were	_	_	O
122	randomly	_	_	O
123	assigned	_	_	O
124	to	_	_	O
125	receive	_	_	O
126	placebo	_	_	O
127	(	_	_	O
128	n	_	_	O
129	=	_	_	O
130	6707	_	_	O
131	)	_	_	O
132	or	_	_	O
133	20	_	_	O
134	mg	_	_	O
135	/	_	_	O
136	day	_	_	O
137	tamoxifen	_	_	O
138	(	_	_	O
139	n	_	_	O
140	=	_	_	O
141	6681	_	_	O
142	)	_	_	O
143	for	_	_	O
144	5	_	_	O
145	years	_	_	O
146	.	_	_	O

147	Gail	_	_	O
148	'	_	_	O
149	s	_	_	O
150	algorithm	_	_	O
151	,	_	_	O
152	based	_	_	O
153	on	_	_	O
154	a	_	_	O
155	multivariate	_	_	O
156	logistic	_	_	O
157	regression	_	_	O
158	model	_	_	O
159	using	_	_	O
160	combinations	_	_	O
161	of	_	_	O
162	risk	_	_	O
163	factors	_	_	O
164	,	_	_	O
165	was	_	_	O
166	used	_	_	O
167	to	_	_	O
168	estimate	_	_	O
169	the	_	_	O
170	probability	_	_	O
171	(	_	_	O
172	risk	_	_	O
173	)	_	_	O
174	of	_	_	O
175	occurrence	_	_	O
176	of	_	_	O
177	breast	_	_	O
178	cancer	_	_	O
179	over	_	_	O
180	time	_	_	O
181	.	_	_	O

182	Tamoxifen	_	_	B-Premise
183	reduced	_	_	I-Premise
184	the	_	_	I-Premise
185	risk	_	_	I-Premise
186	of	_	_	I-Premise
187	invasive	_	_	I-Premise
188	breast	_	_	I-Premise
189	cancer	_	_	I-Premise
190	by	_	_	I-Premise
191	49	_	_	I-Premise
192	%	_	_	I-Premise
193	(	_	_	I-Premise
194	two	_	_	I-Premise
195	-	_	_	I-Premise
196	sided	_	_	I-Premise
197	P	_	_	I-Premise
198	<	_	_	I-Premise
199	.	_	_	I-Premise

200	00001	_	_	I-Premise
201	)	_	_	I-Premise
202	,	_	_	I-Premise
203	with	_	_	I-Premise
204	cumulative	_	_	I-Premise
205	incidence	_	_	I-Premise
206	through	_	_	I-Premise
207	69	_	_	I-Premise
208	months	_	_	I-Premise
209	of	_	_	I-Premise
210	follow	_	_	I-Premise
211	-	_	_	I-Premise
212	up	_	_	I-Premise
213	of	_	_	I-Premise
214	43	_	_	I-Premise
215	.	_	_	I-Premise

216	4	_	_	I-Premise
217	versus	_	_	I-Premise
218	22	_	_	I-Premise
219	.	_	_	I-Premise

220	0	_	_	I-Premise
221	per	_	_	I-Premise
222	1000	_	_	I-Premise
223	women	_	_	I-Premise
224	in	_	_	I-Premise
225	the	_	_	I-Premise
226	placebo	_	_	I-Premise
227	and	_	_	I-Premise
228	tamoxifen	_	_	I-Premise
229	groups	_	_	I-Premise
230	,	_	_	I-Premise
231	respectively	_	_	I-Premise
232	.	_	_	I-Premise

233	The	_	_	O
234	decreased	_	_	O
235	risk	_	_	O
236	occurred	_	_	O
237	in	_	_	O
238	women	_	_	O
239	aged	_	_	O
240	49	_	_	O
241	years	_	_	O
242	or	_	_	O
243	younger	_	_	O
244	(	_	_	O
245	44	_	_	O
246	%	_	_	O
247	)	_	_	O
248	,	_	_	O
249	50	_	_	O
250	-	_	_	O
251	59	_	_	O
252	years	_	_	O
253	(	_	_	O
254	51	_	_	O
255	%	_	_	O
256	)	_	_	O
257	,	_	_	O
258	and	_	_	O
259	60	_	_	O
260	years	_	_	O
261	or	_	_	O
262	older	_	_	O
263	(	_	_	O
264	55	_	_	O
265	%	_	_	O
266	)	_	_	O
267	;	_	_	O
268	risk	_	_	B-Premise
269	was	_	_	I-Premise
270	also	_	_	I-Premise
271	reduced	_	_	I-Premise
272	in	_	_	I-Premise
273	women	_	_	I-Premise
274	with	_	_	I-Premise
275	a	_	_	I-Premise
276	history	_	_	I-Premise
277	of	_	_	I-Premise
278	lobular	_	_	I-Premise
279	carcinoma	_	_	I-Premise
280	in	_	_	I-Premise
281	situ	_	_	I-Premise
282	(	_	_	I-Premise
283	56	_	_	I-Premise
284	%	_	_	I-Premise
285	)	_	_	I-Premise
286	or	_	_	I-Premise
287	atypical	_	_	I-Premise
288	hyperplasia	_	_	I-Premise
289	(	_	_	I-Premise
290	86	_	_	I-Premise
291	%	_	_	I-Premise
292	)	_	_	I-Premise
293	and	_	_	I-Premise
294	in	_	_	I-Premise
295	those	_	_	I-Premise
296	with	_	_	I-Premise
297	any	_	_	I-Premise
298	category	_	_	I-Premise
299	of	_	_	I-Premise
300	predicted	_	_	I-Premise
301	5	_	_	I-Premise
302	-	_	_	I-Premise
303	year	_	_	I-Premise
304	risk	_	_	I-Premise
305	.	_	_	I-Premise

306	Tamoxifen	_	_	B-Premise
307	reduced	_	_	I-Premise
308	the	_	_	I-Premise
309	risk	_	_	I-Premise
310	of	_	_	I-Premise
311	noninvasive	_	_	I-Premise
312	breast	_	_	I-Premise
313	cancer	_	_	I-Premise
314	by	_	_	I-Premise
315	50	_	_	I-Premise
316	%	_	_	I-Premise
317	(	_	_	I-Premise
318	two	_	_	I-Premise
319	-	_	_	I-Premise
320	sided	_	_	I-Premise
321	P	_	_	I-Premise
322	<	_	_	I-Premise
323	.	_	_	I-Premise

324	002	_	_	I-Premise
325	)	_	_	I-Premise
326	.	_	_	I-Premise

327	Tamoxifen	_	_	B-Premise
328	reduced	_	_	I-Premise
329	the	_	_	I-Premise
330	occurrence	_	_	I-Premise
331	of	_	_	I-Premise
332	estrogen	_	_	I-Premise
333	receptor	_	_	I-Premise
334	-	_	_	I-Premise
335	positive	_	_	I-Premise
336	tumors	_	_	I-Premise
337	by	_	_	I-Premise
338	69	_	_	I-Premise
339	%	_	_	I-Premise
340	,	_	_	I-Premise
341	but	_	_	I-Premise
342	no	_	_	I-Premise
343	difference	_	_	I-Premise
344	in	_	_	I-Premise
345	the	_	_	I-Premise
346	occurrence	_	_	I-Premise
347	of	_	_	I-Premise
348	estrogen	_	_	I-Premise
349	receptor	_	_	I-Premise
350	-	_	_	I-Premise
351	negative	_	_	I-Premise
352	tumors	_	_	I-Premise
353	was	_	_	I-Premise
354	seen	_	_	I-Premise
355	.	_	_	I-Premise

356	Tamoxifen	_	_	B-Premise
357	administration	_	_	I-Premise
358	did	_	_	I-Premise
359	not	_	_	I-Premise
360	alter	_	_	I-Premise
361	the	_	_	I-Premise
362	average	_	_	I-Premise
363	annual	_	_	I-Premise
364	rate	_	_	I-Premise
365	of	_	_	I-Premise
366	ischemic	_	_	I-Premise
367	heart	_	_	I-Premise
368	disease	_	_	I-Premise
369	;	_	_	I-Premise
370	however	_	_	I-Premise
371	,	_	_	I-Premise
372	a	_	_	I-Premise
373	reduction	_	_	I-Premise
374	in	_	_	I-Premise
375	hip	_	_	I-Premise
376	,	_	_	I-Premise
377	radius	_	_	I-Premise
378	(	_	_	I-Premise
379	Colles	_	_	I-Premise
380	'	_	_	I-Premise
381	)	_	_	I-Premise
382	,	_	_	I-Premise
383	and	_	_	I-Premise
384	spine	_	_	I-Premise
385	fractures	_	_	I-Premise
386	was	_	_	I-Premise
387	observed	_	_	I-Premise
388	.	_	_	I-Premise

389	The	_	_	B-Premise
390	rate	_	_	I-Premise
391	of	_	_	I-Premise
392	endometrial	_	_	I-Premise
393	cancer	_	_	I-Premise
394	was	_	_	I-Premise
395	increased	_	_	I-Premise
396	in	_	_	I-Premise
397	the	_	_	I-Premise
398	tamoxifen	_	_	I-Premise
399	group	_	_	I-Premise
400	(	_	_	I-Premise
401	risk	_	_	I-Premise
402	ratio	_	_	I-Premise
403	=	_	_	I-Premise
404	2	_	_	I-Premise
405	.	_	_	I-Premise

406	53	_	_	I-Premise
407	;	_	_	I-Premise
408	95	_	_	I-Premise
409	%	_	_	I-Premise
410	confidence	_	_	I-Premise
411	interval	_	_	I-Premise
412	=	_	_	I-Premise
413	1	_	_	I-Premise
414	.	_	_	I-Premise

415	35	_	_	I-Premise
416	-	_	_	I-Premise
417	4	_	_	I-Premise
418	.	_	_	I-Premise

419	97	_	_	I-Premise
420	)	_	_	I-Premise
421	;	_	_	I-Premise
422	this	_	_	I-Premise
423	increased	_	_	I-Premise
424	risk	_	_	I-Premise
425	occurred	_	_	I-Premise
426	predominantly	_	_	I-Premise
427	in	_	_	I-Premise
428	women	_	_	I-Premise
429	aged	_	_	I-Premise
430	50	_	_	I-Premise
431	years	_	_	I-Premise
432	or	_	_	I-Premise
433	older	_	_	I-Premise
434	.	_	_	I-Premise

435	All	_	_	O
436	endometrial	_	_	O
437	cancers	_	_	O
438	in	_	_	O
439	the	_	_	O
440	tamoxifen	_	_	O
441	group	_	_	O
442	were	_	_	O
443	stage	_	_	O
444	I	_	_	O
445	(	_	_	O
446	localized	_	_	O
447	disease	_	_	O
448	)	_	_	O
449	;	_	_	O
450	no	_	_	B-Premise
451	endometrial	_	_	I-Premise
452	cancer	_	_	I-Premise
453	deaths	_	_	I-Premise
454	have	_	_	I-Premise
455	occurred	_	_	I-Premise
456	in	_	_	I-Premise
457	this	_	_	I-Premise
458	group	_	_	I-Premise
459	.	_	_	I-Premise

460	No	_	_	B-Premise
461	liver	_	_	I-Premise
462	cancers	_	_	I-Premise
463	or	_	_	I-Premise
464	increase	_	_	I-Premise
465	in	_	_	I-Premise
466	colon	_	_	I-Premise
467	,	_	_	I-Premise
468	rectal	_	_	I-Premise
469	,	_	_	I-Premise
470	ovarian	_	_	I-Premise
471	,	_	_	I-Premise
472	or	_	_	I-Premise
473	other	_	_	I-Premise
474	tumors	_	_	I-Premise
475	was	_	_	I-Premise
476	observed	_	_	I-Premise
477	in	_	_	I-Premise
478	the	_	_	I-Premise
479	tamoxifen	_	_	I-Premise
480	group	_	_	I-Premise
481	.	_	_	I-Premise

482	The	_	_	B-Premise
483	rates	_	_	I-Premise
484	of	_	_	I-Premise
485	stroke	_	_	I-Premise
486	,	_	_	I-Premise
487	pulmonary	_	_	I-Premise
488	embolism	_	_	I-Premise
489	,	_	_	I-Premise
490	and	_	_	I-Premise
491	deep	_	_	I-Premise
492	-	_	_	I-Premise
493	vein	_	_	I-Premise
494	thrombosis	_	_	I-Premise
495	were	_	_	I-Premise
496	elevated	_	_	I-Premise
497	in	_	_	I-Premise
498	the	_	_	I-Premise
499	tamoxifen	_	_	I-Premise
500	group	_	_	I-Premise
501	;	_	_	I-Premise
502	these	_	_	I-Premise
503	events	_	_	I-Premise
504	occurred	_	_	I-Premise
505	more	_	_	I-Premise
506	frequently	_	_	I-Premise
507	in	_	_	I-Premise
508	women	_	_	I-Premise
509	aged	_	_	I-Premise
510	50	_	_	I-Premise
511	years	_	_	I-Premise
512	or	_	_	I-Premise
513	older	_	_	I-Premise
514	.	_	_	I-Premise

515	Tamoxifen	_	_	B-Claim
516	decreases	_	_	I-Claim
517	the	_	_	I-Claim
518	incidence	_	_	I-Claim
519	of	_	_	I-Claim
520	invasive	_	_	I-Claim
521	and	_	_	I-Claim
522	noninvasive	_	_	I-Claim
523	breast	_	_	I-Claim
524	cancer	_	_	I-Claim
525	.	_	_	I-Claim

526	Despite	_	_	B-Claim
527	side	_	_	I-Claim
528	effects	_	_	I-Claim
529	resulting	_	_	I-Claim
530	from	_	_	I-Claim
531	administration	_	_	I-Claim
532	of	_	_	I-Claim
533	tamoxifen	_	_	I-Claim
534	,	_	_	I-Claim
535	its	_	_	I-Claim
536	use	_	_	I-Claim
537	as	_	_	I-Claim
538	a	_	_	I-Claim
539	breast	_	_	I-Claim
540	cancer	_	_	I-Claim
541	preventive	_	_	I-Claim
542	agent	_	_	I-Claim
543	is	_	_	I-Claim
544	appropriate	_	_	I-Claim
545	in	_	_	I-Claim
546	many	_	_	I-Claim
547	women	_	_	I-Claim
548	at	_	_	I-Claim
549	increased	_	_	I-Claim
550	risk	_	_	I-Claim
551	for	_	_	I-Claim
552	the	_	_	I-Claim
553	disease	_	_	I-Claim
554	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	a	_	_	O
6	standard	_	_	O
7	anthracycline	_	_	O
8	-	_	_	O
9	based	_	_	O
10	regimen	_	_	O
11	to	_	_	O
12	a	_	_	O
13	dose	_	_	O
14	-	_	_	O
15	intensified	_	_	O
16	anthracycline	_	_	O
17	regimen	_	_	O
18	in	_	_	O
19	locally	_	_	O
20	advanced	_	_	O
21	breast	_	_	O
22	cancer	_	_	O
23	.	_	_	O

24	Locally	_	_	O
25	advanced	_	_	O
26	breast	_	_	O
27	cancer	_	_	O
28	patients	_	_	O
29	were	_	_	O
30	randomly	_	_	O
31	assigned	_	_	O
32	onto	_	_	O
33	a	_	_	O
34	study	_	_	O
35	comparing	_	_	O
36	cyclophosphamide	_	_	O
37	(	_	_	O
38	C	_	_	O
39	;	_	_	O
40	75	_	_	O
41	mg	_	_	O
42	/	_	_	O
43	m	_	_	O
44	(	_	_	O
45	2	_	_	O
46	)	_	_	O
47	orally	_	_	O
48	days	_	_	O
49	1	_	_	O
50	to	_	_	O
51	14	_	_	O
52	)	_	_	O
53	,	_	_	O
54	epirubicin	_	_	O
55	(	_	_	O
56	E	_	_	O
57	;	_	_	O
58	60	_	_	O
59	mg	_	_	O
60	/	_	_	O
61	m	_	_	O
62	(	_	_	O
63	2	_	_	O
64	)	_	_	O
65	intravenously	_	_	O
66	[	_	_	O
67	IV	_	_	O
68	]	_	_	O
69	days	_	_	O
70	1	_	_	O
71	,	_	_	O
72	8	_	_	O
73	)	_	_	O
74	,	_	_	O
75	and	_	_	O
76	fluorouracil	_	_	O
77	(	_	_	O
78	F	_	_	O
79	;	_	_	O
80	500	_	_	O
81	mg	_	_	O
82	/	_	_	O
83	m	_	_	O
84	(	_	_	O
85	2	_	_	O
86	)	_	_	O
87	IV	_	_	O
88	days	_	_	O
89	1	_	_	O
90	,	_	_	O
91	8	_	_	O
92	)	_	_	O
93	six	_	_	O
94	cycles	_	_	O
95	every	_	_	O
96	28	_	_	O
97	days	_	_	O
98	versus	_	_	O
99	E	_	_	O
100	(	_	_	O
101	120	_	_	O
102	mg	_	_	O
103	/	_	_	O
104	m	_	_	O
105	(	_	_	O
106	2	_	_	O
107	)	_	_	O
108	IV	_	_	O
109	day	_	_	O
110	1	_	_	O
111	)	_	_	O
112	,	_	_	O
113	C	_	_	O
114	(	_	_	O
115	830	_	_	O
116	mg	_	_	O
117	/	_	_	O
118	m	_	_	O
119	(	_	_	O
120	2	_	_	O
121	)	_	_	O
122	IV	_	_	O
123	day	_	_	O
124	1	_	_	O
125	)	_	_	O
126	,	_	_	O
127	and	_	_	O
128	granulocyte	_	_	O
129	colony	_	_	O
130	-	_	_	O
131	stimulating	_	_	O
132	factor	_	_	O
133	(	_	_	O
134	filgrastim	_	_	O
135	;	_	_	O
136	5	_	_	O
137	micro	_	_	O
138	g	_	_	O
139	/	_	_	O
140	kg	_	_	O
141	/	_	_	O
142	d	_	_	O
143	subcutaneously	_	_	O
144	days	_	_	O
145	2	_	_	O
146	to	_	_	O
147	13	_	_	O
148	)	_	_	O
149	six	_	_	O
150	cycles	_	_	O
151	every	_	_	O
152	14	_	_	O
153	days	_	_	O
154	.	_	_	O

155	The	_	_	O
156	study	_	_	O
157	was	_	_	O
158	designed	_	_	O
159	to	_	_	O
160	detect	_	_	O
161	a	_	_	O
162	15	_	_	O
163	%	_	_	O
164	improvement	_	_	O
165	;	_	_	O
166	that	_	_	O
167	is	_	_	O
168	,	_	_	O
169	from	_	_	O
170	50	_	_	O
171	%	_	_	O
172	to	_	_	O
173	65	_	_	O
174	%	_	_	O
175	in	_	_	O
176	median	_	_	O
177	progression	_	_	O
178	-	_	_	O
179	free	_	_	O
180	survival	_	_	O
181	(	_	_	O
182	PFS	_	_	O
183	)	_	_	O
184	in	_	_	O
185	favor	_	_	O
186	of	_	_	O
187	the	_	_	O
188	dose	_	_	O
189	-	_	_	O
190	intensified	_	_	O
191	regimen	_	_	O
192	.	_	_	O

193	A	_	_	O
194	total	_	_	O
195	of	_	_	O
196	448	_	_	O
197	patients	_	_	O
198	were	_	_	O
199	enrolled	_	_	O
200	over	_	_	O
201	a	_	_	O
202	period	_	_	O
203	of	_	_	O
204	3	_	_	O
205	years	_	_	O
206	.	_	_	O

207	The	_	_	O
208	median	_	_	O
209	dose	_	_	O
210	intensity	_	_	O
211	delivered	_	_	O
212	for	_	_	O
213	C	_	_	O
214	and	_	_	O
215	E	_	_	O
216	reached	_	_	O
217	,	_	_	O
218	respectively	_	_	O
219	,	_	_	O
220	85	_	_	O
221	%	_	_	O
222	and	_	_	O
223	87	_	_	O
224	%	_	_	O
225	of	_	_	O
226	that	_	_	O
227	planned	_	_	O
228	in	_	_	O
229	the	_	_	O
230	CEF	_	_	O
231	arm	_	_	O
232	and	_	_	O
233	96	_	_	O
234	%	_	_	O
235	and	_	_	O
236	95	_	_	O
237	%	_	_	O
238	of	_	_	O
239	that	_	_	O
240	planned	_	_	O
241	in	_	_	O
242	the	_	_	O
243	EC	_	_	O
244	arm	_	_	O
245	.	_	_	O

246	The	_	_	B-Premise
247	dose	_	_	I-Premise
248	-	_	_	I-Premise
249	intensified	_	_	I-Premise
250	arm	_	_	I-Premise
251	was	_	_	I-Premise
252	slightly	_	_	I-Premise
253	more	_	_	I-Premise
254	emetogenic	_	_	I-Premise
255	and	_	_	I-Premise
256	generated	_	_	I-Premise
257	more	_	_	I-Premise
258	grade	_	_	I-Premise
259	3	_	_	I-Premise
260	to	_	_	I-Premise
261	4	_	_	I-Premise
262	anemia	_	_	I-Premise
263	but	_	_	I-Premise
264	less	_	_	I-Premise
265	febrile	_	_	I-Premise
266	neutropenia	_	_	I-Premise
267	episodes	_	_	I-Premise
268	.	_	_	I-Premise

269	After	_	_	O
270	a	_	_	O
271	median	_	_	O
272	follow	_	_	O
273	-	_	_	O
274	up	_	_	O
275	of	_	_	O
276	5	_	_	O
277	.	_	_	O

278	5	_	_	O
279	years	_	_	O
280	,	_	_	O
281	277	_	_	O
282	events	_	_	O
283	have	_	_	O
284	been	_	_	O
285	reported	_	_	O
286	.	_	_	O

287	The	_	_	B-Premise
288	median	_	_	I-Premise
289	PFS	_	_	I-Premise
290	was	_	_	I-Premise
291	34	_	_	I-Premise
292	and	_	_	I-Premise
293	33	_	_	I-Premise
294	.	_	_	I-Premise

295	7	_	_	I-Premise
296	months	_	_	I-Premise
297	for	_	_	I-Premise
298	CEF	_	_	I-Premise
299	and	_	_	I-Premise
300	EC	_	_	I-Premise
301	,	_	_	I-Premise
302	respectively	_	_	I-Premise
303	(	_	_	I-Premise
304	P	_	_	I-Premise
305	=	_	_	I-Premise
306	.	_	_	I-Premise

307	68	_	_	I-Premise
308	)	_	_	I-Premise
309	,	_	_	I-Premise
310	and	_	_	I-Premise
311	the	_	_	I-Premise
312	5	_	_	I-Premise
313	-	_	_	I-Premise
314	year	_	_	I-Premise
315	survival	_	_	I-Premise
316	rate	_	_	I-Premise
317	was	_	_	I-Premise
318	53	_	_	I-Premise
319	%	_	_	I-Premise
320	and	_	_	I-Premise
321	51	_	_	I-Premise
322	%	_	_	I-Premise
323	for	_	_	I-Premise
324	CEF	_	_	I-Premise
325	and	_	_	I-Premise
326	EC	_	_	I-Premise
327	,	_	_	I-Premise
328	respectively	_	_	I-Premise
329	(	_	_	I-Premise
330	P	_	_	I-Premise
331	=	_	_	I-Premise
332	.	_	_	I-Premise

333	94	_	_	I-Premise
334	)	_	_	I-Premise
335	.	_	_	I-Premise

336	Dose	_	_	B-Claim
337	-	_	_	I-Claim
338	intensified	_	_	I-Claim
339	EC	_	_	I-Claim
340	does	_	_	I-Claim
341	not	_	_	I-Claim
342	provide	_	_	I-Claim
343	a	_	_	I-Claim
344	measurable	_	_	I-Claim
345	therapeutic	_	_	I-Claim
346	benefit	_	_	I-Claim
347	over	_	_	I-Claim
348	CEF	_	_	I-Claim
349	as	_	_	I-Claim
350	neoadjuvant	_	_	I-Claim
351	chemotherapy	_	_	I-Claim
352	for	_	_	I-Claim
353	unselected	_	_	I-Claim
354	locally	_	_	I-Claim
355	advanced	_	_	I-Claim
356	breast	_	_	I-Claim
357	cancer	_	_	I-Claim
358	patients	_	_	I-Claim
359	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	prophylactic	_	_	O
6	swallowing	_	_	O
7	exercises	_	_	O
8	on	_	_	O
9	swallowing	_	_	O
10	function	_	_	O
11	in	_	_	O
12	patients	_	_	O
13	undergoing	_	_	O
14	chemoradiation	_	_	O
15	therapy	_	_	O
16	(	_	_	O
17	CRT	_	_	O
18	)	_	_	O
19	for	_	_	O
20	head	_	_	O
21	and	_	_	O
22	neck	_	_	O
23	cancer	_	_	O
24	.	_	_	O

25	Randomized	_	_	O
26	controlled	_	_	O
27	trial	_	_	O
28	.	_	_	O

29	Tertiary	_	_	O
30	care	_	_	O
31	,	_	_	O
32	academic	_	_	O
33	medical	_	_	O
34	center	_	_	O
35	.	_	_	O

36	Twenty	_	_	O
37	-	_	_	O
38	six	_	_	O
39	patients	_	_	O
40	with	_	_	O
41	head	_	_	O
42	and	_	_	O
43	neck	_	_	O
44	cancer	_	_	O
45	receiving	_	_	O
46	CRT	_	_	O
47	.	_	_	O

48	Patients	_	_	O
49	performed	_	_	O
50	5	_	_	O
51	targeted	_	_	O
52	swallowing	_	_	O
53	exercises	_	_	O
54	throughout	_	_	O
55	their	_	_	O
56	CRT	_	_	O
57	and	_	_	O
58	participated	_	_	O
59	in	_	_	O
60	weekly	_	_	O
61	swallowing	_	_	O
62	therapy	_	_	O
63	sessions	_	_	O
64	to	_	_	O
65	promote	_	_	O
66	adherence	_	_	O
67	and	_	_	O
68	accurate	_	_	O
69	technique	_	_	O
70	.	_	_	O

71	Controls	_	_	O
72	had	_	_	O
73	no	_	_	O
74	prophylactic	_	_	O
75	exercises	_	_	O
76	and	_	_	O
77	were	_	_	O
78	referred	_	_	O
79	for	_	_	O
80	swallowing	_	_	O
81	treatment	_	_	O
82	after	_	_	O
83	completion	_	_	O
84	of	_	_	O
85	CRT	_	_	O
86	if	_	_	O
87	indicated	_	_	O
88	.	_	_	O

89	Swallowing	_	_	O
90	function	_	_	O
91	was	_	_	O
92	assessed	_	_	O
93	with	_	_	O
94	the	_	_	O
95	Functional	_	_	O
96	Oral	_	_	O
97	Intake	_	_	O
98	Scale	_	_	O
99	(	_	_	O
100	FOIS	_	_	O
101	)	_	_	O
102	and	_	_	O
103	the	_	_	O
104	Performance	_	_	O
105	Status	_	_	O
106	Scale	_	_	O
107	for	_	_	O
108	Head	_	_	O
109	and	_	_	O
110	Neck	_	_	O
111	Cancer	_	_	O
112	Patients	_	_	O
113	(	_	_	O
114	PSS	_	_	O
115	-	_	_	O
116	H	_	_	O
117	&	_	_	O
118	N	_	_	O
119	)	_	_	O
120	at	_	_	O
121	baseline	_	_	O
122	,	_	_	O
123	immediately	_	_	O
124	after	_	_	O
125	CRT	_	_	O
126	,	_	_	O
127	and	_	_	O
128	at	_	_	O
129	3	_	_	O
130	,	_	_	O
131	6	_	_	O
132	,	_	_	O
133	9	_	_	O
134	,	_	_	O
135	and	_	_	O
136	12	_	_	O
137	months	_	_	O
138	after	_	_	O
139	CRT	_	_	O
140	.	_	_	O

141	There	_	_	B-Premise
142	were	_	_	I-Premise
143	no	_	_	I-Premise
144	statistically	_	_	I-Premise
145	significant	_	_	I-Premise
146	differences	_	_	I-Premise
147	in	_	_	I-Premise
148	FOIS	_	_	I-Premise
149	scores	_	_	I-Premise
150	between	_	_	I-Premise
151	intervention	_	_	I-Premise
152	and	_	_	I-Premise
153	control	_	_	I-Premise
154	patients	_	_	I-Premise
155	immediately	_	_	I-Premise
156	after	_	_	I-Premise
157	CRT	_	_	I-Premise
158	(	_	_	I-Premise
159	immediately	_	_	I-Premise
160	after	_	_	I-Premise
161	CRT	_	_	I-Premise
162	:	_	_	I-Premise
163	intervention	_	_	I-Premise
164	group	_	_	I-Premise
165	median	_	_	I-Premise
166	score	_	_	I-Premise
167	,	_	_	I-Premise
168	3	_	_	I-Premise
169	[	_	_	I-Premise
170	range	_	_	I-Premise
171	,	_	_	I-Premise
172	1	_	_	I-Premise
173	-	_	_	I-Premise
174	7	_	_	I-Premise
175	]	_	_	I-Premise
176	,	_	_	I-Premise
177	vs	_	_	I-Premise
178	median	_	_	I-Premise
179	control	_	_	I-Premise
180	score	_	_	I-Premise
181	,	_	_	I-Premise
182	4	_	_	I-Premise
183	[	_	_	I-Premise
184	range	_	_	I-Premise
185	,	_	_	I-Premise
186	1	_	_	I-Premise
187	-	_	_	I-Premise
188	6	_	_	I-Premise
189	]	_	_	I-Premise
190	(	_	_	I-Premise
191	P	_	_	I-Premise
192	=	_	_	I-Premise
193	.	_	_	I-Premise

194	88	_	_	I-Premise
195	)	_	_	I-Premise
196	.	_	_	I-Premise

197	However	_	_	O
198	,	_	_	O
199	intervention	_	_	B-Premise
200	patients	_	_	I-Premise
201	had	_	_	I-Premise
202	significantly	_	_	I-Premise
203	better	_	_	I-Premise
204	scores	_	_	I-Premise
205	at	_	_	I-Premise
206	months	_	_	I-Premise
207	3	_	_	I-Premise
208	and	_	_	I-Premise
209	6	_	_	I-Premise
210	(	_	_	I-Premise
211	median	_	_	I-Premise
212	3	_	_	I-Premise
213	-	_	_	I-Premise
214	month	_	_	I-Premise
215	intervention	_	_	I-Premise
216	score	_	_	I-Premise
217	,	_	_	I-Premise
218	7	_	_	I-Premise
219	[	_	_	I-Premise
220	range	_	_	I-Premise
221	,	_	_	I-Premise
222	5	_	_	I-Premise
223	-	_	_	I-Premise
224	7	_	_	I-Premise
225	]	_	_	I-Premise
226	,	_	_	I-Premise
227	vs	_	_	I-Premise
228	median	_	_	I-Premise
229	control	_	_	I-Premise
230	score	_	_	I-Premise
231	,	_	_	I-Premise
232	5	_	_	I-Premise
233	[	_	_	I-Premise
234	range	_	_	I-Premise
235	,	_	_	I-Premise
236	3	_	_	I-Premise
237	-	_	_	I-Premise
238	7	_	_	I-Premise
239	]	_	_	I-Premise
240	[	_	_	I-Premise
241	P	_	_	I-Premise
242	=	_	_	I-Premise
243	.	_	_	I-Premise

244	03	_	_	I-Premise
245	]	_	_	I-Premise
246	;	_	_	I-Premise
247	median	_	_	I-Premise
248	6	_	_	I-Premise
249	-	_	_	I-Premise
250	month	_	_	I-Premise
251	intervention	_	_	I-Premise
252	score	_	_	I-Premise
253	,	_	_	I-Premise
254	7	_	_	I-Premise
255	[	_	_	I-Premise
256	range	_	_	I-Premise
257	,	_	_	I-Premise
258	6	_	_	I-Premise
259	-	_	_	I-Premise
260	7	_	_	I-Premise
261	]	_	_	I-Premise
262	,	_	_	I-Premise
263	vs	_	_	I-Premise
264	median	_	_	I-Premise
265	control	_	_	I-Premise
266	score	_	_	I-Premise
267	,	_	_	I-Premise
268	6	_	_	I-Premise
269	[	_	_	I-Premise
270	range	_	_	I-Premise
271	,	_	_	I-Premise
272	3	_	_	I-Premise
273	-	_	_	I-Premise
274	7	_	_	I-Premise
275	]	_	_	I-Premise
276	[	_	_	I-Premise
277	P	_	_	I-Premise
278	=	_	_	I-Premise
279	.	_	_	I-Premise

280	009	_	_	I-Premise
281	]	_	_	I-Premise
282	)	_	_	I-Premise
283	.	_	_	I-Premise

284	There	_	_	B-Premise
285	was	_	_	I-Premise
286	no	_	_	I-Premise
287	significant	_	_	I-Premise
288	difference	_	_	I-Premise
289	in	_	_	I-Premise
290	scores	_	_	I-Premise
291	at	_	_	I-Premise
292	months	_	_	I-Premise
293	9	_	_	I-Premise
294	and	_	_	I-Premise
295	12	_	_	I-Premise
296	(	_	_	I-Premise
297	P	_	_	I-Premise
298	=	_	_	I-Premise
299	.	_	_	I-Premise

300	24	_	_	I-Premise
301	and	_	_	I-Premise
302	P	_	_	I-Premise
303	=	_	_	I-Premise
304	.	_	_	I-Premise

305	93	_	_	I-Premise
306	,	_	_	I-Premise
307	respectively	_	_	I-Premise
308	)	_	_	I-Premise
309	.	_	_	I-Premise

310	The	_	_	B-Premise
311	same	_	_	I-Premise
312	pattern	_	_	I-Premise
313	between	_	_	I-Premise
314	intervention	_	_	I-Premise
315	and	_	_	I-Premise
316	control	_	_	I-Premise
317	patients	_	_	I-Premise
318	was	_	_	I-Premise
319	observed	_	_	I-Premise
320	for	_	_	I-Premise
321	scores	_	_	I-Premise
322	on	_	_	I-Premise
323	the	_	_	I-Premise
324	PSS	_	_	I-Premise
325	-	_	_	I-Premise
326	H	_	_	I-Premise
327	&	_	_	I-Premise
328	N	_	_	I-Premise
329	.	_	_	I-Premise

330	Patients	_	_	B-Claim
331	who	_	_	I-Claim
332	performed	_	_	I-Claim
333	prophylactic	_	_	I-Claim
334	swallowing	_	_	I-Claim
335	exercises	_	_	I-Claim
336	had	_	_	I-Claim
337	improved	_	_	I-Claim
338	swallowing	_	_	I-Claim
339	function	_	_	I-Claim
340	at	_	_	I-Claim
341	3	_	_	I-Claim
342	and	_	_	I-Claim
343	6	_	_	I-Claim
344	months	_	_	I-Claim
345	after	_	_	I-Claim
346	CRT	_	_	I-Claim
347	but	_	_	I-Claim
348	not	_	_	I-Claim
349	immediately	_	_	I-Claim
350	after	_	_	I-Claim
351	CRT	_	_	I-Claim
352	or	_	_	I-Claim
353	at	_	_	I-Claim
354	9	_	_	I-Claim
355	and	_	_	I-Claim
356	12	_	_	I-Claim
357	months	_	_	I-Claim
358	after	_	_	I-Claim
359	CRT	_	_	I-Claim
360	.	_	_	I-Claim

361	The	_	_	B-Claim
362	small	_	_	I-Claim
363	sample	_	_	I-Claim
364	size	_	_	I-Claim
365	may	_	_	I-Claim
366	have	_	_	I-Claim
367	limited	_	_	I-Claim
368	our	_	_	I-Claim
369	ability	_	_	I-Claim
370	to	_	_	I-Claim
371	detect	_	_	I-Claim
372	significant	_	_	I-Claim
373	differences	_	_	I-Claim
374	beyond	_	_	I-Claim
375	6	_	_	I-Claim
376	months	_	_	I-Claim
377	of	_	_	I-Claim
378	observation	_	_	I-Claim
379	as	_	_	I-Claim
380	well	_	_	I-Claim
381	as	_	_	I-Claim
382	additional	_	_	I-Claim
383	significant	_	_	I-Claim
384	differences	_	_	I-Claim
385	in	_	_	I-Claim
386	our	_	_	I-Claim
387	study	_	_	I-Claim
388	.	_	_	I-Claim


0	Maintenance	_	_	O
1	therapy	_	_	O
2	can	_	_	O
3	delay	_	_	O
4	progression	_	_	O
5	and	_	_	O
6	prolong	_	_	O
7	survival	_	_	O
8	in	_	_	O
9	metastatic	_	_	O
10	non	_	_	O
11	-	_	_	O
12	small	_	_	O
13	-	_	_	O
14	cell	_	_	O
15	lung	_	_	O
16	cancer	_	_	O
17	(	_	_	O
18	mNSCLC	_	_	O
19	)	_	_	O
20	.	_	_	O

21	As	_	_	O
22	treatment	_	_	O
23	for	_	_	O
24	mNSCLC	_	_	O
25	is	_	_	O
26	non	_	_	O
27	-	_	_	O
28	curative	_	_	O
29	,	_	_	O
30	its	_	_	O
31	impact	_	_	O
32	on	_	_	O
33	patient	_	_	O
34	health	_	_	O
35	-	_	_	O
36	related	_	_	O
37	quality	_	_	O
38	of	_	_	O
39	life	_	_	O
40	(	_	_	O
41	HRQoL	_	_	O
42	)	_	_	O
43	is	_	_	O
44	an	_	_	O
45	important	_	_	O
46	consideration	_	_	O
47	.	_	_	O

48	SATURN	_	_	O
49	(	_	_	O
50	Sequential	_	_	O
51	Tarceva	_	_	O
52	in	_	_	O
53	Unresectable	_	_	O
54	NSCLC	_	_	O
55	)	_	_	O
56	was	_	_	O
57	a	_	_	O
58	randomised	_	_	O
59	,	_	_	O
60	double	_	_	O
61	-	_	_	O
62	blind	_	_	O
63	,	_	_	O
64	placebo	_	_	O
65	-	_	_	O
66	controlled	_	_	O
67	,	_	_	O
68	multicentre	_	_	O
69	study	_	_	O
70	investigating	_	_	O
71	the	_	_	O
72	impact	_	_	O
73	of	_	_	O
74	erlotinib	_	_	O
75	maintenance	_	_	O
76	therapy	_	_	O
77	on	_	_	O
78	HRQoL	_	_	O
79	in	_	_	O
80	patients	_	_	O
81	with	_	_	O
82	locally	_	_	O
83	advanced	_	_	O
84	or	_	_	O
85	recurrent	_	_	O
86	NSCLC	_	_	O
87	.	_	_	O

88	Eligible	_	_	O
89	patients	_	_	O
90	who	_	_	O
91	had	_	_	O
92	previously	_	_	O
93	completed	_	_	O
94	four	_	_	O
95	cycles	_	_	O
96	of	_	_	O
97	platinum	_	_	O
98	-	_	_	O
99	based	_	_	O
100	chemotherapy	_	_	O
101	were	_	_	O
102	randomised	_	_	O
103	1	_	_	O
104	:	_	_	O
105	1	_	_	O
106	to	_	_	O
107	receive	_	_	O
108	erlotinib	_	_	O
109	150	_	_	O
110	mg	_	_	O
111	/	_	_	O
112	day	_	_	O
113	or	_	_	O
114	placebo	_	_	O
115	until	_	_	O
116	disease	_	_	O
117	progression	_	_	O
118	,	_	_	O
119	unacceptable	_	_	O
120	toxicity	_	_	O
121	or	_	_	O
122	death	_	_	O
123	.	_	_	O

124	Patient	_	_	O
125	HRQoL	_	_	O
126	was	_	_	O
127	assessed	_	_	O
128	using	_	_	O
129	the	_	_	O
130	Functional	_	_	O
131	Assessment	_	_	O
132	of	_	_	O
133	Cancer	_	_	O
134	Therapy	_	_	O
135	-	_	_	O
136	Lung	_	_	O
137	questionnaire	_	_	O
138	,	_	_	O
139	in	_	_	O
140	terms	_	_	O
141	of	_	_	O
142	time	_	_	O
143	to	_	_	O
144	symptom	_	_	O
145	progression	_	_	O
146	(	_	_	O
147	TSP	_	_	O
148	)	_	_	O
149	,	_	_	O
150	time	_	_	O
151	to	_	_	O
152	deterioration	_	_	O
153	(	_	_	O
154	TTD	_	_	O
155	)	_	_	O
156	in	_	_	O
157	Trial	_	_	O
158	Outcome	_	_	O
159	Index	_	_	O
160	(	_	_	O
161	TOI	_	_	O
162	)	_	_	O
163	and	_	_	O
164	TTD	_	_	O
165	.	_	_	O

166	Exploratory	_	_	O
167	analysis	_	_	O
168	was	_	_	O
169	based	_	_	O
170	on	_	_	O
171	time	_	_	O
172	to	_	_	O
173	analgesia	_	_	O
174	and	_	_	O
175	appearance	_	_	O
176	of	_	_	O
177	key	_	_	O
178	symptoms	_	_	O
179	(	_	_	O
180	pain	_	_	O
181	,	_	_	O
182	cough	_	_	O
183	and	_	_	O
184	dyspnoea	_	_	O
185	)	_	_	O
186	.	_	_	O

187	Compared	_	_	B-Premise
188	with	_	_	I-Premise
189	placebo	_	_	I-Premise
190	,	_	_	I-Premise
191	erlotinib	_	_	I-Premise
192	maintenance	_	_	I-Premise
193	therapy	_	_	I-Premise
194	prolonged	_	_	I-Premise
195	progression	_	_	I-Premise
196	-	_	_	I-Premise
197	free	_	_	I-Premise
198	and	_	_	I-Premise
199	overall	_	_	I-Premise
200	survival	_	_	I-Premise
201	by	_	_	I-Premise
202	41	_	_	I-Premise
203	%	_	_	I-Premise
204	and	_	_	I-Premise
205	23	_	_	I-Premise
206	%	_	_	I-Premise
207	,	_	_	I-Premise
208	respectively	_	_	I-Premise
209	.	_	_	I-Premise

210	At	_	_	O
211	baseline	_	_	O
212	,	_	_	O
213	HRQoL	_	_	O
214	measures	_	_	O
215	were	_	_	O
216	comparable	_	_	O
217	between	_	_	O
218	the	_	_	O
219	two	_	_	O
220	treatment	_	_	O
221	groups	_	_	O
222	.	_	_	O

223	Maintenance	_	_	B-Premise
224	therapy	_	_	I-Premise
225	with	_	_	I-Premise
226	erlotinib	_	_	I-Premise
227	did	_	_	I-Premise
228	not	_	_	I-Premise
229	impact	_	_	I-Premise
230	on	_	_	I-Premise
231	deterioration	_	_	I-Premise
232	in	_	_	I-Premise
233	HRQoL	_	_	I-Premise
234	:	_	_	I-Premise
235	TSP	_	_	I-Premise
236	(	_	_	I-Premise
237	hazard	_	_	I-Premise
238	ratio	_	_	I-Premise
239	[	_	_	I-Premise
240	HR	_	_	I-Premise
241	]	_	_	I-Premise
242	=	_	_	I-Premise
243	0	_	_	I-Premise
244	.	_	_	I-Premise

245	91	_	_	I-Premise
246	[	_	_	I-Premise
247	95	_	_	I-Premise
248	%	_	_	I-Premise
249	confidence	_	_	I-Premise
250	interval	_	_	I-Premise
251	(	_	_	I-Premise
252	CI	_	_	I-Premise
253	)	_	_	I-Premise
254	0	_	_	I-Premise
255	.	_	_	I-Premise

256	74	_	_	I-Premise
257	-	_	_	I-Premise
258	1	_	_	I-Premise
259	.	_	_	I-Premise

260	12	_	_	I-Premise
261	]	_	_	I-Premise
262	;	_	_	I-Premise
263	n	_	_	I-Premise
264	=	_	_	I-Premise
265	785	_	_	I-Premise
266	)	_	_	I-Premise
267	,	_	_	I-Premise
268	TTD	_	_	I-Premise
269	in	_	_	I-Premise
270	TOI	_	_	I-Premise
271	(	_	_	I-Premise
272	HR	_	_	I-Premise
273	=	_	_	I-Premise
274	1	_	_	I-Premise
275	.	_	_	I-Premise

276	06	_	_	I-Premise
277	[	_	_	I-Premise
278	95	_	_	I-Premise
279	%	_	_	I-Premise
280	CI	_	_	I-Premise
281	0	_	_	I-Premise
282	.	_	_	I-Premise

283	87	_	_	I-Premise
284	-	_	_	I-Premise
285	1	_	_	I-Premise
286	.	_	_	I-Premise

287	31	_	_	I-Premise
288	]	_	_	I-Premise
289	;	_	_	I-Premise
290	n	_	_	I-Premise
291	=	_	_	I-Premise
292	781	_	_	I-Premise
293	)	_	_	I-Premise
294	and	_	_	I-Premise
295	TTD	_	_	I-Premise
296	in	_	_	I-Premise
297	HRQoL	_	_	I-Premise
298	(	_	_	I-Premise
299	HR	_	_	I-Premise
300	=	_	_	I-Premise
301	0	_	_	I-Premise
302	.	_	_	I-Premise

303	96	_	_	I-Premise
304	[	_	_	I-Premise
305	95	_	_	I-Premise
306	%	_	_	I-Premise
307	CI	_	_	I-Premise
308	0	_	_	I-Premise
309	.	_	_	I-Premise

310	79	_	_	I-Premise
311	-	_	_	I-Premise
312	1	_	_	I-Premise
313	.	_	_	I-Premise

314	16	_	_	I-Premise
315	]	_	_	I-Premise
316	;	_	_	I-Premise
317	n	_	_	I-Premise
318	=	_	_	I-Premise
319	776	_	_	I-Premise
320	)	_	_	I-Premise
321	.	_	_	I-Premise

322	Time	_	_	B-Premise
323	to	_	_	I-Premise
324	pain	_	_	I-Premise
325	and	_	_	I-Premise
326	time	_	_	I-Premise
327	to	_	_	I-Premise
328	analgesic	_	_	I-Premise
329	use	_	_	I-Premise
330	were	_	_	I-Premise
331	significantly	_	_	I-Premise
332	delayed	_	_	I-Premise
333	in	_	_	I-Premise
334	patients	_	_	I-Premise
335	receiving	_	_	I-Premise
336	erlotinib	_	_	I-Premise
337	compared	_	_	I-Premise
338	with	_	_	I-Premise
339	placebo	_	_	I-Premise
340	(	_	_	I-Premise
341	HR	_	_	I-Premise
342	=	_	_	I-Premise
343	0	_	_	I-Premise
344	.	_	_	I-Premise

345	61	_	_	I-Premise
346	[	_	_	I-Premise
347	95	_	_	I-Premise
348	%	_	_	I-Premise
349	CI	_	_	I-Premise
350	0	_	_	I-Premise
351	.	_	_	I-Premise

352	42	_	_	I-Premise
353	-	_	_	I-Premise
354	0	_	_	I-Premise
355	.	_	_	I-Premise

356	88	_	_	I-Premise
357	]	_	_	I-Premise
358	;	_	_	I-Premise
359	p	_	_	I-Premise
360	=	_	_	I-Premise
361	0	_	_	I-Premise
362	.	_	_	I-Premise

363	0080	_	_	I-Premise
364	and	_	_	I-Premise
365	HR	_	_	I-Premise
366	=	_	_	I-Premise
367	0	_	_	I-Premise
368	.	_	_	I-Premise

369	66	_	_	I-Premise
370	[	_	_	I-Premise
371	95	_	_	I-Premise
372	%	_	_	I-Premise
373	CI	_	_	I-Premise
374	0	_	_	I-Premise
375	.	_	_	I-Premise

376	46	_	_	I-Premise
377	-	_	_	I-Premise
378	0	_	_	I-Premise
379	.	_	_	I-Premise

380	94	_	_	I-Premise
381	]	_	_	I-Premise
382	;	_	_	I-Premise
383	p	_	_	I-Premise
384	=	_	_	I-Premise
385	0	_	_	I-Premise
386	.	_	_	I-Premise

387	0199	_	_	I-Premise
388	,	_	_	I-Premise
389	respectively	_	_	I-Premise
390	)	_	_	I-Premise
391	.	_	_	I-Premise

392	A	_	_	B-Premise
393	non	_	_	I-Premise
394	-	_	_	I-Premise
395	significant	_	_	I-Premise
396	trend	_	_	I-Premise
397	towards	_	_	I-Premise
398	delayed	_	_	I-Premise
399	time	_	_	I-Premise
400	to	_	_	I-Premise
401	cough	_	_	I-Premise
402	and	_	_	I-Premise
403	time	_	_	I-Premise
404	to	_	_	I-Premise
405	dyspnoea	_	_	I-Premise
406	(	_	_	I-Premise
407	HR	_	_	I-Premise
408	=	_	_	I-Premise
409	0	_	_	I-Premise
410	.	_	_	I-Premise

411	77	_	_	I-Premise
412	[	_	_	I-Premise
413	95	_	_	I-Premise
414	%	_	_	I-Premise
415	CI	_	_	I-Premise
416	0	_	_	I-Premise
417	.	_	_	I-Premise

418	49	_	_	I-Premise
419	-	_	_	I-Premise
420	1	_	_	I-Premise
421	.	_	_	I-Premise

422	21	_	_	I-Premise
423	]	_	_	I-Premise
424	and	_	_	I-Premise
425	HR	_	_	I-Premise
426	=	_	_	I-Premise
427	0	_	_	I-Premise
428	.	_	_	I-Premise

429	75	_	_	I-Premise
430	[	_	_	I-Premise
431	95	_	_	I-Premise
432	%	_	_	I-Premise
433	CI	_	_	I-Premise
434	0	_	_	I-Premise
435	.	_	_	I-Premise

436	48	_	_	I-Premise
437	-	_	_	I-Premise
438	1	_	_	I-Premise
439	.	_	_	I-Premise

440	17	_	_	I-Premise
441	]	_	_	I-Premise
442	,	_	_	I-Premise
443	respectively	_	_	I-Premise
444	)	_	_	I-Premise
445	was	_	_	I-Premise
446	also	_	_	I-Premise
447	observed	_	_	I-Premise
448	.	_	_	I-Premise

449	Erlotinib	_	_	B-Claim
450	maintenance	_	_	I-Claim
451	therapy	_	_	I-Claim
452	significantly	_	_	I-Claim
453	extends	_	_	I-Claim
454	progression	_	_	I-Claim
455	-	_	_	I-Claim
456	free	_	_	I-Claim
457	survival	_	_	I-Claim
458	without	_	_	I-Claim
459	compromising	_	_	I-Claim
460	patient	_	_	I-Claim
461	HRQoL	_	_	I-Claim
462	in	_	_	I-Claim
463	comparison	_	_	I-Claim
464	with	_	_	I-Claim
465	placebo	_	_	I-Claim
466	,	_	_	I-Claim
467	with	_	_	I-Claim
468	some	_	_	I-Claim
469	improvement	_	_	I-Claim
470	in	_	_	I-Claim
471	symptoms	_	_	I-Claim
472	.	_	_	I-Claim


0	Increased	_	_	B-Claim
1	expression	_	_	I-Claim
2	of	_	_	I-Claim
3	metalloproteinases	_	_	I-Claim
4	is	_	_	I-Claim
5	associated	_	_	I-Claim
6	with	_	_	I-Claim
7	poor	_	_	I-Claim
8	prognosis	_	_	I-Claim
9	in	_	_	I-Claim
10	small	_	_	I-Claim
11	-	_	_	I-Claim
12	cell	_	_	I-Claim
13	lung	_	_	I-Claim
14	cancer	_	_	I-Claim
15	(	_	_	I-Claim
16	SCLC	_	_	I-Claim
17	)	_	_	I-Claim
18	.	_	_	I-Claim

19	This	_	_	O
20	trial	_	_	O
21	was	_	_	O
22	undertaken	_	_	O
23	to	_	_	O
24	determine	_	_	O
25	whether	_	_	O
26	adjuvant	_	_	O
27	treatment	_	_	O
28	with	_	_	O
29	the	_	_	O
30	metalloproteinase	_	_	O
31	inhibitor	_	_	O
32	marimastat	_	_	O
33	could	_	_	O
34	prolong	_	_	O
35	survival	_	_	O
36	in	_	_	O
37	responding	_	_	O
38	patients	_	_	O
39	with	_	_	O
40	SCLC	_	_	O
41	after	_	_	O
42	chemotherapy	_	_	O
43	.	_	_	O

44	SCLC	_	_	O
45	patients	_	_	O
46	in	_	_	O
47	complete	_	_	O
48	or	_	_	O
49	partial	_	_	O
50	remission	_	_	O
51	were	_	_	O
52	eligible	_	_	O
53	.	_	_	O

54	They	_	_	O
55	were	_	_	O
56	stratified	_	_	O
57	by	_	_	O
58	radiotherapy	_	_	O
59	(	_	_	O
60	early	_	_	O
61	,	_	_	O
62	late	_	_	O
63	,	_	_	O
64	or	_	_	O
65	none	_	_	O
66	)	_	_	O
67	,	_	_	O
68	stage	_	_	O
69	(	_	_	O
70	extensive	_	_	O
71	or	_	_	O
72	limited	_	_	O
73	)	_	_	O
74	,	_	_	O
75	response	_	_	O
76	(	_	_	O
77	complete	_	_	O
78	or	_	_	O
79	partial	_	_	O
80	)	_	_	O
81	,	_	_	O
82	and	_	_	O
83	cooperative	_	_	O
84	group	_	_	O
85	(	_	_	O
86	National	_	_	O
87	Cancer	_	_	O
88	Institute	_	_	O
89	of	_	_	O
90	Canada	_	_	O
91	-	_	_	O
92	Clinical	_	_	O
93	Trials	_	_	O
94	Group	_	_	O
95	or	_	_	O
96	European	_	_	O
97	Organization	_	_	O
98	for	_	_	O
99	Research	_	_	O
100	and	_	_	O
101	Treatment	_	_	O
102	of	_	_	O
103	Cancer	_	_	O
104	)	_	_	O
105	.	_	_	O

106	They	_	_	O
107	were	_	_	O
108	randomized	_	_	O
109	to	_	_	O
110	receive	_	_	O
111	marimastat	_	_	O
112	10	_	_	O
113	mg	_	_	O
114	or	_	_	O
115	placebo	_	_	O
116	orally	_	_	O
117	bid	_	_	O
118	for	_	_	O
119	up	_	_	O
120	to	_	_	O
121	2	_	_	O
122	years	_	_	O
123	.	_	_	O

124	There	_	_	O
125	were	_	_	O
126	532	_	_	O
127	eligible	_	_	O
128	patients	_	_	O
129	(	_	_	O
130	266	_	_	O
131	marimastat	_	_	O
132	and	_	_	O
133	266	_	_	O
134	placebo	_	_	O
135	)	_	_	O
136	.	_	_	O

137	Stage	_	_	O
138	was	_	_	O
139	limited	_	_	O
140	for	_	_	O
141	279	_	_	O
142	patients	_	_	O
143	(	_	_	O
144	52	_	_	O
145	%	_	_	O
146	)	_	_	O
147	and	_	_	O
148	extensive	_	_	O
149	for	_	_	O
150	253	_	_	O
151	(	_	_	O
152	48	_	_	O
153	%	_	_	O
154	)	_	_	O
155	.	_	_	O

156	Best	_	_	B-Premise
157	response	_	_	I-Premise
158	to	_	_	I-Premise
159	induction	_	_	I-Premise
160	therapy	_	_	I-Premise
161	was	_	_	I-Premise
162	complete	_	_	I-Premise
163	remission	_	_	I-Premise
164	for	_	_	I-Premise
165	176	_	_	I-Premise
166	patients	_	_	I-Premise
167	(	_	_	I-Premise
168	33	_	_	I-Premise
169	%	_	_	I-Premise
170	)	_	_	I-Premise
171	,	_	_	I-Premise
172	partial	_	_	I-Premise
173	remission	_	_	I-Premise
174	for	_	_	I-Premise
175	341	_	_	I-Premise
176	(	_	_	I-Premise
177	64	_	_	I-Premise
178	%	_	_	I-Premise
179	)	_	_	I-Premise
180	,	_	_	I-Premise
181	and	_	_	I-Premise
182	15	_	_	I-Premise
183	patients	_	_	I-Premise
184	(	_	_	I-Premise
185	3	_	_	I-Premise
186	%	_	_	I-Premise
187	)	_	_	I-Premise
188	had	_	_	I-Premise
189	undergone	_	_	I-Premise
190	surgical	_	_	I-Premise
191	resection	_	_	I-Premise
192	.	_	_	I-Premise

193	The	_	_	B-Premise
194	median	_	_	I-Premise
195	time	_	_	I-Premise
196	to	_	_	I-Premise
197	progression	_	_	I-Premise
198	for	_	_	I-Premise
199	marimastat	_	_	I-Premise
200	patients	_	_	I-Premise
201	was	_	_	I-Premise
202	4	_	_	I-Premise
203	.	_	_	I-Premise

204	3	_	_	I-Premise
205	months	_	_	I-Premise
206	compared	_	_	I-Premise
207	with	_	_	I-Premise
208	4	_	_	I-Premise
209	.	_	_	I-Premise

210	4	_	_	I-Premise
211	months	_	_	I-Premise
212	for	_	_	I-Premise
213	placebo	_	_	I-Premise
214	patients	_	_	I-Premise
215	(	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	.	_	_	I-Premise

219	81	_	_	I-Premise
220	)	_	_	I-Premise
221	.	_	_	I-Premise

222	Median	_	_	B-Premise
223	survivals	_	_	I-Premise
224	for	_	_	I-Premise
225	marimastat	_	_	I-Premise
226	and	_	_	I-Premise
227	placebo	_	_	I-Premise
228	patients	_	_	I-Premise
229	were	_	_	I-Premise
230	9	_	_	I-Premise
231	.	_	_	I-Premise

232	3	_	_	I-Premise
233	months	_	_	I-Premise
234	and	_	_	I-Premise
235	9	_	_	I-Premise
236	.	_	_	I-Premise

237	7	_	_	I-Premise
238	months	_	_	I-Premise
239	,	_	_	I-Premise
240	respectively	_	_	I-Premise
241	(	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	.	_	_	I-Premise

245	90	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	Toxicity	_	_	B-Premise
249	was	_	_	I-Premise
250	generally	_	_	I-Premise
251	limited	_	_	I-Premise
252	to	_	_	I-Premise
253	musculoskeletal	_	_	I-Premise
254	symptoms	_	_	I-Premise
255	(	_	_	I-Premise
256	18	_	_	I-Premise
257	%	_	_	I-Premise
258	grade	_	_	I-Premise
259	3	_	_	I-Premise
260	/	_	_	I-Premise
261	4	_	_	I-Premise
262	for	_	_	I-Premise
263	marimastat	_	_	I-Premise
264	)	_	_	I-Premise
265	.	_	_	I-Premise

266	Dose	_	_	B-Premise
267	modifications	_	_	I-Premise
268	for	_	_	I-Premise
269	musculoskeletal	_	_	I-Premise
270	toxicity	_	_	I-Premise
271	were	_	_	I-Premise
272	required	_	_	I-Premise
273	in	_	_	I-Premise
274	90	_	_	I-Premise
275	patients	_	_	I-Premise
276	(	_	_	I-Premise
277	33	_	_	I-Premise
278	%	_	_	I-Premise
279	)	_	_	I-Premise
280	on	_	_	I-Premise
281	the	_	_	I-Premise
282	marimastat	_	_	I-Premise
283	arm	_	_	I-Premise
284	,	_	_	I-Premise
285	and	_	_	I-Premise
286	87	_	_	I-Premise
287	(	_	_	I-Premise
288	32	_	_	I-Premise
289	%	_	_	I-Premise
290	)	_	_	I-Premise
291	permanently	_	_	I-Premise
292	stopped	_	_	I-Premise
293	marimastat	_	_	I-Premise
294	because	_	_	I-Premise
295	of	_	_	I-Premise
296	toxicity	_	_	I-Premise
297	.	_	_	I-Premise

298	Patients	_	_	B-Premise
299	on	_	_	I-Premise
300	marimastat	_	_	I-Premise
301	had	_	_	I-Premise
302	significantly	_	_	I-Premise
303	poorer	_	_	I-Premise
304	quality	_	_	I-Premise
305	of	_	_	I-Premise
306	life	_	_	I-Premise
307	at	_	_	I-Premise
308	3	_	_	I-Premise
309	and	_	_	I-Premise
310	6	_	_	I-Premise
311	months	_	_	I-Premise
312	.	_	_	I-Premise

313	Treatment	_	_	B-Claim
314	with	_	_	I-Claim
315	marimastat	_	_	I-Claim
316	after	_	_	I-Claim
317	induction	_	_	I-Claim
318	therapy	_	_	I-Claim
319	for	_	_	I-Claim
320	SCLC	_	_	I-Claim
321	did	_	_	I-Claim
322	not	_	_	I-Claim
323	result	_	_	I-Claim
324	in	_	_	I-Claim
325	improved	_	_	I-Claim
326	survival	_	_	I-Claim
327	and	_	_	I-Claim
328	had	_	_	I-Claim
329	a	_	_	I-Claim
330	negative	_	_	I-Claim
331	impact	_	_	I-Claim
332	on	_	_	I-Claim
333	quality	_	_	I-Claim
334	of	_	_	I-Claim
335	life	_	_	I-Claim
336	.	_	_	I-Claim


0	The	_	_	B-Claim
1	role	_	_	I-Claim
2	of	_	_	I-Claim
3	adjuvant	_	_	I-Claim
4	chemotherapy	_	_	I-Claim
5	in	_	_	I-Claim
6	postmenopausal	_	_	I-Claim
7	patients	_	_	I-Claim
8	with	_	_	I-Claim
9	lymph	_	_	I-Claim
10	node	_	_	I-Claim
11	-	_	_	I-Claim
12	negative	_	_	I-Claim
13	breast	_	_	I-Claim
14	cancer	_	_	I-Claim
15	is	_	_	I-Claim
16	controversial	_	_	I-Claim
17	.	_	_	I-Claim

18	After	_	_	O
19	demonstrating	_	_	O
20	the	_	_	O
21	efficacy	_	_	O
22	of	_	_	O
23	chemotherapy	_	_	O
24	combined	_	_	O
25	with	_	_	O
26	tamoxifen	_	_	O
27	for	_	_	O
28	postmenopausal	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	lymph	_	_	O
32	node	_	_	O
33	-	_	_	O
34	positive	_	_	O
35	disease	_	_	O
36	,	_	_	O
37	the	_	_	O
38	International	_	_	O
39	Breast	_	_	O
40	Cancer	_	_	O
41	Study	_	_	O
42	Group	_	_	O
43	launched	_	_	O
44	a	_	_	O
45	randomized	_	_	O
46	trial	_	_	O
47	(	_	_	O
48	Trial	_	_	O
49	IX	_	_	O
50	)	_	_	O
51	to	_	_	O
52	evaluate	_	_	O
53	the	_	_	O
54	role	_	_	O
55	of	_	_	O
56	adjuvant	_	_	O
57	chemotherapy	_	_	O
58	preceding	_	_	O
59	treatment	_	_	O
60	with	_	_	O
61	tamoxifen	_	_	O
62	for	_	_	O
63	patients	_	_	O
64	with	_	_	O
65	lymph	_	_	O
66	node	_	_	O
67	-	_	_	O
68	negative	_	_	O
69	disease	_	_	O
70	.	_	_	O

71	After	_	_	O
72	stratification	_	_	O
73	by	_	_	O
74	estrogen	_	_	O
75	receptor	_	_	O
76	(	_	_	O
77	ER	_	_	O
78	)	_	_	O
79	status	_	_	O
80	,	_	_	O
81	patients	_	_	O
82	were	_	_	O
83	randomly	_	_	O
84	assigned	_	_	O
85	to	_	_	O
86	receive	_	_	O
87	three	_	_	O
88	28	_	_	O
89	-	_	_	O
90	day	_	_	O
91	courses	_	_	O
92	of	_	_	O
93	"	_	_	O
94	classical	_	_	O
95	"	_	_	O
96	adjuvant	_	_	O
97	CMF	_	_	O
98	chemotherapy	_	_	O
99	(	_	_	O
100	cyclophosphamide	_	_	O
101	at	_	_	O
102	100	_	_	O
103	mg	_	_	O
104	/	_	_	O
105	m	_	_	O
106	(	_	_	O
107	2	_	_	O
108	)	_	_	O
109	on	_	_	O
110	days	_	_	O
111	1	_	_	O
112	-	_	_	O
113	14	_	_	O
114	,	_	_	O
115	orally	_	_	O
116	;	_	_	O
117	methotrexate	_	_	O
118	at	_	_	O
119	40	_	_	O
120	mg	_	_	O
121	/	_	_	O
122	m	_	_	O
123	(	_	_	O
124	2	_	_	O
125	)	_	_	O
126	on	_	_	O
127	days	_	_	O
128	1	_	_	O
129	and	_	_	O
130	8	_	_	O
131	,	_	_	O
132	intravenously	_	_	O
133	;	_	_	O
134	and	_	_	O
135	5	_	_	O
136	-	_	_	O
137	fluorouracil	_	_	O
138	at	_	_	O
139	600	_	_	O
140	mg	_	_	O
141	/	_	_	O
142	m	_	_	O
143	(	_	_	O
144	2	_	_	O
145	)	_	_	O
146	on	_	_	O
147	days	_	_	O
148	1	_	_	O
149	and	_	_	O
150	8	_	_	O
151	,	_	_	O
152	intravenously	_	_	O
153	)	_	_	O
154	followed	_	_	O
155	by	_	_	O
156	tamoxifen	_	_	O
157	(	_	_	O
158	20	_	_	O
159	mg	_	_	O
160	/	_	_	O
161	day	_	_	O
162	,	_	_	O
163	orally	_	_	O
164	for	_	_	O
165	57	_	_	O
166	months	_	_	O
167	)	_	_	O
168	(	_	_	O
169	CMF	_	_	O
170	-	_	_	O
171	-	_	_	O
172	>	_	_	O
173	tamoxifen	_	_	O
174	)	_	_	O
175	or	_	_	O
176	to	_	_	O
177	receive	_	_	O
178	tamoxifen	_	_	O
179	alone	_	_	O
180	(	_	_	O
181	20	_	_	O
182	mg	_	_	O
183	/	_	_	O
184	day	_	_	O
185	,	_	_	O
186	orally	_	_	O
187	for	_	_	O
188	60	_	_	O
189	months	_	_	O
190	)	_	_	O
191	.	_	_	O

192	We	_	_	O
193	enrolled	_	_	O
194	1669	_	_	O
195	eligible	_	_	O
196	patients	_	_	O
197	,	_	_	O
198	382	_	_	O
199	(	_	_	O
200	23	_	_	O
201	%	_	_	O
202	)	_	_	O
203	with	_	_	O
204	ER	_	_	O
205	-	_	_	O
206	negative	_	_	O
207	tumors	_	_	O
208	,	_	_	O
209	1217	_	_	O
210	(	_	_	O
211	73	_	_	O
212	%	_	_	O
213	)	_	_	O
214	with	_	_	O
215	ER	_	_	O
216	-	_	_	O
217	positive	_	_	O
218	tumors	_	_	O
219	,	_	_	O
220	and	_	_	O
221	70	_	_	O
222	(	_	_	O
223	4	_	_	O
224	%	_	_	O
225	)	_	_	O
226	with	_	_	O
227	unknown	_	_	O
228	ER	_	_	O
229	status	_	_	O
230	.	_	_	O

231	The	_	_	O
232	median	_	_	O
233	follow	_	_	O
234	-	_	_	O
235	up	_	_	O
236	was	_	_	O
237	71	_	_	O
238	months	_	_	O
239	.	_	_	O

240	All	_	_	O
241	statistical	_	_	O
242	tests	_	_	O
243	were	_	_	O
244	two	_	_	O
245	-	_	_	O
246	sided	_	_	O
247	.	_	_	O

248	The	_	_	B-Premise
249	added	_	_	I-Premise
250	benefit	_	_	I-Premise
251	of	_	_	I-Premise
252	CMF	_	_	I-Premise
253	followed	_	_	I-Premise
254	by	_	_	I-Premise
255	tamoxifen	_	_	I-Premise
256	over	_	_	I-Premise
257	tamoxifen	_	_	I-Premise
258	alone	_	_	I-Premise
259	was	_	_	I-Premise
260	statistically	_	_	I-Premise
261	significantly	_	_	I-Premise
262	dependent	_	_	I-Premise
263	on	_	_	I-Premise
264	ER	_	_	I-Premise
265	status	_	_	I-Premise
266	(	_	_	I-Premise
267	tests	_	_	I-Premise
268	for	_	_	I-Premise
269	interaction	_	_	I-Premise
270	:	_	_	I-Premise
271	P	_	_	I-Premise
272	=	_	_	I-Premise
273	.	_	_	I-Premise

274	01	_	_	I-Premise
275	for	_	_	I-Premise
276	disease	_	_	I-Premise
277	-	_	_	I-Premise
278	free	_	_	I-Premise
279	survival	_	_	I-Premise
280	[	_	_	I-Premise
281	DFS	_	_	I-Premise
282	]	_	_	I-Premise
283	and	_	_	I-Premise
284	P	_	_	I-Premise
285	=	_	_	I-Premise
286	.	_	_	I-Premise

287	07	_	_	I-Premise
288	for	_	_	I-Premise
289	overall	_	_	I-Premise
290	survival	_	_	I-Premise
291	[	_	_	I-Premise
292	OS	_	_	I-Premise
293	]	_	_	I-Premise
294	)	_	_	I-Premise
295	.	_	_	I-Premise

296	For	_	_	B-Premise
297	patients	_	_	I-Premise
298	with	_	_	I-Premise
299	ER	_	_	I-Premise
300	-	_	_	I-Premise
301	negative	_	_	I-Premise
302	tumors	_	_	I-Premise
303	,	_	_	I-Premise
304	the	_	_	I-Premise
305	addition	_	_	I-Premise
306	of	_	_	I-Premise
307	CMF	_	_	I-Premise
308	statistically	_	_	I-Premise
309	significantly	_	_	I-Premise
310	improved	_	_	I-Premise
311	DFS	_	_	I-Premise
312	(	_	_	I-Premise
313	5	_	_	I-Premise
314	-	_	_	I-Premise
315	year	_	_	I-Premise
316	DFS	_	_	I-Premise
317	=	_	_	I-Premise
318	84	_	_	I-Premise
319	%	_	_	I-Premise
320	for	_	_	I-Premise
321	CMF	_	_	I-Premise
322	-	_	_	I-Premise
323	-	_	_	I-Premise
324	>	_	_	I-Premise
325	tamoxifen	_	_	I-Premise
326	versus	_	_	I-Premise
327	69	_	_	I-Premise
328	%	_	_	I-Premise
329	for	_	_	I-Premise
330	tamoxifen	_	_	I-Premise
331	alone	_	_	I-Premise
332	;	_	_	I-Premise
333	difference	_	_	I-Premise
334	=	_	_	I-Premise
335	15	_	_	I-Premise
336	%	_	_	I-Premise
337	;	_	_	I-Premise
338	95	_	_	I-Premise
339	%	_	_	I-Premise
340	confidence	_	_	I-Premise
341	interval	_	_	I-Premise
342	[	_	_	I-Premise
343	CI	_	_	I-Premise
344	]	_	_	I-Premise
345	=	_	_	I-Premise
346	6	_	_	I-Premise
347	%	_	_	I-Premise
348	to	_	_	I-Premise
349	24	_	_	I-Premise
350	%	_	_	I-Premise
351	;	_	_	I-Premise
352	risk	_	_	I-Premise
353	ratio	_	_	I-Premise
354	[	_	_	I-Premise
355	RR	_	_	I-Premise
356	]	_	_	I-Premise
357	=	_	_	I-Premise
358	0	_	_	I-Premise
359	.	_	_	I-Premise

360	52	_	_	I-Premise
361	;	_	_	I-Premise
362	95	_	_	I-Premise
363	%	_	_	I-Premise
364	CI	_	_	I-Premise
365	=	_	_	I-Premise
366	0	_	_	I-Premise
367	.	_	_	I-Premise

368	34	_	_	I-Premise
369	to	_	_	I-Premise
370	0	_	_	I-Premise
371	.	_	_	I-Premise

372	79	_	_	I-Premise
373	;	_	_	I-Premise
374	P	_	_	I-Premise
375	=	_	_	I-Premise
376	.	_	_	I-Premise

377	003	_	_	I-Premise
378	)	_	_	I-Premise
379	and	_	_	I-Premise
380	OS	_	_	I-Premise
381	(	_	_	I-Premise
382	5	_	_	I-Premise
383	-	_	_	I-Premise
384	year	_	_	I-Premise
385	OS	_	_	I-Premise
386	=	_	_	I-Premise
387	89	_	_	I-Premise
388	%	_	_	I-Premise
389	for	_	_	I-Premise
390	CMF	_	_	I-Premise
391	-	_	_	I-Premise
392	-	_	_	I-Premise
393	>	_	_	I-Premise
394	tamoxifen	_	_	I-Premise
395	versus	_	_	I-Premise
396	81	_	_	I-Premise
397	%	_	_	I-Premise
398	for	_	_	I-Premise
399	tamoxifen	_	_	I-Premise
400	alone	_	_	I-Premise
401	;	_	_	I-Premise
402	difference	_	_	I-Premise
403	=	_	_	I-Premise
404	8	_	_	I-Premise
405	%	_	_	I-Premise
406	;	_	_	I-Premise
407	95	_	_	I-Premise
408	%	_	_	I-Premise
409	CI	_	_	I-Premise
410	=	_	_	I-Premise
411	0	_	_	I-Premise
412	%	_	_	I-Premise
413	to	_	_	I-Premise
414	16	_	_	I-Premise
415	%	_	_	I-Premise
416	;	_	_	I-Premise
417	RR	_	_	I-Premise
418	=	_	_	I-Premise
419	0	_	_	I-Premise
420	.	_	_	I-Premise

421	51	_	_	I-Premise
422	;	_	_	I-Premise
423	95	_	_	I-Premise
424	%	_	_	I-Premise
425	CI	_	_	I-Premise
426	=	_	_	I-Premise
427	0	_	_	I-Premise
428	.	_	_	I-Premise

429	30	_	_	I-Premise
430	to	_	_	I-Premise
431	0	_	_	I-Premise
432	.	_	_	I-Premise

433	87	_	_	I-Premise
434	;	_	_	I-Premise
435	P	_	_	I-Premise
436	=	_	_	I-Premise
437	.	_	_	I-Premise

438	01	_	_	I-Premise
439	)	_	_	I-Premise
440	.	_	_	I-Premise

441	By	_	_	B-Premise
442	contrast	_	_	I-Premise
443	,	_	_	I-Premise
444	for	_	_	I-Premise
445	patients	_	_	I-Premise
446	with	_	_	I-Premise
447	ER	_	_	I-Premise
448	-	_	_	I-Premise
449	positive	_	_	I-Premise
450	tumors	_	_	I-Premise
451	,	_	_	I-Premise
452	addition	_	_	I-Premise
453	of	_	_	I-Premise
454	CMF	_	_	I-Premise
455	provided	_	_	I-Premise
456	no	_	_	I-Premise
457	benefit	_	_	I-Premise
458	in	_	_	I-Premise
459	terms	_	_	I-Premise
460	of	_	_	I-Premise
461	DFS	_	_	I-Premise
462	(	_	_	I-Premise
463	5	_	_	I-Premise
464	-	_	_	I-Premise
465	year	_	_	I-Premise
466	DFS	_	_	I-Premise
467	=	_	_	I-Premise
468	84	_	_	I-Premise
469	%	_	_	I-Premise
470	for	_	_	I-Premise
471	CMF	_	_	I-Premise
472	-	_	_	I-Premise
473	-	_	_	I-Premise
474	>	_	_	I-Premise
475	tamoxifen	_	_	I-Premise
476	versus	_	_	I-Premise
477	85	_	_	I-Premise
478	%	_	_	I-Premise
479	for	_	_	I-Premise
480	tamoxifen	_	_	I-Premise
481	alone	_	_	I-Premise
482	;	_	_	I-Premise
483	difference	_	_	I-Premise
484	=	_	_	I-Premise
485	-	_	_	I-Premise
486	1	_	_	I-Premise
487	;	_	_	I-Premise
488	95	_	_	I-Premise
489	%	_	_	I-Premise
490	CI	_	_	I-Premise
491	=	_	_	I-Premise
492	-	_	_	I-Premise
493	6	_	_	I-Premise
494	%	_	_	I-Premise
495	to	_	_	I-Premise
496	4	_	_	I-Premise
497	%	_	_	I-Premise
498	;	_	_	I-Premise
499	RR	_	_	I-Premise
500	=	_	_	I-Premise
501	0	_	_	I-Premise
502	.	_	_	I-Premise

503	99	_	_	I-Premise
504	;	_	_	I-Premise
505	95	_	_	I-Premise
506	%	_	_	I-Premise
507	CI	_	_	I-Premise
508	=	_	_	I-Premise
509	0	_	_	I-Premise
510	.	_	_	I-Premise

511	75	_	_	I-Premise
512	to	_	_	I-Premise
513	1	_	_	I-Premise
514	.	_	_	I-Premise

515	30	_	_	I-Premise
516	;	_	_	I-Premise
517	P	_	_	I-Premise
518	=	_	_	I-Premise
519	.	_	_	I-Premise

520	92	_	_	I-Premise
521	)	_	_	I-Premise
522	or	_	_	I-Premise
523	OS	_	_	I-Premise
524	(	_	_	I-Premise
525	5	_	_	I-Premise
526	-	_	_	I-Premise
527	year	_	_	I-Premise
528	OS	_	_	I-Premise
529	=	_	_	I-Premise
530	95	_	_	I-Premise
531	%	_	_	I-Premise
532	for	_	_	I-Premise
533	CMF	_	_	I-Premise
534	-	_	_	I-Premise
535	-	_	_	I-Premise
536	>	_	_	I-Premise
537	tamoxifen	_	_	I-Premise
538	versus	_	_	I-Premise
539	93	_	_	I-Premise
540	%	_	_	I-Premise
541	for	_	_	I-Premise
542	tamoxifen	_	_	I-Premise
543	alone	_	_	I-Premise
544	;	_	_	I-Premise
545	difference	_	_	I-Premise
546	=	_	_	I-Premise
547	2	_	_	I-Premise
548	%	_	_	I-Premise
549	;	_	_	I-Premise
550	95	_	_	I-Premise
551	%	_	_	I-Premise
552	CI	_	_	I-Premise
553	=	_	_	I-Premise
554	-	_	_	I-Premise
555	1	_	_	I-Premise
556	%	_	_	I-Premise
557	to	_	_	I-Premise
558	5	_	_	I-Premise
559	%	_	_	I-Premise
560	;	_	_	I-Premise
561	RR	_	_	I-Premise
562	=	_	_	I-Premise
563	0	_	_	I-Premise
564	.	_	_	I-Premise

565	95	_	_	I-Premise
566	;	_	_	I-Premise
567	95	_	_	I-Premise
568	%	_	_	I-Premise
569	CI	_	_	I-Premise
570	=	_	_	I-Premise
571	0	_	_	I-Premise
572	.	_	_	I-Premise

573	64	_	_	I-Premise
574	to	_	_	I-Premise
575	1	_	_	I-Premise
576	.	_	_	I-Premise

577	40	_	_	I-Premise
578	;	_	_	I-Premise
579	P	_	_	I-Premise
580	=	_	_	I-Premise
581	.	_	_	I-Premise

582	80	_	_	I-Premise
583	)	_	_	I-Premise
584	.	_	_	I-Premise

585	Postmenopausal	_	_	B-Claim
586	patients	_	_	I-Claim
587	with	_	_	I-Claim
588	lymph	_	_	I-Claim
589	node	_	_	I-Claim
590	-	_	_	I-Claim
591	negative	_	_	I-Claim
592	breast	_	_	I-Claim
593	cancer	_	_	I-Claim
594	benefited	_	_	I-Claim
595	substantially	_	_	I-Claim
596	from	_	_	I-Claim
597	adjuvant	_	_	I-Claim
598	chemotherapy	_	_	I-Claim
599	if	_	_	I-Claim
600	their	_	_	I-Claim
601	cancer	_	_	I-Claim
602	was	_	_	I-Claim
603	ER	_	_	I-Claim
604	-	_	_	I-Claim
605	negative	_	_	I-Claim
606	(	_	_	I-Claim
607	i	_	_	I-Claim
608	.	_	_	I-Claim

609	e	_	_	I-Claim
610	.	_	_	I-Claim

611	,	_	_	I-Claim
612	endocrine	_	_	I-Claim
613	-	_	_	I-Claim
614	nonresponsive	_	_	I-Claim
615	)	_	_	I-Claim
616	.	_	_	I-Claim

617	In	_	_	B-Claim
618	contrast	_	_	I-Claim
619	,	_	_	I-Claim
620	if	_	_	I-Claim
621	their	_	_	I-Claim
622	cancer	_	_	I-Claim
623	was	_	_	I-Claim
624	ER	_	_	I-Claim
625	-	_	_	I-Claim
626	positive	_	_	I-Claim
627	(	_	_	I-Claim
628	i	_	_	I-Claim
629	.	_	_	I-Claim

630	e	_	_	I-Claim
631	.	_	_	I-Claim

632	,	_	_	I-Claim
633	endocrine	_	_	I-Claim
634	-	_	_	I-Claim
635	responsive	_	_	I-Claim
636	)	_	_	I-Claim
637	,	_	_	I-Claim
638	they	_	_	I-Claim
639	obtained	_	_	I-Claim
640	no	_	_	I-Claim
641	benefit	_	_	I-Claim
642	from	_	_	I-Claim
643	the	_	_	I-Claim
644	combination	_	_	I-Claim
645	treatment	_	_	I-Claim
646	compared	_	_	I-Claim
647	with	_	_	I-Claim
648	tamoxifen	_	_	I-Claim
649	alone	_	_	I-Claim
650	.	_	_	I-Claim


0	The	_	_	O
1	physiological	_	_	O
2	and	_	_	O
3	psychological	_	_	O
4	stress	_	_	O
5	that	_	_	O
6	brain	_	_	O
7	tumor	_	_	O
8	patients	_	_	O
9	undergo	_	_	O
10	during	_	_	O
11	the	_	_	O
12	entire	_	_	O
13	surgical	_	_	O
14	experience	_	_	O
15	can	_	_	O
16	considerably	_	_	O
17	affect	_	_	O
18	several	_	_	O
19	aspects	_	_	O
20	of	_	_	O
21	their	_	_	O
22	hospitalization	_	_	O
23	.	_	_	O

24	The	_	_	O
25	purpose	_	_	O
26	of	_	_	O
27	this	_	_	O
28	study	_	_	O
29	was	_	_	O
30	to	_	_	O
31	examine	_	_	O
32	the	_	_	O
33	effects	_	_	O
34	of	_	_	O
35	live	_	_	O
36	music	_	_	O
37	therapy	_	_	O
38	on	_	_	O
39	quality	_	_	O
40	of	_	_	O
41	life	_	_	O
42	indicators	_	_	O
43	,	_	_	O
44	amount	_	_	O
45	of	_	_	O
46	medications	_	_	O
47	administered	_	_	O
48	and	_	_	O
49	length	_	_	O
50	of	_	_	O
51	stay	_	_	O
52	for	_	_	O
53	persons	_	_	O
54	receiving	_	_	O
55	elective	_	_	O
56	surgical	_	_	O
57	procedures	_	_	O
58	of	_	_	O
59	the	_	_	O
60	brain	_	_	O
61	.	_	_	O

62	Subjects	_	_	O
63	(	_	_	O
64	N	_	_	O
65	=	_	_	O
66	27	_	_	O
67	)	_	_	O
68	were	_	_	O
69	patients	_	_	O
70	admitted	_	_	O
71	for	_	_	O
72	some	_	_	O
73	type	_	_	O
74	of	_	_	O
75	surgical	_	_	O
76	procedure	_	_	O
77	of	_	_	O
78	the	_	_	O
79	brain	_	_	O
80	.	_	_	O

81	Subjects	_	_	O
82	were	_	_	O
83	randomly	_	_	O
84	assigned	_	_	O
85	to	_	_	O
86	either	_	_	O
87	the	_	_	O
88	control	_	_	O
89	group	_	_	O
90	receiving	_	_	O
91	no	_	_	O
92	music	_	_	O
93	intervention	_	_	O
94	(	_	_	O
95	n	_	_	O
96	=	_	_	O
97	13	_	_	O
98	)	_	_	O
99	or	_	_	O
100	the	_	_	O
101	experimental	_	_	O
102	group	_	_	O
103	receiving	_	_	O
104	pre	_	_	O
105	and	_	_	O
106	postoperative	_	_	O
107	live	_	_	O
108	music	_	_	O
109	therapy	_	_	O
110	sessions	_	_	O
111	(	_	_	O
112	n	_	_	O
113	=	_	_	O
114	14	_	_	O
115	)	_	_	O
116	.	_	_	O

117	Anxiety	_	_	O
118	,	_	_	O
119	mood	_	_	O
120	,	_	_	O
121	pain	_	_	O
122	,	_	_	O
123	perception	_	_	O
124	of	_	_	O
125	hospitalization	_	_	O
126	or	_	_	O
127	procedure	_	_	O
128	,	_	_	O
129	relaxation	_	_	O
130	,	_	_	O
131	and	_	_	O
132	stress	_	_	O
133	were	_	_	O
134	measured	_	_	O
135	using	_	_	O
136	a	_	_	O
137	self	_	_	O
138	-	_	_	O
139	report	_	_	O
140	Visual	_	_	O
141	Analog	_	_	O
142	Scale	_	_	O
143	(	_	_	O
144	VAS	_	_	O
145	)	_	_	O
146	for	_	_	O
147	each	_	_	O
148	of	_	_	O
149	the	_	_	O
150	variables	_	_	O
151	.	_	_	O

152	The	_	_	O
153	documented	_	_	O
154	administration	_	_	O
155	of	_	_	O
156	postoperative	_	_	O
157	pain	_	_	O
158	medications	_	_	O
159	;	_	_	O
160	the	_	_	O
161	frequency	_	_	O
162	,	_	_	O
163	dosage	_	_	O
164	,	_	_	O
165	type	_	_	O
166	,	_	_	O
167	and	_	_	O
168	how	_	_	O
169	it	_	_	O
170	was	_	_	O
171	given	_	_	O
172	was	_	_	O
173	also	_	_	O
174	compared	_	_	O
175	between	_	_	O
176	groups	_	_	O
177	.	_	_	O

178	Experimental	_	_	O
179	subjects	_	_	O
180	live	_	_	O
181	and	_	_	O
182	interactive	_	_	O
183	music	_	_	O
184	therapy	_	_	O
185	sessions	_	_	O
186	,	_	_	O
187	including	_	_	O
188	a	_	_	O
189	pre	_	_	O
190	-	_	_	O
191	operative	_	_	O
192	session	_	_	O
193	and	_	_	O
194	continuing	_	_	O
195	with	_	_	O
196	daily	_	_	O
197	sessions	_	_	O
198	until	_	_	O
199	the	_	_	O
200	patient	_	_	O
201	was	_	_	O
202	discharged	_	_	O
203	home	_	_	O
204	.	_	_	O

205	Control	_	_	O
206	subjects	_	_	O
207	received	_	_	O
208	routine	_	_	O
209	hospital	_	_	O
210	care	_	_	O
211	without	_	_	O
212	any	_	_	O
213	music	_	_	O
214	therapy	_	_	O
215	intervention	_	_	O
216	.	_	_	O

217	Differences	_	_	O
218	in	_	_	O
219	experimental	_	_	O
220	pretest	_	_	O
221	and	_	_	O
222	posttest	_	_	O
223	scores	_	_	O
224	were	_	_	O
225	analyzed	_	_	O
226	using	_	_	O
227	a	_	_	O
228	Wilcoxon	_	_	O
229	Matched	_	_	O
230	-	_	_	O
231	Pairs	_	_	O
232	Signed	_	_	O
233	-	_	_	O
234	Rank	_	_	O
235	test	_	_	O
236	.	_	_	O

237	Results	_	_	B-Premise
238	indicated	_	_	I-Premise
239	statistically	_	_	I-Premise
240	significant	_	_	I-Premise
241	differences	_	_	I-Premise
242	for	_	_	I-Premise
243	4	_	_	I-Premise
244	of	_	_	I-Premise
245	the	_	_	I-Premise
246	6	_	_	I-Premise
247	quality	_	_	I-Premise
248	of	_	_	I-Premise
249	life	_	_	I-Premise
250	measures	_	_	I-Premise
251	:	_	_	I-Premise
252	anxiety	_	_	I-Premise
253	(	_	_	I-Premise
254	p	_	_	I-Premise
255	=	_	_	I-Premise
256	.	_	_	I-Premise

257	03	_	_	I-Premise
258	)	_	_	I-Premise
259	,	_	_	I-Premise
260	perception	_	_	I-Premise
261	of	_	_	I-Premise
262	hospitalization	_	_	I-Premise
263	(	_	_	I-Premise
264	p	_	_	I-Premise
265	=	_	_	I-Premise
266	.	_	_	I-Premise

267	03	_	_	I-Premise
268	)	_	_	I-Premise
269	,	_	_	I-Premise
270	relaxation	_	_	I-Premise
271	(	_	_	I-Premise
272	p	_	_	I-Premise
273	=	_	_	I-Premise
274	.	_	_	I-Premise

275	001	_	_	I-Premise
276	)	_	_	I-Premise
277	,	_	_	I-Premise
278	and	_	_	I-Premise
279	stress	_	_	I-Premise
280	(	_	_	I-Premise
281	p	_	_	I-Premise
282	=	_	_	I-Premise
283	.	_	_	I-Premise

284	001	_	_	I-Premise
285	)	_	_	I-Premise
286	.	_	_	I-Premise

287	No	_	_	B-Premise
288	statistically	_	_	I-Premise
289	significant	_	_	I-Premise
290	differences	_	_	I-Premise
291	were	_	_	I-Premise
292	found	_	_	I-Premise
293	for	_	_	I-Premise
294	mood	_	_	I-Premise
295	(	_	_	I-Premise
296	p	_	_	I-Premise
297	>	_	_	I-Premise
298	.	_	_	I-Premise

299	05	_	_	I-Premise
300	)	_	_	I-Premise
301	or	_	_	I-Premise
302	pain	_	_	I-Premise
303	(	_	_	I-Premise
304	p	_	_	I-Premise
305	>	_	_	I-Premise
306	.	_	_	I-Premise

307	05	_	_	I-Premise
308	)	_	_	I-Premise
309	levels	_	_	I-Premise
310	.	_	_	I-Premise

311	Administration	_	_	O
312	amounts	_	_	O
313	of	_	_	O
314	nausea	_	_	O
315	and	_	_	O
316	pain	_	_	O
317	medications	_	_	O
318	were	_	_	O
319	compared	_	_	O
320	with	_	_	O
321	a	_	_	O
322	Two	_	_	O
323	-	_	_	O
324	Way	_	_	O
325	ANOVA	_	_	O
326	with	_	_	O
327	One	_	_	O
328	Repeated	_	_	O
329	Measure	_	_	O
330	resulting	_	_	O
331	in	_	_	O
332	no	_	_	O
333	significant	_	_	O
334	differences	_	_	O
335	between	_	_	O
336	groups	_	_	O
337	and	_	_	O
338	medications	_	_	O
339	,	_	_	O
340	F	_	_	O
341	(	_	_	O
342	1	_	_	O
343	,	_	_	O
344	51	_	_	O
345	)	_	_	O
346	=	_	_	O
347	0	_	_	O
348	.	_	_	O

349	03	_	_	O
350	;	_	_	O
351	p	_	_	O
352	>	_	_	O
353	.	_	_	O

354	05	_	_	O
355	.	_	_	O

356	Results	_	_	O
357	indicate	_	_	O
358	no	_	_	O
359	significant	_	_	O
360	differences	_	_	O
361	between	_	_	O
362	groups	_	_	O
363	for	_	_	O
364	length	_	_	O
365	of	_	_	O
366	stay	_	_	O
367	(	_	_	O
368	t	_	_	O
369	=	_	_	O
370	.	_	_	O

371	97	_	_	O
372	,	_	_	O
373	df	_	_	O
374	=	_	_	O
375	25	_	_	O
376	,	_	_	O
377	p	_	_	O
378	>	_	_	O
379	.	_	_	O

380	05	_	_	O
381	)	_	_	O
382	.	_	_	O

383	This	_	_	B-Claim
384	research	_	_	I-Claim
385	study	_	_	I-Claim
386	indicates	_	_	I-Claim
387	that	_	_	I-Claim
388	live	_	_	I-Claim
389	music	_	_	I-Claim
390	therapy	_	_	I-Claim
391	using	_	_	I-Claim
392	patient	_	_	I-Claim
393	-	_	_	I-Claim
394	preferred	_	_	I-Claim
395	music	_	_	I-Claim
396	can	_	_	I-Claim
397	be	_	_	I-Claim
398	beneficial	_	_	I-Claim
399	in	_	_	I-Claim
400	improving	_	_	I-Claim
401	quality	_	_	I-Claim
402	of	_	_	I-Claim
403	life	_	_	I-Claim
404	indicators	_	_	I-Claim
405	such	_	_	I-Claim
406	as	_	_	I-Claim
407	anxiety	_	_	I-Claim
408	,	_	_	I-Claim
409	perception	_	_	I-Claim
410	of	_	_	I-Claim
411	the	_	_	I-Claim
412	hospitalization	_	_	I-Claim
413	or	_	_	I-Claim
414	procedure	_	_	I-Claim
415	,	_	_	I-Claim
416	relaxation	_	_	I-Claim
417	,	_	_	I-Claim
418	and	_	_	I-Claim
419	stress	_	_	I-Claim
420	in	_	_	I-Claim
421	patients	_	_	I-Claim
422	undergoing	_	_	I-Claim
423	surgical	_	_	I-Claim
424	procedures	_	_	I-Claim
425	of	_	_	I-Claim
426	the	_	_	I-Claim
427	brain	_	_	I-Claim
428	.	_	_	I-Claim


0	To	_	_	O
1	examine	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	a	_	_	O
6	scapula	_	_	O
7	-	_	_	O
8	oriented	_	_	O
9	exercise	_	_	O
10	on	_	_	O
11	upper	_	_	O
12	limb	_	_	O
13	dysfunction	_	_	O
14	in	_	_	O
15	breast	_	_	O
16	cancer	_	_	O
17	survivors	_	_	O
18	.	_	_	O

19	A	_	_	O
20	prospective	_	_	O
21	randomized	_	_	O
22	,	_	_	O
23	controlled	_	_	O
24	pilot	_	_	O
25	trial	_	_	O
26	with	_	_	O
27	historical	_	_	O
28	control	_	_	O
29	.	_	_	O

30	Rehabilitation	_	_	O
31	department	_	_	O
32	at	_	_	O
33	a	_	_	O
34	university	_	_	O
35	hospital	_	_	O
36	.	_	_	O

37	Thirty	_	_	O
38	-	_	_	O
39	two	_	_	O
40	women	_	_	O
41	with	_	_	O
42	breast	_	_	O
43	cancer	_	_	O
44	were	_	_	O
45	randomly	_	_	O
46	assigned	_	_	O
47	to	_	_	O
48	scapula	_	_	O
49	-	_	_	O
50	oriented	_	_	O
51	exercise	_	_	O
52	group	_	_	O
53	(	_	_	O
54	n	_	_	O
55	=	_	_	O
56	16	_	_	O
57	)	_	_	O
58	and	_	_	O
59	general	_	_	O
60	exercise	_	_	O
61	group	_	_	O
62	(	_	_	O
63	n	_	_	O
64	=	_	_	O
65	16	_	_	O
66	)	_	_	O
67	.	_	_	O

68	An	_	_	O
69	historical	_	_	O
70	control	_	_	O
71	group	_	_	O
72	(	_	_	O
73	n	_	_	O
74	=	_	_	O
75	18	_	_	O
76	)	_	_	O
77	without	_	_	O
78	exercise	_	_	O
79	was	_	_	O
80	enrolled	_	_	O
81	from	_	_	O
82	breast	_	_	O
83	cancer	_	_	O
84	survivors	_	_	O
85	.	_	_	O

86	The	_	_	O
87	scapula	_	_	O
88	-	_	_	O
89	oriented	_	_	O
90	exercises	_	_	O
91	were	_	_	O
92	designed	_	_	O
93	focusing	_	_	O
94	on	_	_	O
95	scapulothoracic	_	_	O
96	movement	_	_	O
97	.	_	_	O

98	The	_	_	O
99	general	_	_	O
100	exercise	_	_	O
101	group	_	_	O
102	performed	_	_	O
103	body	_	_	O
104	conditioning	_	_	O
105	exercise	_	_	O
106	.	_	_	O

107	Exercise	_	_	O
108	therapies	_	_	O
109	were	_	_	O
110	performed	_	_	O
111	for	_	_	O
112	one	_	_	O
113	session	_	_	O
114	per	_	_	O
115	week	_	_	O
116	for	_	_	O
117	eight	_	_	O
118	weeks	_	_	O
119	.	_	_	O

120	Pain	_	_	O
121	and	_	_	O
122	physical	_	_	O
123	disabilities	_	_	O
124	related	_	_	O
125	to	_	_	O
126	upper	_	_	O
127	limb	_	_	O
128	dysfunction	_	_	O
129	,	_	_	O
130	quality	_	_	O
131	of	_	_	O
132	life	_	_	O
133	and	_	_	O
134	depression	_	_	O
135	were	_	_	O
136	used	_	_	O
137	as	_	_	O
138	subjective	_	_	O
139	outcomes	_	_	O
140	.	_	_	O

141	Objective	_	_	O
142	outcome	_	_	O
143	measures	_	_	O
144	included	_	_	O
145	shoulder	_	_	O
146	range	_	_	O
147	of	_	_	O
148	motion	_	_	O
149	and	_	_	O
150	strength	_	_	O
151	.	_	_	O

152	Outcomes	_	_	O
153	were	_	_	O
154	assessed	_	_	O
155	at	_	_	O
156	baseline	_	_	O
157	and	_	_	O
158	post	_	_	O
159	exercise	_	_	O
160	.	_	_	O

161	At	_	_	O
162	baseline	_	_	O
163	,	_	_	O
164	no	_	_	O
165	significant	_	_	O
166	difference	_	_	O
167	was	_	_	O
168	observed	_	_	O
169	among	_	_	O
170	the	_	_	O
171	three	_	_	O
172	groups	_	_	O
173	.	_	_	O

174	The	_	_	B-Premise
175	scapula	_	_	I-Premise
176	-	_	_	I-Premise
177	oriented	_	_	I-Premise
178	exercise	_	_	I-Premise
179	group	_	_	I-Premise
180	showed	_	_	I-Premise
181	improvements	_	_	I-Premise
182	in	_	_	I-Premise
183	pain	_	_	I-Premise
184	,	_	_	I-Premise
185	physical	_	_	I-Premise
186	function	_	_	I-Premise
187	,	_	_	I-Premise
188	social	_	_	I-Premise
189	function	_	_	I-Premise
190	,	_	_	I-Premise
191	and	_	_	I-Premise
192	global	_	_	I-Premise
193	quality	_	_	I-Premise
194	of	_	_	I-Premise
195	life	_	_	I-Premise
196	compared	_	_	I-Premise
197	with	_	_	I-Premise
198	baseline	_	_	I-Premise
199	,	_	_	I-Premise
200	whereas	_	_	I-Premise
201	the	_	_	I-Premise
202	general	_	_	I-Premise
203	exercise	_	_	I-Premise
204	group	_	_	I-Premise
205	showed	_	_	I-Premise
206	improved	_	_	I-Premise
207	fatigue	_	_	I-Premise
208	and	_	_	I-Premise
209	range	_	_	I-Premise
210	of	_	_	I-Premise
211	motion	_	_	I-Premise
212	.	_	_	I-Premise

213	The	_	_	B-Premise
214	change	_	_	I-Premise
215	in	_	_	I-Premise
216	global	_	_	I-Premise
217	quality	_	_	I-Premise
218	of	_	_	I-Premise
219	life	_	_	I-Premise
220	(	_	_	I-Premise
221	P	_	_	I-Premise
222	=	_	_	I-Premise
223	0	_	_	I-Premise
224	.	_	_	I-Premise

225	067	_	_	I-Premise
226	;	_	_	I-Premise
227	effect	_	_	I-Premise
228	size	_	_	I-Premise
229	,	_	_	I-Premise
230	0	_	_	I-Premise
231	.	_	_	I-Premise

232	33	_	_	I-Premise
233	)	_	_	I-Premise
234	and	_	_	I-Premise
235	strength	_	_	I-Premise
236	of	_	_	I-Premise
237	external	_	_	I-Premise
238	rotation	_	_	I-Premise
239	(	_	_	I-Premise
240	P	_	_	I-Premise
241	=	_	_	I-Premise
242	0	_	_	I-Premise
243	.	_	_	I-Premise

244	001	_	_	I-Premise
245	;	_	_	I-Premise
246	effect	_	_	I-Premise
247	size	_	_	I-Premise
248	,	_	_	I-Premise
249	0	_	_	I-Premise
250	.	_	_	I-Premise

251	55	_	_	I-Premise
252	)	_	_	I-Premise
253	were	_	_	I-Premise
254	significantly	_	_	I-Premise
255	greater	_	_	I-Premise
256	in	_	_	I-Premise
257	the	_	_	I-Premise
258	scapula	_	_	I-Premise
259	-	_	_	I-Premise
260	oriented	_	_	I-Premise
261	exercise	_	_	I-Premise
262	group	_	_	I-Premise
263	than	_	_	I-Premise
264	in	_	_	I-Premise
265	the	_	_	I-Premise
266	general	_	_	I-Premise
267	exercise	_	_	I-Premise
268	and	_	_	I-Premise
269	control	_	_	I-Premise
270	group	_	_	I-Premise
271	.	_	_	I-Premise

272	Scapula	_	_	B-Claim
273	-	_	_	I-Claim
274	oriented	_	_	I-Claim
275	exercise	_	_	I-Claim
276	had	_	_	I-Claim
277	beneficial	_	_	I-Claim
278	effects	_	_	I-Claim
279	on	_	_	I-Claim
280	pain	_	_	I-Claim
281	,	_	_	I-Claim
282	quality	_	_	I-Claim
283	of	_	_	I-Claim
284	life	_	_	I-Claim
285	and	_	_	I-Claim
286	aspects	_	_	I-Claim
287	of	_	_	I-Claim
288	strength	_	_	I-Claim
289	.	_	_	I-Claim

290	The	_	_	O
291	sample	_	_	O
292	size	_	_	O
293	required	_	_	O
294	in	_	_	O
295	a	_	_	O
296	larger	_	_	O
297	definitive	_	_	O
298	study	_	_	O
299	is	_	_	O
300	32	_	_	O
301	subjects	_	_	O
302	per	_	_	O
303	group	_	_	O
304	.	_	_	O


0	The	_	_	O
1	impact	_	_	O
2	of	_	_	O
3	the	_	_	O
4	side	_	_	O
5	effects	_	_	O
6	of	_	_	O
7	megestrol	_	_	O
8	acetate	_	_	O
9	on	_	_	O
10	the	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	of	_	_	O
15	noncachectic	_	_	O
16	women	_	_	O
17	with	_	_	O
18	advanced	_	_	O
19	breast	_	_	O
20	cancer	_	_	O
21	was	_	_	O
22	studied	_	_	O
23	in	_	_	O
24	a	_	_	O
25	dose	_	_	O
26	-	_	_	O
27	response	_	_	O
28	clinical	_	_	O
29	trial	_	_	O
30	of	_	_	O
31	the	_	_	O
32	Cancer	_	_	O
33	and	_	_	O
34	Leukemia	_	_	O
35	Group	_	_	O
36	B	_	_	O
37	(	_	_	O
38	CALGB	_	_	O
39	8741	_	_	O
40	)	_	_	O
41	.	_	_	O

42	Side	_	_	O
43	effects	_	_	O
44	of	_	_	O
45	appetite	_	_	O
46	increase	_	_	O
47	and	_	_	O
48	weight	_	_	O
49	gain	_	_	O
50	at	_	_	O
51	higher	_	_	O
52	doses	_	_	O
53	were	_	_	O
54	predicted	_	_	O
55	to	_	_	O
56	have	_	_	O
57	a	_	_	O
58	negative	_	_	O
59	effect	_	_	O
60	on	_	_	O
61	quality	_	_	O
62	of	_	_	O
63	life	_	_	O
64	.	_	_	O

65	Stage	_	_	O
66	IV	_	_	O
67	breast	_	_	O
68	cancer	_	_	O
69	patients	_	_	O
70	were	_	_	O
71	randomized	_	_	O
72	to	_	_	O
73	receive	_	_	O
74	either	_	_	O
75	160	_	_	O
76	,	_	_	O
77	800	_	_	O
78	,	_	_	O
79	or	_	_	O
80	1	_	_	O
81	,	_	_	O
82	600	_	_	O
83	mg	_	_	O
84	/	_	_	O
85	d	_	_	O
86	of	_	_	O
87	megestrol	_	_	O
88	acetate	_	_	O
89	.	_	_	O

90	Quality	_	_	O
91	of	_	_	O
92	life	_	_	O
93	was	_	_	O
94	assessed	_	_	O
95	in	_	_	O
96	131	_	_	O
97	patients	_	_	O
98	at	_	_	O
99	trial	_	_	O
100	entry	_	_	O
101	and	_	_	O
102	at	_	_	O
103	1	_	_	O
104	and	_	_	O
105	3	_	_	O
106	months	_	_	O
107	while	_	_	O
108	on	_	_	O
109	treatment	_	_	O
110	,	_	_	O
111	by	_	_	O
112	telephone	_	_	O
113	interview	_	_	O
114	,	_	_	O
115	using	_	_	O
116	the	_	_	O
117	following	_	_	O
118	measures	_	_	O
119	:	_	_	O
120	the	_	_	O
121	Functional	_	_	O
122	Living	_	_	O
123	Index	_	_	O
124	-	_	_	O
125	Cancer	_	_	O
126	(	_	_	O
127	FLIC	_	_	O
128	)	_	_	O
129	,	_	_	O
130	Rand	_	_	O
131	Functional	_	_	O
132	Limitations	_	_	O
133	Scale	_	_	O
134	,	_	_	O
135	Rand	_	_	O
136	Mental	_	_	O
137	Health	_	_	O
138	Inventory	_	_	O
139	(	_	_	O
140	MHI	_	_	O
141	)	_	_	O
142	,	_	_	O
143	the	_	_	O
144	Body	_	_	O
145	Image	_	_	O
146	Subscale	_	_	O
147	,	_	_	O
148	and	_	_	O
149	linear	_	_	O
150	analog	_	_	O
151	scales	_	_	O
152	of	_	_	O
153	drug	_	_	O
154	side	_	_	O
155	effects	_	_	O
156	.	_	_	O

157	At	_	_	B-Premise
158	3	_	_	I-Premise
159	months	_	_	I-Premise
160	,	_	_	I-Premise
161	women	_	_	I-Premise
162	treated	_	_	I-Premise
163	with	_	_	I-Premise
164	160	_	_	I-Premise
165	mg	_	_	I-Premise
166	/	_	_	I-Premise
167	d	_	_	I-Premise
168	reported	_	_	I-Premise
169	less	_	_	I-Premise
170	severe	_	_	I-Premise
171	side	_	_	I-Premise
172	effects	_	_	I-Premise
173	(	_	_	I-Premise
174	P	_	_	I-Premise
175	<	_	_	I-Premise
176	.	_	_	I-Premise

177	0005	_	_	I-Premise
178	)	_	_	I-Premise
179	,	_	_	I-Premise
180	better	_	_	I-Premise
181	physical	_	_	I-Premise
182	functioning	_	_	I-Premise
183	(	_	_	I-Premise
184	FLS	_	_	I-Premise
185	,	_	_	I-Premise
186	P	_	_	I-Premise
187	<	_	_	I-Premise
188	.	_	_	I-Premise

189	0005	_	_	I-Premise
190	)	_	_	I-Premise
191	,	_	_	I-Premise
192	less	_	_	I-Premise
193	psychologic	_	_	I-Premise
194	distress	_	_	I-Premise
195	(	_	_	I-Premise
196	MHI	_	_	I-Premise
197	,	_	_	I-Premise
198	P	_	_	I-Premise
199	=	_	_	I-Premise
200	.	_	_	I-Premise

201	008	_	_	I-Premise
202	)	_	_	I-Premise
203	,	_	_	I-Premise
204	and	_	_	I-Premise
205	an	_	_	I-Premise
206	improvement	_	_	I-Premise
207	in	_	_	I-Premise
208	overall	_	_	I-Premise
209	quality	_	_	I-Premise
210	of	_	_	I-Premise
211	life	_	_	I-Premise
212	(	_	_	I-Premise
213	FLIC	_	_	I-Premise
214	,	_	_	I-Premise
215	P	_	_	I-Premise
216	=	_	_	I-Premise
217	.	_	_	I-Premise

218	003	_	_	I-Premise
219	)	_	_	I-Premise
220	from	_	_	I-Premise
221	the	_	_	I-Premise
222	time	_	_	I-Premise
223	of	_	_	I-Premise
224	study	_	_	I-Premise
225	entry	_	_	I-Premise
226	as	_	_	I-Premise
227	compared	_	_	I-Premise
228	with	_	_	I-Premise
229	those	_	_	I-Premise
230	treated	_	_	I-Premise
231	with	_	_	I-Premise
232	1	_	_	I-Premise
233	,	_	_	I-Premise
234	600	_	_	I-Premise
235	mg	_	_	I-Premise
236	/	_	_	I-Premise
237	d	_	_	I-Premise
238	.	_	_	I-Premise

239	Patients	_	_	B-Premise
240	who	_	_	I-Premise
241	received	_	_	I-Premise
242	the	_	_	I-Premise
243	800	_	_	I-Premise
244	-	_	_	I-Premise
245	mg	_	_	I-Premise
246	/	_	_	I-Premise
247	d	_	_	I-Premise
248	dose	_	_	I-Premise
249	fell	_	_	I-Premise
250	between	_	_	I-Premise
251	the	_	_	I-Premise
252	low	_	_	I-Premise
253	-	_	_	I-Premise
254	and	_	_	I-Premise
255	high	_	_	I-Premise
256	-	_	_	I-Premise
257	dose	_	_	I-Premise
258	arms	_	_	I-Premise
259	in	_	_	I-Premise
260	reported	_	_	I-Premise
261	intensity	_	_	I-Premise
262	of	_	_	I-Premise
263	drug	_	_	I-Premise
264	side	_	_	I-Premise
265	effects	_	_	I-Premise
266	,	_	_	I-Premise
267	but	_	_	B-Premise
268	responded	_	_	I-Premise
269	similarly	_	_	I-Premise
270	to	_	_	I-Premise
271	those	_	_	I-Premise
272	in	_	_	I-Premise
273	the	_	_	I-Premise
274	160	_	_	I-Premise
275	-	_	_	I-Premise
276	mg	_	_	I-Premise
277	/	_	_	I-Premise
278	d	_	_	I-Premise
279	group	_	_	I-Premise
280	in	_	_	I-Premise
281	terms	_	_	I-Premise
282	of	_	_	I-Premise
283	physical	_	_	I-Premise
284	functioning	_	_	I-Premise
285	,	_	_	I-Premise
286	psychologic	_	_	I-Premise
287	distress	_	_	I-Premise
288	,	_	_	I-Premise
289	and	_	_	I-Premise
290	overall	_	_	I-Premise
291	quality	_	_	I-Premise
292	of	_	_	I-Premise
293	life	_	_	I-Premise
294	.	_	_	I-Premise

295	Unless	_	_	B-Claim
296	additional	_	_	I-Claim
297	follow	_	_	I-Claim
298	-	_	_	I-Claim
299	up	_	_	I-Claim
300	data	_	_	I-Claim
301	demonstrate	_	_	I-Claim
302	a	_	_	I-Claim
303	survival	_	_	I-Claim
304	advantage	_	_	I-Claim
305	at	_	_	I-Claim
306	higher	_	_	I-Claim
307	doses	_	_	I-Claim
308	,	_	_	I-Claim
309	the	_	_	I-Claim
310	160	_	_	I-Claim
311	-	_	_	I-Claim
312	mg	_	_	I-Claim
313	/	_	_	I-Claim
314	d	_	_	I-Claim
315	dose	_	_	I-Claim
316	is	_	_	I-Claim
317	optimal	_	_	I-Claim
318	,	_	_	I-Claim
319	achieving	_	_	I-Claim
320	maximal	_	_	I-Claim
321	treatment	_	_	I-Claim
322	effect	_	_	I-Claim
323	with	_	_	I-Claim
324	the	_	_	I-Claim
325	fewest	_	_	I-Claim
326	side	_	_	I-Claim
327	effects	_	_	I-Claim
328	and	_	_	I-Claim
329	better	_	_	I-Claim
330	quality	_	_	I-Claim
331	of	_	_	I-Claim
332	life	_	_	I-Claim
333	.	_	_	I-Claim


0	The	_	_	O
1	European	_	_	O
2	Study	_	_	O
3	Group	_	_	O
4	for	_	_	O
5	Pancreatic	_	_	O
6	Cancer	_	_	O
7	(	_	_	O
8	ESPAC	_	_	O
9	-	_	_	O
10	1	_	_	O
11	)	_	_	O
12	study	_	_	O
13	is	_	_	O
14	the	_	_	O
15	largest	_	_	O
16	study	_	_	O
17	of	_	_	O
18	adjuvant	_	_	O
19	treatment	_	_	O
20	for	_	_	O
21	pancreatic	_	_	O
22	ductal	_	_	O
23	adenocarcinoma	_	_	O
24	to	_	_	O
25	date	_	_	O
26	and	_	_	O
27	confirmed	_	_	O
28	a	_	_	O
29	survival	_	_	O
30	advantage	_	_	O
31	for	_	_	O
32	adjuvant	_	_	O
33	chemotherapy	_	_	O
34	but	_	_	O
35	not	_	_	O
36	for	_	_	O
37	chemoradiation	_	_	O
38	.	_	_	O

39	The	_	_	O
40	importance	_	_	O
41	of	_	_	O
42	parallel	_	_	O
43	evaluation	_	_	O
44	of	_	_	O
45	survival	_	_	O
46	and	_	_	O
47	quality	_	_	O
48	of	_	_	O
49	life	_	_	O
50	(	_	_	O
51	QoL	_	_	O
52	)	_	_	O
53	has	_	_	O
54	been	_	_	O
55	recognized	_	_	O
56	as	_	_	O
57	fundamental	_	_	O
58	and	_	_	O
59	the	_	_	O
60	aim	_	_	O
61	was	_	_	O
62	to	_	_	O
63	assess	_	_	O
64	QoL	_	_	O
65	and	_	_	O
66	quality	_	_	O
67	adjusted	_	_	O
68	survival	_	_	O
69	.	_	_	O

70	A	_	_	O
71	longitudinal	_	_	O
72	QoL	_	_	O
73	study	_	_	O
74	on	_	_	O
75	a	_	_	O
76	subset	_	_	O
77	of	_	_	O
78	ESPAC	_	_	O
79	-	_	_	O
80	1	_	_	O
81	patients	_	_	O
82	who	_	_	O
83	prospectively	_	_	O
84	completed	_	_	O
85	the	_	_	O
86	EORTC	_	_	O
87	QLQ	_	_	O
88	C	_	_	O
89	-	_	_	O
90	30	_	_	O
91	questionnaire	_	_	O
92	during	_	_	O
93	treatment	_	_	O
94	and	_	_	O
95	follow	_	_	O
96	-	_	_	O
97	up	_	_	O
98	.	_	_	O

99	An	_	_	O
100	integrated	_	_	O
101	quality	_	_	O
102	-	_	_	O
103	survival	_	_	O
104	product	_	_	O
105	method	_	_	O
106	was	_	_	O
107	used	_	_	O
108	to	_	_	O
109	adjust	_	_	O
110	any	_	_	O
111	treatment	_	_	O
112	effect	_	_	O
113	on	_	_	O
114	survival	_	_	O
115	by	_	_	O
116	a	_	_	O
117	function	_	_	O
118	of	_	_	O
119	measured	_	_	O
120	QoL	_	_	O
121	,	_	_	O
122	calculated	_	_	O
123	over	_	_	O
124	a	_	_	O
125	restricted	_	_	O
126	24	_	_	O
127	-	_	_	O
128	month	_	_	O
129	-	_	_	O
130	period	_	_	O
131	(	_	_	O
132	QALM	_	_	O
133	-	_	_	O
134	24	_	_	O
135	)	_	_	O
136	.	_	_	O

137	Three	_	_	O
138	hundred	_	_	O
139	and	_	_	O
140	sixteen	_	_	O
141	patients	_	_	O
142	completed	_	_	O
143	1	_	_	O
144	,	_	_	O
145	201	_	_	O
146	questionnaires	_	_	O
147	.	_	_	O

148	There	_	_	O
149	were	_	_	O
150	no	_	_	O
151	differences	_	_	O
152	between	_	_	O
153	treatment	_	_	O
154	groups	_	_	O
155	in	_	_	O
156	dimension	_	_	O
157	scores	_	_	O
158	at	_	_	O
159	baseline	_	_	O
160	(	_	_	O
161	randomization	_	_	O
162	)	_	_	O
163	.	_	_	O

164	For	_	_	B-Premise
165	the	_	_	I-Premise
166	chemotherapy	_	_	I-Premise
167	group	_	_	I-Premise
168	,	_	_	I-Premise
169	the	_	_	I-Premise
170	mean	_	_	I-Premise
171	Quality	_	_	I-Premise
172	Adjusted	_	_	I-Premise
173	Life	_	_	I-Premise
174	Months	_	_	I-Premise
175	over	_	_	I-Premise
176	24	_	_	I-Premise
177	months	_	_	I-Premise
178	(	_	_	I-Premise
179	QALM	_	_	I-Premise
180	-	_	_	I-Premise
181	24	_	_	I-Premise
182	)	_	_	I-Premise
183	was	_	_	I-Premise
184	9	_	_	I-Premise
185	.	_	_	I-Premise

186	6	_	_	I-Premise
187	(	_	_	I-Premise
188	95	_	_	I-Premise
189	%	_	_	I-Premise
190	CI	_	_	I-Premise
191	:	_	_	I-Premise
192	8	_	_	I-Premise
193	.	_	_	I-Premise

194	7	_	_	I-Premise
195	,	_	_	I-Premise
196	11	_	_	I-Premise
197	.	_	_	I-Premise

198	2	_	_	I-Premise
199	)	_	_	I-Premise
200	months	_	_	I-Premise
201	compared	_	_	I-Premise
202	with	_	_	I-Premise
203	the	_	_	I-Premise
204	mean	_	_	I-Premise
205	QALM	_	_	I-Premise
206	-	_	_	I-Premise
207	24	_	_	I-Premise
208	of	_	_	I-Premise
209	8	_	_	I-Premise
210	.	_	_	I-Premise

211	6	_	_	I-Premise
212	(	_	_	I-Premise
213	95	_	_	I-Premise
214	%	_	_	I-Premise
215	CI	_	_	I-Premise
216	:	_	_	I-Premise
217	7	_	_	I-Premise
218	.	_	_	I-Premise

219	6	_	_	I-Premise
220	,	_	_	I-Premise
221	10	_	_	I-Premise
222	.	_	_	I-Premise

223	5	_	_	I-Premise
224	)	_	_	I-Premise
225	months	_	_	I-Premise
226	for	_	_	I-Premise
227	the	_	_	I-Premise
228	no	_	_	I-Premise
229	chemotherapy	_	_	I-Premise
230	group	_	_	I-Premise
231	.	_	_	I-Premise

232	For	_	_	B-Premise
233	the	_	_	I-Premise
234	chemoradiation	_	_	I-Premise
235	group	_	_	I-Premise
236	,	_	_	I-Premise
237	the	_	_	I-Premise
238	mean	_	_	I-Premise
239	QALM	_	_	I-Premise
240	-	_	_	I-Premise
241	24	_	_	I-Premise
242	was	_	_	I-Premise
243	7	_	_	I-Premise
244	.	_	_	I-Premise

245	1	_	_	I-Premise
246	(	_	_	I-Premise
247	95	_	_	I-Premise
248	%	_	_	I-Premise
249	CI	_	_	I-Premise
250	:	_	_	I-Premise
251	6	_	_	I-Premise
252	.	_	_	I-Premise

253	0	_	_	I-Premise
254	,	_	_	I-Premise
255	9	_	_	I-Premise
256	.	_	_	I-Premise

257	0	_	_	I-Premise
258	)	_	_	I-Premise
259	months	_	_	I-Premise
260	compared	_	_	I-Premise
261	with	_	_	I-Premise
262	the	_	_	I-Premise
263	mean	_	_	I-Premise
264	QALM	_	_	I-Premise
265	-	_	_	I-Premise
266	24	_	_	I-Premise
267	of	_	_	I-Premise
268	8	_	_	I-Premise
269	.	_	_	I-Premise

270	1	_	_	I-Premise
271	(	_	_	I-Premise
272	95	_	_	I-Premise
273	%	_	_	I-Premise
274	CI	_	_	I-Premise
275	:	_	_	I-Premise
276	7	_	_	I-Premise
277	.	_	_	I-Premise

278	0	_	_	I-Premise
279	,	_	_	I-Premise
280	10	_	_	I-Premise
281	.	_	_	I-Premise

282	0	_	_	I-Premise
283	)	_	_	I-Premise
284	months	_	_	I-Premise
285	for	_	_	I-Premise
286	the	_	_	I-Premise
287	no	_	_	I-Premise
288	chemoradiation	_	_	I-Premise
289	group	_	_	I-Premise
290	.	_	_	I-Premise

291	The	_	_	B-Claim
292	previously	_	_	I-Claim
293	reported	_	_	I-Claim
294	survival	_	_	I-Claim
295	advantage	_	_	I-Claim
296	supporting	_	_	I-Claim
297	the	_	_	I-Claim
298	use	_	_	I-Claim
299	of	_	_	I-Claim
300	adjuvant	_	_	I-Claim
301	chemotherapy	_	_	I-Claim
302	is	_	_	I-Claim
303	maintained	_	_	I-Claim
304	when	_	_	I-Claim
305	adjusted	_	_	I-Claim
306	using	_	_	I-Claim
307	quality	_	_	I-Claim
308	adjusted	_	_	I-Claim
309	survival	_	_	I-Claim
310	methodology	_	_	I-Claim
311	.	_	_	I-Claim

312	Chemotherapy	_	_	B-Claim
313	provided	_	_	I-Claim
314	on	_	_	I-Claim
315	average	_	_	I-Claim
316	an	_	_	I-Claim
317	additional	_	_	I-Claim
318	1	_	_	I-Claim
319	.	_	_	I-Claim

320	0	_	_	I-Claim
321	quality	_	_	I-Claim
322	-	_	_	I-Claim
323	adjusted	_	_	I-Claim
324	life	_	_	I-Claim
325	months	_	_	I-Claim
326	within	_	_	I-Claim
327	a	_	_	I-Claim
328	restricted	_	_	I-Claim
329	2	_	_	I-Claim
330	-	_	_	I-Claim
331	year	_	_	I-Claim
332	time	_	_	I-Claim
333	period	_	_	I-Claim
334	from	_	_	I-Claim
335	the	_	_	I-Claim
336	time	_	_	I-Claim
337	of	_	_	I-Claim
338	resection	_	_	I-Claim
339	.	_	_	I-Claim


0	Pemetrexed	_	_	O
1	maintenance	_	_	O
2	therapy	_	_	O
3	significantly	_	_	O
4	improved	_	_	O
5	overall	_	_	O
6	survival	_	_	O
7	and	_	_	O
8	progression	_	_	O
9	-	_	_	O
10	free	_	_	O
11	survival	_	_	O
12	compared	_	_	O
13	with	_	_	O
14	placebo	_	_	O
15	,	_	_	O
16	and	_	_	O
17	had	_	_	O
18	a	_	_	O
19	good	_	_	O
20	safety	_	_	O
21	profile	_	_	O
22	in	_	_	O
23	a	_	_	O
24	phase	_	_	O
25	3	_	_	O
26	placebo	_	_	O
27	-	_	_	O
28	controlled	_	_	O
29	study	_	_	O
30	in	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	advanced	_	_	O
34	non	_	_	O
35	-	_	_	O
36	small	_	_	O
37	-	_	_	O
38	cell	_	_	O
39	lung	_	_	O
40	cancer	_	_	O
41	(	_	_	O
42	NSCLC	_	_	O
43	)	_	_	O
44	.	_	_	O

45	Results	_	_	O
46	for	_	_	O
47	quality	_	_	O
48	of	_	_	O
49	life	_	_	O
50	,	_	_	O
51	symptom	_	_	O
52	palliation	_	_	O
53	,	_	_	O
54	and	_	_	O
55	tolerability	_	_	O
56	are	_	_	O
57	presented	_	_	O
58	here	_	_	O
59	.	_	_	O

60	After	_	_	O
61	four	_	_	O
62	cycles	_	_	O
63	of	_	_	O
64	platinum	_	_	O
65	-	_	_	O
66	based	_	_	O
67	induction	_	_	O
68	therapy	_	_	O
69	,	_	_	O
70	663	_	_	O
71	patients	_	_	O
72	with	_	_	O
73	stage	_	_	O
74	IIIB	_	_	O
75	or	_	_	O
76	stage	_	_	O
77	IV	_	_	O
78	NSCLC	_	_	O
79	and	_	_	O
80	Eastern	_	_	O
81	Cooperative	_	_	O
82	Oncology	_	_	O
83	Group	_	_	O
84	performance	_	_	O
85	status	_	_	O
86	of	_	_	O
87	0	_	_	O
88	or	_	_	O
89	1	_	_	O
90	were	_	_	O
91	randomly	_	_	O
92	assigned	_	_	O
93	(	_	_	O
94	in	_	_	O
95	a	_	_	O
96	2	_	_	O
97	:	_	_	O
98	1	_	_	O
99	ratio	_	_	O
100	)	_	_	O
101	from	_	_	O
102	March	_	_	O
103	15	_	_	O
104	,	_	_	O
105	2005	_	_	O
106	,	_	_	O
107	to	_	_	O
108	July	_	_	O
109	20	_	_	O
110	,	_	_	O
111	2007	_	_	O
112	,	_	_	O
113	using	_	_	O
114	the	_	_	O
115	Pocock	_	_	O
116	and	_	_	O
117	Simon	_	_	O
118	minimisation	_	_	O
119	method	_	_	O
120	to	_	_	O
121	receive	_	_	O
122	pemetrexed	_	_	O
123	(	_	_	O
124	500	_	_	O
125	mg	_	_	O
126	/	_	_	O
127	m	_	_	O
128	(	_	_	O
129	2	_	_	O
130	)	_	_	O
131	every	_	_	O
132	21	_	_	O
133	days	_	_	O
134	;	_	_	O
135	n	_	_	O
136	=	_	_	O
137	441	_	_	O
138	)	_	_	O
139	or	_	_	O
140	placebo	_	_	O
141	(	_	_	O
142	n	_	_	O
143	=	_	_	O
144	222	_	_	O
145	)	_	_	O
146	plus	_	_	O
147	best	_	_	O
148	supportive	_	_	O
149	care	_	_	O
150	until	_	_	O
151	disease	_	_	O
152	progression	_	_	O
153	.	_	_	O

154	The	_	_	O
155	primary	_	_	O
156	efficacy	_	_	O
157	data	_	_	O
158	have	_	_	O
159	been	_	_	O
160	reported	_	_	O
161	previously	_	_	O
162	.	_	_	O

163	Patients	_	_	O
164	completed	_	_	O
165	the	_	_	O
166	Lung	_	_	O
167	Cancer	_	_	O
168	Symptom	_	_	O
169	Scale	_	_	O
170	(	_	_	O
171	LCSS	_	_	O
172	)	_	_	O
173	at	_	_	O
174	baseline	_	_	O
175	,	_	_	O
176	after	_	_	O
177	each	_	_	O
178	cycle	_	_	O
179	,	_	_	O
180	and	_	_	O
181	post	_	_	O
182	-	_	_	O
183	discontinuation	_	_	O
184	.	_	_	O

185	Worsening	_	_	O
186	of	_	_	O
187	symptoms	_	_	O
188	was	_	_	O
189	defined	_	_	O
190	as	_	_	O
191	an	_	_	O
192	increase	_	_	O
193	of	_	_	O
194	15	_	_	O
195	mm	_	_	O
196	or	_	_	O
197	more	_	_	O
198	from	_	_	O
199	baseline	_	_	O
200	on	_	_	O
201	a	_	_	O
202	100	_	_	O
203	mm	_	_	O
204	scale	_	_	O
205	for	_	_	O
206	each	_	_	O
207	LCSS	_	_	O
208	item	_	_	O
209	.	_	_	O

210	The	_	_	O
211	primary	_	_	O
212	outcome	_	_	O
213	for	_	_	O
214	these	_	_	O
215	quality	_	_	O
216	-	_	_	O
217	of	_	_	O
218	-	_	_	O
219	life	_	_	O
220	analyses	_	_	O
221	was	_	_	O
222	time	_	_	O
223	to	_	_	O
224	worsening	_	_	O
225	of	_	_	O
226	symptoms	_	_	O
227	,	_	_	O
228	analysed	_	_	O
229	for	_	_	O
230	all	_	_	O
231	randomised	_	_	O
232	patients	_	_	O
233	.	_	_	O

234	Baseline	_	_	O
235	characteristics	_	_	O
236	,	_	_	O
237	including	_	_	O
238	LCSS	_	_	O
239	scores	_	_	O
240	,	_	_	O
241	were	_	_	O
242	well	_	_	O
243	balanced	_	_	O
244	between	_	_	O
245	groups	_	_	O
246	.	_	_	O

247	Baseline	_	_	O
248	LCSS	_	_	O
249	scores	_	_	O
250	were	_	_	O
251	low	_	_	O
252	,	_	_	O
253	indicating	_	_	O
254	low	_	_	O
255	symptom	_	_	O
256	burden	_	_	O
257	for	_	_	O
258	patients	_	_	O
259	without	_	_	O
260	disease	_	_	O
261	progression	_	_	O
262	after	_	_	O
263	completion	_	_	O
264	of	_	_	O
265	first	_	_	O
266	-	_	_	O
267	line	_	_	O
268	treatment	_	_	O
269	.	_	_	O

270	Longer	_	_	B-Premise
271	time	_	_	I-Premise
272	to	_	_	I-Premise
273	worsening	_	_	I-Premise
274	was	_	_	I-Premise
275	recorded	_	_	I-Premise
276	for	_	_	I-Premise
277	pain	_	_	I-Premise
278	(	_	_	I-Premise
279	hazard	_	_	I-Premise
280	ratio	_	_	I-Premise
281	[	_	_	I-Premise
282	HR	_	_	I-Premise
283	]	_	_	I-Premise
284	0	_	_	I-Premise
285	·	_	_	I-Premise
286	76	_	_	I-Premise
287	,	_	_	I-Premise
288	95	_	_	I-Premise
289	%	_	_	I-Premise
290	CI	_	_	I-Premise
291	0	_	_	I-Premise
292	·	_	_	I-Premise
293	59	_	_	I-Premise
294	-	_	_	I-Premise
295	0	_	_	I-Premise
296	·	_	_	I-Premise
297	99	_	_	I-Premise
298	;	_	_	I-Premise
299	p	_	_	I-Premise
300	=	_	_	I-Premise
301	0	_	_	I-Premise
302	·	_	_	I-Premise
303	041	_	_	I-Premise
304	)	_	_	I-Premise
305	and	_	_	I-Premise
306	haemoptysis	_	_	I-Premise
307	(	_	_	I-Premise
308	HR	_	_	I-Premise
309	0	_	_	I-Premise
310	·	_	_	I-Premise
311	58	_	_	I-Premise
312	,	_	_	I-Premise
313	95	_	_	I-Premise
314	%	_	_	I-Premise
315	CI	_	_	I-Premise
316	0	_	_	I-Premise
317	·	_	_	I-Premise
318	34	_	_	I-Premise
319	-	_	_	I-Premise
320	0	_	_	I-Premise
321	·	_	_	I-Premise
322	97	_	_	I-Premise
323	;	_	_	I-Premise
324	p	_	_	I-Premise
325	=	_	_	I-Premise
326	0	_	_	I-Premise
327	·	_	_	I-Premise
328	038	_	_	I-Premise
329	)	_	_	I-Premise
330	with	_	_	I-Premise
331	pemetrexed	_	_	I-Premise
332	than	_	_	I-Premise
333	with	_	_	I-Premise
334	placebo	_	_	I-Premise
335	;	_	_	I-Premise
336	no	_	_	B-Premise
337	other	_	_	I-Premise
338	significant	_	_	I-Premise
339	differences	_	_	I-Premise
340	in	_	_	I-Premise
341	analyses	_	_	I-Premise
342	of	_	_	I-Premise
343	time	_	_	I-Premise
344	to	_	_	I-Premise
345	worsening	_	_	I-Premise
346	were	_	_	I-Premise
347	noted	_	_	I-Premise
348	.	_	_	I-Premise

349	Additional	_	_	B-Premise
350	longitudinal	_	_	I-Premise
351	analyses	_	_	I-Premise
352	showed	_	_	I-Premise
353	a	_	_	I-Premise
354	greater	_	_	I-Premise
355	increase	_	_	I-Premise
356	in	_	_	I-Premise
357	loss	_	_	I-Premise
358	of	_	_	I-Premise
359	appetite	_	_	I-Premise
360	in	_	_	I-Premise
361	the	_	_	I-Premise
362	pemetrexed	_	_	I-Premise
363	group	_	_	I-Premise
364	than	_	_	I-Premise
365	in	_	_	I-Premise
366	the	_	_	I-Premise
367	placebo	_	_	I-Premise
368	group	_	_	I-Premise
369	(	_	_	I-Premise
370	4	_	_	I-Premise
371	·	_	_	I-Premise
372	3	_	_	I-Premise
373	mm	_	_	I-Premise
374	vs	_	_	I-Premise
375	0	_	_	I-Premise
376	·	_	_	I-Premise
377	2	_	_	I-Premise
378	mm	_	_	I-Premise
379	;	_	_	I-Premise
380	p	_	_	I-Premise
381	=	_	_	I-Premise
382	0	_	_	I-Premise
383	·	_	_	I-Premise
384	028	_	_	I-Premise
385	)	_	_	I-Premise
386	.	_	_	I-Premise

387	Rates	_	_	B-Premise
388	of	_	_	I-Premise
389	resource	_	_	I-Premise
390	use	_	_	I-Premise
391	were	_	_	I-Premise
392	statistically	_	_	I-Premise
393	higher	_	_	I-Premise
394	for	_	_	I-Premise
395	pemetrexed	_	_	I-Premise
396	than	_	_	I-Premise
397	for	_	_	I-Premise
398	placebo	_	_	I-Premise
399	:	_	_	I-Premise
400	admissions	_	_	I-Premise
401	to	_	_	I-Premise
402	hospital	_	_	I-Premise
403	for	_	_	I-Premise
404	drug	_	_	I-Premise
405	-	_	_	I-Premise
406	related	_	_	I-Premise
407	adverse	_	_	I-Premise
408	events	_	_	I-Premise
409	(	_	_	I-Premise
410	19	_	_	I-Premise
411	[	_	_	I-Premise
412	4	_	_	I-Premise
413	%	_	_	I-Premise
414	]	_	_	I-Premise
415	vs	_	_	I-Premise
416	none	_	_	I-Premise
417	;	_	_	I-Premise
418	p	_	_	I-Premise
419	=	_	_	I-Premise
420	0	_	_	I-Premise
421	·	_	_	I-Premise
422	001	_	_	I-Premise
423	)	_	_	I-Premise
424	,	_	_	I-Premise
425	transfusions	_	_	I-Premise
426	(	_	_	I-Premise
427	42	_	_	I-Premise
428	[	_	_	I-Premise
429	10	_	_	I-Premise
430	%	_	_	I-Premise
431	]	_	_	I-Premise
432	vs	_	_	I-Premise
433	seven	_	_	I-Premise
434	[	_	_	I-Premise
435	3	_	_	I-Premise
436	%	_	_	I-Premise
437	]	_	_	I-Premise
438	;	_	_	I-Premise
439	p	_	_	I-Premise
440	=	_	_	I-Premise
441	0	_	_	I-Premise
442	·	_	_	I-Premise
443	003	_	_	I-Premise
444	)	_	_	I-Premise
445	,	_	_	I-Premise
446	and	_	_	I-Premise
447	erythropoiesis	_	_	I-Premise
448	-	_	_	I-Premise
449	stimulating	_	_	I-Premise
450	agents	_	_	I-Premise
451	(	_	_	I-Premise
452	26	_	_	I-Premise
453	[	_	_	I-Premise
454	6	_	_	I-Premise
455	%	_	_	I-Premise
456	]	_	_	I-Premise
457	vs	_	_	I-Premise
458	four	_	_	I-Premise
459	[	_	_	I-Premise
460	2	_	_	I-Premise
461	%	_	_	I-Premise
462	]	_	_	I-Premise
463	;	_	_	I-Premise
464	p	_	_	I-Premise
465	=	_	_	I-Premise
466	0	_	_	I-Premise
467	·	_	_	I-Premise
468	017	_	_	I-Premise
469	)	_	_	I-Premise
470	.	_	_	I-Premise

471	Quality	_	_	B-Claim
472	of	_	_	I-Claim
473	life	_	_	I-Claim
474	during	_	_	I-Claim
475	maintenance	_	_	I-Claim
476	therapy	_	_	I-Claim
477	with	_	_	I-Claim
478	pemetrexed	_	_	I-Claim
479	is	_	_	I-Claim
480	similar	_	_	I-Claim
481	to	_	_	I-Claim
482	placebo	_	_	I-Claim
483	,	_	_	I-Claim
484	except	_	_	B-Claim
485	for	_	_	I-Claim
486	a	_	_	I-Claim
487	small	_	_	I-Claim
488	increase	_	_	I-Claim
489	in	_	_	I-Claim
490	loss	_	_	I-Claim
491	of	_	_	I-Claim
492	appetite	_	_	I-Claim
493	,	_	_	I-Claim
494	and	_	_	I-Claim
495	significantly	_	_	I-Claim
496	delayed	_	_	I-Claim
497	worsening	_	_	I-Claim
498	of	_	_	I-Claim
499	pain	_	_	I-Claim
500	and	_	_	I-Claim
501	haemoptysis	_	_	I-Claim
502	.	_	_	I-Claim

503	In	_	_	O
504	view	_	_	O
505	of	_	_	O
506	the	_	_	O
507	improvements	_	_	O
508	in	_	_	O
509	overall	_	_	O
510	and	_	_	O
511	progression	_	_	O
512	-	_	_	O
513	free	_	_	O
514	survival	_	_	O
515	noted	_	_	O
516	with	_	_	O
517	pemetrexed	_	_	O
518	maintenance	_	_	O
519	therapy	_	_	O
520	,	_	_	O
521	such	_	_	B-Claim
522	treatment	_	_	I-Claim
523	is	_	_	I-Claim
524	an	_	_	I-Claim
525	option	_	_	I-Claim
526	for	_	_	I-Claim
527	patients	_	_	I-Claim
528	with	_	_	I-Claim
529	advanced	_	_	I-Claim
530	non	_	_	I-Claim
531	-	_	_	I-Claim
532	squamous	_	_	I-Claim
533	NSCLC	_	_	I-Claim
534	who	_	_	I-Claim
535	have	_	_	I-Claim
536	not	_	_	I-Claim
537	progressed	_	_	I-Claim
538	after	_	_	I-Claim
539	platinum	_	_	I-Claim
540	-	_	_	I-Claim
541	based	_	_	I-Claim
542	induction	_	_	I-Claim
543	therapy	_	_	I-Claim
544	.	_	_	I-Claim


0	Bone	_	_	B-Claim
1	metastases	_	_	I-Claim
2	are	_	_	I-Claim
3	a	_	_	I-Claim
4	common	_	_	I-Claim
5	cause	_	_	I-Claim
6	of	_	_	I-Claim
7	morbidity	_	_	I-Claim
8	in	_	_	I-Claim
9	patients	_	_	I-Claim
10	with	_	_	I-Claim
11	prostate	_	_	I-Claim
12	carcinoma	_	_	I-Claim
13	.	_	_	I-Claim

14	We	_	_	O
15	studied	_	_	O
16	the	_	_	O
17	effect	_	_	O
18	of	_	_	O
19	a	_	_	O
20	new	_	_	O
21	bisphosphonate	_	_	O
22	,	_	_	O
23	zoledronic	_	_	O
24	acid	_	_	O
25	,	_	_	O
26	which	_	_	O
27	blocks	_	_	O
28	bone	_	_	O
29	destruction	_	_	O
30	,	_	_	O
31	on	_	_	O
32	skeletal	_	_	O
33	complications	_	_	O
34	in	_	_	O
35	prostate	_	_	O
36	cancer	_	_	O
37	patients	_	_	O
38	with	_	_	O
39	bone	_	_	O
40	metastases	_	_	O
41	.	_	_	O

42	Patients	_	_	O
43	with	_	_	O
44	hormone	_	_	O
45	-	_	_	O
46	refractory	_	_	O
47	prostate	_	_	O
48	cancer	_	_	O
49	and	_	_	O
50	a	_	_	O
51	history	_	_	O
52	of	_	_	O
53	bone	_	_	O
54	metastases	_	_	O
55	were	_	_	O
56	randomly	_	_	O
57	assigned	_	_	O
58	to	_	_	O
59	a	_	_	O
60	double	_	_	O
61	-	_	_	O
62	blind	_	_	O
63	treatment	_	_	O
64	regimen	_	_	O
65	of	_	_	O
66	intravenous	_	_	O
67	zoledronic	_	_	O
68	acid	_	_	O
69	at	_	_	O
70	4	_	_	O
71	mg	_	_	O
72	(	_	_	O
73	N	_	_	O
74	=	_	_	O
75	214	_	_	O
76	)	_	_	O
77	,	_	_	O
78	zoledronic	_	_	O
79	acid	_	_	O
80	at	_	_	O
81	8	_	_	O
82	mg	_	_	O
83	(	_	_	O
84	subsequently	_	_	O
85	reduced	_	_	O
86	to	_	_	O
87	4	_	_	O
88	mg	_	_	O
89	;	_	_	O
90	8	_	_	O
91	/	_	_	O
92	4	_	_	O
93	)	_	_	O
94	(	_	_	O
95	N	_	_	O
96	=	_	_	O
97	221	_	_	O
98	)	_	_	O
99	,	_	_	O
100	or	_	_	O
101	placebo	_	_	O
102	(	_	_	O
103	N	_	_	O
104	=	_	_	O
105	208	_	_	O
106	)	_	_	O
107	every	_	_	O
108	3	_	_	O
109	weeks	_	_	O
110	for	_	_	O
111	15	_	_	O
112	months	_	_	O
113	.	_	_	O

114	Proportions	_	_	O
115	of	_	_	O
116	patients	_	_	O
117	with	_	_	O
118	skeletal	_	_	O
119	-	_	_	O
120	related	_	_	O
121	events	_	_	O
122	,	_	_	O
123	time	_	_	O
124	to	_	_	O
125	the	_	_	O
126	first	_	_	O
127	skeletal	_	_	O
128	-	_	_	O
129	related	_	_	O
130	event	_	_	O
131	,	_	_	O
132	skeletal	_	_	O
133	morbidity	_	_	O
134	rate	_	_	O
135	,	_	_	O
136	pain	_	_	O
137	and	_	_	O
138	analgesic	_	_	O
139	scores	_	_	O
140	,	_	_	O
141	disease	_	_	O
142	progression	_	_	O
143	,	_	_	O
144	and	_	_	O
145	safety	_	_	O
146	were	_	_	O
147	assessed	_	_	O
148	.	_	_	O

149	All	_	_	O
150	statistical	_	_	O
151	tests	_	_	O
152	were	_	_	O
153	two	_	_	O
154	-	_	_	O
155	sided	_	_	O
156	.	_	_	O

157	Approximately	_	_	O
158	38	_	_	O
159	%	_	_	O
160	of	_	_	O
161	patients	_	_	O
162	who	_	_	O
163	received	_	_	O
164	zoledronic	_	_	O
165	acid	_	_	O
166	at	_	_	O
167	4	_	_	O
168	mg	_	_	O
169	,	_	_	O
170	28	_	_	O
171	%	_	_	O
172	who	_	_	O
173	received	_	_	O
174	zoledronic	_	_	O
175	acid	_	_	O
176	at	_	_	O
177	8	_	_	O
178	/	_	_	O
179	4	_	_	O
180	mg	_	_	O
181	,	_	_	O
182	and	_	_	O
183	31	_	_	O
184	%	_	_	O
185	who	_	_	O
186	received	_	_	O
187	placebo	_	_	O
188	completed	_	_	O
189	the	_	_	O
190	study	_	_	O
191	.	_	_	O

192	A	_	_	B-Premise
193	greater	_	_	I-Premise
194	proportion	_	_	I-Premise
195	of	_	_	I-Premise
196	patients	_	_	I-Premise
197	who	_	_	I-Premise
198	received	_	_	I-Premise
199	placebo	_	_	I-Premise
200	had	_	_	I-Premise
201	skeletal	_	_	I-Premise
202	-	_	_	I-Premise
203	related	_	_	I-Premise
204	events	_	_	I-Premise
205	than	_	_	I-Premise
206	those	_	_	I-Premise
207	who	_	_	I-Premise
208	received	_	_	I-Premise
209	zoledronic	_	_	I-Premise
210	acid	_	_	I-Premise
211	at	_	_	I-Premise
212	4	_	_	I-Premise
213	mg	_	_	I-Premise
214	(	_	_	I-Premise
215	44	_	_	I-Premise
216	.	_	_	I-Premise

217	2	_	_	I-Premise
218	%	_	_	I-Premise
219	versus	_	_	I-Premise
220	33	_	_	I-Premise
221	.	_	_	I-Premise

222	2	_	_	I-Premise
223	%	_	_	I-Premise
224	;	_	_	I-Premise
225	difference	_	_	I-Premise
226	=	_	_	I-Premise
227	-	_	_	I-Premise
228	11	_	_	I-Premise
229	.	_	_	I-Premise

230	0	_	_	I-Premise
231	%	_	_	I-Premise
232	,	_	_	I-Premise
233	95	_	_	I-Premise
234	%	_	_	I-Premise
235	confidence	_	_	I-Premise
236	interval	_	_	I-Premise
237	[	_	_	I-Premise
238	CI	_	_	I-Premise
239	]	_	_	I-Premise
240	=	_	_	I-Premise
241	-	_	_	I-Premise
242	20	_	_	I-Premise
243	.	_	_	I-Premise

244	3	_	_	I-Premise
245	%	_	_	I-Premise
246	to	_	_	I-Premise
247	-	_	_	I-Premise
248	1	_	_	I-Premise
249	.	_	_	I-Premise

250	8	_	_	I-Premise
251	%	_	_	I-Premise
252	;	_	_	I-Premise
253	P	_	_	I-Premise
254	=	_	_	I-Premise
255	.	_	_	I-Premise

256	021	_	_	I-Premise
257	)	_	_	I-Premise
258	or	_	_	I-Premise
259	those	_	_	I-Premise
260	who	_	_	I-Premise
261	received	_	_	I-Premise
262	zoledronic	_	_	I-Premise
263	acid	_	_	I-Premise
264	at	_	_	I-Premise
265	8	_	_	I-Premise
266	/	_	_	I-Premise
267	4	_	_	I-Premise
268	mg	_	_	I-Premise
269	(	_	_	I-Premise
270	38	_	_	I-Premise
271	.	_	_	I-Premise

272	5	_	_	I-Premise
273	%	_	_	I-Premise
274	;	_	_	I-Premise
275	difference	_	_	I-Premise
276	versus	_	_	I-Premise
277	placebo	_	_	I-Premise
278	=	_	_	I-Premise
279	-	_	_	I-Premise
280	5	_	_	I-Premise
281	.	_	_	I-Premise

282	8	_	_	I-Premise
283	%	_	_	I-Premise
284	,	_	_	I-Premise
285	95	_	_	I-Premise
286	%	_	_	I-Premise
287	CI	_	_	I-Premise
288	=	_	_	I-Premise
289	-	_	_	I-Premise
290	15	_	_	I-Premise
291	.	_	_	I-Premise

292	1	_	_	I-Premise
293	%	_	_	I-Premise
294	to	_	_	I-Premise
295	3	_	_	I-Premise
296	.	_	_	I-Premise

297	6	_	_	I-Premise
298	%	_	_	I-Premise
299	;	_	_	I-Premise
300	P	_	_	I-Premise
301	=	_	_	I-Premise
302	.	_	_	I-Premise

303	222	_	_	I-Premise
304	)	_	_	I-Premise
305	.	_	_	I-Premise

306	Median	_	_	B-Premise
307	time	_	_	I-Premise
308	to	_	_	I-Premise
309	first	_	_	I-Premise
310	skeletal	_	_	I-Premise
311	-	_	_	I-Premise
312	related	_	_	I-Premise
313	event	_	_	I-Premise
314	was	_	_	I-Premise
315	321	_	_	I-Premise
316	days	_	_	I-Premise
317	for	_	_	I-Premise
318	patients	_	_	I-Premise
319	who	_	_	I-Premise
320	received	_	_	I-Premise
321	placebo	_	_	I-Premise
322	,	_	_	I-Premise
323	was	_	_	I-Premise
324	not	_	_	I-Premise
325	reached	_	_	I-Premise
326	for	_	_	I-Premise
327	patients	_	_	I-Premise
328	who	_	_	I-Premise
329	received	_	_	I-Premise
330	zoledronic	_	_	I-Premise
331	acid	_	_	I-Premise
332	at	_	_	I-Premise
333	4	_	_	I-Premise
334	mg	_	_	I-Premise
335	(	_	_	I-Premise
336	P	_	_	I-Premise
337	=	_	_	I-Premise
338	.	_	_	I-Premise

339	011	_	_	I-Premise
340	versus	_	_	I-Premise
341	placebo	_	_	I-Premise
342	)	_	_	I-Premise
343	,	_	_	I-Premise
344	and	_	_	I-Premise
345	was	_	_	I-Premise
346	363	_	_	I-Premise
347	days	_	_	I-Premise
348	for	_	_	I-Premise
349	those	_	_	I-Premise
350	who	_	_	I-Premise
351	received	_	_	I-Premise
352	zoledronic	_	_	I-Premise
353	acid	_	_	I-Premise
354	at	_	_	I-Premise
355	8	_	_	I-Premise
356	/	_	_	I-Premise
357	4	_	_	I-Premise
358	mg	_	_	I-Premise
359	(	_	_	I-Premise
360	P	_	_	I-Premise
361	=	_	_	I-Premise
362	.	_	_	I-Premise

363	491	_	_	I-Premise
364	versus	_	_	I-Premise
365	placebo	_	_	I-Premise
366	)	_	_	I-Premise
367	.	_	_	I-Premise

368	Compared	_	_	B-Premise
369	with	_	_	I-Premise
370	urinary	_	_	I-Premise
371	markers	_	_	I-Premise
372	in	_	_	I-Premise
373	patients	_	_	I-Premise
374	who	_	_	I-Premise
375	received	_	_	I-Premise
376	placebo	_	_	I-Premise
377	,	_	_	I-Premise
378	urinary	_	_	I-Premise
379	markers	_	_	I-Premise
380	of	_	_	I-Premise
381	bone	_	_	I-Premise
382	resorption	_	_	I-Premise
383	were	_	_	I-Premise
384	statistically	_	_	I-Premise
385	significantly	_	_	I-Premise
386	decreased	_	_	I-Premise
387	in	_	_	I-Premise
388	patients	_	_	I-Premise
389	who	_	_	I-Premise
390	received	_	_	I-Premise
391	zoledronic	_	_	I-Premise
392	acid	_	_	I-Premise
393	at	_	_	I-Premise
394	either	_	_	I-Premise
395	dose	_	_	I-Premise
396	(	_	_	I-Premise
397	P	_	_	I-Premise
398	=	_	_	I-Premise
399	.	_	_	I-Premise

400	001	_	_	I-Premise
401	)	_	_	I-Premise
402	.	_	_	I-Premise

403	Pain	_	_	B-Premise
404	and	_	_	I-Premise
405	analgesic	_	_	I-Premise
406	scores	_	_	I-Premise
407	increased	_	_	I-Premise
408	more	_	_	I-Premise
409	in	_	_	I-Premise
410	patients	_	_	I-Premise
411	who	_	_	I-Premise
412	received	_	_	I-Premise
413	placebo	_	_	I-Premise
414	than	_	_	I-Premise
415	in	_	_	I-Premise
416	patients	_	_	I-Premise
417	who	_	_	I-Premise
418	received	_	_	I-Premise
419	zoledronic	_	_	I-Premise
420	acid	_	_	I-Premise
421	,	_	_	I-Premise
422	but	_	_	O
423	there	_	_	B-Premise
424	were	_	_	I-Premise
425	no	_	_	I-Premise
426	differences	_	_	I-Premise
427	in	_	_	I-Premise
428	disease	_	_	I-Premise
429	progression	_	_	I-Premise
430	,	_	_	I-Premise
431	performance	_	_	I-Premise
432	status	_	_	I-Premise
433	,	_	_	I-Premise
434	or	_	_	I-Premise
435	quality	_	_	I-Premise
436	-	_	_	I-Premise
437	of	_	_	I-Premise
438	-	_	_	I-Premise
439	life	_	_	I-Premise
440	scores	_	_	I-Premise
441	among	_	_	I-Premise
442	the	_	_	I-Premise
443	groups	_	_	I-Premise
444	.	_	_	I-Premise

445	Zoledronic	_	_	B-Claim
446	acid	_	_	I-Claim
447	at	_	_	I-Claim
448	4	_	_	I-Claim
449	mg	_	_	I-Claim
450	given	_	_	I-Claim
451	as	_	_	I-Claim
452	a	_	_	I-Claim
453	15	_	_	I-Claim
454	-	_	_	I-Claim
455	minute	_	_	I-Claim
456	infusion	_	_	I-Claim
457	was	_	_	I-Claim
458	well	_	_	I-Claim
459	tolerated	_	_	I-Claim
460	,	_	_	I-Claim
461	but	_	_	O
462	the	_	_	B-Claim
463	8	_	_	I-Claim
464	-	_	_	I-Claim
465	mg	_	_	I-Claim
466	dose	_	_	I-Claim
467	was	_	_	I-Claim
468	associated	_	_	I-Claim
469	with	_	_	I-Claim
470	renal	_	_	I-Claim
471	function	_	_	I-Claim
472	deterioration	_	_	I-Claim
473	.	_	_	I-Claim

474	Zoledronic	_	_	B-Claim
475	acid	_	_	I-Claim
476	at	_	_	I-Claim
477	4	_	_	I-Claim
478	mg	_	_	I-Claim
479	reduced	_	_	I-Claim
480	skeletal	_	_	I-Claim
481	-	_	_	I-Claim
482	related	_	_	I-Claim
483	events	_	_	I-Claim
484	in	_	_	I-Claim
485	prostate	_	_	I-Claim
486	cancer	_	_	I-Claim
487	patients	_	_	I-Claim
488	with	_	_	I-Claim
489	bone	_	_	I-Claim
490	metastases	_	_	I-Claim
491	.	_	_	I-Claim


0	The	_	_	B-Claim
1	efficacy	_	_	I-Claim
2	and	_	_	I-Claim
3	safety	_	_	I-Claim
4	of	_	_	I-Claim
5	uterine	_	_	I-Claim
6	-	_	_	I-Claim
7	artery	_	_	I-Claim
8	embolization	_	_	I-Claim
9	,	_	_	I-Claim
10	as	_	_	I-Claim
11	compared	_	_	I-Claim
12	with	_	_	I-Claim
13	standard	_	_	I-Claim
14	surgical	_	_	I-Claim
15	methods	_	_	I-Claim
16	,	_	_	I-Claim
17	for	_	_	I-Claim
18	the	_	_	I-Claim
19	treatment	_	_	I-Claim
20	of	_	_	I-Claim
21	symptomatic	_	_	I-Claim
22	uterine	_	_	I-Claim
23	fibroids	_	_	I-Claim
24	remain	_	_	I-Claim
25	uncertain	_	_	I-Claim
26	.	_	_	I-Claim

27	We	_	_	O
28	conducted	_	_	O
29	a	_	_	O
30	randomized	_	_	O
31	trial	_	_	O
32	comparing	_	_	O
33	uterine	_	_	O
34	-	_	_	O
35	artery	_	_	O
36	embolization	_	_	O
37	and	_	_	O
38	surgery	_	_	O
39	in	_	_	O
40	women	_	_	O
41	with	_	_	O
42	symptomatic	_	_	O
43	uterine	_	_	O
44	fibroids	_	_	O
45	.	_	_	O

46	The	_	_	O
47	primary	_	_	O
48	outcome	_	_	O
49	was	_	_	O
50	quality	_	_	O
51	of	_	_	O
52	life	_	_	O
53	at	_	_	O
54	1	_	_	O
55	year	_	_	O
56	of	_	_	O
57	follow	_	_	O
58	-	_	_	O
59	up	_	_	O
60	,	_	_	O
61	as	_	_	O
62	measured	_	_	O
63	by	_	_	O
64	the	_	_	O
65	Medical	_	_	O
66	Outcomes	_	_	O
67	Study	_	_	O
68	36	_	_	O
69	-	_	_	O
70	Item	_	_	O
71	Short	_	_	O
72	-	_	_	O
73	Form	_	_	O
74	General	_	_	O
75	Health	_	_	O
76	Survey	_	_	O
77	(	_	_	O
78	SF	_	_	O
79	-	_	_	O
80	36	_	_	O
81	)	_	_	O
82	.	_	_	O

83	Patients	_	_	O
84	were	_	_	O
85	randomly	_	_	O
86	assigned	_	_	O
87	in	_	_	O
88	a	_	_	O
89	2	_	_	O
90	:	_	_	O
91	1	_	_	O
92	ratio	_	_	O
93	to	_	_	O
94	undergo	_	_	O
95	either	_	_	O
96	uterine	_	_	O
97	-	_	_	O
98	artery	_	_	O
99	embolization	_	_	O
100	or	_	_	O
101	surgery	_	_	O
102	,	_	_	O
103	with	_	_	O
104	106	_	_	O
105	patients	_	_	O
106	undergoing	_	_	O
107	embolization	_	_	O
108	and	_	_	O
109	51	_	_	O
110	undergoing	_	_	O
111	surgery	_	_	O
112	(	_	_	O
113	43	_	_	O
114	hysterectomies	_	_	O
115	and	_	_	O
116	8	_	_	O
117	myomectomies	_	_	O
118	)	_	_	O
119	.	_	_	O

120	There	_	_	B-Premise
121	were	_	_	I-Premise
122	no	_	_	I-Premise
123	significant	_	_	I-Premise
124	differences	_	_	I-Premise
125	between	_	_	I-Premise
126	groups	_	_	I-Premise
127	in	_	_	I-Premise
128	any	_	_	I-Premise
129	of	_	_	I-Premise
130	the	_	_	I-Premise
131	eight	_	_	I-Premise
132	components	_	_	I-Premise
133	of	_	_	I-Premise
134	the	_	_	I-Premise
135	SF	_	_	I-Premise
136	-	_	_	I-Premise
137	36	_	_	I-Premise
138	scores	_	_	I-Premise
139	at	_	_	I-Premise
140	1	_	_	I-Premise
141	year	_	_	I-Premise
142	.	_	_	I-Premise

143	The	_	_	B-Premise
144	embolization	_	_	I-Premise
145	group	_	_	I-Premise
146	had	_	_	I-Premise
147	a	_	_	I-Premise
148	shorter	_	_	I-Premise
149	median	_	_	I-Premise
150	duration	_	_	I-Premise
151	of	_	_	I-Premise
152	hospitalization	_	_	I-Premise
153	than	_	_	I-Premise
154	the	_	_	I-Premise
155	surgical	_	_	I-Premise
156	group	_	_	I-Premise
157	(	_	_	I-Premise
158	1	_	_	I-Premise
159	day	_	_	I-Premise
160	vs	_	_	I-Premise
161	.	_	_	I-Premise

162	5	_	_	I-Premise
163	days	_	_	I-Premise
164	,	_	_	I-Premise
165	P	_	_	I-Premise
166	<	_	_	I-Premise
167	0	_	_	I-Premise
168	.	_	_	I-Premise

169	001	_	_	I-Premise
170	)	_	_	I-Premise
171	and	_	_	I-Premise
172	a	_	_	I-Premise
173	shorter	_	_	I-Premise
174	time	_	_	I-Premise
175	before	_	_	I-Premise
176	returning	_	_	I-Premise
177	to	_	_	I-Premise
178	work	_	_	I-Premise
179	(	_	_	I-Premise
180	P	_	_	I-Premise
181	<	_	_	I-Premise
182	0	_	_	I-Premise
183	.	_	_	I-Premise

184	001	_	_	I-Premise
185	)	_	_	I-Premise
186	.	_	_	I-Premise

187	At	_	_	B-Premise
188	1	_	_	I-Premise
189	year	_	_	I-Premise
190	,	_	_	I-Premise
191	symptom	_	_	I-Premise
192	scores	_	_	I-Premise
193	were	_	_	I-Premise
194	better	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	surgical	_	_	I-Premise
198	group	_	_	I-Premise
199	(	_	_	I-Premise
200	P	_	_	I-Premise
201	=	_	_	I-Premise
202	0	_	_	I-Premise
203	.	_	_	I-Premise

204	03	_	_	I-Premise
205	)	_	_	I-Premise
206	.	_	_	I-Premise

207	During	_	_	B-Premise
208	the	_	_	I-Premise
209	first	_	_	I-Premise
210	year	_	_	I-Premise
211	of	_	_	I-Premise
212	follow	_	_	I-Premise
213	-	_	_	I-Premise
214	up	_	_	I-Premise
215	,	_	_	I-Premise
216	there	_	_	I-Premise
217	were	_	_	I-Premise
218	13	_	_	I-Premise
219	major	_	_	I-Premise
220	adverse	_	_	I-Premise
221	events	_	_	I-Premise
222	in	_	_	I-Premise
223	the	_	_	I-Premise
224	embolization	_	_	I-Premise
225	group	_	_	I-Premise
226	(	_	_	I-Premise
227	12	_	_	I-Premise
228	%	_	_	I-Premise
229	)	_	_	I-Premise
230	and	_	_	I-Premise
231	10	_	_	I-Premise
232	in	_	_	I-Premise
233	the	_	_	I-Premise
234	surgical	_	_	I-Premise
235	group	_	_	I-Premise
236	(	_	_	I-Premise
237	20	_	_	I-Premise
238	%	_	_	I-Premise
239	)	_	_	I-Premise
240	(	_	_	I-Premise
241	P	_	_	I-Premise
242	=	_	_	I-Premise
243	0	_	_	I-Premise
244	.	_	_	I-Premise

245	22	_	_	I-Premise
246	)	_	_	I-Premise
247	,	_	_	I-Premise
248	mostly	_	_	I-Premise
249	related	_	_	I-Premise
250	to	_	_	I-Premise
251	the	_	_	I-Premise
252	intervention	_	_	I-Premise
253	.	_	_	I-Premise

254	Ten	_	_	B-Premise
255	patients	_	_	I-Premise
256	in	_	_	I-Premise
257	the	_	_	I-Premise
258	embolization	_	_	I-Premise
259	group	_	_	I-Premise
260	(	_	_	I-Premise
261	9	_	_	I-Premise
262	%	_	_	I-Premise
263	)	_	_	I-Premise
264	required	_	_	I-Premise
265	repeated	_	_	I-Premise
266	embolization	_	_	I-Premise
267	or	_	_	I-Premise
268	hysterectomy	_	_	I-Premise
269	for	_	_	I-Premise
270	inadequate	_	_	I-Premise
271	symptom	_	_	I-Premise
272	control	_	_	I-Premise
273	.	_	_	I-Premise

274	After	_	_	B-Premise
275	the	_	_	I-Premise
276	first	_	_	I-Premise
277	year	_	_	I-Premise
278	of	_	_	I-Premise
279	follow	_	_	I-Premise
280	-	_	_	I-Premise
281	up	_	_	I-Premise
282	,	_	_	I-Premise
283	14	_	_	I-Premise
284	women	_	_	I-Premise
285	in	_	_	I-Premise
286	the	_	_	I-Premise
287	embolization	_	_	I-Premise
288	group	_	_	I-Premise
289	(	_	_	I-Premise
290	13	_	_	I-Premise
291	%	_	_	I-Premise
292	)	_	_	I-Premise
293	required	_	_	I-Premise
294	hospitalization	_	_	I-Premise
295	,	_	_	I-Premise
296	3	_	_	I-Premise
297	of	_	_	I-Premise
298	them	_	_	I-Premise
299	for	_	_	I-Premise
300	major	_	_	I-Premise
301	adverse	_	_	I-Premise
302	events	_	_	I-Premise
303	and	_	_	I-Premise
304	11	_	_	I-Premise
305	for	_	_	I-Premise
306	reintervention	_	_	I-Premise
307	for	_	_	I-Premise
308	treatment	_	_	I-Premise
309	failure	_	_	I-Premise
310	.	_	_	I-Premise

311	In	_	_	B-Claim
312	women	_	_	I-Claim
313	with	_	_	I-Claim
314	symptomatic	_	_	I-Claim
315	fibroids	_	_	I-Claim
316	,	_	_	I-Claim
317	the	_	_	I-Claim
318	faster	_	_	I-Claim
319	recovery	_	_	I-Claim
320	after	_	_	I-Claim
321	embolization	_	_	I-Claim
322	must	_	_	I-Claim
323	be	_	_	I-Claim
324	weighed	_	_	I-Claim
325	against	_	_	I-Claim
326	the	_	_	I-Claim
327	need	_	_	I-Claim
328	for	_	_	I-Claim
329	further	_	_	I-Claim
330	treatment	_	_	I-Claim
331	in	_	_	I-Claim
332	a	_	_	I-Claim
333	minority	_	_	I-Claim
334	of	_	_	I-Claim
335	patients	_	_	I-Claim
336	.	_	_	I-Claim


0	Dermatitis	_	_	B-Claim
1	is	_	_	I-Claim
2	a	_	_	I-Claim
3	frequent	_	_	I-Claim
4	adverse	_	_	I-Claim
5	effect	_	_	I-Claim
6	of	_	_	I-Claim
7	adjuvant	_	_	I-Claim
8	breast	_	_	I-Claim
9	radiotherapy	_	_	I-Claim
10	.	_	_	I-Claim

11	It	_	_	B-Claim
12	is	_	_	I-Claim
13	more	_	_	I-Claim
14	likely	_	_	I-Claim
15	in	_	_	I-Claim
16	full	_	_	I-Claim
17	-	_	_	I-Claim
18	breasted	_	_	I-Claim
19	women	_	_	I-Claim
20	and	_	_	I-Claim
21	when	_	_	I-Claim
22	the	_	_	I-Claim
23	radiation	_	_	I-Claim
24	is	_	_	I-Claim
25	distributed	_	_	I-Claim
26	nonhomogeneously	_	_	I-Claim
27	in	_	_	I-Claim
28	the	_	_	I-Claim
29	breast	_	_	I-Claim
30	.	_	_	I-Claim

31	Breast	_	_	O
32	intensity	_	_	O
33	-	_	_	O
34	modulated	_	_	O
35	radiation	_	_	O
36	therapy	_	_	O
37	(	_	_	O
38	IMRT	_	_	O
39	)	_	_	O
40	is	_	_	O
41	a	_	_	O
42	technique	_	_	O
43	that	_	_	O
44	ensures	_	_	O
45	a	_	_	O
46	more	_	_	O
47	homogeneous	_	_	O
48	dose	_	_	O
49	distribution	_	_	O
50	.	_	_	O

51	A	_	_	O
52	multicenter	_	_	O
53	,	_	_	O
54	double	_	_	O
55	-	_	_	O
56	blind	_	_	O
57	,	_	_	O
58	randomized	_	_	O
59	clinical	_	_	O
60	trial	_	_	O
61	was	_	_	O
62	performed	_	_	O
63	to	_	_	O
64	test	_	_	O
65	if	_	_	O
66	breast	_	_	O
67	IMRT	_	_	O
68	would	_	_	O
69	reduce	_	_	O
70	the	_	_	O
71	rate	_	_	O
72	of	_	_	O
73	acute	_	_	O
74	skin	_	_	O
75	reaction	_	_	O
76	(	_	_	O
77	notably	_	_	O
78	moist	_	_	O
79	desquamation	_	_	O
80	)	_	_	O
81	,	_	_	O
82	decrease	_	_	O
83	pain	_	_	O
84	,	_	_	O
85	and	_	_	O
86	improve	_	_	O
87	quality	_	_	O
88	of	_	_	O
89	life	_	_	O
90	compared	_	_	O
91	with	_	_	O
92	standard	_	_	O
93	radiotherapy	_	_	O
94	using	_	_	O
95	wedges	_	_	O
96	.	_	_	O

97	Patients	_	_	O
98	were	_	_	O
99	assessed	_	_	O
100	each	_	_	O
101	week	_	_	O
102	during	_	_	O
103	and	_	_	O
104	up	_	_	O
105	to	_	_	O
106	6	_	_	O
107	weeks	_	_	O
108	after	_	_	O
109	radiotherapy	_	_	O
110	.	_	_	O

111	A	_	_	O
112	total	_	_	O
113	of	_	_	O
114	358	_	_	O
115	patients	_	_	O
116	were	_	_	O
117	randomly	_	_	O
118	assigned	_	_	O
119	between	_	_	O
120	July	_	_	O
121	2003	_	_	O
122	and	_	_	O
123	March	_	_	O
124	2005	_	_	O
125	in	_	_	O
126	two	_	_	O
127	Canadian	_	_	O
128	centers	_	_	O
129	,	_	_	O
130	and	_	_	O
131	331	_	_	O
132	were	_	_	O
133	included	_	_	O
134	in	_	_	O
135	the	_	_	O
136	analysis	_	_	O
137	.	_	_	O

138	Breast	_	_	B-Premise
139	IMRT	_	_	I-Premise
140	significantly	_	_	I-Premise
141	improved	_	_	I-Premise
142	the	_	_	I-Premise
143	dose	_	_	I-Premise
144	distribution	_	_	I-Premise
145	compared	_	_	I-Premise
146	with	_	_	I-Premise
147	standard	_	_	I-Premise
148	radiation	_	_	I-Premise
149	.	_	_	I-Premise

150	This	_	_	B-Premise
151	translated	_	_	I-Premise
152	into	_	_	I-Premise
153	a	_	_	I-Premise
154	lower	_	_	I-Premise
155	proportion	_	_	I-Premise
156	of	_	_	I-Premise
157	patients	_	_	I-Premise
158	experiencing	_	_	I-Premise
159	moist	_	_	I-Premise
160	desquamation	_	_	I-Premise
161	during	_	_	I-Premise
162	or	_	_	I-Premise
163	up	_	_	I-Premise
164	to	_	_	I-Premise
165	6	_	_	I-Premise
166	weeks	_	_	I-Premise
167	after	_	_	I-Premise
168	their	_	_	I-Premise
169	radiation	_	_	I-Premise
170	treatment	_	_	I-Premise
171	;	_	_	I-Premise
172	31	_	_	I-Premise
173	.	_	_	I-Premise

174	2	_	_	I-Premise
175	%	_	_	I-Premise
176	with	_	_	I-Premise
177	IMRT	_	_	I-Premise
178	compared	_	_	I-Premise
179	with	_	_	I-Premise
180	47	_	_	I-Premise
181	.	_	_	I-Premise

182	8	_	_	I-Premise
183	%	_	_	I-Premise
184	with	_	_	I-Premise
185	standard	_	_	I-Premise
186	treatment	_	_	I-Premise
187	(	_	_	I-Premise
188	P	_	_	I-Premise
189	=	_	_	I-Premise
190	.	_	_	I-Premise

191	002	_	_	I-Premise
192	)	_	_	I-Premise
193	.	_	_	I-Premise

194	A	_	_	B-Premise
195	multivariate	_	_	I-Premise
196	analysis	_	_	I-Premise
197	found	_	_	I-Premise
198	the	_	_	I-Premise
199	use	_	_	I-Premise
200	of	_	_	I-Premise
201	breast	_	_	I-Premise
202	IMRT	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	.	_	_	I-Premise

207	003	_	_	I-Premise
208	)	_	_	I-Premise
209	and	_	_	I-Premise
210	smaller	_	_	I-Premise
211	breast	_	_	I-Premise
212	size	_	_	I-Premise
213	(	_	_	I-Premise
214	P	_	_	I-Premise
215	<	_	_	I-Premise
216	.	_	_	I-Premise

217	001	_	_	I-Premise
218	)	_	_	I-Premise
219	were	_	_	I-Premise
220	significantly	_	_	I-Premise
221	associated	_	_	I-Premise
222	with	_	_	I-Premise
223	a	_	_	I-Premise
224	decreased	_	_	I-Premise
225	risk	_	_	I-Premise
226	of	_	_	I-Premise
227	moist	_	_	I-Premise
228	desquamation	_	_	I-Premise
229	.	_	_	I-Premise

230	The	_	_	B-Premise
231	use	_	_	I-Premise
232	of	_	_	I-Premise
233	IMRT	_	_	I-Premise
234	did	_	_	I-Premise
235	not	_	_	I-Premise
236	correlate	_	_	I-Premise
237	with	_	_	I-Premise
238	pain	_	_	I-Premise
239	and	_	_	I-Premise
240	quality	_	_	I-Premise
241	of	_	_	I-Premise
242	life	_	_	I-Premise
243	,	_	_	O
244	but	_	_	O
245	the	_	_	B-Premise
246	presence	_	_	I-Premise
247	of	_	_	I-Premise
248	moist	_	_	I-Premise
249	desquamation	_	_	I-Premise
250	did	_	_	I-Premise
251	significantly	_	_	I-Premise
252	correlate	_	_	I-Premise
253	with	_	_	I-Premise
254	pain	_	_	I-Premise
255	(	_	_	I-Premise
256	P	_	_	I-Premise
257	=	_	_	I-Premise
258	.	_	_	I-Premise

259	002	_	_	I-Premise
260	)	_	_	I-Premise
261	and	_	_	I-Premise
262	a	_	_	I-Premise
263	reduced	_	_	I-Premise
264	quality	_	_	I-Premise
265	of	_	_	I-Premise
266	life	_	_	I-Premise
267	(	_	_	I-Premise
268	P	_	_	I-Premise
269	=	_	_	I-Premise
270	.	_	_	I-Premise

271	003	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	Breast	_	_	B-Claim
275	IMRT	_	_	I-Claim
276	significantly	_	_	I-Claim
277	reduced	_	_	I-Claim
278	the	_	_	I-Claim
279	occurrence	_	_	I-Claim
280	of	_	_	I-Claim
281	moist	_	_	I-Claim
282	desquamation	_	_	I-Claim
283	compared	_	_	I-Claim
284	with	_	_	I-Claim
285	a	_	_	I-Claim
286	standard	_	_	I-Claim
287	wedged	_	_	I-Claim
288	technique	_	_	I-Claim
289	.	_	_	I-Claim

290	Moist	_	_	B-Claim
291	desquamation	_	_	I-Claim
292	was	_	_	I-Claim
293	correlated	_	_	I-Claim
294	with	_	_	I-Claim
295	increased	_	_	I-Claim
296	pain	_	_	I-Claim
297	and	_	_	I-Claim
298	reduction	_	_	I-Claim
299	in	_	_	I-Claim
300	the	_	_	I-Claim
301	quality	_	_	I-Claim
302	of	_	_	I-Claim
303	life	_	_	I-Claim
304	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	the	_	_	O
4	project	_	_	O
5	was	_	_	O
6	to	_	_	O
7	identify	_	_	O
8	clinical	_	_	O
9	and	_	_	O
10	quality	_	_	O
11	of	_	_	O
12	life	_	_	O
13	(	_	_	O
14	QL	_	_	O
15	)	_	_	O
16	factors	_	_	O
17	that	_	_	O
18	together	_	_	O
19	predict	_	_	O
20	survival	_	_	O
21	and	_	_	O
22	response	_	_	O
23	to	_	_	O
24	chemotherapy	_	_	O
25	in	_	_	O
26	advanced	_	_	O
27	breast	_	_	O
28	cancer	_	_	O
29	.	_	_	O

30	Potential	_	_	O
31	prognostic	_	_	O
32	factors	_	_	O
33	were	_	_	O
34	studied	_	_	O
35	in	_	_	O
36	187	_	_	O
37	women	_	_	O
38	with	_	_	O
39	baseline	_	_	O
40	QL	_	_	O
41	data	_	_	O
42	from	_	_	O
43	a	_	_	O
44	trial	_	_	O
45	of	_	_	O
46	paclitaxel	_	_	O
47	versus	_	_	O
48	doxorubicin	_	_	O
49	as	_	_	O
50	first	_	_	O
51	-	_	_	O
52	line	_	_	O
53	chemotherapy	_	_	O
54	.	_	_	O

55	Demographic	_	_	O
56	and	_	_	O
57	clinical	_	_	O
58	factors	_	_	O
59	studied	_	_	O
60	were	_	_	O
61	age	_	_	O
62	,	_	_	O
63	performance	_	_	O
64	status	_	_	O
65	,	_	_	O
66	dominant	_	_	O
67	site	_	_	O
68	of	_	_	O
69	disease	_	_	O
70	and	_	_	O
71	preceding	_	_	O
72	disease	_	_	O
73	-	_	_	O
74	free	_	_	O
75	interval	_	_	O
76	(	_	_	O
77	DFI	_	_	O
78	)	_	_	O
79	.	_	_	O

80	Factors	_	_	O
81	from	_	_	O
82	the	_	_	O
83	EORTC	_	_	O
84	QLQ	_	_	O
85	-	_	_	O
86	C30	_	_	O
87	were	_	_	O
88	all	_	_	O
89	function	_	_	O
90	scales	_	_	O
91	,	_	_	O
92	fatigue	_	_	O
93	,	_	_	O
94	nausea	_	_	O
95	/	_	_	O
96	vomiting	_	_	O
97	,	_	_	O
98	pain	_	_	O
99	,	_	_	O
100	dyspnoea	_	_	O
101	,	_	_	O
102	insomnia	_	_	O
103	,	_	_	O
104	loss	_	_	O
105	of	_	_	O
106	appetite	_	_	O
107	and	_	_	O
108	global	_	_	O
109	QL	_	_	O
110	.	_	_	O

111	The	_	_	O
112	proportional	_	_	O
113	hazards	_	_	O
114	regression	_	_	O
115	model	_	_	O
116	with	_	_	O
117	stratification	_	_	O
118	for	_	_	O
119	treatment	_	_	O
120	,	_	_	O
121	and	_	_	O
122	the	_	_	O
123	logistic	_	_	O
124	regression	_	_	O
125	model	_	_	O
126	adjusting	_	_	O
127	for	_	_	O
128	treatment	_	_	O
129	arm	_	_	O
130	were	_	_	O
131	used	_	_	O
132	for	_	_	O
133	univariate	_	_	O
134	and	_	_	O
135	multivariate	_	_	O
136	analyses	_	_	O
137	of	_	_	O
138	survival	_	_	O
139	and	_	_	O
140	response	_	_	O
141	to	_	_	O
142	treatment	_	_	O
143	,	_	_	O
144	respectively	_	_	O
145	.	_	_	O

146	For	_	_	B-Premise
147	survival	_	_	I-Premise
148	,	_	_	I-Premise
149	multiple	_	_	I-Premise
150	sites	_	_	I-Premise
151	of	_	_	I-Premise
152	visceral	_	_	I-Premise
153	disease	_	_	I-Premise
154	,	_	_	I-Premise
155	pain	_	_	I-Premise
156	,	_	_	I-Premise
157	global	_	_	I-Premise
158	QL	_	_	I-Premise
159	and	_	_	I-Premise
160	fatigue	_	_	I-Premise
161	were	_	_	I-Premise
162	significant	_	_	I-Premise
163	prognostic	_	_	I-Premise
164	factors	_	_	I-Premise
165	in	_	_	I-Premise
166	the	_	_	I-Premise
167	univariate	_	_	I-Premise
168	analysis	_	_	I-Premise
169	.	_	_	I-Premise

170	The	_	_	B-Premise
171	final	_	_	I-Premise
172	multivariate	_	_	I-Premise
173	model	_	_	I-Premise
174	predicted	_	_	I-Premise
175	poor	_	_	I-Premise
176	survival	_	_	I-Premise
177	with	_	_	I-Premise
178	multiple	_	_	I-Premise
179	sites	_	_	I-Premise
180	of	_	_	I-Premise
181	visceral	_	_	I-Premise
182	disease	_	_	I-Premise
183	(	_	_	I-Premise
184	P	_	_	I-Premise
185	=	_	_	I-Premise
186	0	_	_	I-Premise
187	.	_	_	I-Premise

188	003	_	_	I-Premise
189	)	_	_	I-Premise
190	,	_	_	I-Premise
191	DFI	_	_	I-Premise
192	<	_	_	I-Premise
193	/	_	_	I-Premise
194	=	_	_	I-Premise
195	2	_	_	I-Premise
196	years	_	_	I-Premise
197	(	_	_	I-Premise
198	P	_	_	I-Premise
199	=	_	_	I-Premise
200	0	_	_	I-Premise
201	.	_	_	I-Premise

202	026	_	_	I-Premise
203	)	_	_	I-Premise
204	and	_	_	I-Premise
205	pain	_	_	I-Premise
206	(	_	_	I-Premise
207	P	_	_	I-Premise
208	=	_	_	I-Premise
209	0	_	_	I-Premise
210	.	_	_	I-Premise

211	003	_	_	I-Premise
212	)	_	_	I-Premise
213	.	_	_	I-Premise

214	For	_	_	B-Premise
215	response	_	_	I-Premise
216	,	_	_	I-Premise
217	age	_	_	I-Premise
218	,	_	_	I-Premise
219	dyspnoea	_	_	I-Premise
220	,	_	_	I-Premise
221	fatigue	_	_	I-Premise
222	and	_	_	I-Premise
223	global	_	_	I-Premise
224	QL	_	_	I-Premise
225	were	_	_	I-Premise
226	significant	_	_	I-Premise
227	predictive	_	_	I-Premise
228	factors	_	_	I-Premise
229	in	_	_	I-Premise
230	the	_	_	I-Premise
231	univariate	_	_	I-Premise
232	analysis	_	_	I-Premise
233	.	_	_	I-Premise

234	The	_	_	B-Premise
235	final	_	_	I-Premise
236	multivariate	_	_	I-Premise
237	model	_	_	I-Premise
238	for	_	_	I-Premise
239	response	_	_	I-Premise
240	selected	_	_	I-Premise
241	DFI	_	_	I-Premise
242	(	_	_	I-Premise
243	P	_	_	I-Premise
244	=	_	_	I-Premise
245	0	_	_	I-Premise
246	.	_	_	I-Premise

247	009	_	_	I-Premise
248	)	_	_	I-Premise
249	,	_	_	I-Premise
250	multiple	_	_	I-Premise
251	sites	_	_	I-Premise
252	of	_	_	I-Premise
253	visceral	_	_	I-Premise
254	disease	_	_	I-Premise
255	(	_	_	I-Premise
256	P	_	_	I-Premise
257	=	_	_	I-Premise
258	0	_	_	I-Premise
259	.	_	_	I-Premise

260	037	_	_	I-Premise
261	)	_	_	I-Premise
262	and	_	_	I-Premise
263	dyspnoea	_	_	I-Premise
264	(	_	_	I-Premise
265	P	_	_	I-Premise
266	=	_	_	I-Premise
267	<	_	_	I-Premise
268	0	_	_	I-Premise
269	.	_	_	I-Premise

270	001	_	_	I-Premise
271	)	_	_	I-Premise
272	using	_	_	I-Premise
273	forward	_	_	I-Premise
274	selection	_	_	I-Premise
275	,	_	_	I-Premise
276	but	_	_	B-Premise
277	model	_	_	I-Premise
278	instability	_	_	I-Premise
279	was	_	_	I-Premise
280	indicated	_	_	I-Premise
281	by	_	_	I-Premise
282	the	_	_	I-Premise
283	inclusion	_	_	I-Premise
284	of	_	_	I-Premise
285	fatigue	_	_	I-Premise
286	and	_	_	I-Premise
287	emotional	_	_	I-Premise
288	function	_	_	I-Premise
289	in	_	_	I-Premise
290	the	_	_	I-Premise
291	final	_	_	I-Premise
292	model	_	_	I-Premise
293	when	_	_	I-Premise
294	backward	_	_	I-Premise
295	selection	_	_	I-Premise
296	was	_	_	I-Premise
297	used	_	_	I-Premise
298	.	_	_	I-Premise

299	In	_	_	O
300	addition	_	_	O
301	to	_	_	O
302	known	_	_	O
303	clinical	_	_	O
304	factors	_	_	O
305	,	_	_	O
306	patient	_	_	B-Claim
307	-	_	_	I-Claim
308	assessed	_	_	I-Claim
309	QL	_	_	I-Claim
310	variables	_	_	I-Claim
311	appear	_	_	I-Claim
312	to	_	_	I-Claim
313	be	_	_	I-Claim
314	prognostic	_	_	I-Claim
315	for	_	_	I-Claim
316	survival	_	_	I-Claim
317	and	_	_	I-Claim
318	response	_	_	I-Claim
319	to	_	_	I-Claim
320	chemotherapy	_	_	I-Claim
321	in	_	_	I-Claim
322	women	_	_	I-Claim
323	with	_	_	I-Claim
324	advanced	_	_	I-Claim
325	breast	_	_	I-Claim
326	cancer	_	_	I-Claim
327	.	_	_	I-Claim

328	However	_	_	B-Claim
329	,	_	_	I-Claim
330	identification	_	_	I-Claim
331	of	_	_	I-Claim
332	prognostic	_	_	I-Claim
333	factors	_	_	I-Claim
334	from	_	_	I-Claim
335	responses	_	_	I-Claim
336	to	_	_	I-Claim
337	questionnaires	_	_	I-Claim
338	may	_	_	I-Claim
339	be	_	_	I-Claim
340	unstable	_	_	I-Claim
341	,	_	_	I-Claim
342	and	_	_	I-Claim
343	their	_	_	I-Claim
344	reliability	_	_	I-Claim
345	and	_	_	I-Claim
346	clinical	_	_	I-Claim
347	utility	_	_	I-Claim
348	should	_	_	I-Claim
349	be	_	_	I-Claim
350	tested	_	_	I-Claim
351	prospectively	_	_	I-Claim
352	.	_	_	I-Claim


0	It	_	_	O
1	is	_	_	O
2	well	_	_	O
3	documented	_	_	O
4	that	_	_	O
5	stress	_	_	O
6	is	_	_	O
7	associated	_	_	O
8	with	_	_	O
9	negative	_	_	O
10	health	_	_	O
11	outcomes	_	_	O
12	in	_	_	O
13	cancer	_	_	O
14	patients	_	_	O
15	.	_	_	O

16	The	_	_	O
17	purpose	_	_	O
18	of	_	_	O
19	this	_	_	O
20	study	_	_	O
21	was	_	_	O
22	to	_	_	O
23	assess	_	_	O
24	the	_	_	O
25	effects	_	_	O
26	of	_	_	O
27	a	_	_	O
28	novel	_	_	O
29	mindfulness	_	_	O
30	intervention	_	_	O
31	called	_	_	O
32	mindfulness	_	_	O
33	-	_	_	O
34	based	_	_	O
35	art	_	_	O
36	therapy	_	_	O
37	(	_	_	O
38	MBAT	_	_	O
39	)	_	_	O
40	versus	_	_	O
41	standard	_	_	O
42	educational	_	_	O
43	support	_	_	O
44	,	_	_	O
45	on	_	_	O
46	indices	_	_	O
47	of	_	_	O
48	stress	_	_	O
49	and	_	_	O
50	quality	_	_	O
51	of	_	_	O
52	life	_	_	O
53	in	_	_	O
54	breast	_	_	O
55	cancer	_	_	O
56	patients	_	_	O
57	with	_	_	O
58	high	_	_	O
59	stress	_	_	O
60	levels	_	_	O
61	.	_	_	O

62	A	_	_	O
63	total	_	_	O
64	of	_	_	O
65	191	_	_	O
66	women	_	_	O
67	were	_	_	O
68	enrolled	_	_	O
69	,	_	_	O
70	stratified	_	_	O
71	by	_	_	O
72	age	_	_	O
73	and	_	_	O
74	stress	_	_	O
75	level	_	_	O
76	,	_	_	O
77	and	_	_	O
78	randomized	_	_	O
79	to	_	_	O
80	receive	_	_	O
81	either	_	_	O
82	an	_	_	O
83	8	_	_	O
84	-	_	_	O
85	week	_	_	O
86	MBAT	_	_	O
87	intervention	_	_	O
88	or	_	_	O
89	a	_	_	O
90	breast	_	_	O
91	cancer	_	_	O
92	educational	_	_	O
93	support	_	_	O
94	program	_	_	O
95	of	_	_	O
96	equal	_	_	O
97	time	_	_	O
98	and	_	_	O
99	duration	_	_	O
100	.	_	_	O

101	Psychosocial	_	_	O
102	stress	_	_	O
103	was	_	_	O
104	measured	_	_	O
105	using	_	_	O
106	the	_	_	O
107	Symptoms	_	_	O
108	Checklist	_	_	O
109	-	_	_	O
110	90	_	_	O
111	-	_	_	O
112	Revised	_	_	O
113	,	_	_	O
114	and	_	_	O
115	quality	_	_	O
116	of	_	_	O
117	life	_	_	O
118	was	_	_	O
119	measured	_	_	O
120	using	_	_	O
121	the	_	_	O
122	Medical	_	_	O
123	Outcomes	_	_	O
124	Study	_	_	O
125	Short	_	_	O
126	-	_	_	O
127	Form	_	_	O
128	Health	_	_	O
129	Survey	_	_	O
130	at	_	_	O
131	baseline	_	_	O
132	,	_	_	O
133	immediately	_	_	O
134	post	_	_	O
135	-	_	_	O
136	intervention	_	_	O
137	,	_	_	O
138	and	_	_	O
139	at	_	_	O
140	6	_	_	O
141	months	_	_	O
142	.	_	_	O

143	Results	_	_	B-Premise
144	showed	_	_	I-Premise
145	overall	_	_	I-Premise
146	significant	_	_	I-Premise
147	improvements	_	_	I-Premise
148	in	_	_	I-Premise
149	psychosocial	_	_	I-Premise
150	stress	_	_	I-Premise
151	and	_	_	I-Premise
152	quality	_	_	I-Premise
153	of	_	_	I-Premise
154	life	_	_	I-Premise
155	in	_	_	I-Premise
156	both	_	_	I-Premise
157	the	_	_	I-Premise
158	MBAT	_	_	I-Premise
159	and	_	_	I-Premise
160	educational	_	_	I-Premise
161	support	_	_	I-Premise
162	groups	_	_	I-Premise
163	immediately	_	_	I-Premise
164	post	_	_	I-Premise
165	-	_	_	I-Premise
166	intervention	_	_	I-Premise
167	;	_	_	I-Premise
168	however	_	_	B-Premise
169	,	_	_	I-Premise
170	participants	_	_	I-Premise
171	with	_	_	I-Premise
172	high	_	_	I-Premise
173	stress	_	_	I-Premise
174	levels	_	_	I-Premise
175	at	_	_	I-Premise
176	baseline	_	_	I-Premise
177	had	_	_	I-Premise
178	significantly	_	_	I-Premise
179	improved	_	_	I-Premise
180	overall	_	_	I-Premise
181	outcomes	_	_	I-Premise
182	only	_	_	I-Premise
183	in	_	_	I-Premise
184	the	_	_	I-Premise
185	MBAT	_	_	I-Premise
186	group	_	_	I-Premise
187	,	_	_	I-Premise
188	both	_	_	I-Premise
189	immediately	_	_	I-Premise
190	post	_	_	I-Premise
191	-	_	_	I-Premise
192	intervention	_	_	I-Premise
193	and	_	_	I-Premise
194	at	_	_	I-Premise
195	6	_	_	I-Premise
196	months	_	_	I-Premise
197	.	_	_	I-Premise

198	In	_	_	O
199	addition	_	_	O
200	,	_	_	O
201	at	_	_	B-Premise
202	6	_	_	I-Premise
203	months	_	_	I-Premise
204	follow	_	_	I-Premise
205	-	_	_	I-Premise
206	up	_	_	I-Premise
207	,	_	_	I-Premise
208	participants	_	_	I-Premise
209	attending	_	_	I-Premise
210	five	_	_	I-Premise
211	or	_	_	I-Premise
212	more	_	_	I-Premise
213	sessions	_	_	I-Premise
214	trended	_	_	I-Premise
215	toward	_	_	I-Premise
216	retaining	_	_	I-Premise
217	treatment	_	_	I-Premise
218	effects	_	_	I-Premise
219	better	_	_	I-Premise
220	in	_	_	I-Premise
221	the	_	_	I-Premise
222	MBAT	_	_	I-Premise
223	than	_	_	I-Premise
224	in	_	_	I-Premise
225	the	_	_	I-Premise
226	control	_	_	I-Premise
227	group	_	_	I-Premise
228	.	_	_	I-Premise

229	Finally	_	_	O
230	,	_	_	O
231	black	_	_	B-Premise
232	women	_	_	I-Premise
233	and	_	_	I-Premise
234	white	_	_	I-Premise
235	women	_	_	I-Premise
236	were	_	_	I-Premise
237	similar	_	_	I-Premise
238	in	_	_	I-Premise
239	terms	_	_	I-Premise
240	of	_	_	I-Premise
241	how	_	_	I-Premise
242	they	_	_	I-Premise
243	benefited	_	_	I-Premise
244	from	_	_	I-Premise
245	the	_	_	I-Premise
246	MBAT	_	_	I-Premise
247	intervention	_	_	I-Premise
248	,	_	_	I-Premise
249	even	_	_	I-Premise
250	though	_	_	I-Premise
251	white	_	_	I-Premise
252	participants	_	_	I-Premise
253	tended	_	_	I-Premise
254	to	_	_	I-Premise
255	have	_	_	I-Premise
256	higher	_	_	I-Premise
257	educational	_	_	I-Premise
258	level	_	_	I-Premise
259	and	_	_	I-Premise
260	marital	_	_	I-Premise
261	status	_	_	I-Premise
262	.	_	_	I-Premise

263	In	_	_	B-Claim
264	conclusion	_	_	I-Claim
265	,	_	_	I-Claim
266	MBAT	_	_	I-Claim
267	is	_	_	I-Claim
268	associated	_	_	I-Claim
269	with	_	_	I-Claim
270	significant	_	_	I-Claim
271	,	_	_	I-Claim
272	sustained	_	_	I-Claim
273	benefits	_	_	I-Claim
274	across	_	_	I-Claim
275	a	_	_	I-Claim
276	diverse	_	_	I-Claim
277	range	_	_	I-Claim
278	of	_	_	I-Claim
279	breast	_	_	I-Claim
280	cancer	_	_	I-Claim
281	patients	_	_	I-Claim
282	,	_	_	I-Claim
283	particularly	_	_	I-Claim
284	those	_	_	I-Claim
285	with	_	_	I-Claim
286	high	_	_	I-Claim
287	stress	_	_	I-Claim
288	levels	_	_	I-Claim
289	.	_	_	I-Claim


0	Extracellular	_	_	O
1	adenosine	_	_	O
2	5	_	_	O
3	'	_	_	O
4	-	_	_	O
5	triphosphate	_	_	O
6	(	_	_	O
7	ATP	_	_	O
8	)	_	_	O
9	is	_	_	O
10	involved	_	_	O
11	in	_	_	O
12	the	_	_	O
13	regulation	_	_	O
14	of	_	_	O
15	a	_	_	O
16	variety	_	_	O
17	of	_	_	O
18	biologic	_	_	O
19	processes	_	_	O
20	,	_	_	O
21	including	_	_	O
22	neurotransmission	_	_	O
23	,	_	_	O
24	muscle	_	_	O
25	contraction	_	_	O
26	,	_	_	O
27	and	_	_	O
28	liver	_	_	O
29	glucose	_	_	O
30	metabolism	_	_	O
31	,	_	_	O
32	via	_	_	O
33	purinergic	_	_	O
34	receptors	_	_	O
35	.	_	_	O

36	In	_	_	B-Claim
37	nonrandomized	_	_	I-Claim
38	studies	_	_	I-Claim
39	involving	_	_	I-Claim
40	patients	_	_	I-Claim
41	with	_	_	I-Claim
42	different	_	_	I-Claim
43	tumor	_	_	I-Claim
44	types	_	_	I-Claim
45	including	_	_	I-Claim
46	non	_	_	I-Claim
47	-	_	_	I-Claim
48	small	_	_	I-Claim
49	-	_	_	I-Claim
50	cell	_	_	I-Claim
51	lung	_	_	I-Claim
52	cancer	_	_	I-Claim
53	(	_	_	I-Claim
54	NSCLC	_	_	I-Claim
55	)	_	_	I-Claim
56	,	_	_	I-Claim
57	ATP	_	_	I-Claim
58	infusion	_	_	I-Claim
59	appeared	_	_	I-Claim
60	to	_	_	I-Claim
61	inhibit	_	_	I-Claim
62	loss	_	_	I-Claim
63	of	_	_	I-Claim
64	weight	_	_	I-Claim
65	and	_	_	I-Claim
66	deterioration	_	_	I-Claim
67	of	_	_	I-Claim
68	quality	_	_	I-Claim
69	of	_	_	I-Claim
70	life	_	_	I-Claim
71	(	_	_	I-Claim
72	QOL	_	_	I-Claim
73	)	_	_	I-Claim
74	and	_	_	I-Claim
75	performance	_	_	I-Claim
76	status	_	_	I-Claim
77	.	_	_	I-Claim

78	We	_	_	O
79	conducted	_	_	O
80	a	_	_	O
81	randomized	_	_	O
82	clinical	_	_	O
83	trial	_	_	O
84	to	_	_	O
85	evaluate	_	_	O
86	the	_	_	O
87	effects	_	_	O
88	of	_	_	O
89	ATP	_	_	O
90	in	_	_	O
91	patients	_	_	O
92	with	_	_	O
93	advanced	_	_	O
94	NSCLC	_	_	O
95	(	_	_	O
96	stage	_	_	O
97	IIIB	_	_	O
98	or	_	_	O
99	IV	_	_	O
100	)	_	_	O
101	.	_	_	O

102	Fifty	_	_	O
103	-	_	_	O
104	eight	_	_	O
105	patients	_	_	O
106	were	_	_	O
107	randomly	_	_	O
108	assigned	_	_	O
109	to	_	_	O
110	receive	_	_	O
111	either	_	_	O
112	10	_	_	O
113	intravenous	_	_	O
114	30	_	_	O
115	-	_	_	O
116	hour	_	_	O
117	ATP	_	_	O
118	infusions	_	_	O
119	,	_	_	O
120	with	_	_	O
121	the	_	_	O
122	infusions	_	_	O
123	given	_	_	O
124	at	_	_	O
125	2	_	_	O
126	-	_	_	O
127	to	_	_	O
128	4	_	_	O
129	-	_	_	O
130	week	_	_	O
131	intervals	_	_	O
132	,	_	_	O
133	or	_	_	O
134	no	_	_	O
135	ATP	_	_	O
136	.	_	_	O

137	Outcome	_	_	O
138	parameters	_	_	O
139	were	_	_	O
140	assessed	_	_	O
141	every	_	_	O
142	4	_	_	O
143	weeks	_	_	O
144	until	_	_	O
145	28	_	_	O
146	weeks	_	_	O
147	.	_	_	O

148	Between	_	_	O
149	-	_	_	O
150	group	_	_	O
151	differences	_	_	O
152	were	_	_	O
153	tested	_	_	O
154	for	_	_	O
155	statistical	_	_	O
156	significance	_	_	O
157	by	_	_	O
158	use	_	_	O
159	of	_	_	O
160	repeated	_	_	O
161	-	_	_	O
162	measures	_	_	O
163	analysis	_	_	O
164	,	_	_	O
165	and	_	_	O
166	reported	_	_	O
167	P	_	_	O
168	values	_	_	O
169	are	_	_	O
170	two	_	_	O
171	-	_	_	O
172	sided	_	_	O
173	.	_	_	O

174	Twenty	_	_	O
175	-	_	_	O
176	eight	_	_	O
177	patients	_	_	O
178	were	_	_	O
179	allocated	_	_	O
180	to	_	_	O
181	receive	_	_	O
182	ATP	_	_	O
183	treatment	_	_	O
184	and	_	_	O
185	30	_	_	O
186	received	_	_	O
187	no	_	_	O
188	ATP	_	_	O
189	.	_	_	O

190	Mean	_	_	B-Premise
191	weight	_	_	I-Premise
192	changes	_	_	I-Premise
193	per	_	_	I-Premise
194	4	_	_	I-Premise
195	-	_	_	I-Premise
196	week	_	_	I-Premise
197	period	_	_	I-Premise
198	were	_	_	I-Premise
199	-	_	_	I-Premise
200	1	_	_	I-Premise
201	.	_	_	I-Premise

202	0	_	_	I-Premise
203	kg	_	_	I-Premise
204	(	_	_	I-Premise
205	95	_	_	I-Premise
206	%	_	_	I-Premise
207	confidence	_	_	I-Premise
208	interval	_	_	I-Premise
209	[	_	_	I-Premise
210	CI	_	_	I-Premise
211	]	_	_	I-Premise
212	=	_	_	I-Premise
213	-	_	_	I-Premise
214	1	_	_	I-Premise
215	.	_	_	I-Premise

216	5	_	_	I-Premise
217	to	_	_	I-Premise
218	-	_	_	I-Premise
219	0	_	_	I-Premise
220	.	_	_	I-Premise

221	5	_	_	I-Premise
222	)	_	_	I-Premise
223	in	_	_	I-Premise
224	the	_	_	I-Premise
225	control	_	_	I-Premise
226	group	_	_	I-Premise
227	and	_	_	I-Premise
228	0	_	_	I-Premise
229	.	_	_	I-Premise

230	2	_	_	I-Premise
231	kg	_	_	I-Premise
232	(	_	_	I-Premise
233	95	_	_	I-Premise
234	%	_	_	I-Premise
235	CI	_	_	I-Premise
236	=	_	_	I-Premise
237	-	_	_	I-Premise
238	0	_	_	I-Premise
239	.	_	_	I-Premise

240	2	_	_	I-Premise
241	to	_	_	I-Premise
242	+	_	_	I-Premise
243	0	_	_	I-Premise
244	.	_	_	I-Premise

245	6	_	_	I-Premise
246	)	_	_	I-Premise
247	in	_	_	I-Premise
248	the	_	_	I-Premise
249	ATP	_	_	I-Premise
250	group	_	_	I-Premise
251	(	_	_	I-Premise
252	P	_	_	I-Premise
253	=	_	_	I-Premise
254	.	_	_	I-Premise

255	002	_	_	I-Premise
256	)	_	_	I-Premise
257	.	_	_	I-Premise

258	Serum	_	_	B-Premise
259	albumin	_	_	I-Premise
260	concentration	_	_	I-Premise
261	declined	_	_	I-Premise
262	by	_	_	I-Premise
263	-	_	_	I-Premise
264	1	_	_	I-Premise
265	.	_	_	I-Premise

266	2	_	_	I-Premise
267	g	_	_	I-Premise
268	/	_	_	I-Premise
269	L	_	_	I-Premise
270	(	_	_	I-Premise
271	95	_	_	I-Premise
272	%	_	_	I-Premise
273	CI	_	_	I-Premise
274	=	_	_	I-Premise
275	-	_	_	I-Premise
276	2	_	_	I-Premise
277	.	_	_	I-Premise

278	0	_	_	I-Premise
279	to	_	_	I-Premise
280	-	_	_	I-Premise
281	0	_	_	I-Premise
282	.	_	_	I-Premise

283	4	_	_	I-Premise
284	)	_	_	I-Premise
285	per	_	_	I-Premise
286	4	_	_	I-Premise
287	weeks	_	_	I-Premise
288	in	_	_	I-Premise
289	the	_	_	I-Premise
290	control	_	_	I-Premise
291	group	_	_	I-Premise
292	but	_	_	I-Premise
293	remained	_	_	I-Premise
294	stable	_	_	I-Premise
295	(	_	_	I-Premise
296	0	_	_	I-Premise
297	.	_	_	I-Premise

298	0	_	_	I-Premise
299	g	_	_	I-Premise
300	/	_	_	I-Premise
301	L	_	_	I-Premise
302	;	_	_	I-Premise
303	95	_	_	I-Premise
304	%	_	_	I-Premise
305	CI	_	_	I-Premise
306	=	_	_	I-Premise
307	-	_	_	I-Premise
308	0	_	_	I-Premise
309	.	_	_	I-Premise

310	3	_	_	I-Premise
311	to	_	_	I-Premise
312	+	_	_	I-Premise
313	0	_	_	I-Premise
314	.	_	_	I-Premise

315	3	_	_	I-Premise
316	)	_	_	I-Premise
317	in	_	_	I-Premise
318	the	_	_	I-Premise
319	ATP	_	_	I-Premise
320	group	_	_	I-Premise
321	(	_	_	I-Premise
322	P	_	_	I-Premise
323	=	_	_	I-Premise
324	.	_	_	I-Premise

325	006	_	_	I-Premise
326	)	_	_	I-Premise
327	.	_	_	I-Premise

328	Elbow	_	_	B-Premise
329	flexor	_	_	I-Premise
330	muscle	_	_	I-Premise
331	strength	_	_	I-Premise
332	declined	_	_	I-Premise
333	by	_	_	I-Premise
334	-	_	_	I-Premise
335	5	_	_	I-Premise
336	.	_	_	I-Premise

337	5	_	_	I-Premise
338	%	_	_	I-Premise
339	(	_	_	I-Premise
340	95	_	_	I-Premise
341	%	_	_	I-Premise
342	CI	_	_	I-Premise
343	=	_	_	I-Premise
344	-	_	_	I-Premise
345	9	_	_	I-Premise
346	.	_	_	I-Premise

347	6	_	_	I-Premise
348	%	_	_	I-Premise
349	to	_	_	I-Premise
350	-	_	_	I-Premise
351	1	_	_	I-Premise
352	.	_	_	I-Premise

353	4	_	_	I-Premise
354	%	_	_	I-Premise
355	)	_	_	I-Premise
356	per	_	_	I-Premise
357	4	_	_	I-Premise
358	weeks	_	_	I-Premise
359	in	_	_	I-Premise
360	the	_	_	I-Premise
361	control	_	_	I-Premise
362	group	_	_	I-Premise
363	but	_	_	I-Premise
364	remained	_	_	I-Premise
365	stable	_	_	I-Premise
366	(	_	_	I-Premise
367	0	_	_	I-Premise
368	.	_	_	I-Premise

369	0	_	_	I-Premise
370	%	_	_	I-Premise
371	;	_	_	I-Premise
372	95	_	_	I-Premise
373	%	_	_	I-Premise
374	CI	_	_	I-Premise
375	=	_	_	I-Premise
376	-	_	_	I-Premise
377	1	_	_	I-Premise
378	.	_	_	I-Premise

379	4	_	_	I-Premise
380	%	_	_	I-Premise
381	to	_	_	I-Premise
382	+	_	_	I-Premise
383	1	_	_	I-Premise
384	.	_	_	I-Premise

385	4	_	_	I-Premise
386	%	_	_	I-Premise
387	)	_	_	I-Premise
388	in	_	_	I-Premise
389	the	_	_	I-Premise
390	ATP	_	_	I-Premise
391	group	_	_	I-Premise
392	(	_	_	I-Premise
393	P	_	_	I-Premise
394	=	_	_	I-Premise
395	.	_	_	I-Premise

396	01	_	_	I-Premise
397	)	_	_	I-Premise
398	.	_	_	I-Premise

399	A	_	_	B-Premise
400	similar	_	_	I-Premise
401	pattern	_	_	I-Premise
402	was	_	_	I-Premise
403	observed	_	_	I-Premise
404	for	_	_	I-Premise
405	knee	_	_	I-Premise
406	extensor	_	_	I-Premise
407	muscles	_	_	I-Premise
408	(	_	_	I-Premise
409	P	_	_	I-Premise
410	=	_	_	I-Premise
411	.	_	_	I-Premise

412	02	_	_	I-Premise
413	)	_	_	I-Premise
414	.	_	_	I-Premise

415	The	_	_	B-Premise
416	effects	_	_	I-Premise
417	of	_	_	I-Premise
418	ATP	_	_	I-Premise
419	on	_	_	I-Premise
420	body	_	_	I-Premise
421	weight	_	_	I-Premise
422	,	_	_	I-Premise
423	muscle	_	_	I-Premise
424	strength	_	_	I-Premise
425	,	_	_	I-Premise
426	and	_	_	I-Premise
427	albumin	_	_	I-Premise
428	concentration	_	_	I-Premise
429	were	_	_	I-Premise
430	especially	_	_	I-Premise
431	marked	_	_	I-Premise
432	in	_	_	I-Premise
433	cachectic	_	_	I-Premise
434	patients	_	_	I-Premise
435	(	_	_	I-Premise
436	P	_	_	I-Premise
437	=	_	_	I-Premise
438	.	_	_	I-Premise

439	0002	_	_	I-Premise
440	,	_	_	I-Premise
441	P	_	_	I-Premise
442	=	_	_	I-Premise
443	.	_	_	I-Premise

444	0001	_	_	I-Premise
445	,	_	_	I-Premise
446	and	_	_	I-Premise
447	P	_	_	I-Premise
448	=	_	_	I-Premise
449	.	_	_	I-Premise

450	0001	_	_	I-Premise
451	,	_	_	I-Premise
452	respectively	_	_	I-Premise
453	,	_	_	I-Premise
454	for	_	_	I-Premise
455	ATP	_	_	I-Premise
456	versus	_	_	I-Premise
457	no	_	_	I-Premise
458	ATP	_	_	I-Premise
459	)	_	_	I-Premise
460	.	_	_	I-Premise

461	QOL	_	_	B-Premise
462	score	_	_	I-Premise
463	changes	_	_	I-Premise
464	per	_	_	I-Premise
465	4	_	_	I-Premise
466	-	_	_	I-Premise
467	week	_	_	I-Premise
468	period	_	_	I-Premise
469	in	_	_	I-Premise
470	the	_	_	I-Premise
471	ATP	_	_	I-Premise
472	group	_	_	I-Premise
473	showed	_	_	I-Premise
474	overall	_	_	I-Premise
475	less	_	_	I-Premise
476	deterioration	_	_	I-Premise
477	than	_	_	I-Premise
478	in	_	_	I-Premise
479	the	_	_	I-Premise
480	control	_	_	I-Premise
481	group	_	_	I-Premise
482	-	_	_	I-Premise
483	physical	_	_	I-Premise
484	scores	_	_	I-Premise
485	(	_	_	I-Premise
486	-	_	_	I-Premise
487	0	_	_	I-Premise
488	.	_	_	I-Premise

489	2	_	_	I-Premise
490	%	_	_	I-Premise
491	versus	_	_	I-Premise
492	-	_	_	I-Premise
493	2	_	_	I-Premise
494	.	_	_	I-Premise

495	4	_	_	I-Premise
496	%	_	_	I-Premise
497	;	_	_	I-Premise
498	P	_	_	I-Premise
499	=	_	_	I-Premise
500	.	_	_	I-Premise

501	0002	_	_	I-Premise
502	)	_	_	I-Premise
503	;	_	_	I-Premise
504	functional	_	_	I-Premise
505	scores	_	_	I-Premise
506	(	_	_	I-Premise
507	+	_	_	I-Premise
508	0	_	_	I-Premise
509	.	_	_	I-Premise

510	4	_	_	I-Premise
511	%	_	_	I-Premise
512	versus	_	_	I-Premise
513	-	_	_	I-Premise
514	5	_	_	I-Premise
515	.	_	_	I-Premise

516	5	_	_	I-Premise
517	%	_	_	I-Premise
518	;	_	_	I-Premise
519	P	_	_	I-Premise
520	=	_	_	I-Premise
521	.	_	_	I-Premise

522	02	_	_	I-Premise
523	)	_	_	I-Premise
524	;	_	_	I-Premise
525	psychologic	_	_	I-Premise
526	scores	_	_	I-Premise
527	(	_	_	I-Premise
528	-	_	_	I-Premise
529	0	_	_	I-Premise
530	.	_	_	I-Premise

531	7	_	_	I-Premise
532	%	_	_	I-Premise
533	versus	_	_	I-Premise
534	-	_	_	I-Premise
535	2	_	_	I-Premise
536	.	_	_	I-Premise

537	4	_	_	I-Premise
538	%	_	_	I-Premise
539	;	_	_	I-Premise
540	P	_	_	I-Premise
541	=	_	_	I-Premise
542	.	_	_	I-Premise

543	11	_	_	I-Premise
544	)	_	_	I-Premise
545	;	_	_	I-Premise
546	overall	_	_	I-Premise
547	QOL	_	_	I-Premise
548	score	_	_	I-Premise
549	(	_	_	I-Premise
550	+	_	_	I-Premise
551	0	_	_	I-Premise
552	.	_	_	I-Premise

553	1	_	_	I-Premise
554	%	_	_	I-Premise
555	versus	_	_	I-Premise
556	-	_	_	I-Premise
557	3	_	_	I-Premise
558	.	_	_	I-Premise

559	5	_	_	I-Premise
560	%	_	_	I-Premise
561	;	_	_	I-Premise
562	P	_	_	I-Premise
563	=	_	_	I-Premise
564	.	_	_	I-Premise

565	0001	_	_	I-Premise
566	)	_	_	I-Premise
567	.	_	_	I-Premise

568	This	_	_	O
569	randomized	_	_	O
570	trial	_	_	O
571	demonstrates	_	_	O
572	that	_	_	O
573	ATP	_	_	B-Claim
574	has	_	_	I-Claim
575	beneficial	_	_	I-Claim
576	effects	_	_	I-Claim
577	on	_	_	I-Claim
578	weight	_	_	I-Claim
579	,	_	_	I-Claim
580	muscle	_	_	I-Claim
581	strength	_	_	I-Claim
582	,	_	_	I-Claim
583	and	_	_	I-Claim
584	QOL	_	_	I-Claim
585	in	_	_	I-Claim
586	patients	_	_	I-Claim
587	with	_	_	I-Claim
588	advanced	_	_	I-Claim
589	NSCLC	_	_	I-Claim
590	.	_	_	I-Claim


0	To	_	_	O
1	carry	_	_	O
2	out	_	_	O
3	a	_	_	O
4	preliminary	_	_	O
5	trial	_	_	O
6	evaluating	_	_	O
7	the	_	_	O
8	effectiveness	_	_	O
9	of	_	_	O
10	two	_	_	O
11	types	_	_	O
12	of	_	_	O
13	homeopathy	_	_	O
14	for	_	_	O
15	the	_	_	O
16	treatment	_	_	O
17	of	_	_	O
18	menopausal	_	_	O
19	symptoms	_	_	O
20	in	_	_	O
21	breast	_	_	O
22	cancer	_	_	O
23	survivors	_	_	O
24	.	_	_	O

25	Randomized	_	_	O
26	,	_	_	O
27	double	_	_	O
28	-	_	_	O
29	blinded	_	_	O
30	,	_	_	O
31	placebo	_	_	O
32	-	_	_	O
33	controlled	_	_	O
34	.	_	_	O

35	Private	_	_	O
36	medical	_	_	O
37	clinic	_	_	O
38	,	_	_	O
39	Seattle	_	_	O
40	,	_	_	O
41	WA	_	_	O
42	.	_	_	O

43	Women	_	_	O
44	with	_	_	O
45	a	_	_	O
46	history	_	_	O
47	of	_	_	O
48	breast	_	_	O
49	cancer	_	_	O
50	who	_	_	O
51	had	_	_	O
52	completed	_	_	O
53	all	_	_	O
54	surgery	_	_	O
55	,	_	_	O
56	chemotherapy	_	_	O
57	,	_	_	O
58	and	_	_	O
59	radiation	_	_	O
60	treatment	_	_	O
61	and	_	_	O
62	who	_	_	O
63	had	_	_	O
64	an	_	_	O
65	average	_	_	O
66	of	_	_	O
67	at	_	_	O
68	least	_	_	O
69	three	_	_	O
70	hot	_	_	O
71	flashes	_	_	O
72	per	_	_	O
73	day	_	_	O
74	for	_	_	O
75	the	_	_	O
76	previous	_	_	O
77	month	_	_	O
78	.	_	_	O

79	Subjects	_	_	O
80	were	_	_	O
81	randomized	_	_	O
82	to	_	_	O
83	receive	_	_	O
84	either	_	_	O
85	an	_	_	O
86	individualized	_	_	O
87	homeopathic	_	_	O
88	single	_	_	O
89	remedy	_	_	O
90	,	_	_	O
91	a	_	_	O
92	homeopathic	_	_	O
93	combination	_	_	O
94	medicine	_	_	O
95	,	_	_	O
96	or	_	_	O
97	placebo	_	_	O
98	.	_	_	O

99	Patients	_	_	O
100	were	_	_	O
101	seen	_	_	O
102	by	_	_	O
103	homeopathic	_	_	O
104	providers	_	_	O
105	every	_	_	O
106	2	_	_	O
107	months	_	_	O
108	for	_	_	O
109	1	_	_	O
110	year	_	_	O
111	.	_	_	O

112	Hot	_	_	O
113	flash	_	_	O
114	frequency	_	_	O
115	and	_	_	O
116	severity	_	_	O
117	,	_	_	O
118	Kupperman	_	_	O
119	Menopausal	_	_	O
120	Index	_	_	O
121	(	_	_	O
122	KMI	_	_	O
123	)	_	_	O
124	,	_	_	O
125	Short	_	_	O
126	Form	_	_	O
127	36	_	_	O
128	(	_	_	O
129	SF	_	_	O
130	-	_	_	O
131	36	_	_	O
132	)	_	_	O
133	.	_	_	O

134	There	_	_	B-Premise
135	was	_	_	I-Premise
136	no	_	_	I-Premise
137	significant	_	_	I-Premise
138	difference	_	_	I-Premise
139	found	_	_	I-Premise
140	in	_	_	I-Premise
141	the	_	_	I-Premise
142	primary	_	_	I-Premise
143	outcome	_	_	I-Premise
144	measure	_	_	I-Premise
145	,	_	_	I-Premise
146	the	_	_	I-Premise
147	hot	_	_	I-Premise
148	flash	_	_	I-Premise
149	severity	_	_	I-Premise
150	score	_	_	I-Premise
151	,	_	_	I-Premise
152	although	_	_	B-Premise
153	there	_	_	I-Premise
154	was	_	_	I-Premise
155	a	_	_	I-Premise
156	positive	_	_	I-Premise
157	trend	_	_	I-Premise
158	in	_	_	I-Premise
159	the	_	_	I-Premise
160	single	_	_	I-Premise
161	remedy	_	_	I-Premise
162	group	_	_	I-Premise
163	during	_	_	I-Premise
164	the	_	_	I-Premise
165	first	_	_	I-Premise
166	3	_	_	I-Premise
167	months	_	_	I-Premise
168	of	_	_	I-Premise
169	the	_	_	I-Premise
170	study	_	_	I-Premise
171	(	_	_	I-Premise
172	p	_	_	I-Premise
173	=	_	_	I-Premise
174	0	_	_	I-Premise
175	.	_	_	I-Premise

176	1	_	_	I-Premise
177	)	_	_	I-Premise
178	.	_	_	I-Premise

179	A	_	_	B-Premise
180	statistically	_	_	I-Premise
181	significant	_	_	I-Premise
182	improvement	_	_	I-Premise
183	in	_	_	I-Premise
184	general	_	_	I-Premise
185	health	_	_	I-Premise
186	score	_	_	I-Premise
187	in	_	_	I-Premise
188	both	_	_	I-Premise
189	homeopathy	_	_	I-Premise
190	groups	_	_	I-Premise
191	(	_	_	I-Premise
192	p	_	_	I-Premise
193	<	_	_	I-Premise
194	0	_	_	I-Premise
195	.	_	_	I-Premise

196	05	_	_	I-Premise
197	)	_	_	I-Premise
198	on	_	_	I-Premise
199	the	_	_	I-Premise
200	SF	_	_	I-Premise
201	-	_	_	I-Premise
202	36	_	_	I-Premise
203	after	_	_	I-Premise
204	1	_	_	I-Premise
205	year	_	_	I-Premise
206	was	_	_	I-Premise
207	found	_	_	I-Premise
208	.	_	_	I-Premise

209	Evidence	_	_	B-Premise
210	of	_	_	I-Premise
211	a	_	_	I-Premise
212	homeopathic	_	_	I-Premise
213	"	_	_	I-Premise
214	drug	_	_	I-Premise
215	proving	_	_	I-Premise
216	"	_	_	I-Premise
217	in	_	_	I-Premise
218	the	_	_	I-Premise
219	subjects	_	_	I-Premise
220	receiving	_	_	I-Premise
221	the	_	_	I-Premise
222	homeopathic	_	_	I-Premise
223	combination	_	_	I-Premise
224	medicine	_	_	I-Premise
225	who	_	_	I-Premise
226	were	_	_	I-Premise
227	not	_	_	I-Premise
228	taking	_	_	I-Premise
229	tamoxifen	_	_	I-Premise
230	also	_	_	I-Premise
231	was	_	_	I-Premise
232	found	_	_	I-Premise
233	.	_	_	I-Premise

234	Small	_	_	B-Claim
235	sample	_	_	I-Claim
236	size	_	_	I-Claim
237	precludes	_	_	I-Claim
238	definitive	_	_	I-Claim
239	answers	_	_	I-Claim
240	,	_	_	I-Claim
241	but	_	_	B-Claim
242	results	_	_	I-Claim
243	from	_	_	I-Claim
244	this	_	_	I-Claim
245	preliminary	_	_	I-Claim
246	trial	_	_	I-Claim
247	suggest	_	_	I-Claim
248	that	_	_	I-Claim
249	homeopathy	_	_	I-Claim
250	may	_	_	I-Claim
251	be	_	_	I-Claim
252	of	_	_	I-Claim
253	value	_	_	I-Claim
254	in	_	_	I-Claim
255	the	_	_	I-Claim
256	treatment	_	_	I-Claim
257	of	_	_	I-Claim
258	menopausal	_	_	I-Claim
259	symptoms	_	_	I-Claim
260	and	_	_	I-Claim
261	improving	_	_	I-Claim
262	quality	_	_	I-Claim
263	of	_	_	I-Claim
264	life	_	_	I-Claim
265	,	_	_	I-Claim
266	especially	_	_	I-Claim
267	in	_	_	I-Claim
268	those	_	_	I-Claim
269	women	_	_	I-Claim
270	not	_	_	I-Claim
271	on	_	_	I-Claim
272	tamoxifen	_	_	I-Claim
273	.	_	_	I-Claim

274	Larger	_	_	B-Claim
275	studies	_	_	I-Claim
276	should	_	_	I-Claim
277	be	_	_	I-Claim
278	carried	_	_	I-Claim
279	out	_	_	I-Claim
280	that	_	_	I-Claim
281	also	_	_	I-Claim
282	include	_	_	I-Claim
283	healthy	_	_	I-Claim
284	women	_	_	I-Claim
285	who	_	_	I-Claim
286	want	_	_	I-Claim
287	to	_	_	I-Claim
288	avoid	_	_	I-Claim
289	hormone	_	_	I-Claim
290	replacement	_	_	I-Claim
291	therapy	_	_	I-Claim
292	.	_	_	I-Claim


0	Chemotherapy	_	_	O
1	-	_	_	O
2	induced	_	_	O
3	anemia	_	_	O
4	(	_	_	O
5	CIA	_	_	O
6	)	_	_	O
7	is	_	_	O
8	responsive	_	_	O
9	to	_	_	O
10	treatment	_	_	O
11	with	_	_	O
12	erythropoiesis	_	_	O
13	-	_	_	O
14	stimulating	_	_	O
15	agents	_	_	O
16	(	_	_	O
17	ESAs	_	_	O
18	)	_	_	O
19	such	_	_	O
20	as	_	_	O
21	darbepoetin	_	_	O
22	alfa	_	_	O
23	.	_	_	O

24	Administration	_	_	O
25	of	_	_	O
26	ESAs	_	_	O
27	on	_	_	O
28	a	_	_	O
29	synchronous	_	_	O
30	schedule	_	_	O
31	with	_	_	O
32	chemotherapy	_	_	O
33	administration	_	_	O
34	could	_	_	O
35	benefit	_	_	O
36	patients	_	_	O
37	by	_	_	O
38	reducing	_	_	O
39	clinic	_	_	O
40	visits	_	_	O
41	and	_	_	O
42	potentially	_	_	O
43	enhancing	_	_	O
44	on	_	_	O
45	-	_	_	O
46	time	_	_	O
47	chemotherapy	_	_	O
48	delivery	_	_	O
49	.	_	_	O

50	This	_	_	O
51	phase	_	_	O
52	2	_	_	O
53	,	_	_	O
54	25	_	_	O
55	-	_	_	O
56	week	_	_	O
57	,	_	_	O
58	open	_	_	O
59	-	_	_	O
60	label	_	_	O
61	study	_	_	O
62	evaluated	_	_	O
63	the	_	_	O
64	noninferiority	_	_	O
65	of	_	_	O
66	darbepoetin	_	_	O
67	alfa	_	_	O
68	administered	_	_	O
69	weekly	_	_	O
70	vs	_	_	O
71	.	_	_	O

72	as	_	_	O
73	an	_	_	O
74	extended	_	_	O
75	dosing	_	_	O
76	schedule	_	_	O
77	(	_	_	O
78	every	_	_	O
79	2	_	_	O
80	or	_	_	O
81	3	_	_	O
82	weeks	_	_	O
83	)	_	_	O
84	in	_	_	O
85	patients	_	_	O
86	with	_	_	O
87	CIA	_	_	O
88	.	_	_	O

89	Patients	_	_	O
90	were	_	_	O
91	randomized	_	_	O
92	1	_	_	O
93	:	_	_	O
94	1	_	_	O
95	to	_	_	O
96	an	_	_	O
97	extended	_	_	O
98	dosing	_	_	O
99	schedule	_	_	O
100	(	_	_	O
101	EDS	_	_	O
102	:	_	_	O
103	darbepoetin	_	_	O
104	alfa	_	_	O
105	300	_	_	O
106	μg	_	_	O
107	Q2W	_	_	O
108	if	_	_	O
109	chemotherapy	_	_	O
110	was	_	_	O
111	QW	_	_	O
112	,	_	_	O
113	Q2W	_	_	O
114	,	_	_	O
115	or	_	_	O
116	Q4W	_	_	O
117	or	_	_	O
118	darbepoetin	_	_	O
119	alfa	_	_	O
120	500	_	_	O
121	μg	_	_	O
122	Q3W	_	_	O
123	if	_	_	O
124	chemotherapy	_	_	O
125	was	_	_	O
126	Q3W	_	_	O
127	)	_	_	O
128	or	_	_	O
129	weekly	_	_	O
130	(	_	_	O
131	150	_	_	O
132	μg	_	_	O
133	QW	_	_	O
134	regardless	_	_	O
135	of	_	_	O
136	chemotherapy	_	_	O
137	schedule	_	_	O
138	)	_	_	O
139	.	_	_	O

140	Stratification	_	_	O
141	factors	_	_	O
142	included	_	_	O
143	chemotherapy	_	_	O
144	cycle	_	_	O
145	length	_	_	O
146	,	_	_	O
147	screening	_	_	O
148	hemoglobin	_	_	O
149	(	_	_	O
150	<	_	_	O
151	10	_	_	O
152	g	_	_	O
153	/	_	_	O
154	dL	_	_	O
155	vs	_	_	O
156	.	_	_	O

157	≥	_	_	O
158	10	_	_	O
159	g	_	_	O
160	/	_	_	O
161	dL	_	_	O
162	)	_	_	O
163	,	_	_	O
164	and	_	_	O
165	tumor	_	_	O
166	type	_	_	O
167	(	_	_	O
168	lung	_	_	O
169	/	_	_	O
170	gynecological	_	_	O
171	vs	_	_	O
172	.	_	_	O

173	other	_	_	O
174	nonmyeloid	_	_	O
175	malignancies	_	_	O
176	)	_	_	O
177	.	_	_	O

178	The	_	_	O
179	primary	_	_	O
180	endpoint	_	_	O
181	was	_	_	O
182	change	_	_	O
183	in	_	_	O
184	hemoglobin	_	_	O
185	from	_	_	O
186	baseline	_	_	O
187	to	_	_	O
188	Week	_	_	O
189	13	_	_	O
190	.	_	_	O

191	Seven	_	_	O
192	hundred	_	_	O
193	fifty	_	_	O
194	-	_	_	O
195	two	_	_	O
196	patients	_	_	O
197	(	_	_	O
198	374	_	_	O
199	QW	_	_	O
200	patients	_	_	O
201	;	_	_	O
202	378	_	_	O
203	EDS	_	_	O
204	patients	_	_	O
205	)	_	_	O
206	received	_	_	O
207	≥	_	_	O
208	1	_	_	O
209	dose	_	_	O
210	of	_	_	O
211	darbepoetin	_	_	O
212	alfa	_	_	O
213	and	_	_	O
214	were	_	_	O
215	included	_	_	O
216	in	_	_	O
217	the	_	_	O
218	analysis	_	_	O
219	.	_	_	O

220	Demographics	_	_	O
221	and	_	_	O
222	disease	_	_	O
223	state	_	_	O
224	were	_	_	O
225	similar	_	_	O
226	between	_	_	O
227	groups	_	_	O
228	.	_	_	O

229	Seventy	_	_	B-Premise
230	-	_	_	I-Premise
231	one	_	_	I-Premise
232	percent	_	_	I-Premise
233	of	_	_	I-Premise
234	patients	_	_	I-Premise
235	in	_	_	I-Premise
236	the	_	_	I-Premise
237	EDS	_	_	I-Premise
238	group	_	_	I-Premise
239	and	_	_	I-Premise
240	76	_	_	I-Premise
241	%	_	_	I-Premise
242	in	_	_	I-Premise
243	the	_	_	I-Premise
244	QW	_	_	I-Premise
245	group	_	_	I-Premise
246	achieved	_	_	I-Premise
247	the	_	_	I-Premise
248	target	_	_	I-Premise
249	hemoglobin	_	_	I-Premise
250	of	_	_	I-Premise
251	≥	_	_	I-Premise
252	11	_	_	I-Premise
253	.	_	_	I-Premise

254	0	_	_	I-Premise
255	g	_	_	I-Premise
256	/	_	_	I-Premise
257	dL	_	_	I-Premise
258	.	_	_	I-Premise

259	There	_	_	O
260	was	_	_	O
261	a	_	_	O
262	minimal	_	_	O
263	difference	_	_	O
264	in	_	_	O
265	the	_	_	O
266	primary	_	_	O
267	endpoint	_	_	O
268	of	_	_	O
269	mean	_	_	O
270	change	_	_	O
271	in	_	_	O
272	hemoglobin	_	_	O
273	(	_	_	O
274	baseline	_	_	O
275	to	_	_	O
276	Week	_	_	O
277	13	_	_	O
278	)	_	_	O
279	between	_	_	O
280	the	_	_	O
281	QW	_	_	O
282	and	_	_	O
283	the	_	_	O
284	EDS	_	_	O
285	groups	_	_	O
286	(	_	_	O
287	-	_	_	O
288	0	_	_	O
289	.	_	_	O

290	04	_	_	O
291	g	_	_	O
292	/	_	_	O
293	dL	_	_	O
294	;	_	_	O
295	95	_	_	O
296	%	_	_	O
297	confidence	_	_	O
298	interval	_	_	O
299	:	_	_	O
300	-	_	_	O
301	0	_	_	O
302	.	_	_	O

303	26	_	_	O
304	,	_	_	O
305	0	_	_	O
306	.	_	_	O

307	17	_	_	O
308	g	_	_	O
309	/	_	_	O
310	dL	_	_	O
311	)	_	_	O
312	.	_	_	O

313	The	_	_	O
314	upper	_	_	O
315	limit	_	_	O
316	of	_	_	O
317	the	_	_	O
318	95	_	_	O
319	%	_	_	O
320	confidence	_	_	O
321	interval	_	_	O
322	was	_	_	O
323	less	_	_	O
324	than	_	_	O
325	the	_	_	O
326	prespecified	_	_	O
327	limit	_	_	O
328	of	_	_	O
329	<	_	_	O
330	0	_	_	O
331	.	_	_	O

332	75	_	_	O
333	g	_	_	O
334	/	_	_	O
335	dL	_	_	O
336	,	_	_	O
337	supporting	_	_	O
338	noninferiority	_	_	O
339	of	_	_	O
340	the	_	_	O
341	EDS	_	_	O
342	dosing	_	_	O
343	schedule	_	_	O
344	.	_	_	O

345	Reported	_	_	B-Premise
346	adverse	_	_	I-Premise
347	events	_	_	I-Premise
348	were	_	_	I-Premise
349	similar	_	_	I-Premise
350	between	_	_	I-Premise
351	groups	_	_	I-Premise
352	.	_	_	I-Premise

353	A	_	_	B-Premise
354	slight	_	_	I-Premise
355	increase	_	_	I-Premise
356	in	_	_	I-Premise
357	transfusions	_	_	I-Premise
358	was	_	_	I-Premise
359	reported	_	_	I-Premise
360	in	_	_	I-Premise
361	the	_	_	I-Premise
362	QW	_	_	I-Premise
363	group	_	_	I-Premise
364	.	_	_	I-Premise

365	Darbepoetin	_	_	B-Claim
366	alfa	_	_	I-Claim
367	,	_	_	I-Claim
368	when	_	_	I-Claim
369	administered	_	_	I-Claim
370	synchronously	_	_	I-Claim
371	with	_	_	I-Claim
372	chemotherapy	_	_	I-Claim
373	,	_	_	I-Claim
374	on	_	_	I-Claim
375	an	_	_	I-Claim
376	EDS	_	_	I-Claim
377	appears	_	_	I-Claim
378	to	_	_	I-Claim
379	be	_	_	I-Claim
380	similarly	_	_	I-Claim
381	efficacious	_	_	I-Claim
382	to	_	_	I-Claim
383	darbepoetin	_	_	I-Claim
384	alfa	_	_	I-Claim
385	weekly	_	_	I-Claim
386	dosing	_	_	I-Claim
387	with	_	_	I-Claim
388	no	_	_	I-Claim
389	unexpected	_	_	I-Claim
390	adverse	_	_	I-Claim
391	events	_	_	I-Claim
392	.	_	_	I-Claim

393	This	_	_	O
394	study	_	_	O
395	provides	_	_	O
396	prospective	_	_	O
397	data	_	_	O
398	on	_	_	O
399	how	_	_	O
400	multiple	_	_	O
401	dosing	_	_	O
402	regimens	_	_	O
403	available	_	_	O
404	with	_	_	O
405	darbepoetin	_	_	O
406	alfa	_	_	O
407	can	_	_	O
408	be	_	_	O
409	synchronized	_	_	O
410	with	_	_	O
411	chemotherapy	_	_	O
412	administered	_	_	O
413	across	_	_	O
414	a	_	_	O
415	range	_	_	O
416	of	_	_	O
417	dosing	_	_	O
418	schedules	_	_	O
419	.	_	_	O


0	To	_	_	O
1	test	_	_	O
2	the	_	_	O
3	equivalence	_	_	O
4	of	_	_	O
5	three	_	_	O
6	versus	_	_	O
7	four	_	_	O
8	cycles	_	_	O
9	of	_	_	O
10	bleomycin	_	_	O
11	,	_	_	O
12	etoposide	_	_	O
13	,	_	_	O
14	and	_	_	O
15	cisplatin	_	_	O
16	(	_	_	O
17	BEP	_	_	O
18	)	_	_	O
19	and	_	_	O
20	of	_	_	O
21	the	_	_	O
22	5	_	_	O
23	-	_	_	O
24	day	_	_	O
25	schedule	_	_	O
26	versus	_	_	O
27	3	_	_	O
28	days	_	_	O
29	per	_	_	O
30	cycle	_	_	O
31	in	_	_	O
32	good	_	_	O
33	-	_	_	O
34	prognosis	_	_	O
35	germ	_	_	O
36	cell	_	_	O
37	cancer	_	_	O
38	.	_	_	O

39	The	_	_	O
40	study	_	_	O
41	was	_	_	O
42	designed	_	_	O
43	as	_	_	O
44	a	_	_	O
45	2	_	_	O
46	x	_	_	O
47	2	_	_	O
48	factorial	_	_	O
49	trial	_	_	O
50	.	_	_	O

51	The	_	_	O
52	aim	_	_	O
53	was	_	_	O
54	to	_	_	O
55	rule	_	_	O
56	out	_	_	O
57	a	_	_	O
58	5	_	_	O
59	%	_	_	O
60	decrease	_	_	O
61	in	_	_	O
62	the	_	_	O
63	2	_	_	O
64	-	_	_	O
65	year	_	_	O
66	progression	_	_	O
67	-	_	_	O
68	free	_	_	O
69	survival	_	_	O
70	(	_	_	O
71	PFS	_	_	O
72	)	_	_	O
73	rate	_	_	O
74	.	_	_	O

75	The	_	_	O
76	study	_	_	O
77	included	_	_	O
78	the	_	_	O
79	assessment	_	_	O
80	of	_	_	O
81	patient	_	_	O
82	quality	_	_	O
83	of	_	_	O
84	life	_	_	O
85	.	_	_	O

86	A	_	_	O
87	cycle	_	_	O
88	of	_	_	O
89	BEP	_	_	O
90	consisted	_	_	O
91	of	_	_	O
92	etoposide	_	_	O
93	500	_	_	O
94	mg	_	_	O
95	/	_	_	O
96	m	_	_	O
97	(	_	_	O
98	2	_	_	O
99	)	_	_	O
100	,	_	_	O
101	administered	_	_	O
102	at	_	_	O
103	either	_	_	O
104	100	_	_	O
105	mg	_	_	O
106	/	_	_	O
107	m	_	_	O
108	(	_	_	O
109	2	_	_	O
110	)	_	_	O
111	days	_	_	O
112	1	_	_	O
113	through	_	_	O
114	5	_	_	O
115	or	_	_	O
116	165	_	_	O
117	mg	_	_	O
118	/	_	_	O
119	m	_	_	O
120	(	_	_	O
121	2	_	_	O
122	)	_	_	O
123	days	_	_	O
124	1	_	_	O
125	through	_	_	O
126	3	_	_	O
127	,	_	_	O
128	cisplatin	_	_	O
129	100	_	_	O
130	mg	_	_	O
131	/	_	_	O
132	m	_	_	O
133	(	_	_	O
134	2	_	_	O
135	)	_	_	O
136	,	_	_	O
137	administered	_	_	O
138	at	_	_	O
139	either	_	_	O
140	20	_	_	O
141	mg	_	_	O
142	/	_	_	O
143	m	_	_	O
144	(	_	_	O
145	2	_	_	O
146	)	_	_	O
147	days	_	_	O
148	1	_	_	O
149	through	_	_	O
150	5	_	_	O
151	or	_	_	O
152	50	_	_	O
153	mg	_	_	O
154	/	_	_	O
155	m	_	_	O
156	(	_	_	O
157	2	_	_	O
158	)	_	_	O
159	days	_	_	O
160	1	_	_	O
161	and	_	_	O
162	2	_	_	O
163	.	_	_	O

164	Bleomycin	_	_	O
165	30	_	_	O
166	mg	_	_	O
167	was	_	_	O
168	administered	_	_	O
169	on	_	_	O
170	days	_	_	O
171	1	_	_	O
172	,	_	_	O
173	8	_	_	O
174	,	_	_	O
175	and	_	_	O
176	15	_	_	O
177	during	_	_	O
178	cycles	_	_	O
179	1	_	_	O
180	through	_	_	O
181	3	_	_	O
182	.	_	_	O

183	The	_	_	O
184	randomization	_	_	O
185	procedure	_	_	O
186	allowed	_	_	O
187	some	_	_	O
188	investigators	_	_	O
189	to	_	_	O
190	participate	_	_	O
191	only	_	_	O
192	in	_	_	O
193	the	_	_	O
194	comparison	_	_	O
195	of	_	_	O
196	three	_	_	O
197	versus	_	_	O
198	four	_	_	O
199	cycles	_	_	O
200	.	_	_	O

201	From	_	_	O
202	March	_	_	O
203	1995	_	_	O
204	until	_	_	O
205	April	_	_	O
206	1998	_	_	O
207	,	_	_	O
208	812	_	_	O
209	patients	_	_	O
210	were	_	_	O
211	randomly	_	_	O
212	assigned	_	_	O
213	to	_	_	O
214	receive	_	_	O
215	three	_	_	O
216	or	_	_	O
217	four	_	_	O
218	cycles	_	_	O
219	:	_	_	O
220	of	_	_	O
221	these	_	_	O
222	,	_	_	O
223	681	_	_	O
224	were	_	_	O
225	also	_	_	O
226	randomly	_	_	O
227	assigned	_	_	O
228	to	_	_	O
229	the	_	_	O
230	5	_	_	O
231	-	_	_	O
232	day	_	_	O
233	or	_	_	O
234	the	_	_	O
235	3	_	_	O
236	-	_	_	O
237	day	_	_	O
238	schedule	_	_	O
239	.	_	_	O

240	Histology	_	_	O
241	,	_	_	O
242	marker	_	_	O
243	values	_	_	O
244	,	_	_	O
245	and	_	_	O
246	disease	_	_	O
247	extent	_	_	O
248	are	_	_	O
249	well	_	_	O
250	balanced	_	_	O
251	in	_	_	O
252	the	_	_	O
253	treatment	_	_	O
254	arms	_	_	O
255	of	_	_	O
256	the	_	_	O
257	two	_	_	O
258	comparisons	_	_	O
259	.	_	_	O

260	The	_	_	B-Premise
261	projected	_	_	I-Premise
262	2	_	_	I-Premise
263	-	_	_	I-Premise
264	year	_	_	I-Premise
265	PFS	_	_	I-Premise
266	is	_	_	I-Premise
267	90	_	_	I-Premise
268	.	_	_	I-Premise

269	4	_	_	I-Premise
270	%	_	_	I-Premise
271	on	_	_	I-Premise
272	three	_	_	I-Premise
273	cycles	_	_	I-Premise
274	and	_	_	I-Premise
275	89	_	_	I-Premise
276	.	_	_	I-Premise

277	4	_	_	I-Premise
278	%	_	_	I-Premise
279	on	_	_	I-Premise
280	four	_	_	I-Premise
281	cycles	_	_	I-Premise
282	.	_	_	I-Premise

283	The	_	_	B-Premise
284	difference	_	_	I-Premise
285	in	_	_	I-Premise
286	PFS	_	_	I-Premise
287	between	_	_	I-Premise
288	three	_	_	I-Premise
289	and	_	_	I-Premise
290	four	_	_	I-Premise
291	cycles	_	_	I-Premise
292	is	_	_	I-Premise
293	-	_	_	I-Premise
294	1	_	_	I-Premise
295	.	_	_	I-Premise

296	0	_	_	I-Premise
297	%	_	_	I-Premise
298	(	_	_	I-Premise
299	80	_	_	I-Premise
300	%	_	_	I-Premise
301	confidence	_	_	I-Premise
302	limit	_	_	I-Premise
303	[	_	_	I-Premise
304	CL	_	_	I-Premise
305	]	_	_	I-Premise
306	,	_	_	I-Premise
307	-	_	_	I-Premise
308	3	_	_	I-Premise
309	.	_	_	I-Premise

310	8	_	_	I-Premise
311	%	_	_	I-Premise
312	,	_	_	I-Premise
313	+	_	_	I-Premise
314	1	_	_	I-Premise
315	.	_	_	I-Premise

316	8	_	_	I-Premise
317	%	_	_	I-Premise
318	)	_	_	I-Premise
319	.	_	_	I-Premise

320	Equivalence	_	_	B-Claim
321	for	_	_	I-Claim
322	three	_	_	I-Claim
323	versus	_	_	I-Claim
324	four	_	_	I-Claim
325	cycles	_	_	I-Claim
326	is	_	_	I-Claim
327	claimed	_	_	I-Claim
328	because	_	_	I-Claim
329	both	_	_	I-Claim
330	the	_	_	I-Claim
331	upper	_	_	I-Claim
332	and	_	_	I-Claim
333	lower	_	_	I-Claim
334	bounds	_	_	I-Claim
335	of	_	_	I-Claim
336	the	_	_	I-Claim
337	80	_	_	I-Claim
338	%	_	_	I-Claim
339	CL	_	_	I-Claim
340	are	_	_	I-Claim
341	less	_	_	I-Claim
342	than	_	_	I-Claim
343	5	_	_	I-Claim
344	%	_	_	I-Claim
345	.	_	_	I-Claim

346	In	_	_	B-Premise
347	the	_	_	I-Premise
348	5	_	_	I-Premise
349	-	_	_	I-Premise
350	versus	_	_	I-Premise
351	3	_	_	I-Premise
352	-	_	_	I-Premise
353	day	_	_	I-Premise
354	comparison	_	_	I-Premise
355	,	_	_	I-Premise
356	the	_	_	I-Premise
357	projected	_	_	I-Premise
358	2	_	_	I-Premise
359	-	_	_	I-Premise
360	year	_	_	I-Premise
361	PFS	_	_	I-Premise
362	is	_	_	I-Premise
363	88	_	_	I-Premise
364	.	_	_	I-Premise

365	8	_	_	I-Premise
366	%	_	_	I-Premise
367	and	_	_	I-Premise
368	89	_	_	I-Premise
369	.	_	_	I-Premise

370	7	_	_	I-Premise
371	%	_	_	I-Premise
372	,	_	_	I-Premise
373	respectively	_	_	I-Premise
374	(	_	_	I-Premise
375	difference	_	_	I-Premise
376	,	_	_	I-Premise
377	-	_	_	I-Premise
378	0	_	_	I-Premise
379	.	_	_	I-Premise

380	9	_	_	I-Premise
381	%	_	_	I-Premise
382	,	_	_	I-Premise
383	(	_	_	I-Premise
384	80	_	_	I-Premise
385	%	_	_	I-Premise
386	CL	_	_	I-Premise
387	,	_	_	I-Premise
388	-	_	_	I-Premise
389	4	_	_	I-Premise
390	.	_	_	I-Premise

391	1	_	_	I-Premise
392	%	_	_	I-Premise
393	,	_	_	I-Premise
394	+	_	_	I-Premise
395	2	_	_	I-Premise
396	.	_	_	I-Premise

397	2	_	_	I-Premise
398	%	_	_	I-Premise
399	)	_	_	I-Premise
400	.	_	_	I-Premise

401	Hence	_	_	O
402	,	_	_	O
403	equivalence	_	_	B-Claim
404	is	_	_	I-Claim
405	claimed	_	_	I-Claim
406	in	_	_	I-Claim
407	this	_	_	I-Claim
408	comparison	_	_	I-Claim
409	also	_	_	I-Claim
410	.	_	_	I-Claim

411	Frequencies	_	_	B-Premise
412	of	_	_	I-Premise
413	hematologic	_	_	I-Premise
414	and	_	_	I-Premise
415	nonhematologic	_	_	I-Premise
416	toxicities	_	_	I-Premise
417	were	_	_	I-Premise
418	essentially	_	_	I-Premise
419	similar	_	_	I-Premise
420	.	_	_	I-Premise

421	Quality	_	_	B-Premise
422	of	_	_	I-Premise
423	life	_	_	I-Premise
424	was	_	_	I-Premise
425	maintained	_	_	I-Premise
426	better	_	_	I-Premise
427	in	_	_	I-Premise
428	patients	_	_	I-Premise
429	receiving	_	_	I-Premise
430	three	_	_	I-Premise
431	cycles	_	_	I-Premise
432	;	_	_	I-Premise
433	no	_	_	B-Premise
434	differences	_	_	I-Premise
435	were	_	_	I-Premise
436	detected	_	_	I-Premise
437	between	_	_	I-Premise
438	3	_	_	I-Premise
439	and	_	_	I-Premise
440	5	_	_	I-Premise
441	days	_	_	I-Premise
442	of	_	_	I-Premise
443	treatment	_	_	I-Premise
444	.	_	_	I-Premise

445	We	_	_	O
446	conclude	_	_	O
447	that	_	_	O
448	three	_	_	B-Claim
449	cycles	_	_	I-Claim
450	of	_	_	I-Claim
451	BEP	_	_	I-Claim
452	,	_	_	I-Claim
453	with	_	_	I-Claim
454	etoposide	_	_	I-Claim
455	at	_	_	I-Claim
456	500	_	_	I-Claim
457	mg	_	_	I-Claim
458	/	_	_	I-Claim
459	m	_	_	I-Claim
460	(	_	_	I-Claim
461	2	_	_	I-Claim
462	)	_	_	I-Claim
463	,	_	_	I-Claim
464	is	_	_	I-Claim
465	sufficient	_	_	I-Claim
466	therapy	_	_	I-Claim
467	in	_	_	I-Claim
468	good	_	_	I-Claim
469	-	_	_	I-Claim
470	prognosis	_	_	I-Claim
471	germ	_	_	I-Claim
472	cell	_	_	I-Claim
473	cancer	_	_	I-Claim
474	and	_	_	O
475	that	_	_	O
476	the	_	_	B-Claim
477	administration	_	_	I-Claim
478	of	_	_	I-Claim
479	the	_	_	I-Claim
480	chemotherapy	_	_	I-Claim
481	in	_	_	I-Claim
482	3	_	_	I-Claim
483	days	_	_	I-Claim
484	has	_	_	I-Claim
485	no	_	_	I-Claim
486	detrimental	_	_	I-Claim
487	effect	_	_	I-Claim
488	on	_	_	I-Claim
489	the	_	_	I-Claim
490	effectiveness	_	_	I-Claim
491	of	_	_	I-Claim
492	the	_	_	I-Claim
493	BEP	_	_	I-Claim
494	regimen	_	_	I-Claim
495	.	_	_	I-Claim


0	The	_	_	O
1	EORTC	_	_	O
2	24971	_	_	O
3	/	_	_	O
4	TAX	_	_	O
5	323	_	_	O
6	,	_	_	O
7	a	_	_	O
8	phase	_	_	O
9	III	_	_	O
10	study	_	_	O
11	of	_	_	O
12	358	_	_	O
13	patients	_	_	O
14	with	_	_	O
15	unresectable	_	_	O
16	locoregionally	_	_	O
17	advanced	_	_	O
18	squamous	_	_	O
19	cell	_	_	O
20	carcinoma	_	_	O
21	of	_	_	O
22	the	_	_	O
23	head	_	_	O
24	and	_	_	O
25	neck	_	_	O
26	,	_	_	O
27	showed	_	_	O
28	an	_	_	O
29	improved	_	_	O
30	progression	_	_	O
31	-	_	_	O
32	free	_	_	O
33	and	_	_	O
34	overall	_	_	O
35	survival	_	_	O
36	(	_	_	O
37	OS	_	_	O
38	)	_	_	O
39	with	_	_	O
40	less	_	_	O
41	toxicity	_	_	O
42	when	_	_	O
43	docetaxel	_	_	O
44	(	_	_	O
45	T	_	_	O
46	)	_	_	O
47	was	_	_	O
48	added	_	_	O
49	to	_	_	O
50	cisplatin	_	_	O
51	and	_	_	O
52	5	_	_	O
53	-	_	_	O
54	fluorouracil	_	_	O
55	(	_	_	O
56	PF	_	_	O
57	)	_	_	O
58	for	_	_	O
59	induction	_	_	O
60	and	_	_	O
61	given	_	_	O
62	before	_	_	O
63	radiotherapy	_	_	O
64	(	_	_	O
65	RT	_	_	O
66	)	_	_	O
67	.	_	_	O

68	The	_	_	O
69	impact	_	_	O
70	of	_	_	O
71	the	_	_	O
72	addition	_	_	O
73	of	_	_	O
74	docetaxel	_	_	O
75	on	_	_	O
76	patients	_	_	O
77	'	_	_	O
78	health	_	_	O
79	-	_	_	O
80	related	_	_	O
81	quality	_	_	O
82	of	_	_	O
83	life	_	_	O
84	(	_	_	O
85	HRQOL	_	_	O
86	)	_	_	O
87	and	_	_	O
88	symptoms	_	_	O
89	was	_	_	O
90	investigated	_	_	O
91	.	_	_	O

92	HRQOL	_	_	O
93	was	_	_	O
94	assessed	_	_	O
95	at	_	_	O
96	baseline	_	_	O
97	,	_	_	O
98	at	_	_	O
99	end	_	_	O
100	of	_	_	O
101	cycle	_	_	O
102	2	_	_	O
103	,	_	_	O
104	and	_	_	O
105	4	_	_	O
106	,	_	_	O
107	6	_	_	O
108	,	_	_	O
109	and	_	_	O
110	9	_	_	O
111	months	_	_	O
112	after	_	_	O
113	completion	_	_	O
114	of	_	_	O
115	RT	_	_	O
116	using	_	_	O
117	the	_	_	O
118	European	_	_	O
119	Organisation	_	_	O
120	for	_	_	O
121	Research	_	_	O
122	and	_	_	O
123	Treatment	_	_	O
124	of	_	_	O
125	Cancer	_	_	O
126	(	_	_	O
127	EORTC	_	_	O
128	)	_	_	O
129	Quality	_	_	O
130	of	_	_	O
131	Life	_	_	O
132	Questionnaire	_	_	O
133	C30	_	_	O
134	(	_	_	O
135	QLQ	_	_	O
136	-	_	_	O
137	C30	_	_	O
138	)	_	_	O
139	and	_	_	O
140	the	_	_	O
141	EORTC	_	_	O
142	QLQ	_	_	O
143	Head	_	_	O
144	and	_	_	O
145	Neck	_	_	O
146	Cancer	_	_	O
147	-	_	_	O
148	Specific	_	_	O
149	Module	_	_	O
150	(	_	_	O
151	EORTC	_	_	O
152	QLQ	_	_	O
153	-	_	_	O
154	H	_	_	O
155	&	_	_	O
156	amp	_	_	O
157	;	_	_	O
158	N35	_	_	O
159	)	_	_	O
160	.	_	_	O

161	The	_	_	O
162	primary	_	_	O
163	HRQOL	_	_	O
164	scale	_	_	O
165	was	_	_	O
166	global	_	_	O
167	HRQOL	_	_	O
168	per	_	_	O
169	protocol	_	_	O
170	.	_	_	O

171	Compliance	_	_	O
172	to	_	_	O
173	HRQOL	_	_	O
174	assessments	_	_	O
175	was	_	_	O
176	97	_	_	O
177	%	_	_	O
178	at	_	_	O
179	baseline	_	_	O
180	,	_	_	O
181	but	_	_	O
182	dropped	_	_	O
183	to	_	_	O
184	54	_	_	O
185	%	_	_	O
186	by	_	_	O
187	6	_	_	O
188	months	_	_	O
189	.	_	_	O

190	Data	_	_	O
191	were	_	_	O
192	analysed	_	_	O
193	up	_	_	O
194	to	_	_	O
195	6	_	_	O
196	months	_	_	O
197	.	_	_	O

198	There	_	_	B-Premise
199	was	_	_	I-Premise
200	a	_	_	I-Premise
201	trend	_	_	I-Premise
202	towards	_	_	I-Premise
203	improved	_	_	I-Premise
204	global	_	_	I-Premise
205	HRQOL	_	_	I-Premise
206	during	_	_	I-Premise
207	the	_	_	I-Premise
208	treatment	_	_	I-Premise
209	period	_	_	I-Premise
210	.	_	_	I-Premise

211	At	_	_	B-Premise
212	6	_	_	I-Premise
213	months	_	_	I-Premise
214	after	_	_	I-Premise
215	the	_	_	I-Premise
216	end	_	_	I-Premise
217	of	_	_	I-Premise
218	RT	_	_	I-Premise
219	,	_	_	I-Premise
220	global	_	_	I-Premise
221	HRQOL	_	_	I-Premise
222	was	_	_	I-Premise
223	higher	_	_	I-Premise
224	in	_	_	I-Premise
225	the	_	_	I-Premise
226	TPF	_	_	I-Premise
227	arm	_	_	I-Premise
228	than	_	_	I-Premise
229	in	_	_	I-Premise
230	the	_	_	I-Premise
231	PF	_	_	I-Premise
232	arm	_	_	I-Premise
233	,	_	_	I-Premise
234	but	_	_	B-Premise
235	the	_	_	I-Premise
236	low	_	_	I-Premise
237	compliance	_	_	I-Premise
238	does	_	_	I-Premise
239	not	_	_	I-Premise
240	allow	_	_	I-Premise
241	to	_	_	I-Premise
242	draw	_	_	I-Premise
243	definitive	_	_	I-Premise
244	conclusions	_	_	I-Premise
245	.	_	_	I-Premise

246	Swallowing	_	_	B-Premise
247	and	_	_	I-Premise
248	coughing	_	_	I-Premise
249	problems	_	_	I-Premise
250	decreased	_	_	I-Premise
251	more	_	_	I-Premise
252	in	_	_	I-Premise
253	the	_	_	I-Premise
254	TPF	_	_	I-Premise
255	arm	_	_	I-Premise
256	than	_	_	I-Premise
257	in	_	_	I-Premise
258	the	_	_	I-Premise
259	PF	_	_	I-Premise
260	arm	_	_	I-Premise
261	at	_	_	I-Premise
262	the	_	_	I-Premise
263	end	_	_	I-Premise
264	of	_	_	I-Premise
265	cycle	_	_	I-Premise
266	2	_	_	I-Premise
267	,	_	_	I-Premise
268	but	_	_	B-Premise
269	to	_	_	I-Premise
270	a	_	_	I-Premise
271	limited	_	_	I-Premise
272	extent	_	_	I-Premise
273	.	_	_	I-Premise

274	Induction	_	_	B-Claim
275	chemotherapy	_	_	I-Claim
276	with	_	_	I-Claim
277	TPF	_	_	I-Claim
278	before	_	_	I-Claim
279	RT	_	_	I-Claim
280	not	_	_	I-Claim
281	only	_	_	I-Claim
282	improves	_	_	I-Claim
283	survival	_	_	I-Claim
284	and	_	_	I-Claim
285	reduces	_	_	I-Claim
286	toxicity	_	_	I-Claim
287	compared	_	_	I-Claim
288	with	_	_	I-Claim
289	PF	_	_	I-Claim
290	but	_	_	I-Claim
291	also	_	_	I-Claim
292	seems	_	_	I-Claim
293	to	_	_	I-Claim
294	improve	_	_	I-Claim
295	global	_	_	I-Claim
296	HRQOL	_	_	I-Claim
297	in	_	_	I-Claim
298	a	_	_	I-Claim
299	more	_	_	I-Claim
300	sustainable	_	_	I-Claim
301	manner	_	_	I-Claim
302	.	_	_	I-Claim


0	Gemcitabine	_	_	O
1	for	_	_	O
2	advanced	_	_	O
3	pancreatic	_	_	O
4	cancer	_	_	O
5	(	_	_	O
6	APC	_	_	O
7	)	_	_	O
8	is	_	_	O
9	palliative	_	_	O
10	and	_	_	O
11	the	_	_	O
12	prognosis	_	_	O
13	is	_	_	O
14	poor	_	_	O
15	,	_	_	O
16	making	_	_	O
17	health	_	_	O
18	-	_	_	O
19	related	_	_	O
20	quality	_	_	O
21	of	_	_	O
22	life	_	_	O
23	(	_	_	O
24	HRQOL	_	_	O
25	)	_	_	O
26	particularly	_	_	O
27	important	_	_	O
28	.	_	_	O

29	We	_	_	O
30	evaluated	_	_	O
31	HRQOL	_	_	O
32	with	_	_	O
33	the	_	_	O
34	EuroQol	_	_	O
35	(	_	_	O
36	EQ	_	_	O
37	-	_	_	O
38	5D	_	_	O
39	™	_	_	O
40	)	_	_	O
41	in	_	_	O
42	patients	_	_	O
43	with	_	_	O
44	APC	_	_	O
45	participating	_	_	O
46	in	_	_	O
47	Cancer	_	_	O
48	and	_	_	O
49	Leukemia	_	_	O
50	Group	_	_	O
51	B	_	_	O
52	80303	_	_	O
53	,	_	_	O
54	a	_	_	O
55	multicenter	_	_	O
56	,	_	_	O
57	double	_	_	O
58	-	_	_	O
59	blind	_	_	O
60	,	_	_	O
61	randomized	_	_	O
62	trial	_	_	O
63	comparing	_	_	O
64	overall	_	_	O
65	survival	_	_	O
66	(	_	_	O
67	OS	_	_	O
68	)	_	_	O
69	between	_	_	O
70	two	_	_	O
71	treatment	_	_	O
72	arms	_	_	O
73	:	_	_	O
74	gemcitabine	_	_	O
75	with	_	_	O
76	bevacizumab	_	_	O
77	or	_	_	O
78	gemcitabine	_	_	O
79	with	_	_	O
80	placebo	_	_	O
81	.	_	_	O

82	A	_	_	O
83	consecutive	_	_	O
84	subsample	_	_	O
85	of	_	_	O
86	patients	_	_	O
87	was	_	_	O
88	invited	_	_	O
89	to	_	_	O
90	complete	_	_	O
91	the	_	_	O
92	EQ	_	_	O
93	-	_	_	O
94	5D	_	_	O
95	surveys	_	_	O
96	.	_	_	O

97	Because	_	_	O
98	neither	_	_	O
99	clinical	_	_	O
100	nor	_	_	O
101	HRQOL	_	_	O
102	outcomes	_	_	O
103	differed	_	_	O
104	based	_	_	O
105	on	_	_	O
106	the	_	_	O
107	study	_	_	O
108	arm	_	_	O
109	,	_	_	O
110	analyses	_	_	O
111	were	_	_	O
112	pooled	_	_	O
113	.	_	_	O

114	Changes	_	_	O
115	in	_	_	O
116	mean	_	_	O
117	scores	_	_	O
118	from	_	_	O
119	baseline	_	_	O
120	to	_	_	O
121	eight	_	_	O
122	weeks	_	_	O
123	and	_	_	O
124	the	_	_	O
125	prognostic	_	_	O
126	value	_	_	O
127	of	_	_	O
128	the	_	_	O
129	EQ	_	_	O
130	-	_	_	O
131	5D	_	_	O
132	were	_	_	O
133	evaluated	_	_	O
134	.	_	_	O

135	Mean	_	_	B-Premise
136	index	_	_	I-Premise
137	scores	_	_	I-Premise
138	remained	_	_	I-Premise
139	stable	_	_	I-Premise
140	(	_	_	I-Premise
141	0	_	_	I-Premise
142	.	_	_	I-Premise

143	78	_	_	I-Premise
144	at	_	_	I-Premise
145	baseline	_	_	I-Premise
146	[	_	_	I-Premise
147	n	_	_	I-Premise
148	=	_	_	I-Premise
149	267	_	_	I-Premise
150	]	_	_	I-Premise
151	,	_	_	I-Premise
152	0	_	_	I-Premise
153	.	_	_	I-Premise

154	79	_	_	I-Premise
155	at	_	_	I-Premise
156	eight	_	_	I-Premise
157	weeks	_	_	I-Premise
158	[	_	_	I-Premise
159	n	_	_	I-Premise
160	=	_	_	I-Premise
161	186	_	_	I-Premise
162	]	_	_	I-Premise
163	,	_	_	I-Premise
164	P	_	_	I-Premise
165	=	_	_	I-Premise
166	0	_	_	I-Premise
167	.	_	_	I-Premise

168	34	_	_	I-Premise
169	,	_	_	I-Premise
170	Wilcoxon	_	_	I-Premise
171	signed	_	_	I-Premise
172	rank	_	_	I-Premise
173	test	_	_	I-Premise
174	)	_	_	I-Premise
175	,	_	_	I-Premise
176	attributable	_	_	I-Premise
177	to	_	_	I-Premise
178	a	_	_	I-Premise
179	modest	_	_	I-Premise
180	deterioration	_	_	I-Premise
181	of	_	_	I-Premise
182	physical	_	_	I-Premise
183	function	_	_	I-Premise
184	domain	_	_	I-Premise
185	scores	_	_	I-Premise
186	coincident	_	_	I-Premise
187	with	_	_	I-Premise
188	small	_	_	I-Premise
189	improvements	_	_	I-Premise
190	in	_	_	I-Premise
191	pain	_	_	I-Premise
192	and	_	_	I-Premise
193	anxiety	_	_	I-Premise
194	/	_	_	I-Premise
195	depression	_	_	I-Premise
196	scores	_	_	I-Premise
197	.	_	_	I-Premise

198	A	_	_	B-Premise
199	small	_	_	I-Premise
200	decline	_	_	I-Premise
201	in	_	_	I-Premise
202	visual	_	_	I-Premise
203	analogue	_	_	I-Premise
204	scale	_	_	I-Premise
205	scores	_	_	I-Premise
206	was	_	_	I-Premise
207	observed	_	_	I-Premise
208	(	_	_	I-Premise
209	70	_	_	I-Premise
210	.	_	_	I-Premise

211	7	_	_	I-Premise
212	vs	_	_	I-Premise
213	.	_	_	I-Premise

214	68	_	_	I-Premise
215	.	_	_	I-Premise

216	2	_	_	I-Premise
217	,	_	_	I-Premise
218	P	_	_	I-Premise
219	=	_	_	I-Premise
220	0	_	_	I-Premise
221	.	_	_	I-Premise

222	026	_	_	I-Premise
223	)	_	_	I-Premise
224	.	_	_	I-Premise

225	HRQOL	_	_	B-Premise
226	changes	_	_	I-Premise
227	within	_	_	I-Premise
228	chemotherapy	_	_	I-Premise
229	response	_	_	I-Premise
230	strata	_	_	I-Premise
231	revealed	_	_	I-Premise
232	stable	_	_	I-Premise
233	index	_	_	I-Premise
234	scores	_	_	I-Premise
235	but	_	_	B-Premise
236	a	_	_	I-Premise
237	trend	_	_	I-Premise
238	of	_	_	I-Premise
239	worsened	_	_	I-Premise
240	physical	_	_	I-Premise
241	function	_	_	I-Premise
242	among	_	_	I-Premise
243	patients	_	_	I-Premise
244	with	_	_	I-Premise
245	disease	_	_	I-Premise
246	progression	_	_	I-Premise
247	compared	_	_	I-Premise
248	with	_	_	I-Premise
249	those	_	_	I-Premise
250	with	_	_	I-Premise
251	stable	_	_	I-Premise
252	or	_	_	I-Premise
253	improved	_	_	I-Premise
254	disease	_	_	I-Premise
255	.	_	_	I-Premise

256	Visual	_	_	B-Premise
257	analogue	_	_	I-Premise
258	scale	_	_	I-Premise
259	scores	_	_	I-Premise
260	trended	_	_	I-Premise
261	downward	_	_	I-Premise
262	over	_	_	I-Premise
263	time	_	_	I-Premise
264	irrespective	_	_	I-Premise
265	of	_	_	I-Premise
266	chemotherapy	_	_	I-Premise
267	response	_	_	I-Premise
268	status	_	_	I-Premise
269	,	_	_	I-Premise
270	with	_	_	I-Premise
271	a	_	_	I-Premise
272	statistically	_	_	I-Premise
273	meaningful	_	_	I-Premise
274	deterioration	_	_	I-Premise
275	in	_	_	I-Premise
276	patients	_	_	I-Premise
277	who	_	_	I-Premise
278	progressed	_	_	I-Premise
279	(	_	_	I-Premise
280	68	_	_	I-Premise
281	.	_	_	I-Premise

282	9	_	_	I-Premise
283	vs	_	_	I-Premise
284	.	_	_	I-Premise

285	64	_	_	I-Premise
286	.	_	_	I-Premise

287	4	_	_	I-Premise
288	,	_	_	I-Premise
289	P	_	_	I-Premise
290	=	_	_	I-Premise
291	0	_	_	I-Premise
292	.	_	_	I-Premise

293	029	_	_	I-Premise
294	)	_	_	I-Premise
295	.	_	_	I-Premise

296	Baseline	_	_	O
297	scores	_	_	O
298	from	_	_	O
299	both	_	_	O
300	EQ	_	_	O
301	-	_	_	O
302	5D	_	_	O
303	scales	_	_	O
304	were	_	_	O
305	significant	_	_	O
306	predictors	_	_	O
307	of	_	_	O
308	OS	_	_	O
309	in	_	_	O
310	Cox	_	_	O
311	proportional	_	_	O
312	hazard	_	_	O
313	models	_	_	O
314	.	_	_	O

315	Response	_	_	B-Claim
316	to	_	_	I-Claim
317	gemcitabine	_	_	I-Claim
318	treatment	_	_	I-Claim
319	in	_	_	I-Claim
320	APC	_	_	I-Claim
321	is	_	_	I-Claim
322	not	_	_	I-Claim
323	associated	_	_	I-Claim
324	with	_	_	I-Claim
325	appreciable	_	_	I-Claim
326	improvement	_	_	I-Claim
327	of	_	_	I-Claim
328	global	_	_	I-Claim
329	HRQOL	_	_	I-Claim
330	.	_	_	I-Claim

331	Small	_	_	O
332	improvements	_	_	O
333	in	_	_	O
334	pain	_	_	O
335	and	_	_	O
336	mood	_	_	O
337	are	_	_	O
338	observed	_	_	O
339	despite	_	_	O
340	progressive	_	_	O
341	functional	_	_	O
342	decline	_	_	O
343	.	_	_	O

344	Those	_	_	B-Claim
345	who	_	_	I-Claim
346	respond	_	_	I-Claim
347	to	_	_	I-Claim
348	gemcitabine	_	_	I-Claim
349	may	_	_	I-Claim
350	experience	_	_	I-Claim
351	a	_	_	I-Claim
352	slight	_	_	I-Claim
353	slowing	_	_	I-Claim
354	of	_	_	I-Claim
355	functional	_	_	I-Claim
356	deterioration	_	_	I-Claim
357	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	examined	_	_	O
3	whether	_	_	O
4	changes	_	_	O
5	in	_	_	O
6	self	_	_	O
7	-	_	_	O
8	efficacy	_	_	O
9	explain	_	_	O
10	the	_	_	O
11	effects	_	_	O
12	of	_	_	O
13	a	_	_	O
14	mailed	_	_	O
15	print	_	_	O
16	intervention	_	_	O
17	on	_	_	O
18	long	_	_	O
19	-	_	_	O
20	term	_	_	O
21	dietary	_	_	O
22	practices	_	_	O
23	of	_	_	O
24	breast	_	_	O
25	and	_	_	O
26	prostate	_	_	O
27	cancer	_	_	O
28	survivors	_	_	O
29	.	_	_	O

30	The	_	_	O
31	relationship	_	_	O
32	between	_	_	O
33	change	_	_	O
34	in	_	_	O
35	self	_	_	O
36	-	_	_	O
37	efficacy	_	_	O
38	and	_	_	O
39	long	_	_	O
40	-	_	_	O
41	term	_	_	O
42	physical	_	_	O
43	activity	_	_	O
44	(	_	_	O
45	PA	_	_	O
46	)	_	_	O
47	also	_	_	O
48	was	_	_	O
49	examined	_	_	O
50	.	_	_	O

51	Breast	_	_	O
52	and	_	_	O
53	prostate	_	_	O
54	cancer	_	_	O
55	survivors	_	_	O
56	(	_	_	O
57	N	_	_	O
58	=	_	_	O
59	543	_	_	O
60	)	_	_	O
61	from	_	_	O
62	39	_	_	O
63	US	_	_	O
64	states	_	_	O
65	and	_	_	O
66	two	_	_	O
67	Canadian	_	_	O
68	provinces	_	_	O
69	participated	_	_	O
70	in	_	_	O
71	the	_	_	O
72	FRESH	_	_	O
73	START	_	_	O
74	intervention	_	_	O
75	trial	_	_	O
76	.	_	_	O

77	Participants	_	_	O
78	were	_	_	O
79	randomly	_	_	O
80	assigned	_	_	O
81	to	_	_	O
82	receive	_	_	O
83	a	_	_	O
84	10	_	_	O
85	-	_	_	O
86	month	_	_	O
87	program	_	_	O
88	of	_	_	O
89	mailed	_	_	O
90	print	_	_	O
91	materials	_	_	O
92	on	_	_	O
93	diet	_	_	O
94	and	_	_	O
95	PA	_	_	O
96	available	_	_	O
97	in	_	_	O
98	the	_	_	O
99	public	_	_	O
100	domain	_	_	O
101	or	_	_	O
102	a	_	_	O
103	10	_	_	O
104	-	_	_	O
105	month	_	_	O
106	program	_	_	O
107	of	_	_	O
108	tailored	_	_	O
109	materials	_	_	O
110	designed	_	_	O
111	to	_	_	O
112	increase	_	_	O
113	fruit	_	_	O
114	and	_	_	O
115	vegetable	_	_	O
116	(	_	_	O
117	F	_	_	O
118	&	_	_	O
119	V	_	_	O
120	)	_	_	O
121	intake	_	_	O
122	,	_	_	O
123	decrease	_	_	O
124	fat	_	_	O
125	intake	_	_	O
126	,	_	_	O
127	and	_	_	O
128	/	_	_	O
129	or	_	_	O
130	increase	_	_	O
131	PA	_	_	O
132	.	_	_	O

133	Changes	_	_	O
134	in	_	_	O
135	self	_	_	O
136	-	_	_	O
137	efficacy	_	_	O
138	for	_	_	O
139	F	_	_	O
140	&	_	_	O
141	V	_	_	O
142	intake	_	_	O
143	and	_	_	O
144	fat	_	_	O
145	restriction	_	_	O
146	were	_	_	O
147	analyzed	_	_	O
148	as	_	_	O
149	potential	_	_	O
150	mediators	_	_	O
151	of	_	_	O
152	the	_	_	O
153	intervention	_	_	O
154	'	_	_	O
155	s	_	_	O
156	effects	_	_	O
157	on	_	_	O
158	diet	_	_	O
159	at	_	_	O
160	2	_	_	O
161	-	_	_	O
162	year	_	_	O
163	follow	_	_	O
164	-	_	_	O
165	up	_	_	O
166	.	_	_	O

167	Because	_	_	O
168	we	_	_	O
169	previously	_	_	O
170	found	_	_	O
171	that	_	_	O
172	change	_	_	O
173	in	_	_	O
174	self	_	_	O
175	-	_	_	O
176	efficacy	_	_	O
177	for	_	_	O
178	PA	_	_	O
179	did	_	_	O
180	not	_	_	O
181	vary	_	_	O
182	by	_	_	O
183	group	_	_	O
184	assignment	_	_	O
185	,	_	_	O
186	the	_	_	O
187	relationship	_	_	O
188	between	_	_	O
189	change	_	_	O
190	in	_	_	O
191	self	_	_	O
192	-	_	_	O
193	efficacy	_	_	O
194	and	_	_	O
195	PA	_	_	O
196	at	_	_	O
197	2	_	_	O
198	-	_	_	O
199	year	_	_	O
200	follow	_	_	O
201	-	_	_	O
202	up	_	_	O
203	was	_	_	O
204	examined	_	_	O
205	across	_	_	O
206	study	_	_	O
207	conditions	_	_	O
208	.	_	_	O

209	Results	_	_	B-Claim
210	suggest	_	_	I-Claim
211	that	_	_	I-Claim
212	change	_	_	I-Claim
213	in	_	_	I-Claim
214	self	_	_	I-Claim
215	-	_	_	I-Claim
216	efficacy	_	_	I-Claim
217	for	_	_	I-Claim
218	fat	_	_	I-Claim
219	restriction	_	_	I-Claim
220	partially	_	_	I-Claim
221	explained	_	_	I-Claim
222	the	_	_	I-Claim
223	intervention	_	_	I-Claim
224	'	_	_	I-Claim
225	s	_	_	I-Claim
226	effect	_	_	I-Claim
227	on	_	_	I-Claim
228	fat	_	_	I-Claim
229	intake	_	_	I-Claim
230	(	_	_	I-Claim
231	mean	_	_	I-Claim
232	indirect	_	_	I-Claim
233	effect	_	_	I-Claim
234	=	_	_	I-Claim
235	-	_	_	I-Claim
236	0	_	_	I-Claim
237	.	_	_	I-Claim

238	28	_	_	I-Claim
239	)	_	_	I-Claim
240	,	_	_	I-Claim
241	and	_	_	I-Claim
242	change	_	_	I-Claim
243	in	_	_	I-Claim
244	self	_	_	I-Claim
245	-	_	_	I-Claim
246	efficacy	_	_	I-Claim
247	for	_	_	I-Claim
248	F	_	_	I-Claim
249	&	_	_	I-Claim
250	V	_	_	I-Claim
251	consumption	_	_	I-Claim
252	partially	_	_	I-Claim
253	explained	_	_	I-Claim
254	the	_	_	I-Claim
255	intervention	_	_	I-Claim
256	'	_	_	I-Claim
257	s	_	_	I-Claim
258	effect	_	_	I-Claim
259	on	_	_	I-Claim
260	daily	_	_	I-Claim
261	F	_	_	I-Claim
262	&	_	_	I-Claim
263	V	_	_	I-Claim
264	intake	_	_	I-Claim
265	(	_	_	I-Claim
266	mean	_	_	I-Claim
267	indirect	_	_	I-Claim
268	effect	_	_	I-Claim
269	=	_	_	I-Claim
270	.	_	_	I-Claim

271	11	_	_	I-Claim
272	)	_	_	I-Claim
273	.	_	_	I-Claim

274	Change	_	_	B-Premise
275	in	_	_	I-Premise
276	self	_	_	I-Premise
277	-	_	_	I-Premise
278	efficacy	_	_	I-Premise
279	for	_	_	I-Premise
280	fat	_	_	I-Premise
281	restriction	_	_	I-Premise
282	partially	_	_	I-Premise
283	accounted	_	_	I-Premise
284	for	_	_	I-Premise
285	the	_	_	I-Premise
286	intervention	_	_	I-Premise
287	'	_	_	I-Premise
288	s	_	_	I-Premise
289	impact	_	_	I-Premise
290	on	_	_	I-Premise
291	overall	_	_	I-Premise
292	diet	_	_	I-Premise
293	quality	_	_	I-Premise
294	among	_	_	I-Premise
295	men	_	_	I-Premise
296	only	_	_	I-Premise
297	(	_	_	I-Premise
298	mean	_	_	I-Premise
299	indirect	_	_	I-Premise
300	effect	_	_	I-Premise
301	=	_	_	I-Premise
302	0	_	_	I-Premise
303	.	_	_	I-Premise

304	60	_	_	I-Premise
305	)	_	_	I-Premise
306	.	_	_	I-Premise

307	Finally	_	_	O
308	,	_	_	O
309	change	_	_	O
310	in	_	_	O
311	self	_	_	O
312	-	_	_	O
313	efficacy	_	_	O
314	for	_	_	O
315	PA	_	_	O
316	predicted	_	_	O
317	PA	_	_	O
318	at	_	_	O
319	2	_	_	O
320	-	_	_	O
321	year	_	_	O
322	follow	_	_	O
323	-	_	_	O
324	up	_	_	O
325	.	_	_	O

326	Findings	_	_	B-Claim
327	suggest	_	_	I-Claim
328	that	_	_	I-Claim
329	self	_	_	I-Claim
330	-	_	_	I-Claim
331	efficacy	_	_	I-Claim
332	may	_	_	I-Claim
333	influence	_	_	I-Claim
334	long	_	_	I-Claim
335	-	_	_	I-Claim
336	term	_	_	I-Claim
337	maintenance	_	_	I-Claim
338	of	_	_	I-Claim
339	healthy	_	_	I-Claim
340	lifestyle	_	_	I-Claim
341	practices	_	_	I-Claim
342	among	_	_	I-Claim
343	cancer	_	_	I-Claim
344	survivors	_	_	I-Claim
345	.	_	_	I-Claim


0	Paclitaxel	_	_	O
1	and	_	_	O
2	pegylated	_	_	O
3	liposomal	_	_	O
4	doxorubicin	_	_	O
5	(	_	_	O
6	PLD	_	_	O
7	)	_	_	O
8	are	_	_	O
9	active	_	_	O
10	cytotoxic	_	_	O
11	agents	_	_	O
12	for	_	_	O
13	the	_	_	O
14	treatment	_	_	O
15	of	_	_	O
16	human	_	_	O
17	immunodeficiency	_	_	O
18	virus	_	_	O
19	(	_	_	O
20	HIV	_	_	O
21	)	_	_	O
22	-	_	_	O
23	associated	_	_	O
24	Kaposi	_	_	O
25	sarcoma	_	_	O
26	(	_	_	O
27	KS	_	_	O
28	)	_	_	O
29	.	_	_	O

30	A	_	_	O
31	randomized	_	_	O
32	trial	_	_	O
33	comparing	_	_	O
34	the	_	_	O
35	efficacy	_	_	O
36	and	_	_	O
37	toxicity	_	_	O
38	of	_	_	O
39	paclitaxel	_	_	O
40	and	_	_	O
41	PLD	_	_	O
42	was	_	_	O
43	performed	_	_	O
44	,	_	_	O
45	and	_	_	O
46	the	_	_	O
47	effects	_	_	O
48	of	_	_	O
49	therapy	_	_	O
50	on	_	_	O
51	symptom	_	_	O
52	palliation	_	_	O
53	and	_	_	O
54	quality	_	_	O
55	of	_	_	O
56	life	_	_	O
57	were	_	_	O
58	determined	_	_	O
59	.	_	_	O

60	Patients	_	_	O
61	with	_	_	O
62	advanced	_	_	O
63	HIV	_	_	O
64	-	_	_	O
65	associated	_	_	O
66	KS	_	_	O
67	were	_	_	O
68	randomly	_	_	O
69	assigned	_	_	O
70	to	_	_	O
71	receive	_	_	O
72	paclitaxel	_	_	O
73	at	_	_	O
74	a	_	_	O
75	dose	_	_	O
76	of	_	_	O
77	100	_	_	O
78	mg	_	_	O
79	/	_	_	O
80	m2	_	_	O
81	intravenously	_	_	O
82	(	_	_	O
83	iv	_	_	O
84	)	_	_	O
85	every	_	_	O
86	2	_	_	O
87	weeks	_	_	O
88	or	_	_	O
89	PLD	_	_	O
90	at	_	_	O
91	a	_	_	O
92	dose	_	_	O
93	of	_	_	O
94	20	_	_	O
95	mg	_	_	O
96	/	_	_	O
97	m2	_	_	O
98	iv	_	_	O
99	every	_	_	O
100	3	_	_	O
101	weeks	_	_	O
102	.	_	_	O

103	The	_	_	O
104	KS	_	_	O
105	Functional	_	_	O
106	Assessment	_	_	O
107	of	_	_	O
108	HIV	_	_	O
109	(	_	_	O
110	FAHI	_	_	O
111	)	_	_	O
112	quality	_	_	O
113	of	_	_	O
114	life	_	_	O
115	instrument	_	_	O
116	was	_	_	O
117	used	_	_	O
118	before	_	_	O
119	and	_	_	O
120	after	_	_	O
121	every	_	_	O
122	other	_	_	O
123	treatment	_	_	O
124	cycle	_	_	O
125	.	_	_	O

126	The	_	_	O
127	study	_	_	O
128	included	_	_	O
129	73	_	_	O
130	analyzable	_	_	O
131	patients	_	_	O
132	enrolled	_	_	O
133	between	_	_	O
134	1998	_	_	O
135	and	_	_	O
136	2002	_	_	O
137	,	_	_	O
138	including	_	_	O
139	36	_	_	O
140	in	_	_	O
141	the	_	_	O
142	paclitaxel	_	_	O
143	arm	_	_	O
144	and	_	_	O
145	37	_	_	O
146	in	_	_	O
147	the	_	_	O
148	PLD	_	_	O
149	arm	_	_	O
150	;	_	_	O
151	73	_	_	O
152	%	_	_	O
153	of	_	_	O
154	patients	_	_	O
155	received	_	_	O
156	highly	_	_	O
157	active	_	_	O
158	antiretroviral	_	_	O
159	therapy	_	_	O
160	(	_	_	O
161	HAART	_	_	O
162	)	_	_	O
163	and	_	_	O
164	32	_	_	O
165	%	_	_	O
166	had	_	_	O
167	an	_	_	O
168	undetectable	_	_	O
169	viral	_	_	O
170	load	_	_	O
171	(	_	_	O
172	<	_	_	O
173	400	_	_	O
174	copies	_	_	O
175	/	_	_	O
176	mL	_	_	O
177	)	_	_	O
178	.	_	_	O

179	Treatment	_	_	B-Premise
180	was	_	_	I-Premise
181	associated	_	_	I-Premise
182	with	_	_	I-Premise
183	significant	_	_	I-Premise
184	improvements	_	_	I-Premise
185	in	_	_	I-Premise
186	pain	_	_	I-Premise
187	(	_	_	I-Premise
188	P	_	_	I-Premise
189	=	_	_	I-Premise
190	.	_	_	I-Premise

191	024	_	_	I-Premise
192	)	_	_	I-Premise
193	and	_	_	I-Premise
194	swelling	_	_	I-Premise
195	(	_	_	I-Premise
196	P	_	_	I-Premise
197	<	_	_	I-Premise
198	.	_	_	I-Premise

199	001	_	_	I-Premise
200	)	_	_	I-Premise
201	.	_	_	I-Premise

202	Of	_	_	B-Premise
203	the	_	_	I-Premise
204	36	_	_	I-Premise
205	patients	_	_	I-Premise
206	who	_	_	I-Premise
207	reported	_	_	I-Premise
208	that	_	_	I-Premise
209	pain	_	_	I-Premise
210	interfered	_	_	I-Premise
211	with	_	_	I-Premise
212	their	_	_	I-Premise
213	normal	_	_	I-Premise
214	work	_	_	I-Premise
215	or	_	_	I-Premise
216	activities	_	_	I-Premise
217	at	_	_	I-Premise
218	baseline	_	_	I-Premise
219	,	_	_	I-Premise
220	25	_	_	I-Premise
221	(	_	_	I-Premise
222	69	_	_	I-Premise
223	%	_	_	I-Premise
224	)	_	_	I-Premise
225	improved	_	_	I-Premise
226	.	_	_	I-Premise

227	Of	_	_	B-Premise
228	the	_	_	I-Premise
229	41	_	_	I-Premise
230	patients	_	_	I-Premise
231	who	_	_	I-Premise
232	reported	_	_	I-Premise
233	swelling	_	_	I-Premise
234	at	_	_	I-Premise
235	baseline	_	_	I-Premise
236	,	_	_	I-Premise
237	38	_	_	I-Premise
238	(	_	_	I-Premise
239	93	_	_	I-Premise
240	%	_	_	I-Premise
241	)	_	_	I-Premise
242	improved	_	_	I-Premise
243	.	_	_	I-Premise

244	Comparing	_	_	B-Premise
245	the	_	_	I-Premise
246	paclitaxel	_	_	I-Premise
247	and	_	_	I-Premise
248	PLD	_	_	I-Premise
249	arms	_	_	I-Premise
250	revealed	_	_	I-Premise
251	comparable	_	_	I-Premise
252	response	_	_	I-Premise
253	rates	_	_	I-Premise
254	(	_	_	I-Premise
255	56	_	_	I-Premise
256	%	_	_	I-Premise
257	vs	_	_	I-Premise
258	46	_	_	I-Premise
259	%	_	_	I-Premise
260	;	_	_	I-Premise
261	P	_	_	I-Premise
262	=	_	_	I-Premise
263	.	_	_	I-Premise

264	49	_	_	I-Premise
265	)	_	_	I-Premise
266	,	_	_	I-Premise
267	median	_	_	I-Premise
268	progression	_	_	I-Premise
269	-	_	_	I-Premise
270	free	_	_	I-Premise
271	survival	_	_	I-Premise
272	(	_	_	I-Premise
273	17	_	_	I-Premise
274	.	_	_	I-Premise

275	5	_	_	I-Premise
276	months	_	_	I-Premise
277	vs	_	_	I-Premise
278	12	_	_	I-Premise
279	.	_	_	I-Premise

280	2	_	_	I-Premise
281	months	_	_	I-Premise
282	;	_	_	I-Premise
283	P	_	_	I-Premise
284	=	_	_	I-Premise
285	.	_	_	I-Premise

286	66	_	_	I-Premise
287	)	_	_	I-Premise
288	,	_	_	I-Premise
289	and	_	_	I-Premise
290	2	_	_	I-Premise
291	-	_	_	I-Premise
292	year	_	_	I-Premise
293	survival	_	_	I-Premise
294	rates	_	_	I-Premise
295	(	_	_	I-Premise
296	79	_	_	I-Premise
297	%	_	_	I-Premise
298	vs	_	_	I-Premise
299	78	_	_	I-Premise
300	%	_	_	I-Premise
301	;	_	_	I-Premise
302	P	_	_	I-Premise
303	=	_	_	I-Premise
304	.	_	_	I-Premise

305	75	_	_	I-Premise
306	)	_	_	I-Premise
307	,	_	_	I-Premise
308	but	_	_	B-Premise
309	somewhat	_	_	I-Premise
310	more	_	_	I-Premise
311	grade	_	_	I-Premise
312	3	_	_	I-Premise
313	to	_	_	I-Premise
314	5	_	_	I-Premise
315	toxicity	_	_	I-Premise
316	for	_	_	I-Premise
317	paclitaxel	_	_	I-Premise
318	(	_	_	I-Premise
319	84	_	_	I-Premise
320	%	_	_	I-Premise
321	vs	_	_	I-Premise
322	66	_	_	I-Premise
323	%	_	_	I-Premise
324	;	_	_	I-Premise
325	P	_	_	I-Premise
326	=	_	_	I-Premise
327	.	_	_	I-Premise

328	077	_	_	I-Premise
329	)	_	_	I-Premise
330	.	_	_	I-Premise

331	Treatment	_	_	B-Claim
332	with	_	_	I-Claim
333	either	_	_	I-Claim
334	paclitaxel	_	_	I-Claim
335	or	_	_	I-Claim
336	PLD	_	_	I-Claim
337	appears	_	_	I-Claim
338	to	_	_	I-Claim
339	produce	_	_	I-Claim
340	significant	_	_	I-Claim
341	improvements	_	_	I-Claim
342	in	_	_	I-Claim
343	pain	_	_	I-Claim
344	and	_	_	I-Claim
345	swelling	_	_	I-Claim
346	in	_	_	I-Claim
347	patients	_	_	I-Claim
348	with	_	_	I-Claim
349	advanced	_	_	I-Claim
350	,	_	_	I-Claim
351	symptomatic	_	_	I-Claim
352	,	_	_	I-Claim
353	HIV	_	_	I-Claim
354	-	_	_	I-Claim
355	associated	_	_	I-Claim
356	KS	_	_	I-Claim
357	treated	_	_	I-Claim
358	in	_	_	I-Claim
359	the	_	_	I-Claim
360	HAART	_	_	I-Claim
361	era	_	_	I-Claim
362	.	_	_	I-Claim


0	The	_	_	O
1	phase	_	_	O
2	3	_	_	O
3	VISTA	_	_	O
4	study	_	_	O
5	in	_	_	O
6	transplant	_	_	O
7	-	_	_	O
8	ineligible	_	_	O
9	myeloma	_	_	O
10	patients	_	_	O
11	demonstrated	_	_	O
12	superior	_	_	O
13	efficacy	_	_	O
14	with	_	_	O
15	bortezomib	_	_	O
16	-	_	_	O
17	melphalan	_	_	O
18	-	_	_	O
19	prednisone	_	_	O
20	(	_	_	O
21	VMP	_	_	O
22	;	_	_	O
23	nine	_	_	O
24	6	_	_	O
25	-	_	_	O
26	wk	_	_	O
27	cycles	_	_	O
28	)	_	_	O
29	vs	_	_	O
30	.	_	_	O

31	melphalan	_	_	O
32	-	_	_	O
33	prednisone	_	_	O
34	(	_	_	O
35	MP	_	_	O
36	)	_	_	O
37	but	_	_	O
38	also	_	_	O
39	increased	_	_	O
40	toxicity	_	_	O
41	.	_	_	O

42	Health	_	_	O
43	-	_	_	O
44	related	_	_	O
45	quality	_	_	O
46	of	_	_	O
47	life	_	_	O
48	(	_	_	O
49	HRQoL	_	_	O
50	;	_	_	O
51	exploratory	_	_	O
52	endpoint	_	_	O
53	)	_	_	O
54	was	_	_	O
55	evaluated	_	_	O
56	using	_	_	O
57	the	_	_	O
58	European	_	_	O
59	Organization	_	_	O
60	for	_	_	O
61	Research	_	_	O
62	and	_	_	O
63	Treatment	_	_	O
64	of	_	_	O
65	Cancer	_	_	O
66	(	_	_	O
67	EORTC	_	_	O
68	)	_	_	O
69	Quality	_	_	O
70	of	_	_	O
71	Life	_	_	O
72	Questionnaire	_	_	O
73	(	_	_	O
74	QLQ	_	_	O
75	-	_	_	O
76	C30	_	_	O
77	)	_	_	O
78	.	_	_	O

79	The	_	_	O
80	phase	_	_	O
81	3	_	_	O
82	VISTA	_	_	O
83	study	_	_	O
84	in	_	_	O
85	transplant	_	_	O
86	-	_	_	O
87	ineligible	_	_	O
88	myeloma	_	_	O
89	patients	_	_	O
90	demonstrated	_	_	O
91	superior	_	_	O
92	efficacy	_	_	O
93	with	_	_	O
94	bortezomib	_	_	O
95	-	_	_	O
96	melphalan	_	_	O
97	-	_	_	O
98	prednisone	_	_	O
99	(	_	_	O
100	VMP	_	_	O
101	;	_	_	O
102	nine	_	_	O
103	6	_	_	O
104	-	_	_	O
105	wk	_	_	O
106	cycles	_	_	O
107	)	_	_	O
108	vs	_	_	O
109	.	_	_	O

110	melphalan	_	_	O
111	-	_	_	O
112	prednisone	_	_	O
113	(	_	_	O
114	MP	_	_	O
115	)	_	_	O
116	but	_	_	O
117	also	_	_	O
118	increased	_	_	O
119	toxicity	_	_	O
120	.	_	_	O

121	Health	_	_	O
122	-	_	_	O
123	related	_	_	O
124	quality	_	_	O
125	of	_	_	O
126	life	_	_	O
127	(	_	_	O
128	HRQoL	_	_	O
129	;	_	_	O
130	exploratory	_	_	O
131	endpoint	_	_	O
132	)	_	_	O
133	was	_	_	O
134	evaluated	_	_	O
135	using	_	_	O
136	the	_	_	O
137	European	_	_	O
138	Organization	_	_	O
139	for	_	_	O
140	Research	_	_	O
141	and	_	_	O
142	Treatment	_	_	O
143	of	_	_	O
144	Cancer	_	_	O
145	(	_	_	O
146	EORTC	_	_	O
147	)	_	_	O
148	Quality	_	_	O
149	of	_	_	O
150	Life	_	_	O
151	Questionnaire	_	_	O
152	(	_	_	O
153	QLQ	_	_	O
154	-	_	_	O
155	C30	_	_	O
156	)	_	_	O
157	.	_	_	O

158	EORTC	_	_	O
159	QLQ	_	_	O
160	-	_	_	O
161	C30	_	_	O
162	was	_	_	O
163	administered	_	_	O
164	at	_	_	O
165	screening	_	_	O
166	,	_	_	O
167	on	_	_	O
168	day	_	_	O
169	1	_	_	O
170	of	_	_	O
171	each	_	_	O
172	cycle	_	_	O
173	,	_	_	O
174	at	_	_	O
175	the	_	_	O
176	end	_	_	O
177	-	_	_	O
178	of	_	_	O
179	-	_	_	O
180	treatment	_	_	O
181	visit	_	_	O
182	,	_	_	O
183	and	_	_	O
184	every	_	_	O
185	8	_	_	O
186	wk	_	_	O
187	until	_	_	O
188	progression	_	_	O
189	.	_	_	O

190	EORTC	_	_	O
191	QLQ	_	_	O
192	-	_	_	O
193	C30	_	_	O
194	scores	_	_	O
195	were	_	_	O
196	evaluated	_	_	O
197	among	_	_	O
198	patients	_	_	O
199	with	_	_	O
200	a	_	_	O
201	valid	_	_	O
202	baseline	_	_	O
203	and	_	_	O
204	at	_	_	O
205	least	_	_	O
206	one	_	_	O
207	post	_	_	O
208	-	_	_	O
209	baseline	_	_	O
210	HRQoL	_	_	O
211	assessment	_	_	O
212	.	_	_	O

213	At	_	_	O
214	baseline	_	_	O
215	,	_	_	O
216	domain	_	_	O
217	scores	_	_	O
218	were	_	_	O
219	similar	_	_	O
220	between	_	_	O
221	arms	_	_	O
222	.	_	_	O

223	By	_	_	B-Premise
224	cycle	_	_	I-Premise
225	4	_	_	I-Premise
226	,	_	_	I-Premise
227	mean	_	_	I-Premise
228	differences	_	_	I-Premise
229	were	_	_	I-Premise
230	clinically	_	_	I-Premise
231	meaningful	_	_	I-Premise
232	for	_	_	I-Premise
233	most	_	_	I-Premise
234	domains	_	_	I-Premise
235	,	_	_	I-Premise
236	indicating	_	_	I-Premise
237	poorer	_	_	I-Premise
238	health	_	_	I-Premise
239	status	_	_	I-Premise
240	with	_	_	I-Premise
241	VMP	_	_	I-Premise
242	.	_	_	I-Premise

243	From	_	_	B-Premise
244	cycle	_	_	I-Premise
245	5	_	_	I-Premise
246	onwards	_	_	I-Premise
247	,	_	_	I-Premise
248	improvements	_	_	I-Premise
249	relative	_	_	I-Premise
250	to	_	_	I-Premise
251	baseline	_	_	I-Premise
252	/	_	_	I-Premise
253	MP	_	_	I-Premise
254	were	_	_	I-Premise
255	observed	_	_	I-Premise
256	for	_	_	I-Premise
257	all	_	_	I-Premise
258	domains	_	_	I-Premise
259	with	_	_	I-Premise
260	VMP	_	_	I-Premise
261	.	_	_	I-Premise

262	Mean	_	_	B-Premise
263	scores	_	_	I-Premise
264	were	_	_	I-Premise
265	generally	_	_	I-Premise
266	improved	_	_	I-Premise
267	by	_	_	I-Premise
268	the	_	_	I-Premise
269	end	_	_	I-Premise
270	-	_	_	I-Premise
271	of	_	_	I-Premise
272	-	_	_	I-Premise
273	treatment	_	_	I-Premise
274	assessment	_	_	I-Premise
275	vs	_	_	I-Premise
276	.	_	_	I-Premise

277	baseline	_	_	I-Premise
278	in	_	_	I-Premise
279	both	_	_	I-Premise
280	arms	_	_	I-Premise
281	.	_	_	I-Premise

282	Among	_	_	B-Premise
283	responding	_	_	I-Premise
284	patients	_	_	I-Premise
285	,	_	_	I-Premise
286	mean	_	_	I-Premise
287	scores	_	_	I-Premise
288	generally	_	_	I-Premise
289	improved	_	_	I-Premise
290	from	_	_	I-Premise
291	time	_	_	I-Premise
292	of	_	_	I-Premise
293	response	_	_	I-Premise
294	to	_	_	I-Premise
295	end	_	_	I-Premise
296	-	_	_	I-Premise
297	of	_	_	I-Premise
298	-	_	_	I-Premise
299	treatment	_	_	I-Premise
300	assessment	_	_	I-Premise
301	,	_	_	I-Premise
302	substantially	_	_	I-Premise
303	driven	_	_	I-Premise
304	by	_	_	I-Premise
305	patients	_	_	I-Premise
306	achieving	_	_	I-Premise
307	complete	_	_	I-Premise
308	response	_	_	I-Premise
309	(	_	_	I-Premise
310	CR	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	Multivariate	_	_	B-Premise
314	analysis	_	_	I-Premise
315	showed	_	_	I-Premise
316	a	_	_	I-Premise
317	significant	_	_	I-Premise
318	impact	_	_	I-Premise
319	of	_	_	I-Premise
320	duration	_	_	I-Premise
321	of	_	_	I-Premise
322	response	_	_	I-Premise
323	/	_	_	I-Premise
324	CR	_	_	I-Premise
325	on	_	_	I-Premise
326	improving	_	_	I-Premise
327	global	_	_	I-Premise
328	health	_	_	I-Premise
329	status	_	_	I-Premise
330	,	_	_	I-Premise
331	pain	_	_	I-Premise
332	,	_	_	I-Premise
333	and	_	_	I-Premise
334	appetite	_	_	I-Premise
335	loss	_	_	I-Premise
336	scores	_	_	I-Premise
337	.	_	_	I-Premise

338	Analyses	_	_	B-Claim
339	by	_	_	I-Claim
340	bortezomib	_	_	I-Claim
341	dose	_	_	I-Claim
342	intensity	_	_	I-Claim
343	indicated	_	_	I-Claim
344	better	_	_	I-Claim
345	HRQoL	_	_	I-Claim
346	in	_	_	I-Claim
347	patients	_	_	I-Claim
348	receiving	_	_	I-Claim
349	lower	_	_	I-Claim
350	dose	_	_	I-Claim
351	intensity	_	_	I-Claim
352	.	_	_	I-Claim

353	These	_	_	B-Claim
354	findings	_	_	I-Claim
355	demonstrate	_	_	I-Claim
356	clinically	_	_	I-Claim
357	meaningful	_	_	I-Claim
358	,	_	_	I-Claim
359	transitory	_	_	I-Claim
360	HRQoL	_	_	I-Claim
361	decrements	_	_	I-Claim
362	with	_	_	I-Claim
363	VMP	_	_	I-Claim
364	and	_	_	I-Claim
365	relatively	_	_	I-Claim
366	lower	_	_	I-Claim
367	HRQoL	_	_	I-Claim
368	vs	_	_	I-Claim
369	.	_	_	I-Claim

370	MP	_	_	I-Claim
371	during	_	_	I-Claim
372	early	_	_	I-Claim
373	treatment	_	_	I-Claim
374	cycles	_	_	I-Claim
375	,	_	_	I-Claim
376	associated	_	_	I-Claim
377	with	_	_	I-Claim
378	the	_	_	I-Claim
379	expected	_	_	I-Claim
380	additional	_	_	I-Claim
381	toxicities	_	_	I-Claim
382	.	_	_	I-Claim

383	However	_	_	B-Claim
384	,	_	_	I-Claim
385	HRQoL	_	_	I-Claim
386	is	_	_	I-Claim
387	not	_	_	I-Claim
388	compromised	_	_	I-Claim
389	in	_	_	I-Claim
390	the	_	_	I-Claim
391	long	_	_	I-Claim
392	term	_	_	I-Claim
393	,	_	_	I-Claim
394	recovering	_	_	I-Claim
395	by	_	_	I-Claim
396	the	_	_	I-Claim
397	end	_	_	I-Claim
398	-	_	_	I-Claim
399	of	_	_	I-Claim
400	-	_	_	I-Claim
401	treatment	_	_	I-Claim
402	visit	_	_	I-Claim
403	to	_	_	I-Claim
404	be	_	_	I-Claim
405	comparable	_	_	I-Claim
406	vs	_	_	I-Claim
407	.	_	_	I-Claim

408	MP	_	_	I-Claim
409	.	_	_	I-Claim


0	Although	_	_	O
1	numerous	_	_	O
2	treatment	_	_	O
3	modalities	_	_	O
4	have	_	_	O
5	been	_	_	O
6	explored	_	_	O
7	in	_	_	O
8	patients	_	_	O
9	with	_	_	O
10	advanced	_	_	O
11	HCC	_	_	O
12	,	_	_	O
13	the	_	_	O
14	therapeutic	_	_	O
15	options	_	_	O
16	are	_	_	O
17	still	_	_	O
18	limited	_	_	O
19	.	_	_	O

20	Somatostatin	_	_	B-Claim
21	has	_	_	I-Claim
22	been	_	_	I-Claim
23	shown	_	_	I-Claim
24	to	_	_	I-Claim
25	have	_	_	I-Claim
26	antimitotic	_	_	I-Claim
27	activity	_	_	I-Claim
28	in	_	_	I-Claim
29	endocrine	_	_	I-Claim
30	as	_	_	I-Claim
31	well	_	_	I-Claim
32	as	_	_	I-Claim
33	in	_	_	I-Claim
34	a	_	_	I-Claim
35	variety	_	_	I-Claim
36	of	_	_	I-Claim
37	nonendocrine	_	_	I-Claim
38	tumors	_	_	I-Claim
39	.	_	_	I-Claim

40	Expression	_	_	B-Premise
41	of	_	_	I-Premise
42	somatostatin	_	_	I-Premise
43	receptors	_	_	I-Premise
44	is	_	_	I-Premise
45	found	_	_	I-Premise
46	in	_	_	I-Premise
47	HCCs	_	_	I-Premise
48	,	_	_	I-Premise
49	but	_	_	O
50	the	_	_	B-Claim
51	efficacy	_	_	I-Claim
52	of	_	_	I-Claim
53	the	_	_	I-Claim
54	somatostatin	_	_	I-Claim
55	analogue	_	_	I-Claim
56	octreotide	_	_	I-Claim
57	remains	_	_	I-Claim
58	controversial	_	_	I-Claim
59	.	_	_	I-Claim

60	Therefore	_	_	O
61	,	_	_	O
62	a	_	_	O
63	randomized	_	_	O
64	double	_	_	O
65	-	_	_	O
66	blind	_	_	O
67	placebo	_	_	O
68	-	_	_	O
69	controlled	_	_	O
70	multicenter	_	_	O
71	trial	_	_	O
72	was	_	_	O
73	performed	_	_	O
74	to	_	_	O
75	assess	_	_	O
76	the	_	_	O
77	efficacy	_	_	O
78	of	_	_	O
79	long	_	_	O
80	-	_	_	O
81	acting	_	_	O
82	octreotide	_	_	O
83	for	_	_	O
84	the	_	_	O
85	treatment	_	_	O
86	of	_	_	O
87	advanced	_	_	O
88	HCC	_	_	O
89	.	_	_	O

90	One	_	_	O
91	hundred	_	_	O
92	twenty	_	_	O
93	untreated	_	_	O
94	patients	_	_	O
95	with	_	_	O
96	histologically	_	_	O
97	confirmed	_	_	O
98	HCC	_	_	O
99	were	_	_	O
100	randomized	_	_	O
101	to	_	_	O
102	receive	_	_	O
103	either	_	_	O
104	long	_	_	O
105	-	_	_	O
106	acting	_	_	O
107	octreotide	_	_	O
108	(	_	_	O
109	Sandostation	_	_	O
110	LAR	_	_	O
111	30	_	_	O
112	mg	_	_	O
113	)	_	_	O
114	intramuscularly	_	_	O
115	every	_	_	O
116	4	_	_	O
117	weeks	_	_	O
118	or	_	_	O
119	placebo	_	_	O
120	.	_	_	O

121	The	_	_	O
122	study	_	_	O
123	groups	_	_	O
124	were	_	_	O
125	comparable	_	_	O
126	with	_	_	O
127	respect	_	_	O
128	to	_	_	O
129	clinical	_	_	O
130	characteristics	_	_	O
131	.	_	_	O

132	There	_	_	B-Premise
133	was	_	_	I-Premise
134	no	_	_	I-Premise
135	difference	_	_	I-Premise
136	in	_	_	I-Premise
137	the	_	_	I-Premise
138	cumulative	_	_	I-Premise
139	survival	_	_	I-Premise
140	.	_	_	I-Premise

141	The	_	_	B-Premise
142	median	_	_	I-Premise
143	survival	_	_	I-Premise
144	time	_	_	I-Premise
145	was	_	_	I-Premise
146	4	_	_	I-Premise
147	.	_	_	I-Premise

148	7	_	_	I-Premise
149	months	_	_	I-Premise
150	in	_	_	I-Premise
151	the	_	_	I-Premise
152	octreotide	_	_	I-Premise
153	group	_	_	I-Premise
154	compared	_	_	I-Premise
155	with	_	_	I-Premise
156	5	_	_	I-Premise
157	.	_	_	I-Premise

158	3	_	_	I-Premise
159	months	_	_	I-Premise
160	in	_	_	I-Premise
161	the	_	_	I-Premise
162	control	_	_	I-Premise
163	group	_	_	I-Premise
164	.	_	_	I-Premise

165	Six	_	_	B-Premise
166	-	_	_	I-Premise
167	month	_	_	I-Premise
168	survival	_	_	I-Premise
169	rates	_	_	I-Premise
170	were	_	_	I-Premise
171	41	_	_	I-Premise
172	%	_	_	I-Premise
173	for	_	_	I-Premise
174	octreotide	_	_	I-Premise
175	patients	_	_	I-Premise
176	and	_	_	I-Premise
177	42	_	_	I-Premise
178	%	_	_	I-Premise
179	for	_	_	I-Premise
180	control	_	_	I-Premise
181	patients	_	_	I-Premise
182	,	_	_	I-Premise
183	respectively	_	_	I-Premise
184	.	_	_	I-Premise

185	The	_	_	B-Premise
186	unadjusted	_	_	I-Premise
187	relative	_	_	I-Premise
188	risk	_	_	I-Premise
189	for	_	_	I-Premise
190	mortality	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	octreotide	_	_	I-Premise
194	group	_	_	I-Premise
195	compared	_	_	I-Premise
196	with	_	_	I-Premise
197	patients	_	_	I-Premise
198	in	_	_	I-Premise
199	the	_	_	I-Premise
200	control	_	_	I-Premise
201	group	_	_	I-Premise
202	was	_	_	I-Premise
203	1	_	_	I-Premise
204	.	_	_	I-Premise

205	11	_	_	I-Premise
206	(	_	_	I-Premise
207	95	_	_	I-Premise
208	%	_	_	I-Premise
209	CI	_	_	I-Premise
210	0	_	_	I-Premise
211	.	_	_	I-Premise

212	76	_	_	I-Premise
213	-	_	_	I-Premise
214	1	_	_	I-Premise
215	.	_	_	I-Premise

216	63	_	_	I-Premise
217	;	_	_	I-Premise
218	P	_	_	I-Premise
219	=	_	_	I-Premise
220	0	_	_	I-Premise
221	.	_	_	I-Premise

222	59	_	_	I-Premise
223	)	_	_	I-Premise
224	.	_	_	I-Premise

225	When	_	_	B-Premise
226	adjusted	_	_	I-Premise
227	for	_	_	I-Premise
228	Okuda	_	_	I-Premise
229	,	_	_	I-Premise
230	CTP	_	_	I-Premise
231	,	_	_	I-Premise
232	and	_	_	I-Premise
233	Cancer	_	_	I-Premise
234	of	_	_	I-Premise
235	the	_	_	I-Premise
236	Liver	_	_	I-Premise
237	Italian	_	_	I-Premise
238	Program	_	_	I-Premise
239	(	_	_	I-Premise
240	CLIP	_	_	I-Premise
241	)	_	_	I-Premise
242	scores	_	_	I-Premise
243	,	_	_	I-Premise
244	the	_	_	I-Premise
245	relative	_	_	I-Premise
246	risk	_	_	I-Premise
247	for	_	_	I-Premise
248	octreotide	_	_	I-Premise
249	did	_	_	I-Premise
250	not	_	_	I-Premise
251	change	_	_	I-Premise
252	markedly	_	_	I-Premise
253	and	_	_	I-Premise
254	was	_	_	I-Premise
255	1	_	_	I-Premise
256	.	_	_	I-Premise

257	05	_	_	I-Premise
258	(	_	_	I-Premise
259	95	_	_	I-Premise
260	%	_	_	I-Premise
261	CI	_	_	I-Premise
262	0	_	_	I-Premise
263	.	_	_	I-Premise

264	71	_	_	I-Premise
265	-	_	_	I-Premise
266	1	_	_	I-Premise
267	.	_	_	I-Premise

268	55	_	_	I-Premise
269	;	_	_	I-Premise
270	P	_	_	I-Premise
271	=	_	_	I-Premise
272	0	_	_	I-Premise
273	.	_	_	I-Premise

274	83	_	_	I-Premise
275	)	_	_	I-Premise
276	.	_	_	I-Premise

277	The	_	_	B-Claim
278	CLIP	_	_	I-Claim
279	score	_	_	I-Claim
280	seems	_	_	I-Claim
281	to	_	_	I-Claim
282	predict	_	_	I-Claim
283	survival	_	_	I-Claim
284	better	_	_	I-Claim
285	than	_	_	I-Claim
286	both	_	_	I-Claim
287	Okuda	_	_	I-Claim
288	and	_	_	I-Claim
289	CTP	_	_	I-Claim
290	score	_	_	I-Claim
291	.	_	_	I-Claim

292	The	_	_	B-Claim
293	randomized	_	_	I-Claim
294	controlled	_	_	I-Claim
295	double	_	_	I-Claim
296	-	_	_	I-Claim
297	blind	_	_	I-Claim
298	HECTOR	_	_	I-Claim
299	trial	_	_	I-Claim
300	showed	_	_	I-Claim
301	no	_	_	I-Claim
302	survival	_	_	I-Claim
303	benefit	_	_	I-Claim
304	for	_	_	I-Claim
305	HCC	_	_	I-Claim
306	patients	_	_	I-Claim
307	treated	_	_	I-Claim
308	with	_	_	I-Claim
309	long	_	_	I-Claim
310	-	_	_	I-Claim
311	acting	_	_	I-Claim
312	octreotide	_	_	I-Claim
313	compared	_	_	I-Claim
314	with	_	_	I-Claim
315	placebo	_	_	I-Claim
316	.	_	_	I-Claim


0	Randomized	_	_	B-Claim
1	trials	_	_	I-Claim
2	in	_	_	I-Claim
3	fluorouracil	_	_	I-Claim
4	(	_	_	I-Claim
5	FU	_	_	I-Claim
6	)	_	_	I-Claim
7	-	_	_	I-Claim
8	refractory	_	_	I-Claim
9	colorectal	_	_	I-Claim
10	cancer	_	_	I-Claim
11	demonstrate	_	_	I-Claim
12	significant	_	_	I-Claim
13	survival	_	_	I-Claim
14	advantages	_	_	I-Claim
15	for	_	_	I-Claim
16	patients	_	_	I-Claim
17	receiving	_	_	I-Claim
18	irinotecan	_	_	I-Claim
19	.	_	_	I-Claim

20	We	_	_	O
21	prospectively	_	_	O
22	compared	_	_	O
23	the	_	_	O
24	efficacy	_	_	O
25	and	_	_	O
26	tolerability	_	_	O
27	of	_	_	O
28	two	_	_	O
29	irinotecan	_	_	O
30	regimens	_	_	O
31	(	_	_	O
32	once	_	_	O
33	a	_	_	O
34	week	_	_	O
35	for	_	_	O
36	4	_	_	O
37	weeks	_	_	O
38	followed	_	_	O
39	by	_	_	O
40	a	_	_	O
41	2	_	_	O
42	-	_	_	O
43	week	_	_	O
44	rest	_	_	O
45	period	_	_	O
46	[	_	_	O
47	weekly	_	_	O
48	]	_	_	O
49	v	_	_	O
50	once	_	_	O
51	every	_	_	O
52	3	_	_	O
53	weeks	_	_	O
54	)	_	_	O
55	in	_	_	O
56	such	_	_	O
57	patients	_	_	O
58	.	_	_	O

59	This	_	_	O
60	multicenter	_	_	O
61	,	_	_	O
62	open	_	_	O
63	-	_	_	O
64	label	_	_	O
65	,	_	_	O
66	phase	_	_	O
67	III	_	_	O
68	study	_	_	O
69	randomly	_	_	O
70	assigned	_	_	O
71	patients	_	_	O
72	in	_	_	O
73	a	_	_	O
74	1	_	_	O
75	:	_	_	O
76	2	_	_	O
77	ratio	_	_	O
78	to	_	_	O
79	irinotecan	_	_	O
80	given	_	_	O
81	either	_	_	O
82	weekly	_	_	O
83	(	_	_	O
84	125	_	_	O
85	mg	_	_	O
86	/	_	_	O
87	m	_	_	O
88	(	_	_	O
89	2	_	_	O
90	)	_	_	O
91	)	_	_	O
92	or	_	_	O
93	once	_	_	O
94	every	_	_	O
95	3	_	_	O
96	weeks	_	_	O
97	(	_	_	O
98	350	_	_	O
99	mg	_	_	O
100	/	_	_	O
101	m	_	_	O
102	(	_	_	O
103	2	_	_	O
104	)	_	_	O
105	,	_	_	O
106	or	_	_	O
107	300	_	_	O
108	mg	_	_	O
109	/	_	_	O
110	m	_	_	O
111	(	_	_	O
112	2	_	_	O
113	)	_	_	O
114	in	_	_	O
115	patients	_	_	O
116	who	_	_	O
117	were	_	_	O
118	>	_	_	O
119	/	_	_	O
120	=	_	_	O
121	70	_	_	O
122	years	_	_	O
123	of	_	_	O
124	age	_	_	O
125	,	_	_	O
126	who	_	_	O
127	had	_	_	O
128	Eastern	_	_	O
129	Cooperative	_	_	O
130	Oncology	_	_	O
131	Group	_	_	O
132	performance	_	_	O
133	status	_	_	O
134	equal	_	_	O
135	to	_	_	O
136	2	_	_	O
137	,	_	_	O
138	or	_	_	O
139	who	_	_	O
140	had	_	_	O
141	prior	_	_	O
142	pelvic	_	_	O
143	irradiation	_	_	O
144	)	_	_	O
145	.	_	_	O

146	With	_	_	B-Premise
147	median	_	_	I-Premise
148	follow	_	_	I-Premise
149	-	_	_	I-Premise
150	up	_	_	I-Premise
151	of	_	_	I-Premise
152	15	_	_	I-Premise
153	.	_	_	I-Premise

154	8	_	_	I-Premise
155	months	_	_	I-Premise
156	,	_	_	I-Premise
157	there	_	_	I-Premise
158	was	_	_	I-Premise
159	no	_	_	I-Premise
160	significant	_	_	I-Premise
161	difference	_	_	I-Premise
162	in	_	_	I-Premise
163	1	_	_	I-Premise
164	-	_	_	I-Premise
165	year	_	_	I-Premise
166	survival	_	_	I-Premise
167	(	_	_	I-Premise
168	46	_	_	I-Premise
169	%	_	_	I-Premise
170	v	_	_	I-Premise
171	41	_	_	I-Premise
172	%	_	_	I-Premise
173	,	_	_	I-Premise
174	respectively	_	_	I-Premise
175	;	_	_	I-Premise
176	P	_	_	I-Premise
177	=	_	_	I-Premise
178	.	_	_	I-Premise

179	42	_	_	I-Premise
180	)	_	_	I-Premise
181	,	_	_	I-Premise
182	median	_	_	I-Premise
183	survival	_	_	I-Premise
184	(	_	_	I-Premise
185	9	_	_	I-Premise
186	.	_	_	I-Premise

187	9	_	_	I-Premise
188	v	_	_	I-Premise
189	9	_	_	I-Premise
190	.	_	_	I-Premise

191	9	_	_	I-Premise
192	months	_	_	I-Premise
193	,	_	_	I-Premise
194	respectively	_	_	I-Premise
195	;	_	_	I-Premise
196	P	_	_	I-Premise
197	=	_	_	I-Premise
198	.	_	_	I-Premise

199	43	_	_	I-Premise
200	)	_	_	I-Premise
201	,	_	_	I-Premise
202	or	_	_	I-Premise
203	median	_	_	I-Premise
204	time	_	_	I-Premise
205	to	_	_	I-Premise
206	progression	_	_	I-Premise
207	(	_	_	I-Premise
208	4	_	_	I-Premise
209	.	_	_	I-Premise

210	0	_	_	I-Premise
211	v	_	_	I-Premise
212	3	_	_	I-Premise
213	.	_	_	I-Premise

214	0	_	_	I-Premise
215	months	_	_	I-Premise
216	,	_	_	I-Premise
217	respectively	_	_	I-Premise
218	;	_	_	I-Premise
219	P	_	_	I-Premise
220	=	_	_	I-Premise
221	.	_	_	I-Premise

222	54	_	_	I-Premise
223	)	_	_	I-Premise
224	between	_	_	I-Premise
225	the	_	_	I-Premise
226	two	_	_	I-Premise
227	regimens	_	_	I-Premise
228	.	_	_	I-Premise

229	Grade	_	_	B-Premise
230	3	_	_	I-Premise
231	/	_	_	I-Premise
232	4	_	_	I-Premise
233	diarrhea	_	_	I-Premise
234	occurred	_	_	I-Premise
235	in	_	_	I-Premise
236	36	_	_	I-Premise
237	%	_	_	I-Premise
238	of	_	_	I-Premise
239	patients	_	_	I-Premise
240	treated	_	_	I-Premise
241	weekly	_	_	I-Premise
242	and	_	_	I-Premise
243	in	_	_	I-Premise
244	19	_	_	I-Premise
245	%	_	_	I-Premise
246	of	_	_	I-Premise
247	those	_	_	I-Premise
248	treated	_	_	I-Premise
249	once	_	_	I-Premise
250	every	_	_	I-Premise
251	3	_	_	I-Premise
252	weeks	_	_	I-Premise
253	(	_	_	I-Premise
254	P	_	_	I-Premise
255	=	_	_	I-Premise
256	.	_	_	I-Premise

257	002	_	_	I-Premise
258	)	_	_	I-Premise
259	.	_	_	I-Premise

260	Grade	_	_	B-Premise
261	3	_	_	I-Premise
262	/	_	_	I-Premise
263	4	_	_	I-Premise
264	neutropenia	_	_	I-Premise
265	occurred	_	_	I-Premise
266	in	_	_	I-Premise
267	29	_	_	I-Premise
268	%	_	_	I-Premise
269	of	_	_	I-Premise
270	patients	_	_	I-Premise
271	treated	_	_	I-Premise
272	weekly	_	_	I-Premise
273	and	_	_	I-Premise
274	34	_	_	I-Premise
275	%	_	_	I-Premise
276	of	_	_	I-Premise
277	those	_	_	I-Premise
278	treated	_	_	I-Premise
279	once	_	_	I-Premise
280	every	_	_	I-Premise
281	3	_	_	I-Premise
282	weeks	_	_	I-Premise
283	(	_	_	I-Premise
284	P	_	_	I-Premise
285	=	_	_	I-Premise
286	.	_	_	I-Premise

287	35	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	Treatment	_	_	B-Premise
291	-	_	_	I-Premise
292	related	_	_	I-Premise
293	mortality	_	_	I-Premise
294	occurred	_	_	I-Premise
295	in	_	_	I-Premise
296	five	_	_	I-Premise
297	patients	_	_	I-Premise
298	(	_	_	I-Premise
299	5	_	_	I-Premise
300	.	_	_	I-Premise

301	3	_	_	I-Premise
302	%	_	_	I-Premise
303	)	_	_	I-Premise
304	receiving	_	_	I-Premise
305	irinotecan	_	_	I-Premise
306	weekly	_	_	I-Premise
307	and	_	_	I-Premise
308	three	_	_	I-Premise
309	patients	_	_	I-Premise
310	(	_	_	I-Premise
311	1	_	_	I-Premise
312	.	_	_	I-Premise

313	6	_	_	I-Premise
314	%	_	_	I-Premise
315	)	_	_	I-Premise
316	given	_	_	I-Premise
317	therapy	_	_	I-Premise
318	once	_	_	I-Premise
319	every	_	_	I-Premise
320	3	_	_	I-Premise
321	weeks	_	_	I-Premise
322	(	_	_	I-Premise
323	P	_	_	I-Premise
324	=	_	_	I-Premise
325	.	_	_	I-Premise

326	12	_	_	I-Premise
327	)	_	_	I-Premise
328	.	_	_	I-Premise

329	Global	_	_	B-Premise
330	quality	_	_	I-Premise
331	of	_	_	I-Premise
332	life	_	_	I-Premise
333	was	_	_	I-Premise
334	not	_	_	I-Premise
335	statistically	_	_	I-Premise
336	different	_	_	I-Premise
337	between	_	_	I-Premise
338	treatment	_	_	I-Premise
339	groups	_	_	I-Premise
340	.	_	_	I-Premise

341	Irinotecan	_	_	B-Claim
342	schedules	_	_	I-Claim
343	of	_	_	I-Claim
344	weekly	_	_	I-Claim
345	and	_	_	I-Claim
346	of	_	_	I-Claim
347	once	_	_	I-Claim
348	every	_	_	I-Claim
349	3	_	_	I-Claim
350	weeks	_	_	I-Claim
351	demonstrated	_	_	I-Claim
352	similar	_	_	I-Claim
353	efficacy	_	_	I-Claim
354	and	_	_	I-Claim
355	quality	_	_	I-Claim
356	of	_	_	I-Claim
357	life	_	_	I-Claim
358	in	_	_	I-Claim
359	patients	_	_	I-Claim
360	with	_	_	I-Claim
361	FU	_	_	I-Claim
362	-	_	_	I-Claim
363	refractory	_	_	I-Claim
364	,	_	_	I-Claim
365	metastatic	_	_	I-Claim
366	colorectal	_	_	I-Claim
367	cancer	_	_	I-Claim
368	.	_	_	I-Claim

369	The	_	_	B-Claim
370	regimen	_	_	I-Claim
371	of	_	_	I-Claim
372	once	_	_	I-Claim
373	every	_	_	I-Claim
374	3	_	_	I-Claim
375	weeks	_	_	I-Claim
376	was	_	_	I-Claim
377	associated	_	_	I-Claim
378	with	_	_	I-Claim
379	a	_	_	I-Claim
380	significantly	_	_	I-Claim
381	lower	_	_	I-Claim
382	incidence	_	_	I-Claim
383	of	_	_	I-Claim
384	severe	_	_	I-Claim
385	diarrhea	_	_	I-Claim
386	.	_	_	I-Claim


0	We	_	_	O
1	aimed	_	_	O
2	to	_	_	O
3	determine	_	_	O
4	the	_	_	O
5	effect	_	_	O
6	of	_	_	O
7	dietary	_	_	O
8	counseling	_	_	O
9	or	_	_	O
10	oral	_	_	O
11	supplements	_	_	O
12	on	_	_	O
13	outcome	_	_	O
14	for	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	cancer	_	_	O
18	,	_	_	O
19	specifically	_	_	O
20	,	_	_	O
21	nutritional	_	_	O
22	outcome	_	_	O
23	,	_	_	O
24	morbidity	_	_	O
25	,	_	_	O
26	and	_	_	O
27	quality	_	_	O
28	of	_	_	O
29	life	_	_	O
30	(	_	_	O
31	QOL	_	_	O
32	)	_	_	O
33	,	_	_	O
34	during	_	_	O
35	and	_	_	O
36	3	_	_	O
37	months	_	_	O
38	after	_	_	O
39	radiotherapy	_	_	O
40	.	_	_	O

41	Seventy	_	_	O
42	-	_	_	O
43	five	_	_	O
44	patients	_	_	O
45	with	_	_	O
46	head	_	_	O
47	and	_	_	O
48	neck	_	_	O
49	cancer	_	_	O
50	who	_	_	O
51	were	_	_	O
52	referred	_	_	O
53	for	_	_	O
54	radiotherapy	_	_	O
55	(	_	_	O
56	RT	_	_	O
57	)	_	_	O
58	were	_	_	O
59	randomized	_	_	O
60	to	_	_	O
61	the	_	_	O
62	following	_	_	O
63	groups	_	_	O
64	:	_	_	O
65	group	_	_	O
66	1	_	_	O
67	(	_	_	O
68	n	_	_	O
69	=	_	_	O
70	25	_	_	O
71	)	_	_	O
72	,	_	_	O
73	patients	_	_	O
74	who	_	_	O
75	received	_	_	O
76	dietary	_	_	O
77	counseling	_	_	O
78	with	_	_	O
79	regular	_	_	O
80	foods	_	_	O
81	;	_	_	O
82	group	_	_	O
83	2	_	_	O
84	(	_	_	O
85	n	_	_	O
86	=	_	_	O
87	25	_	_	O
88	)	_	_	O
89	,	_	_	O
90	patients	_	_	O
91	who	_	_	O
92	maintained	_	_	O
93	usual	_	_	O
94	diet	_	_	O
95	plus	_	_	O
96	supplements	_	_	O
97	;	_	_	O
98	and	_	_	O
99	group	_	_	O
100	3	_	_	O
101	(	_	_	O
102	n	_	_	O
103	=	_	_	O
104	25	_	_	O
105	)	_	_	O
106	,	_	_	O
107	patients	_	_	O
108	who	_	_	O
109	maintained	_	_	O
110	intake	_	_	O
111	ad	_	_	O
112	lib	_	_	O
113	.	_	_	O

114	Nutritional	_	_	O
115	intake	_	_	O
116	(	_	_	O
117	determined	_	_	O
118	by	_	_	O
119	diet	_	_	O
120	history	_	_	O
121	)	_	_	O
122	and	_	_	O
123	status	_	_	O
124	(	_	_	O
125	determined	_	_	O
126	by	_	_	O
127	Ottery	_	_	O
128	'	_	_	O
129	s	_	_	O
130	Subjective	_	_	O
131	Global	_	_	O
132	Assessment	_	_	O
133	)	_	_	O
134	,	_	_	O
135	and	_	_	O
136	QOL	_	_	O
137	(	_	_	O
138	determined	_	_	O
139	by	_	_	O
140	the	_	_	O
141	European	_	_	O
142	Organization	_	_	O
143	for	_	_	O
144	the	_	_	O
145	Research	_	_	O
146	and	_	_	O
147	Treatment	_	_	O
148	of	_	_	O
149	Cancer	_	_	O
150	Quality	_	_	O
151	of	_	_	O
152	Life	_	_	O
153	Questionnaire	_	_	O
154	version	_	_	O
155	3	_	_	O
156	.	_	_	O

157	0	_	_	O
158	[	_	_	O
159	EORTC	_	_	O
160	QLQ	_	_	O
161	-	_	_	O
162	C30	_	_	O
163	]	_	_	O
164	)	_	_	O
165	were	_	_	O
166	evaluated	_	_	O
167	at	_	_	O
168	baseline	_	_	O
169	,	_	_	O
170	at	_	_	O
171	the	_	_	O
172	end	_	_	O
173	of	_	_	O
174	RT	_	_	O
175	,	_	_	O
176	and	_	_	O
177	at	_	_	O
178	3	_	_	O
179	months	_	_	O
180	.	_	_	O

181	Energy	_	_	B-Premise
182	intake	_	_	I-Premise
183	after	_	_	I-Premise
184	RT	_	_	I-Premise
185	increased	_	_	I-Premise
186	in	_	_	I-Premise
187	both	_	_	I-Premise
188	groups	_	_	I-Premise
189	1	_	_	I-Premise
190	and	_	_	I-Premise
191	2	_	_	I-Premise
192	(	_	_	I-Premise
193	p	_	_	I-Premise
194	<	_	_	I-Premise
195	or	_	_	I-Premise
196	=	_	_	I-Premise
197	.	_	_	I-Premise

198	05	_	_	I-Premise
199	)	_	_	I-Premise
200	.	_	_	I-Premise

201	Protein	_	_	B-Premise
202	intake	_	_	I-Premise
203	also	_	_	I-Premise
204	increased	_	_	I-Premise
205	in	_	_	I-Premise
206	both	_	_	I-Premise
207	groups	_	_	I-Premise
208	1	_	_	I-Premise
209	and	_	_	I-Premise
210	2	_	_	I-Premise
211	(	_	_	I-Premise
212	p	_	_	I-Premise
213	<	_	_	I-Premise
214	or	_	_	I-Premise
215	=	_	_	I-Premise
216	.	_	_	I-Premise

217	006	_	_	I-Premise
218	)	_	_	I-Premise
219	.	_	_	I-Premise

220	Both	_	_	B-Premise
221	energy	_	_	I-Premise
222	and	_	_	I-Premise
223	protein	_	_	I-Premise
224	intake	_	_	I-Premise
225	decreased	_	_	I-Premise
226	significantly	_	_	I-Premise
227	in	_	_	I-Premise
228	group	_	_	I-Premise
229	3	_	_	I-Premise
230	(	_	_	I-Premise
231	p	_	_	I-Premise
232	<	_	_	I-Premise
233	.	_	_	I-Premise

234	01	_	_	I-Premise
235	)	_	_	I-Premise
236	.	_	_	I-Premise

237	At	_	_	B-Premise
238	3	_	_	I-Premise
239	months	_	_	I-Premise
240	,	_	_	I-Premise
241	group	_	_	I-Premise
242	1	_	_	I-Premise
243	maintained	_	_	I-Premise
244	intakes	_	_	I-Premise
245	,	_	_	I-Premise
246	whereas	_	_	I-Premise
247	groups	_	_	I-Premise
248	2	_	_	I-Premise
249	and	_	_	I-Premise
250	3	_	_	I-Premise
251	returned	_	_	I-Premise
252	to	_	_	I-Premise
253	or	_	_	I-Premise
254	below	_	_	I-Premise
255	baseline	_	_	I-Premise
256	levels	_	_	I-Premise
257	.	_	_	I-Premise

258	After	_	_	B-Premise
259	RT	_	_	I-Premise
260	,	_	_	I-Premise
261	>	_	_	I-Premise
262	90	_	_	I-Premise
263	%	_	_	I-Premise
264	of	_	_	I-Premise
265	patients	_	_	I-Premise
266	experienced	_	_	I-Premise
267	RT	_	_	I-Premise
268	toxicity	_	_	I-Premise
269	;	_	_	I-Premise
270	this	_	_	B-Premise
271	was	_	_	I-Premise
272	not	_	_	I-Premise
273	significantly	_	_	I-Premise
274	different	_	_	I-Premise
275	between	_	_	I-Premise
276	groups	_	_	I-Premise
277	,	_	_	I-Premise
278	with	_	_	I-Premise
279	a	_	_	I-Premise
280	trend	_	_	I-Premise
281	for	_	_	I-Premise
282	reduced	_	_	I-Premise
283	symptomatology	_	_	I-Premise
284	in	_	_	I-Premise
285	group	_	_	I-Premise
286	1	_	_	I-Premise
287	versus	_	_	I-Premise
288	group	_	_	I-Premise
289	2	_	_	I-Premise
290	/	_	_	I-Premise
291	group	_	_	I-Premise
292	3	_	_	I-Premise
293	(	_	_	I-Premise
294	p	_	_	I-Premise
295	<	_	_	I-Premise
296	.	_	_	I-Premise

297	07	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	At	_	_	B-Premise
301	3	_	_	I-Premise
302	months	_	_	I-Premise
303	,	_	_	I-Premise
304	the	_	_	I-Premise
305	reduction	_	_	I-Premise
306	of	_	_	I-Premise
307	incidence	_	_	I-Premise
308	/	_	_	I-Premise
309	severity	_	_	I-Premise
310	of	_	_	I-Premise
311	grade	_	_	I-Premise
312	1	_	_	I-Premise
313	+	_	_	I-Premise
314	2	_	_	I-Premise
315	anorexia	_	_	I-Premise
316	,	_	_	I-Premise
317	nausea	_	_	I-Premise
318	/	_	_	I-Premise
319	vomiting	_	_	I-Premise
320	,	_	_	I-Premise
321	xerostomia	_	_	I-Premise
322	,	_	_	I-Premise
323	and	_	_	I-Premise
324	dysgeusia	_	_	I-Premise
325	was	_	_	I-Premise
326	different	_	_	I-Premise
327	:	_	_	I-Premise
328	90	_	_	I-Premise
329	%	_	_	I-Premise
330	of	_	_	I-Premise
331	the	_	_	I-Premise
332	patients	_	_	I-Premise
333	improved	_	_	I-Premise
334	in	_	_	I-Premise
335	group	_	_	I-Premise
336	1	_	_	I-Premise
337	versus	_	_	I-Premise
338	67	_	_	I-Premise
339	%	_	_	I-Premise
340	in	_	_	I-Premise
341	group	_	_	I-Premise
342	2	_	_	I-Premise
343	versus	_	_	I-Premise
344	51	_	_	I-Premise
345	%	_	_	I-Premise
346	in	_	_	I-Premise
347	group	_	_	I-Premise
348	3	_	_	I-Premise
349	(	_	_	I-Premise
350	p	_	_	I-Premise
351	<	_	_	I-Premise
352	.	_	_	I-Premise

353	0001	_	_	I-Premise
354	)	_	_	I-Premise
355	.	_	_	I-Premise

356	After	_	_	B-Premise
357	RT	_	_	I-Premise
358	,	_	_	I-Premise
359	QOL	_	_	I-Premise
360	function	_	_	I-Premise
361	scores	_	_	I-Premise
362	improved	_	_	I-Premise
363	(	_	_	I-Premise
364	p	_	_	I-Premise
365	<	_	_	I-Premise
366	.	_	_	I-Premise

367	003	_	_	I-Premise
368	)	_	_	I-Premise
369	proportionally	_	_	I-Premise
370	with	_	_	I-Premise
371	improved	_	_	I-Premise
372	nutritional	_	_	I-Premise
373	intake	_	_	I-Premise
374	and	_	_	I-Premise
375	status	_	_	I-Premise
376	in	_	_	I-Premise
377	group	_	_	I-Premise
378	1	_	_	I-Premise
379	/	_	_	I-Premise
380	group	_	_	I-Premise
381	2	_	_	I-Premise
382	(	_	_	I-Premise
383	p	_	_	I-Premise
384	<	_	_	I-Premise
385	.	_	_	I-Premise

386	05	_	_	I-Premise
387	)	_	_	I-Premise
388	and	_	_	I-Premise
389	worsened	_	_	I-Premise
390	in	_	_	I-Premise
391	group	_	_	I-Premise
392	3	_	_	I-Premise
393	(	_	_	I-Premise
394	p	_	_	I-Premise
395	<	_	_	I-Premise
396	.	_	_	I-Premise

397	05	_	_	I-Premise
398	)	_	_	I-Premise
399	;	_	_	I-Premise
400	at	_	_	B-Premise
401	3	_	_	I-Premise
402	months	_	_	I-Premise
403	,	_	_	I-Premise
404	patients	_	_	I-Premise
405	in	_	_	I-Premise
406	group	_	_	I-Premise
407	1	_	_	I-Premise
408	maintained	_	_	I-Premise
409	or	_	_	I-Premise
410	improved	_	_	I-Premise
411	overall	_	_	I-Premise
412	QOL	_	_	I-Premise
413	,	_	_	I-Premise
414	whereas	_	_	I-Premise
415	patients	_	_	I-Premise
416	in	_	_	I-Premise
417	groups	_	_	I-Premise
418	2	_	_	I-Premise
419	and	_	_	I-Premise
420	3	_	_	I-Premise
421	maintained	_	_	I-Premise
422	or	_	_	I-Premise
423	worsened	_	_	I-Premise
424	overall	_	_	I-Premise
425	QOL	_	_	I-Premise
426	.	_	_	I-Premise

427	During	_	_	B-Claim
428	RT	_	_	I-Claim
429	,	_	_	I-Claim
430	nutritional	_	_	I-Claim
431	interventions	_	_	I-Claim
432	positively	_	_	I-Claim
433	influenced	_	_	I-Claim
434	outcomes	_	_	I-Claim
435	,	_	_	I-Claim
436	and	_	_	I-Claim
437	counseling	_	_	I-Claim
438	was	_	_	I-Claim
439	of	_	_	I-Claim
440	similar	_	_	I-Claim
441	/	_	_	I-Claim
442	higher	_	_	I-Claim
443	benefit	_	_	I-Claim
444	;	_	_	I-Claim
445	in	_	_	B-Claim
446	the	_	_	I-Claim
447	medium	_	_	I-Claim
448	term	_	_	I-Claim
449	,	_	_	I-Claim
450	only	_	_	I-Claim
451	counseling	_	_	I-Claim
452	exerted	_	_	I-Claim
453	a	_	_	I-Claim
454	significant	_	_	I-Claim
455	impact	_	_	I-Claim
456	on	_	_	I-Claim
457	patient	_	_	I-Claim
458	outcomes	_	_	I-Claim
459	.	_	_	I-Claim


0	Due	_	_	O
1	to	_	_	O
2	concerns	_	_	O
3	of	_	_	O
4	fragility	_	_	O
5	fracture	_	_	O
6	,	_	_	O
7	exercise	_	_	O
8	is	_	_	O
9	a	_	_	O
10	perceived	_	_	O
11	contraindication	_	_	O
12	for	_	_	O
13	prostate	_	_	O
14	cancer	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	bone	_	_	O
18	metastases	_	_	O
19	.	_	_	O

20	These	_	_	O
21	patients	_	_	O
22	experience	_	_	O
23	significant	_	_	O
24	functional	_	_	O
25	impairment	_	_	O
26	and	_	_	O
27	muscle	_	_	O
28	atrophy	_	_	O
29	,	_	_	O
30	which	_	_	O
31	may	_	_	O
32	lead	_	_	O
33	to	_	_	O
34	an	_	_	O
35	increased	_	_	O
36	likelihood	_	_	O
37	of	_	_	O
38	skeletal	_	_	O
39	complicaTIOns	_	_	O
40	(	_	_	O
41	i	_	_	O
42	.	_	_	O

43	e	_	_	O
44	.	_	_	O

45	,	_	_	O
46	pathological	_	_	O
47	fracture	_	_	O
48	,	_	_	O
49	bone	_	_	O
50	pain	_	_	O
51	)	_	_	O
52	and	_	_	O
53	/	_	_	O
54	or	_	_	O
55	falls	_	_	O
56	.	_	_	O

57	Safe	_	_	O
58	resistance	_	_	O
59	exercise	_	_	O
60	prescription	_	_	O
61	may	_	_	O
62	counteract	_	_	O
63	this	_	_	O
64	effect	_	_	O
65	.	_	_	O

66	The	_	_	O
67	aim	_	_	O
68	of	_	_	O
69	this	_	_	O
70	feasibility	_	_	O
71	trial	_	_	O
72	was	_	_	O
73	to	_	_	O
74	determine	_	_	O
75	the	_	_	O
76	safety	_	_	O
77	and	_	_	O
78	efficacy	_	_	O
79	of	_	_	O
80	resistance	_	_	O
81	exercise	_	_	O
82	by	_	_	O
83	prostate	_	_	O
84	cancer	_	_	O
85	survivors	_	_	O
86	with	_	_	O
87	bone	_	_	O
88	metastatic	_	_	O
89	disease	_	_	O
90	.	_	_	O

91	Twenty	_	_	O
92	men	_	_	O
93	with	_	_	O
94	established	_	_	O
95	bone	_	_	O
96	metastases	_	_	O
97	secondary	_	_	O
98	to	_	_	O
99	prostate	_	_	O
100	cancer	_	_	O
101	were	_	_	O
102	randomly	_	_	O
103	assigned	_	_	O
104	to	_	_	O
105	a	_	_	O
106	12	_	_	O
107	-	_	_	O
108	week	_	_	O
109	resistance	_	_	O
110	exercise	_	_	O
111	program	_	_	O
112	in	_	_	O
113	which	_	_	O
114	exercise	_	_	O
115	prescription	_	_	O
116	was	_	_	O
117	based	_	_	O
118	on	_	_	O
119	the	_	_	O
120	location	_	_	O
121	of	_	_	O
122	bone	_	_	O
123	lesions	_	_	O
124	(	_	_	O
125	n	_	_	O
126	=	_	_	O
127	10	_	_	O
128	)	_	_	O
129	or	_	_	O
130	usual	_	_	O
131	care	_	_	O
132	(	_	_	O
133	n	_	_	O
134	=	_	_	O
135	10	_	_	O
136	)	_	_	O
137	.	_	_	O

138	Outcomes	_	_	O
139	included	_	_	O
140	safety	_	_	O
141	and	_	_	O
142	tolerance	_	_	O
143	of	_	_	O
144	the	_	_	O
145	exercise	_	_	O
146	program	_	_	O
147	,	_	_	O
148	physical	_	_	O
149	function	_	_	O
150	,	_	_	O
151	physical	_	_	O
152	activity	_	_	O
153	level	_	_	O
154	,	_	_	O
155	body	_	_	O
156	composition	_	_	O
157	,	_	_	O
158	fatigue	_	_	O
159	,	_	_	O
160	quality	_	_	O
161	of	_	_	O
162	life	_	_	O
163	and	_	_	O
164	psychological	_	_	O
165	distress	_	_	O
166	.	_	_	O

167	Outcomes	_	_	O
168	were	_	_	O
169	compared	_	_	O
170	between	_	_	O
171	groups	_	_	O
172	using	_	_	O
173	analysis	_	_	O
174	of	_	_	O
175	covariance	_	_	O
176	adjusted	_	_	O
177	for	_	_	O
178	baseline	_	_	O
179	values	_	_	O
180	.	_	_	O

181	Participants	_	_	O
182	had	_	_	O
183	significant	_	_	O
184	disease	_	_	O
185	load	_	_	O
186	with	_	_	O
187	65	_	_	O
188	%	_	_	O
189	of	_	_	O
190	participants	_	_	O
191	presenting	_	_	O
192	with	_	_	O
193	two	_	_	O
194	or	_	_	O
195	more	_	_	O
196	regions	_	_	O
197	affected	_	_	O
198	by	_	_	O
199	bone	_	_	O
200	metastases	_	_	O
201	and	_	_	O
202	an	_	_	O
203	average	_	_	O
204	Gleason	_	_	O
205	score	_	_	O
206	of	_	_	O
207	8	_	_	O
208	.	_	_	O

209	2	_	_	O
210	±	_	_	O
211	0	_	_	O
212	.	_	_	O

213	9	_	_	O
214	.	_	_	O

215	Five	_	_	O
216	participants	_	_	O
217	(	_	_	O
218	exercise	_	_	O
219	=	_	_	O
220	2	_	_	O
221	;	_	_	O
222	usual	_	_	O
223	care	_	_	O
224	=	_	_	O
225	3	_	_	O
226	)	_	_	O
227	did	_	_	O
228	not	_	_	O
229	complete	_	_	O
230	the	_	_	O
231	intervention	_	_	O
232	,	_	_	O
233	three	_	_	O
234	of	_	_	O
235	which	_	_	O
236	were	_	_	O
237	due	_	_	O
238	to	_	_	O
239	advancing	_	_	O
240	disease	_	_	O
241	(	_	_	O
242	exercise	_	_	O
243	=	_	_	O
244	2	_	_	O
245	;	_	_	O
246	usual	_	_	O
247	care	_	_	O
248	=	_	_	O
249	1	_	_	O
250	)	_	_	O
251	.	_	_	O

252	No	_	_	B-Premise
253	adverse	_	_	I-Premise
254	events	_	_	I-Premise
255	or	_	_	I-Premise
256	skeletal	_	_	I-Premise
257	complications	_	_	I-Premise
258	occurred	_	_	I-Premise
259	during	_	_	I-Premise
260	the	_	_	I-Premise
261	supervised	_	_	I-Premise
262	exercise	_	_	I-Premise
263	sessions	_	_	I-Premise
264	.	_	_	I-Premise

265	The	_	_	B-Premise
266	exercise	_	_	I-Premise
267	program	_	_	I-Premise
268	was	_	_	I-Premise
269	well	_	_	I-Premise
270	tolerated	_	_	I-Premise
271	as	_	_	I-Premise
272	evidenced	_	_	I-Premise
273	by	_	_	I-Premise
274	high	_	_	I-Premise
275	attendance	_	_	I-Premise
276	(	_	_	I-Premise
277	83	_	_	I-Premise
278	%	_	_	I-Premise
279	)	_	_	I-Premise
280	and	_	_	I-Premise
281	compliance	_	_	I-Premise
282	rates	_	_	I-Premise
283	(	_	_	I-Premise
284	93	_	_	I-Premise
285	%	_	_	I-Premise
286	)	_	_	I-Premise
287	,	_	_	I-Premise
288	and	_	_	I-Premise
289	the	_	_	I-Premise
290	ability	_	_	I-Premise
291	of	_	_	I-Premise
292	the	_	_	I-Premise
293	participants	_	_	I-Premise
294	to	_	_	I-Premise
295	exercise	_	_	I-Premise
296	at	_	_	I-Premise
297	an	_	_	I-Premise
298	intensity	_	_	I-Premise
299	within	_	_	I-Premise
300	the	_	_	I-Premise
301	target	_	_	I-Premise
302	range	_	_	I-Premise
303	for	_	_	I-Premise
304	cancer	_	_	I-Premise
305	survivors	_	_	I-Premise
306	(	_	_	I-Premise
307	rating	_	_	I-Premise
308	of	_	_	I-Premise
309	perceived	_	_	I-Premise
310	exertion	_	_	I-Premise
311	=	_	_	I-Premise
312	13	_	_	I-Premise
313	.	_	_	I-Premise

314	8	_	_	I-Premise
315	±	_	_	I-Premise
316	1	_	_	I-Premise
317	.	_	_	I-Premise

318	5	_	_	I-Premise
319	)	_	_	I-Premise
320	.	_	_	I-Premise

321	The	_	_	B-Premise
322	change	_	_	I-Premise
323	in	_	_	I-Premise
324	physical	_	_	I-Premise
325	function	_	_	I-Premise
326	(	_	_	I-Premise
327	muscle	_	_	I-Premise
328	strength	_	_	I-Premise
329	∼	_	_	I-Premise
330	11	_	_	I-Premise
331	%	_	_	I-Premise
332	;	_	_	I-Premise
333	submaximal	_	_	I-Premise
334	aerobic	_	_	I-Premise
335	exercise	_	_	I-Premise
336	capacity	_	_	I-Premise
337	∼	_	_	I-Premise
338	5	_	_	I-Premise
339	%	_	_	I-Premise
340	and	_	_	I-Premise
341	ambulation	_	_	I-Premise
342	∼	_	_	I-Premise
343	12	_	_	I-Premise
344	%	_	_	I-Premise
345	)	_	_	I-Premise
346	,	_	_	I-Premise
347	physical	_	_	I-Premise
348	activity	_	_	I-Premise
349	level	_	_	I-Premise
350	(	_	_	I-Premise
351	∼	_	_	I-Premise
352	24	_	_	I-Premise
353	%	_	_	I-Premise
354	)	_	_	I-Premise
355	and	_	_	I-Premise
356	lean	_	_	I-Premise
357	mass	_	_	I-Premise
358	(	_	_	I-Premise
359	∼	_	_	I-Premise
360	3	_	_	I-Premise
361	%	_	_	I-Premise
362	)	_	_	I-Premise
363	differed	_	_	I-Premise
364	significantly	_	_	I-Premise
365	between	_	_	I-Premise
366	groups	_	_	I-Premise
367	following	_	_	I-Premise
368	the	_	_	I-Premise
369	intervention	_	_	I-Premise
370	,	_	_	I-Premise
371	with	_	_	I-Premise
372	favorable	_	_	I-Premise
373	changes	_	_	I-Premise
374	in	_	_	I-Premise
375	the	_	_	I-Premise
376	exercise	_	_	I-Premise
377	group	_	_	I-Premise
378	compared	_	_	I-Premise
379	with	_	_	I-Premise
380	the	_	_	I-Premise
381	usual	_	_	I-Premise
382	care	_	_	I-Premise
383	group	_	_	I-Premise
384	.	_	_	I-Premise

385	No	_	_	B-Premise
386	significant	_	_	I-Premise
387	between	_	_	I-Premise
388	-	_	_	I-Premise
389	group	_	_	I-Premise
390	differences	_	_	I-Premise
391	were	_	_	I-Premise
392	observed	_	_	I-Premise
393	for	_	_	I-Premise
394	fatigue	_	_	I-Premise
395	,	_	_	I-Premise
396	quality	_	_	I-Premise
397	of	_	_	I-Premise
398	life	_	_	I-Premise
399	or	_	_	I-Premise
400	psychological	_	_	I-Premise
401	distress	_	_	I-Premise
402	.	_	_	I-Premise

403	This	_	_	B-Claim
404	initial	_	_	I-Claim
405	evidence	_	_	I-Claim
406	involving	_	_	I-Claim
407	a	_	_	I-Claim
408	small	_	_	I-Claim
409	sample	_	_	I-Claim
410	size	_	_	I-Claim
411	suggests	_	_	I-Claim
412	that	_	_	I-Claim
413	appropriately	_	_	I-Claim
414	designed	_	_	I-Claim
415	and	_	_	I-Claim
416	supervised	_	_	I-Claim
417	resistance	_	_	I-Claim
418	exercise	_	_	I-Claim
419	may	_	_	I-Claim
420	be	_	_	I-Claim
421	safe	_	_	I-Claim
422	and	_	_	I-Claim
423	well	_	_	I-Claim
424	tolerated	_	_	I-Claim
425	by	_	_	I-Claim
426	prostate	_	_	I-Claim
427	cancer	_	_	I-Claim
428	patients	_	_	I-Claim
429	with	_	_	I-Claim
430	bone	_	_	I-Claim
431	metastatic	_	_	I-Claim
432	disease	_	_	I-Claim
433	and	_	_	I-Claim
434	can	_	_	I-Claim
435	lead	_	_	I-Claim
436	to	_	_	I-Claim
437	improvements	_	_	I-Claim
438	in	_	_	I-Claim
439	physical	_	_	I-Claim
440	function	_	_	I-Claim
441	,	_	_	I-Claim
442	physical	_	_	I-Claim
443	activity	_	_	I-Claim
444	levels	_	_	I-Claim
445	and	_	_	I-Claim
446	lean	_	_	I-Claim
447	mass	_	_	I-Claim
448	.	_	_	I-Claim

449	Future	_	_	B-Claim
450	trials	_	_	I-Claim
451	involving	_	_	I-Claim
452	larger	_	_	I-Claim
453	sample	_	_	I-Claim
454	sizes	_	_	I-Claim
455	are	_	_	I-Claim
456	required	_	_	I-Claim
457	to	_	_	I-Claim
458	expand	_	_	I-Claim
459	these	_	_	I-Claim
460	preliminary	_	_	I-Claim
461	findings	_	_	I-Claim
462	.	_	_	I-Claim


0	We	_	_	O
1	conducted	_	_	O
2	a	_	_	O
3	multicenter	_	_	O
4	,	_	_	O
5	randomized	_	_	O
6	trial	_	_	O
7	to	_	_	O
8	compare	_	_	O
9	progression	_	_	O
10	-	_	_	O
11	free	_	_	O
12	survival	_	_	O
13	(	_	_	O
14	PFS	_	_	O
15	)	_	_	O
16	,	_	_	O
17	overall	_	_	O
18	survival	_	_	O
19	(	_	_	O
20	OS	_	_	O
21	)	_	_	O
22	,	_	_	O
23	and	_	_	O
24	quality	_	_	O
25	of	_	_	O
26	life	_	_	O
27	in	_	_	O
28	women	_	_	O
29	with	_	_	O
30	metastatic	_	_	O
31	breast	_	_	O
32	cancer	_	_	O
33	(	_	_	O
34	MBC	_	_	O
35	)	_	_	O
36	receiving	_	_	O
37	high	_	_	O
38	-	_	_	O
39	dose	_	_	O
40	chemotherapy	_	_	O
41	plus	_	_	O
42	autologous	_	_	O
43	stem	_	_	O
44	-	_	_	O
45	cell	_	_	O
46	transplantation	_	_	O
47	(	_	_	O
48	ASCT	_	_	O
49	;	_	_	O
50	HDCT	_	_	O
51	)	_	_	O
52	compared	_	_	O
53	with	_	_	O
54	standard	_	_	O
55	-	_	_	O
56	dose	_	_	O
57	therapy	_	_	O
58	.	_	_	O

59	Between	_	_	O
60	April	_	_	O
61	1997	_	_	O
62	and	_	_	O
63	December	_	_	O
64	2000	_	_	O
65	,	_	_	O
66	386	_	_	O
67	women	_	_	O
68	with	_	_	O
69	MBC	_	_	O
70	and	_	_	O
71	no	_	_	O
72	prior	_	_	O
73	chemotherapy	_	_	O
74	for	_	_	O
75	metastatic	_	_	O
76	disease	_	_	O
77	were	_	_	O
78	registered	_	_	O
79	.	_	_	O

80	After	_	_	O
81	initial	_	_	O
82	response	_	_	O
83	to	_	_	O
84	anthracycline	_	_	O
85	-	_	_	O
86	or	_	_	O
87	taxane	_	_	O
88	-	_	_	O
89	based	_	_	O
90	induction	_	_	O
91	chemotherapy	_	_	O
92	,	_	_	O
93	224	_	_	O
94	patients	_	_	O
95	were	_	_	O
96	randomly	_	_	O
97	assigned	_	_	O
98	:	_	_	O
99	112	_	_	O
100	to	_	_	O
101	high	_	_	O
102	-	_	_	O
103	dose	_	_	O
104	cyclophosphamide	_	_	O
105	,	_	_	O
106	mitoxantrone	_	_	O
107	,	_	_	O
108	and	_	_	O
109	carboplatin	_	_	O
110	chemotherapy	_	_	O
111	and	_	_	O
112	ASCT	_	_	O
113	(	_	_	O
114	HDCT	_	_	O
115	)	_	_	O
116	,	_	_	O
117	and	_	_	O
118	112	_	_	O
119	to	_	_	O
120	standard	_	_	O
121	therapy	_	_	O
122	(	_	_	O
123	ST	_	_	O
124	)	_	_	O
125	.	_	_	O

126	Median	_	_	O
127	age	_	_	O
128	was	_	_	O
129	47	_	_	O
130	years	_	_	O
131	(	_	_	O
132	range	_	_	O
133	,	_	_	O
134	25	_	_	O
135	to	_	_	O
136	67	_	_	O
137	years	_	_	O
138	)	_	_	O
139	.	_	_	O

140	Thirty	_	_	O
141	two	_	_	O
142	percent	_	_	O
143	of	_	_	O
144	women	_	_	O
145	randomly	_	_	O
146	assigned	_	_	O
147	had	_	_	O
148	estrogen	_	_	O
149	and	_	_	O
150	progesterone	_	_	O
151	receptor	_	_	O
152	-	_	_	O
153	negative	_	_	O
154	breast	_	_	O
155	cancer	_	_	O
156	,	_	_	O
157	42	_	_	O
158	%	_	_	O
159	had	_	_	O
160	visceral	_	_	O
161	metastases	_	_	O
162	,	_	_	O
163	and	_	_	O
164	58	_	_	O
165	%	_	_	O
166	had	_	_	O
167	bone	_	_	O
168	metastases	_	_	O
169	.	_	_	O

170	Complete	_	_	O
171	remission	_	_	O
172	rates	_	_	O
173	before	_	_	O
174	random	_	_	O
175	assignment	_	_	O
176	were	_	_	O
177	11	_	_	O
178	%	_	_	O
179	for	_	_	O
180	those	_	_	O
181	receiving	_	_	O
182	HDCT	_	_	O
183	and	_	_	O
184	12	_	_	O
185	%	_	_	O
186	for	_	_	O
187	those	_	_	O
188	receiving	_	_	O
189	ST	_	_	O
190	.	_	_	O

191	After	_	_	B-Premise
192	a	_	_	I-Premise
193	median	_	_	I-Premise
194	follow	_	_	I-Premise
195	-	_	_	I-Premise
196	up	_	_	I-Premise
197	of	_	_	I-Premise
198	48	_	_	I-Premise
199	months	_	_	I-Premise
200	,	_	_	I-Premise
201	79	_	_	I-Premise
202	deaths	_	_	I-Premise
203	were	_	_	I-Premise
204	observed	_	_	I-Premise
205	in	_	_	I-Premise
206	the	_	_	I-Premise
207	HDCT	_	_	I-Premise
208	arm	_	_	I-Premise
209	and	_	_	I-Premise
210	77	_	_	I-Premise
211	deaths	_	_	I-Premise
212	were	_	_	I-Premise
213	observed	_	_	I-Premise
214	in	_	_	I-Premise
215	the	_	_	I-Premise
216	ST	_	_	I-Premise
217	arm	_	_	I-Premise
218	;	_	_	I-Premise
219	seven	_	_	B-Premise
220	patients	_	_	I-Premise
221	(	_	_	I-Premise
222	6	_	_	I-Premise
223	%	_	_	I-Premise
224	)	_	_	I-Premise
225	in	_	_	I-Premise
226	the	_	_	I-Premise
227	HDCT	_	_	I-Premise
228	arm	_	_	I-Premise
229	died	_	_	I-Premise
230	as	_	_	I-Premise
231	a	_	_	I-Premise
232	result	_	_	I-Premise
233	of	_	_	I-Premise
234	toxicity	_	_	I-Premise
235	.	_	_	I-Premise

236	The	_	_	B-Premise
237	median	_	_	I-Premise
238	OS	_	_	I-Premise
239	was	_	_	I-Premise
240	24	_	_	I-Premise
241	months	_	_	I-Premise
242	for	_	_	I-Premise
243	the	_	_	I-Premise
244	HDCT	_	_	I-Premise
245	arm	_	_	I-Premise
246	(	_	_	I-Premise
247	95	_	_	I-Premise
248	%	_	_	I-Premise
249	CI	_	_	I-Premise
250	,	_	_	I-Premise
251	21	_	_	I-Premise
252	to	_	_	I-Premise
253	35	_	_	I-Premise
254	months	_	_	I-Premise
255	)	_	_	I-Premise
256	and	_	_	I-Premise
257	28	_	_	I-Premise
258	months	_	_	I-Premise
259	for	_	_	I-Premise
260	ST	_	_	I-Premise
261	(	_	_	I-Premise
262	95	_	_	I-Premise
263	%	_	_	I-Premise
264	CI	_	_	I-Premise
265	,	_	_	I-Premise
266	22	_	_	I-Premise
267	to	_	_	I-Premise
268	33	_	_	I-Premise
269	months	_	_	I-Premise
270	;	_	_	I-Premise
271	hazard	_	_	I-Premise
272	ratio	_	_	I-Premise
273	[	_	_	I-Premise
274	HR	_	_	I-Premise
275	]	_	_	I-Premise
276	,	_	_	I-Premise
277	0	_	_	I-Premise
278	.	_	_	I-Premise

279	9	_	_	I-Premise
280	;	_	_	I-Premise
281	95	_	_	I-Premise
282	%	_	_	I-Premise
283	CI	_	_	I-Premise
284	,	_	_	I-Premise
285	0	_	_	I-Premise
286	.	_	_	I-Premise

287	6	_	_	I-Premise
288	to	_	_	I-Premise
289	1	_	_	I-Premise
290	.	_	_	I-Premise

291	2	_	_	I-Premise
292	;	_	_	I-Premise
293	P	_	_	I-Premise
294	=	_	_	I-Premise
295	.	_	_	I-Premise

296	43	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	PFS	_	_	B-Premise
300	was	_	_	I-Premise
301	11	_	_	I-Premise
302	months	_	_	I-Premise
303	for	_	_	I-Premise
304	HDCT	_	_	I-Premise
305	and	_	_	I-Premise
306	9	_	_	I-Premise
307	months	_	_	I-Premise
308	for	_	_	I-Premise
309	ST	_	_	I-Premise
310	(	_	_	I-Premise
311	HR	_	_	I-Premise
312	,	_	_	I-Premise
313	0	_	_	I-Premise
314	.	_	_	I-Premise

315	6	_	_	I-Premise
316	in	_	_	I-Premise
317	favor	_	_	I-Premise
318	of	_	_	I-Premise
319	HDCT	_	_	I-Premise
320	;	_	_	I-Premise
321	95	_	_	I-Premise
322	%	_	_	I-Premise
323	CI	_	_	I-Premise
324	,	_	_	I-Premise
325	0	_	_	I-Premise
326	.	_	_	I-Premise

327	5	_	_	I-Premise
328	to	_	_	I-Premise
329	0	_	_	I-Premise
330	.	_	_	I-Premise

331	9	_	_	I-Premise
332	;	_	_	I-Premise
333	P	_	_	I-Premise
334	=	_	_	I-Premise
335	.	_	_	I-Premise

336	006	_	_	I-Premise
337	)	_	_	I-Premise
338	.	_	_	I-Premise

339	HDCT	_	_	B-Claim
340	did	_	_	I-Claim
341	not	_	_	I-Claim
342	improve	_	_	I-Claim
343	OS	_	_	I-Claim
344	in	_	_	I-Claim
345	women	_	_	I-Claim
346	with	_	_	I-Claim
347	MBC	_	_	I-Claim
348	when	_	_	I-Claim
349	used	_	_	I-Claim
350	as	_	_	I-Claim
351	consolidation	_	_	I-Claim
352	after	_	_	I-Claim
353	response	_	_	I-Claim
354	to	_	_	I-Claim
355	induction	_	_	I-Claim
356	chemotherapy	_	_	I-Claim
357	.	_	_	I-Claim


0	Several	_	_	O
1	guidelines	_	_	O
2	on	_	_	O
3	the	_	_	O
4	treatment	_	_	O
5	of	_	_	O
6	cancer	_	_	O
7	-	_	_	O
8	related	_	_	O
9	fatigue	_	_	O
10	recommend	_	_	O
11	optimizing	_	_	O
12	treatment	_	_	O
13	of	_	_	O
14	accompanying	_	_	O
15	symptoms	_	_	O
16	.	_	_	O

17	However	_	_	O
18	,	_	_	O
19	evidence	_	_	O
20	for	_	_	O
21	this	_	_	O
22	recommendation	_	_	O
23	from	_	_	O
24	randomized	_	_	O
25	clinical	_	_	O
26	trials	_	_	O
27	is	_	_	O
28	lacking	_	_	O
29	.	_	_	O

30	We	_	_	O
31	investigated	_	_	O
32	whether	_	_	O
33	monitoring	_	_	O
34	and	_	_	O
35	protocolized	_	_	O
36	treatment	_	_	O
37	of	_	_	O
38	physical	_	_	O
39	symptoms	_	_	O
40	alleviates	_	_	O
41	fatigue	_	_	O
42	.	_	_	O

43	In	_	_	O
44	all	_	_	O
45	,	_	_	O
46	152	_	_	O
47	fatigued	_	_	O
48	patients	_	_	O
49	with	_	_	O
50	advanced	_	_	O
51	cancer	_	_	O
52	were	_	_	O
53	randomly	_	_	O
54	assigned	_	_	O
55	to	_	_	O
56	protocolized	_	_	O
57	patient	_	_	O
58	-	_	_	O
59	tailored	_	_	O
60	treatment	_	_	O
61	(	_	_	O
62	PPT	_	_	O
63	)	_	_	O
64	of	_	_	O
65	symptoms	_	_	O
66	or	_	_	O
67	care	_	_	O
68	as	_	_	O
69	usual	_	_	O
70	.	_	_	O

71	The	_	_	O
72	PPT	_	_	O
73	group	_	_	O
74	had	_	_	O
75	four	_	_	O
76	appointments	_	_	O
77	with	_	_	O
78	a	_	_	O
79	nurse	_	_	O
80	who	_	_	O
81	assessed	_	_	O
82	nine	_	_	O
83	symptoms	_	_	O
84	on	_	_	O
85	a	_	_	O
86	0	_	_	O
87	to	_	_	O
88	10	_	_	O
89	numeric	_	_	O
90	rating	_	_	O
91	scale	_	_	O
92	(	_	_	O
93	NRS	_	_	O
94	)	_	_	O
95	.	_	_	O

96	Patients	_	_	O
97	received	_	_	O
98	a	_	_	O
99	nonpharmacologic	_	_	O
100	intervention	_	_	O
101	for	_	_	O
102	symptoms	_	_	O
103	with	_	_	O
104	a	_	_	O
105	score	_	_	O
106	≥	_	_	O
107	1	_	_	O
108	and	_	_	O
109	a	_	_	O
110	medical	_	_	O
111	intervention	_	_	O
112	for	_	_	O
113	symptoms	_	_	O
114	with	_	_	O
115	a	_	_	O
116	score	_	_	O
117	≥	_	_	O
118	4	_	_	O
119	.	_	_	O

120	Fatigue	_	_	O
121	dimensions	_	_	O
122	,	_	_	O
123	fatigue	_	_	O
124	NRS	_	_	O
125	score	_	_	O
126	,	_	_	O
127	interference	_	_	O
128	of	_	_	O
129	fatigue	_	_	O
130	with	_	_	O
131	daily	_	_	O
132	life	_	_	O
133	,	_	_	O
134	symptom	_	_	O
135	burden	_	_	O
136	,	_	_	O
137	quality	_	_	O
138	of	_	_	O
139	life	_	_	O
140	,	_	_	O
141	anxiety	_	_	O
142	,	_	_	O
143	and	_	_	O
144	depression	_	_	O
145	were	_	_	O
146	measured	_	_	O
147	at	_	_	O
148	baseline	_	_	O
149	and	_	_	O
150	after	_	_	O
151	1	_	_	O
152	,	_	_	O
153	2	_	_	O
154	,	_	_	O
155	and	_	_	O
156	3	_	_	O
157	months	_	_	O
158	.	_	_	O

159	Differences	_	_	O
160	between	_	_	O
161	the	_	_	O
162	groups	_	_	O
163	over	_	_	O
164	time	_	_	O
165	were	_	_	O
166	assessed	_	_	O
167	by	_	_	O
168	using	_	_	O
169	mixed	_	_	O
170	modeling	_	_	O
171	.	_	_	O

172	Seventy	_	_	O
173	-	_	_	O
174	six	_	_	O
175	patients	_	_	O
176	were	_	_	O
177	randomly	_	_	O
178	assigned	_	_	O
179	to	_	_	O
180	each	_	_	O
181	study	_	_	O
182	arm	_	_	O
183	.	_	_	O

184	Mean	_	_	O
185	age	_	_	O
186	was	_	_	O
187	58	_	_	O
188	±	_	_	O
189	10	_	_	O
190	years	_	_	O
191	,	_	_	O
192	57	_	_	O
193	%	_	_	O
194	were	_	_	O
195	female	_	_	O
196	,	_	_	O
197	and	_	_	O
198	65	_	_	O
199	%	_	_	O
200	were	_	_	O
201	given	_	_	O
202	palliative	_	_	O
203	chemotherapy	_	_	O
204	.	_	_	O

205	We	_	_	B-Premise
206	found	_	_	I-Premise
207	significant	_	_	I-Premise
208	improvements	_	_	I-Premise
209	over	_	_	I-Premise
210	time	_	_	I-Premise
211	in	_	_	I-Premise
212	favor	_	_	I-Premise
213	of	_	_	I-Premise
214	PPT	_	_	I-Premise
215	for	_	_	I-Premise
216	the	_	_	I-Premise
217	primary	_	_	I-Premise
218	outcome	_	_	I-Premise
219	general	_	_	I-Premise
220	fatigue	_	_	I-Premise
221	(	_	_	I-Premise
222	P	_	_	I-Premise
223	=	_	_	I-Premise
224	.	_	_	I-Premise

225	01	_	_	I-Premise
226	)	_	_	I-Premise
227	,	_	_	I-Premise
228	with	_	_	I-Premise
229	significant	_	_	I-Premise
230	group	_	_	I-Premise
231	differences	_	_	I-Premise
232	at	_	_	I-Premise
233	month	_	_	I-Premise
234	1	_	_	I-Premise
235	(	_	_	I-Premise
236	effect	_	_	I-Premise
237	size	_	_	I-Premise
238	,	_	_	I-Premise
239	0	_	_	I-Premise
240	.	_	_	I-Premise

241	26	_	_	I-Premise
242	;	_	_	I-Premise
243	P	_	_	I-Premise
244	=	_	_	I-Premise
245	.	_	_	I-Premise

246	007	_	_	I-Premise
247	)	_	_	I-Premise
248	and	_	_	I-Premise
249	month	_	_	I-Premise
250	2	_	_	I-Premise
251	(	_	_	I-Premise
252	effect	_	_	I-Premise
253	size	_	_	I-Premise
254	,	_	_	I-Premise
255	0	_	_	I-Premise
256	.	_	_	I-Premise

257	35	_	_	I-Premise
258	;	_	_	I-Premise
259	P	_	_	I-Premise
260	=	_	_	I-Premise
261	.	_	_	I-Premise

262	005	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	Improvements	_	_	B-Premise
266	in	_	_	I-Premise
267	favor	_	_	I-Premise
268	of	_	_	I-Premise
269	PPT	_	_	I-Premise
270	were	_	_	I-Premise
271	also	_	_	I-Premise
272	found	_	_	I-Premise
273	for	_	_	I-Premise
274	the	_	_	I-Premise
275	following	_	_	I-Premise
276	secondary	_	_	I-Premise
277	outcomes	_	_	I-Premise
278	:	_	_	I-Premise
279	fatigue	_	_	I-Premise
280	dimensions	_	_	I-Premise
281	"	_	_	I-Premise
282	reduced	_	_	I-Premise
283	activity	_	_	I-Premise
284	"	_	_	I-Premise
285	and	_	_	I-Premise
286	"	_	_	I-Premise
287	reduced	_	_	I-Premise
288	motivation	_	_	I-Premise
289	,	_	_	I-Premise
290	"	_	_	I-Premise
291	fatigue	_	_	I-Premise
292	NRS	_	_	I-Premise
293	,	_	_	I-Premise
294	symptom	_	_	I-Premise
295	burden	_	_	I-Premise
296	,	_	_	I-Premise
297	interference	_	_	I-Premise
298	of	_	_	I-Premise
299	fatigue	_	_	I-Premise
300	with	_	_	I-Premise
301	daily	_	_	I-Premise
302	life	_	_	I-Premise
303	,	_	_	I-Premise
304	and	_	_	I-Premise
305	anxiety	_	_	I-Premise
306	(	_	_	I-Premise
307	all	_	_	I-Premise
308	P	_	_	I-Premise
309	≤	_	_	I-Premise
310	.	_	_	I-Premise

311	03	_	_	I-Premise
312	)	_	_	I-Premise
313	.	_	_	I-Premise

314	In	_	_	B-Claim
315	fatigued	_	_	I-Claim
316	patients	_	_	I-Claim
317	with	_	_	I-Claim
318	advanced	_	_	I-Claim
319	cancer	_	_	I-Claim
320	,	_	_	I-Claim
321	nurse	_	_	I-Claim
322	-	_	_	I-Claim
323	led	_	_	I-Claim
324	monitoring	_	_	I-Claim
325	and	_	_	I-Claim
326	protocolized	_	_	I-Claim
327	treatment	_	_	I-Claim
328	of	_	_	I-Claim
329	physical	_	_	I-Claim
330	symptoms	_	_	I-Claim
331	is	_	_	I-Claim
332	effective	_	_	I-Claim
333	in	_	_	I-Claim
334	alleviating	_	_	I-Claim
335	fatigue	_	_	I-Claim
336	.	_	_	I-Claim


0	To	_	_	O
1	analyze	_	_	O
2	the	_	_	O
3	prospectively	_	_	O
4	collected	_	_	O
5	health	_	_	O
6	-	_	_	O
7	related	_	_	O
8	quality	_	_	O
9	-	_	_	O
10	of	_	_	O
11	-	_	_	O
12	life	_	_	O
13	(	_	_	O
14	HRQOL	_	_	O
15	)	_	_	O
16	data	_	_	O
17	from	_	_	O
18	patients	_	_	O
19	enrolled	_	_	O
20	in	_	_	O
21	two	_	_	O
22	Radiation	_	_	O
23	Therapy	_	_	O
24	Oncology	_	_	O
25	Group	_	_	O
26	randomized	_	_	O
27	Phase	_	_	O
28	III	_	_	O
29	head	_	_	O
30	and	_	_	O
31	neck	_	_	O
32	cancer	_	_	O
33	trials	_	_	O
34	(	_	_	O
35	90	_	_	O
36	-	_	_	O
37	03	_	_	O
38	and	_	_	O
39	91	_	_	O
40	-	_	_	O
41	11	_	_	O
42	)	_	_	O
43	to	_	_	O
44	assess	_	_	O
45	their	_	_	O
46	value	_	_	O
47	as	_	_	O
48	an	_	_	O
49	independent	_	_	O
50	prognostic	_	_	O
51	factor	_	_	O
52	for	_	_	O
53	locoregional	_	_	O
54	control	_	_	O
55	(	_	_	O
56	LRC	_	_	O
57	)	_	_	O
58	and	_	_	O
59	/	_	_	O
60	or	_	_	O
61	overall	_	_	O
62	survival	_	_	O
63	(	_	_	O
64	OS	_	_	O
65	)	_	_	O
66	.	_	_	O

67	HRQOL	_	_	O
68	questionnaires	_	_	O
69	,	_	_	O
70	using	_	_	O
71	a	_	_	O
72	validated	_	_	O
73	instrument	_	_	O
74	,	_	_	O
75	the	_	_	O
76	Functional	_	_	O
77	Assessment	_	_	O
78	of	_	_	O
79	Cancer	_	_	O
80	Therapy	_	_	O
81	-	_	_	O
82	Head	_	_	O
83	and	_	_	O
84	Neck	_	_	O
85	(	_	_	O
86	FACT	_	_	O
87	-	_	_	O
88	H	_	_	O
89	&	_	_	O
90	amp	_	_	O
91	;	_	_	O
92	N	_	_	O
93	)	_	_	O
94	,	_	_	O
95	version	_	_	O
96	2	_	_	O
97	,	_	_	O
98	were	_	_	O
99	completed	_	_	O
100	by	_	_	O
101	patients	_	_	O
102	before	_	_	O
103	the	_	_	O
104	start	_	_	O
105	of	_	_	O
106	treatment	_	_	O
107	.	_	_	O

108	OS	_	_	O
109	and	_	_	O
110	LRC	_	_	O
111	were	_	_	O
112	the	_	_	O
113	outcome	_	_	O
114	measures	_	_	O
115	analyzed	_	_	O
116	using	_	_	O
117	a	_	_	O
118	multivariate	_	_	O
119	Cox	_	_	O
120	proportional	_	_	O
121	hazard	_	_	O
122	model	_	_	O
123	.	_	_	O

124	Baseline	_	_	O
125	FACT	_	_	O
126	-	_	_	O
127	H	_	_	O
128	&	_	_	O
129	amp	_	_	O
130	;	_	_	O
131	N	_	_	O
132	data	_	_	O
133	were	_	_	O
134	available	_	_	O
135	for	_	_	O
136	1	_	_	O
137	,	_	_	O
138	093	_	_	O
139	patients	_	_	O
140	and	_	_	O
141	missing	_	_	O
142	for	_	_	O
143	417	_	_	O
144	patients	_	_	O
145	.	_	_	O

146	No	_	_	O
147	significant	_	_	O
148	difference	_	_	O
149	in	_	_	O
150	outcome	_	_	O
151	was	_	_	O
152	found	_	_	O
153	between	_	_	O
154	the	_	_	O
155	patients	_	_	O
156	with	_	_	O
157	and	_	_	O
158	without	_	_	O
159	baseline	_	_	O
160	FACT	_	_	O
161	-	_	_	O
162	H	_	_	O
163	&	_	_	O
164	amp	_	_	O
165	;	_	_	O
166	N	_	_	O
167	data	_	_	O
168	(	_	_	O
169	p	_	_	O
170	=	_	_	O
171	0	_	_	O
172	.	_	_	O

173	58	_	_	O
174	)	_	_	O
175	.	_	_	O

176	The	_	_	O
177	median	_	_	O
178	follow	_	_	O
179	-	_	_	O
180	up	_	_	O
181	time	_	_	O
182	was	_	_	O
183	27	_	_	O
184	.	_	_	O

185	2	_	_	O
186	months	_	_	O
187	for	_	_	O
188	all	_	_	O
189	patients	_	_	O
190	and	_	_	O
191	49	_	_	O
192	months	_	_	O
193	for	_	_	O
194	surviving	_	_	O
195	patients	_	_	O
196	.	_	_	O

197	Multivariate	_	_	O
198	analyses	_	_	O
199	were	_	_	O
200	performed	_	_	O
201	for	_	_	O
202	both	_	_	O
203	OS	_	_	O
204	and	_	_	O
205	LRC	_	_	O
206	.	_	_	O

207	Beyond	_	_	B-Premise
208	tumor	_	_	I-Premise
209	and	_	_	I-Premise
210	nodal	_	_	I-Premise
211	stage	_	_	I-Premise
212	,	_	_	I-Premise
213	Karnofsky	_	_	I-Premise
214	performance	_	_	I-Premise
215	status	_	_	I-Premise
216	,	_	_	I-Premise
217	primary	_	_	I-Premise
218	site	_	_	I-Premise
219	,	_	_	I-Premise
220	cigarette	_	_	I-Premise
221	use	_	_	I-Premise
222	,	_	_	I-Premise
223	use	_	_	I-Premise
224	of	_	_	I-Premise
225	concurrent	_	_	I-Premise
226	chemotherapy	_	_	I-Premise
227	,	_	_	I-Premise
228	and	_	_	I-Premise
229	altered	_	_	I-Premise
230	fractionation	_	_	I-Premise
231	schedules	_	_	I-Premise
232	,	_	_	I-Premise
233	the	_	_	I-Premise
234	FACT	_	_	I-Premise
235	-	_	_	I-Premise
236	H	_	_	I-Premise
237	&	_	_	I-Premise
238	amp	_	_	I-Premise
239	;	_	_	I-Premise
240	N	_	_	I-Premise
241	score	_	_	I-Premise
242	was	_	_	I-Premise
243	independently	_	_	I-Premise
244	predictive	_	_	I-Premise
245	of	_	_	I-Premise
246	LRC	_	_	I-Premise
247	(	_	_	I-Premise
248	but	_	_	I-Premise
249	not	_	_	I-Premise
250	OS	_	_	I-Premise
251	)	_	_	I-Premise
252	,	_	_	I-Premise
253	with	_	_	I-Premise
254	p	_	_	I-Premise
255	=	_	_	I-Premise
256	0	_	_	I-Premise
257	.	_	_	I-Premise

258	0038	_	_	I-Premise
259	.	_	_	I-Premise

260	The	_	_	B-Premise
261	functional	_	_	I-Premise
262	well	_	_	I-Premise
263	-	_	_	I-Premise
264	being	_	_	I-Premise
265	component	_	_	I-Premise
266	of	_	_	I-Premise
267	the	_	_	I-Premise
268	FACT	_	_	I-Premise
269	-	_	_	I-Premise
270	H	_	_	I-Premise
271	&	_	_	I-Premise
272	amp	_	_	I-Premise
273	;	_	_	I-Premise
274	N	_	_	I-Premise
275	predicted	_	_	I-Premise
276	most	_	_	I-Premise
277	significantly	_	_	I-Premise
278	for	_	_	I-Premise
279	LRC	_	_	I-Premise
280	(	_	_	I-Premise
281	p	_	_	I-Premise
282	=	_	_	I-Premise
283	0	_	_	I-Premise
284	.	_	_	I-Premise

285	0004	_	_	I-Premise
286	)	_	_	I-Premise
287	.	_	_	I-Premise

288	This	_	_	B-Claim
289	study	_	_	I-Claim
290	represents	_	_	I-Claim
291	,	_	_	I-Claim
292	to	_	_	I-Claim
293	our	_	_	I-Claim
294	knowledge	_	_	I-Claim
295	,	_	_	I-Claim
296	the	_	_	I-Claim
297	largest	_	_	I-Claim
298	analysis	_	_	I-Claim
299	of	_	_	I-Claim
300	HRQOL	_	_	I-Claim
301	as	_	_	I-Claim
302	a	_	_	I-Claim
303	prognostic	_	_	I-Claim
304	factor	_	_	I-Claim
305	in	_	_	I-Claim
306	locally	_	_	I-Claim
307	advanced	_	_	I-Claim
308	head	_	_	I-Claim
309	and	_	_	I-Claim
310	neck	_	_	I-Claim
311	cancer	_	_	I-Claim
312	patients	_	_	I-Claim
313	.	_	_	I-Claim

314	The	_	_	B-Claim
315	results	_	_	I-Claim
316	of	_	_	I-Claim
317	this	_	_	I-Claim
318	study	_	_	I-Claim
319	have	_	_	I-Claim
320	demonstrated	_	_	I-Claim
321	the	_	_	I-Claim
322	importance	_	_	I-Claim
323	of	_	_	I-Claim
324	baseline	_	_	I-Claim
325	HRQOL	_	_	I-Claim
326	as	_	_	I-Claim
327	a	_	_	I-Claim
328	significant	_	_	I-Claim
329	and	_	_	I-Claim
330	independent	_	_	I-Claim
331	predictor	_	_	I-Claim
332	of	_	_	I-Claim
333	LRC	_	_	I-Claim
334	in	_	_	I-Claim
335	patients	_	_	I-Claim
336	with	_	_	I-Claim
337	locally	_	_	I-Claim
338	advanced	_	_	I-Claim
339	head	_	_	I-Claim
340	and	_	_	I-Claim
341	neck	_	_	I-Claim
342	cancer	_	_	I-Claim
343	.	_	_	I-Claim


0	Sexual	_	_	O
1	dysfunction	_	_	O
2	represents	_	_	O
3	a	_	_	O
4	complex	_	_	O
5	and	_	_	O
6	multifactorial	_	_	O
7	construct	_	_	O
8	that	_	_	O
9	can	_	_	O
10	affect	_	_	O
11	both	_	_	O
12	men	_	_	O
13	and	_	_	O
14	women	_	_	O
15	and	_	_	O
16	has	_	_	O
17	been	_	_	O
18	noted	_	_	O
19	to	_	_	O
20	often	_	_	O
21	deteriorate	_	_	O
22	significantly	_	_	O
23	after	_	_	O
24	treatment	_	_	O
25	for	_	_	O
26	rectal	_	_	O
27	and	_	_	O
28	anal	_	_	O
29	cancer	_	_	O
30	.	_	_	O

31	Despite	_	_	O
32	this	_	_	O
33	,	_	_	O
34	it	_	_	O
35	remains	_	_	O
36	an	_	_	O
37	understudied	_	_	O
38	,	_	_	O
39	underreported	_	_	O
40	,	_	_	O
41	and	_	_	O
42	undertreated	_	_	O
43	issue	_	_	O
44	in	_	_	O
45	the	_	_	O
46	field	_	_	O
47	of	_	_	O
48	cancer	_	_	O
49	survivorship	_	_	O
50	.	_	_	O

51	This	_	_	O
52	study	_	_	O
53	examined	_	_	O
54	the	_	_	O
55	characteristics	_	_	O
56	of	_	_	O
57	women	_	_	O
58	enrolled	_	_	O
59	in	_	_	O
60	an	_	_	O
61	intervention	_	_	O
62	trial	_	_	O
63	to	_	_	O
64	treat	_	_	O
65	sexual	_	_	O
66	dysfunction	_	_	O
67	,	_	_	O
68	and	_	_	O
69	explored	_	_	O
70	the	_	_	O
71	relationship	_	_	O
72	between	_	_	O
73	sexual	_	_	O
74	functioning	_	_	O
75	and	_	_	O
76	psychological	_	_	O
77	well	_	_	O
78	-	_	_	O
79	being	_	_	O
80	.	_	_	O

81	There	_	_	O
82	were	_	_	O
83	70	_	_	O
84	female	_	_	O
85	posttreatment	_	_	O
86	anal	_	_	O
87	or	_	_	O
88	rectal	_	_	O
89	cancer	_	_	O
90	survivors	_	_	O
91	assessed	_	_	O
92	as	_	_	O
93	part	_	_	O
94	of	_	_	O
95	the	_	_	O
96	current	_	_	O
97	study	_	_	O
98	.	_	_	O

99	Participants	_	_	O
100	were	_	_	O
101	enrolled	_	_	O
102	in	_	_	O
103	a	_	_	O
104	randomized	_	_	O
105	intervention	_	_	O
106	trial	_	_	O
107	to	_	_	O
108	treat	_	_	O
109	sexual	_	_	O
110	dysfunction	_	_	O
111	and	_	_	O
112	completed	_	_	O
113	outcome	_	_	O
114	measures	_	_	O
115	prior	_	_	O
116	to	_	_	O
117	randomization	_	_	O
118	.	_	_	O

119	The	_	_	O
120	main	_	_	O
121	outcome	_	_	O
122	measures	_	_	O
123	are	_	_	O
124	quality	_	_	O
125	of	_	_	O
126	life	_	_	O
127	(	_	_	O
128	QOL	_	_	O
129	)	_	_	O
130	(	_	_	O
131	European	_	_	O
132	Organization	_	_	O
133	for	_	_	O
134	Research	_	_	O
135	and	_	_	O
136	Treatment	_	_	O
137	of	_	_	O
138	Cancer	_	_	O
139	Core	_	_	O
140	Quality	_	_	O
141	of	_	_	O
142	Life	_	_	O
143	Questionnaire	_	_	O
144	[	_	_	O
145	EORTC	_	_	O
146	-	_	_	O
147	QLQ	_	_	O
148	-	_	_	O
149	C30	_	_	O
150	]	_	_	O
151	and	_	_	O
152	Colorectal	_	_	O
153	Cancer	_	_	O
154	-	_	_	O
155	Specific	_	_	O
156	Module	_	_	O
157	[	_	_	O
158	QLQ	_	_	O
159	-	_	_	O
160	CR38	_	_	O
161	]	_	_	O
162	)	_	_	O
163	,	_	_	O
164	sexual	_	_	O
165	functioning	_	_	O
166	(	_	_	O
167	Female	_	_	O
168	Sexual	_	_	O
169	Functioning	_	_	O
170	Index	_	_	O
171	)	_	_	O
172	,	_	_	O
173	and	_	_	O
174	psychological	_	_	O
175	well	_	_	O
176	-	_	_	O
177	being	_	_	O
178	(	_	_	O
179	Brief	_	_	O
180	Symptom	_	_	O
181	Inventory	_	_	O
182	Depression	_	_	O
183	/	_	_	O
184	Anxiety	_	_	O
185	,	_	_	O
186	Impact	_	_	O
187	of	_	_	O
188	Events	_	_	O
189	Scale	_	_	O
190	-	_	_	O
191	Revised	_	_	O
192	,	_	_	O
193	CR	_	_	O
194	-	_	_	O
195	38	_	_	O
196	Body	_	_	O
197	Image	_	_	O
198	)	_	_	O
199	.	_	_	O

200	Women	_	_	O
201	enrolled	_	_	O
202	in	_	_	O
203	the	_	_	O
204	study	_	_	O
205	intervention	_	_	O
206	were	_	_	O
207	on	_	_	O
208	average	_	_	O
209	55	_	_	O
210	years	_	_	O
211	old	_	_	O
212	,	_	_	O
213	predominantly	_	_	O
214	Caucasian	_	_	O
215	(	_	_	O
216	79	_	_	O
217	%	_	_	O
218	)	_	_	O
219	,	_	_	O
220	married	_	_	O
221	(	_	_	O
222	57	_	_	O
223	%	_	_	O
224	)	_	_	O
225	,	_	_	O
226	and	_	_	O
227	a	_	_	O
228	median	_	_	O
229	of	_	_	O
230	4	_	_	O
231	years	_	_	O
232	postprimary	_	_	O
233	treatment	_	_	O
234	.	_	_	O

235	For	_	_	O
236	those	_	_	O
237	reporting	_	_	O
238	sexual	_	_	O
239	activity	_	_	O
240	at	_	_	O
241	baseline	_	_	O
242	(	_	_	O
243	N	_	_	O
244	=	_	_	O
245	41	_	_	O
246	)	_	_	O
247	,	_	_	O
248	sexual	_	_	O
249	dysfunction	_	_	O
250	was	_	_	O
251	associated	_	_	O
252	with	_	_	O
253	a	_	_	O
254	range	_	_	O
255	of	_	_	O
256	specific	_	_	O
257	measures	_	_	O
258	of	_	_	O
259	psychological	_	_	O
260	well	_	_	O
261	-	_	_	O
262	being	_	_	O
263	,	_	_	O
264	all	_	_	O
265	in	_	_	O
266	the	_	_	O
267	hypothesized	_	_	O
268	direction	_	_	O
269	.	_	_	O

270	The	_	_	B-Premise
271	Sexual	_	_	I-Premise
272	/	_	_	I-Premise
273	Relationship	_	_	I-Premise
274	Satisfaction	_	_	I-Premise
275	subscale	_	_	I-Premise
276	was	_	_	I-Premise
277	associated	_	_	I-Premise
278	with	_	_	I-Premise
279	all	_	_	I-Premise
280	measures	_	_	I-Premise
281	of	_	_	I-Premise
282	psychological	_	_	I-Premise
283	well	_	_	I-Premise
284	-	_	_	I-Premise
285	being	_	_	I-Premise
286	(	_	_	I-Premise
287	r	_	_	I-Premise
288	=	_	_	I-Premise
289	-	_	_	I-Premise
290	0	_	_	I-Premise
291	.	_	_	I-Premise

292	45	_	_	I-Premise
293	to	_	_	I-Premise
294	-	_	_	I-Premise
295	0	_	_	I-Premise
296	.	_	_	I-Premise

297	70	_	_	I-Premise
298	,	_	_	I-Premise
299	all	_	_	I-Premise
300	P	_	_	I-Premise
301	<	_	_	I-Premise
302	0	_	_	I-Premise
303	.	_	_	I-Premise

304	01	_	_	I-Premise
305	)	_	_	I-Premise
306	.	_	_	I-Premise

307	Body	_	_	B-Premise
308	image	_	_	I-Premise
309	,	_	_	I-Premise
310	anxiety	_	_	I-Premise
311	,	_	_	I-Premise
312	and	_	_	I-Premise
313	cancer	_	_	I-Premise
314	-	_	_	I-Premise
315	specific	_	_	I-Premise
316	posttraumatic	_	_	I-Premise
317	distress	_	_	I-Premise
318	were	_	_	I-Premise
319	notable	_	_	I-Premise
320	in	_	_	I-Premise
321	their	_	_	I-Premise
322	association	_	_	I-Premise
323	with	_	_	I-Premise
324	subscales	_	_	I-Premise
325	of	_	_	I-Premise
326	sexual	_	_	I-Premise
327	functioning	_	_	I-Premise
328	,	_	_	I-Premise
329	while	_	_	I-Premise
330	a	_	_	I-Premise
331	global	_	_	I-Premise
332	QOL	_	_	I-Premise
333	measure	_	_	I-Premise
334	was	_	_	I-Premise
335	largely	_	_	I-Premise
336	unrelated	_	_	I-Premise
337	.	_	_	I-Premise

338	For	_	_	B-Premise
339	sexually	_	_	I-Premise
340	active	_	_	I-Premise
341	female	_	_	I-Premise
342	rectal	_	_	I-Premise
343	and	_	_	I-Premise
344	anal	_	_	I-Premise
345	cancer	_	_	I-Premise
346	survivors	_	_	I-Premise
347	enrolled	_	_	I-Premise
348	in	_	_	I-Premise
349	a	_	_	I-Premise
350	sexual	_	_	I-Premise
351	health	_	_	I-Premise
352	intervention	_	_	I-Premise
353	,	_	_	I-Premise
354	sexual	_	_	I-Premise
355	dysfunction	_	_	I-Premise
356	was	_	_	I-Premise
357	significantly	_	_	I-Premise
358	and	_	_	I-Premise
359	consistently	_	_	I-Premise
360	associated	_	_	I-Premise
361	with	_	_	I-Premise
362	specific	_	_	I-Premise
363	measures	_	_	I-Premise
364	of	_	_	I-Premise
365	psychological	_	_	I-Premise
366	well	_	_	I-Premise
367	-	_	_	I-Premise
368	being	_	_	I-Premise
369	,	_	_	I-Premise
370	most	_	_	I-Premise
371	notably	_	_	I-Premise
372	Sexual	_	_	I-Premise
373	/	_	_	I-Premise
374	Relationship	_	_	I-Premise
375	Satisfaction	_	_	I-Premise
376	.	_	_	I-Premise

377	These	_	_	B-Claim
378	results	_	_	I-Claim
379	suggest	_	_	I-Claim
380	that	_	_	I-Claim
381	sexual	_	_	I-Claim
382	functioning	_	_	I-Claim
383	may	_	_	I-Claim
384	require	_	_	I-Claim
385	focused	_	_	I-Claim
386	assessment	_	_	I-Claim
387	by	_	_	I-Claim
388	providers	_	_	I-Claim
389	,	_	_	I-Claim
390	beyond	_	_	I-Claim
391	broad	_	_	I-Claim
392	QOL	_	_	I-Claim
393	assessments	_	_	I-Claim
394	,	_	_	I-Claim
395	and	_	_	O
396	that	_	_	O
397	attention	_	_	B-Claim
398	to	_	_	I-Claim
399	Sexual	_	_	I-Claim
400	/	_	_	I-Claim
401	Relationship	_	_	I-Claim
402	Satisfaction	_	_	I-Claim
403	may	_	_	I-Claim
404	be	_	_	I-Claim
405	critical	_	_	I-Claim
406	in	_	_	I-Claim
407	the	_	_	I-Claim
408	development	_	_	I-Claim
409	and	_	_	I-Claim
410	implementation	_	_	I-Claim
411	of	_	_	I-Claim
412	interventions	_	_	I-Claim
413	for	_	_	I-Claim
414	this	_	_	I-Claim
415	cohort	_	_	I-Claim
416	of	_	_	I-Claim
417	patients	_	_	I-Claim
418	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	pilot	_	_	O
5	study	_	_	O
6	was	_	_	O
7	to	_	_	O
8	examine	_	_	O
9	the	_	_	O
10	effects	_	_	O
11	of	_	_	O
12	a	_	_	O
13	combined	_	_	O
14	cardiorespiratory	_	_	O
15	and	_	_	O
16	resistance	_	_	O
17	exercise	_	_	O
18	training	_	_	O
19	program	_	_	O
20	of	_	_	O
21	short	_	_	O
22	duration	_	_	O
23	on	_	_	O
24	the	_	_	O
25	cardiorespiratory	_	_	O
26	fitness	_	_	O
27	,	_	_	O
28	strength	_	_	O
29	endurance	_	_	O
30	,	_	_	O
31	task	_	_	O
32	specific	_	_	O
33	functional	_	_	O
34	muscle	_	_	O
35	capacity	_	_	O
36	,	_	_	O
37	body	_	_	O
38	composition	_	_	O
39	and	_	_	O
40	quality	_	_	O
41	of	_	_	O
42	life	_	_	O
43	(	_	_	O
44	QOL	_	_	O
45	)	_	_	O
46	in	_	_	O
47	women	_	_	O
48	breast	_	_	O
49	cancer	_	_	O
50	survivors	_	_	O
51	.	_	_	O

52	Sixteen	_	_	O
53	subjects	_	_	O
54	were	_	_	O
55	randomly	_	_	O
56	assigned	_	_	O
57	to	_	_	O
58	either	_	_	O
59	a	_	_	O
60	training	_	_	O
61	(	_	_	O
62	n	_	_	O
63	=	_	_	O
64	8	_	_	O
65	;	_	_	O
66	age	_	_	O
67	:	_	_	O
68	50	_	_	O
69	+	_	_	O
70	/	_	_	O
71	-	_	_	O
72	5	_	_	O
73	yrs	_	_	O
74	)	_	_	O
75	or	_	_	O
76	control	_	_	O
77	non	_	_	O
78	-	_	_	O
79	exercising	_	_	O
80	group	_	_	O
81	(	_	_	O
82	n	_	_	O
83	=	_	_	O
84	8	_	_	O
85	;	_	_	O
86	age	_	_	O
87	:	_	_	O
88	51	_	_	O
89	+	_	_	O
90	/	_	_	O
91	-	_	_	O
92	10	_	_	O
93	yrs	_	_	O
94	)	_	_	O
95	.	_	_	O

96	The	_	_	O
97	training	_	_	O
98	group	_	_	O
99	followed	_	_	O
100	an	_	_	O
101	8	_	_	O
102	-	_	_	O
103	week	_	_	O
104	exercise	_	_	O
105	program	_	_	O
106	consisting	_	_	O
107	of	_	_	O
108	3	_	_	O
109	weekly	_	_	O
110	sessions	_	_	O
111	of	_	_	O
112	90	_	_	O
113	-	_	_	O
114	min	_	_	O
115	duration	_	_	O
116	,	_	_	O
117	supervised	_	_	O
118	by	_	_	O
119	an	_	_	O
120	experienced	_	_	O
121	investigator	_	_	O
122	and	_	_	O
123	divided	_	_	O
124	into	_	_	O
125	resistance	_	_	O
126	exercises	_	_	O
127	and	_	_	O
128	aerobic	_	_	O
129	training	_	_	O
130	.	_	_	O

131	Before	_	_	O
132	and	_	_	O
133	after	_	_	O
134	the	_	_	O
135	intervention	_	_	O
136	period	_	_	O
137	,	_	_	O
138	all	_	_	O
139	of	_	_	O
140	the	_	_	O
141	subjects	_	_	O
142	performed	_	_	O
143	a	_	_	O
144	cardiorespiratory	_	_	O
145	test	_	_	O
146	to	_	_	O
147	measure	_	_	O
148	peak	_	_	O
149	oxygen	_	_	O
150	uptake	_	_	O
151	(	_	_	O
152	VO2peak	_	_	O
153	)	_	_	O
154	,	_	_	O
155	a	_	_	O
156	dynamic	_	_	O
157	strength	_	_	O
158	endurance	_	_	O
159	test	_	_	O
160	(	_	_	O
161	maximum	_	_	O
162	number	_	_	O
163	of	_	_	O
164	repetitions	_	_	O
165	for	_	_	O
166	chest	_	_	O
167	and	_	_	O
168	leg	_	_	O
169	press	_	_	O
170	exercise	_	_	O
171	at	_	_	O
172	30	_	_	O
173	-	_	_	O
174	35	_	_	O
175	%	_	_	O
176	and	_	_	O
177	100	_	_	O
178	-	_	_	O
179	110	_	_	O
180	%	_	_	O
181	of	_	_	O
182	body	_	_	O
183	mass	_	_	O
184	,	_	_	O
185	respectively	_	_	O
186	)	_	_	O
187	and	_	_	O
188	a	_	_	O
189	sit	_	_	O
190	-	_	_	O
191	stand	_	_	O
192	test	_	_	O
193	.	_	_	O

194	Quality	_	_	O
195	of	_	_	O
196	life	_	_	O
197	was	_	_	O
198	assessed	_	_	O
199	using	_	_	O
200	the	_	_	O
201	European	_	_	O
202	Organization	_	_	O
203	for	_	_	O
204	Research	_	_	O
205	and	_	_	O
206	Treatment	_	_	O
207	of	_	_	O
208	Cancer	_	_	O
209	QLQ	_	_	O
210	-	_	_	O
211	C30	_	_	O
212	(	_	_	O
213	EORTC	_	_	O
214	-	_	_	O
215	C30	_	_	O
216	)	_	_	O
217	questionnaire	_	_	O
218	.	_	_	O

219	In	_	_	B-Premise
220	response	_	_	I-Premise
221	to	_	_	I-Premise
222	training	_	_	I-Premise
223	,	_	_	I-Premise
224	QOL	_	_	I-Premise
225	,	_	_	I-Premise
226	VO2peak	_	_	I-Premise
227	(	_	_	I-Premise
228	mean	_	_	I-Premise
229	3	_	_	I-Premise
230	.	_	_	I-Premise

231	9	_	_	I-Premise
232	ml	_	_	I-Premise
233	/	_	_	I-Premise
234	kg	_	_	I-Premise
235	/	_	_	I-Premise
236	min	_	_	I-Premise
237	;	_	_	I-Premise
238	95	_	_	I-Premise
239	%	_	_	I-Premise
240	CI	_	_	I-Premise
241	,	_	_	I-Premise
242	0	_	_	I-Premise
243	.	_	_	I-Premise

244	93	_	_	I-Premise
245	,	_	_	I-Premise
246	6	_	_	I-Premise
247	.	_	_	I-Premise

248	90	_	_	I-Premise
249	)	_	_	I-Premise
250	performance	_	_	I-Premise
251	in	_	_	I-Premise
252	leg	_	_	I-Premise
253	press	_	_	I-Premise
254	(	_	_	I-Premise
255	17	_	_	I-Premise
256	.	_	_	I-Premise

257	9	_	_	I-Premise
258	kg	_	_	I-Premise
259	;	_	_	I-Premise
260	95	_	_	I-Premise
261	%	_	_	I-Premise
262	CI	_	_	I-Premise
263	,	_	_	I-Premise
264	12	_	_	I-Premise
265	.	_	_	I-Premise

266	8	_	_	I-Premise
267	,	_	_	I-Premise
268	22	_	_	I-Premise
269	.	_	_	I-Premise

270	4	_	_	I-Premise
271	)	_	_	I-Premise
272	and	_	_	I-Premise
273	sit	_	_	I-Premise
274	-	_	_	I-Premise
275	stand	_	_	I-Premise
276	test	_	_	I-Premise
277	(	_	_	I-Premise
278	-	_	_	I-Premise
279	0	_	_	I-Premise
280	.	_	_	I-Premise

281	67	_	_	I-Premise
282	s	_	_	I-Premise
283	;	_	_	I-Premise
284	95	_	_	I-Premise
285	%	_	_	I-Premise
286	CI	_	_	I-Premise
287	,	_	_	I-Premise
288	-	_	_	I-Premise
289	0	_	_	I-Premise
290	.	_	_	I-Premise

291	52	_	_	I-Premise
292	,	_	_	I-Premise
293	-	_	_	I-Premise
294	1	_	_	I-Premise
295	.	_	_	I-Premise

296	2	_	_	I-Premise
297	)	_	_	I-Premise
298	improved	_	_	I-Premise
299	(	_	_	I-Premise
300	p	_	_	I-Premise
301	<	_	_	I-Premise
302	or	_	_	I-Premise
303	=	_	_	I-Premise
304	0	_	_	I-Premise
305	.	_	_	I-Premise

306	05	_	_	I-Premise
307	)	_	_	I-Premise
308	.	_	_	I-Premise

309	We	_	_	B-Premise
310	observed	_	_	I-Premise
311	no	_	_	I-Premise
312	significant	_	_	I-Premise
313	changes	_	_	I-Premise
314	in	_	_	I-Premise
315	the	_	_	I-Premise
316	control	_	_	I-Premise
317	group	_	_	I-Premise
318	.	_	_	I-Premise

319	Combined	_	_	B-Claim
320	cardiorespiratory	_	_	I-Claim
321	and	_	_	I-Claim
322	resistance	_	_	I-Claim
323	training	_	_	I-Claim
324	,	_	_	I-Claim
325	even	_	_	I-Claim
326	of	_	_	I-Claim
327	very	_	_	I-Claim
328	brief	_	_	I-Claim
329	duration	_	_	I-Claim
330	,	_	_	I-Claim
331	improves	_	_	I-Claim
332	the	_	_	I-Claim
333	QOL	_	_	I-Claim
334	and	_	_	I-Claim
335	the	_	_	I-Claim
336	overall	_	_	I-Claim
337	physical	_	_	I-Claim
338	fitness	_	_	I-Claim
339	of	_	_	I-Claim
340	women	_	_	I-Claim
341	breast	_	_	I-Claim
342	cancer	_	_	I-Claim
343	survivors	_	_	I-Claim
344	.	_	_	I-Claim


0	To	_	_	O
1	pilot	_	_	O
2	an	_	_	O
3	investigation	_	_	O
4	of	_	_	O
5	individualized	_	_	O
6	homeopathy	_	_	O
7	for	_	_	O
8	symptoms	_	_	O
9	of	_	_	O
10	estrogen	_	_	O
11	withdrawal	_	_	O
12	in	_	_	O
13	breast	_	_	O
14	cancer	_	_	O
15	survivors	_	_	O
16	.	_	_	O

17	Randomized	_	_	O
18	,	_	_	O
19	double	_	_	O
20	-	_	_	O
21	blinded	_	_	O
22	,	_	_	O
23	placebo	_	_	O
24	-	_	_	O
25	controlled	_	_	O
26	trial	_	_	O
27	.	_	_	O

28	Outpatient	_	_	O
29	department	_	_	O
30	of	_	_	O
31	a	_	_	O
32	National	_	_	O
33	Health	_	_	O
34	Service	_	_	O
35	(	_	_	O
36	NHS	_	_	O
37	)	_	_	O
38	homeopathic	_	_	O
39	hospital	_	_	O
40	.	_	_	O

41	Fifty	_	_	O
42	-	_	_	O
43	seven	_	_	O
44	(	_	_	O
45	57	_	_	O
46	)	_	_	O
47	women	_	_	O
48	met	_	_	O
49	inclusion	_	_	O
50	criteria	_	_	O
51	and	_	_	O
52	53	_	_	O
53	were	_	_	O
54	randomized	_	_	O
55	to	_	_	O
56	the	_	_	O
57	study	_	_	O
58	.	_	_	O

59	After	_	_	O
60	2	_	_	O
61	weeks	_	_	O
62	of	_	_	O
63	baseline	_	_	O
64	assessment	_	_	O
65	,	_	_	O
66	all	_	_	O
67	participants	_	_	O
68	received	_	_	O
69	a	_	_	O
70	consultation	_	_	O
71	plus	_	_	O
72	either	_	_	O
73	oral	_	_	O
74	homeopathic	_	_	O
75	medicine	_	_	O
76	or	_	_	O
77	placebo	_	_	O
78	,	_	_	O
79	assessed	_	_	O
80	every	_	_	O
81	4	_	_	O
82	weeks	_	_	O
83	for	_	_	O
84	16	_	_	O
85	weeks	_	_	O
86	.	_	_	O

87	The	_	_	O
88	primary	_	_	O
89	outcome	_	_	O
90	measures	_	_	O
91	were	_	_	O
92	the	_	_	O
93	activity	_	_	O
94	score	_	_	O
95	and	_	_	O
96	profile	_	_	O
97	score	_	_	O
98	of	_	_	O
99	the	_	_	O
100	Measure	_	_	O
101	Yourself	_	_	O
102	Medical	_	_	O
103	Outcome	_	_	O
104	Profile	_	_	O
105	(	_	_	O
106	MYMOP	_	_	O
107	)	_	_	O
108	.	_	_	O

109	Eighty	_	_	O
110	-	_	_	O
111	five	_	_	O
112	percent	_	_	O
113	(	_	_	O
114	85	_	_	O
115	%	_	_	O
116	)	_	_	O
117	(	_	_	O
118	45	_	_	O
119	/	_	_	O
120	53	_	_	O
121	)	_	_	O
122	of	_	_	O
123	women	_	_	O
124	completed	_	_	O
125	the	_	_	O
126	study	_	_	O
127	.	_	_	O

128	There	_	_	B-Premise
129	was	_	_	I-Premise
130	no	_	_	I-Premise
131	evidence	_	_	I-Premise
132	of	_	_	I-Premise
133	a	_	_	I-Premise
134	difference	_	_	I-Premise
135	seen	_	_	I-Premise
136	between	_	_	I-Premise
137	groups	_	_	I-Premise
138	for	_	_	I-Premise
139	either	_	_	I-Premise
140	activity	_	_	I-Premise
141	(	_	_	I-Premise
142	adjusted	_	_	I-Premise
143	difference	_	_	I-Premise
144	=	_	_	I-Premise
145	-	_	_	I-Premise
146	0	_	_	I-Premise
147	.	_	_	I-Premise

148	4	_	_	I-Premise
149	,	_	_	I-Premise
150	95	_	_	I-Premise
151	%	_	_	I-Premise
152	confidence	_	_	I-Premise
153	interval	_	_	I-Premise
154	CI	_	_	I-Premise
155	-	_	_	I-Premise
156	1	_	_	I-Premise
157	.	_	_	I-Premise

158	0	_	_	I-Premise
159	to	_	_	I-Premise
160	0	_	_	I-Premise
161	.	_	_	I-Premise

162	2	_	_	I-Premise
163	,	_	_	I-Premise
164	p	_	_	I-Premise
165	=	_	_	I-Premise
166	0	_	_	I-Premise
167	.	_	_	I-Premise

168	17	_	_	I-Premise
169	)	_	_	I-Premise
170	or	_	_	I-Premise
171	profile	_	_	I-Premise
172	scores	_	_	I-Premise
173	(	_	_	I-Premise
174	adjusted	_	_	I-Premise
175	difference	_	_	I-Premise
176	=	_	_	I-Premise
177	-	_	_	I-Premise
178	0	_	_	I-Premise
179	.	_	_	I-Premise

180	4	_	_	I-Premise
181	,	_	_	I-Premise
182	95	_	_	I-Premise
183	%	_	_	I-Premise
184	CI	_	_	I-Premise
185	-	_	_	I-Premise
186	0	_	_	I-Premise
187	.	_	_	I-Premise

188	9	_	_	I-Premise
189	to	_	_	I-Premise
190	0	_	_	I-Premise
191	.	_	_	I-Premise

192	1	_	_	I-Premise
193	,	_	_	I-Premise
194	p	_	_	I-Premise
195	=	_	_	I-Premise
196	0	_	_	I-Premise
197	.	_	_	I-Premise

198	13	_	_	I-Premise
199	)	_	_	I-Premise
200	using	_	_	I-Premise
201	this	_	_	I-Premise
202	trial	_	_	I-Premise
203	design	_	_	I-Premise
204	,	_	_	I-Premise
205	although	_	_	B-Claim
206	post	_	_	I-Claim
207	hoc	_	_	I-Claim
208	power	_	_	I-Claim
209	calculations	_	_	I-Claim
210	suggests	_	_	I-Claim
211	that	_	_	I-Claim
212	65	_	_	I-Claim
213	-	_	_	I-Claim
214	175	_	_	I-Claim
215	would	_	_	I-Claim
216	be	_	_	I-Claim
217	needed	_	_	I-Claim
218	per	_	_	I-Claim
219	group	_	_	I-Claim
220	to	_	_	I-Claim
221	detect	_	_	I-Claim
222	differences	_	_	I-Claim
223	of	_	_	I-Claim
224	this	_	_	I-Claim
225	magnitude	_	_	I-Claim
226	with	_	_	I-Claim
227	sufficient	_	_	I-Claim
228	precision	_	_	I-Claim
229	.	_	_	I-Claim

230	Clinically	_	_	B-Premise
231	relevant	_	_	I-Premise
232	improvements	_	_	I-Premise
233	in	_	_	I-Premise
234	symptoms	_	_	I-Premise
235	and	_	_	I-Premise
236	mood	_	_	I-Premise
237	disturbance	_	_	I-Premise
238	were	_	_	I-Premise
239	seen	_	_	I-Premise
240	for	_	_	I-Premise
241	both	_	_	I-Premise
242	groups	_	_	I-Premise
243	over	_	_	I-Premise
244	the	_	_	I-Premise
245	study	_	_	I-Premise
246	period	_	_	I-Premise
247	.	_	_	I-Premise

248	Improvements	_	_	B-Claim
249	were	_	_	I-Claim
250	seen	_	_	I-Claim
251	for	_	_	I-Claim
252	symptom	_	_	I-Claim
253	scores	_	_	I-Claim
254	over	_	_	I-Claim
255	the	_	_	I-Claim
256	study	_	_	I-Claim
257	period	_	_	I-Claim
258	.	_	_	I-Claim

259	However	_	_	B-Claim
260	,	_	_	I-Claim
261	presuming	_	_	I-Claim
262	these	_	_	I-Claim
263	improvements	_	_	I-Claim
264	were	_	_	I-Claim
265	caused	_	_	I-Claim
266	by	_	_	I-Claim
267	the	_	_	I-Claim
268	individualized	_	_	I-Claim
269	homeopathic	_	_	I-Claim
270	approach	_	_	I-Claim
271	,	_	_	I-Claim
272	the	_	_	I-Claim
273	study	_	_	I-Claim
274	failed	_	_	I-Claim
275	to	_	_	I-Claim
276	show	_	_	I-Claim
277	clearly	_	_	I-Claim
278	that	_	_	I-Claim
279	the	_	_	I-Claim
280	specific	_	_	I-Claim
281	effect	_	_	I-Claim
282	of	_	_	I-Claim
283	the	_	_	I-Claim
284	remedy	_	_	I-Claim
285	added	_	_	I-Claim
286	further	_	_	I-Claim
287	to	_	_	I-Claim
288	the	_	_	I-Claim
289	nonspecific	_	_	I-Claim
290	effects	_	_	I-Claim
291	of	_	_	I-Claim
292	the	_	_	I-Claim
293	consultation	_	_	I-Claim
294	.	_	_	I-Claim

295	Future	_	_	B-Claim
296	trial	_	_	I-Claim
297	design	_	_	I-Claim
298	must	_	_	I-Claim
299	ensure	_	_	I-Claim
300	adequate	_	_	I-Claim
301	power	_	_	I-Claim
302	to	_	_	I-Claim
303	account	_	_	I-Claim
304	for	_	_	I-Claim
305	the	_	_	I-Claim
306	nonspecific	_	_	I-Claim
307	impact	_	_	I-Claim
308	of	_	_	I-Claim
309	such	_	_	I-Claim
310	complex	_	_	I-Claim
311	individualized	_	_	I-Claim
312	interventions	_	_	I-Claim
313	while	_	_	I-Claim
314	pragmatic	_	_	I-Claim
315	designs	_	_	I-Claim
316	may	_	_	I-Claim
317	more	_	_	I-Claim
318	readily	_	_	I-Claim
319	answer	_	_	I-Claim
320	questions	_	_	I-Claim
321	of	_	_	I-Claim
322	clinical	_	_	I-Claim
323	and	_	_	I-Claim
324	cost	_	_	I-Claim
325	effectiveness	_	_	I-Claim
326	.	_	_	O


0	Exercise	_	_	O
1	for	_	_	O
2	Health	_	_	O
3	was	_	_	O
4	a	_	_	O
5	randomized	_	_	O
6	,	_	_	O
7	controlled	_	_	O
8	trial	_	_	O
9	designed	_	_	O
10	to	_	_	O
11	evaluate	_	_	O
12	two	_	_	O
13	modes	_	_	O
14	of	_	_	O
15	delivering	_	_	O
16	(	_	_	O
17	face	_	_	O
18	-	_	_	O
19	to	_	_	O
20	-	_	_	O
21	face	_	_	O
22	[	_	_	O
23	FtF	_	_	O
24	]	_	_	O
25	and	_	_	O
26	over	_	_	O
27	-	_	_	O
28	the	_	_	O
29	-	_	_	O
30	telephone	_	_	O
31	[	_	_	O
32	Tel	_	_	O
33	]	_	_	O
34	)	_	_	O
35	an	_	_	O
36	8	_	_	O
37	-	_	_	O
38	month	_	_	O
39	translational	_	_	O
40	exercise	_	_	O
41	intervention	_	_	O
42	,	_	_	O
43	commencing	_	_	O
44	6	_	_	O
45	-	_	_	O
46	weeks	_	_	O
47	post	_	_	O
48	-	_	_	O
49	breast	_	_	O
50	cancer	_	_	O
51	surgery	_	_	O
52	(	_	_	O
53	PS	_	_	O
54	)	_	_	O
55	.	_	_	O

56	Outcomes	_	_	O
57	included	_	_	O
58	quality	_	_	O
59	of	_	_	O
60	life	_	_	O
61	(	_	_	O
62	QoL	_	_	O
63	)	_	_	O
64	,	_	_	O
65	function	_	_	O
66	(	_	_	O
67	fitness	_	_	O
68	and	_	_	O
69	upper	_	_	O
70	body	_	_	O
71	)	_	_	O
72	and	_	_	O
73	treatment	_	_	O
74	-	_	_	O
75	related	_	_	O
76	side	_	_	O
77	effects	_	_	O
78	(	_	_	O
79	fatigue	_	_	O
80	,	_	_	O
81	lymphoedema	_	_	O
82	,	_	_	O
83	body	_	_	O
84	mass	_	_	O
85	index	_	_	O
86	,	_	_	O
87	menopausal	_	_	O
88	symptoms	_	_	O
89	,	_	_	O
90	anxiety	_	_	O
91	,	_	_	O
92	depression	_	_	O
93	and	_	_	O
94	pain	_	_	O
95	)	_	_	O
96	.	_	_	O

97	Generalised	_	_	O
98	estimating	_	_	O
99	equation	_	_	O
100	modelling	_	_	O
101	determined	_	_	O
102	time	_	_	O
103	(	_	_	O
104	baseline	_	_	O
105	[	_	_	O
106	5	_	_	O
107	weeks	_	_	O
108	PS	_	_	O
109	]	_	_	O
110	,	_	_	O
111	mid	_	_	O
112	-	_	_	O
113	intervention	_	_	O
114	[	_	_	O
115	6	_	_	O
116	months	_	_	O
117	PS	_	_	O
118	]	_	_	O
119	,	_	_	O
120	post	_	_	O
121	-	_	_	O
122	intervention	_	_	O
123	[	_	_	O
124	12	_	_	O
125	months	_	_	O
126	PS	_	_	O
127	]	_	_	O
128	)	_	_	O
129	,	_	_	O
130	group	_	_	O
131	(	_	_	O
132	FtF	_	_	O
133	,	_	_	O
134	Tel	_	_	O
135	,	_	_	O
136	Usual	_	_	O
137	Care	_	_	O
138	[	_	_	O
139	UC	_	_	O
140	]	_	_	O
141	)	_	_	O
142	and	_	_	O
143	time	_	_	O
144	-	_	_	O
145	by	_	_	O
146	-	_	_	O
147	group	_	_	O
148	effects	_	_	O
149	.	_	_	O

150	194	_	_	O
151	women	_	_	O
152	representative	_	_	O
153	of	_	_	O
154	the	_	_	O
155	breast	_	_	O
156	cancer	_	_	O
157	population	_	_	O
158	were	_	_	O
159	randomised	_	_	O
160	to	_	_	O
161	the	_	_	O
162	FtF	_	_	O
163	(	_	_	O
164	n	_	_	O
165	=	_	_	O
166	67	_	_	O
167	)	_	_	O
168	,	_	_	O
169	Tel	_	_	O
170	(	_	_	O
171	n	_	_	O
172	=	_	_	O
173	67	_	_	O
174	)	_	_	O
175	and	_	_	O
176	UC	_	_	O
177	(	_	_	O
178	n	_	_	O
179	=	_	_	O
180	60	_	_	O
181	)	_	_	O
182	groups	_	_	O
183	.	_	_	O

184	There	_	_	B-Premise
185	were	_	_	I-Premise
186	significant	_	_	I-Premise
187	(	_	_	I-Premise
188	p	_	_	I-Premise
189	<	_	_	I-Premise
190	0	_	_	I-Premise
191	.	_	_	I-Premise

192	05	_	_	I-Premise
193	)	_	_	I-Premise
194	interaction	_	_	I-Premise
195	effects	_	_	I-Premise
196	on	_	_	I-Premise
197	QoL	_	_	I-Premise
198	,	_	_	I-Premise
199	fitness	_	_	I-Premise
200	and	_	_	I-Premise
201	fatigue	_	_	I-Premise
202	with	_	_	I-Premise
203	differences	_	_	I-Premise
204	being	_	_	I-Premise
205	observed	_	_	I-Premise
206	between	_	_	I-Premise
207	the	_	_	I-Premise
208	treatment	_	_	I-Premise
209	groups	_	_	I-Premise
210	and	_	_	I-Premise
211	the	_	_	I-Premise
212	UC	_	_	I-Premise
213	group	_	_	I-Premise
214	.	_	_	I-Premise

215	Trends	_	_	B-Premise
216	observed	_	_	I-Premise
217	for	_	_	I-Premise
218	the	_	_	I-Premise
219	treatment	_	_	I-Premise
220	groups	_	_	I-Premise
221	were	_	_	I-Premise
222	similar	_	_	I-Premise
223	.	_	_	I-Premise

224	The	_	_	B-Premise
225	treatment	_	_	I-Premise
226	groups	_	_	I-Premise
227	reported	_	_	I-Premise
228	improved	_	_	I-Premise
229	QoL	_	_	I-Premise
230	,	_	_	I-Premise
231	fitness	_	_	I-Premise
232	and	_	_	I-Premise
233	fatigue	_	_	I-Premise
234	over	_	_	I-Premise
235	time	_	_	I-Premise
236	and	_	_	I-Premise
237	changes	_	_	I-Premise
238	observed	_	_	I-Premise
239	between	_	_	I-Premise
240	baseline	_	_	I-Premise
241	and	_	_	I-Premise
242	post	_	_	I-Premise
243	-	_	_	I-Premise
244	intervention	_	_	I-Premise
245	were	_	_	I-Premise
246	clinically	_	_	I-Premise
247	relevant	_	_	I-Premise
248	.	_	_	I-Premise

249	In	_	_	B-Premise
250	contrast	_	_	I-Premise
251	,	_	_	I-Premise
252	the	_	_	I-Premise
253	UC	_	_	I-Premise
254	group	_	_	I-Premise
255	experienced	_	_	I-Premise
256	no	_	_	I-Premise
257	change	_	_	I-Premise
258	,	_	_	I-Premise
259	or	_	_	I-Premise
260	worsening	_	_	I-Premise
261	QoL	_	_	I-Premise
262	,	_	_	I-Premise
263	fitness	_	_	I-Premise
264	and	_	_	I-Premise
265	fatigue	_	_	I-Premise
266	,	_	_	I-Premise
267	mid	_	_	I-Premise
268	-	_	_	I-Premise
269	intervention	_	_	I-Premise
270	.	_	_	I-Premise

271	Although	_	_	B-Premise
272	improvements	_	_	I-Premise
273	in	_	_	I-Premise
274	the	_	_	I-Premise
275	UC	_	_	I-Premise
276	group	_	_	I-Premise
277	occurred	_	_	I-Premise
278	by	_	_	I-Premise
279	12	_	_	I-Premise
280	-	_	_	I-Premise
281	months	_	_	I-Premise
282	post	_	_	I-Premise
283	-	_	_	I-Premise
284	surgery	_	_	I-Premise
285	,	_	_	I-Premise
286	the	_	_	B-Premise
287	change	_	_	I-Premise
288	did	_	_	I-Premise
289	not	_	_	I-Premise
290	meet	_	_	I-Premise
291	the	_	_	I-Premise
292	clinically	_	_	I-Premise
293	relevant	_	_	I-Premise
294	threshold	_	_	I-Premise
295	.	_	_	I-Premise

296	There	_	_	B-Premise
297	were	_	_	I-Premise
298	no	_	_	I-Premise
299	differences	_	_	I-Premise
300	in	_	_	I-Premise
301	other	_	_	I-Premise
302	treatment	_	_	I-Premise
303	-	_	_	I-Premise
304	related	_	_	I-Premise
305	side	_	_	I-Premise
306	effects	_	_	I-Premise
307	between	_	_	I-Premise
308	groups	_	_	I-Premise
309	.	_	_	I-Premise

310	This	_	_	B-Claim
311	translational	_	_	I-Claim
312	intervention	_	_	I-Claim
313	trial	_	_	I-Claim
314	,	_	_	I-Claim
315	delivered	_	_	I-Claim
316	either	_	_	I-Claim
317	FtF	_	_	I-Claim
318	or	_	_	I-Claim
319	Tel	_	_	I-Claim
320	,	_	_	I-Claim
321	supports	_	_	I-Claim
322	exercise	_	_	I-Claim
323	as	_	_	I-Claim
324	a	_	_	I-Claim
325	form	_	_	I-Claim
326	of	_	_	I-Claim
327	adjuvant	_	_	I-Claim
328	breast	_	_	I-Claim
329	cancer	_	_	I-Claim
330	therapy	_	_	I-Claim
331	that	_	_	I-Claim
332	can	_	_	I-Claim
333	prevent	_	_	I-Claim
334	declines	_	_	I-Claim
335	in	_	_	I-Claim
336	fitness	_	_	I-Claim
337	and	_	_	I-Claim
338	function	_	_	I-Claim
339	during	_	_	I-Claim
340	treatment	_	_	I-Claim
341	and	_	_	I-Claim
342	optimise	_	_	I-Claim
343	recovery	_	_	I-Claim
344	post	_	_	I-Claim
345	-	_	_	I-Claim
346	treatment	_	_	I-Claim
347	.	_	_	I-Claim


0	Depression	_	_	O
1	is	_	_	O
2	common	_	_	O
3	among	_	_	O
4	older	_	_	O
5	cancer	_	_	O
6	patients	_	_	O
7	,	_	_	O
8	but	_	_	O
9	little	_	_	O
10	is	_	_	O
11	known	_	_	O
12	about	_	_	O
13	the	_	_	O
14	optimal	_	_	O
15	approach	_	_	O
16	to	_	_	O
17	caring	_	_	O
18	for	_	_	O
19	this	_	_	O
20	population	_	_	O
21	.	_	_	O

22	This	_	_	O
23	analysis	_	_	O
24	evaluates	_	_	O
25	the	_	_	O
26	effectiveness	_	_	O
27	of	_	_	O
28	the	_	_	O
29	Improving	_	_	O
30	Mood	_	_	O
31	-	_	_	O
32	Promoting	_	_	O
33	Access	_	_	O
34	to	_	_	O
35	Collaborative	_	_	O
36	Treatment	_	_	O
37	(	_	_	O
38	IMPACT	_	_	O
39	)	_	_	O
40	program	_	_	O
41	,	_	_	O
42	a	_	_	O
43	stepped	_	_	O
44	care	_	_	O
45	management	_	_	O
46	program	_	_	O
47	for	_	_	O
48	depression	_	_	O
49	in	_	_	O
50	primary	_	_	O
51	care	_	_	O
52	patients	_	_	O
53	who	_	_	O
54	had	_	_	O
55	an	_	_	O
56	ICD	_	_	O
57	-	_	_	O
58	9	_	_	O
59	cancer	_	_	O
60	diagnosis	_	_	O
61	.	_	_	O

62	Two	_	_	O
63	hundred	_	_	O
64	fifteen	_	_	O
65	cancer	_	_	O
66	patients	_	_	O
67	were	_	_	O
68	identified	_	_	O
69	from	_	_	O
70	the	_	_	O
71	1	_	_	O
72	,	_	_	O
73	801	_	_	O
74	participants	_	_	O
75	in	_	_	O
76	the	_	_	O
77	parent	_	_	O
78	study	_	_	O
79	.	_	_	O

80	Subjects	_	_	O
81	were	_	_	O
82	60	_	_	O
83	years	_	_	O
84	or	_	_	O
85	older	_	_	O
86	with	_	_	O
87	major	_	_	O
88	depression	_	_	O
89	(	_	_	O
90	18	_	_	O
91	%	_	_	O
92	)	_	_	O
93	,	_	_	O
94	dysthymic	_	_	O
95	disorder	_	_	O
96	(	_	_	O
97	33	_	_	O
98	%	_	_	O
99	)	_	_	O
100	,	_	_	O
101	or	_	_	O
102	both	_	_	O
103	(	_	_	O
104	49	_	_	O
105	%	_	_	O
106	)	_	_	O
107	,	_	_	O
108	recruited	_	_	O
109	from	_	_	O
110	18	_	_	O
111	primary	_	_	O
112	care	_	_	O
113	clinics	_	_	O
114	belonging	_	_	O
115	to	_	_	O
116	8	_	_	O
117	health	_	_	O
118	-	_	_	O
119	care	_	_	O
120	organizations	_	_	O
121	in	_	_	O
122	5	_	_	O
123	states	_	_	O
124	.	_	_	O

125	Patients	_	_	O
126	were	_	_	O
127	randomly	_	_	O
128	assigned	_	_	O
129	to	_	_	O
130	the	_	_	O
131	IMPACT	_	_	O
132	intervention	_	_	O
133	(	_	_	O
134	n	_	_	O
135	=	_	_	O
136	112	_	_	O
137	)	_	_	O
138	or	_	_	O
139	usual	_	_	O
140	care	_	_	O
141	(	_	_	O
142	n	_	_	O
143	=	_	_	O
144	103	_	_	O
145	)	_	_	O
146	.	_	_	O

147	Intervention	_	_	O
148	patients	_	_	O
149	had	_	_	O
150	access	_	_	O
151	for	_	_	O
152	up	_	_	O
153	to	_	_	O
154	12	_	_	O
155	months	_	_	O
156	to	_	_	O
157	a	_	_	O
158	depression	_	_	O
159	care	_	_	O
160	manager	_	_	O
161	who	_	_	O
162	was	_	_	O
163	supervised	_	_	O
164	by	_	_	O
165	a	_	_	O
166	psychiatrist	_	_	O
167	and	_	_	O
168	a	_	_	O
169	primary	_	_	O
170	care	_	_	O
171	provider	_	_	O
172	and	_	_	O
173	who	_	_	O
174	offered	_	_	O
175	education	_	_	O
176	,	_	_	O
177	care	_	_	O
178	management	_	_	O
179	,	_	_	O
180	support	_	_	O
181	of	_	_	O
182	antidepressant	_	_	O
183	management	_	_	O
184	,	_	_	O
185	and	_	_	O
186	brief	_	_	O
187	,	_	_	O
188	structured	_	_	O
189	psychosocial	_	_	O
190	interventions	_	_	O
191	including	_	_	O
192	behavioral	_	_	O
193	activation	_	_	O
194	and	_	_	O
195	problem	_	_	O
196	-	_	_	O
197	solving	_	_	O
198	treatment	_	_	O
199	.	_	_	O

200	At	_	_	B-Premise
201	6	_	_	I-Premise
202	and	_	_	I-Premise
203	12	_	_	I-Premise
204	months	_	_	I-Premise
205	,	_	_	I-Premise
206	55	_	_	I-Premise
207	%	_	_	I-Premise
208	and	_	_	I-Premise
209	39	_	_	I-Premise
210	%	_	_	I-Premise
211	of	_	_	I-Premise
212	intervention	_	_	I-Premise
213	patients	_	_	I-Premise
214	had	_	_	I-Premise
215	a	_	_	I-Premise
216	50	_	_	I-Premise
217	%	_	_	I-Premise
218	or	_	_	I-Premise
219	greater	_	_	I-Premise
220	reduction	_	_	I-Premise
221	in	_	_	I-Premise
222	depressive	_	_	I-Premise
223	symptoms	_	_	I-Premise
224	(	_	_	I-Premise
225	SCL	_	_	I-Premise
226	-	_	_	I-Premise
227	20	_	_	I-Premise
228	)	_	_	I-Premise
229	from	_	_	I-Premise
230	baseline	_	_	I-Premise
231	compared	_	_	I-Premise
232	to	_	_	I-Premise
233	34	_	_	I-Premise
234	%	_	_	I-Premise
235	and	_	_	I-Premise
236	20	_	_	I-Premise
237	%	_	_	I-Premise
238	of	_	_	I-Premise
239	usual	_	_	I-Premise
240	care	_	_	I-Premise
241	participants	_	_	I-Premise
242	(	_	_	I-Premise
243	P	_	_	I-Premise
244	=	_	_	I-Premise
245	0	_	_	I-Premise
246	.	_	_	I-Premise

247	003	_	_	I-Premise
248	and	_	_	I-Premise
249	P	_	_	I-Premise
250	=	_	_	I-Premise
251	0	_	_	I-Premise
252	.	_	_	I-Premise

253	029	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	Intervention	_	_	B-Premise
257	patients	_	_	I-Premise
258	also	_	_	I-Premise
259	experienced	_	_	I-Premise
260	greater	_	_	I-Premise
261	remission	_	_	I-Premise
262	rates	_	_	I-Premise
263	(	_	_	I-Premise
264	P	_	_	I-Premise
265	=	_	_	I-Premise
266	0	_	_	I-Premise
267	.	_	_	I-Premise

268	031	_	_	I-Premise
269	)	_	_	I-Premise
270	,	_	_	I-Premise
271	more	_	_	I-Premise
272	depression	_	_	I-Premise
273	-	_	_	I-Premise
274	free	_	_	I-Premise
275	days	_	_	I-Premise
276	(	_	_	I-Premise
277	P	_	_	I-Premise
278	<	_	_	I-Premise
279	0	_	_	I-Premise
280	.	_	_	I-Premise

281	001	_	_	I-Premise
282	)	_	_	I-Premise
283	,	_	_	I-Premise
284	less	_	_	I-Premise
285	functional	_	_	I-Premise
286	impairment	_	_	I-Premise
287	(	_	_	I-Premise
288	P	_	_	I-Premise
289	=	_	_	I-Premise
290	0	_	_	I-Premise
291	.	_	_	I-Premise

292	011	_	_	I-Premise
293	)	_	_	I-Premise
294	,	_	_	I-Premise
295	and	_	_	I-Premise
296	greater	_	_	I-Premise
297	quality	_	_	I-Premise
298	of	_	_	I-Premise
299	life	_	_	I-Premise
300	(	_	_	I-Premise
301	P	_	_	I-Premise
302	=	_	_	I-Premise
303	0	_	_	I-Premise
304	.	_	_	I-Premise

305	039	_	_	I-Premise
306	)	_	_	I-Premise
307	at	_	_	I-Premise
308	12	_	_	I-Premise
309	months	_	_	I-Premise
310	than	_	_	I-Premise
311	usual	_	_	I-Premise
312	care	_	_	I-Premise
313	participants	_	_	I-Premise
314	.	_	_	I-Premise

315	The	_	_	B-Claim
316	IMPACT	_	_	I-Claim
317	collaborative	_	_	I-Claim
318	care	_	_	I-Claim
319	program	_	_	I-Claim
320	appears	_	_	I-Claim
321	to	_	_	I-Claim
322	be	_	_	I-Claim
323	feasible	_	_	I-Claim
324	and	_	_	I-Claim
325	effective	_	_	I-Claim
326	for	_	_	I-Claim
327	depression	_	_	I-Claim
328	among	_	_	I-Claim
329	older	_	_	I-Claim
330	cancer	_	_	I-Claim
331	patients	_	_	I-Claim
332	in	_	_	I-Claim
333	diverse	_	_	I-Claim
334	primary	_	_	I-Claim
335	care	_	_	I-Claim
336	settings	_	_	I-Claim
337	.	_	_	I-Claim


0	Facial	_	_	B-Claim
1	hirsutism	_	_	I-Claim
2	is	_	_	I-Claim
3	one	_	_	I-Claim
4	of	_	_	I-Claim
5	the	_	_	I-Claim
6	characteristic	_	_	I-Claim
7	features	_	_	I-Claim
8	of	_	_	I-Claim
9	polycystic	_	_	I-Claim
10	ovary	_	_	I-Claim
11	syndrome	_	_	I-Claim
12	(	_	_	I-Claim
13	PCOS	_	_	I-Claim
14	)	_	_	I-Claim
15	,	_	_	I-Claim
16	and	_	_	I-Claim
17	this	_	_	I-Claim
18	can	_	_	I-Claim
19	lead	_	_	I-Claim
20	to	_	_	I-Claim
21	high	_	_	I-Claim
22	levels	_	_	I-Claim
23	of	_	_	I-Claim
24	depression	_	_	I-Claim
25	and	_	_	I-Claim
26	anxiety	_	_	I-Claim
27	.	_	_	I-Claim

28	To	_	_	O
29	evaluate	_	_	O
30	the	_	_	O
31	impact	_	_	O
32	of	_	_	O
33	laser	_	_	O
34	treatment	_	_	O
35	on	_	_	O
36	the	_	_	O
37	severity	_	_	O
38	of	_	_	O
39	facial	_	_	O
40	hirsutism	_	_	O
41	and	_	_	O
42	on	_	_	O
43	psychological	_	_	O
44	morbidity	_	_	O
45	in	_	_	O
46	women	_	_	O
47	with	_	_	O
48	PCOS	_	_	O
49	.	_	_	O

50	A	_	_	O
51	randomized	_	_	O
52	controlled	_	_	O
53	trial	_	_	O
54	of	_	_	O
55	five	_	_	O
56	high	_	_	O
57	-	_	_	O
58	fluence	_	_	O
59	treatments	_	_	O
60	(	_	_	O
61	intervention	_	_	O
62	)	_	_	O
63	vs	_	_	O
64	.	_	_	O

65	five	_	_	O
66	low	_	_	O
67	-	_	_	O
68	fluence	_	_	O
69	treatments	_	_	O
70	(	_	_	O
71	control	_	_	O
72	)	_	_	O
73	was	_	_	O
74	performed	_	_	O
75	over	_	_	O
76	6	_	_	O
77	months	_	_	O
78	in	_	_	O
79	a	_	_	O
80	National	_	_	O
81	Health	_	_	O
82	Service	_	_	O
83	teaching	_	_	O
84	hospital	_	_	O
85	.	_	_	O

86	Subjects	_	_	O
87	were	_	_	O
88	88	_	_	O
89	women	_	_	O
90	with	_	_	O
91	facial	_	_	O
92	hirsutism	_	_	O
93	due	_	_	O
94	to	_	_	O
95	PCOS	_	_	O
96	recruited	_	_	O
97	from	_	_	O
98	hospital	_	_	O
99	outpatient	_	_	O
100	clinics	_	_	O
101	and	_	_	O
102	a	_	_	O
103	patient	_	_	O
104	support	_	_	O
105	group	_	_	O
106	in	_	_	O
107	2001	_	_	O
108	-	_	_	O
109	2002	_	_	O
110	.	_	_	O

111	The	_	_	O
112	main	_	_	O
113	outcomes	_	_	O
114	were	_	_	O
115	self	_	_	O
116	-	_	_	O
117	reported	_	_	O
118	severity	_	_	O
119	of	_	_	O
120	facial	_	_	O
121	hair	_	_	O
122	(	_	_	O
123	measured	_	_	O
124	on	_	_	O
125	a	_	_	O
126	scale	_	_	O
127	of	_	_	O
128	1	_	_	O
129	-	_	_	O
130	10	_	_	O
131	)	_	_	O
132	,	_	_	O
133	depression	_	_	O
134	,	_	_	O
135	anxiety	_	_	O
136	(	_	_	O
137	measured	_	_	O
138	on	_	_	O
139	the	_	_	O
140	Hospital	_	_	O
141	Anxiety	_	_	O
142	and	_	_	O
143	Depression	_	_	O
144	Scale	_	_	O
145	)	_	_	O
146	and	_	_	O
147	quality	_	_	O
148	of	_	_	O
149	life	_	_	O
150	(	_	_	O
151	measured	_	_	O
152	on	_	_	O
153	the	_	_	O
154	WHOQOL	_	_	O
155	-	_	_	O
156	BREF	_	_	O
157	)	_	_	O
158	.	_	_	O

159	Self	_	_	B-Premise
160	-	_	_	I-Premise
161	reported	_	_	I-Premise
162	severity	_	_	I-Premise
163	of	_	_	I-Premise
164	facial	_	_	I-Premise
165	hair	_	_	I-Premise
166	in	_	_	I-Premise
167	the	_	_	I-Premise
168	intervention	_	_	I-Premise
169	group	_	_	I-Premise
170	(	_	_	I-Premise
171	n	_	_	I-Premise
172	=	_	_	I-Premise
173	51	_	_	I-Premise
174	)	_	_	I-Premise
175	fell	_	_	I-Premise
176	from	_	_	I-Premise
177	7	_	_	I-Premise
178	.	_	_	I-Premise

179	3	_	_	I-Premise
180	to	_	_	I-Premise
181	3	_	_	I-Premise
182	.	_	_	I-Premise

183	6	_	_	I-Premise
184	over	_	_	I-Premise
185	the	_	_	I-Premise
186	6	_	_	I-Premise
187	-	_	_	I-Premise
188	month	_	_	I-Premise
189	study	_	_	I-Premise
190	period	_	_	I-Premise
191	;	_	_	I-Premise
192	for	_	_	I-Premise
193	the	_	_	I-Premise
194	control	_	_	I-Premise
195	group	_	_	I-Premise
196	(	_	_	I-Premise
197	n	_	_	I-Premise
198	=	_	_	I-Premise
199	37	_	_	I-Premise
200	)	_	_	I-Premise
201	the	_	_	I-Premise
202	corresponding	_	_	I-Premise
203	scores	_	_	I-Premise
204	were	_	_	I-Premise
205	7	_	_	I-Premise
206	.	_	_	I-Premise

207	1	_	_	I-Premise
208	and	_	_	I-Premise
209	6	_	_	I-Premise
210	.	_	_	I-Premise

211	1	_	_	I-Premise
212	.	_	_	I-Premise

213	The	_	_	B-Premise
214	change	_	_	I-Premise
215	was	_	_	I-Premise
216	significantly	_	_	I-Premise
217	greater	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	intervention	_	_	I-Premise
221	group	_	_	I-Premise
222	[	_	_	I-Premise
223	ancova	_	_	I-Premise
224	F	_	_	I-Premise
225	(	_	_	I-Premise
226	(	_	_	I-Premise
227	1	_	_	I-Premise
228	,	_	_	I-Premise
229	83	_	_	I-Premise
230	)	_	_	I-Premise
231	)	_	_	I-Premise
232	=	_	_	I-Premise
233	24	_	_	I-Premise
234	.	_	_	I-Premise

235	5	_	_	I-Premise
236	,	_	_	I-Premise
237	P	_	_	I-Premise
238	<	_	_	I-Premise
239	0	_	_	I-Premise
240	.	_	_	I-Premise

241	05	_	_	I-Premise
242	]	_	_	I-Premise
243	.	_	_	I-Premise

244	Self	_	_	B-Premise
245	-	_	_	I-Premise
246	reported	_	_	I-Premise
247	time	_	_	I-Premise
248	spent	_	_	I-Premise
249	on	_	_	I-Premise
250	hair	_	_	I-Premise
251	removal	_	_	I-Premise
252	declined	_	_	I-Premise
253	from	_	_	I-Premise
254	112	_	_	I-Premise
255	to	_	_	I-Premise
256	21	_	_	I-Premise
257	min	_	_	I-Premise
258	per	_	_	I-Premise
259	week	_	_	I-Premise
260	in	_	_	I-Premise
261	the	_	_	I-Premise
262	intervention	_	_	I-Premise
263	group	_	_	I-Premise
264	and	_	_	I-Premise
265	from	_	_	I-Premise
266	92	_	_	I-Premise
267	to	_	_	I-Premise
268	56	_	_	I-Premise
269	min	_	_	I-Premise
270	in	_	_	I-Premise
271	the	_	_	I-Premise
272	control	_	_	I-Premise
273	group	_	_	I-Premise
274	[	_	_	I-Premise
275	F	_	_	I-Premise
276	(	_	_	I-Premise
277	(	_	_	I-Premise
278	1	_	_	I-Premise
279	,	_	_	I-Premise
280	80	_	_	I-Premise
281	)	_	_	I-Premise
282	)	_	_	I-Premise
283	=	_	_	I-Premise
284	10	_	_	I-Premise
285	.	_	_	I-Premise

286	2	_	_	I-Premise
287	,	_	_	I-Premise
288	P	_	_	I-Premise
289	<	_	_	I-Premise
290	/	_	_	I-Premise
291	=	_	_	I-Premise
292	0	_	_	I-Premise
293	.	_	_	I-Premise

294	05	_	_	I-Premise
295	]	_	_	I-Premise
296	.	_	_	I-Premise

297	Mean	_	_	B-Premise
298	depression	_	_	I-Premise
299	scores	_	_	I-Premise
300	fell	_	_	I-Premise
301	from	_	_	I-Premise
302	6	_	_	I-Premise
303	.	_	_	I-Premise

304	7	_	_	I-Premise
305	to	_	_	I-Premise
306	3	_	_	I-Premise
307	.	_	_	I-Premise

308	6	_	_	I-Premise
309	in	_	_	I-Premise
310	the	_	_	I-Premise
311	intervention	_	_	I-Premise
312	group	_	_	I-Premise
313	,	_	_	I-Premise
314	compared	_	_	I-Premise
315	with	_	_	I-Premise
316	6	_	_	I-Premise
317	.	_	_	I-Premise

318	1	_	_	I-Premise
319	to	_	_	I-Premise
320	5	_	_	I-Premise
321	.	_	_	I-Premise

322	4	_	_	I-Premise
323	in	_	_	I-Premise
324	the	_	_	I-Premise
325	control	_	_	I-Premise
326	group	_	_	I-Premise
327	[	_	_	I-Premise
328	F	_	_	I-Premise
329	(	_	_	I-Premise
330	(	_	_	I-Premise
331	1	_	_	I-Premise
332	,	_	_	I-Premise
333	83	_	_	I-Premise
334	)	_	_	I-Premise
335	)	_	_	I-Premise
336	=	_	_	I-Premise
337	14	_	_	I-Premise
338	.	_	_	I-Premise

339	7	_	_	I-Premise
340	,	_	_	I-Premise
341	P	_	_	I-Premise
342	<	_	_	I-Premise
343	0	_	_	I-Premise
344	.	_	_	I-Premise

345	05	_	_	I-Premise
346	]	_	_	I-Premise
347	.	_	_	I-Premise

348	A	_	_	B-Premise
349	similar	_	_	I-Premise
350	change	_	_	I-Premise
351	was	_	_	I-Premise
352	seen	_	_	I-Premise
353	for	_	_	I-Premise
354	mean	_	_	I-Premise
355	anxiety	_	_	I-Premise
356	scores	_	_	I-Premise
357	:	_	_	I-Premise
358	intervention	_	_	I-Premise
359	11	_	_	I-Premise
360	.	_	_	I-Premise

361	1	_	_	I-Premise
362	to	_	_	I-Premise
363	8	_	_	I-Premise
364	.	_	_	I-Premise

365	2	_	_	I-Premise
366	,	_	_	I-Premise
367	control	_	_	I-Premise
368	9	_	_	I-Premise
369	.	_	_	I-Premise

370	6	_	_	I-Premise
371	to	_	_	I-Premise
372	9	_	_	I-Premise
373	.	_	_	I-Premise

374	3	_	_	I-Premise
375	[	_	_	I-Premise
376	F	_	_	I-Premise
377	(	_	_	I-Premise
378	(	_	_	I-Premise
379	1	_	_	I-Premise
380	,	_	_	I-Premise
381	84	_	_	I-Premise
382	)	_	_	I-Premise
383	)	_	_	I-Premise
384	=	_	_	I-Premise
385	17	_	_	I-Premise
386	.	_	_	I-Premise

387	8	_	_	I-Premise
388	,	_	_	I-Premise
389	P	_	_	I-Premise
390	<	_	_	I-Premise
391	0	_	_	I-Premise
392	.	_	_	I-Premise

393	05	_	_	I-Premise
394	]	_	_	I-Premise
395	.	_	_	I-Premise

396	Psychological	_	_	B-Premise
397	quality	_	_	I-Premise
398	of	_	_	I-Premise
399	life	_	_	I-Premise
400	also	_	_	I-Premise
401	improved	_	_	I-Premise
402	more	_	_	I-Premise
403	in	_	_	I-Premise
404	the	_	_	I-Premise
405	intervention	_	_	I-Premise
406	group	_	_	I-Premise
407	,	_	_	I-Premise
408	from	_	_	I-Premise
409	49	_	_	I-Premise
410	.	_	_	I-Premise

411	6	_	_	I-Premise
412	to	_	_	I-Premise
413	61	_	_	I-Premise
414	.	_	_	I-Premise

415	2	_	_	I-Premise
416	vs	_	_	I-Premise
417	.	_	_	I-Premise

418	50	_	_	I-Premise
419	.	_	_	I-Premise

420	1	_	_	I-Premise
421	to	_	_	I-Premise
422	51	_	_	I-Premise
423	.	_	_	I-Premise

424	5	_	_	I-Premise
425	in	_	_	I-Premise
426	the	_	_	I-Premise
427	control	_	_	I-Premise
428	group	_	_	I-Premise
429	[	_	_	I-Premise
430	F	_	_	I-Premise
431	(	_	_	I-Premise
432	(	_	_	I-Premise
433	1	_	_	I-Premise
434	,	_	_	I-Premise
435	84	_	_	I-Premise
436	)	_	_	I-Premise
437	)	_	_	I-Premise
438	=	_	_	I-Premise
439	10	_	_	I-Premise
440	.	_	_	I-Premise

441	9	_	_	I-Premise
442	,	_	_	I-Premise
443	P	_	_	I-Premise
444	<	_	_	I-Premise
445	0	_	_	I-Premise
446	.	_	_	I-Premise

447	05	_	_	I-Premise
448	]	_	_	I-Premise
449	.	_	_	I-Premise

450	Laser	_	_	B-Claim
451	treatment	_	_	I-Claim
452	appeared	_	_	I-Claim
453	to	_	_	I-Claim
454	reduce	_	_	I-Claim
455	the	_	_	I-Claim
456	severity	_	_	I-Claim
457	of	_	_	I-Claim
458	facial	_	_	I-Claim
459	hair	_	_	I-Claim
460	and	_	_	I-Claim
461	time	_	_	I-Claim
462	spent	_	_	I-Claim
463	on	_	_	I-Claim
464	hair	_	_	I-Claim
465	removal	_	_	I-Claim
466	as	_	_	I-Claim
467	well	_	_	I-Claim
468	as	_	_	I-Claim
469	alleviating	_	_	I-Claim
470	depression	_	_	I-Claim
471	and	_	_	I-Claim
472	anxiety	_	_	I-Claim
473	in	_	_	I-Claim
474	women	_	_	I-Claim
475	with	_	_	I-Claim
476	PCOS	_	_	I-Claim
477	.	_	_	I-Claim

478	These	_	_	B-Claim
479	findings	_	_	I-Claim
480	suggest	_	_	I-Claim
481	that	_	_	I-Claim
482	ways	_	_	I-Claim
483	of	_	_	I-Claim
484	making	_	_	I-Claim
485	this	_	_	I-Claim
486	method	_	_	I-Claim
487	of	_	_	I-Claim
488	hair	_	_	I-Claim
489	removal	_	_	I-Claim
490	more	_	_	I-Claim
491	widely	_	_	I-Claim
492	available	_	_	I-Claim
493	to	_	_	I-Claim
494	women	_	_	I-Claim
495	with	_	_	I-Claim
496	facial	_	_	I-Claim
497	hirsutism	_	_	I-Claim
498	should	_	_	I-Claim
499	be	_	_	I-Claim
500	considered	_	_	I-Claim
501	.	_	_	I-Claim


0	There	_	_	O
1	are	_	_	O
2	no	_	_	O
3	known	_	_	O
4	effective	_	_	O
5	treatments	_	_	O
6	for	_	_	O
7	painful	_	_	O
8	chemotherapy	_	_	O
9	-	_	_	O
10	induced	_	_	O
11	peripheral	_	_	O
12	neuropathy	_	_	O
13	.	_	_	O

14	To	_	_	O
15	determine	_	_	O
16	the	_	_	O
17	effect	_	_	O
18	of	_	_	O
19	duloxetine	_	_	O
20	,	_	_	O
21	60	_	_	O
22	mg	_	_	O
23	daily	_	_	O
24	,	_	_	O
25	on	_	_	O
26	average	_	_	O
27	pain	_	_	O
28	severity	_	_	O
29	.	_	_	O

30	Randomized	_	_	O
31	,	_	_	O
32	double	_	_	O
33	-	_	_	O
34	blind	_	_	O
35	,	_	_	O
36	placebo	_	_	O
37	-	_	_	O
38	controlled	_	_	O
39	crossover	_	_	O
40	trial	_	_	O
41	at	_	_	O
42	8	_	_	O
43	National	_	_	O
44	Cancer	_	_	O
45	Institute	_	_	O
46	(	_	_	O
47	NCI	_	_	O
48	)	_	_	O
49	-	_	_	O
50	funded	_	_	O
51	cooperative	_	_	O
52	research	_	_	O
53	networks	_	_	O
54	that	_	_	O
55	enrolled	_	_	O
56	231	_	_	O
57	patients	_	_	O
58	who	_	_	O
59	were	_	_	O
60	25	_	_	O
61	years	_	_	O
62	or	_	_	O
63	older	_	_	O
64	being	_	_	O
65	treated	_	_	O
66	at	_	_	O
67	community	_	_	O
68	and	_	_	O
69	academic	_	_	O
70	settings	_	_	O
71	between	_	_	O
72	April	_	_	O
73	2008	_	_	O
74	and	_	_	O
75	March	_	_	O
76	2011	_	_	O
77	.	_	_	O

78	Study	_	_	O
79	follow	_	_	O
80	-	_	_	O
81	up	_	_	O
82	was	_	_	O
83	completed	_	_	O
84	July	_	_	O
85	2012	_	_	O
86	.	_	_	O

87	Stratified	_	_	O
88	by	_	_	O
89	chemotherapeutic	_	_	O
90	drug	_	_	O
91	and	_	_	O
92	comorbid	_	_	O
93	pain	_	_	O
94	risk	_	_	O
95	,	_	_	O
96	patients	_	_	O
97	were	_	_	O
98	randomized	_	_	O
99	to	_	_	O
100	receive	_	_	O
101	either	_	_	O
102	duloxetine	_	_	O
103	followed	_	_	O
104	by	_	_	O
105	placebo	_	_	O
106	or	_	_	O
107	placebo	_	_	O
108	followed	_	_	O
109	by	_	_	O
110	duloxetine	_	_	O
111	.	_	_	O

112	Eligibility	_	_	O
113	required	_	_	O
114	that	_	_	O
115	patients	_	_	O
116	have	_	_	O
117	grade	_	_	O
118	1	_	_	O
119	or	_	_	O
120	higher	_	_	O
121	sensory	_	_	O
122	neuropathy	_	_	O
123	according	_	_	O
124	to	_	_	O
125	the	_	_	O
126	NCI	_	_	O
127	Common	_	_	O
128	Terminology	_	_	O
129	Criteria	_	_	O
130	for	_	_	O
131	Adverse	_	_	O
132	Events	_	_	O
133	and	_	_	O
134	at	_	_	O
135	least	_	_	O
136	4	_	_	O
137	on	_	_	O
138	a	_	_	O
139	scale	_	_	O
140	of	_	_	O
141	0	_	_	O
142	to	_	_	O
143	10	_	_	O
144	,	_	_	O
145	representing	_	_	O
146	average	_	_	O
147	chemotherapy	_	_	O
148	-	_	_	O
149	induced	_	_	O
150	pain	_	_	O
151	,	_	_	O
152	after	_	_	O
153	paclitaxel	_	_	O
154	,	_	_	O
155	other	_	_	O
156	taxane	_	_	O
157	,	_	_	O
158	or	_	_	O
159	oxaliplatin	_	_	O
160	treatment	_	_	O
161	.	_	_	O

162	The	_	_	O
163	initial	_	_	O
164	treatment	_	_	O
165	consisted	_	_	O
166	of	_	_	O
167	taking	_	_	O
168	1	_	_	O
169	capsule	_	_	O
170	daily	_	_	O
171	of	_	_	O
172	either	_	_	O
173	30	_	_	O
174	mg	_	_	O
175	of	_	_	O
176	duloxetine	_	_	O
177	or	_	_	O
178	placebo	_	_	O
179	for	_	_	O
180	the	_	_	O
181	first	_	_	O
182	week	_	_	O
183	and	_	_	O
184	2	_	_	O
185	capsules	_	_	O
186	of	_	_	O
187	either	_	_	O
188	30	_	_	O
189	mg	_	_	O
190	of	_	_	O
191	duloxetine	_	_	O
192	or	_	_	O
193	placebo	_	_	O
194	daily	_	_	O
195	for	_	_	O
196	4	_	_	O
197	additional	_	_	O
198	weeks	_	_	O
199	.	_	_	O

200	The	_	_	O
201	primary	_	_	O
202	hypothesis	_	_	O
203	was	_	_	O
204	that	_	_	O
205	duloxetine	_	_	O
206	would	_	_	O
207	be	_	_	O
208	more	_	_	O
209	effective	_	_	O
210	than	_	_	O
211	placebo	_	_	O
212	in	_	_	O
213	decreasing	_	_	O
214	chemotherapy	_	_	O
215	-	_	_	O
216	induced	_	_	O
217	peripheral	_	_	O
218	neuropathic	_	_	O
219	pain	_	_	O
220	.	_	_	O

221	Pain	_	_	O
222	severity	_	_	O
223	was	_	_	O
224	assessed	_	_	O
225	using	_	_	O
226	the	_	_	O
227	Brief	_	_	O
228	Pain	_	_	O
229	Inventory	_	_	O
230	-	_	_	O
231	Short	_	_	O
232	Form	_	_	O
233	"	_	_	O
234	average	_	_	O
235	pain	_	_	O
236	"	_	_	O
237	item	_	_	O
238	with	_	_	O
239	0	_	_	O
240	representing	_	_	O
241	no	_	_	O
242	pain	_	_	O
243	and	_	_	O
244	10	_	_	O
245	representing	_	_	O
246	as	_	_	O
247	bad	_	_	O
248	as	_	_	O
249	can	_	_	O
250	be	_	_	O
251	imagined	_	_	O
252	.	_	_	O

253	Individuals	_	_	B-Premise
254	receiving	_	_	I-Premise
255	duloxetine	_	_	I-Premise
256	as	_	_	I-Premise
257	their	_	_	I-Premise
258	initial	_	_	I-Premise
259	5	_	_	I-Premise
260	-	_	_	I-Premise
261	week	_	_	I-Premise
262	treatment	_	_	I-Premise
263	reported	_	_	I-Premise
264	a	_	_	I-Premise
265	mean	_	_	I-Premise
266	decrease	_	_	I-Premise
267	in	_	_	I-Premise
268	average	_	_	I-Premise
269	pain	_	_	I-Premise
270	of	_	_	I-Premise
271	1	_	_	I-Premise
272	.	_	_	I-Premise

273	06	_	_	I-Premise
274	(	_	_	I-Premise
275	95	_	_	I-Premise
276	%	_	_	I-Premise
277	CI	_	_	I-Premise
278	,	_	_	I-Premise
279	0	_	_	I-Premise
280	.	_	_	I-Premise

281	72	_	_	I-Premise
282	-	_	_	I-Premise
283	1	_	_	I-Premise
284	.	_	_	I-Premise

285	40	_	_	I-Premise
286	)	_	_	I-Premise
287	vs	_	_	I-Premise
288	0	_	_	I-Premise
289	.	_	_	I-Premise

290	34	_	_	I-Premise
291	(	_	_	I-Premise
292	95	_	_	I-Premise
293	%	_	_	I-Premise
294	CI	_	_	I-Premise
295	,	_	_	I-Premise
296	0	_	_	I-Premise
297	.	_	_	I-Premise

298	01	_	_	I-Premise
299	-	_	_	I-Premise
300	0	_	_	I-Premise
301	.	_	_	I-Premise

302	66	_	_	I-Premise
303	)	_	_	I-Premise
304	among	_	_	I-Premise
305	those	_	_	I-Premise
306	who	_	_	I-Premise
307	received	_	_	I-Premise
308	placebo	_	_	I-Premise
309	(	_	_	I-Premise
310	P	_	_	I-Premise
311	=	_	_	I-Premise
312	.	_	_	I-Premise

313	003	_	_	I-Premise
314	;	_	_	I-Premise
315	effect	_	_	I-Premise
316	size	_	_	I-Premise
317	,	_	_	I-Premise
318	0	_	_	I-Premise
319	.	_	_	I-Premise

320	513	_	_	I-Premise
321	)	_	_	I-Premise
322	.	_	_	I-Premise

323	The	_	_	B-Premise
324	observed	_	_	I-Premise
325	mean	_	_	I-Premise
326	difference	_	_	I-Premise
327	in	_	_	I-Premise
328	the	_	_	I-Premise
329	average	_	_	I-Premise
330	pain	_	_	I-Premise
331	score	_	_	I-Premise
332	between	_	_	I-Premise
333	duloxetine	_	_	I-Premise
334	and	_	_	I-Premise
335	placebo	_	_	I-Premise
336	was	_	_	I-Premise
337	0	_	_	I-Premise
338	.	_	_	I-Premise

339	73	_	_	I-Premise
340	(	_	_	I-Premise
341	95	_	_	I-Premise
342	%	_	_	I-Premise
343	CI	_	_	I-Premise
344	,	_	_	I-Premise
345	0	_	_	I-Premise
346	.	_	_	I-Premise

347	26	_	_	I-Premise
348	-	_	_	I-Premise
349	1	_	_	I-Premise
350	.	_	_	I-Premise

351	20	_	_	I-Premise
352	)	_	_	I-Premise
353	.	_	_	I-Premise

354	Fifty	_	_	B-Premise
355	-	_	_	I-Premise
356	nine	_	_	I-Premise
357	percent	_	_	I-Premise
358	of	_	_	I-Premise
359	those	_	_	I-Premise
360	initially	_	_	I-Premise
361	receiving	_	_	I-Premise
362	duloxetine	_	_	I-Premise
363	vs	_	_	I-Premise
364	38	_	_	I-Premise
365	%	_	_	I-Premise
366	of	_	_	I-Premise
367	those	_	_	I-Premise
368	initially	_	_	I-Premise
369	receiving	_	_	I-Premise
370	placebo	_	_	I-Premise
371	reported	_	_	I-Premise
372	decreased	_	_	I-Premise
373	pain	_	_	I-Premise
374	of	_	_	I-Premise
375	any	_	_	I-Premise
376	amount	_	_	I-Premise
377	.	_	_	I-Premise

378	Among	_	_	B-Claim
379	patients	_	_	I-Claim
380	with	_	_	I-Claim
381	painful	_	_	I-Claim
382	chemotherapy	_	_	I-Claim
383	-	_	_	I-Claim
384	induced	_	_	I-Claim
385	peripheral	_	_	I-Claim
386	neuropathy	_	_	I-Claim
387	,	_	_	I-Claim
388	the	_	_	I-Claim
389	use	_	_	I-Claim
390	of	_	_	I-Claim
391	duloxetine	_	_	I-Claim
392	compared	_	_	I-Claim
393	with	_	_	I-Claim
394	placebo	_	_	I-Claim
395	for	_	_	I-Claim
396	5	_	_	I-Claim
397	weeks	_	_	I-Claim
398	resulted	_	_	I-Claim
399	in	_	_	I-Claim
400	a	_	_	I-Claim
401	greater	_	_	I-Claim
402	reduction	_	_	I-Claim
403	in	_	_	I-Claim
404	pain	_	_	I-Claim
405	.	_	_	I-Claim


0	Abiraterone	_	_	B-Claim
1	acetate	_	_	I-Claim
2	plus	_	_	I-Claim
3	prednisone	_	_	I-Claim
4	significantly	_	_	I-Claim
5	improves	_	_	I-Claim
6	radiographic	_	_	I-Claim
7	progression	_	_	I-Claim
8	-	_	_	I-Claim
9	free	_	_	I-Claim
10	survival	_	_	I-Claim
11	in	_	_	I-Claim
12	asymptomatic	_	_	I-Claim
13	or	_	_	I-Claim
14	mildly	_	_	I-Claim
15	symptomatic	_	_	I-Claim
16	,	_	_	I-Claim
17	chemotherapy	_	_	I-Claim
18	-	_	_	I-Claim
19	naive	_	_	I-Claim
20	patients	_	_	I-Claim
21	with	_	_	I-Claim
22	metastatic	_	_	I-Claim
23	castration	_	_	I-Claim
24	-	_	_	I-Claim
25	resistant	_	_	I-Claim
26	prostate	_	_	I-Claim
27	cancer	_	_	I-Claim
28	compared	_	_	I-Claim
29	with	_	_	I-Claim
30	prednisone	_	_	I-Claim
31	alone	_	_	I-Claim
32	.	_	_	I-Claim

33	We	_	_	O
34	describe	_	_	O
35	analyses	_	_	O
36	of	_	_	O
37	data	_	_	O
38	for	_	_	O
39	patient	_	_	O
40	-	_	_	O
41	reported	_	_	O
42	pain	_	_	O
43	and	_	_	O
44	functional	_	_	O
45	status	_	_	O
46	in	_	_	O
47	a	_	_	O
48	preplanned	_	_	O
49	interim	_	_	O
50	analysis	_	_	O
51	of	_	_	O
52	a	_	_	O
53	phase	_	_	O
54	3	_	_	O
55	trial	_	_	O
56	.	_	_	O

57	Between	_	_	O
58	April	_	_	O
59	28	_	_	O
60	,	_	_	O
61	2009	_	_	O
62	,	_	_	O
63	and	_	_	O
64	June	_	_	O
65	23	_	_	O
66	,	_	_	O
67	2010	_	_	O
68	,	_	_	O
69	patients	_	_	O
70	with	_	_	O
71	progressive	_	_	O
72	,	_	_	O
73	metastatic	_	_	O
74	castration	_	_	O
75	-	_	_	O
76	resistant	_	_	O
77	prostate	_	_	O
78	cancer	_	_	O
79	were	_	_	O
80	enrolled	_	_	O
81	into	_	_	O
82	a	_	_	O
83	multinational	_	_	O
84	,	_	_	O
85	double	_	_	O
86	-	_	_	O
87	blind	_	_	O
88	,	_	_	O
89	placebo	_	_	O
90	-	_	_	O
91	controlled	_	_	O
92	trial	_	_	O
93	.	_	_	O

94	Patients	_	_	O
95	were	_	_	O
96	eligible	_	_	O
97	if	_	_	O
98	they	_	_	O
99	were	_	_	O
100	asymptomatic	_	_	O
101	(	_	_	O
102	score	_	_	O
103	of	_	_	O
104	0	_	_	O
105	or	_	_	O
106	1	_	_	O
107	on	_	_	O
108	item	_	_	O
109	three	_	_	O
110	of	_	_	O
111	the	_	_	O
112	Brief	_	_	O
113	Pain	_	_	O
114	Inventory	_	_	O
115	Short	_	_	O
116	Form	_	_	O
117	[	_	_	O
118	BPI	_	_	O
119	-	_	_	O
120	SF	_	_	O
121	]	_	_	O
122	questionnaire	_	_	O
123	)	_	_	O
124	or	_	_	O
125	mildly	_	_	O
126	symptomatic	_	_	O
127	(	_	_	O
128	score	_	_	O
129	of	_	_	O
130	2	_	_	O
131	or	_	_	O
132	3	_	_	O
133	)	_	_	O
134	and	_	_	O
135	had	_	_	O
136	not	_	_	O
137	previously	_	_	O
138	received	_	_	O
139	chemotherapy	_	_	O
140	.	_	_	O

141	Patients	_	_	O
142	were	_	_	O
143	randomly	_	_	O
144	assigned	_	_	O
145	(	_	_	O
146	1	_	_	O
147	:	_	_	O
148	1	_	_	O
149	)	_	_	O
150	to	_	_	O
151	receive	_	_	O
152	oral	_	_	O
153	abiraterone	_	_	O
154	(	_	_	O
155	1	_	_	O
156	g	_	_	O
157	daily	_	_	O
158	)	_	_	O
159	plus	_	_	O
160	prednisone	_	_	O
161	(	_	_	O
162	5	_	_	O
163	mg	_	_	O
164	twice	_	_	O
165	daily	_	_	O
166	)	_	_	O
167	or	_	_	O
168	placebo	_	_	O
169	plus	_	_	O
170	prednisone	_	_	O
171	in	_	_	O
172	continuous	_	_	O
173	4	_	_	O
174	-	_	_	O
175	week	_	_	O
176	cycles	_	_	O
177	.	_	_	O

178	Pain	_	_	O
179	was	_	_	O
180	assessed	_	_	O
181	with	_	_	O
182	the	_	_	O
183	BPI	_	_	O
184	-	_	_	O
185	SF	_	_	O
186	questionnaire	_	_	O
187	,	_	_	O
188	and	_	_	O
189	health	_	_	O
190	-	_	_	O
191	related	_	_	O
192	quality	_	_	O
193	of	_	_	O
194	life	_	_	O
195	(	_	_	O
196	HRQoL	_	_	O
197	)	_	_	O
198	with	_	_	O
199	the	_	_	O
200	Functional	_	_	O
201	Assessment	_	_	O
202	of	_	_	O
203	Cancer	_	_	O
204	Therapy	_	_	O
205	-	_	_	O
206	Prostate	_	_	O
207	(	_	_	O
208	FACT	_	_	O
209	-	_	_	O
210	P	_	_	O
211	)	_	_	O
212	questionnaire	_	_	O
213	.	_	_	O

214	We	_	_	O
215	analysed	_	_	O
216	data	_	_	O
217	with	_	_	O
218	prespecified	_	_	O
219	criteria	_	_	O
220	for	_	_	O
221	clinically	_	_	O
222	meaningful	_	_	O
223	pain	_	_	O
224	progression	_	_	O
225	and	_	_	O
226	deterioration	_	_	O
227	in	_	_	O
228	HRQoL	_	_	O
229	.	_	_	O

230	All	_	_	O
231	patients	_	_	O
232	who	_	_	O
233	underwent	_	_	O
234	randomisation	_	_	O
235	were	_	_	O
236	included	_	_	O
237	in	_	_	O
238	analyses	_	_	O
239	.	_	_	O

240	1088	_	_	O
241	patients	_	_	O
242	underwent	_	_	O
243	randomisation	_	_	O
244	:	_	_	O
245	546	_	_	O
246	were	_	_	O
247	assigned	_	_	O
248	to	_	_	O
249	abiraterone	_	_	O
250	plus	_	_	O
251	prednisone	_	_	O
252	and	_	_	O
253	542	_	_	O
254	to	_	_	O
255	placebo	_	_	O
256	plus	_	_	O
257	prednisone	_	_	O
258	.	_	_	O

259	At	_	_	O
260	the	_	_	O
261	time	_	_	O
262	of	_	_	O
263	the	_	_	O
264	second	_	_	O
265	prespecified	_	_	O
266	interim	_	_	O
267	analysis	_	_	O
268	,	_	_	O
269	median	_	_	O
270	follow	_	_	O
271	-	_	_	O
272	up	_	_	O
273	was	_	_	O
274	22	_	_	O
275	·	_	_	O
276	2	_	_	O
277	months	_	_	O
278	(	_	_	O
279	IQR	_	_	O
280	20	_	_	O
281	·	_	_	O
282	2	_	_	O
283	-	_	_	O
284	24	_	_	O
285	·	_	_	O
286	8	_	_	O
287	)	_	_	O
288	.	_	_	O

289	Median	_	_	B-Premise
290	time	_	_	I-Premise
291	to	_	_	I-Premise
292	progression	_	_	I-Premise
293	of	_	_	I-Premise
294	mean	_	_	I-Premise
295	pain	_	_	I-Premise
296	intensity	_	_	I-Premise
297	was	_	_	I-Premise
298	longer	_	_	I-Premise
299	in	_	_	I-Premise
300	patients	_	_	I-Premise
301	assigned	_	_	I-Premise
302	to	_	_	I-Premise
303	abiraterone	_	_	I-Premise
304	plus	_	_	I-Premise
305	prednisone	_	_	I-Premise
306	(	_	_	I-Premise
307	26	_	_	I-Premise
308	·	_	_	I-Premise
309	7	_	_	I-Premise
310	months	_	_	I-Premise
311	[	_	_	I-Premise
312	95	_	_	I-Premise
313	%	_	_	I-Premise
314	CI	_	_	I-Premise
315	19	_	_	I-Premise
316	·	_	_	I-Premise
317	3	_	_	I-Premise
318	-	_	_	I-Premise
319	not	_	_	I-Premise
320	estimable	_	_	I-Premise
321	]	_	_	I-Premise
322	)	_	_	I-Premise
323	than	_	_	I-Premise
324	in	_	_	I-Premise
325	those	_	_	I-Premise
326	assigned	_	_	I-Premise
327	to	_	_	I-Premise
328	placebo	_	_	I-Premise
329	plus	_	_	I-Premise
330	prednisone	_	_	I-Premise
331	(	_	_	I-Premise
332	18	_	_	I-Premise
333	·	_	_	I-Premise
334	4	_	_	I-Premise
335	months	_	_	I-Premise
336	[	_	_	I-Premise
337	14	_	_	I-Premise
338	·	_	_	I-Premise
339	9	_	_	I-Premise
340	-	_	_	I-Premise
341	not	_	_	I-Premise
342	estimable	_	_	I-Premise
343	]	_	_	I-Premise
344	;	_	_	I-Premise
345	hazard	_	_	I-Premise
346	ratio	_	_	I-Premise
347	[	_	_	I-Premise
348	HR	_	_	I-Premise
349	]	_	_	I-Premise
350	0	_	_	I-Premise
351	·	_	_	I-Premise
352	82	_	_	I-Premise
353	,	_	_	I-Premise
354	95	_	_	I-Premise
355	%	_	_	I-Premise
356	CI	_	_	I-Premise
357	0	_	_	I-Premise
358	·	_	_	I-Premise
359	67	_	_	I-Premise
360	-	_	_	I-Premise
361	1	_	_	I-Premise
362	·	_	_	I-Premise
363	00	_	_	I-Premise
364	;	_	_	I-Premise
365	p	_	_	I-Premise
366	=	_	_	I-Premise
367	0	_	_	I-Premise
368	·	_	_	I-Premise
369	0490	_	_	I-Premise
370	)	_	_	I-Premise
371	,	_	_	I-Premise
372	as	_	_	I-Premise
373	was	_	_	I-Premise
374	median	_	_	I-Premise
375	time	_	_	I-Premise
376	to	_	_	I-Premise
377	progression	_	_	I-Premise
378	of	_	_	I-Premise
379	pain	_	_	I-Premise
380	interference	_	_	I-Premise
381	with	_	_	I-Premise
382	daily	_	_	I-Premise
383	activities	_	_	I-Premise
384	(	_	_	I-Premise
385	10	_	_	I-Premise
386	·	_	_	I-Premise
387	3	_	_	I-Premise
388	months	_	_	I-Premise
389	[	_	_	I-Premise
390	95	_	_	I-Premise
391	%	_	_	I-Premise
392	CI	_	_	I-Premise
393	9	_	_	I-Premise
394	·	_	_	I-Premise
395	3	_	_	I-Premise
396	-	_	_	I-Premise
397	13	_	_	I-Premise
398	·	_	_	I-Premise
399	0	_	_	I-Premise
400	]	_	_	I-Premise
401	vs	_	_	I-Premise
402	7	_	_	I-Premise
403	·	_	_	I-Premise
404	4	_	_	I-Premise
405	months	_	_	I-Premise
406	[	_	_	I-Premise
407	6	_	_	I-Premise
408	·	_	_	I-Premise
409	4	_	_	I-Premise
410	-	_	_	I-Premise
411	8	_	_	I-Premise
412	·	_	_	I-Premise
413	6	_	_	I-Premise
414	]	_	_	I-Premise
415	;	_	_	I-Premise
416	HR	_	_	I-Premise
417	0	_	_	I-Premise
418	·	_	_	I-Premise
419	79	_	_	I-Premise
420	,	_	_	I-Premise
421	95	_	_	I-Premise
422	%	_	_	I-Premise
423	CI	_	_	I-Premise
424	0	_	_	I-Premise
425	·	_	_	I-Premise
426	67	_	_	I-Premise
427	-	_	_	I-Premise
428	0	_	_	I-Premise
429	·	_	_	I-Premise
430	93	_	_	I-Premise
431	;	_	_	I-Premise
432	p	_	_	I-Premise
433	=	_	_	I-Premise
434	0	_	_	I-Premise
435	·	_	_	I-Premise
436	005	_	_	I-Premise
437	)	_	_	I-Premise
438	.	_	_	I-Premise

439	Median	_	_	B-Premise
440	time	_	_	I-Premise
441	to	_	_	I-Premise
442	progression	_	_	I-Premise
443	of	_	_	I-Premise
444	worst	_	_	I-Premise
445	pain	_	_	I-Premise
446	was	_	_	I-Premise
447	also	_	_	I-Premise
448	longer	_	_	I-Premise
449	with	_	_	I-Premise
450	abiraterone	_	_	I-Premise
451	plus	_	_	I-Premise
452	prednisone	_	_	I-Premise
453	(	_	_	I-Premise
454	26	_	_	I-Premise
455	·	_	_	I-Premise
456	7	_	_	I-Premise
457	months	_	_	I-Premise
458	[	_	_	I-Premise
459	95	_	_	I-Premise
460	%	_	_	I-Premise
461	CI	_	_	I-Premise
462	19	_	_	I-Premise
463	·	_	_	I-Premise
464	4	_	_	I-Premise
465	-	_	_	I-Premise
466	not	_	_	I-Premise
467	estimable	_	_	I-Premise
468	]	_	_	I-Premise
469	)	_	_	I-Premise
470	than	_	_	I-Premise
471	with	_	_	I-Premise
472	placebo	_	_	I-Premise
473	plus	_	_	I-Premise
474	prednisone	_	_	I-Premise
475	(	_	_	I-Premise
476	19	_	_	I-Premise
477	·	_	_	I-Premise
478	4	_	_	I-Premise
479	months	_	_	I-Premise
480	[	_	_	I-Premise
481	16	_	_	I-Premise
482	·	_	_	I-Premise
483	6	_	_	I-Premise
484	-	_	_	I-Premise
485	not	_	_	I-Premise
486	estimable	_	_	I-Premise
487	]	_	_	I-Premise
488	)	_	_	I-Premise
489	,	_	_	I-Premise
490	but	_	_	I-Premise
491	the	_	_	I-Premise
492	difference	_	_	I-Premise
493	was	_	_	I-Premise
494	not	_	_	I-Premise
495	significant	_	_	I-Premise
496	(	_	_	I-Premise
497	HR	_	_	I-Premise
498	0	_	_	I-Premise
499	·	_	_	I-Premise
500	85	_	_	I-Premise
501	,	_	_	I-Premise
502	95	_	_	I-Premise
503	%	_	_	I-Premise
504	CI	_	_	I-Premise
505	0	_	_	I-Premise
506	·	_	_	I-Premise
507	69	_	_	I-Premise
508	-	_	_	I-Premise
509	1	_	_	I-Premise
510	·	_	_	I-Premise
511	04	_	_	I-Premise
512	;	_	_	I-Premise
513	p	_	_	I-Premise
514	=	_	_	I-Premise
515	0	_	_	I-Premise
516	·	_	_	I-Premise
517	109	_	_	I-Premise
518	)	_	_	I-Premise
519	.	_	_	I-Premise

520	Median	_	_	B-Premise
521	time	_	_	I-Premise
522	to	_	_	I-Premise
523	HRQoL	_	_	I-Premise
524	deterioration	_	_	I-Premise
525	was	_	_	I-Premise
526	longer	_	_	I-Premise
527	in	_	_	I-Premise
528	patients	_	_	I-Premise
529	assigned	_	_	I-Premise
530	to	_	_	I-Premise
531	abiraterone	_	_	I-Premise
532	plus	_	_	I-Premise
533	prednisone	_	_	I-Premise
534	than	_	_	I-Premise
535	in	_	_	I-Premise
536	those	_	_	I-Premise
537	assigned	_	_	I-Premise
538	to	_	_	I-Premise
539	placebo	_	_	I-Premise
540	plus	_	_	I-Premise
541	prednisone	_	_	I-Premise
542	as	_	_	I-Premise
543	assessed	_	_	I-Premise
544	by	_	_	I-Premise
545	the	_	_	I-Premise
546	FACT	_	_	I-Premise
547	-	_	_	I-Premise
548	P	_	_	I-Premise
549	total	_	_	I-Premise
550	score	_	_	I-Premise
551	(	_	_	I-Premise
552	12	_	_	I-Premise
553	·	_	_	I-Premise
554	7	_	_	I-Premise
555	months	_	_	I-Premise
556	[	_	_	I-Premise
557	95	_	_	I-Premise
558	%	_	_	I-Premise
559	CI	_	_	I-Premise
560	11	_	_	I-Premise
561	·	_	_	I-Premise
562	1	_	_	I-Premise
563	-	_	_	I-Premise
564	14	_	_	I-Premise
565	·	_	_	I-Premise
566	0	_	_	I-Premise
567	]	_	_	I-Premise
568	vs	_	_	I-Premise
569	8	_	_	I-Premise
570	·	_	_	I-Premise
571	3	_	_	I-Premise
572	months	_	_	I-Premise
573	[	_	_	I-Premise
574	7	_	_	I-Premise
575	·	_	_	I-Premise
576	4	_	_	I-Premise
577	-	_	_	I-Premise
578	10	_	_	I-Premise
579	·	_	_	I-Premise
580	6	_	_	I-Premise
581	]	_	_	I-Premise
582	;	_	_	I-Premise
583	HR	_	_	I-Premise
584	0	_	_	I-Premise
585	·	_	_	I-Premise
586	78	_	_	I-Premise
587	,	_	_	I-Premise
588	95	_	_	I-Premise
589	%	_	_	I-Premise
590	CI	_	_	I-Premise
591	0	_	_	I-Premise
592	·	_	_	I-Premise
593	66	_	_	I-Premise
594	-	_	_	I-Premise
595	0	_	_	I-Premise
596	·	_	_	I-Premise
597	92	_	_	I-Premise
598	;	_	_	I-Premise
599	p	_	_	I-Premise
600	=	_	_	I-Premise
601	0	_	_	I-Premise
602	·	_	_	I-Premise
603	003	_	_	I-Premise
604	)	_	_	I-Premise
605	and	_	_	I-Premise
606	by	_	_	I-Premise
607	the	_	_	I-Premise
608	score	_	_	I-Premise
609	on	_	_	I-Premise
610	its	_	_	I-Premise
611	prostate	_	_	I-Premise
612	-	_	_	I-Premise
613	cancer	_	_	I-Premise
614	-	_	_	I-Premise
615	specific	_	_	I-Premise
616	subscale	_	_	I-Premise
617	(	_	_	I-Premise
618	11	_	_	I-Premise
619	·	_	_	I-Premise
620	1	_	_	I-Premise
621	months	_	_	I-Premise
622	[	_	_	I-Premise
623	8	_	_	I-Premise
624	·	_	_	I-Premise
625	6	_	_	I-Premise
626	-	_	_	I-Premise
627	13	_	_	I-Premise
628	·	_	_	I-Premise
629	8	_	_	I-Premise
630	]	_	_	I-Premise
631	vs	_	_	I-Premise
632	5	_	_	I-Premise
633	·	_	_	I-Premise
634	8	_	_	I-Premise
635	months	_	_	I-Premise
636	[	_	_	I-Premise
637	5	_	_	I-Premise
638	·	_	_	I-Premise
639	5	_	_	I-Premise
640	-	_	_	I-Premise
641	8	_	_	I-Premise
642	·	_	_	I-Premise
643	3	_	_	I-Premise
644	]	_	_	I-Premise
645	;	_	_	I-Premise
646	HR	_	_	I-Premise
647	0	_	_	I-Premise
648	·	_	_	I-Premise
649	70	_	_	I-Premise
650	,	_	_	I-Premise
651	95	_	_	I-Premise
652	%	_	_	I-Premise
653	CI	_	_	I-Premise
654	0	_	_	I-Premise
655	·	_	_	I-Premise
656	60	_	_	I-Premise
657	-	_	_	I-Premise
658	0	_	_	I-Premise
659	·	_	_	I-Premise
660	83	_	_	I-Premise
661	;	_	_	I-Premise
662	p	_	_	I-Premise
663	<	_	_	I-Premise
664	0	_	_	I-Premise
665	·	_	_	I-Premise
666	0001	_	_	I-Premise
667	)	_	_	I-Premise
668	.	_	_	I-Premise

669	Abiraterone	_	_	B-Claim
670	plus	_	_	I-Claim
671	prednisone	_	_	I-Claim
672	delays	_	_	I-Claim
673	patient	_	_	I-Claim
674	-	_	_	I-Claim
675	reported	_	_	I-Claim
676	pain	_	_	I-Claim
677	progression	_	_	I-Claim
678	and	_	_	I-Claim
679	HRQoL	_	_	I-Claim
680	deterioration	_	_	I-Claim
681	in	_	_	I-Claim
682	chemotherapy	_	_	I-Claim
683	-	_	_	I-Claim
684	naive	_	_	I-Claim
685	patients	_	_	I-Claim
686	with	_	_	I-Claim
687	metastatic	_	_	I-Claim
688	castration	_	_	I-Claim
689	-	_	_	I-Claim
690	resistant	_	_	I-Claim
691	prostate	_	_	I-Claim
692	cancer	_	_	I-Claim
693	.	_	_	I-Claim

694	These	_	_	B-Claim
695	results	_	_	I-Claim
696	provide	_	_	I-Claim
697	further	_	_	I-Claim
698	support	_	_	I-Claim
699	for	_	_	I-Claim
700	the	_	_	I-Claim
701	efficacy	_	_	I-Claim
702	of	_	_	I-Claim
703	abiraterone	_	_	I-Claim
704	in	_	_	I-Claim
705	this	_	_	I-Claim
706	population	_	_	I-Claim
707	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	a	_	_	O
6	multimodal	_	_	O
7	group	_	_	O
8	exercise	_	_	O
9	intervention	_	_	O
10	,	_	_	O
11	as	_	_	O
12	an	_	_	O
13	adjunct	_	_	O
14	to	_	_	O
15	conventional	_	_	O
16	care	_	_	O
17	,	_	_	O
18	on	_	_	O
19	fatigue	_	_	O
20	,	_	_	O
21	physical	_	_	O
22	capacity	_	_	O
23	,	_	_	O
24	general	_	_	O
25	wellbeing	_	_	O
26	,	_	_	O
27	physical	_	_	O
28	activity	_	_	O
29	,	_	_	O
30	and	_	_	O
31	quality	_	_	O
32	of	_	_	O
33	life	_	_	O
34	in	_	_	O
35	patients	_	_	O
36	with	_	_	O
37	cancer	_	_	O
38	who	_	_	O
39	were	_	_	O
40	undergoing	_	_	O
41	adjuvant	_	_	O
42	chemotherapy	_	_	O
43	or	_	_	O
44	treatment	_	_	O
45	for	_	_	O
46	advanced	_	_	O
47	disease	_	_	O
48	.	_	_	O

49	Randomised	_	_	O
50	controlled	_	_	O
51	trial	_	_	O
52	.	_	_	O

53	Two	_	_	O
54	university	_	_	O
55	hospitals	_	_	O
56	in	_	_	O
57	Copenhagen	_	_	O
58	,	_	_	O
59	Denmark	_	_	O
60	.	_	_	O

61	269	_	_	O
62	patients	_	_	O
63	with	_	_	O
64	cancer	_	_	O
65	;	_	_	O
66	73	_	_	O
67	men	_	_	O
68	,	_	_	O
69	196	_	_	O
70	women	_	_	O
71	,	_	_	O
72	mean	_	_	O
73	age	_	_	O
74	47	_	_	O
75	years	_	_	O
76	(	_	_	O
77	range	_	_	O
78	20	_	_	O
79	-	_	_	O
80	65	_	_	O
81	)	_	_	O
82	representing	_	_	O
83	21	_	_	O
84	diagnoses	_	_	O
85	.	_	_	O

86	Main	_	_	O
87	exclusion	_	_	O
88	criteria	_	_	O
89	were	_	_	O
90	brain	_	_	O
91	or	_	_	O
92	bone	_	_	O
93	metastases	_	_	O
94	.	_	_	O

95	235	_	_	O
96	patients	_	_	O
97	completed	_	_	O
98	follow	_	_	O
99	-	_	_	O
100	up	_	_	O
101	.	_	_	O

102	Supervised	_	_	O
103	exercise	_	_	O
104	comprising	_	_	O
105	high	_	_	O
106	intensity	_	_	O
107	cardiovascular	_	_	O
108	and	_	_	O
109	resistance	_	_	O
110	training	_	_	O
111	,	_	_	O
112	relaxation	_	_	O
113	and	_	_	O
114	body	_	_	O
115	awareness	_	_	O
116	training	_	_	O
117	,	_	_	O
118	massage	_	_	O
119	,	_	_	O
120	nine	_	_	O
121	hours	_	_	O
122	weekly	_	_	O
123	for	_	_	O
124	six	_	_	O
125	weeks	_	_	O
126	in	_	_	O
127	addition	_	_	O
128	to	_	_	O
129	conventional	_	_	O
130	care	_	_	O
131	,	_	_	O
132	compared	_	_	O
133	with	_	_	O
134	conventional	_	_	O
135	care	_	_	O
136	.	_	_	O

137	The	_	_	O
138	general	_	_	O
139	linear	_	_	O
140	model	_	_	O
141	was	_	_	O
142	used	_	_	O
143	for	_	_	O
144	continuous	_	_	O
145	outcome	_	_	O
146	while	_	_	O
147	analysis	_	_	O
148	of	_	_	O
149	associates	_	_	O
150	between	_	_	O
151	categorical	_	_	O
152	outcomes	_	_	O
153	was	_	_	O
154	performed	_	_	O
155	as	_	_	O
156	analysis	_	_	O
157	of	_	_	O
158	marginal	_	_	O
159	homogeneity	_	_	O
160	in	_	_	O
161	contingency	_	_	O
162	tables	_	_	O
163	.	_	_	O

164	Adjusted	_	_	B-Premise
165	for	_	_	I-Premise
166	baseline	_	_	I-Premise
167	score	_	_	I-Premise
168	,	_	_	I-Premise
169	disease	_	_	I-Premise
170	,	_	_	I-Premise
171	and	_	_	I-Premise
172	demographic	_	_	I-Premise
173	covariates	_	_	I-Premise
174	,	_	_	I-Premise
175	the	_	_	I-Premise
176	intervention	_	_	I-Premise
177	group	_	_	I-Premise
178	showed	_	_	I-Premise
179	an	_	_	I-Premise
180	estimated	_	_	I-Premise
181	improvement	_	_	I-Premise
182	at	_	_	I-Premise
183	six	_	_	I-Premise
184	weeks	_	_	I-Premise
185	for	_	_	I-Premise
186	the	_	_	I-Premise
187	primary	_	_	I-Premise
188	outcome	_	_	I-Premise
189	,	_	_	I-Premise
190	fatigue	_	_	I-Premise
191	,	_	_	I-Premise
192	of	_	_	I-Premise
193	-	_	_	I-Premise
194	6	_	_	I-Premise
195	.	_	_	I-Premise

196	6	_	_	I-Premise
197	points	_	_	I-Premise
198	(	_	_	I-Premise
199	95	_	_	I-Premise
200	%	_	_	I-Premise
201	confidence	_	_	I-Premise
202	interval	_	_	I-Premise
203	-	_	_	I-Premise
204	12	_	_	I-Premise
205	.	_	_	I-Premise

206	3	_	_	I-Premise
207	to	_	_	I-Premise
208	-	_	_	I-Premise
209	0	_	_	I-Premise
210	.	_	_	I-Premise

211	9	_	_	I-Premise
212	,	_	_	I-Premise
213	P	_	_	I-Premise
214	=	_	_	I-Premise
215	0	_	_	I-Premise
216	.	_	_	I-Premise

217	02	_	_	I-Premise
218	;	_	_	I-Premise
219	effect	_	_	I-Premise
220	size	_	_	I-Premise
221	=	_	_	I-Premise
222	0	_	_	I-Premise
223	.	_	_	I-Premise

224	33	_	_	I-Premise
225	,	_	_	I-Premise
226	0	_	_	I-Premise
227	.	_	_	I-Premise

228	04	_	_	I-Premise
229	to	_	_	I-Premise
230	0	_	_	I-Premise
231	.	_	_	I-Premise

232	61	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	Significant	_	_	B-Premise
236	effects	_	_	I-Premise
237	were	_	_	I-Premise
238	seen	_	_	I-Premise
239	on	_	_	I-Premise
240	vitality	_	_	I-Premise
241	(	_	_	I-Premise
242	effect	_	_	I-Premise
243	size	_	_	I-Premise
244	0	_	_	I-Premise
245	.	_	_	I-Premise

246	55	_	_	I-Premise
247	,	_	_	I-Premise
248	95	_	_	I-Premise
249	%	_	_	I-Premise
250	CI	_	_	I-Premise
251	0	_	_	I-Premise
252	.	_	_	I-Premise

253	27	_	_	I-Premise
254	to	_	_	I-Premise
255	0	_	_	I-Premise
256	.	_	_	I-Premise

257	82	_	_	I-Premise
258	)	_	_	I-Premise
259	,	_	_	I-Premise
260	physical	_	_	I-Premise
261	functioning	_	_	I-Premise
262	(	_	_	I-Premise
263	0	_	_	I-Premise
264	.	_	_	I-Premise

265	37	_	_	I-Premise
266	,	_	_	I-Premise
267	0	_	_	I-Premise
268	.	_	_	I-Premise

269	09	_	_	I-Premise
270	to	_	_	I-Premise
271	0	_	_	I-Premise
272	.	_	_	I-Premise

273	65	_	_	I-Premise
274	)	_	_	I-Premise
275	,	_	_	I-Premise
276	role	_	_	I-Premise
277	physical	_	_	I-Premise
278	(	_	_	I-Premise
279	0	_	_	I-Premise
280	.	_	_	I-Premise

281	37	_	_	I-Premise
282	,	_	_	I-Premise
283	0	_	_	I-Premise
284	.	_	_	I-Premise

285	10	_	_	I-Premise
286	to	_	_	I-Premise
287	0	_	_	I-Premise
288	.	_	_	I-Premise

289	64	_	_	I-Premise
290	)	_	_	I-Premise
291	,	_	_	I-Premise
292	role	_	_	I-Premise
293	emotional	_	_	I-Premise
294	(	_	_	I-Premise
295	0	_	_	I-Premise
296	.	_	_	I-Premise

297	32	_	_	I-Premise
298	,	_	_	I-Premise
299	0	_	_	I-Premise
300	.	_	_	I-Premise

301	05	_	_	I-Premise
302	to	_	_	I-Premise
303	0	_	_	I-Premise
304	.	_	_	I-Premise

305	59	_	_	I-Premise
306	)	_	_	I-Premise
307	,	_	_	I-Premise
308	and	_	_	I-Premise
309	mental	_	_	I-Premise
310	health	_	_	I-Premise
311	(	_	_	I-Premise
312	0	_	_	I-Premise
313	.	_	_	I-Premise

314	28	_	_	I-Premise
315	,	_	_	I-Premise
316	0	_	_	I-Premise
317	.	_	_	I-Premise

318	02	_	_	I-Premise
319	to	_	_	I-Premise
320	0	_	_	I-Premise
321	.	_	_	I-Premise

322	56	_	_	I-Premise
323	)	_	_	I-Premise
324	scores	_	_	I-Premise
325	.	_	_	I-Premise

326	Improvement	_	_	B-Premise
327	was	_	_	I-Premise
328	noted	_	_	I-Premise
329	in	_	_	I-Premise
330	physical	_	_	I-Premise
331	capacity	_	_	I-Premise
332	:	_	_	I-Premise
333	estimated	_	_	I-Premise
334	mean	_	_	I-Premise
335	difference	_	_	I-Premise
336	between	_	_	I-Premise
337	groups	_	_	I-Premise
338	for	_	_	I-Premise
339	maximum	_	_	I-Premise
340	oxygen	_	_	I-Premise
341	consumption	_	_	I-Premise
342	was	_	_	I-Premise
343	0	_	_	I-Premise
344	.	_	_	I-Premise

345	16	_	_	I-Premise
346	l	_	_	I-Premise
347	/	_	_	I-Premise
348	min	_	_	I-Premise
349	(	_	_	I-Premise
350	95	_	_	I-Premise
351	%	_	_	I-Premise
352	CI	_	_	I-Premise
353	0	_	_	I-Premise
354	.	_	_	I-Premise

355	1	_	_	I-Premise
356	to	_	_	I-Premise
357	0	_	_	I-Premise
358	.	_	_	I-Premise

359	2	_	_	I-Premise
360	,	_	_	I-Premise
361	P	_	_	I-Premise
362	<	_	_	I-Premise
363	0	_	_	I-Premise
364	.	_	_	I-Premise

365	0001	_	_	I-Premise
366	)	_	_	I-Premise
367	and	_	_	I-Premise
368	for	_	_	I-Premise
369	muscular	_	_	I-Premise
370	strength	_	_	I-Premise
371	(	_	_	I-Premise
372	leg	_	_	I-Premise
373	press	_	_	I-Premise
374	)	_	_	I-Premise
375	was	_	_	I-Premise
376	29	_	_	I-Premise
377	.	_	_	I-Premise

378	7	_	_	I-Premise
379	kg	_	_	I-Premise
380	(	_	_	I-Premise
381	23	_	_	I-Premise
382	.	_	_	I-Premise

383	4	_	_	I-Premise
384	to	_	_	I-Premise
385	34	_	_	I-Premise
386	.	_	_	I-Premise

387	9	_	_	I-Premise
388	,	_	_	I-Premise
389	P	_	_	I-Premise
390	<	_	_	I-Premise
391	0	_	_	I-Premise
392	.	_	_	I-Premise

393	0001	_	_	I-Premise
394	)	_	_	I-Premise
395	.	_	_	I-Premise

396	No	_	_	B-Premise
397	significant	_	_	I-Premise
398	effect	_	_	I-Premise
399	was	_	_	I-Premise
400	seen	_	_	I-Premise
401	on	_	_	I-Premise
402	global	_	_	I-Premise
403	health	_	_	I-Premise
404	status	_	_	I-Premise
405	/	_	_	I-Premise
406	quality	_	_	I-Premise
407	of	_	_	I-Premise
408	life	_	_	I-Premise
409	.	_	_	I-Premise

410	A	_	_	B-Claim
411	supervised	_	_	I-Claim
412	multimodal	_	_	I-Claim
413	exercise	_	_	I-Claim
414	intervention	_	_	I-Claim
415	including	_	_	I-Claim
416	high	_	_	I-Claim
417	and	_	_	I-Claim
418	low	_	_	I-Claim
419	intensity	_	_	I-Claim
420	components	_	_	I-Claim
421	was	_	_	I-Claim
422	feasible	_	_	I-Claim
423	and	_	_	I-Claim
424	could	_	_	I-Claim
425	safely	_	_	I-Claim
426	be	_	_	I-Claim
427	used	_	_	I-Claim
428	in	_	_	I-Claim
429	patients	_	_	I-Claim
430	with	_	_	I-Claim
431	various	_	_	I-Claim
432	cancers	_	_	I-Claim
433	who	_	_	I-Claim
434	were	_	_	I-Claim
435	receiving	_	_	I-Claim
436	adjuvant	_	_	I-Claim
437	chemotherapy	_	_	I-Claim
438	or	_	_	I-Claim
439	treatment	_	_	I-Claim
440	for	_	_	I-Claim
441	advanced	_	_	I-Claim
442	disease	_	_	I-Claim
443	.	_	_	I-Claim

444	The	_	_	B-Claim
445	intervention	_	_	I-Claim
446	reduced	_	_	I-Claim
447	fatigue	_	_	I-Claim
448	and	_	_	I-Claim
449	improved	_	_	I-Claim
450	vitality	_	_	I-Claim
451	,	_	_	I-Claim
452	aerobic	_	_	I-Claim
453	capacity	_	_	I-Claim
454	,	_	_	I-Claim
455	muscular	_	_	I-Claim
456	strength	_	_	I-Claim
457	,	_	_	I-Claim
458	and	_	_	I-Claim
459	physical	_	_	I-Claim
460	and	_	_	I-Claim
461	functional	_	_	I-Claim
462	activity	_	_	I-Claim
463	,	_	_	I-Claim
464	and	_	_	I-Claim
465	emotional	_	_	I-Claim
466	wellbeing	_	_	I-Claim
467	,	_	_	I-Claim
468	but	_	_	B-Claim
469	not	_	_	I-Claim
470	quality	_	_	I-Claim
471	of	_	_	I-Claim
472	life	_	_	I-Claim
473	.	_	_	I-Claim


0	Menopausal	_	_	B-Claim
1	symptoms	_	_	I-Claim
2	(	_	_	I-Claim
3	e	_	_	I-Claim
4	.	_	_	I-Claim

5	g	_	_	I-Claim
6	.	_	_	I-Claim

7	,	_	_	I-Claim
8	hot	_	_	I-Claim
9	flashes	_	_	I-Claim
10	,	_	_	I-Claim
11	vaginal	_	_	I-Claim
12	dryness	_	_	I-Claim
13	,	_	_	I-Claim
14	and	_	_	I-Claim
15	stress	_	_	I-Claim
16	urinary	_	_	I-Claim
17	incontinence	_	_	I-Claim
18	)	_	_	I-Claim
19	are	_	_	I-Claim
20	very	_	_	I-Claim
21	common	_	_	I-Claim
22	in	_	_	I-Claim
23	breast	_	_	I-Claim
24	cancer	_	_	I-Claim
25	survivors	_	_	I-Claim
26	and	_	_	I-Claim
27	cannot	_	_	I-Claim
28	be	_	_	I-Claim
29	managed	_	_	I-Claim
30	with	_	_	I-Claim
31	standard	_	_	I-Claim
32	estrogen	_	_	I-Claim
33	replacement	_	_	I-Claim
34	therapy	_	_	I-Claim
35	(	_	_	I-Claim
36	ERT	_	_	I-Claim
37	)	_	_	I-Claim
38	in	_	_	I-Claim
39	these	_	_	I-Claim
40	patients	_	_	I-Claim
41	.	_	_	I-Claim

42	The	_	_	O
43	purpose	_	_	O
44	of	_	_	O
45	this	_	_	O
46	study	_	_	O
47	was	_	_	O
48	to	_	_	O
49	test	_	_	O
50	the	_	_	O
51	efficacy	_	_	O
52	of	_	_	O
53	a	_	_	O
54	comprehensive	_	_	O
55	menopausal	_	_	O
56	assessment	_	_	O
57	(	_	_	O
58	CMA	_	_	O
59	)	_	_	O
60	intervention	_	_	O
61	program	_	_	O
62	in	_	_	O
63	achieving	_	_	O
64	relief	_	_	O
65	of	_	_	O
66	symptoms	_	_	O
67	,	_	_	O
68	the	_	_	O
69	improvement	_	_	O
70	in	_	_	O
71	quality	_	_	O
72	of	_	_	O
73	life	_	_	O
74	(	_	_	O
75	QOL	_	_	O
76	)	_	_	O
77	,	_	_	O
78	and	_	_	O
79	sexual	_	_	O
80	functioning	_	_	O
81	in	_	_	O
82	breast	_	_	O
83	cancer	_	_	O
84	survivors	_	_	O
85	.	_	_	O

86	Using	_	_	O
87	a	_	_	O
88	two	_	_	O
89	-	_	_	O
90	group	_	_	O
91	,	_	_	O
92	randomized	_	_	O
93	controlled	_	_	O
94	design	_	_	O
95	,	_	_	O
96	we	_	_	O
97	assigned	_	_	O
98	76	_	_	O
99	postmenopausal	_	_	O
100	breast	_	_	O
101	cancer	_	_	O
102	survivors	_	_	O
103	with	_	_	O
104	at	_	_	O
105	least	_	_	O
106	one	_	_	O
107	severe	_	_	O
108	target	_	_	O
109	symptom	_	_	O
110	either	_	_	O
111	to	_	_	O
112	the	_	_	O
113	intervention	_	_	O
114	group	_	_	O
115	or	_	_	O
116	to	_	_	O
117	a	_	_	O
118	usual	_	_	O
119	-	_	_	O
120	care	_	_	O
121	group	_	_	O
122	.	_	_	O

123	Seventy	_	_	O
124	-	_	_	O
125	two	_	_	O
126	women	_	_	O
127	were	_	_	O
128	evaluable	_	_	O
129	at	_	_	O
130	the	_	_	O
131	end	_	_	O
132	of	_	_	O
133	the	_	_	O
134	study	_	_	O
135	period	_	_	O
136	.	_	_	O

137	The	_	_	O
138	CMA	_	_	O
139	intervention	_	_	O
140	,	_	_	O
141	delivered	_	_	O
142	by	_	_	O
143	a	_	_	O
144	nurse	_	_	O
145	practitioner	_	_	O
146	,	_	_	O
147	focused	_	_	O
148	on	_	_	O
149	symptom	_	_	O
150	assessment	_	_	O
151	,	_	_	O
152	education	_	_	O
153	,	_	_	O
154	counseling	_	_	O
155	and	_	_	O
156	,	_	_	O
157	as	_	_	O
158	appropriate	_	_	O
159	,	_	_	O
160	specific	_	_	O
161	pharmacologic	_	_	O
162	and	_	_	O
163	behavioral	_	_	O
164	interventions	_	_	O
165	for	_	_	O
166	each	_	_	O
167	of	_	_	O
168	the	_	_	O
169	three	_	_	O
170	target	_	_	O
171	symptoms	_	_	O
172	.	_	_	O

173	Psychosocial	_	_	O
174	symptoms	_	_	O
175	were	_	_	O
176	assessed	_	_	O
177	with	_	_	O
178	the	_	_	O
179	use	_	_	O
180	of	_	_	O
181	a	_	_	O
182	self	_	_	O
183	-	_	_	O
184	report	_	_	O
185	screening	_	_	O
186	instrument	_	_	O
187	,	_	_	O
188	and	_	_	O
189	distressed	_	_	O
190	women	_	_	O
191	were	_	_	O
192	referred	_	_	O
193	for	_	_	O
194	counseling	_	_	O
195	if	_	_	O
196	needed	_	_	O
197	.	_	_	O

198	The	_	_	O
199	intervention	_	_	O
200	took	_	_	O
201	place	_	_	O
202	over	_	_	O
203	a	_	_	O
204	4	_	_	O
205	-	_	_	O
206	month	_	_	O
207	period	_	_	O
208	.	_	_	O

209	Outcomes	_	_	O
210	measured	_	_	O
211	were	_	_	O
212	scores	_	_	O
213	on	_	_	O
214	a	_	_	O
215	composite	_	_	O
216	menopausal	_	_	O
217	symptom	_	_	O
218	scale	_	_	O
219	,	_	_	O
220	the	_	_	O
221	RAND	_	_	O
222	Short	_	_	O
223	Form	_	_	O
224	Health	_	_	O
225	Survey	_	_	O
226	Vitality	_	_	O
227	Scale	_	_	O
228	,	_	_	O
229	and	_	_	O
230	the	_	_	O
231	Cancer	_	_	O
232	Rehabilitation	_	_	O
233	Evaluation	_	_	O
234	System	_	_	O
235	(	_	_	O
236	CARES	_	_	O
237	)	_	_	O
238	Sexual	_	_	O
239	Functioning	_	_	O
240	Scale	_	_	O
241	at	_	_	O
242	baseline	_	_	O
243	and	_	_	O
244	at	_	_	O
245	4	_	_	O
246	-	_	_	O
247	month	_	_	O
248	follow	_	_	O
249	-	_	_	O
250	up	_	_	O
251	.	_	_	O

252	All	_	_	O
253	statistical	_	_	O
254	tests	_	_	O
255	were	_	_	O
256	two	_	_	O
257	-	_	_	O
258	sided	_	_	O
259	and	_	_	O
260	were	_	_	O
261	performed	_	_	O
262	at	_	_	O
263	the	_	_	O
264	alpha	_	_	O
265	=	_	_	O
266	.	_	_	O

267	05	_	_	O
268	significance	_	_	O
269	level	_	_	O
270	.	_	_	O

271	Patients	_	_	B-Premise
272	receiving	_	_	I-Premise
273	the	_	_	I-Premise
274	intervention	_	_	I-Premise
275	demonstrated	_	_	I-Premise
276	statistically	_	_	I-Premise
277	significant	_	_	I-Premise
278	improvement	_	_	I-Premise
279	(	_	_	I-Premise
280	P	_	_	I-Premise
281	=	_	_	I-Premise
282	.	_	_	I-Premise

283	0004	_	_	I-Premise
284	)	_	_	I-Premise
285	in	_	_	I-Premise
286	menopausal	_	_	I-Premise
287	symptoms	_	_	I-Premise
288	but	_	_	I-Premise
289	no	_	_	I-Premise
290	significant	_	_	I-Premise
291	change	_	_	I-Premise
292	in	_	_	I-Premise
293	vitality	_	_	I-Premise
294	(	_	_	I-Premise
295	P	_	_	I-Premise
296	=	_	_	I-Premise
297	.	_	_	I-Premise

298	77	_	_	I-Premise
299	)	_	_	I-Premise
300	.	_	_	I-Premise

301	Sexual	_	_	B-Premise
302	functioning	_	_	I-Premise
303	was	_	_	I-Premise
304	statistically	_	_	I-Premise
305	significantly	_	_	I-Premise
306	improved	_	_	I-Premise
307	(	_	_	I-Premise
308	P	_	_	I-Premise
309	=	_	_	I-Premise
310	.	_	_	I-Premise

311	04	_	_	I-Premise
312	)	_	_	I-Premise
313	in	_	_	I-Premise
314	the	_	_	I-Premise
315	treatment	_	_	I-Premise
316	group	_	_	I-Premise
317	compared	_	_	I-Premise
318	with	_	_	I-Premise
319	the	_	_	I-Premise
320	usual	_	_	I-Premise
321	-	_	_	I-Premise
322	care	_	_	I-Premise
323	group	_	_	I-Premise
324	.	_	_	I-Premise

325	A	_	_	B-Claim
326	clinical	_	_	I-Claim
327	assessment	_	_	I-Claim
328	and	_	_	I-Claim
329	intervention	_	_	I-Claim
330	program	_	_	I-Claim
331	for	_	_	I-Claim
332	menopausal	_	_	I-Claim
333	symptom	_	_	I-Claim
334	management	_	_	I-Claim
335	in	_	_	I-Claim
336	breast	_	_	I-Claim
337	cancer	_	_	I-Claim
338	survivors	_	_	I-Claim
339	is	_	_	I-Claim
340	feasible	_	_	I-Claim
341	and	_	_	I-Claim
342	acceptable	_	_	I-Claim
343	to	_	_	I-Claim
344	patients	_	_	I-Claim
345	,	_	_	I-Claim
346	leading	_	_	I-Claim
347	to	_	_	I-Claim
348	reduction	_	_	I-Claim
349	in	_	_	I-Claim
350	symptoms	_	_	I-Claim
351	and	_	_	I-Claim
352	improvement	_	_	I-Claim
353	in	_	_	I-Claim
354	sexual	_	_	I-Claim
355	functioning	_	_	I-Claim
356	.	_	_	I-Claim

357	Measurable	_	_	B-Claim
358	improvement	_	_	I-Claim
359	in	_	_	I-Claim
360	a	_	_	I-Claim
361	general	_	_	I-Claim
362	QOL	_	_	I-Claim
363	measure	_	_	I-Claim
364	was	_	_	I-Claim
365	not	_	_	I-Claim
366	demonstrated	_	_	I-Claim
367	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	topotecan	_	_	O
6	in	_	_	O
7	combination	_	_	O
8	with	_	_	O
9	standard	_	_	O
10	chemotherapy	_	_	O
11	in	_	_	O
12	previously	_	_	O
13	untreated	_	_	O
14	patients	_	_	O
15	with	_	_	O
16	extensive	_	_	O
17	-	_	_	O
18	stage	_	_	O
19	small	_	_	O
20	-	_	_	O
21	cell	_	_	O
22	lung	_	_	O
23	cancer	_	_	O
24	(	_	_	O
25	SCLC	_	_	O
26	)	_	_	O
27	,	_	_	O
28	the	_	_	O
29	Eastern	_	_	O
30	Cooperative	_	_	O
31	Oncology	_	_	O
32	Group	_	_	O
33	(	_	_	O
34	ECOG	_	_	O
35	)	_	_	O
36	conducted	_	_	O
37	a	_	_	O
38	phase	_	_	O
39	III	_	_	O
40	trial	_	_	O
41	.	_	_	O

42	Eligible	_	_	O
43	patients	_	_	O
44	had	_	_	O
45	measurable	_	_	O
46	or	_	_	O
47	assessable	_	_	O
48	disease	_	_	O
49	and	_	_	O
50	an	_	_	O
51	ECOG	_	_	O
52	performance	_	_	O
53	status	_	_	O
54	of	_	_	O
55	0	_	_	O
56	to	_	_	O
57	2	_	_	O
58	;	_	_	O
59	stable	_	_	O
60	brain	_	_	O
61	metastases	_	_	O
62	were	_	_	O
63	allowed	_	_	O
64	.	_	_	O

65	All	_	_	O
66	patients	_	_	O
67	received	_	_	O
68	four	_	_	O
69	cycles	_	_	O
70	of	_	_	O
71	cisplatin	_	_	O
72	and	_	_	O
73	etoposide	_	_	O
74	every	_	_	O
75	3	_	_	O
76	weeks	_	_	O
77	(	_	_	O
78	step	_	_	O
79	1	_	_	O
80	;	_	_	O
81	PE	_	_	O
82	)	_	_	O
83	.	_	_	O

84	Patients	_	_	O
85	with	_	_	O
86	stable	_	_	O
87	or	_	_	O
88	responding	_	_	O
89	disease	_	_	O
90	were	_	_	O
91	then	_	_	O
92	randomized	_	_	O
93	to	_	_	O
94	observation	_	_	O
95	or	_	_	O
96	four	_	_	O
97	cycles	_	_	O
98	of	_	_	O
99	topotecan	_	_	O
100	(	_	_	O
101	1	_	_	O
102	.	_	_	O

103	5	_	_	O
104	mg	_	_	O
105	/	_	_	O
106	m	_	_	O
107	(	_	_	O
108	2	_	_	O
109	)	_	_	O
110	/	_	_	O
111	d	_	_	O
112	for	_	_	O
113	5	_	_	O
114	days	_	_	O
115	,	_	_	O
116	every	_	_	O
117	3	_	_	O
118	weeks	_	_	O
119	;	_	_	O
120	step	_	_	O
121	2	_	_	O
122	)	_	_	O
123	.	_	_	O

124	A	_	_	O
125	total	_	_	O
126	of	_	_	O
127	402	_	_	O
128	eligible	_	_	O
129	patients	_	_	O
130	were	_	_	O
131	registered	_	_	O
132	to	_	_	O
133	step	_	_	O
134	1	_	_	O
135	,	_	_	O
136	and	_	_	O
137	223	_	_	O
138	eligible	_	_	O
139	patients	_	_	O
140	were	_	_	O
141	registered	_	_	O
142	to	_	_	O
143	step	_	_	O
144	2	_	_	O
145	(	_	_	O
146	observation	_	_	O
147	,	_	_	O
148	n	_	_	O
149	=	_	_	O
150	111	_	_	O
151	;	_	_	O
152	topotecan	_	_	O
153	,	_	_	O
154	n	_	_	O
155	=	_	_	O
156	112	_	_	O
157	)	_	_	O
158	.	_	_	O

159	Complete	_	_	B-Premise
160	and	_	_	I-Premise
161	partial	_	_	I-Premise
162	response	_	_	I-Premise
163	rates	_	_	I-Premise
164	to	_	_	I-Premise
165	induction	_	_	I-Premise
166	PE	_	_	I-Premise
167	were	_	_	I-Premise
168	3	_	_	I-Premise
169	%	_	_	I-Premise
170	and	_	_	I-Premise
171	32	_	_	I-Premise
172	%	_	_	I-Premise
173	,	_	_	I-Premise
174	respectively	_	_	I-Premise
175	.	_	_	I-Premise

176	A	_	_	B-Premise
177	7	_	_	I-Premise
178	%	_	_	I-Premise
179	response	_	_	I-Premise
180	rate	_	_	I-Premise
181	was	_	_	I-Premise
182	observed	_	_	I-Premise
183	with	_	_	I-Premise
184	topotecan	_	_	I-Premise
185	(	_	_	I-Premise
186	complete	_	_	I-Premise
187	response	_	_	I-Premise
188	,	_	_	I-Premise
189	2	_	_	I-Premise
190	%	_	_	I-Premise
191	;	_	_	I-Premise
192	partial	_	_	I-Premise
193	response	_	_	I-Premise
194	,	_	_	I-Premise
195	5	_	_	I-Premise
196	%	_	_	I-Premise
197	)	_	_	I-Premise
198	.	_	_	I-Premise

199	The	_	_	B-Premise
200	median	_	_	I-Premise
201	survival	_	_	I-Premise
202	time	_	_	I-Premise
203	for	_	_	I-Premise
204	all	_	_	I-Premise
205	402	_	_	I-Premise
206	eligible	_	_	I-Premise
207	patients	_	_	I-Premise
208	was	_	_	I-Premise
209	9	_	_	I-Premise
210	.	_	_	I-Premise

211	6	_	_	I-Premise
212	months	_	_	I-Premise
213	.	_	_	I-Premise

214	Progression	_	_	B-Premise
215	-	_	_	I-Premise
216	free	_	_	I-Premise
217	survival	_	_	I-Premise
218	(	_	_	I-Premise
219	PFS	_	_	I-Premise
220	)	_	_	I-Premise
221	from	_	_	I-Premise
222	date	_	_	I-Premise
223	of	_	_	I-Premise
224	randomization	_	_	I-Premise
225	on	_	_	I-Premise
226	step	_	_	I-Premise
227	2	_	_	I-Premise
228	was	_	_	I-Premise
229	significantly	_	_	I-Premise
230	better	_	_	I-Premise
231	with	_	_	I-Premise
232	topotecan	_	_	I-Premise
233	compared	_	_	I-Premise
234	with	_	_	I-Premise
235	observation	_	_	I-Premise
236	(	_	_	I-Premise
237	3	_	_	I-Premise
238	.	_	_	I-Premise

239	6	_	_	I-Premise
240	months	_	_	I-Premise
241	v	_	_	I-Premise
242	2	_	_	I-Premise
243	.	_	_	I-Premise

244	3	_	_	I-Premise
245	months	_	_	I-Premise
246	;	_	_	I-Premise
247	P	_	_	I-Premise
248	<	_	_	I-Premise
249	.	_	_	I-Premise

250	001	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	However	_	_	O
254	,	_	_	O
255	overall	_	_	B-Premise
256	survival	_	_	I-Premise
257	from	_	_	I-Premise
258	date	_	_	I-Premise
259	of	_	_	I-Premise
260	randomization	_	_	I-Premise
261	on	_	_	I-Premise
262	step	_	_	I-Premise
263	2	_	_	I-Premise
264	was	_	_	I-Premise
265	not	_	_	I-Premise
266	significantly	_	_	I-Premise
267	different	_	_	I-Premise
268	between	_	_	I-Premise
269	the	_	_	I-Premise
270	observation	_	_	I-Premise
271	and	_	_	I-Premise
272	topotecan	_	_	I-Premise
273	arms	_	_	I-Premise
274	(	_	_	I-Premise
275	8	_	_	I-Premise
276	.	_	_	I-Premise

277	9	_	_	I-Premise
278	months	_	_	I-Premise
279	v	_	_	I-Premise
280	9	_	_	I-Premise
281	.	_	_	I-Premise

282	3	_	_	I-Premise
283	months	_	_	I-Premise
284	;	_	_	I-Premise
285	P	_	_	I-Premise
286	=	_	_	I-Premise
287	.	_	_	I-Premise

288	43	_	_	I-Premise
289	)	_	_	I-Premise
290	.	_	_	I-Premise

291	Grade	_	_	B-Premise
292	4	_	_	I-Premise
293	neutropenia	_	_	I-Premise
294	and	_	_	I-Premise
295	thrombocytopenia	_	_	I-Premise
296	occurred	_	_	I-Premise
297	in	_	_	I-Premise
298	50	_	_	I-Premise
299	%	_	_	I-Premise
300	and	_	_	I-Premise
301	3	_	_	I-Premise
302	%	_	_	I-Premise
303	,	_	_	I-Premise
304	respectively	_	_	I-Premise
305	,	_	_	I-Premise
306	of	_	_	I-Premise
307	PE	_	_	I-Premise
308	patients	_	_	I-Premise
309	in	_	_	I-Premise
310	step	_	_	I-Premise
311	1	_	_	I-Premise
312	and	_	_	I-Premise
313	60	_	_	I-Premise
314	%	_	_	I-Premise
315	and	_	_	I-Premise
316	13	_	_	I-Premise
317	%	_	_	I-Premise
318	of	_	_	I-Premise
319	topotecan	_	_	I-Premise
320	patients	_	_	I-Premise
321	in	_	_	I-Premise
322	step	_	_	I-Premise
323	2	_	_	I-Premise
324	.	_	_	I-Premise

325	Grade	_	_	B-Premise
326	4	_	_	I-Premise
327	/	_	_	I-Premise
328	5	_	_	I-Premise
329	infection	_	_	I-Premise
330	was	_	_	I-Premise
331	observed	_	_	I-Premise
332	in	_	_	I-Premise
333	4	_	_	I-Premise
334	.	_	_	I-Premise

335	6	_	_	I-Premise
336	%	_	_	I-Premise
337	of	_	_	I-Premise
338	PE	_	_	I-Premise
339	patients	_	_	I-Premise
340	and	_	_	I-Premise
341	1	_	_	I-Premise
342	.	_	_	I-Premise

343	8	_	_	I-Premise
344	%	_	_	I-Premise
345	of	_	_	I-Premise
346	topotecan	_	_	I-Premise
347	patients	_	_	I-Premise
348	.	_	_	I-Premise

349	Grade	_	_	B-Premise
350	3	_	_	I-Premise
351	/	_	_	I-Premise
352	4	_	_	I-Premise
353	anemia	_	_	I-Premise
354	developed	_	_	I-Premise
355	in	_	_	I-Premise
356	22	_	_	I-Premise
357	%	_	_	I-Premise
358	of	_	_	I-Premise
359	patients	_	_	I-Premise
360	who	_	_	I-Premise
361	received	_	_	I-Premise
362	topotecan	_	_	I-Premise
363	.	_	_	I-Premise

364	No	_	_	B-Premise
365	difference	_	_	I-Premise
366	in	_	_	I-Premise
367	quality	_	_	I-Premise
368	of	_	_	I-Premise
369	life	_	_	I-Premise
370	between	_	_	I-Premise
371	topotecan	_	_	I-Premise
372	and	_	_	I-Premise
373	observation	_	_	I-Premise
374	was	_	_	I-Premise
375	observed	_	_	I-Premise
376	at	_	_	I-Premise
377	any	_	_	I-Premise
378	assessment	_	_	I-Premise
379	time	_	_	I-Premise
380	or	_	_	I-Premise
381	for	_	_	I-Premise
382	any	_	_	I-Premise
383	of	_	_	I-Premise
384	the	_	_	I-Premise
385	subscale	_	_	I-Premise
386	scores	_	_	I-Premise
387	.	_	_	I-Premise

388	Four	_	_	B-Claim
389	cycles	_	_	I-Claim
390	of	_	_	I-Claim
391	PE	_	_	I-Claim
392	induction	_	_	I-Claim
393	therapy	_	_	I-Claim
394	followed	_	_	I-Claim
395	by	_	_	I-Claim
396	four	_	_	I-Claim
397	cycles	_	_	I-Claim
398	of	_	_	I-Claim
399	topotecan	_	_	I-Claim
400	improved	_	_	I-Claim
401	PFS	_	_	I-Claim
402	but	_	_	I-Claim
403	failed	_	_	I-Claim
404	to	_	_	I-Claim
405	improve	_	_	I-Claim
406	overall	_	_	I-Claim
407	survival	_	_	I-Claim
408	or	_	_	I-Claim
409	quality	_	_	I-Claim
410	of	_	_	I-Claim
411	life	_	_	I-Claim
412	in	_	_	I-Claim
413	extensive	_	_	I-Claim
414	-	_	_	I-Claim
415	stage	_	_	I-Claim
416	SCLC	_	_	I-Claim
417	.	_	_	I-Claim

418	Four	_	_	B-Claim
419	cycles	_	_	I-Claim
420	of	_	_	I-Claim
421	standard	_	_	I-Claim
422	PE	_	_	I-Claim
423	remains	_	_	I-Claim
424	an	_	_	I-Claim
425	appropriate	_	_	I-Claim
426	first	_	_	I-Claim
427	-	_	_	I-Claim
428	line	_	_	I-Claim
429	treatment	_	_	I-Claim
430	for	_	_	I-Claim
431	extensive	_	_	I-Claim
432	-	_	_	I-Claim
433	stage	_	_	I-Claim
434	SCLC	_	_	I-Claim
435	patients	_	_	I-Claim
436	with	_	_	I-Claim
437	good	_	_	I-Claim
438	performance	_	_	I-Claim
439	status	_	_	I-Claim
440	.	_	_	I-Claim


0	Study	_	_	O
1	Type	_	_	O
2	-	_	_	O
3	-	_	_	O
4	Therapy	_	_	O
5	(	_	_	O
6	RCT	_	_	O
7	)	_	_	O
8	Level	_	_	O
9	of	_	_	O
10	Evidence	_	_	O
11	1b	_	_	O
12	.	_	_	O

13	What	_	_	O
14	'	_	_	O
15	s	_	_	O
16	known	_	_	O
17	on	_	_	O
18	the	_	_	O
19	subject	_	_	O
20	?	_	_	O
21	and	_	_	O
22	What	_	_	O
23	does	_	_	O
24	the	_	_	O
25	study	_	_	O
26	add	_	_	O
27	?	_	_	O
28	Androgen	_	_	O
29	deprivation	_	_	O
30	therapy	_	_	O
31	(	_	_	O
32	ADT	_	_	O
33	)	_	_	O
34	is	_	_	O
35	commonly	_	_	O
36	used	_	_	O
37	as	_	_	O
38	a	_	_	O
39	primary	_	_	O
40	treatment	_	_	O
41	for	_	_	O
42	patients	_	_	O
43	with	_	_	O
44	prostate	_	_	O
45	cancer	_	_	O
46	(	_	_	O
47	PCa	_	_	O
48	)	_	_	O
49	who	_	_	O
50	are	_	_	O
51	not	_	_	O
52	eligible	_	_	O
53	for	_	_	O
54	radical	_	_	O
55	treatment	_	_	O
56	options	_	_	O
57	.	_	_	O

58	ADT	_	_	O
59	is	_	_	O
60	also	_	_	O
61	used	_	_	O
62	in	_	_	O
63	patients	_	_	O
64	with	_	_	O
65	PCa	_	_	O
66	as	_	_	O
67	neo	_	_	O
68	-	_	_	O
69	adjuvant	_	_	O
70	hormone	_	_	O
71	therapy	_	_	O
72	to	_	_	O
73	reduce	_	_	O
74	prostate	_	_	O
75	volume	_	_	O
76	and	_	_	O
77	down	_	_	O
78	-	_	_	O
79	stage	_	_	O
80	the	_	_	O
81	disease	_	_	O
82	before	_	_	O
83	radiotherapy	_	_	O
84	with	_	_	O
85	curative	_	_	O
86	intent	_	_	O
87	.	_	_	O

88	The	_	_	O
89	present	_	_	O
90	study	_	_	O
91	showed	_	_	O
92	that	_	_	O
93	ADT	_	_	O
94	with	_	_	O
95	the	_	_	O
96	gonadotropin	_	_	O
97	hormone	_	_	O
98	-	_	_	O
99	releasing	_	_	O
100	hormone	_	_	O
101	(	_	_	O
102	GhRH	_	_	O
103	)	_	_	O
104	antagonist	_	_	O
105	degarelix	_	_	O
106	is	_	_	O
107	non	_	_	O
108	-	_	_	O
109	inferior	_	_	O
110	to	_	_	O
111	combined	_	_	O
112	treatment	_	_	O
113	with	_	_	O
114	the	_	_	O
115	LHRH	_	_	O
116	agonist	_	_	O
117	goserelin	_	_	O
118	and	_	_	O
119	bicalutamide	_	_	O
120	in	_	_	O
121	terms	_	_	O
122	of	_	_	O
123	reducing	_	_	O
124	prostate	_	_	O
125	volume	_	_	O
126	during	_	_	O
127	the	_	_	O
128	treatment	_	_	O
129	period	_	_	O
130	of	_	_	O
131	3	_	_	O
132	months	_	_	O
133	.	_	_	O

134	Degarelix	_	_	O
135	treatment	_	_	O
136	evokes	_	_	O
137	,	_	_	O
138	however	_	_	O
139	,	_	_	O
140	significantly	_	_	O
141	better	_	_	O
142	relief	_	_	O
143	of	_	_	O
144	lower	_	_	O
145	urinary	_	_	O
146	tract	_	_	O
147	symptoms	_	_	O
148	in	_	_	O
149	patients	_	_	O
150	having	_	_	O
151	moderate	_	_	O
152	and	_	_	O
153	severe	_	_	O
154	voiding	_	_	O
155	problems	_	_	O
156	.	_	_	O

157	To	_	_	O
158	assess	_	_	O
159	the	_	_	O
160	efficacy	_	_	O
161	of	_	_	O
162	monthly	_	_	O
163	degarelix	_	_	O
164	treatment	_	_	O
165	for	_	_	O
166	reduction	_	_	O
167	of	_	_	O
168	total	_	_	O
169	prostate	_	_	O
170	volume	_	_	O
171	(	_	_	O
172	TPV	_	_	O
173	)	_	_	O
174	,	_	_	O
175	relief	_	_	O
176	of	_	_	O
177	lower	_	_	O
178	urinary	_	_	O
179	tract	_	_	O
180	symptoms	_	_	O
181	(	_	_	O
182	LUTS	_	_	O
183	)	_	_	O
184	and	_	_	O
185	improvement	_	_	O
186	of	_	_	O
187	quality	_	_	O
188	of	_	_	O
189	life	_	_	O
190	(	_	_	O
191	QoL	_	_	O
192	)	_	_	O
193	in	_	_	O
194	patients	_	_	O
195	with	_	_	O
196	prostate	_	_	O
197	cancer	_	_	O
198	(	_	_	O
199	PCa	_	_	O
200	)	_	_	O
201	using	_	_	O
202	monthly	_	_	O
203	goserelin	_	_	O
204	as	_	_	O
205	active	_	_	O
206	control	_	_	O
207	.	_	_	O

208	This	_	_	O
209	was	_	_	O
210	a	_	_	O
211	randomized	_	_	O
212	,	_	_	O
213	parallel	_	_	O
214	-	_	_	O
215	arm	_	_	O
216	,	_	_	O
217	active	_	_	O
218	-	_	_	O
219	controlled	_	_	O
220	,	_	_	O
221	open	_	_	O
222	-	_	_	O
223	label	_	_	O
224	,	_	_	O
225	multicentre	_	_	O
226	trial	_	_	O
227	on	_	_	O
228	182	_	_	O
229	patients	_	_	O
230	treated	_	_	O
231	with	_	_	O
232	either	_	_	O
233	monthly	_	_	O
234	degarelix	_	_	O
235	(	_	_	O
236	240	_	_	O
237	/	_	_	O
238	80	_	_	O
239	mg	_	_	O
240	)	_	_	O
241	or	_	_	O
242	goserelin	_	_	O
243	(	_	_	O
244	3	_	_	O
245	.	_	_	O

246	6	_	_	O
247	mg	_	_	O
248	)	_	_	O
249	for	_	_	O
250	12	_	_	O
251	weeks	_	_	O
252	.	_	_	O

253	For	_	_	O
254	flare	_	_	O
255	protection	_	_	O
256	,	_	_	O
257	goserelin	_	_	O
258	-	_	_	O
259	treated	_	_	O
260	patients	_	_	O
261	also	_	_	O
262	received	_	_	O
263	daily	_	_	O
264	bicalutamide	_	_	O
265	(	_	_	O
266	50	_	_	O
267	mg	_	_	O
268	)	_	_	O
269	during	_	_	O
270	the	_	_	O
271	initial	_	_	O
272	28	_	_	O
273	days	_	_	O
274	.	_	_	O

275	Key	_	_	O
276	trial	_	_	O
277	variables	_	_	O
278	monitored	_	_	O
279	monthly	_	_	O
280	were	_	_	O
281	TPV	_	_	O
282	(	_	_	O
283	primary	_	_	O
284	endpoint	_	_	O
285	)	_	_	O
286	,	_	_	O
287	serum	_	_	O
288	testosterone	_	_	O
289	,	_	_	O
290	prostate	_	_	O
291	-	_	_	O
292	specific	_	_	O
293	antigen	_	_	O
294	(	_	_	O
295	PSA	_	_	O
296	)	_	_	O
297	,	_	_	O
298	the	_	_	O
299	International	_	_	O
300	Prostate	_	_	O
301	Symptom	_	_	O
302	Score	_	_	O
303	(	_	_	O
304	IPSS	_	_	O
305	)	_	_	O
306	and	_	_	O
307	the	_	_	O
308	Benign	_	_	O
309	Prostate	_	_	O
310	Hyperplasia	_	_	O
311	Impact	_	_	O
312	Index	_	_	O
313	.	_	_	O

314	In	_	_	O
315	all	_	_	O
316	,	_	_	O
317	175	_	_	O
318	patients	_	_	O
319	completed	_	_	O
320	the	_	_	O
321	trial	_	_	O
322	(	_	_	O
323	96	_	_	O
324	.	_	_	O

325	1	_	_	O
326	%	_	_	O
327	)	_	_	O
328	.	_	_	O

329	At	_	_	B-Premise
330	week	_	_	I-Premise
331	12	_	_	I-Premise
332	,	_	_	I-Premise
333	changes	_	_	I-Premise
334	in	_	_	I-Premise
335	TPV	_	_	I-Premise
336	for	_	_	I-Premise
337	degarelix	_	_	I-Premise
338	and	_	_	I-Premise
339	goserelin	_	_	I-Premise
340	were	_	_	I-Premise
341	similar	_	_	I-Premise
342	(	_	_	I-Premise
343	-	_	_	I-Premise
344	37	_	_	I-Premise
345	.	_	_	I-Premise

346	2	_	_	I-Premise
347	%	_	_	I-Premise
348	vs	_	_	I-Premise
349	-	_	_	I-Premise
350	39	_	_	I-Premise
351	.	_	_	I-Premise

352	0	_	_	I-Premise
353	%	_	_	I-Premise
354	)	_	_	I-Premise
355	and	_	_	I-Premise
356	met	_	_	I-Premise
357	the	_	_	I-Premise
358	predefined	_	_	I-Premise
359	non	_	_	I-Premise
360	-	_	_	I-Premise
361	inferiority	_	_	I-Premise
362	criterion	_	_	I-Premise
363	.	_	_	I-Premise

364	Decreases	_	_	B-Premise
365	in	_	_	I-Premise
366	IPSS	_	_	I-Premise
367	were	_	_	I-Premise
368	greater	_	_	I-Premise
369	in	_	_	I-Premise
370	degarelix	_	_	I-Premise
371	than	_	_	I-Premise
372	in	_	_	I-Premise
373	goserelin	_	_	I-Premise
374	-	_	_	I-Premise
375	treated	_	_	I-Premise
376	patients	_	_	I-Premise
377	,	_	_	I-Premise
378	differences	_	_	I-Premise
379	being	_	_	I-Premise
380	statistically	_	_	I-Premise
381	significant	_	_	I-Premise
382	in	_	_	I-Premise
383	patients	_	_	I-Premise
384	with	_	_	I-Premise
385	baseline	_	_	I-Premise
386	IPSS	_	_	I-Premise
387	>	_	_	I-Premise
388	13	_	_	I-Premise
389	(	_	_	I-Premise
390	-	_	_	I-Premise
391	6	_	_	I-Premise
392	.	_	_	I-Premise

393	7	_	_	I-Premise
394	±	_	_	I-Premise
395	1	_	_	I-Premise
396	.	_	_	I-Premise

397	8	_	_	I-Premise
398	vs	_	_	I-Premise
399	-	_	_	I-Premise
400	4	_	_	I-Premise
401	.	_	_	I-Premise

402	0	_	_	I-Premise
403	±	_	_	I-Premise
404	1	_	_	I-Premise
405	.	_	_	I-Premise

406	0	_	_	I-Premise
407	;	_	_	I-Premise
408	P	_	_	I-Premise
409	=	_	_	I-Premise
410	0	_	_	I-Premise
411	.	_	_	I-Premise

412	02	_	_	I-Premise
413	)	_	_	I-Premise
414	.	_	_	I-Premise

415	The	_	_	B-Premise
416	number	_	_	I-Premise
417	of	_	_	I-Premise
418	patients	_	_	I-Premise
419	with	_	_	I-Premise
420	an	_	_	I-Premise
421	IPSS	_	_	I-Premise
422	change	_	_	I-Premise
423	of	_	_	I-Premise
424	≥	_	_	I-Premise
425	3	_	_	I-Premise
426	over	_	_	I-Premise
427	baseline	_	_	I-Premise
428	was	_	_	I-Premise
429	also	_	_	I-Premise
430	significantly	_	_	I-Premise
431	higher	_	_	I-Premise
432	in	_	_	I-Premise
433	patients	_	_	I-Premise
434	treated	_	_	I-Premise
435	with	_	_	I-Premise
436	degarelix	_	_	I-Premise
437	(	_	_	I-Premise
438	61	_	_	I-Premise
439	.	_	_	I-Premise

440	0	_	_	I-Premise
441	vs	_	_	I-Premise
442	44	_	_	I-Premise
443	.	_	_	I-Premise

444	3	_	_	I-Premise
445	%	_	_	I-Premise
446	,	_	_	I-Premise
447	P	_	_	I-Premise
448	=	_	_	I-Premise
449	0	_	_	I-Premise
450	.	_	_	I-Premise

451	02	_	_	I-Premise
452	)	_	_	I-Premise
453	.	_	_	I-Premise

454	Both	_	_	B-Claim
455	treatments	_	_	I-Claim
456	were	_	_	I-Claim
457	safe	_	_	I-Claim
458	and	_	_	I-Claim
459	well	_	_	I-Claim
460	tolerated	_	_	I-Claim
461	.	_	_	I-Claim

462	Medical	_	_	B-Claim
463	castration	_	_	I-Claim
464	reduces	_	_	I-Claim
465	TPV	_	_	I-Claim
466	and	_	_	I-Claim
467	could	_	_	I-Claim
468	also	_	_	I-Claim
469	improve	_	_	I-Claim
470	LUTS	_	_	I-Claim
471	in	_	_	I-Claim
472	patients	_	_	I-Claim
473	with	_	_	I-Claim
474	PCa	_	_	I-Claim
475	.	_	_	I-Claim

476	While	_	_	O
477	the	_	_	B-Claim
478	short	_	_	I-Claim
479	-	_	_	I-Claim
480	term	_	_	I-Claim
481	efficacy	_	_	I-Claim
482	of	_	_	I-Claim
483	degarelix	_	_	I-Claim
484	and	_	_	I-Claim
485	goserelin	_	_	I-Claim
486	+	_	_	I-Claim
487	bicalutamide	_	_	I-Claim
488	was	_	_	I-Claim
489	the	_	_	I-Claim
490	same	_	_	I-Claim
491	in	_	_	I-Claim
492	terms	_	_	I-Claim
493	of	_	_	I-Claim
494	TPV	_	_	I-Claim
495	reduction	_	_	I-Claim
496	,	_	_	I-Claim
497	degarelix	_	_	B-Claim
498	showed	_	_	I-Claim
499	superiority	_	_	I-Claim
500	in	_	_	I-Claim
501	LUTS	_	_	I-Claim
502	relief	_	_	I-Claim
503	in	_	_	I-Claim
504	symptomatic	_	_	I-Claim
505	patients	_	_	I-Claim
506	,	_	_	I-Claim
507	which	_	_	I-Claim
508	could	_	_	I-Claim
509	highlight	_	_	I-Claim
510	the	_	_	I-Claim
511	different	_	_	I-Claim
512	actions	_	_	I-Claim
513	of	_	_	I-Claim
514	these	_	_	I-Claim
515	drugs	_	_	I-Claim
516	on	_	_	I-Claim
517	extrapituitary	_	_	I-Claim
518	gonadotrophin	_	_	I-Claim
519	-	_	_	I-Claim
520	releasing	_	_	I-Claim
521	hormone	_	_	I-Claim
522	(	_	_	I-Claim
523	GnRH	_	_	I-Claim
524	)	_	_	I-Claim
525	receptors	_	_	I-Claim
526	in	_	_	I-Claim
527	the	_	_	I-Claim
528	bladder	_	_	I-Claim
529	and	_	_	I-Claim
530	/	_	_	I-Claim
531	or	_	_	I-Claim
532	the	_	_	I-Claim
533	prostate	_	_	I-Claim
534	.	_	_	I-Claim


